FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Van den Broek, BTA
   Lindemans, CA
   Boelens, JJ
   Delemarre, EM
   Drylewicz, J
   Verhoeven Duif, N
   Van Hasselt, PM
   Nierkens, S
AF van den Broek, Brigitte T. A.
   Lindemans, Caroline A.
   Boelens, Jaap Jan
   Delemarre, Eveline M.
   Drylewicz, Julia
   Verhoeven Duif, Nanda
   van Hasselt, Peter M.
   Nierkens, Stefan
TI Long term effect of hematopoietic cell transplantation on systemic
   inflammation in patients with mucopolysaccharidoses
SO BLOOD ADVANCES
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION; HURLER SYNDROME; JOINT DISEASE; TNF ALPHA;
   TYPES I; RANKL; BONE; GLYCOSAMINOGLYCANS; EXPRESSION; MECHANISM
AB Mucopolysaccharidoses (MPS) are devastating inherited diseases treated with hematopoietic cell transplantation (HCT). However, disease progression, especially skeletal, still occurs in all patients. Secondary inflammation has been hypothesized to be a cause. To investigate whether systemic inflammation is present in untreated patients and to evaluate the effect of HCT on systemic inflammation, dried blood spots (n = 66) of patients with MPS (n = 33) treated with HCT between 2003 and 2019 were included. Time points consisted of pre HCT and, for patients with MPS type I (MPS I), also at 1, 3, and 10 years of follow up. Ninety two markers of the OLINK inflammation panel were measured and compared with those of age matched control subjects (n = 31) by using principal component analysis and Wilcoxon rank sum tests with correction. Median age at transplantation was 1.3 years (range, 0.2 4.8 years), and median time of pre HCT sample to transplantation was 0.1 year. Normal leukocyte enzyme activity levels were achieved in 93% of patients post HCT. Pretransplant samples showed dear separation of patients and control subjects. Markers that differentiated pre HCT between control subjects and patients were mainly pro inflammatory (50%) or related to bone homeostasis and extracellular matrix degradation (33%). After 10 years' follow up, only 5 markers (receptor activator of nuclear factor kappa B ligand, osteoprotegerin, axis inhibition protein 1 [AXIN1], stem cell factor, and Fms related tyrosine kinase 3 ligand) remained significantly increased, with a large fold change difference between patients with MPS I and control subjects. In conclusion, systemic inflammation is present in untreated MPS patients and is reduced upon treatment with HCT. Markers related to bone homeostasis remain elevated up to 10 years after HCT and possibly reflect the ongoing skeletal disease, making them potential biomarkers for the evaluation of new therapies.
C1 [van den Broek, Brigitte T. A.; van Hasselt, Peter M.] Univ Utrecht, Univ Med Ctr Utrecht, Sylvia Toth Ctr Multidisciplinary Follow Hematopo, Utrecht, Netherlands.
   [van den Broek, Brigitte T. A.] Univ Utrecht, Univ Med Ctr Utrecht, Pediat Blood & Marrow Transplantat Program, Dept Child Hlth, Utrecht, Netherlands.
   [van den Broek, Brigitte T. A.; van Hasselt, Peter M.] Univ Utrecht, Univ Med Ctr Utrecht, Sect Metab Dis, Dept Child Hlth, Utrecht, Netherlands.
   [van den Broek, Brigitte T. A.; Delemarre, Eveline M.; Drylewicz, Julia; Nierkens, Stefan] Univ Utrecht, Univ Med Ctr Utrecht, Ctr Translat Immunol, Heidelberglaan 100, NL 3584 CX Utrecht, Netherlands.
   [Lindemans, Caroline A.] Princess Maxima Ctr, Utrecht, Netherlands.
   [Lindemans, Caroline A.] Univ Med Ctr Utrecht, Utrecht, Netherlands.
   [Boelens, Jaap Jan] Mem Sloan Kettering Canc Ctr, MSK Kids, Stem Cell Transplantat & Cellular Therapies, 1275 York Ave, New York, NY 10021 USA.
   [Verhoeven Duif, Nanda] Univ Utrecht, Univ Med Ctr Utrecht, Sect Metab Diagnost, Dept Genet, Utrecht, Netherlands.
   [Nierkens, Stefan] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands.
C3 Utrecht University; Utrecht University Medical Center; Utrecht
   University; Utrecht University Medical Center; Utrecht University;
   Utrecht University Medical Center; Utrecht University; Utrecht
   University Medical Center; Princess Maxima Center; Utrecht University;
   Utrecht University Medical Center; Memorial Sloan Kettering Cancer
   Center; Utrecht University; Utrecht University Medical Center; Princess
   Maxima Center
RP Nierkens, S (通讯作者)，Univ Utrecht, Univ Med Ctr Utrecht, Ctr Translat Immunol, Heidelberglaan 100, NL 3584 CX Utrecht, Netherlands.
EM s.nierkens@umcutrecht.nl
RI Drylewicz, Julia/I 4703 2019; Nierkens, Stefan/AAQ 5564 2021
OI Drylewicz, Julia/0000 0002 9434 8459; van den Broek,
   Brigitte/0000 0003 3208 0685; Nierkens, Stefan/0000 0003 3406 817X;
   Boelens, Jaap Jan/0000 0003 2232 6952
FU Sylvia Toth Charity Foundation
FX B.T.A.v.d.B. was supported by a research grant from the Sylvia Toth
   Charity Foundation while working on this study. B.T.A.v.d.B. is a PhD
   candidate at Utrecht University. Funding support for this article was
   provided by the Sylvia Toth Charity Foundation. The sponsors of this
   study are public or nonprofit organizations that support science in
   general. They had no role in gathering, analyzing, or interpreting the
   data.
CR Aldenhoven M, 2015, BIOL BLOOD MARROW TR, V21, P1106, DOI 10.1016/j.bbmt.2015.02.011
   Aldenhoven M, 2015, BLOOD, V125, P2164, DOI 10.1182/blood 2014 11 608075
   ASH P, 1980, NATURE, V283, P669, DOI 10.1038/283669a0
   Assarsson E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095192
   Atkins GJ, 2003, J BONE MINER RES, V18, P1088, DOI 10.1359/jbmr.2003.18.6.1088
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Binari RC, 1997, DEVELOPMENT, V124, P2623
   Bjorkesten J, 2017, MOL CELL PROTEOMICS, V16, P1286, DOI 10.1074/mcp.RA117.000015
   Boelens JJ, 2013, BLOOD, V121, P3981, DOI 10.1182/blood 2012 09 455238
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Evans CH, 2007, J ORTHOP RES, V25, P556, DOI 10.1002/jor.20386
   Gatto F, 2012, STEM CELLS DEV, V21, P1466, DOI 10.1089/scd.2011.0555
   Hennermann JB, 2016, J INHERIT METAB DIS, V39, P831, DOI 10.1007/s10545 016 9974 5
   Javed A, 2018, ACTA OPHTHALMOL, V96, P494, DOI 10.1111/aos.13627
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Langereis EJ, 2016, J BONE JOINT SURG AM, V98, P386, DOI 10.2106/JBJS.O.00601
   Lean JM, 2001, BLOOD, V98, P2707, DOI 10.1182/blood.V98.9.2707
   Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034
   Ling L, 2010, J BIOL CHEM, V285, P26233, DOI 10.1074/jbc.M110.122069
   Lundberg M, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr424
   Muenzer J, 2011, RHEUMATOLOGY, V50, pV4, DOI 10.1093/rheumatology/ker394
   Opoka Winiarska V, 2013, OSTEOARTHR CARTILAGE, V21, P1813, DOI 10.1016/j.joca.2013.08.001
   Orii K, 2019, DIAGNOSTICS BASEL, V9, P1
   Polgreen LE, 2017, MOL GENET METAB REP, V10, P75, DOI 10.1016/j.ymgmr.2017.01.002
   Polgreen LE, 2016, MOL GENET METAB, V117, P427, DOI 10.1016/j.ymgme.2016.01.012
   Raymond GV, 2016, SCI REP UK, V6, DOI 10.1038/srep38305
   Rout Pitt NB, 2015, THESIS U ADELAIDE AD
   Sano T, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2609 x
   Schuchman EH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054459
   Simonaro CM, 2008, AM J PATHOL, V172, P112, DOI 10.2353/ajpath.2008.070564
   Simonaro CM, 2010, P NATL ACAD SCI USA, V107, P222, DOI 10.1073/pnas.0912937107
   Simonaro CM, 2001, LAB INVEST, V81, P1319, DOI 10.1038/labinvest.3780345
   Takeuchi T, 2019, ANN RHEUM DIS, V78, P899, DOI 10.1136/annrheumdis 2018 214827
   Théoleyre S, 2006, BIOCHEM BIOPH RES CO, V347, P460, DOI 10.1016/j.bbrc.2006.06.120
   van den Broek BTA, 2020, BIOL BLOOD MARROW TR, V26, P928, DOI 10.1016/j.bbmt.2019.11.025
   Villani GRD, 2007, J NEUROSCI RES, V85, P612, DOI 10.1002/jnr.21134
NR 37
TC 5
Z9 5
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2473 9529
EI 2473 9537
J9 BLOOD ADV
JI Blood Adv.
PD AUG 24
PY 2021
VL 5
IS 16
BP 3092
EP 3101
DI 10.1182/bloodadvances.2020003824
EA AUG 2021
PG 10
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA UF4HP
UT WOS:000688536600005
PM 34402882
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cai, XJ
   Wang, Z
   Cao, JW
   Ni, JJ
   Xu, YY
   Yao, J
AF Cai, Xin jun
   Wang, Zeng
   Cao, Jia wei
   Ni, Jian jun
   Xu, Ying ying
   Yao, Jun
TI Anti Tumor and Anti Angiogenic Effects of Metronomic Use of Zolendronic
   Acid Encapsulated in APRPG modified PEGylated Liposomes
SO LATIN AMERICAN JOURNAL OF PHARMACY
LA English
DT Article
DE anti angiogenic; anti tumor; APRPG; metronomic administration; PEGylated
   liposomes; zoledronic acid
ID SMALL INTERFERING RNA; ZOLEDRONIC ACID; MAMMALIAN TARGET; DOSE THERAPY;
   CHEMOTHERAPY; CANCER; BISPHOSPHONATES; BREAST; IMMUNOTHERAPY; DECADE
AB Zoledronic acid (ZOL) represents a 3rd generation bisphosphonate that has been reported to possess anti tumor activity. However, its use as a chemotherapeutic drug is hindered by its short plasma half life and rapid accumulation in bone. Therefore, the current study demonstrates the anti angiogenic efficacy of metronomic administration of ZOL encapsulated in APRPG modified PEGylated liposomes (APRPG PEG LP ZOL), specifically in targeting vascular endothelial growth factor receptor 1 (VEGFR 1) that is known to be involved in tumor neovascularization. APRPG PEG LP ZOL was synthesized using the thin film hydration method. In vivo experiments on PC3 tumor bearing mice were done to investigate the anti tumor activity of metronomic APRPG PEG LP ZOL administration From our results, metronomic APRPG PEG LP ZOL appears to restrict tumor growth more effectively than the conventional regimen. Decreased microvessel density (MVD) confirms the anti tumor and anti angiogenic activity of APRPG PEG LP ZOL in vivo. Our results indicate that APRPG PEG LP ZOL is a rational chemotherapeutic option for cancer patients.
C1 [Cai, Xin jun; Cao, Jia wei; Ni, Jian jun; Xu, Ying ying; Yao, Jun] Hangzhou Red Cross Hosp, Dept Pharm, Hangzhou 310003, Zhejiang, Peoples R China.
   [Wang, Zeng] Zhejiang Canc Hosp, Dept Pharm, Hangzhou 310022, Zhejiang, Peoples R China.
C3 Zhejiang Cancer Hospital
RP Yao, J (通讯作者)，Hangzhou Red Cross Hosp, Dept Pharm, Hangzhou 310003, Zhejiang, Peoples R China.
EM zjtcmcxj@zcmu.edu.cn
RI Yao, Jun/HCI 2731 2022; Cao, Jiawei/JSK 4090 2023; Ni,
   Jianjun/AFW 0120 2022
FU Public Welfare Technology Application Studies Program of Zhejiang
   [2015C33286]; Medicine and Health Care Studies Program of Zhejiang
   [2014KYB039]; Natural Science Foundation of Zhejiang Province
   [Q18H290004, YY18H300008]; Health Science and Technology Program of
   Hangzhou [2015A27]; Talent Training Program of Zhejiang Cancer Hospital
FX This work was supported by the Public Welfare Technology Application
   Studies Program of Zhejiang (NO 2015C33286), the Medicine and Health
   Care Studies Program of Zhejiang (NO 2014KYB039), the Natural Science
   Foundation of Zhejiang Province (NO Q18H290004, NO YY18H300008), the
   Health Science and Technology Program of Hangzhou (NO 2015A27), and The
   Talent Training Program of Zhejiang Cancer Hospital.
CR Adesunloye BA, 2014, CHEM IMMUNOL ALLERGY, V99, P197, DOI 10.1159/000353255
   Biziota E, 2017, CANCER LETT, V400, P243, DOI 10.1016/j.canlet.2016.12.018
   Browder T, 2000, CANCER RES, V60, P1878
   Brown JE, 2004, ENDOCR RELAT CANCER, V11, P207, DOI 10.1677/erc.0.0110207
   Cai XJ, 2015, LAT AM J PHARM, V34, P1239
   Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020
   Caraglia M, 2010, EXPERT OPIN PHARMACO, V11, P141, DOI 10.1517/14656560903485664
   Chen YL, 2017, CANCER LETT, V400, P282, DOI 10.1016/j.canlet.2017.01.040
   Drake MJ, 2003, BRIT J CANCER, V88, P822, DOI 10.1038/sj.bjc.6600817
   Jordan M, 2016, CANCER LETT, V373, P88, DOI 10.1016/j.canlet.2015.11.029
   Kareva I, 2015, CANCER LETT, V358, P100, DOI 10.1016/j.canlet.2014.12.039
   Kerbel RS, 2015, CANCER J, V21, P274, DOI 10.1097/PPO.0000000000000134
   Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829
   Koide H, 2015, NANOMED NANOTECHNOL, V11, P185, DOI 10.1016/j.nano.2014.09.003
   Koide H, 2011, BIOL PHARM BULL, V34, P602, DOI 10.1248/bpb.34.602
   Krzyzanowska MK, 2007, CANCER CHEMOTH PHARM, V60, P135, DOI 10.1007/s00280 006 0347 x
   Lee K, 2009, P NATL ACAD SCI USA, V106, P2353, DOI 10.1073/pnas.0812801106
   Lee MV, 2001, CANCER RES, V61, P2602
   Luo KW, 2013, CANCER LETT, V339, P42, DOI 10.1016/j.canlet.2013.07.024
   Marra M, 2012, BIOTECHNOL ADV, V30, P302, DOI 10.1016/j.biotechadv.2011.06.018
   Marra M, 2011, NANOMED NANOTECHNOL, V7, P955, DOI 10.1016/j.nano.2011.03.004
   Okamoto A, 2016, J CLIN MED, V5, DOI 10.3390/jcm5010010
   Pasquier E, 2010, NAT REV CLIN ONCOL, V7, P455, DOI 10.1038/nrclinonc.2010.82
   Romiti A, 2013, CANCER CHEMOTH PHARM, V72, P13, DOI 10.1007/s00280 013 2125 x
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Shmeeda H, 2013, J CONTROL RELEASE, V167, P265, DOI 10.1016/j.jconrel.2013.02.003
   Zhao XM, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 403
   Zhao XM, 2010, BREAST CANCER RES TR, V124, P733, DOI 10.1007/s10549 010 1183 6
NR 28
TC 0
Z9 0
U1 0
U2 12
PU COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRES
PI LA PLATA
PA DEPT CIENTIFICO, CALLE 5 NO 966, LA PLATA, 00000, ARGENTINA
SN 0326 2383
J9 LAT AM J PHARM
JI Lat. Am. J. Pharm.
PY 2019
VL 38
IS 1
BP 85
EP 91
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HL4YZ
UT WOS:000458733500014
DA 2025 08 17
ER

PT J
AU Madanhire, T
   Ward, KA
   Macdougall, A
   Mohammed, N
   Filteau, S
   Kasonka, L
   Mabuda, HB
   Chisenga, M
   Tang, JAT
   Fraser, WD
   Bandason, T
   Dzavakwa, N
   Simms, V
   Ferrand, RA
   Gregson, CL
AF Madanhire, Tafadzwa
   Ward, Kate A.
   Macdougall, Amy
   Mohammed, Nuredin
   Filteau, Suzanne
   Kasonka, Lackson
   Mabuda, Hilda B.
   Chisenga, Molly
   Tang, Jonathan
   Fraser, William D.
   Bandason, Tsitsi
   Dzavakwa, Nyasha, V
   Simms, Victoria
   Ferrand, Rashida A.
   Gregson, Celia L.
TI The role of vitamin D metabolism in regulating bone turnover in
   adolescents with perinatally acquired HIV in Southern Africa: a
   cross sectional study in Zimbabwe and Zambia
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE HIV; adolescents; vitamin D; parathyroid hormone; Africa
ID DIETARY CALCIUM INTAKE; X RAY ABSORPTIOMETRY; 25 HYDROXYVITAMIN D;
   24,25 DIHYDROXYVITAMIN D; D DEFICIENCY; CHILDREN; QUANTITATION;
   CALIBRATION; MECHANISM; PHANTOM
AB Vitamin D dysregulation can occur in people living with HIV, disrupting calcium homeostasis, and bone turnover. We aimed to investigate the potential mechanisms by which vitamin D regulates bone turnover in adolescents living with perinatally acquired HIV (ALWH) in Southern Africa. A pre planned secondary analysis was performed of baseline data from the vitamin D for adolescents with HIV to reduce musculoskeletal morbidity and immunopathology trial (PACTR20200989766029) which enrolled ALWH (11 19 yr) taking antiretroviral therapy for >= 6 mo, and recorded socio demographic, clinical and dietary data. After over night fasting, vitamin D metabolites (25(OH)D, 1,25(OH)(2)D, and 24,25(OH)(2)D), intact parathyroid hormone (PTH), and bone turnover markers (BTMs) (C terminal telopeptide of type I collagen (CTX) and procollagen type 1 N terminal propeptide (P1NP)) were measured. Tandem Mass Spectrometry measured vitamin D metabolites, while intact PTH and BTMs were analyzed by electrochemiluminescence immunoassay. Stratified by 25(OH)D (<75 vs >= 75 nmol/L), associations between standardized concentrations (beta = standard deviations) of vitamin D metabolites, intact PTH and BTMs were assessed using structural equations modelling (SEM) adjusted for age, sex, and country (Zimbabwe/Zambia). Among the 842 ALWH enrolled, the median dietary calcium intake was 100 mg (IQR: 55 145). The SEM showed PTH was positively associated (beta: 0.21; 95% CI, 0.1, 0.32) with 1,25(OH)(2)D, only when 25(OH)D was <75 vs >= 75 nmol/L (beta: 0.23; 95%CI,  0.13, 0.59), with evidence of an interaction (beta:  0.11; 95%CI,  0.20,  0.02). A positive relationship between 25(OH)D and 24,25(OH)(2)D was seen irrespective of 25(OH)D concentration. 24,25(OH)(2)D was inversely related to BTMs, particularly when 25(OH)D was <75 nmol/L (CTX: beta:  0.15; 95% CI,  0.24,  0.06 and P1NP: beta:  0.14; 95%CI,  0.22,  0.06). There was interaction between dietary calcium and 25(OH)D on PTH (beta:  0.15; 95% CI,  0.22,  0.07) suggesting an interaction between low 25(OH)D and low dietary calcium which increases PTH. In conclusion, associations between 25(OH)D, PTH, 1,25(OH)(2)D, and BTMs in ALWH appear dependent upon 25(OH)D concentrations <75 nmol/L and calcium intake. A novel, potentially causal pathway between 25(OH)D, 24,25(OH)(2)D, and BTMs was seen. Findings enhance understanding of vitamin D metabolism in people living with HIV.
C1 [Madanhire, Tafadzwa; Bandason, Tsitsi; Dzavakwa, Nyasha, V; Simms, Victoria; Ferrand, Rashida A.; Gregson, Celia L.] Hlth Res Unit Zimbabwe, Biomed Res & Training Inst, 8 Ross Ave, Harare, Zimbabwe.
   [Madanhire, Tafadzwa; Macdougall, Amy] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Fac Epidemiol & Populat Hlth, London WC1E 7HT, England.
   [Ward, Kate A.] Univ Southampton, MRC Lifecourse Epidemiol Ctr, Human Dev & Hlth, Southampton SO16 6YD, England.
   [Ward, Kate A.; Mohammed, Nuredin] Gambia London Sch Hyg & Trop Med, Med Res Council Unit, Banjul, Gambia.
   [Mohammed, Nuredin; Dzavakwa, Nyasha, V; Simms, Victoria] London Sch Hyg & Trop Med, MRC Int Stat & Epidemiol Grp, Fac Epidemiol & Populat Hlth, London WC1E 7HT, England.
   [Filteau, Suzanne] London Sch Hyg & Trop Med, Dept Populat Hlth, Fac Epidemiol & Populat Hlth, London WC1E 7HT, England.
   [Kasonka, Lackson; Mabuda, Hilda B.; Chisenga, Molly] Univ Zambia, Univ Teaching Hosp, Box 50110, Lusaka, Zambia.
   [Tang, Jonathan; Fraser, William D.] Univ East Anglia, Norwich Med Sch, Bioanalyt Facil, Norwich Res Pk, Norwich NR4 7UG, England.
   [Tang, Jonathan; Fraser, William D.] Norfolk & Norwich Univ Hosp, Clin Biochem, Diabet & Endocrinol, Norwich NR4 7UY, England.
   [Ferrand, Rashida A.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Clin Res Dept, London WC1E 7HT, England.
   [Gregson, Celia L.] Univ Bristol, Bristol Med Sch, Musculoskeletal Res Unit, Global Musculoskeletal Res Grp, Bristol BS8 1QU, England.
C3 Biomedical Research Training Institute; University of London; London
   School of Hygiene & Tropical Medicine; University of Southampton;
   University of London; London School of Hygiene & Tropical Medicine;
   University of London; London School of Hygiene & Tropical Medicine;
   University of London; London School of Hygiene & Tropical Medicine;
   University of Zambia; University of East Anglia; Norfolk & Norwich
   University Hospitals NHS Foundation Trust; Norfolk & Norwich University
   Hospital; University of London; London School of Hygiene & Tropical
   Medicine; University of Bristol
RP Madanhire, T (通讯作者)，Hlth Res Unit Zimbabwe, Biomed Res & Training Inst, 8 Ross Ave, Harare, Zimbabwe.
EM tafadzwa.madanhire@lshtm.ac.uk; amy.macdougall@lshtm.ac.uk;
   nuredin.mohammed@lshtm.ac.uk; suzanne.filteau@lshtm.ac.uk;
   kasonkalm@gmail.com; hildahk21@yahoo.co.uk; mchisenga04@yahoo.co.uk;
   jonathan.tang@uea.ac.uk; vakoma@gmail.com; victoria.simms@lshtm.ac.uk;
   rashida.ferrand@lshtm.ac.uk; celia.gregson@bristol.ac.uk
RI ; Simms, Victoria/C 3278 2009; Ward, Katherine/HKV 3840 2023; Dzavakwa,
   Nyasha/JVO 6336 2024; Gregson, Celia/AAE 1216 2021; Madanhire,
   Tafadzwa/MIP 6510 2025; Tang, Jonathan/G 3090 2011
OI Madanhire, Tafadzwa/0000 0003 2449 0027; Filteau,
   Suzanne/0000 0002 1119 6825; Gregson, Celia/0000 0001 6414 0529; Tang,
   Jonathan/0000 0001 6305 6333; Ward, Kate/0000 0001 7034 6750
FU European Union [RIA2018CO 2512]; Fogarty International Center of the
   National Institutes of Health [D43TW011326]; National Institute for
   Health and Care Research [NIHR302394]; National Institutes of Health
   Research (NIHR) [NIHR302394] Funding Source: National Institutes of
   Health Research (NIHR)
FX This project is part of the EDCTP2 programme supported by the European
   Union (Grant number RIA2018CO 2512) The research reported in this
   publication was supported by the Fogarty International Center of the
   National Institutes of Health under Award Number D43TW011326 to T.M. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health. CLG is funded by the National Institute for Health and Care
   Research (NIHR302394). The views expressed are those of the authors and
   not necessarily those of the NIHR or the Department of Health and Social
   Care.
CR Agostoni C, 2010, EFSA J, V8, DOI 10.2903/j.efsa.2010.1458
   [Anonymous], 2022, UNAIDS epidemiological estimates
   [Anonymous], CALCIUM Calcium Calculator
   [Anonymous], 2004, Solar Energy, V76
   Balk EM, 2017, OSTEOPOROSIS INT, V28, P3315, DOI 10.1007/s00198 017 4230 x
   Bikle DD, 2014, CHEM BIOL, V21, P319, DOI 10.1016/j.chembiol.2013.12.016
   Carlson RV, 2004, BRIT J CLIN PHARMACO, V57, P695, DOI 10.1111/j.1365 2125.2004.02103.x
   Carmeliet G, 2015, BEST PRACT RES CL EN, V29, P621, DOI 10.1016/j.beem.2015.06.001
   Chasekwa B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199393
   Christakos S, 2016, PHYSIOL REV, V96, P365, DOI 10.1152/physrev.00014.2015
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Cole TJ, 1998, STAT MED, V17, P407, DOI 10.1002/(SICI)1097 0258(19980228)17:4<407::AID SIM742>3.0.CO;2 L
   Crabtree NJ, 2017, J BONE MINER RES, V32, P172, DOI 10.1002/jbmr.2935
   Crabtree NJ, 2014, J CLIN DENSITOM, V17, P225, DOI 10.1016/j.jocd.2014.01.003
   Currò M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207558
   Dibba B, 2000, AM J CLIN NUTR, V71, P544
   DUKE PM, 1980, PEDIATRICS, V66, P918
   Dzavakwa NV, 2024, TRIALS, V25, DOI 10.1186/s13063 024 08342 z
   Fabian J, 2022, LANCET GLOB HEALTH, V10, pE1159, DOI 10.1016/S2214 109X(22)00239 X
   Fux CA, 2008, ANTIVIR THER, V13, P1077
   GENANT HK, 1994, J BONE MINER RES, V9, P1503
   Ginsberg C, 2021, J BONE MINER RES, V36, P2343, DOI 10.1002/jbmr.4426
   HAYCOCK GB, 1978, J PEDIATR US, V93, P62, DOI 10.1016/S0022 3476(78)80601 5
   Joint United Nations Programme on HIV/AIDS, 2023, The path that ends AIDS: UNAIDS Global AIDS Update 2023 [Internet]
   Kaufmann M, 2014, J CLIN ENDOCR METAB, V99, P2567, DOI 10.1210/jc.2013 4388
   Kennedy G., 2011, Guidelines for measuring household and individual dietary diversity
   Kline RB., 2016, Principles and practice of structural equation modeling, VFourth, P534, DOI DOI 10.1016/J.PSYCHRES.2015.07.056
   Kumar J, 2009, PEDIATRICS, V124, pE362, DOI 10.1542/peds.2009 0051
   Mogire RM, 2020, LANCET GLOB HEALTH, V8, pE134, DOI 10.1016/S2214 109X(19)30457 7
   Mostafa WZ, 2015, J ADV RES, V6, P793, DOI 10.1016/j.jare.2014.01.011
   Naska Androniki, 2017, F1000Res, V6, P926, DOI 10.12688/f1000research.10703.1
   National Osteoporosis Foundation, 2016, A Guide to Calcium Rich Foods
   Nguyen HS, 2023, J NUTR, V153, P138, DOI 10.1016/j.tjnut.2022.10.008
   Patel P, 2016, ARCH DIS CHILD, V101, P316, DOI 10.1136/archdischild 2015 308985
   PEARSON J, 1995, OSTEOPOROSIS INT, V5, P174, DOI 10.1007/BF02106097
   Pettifor JM, 2014, ANN NUTR METAB, V64, P15, DOI 10.1159/000365124
   Piloya TW, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253689
   Priemel M, 2010, J BONE MINER RES, V25, P305, DOI 10.1359/jbmr.090728
   Rukuni R, 2021, LANCET CHILD ADOLESC, V5, P569, DOI 10.1016/S2352 4642(21)00133 4
   Rukuni R, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen 2019 031792
   Schermelleh Engel Karin, 2003, Methods Psychol. Res, V8, P23, DOI DOI 10.23668/PSYCHARCHIVES.12784
   Schnitzler CM, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10169
   Seiler J, 2022, J CLIN MED, V11, DOI 10.3390/jcm11216537
   Sellers EAC, 2003, CAN MED ASSOC J, V168, P1141
   Sempos CT, 2021, AM J CLIN NUTR, V114, P231, DOI 10.1093/ajcn/nqab048
   Shlisky J, 2022, ANN NY ACAD SCI, V1512, P10, DOI 10.1111/nyas.14758
   Sirajudeen S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153832
   StataCorp, 2023, Stata Statistical Software: Release 18 StataCorp LLC
   Tang JCY, 2019, Chapter 10 Immunoaffinity Extraction and DAPTAD Derivatisation for LC MS/MS Quantification of Serum 1,25 Dihydroxyvitamin D. Methods for the Measurement of Vitamin D Metabolites and Studies on their Relationships in Health and Dis e ase, p145 162
   Tang JCY, 2017, J NUTR BIOCHEM, V46, P21, DOI 10.1016/j.jnutbio.2017.04.005
NR 50
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD DEC 16
PY 2024
VL 40
IS 1
BP 59
EP 68
DI 10.1093/jbmr/zjae190
EA DEC 2024
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA R1V3L
UT WOS:001380354400001
PM 39566074
DA 2025 08 17
ER

PT J
AU Isensee, G
   Péporté, A
   Müller, J
   Schmid, S
   Gillessen, S
   Omlin, A
AF Isensee, Gesa
   Peporte, Anne
   Mueller, Joachim
   Schmid, Sabine
   Gillessen, Silke
   Omlin, Aurelius
TI Is There a Flare Phenomenon on Bone Scintigraphy in Men With Advanced
   Prostate Cancer Treated With Radium 223?
SO CLINICAL GENITOURINARY CANCER
LA English
DT Article
DE Bone metastases; Flare phenomenon; Radium 223; Targeted alpha therapy;
   Treatment monitoring
ID TRIALS WORKING GROUP; IMAGING BIOMARKER; CLINICAL TRIALS; SCAN INDEX;
   RECOMMENDATIONS; METASTASES; DESIGN
AB Radium 223 is an approved survival prolonging treatment option in men with castration resistant prostate cancer and bone metastases, but data on treatment monitoring by imaging are scarce. We systematically evaluated imaging data of 19 patients treated with radium 223. On bone scintigraphy a flare phenomenon on therapy with radium 223 may be observed; this should be taken into consideration when evaluating men receiving therapy with radium 223.
   Introduction: Radium 223 is an approved survival prolonging treatment option in men with castration resistant prostate cancer (mCRPC) and bone metastases. In the registration trial (ALSYMPCA), no regular imaging was mandated. We aimed to analyze men with metastatic mCRPC treated with radium 223 who had bone scintigraphy for staging and treatment monitoring. Patients and Methods: Retrospective chart review was performed of mCRPC patients who received 6 cycles of radium 223 and who underwent bone scintigraphy before start of radium 223 and after 3 and 6 cycles of treatment. Results: Nineteen patients with a median age of 74 years met the selection criteria and were included in the analysis. On bone scintigraphy, 4 of 19 patients showed a total of >= 2 new lesions after 3 cycles of radium 223 therapy, but 3 of 4 patients did not have >= 2 new lesions after 6 cycles, meeting the criteria for bone scintigraphy flare. Of these 4 patients, 2 received radium 223 before docetaxel therapy, and all 4 had concomitant treatment with denosumab. In the entire cohort, 3 of 19 patients showed soft tissue progression on computed tomography after 3 cycles of radium 223. Conclusion: Bone scintigraphy flare in patients undergoing therapy with radium 223 was observed. Bone scintigraphy data acquired during treatment with radium 223 should be interpreted with caution, and treatment should not be changed according to increase in number of lesions on bone scintigraphy alone after 3 cycles of radium 223. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Isensee, Gesa; Schmid, Sabine; Gillessen, Silke; Omlin, Aurelius] Cantonal Hosp St Gallen, Dept Haematol & Oncol, St Gallen, Switzerland.
   [Peporte, Anne; Mueller, Joachim] Cantonal Hosp St Gallen, Dept Radiol & Nucl Med, St Gallen, Switzerland.
   [Gillessen, Silke; Omlin, Aurelius] Univ Bern, Bern Univ Hosp, Inselspital, Dept Med Oncol, Bern, Switzerland.
C3 Kantonsspital St. Gallen; Kantonsspital St. Gallen; University of Bern;
   University Hospital of Bern
RP Omlin, A (通讯作者)，Kantonsspital St Gallen, Klin Med Onkol & Hamatol, Facharzt Onkol, Rorschacherstr 95, CH 9007 St Gallen, Switzerland.
EM aurelius.omlin@kssg.ch
RI ; Gillessen, Silke/C 6093 2019
OI Schmid, Sabine/0009 0008 8545 9588; Gillessen, Silke/0000 0001 5746 6555
FU Teva; Janssen; BMS; AstraZeneca
FX A.O. discloses advisory role (compensated, institutional): Astellas,
   Bayer, Sanofi, Roche, Janssen, MSD, Molecular Partners; research support
   (institutional): Teva, Janssen; travel support: Astellas, Bayer, Sanofi.
   J. M. discloses advisory role (compensated, institutional): Bayer;
   Travel support: GE, Bayer. S. G. discloses advisory boards/IDMC
   (compensated): AAA International, Active Biotech AB IDMC, Astellas
   Pharma, Bayer, Bristol Myers Squibb, Clovis, Curevac, Dendreon
   Corporation, Ferring, Innocrin Pharmaceuticals, Janssen Cilag, MaxiVAX
   SA, Millennium Pharmaceuticals, Orion, Roche, Sanofi Aventis Group;
   advisory boards (uncompensated): Astellas Pharma, Bayer, ESSA
   Pharmaceuticals Corp, Nectar, ProteoMediX, Sanofi; speakers bureau
   (compensated), Janssen, Novartis; speakers bureau (uncompensated):
   Astellas Pharma, Janssen, Sanofi Aventis Group; and pending patent
   application for a method for biomarker WO 2009138392 A1. S. S. discloses
   advisory role (compensated, institutional): Boehringer Ingelheim;
   research support (institutional): BMS, AstraZeneca. The other authors
   have stated that they have no conflict of interest.
CR Anand A, 2016, EJNMMI RES, V6, DOI 10.1186/s13550 016 0173 z
   Anand A, 2016, J NUCL MED, V57, P41, DOI 10.2967/jnumed.115.160085
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   Keizman D, 2017, PROSTATE CANCER P D, V20, P289, DOI 10.1038/pcan.2017.6
   Messiou C, 2011, ACTA RADIOL, V52, P557, DOI 10.1258/ar.2011.100342
   Morris MJ, 2013, SEMIN ONCOL, V40, P375, DOI 10.1053/j.seminoncol.2013.04.008
   Pacilio M, 2016, EUR J NUCL MED MOL I, V43, P21, DOI 10.1007/s00259 015 3150 2
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Ryan CJ, 2011, CLIN CANCER RES, V17, P4854, DOI 10.1158/1078 0432.CCR 11 0815
   Sartor O, 2017, ANN ONCOL, V28, P2464, DOI 10.1093/annonc/mdx331
   Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487
   Scher HI, 2016, J CLIN ONCOL, V34, P1402, DOI 10.1200/JCO.2015.64.2702
NR 12
TC 11
Z9 11
U1 0
U2 4
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219 3931 USA
SN 1558 7673
EI 1938 0682
J9 CLIN GENITOURIN CANC
JI Clin. Genitourin. Cancer
PD OCT
PY 2018
VL 16
IS 5
BP 349
EP 354
DI 10.1016/j.clgc.2018.04.002
PG 6
WC Oncology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Urology & Nephrology
GA GV7UP
UT WOS:000446339100019
PM 29778323
DA 2025 08 17
ER

PT J
AU Liu, M
   Meng, Y
   He, KR
   Luan, CL
AF Liu, Man
   Meng, Yao
   He, Keren
   Luan, Chonglin
TI Hsa _circ_0002060 Knockdown Ameliorates Osteoporosis by Targeting
   MiR 198 5p
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE osteoporosis; hsa_circ_0002060; miR 198 5p
ID PATHWAY
AB Osteoporosis (OP) is increasingly becoming one of a major health concerns all over the world. However, the limitations of current therapeutic drugs for OP are including considerable side effects and low efficacy. Therefore, it is required to develop new therapeutic drugs for OP. This study aimed to investigate the role of hsa_circ_0002060 in the regulation of osteoporosis. Osteoblast cells (hFOB 1.19) were transfected with hsa_circ_0002060 small interfering RNA (siRNA), following by stimulated with dexamethasone (DEX) to mimic OP in vitro. Cell counting kit 8, apoptosis, and JC 1 mitochondria) membrane potential assays were used to evaluate the cell viability, apoptosis, and mitochondrial membrane potential, respectively. Western blot was conducted to detect the expression of proteins. In addition, the levels of reactive oxygen species, superoxide dismutase, glutathione and malondialdehyde were measured with enzyme linked immunosorbent assay (ELISA). The putative target of hsa_circ_0002060 was verified by dual luciferase reporter assay and RNA pull down. At last, the role of hsa_circ_0002060 in the progression of OP was investigated with an ovariectomy (OVX) induced OP mouse model. The results indicated DEX could induce cell viability decline in hFOB 1.19 cells, which was ameliorated by hsa_circ_0002060 knockdown. Consistently, DEX induced cell apoptosis of hFOB 1.19 was ameliorated by hsa_circ_0002060 knockdown as well. As for the underlying mechanisms study, hsa_circ_0002060 was proved to regulate the viability of hFOB 1.19 cells through targeting miR 198 5p/Bax axis. Additionally, hsa_circ_0002060 knockdown alleviated ovariectomy induced OP in a mouse model. Taken together, hsa_circ_0002060 knockdown alleviated the progression of OP by targeting miR 198 5p. Hsa_circ_0002060 might possibly be served as a therapeutic target for treating OP.
C1 [Liu, Man; He, Keren] Shenzhen Polytech, Sch Med Technol & Nursing, Shenzhen 508055, Guangdong, Peoples R China.
   [Meng, Yao] Shenzhen Childrens Hosp, Orthodont Ctr, Shenzhen 518026, Guangdong, Peoples R China.
   [Luan, Chonglin] Shenzhen Polytech, Chem Coll, Shenzhen 508055, Guangdong, Peoples R China.
C3 Shenzhen Polytechnic University; Shenzhen Children's Hospital; Shenzhen
   Polytechnic University
RP He, KR (通讯作者)，Shenzhen Polytech, Sch Med Technol & Nursing, Shenzhen 508055, Guangdong, Peoples R China.
EM szpt2016@126.com
FU Key Basic Research Project of Shenzhen Polytechnic [6019310002 K];
   Project of Science and Technology Plan of Shenzhen
   [JCYJ20180228164957104]
FX This study was supported by the funding of Key Basic Research Project of
   Shenzhen Polytechnic (#6019310002 K) and Project of Science and
   Technology Plan of Shenzhen (#JCYJ20180228164957104).
CR Chen LR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092213
   Fan J, 2016, CELL PHYSIOL BIOCHEM, V38, P1063, DOI 10.1159/000443057
   Gomes Clarissa P C, 2018, Noncoding RNA Res, V3, P1, DOI 10.1016/j.ncrna.2018.02.002
   Guo C, 2014, INFLAMMATION, V37, P621, DOI 10.1007/s10753 013 9778 9
   Hua X, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109233
   Huang YP, 2019, J CELL BIOCHEM, V120, P15688, DOI 10.1002/jcb.28838
   Jiang WD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220118
   Liu S, 2019, THERIOGENOLOGY, V131, P89, DOI 10.1016/j.theriogenology.2019.03.023
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Zhu LJ, 2018, BIOMED PHARMACOTHER, V103, P499, DOI 10.1016/j.biopha.2018.04.073
NR 10
TC 4
Z9 7
U1 0
U2 5
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 0918 6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD JAN
PY 2021
VL 44
IS 1
BP 88
EP 95
DI 10.1248/bpb.b20 00643
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA QL0VB
UT WOS:000620798500014
PM 33148890
OA gold
DA 2025 08 17
ER

PT J
AU Di, GJ
   Kong, LL
   Zhao, Q
   Ding, T
AF Di, Guijuan
   Kong, Lingli
   Zhao, Qing
   Ding, Tao
TI MicroRNA 146a knockdown suppresses the progression of ankylosing
   spondylitis by targeting dickkopf 1
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Ankylosing spondylitis; miR 146a; Dickkopf 1; Proliferation;
   Osteogenesis; Apoptosis
ID IN VITRO; PROLIFERATION; FIBROBLASTS; CELLS; DIFFERENTIATION;
   EXPRESSION; OSTEOBLAST; APOPTOSIS; ARTHRITIS
AB Ankylosing spondylitis (AS) seriously threatens healthy and life quality of patients, however, there is no extremely effective drug to cure the disease. Therefore, it is urgent to understand molecular basis in the progression of AS. MicroRNA 146a (miR 146a) has been demonstrated to be associated with the development of AS. However, its molecular mechanism has not been fully established. In this study, it is found that the expression levels of miR 146a and dickkopf 1 (DKK1) were respectively upregulated and downregulated in hip capsule tissues of AS patients. Moreover, a negative correlation was displayed between miR 146a and DKK1 expression. Functional analysis revealed that miR 146a inhibitor restrained cell proliferation and osteogenic potential as well as enhanced apoptosis in AS fibroblasts, while miR 146a overexpression enhanced proliferation and osteogenic potential of AS fibroblasts. Bioinformatics analysis, dual luciferase reporter assays, qRT PCR and im munoblotting assays revealed that miR 146a inhibited DKK1 expression by directly targeting 3' UTR region of DKK1. Mechanism studies further revealed that loss of DKK1 partly reversed the effect of miR 146a inhibitor on cell proliferation, apoptosis and osteogenic potential in AS fibroblasts. Taken together, our finding revealed that miR 146a knockdown hindered AS progression partially by regulating target DKK1 expression, offering a potential therapy application for AS patients.
C1 [Di, Guijuan; Kong, Lingli; Zhao, Qing] Henan Univ, Huaihe Hosp, Dept Rheumatol & Immunol, 115 Ximen St, Kaifeng 475000, Peoples R China.
   [Ding, Tao] Henan Univ, Huaihe Hosp, Dept Anesthesiol, Kaifeng 475000, Peoples R China.
C3 Henan University; Henan University
RP Di, GJ (通讯作者)，Henan Univ, Huaihe Hosp, Dept Rheumatol & Immunol, 115 Ximen St, Kaifeng 475000, Peoples R China.
EM diguijuanvst@sina.com
RI Ding, Tao/GQH 6632 2022
CR Alenzi FQB, 2004, BRIT J BIOMED SCI, V61, P99, DOI 10.1080/09674845.2004.11732652
   Bakland G, 2011, ANN RHEUM DIS, V70, P1921, DOI 10.1136/ard.2011.151191
   Braun J, 2010, ANN RHEUM DIS, V2011, P896, DOI DOI 10.1093/RHEUMATOLOGY/KES066
   Braun J, 2007, LANCET, V369, P1379, DOI 10.1016/S0140 6736(07)60635 7
   Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097 4644(199702)64:2<278::AID JCB11>3.0.CO;2 F
   CARETTE S, 1983, ARTHRITIS RHEUM US, V26, P186, DOI 10.1002/art.1780260210
   Chen L, 2017, ANN RHEUM DIS, V76, P620, DOI 10.1136/annrheumdis 2016 210175
   Daoussis D, 2010, ARTHRITIS RHEUM US, V62, P150, DOI 10.1002/art.27231
   Deodhar AA, 2016, ARTHRITIS RHEUMATOL, V68, P2901, DOI 10.1002/art.39805
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Elshishtawy H, 2012, EGYPT RHEUMATOL, V34, P111, DOI 10.1016/j.ejr.2012.05.002
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955 0674(99)00046 0
   Haynes K. R., ARTHRITIS RES THER, V14
   Heiland GR, 2012, ANN RHEUM DIS, V71, P572, DOI 10.1136/annrheumdis 2011 200216
   Hematti P, 2012, CYTOTHERAPY, V14, P516, DOI 10.3109/14653249.2012.677822
   Li Z, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003325
   Lories RJ, 2010, RHEUMATOLOGY, V49, P617, DOI 10.1093/rheumatology/kep365
   Nakasa T, 2011, ARTHRITIS RHEUM US, V63, P1582, DOI 10.1002/art.30321
   Niu Z., PLOS ONE, V10
   Qian BP, 2016, SPINE, V41, P735, DOI 10.1097/BRS.0000000000001339
   Rusca Nicole, 2011, Mol Biol Int, V2011, P437301, DOI 10.4061/2011/437301
   Rutherford RB, 2002, TISSUE ENG, V8, P441, DOI 10.1089/107632702760184709
   Saferding V, 2017, J AUTOIMMUN, V82, P74, DOI 10.1016/j.jaut.2017.05.006
   Shah AA, 2010, J APPL GENET, V51, P501, DOI 10.1007/BF03208880
   Sieper J, 2008, ARTHRITIS RHEUM US, V58, P649, DOI 10.1002/art.23260
   Uderhardt S, 2010, ANN RHEUM DIS, V69, P592, DOI 10.1136/ard.2008.102046
   Vaes BLT, 2010, BONE, V46, P514, DOI 10.1016/j.bone.2009.09.033
   Wanders A, 2005, ANN RHEUM DIS, V64, P988, DOI 10.1136/ard.2004.029728
   Xu HM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124425
   Zou YC, 2016, CONNECT TISSUE RES, V57, P200, DOI 10.3109/03008207.2015.1127916
   Zou YC, 2016, DRUG DES DEV THER, V10, P933, DOI 10.2147/DDDT.S97463
   Zou YC, 2014, CLIN LAB, V60, P1527, DOI 10.7754/Clin.Lab.2014.131119
NR 33
TC 27
Z9 28
U1 0
U2 10
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JAN
PY 2018
VL 97
BP 1243
EP 1249
DI 10.1016/j.biopha.2017.11.067
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FR4NC
UT WOS:000419041300150
PM 29145150
DA 2025 08 17
ER

PT J
AU Zhang, LZ
   Wang, T
   Chang, M
   Kaiser, C
   Kim, JD
   Wu, TY
   Cao, XY
   Zhang, XP
   Schwarz, EM
AF Zhang, Longze
   Wang, Tao
   Chang, Martin
   Kaiser, Claire
   Kim, Jason D.
   Wu, Tianyu
   Cao, Xiaoyi
   Zhang, Xinping
   Schwarz, Edward M.
TI Teriparatide Treatment Improves Bone Defect Healing Via Anabolic Effects
   on New Bone Formation and Non Anabolic Effects on Inhibition of Mast
   Cells in a Murine Cranial Window Model
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE GENETIC ANIMAL MODELS; INJURY/FRACTURE HEALING; ORTHOPAEDICS;
   OSTEOIMMUNOLOGY; BONE INTERACTORS; ANABOLICS; THERAPEUTICS; PTH; VITAMIN
   D; FGF23; CELL/TISSUE SIGNALING
ID MESENCHYMAL STEM CELLS; ANGIOGENESIS; ARTERIOGENESIS; PTH;
   DIFFERENTIATION; OSTEOGENESIS; INTEGRATION; PERIOSTEUM; FRACTURES;
   RECEPTOR
AB Investigations of teriparatide (recombinant parathyroid hormone [rPTH]) as a potential treatment for critical defects have demonstrated the predicted anabolic effects on bone formation, and significant non anabolic effects on healing via undefined mechanisms. Specifically, studies in murine models of structural allograft healing demonstrated that rPTH treatment increased angiogenesis (vessels <30 mu m), and decreased arteriogenesis (>30 mu m) and mast cell numbers, which lead to decreased fibrosis and accelerated healing. To better understand these non anabolic effects, we interrogated osteogenesis, vasculogenesis, and mast cell accumulation in mice randomized to placebo (saline), rPTH (20 mu g/kg/2 days), or the mast cell inhibitor sodium cromolyn (SC) (24 mu g/kg/2days), via longitudinal micro computed tomography (mu CT) and multiphoton laser scanning microscopy (MPLSM), in a critical calvaria defect model. mCT demonstrated that SC significantly increased defect window closure and new bone volume versus placebo (p<0.05), although these effects were not as great as rPTH. Interestingly, both rPTH and SC have similar inhibitory effects on arteriogenesis versus placebo (p<0.05) without affecting total vascular volume. MPLSM time course studies in untreated mice revealed that large numbers of mast cells were detected 1 day postoperation (43 +/  17), peaked at 6 days (76 +/  6), and were still present in the critical defect at the end of the experiment on day 30 (20 +/  12). In contrast, angiogenesis was not observed until day 4, and functional vessels were first observed on 6 days, demonstrating that mast cell accumulation precedes vasculogenesis. To confirm a direct role of mast cells on osteogenesis and vasculogenesis, we demonstrated that specific diphtheria toxin alpha deletion in Mcpt5 Cre iDTR mice results in similar affects as SC treatment in WT mice. Collectively, these findings demonstrate that mast cells inhibit bone defect healing by stimulating arteriogenesis associated with fibrotic scaring, and that an efficacious non anabolic effect of rPTH therapy on bone repair is suppression of arteriogenesis and fibrosis secondary to mast cell inhibition. (C) 2017 American Society for Bone and Mineral Research.
C1 [Zhang, Longze; Wang, Tao; Chang, Martin; Kaiser, Claire; Kim, Jason D.; Wu, Tianyu; Cao, Xiaoyi; Zhang, Xinping; Schwarz, Edward M.] Univ Rochester, Sch Med & Dent, Ctr Musculoskeletal Res, Rochester, NY USA.
   [Zhang, Longze; Wang, Tao; Chang, Martin; Zhang, Xinping; Schwarz, Edward M.] Univ Rochester, Sch Med & Dent, Dept Orthopaed, Rochester, NY USA.
   [Kaiser, Claire; Schwarz, Edward M.] Univ Rochester, Sch Med & Dent, Dept Biomed Engn, Rochester, NY USA.
C3 University of Rochester; University of Rochester; University of
   Rochester
RP Schwarz, EM (通讯作者)，Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, 601 Elmwood Ave,Box 665, Rochester, NY 14642 USA.
EM Edward_Schwarz@URMC.Rochester.edu
RI ; Cao, XiaoYi/H 1548 2017
OI Wu, Tianyu/0000 0002 7341 2781; Wang, Tao/0000 0002 4574 4260; Schwarz,
   Edward/0000 0002 4854 9698
FU NIH [R01 DE019902, R01AR067859, R21DE026256, P30 AR069655, P50AR054041,
   1S10RR027340, T32AR53459]
FX This research was funded by grants from the NIH (R01 DE019902,
   R01AR067859, R21DE026256, P30 AR069655, P50AR054041, 1S10RR027340, and
   T32AR53459). The teriparatide used in this study was a gift from Lilly
   Inc. We thank Michael Thullen for technical assistance with mu CT, and
   Sarah Mack and Karen de Mesy Bentley for technical assistance with
   histology.
CR Alford AI, 2013, CONNECT TISSUE RES, V54, P275, DOI 10.3109/03008207.2013.811236
   Antebi Ben, 2016, Bioengineering Basel, V3, P6, DOI 10.3390/bioengineering3010006
   Ashmole I, 2013, CLIN EXP ALLERGY, V43, P491, DOI 10.1111/cea.12043
   Aspenberg P, 2010, ACTA ORTHOP, V81, P236, DOI 10.3109/17453671003761946
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Bae ON, 2013, ARTERIOSCL THROM VAS, V33, P1920, DOI 10.1161/ATVBAHA.113.301609
   BANOVAC K, 1995, J ORTHOP TRAUMA, V9, P482, DOI 10.1097/00005131 199509060 00005
   Bashutski JD, 2010, NEW ENGL J MED, V363, P2396, DOI 10.1056/NEJMoa1005361
   Behzad H, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4374
   Bragdon B, 2017, BONE, V101, P49, DOI 10.1016/j.bone.2017.04.002
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Carvalho RS, 2004, BONE, V34, P849, DOI 10.1016/j.bone.2003.12.027
   Chillo O, 2016, CELL REP, V16, P2197, DOI 10.1016/j.celrep.2016.07.040
   Choudhary S, 2008, BIOCHEM BIOPH RES CO, V372, P536, DOI 10.1016/j.bbrc.2008.05.050
   Dhillon RS, 2013, J BONE MINER RES, V28, P586, DOI 10.1002/jbmr.1765
   Dhillon RS, 2011, MATERIALS, V4, P1117, DOI 10.3390/ma4061117
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Farina G, 2010, ARTHRITIS RHEUM US, V62, P580, DOI 10.1002/art.27220
   Ferguson MWJ, 2004, PHILOS T R SOC B, V359, P839, DOI 10.1098/rstb.2004.1475
   Gailit J, 2001, J INVEST DERMATOL, V117, P1113, DOI 10.1046/j.1523 1747.2001.15211.x
   Heil M, 2006, J CELL MOL MED, V10, P45, DOI 10.1111/j.1582 4934.2006.tb00290.x
   Holdsworth SR, 2008, J AM SOC NEPHROL, V19, P2254, DOI 10.1681/ASN.2008010015
   Huang CL, 2015, J BONE MINER RES, V30, P1217, DOI 10.1002/jbmr.2460
   Hügle T, 2014, SWISS MED WKLY, V144, DOI 10.4414/smw.2014.13999
   Ito H, 2005, NAT MED, V11, P291, DOI 10.1038/nm1190
   Kennedy LL, 2014, LAB INVEST, V94, P1406, DOI 10.1038/labinvest.2014.129
   LINDHOLM R, 1967, ACTA ORTHOP SCAND, V38, P115, DOI 10.3109/17453676708989624
   Long T, 2014, BIOMATERIALS, V35, P2752, DOI 10.1016/j.biomaterials.2013.12.039
   Mahoney JM, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004005
   Manley E, 2015, J APPL PHYSIOL, V119, P872, DOI 10.1152/japplphysiol.00340.2015
   Molina CS, 2014, JBJS REV, V2, DOI 10.2106/JBJS.RVW.M.00062
   Morgan EF, 2012, BONE, V51, P535, DOI 10.1016/j.bone.2012.05.008
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Norrby K, 2002, APMIS, V110, P355, DOI 10.1034/j.1600 0463.2002.100501.x
   Ohishi M, 2011, J ENDOCRINOL INVEST, V34, P552, DOI 10.3275/7620
   PEARSON ME, 1988, ARTHRITIS RHEUM US, V31, P672, DOI 10.1002/art.1780310514
   Peichl P, 2011, J BONE JOINT SURG AM, V93A, P1583, DOI 10.2106/JBJS.J.01379
   Puxeddu I, 2003, INT J BIOCHEM CELL B, V35, P1601, DOI 10.1016/S1357 2725(03)00208 5
   Reynolds DG, 2007, J BIOMECH, V40, P3178, DOI 10.1016/j.jbiomech.2007.04.004
   Reynolds DG, 2011, BONE, V48, P562, DOI 10.1016/j.bone.2010.10.003
   Reynolds DG, 2009, J BONE MINER RES, V24, P899, DOI 10.1359/JBMR.081232
   Ribatti D, 2012, BBA MOL BASIS DIS, V1822, P2, DOI 10.1016/j.bbadis.2010.11.010
   Rubery PT, 2010, J SPINAL DISORD TECH, V23, P151, DOI 10.1097/BSD.0b013e31819a8b7a
   Saito M, 2001, NAT BIOTECHNOL, V19, P746, DOI 10.1038/90795
   Scholten J, 2008, TRANSGENIC RES, V17, P307, DOI 10.1007/s11248 007 9153 4
   Scholz D, 2002, J MOL CELL CARDIOL, V34, P775, DOI 10.1006/jmcc.2002.2013
   Scott A, 2008, BRIT J SPORT MED, V42, P753, DOI 10.1136/bjsm.2007.040212
   Segev O, 2004, BONE, V34, P246, DOI 10.1016/j.bone.2003.10.003
   Sheyn D, 2016, MOL THER, V24, P318, DOI 10.1038/mt.2015.211
   Sheyn D, 2013, MOL PHARMACEUT, V10, P4462, DOI 10.1021/mp400292p
   Shireman PK, 2007, J VASC SURG, V45, p48A, DOI 10.1016/j.jvs.2007.02.030
   TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689
   Tang GL, 2005, J VASC SURG, V41, P312, DOI 10.1016/j.jvs.2004.11.012
   Tiyapatanaputi P, 2004, J ORTHOP RES, V22, P1254, DOI 10.1016/j.orthres.2004.03.017
   Ud Din S, 2014, EXP DERMATOL, V23, P615, DOI 10.1111/exd.12457
   Veerappan A, 2013, DNA CELL BIOL, V32, P206, DOI 10.1089/dna.2013.2005
   Wang XD, 2006, CELL, V127, P803, DOI 10.1016/j.cell.2006.09.043
   Wygrecka M, 2013, AM J PATHOL, V182, P2094, DOI 10.1016/j.ajpath.2013.02.013
   Xie C, 2008, J BONE JOINT SURG AM, V90A, P9, DOI 10.2106/JBJS.G.01212
   Xie C, 2007, TISSUE ENG, V13, P435, DOI 10.1089/ten.2006.0182
   Yan L, 2016, AM J RESP CRIT CARE, V193, P898, DOI 10.1164/rccm.201502 0407OC
   Yokota M, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4512
   Yu B, 2012, J BONE MINER RES, V27, P2001, DOI 10.1002/jbmr.1663
   Yu M, 2010, CURR GENOMICS, V11, P287, DOI 10.2174/138920210791233117
   Zhang XP, 2008, CLIN ORTHOP RELAT R, V466, P1777, DOI 10.1007/s11999 008 0312 6
   Zhang XP, 2005, J BONE MINER RES, V20, P2124, DOI 10.1359/JBMR.050806
NR 66
TC 27
Z9 28
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD SEP
PY 2017
VL 32
IS 9
BP 1870
EP 1883
DI 10.1002/jbmr.3178
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FD6ZH
UT WOS:000407675900011
PM 28556967
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Rapp, AE
   Hachemi, Y
   Kemmler, J
   Koenen, M
   Tuckermann, J
   Ignatius, A
AF Rapp, Anna E.
   Hachemi, Yasmine
   Kemmler, Julia
   Koenen, Mascha
   Tuckermann, Jan
   Ignatius, Anita
TI Induced global deletion of glucocorticoid receptor impairs fracture
   healing
SO FASEB JOURNAL
LA English
DT Article
DE inflammation; knockout mice; steroids; bone repair; endochondral
   ossification
ID OSTEOBLAST TARGETED DISRUPTION; T CELLS; BONE; MICE; DIFFERENTIATION;
   THERAPY; INFLAMMATION; DIMERIZATION; MACROPHAGES; SUPPRESSION
AB Although endogenous glucocorticoids (GCs) are important regulators of bone integrity and the immune system, their role in bone repair after fracture a process highly dependent on inflammation and bone formationis unclear. Because most effects of GCs are mediated by the glucocorticoid receptor (GR), we used an inducible global GR knockout (GR(gtROSACreERT2)) mouse model to eliminate endogenous GC action in all cells contributing to bone repair. The healing process was analyzed by cytokine/chemokine multiplex analysis, flow cytometry, histology, gene expression analysis, microcomputed tomography, and biomechanical analysis. We observed increased early systemic and local inflammatory responses, as well as a significantly higher number of T cells infiltrating the fracture callus. Later in the healing process, we found impaired endochondral ossification in the absence of the GR, leading to persistent cartilage in the calli of the GR(gtROSACreERT2) mice, decreased bending stiffness, and a significantly lower proportion of healed bones. Collectively, our data show that the absence of the GR significantly impairs fracture healing associated with a defective cartilage to bone transition, underscoring an important role of GCs during fracture healing.
C1 [Rapp, Anna E.; Kemmler, Julia; Ignatius, Anita] Ulm Univ, Med Ctr, Ctr Trauma Res Ulm, Inst Orthopaed Res & Biomech, Helmholtzstr 14, D 89081 Ulm, Germany.
   [Hachemi, Yasmine; Koenen, Mascha; Tuckermann, Jan] Ulm Univ, Inst Comparat Mol Endocrinol, Helmholtzstrasse 8 1,Room 3 34, D 89081 Ulm, Germany.
C3 Ulm University; Ulm University
RP Ignatius, A (通讯作者)，Ulm Univ, Med Ctr, Ctr Trauma Res Ulm, Inst Orthopaed Res & Biomech, Helmholtzstr 14, D 89081 Ulm, Germany.; Tuckermann, J (通讯作者)，Ulm Univ, Inst Comparat Mol Endocrinol, Helmholtzstrasse 8 1,Room 3 34, D 89081 Ulm, Germany.
EM jan.tuckermann@uni ulm.de; anita.ignatius@uni ulm.de
RI Rapp, Anna/L 8807 2016; Hachemi, Yasmine/LZG 4846 2025; Rapp, Anna
   Elise/L 8807 2016; Ignatius, Anita/M 6012 2013; Koenen,
   Mascha/GWZ 9700 2022
OI Rapp, Anna Elise/0000 0001 5122 765X; Koenen, Mascha/0000 0002 1024 4506
FU German Research Foundation in the Collaborative Research Centre 1149
   Study, Danger Response, Disturbance Factors, and Regenerative Potential
   after Acute Trauma [CRC 1149, C02/INST 40/492 1]
FX The authors thank G. Strauss (Department of Pediatrics and Adolescent
   Medicine, Ulm University Medical Center) for the use of the
   fluorescence activated cell sorting facility and her support. The
   authors acknowledge the excellent technical assistance of N. Mobius
   (Institute of Comparative Molecular Endocrinology, Ulm University), I.
   Baum, S. Schroth, U. Maile, and M. Tomo (Institute of Orthopaedic
   Research and Biomechanics, Ulm University Medical Centre). This work was
   financed by the German Research Foundation in the context of the
   Collaborative Research Centre 1149 Study, Danger Response, Disturbance
   Factors, and Regenerative Potential after Acute Trauma (CRC 1149,
   C02/INST 40/492 1). The authors declare no conflicts of interest.
CR Aslan M, 2005, DENT TRAUMATOL, V21, P222, DOI 10.1111/j.1600 9657.2005.00300.x
   Baschant U, 2011, P NATL ACAD SCI USA, V108, P19317, DOI 10.1073/pnas.1105857108
   Baschant U, 2010, J STEROID BIOCHEM, V120, P69, DOI 10.1016/j.jsbmb.2010.03.058
   Cárcamo Orive I, 2010, J BONE MINER RES, V25, P2115, DOI 10.1002/jbmr.120
   Conaway HH, 2016, BONE, V93, P43, DOI 10.1016/j.bone.2016.08.024
   Coutinho AE, 2012, ENDOCRINOLOGY, V153, P234, DOI 10.1210/en.2011 1398
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dunn AJ, 2000, ANN NY ACAD SCI, V917, P608, DOI 10.1111/j.1749 6632.2000.tb05426.x
   Frenkel B, 2015, ADV EXP MED BIOL, V872, P179, DOI 10.1007/978 1 4939 2895 8_8
   Hartmann K, 2016, PHYSIOL REV, V96, P409, DOI 10.1152/physrev.00011.2015
   Hubner Sabine, 2012, Biomol Concepts, V3, P241, DOI 10.1515/bmc 2011 0033
   Hübner S, 2015, BIOL CHEM, V396, P1223, DOI 10.1515/hsz 2015 0106
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Kalak R, 2009, BONE, V45, P61, DOI 10.1016/j.bone.2009.03.673
   Kleiman A, 2012, FASEB J, V26, P722, DOI 10.1096/fj.11 192112
   Koetz KR, 2012, J CLIN ENDOCR METAB, V97, P85, DOI 10.1210/jc.2011 2036
   Li J, 2012, INJURY, V43, P1284, DOI 10.1016/j.injury.2012.04.014
   Lim HW, 2015, GENOME RES, V25, P836, DOI 10.1101/gr.188581.114
   Maes C, 2013, CALCIFIED TISSUE INT, V92, P307, DOI 10.1007/s00223 012 9689 z
   Morgan EF, 2009, BONE, V44, P335, DOI 10.1016/j.bone.2008.10.039
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Piemontese M, 2016, AM J PHYSIOL ENDOC M, V311, pE587, DOI 10.1152/ajpendo.00219.2016
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Röntgen V, 2010, J ORTHOP RES, V28, P1456, DOI 10.1002/jor.21148
   Sher LB, 2006, CALCIFIED TISSUE INT, V79, P118, DOI 10.1007/s00223 005 0297 z
   Sher LB, 2004, ENDOCRINOLOGY, V145, P922, DOI 10.1210/en.2003 0655
   Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703
   Tronche F, 1998, CURR OPIN GENET DEV, V8, P532, DOI 10.1016/S0959 437X(98)80007 5
   Tu JW, 2014, BONE, V69, P12, DOI 10.1016/j.bone.2014.08.016
   Tuckermann JP, 2007, J CLIN INVEST, V117, P1381, DOI 10.1172/JCI28034
   Vandevyver S, 2012, J CLIN INVEST, V122, P2130, DOI 10.1172/JCI60006
   Waters RV, 2000, ACTA ORTHOP SCAND, V71, P316, DOI 10.1080/000164700317411951
   Weber AJ, 2010, STEROIDS, V75, P282, DOI 10.1016/j.steroids.2010.01.005
   Wüst S, 2008, J IMMUNOL, V180, P8434, DOI 10.4049/jimmunol.180.12.8434
   Zhou H, 2008, J BIOL CHEM, V283, P1936, DOI 10.1074/jbc.M702687200
   Zhou H, 2009, DEVELOPMENT, V136, P427, DOI 10.1242/dev.027706
NR 36
TC 25
Z9 27
U1 1
U2 4
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2018
VL 32
IS 4
BP 2235
EP 2245
DI 10.1096/fj.201700459RR
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA GB4SP
UT WOS:000429051400041
PM 29217668
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU McQueen, FM
   Issa, S
AF McQueen, Fiona M.
   Issa, Samar
TI Is rheumatoid arthritis a B cell haematological disease with a
   predilection for the joints? Following the B cell thread to its logical
   conclusion
SO MEDICAL HYPOTHESES
LA English
DT Article
ID BONE MARROW EDEMA; CITRULLINATED VIMENTIN; MULTIPLE MYELOMA; MRI BONE;
   RITUXIMAB; AUTOANTIBODIES; PATHOGENESIS; ANTIBODIES; LYMPHOMA;
   PROGRESSION
AB B cell depleting therapy (BCDT) is effective in suppressing synovitis and erosions in rheumatoid arthritis suggesting that a cell of the B lymphocyte lineage is critical in the pathogenesis of this disease. Non Hodgkins lymphoma (NHL) also responds to BCDT but multiple myeloma (MM), does not as cells have differentiated beyond the CD20 bearing stage. However, there are similarities between B NHL, MM and RA that suggest all 3 conditions could be initiated and perpetuated by the same cellular players. Numerous plasma cells and B cells are present within rheumatoid synovial membrane, and subarticular bone where they contribute to osteitis. On MRI scans this appears as bone oedema, which has been demonstrated to precede the development of bone erosions. Plasma cell clonality has been detected within RA synovial membrane and bone marrow. It is proposed that RA could represent a "forme fruste" of a B cell neoplastic condition, with production of autoantibodies that target a self antigen within the joint. The activation of rheumatoid bone osteoclasts by anticitrullinated protein antibodies supports this theory. The erosions of RA would have parallels with the lytic lesions of MM but autoantigen targeting dictates that erosions occur at joint margins. This theory is discussed from rheumatologic and haematologic perspectives. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [McQueen, Fiona M.] Univ Auckland, Dept Mol Med & Pathol, FMHS, Auckland 1, New Zealand.
   Middlemore Hosp, Dept Haematol, Counties Manakau Dist Hlth Board, Auckland 6, New Zealand.
C3 University of Auckland
RP McQueen, FM (通讯作者)，Univ Auckland, Dept Mol Med & Pathol, FMHS, Auckland 1, New Zealand.
EM f.mcqueen@auckland.ac.nz
OI Issa, Samar/0009 0008 2534 3428
FU Auckland Medical Research Foundation
FX Support: Auckland Medical Research Foundation.
CR Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933
   Avet Loiseau H, 2011, J CLIN ONCOL, V29, P1893, DOI 10.1200/JCO.2010.32.8435
   Bugatti S, 2012, ARTHRITIS RES THER, V27, P229
   BURNET FM, 1972, AUST J EXP BIOL MED, V50, P1, DOI 10.1038/icb.1972.1
   Dalbeth N, 2009, ANN RHEUM DIS, V68, P279, DOI 10.1136/ard.2008.096024
   Dias C, 2011, NAT REV RHEUMATOL, V7, P360, DOI 10.1038/nrrheum.2011.62
   Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534
   Engels K, 2007, HUM PATHOL, V38, P1402, DOI 10.1016/j.humpath.2007.02.009
   Ezealah E, 2012, ARTHRITIS RHEUM, P42
   Haavardsholm EA, 2008, ANN RHEUM DIS, V67, P794, DOI 10.1136/ard.2007.071977
   Harre U, 2012, J CLIN INVEST, V122, P1791, DOI 10.1172/JCI60975
   Hetland ML, 2010, ANN RHEUM DIS, V69, P1789, DOI 10.1136/ard.2009.125534
   Humby F, 2009, PLOS MED, V6, P59, DOI 10.1371/journal.pmed.0060001
   Iravani S, 1999, AM J CLIN PATHOL, V112, P836
   James JA, 1998, IMMUNOL REV, V164, P185, DOI 10.1111/j.1600 065X.1998.tb01220.x
   Keystone E, 2009, ANN RHEUM DIS, V68, P216, DOI 10.1136/ard.2007.085787
   Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113
   Kyle Robert A, 2005, Clin Lymphoma Myeloma, V6, P102, DOI 10.3816/CLM.2005.n.036
   Landgren O, 2007, BRIT J HAEMATOL, V139, P717, DOI 10.1111/j.1365 2141.2007.06866.x
   Leandro MJ, 2007, RHEUMATOLOGY, V46, P29, DOI 10.1093/rheumatology/kel148
   Leandro MJ, 2002, ANN RHEUM DIS, V61, P883, DOI 10.1136/ard.61.10.883
   McQueen FM, 2007, ANN RHEUM DIS, V66, P1581, DOI 10.1136/ard.2007.070326
   McQueen FM, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4035
   McQueen FM, 2009, MED HYPOTHESES, V73, P651, DOI 10.1016/j.mehy.2009.03.050
   McQueen FM, 2003, ARTHRITIS RHEUM, V48, P1814, DOI 10.1002/art.11162
   McQueen FM, 2012, POSTGRAD MED J, DOI [10.1136/postgradmedj 2011 130364, DOI 10.1136/P0STGRADMEDJ 2011 130364]
   Narváez J, 2011, CLIN EXP RHEUMATOL, V29, P991
   Ohno H, 2010, LEUKEMIA LYMPHOMA, V51, P2144, DOI 10.3109/10428194.2010.513750
   Pasqualucci L, 2003, LEUKEMIA LYMPHOMA, V44, pS5, DOI 10.1080/10428190310001621588
   Peterfy C, 2011, ANN RHEUM DIS S3, V70
   Rantapää Dahlqvist S, 2003, ARTHRITIS RHEUM, V48, P2741, DOI 10.1002/art.11223
   Reparon Schuijt CC, 2001, ARTHRITIS RHEUM, V44, P41, DOI 10.1002/1529 0131(200101)44:1<41::AID ANR6>3.0.CO;2 0
   RICHMOND J, 1956, ANN RHEUM DIS, V15, P217, DOI 10.1136/ard.15.3.217
   Routsias JG, 2010, J AUTOIMMUN, V35, P256, DOI 10.1016/j.jaut.2010.06.016
   Scheel T, 2011, ARTHRITIS RHEUM US, V63, P63, DOI 10.1002/art.27767
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Shiokawa S, 2003, SCAND J RHEUMATOL, V32, P12, DOI 10.1080/03009740310000346
   Snir O, 2011, ARTHRITIS RHEUM US, V63, P2873, DOI 10.1002/art.30445
   Taylor RP, 2008, CURR OPIN IMMUNOL, V20, P444, DOI 10.1016/j.coi.2008.05.011
   Tefferi A, 2011, J CLIN ONCOL, V29, P573, DOI 10.1200/JCO.2010.29.8711
   Van Steendam K, 2011, RHEUMATOLOGY, V50, P830, DOI 10.1093/rheumatology/keq419
   Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907
   Weyand CM, 2005, ARTHRITIS RES THER, V7, pS9, DOI 10.1186/ar1737
   Winter MC, 2009, EXPERT OPIN DRUG SAF, V8, P223, DOI [10.1517/14740330902750114 , 10.1517/14740330902750114]
   Wöhrer S, 2007, ANN ONCOL, V18, P647, DOI 10.1093/annonc/mdl467
   Yazici Y, 2011, NAT REV RHEUMATOL, V7, P379, DOI 10.1038/nrrheum.2011.79
   Youinou P, 2006, CLIN EXP RHEUMATOL, V24, P491
NR 47
TC 3
Z9 4
U1 0
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306 9877
EI 1532 2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD MAR
PY 2014
VL 82
IS 3
BP 266
EP 270
DI 10.1016/j.mehy.2013.12.007
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA AD8CM
UT WOS:000333494100005
PM 24447777
DA 2025 08 17
ER

PT J
AU Zha, ZH
   Wu, ZH
   Choi, SR
   Ploessl, K
   Smith, M
   Alexoff, D
   Zhu, L
   Kung, HF
AF Zha, Zhihao
   Wu, Zehui
   Choi, Seok Rye
   Ploessl, Karl
   Smith, Megan
   Alexoff, David
   Zhu, Lin
   Kung, Hank F.
TI A New [<SUP>68</SUP>Ga]Ga HBED CC Bisphosphonate as a Bone Imaging Agent
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE tumor metastasis; gallium 68; biodistribution; PET imaging agent
ID PET/CT; GA 68; BISPHOSPHONATES; DERIVATIVES; COMPLEXES; IMPACT; DOTA
AB Positron emission tomography (PET) imaging using Ga 68 labeled bisphosphonates to target bone metastasis could be a valuable tool in cancer diagnosis and monitoring therapeutic treatment. A Ga 68 labeled ligand, N,N' bis[2 hydrox y 5 (carboxyethyl)benzyl]ethylenediamine N,N' diacetic acid (HBED CC) containing one bisphosphonate group (HBED CC BP, 1) was prepared and evaluated. The new ligand, 1, reacted rapidly to form [Ga 68]Ga 1, via complexing with [Ga 68]GaCl3 eluted from a commercially available Ge 68/Ga 68 generator (in a sodium acetate buffer at pH 4, reaching >95% labeling yield at room temperature in 5 min). The resulting [Ga 68]Ga 1 showed excellent stability in vitro and in vivo. [Ga 68]Ga 1 displayed high binding affinity to hydroxyapatite and good uptake in the tibia and femur bone of normal mice. Biodistribution and MicroPET imaging studies of [Ga 68]Ga 1 in normal mice and rats showed excellent bone uptake and retention comparable to that of Na[F 18]F. The results suggested that [Ga 68]Ga 1 might be suitable as a bone imaging agent in humans and it could convenient alternative to the current bone imaging PET agent, Na[F 18]F, without the need of a near by cyclotron. Also, an automated synthesis module was developed to produce clinical doses of [Ga 68]Ga 1 in a consistent and reproducible manner. Currently, the investigation new drug application (IND) for [Ga 68]Ga HBED CC BP, [Ga 68]Ga 1, has received FDA approval, and it is currently under clinical trial (IND #129870).
C1 [Zha, Zhihao; Wu, Zehui; Smith, Megan; Kung, Hank F.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
   [Choi, Seok Rye; Ploessl, Karl; Alexoff, David; Kung, Hank F.] Five Eleven Pharma Inc, Philadelphia, PA 19104 USA.
   [Zhu, Lin] Beijing Normal Univ, Coll Chem, Beijing 100875, Peoples R China.
C3 University of Pennsylvania; Beijing Normal University
RP Kung, HF (通讯作者)，Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.; Kung, HF (通讯作者)，Five Eleven Pharma Inc, Philadelphia, PA 19104 USA.
EM kunghf@sunmac.spect.upenn.edu
OI Smith, Megan/0000 0002 2835 9467; Ploessl, Karl/0000 0001 7896 5900
FU Five Eleven Pharma, Inc.
FX Five Eleven Pharma, Inc. was the sponsor of this study. Authors thank
   Dr. Daniel Pryma, Department of Radiology, University of Pennsylvania
   for helpful discussions. Authors also thank Dr. Zhi Yang, Nuclear
   Medicine, Peking Tumor Hospital, Beijing, China for helpful discussion
   and providing the SPECT and PET/CT bone images shown in the Supporting
   Information.
CR Alexoff D, 2017, J NUCL MED, V58
   [Anonymous], 2017, J NUCL MED, V58, P1793
   Banerjee SR, 2013, APPL RADIAT ISOTOPES, V76, P2, DOI 10.1016/j.apradiso.2013.01.039
   Barrio M, 2017, J NUCL MED, V58, P756, DOI 10.2967/jnumed.116.185587
   BROAN CJ, 1991, J CHEM SOC PERK T 2, P87, DOI 10.1039/p29910000087
   Calais J., 1796, MOST INTENDED MANAGE, V58, P1793
   Ceci F, 2020, EUR J NUCL MED MOL I, V47, P136, DOI 10.1007/s00259 019 04505 2
   Chakravarty R, 2017, NUCL MED BIOL, V46, P1, DOI 10.1016/j.nucmedbio.2016.11.006
   CLARKE ET, 1991, INORG CHIM ACTA, V190, P37, DOI 10.1016/S0020 1693(00)80229 7
   Fellner M, 2010, EUR J NUCL MED MOL I, V37, P834, DOI 10.1007/s00259 009 1355 y
   Fendler WP, 2019, JAMA ONCOL, V5, P856, DOI 10.1001/jamaoncol.2019.0096
   Guleria M, 2019, CANCER BIOTHER RADIO, V34, P67, DOI 10.1089/cbr.2018.2605
   Hennrich U, 2019, PHARMACEUTICALS BASE, V12, DOI 10.3390/ph12030114
   Holub J, 2015, CONTRAST MEDIA MOL I, V10, P122, DOI 10.1002/cmmi.1606
   Iagaru A, 2013, CLIN NUCL MED, V38, pE290, DOI 10.1097/RLU.0b013e3182815f64
   Jadvar H, 2015, SEMIN NUCL MED, V45, P58, DOI 10.1053/j.semnuclmed.2014.07.008
   Khawar A, 2019, ANN NUCL MED, V33, P404, DOI 10.1007/s12149 019 01348 7
   Meckel M, 2013, NUCL MED BIOL, V40, P823, DOI 10.1016/j.nucmedbio.2013.04.012
   Motekaitis RJ, 1996, INORG CHEM, V35, P3821, DOI 10.1021/ic960067g
   Nedrow JR, 2014, MOL IMAGING, V13, DOI 10.2310/7290.2014.00020
   Ogawa K, 2011, NUCL MED BIOL, V38, P631, DOI 10.1016/j.nucmedbio.2010.12.004
   Passah A, 2017, EUR J NUCL MED MOL I, V44, P41, DOI 10.1007/s00259 016 3469 3
   Pfannkuchen N, 2017, PHARMACEUTICALS BASE, V10, DOI 10.3390/ph10020045
   Price EW, 2014, CHEM SOC REV, V43, P260, DOI 10.1039/c3cs60304k
   Rösch F, 2013, APPL RADIAT ISOTOPES, V76, P24, DOI 10.1016/j.apradiso.2012.10.012
   Sanchez Crespo A, 2013, APPL RADIAT ISOTOPES, V76, P55, DOI 10.1016/j.apradiso.2012.06.034
   Simecek J, 2014, MOL PHARMACEUT, V11, P1687, DOI 10.1021/mp5000746
   Smith DL, 2013, APPL RADIAT ISOTOPES, V76, P14, DOI 10.1016/j.apradiso.2012.10.014
   Sonni I., 2020, J NUCL MED
   Stasiuk GJ, 2013, CHEM COMMUN, V49, P2732, DOI 10.1039/c3cc38507h
   Toegel S, 2008, EUR J PHARM BIOPHARM, V68, P406, DOI 10.1016/j.ejpb.2007.05.015
   Velikyan I, 2015, J LABELLED COMPD RAD, V58, P99, DOI 10.1002/jlcr.3250
   Velikyan I, 2014, THERANOSTICS, V4, P47, DOI 10.7150/thno.7447
   Velikyan I, 2014, J NUCL MED, V55, P204, DOI 10.2967/jnumed.113.126177
   Wong KK, 2013, J NUCL MED, V54, P590, DOI 10.2967/jnumed.112.114298
   Wu ZH, 2016, NUCL MED BIOL, V43, P360, DOI 10.1016/j.nucmedbio.2016.03.002
   Zimmerman ME, 2019, CLIN ADV HEMATOL ONC, V17, P455
NR 37
TC 28
Z9 29
U1 0
U2 20
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543 8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD MAY 4
PY 2020
VL 17
IS 5
BP 1674
EP 1684
DI 10.1021/acs.molpharmaceut.0c00103
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA LK2BV
UT WOS:000530663800022
PM 32251600
DA 2025 08 17
ER

PT J
AU Shokoohmand, A
   Ren, J
   Baldwin, J
   Atack, A
   Shafiee, A
   Theodoropoulos, C
   Wille, ML
   Tran, PA
   Bray, LJ
   Smith, D
   Chetty, N
   Pollock, PM
   Hutmacher, DW
   Clements, JA
   Williams, ED
   Bock, N
AF Shokoohmand, Ali
   Ren, Jiongyu
   Baldwin, Jeremy
   Atack, Anthony
   Shafiee, Abbas
   Theodoropoulos, Christina
   Wille, Marie Luise
   Tran, Phong A.
   Bray, Laura J.
   Smith, Deborah
   Chetty, Naven
   Pollock, Pamela M.
   Hutmacher, Dietmar W.
   Clements, Judith A.
   Williams, Elizabeth D.
   Bock, Nathalie
TI Microenvironment engineering of osteoblastic bone metastases reveals
   osteomimicry of patient derived prostate cancer xenografts
SO BIOMATERIALS
LA English
DT Article
DE Osteomimicry; Prostate cancer; Cancer model; Bone metastasis;
   Patient derived xenograft; Osteocyte
ID TISSUE GROWTH FACTOR; IN VITRO; MATRIX PROTEINS; CANCELLOUS BONE;
   ANNEXIN II; EXPRESSION; CELLS; MODEL; DIFFERENTIATION; HETEROGENEITY
AB Representative in vitro models that mimic the native bone tumor microenvironment are warranted to support the development of more successful treatments for bone metastases. Here, we have developed a primary cell 3D model consisting of a human osteoblast derived tissue engineered construct (hOTEC) indirectly co cultured with patient derived prostate cancer xenografts (PDXs), in order to study molecular interactions in a patient derived microenvironment context. The engineered biomimetic microenvironment had high mineralization and embedded osteocytes, and supported a high degree of cancer cell osteomimicry at the gene, protein and mineralization levels when co cultured with prostate cancer PDXs from a lymph node metastasis (LuCaP35) and bone metastasis (BM18) from patients with primary prostate cancer. This fully patient derived model is a promising tool for the assessment of new molecular mechanisms and as a personalized pre clinical platform for therapy testing for patients with prostate cancer bone metastases.
C1 [Shokoohmand, Ali; Ren, Jiongyu; Baldwin, Jeremy; Atack, Anthony; Shafiee, Abbas; Theodoropoulos, Christina; Wille, Marie Luise; Tran, Phong A.; Bray, Laura J.; Pollock, Pamela M.; Hutmacher, Dietmar W.; Clements, Judith A.; Williams, Elizabeth D.; Bock, Nathalie] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia.
   [Shokoohmand, Ali; Ren, Jiongyu; Baldwin, Jeremy; Shafiee, Abbas; Theodoropoulos, Christina; Wille, Marie Luise; Tran, Phong A.; Bray, Laura J.; Hutmacher, Dietmar W.] QUT, Sci & Engn Fac, Sch Chem Phys & Mech Engn, Brisbane, Qld, Australia.
   [Shokoohmand, Ali; Atack, Anthony; Hutmacher, Dietmar W.; Clements, Judith A.; Williams, Elizabeth D.; Bock, Nathalie] QUT, APCRC Q, Brisbane, Qld, Australia.
   [Shokoohmand, Ali; Atack, Anthony; Bray, Laura J.; Pollock, Pamela M.; Hutmacher, Dietmar W.; Clements, Judith A.; Williams, Elizabeth D.; Bock, Nathalie] QUT, Translat Res Inst, Brisbane, Qld, Australia.
   [Shokoohmand, Ali; Ren, Jiongyu; Baldwin, Jeremy; Shafiee, Abbas; Theodoropoulos, Christina; Wille, Marie Luise; Tran, Phong A.; Bray, Laura J.; Hutmacher, Dietmar W.; Bock, Nathalie] QUT, Ctr Regenerat Med, IHBI, Kelvin Grove, Qld, Australia.
   [Hutmacher, Dietmar W.; Clements, Judith A.] QUT, Arc Training Ctr Addit Biomfg, Kelvin Grove, Qld, Australia.
   [Atack, Anthony; Pollock, Pamela M.; Hutmacher, Dietmar W.; Clements, Judith A.; Williams, Elizabeth D.; Bock, Nathalie] QUT, Sch Biomed Sci, Fac Hlth, Brisbane, Qld, Australia.
   [Smith, Deborah; Chetty, Naven] Univ Queensland, Mater Res Inst, Translat Res Inst, Canc Pathol Res Grp, Woolloongabba, Qld, Australia.
   [Smith, Deborah; Chetty, Naven] Mater Hosp Brisbane, Dept Anat Pathol, Brisbane, Qld, Australia.
C3 Queensland University of Technology (QUT); Queensland University of
   Technology (QUT); Queensland University of Technology (QUT); University
   of Queensland; Queensland University of Technology (QUT); Queensland
   University of Technology (QUT); Queensland University of Technology
   (QUT); Queensland University of Technology (QUT); Mater Research;
   University of Queensland; Mater Health Services; Mater Hospital Brisbane
RP Bock, N (通讯作者)，Queensland Univ Technol, Translat Res Inst, 37 Kent St, Woolloongabba, Qld 4102, Australia.
EM n.bock@qut.edu.au
RI Wille, Marie Luise/D 4278 2016; Hutmacher, Dietmar/AEO 9578 2022;
   Shafiee, Abbas/H 9230 2019; Bray, Laura/D 8514 2014; Tran,
   Phong/I 4039 2017; Ren, Edward/ACW 5243 2022; Williams,
   Elizabeth/B 1538 2008; WILLIAMS, ELIZABETH/NSV 3246 2025; Baldwin,
   Jeremy/ABA 3910 2021
OI Bray, Laura/0000 0002 1174 0018; Theodoropoulos,
   Christina/0000 0002 1140 7813; Shokoohmand, Ali/0009 0005 9182 2054;
   Hutmacher, Dietmar Werner/0000 0001 5678 2134; Shafiee,
   Abbas/0000 0002 8885 9025; Tran, Phong/0000 0003 2820 7399; Pollock,
   Pamela/0000 0001 8420 1026; Williams, Elizabeth/0000 0002 3364 6655;
   Bock, Nathalie/0000 0001 9331 4698; Wille,
   Marie Luise/0000 0003 4962 7587
FU Advance Queensland (AQ) Maternity Fund Award from the Queensland
   Government (DSITI); National Health and Medical Research Council (NHMRC)
   Peter Doherty Early Career Research Fellowship (RF) [APP1091734]; John
   Mills Young Investigator Award from the Prostate Cancer Foundation of
   Australia (PCFA) [YI0715]; JJ Richards & Sons via an In Vitro Excellence
   Research grant; QUT; AQ RF (QLD); NHMRC PRF; Humboldt RF; ARC Industrial
   Transformation Training Centre in Additive Biomanufacturing
   [IC160100026]; World Cancer Foundation; Movember Revolutionary Team
   Award (Movember); Australian Government; NHMRC; National Breast Cancer
   Foundation; PCFA; Movember Revolutionary Team Award (PCFA)
FX The authors acknowledge the Translational Research Institute for the
   excellent core facilities that enabled this research, and thank Adler Ju
   from the TRI microscopy facility. The authors also thank Jose Malayil,
   Dr Asha Mathew, Tejasri Yarlagadda and Dr Elena M. De Juan Pardo (QUT)
   for scaffold production, treatment and coating; Dr Felicity Lawrence at
   the CARF histology facility from IHBI (QUT); A/Prof. Sally Anne
   Stephenson (QUT) and Dr Thomas Kryza (Mater Research, Brisbane,
   Australia) for the mKO2 vector and transfection, respectively, Colin
   Rohner (University of Zurich, Switzerland) for Matlab programming, Prof.
   Yin Xiao (QUT) for the DMP 1 antibody and Prof. Ross Crawford (QUT) for
   collecting bone samples. This study was supported as follows; N.B.:
   Advance Queensland (AQ) Maternity Fund Award from the Queensland
   Government (DSITI), National Health and Medical Research Council (NHMRC)
   Peter Doherty Early Career Research Fellowship (RF, APP1091734), John
   Mills Young Investigator Award (YI0715) from the Prostate Cancer
   Foundation of Australia (PCFA) and JJ Richards & Sons via an In Vitro
   Excellence Research grant; P.A.T.: Vice Chancellor's RF (QUT) and AQ RF
   (QLD); J.A.C.: NHMRC PRF; D.W.H.: Humboldt RF, ARC Industrial
   Transformation Training Centre in Additive Biomanufacturing
   (IC160100026), NHMRC, National Breast Cancer Foundation, PCFA. D.W.H.,
   E.D.W.: World Cancer Foundation. D.W.H., J.A.C., E.D.W.: Movember
   Revolutionary Team Award (from Movember and PCFA). APCRC Q and the
   Translational Research Institute are supported by grants from the
   Australian Government..
CR Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a
   Bentmann A., 2009, J BONE MINER RES, V25, DOI [10.1359/jbmr.091011091012153414059 30, DOI 10.1359/JBMR.091011091012153414059 30]
   Beshiri ML, 2018, CLIN CANCER RES, V24, P4332, DOI 10.1158/1078 0432.CCR 18 0409
   Bock N, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0049 8
   Body JJ, 2015, NAT REV UROL, V12, P340, DOI 10.1038/nrurol.2015.90
   Brown TD, 2012, BIOINTERPHASES, V7, DOI 10.1007/s13758 011 0013 7
   Cassidy JW, 2015, CANCER RES, V75, P2963, DOI 10.1158/0008 5472.CAN 15 0727
   Chen G, 2006, CANCER AM CANCER SOC, V107, P289, DOI 10.1002/cncr.21978
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Corey E, 2002, PROSTATE, V52, P20, DOI 10.1002/pros.10091
   Cowles EA, 1998, CALCIFIED TISSUE INT, V62, P74, DOI 10.1007/s002239900397
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   Curtin P, 2012, BIOMATERIALS, V33, P1065, DOI 10.1016/j.biomaterials.2011.10.046
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Das S, 2010, BIOCHEMISTRY US, V49, P2216, DOI 10.1021/bi9013038
   Delgado Calle J, 2011, BONE, V49, P830, DOI 10.1016/j.bone.2011.06.006
   Ferreira LP, 2018, ACTA BIOMATER, V75, P11, DOI 10.1016/j.actbio.2018.05.034
   Fischer A. H., 2008, CSH PROTOC, DOI [10.1101/pdb.prot49862008)pdb, DOI 10.1101/PDB.PROT49862008)PDB]
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Fong ELS, 2016, BIOMATERIALS, V108, P197, DOI 10.1016/j.biomaterials.2016.08.052
   Fong ELS, 2016, BIOMATERIALS, V77, P164, DOI 10.1016/j.biomaterials.2015.10.059
   Franz Odendaal TA, 2006, DEV DYNAM, V235, P176, DOI 10.1002/dvdy.20603
   Gartrell BA, 2014, NAT REV CLIN ONCOL, V11, P335, DOI 10.1038/nrclinonc.2014.70
   Genetos DC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107482
   Gillet JP, 2013, JNCI J NATL CANCER I, V105, P452, DOI 10.1093/jnci/djt007
   Guo DY, 2009, THER ADV MUSCULOSKEL, V1, P87, DOI 10.1177/1759720X09341484
   Hauge EM, 2001, J BONE MINER RES, V16, P1575, DOI 10.1359/jbmr.2001.16.9.1575
   Hesami P, 2014, CLIN EXP METASTAS, V31, P435, DOI 10.1007/s10585 014 9638 5
   Hildebrand T, 1999, J BONE MINER RES, V14, P1167, DOI 10.1359/jbmr.1999.14.7.1167
   Holzapfel BM, 2014, BIOMATERIALS, V35, P4108, DOI 10.1016/j.biomaterials.2014.01.062
   Huang WC, 2005, CANCER RES, V65, P2303, DOI 10.1158/0008 5472.CAN 04 3448
   Inokuchi J, 2009, INT J CANCER, V124, P68, DOI 10.1002/ijc.23928
   Jacob K, 1999, CANCER RES, V59, P4453
   Josson S, 2010, SEMIN CELL DEV BIOL, V21, P26, DOI 10.1016/j.semcdb.2009.11.016
   Koeneman KS, 1999, PROSTATE, V39, P246
   Lee YC, 2015, CANCER RES, V75, P4949, DOI 10.1158/0008 5472.CAN 15 1215
   Lin DL, 2001, PROSTATE, V47, P212, DOI 10.1002/pros.1065
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Lv FJ, 2014, STEM CELLS, V32, P1408, DOI 10.1002/stem.1681
   Majid S, 2012, MOL CANCER, V11, DOI 10.1186/1476 4598 11 7
   Martine LC, 2017, NAT PROTOC, V12, P639, DOI 10.1038/nprot.2017.002
   McCulloch DR, 2005, PROSTATE, V65, P35, DOI 10.1002/pros.20255
   McGovern JA, 2018, CANCERS, V10, DOI 10.3390/cancers10110438
   Msaouel P, 2013, EXPERT OPIN INV DRUG, V22, P1385, DOI 10.1517/13543784.2013.824422
   Muerza Cascante ML, 2017, ACTA BIOMATER, V52, P145, DOI 10.1016/j.actbio.2016.12.040
   Mundy C, 2014, J CELL PHYSIOL, V229, P672, DOI 10.1002/jcp.24491
   Nguyen HM, 2017, PROSTATE, V77, P654, DOI 10.1002/pros.23313
   Ortiz A., 2012, OSTEOLYTIC OSTEOBLAS, P225, DOI [10.1007/978 3.642 21892 7_11, DOI 10.1007/978 3.642 21892 7_11]
   Peela N, 2017, BIOMATERIALS, V133, P176, DOI 10.1016/j.biomaterials.2017.04.017
   Prideaux M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036786
   Qiao H, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0008 9
   Quent VMC, 2018, J TISSUE ENG REGEN M, V12, P494, DOI 10.1002/term.2517
   Reichert JC, 2010, BIOMATERIALS, V31, P7928, DOI 10.1016/j.biomaterials.2010.06.055
   Risbridger GP, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a030536
   Rodenhizer D, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701174
   Rosen CJ, 2009, CRIT REV EUKAR GENE, V19, P109, DOI 10.1615/CritRevEukarGeneExpr.v19.i2.20
   Rucci N, 2018, CALCIFIED TISSUE INT, V102, P131, DOI 10.1007/s00223 017 0365 1
   Rucci Nadia, 2010, Front Biosci (Schol Ed), V2, P907
   Safadi FF, 2003, J CELL PHYSIOL, V196, P51, DOI 10.1002/jcp.10319
   Salamanna F, 2016, ONCOTARGET, V7, P44803, DOI 10.18632/oncotarget.8394
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shafiee A, 2018, INT J CANCER, V143, P1470, DOI 10.1002/ijc.31528
   Shiozawa Y, 2008, J CELL BIOCHEM, V105, P370, DOI 10.1002/jcb.21835
   Shum LC, 2016, STEM CELLS DEV, V25, P114, DOI 10.1089/scd.2015.0193
   Sieh S, 2014, BONE, V63, P121, DOI 10.1016/j.bone.2014.02.001
   Sieh S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040217
   Sieh S, 2010, ORGANOGENESIS, V6, P181, DOI 10.4161/org.6.3.12041
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Siolas D, 2013, CANCER RES, V73, P5315, DOI 10.1158/0008 5472.CAN 13 1069
   Smitherman AB, 2004, J UROLOGY, V171, P916, DOI 10.1097/01.ju.0000104674.70170.cd
   Sommer B, 1996, BONE, V19, P371, DOI 10.1016/S8756 3282(96)00218 9
   Thibaudeau L, 2015, ONCOTARGET, V6, P332, DOI 10.18632/oncotarget.2788
   Thibaudeau L, 2014, DIS MODEL MECH, V7, P299, DOI 10.1242/dmm.014076
   Thurner PJ, 2010, BONE, V46, P1564, DOI 10.1016/j.bone.2010.02.014
   Vaquette C, 2013, BIOMATERIALS, V34, P5538, DOI 10.1016/j.biomaterials.2013.03.088
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Yang F, 2005, CANCER RES, V65, P8887, DOI 10.1158/0008 5472.CAN 05 1702
   Zhang SL, 2018, ONCOL LETT, V16, P2305, DOI 10.3892/ol.2018.8960
NR 78
TC 31
Z9 32
U1 2
U2 40
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD NOV
PY 2019
VL 220
AR 119402
DI 10.1016/j.biomaterials.2019.119402
PG 17
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA JB6LD
UT WOS:000488674700005
PM 31400612
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Yasui, K
   Yashiro, M
   Tsuge, M
   Manki, A
   Takemoto, K
   Yamamoto, M
   Morishima, T
AF Yasui, Kozo
   Yashiro, Masato
   Tsuge, Mitsuru
   Manki, Akira
   Takemoto, Kei
   Yamamoto, Michiko
   Morishima, Tsuneo
TI Thalidomide Dramatically Improves the Symptoms of Early Onset
   Sarcoidosis/Blau Syndrome Its Possible Action and Mechanism
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID KAPPA B ACTIVATION; CUTANEOUS SARCOIDOSIS; ALPHA PRODUCTION;
   BLAU SYNDROME; CELLS; DIFFERENTIATION; ARTHRITIS; DISEASE; TNF
AB Objective. Early onset sarcoidosis (EOS), which occurs in children younger than 5 years of age, is associated with granulomatous lesions and a sporadic genetic mutation of the nucleotide binding oligomerization domain 2 that causes constitutive NF kappa B activation. The symptoms of EOS can be uncontrollable, progressive, and associated with profound complications. However, appropriate therapy is still under investigation. The aim of this study was to assess the efficacy of thalidomide in patients with severe EOS, based on etiology supporting an initial role of NF kappa B in activation of this disease.
   Methods. Thalidomide was given to 2 patients with EOS (a 16 year old girl and an 8 year old boy) at an initial dosage of 2 mg/kg/day, and the dosage was increased if necessary. To elucidate the mechanism of the drug, peripheral blood monocytes were isolated from the patients and stimulated with cytokines (macrophage colony stimulating factor, tumor necrosis factor alpha, and interleukin 4), and their ability to form multinucleated giant cells (MGCs) and osteoclasts was measured.
   Results. Both patients showed dramatic improvement of their clinical symptoms (alleviation of fever and optic nerve papillitis, achievement of a response according to the American College of Rheumatology Pediatric 50 and Pediatric 70 criteria) and laboratory findings. Monocytes from patients with EOS had a greater ability to survive and induce MGCs and osteoclasts than those from healthy control subjects. The formation of MGCs and osteoclasts was inhibited by the presence of thalidomide.
   Conclusion. The ability of thalidomide to improve clinical symptoms and laboratory findings in patients with EOS indicates a central role for NF kappa B activity in this disorder. Inhibition of IKK might be a pharmacologic action by which thalidomide down regulates NF kappa B signaling. Thalidomide may be an effective medication in patients with severe complications of EOS, including ocular involvement.
C1 [Yasui, Kozo] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pediat, Okayama 7008558, Japan.
C3 Okayama University
RP Yasui, K (通讯作者)，Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pediat, 2 5 1 Shikata Cho, Okayama 7008558, Japan.
EM k yasui@md.okayama u.ac.jp
RI Yashiro, Masato/JUF 2638 2023
CR Anderson G, 2006, BLOOD, V107, P3098, DOI 10.1182/blood 2005 08 3450
   Baughman RP, 2007, CLIN DERMATOL, V25, P334, DOI 10.1016/j.clindermatol.2007.03.011
   BESSIS D, 1992, LANCET, V339, P549, DOI 10.1016/0140 6736(92)90365 A
   COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458
   Dredge K, 2002, CRIT REV IMMUNOL, V22, P425, DOI 10.1615/CritRevImmunol.v22.i5 6.40
   FALLON MD, 1981, METAB BONE DIS RELAT, V3, P171, DOI 10.1016/0221 8747(81)90004 7
   FERRERO D, 1983, BLOOD, V61, P171
   Fink CW, 1997, J RHEUMATOL, V24, P174
   Giannini EH, 1997, ARTHRITIS RHEUM, V40, P1202
   HETHERINGTON S, 1982, AM J DIS CHILD, V136, P13, DOI 10.1001/archpedi.1982.03970370015002
   Kanazawa N, 2005, BLOOD, V105, P1195, DOI 10.1182/blood 2004 07 2972
   Kaplan G, 2000, AIDS RES HUM RETROV, V16, P1345, DOI 10.1089/08892220050140892
   LENTZ W, 1962, LANCET, V1, P45
   Majumdar S, 2002, J IMMUNOL, V168, P2644, DOI 10.4049/jimmunol.168.6.2644
   Marriott JB, 1999, IMMUNOL TODAY, V20, P538, DOI 10.1016/S0167 5699(99)01531 5
   MCBRIDE WG, 1961, LANCET, V2, P1358
   MELLIN G W, 1962, N Engl J Med, V267, P1184, DOI 10.1056/NEJM196212062672305
   Miyamoto T, 2001, BLOOD, V98, P2544, DOI 10.1182/blood.V98.8.2544
   Nakao A, 2007, BIOCHEM BIOPH RES CO, V357, P945, DOI 10.1016/j.bbrc.2007.04.058
   Okafuji I, 2009, ARTHRITIS RHEUM US, V60, P242, DOI 10.1002/art.24134
   Okamoto H, 2003, J DERMATOL SCI, V31, P119, DOI 10.1016/S0923 1811(02)00148 2
   Oliver SJ, 2002, CLIN IMMUNOL, V102, P225, DOI 10.1006/clim.2001.5173
   Rosé CD, 2006, ARTHRITIS RHEUM, V54, P3337, DOI 10.1002/art.22122
   Rousseau L, 1998, ARCH DERMATOL, V134, P1045, DOI 10.1001/archderm.134.8.1045
   SAMPAIO EP, 1991, J EXP MED, V173, P699, DOI 10.1084/jem.173.3.699
   Shetty AK, 1998, CLIN PEDIATR, V37, P707, DOI 10.1177/000992289803701201
NR 26
TC 59
Z9 63
U1 0
U2 2
PU WILEY LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0004 3591
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD JAN
PY 2010
VL 62
IS 1
BP 250
EP 257
DI 10.1002/art.25035
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 617JA
UT WOS:000279275700027
PM 20039400
DA 2025 08 17
ER

PT J
AU Ureña, P
   Jacobson, SH
   Zitt, E
   Vervloet, M
   Malberti, F
   Ashman, N
   Leavey, S
   Rix, M
   Os, I
   Saha, H
   Ryba, M
   Bencova, V
   Baños, A
   Zani, V
   Fouque, D
AF Urena, Pablo
   Jacobson, Stefan H.
   Zitt, Emanuel
   Vervloet, Marc
   Malberti, Fabio
   Ashman, Neil
   Leavey, Sean
   Rix, Marianne
   Os, Ingrid
   Saha, Heikki
   Ryba, Miroslav
   Bencova, Veronika
   Banos, Ana
   Zani, Valter
   Fouque, Denis
TI Cinacalcet and achievement of the NKF/K DOQI<SUP>TM</SUP> recommended
   target values for bone and mineral metabolism in real world clinical
   practice the ECHO observational study
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE calcimimetic; cinacalcet; clinical practice; secondary
   hyperparathyroidism; targets
ID SECONDARY HYPERPARATHYROIDISM; DIALYSIS PATIENTS; MORTALITY RISK;
   CALCIUM; HEMODIALYSIS; PHOSPHORUS; ASSAYS; PTH
AB Methods. Adult patients with chronic kidney disease on dialysis who had initiated cinacalcet treatment were enrolled. Data were collected 6 months before initiating cinacalcet, at baseline (initiation of cinacalcet) and up to 12 months after cinacalcet initiation.
   Results. A total of 1865 patients [mean (SD) age 58 (15) years] were enrolled from 187 sites in 12 countries. Most patients had a dialysis vintage of >= 1 year (1 5 years, n = 833; > 5 years, n = 748 versus < 1 year, n = 265). The patients generally had severely uncontrolled intact parathyroid hormone (iPTH) serum levels (median 721 pg/ml) and elevated phosphorus (median 5.9 mg/dl) and calcium (median 9.6 mg/dl) at baseline, despite being prescribed conventional therapies. The proportions of patients achieving the recommended [NKF K/DOQI(TM) (KDOQI(TM))] targets increased from baseline [4%, 39%, 40% and 46% for iPTH, phosphorus, calcium and calcium phosphorus product (Ca x P), respectively] to Month 12 (28%, 48%, 51% and 68%, respectively). At Month 12, 18% of patients had achieved the combined target for iPTH + Ca x P compared with 2% at baseline. Most patients (65%) received < 60 mg/day cinacalcet at Month 12. Vitamin D sterol use remained fairly stable throughout the study. There was a 13% decrease in prescribed sevelamer; use of calcium based phosphate binders increased by 5.6%. There was no unexpected safety or tolerability concerns.
   Conclusion. This analysis of current European clinical practice shows that consistent with findings from randomized controlled trials and retrospective observational studies cinacalcet improves attainment of KDOQI(TM) bone metabolism targets in dialysis patients with various stages of SHPT.
C1 [Urena, Pablo] Clin Landy, St Ouen, France.
   [Jacobson, Stefan H.] Karolinska Inst, Stockholm, Sweden.
   [Jacobson, Stefan H.] Danderyd Hosp, Stockholm, Sweden.
   [Zitt, Emanuel] Acad Teaching Hosp, Feldkirch, Austria.
   [Vervloet, Marc] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands.
   [Malberti, Fabio] Ospitalieri Cremona, AO Ist, Cremona, Italy.
   [Ashman, Neil] Royal London Hosp, London E1 1BB, England.
   [Leavey, Sean] Waterford Reg Hosp, Waterford, Ireland.
   [Rix, Marianne] Univ Copenhagen Hosp, DK 2100 Copenhagen, Denmark.
   [Os, Ingrid] Univ Oslo, Ulleval Univ Hosp, Oslo, Norway.
   [Saha, Heikki] Tampere Univ Hosp, Tampere, Finland.
   [Ryba, Miroslav] Krajska Nemocnice Liberec, Liberec, Czech Republic.
   [Bencova, Veronika] DIA NE Sro, Nitra, Slovakia.
   [Banos, Ana] Amgen Europe GmBH, Zug, Switzerland.
   [Fouque, Denis] Univ Lyon 1, Hop Edouard Herriot, F 69622 Villeurbanne, France.
C3 Karolinska Institutet; Danderyds Hospital; Vrije Universiteit Amsterdam;
   VU UNIVERSITY MEDICAL CENTER; Barts Health NHS Trust; Royal London
   Hospital; University of Copenhagen; Copenhagen University Hospital;
   University of Oslo; Tampere University; Tampere University Hospital;
   Amgen; AMGEN Europe; CHU Lyon; Universite Claude Bernard Lyon 1
RP Ureña, P (通讯作者)，Clin Landy, St Ouen, France.
EM urena.pablo@wanadoo.fr
RI Fouque, Denis/C 5338 2014; Vervoort, G.M.M./L 4718 2015; Torres,
   Pablo/LBH 6671 2024; fouque, denis/C 5338 2014; Zitt,
   Emanuel/ABE 1926 2020
OI Vervloet, Marc/0000 0003 4607 9415; fouque, denis/0000 0002 9707 7199; 
FU Korea government (MOST) [R13 2002 054 04001 0]; Ministry for Health,
   Welfare & Family Affairs, Republic of Korea [A084001]
FX This work was supported by the BK21 (Brain Korea 21) Project for Medical
   Sciences, Yonsei University, the Korea Science and Engineering
   Foundation (KOSEF) grant funded by the Korea government (MOST)
   (R13 2002 054 04001 0), and a grant of the Korea Healthcare Technology
   R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of
   Korea (A084001).
CR Block G, 2001, AM J KIDNEY DIS, V37, P1332
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Cano NJM, 2007, J AM SOC NEPHROL, V18, P2583, DOI 10.1681/ASN.2007020184
   Danese MD, 2008, CLIN J AM SOC NEPHRO, V3, P1423, DOI 10.2215/CJN.01060308
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   FRAZAO JM, 2005, NEPHROL DIAL TRAN S5, V20, pSP209
   Hammerland LG, 1998, MOL PHARMACOL, V53, P1083
   Henley C, 2007, NEPHROL DIAL TRANSPL, V22, P217
   Isakova T, 2008, J AM SOC NEPHROL, V19, P615, DOI 10.1681/ASN.2007060673
   Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512
   Lopez I, 2008, KIDNEY INT, V73, P300, DOI 10.1038/sj.ki.5002675
   Martin KJ, 2005, KIDNEY INT, V68, P1236, DOI 10.1111/j.1523 1755.2005.00517.x
   MASSRY SG, 1994, SEMIN NEPHROL, V14, P219
   Melamed ML, 2008, NEPHROL DIAL TRANSPL, V23, P1650, DOI 10.1093/ndt/gfm849
   Messa P, 2008, CLIN J AM SOC NEPHRO, V3, P36, DOI 10.2215/CJN.03591006
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Moe SM, 2003, AM J NEPHROL, V23, P369, DOI 10.1159/000073945
   Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040
   Peter WLS, 2009, CLIN J AM SOC NEPHRO, V4, P354, DOI 10.2215/CJN.05241008
   Slatopolsky E, 1999, KIDNEY INT, V56, pS14, DOI 10.1046/j.1523 1755.1999.07304.x
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
NR 23
TC 84
Z9 86
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931 0509
EI 1460 2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD SEP
PY 2009
VL 24
IS 9
BP 2852
EP 2859
DI 10.1093/ndt/gfp144
PG 8
WC Transplantation; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Transplantation; Urology & Nephrology
GA 486PD
UT WOS:000269208500038
PM 19369690
OA Bronze
DA 2025 08 17
ER

PT J
AU Su, BH
   Yuan, YG
   Zhang, JS
   Li, YZ
   Zhang, QH
AF Su, Baohui
   Yuan, Yanguang
   Zhang, Junshan
   Li, Yuezhong
   Zhang, Qihui
TI Fluorescent Mitoxantrone Hydrochloride Nanoparticles Inhibit the
   Malignant Behavior of Giant Cell Tumor of Bone via miR 125b/PTH1R Axis
SO JOURNAL OF NANOMATERIALS
LA English
DT Article
ID DRUG DELIVERY; STEM CELLS; CANCER; PTHRP
AB Objective. To explore the therapeutic effects and mechanism of fluorescent mitoxantrone hydrochloride nanoparticles on giant cell tumor of bone.Methods. The adsorption capacity of nanoparticles to hydroxyapatite (HA), cell adsorption capacity, encapsulation rate, particle size, and potential of the nanoparticles were determined by HPLC and Zetasizer Nano ZS nanomicelle potentiometer. MTT assay was used to determine the toxicity of nanoparticles to cells. The fluorescent intensity of the nanoparticles and their location in the cells were observed under a fluorescence microscope. RT qPCR and Western blotting were then used to measure the expression levels of miRNA, mRNA, and proteins in cells. Transwell and Annexin V FITC/PI staining tests were used to study the cell invasion and apoptotic rate, respectively. The dual luciferase reporter gene experiment was then carried out to verify the binding relationship between miR 125b and its predicted target.Results. ALN FOL MTO NLC nanoparticles showed a stronger adsorption capacity for HA and stronger toxicity to GCTB28 cells. Compared to normal tissues, the expression level of miR 125b in giant bone tumor tissue and cells was significantly downregulated, and the expression level of miR 125b was upregulated to some extent after treatment. Overexpression of miR 125b or treatment of ALN FOL MTO NLC nanoparticles can inhibit the malignant behavior of GCTB28 cells, whereas the inhibition of the expression of miR 125b can promote the malignant behavior of GCTB28 cells. The result showed that parathyroid hormone receptor 1 (PTH1R) was a downstream target gene for miR 125b. Rescue experiment showed that the treatment of GCTB28 with ALN FOL MTO NLC nanoparticles while inhibiting miR 125b expression can reduce the inhibitory effect of miR 125b on the malignant behavior of GCTB28 cells, whereas upregulating the expression levels of miR 125b and PTH1R in GCTB28 cells had no significant effect on the malignant behavior of GCTB28 cells.Conclusion. ALN FOL MTO NLC nanoparticles have a certain inhibitory effect on the malignant behavior of giant cell tumor of bone through the miR 125b/PTH1R molecular axis.
C1 [Su, Baohui; Zhang, Junshan; Li, Yuezhong] Weifang Peoples Hosp, Dept Spinal Surg, Weifang 261041, Shandong, Peoples R China.
   [Yuan, Yanguang] Anqiu Peoples Hosp, Dept Orthopaed, Weifang 262100, Shandong, Peoples R China.
   [Zhang, Qihui] Anqiu Peoples Hosp, Dept Nursing, Weifang 262100, Shandong, Peoples R China.
RP Zhang, QH (通讯作者)，Anqiu Peoples Hosp, Dept Nursing, Weifang 262100, Shandong, Peoples R China.
EM subaohui520@163.com; anqiuyuanyanguang@163.com; zhangjunshan_1@163.com;
   yozolee@sina.com; 2580332003@qq.com
RI li, yuying/JDW 4642 2023
FU Weifang City Health and Family Planning Commission Scientific Research
   Project Plan [wfwsjs 2018 107]
FX This work supported by the Weifang City Health and Family Planning
   Commission Scientific Research Project Plan (grant no. wfwsjs 2018 107).
CR Aftab S, 2018, INT J PHARMACEUT, V540, P132, DOI 10.1016/j.ijpharm.2018.02.007
   Bahrami B, 2017, IMMUNOL LETT, V190, P64, DOI 10.1016/j.imlet.2017.07.015
   Cheng H, 2017, DRUG DISCOV TODAY, V22, P1336, DOI 10.1016/j.drudis.2017.04.021
   Cowan RW, 2012, J ORTHOP RES, V30, P877, DOI 10.1002/jor.22020
   Huang S, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0719 7
   Hui GN, 2018, ONCOL LETT, V15, P1621, DOI 10.3892/ol.2017.7476
   Jie S, 2019, INT J NANOMED, V14, P7353, DOI 10.2147/IJN.S217974
   Liu JS, 2017, INT J NANOMED, V12, P3561, DOI 10.2147/IJN.S133787
   Lüke J, 2018, PATHOLOGE, V39, P125, DOI 10.1007/s00292 017 0391 9
   Nishimori S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.97903
   Noh BJ, 2018, HUM PATHOL, V81, P1, DOI 10.1016/j.humpath.2018.06.017
   Palmerini E, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819840000
   Pu MF, 2019, CELL MOL LIFE SCI, V76, P441, DOI 10.1007/s00018 018 2940 7
   Qadri S, 2017, NANOMED NANOTECHNOL, V13, P2241, DOI 10.1016/j.nano.2017.05.013
   Shi YP, 2013, MOL PHARMACEUT, V10, P2479, DOI 10.1021/mp4001266
   Takeuchi I, 2017, COLLOID SURFACE B, V155, P35, DOI 10.1016/j.colsurfb.2017.03.047
   Vibet S, 2007, DRUG METAB DISPOS, V35, P822, DOI 10.1124/dmd.106.013474
   Wang F, 2016, TECHNOL CANCER RES T, V15, pNP105, DOI 10.1177/1533034615618849
   Zhang R, 2019, ADV EXP MED BIOL, V1164, P161, DOI 10.1007/978 3 030 22254 3_13
   Zhang XY, 2018, ONCOTARGET, V9, P2105, DOI 10.18632/oncotarget.23249
NR 20
TC 1
Z9 1
U1 1
U2 13
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 4110
EI 1687 4129
J9 J NANOMATER
JI J. Nanomater.
PD AUG 1
PY 2020
VL 2020
AR 2391412
DI 10.1155/2020/2391412
PG 10
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA NC7FV
UT WOS:000561382000001
OA gold
DA 2025 08 17
ER

PT J
AU Funayama, N
   Yagyuu, T
   Imada, M
   Ueyama, Y
   Nakagawa, Y
   Kirita, T
AF Funayama, Naoki
   Yagyuu, Takahiro
   Imada, Mitsuhiko
   Ueyama, Yoshihiro
   Nakagawa, Yosuke
   Kirita, Tadaaki
TI Impact of beta tricalcium phosphate on preventing tooth
   extraction triggered bisphosphonate related osteonecrosis of the jaw in
   rats
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SEQUENCE DATABASES; BONE REGENERATION; AUTOPHAGY; PEPTIDES; PROTEIN;
   MODEL; ACID; CARCINOGENICITY; IDENTIFICATION; PREDICTION
AB Antiresorptive or antiangiogenic drugs can cause medication related osteonecrosis of the jaw that is refractory. Bisphosphonate related osteonecrosis of the jaw (BRONJ) may be caused by procedures such as tooth extraction damage the alveolar bone, release bisphosphonates (BPs) and impede healing. This study investigated strategies for BRONJ prevention and molecular mechanisms of its onset. We assessed the effectiveness of filling extraction sockets with beta tricalcium phosphate (beta TCP). Rats were administered zoledronic acid (ZA) 1.2 mg/kg once per week for 2 weeks, and a molar was extracted. They were randomly assigned to the beta TCP group (bone defects filled with 0.01 g of beta TCP) or control group. Tissue content measurements indicated 2.2 ng of ZA per socket in the beta TCP group and 4.9 ng in the control group, confirming BP distribution and BP adsorption by beta TCP in vivo. At 4 weeks after extraction, the beta TCP group had normal mucosal coverage without inflammation. Moreover, at 8 weeks after extraction, enhanced bone healing, socket coverage, and new bone formation were observed in the beta TCP group. Connective tissue in the extraction sockets suggested that local increases in BP concentrations may suppress the local autophagy mechanisms involved in BRONJ. Filling extraction sockets with beta TCP may prevent BRONJ.
C1 [Funayama, Naoki; Yagyuu, Takahiro; Imada, Mitsuhiko; Ueyama, Yoshihiro; Nakagawa, Yosuke; Kirita, Tadaaki] Nara Med Univ, Dept Oral & Maxillofacial Surg, 840 Shijo Cho,Kashihara Shi, Nara 6348521, Japan.
C3 Nara Medical University
RP Yagyuu, T (通讯作者)，Nara Med Univ, Dept Oral & Maxillofacial Surg, 840 Shijo Cho,Kashihara Shi, Nara 6348521, Japan.
EM t yagyuu@naramed u.ac.jp
RI Yagyuu, Takahiro/GZK 7684 2022
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Aisa Z, 2017, EUR REV MED PHARMACO, V21, P3705
   Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159 8290.CD 19 0292
   Baradari H, 2011, SCI TECHNOL ADV MAT, V12, DOI 10.1088/1468 6996/12/5/055008
   Bigi A, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9010006
   Boanini E, 2012, J PHYS CHEM C, V116, P15812, DOI 10.1021/jp304472s
   Borke JL, 2015, J CRANIO MAXILL SURG, V43, P1144, DOI 10.1016/j.jcms.2015.05.021
   Bullock G, 2020, MATERIALS, V13, DOI 10.3390/ma13092086
   Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673
   Cui YT, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201901073
   Czaja MJ, 2016, DIGEST DIS SCI, V61, P1304, DOI 10.1007/s10620 015 4025 x
   da Silva JR, 2022, CRANIOMAX TRAUM REC, V15, P304, DOI 10.1177/19433875211048367
   de Almeida AD, 2018, J BIOMED MATER RES B, V106, P1799, DOI 10.1002/jbm.b.33995
   Drake LE, 2017, SEMIN CANCER BIOL, V47, P110, DOI 10.1016/j.semcancer.2017.04.008
   ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044 0305(94)80016 2
   Fazil M, 2015, DRUG DELIV, V22, P1, DOI 10.3109/10717544.2013.870259
   Flecknell P A., 2016, Laboratory animal anaesthesia, VFourth
   Hadad H, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 20128 4
   Hirota M, 2009, DENT MATER J, V28, P153, DOI 10.4012/dmj.28.153
   Ikebe T, 2013, ORAL SCI INT, V10, P1, DOI 10.1016/S1348 8643(12)00045 6
   Imada M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211928
   Josse S, 2005, BIOMATERIALS, V26, P2073, DOI 10.1016/j.biomaterials.2004.05.019
   Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Kitasato S, 2020, J BIOMED MATER RES A, V108, P528, DOI 10.1002/jbm.a.36833
   Laohakulvivat N., 2022, P RSU INT RES C
   Liu J, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00203
   Lodi G, 2010, J ORAL MAXIL SURG, V68, P107, DOI 10.1016/j.joms.2009.07.068
   MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002
   Mann M, 1996, TRENDS BIOCHEM SCI, V21, P494, DOI 10.1016/S0968 0004(96)30042 X
   Matsumoto T, 2011, TISSUE ENG PT A, V17, P171, DOI 10.1089/ten.TEA.2010.0077
   McLeod NMH, 2014, J ORAL MAXIL SURG, V72, P503, DOI 10.1016/j.joms.2013.08.007
   Morishita H, 2019, ANNU REV CELL DEV BI, V35, P453, DOI 10.1146/annurev cellbio 100818 125300
   Nixon RA, 2007, J CELL SCI, V120, P4081, DOI 10.1242/jcs.019265
   Ogino N, 2019, EXP CELL RES, V385, DOI 10.1016/j.yexcr.2019.111651
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Paulo S, 2020, MATERIALS, V13, DOI 10.3390/ma13081955
   Paulo S, 2019, MATERIALS, V12, DOI 10.3390/ma12111840
   Peng LF, 2011, PROTEOMICS, V11, P4376, DOI 10.1002/pmic.201100169
   Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522 2683(19991201)20:18<3551::AID ELPS3551>3.0.CO;2 2
   Poxleitner P, 2017, DTSCH ARZTEBL INT, V114, P63, DOI 10.3238/arztebl.2017.0063
   Roberts J., 2008, Trans. Orthop. Res. Soc, V33, P615
   Román J, 2008, J BIOMED MATER RES A, V84A, P99, DOI 10.1002/jbm.a.31394
   Scheper MA, 2009, BRIT J HAEMATOL, V144, P667, DOI 10.1111/j.1365 2141.2008.07504.x
   Silverman LD, 2007, J ORTHOP RES, V25, P23, DOI 10.1002/jor.20284
   Sun ZP, 2021, CIRCULATION, V144, P788, DOI 10.1161/CIRCULATIONAHA.121.053255
   Tarafder S, 2014, ACS APPL MATER INTER, V6, P9955, DOI 10.1021/am501048n
   Udoh UAS, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23147734
   Ueyama Y, 2016, ARCH ORAL BIOL, V72, P138, DOI 10.1016/j.archoralbio.2016.08.017
   Wojda U, 2008, IUBMB LIFE, V60, P575, DOI 10.1002/iub.91
   Yagyuu T, 2015, J ORAL PATHOL MED, V44, P523, DOI 10.1111/jop.12262
   Yagyuu T, 2015, J TISSUE ENG REGEN M, V9, P276, DOI 10.1002/term.1674
   Yamanaka H, 2007, PROTEOMICS, V7, P781, DOI 10.1002/pmic.200600235
   Yamanaka Hidenori, 2008, Cancer Genomics & Proteomics, V5, P105
   YATES JR, 1995, ANAL CHEM, V67, P3202, DOI 10.1021/ac00114a016
   Yoneda T, 2017, J BONE MINER METAB, V35, P6, DOI 10.1007/s00774 016 0810 7
   Zhao JD, 2010, ORTHOPEDICS, V33, P546, DOI 10.3928/01477447 20100625 15
NR 57
TC 3
Z9 3
U1 1
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD SEP 25
PY 2023
VL 13
IS 1
AR 16032
DI 10.1038/s41598 023 43315 3
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AD6I3
UT WOS:001116558400094
PM 37749392
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Satija, NK
   Sharma, D
   Afrin, F
   Tripathi, RP
   Gangenahalli, G
AF Satija, Neeraj Kumar
   Sharma, Deepa
   Afrin, Farhat
   Tripathi, Rajendra P.
   Gangenahalli, Gurudutta
TI High Throughput Transcriptome Profiling of Lithium Stimulated Human
   Mesenchymal Stem Cells Reveals Priming towards Osteoblastic Lineage
SO PLOS ONE
LA English
DT Article
ID MARROW STROMAL CELLS; INHIBITS OSTEOGENIC DIFFERENTIATION; BINDING
   PROTEIN ALPHA; IN VITRO EXPANSION; BONE MARROW; GENE EXPRESSION;
   GROWTH FACTOR; KINASE ACTIVATION; MICROARRAY DATA; WNT
AB Human mesenchymal stem cells (hMSCs) present in the bone marrow are the precursors of osteoblasts, chondrocytes and adipocytes, and hold tremendous potential for osteoregenerative therapy. However, achieving directed differentiation into osteoblasts has been a major concern. The use of lithium for enhancing osteogenic differentiation has been documented in animal models but its effect in humans is not clear. We, therefore, performed high throughput transcriptome analysis of lithium treated hMSCs to identify altered gene expression and its relevance to osteogenic differentiation. Our results show suppression of proliferation and enhancement of alkaline phosphatase (ALP) activity upon lithium treatment of hMSCs under non osteogenic conditions. Microarray profiling of lithium stimulated hMSC revealed decreased expression of adipogenic genes (CEBPA, CMKLR1, HSD11B1) and genes involved in lipid biosynthesis. Interestingly, osteoclastogenic factors and immune responsive genes (IL7, IL8, CXCL1, CXCL12, CCL20) were also downregulated. Negative transcriptional regulators of the osteogenic program (TWIST1 and PBX1) were suppressed while genes involved in mineralization like CLEC3B and ATF4 were induced. Gene ontology analysis revealed enrichment of upregulated genes related to mesenchymal cell differentiation and signal transduction. Lithium priming led to enhanced collagen 1 synthesis and osteogenic induction of lithium pretreated MSCs resulted in enhanced expression of Runx2, ALP and bone sialoprotein. However, siRNA mediated knockdown of RRAD, CLEC3B and ATF4 attenuated lithium induced osteogenic priming, identifying a role for RRAD, a member of small GTP binding protein family, in osteoblast differentiation. In conclusion, our data highlight the transcriptome reprogramming potential of lithium resulting in higher propensity of lithium "primed" MSCs for osteoblastic differentiation.
C1 [Satija, Neeraj Kumar; Sharma, Deepa; Tripathi, Rajendra P.; Gangenahalli, Gurudutta] Inst Nucl Med & Allied Sci, Stem Cell & Gene Therapy Res Grp, Delhi, India.
   [Afrin, Farhat] Hamdard Univ, Dept Biotechnol, New Delhi, India.
C3 Defence Research & Development Organisation (DRDO); Institute of Nuclear
   Medicine & Allied Sciences (INMAS); Jamia Hamdard University
RP Gangenahalli, G (通讯作者)，Inst Nucl Med & Allied Sci, Stem Cell & Gene Therapy Res Grp, Brig SK Mazumdar Marg, Delhi, India.
EM gugdutta@rediffmail.com
RI ; Afrin, Farhat/F 2346 2018; Sharma, Dr Deepa/HNR 6780 2023
OI Satija, Neeraj/0000 0002 4571 327X; Afrin, Farhat/0000 0003 4443 4284; 
FU Defence Research and Development Organisation, Ministry of Defence,
   Government of India
FX This work was supported by funding from Defence Research and Development
   Organisation, Ministry of Defence, Government of India. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Baghaban Eslaminejad M., 2008, IRAN J BASIC MED SCI, V11, P143
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509
   Berridge M.V., 1996, Biochemica, P14, DOI DOI 10.1016/J.YEXMP.2016.05.008
   Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534 5807(04)00058 9
   Bolton JM, 2008, J CLIN PSYCHOPHARM, V28, P384, DOI 10.1097/JCP.0b013e31817d5943
   Bujalska IJ, 2008, J ENDOCRINOL, V197, P297, DOI 10.1677/JOE 08 0050
   Caunt CJ, 2008, J BIOL CHEM, V283, P6241, DOI 10.1074/jbc.M706624200
   Chen SQ, 2007, J CELL COMMUN SIGNAL, V1, P175, DOI 10.1007/s12079 007 0015 x
   Choi YA, 2010, J PROTEOME RES, V9, P2946, DOI 10.1021/pr901110q
   Churchill GA, 2002, NAT GENET, V32, P490, DOI 10.1038/ng1031
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698
   Curtis RK, 2005, TRENDS BIOTECHNOL, V23, P429, DOI 10.1016/j.tibtech.2005.05.011
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   De Boer J, 2004, TISSUE ENG, V10, P393, DOI 10.1089/107632704323061753
   Elabd C, 2008, STEM CELLS, V26, P2399, DOI 10.1634/stemcells.2008 0127
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gordon JAR, 2010, MOL CELL BIOL, V30, P3531, DOI 10.1128/MCB.00889 09
   Gregory CA, 2003, J BIOL CHEM, V278, P28067, DOI 10.1074/jbc.M300373200
   Gregory CA, 2005, J BIOL CHEM, V280, P2309, DOI 10.1074/jbc.M406275200
   Harmey D, 2004, J BONE MINER RES, V19, P661, DOI 10.1359/JBMR.040105
   Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001
   Hipskind Robert A., 1998, Frontiers in Bioscience, V3, pD804
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Isenmann S, 2009, STEM CELLS, V27, P2457, DOI 10.1002/stem.181
   Johnston J, 2010, TRANSGENIC RES, V19, P1017, DOI 10.1007/s11248 010 9376 7
   Justesen J, 2004, ENDOCRINOLOGY, V145, P1916, DOI 10.1210/en.2003 1427
   Kanazawa I, 2009, AM J PHYSIOL ENDOC M, V296, pE139, DOI 10.1152/ajpendo.90677.2008
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Klapholz Brown Z, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000945
   Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood 2004 11 4349
   Krause U, 2010, P NATL ACAD SCI USA, V107, P4147, DOI 10.1073/pnas.0914360107
   Kubo H, 2009, GENES CELLS, V14, P407, DOI 10.1111/j.1365 2443.2009.01281.x
   Kugimiya F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000837
   Lai WT, 2011, STEM CELLS, V29, P1102, DOI 10.1002/stem.661
   Larsen KH, 2010, J BONE MINER RES, V25, P796, DOI 10.1359/jbmr.091018
   Larson BL, 2008, STEM CELLS, V26, P193, DOI 10.1634/stemcells.2007 0524
   Li JJ, 2011, BONE, V48, P321, DOI 10.1016/j.bone.2010.09.033
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003 4819 112 5 352
   McEachin RC, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752 0509 4 158
   Motomura H, 2007, BIOCHEM BIOPH RES CO, V357, P997, DOI 10.1016/j.bbrc.2007.04.035
   Murie C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471 2105 10 45
   Muruganandan S, 2010, J BONE MINER RES, V25, P222, DOI 10.1359/jbmr.091106
   Neth P, 2006, STEM CELLS, V24, P1892, DOI 10.1634/stemcells.2005 0503
   Neuhuber B, 2008, EXP HEMATOL, V36, P1176, DOI 10.1016/j.exphem.2008.03.019
   Oh YT, 2010, J BIOL CHEM, V285, P41310, DOI 10.1074/jbc.M110.153775
   Ohnaka K, 2001, BIOCHEM BIOPH RES CO, V287, P337, DOI 10.1006/bbrc.2001.5597
   Okuda A, 1998, EMBO J, V17, P2019, DOI 10.1093/emboj/17.7.2019
   Pandey R, 2004, BIOINFORMATICS, V20, P2156, DOI 10.1093/bioinformatics/bth215
   Qu GW, 2006, BONE, V38, P21, DOI 10.1016/j.bone.2005.07.013
   Quarto R, 2001, NEW ENGL J MED, V344, P385, DOI 10.1056/NEJM200102013440516
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Riekstina U, 2009, STEM CELL REV REP, V5, P378, DOI 10.1007/s12015 009 9094 9
   Rintala J, 1999, NEUROREPORT, V10, P3887, DOI 10.1097/00001756 199912160 00030
   Rosário M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801
   Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500
   Satija NK, 2007, STEM CELLS DEV, V16, P7, DOI 10.1089/scd.2006.9998
   Satija NK, 2009, J CELL MOL MED, V13, P4385, DOI 10.1111/j.1582 4934.2009.00857.x
   Seelan RS, 2008, NEUROSCIENCE, V151, P1184, DOI 10.1016/j.neuroscience.2007.10.045
   Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20 6 530
   Shahdadfar A, 2005, STEM CELLS, V23, P1357, DOI 10.1634/stemcells.2005 0094
   Shim M, 2003, J BIOL CHEM, V278, P19674, DOI 10.1074/jbc.M301356200
   Sinha D, 2005, AM J PHYSIOL RENAL, V288, pF703, DOI 10.1152/ajprenal.00189.2004
   Smith JR, 2004, STEM CELLS, V22, P823, DOI 10.1634/stemcells.22 5 823
   Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960 9822(02)70790 2
   Tamma R, 2009, P NATL ACAD SCI USA, V106, P7149, DOI 10.1073/pnas.0901890106
   Tamura M, 2011, INT J BIOCHEM CELL B, V43, P760, DOI 10.1016/j.biocel.2011.01.021
   Tang GH, 2011, J DENT RES, V90, P336, DOI 10.1177/0022034510389180
   Vestergaard P, 2005, CALCIFIED TISSUE INT, V77, P1, DOI 10.1007/s00223 004 0258 y
   WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0
   Ward Y, 2002, J CELL BIOL, V157, P291, DOI 10.1083/jcb.200111026
   Warden SJ, 2010, BONE, V46, P985, DOI 10.1016/j.bone.2009.12.031
   WEWER UM, 1994, J CELL BIOL, V127, P1767, DOI 10.1083/jcb.127.6.1767
   Wilting I, 2007, BONE, V40, P1252, DOI 10.1016/j.bone.2006.12.055
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yang XL, 2004, J BIOL CHEM, V279, P47109, DOI 10.1074/jbc.M410010200
   Yoshida K, 2007, ORAL DIS, V13, P32, DOI 10.1111/j.1601 0825.2006.01239.x
   Yoshiko Y, 2003, ENDOCRINOLOGY, V144, P4134, DOI 10.1210/en.2003 0130
   Zamani A, 2009, BONE, V44, P331, DOI 10.1016/j.bone.2008.10.001
   Zaragosi LE, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471 2121 9 11
   Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200
   Zhang WV, 2005, APOPTOSIS, V10, P75, DOI 10.1007/s10495 005 6063 x
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zhao YX, 2007, P NATL ACAD SCI USA, V104, P9673, DOI 10.1073/pnas.0703407104
NR 92
TC 55
Z9 65
U1 1
U2 31
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JAN 30
PY 2013
VL 8
IS 1
AR e55769
DI 10.1371/journal.pone.0055769
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 098QM
UT WOS:000315563800188
PM 23383279
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Taheem, DK
   Jell, G
   Gentleman, E
AF Taheem, Dheraj K.
   Jell, Gavin
   Gentleman, Eileen
TI Hypoxia Inducible Factor 1α in Osteochondral Tissue Engineering
SO TISSUE ENGINEERING PART B REVIEWS
LA English
DT Article
DE HIF 1 alpha; hypoxia; cartilage; osteochondral tissue engineering
ID MESENCHYMAL STEM CELLS; LIMB BUD MESENCHYME; NITRIC OXIDE; CHONDROGENIC
   DIFFERENTIATION; ARTICULAR CARTILAGE; GENE EXPRESSION; OXYGEN TENSION;
   PROLYL 4 HYDROXYLASES; MATRIX SYNTHESIS; II COLLAGEN
AB Damage to osteochondral (OC) tissues can lead to pain, loss of motility, and progress to osteoarthritis. Tissue engineering approaches offer the possibility of replacing damaged tissues and restoring joint function; however, replicating the spatial and functional heterogeneity of native OC tissue remains a pressing challenge. Chondrocytes in healthy cartilage exist in relatively low oxygen conditions, while osteoblasts in the underlying bone experience higher oxygen pressures. Such oxygen gradients also exist in the limb bud, where they influence OC tissue development. The cellular response to these spatial variations in oxygen pressure, which is mediated by the hypoxia inducible factor (HIF) pathway, plays a central role in regulating osteo  and chondrogenesis by directing progenitor cell differentiation and promoting and maintaining appropriate extracellular matrix production. Understanding the role of the HIF pathway in OC tissue development may enable new approaches to engineer OC tissue. In this review, we discuss strategies to spatially and temporarily regulate the HIF pathway in progenitor cells to create functional OC tissue for regenerative therapies. Impact statement Strategies to engineer osteochondral (OC) tissue are limited by the complex and varying microenvironmental conditions in native bone and cartilage. Indeed, native cartilage experiences low oxygen conditions, while the underlying bone is relatively normoxic. The cellular response to these low oxygen conditions, which is mediated through the hypoxia inducible factor (HIF) pathway, is known to promote and maintain the chondrocyte phenotype. By using tissue engineering scaffolds to spatially and temporally harness the HIF pathway, it may be possible to improve OC tissue engineering strategies for the regeneration of damaged cartilage and its underlying subchondral bone.
C1 [Taheem, Dheraj K.; Gentleman, Eileen] Kings Coll London, Ctr Craniofacial & Regenerat Biol, London SE1 9RT, England.
   [Jell, Gavin] UCL, Div Surg & Intervent Sci, London, England.
C3 University of London; King's College London; University of London;
   University College London
RP Gentleman, E (通讯作者)，Kings Coll London, Ctr Craniofacial & Regenerat Biol, London SE1 9RT, England.
EM eileen.gentleman@kcl.ac.uk
RI ; Jell, Gavin/C 4893 2009
OI Gentleman, Eileen/0000 0003 0447 5137; Jell, Gavin/0000 0001 8115 1609
FU Orthopaedic Research United Kingdom; Rosetrees Trust; Wellcome Trust
   [WT093687]; Leverhulme Trust; Rosetrees [M572] Funding Source:
   researchfish
FX D.K.T. acknowledges a PhD studentship from Orthopaedic Research United
   Kingdom and support from the Rosetrees Trust. E.G. was supported by a
   Research Career Development Fellowship from the Wellcome Trust
   (WT093687) and a Philip Leverhulme Prize from the Leverhulme Trust.
CR Ahn DR, 2009, BIOORG MED CHEM LETT, V19, P4403, DOI 10.1016/j.bmcl.2009.05.083
   Alemdar N, 2017, ACS BIOMATER SCI ENG, V3, P1964, DOI 10.1021/acsbiomaterials.6b00109
   Amarilio R, 2007, DEVELOPMENT, V134, P3917, DOI 10.1242/dev.008441
   Araldi E, 2011, NAT MED, V17, P25, DOI 10.1038/nm0111 25
   Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969
   Armstrong JPK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8405
   Aro E, 2012, J BIOL CHEM, V287, P37134, DOI 10.1074/jbc.M112.352872
   Bao WK, 2010, J CARDIOVASC PHARM, V56, P147, DOI 10.1097/FJC.0b013e3181e2bfef
   Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392
   Beuck S, 2012, DRUG TEST ANAL, V4, P830, DOI 10.1002/dta.390
   Brix B, 2012, J NEUROSCI, V32, P9727, DOI 10.1523/JNEUROSCI.0879 12.2012
   Brucker PU, 2005, ARTHRITIS RHEUM US, V52, P3181, DOI 10.1002/art.21346
   Buckley DL, 2012, J AM CHEM SOC, V134, P4465, DOI 10.1021/ja209924v
   Chin K, 2008, BIOTECHNOL PROGR, V24, P358, DOI 10.1021/bp070160f
   Chowdhury R, 2013, ACS CHEM BIOL, V8, P1488, DOI 10.1021/cb400088q
   Chowdhury R, 2011, J MOL BIOL, V410, P268, DOI 10.1016/j.jmb.2011.04.075
   Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200
   Coyle CH, 2009, J ORTHOP RES, V27, P793, DOI 10.1002/jor.20816
   Da H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054838
   Déry MAC, 2005, INT J BIOCHEM CELL B, V37, P535, DOI 10.1016/j.biocel.2004.08.012
   Duval E, 2012, BIOMATERIALS, V33, P6042, DOI 10.1016/j.biomaterials.2012.04.061
   Duval E, 2009, ARTHRITIS RHEUM US, V60, P3038, DOI 10.1002/art.24851
   Dy P, 2012, DEV CELL, V22, P597, DOI 10.1016/j.devcel.2011.12.024
   Flagg SC, 2012, J INORG BIOCHEM, V113, P25, DOI 10.1016/j.jinorgbio.2012.03.002
   Foyt DA, 2019, ACTA BIOMATER, V89, P73, DOI 10.1016/j.actbio.2019.03.002
   Foyt DA, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201700939
   Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899
   Gelse K, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2508
   Gorres KL, 2010, CRIT REV BIOCHEM MOL, V45, P106, DOI 10.3109/10409231003627991
   Grayson WL, 2010, OSTEOARTHR CARTILAGE, V18, P714, DOI 10.1016/j.joca.2010.01.008
   Grogan SP, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2719
   Harley BA, 2010, J BIOMED MATER RES A, V92A, P1078, DOI 10.1002/jbm.a.32387
   Hatta T, 2014, TISSUE ENG PT A, V20, P2720, DOI [10.1089/ten.tea.2013.0353, 10.1089/ten.TEA.2013.0353]
   Hattori T, 2010, DEVELOPMENT, V137, P901, DOI 10.1242/dev.045203
   Henry SP, 2012, J BONE MINER RES, V27, P2511, DOI 10.1002/jbmr.1696
   Holden P, 2019, TISSUE ENG PART B RE, V25, P461, DOI [10.1089/ten.TEB.2019.0111, 10.1089/ten.teb.2019.0111]
   Hong YR, 2013, BIOORG MED CHEM LETT, V23, P5953, DOI 10.1016/j.bmcl.2013.08.067
   Isaacs JS, 2004, J BIOL CHEM, V279, P16128, DOI 10.1074/jbc.M313342200
   Jeon JE, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0184
   Kanichai M, 2008, J CELL PHYSIOL, V216, P708, DOI 10.1002/jcp.21446
   Kelly TJ, 2011, MOL CELL BIOL, V31, P2696, DOI 10.1128/MCB.01242 10
   Kim J, 2019, ACS NANO, V13, P3206, DOI 10.1021/acsnano.8b08785
   Koga H, 2007, STEM CELLS, V25, P689, DOI 10.1634/stemcells.2006 0281
   Koivunen P, 2007, J BIOL CHEM, V282, P4524, DOI 10.1074/jbc.M610415200
   Kon E, 2013, BONE JOINT RES, V2, P18, DOI 10.1302/2046 3758.22.2000092
   Kon E, 2010, INJURY, V41, P693, DOI 10.1016/j.injury.2009.11.014
   Lafont JE, 2007, ARTHRITIS RHEUM, V56, P3297, DOI 10.1002/art.22878
   Lam J, 2014, ACTA BIOMATER, V10, P1112, DOI 10.1016/j.actbio.2013.11.020
   Leijten JCH, 2012, ARTHRITIS RHEUM US, V64, P3302, DOI 10.1002/art.34535
   Leijten J, 2014, P NATL ACAD SCI USA, V111, P13954, DOI 10.1073/pnas.1410977111
   Li F, 2007, MOL CELL, V26, P63, DOI 10.1016/j.molcel.2007.02.024
   Li H, 2018, INT J MOL MED, V42, P3181, DOI 10.3892/ijmm.2018.3921
   Littmann E, 2018, J EUR CERAM SOC, V38, P877, DOI 10.1016/j.jeurceramsoc.2017.08.001
   Liu YV, 2007, J BIOL CHEM, V282, P37064, DOI 10.1074/jbc.M705015200
   Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001
   Long FX, 1998, DEVELOPMENT, V125, P1067
   Luo L, 2017, J TISSUE ENG REGEN M, V11, P2613, DOI 10.1002/term.2162
   Mabjeesh NJ, 2002, CANCER RES, V62, P2478
   Mackie EJ, 2011, J ENDOCRINOL, V211, P109, DOI 10.1530/JOE 11 0048
   Maes C, 2012, NAT REV RHEUMATOL, V8, P358, DOI 10.1038/nrrheum.2012.36
   Maes C, 2012, J BONE MINER RES, V27, P596, DOI 10.1002/jbmr.1487
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Makris EA, 2013, OSTEOARTHR CARTILAGE, V21, P634, DOI 10.1016/j.joca.2013.01.007
   Makris EA, 2014, P NATL ACAD SCI USA, V111, pE4832, DOI 10.1073/pnas.1414271111
   Mangiavini L, 2014, DEV BIOL, V393, P124, DOI 10.1016/j.ydbio.2014.06.013
   Markway BD, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4272
   Mateo J, 2003, BIOCHEM J, V376, P537, DOI 10.1042/BJ20031155
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   McCullen SD, 2012, TISSUE ENG PT A, V18, P2073, DOI [10.1089/ten.tea.2011.0606, 10.1089/ten.TEA.2011.0606]
   Mcgrath K., 2019, PEPTIDE ACTIVATORS V
   Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.E02 12 0791
   Mohan N, 2011, TISSUE ENG PT A, V17, P2845, DOI 10.1089/ten.tea.2011.0135
   Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945 053X(03)00006 4
   Nagel S, 2010, ANTIOXID REDOX SIGN, V12, P481, DOI 10.1089/ars.2009.2711
   Nakayama K, 2009, MOL CANCER RES, V7, P443, DOI 10.1158/1541 7786.MCR 08 0458
   Nguyen LK, 2013, J CELL SCI, V126, P1454, DOI 10.1242/jcs.119974
   Nilsson O, 2007, J ENDOCRINOL, V193, P75, DOI 10.1677/joe.1.07099
   Paciello A, 2016, ADV HEALTHC MATER, V5, P2655, DOI 10.1002/adhm.201600559
   Palmer LA, 2007, J CLIN INVEST, V117, P2592, DOI 10.1172/JCI29444
   Park YK, 2008, MOL PHARMACOL, V74, P236, DOI 10.1124/mol.108.045278
   Pfander D, 2003, J CELL SCI, V116, P1819, DOI 10.1242/jcs.00385
   Pfander D, 2004, DEVELOPMENT, V131, P2497, DOI 10.1242/dev.01138
   Prosser HCG, 2014, CARDIOVASC RES, V101, P145, DOI 10.1093/cvr/cvt234
   Provot S, 2007, J CELL BIOL, V177, P451, DOI 10.1083/jcb.200612023
   Robins JC, 2005, BONE, V37, P313, DOI 10.1016/j.bone.2005.04.040
   Saadat E, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2040
   Sant S, 2010, CAN J CHEM ENG, V88, P899, DOI 10.1002/cjce.20411
   Sathy BN, 2019, ACTA BIOMATER, V88, P314, DOI 10.1016/j.actbio.2019.02.042
   Schipani E, 2001, GENE DEV, V15, P2865
   Semenza GL., 2007, SCI STKE, DOI DOI 10.1126/STKE.4072007CM8
   Serra Pérez A, 2010, J BIOL CHEM, V285, P18217, DOI 10.1074/jbc.M110.101048
   Sthijns MMJPE, 2018, J TISSUE ENG REGEN M, V12, P2013, DOI 10.1002/term.2730
   Ströbel S, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2942
   Sun GX, 2013, J BIOMED SCI, V20, DOI 10.1186/1423 0127 20 100
   Swieszkowski W, 2007, BIOMOL ENG, V24, P489, DOI 10.1016/j.bioeng.2007.07.014
   Taheem DK, 2018, STEM CELLS, V36, P1380, DOI 10.1002/stem.2844
   Tamaddon M, 2017, SCI REP UK, V7, DOI 10.1038/srep43519
   Tan GK, 2011, BIOMATERIALS, V32, P5600, DOI 10.1016/j.biomaterials.2011.04.033
   Tan JTM, 2014, FASEB J, V28, P206, DOI 10.1096/fj.13 233874
   Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298
   Teti G, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3237253
   Thoms BL, 2013, ARTHRITIS RHEUM US, V65, P1302, DOI 10.1002/art.37867
   Thoms BL, 2010, J BIOL CHEM, V285, P20472, DOI 10.1074/jbc.M110.115238
   Tian YM, 2011, J BIOL CHEM, V286, P13041, DOI 10.1074/jbc.M110.211110
   Undt G, 2018, OR SURG OR MED OR PA, V126, P117, DOI 10.1016/j.oooo.2018.02.017
   WANG GL, 1993, BLOOD, V82, P3610
   Wang XQ, 2009, J CONTROL RELEASE, V134, P81, DOI 10.1016/j.jconrel.2008.10.021
   Wetterau M, 2011, WOUND REPAIR REGEN, V19, P481, DOI 10.1111/j.1524 475X.2011.00697.x
   Yang S, 2010, NAT MED, V16, P687, DOI 10.1038/nm.2153
   Yang XM, 2009, INVEST OPHTH VIS SCI, V50, P1873, DOI 10.1167/iovs.08 2591
   Yasinska IM, 2003, FEBS LETT, V549, P105, DOI 10.1016/S0014 5793(03)00807 X
   Zhou NA, 2015, CELL PHYSIOL BIOCHEM, V36, P44, DOI 10.1159/000374052
NR 112
TC 35
Z9 36
U1 1
U2 33
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3368
EI 1937 3376
J9 TISSUE ENG PART B RE
JI Tissue Eng. Part B Rev.
PD APR 1
PY 2020
VL 26
IS 2
BP 105
EP 115
DI 10.1089/ten.teb.2019.0283
EA JAN 2020
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering;
   Materials Science
GA LD8KZ
UT WOS:000506452700001
PM 31774026
OA Green Submitted, Green Published, hybrid, Green Accepted
DA 2025 08 17
ER

PT J
AU Murnaghan, M
   Li, G
   Marsh, DR
AF Murnaghan, Mark
   Li, Gang
   Marsh, David R.
TI Nonsteroidal anti inflammatory drug induced fracture nonunion: An
   inhibition of angiogenesis?
SO JOURNAL OF BONE AND JOINT SURGERY AMERICAN VOLUME
LA English
DT Article; Proceedings Paper
CT 13th International Symposium on Bone Circulation
CY SEP 15 17, 2005
CL Imperial Coll, London, ENGLAND
SP Assoc Res Circulat Osseous
HO Imperial Coll
ID ENDOTHELIAL GROWTH FACTOR; TUMOR NECROSIS FACTOR; BONE REPAIR;
   SPINAL FUSION; FACTOR ALPHA; IN VIVO; CANCER; NSAID; PROSTAGLANDIN E2;
   RECEPTORS
AB Background: Approximately 5% to 10% of fractures may result in delayed union or nonunion. The results of research done over the past three decades have shown that the use of nonsteroidal anti inflammatory drugs (NSAIDs) has an inhibitory effect on fracture repair, but the exact mechanism of action remains to be elucidated. Cancer research has identified that NSAIDs impede cell proliferation by inhibiting angiogenesis. It is proposed that a similar mechanism occurs in the induction of NSAID induced nonunions. This hypothesis was investigated in a randomized placebo controlled trial of the NSAID rofecoxib with use of a murine femoral fracture model.
   Methods: Two hundred and forty mice were randomized to receive either the nonsteroidal anti inflammatory drug rofecoxib (5 mg/kg orally) in a 0.5% methylcellulose solution (the NSAID group) or the 0.5% methylcellulose solution only (the control group). Two hundred and thirty five of the 240 mice underwent surgery to induce an open transverse mid diaphyseal femoral fracture, which was then treated with use of a custom made external fixator. Five additional animals underwent sham surgery with no fracture induced. Outcomes measures included radiographic assessment, histologic analysis, biomechanical testing, and use of laser Doppler flowmetry to assess blood flow across the fracture gap.
   Results: Radiography revealed similar healing patterns in both groups; however, at the later stages (day 32), the NSAID group had poorer healing. Histological analysis demonstrated that the control animals healed quicker (at days 24 and 32) and had more callus and less fibrous tissue (at days 8 and 32) than the NSAID animals did. Biomechanical testing found that the control animals were stronger at day 32. Both groups exhibited a similar pattern of blood flow; however, the NSAID group exhibited a lower median flow from day 4 onward (significant at days 4, 16, and 24). Positive correlations were demonstrated between both histological and radiographic assessments of healing and increasing blood flow. NSAID treated animals exhibited lower blood flow and poorer healing by all parameters. Regression analysis, however, demonstrated that the negative effect of NSAIDs on fracture repair is independent of its inhibitory action on blood flow.
   Conclusions: Following the development of a novel method of analyzing functional vascularity across a fracture gap, we have demonstrated that the cyclooxygenase .2 (COX 2) inhibitor rofecoxib has a significant negative effect on blood flow across the fracture gap as well as an inhibiting effect on fracture repair.
   Clinical Relevance: COX 2 inhibitors are marketed as having low side effect profiles. We propose that these drugs should be used with caution in all patients following osseous trauma and, in particular, after injuries that may already predispose a fracture to a delayed union due to osseous, vascular, or patient related factors.
C1 Queens Univ Belfast, Musgrave Pk Hosp, Dept Trauma & Orthopaed Surg, Belfast BT9 7JB, Antrim, North Ireland.
C3 Queens University Belfast
RP Murnaghan, M (通讯作者)，Queens Univ Belfast, Musgrave Pk Hosp, Dept Trauma & Orthopaed Surg, 20 Stockmans Lane, Belfast BT9 7JB, Antrim, North Ireland.
EM m.murnaghan@qub.ac.uk
CR Aizawa T, 2001, J ORTHOP RES, V19, P785, DOI 10.1016/S0736 0266(00)00078 4
   Burd TA, 2003, J BONE JOINT SURG BR, V85B, P700, DOI 10.1302/0301 620X.85B5.13970
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   Clauss M, 2001, BLOOD, V97, P1321, DOI 10.1182/blood.V97.5.1321
   CONNOLLY C, 2001, THESIS QUEENS U BELF, P265
   Connolly CK, 2003, J ORTHOPAED RES, V21, P843, DOI 10.1016/S0736 0266(03)00041 X
   Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523 1747.1998.00262.x
   Fendrick AM, 2002, AM J MANAG CARE, V8, pS529
   GarciaVicuna R, 1997, ARTHRITIS RHEUM US, V40, P143, DOI 10.1002/art.1780400119
   Gaudry M, 1997, BLOOD, V90, P4153, DOI 10.1182/blood.V90.10.4153
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   Gerstenfeld LC, 2001, CELLS TISSUES ORGANS, V169, P285, DOI 10.1159/000047893
   Giannoudis PV, 2000, J BONE JOINT SURG BR, V82B, P655, DOI 10.1302/0301 620X.82B5.9899
   Glassman SD, 1998, SPINE, V23, P834, DOI 10.1097/00007632 199804010 00020
   Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736 0266(02)00079 7
   Harada S I, 1995, Connect Tissue Res, V31, P279, DOI 10.3109/03008209509010823
   in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178
   Jänne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606
   Jee WSS, 1997, BONE, V21, P297, DOI 10.1016/S8756 3282(97)00147 6
   Jones MK, 1999, NAT MED, V5, P1418
   KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36
   KEASTBUTLER O, 2005, ARCO ISFR COMB S
   LI XJ, 1990, BONE, V11, P353, DOI 10.1016/8756 3282(90)90091 C
   Long J, 2002, J BONE JOINT SURG AM, V84A, P1763, DOI 10.2106/00004623 200210000 00004
   MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149
   Martin GJ, 1999, SPINE, V24, P2188, DOI 10.1097/00007632 199911010 00003
   McCourt M, 1999, ARCH SURG CHICAGO, V134, P1325, DOI 10.1001/archsurg.134.12.1325
   MORI S, 1990, BONE, V11, P103, DOI 10.1016/8756 3282(90)90057 6
   Müller N, 2002, AM J PSYCHIAT, V159, P1029, DOI 10.1176/appi.ajp.159.6.1029
   Murnaghan JM, 2003, BRIT J GEN PRACT, V53, P407
   Pufe T, 2002, CELL TISSUE RES, V309, P387, DOI 10.1007/s00441 002 0605 0
   RO J, 1976, ACTA ORTHOP SCAND, V47, P588, DOI 10.3109/17453677608988744
   Shirley D, 2005, J ORTHOP RES, V23, P1013, DOI 10.1016/j.orthres.2005.01.013
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Thun MJ, 2002, JNCI J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252
   TRUETA J, 1960, J BONE JOINT SURG BR, V42, P97, DOI 10.1302/0301 620X.42B1.97
   Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092 8674(00)81433 6
   Tsujii M, 1998, CELL, V94
   Uchida S, 2003, BONE, V32, P491, DOI 10.1016/S8756 3282(03)00053 X
   *US FDA CTR DRUG E, DOS CALC
   VONHALLER A, 1762, OPERA MINORA EMENDAT, P400
   Winet H, 1996, BONE, V19, pS39, DOI 10.1016/S8756 3282(96)00133 0
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 43
TC 93
Z9 101
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0021 9355
EI 1535 1386
J9 J BONE JOINT SURG AM
JI J. Bone Joint Surg. Am. Vol.
PD NOV
PY 2006
VL 88A
SU 3
BP 140
EP 147
DI 10.2106/JBJS.F.00454
PG 8
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Orthopedics; Surgery
GA 102XX
UT WOS:000241848000021
PM 17079380
DA 2025 08 17
ER

PT J
AU Wakasugi, M
   Narita, I
AF Wakasugi, Minako
   Narita, Ichiei
TI Impact of adherence to CKD MBD guidelines on mortality among Japanese
   dialysis patients: an ecological study
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE CKD MBD; Dialysis; Ecological study; Regional variation; Standardized
   mortality ratio
ID GENERAL POPULATION; THERAPY GUIDELINES; DISEASE; HEMODIALYSIS;
   PHOSPHATE; SURVIVAL; OUTCOMES; SOCIETY; CALCIUM; MANAGEMENT
AB Introduction This study evaluated the association between prefecture level achievement of chronic kidney disease mineral and bone disorder (CKD MBD) parameter targets and mortality in Japanese dialysis patients. Materials and methods We conducted an ecological study of all prefectures in Japan using data from the Japanese Society of Dialysis Therapy and National Vital Statistics between 2016 and 2017. We calculated adherence rates to recommend target ranges for CKD MBD parameters, including phosphate, corrected calcium, and parathyroid hormone (PTH), and explored associations of these rates with prefecture specific standardized mortality rates (SMRs) among the general population and among prevalent dialysis patients using bivariate association analysis and structural equation modeling. Results Prefecture level adherence to the target phosphate range was significantly and negatively associated with prefecture specific SMRs in men (standardized estimate (beta) =   0.61, p < 0.001) and women (beta =   0.41, p < 0.001). However, prefecture level adherence to the target corrected calcium range was significantly and negatively associated with prefecture specific SMRs only in men (beta =   0.28, p = 0.01). Meanwhile, prefecture level adherence to the target PTH range was significantly and positively associated with prefecture specific SMRs in men (beta = 0.23, p = 0.04). Prefecture level SMRs of females in the general population had a significant impact on prefecture level SMRs of female dialysis patients (beta = 0.27, p = 0.03). The models explained 52% of variance in SMR for men and 33% for women. Conclusion A higher prefecture level achievement rate of the target phosphate range recommended by the Japanese CKD MBD guidelines was associated with a lower prefecture specific SMR in the Japanese dialysis population.
C1 [Wakasugi, Minako] Niigata Univ, Dept Interorgan Commun Res, Grad Sch Med & Dent Sci, Chuo Ku, Asahimachi 1 757, Niigata 9518510, Japan.
   [Narita, Ichiei] Niigata Univ, Div Clin Nephrol & Rheumatol, Grad Sch Med & Dent Sci, Niigata, Japan.
C3 Niigata University; Niigata University
RP Wakasugi, M (通讯作者)，Niigata Univ, Dept Interorgan Commun Res, Grad Sch Med & Dent Sci, Chuo Ku, Asahimachi 1 757, Niigata 9518510, Japan.
EM minakowa@med.niigata u.ac.jp
RI Wakasugi, Minako/D 6814 2018; Narita, Ichiei/G 5204 2017
OI Wakasugi, Minako/0000 0003 1555 7736; 
FU JSPS KAKENHI [JP18K08202]
FX This work was supported by a research grant from JSPS KAKENHI
   (Grants in Aid for Scientific Research, Grant Number JP18K08202) to MW.
   No funding agency had any role in the study design, collection, analysis
   and interpretation of data, writing the report, and the decision to
   submit the report for publication.
CR Akiba T, 2012, THER APHER DIAL, V16, P289, DOI 10.1111/j.1744 9987.2012.01078.x
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Floege J, 2011, NEPHROL DIAL TRANSPL, V26, P1948, DOI 10.1093/ndt/gfq219
   Fouque D, 2018, CLIN KIDNEY J, V11, P73, DOI 10.1093/ckj/sfx101
   Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744 9987.12058
   Furumatsu Y, 2010, NEPHROL DIAL TRANSPL, V25, P1930, DOI 10.1093/ndt/gfp738
   Hirakata H, 2012, THER APHER DIAL, V16, P387, DOI 10.1111/j.1744 9987.2012.01088.x
   Ijaz K, 2020, INT J HUM COMPUT INT, V36, P1195, DOI 10.1080/10447318.2020.1726107
   Isaka Y, 2021, J AM SOC NEPHROL, V32, P723, DOI 10.1681/ASN.2020050598
   Itaya T, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen 2021 051002
   Kakuta T, 2018, THER APHER DIAL, V22, P220, DOI 10.1111/1744 9987.12690
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Ketteler M, 2017, KIDNEY INT, V92, P26, DOI 10.1016/j.kint.2017.04.006
   Kukita K, 2015, THER APHER DIAL, V19, P1, DOI 10.1111/1744 9987.12296
   Masakane I, 2018, Renal Replacement Therapy, V4, P45, DOI [10.1186/s41100 018 0183 6, DOI 10.1186/S41100 018 0183 6]
   Nitta K, 2019, RENAL REPLACE THER, V5, DOI 10.1186/s41100 019 0248 1
   Noordzij M, 2005, AM J KIDNEY DIS, V46, P925, DOI 10.1053/j.ajkd.2005.08.013
   Ogata S, 2015, HEMODIAL INT, V19, pS5, DOI 10.1111/hdi.12346
   Ogata S, 2011, CLIN EXP NEPHROL, V15, P405, DOI 10.1007/s10157 010 0400 2
   Palomares I, 2013, BLOOD PURIFICAT, V36, P122, DOI 10.1159/000353418
   Schober P, 2018, ANESTH ANALG, V126, P1763, DOI 10.1213/ANE.0000000000002864
   Suzuki E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039876
   Taniguchi M, 2013, THER APHER DIAL, V17, P221, DOI 10.1111/1744 9987.12030
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Wakasugi M., 2021, JPN J NEPHROL, V63, P179
   Wakasugi M., 2022, INTERNAL MED, DOI 10.2169/internalmedicine.8981 21
   Wakasugi M, 2019, NEPHROL DIAL TRANSPL, V34, P1207, DOI 10.1093/ndt/gfy253
   Wakasugi M, 2016, NEPHROL DIAL TRANSPL, V31, P1501, DOI 10.1093/ndt/gfw249
   Wakasugi M, 2015, THER APHER DIAL, V19, P45, DOI 10.1111/1744 9987.12192
   Wakasugi M, 2013, THER APHER DIAL, V17, P298, DOI 10.1111/j.1744 9987.2012.01144.x
   Wakasugi M, 2012, THER APHER DIAL, V16, P226, DOI 10.1111/j.1744 9987.2012.01062.x
   Watanabe Y, 2015, THER APHER DIAL, V19, P93, DOI 10.1111/1744 9987.12293
   Yamamoto H., 2017, Ren Replace Ther, V3, DOI DOI 10.1186/S41100 017 0114 Y
   Yoshino M, 2006, J AM SOC NEPHROL, V17, P3510, DOI 10.1681/ASN.2006020156
   Young EW, 2004, AM J KIDNEY DIS, V44, pS34, DOI 10.1053/j.ajkd.2004.08.009
NR 35
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD SEP
PY 2022
VL 40
IS 5
BP 810
EP 818
DI 10.1007/s00774 022 01351 5
EA JUN 2022
PG 9
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 4L1QG
UT WOS:000817061900002
PM 35759144
DA 2025 08 17
ER

PT J
AU Kelly, SP
   Ramkumar, DB
   Peacock, ZS
   Newman, ET
   Venrick, C
   Lozano Calderon, SA
   Raskin, KA
   Chebib, I
   Schwab, JH
AF Kelly, Sean P.
   Ramkumar, Dipak B.
   Peacock, Zachary S.
   Newman, Erik T.
   Venrick, Connor
   Lozano Calderon, Santiago A.
   Raskin, Kevin A.
   Chebib, Ivan
   Schwab, Joseph H.
TI Sclerostin immunohistochemical staining in surgically treated giant cell
   tumor of bone
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE giant cell tumor of bone; immunohistochemistry; sclerostin
ID POSTMENOPAUSAL WOMEN; EXPRESSION; OSTEOPROTEGERIN; DENOSUMAB
AB Background Giant cell tumor of bone (GCTB) is a destructive lesion with a high potential for recurrence. RANK ligand targeted therapy has provided promising, yet mixed results. Sclerostin (SOST) inhibition results in a net anabolic response and is currently used in the treatment of osteoporosis. The application to GCTB is unknown. Objectives We sought to determine if GCTB stained for SOST on immunohistochemistry and correlate its expression with predictor variables. Methods All patients at a single institution undergoing surgery for GCTB between 1993 and 2008 with a minimum of 6 months follow up were included. Primary outcomes included the presence of SOST staining, secondary outcomes included the correlation of patient and tumor specific predictor variables. Results SOST antibody staining of any cell type was present in 47 of 48 cases (97.9%). Positivity of the stromal cells was present in 39 of 48 cases (81.3%) and was associated with radiographic aggressiveness (p = 0.023), symptomatic presentation (p = 0.032), prior surgery (p = 0.005), and patient age (p = 0.034). Positivity of giant cells was present in 41 of 48 cases (85.4%) and was not significant with predictive factors. Conclusions Sclerostin staining in GCTB is a novel finding and warrants further research to define the role of sclerostin as a prognostic factor and therapeutic target.
C1 [Kelly, Sean P.; Venrick, Connor] Tripler Army Med Ctr, Dept Orthopaed Surg, Honolulu, HI 96859 USA.
   [Ramkumar, Dipak B.; Newman, Erik T.; Lozano Calderon, Santiago A.; Raskin, Kevin A.; Schwab, Joseph H.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
   [Ramkumar, Dipak B.] Boston Childrens Hosp, Dept Orthopaed Surg, Boston, MA USA.
   [Peacock, Zachary S.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA.
   [Chebib, Ivan] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
C3 Tripler Army Medical Center; United States Department of Defense; United
   States Army; Harvard University; Harvard University Medical Affiliates;
   Massachusetts General Hospital; Harvard University; Harvard University
   Medical Affiliates; Boston Children's Hospital; Harvard University;
   Harvard University Medical Affiliates; Massachusetts General Hospital;
   Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital
RP Kelly, SP (通讯作者)，Tripler Army Med Ctr, Dept Orthopaed Surg, Med Ctr, 1 Jarrett White Rd, Honolulu, HI 96859 USA.
EM spk2117@gmail.com
RI ; Peacock, Zachary/AAF 9942 2019
OI Peacock, Zachary/0000 0001 7683 3111; Kelly, Sean/0000 0003 4254 9504;
   HUITRON, EFREN/0009 0008 2046 3359
CR Al Sukaini A, 2017, CLIN ORTHOP RELAT R, V475, P3071, DOI 10.1007/s11999 017 5451 1
   Atkins GJ, 2001, BONE, V28, P370, DOI 10.1016/S8756 3282(01)00404 5
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   ENNEKING WF, 1986, CLIN ORTHOP RELAT R, P9
   Errani C, 2018, J BONE JOINT SURG AM, V100, P496, DOI 10.2106/JBJS.17.00057
   Evenepoel P, 2015, J CLIN ENDOCR METAB, V100, P4669, DOI 10.1210/jc.2015 3056
   Guañabens N, 2016, J BONE MINER RES, V31, P1725, DOI 10.1002/jbmr.2845
   Huang L, 2000, AM J PATHOL, V156, P761, DOI 10.1016/S0002 9440(10)64942 5
   Inagaki Y, 2016, HISTOPATHOLOGY, V69, P470, DOI 10.1111/his.12953
   James IE, 1996, J BONE MINER RES, V11, P1453
   Kelly SP., 2021, J CRANIOFAC SURG, DOI [10.1097/scs.0000000000008344, DOI 10.1097/SCS.0000000000008344]
   Kendler DL, 2019, OSTEOPOROSIS INT, V30, P2437, DOI 10.1007/s00198 019 05146 9
   Langdahl Bente L, 2017, Lancet, V390, P1585, DOI 10.1016/S0140 6736(17)31613 6
   Mak IWY, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.01332
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Peacock ZS, 2012, J ORAL MAXIL SURG, V70, P2573, DOI 10.1016/j.joms.2011.12.005
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Sano K, 2020, J ORTHOP SURG HONG K, V28, DOI 10.1177/2309499020929786
   Shen J, 2016, HUM PATHOL, V58, P24, DOI 10.1016/j.humpath.2016.07.016
   Tsukamoto S, 2020, CLIN ORTHOP RELAT R, V478, P1076, DOI 10.1097/CORR.0000000000001074
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   van Bezooijen RL, 2007, DEV DYNAM, V236, P606, DOI 10.1002/dvdy.21054
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Wu L, 2016, INT J MOL MED, V38, P1395, DOI 10.3892/ijmm.2016.2741
   Zhu MH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11913 7
NR 26
TC 1
Z9 2
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 4790
EI 1096 9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD SEP
PY 2022
VL 126
IS 3
BP 571
EP 576
DI 10.1002/jso.26903
EA APR 2022
PG 6
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Surgery
GA 3G4GI
UT WOS:000784270700001
PM 35446992
DA 2025 08 17
ER

PT J
AU Zhao, JJ
   Zhang, YY
   Liu, B
AF Zhao, Jianjun
   Zhang, Yanyan
   Liu, Bo
TI MicroRNA 204 5p inhibits the osteogenic differentiation of ankylosing
   spondylitis fibroblasts by regulating the Notch2 signaling pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE ankylosing spondylitis; miRNA 204 5p; Notch2; osteogenic
   differentiation; ligament fibroblasts
ID BONE MORPHOGENETIC PROTEIN 2; MESENCHYMAL STEM CELLS; OSTEOBLAST
   DIFFERENTIATION; EXPRESSION; PROLIFERATION; THERAPY; OSSIFICATION;
   OSTEOCALCIN; ACTIVATION; RUNX2
AB Ankylosing spondylitis (AS) is a chronic inflammatory systemic disease and is difficult to detect in the early stages. The present study aimed to investigate the role of microRNA(miR) 204 5pin osteogenic differentiation of AS fibroblasts. Bone morphogenetic protein 2 (BMP 2) was used to induce osteogenic differentiation. Cells were divided into the following groups: AS group, AS + BMP 2 group, AS + BMP 2 + miR negative control group, AS + BMP 2 +miR 204 5pmimics group and AS + BMP 2 +miR 204 5pmimics + pcDNA Notch2 group. The expression levels ofmiR 204 5p, Notch2, runt related transcription factor 2 (RUNX2) and osteocalcin were detected via reverse transcription quantitative PCR analysis. The binding site between Notch2 andmiR 204 5pwas predicted using TargetScan software and verified via the dual luciferase reporter assay. Alkaline phosphatase (ALP) activity was assessed via the ALP assay, while the mineralized nodules area was determined via the Alizarin Red S staining assay. The results demonstrated that Notch2 is a target gene ofmiR 204 5p. Furthermore, treatment with BMP 2 significantly decreasedmiR 204 5pexpression, and significantly increased ALP activity, the mineralized nodules area and the expression levels of Notch2, RUNX2 and osteocalcin in ligament fibroblasts (all P<0.05). Conversely, transfection withmiR 204 5pmimics significantly increasedmiR 204 5pexpression, and significantly decreased ALP activity, the mineralized nodules area and the expression levels of Notch2, RUNX2 and osteocalcin in ligament fibroblasts (all P<0.05). Notably, transfection with pcDNA Notch2 significantly reversed the inhibitory effects induced by miR 204 5p mimics on the osteogenic differentiation of ligament fibroblasts (all P<0.05). Furthermore,miR 204 5pinhibited the osteogenic differentiation of ligament fibroblasts in patients with AS by targeting Notch2. Thus,miR 204 5pmay negatively regulate Notch2 expression and may be a potential therapeutic target for AS. Collectively, the results of the present study provide a theoretical basis for the effective treatment of patients with AS.
C1 [Zhao, Jianjun] Shouguang Peoples Hosp, Dept Joint Surg & Traumat Orthoped, Shouguang 262700, Shandong, Peoples R China.
   [Zhang, Yanyan] Shouguang Peoples Hosp, Dept Gen Surg, Shouguang 262700, Shandong, Peoples R China.
   [Liu, Bo] 4 Hosp Jinan, Dept Trauma Orthoped, 50 Shifan Rd, Jinan 250031, Shandong, Peoples R China.
RP Liu, B (通讯作者)，4 Hosp Jinan, Dept Trauma Orthoped, 50 Shifan Rd, Jinan 250031, Shandong, Peoples R China.
EM libo20199@163.com
RI Zhao, Hong/IUQ 0043 2023
CR Ahsan T, 2016, PAK J MED SCI, V32, P365, DOI 10.12669/pjms.322.9366
   [Anonymous], 2016, CHINESE PHARMACOL B, DOI DOI 10.3969/J.ISSN.1001 1978.2016.10.024
   [Anonymous], 2016, WIRELESS NETW GER, DOI DOI 10.1007/978 3 319 33207 9_1
   Cai BJ, 2017, INT J ONCOL, V51, P1941, DOI 10.3892/ijo.2017.4173
   DARBY SC, 1987, BRIT J CANCER, V55, P179, DOI 10.1038/bjc.1987.35
   Dean LE, 2014, RHEUMATOLOGY, V53, P650, DOI 10.1093/rheumatology/ket387
   FRANCK H, 1993, ANN RHEUM DIS, V52, P343, DOI 10.1136/ard.52.5.343
   Hayes AJ, 2003, J ANAT, V202, P495, DOI 10.1046/j.1469 7580.2003.00185.x
   He HH, 2015, INT J MOL MED, V35, P1587, DOI 10.3892/ijmm.2015.2160
   Huang JX, 2017, CLIN LAB, V63, P955, DOI 10.7754/Clin.Lab.2017.161214
   Hupkes M, 2014, BMC MOL BIOL, V15, DOI 10.1186/1471 2199 15 1
   Jeon MJ, 2003, J BIOL CHEM, V278, P23270, DOI 10.1074/jbc.M211610200
   Jethwa H, 2016, CLIN EXP IMMUNOL, V183, P30, DOI 10.1111/cei.12670
   Jung JI, 2018, DIFFERENTIATION, V101, P1, DOI 10.1016/j.diff.2018.03.001
   Kanayama S, 2018, SPINE, V43, pE616, DOI 10.1097/BRS.0000000000002439
   Karamanlioglu DS, 2016, RHEUMATOL INT, V36, P653, DOI 10.1007/s00296 016 3441 3
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Kwon SR, 2012, RHEUMATOL INT, V32, P2523, DOI 10.1007/s00296 011 1981 0
   Lee H, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477 7819 12 334
   Liu Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11149
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Perez Sanchez C, 2018, HUM MOL GENET, V27, P875, DOI 10.1093/hmg/ddy008
   Qin X, 2018, J CELL BIOCHEM, V119, P1074, DOI 10.1002/jcb.26275
   Raychaudhuri SP, 2014, J AUTOIMMUN, V48 49, P128, DOI 10.1016/j.jaut.2014.01.015
   Robinson PC, 2016, NPJ GENOM MED, V3, DOI 10.1038/npjgenmed.2016.8
   Roozbehkia M, 2017, INT IMMUNOPHARMACOL, V52, P191, DOI 10.1016/j.intimp.2017.08.018
   Ruan ZB, 2016, BIOMED PHARMACOTHER, V84, P666, DOI 10.1016/j.biopha.2016.09.078
   Shang GW, 2018, J CELL PHYSIOL, V233, P6041, DOI 10.1002/jcp.26424
   Smith DM, 2008, J CRANIOFAC SURG, V19, P1244, DOI 10.1097/SCS.0b013e3181843312
   Solmaz D, 2015, BMJ S2, V74, pAB0157
   Song R, 2017, J BIOL CHEM, V292, P8657, DOI 10.1074/jbc.M117.783308
   Sun J, 2015, MOL MED REP, V12, P4230, DOI 10.3892/mmr.2015.3954
   VANDERLINDEN SM, 1984, ARTHRITIS RHEUM, V27, P241
   Wang GL, 2018, MOL MED REP, V17, P2731, DOI 10.3892/mmr.2017.8117
   Wang MM, 2017, MED SCI MONITOR, V23, P5488, DOI 10.12659/MSM.905238
   Wang T, 2017, CLIN SPINE SURG, V30, pE13, DOI 10.1097/BSD.0000000000000171
   Wang Y, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.217
   Wang YJ, 2015, J CARDIOVASC PHARM, V66, P63, DOI 10.1097/FJC.0000000000000244
   Wegman F, 2011, EUR CELLS MATER, V21, P230, DOI 10.22203/eCM.v021a18
   Wei Y., 2018, CHIN J CELL BIOL, V40, P478
   Xu W, 2015, INT J CLIN EXP PATHO, V8, P2737
   Yu C, 2018, CARDIOVASC RES, V114, P168, DOI 10.1093/cvr/cvx180
   Yu FC, 2011, BIOSCI TRENDS, V5, P46, DOI 10.5582/bst.2011.v5.2.46
   Zhao JL, 2020, RHEUMATOL INT, V40, P859, DOI 10.1007/s00296 020 04537 0
   Zhao JM, 2014, ACTA BIOCH BIOPH SIN, V46, P885, DOI 10.1093/abbs/gmu082
   Zhou Y, 2013, P NATL ACAD SCI USA, V110, P8966, DOI 10.1073/pnas.1218145110
   Zhou YY, 2016, EXP THER MED, V12, P347, DOI 10.3892/etm.2016.3292
   Zhou YY, 2015, JOINT BONE SPINE, V82, P100, DOI 10.1016/j.jbspin.2014.05.004
   Zou YC, 2016, CONNECT TISSUE RES, V57, P200, DOI 10.3109/03008207.2015.1127916
   Zou YC, 2016, DRUG DES DEV THER, V10, P933, DOI 10.2147/DDDT.S97463
NR 50
TC 9
Z9 11
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD SEP
PY 2020
VL 22
IS 3
BP 2537
EP 2544
DI 10.3892/mmr.2020.11303
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA NG4EI
UT WOS:000563936800090
PM 32705191
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Parker, C
   Nilsson, S
   Heinrich, D
   Helle, SI
   O'Sullivan, JM
   Fosså, SD
   Chodacki, A
   Wiechno, P
   Logue, J
   Seke, M
   Widmark, A
   Johannessen, DC
   Hoskin, P
   Bottomley, D
   James, ND
   Solberg, A
   Syndikus, I
   Kliment, J
   Wedel, S
   Boehmer, S
   Dall'Oglio, M
   Franzén, L
   Coleman, R
   Vogelzang, NJ
   O'Bryan Tear, CG
   Staudacher, K
   Garcia Vargas, J
   Shan, M
   Bruland, OS
   Sartor, O
AF Parker, C.
   Nilsson, S.
   Heinrich, D.
   Helle, S. I.
   O'Sullivan, J. M.
   Fossa, S. D.
   Chodacki, A.
   Wiechno, P.
   Logue, J.
   Seke, M.
   Widmark, A.
   Johannessen, D. C.
   Hoskin, P.
   Bottomley, D.
   James, N. D.
   Solberg, A.
   Syndikus, I.
   Kliment, J.
   Wedel, S.
   Boehmer, S.
   Dall'Oglio, M.
   Franzen, L.
   Coleman, R.
   Vogelzang, N. J.
   O'Bryan Tear, C. G.
   Staudacher, K.
   Garcia Vargas, J.
   Shan, M.
   Bruland, O. S.
   Sartor, O.
CA ALSYMPCA Investigators
TI Alpha Emitter Radium 223 and Survival in Metastatic Prostate Cancer
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID BONE METASTASES; SKELETAL METASTASES; PHASE II; TARGETED THERAPY;
   CLINICAL TRIALS; RA 223; MULTICENTER; BISPHOSPHONATES; CHEMOTHERAPY;
   MITOXANTRONE
AB Background
   Radium 223 dichloride (radium 223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium 223 as compared with placebo, in addition to the best standard of care, in men with castration resistant prostate cancer and bone metastases.
   Methods
   In our phase 3, randomized, double blind, placebo controlled study, we randomly assigned 921 patients who had received, were not eligible to receive, or declined docetaxel, in a 2:1 ratio, to receive six injections of radium 223 (at a dose of 50 kBq per kilogram of body weight intravenously) or matching placebo; one injection was administered every 4 weeks. In addition, all patients received the best standard of care. The primary end point was overall survival. The main secondary efficacy end points included time to the first symptomatic skeletal event and various biochemical end points. A prespecified interim analysis, conducted when 314 deaths had occurred, assessed the effect of radium 223 versus placebo on survival. An updated analysis, when 528 deaths had occurred, was performed before crossover from placebo to radium 223.
   Results
   At the interim analysis, which involved 809 patients, radium 223, as compared with placebo, significantly improved overall survival (median, 14.0 months vs. 11.2 months; hazard ratio, 0.70; 95% confidence interval [CI], 0.55 to 0.88; two sided P=0.002). The updated analysis involving 921 patients confirmed the radium 223 survival benefit (median, 14.9 months vs. 11.3 months; hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P<0.001). Assessments of all main secondary efficacy end points also showed a benefit of radium 233 as compared with placebo. Radium 223 was associated with low myelosuppression rates and fewer adverse events.
   Conclusions
   In this study, which was terminated for efficacy at the prespecified interim analysis, radium 223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.)
C1 [Parker, C.] Royal Marsden Natl Hlth Serv Fdn Trust, Sutton, Surrey, England.
   [Parker, C.] Inst Canc Res, Sutton, Surrey, England.
   [O'Sullivan, J. M.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland.
   [Logue, J.] Christie Hosp, Manchester, Lancs, England.
   [Hoskin, P.] Mt Vernon Hosp, Ctr Canc, Northwood HA6 2RN, Middx, England.
   [Bottomley, D.] St James Univ Hosp, Leeds, W Yorkshire, England.
   [James, N. D.] Canc Res UK Clin Trials Unit, Sch Canc Sci, Birmingham, W Midlands, England.
   [Syndikus, I.] Clatterbridge Ctr Oncol, Wirral, Merseyside, England.
   [Coleman, R.] Weston Pk Hosp, Sheffield, S Yorkshire, England.
   [Nilsson, S.] Karolinska Univ Hosp, Stockholm, Sweden.
   [Seke, M.] Cent Lasarettet Vaxjo, Vaxjo, Sweden.
   [Widmark, A.] Umea Univ, Umea, Sweden.
   [Franzen, L.] Umea Univ Hosp, S 90185 Umea, Sweden.
   [Franzen, L.] Lanssjukhuset Sundsvall Harnosand Cty Hosp, Sundsvall, Sweden.
   [Heinrich, D.] Akershus Univ Hosp, Lorenskog, Norway.
   [Helle, S. I.] Haukeland Hosp, N 5021 Bergen, Norway.
   [Fossa, S. D.] Radiumhospitalet, Oslo, Norway.
   [Johannessen, D. C.] Ullevaal Univ Hosp, Oslo, Norway.
   [O'Bryan Tear, C. G.; Staudacher, K.] Algeta, Oslo, Norway.
   [Bruland, O. S.] Univ Oslo, Norwegian Radium Hosp, Oslo, Norway.
   [Bruland, O. S.] Univ Oslo, Fac Med, Oslo, Norway.
   [Solberg, A.] St Olavs Hosp, Trondheim, Norway.
   [Chodacki, A.] Hosp Kochova, Chomutov, Czech Republic.
   [Wiechno, P.] Maria Sklodowska Curie Inst Oncol, Warsaw, Poland.
   [Kliment, J.] Univ Hosp, Jessenius Sch Med, Martin, Slovakia.
   [Wedel, S.] Ortenau Klinikum Offenburg Gengenbach, Klin Urol & Kinderurol, Offenburg, Germany.
   [Dall'Oglio, M.] Univ Sao Paulo, Fac Med, Inst Canc Estado Sao Paulo, Hosp Clin, Sao Paulo, Brazil.
   [Vogelzang, N. J.] Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
   [Garcia Vargas, J.; Shan, M.] Bayer HealthCare Pharmaceut, Montville, NJ USA.
   [Sartor, O.] Tulane Canc Ctr, New Orleans, LA USA.
C3 Royal Marsden NHS Foundation Trust; University of London; Institute of
   Cancer Research   UK; Queens University Belfast; Christie NHS Foundation
   Trust; Christie Hospital; Saint James's University Hospital; University
   of Birmingham; Cancer Research UK; Clatterbridge Cancer Centre; Weston
   Park Hospital; Karolinska Institutet; Karolinska University Hospital;
   Umea University; Umea University; Umea University Hospital; University
   of Oslo; University of Oslo; University of Oslo; University of Oslo;
   University of Oslo; Norwegian University of Science & Technology (NTNU);
   Maria Sklodowska Curie National Research Institute of Oncology; Comenius
   University Bratislava; Universidade de Sao Paulo; Comprehensive Cancer
   Centers of Nevada; Bayer AG; Bayer Healthcare Pharmaceuticals; Tulane
   University; Tulane University Hospital
RP Parker, C (通讯作者)，Royal Marsden Hosp, Acad Urol Unit, Downs Rd, Sutton SM2 5PT, Surrey, England.
EM chris.parker@rmh.nhs.uk
RI Perez Gracia, Jose Luis/I 8372 2017; Shan, Ming/D 8582 2012; Sapienza,
   Marcelo/A 4438 2013; James, Nick/AAL 6802 2020; Dall'Oglio,
   Marcos/LIF 3282 2024; Jarzab, Barbara/AAI 7942 2020; Dall'Oglio, Marcos
   Francisco/K 5515 2016; Arbizu, Javier/H 9255 2017
OI Perez Gracia, Jose Luis/0000 0003 4941 9075; Sapienza,
   Marcelo/0000 0001 9766 6332; Mitjavila Casanovas,
   Mercedes/0000 0001 6030 4266; Carles, Joan/0000 0002 9983 5934; Wiechno,
   Pawel/0000 0002 4894 3273; Jarzab, Barbara/0000 0001 9811 9584;
   Dall'Oglio, Marcos Francisco/0000 0002 9611 6846; Bruland, Oyvind
   Sverre/0000 0003 1631 3733; James, Nicholas/0000 0002 7314 8204;
   Falkmer, Ursula/0000 0002 9245 7678; Jarzemski,
   Piotr/0000 0002 9451 7320; O'Sullivan, Joe/0000 0001 6999 2739; Arbizu,
   Javier/0000 0002 8370 5510; Reynes, Gaspar/0000 0001 8636 6094; Hoskin,
   Peter/0000 0001 8323 9567
FU Amgen; Astellas; Bayer; Janssen; Bristol Myers Squibb; BN
   ImmunoTherapeutics; Takeda; Sanofi Aventis; Pfizer; Novartis; Sanofi;
   Janssen Cilag; Medivation; Pierre Fabre; Roche; Debiopharm; Novartis
   Biociencias; AstraZeneca; Dendreon; Johnson Johnson; Aragon; Bavarian
   Nordic; Bellicum; OncoGeneX; Algeta; Bayer HealthCare Pharmaceuticals
FX Supported by Algeta and Bayer HealthCare Pharmaceuticals. Dr. Parker
   reports receiving consulting and lecture fees from Amgen, Astellas,
   Bayer, and Janssen, consulting fees from Bristol Myers Squibb, BN
   ImmunoTherapeutics, and Takeda, and lecture fees from Sanofi Aventis;
   Dr. Nilsson reports serving as an advisory board member for Algeta; Dr.
   Heinrich reports receiving lecture fees from Bayer, Sanofi Aventis,
   Pfizer, and Novartis, payment for the development of educational
   presentations from Bayer and travel support from Bayer, Sanofi Aventis,
   Pfizer, Novartis, and GlaxoSmithKline; Dr. Fossa reports serving as a
   board member for Bristol Myers Squibb and receiving consulting and
   lecture fees from Amgen, Sanofi, and Janssen Cilag; Dr. Widmark reports
   serving as a board member and receiving lecture fees from Astellas, and
   being employed by Sanofi; Dr. James reports receiving consulting fees
   from Janssen, Sanofi, Medivation, Bayer, and Pierre Fabre, receiving
   grant support through his institution from Pfizer, Sanofi, Novartis,
   Amgen, Bayer, Astellas, Janssen, and GlaxoSmithKline, receiving lecture
   fees from Sanofi, Pierre Fabre, Amgen, and Janssen, and travel support
   from Sanofi and Ferring; Dr. Wedel reports receiving consulting fees
   from Roche and Sanofi Aventis, payment for the development of
   educational presentations from Roche, Amgen, and Sanofi Aventis, and
   travel support from Sanofi Aventis, Janssen, Roche, and Pfizer; Dr.
   Dall'Oglio reports serving as a board member and receiving consulting
   fees from Debiopharm, serving as an unpaid consultant to Ferring
   Pharmaceuticals, receiving grant support through his institution from
   GlaxoSmithKline and Novartis Biociencias, and receiving lecture fees
   from AstraZeneca; Dr. Coleman reports receiving consulting and lecture
   fees from Amgen and providing expert testimony for Novartis in cases
   regarding the development of osteonecrosis of the jaw associated with
   use of zoledronic acid, a Novartis product; Dr. Vogelzang reports
   receiving consulting fees from Dendreon, Sanofi Aventis, Amgen, and
   Novartis, consulting and lecture fees from Johnson & Johnson, and
   lecture fees and payment for the development of educational
   presentations from Astellas; Dr. O'Bryan Tear and Ms. Staudacher report
   being employees of and holding stock in Algeta; Dr. Garcia Vargas
   reports being an employee of Bayer; Dr. Shan reports being an employee
   of and holding stock in Bayer; Dr. Bruland reports serving as a board
   member for and holding stock in Algeta, being a co inventor on U. S.
   patent number 6,635,234 B1 regarding Alpharadin, which is owned by
   Algeta, and receiving lecture fees from Novartis and Amgen; and Dr.
   Sartor reports receiving consulting fees from Aragon, Astellas, Bavarian
   Nordic, Bellicum, Dendreon, Medivation, OncoGeneX, and Pfizer,
   consulting fees and grant support through his institution from Johnson &
   Johnson and Sanofi Aventis, and grant support through his institution
   from Algeta, Bayer, and Takeda. No other potential conflict of interest
   relevant to this article was reported.
CR Adami S, 1997, CANCER, V80, P1674, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1674::AID CNCR18>3.0.CO;2 X
   Bruland OS, 2006, CLIN CANCER RES, V12, p6250S, DOI 10.1158/1078 0432.CCR 06 0841
   Cella D, 2009, VALUE HEALTH, V12, P124, DOI 10.1111/j.1524 4733.2008.00409.x
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140 6736(10)61389 X
   Finlay OG, 2005, LANCET ONCOL, V6, P392, DOI 10.1016/S1470 2045(05)70206 0
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Harris V, 2011, CLIN ONCOL UK, V23, P706, DOI 10.1016/j.clon.2011.04.014
   Henriksen G, 2003, J NUCL MED, V44, P252
   Henriksen G, 2002, CANCER RES, V62, P3120
   Kerr C, 2002, LANCET ONCOL, V3, P453, DOI 10.1016/S1470 2045(02)00835 5
   LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502
   Lange PH, 1998, CANCER METAST REV, V17, P331, DOI 10.1023/A:1006106209527
   Lewington VJ, 2005, J NUCL MED, V46, p38S
   Li Yong, 2004, Expert Rev Anticancer Ther, V4, P459, DOI 10.1586/14737140.4.3.459
   Liepe K, 2009, CURR OPIN INVEST DR, V10, P1346
   Lipton A, 2010, SEMIN ONCOL, V37, pS15, DOI 10.1053/j.seminoncol.2010.10.002
   McDevitt MR, 1998, EUR J NUCL MED, V25, P1341, DOI 10.1007/s002590050306
   Nilsson S, 2005, CLIN CANCER RES, V11, P4451, DOI 10.1158/1078 0432.CCR 04 2244
   Nilsson S, 2012, EUR J CANCER, V48, P678, DOI 10.1016/j.ejca.2011.12.023
   Nilsson S, 2007, LANCET ONCOL, V8, P587, DOI 10.1016/S1470 2045(07)70147 X
   OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245
   OKEN MM, 1982, AM J CLIN ONCOL CANC, V5, P649, DOI 10.1097/00000421 198212000 00014
   Parker CC, 2013, EUR UROL, V63, P189, DOI 10.1016/j.eururo.2012.09.008
   Perlroth DJ, 2012, AM SOC CLIN ONC GEN
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sartor O, 2011, ASIAN J ANDROL, V13, P783, DOI 10.1038/aja.2011.120
   Sartor O, 2011, CLIN GENITOURIN CANC, V9, P1, DOI 10.1016/j.clgc.2011.08.001
   Sartor O, 2011, ASIAN J ANDROL, V13, P366, DOI 10.1038/aja.2011.23
   Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
   Silberstein EB, 2000, SEMIN RADIAT ONCOL, V10, P240, DOI 10.1053/srao.2000.6592
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
NR 33
TC 2568
Z9 2730
U1 2
U2 199
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451 1413 USA
SN 0028 4793
EI 1533 4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUL 18
PY 2013
VL 369
IS 3
BP 213
EP 223
DI 10.1056/NEJMoa1213755
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 185DQ
UT WOS:000321945800007
PM 23863050
OA Bronze
DA 2025 08 17
ER

PT J
AU He, HB
   Ren, XB
   Wang, XY
   Shi, XZ
   Wang, XL
   Ding, ZJ
   Gao, P
   Xu, GW
AF He, Hongbing
   Ren, Xiaobin
   Wang, Xiyue
   Shi, Xianzhe
   Wang, Xiaolin
   Ding, Zhongjuan
   Gao, Peng
   Xu, Guowang
TI Therapeutic effect of Yunnan Baiyao on rheumatoid arthritis was
   partially due to regulating arachidonic acid metabolism in osteoblasts
SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
LA English
DT Article
DE Rheumatoid arthritis; Arachidonic acid; Traditional Chinese Medicine;
   Osteoblast; Metabonomics
ID COLLAGEN INDUCED ARTHRITIS; MASS SPECTROMETRY; METHOTREXATE;
   METABONOMICS; SULFASALAZINE; METABOLOMICS; MECHANISMS; INHIBITOR; RATS
AB In order to explore the potential therapeutic effect of Yunnan Baiyao (YNB) on rheumatoid arthritis (RA), rat models were constructed and orally administrated with YNB or methotrexate (MTX) in parallel. Clinical physical, histological and biochemical parameters showed trivial therapeutic difference between YNB and MTX applications. Urine and serum metabonomics results indicated that many endogenous metabolites differentially changed among the rats receiving diverse therapeutic interventions. Among them, the fluctuation of arachidonic acid (AA) was thought to make sense. Thus, its relevant metabolites were subjected to quantitation by using osteoblasts treated by YNB in vitro. It was found that YNB extract of 20 mu g/mL could greatly activate the synthesis of intracellular prostaglandin E 2 and thromboxane B 2 in osteoblasts. Excretion of prostaglandin D 2 could be suppressed but not the thromboxane B 2. This study proved the efficacy of YNB on curing RA and its potential mechanism through modulating AA metabolism in osteoblasts to some extent. (C) 2011 Elsevier B.V. All rights reserved.
C1 [He, Hongbing; Wang, Xiyue; Shi, Xianzhe; Wang, Xiaolin; Gao, Peng; Xu, Guowang] Chinese Acad Sci, Dalian Inst Chem Phys, CAS Key Lab Separat Sci Analyt Chem, Dalian 116023, Peoples R China.
   [He, Hongbing; Ren, Xiaobin; Ding, Zhongjuan] Kunming Med Univ, Affiliated Stomatol Hosp, Kunming 650031, Peoples R China.
C3 Chinese Academy of Sciences; Dalian Institute of Chemical Physics, CAS;
   Kunming Medical University
RP Gao, P (通讯作者)，Chinese Acad Sci, Dalian Inst Chem Phys, CAS Key Lab Separat Sci Analyt Chem, Dalian 116023, Peoples R China.
EM xuhe@medmail.com.cn; xugw@dicp.ac.cn
RI Xu, Guowang/L 6910 2014
FU National Natural Science Foundation of China [81060086, 20805045];
   Nature Science Foundation of Yunnan Province [2010CD215]; China
   International Science and Technology Cooperation [2009DFA41250];
   Ministry of Science and Technology of China; Chinese Academy of Sciences
FX The studies have been supported by the National Natural Science
   Foundation of China (Nos. 81060086 and 20805045), Nature Science
   Foundation of Yunnan Province (2010CD215), China International Science
   and Technology Cooperation Program (2009DFA41250) from the Ministry of
   Science and Technology of China and the Knowledge Innovation Program of
   the Chinese Academy of Sciences.
CR Bijlsma S, 2006, ANAL CHEM, V78, P567, DOI 10.1021/ac051495j
   Chen Q, 2003, INT IMMUNOPHARMACOL, V3, P593, DOI 10.1016/S1567 5769(03)00051 1
   Criswell LA, 2010, IMMUNOL REV, V233, P55, DOI 10.1111/j.0105 2896.2009.00862.x
   Dale J, 2007, NAT CLIN PRACT RHEUM, V3, P450, DOI 10.1038/ncprheum0562
   Dietmair S, 2010, ANAL BIOCHEM, V404, P155, DOI 10.1016/j.ab.2010.04.031
   DINARELLO CA, 1986, J EXP MED, V163, P1433, DOI 10.1084/jem.163.6.1433
   Fraser DA, 1999, RHEUMATOLOGY, V38, P948, DOI 10.1093/rheumatology/38.10.948
   Goldring SR, 2000, ARTHRITIS RES, V2, P33, DOI 10.1186/ar67
   Kaji H, 1996, J BONE MINER RES, V11, P62
   Kooloos WM, 2010, CURR PHARM DESIGN, V16, P164, DOI 10.2174/138161210790112764
   Mayoux Benhamou M. A., 2006, Annales de Readaptation et de Medecine Physique, V49, P385, DOI 10.1016/j.annrmp.2006.04.012
   Mello SBV, 2000, RHEUMATOLOGY, V39, P533, DOI 10.1093/rheumatology/39.5.533
   Nicholson JK, 2011, PHARMACOGENOMICS, V12, P103, DOI 10.2217/PGS.10.157
   Nishikawa M, 2003, ARTHRITIS RHEUM US, V48, P2670, DOI 10.1002/art.11227
   Park YG, 2004, INT IMMUNOPHARMACOL, V4, P779, DOI 10.1016/j.intimp.2004.03.003
   Qiu Yunping, 2008, Chin Med, V3, P3, DOI 10.1186/1749 8546 3 3
   Strand V, 2005, J RHEUMATOL, V32, P590
   Tobón GJ, 2010, J AUTOIMMUN, V35, P10, DOI 10.1016/j.jaut.2009.12.009
   van Wietmarschen H, 2009, JCR J CLIN RHEUMATOL, V15, P330, DOI 10.1097/RHU.0b013e3181ba3926
   Wu ZM, 2010, MOL BIOSYST, V6, P2157, DOI 10.1039/c005291d
   Xiang Z, 2011, PHYTOCHEM ANALYSIS, V22, P411, DOI 10.1002/pca.1296
   Yin PY, 2008, J CHROMATOGR B, V871, P322, DOI 10.1016/j.jchromb.2008.05.043
   Yin PY, 2006, J PROTEOME RES, V5, P2135, DOI 10.1021/pr060256p
   Yin PY, 2009, MOL BIOSYST, V5, P868, DOI 10.1039/b820224a
   Yoshida M, 2005, J RHEUMATOL, V32, P787
   Yoshida M, 2004, PROSTAG LEUKOTR ESS, V71, P351, DOI 10.1016/j.plefa.2004.06.003
   Zhang FX, 2009, TALANTA, V79, P836, DOI 10.1016/j.talanta.2009.05.010
   Zhang P, 2010, RHEUMATOL INT, V30, P713, DOI 10.1007/s00296 010 1370 0
NR 28
TC 30
Z9 40
U1 0
U2 64
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0731 7085
EI 1873 264X
J9 J PHARMACEUT BIOMED
JI J. Pharm. Biomed. Anal.
PD FEB 5
PY 2012
VL 59
BP 130
EP 137
DI 10.1016/j.jpba.2011.10.019
PG 8
WC Chemistry, Analytical; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 857KD
UT WOS:000297716500018
PM 22075375
DA 2025 08 17
ER

PT J
AU Wang, J
   Wang, G
   Gong, L
   Sun, GW
   Shi, B
   Bao, HH
   Duan, Y
AF Wang, Jian
   Wang, Gang
   Gong, Li
   Sun, Guanwen
   Shi, Bin
   Bao, Huhe
   Duan, Yan
TI Isopsoralen regulates PPAR /WNT to inhibit oxidative stress in
   osteoporosis
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE isopsoralen; osteoporosis; oxidative stress; peroxisome
   proliferators activated receptor; WNT
ID POSTMENOPAUSAL OSTEOPOROSIS; INDUCED APOPTOSIS; DIFFERENTIATION;
   PATHWAY; CELLS; WOMEN; PROLIFERATION; OSTEOBLASTS; RISEDRONATE;
   SCLEROSTIN
AB The present study aimed to examine the effects of isopsoralen against postmenopausal osteoporosis in an ovariectomized rat model. The ovariectomized rats were treated with three days 10 mg/kg isopsoralen or with three days 20 mg/kg isopsoralen. Alkaline phosphatase, the oxidative stress indicators and caspase 3/9 were measured using ELISA assay kits. Reverse transcription quantitative polymerase chain reaction was used to measure collagen type I (Col I), osteocalcin and osteoprotegerin mRNA levels. Wnt,  catenin and peroxisome proliferators activated receptor (PPAR ) were analyzed using western blot analysis. Isopsoralen suppressed mature adipocyte differentiation of C2C12 cells, inhibited serum calcium and urinary calcium levels, and reduced the structural scores of articular cartilage and cancellous bone in the proximal tibia metaphysis of mice with postmenopausal osteoporosis. Isopsoralen also promoted the activity of alkaline phosphatase and the mRNA expression levels of Col 1, osterix and osteopontin in mice with postmenopausal osteoporosis. Oxidative stress and activities of caspase 3/9 in the mice with postmenopausal osteoporosis were effectively suppressed by isopsoralen treatment, which upregulated the protein expression of Wnt/ catenin and downregulated the protein expression of PPAR . These findings demonstrated that isopsoralen prevented osteoporosis through the regulation of PPAR /WNT, inhibiting oxidative stress by targeting the PPAR /WNT pathway. These results provide evidence of the potential targeted therapy for isopsoralen in the clinical treatment of postmenopausal osteoporosis.
C1 [Wang, Jian; Sun, Guanwen; Shi, Bin; Bao, Huhe; Duan, Yan] Inner Mongolia Peoples Hosp, Dept Orthoped, 20 Zhaowuda Rd, Hohhot 010010, Inner Mongolia, Peoples R China.
   [Wang, Gang; Gong, Li] Southern Med Univ, Dept Orthoped, Guangzhou 510050, Guangdong, Peoples R China.
C3 Southern Medical University   China
RP Duan, Y (通讯作者)，Inner Mongolia Peoples Hosp, Dept Orthoped, 20 Zhaowuda Rd, Hohhot 010010, Inner Mongolia, Peoples R China.
EM yanduan5058@163.com
RI Wang, Zhiqiang/G 7827 2019
FU Natural Science Foundation of China [81560368]
FX This study was supported by the Natural Science Foundation of China
   (grant no. 81560368).
CR Almeida M, 2009, J BIOL CHEM, V284, P27438, DOI 10.1074/jbc.M109.023572
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Chen GM, 2016, EXP THER MED, V12, P279, DOI 10.3892/etm.2016.3333
   Chen JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013704
   Chung HY, 2013, CLIN INTERV AGING, V8, P597, DOI 10.2147/CIA.S44395
   Feng CY, 2012, CHIN J INTEGR MED, V18, P529, DOI 10.1007/s11655 012 1144 5
   Gatti D, 2014, BONE, V67, P189, DOI 10.1016/j.bone.2014.06.037
   Ge CX, 2016, J CELL PHYSIOL, V231, P587, DOI 10.1002/jcp.25102
   Jiao GL, 2015, MOL MED REP, V12, P7011, DOI 10.3892/mmr.2015.4265
   Krantz E, 2015, J CLIN ENDOCR METAB, V100, P3251, DOI 10.1210/jc.2015 1757
   LeBlanc A, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0128063, 10.1371/journal.pone.0129622]
   Leder BZ, 2014, J CLIN ENDOCR METAB, V99, P1694, DOI 10.1210/jc.2013 4440
   Lee SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080873
   Li J, 2015, INT J CLIN EXP PATHO, V8, P13695
   Liao L, 2016, STEM CELLS, V34, P1054, DOI 10.1002/stem.2274
   Lin H, 2015, BIOCHEM BIOPH RES CO, V460, P422, DOI 10.1016/j.bbrc.2015.03.049
   Lu D, 2016, XENOBIOTICA, V46, P335, DOI 10.3109/00498254.2015.1077403
   Lu HH, 2014, AFR HEALTH SCI, V14, P641, DOI 10.4314/ahs.v14i3.20
   Lv JW, 2015, BIOCHEM BIOPH RES CO, V468, P587, DOI 10.1016/j.bbrc.2015.10.152
   Ming Leiguo, 2011, Zhongguo Zhong Yao Za Zhi, V36, P2124
   Sang CL, 2016, BONE, V84, P78, DOI 10.1016/j.bone.2015.12.012
   Schröder K, 2015, CELL MOL LIFE SCI, V72, P25, DOI 10.1007/s00018 014 1712 2
   Takakuwa M, 2012, BIOL PHARM BULL, V35, P1159, DOI 10.1248/bpb.b12 00200
   Tu MY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144231
   Wang Y, 2011, EVID BASED COMPL ALT, V2011, DOI DOI 10.1093/ECAM/NEN087
   Xu CY, 2016, CURR STEM CELL RES T, V11, P247, DOI 10.2174/1574888X10666150723145707
   Zhu FB, 2015, INT J CLIN EXP MED, V8, P12337
   Zhuang XM, 2013, DRUG METAB DISPOS, V41, P1914, DOI 10.1124/dmd.113.053199
NR 28
TC 31
Z9 39
U1 0
U2 29
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JAN
PY 2018
VL 17
IS 1
BP 1125
EP 1131
DI 10.3892/mmr.2017.7954
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA FT8WG
UT WOS:000423433300144
PM 29115612
OA Bronze
DA 2025 08 17
ER

PT J
AU Camp, E
   Anderson, PJ
   Zannettino, ACW
   Glackin, CA
   Gronthos, S
AF Camp, Esther
   Anderson, Peter J.
   Zannettino, Andrew C. W.
   Glackin, Carlotta A.
   Gronthos, Stan
TI Tyrosine kinase receptor c ros oncogene 1 inhibition alleviates aberrant
   bone formation of TWIST 1 haploinsufficient calvarial cells from
   Saethre Chotzen syndrome patients
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE C ROS 1; calvarial cells; osteoblasts; Saethre Chotzen; TWIST 1;
   Twist 1(del+ ) heterozygous mice
ID CRANIAL SUTURE BIOLOGY; INTRAMEMBRANOUS BONE; CRANIOSYNOSTOSIS;
   EXPRESSION; MET; DIFFERENTIATION; MUTATIONS; GROWTH; GENE; PROTOONCOGENE
AB Saethre Chotzen syndrome (SCS), associated with TWIST 1 mutations, is characterized by premature fusion of cranial sutures. TWIST 1 haploinsufficiency, leads to alterations in suture mesenchyme cellular gene expression patterns, resulting in aberrant osteogenesis and craniosynostosis. We analyzed the expression of the TWIST 1 target, Tyrosine kinase receptor c ros oncogene 1 (C ROS 1) in TWIST 1 haploinsufficient calvarial cells derived from SCS patients and calvaria of Twist 1(del/+) mutant mice and found it to be highly expressed when compared to TWIST 1 wild type controls. Knock down of C ROS 1 expression in TWIST 1 haploinsufficient calvarial cells derived from SCS patients was associated with decreased capacity for osteogenic differentiation in vitro. Furthermore, treatment of human SCS calvarial cells with the tyrosine kinase chemical inhibitor, Crizotinib, resulted in reduced C ROS 1 activity and the osteogenic potential of human SCS calvarial cells with minor effects on cell viability or proliferation. Cultured human SCS calvarial cells treated with Crizotinib exhibited a dose dependent decrease in alkaline phosphatase activity and mineral deposition, with an associated decrease in expression levels of Runt related transcription factor 2 and OSTEOPONTIN, with reduced PI3K/Akt signalling in vitro. Furthermore, Crizotinib treatment resulted in reduced BMP 2 mediated bone formation potential of whole Twist 1(del/+) mutant mouse calvaria organotypic cultures. Collectively, these results suggest that C ROS 1 promotes osteogenic differentiation of TWIST 1 haploinsufficient calvarial osteogenic progenitor cells. Furthermore, the aberrant osteogenic potential of these cells is inhibited by the reduction of C ROS 1. Therefore, targeting C ROS 1 with a pharmacological agent, such as Crizotinib, may serve as a novel therapeutic strategy to alleviate craniosynostosis associated with aberrant TWIST 1 function.
C1 [Camp, Esther; Gronthos, Stan] Univ Adelaide, Adelaide Med Sch, Fac Hlth & Med Sci, Mesenchymal Stem Cell Lab, Adelaide, SA 5005, Australia.
   [Camp, Esther; Anderson, Peter J.; Zannettino, Andrew C. W.; Gronthos, Stan] South Australian Hlth & Med Res Inst, Canc Theme, Adelaide, SA, Australia.
   [Anderson, Peter J.] Womens & Childrens Hosp, Australian Craniofacial Unit, North Adelaide, SA, Australia.
   [Zannettino, Andrew C. W.] Univ Adelaide, Adelaide Med Sch, Fac Hlth & Med Sci, Myeloma Res Lab, Adelaide, SA, Australia.
   [Glackin, Carlotta A.] City Hope Natl Med Ctr, Mol Med & Neurosci, 1500 E Duarte Rd, Duarte, CA 91010 USA.
   [Glackin, Carlotta A.] Beckman Res Inst, Duarte, CA USA.
C3 University of Adelaide; South Australian Health & Medical Research
   Institute (SAHMRI); University of Adelaide; City of Hope; City of Hope;
   Beckman Research Institute of City of Hope
RP Gronthos, S (通讯作者)，Univ Adelaide, Adelaide Med Sch, Fac Hlth & Med Sci, Mesenchymal Stem Cell Lab, Adelaide, SA 5005, Australia.
EM stan.gronthos@adelaide.edu.au
RI ; Gronthos, Stan/Y 4419 2019
OI Zannettino, Andrew/0000 0002 6646 6167; Gronthos,
   Stan/0000 0002 6225 3084
FU National Health and Medical Research Council (Australia) [APP1120989,
   APP1042677]
FX National Health and Medical Research Council (Australia), Grant numbers:
   APP1120989, APP1042677
CR Acquaviva J, 2009, BBA REV CANCER, V1795, P37, DOI 10.1016/j.bbcan.2008.07.006
   Aljohani H, 2015, ONCOTARGET, V6, P20388, DOI 10.18632/oncotarget.3981
   Anderson PJ, 1996, J CRAN GENET DEV BIO, V16, P228
   Anderson PJ, 1997, CLEFT PALATE CRAN J, V34, P79, DOI 10.1597/1545 1569(1997)034<0079:TCSISC>2.3.CO;2
   Arnaoutakis K, 2015, NEW ENGL J MED, V372, P683, DOI 10.1056/NEJMc1415359
   Behr B, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00037
   Bergethon K, 2012, J CLIN ONCOL, V30, P863, DOI 10.1200/JCO.2011.35.6345
   Bradley JP, 1996, CLEFT PALATE CRAN J, V33, P150, DOI 10.1597/1545 1569(1996)033<0150:SICSBV>2.3.CO;2
   Bradley JP, 1996, PLAST RECONSTR SURG, V98, P1039, DOI 10.1097/00006534 199611000 00018
   Cakouros D, 2015, STEM CELLS DEV, V24, P1297, DOI 10.1089/scd.2014.0471
   Cakouros D, 2012, MOL CELL BIOL, V32, P1433, DOI 10.1128/MCB.06315 11
   Camp E, 2017, BONE, V94, P98, DOI 10.1016/j.bone.2016.09.019
   Carver EA, 2002, ANAT REC, V268, P90, DOI 10.1002/ar.10124
   CHEN JM, 1991, ONCOGENE, V6, P257
   CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686
   Christensen JG, 2007, MOL CANCER THER, V6, P3314, DOI 10.1158/1535 7163.MCT 07 0365
   Connerney J, 2008, DEV BIOL, V318, P323, DOI 10.1016/j.ydbio.2008.03.037
   Connerney J, 2006, DEV DYNAM, V235, P1345, DOI 10.1002/dvdy.20717
   Elanko N, 2001, HUM MUTAT, V18, P535, DOI 10.1002/humu.1230
   ElGhouzzi V, 1997, NAT GENET, V15, P42
   Garrett IR, 2003, METH MOLEC MED, V80, P183
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Golden LH, 2004, BONE, V34, P3, DOI 10.1016/j.bone.2003.09.005
   Guenou H, 2005, HUM MOL GENET, V14, P1429, DOI 10.1093/hmg/ddi152
   Guenou H, 2006, AM J PATHOL, V169, P1303, DOI 10.2353/ajpath.2006.060102
   Hayashi M, 2007, J CELL SCI, V120, P1350, DOI 10.1242/jcs.000067
   Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197 36
   Isenmann S, 2009, STEM CELLS, V27, P2457, DOI 10.1002/stem.181
   Johnson D. H. S. W., 1998, HUM GENET, V63, P11
   Johnson D. I. S., 2000, MECH DEVELOP, V1, P4
   Kimonis V. G. J., 2007, SEMINARS PEDIAT NEUR, V14, P11
   Knight SJ, 2014, DEV NEUROPSYCHOL, V39, P159, DOI 10.1080/87565641.2014.886690
   Li Q, 2017, J ELECTR COMPUT ENG, V2017, DOI 10.1155/2017/3451358
   Martin SK, 2010, J BONE MINER RES, V25, P2126, DOI 10.1002/jbmr.114
   Maruyama T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000727
   Menicanin D, 2010, STEM CELLS DEV, V19, P1501, DOI 10.1089/scd.2009.0492
   Mohammad Khalid S., 2008, V455, P37, DOI 10.1007/978 1 59745 104 8_3
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Murray S. S. G. C., 1992, J BONE MINER RES, V7, P7
   Opperman LA, 2000, DEV DYNAM, V219, P472, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1073>3.0.CO;2 F
   Rice D. P. A. T., 2000, DEVELOPMENT, V127, P10
   Rice D. P. R. R., 2003, EUROPEAN J ORTHODONT, V25, P9
   Rice David P., 2008, V12, P22, DOI 10.1159/000115030
   Sahar DE, 2005, DEV BIOL, V280, P344, DOI 10.1016/j.ydbio.2005.01.022
   Shibasaki S, 2015, FEBS OPEN BIO, V5, P341, DOI 10.1016/j.fob.2015.04.008
   SONNENBERG E, 1991, EMBO J, V10, P3693, DOI 10.1002/j.1460 2075.1991.tb04937.x
   SonnenbergRiethmacher E, 1996, GENE DEV, V10, P1184, DOI 10.1101/gad.10.10.1184
   TESSAROLLO L, 1992, DEVELOPMENT, V115, P11
   Timofeevski SL, 2009, BIOCHEMISTRY US, V48, P5339, DOI 10.1021/bi900438w
   Ting MC, 2009, DEVELOPMENT, V136, P855, DOI 10.1242/dev.028605
   Wilkie AOM, 1997, HUM MOL GENET, V6, P1647, DOI 10.1093/hmg/6.10.1647
   Yen HY, 2010, DEV BIOL, V347, P258, DOI 10.1016/j.ydbio.2010.08.010
   Yoshida T, 2005, J ANAT, V206, P437, DOI 10.1111/j.1469 7580.2005.00411.x
   Yousfi M, 2002, HUM MOL GENET, V11, P359, DOI 10.1093/hmg/11.4.359
   Yousfi M, 2001, J CLIN INVEST, V107, P1153, DOI 10.1172/JCI11846
   Zhao H, 2015, NAT CELL BIOL, V17, P386, DOI 10.1038/ncb3139
   Zou HY, 2007, CANCER RES, V67, P4408, DOI 10.1158/0008 5472.CAN 06 4443
NR 57
TC 7
Z9 10
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD SEP
PY 2018
VL 233
IS 9
BP 7320
EP 7332
DI 10.1002/jcp.26563
PG 13
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA GI1JX
UT WOS:000434127700089
PM 29663378
DA 2025 08 17
ER

PT J
AU He, Y
   Chen, GH
   Li, Y
   Li, YM
   Yi, C
   Zhang, XL
   Li, HY
   Zeng, BH
   Wang, C
   Xie, WH
   Zhao, W
   Yu, DS
AF He, Yi
   Chen, Guanhui
   Li, Ye
   Li, Yiming
   Yi, Chen
   Zhang, Xiliu
   Li, Hongyu
   Zeng, Binghui
   Wang, Chao
   Xie, Weihong
   Zhao, Wei
   Yu, Dongsheng
TI Effect of magnetic graphene oxide on cellular behaviors and osteogenesis
   under a moderate static magnetic field
SO NANOMEDICINE NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Osteogenesis; Magnetic graphene oxide; BMSCs; Static magnetic field;
   Wnt/beta cateninAbbreviations: MGO; magnetic graphene oxide; SMF, static
   magnetic field; BMSC, bone mesenchymal stem cells; TE, tissue
   engineering; GO, graphene oxide; IONPs, iron oxide nanoparticles; FDA,
   Food and Drug Administration; DPSCs, dental pulp stem cells; MAPK,
   mitogen activated protein kinase; BTE, bone tissue engineering; BMP 2,
   bone morphogenetic protein 2; DKK1, Dickkopf 1; OIM, osteogenic inducing
   medium; TEM, transmission electron microscopy; EDS, energy dispersive
   spectrometry; FTIR, Fourier transform infrared spectroscopy; VSM,
   vibrating sample magnetometer; DAPI, 4 ',6 diamidino 2 phenylindole;
   CLSM, confocal laser scanning microscopy; CCK 8, Cell Counting Kit 8
   test; OD, optical density; GAPDH, reduced glyceraldehyde phosphate
   dehydrogenase; PVDF, polyvinylidene fluoride; ECL,
   electro chemiluminescence substrate; Runx2, Runt related transcription
   factor 2; GSK 3 beta, glycogen synthase kinase 3 beta; p GSK 3 beta,
   phosphorylation glycogen synthase kinase 3 beta; ANOVA, one way analysis
   of variance; OPN, osteopontin; APC, adenomatous polyposis coli
ID BONE REGENERATION; STEM CELLS; DIFFERENTIATION; SCAFFOLDS; IRON;
   NANOCOMPOSITE; NANOPARTICLES; CYTOTOXICITY; OSTEOBLASTS; TOXICITY
AB The biological behaviors of magnetic graphene oxide (MGO) in a static magnetic field (SMF) are unknown. The current study is to investigate the cellular behaviors, osteogenesis and the mechanism in BMSCs treated with MGO combined with an SMF. Results showed that the synthetic MGO particles were bio compatible and could significantly improve the osteogenesis of BMSCs under SMFs, as verified by elevated alkaline phosphatase activity, mineralized nodule formation, and expressions of mRNA and protein levels. Under SMF at the same intensity, the addition of graphene oxide to Fe3O4 could increase the osteogenic ability of BMSCs. The Wnt/beta catenin pathway was indicated to be related to the MGO driven osteogenic behavior of the BMSCs under SMF. Taken together, our findings suggested that MGO under an SMF could promote osteogenesis in BMSCs through the Wnt/beta catenin pathway and hence should attract more attention for practical applications in bone tissue regeneration. (C) 2021 The Author(s). Published by Elsevier Inc.
C1 [He, Yi; Li, Ye; Li, Yiming; Yi, Chen; Zhang, Xiliu; Li, Hongyu; Zeng, Binghui; Wang, Chao; Xie, Weihong; Zhao, Wei; Yu, Dongsheng] Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Inst Stomatol Res, Guangzhou, Peoples R China.
   [He, Yi; Li, Ye; Li, Yiming; Yi, Chen; Zhang, Xiliu; Li, Hongyu; Zeng, Binghui; Wang, Chao; Xie, Weihong; Zhao, Wei; Yu, Dongsheng] Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, Guangzhou, Peoples R China.
   [Chen, Guanhui] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Stomatol, Shenzhen, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University
RP Zhao, W; Yu, DS (通讯作者)，Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Inst Stomatol Res, Guangzhou, Peoples R China.
EM zhaowei3@mail.sysu.edu.cn; yudsh@mail.sysu.edu.cn
RI li, hongyu/MSZ 8080 2025; Jiang, Yu Chuan/ABD 2011 2021
FU National Natural Science Foundation of China [81873711, 81974146]
FX This study was funded by the National Natural Science Foundation of
   China (grant nos. 81873711 and 81974146).
CR Abuna RPF, 2019, BIOINTERFACES
   Aydin N, 2011, INT ORTHOP, V35, P135, DOI 10.1007/s00264 009 0932 9
   Bangeppagari M, 2019, SCI TOTAL ENVIRON, V673, P810, DOI 10.1016/j.scitotenv.2019.04.082
   Brett E, 2017, STEM CELL TRANSL MED, V6, P151, DOI 10.5966/sctm.2016 0051
   Cai T, 2016, EXP CELL RES, V345, P206, DOI 10.1016/j.yexcr.2016.06.007
   Cao Y, 2021, TOXICOL MECH METHOD, V31, P1, DOI 10.1080/15376516.2020.1828521
   Durán M, 2017, CURR MOL MED, V17, P619, DOI 10.2174/1566524018666180308111915
   Felton C, 2014, DRUG METAB REV, V46, P142, DOI 10.3109/03602532.2013.876429
   Filippi M, 2019, BIOMATERIALS, V223, DOI 10.1016/j.biomaterials.2019.119468
   Girelli D, 2018, INT J HEMATOL, V107, P16, DOI 10.1007/s12185 017 2373 3
   Hao SS, 2017, BIOMATERIALS, V140, P16, DOI 10.1016/j.biomaterials.2017.06.013
   He Y, 2021, TRAC TREND ANAL CHEM, V136, DOI 10.1016/j.trac.2021.116191
   He Y, 2020, J BIOMED MATER RES A, V108, P50, DOI 10.1002/jbm.a.36791
   Hong GJ, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1375 x
   Hu Y, 2018, CHEM SOC REV, V47, P1874, DOI 10.1039/c7cs00657h
   Huang ZF, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.202000318
   Jiang PF, 2016, ACTA BIOMATER, V46, P141, DOI 10.1016/j.actbio.2016.09.020
   Kim EC, 2017, J PERIODONTAL IMPLAN, V47, P273, DOI 10.5051/jpis.2017.47.5.273
   Kim EC, 2015, BIOELECTROMAGNETICS, V36, P267, DOI 10.1002/bem.21903
   Lalande C, 2011, EUR CELLS MATER, V21, P341, DOI 10.22203/eCM.v021a25
   Lee WC, 2011, ACS NANO, V5, P7334, DOI 10.1021/nn202190c
   Lew WZ, 2018, J TISSUE ENG REGEN M, V12, P19, DOI 10.1002/term.2333
   Li RB, 2018, ACS NANO, V12, P1390, DOI 10.1021/acsnano.7b07737
   Liao CZ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113564
   Lin J, 2020, J ORTHOP TRANSL, V24, P131, DOI [10.1016/j.jot.2020.04.010, 10.1016/j.jot.2020.04.011]
   Lingamdinne LP, 2019, J ENVIRON MANAGE, V231, P622, DOI 10.1016/j.jenvman.2018.10.063
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Mohammadrezaei D, 2018, J BIOMED MATER RES A, V106, P2284, DOI 10.1002/jbm.a.36422
   Olsen TR, 2015, ACTA BIOMATER, V13, P188, DOI 10.1016/j.actbio.2014.11.024
   Panetta NJ, 2010, CURR STEM CELL RES T, V5, P122
   Raslan A, 2020, INT J PHARMACEUT, V580, DOI 10.1016/j.ijpharm.2020.119226
   Shimizu K, 2006, J BIOMED MATER RES B, V77B, P265, DOI 10.1002/jbm.b.30443
   Shimizu K, 2007, J BIOMED MATER RES B, V82B, P471, DOI 10.1002/jbm.b.30752
   Sun JP, 2015, TALANTA, V132, P557, DOI 10.1016/j.talanta.2014.09.043
   Sun ZZ, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109436
   Tay ZW, 2018, ACS NANO, V12, P3699, DOI 10.1021/acsnano.8b00893
   Wang K, 2011, NANOSCALE RES LETT, V6, DOI 10.1007/s11671 010 9751 6
   Wang QW, 2016, BIOMATERIALS, V86, P11, DOI 10.1016/j.biomaterials.2016.02.004
   Wei CB, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12367
   Xia Y, 2019, MAT SCI ENG C MATER, V104, DOI 10.1016/j.msec.2019.109955
   Xia Y, 2018, BIOMATERIALS, V183, P151, DOI 10.1016/j.biomaterials.2018.08.040
   Yamamoto Y, 2003, J DENT RES, V82, P962, DOI 10.1177/154405910308201205
   Yang AF, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/5747298
   Yao QQ, 2017, BONE, V97, P175, DOI 10.1016/j.bone.2017.01.028
   Ye NS, 2014, MAT SCI ENG C MATER, V45, P8, DOI 10.1016/j.msec.2014.08.064
   Yun HM, 2016, BIOMATERIALS, V85, P88, DOI 10.1016/j.biomaterials.2016.01.035
   Zan P, 2016, COLLOID SURFACE B, V145, P208, DOI 10.1016/j.colsurfb.2016.04.049
   Zhang J, 2014, PROG BIOPHYS MOL BIO, V114, P146, DOI 10.1016/j.pbiomolbio.2014.02.001
   Zhang WJ, 2017, ADV MATER, V29, DOI 10.1002/adma.201703795
   Zhang XL, 2020, J BIOMED MATER RES A, V108, P614, DOI 10.1002/jbm.a.36841
NR 50
TC 15
Z9 15
U1 2
U2 83
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1549 9634
EI 1549 9642
J9 NANOMED NANOTECHNOL
JI Nanomed. Nanotechnol. Biol. Med.
PD OCT
PY 2021
VL 37
AR 102435
DI 10.1016/j.nano.2021.102435
EA JUL 2021
PG 15
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Research & Experimental Medicine
GA WE1MB
UT WOS:000705390700008
PM 34186257
OA hybrid
DA 2025 08 17
ER

PT J
AU Lee, MS
   Wang, J
   Yuan, HH
   Jiao, HL
   Tsai, TL
   Squire, MW
   Li, WJ
AF Lee, Ming Song
   Wang, Jesse
   Yuan, Huihua
   Jiao, Hongli
   Tsai, Tsung Lin
   Squire, Matthew W.
   Li, Wan Ju
TI Endothelin 1 differentially directs lineage specification of adipose 
   and bone marrow derived mesenchymal stem cells
SO FASEB JOURNAL
LA English
DT Article
DE endothelin receptor; adipogenesis; osteogenesis; regenerative medicine
ID B RECEPTOR; STROMAL CELLS; EXPRESSION; TISSUE; ACTIVATION; LIPOLYSIS;
   BIOLOGY; CLONING; RESIDE
AB Blood vessels composed of endothelial cells (ECs) contact with mesenchymal stem cells (MSCs) in different tissues, suggesting possible interaction between these 2 types of cells. We hypothesized that endothelin 1 (ET1), a secreted paracrine factor of ECs, can differentially direct the lineages of adipose derived stem cells (ASCs) and bone marrow derived MSCs (BMSCs). Predifferentiated ASCs and BMSCs were treated with ET1 for 2 cell passages and then induced for multilineage differentiation. Our results showed that adipogenesis of ET1 pretreated ASCs and osteogenesis of ET1 pretreated BMSCs were increased compared to those of control cells. The effect of ET1 on enhancing adipogenesis of ASCs and osteogenesis of BMSCs was attenuated by blocking endothelin receptor type A (ETAR) and/or endothelin receptor type B (ETBR). Western blot analysis indicated that regulation by ET1 was mediated through activation of the protein kinase B and ERK1/2 signaling pathways. We analyzed subpopulations of ASCs and BMSCs with or without ETAR and/or ETBR, and we found that ETAR(+)/ETBR  and ETAR( )/ETBR+ subpopulations of ASCs and those of BMSCs pretreated with ET1 were prone to turning into adipocytes and osteoblasts, respectively, after differentiation induction. Our findings provide insight into the differential regulation of MSC specification by ET1, which may help develop viable approaches for tissue regeneration.Lee, M. S., Wang, J., Yuan, H., Jiao, H., Tsai, T. L., Squire, M. W., Li, W. J. Endothelin 1 differentially directs lineage specification of adipose  and bone marrow derived mesenchymal stem cells.
C1 [Lee, Ming Song; Wang, Jesse; Yuan, Huihua; Jiao, Hongli; Tsai, Tsung Lin; Squire, Matthew W.; Li, Wan Ju] Univ Wisconsin, Dept Orthoped & Rehabil, Lab Musculoskeletal Biol & Regenerat Med, Madison, WI USA.
   [Lee, Ming Song; Wang, Jesse; Tsai, Tsung Lin; Li, Wan Ju] Univ Wisconsin, Dept Biomed Engn, 1111 Highland Ave,WIMR 5051, Madison, WI 53705 USA.
   [Yuan, Huihua] Donghua Univ, Coll Chem, Chem Engn & Biotechnol, Shanghai, Peoples R China.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison; Donghua
   University
RP Li, WJ (通讯作者)，Univ Wisconsin, Dept Biomed Engn, 1111 Highland Ave,WIMR 5051, Madison, WI 53705 USA.
EM li@ortho.wisc.edu
RI Li, Wan Ju/B 4911 2011; Yuan, Huihua/G 8590 2012
OI Yuan, Huihua/0000 0001 8657 984X
FU U.S. National Institutes of Health (NIH) National Institute of Arthritis
   and Musculoskeletal and Skin Diseases [R01 AR064803]
FX The authors thank E. L. Hsieh (Shih Chien University, Taipei, Taiwan),
   J. L. Michel (University of Wisconsin La Crosse, WI, USA), and C. Ma
   (Wellesley College, MA, USA) for their help in this study. Research
   reported in this publication was partially supported by the U.S.
   National Institutes of Health (NIH) National Institute of Arthritis and
   Musculoskeletal and Skin Diseases (R01 AR064803). The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the NIH. The authors declare no conflicts of interest.
CR ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0
   Brown PT, 2014, CELL TISSUE RES, V358, P149, DOI 10.1007/s00441 014 1926 5
   Caplan AI, 2017, J ORTHOP RES, V35, P1151, DOI 10.1002/jor.23560
   Chen S, 2015, GENES DIS, V2, P76, DOI 10.1016/j.gendis.2014.12.003
   Cianfrocca R, 2010, CAN J PHYSIOL PHARM, V88, P796, DOI 10.1139/Y10 052
   CLERK A, 1994, J BIOL CHEM, V269, P32848
   Clines GA, 2011, J BONE MINER RES, V26, P2523, DOI 10.1002/jbmr.450
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Dawson LA, 2004, BRIT J CANCER, V90, P1577, DOI 10.1038/sj.bjc.6601717
   De Ugarte DA, 2003, CELLS TISSUES ORGANS, V174, P101, DOI 10.1159/000071150
   Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301 472X(00)00482 3
   Dibra D, 2016, HEPATOLOGY, V63, P1000, DOI 10.1002/hep.28379
   Diekman BO, 2010, TISSUE ENG PT A, V16, P523, DOI [10.1089/ten.tea.2009.0398, 10.1089/ten.TEA.2009.0398]
   DiMarino AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00201
   Eriksson AKS, 2009, INT J OBESITY, V33, P67, DOI 10.1038/ijo.2008.212
   Fiedler J, 2002, J CELL BIOCHEM, V87, P305, DOI 10.1002/jcb.10309
   Galié N, 2004, CARDIOVASC RES, V61, P227, DOI 10.1016/j.cardiores.2003.11.026
   Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478 811X 9 12
   Hiruma Y, 1998, AM J PHYSIOL REG I, V275, pR1099, DOI 10.1152/ajpregu.1998.275.4.R1099
   Jin HJ, 2013, INT J MOL SCI, V14, P17986, DOI 10.3390/ijms140917986
   Juan CC, 2005, AM J PHYSIOL ENDOC M, V288, pE1146, DOI 10.1152/ajpendo.00481.2004
   Khimji AK, 2010, CELL SIGNAL, V22, P1615, DOI 10.1016/j.cellsig.2010.05.002
   Kwon A, 2016, SCI REP UK, V6, DOI 10.1038/srep23544
   Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341
   Liao Han Tsung, 2014, World J Stem Cells, V6, P288, DOI 10.4252/wjsc.v6.i3.288
   Lin RZ, 2014, P NATL ACAD SCI USA, V111, P10137, DOI 10.1073/pnas.1405388111
   Mayer H, 2005, J CELL BIOCHEM, V95, P827, DOI 10.1002/jcb.20462
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Mundy AL, 2007, CARDIOVASC RES, V73, P368, DOI 10.1016/j.cardiores.2006.11.019
   Musina RA, 2005, B EXP BIOL MED+, V139, P504, DOI 10.1007/s10517 005 0331 1
   Nadiminty N, 2006, CLIN CANCER RES, V12, P1420, DOI 10.1158/1078 0432.CCR 05 1849
   Nassiri SM, 2014, STEM CELLS DEV, V23, P319, DOI 10.1089/scd.2013.0419
   Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990
   Nelson JB, 1999, UROLOGY, V53, P1063, DOI 10.1016/S0090 4295(98)00658 X
   Ohicita M, 2012, J PHARMACOL SCI, V119, P302, DOI 10.1254/jphs.12R01CR
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Robertson JA, 2001, NAT REV GENET, V2, P74, DOI 10.1038/35047594
   Rosanò L, 2013, NAT REV CANCER, V13, P637, DOI 10.1038/nrc3546
   Sakaguchi Y, 2005, ARTHRITIS RHEUM US, V52, P2521, DOI 10.1002/art.21212
   SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0
   Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696
   Spinella F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011241
   Tanaka S, 2017, J ORAL MAX SURG MED, V29, P85, DOI 10.1016/j.ajoms.2016.09.002
   Tang LP, 2007, AM J PHYSIOL LUNG C, V292, pL1467, DOI 10.1152/ajplung.00446.2006
   Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232
   Traktuev DO, 2008, CIRC RES, V102, P77, DOI 10.1161/CIRCRESAHA.107.159475
   Tsai TL, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0065 6
   van Harmelen V, 2008, DIABETES, V57, P378, DOI 10.2337/db07 0893
   Winter A, 2003, ARTHRITIS RHEUM US, V48, P418, DOI 10.1002/art.10767
   Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007 0226
   Yamaguchi T, 2003, EUR J BIOCHEM, V270, P1816, DOI 10.1046/j.1432 1033.2003.03544.x
   YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0
   Zhang JL, 2014, AM J PATHOL, V184, P1706, DOI 10.1016/j.ajpath.2014.02.027
   Zhong Q, 2002, BIOCHEM BIOPH RES CO, V296, P383, DOI 10.1016/S0006 291X(02)00882 3
NR 55
TC 21
Z9 23
U1 0
U2 6
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD JAN
PY 2019
VL 33
IS 1
BP 996
EP 1007
DI 10.1096/fj.201800614R
PG 12
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA HJ7TZ
UT WOS:000457401500078
PM 30096039
OA Green Published
DA 2025 08 17
ER

PT J
AU Eapen, A
   Kulkarni, R
   Ravindran, S
   Ramachandran, A
   Sundivakkam, P
   Tiruppathi, C
   George, A
AF Eapen, Asha
   Kulkarni, Roma
   Ravindran, Sriram
   Ramachandran, Amsaveni
   Sundivakkam, Premanand
   Tiruppathi, Chinnaswammy
   George, Anne
TI Dentin Phosphophoryn Activates Smad Protein Signaling through
   Ca<SUP>2+</SUP> Calmodulin dependent Protein Kinase II in
   Undifferentiated Mesenchymal Cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID PHOSPHOPROTEIN; EXPRESSION; INHIBITOR; GENE; DPP; DIFFERENTIATION;
   SIALOPROTEIN; GROWTH; KN 62; BMP
AB Dentin phosphophoryn (DPP) is a major noncollagenous protein in the dentin matrix. In this study, we demonstrate that pluripotent stem cells such as C3H10T1/2 and human bone marrow cells can be committed to the osteogenic lineage by DPP. Treatment with DPP can stimulate the release of intracellular Ca2+. This calcium flux triggered the activation of Ca2+ calmodulin dependent protein kinase II (CaMKII). Activated CaMKII induced the phosphorylation of Smad1 and promoted nuclear translocation of p Smad1. Inhibition of store Ca2+ depletion by 1,2 bis(2 aminophenoxy) ethane N,N,N',N' tetraacetic acid tetrakis(acetoxymethyl ester) or down regulation of CaMKII by KN 62, a selective cell permeable pharmacological inhibitor or a dominant negative plasmid of CaMKII, blocked DPP mediated Smad1 phosphorylation. Activation of Smad1 resulted in the expression of osteogenic markers such as Runx2, Osterix, DMP1, Bone sialoprotein, Osteocalcin, NFATc1, and Schnurri 2, which have been implicated in osteoblast differentiation. These findings suggest that DPP is capable of triggering commitment of pluripotent stem cells to the osteogenic lineage.
C1 [Eapen, Asha; Kulkarni, Roma; Ravindran, Sriram; Ramachandran, Amsaveni; George, Anne] Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA.
   [Sundivakkam, Premanand; Tiruppathi, Chinnaswammy] Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital
RP George, A (通讯作者)，Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA.
EM anneg@uic.edu
OI GEORGE, ANNE/0000 0002 9008 7642
FU National Institutes of Health [DE 19633]; Brodie Endowment Fund
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant DE 19633. This work was also supported by The Brodie
   Endowment Fund.
CR Alvares K, 2006, DEV DYNAM, V235, P2980, DOI 10.1002/dvdy.20935
   BOSKEY AL, 1990, BONE MINER, V11, P55, DOI 10.1016/0169 6009(90)90015 8
   Byers BA, 2002, J BONE MINER RES, V17, P1931, DOI 10.1359/jbmr.2002.17.11.1931
   Eapen A, 2012, CELL ADHES MIGR, V6, P307, DOI 10.4161/cam.20627
   Eapen A, 2012, J BIOL CHEM, V287, P5211, DOI 10.1074/jbc.M111.290080
   Eapen A, 2010, J BIOL CHEM, V285, P36339, DOI 10.1074/jbc.M110.145607
   Feng JQ, 1998, J BIOL CHEM, V273, P9457, DOI 10.1074/jbc.273.16.9457
   Fukuno N, 2011, BIOCHEM BIOPH RES CO, V408, P202, DOI 10.1016/j.bbrc.2011.02.127
   George A, 2005, CELLS TISSUES ORGANS, V181, P232, DOI 10.1159/000091384
   Jadlowiec J, 2004, J BIOL CHEM, V279, P53323, DOI 10.1074/jbc.M404934200
   Jadlowiec JA, 2006, J BIOL CHEM, V281, P5341, DOI 10.1074/jbc.M506158200
   Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348
   LEE SL, 1977, BIOCHEMISTRY US, V16, P2971, DOI 10.1021/bi00632a026
   LINDE A, 1980, J BIOL CHEM, V255, P5931
   MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835
   Massagué J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745
   Moustakas A, 2001, J CELL SCI, V114, P4359
   Ogbureke KUE, 2007, J HISTOCHEM CYTOCHEM, V55, P403, DOI 10.1369/jhc.6A7075.2007
   Ogbureke KUE, 2004, J DENT RES, V83, P664, DOI 10.1177/154405910408300902
   Pera EM, 2003, GENE DEV, V17, P3023, DOI 10.1101/gad.1153603
   Praskova M, 2002, ARCH DERMATOL RES, V294, P198, DOI 10.1007/s00403 002 0312 4
   RICHARDSON WS, 1978, J BIOL CHEM, V253, P8042
   Saita Y, 2007, J BIOL CHEM, V282, P12907, DOI 10.1074/jbc.M611203200
   SCHWEITZER ES, 1995, J CELL SCI, V108, P2619
   Sfeir C., 2000, CHEM BIOL MINERALIZE, P181
   Souchelnytskyi S, 2002, TRENDS CELL BIOL, V12, P304, DOI 10.1016/S0962 8924(02)02300 0
   Srinivasan R, 1999, CONNECT TISSUE RES, V40, P251, DOI 10.3109/03008209909000703
   Sundivakkam PC, 2009, AM J PHYSIOL CELL PH, V296, pC403, DOI 10.1152/ajpcell.00470.2008
   TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315
   VEIS A, 1967, BIOCHEMISTRY US, V6, P2409, DOI 10.1021/bi00860a017
   Wang YQ, 2010, J AM SOC NEPHROL, V21, P1657, DOI 10.1681/ASN.2009121253
   Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103 8111.2000
   Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359 6101(99)00024 6
   ZANETTI M, 1981, EUR J BIOCHEM, V113, P541, DOI 10.1111/j.1432 1033.1981.tb05096.x
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
   Zayzafoon M, 2005, J BIOL CHEM, V280, P7049, DOI 10.1074/jbc.M412680200
NR 36
TC 24
Z9 26
U1 0
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 22
PY 2013
VL 288
IS 12
BP 8585
EP 8595
DI 10.1074/jbc.M112.413997
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 112AS
UT WOS:000316564500059
PM 23362283
OA Green Published
DA 2025 08 17
ER

PT J
AU Panayiotopoulos, A
   Bhat, N
   Bhangoo, A
AF Panayiotopoulos, Aristotle
   Bhat, Nandini
   Bhangoo, Amrit
TI Bone and vitamin D metabolism in HIV
SO REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
LA English
DT Article
DE Hypothalamic pituitary adrenal (HPA) axis; HIV; AIDS; Cytokines;
   Glucocorticoids
ID VIRUS INFECTED MEN; MINERAL DENSITY; ANTIRETROVIRAL THERAPY; FRACTURE
   RISK; PROTEASE INHIBITORS; OSTEOPOROSIS; CHILDREN; ALENDRONATE;
   OSTEOPENIA; TURNOVER
AB Human immunodeficiency virus (HIV) infection has progressed to a chronic disease and HIV positive individuals are living longer lives. This has lead to an increase in morbidity and mortality due to secondary issues, one being HIV bone disease. HIV infected pediatric and adult populations have a greater incidence in reduction of BMD as compared to the controls. Osteoporosis has been reported to be present in up to 15 % of HIV positive patients. We are starting to understand the mechanism behind the changes in HIV bone disease. Viral proteins interfere with osteoblastic activity either by direct interaction or by the inflammatory process that they induce. Anti viral management, including highly active antiretroviral therapy (HAART), protease inhibitors, and nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) also are involved in disrupting proper bone metabolism. Vitamin D levels have strong correlation with bone disease in HIV patients, and are dependent not only to chronic disease state, but interaction of pharmacologic management and inflammatory process as well. Work up of the secondary causes of osteopenia and osteoporosis should be undertaken in all patients. DEXA scan is recommended in all post menopausal women with HIV, all HIV infected men 50 years of age or older and in those with a history of fragility fractures regardless of age or gender. Preventive measures include adequate nutrition, calcium and Vitamin D intake daily, muscle strengthening and balance exercises to increase BMD and reduce fractures. Bisphosphonates are considered to be the first line for the treatment of HIV associated bone disease. This review will describe how the balanced mechanism of bone metabolism is interrupted by the HIV infection itself, the complications that arise from HIV/AIDS, and its treatment options.
C1 [Panayiotopoulos, Aristotle; Bhangoo, Amrit] Childrens Hosp SUNY Downstate, Dept Pediat Endocrinol, Kings Cty Hosp Ctr, Brooklyn, NY 11219 USA.
   [Panayiotopoulos, Aristotle; Bhangoo, Amrit] Infants & Childrens Hosp Maimonides, Brooklyn, NY 11219 USA.
   [Bhat, Nandini] Kings Cty Hosp Ctr, Dept Pediat, Brooklyn, NY USA.
   [Bhat, Nandini] Childrens Hosp SUNY Downstate, Brooklyn, NY 11219 USA.
C3 Maimonides Medical Center
RP Bhangoo, A (通讯作者)，Childrens Hosp SUNY Downstate, Dept Pediat Endocrinol, Kings Cty Hosp Ctr, 977 48th St, Brooklyn, NY 11219 USA.
EM drapsbhangoo@yahoo.com
OI Panayiotopoulos, Aristotle/0000 0003 3571 9026
CR Adami S, 2009, OSTEOPOROSIS INT, V20, P239, DOI 10.1007/s00198 008 0650 y
   Amiel C, 2004, J BONE MINER RES, V19, P402, DOI 10.1359/JBMR.0301246
   Amorosa V, 2006, CLIN INFECT DIS, V42, P108, DOI 10.1086/498511
   [Anonymous], 2012 AIDS EP UP
   Armas LAG, 2004, J CLIN ENDOCR METAB, V89, P5387, DOI 10.1210/jc.2004 0360
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Bolland MJ, 2007, J CLIN ENDOCR METAB, V92, P1283, DOI 10.1210/jc.2006 2216
   Brown TT, 2006, AIDS, V20, P2165, DOI 10.1097/QAD.0b013e32801022eb
   Brown TT, 2004, J CLIN ENDOCR METAB, V89, P1200, DOI 10.1210/jc.2003 031506
   Calmy A, 2009, J INFECT DIS, V200, P1746, DOI 10.1086/644785
   Cannell J, 2008, EXPERT OPIN PHARMACO, V9, P107, DOI 10.1517/14656566.9.1.107
   Cotter EJ, 2007, AIDS RES HUM RETROV, V23, P1521, DOI 10.1089/aid.2007.0112
   Cotter EJ, 2009, PPAR RES, V2009, DOI 10.1155/2009/421376
   Fakruddin JM, 2003, J BIOL CHEM, V278, P48251, DOI 10.1074/jbc.M304676200
   Gallant JE, 2004, JAMA J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191
   Gazzola L, 2010, J INFECT DIS, V202, P330, DOI 10.1086/653584
   Gibellini D, 2008, J MED VIROL, V80, P1507, DOI 10.1002/jmv.21266
   Gregg EW, 1998, ANN INTERN MED, V129, P81, DOI 10.7326/0003 4819 129 2 199807150 00002
   Grund B, 2009, AIDS, V23, P1519, DOI 10.1097/QAD.0b013e32832c1792
   Gutiérrez F, 2011, AIDS REV, V13, P109
   Hittinger G, 1998, INFECTION, V26, P100, DOI 10.1007/BF02767768
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Huang J, 2009, AIDS, V23, P51, DOI 10.1097/QAD.0b013e32831c8adc
   Jacobson DL, 2010, AIDS, V24, P687, DOI 10.1097/QAD.0b013e328336095d
   Jacobson DL, 2005, J PEDIATR GASTR NUTR, V41, P339, DOI 10.1097/01.mpg.0000174468.75219.30
   Johnell O, 2004, J BONE MINER RES, V19, P764, DOI 10.1359/JBMR.040211
   KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200
   Kim JH, 2012, AIDS RES HUM RETROV, V28, P235, DOI [10.1089/aid.2011.0040, 10.1089/AID.2011.0040]
   Koutkia P, 2005, J CLIN ENDOCR METAB, V90, P2154, DOI 10.1210/jc.2004 1466
   Landonio S, 2004, BIOMED PHARMACOTHER, V58, P505, DOI 10.1016/j.biopha.2004.08.019
   Lips P, 2006, PROG BIOPHYS MOL BIO, V92, P4, DOI 10.1016/j.pbiomolbio.2006.02.016
   Maalouf Naim M, 2006, Endocr Pract, V12, P48
   Malizia AP, 2007, AIDS RES HUM RETROV, V23, P243, DOI 10.1089/aid.2006.0084
   McComsey GA, 2002, J INT ASS PHYS AIDS, V3, P86
   McComsey GA, 2007, AIDS, V21, P2473, DOI 10.1097/QAD.0b013e3282ef961d
   McComsey GA, 2011, J INFECT DIS, V203, P1791, DOI 10.1093/infdis/jir188
   McComsey GA, 2010, CLIN INFECT DIS, V51, P937, DOI 10.1086/656412
   Miller PD, 2007, SEMIN DIALYSIS, V20, P186, DOI 10.1111/j.1525 139X.2007.00271.x
   Mondy K, 2005, JAIDS J ACQ IMM DEF, V38, P426, DOI 10.1097/01.qai.0000145352.04440.1e
   Mondy K, 2003, CLIN INFECT DIS, V36, P482, DOI 10.1086/367569
   Moore AL, 2001, AIDS, V15, P1731, DOI 10.1097/00002030 200109070 00019
   Mora S, 2005, CALCIFIED TISSUE INT, V76, P336, DOI 10.1007/s00223 004 0020 5
   Mora S, 2004, J CLIN ENDOCR METAB, V89, P24, DOI 10.1210/jc.2003 030767
   Mora S, 2001, AIDS, V15, P1823, DOI 10.1097/00002030 200109280 00011
   Mora Stefano, 2010, Front Biosci (Elite Ed), V2, P1265
   Mulligan K, 2012, CLIN INFECT DIS, V55, P461, DOI 10.1093/cid/cis455
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Ott SM, 2005, J CLIN ENDOCR METAB, V90, P1897, DOI 10.1210/jc.2005 0057
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Pitukcheewanont P, 2005, OSTEOPOROSIS INT, V16, P1393, DOI 10.1007/s00198 005 1849 9
   Romagnoli E, 2008, J CLIN ENDOCR METAB, V93, P3015, DOI 10.1210/jc.2008 0350
   Sanders KM, 2010, JAMA J AM MED ASSOC, V303, P1815, DOI 10.1001/jama.2010.594
   Schrumpf JA, 2012, INFECT IMMUN, V80, P4485, DOI 10.1128/IAI.06224 11
   Stone B, 2010, ARCH BIOCHEM BIOPHYS, V503, P66, DOI 10.1016/j.abb.2010.07.029
   Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030 200003100 00005
   van Vonderen MGA, 2009, AIDS, V23, P1367, DOI 10.1097/QAD.0b013e32832c4947
   Wang MWH, 2004, J CLIN INVEST, V114, P206, DOI 10.1172/JCI200415797
   Wasserman P, 2010, AIDS PATIENT CARE ST, V24, P223, DOI 10.1089/apc.2009.0241
   Watts NB, 2008, J CLIN DENSITOM, V11, P473, DOI 10.1016/j.jocd.2008.04.003
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
NR 60
TC 14
Z9 15
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389 9155
EI 1573 2606
J9 REV ENDOCR METAB DIS
JI Rev. Endocr. Metab. Disord.
PD JUN
PY 2013
VL 14
IS 2
BP 119
EP 125
DI 10.1007/s11154 013 9246 8
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 168QW
UT WOS:000320721600004
PM 23657562
DA 2025 08 17
ER

PT J
AU Mushtaq, A
   Li, L
   Grondahl, L
   Anitha, A
AF Mushtaq, Asim
   Li, Li
   Grondahl, Lisbeth
   Anitha, A.
TI Targeted Nanoparticles Based on Alendronate Polyethylene Glycol
   Conjugated Chitosan for the Delivery of siRNA and Curcumin for Bone
   Metastasized Breast Cancer Applications
SO MACROMOLECULAR BIOSCIENCE
LA English
DT Article
DE alendronate; bone seeking; cell death siRNA; chitosan; curcumin;
   poly ethylene glycol; targeted delivery
ID IN VITRO; CO DELIVERY; CELL LINE; VIVO; MCF 7; INHIBITION; MDA MB 231;
   BISPHOSPHONATES; CYTOTOXICITY; NANOCARRIERS
AB Bone metastasized breast cancer reduces the quality of life and median survival. Targeted delivery of small interfering RNA (siRNA) and chemotherapeutic drugs using nanoparticles (NPs) is a promising strategy to overcome current limitations in treating these metastatic breast cancers. This research develops alendronate conjugated polyethylene glycol functionalized chitosan (ALD PEG CHI) NP for the delivery of cell death siRNA (CD siRNA) and curcumin (CUR) and explores its targeting ability and in vitro cell cytotoxicity. Polyethylene glycol functionalized CHI (mPEG CHI) NPs serve as control. The size of CD siRNA loaded NPs is below 100 nm while CUR loaded NPs is below 200 nm, with near neutral zeta potential for all NPs. The CUR encapsulation efficiency (EE) is 70% and 88% for targeted and control NPs, respectively, while complete encapsulation of CD siRNA is achieved in both NP systems. The bone targeting ability of CY5 dsDNA loaded ALD PEG CHI NPs using hydroxyapatite discs is fivefold compared to control indicating ALD presentation at the targeting NP surface. Delivery of CD siRNA loaded NPs and CUR loaded NPs show synergistic and additive growth inhibition effects against MCF 7 cells by mPEG CHI and ALD PEG CHI NPs, respectively. Overall, these in vitro results illustrate the potential of the targeted NPs as an effective therapeutic system toward bone metastasized breast cancer.
   In vitro hydroxyapatite seeking of the nanoparticles showing a fivefold enhancement in affinity for the targeted nanoparticles unlike the untargeted particles. Delivery of cell death small interfering RNA (CD siRNA) and curcumin (CUR) loaded nanoparticles (NPs) showing synergistic and additive growth inhibition effects against breast cancer cells.image
C1 [Mushtaq, Asim; Grondahl, Lisbeth; Anitha, A.] Univ Queensland, Sch Chem & Mol Biosci, Cooper Rd, Brisbane, Qld 4072, Australia.
   [Li, Li; Grondahl, Lisbeth] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Corner Coll & Cooper Rd, Brisbane, Qld 4072, Australia.
C3 University of Queensland; University of Queensland
RP Grondahl, L; Anitha, A (通讯作者)，Univ Queensland, Sch Chem & Mol Biosci, Cooper Rd, Brisbane, Qld 4072, Australia.; Grondahl, L (通讯作者)，Univ Queensland, Australian Inst Bioengn & Nanotechnol, Corner Coll & Cooper Rd, Brisbane, Qld 4072, Australia.
EM l.grondahl@uq.edu.au; a.sudheeshkumar@uq.edu.au
RI Sudheesh Kumar, Anitha/I 3739 2016; Li, Li/D 3641 2016; Grondahl,
   Lisbeth/D 2916 2018
OI Sudheesh Kumar, Anitha/0000 0003 0964 741X; Mushtaq,
   Asim/0000 0003 2592 1562; Li, Li/0000 0001 6545 858X; Grondahl,
   Lisbeth/0000 0001 6012 9808
FU Open access publishing facilitated by The University of Queensland, as
   part of the Wiley   The University of Queensland agreement via the
   Council of Australian University Librarians.; University of Queensland,
   as part of the Wiley   The University of Queensland agreement via the
   Council of Australian University Librarians
FX The manuscript was written through contributions of all authors. A.A. is
   thankful to the University of Queensland, Australia (ECR Grant, UQ
   Amplify Fellowship (2021 Dec 2023 Nov)) and to National Health and
   Medical Research Council, Australia (Early Career Research Fellowship,
   APP1123340, 2017 2021). L.L. acknowledges Australian Centre for HIV and
   Hepatitis Virology Research fund (ACH4) and A.M. is thankful to the
   University of Queensland for UQ RTP Scholarship for providing financial
   support. The authors are also thankful to Ms. Gautami Gaidhani for their
   initial helps in conducting some of the hydroxyapatite seeking
   experiments.r Open access publishing facilitated by The University of
   Queensland, as part of the Wiley   The University of Queensland
   agreement via the Council of Australian University Librarians.
CR Afzali E, 2021, INT J NANOMED, V16, P579, DOI 10.2147/IJN.S251056
   Alameh M, 2018, BIOMACROMOLECULES, V19, P112, DOI 10.1021/acs.biomac.7b01297
   Anitha A, 2012, J BIOMAT SCI POLYM E, V23, P1381, DOI 10.1163/092050611X581534
   Anitha A, 2011, CARBOHYD POLYM, V84, P1158, DOI 10.1016/j.carbpol.2011.01.005
   BUCKWALTER JA, 1995, J BONE JOINT SURG AM, V77A, P1256, DOI 10.2106/00004623 199508000 00019
   Chen J, 2014, MOL PHARMACEUT, V11, P2213, DOI 10.1021/mp400269z
   Cheng J, 2007, BIOMATERIALS, V28, P869, DOI 10.1016/j.biomaterials.2006.09.047
   Cho EC, 2011, NAT NANOTECHNOL, V6, P385, DOI [10.1038/nnano.2011.58, 10.1038/NNANO.2011.58]
   Creixell M, 2012, NANO TODAY, V7, P367, DOI 10.1016/j.nantod.2012.06.013
   Du BY, 2006, CHEMOTHERAPY, V52, P23, DOI 10.1159/000090238
   Duan JH, 2010, INT J PHARMACEUT, V400, P211, DOI 10.1016/j.ijpharm.2010.08.033
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Facchi SP, 2016, INT J BIOL MACROMOL, V87, P237, DOI 10.1016/j.ijbiomac.2016.02.063
   Garcia Fuentes M, 2012, J CONTROL RELEASE, V161, P496, DOI 10.1016/j.jconrel.2012.03.017
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   Ghaffari M, 2020, COLLOID SURFACE B, V188, DOI 10.1016/j.colsurfb.2019.110762
   Gomathi T, 2017, INT J BIOL MACROMOL, V104, P1794, DOI 10.1016/j.ijbiomac.2017.08.057
   Grubczak K, 2021, CELLS BASEL, V10, DOI 10.3390/cells10082044
   Hansen CG, 2009, J CELL SCI, V122, P1713, DOI 10.1242/jcs.033951
   Hashim D, 2016, ANN ONCOL, V27, P926, DOI 10.1093/annonc/mdw027
   He YF, 2017, J CONTROL RELEASE, V264, P76, DOI 10.1016/j.jconrel.2017.08.024
   Helmi O, 2021, INT J BIOL MACROMOL, V184, P325, DOI 10.1016/j.ijbiomac.2021.06.014
   Hillaireau H, 2009, CELL MOL LIFE SCI, V66, P2873, DOI 10.1007/s00018 009 0053 z
   Hirpara MR, 2018, INT J BIOL MACROMOL, V107, P2190, DOI 10.1016/j.ijbiomac.2017.10.086
   Hu B, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 0207 x
   Huang YJ, 2020, ACTA PHARMACOL SIN B, V10, P2384, DOI 10.1016/j.apsb.2020.06.006
   Javan N, 2019, NUTR CANCER, V71, P1201, DOI 10.1080/01635581.2019.1599968
   Jesus S, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00100
   Jose A, 2018, AAPS PHARMSCITECH, V19, P166, DOI 10.1208/s12249 017 0833 y
   Kafshgari MH, 2015, CURR DRUG DELIV, V12, P63, DOI 10.2174/1567201811666140821110631
   Key TJ, 2001, LANCET ONCOL, V2, P133, DOI 10.1016/S1470 2045(00)00254 0
   Kharat M, 2017, J AGR FOOD CHEM, V65, P1525, DOI 10.1021/acs.jafc.6b04815
   Khesht AMS, 2021, INT J BIOL MACROMOL, V186, P849, DOI 10.1016/j.ijbiomac.2021.07.034
   Kunnumakkara AB, 2008, CANCER LETT, V269, P199, DOI 10.1016/j.canlet.2008.03.009
   Lainetti PD, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12121193
   Li JM, 2016, J MATER CHEM B, V4, P6620, DOI 10.1039/c6tb01462c
   Li QP, 2022, CARBOHYD POLYM, V287, DOI 10.1016/j.carbpol.2022.119315
   Liu C, 2022, CARBOHYD POLYM, V283, DOI 10.1016/j.carbpol.2022.119097
   Mushtaq A, 2022, INT J BIOL MACROMOL, V221, P204, DOI 10.1016/j.ijbiomac.2022.08.179
   Mushtaq A, 2021, MACROMOL BIOSCI, V21, DOI 10.1002/mabi.202100005
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Nohara K, 1998, BREAST CANCER RES TR, V48, P149, DOI 10.1023/A:1005986606010
   Patra JK, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951 018 0392 8
   Pelaz B, 2015, ACS NANO, V9, P6996, DOI 10.1021/acsnano.5b01326
   Poli H, 2021, EUR POLYM J, V155, DOI 10.1016/j.eurpolymj.2021.110571
   Poma P, 2007, INT J MOL MED, V20, P329
   Prabaharan M, 2015, INT J BIOL MACROMOL, V72, P1313, DOI 10.1016/j.ijbiomac.2014.10.052
   Prencipe G, 2009, J AM CHEM SOC, V131, P4783, DOI 10.1021/ja809086q
   Rohanizadeh R, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.20
   Sadreddini S, 2017, IMMUNOL LETT, V181, P79, DOI 10.1016/j.imlet.2016.11.013
   Salerno M, 2010, CURR CANCER DRUG TAR, V10, P649, DOI 10.2174/156800910793605767
   Shi JJ, 2017, NAT REV CANCER, V17, P20, DOI 10.1038/nrc.2016.108
   Shi LW, 2021, NANOSCALE, V13, P10748, DOI 10.1039/d1nr02065j
   Shrestha B, 2019, ADV THER GERMANY, V2, DOI 10.1002/adtp.201900076
   Song HZ, 2019, BIOTECHNOL BIOTEC EQ, V33, P1671, DOI 10.1080/13102818.2019.1694436
   Sun YS, 2017, INT J BIOL SCI, V13, P1387, DOI 10.7150/ijbs.21635
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Tahara RK, 2019, ADV EXP MED BIOL, V1152, P105, DOI 10.1007/978 3 030 20301 6_7
   Tanvir S, 2015, MOJ Toxicol, V1, P78, DOI DOI 10.15406/MOJT.2015.01.00011
   VAUPEL P, 1989, CANCER RES, V49, P6449
   Wang H, 2018, ARTIF CELL NANOMED B, V46, pS293, DOI 10.1080/21691401.2017.1423494
   Wilhelm S, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.14
   Wright LE, 2013, CURR PHARM DESIGN, V19, P6218, DOI 10.2174/1381612811319340013
   Xue XD, 2022, EXPLORATION PRC, V2, DOI 10.1002/EXP.20210134
   Yang ML, 2013, J AGR FOOD CHEM, V61, P7150, DOI 10.1021/jf401827x
   Zhang CY, 2013, FOOD CHEM, V139, P1021, DOI 10.1016/j.foodchem.2013.02.016
NR 67
TC 11
Z9 11
U1 4
U2 25
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 5187
EI 1616 5195
J9 MACROMOL BIOSCI
JI Macromol. Biosci.
PD FEB
PY 2024
VL 24
IS 2
DI 10.1002/mabi.202300268
EA OCT 2023
PG 10
WC Biochemistry & Molecular Biology; Materials Science, Biomaterials;
   Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Materials Science; Polymer Science
GA LV5J7
UT WOS:001083024400001
PM 37794635
OA hybrid
DA 2025 08 17
ER

PT J
AU Liu, YT
   Ding, HH
   Lin, ZM
   Wang, Q
   Chen, L
   Liu, SS
   Yang, XQ
   Zhu, FH
   Huang, YT
   Cao, SQ
   Yang, FM
   Song, ZL
   Ding, J
   Geng, MY
   Xie, H
   Zhang, AO
   He, SJ
   Zuo, JP
AF Liu, Yu ting
   Ding, Hui hua
   Lin, Ze min
   Wang, Que
   Chen, Li
   Liu, Shuang shuang
   Yang, Xiao qian
   Zhu, Feng hua
   Huang, Yue teng
   Cao, Shi qi
   Yang, Fang ming
   Song, Zi lan
   Ding, Jian
   Geng, Mei yu
   Xie, Hua
   Zhang, Ao
   He, Shi jun
   Zuo, Jian ping
TI A novel tricyclic BTK inhibitor suppresses B cell responses and
   osteoclastic bone erosion in rheumatoid arthritis
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE rheumatoid arthritis; BTK inhibitors; B cells; macrophages; RANKL;
   osteoclastogenesis
ID COLLAGEN INDUCED ARTHRITIS; TYROSINE KINASE INHIBITOR; RECEPTOR
   ACTIVATOR; DIFFERENTIATION; MICE; TEC; AUTOANTIBODIES; DESTRUCTION;
   GENERATION; MONOCYTES
AB Rheumatoid arthritis (RA) is characterized by joint leukocyte infiltration, synovial inflammation and bone damage result from osteoclastogenesis. Bruton's tyrosine kinase (BTK) is a key regulator of B cell receptor (BCR) and Fc gamma receptor (Fc gamma R) signaling involved in the pathobiology of RA and other autoimmune disorders. SOMCL 17 016 is a potent and selective tricyclic BTK inhibitor, structurally distinct from other known BTK inhibitors. In present study we investigated the therapeutic efficacy of SOMCL 17 016 in a mouse collagen induced arthritis (CIA) model and underlying mechanisms. CIA mice were administered SOMCL 17 016 (6.25, 12.5, 25 mg.kg( 1).d( 1), ig), or ibrutinib (25 mg.kg( 1).d( 1), ig) or acalabrutinib (25 mg.kg( 1).d( 1), ig) for 15 days. We showed that oral administration of SOMCL 17 016 dose dependently ameliorated arthritis severity and bone damage in CIA mice; it displayed a higher in vivo efficacy than ibrutinib and acalabrutinib at the corresponding dosage. We found that SOMCL 17 016 administration dose dependently inhibited anti IgM induced proliferation and activation of B cells from CIA mice, and significantly decreased anti IgM/anti CD40 stimulated RANKL expression in memory B cells from RA patients. In RANKL/M CSF stimulated RAW264.7 cells, SOMCL 17 016 prevented osteoclast differentiation and abolished RANK BTK PLC gamma 2 NFATc1 signaling. In summary, this study demonstrates that SOMCL 17 016 presents distinguished therapeutic effects in the CIA model. SOMCL 17 016 exerts a dual inhibition of B cell function and osteoclastogenesis, suggesting that it to be a promising drug candidate for RA treatment.
C1 [Liu, Yu ting; Lin, Ze min; Wang, Que; Chen, Li; Liu, Shuang shuang; Yang, Xiao qian; Zhu, Feng hua; Huang, Yue teng; Cao, Shi qi; Yang, Fang ming; He, Shi jun; Zuo, Jian ping] Chinese Acad Sci, Shanghai Inst Mat Med, Lab Immunopharmacol, State Key Lab Drug Res, Shanghai 201203, Peoples R China.
   [Liu, Yu ting; Chen, Li; Liu, Shuang shuang; Yang, Xiao qian; Zhu, Feng hua; Cao, Shi qi; Ding, Jian; Geng, Mei yu; Xie, Hua; Zhang, Ao; He, Shi jun; Zuo, Jian ping] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Ding, Hui hua] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Rheumatol, Shanghai 200001, Peoples R China.
   [Wang, Que; Huang, Yue teng; Yang, Fang ming; Zuo, Jian ping] Shanghai Univ Tradit Chinese Med, Lab Immunol & Virol, Shanghai 201203, Peoples R China.
   [Song, Zi lan; Zhang, Ao] Chinese Acad Sci, Shanghai Inst Materia Med, CAS Key Lab Receptor Res, State Key Lab Drug Res, Shanghai 201203, Peoples R China.
   [Ding, Jian; Geng, Mei yu; Xie, Hua] Chinese Acad Sci, Shanghai Inst Materia Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Shanghai 201203, Peoples R China.
   [Zhang, Ao] Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200240, Peoples R China.
C3 Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS;
   Chinese Academy of Sciences; University of Chinese Academy of Sciences,
   CAS; Shanghai Jiao Tong University; Shanghai University of Traditional
   Chinese Medicine; Chinese Academy of Sciences; Shanghai Institute of
   Materia Medica, CAS; Chinese Academy of Sciences; Shanghai Institute of
   Materia Medica, CAS; Shanghai Jiao Tong University
RP He, SJ; Zuo, JP (通讯作者)，Chinese Acad Sci, Shanghai Inst Mat Med, Lab Immunopharmacol, State Key Lab Drug Res, Shanghai 201203, Peoples R China.; Zhang, AO; He, SJ; Zuo, JP (通讯作者)，Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Zuo, JP (通讯作者)，Shanghai Univ Tradit Chinese Med, Lab Immunol & Virol, Shanghai 201203, Peoples R China.; Zhang, AO (通讯作者)，Chinese Acad Sci, Shanghai Inst Materia Med, CAS Key Lab Receptor Res, State Key Lab Drug Res, Shanghai 201203, Peoples R China.; Zhang, AO (通讯作者)，Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200240, Peoples R China.
EM aozhang@simm.ac.cn; heshijun@simm.ac.cn; jpzuo@simm.ac.cn
RI Lin, Zemin/ADR 2173 2022; Ding, Huihua/H 7768 2019
FU Personalized Medicines Molecular Signature based "Drug Discovery and
   Development," Strategic Priority Research Program of the Chinese Academy
   of Sciences [XDA12020369]; National Natural Science Foundation of China
   (NSFC) [81903882]; National Science and Technology Major Project "New
   Drug Creation and Manufacturing Program," China [2018ZX09711002 014 001]
FX This work was supported by the Personalized Medicines Molecular
   Signature based "Drug Discovery and Development," Strategic Priority
   Research Program of the Chinese Academy of Sciences (grant No.
   XDA12020369); the National Natural Science Foundation of China (NSFC)
   (grant No. 81903882); and the National Science and Technology Major
   Project "New Drug Creation and Manufacturing Program," China (grant No.
   2018ZX09711002 014 001).
CR Ariza Y, 2019, BONE REP, V10, DOI 10.1016/j.bonr.2019.100201
   Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Barf T, 2017, J PHARMACOL EXP THER, V363, P240, DOI 10.1124/jpet.117.242909
   Chang Y, 2011, RHEUMATOLOGY, V50, P862, DOI 10.1093/rheumatology/keq404
   Derksen VFAM, 2017, SEMIN IMMUNOPATHOL, V39, P437, DOI 10.1007/s00281 017 0627 z
   Di Paolo JA, 2011, NAT CHEM BIOL, V7, P41, DOI 10.1038/NCHEMBIO.481
   Engdahl C, 2017, J BONE MINER RES, V32, P1681, DOI 10.1002/jbmr.3158
   Evans EK, 2013, J PHARMACOL EXP THER, V346, P219, DOI 10.1124/jpet.113.203489
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Gibofsky Allan, 2012, Am J Manag Care, V18, pS295
   Guo QY, 2018, BAMBOO SILK, V1, P1, DOI [10.1163/24689246 00101001, 10.1038/s41413 018 0016 9]
   Hamilton JA, 2009, ARTHRITIS RHEUM US, V60, P1210, DOI 10.1002/art.24505
   Han L, 2020, ACTA PHARMACOL SIN, V41, P800, DOI 10.1038/s41401 019 0337 2
   He SJ, 2014, ACTA PHARMACOL SIN, V35, P219, DOI 10.1038/aps.2013.167
   Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107
   Hou LF, 2011, ARTHRITIS RHEUM US, V63, P2445, DOI 10.1002/art.30392
   Hou LF, 2009, INT IMMUNOPHARMACOL, V9, P1509, DOI 10.1016/j.intimp.2009.09.003
   Jia XY, 2019, ACTA PHARMACOL SIN, V40, P1029, DOI 10.1038/s41401 018 0196 2
   Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432
   Komine M, 2001, BONE, V28, P474, DOI 10.1016/S8756 3282(01)00420 3
   Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529 0131(200105)44:5<1003::AID ANR179>3.3.CO;2 R
   Lee SH, 2008, J BIOL CHEM, V283, P11526, DOI 10.1074/jbc.M708935200
   Lin ZM, 2016, SCI REP UK, V6, DOI 10.1038/srep38115
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Musilova K, 2015, LEUKEMIA, V29, P1004, DOI 10.1038/leu.2014.351
   Ota Y, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 0957 6
   Pan ZY, 2007, CHEMMEDCHEM, V2, P58, DOI 10.1002/cmdc.200600221
   Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5
   Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600 065X.2000.017504.x
   Schramm C, 2004, ARTHRITIS RES THER, V6, pR114, DOI 10.1186/ar1039
   Seeling M, 2013, P NATL ACAD SCI USA, V110, P10729, DOI 10.1073/pnas.1301001110
   Shinohara M, 2008, CELL, V132, P794, DOI 10.1016/j.cell.2007.12.037
   Shinohara M, 2014, BONE, V60, P8, DOI 10.1016/j.bone.2013.11.025
   Steffen U, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01483
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Tomlinson MG, 2004, MOL CELL BIOL, V24, P2455, DOI 10.1128/MCB.24.6.2455 2466.2004
   Yeo L, 2011, ANN RHEUM DIS, V70, P2022, DOI 10.1136/ard.2011.153312
   Yu H, 2018, SLAS DISCOV, V23, P919, DOI 10.1177/2472555218786165
   Zhou R, 2006, J PHARMACOL EXP THER, V318, P35, DOI 10.1124/jpet.106.101113
NR 39
TC 21
Z9 24
U1 2
U2 17
PU NATURE PUBL GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1671 4083
EI 1745 7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD OCT
PY 2021
VL 42
IS 10
BP 1653
EP 1664
DI 10.1038/s41401 020 00578 0
EA JAN 2021
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA UU7GC
UT WOS:000607492200001
PM 33441995
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Rutten, S
   Nolte, PA
   Korstjens, CM
   Klein Nulend, J
AF Rutten, Sjoerd
   Nolte, Peter A.
   Korstjens, Clara M.
   Klein Nulend, Jenneke
TI Low intensity pulsed ultrasound affects RUNX2 immunopositive osteogenic
   cells in delayed clinical fracture healing
SO BONE
LA English
DT Article
DE Fracture healing; Delayed union; Low intensity pulsed ultrasound; RUNX2;
   Immunolocalization; Bone progenitor cells
ID OSTEOBLAST DIFFERENTIATION; MECHANICAL SIGNALS; BONE FORMATION; LONG
   BONES; IN VITRO; TRANSCRIPTION; OSTEOCYTES; NONUNIONS; GROWTH;
   RUNX2/CBFA1/PEBP2 ALPHA A
AB Introduction: Cisteogenic cell proliferation and differentiation play an important role in adequate fracture healing, and is target for osteoinductive therapies in delayed fracture healing. The aim of this study was to investigate whether low intensity pulsed ultrasound enhances fracture healing at the tissue level in patients with a delayed union of the osteotomized fibula through an effect on the presence of RUNX2 immunopositive osteogenic cells. The effect was studied in both atrophic and hypertrophic delayed unions.
   Materials and methods: Biopsies were obtained from 6 female and I male patient (age 43 63) with a delayed union of the osteotomized fibula after a high tibial osteotomy treated for 2 4 months with or without low intensity pulsed ultrasound in a randomized prospective double blind placebo controlled trial. Immunolocalization of RLINX2 protein was performed to identify osteogenic cells. Histomorphometrical analysis was performed to determine the number of cells expressing RLINX2 located within and around the newly formed woven bone at the fracture end (area of new bone formation), and up to 3 mm distant from the fracture end.
   Results: Cells expressing RLINX2 were present in all histological sections of control and low intensity pulsed ultrasound treated bone evaluated. Within the area of new bone formation, RUNX2 immunopositive cells were found in the undifferentiated soft connective tissue, at the bone surface (presumably osteoblasts), and within the newly formed woven bone. Low intensity pulsed ultrasound treatment of fibula delayed unions significantly reduced the number of RUNX2 immunopositive cells within the soft connective tissue at the fracture ends, whereas the number of RUNX2 immunopositive cells at the bone surface was not affected. The number of RUNX2 immunopositive cells was similar for the atrophic and hypertrophic delayed unions.
   Conclusions: Immunolocalization of RUNX2 positive cells in delayed unions of the fibula reveals that delayed clinical fracture healing does not result in impairment of osteogenic cell proliferation and/or differentiation at the tissue level, even if delayed unions are clinically regarded as atrophic. Reduced number of osteogenic RLINX2 immunopositive cells within the soft connective tissue, and unchanged number of RLINX2 immunopositive cells at the bone surface, implicate that low intensity pulsed ultrasound does not increase osteogenic cell presence, but likely affects osteogenic cell differentiation. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Rutten, Sjoerd; Korstjens, Clara M.; Klein Nulend, Jenneke] ACTA Univ Amsterdam, Dept Oral Cell Biol, Amsterdam, Netherlands.
   [Rutten, Sjoerd; Korstjens, Clara M.; Klein Nulend, Jenneke] Vrije Univ Amsterdam, Res Inst MOVE, Amsterdam, Netherlands.
   [Rutten, Sjoerd; Nolte, Peter A.] Spaarne Hosp, Dept Orthopaed Surg, Hoofddorp, Netherlands.
C3 Academic Center for Dentistry Amsterdam; Vrije Universiteit Amsterdam;
   Vrije Universiteit Amsterdam; Spaarne Hospital
RP Klein Nulend, J (通讯作者)，ACTA VU Univ Amsterdam, Dept Oral Cell Biol, Boechorststr 7, NL 1081 BT Amsterdam, Netherlands.
EM j.kleinnulend@vumc.nl
RI Nolte, Peter/F 3657 2012
FU Smith & Nephew (Memphis, TN, USA)
FX The authors would like to thank Dr. A.L.J.J. Bronckers (Dept. Oral Cell
   Biology, ACTA, University of Amsterdam and VU University Amsterdam, the
   Netherlands) for his help and expertise with RUNX2 immunostaining.
   Furthermore the authors wish to thank J.J. Schrik, D.A. Vergroesen
   (Spaarne Ziekenhuis, Hoofddorp, the Netherlands), G.H.R. Albers, A.J.W.
   Marsman, R.A.W. Verhagen, and H.M. van der Vis (Tergooiziekenhuizen,
   Hilversum, the Netherlands) for performing the surgical procedure
   enabling the biopsy procedure. The work of S. Rutten is performed under
   auspices of the Skeletal Tissue Engineering Group Amsterdam (STEGA),
   which has received financial support from Smith & Nephew (Memphis, TN,
   USA). S. Rutten received salary from the Foundation Orthopaedic Research
   Spaarne Hospital (Hoofddorp, the Netherlands), and the STEGA Foundation
   (Amsterdam, the Netherlands).
CR Amir LR, 2007, J HISTOCHEM CYTOCHEM, V55, P1095, DOI 10.1369/jhc.6A7162.2007
   ANNA EFS, 2004, J ORTHOP RES, V23, P646
   AUBIN JE, 2002, PEDIAT BONE, V43, P75
   Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671
   Bacabac RG, 2006, FASEB J, V20, P858, DOI 10.1096/fj.05 4966.com
   Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026
   BOLANDER ME, 1992, P SOC EXP BIOL MED, V200, P165
   Bronckers ALJJ, 2005, J BONE MINER RES, V20, P428, DOI 10.1359/JBMR.041118
   Bronckers ALJJ, 2003, MICROSC RES TECHNIQ, V61, P540, DOI 10.1002/jemt.10377
   BROWN BS, 1984, CAN MED ASSOC J, V131, P307
   Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101
   Chen YJ, 2003, FEBS LETT, V554, P154, DOI 10.1016/S0014 5793(03)01157 8
   DUARTE LR, 1983, ARCH ORTHOP TRAUM SU, V101, P153, DOI 10.1007/BF00436764
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   EINHORN TA, 1995, J BONE JOINT SURG AM, V77A, P940, DOI 10.2106/00004623 199506000 00016
   Evans CH, 2005, J BONE JOINT SURG AM, V87A, P2550, DOI 10.2106/JBJS.E.00019
   Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS151
   Heckman J D, 1997, Bull Hosp Jt Dis, V56, P63
   Heino TJ, 2004, EXP CELL RES, V294, P458, DOI 10.1016/j.yexcr.2003.11.016
   Ikeda K, 2006, LIFE SCI, V79, P1936, DOI 10.1016/j.lfs.2006.06.029
   Kokubu T, 1999, BIOCHEM BIOPH RES CO, V256, P284, DOI 10.1006/bbrc.1999.0318
   Korstjens CM, 2004, J ORTHOP RES, V22, P495, DOI 10.1016/j.orthres.2003.09.011
   Leung KS, 2004, CLIN ORTHOP RELAT R, P253
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Naruse K, 2000, BIOCHEM BIOPH RES CO, V268, P216, DOI 10.1006/bbrc.2000.2094
   Nolte PA, 2001, J TRAUMA, V51, P693, DOI 10.1097/00005373 200110000 00012
   Nolte PA, 2001, J ORTHOP RES, V19, P301, DOI 10.1016/S0736 0266(00)00027 9
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pilla A A, 1990, J Orthop Trauma, V4, P246, DOI 10.1097/00005131 199004030 00002
   Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097 4644(20010301)80:3<424::AID JCB160>3.0.CO;2 6
   Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122
   Rubin C, 2002, BONE, V30, P445, DOI 10.1016/S8756 3282(01)00689 5
   RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623 198466030 00012
   Rutten S, 2008, BONE, V43, P348, DOI 10.1016/j.bone.2008.04.010
   Rutten S, 2007, J TRAUMA, V62, P902, DOI 10.1097/01.ta.0000238663.33796.fb
   SCOTT G, 1994, J BONE JOINT SURG AM, V76A, P820, DOI 10.2106/00004623 199406000 00005
   Takayama T, 2007, LIFE SCI, V80, P965, DOI 10.1016/j.lfs.2006.11.037
   Vezeridis PS, 2006, BIOCHEM BIOPH RES CO, V348, P1082, DOI 10.1016/j.bbrc.2006.07.146
   Wang CJ, 2001, CLIN ORTHOP RELAT R, P95
   WANG SJ, 1994, J ORTHOP RES, V12, P40, DOI 10.1002/jor.1100120106
   Zerbo IR, 2005, BIOMATERIALS, V26, P1445, DOI 10.1016/j.biomaterials.2004.05.003
   Ziros PG, 2002, J BIOL CHEM, V277, P23934, DOI 10.1074/jbc.M109881200
NR 43
TC 26
Z9 31
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD NOV
PY 2009
VL 45
IS 5
BP 862
EP 869
DI 10.1016/j.bone.2009.07.012
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 510ET
UT WOS:000271071500005
PM 19631773
DA 2025 08 17
ER

PT J
AU Wang, L
   Liu, YY
   Zhou, YL
   Wang, JT
   Tu, L
   Sun, Z
   Wang, XJ
   Luo, F
AF Wang, Li
   Liu, Yanyang
   Zhou, Yueling
   Wang, Jiantao
   Tu, Li
   Sun, Zhen
   Wang, Xiujie
   Luo, Feng
TI Zoledronic acid inhibits the growth of cancer stem cell derived from
   cervical cancer cell by attenuating their stemness phenotype and
   inducing apoptosis and cell cycle arrest through the Erk1/2 and Akt
   pathways
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
DE Zoledronic acid; Cancer stem cell; Cervical cancer; Erk1; 2; PI3K; Akt
ID IN VIVO; BONE METASTASES; LUNG CANCER; PROLIFERATION; ANGIOGENESIS;
   ACTIVATION; EXPRESSION; DENOSUMAB; EFFICACY; THERAPY
AB BackgroundZoledronic acid is the most potent osteoclast inhibitor and is widely used for advanced cancer patients with bone metastasis, but its role on cancer stem cells (CSCs) remains unclear. In the present study, we aimed to identify the stemness phenotypic characteristics of CSCs derived from cervical cancer cells and explore the anti cancer efficiency of zoledronic acid on these cells, as well as the possible molecular mechanisms.MethodsStemness phenotypic identification of cervical cancer cells derived CSCs was performed via sphere formation efficiency (SFE), tumorigenesis, immunofluorescence staining, Transwell assay, and western blot. Anti cancer efficiency of zoledronic acid on these cells (including proliferation, stemness phenotype, apoptosis, and cell cycle) was carried out through MTT assay, SFE, transwell, DAPI staining, flow cytometry, immunofluorescence, TUNEL staining, and western blot, both in vitro and in vivo.ResultsEnhanced self renewal ability, including SFE and tumorigenesis, was verified in cervical cancer cells derived CSCs compared to parental cervical cancer cells. Specifically, the expression of ALDH1, Sox2, CD49f, Nanog, and Oct4 was significantly up regulated in cervical cancer cells derived CSCs. Furthermore, enhanced migratory ability was observed in these cells along with up regulated N cadherin and Vimentin and down regulated E cadherin. Zoledronic acid inhibited cervical cancer cells derived CSCs proliferation in vitro and in vivo. The stemness phenotype of these CSCs including tumor sphere formation, migration, as well as the expression of the aforementioned associated markers was also suppressed. In addition, zoledronic acid significantly induced apoptosis and cell cycle arrest of cervical cancer cells derived CSCs in a dose dependent manner. Mechanistically, the expression of phosphorylated Erk1/2 and Akt was significantly increased in cervical cancer cells derived CSCs compared to parental cervical cancer cells. Zoledronic acid inhibited phosphorylated Erk1/2 and Akt in cervical cancer cells derived CSCs. IGF 1, a potent stimulator for Erk1/2 and PI3K/Akt, attenuated the aforementioned anti cancer effect of zoledronic acid.ConclusionsZoledronic acid inhibited the growth of cervical cancer cells derived CSCs through attenuating their stemness phenotype, inducing apoptosis, and arresting cell cycle. The suppression of phosphorylated Erk1/2 and Akt was involved in this process.
C1 [Wang, Li; Liu, Yanyang; Wang, Jiantao; Tu, Li; Luo, Feng] Sichuan Univ, Lung Canc Ctr, Lab Lung Canc, West China Hosp, Chengdu 610041, Sichuan, Peoples R China.
   [Wang, Li; Liu, Yanyang; Wang, Jiantao; Tu, Li; Luo, Feng] Sichuan Univ, Dept Med Oncol, Ctr Canc, West China Hosp, Chengdu 610041, Sichuan, Peoples R China.
   [Wang, Li; Liu, Yanyang; Wang, Jiantao; Tu, Li; Luo, Feng] Sichuan Univ, State Key Lab Biotherapy, West China Hosp, Chengdu 610041, Sichuan, Peoples R China.
   [Wang, Li; Zhou, Yueling; Sun, Zhen; Wang, Xiujie] Sichuan Univ, Lab Expt Oncol, State Key Lab Biotherapy, West China Hosp, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University; Sichuan
   University
RP Luo, F (通讯作者)，Sichuan Univ, Lung Canc Ctr, Lab Lung Canc, West China Hosp, Chengdu 610041, Sichuan, Peoples R China.; Luo, F (通讯作者)，Sichuan Univ, Dept Med Oncol, Ctr Canc, West China Hosp, Chengdu 610041, Sichuan, Peoples R China.; Luo, F (通讯作者)，Sichuan Univ, State Key Lab Biotherapy, West China Hosp, Chengdu 610041, Sichuan, Peoples R China.
EM wangli37029192@sina.com; hxyyluofeng@sina.com
RI Wang, Xiu Jie/L 1312 2019; wang, jiantao/GRS 9485 2022; Liu,
   Yanyang/AAL 8494 2020
FU National Natural Science Foundation of China [81802512, 81372506];
   project of Science and Technology Department of Sichuan Province
   [2018FZ0115]; full time post doctoral research and development
   foundation of Sichuan University [2018SCU12034]
FX This study was funded by the National Natural Science Foundation of
   China (no. 81802512 and 81372506), the project of Science and Technology
   Department of Sichuan Province (no. 2018FZ0115) and full time
   post doctoral research and development foundation of Sichuan University
   (no. 2018SCU12034).
CR Abdullah LN, 2013, CLIN TRANSL MED, V2, DOI 10.1186/2001 1326 2 3
   [Anonymous], BIOMED RES INT
   Bray F, 2018, CA CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Chang JH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005541
   Chen FX, 2016, ONCOL RES TREAT, V39, P453, DOI 10.1159/000447372
   Costa L, 2017, LANCET ONCOL, V18, P1437, DOI 10.1016/S1470 2045(17)30695 2
   Costa L, 2011, CRIT REV ONCOL HEMAT, V77, pS31, DOI 10.1016/S1040 8428(11)70006 3
   Dragu DL, 2015, WORLD J STEM CELLS, V7, P1185, DOI 10.4252/wjsc.v7.i9.1185
   Fan CW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.337
   Fukai J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104538
   Guenther A, 2010, INT J CANCER, V126, P239, DOI 10.1002/ijc.24758
   Guo HJ, 2016, MOL CARCINOGEN, V55, P77, DOI 10.1002/mc.22260
   Hattori Y, 2015, INT J ONCOL, V47, P211, DOI 10.3892/ijo.2015.2991
   Karimi Busheri F, 2013, CELL TISSUE BANK, V14, P175, DOI 10.1007/s10561 012 9315 3
   Kim MS, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 24903 0
   Kim Yonghyun, 2009, Int J Stem Cells, V2, P109
   Konge Julie, 2018, Oncotarget, V9, P23519, DOI 10.18632/oncotarget.25240
   Li HR, 2016, J GYNECOL ONCOL, V27, DOI 10.3802/jgo.2016.27.e43
   Li XL, 2018, LIFE SCI, V196, P56, DOI 10.1016/j.lfs.2018.01.014
   Lin CY, 2013, J CELL BIOCHEM, V114, P2061, DOI 10.1002/jcb.24553
   Liu SS, 2014, BIOMED PHARMACOTHER, V68, P1031, DOI 10.1016/j.biopha.2014.09.004
   Ma XY, 2016, BIOMED PHARMACOTHER, V84, P373, DOI 10.1016/j.biopha.2016.08.066
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   Mrklas KJ, 2018, SYST REV LONDON, V7, DOI 10.1186/s13643 018 0692 y
   Murillo R, 2016, CANCER EPIDEMIOL, V44, pS121, DOI 10.1016/j.canep.2016.07.015
   Porru M, 2014, ONCOTARGET, V5, P10446, DOI 10.18632/oncotarget.2182
   Prabavathy D, 2018, Stem Cell Investig, V5, P6, DOI 10.21037/sci.2018.02.01
   Rao QX, 2012, ASIAN PAC J CANCER P, V13, P1325, DOI 10.7314/APJCP.2012.13.4.1325
   Rietkötter E, 2013, ONCOTARGET, V4, P1449, DOI 10.18632/oncotarget.1201
   Rouhrazi H, 2018, BIOTECH HISTOCHEM, V93, P77, DOI 10.1080/10520295.2017.1387286
   Sarhan D, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1338238
   Scagliotti GV, 2012, J THORAC ONCOL, V7, P1823, DOI 10.1097/JTO.0b013e31826aec2b
   Shen MR, 2006, CARCINOGENESIS, V27, P962, DOI 10.1093/carcin/bgi336
   Shirali S, 2013, TUMOR BIOL, V34, P1085, DOI 10.1007/s13277 013 0650 1
   Singla M, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935 018 0555 6
   Tang WQ, 2015, CELL PHYSIOL BIOCHEM, V36, P1223, DOI 10.1159/000430292
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Teng JA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149822
   Tyagi A, 2016, CLIN CANCER RES, V22, P4170, DOI 10.1158/1078 0432.CCR 15 2574
   Ngo VA, 2018, J ENDODONT, V44, P585, DOI 10.1016/j.joen.2017.11.018
   Vishnubalaji Radhakrishnan, 2018, Oncotarget, V9, P13551, DOI 10.18632/oncotarget.24420
   Wang J, 2018, EXP THER MED, V15, P3650, DOI 10.3892/etm.2018.5805
   Wang L, 2016, TUMOR BIOL, V37, P7213, DOI 10.1007/s13277 015 4577 6
   Wang L, 2014, MOL MED REP, V9, P2117, DOI 10.3892/mmr.2014.2063
   Xia P, 2015, AM J CANCER RES, V5, P1602
   Xu R, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935 018 0540 0
   Yang BL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129138
   Yang T, 2015, ONCOL LETT, V10, P27, DOI 10.3892/ol.2015.3172
   Yulyana Y, 2015, MOL THER, V23, P746, DOI 10.1038/mt.2015.13
   Zekri J, 2014, J BONE ONCOL, V3, P25, DOI 10.1016/j.jbo.2013.12.001
   Zhang LL, 2012, J CANCER RES CLIN, V138, P675, DOI 10.1007/s00432 011 1146 2
   Zhang MY, 2015, ONCOL REP, V33, P856, DOI 10.3892/or.2014.3663
   Zhang YP, 2018, J CLIN INVEST, V128, P1737, DOI 10.1172/JCI93198
   Zhao M, 2012, CANCER SCI, V103, P58, DOI 10.1111/j.1349 7006.2011.02113.x
   Zhou DY, 2017, ONCOL LETT, V14, P4078, DOI 10.3892/ol.2017.6717
NR 55
TC 55
Z9 57
U1 1
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756 9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD FEB 21
PY 2019
VL 38
AR 93
DI 10.1186/s13046 019 1109 z
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA HM4SM
UT WOS:000459464700001
PM 30791957
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Gupta, A
   Ahmad, I
   Kureel, J
   Hasanain, M
   Pandey, P
   Singh, S
   John, AA
   Sarkar, J
   Singh, D
AF Gupta, Atul
   Ahmad, Imran
   Kureel, Jyoti
   Hasanain, Mohammad
   Pandey, Praveen
   Singh, Sarita
   John, Aijaz A.
   Sarkar, Jayanta
   Singh, Divya
TI Induction of targeted osteogenesis with 3 aryl 2H benzopyrans and
   3 aryl 3H benzopyrans: Novel osteogenic
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article
DE Estrogen; Antiestrogen; SERMs; Isoflavone; Anticancer; Antiosteoporotic
ID ESTROGEN RECEPTOR ALPHA; HUMAN OSTEOBLASTIC CELLS; GENE EXPRESSION;
   MESSENGER RNA; BONE LOSS; BETA; EQUOL; OSTEOPOROSIS; OSTEOPROTEGERIN;
   METABOLITE
AB Development of target oriented chemotherapeutics for treatment of chronic diseases have been considered as an important approach in drug development. Following this approach, in our efforts for exploration of new osteogenic leads, substituted 3 aryl 2H benzopyran and 3 aryl 3H benzopyran derivatives (19, 20a e, 21, 22a e, 26, 27, 28a e, 29, 31a b, 32 and 33) have been characterized as estrogen receptor (3 selective osteogenic (bone forming) agents. The synthesized compounds were evaluated for osteogenic activity using mouse calvarial osteoblast cells. Four compounds viz 20b, 22a, 27and 32 showed significant osteogenic activity at EC50 values 1.35, 34.5, 407 and 29.5 pM respectively. Out of these, 20b and 32 were analyzed for their bone mineralization efficacy and osteogenic gene expression by qPCR. The results showed that 20b and 32 significantly increased mineral nodule formation and the transcript levels of BMP 2, RUNX 2 and osteocalcin at 100 pM concentrations respectively. Further mechanistic studies of 20b and 32 using transiently knocked down expression of ER alpha and beta in mouse osteoblast (MOBs) showed that 20b and 32 exerts osteogenic efficacy via activation of estrogen receptor beta preferentially. Additionally, compounds showed significant anticancer activity in a panel of cancer cell lines within the range of (IC50) 6.54 27.79 mu M. The most active molecule, 22b inhibited proliferation of cells by inducing apoptosis and arresting cell cycle at sub G(0) phase with concomitant decrease in cells at S phase. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Gupta, Atul; Ahmad, Imran; Singh, Sarita] CSIR Cent Inst Med & Aromat Plants, Dept Med Chem, PO CIMAP,Kukrail Rd, Lucknow 226015, Uttar Pradesh, India.
   [Kureel, Jyoti; John, Aijaz A.; Singh, Divya] CSIR Cent Drug Res Inst, Div Endocrinol, Sect 10, Lucknow 226031, Uttar Pradesh, India.
   [Hasanain, Mohammad; Pandey, Praveen; Sarkar, Jayanta] CSIR Cent Drug Res Inst, Div Biochem, Sect 10, Lucknow 226031, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Institute of Medicinal & Aromatic Plants (CIMAP); Council of
   Scientific & Industrial Research (CSIR)   India; CSIR   Central Drug
   Research Institute (CDRI); Council of Scientific & Industrial Research
   (CSIR)   India; CSIR   Central Drug Research Institute (CDRI)
RP Gupta, A (通讯作者)，CSIR Cent Inst Med & Aromat Plants, Dept Med Chem, PO CIMAP,Kukrail Rd, Lucknow 226015, Uttar Pradesh, India.
EM atisky2001@yahoo.co.in
RI Ahmad, Imran/GRJ 0536 2022; Singh, Divya/IUM 7944 2023; Sarkar,
   Jayanta/C 3250 2009; HASANAIN, MOHAMMAD/KDO 7229 2024; Bhat,
   Aijaz/HOI 0728 2023
OI Bhat (Ph.D), Aijaz Ahmad John/0000 0002 8261 2742; HASANAIN,
   MOHAMMAD/0000 0001 5207 101X; Singh, Sarita/0009 0001 2901 1374; Sarkar,
   Jayanta/0000 0002 9905 7722
FU CSIR India; CSIR, New Delhi, India; CSIR CDRI India
FX A.G. acknowledges CSIR India for financial support. I.A. acknowledges
   CSIR, New Delhi, India for senior research fellowship. Support received
   from Director, CSIR CIMAP and CSIR CDRI India is dully acknowledged.
CR [Anonymous], [No title captured]
   Arts J, 1997, ENDOCRINOLOGY, V138, P5067, DOI 10.1210/en.138.11.5067
   Burr DB, 2002, BONE, V30, P2, DOI 10.1016/S8756 3282(01)00619 6
   Cauley JA, 2015, STEROIDS, V99, P11, DOI 10.1016/j.steroids.2014.12.010
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Christenson RH, 1997, CLIN BIOCHEM, V30, P573, DOI 10.1016/S0009 9120(97)00113 6
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   ERNST M, 1988, P NATL ACAD SCI USA, V85, P2307, DOI 10.1073/pnas.85.7.2307
   Fujioka M, 2004, J NUTR, V134, P2623, DOI 10.1093/jn/134.10.2623
   GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668
   Gupta A, 2008, SYNTHESIS STUTTGART, P3783, DOI 10.1055/s 0028 1083234
   Hajela K, 1999, BIOORGAN MED CHEM, V7, P2083, DOI 10.1016/S0968 0896(99)00131 5
   Hajela K., 1999, PCT Int. Appl., Patent No. [19990121 WO 9902513 A1 19990121(b), 9902513]
   Harvey N, 2014, J BONE MINER RES, V29, P1917, DOI 10.1002/jbmr.2286
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   Kanis JA, 2014, J BONE MINER RES, V29, P1926, DOI 10.1002/jbmr.2301
   Katzenellenbogen JA, 2011, J MED CHEM, V54, P5271, DOI 10.1021/jm200801h
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kiberstis P, 2000, SCIENCE, V289, P1497, DOI 10.1126/science.289.5484.1497
   Koehler KF, 2005, ENDOCR REV, V26, P465, DOI 10.1210/er.2004 0027
   KOMM BS, 1988, SCIENCE, V241, P81, DOI 10.1126/science.3164526
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marrian GF, 1932, BIOCHEM J, V26, P1227, DOI 10.1042/bj0261227
   Mazziotti G, 2012, ENDOCRINE, V41, P58, DOI 10.1007/s12020 011 9570 2
   Minutolo F, 2011, MED RES REV, V31, P364, DOI 10.1002/med.20186
   MITTAL S, 1985, J MED CHEM, V28, P492, DOI 10.1021/jm00382a019
   Murkies A. L., 1998, J CLIN ENDOCR METAB, V83, P97
   Muthyala RS, 2004, BIOORGAN MED CHEM, V12, P1559, DOI 10.1016/j.bmc.2003.11.035
   Nilsson S, 2011, NAT REV DRUG DISCOV, V10, P778, DOI 10.1038/nrd3551
   Parfitt AM, 2002, BONE, V30, P5, DOI 10.1016/S8756 3282(01)00642 1
   Parikka V, 2001, ENDOCRINOLOGY, V142, P5371, DOI 10.1210/en.142.12.5371
   Picherit C, 2000, J NUTR, V130, P1675, DOI 10.1093/jn/130.7.1675
   Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608
   Pittas AG, 2009, J CLIN ENDOCR METAB, V94, P827, DOI 10.1210/jc.2008 1422
   Rasmussen LM, 2007, BREAST CANCER RES TR, V106, P191, DOI 10.1007/s10549 007 9494 y
   Ray S., 1997, Adv. Drug Res, V29, P171, DOI [10.1016/S0065 2490(97)80015 9, DOI 10.1016/S0065 2490(97)80015 9]
   Rickard DJ, 2003, J CELL BIOCHEM, V89, P633, DOI 10.1002/jcb.10539
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Saika M, 2001, ENDOCRINOLOGY, V142, P2205, DOI 10.1210/en.142.6.2205
   Salman M., 1984, U.S., Patent No. [US 4447622 A 19840508, 4447622]
   Sangeeta S. Ray, 2004, DRUGS FUTURE, V29, P185
   Sato M., 2016, J MED CHEM, V42, P19991
   Sehmisch S, 2010, PHYTOMEDICINE, V17, P424, DOI 10.1016/j.phymed.2009.10.004
   Service RF, 2000, SCIENCE, V289, P1498, DOI 10.1126/science.289.5484.1498
   Setchell KDR, 2002, J NUTR, V132, P3577, DOI 10.1093/jn/132.12.3577
   Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537
   SHARMA AP, 1990, J MED CHEM, V33, P3222, DOI 10.1021/jm00174a020
   Sirtori CR, 2001, DRUG SAFETY, V24, P665, DOI 10.2165/00002018 200124090 00003
   SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604
   Srivastava K, 2013, PHYTOMEDICINE, V20, P470, DOI 10.1016/j.phymed.2012.12.021
   TAKUWA Y, 1991, BIOCHEM BIOPH RES CO, V174, P96, DOI 10.1016/0006 291X(91)90490 X
   Tanabe M., 2002, U.S. Pat. Appl. Publ., Patent No. [US 20020032180 Al 20020314(d), 20020032180]
   Tanabe M., 2001, Patent No. [US 6281205 B1 20010828(c), 6281205]
   Tanabe M., 2003, U.S., Patent No. [US 6503896 B1 20030107, 6503896]
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
NR 61
TC 12
Z9 11
U1 0
U2 6
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD APR
PY 2016
VL 158
BP 63
EP 75
DI 10.1016/j.jsbmb.2016.01.010
PG 13
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA DH3MD
UT WOS:000372690200008
PM 26807865
DA 2025 08 17
ER

PT J
AU Zhu, W
   Zhao, Y
   Ma, Q
   Wang, YJ
   Wu, ZH
   Weng, XS
AF Zhu, Wei
   Zhao, Yan
   Ma, Qi
   Wang, Yingjie
   Wu, Zhihong
   Weng, Xisheng
TI 3D printed porous titanium changed femoral head repair growth patterns:
   osteogenesis and vascularisation in porous titanium
SO JOURNAL OF MATERIALS SCIENCE MATERIALS IN MEDICINE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; BONE REGENERATION; EXTRACELLULAR MATRIX;
   COMPOSITE SCAFFOLDS; IN VIVO; OSTEONECROSIS; RELEASE; RICH; STRATEGIES;
   IMPLANTS
AB Osteonecrosis of the femoral head (ONFH) is a major cause of morbidity, and total hip arthroplasty is both traumatic and expensive. Here, we created a gelatine scaffold embedded in uniquely shaped, 3D printed porous titanium parts, which could attract and promote the proliferation of osteoblasts as well as bone regeneration, as the extracellular matrix (ECM) does in vivo. Interestingly, after hybridisation with platelets, the scaffold exhibited a low yet considerable rate of stable, safe and long term growth factor release. Additionally, a novel ONFH model was constructed and verified. Scaffolds implanted in this model were found to accelerate bone repair. In conclusion, our scaffold successfully simulates the ECM and considerably accelerates bone regeneration, in which platelets play an indispensable role. We believe that platelets should be emphasised as carriers that may be employed to transport drugs, cytokines and other small molecules to target locations in vivo. In addition, this novel scaffold is a useful material for treating ONFH.
C1 [Zhu, Wei; Zhao, Yan; Ma, Qi; Wang, Yingjie; Weng, Xisheng] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Orthopaed, Beijing 100730, Peoples R China.
   [Zhu, Wei; Zhao, Yan; Ma, Qi; Wang, Yingjie; Weng, Xisheng] Peking Union Med Coll, Beijing 100730, Peoples R China.
   [Wu, Zhihong] Peking Union Med Coll, Peking Union Med Coll Hosp, Beijing Key Lab Genet Res Bone & Joint Dis, Cent Lab, 1 Shuaifuyuan, Beijing 100730, Peoples R China.
   [Wu, Zhihong] Chinese Acad Med Sci, 1 Shuaifuyuan, Beijing 100730, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College Hospital; Chinese Academy of Medical
   Sciences   Peking Union Medical College; Peking Union Medical College;
   Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College; Peking Union Medical College Hospital;
   Chinese Academy of Medical Sciences   Peking Union Medical College
RP Weng, XS (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Orthopaed, Beijing 100730, Peoples R China.; Weng, XS (通讯作者)，Peking Union Med Coll, Beijing 100730, Peoples R China.; Wu, ZH (通讯作者)，Peking Union Med Coll, Peking Union Med Coll Hosp, Beijing Key Lab Genet Res Bone & Joint Dis, Cent Lab, 1 Shuaifuyuan, Beijing 100730, Peoples R China.; Wu, ZH (通讯作者)，Chinese Acad Med Sci, 1 Shuaifuyuan, Beijing 100730, Peoples R China.
EM wuzh3000@126.com; xshweng@medmail.com.cn
RI Yingjie, Wang/JAN 7608 2023; Weng, Xiaoyu/J 4899 2019
OI Weng, Xisheng/0000 0002 6021 1462
FU Central Laboratory of Peking Union Medical College Hospital; National
   High tech R&D Programme of China [2015AA020316, 2015AA033601];
   Laboratory Animal Centre of Peking Union Medical College Hospital
FX We would like to express our sincere gratitude to the Central Laboratory
   and Laboratory Animal Centre of Peking Union Medical College Hospital
   and the National High tech R&D Programme of China for the provided
   support (863 Programme) (2015AA020316, 2015AA033601). We would also like
   to thank Uppsala University in Sweden for the support provided in the
   preparation and verification of the scaffolds.
CR Akar B, 2015, BIOMATERIALS, V72, P61, DOI 10.1016/j.biomaterials.2015.08.049
   Bai R, 2015, EXP THER MED, V10, P591, DOI 10.3892/etm.2015.2521
   Bansiddhi A, 2008, ACTA BIOMATER, V4, P773, DOI 10.1016/j.actbio.2008.02.009
   Sánchez Ilárduya MB, 2013, J BIOMED MATER RES A, V101, P1478, DOI 10.1002/jbm.a.34428
   Briggs T, 2015, J BIOMED MATER RES A, V103, P3117, DOI 10.1002/jbm.a.35444
   Bsat S, 2015, MATERIALS, V8, P1612, DOI 10.3390/ma8041612
   Chang NJ, 2015, ACTA BIOMATER, V28, P128, DOI 10.1016/j.actbio.2015.09.026
   Chaudhary C, 2015, CRIT REV THER DRUG, V32, P277, DOI 10.1615/CritRevTherDrugCarrierSyst.2015011246
   Chen LJ, 2016, J MATER SCI MATER M, V27, DOI 10.1007/s10856 016 5668 7
   Donda RS, Patent No. [US2001041792 A1, 2001041792]
   Donda RS, Patent No. [ASU200136632 A, 200136632]
   Donda RS, Patent No. [WO200157082 A3, 200157082]
   Flauder S, 2014, ACTA BIOMATER, V10, P5148, DOI 10.1016/j.actbio.2014.08.020
   Grasman JM, 2015, BIOMATERIALS, V72, P49, DOI 10.1016/j.biomaterials.2015.08.047
   Gu JS, 2016, J MATER SCI MATER M, V27, DOI 10.1007/s10856 016 5671 z
   Hollister SJ, 2015, ANN BIOMED ENG, V43, P774, DOI 10.1007/s10439 015 1270 2
   Hoshiba T, 2010, ADV MATER, V22, P3042, DOI 10.1002/adma.201000038
   Inzunza D, 2014, J BIOMED MATER RES A, V102, P37, DOI 10.1002/jbm.a.34673
   Jhala D, 2015, POLYM REV, V55, P561, DOI 10.1080/15583724.2015.1040552
   Kang YQ, 2011, BIOMATERIALS, V32, P6119, DOI 10.1016/j.biomaterials.2011.05.015
   Kim M, 2015, J COLLOID INTERF SCI, V457, P180, DOI 10.1016/j.jcis.2015.07.007
   Landesberg R, 2000, J ORAL MAXIL SURG, V58, P297, DOI 10.1016/S0278 2391(00)90058 2
   Li LM, 2015, ACS APPL MATER INTER, V7, P22618, DOI 10.1021/acsami.5b07327
   Lindner R, 2014, J BIOTECHNOL, V192, P136, DOI 10.1016/j.jbiotec.2014.10.003
   Lucarelli E, 2010, EUR CELLS MATER, V20, P13
   Mont Michael A, 2007, Instr Course Lect, V56, P213
   Mont MA, 2015, J BONE JOINT SURG AM, V97A, P1604, DOI 10.2106/JBJS.O.00071
   Mukhatyar V, 2009, ADV MATER, V21, P4670
   Papakostidis C, 2016, ACTA ORTHOP, V87, P72, DOI 10.3109/17453674.2015.1077418
   Park KE, 2015, POLYMER, V76, P8, DOI 10.1016/j.polymer.2015.08.024
   Passaretti F, 2014, PLATELETS, V25, P252, DOI 10.3109/09537104.2013.809060
   Qin L, 2006, BONE, V39, P863, DOI 10.1016/j.bone.2006.04.018
   Ravindran S, 2015, BIOMATERIALS, V71, P58, DOI 10.1016/j.biomaterials.2015.08.030
   Sharmin F, 2015, J BIOMED MATER RES A, V103, P2847, DOI 10.1002/jbm.a.35435
   Shen J, 2015, MOL MED REP, V11, P1298, DOI 10.3892/mmr.2014.2875
   Suliman S, 2015, J CONTROL RELEASE, V197, P148, DOI 10.1016/j.jconrel.2014.11.003
   Thomas CV, 2013, INT J ORAL MAX SURG, V42, P1414, DOI 10.1016/j.ijom.2013.06.015
   Vadasz Z, 2004, EXP MOL PATHOL, V77, P145, DOI 10.1016/j.yexmp.2004.06.002
   Vaquette C, 2013, BIOMATERIALS, V34, P5538, DOI 10.1016/j.biomaterials.2013.03.088
   Vetillard J, Patent No. [CN1258588 C, 1258588]
   Vetillard J, Patent No. [EP1174497 A1, 1174497]
   Vetillard J, Patent No. [WO200206441 A1, 200206441]
   Wang C, 2015, INT J CLIN EXP MED, V8, P3127
   Wang Q, 2015, EXP THER MED, V9, P780, DOI 10.3892/etm.2015.2208
   Wang Y, 2014, ADV MATER, V26, P4163, DOI 10.1002/adma.201400323
   Wang ZX, 2015, TISSUE ENG PT A, V21, P2346, DOI [10.1089/ten.tea.2015.0071, 10.1089/ten.TEA.2015.0071]
   Wieding J, 2014, J MECH BEHAV BIOMED, V37, P56, DOI 10.1016/j.jmbbm.2014.05.002
   Xiao X, 2015, SCI REP UK, V5, DOI 10.1038/srep09409
   Yang JW, 2015, J CRANIOFAC SURG, V26, pE148, DOI 10.1097/SCS.0000000000001383
   Zhang AP, 2012, ADV MATER, V24, P4266, DOI 10.1002/adma.201202024
   Zhang M, 2014, ARTIF ORGANS, V38, P493, DOI 10.1111/aor.12208
   Zhang S, 2015, MAT SCI ENG C MATER, V53, P50, DOI 10.1016/j.msec.2015.04.005
NR 52
TC 24
Z9 27
U1 1
U2 74
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957 4530
EI 1573 4838
J9 J MATER SCI MATER M
JI J. Mater. Sci. Mater. Med.
PD APR
PY 2017
VL 28
IS 4
AR 62
DI 10.1007/s10856 017 5862 2
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA ER7UY
UT WOS:000399020800008
PM 28251470
DA 2025 08 17
ER

PT J
AU Luo, ST
   Li, ZL
   Liu, LZY
   Zhao, J
   Ge, WB
   Zhang, K
   Zhou, Z
   Liu, YL
AF Luo, Shitong
   Li, Zhilian
   Liu, Lizhiyi
   Zhao, Juan
   Ge, Wenbin
   Zhang, Kun
   Zhou, Zhi
   Liu, Yali
TI Static magnetic field induced IL 6 secretion in periodontal ligament
   stem cells accelerates orthodontic tooth movement
SO SCIENTIFIC REPORTS
LA English
DT Article
DE Tooth movement; Static magnetic field; IL 6; Osteoclast; Acceleration
ID CYTOKINES; OSTEOCLASTOGENESIS; DIFFERENTIATION; INTERLEUKIN 6;
   EXPRESSION; ARTHRITIS
AB Static magnetic field (SMF) promoting bone tissue remodeling is a potential non invasive therapy technique to accelerate orthodontic tooth movement (OTM). The periodontal ligament stem cells (PDLSCs), which are mechanosensitive cells, are essential for force induced bone remodeling and OTM. However, whether and how the PDLSCs influence the process of inflammatory bone remodeling under mechanical force stimuli in the presence of SMFs remains unclear. In this study, we found that local SMF stimulation significantly enhanced the OTM distance and induced osteoclastogenesis on the compression side of a rat model of OTM. Further experiments with macrophages cultured with supernatants from force loaded PDLSCs exposed to an SMF showed enhanced osteoclast formation. RNA seq analysis showed that interleukin 6 (IL 6) was elevated in force loaded PDLSCs exposed to SMFs. IL 6 expression was also elevated on the pressure side of a rat OTM model with an SMF. The OTM distance induced by an SMF was significantly decreased after injection of the IL 6 inhibitor tocilizumab. These results imply that SMF promotes osteoclastogenesis by inducing force loaded PDLSCs to secrete the inflammatory cytokine IL 6, which accelerates OTM. This will help to reveal the mechanism of SMF accelerates tooth movement and should be evaluated for application in periodontitis patients.
C1 [Luo, Shitong; Li, Zhilian; Liu, Lizhiyi; Ge, Wenbin; Zhang, Kun; Liu, Yali] Kunming Med Univ, Sch & Hosp Stomatol, Dept Orthodont, 1088 Middle Haiyuan Rd,High Tech Zone, Kunming 650106, Yunnan, Peoples R China.
   [Luo, Shitong; Li, Zhilian; Liu, Lizhiyi; Ge, Wenbin; Zhang, Kun; Liu, Yali] Yunnan Key Lab Stomatol, Kunming 650106, Peoples R China.
   [Luo, Shitong] Suining Cent Hosp, Dept Orthodont, Suining 629000, Peoples R China.
   [Zhao, Juan] Suining Cent Hosp, Dept Pathol, Suining 629000, Peoples R China.
   [Zhou, Zhi] Yunnan Univ, Affiliated Hosp, Dept Orthodont, 176 Qingnian Rd, Kunming 650021, Yunnan, Peoples R China.
C3 Kunming Medical University; Yunnan University
RP Liu, YL (通讯作者)，Kunming Med Univ, Sch & Hosp Stomatol, Dept Orthodont, 1088 Middle Haiyuan Rd,High Tech Zone, Kunming 650106, Yunnan, Peoples R China.; Liu, YL (通讯作者)，Yunnan Key Lab Stomatol, Kunming 650106, Peoples R China.; Zhou, Z (通讯作者)，Yunnan Univ, Affiliated Hosp, Dept Orthodont, 176 Qingnian Rd, Kunming 650021, Yunnan, Peoples R China.
EM zhouzhi12021@163.com; liuyalizu@163.com
RI Wei, Bing Yan/T 1552 2019
FU National Natural Science Foundation of China
FX We thank the Yunnan Lancheng Dental Hospital for their help and support.
CR Almpani K, 2016, FRONT ORAL BIOL, V18, P92, DOI 10.1159/000382051
   Ariffin SHZ, 2011, THESCIENTIFICWORLDJO, V11, P1788, DOI 10.1100/2011/761768
   Bartzela T, 2009, AM J ORTHOD DENTOFAC, V135, P16, DOI 10.1016/j.ajodo.2008.08.016
   Benjakul Sutiwa, 2020, J Oral Biol Craniofac Res, V10, P412, DOI 10.1016/j.jobcr.2020.06.005
   Benjakul S, 2018, EUR J ORTHODONT, V40, P356, DOI 10.1093/ejo/cjx062
   Chen GL, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02004 y
   Cui WT, 2021, HUM GENOMICS, V15, DOI 10.1186/s40246 021 00308 5
   DELLINGER EL, 1986, AM J ORTHOD DENTOFAC, V89, P428, DOI 10.1016/0002 9416(86)90075 8
   Feng W, 2022, J MOL HISTOL, V53, P599, DOI 10.1007/s10735 022 10077 7
   Fernandes MRU, 2019, J BIOPHOTONICS, V12, DOI 10.1002/jbio.201800311
   GIANELLY AA, 1989, AM J ORTHOD DENTOFAC, V96, P161, DOI 10.1016/0889 5406(89)90257 6
   Guttal SS, 2018, J INDIAN PROSTHODONT, V18, P29, DOI 10.4103/jips.jips_114_17
   He DQ, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01607 9
   Hsieh Sung Chih, 2015, ScientificWorldJournal, V2015, P492683, DOI 10.1155/2015/492683
   Huang HM, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/6531216
   Isola G, 2019, AM J ORTHOD DENTOFAC, V155, P456, DOI 10.1016/j.ajodo.2019.01.004
   Jin SS, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12912
   Karabel MA, 2020, ACTA CIR BRAS, V35, DOI [10.1590/ACB351204, 10.1590/acb351204]
   Krishnan V., 2006, AM J ORTHOD DENTOFAC, V129, p469., DOI [10.1016/j.ajodo.2005.10.007, DOI 10.1016/J.AJODO.2005.10.007]
   Lee SI, 2012, CLIN EXP IMMUNOL, V168, P113, DOI 10.1111/j.1365 2249.2011.04549.x
   Lew WZ, 2021, CELLS BASEL, V10, DOI 10.3390/cells10102662
   Li XB., 2021, West China J Stomatology, V39, P369, DOI [10.7518/hxkq.2021.04.001, DOI 10.7518/HXKQ.2021.04.001]
   Li Y, 2021, INT J ORAL SCI, V13, DOI 10.1038/s41368 021 00125 5
   Liu YL, 2011, STEM CELLS, V29, P1804, DOI 10.1002/stem.728
   MANOLAGAS SC, 1995, BONE, V17, pS63, DOI 10.1016/8756 3282(95)00180 L
   Mayr A, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.716441
   Moon SJ, 2013, INT J MOL MED, V31, P769, DOI 10.3892/ijmm.2013.1269
   Mootoo Amanda, 2009, Inflammation & Allergy Drug Targets, V8, P53
   O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301
   Padisar Parviz, 2018, Electron Physician, V10, P7146, DOI 10.19082/7146
   Phusuntornsakul P, 2018, J PERIODONTOL, V89, P1131, DOI 10.1002/JPER.17 0653
   Ren YJ, 2014, CLIN ORAL INVEST, V18, P1711, DOI 10.1007/s00784 014 1240 3
   Segal NA, 2001, ARCH PHYS MED REHAB, V82, P1453, DOI 10.1053/apmr.2001.24309
   Shan Y, 2021, BIOELECTROMAGNETICS, V42, P398, DOI 10.1002/bem.22346
   Shang WL, 2019, J DIABETES RES, V2019, DOI 10.1155/2019/5641271
   Shen LK, 2014, ELECTROMAGN BIOL MED, V33, P132, DOI 10.3109/15368378.2013.794734
   STEGER ER, 1995, AM J ORTHOD DENTOFAC, V108, P547, DOI 10.1016/S0889 5406(95)70056 0
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   Taniguchi N, 2004, EVID BASED COMPL ALT, V1, P187, DOI 10.1093/ecam/neh024
   Tsuka Y, 2020, LASER MED SCI, V35, P2059, DOI 10.1007/s10103 020 03079 y
   Wu Q, 2017, CELL PHYSIOL BIOCHEM, V41, P1360, DOI 10.1159/000465455
   Yang JC, 2021, INT J RADIAT BIOL, V97, P746, DOI 10.1080/09553002.2021.1900944
   Zhang J, 2017, ELECTROMAGN BIOL MED, V36, P8, DOI 10.3109/15368378.2016.1141362
   Zhang K, 2023, CELLS TISSUES ORGANS, V212, P317, DOI 10.1159/000524291
   Zheng JY, 2021, BMC ORAL HEALTH, V21, DOI 10.1186/s12903 021 01684 z
   Zhou RP, 2015, INT IMMUNOPHARMACOL, V29, P748, DOI 10.1016/j.intimp.2015.08.044
NR 46
TC 5
Z9 6
U1 2
U2 6
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD APR 29
PY 2024
VL 14
IS 1
AR 9851
DI 10.1038/s41598 024 60621 6
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA PA2L7
UT WOS:001211293200014
PM 38684732
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Yamaguchi, Y
   Morita, A
   Maeda, A
   Hearing, VJ
AF Yamaguchi, Yuji
   Morita, Akimichi
   Maeda, Akira
   Hearing, Vincent J.
TI Regulation of Skin Pigmentation and Thickness by Dickkopf 1 (DKK1)
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS
LA English
DT Article
CT 9th Annual Meeting of the Society of Japanese Photo Aging Research
CY MAY 13, 2008
CL Kyoto, JAPAN
SP Soc Japanese Photo Aging Res
ID EPITHELIAL MESENCHYMAL INTERACTIONS; EXPOSING BONE MARROW; PALMOPLANTAR
   FIBROBLASTS; DIFFERENTIATION; CELLS; KERATINOCYTES; EXPRESSION; THERAPY;
   PROGRAM
AB Dickkopf 1 (DKK1), an inhibitor of Wnt signaling, not only functions as a head inducer during development, but also regulates joint remodeling and bone formation, which suggests roles for DKK1 in the pathogenesis of rheumatoid arthritis and multiple myeloma. We recently demonstrated that levels of DKK1 in palmoplantar dermal fibroblasts are physiologically higher than those observed in non palmoplantar dermal fibroblasts. Thus, the DKK1 rich mesenchyme in palmoplantar dermis affects the overlying epithelium and induces a palmoplantar phenotype in the epidermis. More specifically, DKK1 suppresses melanocyte function and growth through the regulation of microphthalmia associated transcription factor (MITF) and P catenin. Furthermore, DKK1 induces the expression of keratin 9 and a Kelch like ECT2 interacting protein (alpha KLEIP) but downregulates the expression of beta catenin, glycogen synthase kinase 3 beta, protein kinase C, and proteinase activated receptor 2 (PAR 2) in keratinocytes. Treatment of reconstructed skin with DKK1 reproduces the hypopigmentation and thickening of skin through Wnt/beta catenin signaling. These studies elucidate why human palmoplantar skin is thicker and paler than non palmoplantar skin through the secretion of DKK1 by fibroblasts that affect the overlying epidermis. Thus, DKK1 may be useful for reducing skin pigmentation and for thickening photo aged skin and palmoplantar wounds caused by diabetes mellitus and rheumatic skin diseases.
C1 [Yamaguchi, Yuji; Morita, Akimichi; Maeda, Akira] Nagoya City Univ, Grad Sch Med Sci, Dept Geriatr & Environm Dermatol, Mizuho Ku, Nagoya, Aichi 4678601, Japan.
   [Hearing, Vincent J.] NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA.
C3 Nagoya City University; National Institutes of Health (NIH)   USA; NIH
   National Cancer Institute (NCI)
RP Yamaguchi, Y (通讯作者)，Nagoya City Univ, Grad Sch Med Sci, Dept Geriatr & Environm Dermatol, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.
EM yujin@med.nagoya cu.ac.jp
RI Yamaguchi, Yuji/X 6681 2019
OI Maeda, Akira/0000 0001 7334 5438; Yamaguchi, Yuji/0000 0003 4338 2662
FU Intramural NIH HHS [ZIA BC010786] Funding Source: Medline
CR Chang HY, 2002, P NATL ACAD SCI USA, V99, P12877, DOI 10.1073/pnas.162488599
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Gregory CA, 2005, J BIOL CHEM, V280, P2309, DOI 10.1074/jbc.M406275200
   Hara T, 2004, MOL BIOL CELL, V15, P1172, DOI 10.1091/mbc.E03 07 0531
   KNAPP AC, 1986, J CELL BIOL, V103, P657, DOI 10.1083/jcb.103.2.657
   Muneoka K, 2008, SCI AM, V298, P56, DOI 10.1038/scientificamerican0408 56
   Rinn JL, 2008, GENE DEV, V22, P303, DOI 10.1101/gad.1610508
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Seiberg M, 2000, EXP CELL RES, V254, P25, DOI 10.1006/excr.1999.4692
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Yamaguchi Y, 2005, BRIT J DERMATOL, V152, P664, DOI 10.1111/j.1365 2133.2005.06401.x
   Yamaguchi Y, 2004, J CELL BIOL, V165, P275, DOI 10.1083/jcb.200311122
   Yamaguchi Y, 2004, BRIT J DERMATOL, V151, P1019, DOI 10.1111/j.1365 2133.2004.06170.x
   Yamaguchi Y, 2001, ARCH DERMATOL, V137, P621
   Yamaguchi Y, 1999, J INVEST DERMATOL, V112, P483, DOI 10.1046/j.1523 1747.1999.00544.x
   YAMAGUCHI Y, 2005, WOUND HEALING SCI PR, P535
   Yamaguchi Y, 2008, FASEB J, V22, P1009, DOI 10.1096/fj.07 9475com
   Yamaguchi Y, 2007, J BIOL CHEM, V282, P27557, DOI 10.1074/jbc.R700026200
   Yamaguchi Y, 2006, FROM MELANOCYTES TO MELANOMA: THE PROGRESSION TO MALIGNANCY, P101, DOI 10.1007/978 1 59259 994 3_6
   Yamaguchi Y, 2007, J INVEST DERMATOL, V127, P1217, DOI 10.1038/sj.jid.5700629
   Yamaguchi Y, 2006, FASEB J, V20, P1486, DOI 10.1096/fj.06 5725fje
   Yasuda M, 2006, BRIT J DERMATOL, V155, P522, DOI 10.1111/j.1365 2133.2006.07399.x
NR 24
TC 58
Z9 69
U1 1
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1087 0024
J9 J INVEST DERM SYMP P
JI J. Invest. Dermatol. Symp. Proc.
PD AUG
PY 2009
VL 14
IS 1
BP 73
EP 75
DI 10.1038/jidsymp.2009.4
PG 3
WC Dermatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dermatology
GA 483LD
UT WOS:000268967100016
PM 19675559
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Lesclous, P
   Grabar, S
   Najm, SA
   Carrel, JP
   Lombardi, T
   Saffar, JL
   Samson, J
AF Lesclous, Philippe
   Grabar, Sophie
   Najm, Semaan Abi
   Carrel, Jean Pierre
   Lombardi, Tommaso
   Saffar, Jean Louis
   Samson, Jacky
TI Relevance of surgical management of patients affected by
   bisphosphonate associated osteonecrosis of the jaws. A prospective
   clinical and radiological study
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Nitrogen containing bisphosphonates; Osteonecrosis of the jaws; Surgical
   management; Clinical follow up
ID CANCER PATIENTS; ALVEOLAR BONE; RISK FACTORS; THERAPY; MECHANISMS;
   RESECTION
AB Actually, consensus management of osteonecrosis of the jaws (ONJ) related to nitrogen containing bisphosphonates (NBPs) is mostly a conservative approach. It does not always control the symptoms and the progression of the disease. The aim of this study was to evaluate the clinical and radiological outcomes of three therapeutic management strategies of established ONJ.
   Three treatment strategies, i.e., conservative approach, minimal invasive surgery, and extensive surgery were evaluated in 39 ONJ patients treated with NBPs for malignant diseases or osteoporosis. The patients were closely monitored, and the outcome (extension, improvement, or healing) of mucosa and bone was clinically and radiographically evaluated on a long term period (27.05 +/  2.96 months).
   Primary pathology (osteoporosis or malignancies) and clinical severity of ONJ (mild, moderate, severe) were decisive factors. Osteoporotic patients showed more frequently complete mucosa or bone healing (p = 0.0128 and p = 0.00021, respectively) than malignant patients. Mucosa closure and bone improvement occurred more in mild ONJ patients than in severe ONJ (p = 0.0053 and p = 0.0319, respectively). Treatment strategy appeared to be a crucial factor for mucosa but not for bone healing. The rate of complete mucosa healing increased after an extensive surgical procedure (p = 0.0096).
   A surgical management of patients with ONJ positively influenced the clinical outcome by enhancing mucosa healing.
   These results deserve further investigations involving a larger cohort. However, they strongly suggest that the guidelines of management of patients with ONJ related to NBPs have to be reconsidered.
C1 [Lesclous, Philippe; Saffar, Jean Louis] Univ Paris 05, Fac Chirurg Dentaire, Lab Biotherapie Organe Dentaire, Paris, France.
   [Lesclous, Philippe] Univ Nantes, Sch Dent, Skeletal Tissue Engn & Physiopathol Grp STEP, Ctr Osteoarticular & Dent Tissue Engn LIOAD,Inser, Nantes, France.
   [Grabar, Sophie] Univ Paris 05, AP HP, Unite Biostat & Epidemiol, Hop Cochin, Paris, France.
   [Najm, Semaan Abi; Carrel, Jean Pierre; Lombardi, Tommaso; Samson, Jacky] Univ Geneva, Sch Dent Med, Div Stomatol & Oral Surg, Geneva, Switzerland.
   [Lesclous, Philippe] Fac Chirurg Dentaire Nantes, F 44042 Nantes 1, France.
C3 Universite Paris Cite; Nantes Universite; Institut National de la Sante
   et de la Recherche Medicale (Inserm); Universite Paris Cite; Assistance
   Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin   APHP;
   University of Geneva
RP Lesclous, P (通讯作者)，Fac Chirurg Dentaire Nantes, 1 Pl Alexis Ricordeau BP 84215, F 44042 Nantes 1, France.
EM philippe.lesclous@univ nantes.fr
RI Lesclous, Philippe/P 6255 2014; Grabar, Sophie/AAM 9857 2020
OI Saffar, Jean Louis/0000 0001 6288 9325; lesclous,
   Philippe/0000 0002 9840 4542; 
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Barasch A, 2011, J DENT RES, V90, P439, DOI 10.1177/0022034510397196
   BARON R, 1977, CALC TISS RES, V22, P502
   Boonyapakorn T, 2008, ORAL ONCOL, V44, P857, DOI 10.1016/j.oraloncology.2007.11.012
   Carlson ER, 2009, J ORAL MAXIL SURG, V67, P85, DOI 10.1016/j.joms.2009.01.006
   Cornish J, 2011, BONE, V49, P710, DOI 10.1016/j.bone.2011.07.020
   Curi MM, 2007, J ORAL MAXIL SURG, V65, P349, DOI 10.1016/j.joms.2005.12.051
   Diel IJ, 2007, CRIT REV ONCOL HEMAT, V64, P198, DOI 10.1016/j.critrevonc.2007.07.005
   DIMOPOULOS MA, 2007, HAEMATOLOGICA, V91, P968
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Hellstein JW, 2011, J AM DENT ASSOC, V142, P1243, DOI 10.14219/jada.archive.2011.0108
   Hoefert S, 2011, J ORAL MAXIL SURG, V69, P362, DOI 10.1016/j.joms.2010.06.200
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   Hoff AO, 2011, ANN NY ACAD SCI, V1218, P47, DOI 10.1111/j.1749 6632.2010.05771.x
   Holzinger D, 2012, ORAL ONCOL, DOI [10.1016/j.oraloncology2012.07.008, DOI 10.1016/J.0RAL0NC0L0GY2012.07.008]
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Landesberg R, 2011, ANN NY ACAD SCI, V1218, P62, DOI 10.1111/j.1749 6632.2010.05835.x
   Lemound J, 2012, CLIN ORAL INVEST, V16, P1143, DOI 10.1007/s00784 011 0596 x
   Lesclous P, 2009, BONE, V45, P843, DOI 10.1016/j.bone.2009.07.011
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Migliorati CA, 2006, LANCET ONCOL, V7, P508, DOI 10.1016/S1470 2045(06)70726 4
   Mozzati M, 2013, CLIN ORAL INVEST, V17, P1259, DOI 10.1007/s00784 012 0800 7
   Reid IR, 2007, BONE, V41, P318, DOI 10.1016/j.bone.2007.04.196
   Richards Derek, 2008, Evid Based Dent, V9, P101, DOI 10.1038/sj.ebd.6400608
   Rizzoli R, 2008, BONE, V42, P841, DOI 10.1016/j.bone.2008.01.003
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212
   Saffar JL, 1997, PERIODONTOL 2000, V13, P76, DOI 10.1111/j.1600 0757.1997.tb00096.x
   Scheper MA, 2009, BRIT J HAEMATOL, V144, P667, DOI 10.1111/j.1365 2141.2008.07504.x
   Stockmann P, 2010, SUPPORT CARE CANCER, V18, P449, DOI 10.1007/s00520 009 0688 1
   Tubiana Hulin M, 2009, CRIT REV ONCOL HEMAT, V71, P12, DOI 10.1016/j.critrevonc.2008.10.009
   Van den Wyngaert T, 2009, ANN ONCOL, V20, P331, DOI 10.1093/annonc/mdn630
   Wang J, 2003, J ORAL MAXIL SURG, V61, P1104, DOI 10.1016/S0278 2391(03)00328 8
   Watters AL, 2012, ORAL SURG ORAL MED O, DOI [10.1016/j.OOOO.2012.05.017, DOI 10.1016/J.0000.2012.05.017]
   Wilde F, 2011, ORAL SURG ORAL MED O, V111, P153, DOI 10.1016/j.tripleo.2010.04.015
   Williamson RA, 2010, INT J ORAL MAX SURG, V39, P251, DOI 10.1016/j.ijom.2009.11.014
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   WOWERN NV, 1977, SCAND J DENT RES, V85, P613
NR 42
TC 21
Z9 23
U1 0
U2 9
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1432 6981
EI 1436 3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD MAR
PY 2014
VL 18
IS 2
BP 391
EP 399
DI 10.1007/s00784 013 0979 2
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA AC2GL
UT WOS:000332317500007
PM 23604698
DA 2025 08 17
ER

PT J
AU Mahon, OR
   O'Hanlon, S
   Cunningham, CC
   McCarthy, GM
   Hobbs, C
   Nicolosi, V
   Kelly, DJ
   Dunne, A
AF Mahon, Olwyn R.
   O'Hanlon, Sarah
   Cunningham, Clare C.
   McCarthy, Geraldine M.
   Hobbs, Christopher
   Nicolosi, Valeria
   Kelly, Daniel J.
   Dunne, Aisling
TI Orthopaedic implant materials drive M1 macrophage polarization in a
   spleen tyrosine kinase  and mitogen activated protein kinase dependent
   manner
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Osteolysis; Wear particles; Macrophage polarization; Syk; MAPK
ID TUMOR NECROSIS FACTOR; INFLAMMASOME COMPONENTS ASC; EVALUATE DRUG
   EFFICACY; WEAR DEBRIS; GENE THERAPY; FACTOR ALPHA; TOTAL HIP;
   PARTICULATE DEBRIS; KNEE ARTHROPLASTY; SYK
AB Total joint replacements (TJR) are costly procedures required to relieve pain and restore function in patients suffering from end stage arthritis. Despite great progress in the development and durability of TJRs, the generation of prosthesis associated wear particles over time leads to an inflammatory cascade which culminates in periprosthetic osteolysis. Studies suggest that wear particles drive the polarization/differentiation of immature macrophages towards a pro inflammatory M1 phenotype rather than an anti inflammatory M2 phenotype associated with normal bone and wound healing. This, in turn, contributes to the initiation of peri implant inflammation. As a result, modulating M1 macrophage cytokine production has been recognised as a viable therapeutic option. The aim of this study was to examine the impact of hydroxyapatite (HA) and poly(methyl methacrylate) (PMMA) particles on human macrophage polarization by comparing their effect on M1/M2 associated gene expression using real time PCR. Furthermore, using immunoblotting to assess kinase activation, we sought to identify the intracellular signalling molecules activated by PMMA/HA particles and to determine whether pharmacological blockade of these molecules impacts on macrophage phenotype and cytokine production as measured by ELISA. We report that wear particles preferentially polarize macrophages towards an M1 phenotype, an effect that is dependent on activation of the membrane proximal kinase, Syk and members of the mitogen activated protein kinase (MAPK) family of signalling molecules. Pre treatment of macrophages with Syk inhibitors (R788/piceatannol) or MAPK inhibitors (SB203580 and PD98059), not only prevents M1 polarization, but also attenuates production of key pro inflammatory mediators that have been specifically implicated in periprosthetic osteolysis and osteoclast differentiation. (C) 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Mahon, Olwyn R.; O'Hanlon, Sarah; Cunningham, Clare C.; Dunne, Aisling] Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Biochem & Immunol, Dublin, Ireland.
   [Mahon, Olwyn R.; O'Hanlon, Sarah; Cunningham, Clare C.; Dunne, Aisling] Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Med, Dublin, Ireland.
   [McCarthy, Geraldine M.] Mater Misericordiae Univ Hosp, Dublin 7, Ireland.
   [Hobbs, Christopher; Nicolosi, Valeria] Trinity Coll Dublin, CRANN, Dublin, Ireland.
   [Hobbs, Christopher; Nicolosi, Valeria] Trinity Coll Dublin, AMBER Ctr, Dublin, Ireland.
   [Kelly, Daniel J.] Trinity Coll Dublin, Trinity Ctr Bioengn, Dublin, Ireland.
C3 Trinity College Dublin; Trinity College Dublin; University College
   Dublin; Mater Misericordiae University Hospital; Trinity College Dublin;
   Trinity College Dublin; Trinity College Dublin
RP Dunne, A (通讯作者)，Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Biochem & Immunol, Dublin, Ireland.
EM aidunne@tcd.ie
RI McCarthy, Geraldine/AFQ 5733 2022; Nicolosi, Valeria/Y 2419 2019
OI Nicolosi, Valeria/0000 0002 7637 4813; Kelly,
   Daniel/0000 0003 4091 0992; dunne, aisling/0000 0002 2342 9518;
   McCarthy, Geraldine/0000 0003 4078 8499
FU Trinity College Dublin, Student Award; ERC (StG 2DNanocaps); SFI
   (PIYRA); SFI (AMBER)
FX This study is supported by a Trinity College Dublin, Student Award. C.
   Hobbs and V. Nicolosi would like to thank the ERC (StG 2DNanocaps) and
   SFI (PIYRA and AMBER) for their support. The Advanced Microscopy
   Laboratory, TCD are also acknowledged for their provision of their
   facilities.
CR Antonios JK, 2013, CELL MOL IMMUNOL, V10, P471, DOI 10.1038/cmi.2013.39
   Badylak SF, 2008, TISSUE ENG PT A, V14, P1835, DOI 10.1089/ten.tea.2007.0264
   Bi FG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139793
   Blaine TA, 1996, J BONE JOINT SURG AM, V78A, P1181, DOI 10.2106/00004623 199608000 00008
   BLOEBAUM RD, 1993, J ARTHROPLASTY, V8, P195, DOI 10.1016/S0883 5403(09)80013 2
   Carmody EE, 2002, ARTHRITIS RHEUM US, V46, P1298, DOI 10.1002/art.10227
   Christo SN, 2016, SCI REP UK, V6, DOI 10.1038/srep20635
   Corr EM, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1225 0
   Corr EM, 2016, ATHEROSCLEROSIS, V251, P197, DOI 10.1016/j.atherosclerosis.2016.06.035
   Cunningham CC, 2012, CLIN IMMUNOL, V144, P228, DOI 10.1016/j.clim.2012.06.007
   Desaulniers P, 2001, J LEUKOCYTE BIOL, V70, P659
   GELB H, 1994, J ORTHOP RES, V12, P83, DOI 10.1002/jor.1100120111
   Goater JJ, 2002, J ORTHOPAED RES, V20, P169, DOI 10.1016/S0736 0266(01)00083 3
   Goodman SB, 1998, J BONE JOINT SURG BR, V80B, P531, DOI 10.1302/0301 620X.80B3.8158
   Hallab NJ, 2009, BULL HOSP JT DIS, V67, P182
   Haynes DR, 2004, BIOMATERIALS, V25, P4877, DOI 10.1016/j.biomaterials.2004.01.003
   Haynes DR, 2001, J BONE JOINT SURG BR, V83B, P902, DOI 10.1302/0301 620X.83B6.10905
   Huang ZN, 2010, J BIOMED MATER RES A, V94A, P1264, DOI 10.1002/jbm.a.32803
   Im GI, 2004, BIOMATERIALS, V25, P269, DOI 10.1016/S0142 9612(03)00523 4
   Ingham E, 2005, BIOMATERIALS, V26, P1271, DOI 10.1016/j.biomaterials.2004.04.035
   Ingham E, 2000, BIOMATERIALS, V21, P1005, DOI 10.1016/S0142 9612(99)00261 6
   Jin CC, 2011, P NATL ACAD SCI USA, V108, P14867, DOI 10.1073/pnas.1111101108
   King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406
   Kurtz S, 2007, J BONE JOINT SURG AM, V89A, P780, DOI 10.2106/JBJS.F.00222
   Lebre F, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03086 0
   Lin TH, 2014, ACTA BIOMATER, V10, P1, DOI 10.1016/j.actbio.2013.09.034
   Lin YC, 2015, J LEUKOCYTE BIOL, V97, P825, DOI 10.1189/jlb.3HI0814 371RR
   Malik AF, 2011, P NATL ACAD SCI USA, V108, P20095, DOI 10.1073/pnas.1105152108
   Mandelin J, 2003, J BONE JOINT SURG BR, V85B, P1196, DOI 10.1302/0301 620X.85B8.13311
   Massin P, 2004, J BIOMED MATER RES B, V68B, P140, DOI 10.1002/jbm.b.10072
   Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002 9440(10)65266 2
   Mócsai A, 2010, NAT REV IMMUNOL, V10, P387, DOI 10.1038/nri2765
   Moreau MF, 2007, BIOCHEM PHARMACOL, V73, P718, DOI 10.1016/j.bcp.2006.09.031
   Nakashima Y, 1999, J BONE JOINT SURG AM, V81A, P603, DOI 10.2106/00004623 199905000 00002
   Narayan S, 2011, ARTHRITIS RHEUM US, V63, P422, DOI 10.1002/art.30147
   Nasi S, 2016, ANN RHEUM DIS, V75, P1372, DOI 10.1136/annrheumdis 2015 207487
   Ng G, 2008, IMMUNITY, V29, P807, DOI 10.1016/j.immuni.2008.09.013
   Ohradanova Repic A, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2015.39
   Pazár B, 2011, J IMMUNOL, V186, P2495, DOI 10.4049/jimmunol.1001284
   Rakshit D. S., 2006, JBJS, V88
   Rao AJ, 2012, ACTA BIOMATER, V8, P2815, DOI 10.1016/j.actbio.2012.03.042
   Ren K, 2013, ACTA PHARM SIN B, V3, P76, DOI 10.1016/j.apsb.2013.02.005
   Ren PG, 2008, BIOMATERIALS, V29, P4760, DOI 10.1016/j.biomaterials.2008.09.004
   Ren PG, 2011, CLIN ORTHOP RELAT R, V469, P113, DOI 10.1007/s11999 010 1645 5
   SCHMALZRIED TP, 1992, J BONE JOINT SURG AM, V74A, P849, DOI 10.2106/00004623 199274060 00006
   Schwarz EM, 2003, J ORTHOPAED RES, V21, P1049, DOI 10.1016/S0736 0266(03)00093 7
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P849, DOI 10.1002/jor.1100180602
   Sedlik C, 2003, J IMMUNOL, V170, P846, DOI 10.4049/jimmunol.170.2.846
   Shanbhag AS, 2007, J BONE JOINT SURG AM, V89A, P1081, DOI 10.2106/JBJS.F.00330
   Sridharan R, 2015, MATER TODAY, V18, P313, DOI 10.1016/j.mattod.2015.01.019
   Teeny SM, 2003, J ARTHROPLASTY, V18, P954, DOI 10.1016/j.arth.2003.09.001
   Ulrich Vinther M, 2002, J BONE JOINT SURG AM, V84A, P1405, DOI 10.2106/00004623 200208000 00017
   Wang H, 2013, GENE THER, V20, P128, DOI 10.1038/gt.2012.1
   Weinblatt ME, 2008, ARTHRITIS RHEUM US, V58, P3309, DOI 10.1002/art.23992
   Zhang XP, 2001, J BONE MINER RES, V16, P660, DOI 10.1359/jbmr.2001.16.4.660
   Zwerina J, 2004, ARTHRITIS RHEUM, V50, P277, DOI 10.1002/art.11487
NR 56
TC 46
Z9 47
U1 0
U2 46
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JAN
PY 2018
VL 65
BP 426
EP 435
DI 10.1016/j.actbio.2017.10.041
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA FQ4GO
UT WOS:000418315900037
PM 29104084
DA 2025 08 17
ER

PT J
AU Yokoyama, T
   Mizuguchi, M
   Ostermann, A
   Kusaka, K
   Niimura, N
   Schrader, TE
   Tanaka, I
AF Yokoyama, Takeshi
   Mizuguchi, Mineyuki
   Ostermann, Andreas
   Kusaka, Katsuhiro
   Niimura, Nobuo
   Schrader, Tabias E.
   Tanaka, Ichiro
TI Protonation State and Hydration of Bisphosphonate Bound to Farnesyl
   Pyrophosphate Synthase
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID SITE DIRECTED MUTAGENESIS; NITROGEN CONTAINING BISPHOSPHONATES;
   DIPHOSPHATE SYNTHASE; CONSERVED ASPARTATE; STRUCTURAL BASIS; RESIDUES;
   BINDING; DIFFRACTOMETER; INSIGHTS; PATHWAY
AB Farnsyl pyrophosphate synthase (FPPS) catalyzes the condensation of isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate to FPP and is known to be a molecular target of osteoporosis drugs, such as risedronate (RIS), which is a nitrogen containing bisphosphonate. The protonation states and hydration structure of RIS bound to FPPS were determined by neutron protein crystallography, which allows direct visualization of hydrogens and deuteriums. The structure analysis revealed that the phosphate groups of RIS were fully deprotonated with the abnormally decreased plc, and that the roles of E93 and D264 consisted of canceling the extra negative charges upon the binding of ligands. Collectively, our neutron structures provided insights into the physicochemical properties during the bisphosphonate binding event.
C1 [Yokoyama, Takeshi; Mizuguchi, Mineyuki] Toyama Univ, Fac Pharmaceut Sci, Toyama 9300914, Japan.
   [Ostermann, Andreas] Tech Univ Munich, Heinz Maier Leibnitz Zentrum MLZ, D 85748 Garching, Germany.
   [Kusaka, Katsuhiro; Niimura, Nobuo; Tanaka, Ichiro] Ibaraki Univ, Frontier Res Ctr Appl Atom Sci, Tokai, Ibaraki 3191106, Japan.
   [Schrader, Tabias E.] Forschungszentrum Julich, Heinz Maier Leibnitz Zentrum MLZ, JCNS, D 85747 Garching, Germany.
   [Tanaka, Ichiro] Ibaraki Univ, Coll Engn, Hitachi, Ibaraki 3168511, Japan.
C3 University of Toyama; Technical University of Munich; Ibaraki
   University; Helmholtz Association; Research Center Julich; Ibaraki
   University
RP Yokoyama, T (通讯作者)，Toyama Univ, Fac Pharmaceut Sci, 2630 Sugitani, Toyama 9300914, Japan.
EM tyokoya3@pha.u toyama.ac.jp
RI Mineyuki, Mizuguchi/IUM 3999 2023; Schrader, Tobias/LKJ 0868 2024
OI Schrader, Tobias Erich/0000 0001 5159 0846; Yokoyama,
   Takeshi/0000 0002 5362 8606; 
FU [25860022]; Grants in Aid for Scientific Research [25860022] Funding
   Source: KAKEN
FX We gratefully acknowledge access to the synchrotron radiation facility
   at PF, Japan. X ray diffraction experiments in PF were conducted under
   Proposals 2013G016 and 2013G503. Neutron diffraction experiments in FRM
   II and J PARC were conducted under Proposals 8403 and 2013B0032,
   respectively. This work was supported by a Grant in Aid for Young
   Scientists (B) (Project 25860022).
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Coleman RE, 2005, ANN ONCOL, V16, P687, DOI 10.1093/annonc/mdi162
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Desiraju GR., 2001, The Weak Hydrogen Bond: In Structural Chemistry and Biology
   Dhar MK, 2013, NEW BIOTECHNOL, V30, P114, DOI 10.1016/j.nbt.2012.07.001
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Ferrer Casal M, 2014, BIOORGAN MED CHEM, V22, P398, DOI 10.1016/j.bmc.2013.11.010
   Harris TK, 2002, IUBMB LIFE, V53, P85, DOI 10.1080/15216540211468
   Hosking D, 2007, J BONE MINER RES, V22, P142, DOI 10.1359/JBMR.061001
   JOLY A, 1993, J BIOL CHEM, V268, P26983
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kawasaki Y, 2014, CHEM PHARM BULL, V62, P77, DOI 10.1248/cpb.c13 00710
   Koyama T, 1996, BIOCHEMISTRY US, V35, P9533, DOI 10.1021/bi960137v
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   MARRERO PF, 1992, J BIOL CHEM, V267, P21873
   Meloun M, 2012, CENT EUR J CHEM, V10, P338, DOI 10.2478/s11532 011 0150 3
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Niimura N., 2011, INT UNION CRYSTALLOG, V25, pxvi
   Ohhara T, 2009, NUCL INSTRUM METH A, V600, P195, DOI 10.1016/j.nima.2008.11.030
   Onufriev AV, 2013, Q REV BIOPHYS, V46, P181, DOI 10.1017/S0033583513000024
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076 6879(97)76066 X
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044
   Szkopinska A, 2005, ACTA BIOCHIM POL, V52, P45
   Tanaka I, 2010, ACTA CRYSTALLOGR D, V66, P1194, DOI 10.1107/S0907444910033020
   Yokoyama T, 2014, ACTA CRYSTALLOGR F, V70, P470, DOI 10.1107/S2053230X14004087
   Yokoyama T, 2012, J STRUCT BIOL, V177, P283, DOI 10.1016/j.jsb.2011.12.022
NR 29
TC 26
Z9 26
U1 1
U2 25
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD SEP 24
PY 2015
VL 58
IS 18
BP 7549
EP 7556
DI 10.1021/acs.jmedchem.5b01147
PG 8
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CS2SL
UT WOS:000361921800033
PM 26314394
DA 2025 08 17
ER

PT J
AU Rios, C
   Maldonado, G
   Vargas, S
   González, J
   Vera, C
   Zuñiga, A
   Martínez, J
   Castillo, M
   Jervis, R
   Ventura, R
   Guevara, S
   Torres, G
   Uguña, F
   Messina, OD
   Neyro, JL
   Fernández, D
   Guerrero, R
   Moreno, M
AF Rios, Carlos
   Maldonado, Genessis
   Vargas, Sara
   Gonzalez, Jose
   Vera, Claudia
   Zuniga, Andres
   Martinez, Jose
   Castillo, Mayra
   Jervis, Raul
   Ventura, Rosa
   Guevara, Sergio
   Torres, Gabriela
   Uguna, Franklin
   Messina, Osvaldo Daniel
   Neyro, Jose Luis
   Fernandez, Daniel
   Guerrero, Roberto
   Moreno, Mario
TI First Ecuadorian statement consensus for the evaluation and treatment of
   osteoporosis
SO ARCHIVES OF OSTEOPOROSIS
LA English
DT Article
DE Ecuador; Osteoporosis; Osteopenia; Treatment
ID BONE MINERAL DENSITY; VERTEBRAL FRACTURE ASSESSMENT; POSTMENOPAUSAL
   WOMEN; VITAMIN D; OLDER ADULTS; MOLECULAR MECHANISMS; CARBONATED
   BEVERAGES; PARATHYROID HORMONE; POSITION STATEMENT; SMOKING CESSATION
AB Osteoporosis management has become more relevant as the life expectancy increases. In Ecuador, approximately 19% of adults over 65 years of age have been diagnosed with osteoporosis. There is no national consensus for the management and prevention of the disease being this proposal the first Ecuadorian consensus.IntroductionIn Ecuador, it is estimated that around 19% of adults over 65 years of age have osteoporosis. Due to the increase in life expectancy in the world population, the evaluation and management of osteoporosis has become more relevant. Currently, there is no national consensus for the management and prevention of the disease. The Ecuadorian Society of Rheumatology presented the project for the elaboration of the first Ecuadorian consensus for the management and prevention of osteoporosis.MethodsA panel of experts in multiple areas and extensive experience was invited to participate. The consensus was carried out using the Delphi method. Six working dimensions were created: definition and epidemiology of osteoporosis, fracture risk prediction tools, non pharmacological treatment, pharmacological treatment, calcium and vitamin D, and glucocorticoid induced osteoporosis.ResultsThe first round was held in December 2021, followed by the second round in February 2022 and the third round in March 2022. The data was shared with the specialists at the end of each round. After three rounds of work, a consensus was reached for the management and preventionof osteoporosis.ConclusionThis is the first Ecuadorian consensus for the management and treatment of postmenopausal osteoporosis.
C1 [Rios, Carlos; Vargas, Sara; Gonzalez, Jose; Vera, Claudia; Zuniga, Andres; Martinez, Jose; Castillo, Mayra; Jervis, Raul; Ventura, Rosa; Guevara, Sergio; Torres, Gabriela; Uguna, Franklin; Moreno, Mario] Ecuadorian Soc Rheumatol, Guayaquil, Ecuador.
   [Maldonado, Genessis; Guerrero, Roberto] Loyola MacNeal Hosp, Berwyn, IL 60402 USA.
   [Messina, Osvaldo Daniel] Cosme Argerich Hosp, Rheumatol Dept, Buenos Aires, Argentina.
   [Neyro, Jose Luis] Vasco Country Univ EHU UPV, Cruces Univ Hosp, Obstet & Gynecol Dept, Baracaldo, Bizkaia, Spain.
   [Fernandez, Daniel] San Ignacio Univ Hosp, Rheumatol Dept, Bogota, Colombia.
C3 University of Buenos Aires; University of Buenos Aires Hospital;
   Hospital Universitario Cruces; Hospital Universitario San Ignacio
RP Maldonado, G (通讯作者)，Loyola MacNeal Hosp, Berwyn, IL 60402 USA.
EM genessis.maldonado@luhs.org
RI ; Rios Acosta, Carlos Ramon/M 2066 2017; Guerrero, Roberto
   J./AEO 6967 2022; Maldonado, Genessis/N 9636 2019; Maldonado,
   Genessis/M 8053 2017; Zuniga Vera, Andres/A 5623 2008; Acosta,
   Carlos/M 2066 2017; Torres, Gabriela/S 2405 2016
OI Neyro, Jose Luis/0000 0003 4345 7089; Rios Acosta, Carlos
   Ramon/0000 0003 0221 8276; Maldonado, Genessis/0000 0003 3978 0799;
   Zuniga Vera, Andres/0000 0002 0089 8565; 
CR Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   Amato D, 1998, REV INVEST CLIN, V50, P185
   Anastasilakis AD, 2020, EXPERT OPIN PHARMACO, V21, P477, DOI 10.1080/14656566.2020.1717468
   Anastasilakis AD, 2017, J BONE MINER RES, V32, P1291, DOI 10.1002/jbmr.3110
   Andreoli A, 2011, RADIOL MED, V116, P1115, DOI 10.1007/s11547 011 0689 2
   [Anonymous], 2020, WHO FRACT RISK ASS T
   Betancourt OS, 2014, NUTR HOSP, V30, P372
   Bilezikian JP, 1998, NEW ENGL J MED, V339, P599, DOI 10.1056/NEJM199808273390905
   Bischoff Ferrari HA, 2016, JAMA INTERN MED, V176, P175, DOI 10.1001/jamainternmed.2015.7148
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bone HG, 2018, J CLIN ENDOCR METAB, V103, P2949, DOI 10.1210/jc.2018 00163
   Buckley L, 2017, ARTHRITIS RHEUMATOL, V69, P1521, DOI [10.1002/art.40137, 10.1002/acr.23279]
   Cadore EL, 2013, REJUV RES, V16, P105, DOI 10.1089/rej.2012.1397
   Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL 2020 0524SUPPL
   Carani C, 1997, NEW ENGL J MED, V337, P91, DOI 10.1056/NEJM199707103370204
   Celi M, 2013, AGING CLIN EXP RES, V25, pS47, DOI 10.1007/s40520 013 0074 1
   Chang V, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.4.FOCUS1477
   Compston J, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0324 5
   Compston J, 2015, MATURITAS, V82, P284, DOI 10.1016/j.maturitas.2015.07.024
   Confavreux CB, 2010, JOINT BONE SPINE, V77, pS128, DOI 10.1016/S1297 319X(10)70008 7
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cosman F, 2017, J BONE MINER RES, V32, P198, DOI 10.1002/jbmr.3051
   Costa AG, 2015, CURR OSTEOPOROS REP, V13, P415, DOI 10.1007/s11914 015 0295 7
   Cummings S., Journal of Bone and Mineral Research, DOI [10.1002/jbmr.3359, DOI 10.1002/JBMR.3359]
   Cummings SR, 2008, NEW ENGL J MED, V359, P697, DOI 10.1056/NEJMoa0800743
   Curtis EM, 2022, AGING CLIN EXP RES, V34, P695, DOI 10.1007/s40520 022 02100 4
   Dalkey NC, 2018, DELPHI
   Deer RR, 2015, CURR OPIN CLIN NUTR, V18, P248, DOI 10.1097/MCO.0000000000000162
   DELBECQ AL, 1975, GROUP TECHNIQUES PRO
   Dempster DW, 2018, J CLIN ENDOCR METAB, V103, P2498, DOI 10.1210/jc.2017 02669
   Dufour AB, 2013, J GERONTOL A BIOL, V68, P168, DOI 10.1093/gerona/gls109
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Ferrar L, 2005, OSTEOPOROSIS INT, V16, P717, DOI 10.1007/s00198 005 1880 x
   FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979
   Fitzpatrick L, 2003, J BONE MINER RES, V18, P1570, DOI 10.1359/jbmr.2003.18.9.1570
   Fleet JC, 2010, CRIT REV CL LAB SCI, V47, P181, DOI 10.3109/10408363.2010.536429
   Formoso G, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008536.pub3
   Freemantle N, 2012, OSTEOPOROSIS INT, V23, P317, DOI 10.1007/s00198 011 1780 1
   Gattrell WT, 2022, RES INTEGR PEER REV, V7, DOI 10.1186/s41073 022 00122 0
   Gavilánez L, 2018, REV OSTEOPOR METAB M, V10, P63, DOI 10.4321/S1889 836X2018000200002
   Gavilanez EL, 2019, ARCH OSTEOPOROS, V14, DOI 10.1007/s11657 019 0644 8
   Geusens P, 2018, J BONE MINER RES, V33, P783, DOI 10.1002/jbmr.3384
   Gilsenan A, 2021, J BONE MINER RES, V36, P244, DOI 10.1002/jbmr.4188
   Goodwin VA, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen 2015 010657
   Griffith JF, 2010, RADIOL CLIN N AM, V48, P519, DOI 10.1016/j.rcl.2010.02.012
   Guañabens N, 2019, ENDOCRINE, V64, P441, DOI 10.1007/s12020 019 01919 8
   Guiducci L, 2017, GYNECOL ENDOCRINOL, V33, P383, DOI 10.1080/09513590.2016.1270932
   Hamdy Ronald C, 2002, J Clin Densitom, V5 Suppl, pS11, DOI 10.1385/JCD:5:3S:S11
   HARRIS SS, 1994, AM J CLIN NUTR, V60, P573, DOI 10.1093/ajcn/60.4.573
   Harslof T, 2016, CURR OPIN PHARMACOL, V28, P38, DOI 10.1016/j.coph.2016.02.012
   Heckman MA, 2010, J FOOD SCI, V75, pR77, DOI 10.1111/j.1750 3841.2010.01561.x
   Henriksen K, 2011, WOMENS HEALTH, V7, P689, DOI [10.2217/whe.11.74, 10.2217/WHE.11.74]
   Hlaing TT, 2014, ANN CLIN BIOCHEM, V51, P189, DOI 10.1177/0004563213515190
   Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI [10.1210/jc.2011 0385, 10.1210/jc.2011 1193]
   Jackson S.E., 1992, GROUP PROCESS PRODUC, P138
   Jia HM, 2019, PREV MED, V126, DOI 10.1016/j.ypmed.2019.05.025
   Jin YZ, 2016, J KOREAN MED SCI, V31, P1641, DOI 10.3346/jkms.2016.31.10.1641
   Kado DM, 1999, ARCH INTERN MED, V159, P1215, DOI 10.1001/archinte.159.11.1215
   Kanis J, 2007, Technical Report
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P1, DOI 10.1007/s00198 019 05176 3
   Kanis JA, 2013, OSTEOPOROSIS INT, V24, P23, DOI 10.1007/s00198 012 2074 y
   Kanis J.A., 2007, ASSESSMENT OSTEOPORO
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P581, DOI 10.1007/s00198 004 1780 5
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P155, DOI 10.1007/s00198 004 1640 3
   Kaptoge S, 2004, J BONE MINER RES, V19, P1982, DOI 10.1359/JBMR.040901
   Kemmler W, 2015, CLIN INTERV AGING, V10, P1565, DOI 10.2147/CIA.S89585
   Kim J, 2013, KOREAN J FAM MED, V34, P43, DOI 10.4082/kjfm.2013.34.1.43
   Lamy O, 2017, J CLIN ENDOCR METAB, V102, P354, DOI 10.1210/jc.2016 3170
   Leder BZ, 2017, CURR OSTEOPOROS REP, V15, P110, DOI 10.1007/s11914 017 0353 4
   Leeming DJ, 2006, EUR J CLIN PHARMACOL, V62, P781, DOI 10.1007/s00228 006 0174 3
   Lewiecki EM, 2006, J CLIN ENDOCR METAB, V91, P4215, DOI 10.1210/jc.2006 1178
   Lewiecki EM, 2020, J CLIN DENSITOM, V23, P1, DOI 10.1016/j.jocd.2019.09.006
   Liao EY., 2018, BMC MUSCULOSKEL DIS, V19, P1
   Licata AA, 2005, NEW ENGL J MED, V352, P1930, DOI 10.1056/NEJM200505053521822
   LINSTONE HA, 1975, DELPHI METHOD TECHNI
   Lopez Gavilanez E., 2018, Int J Osteoporosis Metab Disorders, V11, P23, DOI [10.3923/ijom.2018.23.28, DOI 10.3923/IJOM.2018.23.28]
   Lukert B. P., 2020, J CLIN ENDOCR METAB, V105, P879
   Luo ZH, 2017, CELL MOL LIFE SCI, V74, P4443, DOI 10.1007/s00018 017 2585 y
   Maldonado G., 2017, Sci World J, P3831275, DOI [10.1155/2017/3831275, DOI 10.1155/2017/3831275]
   Maldonado G, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 019 0673 3
   Maldonado Génessis, 2017, Rev.Colomb.Reumatol., V24, P205, DOI 10.1016/j.rcreu.2017.08.001
   Marinucci L, 2018, FREE RADICAL BIO MED, V117, P6, DOI 10.1016/j.freeradbiomed.2018.01.017
   Marques EA, 2018, BONE, V108, P186, DOI 10.1016/j.bone.2018.01.014
   Martineau P, 2018, CURR OPIN RHEUMATOL, V30, P412, DOI 10.1097/BOR.0000000000000504
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McGartland C, 2003, J BONE MINER RES, V18, P1563, DOI 10.1359/jbmr.2003.18.9.1563
   Melton LJ, 1999, OSTEOPOROSIS INT, V10, P214, DOI 10.1007/s001980050218
   Miller PD, 2008, J BONE MINER RES, V23, P525, DOI 10.1359/JBMR.071206
   Ministerio de Salud Publica del Ecuador, 2017, REG EST CAM EGR HOSP
   Modelska K, 2002, J CLIN ENDOCR METAB, V87, P16, DOI 10.1210/jc.87.1.16
   Moher D, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000217
   Montala N, 2011, J RHEUMATOL, V38, P893, DOI 10.3899/jrheum.100851
   Morin SN, 2014, J BONE MINER RES, V29, P1675, DOI 10.1002/jbmr.2204
   Murray C, 1996, GLOBAL REGIONAL DESC
   Nair R, 2011, SEMIN ARTHRITIS RHEU, V41, P95, DOI 10.1016/j.semarthrit.2010.12.001
   Narvaez J, 2020, OPEN ACCESS RHEUMATO, V12, P105, DOI 10.2147/OARRR.S252245
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Orces Carlos H, 2015, ScientificWorldJournal, V2015, P545297, DOI 10.1155/2015/545297
   Orces CH, 2009, REV PANAM SALUD PUBL, V25, P438, DOI 10.1590/S1020 49892009000500009
   Pepe J, 2020, J CLIN ENDOCR METAB, V105, P2487, DOI 10.1210/clinem/dgaa306
   Pilz S, 2019, ENDOCR CONNECT, V8, pR27, DOI 10.1530/EC 18 0432
   Poole R, 2017, BMJ BRIT MED J, V359, DOI 10.1136/bmj.j5024
   Prost S, 2021, ORTHOP TRAUMATOL SUR, V107, DOI 10.1016/j.otsr.2020.102779
   Rapuri PB, 2001, AM J CLIN NUTR, V74, P694
   Rizzoli R, 2004, J BONE MINER RES, V19, P527, DOI 10.1359/JBMR.040204
   Robinson WA, 2019, SPINE PHILA PA 1976
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Rom O, 2015, ADDICTION, V110, P326, DOI 10.1111/add.12761
   Ross Philip D., 1997, American Journal of Medicine, V103, p30S, DOI 10.1016/S0002 9343(97)90025 5
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Sámano R, 2013, NUTR HOSP, V28, P1750, DOI 10.3305/nh.2013.28.5.6773
   Sanders KM, 2010, JAMA J AM MED ASSOC, V303, P1815, DOI 10.1001/jama.2010.594
   Santen RJ, 2010, J CLIN ENDOCR METAB, V95, pS7, DOI 10.1210/jc.2009 2509
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Schousboe JT, 2006, OSTEOPOROSIS INT, V17, P281, DOI 10.1007/s00198 005 2010 5
   Schunemann H, 2013, GRADE HDB GRADING QU
   Schürch MA, 1998, ANN INTERN MED, V128, P801, DOI 10.7326/0003 4819 128 10 199805150 00002
   SHOBACK D, 2020, J CLIN ENDOCR METAB, V105
   Shuhart CR, 2019, J CLIN DENSITOM, V22, P453, DOI 10.1016/j.jocd.2019.07.001
   Silverman SL, 2012, OSTEOPOROSIS INT, V23, P351, DOI 10.1007/s00198 011 1691 1
   Siris E, 2014, OSTEOPOROSIS INT, V25, P1439, DOI 10.1007/s00198 014 2655 z
   Stoch SA, 2009, J RHEUMATOL, V36, P1705, DOI 10.3899/jrheum.081207
   Stumpf U, 2019, Z GERONTOL GERIATR, V52, P414, DOI 10.1007/s00391 019 01571 x
   Symonds C, 2018, CAN MED ASSOC J, V190, pE485, DOI 10.1503/cmaj.180115
   Tedeschi SK, 2019, ARTHRITIS RHEUMATOL, V71, P1141, DOI 10.1002/art.40818
   Thorin MH, 2016, OSTEOPOROSIS INT, V27, P249, DOI 10.1007/s00198 015 3290 z
   TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604
   Tromp AM, 2001, J CLIN EPIDEMIOL, V54, P837, DOI 10.1016/S0895 4356(01)00349 3
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
   Tucker KL, 2006, AM J CLIN NUTR, V84, P936, DOI 10.1093/ajcn/84.4.936
   U.S. Food and Drug Administration, 2019, ROM FDA LAB
   Uetani M, 2004, CLIN RADIOL, V59, P124, DOI 10.1016/j.crad.2003.07.005
   Wang X, 2016, OSTEOPOROSIS INT, V27, P1413, DOI 10.1007/s00198 015 3449 7
   Watts NB, 2012, J CLIN ENDOCR METAB, V97, P1802, DOI 10.1210/jc.2011 3045
   Wengreen HJ, 2004, J BONE MINER RES, V19, P537, DOI 10.1359/JBMR.040208
   Whiting SJ, 2001, NUTR RES, V21, P1107, DOI 10.1016/S0271 5317(01)00324 4
   Wyshak G, 2000, ARCH PEDIAT ADOL MED, V154, P610, DOI 10.1001/archpedi.154.6.610
   Yeap SS, 2008, J RHEUMATOL, V35, P2344, DOI 10.3899/jrheum.080634
   Zhang YL, 2019, CLIN INTERV AGING, V14, P91, DOI 10.2147/CIA.S187588
NR 142
TC 1
Z9 1
U1 0
U2 5
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 1862 3522
EI 1862 3514
J9 ARCH OSTEOPOROS
JI Arch. Osteoporos.
PD JUN 15
PY 2023
VL 18
IS 1
AR 81
DI 10.1007/s11657 023 01263 5
PG 19
WC Endocrinology & Metabolism; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Orthopedics
GA J2GS0
UT WOS:001007852100001
PM 37316765
DA 2025 08 17
ER

PT J
AU Eskandarynasab, M
   Doustimotlagh, AH
   Takzaree, N
   Etemad Moghadam, S
   Alaeddini, M
   Dehpour, AR
   Goudarzi, R
   Partoazar, A
AF Eskandarynasab, Maryam
   Doustimotlagh, Amir Hossein
   Takzaree, Nasrin
   Etemad Moghadam, Shahroo
   Alaeddini, Mojgan
   Dehpour, Ahmad Reza
   Goudarzi, Ramin
   Partoazar, Alireza
TI Phosphatidylserine nanoliposomes inhibit glucocorticoid induced
   osteoporosis: A potential combination therapy with alendronate
SO LIFE SCIENCES
LA English
DT Article
DE Phosphatidylserine; Nanoliposome; Alendronate; Glucocorticoid;
   Osteoporosis; Prednisolone
ID BONE REPAIR; DIFFERENTIATION; OSTEOPROTEGERIN; MECHANISMS; LIPOSOMES
AB The present study aimed to investigate the effects of phosphatidylserine liposomes (PSLs) and phosphatidylserine liposomes containing alendronate (AL PSLs) on the improvement of methylprednisolone (MP) induced osteoporosis in a rat model. AL PSLs formulation was prepared, characterized, and evaluated in different pH media to simulate gastrointestinal condition. Osteoporosis was induced by 3 weeks oral administration of MP (10 mg/kg) and then treatment by PSLs, AL PSLs, and alendronate (AL). Bone metabolic and biomechanical markers were measured in treated rat groups. Also, Tartrate resistant acid phosphatase (TRAP) staining and histomorphometry were evaluated on bone tissues of treated rats. AL PSLs were obtained in a size range of 155 nm and negatively surface charge with an entrapment efficiency of 42%. The AL leakage from AL PSLs did not exhibit a significant difference in acidic or basic media in comparison with the neutral condition. The concentrations of calcium, osteocalcin, bone alkaline phosphatase, and osteoprotegerin (OPG) of serum were significantly increased in PSLs and AL PSLs treated groups compared to the MP group. Also, PSLs and AL PSLs significantly improved the thickness and volume of the cortical and trabecular bone mass in treated groups. In addition, TRAP staining indicated a significant decrease of osteoclast number in osteoporotic rats treated with AL PSLs and PSLs. In this study, AL PSLs and even PSLs alone made a potential bone mechanical strength in glucocorticoid induced bone loss more than AL in rats. In conclusion, our findings suggest that PSLs consumption with or without an antiosteoporotic drug might be an applicable choice in control of osteoporosis.
C1 [Eskandarynasab, Maryam; Dehpour, Ahmad Reza] Univ Tehran Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran.
   [Doustimotlagh, Amir Hossein] Yasuj Univ Med Sci, Med Plants Res Ctr, Yasuj, Iran.
   [Takzaree, Nasrin] Univ Tehran Med Sci, Sch Med, Dept Anat, Tehran, Iran.
   [Etemad Moghadam, Shahroo; Alaeddini, Mojgan] Univ Tehran Med Sci, Dent Res Inst, Dent Res Ctr, Tehran, Iran.
   [Goudarzi, Ramin] Pharmin USA LLC, Div Res & Dev, San Jose, CA USA.
   [Dehpour, Ahmad Reza; Partoazar, Alireza] Univ Tehran Med Sci, Expt Med Res Ctr, POB 13145 784, Tehran, Iran.
C3 Tehran University of Medical Sciences; Yasouj University; Tehran
   University of Medical Sciences; Tehran University of Medical Sciences;
   Tehran University of Medical Sciences
RP Partoazar, A (通讯作者)，Univ Tehran Med Sci, Expt Med Res Ctr, POB 13145 784, Tehran, Iran.
EM partoazar@tums.ac.ir
RI ; Dehpour, Ahmad/I 6422 2019; Etemad Moghadam, Shahroo/AAC 8639 2022;
   Doustimotlagh, Amir/L 6243 2017; Alaeddini, Mojgan/AAA 4257 2021
OI Goudarzi, Ramin/0000 0003 0648 7588; dehpour, ahmad
   reza/0000 0002 8001 5565; Etemad Moghadam, Shahroo/0000 0002 2548 9493;
   Alaeddini, Mojgan/0000 0002 3634 7992; 
FU Tehran University of Medical Sciences and Health Services
   [96 03 158 36098]; Office of the President Vice presidency for Science
   and Technology Iran National Science Foundation [95848872]
FX This research has been supported by Tehran University of Medical
   Sciences and Health Services grant (No. 96 03 158 36098).This research
   has been also financially sustained by "The Office of the President
   Vice presidency for Science and Technology Iran National Science
   Foundation" grant: No. 95848872.
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Anderson HC, 2005, FRONT BIOSCI LANDMRK, V10, P822, DOI 10.2741/1576
   Berg AO, 2003, AM J NURS, V103, P73
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Carbonare LD, 2001, J BONE MINER RES, V16, P97, DOI 10.1359/jbmr.2001.16.1.97
   CEVC G, 1981, BIOCHEMISTRY US, V20, P4955, DOI 10.1021/bi00520a023
   COSMAN F, 1994, J BONE MINER RES, V9, P1097
   Daeihamed M, 2017, CURR DRUG DELIV, V14, P289, DOI 10.2174/1567201813666160115125756
   Derakhshanian H, 2013, HEPATOL RES, V43, P394, DOI 10.1111/j.1872 034X.2012.01075.x
   Doustimotlagh AH, 2017, HISTOL HISTOPATHOL, V32, P743, DOI 10.14670/HH 11 836
   Elshal MF, 2013, AFR J TRADIT COMPLEM, V10, P267, DOI 10.4314/ajtcam.v10i5.8
   Epstein H, 2008, AAPS J, V10, P505, DOI 10.1208/s12248 008 9060 5
   Faienza MF, 2009, J CLIN ENDOCR METAB, V94, P2269, DOI 10.1210/jc.2008 2446
   Glade MJ, 2015, NUTRITION, V31, P781, DOI 10.1016/j.nut.2014.10.014
   Goudarzi R, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249 019 1445 5
   Hatakeyama J, 2019, J ORAL SCI, V61, P111, DOI 10.2334/josnusd.17 0488
   He HS, 2019, ACTA PHARM SIN B, V9, P36, DOI 10.1016/j.apsb.2018.06.005
   Hosny KM, 2013, EXPERT OPIN DRUG DEL, V10, P741, DOI 10.1517/17425247.2013.799136
   Jakubowitz E, 2009, MED SCI MONITOR, V15, pBR307
   Kaczmarczyk Sedlak I, 2012, PHARMACOL REP, V64, P386
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li BJ, 2011, J CELL BIOCHEM, V112, P1229, DOI 10.1002/jcb.23049
   Ma B, 2012, ACTA PHARMACOL SIN, V33, P479, DOI 10.1038/aps.2011.177
   Merolli A, 2009, MOLECULES, V14, P5367, DOI 10.3390/molecules14125367
   Payer J, 2010, DRUG HEALTHC PATIENT, V2, P49
   REID IR, 1987, HORM RES, V27, P200, DOI 10.1159/000180820
   Reyes C, 2016, J CELL BIOCHEM, V117, P20, DOI 10.1002/jcb.25266
   RICHARDS MH, 1978, BIOCHIM BIOPHYS ACTA, V543, P508, DOI 10.1016/0304 4165(78)90305 7
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Saffari PM, 2020, LIFE SCI, V255, DOI 10.1016/j.lfs.2020.117861
   Shouhed D, 2005, J CELL BIOCHEM, V95, P1276, DOI 10.1002/jcb.20497
   Struijs A, 2000, RHEUMATOLOGY, V39, P523, DOI 10.1093/rheumatology/39.5.523
   Ton FN, 2005, J BONE MINER RES, V20, P464, DOI 10.1359/JBMR.041125
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   VANDEWIJNGAERT FP, 1986, J HISTOCHEM CYTOCHEM, V34, P1317, DOI 10.1177/34.10.3745910
   Ventura A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/250462
   Wu Z, 2010, J IMMUNOL, V184, P3191, DOI 10.4049/jimmunol.0803609
   Xu CX, 2009, J BIOMED MATER RES A, V88A, P264, DOI 10.1002/jbm.a.31931
   Yang CR, 2017, BIOMED ENG BIOMED TE, V62, P487, DOI 10.1515/bmt 2016 0151
   Zhao HX, 2017, J CELL BIOCHEM, V118, P2072, DOI 10.1002/jcb.25812
   Zheng XF, 2015, EXP THER MED, V10, P541, DOI 10.3892/etm.2015.2553
   Zhou MR, 2017, EXP THER MED, V14, P2445, DOI 10.3892/etm.2017.4802
NR 43
TC 12
Z9 14
U1 0
U2 14
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD SEP 15
PY 2020
VL 257
AR 118033
DI 10.1016/j.lfs.2020.118033
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA NN3SR
UT WOS:000568711600010
PM 32621924
DA 2025 08 17
ER

PT J
AU Kim, JJ
   Singh, RK
   Patel, KD
   Kim, HW
AF Kim, Jung Ju
   Singh, Rajendra K.
   Patel, Kapil D.
   Kim, Hae Won
TI Delivery of Small Genetic Molecules through Hollow Porous Nanoparticles
   Silences Target Gene and in Turn Stimulates Osteoblastic Differentiation
SO PARTICLE & PARTICLE SYSTEMS CHARACTERIZATION
LA English
DT Article
ID MESOPOROUS SILICA NANOPARTICLES; DRUG DELIVERY; CELL MORPHOLOGY; CKIP 1;
   SYSTEM; NANOSPHERES; RNA
AB Nanocarriers are one of the key elements to improve the therapeutic potential of signaling molecules, including genes for the disease treatment and tissue repair. Here, a nanocarrier system is reported that delivers genetic molecule small interference RNA (siRNA) for osteoblastic stimulation. For this, a hollow form of mesoporous silica nanoshell (MSns) is designed to load and release siRNA to silence Plekho 1 gene. In particular, a pressure induced loading method is effective in enhancing the incorporation of siRNA within a hollow space; a loading level attained approximate to 30% is almost three times higher than that of a non hollow form. Furthermore, the release of siRNA from the nanocarriers is highly sustainable; continued over 18 d in a diffusion controlled manner, in striking contrast to the rapid release (3 d) from a non hollow form. The nanocarriers exhibit excellent cell viability, and the siRNA nanocarrier complexes are efficiently internalized to osteoblastic cells (uptake level over 90%). The intracellular delivery suppresses the target gene Plekho 1 expression down to 20%, which in turn up regulates the expression of osteoblast transcriptional factors (Runx2 and Smad2), demonstrating an effective gene delivery system for bone repair.
C1 [Kim, Jung Ju; Singh, Rajendra K.; Patel, Kapil D.; Kim, Hae Won] Dankook Univ, Inst Tissue Regenerat Engn ITREN, Cheonan 330714, South Korea.
   [Kim, Jung Ju; Singh, Rajendra K.; Kim, Hae Won] Dankook Univ, Dept Nanobiomed Sci, Cheonan 330714, South Korea.
   [Kim, Jung Ju; Singh, Rajendra K.; Kim, Hae Won] Dankook Univ, PLUS NBM Global Res Ctr Regenerat Med BK21, Cheonan 330714, South Korea.
   [Kim, Hae Won] Dankook Univ, Dept Biomat Sci, Coll Dent, Cheonan 330714, South Korea.
C3 Dankook University; Dankook University; Dankook University; Dankook
   University
RP Kim, HW (通讯作者)，Dankook Univ, Inst Tissue Regenerat Engn ITREN, Cheonan 330714, South Korea.; Kim, HW (通讯作者)，Dankook Univ, Dept Nanobiomed Sci, Cheonan 330714, South Korea.; Kim, HW (通讯作者)，Dankook Univ, PLUS NBM Global Res Ctr Regenerat Med BK21, Cheonan 330714, South Korea.; Kim, HW (通讯作者)，Dankook Univ, Dept Biomat Sci, Coll Dent, Cheonan 330714, South Korea.
EM kimhw@dku.edu
RI Patel, Kapil D/F 3874 2012; Singh, Rajendra/O 9797 2016; Singh, Rajendra
   K/O 9797 2016; Patel, Kapil/AAO 2366 2020
OI Patel, Kapil D/0000 0002 0393 9166; Singh, Rajendra
   K/0000 0003 3127 3346; 
FU National Research Foundation, Republic of Korea [2015 032163,
   2009 0093829]
FX This work was supported by the grants from National Research Foundation
   (Global Research Laboratory Program 2015 032163 & Priority Research
   Centers Program 2009 0093829), Republic of Korea.
CR Adachi T, 2010, DEV GROWTH DIFFER, V52, P693, DOI 10.1111/j.1440 169X.2010.01206.x
   Canton DA, 2005, MOL CELL BIOL, V25, P3519, DOI 10.1128/MCB.25.9.3519 3534.2005
   Canton DA, 2006, J BIOL CHEM, V281, P36347, DOI 10.1074/jbc.M607595200
   Cheng TL, 2015, J TISSUE ENG, V6, DOI 10.1177/2041731415609448
   David D, 2013, BBA REV CANCER, V1835, P119, DOI 10.1016/j.bbcan.2012.11.003
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Guo BS, 2014, BONE, V59, P76, DOI 10.1016/j.bone.2013.11.007
   Hu FQ, 2002, INT J PHARMACEUT, V239, P121, DOI 10.1016/S0378 5173(02)00081 9
   Islam SKF, 2016, NANOTECHNOLOGY, V27, DOI 10.1088/0957 4484/27/38/385203
   Kwon S, 2014, ACTA BIOMATER, V10, P1431, DOI 10.1016/j.actbio.2013.10.028
   Lai NC, 2014, NANO RES, V7, P1439, DOI 10.1007/s12274 014 0503 2
   Lewinski N, 2008, SMALL, V4, P26, DOI 10.1002/smll.200700595
   Lim J, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556 276X 8 381
   Liu F, 2015, CHEM COMMUN, V51, P2357, DOI 10.1039/c4cc08914f
   Lu KF, 2008, NAT CELL BIOL, V10, P994, DOI 10.1038/ncb1760
   Pabisch S, 2012, CHEM PHYS LETT, V521, P91, DOI 10.1016/j.cplett.2011.11.049
   Patel KD, 2014, ACS APPL MATER INTER, V6, P20214, DOI 10.1021/am505759p
   Rosen CJ, 2012, NAT MED, V18, P202, DOI 10.1038/nm.2630
   Singh RK, 2014, J AM CERAM SOC, V97, P3071, DOI 10.1111/jace.13075
   Singh RK, 2013, RSC ADV, V3, P8692, DOI 10.1039/c3ra22975k
   Sun JT, 2010, J PHYS CHEM C, V114, P12481, DOI 10.1021/jp103982a
   Suteewong T, 2013, SCIENCE, V340, P337, DOI 10.1126/science.1231391
   Torney F, 2007, NAT NANOTECHNOL, V2, P295, DOI 10.1038/nnano.2007.108
   Wang MQ, 2013, INT J PHARMACEUT, V448, P51, DOI 10.1016/j.ijpharm.2013.03.022
   Yazdi IK, 2014, J TISSUE ENG, V5, DOI 10.1177/2041731414536573
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
NR 26
TC 4
Z9 4
U1 0
U2 19
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0934 0866
EI 1521 4117
J9 PART PART SYST CHAR
JI Part. Part. Syst. Charact.
PD DEC
PY 2016
VL 33
IS 12
BP 878
EP 886
DI 10.1002/ppsc.201600098
PG 9
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA EG1MT
UT WOS:000390797500003
DA 2025 08 17
ER

PT J
AU Jia, M
   Li, Y
   Xin, HL
   Hou, TT
   Zhang, ND
   Xu, HT
   Zhang, QY
   Qin, LP
AF Jia Min
   Li Yuan
   Xin Hai Liang
   Hou Ting Ting
   Zhang Nai Dai
   Xu Hong Tao
   Zhang Qiao Yan
   Qin Lu Ping
TI Estrogenic activity of osthole and imperatorin in MCF 7 cells and their
   osteoblastic effects in Saos 2 cells
SO CHINESE JOURNAL OF NATURAL MEDICINES
LA English
DT Article
DE Osthole; Imperatorin; MCF 7; Estrogenic activity; Estrogen receptors;
   Osteoblasts; Alkaline phosphatase
ID BREAST CANCER CELLS; GENE EXPRESSION; CNIDIUM MONNIERI; RECEPTOR ALPHA;
   MAP KINASE; ESTRADIOL; DIFFERENTIATION; PATHWAY; PHYTOESTROGENS;
   PROLIFERATION
AB There is an increasing interest in phytoestrogens due to their potential medical usage in hormone replacement therapy (HRT). The present study was designed to investigate the in vitro effects of estrogen like activities of two widespread coumarins, osthole and imperatorin, using the MCF 7 cell proliferation assay and their alkaline phosphatase (ALP) activities in osteoblasts Saos 2 cells. The two compounds were found to strongly stimulate the proliferation of MCF 7 cells. The estrogen receptor regulated ER alpha, progesterone receptor (PR) and PS2 mRNA levels were increased by treatment with osthole and imperatorin. All these effects were significantly inhibited by the specific estrogen receptor antagonist ICI182, 780. Cell cycle analysis revealed that their proliferation stimulatory effect was associated with a marked increase in the number of MCF 7 cells in S phase, which was similar to that observed with estradiol. It was also observed that they significantly increased ALP activity, which was reversed by ICI182,780. These results suggested that osthole and imperatorin could stimulate osteoblastic activity by displaying estrogenic properties or through the ER pathway. In conclusion, osthole and imperatorin may represent new pharmacological tools for the treatment of osteoporosis.
C1 [Jia Min; Li Yuan; Xin Hai Liang; Hou Ting Ting; Zhang Nai Dai; Xu Hong Tao; Zhang Qiao Yan; Qin Lu Ping] Second Mil Med Univ, Sch Pharm, Dept Pharmacognosy, Shanghai 200433, Peoples R China.
C3 Naval Medical University
RP Zhang, QY; Qin, LP (通讯作者)，Second Mil Med Univ, Sch Pharm, Dept Pharmacognosy, Shanghai 200433, Peoples R China.
EM zqy1965@163.com; qinsmmu@126.com
FU National Natural Science Foundation of China [81202865]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81202865).
CR Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500
   Chian T., 1959, FOLIA PHARMACOL JPN, V55, P153
   Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746
   Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043 2760(01)00436 2
   Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003 0567
   Guo C, 2014, INFLAMMATION, V37, P621, DOI 10.1007/s10753 013 9778 9
   Hatae J, 2009, J PHYSIOL SCI, V59, P181, DOI 10.1007/s12576 009 0023 0
   Kuo PL, 2005, J PHARMACOL EXP THER, V314, P1290, DOI 10.1124/jpet.105.085092
   Kurita T, 2001, BIOL REPROD, V64, P272, DOI 10.1095/biolreprod64.1.272
   Lagari VS, 2014, J STEROID BIOCHEM, V139, P294, DOI 10.1016/j.jsbmb.2012.12.002
   Leclercq G, 2014, J STEROID BIOCHEM, V139, P237, DOI 10.1016/j.jsbmb.2012.12.010
   Leygue E, 1999, CANCER RES, V59, P1175
   Li XX, 2002, BIOL PHARM BULL, V25, P738, DOI 10.1248/bpb.25.738
   Matsumura A, 2005, J STEROID BIOCHEM, V94, P431, DOI 10.1016/j.jsbmb.2004.12.041
   MD M, 2011, FRONT BIOSCI, V1, P191
   Meng F, 2004, PHARMAZIE, V59, P643
   NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P935, DOI 10.1210/endo 122 3 935
   Ojala T, 2001, PLANTA MED, V67, P236, DOI 10.1055/s 2001 12010
   Otsuki T, 2000, CANCER RES, V60, P1434
   Prouillet C, 2004, BIOCHEM PHARMACOL, V67, P1307, DOI 10.1016/j.bcp.2003.11.009
   Ren LF, 1997, CHEM BIOL INTERACT, V104, P55, DOI 10.1016/S0009 2797(97)03767 8
   Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930
   Schultz JR, 2003, MOL CELL ENDOCRINOL, V201, P165, DOI 10.1016/S0303 7207(02)00415 X
   So KS, 2015, ANTICANCER RES, V35, P1537
   TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315
   WAKELING AE, 1991, CANCER RES, V51, P3867
   Wanachewin O, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472 6882 12 71
   Wei B, 2009, J INT OBSTET GYNECOL, V36, P90
   WEI LL, 1988, MOL ENDOCRINOL, V2, P62, DOI 10.1210/mend 2 1 62
   Yang SH, 2013, GENE, V513, P1, DOI 10.1016/j.gene.2012.10.033
   Zhang JY, 2013, PAIN, V154, P2452, DOI 10.1016/j.pain.2013.07.027
   Zhang QY, 2007, PLANTA MED, V73, P13, DOI 10.1055/s 2006 951724
   Zhao WJ, 2010, J PHARMACOL EXP THER, V332, P248, DOI 10.1124/jpet.109.158816
NR 33
TC 18
Z9 20
U1 0
U2 10
PU CHINESE JOURNAL NATURAL MEDICINES
PI NANJING
PA 24, TONGJIA XIANG, NANJING, 210009, PEOPLES R CHINA
SN 2095 6975
EI 1875 5364
J9 CHIN J NAT MEDICINES
JI Chin. J. Nat. Med.
PD JUN
PY 2016
VL 14
IS 6
BP 413
EP 420
AR 2095 6975(2016)06 0413 08
PG 8
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA DS4NI
UT WOS:000380757400003
PM 27473958
DA 2025 08 17
ER

PT J
AU Hong, C
   Yang, LL
   Zhang, YF
   Li, YM
   Wu, HL
AF Hong, Chen
   Yang, Lili
   Zhang, Yifan
   Li, Yiming
   Wu, Huali
TI Epimedium brevicornum Maxim. Extract exhibits pigmentation by
   melanin biosynthesis and melanosome biogenesis/transfer
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Epimedium brevicornum Maxim; melanogenesis; melanosome biogenesis;
   tyrosinase activity; melanogenic ingredients
ID MYOSIN VA; TRANSCRIPTION FACTOR; SKIN PIGMENTATION; CYCLIC AMP;
   IFN GAMMA; CELLS; SLAC2 A/MELANOPHILIN; MICROPHTHALMIA; MELANOCYTES;
   OSTEOCLASTS
AB Epimedium brevicornum Maxim. (Epimedii Folium) is a traditional medicine widely utilized in China for sexual dysfunction and osteoporosis treatment. Recently, studies have reported that Epimedium flavonoid icariin displayed hair growth and melanogenic ability by targeting tyrosinase activity. Nevertheless, icariin hydrolysate icariside II and icaritin cause depigmentation due to their tyrosinase inhibition. These pigment functional discrepancies from Epimedium constituents arouse our great interest. Then, this study focused on the pigmentation effects of Epimedii Folium extract (EFE) on melanin synthesis and melanosome biogenesis/transfer, and further identified the bioactive constituents. First, in in vitro systemic studies, we discovered that the potent melanogenic and repigmented effects of EFE were dependent on concentration and amount of time in multi melanocytes, normal human skin tissue, and vitiligo perilesional areas. In vivo, EFE exhibited repigmented effect on two kinds of depigmented models of N phenylthiourea induced zebrafish and hydroquinone induced mice. Mechanistically, EFE strongly promoted tyrosinase activity and upregulated the protein expression of tyrosinase families which finally contribute to melanin biosynthesis by activating the MAPK/ERK1/2 signal pathway. In addition, EFE effectively increased melanosome number, accelerated melanosome maturity and cytoplasmic transport through the growth/extension of melanocyte dendrites, and induced melanosome transfer from melanocyte to keratinocyte for pigmentation. The six main flavonoid ingredients were identified among EFE. Compared to others, epimedin B (EB) was confirmed as a high content, low toxicity, and effective melanogenic compound in EFE. Taking all these together, this study systematically demonstrates the potential pigmentation effect of Epimedium brevicornum Maxim., and clarifies its related molecular mechanisms and melanogenesis basis. These results give additional insight into Epimedium herb pharmacology and may provide a novel therapy basis for hypopigmentation disorders.
C1 [Hong, Chen; Zhang, Yifan; Li, Yiming; Wu, Huali] Shanghai Univ Tradit Chinese Med, Sch Pharm, Dept TCM Chem, Shanghai, Peoples R China.
   [Yang, Lili] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Dermatol, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine
RP Li, YM; Wu, HL (通讯作者)，Shanghai Univ Tradit Chinese Med, Sch Pharm, Dept TCM Chem, Shanghai, Peoples R China.
EM wu5254307@163.com; ymlius@163.com
FU Open Project of National Major Science and Technology Infrastructure of
   Translational Medicine [TMSK 2021 404]; Youth Innovation Research
   Foundation [A1 U21 205 01010109]; National Natural Science Foundation of
   China [81972932]; program of Shanghai E research Institute of Bioactive
   Constituents in Traditional Chinese Medicine
FX This work was supported by the Open Project of National Major Science
   and Technology Infrastructure of Translational Medicine (TMSK 2021 404),
   the Youth Innovation Research Foundation (A1 U21 205 01010109), the
   National Natural Science Foundation of China (81972932), and the program
   of Shanghai E research Institute of Bioactive Constituents in
   Traditional Chinese Medicine.
CR Benito Martínez S, 2021, INTEGR COMP BIOL, V61, P1546, DOI 10.1093/icb/icab094
   Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694
   Buscà R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900
   Buscà R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600 0749.2000.130203.x
   Chen JR, 2021, MED RES REV, V41, P1138, DOI 10.1002/med.21754
   Chen XJ, 2015, AM J CHINESE MED, V43, P783, DOI 10.1142/S0192415X15500494
   Costin GE, 2007, FASEB J, V21, P976, DOI 10.1096/fj.06 6649rev
   D'Mello SAN, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071144
   Videira IFD, 2013, AN BRAS DERMATOL, V88, P76
   Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200
   Harris JE, 2017, DERMATOL CLIN, V35, P151, DOI 10.1016/j.det.2016.11.006
   Harris JE, 2012, J INVEST DERMATOL, V132, P1869, DOI 10.1038/jid.2011.463
   HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358
   Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P645, DOI 10.1111/j.1751 1097.2007.00228.x
   Kim D, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/7642019
   Ko HH, 2014, J ETHNOPHARMACOL, V151, P386, DOI 10.1016/j.jep.2013.10.054
   Kuroda TS, 2003, MOL CELL BIOL, V23, P5245, DOI 10.1128/MCB.23.15.5245 5255.2003
   Kushimoto T, 2001, P NATL ACAD SCI USA, V98, P10698, DOI 10.1073/pnas.191184798
   Le L, 2021, INTEGR COMP BIOL, V61, P1517, DOI 10.1093/icb/icab078
   Lin JY, 2007, NATURE, V445, P843, DOI 10.1038/nature05660
   MARKS SC, 1981, AM J ANAT, V161, P1, DOI 10.1002/aja.1001610102
   Natarajan VT, 2014, P NATL ACAD SCI USA, V111, P2301, DOI 10.1073/pnas.1304988111
   Niu C, 2017, MOLECULES, V22, DOI 10.3390/molecules22081303
   ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523 1747.ep12312291
   Park JS, 2008, J MICROBIOL BIOTECHN, V18, P110
   Raposo G, 2007, NAT REV MOL CELL BIO, V8, P786, DOI 10.1038/nrm2258
   Riding RL, 2019, J IMMUNOL, V203, P11, DOI 10.4049/jimmunol.1900027
   Rose PT, 2009, MED CLIN N AM, V93, P1225, DOI 10.1016/j.mcna.2009.08.005
   Ross JL, 2008, CURR OPIN CELL BIOL, V20, P41, DOI 10.1016/j.ceb.2007.11.006
   Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003
   STECHSCHULTE DJ, 1987, J CELL PHYSIOL, V132, P565, DOI 10.1002/jcp.1041320321
   Su YS, 2017, CLIN EXP DERMATOL, V42, P287, DOI 10.1111/ced.13043
   Tadokoro R, 2017, CURR OPIN GENET DEV, V45, P132, DOI 10.1016/j.gde.2017.05.001
   Tang HH, 2021, J PHARMACOL SCI, V147, P348, DOI 10.1016/j.jphs.2021.08.009
   Tian XY, 2021, PHARMACOL THERAPEUT, V219, DOI 10.1016/j.pharmthera.2020.107707
   Wang D, 2017, ONCOTARGET, V8, P99504, DOI 10.18632/oncotarget.20118
   Westbroek W, 2003, J INVEST DERMATOL, V120, P465, DOI 10.1046/j.1523 1747.2003.12068.x
   Wu LC, 2011, J BIOMED SCI, V18, DOI 10.1186/1423 0127 18 74
   Wu XF, 2001, J CELL SCI, V114, P1091
   Wu XF, 2014, CURR OPIN CELL BIOL, V29, P1, DOI 10.1016/j.ceb.2014.02.003
   Yasumoto K, 1997, J BIOL CHEM, V272, P503
   Ye Y, 2010, PHYTOMEDICINE, V18, P32, DOI 10.1016/j.phymed.2010.06.004
   Zhang B, 2020, NATURE, V577, P676, DOI 10.1038/s41586 020 1935 3
   Zmigrodzka M, 2018, J PHYSIOL PHARMACOL, V69, P653, DOI 10.26402/jpp.2018.5.01
NR 45
TC 14
Z9 14
U1 8
U2 43
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 29
PY 2022
VL 13
AR 963160
DI 10.3389/fphar.2022.963160
PG 21
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 5I8TW
UT WOS:000868623400001
PM 36249817
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liu, Y
   Zhang, T
   Zhang, C
   Jin, SS
   Yang, RL
   Wang, XD
   Jiang, N
   Gan, YH
   Kou, XX
   Zhou, YH
AF Liu, Y.
   Zhang, T.
   Zhang, C.
   Jin, S. S.
   Yang, R. L.
   Wang, X. D.
   Jiang, N.
   Gan, Y. H.
   Kou, X. X.
   Zhou, Y. H.
TI Aspirin Blocks Orthodontic Relapse via Inhibition of CD4<SUP>+</SUP> T
   Lymphocytes
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE orthodontic tooth movement; immunity; bone remodeling/regeneration;
   cytokine; inflammation; oral medicine
ID TOOTH MOVEMENT; OSTEOCLAST DIFFERENTIATION; IFN GAMMA; PROSTAGLANDIN
   E 2; IMMUNE RESPONSES; RAT MOLARS; TNF ALPHA; CELLS; BONE;
   OSTEOIMMUNOLOGY
AB Immunologic response plays an important role in orthodontic tooth movement (OTM) and relapse. Nonsteroidal anti inflammatory drugs, such as aspirin, affect immune cells and clinical orthodontic treatment. However, the mechanisms by which nonsteroidal anti inflammatory drugs regulate immune cells to affect orthodontic relapse are unclear. In this study, male Sprague Dawley rats were grouped as relapse and relapse + aspirin for 10 d after 14 d of OTM. Silicone impressions of the rats' maxillary dentitions were obtained to record the distance of OTM at the indicated time point. CD4(+) T lymphocytes in spleen were examined by flow cytometry. Serum levels of type 1 T helper (Th1) cell associated cytokines tumor necrosis factor alpha (TNF alpha), and interferon. (IFN beta) were determined through enzyme linked immunosorbent assay. The effects of aspirin on CD4(+) T and Th1 cells were also analyzed in vitro. Aspirin treatment significantly reduced the relapse rate. More interestingly, injection of CD25 neutralizing antibody basiliximab or TNF alpha inhibitor etanercept can significantly reduce the relapse rate as well. Correspondingly, aspirin treatment significantly accelerated the decrease of orthodontic force induced secretion of TNF alpha and IFN beta in serum and the expression of TNF alpha and IFN beta in periodontal ligament during relapse. Furthermore, aspirin treatment in vitro significantly repressed the differentiation of CD4(+) T and Th1 cells. Overall, results indicated that aspirin treatment can block orthodontic relapse by regulating Th1 cells.
C1 [Liu, Y.; Zhang, T.; Zhang, C.; Jin, S. S.; Yang, R. L.; Wang, X. D.; Kou, X. X.; Zhou, Y. H.] Peking Univ, Sch & Hosp Stomatol, Dept Orthodont, 22 Zhongguancun South Ave, Beijing 100081, Peoples R China.
   [Liu, Y.; Zhang, T.; Zhang, C.; Jin, S. S.; Yang, R. L.; Wang, X. D.; Kou, X. X.; Zhou, Y. H.] Peking Univ, Sch & Hosp Stomatol, Ctr Craniofacial Stem Cell Res & Regenerat, Beijing, Peoples R China.
   [Jiang, N.; Gan, Y. H.] Peking Univ, Sch & Hosp Stomatol, Ctr Lab, Beijing, Peoples R China.
   [Gan, Y. H.] Peking Univ, Sch & Hosp Stomatol, Ctr Temporomandibular Disorders & Orofacial Pain, Beijing, Peoples R China.
C3 Peking University; Peking University; Peking University; Peking
   University
RP Kou, XX; Zhou, YH (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Dept Orthodont, 22 Zhongguancun South Ave, Beijing 100081, Peoples R China.
EM kouxiaoxing@gmail.com; yanhengzhou@vip.163.com
RI Jiang, Nan/LDF 6447 2024; Yang, Ruili/JPL 6383 2023; Kou,
   Xiaoxing/IQS 3208 2023; Liu, Yang/LRU 6311 2024; Zhou,
   Yanheng/AFX 1820 2022
OI Jiang, Nan/0000 0002 0671 6822; Kou, Xiaoxing/0000 0001 9680 0077; Liu,
   Yang/0000 0002 9846 7359
FU International Science and Technology Cooperation Program of China
   [2015DFB30040]; National Science Foundations of China [81300897,
   81571815, 81300850, 81470717]; Beijing Municipal Natural Science
   Foundation [7152156]; China Scholarship Council [201506010245]
FX This work was supported by the International Science and Technology
   Cooperation Program of China (No. 2015DFB30040, Y.Z.), the National
   Science Foundations of China (No. 81300897, X.K.; No. 81571815, Y.L.;
   No. 81300850, X.W.; No. 81470717, Y.Z.), the Beijing Municipal Natural
   Science Foundation (No. 7152156, Y.L.), and the China Scholarship
   Council (No. 201506010245, Y.L.). The authors declare no potential
   conflicts of interest with respect to the authorship and/or publication
   of this article.
CR ANASTASSIOU ED, 1992, J IMMUNOL, V148, P2845
   Arias OR, 2006, AM J ORTHOD DENTOFAC, V130, P364, DOI 10.1016/j.ajodo.2004.12.027
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Ashkenazi Malka, 2012, Orthodontics (Chic.), V13, pe76
   BETZ M, 1991, J IMMUNOL, V146, P108
   Bryn T, 2008, INT IMMUNOL, V20, P235, DOI 10.1093/intimm/dxm134
   Caetano Lopes J, 2009, AUTOIMMUN REV, V8, P250, DOI 10.1016/j.autrev.2008.07.038
   Cao H, 2014, J DENT RES, V93, P1163, DOI 10.1177/0022034514551769
   Cheng J, 2012, J INTERF CYTOK RES, V32, P34, DOI 10.1089/jir.2011.0019
   Franzen TJ, 2013, EUR J ORTHODONT, V35, P152, DOI 10.1093/ejo/cjr127
   Franzen TJ, 2015, EUR J ORTHODONT, V37, P111, DOI 10.1093/ejo/cju053
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Gillespie MT, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2141
   Grotz W, 2004, TRANSPLANTATION, V77, P1848, DOI 10.1097/01.tp.0000129407.31494.45
   Han G., 2010, AM J ORTHOD DENTOFAC, V138, P1
   He D, 2015, J DENT RES, V94, P129, DOI 10.1177/0022034514553817
   Hirate Y, 2012, CONNECT TISSUE RES, V53, P207, DOI 10.3109/03008207.2011.628060
   Kalinski P, 2012, J IMMUNOL, V188, P21, DOI 10.4049/jimmunol.1101029
   Kehoe MJ, 1996, ANGLE ORTHOD, V66, P339
   Kim TW, 1999, AM J ORTHOD DENTOFAC, V115, P645, DOI 10.1016/S0889 5406(99)70290 8
   Kohara H, 2011, IMMUNOL LETT, V137, P53, DOI 10.1016/j.imlet.2011.02.017
   Kook SH, 2011, J CELL BIOCHEM, V112, P2891, DOI 10.1002/jcb.23205
   Koritsanszky Nelli, 2011, Fogorv Sz, V104, P117
   Kuijpers Jagtman A M, 2002, Ned Tijdschr Tandheelkd, V109, P42
   LITTLE RM, 1988, AM J ORTHOD DENTOFAC, V93, P423, DOI 10.1016/0889 5406(88)90102 3
   Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542
   Masella RS, 2006, AM J ORTHOD DENTOFAC, V129, P458, DOI 10.1016/j.ajodo.2005.12.013
   Mazzeo D, 1998, EUR J IMMUNOL, V28, P3205, DOI 10.1002/(SICI)1521 4141(199810)28:10<3205::AID IMMU3205>3.0.CO;2 8
   Mirosavljevic D, 2003, J BONE MINER RES, V18, P984, DOI 10.1359/jbmr.2003.18.6.984
   Okano M, 2006, IMMUNOLOGY, V118, P343, DOI 10.1111/j.1365 2567.2006.02376.x
   Polat O, 2005, ANGLE ORTHOD, V75, P214
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takayanagi H, 2013, ANN RHEUM DIS, V72, P16
   Takayanagi H, 2002, ARTHRITIS RES THER, V4, pS227, DOI 10.1186/ar581
   Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756 3282(99)00210 0
   Verna C, 1999, BONE, V24, P371, DOI 10.1016/S8756 3282(99)00009 5
   Wang L, 2013, STEM CELLS, V31, P1383, DOI 10.1002/stem.1388
   Xiong Q, 2016, JOINT BONE SPINE, V83, P276, DOI 10.1016/j.jbspin.2015.07.010
   Yan Y, 2015, J DENT RES, V94, P1463, DOI 10.1177/0022034515595003
   Yoshida Y, 1999, J ELECTRON MICROSC, V48, P147, DOI 10.1093/oxfordjournals.jmicro.a023661
   Zhao NN, 2012, AM J ORTHOD DENTOFAC, V141, P30, DOI 10.1016/j.ajodo.2011.06.035
NR 41
TC 30
Z9 33
U1 4
U2 36
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD MAY
PY 2017
VL 96
IS 5
BP 586
EP 594
DI 10.1177/0022034516685527
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA ES9YM
UT WOS:000399917900015
PM 28060561
DA 2025 08 17
ER

PT J
AU Chen, L
   Dai, ZC
   Song, HR
   Zhang, JF
   Li, T
AF Chen, Lin
   Dai, Zhicheng
   Song, Huangrong
   Zhang, Jiafeng
   Li, Tuo
TI Disproportionality analysis of oesophageal toxicity associated with oral
   bisphosphonates using the FAERS database (2004 2023)
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE adverse events; bisphosphonates; oesophageal; FAERS; disproportionality
   analysis
ID GASTROESOPHAGEAL REFLUX; SKELETAL COMPLICATIONS; GASTROINTESTINAL TRACT;
   DOUBLE BLIND; DRUGS; CANCER; SAFETY; RISK
AB Background This study analyzed the FDA's Adverse Event Reporting System (FAERS) data to investigate the correlation between oral bisphosphonates (BPs) and oesophageal adverse events (AEs). Methods We systematically extracted data on adverse reactions to oral alendronate, risedronate, and ibandronate from the FAERS database, covering the period from the 2004 Q1 to the 2023 Q4. The role_code of AEs mainly includes primary suspect (PS), secondary suspect (SS), concomitant (C), and interaction (I). This study targeted reports with a role_code of "PS." According to the FDA deduplication rule, the latest FDA_DT is selected when the CASEID is the same, and the higher PRIMARYID is selected when the CASEID and FDA_DT are the same. Our analysis leveraged four statistical methods, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and the multi item gamma Poisson shrinker (MGPS), to assess the relationship between oral bisphosphonates and oesophageal AEs. The Kaplan Meier method was utilized to evaluate the cumulative incidence of oesophageal toxicity, while the log rank test examined the temporal onset profiles of these toxicities. Additionally, the Pearson chi squared test was employed to identify any significant differences in mortality and hospitalization rates associated with the oesophageal AEs caused by these medications. Results The FAERS database had 41,590 AE reports for oral BPs, with 3,497 (8.41%) related to oesophageal AEs. Our findings indicate that oral BPs are disproportionately associated with an increased incidence of gastrointestinal system AEs at the system organ class (SOC) level. The adverse events identified at the preferred terms (PTs) level encompassed conditions such as gastroesophageal reflux disease, oesophagitis, and oesophageal pain. A significant divergence in the cumulative incidence of oesophageal AEs was observed among patients treated with the three different oral bisphosphonates, as confirmed by the log rank test (p < 0.0001). Hospitalization rates varied significantly among patients receiving different BPs (p < 0.05), but no significant difference in mortality rates was found. Conclusion The study establishes a significant link between oral BPs and oesophageal toxicity, highlighting the need for further research into the mechanisms of BP induced oesophageal toxicity and potential preventive measures.
C1 [Chen, Lin] Wenzhou Med Univ, Xiaoshan Affiliated Hosp, Peoples Hosp Xiaoshan Dist 1, Dept Cardiol, Hangzhou, Peoples R China.
   [Dai, Zhicheng] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Orthoped, Shanghai, Peoples R China.
   [Song, Huangrong] Naval Med Univ, Shanghai Changzheng Hosp, Dept Reprod Med, Shanghai, Peoples R China.
   [Zhang, Jiafeng] Naval Med Univ, Shanghai Changzheng Hosp, Dept Lab Med, Shanghai, Peoples R China.
   [Li, Tuo] Naval Med Univ, Shanghai Changzheng Hosp, Dept Endocrinol, Shanghai, Peoples R China.
C3 Wenzhou Medical University; Shanghai Jiao Tong University; Naval Medical
   University; Naval Medical University; Naval Medical University
RP Zhang, JF (通讯作者)，Naval Med Univ, Shanghai Changzheng Hosp, Dept Lab Med, Shanghai, Peoples R China.; Li, T (通讯作者)，Naval Med Univ, Shanghai Changzheng Hosp, Dept Endocrinol, Shanghai, Peoples R China.
EM dr_lituo@126.com; zjfzzllz@163.com
RI zhang, Jiafeng/LFT 9817 2024
OI Zhang, Jiafeng/0000 0003 2561 8045
FU National Natural Science and Foundation of China [82170858]
FX The author(s) declare that financial support was received for the
   research, authorship, and/or publication of this article. This study was
   funded by the National Natural Science and Foundation of China
   (82170858).
CR Ang C, 2016, WORLD J GASTROENTERO, V22, P906, DOI 10.3748/wjg.v22.i3.906
   Biggin A, 2017, CURR OSTEOPOROS REP, V15, P412, DOI 10.1007/s11914 017 0401 0
   Bijelic Radojka, 2017, Med Arch, V71, P25, DOI 10.5455/medarh.2017.71.25 28
   Body JJ, 2003, ANN ONCOL, V14, P1399, DOI 10.1093/annonc/mdg367
   Cardwell CR, 2010, JAMA J AM MED ASSOC, V304, P657, DOI 10.1001/jama.2010.1098
   Chang JT, 2003, NEW ENGL J MED, V349, P1676
   Chapurlat R, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115784
   Ciccaglione AF, 2001, AM J GASTROENTEROL, V96, P2306
   Coleman R, 2020, BONE, V140, DOI 10.1016/j.bone.2020.115570
   Cryer B, 2002, MAYO CLIN PROC, V77, P1031, DOI 10.4065/77.10.1031
   Findling Richard, 1996, Am J Ther, V3, P383, DOI 10.1097/00045391 199605000 00009
   Giunchi V, 2023, DRUG SAFETY, DOI 10.1007/s40264 023 01345 w
   Green J, 2010, BMJ BRIT MED J, V341, DOI 10.1136/bmj.c4444
   Grima DT, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 68
   Harirforoosh S, 2013, J PHARM PHARM SCI, V16, P821, DOI 10.18433/J3VW2F
   Hu YY, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106601
   Huang L, 2014, THER INNOV REGUL SCI, V48, P98, DOI 10.1177/2168479013514236
   Huang ZY, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/fpubh.2022.836357
   Jaffa MA, 2015, STAT METHODS MED RES, V24, P819, DOI 10.1177/0962280211430681
   Koerselman J, 1999, AM J GASTROENTEROL, V94, P925
   Lambrinoudaki I, 2006, ANN NY ACAD SCI, V1092, P397, DOI 10.1196/annals.1365.036
   Modi Ankita, 2016, Bone Rep, V5, P208, DOI 10.1016/j.bonr.2016.06.001
   Morden NE, 2015, OSTEOPOROSIS INT, V26, P663, DOI 10.1007/s00198 014 2925 9
   Mungan Z, 2017, TURK J GASTROENTEROL, V28, pS38, DOI 10.5152/tjg.2017.11
   Nguyen PVQ, 2021, OSTEOPOROSIS INT, V32, P193, DOI 10.1007/s00198 020 05498 7
   Osadchuk AM, 2019, TERAPEVT ARKH, V91, P135, DOI 10.26442/00403660.2019.08.000228
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Parfitt JR, 2007, HUM PATHOL, V38, P527, DOI 10.1016/j.humpath.2007.01.014
   Peng L, 2020, EXPERT OPIN DRUG SAF, V19, P1505, DOI 10.1080/14740338.2020.1799975
   Peng YL, 2014, OSTEOPOROSIS INT, V25, P1617, DOI 10.1007/s00198 014 2647 z
   Peris P, 2021, BONE, V146, DOI 10.1016/j.bone.2021.115887
   Psimma C, 2022, GERODONTOLOGY, V39, P330, DOI 10.1111/ger.12590
   Ralston SH, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115465
   Ramaswamy Bhuvaneswari, 2003, Oncology (Williston Park), V17, P1261
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   RUSHNAK MJ, 1980, AM J GASTROENTEROL, V73, P127
   Sedghizadeh PP, 2021, BONE, V147, DOI 10.1016/j.bone.2021.115933
   Shi MM, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891 018 2101 z
   Shu YM, 2023, CNS NEUROSCI THER, V29, P2705, DOI 10.1111/cns.14215
   Vytrisalova M, 2015, CLIMACTERIC, V18, P608, DOI 10.3109/13697137.2014.995164
   Wang DY, 2021, FRONT NEUROSCI SWITZ, V15, DOI 10.3389/fnins.2021.750458
   Wright E, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen 2014 007133
   Wysowski DK, 2010, BMJ BRIT MED J, V341, DOI 10.1136/bmj.c4506
   Zameer S, 2018, PHARMACOL REP, V70, P900, DOI 10.1016/j.pharep.2018.03.011
   Zhai YH, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.735466
   Zografos GN, 2009, DIS ESOPHAGUS, V22, P633, DOI 10.1111/j.1442 2050.2009.00972.x
NR 46
TC 1
Z9 1
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 7
PY 2024
VL 15
AR 1473756
DI 10.3389/fphar.2024.1473756
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA M9S5P
UT WOS:001360855900001
PM 39575385
OA gold
DA 2025 08 17
ER

PT J
AU Kokubun, K
   Matsumura, S
   Yudasaka, M
   Iijima, S
   Shiba, K
AF Kokubun, Katsutoshi
   Matsumura, Sachiko
   Yudasaka, Masako
   Iijima, Sumio
   Shiba, Kiyotaka
TI Immobilization of a carbon nanomaterial based localized drug release
   system using a bispecific material binding peptide
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE drug carrier; drug delivery; carbon nanomaterial; carbon nanohorn;
   peptide aptamer
ID BONE MORPHOGENETIC PROTEIN 2; TITANIUM SURFACES; FORMATION MECHANISM;
   ION IMPLANTATION; GENE EXPRESSION; IN VITRO; NANOHORNS; NANOTUBES;
   OSTEOBLASTS; TI
AB Introduction: Inorganic materials are widely used in medical devices, such as artificial hearts, vessels, and joints, in stents, and as nanocarriers for drug delivery systems. Carbon nano materials are of particular interest due to their biological inertness and their capability to accommodate molecules. Several attempts have been proposed, in which carbon nanomaterials are used as nanocarriers for the systemic delivery of drugs.
   Materials and methods: We developed a drug delivery system in which oxidized single walled carbon nanohorns (oxSWNHs) were immobilized on a titanium (Ti) surface using material binding peptides to enable localized drug delivery. For this purpose, we utilized a bispecific peptidic aptamer comprising a core sequence of a Ti binding peptide and a SWNH binding peptide to immobilize oxSWNHs on Ti.
   Results: Scanning electron microscopy was used to confirm the presence of oxSWNHs adsorbed onto the Ti surface, and a quartz crystal microbalance was used to evaluate the binding process during oxSWNH adsorption. The oxSWNHs ornamented Ti substrate was nontoxic to cells and released biologically active dexamethasone over a sustained period.
   Conclusion: This oxSWNHs immobilized system can be used to modify the surface of Ti in implants and be loaded with drugs that stimulate osteogenesis and bone regeneration.
C1 [Kokubun, Katsutoshi; Matsumura, Sachiko; Shiba, Kiyotaka] Japanese Fdn Canc Res, Canc Inst, Div Prot Engn, Tokyo, Japan.
   [Kokubun, Katsutoshi] Tokyo Dent Coll, Dept Clin Pathophysiol, Tokyo, Japan.
   [Yudasaka, Masako; Iijima, Sumio] Natl Inst Adv Ind Sci & Technol, Nanomat Res Inst, Tsukuba, Ibaraki, Japan.
   [Yudasaka, Masako; Iijima, Sumio] Meijo Univ, Grad Sch Sci & Technol, Nagoya, Aichi, Japan.
C3 Japanese Foundation for Cancer Research; Tokyo Dental College; National
   Institute of Advanced Industrial Science & Technology (AIST); Meijo
   University
RP Kokubun, K (通讯作者)，Tokyo Dent Coll, Dept Clin Pathophysiol, Chiyoda Ku, 2 9 18 Kandamisaki Cho, Tokyo 1010061, Japan.
EM kkokubun@tdc.ac.jp
RI Yudasaka, Masako/M 1011 2018; Iijima, Sumio/E 6234 2015; Shiba,
   Kiyotaka/I 9588 2014
OI Yudasaka, Masako/0000 0002 7610 3124; Shiba,
   Kiyotaka/0000 0001 6459 0204
FU JSPS KAKENHI [21791959, 16K11524]; Grants in Aid for Scientific Research
   [16K11524, 21791959] Funding Source: KAKEN
FX We thank Dr T Imamura for kindly providing the MC3T3 E1 cells and ST2
   cells, Dr K I Sano for valuable discussion, and Ms T Minamisawa for
   technical assistance.This work was supported by a JSPS KAKENHI (grant no
   21791959, 16K11524).
CR Abe I, 2001, BIOCHEM BIOPH RES CO, V281, P122, DOI 10.1006/bbrc.2001.4325
   Ajima K, 2005, MOL PHARMACEUT, V2, P475, DOI 10.1021/mp0500566
   Amigó V, 2003, J MATER PROCESS TECH, V141, P117, DOI 10.1016/S0924 0136(03)00243 7
   Aninwene GE, 2008, INT J NANOMED, V3, P257
   Antoci V, 2007, J ORTHOP RES, V25, P858, DOI 10.1002/jor.20348
   Brunette D.M., 2001, TITANIUM MED MAT SCI
   Chen RJ, 2003, P NATL ACAD SCI USA, V100, P4984, DOI 10.1073/pnas.0837064100
   Choi J, 2009, BIOMATERIALS, V30, P5201, DOI 10.1016/j.biomaterials.2009.06.003
   Depan D, 2013, ACTA BIOMATER, V9, P6084, DOI 10.1016/j.actbio.2012.12.019
   Diefenderfer DL, 2003, J BONE JOINT SURG AM, V85A, P19, DOI 10.2106/00004623 200300003 00005
   Fan J, 2006, J PHYS CHEM B, V110, P1587, DOI 10.1021/jp0538870
   Hayashi T, 2009, LANGMUIR, V25, P10901, DOI 10.1021/la901242q
   Hirata E, 2016, NANOSCALE, V8, P14514, DOI 10.1039/c6nr02756c
   Iijima S, 1999, CHEM PHYS LETT, V309, P165, DOI 10.1016/S0009 2614(99)00642 9
   Jenny G, 2016, J BIOMED MATER RES A, V104, P2898, DOI 10.1002/jbm.a.35805
   Jiang BP, 2014, ACS APPL MATER INTER, V6, P18008, DOI 10.1021/am504860c
   Kasai T, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/6/065102
   Kase D, 2004, LANGMUIR, V20, P8939, DOI 10.1021/la048968m
   Kashiwagi K, 2009, BIOMATERIALS, V30, P1166, DOI 10.1016/j.biomaterials.2008.10.040
   Kasuya D, 2002, J PHYS CHEM B, V106, P4947, DOI 10.1021/jp020387n
   Kazemzadeh Narbat M, 2010, BIOMATERIALS, V31, P9519, DOI 10.1016/j.biomaterials.2010.08.035
   Kim HM, 1997, J MATER SCI MATER M, V8, P341, DOI 10.1023/A:1018524731409
   Kokubun K, 2008, BIOMACROMOLECULES, V9, P3098, DOI 10.1021/bm800638z
   Li N, 2010, CARBON, V48, P1580, DOI 10.1016/j.carbon.2009.12.055
   Liang CY, 2013, ACS APPL MATER INTER, V5, P8179, DOI 10.1021/am402290e
   Luppen CA, 2003, J BIOL CHEM, V278, P44995, DOI 10.1074/jbc.M306730200
   Luppen CA, 2003, J BONE MINER RES, V18, P1186, DOI 10.1359/jbmr.2003.18.7.1186
   Mani G, 2008, BIOMATERIALS, V29, P4561, DOI 10.1016/j.biomaterials.2008.08.014
   Matsumura S, 2007, MOL PHARMACEUT, V4, P723, DOI 10.1021/mp070022t
   Mattson MP, 2000, J MOL NEUROSCI, V14, P175, DOI 10.1385/JMN:14:3:175
   Misra RDK, 2013, J BIOMED MATER RES A, V101, P1059, DOI 10.1002/jbm.a.34409
   Miyako E, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2233
   Miyako E, 2012, P NATL ACAD SCI USA, V109, P7523, DOI 10.1073/pnas.1204391109
   Miyawaki J, 2008, ACS NANO, V2, P213, DOI 10.1021/nn700185t
   Murakami T, 2008, NANOMEDICINE UK, V3, P453, DOI 10.2217/17435889.3.4.453
   Muralkami T, 2006, MOL PHARMACEUT, V3, P407, DOI 10.1021/mp060027a
   Muralkami T, 2004, MOL PHARMACEUT, V1, P399, DOI 10.1021/mp049928e
   Murata K, 2002, J PHYS CHEM B, V106, P12668, DOI 10.1021/jp026909g
   Murata K, 2002, J PHYS CHEM B, V106, P11132, DOI 10.1021/jp020583u
   Murata K, 2001, J PHYS CHEM B, V105, P10210, DOI 10.1021/jp010754f
   Nayab SN, 2007, J BIOMED MATER RES A, V83A, P296, DOI 10.1002/jbm.a.31218
   Pantarotto D, 2003, CHEM BIOL, V10, P961, DOI 10.1016/j.chembiol.2003.09.011
   Pantarotto D, 2003, J AM CHEM SOC, V125, P6160, DOI 10.1021/ja034342r
   Popa C, 2005, J MATER SCI MATER M, V16, P1165, DOI 10.1007/s10856 005 4724 5
   Qiao YQ, 2014, BIOMATERIALS, V35, P6882, DOI 10.1016/j.biomaterials.2014.04.101
   Radin S, 2007, BIOMATERIALS, V28, P1721, DOI 10.1016/j.biomaterials.2006.11.035
   Rautray TR, 2010, J BIOMED MATER RES B, V93B, P581, DOI 10.1002/jbm.b.31596
   Saito N, 2008, CURR MED CHEM, V15, P523, DOI 10.2174/092986708783503140
   Sano K, 2006, J AM CHEM SOC, V128, P1717, DOI 10.1021/ja057262r
   Sano K, 2005, SMALL, V1, P826, DOI 10.1002/smll.200500010
   Sano KI, 2003, J AM CHEM SOC, V125, P14234, DOI 10.1021/ja038414q
   Schuler M, 2006, NANOMEDICINE UK, V1, P449, DOI 10.2217/17435889.1.4.449
   Shen XK, 2014, ACS APPL MATER INTER, V6, P16426, DOI 10.1021/am5049338
   Shimizu M, 2012, ADV MATER, V24, P2176, DOI 10.1002/adma.201103832
   Shvedova AA, 2003, J TOXICOL ENV HEAL A, V66, P1909, DOI 10.1080/713853956
   Tahara Y, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/26/265106
   YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209
   Yuasa K, 2014, J BIOMED MATER RES A, V102, P1180, DOI 10.1002/jbm.a.34765
   Yuge R, 2009, J PHYS CHEM C, V113, P2741, DOI 10.1021/jp810121a
   Zavgorodniy AV, 2011, J MATER SCI MATER M, V22, P1, DOI 10.1007/s10856 010 4179 1
   Zhang MF, 2013, NANOMED NANOTECHNOL, V9, P657, DOI 10.1016/j.nano.2012.11.011
NR 61
TC 13
Z9 13
U1 2
U2 30
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2018
VL 13
BP 1643
EP 1652
DI 10.2147/IJN.S155913
PG 10
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA GA0XG
UT WOS:000428037500004
PM 29588591
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Nickolas, TL
   Yin, MT
   Hong, T
   Mugwanya, KK
   Branch, AD
   Heffron, R
   Ramalho, J
   Nandakumar, R
   Dworakowski, E
   Wanga, V
   Mugo, NR
   Ronald, A
   Celum, C
   Donnell, D
   Baeten, JM
   Wyatt, CM
   Celum, C
   Baeten, JM
   Donnell, D
   Coombs, RW
   Frenkel, L
   Hendrix, CW
   Lingappa, JR
   McElrath, MJ
   Fife, KH
   Were, E
   Tumwesigye, E
   Ndase, P
   Katabira, E
   Ronald, A
   Bukusi, E
   Cohen, CR
   Wangisi, J
   Campbell, JD
   Tappero, JW
   Kiarie, J
   Farquhar, C
   John Stewart, G
   Mugo, NR
   Campbell, JD
   Tappero, JW
   Wangisi, J
AF Nickolas, Thomas L.
   Yin, Michael T.
   Hong, Ting
   Mugwanya, Kenneth K.
   Branch, Andrea D.
   Heffron, Renee
   Ramalho, Janaina
   Nandakumar, Renu
   Dworakowski, Elzbieta
   Wanga, Valentine
   Mugo, Nelly R.
   Ronald, Allan
   Celum, Connie
   Donnell, Deborah
   Baeten, Jared M.
   Wyatt, Christina M.
   Celum, Connie
   Baeten, Jared M.
   Donnell, Deborah
   Coombs, Robert W.
   Frenkel, Lisa
   Hendrix, Craig W.
   Lingappa, Jairam R.
   McElrath, M. Juliana
   Fife, Kenneth H.
   Were, Edwin
   Tumwesigye, Elioda
   Ndase, Patrick
   Katabira, Elly
   Ronald, Allan
   Bukusi, Elizabeth
   Cohen, Craig R.
   Wangisi, Jonathan
   Campbell, James D.
   Tappero, Jordan W.
   Kiarie, James
   Farquhar, Carey
   John Stewart, Grace
   Mugo, Nelly R.
   Campbell, James D.
   Tappero, Jordan W.
   Wangisi, Jonathan
CA Partners PrEP Study Team
TI Impact of Tenofovir Based Pre exposure Prophylaxis on Biomarkers of Bone
   Formation, Bone Resorption, and Bone Mineral Metabolism in HIV Negative
   Adults
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE antiretroviral therapy; bone turnover; HIV prevention; kidney; tubular
   dysfunction
ID DISOPROXIL FUMARATE; ABACAVIR LAMIVUDINE; VITAMIN D; DENSITY;
   EMTRICITABINE; MEN; FUMARATE/EMTRICITABINE; INITIATION; TURNOVER
AB Background. Pre exposure prophylaxis (PrEP) with emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) reduces the risk of HIV seroconversion but may promote bone mineral density (BMD) decline. The mechanisms of BMD decline with FTC/TDF remain unclear, and studies in HIV positive individuals have been confounded by the effects of HIV and concomitant antiretroviral medications. We evaluated the impact of FTC/TDF on biomarkers of bone remodeling and bone mineral metabolism in HIV negative men and women enrolled in the Partners PrEP Study.
   Methods. In a random sample of HIV negative participants randomized to FTC/TDF PrEP (n = 50) or placebo (n = 50), serum parathyroid hormone (PTH), bone biomarkers (C telopeptide, procollagen 1 intact N terminal propeptide, and sclerostin), and plasma fibroblast growth factor 23 were measured at baseline and month 24, and the percentage change was compared between groups. In a complementary analysis, we compared the change in biomarkers between participants with and without a 25% decline in glomerular filtration rate (GFR) on FTC/TDF.
   Results. Baseline characteristics were similar between the groups (median age, 38 years; 40% women). Vitamin D insufficiency was common, but baseline GFR and PTH were in the normal range. We observed a significantly greater percent increase in serum C telopeptide in participants randomized to FTC/TDF vs placebo (P = .03), suggesting an increase in bone remodeling. We observed no differences in the other biomarkers, or in a separate analysis comparing participants with and without a decline in GFR.
   Conclusions. Increased bone remodeling may mediate the BMD decline observed with tenofovir containing PrEP and antiretroviral therapy, independent of a TDF mediated decrease in kidney function.
C1 [Nickolas, Thomas L.; Yin, Michael T.; Ramalho, Janaina; Nandakumar, Renu; Dworakowski, Elzbieta] Columbia Univ, Dept Med, Med Ctr, New York, NY USA.
   [Hong, Ting; Mugwanya, Kenneth K.; Heffron, Renee; Wanga, Valentine; Mugo, Nelly R.; Celum, Connie; Donnell, Deborah; Baeten, Jared M.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
   [Hong, Ting; Mugwanya, Kenneth K.; Heffron, Renee; Wanga, Valentine; Mugo, Nelly R.; Celum, Connie; Donnell, Deborah; Baeten, Jared M.] Univ Washington, Dept Med, Seattle, WA USA.
   [Hong, Ting; Mugwanya, Kenneth K.; Heffron, Renee; Wanga, Valentine; Mugo, Nelly R.; Celum, Connie; Donnell, Deborah; Baeten, Jared M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
   [Branch, Andrea D.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
   [Mugo, Nelly R.] Kenya Govt Med Res Ctr, Nairobi, Kenya.
   [Ronald, Allan] Univ Manitoba, Dept Med, Winnipeg, MB, Canada.
   [Ronald, Allan] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada.
   [Wyatt, Christina M.] Duke Univ, Sch Med, Dept Med Ctr, Durham, NC USA.
   [Wyatt, Christina M.] Duke Clin Res Inst, Durham, NC USA.
C3 Columbia University; University of Washington; University of Washington
   Seattle; University of Washington; University of Washington Seattle;
   University of Washington; University of Washington Seattle; Icahn School
   of Medicine at Mount Sinai; Kenya Medical Research Institute; University
   of Manitoba; University of Manitoba; Duke University; Duke University
RP Wyatt, CM (通讯作者)，Duke Univ, Sch Med, Dept Med, Div Nephrol,Duke Clin Res Inst, 200 Morris St, Durham, NC 27705 USA.
EM christina.wyatt@duke.edu
RI Campbell, James D/AFN 5982 2022; Wyatt, Christina/KIB 2660 2024;
   Lingappa, Jairam/N 7760 2017; Wanga, Valentine/W 8553 2019; Ramalho,
   Janaina/P 2130 2014; Hendrix, Craig/G 4182 2014; Heffron,
   Renee/AAG 5002 2020; John Stewart, Grace/L 3650 2019
OI kiarie, james/0000 0003 4180 7858; John Stewart,
   Grace/0000 0002 4301 1573; Wanga, Valentine/0000 0002 9104 0125; Yin,
   Michael T/0000 0002 9346 9056; Nandakumar, Renu/0009 0009 9273 504X;
   Were, Edwin/0000 0002 4783 0795; Hendrix, Craig/0000 0002 5696 8665; 
FU Bill and Melinda Gates Foundation [OPP47674]; National Institutes of
   Health, National Institute for Diabetes, Digestive, and Kidney Diseases
   [R01DK100272, R01DK112258]; National Institutes of Health, National
   Institute of Child Health and Human Development [R01HD089843]; National
   Institutes of Health, National Institute for Allergy and Infectious
   Disease [P30AI027757]
FX The Partners PrEP Study was funded by the Bill and Melinda Gates
   Foundation (OPP47674). This work was also supported by the National
   Institutes of Health, National Institute for Diabetes, Digestive, and
   Kidney Diseases (R01DK100272 and R01DK112258), the National Institute of
   Child Health and Human Development (R01HD089843), and the National
   Institute for Allergy and Infectious Disease (P30AI027757).
CR Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Brown TT, 2015, J INFECT DIS, V212, P1241, DOI 10.1093/infdis/jiv194
   Childs KE, 2010, AIDS RES HUM RETROV, V26, P855, DOI 10.1089/aid.2009.0308
   Custodio JM, 2016, ANTIMICROB AGENTS CH, V60, P5135, DOI 10.1128/AAC.00005 16
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Havens PL, 2018, CLIN INFECT DIS, V66, P220, DOI 10.1093/cid/cix753
   Havens PL, 2017, CLIN INFECT DIS, V64, P317, DOI 10.1093/cid/ciw765
   Kasonde M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090111
   Liu AY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023688
   McComsey GA, 2011, J INFECT DIS, V203, P1791, DOI 10.1093/infdis/jir188
   Mugwanya K, 2016, J INFECT DIS, V214, P1050, DOI 10.1093/infdis/jiw125
   Mugwanya KK, 2015, JAMA INTERN MED, V175, P246, DOI 10.1001/jamainternmed.2014.6786
   Mulligan K, 2015, CLIN INFECT DIS, V61, P572, DOI 10.1093/cid/civ324
   Overton ET, 2015, ANN INTERN MED, V162, P815, DOI 10.7326/M14 1409
   Reynes J, 2013, AIDS RES HUM RETROV, V29, P256, DOI [10.1089/aid.2011.0275, 10.1089/AID.2011.0275]
   Stellbrink HJ, 2010, CLIN INFECT DIS, V51, P963, DOI 10.1086/656417
   Tebas P, 2015, AIDS, V29, P2459, DOI 10.1097/QAD.0000000000000863
NR 17
TC 4
Z9 5
U1 1
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328 8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD OCT
PY 2019
VL 6
IS 10
AR ofz338
DI 10.1093/ofid/ofz338
PG 6
WC Immunology; Infectious Diseases; Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Infectious Diseases; Microbiology
GA KG7YI
UT WOS:000510164000008
PM 31660332
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Granéli, C
   Karlsson, C
   Lindahl, A
   Thomsen, P
AF Graneli, Cecilia
   Karlsson, Camilla
   Lindahl, Anders
   Thomsen, Peter
TI Virtual Ligand Based Screening Reveals Purmorphamine Analogs with the
   Capacity to Induce the Osteogenic Differentiation of Human Mesenchymal
   Stem Cells
SO CELLS TISSUES ORGANS
LA English
DT Article
DE Virtual ligand based screening; Purmorphamine; Mesenchymal stem cells;
   Osteoblast differentiation
ID HUMAN BONE MARROW; OSTEOBLAST DIFFERENTIATION; TISSUE; ACTIVATION;
   SIMILARITY; BIOLOGY; PLAYS; WNT
AB Human mesenchymal stem cells (hMSCs) have extensive proliferative capacity, are able to self renew and have the potential to differentiate into cells of the connective tissue lineages. These properties make them a putative cell type for tissue engineering applications, as well as a possible in vivo target for the pharmaceutical modulation of the differentiation processes. The aim of this study was to find one or more small molecule substances that would enhance the osteogenic differentiation of hMSCs in vitro. The strategy used here was ligand based virtual screening for substances similar to the previously suggested osteoinductive purmorphamine followed by an in vitro screening of the selected analogs in hMSCs isolated from bone marrow. We investigated the osteoinductive capacity of several purmorphamine analogs by determining the protein and gene expression of markers for osteogenic differentiation as well as the extracellular matrix (ECM) mineralization of these cells. Treatment with two candidate substances or purmorphamine resulted in increased levels of alkaline phosphatase (ALP) activity compared to the control. Other purmorphamine analogs demonstrated higher calcium deposition in the ECM after 5 weeks of osteogenic differentiation, compared to both purmorphamine and the control condition. The resulting substances, which had positive effects on the osteogenic differentiation, are promising as possible modes of treatment for bone related diseases or defects that target and enhance the osteogenic differentiation of MSCs, in vitro or in vivo. Furthermore, the concept of combining the virtual ligand based screening method with in vitro screening, using human adult stem cells as a possible strategy for drug discovery, is demonstrated. Copyright (c) 2012 S. Karger AG, Basel
C1 [Graneli, Cecilia; Karlsson, Camilla; Thomsen, Peter] Univ Gothenburg, Sahlgrenska Acad, Dept Biomat, SE 40530 Gothenburg, Sweden.
   [Lindahl, Anders] Univ Gothenburg, Sahlgrenska Acad, Dept Clin Chem & Transfus Med, SE 40530 Gothenburg, Sweden.
   [Graneli, Cecilia; Karlsson, Camilla; Lindahl, Anders; Thomsen, Peter] VINN Excellence Ctr Biomat & Cell Therapy, BIOMATCELL, Gothenburg, Sweden.
C3 University of Gothenburg; University of Gothenburg
RP Granéli, C (通讯作者)，Univ Gothenburg, Sahlgrenska Acad, Dept Biomat, Arvid Wallgrens Backe 20,Box 412, SE 40530 Gothenburg, Sweden.
EM cecilia.graneli@gu.se
RI Lindahl, Anders/H 9550 2014; Thomsen, Peter/AAI 1502 2021
OI Lindahl, Anders/0000 0003 2871 5166; Thomsen, Peter/0000 0003 3910 6665;
   Graneli, Cecilia/0000 0003 1133 8755
FU Swedish Research Council [K2009 52X 09495 22 3]; VINN Excellence Center
   of Biomaterials and Cell Therapy; Region Vastra Gotaland; Handlanden
   Hjalmar Svensson's Research Fund
FX The support of the Swedish Research Council (grant
   K2009 52X 09495 22 3), the VINN Excellence Center of Biomaterials and
   Cell Therapy, Region Vastra Gotaland and Handlanden Hjalmar Svensson's
   Research Fund is gratefully acknowledged. We thank P.G. Nyholm and
   Francesco Strino at Biognos AB for providing the virtual screening
   services and Dr. Helena Brisby for providing the bone marrow biopsies.
CR Arvidson K, 2011, J CELL MOL MED, V15, P718, DOI 10.1111/j.1582 4934.2010.01224.x
   Axelrad TW, 2009, CYTOKINE GROWTH F R, V20, P481, DOI 10.1016/j.cytogfr.2009.10.003
   Bains W., 2004, DDW DRUG DISCOVERY W, V5, P9
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   Beloti MM, 2005, CELL BIOL INT, V29, P537, DOI 10.1016/j.cellbi.2005.02.007
   Beloti MM, 2005, BIOMATERIALS, V26, P4245, DOI 10.1016/j.biomaterials.2004.10.039
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   Cramer RD, 2004, J MED CHEM, V47, P6777, DOI 10.1021/jm049501b
   Cramer RD, 2002, J MOL GRAPH MODEL, V20, P447, DOI 10.1016/S1093 3263(01)00146 2
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Eglen R, 2011, ASSAY DRUG DEV TECHN, V9, P108, DOI 10.1089/adt.2010.0305
   Fontaine C, 2008, STEM CELLS, V26, P1037, DOI 10.1634/stemcells.2007 0974
   Glassman SD, 2011, SPINE J, V11, P522, DOI 10.1016/j.spinee.2010.05.016
   Hou TY, 2009, TISSUE ENG PT A, V15, P2325, DOI 10.1089/ten.tea.2008.0402
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010
   Kassem M, 2004, BASIC CLIN PHARMACOL, V95, P209, DOI 10.1111/j.1742 7843.2004.pto950502.x
   Lee SJ, 2008, MOL CELLS, V26, P380
   Li XJ, 2008, STEM CELLS, V26, P886, DOI 10.1634/stemcells.2007 0620
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Nakamura T, 1997, BIOCHEM BIOPH RES CO, V237, P465, DOI 10.1006/bbrc.1997.7156
   Nirmalanandhan VS, 2009, J BIOMOL SCREEN, V14, P755, DOI 10.1177/1087057109336591
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Plaisant M, 2009, STEM CELLS, V27, P703, DOI 10.1634/stemcells.2008 0888
   Rissanen JP, 2010, EXPERT OPIN DRUG DIS, V5, P1163, DOI 10.1517/17460441.2010.532484
   Schugar RC, 2008, GENE THER, V15, P126, DOI 10.1038/sj.gt.3303062
   Shields LBE, 2006, SPINE, V31, P542, DOI 10.1097/01.brs.0000201424.27509.72
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Sinha S, 2006, NAT CHEM BIOL, V2, P29, DOI 10.1038/nchembio753
   Suh JM, 2006, CELL METAB, V3, P25, DOI 10.1016/j.cmet.2005.11.012
   Troyer DL, 2008, STEM CELLS, V26, P591, DOI 10.1634/stemcells.2007 0439
   van der Horst G, 2003, BONE, V33, P899, DOI 10.1016/j.bone.2003.07.004
   Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003
   Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004 0013
   Wu X, 2004, CHEM BIOL, V11, P1229, DOI 10.1016/j.chembiol.2004.06.010
   Wu X, 2002, J AM CHEM SOC, V124, P14520, DOI 10.1021/ja0283908
NR 37
TC 4
Z9 4
U1 0
U2 18
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1422 6405
EI 1422 6421
J9 CELLS TISSUES ORGANS
JI Cells Tissues Organs
PY 2013
VL 197
IS 2
BP 89
EP 102
DI 10.1159/000342796
PG 14
WC Anatomy & Morphology; Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology; Cell Biology; Developmental Biology
GA 077FR
UT WOS:000314013800001
PM 23147751
DA 2025 08 17
ER

PT J
AU Zhou, CC
   Cui, YJ
   Yang, YY
   Guo, DM
   Zhang, DM
   Fan, Y
   Li, XB
   Zou, J
   Xie, J
AF Zhou, Chenchen
   Cui, Yujia
   Yang, Yueyi
   Guo, Daimo
   Zhang, Demao
   Fan, Yi
   Li, Xiaobing
   Zou, Jing
   Xie, Jing
TI Runx1 protects against the pathological progression of osteoarthritis
SO BONE RESEARCH
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; GROWTH; CARTILAGE; GENE; EXPRESSION;
   MATURATION
AB Runt related transcription factor 1 (Runx1) is required for chondrocyte to osteoblast lineage commitment by enhancing both chondrogenesis and osteogenesis during vertebrate development. However, the potential role of Runx1 in joint diseases is not well known. In the current study, we aimed to explore the role of Runx1 in osteoarthritis induced by anterior cruciate ligament transaction (ACLT) surgery. We showed that chondrocyte specific Runx1 knockout (Runx1(f/f)Col2a1 Cre) aggravated cartilage destruction by accelerating the loss of proteoglycan and collagen II in early osteoarthritis. Moreover, we observed thinning and ossification of the growth plate, a decrease in chondrocyte proliferative capacity and the loss of bone matrix around the growth plate in late osteoarthritis. We overexpressed Runx1 by adeno associated virus (AAV) in articular cartilage and identified its protective effect by slowing the destruction of osteoarthritis in cartilage in early osteoarthritis and alleviating the pathological progression of growth plate cartilage in late osteoarthritis. ChIP seq analysis identified new targets that interacted with Runx1 in cartilage pathology, and we confirmed the direct interactions of these factors with Runx1 by ChIP qPCR. This study helps us to understand the function of Runx1 in osteoarthritis and provides new clues for targeted osteoarthritis therapy.
C1 [Zhou, Chenchen; Cui, Yujia; Yang, Yueyi; Guo, Daimo; Zhang, Demao; Fan, Yi; Xie, Jing] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Zhou, Chenchen; Li, Xiaobing; Zou, Jing] Sichuan Univ, Natl Clin Res Ctr Oral Dis, Chengdu, Peoples R China.
   [Zhou, Chenchen; Li, Xiaobing; Zou, Jing] Sichuan Univ, West China Hosp Stomatol, Dept Pediat Dent, Chengdu, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University
RP Xie, J (通讯作者)，Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.
EM xiejing2012@scu.edu.cn
RI Yujia, Cui/GRX 7175 2022; Xie, Jing/P 6112 2014; Zhou,
   Chenchen/LKJ 8704 2024; Xiao, Li/I 3309 2014
OI Li, Xiaobing/0000 0002 4177 5887; Xie, Jing/0000 0001 8156 0322; Zou,
   Jing/0000 0002 3618 9672; 
FU National Natural Science Foundation of China [81771047, 81901040]; China
   Postdoctoral Science Foundation [2019M653440]; Sichuan Provincial
   Science and Technology Department [2019YJ0101]; Young Elite Scientist
   Sponsorship Program by CAST [2020QNR001]
FX This work was supported by the National Natural Science Foundation of
   China (81771047 to J.X., 81901040 to C.Z.), the China Postdoctoral
   Science Foundation (2019M653440), the Sichuan Provincial Science and
   Technology Department (2019YJ0101) and the Young Elite Scientist
   Sponsorship Program by CAST (2020QNR001).
CR Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607
   Burchfield JS, 2013, CIRCULATION, V128, P388, DOI 10.1161/CIRCULATIONAHA.113.001878
   Chen H, 2021, LIFE SCI, V265, DOI 10.1016/j.lfs.2020.118804
   Coryell PR, 2021, NAT REV RHEUMATOL, V17, P47, DOI 10.1038/s41584 020 00533 7
   Deng ZH, 2018, OSTEOARTHR CARTILAGE, V26, P1153, DOI 10.1016/j.joca.2018.03.007
   Ellman MB, 2008, GENE, V420, P82, DOI 10.1016/j.gene.2008.04.019
   Fortier LA, 2011, CLIN ORTHOP RELAT R, V469, P2706, DOI 10.1007/s11999 011 1857 3
   Howell GR, 2007, GENETICS, V175, P699, DOI 10.1534/genetics.106.065177
   Kameda T, 2000, DEV GROWTH DIFFER, V42, P229
   Kawaguchi J, 2005, BONE, V36, P758, DOI 10.1016/j.bone.2004.07.019
   Kimura A, 2010, DEVELOPMENT, V137, P1159, DOI 10.1242/dev.045005
   Klco JM, 2021, NAT REV CANCER, V21, P122, DOI 10.1038/s41568 020 00315 z
   Krishnan V, 2017, ADV EXP MED BIOL, V962, P491, DOI 10.1007/978 981 10 3233 2_29
   Kwon TG, 2011, J CELL BIOCHEM, V112, P3582, DOI 10.1002/jcb.23289
   Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925 4773(01)00537 8
   Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370
   Levanon D, 2004, ONCOGENE, V23, P4211, DOI 10.1038/sj.onc.1207670
   Lian JB, 2003, J CELL PHYSIOL, V196, P301, DOI 10.1002/jcp.10316
   Luo Y, 2019, ARCH ORAL BIOL, V97, P176, DOI 10.1016/j.archoralbio.2018.10.028
   Mariani E, 2014, INT J MOL SCI, V15, P8667, DOI 10.3390/ijms15058667
   McCarroll CS, 2018, CIRCULATION, V137, P57, DOI 10.1161/CIRCULATIONAHA.117.028911
   McHugh Jessica, 2021, Nat Rev Rheumatol, V17, P312, DOI 10.1038/s41584 021 00631 0
   Nishida Y, 2004, OSTEOARTHR CARTILAGE, V12, P374, DOI 10.1016/j.joca.2004.01.008
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Riddell A, 2020, CARDIOVASC RES, V116, P1410, DOI 10.1093/cvr/cvaa034
   Shao Y, 2021, AGING US, V13, P9646, DOI 10.18632/aging.202708
   Soung DY, 2007, J BONE MINER RES, V22, P1260, DOI 10.1359/JBMR.070502
   Soung DY, 2014, MOL ENDOCRINOL, V28, P546, DOI 10.1210/me.2013 1305
   Symoens S, 2015, AM J HUM GENET, V97, P521, DOI 10.1016/j.ajhg.2015.08.009
   Tang CY, 2021, PLOS GENET, V17, DOI 10.1371/journal.pgen.1009233
   Tang CY, 2020, BIOCHEM J, V477, P2421, DOI 10.1042/BCJ20200036
   Tang J, 2020, J BIOL CHEM, V295, P11669, DOI 10.1074/jbc.RA119.007896
   Unlu G, 2020, NAT MED, V26, P98, DOI 10.1038/s41591 019 0705 y
   Venezian R, 1998, J CELL PHYSIOL, V174, P331
   Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444
   Wang YJ, 2005, J BONE MINER RES, V20, P1624, DOI 10.1359/JBMR.050516
   Xie J, 2018, AM J SPORT MED, V46, P1185, DOI 10.1177/0363546518756087
   Yokomizo Nakano T, 2021, EXP HEMATOL, V97, P14, DOI 10.1016/j.exphem.2021.02.005
   Yoon BS, 2006, DEVELOPMENT, V133, P4667, DOI 10.1242/dev.02680
   Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704
NR 40
TC 52
Z9 58
U1 0
U2 27
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD DEC 7
PY 2021
VL 9
IS 1
AR 50
DI 10.1038/s41413 021 00173 x
PG 12
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA XL7IQ
UT WOS:000728315900001
PM 34876557
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Somjen, D
   Shen, M
   Stern, N
   Mirsky, N
AF Somjen, Dalia
   Shen, Michal
   Stern, Naftali
   Mirsky, Nitsa
TI Diabetes modulates differentially creatine kinase specific activity
   responsiveness to estradiol 17β and to raloxifene in rat organs
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE estradiol 17 beta; raloxifene; diabetes; bone; vascular organs; uterus;
   pituitary; creatine kinase; hyperglycemia
ID ESTROGEN RECEPTOR MODULATORS; HORMONE REPLACEMENT THERAPY;
   OSTEOBLAST LIKE CELLS; SMOOTH MUSCLE CELLS; BONE DERIVED CELLS;
   DNA SYNTHESIS; POSTMENOPAUSAL WOMEN; ELEVATED GLUCOSE; GONADAL STEROIDS;
   VASCULAR CELLS
AB Diabetes mellitus increases the risk for CVD in women. While there is considerable evidence suggesting beneficial effects of estrogen on decreasing lipid peroxidation, atherosclerotic processes, and cardiovascular diseases, diabetes negates most estrogen protective effects as well as the skeletal protective effects of estrogens, which are not discernable in diabetic women. In the present study, we examined the in vivo effects of estradiol 17 beta (E 2), on creatine kinase (CK) specific activity, in estrogen responsive organs from healthy and diabetic rats. Healthy or diabetic (streptozotocin induced) female rats were injected with either E 2 (10 50 mu g/rat) or raloxifene (Ral; 500 1,000 mu g/rat). Twenty four hours following the injection, animals were sacrificed; their organs removed and assayed for CK specific activity. CK specific activity in different organs [Left ventricle of heart (Lv), uterus (Ut), aorta (Ao), para uterine adipose tissue (Ad), epiphyseal cartilage (Ep), and diaphyseal bone (Di)] from healthy animals, was stimulated with increased doses of E 2, with maximum at 20 mu g/rat. Age matched diabetic female rats exhibited a remarkable decreased response to E 2 in all organs except Ut. In contrast, the response to Ral was not altered in diabetic rats. Similar results were observed in organs from ovariectomized female rats (Ovx), healthy or diabetic. These results support our previous in vitro findings, demonstrating that hyperglycemia decreases CK response to E 2 but not to Ral in cultured human vascular and bone cells. In summary, diabetes mellitus decreases CK response to E 2 but not that of Ral in skeletal and vascular tissues. The decreased response to E 2 detected in organs derived from diabetic rats might be due to changes in nuclear and/or membrane estrogen receptors and/or other genomic and non genomic pathways, as was shown in in vitro cellular models.
C1 Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Inst Endocrinol Metab & Hypertens, IL 64239 Tel Aviv, Israel.
   Tel Aviv Univ, Sackler Fac Med, IL 64239 Tel Aviv, Israel.
   Univ Haifa, Fac Sci, IL 31905 Haifa, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky
   Medical Center; Tel Aviv University; Sackler Faculty of Medicine;
   University of Haifa
RP Somjen, D (通讯作者)，Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Inst Endocrinol Metab & Hypertens, 6 Weizman St, IL 64239 Tel Aviv, Israel.
EM dalias@tasmc.health.gov.il
CR Avena R, 2000, ANN VASC SURG, V14, P37, DOI 10.1007/s100169910007
   Cosman F, 1999, ENDOCR REV, V20, P418, DOI 10.1210/er.20.3.418
   Enmark E, 1999, J INTERN MED, V246, P133, DOI 10.1046/j.1365 2796.1999.00545.x
   ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021
   Fournier B, 1996, J ENDOCRINOL, V150, P275, DOI 10.1677/joe.0.1500275
   GOODMAN WG, 1984, DIABETES, V33, P825, DOI 10.2337/diabetes.33.9.825
   He HB, 2004, ENDOCRINOLOGY, V145, P447, DOI 10.1210/en.2003 1239
   KANNEL WB, 1979, JAMA J AM MED ASSOC, V241, P2038
   Kaseta JR, 1999, J CLIN ENDOCR METAB, V84, P1835, DOI 10.1210/jc.84.6.1835
   Katzburg S, 1999, BONE, V25, P667, DOI 10.1016/S8756 3282(99)00225 2
   Katzburg S, 2001, J ENDOCRINOL INVEST, V24, P166, DOI 10.1007/BF03343837
   Koh KK, 1997, NEW ENGL J MED, V336, P683, DOI 10.1056/NEJM199703063361002
   KOMM BS, 1988, SCIENCE, V241, P81, DOI 10.1126/science.3164526
   Liu EY, 2003, DIABETES CARE, V26, P2365, DOI 10.2337/diacare.26.8.2365
   MALNICK SDH, 1983, ENDOCRINOLOGY, V113, P1907, DOI 10.1210/endo 113 5 1907
   Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385
   NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501
   NATARAJAN R, 1992, BIOCHEM BIOPH RES CO, V187, P552, DOI 10.1016/S0006 291X(05)81529 3
   Node K, 1997, CIRCULATION, V96, P1953, DOI 10.1161/01.CIR.96.6.1953
   ORCHARD TJ, 1990, DIABETES, V39, P1116, DOI 10.2337/diabetes.39.9.1116
   REISS NA, 1981, J BIOL CHEM, V256, P5741
   Shao WL, 2004, P NATL ACAD SCI USA, V101, P11599, DOI 10.1073/pnas.0402997101
   Somjen D, 2005, J STEROID BIOCHEM, V93, P293, DOI 10.1016/j.jsbmb.2004.12.029
   SOMJEN D, 1989, P NATL ACAD SCI USA, V86, P3361, DOI 10.1073/pnas.86.9.3361
   Somjen D, 2004, AM J HYPERTENS, V17, P462, DOI 10.1016/j.amjhyper.2004.01.002
   Somjen D, 2004, J STEROID BIOCHEM, V88, P101, DOI 10.1016/j.jsbmb.2003.11.002
   Somjen D, 2001, AM J HYPERTENS, V14, P1256, DOI 10.1016/S0895 7061(01)02214 2
   Somjen D, 2001, J STEROID BIOCHEM, V77, P205, DOI 10.1016/S0960 0760(01)00065 6
   Somjen D, 2000, J STEROID BIOCHEM, V72, P79, DOI 10.1016/S0960 0760(00)00028 5
   Somjen D, 1998, HYPERTENSION, V32, P39, DOI 10.1161/01.HYP.32.1.39
   SOMJEN D, 2005, IN PRESS J STEROID B
   Talukder AH, 2004, MOL CELL BIOL, V24, P6581, DOI 10.1128/mcb.24.15.6581 6591.2004
   Williams JK, 1997, CIRCULATION, V96, P1970, DOI 10.1161/01.CIR.96.6.1970
   YAMAUCHI T, 1990, FEBS LETT, V267, P16, DOI 10.1016/0014 5793(90)80276 O
NR 34
TC 6
Z9 7
U1 0
U2 7
PU WILEY LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0730 2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD SEP 1
PY 2006
VL 99
IS 1
BP 133
EP 139
DI 10.1002/jcb.20916
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 077TE
UT WOS:000240052400012
PM 16598752
DA 2025 08 17
ER

PT J
AU Uddin, SMZ
   Qin, YX
AF Uddin, Sardar M. Z.
   Qin, Yi Xian
TI Dynamic acoustic radiation force retains bone structural and mechanical
   integrity in a functional disuse osteopenia model
SO BONE
LA English
DT Article
DE Low Intensity Pulsed Ultrasound; Disuse osteopenia; Osteoporosis;
   Nonunion fracture; LIPUS; Microgravity
ID INTENSITY PULSED ULTRASOUND; LONG TERM IMMOBILIZATION; FOCAL ADHESION
   KINASE; NF KAPPA B; MINERAL DENSITY; CYCLOOXYGENASE 2 EXPRESSION;
   SIGNALING PATHWAYS; AKT PATHWAY; OSTEOBLASTS; OSTEOPOROSIS
AB Disuse osteopenia and bone loss have been extensively reported in long duration space mission and long term bed rest. The pathology of the bone loss is similar to osteoporosis but highly confined to weight bearing bones. The current anabolic and/or anti resorptive drugs have systemic effects and are costly over extended time, with concerns of long term fracture risk. This study use Low Intensity Pulsed Ultrasound (LIPUS) as a non invasive acoustic force and anabolic stimulus to countermeasure disuse induced bone loss. Four month old C57BL/6 mice were randomized into five groups, 1) age matched (AM), 2) non suspended sham (NS), 3) non suspended LIPUS (NU), 4) suspended sham (SS), and 5) suspended LIPUS (SU) groups. After four weeks of suspension, mu CT analyses showed significant decreases in trabecular bone volume fraction (BV/TV) ( 36%, p < 0.005), bone tissue mineral density (TMD) ( 3%, p < 0.05),trabecular thickness (Tb.Th) ( 12.5%, p < 0.005), and increase in bone surface/bone volume (+BS/BV) (+16%, p < 0.005), relative to age matched (AM). The application of LIPUS for 20 min/day for 5 days/week, significantly increased TMD (+3%, p < 0.05), Tb.Th (+ 6%, p < 0.05), and decreased BS/BV ( 10%, p < 0.005), relative to suspension alone (SS) mice. Histomorphometry analyses showed a breakdown of bone microstructure under disuse conditions consist with mu CT results. In comparison to SS mice, LIPUS treated bone showed increased structural. integrity with increased bone formation rates at metaphysical endosteal and trabecular surfaces (+0.164, +/  0.07 vs 0.031 0.30 mu m(3)/mu m(2)/day) relative to SS. Four point bending mechanical tests of disused SS femurs showed reduced elastic modulus ( 53%, p < 0.05), yield ( 33%, p < 0.05) and ultimate strength ( 45%, p < 0.05) at the femoral diaphysis relative to AM bone. LIPUS stimulation mitigated the adverse effects of disuse on bone elastic modulus (+42%, p < 0.05), yield strength (+29%, p < 0.05), and ultimate strength (+39%, p < 0.05) relative to SS femurs. LIPUS provides the essential mechanical stimulus to retain bone morphological and mechanical integrity in disuse conditions. This study demonstrates LIPUS potential as regional therapeutic agent to countermeasure disuse induced bone loss while maintaining bone's integrity. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Uddin, Sardar M. Z.; Qin, Yi Xian] SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA.
C3 State University of New York (SUNY) System; Stony Brook University
RP Qin, YX (通讯作者)，SUNY Stony Brook, Dept Biomed Engn, Bioengn Bldg,Rm 215, Stony Brook, NY 11794 USA.
EM yi xian.qin@stonybrook.edu
RI Uddin, Sardar/AAO 9222 2020
FU National Institutes of Health [R01 AR52379, R01 AR61821]; US Army
   Medical Research and Materiel Command [W81 XWH 07 1 0337]; National
   Space Biomedical Research Institute through NASA [NCC 9 58]
FX This research is kindly supported by the National Institutes of Health
   (R01 AR52379 and R01 AR61821), the US Army Medical Research and Materiel
   Command (W81 XWH 07 1 0337), and the National Space Biomedical Research
   Institute through NASA Cooperative Agreement NCC 9 58.
CR Agnusdei D, 1991, Minerva Endocrinol, V16, P73
   Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671
   Baker KG, 2001, PHYS THER, V81, P1351, DOI 10.1093/ptj/81.7.1351
   Boutahar N, 2004, J BIOL CHEM, V279, P30588, DOI 10.1074/jbc.M313244200
   Boyd JL, 2002, J CLIN DENSITOM, V5, P375, DOI 10.1385/JCD:5:4:375
   Broe KE, 2000, OSTEOPOROSIS INT, V11, P765, DOI 10.1007/s001980070055
   Brouwers JEM, 2010, J ORTHOP RES, V28, P62, DOI 10.1002/jor.20951
   BUCKLEY MJ, 1988, BONE MINER, V4, P225
   Carvalho DCL, 2004, ARTIF ORGANS, V28, P114, DOI 10.1111/j.1525 1594.2004.07091.x
   Chow DHK, 2011, J ORTHOP RES, V29, P746, DOI 10.1002/jor.21303
   Cook S D, 2001, Spine J, V1, P246, DOI 10.1016/S1529 9430(01)00086 9
   Cook SD, 1997, CLIN ORTHOP RELAT R, P198
   Ferreri SL, 2011, BONE, V48, P1095, DOI 10.1016/j.bone.2011.01.002
   Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Gross TS, 1997, J BONE MINER RES, V12, P982, DOI 10.1359/jbmr.1997.12.6.982
   GROSS TS, 1992, J BIOMECH, V25, P1081, DOI 10.1016/0021 9290(92)90044 2
   Guignandon A, 2003, CELL COMMUN ADHES, V10, P69, DOI 10.1080/cac.10.2.69.83
   HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623 199401000 00004
   HOCK JM, 1988, ENDOCRINOLOGY, V122, P2899, DOI 10.1210/endo 122 6 2899
   Horan MP, 2005, WILEY ENCY BIOMEDICA
   Hsu HC, 2007, CELL SIGNAL, V19, P2317, DOI 10.1016/j.cellsig.2007.07.006
   Jagodzinski M, 2004, Eur Cell Mater, V7, P35
   JAGODZINSKI M, 2004, EUR CELLS MATER, V7, P41
   Jansen JH, 2006, J ORTHOP RES, V24, P1480, DOI 10.1002/jor.20186
   JAWORSKI ZFG, 1980, J BONE JOINT SURG BR, V62, P104, DOI 10.1302/0301 620X.62B1.6985912
   Jessop HL, 2002, BONE, V31, P186, DOI 10.1016/S8756 3282(02)00797 4
   Jingushi S, 2007, J ORTHOP SCI, V12, P35, DOI 10.1007/s00776 006 1080 3
   Jingushi Seiya, 2009, Clin Calcium, V19, P704, DOI CliCa0905704708
   Kiratli BJ, 2000, J REHABIL RES DEV, V37, P225
   LANYON LE, 1980, J ZOOL, V192, P457
   LEBLANC AD, 1990, J BONE MINER RES, V5, P843
   Lems WF, 2014, CURR OPIN RHEUMATOL, V26, P245, DOI 10.1097/BOR.0000000000000057
   Li JK, 2003, BIOMATERIALS, V24, P2379, DOI 10.1016/S0142 9612(03)00033 4
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Little D G, 2001, Injury, V32 Suppl 4, pSD14
   O'Brien M, 2001, IRISH J MED SCI, V170, P58, DOI 10.1007/BF03167724
   Oppl B, 2014, J BONE MINER RES, V29, P1096, DOI 10.1002/jbmr.2122
   Plotkin LI, 2005, AM J PHYSIOL CELL PH, V289, pC633, DOI 10.1152/ajpcell.00278.2004
   POHL P, 1993, BIOCHIM BIOPHYS ACTA, V1145, P279, DOI 10.1016/0005 2736(93)90300 O
   Rubin C, 2006, AGE AGEING, V35, P32, DOI 10.1093/ageing/afl082
   Saito M, 2004, CALCIFIED TISSUE INT, V75, P384, DOI 10.1007/s00223 004 0292 9
   SIMSKE SJ, 1992, J BIOMECH, V25, P489, DOI 10.1016/0021 9290(92)90089 J
   Takeuchi R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2451
   Tang CH, 2007, J BIOL CHEM, V282, P25406, DOI 10.1074/jbc.M701001200
   Tang CH, 2006, MOL PHARMACOL, V69, P2047, DOI 10.1124/mol.105.022160
   Tang L, 2006, BIOCHEM BIOPH RES CO, V344, P122, DOI 10.1016/j.bbrc.2006.03.123
   Thomsen JS, 2012, CALCIFIED TISSUE INT, V90, P294, DOI 10.1007/s00223 012 9576 7
   UHTHOFF HK, 1978, J BONE JOINT SURG BR, V60, P420, DOI 10.1302/0301 620X.60B3.681422
   Varenna M, 2013, REUMATISMO, V65, P143, DOI 10.4081/reumatismo.2013.143
   Vico L, 2000, LANCET, V355, P1607, DOI 10.1016/S0140 6736(00)02217 0
   Wallace RJ, 2014, J BONE MINER RES, V29, P2697, DOI 10.1002/jbmr.2304
   Warden SJ, 2001, ULTRASOUND MED BIOL, V27, P989, DOI 10.1016/S0301 5629(01)00376 3
   Yang RS, 2005, BONE, V36, P276, DOI 10.1016/j.bone.2004.10.009
   Yoshitake F, 2008, J BIOL CHEM, V283, P11535, DOI 10.1074/jbc.M607999200
NR 55
TC 19
Z9 24
U1 0
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUN
PY 2015
VL 75
BP 8
EP 17
DI 10.1016/j.bone.2015.01.020
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CG1ZQ
UT WOS:000353075100002
PM 25661670
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Li, G
   Li, YB
   Zhang, XH
   Gao, PF
   Xia, X
   Xiao, SQ
   Wen, J
   Guo, T
   Yang, WH
   Li, JD
AF Li, Gen
   Li, Yubao
   Zhang, Xianhui
   Gao, Pengfei
   Xia, Xue
   Xiao, Shiqi
   Wen, Jing
   Guo, Tao
   Yang, Weihu
   Li, Jidong
TI Strontium and simvastatin dual loaded hydroxyapatite microsphere
   reinforced poly(ε caprolactone) scaffolds promote vascularized bone
   regeneration
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID MESENCHYMAL STEM CELLS; IN VIVO; PORE SIZE; ANGIOGENESIS; DELIVERY;
   OSTEOGENESIS; PHOSPHATE; EFFICACY; VITRO; DRUG
AB The promotion of vascular network formation in the early stages of implantation is considered a prerequisite for successful functional bone regeneration. In this study, we successfully constructed 3D printed scaffolds with strong mechanical strength and a controllable pore structure that can sustainably release strontium (Sr) ions and simvastatin (SIM) for up to 28 days by incorporation of Sr2+ and SIM loaded hydroxyapatite microspheres (MHA) into a poly(epsilon caprolactone) (PCL) matrix. In vitro cell experiments showed that Sr doped scaffolds were beneficial to the proliferation and osteogenic differentiation of bone mesenchymal stem cells (BMSCs), an appropriate dose of SIM was beneficial to cell proliferation and angiogenesis, and a high dose of SIM was cytotoxic. The Sr  and SIM dual loaded scaffolds with an appropriate dose significantly induced osteogenic differentiation of BMSCs and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro and promoted vascular network and functional bone formation in vivo. Ribose nucleic acid (RNA) sequencing analysis suggested that the mechanism of promotion of vascularized bone regeneration by fabricated scaffolds is that dual loaded Sr2+ and SIM can upregulate osteogenic and vasculogenic related genes and downregulate osteoclast related genes, which is beneficial for vascular and new bone regeneration. The 3D printed composite scaffolds loaded with high stability and low cost inorganic Sr2+ ions and SIM small molecule drugs hold great promise in the field of promoting vascularized bone regeneration.
C1 [Li, Gen; Li, Yubao; Xia, Xue; Xiao, Shiqi; Wen, Jing; Li, Jidong] Sichuan Univ, Res Ctr Nanobiomat, Analyt & Testing Ctr, Chengdu 610064, Peoples R China.
   [Zhang, Xianhui; Gao, Pengfei; Yang, Weihu] Chongqing Univ, Minist Educ, Coll Bioengn, Key Lab Biorheol Sci & Technol, Chongqing 400044, Peoples R China.
   [Guo, Tao] Guizhou Prov Peoples Hosp, Dept Orthopaed, Guiyang 550002, Peoples R China.
C3 Sichuan University; Chongqing University
RP Li, JD (通讯作者)，Sichuan Univ, Res Ctr Nanobiomat, Analyt & Testing Ctr, Chengdu 610064, Peoples R China.; Yang, WH (通讯作者)，Chongqing Univ, Minist Educ, Coll Bioengn, Key Lab Biorheol Sci & Technol, Chongqing 400044, Peoples R China.
EM yangweihu@cqu.edu.cn; nic1979@scu.edu.cn
RI Gao, pengfei/AAA 3577 2021; Li, Jidong/E 2767 2012
FU National Key Research and Development Program of China [2021YFA1201300];
   NSFC [32171338]; International Science and Technology Innovation
   Cooperation Project of Sichuan [2021YFH0122]; Basic Plan Project of
   Guizhou Science and Technology Department [ZK [2022] Normal 247]
FX This work was supported by the National Key Research and Development
   Program of China (2021YFA1201300), NSFC (32171338), the International
   Science and Technology Innovation Cooperation Project of Sichuan
   (2021YFH0122), and the Basic Plan Project of Guizhou Science and
   Technology Department (ZK [2022] Normal 247). We would like to thank Dr
   Chenghui Li and Dr Li Chen from the Analytical & Testing Center, Sichuan
   University, for their help with CLSM and micro CT analysis,
   respectively.
CR Armiento AR, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201909874
   Bharadwaz A, 2020, MAT SCI ENG C MATER, V110, DOI 10.1016/j.msec.2020.110698
   Boanini E, 2011, J MATER SCI MATER M, V22, P2079, DOI 10.1007/s10856 011 4379 3
   Cheshmedzhieva D, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11111576
   Day RM, 2005, TISSUE ENG, V11, P768, DOI 10.1089/ten.2005.11.768
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Garcia AG, 2018, ACS BIOMATER SCI ENG, V4, P3317, DOI 10.1021/acsbiomaterials.8b00521
   Hao J, 2018, CLIN ORAL IMPLAN RES, V29, P227, DOI 10.1111/clr.13105
   Hassan MN, 2019, ACTA BIOMATER, V91, P1, DOI 10.1016/j.actbio.2019.04.017
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   Huang JH, 2021, COLLOID SURFACE A, V613, DOI 10.1016/j.colsurfa.2020.126117
   Jafari M, 2017, J BIOMED MATER RES B, V105, P431, DOI 10.1002/jbm.b.33547
   Jiang X, 2019, MOL MED REP, V20, P2143, DOI 10.3892/mmr.2019.10468
   Julian M., 2006, J THORAC ONCOL, V1, P7
   Karr LP, 2015, INT J OSTEOARCHAEOL, V25, P201, DOI 10.1002/oa.2275
   Kasten P, 2008, ACTA BIOMATER, V4, P1904, DOI 10.1016/j.actbio.2008.05.017
   Kloss FR, 2018, CLIN ORAL IMPLAN RES, V29, P1163, DOI 10.1111/clr.13380
   Lee JH, 2017, ACTA BIOMATER, V60, P93, DOI 10.1016/j.actbio.2017.07.021
   Li CX, 2014, ADV MATER, V26, P3207, DOI 10.1002/adma.201306198
   Li C, 2019, J CELL PHYSIOL, V234, P22365, DOI 10.1002/jcp.28802
   Li G, 2021, MATER LETT, V300, DOI 10.1016/j.matlet.2021.130234
   Liu LJ, 2020, J POLYM RES, V27, DOI 10.1007/s10965 020 02046 z
   Liu XN, 2013, COLLOID SURFACE B, V102, P420, DOI 10.1016/j.colsurfb.2012.06.037
   Liu YS, 2014, BIOMATERIALS, V35, P4489, DOI 10.1016/j.biomaterials.2014.02.025
   Lo KWH, 2012, REGEN MED, V7, P535, DOI [10.2217/rme.12.33, 10.2217/RME.12.33]
   Magni P, 2015, EUR J INTERN MED, V26, P82, DOI 10.1016/j.ejim.2015.01.002
   Malikmammadov E, 2018, J BIOMAT SCI POLYM E, V29, P863, DOI 10.1080/09205063.2017.1394711
   Nasr HF, 1999, PERIODONTOL 2000, V19, P74, DOI 10.1111/j.1600 0757.1999.tb00148.x
   Niu JL, 2016, CORROS SCI, V113, P183, DOI 10.1016/j.corsci.2016.10.009
   O'Neill E, 2018, DRUG DISCOV TODAY, V23, P879, DOI 10.1016/j.drudis.2018.01.049
   Oryan A, 2015, J CONTROL RELEASE, V215, P12, DOI 10.1016/j.jconrel.2015.07.022
   Prasadam I, 2014, MOL CELL BIOCHEM, V386, P15, DOI 10.1007/s11010 013 1840 2
   Qi C, 2013, CHEM EUR J, V19, P5332, DOI 10.1002/chem.201203886
   Rather HA, 2020, BIOMED MATER, V15, DOI 10.1088/1748 605X/ab7978
   Ray S, 2018, BIOMATERIALS, V157, P1, DOI 10.1016/j.biomaterials.2017.11.049
   Silva AS, 2020, BIOMATERIALS, V231, DOI 10.1016/j.biomaterials.2019.119664
   Subbiah R, 2015, ADV HEALTHC MATER, V4, P1982, DOI 10.1002/adhm.201500341
   Troeltzsch M, 2016, J CRANIO MAXILL SURG, V44, P1618, DOI 10.1016/j.jcms.2016.07.028
   Tuerlings M, 2021, ARTHRITIS RHEUMATOL, V73, P789, DOI 10.1002/art.41600
   Venkatesan N, 2019, ACTA BIOMATER, V93, P192, DOI 10.1016/j.actbio.2019.04.059
   Wang C, 2021, BIOACT MATER, V6, P137, DOI 10.1016/j.bioactmat.2020.07.007
   Wang DF, 2019, ACS APPL MATER INTER, V11, P32533, DOI 10.1021/acsami.9b10621
   Wang S, 2017, OSTEOARTHR CARTILAGE, V25, P742, DOI 10.1016/j.joca.2016.10.017
   Wang YJ, 2016, CELL BIOSCI, V6, DOI 10.1186/s13578 016 0119 1
   Wei PF, 2019, ACS APPL MATER INTER, V11, P30596, DOI 10.1021/acsami.9b10219
   Wu T, 2020, BIOACT MATER, V5, P348, DOI 10.1016/j.bioactmat.2020.03.004
   Xiao Q, 2021, DIABETOL METAB SYNDR, V13, DOI 10.1186/s13098 021 00769 7
   Xing HL, 2020, BIOMATERIALS, V235, DOI 10.1016/j.biomaterials.2020.119784
   Yang XY, 2020, J MATER SCI MATER M, V31, DOI 10.1007/s10856 020 06385 7
   Yin Y, 2020, APPL MATER TODAY, V18, DOI 10.1016/j.apmt.2019.100466
   Yu WL, 2017, SCI REP UK, V7, DOI 10.1038/srep44129
   Zhang CY, 2020, BIOMATERIALS, V237, DOI 10.1016/j.biomaterials.2020.119835
   Zhang YQ, 2012, MOL BIOL REP, V39, P285, DOI 10.1007/s11033 011 0737 y
   Zhao FJ, 2018, BIOMATERIALS, V178, P36, DOI 10.1016/j.biomaterials.2018.06.004
   Zhao HX, 2018, MATER LETT, V223, P21, DOI 10.1016/j.matlet.2018.03.205
   Zhao R, 2020, THERANOSTICS, V10, P1572, DOI 10.7150/thno.40103
   Zhou YS, 2010, BIOMATERIALS, V31, P5325, DOI 10.1016/j.biomaterials.2010.03.037
NR 57
TC 17
Z9 17
U1 6
U2 54
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PD FEB 1
PY 2023
VL 11
IS 5
BP 1115
EP 1130
DI 10.1039/d2tb02309a
EA DEC 2022
PG 16
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 8C6UV
UT WOS:000912796900001
PM 36636931
DA 2025 08 17
ER

PT J
AU Moe, SM
   Chertow, GM
   Coburn, JW
   Quarles, LD
   Goodman, WG
   Block, GA
   Drüeke, TB
   Cunningham, J
   Sherrard, DJ
   McCary, LC
   Olson, KA
   Turner, SA
   Martin, KJ
AF Moe, SM
   Chertow, GM
   Coburn, JW
   Quarles, LD
   Goodman, WG
   Block, GA
   Drüeke, TB
   Cunningham, J
   Sherrard, DJ
   McCary, LC
   Olson, KA
   Turner, SA
   Martin, KJ
TI Achieving NKF K/DOQI™ bone metabolism and disease treatment goals with
   cinacalcet HCl
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE calcimimetic; cinacalcet HCl; NKF K/DOQI guidelines; secondary
   hyperparathyroidism (HPT); chronic kidney disease (CKD); dialysis
ID INTRAVENOUS CALCITRIOL TREATMENT; INTACT PARATHYROID HORMONE; SECONDARY
   HYPERPARATHYROIDISM; PHOSPHORUS RESTRICTION; HEMODIALYSIS PATIENTS;
   CALCIMIMETIC AMG 073; DIALYSIS PATIENTS; MORTALITY RISK; RENAL FAILURE;
   CALCIUM
AB Background. The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF K/DOQI(TM)) has established guidelines for treatment of secondary hyperparathyroidism (HPT). The ability of cinacalcet HCl (Sensipar(TM)) treatment to improve achievement of target levels of parathyroid hormone (PTH), calcium, phosphorus, and calcium phosphorus product (Ca x P) was investigated in subjects on dialysis with secondary HPT.
   Methods. Data were combined from three placebo controlled, double blind, 26 week studies with similar design that randomized 1136 subjects on dialysis to receive traditional therapy plus cinacalcet or placebo. Oral cinacalcet was titrated from 30 to 180 mg/day. Achievement of K/DOQI goals was determined for each treatment group overall and for subgroups defined by baseline intact PTH (iPTH) and Ca x P levels.
   Results. Cinacalcet treated subjects were more likely to achieve a mean iPTH less than or equal to300 pg/mL (31.8 pmol/L) than were control subjects on traditional therapy (56% vs. 10%, P < 0.001). Cinacalcet treated subjects were more likely to achieve concentrations of serum calcium within 8.4 to 9.5 mg/dL (2.10 2.37 mmol/L) and serum phosphorus within 3.5 to 5.5 mg/dL (1.13 1.78 mmol/L) than were control subjects (49% vs. 24% and 46% vs. 33%, P < 0.001 for each). Cinacalcet also improved achievement of Ca x P < 55 mg(2)/dL(2) (4.44 mmol(2)/L 2) and concurrent achievement of Ca x P < 55 mg(2)/dL(2) (4.44 mmol(2)/L 2) and iPTH less than or equal to300 pg/mL (31.8 pmol/L) (65% vs. 36% and 41% vs. 6%, P < 0.001 for each).
   Conclusion. In subjects on dialysis with secondary HPT, cinacalcet facilitates achievement of the K/DOQI recommended targets for PTH, calcium, phosphorus, and Ca x P.
C1 Indiana Univ, Sch Med, Indianapolis, IN 46202 USA.
   Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
   VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA.
   Duke Univ, Med Ctr, Durham, NC USA.
   Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
   Denver Nephrol, Denver, CO USA.
   Hop Necker Enfants Malad, Paris, France.
   UCL Hosp, London, England.
   Univ Washington, Seattle, WA 98195 USA.
   VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
   Amgen Inc, Thousand Oaks, CA 91320 USA.
   St Louis Univ, St Louis, MO 63103 USA.
C3 Indiana University System; Indiana University Indianapolis; University
   of California System; University of California San Francisco; US
   Department of Veterans Affairs; Veterans Health Administration (VHA); VA
   Greater Los Angeles Healthcare System; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; David Geffen School of Medicine at UCLA; Duke
   University; University of California System; University of California
   Los Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA; Assistance Publique Hopitaux Paris
   (APHP); Universite Paris Cite; Hopital Universitaire Necker Enfants
   Malades   APHP; University of London; University College London;
   University College London Hospitals NHS Foundation Trust; University of
   Washington; University of Washington Seattle; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound
   Health Care System; Amgen; Saint Louis University
RP Indiana Univ, Sch Med, 1001 W 10th St,OPW 526, Indianapolis, IN 46202 USA.
EM smoe@iupui.edu
RI ; Block, Geoffrey/AAV 8070 2021
OI Chertow, Glenn/0000 0002 7599 0534; Quarles, L.
   Darryl/0000 0002 5082 7896; 
CR ANDRESS DL, 1989, NEW ENGL J MED, V321, P274, DOI 10.1056/NEJM198908033210502
   APARICIO M, 1993, NEPHRON, V63, P122, DOI 10.1159/000187162
   Block G, 2003, SEMIN DIALYSIS, V16, P140, DOI 10.1046/j.1525 139X.2003.160301.x
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 2000, AM J KIDNEY DIS, V35, P1226, DOI 10.1016/S0272 6386(00)70064 3
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   FEINFELD DA, 1988, KIDNEY INT, V33, P1049, DOI 10.1038/ki.1988.110
   GALLIENI M, 1992, KIDNEY INT, V42, P1191, DOI 10.1038/ki.1992.404
   Gallieni M, 2000, CLIN NEPHROL, V53, P188
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   GINSBURG DS, 1973, LANCET, V1, P1271
   GONELLA M, 1985, CLIN NEPHROL, V24, P147
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   Goodman WG, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341017
   Henderson J, 2003, NEPHRON CLIN PRACT, V94, pC53, DOI 10.1159/000072021
   HUTCHISON AJ, 1993, KIDNEY INT, V44, P1071, DOI 10.1038/ki.1993.350
   KURITZ SJ, 1988, ANNU REV PUBL HEALTH, V9, P123, DOI 10.1146/annurev.pu.09.050188.001011
   Lindberg JS, 2003, KIDNEY INT, V63, P248, DOI 10.1046/j.1523 1755.2003.00720.x
   MALLUCHE H, 1990, KIDNEY INT, V38, P193, DOI 10.1038/ki.1990.187
   Martin KJ, 1998, J AM SOC NEPHROL, V9, P1427
   Martinez I, 1997, AM J KIDNEY DIS, V29, P496, DOI 10.1016/S0272 6386(97)90330 9
   Moe SM, 2003, AM J NEPHROL, V23, P369, DOI 10.1159/000073945
   Pasieka JL, 2000, SURGERY, V128, P531, DOI 10.1067/msy.2000.108117
   QUARLES LD, 1994, KIDNEY INT, V45, P1710, DOI 10.1038/ki.1994.223
   QUARLES LD, 1992, J CLIN ENDOCR METAB, V75, P145, DOI 10.1210/jc.75.1.145
   Quarles LD, 2003, J AM SOC NEPHROL, V14, P575, DOI 10.1097/01.ASN.0000050224.03126.AD
   Salusky IB, 1998, KIDNEY INT, V54, P907, DOI 10.1046/j.1523 1755.1998.00045.x
   SHERRARD DJ, 1993, KIDNEY INT, V43, P436, DOI 10.1038/ki.1993.64
   SLATOPOLSKY E, 1973, KIDNEY INT, V4, P141, DOI 10.1038/ki.1973.92
   Sprague SM, 2003, KIDNEY INT, V63, P1483, DOI 10.1046/j.1523 1755.2003.00878.x
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
NR 32
TC 246
Z9 261
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0085 2538
EI 1523 1755
J9 KIDNEY INT
JI Kidney Int.
PD FEB
PY 2005
VL 67
IS 2
BP 760
EP 771
DI 10.1111/j.1523 1755.2005.67139.x
PG 12
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 889CH
UT WOS:000226420600041
PM 15673327
OA Bronze
DA 2025 08 17
ER

PT J
AU Sukegawa, S
   Kanno, T
   Kawai, H
   Nakamura, S
   Shibata, A
   Sukegawa Takahashi, Y
   Nagatsuka, H
   Furuki, Y
AF Sukegawa, Shintaro
   Kanno, Takahiro
   Kawai, Hotaka
   Nakamura, Satoko
   Shibata, Akane
   Sukegawa Takahashi, Yuka
   Nagatsuka, Hitoshi
   Furuki, Yoshihiko
TI A Clinical Retrospective Study of Surgical Treatment for
   Medication Related Osteonecrosis of the Jaw
SO JOURNAL OF HARD TISSUE BIOLOGY
LA English
DT Article
DE Medication related osteonecrosis of the jaw; Drug holiday; Sequestrum
ID BISPHOSPHONATE RELATED OSTEONECROSIS; CANCER PATIENTS; AVASCULAR
   NECROSIS; RISK FACTORS; IN VITRO; DENOSUMAB; PROTOCOL; THERAPY
AB In 2014, the American Association of Oral and Maxillofacial Surgery recommended surgical treatment for medication related osteonecrosis of the jaw (MRONJ) patients classified as stage 3 or those with mobile segments of bony sequestrum. However, there is limited information regarding the healing mechanism in MRONJ surgical treatments. This study aimed to retrospectively elucidate clinical outcomes of the surgical treatment of MRONJ patients. This study included 26 patients (7 men, 19 women; age: 42 92 years; mean standard deviation, 75.3 +/  11.7 years) who were classified as stage 3 or had mobile segments of bony sequestrum, and intake of the offending drug was ceased. The sequestrum was removed with surrounding vital bone, and segmental resection was performed in one patient with a pathological mandibular fracture. The outcome was classified into one of the following three categories: "Healing," "Improvement," "Unchanged." and "Exacerbation." The mean postoperative follow up period was 16.6 months (3.0 57.9 months), and complete healing was observed in 21 patients (80.8%), improvement of the lesion was observed in four patients (15.4%), and the outcome of one patient was unchanged (3.8%). The procedure described here may be recommended with relatively high clinical success rate for the patients with MRONJ requiring surgical treatment.
C1 [Sukegawa, Shintaro; Shibata, Akane; Sukegawa Takahashi, Yuka; Furuki, Yoshihiko] Kagawa Prefectural Cent Hosp, Div Oral & Maxillofacial Surg, 1 2 1 Asahi Cho, Takamatsu, Kagawa 7608557, Japan.
   [Kanno, Takahiro] Shimane Univ, Fac Med, Dept Oral & Maxillofacial Surg, Matsue, Shimane, Japan.
   [Kawai, Hotaka; Nagatsuka, Hitoshi] Okayama Univ, Dept Oral Pathol & Med, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan.
   [Nakamura, Satoko] Kagawa Prefectural Cent Hosp, Div Pathol, Takamatsu, Kagawa, Japan.
C3 Shimane University; Okayama University
RP Sukegawa, S (通讯作者)，Kagawa Prefectural Cent Hosp, Div Oral & Maxillofacial Surg, 1 2 1 Asahi Cho, Takamatsu, Kagawa 7608557, Japan.
EM gouwan19@gmail.com
RI ; Sukegawa, Shintaro/AAI 2176 2019
OI Sukegawa, Shintaro/0000 0001 7986 2735; 
CR Abu Id MH, 2008, J CRANIO MAXILL SURG, V36, P95, DOI 10.1016/j.jcms.2007.06.008
   Aghaloo TL, 2010, J ORAL MAXIL SURG, V68, P959, DOI 10.1016/j.joms.2009.10.010
   Agrillo A, 2006, J CRANIOFAC SURG, V17, P1080, DOI 10.1097/01.scs.0000249350.59096.d0
   Arce K, 2009, J ORAL MAXIL SURG, V67, P75, DOI 10.1016/j.joms.2008.12.002
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Berenson JR, 1999, ANNU REV MED, V50, P237
   Coleman R, 2011, BREAST CANCER RES TR, V127, P429, DOI 10.1007/s10549 011 1429 y
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lazarovici TS, 2009, J ORAL MAXIL SURG, V67, P850, DOI 10.1016/j.joms.2008.11.015
   Lemound J, 2012, CLIN ORAL INVEST, V16, P1143, DOI 10.1007/s00784 011 0596 x
   Markose G, 2009, BRIT J ORAL MAX SURG, V47, P294, DOI 10.1016/j.bjoms.2009.01.007
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mauri D, 2009, BREAST CANCER RES TR, V116, P433, DOI 10.1007/s10549 009 0432 z
   Ohbayashi Y, 2013, ORAL SURG ORAL MED O, V115, P31
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Pautke C, 2011, J ORAL MAXIL SURG, V69, P84, DOI 10.1016/j.joms.2010.07.014
   Qi WX, 2014, INT J CLIN ONCOL, V19, P403, DOI 10.1007/s10147 013 0561 6
   Reich W, 2015, J CRANIO MAXILL SURG, V43, P1809, DOI 10.1016/j.jcms.2015.07.035
   Reszka Alfred A, 2003, Curr Osteoporos Rep, V1, P45, DOI 10.1007/s11914 003 0008 5
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Stopeck A, 2009, EJC SUPPL, V7, P2, DOI 10.1016/S1359 6349(09)72028 2
   Sukegawa S, 2016, J ORAL MAX SURG MED, V28, P255, DOI 10.1016/j.ajoms.2015.10.001
   Taylor KH, 2010, BRIT J ORAL MAX SURG, V48, P221, DOI 10.1016/j.bjoms.2009.08.030
   Voss PJ, 2012, J CRANIO MAXILL SURG, V40, P719, DOI 10.1016/j.jcms.2012.01.005
   Walter C, 2011, ORAL DIS, V17, P194, DOI 10.1111/j.1601 0825.2010.01720.x
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
NR 30
TC 7
Z9 7
U1 1
U2 12
PU JOURNAL HARD TISSUE BIOLOGY
PI MINATO KU
PA NIHON GAKUKUTSU KYORYOKU ZAIDAN, 3  24  20, NISHIAZABU, MINATO KU, TOKYO
   106 0031, JAPAN
SN 1341 7649
J9 J HARD TISSUE BIOL
JI J. Hard Tissue Biol.
PD OCT
PY 2016
VL 25
IS 4
BP 447
EP 454
DI 10.2485/jhtb.25.447
PG 8
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA DY4GH
UT WOS:000385056500016
OA Bronze
DA 2025 08 17
ER

PT J
AU Crawford, LJ
   Anderson, G
   Johnston, CK
   Irvine, AE
AF Crawford, Lisa J.
   Anderson, Gordon
   Johnston, Cliona K.
   Irvine, Alexandra E.
TI Identification of the APC/C co factor FZR1 as a novel therapeutic target
   for multiple myeloma
SO ONCOTARGET
LA English
DT Article
DE multiple myeloma; ubiquitin proteasome system; APC/C; FZR1; proTAME
ID ANAPHASE PROMOTING COMPLEX; SMALL MOLECULE INHIBITOR; CELL DEATH;
   MITOTIC EXIT; OSTEOBLAST FUNCTION; DRUG RESISTANCE; APOPTOSIS;
   EXPRESSION; LEUKEMIA; ARREST
AB Multiple Myeloma (MM) is a haematological neoplasm characterised by the clonal proliferation of malignant plasma cells in the bone marrow. The success of proteasome inhibitors in the treatment of MM has highlighted the importance of the ubiquitin proteasome system (UPS) in the pathogenesis of this disease. In this study, we analysed gene expression of UPS components to identify novel therapeutic targets within this pathway in MM. Here we demonstrate how this approach identified previously validated and novel therapeutic targets. In addition we show that FZR1 (Fzr), a cofactor of the multi subunit E3 ligase complex anaphase promoting complex/ cyclosome (APC/C), represents a novel therapeutic target in myeloma. The APC/C associates independently with two cofactors, Fzr and Cdc20, to control cell cycle progression. We found high levels of FZR1 in MM primary cells and cell lines and demonstrate that expression is further increased on adhesion to bone marrow stromal cells (BMSCs). Specific knockdown of either FZR1 or CDC20 reduced viability and induced growth arrest of MM cell lines, and resulted in accumulation of APC/C Fzr substrate Topoisomerase IIa (TOPIIa) or APC/C Cdc20 substrate Cyclin B. Similar effects were observed following treatment with proTAME, an inhibitor of both APC/C Fzr and APC/C Cdc20. Combinations of proTAME with topoisomerase inhibitors, etoposide and doxorubicin, significantly increased cell death in MM cell lines and primary cells, particularly if TOPIIa levels were first increased through pre treatment with proTAME. Similarly, combinations of proTAME with the microtubule inhibitor vincristine resulted in enhanced cell death. This study demonstrates the potential of targeting the APC/C and its cofactors as a therapeutic approach in MM.
C1 [Crawford, Lisa J.; Anderson, Gordon; Johnston, Cliona K.; Irvine, Alexandra E.] Queens Univ Belfast, Ctr Canc Res & Cell Biol CCRCB, Belfast, Antrim, North Ireland.
C3 Queens University Belfast
RP Irvine, AE (通讯作者)，Queens Univ Belfast, Ctr Canc Res & Cell Biol CCRCB, Belfast, Antrim, North Ireland.
EM s.irvine@qub.ac.uk
RI IRVINE, ALEXANDRA/B 3497 2009
OI Crawford, Lisa/0000 0001 5162 1809
FU Belfast Health and Social Care Trust; Leukaemia Lymphoma NI; Haematology
   Association of Ireland; Leukaemia & Lymphoma NI [R2031HAE, R2783CNR,
   R2029HAE, R2054CNR, R2043HAE] Funding Source: researchfish
FX This work was supported by grants from Belfast Health and Social Care
   Trust, Leukaemia & Lymphoma NI and Haematology Association of Ireland.
CR Accardi F, 2015, BIOMED RES INT UK, V2015, DOI 10.1155/2015/172458
   [Anonymous], ONCOTARGET
   Bailey CK, 2015, CANCER BIOL THER, V16, P1422, DOI 10.1080/15384047.2015.1071743
   Bories C, 2014, CL LYMPH MYELOM LEUK, V14, pS78, DOI 10.1016/j.clml.2014.05.004
   Broyl A, 2010, BLOOD, V116, P2543, DOI 10.1182/blood 2009 12 261032
   Cavaletti G, 2010, LEUKEMIA LYMPHOMA, V51, P1178, DOI 10.3109/10428194.2010.483303
   Chang LF, 2014, CURR OPIN STRUC BIOL, V29, P1, DOI 10.1016/j.sbi.2014.08.003
   Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007
   Chng WJ, 2007, CANCER RES, V67, P2982, DOI 10.1158/0008 5472.CAN 06 4046
   Crawford LJ, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.3
   Crawford LJ, 2013, BLOOD REV, V27, P297, DOI 10.1016/j.blre.2013.10.002
   Du HF, 2013, LEUKEMIA LYMPHOMA, V54, P607, DOI 10.3109/10428194.2012.720371
   Eguren M, 2014, CELL REP, V6, P670, DOI 10.1016/j.celrep.2014.01.017
   Eguren M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3880
   Feng YD, 2010, STEM CELLS DEV, V19, P1289, DOI 10.1089/scd.2010.0010
   García Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742
   Gu DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103015
   Gutiérrez NC, 2007, LEUKEMIA, V21, P541, DOI 10.1038/sj.leu.2404520
   Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782
   Herndon TM, 2013, CLIN CANCER RES, V19, P4559, DOI 10.1158/1078 0432.CCR 13 0755
   Huang HC, 2009, CANCER CELL, V16, P347, DOI 10.1016/j.ccr.2009.08.020
   Kim JA, 2013, J BIOL CHEM, V288, P28713, DOI 10.1074/jbc.M113.488346
   Kraus M, 2007, LEUKEMIA, V21, P84, DOI 10.1038/sj.leu.2404414
   Le Ray E, 2016, EXPERT REV HEMATOL, V9, P91, DOI 10.1586/17474086.2016.1119041
   Liu YB, 2015, FASEB J, V29, P4829, DOI 10.1096/fj.15 274050
   Lub S, 2016, ONCOTARGET, V7, P1
   Lwin T, 2007, BLOOD, V110, P1631, DOI 10.1182/blood 2006 11 060350
   Manchado E, 2010, CANCER CELL, V18, P641, DOI 10.1016/j.ccr.2010.10.028
   McMillin DW, 2012, MOL CANCER THER, V11, P942, DOI 10.1158/1535 7163.MCT 11 0563
   Moreau Philippe, 2015, Am Soc Clin Oncol Educ Book, pe504, DOI 10.14694/EdBook_AM.2015.35.e504
   Munshi NC, 2004, BLOOD, V103, P1799, DOI 10.1182/blood 2003 02 0402
   Nefedova Y, 2004, BLOOD, V103, P3503, DOI 10.1182/blood 2003 07 2340
   Niewerth D, 2015, DRUG RESIST UPDATE, V18, P18, DOI 10.1016/j.drup.2014.12.001
   Nooka AK, 2015, BLOOD, V125, P3085, DOI 10.1182/blood 2014 11 568923
   Roodman GD, 2011, BONE, V48, P135, DOI 10.1016/j.bone.2010.06.016
   Sackton KL, 2014, NATURE, V514, P646, DOI 10.1038/nature13660
   Sagawa M, 2008, CANCER SCI, V99, P1820, DOI 10.1111/j.1349 7006.2008.00872.x
   Saha MN, 2010, CANCER BIOL THER, V10, P567, DOI 10.4161/cbt.10.6.12535
   Shah JJ, 2016, CLIN CANCER RES, V22, P34, DOI 10.1158/1078 0432.CCR 15 1237
   Sigl R, 2009, J CELL SCI, V122, P4208, DOI 10.1242/jcs.054197
   Smolders L, 2011, EXPERT OPIN THER TAR, V15, P767, DOI 10.1517/14728222.2011.558008
   Tian Z, 2014, BLOOD, V123, P706, DOI 10.1182/blood 2013 05 500033
   Wan LX, 2014, DEV CELL, V29, P377, DOI 10.1016/j.devcel.2014.04.022
   Wan LX, 2011, MOL CELL, V44, P721, DOI 10.1016/j.molcel.2011.09.024
   Wang LX, 2015, PHARMACOL THERAPEUT, V151, P141, DOI 10.1016/j.pharmthera.2015.04.002
   Zeng X, 2010, CANCER CELL, V18, P382, DOI 10.1016/j.ccr.2010.08.010
   Zhang L, 2013, CANCER LETT, V339, P49, DOI 10.1016/j.canlet.2013.07.023
NR 47
TC 22
Z9 24
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 25
PY 2016
VL 7
IS 43
BP 70481
EP 70493
DI 10.18632/oncotarget.12026
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA EB5VI
UT WOS:000387448300106
PM 27655696
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Morelli, KM
   Brown, LB
   Warren, GL
AF Morelli, Kimberly M.
   Brown, Laura B.
   Warren, Gordon L.
TI Effect of NSAIDs on Recovery From Acute Skeletal Muscle Injury A
   Systematic Review and Meta analysis
SO AMERICAN JOURNAL OF SPORTS MEDICINE
LA English
DT Article
DE nonsteroidal anti inflammatory drug; soreness; strength; creatine kinase
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PUBLICATION BIAS; LENGTHENING
   CONTRACTIONS; COX 2 PATHWAY; IBUPROFEN USE; EXERCISE; SORENESS; ONSET;
   PERFORMANCE; DAMAGE
AB Background: There is debate as to whether the use of nonsteroidal anti inflammatory drugs (NSAIDs) is beneficial after acute skeletal muscle injury. Some studies have suggested that NSAID use may be detrimental to injured muscle.
   Purpose: To determine whether NSAID use affects recovery from skeletal muscle injury as assessed by strength loss, soreness, and/or blood creatine kinase level.
   Study Design: Systematic review and meta analysis.
   Methods: An extensive systematic review was completed searching 16 databases (eg, PubMed, Cochrane Library, EMBASE). Inclusion criteria were (1) acute injury to skeletal muscle, (2) use of a control condition, (3) certainty of the NSAID dose administered, and (4) use of 1 or more of the 3 desired outcome measures. A total of 5343 study reports were screened, of which 41 studies were deemed suitable for inclusion. The standardized mean difference was used as the effect size (ES) and was calculated such that a positive ES indicated NSAID efficacy. Meta analyses were run using a random effects model.
   Results: For all studies, time points after injury, and injury markers combined, NSAID use was found to elicit a small to medium, significant decrease in the markers of injury (overall ES = +0.34; P = .0001). Because heterogeneity in study ES was apparent (ie, Q df = 52.4, P = .000005; I 2 = 57%), subgroup meta analyses and meta regressions were run in an attempt to explain the heterogeneity. In human studies, study ESs were higher when lower body muscles were injured (P = .045). In animal studies, study ESs were lower with longer NSAID administration durations (P = .023) and at longer follow up times after injury (P = .010).
   Conclusion: Overall, our analysis supports NSAID use for reducing strength loss, soreness, and blood creatine kinase level after an acute muscle injury, at least for humans and in the short term. Additional research is required to determine why NSAID use appears to be more effective when lower body muscles in humans are injured. It would also be important to determine why NSAID use appears detrimental at later times after injury in animals but not humans.
C1 [Morelli, Kimberly M.; Brown, Laura B.; Warren, Gordon L.] Georgia State Univ, Atlanta, GA 30303 USA.
   [Morelli, Kimberly M.; Brown, Laura B.; Warren, Gordon L.] Georgia State Univ, Dept Phys Therapy, POB 4019, Atlanta, GA 30302 USA.
C3 University System of Georgia; Georgia State University; University
   System of Georgia; Georgia State University
RP Morelli, KM (通讯作者)，Georgia State Univ, Dept Phys Therapy, POB 4019, Atlanta, GA 30302 USA.
EM kmorelli@gsu.edu
RI Warren, Gordon/A 9794 2008
OI Warren, Gordon/0000 0002 7073 8524
CR [Anonymous], AHRQ PUBLICATION
   [Anonymous], PUBLICATION BIAS
   [Anonymous], 2004, INT SPORTMED J
   [Anonymous], THESIS
   [Anonymous], 1995, SPORTS MED TRAIN REH
   [Anonymous], BR J SPORTS MED
   [Anonymous], THESIS
   [Anonymous], THESIS
   [Anonymous], SKELETAL MUSCLE DAMA
   ARMSTRONG RB, 1991, SPORTS MED, V12, P184, DOI 10.2165/00007256 199112030 00004
   Baldwin AC, 2001, J GERONTOL A BIOL, V56, pM510, DOI 10.1093/gerona/56.8.M510
   Barlas P, 2000, ARCH PHYS MED REHAB, V81, P966, DOI 10.1053/apmr.2000.6277
   Bondesen BA, 2006, AM J PHYSIOL CELL PH, V290, pC1651, DOI 10.1152/ajpcell.00518.2005
   Bondesen BA, 2004, AM J PHYSIOL CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004
   Borenstein M, 2009, Introduction to meta analysis, P421
   Bourgeois J, 1999, MED SCI SPORT EXER, V31, P4, DOI 10.1097/00005768 199901000 00002
   Brickson S, 2003, J APPL PHYSIOL, V95, P969, DOI 10.1152/japplphysiol.00005.2003
   Cohen J., 2013, Statistical Power Analysis for the Behavioral Sciences, V2nd, DOI DOI 10.4324/9780203771587
   Croisier JL, 1996, MEDIAT INFLAMM, V5, P230, DOI 10.1155/S0962935196000336
   Cryer B, 2005, AM J GASTROENTEROL, V100, P1694, DOI 10.1111/j.1572 0241.2005.50565.x
   De Carli A, 2009, ADV THER, V26, P1072, DOI 10.1007/s12325 009 0086 6
   Donnelly A E, 1990, Br J Sports Med, V24, P191
   Donnelly A E, 1988, Br J Sports Med, V22, P35
   Dudley GA, 1997, CLIN J SPORT MED, V7, P3, DOI 10.1097/00042752 199701000 00002
   FAULKNER JA, 1993, PHYS THER, V73, P911, DOI 10.1093/ptj/73.12.911
   FRANCIS KT, 1987, J SPORT MED PHYS FIT, V27, P333
   Gehrig SM, 2011, EXPERT OPIN EMERG DR, V16, P163, DOI 10.1517/14728214.2010.524743
   Grossman JM., 1995, J Sport Rehabil, V4, P253, DOI DOI 10.1123/JSR.4.4.253
   Hall R, 2007, CAN J ANAESTH, V54, P380, DOI 10.1007/BF03022661
   HASSON SM, 1993, MED SCI SPORT EXER, V25, P9, DOI 10.1249/00005768 199301000 00003
   Higgins JP., 2011, BMJ, V343, pd5928, DOI DOI 10.1136/BMJ.D5928
   Hopewell S, 2005, PUBLICATION BIAS IN META ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P49, DOI 10.1002/0470870168.ch4
   Hopewell S, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000006.pub3
   Howell JN, 1998, J MUSCULOSKELET PAIN, V6, P59, DOI 10.1300/J094v06n04_06
   Howell JN, 1998, J MUSCULOSKELET PAIN, V6, P69, DOI 10.1300/J094v06n04_07
   KELLETT J, 1986, MED SCI SPORT EXER, V18, P489
   Kraemer WJ, 2002, J SPORT REHABIL, V11, P104, DOI 10.1123/jsr.11.2.104
   KUIPERS H, 1985, INT J SPORTS MED, V6, P336, DOI 10.1055/s 2008 1025866
   Kyzas PA, 2005, JNCI J NATL CANCER I, V97, P1043, DOI 10.1093/jnci/dji184
   Lanier AB, 2003, SPORTS MED, V33, P177
   Lapointe BM, 2003, ARCH PHYS MED REHAB, V84, P651, DOI 10.1016/S0003 9993(03)04899 2
   Lapointe BM, 2002, J APPL PHYSIOL, V92, P1995, DOI 10.1152/japplphysiol.00803.2001
   Lapointe BM, 2002, AM J PHYSIOL REG I, V282, pR323, DOI 10.1152/ajpregu.00339.2001
   Lecomte JM, 1998, CLIN J SPORT MED, V8, P82, DOI 10.1097/00042752 199804000 00003
   Mackey AL, 2007, J APPL PHYSIOL, V103, P425, DOI 10.1152/japplphysiol.00157.2007
   Meamarbashi A, 2015, CLIN J SPORT MED, V25, P105, DOI 10.1097/JSM.0000000000000113
   Mehallo CJ, 2006, CLIN J SPORT MED, V16, P170, DOI 10.1097/00042752 200603000 00015
   Mikkelsen UR, 2009, J APPL PHYSIOL, V107, P1600, DOI 10.1152/japplphysiol.00707.2009
   MISHRA DK, 1995, J BONE JOINT SURG AM, V77, P1510, DOI 10.2106/00004623 199510000 00005
   Moher D, 2010, INT J SURG, V8, P336, DOI [10.1371/journal.pmed.1000097, 10.1186/2046 4053 4 1, 10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299, 10.1136/bmj.i4086]
   O'Grady M, 2000, MED SCI SPORT EXER, V32, P1191, DOI 10.1097/00005768 200007000 00001
   OBREMSKY WT, 1994, AM J SPORT MED, V22, P558, DOI 10.1177/036354659402200420
   Otis JS, 2005, EXP CELL RES, V310, P417, DOI 10.1016/j.yexcr.2005.08.009
   Paulsen G, 2010, SCAND J MED SCI SPOR, V20, pE195, DOI 10.1111/j.1600 0838.2009.00947.x
   Peters JL, 2007, STAT MED, V26, P4544, DOI 10.1002/sim.2889
   Pizza FX, 2005, J PHYSIOL LONDON, V562, P899, DOI 10.1113/jphysiol.2004.073965
   Pizza FX, 1999, INT J SPORTS MED, V20, P98, DOI 10.1055/s 2007 971100
   Rahnama N, 2005, J SPORT SCI, V23, P843, DOI 10.1080/02640410400021989
   Ramos L, 2012, PHOTOCHEM PHOTOBIOL, V88, P154, DOI 10.1111/j.1751 1097.2011.01030.x
   REYNOLDS JF, 1995, S AFR MED J, V85, P517
   Rother M, 2009, DRUG DES DEV THER, V3, P143
   Sayers SP, 2001, MED SCI SPORT EXER, V33, P702
   Stone MB, 2002, CLIN J SPORT MED, V12, P373, DOI 10.1097/00042752 200211000 00009
   Svensson Peter, 1997, Journal of Orofacial Pain, V11, P353
   Terrin N, 2003, STAT MED, V22, P2113, DOI 10.1002/sim.1461
   Tokmakidis SP, 2003, J STRENGTH COND RES, V17, P53, DOI 10.1519/00124278 200302000 00009
   Trappe RA, 2002, AM J PHYSIOL ENDOC M, V282, pE551, DOI 10.1152/ajpendo.00352.2001
   VanHeest JL, 2002, J SPORT REHABIL, V11, P224, DOI 10.1123/jsr.11.3.224
   Vignaud A, 2005, EXP PHYSIOL, V90, P487, DOI 10.1113/expphysiol.2005.029835
   Warren GL, 2004, FASEB J, V18, P413, DOI 10.1096/fj.04 2421fje
   Warren GL, 1999, SPORTS MED, V27, P43, DOI 10.2165/00007256 199927010 00004
   Warren GL, 2004, AM J PHYSIOL CELL PH, V286, pC1031, DOI 10.1152/ajpcell.00467.2003
   Warren GL, 2002, FASEB J, V16, P1630, DOI 10.1096/fj.02 0187fje
   Warren GL, 2017, SPORTS MED, V47, P41, DOI 10.1007/s40279 016 0528 7
   Warren GL, 2010, MED SCI SPORT EXER, V42, P1375, DOI 10.1249/MSS.0b013e3181cabbd8
   Ziltener J.  L., 2010, Annals of Physical and Rehabilitation Medicine, V53, P278, DOI 10.1016/j.rehab.2010.03.001
NR 76
TC 37
Z9 41
U1 0
U2 19
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0363 5465
EI 1552 3365
J9 AM J SPORT MED
JI Am. J. Sports Med.
PD JAN
PY 2018
VL 46
IS 1
BP 224
EP 233
DI 10.1177/0363546517697957
PG 10
WC Orthopedics; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Sport Sciences
GA FR4FG
UT WOS:000419020500027
PM 28355084
OA Bronze
DA 2025 08 17
ER

PT J
AU Farr, JN
   Khosla, S
AF Farr, Joshua N.
   Khosla, Sundeep
TI Cellular senescence in bone
SO BONE
LA English
DT Article
DE Aging; Bone; Osteocyte; Osteoporosis; Disease prevention
ID SECRETORY PHENOTYPE; DNA DAMAGE; OSTEOBLAST DIFFERENTIATION; FRACTURE
   RISK; MOUSE MODELS; STEM CELLS; OSTEOPOROSIS; ROMOSOZUMAB; WOMEN;
   DYSFUNCTION
AB Cellular senescence refers to a process induced by various types of stress that causes irreversible cell cycle arrest and distinct cellular alterations, including profound changes in gene expression, metabolism, and chromatin organization as well as activation/reinforcement of anti apoptotic pathways and development of a pro inflammatory secretome or senescence associated secretory phenotype (SASP). However, because of challenges and technical limitations in identifying and characterizing senescent cells in living organisms, only recently have some of the diverse in vivo roles of these unique cells been discovered. New findings indicate that senescent cells and their SASP can have acute beneficial functions, such as in tissue regeneration and wound healing. However, in contrast, when senescent cells accumulate in excess chronically at sites of pathology or in old tissues they drive multiple age associated chronic diseases. Senotherapeutics that selectively eliminate senescent cells ("senolytics") or inhibit their detrimental SASP ("senomorphics") have been developed and tested in aged preclinical models. These studies have established that targeting senescence is a powerful anti aging strategy to improve "healthspan"   ie., the healthy period of life free of chronic disease. The roles of senescence in mediating age related bone loss have been a recent focus of rigorous investigation. Studies in mice and humans demonstrate that with aging, at least a subset of most cell types in the bone microenvironment become senescent and develop a heterogeneous SASP. Furthermore, age related bone loss can be alleviated in old mice, with apparent advantages over anti resorptive therapy, by reducing the senescent cell burden genetically or pharmacologically with the first class of senolytics or a senomorphic. Collectively, these findings point to targeting senescence as a transformational strategy to extend healthspan, therefore providing strong rationale for identifying and optimizing senotherapeutics to alleviate multiple chronic diseases of aging, including osteoporosis, and set the stage for translating senotherapeutics to humans, with clinical trials currently ongoing.
C1 Mayo Clin, Div Endocrinol & Metab, Rochester, MN USA.
   Mayo Clin, Kogod Ctr Aging, Rochester, MN USA.
C3 Mayo Clinic; Mayo Clinic
RP Farr, JN; Khosla, S (通讯作者)，Mayo Clin, Coll Med, Guggenheim 7,200 First St SW, Rochester, MN 55905 USA.
EM farr.joshua@mayo.edu; khosla.sundeep@mayo.edu
RI ; Khosla, Sundeep/AAE 6170 2020; Farr, Joshua/B 3355 2011
OI Farr, Joshua/0000 0002 3179 6414; Khosla, Sundeep/0000 0002 2936 4372
FU NIH [P01 AG004875, R01 AG048792, R01 AR027065, K01 AR070241]; Career
   Development Awards from the Mayo Clinic Robert and Arlene Kogod Center
   on Aging; Richard F. Emslander Career Development Award in Endocrinology
FX Dr. Farr was supported by NIH Grant K01 AR070241 and Career Development
   Awards from the Mayo Clinic Robert and Arlene Kogod Center on Aging, as
   well as the Richard F. Emslander Career Development Award in
   Endocrinology. Dr. Khosla was supported by NIH grants P01 AG004875, R01
   AG048792, and R01 AR027065.
CR Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784
   Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Baker DJ, 2016, NATURE, V530, P184, DOI 10.1038/nature16932
   Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600
   Blasco MA, 2007, NAT CHEM BIOL, V3, P640, DOI 10.1038/nchembio.2007.38
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Burd CE, 2013, CELL, V152, P340, DOI 10.1016/j.cell.2012.12.010
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Burtner CR, 2010, NAT REV MOL CELL BIO, V11, P567, DOI 10.1038/nrm2944
   Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Chan CKF, 2018, CELL, V175, P43, DOI 10.1016/j.cell.2018.07.029
   Chen Q, 2013, J BONE MINER RES, V28, P1214, DOI 10.1002/jbmr.1851
   Childs BG, 2016, SCIENCE, V354, P472, DOI 10.1126/science.aaf6659
   Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003
   Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772
   Coppé JP, 2010, ANNU REV PATHOL MECH, V5, P99, DOI 10.1146/annurev pathol 121808 102144
   Coppé JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   Criscione SW, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1500882
   D'Andrea G, 2015, FITOTERAPIA, V106, P256, DOI 10.1016/j.fitote.2015.09.018
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Davalos AR, 2013, J CELL BIOL, V201, P613, DOI 10.1083/jcb.201206006
   Debnath S, 2018, NATURE, V562, P133, DOI 10.1038/s41586 018 0554 8
   Demaria M, 2014, DEV CELL, V31, P722, DOI 10.1016/j.devcel.2014.11.012
   Devlin MJ, 2015, LANCET DIABETES ENDO, V3, P141, DOI 10.1016/S2213 8587(14)70007 5
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Dou ZX, 2017, NATURE, V550, P402, DOI 10.1038/nature24050
   Efron B, 2007, ANN APPL STAT, V1, P107, DOI 10.1214/07 AOAS101
   Evangelou K, 2017, AGING CELL, V16, P192, DOI 10.1111/acel.12545
   Farr JN, 2018, J BONE MINER RES, V33, P1568, DOI 10.1002/jbmr.3564
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Farr JN, 2016, J BONE MINER RES, V31, P1920, DOI 10.1002/jbmr.2892
   Fatayerji D, 1999, J BONE MINER RES, V14, P1203, DOI 10.1359/jbmr.1999.14.7.1203
   Freund A, 2012, MOL BIOL CELL, V23, P2066, DOI 10.1091/mbc.E11 10 0884
   Giunta S, 2017, P NATL ACAD SCI USA, V114, P1928, DOI 10.1073/pnas.1615133114
   Gronthos S, 2003, J CELL SCI, V116, P1827, DOI 10.1242/jcs.00369
   Hernandez Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001
   Hernandez Segura A, 2017, CURR BIOL, V27, P2652, DOI 10.1016/j.cub.2017.07.033
   Hewitt G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1708
   Hoeijmakers JHJ, 2009, NEW ENGL J MED, V361, P1475, DOI 10.1056/NEJMra0804615
   Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Jun JI, 2010, NAT CELL BIOL, V12, P676, DOI 10.1038/ncb2070
   Jurk D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5172
   Jurk D, 2012, AGING CELL, V11, P996, DOI 10.1111/j.1474 9726.2012.00870.x
   Kanis JA, 2000, OSTEOPOROSIS INT, V11, P669, DOI 10.1007/s001980070064
   Khosla S, 1998, J CLIN ENDOCR METAB, V83, P2266, DOI 10.1210/jc.83.7.2266
   Khosla S, 2018, J CLIN ENDOCR METAB, V103, P1282, DOI 10.1210/jc.2017 02694
   Khosla S, 2017, NAT REV ENDOCRINOL, V13, P697, DOI 10.1038/nrendo.2017.136
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Khosla S, 2017, J BONE MINER RES, V32, P424, DOI 10.1002/jbmr.3074
   Khosla S, 2016, J BONE MINER RES, V31, P1485, DOI 10.1002/jbmr.2888
   Khosla S, 2012, J BONE MINER RES, V27, P506, DOI 10.1002/jbmr.1541
   Kim HN, 2017, AGING CELL, V16, P693, DOI 10.1111/acel.12597
   Kirkland JL, 2017, J AM GERIATR SOC, V65, P2297, DOI 10.1111/jgs.14969
   Kirkland JL, 2017, EBIOMEDICINE, V21, P21, DOI 10.1016/j.ebiom.2017.04.013
   Kirkland JL, 2015, EXP GERONTOL, V68, P19, DOI 10.1016/j.exger.2014.10.012
   Kitada K, 2014, J DIABETES COMPLICAT, V28, P604, DOI 10.1016/j.jdiacomp.2014.05.010
   Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475
   Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049
   Laberge RM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.199
   Lewiecki EM, 2009, ENDOCR PRACT, V15, P573, DOI 10.4158/EP09107.RA
   LIPS P, 1978, CALC TISS RES, V26, P13, DOI 10.1007/BF02013227
   López Otín C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Manolagas SC, 2010, TRENDS ENDOCRIN MET, V21, P369, DOI 10.1016/j.tem.2010.01.010
   Matheu A, 2009, AGING CELL, V8, P152, DOI 10.1111/j.1474 9726.2009.00458.x
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Melton LJ, 1998, J BONE MINER RES, V13, P1915, DOI 10.1359/jbmr.1998.13.12.1915
   Minamino T, 2009, NAT MED, V15, P1082, DOI 10.1038/nm.2014
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, P669, DOI 10.1038/nrd.2016.207
   Muñoz Espín D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823
   Muñoz Espín D, 2013, CELL, V155, P1104, DOI 10.1016/j.cell.2013.10.019
   Musi N, 2018, AGING CELL, V17, DOI 10.1111/acel.12840
   Nelson G, 2012, AGING CELL, V11, P345, DOI 10.1111/j.1474 9726.2012.00795.x
   Nelsons G, 2018, MECH AGEING DEV, V170, P30, DOI 10.1016/j.mad.2017.08.005
   Niedernhofer LJ, 2006, NATURE, V444, P1038, DOI 10.1038/nature05456
   Odgren PR, 2006, CONNECT TISSUE RES, V47, P229, DOI 10.1080/03008200600860086
   Ogrodnik M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15691
   Oubaha M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9440
   Paccou J, 2019, BONE, V118, P8, DOI 10.1016/j.bone.2018.02.008
   Parente L, 2008, ARCH GYNECOL OBSTET, V277, P219, DOI 10.1007/s00404 007 0442 1
   PARFITT AM, 1991, J BONE MINER RES, V6, P95
   Piemontese M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93771
   Pignolo RJ, 2008, AGING CELL, V7, P23, DOI 10.1111/j.1474 9726.2007.00350.x
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Roos CM, 2016, AGING CELL, V15, P973, DOI 10.1111/acel.12458
   Rosen CJ, 2017, NEW ENGL J MED, V377, P1479, DOI 10.1056/NEJMe1711298
   Saag KG, 2018, NEW ENGL J MED, V378, P195, DOI 10.1056/NEJMc1714810
   Saeed H, 2011, J BONE MINER RES, V26, P1494, DOI 10.1002/jbmr.349
   Sierra F, 2017, GEROSCIENCE, V39, P1, DOI 10.1007/s11357 016 9954 6
   Storer M, 2013, CELL, V155, P1119, DOI 10.1016/j.cell.2013.10.041
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Swanson EC, 2013, J CELL BIOL, V203, P929, DOI 10.1083/jcb.201306073
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Tchkonia T, 2013, J CLIN INVEST, V123, P966, DOI 10.1172/JCI64098
   Trujillo ME, 2005, CELL CYCLE, V4, P1141, DOI 10.4161/cc.4.9.2030
   WANG E, 1995, CANCER RES, V55, P2284
   Wang HT, 2012, AGING CELL, V11, P704, DOI 10.1111/j.1474 9726.2012.00838.x
   Wang JW, 2011, CURR OPIN IMMUNOL, V23, P532, DOI 10.1016/j.coi.2011.05.004
   Wiley CD, 2017, AGING CELL, V16, P1043, DOI 10.1111/acel.12632
   Wiley CD, 2016, CELL METAB, V23, P303, DOI 10.1016/j.cmet.2015.11.011
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592
   Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591 018 0092 9
   Xu M, 2017, J GERONTOL A BIOL, V72, P780, DOI 10.1093/gerona/glw154
   Xu M, 2015, ELIFE, V4, DOI 10.7554/eLife.12997
   Xu M, 2015, P NATL ACAD SCI USA, V112, pE6301, DOI 10.1073/pnas.1515386112
   Yi JS, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.90220
   Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344
NR 110
TC 169
Z9 184
U1 1
U2 55
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2019
VL 121
BP 121
EP 133
DI 10.1016/j.bone.2019.01.015
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HN9CE
UT WOS:000460495000014
PM 30659978
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Souchon, R
   Wenz, F
   Sedlmayer, F
   Budach, W
   Dunst, J
   Feyer, P
   Haase, W
   Harms, W
   Sautter Bihl, ML
   Sauer, R
AF Souchon, Rainer
   Wenz, Frederik
   Sedlmayer, Felix
   Budach, Wilfried
   Dunst, Juergen
   Feyer, Petra
   Haase, Wulf
   Harms, Wolfgang
   Sautter Bihl, Marie Luise
   Sauer, Rolf
TI DEGRO Practice Guidelines for Palliative Radiotherapy of Metastatic
   Breast Cancer Bone Metastases and Metastatic Spinal Cord Compression
   (MSCC)
SO STRAHLENTHERAPIE UND ONKOLOGIE
LA English
DT Article
DE Breast cancer; Bone metastases; Metastatic spinal cord compression
   (MSCC); Radiotherapy Decision making parameters
ID INTENSITY MODULATED RADIOTHERAPY; PROGNOSTIC FACTORS; BIOCHEMICAL
   MARKERS; CLINICAL EVALUATION; RADIATION THERAPY; SINGLE FRACTION; 30 GY;
   SURVIVAL; BISPHOSPHONATES; REIRRADIATION
AB Purpose: To provide practice guidelines and clinical recommendations on preferred standard palliative radiation therapy of bone metastases as well as metastatic spinal cord compression (MSCC) for metastatic breast cancer patients.
   Methods: The breast cancer expert panel of the German Society of Radiation Oncology (DEGRO) performed a comprehensive survey of the literature comprising recently published data from clinical controlled trials. The literature search encompassed the period 1995 2008 using databases of PubMed and Guidelines International Network (G I N). Search terms were "breast cancer", "bone metastasis", "osseous metastasis", "metastatic spinal cord compression" as well as "radiotherapy" and "radiation therapy" . Clinical recommendations were formulated based on the panel's interpretation of the level of evidence referring to the criteria of evidence based medicine.
   Results: Different therapeutic goals (pain relief, local tumor control, prevention or improvement of motor deficits, stabilization of the spine or other bones) require complex approaches considering individual factors (i.e., life expectancy, tumor progression at other sites). Best results are achieved by close interdisciplinary cooperation minimizing the interval between diagnosis and onset of treatment. Most important criteria for prognosis and choice of treatment (mostly combined multimodal therapy) are neurologic status at diagnosis of MSCC, time course of duration and progression of the neurologic symptoms. Radiation therapy is effective and regarded as treatment of choice for MSCC with or without motor deficits and/or bone metastases, which do not need immediate surgical intervention. It may be used either postoperatively or as primary treatment in case of inoperabitity. An optimal dose fractionation schedule or optimal standard dose for treatment of bone metastases has not been established. With regard to different therapeutic goats, different dose concepts and fractionation schedules, single  versus multifraction palliative radiation therapy (1 x 8, 5 x 4, 10 x 3, 15 x 2.5, 20 x 2 Gy), should be adapted individually.
   Conclusion: Bone metastases as well as MSCC should be managed in an interdisciplinary approach mostly as combined modality treatment according to the specific clinical situation. The present practice guidelines offer criteria and recommendations for different radiooncologic treatment schedules based on the best available levels of evidence. Preferred technique, targeting and different dose schedules are described in detail.
C1 [Souchon, Rainer] UKT Tubingen, Dept Radiat Oncol, D 72079 Tubingen, Germany.
   [Wenz, Frederik] Univ Hosp Mannheim, Mannheim, Germany.
   [Sedlmayer, Felix] Salzburger Landeskliniken, Univ Hosp, Salzburg, Austria.
   [Budach, Wilfried] Univ Hosp Duesseldorf, Dusseldorf, Germany.
   [Dunst, Juergen] Univ Hosp Schleswig Holstein, Lubeck, Germany.
   [Feyer, Petra] Klinikum Neukoelln, Berlin, Germany.
   [Haase, Wulf] St Vincentius Kliniken, Karlsruhe, Germany.
   [Harms, Wolfgang] St Clara Hosp, Basel, Switzerland.
   [Sautter Bihl, Marie Luise] Municipal Hosp, Karlsruhe, Germany.
   [Sauer, Rolf] Univ Hosp Erlangen, Erlangen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Ruprecht Karls University Heidelberg; University of Kiel;
   Schleswig Holstein University Hospital; VIivantes Klinikum Neukolln;
   Municipal Hospital Karlsruhe; University of Erlangen Nuremberg
RP Souchon, R (通讯作者)，UKT Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D 72079 Tubingen, Germany.
EM rainer.souchon@med.uni tuebingen.de
RI ; Sedlmayer, Felix/AAC 7764 2022; Dunst, Juergen/D 2138 2010
OI Sedlmayer, Felix/0000 0002 1181 0178; 
CR ABDU WA, 2002, QUALITY MED, P370
   ANG KK, 1993, INT J RADIAT ONCOL, V25, P459, DOI 10.1016/0360 3016(93)90067 6
   [Anonymous], COCHRANE DATABASE SY
   Baumann M., 1994, Strahlentherapie und Onkologie, V170, P131
   Baur A, 1998, RADIOLOGY, V207, P349, DOI 10.1148/radiology.207.2.9577479
   Body JJ, 1998, J CLIN ONCOL, V16, P3890, DOI 10.1200/JCO.1998.16.12.3890
   BRICE J, 1965, BMJ BRIT MED J, V1, P1341, DOI 10.1136/bmj.1.5446.1341
   Chow E, 2007, J CLIN ONCOL, V25, P1423, DOI 10.1200/JCO.2006.09.5281
   Clemons M, 2006, ONCOLOGIST, V11, P227, DOI 10.1634/theoncologist.11 3 227
   Coleman RE, 2005, ANN ONCOL, V16, P687, DOI 10.1093/annonc/mdi162
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   COLMAN LK, 1988, J COMPUT ASSIST TOMO, V12, P423, DOI 10.1097/00004728 198805010 00013
   Combs SE, 2007, STRAHLENTHER ONKOL, V183, P63, DOI 10.1007/s00066 007 1616 2
   DOMAN U, 2006, ONKOLOGE, V12, P421
   Enkaoua EA, 1997, SPINE, V22, P2293, DOI 10.1097/00007632 199710010 00020
   Arnalot PF, 2008, RADIOTHER ONCOL, V89, P150, DOI 10.1016/j.radonc.2008.05.018
   Galasko CSB, 2000, J BONE JOINT SURG AM, V82A, P570, DOI 10.2106/00004623 200004000 00012
   Grötz KA, 2007, STRAHLENTHER ONKOL, V183, P190, DOI 10.1007/s00066 007 1666 5
   HADDAD MC, 1993, EUR RADIOL, V3, P439
   HARRINGTON KD, 1986, J BONE JOINT SURG AM, V68A, P1110, DOI 10.2106/00004623 198668070 00025
   Helweg Larsen S, 2000, INT J RADIAT ONCOL, V46, P1163, DOI 10.1016/S0360 3016(99)00333 8
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   HITT ME, 1993, BRIT J CANCER, V68, P969
   Hoskin PJ, 2003, RADIOTHER ONCOL, V68, P175, DOI 10.1016/S0167 8140(03)00191 9
   Jereczek Fossa BA, 2008, STRAHLENTHER ONKOL, V184, P36, DOI 10.1007/s00066 008 1783 9
   Koswig S, 1999, STRAHLENTHER ONKOL, V175, P509, DOI 10.1007/s000660050062
   Kouloulias V, 2003, INT J RADIAT ONCOL, V57, P143, DOI 10.1016/S0360 3016(03)00525 X
   Létourneau D, 2007, INT J RADIAT ONCOL, V67, P1229, DOI 10.1016/j.ijrobp.2006.09.058
   Loblaw DA, 1998, J CLIN ONCOL, V16, P1613, DOI 10.1200/JCO.1998.16.4.1613
   MARANZANO E, 1995, INT J RADIAT ONCOL, V32, P959, DOI 10.1016/0360 3016(95)00572 G
   MARANZANO E, 2002, RADIOTHER ONCOL S1, V64, pS82
   Milker Zabel S, 2003, INT J RADIAT ONCOL, V55, P162, DOI 10.1016/S0360 3016(02)03864 6
   Nieder C, 2006, INT J RADIAT ONCOL, V66, P1446, DOI 10.1016/j.ijrobp.2006.07.1383
   Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140 6736(05)66954 1
   Poortmans P, 2001, ACTA ONCOL, V40, P88
   Prasad D, 2005, LANCET ONCOL, V6, P15, DOI 10.1016/S1470 2045(04)01709 7
   Rades D, 2006, INT J RADIAT ONCOL, V64, P182, DOI 10.1016/j.ijrobp.2005.06.036
   Rades D, 2005, STRAHLENTHER ONKOL, V181, P595, DOI 10.1007/s00066 005 1406 7
   Rades D, 2005, J CLIN ONCOL, V23, P3366, DOI 10.1200/JCO.2005.04.754
   Rades D, 2002, INT J RADIAT ONCOL, V53, P975, DOI 10.1016/S0360 3016(02)02819 5
   Rades D, 2008, CANCER, V112, P157, DOI 10.1002/cncr.23150
   Rades D, 2007, NAT CLIN PRACT ONCOL, V4, P400, DOI 10.1038/ncponc0846
   Rades D, 2007, INT J RADIAT ONCOL, V67, P1506, DOI 10.1016/j.ijrobp.2006.11.029
   Rades D, 2007, J CLIN ONCOL, V25, P50, DOI 10.1200/JCO.2006.08.7155
   Rades D, 2007, INT J RADIAT ONCOL, V67, P256, DOI 10.1016/j.ijrobp.2006.08.011
   Rades D, 2007, INT J RADIAT ONCOL, V67, P532, DOI 10.1016/j.ijrobp.2006.08.047
   Rades D, 2007, INT J RADIAT ONCOL, V67, P525, DOI 10.1016/j.ijrobp.2006.09.025
   Rades D, 2006, J CLIN ONCOL, V24, P3388, DOI 10.1200/JCO.2005.05.0542
   Regine W. F., 2003, International Journal of Radiation Oncology Biology Physics, V57, pS125, DOI 10.1016/S0360 3016(03)00825 3
   RIEDEN K, 1989, STRAHLENTHER ONKOL, V165, P380
   Ross JR, 2003, BMJ BRIT MED J, V327, P469, DOI 10.1136/bmj.327.7413.469
   Ross PD, 1998, J BONE MINER RES, V13, P297, DOI 10.1359/jbmr.1998.13.2.297
   Saarto T, 2002, EUR J PAIN LONDON, V6, P323, DOI 10.1016/S1090 3801(02)00028 9
   Sautter Bihl ML, 2008, STRAHLENTHER ONKOL, V184, P347, DOI 10.1007/s00066 008 1901 8
   Sautter Bihl ML, 2007, STRAHLENTHER ONKOL, V183, P661, DOI 10.1007/s00066 007 1811 1
   SCHNABEL K, 1998, 052005 AWMF LEITL RE
   Sze WM, 2003, CLIN ONCOL UK, V15, P345, DOI 10.1016/S0936 6555(03)00113 4
   Taneichi H, 1997, SPINE, V22, P239, DOI 10.1097/00007632 199702010 00002
   TOKUHASHI Y, 1990, SPINE, V15, P1110, DOI 10.1097/00007632 199011010 00005
   Tomita K, 2001, SPINE, V26, P298, DOI 10.1097/00007632 200102010 00016
   Vassiliou V, 2007, INT J RADIAT ONCOL, V67, P264, DOI 10.1016/j.ijrobp.2006.08.022
   Walker MP, 2003, CLIN ORTHOP RELAT R, pS165, DOI 10.1097/01.blo.0000092977.12414.f9
   WANNEMMACHER M, 2006, STANDARDLEHRBUCH STR, P745
   Weis J, 2006, RES REHABILITATION R, P162
   Wiezorek T, 2008, STRAHLENTHER ONKOL, V184, P73, DOI 10.1007/s00066 008 1743 4
NR 65
TC 60
Z9 62
U1 0
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0179 7158
EI 1439 099X
J9 STRAHLENTHER ONKOL
JI Strahlenther. Onkol.
PD JUL
PY 2009
VL 185
IS 7
BP 417
EP 424
DI 10.1007/s00066 009 2044 2
PG 8
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 473QZ
UT WOS:000268224900001
PM 19714302
DA 2025 08 17
ER

PT J
AU Bai, TT
   Liu, FL
   Zou, F
   Zhao, GF
   Jiang, YX
   Liu, L
   Shi, JH
   Hao, DS
   Zhang, Q
   Zheng, T
   Zhang, YY
   Liu, MS
   Li, SL
   Qi, LC
   Liu, JY
AF Bai, Tingting
   Liu, Feilin
   Zou, Fei
   Zhao, Guifang
   Jiang, Yixu
   Liu, Li
   Shi, Jiahong
   Hao, Deshun
   Zhang, Qi
   Zheng, Tong
   Zhang, Yingyao
   Liu, Mingsheng
   Li, Shilun
   Qi, Liangchen
   Liu, Jin Yu
TI Epidermal Growth Factor Induces Proliferation of Hair Follicle Derived
   Mesenchymal Stem Cells Through Epidermal Growth Factor Receptor Mediated
   Activation of ERK and AKT Signaling Pathways Associated with
   Upregulation of Cyclin D1 and Downregulation of p16
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
DE cell cycle; EGFR; hair follicle; mesenchymal stem cells; proliferation
ID SMOOTH MUSCLE CELLS; SELF RENEWAL; EGFR FAMILY; EXPANSION; BULGE;
   DIFFERENTIATION; MULTIPOTENCY; INHIBITORS; EXPRESSION; 3 KINASE
AB The maintenance of highly proliferative capacity and full differentiation potential is a necessary step in the initiation of stem cell based regenerative medicine. Our recent study showed that epidermal growth factor (EGF) significantly enhanced hair follicle derived mesenchymal stem cell (HF MSC) proliferation while maintaining the multilineage differentiation potentials. However, the underlying mechanism remains unclear. Herein, we investigated the role of EGF in HF MSC proliferation. HF MSCs were isolated and cultured with or without EGF. Immunofluorescence staining, flow cytometry, cytochemistry, and western blotting were used to assess proliferation, cell signaling pathways related to the EGF receptor (EGFR), and cell cycle progression. HF MSCs exhibited surface markers of mesenchymal stem cells and displayed trilineage differentiation potentials toward adipocytes, chondrocytes, and osteoblasts. EGF significantly increased HF MSC proliferation as well as EGFR, ERK1/2, and AKT phosphorylation (p EGFR, p ERK1/2, and p AKT) in a time and dosedependent manner, but not STAT3 phosphorylation. EGFR inhibitor (AG1478), PI3K AKT inhibitor (LY294002), ERK inhibitor (U0126), and STAT3 inhibitor (STA 21) significantly blocked EGF induced HF MSC proliferation. Moreover, AG1478, LY294002, and U0126 significantly decreased p EGFR, p AKT, and p ERK1/2 expression. EGF shifted HF MSCs at the G1 phase to the S and G2 phase. Concomitantly, cyclinD1, phosphorylated Rb, and E2F1expression increased, while that of p16 decreased. In conclusion, EGF induces HF MSC proliferation through the EGFR/ERK and AKT pathways, but not through STAT 3. The G1/S transition was stimulated by upregulation of cyclinD1 and inhibition of p16 expression.
C1 [Bai, Tingting; Jiang, Yixu; Liu, Li; Hao, Deshun] Jilin Univ, Coll Basic Med, Minist Educ, Dept Pathobiol,Key Lab, Changchun, Peoples R China.
   [Bai, Tingting; Liu, Feilin; Zou, Fei; Jiang, Yixu; Liu, Li; Shi, Jiahong; Hao, Deshun; Zhang, Qi; Zheng, Tong; Zhang, Yingyao; Liu, Mingsheng; Liu, Jin Yu] Jilin Univ, Sch Publ Hlth, Dept Toxicol, Changchun 130021, Jilin, Peoples R China.
   [Liu, Feilin] Jilin Univ, Hosp 2, Dept Ophthalmol, Changchun, Peoples R China.
   [Zou, Fei] Jilin Univ, Hosp 1, Dept Pediat, Changchun, Peoples R China.
   [Zhao, Guifang] Jilin Med Coll, Dept Pathol, Jilin, Peoples R China.
   [Li, Shilun] First Peoples Hosp Lishu Cty, Dept Oncol, Lishu, Lishu County, Peoples R China.
   [Qi, Liangchen] Jilin Univ, China Japan Union Hosp, Dept Thorac Surg, Changchun, Peoples R China.
C3 Jilin University; Jilin University; Jilin University; Jilin University;
   Jilin Medical University; Jilin University
RP Liu, JY (通讯作者)，Jilin Univ, Sch Publ Hlth, Dept Toxicol, Changchun 130021, Jilin, Peoples R China.
EM drliujinyu@yahoo.com
RI Ni, Mingli/HJP 2387 2023; 郑, 桐/JPY 3256 2023
FU National Natural Science Foundation of China [81573067]; Frontier
   Interdiscipline Program of Norman Bethune Health Science Center of Jilin
   University [2013101007]; Specialized Research Fund for the Doctoral
   Program of Higher Education [20130061110077]
FX This study was supported by grants from the National Natural Science
   Foundation of China (81573067), the Frontier Interdiscipline Program of
   Norman Bethune Health Science Center of Jilin University (2013101007),
   and the Specialized Research Fund for the Doctoral Program of Higher
   Education (20130061110077).
CR Amoh Y, 2005, P NATL ACAD SCI USA, V102, P5530, DOI 10.1073/pnas.0501263102
   Amoh Y, 2008, CELL CYCLE, V7, P1865, DOI 10.4161/cc.7.12.6056
   Bajpai VK, 2012, STEM CELL RES, V8, P74, DOI 10.1016/j.scr.2011.07.003
   Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006
   Bressan RB, 2014, EXP CELL RES, V327, P37, DOI 10.1016/j.yexcr.2014.05.020
   Burgess AW, 2008, GROWTH FACTORS, V26, P263, DOI 10.1080/08977190802312844
   Chen JX, 2011, MOL CELL BIOCHEM, V358, P67, DOI 10.1007/s11010 011 0922 2
   Dombrowski C, 2013, STEM CELLS, V31, P2724, DOI 10.1002/stem.1514
   Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623
   Ferguson KM, 2008, ANNU REV BIOPHYS, V37, P353, DOI 10.1146/annurev.biophys.37.032807.125829
   Gao YH, 2014, ANN BIOMED ENG, V42, P2177, DOI 10.1007/s10439 014 1061 1
   García Hernández V, 2015, J CELL PHYSIOL, V230, P105, DOI 10.1002/jcp.24687
   Han WN, 2009, PHOTOCHEM PHOTOBIOL, V85, P997, DOI 10.1111/j.1751 1097.2008.00531.x
   Harashima M, 2013, BIOMED RES TOKYO, V34, P269
   Hoogduijn MJ, 2006, STEM CELLS DEV, V15, P49, DOI 10.1089/scd.2006.15.49
   Hu QK, 2010, STEM CELLS, V28, P279, DOI 10.1002/stem.246
   Kamiya A, 2015, STEM CELLS DEV, V24, P2525, DOI 10.1089/scd.2015.0015
   Knudsen SLJ, 2014, GROWTH FACTORS, V32, P155, DOI 10.3109/08977194.2014.952410
   Krampera M, 2005, BLOOD, V106, P59, DOI 10.1182/blood 2004 09 3645
   Lai WT, 2011, STEM CELLS, V29, P1102, DOI 10.1002/stem.661
   Lako M, 2002, J CELL SCI, V115, P3967, DOI 10.1242/jcs.00060
   LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601
   Li L, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/691310
   Li PD, 2015, CELL TISSUE RES, V362, P69, DOI 10.1007/s00441 015 2182 z
   Liu DM, 2007, ENDOCRINOLOGY, V148, P3068, DOI 10.1210/en.2006 1378
   Liu JY, 2008, CARDIOVASC RES, V79, P24, DOI 10.1093/cvr/cvn059
   Liu JY, 2010, TISSUE ENG PT A, V16, P2553, DOI [10.1089/ten.tea.2009.0833, 10.1089/ten.TEA.2009.0833]
   Liu W, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/651207
   Marqués MM, 1999, EXP CELL RES, V252, P432, DOI 10.1006/excr.1999.4634
   Nishikawa Torikai S, 2011, J INVEST DERMATOL, V131, P2358, DOI 10.1038/jid.2011.195
   Oda K, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100014
   PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075
   Park JH, 2009, AM J PHYSIOL CELL PH, V297, pC935, DOI 10.1152/ajpcell.00121.2009
   Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640
   Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347
   Rompolas P, 2014, SEMIN CELL DEV BIOL, V25, P34, DOI 10.1016/j.semcdb.2013.12.005
   Sennett R, 2012, SEMIN CELL DEV BIOL, V23, P917, DOI 10.1016/j.semcdb.2012.08.011
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   Song H, 2005, P NATL ACAD SCI USA, V102, P4700, DOI 10.1073/pnas.0409894102
   Tamama K, 2006, STEM CELLS, V24, P686, DOI 10.1634/stemcells.2005 0176
   Trempus CS, 2003, J INVEST DERMATOL, V120, P501, DOI 10.1046/j.1523 1747.2003.12088.x
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
   Wu CL, 2015, CELL TRANSPLANT, V24, P891, DOI 10.3727/096368914X681919
   Yashiro M, 2015, CELL CYCLE, V14, P2362, DOI 10.1080/15384101.2015.1042633
   Yu H, 2010, J INVEST DERMATOL, V130, P1227, DOI 10.1038/jid.2009.322
   Zhang XY, 2013, INT J MOL MED, V31, P913, DOI 10.3892/ijmm.2013.1272
   Zhao GF, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0031 3
NR 47
TC 70
Z9 74
U1 0
U2 62
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD JAN 15
PY 2017
VL 26
IS 2
BP 113
EP 122
DI 10.1089/scd.2016.0234
PG 10
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA EI9OK
UT WOS:000392837600005
PM 27702388
DA 2025 08 17
ER

PT J
AU Banerjee, SS
   Bandyopadhyay, A
   Bose, S
AF Banerjee, Shashwat S.
   Bandyopadhyay, Amit
   Bose, Susmita
TI Biphasic Resorbable Calcium Phosphate Ceramic for Bone Implants and
   Local Alendronate Delivery
SO ADVANCED ENGINEERING MATERIALS
LA English
DT Article
ID ALPHA TRICALCIUM PHOSPHATE; MECHANICAL PROPERTIES; HYDROXYAPATITE;
   PYROPHOSPHATE; APATITE; ZNO; TCP
AB A novel biphasic calcium phosphate ceramic composed of tricalcium phosphate (TCP) and calcium pyrophosphate (CP) is synthesized in order to tailor the biodegradation behavior of the ceramic. The results show that biphasic TCP/CP ceramic has a strength of 62.2 +/  2.1 MPa, which is superior to single phase TCP and CP ceramics, which show strengths of 44.3 +/  3.0 and 53.0 +/  4.8 MPa, respectively. In addition, biphasic TCP/CP ceramic displays a controlled strength degradation from 62.2 +/  2.1 to 40.5 +/  1.0 MPa in stimulated body fluid over a period of 28 d. An in vitro cell materials interaction study using human fetal osteoblast cells indicates that TCP/CP ceramic is cytocompatible. TCP/CP ceramic also show a good loading capacity for alendronate. Adsorption of alendronate (AD) on the TCP/CP surface is found to proceed via ligand exchange mechanism and the in vitro release profile of AD from TCP/CP surface is characterized by an initial fast release followed by a slow and sustained release. Strong electrostatic interactions between AD groups and surface Ca2+ ions enable the slow and sustained release of AD. These results demonstrate that the newly developed biphasic ceramic, with its controlled strength degradation and drug release, shows promise for use in orthopedic and tissue engineering applications.
C1 [Banerjee, Shashwat S.; Bandyopadhyay, Amit] Washington State Univ, Sch Mech & Mat Engn, WM Keck Biomed Mat Res Lab, Pullman, WA 99164 USA.
C3 Washington State University
RP Banerjee, SS (通讯作者)，Washington State Univ, Sch Mech & Mat Engn, WM Keck Biomed Mat Res Lab, Pullman, WA 99164 USA.
EM sbose@wsu.edu
RI Bandyopadhyay, Amit/A 7780 2012; Banerjee, Shashwat/A 9252 2010
OI Bandyopadhyay, Amit/0000 0003 0992 5387; Banerjee,
   Shashwat/0000 0002 9504 7690
FU National Institutes of Health, NIBIB [NIH R01 EB 007351]
FX The authors would like to acknowledge financial support from the
   National Institutes of Health, NIBIB (Grant # NIH R01 EB 007351),
   Program manager Dr. Albert Lee.
CR Bandyopadhyay A, 2007, MAT SCI ENG C BIO S, V27, P14, DOI 10.1016/j.msec.2005.11.004
   Bandyopadhyay A, 2006, J AM CERAM SOC, V89, P2675, DOI 10.1111/j.1551 2916.2006.01207.x
   Beruto DT, 2000, J BIOMED MATER RES, V49, P498, DOI 10.1002/(SICI)1097 4636(20000315)49:4<498::AID JBM8>3.3.CO;2 T
   Daculsi G, 1998, BIOMATERIALS, V19, P1473, DOI 10.1016/S0142 9612(98)00061 1
   Daculsi G, 2003, J MATER SCI MATER M, V14, P195, DOI 10.1023/A:1022842404495
   Dahl SG, 2001, BONE, V28, P446, DOI 10.1016/S8756 3282(01)00419 7
   Enderle R, 2005, BIOMATERIALS, V26, P3379, DOI 10.1016/j.biomaterials.2004.09.017
   FLEISH H, 1961, AM J PHYSIOL, V200, P1296, DOI 10.1152/ajplegacy.1961.200.6.1296
   Guo X, 2002, J ORTHOPAED RES, V20, P740, DOI 10.1016/S0736 0266(01)00167 X
   Hench LL, 1998, J AM CERAM SOC, V81, P1705
   Kalita SJ, 2004, BIOMATERIALS, V25, P2331, DOI 10.1016/j.biomaterials.2003.09.012
   Kannan S, 2005, CHEM MATER, V17, P3065, DOI 10.1021/cm050342+
   Kasuga T, 2005, ACTA BIOMATER, V1, P55, DOI 10.1016/j.actbio.2004.08.001
   Kim HM, 2005, BIOMATERIALS, V26, P4366, DOI 10.1016/j.biomaterials.2004.11.022
   Klein CPAT., 1984, J Biomed Mat Res, V18, P845
   KOKUBO T, 1990, J BIOMED MATER RES, V24, P721, DOI 10.1002/jbm.820240607
   Koo S, 2006, J BIOMED MATER RES B, V76B, P373, DOI 10.1002/jbm.b.30383
   Kuljanin J, 2002, J PHARMACEUT BIOMED, V28, P1215, DOI 10.1016/S0731 7085(02)00021 3
   Li YB, 2007, ACTA BIOMATER, V3, P251, DOI 10.1016/j.actbio.2006.07.003
   LIN FH, 1995, BIOMATERIALS, V16, P793, DOI 10.1016/0142 9612(95)99642 Y
   Loher S, 2005, CHEM MATER, V17, P36, DOI 10.1021/cm048776c
   Metsger DS, 1999, J MATER SCI MATER M, V10, P9, DOI 10.1023/A:1008883809160
   Mukherjee S, 2008, J AM CHEM SOC, V130, P1264, DOI 10.1021/ja0759949
   RATNER B, 2004, BIOMATERIALS SCI INT, P82
   Ryu HS, 2002, BIOMATERIALS, V23, P909, DOI 10.1016/S0142 9612(01)00201 0
   Seeley Z, 2008, MAT SCI ENG C BIO S, V28, P11, DOI 10.1016/j.msec.2006.12.010
   Seeley Z, 2007, J BIOMED MATER RES A, V82A, P113, DOI 10.1002/jbm.a.31077
   Williams D. F., 1985, BIOCOMPATIBILITY TIS, VII
   Xue WC, 2008, J MATER SCI MATER M, V19, P2669, DOI 10.1007/s10856 008 3395 4
   YATES AJ, 1997, Patent No. 5646134
   Yin XL, 2002, BIOMATERIALS, V23, P4155, DOI 10.1016/S0142 9612(02)00199 0
NR 31
TC 26
Z9 29
U1 0
U2 19
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1438 1656
EI 1527 2648
J9 ADV ENG MATER
JI Adv. Eng. Mater.
PD MAY
PY 2010
VL 12
IS 5
SI SI
BP B148
EP B155
DI 10.1002/adem.200980072
PG 8
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 613AM
UT WOS:000278948100016
DA 2025 08 17
ER

PT J
AU Ek, ETH
   Dass, CR
   Contreras, KG
   Choong, PFM
AF Ek, Eugene T. H.
   Dass, Crispin R.
   Contreras, Karla G.
   Choong, Peter F. M.
TI Inhibition of orthotopic osteosarcoma growth and metastasis by
   multitargeted antitumor activities of pigment epithelium derived factor
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE PEDF; osteosarcoma; targeted therapy; angiogenesis; metastasis;
   antitumor
ID FACTOR VEGF EXPRESSION; OSTEOBLAST DIFFERENTIATION; TUMOR GROWTH; FACTOR
   PEDF; IN VIVO; ANGIOGENESIS; CANCER; CELLS; COLLAGEN; BONE
AB Osteosarcoma is major cause of cancer related death in the pediatric age group, and this is due to the development of pulmonary metastases that fail to be eradicated with current treatment regimes. Although there have been significant improvements in the long term survival of such patients, 25 50% with initially non metastatic disease, subsequently develop metastases and this remains the major cause of death for these patients. In this study, we report the multimodal activity of pigment epithelium derived factor (PEDF) in inhibiting osteosarcoma growth, angiogenesis and metastasis. In vitro, we found that administration of recombinant PEDF (rPEDF) on two osteosarcoma cell lines (rat UMR 106 01 and human SaOS 2) significantly reduced tumor cell proliferation and increased apoptosis, as well as decreased cell invasion, angiogenesis, and increased adhesion to collagen type 1. Administration of rPEDF upregulated the mRNA expression of phenotypic osteoblast differentiation markers (ALP, pro alpha(1) collagen and osteocalcin) in a pre osteoblastic cell line, UMR 201, and also increased mineralized nodule formation in both UMR 106 01 and SaOS 2. In vivo, rPEDF dramatically suppressed primary osteosarcoma growth and the development of macroscopic pulmonary metastases in an orthotopic model of human osteosarcoma (SaOS 2). Interestingly, no activity was seen in tumors grown subcutaneously, suggesting a paracrine interaction between PEDF and the bone microenvironment. Preliminary pharmacoevaluation studies demonstrated rPEDF stability within media containing serum and osteosarcoma cells, and no gross systemic toxicity was observed in vivo with rPEDF administration. These results suggest that PEDF is emerging as an attractive and clinically appealing drug candidate for the treatment of osteosarcoma
C1 Univ Melbourne, St Vincents Hosp, Dept Orthopaed, Melbourne, Vic 3065, Australia.
   Peter MacCallum Canc Ctr, Bone & Soft Tissue Sarcoma Serv, Melbourne, Vic, Australia.
C3 University of Melbourne; NSW Health; St Vincents Hospital Sydney; St
   Vincent's Health; St Vincent's Hospital Melbourne; Peter Maccallum
   Cancer Center
RP Dass, CR (通讯作者)，Univ Melbourne, St Vincents Hosp, Dept Orthopaed, POB 2900, Melbourne, Vic 3065, Australia.
EM crispin.dass@svhm.org.au
RI ; Choong, Peter/F 1109 2014
OI Choong, Peter/0000 0001 7333 7665; Ek, Eugene/0000 0003 3779 3545; Dass,
   Crispin/0000 0001 7087 7957; Choong, Peter/0000 0002 3522 7374
CR Abe R, 2004, AM J PATHOL, V164, P1225, DOI 10.1016/S0002 9440(10)63210 5
   Bilak MM, 1999, J NEUROPATH EXP NEUR, V58, P719, DOI 10.1097/00005072 199907000 00006
   Browne M, 2006, PEDIATR RES, V60, P282, DOI 10.1203/01.pdr.0000232789.86632.91
   Cai J, 2006, J BIOL CHEM, V281, P3604, DOI 10.1074/jbc.M507401200
   Cheung LWT, 2006, ENDOCRINOLOGY, V147, P4179, DOI 10.1210/en.2006 0168
   CHOONG PFM, 1993, J ORTHOP RES, V11, P638, DOI 10.1002/jor.1100110505
   Crawford SE, 2001, J CELL SCI, V114, P4421
   Dass CR, 2006, CLIN EXP METASTAS, V23, P367, DOI 10.1007/s10585 006 9046 6
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Doll JA, 2003, NAT MED, V9, P774, DOI 10.1038/nm870
   Ek ETH, 2006, TRENDS MOL MED, V12, P497, DOI 10.1016/j.molmed.2006.08.009
   Ek ETH, 2006, EXPERT REV ANTICANC, V6, P225, DOI 10.1586/14737140.6.2.225
   Ek ETH, 2006, MOL CANCER THER, V5, P1641, DOI 10.1158/1535 7163.MCT 06 0107
   Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905
   Ferrari S, 2005, J CLIN ONCOL, V23, P8845, DOI 10.1200/JCO.2004.00.5785
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Filleur S, 2005, CANCER RES, V65, P5144, DOI 10.1158/0008 5472.CAN 04 3744
   Fisher JL, 2001, CLIN CANCER RES, V7, P1654
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Garcia M, 2004, CANCER RES, V64, P5632, DOI 10.1158/0008 5472.CAN 04 0230
   Guan M, 2004, CANCER GENE THER, V11, P325, DOI 10.1038/sj.cgt.7700675
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092 8674(00)81683 9
   Hase R, 2005, CLIN CANCER RES, V11, P8737, DOI 10.1158/1078 0432.CCR 05 1323
   Hosomichi J, 2005, BIOCHEM BIOPH RES CO, V335, P756, DOI 10.1016/j.bbrc.2005.07.140
   Kido A, 1999, CANCER LETT, V137, P209, DOI 10.1016/S0304 3835(98)00368 1
   Kozaki K, 1998, J BIOL CHEM, V273, P15125, DOI 10.1074/jbc.273.24.15125
   Kuncl RW, 2002, J NEUROCHEM, V81, P178, DOI 10.1046/j.1471 4159.2002.00813.x
   Meyer C, 2002, J BIOL CHEM, V277, P45400, DOI 10.1074/jbc.M208339200
   Nadiminty N, 2006, CLIN CANCER RES, V12, P1420, DOI 10.1158/1078 0432.CCR 05 1849
   Notari L, 2005, INVEST OPHTH VIS SCI, V46, P2736, DOI 10.1167/iovs.04 1489
   Petrilli AS, 2006, J CLIN ONCOL, V24, P1161, DOI 10.1200/JCO.2005.03.5352
   Pignolo RJ, 2003, J CELL PHYSIOL, V195, P12, DOI 10.1002/jcp.10212
   Quan GMY, 2005, CALCIFIED TISSUE INT, V76, P146, DOI 10.1007/s00223 004 0068 2
   Quan GMY, 2002, PATHOBIOLOGY, V70, P361, DOI 10.1159/000071277
   Sawant S, 2004, BIOCHEM BIOPH RES CO, V325, P408, DOI 10.1016/j.bbrc.2004.10.041
   Streck CJ, 2005, J PEDIATR SURG, V40, P236, DOI 10.1016/j.jpedsurg.2004.09.049
   Takasaki Shuji, 1995, Journal of Dermatology (Tokyo), V22, P480
   Takenaka K, 2005, LIFE SCI, V77, P3231, DOI 10.1016/j.lfs.2005.05.048
   Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187
   Tombran Tink J, 1996, Mol Vis, V2, P11
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014 4835(91)90248 D
   Uehara H, 2004, CANCER RES, V64, P3533, DOI 10.1158/0008 5472.CAN 03 3725
   Viguet Carrin S, 2006, OSTEOPOROSIS INT, V17, P319, DOI 10.1007/s00198 005 2035 9
   Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402 349
   Zaichuk TA, 2004, J EXP MED, V199, P1513, DOI 10.1084/jem.20040474
   Zhang SX, 2006, J MOL ENDOCRINOL, V37, P1, DOI 10.1677/jme.1.02008
NR 46
TC 77
Z9 81
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262 0898
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD APR
PY 2007
VL 24
IS 2
BP 93
EP 106
DI 10.1007/s10585 007 9062 1
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 162QM
UT WOS:000246103400004
PM 17458711
DA 2025 08 17
ER

PT J
AU Huang, FH
   Su, ZP
   Huang, YB
   Huang, YX
   Zhou, CY
   Feng, ST
   Qin, X
   Xie, X
   Liu, C
   Yu, CJ
AF Huang, Feihong
   Su, Zhiping
   Huang, Yibin
   Huang, Yuxiang
   Zhou, Chengyu
   Feng, Sitan
   Qin, Xiong
   Xie, Xi
   Liu, Chong
   Yu, Chaojie
TI Exploration of the combined role of immune checkpoints and immune cells
   in the diagnosis and treatment of ankylosing spondylitis: a preliminary
   study immune checkpoints in ankylosing spondylitis
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE Immune checkpoints; Ankylosing spondylitis; Immune cell; Drug
   sensitivity; Proteomic sequencing
ID SIRP ALPHA; INHIBITORS; CD47; PATHOGENESIS; DISEASE; TARGETS; CANCER;
   MHC
AB Objective Immune checkpoints have emerged as promising therapeutic targets for autoimmune diseases. However, the specific roles of immune checkpoints in the pathophysiology of ankylosing spondylitis (AS) remain unclear.Methods Hip ligament samples were obtained from two patient groups: those with AS and femoral head deformity, and those with femoral head necrosis but without AS, undergoing hip arthroplasty. Label Free Quantification (LFQ) Protein Park Analysis was used to identify the protein composition of the ligaments. Peripheral blood samples of 104 AS patients from public database were used to validate the expression of key proteins. KEGG, GO, and GSVA were employed to explore potential pathways regulated by immune checkpoints in AS progression. xCell was used to calculate cell infiltration levels, LASSO regression was applied to select key cells, and the correlation between immune checkpoints and immune cells was analyzed. Drug sensitivity analysis was conducted to identify potential therapeutic drugs targeting immune checkpoints in AS. The expression of key genes was validated through immunohistochemistry (IHC).Results HLA DMB and HLA DPA1 were downregulated in the ligaments of AS and this has been validated through peripheral blood datasets and IHC. Significant differences in expression were observed in CD8 + Tcm, CD8 + T cells, CD8 + Tem, osteoblasts, Th1 cells, and CD8 + naive T cells in AS. The infiltration levels of CD8 + Tcm and CD8 + naive T cells were significantly positively correlated with the expression levels of HLA DMB and HLA DPA1. Immune cell selection using LASSO regression showed good predictive ability for AS, with AUC values of 0.98, 0.81, and 0.75 for the three prediction models, respectively. Furthermore, this study found that HLA DMB and HLA DPA1 are involved in Th17 cell differentiation, and both Th17 cell differentiation and the NF kappa B signaling pathway are activated in the AS group. Drug sensitivity analysis showed that AS patients are more sensitive to drugs such as doramapimod and GSK269962A.Conclusion Immune checkpoints and immune cells could serve as avenues for exploring diagnostic and therapeutic strategies for AS.
C1 [Huang, Feihong; Su, Zhiping; Qin, Xiong; Xie, Xi; Yu, Chaojie] Guangxi Med Univ, Dept Bone & Soft Tissue Surg, Canc Hosp, Nanning 530021, Guangxi, Peoples R China.
   [Huang, Feihong; Su, Zhiping; Huang, Yibin; Huang, Yuxiang; Zhou, Chengyu; Feng, Sitan; Yu, Chaojie] Guangxi Med Univ, Nanning 530021, Guangxi Zhuang, Peoples R China.
   [Su, Zhiping] Guangxi Med Univ Canc Hosp, Dept Radiat Oncol, Nanning 530021, Guangxi Zhuang, Peoples R China.
   [Huang, Feihong; Liu, Chong] Guangxi Med Univ, Spine & Osteopathy Ward, Affiliated Hosp 1, Nanning 530021, Guangxi Zhuang, Peoples R China.
   [Yu, Chaojie] Guangxi Med Univ, Orthopaed Dept, Guangxi Key Lab Regenerat Med, Affiliated Hosp 1, Nanning 530021, Guangxi Zhuang, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University; Guangxi Medical University; Guangxi Medical University
RP Yu, CJ (通讯作者)，Guangxi Med Univ, Dept Bone & Soft Tissue Surg, Canc Hosp, Nanning 530021, Guangxi, Peoples R China.; Yu, CJ (通讯作者)，Guangxi Med Univ, Nanning 530021, Guangxi Zhuang, Peoples R China.; Liu, C (通讯作者)，Guangxi Med Univ, Spine & Osteopathy Ward, Affiliated Hosp 1, Nanning 530021, Guangxi Zhuang, Peoples R China.; Yu, CJ (通讯作者)，Guangxi Med Univ, Orthopaed Dept, Guangxi Key Lab Regenerat Med, Affiliated Hosp 1, Nanning 530021, Guangxi Zhuang, Peoples R China.
EM lliuchong@stu.gxmu.edu.cn; h2021020@sr.gxmu.edu.cn
RI SU, ZHIPING/GWU 6126 2022; Zhou, Chengyu/LKK 4482 2024
FU Guangxi Natural Science Foundation; Guangxi Zhuang Autonomous Region
   Health Commission [Z A20230715];  [2023GXNSFBA026238]
FX We thank all the patients who participated in this study. We thank all
   reviewers for their time and thoughtful critiques to refine our
   manuscript. We acknowledge support from Guangxi Natural Science
   Foundation (No. 2023GXNSFBA026238) and Guangxi Zhuang Autonomous Region
   Health Commission Self funded Research Project (No. Z A20230715), we
   would like to extend our appreciation to the research teams who have
   made the gene sets readily available in the NCBI GEO database
   (https://www.ncbi.nlm.nih.gov/geo/).
CR Abdel Wahab N, 2018, ANN INTERN MED, V168, P121, DOI 10.7326/M17 2073
   Abril Rodriguez G, 2017, CANCER CELL, V31, DOI 10.1016/j.ccell.2017.05.010
   Alenghat FJ, 2012, J CELL SCI, V125, P5535, DOI 10.1242/jcs.111260
   Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059 017 1349 1
   Baba N, 2013, J EXP MED, V210, P1251, DOI 10.1084/jem.20122037
   Barclay AN, 2014, ANNU REV IMMUNOL, V32, P25, DOI 10.1146/annurev immunol 032713 120142
   Barclay AN, 2006, NAT REV IMMUNOL, V6, P457, DOI 10.1038/nri1859
   Baxi S, 2018, BMJ BRIT MED J, V360, DOI 10.1136/bmj.k793
   Cai JF, 2023, IMMUN INFLAMM DIS, V11, DOI 10.1002/iid3.870
   Carlino MS, 2021, LANCET, V398, P1002, DOI 10.1016/S0140 6736(21)01206 X
   Chen B, 2017, MOL MED REP, V15, P1943, DOI 10.3892/mmr.2017.6248
   Curry WT, 2015, NEURO ONCOLOGY, V17, P26, DOI 10.1093/neuonc/nov174
   Dai WB, 2023, INFLAMMATION, V46, P1697, DOI 10.1007/s10753 023 01834 1
   de Vries NL, 2023, NATURE, V613, DOI 10.1038/s41586 022 05593 1
   Faiena I, 2018, DRUG DES DEV THER, V12, P209, DOI 10.2147/DDDT.S141491
   Feng XZ, 2023, J TRANSL MED, V21, DOI 10.1186/s12967 023 04449 0
   Fiorillo MT, 2000, J CLIN INVEST, V106, P47, DOI 10.1172/JCI9295
   Fortin G, 2009, J EXP MED, V206, P1995, DOI 10.1084/jem.20082805
   Gao ZF, 2023, MOL CANCER, V22, DOI 10.1186/s12943 023 01722 0
   Guy C, 2022, NAT IMMUNOL, V23, P757, DOI 10.1038/s41590 022 01176 4
   Hänzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471 2105 14 7
   Heinhuis KM, 2019, ANN ONCOL, V30, P219, DOI 10.1093/annonc/mdy551
   Hu FF, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbaa176
   Kuma Y, 2005, J BIOL CHEM, V280, P19472, DOI 10.1074/jbc.M414221200
   Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471 2105 9 559
   Maeser D, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbab260
   Marin Acevedo JA, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045 018 0582 8
   Marusina AI, 2023, J INVEST DERMATOL, V143, DOI 10.1016/j.jid.2023.01.012
   Miossec P, 2012, NAT REV DRUG DISCOV, V11, P763, DOI 10.1038/nrd3794
   Naimi A, 2022, CELL COMMUN SIGNAL, V20, DOI 10.1186/s12964 022 00854 y
   Pan T, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1064470
   Raychaudhuri S, 2012, NAT GENET, V44, P291, DOI 10.1038/ng.1076
   Regan J, 2002, J MED CHEM, V45, P2994, DOI 10.1021/jm020057r
   Reits E, 2022, HLA, V100, P301, DOI 10.1111/tan.14626
   Ritchlin C, 2021, BMJ BRIT MED J, V372, DOI 10.1136/bmj.m4447
   Ruffo E, 2019, SEMIN IMMUNOL, V42, DOI 10.1016/j.smim.2019.101305
   Ruterbusch M, 2020, ANNU REV IMMUNOL, V38, P705, DOI 10.1146/annurev immunol 103019 085803
   Schuetz C, 2023, CLIN EXP IMMUNOL, V213, P288, DOI 10.1093/cei/uxad032
   Smith JA, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882 014 0489 6
   Tam LS, 2010, NAT REV RHEUMATOL, V6, P399, DOI 10.1038/nrrheum.2010.79
   Tanaka K, 2008, J RHEUMATOL, V35, P2316, DOI 10.3899/jrheum.080369
   Unanue ER, 2016, ANNU REV IMMUNOL, V34, P265, DOI 10.1146/annurev immunol 041015 055420
   Urayama KY, 2012, BLOOD, V120, P3039, DOI 10.1182/blood 2012 01 404723
   van den Berg TK, 2008, TRENDS IMMUNOL, V29, P203, DOI 10.1016/j.it.2008.02.004
   van der Vlist M, 2016, NAT REV RHEUMATOL, V12, P593, DOI 10.1038/nrrheum.2016.131
   Vernon Wilson EF, 2000, EUR J IMMUNOL, V30, P2130
   Vogt AB, 1999, TRENDS BIOCHEM SCI, V24, P150, DOI 10.1016/S0968 0004(99)01364 X
   Yi KJ, 2023, ARTHRITIS RHEUMATOL, V75, P1176, DOI 10.1002/art.42476
   Yu HC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.591706
   Zeng DQ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687975
   Zhang JY, 2007, TRENDS PHARMACOL SCI, V28, P286, DOI 10.1016/j.tips.2007.04.008
   Zhang ZZ, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10397
NR 53
TC 0
Z9 0
U1 1
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD JUN 4
PY 2024
VL 26
IS 1
AR 115
DI 10.1186/s13075 024 03341 6
PG 15
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA TB0K5
UT WOS:001238677600001
PM 38835033
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, H
   Wang, X
   Hu, R
   Yang, W
   Liao, A
   Zhao, C
   Zhang, J
   Liu, Z
AF Wang, H.
   Wang, X.
   Hu, R.
   Yang, W.
   Liao, A.
   Zhao, C.
   Zhang, J.
   Liu, Z.
TI Methylation of SFRP5 is related to multidrug resistance in leukemia
   cells
SO CANCER GENE THERAPY
LA English
DT Article
DE methylation of SFRP; Wnt; beta catenin; mdr1; P glycoprotein; multidrug
   resistance
ID WNT SIGNALING PATHWAY; CHRONIC LYMPHOCYTIC LEUKEMIA; FRIZZLED RELATED
   PROTEIN 5; ACUTE MYELOID LEUKEMIA; DRUG RESISTANCE; P GLYCOPROTEIN;
   EPIGENETIC INACTIVATION; ABC TRANSPORTERS; BREAST CANCER; IN VITRO
AB Methylation of secreted frizzle related protein (SFRP) genes activates Wnt/beta catenin signaling and promotes tumor development. This study investigated whether SFRP5 gene methylation causes multidrug resistance (MDR) in leukemia through the Wnt/beta catenin signaling, leading to the upregulation of the mdr1 gene and its product, P glycoprotein (P gp). Methylation specific PCR identified SFRP5 gene methylation in cultured bone mononuclear cells from 7/12 patients with acute leukemia and in four human leukemia cell lines (HL 60, Raji, U937 and KG1a). Western blotting revealed absent SFRP5 protein expression in cells from 5/7 patients with SFRP5 gene methylation and in all cell lines. Treatment with a demethylation agent (DAC) rescued SFRP5 expression. mdr1 mRNA and P gp protein were detected in cells from 3/5 patients with absent SFRP5, and in the KG1a cell line; these cells also had the highest levels of activated beta catenin. In cells from these three patients, DAC rescued SFRP5 expression and downregulated mdr1 and P gp. SFRP5 protein expression was rescued in transgenic KG1a/SFRP5 cells, compared with KG1a/eGFP or untransfected KG1a cells. mdr1 and P gp in KG1a/SFRP5 cells were downregulated. Doxorubicin IC50 values were significantly lower in KG1a/SFRP5 (0.573 +/  0.131 mu m) than in KG1a (0.963 +/  0.115) or KG1a/eGFP (0.917 +/  0.138) cells (P <0.05). We conclude that SFRP5 gene methylation in leukemia cells activates Wnt/beta catenin signaling to upregulate mdr1/P gp expression and cause MDR. Recovery of SFRP5 expression reversed MDR in the KG1a leukemia cell line. Our results suggest that modulating SFRP5 methylation could decrease MDR in leukemia patients.
C1 [Wang, H.; Hu, R.; Yang, W.; Liao, A.; Zhang, J.; Liu, Z.] China Med Univ, Shengjing Hosp, Dept Hematol, Shenyang 110016, Peoples R China.
   [Wang, X.] China Med Univ, Shengjing Hosp, Dept Urol, Shenyang 110016, Peoples R China.
   [Zhao, C.] China Med Univ, Dept Pathophysiol, Shenyang 110016, Peoples R China.
C3 China Medical University; China Medical University; China Medical
   University
RP Liu, Z (通讯作者)，China Med Univ, Shengjing Hosp, Dept Hematol, Shenyang 110016, Peoples R China.
EM liuzhuogangmedsci@126.com
FU National Natural Science Foundation [81100376]
FX This study was supported by the National Natural Science Foundation
   (81100376).
CR Amado NG, 2011, LIFE SCI, V89, P545, DOI 10.1016/j.lfs.2011.05.003
   Baguley BC, 2010, MOL BIOTECHNOL, V46, P308, DOI 10.1007/s12033 010 9321 2
   Chen ZS, 2011, FEBS J, V278, P3226, DOI 10.1111/j.1742 4658.2011.08235.x
   Dabdoub A, 2005, J NEUROBIOL, V64, P446, DOI 10.1002/neu.20171
   De A, 2011, ACTA BIOCH BIOPH SIN, V43, P745, DOI 10.1093/abbs/gmr079
   El Wakil A, 2011, MOL CELL ENDOCRINOL, V332, P32, DOI 10.1016/j.mce.2010.11.014
   Filipovich A, 2011, EUR J HAEMATOL, V86, P453, DOI 10.1111/j.1600 0609.2011.01592.x
   Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770
   Gandhirajan RK, 2010, CURR CANCER DRUG TAR, V10, P716
   Griffiths EA, 2010, LEUKEMIA LYMPHOMA, V51, P1711, DOI 10.3109/10428194.2010.496505
   Ho CM, 2010, EUR J CLIN INVEST, V40, P310, DOI 10.1111/j.1365 2362.2010.02266.x
   Jost E, 2008, BRIT J HAEMATOL, V142, P745, DOI 10.1111/j.1365 2141.2008.07242.x
   Kawakami K, 2011, INT J CANCER, V128, P541, DOI 10.1002/ijc.25357
   Kikuchi A, 2011, INT REV CEL MOL BIO, V291, P21, DOI 10.1016/B978 0 12 386035 4.00002 1
   Kinoshita T, 2011, HEPATO GASTROENTEROL, V58, P1051
   Knez L, 2011, LUNG CANCER, V72, P271, DOI 10.1016/j.lungcan.2011.02.014
   Koenderink JB, 2010, TRENDS PARASITOL, V26, P440, DOI 10.1016/j.pt.2010.05.002
   Leslie EM, 2005, TOXICOL APPL PHARM, V204, P216, DOI 10.1016/j.taap.2004.10.012
   Li Y, 2010, CURR MED CHEM, V17, P786, DOI 10.2174/092986710790514507
   Li Y, 2008, GENE DEV, V22, P3050, DOI 10.1101/gad.1687308
   Lim JC, 2008, J NEUROCHEM, V106, P1855, DOI 10.1111/j.1471 4159.2008.05537.x
   Lin YW, 2009, J CANCER RES CLIN, V135, P1665, DOI 10.1007/s00432 009 0613 5
   Liu JB, 2011, WORLD J GASTROENTERO, V17, P4917, DOI 10.3748/wjg.v17.i44.4917
   Liu TH, 2006, CANCER RES, V66, P653, DOI 10.1158/0008 5472.CAN 05 3712
   Montcouquiol M, 2006, ANNU REV NEUROSCI, V29, P363, DOI 10.1146/annurev.neuro.29.051605.112933
   Pan GD, 2009, WORLD J GASTROENTERO, V15, P431, DOI 10.3748/wjg.15.431
   Prosperi JR, 2010, CURR DRUG TARGETS, V11, P1074
   Ravna AW, 2009, MINI REV MED CHEM, V9, P186, DOI 10.2174/138955709787316065
   Ren YH, 2008, MOL PHARMACEUT, V5, P579, DOI 10.1021/mp800001j
   Román Gómez J, 2007, BLOOD, V109, P3462, DOI 10.1182/blood 2006 09 047043
   Shekhar MPV, 2011, CURR CANCER DRUG TAR, V11, P613
   Slot AJ, 2011, ESSAYS BIOCHEM, V50, P179, DOI [10.1042/bse0500179, 10.1042/BSE0500179]
   Su HY, 2010, INT J CANCER, V127, P555, DOI 10.1002/ijc.25083
   Tamaki A, 2011, ESSAYS BIOCHEM, V50, P209, DOI [10.1042/BSE0500209, 10.1042/bse0500209]
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   Verkaar F, 2011, DRUG DISCOV TODAY, V16, P35, DOI 10.1016/j.drudis.2010.11.007
   Wang YY, 2010, ONCOTARGET, V1, P674, DOI 10.18632/oncotarget.201
   Wansleeben C, 2011, DEV DYNAM, V240, P616, DOI 10.1002/dvdy.22564
   Weisberg E, 2010, ONCOGENE, V29, P5120, DOI 10.1038/onc.2010.273
   Yao H, 2011, EXPERT OPIN THER TAR, V15, P873, DOI 10.1517/14728222.2011.577418
   Ye XS, 2009, LEUKEMIA RES, V33, P1114, DOI 10.1016/j.leukres.2008.10.011
NR 41
TC 20
Z9 24
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0929 1903
EI 1476 5500
J9 CANCER GENE THER
JI Cancer Gene Ther.
PD FEB
PY 2014
VL 21
IS 2
BP 83
EP 89
DI 10.1038/cgt.2013.87
PG 7
WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Research & Experimental Medicine
GA AB3IN
UT WOS:000331684600007
PM 24434572
OA Bronze
DA 2025 08 17
ER

PT J
AU Sigalov, AB
AF Sigalov, Alexander B.
TI Inhibition of TREM 2 Markedly Suppresses Joint Inflammation and Damage
   in Experimental Arthritis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE triggering receptors expressed on myeloid cells; TREM 1; TREM 2;
   inflammation; innate immunity; signal transduction; macrophages;
   cytokines; nanomedicine; drug delivery systems; rheumatoid arthritis
ID COLLAGEN INDUCED ARTHRITIS; ANTI TNF THERAPY; MYELOID CELLS 1;
   RHEUMATOID ARTHRITIS; DISEASE PROGRESSION; ALZHEIMERS DISEASE; SERIOUS
   INFECTIONS; TUMOR GROWTH; MACROPHAGES; INFLIXIMAB
AB The triggering receptors expressed on myeloid cells (TREMs) are a family of activating immune receptors that regulate the inflammatory response. TREM 1, which is expressed on monocytes and/or macrophages and neutrophils, functions as an inflammation amplifier and plays a role in the pathogenesis of rheumatoid arthritis (RA). Unlike TREM 1, the role in RA of TREM 2, which is expressed on macrophages, immature monocyte derived dendritic cells, osteoclasts, and microglia, remains unclear and controversial. TREM 2 ligands are still unknown, adding further uncertainty to our understanding of TREM 2 function. Previously, we demonstrated that TREM 1 blockade, using a ligand independent TREM 1 inhibitory peptide sequence GF9 rationally designed by our signaling chain homooligomerization (SCHOOL) model of cell signaling, ameliorates collagen induced arthritis (CIA) severity in mice. Here, we designed a TREM 2 inhibitory peptide sequence IA9 and tested it in the therapeutic CIA model, either as a free 9 mer peptide IA9, or as a part of a 31 mer peptide IA31 incorporated into lipopeptide complexes (IA31 LPC), for targeted delivery. We demonstrated that administration of IA9, but not a control peptide, after induction of arthritis diminished release of proinflammatory cytokines and dramatically suppressed joint inflammation and damage, suggesting that targeting TREM 2 may be a promising approach for the treatment of RA.
C1 [Sigalov, Alexander B.] SignaBlok Inc, POB 4064, Shrewsbury, MA 01545 USA.
RP Sigalov, AB (通讯作者)，SignaBlok Inc, POB 4064, Shrewsbury, MA 01545 USA.
EM sigalov@signablok.com
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases of
   the National Institutes of Health [R44AR077456]
FX This work was partly supported by a grant R44AR077456 (ABS; Alexander B.
   Sigalov, Principal investigator) from National Institute of Arthritis
   and Musculoskeletal and Skin Diseases of the National Institutes of
   Health. The additional funding has come from SignaBlok, Inc. The funding
   sources have no role in the design of the study, conduction of the
   experiments, interpretation of the data, and writing of the manuscript.
CR Alivernini S, 2018, CLIN EXP IMMUNOL, V193, P13, DOI 10.1111/cei.13098
   Alivernini S, 2020, NAT MED, V26, P1295, DOI 10.1038/s41591 020 0939 8
   Atzeni F, 2012, AUTOIMMUN REV, V12, P225, DOI 10.1016/j.autrev.2012.06.008
   Axmann R, 2009, ARTHRITIS RHEUM US, V60, P2747, DOI 10.1002/art.24781
   Bansard C, 2009, RHEUMATOLOGY, V48, P1021, DOI 10.1093/rheumatology/kep112
   Benucci M, 2012, Open Rheumatol J, V6, P33, DOI 10.2174/1874312901206010033
   Binnewies M, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109844
   Bongartz T, 2006, JAMA J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Bresnihan B, 2007, J RHEUMATOL, V34, P620
   Burmester GR, 1997, ARTHRITIS RHEUM, V40, P5, DOI 10.1002/art.1780400104
   Cheng X, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.646523
   Choy EH, 2013, NAT REV RHEUMATOL, V9, P154, DOI 10.1038/nrrheum.2013.8
   Colonna M, 2003, NAT REV IMMUNOL, V3, P445, DOI 10.1038/nri1106
   Correale C, 2013, GASTROENTEROLOGY, V144, P346, DOI [10.1053/j.gastro.2012.10.040, 10.1053/j.gastro.2012.12.016]
   Corvo ML, 1999, BBA BIOMEMBRANES, V1419, P325, DOI 10.1016/S0005 2736(99)00081 4
   Corvo ML, 2000, PHARMACEUT RES, V17, P600, DOI 10.1023/A:1007577101964
   Crotti TN, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4088
   Curtis JR, 2011, CLIN THER, V33, P679, DOI 10.1016/j.clinthera.2011.05.044
   Deczkowska A, 2020, CELL, V181, P1207, DOI 10.1016/j.cell.2020.05.003
   Dinarello CA, 2009, BIOL BLOOD MARROW TR, V15, P134, DOI 10.1016/j.bbmt.2008.11.006
   Dower K, 2008, J IMMUNOL, V180, P3520, DOI 10.4049/jimmunol.180.5.3520
   Edrees AF, 2005, CLIN EXP RHEUMATOL, V23, P469
   Fan DP, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040498
   Galloway JB, 2011, ANN RHEUM DIS, V70, P1810, DOI 10.1136/ard.2011.152769
   Gao XL, 2013, MOL MED REP, V7, P921, DOI 10.3892/mmr.2013.1268
   Garrood T, 2006, ARTHRITIS RHEUM US, V54, P1055, DOI 10.1002/art.21720
   Genua M, 2014, J TRANSL MED, V12, DOI 10.1186/s12967 014 0293 z
   Gibofsky Allan, 2012, Am J Manag Care, V18, pS295
   Greaves DR, 2005, J LIPID RES, V46, P11, DOI 10.1194/jlr.R400011 JLR200
   Jay TR, 2015, J EXP MED, V212, P287, DOI 10.1084/jem.20142322
   Joosten LAB, 1999, J IMMUNOL, V163, P5049
   Kinne RW, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2333
   Kinne RW, 2000, ARTHRITIS RES, V2, P189, DOI 10.1186/ar86
   Kober DL, 2017, J MOL BIOL, V429, P1607, DOI 10.1016/j.jmb.2017.04.004
   Kuai J, 2009, RHEUMATOLOGY, V48, P1352, DOI 10.1093/rheumatology/kep235
   Li J, 2012, CURR RHEUMATOL REP, V14, P445, DOI 10.1007/s11926 012 0272 4
   Li TT, 2022, CELLS BASEL, V11, DOI 10.3390/cells11121925
   Lin YL, 2007, J BIOL CHEM, V282, P4653, DOI 10.1074/jbc.M608552200
   McInnes IB, 2010, ANN RHEUM DIS, V69, P1898, DOI 10.1136/ard.2010.134684
   Mewar D, 2011, BRIT J PHARMACOL, V162, P785, DOI 10.1111/j.1476 5381.2010.01099.x
   Molgora M, 2020, CELL, V182, P886, DOI 10.1016/j.cell.2020.07.013
   Mulherin D, 1996, ARTHRITIS RHEUM, V39, P115, DOI 10.1002/art.1780390116
   Murakami Y, 2009, ARTHRITIS RHEUM US, V60, P1615, DOI 10.1002/art.24554
   Ohno H, 2008, EUR J IMMUNOL, V38, P283, DOI 10.1002/eji.200737199
   Pandupuspitasari NS, 2016, CURR ISSUES MOL BIOL, V20, P47
   PINCUS T, 1986, J RHEUMATOL, V13, P841
   Prasad P, 2023, MOL CELL BIOCHEM, V478, P69, DOI 10.1007/s11010 022 04492 3
   Rai V, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1099 6
   Rojas MA, 2018, BBA MOL BASIS DIS, V1864, P2761, DOI 10.1016/j.bbadis.2018.05.001
   Rommel C, 2007, NAT REV IMMUNOL, V7, P191, DOI 10.1038/nri2036
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110
   Schmitz N, 2010, OSTEOARTHR CARTILAGE, V18, pS113, DOI 10.1016/j.joca.2010.05.026
   SCOTT DL, 1987, LANCET, V1, P1108
   Sharif O, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004167
   Shen ZT, 2017, MOL PHARMACEUT, V14, P4572, DOI 10.1021/acs.molpharmaceut.7b00711
   Shen ZT, 2017, J CELL MOL MED, V21, P2524, DOI 10.1111/jcmm.13173
   Shen ZT, 2016, SCI REP UK, V6, DOI 10.1038/srep28672
   Sica A, 2017, J AUTOIMMUN, V85, P117, DOI 10.1016/j.jaut.2017.07.010
   Siegel J, 2008, ANN INTERN MED, V148, P162, DOI 10.7326/0003 4819 148 2 200801150 00012
   Sigalov AB, 2004, TRENDS IMMUNOL, V25, P583, DOI 10.1016/j.it.2004.08.009
   Sigalov AB, 2006, TRENDS PHARMACOL SCI, V27, P518, DOI 10.1016/j.tips.2006.08.004
   Sigalov AB, 2020, DRUG DISCOV TODAY, V25, P1298, DOI 10.1016/j.drudis.2020.05.005
   Sigalov AB, 2014, CONTRAST MEDIA MOL I, V9, P372, DOI 10.1002/cmmi.1587
   Sigalov AB, 2014, INT IMMUNOPHARMACOL, V21, P208, DOI 10.1016/j.intimp.2014.05.001
   Sigalov Alexander B, 2010, Self Nonself, V1, P192, DOI 10.4161/self.1.3.12794
   Simms RW, 1996, ARTHRITIS RHEUM US, V39, P723
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140 6736(16)30173 8
   Smolen JS, 2012, ANN RHEUM DIS, V71, P687, DOI 10.1136/annrheumdis 2011 200395
   Stolina M, 2009, J CLIN IMMUNOL, V29, P158, DOI 10.1007/s10875 008 9238 8
   Stolina M, 2008, BIOMARKERS, V13, P692, DOI 10.1080/13547500802651911 
   Suchankova M, 2013, RESPIROLOGY, V18, P455, DOI 10.1111/resp.12028
   Sun HF, 2020, CELLS BASEL, V9, DOI 10.3390/cells9122626
   Takagi N, 1998, ARTHRITIS RHEUM, V41, P2117, DOI 10.1002/1529 0131(199812)41:12<2117::AID ART6>3.3.CO;2 G
   Takemura K, 2010, BIOCHEM BIOPH RES CO, V391, P1675, DOI 10.1016/j.bbrc.2009.12.126
   Takeuchi T, 2011, ANN RHEUM DIS, V70, P1208, DOI 10.1136/ard.2011.153023
   Tammaro A, 2017, PHARMACOL THERAPEUT, V177, P81, DOI 10.1016/j.pharmthera.2017.02.043
   Tornai D, 2019, HEPATOL COMMUN, V3, P99, DOI 10.1002/hep4.1269
   Turnbull IR, 2006, J IMMUNOL, V177, P3520, DOI 10.4049/jimmunol.177.6.3520
   Wang M, 2019, ANN CLIN LAB SCI, V49, P249
   Wang S, 2021, AAPS PHARMSCITECH, V22, DOI 10.1208/s12249 020 01870 2
   Weber B, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003900
   Ye P., 2015, CHIN J TISSUE ENG RE, V19, P2807, DOI [10.3969/j.issn.2095 4344.2015.18.004, DOI 10.3969/J.ISSN.2095 4344.2015.18.004]
NR 84
TC 12
Z9 13
U1 0
U2 7
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2022
VL 23
IS 16
AR 8857
DI 10.3390/ijms23168857
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 4C6NQ
UT WOS:000846567900001
PM 36012120
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lasco, A
   Catalano, A
   Pilato, A
   Basile, G
   Mallamace, A
   Atteritano, M
AF Lasco, A.
   Catalano, A.
   Pilato, A.
   Basile, G.
   Mallamace, A.
   Atteritano, M.
TI Subclinical hypercortisol assessment of bone fragility: experience of
   single osteoporosis center in Sicily
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Bone density; Fractures; Hypercortisolism; Menopause; Osteoporosis
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; PRECLINICAL CUSHINGS SYNDROME;
   DISCOVERED ADRENAL MASSES; MINERAL DENSITY; INCIDENTALOMA;
   COMPLICATIONS; PATHOGENESIS; OSTEOBLASTS; PREVALENCE; MECHANISMS
AB AIM: Hypercortisolism is known to cause osteoporosis. Some evidence suggests that osteoporotic fractures may be the presenting manifestations of otherwise asymptomatic hypercortisolism. The aim of our research was to investigate the prevalence of subclinical hypercortisolism (SH) in postmenopausal women evaluated for bone fragility.
   PATIENTS AND METHODS: One hundred consecutive postmenopausal women attending the Osteoporosis Centre in the Department of Internal Medicine of the University of Messina (Messina, Italy), for the first time, were screened and a total of 50 patients (age 58 +/  5 years) were studied. Hypercortisolism was diagnosed by un suppressed serum cortisol levels after 2 day low dose dexamethasone suppression test.
   RESULTS: Among the 50 postmenopausal women studied, 3 had SH. This prevalence was 6%. The three patients with SH had a normal bone mineral density (BMD) at lumbar spine and were osteopenic at femoral neck, and presented one or more vertebral fractures at spinal radiography.
   CONCLUSIONS: Physicians should always consider SH among the causes of bone fragility, especially in individuals with vertebral fractures and the presence of an only slightly reduced BMD.
C1 [Lasco, A.; Catalano, A.; Pilato, A.; Basile, G.; Mallamace, A.; Atteritano, M.] Univ Messina, Dept Internal Med, I 98100 Messina, Italy.
C3 University of Messina
RP Atteritano, M (通讯作者)，Univ Messina, Dept Internal Med, I 98100 Messina, Italy.
EM matteritano@unime.it
RI Catalano, Antonino/H 7109 2016; Catalano, Antonino/L 5740 2019;
   Atteritano, Marco/AAL 9565 2020; Basile, Giorgio/GLS 6497 2022
OI Catalano, Antonino/0000 0003 3890 2299; BASILE,
   Giorgio/0000 0002 0040 8618; Atteritano, Marco/0000 0001 9342 802X; 
CR Angeli A, 2002, J CLIN ENDOCR METAB, V87, P4869, DOI 10.1210/jc.2002 021436
   Arnaldi G, 2003, J CLIN ENDOCR METAB, V88, P5593, DOI 10.1210/jc.2003 030871
   Arnaldi G, 1997, AGGIORNAMENTO MED, V21, P231
   Bondanelli M, 1997, METABOLISM, V46, P107, DOI 10.1016/S0026 0495(97)90176 1
   Boscaro M, 2001, LANCET, V357, P783, DOI 10.1016/S0140 6736(00)04172 6
   Canalis E, 1996, J CLIN ENDOCR METAB, V81, P3441, DOI 10.1210/jc.81.10.3441
   Catargi B, 2003, J CLIN ENDOCR METAB, V88, P5808, DOI 10.1210/jc.2003 030254
   Chiodini I, 2001, J CLIN ENDOCR METAB, V86, P5337, DOI 10.1210/jc.86.11.5337
   Chiodini I, 2007, ANN INTERN MED, V147, P541, DOI 10.7326/0003 4819 147 8 200710160 00006
   Chiodini I, 2009, J CLIN ENDOCR METAB, V94, P3207, DOI 10.1210/jc.2009 0468
   Cook DM, 1997, ENDOCRIN METAB CLIN, V26, P829, DOI 10.1016/S0889 8529(05)70284 X
   Cooper MS, 2002, J BONE MINER RES, V17, P979, DOI 10.1359/jbmr.2002.17.6.979
   Crans GG, 2005, BONE, V37, P175, DOI 10.1016/j.bone.2005.04.003
   Cushing H, 1932, B JOHNS HOPKINS HOSP, V50, P137
   Devogelaer JP, 2001, EUR J ENDOCRINOL, V145, P237, DOI 10.1530/eje.0.1450237
   Fernández Real JM, 1998, CLIN ENDOCRINOL, V49, P53, DOI 10.1046/j.1365 2265.1998.00437.x
   Genant HK, 2007, OSTEOPOROSIS INT, V18, P69, DOI 10.1007/s00198 006 0199 6
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   GROSS MD, 1993, J CLIN ENDOCR METAB, V77, P885, DOI 10.1210/jc.77.4.885
   Hadjidakis D, 2003, CLIN ENDOCRINOL, V58, P72, DOI 10.1046/j.1365 2265.2003.01676.x
   Huizenga NA, 1998, J CLIN ENDOCR METAB, V1, P144
   Khanine V, 2000, JOINT BONE SPINE, V67, P341
   KLOOS RT, 1995, ENDOCR REV, V16, P460, DOI 10.1210/er.16.4.460
   Lindholm J, 2001, J CLIN ENDOCR METAB, V86, P117, DOI 10.1210/jc.86.1.117
   LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003 4819 112 5 352
   Mantero F, 2000, J CLIN ENDOCR METAB, V85, P637, DOI 10.1210/jc.85.2.637
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Moran C, 1994, Arch Med Res, V25, P311
   Morelli V, 2010, EUR J CLIN INVEST, V40, P803, DOI 10.1111/j.1365 2362.2010.02330.x
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Omura M, 2004, HYPERTENS RES, V27, P193, DOI 10.1291/hypres.27.193
   ORTH DN, 1995, NEW ENGL J MED, V332, P791, DOI 10.1056/NEJM199503233321207
   Pereira RMR, 2001, BONE, V28, P484, DOI 10.1016/S8756 3282(01)00422 7
   Reid IR, 1997, EUR J ENDOCRINOL, V137, P209, DOI 10.1530/eje.0.1370209
   Reid IR, 1998, J CLIN ENDOCR METAB, V83, P1860, DOI 10.1210/jc.83.6.1860
   REINCKE M, 1992, J CLIN ENDOCR METAB, V75, P826, DOI 10.1210/jc.75.3.826
   Report of a WHO Study Group, 1994, TECHN REP SER WHO ST
   ROSS NS, 1990, NEW ENGL J MED, V323, P1401
   Rosse R, 2001, J CLIN ENDOCR METAB, V86, P951, DOI 10.1210/jc.86.2.951
   Rossi R, 2000, J CLIN ENDOCR METAB, V85, P1440, DOI 10.1210/jc.85.4.1440
   Rubin MR, 2002, J CLIN ENDOCR METAB, V87, P4033, DOI 10.1210/jc.2002 012101
   Sartorio A, 1998, EUR J ENDOCRINOL, V138, P146, DOI 10.1530/eje.0.1380146
   Tauchmanová L, 2001, EUR J ENDOCRINOL, V145, P241, DOI 10.1530/eje.0.1450241
   Terzolo M, 2002, J CLIN ENDOCR METAB, V87, P998, DOI 10.1210/jc.87.3.998
   Torlontano M, 1999, J CLIN ENDOCR METAB, V84, P2381, DOI 10.1210/jc.84.7.2381
NR 45
TC 18
Z9 19
U1 0
U2 1
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186 00165, ITALY
SN 1128 3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD FEB
PY 2014
VL 18
IS 3
BP 352
EP 358
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AP3HZ
UT WOS:000341967500008
PM 24563434
DA 2025 08 17
ER

PT J
AU Li, YQ
   Yang, C
   Jia, KX
   Wang, JX
   Wang, JX
   Ming, RR
   Xu, TT
   Su, XH
   Jing, Y
   Miao, YD
   Liu, CF
   Lin, N
AF Li, Yiqun
   Yang, Chao
   Jia, Kexin
   Wang, Jinxia
   Wang, Jingxia
   Ming, Ruirui
   Xu, Tengteng
   Su, Xiaohui
   Jing, Yu
   Miao, Yandong
   Liu, Chunfang
   Lin, Na
TI Fengshi Qutong capsule ameliorates bone destruction of experimental
   rheumatoid arthritis by inhibiting osteoclastogenesis
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Fengshi qutong capsule; Bone destruction; Osteoclast; Collagen induced
   arthritis; Osteoclastogenesis
ID COLLAGEN INDUCED ARTHRITIS; NF KAPPA B; SYNOVIAL INFLAMMATION;
   IMMUNE RESPONSES
AB Ethnopharmacological relevance: Bone destruction plays a key role in damaging the joint function of rheumatoid arthritis (RA). Fengshi Qutong capsule (FSQTC) consisting of 19 traditional Chinese medicines has been used for treating RA in China for many years. Preliminary studies show that FSQTC has analgesic activity and inhibits synovial angiogenesis of collagen induced arthritis (CIA), but its role on bone destruction of RA is still unclear. Aim of the study: To explore the effect of FSQTC on bone destruction of RA and the possible mechanism of osteoclastogenesis in vivo and in vitro. Materials and methods: LC MS system was used to detect the quality control components of FSQTC. The antiarthritic effect of FSQTC on CIA rats was evaluated by arthritis score, arthritis incidence and histopathology evaluation of inflamed joints. The effect of treatment with FSQTC on bone destruction of joint tissues was determined with X ray and micro CT quantification, and on bone resorption marker CTX I and formation marker osteocalcin in sera were detected by ELISA. Then, osteoclast differentiation and mature were evaluated by TRAP staining, actin ring immunofluorescence and bone resorption assay both in joints and RANKL induced RAW264.7 cells. In addition, RANKL, OPG, IL 1 beta and TNF alpha in sera were evaluated by ELISA. The molecular mechanisms of the inhibitions were elucidated by analyzing the protein and gene expression of osteoclastic markers CTSK, MMP 9 and beta 3 Integrin, transcriptional factors c Fos and NFATc1, as well as phosphorylation of ERK1/2, JNK and P38 in joints and in RANKL induced RAW264.7 cells using western blot and/or qPCR. Results: In this study, 12 major quality control components were identified. Our data showed that FSQTC significantly increased bone mineral density, volume fraction, trabecular thickness, and decreased trabecular separation of inflamed joints both at periarticular and extra articular locations in CIA rats. FSQTC also diminished the level of CTX I and simultaneously increased osteocalcin in sera of CIA rats. The effects were accompanied by reductions of osteoclast differentiation, bone resorption, and expression of osteoclastic markers (CTSK, MMP 9 and beta 3 Integrin) in joints. Interestingly, FSQTC treatment could reduce the protein level of RANKL, increase the expression of OPG, and decrease the ratio of RANKL to OPG in inflamed joints and sera of CIA rats. In addition, FSQTC inhibited the levels of pro inflammatory cytokines implicated in bone resorption, such as IL 1 beta and TNF alpha in sera. When RAW264.7 cells were treated with RANKL, FSQTC inhibited the formation of TRAP + multinucleated cells, actin ring and the bone resorbing activity in dose dependent manners. Furthermore, FSQTC reduced the RANKL induced expression of osteoclastic genes and proteins and transcriptional factors (c Fos and NFATc1), as well as phosphorylation of mitogen activated protein kinases (MAPKs). Conclusion: FSQTC may inhibit bone destruction of RA by its anti osteoclastogenic activity both in vivo and in vitro.
C1 [Li, Yiqun; Jia, Kexin; Wang, Jinxia; Wang, Jingxia; Ming, Ruirui; Xu, Tengteng; Su, Xiaohui; Liu, Chunfang; Lin, Na] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing 100700, Peoples R China.
   [Yang, Chao] Guangzhou Univ Chinese Med, Sci & Technol Innovat Ctr, Guangzhou 510405, Peoples R China.
   [Jing, Yu; Miao, Yandong] Tonghua Golden Horse Pharmaceut Ind Co Ltd, Beijing 100028, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Institute of Chinese Materia
   Medica, CACMS; Guangzhou University of Chinese Medicine
RP Liu, CF; Lin, N (通讯作者)，China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing 100700, Peoples R China.
EM cfliu@icmm.ac.cn; nlin@icmm.ac.cn
RI Miao, Yandong/ABC 5639 2020; Wang, Min/JGL 8741 2023
OI Miao, Yandong/0000 0002 1429 8915; 
CR An J, 2016, INT IMMUNOPHARMACOL, V36, P118, DOI 10.1016/j.intimp.2016.04.024
   Bai JX, 2019, BIOMED PHARMACOTHER, V116, DOI 10.1016/j.biopha.2019.109025
   Banu J, 2012, NUTR REV, V70, P22, DOI 10.1111/j.1753 4887.2011.00451.x
   Binder NB, 2013, ARTHRITIS RHEUM US, V65, P608, DOI 10.1002/art.37797
   Bonnet N, 2019, J CLIN INVEST, V129, P3214, DOI 10.1172/JCI125915
   Chen Z, 2017, PHYTOMEDICINE, V27, P15, DOI 10.1016/j.phymed.2017.01.012
   Chinese Pharmacopoeia Commission, 2020, Pharmacopoeia of People's Republic of China M, V1
   Choi JK, 2016, TOXICOL APPL PHARM, V290, P1, DOI 10.1016/j.taap.2015.11.005
   Chuang CH, 2019, J AGR FOOD CHEM, V67, P6773, DOI 10.1021/acs.jafc.9b01163
   Gu JH, 2015, J STEROID BIOCHEM, V152, P25, DOI 10.1016/j.jsbmb.2015.04.003
   Huang DN, 2021, PHARMACOL RES, V169, DOI 10.1016/j.phrs.2021.105667
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Khalid AB, 2018, BONE, V116, P78, DOI 10.1016/j.bone.2018.07.014
   Kim JH, 2011, BIOCHEM J, V436, P253, DOI 10.1042/BJ20110062
   Kim K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020601
   Lee CJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0433 0
   Lee WS, 2014, INFLAMMATION, V37, P1221, DOI 10.1007/s10753 014 9849 6
   Leibbrandt A., 2010, ANN NY ACAD SCI, V1143, P123
   Liao HJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1353 3
   Liu Chun Fang, 2020, Zhongguo Zhong Yao Za Zhi, V45, P916, DOI 10.19540/j.cnki.cjcmm.20191105.401
   Liu Chun Fang, 2019, Zhongguo Zhong Yao Za Zhi, V44, P1457, DOI 10.19540/j.cnki.cjcmm.20181220.001
   Liu CF, 2020, J ETHNOPHARMACOL, V260, DOI 10.1016/j.jep.2020.113039
   Liu CF, 2015, REJUV RES, V18, P528, DOI 10.1089/rej.2015.1688
   Makuch S, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14040309
   Minichiello E, 2016, JOINT BONE SPINE, V83, P625, DOI 10.1016/j.jbspin.2016.07.007
   Nepal M, 2013, EUR J PHARMACOL, V715, P96, DOI 10.1016/j.ejphar.2013.06.002
   Noguchi T, 2018, BIOCHEM BIOPH RES CO, V503, P644, DOI 10.1016/j.bbrc.2018.06.055
   Nygaard G, 2020, NAT REV RHEUMATOL, V16, P316, DOI 10.1038/s41584 020 0413 5
   Remmers EF, 2002, ARTHRITIS RHEUM, V46, P2225, DOI 10.1002/art.10439
   Shang W, 2016, MOL MED REP, V14, P3620, DOI 10.3892/mmr.2016.5674
   Song CC, 2019, J CELL PHYSIOL, V234, P11969, DOI 10.1002/jcp.27852
   Takayanagi H, 2012, NAT REV RHEUMATOL, V8, P684, DOI 10.1038/nrrheum.2012.167
   Vita AA, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073522
   Wang Q, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108158
   Wang ZM, 2011, J ETHNOPHARMACOL, V137, P774, DOI 10.1016/j.jep.2011.06.037
   Xu RG, 2018, CELL MOL BIOL LETT, V23, DOI 10.1186/s11658 018 0086 0
   Yahiro Y, 2020, BONE RES, V8, DOI 10.1038/s41413 020 00106 0
   Zarei A, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.30
   Zhang C, 2020, J ETHNOPHARMACOL, V260, DOI 10.1016/j.jep.2020.113051
   Zhao DF, 2020, J CELL BIOCHEM, V121, P152, DOI 10.1002/jcb.28994
NR 40
TC 13
Z9 17
U1 4
U2 44
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JAN 10
PY 2022
VL 282
AR 114602
DI 10.1016/j.jep.2021.114602
EA OCT 2021
PG 15
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA WL1MT
UT WOS:000710178800001
PM 34492323
DA 2025 08 17
ER

PT J
AU Yau, WWY
   Tang, MK
   Chen, E
   YaoYao
   Wong, IWC
   Lee, HSS
   Lee, KKH
AF Yau, Winifred W. Y.
   Tang, Mei Kuen
   Chen, Elve
   YaoYao
   Wong, Ivan W. C.
   Lee, Henry S. S.
   Lee, Kenneth K. H.
TI Cardiogenol C can induce Mouse Hair Bulge Progenitor Cells to
   Transdifferentiate into Cardiomyocyte like Cells
SO PROTEOME SCIENCE
LA English
DT Article
ID EMBRYONIC STEM CELLS; SMOOTH MUSCLE CELLS; NEURAL CREST CELLS; FOLLICLE
   BULGE; BETA CATENIN; CARDIAC DIFFERENTIATION; TRANSCRIPTION FACTORS;
   HEART DEVELOPMENT; GENE EXPRESSION; KREMEN PROTEINS
AB Background: Hair bulge progenitor cells (HBPCs) are multipotent stem cells derived from the bulge region of mice vibrissal hairs. The purified HBPCs express CD34, K15 and K14 surface markers. It has been reported that HBPCs could be readily induced to transdifferentiate into adipocytes and osteocytes. However, the ability of HBPCs to transdifferentiate into cardiomyocytes has not yet been investigated.
   Methodology/Principal Findings: The cardiomyogenic potential of HBPCs was investigated using a small cell permeable molecule called Cardiogenol C. We established that Cardiogenol C could induce HBPCs to express transcription factors GATA4, Nkx2.5 and Tbx5, which are early specific markers for pre cardiomyogenic cells. In prolonged cultures, the Cardiogenol C treated HBPCs can also express muscle proteins, cardiac specific troponin I and sarcomeric myosin heavy chain. However, we did not observe the ability of these cells to functionally contract. Hence, we called these cells cardiomyocyte like cells rather than cardiomyocytes. We tried to remedy this deficiency by pre treating HBPCs with Valproic acid first before exposing them to Cardiogenol C. This pretreatment inhibited, rather than improved, the effectiveness of Cardiogenol C in reprogramming the HBPCs. We used comparative proteomics to determine how Cardiogenol C worked by identifying proteins that were differentially expressed. We identified proteins that were involved in promoting cell differentiation, cardiomyocyte development and for the normal function of striated muscles. From those differentially expressed proteins, we further propose that Cardiogenol C might exert its effect by activating the Wnt signaling pathway through the suppression of Kremen1. In addition, by up regulating the expression of chromatin remodeling proteins, SIK1 and Smarce1 would initiate cardiac differentiation.
   Conclusions/Significance: In conclusion, our CD34(+)/K15(+) HBPCs could be induced to transdifferentiate into cardiomyocyte like cells using a small molecule called Cardiogenol C. The process involves activation of the Wnt signaling pathway and altered expression of several key chromatin remodeling proteins. The finding is clinically significant as HBPCs offer a readily accessible and autologous source of progenitor cells for cell based therapy of heart disease, which is one of major killers in developed countries.
C1 [Yau, Winifred W. Y.; Tang, Mei Kuen; Chen, Elve; YaoYao; Wong, Ivan W. C.; Lee, Henry S. S.; Lee, Kenneth K. H.] Chinese Univ Hong Kong, Stem Cell & Regenerat Themat Res Programme, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
   [Lee, Kenneth K. H.] Minist Educ, Key Lab Regenerat Med, Beijing, Peoples R China.
C3 Chinese University of Hong Kong
RP Lee, KKH (通讯作者)，Chinese Univ Hong Kong, Stem Cell & Regenerat Themat Res Programme, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
EM kaholee@cuhk.edu.hk
RI Lee, Kenneth/H 6698 2013; Tang, Florence/AAW 4103 2021; Wong, Wai Chung
   Ivan/ISB 8578 2023
OI Lee, Kenneth/0000 0002 6520 304X; Tang, Mei Kuen/0000 0002 5077 0682;
   Wong, Wai Chung/0000 0002 0098 5570; 
FU RGC [CUHK469809];  [2041396]
FX This study was supported by GRF grant (RGC Ref. No. CUHK469809) and
   Direct Grant (Project ID: 2041396) to KKH Lee.
CR Akazawa H, 2005, PHARMACOL THERAPEUT, V107, P252, DOI 10.1016/j.pharmthera.2005.03.005
   Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503
   BARTH JH, 1997, DIS HAIR SCALP, P564
   Berdeaux R, 2007, NAT MED, V13, P597, DOI 10.1038/nm1573
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467 8476.2004
   Choi SC, 2004, EXP MOL MED, V36, P515, DOI 10.1038/emm.2004.66
   COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092 8674(90)90696 C
   Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502
   Davidson G, 2002, DEVELOPMENT, V129, P5587, DOI 10.1242/dev.00154
   Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687
   Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955 0674(00)00151 4
   Etchevers HC, 2001, DEVELOPMENT, V128, P1059
   Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092 8674(00)81691 8
   Fukuda K, 2002, CR BIOL, V325, P1027, DOI 10.1016/S1631 0691(02)01524 X
   Gottlieb PD, 2002, NAT GENET, V31, P25, DOI 10.1038/ng866
   Greco V, 2009, CELL STEM CELL, V4, P155, DOI 10.1016/j.stem.2008.12.009
   Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807
   Huangfu DW, 2008, NAT BIOTECHNOL, V26, P795, DOI 10.1038/nbt1418
   Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328
   Koyanagi M, 2005, J BIOL CHEM, V280, P16838, DOI 10.1074/jbc.M500323200
   Kwon C, 2007, P NATL ACAD SCI USA, V104, P10894, DOI 10.1073/pnas.0704044104
   Lee G, 2007, NAT BIOTECHNOL, V25, P1468, DOI 10.1038/nbt1365
   Lefebvre V, 2007, INT J BIOCHEM CELL B, V39, P2195, DOI 10.1016/j.biocel.2007.05.019
   Lickert H, 2004, NATURE, V432, P107, DOI 10.1038/nature03071
   Lin LZ, 2007, P NATL ACAD SCI USA, V104, P9313, DOI 10.1073/pnas.0700923104
   Liu JY, 2008, CARDIOVASC RES, V79, P24, DOI 10.1093/cvr/cvn059
   Liu Y, 2007, PROTEOMICS, V7, P23, DOI 10.1002/pmic.200600456
   Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Morissette MR, 2006, CIRC RES, V99, P15, DOI 10.1161/01.RES.0000231290.45676.d4
   MORLEY P, 1993, J CELL PHYSIOL, V156, P219, DOI 10.1002/jcp.1041560202
   Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950
   Nakamura T, 2003, P NATL ACAD SCI USA, V100, P5834, DOI 10.1073/pnas.0935626100
   Ogasawara T, 2004, J BONE MINER RES, V19, P1128, DOI 10.1359/jbmr.2004.19.7.1128
   Ohyama M, 2006, J CLIN INVEST, V116, P249, DOI 10.1172/JCI26043
   Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092 8674(01)00208 2
   Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921
   Rangappa S, 2003, ANN THORAC SURG, V75, P775, DOI 10.1016/S0003 4975(02)04568 X
   Rao MS, 1999, ANAT RECORD, V257, P137
   RICHARDSON MK, 1993, DEV BIOL, V157, P348, DOI 10.1006/dbio.1993.1140
   Shan SW, 2007, PROTEOMICS, V7, P4303, DOI 10.1002/pmic.200700636
   Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092 8674(00)80604 2
   Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960 9822(99)80310 8
   Shirai M, 2002, J CLIN INVEST, V110, P177, DOI 10.1172/JCI200214839
   Sieber Blum M, 2004, DEV DYNAM, V231, P258, DOI 10.1002/dvdy.20129
   Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006
   Skerjanc IS, 1999, TRENDS CARDIOVAS MED, V9, P139, DOI 10.1016/S1050 1738(99)00017 1
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tang MK, 2006, PROTEOMICS, V6, P2376, DOI 10.1002/pmic.200500603
   TAYLOR SM, 1982, J CELL PHYSIOL, V111, P187, DOI 10.1002/jcp.1041110210
   Terami H, 2004, BIOCHEM BIOPH RES CO, V325, P968, DOI 10.1016/j.bbrc.2004.10.103
   Tomita Y, 2005, J CELL BIOL, V170, P1135, DOI 10.1083/jcb.200504061
   Trempus CS, 2003, J INVEST DERMATOL, V120, P501, DOI 10.1046/j.1523 1747.2003.12088.x
   van der Linden AM, 2007, EMBO J, V26, P358, DOI 10.1038/sj.emboj.7601479
   Wu X, 2004, J AM CHEM SOC, V126, P1590, DOI 10.1021/ja038950i
   Xu CH, 2002, CIRC RES, V91, P501, DOI 10.1161/01.RES.0000035254.80718.91
NR 58
TC 15
Z9 18
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1477 5956
J9 PROTEOME SCI
JI Proteome Sci.
PD JAN 19
PY 2011
VL 9
AR 3
DI 10.1186/1477 5956 9 3
PG 16
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 718VI
UT WOS:000287154100001
PM 21247432
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Byun, MR
   Lee, CH
   Hwang, JH
   Kim, AR
   Moon, SA
   Sung, MK
   Roh, JR
   Hwang, ES
   Hong, JH
AF Byun, Mi Ran
   Lee, Cham Han
   Hwang, Jun Ha
   Kim, A. Rum
   Moon, Sung Ah
   Sung, Mi Kyung
   Roh, Jung Rae
   Hwang, Eun Sook
   Hong, Jeong Ho
TI Phorbaketal A inhibits adipogenic differentiation through the
   suppression of PPARγ mediated gene transcription by TAZ
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Adipogenesis; Phorbaketal A; TAZ; PPAR gamma; ERK
ID MESENCHYMAL STEM CELLS; HIPPO PATHWAY; ADIPOCYTE DIFFERENTIATION;
   SELF RENEWAL; OSTEOBLAST DIFFERENTIATION; COACTIVATOR; OSTEOGENESIS;
   PROGENITORS; TRANSITION; INTERACTS
AB Obesity causes several metabolic diseases, including diabetes. Adipogenic differentiation is an important event for fat formation in obesity. Natural compounds that inhibit adipogenic differentiation are frequently screened to develop therapeutic drugs for treating obesity. Here we investigated the effects of phorbaketal A, a natural marine compound, on adipogenic differentiation of mesenchymal stem cells. Phorbaketal A significantly inhibited adipogenic differentiation as indicated by less fat droplets and decreased expression of adipogenic marker genes. The expression of TAZ (transcriptional coactivator with PDZ binding motif), an inhibitor of aclipogenic differentiation, significantly increased during adipogenic differentiation in the presence of phorbaketal A. Phorbaketal A increased the interaction of TAZ and PPAR gamma to suppress PPAR gamma (peroxisome proliferator activated receptor gamma) target gene expression. TAZ depleted cells showed higher adipogenic potential than that of control cells even in the presence of phorbaketal A During cellular signaling induced by phorbaketal A. ERK (extracellular signal regulated kinase) played an important role in adipogenic suppression; an inhibitor of ERK blocked phorbaketal induced adiponicnic suppression. Thus, the results show that phorbaketal A inhibits adipocyte differentiation through TAZ. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Byun, Mi Ran; Lee, Cham Han; Hwang, Jun Ha; Kim, A. Rum; Moon, Sung Ah; Sung, Mi Kyung; Hong, Jeong Ho] Korea Univ, Dept Life Sci, Seoul 136701, South Korea.
   [Roh, Jung Rae] Kunsan Natl Univ, Dept Oceanog, Jeonbuk 573701, South Korea.
   [Hwang, Eun Sook] Ewha Womans Univ, Coll Pharm, Seoul 120750, South Korea.
C3 Korea University; Kunsan National University; Ewha Womans University
RP Hong, JH (通讯作者)，Korea Univ, Dept Life Sci, Seoul 136701, South Korea.
EM jh_hong@korea.ac.kr
RI Hwang, Jun Ha/LYP 0139 2024
FU National Research Foundation of Korea (NRF) [2011 0022926,
   2009 0001197]; Marine Biotechnology Program; Land, Transport and
   Maritime Affairs, Republic of Korea; Korea University Grant
FX This work was supported by Research Programs (2011 0022926 and
   2009 0001197) through the National Research Foundation of Korea (NRF)
   and a Grant from the Marine Biotechnology Program funded by the Land,
   Transport and Maritime Affairs, Republic of Korea. This work was also
   supported by a Korea University Grant (to M. R. Byun).
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Boney CM, 2000, MOL ENDOCRINOL, V14, P805, DOI 10.1210/me.14.6.805
   Byun MR, 2012, FEBS LETT, V586, P1086, DOI 10.1016/j.febslet.2012.03.008
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200
   Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200
   Cho SW, 2011, J BONE MINER RES, V26, P1939, DOI 10.1002/jbmr.366
   Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140 6736(05)67483 1
   Hiemer SE, 2013, BBA GEN SUBJECTS, V1830, P2323, DOI 10.1016/j.bbagen.2012.07.005
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100
   Ichida F, 2004, J BIOL CHEM, V279, P34015, DOI 10.1074/jbc.M403621200
   Jeong H, 2010, FASEB J, V24, P3310, DOI 10.1096/fj.09 151324
   Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778
   Kim KA, 2007, MOL CELL BIOL, V27, P2294, DOI 10.1128/MCB.02207 06
   Kolf CM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2116
   Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508
   Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874 07
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Liu CY, 2011, J BIOL CHEM, V286, P5558, DOI 10.1074/jbc.M110.194019
   Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942
   Mahoney WM, 2005, BIOCHEM J, V388, P217, DOI 10.1042/BJ20041434
   Murakami M, 2006, BIOCHEM BIOPH RES CO, V339, P533, DOI 10.1016/j.bbrc.2005.10.214
   Murakami M, 2005, P NATL ACAD SCI USA, V102, P18034, DOI 10.1073/pnas.0509109102
   Park KS, 2004, J BIOL CHEM, V279, P17384, DOI 10.1074/jbc.M312569200
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ramos A, 2012, TRENDS CELL BIOL, V22, P339, DOI 10.1016/j.tcb.2012.04.006
   Rho JR, 2009, ORG LETT, V11, P5590, DOI 10.1021/ol902223m
   Rosen ED, 2000, GENE DEV, V14, P1293
   Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097 2765(00)80211 7
   Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066
   Varelas X, 2008, NAT CELL BIOL, V10, P837, DOI 10.1038/ncb1748
   Varelas X, 2012, TRENDS CELL BIOL, V22, P88, DOI 10.1016/j.tcb.2011.10.002
   Zhang H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200
   Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303
NR 36
TC 28
Z9 30
U1 0
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD OCT 15
PY 2013
VL 718
IS 1 3
BP 181
EP 187
DI 10.1016/j.ejphar.2013.08.035
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 242HM
UT WOS:000326229700025
PM 24036109
DA 2025 08 17
ER

PT J
AU Honda, Y
   Ding, XT
   Mussano, F
   Wiberg, A
   Ho, CM
   Nishimura, I
AF Honda, Yoshitomo
   Ding, Xianting
   Mussano, Federico
   Wiberg, Akira
   Ho, Chih ming
   Nishimura, Ichiro
TI Guiding the osteogenic fate of mouse and human mesenchymal stem cells
   through feedback system control
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MARROW STROMAL CELLS; BONE FORMATION; OSTEOBLAST DIFFERENTIATION; BMP;
   TRANSCRIPTION; GENE; PHENOTYPE; REQUIRES; RECEPTOR; ENHANCE
AB Stem cell based disease modeling presents unique opportunities for mechanistic elucidation and therapeutic targeting. The stable induction of fate specific differentiation is an essential prerequisite for stem cell based strategy. Bone morphogenetic protein 2 (BMP 2) initiates receptor regulated Smad phosphorylation, leading to the osteogenic differentiation of mesenchymal stromal/stem cells (MSC) in vitro; however, it requires supra physiological concentrations, presenting a bottleneck problem for large scale drug screening. Here, we report the use of a double objective feedback system control (FSC) with a differential evolution (DE) algorithm to identify osteogenic cocktails of extrinsic factors. Cocktails containing significantly reduced doses of BMP 2 in combination with physiologically relevant doses of dexamethasone, ascorbic acid, beta glycerophosphate, heparin, retinoic acid and vitamin D achieved accelerated in vitro mineralization of mouse and human MSC. These results provide insight into constructive approaches of FSC to determine the applicable functional and physiological environment for MSC in disease modeling, drug screening and tissue engineering.
C1 [Honda, Yoshitomo; Mussano, Federico; Wiberg, Akira; Nishimura, Ichiro] Univ Calif Los Angeles, Weintraub Ctr Reconstruct Biotechnol, Div Adv Prosthodont, Sch Dent, Los Angeles, CA 90095 USA.
   [Honda, Yoshitomo] Tohoku Univ, Grad Sch Dent, Craniofacial Funct Engn & Res Unit Interface Oral, Aoba Ku, Sendai, Miyagi 9808575, Japan.
   [Honda, Yoshitomo] Osaka Dent Univ, Inst Dent Res, Hirakata, Osaka 5731121, Japan.
   [Ding, Xianting; Ho, Chih ming] Univ Calif Los Angeles, Dept Mech & Aerosp Engn, Henry Samueli Sch Engn & Appl Sci, Los Angeles, CA 90095 USA.
   [Ding, Xianting] Shanghai Jiao Tong Univ, Med X Res Inst, Dept Biomed Engn, Shanghai 200030, Peoples R China.
   [Mussano, Federico] Univ Turin, Sch Dent, Dept Surg, I 10127 Turin, Italy.
C3 University of California System; University of California Los Angeles;
   Tohoku University; University of California System; University of
   California Los Angeles; Shanghai Jiao Tong University; A.O.U. Citta
   della Salute e della Scienza di Torino; University of Turin
RP Nishimura, I (通讯作者)，Univ Calif Los Angeles, Weintraub Ctr Reconstruct Biotechnol, Div Adv Prosthodont, Sch Dent, Box 951668, Los Angeles, CA 90095 USA.
EM inishimura@dentistry.ucla.edu
RI ; Ho, Chih Ming/I 6537 2012; Honda, Yoshitomo/AAC 3994 2020
OI Mussano, Federico/0000 0001 5800 0749; Wiberg,
   Akira/0000 0003 4944 123X; Ho, Chih Ming/0000 0001 7369 5446; Ding,
   Xianting/0000 0002 1549 3499; 
FU UCLA Center for Biological Radioprotectors [NIH/NIAID U19 AI67769]; NIH
   Nanomedicine Development Center [PN2EY018228]; Research Facilities
   Improvement Program from NIH/NCRR [C06 RR014529]; Ministry of Education,
   Science, Sports and Culture of Japan [23792272]; Grants in Aid for
   Scientific Research [23792272] Funding Source: KAKEN
FX This study was funded in part through NIH/NIAID U19 AI67769 UCLA Center
   for Biological Radioprotectors, and the NIH Nanomedicine Development
   Center, grant number PN2EY018228. This investigation was conducted at a
   facility constructed with support from the Research Facilities
   Improvement Program C06 RR014529 from NIH/NCRR. This study was supported
   in part through Grants in Aid (23792272) from the Ministry of Education,
   Science, Sports and Culture of Japan. The authors would like to thank O.
   Suzuki, Craniofacial Function Engineering, Tohoku University Graduate
   School of Dentistry, and S. Takeda, Y. Hashimoto and W. Liao, Osaka
   Dental University, for support and discussion.
CR Alves H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026678
   Anderson GJ, 2008, NAT CHEM BIOL, V4, P15, DOI 10.1038/nchembio0108 15
   Augello A, 2010, EUR CELLS MATER, V20, P121
   Bais MV, 2009, BONE, V45, P254, DOI 10.1016/j.bone.2009.04.239
   Brey DM, 2011, BIOTECHNOL BIOENG, V108, P163, DOI 10.1002/bit.22925
   Cai J, 2012, FEBS LETT, V586, P1993, DOI 10.1016/j.febslet.2012.04.030
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Colman A, 2009, CELL STEM CELL, V5, P244, DOI 10.1016/j.stem.2009.08.010
   Csiszar A, 2008, AM J PHYSIOL HEART C, V295, pH569, DOI 10.1152/ajpheart.00180.2008
   De Biase P, 2005, INJURY, V36, P43, DOI 10.1016/j.injury.2005.07.034
   Diefenderfer DL, 2003, CONNECT TISSUE RES, V44, P305, DOI 10.1080/03008200390181825
   Ding XT, 2012, INT J NANOMED, V7, P2281, DOI 10.2147/IJN.S27540
   Egawa N, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004052
   Franceschi RT, 2007, ANN NY ACAD SCI, V1116, P196, DOI 10.1196/annals.1402.081
   Hata K, 2003, MOL BIOL CELL, V14, P545, DOI 10.1091/mbc.E02 06 0356
   Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004
   Hsiong SX, 2009, TISSUE ENG PT A, V15, P263, DOI 10.1089/ten.tea.2007.0411
   Javed A, 2008, J BIOL CHEM, V283, P8412, DOI 10.1074/jbc.M705578200
   Jorgensen NR, 2004, STEROIDS, V69, P219, DOI 10.1016/j.steroids.2003.12.005
   Kato S, 2007, J STEROID BIOCHEM, V103, P372, DOI 10.1016/j.jsbmb.2006.12.038
   Kim HK, 2009, LASER MED SCI, V24, P214, DOI 10.1007/s10103 008 0550 6
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0
   Liu YQ, 2012, J CLIN INVEST, V122, P3101, DOI 10.1172/JCI61209
   Massagué J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705
   Mohal JS, 2012, CURR STEM CELL RES T, V7, P103
   Mussano F, 2010, J CELL BIOCHEM, V111, P322, DOI 10.1002/jcb.22699
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Osyczka AM, 2005, ENDOCRINOLOGY, V146, P3428, DOI 10.1210/en.2005 0303
   Osyczka AM, 2004, CELLS TISSUES ORGANS, V176, P109, DOI 10.1159/000075032
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Quarto N, 2012, P NATL ACAD SCI USA, V109, P215, DOI 10.1073/pnas.1113442109
   Rodríguez JP, 2000, J CELL BIOCHEM, V79, P557, DOI 10.1002/1097 4644(20001215)79:4<557::AID JCB40>3.0.CO;2 H
   Shimer AL, 2009, INJURY, V40, P32
   Siddappa R, 2009, TISSUE ENG PT A, V15, P2135, DOI 10.1089/ten.tea.2008.0512
   Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339 3351.2003
   Sottile V, 2000, FEBS LETT, V475, P201, DOI 10.1016/S0014 5793(00)01655 0
   Sun CP, 2009, INTEGR BIOL UK, V1, P123, DOI 10.1039/b815225j
   Szpalski C, 2012, TISSUE ENG PART B RE, V18, P258, DOI [10.1089/ten.TEB.2011.0440, 10.1089/ten.teb.2011.0440]
   Tanaka T, 2012, BLOOD, V120, P1299, DOI 10.1182/blood 2012 03 417881
   Tsutsui H, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1165
   Wang YK, 2012, STEM CELLS DEV, V21, P1176, DOI 10.1089/scd.2011.0293
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Yuan WH, 2007, J BIOL CHEM, V282, P29821, DOI 10.1074/jbc.M705495200
   Zehentner BK, 2000, DNA CELL BIOL, V19, P275, DOI 10.1089/10445490050021186
   Zhao BH, 2006, J BIOL CHEM, V281, P23246, DOI 10.1074/jbc.M511039200
NR 47
TC 46
Z9 52
U1 0
U2 25
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD DEC 5
PY 2013
VL 3
AR 3420
DI 10.1038/srep03420
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 264MB
UT WOS:000327880600002
PM 24305548
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Tsai, SW
   Chang, YH
   Yu, JL
   Hsu, HW
   Rau, LR
   Hsu, FY
AF Tsai, Shiao Wen
   Chang, Yu Han
   Yu, Jing Lun
   Hsu, Hsien Wen
   Rau, Lih Rou
   Hsu, Fu Yin
TI Preparation of Nanofibrous Structure of Mesoporous Bioactive Glass
   Microbeads for Biomedical Applications
SO MATERIALS
LA English
DT Article
DE mesoporous bioactive glasses; nanofiber; microbead
ID DRUG DELIVERY; EXTRACELLULAR MATRIX; BONE REGENERATION; FIBERS;
   MICROSPHERES; FABRICATION; SCAFFOLD; RELEASE
AB A highly ordered, mesoporous (pore size 2 similar to 50 nm) bioactive glass (MBG) structure has a greater surface area and pore volume and excellent bone forming bioactivity compared with traditional bioactive glasses (BGs). Hence, MBGs have been used in drug delivery and bone tissue engineering. MBGs can be developed as either a dense or porous block. Compared with a block, microbeads provide greater flexibility for filling different shaped cavities and are suitable for culturing cells in vitro. In contrast, the fibrous structure of a scaffold has been shown to increase cell attachment and differentiation due to its ability to mimic the three dimensional structure of natural extracellular matrices. Hence, the aim of this study is to fabricate MBG microbeads with a fibrous structure. First, a sol gel/electrospinning technique was utilized to fabricate the MBG nanofiber (MBGNF) structure. Subsequently, the MBGNF microbeads (MFBs) were produced by an electrospraying technology. The results show that the diameter of the MFBs decreases when the applied voltage increases. The drug loading and release profiles and mechanisms of the MFBs were also evaluated. MFBs had a better drug entrapment efficiency, could reduce the burst release of tetracycline, and sustain the release over 10 days. Hence, the MFBs may be suitable drug carriers. In addition, the cellular attachment of MG63 osteoblast like cells is significantly higher for MFBs than for glass microbeads after culturing for 4 h. The nanofibrous structure of MFBs could provide an appropriate environment for cellular spreading. Therefore, MFBs have great potential for use as a bone graft material in bone tissue engineering applications.
C1 [Tsai, Shiao Wen; Rau, Lih Rou] Chang Gung Univ, Grad Inst Biochem & Biomed Engn, Taoyuan 33302, Taiwan.
   [Tsai, Shiao Wen; Chang, Yu Han] Chang Gung Mem Hosp, Dept Orthopaed Surg, Linkou 33305, Taiwan.
   [Yu, Jing Lun; Hsu, Hsien Wen; Hsu, Fu Yin] Natl Taiwan Ocean Univ, Dept Life Sci & Biotechnol, Keelung 20224, Taiwan.
C3 Chang Gung University; Chang Gung Memorial Hospital; National Taiwan
   Ocean University
RP Hsu, FY (通讯作者)，Natl Taiwan Ocean Univ, Dept Life Sci & Biotechnol, Keelung 20224, Taiwan.
EM swtsai@mail.cgu.edu.tw; yhchang@adm.cgmh.org.tw; tom081211@yahoo.com.tw;
   s0958292415@gmail.com; elaine_rau12@hotmail.com; fyhsu@mail.ntou.edu.tw
RI ; Yeh, Chun Hung/JDM 9927 2023
OI Tsai, Shiao Wen/0000 0002 6225 6613; Rau, Lih Rou/0000 0003 2500 860X;
   hsu, Fu Yin/0000 0002 8221 4218
FU Ministry of Science and Technology of Taiwan [MOST
   102 2221 E 019 003 MY3]; Chang Gung Memorial Hospital CMRP project
   [CMRPD1D0401, CMRPD1D0402]
FX The authors would like to thank the Ministry of Science and Technology
   of Taiwan for financial supporting this research under contract No. MOST
   102 2221 E 019 003 MY3 and Chang Gung Memorial Hospital CMRP project
   CMRPD1D0401 and CMRPD1D0402.
CR Baino F, 2012, J APPL BIOMATER FUNC, V10, P12, DOI 10.5301/JABFM.2012.9270
   Clupper DC, 2003, J BIOMED MATER RES A, V67A, P285, DOI 10.1002/jbm.a.10040
   Durgalakshmi D, 2015, PHYS CHEM CHEM PHYS, V17, P15316, DOI 10.1039/c5cp01738f
   Fu Y, 2010, EXPERT OPIN DRUG DEL, V7, P429, DOI 10.1517/17425241003602259
   Hench L.L., 1971, Journal of Biomedical Materials Research Symposium, V36, P117, DOI DOI 10.1002/JBM.820050611
   HENCH LL, 1991, J AM CERAM SOC, V74, P1487, DOI 10.1111/j.1151 2916.1991.tb07132.x
   Hong YL, 2010, ADV FUNCT MATER, V20, P1503, DOI 10.1002/adfm.200901627
   Hsu FY, 2015, MICROPOR MESOPOR MAT, V212, P56, DOI 10.1016/j.micromeso.2015.03.027
   Hsu FY, 2010, ACTA BIOMATER, V6, P2140, DOI 10.1016/j.actbio.2009.12.023
   Kang SW, 2008, J BIOMED MATER RES A, V85A, P747, DOI 10.1002/jbm.a.31572
   Kim HW, 2006, ADV FUNCT MATER, V16, P1529, DOI 10.1002/adfm.200500750
   Liou HM, 2013, J NANOMATER, V2013, DOI 10.1155/2013/613638
   Lu H, 2009, J MATER SCI MATER M, V20, P793, DOI 10.1007/s10856 008 3649 1
   Oréfice RL, 2001, J BIOMED MATER RES, V55, P460, DOI 10.1002/1097 4636(20010615)55:4<460::AID JBM1037>3.0.CO;2 3
   Salome C., 2013, J. Pharm. Biol. Chem. Sci, V4, P97, DOI DOI 10.3390/polym6092451
   Tallia F, 2014, MATER LETT, V130, P281, DOI 10.1016/j.matlet.2014.05.062
   Tsai SW, 2014, J NANOMATER, V2014, DOI 10.1155/2014/498131
   Tsai SW, 2013, INT J NANOMED, V8, P2399, DOI 10.2147/IJN.S46613
   Wu CT, 2012, INTERFACE FOCUS, V2, P292, DOI 10.1098/rsfs.2011.0121
   Wu CT, 2010, J BIOMED MATER RES A, V95A, P476, DOI 10.1002/jbm.a.32873
   Xu CY, 2004, TISSUE ENG, V10, P1160, DOI 10.1089/ten.2004.10.1160
   Yi J, 2008, J SOL GEL SCI TECHN, V45, P115, DOI 10.1007/s10971 007 1668 x
   Zamani Z, 2015, IRAN J PHARM RES, V14, P1031
   Zhou J, 2016, MAT SCI ENG C MATER, V60, P437, DOI 10.1016/j.msec.2015.11.068
NR 24
TC 14
Z9 14
U1 2
U2 57
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1996 1944
J9 MATERIALS
JI Materials
PD JUN
PY 2016
VL 9
IS 6
AR 487
DI 10.3390/ma9060487
PG 9
WC Chemistry, Physical; Materials Science, Multidisciplinary; Metallurgy &
   Metallurgical Engineering; Physics, Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science; Metallurgy & Metallurgical Engineering;
   Physics
GA DP6TB
UT WOS:000378630600086
PM 28773610
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Chu, K
   Cornetta, KG
   Econs, MJ
AF Chu, Kang
   Cornetta, Kenneth G.
   Econs, Michael J.
TI Efficient and stable gene expression into human osteoclasts using an
   HIV 1 Based lentiviral vector
SO DNA AND CELL BIOLOGY
LA English
DT Article
ID HUMAN IMMUNODEFICIENCY VIRUS; DIFFERENTIATION; CELLS; TRANSDUCTION;
   INTEGRATION; RECEPTOR; DISEASE; MITOSIS
AB Since osteoclasts are terminally differentiated cells without proliferating activity, efficient and stable gene expression into these cells remains a difficulty. In the current study, we investigate gene transduction into human preosteoclasts by a replication defective lentivirus based vector containing a modified HIV 1 genome. Human preosteoclasts (differentiating osteoclasts) were transduced with lentiviruses bearing an enhanced green fluorescent protein (EFGP) reporter gene. Transduction efficiencies were measured by flow cytometry for EGFP protein expression. Sorted human transduced preosteoclasts were replated and differentiated under human macrophage colony stimulating factor and human receptor activator of NF kappa B ligand. Mature osteoclasts were then analyzed by the cell viability assay, TRACP assay, and pit formation assay. Efficient gene transduction was obtained at multiplicity of infection of 10, and gene expression lasted for over 4 weeks using our protocol. Lentiviral transduction did not affect osteoclast survival, formation, or function. These results establish an efficient method for gene transduction into human preosteoclasts using a lentiviral vector. Importantly, these transduced preosteoclasts could differentiate into mature osteoclasts without a negative impact from the lentiviruses. This protocol provides a new tool for studies of osteoclast biology. Further work in this area may open new avenues for the study of osteoclast gene signaling and gene therapy of disorders of osteoclast function.
C1 [Chu, Kang; Econs, Michael J.] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA.
   [Cornetta, Kenneth G.; Econs, Michael J.] Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Indianapolis; Indiana
   University System; Indiana University Indianapolis
RP Chu, K (通讯作者)，Indiana Univ, Sch Med, Dept Med, 541 N Clin Dr,CL 459, Indianapolis, IN 46202 USA.
EM kachu@iupui.edu
OI Econs, Michael/0000 0003 0940 1911; Cornetta,
   Kenneth/0000 0003 1415 3668
FU NCRR NIH HHS [M01 RR 00750] Funding Source: Medline; NIAMS NIH HHS [R01
   AR 43476] Funding Source: Medline
CR Amado RG, 2002, CURR TOP MICROBIOL, V261, P229
   Blomer U, 1997, J VIROL, V71, P6641
   Chu K, 2006, J BONE MINER RES, V21, P1089, DOI 10.1359/JBMR.060409
   Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463 8471.1998
   Fukuda A, 2005, J BONE MINER RES, V20, P2245, DOI 10.1359/JBMR.050816
   Humphrey MB, 2006, J BONE MINER RES, V21, P237, DOI 10.1359/JBMR.051016
   Kahl CA, 2004, J VIROL, V78, P1421, DOI 10.1128/JVI.78.3.1421 1430.2004
   Kobayashi Y, 2005, J BIOL CHEM, V280, P24035, DOI 10.1074/jbc.M500926200
   Korin YD, 1998, J VIROL, V72, P3161, DOI 10.1128/JVI.72.4.3161 3168.1998
   Laitala Leinonen T, 2005, J NEGAT RESULTS BIOM, V4, DOI 10.1186/1477 5751 4 5
   Lever AML, 2000, CURR OPIN MOL THER, V2, P488
   Lever AML, 2004, J BIOMED SCI, V11, P439, DOI 10.1159/000077893
   LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510 516.1994
   MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239
   Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382
   Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263
   ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460 2075.1993.tb05858.x
   Shin CS, 2005, J BONE MINER RES, V20, P2200, DOI 10.1359/JBMR.050809
   Tanaka S, 1998, J BONE MINER RES, V13, P1714, DOI 10.1359/jbmr.1998.13.11.1714
   Taylor A, 2007, CALCIFIED TISSUE INT, V80, P132, DOI 10.1007/s00223 006 0245 6
   Watson DJ, 2002, MOL THER, V5, P528, DOI 10.1006/mthe.2002.0584
NR 21
TC 8
Z9 14
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044 5498
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD JUN
PY 2008
VL 27
IS 6
BP 315
EP 320
DI 10.1089/dna.2007.0656
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA 317UQ
UT WOS:000257046100003
PM 18363548
OA Green Published
DA 2025 08 17
ER

PT J
AU Aldea, MD
   Petrushev, B
   Soritau, O
   Tomuleasa, CI
   Berindan Neagoe, I
   Filip, AG
   Chereches, G
   Cenariu, M
   Craciun, L
   Tatomir, C
   Florian, IS
   Crivii, CB
   Kacso, G
AF Aldea, Mihaela D.
   Petrushev, Bobe
   Soritau, Olga
   Tomuleasa, Ciprian I.
   Berindan Neagoe, Ioana
   Filip, Adriana G.
   Chereches, Gabriela
   Cenariu, Mihai
   Craciun, Lucian
   Tatomir, Corina
   Florian, Ioan Stefan
   Crivii, Carmen B.
   Kacso, Gabriel
TI Metformin plus sorafenib highly impacts temozolomide resistant
   glioblastoma stem like cells
SO JOURNAL OF BUON
LA English
DT Article
DE glioblastoma; metformin; sorafenib; stem like cells; temozolomide
ID P GLYCOPROTEIN EXPRESSION; ADJUVANT TEMOZOLOMIDE; MALIGNANT GLIOMAS;
   CANCER THERAPY; PHASE II; PATHWAY; GROWTH; CHEMORESISTANCE;
   RADIOTHERAPY; ACTIVATION
AB Purpose: Glioblastoma stein cells (GSCs), responsible for the dismal disease prognosis after conventional treatments, are driven by overactive signaling pathways, such as PI3K/AKT/mTOR and RAS/RAF/MAPK. The objective of our study was to target in vitro GSCs by combining metformin (Met) as a mTOR inhibitor, with sorafenib (Soraf) as a RAF inhibitor.
   Methods: GSCs cultured under basal conditions were treated with Met, temozolomide (TMZ), Soraf, Met+TMZ and Met+Soraf; as untreated arm served as control. At 4 hrs of drug exposure, we measured the level of reactive oxygen species (ROS) by 2',7' dichlorofluorescein diacetate (DCFDA) assay, apoptosis by prodium iodide (PI) V Annexin staining and efflux pump activity by using the fluorescent dye rhodamine 123. At 24 hrs, we measured cell proliferation by 3 (4,5 dimethylthiazolyl 2) 2,5 diphenyltetrazoliurn bromide (MTT) assay, apoptosis and malondialdehyde (MDA) levels. MTT results were compared with corresponding measurements on cultures of non stem glioblastoma cells and osteoblasts.
   Results: Met+Soraf exerted the highest antiproliferative effects in GSCs and non stern glioblastoma cells (p<0.001). Both Met and Soraf monotherapy exhibited a selective cytotoxic effect on GSCs (p<0.001), while no effect was detected on non stem glioblastoma cells (p>0.05). Soraf, but not Met, impacted the proliferation of normal cells. Soraf displayed synergism with Met in producing high levels of ROS, decreasing efflux pump activity and generating the highest apoptotic rates when compared to either drug alone (p<0.001).
   Conclusion: GSCs were highly sensitive to the combination of Met and Soraf which reduced cell proliferation, increased oxidative stress, inhibited efflux pump activity and ultimately killed GSCs. We strongly believe that these results warrant further in vivo exploration.
C1 [Aldea, Mihaela D.; Petrushev, Bobe; Tomuleasa, Ciprian I.; Berindan Neagoe, Ioana; Craciun, Lucian] Iuliu Hatieganu Univ Med & Pharm, Res Ctr Funct Genom Biomed & Translat Med, Cluj Napoca, Cluj, Romania.
   [Soritau, Olga; Chereches, Gabriela; Tatomir, Corina] Ion Chiricuta Canc Ctr, Dept Radiobiol & Tumor Biol, Cluj Napoca, Romania.
   [Filip, Adriana G.] Iuliu Hatieganu Univ Med & Pharm, Dept Physiol, Cluj Napoca, Cluj, Romania.
   [Cenariu, Mihai] Univ Agr Sci & Vet Med, Fac Vet Med, Cluj Napoca, Romania.
   [Florian, Ioan Stefan] Iuliu Hatieganu Univ Med & Pharm, Dept Neurosurg, Cluj Napoca, Cluj, Romania.
   [Crivii, Carmen B.] Iuliu Hatieganu Univ Med & Pharm, Dept Morphol Sci, Cluj Napoca, Cluj, Romania.
   [Kacso, Gabriel] Iuliu Hatieganu Univ Med & Pharm, Dept Oncol & Radiotherapy, Cluj Napoca, Cluj, Romania.
C3 Iuliu Hatieganu University of Medicine & Pharmacy; Oncology Institute
   Prof. Dr. Ion Chiricuta; Iuliu Hatieganu University of Medicine &
   Pharmacy; University of Agricultural Sciences & Veterinary Medicine Cluj
   Napoca; Iuliu Hatieganu University of Medicine & Pharmacy; Iuliu
   Hatieganu University of Medicine & Pharmacy; Iuliu Hatieganu University
   of Medicine & Pharmacy
RP Crivii, CB (通讯作者)，Iuliu Hatieganu Univ Med & Pharm, Dept Morphol Sci, 3 5 Clinicilor St, Cluj Napoca, Cluj, Romania.
EM bianca.crivii@umfcluj.ro
RI Kacso, Gabriel/AEE 3611 2022; Berindan Neagoe, Ioana/AAH 9854 2019;
   Petrushev, Bobe/AAA 7810 2019; Tomuleasa, Ciprian/F 3030 2017; Filip,
   Gabriela Adriana/AAB 7418 2019; Cenariu, Mihai/C 2558 2012; Crivii,
   Carmen Bianca/AAS 4040 2020; Aldea, Mihaela/MDT 8065 2025; Cenariu,
   Mihai Cosmin/C 2558 2012; Florian, Ioan Stefan/D 5934 2016; Florian,
   Ioan/D 5934 2016
OI KACSO, Gabriel/0000 0003 2245 3302; Aldea, Mihaela/0000 0001 7685 051X;
   Tomuleasa, Ciprian/0000 0001 5500 1519; Filip, Gabriela
   Adriana/0000 0002 7447 4925; Cenariu, Mihai Cosmin/0000 0001 6501 0128;
   Crivii, Carmen Bianca/0000 0001 5275 5753; Florian, Ioan
   Stefan/0000 0001 7127 0946; 
FU Iuliu Hatieganu University of Medicine and Pharmacy
   [22714/38/06.10.2011]
FX This research was financially supported by a research grant of the Iuliu
   Hatieganu University of Medicine and Pharmacy (Contract
   22714/38/06.10.2011). All the experiments were carried out at the
   Laboratory of Cell Cultures Department of Radiobiology and Tumor
   Biology, Ion Chiricuta Comprehensive Cancer Center in Cluj Napoca,
   Romania.
CR Carra E, 2013, CELL CYCLE, V12, P491, DOI 10.4161/cc.23372
   Chamberlain MC, 2010, EXPERT REV NEUROTHER, V10, P1537, DOI 10.1586/ERN.10.32
   Cheng CK, 2009, BRAIN PATHOL, V19, P112, DOI 10.1111/j.1750 3639.2008.00233.x
   CONTI M, 1991, CLIN CHEM, V37, P1273
   Dimov I, 2011, THESCIENTIFICWORLDJO, V11, P930, DOI 10.1100/tsw.2011.42
   Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008 5472.CAN 07 2310
   Eum KH, 2013, MOL CELL BIOCHEM, V372, P65, DOI 10.1007/s11010 012 1446 0
   Ferla R, 2012, ONCOL LETT, V4, P1077, DOI 10.3892/ol.2012.843
   Fouse SD, 2014, NEURO ONCOLOGY, V16, P361, DOI 10.1093/neuonc/not223
   Gao QL, 2013, EXPERT OPIN INV DRUG, V22, P1023, DOI 10.1517/13543784.2013.806484
   Gomez Pinillos A, 2012, HEMATOL ONCOL CLIN N, V26, P483, DOI 10.1016/j.hoc.2012.02.014
   Hainsworth JD, 2010, CANCER AM CANCER SOC, V116, P3663, DOI 10.1002/cncr.25275
   Halliwell B, 2000, CARDIOVASC RES, V47, P410, DOI 10.1016/S0008 6363(00)00097 3
   HAUGAARD N, 1968, PHYSIOL REV, V48, P311, DOI 10.1152/physrev.1968.48.2.311
   Hegi ME, 2011, MOL CANCER THER, V10, P1102, DOI 10.1158/1535 7163.MCT 11 0048
   Hemauer SJ, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.01.035
   Isakovic A, 2007, CELL MOL LIFE SCI, V64, P1290, DOI 10.1007/s00018 007 7080 4
   Kim HG, 2011, BRIT J PHARMACOL, V162, P1096, DOI 10.1111/j.1476 5381.2010.01101.x
   Kim Y, 2012, GENE DEV, V26, P1247, DOI 10.1101/gad.193565.112
   Labuzek K, 2010, PHARMACOL REP, V62, P956
   LEE JS, 1994, MOL PHARMACOL, V46, P627
   Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476 4598 5 67
   Mirmiranpour H, 2013, J DIABETES COMPLICAT, V27, P501, DOI 10.1016/j.jdiacomp.2013.05.006
   Nakai E, 2009, CANCER INVEST, V27, P901, DOI 10.3109/07357900801946679
   Narita Y, 2002, CANCER RES, V62, P6764
   Niyazi M, 2011, RADIOTHER ONCOL, V98, P1, DOI 10.1016/j.radonc.2010.11.006
   Orza A, 2013, INT J NANOMED, V8, P689, DOI 10.2147/IJN.S37481
   Peereboom DM, 2013, NEURO ONCOLOGY, V15, P490, DOI 10.1093/neuonc/nos322
   Pistollato F, 2010, STEM CELLS, V28, P851, DOI 10.1002/stem.415
   Polivka J, 2014, PHARMACOL THERAPEUT, V142, P164, DOI 10.1016/j.pharmthera.2013.12.004
   Puputti M, 2006, MOL CANCER RES, V4, P927, DOI 10.1158/1541 7786.MCR 06 0085
   Riganti C, 2013, NEURO ONCOLOGY, V15, P1502, DOI 10.1093/neuonc/not104
   Robinson JP, 2011, AM J CANCER RES, V1, P155
   Ropolo M, 2009, MOL CANCER RES, V7, P383, DOI 10.1158/1541 7786.MCR 08 0409
   Sato A, 2012, STEM CELL TRANSL MED, V1, P811, DOI 10.5966/sctm.2012 0058
   SCHLEGEL J, 1994, INT J CANCER, V56, P72
   Soritau O, 2011, J BUON, V16, P282
   Soroceanu L, 2007, P NATL ACAD SCI USA, V104, P3466, DOI 10.1073/pnas.0611271104
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470 2045(09)70025 7
   Tomuleasa C, 2010, J BUON, V15, P583
   Tomuleasa CI, 2009, ROM J MORPHOL EMBRYO, V50, P349
   Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008 5472.CAN 04 1443
   Würth R, 2013, CELL CYCLE, V12, P145, DOI 10.4161/cc.23050
   Xu C, 2013, SCI WORLD J, V2013, P413
NR 46
TC 51
Z9 55
U1 0
U2 10
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107 0625
EI 2241 6293
J9 J BUON
JI J. BUON
PD APR JUN
PY 2014
VL 19
IS 2
BP 502
EP 511
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AK4PX
UT WOS:000338407700026
PM 24965413
DA 2025 08 17
ER

PT J
AU Gao, XL
   Cao, MG
   Ai, GG
   Hu, YB
AF Gao, X.  L.
   Cao, M.  G.
   A, G.  G., I
   Hu, Y.  B.
TI Mir 98 reduces the expression of HMGA2 and promotes osteogenic
   differentiation of mesenchymal stem cells
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE MiR 98; HMGA2; Osteogenic differentiation; Mesenchymal stem cells
ID BREAST CANCER; BONE REGENERATION; OSTEOBLAST; MIGRATION; THERAPY; GROWTH
AB OBJECTIVE: To study effects of microRNA 98 (miR 98) on osteogenic differentiation of mesenchymal stem cells (MSCs).
   PATIENTS AND METHODS: We predicted target gene of miR 98 with software test, and detected expression changes of miR 98, as well as its target gene HMGA2, in the process of osteogenic differentiation of mesenchymal stem cells. After transfection of miR 98 mimic and HMGA2 siRNA, we induced osteogenic differentiation and detected expression changes of osteogenic differentiation markers (RUNX2, ALP, OCN, and BSP).
   RESULTS: MiR 98 combined directly with target gene HMGA2 and inhibited its expression. During the process of osteogenic differentiation, expression of miR 98 was up regulated, while HMGA2 expression was down regulated. In addition, the expression of osteogenesis maker genes increased in cells being transfected with miR 98 mimics and HMGA2 siRNA.
   CONCLUSIONS: MiR 98 can promote osteogenic differentiation of mesenchymal stem cells by targeting gene HMGA2.
C1 [Gao, X.  L.; Hu, Y.  B.] Xinjiang Med Univ, Affiliated Hosp 6, Dept Spine Surg, Urumqi, Peoples R China.
   [Cao, M.  G.] Xinjiang Med Univ, Affiliated Hosp 6, Dept Joint Surg, Urumqi, Peoples R China.
   [A, G.  G., I] Xinjiang Dushanzi Peoples Hosp, Dept Orthoped, Karamay, Peoples R China.
C3 Xinjiang Medical University; Xinjiang Medical University
RP Hu, YB (通讯作者)，Xinjiang Med Univ, Affiliated Hosp 6, Dept Spine Surg, Urumqi, Peoples R China.
EM hyb4499@126.com
RI Ai, guoguo/NGR 2410 2025
CR Ahlmann E, 2002, J BONE JOINT SURG AM, V84A, P716, DOI 10.2106/00004623 200205000 00003
   AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   Bais MV, 2012, BIOCHEM BIOPH RES CO, V417, P211, DOI 10.1016/j.bbrc.2011.11.087
   Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582 4934.2004.tb00320.x
   Cai C, 2017, BIOCHEM BIOPH RES CO, V485, P272, DOI 10.1016/j.bbrc.2017.02.094
   Dong CH, 2017, EUR REV MED PHARMACO, V21, P5542, DOI 10.26355/eurrev_201712_13990
   Fu T, 2014, MOL CELL BIOL, V34, P4130, DOI 10.1128/MCB.00596 14
   Ge DW, 2017, EUR REV MED PHARMACO, V21, P4784
   He XN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071895
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   in't Anker PS, 2004, STEM CELLS, V22, P1338, DOI 10.1634/stemcells.2004 0058
   Kang SW, 2008, BIOTECHNOL LETT, V30, P1163, DOI 10.1007/s10529 008 9675 8
   Koç ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307
   Levy O, 2010, INT J BIOCHEM CELL B, V42, P1823, DOI 10.1016/j.biocel.2010.07.017
   Li HL, 2013, STEM CELL RES, V10, P313, DOI 10.1016/j.scr.2012.11.007
   Luo W, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.289
   Miao ZN, 2006, CELL BIOL INT, V30, P681, DOI 10.1016/j.cellbi.2006.03.009
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Noda Masaki, 2002, Clin Calcium, V12, P187
   Oreffo ROC, 1998, CLIN SCI, V94, P549, DOI 10.1042/cs0940549
   Orfanidou T, 2009, J CELL MOL MED, V13, P3186, DOI 10.1111/j.1582 4934.2009.00678.x
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Semenov OV, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.10.869
   Wang KC, 2017, CANCER BIOMARK, V20, P283, DOI 10.3233/CBM 170124
   Wei JW, 2012, J CELL BIOL, V197, P509, DOI 10.1083/jcb.201201057
   Wu JJ, 2016, CANCER LETT, V376, P284, DOI 10.1016/j.canlet.2016.04.005
   Zhang HB, 2015, EMBO REP, V16, P1378, DOI 10.15252/embr.201540837
   Zhang JF, 2011, RNA BIOL, V8, P829, DOI 10.4161/rna.8.5.16043
NR 29
TC 18
Z9 20
U1 0
U2 9
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186 00165, ITALY
SN 1128 3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD JUN
PY 2018
VL 22
IS 11
BP 3311
EP 3317
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GJ8XT
UT WOS:000435675800006
PM 29917180
DA 2025 08 17
ER

PT J
AU Mori, Y
   Kasai, H
   Ose, A
   Serada, M
   Ishiguro, M
   Shiraki, M
   Tanigawara, Y
AF Mori, Y.
   Kasai, H.
   Ose, A.
   Serada, M.
   Ishiguro, M.
   Shiraki, M.
   Tanigawara, Y.
TI Modeling and simulation of bone mineral density in Japanese osteoporosis
   patients treated with zoledronic acid using tartrate resistant acid
   phosphatase 5b, a bone resorption marker
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bone mineral density; Bone resorption marker; Modeling and simulation;
   Osteoporosis; Tartrate resistant acid phosphatase 5b (TRACP 5b);
   Zoledronic acid
ID POSTMENOPAUSAL WOMEN; THERAPY; PHARMACODYNAMICS; TERIPARATIDE;
   HOMEOSTASIS; PREVENTION; DENOSUMAB; TRIAL; BMD
AB A Summary Annual intravenous administration of zoledronic acid is used in the treatment of osteoporosis. A mathematical model was developed to predict bone mineral density up to 2 years after two annual doses of zoledronic acid from the early values of a bone resorption marker in osteoporosis patients.
   Introduction The measurement of bone mineral density (BMD) has been used as a surrogate marker instead of the observation of incident fractures to detect the efficacy of treatment. However, this method requires a long time to obtain significant changes. On the other hand, bone resorption markers respond to bone resorption inhibitors within a few weeks. Therefore, the aim of this study was to develop a mathematical model predicting long term BMD after two annual doses of zoledronic acid (ZOL) using the early response of a bone resorption marker in osteoporosis patients.
   Methods The model was constructed using 3410 tartrate resistant acid phosphatase 5b (TRACP 5b) serum concentrations and 1146 lumbar spine (L2 L4) BMD values from 306 patients with primary osteoporosis. A mathematical model was developed to describe the time dependent profiles of TRACP 5b and BMD.
   Results The percentage changes from baseline of the BMD (%BMD) at up to 2 years were predicted from patients' baseline BMD and baseline and 12 week TRACP 5b values by the model obtained. The simulated 90% prediction interval almost covered the observed %BMD distribution at each time point, and the predictions were comparable to the observed %BMD.
   Conclusions This is the first model to predict BMD for up to 2 years following two annual doses of ZOL using patients' background characteristics and the early response of TRACP 5b. This model allows us to inform patients at the initial stage of ZOL treatment of their predicted response to treatment.
C1 [Mori, Y.; Ose, A.; Serada, M.] Asahi Kasei Pharma Corp, Clin Dev Ctr, Dev Planning, Chiyoda Ku, 1 105 Kanda Jinbocho, Tokyo 1018101, Japan.
   [Kasai, H.] Certara GK, Minato Ku, 4 2 12 Toranomon, Tokyo 1050001, Japan.
   [Ishiguro, M.] Asahi Kasei Pharma Corp, Pharmaceut Res Ctr, Lab Safety Assessment, 632 1 Mifuku, Izunokuni, Shizuoka 4102321, Japan.
   [Ishiguro, M.] Asahi Kasei Pharma Corp, Pharmaceut Res Ctr, ADME, 632 1 Mifuku, Izunokuni, Shizuoka 4102321, Japan.
   [Shiraki, M.] Res Inst & Practice Involut Dis, Dept Internal Med, 1610 1 Meisei, Azumino, Nagano 3998101, Japan.
   [Tanigawara, Y.] Keio Univ, Sch Med, Dept Clin Pharmacokinet & Pharmacodynam, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
C3 Asahi Kasei Pharma Corporation; Asahi Kasei Pharma Corporation; Asahi
   Kasei Pharma Corporation; Keio University
RP Tanigawara, Y (通讯作者)，Keio Univ, Sch Med, Dept Clin Pharmacokinet & Pharmacodynam, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM tanigawara yusuke@umin.ac.jp
RI Tanigawara, Yusuke/KIB 8896 2024
OI Tanigawara, Yusuke/0000 0002 6309 955X
CR [Anonymous], 2005, PAGE ABSTRACTS ANN M
   Bell KJL, 2016, J BONE MINER RES, V31, P1767, DOI 10.1002/jbmr.2847
   Chen PQ, 2005, J BONE MINER RES, V20, P962, DOI 10.1359/JBMR.050105
   Cummings SR, 2017, J BONE MINER RES, V32, P3, DOI 10.1002/jbmr.3039
   Diez Perez A, 2017, OSTEOPOROSIS INT, V28, P767, DOI 10.1007/s00198 017 3906 6
   Diez Perez A, 2012, OSTEOPOROSIS INT, V23, P2769, DOI 10.1007/s00198 012 2093 8
   Hannon RA, 2004, BONE, V34, P187, DOI 10.1016/j.bone.2003.04.002
   Hasegawa C, 2014, J CLIN PHARMACOL, V54, P937, DOI 10.1002/jcph.279
   Hooker AC, 2007, PHARM RES, V24, P2187, DOI 10.1007/s11095 007 9361 x
   Kanis JA, 2007, ASSESSMENT OSTEOPORO
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kuroda T, 2012, J CLIN DENSITOM, V15, P392, DOI 10.1016/j.jocd.2012.02.005
   Marathe A, 2008, J PHARMACOL EXP THER, V326, P555, DOI 10.1124/jpet.108.137703
   Marathe DD, 2011, BIOPHARM DRUG DISPOS, V32, P471, DOI 10.1002/bdd.770
   Nakai K, 2015, CLIN PHARMACOKINET, V54, P295, DOI 10.1007/s40262 014 0206 6
   Nakamura T, 2017, OSTEOPOROSIS INT, V28, P389, DOI 10.1007/s00198 016 3736 y
   Parke J, 1999, COMPUT METH PROG BIO, V59, P19, DOI 10.1016/S0169 2607(98)00098 4
   Peterson MC, 2012, CPT PHARMACOMET SYST, V1, DOI 10.1038/psp.2012.15
   Peterson MC, 2010, BONE, V46, P49, DOI 10.1016/j.bone.2009.08.053
   Shiraki M, 2016, OSTEOPOROSIS INT, V27, P3057, DOI 10.1007/s00198 016 3640 5
   Tihsluram R.J., 1993, MONOGRAPHS STAT APPL, DOI DOI 10.1007/978
   Tsujimoto M, 2011, BONE, V48, P798, DOI 10.1016/j.bone.2010.12.006
   Unnanuntana A, 2010, J BONE JOINT SURG AM, V92A, P743, DOI 10.2106/JBJS.I.00919
   Yamada S, 2008, CLIN ENDOCRINOL, V69, P189, DOI 10.1111/j.1365 2265.2008.03187.x
NR 24
TC 17
Z9 20
U1 0
U2 3
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAY
PY 2018
VL 29
IS 5
BP 1155
EP 1163
DI 10.1007/s00198 018 4376 1
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GF4KK
UT WOS:000431931400013
PM 29423715
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Bar Yehuda, S
   Rath Wolfson, L
   Del Valle, L
   Ochaion, A
   Cohen, S
   Patoka, R
   Zozulya, G
   Barer, F
   Atar, E
   Piña Oviedo, S
   Perez Liz, G
   Castel, D
   Fishman, P
AF Bar Yehuda, S.
   Rath Wolfson, L.
   Del Valle, L.
   Ochaion, A.
   Cohen, S.
   Patoka, R.
   Zozulya, G.
   Barer, F.
   Atar, E.
   Pina Oviedo, S.
   Perez Liz, G.
   Castel, D.
   Fishman, P.
TI Induction of an Antiinflammatory Effect and Prevention of Cartilage
   Damage in Rat Knee Osteoarthritis by CF101 Treatment
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID NF KAPPA B; A(3) ADENOSINE RECEPTOR; ADJUVANT INDUCED ARTHRITIS;
   COLLAGEN INDUCED ARTHRITIS; HUMAN ARTICULAR CHONDROCYTES;
   RHEUMATOID ARTHRITIS; TRANSCRIPTION FACTORS; SIGNAL TRANSDUCTION;
   MECHANICAL STRAIN; GENE EXPRESSION
AB Objective. Studies have suggested that rheumatoid arthritis (RA) and osteoarthritis (OA) share common characteristics. The highly selective A(3) adenosine receptor agonist CF101 was recently defined as a potent antiinflammatory agent for the treatment of RA. The purpose of this study was to examine the effects of CF101 on the clinical and pathologic manifestations of OA in an experimental animal model.
   Methods. OA was induced in rats by monosodium iodoacetate, and upon disease onset, oral treatment with CF101 (100 mu g/kg given twice daily) was initiated. The A(3) adenosine receptor antagonist MRS1220 (100 mu g/kg given twice daily) was administered orally, 30 minutes before CF101 treatment. The OA clinical score was monitored by knee diameter measurements and by radiographic analyses. Histologic analyses were performed following staining with hematoxylin and eosin, Safranin O fast green, or toluidine blue, and histologic changes were scored according to a modified Mankin system. Signaling proteins were assayed by Western blotting; apoptosis was detected via immunohistochemistry and TUNEL analyses.
   Results. CF101 induced a marked decrease in knee diameter and improved the changes noted on radiographs. Administration of MRS1220 counteracted the effects of CF101. CF101 prevented cartilage damage, osteoclast/osteophyte formation, and bone destruction. In addition, CF101 markedly reduced pannus formation and lymphocyte infiltration. Mechanistically, CF101 induced deregulation of the NF kappa B signaling pathway, resulting in down regulation of tumor necrosis factor alpha. Consequently, CF101 induced apoptosis of inflammatory cells that had infiltrated the knee joints; however, it prevented apoptosis of chondrocytes.
   Conclusion. CF101 deregulated the NF kappa B signaling pathway involved in the pathogenesis of OA. CF101 induced apoptosis of inflammatory cells and acted as a cartilage protective agent, which suggests that it would be a suitable candidate drug for the treatment of OA.
C1 [Bar Yehuda, S.; Ochaion, A.; Cohen, S.; Patoka, R.; Zozulya, G.; Barer, F.; Castel, D.; Fishman, P.] Can Fite BioPharma, IL 49170 Petah Tiqwa, Israel.
   [Rath Wolfson, L.; Atar, E.] Rabin Med Ctr, Petah Tiqwa, Israel.
   [Rath Wolfson, L.; Atar, E.] Tel Aviv Univ, Petah Tiqwa, Israel.
   [Del Valle, L.; Pina Oviedo, S.; Perez Liz, G.] Temple Univ, Sch Med, Philadelphia, PA 19122 USA.
C3 Tel Aviv University; Rabin Medical Center; Tel Aviv University;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University
RP Fishman, P (通讯作者)，Can Fite BioPharma, 10 Bareket St,POB 7537, IL 49170 Petah Tiqwa, Israel.
EM pninia@canfite.co.il
RI Oviedo, Sergio/AAV 8814 2021; Del Valle, Luis/J 4085 2015
OI Cohen, Shira/0000 0003 4958 0731; Del Valle, Luis/0000 0003 3894 9206
FU Can Fite BioPharma
FX Supported by Can Fite BioPharma.
CR Agarwal S, 2003, FASEB J, V17, P899, DOI 10.1096/fj.02 0901fje
   Arii K, 2008, MOL IMMUNOL, V45, P463, DOI 10.1016/j.molimm.2007.05.020
   Baddour V T, 1999, Curr Rheumatol Rep, V1, P59, DOI 10.1007/s11926 999 0027 z
   Baharav E, 2005, J RHEUMATOL, V32, P469
   Bar Yehuda S, 2007, EXPERT OPIN INV DRUG, V16, P1601, DOI 10.1517/13543784.16.10.1601
   Berenbaum F, 2004, CURR OPIN RHEUMATOL, V16, P616, DOI 10.1097/01.bor.0000133663.37352.4a
   Chen YF, 2008, HEALTH TECHNOL ASSES, V12, P1, DOI 10.3310/hta12110
   Delcenserie V, 2008, CURR ISSUES MOL BIOL, V10, P37
   Deschner J, 2003, CURR OPIN CLIN NUTR, V6, P289, DOI 10.1097/01.mco.0000068964.34812.2b
   Felson DT, 2005, CURR OPIN RHEUMATOL, V17, P624, DOI 10.1097/01.bor.0000172800.49120.97
   Fernandes JC, 2002, BIORHEOLOGY, V39, P237
   Fishman P, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1887
   Forsyth CB, 2005, J GERONTOL A BIOL, V60, P1118, DOI 10.1093/gerona/60.9.1118
   Furuzawa Carballeda J, 2008, CLIN EXP RHEUMATOL, V26, P554
   Guingamp C, 1997, ARTHRITIS RHEUM, V40, P1670, DOI 10.1002/art.1780400917
   Hardingham Tim, 2008, Curr Rheumatol Rep, V10, P30, DOI 10.1007/s11926 008 0006 9
   Hinz B, 2004, CURR OPIN RHEUMATOL, V16, P628, DOI 10.1097/01.hco.0000136130.95746.14
   Jacques C, 2006, VITAM HORM, V74, P371, DOI 10.1016/S0083 6729(06)74016 X
   Liacini A, 2003, EXP CELL RES, V288, P208, DOI 10.1016/S0014 4827(03)00180 0
   Liacini A, 2002, MATRIX BIOL, V21, P251, DOI 10.1016/S0945 053X(02)00007 0
   Madi L, 2007, J RHEUMATOL, V34, P20
   Malemud CJ., 2008, Future Rheumatol, V3, P253
   MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623 197153030 00009
   Martel Pelletier J, 2008, BEST PRACT RES CL RH, V22, P351, DOI 10.1016/j.berh.2008.02.001
   McMahon K, 2008, AUST FAM PHYSICIAN, V37, P133
   Mistry D, 2004, OSTEOARTHR CARTILAGE, V12, P131, DOI 10.1016/j.joca.2003.10.006
   Ochaion A, 2008, BIOCHEM PHARMACOL, V76, P482, DOI 10.1016/j.bcp.2008.05.032
   Ochaion A, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2078
   Pelletier JP, 2001, ARTHRITIS RHEUM US, V44, P1237, DOI 10.1002/1529 0131(200106)44:6<1237::AID ART214>3.0.CO;2 F
   Pulai JI, 2005, J IMMUNOL, V174, P5781, DOI 10.4049/jimmunol.174.9.5781
   Rath Wolfson L, 2006, CLIN EXP RHEUMATOL, V24, P400
   Roman Blas JA, 2006, OSTEOARTHR CARTILAGE, V14, P839, DOI 10.1016/j.joca.2006.04.008
   Saklatvala J, 2007, CURR DRUG TARGETS, V8, P305, DOI 10.2174/138945007779940115
   SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092 8674(88)90532 6
   Séguin CA, 2003, J CELL PHYSIOL, V197, P357, DOI 10.1002/jcp.10371
   Shaw T, 2000, EXPERT OPIN INV DRUG, V9, P1469, DOI 10.1517/13543784.9.7.1469
   Silverman MH, 2008, J RHEUMATOL, V35, P41
   Sowers M, 2001, CURR OPIN RHEUMATOL, V13, P447, DOI 10.1097/00002281 200109000 00018
   Tomita T, 1999, ARTHRITIS RHEUM, V42, P2532, DOI 10.1002/1529 0131(199912)42:12<2532::AID ANR5>3.0.CO;2 2
   van den Berg WB, 1999, Z RHEUMATOL, V58, P136, DOI 10.1007/s003930050163
   van Troostenburg AR, 2004, INT J CLIN PHARM TH, V42, P534
   Yin HG, 2005, NEUROENDOCRINOLOGY, V81, P10, DOI 10.1159/000084828
   Yoon MH, 2005, ANESTH ANALG, V101, P1417, DOI 10.1213/01.ANE.0000180994.10087.6F
NR 43
TC 101
Z9 106
U1 1
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
EI 1529 0131
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD OCT
PY 2009
VL 60
IS 10
BP 3061
EP 3071
DI 10.1002/art.24817
PG 11
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 505MB
UT WOS:000270696600023
PM 19790055
DA 2025 08 17
ER

PT J
AU Lim, EK
   Keem, JO
   Yun, HS
   Jung, J
   Chung, BH
AF Lim, Eun Kyung
   Keem, Joo Oak
   Yun, Hui suk
   Jung, Jinyoung
   Chung, Bong Hyun
TI Smart nanoprobes for the detection of alkaline phosphatase activity
   during osteoblast differentiation
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID OSTEOGENIC DIFFERENTIATION; GOLD NANOPARTICLES; CALCIUM PHOSPHATE;
   MC3T3 E1 CELLS; DRUG RELEASE; HYDROXYAPATITE; PROLIFERATION; SURFACE;
   COMPOSITE; TITANIUM
AB Gold nanoparticle conjugated fluorescent hydroxyapatite (AuFHAp) was developed as a smart nanoprobe for measuring alkaline phosphatase (ALP) activity. AuFHAp showed NIR fluorescence due to the hydrolysis of its phosphate groups by ALP. In addition, gold nanoparticles help reduce the nonspecific signal by absorbing nonspecific fluorescence. Through in vitro tests, we confirmed that the AuFHAp probe was capable of detecting ALP levels related to osteoblast activity in living cells with high fluorescence intensity.
C1 [Lim, Eun Kyung; Jung, Jinyoung; Chung, Bong Hyun] Korea Res Inst Biosci & Biotechnol, BioNanotechnol Res Ctr, Taejon 305806, South Korea.
   [Lim, Eun Kyung; Keem, Joo Oak; Jung, Jinyoung; Chung, Bong Hyun] Korea Res Inst Biosci & Biotechnol, BioNano Hlth Guard Res Ctr, Taejon 305806, South Korea.
   [Yun, Hui suk] Korea Inst Mat Sci, Powder & Ceram Div, Chang Won 642831, South Korea.
   [Jung, Jinyoung; Chung, Bong Hyun] Univ Sci & Technol, Sch Engn, Taejon 305806, South Korea.
C3 Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea
   Research Institute of Bioscience & Biotechnology (KRIBB); Korea
   Institute of Materials Science (KIMS)
RP Jung, J (通讯作者)，Korea Res Inst Biosci & Biotechnol, BioNanotechnol Res Ctr, Taejon 305806, South Korea.
EM jyjeong@kribb.re.kr; chungbh@kribb.re.kr
RI ; Lim, Eun Kyung/AAR 8644 2020; Jeong, Jinyoung/MBH 8618 2025
OI Lim, Eun Kyung/0000 0003 2793 3700; 
FU BioNano Health Guard Research Center   Ministry of Science, ICT & Future
   Planning (MSIP) of Korea as Global Frontier Project [H GUARD_2013
   M3A6B2078950]; National Research Foundation of Korea (NRF)
   [NRF 2012R1A1A2043991]; KRIBB Research Initiative Program, Republic of
   Korea
FX The authors acknowledge the financial support from BioNano Health Guard
   Research Center funded by the Ministry of Science, ICT & Future Planning
   (MSIP) of Korea as Global Frontier Project (H GUARD_2013 M3A6B2078950),
   National Research Foundation of Korea (NRF) grants
   (NRF 2012R1A1A2043991), and KRIBB Research Initiative Program, Republic
   of Korea.
CR Altinoglu EI, 2008, ACS NANO, V2, P2075, DOI 10.1021/nn800448r
   Ansari M, 2011, CERAM SILIKATY, V55, P123
   Beck GR, 1998, J CELL BIOCHEM, V68, P269, DOI 10.1002/(SICI)1097 4644(19980201)68:2<269::AID JCB13>3.0.CO;2 A
   Belle H. V., 1976, CLIN CHEM, V22, P972
   Cha KJ, 2013, BIOFABRICATION, V5, DOI 10.1088/1758 5082/5/2/025007
   Chen F, 2012, BIOMATERIALS, V33, P6447, DOI 10.1016/j.biomaterials.2012.05.059
   Chen NT, 2012, INT J MOL SCI, V13, P16598, DOI 10.3390/ijms131216598
   Chou YF, 2005, BIOMATERIALS, V26, P285, DOI 10.1016/j.biomaterials.2004.02.030
   Fricain JC, 2013, BIOMATERIALS, V34, P2947, DOI 10.1016/j.biomaterials.2013.01.049
   Gade TP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022608
   Gao A, 2014, BIOMATERIALS, V35, P4223, DOI 10.1016/j.biomaterials.2014.01.058
   Ghosh D., 2013, Opt. Photon. J, V3, P18, DOI [10.4236/opj.2013.31004, DOI 10.4236/OPJ.2013.31004]
   Hong ZK, 2004, POLYMER, V45, P6699, DOI 10.1016/j.polymer.2004.07.036
   Isama K, 2003, BIOMATERIALS, V24, P3303, DOI 10.1016/S0142 9612(03)00216 3
   Jana NR, 2001, LANGMUIR, V17, P6782, DOI 10.1021/1a0104323
   Kang J, 2009, J MATER CHEM, V19, P2902, DOI 10.1039/b822835c
   Kim H, 2015, J BONE MINER METAB, V33, P30, DOI 10.1007/s00774 014 0567 9
   Kim TI, 2011, CHEM COMMUN, V47, P9825, DOI 10.1039/c1cc13819g
   Kyllönen L, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt165
   Lee HJ, 2006, CHEM MATER, V18, P5111, DOI 10.1021/cm061139x
   Lee HJ, 2013, J CONTROL RELEASE, V170, P198, DOI 10.1016/j.jconrel.2013.05.017
   Lee J, 2008, ADV FUNCT MATER, V18, P258, DOI 10.1002/adfm.200700482
   Lim EK, 2011, BIOMATERIALS, V32, P7941, DOI 10.1016/j.biomaterials.2011.06.077
   Mir M, 2012, MATER RES IBERO AM J, V15, P622, DOI 10.1590/S1516 14392012005000069
   Moore NM, 2010, BIOMATERIALS, V31, P1604, DOI 10.1016/j.biomaterials.2009.11.011
   Oya K, 2009, BIOMATERIALS, V30, P1281, DOI 10.1016/j.biomaterials.2008.11.030
   Ross RD, 2011, J BIOMED MATER RES A, V99A, P58, DOI 10.1002/jbm.a.33165
   SABOKBAR A, 1994, BONE MINER, V27, P57, DOI 10.1016/S0169 6009(08)80187 0
   Santos JL, 2009, J CONTROL RELEASE, V134, P141, DOI 10.1016/j.jconrel.2008.11.007
   Shu R, 2003, J BIOMED MATER RES A, V67A, P1196, DOI 10.1002/jbm.a.20021
   TSUKAMOTO Y, 1992, J MATER SCI MATER M, V3, P180, DOI 10.1007/BF00713446
   Wang K, 2012, ADV HEALTHC MATER, V1, P292, DOI 10.1002/adhm.201200030
   Wang LX, 2014, BIOMATERIALS, V35, P6758, DOI 10.1016/j.biomaterials.2014.04.085
   Wang SG, 2011, INT J NANOMED, V6, P3449, DOI 10.2147/IJN.S27166
   Yang L, 2010, BIOMATERIALS, V31, P2976, DOI 10.1016/j.biomaterials.2010.01.002
   Yao YY, 2014, J NANOSCI NANOTECHNO, V14, P4851, DOI 10.1166/jnn.2014.8717
   Yoon HJ, 2013, NUTR RES, V33, P1053, DOI 10.1016/j.nutres.2013.08.004
   Yuasa T, 2004, BIOMATERIALS, V25, P1159, DOI 10.1016/j.biomaterials.2003.08.003
   Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201 1148
NR 39
TC 53
Z9 56
U1 0
U2 91
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359 7345
EI 1364 548X
J9 CHEM COMMUN
JI Chem. Commun.
PY 2015
VL 51
IS 15
BP 3270
EP 3272
DI 10.1039/c4cc09620g
PG 3
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA CB0NV
UT WOS:000349324200061
PM 25623488
DA 2025 08 17
ER

PT J
AU Quan, K
   Xu, Q
   Zhu, MS
   Liu, XQ
   Dai, M
AF Quan, Kun
   Xu, Qiang
   Zhu, Meisong
   Liu, Xuqiang
   Dai, Min
TI Analysis of Risk Factors for Non union After Surgery for Limb Fractures:
   A Case Control Study of 669 Subjects
SO FRONTIERS IN SURGERY
LA English
DT Article
DE limb fractures; bone non union; fracture healing; risk factors;
   multivariate logistic regression
ID BONE FRACTURE; FEMORAL NECK; FIXATION; COHORT; INFECTION; DIAPHYSIS
AB Objective: The purpose of this study was to analyze the risk factors for limb fracture non union in order to improve non union prevention and early detection.Methods: A total of 223 patients with non union after surgery for limb fractures performed at our institution from January 2005 to June 2017 were included as the case group, while a computer generated random list was created to select 446 patients with successful bone healing after surgery for limb fractures who were treated during the same period as the control group, thus achieving a ratio of 1:2. The medical records of these patients were reviewed retrospectively. Age, sex, body mass index, obesity, smoking, alcohol, diabetes, hypertension, osteoporosis, fracture type, multiple fractures, non steroidal anti inflammatory drugs (NSAIDs) use, delayed weight bearing, internal fixation failure, and infection data were analyzed and compared between the two groups. A multivariate logistic regression model was constructed to determine relevant factors associated with non union.Results: After comparison between two groups by univariate analysis and multivariate logistic regression, we found some risk factors associated that osteoporosis (odds ratio [OR] = 3.16, 95% confidence interval [CI]: 2.05 4.89, p < 0.001), open fracture (OR = 2.71, 95%CI: 1.72 4.27, p < 0.001), NSAIDs use (OR = 2.04, 95%CI: 1.24 3.37, p = 0.005), delayed weight bearing (OR = 1.72, 95%CI: 1.08 2.74, p = 0.023), failed internal fixation (OR = 5.93, 95%CI: 2.85 12.36, p < 0.001), and infection (OR = 6.77, 95%CI: 2.92 15.69, p < 0.001) were independent risk factors for non union after surgery for limb fractures.Conclusions: Osteoporosis, open fracture type, NSAIDs use, delayed weight bearing, failed internal fixation, and infection were found to be the main causes of bone non union; clinicians should, therefore, take targeted measures to intervene in high risk groups early.
C1 [Quan, Kun; Xu, Qiang; Zhu, Meisong; Liu, Xuqiang; Dai, Min] Nanchang Univ, Dept Orthoped, Affiliated Hosp 1, Artificial Joints Engn & Technol Res Ctr Jiangxi, Nanchang, Jiangxi, Peoples R China.
C3 Nanchang University
RP Liu, XQ; Dai, M (通讯作者)，Nanchang Univ, Dept Orthoped, Affiliated Hosp 1, Artificial Joints Engn & Technol Res Ctr Jiangxi, Nanchang, Jiangxi, Peoples R China.
EM shliuxuqiang@163.com; daimin@medmail.com.cn
RI DAI, M/GPS 8291 2022
FU National Natural Science Foundation [81860404]
FX Funding This work was supported by the National Natural Science
   Foundation (No. 81860404).
CR Ali A, 2005, J BONE JOINT SURG BR, V87B, P1107, DOI 10.1302/0301 620X.87B8.15610
   Audigé L, 2005, CLIN ORTHOP RELAT R, P221, DOI 10.1097/01.blo.0000163836.66906.74
   Bailón Plaza A, 2003, J BIOMECH, V36, P1069, DOI 10.1016/S0021 9290(03)00117 9
   Bhandari M, 2003, J ORTHOP TRAUMA, V17, P353, DOI 10.1097/00005131 200305000 00006
   Brinker MR, 2017, J ORTHOP TRAUMA, V31, pE37, DOI 10.1097/BOT.0000000000000736
   Calori GM, 2007, INJURY, V38, pS11, DOI 10.1016/S0020 1383(07)80004 0
   Calori GM, 2011, INJURY, V42, P587, DOI 10.1016/j.injury.2011.03.046
   Cappuccio FP, 1999, LANCET, V354, P971, DOI 10.1016/S0140 6736(99)01437 3
   Chahar Hemant Singh, 2021, J Orthop Case Rep, V11, P5, DOI 10.13107/jocr.2021.v11.i01.1942
   Copuroglu C, 2013, INJURY, V44, P1379, DOI 10.1016/j.injury.2013.08.003
   Ding L, 2014, J ORTHOP SCI, V19, P973, DOI 10.1007/s00776 014 0640 1
   Drosos GI, 2006, J BONE JOINT SURG BR, V88B, P227, DOI 10.1302/0301 620X.88B2.16456
   Duckworth AD, 2011, J BONE JOINT SURG BR, V93B, P811, DOI 10.1302/0301 620X.93B6.26432
   Giannoudis PV, 2000, J BONE JOINT SURG BR, V82B, P655, DOI 10.1302/0301 620X.82B5.9899
   Goodship AE, 1998, CLIN ORTHOP RELAT R, pS105
   Hak DJ, 2014, INJURY, V45, pS3, DOI 10.1016/j.injury.2014.04.002
   Hernandez RK, 2012, ACTA ORTHOP, V83, P653, DOI 10.3109/17453674.2012.747054
   Houben I B, 2018, Eur J Orthop Surg Traumatol, V28, P1429, DOI 10.1007/s00590 018 2190 2
   Jeffcoach DR, 2014, J TRAUMA ACUTE CARE, V76, P779, DOI 10.1097/TA.0b013e3182aafe0d
   Kanakaris NK, 2007, INJURY, V38, pS77, DOI 10.1016/S0020 1383(07)80012 X
   Meidinger G, 2011, KNEE SURG SPORT TR A, V19, P333, DOI 10.1007/s00167 010 1335 6
   Metsemakers WJ, 2015, INJURY, V46, P740, DOI 10.1016/j.injury.2014.12.018
   Mills LA, 2017, ACTA ORTHOP, V88, P434, DOI 10.1080/17453674.2017.1321351
   Mills LA, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen 2012 002276
   Reahl GB, 2020, CURR OSTEOPOROS REP, V18, P157, DOI 10.1007/s11914 020 00575 6
   Rodriguez EK, 2014, INJURY, V45, P554, DOI 10.1016/j.injury.2013.10.042
   Salem KH, 2012, INT ORTHOP, V36, P1471, DOI 10.1007/s00264 012 1505 x
   Schemitsch EH, 2012, J BONE JOINT SURG AM, V94A, P1786, DOI 10.2106/JBJS.J.01418
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   Solomon DH, 2009, OSTEOPOROSIS INT, V20, P895, DOI 10.1007/s00198 008 0759 z
   Tzioupis C, 2007, INJURY, V38, pS3, DOI 10.1016/S0020 1383(07)80003 9
   van Wunnik BPW, 2011, INJURY, V42, P1491, DOI 10.1016/j.injury.2011.08.019
   Westgeest J, 2016, J ORTHOP TRAUMA, V30, P149, DOI 10.1097/BOT.0000000000000488
   Wildemann B, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572 021 00289 8
   Wiss DA, 2021, J ORTHOP TRAUMA, V35, pE316, DOI 10.1097/BOT.0000000000002060
   Yang JJ, 2013, J BONE JOINT SURG AM, V95A, P61, DOI 10.2106/JBJS.K.01081
   Ziran Bruce, 2005, Am J Orthop (Belle Mead NJ), V34, P329
   Zura R, 2017, INJURY, V48, P1194, DOI 10.1016/j.injury.2017.03.036
   Zura R, 2017, BONE, V95, P26, DOI 10.1016/j.bone.2016.11.006
   Zura R, 2016, JAMA SURG, V151, DOI 10.1001/jamasurg.2016.2775
NR 40
TC 28
Z9 33
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 875X
J9 FRONT SURG
JI Front. Surg.
PD DEC 14
PY 2021
VL 8
AR 754150
DI 10.3389/fsurg.2021.754150
PG 7
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA XZ7XU
UT WOS:000737862700001
PM 34970588
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Guo, CJ
   Li, CW
   Yang, K
   Kang, H
   Xu, XY
   Xu, XY
   Deng, LF
AF Guo, Changjun
   Li, Changwei
   Yang, Kai
   Kang, Hui
   Xu, Xiaoya
   Xu, Xiangyang
   Deng, Lianfu
TI Increased EZH2 and decreased osteoblastogenesis during local
   irradiation induced bone loss in rats
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OSTEOGENIC DIFFERENTIATION; INDUCED OSTEOPOROSIS; RADIATION;
   METHYLATION; MICE; OSTEOCLASTS; EXPRESSION; PREVENTS; CELLS; RUNX2
AB Radiation therapy is commonly used to treat cancer patients but exhibits adverse effects, including insufficiency fractures and bone loss. Epigenetic regulation plays an important role in osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). Here, we reported local bone changes after single dose exposure to C 137(S) irradiation in rats. Femur bone mineral density (BMD) and trabecular bone volume in the tibia were significantly decreased at 12 weeks after irradiation. Micro CT results showed that tBMD, Tb.h and Tb.N were also significantly reduced at 12 weeks after irradiation exposure. ALP positive OB.S/BS was decreased by 42.3% at 2 weeks after irradiation and was decreased by 50.8% at 12 weeks after exposure. In contrast to the decreased expression of Runx2 and BMP2, we found EZH2 expression was significantly increased at 2 weeks after single dose C 137(S) irradiation in BMSCs. Together, our results demonstrated that single dose C 137(S) irradiation induces BMD loss and the deterioration of bone microarchitecture in the rat skeleton. Furthermore, EZH2 expression increased and osteoblastogenesis decreased after irradiation. The underlying mechanisms warrant further investigation.
C1 [Guo, Changjun; Li, Changwei; Yang, Kai; Kang, Hui; Deng, Lianfu] Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, Shanghai Inst Traumatol & Orthoped,Shanghai Key L, 197 Rui Jin Er Rd, Shanghai 200025, Peoples R China.
   [Xu, Xiaoya] Fudan Univ, Inst Radiat Med, Dept Bone Metab, 2094 Xietu Rd, Shanghai 200032, Peoples R China.
   [Xu, Xiangyang] Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Orthoped, Sch Med, 197 Rui Jin Er Rd, Shanghai 200025, Peoples R China.
C3 Shanghai Jiao Tong University; Fudan University; Shanghai Jiao Tong
   University
RP Deng, LF (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, Shanghai Inst Traumatol & Orthoped,Shanghai Key L, 197 Rui Jin Er Rd, Shanghai 200025, Peoples R China.; Xu, XY (通讯作者)，Fudan Univ, Inst Radiat Med, Dept Bone Metab, 2094 Xietu Rd, Shanghai 200032, Peoples R China.; Xu, XY (通讯作者)，Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Orthoped, Sch Med, 197 Rui Jin Er Rd, Shanghai 200025, Peoples R China.
EM xuxiaoya1980@sina.com; xu664531@hotmail.com; lf_deng@126.com
RI ; Li, Changwei/JWQ 0219 2024; Xu, Xiaoya/AAF 1426 2020; Yang,
   Kai/JQW 2039 2023; guo, changjun/GWV 9962 2022
OI guo, changjun/0000 0003 4151 5150; Changwei, Li/0000 0001 9324 4685; 
FU National Natural Science Foundation of China [81102071]
FX This work was supported by National Natural Science Foundation of China
   grants (No. 81102071) to Xiaoya Xu.
CR Aksnes LH, 2007, ACTA ONCOL, V46, P490, DOI 10.1080/02841860701218642
   Alesci S, 2005, NEUROIMMUNOMODULAT, V12, P1, DOI 10.1159/000082360
   Cannon CP, 2008, J AM ACAD ORTHOP SUR, V16, P541
   Cao X, 2011, P NATL ACAD SCI USA, V108, P1609, DOI 10.1073/pnas.1015350108
   Chandra A, 2013, BONE, V55, P449, DOI 10.1016/j.bone.2013.02.023
   Dudakovic A, 2015, J BIOL CHEM, V290, P27604, DOI 10.1074/jbc.M115.672345
   Dudziak ME, 2000, PLAST RECONSTR SURG, V106, P1049, DOI 10.1097/00006534 200010000 00015
   Gao JJ, 2007, ENDOCRINOLOGY, V148, P2613, DOI 10.1210/en.2006 1404
   Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565
   Gori F, 2001, J BIOL CHEM, V276, P46515, DOI 10.1074/jbc.M105757200
   Green DE, 2012, J BONE MINER RES, V27, P749, DOI 10.1002/jbmr.1505
   Hamilton SA, 2006, J APPL PHYSIOL, V101, P789, DOI 10.1152/japplphysiol.01078.2005
   Hemming S, 2014, STEM CELLS, V32, P802, DOI 10.1002/stem.1573
   Huh SJ, 2002, GYNECOL ONCOL, V86, P264, DOI 10.1006/gyno.2002.6756
   Jia D, 2011, RADIAT RES, V176, P624, DOI 10.1667/RR2505.1
   Kondo H, 2010, J APPL PHYSIOL, V108, P152, DOI 10.1152/japplphysiol.00294.2009
   Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935
   Lee JY, 2006, MOL CELLS, V22, P182
   Oest ME, 2015, J ORTHOP RES, V33, P334, DOI 10.1002/jor.22761
   Pacheco R, 2013, CURR OSTEOPOROS REP, V11, P299, DOI 10.1007/s11914 013 0174 z
   Park SS, 2012, BMB REP, V45, P571, DOI 10.5483/BMBRep.2012.45.10.101
   Sakurai T, 2011, INT J RADIAT BIOL, V87, P447, DOI 10.3109/09553002.2011.542545
   Sawajiri M, 2003, RADIAT ENVIRON BIOPH, V42, P219, DOI 10.1007/s00411 003 0204 9
   Sun J, 2015, MOL MED REP, V12, P4230, DOI 10.3892/mmr.2015.3954
   Villagra A, 2002, J CELL BIOCHEM, V85, P112, DOI 10.1002/jcb.10113
   Wang Tilz Y, 2006, EPILEPSIA, V47, P233, DOI 10.1111/j.1528 1167.2006.00414.x
   Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139
   Wernle JD, 2010, J BIOMECH, V43, P2738, DOI 10.1016/j.jbiomech.2010.06.017
   Willey JS, 2010, BONE, V46, P101, DOI 10.1016/j.bone.2009.09.002
   Wu H, 2014, GENOME BIOL, V15, DOI 10.1186/gb 2014 15 3 r52
   Zaidi M, 2003, J BONE MINER RES, V18, P599, DOI 10.1359/jbmr.2003.18.4.599
   Zhu L, 2013, BIOCHEM BIOPH RES CO, V432, P612, DOI 10.1016/j.bbrc.2013.02.036
NR 32
TC 16
Z9 18
U1 0
U2 16
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD AUG 8
PY 2016
VL 6
AR 31318
DI 10.1038/srep31318
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DT4MD
UT WOS:000381454300001
PM 27499068
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU 't Hoen, PAC
   Jirka, SMG
   ten Broeke, BR
   Schultes, EA
   Aguilera, B
   Pang, KH
   Heemskerk, H
   Aartsma Rus, A
   van Ommen, GJ
   den Dunnen, JT
AF 't Hoen, Peter A. C.
   Jirka, Silvana M. G.
   ten Broeke, Bradley R.
   Schultes, Erik A.
   Aguilera, Begona
   Pang, Kar Him
   Heemskerk, Hans
   Aartsma Rus, Annemieke
   van Ommen, Gertjan J.
   den Dunnen, Johan T.
TI Phage display screening without repetitious selection rounds
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
DE Phage display; Next generation sequencing; Bone; Drug targeting
ID OSTEOBLAST DIFFERENTIATION; EXPRESSION; LIBRARIES; PEPTIDES; CELLS;
   AMPLIFICATION; VECTORS
AB Phage display screenings are frequently employed to identify high affinity peptides or antibodies. Although successful, phage display is a laborious technology and is notorious for identification of false positive hits. To accelerate and improve the selection process, we have employed Illumina next generation sequencing to deeply characterize the Ph.D. 7 M13 peptide phage display library before and after several rounds of biopanning on KS483 osteoblast cells. Sequencing of the naive library after one round of amplification in bacteria identifies propagation advantage as an important source of false positive hits. Most important, our data show that deep sequencing of the phage pool after a first round of biopanning is already sufficient to identify positive phages. Whereas traditional sequencing of a limited number of clones after one or two rounds of selection is uninformative, the required additional rounds of biopanning are associated with the risk of losing promising clones propagating slower than nonbinding phages. Confocal and live cell imaging confirms that our screen successfully selected a peptide with very high binding and uptake in osteoblasts. We conclude that next generation sequencing can significantly empower phage display screenings by accelerating the finding of specific binders and restraining the number of false positive hits. (C) 2011 Elsevier Inc. All rights reserved.
C1 ['t Hoen, Peter A. C.; Jirka, Silvana M. G.; ten Broeke, Bradley R.; Schultes, Erik A.; Heemskerk, Hans; Aartsma Rus, Annemieke; van Ommen, Gertjan J.; den Dunnen, Johan T.] Leiden Univ, Med Ctr, Ctr Human & Clin Genet, NL 2300 RC Leiden, Netherlands.
   ['t Hoen, Peter A. C.; Jirka, Silvana M. G.; ten Broeke, Bradley R.; Schultes, Erik A.; Heemskerk, Hans; Aartsma Rus, Annemieke; van Ommen, Gertjan J.; den Dunnen, Johan T.] Leiden Univ, Med Ctr, Leiden Genome Technol Ctr, NL 2300 RC Leiden, Netherlands.
   [Aguilera, Begona; Pang, Kar Him] Prosensa Therapeut, NL 2333 CH Leiden, Netherlands.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden
   University   Excl LUMC; Leiden University   Excl LUMC; Leiden
   University; Leiden University Medical Center (LUMC); BioMarin
   Pharmaceutical Inc.; Prosensa
RP 't Hoen, PAC (通讯作者)，Leiden Univ, Med Ctr, Ctr Human & Clin Genet, NL 2300 RC Leiden, Netherlands.
EM p.a.c.hoen@lumc.nl
RI 't Hoen, Peter/D 3950 2018; Schultes, Erik/B 6035 2012; dunnen,
   johan/ABH 4228 2020
OI 't Hoen, Peter/0000 0003 4450 3112; Aartsma Rus,
   Annemieke/0000 0003 1565 654X; Jirka, Silvana/0000 0003 0016 709X; den
   Dunnen, Johan/0000 0002 6304 1710; Schultes, Erik/0000 0001 8888 635X
FU Dutch Ministry of Economic Affairs (IOP) [IGE7001]; Centre for Medical
   Systems Biology within the framework of the Netherlands Genomics
   Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO);
   Center for Biomedical Genetics
FX This research was supported by a grant from the Dutch Ministry of
   Economic Affairs (IOP Genomics grant IGE7001), the Centre for Medical
   Systems Biology within the framework of the Netherlands Genomics
   Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO),
   and the Center for Biomedical Genetics. We thank Annelies Boonzaier van
   der Laan (Department of Molecular and Cellular Biology, Leiden
   University Medical Center) for microscopy assistance; Ineke Oudshoorn
   (Department of Endocrinology, Leiden University Medical Center), Karien
   de Rooij (Department of Endocrinology, Leiden University Medical Center,
   and Percuros), and David. de Gorter (Department of Molecular and
   Cellular Biology, Leiden University Medical Center) for assistance with
   cell culturing; and Rinse Klooster (Department of Molecular and Cellular
   Biology, Leiden University Medical Center) for comments on the
   manuscript.
CR Bentley DR, 2006, CURR OPIN GENET DEV, V16, P545, DOI 10.1016/j.gde.2006.10.009
   Brammer LA, 2008, ANAL BIOCHEM, V373, P88, DOI 10.1016/j.ab.2007.10.015
   Bratkovic T, 2010, CELL MOL LIFE SCI, V67, P749, DOI 10.1007/s00018 009 0192 2
   Dang ZC, 2002, J BONE MINER RES, V17, P394, DOI 10.1359/jbmr.2002.17.3.394
   de Gorter DJJ, 2011, J BONE MINER RES, V26, P1178, DOI 10.1002/jbmr.313
   Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667
   Derda R, 2011, MOLECULES, V16, P1776, DOI 10.3390/molecules16021776
   Derda R, 2010, ANGEW CHEM INT EDIT, V49, P5301, DOI 10.1002/anie.201001143
   Di Niro R, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq052
   Dias Neto E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008338
   Georgieva Y, 2011, MOLECULES, V16, P1667, DOI 10.3390/molecules16021667
   HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0
   Huang J, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/101932
   Krumpe LRH, 2006, PROTEOMICS, V6, P4210, DOI 10.1002/pmic.200500606
   Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959
   Ravn U, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq789
   Reddy ST, 2010, NAT BIOTECHNOL, V28, P965, DOI 10.1038/nbt.1673
   Serizawa T, 2007, CHEMBIOCHEM, V8, P989, DOI 10.1002/cbic.200700133
   Shtatland T, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471 2105 8 280
   SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944
   t Hoen PAC, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn705
   Vodnik M, 2011, MOLECULES, V16, P790, DOI 10.3390/molecules16010790
   Work LM, 2004, MOL THER, V9, P198, DOI 10.1016/j.ymthe.2003.11.006
   Yamashita T, 1996, BONE, V19, P429, DOI 10.1016/S8756 3282(96)00255 4
NR 24
TC 139
Z9 167
U1 0
U2 63
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0003 2697
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD FEB 15
PY 2012
VL 421
IS 2
BP 622
EP 631
DI 10.1016/j.ab.2011.11.005
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 895WW
UT WOS:000300528400035
PM 22178910
OA hybrid
DA 2025 08 17
ER

PT J
AU Higano, CS
AF Higano, Celestia S.
TI To Treat or Not to Treat, That Is the Question: The Role of
   Bone Targeted Therapy in Metastatic Prostate Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID ANDROGEN DEPRIVATION THERAPY; RANDOMIZED CONTROLLED TRIAL; ORAL SODIUM
   CLODRONATE; ZOLEDRONIC ACID; DOUBLE BLIND; LONG TERM; MEN; SURVIVAL;
   MORTALITY; DENOSUMAB
AB A 62 year old construction site manager experienced 6 weeks of back pain that was not responsive to over the counter nonsteroidal anti inflammatory medications. He visited his wife's primary care physician for evaluation. He denied neurologic symptoms or worsening of pain while lying down. He smoked (30 pack years, quit 4 years ago), and drinks 3 beers each evening and more on weekends (up to a six pack). He has had two lower extremity fractures from falls at construction sites. At the time of the physical examination, he was 5 feet 11 inches tall and weighed 194 pounds. He was alert, oriented, and in mild distress. He had no percussion tenderness of his spine, and a neurologic examination was negative. A digital rectal examination revealed an enlarged prostate with an area of induration of the left, normal rectal tone, and guaiac negative stool. Laboratory studies included normal blood counts, electrolytes, and renal and liver function tests (including lactic acid dehydrogenase and total protein). The prostate specific antigen (PSA) was 114 ng/mL; he had no prior PSA test. A bone scan showed diffuse bony involvement including the T7 vertebral body and left pedicle, ribs, pelvis, and calvarium. Magnetic resonance imaging of his spine confirmed bone metastases but showed no evidence of extension into the epidural space or spinal cord compromise. A prostate biopsy revealed Gleason 4+4 adenocarcinoma of the prostate. Androgen deprivation therapy with leuprolide acetate was initiated, and the addition of a bone targeted agent was considered.
C1 Univ Washington, Seattle, WA 98195 USA.
C3 University of Washington; University of Washington Seattle
RP Higano, CS (通讯作者)，Univ Washington, Seattle, WA 98195 USA.
RI Higano, Celestia/ABB 1153 2022
CR Breen TL, 2004, J CLIN ONCOL, V22, P1531, DOI 10.1200/JCO.2004.99.013
   Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140 6736(98)09075 8
   Cree M, 2000, J AM GERIATR SOC, V48, P283, DOI 10.1111/j.1532 5415.2000.tb02647.x
   Dearnaley DP, 2009, LANCET ONCOL, V10, P872, DOI 10.1016/S1470 2045(09)70201 3
   Dearnaley DP, 2003, J NATL CANCER I, V95, P1300, DOI 10.1093/jnci/djg038
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Greenspan SL, 2007, ANN INTERN MED, V146, P416, DOI 10.7326/0003 4819 146 6 200703200 00006
   Hagiwara M, 2014, SUPPORT CARE CANCER, V22, P103, DOI 10.1007/s00520 013 1951 z
   Hussain M, 2006, J CLIN ONCOL, V24, P3984, DOI 10.1200/JCO.2006.06.4246
   Michaelson MD, 2007, J CLIN ONCOL, V25, P1038, DOI 10.1200/JCO.2006.07.3361
   National Cancer Institute, SEER CANC STAT FACTS
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943
   Small EJ, 2003, J CLIN ONCOL, V21, P4277, DOI 10.1200/JCO.2003.05.147
   Smith MR, 2014, J CLIN ONCOL, V32, P1143, DOI 10.1200/JCO.2013.51.6500
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   von Moos R, 2013, SUPPORT CARE CANCER, V21, P3497, DOI 10.1007/s00520 013 1932 2
NR 20
TC 7
Z9 7
U1 0
U2 8
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732 183X
EI 1527 7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD APR 10
PY 2014
VL 32
IS 11
BP 1107
EP 1111
DI 10.1200/JCO.2013.53.8900
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AG3KG
UT WOS:000335314300007
PM 24590651
DA 2025 08 17
ER

PT J
AU Armstrong, AJ
   Gupta, S
   Healy, P
   Kemeny, G
   Leith, B
   Zalutsky, MR
   Spritzer, C
   Davies, C
   Rothwell, C
   Ware, K
   Somarelli, JA
   Wood, K
   Ribar, T
   Giannakakou, P
   Zhang, JR
   Gerber, D
   Anand, M
   Foo, WC
   Halabi, S
   Gregory, SG
   George, DJ
AF Armstrong, Andrew J.
   Gupta, Santosh
   Healy, Patrick
   Kemeny, Gabor
   Leith, Beth
   Zalutsky, Michael R.
   Spritzer, Charles
   Davies, Catrin
   Rothwell, Colin
   Ware, Kathryn
   Somarelli, Jason A.
   Wood, Kris
   Ribar, Thomas
   Giannakakou, Paraskevi
   Zhang, Jiaren
   Gerber, Drew
   Anand, Monika
   Foo, Wen Chi
   Halabi, Susan
   Gregory, Simon G.
   George, Daniel J.
TI Pharmacodynamic study of radium 223 in men with bone metastatic
   castration resistant prostate cancer
SO PLOS ONE
LA English
DT Article
ID CIRCULATING TUMOR CELLS; EPITHELIAL PLASTICITY; ALKALINE PHOSPHATASE;
   DOUBLE BLIND; DNA REPAIR; SURVIVAL; PHASE 3; GROWTH; TRANSITION;
   EXPRESSION
AB Background
   Radium 223 is a targeted alpha particle therapy that improves survival in men with metastatic castration resistant prostate cancer (mCRPC), particularly in men with elevated serum levels of bone alkaline phosphatase (B ALP). We hypothesized that osteomimicry, a form of epithelial plasticity leading to an osteoblastic phenotype, may contribute to intralesional deposition of radium 223 and subsequent irradiation of the tumor microenvironment.
   Methods
   We conducted a pharmacodynamic study (NCT02204943) of radium 223 in men with bone mCRPC. Prior to and three and six months after radium 223 treatment initiation, we collected CTCs and metastatic biopsies for phenotypic characterization and CTC genomic analysis. The primary objective was to describe the impact of radium 223 on the prevalence of CTC B ALP over time. We measured radium 223 decay products in tumor and surrounding normal bone during treatment. We validated genomic findings in a separate independent study of men with bone metastatic mCRPC (n = 45) and publicly accessible data of metastatic CRPC tissues.
   Results
   We enrolled 20 men with symptomatic bone predominant mCRPC and treated with radium 223. We observed greater radium 223 radioactivity levels in metastatic bone tumor containing biopsies compared with adjacent normal bone. We found evidence of persistent Cellsearch CTCs and B ALP (+) CTCs in the majority of men over time during radium 223 therapy despite serum B ALP normalization. We identified genomic gains in osteoblast mimicry genes including gains of ALPL, osteopontin, SPARC, OB cadherin and loss of RUNX2, and validated genomic alterations or increased expression at the DNA and RNA level in an independent cohort of 45 men with bone metastatic CRPC and in 150 metastatic biopsies from men with mCRPC.
   Conclusions
   Osteomimicry may contribute in part to the uptake of radium 223 within bone metastases and may thereby enhance the therapeutic benefit of this bone targeting radiotherapy.
C1 [Armstrong, Andrew J.; Gupta, Santosh; Kemeny, Gabor; Leith, Beth; Davies, Catrin; Rothwell, Colin; Ware, Kathryn; Somarelli, Jason A.; Gerber, Drew; Anand, Monika; George, Daniel J.] Duke Univ, Dept Med, Duke Canc Inst, Div Med Oncol, Durham, NC 27708 USA.
   [Armstrong, Andrew J.; Wood, Kris; Ribar, Thomas] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA.
   [Armstrong, Andrew J.; Gupta, Santosh; Healy, Patrick; Kemeny, Gabor; Zalutsky, Michael R.; Spritzer, Charles; Davies, Catrin; Rothwell, Colin; Ware, Kathryn; Somarelli, Jason A.; Anand, Monika; Halabi, Susan; Gregory, Simon G.; George, Daniel J.] Duke Canc Inst, Duke Prostate & Urol Canc Ctr, Durham, NC 27710 USA.
   [Gupta, Santosh; Gregory, Simon G.] Duke Univ, Duke Mol Physiol Inst, Durham, NC USA.
   [Healy, Patrick; Halabi, Susan] Duke Univ, Dept Biostat, Durham, NC USA.
   [Zalutsky, Michael R.; Spritzer, Charles] Duke Univ, Dept Radiol, Durham, NC 27710 USA.
   [Giannakakou, Paraskevi; Zhang, Jiaren] Weill Cornell Med Coll, New York, NY USA.
   [Foo, Wen Chi] Duke Univ, Duke Dept Pathol, Durham, NC USA.
C3 Duke University; Duke University; Duke University; Duke University; Duke
   University; Duke University; Cornell University; Weill Cornell Medicine;
   Duke University
RP Armstrong, AJ (通讯作者)，Duke Univ, Dept Med, Duke Canc Inst, Div Med Oncol, Durham, NC 27708 USA.; Armstrong, AJ (通讯作者)，Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA.; Armstrong, AJ (通讯作者)，Duke Canc Inst, Duke Prostate & Urol Canc Ctr, Durham, NC 27710 USA.
EM andrew.armstrong@duke.edu
RI ; Akash, Infant/NTP 9859 2025; Halabi, Susan/AFL 7973 2022
OI Gregory, Simon/0000 0002 7805 1743; Somarelli,
   Jason/0000 0003 1510 9343; Halabi, Susan/0000 0003 4135 2777; zalutsky,
   michael/0000 0002 5456 0324; Armstrong, Andrew/0000 0001 7012 1754
FU Prostate Cancer Foundation; Department of Defense Prostate Cancer
   Clinical Trials Consortium (DOD PCCTC); Movember; Bayer
FX Funded as an investigator initiated study to Duke University by Bayer.
   For the PROPHECY study, we acknowledge funding from the Prostate Cancer
   Foundation and Movember and support from the Department of Defense
   Prostate Cancer Clinical Trials Consortium (DOD PCCTC).
CR Abida W, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00029
   Armenia J, 2018, NAT GENET, V50, P645, DOI 10.1038/s41588 018 0078 z
   Armstrong AJ, 2011, MOLCANCER RES
   Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   Bitting RL, 2014, CANCER METAST REV, V33, P441, DOI 10.1007/s10555 013 9483 z
   Cho HJ, 2014, CANCER DISCOV, V4, P318, DOI 10.1158/2159 8290.CD 13 0346
   Chu GCY, 2014, ENDOCR RELAT CANCER, V21, P311, DOI 10.1530/ERC 13 0548
   Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541 7786.MCR 08 0077
   de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078 0432.CCR 08 0872
   Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Flux GD, 2017, BRIT J RADIOL, V90, DOI 10.1259/bjr.20160748
   González A, 2017, PROSTATE, V77, P321, DOI 10.1002/pros.23270
   Goodwin JF, 2013, CANCER DISCOV, V3, P1254, DOI 10.1158/2159 8290.CD 13 0108
   Gupta S, 2017, CLIN CANCER RES, V23, P1346, DOI 10.1158/1078 0432.CCR 16 1211
   Haider M, 2016, CLIN EXP METASTAS, V33, P239, DOI 10.1007/s10585 015 9773 7
   Heller G, 2018, J CLIN ONCOL, V36, P572, DOI 10.1200/JCO.2017.75.2998
   Hoskin P, 2014, LANCET ONCOL, V15, P1397, DOI 10.1016/S1470 2045(14)70474 7
   Huang CF, 2010, CANCER RES, V70, P4580, DOI 10.1158/0008 5472.CAN 09 3016
   Huggins C, 1972, CA Cancer J Clin, V22, P232, DOI 10.3322/canjclin.22.4.232
   Knerr K, 2004, INT J CANCER, V111, P152, DOI 10.1002/ijc.20223
   Koeneman KS, 1999, PROSTATE, V39, P246
   Li P, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 55
   Lin DL, 2001, PROSTATE, V47, P212, DOI 10.1002/pros.1065
   Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036
   López Riquelme N, 2013, APMIS, V121, P1139, DOI 10.1111/apm.12061
   Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008 5472.CAN 11 3132
   Norgaard M, 2010, J UROLOGY, V184, P162, DOI 10.1016/j.juro.2010.03.034
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Perez Lopez R, 2016, RADIOLOGY, V280, P151, DOI 10.1148/radiol.2015150799
   Polkinghorn WR, 2013, CANCER DISCOV, V3, P1245, DOI 10.1158/2159 8290.CD 13 0172
   Ramsköld D, 2012, NAT BIOTECHNOL, V30, P777, DOI 10.1038/nbt.2282
   Rao SR, 2017, BRIT J CANCER, V116, P227, DOI 10.1038/bjc.2016.402
   Reyes EE, 2014, J TRANSL MED, V12, DOI 10.1186/s12967 014 0313 z
   Robinson D, 2015, CELL, V161, P1215, DOI [10.1016/j.cell.2015.06.053, 10.1016/j.cell.2015.05.001]
   Ruscetti M, 2015, CANCER RES, V75, P2749, DOI 10.1158/0008 5472.CAN 14 3476
   Sailer V, 2018, CANCER AM CANCER SOC, V124, P1008, DOI 10.1002/cncr.31173
   San Martin IA, 2009, J CELL PHYSIOL, V221, P560, DOI 10.1002/jcp.21894
   Sartor O, 2017, ANN ONCOL, V28, P1090, DOI 10.1093/annonc/mdx044
   Sartor O, 2014, LANCET ONCOL, V15, P738, DOI 10.1016/S1470 2045(14)70183 4
   Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487
   Scher HI, 2015, J CLIN ONCOL, V33, P1348, DOI 10.1200/JCO.2014.55.3487
   Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008 5472.CAN 04 2442
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Sieh S, 2014, BONE, V63, P121, DOI 10.1016/j.bone.2014.02.001
   Spritzer CE, 2013, RADIOLOGY, V269, P816, DOI 10.1148/radiol.13121782
   Taichman RS, 2007, J CLIN INVEST, V117, P2351, DOI 10.1172/JCI31791
   Ware KE, 2016, ONCOTARGET, V7, P50520, DOI 10.18632/oncotarget.10476
   Zou M, 2017, CANCER DISCOV, V7, P736, DOI 10.1158/2159 8290.CD 16 1174
NR 49
TC 11
Z9 11
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 28
PY 2019
VL 14
IS 5
AR e0216934
DI 10.1371/journal.pone.0216934
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA IA0CM
UT WOS:000469224300012
PM 31136607
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lee, MS
   Su, CM
   Yeh, JC
   Wu, PR
   Tsai, TY
   Lou, SL
AF Lee, Ming Song
   Su, Chao Ming
   Yeh, Jih Chao
   Wu, Pei Ru
   Tsai, Tien Yao
   Lou, Shyh Liang
TI Synthesis of composite magnetic nanoparticles
   Fe3O4 with alendronate for osteoporosis treatment
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE iron oxide; thermotherapy; bisphosphonate; radiofrequency; thermolysis
ID IRON OXIDE NANOPARTICLES; DRUG DELIVERY; POSTMENOPAUSAL OSTEOPOROSIS;
   INTRACRANIAL THERMOTHERAPY; BIOMEDICAL APPLICATIONS; IN VIVO;
   HYPERTHERMIA; RADIOTHERAPY; MECHANISMS; PREVENTION
AB Osteoporosis is a result of imbalance between bone formation by osteoblasts and resorption by osteoclasts (OCs). In the present study, we investigated the potential of limiting the aggravation of osteoporosis by reducing the activity of OCs through thermolysis. The proposed method is to synthesize bisphosphonate (Bis) conjugated iron (II, III) oxide (Fe3O4) nanoparticles and incorporate them into OCs. The cells should be subsequently exposed to radiofrequency (RF) to induce thermolysis. In this study, particles of Fe3O4 were first synthesized by chemical co precipitation and then coated with dextran (Dex). The Dex/Fe3O4 particles were then conjugated with Bis to form Bis/Dex/Fe3O4. Transmission electron microscopy revealed that the average diameter of the Bis/Dex/Fe3O4 particles was similar to 20 nm. All three kinds of nanoparticles were found to have cubic inverse spinel structure of Fe3O4 by the X ray diffraction analysis. Fourier transform infrared spectroscopy confirmed that the Dex/Fe3O4 and Bis/Dex/Fe3O4 nanoparticles possessed their respective Dex and Bis functional groups, while a superconducting quantum interference device magnetometer measured the magnetic moment to be 24.5 emu. In addition, the Bis/Dex/Fe3O4 nanoparticles were fully dispersed in double distilled water. Osteoblasts and OCs were individually cultured with the nanoparticles, and an MTT assay revealed that they were non cytotoxic. An RF system (42 kHz and 450 A) was used to raise the temperature of the nanoparticles for 20 minutes, and the thermal effect was found to be sufficient to destroy OCs. Furthermore, in vivo studies verified that nanoparticles were indeed magnetic resonance imaging contrast agents and that they accumulated after being injected into the body of rats. In conclusion, we developed a water dispersible magnetic nanoparticle that had RF induced thermogenic properties, and the results indicated that the Bis/Dex/Fe3O4 nanoparticle had the potential for controlling osteoporosis.
C1 [Lee, Ming Song; Su, Chao Ming; Yeh, Jih Chao; Tsai, Tien Yao; Lou, Shyh Liang] Chung Yuan Christian Univ, Dept Biomed Engn, 200,Zhongbei Rd, Taoyuan 320, Taiwan.
   [Lee, Ming Song; Lou, Shyh Liang] Chung Yuan Christian Univ, Dept Nanotechnol, Taoyuan 320, Taiwan.
   [Yeh, Jih Chao] Univ Southern Calif, Inst Urol, Los Angeles, CA USA.
   [Wu, Pei Ru] Chang Gung Univ, Coll Med, Dept Biomed Sci, Taoyuan, Taiwan.
C3 Chung Yuan Christian University; Chung Yuan Christian University;
   University of Southern California; Chang Gung University
RP Lou, SL (通讯作者)，Chung Yuan Christian Univ, Dept Biomed Engn, 200,Zhongbei Rd, Taoyuan 320, Taiwan.
EM pacslou@gmail.com
FU Ministry of Science and Technology, Taiwan, Republic of China
   [101 2314 B 033 001]
FX The authors would like to acknowledge the financial support received
   from the Ministry of Science and Technology (grant no
   101 2314 B 033 001), Taiwan, Republic of China, for this work. They
   would also like to acknowledge Jesse Wang En Lin Hsieh, and Christina Ma
   for their help with this work.
CR Abdelmalek MF, 1996, AM J GASTROENTEROL, V91, P1282
   BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006 2952(90)90733 2
   BLUTE ML, 1993, J UROLOGY, V150, P1591, DOI 10.1016/S0022 5347(17)35852 4
   Boivin G, 2012, J TRACE ELEM MED BIO, V26, P153, DOI 10.1016/j.jtemb.2012.03.013
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Burshell AL, 2010, BONE, V46, P935, DOI 10.1016/j.bone.2009.12.032
   Dempster DW, 2012, CLIN THER, V34, P521, DOI 10.1016/j.clinthera.2012.02.002
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Figuerola A, 2010, PHARMACOL RES, V62, P126, DOI 10.1016/j.phrs.2009.12.012
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Jiang W, 2007, EXPERT OPIN DRUG DEL, V4, P621, DOI 10.1517/17425247.4.6.621
   Jordan A, 1997, INT J HYPERTHER, V13, P587, DOI 10.3109/02656739709023559
   Jordan A, 2006, J NEURO ONCOL, V78, P7, DOI 10.1007/s11060 005 9059 z
   Jordan A, 2007, J NANOSCI NANOTECHNO, V7, P4604, DOI 10.1166/jnn.2007.011
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Kendler D, 2004, MATURITAS, V48, P243, DOI 10.1016/j.maturitas.2003.12.012
   Lee H, 2006, J AM CHEM SOC, V128, P7383, DOI 10.1021/ja061529k
   Lewis S., 2014, Medical surgical nursing: Assessment and management of clinical problems, V9th
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Ling DS, 2014, NANO TODAY, V9, P457, DOI 10.1016/j.nantod.2014.06.005
   Lowe CE, 2000, AM J GASTROENTEROL, V95, P634
   Lu AH, 2007, ANGEW CHEM INT EDIT, V46, P1222, DOI 10.1002/anie.200602866
   Maier Hauff K, 2007, J NEURO ONCOL, V81, P53, DOI 10.1007/s11060 006 9195 0
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   MASSART R, 1981, IEEE T MAGN, V17, P1247, DOI 10.1109/TMAG.1981.1061188
   Minamimura T, 2000, INT J ONCOL, V16, P1153
   Oka C, 2015, J MAGN MAGN MATER, V381, P278, DOI 10.1016/j.jmmm.2015.01.005
   Orwoll E, 2000, NEW ENGL J MED, V343, P604, DOI 10.1056/NEJM200008313430902
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161 6420(99)90400 1
   Rossini M, 2000, BONE, V27, P119, DOI 10.1016/S8756 3282(00)00291 X
   SAMBROOK P, 1993, NEW ENGL J MED, V328, P1747, DOI 10.1056/NEJM199306173282404
   Sato H, 2011, CLIN CHIM ACTA, V412, P2146, DOI 10.1016/j.cca.2011.07.025
   Vernon CC, 1996, INT J RADIAT ONCOL, V35, P731
   Wang Y, 2015, NANOMED NANOTECHNOL, V11, P313, DOI 10.1016/j.nano.2014.09.014
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Xie J, 2010, ADV DRUG DELIVER REV, V62, P1064, DOI 10.1016/j.addr.2010.07.009
NR 37
TC 51
Z9 53
U1 2
U2 45
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2016
VL 11
BP 4583
EP 4594
DI 10.2147/IJN.S112415
PG 12
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA DV8KU
UT WOS:000383186700002
PM 27695319
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ratti, C
   Botti, L
   Cancila, V
   Galvan, S
   Torselli, I
   Garofalo, C
   Manara, MC
   Bongiovanni, L
   Valenti, CF
   Burocchi, A
   Parenza, M
   Cappetti, B
   Sangaletti, S
   Tripodo, C
   Scotlandi, K
   Colombo, MP
   Chiodoni, C
AF Ratti, Chiara
   Botti, Laura
   Cancila, Valeria
   Galvan, Silvia
   Torselli, Ilaria
   Garofalo, Cecilia
   Manara, Maria Cristina
   Bongiovanni, Lucia
   Valenti, Cesare F.
   Burocchi, Alessia
   Parenza, Mariella
   Cappetti, Barbara
   Sangaletti, Sabina
   Tripodo, Claudio
   Scotlandi, Katia
   Colombo, Mario P.
   Chiodoni, Claudia
TI Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms
   the Tumor Immune Environment Enabling Effective Combination with Immune
   Checkpoint Inhibitors
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID ANTIBODY BLOCKADE; OVARIAN CANCER; MICROENVIRONMENT; THERAPY; CELLS;
   ECTEINASCIDIN 743; IMMUNOTHERAPY; CHEMOTHERAPY; SARCOMA; FUTURE
AB Purpose: Osteosarcoma, the most common primary bone tumor, is characterized by an aggressive behavior with high tendency to develop lung metastases as well as by multiple genetic aberrations that have hindered the development of targeted therapies. New therapeutic approaches are urgently needed; however, novel combinations with immunotherapies and checkpoint inhibitors require suitable preclinical models with intact immune systems to be properly tested.
   Experimental Design: We have developed immunocompetent osteosarcoma models that grow orthotopically in the bone and spontaneously metastasize to the lungs, mimicking human osteosarcoma. These models have been used to test the efficacy of trabectedin, a chemotherapeutic drug utilized clinically for sarcomas and ovarian cancer.
   Results: Trabectedin, as monotherapy, significantly inhibited osteosarcoma primary tumor growth and lung metastases by both targeting neoplastic cells and reprogramming the tumor immune microenvironment. Specifically, trabectedin induced a striking differentiation of tumor cells by favoring the recruitment of Runx2, the master genetic regulator of osteoblastogenesis, on the promoter of genes involved in the physiologic process of terminal osteoblast differentiation. Differentiated neoplastic cells, as expected, showed reduced proliferation rate. Concomitantly, trabectedin enhanced the number of tumor infiltrating T lymphocytes, with local CD8 T cells, however, likely post activated or exhausted, as suggested by their high expression of the inhibitory checkpoint molecule PD 1. Accordingly, the combination with a PD 1 blocking antibody significantly increased trabectedin efficacy in controlling osteosarcoma progression.
   Conclusions: These results demonstrate the therapeutic efficacy of trabectedin in osteosarcoma treatment, unveiling its multiple activities and providing a solid rationale for its combination with immune checkpoint inhibitors. (C) 2017 AACR.
C1 [Ratti, Chiara; Botti, Laura; Galvan, Silvia; Torselli, Ilaria; Burocchi, Alessia; Parenza, Mariella; Cappetti, Barbara; Sangaletti, Sabina; Colombo, Mario P.; Chiodoni, Claudia] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Mol Immunol Unit, Via Amadeo 42, I 20133 Milan, Italy.
   [Cancila, Valeria; Bongiovanni, Lucia; Tripodo, Claudio] Univ Palermo, Sch Med, Dept Hlth Sci, Tumor Immunol Unit,Human Pathol Sect, Palermo, Italy.
   [Garofalo, Cecilia; Manara, Maria Cristina; Scotlandi, Katia] Ist Ortoped Rizzoli, Expt Oncol Lab, CRS Dev Biomol Therapies, Bologna, Italy.
   [Valenti, Cesare F.] Univ Palermo, Dept Math & Informat, Palermo, Italy.
C3 Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Palermo;
   IRCCS Istituto Ortopedico Rizzoli; University of Palermo
RP Colombo, MP; Chiodoni, C (通讯作者)，Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Mol Immunol Unit, Via Amadeo 42, I 20133 Milan, Italy.
EM mariopaolo.colombo@istitutotumori.mi.it;
   claudia.chiodoni@istitutotumori.mi.it
RI Sangaletti, Sabina/AAB 5873 2019; Manara, Maria/K 3366 2018; Chiodoni,
   Claudia/C 2172 2017; Sangaletti, Sabina/C 4495 2017; Manara, Maria
   Cristina/K 3366 2018; Garofalo, Cecilia/B 3834 2017; Tripodo,
   Claudio/O 4536 2016; Scotlandi, Katia/J 9009 2016; scotlandi,
   katia/J 9009 2016; Colombo, Mario/V 7166 2017; Lucia,
   Bongiovanni/AAC 2514 2022; Cancila, Valeria/AAJ 3041 2021; Tripodo,
   Claudio/AAB 6004 2022; Burocchi, Alessia/C 5512 2017; Valenti,
   Cesare/V 2021 2019; Botti, Laura/L 1684 2017; Colombo, Mario
   Paolo/V 7166 2017; Cappetti, Barbara/AAC 2907 2019
OI Cancila, Valeria/0000 0002 9502 1191; VALENTI, Cesare
   Fabio/0000 0002 4961 2054; Chiodoni, Claudia/0000 0002 7644 9969;
   Sangaletti, Sabina/0000 0001 7047 287X; Manara, Maria
   Cristina/0000 0001 5686 720X; Garofalo, Cecilia/0000 0001 5334 8930;
   Tripodo, Claudio/0000 0002 0821 6231; scotlandi,
   katia/0000 0001 6114 9499; Lucia, Bongiovanni/0000 0002 3558 2771;
   Colombo, Mario Paolo/0000 0003 0042 7955; Cappetti,
   Barbara/0000 0001 7115 5649
FU AIRC IG [17261, 10137]; AIRCIG [14049]; Italian Ministry of Health; FIRC
FX This work has been supported by AIRC IG grant (17261) to C. Chiodoni,
   AIRC IG grant (10137) to M.P. Colombo, AIRCIG grant (14049) to K.
   Scotlandi and the Italian Ministry of Health. I. Torselli has been
   recipient of a FIRC fellowship.
CR Ando Kosei, 2013, Cancers (Basel), V5, P591, DOI 10.3390/cancers5020591
   Bacci G, 2006, CANCER AM CANCER SOC, V106, P1154, DOI 10.1002/cncr.21724
   Buddingh EP, 2011, CLIN CANCER RES, V17, P2110, DOI 10.1158/1078 0432.CCR 10 2047
   Casali PG, 2010, CURR OPIN ONCOL, V22, P342, DOI 10.1097/CCO.0b013e32833aaac1
   Chen CF, 2013, ISPRS J PHOTOGRAMM, V82, P1, DOI 10.1016/j.isprsjprs.2013.05.001
   D'Incalci M, 2014, BRIT J CANCER, V111, P646, DOI 10.1038/bjc.2014.149
   Daud AI, 2016, J CLIN INVEST, V126, P3447, DOI 10.1172/JCI87324
   Forni C, 2009, MOL CANCER THER, V8, P449, DOI 10.1158/1535 7163.MCT 08 0848
   Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601
   Gajewski TF, 2015, SEMIN ONCOL, V42, P663, DOI 10.1053/j.seminoncol.2015.05.011
   Germano G, 2013, CANCER CELL, V23, P249, DOI 10.1016/j.ccr.2013.01.008
   Guo Z, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0613 y
   Gurung B, 2013, MOL CANCER RES, V11, P1215, DOI 10.1158/1541 7786.MCR 13 0170
   Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022
   Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626
   Komori T, 2008, FRONT BIOSCI LANDMRK, V13, P898, DOI 10.2741/2730
   Kuijjer ML, 2012, GENE CHROMOSOME CANC, V51, P696, DOI 10.1002/gcc.21956
   Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002 9440(10)64853 5
   Laverdiere C, 2003, CANCER AM CANCER SOC, V98, P832, DOI 10.1002/cncr.11563
   Lussier DM, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425 015 0067 z
   Lussier DM, 2015, J IMMUNOTHER, V38, P96, DOI 10.1097/CJI.0000000000000065
   Manara MC, 2005, INT J ONCOL, V27, P1605
   Mantovani A, 2011, EUR J IMMUNOL, V41, P2522, DOI 10.1002/eji.201141894
   Martin J. W., 2011, Sarcoma, V2011, P282745, DOI 10.1155/2011/282745
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Palmerini E, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw388.5
   Rocchi A, 2010, J CLIN INVEST, V120, P668, DOI 10.1172/JCI36667
   Sangaletti S, 2014, CANCER RES, V74, P4706, DOI 10.1158/0008 5472.CAN 13 3334
   Scotlandi K, 2002, CLIN CANCER RES, V8, P3893
   Sehouli J, 2012, ANN ONCOL, V23, P556, DOI 10.1093/annonc/mdr321
   Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172
   Ta H, 2009, CANCER METAST REV, V28, P247, DOI 10.1007/s10555 009 9186 7
   Amaral AT, 2015, CLIN CANCER RES, V21, P1373, DOI 10.1158/1078 0432.CCR 14 1688
   Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216
NR 34
TC 65
Z9 67
U1 0
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2017
VL 23
IS 17
BP 5149
EP 5161
DI 10.1158/1078 0432.CCR 16 3186
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FF5NB
UT WOS:000409037300021
PM 28600479
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Bertrand, J
   Despeaux, M
   Joly, S
   Bourogaa, E
   Gallay, N
   Demur, C
   Bonnevialle, P
   Louache, F
   Maguer Satta, V
   Vergnolle, N
   Payrastre, B
   Racaud Sultan, C
AF Bertrand, J.
   Despeaux, M.
   Joly, S.
   Bourogaa, E.
   Gallay, N.
   Demur, C.
   Bonnevialle, P.
   Louache, F.
   Maguer Satta, V.
   Vergnolle, N.
   Payrastre, B.
   Racaud Sultan, C.
TI Sex differences in the GSK3β mediated survival of adherent leukemic
   progenitors
SO ONCOGENE
LA English
DT Article
DE cell survival; cell adhesion; GSK3 beta; leukemia
ID ACUTE MYELOID LEUKEMIA; GLYCOGEN SYNTHASE KINASE 3; RECEPTOR ALPHA
   CHAIN; STEM CELLS; EXPRESSION; INTEGRIN; INHIBITION; PROTEIN;
   MICROENVIRONMENT; PROLIFERATION
AB Therapeutic resistance of acute myeloid leukemia stem cells, enriched in the CD34(+)38( )123(+) progenitor population, is supported by extrinsic factors such as the bone marrow niche. Here, we report that when adherent onto fibronectin or osteoblast components, CD34(+)38( )123(+) progenitors survive through an integrin dependent activation of glycogen synthase kinase 3 beta (GSK3 beta) by serine 9 dephosphorylation. Strikingly, GSK3 beta mediated survival was restricted to leukemic progenitors from female patients. GSK3 beta inhibition restored sensitivity to etoposide, and impaired the clonogenic capacities of adherent leukemic progenitors from female patients. In leukemic progenitors from female but not male patients, the scaffolding protein RACK1, activated downstream of alpha 5 beta 1  integrin engagement, was specifically upregulated and controlled GSK3 beta activation through the phosphatase protein phosphatase 2A (PP2A). In a mirrored manner, survival of adherent progenitors (CD34(+)38( )) from male but not female healthy donors was partially dependent on this pathway. We conclude that the GSK3 beta dependent survival pathway might be sex specific in normal immature population and flip flopped upon leukemogenesis. Taken together, our results strengthen GSK3 beta as a promising target for leukemic stem cell therapy and reveal gender differences as a new parameter in anti leukemia therapy. Oncogene (2012) 31, 694 705; doi:10.1038/onc.2011.258; published online 4 July 2011
C1 [Bertrand, J.; Despeaux, M.; Bourogaa, E.; Gallay, N.; Vergnolle, N.; Racaud Sultan, C.] Univ Toulouse UPS, Inserm U1043, CNRS U5282, CPTP, F 31024 Toulouse 3, France.
   [Joly, S.; Maguer Satta, V.] CRCL, CNRS U5286, Inserm U1052, Lyon, France.
   [Demur, C.] Univ Toulouse, Ctr Rech Cancerol Toulouse, Inserm UMR1037, CNRS ERL5294, Toulouse, France.
   [Demur, C.; Payrastre, B.] CHU Toulouse, Hematol Lab, Toulouse, France.
   [Bonnevialle, P.] CHU Toulouse, Serv Clin Chirurg Orthoped & Traumatol, Toulouse, France.
   [Louache, F.] Inst Gustave Roussy, Inserm U790, Villejuif, France.
   [Payrastre, B.] Univ Toulouse UPS, Inserm U1048, Inst Malad Metab & Cardiovasc, F 31024 Toulouse 3, France.
C3 Universite de Toulouse; Universite Toulouse III   Paul Sabatier; Centre
   National de la Recherche Scientifique (CNRS); Institut National de la
   Sante et de la Recherche Medicale (Inserm); Universite Federale Toulouse
   Midi Pyrenees (ComUE); Universite Claude Bernard Lyon 1; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UNICANCER;
   Centre Leon Berard; Centre de Recherche en cancerologie (CRCL);
   Universite de Toulouse; Universite Toulouse III   Paul Sabatier;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Centre National de la Recherche Scientifique (CNRS); CNRS   National
   Institute for Biology (INSB); Universite de Toulouse; Universite
   Toulouse III   Paul Sabatier; CHU de Toulouse; Universite de Toulouse;
   Universite Toulouse III   Paul Sabatier; CHU de Toulouse; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UNICANCER;
   Gustave Roussy; Universite de Toulouse; Universite Toulouse III   Paul
   Sabatier; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite Federale Toulouse Midi Pyrenees (ComUE)
RP Racaud Sultan, C (通讯作者)，Univ Toulouse UPS, CHU Purpan, Hop Purpan, INSERM U1043,CNRS U5282,CPTP, Pl Dr Baylac, F 31024 Toulouse 3, France.
EM claire.racaud@inserm.fr
RI Maguer Satta, Veronique/U 8857 2019; Vergnolle, Nathalie/C 7677 2018;
   Payrastre, Bernard/M 5295 2014; DUCOMMUN, Bernard/B 3208 2008
OI Racaud Sultan, Claire/0000 0002 6549 1088; Vergnolle,
   Nathalie/0000 0003 1825 6015; , Nathalie GALLAY/0000 0002 4236 4780; ,
   Bernard/0000 0002 8693 0190; Maguer Satta, Veronique/0000 0002 1556 068X
FU Association de Recherche contre le Cancer [3638, 8407]; Institut
   National du Cancer [07/3D1616/IABC 23 8/NC NG]; DGRSRT/INSERM
   cooperation
FX We thank Dr Jean Emmanuel Sarry for critical reading of the manuscript
   and the 'plateforme de cytometrie' of IFR150. Association de Recherche
   contre le Cancer (Contract Nos. 3638 and 8407), Institut National du
   Cancer (Contract no. 07/3D1616/IABC 23 8/NC NG), DGRSRT/INSERM
   cooperation.
CR Berghöfer B, 2006, J IMMUNOL, V177, P2088, DOI 10.4049/jimmunol.177.4.2088
   Bhatia R, 1996, BLOOD, V87, P3883, DOI 10.1182/blood.V87.9.3883.bloodjournal8793883
   De Toni F, 2006, ONCOGENE, V25, P3113, DOI 10.1038/sj.onc.1209346
   De Toni Costes F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009807
   de Vries JF, 2006, HAEMATOL HEMATOL J, V91, P912
   Del Vecchio I, 2009, GENE, V430, P17, DOI 10.1016/j.gene.2008.10.005
   Despeaux M, 2011, LEUKEMIA, V25, P1789, DOI 10.1038/leu.2011.145
   Dick JE, 2005, INT J HEMATOL, V82, P389, DOI 10.1532/IJH97.05144
   Ding QQ, 2007, MOL CELL BIOL, V27, P4006, DOI 10.1128/MCB.00620 06
   Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200
   Edderkaoui M, 2007, J BIOL CHEM, V282, P26646, DOI 10.1074/jbc.M702836200
   Guzman ML, 2005, BLOOD, V105, P4163, DOI 10.1182/blood 2004 10 4135
   Holmes T, 2008, STEM CELLS, V26, P1288, DOI 10.1634/stemcells.2007 0600
   Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350
   Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352 1359.2002
   Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483
   Jin LQ, 2009, CELL STEM CELL, V5, P31, DOI 10.1016/j.stem.2009.04.018
   Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903
   Kiely PA, 2008, J BIOL CHEM, V283, P22952, DOI 10.1074/jbc.M800802200
   Kornblau SM, 2009, BLOOD, V113, P154, DOI 10.1182/blood 2007 10 119438
   Kubota T, 2002, J VIROL, V76, P12676, DOI 10.1128/JVI.76.24.12676 12682.2002
   Li ZW, 2006, BLOOD REV, V20, P333, DOI 10.1016/j.blre.2005.08.003
   Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045
   Matsunaga T, 2003, NAT MED, V9, P1158, DOI 10.1038/nm909
   Mayack SR, 2010, NATURE, V463, P495, DOI 10.1038/nature08749
   Ougolkov AV, 2007, BLOOD, V110, P735, DOI 10.1182/blood 2006 12 060947
   Papasozomenos SC, 2002, P NATL ACAD SCI USA, V99, P1140, DOI 10.1073/pnas.032646799
   Recher C, 2004, CANCER RES, V64, P3191, DOI 10.1158/0008 5472.CAN 03 3005
   Saito Y, 2010, NAT BIOTECHNOL, V28, P275, DOI 10.1038/nbt.1607
   Sampaio ALF, 2010, J LEUKOCYTE BIOL, V87, P877, DOI 10.1189/jlb.1009670
   SCHILLER G, 1994, LEUKEMIA LYMPHOMA, V15, P85, DOI 10.3109/10428199409051682
   Sun M, 2008, CELL DEATH DIFFER, V15, P1887, DOI 10.1038/cdd.2008.124
   Trowbridge JJ, 2006, NAT MED, V12, P89, DOI 10.1038/nm1339
   Vialle Castellano A, 2004, LEUKEMIA, V18, P426, DOI 10.1038/sj.leu.2403273
   Wang Z, 2008, NATURE, V455, P1205, DOI 10.1038/nature07284
   Wang Z, 2010, CANCER CELL, V17, P597, DOI 10.1016/j.ccr.2010.04.024
   Xu Q, 2005, BLOOD, V106, P4261, DOI 10.1182/blood 2004 11 4468
   Ysebaert L, 2006, LEUKEMIA, V20, P1211, DOI 10.1038/sj.leu.2404239
NR 38
TC 15
Z9 16
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950 9232
EI 1476 5594
J9 ONCOGENE
JI Oncogene
PD FEB
PY 2012
VL 31
IS 6
BP 694
EP 705
DI 10.1038/onc.2011.258
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 891MU
UT WOS:000300222100003
PM 21725365
DA 2025 08 17
ER

PT J
AU Garcia, VG
   Gualberto, EC
   Ervolino, E
   Nagata, MJH
   de Almeida, JM
   Theodoro, LH
AF Garcia, Valdir Gouveia
   Gualberto Junior, Erivan Clementino
   Ervolino, Edilson
   Hitomi Nagata, Maria Jose
   de Almeida, Juliano Milanezi
   Theodoro, Leticia Helena
TI aPDT for periodontitis treatment in ovariectomized rats under systemic
   nicotine
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Nicotine; Ovariectomy; Periodontitis; Photochemotherapy; RANK ligand
ID ANTIMICROBIAL PHOTODYNAMIC THERAPY; DISEASE; LASER; PATHWAY; CELLS; BONE
AB Background This study evaluated the antimicrobial photodynamic therapy (aPDT) as an adjunctive therapy to scaling and root planning (SRP) for the treatment of experimental periodontitis (EP) in ovariectomized rats under systemic nicotine.
   Methods: Female ovariectomized rats (n = 180) were divided into two groups: vehicle administration (Veh) and nicotine administration (Nic). Mini pumps containing either vehicle or nicotine were inserted in the rats 30 days before the induction of EP, which was induced by placing a ligature around the left mandibular first molar. The rats were randomly divided into three treatment subgroups: SRP, SRP plus low level laser therapy (LLLT), and SRP plus aPDT. aPDT consisted of the application of a phenothiazine photosensitizer followed by LLLT. Ten animals from each group were euthanized at days 7, 15, and 30 after periodontal treatment. The furcation region was evaluated using histological, histometric analyses and immunolabelling for PCNA, TRAP, RANKL, and OPG.
   Results: Nicotine administration resulted in greater bone loss (BL). aPDT resulted in lower BL compared to SRP. aPDT showed higher quantities of PCNA positive cells compared to SRP, regardless of the nicotine status. aPDT resulted in less recruitment of osteoclasts and lower RANKL immunolabelling compared to LLLT and SRP.
   Conclusion: aPDT was effective in animals treated with nicotine.
C1 [Garcia, Valdir Gouveia; Gualberto Junior, Erivan Clementino; Ervolino, Edilson; Hitomi Nagata, Maria Jose; de Almeida, Juliano Milanezi; Theodoro, Leticia Helena] Sao Paulo State Univ UNESP, Grp Res & Study Laser Dent, Dept Surg & Integrated Clin, Div Periodont,Sch Dent, 1193 Jose Bonifacio, BR 16015050 Aracatuba, SP, Brazil.
   [Ervolino, Edilson] Sao Paulo State Univ UNESP, Dept Basic Sci, Sch Dent, 1193 Jose Bonifacio, BR 16015050 Aracatuba, SP, Brazil.
C3 Universidade Estadual Paulista; Universidade Estadual Paulista
RP Garcia, VG (通讯作者)，Sao Paulo State Univ UNESP, Grp Res & Study Laser Dent, Dept Surg & Integrated Clin, Div Periodont,Sch Dent, 1193 Jose Bonifacio, BR 16015050 Aracatuba, SP, Brazil.
EM vgouveia@foa.unesp.br; erivangualberto@ufam.edu.br;
   eervolino@foa.unesp.br; mjnagata@uol.com.br; jumilanezi@hotmail.com;
   letheodoro@uol.com.br
RI ERVOLINO, EDILSON/HJZ 4522 2023; Garcia, Valdir/C 8765 2012; Nagata,
   Maria Jose/C 3737 2013; Theodoro, Leticia/KXR 0044 2024; Nagata,
   Maria/C 3737 2013; Júnior, Erivan/AAZ 2022 2020; Almeida,
   Juliano/F 7995 2012
OI Ervolino, Edilson/0000 0003 4859 0583; Garcia,
   Valdir/0000 0002 6715 8334; Theodoro, Leticia
   Helena/0000 0003 3026 8369; Nagata, Maria Jose/0000 0001 5903 5652;
   Almeida, Juliano/0000 0002 5995 5747
FU Sao Paulo Research Foundation FAPESP, Sao Paulo, SP, Brazil (FAPESP)
   [2011/00936 0, 2010/15094 2]; Prointer (Unesp) [2015/1028]; Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [10/15094 2] Funding
   Source: FAPESP
FX This study was financially supported by the Sao Paulo Research
   Foundation FAPESP, Sao Paulo, SP, Brazil (FAPESP process no.2011/00936 0
   and no. 2010/15094 2) and Prointer (Unesp Process no. 2015/1028). The
   authors are grateful to Dr. Guilherme de Paula Nogueira (Faculty of
   Veterinary Medicine, UNESP, Aracatuba, SP, Brazil) for his guidance in
   performing radioimmunoassays.
CR Akram Z, 2016, PHOTODIAGN PHOTODYN, V16, P142, DOI 10.1016/j.pdpdt.2016.09.004
   An N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096942
   Braham P, 2009, J PERIODONTOL, V80, P1790, DOI 10.1902/jop.2009.090214
   Breivik T, 2009, J PERIODONTAL RES, V44, P110, DOI 10.1111/j.1600 0765.2008.01095.x
   Cochran DL, 2008, J PERIODONTOL, V79, P1569, DOI 10.1902/jop.2008.080233
   Costa Rodrigues J, 2018, J CELL PHYSIOL, V233, P1029, DOI 10.1002/jcp.25956
   FLEISCHER HC, 1989, J PERIODONTOL, V60, P402, DOI 10.1902/jop.1989.60.7.402
   Garcia VG, 2013, J PERIODONTOL, V84, P556, DOI 10.1902/jop.2012.120163
   Garcia VG, 2013, LASER MED SCI, V28, P143, DOI 10.1007/s10103 012 1099 y
   Garcia VG, 2011, J CLIN PERIODONTOL, V38, P1106, DOI 10.1111/j.1600 051X.2011.01785.x
   Genco RJ, 2013, PERIODONTOL 2000, V62, P59, DOI 10.1111/j.1600 0757.2012.00457.x
   Gualberto EC, 2016, LASER MED SCI, V31, P83, DOI 10.1007/s10103 015 1820 8
   Haffajee AD, 1997, J CLIN PERIODONTOL, V24, P324, DOI 10.1111/j.1600 051X.1997.tb00765.x
   Malgikar Suryakanth, 2016, Indian J Dent Res, V27, P121, DOI 10.4103/0970 9290.183130
   Meenawat Ajita, 2015, J Indian Soc Periodontol, V19, P381, DOI 10.4103/0972 124X.157879
   Nguyen NT, 2015, J PERIODONTOL, V86, P1133, DOI 10.1902/jop.2015.150152
   Pejcic A, 2010, PHOTOMED LASER SURG, V28, P69, DOI 10.1089/pho.2008.2301
   Preshaw PM, 2005, J CLIN PERIODONTOL, V32, P869, DOI 10.1111/j.1600 051X.2005.00779.x
   Song S, 2013, FEBS LETT, V587, P128, DOI 10.1016/j.febslet.2012.11.026
   Tadakuma Takushi, 1993, Keio Journal of Medicine, V42, P180
   Tavares LJ, 2017, PHOTODIAGN PHOTODYN, V17, P236, DOI 10.1016/j.pdpdt.2016.11.016
   Theodoro LH, 2016, J PERIODONTAL RES, V51, P669, DOI 10.1111/jre.12347
   Theodoro LH, 2017, SUPPORT CARE CANCER, V25, P3261, DOI 10.1007/s00520 017 3738 0
   Wu LZ, 2014, CELL PHYSIOL BIOCHEM, V34, P423, DOI 10.1159/000363011
   Yan X, 2015, INT J CLIN EXP MED, V8, P5470
   Zeng HL, 2014, J BIOCHEM MOL TOXIC, V28, P181, DOI 10.1002/jbt.21551
NR 26
TC 19
Z9 19
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572 1000
EI 1873 1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD JUN
PY 2018
VL 22
BP 70
EP 78
DI 10.1016/j.pdpdt.2018.02.017
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA GJ1UR
UT WOS:000435053900013
PM 29481872
OA Green Published
DA 2025 08 17
ER

PT J
AU Xiong, A
   He, YJ
   Gao, L
   Li, GQ
   Weng, J
   Kang, B
   Wang, DL
   Zeng, H
AF Xiong, Ao
   He, Yijun
   Gao, Liang
   Li, Guoqing
   Weng, Jian
   Kang, Bin
   Wang, Deli
   Zeng, Hui
TI Smurf1 targeting miR 19b 3p modified BMSCs combined PLLA composite
   scaffold to enhance osteogenic activity and treat critical sized bone
   defects
SO BIOMATERIALS SCIENCE
LA English
DT Article
ID INDUCED PHASE SEPARATION; LIGASE SMURF1; NANOCOMPOSITE SCAFFOLDS;
   TISSUE; DEGRADATION; DIFFERENTIATION; MORPHOGENESIS; REGENERATION;
   INHIBITION; CHITOSAN
AB Over the past few years, tissue engineering technology provided a new direction for bone defects therapy, which involved developing applicable biological materials composite with seed cells to repair bone defects tissue. However, as one of the commonest seed cells for tissue engineering, BMSCs (bone marrow mesenchymal stem cells), are still lacking an efficient and accurate differentiation ability into functional osteoblast. Given these facts, the development of a novel tissue engineering technology integrated BMSCs and scaffold materials have become an urgent need for bone defects repair. In this work, we found that miR 19b 3p could suppress the expression of Smurf1 which is a negative regulator of osteogenesis. By employing lentivirus pLVTHM miR 19b 3p transfected BMSCs, we verified that miR 19b 3p could promote BMSCs osteogenic differentiation via suppressing Smurf1 expression. Furthermore, we designed a new porous PLLA/POSS scaffold combined with BMSCs for tissue engineering. In vitro experiment showed that miR 19b 3p modified BMSCs facilitated the expansion and proliferation of BMSCs when culturing with the PLLA/POSS scaffold. We established rats calvarial critical sized defect model, after transplanting the BMSCs/PLLA/POSS for 3 month, the pathology, immunohistochemical and Micro CT results showed that miR 19b BMSCs/PLLA/POSS significantly facilitated the osteogenesis differentiation, enhanced the bone density of defect area and accelerated the repair of bone defect. We elucidated the mechanism that miR 19b 3p suppressed the expression of Smurf1 and provided a novel tissue engineering strategy for using microRNA gene modified BMSCs combined with PLLA/POSS scaffold in bone tissue engineering.
C1 [Xiong, Ao; Li, Guoqing; Weng, Jian; Kang, Bin; Wang, Deli; Zeng, Hui] Peking Univ, Shenzhen Hosp, Dept Bone & Joint Surg, Shenzhen 518036, Peoples R China.
   [Xiong, Ao; Li, Guoqing; Weng, Jian; Kang, Bin; Wang, Deli; Zeng, Hui] Peking Univ, Shenzhen Hosp, Natl & Local Joint Engn Res Ctr Orthopaed Biomat, Shenzhen 518036, Peoples R China.
   [He, Yijun] Guangzhou Med Univ, Translat Res Ctr Regenerat Med & Printing 3D, Affiliated Hosp 3, Guangzhou 510150, Peoples R China.
   [Gao, Liang] Saarland Univ, Med Ctr, Ctr Expt Orthopaed, D 66421 Homburg, Germany.
C3 Peking University; Peking University; Guangzhou Medical University;
   Universitatsklinikum des Saarlandes
RP Wang, DL; Zeng, H (通讯作者)，Peking Univ, Shenzhen Hosp, Dept Bone & Joint Surg, Shenzhen 518036, Peoples R China.; Wang, DL; Zeng, H (通讯作者)，Peking Univ, Shenzhen Hosp, Natl & Local Joint Engn Res Ctr Orthopaed Biomat, Shenzhen 518036, Peoples R China.
EM wangdelinavy@163.com; zenghui_36@163.com
RI HE, YIJUN/MHR 4349 2025; Wang, Deli/G 3379 2010; Gao, Liang/G 8508 2019
OI Gao, Liang/0000 0003 1438 9670
FU San Ming" Project of Medicine in Shenzhen [SZSM201612092]; Natural
   Science Foundation of Guangdong Province [2019A1515011290]; Research and
   Development Projects of Shenzhen [JCYJ20170307111755218]
FX This study was supported by grants from "San Ming" Project of Medicine
   in Shenzhen (No. SZSM201612092), Natural Science Foundation of Guangdong
   Province (No. 2019A1515011290) and Research and Development Projects of
   Shenzhen (No. JCYJ20170307111755218).
CR [Anonymous], 2020, J BIOENCES
   Badylak SF, 2009, ACTA BIOMATER, V5, P1, DOI 10.1016/j.actbio.2008.09.013
   Cao Y, 2014, SCI REP UK, V4, DOI 10.1038/srep04965
   Chen M., 2020, INTERFACES, P22410
   Chen S, 2018, EUR POLYM J, V109, P303, DOI 10.1016/j.eurpolymj.2018.10.003
   Chuan D, 2020, COMPOS SCI TECHNOL, V192, DOI 10.1016/j.compscitech.2020.108107
   Huynh CT, 2016, NANOMEDICINE UK, V11, P1535, DOI 10.2217/nnm 2016 0088
   Dumas JE, 2010, TISSUE ENG PT A, V16, P2505, DOI [10.1089/ten.tea.2009.0672, 10.1089/ten.TEA.2009.0672]
   Geiger M, 2003, ADV DRUG DELIVER REV, V55, P1613, DOI 10.1016/j.addr.2003.08.010
   Gonzalez Fernandez T, 2019, J CONTROL RELEASE, V301, P13, DOI 10.1016/j.jconrel.2019.03.006
   Guo R, 2008, J BIOL CHEM, V283, P23084, DOI 10.1074/jbc.M709848200
   Hu B, 2018, ACTA BIOMATER, V76, P275, DOI 10.1016/j.actbio.2018.06.017
   Hu C, 2017, J MATER CHEM C, V5, P2318, DOI 10.1039/c6tc05261d
   Huang QL, 2020, BIOACT MATER, V5, P980, DOI 10.1016/j.bioactmat.2020.06.018
   Hutmacher DW, 2000, BIOMATERIALS, V21, P2529, DOI 10.1016/S0142 9612(00)00121 6
   Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200
   Lee HL, 2014, EXP CELL RES, V323, P276, DOI 10.1016/j.yexcr.2014.03.004
   Liu K, 2020, COMPOS PART B ENG, V192, DOI 10.1016/j.compositesb.2020.108001
   Liu YS, 2013, BIOMED MATER, V8, DOI 10.1088/1748 6041/8/6/065001
   Liu Z, 2018, MOL MED REP, V18, P5317, DOI 10.3892/mmr.2018.9596
   Liu ZB, 2018, CHEM ENG J, V346, P649, DOI 10.1016/j.cej.2018.03.077
   Lou T, 2014, INT J BIOL MACROMOL, V69, P464, DOI 10.1016/j.ijbiomac.2014.06.004
   Lu NN, 2019, BIOMACROMOLECULES, V20, P3485, DOI 10.1021/acs.biomac.9b00771
   Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055
   Malcolm DW, 2020, CURR OSTEOPOROS REP, V18, P312, DOI 10.1007/s11914 020 00587 2
   Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02 07 0441
   Pavia FC, 2018, INT J BIOL MACROMOL, V119, P945, DOI 10.1016/j.ijbiomac.2018.08.007
   Pötzinger Y, 2019, CARBOHYD POLYM, V209, P62, DOI 10.1016/j.carbpol.2019.01.009
   Rad SM, 2016, POLYM ADVAN TECHNOL, V27, P325, DOI 10.1002/pat.3644
   Rezwan K, 2006, BIOMATERIALS, V27, P3413, DOI 10.1016/j.biomaterials.2006.01.039
   Salehi M, 2015, INT J POLYM MATER PO, V64, P675, DOI 10.1080/00914037.2014.1002093
   Saravanan Sekaran, 2019, Marine Derived Biomaterials for Tissue Engineering Applications, P413
   Shi W, 2004, AM J PHYSIOL LUNG C, V286, pL293, DOI 10.1152/ajplung.00228.2003
   Sun YX, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00466 4
   Tamburaci S, 2020, INT J BIOL MACROMOL, V142, P643, DOI 10.1016/j.ijbiomac.2019.10.006
   Tan YW, 2019, CELL SIGNAL, V53, P49, DOI 10.1016/j.cellsig.2018.09.013
   Tavernier G, 2011, J CONTROL RELEASE, V150, P238, DOI 10.1016/j.jconrel.2010.10.020
   van Wijk SJL, 2019, EMBO REP, V20, DOI 10.15252/embr.201846520
   Wang Q, 2007, J BIOL CHEM, V282, P10742, DOI 10.1074/jbc.M610997200
   Xiao GY, 2016, J BIOMAT SCI POLYM E, V27, P1462, DOI 10.1080/09205063.2016.1211000
   Xie Q, 2016, BIOMATERIALS, V75, P279, DOI 10.1016/j.biomaterials.2015.10.042
   Yang F, 2014, J ENDODONT, V40, P1579, DOI 10.1016/j.joen.2014.04.010
   Yang J, 2016, ACS APPL MATER INTER, V8, P26578, DOI 10.1021/acsami.6b09074
   Yang L, 2019, MOL THER, V27, P394, DOI 10.1016/j.ymthe.2018.11.019
   Zhang QW, 2012, BIOMATERIALS, V33, P5067, DOI 10.1016/j.biomaterials.2012.03.063
   Zhao L, 2010, J BONE MINER RES, V25, P1246, DOI 10.1002/jbmr.28
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
NR 47
TC 25
Z9 25
U1 0
U2 38
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2047 4830
EI 2047 4849
J9 BIOMATER SCI UK
JI Biomater. Sci.
PD NOV 7
PY 2020
VL 8
IS 21
BP 6069
EP 6081
DI 10.1039/d0bm01251c
PG 13
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA OJ2XF
UT WOS:000583829100020
PM 33000773
DA 2025 08 17
ER

PT J
AU Zhao, ZY
   Ji, HX
   Zhang, CH
   Wang, ZD
   Ren, SQ
   Liu, CL
   Wu, CF
   Wang, J
   Ding, XH
AF Zhao, Ziyi
   Ji, Hongxiang
   Zhang, Chenghao
   Wang, Zhengdan
   Ren, Shengquan
   Liu, Chunlei
   Wu, Caifeng
   Wang, Jian
   Ding, Xiaoheng
TI Mining and analysis of adverse event signals for alendronate based on
   the real world data of FDA adverse event reporting system database
SO EXPERT OPINION ON DRUG SAFETY
LA English
DT Article
DE Alendronate; adverse events; data mining; FAERS; pharmacovigilance
ID BISPHOSPHONATE USE; OSTEOBLAST APOPTOSIS; FEMORAL FRACTURES; BONE
   TURNOVER; OSTEOPOROSIS; RISEDRONATE; RISK; PREVENTION; OSTEOCYTE;
   OSTEONECROSIS
AB ObjectiveOur study aims to assess alendronate related adverse events (AEs) from the US FDA adverse event reporting system database.MethodsThe AE data associated with alendronate between the first quarter of 2004 and the first quarter of 2024 were selected. Various signal quantification methods, including the ROR, PRR, BCPNN, and EBGM, were applied for analysis.ResultsIn 34,943 reports where alendronate was the primary suspected drug for the AE, 24 affected system organ classes and 1046 significant preferred terms were identified in this study. Several significant AEs beyond drug instructions with strong signals were determined, including low turnover osteopathy, fracture delayed union, fracture nonunion, loss of anatomical alignment after fracture reduction, fracture malunion, periprosthetic fracture, carotid bruit, oral fibroma, traumatic occlusion, and phlebolith. The median time to onset of alendronate related AEs was 306 days (interquartile range [IQR] 12 1,461 days), and the majority of cases occurred 2 years later (18.80%) and within 30 days (14.49%).ConclusionsThe current study detected multiple potential new AE signals for alendronate, and more clinical research is required to further validate our results and clarify their associations.
C1 [Zhao, Ziyi; Zhang, Chenghao; Wang, Zhengdan; Ren, Shengquan; Liu, Chunlei; Wu, Caifeng; Wang, Jian; Ding, Xiaoheng] Qingdao Univ, Affiliated Hosp, Dept Hand & Foot, Microsurg, 59 Haier Rd, Qingdao, Shandong, Peoples R China.
   [Ji, Hongxiang] Shandong Univ Tradit Chinese Med, Clin Med Coll 1, Jinan, Shandong, Peoples R China.
C3 Qingdao University; Shandong University of Traditional Chinese Medicine
RP Ding, XH (通讯作者)，Qingdao Univ, Affiliated Hosp, Dept Hand & Foot, Microsurg, 59 Haier Rd, Qingdao, Shandong, Peoples R China.
EM dingxiaoheng@qdu.edu.cn
RI Zhao, Ziyi/GXH 2348 2022
CR Allen MR, 2011, BONE, V49, P56, DOI 10.1016/j.bone.2010.10.159
   Amerling R, 2010, BLOOD PURIFICAT, V29, P293, DOI 10.1159/000276666
   Bate A, 1998, EUR J CLIN PHARMACOL, V54, P315, DOI 10.1007/s002280050466
   Biswas PN, 2003, OSTEOPOROSIS INT, V14, P507, DOI 10.1007/s00198 003 1399 y
   Black DM, 2020, NEW ENGL J MED, V383, P743, DOI 10.1056/NEJMoa1916525
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cardoso L, 2009, J BONE MINER RES, V24, P597, DOI 10.1359/JBMR.081210
   Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140 6736(98)09075 8
   CHESTNUT CH, 1995, AM J MED, V99, P144, DOI 10.1016/S0002 9343(99)80134 X
   Compston J, 2020, LANCET DIABETES ENDO, V8, P7, DOI 10.1016/S2213 8587(19)30378 X
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cooper C., 1997, AM J MED, V103, p12S, DOI [DOI 10.1016/S0002 9343(97)90022 X, 10.1016/s0002 9343(97)90022 x]
   DuMouchel W, 1999, AM STAT, V53, P177, DOI 10.2307/2686093
   Evans SJW, 2001, PHARMACOEPIDEM DR S, V10, P483, DOI 10.1002/pds.677
   Fan Q, 2020, CURR PHARM DESIGN, V26, P4022, DOI 10.2174/1381612826666200423092602
   Ferreira P, 2023, ORTHOP TRAUMATOL SUR, V109, DOI 10.1016/j.otsr.2022.103475
   Follet H, 2007, BONE, V40, P1172, DOI 10.1016/j.bone.2006.12.052
   Goodwin JS, 2017, MAYO CLIN PROC, V92, P106, DOI 10.1016/j.mayocp.2016.09.015
   Hankenson KD, 2011, INJURY, V42, P556, DOI 10.1016/j.injury.2011.03.035
   HARRIS ST, 1993, J CLIN ENDOCR METAB, V76, P1399, DOI 10.1210/jc.76.6.1399
   Hochberg MC, 2006, EXPERT OPIN PHARMACO, V7, P1201, DOI 10.1517/14656566.7.9.1201
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Ishtiaq S, 2015, CYTOKINE, V71, P154, DOI 10.1016/j.cyto.2014.10.025
   Iwamoto J, 2006, CURR MED RES OPIN, V22, P919, DOI 10.1185/030079906X100276
   Iwata K, 2006, BONE, V39, P1053, DOI 10.1016/j.bone.2006.05.006
   Johnston CB, 2020, MED CLIN N AM, V104, P873, DOI 10.1016/j.mcna.2020.06.004
   Kang JS, 2014, INT ORTHOP, V38, P1247, DOI 10.1007/s00264 013 2259 9
   Lee SH, 2014, OSTEOPOROSIS INT, V25, P1131, DOI 10.1007/s00198 013 2575 3
   Lee YK, 2018, J KOREAN MED SCI, V33, DOI 10.3346/jkms.2018.33.e38
   Li J, 2001, CALCIFIED TISSUE INT, V69, P281, DOI 10.1007/s002230010036
   Liang B, 2022, CELL MOL BIOL LETT, V27, DOI 10.1186/s11658 022 00371 3
   Liu L, 2015, ENDOCR CONNECT, V4, DOI 10.1530/EC 14 0120
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Molvik H, 2015, OSTEOPOROSIS INT, V26, P1251, DOI 10.1007/s00198 014 3007 8
   Nagai T, 2013, THER CLIN RISK MANAG, V9, P191, DOI 10.2147/TCRM.S40734
   Namba RS, 2016, J ARTHROPLASTY, V31, P537, DOI 10.1016/j.arth.2015.09.005
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Palacios S, 2022, CLIMACTERIC, V25, P43, DOI 10.1080/13697137.2021.1951697
   Parfitt AM, 2002, BONE, V30, P5, DOI 10.1016/S8756 3282(01)00642 1
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Polymeri AA, 2015, ORAL HLTH PREV DENT, V13, P289, DOI 10.3290/j.ohpd.a34370
   Rothman KJ, 2004, PHARMACOEPIDEM DR S, V13, P519, DOI 10.1002/pds.1001
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Santora AC, 2020, CONTEMP ENDOCRINOL S, P277, DOI 10.1007/978 3 319 69287 6_14
   Saran U, 2014, ARCH BIOCHEM BIOPHYS, V561, P109, DOI 10.1016/j.abb.2014.07.006
   Savaridas T, 2013, BONE JOINT J, V95B, P1263, DOI 10.1302/0301 620X.95B9.31562
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Sharpe M, 2001, DRUGS, V61, P999, DOI 10.2165/00003495 200161070 00010
   Shimizu E, 2012, J DENT RES, V91, P268, DOI 10.1177/0022034511432170
   Solomon DH, 2009, OSTEOPOROSIS INT, V20, P895, DOI 10.1007/s00198 008 0759 z
   Vargas Franco JW, 2018, J CELL PHYSIOL, V233, P5696, DOI 10.1002/jcp.26465
   Volpin G., 2014, European surgical Orthopaedics and traumatology, P241, DOI [10.1007/978 3 642 34746 710, DOI 10.1007/978 3 642 34746 7_10]
   Watts NB, 2003, CLIN GERIATR MED, V19, P395, DOI 10.1016/S0749 0690(02)00069 1
   Wysowski DK, 2005, ARCH INTERN MED, V165, P346, DOI 10.1001/archinte.165.3.346 b
NR 55
TC 1
Z9 1
U1 1
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1474 0338
EI 1744 764X
J9 EXPERT OPIN DRUG SAF
JI Expert Opin. Drug Saf.
PD MAR 4
PY 2025
VL 24
IS 3
BP 297
EP 304
DI 10.1080/14740338.2024.2419995
EA OCT 2024
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 0ER7M
UT WOS:001339473300001
PM 39435467
DA 2025 08 17
ER

PT J
AU Chesnick, IE
   Fowler, CB
   Mason, JT
   Potter, K
AF Chesnick, Ingrid E.
   Fowler, Carol B.
   Mason, Jeffrey T.
   Potter, Kimberlee
TI Novel mineral contrast agent for magnetic resonance studies of bone
   implants grown on a chick chorioallantoic membrane
SO MAGNETIC RESONANCE IMAGING
LA English
DT Article
DE Magnetic resonance imaging; Osteoblasts; Mineralization; Chorioallantoic
   membrane; Mineral contrast agent
ID TISSUE ENGINEERED CONSTRUCTS; X RAY MICROTOMOGRAPHY; IN VIVO; OSTEOGENIC
   DIFFERENTIATION; MICROSCOPY; BISPHOSPHONATE; CARTILAGE; DOTA; MR;
   ANGIOGENESIS
AB Magnetic resonance imaging (MRI) studies of tissue engineered constructs prior to implantation clearly demonstrate the utility of the MRI technique for studying the bone formation process. To test the utility of our MRI protocols for explant studies, we present a novel test platform in which osteoblast seeded scaffolds were implanted on the chorioallantoic membrane of a chick embryo. Scaffolds from the following experimental groups were examined by high resolution MRI: (a) cell seeded implanted scaffolds (CIM), (b) unseeded implanted scaffolds (UCIM), (c) cell seeded scaffolds in static culture (CIV) and (d) unseeded scaffolds in static culture (UCIV). The reduction in water proton transverse relaxation times and the concomitant increase in water proton magnetization transfer ratios for CIM and CIV scaffolds, compared to UCIV scaffolds, were consistent with the formation of a bone like tissue within the polymer scaffold, which was confirmed by immunohistochemistry and fluorescence microscopy. However, the presence of angiogenic vessels and fibrotic adhesions around UCIM scaffolds can confound MRI findings of bone deposition. Consequently, to improve the specificity of the MRI technique for detecting mineralized deposits within explanted tissue engineered bone constructs, we introduce a novel contrast agent that uses alendronate to target a Food and Drug Administration approved MRI contrast agent (Gd DOTA) to bone mineral. Our contrast agent termed GdALN was used to uniquely identify mineralized deposits in representative samples from our four experimental groups. After GdALN treatment, both CIM and CIV scaffolds, containing mineralized deposits, showed marked signal enhancement on longitudinal relaxation time weighted (T1W) images compared to UCIV scaffolds. Relative to UCIV scaffolds, some enhancement was observed in T1W images of GdALN treated UCIM scaffolds, subjacent to the dark adhesions at the scaffold surface, possibly from dystrophic mineral formed in the fibrotic adhesions. Notably, residual dark areas on T1W images of CIM and UCIM scaffolds were attributable to blood inside infiltrating vessels. In summary, we present the efficacy of GdALN for sensitizing the MRI technique to the deposition of mineralized deposits in explanted polymeric scaffolds. Published by Elsevier Inc.
C1 [Chesnick, Ingrid E.; Fowler, Carol B.; Mason, Jeffrey T.; Potter, Kimberlee] Armed Forces Inst Pathol Annex, Dept Biophys, Rockville, MD 20850 USA.
RP Potter, K (通讯作者)，Armed Forces Inst Pathol Annex, Dept Biophys, Rockville, MD 20850 USA.
EM kimberlee.potter@va.gov
OI Graves, Ingrid E/0009 0009 7244 7569
FU National Institutes of Health [AR51446]
FX The authors are indebted to Mr. Frank Avallone in the Department of
   Genitourinary Pathology at the Armed Forces Institute of Pathology for
   his expert sectioning of polymeric scaffolds and undecalcified embryonic
   femurs. We thank the Office of the Armed Forces Medical Examiner System
   for the photographs presented in this manuscript. This work was
   supported in part by National Institutes of Health grant AR51446 (KP).
CR ADAZAMLI IK, 1989, J MED CHEM, V32, P139, DOI 10.1021/jm00121a026
   Bain MM, 2007, J MAGN RESON IMAGING, V26, P198, DOI 10.1002/jmri.20963
   BONE SN, 1986, INVEST RADIOL, V21, P782, DOI 10.1097/00004424 198610000 00003
   Borges J, 2003, TISSUE ENG, V9, P441, DOI 10.1089/107632703322066624
   Boskey AL, 2008, CHEM REV, V108, P4716, DOI 10.1021/cr0782473
   BOUSQUET JC, 1988, RADIOLOGY, V166, P693, DOI 10.1148/radiology.166.3.3340763
   CASSELMAN JW, 1993, AM J NEURORADIOL, V14, P47
   CHESNICK IE, 2010, P INT SOC MAGN RESON, V18, P786
   Chesnick IE, 2008, BIOPHYS J, V95, P2017, DOI 10.1529/biophysj.107.120923
   Chesnick IE, 2007, BONE, V40, P904, DOI 10.1016/j.bone.2006.10.020
   Dewitt N, 2003, NATURE, V423, P315, DOI 10.1038/423315a
   EFFMANN EL, 1988, TERATOLOGY, V38, P59, DOI 10.1002/tera.1420380109
   GERSTENFELD LC, 1987, DEV BIOL, V122, P49, DOI 10.1016/0012 1606(87)90331 9
   GRAY ML, 1995, MAGNET RESON MED, V34, P319, DOI 10.1002/mrm.1910340307
   HAJNAL JV, 1992, J COMPUT ASSIST TOMO, V16, P7, DOI 10.1097/00004728 199201000 00003
   Hartman EHM, 2004, TISSUE ENG, V10, P747, DOI 10.1089/1076327041348374
   Hartman EHM, 2002, TISSUE ENG, V8, P1029, DOI 10.1089/107632702320934128
   HENNIG J, 1986, MAGN RESON MED, V3, P823, DOI 10.1002/mrm.1910030602
   Hogers B, 2001, J MAGN RESON IMAGING, V14, P83, DOI 10.1002/jmri.1155
   Hong L, 2006, J ORTHOP RES, V24, P889, DOI 10.1002/jor.20140
   KIM DK, 1993, MAGNET RESON MED, V29, P211, DOI 10.1002/mrm.1910290209
   Kozloff KM, 2007, J BONE MINER RES, V22, P1208, DOI 10.1359/JBMR.070504
   Kubícek V, 2005, J AM CHEM SOC, V127, P16477, DOI 10.1021/ja054905u
   Landis W J, 2005, Orthod Craniofac Res, V8, P303, DOI 10.1111/j.1601 6343.2005.00353.x
   Laschke MW, 2006, TISSUE ENG, V12, P2093, DOI 10.1089/ten.2006.12.2093
   Lewis MR, 2001, BIOCONJUGATE CHEM, V12, P320, DOI 10.1021/bc0000886
   Li XJ, 2007, J ANAT, V211, P798, DOI 10.1111/j.1469 7580.2007.00825.x
   Mancini L, 2007, ANN NY ACAD SCI, V1116, P306, DOI 10.1196/annals.1402.008
   MOSELEY ME, 1989, PEDIATR RADIOL, V19, P400, DOI 10.1007/BF02387637
   Ogawa K, 2009, NUCL MED BIOL, V36, P129, DOI 10.1016/j.nucmedbio.2008.11.007
   Peptan IA, 2006, TISSUE ENG, V12, P843, DOI 10.1089/ten.2006.12.843
   Potter K, 2006, BONE, V38, P350, DOI 10.1016/j.bone.2005.08.025
   Potter K, 2002, J BONE MINER RES, V17, P652, DOI 10.1359/jbmr.2002.17.4.652
   POTTER K, 2005, P INT SOC MAGN RESON, V13, P1900
   Potter Kimberlee, 2008, P423
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Seo GS, 1996, RADIOLOGY, V201, P525, DOI 10.1148/radiology.201.2.8888253
   SMITH BR, 1992, JMRI J MAGN RESON IM, V2, P237, DOI 10.1002/jmri.1880020220
   SUBRAMANIAN G, 1975, J NUCL MED, V16, P744
   Tan Q, 2007, EUR J CARDIO THORAC, V31, P806, DOI 10.1016/j.ejcts.2007.01.045
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Vitha T, 2008, LANGMUIR, V24, P1952, DOI 10.1021/la702753j
   Vitha T, 2009, DALTON T, P3204, DOI 10.1039/b820705d
   Washburn NR, 2004, J BIOMED MATER RES A, V69A, P738, DOI 10.1002/jbm.a.30054
   Xu HH, 2006, PHYS MED BIOL, V51, P719, DOI 10.1088/0031 9155/51/3/016
   Xu HH, 2008, J BIOSCI BIOENG, V106, P515, DOI 10.1263/jbb.106.515
   Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201 1148
   Zhang XW, 2003, MAGNET RESON MED, V49, P1192, DOI 10.1002/mrm.10460
NR 48
TC 14
Z9 15
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0730 725X
EI 1873 5894
J9 MAGN RESON IMAGING
JI Magn. Reson. Imaging
PD NOV
PY 2011
VL 29
IS 9
BP 1244
EP 1254
DI 10.1016/j.mri.2011.07.022
PG 11
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 839LH
UT WOS:000296366700010
PM 21920685
DA 2025 08 17
ER

PT J
AU Cheng, SH
   Chu, W
   Chou, WH
   Chu, WC
   Kang, YN
AF Cheng, Shih Hao
   Chu, William
   Chou, Wen Hsiang
   Chu, Woei Chyn
   Kang, Yi No
TI Cardiovascular Safety of Romosozumab Compared to Commonly Used
   Anti osteoporosis Medications in Postmenopausal Osteoporosis: A
   Systematic Review and Network Meta analysis of Randomized Controlled
   Trials
SO DRUG SAFETY
LA English
DT Article
ID BONE MINERAL DENSITY; ORAL ALENDRONATE; DOUBLE BLIND; D SUPPLEMENTATION;
   RISK REDUCTION; CHINESE WOMEN; TERIPARATIDE; EFFICACY; FRACTURES;
   DENOSUMAB
AB IntroductionThe aim of this study was to investigate the cardiovascular safety of romosozumab in postmenopausal women with osteoporosis. Romosozumab, a monoclonal antibody targeting sclerostin, has been shown to increase bone mineral density and reduce the risk of osteoporotic fractures. However, in previous studies, romosozumab therapy was identified as a potential risk factor for cardiovascular events, particularly in patients with predisposing cardiovascular disease.MethodsA systematic literature search was performed in the Cochrane Library, Embase, PubMed, and Web of Science databases to identify randomized controlled trials (RCTs) comparing the safety and efficacy of romosozumab versus alendronate, teriparatide, denosumab, or placebo in postmenopausal women with osteoporosis. Contrast based network meta analysis was performed using a random effects model. The pooled estimates are presented as risk ratios with 95% confidence intervals.ResultsOf the 5282 articles retrieved, 25 RCTs were included in this review (n = 24,942), and 18 randomized controlled trials (n = 16,777) were included in the network meta analysis. The results indicated no significant differences in cardiovascular mortality rate between romosozumab and placebo. Regarding the risk of major cardiovascular events, no significant differences were found in the direct evidence or the network meta analysis with placebo as the reference.ConclusionRomosozumab might be a safe option for treating postmenopausal women with osteoporosis. The cardiovascular concerns associated with this treatment seem less significant than previously suggested, although additional real world data are required to confirm this conclusion.
C1 [Cheng, Shih Hao; Chu, Woei Chyn] Natl Yang Ming Chiao Tung Univ, Dept Biomed Engn, Taipei, Taiwan.
   [Cheng, Shih Hao; Chu, William; Chou, Wen Hsiang] Cheng Hsin Gen Hosp, Dept Orthoped, Taipei, Taiwan.
   [Cheng, Shih Hao] Med Univ Hosp, Wan Fang Hosp, Dept Orthoped, Taipei, Taiwan.
   [Chu, William; Kang, Yi No] Natl Taipei Univ Nursing & Hlth Sci, Taipei, Taiwan.
   [Kang, Yi No] Taipei Med Univ, Wan Fang Hosp, Evidence Based Med Ctr, Taipei, Taiwan.
   [Kang, Yi No] Natl Taiwan Univ, Inst Hlth Policy & Management, Coll Publ Hlth, Taipei, Taiwan.
   [Kang, Yi No] Taipei Med Univ, Cochrane Taiwan, Taipei, Taiwan.
C3 National Yang Ming Chiao Tung University; Cheng Hsin General Hospital;
   Taipei Municipal WanFang Hospital; National Taipei University of Nursing
   & Health Science (NTUNHS); Taipei Municipal WanFang Hospital; Taipei
   Medical University; National Taiwan University; Taipei Medical
   University
RP Chu, WC (通讯作者)，Natl Yang Ming Chiao Tung Univ, Dept Biomed Engn, Taipei, Taiwan.; Kang, YN (通讯作者)，Natl Taipei Univ Nursing & Hlth Sci, Taipei, Taiwan.; Kang, YN (通讯作者)，Taipei Med Univ, Wan Fang Hosp, Evidence Based Med Ctr, Taipei, Taiwan.; Kang, YN (通讯作者)，Natl Taiwan Univ, Inst Hlth Policy & Management, Coll Publ Hlth, Taipei, Taiwan.; Kang, YN (通讯作者)，Taipei Med Univ, Cochrane Taiwan, Taipei, Taiwan.
EM wchu@nycu.edu.tw; academicnono@gmail.com
FU National Yang Ming Chiao Tung University
FX Open Access funding enabled and organized by National Yang Ming Chiao
   Tung University.
CR [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   Baek KH, 2021, ENDOCRINOL METAB, V36, P60, DOI 10.3803/EnM.2020.848
   Barbarawi M, 2019, JAMA CARDIOL, V4, P765, DOI 10.1001/jamacardio.2019.1870
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Body JJ, 2002, J CLIN ENDOCR METAB, V87, P4528, DOI 10.1210/jc.2002 020334
   Bolland MJ, 2008, BMJ BRIT MED J, V336, P262, DOI 10.1136/bmj.39440.525752.BE
   Bolland MJ, 2010, BMJ BRIT MED J, V341, DOI 10.1136/bmj.c3691
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL 2020 0524SUPPL
   Casula M, 2020, ATHEROSCLEROSIS, V301, P1, DOI 10.1016/j.atherosclerosis.2020.03.021
   Chavassieux P, 2019, J BONE MINER RES, V34, P1597, DOI 10.1002/jbmr.3735
   Compton JT, 2014, J BONE JOINT SURG AM, V96A, P1659, DOI 10.2106/JBJS.M.01096
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cryer Byron, 2005, Am J Geriatr Pharmacother, V3, P127, DOI 10.1016/S1543 5946(05)80019 4
   Cummings SR, 2020, OSTEOPOROSIS INT, V31, P1019, DOI 10.1007/s00198 020 05379 z
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Devogelaer JP, 1996, BONE, V18, P141, DOI 10.1016/8756 3282(95)00436 X
   Eastell R, 2009, J BONE MINER RES, V24, P726, DOI 10.1359/JBMR.081215
   El Khoudary SR, 2020, CIRCULATION, V142, pe506, DOI 10.1161/CIR.0000000000000912
   Farr JN, 2024, J CLIN ENDOCR METAB, V110, pe190, DOI 10.1210/clinem/dgae313
   Felsenberg D, 1998, MATURITAS, V31, P35, DOI 10.1016/S0378 5122(98)00050 4
   Fuggle NR, 2020, DRUGS, V80, P1537, DOI 10.1007/s40265 020 01364 2
   Gallagher JC, 2005, J CLIN ENDOCR METAB, V90, P1583, DOI 10.1210/jc.2004 0826
   Harvey NC, 2018, J BONE MINER RES, V33, P803, DOI 10.1002/jbmr.3375
   Henriksen K, 2013, BONE, V53, P160, DOI 10.1016/j.bone.2012.11.045
   Ho AYY, 2005, ANN PHARMACOTHER, V39, P1428, DOI 10.1345/aph.1E580
   Institute for Health Metrics and Evaluation (IHME), 2021, GBD compare
   Ishibashi H, 2017, BONE, V103, P209, DOI 10.1016/j.bone.2017.07.005
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P1, DOI 10.1007/s00198 019 05176 3
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]
   Kim DH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122646
   Kobayakawa T, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 91248 6
   Kobayakawa T, 2021, BONE REP, V14, DOI 10.1016/j.bonr.2021.101068
   Kranenburg G, 2016, ATHEROSCLEROSIS, V252, P106, DOI 10.1016/j.atherosclerosis.2016.06.039
   Krishna SM, 2017, ARTERIOSCL THROM VAS, V37, P553, DOI 10.1161/ATVBAHA.116.308723
   Kung AWC, 2000, CALCIFIED TISSUE INT, V67, P286, DOI 10.1007/s002230001142
   Langdahl Bente L, 2017, Lancet, V390, P1585, DOI 10.1016/S0140 6736(17)31613 6
   Lau EMC, 2020, OSTEOPOROSIS INT, V31, P677, DOI 10.1007/s00198 020 05324 0
   Lau EMC, 2000, BONE, V27, P677, DOI 10.1016/S8756 3282(00)00378 1
   Lim SY, 2017, DRUG DES DEV THER, V11, P1221, DOI 10.2147/DDDT.S127568
   Manson JE, 2019, NEW ENGL J MED, V380, P33, DOI [10.1056/NEJMoa1809944, 10.1056/nejmoa1809944]
   Manson JE, 2010, MENOPAUSE, V17, P683, DOI 10.1097/gme.0b013e3181d683b5
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Mineta K, 2024, BONE, V186, DOI 10.1016/j.bone.2024.117164
   Miyauchi A, 2010, BONE, V47, P493, DOI 10.1016/j.bone.2010.05.022
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nikolakopoulou A, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003082
   Oglesby AK, 2003, J RHEUMATOL, V30, P1579
   Page MJ, 2021, INT J SURG, V88, DOI [10.1186/s13643 021 01626 4, 10.1016/j.jclinepi.2021.02.003, 10.1016/j.ijsu.2021.105906]
   Prentice RL, 2013, OSTEOPOROSIS INT, V24, P567, DOI 10.1007/s00198 012 2224 2
   Rauner M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040787
   Rodríguez AJ, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgaa481
   Rosano GMC, 2007, CLIMACTERIC, V10, P19, DOI 10.1080/13697130601114917
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Seeman E, 2010, OSTEOPOROSIS INT, V21, P362
   Shao JS, 2005, J CLIN INVEST, V115, P1210, DOI 10.1172/JCI200524140
   Stokar J, 2024, J CLIN ENDOCR METAB, V110, pe861, DOI 10.1210/clinem/dgae173
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Tsang HG, 2016, CELL BIOCHEM FUNCT, V34, P113, DOI 10.1002/cbf.3173
   Tucci JR, 1996, AM J MED, V101, P488, DOI 10.1016/S0002 9343(96)00282 3
   Turk JR, 2020, REGUL TOXICOL PHARM, V115, DOI 10.1016/j.yrtph.2020.104697
   Wu ST, 2021, J FORMOS MED ASSOC, V120, P1957, DOI 10.1016/j.jfma.2020.12.014
   Yang C, 2020, J AM COLL NUTR, V39, P352, DOI 10.1080/07315724.2019.1649219
   Zheng J, 2023, ARTHRITIS RHEUMATOL, V75, P1781, DOI 10.1002/art.42538
NR 66
TC 7
Z9 7
U1 0
U2 0
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114 5916
EI 1179 1942
J9 DRUG SAFETY
JI Drug Saf.
PD JAN
PY 2025
VL 48
IS 1
BP 7
EP 23
DI 10.1007/s40264 024 01475 9
EA SEP 2024
PG 17
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
GA R6F2L
UT WOS:001303743100001
PM 39227560
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Lee, YJ
   Jeong, JK
   Lee, JH
   Park, YG
   Moon, JH
   Seol, JW
   Jackson, CJ
   Park, SY
AF Lee, You Jin
   Jeong, Jae Kyo
   Lee, Ju Hee
   Park, Yang Gyu
   Moon, Ji Hong
   Seol, Jab Won
   Jackson, Christopher J.
   Park, Sang Youel
TI Sphingosine l phosphate protects against bisphosphonate induced HUVEC
   cell death via regulation of c Jun N terminal kinase signaling
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE sphingosine l phosphate; endothelial cell; bisphosphonate;
   c Jun N terminal kinase
ID PRENYLATION; APOPTOSIS; 1 PHOSPHATE; ALENDRONATE; INHIBITION;
   ACTIVATION; PATHWAY; MULTIPLE; SURVIVAL; PLASMA
AB Bisphosphonates (BPs) remain the most widely used and effective antiresorptive agents in the treatment of post menopausal osteoporosis. In particular, nitrogen containing BPs (N BPs) are more potent at inhibiting bone resorption in vivo than simple BPs, but they are associated with a number of side effects including increased endothelial cell apoptosis in patients with multiple myeloma. Sphingosine l phosphate (S1P), a sphingolipid metabolite, plays important roles in the regulation of cell growth, differentiation and programmed cell death as a multifunctional bioactive lipid mediator. The aim of this study was to elucidate the protective effect and the possible mechanism of SIP against BP induced cell damage using human umbilical vein endothelial cells (HUVECs). HUVECs were treated with SlP for 1 h and then with BP including alendronate, zoledronate and risedronate. SIP protects HUVECs against BP induced cell death and the protective effect was increased by SIP in a dose dependent manner. SlP blocked BP induced caspase 3 activation, nuclear factor kappa B activation, c Jun N terminal kinase (JNK) phosphorylation and DNA fragmentation. The blocking of JNK phosphorylation inhibited BP induced caspase activation and HUVEC cell death. The present study demonstrates that SIP inhibits BP induced endothelial cell death via regulation of JNK phosphorylation, and also suggests that SlP has the potential to be a therapeutic drug in various vascular diseases induced by BR
C1 [Lee, You Jin; Jeong, Jae Kyo; Lee, Ju Hee; Park, Yang Gyu; Moon, Ji Hong; Seol, Jab Won; Park, Sang Youel] Chonbuk Natl Univ, Coll Vet Med, Biosafety Res Inst, Jeonju 561756, Jeonbuk, South Korea.
   [Jackson, Christopher J.] Univ Sydney, Royal N Shore Hosp, Kolling Inst, Inst Bone & Joint Res, St Leonards, NSW 2065, Australia.
C3 Jeonbuk National University; University of Sydney; Kolling Institute of
   Medical Research; Royal North Shore Hospital
RP Park, SY (通讯作者)，Chonbuk Natl Univ, Coll Vet Med, Biosafety Res Inst, Dukjin Dong 664 14, Jeonju 561756, Jeonbuk, South Korea.
EM sypark@chonbuk.ac.kr
RI Park, Sang Youel/D 5966 2012; Lee, Sang Jin/S 4056 2019; Lee,
   Sung Min/MIN 7857 2025; Park, yang gyu/KSL 8100 2024
OI Jackson, Christopher/0000 0002 9234 9116; 
FU National Research Foundation of the Korea; Korean Government
   [2010 E00019, 2010 21492]
FX This study was supported by the National Research Foundation of the
   Korea Grant funded by the Korean Government (2010 E00019, 2010 21492).
CR Allegra A, 2010, ACTA HAEMATOL BASEL, V124, P79, DOI 10.1159/000313787
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Fu LJ, 2008, BONE, V43, P40, DOI 10.1016/j.bone.2008.03.008
   Hashimoto K, 2007, BIOCHEM BIOPH RES CO, V354, P478, DOI 10.1016/j.bbrc.2007.01.014
   Hasmim M, 2007, J THROMB HAEMOST, V5, P166, DOI 10.1111/j.1538 7836.2006.02259.x
   Inoue R, 2005, BRIT J PHARMACOL, V146, P633, DOI 10.1038/sj.bjp.0706373
   Ishii M, 2013, BBA MOL CELL BIOL L, V1831, P223, DOI 10.1016/j.bbalip.2012.06.002
   Kimura T, 2001, J BIOL CHEM, V276, P31780, DOI 10.1074/jbc.M104353200
   Kumar A, 2011, CELL SIGNAL, V23, P1144, DOI 10.1016/j.cellsig.2011.02.009
   Limaye V, 2005, BLOOD, V105, P3169, DOI 10.1182/blood 2004 02 0452
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003
   Morales Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200
   PEREZSALA D, 1994, BIOCHEM BIOPH RES CO, V199, P1209, DOI 10.1006/bbrc.1994.1359
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   ROGERS MJ, 1992, BIOCHEM BIOPH RES CO, V189, P414, DOI 10.1016/0006 291X(92)91574 A
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Seol JW, 2011, INT J MOL MED, V27, P835, DOI 10.3892/ijmm.2011.649
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Tsai SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041065
   Wolf AM, 2006, HAEMATOLOGICA, V91, P1165
   Yatomi Y, 1997, J BIOCHEM, V121, P969
NR 23
TC 5
Z9 5
U1 0
U2 12
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD APR
PY 2013
VL 31
IS 4
BP 811
EP 816
DI 10.3892/ijmm.2013.1266
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 111HE
UT WOS:000316511600007
PM 23381659
OA Bronze
DA 2025 08 17
ER

PT J
AU Huebner, AK
   Schinke, T
   Priemel, M
   Schilling, S
   Schilling, AF
   Emeson, RB
   Rueger, JM
   Amling, M
AF Huebner, Antje K.
   Schinke, Thorsten
   Priemel, Matthias
   Schilling, Sarah
   Schilling, Arndt F.
   Emeson, Ronald B.
   Rueger, Johannes M.
   Amling, Michael
TI Calcitonin deficiency in mice progressively results in high bone
   turnover
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE calcitonin; alpha calcitonin gene related peptide; bone remodeling; high
   turnover
ID GENE RELATED PEPTIDE; SYMPATHETIC NERVOUS SYSTEM; RESORPTION; RECEPTOR;
   RAT; OSTEOCLASTS; PHENOTYPE; HORMONE; MASS
AB Although the pharmacological action of calcitonin (CT) as an inhibitor of bone resorption is well established, there is still some controversy regarding its physiological function. Unexpectedly, Calca deficient mice lacking CT and alpha calcitonin gene related peptide (alpha CGRP) were described to have a high bone mass phenotype caused by increased bone formation with normal bone resorption. Here we show that these mice develop a phenotype of high bone turnover with age, suggesting that CT is a physiological inhibitor of bone remodeling.
   Introduction: The absence of significant changes in bone mineral density caused by decline or overproduction of CT in humans has raised the question, whether the pharmacological action of CT as an inhibitor of bone resorption is also of physiological relevance. To study the physiological role of mammalian CT, we have analyzed the age dependent bone phenotype of two mouse models, one lacking CT and alpha CGRP (Calca( / )), the other one lacking only aCGRP (alpha CGRP( / )).
   Materials and Methods: Bones from wildtype, Calca( / ) mice and alpha CGRP( / ) mice were analyzed at the ages of 6,12 and IS months using undecalcified histology. Differences of bone remodeling were quantified by static and dynamic histomorphometry as well as by measuring the urinary collagen degradation products. To rule out secondary mechanisms underlying the observed phenotype, we determined serum concentrations of relevant hormones using commercially available antibody based detection kits.
   Results: Whereas alpha CGRP( / ) mice display an osteopenia at all ages analyzed, the Calca( / ) mice develop a phenotype of high bone turnover with age. Histomorphometric analysis performed at the age of 12 months revealed significant increases of bone formation and bone resorption specifically in the Calca( / ) mice. This severe phenotype that can result in hyperostotic lesions, can not be explained by obvious endocrine abnormalities other than the absence of CT.
   Conclusions: In addition to the previously described increase of bone formation in the Calca deficient mice, we have observed that there is also an increase of bone resorption with age. This suggests that CT has a dual action as an inhibitor of bone remodeling, which may explain why alterations of CT serum levels in humans do not result in major changes of bone mineral density.
C1 Univ Hamburg, Ctr Med, Dept Trauma Hand & Reconstruct Surg, Ctr Biomech & Reconstruct Surg, D 20246 Hamburg, Germany.
   Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37212 USA.
   Vanderbilt Univ, Sch Med, Dept Mol Physiol, Nashville, TN 37212 USA.
   Vanderbilt Univ, Sch Med, Dept Biophys, Nashville, TN 37212 USA.
C3 University of Hamburg; Vanderbilt University; Vanderbilt University;
   Vanderbilt University
RP Amling, M (通讯作者)，Univ Hamburg, Ctr Med, Dept Trauma Hand & Reconstruct Surg, Ctr Biomech & Reconstruct Surg, Martinistr 52, D 20246 Hamburg, Germany.
EM amling@uke.uni hamburg.de
OI Emeson, Ronald/0000 0002 4585 1648
CR ALAM ASMT, 1993, J ENDOCRINOL, V136, P7, DOI 10.1677/joe.0.1360007
   AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0
   AMARA SG, 1985, SCIENCE, V229, P1094, DOI 10.1126/science.2994212
   Amling M, 1999, ENDOCRINOLOGY, V140, P4982, DOI 10.1210/en.140.11.4982
   CHAMBERS TJ, 1982, J PATHOL, V136, P27, DOI 10.1002/path.1711360104
   COPP DH, 1962, NATURE, V193, P381, DOI 10.1038/193381a0
   Dacquin R, 2004, J CELL BIOL, V164, P509, DOI 10.1083/jcb.200312135
   Deftos LJ, 1997, ENDOCRINOLOGY, V138, P519
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   FOSTER GV, 1964, NATURE, V202, P1303, DOI 10.1038/2021303a0
   FRANCOCERECEDA A, 1987, CIRC RES, V60, P393, DOI 10.1161/01.RES.60.3.393
   FRIEDMAN J, 1965, SCIENCE, V150, P1465, DOI 10.1126/science.150.3702.1465
   GALANTE L, 1971, CLIN SCI, V40, pP9
   HIRSCH PF, 2001, J MUSCULOSKEL NEURON, V4, P299
   Hoff AO, 2002, J CLIN INVEST, V110, P1849, DOI 10.1172/JCI200214218
   HURLEY DL, 1987, NEW ENGL J MED, V317, P537, DOI 10.1056/NEJM198708273170904
   JACOBS JW, 1981, SCIENCE, V213, P457, DOI 10.1126/science.6264603
   KALU DN, 1989, ENDOCRINOLOGY, V124, P7, DOI 10.1210/endo 124 1 7
   KAPURNIOTU A, 1995, J MED CHEM, V38, P836, DOI 10.1021/jm00005a011
   LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940
   Lu JT, 1999, MOL CELL NEUROSCI, V14, P99, DOI 10.1006/mcne.1999.0767
   Minisola S, 1997, J ENDOCRINOL INVEST, V20, P559, DOI 10.1007/BF03348019
   MOONGA BS, 1992, J ENDOCRINOL, V132, P24124
   NICHOLSON GC, 1986, J CLIN INVEST, V78, P3553
   OKAMOTO H, 1992, AM J PHYSIOL, V263, pR874, DOI 10.1152/ajpregu.1992.263.4.R874
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   REGINSTER JY, 1993, AM J MED S5A, V95, P44
   Roodman GD, 2005, J CLIN INVEST, V115, P200, DOI 10.1172/JCI200524281
   ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0
   Schinke T, 2004, J BONE MINER RES, V19, P2049, DOI 10.1359/JBMR.040915
   SEXTON PM, 1991, MOL NEUROBIOL, V5, P251, DOI 10.1007/BF02935550
   Singer FR., 1976, CLIN ENDOCRINOL, V5, P333
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Wallach S, 1999, BONE, V25, P509, DOI 10.1016/S8756 3282(99)00200 8
   Zaidi M, 2002, J CLIN INVEST, V110, P1769, DOI 10.1172/JCI200217425
NR 36
TC 65
Z9 70
U1 0
U2 4
PU AMER SOC BONE & MINERAL RES
PI WASHINGTON
PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036 3309 USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD DEC
PY 2006
VL 21
IS 12
BP 1924
EP 1934
DI 10.1359/JBMR.060820
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 108ZY
UT WOS:000242278900014
PM 17002587
OA Bronze
DA 2025 08 17
ER

PT J
AU Kar, P
   Millo, T
   Saha, S
   Mahtab, S
   Agarwal, S
   Goswami, R
AF Kar, Parmita
   Millo, Tabin
   Saha, Soma
   Mahtab, Samrina
   Agarwal, Shipra
   Goswami, Ravinder
TI Osteogenic Mechanisms of Basal Ganglia Calcification and its ex vivo
   Model in the Hypoparathyroid Milieu
SO ENDOCRINOLOGY
LA English
DT Article
DE hypoparathyroidism; basal ganglia calcification; hyperphosphatemia; ex
   vivo model; osteogenic molecules
ID DIFFERENTIAL EXPRESSION; VASCULAR CALCIFICATION; BONE; GENE; DEFICIENCY;
   SCLEROSTIN; OSTEOPOROSIS; OSTEOPONTIN; PREVALENCE; REGULATOR
AB Context: Basal ganglia calcification (BGC) is common (70%) in patients with chronic hypoparathyroidism. Interestingly, cortical gray matter is spared from calcification. The mechanism of BGC, role of hyperphosphatemia, and modulation of osteogenic molecules by parathyroid hormone (PTH) in its pathogenesis is not clear.
   Objective: We assessed the expression of a large repertoire of molecules with proosteogenic or antiosteogenic effects, including neuroprogenitor cells in caudate, dentate, and cortical gray matter from normal autopsy tissues. The effect of high phosphate and PTH was assessed in an ex vivo model of BGC using striatum tissue culture of the Sprague Dawley rat.
   Methods: The messenger RNA and protein expression of 39 molecules involved in multiple osteogenic pathways were assessed in 25 autopsy tissues using reverse transcriptase polymerase chain reaction, Western blot, and immunofluorescence. The striatal culture was maintained in a hypoparathyroid milieu for 24 days with and without (a) high phosphate (10 mm beta glycerophosphate) and (b) PTH(1 34) (50 ng/mL Dulbecco's modified Eagle's medium F12 media) for their effect on striatal calcification and osteogenic molecules.
   Results: Procalcification molecules (osteonectin, beta catenin, klotho, FZD4, NT5E, LRP5, WNT3A, collagen 1 alpha, and SOX2 positive neuroprogenitor stem cells) had significantly higher expression in the caudate than gray matter. Caudate nuclei also had higher expression of antiosteogenic molecules (osteopontin, carbonic anhydrase II [CA II], MGP, sclerostin, ISG15, ENPP1, and USP18). In an ex vivo model, striatum culture showed an increased propensity for calcified nodules with mineral deposition similar to that of bone tissue on Fourier transformed infrared spectroscopy, alizarin, and von Kossa stain. Mineralization in striatel culture was enhanced by high phosphate and decreased by exogenous PTH through increased expression of CA II.
   Conclusion: This study provides a conceptual advance on the molecular mechanisms of BGC and the possibility of PTH therapy to prevent this complication in a hypoparathyroid milieu.
C1 [Kar, Parmita; Saha, Soma; Mahtab, Samrina; Goswami, Ravinder] All India Inst Med Sci, Dept Endocrinol & Metab, Biotechnol Block Ansari Nagar,Rm 304, Delhi 110029, India.
   [Millo, Tabin] Dept Forens Med & Toxicol, Delhi 110029, India.
   [Agarwal, Shipra] All India Inst Med Sci, Dept Pathol, Delhi 110029, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; All India
   Institute of Medical Sciences (AIIMS) New Delhi
RP Goswami, R (通讯作者)，All India Inst Med Sci, Dept Endocrinol & Metab, Biotechnol Block Ansari Nagar,Rm 304, Delhi 110029, India.
RI ; Agarwal, Shipra/KLY 2487 2024
OI Goswami, Ravinder/0000 0002 3097 5074; 
FU All India Institute of Medical Sciences, New Delhi [A 252]; Indian
   Council of Medical Research, New Delhi, India [3/1/2/39/2014 15];
   Department of Biotechnology, Department of Science and Technology, India
   [BT/PR22675/MED/30/1806/2016]
FX This work was supported by the All India Institute of Medical Sciences,
   New Delhi (intramural grant No. A 252), the Indian Council of Medical
   Research, New Delhi, India (3/1/2/39/2014 15 (Nut. 2016 2019 for
   fellowship of Ms Parmita Kar), and Department of Biotechnology,
   Department of Science and Technology, India
   (BT/PR22675/MED/30/1806/2016, 2019 to the present).
CR Addison WN, 2015, BONE, V71, P244, DOI 10.1016/j.bone.2014.11.003
   Aggarwal S, 2013, EUR J ENDOCRINOL, V168, P895, DOI 10.1530/EJE 12 0946
   [Anonymous], **DATA OBJECT**, DOI DOI 10.6084/M9.FIGSHARE.13516457.V2
   Augusto E, 2013, J NEUROSCI, V33, P11390, DOI 10.1523/JNEUROSCI.5817 12.2013
   Bek MJ, 2001, KIDNEY INT, V60, P890, DOI 10.1046/j.1523 1755.2001.060003890.x
   Bonefeld BE, 2008, SYNAPSE, V62, P302, DOI 10.1002/syn.20496
   Bosley TM, 2011, BRAIN, V134, P3499, DOI 10.1093/brain/awr302
   Claus P, 2004, NEUROSCI LETT, V360, P117, DOI 10.1016/j.neulet.2004.01.046
   Diefenderfer DL, 2003, J BONE JOINT SURG AM, V85A, P19, DOI 10.2106/00004623 200300003 00005
   Forget MA, 2007, BRIT J CANCER, V96, P646, DOI 10.1038/sj.bjc.6603579
   Gafni RI, 2019, NEW ENGL J MED, V380, P1738, DOI 10.1056/NEJMcp1800213
   Goswami R, 2004, J CLIN ENDOCR METAB, V89, P4840, DOI 10.1210/jc.2004 0273
   Goswami R, 2004, EUR J ENDOCRINOL, V150, P9, DOI 10.1530/eje.0.1500009
   Goswami R, 2014, J CLIN ENDOCR METAB, V99, P1741, DOI 10.1210/jc.2013 3863
   Goswami R, 2012, CLIN ENDOCRINOL, V77, P200, DOI 10.1111/j.1365 2265.2012.04353.x
   Gratsch TE, 2002, DEV BIOL, V245, P83, DOI 10.1006/dbio.2002.0629
   Grünblatt E, 2019, AM J MED GENET B, V180, P365, DOI 10.1002/ajmg.b.32695
   Guo XX, 2019, HUM MUTAT, V40, P392, DOI 10.1002/humu.23703
   Hampson G, 2013, BONE, V56, P42, DOI 10.1016/j.bone.2013.05.010
   Hofbauer LC, 2007, OSTEOPOROSIS INT, V18, P251, DOI 10.1007/s00198 006 0282 z
   Huang L, 2000, AM J PATHOL, V156, P761, DOI 10.1016/S0002 9440(10)64942 5
   Jahnen Dechent W, 2008, J MOL MED, V86, P379, DOI 10.1007/s00109 007 0294 y
   Jia L, 2019, MOL BRAIN, V12, DOI 10.1186/s13041 019 0525 5
   Kar P, 2016, MOL CELL BIOCHEM, V417, P49, DOI 10.1007/s11010 016 2712 3
   Keller D, 2018, FRONT NEUROANAT, V12, DOI 10.3389/fnana.2018.00083
   Kirikoshi H, 2001, INT J ONCOL, V19, P767
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Lee K., 2014, Bio Protoc, V4, pe1036, DOI DOI 10.21769/BIOPROTOC.1036
   Lee Y, 2008, GLIA, V56, P481, DOI 10.1002/glia.20622
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Louvet L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115342
   MARINO LR, 1993, J BIOL CHEM, V268, P7081
   Matsuoka I, 1997, J NEUROCHEM, V68, P498
   Meuwissen MEC, 2016, J EXP MED, V213, P1163, DOI 10.1084/jem.20151529
   MUENTER MD, 1968, NEUROLOGY, V18, P1075, DOI 10.1212/WNL.18.11.1075
   Nicolas G, 2017, NEUROL GENET, V3, DOI 10.1212/NXG.0000000000000166
   Oheim R, 2020, J BONE MINER RES, V35, P528, DOI 10.1002/jbmr.3911
   Osyczka AM, 2004, CELLS TISSUES ORGANS, V176, P109, DOI 10.1159/000075032
   Pereira S, 2004, ATLA ALTERN LAB ANIM, V32, P411, DOI 10.1177/026119290403201s67
   Razzaque MS, 2009, NAT REV ENDOCRINOL, V5, P611, DOI 10.1038/nrendo.2009.196
   Rubio FJ, 2016, JOVE J VIS EXP, DOI 10.3791/54358
   Sakamoto A, 1999, HUM PATHOL, V30, P1418, DOI 10.1016/S0046 8177(99)90162 4
   Schwartz PH, 2003, J NEUROSCI RES, V74, P838, DOI 10.1002/jnr.10854
   SMITS MG, 1983, CLIN NEUROL NEUROSUR, V85, P145, DOI 10.1016/0303 8467(83)90044 6
   Smyth LCD, 2018, J CHEM NEUROANAT, V92, P48, DOI 10.1016/j.jchemneu.2018.06.001
   Spijker S, 2011, NEUROMETHODS, V57, P13, DOI 10.1007/978 1 61779 111 6_2
   Stan AD, 2006, BRAIN RES, V1123, P1, DOI 10.1016/j.brainres.2006.09.025
   Strazzabosco M, 2009, HEPATOLOGY, V50, P244, DOI 10.1002/hep.22926
   Superti Furga A, 2001, AM J MED GENET, V106, P282, DOI 10.1002/ajmg.10233.abs
   Takedachi M, 2012, J CELL PHYSIOL, V227, P2622, DOI 10.1002/jcp.23001
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Wang Cheng, 2015, Yichuan, V37, P731, DOI 10.16288/j.yczz.15 033
   Witkowski JM, 2007, J IMMUNOL, V178, P771, DOI 10.4049/jimmunol.178.2.771
   Zhai YH, 2010, NEPHROL DIAL TRANSPL, V25, P3213, DOI 10.1093/ndt/gfq190
NR 54
TC 6
Z9 7
U1 0
U2 9
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD APR
PY 2021
VL 162
IS 4
AR bqab024
DI 10.1210/endocr/bqab024
EA FEB 2021
PG 22
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA QW6CY
UT WOS:000628736500012
PM 33539507
OA Bronze
DA 2025 08 17
ER

PT J
AU Hager, S
   Lampert, FM
   Orimo, H
   Stark, GB
   Finkenzeller, G
AF Hager, Sven
   Lampert, Florian M.
   Orimo, Hideo
   Stark, G. Bjoern
   Finkenzeller, Guenter
TI Up Regulation of Alkaline Phosphatase Expression in Human Primary
   Osteoblasts by Cocultivation with Primary Endothelial Cells is Mediated
   by p38 Mitogen Activated Protein Kinase Dependent mRNA Stabilization
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID SPHEROIDAL COCULTURE MODEL; TISSUE ENGINEERED BONE; GENE EXPRESSION;
   GROWTH FACTOR; STEM CELLS; IN VITRO; BLOOD VESSELS; DIFFERENTIATION;
   ANGIOGENESIS; ACID
AB For the regeneration of bone in tissue engineering applications, it is essential to provide cues that support neovascularization. This can be achieved by cell based therapies using mature endothelial cells (ECs) or endothelial progenitor cells. In this context, ECs were used in various in vivo studies in combination with primary osteoblasts to enhance neovascularization of bone grafts. In a previous study, we have shown that cocultivation of human primary ECs and human primary osteoblasts (hOBs) leads to a cell contact dependent up regulation of alkaline phosphatase (ALP) expression in osteoblasts, indicating that cocultivated ECs may support osteogenic differentiation and osteoblastic cell functions. In the present study, we investigated this effect in more detail, revealing a time and cell number dependency of EC mediated up regulation of the early osteoblastic marker ALP, whereas osteocalcin, a late marker of osteogenesis, was down regulated. The effect on ALP expression was bidirectional specific for both cell types. Functional inhibition of gap junctional communication between ECs and hOBs by 18 alpha glycyrrhetinic acid had only a weak suppressive effect on EC mediated ALP up regulation. In contrast, inhibition of p38 mitogen activated protein kinase nearly completely prevented the EC mediated stimulation of osteoblastic ALP expression. To investigate the molecular mechanism underlying the ALP up regulation, we examined the effect of EC cocultivation on osteoblastic ALP promoter activity as well as mRNA stability. Cocultivation of ECs with hOBs significantly elevated the half life of osteoblastic ALP mRNA without affecting its promoter activity. In summary, our data show that EC mediated up regulation of osteoblastic ALP expression is cell type specific and is posttranscriptionally regulated via p38 mitogen activated protein kinase dependent mRNA turn over.
C1 [Hager, Sven; Lampert, Florian M.; Stark, G. Bjoern; Finkenzeller, Guenter] Univ Freiburg, Med Ctr, Dept Plast & Hand Surg, D 79106 Freiburg, Germany.
   [Orimo, Hideo] Nippon Med Sch, Dept Biochem & Mol Biol, Tokyo 113, Japan.
C3 University of Freiburg; Nippon Medical School
RP Finkenzeller, G (通讯作者)，Univ Freiburg, Med Ctr, Dept Plast & Hand Surg, Hugstetter Str 55, D 79106 Freiburg, Germany.
EM guenter.finkenzeller@uniklinik freiburg.de
OI Lampert, Florian/0000 0003 4052 0601
FU Deutsche Forschungsgemeinschaft [FI 790/2 1]
FX We thank Beate vom Hoevel for excellent technical assistance. This work
   was supported by funding through the Deutsche Forschungsgemeinschaft (FI
   790/2 1).
CR Alajati A, 2008, NAT METHODS, V5, P439, DOI [10.1038/nmeth.1198, 10.1038/NMETH.1198]
   Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114
   BLUM JS, 2001, J CELL BIOCH, V80
   Bouletreau PJ, 2002, PLAST RECONSTR SURG, V109, P2384, DOI 10.1097/00006534 200206000 00033
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   DECKER B, 1995, ANAT RECORD, V242, P310, DOI 10.1002/ar.1092420304
   Donahue HJ, 2000, AM J PHYSIOL CELL PH, V278, pC315, DOI 10.1152/ajpcell.2000.278.2.C315
   Enis DR, 2005, P NATL ACAD SCI USA, V102, P425, DOI 10.1073/pnas.0408357102
   Fuchs S, 2007, TISSUE ENG, V13, P2577, DOI 10.1089/ten.2007.0022
   Gabriels JE, 1998, CIRC RES, V83, P636, DOI 10.1161/01.RES.83.6.636
   Gaestel M, 2006, NAT REV MOL CELL BIO, V7, P120, DOI 10.1038/nrm1834
   GUENTHER HL, 1986, ENDOCRINOLOGY, V119, P193, DOI 10.1210/endo 119 1 193
   Guillotin B, 2008, BONE, V42, P1080, DOI 10.1016/j.bone.2008.01.025
   Henry TD, 2001, AM HEART J, V142, P872, DOI 10.1067/mhj.2001.118471
   HUNTER WL, 1991, ANAT REC, V229, P453, DOI 10.1002/ar.1092290404
   Karsenty G, 2001, ENDOCRINOLOGY, V142, P2731, DOI 10.1210/en.142.7.2731
   Kilpadi KL, 2004, J BIOMED MATER RES A, V68A, P273, DOI 10.1002/jbm.a.20043
   Kneser U, 1999, J BIOMED MATER RES, V47, P494, DOI 10.1002/(SICI)1097 4636(19991215)47:4<494::AID JBM5>3.0.CO;2 L
   Koike N, 2004, NATURE, V428, P138, DOI 10.1038/428138a
   KYEYUNENYOMBI E, 1991, ARCH BIOCHEM BIOPHYS, V291, P316, DOI 10.1016/0003 9861(91)90141 5
   Lecanda F, 1998, MOL BIOL CELL, V9, P2249, DOI 10.1091/mbc.9.8.2249
   Magnitsky S, 2008, ACAD RADIOL, V15, P1269, DOI 10.1016/j.acra.2008.05.003
   Mayr Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756 3282(01)00690 1
   Medhurst AD, 2000, J NEUROSCI METH, V98, P9, DOI 10.1016/S0165 0270(00)00178 3
   Mehlhorn AT, 2006, TISSUE ENG, V12, P1393, DOI 10.1089/ten.2006.12.1393
   Mikami Y, 2007, BIOCHEM BIOPH RES CO, V362, P368, DOI 10.1016/j.bbrc.2007.07.192
   Orban JM, 2002, TISSUE ENG, V8, P529, DOI 10.1089/107632702760240454
   Orimo H, 2005, BONE, V36, P866, DOI 10.1016/j.bone.2005.02.010
   Rouwkema J, 2006, TISSUE ENG, V12, P2685, DOI 10.1089/ten.2006.12.2685
   Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297
   Schumacher B, 1998, CIRCULATION, V97, P645, DOI 10.1161/01.CIR.97.7.645
   Shaked H, 2008, CANCER RES, V68, P9671, DOI 10.1158/0008 5472.CAN 08 0865
   Sieminski AL, 2005, TISSUE ENG, V11, P1332, DOI 10.1089/ten.2005.11.1332
   Stahl A, 2004, BIOCHEM BIOPH RES CO, V322, P684, DOI 10.1016/j.bbrc.2004.07.175
   Stains JP, 2005, MOL BIOL CELL, V16, P64, DOI 10.1091/mbc.E04 04 0339
   Steffens L., 2008, J CELL MOL MED
   Stevens DA, 1999, MOL CELL ENDOCRINOL, V151, P195, DOI 10.1016/S0303 7207(99)00037 4
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Sun HC, 2007, BIOMED ENG ONLINE, V6, DOI 10.1186/1475 925X 6 41
   Taylor HJ, 1998, BRIT J PHARMACOL, V125, P1, DOI 10.1038/sj.bjp.0702078
   Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177 7188.2003
   Villars F, 2000, J CELL BIOCHEM, V79, P672, DOI 10.1002/1097 4644(20001215)79:4<672::AID JCB150>3.0.CO;2 2
   Villars F, 2002, AM J PHYSIOL CELL PH, V282, pC775, DOI 10.1152/ajpcell.00310.2001
   Wang DS, 1997, ENDOCRINOLOGY, V138, P2953, DOI 10.1210/en.138.7.2953
   Wenger A, 2004, TISSUE ENG, V10, P1536, DOI 10.1089/ten.2004.10.1536
   Yamamoto Y, 1998, J PHYSIOL LONDON, V511, P501, DOI 10.1111/j.1469 7793.1998.501bh.x
   Yu HY, 2008, J ORTHOP RES, V26, P1147, DOI 10.1002/jor.20609
   Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257
NR 48
TC 42
Z9 53
U1 0
U2 14
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD NOV
PY 2009
VL 15
IS 11
BP 3437
EP 3447
DI 10.1089/ten.tea.2009.0133
PG 11
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA 519EC
UT WOS:000271746800021
PM 19409035
DA 2025 08 17
ER

PT J
AU Ling, ZH
   Fan, GT
   Yao, DH
   Zhao, JN
   Zhou, YH
   Feng, JZ
   Zhou, GX
   Chen, Y
AF Ling, Zhonghua
   Fan, Gentao
   Yao, Danhua
   Zhao, Jianning
   Zhou, Yinhua
   Feng, Jinzhu
   Zhou, Guangxin
   Chen, Yong
TI MicroRNA 150 functions as a tumor suppressor and sensitizes osteosarcoma
   to doxorubicin induced apoptosis by targeting RUNX2
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE osteosarcoma; microRNA 150; runt related transcription factor 2;
   proliferation; chemotherapy
ID EXPRESSION; PROLIFERATION; PROGRESSION; MIGRATION; PROGNOSIS; INVASION;
   TXNIP
AB Osteosarcoma (OS) is the most common form of bone malignancy in children and adolescents. MicroRNAs (miRNAs) have been associated with the development and progression of OS. In the present study, reverse transcription quantitative PCR, western blotting, Cell Counting Kit 8, luciferase and Transwell assays were performed to investigate the biological function of microRNA 150 (miR 150) in OS. The results revealed that miR 150 was significantly downregulated in OS cell lines (HOS, SAOS2, MG 63 and U2OS) in comparison with the normal osteoblast cells (hFOB1.19). Overexpression of miR 150 significantly inhibited cell proliferation in OS cells. miR 150 could sensitize OS cells to chemotherapy treatment of doxorubicin. Runt related transcription factor 2 (RUNX2) was identified as a target gene of miR 150. RUNX2 knockdown exhibited similar inhibitory effects on both OS cell proliferation and chemotherapy sensitivity. Restoration of RUNX2 reversed the biological function of miR 150. Finally, miR 150 overexpression and RUNX2 knockdown enhanced caspase 3 cleavage. Taken together, the present study established a novel molecular mechanism, in that miR 150 plays tumor suppressor and chemoprotective roles by targeting RUNX2 in OS, indicating that miR 150 may be a potential therapeutic target for OS therapy in the future.
C1 [Ling, Zhonghua; Fan, Gentao; Yao, Danhua; Zhao, Jianning; Zhou, Yinhua; Feng, Jinzhu; Zhou, Guangxin; Chen, Yong] Jinling Hosp, Dept Orthoped, 305 Zhongshan East Rd, Nanjing 210002, Jiangsu, Peoples R China.
RP Chen, Y (通讯作者)，Jinling Hosp, Dept Orthoped, 305 Zhongshan East Rd, Nanjing 210002, Jiangsu, Peoples R China.
EM chenyong201707@163.com
FU national natural science foundation of China [81802693]
FX This article is supported by the national natural science foundation of
   China (grant no. 81802693).
CR Bacci G, 2003, ANN ONCOL, V14, P1126, DOI 10.1093/annonc/mdg286
   Bielack SS, 2008, J CLIN ONCOL, V26, P3102, DOI 10.1200/JCO.2008.17.1108
   Chen XX, 2018, AGING US, V10, P3421, DOI 10.18632/aging.101656
   Chiyomaru T, 2011, PROSTATE, V71, P1559, DOI 10.1002/pros.21372
   Dreyer F, 2016, METHODS MOL BIOL, V1448, P201, DOI 10.1007/978 1 4939 3753 0_15
   Esquela Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Forrester MT, 2009, J BIOL CHEM, V284, P36160, DOI 10.1074/jbc.M109.057729
   Ghali O, 2010, J BONE MINER RES, V25, P1616, DOI 10.1002/jbmr.52
   Gorlick R, 2010, J BONE MINER RES, V25, P683, DOI 10.1002/jbmr.77
   Jin MM, 2019, MOL THER NUCL ACIDS, V18, P219, DOI 10.1016/j.omtn.2019.08.016
   Jones KB, 2012, CANCER RES, V72, P1865, DOI 10.1158/0008 5472.CAN 11 2663
   Lee DH, 2015, INT J CANCER, V136, P2055, DOI 10.1002/ijc.29269
   Lee JH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112684
   Li CH, 2017, ONCOL LETT, V13, P2191, DOI 10.3892/ol.2017.5709
   Li X, 2015, CYTOGENET GENOME RES, V146, P124, DOI 10.1159/000437379
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Longhi A, 2006, CANCER TREAT REV, V32, P423, DOI 10.1016/j.ctrv.2006.05.005
   Mousa SA, 2009, AGING US, V1, P412, DOI 10.18632/aging.100035
   Muoio DM, 2007, CELL METAB, V5, P412, DOI 10.1016/j.cmet.2007.05.011
   Nathan SS, 2009, MOL BIOL REP, V36, P153, DOI 10.1007/s11033 008 9378 1
   Olfa G, 2010, BONE, V46, P901, DOI 10.1016/j.bone.2009.12.027
   Pereira BP, 2009, J CELL PHYSIOL, V221, P778, DOI 10.1002/jcp.21921
   Quan XY, 2019, EXP THER MED, V18, P2667, DOI 10.3892/etm.2019.7828
   Rainusso N, 2013, CURR ONCOL REP, V15, P296, DOI 10.1007/s11912 013 0321 9
   Sadikovic B, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 202
   Takagi T, 2009, ONCOLOGY BASEL, V77, P12, DOI 10.1159/000218166
   Tang MJ, 2013, ONCOTARGETS THER, V6, P833, DOI 10.2147/OTT.S40080
   Villadsen SB, 2012, BRIT J CANCER, V106, P366, DOI 10.1038/bjc.2011.520
   Wang D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013067
   Wang L, 2019, PATHOL ONCOL RES, V25, P527, DOI 10.1007/s12253 018 0454 0
   Wang T, 2015, CANCER BIOMARK, V15, P543, DOI 10.3233/CBM 150493
   Watanabe A, 2011, LEUKEMIA, V25, P1324, DOI 10.1038/leu.2011.81
   Yang JL, 2013, CURR OPIN ONCOL, V25, P398, DOI 10.1097/CCO.0b013e3283622c1b
NR 33
TC 13
Z9 13
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD JAN
PY 2020
VL 19
IS 1
BP 481
EP 488
DI 10.3892/etm.2019.8231
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA KE2FG
UT WOS:000508373500060
PM 31897096
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Monfoulet, L
   Rabier, B
   Chassande, O
   Fricain, JC
AF Monfoulet, Laurent
   Rabier, Benedicte
   Chassande, Olivier
   Fricain, Jean Christophe
TI Drilled Hole Defects in Mouse Femur as Models of Intramembranous
   Cortical and Cancellous Bone Regeneration
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Bone healing; Bone regeneration; Cortical bone; Spongy bone; Mouse bone
ID GROWTH PLATE CARTILAGE; FRACTURE REPAIR; OSTEOBLASTS; MARROW; CELLS;
   EXPRESSION; INJURY; RATS
AB In order to identify pertinent models of cortical and cancellous bone regeneration, we compared the kinetics and patterns of bone healing in mouse femur using two defect protocols. The first protocol consisted of a 0.9 mm diameter through and through cortical hole drilled in the mid diaphysis. The second protocol was a 0.9 mm diameter, 1 mm deep perforation in the distal epimetaphyseal region, which destroyed part of the growth plate and cancellous bone. Bone healing was analyzed by ex vivo micro computerized X ray tomography and histology. In the diaphysis, the cortical gap was bridged with woven bone within 2 weeks. This newly formed bone was rapidly remodeled into compact cortical bone, which showed characteristic parameters of intact cortex 4 weeks after surgery. In the epimetaphysis, bone formation was initiated at the deepest region of the defect and spread slowly toward the cortical gap. In this position, newly formed bone quickly adopted the characteristics of trabecular bone, whereas a thin compact wall was formed at its external border, which reached the density of intact cortical bone but failed to bridge the cortical gap even 13 weeks after surgery. This comparative study indicates that the diaphyseal defect is a model of cortical bone healing and that the epimetaphyseal defect is a model of cancellous bone repair. These models enable experimental genetics studies to investigate the cellular and molecular mechanisms of spontaneous cortical and cancellous bone repair and may be useful for pharmacological studies.
C1 [Monfoulet, Laurent; Rabier, Benedicte; Chassande, Olivier; Fricain, Jean Christophe] Univ Victor Segalen Bordeaux 2, F 33076 Bordeaux, France.
   [Monfoulet, Laurent; Rabier, Benedicte; Chassande, Olivier; Fricain, Jean Christophe] INSERM, U577, F 33076 Bordeaux, France.
   [Chassande, Olivier] Univ Victor Segalen Bordeaux 2, CHU, F 33604 Bordeaux, France.
C3 Universite de Bordeaux; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite de Bordeaux; CHU Bordeaux
RP Chassande, O (通讯作者)，Univ Victor Segalen Bordeaux 2, F 33076 Bordeaux, France.
EM lmonfo100p@u bordeaux2.fr; olivier.chassande@inserm.fr
RI Monfoulet, Laurent Emmanuel/O 6508 2016; Chassande, Olivier/J 3582 2015;
   jean christophe, fricain/AGN 5552 2022
OI Monfoulet, Laurent Emmanuel/0000 0001 9836 0255; fricain, jean
   christophe/0000 0001 7855 6437; 
CR Alford AI, 2006, BONE, V38, P749, DOI 10.1016/j.bone.2005.11.017
   Ayukawa Y, 2009, ORAL SURG ORAL MED O, V107, P336, DOI 10.1016/j.tripleo.2008.07.013
   Baron R., 1983, Bone histomorphometry: Techniques and interpretation, P13
   Bilic Curcic I, 2005, BONE, V37, P678, DOI 10.1016/j.bone.2005.06.009
   Campbell TM, 2003, CALCIFIED TISSUE INT, V73, P49, DOI 10.1007/s00223 002 2120 4
   Choi P, 2004, J ORTHOP RES, V22, P1100, DOI 10.1016/j.orthres.2004.03.008
   Colnot C, 2009, J BONE MINER RES, V24, P274, DOI 10.1359/JBMR.081003
   Cottalorda J, 1996, J PEDIATR ORTHOPED, V16, P664, DOI 10.1097/01241398 199609000 00022
   Cui QJ, 2006, J BONE JOINT SURG AM, V88A, P167, DOI 10.2106/JBJS.F.00891
   GOLDNER JACQUES, 1938, AMER JOUR PATH, V14, P237
   Grellier M, 2009, BIOMATERIALS, V30, P3271, DOI 10.1016/j.biomaterials.2009.02.033
   Lee MA, 2000, J PEDIATR ORTHOPED, V20, P802, DOI 10.1097/01241398 200011000 00021
   MAKELA EA, 1988, J BONE JOINT SURG BR, V70, P187, DOI 10.1302/0301 620X.70B2.3346285
   MONFOULET L, 2009, BONE IN PRESS
   Nagashima M, 2005, BONE, V36, P502, DOI 10.1016/j.bone.2004.11.013
   Schenk RK., 1984, METHODS CALCIFIED TI, P1
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05
   SUVA LJ, 1993, J BONE MINER RES, V8, P379
   Uusitalo H, 2001, BONE, V28, P423, DOI 10.1016/S8756 3282(01)00406 9
   Wahl EC, 2006, ALCOHOL, V39, P159, DOI 10.1016/j.alcohol.2006.08.004
   Xian CJ, 2004, J ORTHOPAED RES, V22, P417, DOI 10.1016/j.orthres.2003.08.003
   Zhou FH, 2004, BONE, V35, P1307, DOI 10.1016/j.bone.2004.09.014
NR 23
TC 79
Z9 92
U1 0
U2 19
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD JAN
PY 2010
VL 86
IS 1
BP 72
EP 81
DI 10.1007/s00223 009 9314 y
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 537HA
UT WOS:000273102700010
PM 19953233
DA 2025 08 17
ER

PT J
AU Barisione, C
   Ghigliotti, G
   Canepa, M
   Balbi, M
   Brunelli, C
   Ameri, P
AF Barisione, Chiara
   Ghigliotti, Giorgio
   Canepa, Marco
   Balbi, Manrico
   Brunelli, Claudio
   Ameri, Pietro
TI Indoxyl Sulfate: A Candidate Target for the Prevention and Treatment of
   Cardiovascular Disease in Chronic Kidney Disease
SO CURRENT DRUG TARGETS
LA English
DT Article
DE Aneurysm; atherosclerosis; cardiovascular; chronic kidney disease;
   indoxyl sulfate; inflammation; therapy; toxin
ID ARYL HYDROCARBON RECEPTOR; BOUND UREMIC TOXINS; ORGANIC ANION
   TRANSPORTERS; ENDOTHELIAL PROGENITOR CELLS; OSTEOBLAST SPECIFIC
   PROTEINS; ABDOMINAL AORTIC ANEURYSMS; GLOMERULAR FILTRATION RATE;
   CORONARY HEART DISEASE; P CRESYL SULFATE; OXIDATIVE STRESS
AB The awareness that chronic kidney disease (CKD) is a condition of dramatically increased cardiovascular risk has prompted an intense research activity, aimed at identifying factors that are specifically involved in the development of cardiovascular complications of CKD and that can be delayed or reduced by novel pharmacological approaches. This may be the case with indoxyl sulfate (IS). IS is an endogenous molecule derived from indole, a product of protein metabolism by intestinal bacteria, which acts via the aryl hydrocarbon receptor (AhR). IS accumulates early in CKD and exerts pro inflammatory and other detrimental effects on the cardiovascular system, in particular promoting atherosclerosis and atherosclerosis related arterial remodeling. Furthermore, IS also contributes to renal damage, thereby fueling a vicious circle. Dialysis is poorly effective in removing IS, but its levels can be lowered by preventing the bacterial generation of indole or by absorbing this latter within the intestine. More intriguing, although still theoretical, is the possibility of inhibiting the action of IS at the cell level, by antagonizing the binding to AhR or IS intracellular signaling. Therefore, IS targeting might become an option for reducing the cardiovascular burden of CKD.
C1 [Barisione, Chiara; Ghigliotti, Giorgio; Canepa, Marco; Balbi, Manrico; Brunelli, Claudio; Ameri, Pietro] Univ Genoa, Dept Internal Med, Res Ctr Cardiovasc Biol, Genoa, Italy.
C3 University of Genoa
RP Ameri, P (通讯作者)，Univ Genoa, Dept Internal Med, Res Ctr Cardiovasc Biol, Genoa, Italy.
EM pietroameri@unige.it
RI Canepa, Marco/K 3850 2018; balbi, manrico/AAC 9676 2019; Ameri,
   Pietro/K 8556 2016; Barisione, Chiara/B 3993 2012
OI CANEPA, MARCO/0000 0001 9063 5576; Ameri, Pietro/0000 0001 7167 7287;
   barisione, chiara/0000 0001 8831 1054; Ghigliotti,
   Giorgio/0000 0001 8484 542X; 
CR Adelibieke Y, 2013, CIRC J, V77, P1326, DOI 10.1253/circj.CJ 12 0884
   Adesso S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076778
   Adijiang A, 2008, NEPHROL DIAL TRANSPL, V23, P1892, DOI 10.1093/ndt/gfm861
   Akizawa T, 2009, AM J KIDNEY DIS, V54, P459, DOI 10.1053/j.ajkd.2009.05.011
   Aronov PA, 2011, J AM SOC NEPHROL, V22, P1769, DOI 10.1681/ASN.2010121220
   Arsenescu R, 2011, INFLAMM BOWEL DIS, V17, P1149, DOI 10.1002/ibd.21463
   Arsenescu V, 2011, TOXICOL APPL PHARM, V257, P148, DOI 10.1016/j.taap.2011.08.028
   Astor BC, 2006, AM HEART J, V151, P492, DOI 10.1016/j.ahj.2005.03.055
   Barreto FC, 2009, CLIN J AM SOC NEPHRO, V4, P1551, DOI 10.2215/CJN.03980609
   Bolati D, 2013, BMC NEPHROL, V14, DOI 10.1186/1471 2369 14 56
   Bro S, 2003, J AM SOC NEPHROL, V14, P2466, DOI 10.1097/01.ASN.0000088024.72216.2E
   Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580
   Chade AR, 2005, HYPERTENSION, V45, P1042, DOI 10.1161/01.HYP.0000167121.14254.a0
   Chiu Cheng An, 2010, Rev Diabet Stud, V7, P275, DOI 10.1900/RDS.2010.7.275
   De Preter V, 2006, J AM COLL NUTR, V25, P541, DOI 10.1080/07315724.2006.10719570
   De Preter V, 2007, AM J PHYSIOL GASTR L, V292, pG358, DOI 10.1152/ajpgi.00052.2006
   Deguchi T, 2004, KIDNEY INT, V65, P162, DOI 10.1111/j.1523 1755.2004.00354.x
   Dou L, 2004, KIDNEY INT, V65, P442, DOI 10.1111/j.1523 1755.2004.00399.x
   Eckardt KU, 2013, LANCET, V382, P158, DOI 10.1016/S0140 6736(13)60439 0
   Enomoto A, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022017.96399.B2
   Faure V, 2006, J THROMB HAEMOST, V4, P566, DOI 10.1111/j.1538 7836.2005.01780.x
   Gansevoort RT, 2013, LANCET, V382, P339, DOI 10.1016/S0140 6736(13)60595 4
   Gasiewicz TA, 2010, CHEM BIOL INTERACT, V184, P246, DOI 10.1016/j.cbi.2009.10.019
   Ghigliotti G, 2013, DIS MARKERS, V34, P131, DOI 10.1155/2013/836849
   Gondouin B, 2013, KIDNEY INT, V84, P733, DOI 10.1038/ki.2013.133
   Hedin U, 2004, CURR OPIN LIPIDOL, V15, P559, DOI 10.1097/00041433 200410000 00010
   Hsu CC, 2013, CLIN INVEST MED, V36, pE42
   Hwang SJ, 2013, TOXICOL LETT, V220, P109, DOI 10.1016/j.toxlet.2013.04.016
   Ito S, 2013, J LEUKOCYTE BIOL, V93, P837, DOI 10.1189/jlb.0112023
   Itoh Y, 2012, ANAL BIOANAL CHEM, V403, P1841, DOI 10.1007/s00216 012 5929 3
   Kikuchi K, 2010, J CHROMATOGR B, V878, P2997, DOI 10.1016/j.jchromb.2010.09.006
   Koizumi M, 2014, J ATHEROSCLER THROMB, V21, P904, DOI 10.5551/jat.23663
   Lee CT, 2010, PERITON DIALYSIS INT, V30, P456, DOI 10.3747/pdi.2009.00092
   Lim CC, 2014, PREV CARDIOL
   Lin CJ, 2012, ATHEROSCLEROSIS, V225, P173, DOI 10.1016/j.atherosclerosis.2012.07.012
   Lin CJ, 2011, J CLIN LAB ANAL, V25, P191, DOI 10.1002/jcla.20456
   LINDNER A, 1974, NEW ENGL J MED, V290, P697, DOI 10.1056/NEJM197403282901301
   Liu S, 2012, INT J CARDIOL, V158, P457, DOI 10.1016/j.ijcard.2012.05.022
   Marzocco S, 2013, BLOOD PURIFICAT, V35, P196, DOI 10.1159/000346628
   Masai N, 2010, CIRC J, V74, P2216, DOI 10.1253/circj.CJ 10 0117
   Massy ZA, 2005, J AM SOC NEPHROL, V16, P109, DOI 10.1681/ASN.2004060495
   Matsushita K, 2010, LANCET, V375, P2073, DOI 10.1016/S0140 6736(10)60674 5
   Meijers BKI, 2011, NEPHROL DIAL TRANSPL, V26, P759, DOI 10.1093/ndt/gfq818
   Meisinger C, 2006, EUR HEART J, V27, P1245, DOI 10.1093/eurheartj/ehi880
   Miyamoto Y, 2010, FEBS LETT, V584, P2816, DOI 10.1016/j.febslet.2010.04.046
   Mozar A, 2011, THER APHER DIAL, V15, P135, DOI 10.1111/j.1744 9987.2010.00885.x
   Muntner P, 2005, J AM SOC NEPHROL, V16, P529, DOI 10.1681/ASN.2004080656
   Murray IA, 2011, MOL PHARMACOL, V79, P508, DOI 10.1124/mol.110.069369
   Murray IA, 2010, J PHARMACOL EXP THER, V332, P135, DOI 10.1124/jpet.109.158261
   Muteliefu G, 2009, J RENAL NUTR, V19, P29, DOI 10.1053/j.jrn.2008.10.014
   Muteliefu G, 2012, AM J PHYSIOL CELL PH, V303, pC126, DOI 10.1152/ajpcell.00329.2011
   Muteliefu G, 2009, NEPHROL DIAL TRANSPL, V24, P2051, DOI 10.1093/ndt/gfn757
   Nakamura T, 2004, KIDNEY BLOOD PRESS R, V27, P121, DOI 10.1159/000077536
   Nakano T, 2010, AM J KIDNEY DIS, V55, P21, DOI 10.1053/j.ajkd.2009.06.034
   Namikoshi T, 2009, HYPERTENS RES, V32, P194, DOI 10.1038/hr.2008.29
   Neirynck N, 2013, INT UROL NEPHROL, V45, P139, DOI 10.1007/s11255 012 0258 1
   Ng HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091517
   Niwa T, 1997, MINER ELECTROL METAB, V23, P179
   Niwa T, 1997, KIDNEY INT, V52, pS23
   NIWA T, 1991, NEPHROL DIAL TRANSPL, V6, P105, DOI 10.1093/ndt/6.2.105
   Niwa T, 2013, EXPERT OPIN THER TAR, V17, P1287, DOI 10.1517/14728222.2013.829456
   Niwa T, 2012, J RENAL NUTR, V22, P102, DOI 10.1053/j.jrn.2011.10.032
   Patel KP, 2012, CLIN J AM SOC NEPHRO, V7, P982, DOI 10.2215/CJN.12491211
   Platzer B, 2009, J IMMUNOL, V183, P66, DOI 10.4049/jimmunol.0802997
   Puppala D, 2008, MOL PHARMACOL, V73, P1064, DOI 10.1124/mol.107.040840
   Rossi M, 2014, NUTR METAB CARDIOVAS, V24, P1035, DOI 10.1016/j.numecd.2014.04.006
   Rossi M, 2014, ARCH MED RES, V45, P309, DOI 10.1016/j.arcmed.2014.04.002
   Rossi M, 2012, INT J NEPHROL, V2012, DOI 10.1155/2012/673631
   Ryu JH, 2011, BLOOD PURIFICAT, V32, P186, DOI 10.1159/000326297
   Schiffrin EL, 2007, CIRCULATION, V116, P85, DOI 10.1161/CIRCULATIONAHA.106.678342
   Schroeder JC, 2010, BIOCHEMISTRY US, V49, P393, DOI 10.1021/bi901786x
   Schulman G, 2006, AM J KIDNEY DIS, V47, P565, DOI 10.1053/j.ajkd.2005.12.036
   Schulman G, 2014, INT J NEPHROL RENOV, V7, P49, DOI 10.2147/IJNRD.S41339
   Shara NM, 2012, AM J KIDNEY DIS, V60, P795, DOI 10.1053/j.ajkd.2012.06.015
   Shimizu H, 2012, AM J NEPHROL, V36, P184, DOI 10.1159/000341515
   Shimizu H, 2012, LIFE SCI, V91, P172, DOI 10.1016/j.lfs.2012.06.033
   Shimizu H, 2009, AM J PHYSIOL CELL PH, V297, pC389, DOI 10.1152/ajpcell.00206.2009
   Shimoishi K, 2007, PHARM RES DORDR, V24, P1283, DOI 10.1007/s11095 007 9248 x
   Song ZJ, 2002, MOL PHARMACOL, V62, P806, DOI 10.1124/mol.62.4.806
   Stejskalova L, 2011, CURR DRUG METAB, V12, P198, DOI 10.2174/138920011795016818
   Taki K, 2005, J RENAL NUTR, V15, P77, DOI 10.1053/j.jrn.2004.09.028
   Taleb S, 2010, CURR OPIN PHARMACOL, V10, P197, DOI 10.1016/j.coph.2010.02.003
   Tumur Z, 2009, AM J NEPHROL, V29, P551, DOI 10.1159/000191468
   van der Velde M, 2011, KIDNEY INT, V79, P1341, DOI 10.1038/ki.2010.536
   Watanabe I, 2013, CIRC J, V77, P224, DOI 10.1253/circj.CJ 12 0647
   Wattanakit K, 2007, J AM SOC NEPHROL, V18, P629, DOI 10.1681/ASN.2005111204
   Wu IW, 2011, NEPHROL DIAL TRANSPL, V26, P938, DOI 10.1093/ndt/gfq580
   Wu VC, 2013, ANGIOGENESIS, V16, P609, DOI 10.1007/s10456 013 9339 8
   Yamamoto H, 2006, KIDNEY INT, V69, P1780, DOI 10.1038/sj.ki.5000340
   Yamamoto S, 2011, NEPHROL DIAL TRANSPL, V26, P2491, DOI 10.1093/ndt/gfq759
   Ying Y, 2011, CIRC J, V75, P2252, DOI 10.1253/circj.CJ 11 0046
   Yisireyili M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109268
   Yu M, 2011, CLIN J AM SOC NEPHRO, V6, P30, DOI 10.2215/CJN.05340610
NR 93
TC 26
Z9 30
U1 0
U2 12
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389 4501
EI 1873 5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PY 2015
VL 16
IS 4
BP 366
EP 372
DI 10.2174/1389450116666141230114500
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CF4IW
UT WOS:000352513400008
PM 25537654
DA 2025 08 17
ER

PT J
AU Baek, HS
   Hong, VS
   Kang, H
   Lee, SJ
   Lee, JY
   Kang, H
   Jeong, S
   Jung, H
   Park, JW
   Kwon, TK
   Son, CN
   Kim, SH
   Lee, J
   Kim, KS
   Kim, S
AF Baek, Hye Suk
   Hong, Victor Sukbong
   Kang, Hyunsu
   Lee, Sang Jin
   Lee, Jin Young
   Kang, Hyunju
   Jeong, Seungik
   Jung, Hyunho
   Park, Jong Wook
   Kwon, Taeg Kyu
   Son, Chang Nam
   Kim, Sang Hyon
   Lee, Jinho
   Kim, Ki Suk
   Kim, Shin
TI Anti rheumatic property and physiological safety of KMU 11342 in in
   vitro and in vivo models
SO INFLAMMATION RESEARCH
LA English
DT Article
DE Rheumatoid arthritis; Protein kinase; Inflammation; NLRP3 inflammasome;
   Macrophage; Osteoclast differentiation
ID ACTIVATED PROTEIN KINASE; RHEUMATOID ARTHRITIS; THERAPEUTIC TARGETS;
   BONE DESTRUCTION; GENE EXPRESSION; SYNOVIAL TISSUE; OSTEOCLASTOGENESIS;
   LOCALIZATION; PROLONGATION; MECHANISMS
AB Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder characterized by joint destruction due to synovial hypertrophy and the infiltration of inflammatory cells. Despite substantial progress in RA treatment, challenges persist, including suboptimal treatment responses and adverse effects associated with current therapies. This study investigates the anti rheumatic capabilities of the newly identified multi protein kinase inhibitor, KMU 11342, aiming to develop innovative agents targeting RA. In this study, we synthesized the novel multi protein kinase inhibitor KMU 11342, based on indolin 2 one. We assessed its cardiac electrophysiological safety using the Langendorff system in rat hearts and evaluated its toxicity in zebrafish in vivo. Additionally, we examined the anti rheumatic effects of KMU 11342 on human rheumatoid arthritis fibroblast like synoviocytes (RA FLS), THP 1 cells, and osteoclastogenesis in RAW264.7 cells. KMU 11342 demonstrated the ability to inhibit LPS induced chemokine inhibition and the upregulation of pro inflammatory cytokines, cyclooxygenase 2, inducible nitric oxide synthase, p IKK alpha/beta, p NF kappa B p65, and the nuclear translocation of NF kappa B p65 in RA FLS. It effectively suppressed the upregulation of NLR family pyrin domain containing 3 (NLRP3) and caspase 1 cleavage. Furthermore, KMU 11342 hindered the activation of osteoclast differentiation factors such as RANKL induced TRAP, cathepsin K, NFATc 1, and c Fos in RAW264.7 cells. KMU 11342 mitigates LPS mediated inflammatory responses in THP 1 cells by inhibiting the activation of NLRP3 inflammasome. Notably, KMU 11342 exhibited minimal cytotoxicity in vivo and electrophysiological cardiotoxicity ex vivo. Consequently, KMU 11342 holds promise for development as a therapeutic agent in RA treatment.
C1 [Baek, Hye Suk; Park, Jong Wook; Kwon, Taeg Kyu; Kim, Shin] Keimyung Univ, Sch Med, Dept Immunol, 1095 Dalgubeol Daero, Daegu 42601, South Korea.
   [Park, Jong Wook; Kwon, Taeg Kyu; Kim, Shin] Keimyung Univ, Inst Med Sci, Sch Med, 1095 Dalgubeol Daero, Daegu 42601, South Korea.
   [Kwon, Taeg Kyu; Kim, Shin] Keimyung Univ, Inst Canc Res, Sch Med, 1095 Dalgubeol Daero, Daegu 42601, South Korea.
   [Hong, Victor Sukbong; Jung, Hyunho; Lee, Jinho] Keimyung Univ, Dept Chem, 1095 Dalgubeol Daero, Daegu 42601, South Korea.
   [Kang, Hyunsu; Kim, Ki Suk] Korea Inst Toxicol, R&D Ctr Adv Pharmaceut & Evaluat, Daejeon 34114, South Korea.
   [Kang, Hyunsu] Sungkyunkwan Univ, Sch Med, Dept Physiol, Suwon 16419, South Korea.
   [Lee, Sang Jin; Lee, Jin Young] Keimyung Univ, Dept Biol Sci, Daegu 42601, South Korea.
   [Kang, Hyunju] Keimyung Univ, Dept Food & Nutr, Daegu 42601, South Korea.
   [Jeong, Seungik] Daegu Gyeongbuk Med Innovat Fdn, New Drug Dev Ctr, Daegu 41061, South Korea.
   [Son, Chang Nam] Eulji Univ, Uijeongbu Eulji Med Ctr, Dept Rheumatol, Sch Med, 712 Dongil Ro, Uijeongbu Si 11759, Gyeonggi Do, South Korea.
   [Kim, Sang Hyon] Keimyung Univ, Sch Med, Dept Internal Med, Div Rheumatol, Daegu 42601, South Korea.
C3 Keimyung University; Keimyung University; Keimyung University; Keimyung
   University; Korea Institute of Toxicology; Sungkyunkwan University
   (SKKU); Keimyung University; Keimyung University; Eulji University;
   Keimyung University
RP Kim, S (通讯作者)，Keimyung Univ, Sch Med, Dept Immunol, 1095 Dalgubeol Daero, Daegu 42601, South Korea.; Kim, S (通讯作者)，Keimyung Univ, Inst Med Sci, Sch Med, 1095 Dalgubeol Daero, Daegu 42601, South Korea.; Kim, S (通讯作者)，Keimyung Univ, Inst Canc Res, Sch Med, 1095 Dalgubeol Daero, Daegu 42601, South Korea.; Lee, J (通讯作者)，Keimyung Univ, Dept Chem, 1095 Dalgubeol Daero, Daegu 42601, South Korea.; Kim, KS (通讯作者)，Korea Inst Toxicol, R&D Ctr Adv Pharmaceut & Evaluat, Daejeon 34114, South Korea.
EM jinho@kmu.ac.kr; idkks@kitox.re.kr; god98005@dsmc.or.kr
RI Park, Jung Hwan/AAA 1951 2022; Kim, Yon/J 2743 2012; Kim,
   Shin/D 1669 2013
OI Lee, Sang Jin/0009 0003 2144 5615; Kim, Shin/0000 0002 1099 5027; 
FU National Research Foundation of Korea
FX We would like to thank all members of our research group for their
   enthusiastic participation in this study.
CR Ajibade AA, 2013, TRENDS IMMUNOL, V34, P307, DOI 10.1016/j.it.2013.03.007
   Baek HS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031194
   Baek HS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145138
   Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105 2896.2009.00859.x
   Beiche F, 1998, INFLAMM RES, V47, P482, DOI 10.1007/s000110050362
   Cayci T, 2012, J ASSIST REPROD GEN, V29, P855, DOI 10.1007/s10815 012 9803 1
   Chaudhari K, 2016, NAT REV DRUG DISCOV, V15, P305, DOI 10.1038/nrd.2016.21
   Cohen P, 2022, NAT REV DRUG DISCOV, DOI 10.1038/s41573 022 00418 2
   Fang QH, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/3830212
   Ferdinandy P, 2019, EUR HEART J, V40, P1771, DOI 10.1093/eurheartj/ehy365
   Flanagan ME, 2010, J MED CHEM, V53, P8468, DOI 10.1021/jm1004286
   Gravallese EM, 2002, ANN RHEUM DIS, V61, P84, DOI 10.1136/ard.61.suppl_2.ii84
   Guideline IHT, 2005, NONCLINICAL EVALUATI
   Guo QY, 2018, BAMBOO SILK, V1, P1, DOI [10.1163/24689246 00101001, 10.1038/s41413 018 0016 9]
   Han GH, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9010017
   Hsu JY, 2023, BIOMED PHARMACOTHER, V159, DOI 10.1016/j.biopha.2023.114258
   Huang JB, 2023, MOLECULES, V28, DOI 10.3390/molecules28114414
   Huang MTH, 2009, J IMMUNOL, V182, P2395, DOI 10.4049/jimmunol.0800909
   Huang Qi Quan, 2009, Curr Rheumatol Rep, V11, P357
   Joosten LAB, 2016, NAT REV RHEUMATOL, V12, P344, DOI 10.1038/nrrheum.2016.61
   Kang RY, 1996, BRIT J RHEUMATOL, V35, P711
   Karami J, 2020, IMMUNOL CELL BIOL, V98, P171, DOI 10.1111/imcb.12311
   Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461
   Kim M, 2022, IMMUNE NETW, V22, DOI 10.4110/in.2022.22.e8
   Lamore SD, 2020, CHEM RES TOXICOL, V33, P125, DOI 10.1021/acs.chemrestox.9b00387
   Larsson NG, 1997, MAMM GENOME, V8, P139, DOI 10.1007/s003359900373
   Lee HY, 2006, ARTHRITIS RHEUM US, V54, P1747, DOI 10.1002/art.21873
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Leoni A, 2016, EXPERT OPIN THER PAT, V26, P149, DOI 10.1517/13543776.2016.1118059
   Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629
   Lopez Castejon G, 2013, J BIOL CHEM, V288, P2721, DOI 10.1074/jbc.M112.422238
   Ma Y, 2021, CLIN EXP RHEUMATOL, V39, P162, DOI 10.55563/clinexprheumatol/1jlh15
   Macfarlane LA, 2014, INT J RHEUM DIS, V17, P359, DOI 10.1111/1756 185X.12293
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Norton K., 2009, Journal of Pharmacological and Toxicological Methods, V60, P193, DOI 10.1016/j.vascn.2009.05.008
   O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev med 051113 024537
   Pan TH, 2023, MOLECULES, V28, DOI 10.3390/molecules28124668
   Patterson H, 2014, CLIN EXP IMMUNOL, V176, P1, DOI 10.1111/cei.12248
   Qiao Y, 2012, FEBS LETT, V586, P1022, DOI 10.1016/j.febslet.2012.02.045
   Radstake TRDJ, 2004, ARTHRITIS RHEUM US, V50, P3856, DOI 10.1002/art.20678
   Redfern WS, 2003, CARDIOVASC RES, V58, P32, DOI 10.1016/S0008 6363(02)00846 5
   Roden DM, 2004, NEW ENGL J MED, V350, P1013, DOI 10.1056/NEJMra032426
   Sabio G, 2014, SEMIN IMMUNOL, V26, P237, DOI 10.1016/j.smim.2014.02.009
   SANO H, 1992, J CLIN INVEST, V89, P97, DOI 10.1172/JCI115591
   Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255
   Scarpulla RC, 2012, TRENDS ENDOCRIN MET, V23, P459, DOI 10.1016/j.tem.2012.06.006
   Schett G, 2000, ARTHRITIS RHEUM, V43, P2501, DOI 10.1002/1529 0131(200011)43:11<2501::AID ANR18>3.0.CO;2 K
   Shimizu T, 2009, ANNU REV PHARMACOL, V49, P123, DOI 10.1146/annurev.pharmtox.011008.145616
   Siccardi AJ, 2009, ZEBRAFISH, V6, P275, DOI 10.1089/zeb.2008.0553
   Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3
   Siouti E, 2019, BIOCHEM PHARMACOL, V165, P152, DOI 10.1016/j.bcp.2019.03.029
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Stoker ML, 2019, BIOCHEM SOC T, V47, P1757, DOI 10.1042/BST20190280
   Sucur A, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1337 6
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Tanaka Y, 2018, CURR OPIN PHARMACOL, V40, P110, DOI 10.1016/j.coph.2018.03.006
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Weissmann G, 2006, BULL HOSP JT DIS, V64, P12
   Wiley DS, 2017, METHOD CELL BIOL, V138, P651, DOI 10.1016/bs.mcb.2016.10.004
   Yeung YT, 2018, CURR PHARM DESIGN, V24, P1449, DOI 10.2174/1381612824666180327165604
   Yin H, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.931690
NR 62
TC 0
Z9 0
U1 1
U2 6
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1023 3830
EI 1420 908X
J9 INFLAMM RES
JI Inflamm. Res.
PD AUG
PY 2024
VL 73
IS 8
BP 1371
EP 1391
DI 10.1007/s00011 024 01904 6
EA JUN 2024
PG 21
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Immunology
GA ZU4U4
UT WOS:001248103600001
PM 38879731
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Jin, J
   Li, YB
   Tanui, EK
   Han, LW
   Jia, Y
   Zhang, L
   Wang, YM
   Zhang, XX
   Zhang, YJ
AF Jin, Jing
   Li, Yubo
   Tanui, Emmanuel Kipletting
   Han, Liwen
   Jia, Yuan
   Zhang, Lu
   Wang, Yuming
   Zhang, Xiuxiu
   Zhang, Yanjun
TI Fishing and knockout of bioactive compounds using a combination of
   high speed counter current chromatography (HSCCC) and preparative HPLC
   for evaluating the holistic efficacy and interaction of the components
   of Herba Epimedii
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Herba Epimedii; Bioactive compositions; Fishing and knockout; Holistic
   efficacy; Interaction; Pharmacodynamic contribution ratio
ID PERFORMANCE LIQUID CHROMATOGRAPHY; CELL EXTRACTION; PURIFICATION;
   FLAVONOIDS
AB Due to the complex chemical compositions and pharmacological effects of traditional Chinese medicines, we developed a strategy based on fishing and knockout of bioactive compounds using a combination of high speed counter current chromatography (HSCCC) and preparative HPLC for evaluating the holistic activity and interaction of the components of Herba Epimedii. First, osteoblast target cell extraction was used for preliminary screening of the potential bioactive compounds of Herba Epimedii. Second, the bioactive compounds identified (epimedin A, epimedin B, epimedin C and icariin) were fished and knocked out using high speed counter current chromatography and preparative HPLC. Third, the bioactivity of resulting fractions was assessed by determining their influence on cell proliferation and differentiation, thereby allowing for an evaluation of their interaction. The pharmacodynamic contribution ratio of each bioactive compound to the efficacy of the herbal medicine could then be comprehensively and intuitively determined based on the spectra activity correlations (VIP values) of the tested compositions using partial least squares regression (PLS R), through which the reliability of the screening and isolation of bioactive compounds by the target cell extraction technique were verified. The proposed strategy is a useful approach with potential application in other traditional Chinese medicines. Crown Copyright (C) 2013 Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Jin, Jing; Li, Yubo; Tanui, Emmanuel Kipletting; Jia, Yuan; Zhang, Lu; Wang, Yuming; Zhang, Xiuxiu; Zhang, Yanjun] Tianjin Univ TCM, Sch Tradit Chinese Mat Med, Tianjin Key Lab TCM Chem & Anal, Tianjin 300193, Peoples R China.
   [Han, Liwen] Shandong Acad Sci, Inst Biol, Jinan 250014, Shandong, Peoples R China.
C3 Qilu University of Technology
RP Zhang, YJ (通讯作者)，Tianjin Univ TCM, Sch Tradit Chinese Mat Med, Tianjin Key Lab TCM Chem & Anal, Tianjin 300193, Peoples R China.
EM tianjin_tcm001@sina.com
RI Li, Yubo/MFH 4301 2025; zhang, yanjun/GPG 2157 2022; HAN,
   Liwen/AAH 6232 2020
FU National Basic Research Program of China (973 Program) [2011CB505300,
   2011CB505302]; National Key Technology RD Program [2011BAI07B08]
FX This project was financially supported by the National Basic Research
   Program of China (973 Program, No. 2011CB505300, 2011CB505302) and the
   National Key Technology R&D Program (No. 2011BAI07B08).
CR An SJ, 2000, CHIN J OSTEOPOROSIS, V6, P55
   [Anonymous], ZHONG CAO YAO
   [Anonymous], 2000, Chinese Pharmaceutical Journal, V35, P13
   Cai ManLing Cai ManLing, 2004, Chinese Journal of Natural Medicines, V2, P235
   Dong QQ, 2007, CHINESE J ANAL CHEM, V35, P648
   Du QZ, 2009, J CHROMATOGR A, V1216, P4176, DOI 10.1016/j.chroma.2008.11.066
   Du QZ, 2002, J CHROMATOGR A, V962, P239, DOI 10.1016/S0021 9673(02)00538 1
   Fang Y. L., 2008, CHIN TRADIT HERBAL D, V39, P3
   Gu M, 2007, J CHROMATOGR A, V1140, P107, DOI 10.1016/j.chroma.2006.11.057
   Li Q., 2011, ACTA CHINESE MED PHA, V39, P63
   Li SL, 2006, J PHARMACEUT BIOMED, V41, P576, DOI 10.1016/j.jpba.2006.01.014
   [林蓉 Lin Rong], 2006, [中药材, Journal of Chinese Medicinal Materials], V29, P1315
   Liu RM, 2005, J CHROMATOGR A, V1064, P53, DOI 10.1016/j.chroma.2004.12.026
   Liu Y, 2010, J CHROMATOGR A, V1217, P5239, DOI 10.1016/j.chroma.2010.06.039
   [罗晓 LUO Xiao], 2008, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V14, P818
   Ma HP, 2002, W CHINA J PHARM SCI, V17, P163
   Meng FH, 2005, PHYTOMEDICINE, V12, P189, DOI 10.1016/j.phymed.2004.03.007
   Peng JingBo Peng JingBo, 2011, China Journal of Traditional Chinese Medicine and Pharmacy, V26, P1964
   WANG JQ, 2002, CHINESE J CLIN REHAB, V6, P1307
   Wu You Lian, 2011, Zhong Yao Cai, V34, P1562
   Yin Xiao xue, 2005, Zhongguo Zhongyao Zazhi, V30, P289
   Zhai YuanKun Zhai YuanKun, 2012, China Journal of Traditional Chinese Medicine and Pharmacy, V27, P480
   Zhang DW, 2008, PHYTOMEDICINE, V15, P55, DOI 10.1016/j.phymed.2007.04.002
   Zhao K., 2009, CHINESE J TRADITIONA, V17, P8
NR 24
TC 32
Z9 34
U1 0
U2 98
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD MAY 20
PY 2013
VL 147
IS 2
BP 357
EP 365
DI 10.1016/j.jep.2013.03.018
PG 9
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 147PY
UT WOS:000319180700012
PM 23541932
DA 2025 08 17
ER

PT J
AU Ha, W
   Wang, ZH
   Zhao, XB
   Shi, YP
AF Ha, Wei
   Wang, Ze Hao
   Zhao, Xiao Bo
   Shi, Yan Ping
TI Reinforced Supramolecular Hydrogels from Attapulgite and Cyclodextrin
   Pseudopolyrotaxane for Sustained Intra Articular Drug Delivery
SO MACROMOLECULAR BIOSCIENCE
LA English
DT Article
DE attapulgite; injectable; intra articular drug delivery; supramolecular
   hydrogel; sustained release
ID INCLUSION COMPLEXES; ALPHA CYCLODEXTRIN; GRAPHENE OXIDE; OSTEOARTHRITIS;
   CODELIVERY; PRODRUGS; RELEASE; CLAY
AB Injectable hydrogels for nonsteroidal anti inflammatory drugs' (NSAIDs) delivery to minimize the side effects of NSAIDs and achieve long term sustained release at the targeted site of synovial joint are attractive for osteoarthritis therapy, but how to improve its mechanical strength remains a challenge. In this work, a kind of 1D natural clay mineral material, attapulgite (ATP), is introduced to a classical cyclodextrin pseudopolyrotaxane (PPR) system to form a reinforced supramolecular hydrogel for sustained release of diclofenac sodium (DS) due to its rigid, rod like morphology, and unique structure, which has great potential in tissue regeneration, repair, and engineering. Investigation on the interior morphology and rheological property of the obtained hydrogel points out that the ATP distributed in PPR hydrogel plays a role similar to the "reinforcement in concrete" and exhibits a positive effect on improving the mechanical properties of PPR hydrogel by regulating their interior morphology from a randomly distributed style to the well ordered porous frame structure. The hybrid hydrogels demonstrate good shear thinning and thixotropic properties, excellent biocompability, and sustained release behavior both in vitro and in vivo. Furthermore, preliminary in vivo treatment in an acute inflammatory rat model reveals that the ATP hybrid hydrogels present sustained anti inflammatory effect.
C1 [Ha, Wei; Zhao, Xiao Bo; Shi, Yan Ping] Chinese Acad Sci, Lanzhou Inst Chem Phys, CAS Key Lab Chem Northwestern Plant Resources, Lanzhou 730000, Peoples R China.
   [Ha, Wei; Zhao, Xiao Bo; Shi, Yan Ping] Chinese Acad Sci, Lanzhou Inst Chem Phys, Key Lab Nat Med Gansu Prov, Lanzhou 730000, Peoples R China.
   [Wang, Ze Hao] Shanghai Jiao Tong Univ, Dept Orthoped, Shanghai 200233, Peoples R China.
C3 Chinese Academy of Sciences; Lanzhou Institute of Chemical Physics, CAS;
   Chinese Academy of Sciences; Lanzhou Institute of Chemical Physics, CAS;
   Shanghai Jiao Tong University
RP Shi, YP (通讯作者)，Chinese Acad Sci, Lanzhou Inst Chem Phys, CAS Key Lab Chem Northwestern Plant Resources, Lanzhou 730000, Peoples R China.; Shi, YP (通讯作者)，Chinese Acad Sci, Lanzhou Inst Chem Phys, Key Lab Nat Med Gansu Prov, Lanzhou 730000, Peoples R China.
EM shiyp@licp.cas.cn
OI shi, yan ping/0000 0001 6517 9556
FU National Natural Science Foundation of China [21974145]; Youth
   Innovation Promotion Association of the Chinese Academy of Sciences
   [2017457]; opening foundation of Key Laboratory of Clay Mineral Applied
   Research of Gansu Province [CMAR 2017 2]
FX W.H. and Z.H.W. contributed equally to this work. This work was
   supported by the National Natural Science Foundation of China (Grant No.
   21974145), the Youth Innovation Promotion Association of the Chinese
   Academy of Sciences (Grant No. 2017457), and the opening foundation of
   Key Laboratory of Clay Mineral Applied Research of Gansu Province (Grant
   No. CMAR 2017 2).
CR Ceccato M, 1997, LANGMUIR, V13, P2436, DOI 10.1021/la9609231
   Chen H, 2012, IND ENG CHEM RES, V51, P14026, DOI 10.1021/ie300702j
   Chen H, 2011, CHEM ENG J, V174, P143, DOI 10.1016/j.cej.2011.08.062
   Chen PF, 2016, BIOMATERIALS, V81, P1, DOI 10.1016/j.biomaterials.2015.12.006
   Chen WF, 2014, RSC ADV, V4, P21619, DOI 10.1039/c4ra00914b
   Chen YF, 2008, HEALTH TECHNOL ASSES, V12, P1, DOI 10.3310/hta12110
   Dawson JI, 2013, ADV MATER, V25, P4069, DOI 10.1002/adma.201301034
   Flood J, 2010, AM J MANAG CARE, V16, pS48
   Gerwin N, 2006, ADV DRUG DELIVER REV, V58, P226, DOI 10.1016/j.addr.2006.01.018
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   Guo MY, 2008, MACROMOLECULES, V41, P9744, DOI 10.1021/ma801975s
   Guvendiren M, 2012, SOFT MATTER, V8, P260, DOI 10.1039/c1sm06513k
   Ha W, 2016, CHEM COMMUN, V52, P14384, DOI 10.1039/c6cc08123a
   Ha W, 2014, ACS APPL MATER INTER, V6, P10623, DOI 10.1021/am5022864
   Ha W, 2013, J MATER CHEM B, V1, P5532, DOI 10.1039/c3tb20956c
   HARADA A, 1992, NATURE, V356, P325, DOI 10.1038/356325a0
   HARADA A, 1994, NATURE, V370, P126, DOI 10.1038/370126a0
   He ZW, 2017, COLLOID SURFACE B, V154, P33, DOI 10.1016/j.colsurfb.2017.03.003
   Huang Y, 2009, BIOMATERIALS, V30, P5041, DOI 10.1016/j.biomaterials.2009.05.077
   Kang ML, 2014, EXPERT OPIN DRUG DEL, V11, P269, DOI 10.1517/17425247.2014.867325
   Kourounakis PN, 2000, TOXICOLOGY, V144, P205, DOI 10.1016/S0300 483X(99)00208 5
   Kumru B, 2017, MACROMOLECULES, V50, P1862, DOI 10.1021/acs.macromol.6b02691
   Li J, 2006, BIOMATERIALS, V27, P4132, DOI 10.1016/j.biomaterials.2006.03.025
   Li J, 2010, NPG ASIA MATER, V2, P112, DOI 10.1038/asiamat.2010.84
   Li Tingting, 2018, Polymers (Basel), V10, DOI 10.3390/polym10060576
   Liao XJ, 2011, LANGMUIR, V27, P12650, DOI 10.1021/la202555t
   Liu X, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201700159
   Liu Bryan R, 2015, NAT REV RHEUMATOL, V11, P35, DOI 10.1038/nrrheum.2014.162
   Loizou E, 2006, MACROMOLECULES, V39, P1614, DOI 10.1021/ma0517547
   Mao XY, 2018, J CHEM ENG DATA, V63, P4241, DOI 10.1021/acs.jced.8b00744
   Maudens P, 2018, DRUG DISCOV TODAY, V23, P1761, DOI 10.1016/j.drudis.2018.05.023
   Morris Christopher J, 2003, Methods Mol Biol, V225, P115
   Mwangi TK, 2015, INT J PHARMACEUT, V485, P7, DOI 10.1016/j.ijpharm.2015.02.059
   Prince DA, 2019, ACS APPL BIO MATER, V2, P3498, DOI 10.1021/acsabm.9b00410
   Qian L, 2014, RSC ADV, V4, P38273, DOI 10.1039/c4ra07707e
   Rey Rico A, 2019, POLYMERS BASEL, V11, DOI 10.3390/polym11030514
   Rogoveanu O C, 2015, J Med Life, V8, P458
   Serres Gómez M, 2018, LANGMUIR, V34, P10591, DOI 10.1021/acs.langmuir.8b01744
   Singh A, 2014, ADV HEALTHC MATER, V3, P1562, DOI 10.1002/adhm.201400051
   Sulistio A, 2017, J MATER CHEM B, V5, P6221, DOI 10.1039/c7tb01518f
   Wang Q, 2010, NATURE, V463, P339, DOI 10.1038/nature08693
   Wang YQ, 2019, ACS SUSTAIN CHEM ENG, V7, P1855, DOI 10.1021/acssuschemeng.8b05823
   Wang Z, 2015, RSC ADV, V5, P2383, DOI 10.1039/c4ra09839k
   Xu ZY, 2014, ACS APPL MATER INTER, V6, P17268, DOI 10.1021/am505308f
   Yu J, 2014, RSC ADV, V4, P58982, DOI 10.1039/c4ra11311j
   Yu J, 2014, ACS APPL MATER INTER, V6, P19544, DOI 10.1021/am505649q
   Zagerl H., 1993, Z ORTHOP IHRE GRENZG, V131, P385
   Zhang Y, 2019, SOFT MATTER, V15, P73, DOI 10.1039/c8sm02203h
NR 48
TC 18
Z9 18
U1 1
U2 77
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 5187
EI 1616 5195
J9 MACROMOL BIOSCI
JI Macromol. Biosci.
PD JAN
PY 2021
VL 21
IS 1
AR 2000299
DI 10.1002/mabi.202000299
EA OCT 2020
PG 10
WC Biochemistry & Molecular Biology; Materials Science, Biomaterials;
   Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Materials Science; Polymer Science
GA PU7XC
UT WOS:000578466100001
PM 33043625
DA 2025 08 17
ER

PT J
AU Przybylowski, C
   Quinn, T
   Callahan, A
   Kaplan, M
   Golding, A
   Alesi, C
   Ammar, M
   LeBlon, CE
   Guo, Y
   Zhang, XH
   Jedlicka, SS
AF Przybylowski, Colin
   Quinn, Therese
   Callahan, Alyson
   Kaplan, Max
   Golding, Anne
   Alesi, Christopher
   Ammar, Mohamed
   LeBlon, Courtney E.
   Guo, Yan
   Zhang, Xiaohui
   Jedlicka, Sabrina S.
TI MC3T3 preosteoblast differentiation on bone morphogenetic protein 2
   peptide ormosils
SO JOURNAL OF MATERIALS CHEMISTRY
LA English
DT Article
ID BIOACTIVE GLASS DISSOLUTION; CALCIUM PHOSPHATE CERAMICS; OSTEOBLAST LIKE
   CELLS; GROWTH FACTOR PDGF; IN VITRO; GENE EXPRESSION; POROUS
   HYDROXYAPATITE; DRUG DELIVERY; MESSENGER RNA; OSTEOGENIC DIFFERENTIATION
AB The design of biointerfaces that stimulate cell differentiation is a rapidly growing area of research that has significant implications in biomedicine. Biointerfaces that stimulate osteogenesis are typically composed, at least in part, of a biomimetic ceramic material, such as bioactive glass. Cell differentiation on these materials is quite remarkable, and can be enhanced by further addition of extracellular signals, such as growth factors or extracellular matrix proteins. However, addition of whole proteins can be difficult to replicate due to protein conformational changes on surfaces of interest. To investigate whether well controlled synthetic peptide combinations can stimulate osteogenesis of MC3T3 pre osteoblast cells, we decorated the surface of 2D silica thin films made by the sol gel technique with 3 peptide sequences from different proteins known for their capabilities to stimulate the osteogenesis process (fibronectin, BMP 2, and BMP 9). MC3T3 pre osteoblasts were seeded onto the materials in a standard proliferation medium and grown for five weeks. Cells were also grown on tissue culture treated cover slips with and without differentiation induction media as positive and negative controls, respectively. Cells were examined weekly to assess osteogenesis. MC3T3 pre osteoblasts appear to undergo enhanced differentiation on the peptide silane samples over silica thin films, and the differentiation capacity of the cells exposed only to peptide silane surfaces approaches that of cells grown in chemical differentiation induction media.
C1 [Przybylowski, Colin; Quinn, Therese; Callahan, Alyson; Golding, Anne; Guo, Yan; Zhang, Xiaohui; Jedlicka, Sabrina S.] Lehigh Univ, Bioengn Program, Bethlehem, PA 18015 USA.
   [Przybylowski, Colin] Lehigh Univ, Integrated Degree Engn Arts & Sci IDEAS Program, Bethlehem, PA 18015 USA.
   [Kaplan, Max; Alesi, Christopher; Ammar, Mohamed; Jedlicka, Sabrina S.] Lehigh Univ, Dept Mat Sci & Engn, Bethlehem, PA 18015 USA.
   [LeBlon, Courtney E.; Guo, Yan; Zhang, Xiaohui] Lehigh Univ, Dept Mech Engn & Mech, Bethlehem, PA 18015 USA.
   [Zhang, Xiaohui; Jedlicka, Sabrina S.] Lehigh Univ, Ctr Adv Mat & Nanotechnol, Bethlehem, PA 18015 USA.
C3 Lehigh University; Lehigh University; Lehigh University; Lehigh
   University; Lehigh University
RP Jedlicka, SS (通讯作者)，Lehigh Univ, Bioengn Program, Bethlehem, PA 18015 USA.
EM ssj207@lehigh.edu
RI ; Ammar, Mohamed/GYU 2097 2022
OI Ammar, Mohamed/0000 0002 3002 7429; Zhang, Xiaohui
   (Frank)/0000 0002 8778 595X
FU International Material Institute for New Functionality of Glass (NSF)
   [DMR 0844014]; Lehigh University; NICHD; Division Of Physics; Direct For
   Mathematical & Physical Scien [0849416] Funding Source: National Science
   Foundation
FX We would like to thank the International Material Institute for New
   Functionality of Glass (NSF GRANT # DMR 0844014) for summer
   undergraduate research funding for C. Przybylowski (2010), T. Quinn
   (2009), and M. Kaplan (2008). We also acknowledge the Lehigh University
   Faculty Innovation Grant (2009 2010) for seed funding to assist with
   peptide development and analysis. In addition, we would like to thank Dr
   Alfred Miller for providing the XPS spectra, Dr Jutta Marzillier for
   qRT PCR assistance, and Drs Himanshu Jain and Matthias Falk for useful
   discussion during the project. The AON 1 antibody, developed by J.D.
   Termine, and the MPIIIB10 antibody, developed by M. Solursh and A.
   Franzen, were both obtained from the Developmental Studies Hybridoma
   Bank, developed under the auspices of the NICHD and maintained by The
   University of Iowa, Department of Biology, Iowa City, IA 52242. In
   addition, the qRT PCR instrument was provided through an in kind
   donation to Lehigh University from BD.
CR Abiraman S, 2002, B MATER SCI, V25, P419, DOI 10.1007/BF02708021
   Abiraman S, 2002, BIOMATERIALS, V23, P3023, DOI 10.1016/S0142 9612(02)00064 9
   AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871
   Arcos D, 2001, BIOMATERIALS, V22, P701, DOI 10.1016/S0142 9612(00)00233 7
   Arinzeh TL, 2005, BIOMATERIALS, V26, P3631, DOI 10.1016/j.biomaterials.2004.09.035
   Au AY, 2010, J BIOMED MATER RES A, V94A, P380, DOI 10.1002/jbm.a.32668
   Bacakova L, 2007, J MATER SCI MATER M, V18, P1317, DOI 10.1007/s10856 006 0074 1
   Bailey MM, 2008, LANGMUIR, V24, P13614, DOI 10.1021/la802405p
   BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092 8674(93)90680 O
   Balint E, 2003, J CELL BIOCHEM, V89, P401, DOI 10.1002/jcb.10515
   Bandyopadhyay Amitabha, 2006, PLoS Genet, V2, pe216
   Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026
   Barboza EP, 2004, J PERIODONTOL, V75, P702, DOI 10.1902/jop.2004.75.5.702
   Bergeron E, 2007, J MATER SCI MATER M, V18, P255, DOI 10.1007/s10856 006 0687 4
   Best SM, 2008, J EUR CERAM SOC, V28, P1319, DOI 10.1016/j.jeurceramsoc.2007.12.001
   Blaker JJ, 2004, BIOMATERIALS, V25, P1319, DOI 10.1016/j.biomaterials.2003.08.007
   Blaker JJ, 2003, J BIOMED MATER RES A, V67A, P1401, DOI 10.1002/jbm.a.20055
   Boccaccini AR, 2003, COMPOS SCI TECHNOL, V63, P2417, DOI 10.1016/S0266 3538(03)00275 6
   Chang BS, 2000, BIOMATERIALS, V21, P1291, DOI 10.1016/S0142 9612(00)00030 2
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Chu TMG, 2002, BIOMATERIALS, V23, P1283, DOI 10.1016/S0142 9612(01)00243 5
   Cochran DL, 1999, J PERIODONTOL, V70, P139, DOI 10.1902/jop.1999.70.2.139
   Danilchenko SN, 2011, J BIOMED MATER RES A, V96A, P639, DOI 10.1002/jbm.a.33017
   Day RM, 2004, BIOMATERIALS, V25, P5857, DOI 10.1016/j.biomaterials.2004.01.043
   De Giglio E, 2000, J BIOMAT SCI POLYM E, V11, P1073, DOI 10.1163/156856200743580
   Dong J, 2001, J BIOMED MATER RES, V57, P208, DOI 10.1002/1097 4636(200111)57:2<208::AID JBM1160>3.0.CO;2 N
   Ducy P, 1996, CONNECT TISSUE RES, V35, P7, DOI 10.3109/03008209609029169
   El Ghannam A, 2004, J BIOMED MATER RES A, V71A, P377, DOI 10.1002/jbm.a.30128
   ElGhannam A, 1997, J BIOMED MATER RES, V36, P167, DOI 10.1002/(SICI)1097 4636(199708)36:2<167::AID JBM5>3.0.CO;2 I
   Erlacher L, 1998, J BONE MINER RES, V13, P383, DOI 10.1359/jbmr.1998.13.3.383
   Feng B., BIOMED MAT, V6
   Gao TJ, 2001, BIOMATERIALS, V22, P1475, DOI 10.1016/S0142 9612(00)00288 X
   García AJ, 2002, CRIT REV EUKAR GENE, V12, P151, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i2.50
   García AJ, 1999, MOL BIOL CELL, V10, P785, DOI 10.1091/mbc.10.3.785
   García AJ, 1998, J BIOMED MATER RES, V40, P48, DOI 10.1002/(SICI)1097 4636(199804)40:1<48::AID JBM6>3.0.CO;2 R
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Giannobile WV, 2001, J PERIODONTOL, V72, P815, DOI 10.1902/jop.2001.72.6.815
   Groeneveld EHJ, 2000, EUR J ENDOCRINOL, V142, P9, DOI 10.1530/eje.0.1420009
   Habraken WJEM, 2007, ADV DRUG DELIVER REV, V59, P234, DOI 10.1016/j.addr.2007.03.011
   Hanada K, 1997, J BONE MINER RES, V12, P1606, DOI 10.1359/jbmr.1997.12.10.1606
   Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283
   Hench LL, 2009, J EUR CERAM SOC, V29, P1257, DOI 10.1016/j.jeurceramsoc.2008.08.002
   Hench LL, 2000, MATER RES INNOV, V3, P313, DOI 10.1007/s100190000055
   Hench LL, 2004, J BIOMAT SCI POLYM E, V15, P543, DOI 10.1163/156856204323005352
   Hench LL, 1998, J AM CERAM SOC, V81, P1705
   Hench LL, 2002, J INORG MATER, V17, P897
   Hoffmann A, 2005, J BIOL CHEM, V280, P27271, DOI 10.1074/jbc.M503368200
   Hoffmann A, 2001, CRIT REV EUKAR GENE, V11, P23, DOI 10.1615/CritRevEukarGeneExpr.v11.i1 3.20
   Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580
   Horner A, 1996, BONE, V19, P353, DOI 10.1016/S8756 3282(96)00217 7
   Hott M, 1997, J BIOMED MATER RES, V37, P508, DOI 10.1002/(SICI)1097 4636(19971215)37:4<508::AID JBM9>3.0.CO;2 P
   Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959 437X(03)00007 8
   Itoh D, 2002, J BIOMED MATER RES, V62, P292, DOI 10.1002/jbm.10338
   Jedlicka SS, 2007, J MATER CHEM, V17, P5058, DOI 10.1039/b705393b
   Jedlicka SS, 2007, J PHYS CHEM B, V111, P11850, DOI 10.1021/jp0744230
   Jin QM, 2000, J BIOMED MATER RES, V51, P491, DOI 10.1002/1097 4636(20000905)51:3<491::AID JBM25>3.3.CO;2 T
   Kamakura S, 2002, J BIOMED MATER RES, V59, P29, DOI 10.1002/jbm.1213
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kasten P, 2005, BIOMATERIALS, V26, P5879, DOI 10.1016/j.biomaterials.2005.03.001
   Kaufmann EABE, 2000, TISSUE ENG, V6, P19, DOI 10.1089/107632700320856
   Kawai N, 1997, J BIOMED MATER RES, V37, P1
   Kay S, 2002, TISSUE ENG, V8, P753, DOI 10.1089/10763270260424114
   Kellomäki M, 2000, BIOMATERIALS, V21, P2495, DOI 10.1016/S0142 9612(00)00117 4
   Kieswetter K, 1996, CRIT REV ORAL BIOL M, V7, P329, DOI 10.1177/10454411960070040301
   Kim HW, 2008, J NANOSCI NANOTECHNO, V8, P3013, DOI 10.1166/jnn.2008.106
   Kim JH, 2009, J CELL BIOCHEM, V107, P557, DOI 10.1002/jcb.22157
   Knabe C, 2005, CLIN ORAL IMPLAN RES, V16, P119, DOI 10.1111/j.1600 0501.2004.01066.x
   Knabe C, 2004, J BIOMED MATER RES A, V69A, P145, DOI 10.1002/jbm.a.20131
   Knabe C, 2004, BIOMATERIALS, V25, P335, DOI 10.1016/S0142 9612(03)00525 8
   Kontonasaki E, 2006, KEY ENG MATER, V309 311, P727, DOI 10.4028/www.scientific.net/KEM.309 311.727
   Leach JK, 2006, REGEN MED, V1, P447, DOI 10.2217/17460751.1.4.447
   Lee JS, 2010, ACTA BIOMATER, V6, P21, DOI 10.1016/j.actbio.2009.08.003
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   LeGeros RZ, 2002, CLIN ORTHOP RELAT R, P81
   Li J, 1998, J BIOL CHEM, V273, P31009, DOI 10.1074/jbc.273.47.31009
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   Lossdörfer S, 2004, J BIOMED MATER RES A, V70A, P361, DOI 10.1002/jbm.a.30025
   Loty C, 2001, J BONE MINER RES, V16, P231, DOI 10.1359/jbmr.2001.16.2.231
   Lu HH, 2003, J BIOMED MATER RES A, V64A, P465, DOI 10.1002/jbm.a.10399
   Maquet V, 2003, J BIOMED MATER RES A, V66A, P335, DOI 10.1002/jbm.a.10587
   McKee MD, 1996, CONNECT TISSUE RES, V35, P197, DOI 10.3109/03008209609029192
   MIDDLETON J, 1995, BONE, V16, P287, DOI 10.1016/8756 3282(94)00040 9
   Misra SK, 2006, BIOMACROMOLECULES, V7, P2249, DOI 10.1021/bm060317c
   Morgan AW, 2008, BIOMATERIALS, V29, P2556, DOI 10.1016/j.biomaterials.2008.02.007
   Moura J, 2007, J BIOMED MATER RES A, V82A, P545, DOI 10.1002/jbm.a.31165
   Moursi AM, 1996, J CELL SCI, V109, P1369
   Nakamura T, 1997, BIOCHEM BIOPH RES CO, V237, P465, DOI 10.1006/bbrc.1997.7156
   Nazhat SN, 2001, J BIOMED MATER RES, V58, P335, DOI 10.1002/jbm.1026
   NEO M, 1993, J BIOMED MATER RES, V27, P999, DOI 10.1002/jbm.820270805
   Noshi T, 2000, J BIOMED MATER RES, V52, P621
   OHGUSHI H, 1990, J BIOMED MATER RES, V24, P1563, DOI 10.1002/jbm.820241202
   Okumura M, 1997, J BIOMED MATER RES, V37, P122, DOI 10.1002/(SICI)1097 4636(199710)37:1<122::AID JBM15>3.3.CO;2 3
   Oonishi H, 1997, CLIN ORTHOP RELAT R, P316
   Osyczka AM, 2005, ENDOCRINOLOGY, V146, P3428, DOI 10.1210/en.2005 0303
   Pamula E, 2011, ANN BIOMED ENG, V39, P2114, DOI 10.1007/s10439 011 0307 4
   Paul W, 2003, J BIOMATER APPL, V17, P253, DOI 10.1177/0885328203017004001
   Radin S, 2005, J BIOMED MATER RES A, V73A, P21, DOI 10.1002/jbm.a.30241
   Ragel CV, 2000, J BIOMED MATER RES, V51, P424, DOI 10.1002/1097 4636(20000905)51:3<424::AID JBM17>3.0.CO;2 E
   Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398 247
   Redey SA, 2000, J BIOMED MATER RES, V50, P353, DOI 10.1002/(SICI)1097 4636(20000605)50:3<353::AID JBM9>3.3.CO;2 3
   Rezwan K, 2006, BIOMATERIALS, V27, P3413, DOI 10.1016/j.biomaterials.2006.01.039
   Ripamonti U, 1997, CRIT REV ORAL BIOL M, V8, P154, DOI 10.1177/10454411970080020401
   Roether JA, 2002, BIOMATERIALS, V23, P3871, DOI 10.1016/S0142 9612(02)00131 X
   Ruhé PQ, 2004, BIOMATERIALS, V25, P2123, DOI 10.1016/j.biomaterials.2003.09.007
   Santos EM, 1998, J BIOMED MATER RES, V41, P87, DOI 10.1002/(SICI)1097 4636(199807)41:1<87::AID JBM11>3.0.CO;2 E
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Taboas JM, 2003, BIOMATERIALS, V24, P181, DOI 10.1016/S0142 9612(02)00276 4
   THIES RS, 1992, ENDOCRINOLOGY, V130, P1318, DOI 10.1210/en.130.3.1318
   Valerio P, 2004, BIOMATERIALS, V25, P2941, DOI 10.1016/j.biomaterials.2003.09.086
   Varanasi VG, 2009, ACTA BIOMATER, V5, P3536, DOI 10.1016/j.actbio.2009.05.035
   Verrier S, 2004, BIOMATERIALS, V25, P3013, DOI 10.1016/j.biomaterials.2003.09.081
   Vikjaer D, 1997, EUR J ORAL SCI, V105, P59, DOI 10.1111/j.1600 0722.1997.tb00181.x
   Virolainen P, 1997, J BIOMED MATER RES, V35, P9, DOI 10.1002/(SICI)1097 4636(199704)35:1<9::AID JBM2>3.0.CO;2 S
   Vogel M, 2001, BIOMATERIALS, V22, P357, DOI 10.1016/S0142 9612(00)00191 5
   WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582
   WANG EM, 1995, ENDOCRINOLOGY, V136, P2741, DOI 10.1210/en.136.6.2741
   Wang LA, 2010, CELL PHYSIOL BIOCHEM, V26, P1093, DOI 10.1159/000323987
   WATSON KE, 1994, J CLIN INVEST, V93, P2106, DOI 10.1172/JCI117205
   Wozney JM, 1998, EUR J ORAL SCI, V106, P160, DOI 10.1111/j.1600 0722.1998.tb02170.x
   Xue T, 2010, GENE THER, V17, P370, DOI 10.1038/gt.2009.154
   Xynos ID, 2000, CALCIFIED TISSUE INT, V67, P321, DOI 10.1007/s002230001134
   Xynos ID, 2000, BIOCHEM BIOPH RES CO, V276, P461, DOI 10.1006/bbrc.2000.3503
   Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705
   Yao J, 2005, J BIOMED MATER RES A, V75A, P794, DOI 10.1002/jbm.a.30494
   Yao J, 2005, BIOMATERIALS, V26, P1935, DOI 10.1016/j.biomaterials.2004.06.027
   Yoshinari M, 2002, BIOMATERIALS, V23, P2879, DOI 10.1016/S0142 9612(01)00415 X
   Yuan HP, 2001, J BIOMED MATER RES, V58, P270, DOI 10.1002/1097 4636(2001)58:3<270::AID JBM1016>3.0.CO;2 2
   Yuan HP, 2002, J MATER SCI MATER M, V13, P1271, DOI 10.1023/A:1021191432366
   Yuan HP, 1999, BIOMATERIALS, V20, P1799, DOI 10.1016/S0142 9612(99)00075 7
   Zhang K, 2004, BIOMATERIALS, V25, P2489, DOI 10.1016/j.biomaterials.2003.09.033
NR 131
TC 9
Z9 11
U1 0
U2 27
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0959 9428
EI 1364 5501
J9 J MATER CHEM
JI J. Mater. Chem.
PY 2012
VL 22
IS 21
BP 10672
EP 10683
DI 10.1039/c2jm16490f
PG 12
WC Chemistry, Physical; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science
GA 939MV
UT WOS:000303816200039
DA 2025 08 17
ER

PT J
AU Yamaguchi, K
   Whitlock, NC
   Liggett, JL
   Legendre, AM
   Fry, MM
   Baek, SJ
AF Yamaguchi, Kiyoshi
   Whitlock, Nichelle C.
   Liggett, Jason L.
   Legendre, Alfred M.
   Fry, Michael M.
   Baek, Seung Joon
TI Molecular characterisation of canine nonsteroidal anti inflammatory
   drug activated gene (NAG 1)
SO VETERINARY JOURNAL
LA English
DT Article
DE NAG 1; NSAID; PPAR gamma ligand; TGF beta; canine osteosarcoma
ID BETA SUPERFAMILY MEMBER; COLORECTAL CANCER CELLS; GROWTH FACTOR BETA;
   MACROPHAGE INHIBITORY CYTOKINE; TGF BETA; COLON CANCER; MORPHOGENETIC
   PROTEIN; TUMOR SUPPRESSOR; GAMMA LIGAND; PPAR GAMMA
AB Nonsteroidal anti inflammatory drug(NSAID) activated gene (NAG 1), a divergent member of the transforming growth factor beta superfamily, was previously identified as a gene induced by several anti tumorigenic compounds, including NSAIDs and peroxisome proliferator activated receptor gamma (PPAR gamma) ligands in humans. In this study, canine NAG 1 was characterised from a canine genomic database. Gene induction by some NSAIDs and PPAR gamma ligands was demonstrated in canine osteosarcoma cell lines. Phylogenetic analysis indicates that canine NAG 1 is more homologous with the corresponding mouse and rat genes than with human NAG 1. Expression of canine NAG 1 was increased by treatment with piroxicam and SC 560 (NSAIDs) and the PPAR gamma ligaDd rosiglitazone. This study demonstrates that canine NAG 1 is up regulated by some anti tumorigenic compounds in osteosarcoma cell lines and may provide an important target of chemotherapy in canine cancer, (C) 2007 Elsevier Ltd. All rights reserved.
C1 [Yamaguchi, Kiyoshi; Whitlock, Nichelle C.; Liggett, Jason L.; Fry, Michael M.; Baek, Seung Joon] Univ Tennessee, Coll Vet Med, Dept Pathobiol, Knoxville, TN 37996 USA.
   [Legendre, Alfred M.] Univ Tennessee, Coll Vet Med, Dept Small Anim Clin Sci, Knoxville, TN 37996 USA.
C3 University of Tennessee System; University of Tennessee Knoxville; UT
   Institute of Agriculture; University of Tennessee System; University of
   Tennessee Knoxville; UT Institute of Agriculture
RP Baek, SJ (通讯作者)，Univ Tennessee, Coll Vet Med, Dept Pathobiol, POB 1071, Knoxville, TN 37996 USA.
EM sbaek2@utk.edu
OI Fry, Michael/0000 0002 1744 8739; Baek, Seung/0000 0001 7866 7778
FU NIEHS NIH HHS [K22 ES011657] Funding Source: Medline
CR Baek SJ, 2006, PROG LIPID RES, V45, P1, DOI 10.1016/j.plipres.2005.10.001
   Baek SJ, 2005, MOL PHARMACOL, V67, P356, DOI 10.1124/mol.104.005108
   Baek SJ, 2004, CARCINOGENESIS, V25, P2425, DOI 10.1093/carcin/bgh255
   Baek SJ, 2004, J BIOL CHEM, V279, P6883, DOI 10.1074/jbc.M305295200
   Baek SJ, 2003, J BIOL CHEM, V278, P5845, DOI 10.1074/jbc.M208394200
   Baek SJ, 2002, J PHARMACOL EXP THER, V301, P1126, DOI 10.1124/jpet.301.3.1126
   Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425
   Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901
   Bauskin AR, 2000, EMBO J, V19, P2212, DOI 10.1093/emboj/19.10.2212
   Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926
   Boolbol SK, 1996, CANCER RES, V56, P2556
   Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514
   Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016 5085(98)70072 1
   Goldberg Y, 1996, ONCOGENE, V12, P893
   Grösch S, 2006, JNCI J NATL CANCER I, V98, P736, DOI 10.1093/jnci/djj206
   Hromas R, 1997, BBA GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167 4781(97)00122 X
   Hsiao EC, 2000, MOL CELL BIOL, V20, P3742, DOI 10.1128/MCB.20.10.3742 3751.2000
   Kim KS, 2002, GASTROENTEROLOGY, V122, P1388, DOI 10.1053/gast.2002.32972
   KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133
   Lee SH, 2006, CARCINOGENESIS, V27, P972, DOI 10.1093/carcin/bgi268
   Lee SH, 2005, BIOCHEM BIOPH RES CO, V328, P63, DOI 10.1016/j.bbrc.2004.12.138
   Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199
   Lin MT, 2001, J BIOL CHEM, V276, P48997, DOI 10.1074/jbc.M107829200
   Liu T, 2003, CANCER RES, V63, P5034
   Mohammed SI, 2003, MOL CANCER THER, V2, P183
   Nzeako UC, 2002, HEPATOLOGY, V35, P552, DOI 10.1053/jhep.2002.31774
   Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760
   Reddy BS, 2000, CANCER RES, V60, P293
   Rodríguez LAG, 2001, EPIDEMIOLOGY, V12, P88, DOI 10.1097/00001648 200101000 00015
   Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109
   Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336
   Ulrich CM, 2006, NAT REV CANCER, V6, P130, DOI 10.1038/nrc1801
   Xu XM, 1999, P NATL ACAD SCI USA, V96, P5292, DOI 10.1073/pnas.96.9.5292
   Yamaguchi K, 2006, ONCOL REP, V15, P275
   Yamaguchi K, 2004, J BIOL CHEM, V279, P49617, DOI 10.1074/jbc.M408796200
   Yamaguchi K, 2006, MOL CANCER THER, V5, P1352, DOI 10.1158/1535 7163.MCT 05 0528
NR 36
TC 11
Z9 12
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1090 0233
EI 1532 2971
J9 VET J
JI Vet. J.
PD JAN
PY 2008
VL 175
IS 1
BP 89
EP 95
DI 10.1016/j.tvjl.2006.12.001
PG 7
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA 269HI
UT WOS:000253639700014
PM 17275371
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Gnant, M
   Baselga, J
   Rugo, HS
   Noguchi, S
   Burris, HA
   Piccart, M
   Hortobagyi, GN
   Eakle, J
   Mukai, H
   Iwata, H
   Geberth, M
   Hart, LL
   Hadji, P
   El Hashimy, M
   Rao, S
   Taran, T
   Sahmoud, T
   Lebwohl, D
   Campone, M
   Pritchard, KI
AF Gnant, Michael
   Baselga, Jose
   Rugo, Hope S.
   Noguchi, Shinzaburo
   Burris, Howard A.
   Piccart, Martine
   Hortobagyi, Gabriel N.
   Eakle, Janice
   Mukai, Hirofumi
   Iwata, Hiroji
   Geberth, Matthias
   Hart, Lowell L.
   Hadji, Peyman
   El Hashimy, Mona
   Rao, Shantha
   Taran, Tetiana
   Sahmoud, Tarek
   Lebwohl, David
   Campone, Mario
   Pritchard, Kathleen I.
TI Effect of Everolimus on Bone Marker Levels and Progressive Disease in
   Bone in BOLERO 2
SO JNCI JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID BREAST CANCER CELLS; POSTMENOPAUSAL WOMEN; MINERAL DENSITY; AROMATASE
   INHIBITORS; ENDOCRINE THERAPY; COMPETING RISKS; ZOLEDRONIC ACID;
   EXEMESTANE; TAMOXIFEN; RESISTANCE
AB Background Breast Cancer Trials of Oral Everolimus 2 (BOLERO 2), a phase III study in postmenopausal women with estrogen receptor positive breast cancer progressing despite nonsteroidal aromatase inhibitor therapy, showed statistically significant benefits with adding everolimus to exemestane. Moreover, in preclinical studies, mammalian target of rapamycin inhibition was associated with decreased osteoclast survival and activity. Exploratory analyses in BOLERO 2 evaluated the effect of everolimus on bone marker levels and progressive disease in bone.
   Methods Patients were treated with exemestane (25 mg/day) and randomized (2:1) to everolimus (10 mg/day; combination) or placebo (exemestane only). Exploratory endpoints included changes in bone turnover marker levels vs baseline and progressive disease in bone, defined as unequivocal progression of a preexisting bone lesion or the appearance of a new bone lesion.
   Results Baseline disease characteristics were well balanced between arms (N = 724); baseline bisphosphonate use was not (43.9% combination vs 54.0% exemestane only). At a median of 18 months of follow up, median progression free survival (primary endpoint) was statistically significantly longer with the combination vs exemestane only (Cox proportional hazard ratio = 0.45, 95% confidence interval = 0.38 to 0.54; log rank, 1 sided P < .0001). Bone marker levels at 6 and 12 weeks increased with exemestane only, as expected, but decreased with the combination. The cumulative incidence rate of progressive disease in bone was lower in the combination arm. Bone related adverse events occurred with similar frequency in both arms (3.3% combination vs 4.2% exemestane only).
   Conclusion These exploratory analyses suggest that everolimus has beneficial effects on bone turnover and progressive disease in bone in patients receiving exemestane for hormone receptor positive breast cancer progressing during/after nonsteroidal aromatase inhibitor therapy.
C1 [Gnant, Michael] Med Univ Vienna, Dept Surg, A 1090 Vienna, Austria.
   [Gnant, Michael] Med Univ Vienna, Ctr Comprehens Canc, A 1090 Vienna, Austria.
   [Baselga, Jose] Mem Sloan Kettering Canc Ctr, Solid Tumor Breast Dept, New York, NY 10021 USA.
   [Rugo, Hope S.] Univ Calif San Francisco, Dept Med Hematol Oncol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
   [Noguchi, Shinzaburo] Osaka Natl Hosp, Dept Surg Oncol, Osaka, Japan.
   [Burris, Howard A.] Sarah Cannon Res Inst, Drug Dev Program, Nashville, TN USA.
   [Piccart, Martine] Univ Libre Brussels, Inst Jules Bordet, Dept Med, Brussels, Belgium.
   [Hortobagyi, Gabriel N.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA.
   [Eakle, Janice; Hart, Lowell L.] Florida Canc Specialists, Ft Myers, FL USA.
   [Mukai, Hirofumi] Natl Canc Ctr Hosp East, Dept Breast Oncol, Chiba, Japan.
   [Iwata, Hiroji] Aichi Canc Ctr Hosp, Dept Oncol, Nagoya, Aichi 464, Japan.
   [Geberth, Matthias] SPGO Mannheim, Dept Obstet & Gynecol, Mannheim, Germany.
   [Hadji, Peyman] Univ Marburg, Dept Endocrinol Reprod Med & Osteoporosis, Marburg, Germany.
   [El Hashimy, Mona] Novartis Pharmaceut, Dept Oncol Global Dev, Florham Pk, NJ USA.
   [Rao, Shantha] Novartis Pharmaceut, Dept Biostat, Florham Pk, NJ USA.
   [Taran, Tetiana] Novartis Pharmaceut, Dept BU Oncol, Florham Pk, NJ USA.
   [Sahmoud, Tarek] Novartis Pharmaceut, Dept Global Clin Program, Florham Pk, NJ USA.
   [Lebwohl, David] Novartis Pharmaceut, Dept Oncol, Florham Pk, NJ USA.
   [Campone, Mario] Ctr Rech Cancerol, Inst Cancerol Ouest Rene Gauducheau, Dept Med Oncol, St Herblain, France.
   [Pritchard, Kathleen I.] Sunnybrook Odette Canc Ctr, Dept Oncol, Toronto, ON, Canada.
   [Pritchard, Kathleen I.] Univ Toronto, Toronto, ON, Canada.
C3 Medical University of Vienna; Medical University of Vienna; Memorial
   Sloan Kettering Cancer Center; University of California System;
   University of California San Francisco; UCSF Medical Center; UCSF Helen
   Diller Family Comprehensive Cancer Center; Osaka National Hospital;
   Sarah Cannon Research Institute; Institut Jules Bordet; Universite Libre
   de Bruxelles; University of Texas System; UTMD Anderson Cancer Center;
   Florida Cancer Specialists; National Cancer Center   Japan; Aichi Cancer
   Center; Philipps University Marburg; Novartis; Novartis USA; Novartis;
   Novartis USA; Novartis; Novartis USA; Novartis; Novartis USA; Novartis;
   Novartis USA; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UNICANCER; Institut de Cancerologie de l'Ouest (ICO);
   University of Toronto; Sunnybrook Research Institute; Sunnybrook Health
   Science Center; University of Toronto
RP Gnant, M (通讯作者)，Med Univ Vienna, Dept Surg, Wahringer Gurtel 18 20, A 1090 Vienna, Austria.
EM michael.gnant@meduniwien.ac.at
RI Iwata, Hiroji/AFO 7749 2022; Baselga, Jose/L 1629 2016; Gnant,
   Michael/AAN 7054 2020; campone, mario/L 4880 2015; Pritchard,
   Kathleen/I 2184 2014
OI Gnant, Michael/0000 0003 1002 2118; Pritchard,
   Kathleen/0000 0003 0758 9666
FU Novartis Pharmaceuticals; GlaxoSmithKline; sanofi aventis; Novartis;
   Roche; Pfizer; Merck; AstraZeneca; Chugai; Taiho; Takeda; Amgen; Bayer;
   Boehringer Ingelheim; Bristol Myers Squibb; National Cancer Institute of
   Canada Clinical Trials Group
FX This work was supported by Novartis Pharmaceuticals. Financial support
   for medical editorial assistance was provided by Novartis
   Pharmaceuticals.M. Gnant has received research support from
   GlaxoSmithKline, sanofi aventis, Novartis, and Roche, is a consultant to
   Merrion and Novartis, and has received honoraria (speaking, advisory
   boards, etc) and travel support from Amgen, Pfizer, Novartis,
   GlaxoSmithKline, Bayer, Sandoz, AstraZeneca, and GenomicHealth. J.
   Baselga is a consultant to Novartis, Roche, Merck, sanofi aventis,
   Verastem, Bayer, Chugai, Exelixis, Onyx, and Constellation. H. Rugo has
   received grant support from Novartis, Pfizer, and Merck and has received
   travel and research support from Novartis. S. Noguchi has received grant
   support and honoraria from AstraZeneca, Chugai, Novartis, Pfizer,
   sanofi aventis, GlaxoSmithKline, Taiho, and Takeda. M. Piccart is a
   board member for PharmaMar, is a consultant to sanofi aventis, Amgen,
   Bristol Myers Squibb, GlaxoSmithKline, Boehringer Ingelheim, Roche, and
   Bayer, has received grant support from Pfizer, Amgen, Bayer, Boehringer
   Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Roche, and
   sanofi aventis, and has received honoraria from Bayer, Bristol Myers
   Squibb, GlaxoSmithKline, Boehringer Ingelheim, Roche, Amgen, and
   AstraZeneca. G.N. Hortobagyi is a member of the Scientific Advisory
   Board of Allergan, is a consultant to Allergan, Novartis, Genentech, and
   sanofi aventis, has received grant support from Novartis, and has
   received travel expense reimbursement from Novartis, Genentech, and
   sanofi aventis. H. Iwata has received honoraria from AstraZeneca,
   Chugai, Daiichi Sankyo, and Eisai. M. El Hashimy, S. Rao, T. Taran, T.
   Sahmoud, and D. Lebwohl are employees of Novartis. K. Pritchard is a
   consultant with sanofi aventis, AstraZeneca, Roche, Pfizer, Novartis,
   Abraxis, Amgen, and GlaxoSmithKline, has received research funding
   either directly through per case funding for studies or indirectly
   through the National Cancer Institute of Canada Clinical Trials Group,
   has contracted with pharmaceutical companies including AstraZeneca,
   Bristol Myers Squibb, sanofi aventis, Amgen, Pfizer, Novartis,
   GlaxoSmithKline, and Ortho Biotech, has received honoraria from or
   participated in speaker's bureaus for sanofi aventis, AstraZeneca,
   Pfizer, Roche, Novartis, and Amgen, has given paid expert testimony for
   sanofi aventis, AstraZeneca, and GlaxoSmithKline, and has been an
   Advisory Committee member for sanofi aventis, AstraZeneca, Roche,
   Pfizer, Novartis, GlaxoSmithKline, and Amgen. All other authors report
   no conflicts.
CR [Anonymous], 2012 CTRC AACR SAN A
   [Anonymous], CLIN GUID PREV TREAT
   [Anonymous], 2011, AF EV PRESCR INF
   Ariazi EA, 2007, MOL CANCER THER, V6, P2817, DOI 10.1158/1535 7163.MCT 07 0312
   Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653
   Benslimane Ahmim Z, 2011, J THROMB HAEMOST, V9, P834, DOI 10.1111/j.1538 7836.2011.04207.x
   Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362
   Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200
   Campos SM, 2004, ONCOLOGIST, V9, P126, DOI 10.1634/theoncologist.9 2 126
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman RE, 2007, LANCET ONCOL, V8, P119, DOI 10.1016/S1470 2045(07)70003 7
   Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331
   Dignam JJ, 2008, J CLIN ONCOL, V26, P4027, DOI 10.1200/JCO.2007.12.9866
   Eastell R, 2008, J CLIN ONCOL, V26, P1051, DOI 10.1200/JCO.2007.11.0726
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Gnant M, 2008, LANCET ONCOL, V9, P840, DOI 10.1016/S1470 2045(08)70204 3
   Goss PE, 2007, BREAST CANC, V9, P52
   Hadji P, 2009, ANN ONCOL, V20, P1203, DOI 10.1093/annonc/mdn762
   Hadji P, 2009, BREAST, V18, P159, DOI 10.1016/j.breast.2009.03.003
   Hadji P, 2011, J CANCER RES CLIN, V137, P1015, DOI 10.1007/s00432 010 0964 y
   Hortobagyi GN, 2011, CANC RES, V71
   Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140 6736(04)17666 6
   Kaufmann M, 2000, J CLIN ONCOL, V18, P1399, DOI 10.1200/JCO.2000.18.7.1399
   Kim HT, 2007, CLIN CANCER RES, V13, P559, DOI 10.1158/1078 0432.CCR 06 1210
   Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013
   Lonning PE, 2005, J CLIN ONCOL, V23, P5126, DOI 10.1200/JCO.2005.07.097
   Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680
   Miller WR, 2008, ONCOLOGIST, V13, P829, DOI 10.1634/theoncologist.2008 0055
   Mogi M, 2009, BIOCHEM BIOPH RES CO, V384, P82, DOI 10.1016/j.bbrc.2009.04.084
   Moriceau G, 2010, CANCER RES, V70, P10329, DOI 10.1158/0008 5472.CAN 10 0578
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nabholtz JMA, 2001, J CLIN ONCOL, V19, P2107, DOI 10.1200/JCO.2001.19.7.2107
   Ory B, 2007, CURR MED CHEM, V14, P1381, DOI 10.2174/092986707780831159
   Rachner TD, 2009, J CELL BIOCHEM, V108, P106, DOI 10.1002/jcb.22232
   Santen RJ, 2005, J STEROID BIOCHEM, V95, P155, DOI 10.1016/j.jsbmb.2005.04.025
   Shapiro CL, 2011, EUR J CANCER, V47, P683, DOI 10.1016/j.ejca.2010.11.024
   Tang XD, 2010, INT J CANCER, V126, P90, DOI 10.1002/ijc.24710
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Thürlimann B, 2005, NEW ENGL J MED, V353, P2747
   Tokunaga Eriko, 2006, Breast Cancer, V13, P137, DOI 10.2325/jbcs.13.137
   US Food and Drug Administration, SUPPL APPR JUL 20 20
   van de Velde CJH, 2011, LANCET, V377, P321, DOI 10.1016/S0140 6736(10)62312 4
   Yue W, 2007, J STEROID BIOCHEM, V106, P102, DOI 10.1016/j.jsbmb.2007.05.008
NR 43
TC 76
Z9 81
U1 0
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027 8874
J9 JNCI J NATL CANCER I
JI JNCI . Natl. Cancer Inst.
PD MAY
PY 2013
VL 105
IS 9
BP 654
EP 663
DI 10.1093/jnci/djt026
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 140UK
UT WOS:000318681200012
PM 23425564
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Wu, YS
   Wang, Y
   Chen, FY
   Wang, BZ
AF Wu, Yinsheng
   Wang, Yong
   Chen, Fengyan
   Wang, Bingzhang
TI Loading rutin on surfaces by the layer by layer assembly technique to
   improve the oxidation resistance and osteogenesis of titanium implants
   in osteoporotic rats
SO BIOMEDICAL MATERIALS
LA English
DT Article
DE osseointegration; oxidation resistance; layer by layer; titanium; rutin
ID DENTAL IMPLANT; BONE FORMATION; QUERCETIN; STRESS; ACID; DELIVERY;
   CELLS; FUNCTIONALIZATION; OSSEOINTEGRATION; BIOMATERIALS
AB The purpose of this study was to construct a rutin controlled release system on the surface of Ti substrates and investigate its effects on osteogenesis and osseointegration on the surface of implants. The base layer, polyethylenimine (PEI), was immobilised on a titanium substrate. Then, hyaluronic acid (HA)/chitosan (CS) rutin (RT) multilayer films were assembled on the PEI using layer by layer (LBL) assembly technology. We used scanning electron microscopy (SEM), Fourier transform infrared (FTIR) spectroscopy and contact angle measurements to examine all Ti samples. The drug release test of rutin was also carried out to detect the slow release performance. The osteogenic abilities of the samples were evaluated by experiments on an osteoporosis rat model and MC3T3 E1 cells. The results (SEM, FTIR and contact angle measurements) all confirmed that the PEI substrate layer and HA/CS RT multilayer film were effectively immobilised on titanium. The drug release test revealed that a rutin controlled release mechanism had been successfully established. Furthermore, the in vitro data revealed that osteoblasts on the coated titanium matrix had greater adhesion, proliferation, and differentiation capacity than the osteoblasts on the pure titanium surface. When MC3T3 E1 cells were exposed to H2O2 induced oxidative stress in vitro, cell based tests revealed great tolerance and increased osteogenic potential on HA/CS RT substrates. We also found that the HA/CS RT coating significantly increased the new bone mass around the implant. The LBL deposited HA/CS RT multilayer coating on the titanium base surface established an excellent rutin controlled release system, which significantly improved osseointegration and promoted osteogenesis under oxidative stress conditions, suggesting a new implant therapy strategy for patients with osteoporosis.
C1 [Wu, Yinsheng; Wang, Yong; Chen, Fengyan; Wang, Bingzhang] Wenzhou Hosp Integrated Tradit Chinese & Western M, Dept Orthoped, 75,JinXiu Rd, Wenzhou 325000, Zhejiang, Peoples R China.
RP Wang, BZ (通讯作者)，Wenzhou Hosp Integrated Tradit Chinese & Western M, Dept Orthoped, 75,JinXiu Rd, Wenzhou 325000, Zhejiang, Peoples R China.
EM 1048426222@qq.com; 3810636274@qq.com; 2062383445@qq.com;
   804030083@qq.com
FU The Wenzhou Science and Technology Bureau [Y20180028]; Wenzhou Science
   and Technology Bureau
FX The Wenzhou Science and Technology Bureau [Grant Number Y20180028].Thank
   you to Dr. Lei Yang (Department of Orthopedics, The Second Affiliated
   Hospital and Yuying Children's Hospital of Wenzhou Medical University)
   for his guidance on this study. Thank you to Dr. Jiongming You
   (Department of Orthopedics, Wenzhou Hospital of Integrated Traditional
   Chinese and Western Medicine) for his guidance on this study.
CR Agarwal R, 2015, ADV DRUG DELIVER REV, V94, P53, DOI 10.1016/j.addr.2015.03.013
   Al Dhabi NA, 2015, EXCLI J, V14, P59, DOI 10.17179/excli2014 663
   Antebi B, 2014, CURR OSTEOPOROS REP, V12, P41, DOI 10.1007/s11914 013 0184 x
   Arlin ML, 2007, J CAN DENT ASSOC, V73, P821
   Arpornmaeklong P, 2007, INT J ORAL MAX SURG, V36, P328, DOI 10.1016/j.ijom.2006.09.023
   Chen WZ, 2017, BIOMATERIALS, V114, P82, DOI 10.1016/j.biomaterials.2016.10.055
   Dickinson BC, 2011, NAT CHEM BIOL, V7, P504, DOI [10.1038/NCHEMBIO.607, 10.1038/nchembio.607]
   Durao SF, 2014, OSTEOPOROSIS INT, V25, P1535, DOI 10.1007/s00198 014 2656 y
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Forster Yvonne, 2012, Biomatter, V2, P149, DOI 10.4161/biom.21563
   Ganeshpurkar A, 2017, SAUDI PHARM J, V25, P149, DOI 10.1016/j.jsps.2016.04.025
   Gera S, 2020, PHARM DEV TECHNOL, V25, P971, DOI 10.1080/10837450.2020.1765378
   Gilbert JL, 2015, J BIOMED MATER RES A, V103, P211, DOI 10.1002/jbm.a.35165
   Gittens RA, 2014, ACTA BIOMATER, V10, P2907, DOI 10.1016/j.actbio.2014.03.032
   HANASAKI Y, 1994, FREE RADICAL BIO MED, V16, P845, DOI 10.1016/0891 5849(94)90202 X
   Isai M, 2009, Mol Vis, V15, P2570
   Jeon S, 2015, COLLOID SURFACE B, V129, P7, DOI 10.1016/j.colsurfb.2015.03.018
   Jere D, 2009, EXPERT OPIN DRUG DEL, V6, P827, DOI 10.1517/17425240903029183
   Jie J, 2021, INFLAMM RES, V70, P789, DOI 10.1007/s00011 021 01452 3
   Junter GA, 2016, ACTA BIOMATER, V30, P13, DOI 10.1016/j.actbio.2015.11.010
   Kandemir FM, 2015, RENAL FAILURE, V37, P518, DOI 10.3109/0886022X.2015.1006100
   Kannan, 2000, Pathophysiology, V7, P153, DOI 10.1016/S0928 4680(00)00053 5
   Kaur M, 2019, MAT SCI ENG C MATER, V102, P844, DOI 10.1016/j.msec.2019.04.064
   Kim MH, 2015, INT J MOL SCI, V16, P10324, DOI 10.3390/ijms160510324
   Lee HH, 2020, J KOREAN NEUROSURG S, V63, P433, DOI 10.3340/jkns.2019.0097
   Lee JY, 2002, J CONTROL RELEASE, V78, P187, DOI 10.1016/S0168 3659(01)00498 9
   Lee YH, 2013, BIOMATERIALS, V34, P10199, DOI 10.1016/j.biomaterials.2013.08.080
   Lee YH, 2010, CELL BIOCHEM FUNCT, V28, P678, DOI 10.1002/cbf.1708
   Litwiniuk M, 2016, WOUNDS, V28, P78
   Liu H, 2017, MAT SCI ENG C MATER, V79, P399, DOI 10.1016/j.msec.2017.05.077
   Maher S, 2018, EXPERT OPIN DRUG DEL, V15, P1021, DOI 10.1080/17425247.2018.1517743
   Manach C, 1997, FEBS LETT, V409, P12, DOI 10.1016/S0014 5793(97)00467 5
   Mellado Valero A, 2010, MED ORAL PATOL ORAL, V15, pE52, DOI 10.4317/medoral.15.e52
   Mendes VC, 2009, J BIOMED MATER RES A, V90A, P577, DOI 10.1002/jbm.a.32126
   Meng HW, 2016, BIOMARK RES, V4, DOI 10.1186/s40364 016 0078 z
   Meng XL, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.834077
   Nathan C, 2013, NAT REV IMMUNOL, V13, P349, DOI 10.1038/nri3423
   Oluranti OI, 2021, LIFE SCI, V284, DOI 10.1016/j.lfs.2021.119878
   Pandey AP, 2016, MAT SCI ENG C MATER, V68, P904, DOI 10.1016/j.msec.2016.07.066
   Park JH, 2011, LANGMUIR, V27, P5976, DOI 10.1021/la2000415
   Romano C L, 2017, J Bone Jt Infect, V2, P63, DOI 10.7150/jbji.17705
   Scalize PH, 2019, ANIM MODEL EXP MED, V2, P51, DOI 10.1002/ame2.12056
   Smeets R, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6285620
   Smith RC, 2009, ANGEW CHEM INT EDIT, V48, P8974, DOI 10.1002/anie.200902782
   Song YJ, 2018, INT J NANOMED, V13, P6751, DOI 10.2147/IJN.S174953
   Tang JH, 2020, INT J NANOMED, V15, P1643, DOI 10.2147/IJN.S231339
   Tao J, 2012, J NANOSCI NANOTECHNO, V12, P1852, DOI 10.1166/jnn.2012.5189
   Tsaryk R, 2007, BIOMATERIALS, V28, P806, DOI 10.1016/j.biomaterials.2006.09.033
   Wang BZ, 2021, J BIOMED NANOTECHNOL, V17, P1392, DOI 10.1166/jbn.2021.3115
   Wang L, 2015, BIOCHIMIE, V108, P85, DOI 10.1016/j.biochi.2014.10.004
   Wang QL, 2017, EUR REV MED PHARMACO, V21, P1911
   Weng SJ, 2019, BIOMED PHARMACOTHER, V109, P573, DOI 10.1016/j.biopha.2018.10.085
   Xiao YH, 2019, AM J TRANSL RES, V11, P6680
   Xu N, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.202000681
   Yang LL, 2021, CHEM REV, V121, P4561, DOI 10.1021/acs.chemrev.0c00752
   Yao SD, 2021, ACTA CIR BRAS, V36, DOI [10.1590/ACB360307, 10.1590/acb360307]
   Zhang YF, 2012, BIOMATERIALS, V33, P6698, DOI 10.1016/j.biomaterials.2012.06.021
   Zhao B, 2020, ARCH ORAL BIOL, V109, DOI 10.1016/j.archoralbio.2019.104584
   Zhao XJ, 2020, INT J NANOMED, V15, P8583, DOI 10.2147/IJN.S270311
   Zhu JX, 2004, J ETHNOPHARMACOL, V93, P133, DOI 10.1016/j.jep.2004.03.037
   Zou DB, 2021, AGING CELL, V20, DOI 10.1111/acel.13367
NR 61
TC 1
Z9 1
U1 4
U2 17
PU IOP Publishing Ltd
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1748 6041
EI 1748 605X
J9 BIOMED MATER
JI Biomed. Mater.
PD JUL 1
PY 2024
VL 19
IS 4
AR 045011
DI 10.1088/1748 605X/ad4aa8
PG 15
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA RP8T6
UT WOS:001228963300001
PM 38740037
OA hybrid
DA 2025 08 17
ER

PT J
AU Wang, ZY
   Wang, J
   Li, X
   Xing, LP
   Ding, Y
   Shi, PH
   Zhang, YH
   Guo, SH
   Shu, X
   Shan, BE
AF Wang, Zhiyu
   Wang, Juan
   Li, Xing
   Xing, Lianping
   Ding, Yan
   Shi, Penghui
   Zhang, Yuehua
   Guo, Shenghu
   Shu, Xin
   Shan, Baoen
TI Bortezomib prevents oncogenesis and bone metastasis of prostate cancer
   by inhibiting WWP1, Smurf1 and Smurf2
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
ID E3 UBIQUITIN LIGASES; PROTEASOME INHIBITOR; MULTIPLE MYELOMA; IN VITRO;
   OSTEOBLAST DIFFERENTIATION; TUMOR CELLS; EXPRESSION; VIVO; ANGIOGENESIS;
   ACTIVATION
AB Prostate cancer is the most common malignancy diagnosed in males, and bone metastases remain a significant source of morbidity and mortality in this population. Ubiquitin ligase E3s and proteasomes were thought to play essential roles in the development of cancers, therefore, they were proposed as therapy targets for the treatment of solid and hematological malignancies. Bortezomib, well known as a proteasome inhibitor, has been observed with exact anticancer effect both in cell and animal models for several solid tumor types, including prostate cancer. To explore activities of the ubiquitin ligase E3s WWP1, Smurf1 and Smurf2 in oncogenesis and bone metastasis of prostate cancer, as well as in the functional mechanism of bortezomib, in preventing prostate cancer, transcription and expression levels of WWP1, Smurf1 and Smurf2 genes in cell lines or tissues of benign prostate hyperplasia and human prostate cancer with and without bone metastasis were tested. Moreover, human prostate cancer PC3 cell lines were treated with bortezomib at different concentration gradients and then their proliferation at different time points, mRNA and protein levels were investigated. The results indicated that transcription and expression levels of WWP1, Smurf1 and Smurf2 genes in prostate cancer without bone metastasis were significantly higher compared to those in benign prostate hyperplasia (P<0.05), whereas significantly lower than prostate cancer metastatic to bone (P<0.05). Furthermore, bortezomib reduced the transcription and expression levels of WWP1, Smurf1 and Smurf2 genes in prostate cancer cell lines in a dose dependent manner, thus, inhibiting the proliferation of prostate cancer cells. Elevated transcription and expression levels of ubiquitin ligase E3s WWP1, Smurf1 and Smurf2 genes may be the mechanisms of occurrence, development and metastasis of prostate cancer. In addition, bortezomib can prevent prostate cancer and its bone metastasis by downregulating WWP1, Smurf1 and Smurf2.
C1 [Wang, Zhiyu; Wang, Juan; Li, Xing; Shi, Penghui; Zhang, Yuehua; Guo, Shenghu] Hebei Med Univ, Dept Immunol & Immunotherapy, Hosp 4, Shijiazhuang 050011, Hebei, Peoples R China.
   [Xing, Lianping] Univ Rochester, Sch Med & Dent, Med Ctr, Rochester, NY 14642 USA.
   [Ding, Yan] Hebei Med Univ, Dept Pathol, Hosp 4, Shijiazhuang 050011, Hebei, Peoples R China.
   [Shu, Xin] Armed Police Gen Hosp, Dept Oncol, Beijing 100039, Peoples R China.
   [Shan, Baoen] Hebei Med Univ, Ctr Sci Res, Hosp 4, Shijiazhuang 050011, Hebei, Peoples R China.
C3 Hebei Medical University; University of Rochester; Hebei Medical
   University; Hebei Medical University
RP Shan, BE (通讯作者)，Hebei Med Univ, Ctr Sci Res, Hosp 4, Shijiazhuang 050011, Hebei, Peoples R China.
EM baoenshanprofessor@hotmail.com
FU National Natural Science Foundation [81202037]
FX This study was supported by grants from the National Natural Science
   Foundation (81202037).
CR Adams J, 1999, CANCER RES, V59, P2615
   Alaaeddine N, 2011, CLIN LAB, V57, P799
   Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678
   Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001
   Buijs JT, 2007, CLIN EXP METASTAS, V24, P609, DOI 10.1007/s10585 007 9118 2
   Chen C, 2007, ONCOGENE, V26, P2386, DOI 10.1038/sj.onc.1210021
   Chen C, 2007, CANCER METAST REV, V26, P587, DOI 10.1007/s10555 007 9091 x
   Farooqi AA, 2011, J MEMBRANE BIOL, V244, P1, DOI 10.1007/s00232 011 9394 2
   Festuccia C, 2007, PROSTATE, V67, P1255, DOI 10.1002/pros.20616
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Hellwinkel OJC, 2011, PROSTATE CANCER P D, V14, P38, DOI 10.1038/pcan.2010.48
   Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313
   Kane RC, 2006, CLIN CANCER RES, V12, P2955, DOI 10.1158/1078 0432.CCR 06 0170
   Ma MH, 2003, CLIN CANCER RES, V9, P1136
   Micel LN, 2013, J CLIN ONCOL, V31, P1231, DOI 10.1200/JCO.2012.44.0958
   Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02 07 0441
   Obertova Z, 2012, RURAL REMOTE HEALTH, V12
   Oyajobi BO, 2007, BRIT J HAEMATOL, V139, P434, DOI 10.1111/j.1365 2141.2007.06829.x
   Papandreou CN, 2004, CANCER RES, V64, P5036, DOI 10.1158/0008 5472.CAN 03 2707
   Qiang YW, 2009, BLOOD, V113, P4319, DOI 10.1182/blood 2008 08 174300
   Rieser E, 2013, TRENDS BIOCHEM SCI, V38, P94, DOI 10.1016/j.tibs.2012.11.007
   Satoh F, 2001, INT J UROL, V8, pS28, DOI 10.1046/j.1442 2042.2001.00331.x
   Sévère N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.217
   Sterz J, 2008, EXPERT OPIN INV DRUG, V17, P879, DOI 10.1517/13543784.17.6.879 
   Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419
   Uy GL, 2007, CLIN LYMPHOMA MYELOM, V7, P587, DOI 10.3816/CLM.2007.n.045
   Weeraratna AT, 2001, CLIN CANCER RES, V7, P2237
   Whang PG, 2005, PROSTATE CANCER P D, V8, P327, DOI 10.1038/sj.pcan.4500823
   Williams S, 2003, MOL CANCER THER, V2, P835
   Yang B, 2010, CELL DEATH DIFFER, V17, P68, DOI 10.1038/cdd.2009.84
   Zhao L, 2011, STEM CELLS, V29, P1601, DOI 10.1002/stem.703
   Zhu Y, 2011, BASIC RES CARDIOL, V106, P787, DOI 10.1007/s00395 011 0182 z
NR 33
TC 34
Z9 36
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019 6439
EI 1791 2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD OCT
PY 2014
VL 45
IS 4
BP 1469
EP 1478
DI 10.3892/ijo.2014.2545
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AQ1FT
UT WOS:000342528000016
PM 25051198
OA Bronze
DA 2025 08 17
ER

PT J
AU Yan, Y
   Liu, Y
   Lu, R
AF Yan, Yan
   Liu, Yu
   Lu, Ran
TI PELP1 promotes the expression of RUNX2 via the ERK pathway during the
   osteogenic differentiation of human periodontal ligament stem cells
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE Proline , glutamic acid , and leucine rich protein 1; Human periodontal
   ligament stem cells; Osteogenic differentiation; RUNX2
ID OSTEOBLAST DIFFERENTIATION; BONE; MINERALIZATION; PREVALENCE; UPDATE;
   ADULTS
AB Objective: The aim of this study was to determine the physiological function and mechanism of proline , glutamic acid , and leucine rich protein 1 (PELP1) in the osteogenic differentiation of human periodontal ligament stem cells (hPDLSCs) at the molecular level in vitro.
   Design: During the osteogenic differentiation of hPDLSCs, the change of PELP1 and the osteogenic commitment markers runt related transcription factor 2(RUNX2), alkaline phosphatase (ALP) and osteocalcin (OCN) were monitored by quantitative real time PCR (qRT PCR) and western blots. To elucidate how PELP1 regulates RUNX2, the expression of RUNX2, the phosphorylation of extracellular regulated protein kinases (ERK) and subcellular location of PELP1 were detected under conditions that PELP1 was either knockdown by specific siRNA or overexpressed. A pharmacological inhibitor of ERK, U0126 was used while PELP1 was overexpressed, and the expression of RUNX2 was monitored by qRT PCR.
   Results: PELP1 was upregulated during the osteogenic differentiation of hPDLSCs. Knockdown of PELP1 suppressed the expression of RUNX2, whereas overexpression of PELP1 increased RUNX2 expression. Moreover, PELP1 knockdown resulted in reduced ERK phosphorylation and RUNX2 expression, and PELP1 overexpression induced RUNX2 expression was inhibited by U0126 in the hPDLSCs.
   Conclusions: PELP1 regulates the expression of RUNX2 during the osteogenic differentiation of hPDLSCs and that the ERK pathway is involved in this process.
C1 [Yan, Yan] Capital Med Univ, Beijing Stomatol Hosp, Sch Stomatol, Dept Endodont, Beijing 10050, Peoples R China.
   [Liu, Yu] Bejing Zebro Dent Clin, Beijing 100097, Peoples R China.
   [Lu, Ran] Capital Med Univ, Sch Stomatol, Beijing Key Lab Tooth Regenerat & Funct Reconstru, Beijing 100050, Peoples R China.
C3 Capital Medical University; Capital Medical University
RP Yan, Y (通讯作者)，Capital Med Univ, Sch Stomatol, Beijing Stomatol Hosp, 4 Tiantan Xili, Beijing 100050, Peoples R China.
EM yanandf3enc@163.com
RI lu, ran/HHC 8613 2022
FU National Natural Science Foundation of China [81500852]
FX This work was supported by the National Natural Science Foundation of
   China (grant number 81500852). The authors declare no potential
   conflicts of interest with respect to the authorship and/or publication
   of this article. The authors also thank AiMi Academic Services
   (www.aimie ditor.com) for English language editing and review services.
CR Bassir SH, 2016, J CELL PHYSIOL, V231, P50, DOI 10.1002/jcp.25067
   Cai C, 2013, INT J MOL MED, V31, P1195, DOI 10.3892/ijmm.2013.1305
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Cohen MM, 2013, J CRANIOFAC SURG, V24, P130, DOI 10.1097/SCS.0b013e3182636b7e
   E LL, 2016, INT J MOL MED, V37, P1475, DOI 10.3892/ijmm.2016.2559
   Eke PI, 2012, J DENT RES, V91, P914, DOI 10.1177/0022034512457373
   Eke PI, 2015, J PERIODONTOL, V86, P611, DOI 10.1902/jop.2015.140520
   Fisher MA, 2008, J PERIODONTOL, V79, P1670, DOI [10.1902/jop.2008.070569, 10.1902/jop.2008.070569 ]
   Gordon JAR, 2007, BONE, V41, P462, DOI 10.1016/j.bone.2007.04.191
   Hashioka S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153723
   Hernández Monjaraz B, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040944
   Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785
   Holmstrup P, 2017, J ORAL MICROBIOL, V9, DOI 10.1080/20002297.2017.1332710
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Ide M, 2013, J CLIN PERIODONTOL, V40, pS181, DOI [10.1902/jop.2013.134009, 10.1111/jcpe.12063]
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Jun JH, 2010, J BIOL CHEM, V285, P36410, DOI 10.1074/jbc.M110.142307
   Jung IH, 2013, J PERIODONTOL, V84, P1434, DOI 10.1902/jop.2013.120541
   Kim HY, 2018, EUR J PHARMACOL, V834, P84, DOI 10.1016/j.ejphar.2018.07.012
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Lee SW, 2017, J PERIODONTOL, V88, P575, DOI 10.1902/jop.2017.160706
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Mamalis A, 2011, ARCH ORAL BIOL, V56, P446, DOI 10.1016/j.archoralbio.2010.11.001
   Manavathi B, 2006, J CELL PHYSIOL, V207, P594, DOI 10.1002/jcp.20551
   Nair S, 2007, HISTOL HISTOPATHOL, V22, P91, DOI 10.14670/HH 22.91
   Nakayama K, 2003, J BONE MINER RES, V18, P827, DOI 10.1359/jbmr.2003.18.5.827
   Ou QM, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12396
   Pan F, 2011, BIOSCIENCE REP, V31, P117, DOI 10.1042/BSR20100029
   Pandula PKCP, 2014, J INVESTIG CLIN DENT, V5, P81, DOI 10.1111/jicd.12089
   Polo Corrales L, 2014, J NANOSCI NANOTECHNO, V14, P15, DOI 10.1166/jnn.2014.9127
   Ravindranathan P, 2015, MOL ENDOCRINOL, V29, P1222, DOI [10.1210/ME.2015 1049, 10.1210/me.2015 1049]
   Rayala SK, 2006, J BIOL CHEM, V281, P4395, DOI 10.1074/jbc.M510368200
   Reddy MS, 2015, J PERIODONTOL, V86, pS131, DOI 10.1902/jop.2015.140379
   Román Malo L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071438
   Salvi GE, 2014, J CLIN PERIODONTOL, V41, P701, DOI 10.1111/jcpe.12266
   Sareddy GR, 2015, P NATL ACAD SCI USA, V112, pE6673, DOI 10.1073/pnas.1516729112
   Sareddy GR, 2016, GENE, V585, P128, DOI 10.1016/j.gene.2016.03.017
   Scannapieco Frank A, 2003, Ann Periodontol, V8, P54, DOI 10.1902/annals.2003.8.1.54
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shi JW, 2019, ORTHOD CRANIOFAC RES, V22, P168, DOI 10.1111/ocr.12307
   Skibinska I, 2018, ASIAN J ANDROL, V20, P425, DOI 10.4103/aja.aja_11_18
   Thakkar R, 2018, J NEUROENDOCRINOL, V30, DOI 10.1111/jne.12484
   Tomokiyo A, 2019, STEM CELLS DEV, V28, P974, DOI 10.1089/scd.2019.0031
   Tomokiyo A, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/5450768
   Vadlamudi RK, 2005, CANCER RES, V65, P7724, DOI 10.1158/0008 5472.CAN 05 0614
   WANG J, 2013, HISTOCHEM J, V44, P347, DOI DOI 10.1007/S10735 013 9490 Y
   Wang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075477
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Yan Y, 2013, PROTEIN CELL, V4, P620, DOI 10.1007/s13238 013 3030 0
   Yang L, 2019, EUR REV MED PHARMACO, V23, P949, DOI 10.26355/eurrev_201902_16981
   Yao W, 2013, STEM CELLS, V31, P2003, DOI 10.1002/stem.1461
   Zhu WJ, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/972313
NR 54
TC 4
Z9 4
U1 1
U2 9
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0003 9969
EI 1879 1506
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD APR
PY 2021
VL 124
AR 105078
DI 10.1016/j.archoralbio.2021.105078
EA FEB 2021
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA RN0OB
UT WOS:000640053800022
PM 33607589
DA 2025 08 17
ER

PT J
AU Diaz, RL
   Gardeazabal, J
   Manrique, P
   Raton, JA
   Urrutia, I
   Rodríguez Sasiain, JM
   Aguirre, C
AF Diaz, Ruth L.
   Gardeazabal, Jesus
   Manrique, Pilar
   Raton, Juan A.
   Urrutia, Ignacio
   Rodriguez Sasiain, Jose M.
   Aguirre, Carmelo
TI Greater allergenicity of topical ketoprofen in contact dermatitis
   confirmed by use
SO CONTACT DERMATITIS
LA English
DT Article
DE contact dermatitis; cross reactions; ketoprofen; photocontact
   dermatitis; topical NSAIDs
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RANDOMIZED CONTROLLED TRIAL;
   PHOTOCONTACT DERMATITIS; CONSECUTIVE PATIENTS; OSTEOARTHRITIS;
   DICLOFENAC; ALLERGY; KNEE; PHOTOSENSITIVITY; PHOTOALLERGY
AB The use of topical non steroidal anti inflammatory drugs (NSAIDs) is very popular in spite of their doubtful efficacy and high number of generally not serious, but preventable, adverse effects, especially photoallergy. The allergenic potential of different topical NSAIDs was determined by performing a retrospective observational study of the period 1996 2001 and comparing the cases of allergy and photoallergy with the use of each topical NSAID. The diagnoses were obtained from a review of the clinical records of patch/photopatch testing carried out in the dermatology departments of 2 public hospitals in Bizkaia (Spain). The use of the different topical NSAIDs was obtained from invoices sent to the National Health System and the Reporting odds ratio (ROR) and Proportional reporting ratio (PRR) disproportionality estimates of the FEDRA database of the Spanish Pharmacovigilance System. A total of 139 contact reactions to topical NSAIDs were found with ketoprofen being responsible for 28% of the allergies and 82% of the contact photoallergies in spite of not being the most used topical NSAID (third in the ranking, diclofenac was the first). The ROR for ketoprofen was 3.9 (2.4 6.4) and the PRR 3.4 (2.1 5.5), thus confirming the possibility of a warning signal. The results support the need for regulatory action on topical ketoprofen.
C1 Hosp Galdakao, Unidad Farmacovigilancia Pais Vaso, E 48960 Galadokao, Spain.
   Hosp Galdakao, Dermatol Serv, E 48960 Galadokao, Spain.
   Hosp Cruces, Dermatol Serv, Baracaldo, Spain.
   Pharmacovigilance Unit, Galdakao, Spain.
C3 Galdakao Hospital; Galdakao Hospital; Hospital Universitario Cruces
RP Aguirre, C (通讯作者)，Hosp Galdakao, Unidad Farmacovigilancia Pais Vaso, Barrio Labeaga S N, E 48960 Galadokao, Spain.
EM gafarmcv@hgda.osakidetza.net
RI Gardeazabal, Jesus/E 1751 2012
CR Adamski H, 1998, CONTACT DERMATITIS, V38, P171, DOI 10.1111/j.1600 0536.1998.tb05692.x
   *AG FRANC SEC SAN, 2003, GELS KET REACT PHOT
   [Anonymous], COCHRANE DATABASE SY
   Bastien M, 1997, ANN DERMATOL VENER, V124, P523
   Bookman AAM, 2004, CAN MED ASSOC J, V171, P333, DOI 10.1503/cmaj.1031793
   BRUYNZEEL DP, 1995, CONTACT DERMATITIS, V33, P145, DOI 10.1111/j.1600 0536.1995.tb00534.x
   DEFRUTOS FJO, 1999, DERMATITIS CONTACTO, P39
   Durbize E, 2003, CONTACT DERMATITIS, V48, P144, DOI 10.1034/j.1600 0536.2003.00066.x
   Durieu C, 2001, ANN DERMATOL VENER, V128, P1020
   Evans SJW, 2001, PHARMACOEPIDEM DR S, V10, P483, DOI 10.1002/pds.677
   FERNANDO AHN, 1994, BRIT MED J, V308, P533, DOI 10.1136/bmj.308.6927.533
   Hindsén M, 2004, J AM ACAD DERMATOL, V50, P215, DOI 10.1016/j.jaad.2003.07.007
   Horn HM, 1998, CONTACT DERMATITIS, V38, P353, DOI 10.1111/j.1600 0536.1998.tb05785.x
   Jeanmougin M, 1996, ANN DERMATOL VENER, V123, P251
   Kawada A, 2001, CONTACT DERMATITIS, V44, P370
   Le Coz CJ, 1998, CONTACT DERMATITIS, V38, P245
   Lin FY, 2004, BMJ BRIT MED J, V329, P324, DOI 10.1136/bmj.38159.639028.7C
   Matthieu L, 2004, CONTACT DERMATITIS, V50, P238, DOI 10.1111/j.0105 1873.2004.00323.x
   Montoro J, 2003, CONTACT DERMATITIS, V48, P115, DOI 10.1034/j.1600 0536.2003.480212_1.x
   Moore DE, 2002, DRUG SAFETY, V25, P345, DOI 10.2165/00002018 200225050 00004
   Pigatto P, 1996, Am J Contact Dermat, V7, P220, DOI 10.1016/S1046 199X(96)90053 6
   Rovensky J, 2001, DRUG EXP CLIN RES, V27, P209
   SERRABALDRICH E, 1999, DERMATITIS CONTACTO, P77
   Sharir M, 1997, ARCH OPHTHALMOL CHIC, V115, P294, DOI 10.1001/archopht.1997.01100150296037
   Sitenga GL, 1996, OPHTHALMOLOGY, V103, P890, DOI 10.1016/S0161 6420(96)30591 5
   TOSTI A, 1990, CONTACT DERMATITIS, V23, P112, DOI 10.1111/j.1600 0536.1990.tb03233.x
   van Haselen RA, 2000, RHEUMATOLOGY, V39, P714, DOI 10.1093/rheumatology/39.7.714
   van Puijenbroek EP, 2002, PHARMACOEPIDEM DR S, V11, P3, DOI 10.1002/pds.668
   Vasconcelos C, 1998, CONTACT DERMATITIS, V39, P145, DOI 10.1111/j.1600 0536.1998.tb05876.x
   Veyrac G, 2002, THERAPIE, V57, P55
   Whittle BJR, 2003, FUND CLIN PHARMACOL, V17, P301, DOI 10.1046/j.1472 8206.2003.00135.x
   2004, BANDOLIER EXTRA 0801
NR 32
TC 36
Z9 39
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0105 1873
EI 1600 0536
J9 CONTACT DERMATITIS
JI Contact Dermatitis
PD MAY
PY 2006
VL 54
IS 5
BP 239
EP 243
DI 10.1111/j.0105 1873.2006.00797.x
PG 5
WC Allergy; Dermatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Allergy; Dermatology
GA 041NU
UT WOS:000237463700002
PM 16689806
DA 2025 08 17
ER

PT J
AU Bansal, SS
   Joshi, A
   Bansal, AK
AF Bansal, Shyam S.
   Joshi, Abhijeet
   Bansal, Arvind K.
TI New dosage formulations for targeted delivery of cyclo oxygenase 2
   inhibitors   Focus on use in the elderly
SO DRUGS & AGING
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; DIABETIC RETINOPATHY; LUNG CANCER;
   IN VITRO; CYCLOOXYGENASE INHIBITORS; PENETRATION ENHANCERS; INTRAOCULAR
   DELIVERY; SUSTAINED RELEASE; COX 2 INHIBITORS; NIMESULIDE GEL
AB NSAIDs are a widely used class of analgesic and anti inflammatory drugs that act by inhibiting the cyclo oxygenase (COX) enzyme. However, because of their nonspecificity of action, use of these agents as long term therapy for chronic pain in diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA) is often discouraged. Among NSAIDs, COX 2 inhibitors are promising candidates for long term therapy of chronic diseases, particularly in the elderly, because of their reduced incidence of gastrointestinal adverse effects. However, in recent times these agents have also been shown to cause adverse effects such as cardiovascular effects (myocardial infarction, stroke and hypertension) and renal effects (decreased renal blood flow/glomerular filtration rate), which in 2004 led to the withdrawal of rofecoxib and in 2005 the withdrawal of valdecoxib from the US market. Importantly, these adverse effects can be effectively reduced by achieving site specific/targeted delivery through new formulation approaches. These formulations not only restrict the drug supply to specific organs but also reduce the dose required. As a result, use of now delivery systems such as nanoparticles, microparticles, microemulsions and nanogels has gained widespread applicability in the management of chronic disease, especially in the elderly, and particularly when there is a need to decrease dose dependent adverse effects (as is the case with COX 2 inhibitors). This article reviews various new approaches to the delivery of COX 2 inhibitors and highlights issues related to the development of delivery systems for these agents for RA, OA, cancer (familial adenomatous polyposis, prostate, breast and non small cell lung cancer), ocular diseases (such as diabetic retinopathy) and inflammatory diseases of the skin, with emphasis on their potential for use in the elderly. Emphasis is also placed on the preparation of these particulate systems, their release profile and behaviour in biological systems.
C1 Natl Inst Pharmaceut Educ & Res, Dept Pharmaceut, SAS Nagar, Punjab, India.
   Natl Inst Pharmaceut Educ & Res, Dept Pharmaceut Technol, SAS Nagar, Punjab, India.
C3 National Institute of Pharmaceutical Education & Research, S.A.S. Nagar
   (Mohali); National Institute of Pharmaceutical Education & Research,
   S.A.S. Nagar (Mohali)
RP Bansal, SS (通讯作者)，Natl Inst Pharmaceut Educ & Res, Dept Pharmaceut, SAS Nagar, Punjab, India.
EM akbansal@niper.ac.in
RI Bansal, Arvind/ABG 4929 2020
CR Aiello LP, 1998, DIABETES CARE, V21, P143, DOI 10.2337/diacare.21.1.143
   Alves PM, 2005, PHARMAZIE, V60, P900
   Amrite AC, 2006, INVEST OPHTH VIS SCI, V47, P1149, DOI 10.1167/iovs.05 0531
   Amrite AC, 2005, J PHARM PHARMACOL, V57, P1555, DOI 10.1211/jpp.57.12.0005
   ASSIL KK, 1988, OPHTHALMIC SURG LAS, V19, P408
   Ayalasomayajula SP, 2005, EUR J PHARMACOL, V511, P191, DOI 10.1016/j.ejphar.2005.02.019
   Ayalasomayajula SP, 2004, PHARM RES DORDR, V21, P1797, DOI 10.1023/B:PHAM.0000045231.51924.e8
   Ayalasomayajula SP, 2004, EUR J PHARMACOL, V498, P275, DOI 10.1016/j.ejphar.2004.07.046
   BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307
   Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153
   Barry BW, 2001, EUR J PHARM SCI, V14, P101, DOI 10.1016/S0928 0987(01)00167 1
   Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   BOMMANNAN DB, 1994, PHARMACEUT RES, V11, P1809, DOI 10.1023/A:1018983804635
   CASTRO V, 2005, J PHARM PHARM S, V57, pS85
   Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699
   Cheruvu N. P. S., 2003, DRUG DELIV TECHNOL, V3, P62
   Chetoni P, 1996, J OCUL PHARMACOL TH, V12, P245, DOI 10.1089/jop.1996.12.245
   Chowdhury DK, 2000, PHARM DEV TECHNOL, V5, P279, DOI 10.1081/PDT 100100542
   COUVREUR P, 1995, EUR J PHARM BIOPHARM, V41, P2
   Cryer B, 1998, AM J MED, V104, P413, DOI 10.1016/S0002 9343(98)00091 6
   CUSACK BJ, 2004, AM J GERIATR PHARMAC, V2, P275
   Dannhardt G, 2001, EUR J MED CHEM, V36, P109, DOI 10.1016/S0223 5234(01)01197 7
   DINGLE JT, 1978, NATURE, V271, P372, DOI 10.1038/271372a0
   DOLOVICH M, 1993, AEROSOL SCI TECH, V18, P230, DOI 10.1080/02786829308959600
   EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016 5085(94)90246 1
   Emery P, 2002, CLIN THER, V24, P1225, DOI 10.1016/S0149 2918(02)80033 9
   Erdogan F, 2006, INT J CLIN PHARM TH, V44, P270
   Estensen RD, 2004, CARCINOGENESIS, V25, P197, DOI 10.1093/carcin/bgg196
   FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288
   Freitas MN, 2005, INT J PHARMACEUT, V295, P201, DOI 10.1016/j.ijpharm.2005.03.003
   Friend DR, 2005, ADV DRUG DELIVER REV, V57, P247, DOI 10.1016/j.addr.2004.08.011
   Gasparini G, 2003, LANCET ONCOL, V4, P605, DOI 10.1016/S1470 2045(03)01220 8
   Gautam A, 2002, GENE THER, V9, P353, DOI 10.1038/sj.gt.3301662
   Gautam A, 2003, CURR CANCER DRUG TAR, V3, P287, DOI 10.2174/1568009033481912
   GREEN PG, 1992, J CONTROL RELEASE, V21, P187, DOI 10.1016/0168 3659(92)90020 R
   Güngör S, 2004, PHARMAZIE, V59, P39
   Haupt S, 2006, EUR J PHARM SCI, V28, P204, DOI 10.1016/j.ejps.2006.02.001
   Haynes A, 2005, PHARM RES DORDR, V22, P427, DOI 10.1007/s11095 004 1881 z
   Haynes A, 2003, PHARM RES DORDR, V20, P1485, DOI 10.1023/A:1025774630993
   Hersh EV, 2005, CURR MED RES OPIN, V21, P1217, DOI 10.1185/030079905X56367
   INOO K, 2005, Patent No. 20050020658
   Johnson AG, 1998, DRUG AGING, V12, P17, DOI 10.2165/00002512 199812010 00003
   Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01 0707fje
   Kanikkannan N, 2001, J CONTROL RELEASE, V71, P99, DOI 10.1016/S0168 3659(01)00208 5
   Katsuma M, 2002, INT J PHARMACEUT, V249, P33, DOI 10.1016/S0378 5173(02)00429 5
   KLEIN R, 1989, OPHTHALMOLOGY, V96, P1501
   Koshkina NV, 2003, CURR CANCER DRUG TAR, V3, P251, DOI 10.2174/1568009033481930
   Kunou N, 2000, J BIOMED MATER RES, V51, P635, DOI 10.1002/1097 4636(20000915)51:4<635::AID JBM11>3.0.CO;2 O
   LANG JC, 1995, ADV DRUG DELIVER REV, V16, P39, DOI 10.1016/0169 409X(95)00012 V
   Lawson KA, 2003, MOL CANCER THER, V2, P437
   Le Bourlais C, 1998, PROG RETIN EYE RES, V17, P33, DOI 10.1016/S1350 9462(97)00002 5
   Lee JL, 2003, TOXICOL APPL PHARM, V192, P294, DOI 10.1016/S0041 008X(03)00301 6
   LEWIS DA, 1992, J PHARM PHARMACOL, V44, P271, DOI 10.1111/j.2042 7158.1992.tb03600.x
   LIM J, 2005, PFITZERS VOLUNTARY S
   Maier TJ, 2004, BIOCHEM PHARMACOL, V67, P1469, DOI 10.1016/j.bcp.2003.12.014
   Marnett LJ, 1999, TRENDS PHARMACOL SCI, V20, P465, DOI 10.1016/S0165 6147(99)01385 1
   MAROUF W, 2005, J PHARM PHARM S, V57, pS88
   McGeer PL, 2000, DRUG AGING, V17, P1, DOI 10.2165/00002512 200017010 00001
   MEIDAN VM, 1995, INT J PHARMACEUT, V118, P129, DOI 10.1016/0378 5173(94)00371 B
   Miller K, 2002, DRUG AGING, V19, P393, DOI 10.2165/00002512 200219060 00001
   Motsko SP, 2006, DRUG SAFETY, V29, P621, DOI 10.2165/00002018 200629070 00007
   Olsen SR, 2005, BIOMED PHARMACOTHER, V59, pS306, DOI 10.1016/S0753 3322(05)80052 6
   Panchagnula Ramesh, 1997, Indian Journal of Pharmacology, V29, P140
   Park JH, 2005, J CONTROL RELEASE, V104, P51, DOI 10.1016/j.jconrel.2005.02.002
   Park K, 2005, J CONTROL RELEASE, V104, P167, DOI 10.1016/j.jconrel.2005.01.013
   Patrignani P, 2005, BRAIN RES REV, V48, P352, DOI 10.1016/j.brainresrev.2004.12.024
   Price DD, 1996, PAIN, V68, P119, DOI 10.1016/S0304 3959(96)03183 1
   Riedl K, 2004, DRUG RESIST UPDATE, V7, P169, DOI 10.1016/j.drup.2004.04.003
   Savage R, 2005, DRUG AGING, V22, P185, DOI 10.2165/00002512 200522030 00001
   Sengupta S, 1998, EUR J CLIN PHARMACOL, V54, P541, DOI 10.1007/s002280050510
   Shahiwala A, 2002, J PHARM PHARM SCI, V5, P220
   Singh Bhupinder, 2005, Current Drug Delivery, V2, P143
   Singh M. Meghachandra, 1997, Indian Journal of Ophthalmology, V45, P61
   Srinath P, 2000, Pharm Acta Helv, V74, P399, DOI 10.1016/S0031 6865(00)00023 6
   Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603
   Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165 6147(02)00043 3
   Thakkar H, 2005, ARS PHARM, V46, P19
   Thakkar H, 2004, J PHARM PHARMACOL, V56, P1091, DOI 10.1211/0022357044166
   Thakkar Hetal, 2005, AAPS PharmSciTech, V6, pE65, DOI 10.1208/pt060112
   Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092 8674(00)81433 6
   WALLACE JL, 1999, TIPS, V20, P389
   WILLIAMS AC, 1992, CRIT REV THER DRUG, V9, P305
   Williams AC, 2004, ADV DRUG DELIVER REV, V56, P603, DOI 10.1016/j.addr.2003.10.025
   Wormald R, 1999, Community Eye Health, V12, P6
NR 84
TC 19
Z9 21
U1 0
U2 6
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170 229X
EI 1179 1969
J9 DRUG AGING
JI Drugs Aging
PY 2007
VL 24
IS 6
BP 441
EP 451
DI 10.2165/00002512 200724060 00001
PG 11
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 189JV
UT WOS:000247986100001
PM 17571910
DA 2025 08 17
ER

PT J
AU Wang, HJ
   Liu, Y
   Fan, LQ
   Han, CL
   Jiang, Y
   Cheng, SJ
   Li, Y
AF Wang, Hai jun
   Liu, Yu
   Fan, Li qiao
   Han, Cai li
   Jiang, Ye
   Cheng, Shu jie
   Li, Yong
TI A new bisphosphonate derivative, CP, induces gastric cancer cell
   apoptosis via activation of the ERK1/2 signaling pathway
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE gastric cancer; anticancer drug; bisphosphonate; apoptosis; xenograft
   nude mouse model; ERK1/2
ID ZOLEDRONIC ACID; BREAST CANCER; BONE METASTASES; IN VITRO; CYCLE ARREST;
   IBANDRONATE; CASPASE; INHIBIT; LINES; EXPRESSION
AB Aim: To investigate the effects of a new derivative of bisphosphonates, [2 (6 aminopurine 9 yl) 1 hydroxy phosphine acyl ethyl] phosphonic acid (CP), on human gastric cancer.
   Methods: Human gastric cancer cell lines (SGC 7901, BGC 823, MKN 45, and MKN 28) and human colon carcinoma cell lines (LoVo and HT 29) were tested. Cell growth was determined using the MTT assay. Flow cytometry, Western blot, caspase activity assay and siRNA transfection were used to examine the mechanisms of anticancer action. Female BALB/c nude mice were implanted with SGC 7901 cells. From d6 after inoculation, the animals were injected with CP (200 mu g/kg, ip) or vehicle daily for 24 d.
   Results: CP suppressed the growth of the 6 human cancer cell lines with similar IC50 values (3239 mu mol/L). In SGC 7901 cells, CP arrested cell cycle progression at the G(2)/M phase. The compound activated caspase 9, increased the expression of pro apoptotic proteins Bax and Bad, decreased the expression of anti apoptotic protein Bcl 2. Furthermore, the compound selectively activated ERK1/2 without affecting JNK and p38 in SGC 7901 cells. Treatment of SGC 7901 cells with the specific ERK1/2 inhibitor PD98059 or ERK1/2 siRNA hampered CP mediated apoptosis. In the human gastric cancer xenograft nude mouse model, chronic administration of CP significantly retarded the tumor growth.
   Conclusion: CP is a broad spectrum inhibitor of human carcinoma cells in vitro, and it also exerts significant inhibition on gastric cancer cell growth in vivo. CP induces human gastric cancer apoptosis via activation of the ERK1/2 signaling pathway.
C1 [Wang, Hai jun; Fan, Li qiao; Li, Yong] Hebei Med Univ, Affiliated Hosp 4, Dept Surg, Shijiazhuang 050011, Peoples R China.
   [Liu, Yu] Hebei Med Univ, Tradit Chinese Med Coll, Dept Biochem & Mol Biol, Shijiazhuang 050091, Peoples R China.
   [Han, Cai li] Hebei Med Univ, Inst Basic Med, Dept Pathol, Shijiazhuang 050017, Peoples R China.
   [Jiang, Ye] Hebei Med Univ, Coll Pharm, Dept Pharm, Shijiazhuang 050017, Peoples R China.
   [Wang, Hai jun; Cheng, Shu jie] Hebei Univ, Affiliated Hosp, Dept Surg, Baoding 071000, Peoples R China.
C3 Hebei Medical University; Hebei Medical University; Hebei Medical
   University; Hebei Medical University; Hebei University
RP Li, Y (通讯作者)，Hebei Med Univ, Affiliated Hosp 4, Dept Surg, Shijiazhuang 050011, Peoples R China.
EM li_yong_hbth@126.com
RI Liu, Lu/AAM 4152 2020
FU National Natural Science Foundation of China [81072033]
FX This research was supported by the National Natural Science Foundation
   of China (No 81072033).
CR Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322
   Bergner R, 2007, J CLIN PHARMACOL, V47, P942, DOI 10.1177/0091270007301801
   Boissier S, 2000, CANCER RES, V60, P2949
   Bundred N, 2012, CANCER TREAT REV, V38, P776, DOI 10.1016/j.ctrv.2012.02.002
   Chambon JP, 2002, DEVELOPMENT, V129, P3105
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   Daubine F, 2011, ANTICANCER RES, V31, P4141
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Han LL, 2009, ENVIRON TOXICOL PHAR, V28, P97, DOI 10.1016/j.etap.2009.03.005
   Hiraga T, 2001, CANCER RES, V61, P4418
   Jiang C, 2001, CANCER RES, V61, P3062
   Kiagia M, 2006, ANTICANCER RES, V26, P3133
   Kim GS, 2003, J BIOL CHEM, V278, P21920, DOI 10.1074/jbc.M204598200
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Lee MV, 2001, CANCER RES, V61, P2602
   Lipton A, 2007, ONCOLOGIST, V12, P1035, DOI 10.1634/theoncologist.12 9 1035
   Liu ZF, 2006, J MED MICROBIOL, V55, P1009, DOI 10.1099/jmm.0.46456 0
   Lowe LC, 2005, BIOCHEM BIOPH RES CO, V329, P772, DOI 10.1016/j.bbrc.2005.02.032
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Modi PK, 2012, MOL BIOL CELL, V23, P3722, DOI 10.1091/mbc.E12 02 0125
   Mohanty IR, 2008, CLIN NUTR, V27, P635, DOI 10.1016/j.clnu.2008.05.006
   Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092 8674(03)01080 8
   NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0
   Nicholson DW, 2003, SCIENCE, V299, P214, DOI 10.1126/science.1081274
   Oura Shoji, 2003, Breast Cancer, V10, P28, DOI 10.1007/BF02967622
   Pazianas M, 2012, OSTEOPOROSIS INT, V23, P2693, DOI 10.1007/s00198 012 1902 4
   Pietenpol JA, 2002, TOXICOLOGY, V181, P475, DOI 10.1016/S0300 483X(02)00460 2
   Rodrigues P, 2011, CANCER RES TREAT, V43, P231, DOI 10.4143/crt.2011.43.4.231
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Stefanelli C, 2002, FEBS LETT, V527, P223, DOI 10.1016/S0014 5793(02)03242 8
   Tamm I, 2001, LANCET ONCOL, V2, P33, DOI 10.1016/S1470 2045(00)00193 5
   Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Thaler R, 2013, BIOCHEM PHARMACOL, V85, P173, DOI 10.1016/j.bcp.2012.10.016
   Trojan J, 2005, ANTI CANCER DRUG, V16, P87, DOI 10.1097/00001813 200501000 00013
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841
   Verdijk R, 2007, CANCER LETT, V246, P308, DOI 10.1016/j.canlet.2006.03.011
   Yamada Jun, 2006, Proceedings of the American Association for Cancer Research Annual Meeting, V47, P895
   Yang R, 2008, CLIN CANCER RES, V14, P6396, DOI 10.1158/1078 0432.CCR 07 5113
   Ye J, 2008, China patent, Patent No. [200710185250.7, 2007101852507]
NR 45
TC 11
Z9 13
U1 0
U2 20
PU ACTA PHARMACOLOGICA SINICA
PI SHANGHAI
PA 294 TAI YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1671 4083
EI 1745 7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD DEC
PY 2013
VL 34
IS 12
BP 1535
EP 1544
DI 10.1038/aps.2013.103
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 269UV
UT WOS:000328268600007
PM 24241351
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Sharma, D
   Hamlet, SM
   Petcu, EB
   Ivanovski, S
AF Sharma, Dileep
   Hamlet, Stephen Mark
   Petcu, Eugen Bogdan
   Ivanovski, Saso
TI The effect of bisphosphonates on the endothelial differentiation of
   mesenchymal stem cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID STROMAL CELLS; OSTEONECROSIS; JAW; ANGIOGENESIS; PAMIDRONATE;
   MECHANISMS; DECREASE; THERAPY
AB The contribution of the local stem cell niche to providing an adequate vascular framework during healing cannot be overemphasized. Bisphosphonates (BPs) are known to have a direct effect on the local vasculature, but their effect on progenitor cell differentiation is unknown. This in vitro study evaluated the effect(s) of various BPs on the differentiation of human placental mesenchymal stem cells (pMSCs) along the endothelial lineage and their subsequent functional and morphogenic capabilities. pMSC multipotency was confirmed by successful differentiation into cells of both the osteogenic and endothelial lineages, as demonstrated by positive Alizarin Red S staining and Ac LDL uptake. pMSC differentiation in the presence of non cytotoxic BP concentrations showed that nitrogen containing BPs had a significant inhibitory effect on cell migration and endothelial marker gene expression, as well as compromised endothelial differentiation as demonstrated using von Willebrand factor immunofluorescence staining and tube formation assay. This in vitro study demonstrated that at non cytotoxic levels, nitrogen containing BPs inhibit differentiation of pMSCs into cells of an endothelial lineage and affect the downstream functional capability of these cells supporting a multi modal effect of BPs on angiogenesis as pathogenic mechanism contributing to bone healing disorders such as bisphosphonate related osteonecrosis of the jaws (BRONJ).
C1 [Sharma, Dileep; Hamlet, Stephen Mark; Ivanovski, Saso] Griffith Univ, Sch Dent & Oral Hlth, QLD, Mol Basis Dis Grp,Regenerat Med Ctr,Menzies Hlth, Gold Coast Campus, Nathan, Qld 4111, Australia.
   [Petcu, Eugen Bogdan] Griffith Univ, Sch Med, QLD, Mol Basis Dis Grp,Regenerat Med Ctr,Menzies Hlth, Gold Coast Campus, Nathan, Qld 4111, Australia.
C3 Griffith University; Griffith University
RP Ivanovski, S (通讯作者)，Griffith Univ, Sch Dent & Oral Hlth, QLD, Mol Basis Dis Grp,Regenerat Med Ctr,Menzies Hlth, Gold Coast Campus, Nathan, Qld 4111, Australia.
EM s.ivanovski@griffith.edu.au
RI Sharma, Dileep/G 5394 2015; Petcu, Eugen/C 3824 2011; SHARMA,
   DILEEP/G 5394 2015; Ivanovski, Saso/I 1835 2016
OI Petcu, Eugen/0000 0001 5726 729X; SHARMA, DILEEP/0000 0003 4463 1480; 
FU Australian Dental Research Foundation grant (ADRF Grant) [86 2014]
FX The authors would like to acknowledge Professor Kiarash Khosrotehrani,
   UQCCR, The University of Queensland, for providing the pMSCs used in the
   study. This work was funded by the Australian Dental Research Foundation
   grant (ADRF Grant No. 86 2014).
CR Allegra A, 2007, HEMATOL ONCOL, V25, P164, DOI 10.1002/hon.819
   Allegra A, 2010, ACTA HAEMATOL BASEL, V124, P79, DOI 10.1159/000313787
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Asatrian G, 2015, STEM CELLS CLONING, V8, P39, DOI 10.2147/SCCAA.S48423
   Assaf AT, 2013, ANTICANCER RES, V33, P3917
   Berenson James R, 2011, Curr Opin Support Palliat Care, V5, P233, DOI 10.1097/SPC.0b013e328349dc17
   Carvalho MM, 2011, CURR STEM CELL RES T, V6, P221
   Chen CY, 2015, BIOL REPROD, V93, DOI 10.1095/biolreprod.115.131250
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Fischer J, 2007, J Stem Cells Regen Med, V2, P121
   Gebäck T, 2009, BIOTECHNIQUES, V46, P265, DOI 10.2144/000113083
   Grayson WL, 2015, NAT REV ENDOCRINOL, V11, P140, DOI 10.1038/nrendo.2014.234
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Kita K, 2010, STEM CELLS DEV, V19, P491, DOI 10.1089/scd.2009.0192
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   McGuckin C, 2008, NAT PROTOC, V3, P1046, DOI 10.1038/nprot.2008.69
   Montanucci P, 2011, TISSUE ENG PT A, V17, P2651, DOI [10.1089/ten.tea.2010.0587, 10.1089/ten.TEA.2010.0587]
   Mueller AA, 2014, PLAST RECONSTR SURG, V134, p59E, DOI 10.1097/PRS.0000000000000305
   Oswald J, 2004, STEM CELLS, V22, P377, DOI 10.1634/stemcells.22 3 377
   Otto S, 2010, J ORAL MAXIL SURG, V68, P2837, DOI 10.1016/j.joms.2010.07.017
   Parfitt AM, 2008, OSTEOPOROSIS, VOLS I AND II, 3RD EDITION, P71
   Patel J, 2014, PLACENTA, V35, P969, DOI 10.1016/j.placenta.2014.09.001
   Petcu EB, 2002, J PAIN SYMPTOM MANAG, V24, P281, DOI 10.1016/S0885 3924(02)00478 5
   Pichardo SEC, 2013, OR SURG OR MED OR PA, V116, P287, DOI 10.1016/j.oooo.2013.05.005
   Portalska KJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046842
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Ribatti D., 2008, ONCOLOGY REPORTS
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Santini D, 2007, CLIN CANCER RES, V13, P4482, DOI 10.1158/1078 0432.CCR 07 0551
   Santini D, 2013, ONCOLOGY BASEL, V85, P342, DOI 10.1159/000347226
   Sharma D., 2014, ZOLEDRONIC ACID CLIN, P173
   Sharma D, 2013, VASC CELL, V5, DOI 10.1186/2045 824X 5 1
   Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696
   Terpos E, 2011, CRIT REV ONCOL HEMAT, V77, pS13, DOI 10.1016/S1040 8428(11)70004 X
   VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034
   Walter C, 2011, ORAL DIS, V17, P194, DOI 10.1111/j.1601 0825.2010.01720.x
   Wehrhan F, 2011, ORAL SURG ORAL MED O, V112, P216, DOI 10.1016/j.tripleo.2011.02.028
   Xie N., 2015, J CELL MOL MED
NR 40
TC 29
Z9 30
U1 0
U2 11
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD FEB 9
PY 2016
VL 6
AR 20580
DI 10.1038/srep20580
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DC9ZI
UT WOS:000369579700001
PM 26857282
OA Green Published, Green Submitted, Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Pal, S
   Kumar, P
   Ramakrishna, E
   Kumar, S
   Porwal, K
   Kumar, B
   Arya, KR
   Maurya, R
   Chattopadhyay, N
AF Pal, Subhashis
   Kumar, Padam
   Ramakrishna, Eppalapally
   Kumar, Sudhir
   Porwal, Konica
   Kumar, Brijesh
   Arya, Kamal R.
   Maurya, Rakesh
   Chattopadhyay, Naibedya
TI Extract and fraction of Cassia occidentalis L. (a synonym of
   Senna occidentalis) have osteogenic effect and prevent
   glucocorticoid induced osteopenia
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Folk medicine; Osteoanabolic; Anti resorptive; Fracture healing;
   Glucocorticoid induced osteoporosis; Bone strength
ID BONE MINERAL DENSITY; INDUCED OSTEOPOROSIS; BODY COMPOSITION;
   EXPRESSION; ACTIVATION; MECHANISMS; OSTEOCYTES; APOPTOSIS; INCREASE;
   PEPTIDE
AB Ethnopharmacological relevance: Cassia occidentalis L., a synonym of Senna occidentalis (belongs to Caesalpiniaceae family) is an annual plant. Pursuing a lead from a folk practice prevalent since the late nineteenth century in Andhra Pradesh, a Southern state of India, of use of Cassia occidentalis leaf and stem for treating patients with fracture and bone diseases, we have not only confirmed its fracture healing activity but also demonstrated efficacy in preventing glucocorticoid induced osteoporosis (GIO), the commonest form of medication induced bone loss caused chiefly due to impairment of bone formation.
   Aim of the study: In the present work, the effects of extract and fraction of leaf and stem of Cassia occidentalis was investigated in fracture healing and GIO models of rat. The study also aimed to identify osteogenic compounds from this plant.
   Materials and methods: Ethanolic extracts from leaf and stem of Cassia occidentalis were prepared and their efficacy tested in rat femur osteotomy (fracture healing) model. Subsequently, a butanolic fraction was prepared and osteogenic efficacy compared with the ethanolic extract, and upon finding the former to be more potent, its osteogenic effect was studied in details in GIO model. Chemical finger printing and isolation of ten pure compounds were done to assess their osteogenic effect in rat primary osteoblast cultures.
   Results: Ethanolic extract of stem was more effective than the leaf extract in enhancing bone regeneration at the site of osteotomy. Further, butanolic fraction of the ethanolic extract of stem was more effective than the later in bone regeneration at the femur osteotomy site and in preventing bone loss in GIO model. The mechanism of skeletal preservation involved stimulation of new bone formation and inhibition of bone resorption. As many as six osteogenic compounds were isolated out of which apigenin 6C glucopyranoside was most effective in vitro.
   Conclusion: Our study found that a standardized extract of an ethanolic extract and its butanolic fraction from the stem of Cassia occidentalis has osteogenic as well as anti resorptive effects, resulting in the protection against glucocorticoid induced bone loss. Our results contribute towards validation of the traditional use of Cassia occidentalis in fracture healing and also suggest its beneficial use in GIO for which clinical trials are warranted.
C1 [Pal, Subhashis; Porwal, Konica; Chattopadhyay, Naibedya] CSIR, Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
   [Kumar, Padam; Ramakrishna, Eppalapally; Kumar, Sudhir; Maurya, Rakesh] CSIR CDRI, Div Med & Proc Chem, Lucknow, Uttar Pradesh, India.
   [Kumar, Brijesh] CSIR CDRI, Sophisticated Analyt Instrument Facil, Lucknow, Uttar Pradesh, India.
   [Arya, Kamal R.] CSIR CDRI, Div Ethnobot, Lucknow, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI); Council of Scientific & Industrial Research (CSIR)  
   India; CSIR   Central Drug Research Institute (CDRI); Council of
   Scientific & Industrial Research (CSIR)   India; CSIR   Central Drug
   Research Institute (CDRI)
RP Chattopadhyay, N (通讯作者)，CSIR, Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
EM n_chattopadhyay@cdri.res.in
RI ; Kumar, Pradeep/GQA 7930 2022; Technical University for Women,
   Professor, Indira Gandhi Delhi/A 7485 2012; Pal,
   Subhashis/IXD 3635 2023; maurya, rakesh/AAV 7598 2021; Kumar, Prof.
   Brijesh/A 7485 2012; Chattopadhyay, Naibedya/AAF 2058 2019
OI Pal, Subhashis/0000 0002 3916 5545; Technical University for Women,
   Professor, Indira Gandhi Delhi/0000 0003 0271 3445; Chattopadhyay,
   Naibedya/0000 0003 2473 0246; Porwal, Konica/0000 0002 6447 4681; 
FU Council of Scientific and Industrial Research of Government of India
   [BSC0201]; CSIR Phytopharmaceuticals Mission Project, Government of
   India [HCP0010]
FX Council of Scientific and Industrial Research of (BSC0201), Government
   of India, and CSIR Phytopharmaceuticals Mission Project (HCP0010 to
   N.C.), Government of India.
CR Abu Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100
   Alwahsh MAA, 2015, REC NAT PROD, V9, P159
   Baker MS, 2015, INT J OBESITY, V39, P98, DOI 10.1038/ijo.2013.146
   BANKS SW, 1982, PHYTOCHEMISTRY, V21, P2235, DOI 10.1016/0031 9422(82)85184 4
   BERESTETSKII O A, 1975, Mikologiya i Fitopatologiya, V9, P325
   Bouvard B, 2009, OSTEOPOROSIS INT, V20, P1089, DOI 10.1007/s00198 009 0864 7
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Carpinteri R, 2010, J Endocrinol Invest, V33, P16
   Chen FJ, 2014, CALCIFIED TISSUE INT, V94, P640, DOI 10.1007/s00223 014 9847 6
   China SP, 2017, BONE, V105, P75, DOI 10.1016/j.bone.2017.08.005
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Eastell R, 1998, J INTERN MED, V244, P271, DOI 10.1046/j.1365 2796.1998.00408.x
   Fraser LA, 2009, THER ADV MUSCULOSKEL, V1, P71, DOI 10.1177/1759720X09343729
   Hamed MM, 2015, ORIENT J CHEM, V31, P1133, DOI 10.13005/ojc/310266
   Hara K, 2002, BONE, V31, P575, DOI 10.1016/S8756 3282(02)00874 8
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Hunter R, 2014, J PHYSIOL LONDON, V592, P1731, DOI 10.1113/jphysiol.2013.267609
   Ito H, 2004, CHEM PHARM BULL, V52, P1262, DOI 10.1248/cpb.52.1262
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Júnior GMV, 2008, HELV CHIM ACTA, V91, P2159, DOI 10.1002/hlca.200890233
   Khan K, 2013, OSTEOPOROSIS INT, V24, P1455, DOI 10.1007/s00198 012 2121 8
   Khan MP, 2013, PHYTOMEDICINE, V20, P1256, DOI 10.1016/j.phymed.2013.07.007
   Klein Gordon L, 2015, Osteoporos Sarcopenia, V1, P39, DOI 10.1016/j.afos.2015.07.008
   Lems WF, 2007, ARTHRITIS RHEUM US, V56, P3518, DOI 10.1002/art.22975
   Li SF, 2010, HELV CHIM ACTA, V93, P1795, DOI 10.1002/hlca.200900460
   Li X, 2008, MOLECULES, V13, P1530, DOI 10.3390/molecules13081530
   Lin LC, 2015, J AGR FOOD CHEM, V63, P7700, DOI 10.1021/jf505848z
   Liu XY, 2011, EXP THER MED, V2, P977, DOI 10.3892/etm.2011.292
   Lu Tai sheng, 2001, Yaoxue Xuebao, V36, P547
   Mittal M, 2017, TOXICOL APPL PHARM, V316, P63, DOI 10.1016/j.taap.2016.12.013
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Pal S, 2016, TOXICOL APPL PHARM, V295, P12, DOI 10.1016/j.taap.2016.02.002
   Piemontese M, 2016, AM J PHYSIOL ENDOC M, V311, pE587, DOI 10.1152/ajpendo.00219.2016
   Rao A. S., 2012, Journal of Pharmacognosy, V3, P121
   Schäcke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163 7258(02)00297 8
   Silva MGB, 2011, J ETHNOPHARMACOL, V136, P341, DOI 10.1016/j.jep.2011.04.070
   Singh Vibha, 2017, Natl J Maxillofac Surg, V8, P4, DOI 10.4103/0975 5950.208972
   Taicher GZ, 2003, ANAL BIOANAL CHEM, V377, P990, DOI 10.1007/s00216 003 2224 3
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Traslavina RP, 2010, J AM ASSOC LAB ANIM, V49, P316
   Tripathi JK, 2015, BIOMATERIALS, V56, P92, DOI 10.1016/j.biomaterials.2015.03.046
   Wu SF, 2016, MED SCI MONITOR, V22, P145, DOI 10.12659/MSM.895512
   Yadav JP, 2010, FITOTERAPIA, V81, P223, DOI 10.1016/j.fitote.2009.09.008
   Yonemura K, 1999, CALCIFIED TISSUE INT, V65, P267, DOI 10.1007/s002239900696
NR 44
TC 33
Z9 33
U1 1
U2 15
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD MAY 10
PY 2019
VL 235
BP 8
EP 18
DI 10.1016/j.jep.2019.01.029
PG 11
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA HR4OW
UT WOS:000463126800002
PM 30703497
DA 2025 08 17
ER

PT J
AU Wang, C
   Liu, C
   Liang, C
   Qu, XY
   Zou, XY
   Du, SY
   Zhang, Q
   Wang, L
AF Wang, Chang
   Liu, Chang
   Liang, Chen
   Qu, Xingyuan
   Zou, Xinying
   Du, Siyu
   Zhang, Qian
   Wang, Lei
TI Role of Berberine Thermosensitive Hydrogel in Periodontitis via PI3K/AKT
   Pathway In Vitro
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE periodontitis; berberine; thermosensitive hydrogel; anti inflammatory;
   osteogenesis
ID OSTEOBLAST DIFFERENTIATION; CELLS
AB Periodontitis is a long term inflammatory illness and a leading contributor to tooth loss in humans. Due to the influence of the anatomic parameters of teeth, such as root bifurcation lesions and the depth of the periodontal pocket, basic periodontal treatment on its own often does not completely obliterate flora microorganisms. As a consequence, topical medication has become a significant supplement in the treatment of chronic periodontitis. Berberine (BBR) has various pharmacological effects, such as hypoglycemic, antitumor, antiarrhythmic, anti inflammatory, etc. The target of our project is to develop a safe and non toxic carrier that can effectively release berberine, which can significantly reduce periodontal tissue inflammation, and to investigate whether berberine thermosensitive hydrogel can exert anti inflammatory and osteogenic effects by modulating phosphatifylinositol 3 kinase/Protein Kinase B (PI3K/AKT) signaling pathway. Consequently, firstly berberine temperature sensitive hydrogel was prepared, and its characterizations showed that the mixed solution gelated within 3 min under 37 degrees C with a hole diameter of 10 130 mu m, and the accumulation of berberine release amounted to 89.99% at 21 days. CCK 8 and live dead cell staining results indicated that this hydrogel was not biotoxic, and it is also presumed that the optimum concentration of berberine is 5 mu M, which was selected for subsequent experiments. Real time polymerase chain reaction (qRT PCR) and Western blotting (WB)results demonstrated that inflammatory factors, as well as protein levels, were significantly reduced in the berberine loaded hydrogel group, and LY294002 (PI3K inhibitor) could enhance this effect (p < 0.05). In the berberine loaded hydrogel group, osteogenesis related factor levels and protein profiles were visibly increased, along with an increase in alkaline phosphatase expression, which was inhibited by LY294002 (p < 0.05). Therefore, berberine thermosensitive hydrogel may be an effective treatment for periodontitis, and it may exert anti inflammatory and osteogenic effects through the PI3K/AKT signaling pathway.
C1 [Wang, Chang; Liang, Chen; Qu, Xingyuan; Du, Siyu; Zhang, Qian; Wang, Lei] Jilin Univ, Hosp Stomatol, Dept Periodontol, 1500 Tsinghua Rd, Changchun 130021, Peoples R China.
   [Liu, Chang] Jilin Univ, Hosp Stomatol, Dept Prosthodont, Changchun 130021, Peoples R China.
   [Zou, Xinying] Jilin Univ, Hosp Stomatol, Dept Endodont, Changchun 130021, Peoples R China.
C3 Jilin University; Jilin University; Jilin University
RP Wang, L (通讯作者)，Jilin Univ, Hosp Stomatol, Dept Periodontol, 1500 Tsinghua Rd, Changchun 130021, Peoples R China.
EM wangchang20@mails.jlu.edu.cn; wang_lei99@jlu.edu.cn
RI li, tao/JVO 9006 2024; Liang, Chen/HNP 5916 2023
FU Science and Technology Development Program Project of Jilin Province
   [20200201389JC]
FX This work was funded by the Science and Technology Development Program
   Project of Jilin Province (20200201389JC).
CR Bagher Z, 2021, INT J POLYM MATER PO, V70, P299, DOI 10.1080/00914037.2020.1713781
   Beck GR, 2003, J CELL BIOCHEM, V90, P234, DOI 10.1002/jcb.10622
   Braz Silva PH, 2019, ACTA ODONTOL SCAND, V77, P173, DOI 10.1080/00016357.2018.1521005
   Chen JY, 2022, FRONT NUTR, V9, DOI 10.3389/fnut.2022.851255
   Chen XY, 2018, MOL MED REP, V18, P4468, DOI 10.3892/mmr.2018.9476
   Chenite A, 2000, BIOMATERIALS, V21, P2155, DOI 10.1016/S0142 9612(00)00116 2
   Choi JK, 2016, TOXICOL APPL PHARM, V290, P1, DOI 10.1016/j.taap.2015.11.005
   Galimanas V, 2014, MICROBIOME, V2, DOI 10.1186/2049 2618 2 32
   Gao CD, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.59
   Garakani SS, 2020, INT J BIOL MACROMOL, V143, P533, DOI 10.1016/j.ijbiomac.2019.12.040
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Greenstein G, 2000, J AM DENT ASSOC, V131, P1580, DOI 10.14219/jada.archive.2000.0087
   Gu LP, 2021, ARCH ORAL BIOL, V122, DOI 10.1016/j.archoralbio.2020.104992
   Jia QY, 2015, INT IMMUNOPHARMACOL, V29, P884, DOI 10.1016/j.intimp.2015.08.026
   Jin H, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.724525
   Kantak MN, 2022, CARBOHYD POLYM, V278, DOI 10.1016/j.carbpol.2021.118999
   Kaufman J., 2011, Journal of Commercial Biotechnology, V17, P173, DOI 10.1057/jcb.2010.37
   Kim EN, 2021, MAR DRUGS, V19, DOI 10.3390/md19070388
   Kim MS, 2014, CARBOHYD POLYM, V114, P213, DOI 10.1016/j.carbpol.2014.08.008
   Konkel JE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01403
   Lin CX, 2018, J CELL PHYSIOL, V233, P6135, DOI 10.1002/jcp.26460
   Liu F, 2019, MICROB PATHOGENESIS, V127, P208, DOI 10.1016/j.micpath.2018.11.034
   Liu J, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21116 3
   Liu Y, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232213939
   Liu Y, 2022, ACTA BIOMATER, V146, P37, DOI 10.1016/j.actbio.2022.03.046
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Nardone V, 2014, CLINICS, V69, P438, DOI 10.6061/clinics/2014(06)12
   Qiao SW, 2023, ORAL DIS, V29, P3571, DOI 10.1111/odi.14292
   Rajeshwari HR, 2019, J CONTROL RELEASE, V307, P393, DOI 10.1016/j.jconrel.2019.06.038
   Ren S, 2021, BIOCHEM PHARMACOL, V188, DOI 10.1016/j.bcp.2021.114576
   Russo E, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11120671
   Romero Castro NS, 2020, ODONTOLOGY, V108, P25, DOI 10.1007/s10266 019 00435 5
   Sartori EM, 2018, INT J ORAL MAX IMPL, V33, P269, DOI 10.11607/jomi.5372
   Shi ZJ, 2016, BIOMATERIALS, V111, P40, DOI 10.1016/j.biomaterials.2016.09.020
   Singh N, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00021
   Steinberg D, 2020, PERIODONTOL 2000, V84, P176, DOI 10.1111/prd.12341
   Torelli Souza RR, 2012, J APPL POLYM SCI, V126, pE408, DOI 10.1002/app.36928
   Van Dyke TE, 2003, J DENT RES, V82, P82, DOI 10.1177/154405910308200202
   VANSTRAALEN JP, 1991, CLIN CHIM ACTA, V201, P27, DOI 10.1016/0009 8981(91)90021 4
   Wang G, 2017, BIOTECHNOL BIOTEC EQ, V31, P766, DOI 10.1080/13102818.2017.1332493
   Wang QB, 2016, INFLAMMATION, V39, P237, DOI 10.1007/s10753 015 0243 9
   Webber MJ, 2016, NAT MATER, V15, P13, DOI [10.1038/nmat4474, 10.1038/NMAT4474]
   Williams DF, 2014, BIOMATERIALS, V35, P10009, DOI 10.1016/j.biomaterials.2014.08.035
   Wu CM, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 277
   Xia ZX, 2023, J ETHNOPHARMACOL, V303, DOI 10.1016/j.jep.2022.115900
   Xu XW, 2019, ACTA BIOMATER, V86, P235, DOI 10.1016/j.actbio.2019.01.001
   Xue P, 2016, CELL DEATH DIFFER, V23, P1862, DOI 10.1038/cdd.2016.74
   Yang S, 2022, BIOMED ENVIRON SCI, V35, P811, DOI 10.3967/bes2022.105
   Zhang R, 2019, EUR J PHARMACOL, V851, P144, DOI 10.1016/j.ejphar.2019.02.026
   Zheng Z, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.975840
NR 50
TC 21
Z9 23
U1 7
U2 55
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2023
VL 24
IS 7
AR 6364
DI 10.3390/ijms24076364
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA D4SM7
UT WOS:000968647200001
PM 37047340
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zou, Q
   Li, JF
   Li, YB
AF Zou, Qin
   Li, Junfeng
   Li, Yubao
TI Preparation and characterization of vanillin crosslinked chitosan
   therapeutic bioactive microcarriers
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Vanillin crosslinked chitosan microspheres; Drug delivery;
   Biocompatibility
ID HYDROXYAPATITE/CHITOSAN BONE CEMENT; CONTROLLED RELEASE; DRUG DELIVERY;
   STEM CELLS; MICROSPHERES; POLYMER; BIOCOMPATIBILITY; DIFFERENTIATION;
   GLUTARALDEHYDE; OSTEOBLASTS
AB Chitosan microspheres with diameter of 14.3 48.5 mu m were prepared by emulsion method and using natural vanillin as cross linking agent. The surface morphology and microstructure of the microspheres were characterized by scanning electron microscopy, X ray diffraction and Fourier transform infrared spectroscopy, etc. The hollow microspheres showed a well defined spherical shape with median diameter of 30.3 mu m and possessed a uniform surface with micro wrinkles, which is in favor of the drug release. Interpenetrating network cross linking mechanism might result from the Schiff base reaction and the acetalization of hydroxyl and carbonyl between chitosan and vanillin. Berberine, as a model drug, was loaded in the microspheres and released in a sustainable manner. The drug loading ratio could change from 9.16% to 29.70% corresponding to the entrapment efficiency of 91.61% to 74.25%. In vitro cell culture study using MG63 cells and in vivo implantation clearly showed that the microspheres could provide favorable cell attachment and biocompatibility. The results confirm that the drug loaded vanillin crosslinked chitosan microspheres could be a worthy candidate either as carriers of drugs and cells, or as therapeutic matrix for bone repair and regeneration. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Zou, Qin; Li, Yubao] Sichuan Univ, Res Ctr Nanobiomat, Analyt & Testing Ctr, Chengdu 610064, Peoples R China.
   [Li, Junfeng] Chengdu Univ Technol, Dept Mat Sci & Engn, Chengdu 610059, Peoples R China.
C3 Sichuan University; Chengdu University of Technology
RP Li, YB (通讯作者)，Sichuan Univ, Res Ctr Nanobiomat, Analyt & Testing Ctr, Chengdu 610064, Peoples R China.
EM nic7504@scu.edu.cn
RI Zou, Qin/GVU 2237 2022; Li, Junfeng/S 8207 2017
OI Li, Junfeng/0000 0001 9921 4727
FU China NSFC [31370971]; Sichuan project [2012FZ0125]; Chengdu project
   [12DXYB145JH 005]
FX The authors thanks for the financial support of China NSFC project (No.
   31370971), Sichuan project (No. 2012FZ0125) and Chengdu project (No.
   12DXYB145JH 005).
CR Ansboro S, 2014, J CONTROL RELEASE, V179, P42, DOI 10.1016/j.jconrel.2014.01.023
   Armentano I, 2010, POLYM DEGRAD STABIL, V95, P2126, DOI 10.1016/j.polymdegradstab.2010.06.007
   Avila M, 2007, TALANTA, V72, P1362, DOI 10.1016/j.talanta.2007.01.045
   Bagheri Khoulenjani S, 2013, J BIOMED MATER RES A, V101, P1758, DOI 10.1002/jbm.a.34481
   Berger J, 2004, EUR J PHARM BIOPHARM, V57, P19, DOI 10.1016/s0939 6411(03)00161 9
   Bernkop Schnürch A, 2012, EUR J PHARM BIOPHARM, V81, P463, DOI 10.1016/j.ejpb.2012.04.007
   Bibbo C, 2014, J FOOT ANKLE SURG, V53, P472, DOI 10.1053/j.jfas.2014.02.022
   Bibbo C, 2014, J FOOT ANKLE SURG, V53, P344, DOI 10.1053/j.jfas.2013.12.008
   Costa ES, 2009, CARBOHYD POLYM, V76, P472, DOI 10.1016/j.carbpol.2008.11.015
   Neto BPD, 2014, POWDER TECHNOL, V255, P109, DOI 10.1016/j.powtec.2013.10.046
   Devi DA, 2005, J MEMBRANE SCI, V262, P91, DOI 10.1016/j.memsci.2005.03.051
   Gupta KC, 2006, INT J BIOL MACROMOL, V38, P272, DOI 10.1016/j.ijbiomac.2006.03.013
   Gupta KC, 2006, CARBOHYD RES, V341, P744, DOI 10.1016/j.carres.2006.02.003
   Jose S, 2012, COLLOID SURFACE B, V92, P175, DOI 10.1016/j.colsurfb.2011.11.040
   Kim H, 1997, J PHARM SCI, V86, P323, DOI 10.1021/js960307p
   Kim S, 2012, ACTA BIOMATER, V8, P1768, DOI 10.1016/j.actbio.2012.01.009
   Kulkarni PV, 2007, POLYM ADVAN TECHNOL, V18, P814, DOI 10.1002/pat.940
   Lacerda L, 2014, MAT SCI ENG C MATER, V39, P161, DOI 10.1016/j.msec.2014.01.054
   Lahiji A, 2000, J BIOMED MATER RES, V51, P586
   Lakhkar NJ, 2012, ACTA BIOMATER, V8, P4181, DOI 10.1016/j.actbio.2012.07.023
   Lee SH, 2007, ADV DRUG DELIVER REV, V59, P339, DOI 10.1016/j.addr.2007.03.016
   Li JF, 2013, J CONTROL RELEASE, V172, pE46, DOI 10.1016/j.jconrel.2013.08.097
   Ma J, 2013, CARBOHYD POLYM, V92, P955, DOI 10.1016/j.carbpol.2012.10.015
   Ma PX, 2008, ADV DRUG DELIVER REV, V60, P184, DOI 10.1016/j.addr.2007.08.041
   Mi FL, 2002, BIOMATERIALS, V23, P181, DOI 10.1016/S0142 9612(01)00094 1
   Miao TX, 2014, J CONTROL RELEASE, V192, P57, DOI 10.1016/j.jconrel.2014.06.029
   Michio H., 1992, STUDIES ORGANIC CHEM, pv
   Muzzarelli RAA, 2009, CARBOHYD POLYM, V76, P167, DOI 10.1016/j.carbpol.2008.11.002
   Nath SD, 2013, INT J PHARMACEUT, V443, P87, DOI 10.1016/j.ijpharm.2012.12.037
   Peng HL, 2010, FOOD CHEM, V121, P23, DOI 10.1016/j.foodchem.2009.11.085
   Perez RA, 2014, ACTA BIOMATER, V10, P520, DOI 10.1016/j.actbio.2013.09.042
   Prashanth KVH, 2006, CARBOHYD RES, V341, P169, DOI 10.1016/j.carres.2005.10.016
   Rahaman MN, 2014, MAT SCI ENG C MATER, V41, P224, DOI 10.1016/j.msec.2014.04.055
   Rokhade AP, 2007, CARBOHYD POLYM, V67, P605, DOI 10.1016/j.carbpol.2006.07.001
   Samanta HS, 2014, CARBOHYD POLYM, V106, P109, DOI 10.1016/j.carbpol.2014.01.097
   Shi ZL, 2006, BIOMATERIALS, V27, P2440, DOI 10.1016/j.biomaterials.2005.11.036
   Shukla SK, 2013, INT J BIOL MACROMOL, V59, P46, DOI 10.1016/j.ijbiomac.2013.04.043
   Soares PAG, 2014, MAT SCI ENG C MATER, V42, P219, DOI 10.1016/j.msec.2014.05.009
   Sokolsky Papkov M, 2007, ADV DRUG DELIVER REV, V59, P187, DOI 10.1016/j.addr.2007.04.001
   SPEER DP, 1980, J BIOMED MATER RES, V14, P753, DOI 10.1002/jbm.820140607
   Su Y, 2012, ACTA BIOMATER, V8, P763, DOI 10.1016/j.actbio.2011.11.002
   Trifkovic KT, 2014, CARBOHYD POLYM, V111, P901, DOI 10.1016/j.carbpol.2014.05.053
   Uskokovic V, 2014, MAT SCI ENG C MATER, V37, P210, DOI 10.1016/j.msec.2014.01.008
   van Dijkhuizen Radersma R, 2002, BIOMATERIALS, V23, P4719, DOI 10.1016/S0142 9612(02)00220 X
   Zou Q, 2009, J BIOMED MATER RES B, V90B, P156, DOI 10.1002/jbm.b.31267
   Zou Q, 2009, J BIOMED MATER RES A, V89A, P1108, DOI 10.1002/jbm.a.32199
NR 46
TC 57
Z9 58
U1 4
U2 104
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD AUG
PY 2015
VL 79
BP 736
EP 747
DI 10.1016/j.ijbiomac.2015.05.037
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA CO4YH
UT WOS:000359166300094
PM 26051343
DA 2025 08 17
ER

PT J
AU Hatori, A
   Fujii, Y
   Kawase Koga, Y
   Ogasawara, T
   Chikira, J
   Minami, S
   Yamakawa, D
   Chikazu, D
AF Hatori, Ayano
   Fujii, Yasuyuki
   Kawase Koga, Yoko
   Ogasawara, Toru
   Chikira, Jin
   Minami, Sakura
   Yamakawa, Daiki
   Chikazu, Daichi
TI VCAM 1 and GFPT 2: Predictive markers of osteoblast
   differentiation in human dental pulp stem cells
SO BONE
LA English
DT Article
DE Dental pulp stem cells; Osteogenic differentiation; Vascular cell
   adhesion molecule 1; transaminase 2; Small interfering RNA; Cell
   signaling
ID O GLCNAC MODIFICATION; ADHESION MOLECULE 1; BONE MARROW; IN VITRO;
   EXPRESSION; GLCNACYLATION; TRANSCRIPTION; INCREASE
AB Introduction: Dental pulp stem cells (DPSCs) have high proliferative and multilineage differentiation potential in mesenchymal stem cells. However, several studies have indicated that there are individual differences in the potential for osteogenic differentiation of DPSCs, and the factors determining these differences are unknown.Objective: To identify the genes responsible for the individual differences in the osteogenic differentiation ability of DPSCs.Methods: We divided DPSCs into high and low osteogenic differentiation ability groups (HG or LG) with ALP and von Kossa stain, and compared the gene expression patterns using RNA seq. In addition, genes that may affect osteogenic differentiation were knocked down using small interfering RNA (siRNA) and their effects were investigated.Results: The RNA seq patterns revealed that VCAM1 and GFPT2 were significantly expressed at higher levels in the HG than in the LG. The results of siRNA analysis showed that VCAM1 and GFPT2 knockdown significantly reduced the expression of osteogenic markers. Furthermore, we analyzed the involvement of these two genes in cell signaling in DPSC differentiation. The results indicated that the VCAM1 mediated Ras MEK Erk and PI3K/ Akt pathways are involved in the osteogenic differentiation of DPSCs, and that GFPT2 mediated HBP signaling influences the osteogenic differentiation of DPSCs.Conclusions: These findings indicate that DPSCs that highly express VCAM1 and GFPT2 have a high capacity for osteogenic differentiation. Evaluation of VCAM1 and GFPT2 expression in undifferentiated DPSCs may predict the outcome of bone regenerative therapy using DPSCs. Moreover, the expression levels of VCAM1 and GFPT2 in DPSCs may be useful in setting criteria for selecting donors for allogeneic cell transplantation for bone regeneration.
C1 [Hatori, Ayano; Fujii, Yasuyuki; Kawase Koga, Yoko; Chikira, Jin; Minami, Sakura; Yamakawa, Daiki; Chikazu, Daichi] Tokyo Med Univ, Dept Oral & Maxillofacial Surg, 6 7 1 Nishishinjuku,Shinju Ku, Tokyo 1600023, Japan.
   [Kawase Koga, Yoko] Tokyo Womens Med Univ, Sch Med, Dept Oral & Maxillofacial Surg, 8 1 Kawadachou,Shinjuku Ku, Tokyo 1600023, Japan.
   [Ogasawara, Toru] Univ Tokyo, Grad Sch Med, Dept Oral & Maxillofacial Surg, 7 3 1 Hongo,Bunkyo Ku, Tokyo 1138655, Japan.
   [Fujii, Yasuyuki] Univ Tokyo, Fac Med, 7 3 1 Hongo,Bunkyo Ku, Tokyo 1138655, Japan.
C3 Tokyo Medical University; Tokyo Women's Medical University; University
   of Tokyo; University of Tokyo
RP Fujii, Y (通讯作者)，Tokyo Med Univ, Dept Oral & Maxillofacial Surg, 6 7 1 Nishishinjuku,Shinju Ku, Tokyo 1600023, Japan.
EM yfujii@tokyo med.ac.jp
RI Ogasawara, Toru/I 1629 2014
OI Ogasawara, Toru/0000 0002 2996 081X
FU Japan Society for the Promotion of Science (JSPS) [19K10189];
   Grants in Aid for Scientific Research [21K21098] Funding Source: KAKEN
FX This study was supported by grants from the Japan Society for the
   Promotion of Science (JSPS) (No.19K10189).
CR Binion DG, 2009, AM J PHYSIOL GASTR L, V297, pG259, DOI 10.1152/ajpgi.00087.2009
   Carter RA, 2001, ARTHRITIS RHEUM US, V44, P985, DOI 10.1002/1529 0131(200105)44:5<985::AID ANR176>3.0.CO;2 P
   Chamieh F, 2016, SCI REP UK, V6, DOI 10.1038/srep38814
   Fujii Y, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0783 7
   Gabrielyan A, 2020, STEM CELL RES, V45, DOI 10.1016/j.scr.2020.101814
   Gronthos S, 2002, J DENT RES, V81, P531, DOI 10.1177/154405910208100806
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Hart GW, 2011, ANNU REV BIOCHEM, V80, P825, DOI 10.1146/annurev biochem 060608 102511
   Iohara K, 2011, TISSUE ENG PT A, V17, P1911, DOI [10.1089/ten.tea.2010.0615, 10.1089/ten.TEA.2010.0615]
   Kawagishi Hotta M, 2019, REGEN THER, V11, P324, DOI 10.1016/j.reth.2019.09.002
   Kawagishi Hotta M, 2017, REGEN THER, V6, P29, DOI 10.1016/j.reth.2016.12.004
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Kim SH, 2007, BIOCHEM BIOPH RES CO, V362, P325, DOI 10.1016/j.bbrc.2007.07.149
   Koyama T, 2015, EXP CELL RES, V338, P194, DOI 10.1016/j.yexcr.2015.08.009
   Lee HM, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01714 7
   Li XJ, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10482
   Mabuchi Y, 2013, STEM CELL REP, V1, P152, DOI 10.1016/j.stemcr.2013.06.001
   Nagel AK, 2014, MOL CELL PROTEOMICS, V13, P3381, DOI 10.1074/mcp.M114.040691
   Nagel AK, 2013, MOL CELL PROTEOMICS, V12, P945, DOI 10.1074/mcp.M112.026633
   Nakajima K, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 53265 4
   Nie H, 2019, J ZHEJIANG UNIV SC B, V20, P437, DOI 10.1631/jzus.B1900150
   OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092 8674(89)90775 7
   Pisciotta A, 2015, BMC DEV BIOL, V15, DOI 10.1186/s12861 015 0065 x
   Sato M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207731
   Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497
   Tamaki Y, 2013, ODONTOLOGY, V101, P121, DOI 10.1007/s10266 012 0075 0
   Yamakawa D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239158
   Yasui T, 2016, J DENT RES, V95, P206, DOI 10.1177/0022034515610748
   Zhao SJ, 2020, THERANOSTICS, V10, P17, DOI 10.7150/thno.36930
NR 29
TC 6
Z9 7
U1 3
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2023
VL 166
AR 116575
DI 10.1016/j.bone.2022.116575
EA OCT 2022
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 8C0TP
UT WOS:000917330600002
PM 36195245
DA 2025 08 17
ER

PT J
AU Krishnan, AV
   Swami, S
   Peng, LH
   Wang, JN
   Moreno, J
   Feldman, D
AF Krishnan, Aruna V.
   Swami, Srilatha
   Peng, Lihong
   Wang, Jining
   Moreno, Jacqueline
   Feldman, David
TI Tissue Selective Regulation of Aromatase Expression by Calcitriol:
   Implications for Breast Cancer Therapy
SO ENDOCRINOLOGY
LA English
DT Article
ID CYTOCHROME P450 CYP19 GENE; VITAMIN D COMPOUNDS; D RESPONSE ELEMENT;
   ADIPOSE FIBROBLASTS; 1 ALPHA,25 DIHYDROXYVITAMIN D 3; ADIPOCYTE
   DIFFERENTIATION; POSTMENOPAUSAL WOMEN; HUMAN OSTEOBLASTS; REGION
   UPSTREAM; BONE LOSS
AB Aromatase, the enzyme that catalyzes estrogen synthesis, is critical for the progression of estrogen receptor positive breast cancer (BCa) in postmenopausal women. We show that calcitriol, the hormonally active form of vitamin D, regulates the expression of aromatase in a tissue selective manner. Calcitriol significantly decreased aromatase expression in human BCa cells and adipocytes and caused substantial increases in human osteosarcoma cells (a bone cell model exhibiting osteoblast phenotype in culture) and modest increases in ovarian cancer cells. Calcitriol administration to immunocompromised mice bearing human BCa xenografts decreased aromatase mRNA levels in the tumors and the surrounding mammary adipose tissue but did not alter ovarian aromatase expression. In BCa cells, calcitriol also reduced the levels of prostaglandins (PGs), major stimulators of aromatase transcription, by suppressing the expression of cyclooxygenase 2 (which catalyzes PG synthesis) and increasing that of 15 hydroxyprostaglandin dehydrogenase (which catalyzes PG degradation). The mechanism of aromatase down regulation by calcitriol in BCa cells is therefore 2 fold: a direct repression of aromatase transcription via promoter II through the vitamin D response elements identified in this promoter and an indirect suppression by reducing the levels of PGs. Combinations of calcitriol with three different aromatase inhibitors (AIs) caused enhanced inhibition of BCa cell growth. The combination of calcitriol and an AI may have potential benefits for BCa therapy. In addition to augmenting the ability of AIs to inhibit BCa growth, calcitriol acting as a selective aromatase modulator that increases aromatase expression in bone would reduce the estrogen deprivation in bone caused by the AIs, thus ameliorating the AI induced side effect of osteoporosis. (Endocrinology 151: 32 42, 2010)
C1 [Krishnan, Aruna V.; Swami, Srilatha; Peng, Lihong; Wang, Jining; Moreno, Jacqueline; Feldman, David] Stanford Univ, Sch Med, Div Endocrinol, Dept Med, Stanford, CA 94305 USA.
C3 Stanford University
RP Feldman, D (通讯作者)，Stanford Univ, Sch Med, Div Endocrinol, Dept Med, 300 Pasteur Dr,Room S025, Stanford, CA 94305 USA.
EM dfeldman@stanford.edu
FU National Cancer Institute [CA130991]; Komen Foundation [070101]
FX This work was supported by National Cancer Institute Grant CA130991 and
   Komen Foundation Grant 070101 ( to D. F.).
CR Agarwal VR, 1996, J CLIN ENDOCR METAB, V81, P3843, DOI 10.1210/jc.81.11.3843
   Agarwal VR, 1995, MOL CELL PROBE, V9, P453, DOI 10.1006/mcpr.1995.0069
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   BRIAN H, 2001, P 192 ANN M SOC END
   Brodie A, 1998, BREAST CANCER RES TR, V49, pS85, DOI 10.1023/A:1006029612990
   Brodie A, 1998, BREAST CANC RES T S1, V49, pS109
   Brodie AMH, 2001, J STEROID BIOCHEM, V79, P41, DOI 10.1016/S0960 0760(01)00131 5
   Brueggemeier RW, 2006, EXPERT OPIN PHARMACO, V7, P1919, DOI 10.1517/14656566.7.14.1919
   Brueggemeier RW, 1999, CANCER LETT, V140, P27, DOI 10.1016/S0304 3835(99)00050 6
   Bulun SE, 2005, PHARMACOL REV, V57, P359, DOI 10.1124/pr.57.3.6
   Bulun SE, 1996, J CLIN ENDOCR METAB, V81, P1273, DOI 10.1210/jc.81.3.1273
   Chen D, 2007, CANCER RES, V67, P8914, DOI 10.1158/0008 5472.CAN 06 4751
   Chen SA, 1998, FRONT BIOSCI LANDMRK, V3, P922
   Chen TL, 2007, STEM CELLS DEV, V16, P371, DOI 10.1089/scd.2006.0037
   Colston K, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P1663
   Confavreux CB, 2007, BONE, V41, P346, DOI 10.1016/j.bone.2007.06.004
   Díaz Cruz ES, 2005, J CLIN ENDOCR METAB, V90, P2563, DOI 10.1210/jc.2004 2029
   Enjuanes A, 2005, EUR J ENDOCRINOL, V153, P981, DOI 10.1530/eje.1.02032
   Enjuanes A, 2003, EUR J ENDOCRINOL, V148, P519, DOI 10.1530/eje.0.1480519
   Geisler J, 2005, CLIN CANCER RES, V11, P2809, DOI 10.1158/1078 0432.CCR 04 2187
   Gombart AF, 2006, ANTICANCER RES, V26, P2531
   HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312
   Hershberger PA, 1999, CANCER RES, V59, P2644
   Hershberger PA, 2001, CLIN CANCER RES, V7, P1043
   Hughes SV, 1997, ENDOCRINOLOGY, V138, P3711, DOI 10.1210/en.138.9.3711
   Jääskeläinen T, 2005, BIOCHEM BIOPH RES CO, V328, P831, DOI 10.1016/j.bbrc.2005.01.033
   Khan QJ, 2010, BREAST CANCER RES TR, V119, P111, DOI 10.1007/s10549 009 0495 x
   Kinuta K, 2000, ENDOCRINOLOGY, V141, P1317, DOI 10.1210/en.141.4.1317
   Koszewski NJ, 2004, J BIOL CHEM, V279, P42431, DOI 10.1074/jbc.M407742200
   Krishnan AV, 2007, J BONE MINER RES, V22, pV74, DOI 10.1359/JBMR.07S213
   Krishnan AV, 2003, J CELL BIOCHEM, V88, P363, DOI 10.1002/jcb.10334
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lou YR, 2005, J STEROID BIOCHEM, V94, P151, DOI 10.1016/j.jsbmb.2005.01.024
   Meng L, 2001, CANCER RES, V61, P2250
   Mincey BA, 2006, CLIN BREAST CANCER, V7, P127, DOI 10.3816/CBC.2006.n.021
   Moreno J, 2005, CANCER RES, V65, P7917, DOI 10.1158/0008 5472.CAN 05 1435
   Ohno K, 2004, TOXICOL SCI, V82, P443, DOI 10.1093/toxsci/kfh292
   Peng LH, 2004, MOL ENDOCRINOL, V18, P1109, DOI 10.1210/me.2003 0344
   PRICE T, 1992, J CLIN ENDOCR METAB, V74, P1247, DOI 10.1210/jc.74.6.1247
   Richards JA, 2002, J STEROID BIOCHEM, V80, P203, DOI 10.1016/S0960 0760(01)00187 X
   SimboliCampbell M, 1997, BREAST CANCER RES TR, V42, P31, DOI 10.1023/A:1005772432465
   Simpson ER, 2002, ANNU REV PHYSIOL, V64, P93, DOI 10.1146/annurev.physiol.64.081601.142703
   Sjögren K, 2009, J BONE MINER RES, V24, P1263, DOI [10.1359/JBMR.090208, 10.1359/jbmr.090208]
   Stoica A, 1999, J CELL BIOCHEM, V75, P640, DOI 10.1002/(SICI)1097 4644(19991215)75:4<640::AID JCB10>3.0.CO;2 8
   Sun TJ, 1998, ENDOCRINOLOGY, V139, P1684, DOI 10.1210/en.139.4.1684
   Swami S, 2000, CLIN CANCER RES, V6, P3371
   Tallarida RJ, 2002, PAIN, V98, P163, DOI 10.1016/S0304 3959(02)00041 6
   Trösken ER, 2006, TOXICOLOGY, V219, P33, DOI 10.1016/j.tox.2005.10.020
   Trump DL, 2006, ANTICANCER RES, V26, P2551
   Vu D, 1996, ENDOCRINOLOGY, V137, P1540, DOI 10.1210/en.137.5.1540
   Welsh J, 2002, J STEROID BIOCHEM, V83, P85, DOI 10.1016/S0960 0760(02)00277 7
   Welsh J, 2007, J BONE MINER RES, V22, pV86, DOI 10.1359/JBMR.07S204
   Wheler J, 2006, SEMIN ONCOL, V33, P672, DOI 10.1053/j.seminoncol.2006.08.018
   Wolf I, 2006, CANCER RES, V66, P7818, DOI 10.1158/0008 5472.CAN 05 4368
   Yanase T, 2003, J STEROID BIOCHEM, V86, P393, DOI 10.1016/S0960 0760(03)00349 2
   Yanase T, 2001, J STEROID BIOCHEM, V79, P187, DOI 10.1016/S0960 0760(01)00161 3
   Zhou DJ, 1997, J STEROID BIOCHEM, V61, P273
   Zhou DJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P179, DOI 10.1006/abbi.1999.1454
   Zhou JF, 2001, CANCER RES, V61, P2328
NR 59
TC 155
Z9 170
U1 1
U2 7
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD JAN
PY 2010
VL 151
IS 1
BP 32
EP 42
DI 10.1210/en.2009 0855
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 535NT
UT WOS:000272977700006
PM 19906814
OA Green Published
DA 2025 08 17
ER

PT J
AU Yang, T
   Zheng, XF
   Li, M
   Lin, X
   Yin, QS
AF Yang, Tao
   Zheng, Xiao Fei
   Li, Mei
   Lin, Xi
   Yin, Qing Shui
TI Stimulation of Osteogenic Differentiation in Stromal Cells of Giant Cell
   Tumour of Bone by Zoledronic Acid
SO ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE Giant cell tumour of bone; zoledronic acid; apoptosis; osteogenic
   differentiation
ID BISPHOSPHONATES INHIBIT; RECURRENCE; APOPTOSIS; THERAPY
AB Therapeutic effects of zoledronic acid (ZOL) on giant cell tumour of bone (GCT) have been proven. Apoptosis induction was considered to be one of the mechanisms of ZOL tumour inhibition. In this study, we presented the possibility of an osteogenic differentiation stimulation mechanism of ZOL and further investigated dosage and time effects. We treated stromal cells of GCT (GCTSC) with ZOL for 48 hours at different concentrations (0 mu M, 0.01 mu M, 0.1 mu M, 1 mu M, 5 mu M, 30 mu M) and assessed apoptotic and osteogenic differentiation markers with immunohistochemical techniques and real time quantitative RT PCR. Our results suggested that ZOL enhanced mRNA expression of Cbfa 1, osterix and osteocalcin genes with a maximum effect at 1 mu M in GCTSC. Time course experiments indicated a time dependent osteogenic differentiation effect. In conclusion, ZOL may be considered as an adjuvant in the treatment of GCT not only by inducing apoptosis but also by stimulating osteogenic differentiation of remaining tumor stromal cells after surgery.
C1 [Yang, Tao; Zheng, Xiao Fei; Li, Mei; Yin, Qing Shui] Guangzhou Liu Hua Qiao Hosp, Dept Orthopaed, Guangzhou, Guangdong, Peoples R China.
   [Lin, Xi] Southern Med Univ, Guangzhou, Guangdong, Peoples R China.
C3 Southern Medical University   China
RP Zheng, XF (通讯作者)，Guangzhou Liu Hua Qiao Hosp, Dept Orthopaed, Guangzhou, Guangdong, Peoples R China.
EM xiaofeizhengcn@163.com
RI Yin, Qing/HNC 6727 2023
FU National Nature Science Foundation of China [81172012]; Guangdong
   Natural Science Foundation [S2011010001062]
FX This study is supported in part by the National Nature Science
   Foundation of China (Grant No. 81172012) and Guangdong Natural Science
   Foundation (Grant No. S2011010001062).
CR Arpornchayanon Olarn, 2008, Journal of the Medical Association of Thailand, V91, P1609
   Balke M, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 462
   Boissier S, 2000, CANCER RES, V60, P2949
   BOONEKAMP PM, 1986, BONE MINER, V1, P27
   Chang SS, 2004, CLIN ORTHOP RELAT R, P103, DOI 10.1097/01.blo.0000141372.54456.80
   Cheng YY, 2004, CALCIFIED TISSUE INT, V75, P71, DOI 10.1007/s00223 004 0120 2
   Cowan RW, 2013, BONE, V52, P238, DOI 10.1016/j.bone.2012.10.002
   Fu LJ, 2008, BONE, V43, P40, DOI 10.1016/j.bone.2008.03.008
   Gibbs C Parker, 2005, Instr Course Lect, V54, P497
   Gille O, 2012, SPINE, V37, pE396, DOI 10.1097/BRS.0b013e31823ed70d
   Huang L, 2004, BONE, V34, P393, DOI 10.1016/j.bone.2003.10.013
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Mendenhall WM, 2006, AM J CLIN ONCOL CANC, V29, P96, DOI 10.1097/01.coc.0000195089.11620.b7
   Nishisho T, 2011, ORTHOPEDICS, V34, pE312, DOI 10.3928/01477447 20110526 22
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   SUNG HW, 1982, J BONE JOINT SURG AM, V64, P755, DOI 10.2106/00004623 198264050 00015
   Szendröi M, 2004, J BONE JOINT SURG BR, V86B, P5, DOI 10.1302/0301 620X.86B1.14053
   Tse LF, 2008, BONE, V42, P68, DOI 10.1016/j.bone.2007.08.038
   Turcotte RE, 2006, ORTHOP CLIN N AM, V37, P35, DOI 10.1016/j.ocl.2005.08.005
   Wang CZ, 2010, BIOMATERIALS, V31, P8674, DOI 10.1016/j.biomaterials.2010.07.096
   Werner M, 2006, INT ORTHOP, V30, P484, DOI 10.1007/s00264 006 0215 7
   Zheng MH, 2001, HISTOL HISTOPATHOL, V16, P297, DOI 10.14670/HH 16.297
   Zwolak P, 2010, J BONE JOINT SURG AM, V92A, P162, DOI 10.2106/JBJS.H.01679
NR 23
TC 13
Z9 14
U1 0
U2 9
PU ASIAN PACIFIC ORGANIZATION CANCER PREVENTION
PI GYEONGGI DO
PA APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN  RO,
   ILSANDONG GU, GOYANG SI, GYEONGGI DO, 410 769, SOUTH KOREA
SN 1513 7368
J9 ASIAN PAC J CANCER P
JI Asian Pac. J. Cancer Prev.
PY 2013
VL 14
IS 9
BP 5379
EP 5383
DI 10.7314/APJCP.2013.14.9.5379
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 269WG
UT WOS:000328273000074
PM 24175830
OA gold
DA 2025 08 17
ER

PT J
AU Ghalandarzadeh, A
   Ganjali, M
   Hosseini, M
AF Ghalandarzadeh, Arash
   Ganjali, Monireh
   Hosseini, Milad
TI Tailoring zirconia surface topography via femtosecond laser induced
   nanoscale features: effects on osteoblast cells and antibacterial
   properties
SO BIOMEDICAL MATERIALS
LA English
DT Article
DE zirconia implants; femtosecond laser ablation; osteoblast behavior;
   nanoscale groove geometries; antibacterial activity; sustained drug
   release
ID OSTEOGENIC DIFFERENTIATION; TITANIUM IMPLANT; DENTAL IMPLANTS;
   STEM CELLS; ADHESION; OSSEOINTEGRATION; CERAMICS; WETTABILITY;
   MECHANISMS; CHEMISTRY
AB The performance and long term durability of dental implants hinge on the quality of bone integration and their resistance to bacteria. This research aims to introduce a surface modification strategy for zirconia implants utilizing femtosecond laser ablation techniques, exploring their impact on osteoblast cell behavior and bacterial performance, as well as the integral factors influencing the soft tissue quality surrounding dental implants. Ultrafast lasers were employed to craft nanoscale groove geometries on zirconia surfaces, with thorough analyses conducted using x ray diffraction, scanning electron microscopy, atomic force microscopy, and water contact angle measurements. The study evaluated the response of human fetal osteoblastic cell lines to textured zirconia ceramics by assessing alkaline phosphatase activity, collagen I, and interleukin 1 beta secretion over a 7 day period. Additionally, the antibacterial behavior of the textured surfaces was investigated using Fusobacterium nucleatum, a common culprit in infections associated with dental implants. Ciprofloxacin (CIP), a widely used antibacterial antibiotic, was loaded onto zirconia ceramic surfaces. The results of this study unveiled a substantial reduction in bacterial adhesion on textured zirconia surfaces. The fine biocompatibility of these surfaces was confirmed through the MTT assay and observations of cell morphology. Moreover, the human fetal osteoblastic cell line exhibited extensive spreading and secreted elevated levels of collagen I and interleukin 1 beta in the modified samples. Drug release evaluations demonstrated sustained CIP release through a diffusion mechanism, showcasing excellent antibacterial activity against pathogenic bacteria, including Streptococcus mutans, Pseudomonas aeruginosa, and Escherichia coli.
C1 [Ghalandarzadeh, Arash] Iran Univ Sci & Technol, Sch Met & Mat Engn, POB 16846, Tehran, Iran.
   [Ganjali, Monireh] Mat & Energy Res Ctr, Dept Nanotechnol & Adv Mat, Biomat Grp, POB 31787 316, Karaj, Iran.
   [Hosseini, Milad] Sahand Univ Technol, Fac Mat Engn, Res Ctr Adv Mat, POB 51335 1996, Tabriz, Iran.
C3 Iran University Science & Technology; Materials & Energy Research Center
   (MERC); Sahand University of Technology
RP Ghalandarzadeh, A (通讯作者)，Iran Univ Sci & Technol, Sch Met & Mat Engn, POB 16846, Tehran, Iran.
EM Arash.ghalandarzadehh@gmail.com
RI ; hosseini, milad/MIJ 8034 2025; Ghalandarzadeh, Arash/HGU 9712 2022
OI Ghalandarzadeh, Arash/0000 0001 6514 6754; 
FU Materials and Energy Research Center (MERC);  [791400006]
FX Financial support for this study was provided by a Grant No. 791400006
   from the Materials and Energy Research Center (MERC).
CR Aboushellib MN, 2007, J PROSTHET DENT, V98, P379, DOI 10.1016/S0022 3913(07)60123 1
   ADAMSON AW, 1967, PHYS CHEM SURFACES
   Ahmed W, 2019, MATER TODAY BIO, V2, DOI 10.1016/j.mtbio.2019.100017
   Albrektsson T, 2001, EUR SPINE J, V10, pS96, DOI 10.1007/s005860100282
   Att W, 2009, BIOMATERIALS, V30, P1273, DOI 10.1016/j.biomaterials.2008.11.024
   Avetta P, 2014, J MATER CHEM B, V2, P5287, DOI 10.1039/c4tb00236a
   Bacchelli B, 2009, ACTA BIOMATER, V5, P2246, DOI 10.1016/j.actbio.2009.01.024
   Bao YC, 2021, SURF COAT TECH, V419, DOI 10.1016/j.surfcoat.2021.127296
   Bettinger CJ, 2009, ANGEW CHEM INT EDIT, V48, P5406, DOI 10.1002/anie.200805179
   Brennan CA, 2019, NAT REV MICROBIOL, V17, P156, DOI 10.1038/s41579 018 0129 6
   Bruschi ML., 2015, Strategies to Modify the Drug Release from Pharmaceutical Systems, P63, DOI [10.1016/B978 0 08 100092 2.00005 9, DOI 10.1016/B978 0 08 100092 2.00005 9]
   Butler J, 2023, ACS NANO, V17, P7064, DOI 10.1021/acsnano.2c12488
   Cao QH, 2021, APPL SURF SCI, V557, DOI 10.1016/j.apsusc.2021.149842
   Carvalho A, 2018, APPL SURF SCI, V435, P1237, DOI 10.1016/j.apsusc.2017.11.206
   Chevalier J, 2009, J EUR CERAM SOC, V29, P1245, DOI 10.1016/j.jeurceramsoc.2008.08.025
   Chevalier J, 2009, J AM CERAM SOC, V92, P1901, DOI 10.1111/j.1551 2916.2009.03278.x
   Cunha A, 2016, APPL SURF SCI, V360, P485, DOI 10.1016/j.apsusc.2015.10.102
   da Cruz MB, 2022, J ORAL BIOSCI, V64, P100, DOI 10.1016/j.job.2022.02.002
   Dalby MJ, 2007, NAT MATER, V6, P997, DOI 10.1038/nmat2013
   Dalby MJ, 2002, TISSUE ENG, V8, P1099, DOI 10.1089/107632702320934191
   Daskalova A, 2018, APPL PHYS A MATER, V124, DOI 10.1007/s00339 018 1628 z
   Ehrenfest DMD, 2010, TRENDS BIOTECHNOL, V28, P198, DOI 10.1016/j.tibtech.2009.12.003
   EICHLER J, 1977, APPL OPTICS, V16, P27, DOI 10.1364/AO.16.000027
   Esposito M, 2006, INT J ORAL MAX IMPL, V21, P696
   Faia Torres AB, 2014, BIOMATERIALS, V35, P9023, DOI 10.1016/j.biomaterials.2014.07.015
   Flemming HC, 2010, NAT REV MICROBIOL, V8, P623, DOI 10.1038/nrmicro2415
   Ganjali M., 2024, Surface Strategies and Classification of Biomaterials, Surface Engineering of Biomaterials, P558
   García AJ, 2011, PRINCIPLES OF REGENERATIVE MEDICINE, 2ND EDITION, P663, DOI 10.1016/B978 0 12 381422 7.10036 7
   Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593
   Ghalandarzadeh A, 2023, SURF TOPOGR METROL, V11, DOI 10.1088/2051 672X/acd076
   Ghalandarzadeh A, 2023, ODONTOLOGY, V111, P580, DOI 10.1007/s10266 022 00781 x
   Gittens RA, 2014, ACTA BIOMATER, V10, P3363, DOI 10.1016/j.actbio.2014.03.037
   Hao L, 2005, J MATER SCI MATER M, V16, P719, DOI 10.1007/s10856 005 2608 3
   Hao L, 2004, J BIOMATER APPL, V19, P81, DOI 10.1177/0885328204043546
   Heiroth S, 2010, J APPL PHYS, V107, DOI 10.1063/1.3275868
   Hosseini M, 2023, MATER CHEM PHYS, V293, DOI 10.1016/j.matchemphys.2022.126899
   HSIEH YL, 1988, J COLLOID INTERF SCI, V123, P275, DOI 10.1016/0021 9797(88)90244 5
   Huang D, 2020, E POLYMERS, V20, P759, DOI 10.1515/epoly 2020 0071
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092 8674(02)00971 6
   Jaffe H L., 1990, Poly (Vinyl Alcohol) for Adhesives, Handbook of Adhesives, P401
   Jeyachandran YL, 2006, SURF COAT TECH, V201, P3462, DOI 10.1016/j.surfcoat.2006.07.236
   Ji M, 2021, WEAR, V484, DOI 10.1016/j.wear.2021.203845
   Ji M, 2020, CERAM INT, V46, P7161, DOI 10.1016/j.ceramint.2019.11.210
   Jia XS, 2022, OPT LASER TECHNOL, V153, DOI 10.1016/j.optlastec.2022.108209
   Jing XB, 2022, COLLOID SURFACE A, V654, DOI 10.1016/j.colsurfa.2022.130198
   Jing XB, 2020, CERAM INT, V46, P24173, DOI 10.1016/j.ceramint.2020.06.197
   Jorge Mora A, 2018, OPT LASER ENG, V111, P34, DOI 10.1016/j.optlaseng.2018.07.008
   Kapatral V, 2002, J BACTERIOL, V184, P2005, DOI 10.1128/JB.184.7.2005 2018.2002
   Kaplan CW, 2009, MOL MICROBIOL, V71, P35, DOI 10.1111/j.1365 2958.2008.06503.x
   Keselowsky BG, 2003, J BIOMED MATER RES A, V66A, P247, DOI 10.1002/jbm.a.10537
   Khecho A., 2021, Adv. Ceram. Prog, V7, P23, DOI [10.30501/ACP.2021.287468.1062, DOI 10.30501/ACP.2021.287468.1062]
   Khecho A, 2022, INT J APPL CERAM TEC, V19, P2472, DOI 10.1111/ijac.14109
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Kochkodan V, 2008, DESALINATION, V220, P380, DOI 10.1016/j.desal.2007.01.042
   Kohal R. J., 2020, CURR ORAL HLTH REP, V7, P344, DOI [10.1007/S40496 020 00289 9/TABLES/1, DOI 10.1007/S40496 020 00289 9, 10.1007/s40496 020 00289 9]
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Lawrence J, 2002, J LASER APPL, V14, P107, DOI 10.2351/1.1471560
   Laxminarayan R, 2013, LANCET INFECT DIS, V13, P1057, DOI 10.1016/S1473 3099(13)70318 9
   Li Q., 2003, The influence of microgrooved surfaces on the behavior and celluar function of osteoblasts RBM, P27
   Liu XH, 2015, MAT SCI ENG C MATER, V48, P256, DOI 10.1016/j.msec.2014.12.011
   Liu XL, 2021, SCI CHINA TECHNOL SC, V64, P2485, DOI 10.1007/s11431 021 1813 0
   Lord MS, 2006, BIOMATERIALS, V27, P4856, DOI 10.1016/j.biomaterials.2006.05.037
   Lu AG, 2020, CERAM INT, V46, P6550, DOI 10.1016/j.ceramint.2019.11.139
   Mahanta U, 2021, J MATER SCI, V56, P17915, DOI 10.1007/s10853 021 06404 0
   Majidian H, 2024, ODONTOLOGY, V112, P408, DOI 10.1007/s10266 023 00853 6
   Manicone PF, 2007, J DENT, V35, P819, DOI 10.1016/j.jdent.2007.07.008
   Marin Cardona E.S., 2014, A review of polyvinyl alcohol derivatives: promising materials for pharmaceutical biomedical applications
   McCracken M, 1999, J Prosthodont, V8, P40, DOI 10.1111/j.1532 849X.1999.tb00006.x
   Minguela J, 2020, J EUR CERAM SOC, V40, P4304, DOI 10.1016/j.jeurceramsoc.2020.03.049
   Moura CG, 2017, CERAM INT, V43, P15227, DOI 10.1016/j.ceramint.2017.08.058
   Musumeci R, 2003, INT J ANTIMICROB AG, V22, P48, DOI 10.1016/S0924 8579(03)00085 2
   Orazi L, 2021, CIRP ANN MANUF TECHN, V70, P543, DOI 10.1016/j.cirp.2021.05.007
   Panchal R, 2022, REACT FUNCT POLYM, V178, DOI 10.1016/j.reactfunctpolym.2022.105339
   Paradossi G, 2003, J MATER SCI MATER M, V14, P687, DOI 10.1023/A:1024907615244
   Park SH, 2016, J ADV PROSTHODONT, V8, P110, DOI 10.4047/jap.2016.8.2.110
   Patel DS, 2018, SURF COAT TECH, V349, P816, DOI 10.1016/j.surfcoat.2018.05.032
   Ramburrun P, 2021, MATERIALS, V14, DOI 10.3390/ma14123167
   Rubinstein MR, 2013, CELL HOST MICROBE, V14, P195, DOI 10.1016/j.chom.2013.07.012
   Rupp F, 2006, J BIOMED MATER RES A, V76A, P323, DOI 10.1002/jbm.a.30518
   Santos RLP, 2016, TRIBOL INT, V102, P361, DOI 10.1016/j.triboint.2016.05.047
   Scarano A, 2004, J PERIODONTOL, V75, P292, DOI 10.1902/jop.2004.75.2.292
   Schnell G, 2019, MATERIALS, V12, DOI 10.3390/ma12132210
   Silva DM, 2018, INT J PHARMACEUT, V547, P114, DOI 10.1016/j.ijpharm.2018.05.060
   Taha M, 2014, INT J PHARMACEUT, V477, P380, DOI 10.1016/j.ijpharm.2014.10.026
   Tartaglia GM, 2016, IMPLANT DENT, V25, P74, DOI 10.1097/ID.0000000000000368
   VANLOOSDRECHT MCM, 1990, MICROBIOL REV, V54, P75, DOI 10.1128/MMBR.54.1.75 87.1990
   Verma A, 2010, SMALL, V6, P12, DOI 10.1002/smll.200901158
   Vorobyev A Y., 2009, Femtosecond Laser Surface Structuring of Biocompatible Metals, P92
   Wang XC, 2010, APPL PHYS A MATER, V101, P271, DOI 10.1007/s00339 010 5816 8
   Webster TJ, 2000, BIOMATERIALS, V21, P1803, DOI 10.1016/S0142 9612(00)00075 2
   Wenz HJ, 2008, INT J PROSTHODONT, V21, P27
   Yada S, 2015, OPT EXPRESS, V23, P5694, DOI 10.1364/OE.23.005694
   Yang Z, 2020, RSC ADV, V10, P6200, DOI 10.1039/c9ra08575k
   Yim EKF, 2005, BIOMATERIALS, V26, P5405, DOI 10.1016/j.biomaterials.2005.01.058
NR 94
TC 6
Z9 6
U1 7
U2 19
PU IOP Publishing Ltd
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1748 6041
EI 1748 605X
J9 BIOMED MATER
JI Biomed. Mater.
PD SEP 1
PY 2024
VL 19
IS 5
AR 055017
DI 10.1088/1748 605X/ad606f
PG 21
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA YR8E4
UT WOS:001270293000001
PM 39016135
DA 2025 08 17
ER

PT J
AU Luo, Y
   Zhou, F
   Wu, XC
   Li, Y
   Ye, B
AF Luo, Yan
   Zhou, Feng
   Wu, Xiaochun
   Li, Yi
   Ye, Bin
TI miR 30b 5p inhibits osteoblast differentiation through targeting BCL6
SO CELL CYCLE
LA English
DT Article
DE miR 30b 5p; human mesenchymal stem cell; osteogenic differentiation;
   BCL6; miRNA
ID MESENCHYMAL STEM CELLS; BONE FORMATION; PROTEIN
AB Human bone marrow mesenchymal stem cells (hBMSCs) are attractive candidates for new therapies to improve bone regeneration and repair. This study was to identify the function of the miR 30b 5p/BCL6 axis in osteogenic differentiation of hBMSCs. Realtime quantitative PCR (RT qPCR) and Western blotting were used to measure the relative expression of ALP, OCN, RUNX2, miR 30b 5p, and BCL6 during osteogenic differentiation of hBMSCs. The relationship between miR 30b 5p and BCL6 in hBMSCs was identified using dual luciferase reporter system and RNA pull down assay. Alizarin red S staining (ARS) was used to detect the calcium nodules in hBMSCs. We found that the expression of miR 30b 5p was downregulated, whereas that of BCL6 was upregulated during osteogenic differentiation of hBMSCs. Downregulating miR 30b 5p enhanced the expression of OCN, RUNX2, and ALP, and promoted calcium deposition. Conversely, transfection with si BCL6 had the opposite effect that it inhibited osteogenic differentiation. However, the inhibitory effect of si BCL6 was abrogated by miR 30b 5p inhibitor. miR 30b 5p inhibits the osteogenic differentiation of hBMSCs by targeting BCL6.
C1 [Luo, Yan; Li, Yi] Wuhan Puren Hosp, Dept Gen Practice, Wuhan, Hubei, Peoples R China.
   [Zhou, Feng] Wuhan Puren Hosp, Dept Endocrinol, Wuhan, Hubei, Peoples R China.
   [Wu, Xiaochun] Wuhan Huangpi People Hosp, Dept Orthopaed, Wuhan, Hubei, Peoples R China.
   [Ye, Bin] Wuhan 9 Hosp, Dept Orthopaed, 1 Benxi St, Wuhan 430080, Hubei, Peoples R China.
RP Ye, B (通讯作者)，Wuhan 9 Hosp, Dept Orthopaed, 1 Benxi St, Wuhan 430080, Hubei, Peoples R China.
EM yebin259@163.com
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood 2004 04 1559
   Balderman JAF, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.003905
   Bottini S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01126 x
   Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947
   Chen SJ, 2020, AGING DIS, V11, P1058, DOI 10.14336/AD.2019.0724
   Chu DT, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030708
   Cloonan N, 2015, BIOESSAYS, V37, P379, DOI 10.1002/bies.201400191
   Croset M, 2018, CANCER RES, V78, P5259, DOI 10.1158/0008 5472.CAN 17 3058
   Dawson E, 2008, ADV DRUG DELIVER REV, V60, P215, DOI 10.1016/j.addr.2007.08.037
   Derubeis AR, 2004, ANN BIOMED ENG, V32, P160, DOI 10.1023/B:ABME.0000007800.89194.95
   Eguchi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058796
   Estevao Pereira H, 2019, J TRANSL MED, V17, DOI 10.1186/s12967 019 02193 y
   Fujie A, 2015, BIOCHEM BIOPH RES CO, V457, P451, DOI 10.1016/j.bbrc.2015.01.012
   Gagnon KT, 2014, CELL REP, V6, P211, DOI 10.1016/j.celrep.2013.12.013
   Guan M, 2012, NAT MED, V18, P456, DOI 10.1038/nm.2665
   Ihn HJ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00367
   Jang WG, 2012, J BIOL CHEM, V287, P905, DOI 10.1074/jbc.M111.253187
   Jardin F, 2007, PATHOL BIOL, V55, P73, DOI 10.1016/j.patbio.2006.04.001
   Kumar P, 2013, MOL CELL BIOL, V33, P1782, DOI 10.1128/MCB.01228 12
   Li J, 2018, ACTA BIOMATER, V79, P202, DOI 10.1016/j.actbio.2018.08.029
   Li Y, 2019, J CELL MOL MED, V23, P6140, DOI 10.1111/jcmm.14490
   Liu C, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/4069032
   Liu GQ, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/7547506
   Liu L, 2018, J CELL PHYSIOL, V233, P6822, DOI 10.1002/jcp.26432
   Long C, 2021, HUM CELL, V34, P14, DOI 10.1007/s13577 020 00421 y
   Mao L, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9623412
   Miyauchi Y, 2010, J EXP MED, V207, P751, DOI 10.1084/jem.20091957
   Ng D, 2004, NAT GENET, V36, P411, DOI 10.1038/ng1321
   Qin X, 2017, BIOMED PHARMACOTHER, V89, P742, DOI 10.1016/j.biopha.2017.02.062
   Salingcarnboriboon R, 2006, ENDOCRINOLOGY, V147, P2296, DOI 10.1210/en.2005 1020
   Schoolmeesters A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005605
   Sun H, 2019, J CELL BIOCHEM, V120, P171, DOI 10.1002/jcb.27289
   Wang F, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8361237
   Wu TT, 2012, J BIOL CHEM, V287, P7503, DOI 10.1074/jbc.M111.292722
   Yang JZ, 2017, INT J MOL MED, V39, P1605, DOI 10.3892/ijmm.2017.2955
   Yang SD, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/1351860
   Zang JN, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 47504 x
   Zha JP, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01775 7
   Zhang LF, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658 019 0187 4
   Zhang LJ, 2020, BIOCHEM BIOPH RES CO, V522, P164, DOI 10.1016/j.bbrc.2019.11.057
   Zhang S, 2016, OSTEOARTHR CARTILAGE, V24, P2135, DOI 10.1016/j.joca.2016.06.022
NR 41
TC 6
Z9 7
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538 4101
EI 1551 4005
J9 CELL CYCLE
JI Cell Cycle
PD MAR 19
PY 2022
VL 21
IS 6
BP 630
EP 640
DI 10.1080/15384101.2022.2031428
EA JAN 2022
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA ZW0MU
UT WOS:000748830700001
PM 35100079
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Hassanshahi, M
   Su, YW
   Khabbazi, S
   Fan, CM
   Chen, KM
   Wang, JF
   Qian, AR
   Howe, PR
   Yan, DW
   Zhou, HD
   Xian, CJ
AF Hassanshahi, Mohammadhossein
   Su, Yu Wen
   Khabbazi, Samira
   Fan, Chia Ming
   Chen, Ke Ming
   Wang, Ju Fang
   Qian, Airong
   Howe, Peter R.
   Yan, De Wen
   Zhou, Hou De
   Xian, Cory J.
TI Flavonoid genistein protects bone marrow sinusoidal blood vessels from
   damage by methotrexate therapy in rats
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE angiogenesis; apoptosis; bone marrow sinusoidal endothelial cells (BM
   SECs); genistein
ID NITRIC OXIDE SYNTHASE; PHYTOESTROGEN GENISTEIN; EXPRESSION;
   ANGIOGENESIS; CHEMOTHERAPY; MECHANISMS; CELLS; DIFFERENTIATION;
   HEMATOPOIESIS; REGENERATION
AB Cancer chemotherapy can cause significant damage to the bone marrow (BM) microvascular (sinusoidal) system. Investigations must now address whether and how BM sinusoidal endothelial cells (SECs) can be protected during chemotherapy. Herein we examined the potential protective effects of genistein, a soy derived flavonoid, against BM sinusoidal damage caused by treatment with methotrexate (MTX). The groups of young adult rats were gavaged daily with genistein (20mg/kg) or placebo. After 1 week, rats also received daily injections of MTX (0.75mg/kg) or saline for 5 days and were killed after a further 4 days. Histological analyses showed that BM sinusoids were markedly dilated (p<0.001) in the MTX alone group but were unaffected or less dilated in the genistein+MTX group. In control rats, genistein significantly enhanced expression of vascular endothelial growth factor (VEGF; p<0.01), particularly in osteoblasts, and angiogenesis marker CD31 (p<0.001) in bone. In MTX treated rats, genistein suppressed MTX induced apoptosis of BM SECs (p<0.001 vs MTX alone group) and tended to increase expression of CD31 and VEGF (p<0.05). Our in vitro studies showed that genistein in certain concentrations protected cultured SECs from MTX cytotoxic effects. Genistein enhanced tube formation of cultured SECs, which is associated with its ability to induce expression of endothelial nitric oxide synthase and production of nitric oxide. These data suggest that genistein can protect BM sinusoids during MTX therapy, which is associated, at least partially, with its indirect effect of promoting VEGF expression in osteoblasts and its direct effect of enhancing nitric oxide production in SECs.
C1 [Hassanshahi, Mohammadhossein; Su, Yu Wen; Khabbazi, Samira; Fan, Chia Ming; Xian, Cory J.] Univ South Australia, Sch Pharm & Med Sci, GPO Box 2471, Adelaide, SA 5001, Australia.
   [Hassanshahi, Mohammadhossein; Su, Yu Wen; Khabbazi, Samira; Fan, Chia Ming; Xian, Cory J.] Univ South Australia, UniSA Canc Res Inst, GPO Box 2471, Adelaide, SA 5001, Australia.
   [Chen, Ke Ming] Lanzhou Gen Hosp CPLA, Inst Orthopaed, Lanzhou, Gansu, Peoples R China.
   [Wang, Ju Fang] Chinese Acad Sci, Inst Modern Phys, Lanzhou, Gansu, Peoples R China.
   [Qian, Airong] Northwestern Polytech Univ, Key Lab Space Biosci & Biotechnol, Sch Life Sci, Lab Bone Metab, Xian, Shaanxi, Peoples R China.
   [Howe, Peter R.] Univ Southern Queensland, Inst Resilient Reg, Springfield, Qld, Australia.
   [Howe, Peter R.] Univ Newcastle, Clin Nutr Res Ctr, Callaghan, NSW, Australia.
   [Yan, De Wen] Shenzhen Univ, Affiliated Hosp 1, Dept Endocrinol, Shenzhen, Guangdong, Peoples R China.
   [Zhou, Hou De] Cent S Univ, Xiangya Hosp 2, Natl Clin Res Ctr Metab Dis, Dept Endocrinol & Metab, Changsha, Hunan, Peoples R China.
C3 University of South Australia; University of South Australia; Chinese
   Academy of Sciences; Institute of Modern Physics, CAS; Northwestern
   Polytechnical University; University of Southern Queensland; University
   of Newcastle; Shenzhen University; Central South University
RP Xian, CJ (通讯作者)，Univ South Australia, Sch Pharm & Med Sci, GPO Box 2471, Adelaide, SA 5001, Australia.; Xian, CJ (通讯作者)，Univ South Australia, UniSA Canc Res Inst, GPO Box 2471, Adelaide, SA 5001, Australia.
EM cory.xian@unisa.edu.au
RI ; SU, Yu Wen/V 4948 2018; Howe, Peter/A 5006 2008; Xian,
   Cory/D 2646 2009; Zhou, Hou De/IQU 6646 2023; Hassanshahi,
   Mohammadhossein/ABF 5123 2020; Jia, Wei/AAN 5102 2020; khabbazi,
   samira/B 9907 2014; Su, Yu Wen/V 4948 2018
OI Zhou, Hou De/0000 0001 9131 4141; SU, Yu Wen/0000 0002 2067 5270;
   Hassanshahi, Mohammadhossein/0000 0002 4097 8527; Khabbazi,
   Samira/0000 0002 5410 795X; 
FU National Natural Science Foundation of China [81671928]; National Health
   and Medical Research Council [1042105, 1127396, 1010752, 0508046,
   0508047]; Research Training Program international (RTPi) scholarship of
   University of South Australia; National Health and Medical Research
   Council of Australia [1127396] Funding Source: NHMRC
FX National Natural Science Foundation of China, Grant/Award Number:
   81671928; National Health and Medical Research Council, Grant/Award
   Numbers: 1042105, 1127396, 1010752, 0508046, 0508047; Research Training
   Program international (RTPi) scholarship of University of South
   Australia
CR Bermejo A, 2003, J CARDIOVASC PHARM, V42, P329, DOI 10.1097/00005344 200309000 00003
   Colacurci N, 2005, MENOPAUSE, V12, P299, DOI 10.1097/01.GME.0000147017.23173.5B
   Cooke JP, 2002, CIRCULATION, V105, P2133, DOI 10.1161/01.CIR.0000014928.45119.73
   Ewalt MD, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.4170.4170
   Fliedner TM, 2002, CANCER BIOTHER RADIO, V17, P405, DOI 10.1089/108497802760363204
   Hassanshahi M, 2019, J CELL BIOCHEM, V120, P3220, DOI 10.1002/jcb.27589
   Hassanshahi M, 2017, ANGIOGENESIS, V20, P427, DOI 10.1007/s10456 017 9577 2
   Hooper AT, 2009, CELL STEM CELL, V4, P263, DOI 10.1016/j.stem.2009.01.006
   Huang B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13885
   Khabbazi S, 2016, SCI REP UK, V6, DOI 10.1038/srep31572
   King TJ, 2015, INT J MOL SCI, V16, P18293, DOI 10.3390/ijms160818293
   Kitayama J, 2002, J HYPERTENS, V20, P2205, DOI 10.1097/00004872 200211000 00020
   Lee PC, 1999, AM J PHYSIOL HEART C, V277, pH1600, DOI 10.1152/ajpheart.1999.277.4.H1600
   Lee SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096155
   Liu C, 2016, INTEGR BIOL UK, V8, P785, DOI 10.1039/c6ib00070c
   Liu Xiaojing, 2002, Zhonghua Gan Zang Bing Za Zhi, V10, P200
   MacLauchlan S, 2011, P NATL ACAD SCI USA, V108, pE1137, DOI 10.1073/pnas.1104357108
   Mäkelä S, 1999, P NATL ACAD SCI USA, V96, P7077, DOI 10.1073/pnas.96.12.7077
   May MJ, 1996, BRIT J PHARMACOL, V118, P1761, DOI 10.1111/j.1476 5381.1996.tb15602.x
   Ming LG, 2013, J CELL PHYSIOL, V228, P513, DOI 10.1002/jcp.24158
   Nadhanan RR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071592
   Nolan DJ, 2013, DEV CELL, V26, P204, DOI 10.1016/j.devcel.2013.06.017
   Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699
   Sakamoto M, 2001, J HEPATOL, V34, P858, DOI 10.1016/S0168 8278(01)00023 X
   Si HW, 2008, J NUTR, V138, P297, DOI 10.1093/jn/138.2.297
   Si HW, 2012, ENDOCRINOLOGY, V153, P3190, DOI 10.1210/en.2012 1076
   Squadrito F, 2002, ATHEROSCLEROSIS, V163, P339, DOI 10.1016/S0021 9150(02)00013 8
   Su YW, 2016, J BONE MINER RES, V31, P1258, DOI 10.1002/jbmr.2786
   Tie L, 2013, J NUTR BIOCHEM, V24, P88, DOI 10.1016/j.jnutbio.2012.02.011
   Vera R, 2007, CLIN SCI, V112, P183, DOI 10.1042/CS20060185
   Wang B, 2003, J OCUL PHARMACOL TH, V19, P457, DOI 10.1089/108076803322473015
   Wang TTY, 1996, CARCINOGENESIS, V17, P271, DOI 10.1093/carcin/17.2.271
   WITTELS B, 1980, AM J SURG PATHOL, V4, P135, DOI 10.1097/00000478 198004000 00005
   Xian CJ, 2007, BONE, V41, P842, DOI 10.1016/j.bone.2007.07.021
   Yang Y, 2010, EXP MOL MED, V42, P768, DOI 10.3858/emm.2010.42.11.078
   Yu J, 2005, P NATL ACAD SCI USA, V102, P10999, DOI 10.1073/pnas.0501444102
   Yu XP, 2012, MED ONCOL, V29, P349, DOI 10.1007/s12032 010 9770 2
   Zhai YK, 2014, BONE, V66, P189, DOI 10.1016/j.bone.2014.06.016
NR 38
TC 12
Z9 12
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUL
PY 2019
VL 234
IS 7
BP 11276
EP 11286
DI 10.1002/jcp.27785
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA HQ8AL
UT WOS:000462645700127
PM 30565680
DA 2025 08 17
ER

PT J
AU Dinneen, B
   Shea, FO'
   Gensler, L
AF Dinneen, Brona
   Shea, Finbar O. '
   Gensler, Lianne
TI Structural disease modification in axial spondyloarthritis
SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
LA English
DT Article
DE Axial spondylarthritis; Ankylosing spondylitis; Spondylarthritis;
   Radiographic progression; Imaging; Risk factors; Smoking; Structural
   progression; Non Steroidal anti in flammatory agents; Antirheumatic
   agents; Disease progression; Outcomes assessment; Tumor necrosis
   factor alpha; Diagnostic imaging
ID SPINAL RADIOGRAPHIC PROGRESSION; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
   ANKYLOSING SPONDYLITIS; DOUBLE BLIND; INFLAMMATORY PATHWAYS;
   PSORIATIC ARTHRITIS; EFFICACY; SAFETY; MULTICENTER; ADALIMUMAB
AB "Disease modification" in axial spondyloarthritis (axSpA) seeks to not only alleviate clinical symptoms but also alter the disease's natural course by impeding new bone formation. Recent years have witnessed the effectiveness of treatments, including biologics and nonsteroidal anti inflammatory drugs, in managing axSpA symptoms. Emerging evidence points toward their potential impact on slowing structural disease progression. This comprehensive review centers on the pivotal role of inhibiting new bone formation in axSpA disease modification. It delves into the significance of imaging techniques for assessing disease progression and explores the disease modifying properties of available axSpA treatments, encompassing NSAIDs, TNF inhibitors, IL 17 inhibitors, and JAK inhibitors. This article offers valuable insights into the evolving landscape of disease modification strategies in axial spondyloarthritis, highlighting the multifaceted approaches used to attain these objectives.(c) 2023 Elsevier Ltd. All rights reserved.
C1 [Dinneen, Brona; Shea, Finbar O. '] St James Hosp, Dept Rheumatol, Dublin, Ireland.
   [Shea, Finbar O. '] Trinity Coll Dublin, Sch Med, Dublin, Ireland.
   [Gensler, Lianne] Univ Calif San Francisco, UCSF Diabet Ctr, Dept Med, San Francisco, CA 94143 USA.
   [Dinneen, Brona] St James Hosp, Rheumatol Dept, James St, Dublin, Ireland.
C3 Trinity College Dublin; Trinity College Dublin; University of California
   System; University of California San Francisco; Trinity College Dublin
RP Dinneen, B (通讯作者)，St James Hosp, Rheumatol Dept, James St, Dublin, Ireland.
EM bronadinneen@gmail.com
OI dinneen, brona/0000 0002 8751 1684
CR Aletaha D, 2006, RHEUM DIS CLIN N AM, V32, P9, DOI 10.1016/j.rdc.2005.09.005
   Atzeni F, 2021, IMMUNOTARGETS THER, V10, P141, DOI 10.2147/ITT.S259126
   Baraliakos X, 2022, ARTHRITIS RHEUMATOL, V74, P1943, DOI 10.1002/art.42282
   Baraliakos X, 2020, CLIN DRUG INVEST, V40, P269, DOI 10.1007/s40261 020 00886 7
   BOERSMA JW, 1976, SCAND J RHEUMATOL, V5, P60
   Braun J, 2019, RHEUMATOLOGY, V58, P859, DOI 10.1093/rheumatology/key375
   Coates LC, 2016, ARTHRITIS RHEUMATOL, V68, P1060, DOI 10.1002/art.39573
   Creemers MCW, 2005, ANN RHEUM DIS, V64, P127, DOI 10.1136/ard.2004.020503
   Cross JH, 2020, EUR J PAEDIATR NEURO, V24, P43, DOI 10.1016/j.ejpn.2019.12.005
   Davis JC, 2005, ANN RHEUM DIS, V64, P1557, DOI 10.1136/ard.2004.035105
   Dougados M, 2014, ARTHRITIS RHEUMATOL, V66, P2091, DOI 10.1002/art.38721
   Furst DE, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 1885 z
   Gensler LS, 2018, ANN RHEUM DIS, V77, P148, DOI 10.1136/annrheumdis 2018 eular.4027
   Haroon N, 2013, ARTHRITIS RHEUM US, V65, P2645, DOI 10.1002/art.38070
   Hebeisen M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230268
   Hreggvidsdottir HS, 2014, MOL IMMUNOL, V57, P28, DOI 10.1016/j.molimm.2013.07.016
   Inman RD, 2008, ARTHRITIS RHEUM US, V58, P3402, DOI 10.1002/art.23969
   Jo S, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1582 3
   Kampylafka E, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1653 5
   Karmacharya P, 2020, ARTHRITIS RHEUMATOL, V72, P733, DOI 10.1002/art.41206
   Khmelinskii N, 2018, FRONT MED LAUSANNE, V5, DOI 10.3389/fmed.2018.00106
   Kroon FPB, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010952.pub2
   Lambert RGW, 2016, ANN RHEUM DIS, V75, P1958, DOI 10.1136/annrheumdis 2015 208642
   Landewé R, 2014, ANN RHEUM DIS, V73, P39, DOI 10.1136/annrheumdis 2013 204231
   Lubberts E, 2015, NAT REV RHEUMATOL, V11, P562, DOI 10.1038/nrrheum.2015.128
   Maksymowych WP, 2017, RMD OPEN, V3, DOI 10.1136/rmdopen 2016 000399
   Maksymowych WP, 2022, RHEUMATOLOGY, V61, P2063, DOI 10.1093/rheumatology/keab543
   Maksymowych WP, 2010, NAT REV RHEUMATOL, V6, P75, DOI 10.1038/nrrheum.2009.258
   Maseda D, 2018, J IMMUNOL, V200, P725, DOI 10.4049/jimmunol.1601808
   Mitoma H, 2018, CYTOKINE, V101, P56, DOI 10.1016/j.cyto.2016.08.014
   Molnar C, 2018, ANN RHEUM DIS, V77, P63, DOI 10.1136/annrheumdis 2017 211544
   Morelli M, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/7897263
   Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896
   Ono T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10928
   Poddubnyy D, 2012, ANN RHEUM DIS, V71, P1616, DOI 10.1136/annrheumdis 2011 201252
   Poddubnyy D, 2012, ARTHRITIS RHEUM US, V64, P1388, DOI 10.1002/art.33465
   Popova V, 2023, ARTHRITIS RES THER, V25, DOI 10.1186/s13075 023 03026 6
   Ramiro S, 2022, ARTHRITIS RHEUMATOL, V74, P1094, DOI 10.1136/ard 2022 223296
   Ramiro S, 2014, ANN RHEUM DIS, V73, P1455, DOI 10.1136/annrheumdis 2014 205178
   Ramiro S, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4144
   Raychaudhuri S, 2021, CURR OPIN RHEUMATOL, V33, P348, DOI 10.1097/BOR.0000000000000810
   Reijnierse M, 2023, SEMIN MUSCULOSKEL R, V27, P91, DOI 10.1055/s 0043 1761496
   Rodriguez VR, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2015 000054
   ROUVIER E, 1993, J IMMUNOL, V150, P5445
   Rudwaleit M, 2006, ANN RHEUM DIS, V65, P1251, DOI 10.1136/ard.2005.051045
   Rudwaleit M, 2004, ANN RHEUM DIS, V63, P535, DOI 10.1136/ard.2003.011247
   Sari I, 2018, BEST PRACT RES CL RH, V32, P427, DOI 10.1016/j.berh.2019.02.007
   Sari I, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926 018 0795 4
   Schueller Weidekamm C, 2014, SEMIN MUSCULOSKEL R, V18, P265, DOI 10.1055/s 0034 1375569
   Sepriano A, 2021, RMD OPEN, V7, DOI 10.1136/rmdopen 2021 001654
   Sieper J, 2014, ARTHRITIS RHEUMATOL, V66, pS1283
   Sieper J, 2017, LANCET, V390, P73, DOI 10.1016/S0140 6736(16)31591 4
   Sieper J, 2016, ANN RHEUM DIS, V75, P1438, DOI 10.1136/annrheumdis 2015 207897
   Sieper J, 2013, ANN RHEUM DIS, V72, P815, DOI 10.1136/annrheumdis 2012 201766
   Smolen JS, 2020, ANN RHEUM DIS, V79, P685, DOI 10.1136/annrheumdis 2019 216655
   Sudot Szopinska I, 2013, POL J RADIOL, V78, P43, DOI 10.12659/PJR.889039
   Toussirot E, 2022, PHARMACEUTICALS BASE, V15, DOI 10.3390/ph15030270
   van der Heijde D, 2005, ARTHRITIS RHEUM US, V52, P582, DOI 10.1002/art.20852
   van der Heijde D, 2022, J RHEUMATOL, V49, P265, DOI 10.3899/jrheum.210471
   van der Heijde D, 2006, ARTHRITIS RHEUM US, V54, P2136, DOI 10.1002/art.21913
   van der Heijde D, 2019, RHEUMATOLOGY, V58, P388, DOI 10.1093/rheumatology/key128
   van der Heijde D, 2018, ANN RHEUM DIS, V77, P699, DOI 10.1136/annrheumdis 2017 212377
   Veale DJ, 2019, RHEUMATOLOGY, V58, P197, DOI 10.1093/rheumatology/key070
   Villaverde García V, 2017, SEMIN ARTHRITIS RHEU, V46, P569, DOI 10.1016/j.semarthrit.2016.11.004
   Wanders A, 2005, ARTHRITIS RHEUM US, V52, P1756, DOI 10.1002/art.21054
   Wanders AJB, 2004, ARTHRITIS RHEUM US, V50, P2622, DOI 10.1002/art.20446
NR 66
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1521 6942
EI 1521 1770
J9 BEST PRACT RES CL RH
JI Best Pract. Res. Clin. Rheumatol.
PD SEP
PY 2023
VL 37
IS 3
AR 101898
DI 10.1016/j.berh.2023.101898
EA DEC 2023
PG 12
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA FR2R0
UT WOS:001147520000001
PM 38042689
DA 2025 08 17
ER

PT J
AU Kragstrup, TW
   Greisen, SR
   Nielsen, MA
   Rhodes, C
   Stengaard Pedersen, K
   Hetland, ML
   Horslev Petersen, K
   Junker, P
   Ostergaard, M
   Hvid, M
   Vorup Jensen, T
   Robinson, WH
   Sokolove, J
   Deleuran, B
AF Kragstrup, Tue Wenzel
   Greisen, Stinne Ravn
   Nielsen, Morten Aagaard
   Rhodes, Christopher
   Stengaard Pedersen, Kristian
   Hetland, Merete Lund
   Horslev Petersen, Kim
   Junker, Peter
   Ostergaard, Mikkel
   Hvid, Malene
   Vorup Jensen, Thomas
   Robinson, William H.
   Sokolove, Jeremy
   Deleuran, Bent
TI The interleukin 20 receptor axis in early rheumatoid arthritis: novel
   links between disease associated autoantibodies and radiographic
   progression
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE Cytokines; Rheumatoid arthritis; Autoantibody(ies); Bone resorption;
   Monocytes/macrophages
ID TOLL LIKE RECEPTOR; FC GAMMA RECEPTOR; INCREASED EXPRESSION;
   MONOCLONAL ANTIBODY; FAMILY CYTOKINES; SYNOVIAL FLUID; CUTTING EDGE;
   BONE LOSS; IL 20; CELLS
AB Background: Rheumatoid arthritis (RA) is often characterized by the presence of rheumatoid factor, anti citrullinated protein antibodies, and bone erosions. Current therapies can compromise immunity, leading to risk of infection. The interleukin 20 receptor (IL 20R) axis comprising IL 19, IL 20, and IL 24 and their shared receptors activates tissue homeostasis processes but not the immune system. Consequently, modulation of the IL 20R axis may not lead to immunosuppression, making it an interesting drug target. We evaluated the role of the IL 20R axis in RA and associations between plasma cytokine levels and clinical disease.
   Methods: Plasma IL 19, IL 20, and IL 24 levels were measured in early RA patients during a treat to target strategy by enzyme linked immunosorbent assays. The IL 20R1 and IL 22R1 levels in paired peripheral blood mononuclear cells and synovial fluid mononuclear cells from a different cohort of RA patients were evaluated by flow cytometry and confocal microscopy. Monocytes/macrophages were stimulated with heat aggregated human immunoglobulin immune complexes and immune complexes containing citrullinated fibrinogen, and osteoclasts were incubated with IL 19, IL 20, and IL 24.
   Results: The plasma concentrations of IL 20 and IL 24 (but not IL 19) were increased in early RA patients compared with healthy controls (both P < 0.002) and decreased after 6 months of treatment (both P < 0.0001). The expression of IL 22R1 (but not IL 20R1) was increased on monocytes from RA synovial fluid compared with monocytes from both RA and healthy control peripheral blood. The plasma concentrations of IL 20 and IL 24 were increased in rheumatoid factor and anti citrullinated protein antibody positive compared with negative early RA patients (all P < 0.0001). Immune complexes stimulated the production of the IL 20R cytokines by monocytes/macrophages. Increased baseline plasma concentrations of IL 20 and IL 24 were associated with Sharp van der Heijde score progression after 24 months (Spearman's rho = 0.19 and 0.26, both P < 0.05) in the early RA patients. The IL 22R1 was expressed by osteoclast precursors and in multinucleated osteoclasts. IL 20 and IL 24 increased the secretion of monocyte chemoattractant protein 1 by these cells.
   Conclusions: This study suggests that IL 20 and IL 24 link RA associated autoantibodies with radiographic progression via the IL 22R1. Modulation of this axis holds promise as feasible anti erosive treatment modalities in seropositive RA.
C1 [Kragstrup, Tue Wenzel; Greisen, Stinne Ravn; Nielsen, Morten Aagaard; Hvid, Malene; Vorup Jensen, Thomas; Deleuran, Bent] Aarhus Univ, Dept Biomed, Aarhus, Denmark.
   [Kragstrup, Tue Wenzel; Rhodes, Christopher; Robinson, William H.; Sokolove, Jeremy] Stanford Univ, Dept Immunol & Rheumatol, Stanford, CA 94305 USA.
   [Kragstrup, Tue Wenzel; Stengaard Pedersen, Kristian; Deleuran, Bent] Aarhus Univ Hosp, Dept Rheumatol, DK 8000 Aarhus, Denmark.
   [Hetland, Merete Lund; Ostergaard, Mikkel] Rigshosp, Ctr Rheumatol & Spine Dis, Copenhagen Ctr Arthritis Res, Glostrup, Denmark.
   [Hetland, Merete Lund; Ostergaard, Mikkel] Glostrup Cty Hosp, Glostrup, Denmark.
   [Hetland, Merete Lund; Ostergaard, Mikkel] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark.
   [Horslev Petersen, Kim] Univ Southern Denmark, Odense, Denmark.
   [Junker, Peter] Odense Univ Hosp, DK 5000 Odense, Denmark.
   [Hvid, Malene; Deleuran, Bent] Aarhus Univ, Dept Clin Med, Aarhus, Denmark.
C3 Aarhus University; Stanford University; Aarhus University;
   Rigshospitalet; University of Copenhagen; University of Copenhagen;
   University of Southern Denmark; University of Southern Denmark; Odense
   University Hospital; Aarhus University
RP Kragstrup, TW (通讯作者)，Aarhus Univ, Dept Biomed, Aarhus, Denmark.; Kragstrup, TW (通讯作者)，Stanford Univ, Dept Immunol & Rheumatol, Stanford, CA 94305 USA.; Kragstrup, TW (通讯作者)，Aarhus Univ Hosp, Dept Rheumatol, DK 8000 Aarhus, Denmark.
EM kragstrup@biomed.au.dk
RI ; Hetland, Merete L/AAE 5297 2019; Nielsen, Morten
   Aagaard/LWJ 1185 2024; Greisen, Stinne/H 4837 2019; Hetland, Merete
   Lund/AAE 5297 2019; Vorup Jensen, Thomas/N 9082 2016
OI Hvid, Malene/0000 0002 3602 4261; Stengaard Pedersen,
   Kristian/0000 0001 7991 2456; Deleuran, Bent/0000 0002 7079 1587;
   Greisen, Stinne/0000 0003 2922 3307; Nielsen, Morten
   Aagaard/0000 0003 1077 9727; Horslev Petersen, Kim/0000 0002 5475 7610;
   Robinson, William/0000 0003 4385 704X; Hetland, Merete
   Lund/0000 0003 4229 6818; Kragstrup, Tue Wenzel/0000 0002 6439 397X;
   Vorup Jensen, Thomas/0000 0002 4140 6563
FU Danish Rheumatism Association; Faculty of Health at Aarhus University
FX We thank Karin Skovgard Sorensen and Bettina Grumsen (Department of
   Biomedicine, Aarhus University) for technical assistance concerning the
   ELISA assays, Charlotte Christie Petersen (FACS core facility, Aarhus
   University) for advising us on the flow cytometry analyses, Professor
   Michael Vaeth (Department of Biostatistics, Aarhus University) for help
   with the statistical analysis, and Professor Julia Johansen (Department
   of Rheumatology, Herlev Hospital) for assistance with handling the
   plasma samples from the OPERA cohort. This work was supported by the
   Danish Rheumatism Association and the Faculty of Health at Aarhus
   University.
CR Alanärä T, 2010, SCAND J RHEUMATOL, V39, P118, DOI 10.3109/03009740903170823
   Aletaha D, 2013, ANN RHEUM DIS, V72, P875, DOI 10.1136/annrheumdis 2012 201517
   Blom AB, 2003, ARTHRITIS RHEUM, V48, P1002, DOI 10.1002/art.10871
   BURNS TM, 1983, ANN RHEUM DIS, V42, P605, DOI 10.1136/ard.42.6.605
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Drexler SK, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2481
   Dumoutier L, 2001, J IMMUNOL, V167, P3545, DOI 10.4049/jimmunol.167.7.3545
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   Galson DL, 2011, OSTEOIMMUNOLOGY: INTERACTIONS OF THE IMMUNE AND SKELETAL SYSTEMS, P7, DOI 10.1016/B978 0 12 375670 1.10002 0
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074 7613(03)00174 2
   Greisen SR, 2015, APMIS, V123, P779, DOI 10.1111/apm.12416
   Harre U, 2012, J CLIN INVEST, V122, P1791, DOI 10.1172/JCI60975
   Horslev Petersen K, 2016, ANN RHEUM DIS, V75, P1645, DOI 10.1136/annrheumdis 2015 208166
   Horslev Petersen K, 2014, ANN RHEUM DIS, V73, P654, DOI 10.1136/annrheumdis 2012 202735
   Hsu YH, 2006, ARTHRITIS RHEUM US, V54, P2722, DOI 10.1002/art.22039
   Hsu YH, 2011, J EXP MED, V208, P1849, DOI 10.1084/jem.20102234
   Kragstrup TW, 2015, CLIN EXP IMMUNOL, V180, P233, DOI 10.1111/cei.12577
   Kragstrup TW, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193 1801 2 263
   Kragstrup TW, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4471
   Kragstrup TW, 2008, CYTOKINE, V41, P16, DOI 10.1016/j.cyto.2007.10.004
   Kroot EJJA, 2000, ARTHRITIS RHEUM, V43, P1831, DOI 10.1002/1529 0131(200008)43:8<1831::AID ANR19>3.0.CO;2 6
   Lebre MC, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4038
   Leipe J, 2011, ANN RHEUM DIS, V70, P1453, DOI 10.1136/ard.2011.152074
   Leng RX, 2011, EXPERT OPIN THER TAR, V15, P119, DOI 10.1517/14728222.2011.534461
   Li Y, 2010, MOL ORAL MICROBIOL, V25, P275, DOI 10.1111/j.2041 1014.2010.00576.x
   Marijnissen RJ, 2011, ARTHRITIS RHEUM US, V63, P2939, DOI 10.1002/art.30469
   Matsubara R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047930
   Matt P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137474
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Myles IA, 2013, NAT IMMUNOL, V14, P804, DOI 10.1038/ni.2637
   Nagalakshmi ML, 2004, INT IMMUNOPHARMACOL, V4, P577, DOI 10.1016/j.intimp.2004.01.007
   Novak JP, 2002, J BIOL CHEM, V277, P47517, DOI 10.1074/jbc.M205114200
   O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev med 051113 024537
   Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873
   Omoyinmi E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047673
   Rutz S, 2014, NAT REV IMMUNOL, V14, P783, DOI 10.1038/nri3766
   Sabat R, 2014, NAT REV DRUG DISCOV, V13, P21, DOI 10.1038/nrd4176
   Sakurai N, 2008, RHEUMATOLOGY, V47, P815, DOI 10.1093/rheumatology/ken061
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Scrivo R, 2015, CLIN EXP IMMUNOL, V179, P300, DOI 10.1111/cei.12449
   Senolt L, 2015, ARTHRITIS RHEUMATOL, V67, P1438, DOI 10.1002/art.39083
   Sokolove J, 2011, ARTHRITIS RHEUM US, V63, P53, DOI 10.1002/art.30081
   van der Heijde D, 1999, J RHEUMATOL, V26, P743
   Wolk K, 2002, J IMMUNOL, V168, P5397, DOI 10.4049/jimmunol.168.11.5397
   Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007
NR 46
TC 33
Z9 34
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD MAR 11
PY 2016
VL 18
AR 61
DI 10.1186/s13075 016 0964 7
PG 12
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA DG5JS
UT WOS:000372114700001
PM 26968800
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Asensio, G
   Martín del Campo, M
   Ramírez, RA
   Rojo, L
   Vázquez Lasa, B
AF Asensio, Gerardo
   Martin del Campo, Marcela
   Ramirez, Rosa Ana
   Rojo, Luis
   Vazquez Lasa, Blanca
TI New Insights into the In Vitro Antioxidant Routes and Osteogenic
   Properties of Sr/Zn Phytate Compounds
SO PHARMACEUTICS
LA English
DT Article
DE tissue engineering; bone regeneration; antioxidant; phytic acid;
   strontium; zinc
ID MESENCHYMAL STEM CELLS; LIPID PEROXIDATION; PHYTIC ACID; OXIDATIVE
   STRESS; STRONTIUM RANELATE; POSTMENOPAUSAL OSTEOPOROSIS; OSTEOCLAST
   FORMATION; BONE FORMATION; ZINC; OSTEOBLAST
AB Sr/Zn phytate compounds have been shown interest in biomaterial science, specifically in dental implantology, due to their antimicrobial effects against Streptococcus mutans and their capacity to form bioactive coatings. Phytic acid is a natural chelating compound that shows antioxidant and osteogenic properties that can play an important role in bone remodelling processes affected by oxidative stress environments, such as those produced during infections. The application of non protein cell signalling molecules that regulate both bone and ROS homeostasis is a promising strategy for the regeneration of bone tissues affected by oxidative stress processes. In this context, phytic acid (PA) emerged as an excellent option since its antioxidant and osteogenic properties can play an important role in bone remodelling processes. In this study, we explored the antioxidant and osteogenic properties of two metallic PA complexes bearing bioactive cations, i.e., Sr2+ (SrPhy) and Zn2+ (ZnPhy), highlighting the effect of the divalent cations anchored to phytate moieties and their capability to modulate the PA properties. The in vitro features of the complexes were analyzed and compared with those of their precursor PA. The ferrozine/FeCl2 method indicated that SrPhy exhibited a more remarkable ferrous ion affinity than ZnPhy, while the antioxidant activity demonstrated by a DPPH assay showed that only ZnPhy reduced the content of free radicals. Likewise, the antioxidant potential was assessed with RAW264.7 cell cultures. An ROS assay indicated again that ZnPhy was the only one to reduce the ROS content (20%), whereas all phytate compounds inhibited lipid peroxidation following the decreasing order of PA > SrPhy > ZnPhy. The in vitro evaluation of the phytate's osteogenic ability was performed using hMSC cells. The results showed tailored properties related to the cation bound in each complex. ZnPhy overexpressed ALP activity at 3 and 14 days, and SrPhy significantly increased calcium deposition after 21 days. This study demonstrated that Sr/Zn phytates maintained the antioxidant and osteogenic properties of PA and can be used in bone regenerative therapies involving oxidative environments, such as infected implant coatings and periodontal tissues.
C1 [Asensio, Gerardo; Martin del Campo, Marcela; Ramirez, Rosa Ana; Rojo, Luis; Vazquez Lasa, Blanca] CSIC, Inst Ciencia & Tecnol Polimeros ICTP, Calle Juan Cierva 3, Madrid 28006, Spain.
   [Martin del Campo, Marcela] Univ Autonoma San Luis Potosi UASLP, Fac Estomatol, San Luis Potosi 78290, Mexico.
   [Ramirez, Rosa Ana; Rojo, Luis; Vazquez Lasa, Blanca] Inst Salud Carlos III, Ctr Invest Biomed Red Bioingn Biomat & Nanomed, Madrid 28006, Spain.
   [Rojo, Luis; Vazquez Lasa, Blanca] Spanish Natl Res Council SusPlast CSIC, Interdisciplinary Platform Sustainable Plast Circ, Madrid 28006, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC   Instituto
   de Ciencia & Tecnologia de Polimeros (ICTP); Universidad Autonoma de San
   Luis Potosi; CIBER   Centro de Investigacion Biomedica en Red; CIBERBBN;
   Instituto de Salud Carlos III
RP Rojo, L (通讯作者)，CSIC, Inst Ciencia & Tecnol Polimeros ICTP, Calle Juan Cierva 3, Madrid 28006, Spain.; Rojo, L (通讯作者)，Inst Salud Carlos III, Ctr Invest Biomed Red Bioingn Biomat & Nanomed, Madrid 28006, Spain.; Rojo, L (通讯作者)，Spanish Natl Res Council SusPlast CSIC, Interdisciplinary Platform Sustainable Plast Circ, Madrid 28006, Spain.
EM rojodelolmo@ictp.csic.es
RI Vázquez Lasa, Blanca/U 9722 2018; Fierro, Marcela/S 6679 2018; Rojo del
   Olmo, Luis/B 3073 2009; JIMENEZ, ROSA/ABH 8794 2020; Rojo,
   Luis/B 3073 2009
OI Rojo del Olmo, Luis/0000 0001 6334 6736; RAMIREZ JIMENEZ, ROSA
   ANA/0000 0001 7563 2553; 
FU Comunidad de Madrid (Spain);  [IND2018/BMD 9485]
FX This study was supported by the Comunidad de Madrid (Spain)
   (IND2018/BMD 9485).
CR Abd Elkodous M, 2020, BIOL TRACE ELEM RES, V196, P297, DOI 10.1007/s12011 019 01894 1
   Abrahamsen B, 2014, OSTEOPOROSIS INT, V25, P757, DOI 10.1007/s00198 013 2469 4
   Addison WN, 2010, BONE, V46, P1100, DOI 10.1016/j.bone.2010.01.367
   Asensio G, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 24300 8
   Asensio G, 2022, POLYMERS BASEL, V14, DOI 10.3390/polym14010012
   Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Bagchi D, 1997, GEN PHARMACOL, V28, P85, DOI 10.1016/S0306 3623(96)00178 4
   Baltaci AK, 2018, BIOL TRACE ELEM RES, V183, P22, DOI 10.1007/s12011 017 1119 7
   Baran A, 2020, ORG COMMUN, V13, P65, DOI 10.25135/acg.oc.80.20.05.1639
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Bose C, 2021, CANCERS, V13, DOI 10.3390/cancers13246377
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Cabrera WE, 1999, J BONE MINER RES, V14, P661, DOI 10.1359/jbmr.1999.14.5.661
   Callaway DA, 2015, J BONE MINER METAB, V33, P359, DOI 10.1007/s00774 015 0656 4
   Capuccini C, 2008, ACTA BIOMATER, V4, P1885, DOI 10.1016/j.actbio.2008.05.005
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Castaneda OA, 2017, J FOOD DRUG ANAL, V25, P111, DOI 10.1016/j.jfda.2016.11.006
   Catalá A, 2009, CHEM PHYS LIPIDS, V157, P1, DOI 10.1016/j.chemphyslip.2008.09.004
   Choukroun E, 2021, Immunol Res and Ther J, V3, P119
   Cooper C, 2014, OSTEOPOROSIS INT, V25, P737, DOI 10.1007/s00198 013 2582 4
   Del Favero G, 2020, CHEM RES TOXICOL, V33, P492, DOI 10.1021/acs.chemrestox.9b00378
   Arriero MD, 2012, CELL PHYSIOL BIOCHEM, V30, P974, DOI 10.1159/000341474
   Arriero MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043187
   DINIS TCP, 1994, ARCH BIOCHEM BIOPHYS, V315, P161, DOI 10.1006/abbi.1994.1485
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Ebrahimiasl S, 2015, INT J NANOMED, V10, P217, DOI 10.2147/IJN.S69740
   El Refai A, 2018, J NANOSTRUCTURE CHEM, V8, P71, DOI 10.1007/s40097 018 0255 8
   Erdman J W Jr, 1989, Adv Exp Med Biol, V249, P161
   Fernández Villa D, 2021, EUR J MED CHEM, V212, DOI 10.1016/j.ejmech.2021.113152
   FUHRMAN B, 1994, ATHEROSCLEROSIS, V111, P65, DOI 10.1016/0021 9150(94)90192 9
   Gaschler MM, 2017, BIOCHEM BIOPH RES CO, V482, P419, DOI 10.1016/j.bbrc.2016.10.086
   GRAF E, 1987, J BIOL CHEM, V262, P11647
   Grases F, 2010, J MED FOOD, V13, P1301, DOI 10.1089/jmf.2009.0152
   HALLIWELL B, 1993, AM J CLIN NUTR, V57, P715
   Huntosova V, 2021, MOLECULES, V26, DOI 10.3390/molecules26020485
   Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015
   Jiménez M, 2019, J MATER CHEM B, V7, P1974, DOI 10.1039/c8tb02738b
   Kim H, 2017, J BONE MINER RES, V32, P397, DOI 10.1002/jbmr.2974
   KO KM, 1990, MOL CELL BIOCHEM, V95, P125
   LEE BJ, 1995, J FOOD SCI, V60, P241, DOI 10.1111/j.1365 2621.1995.tb05646.x
   Li HR, 2019, ADV MATER SCI ENG, V2019, DOI 10.1155/2019/3027303
   Li J, 2021, INT ENDOD J, V54, P1129, DOI 10.1111/iej.13505
   Liu LW, 2018, AQUACULT NUTR, V24, P850, DOI 10.1111/anu.12614
   Liu YJ, 2021, COLLOID SURFACE B, V203, DOI 10.1016/j.colsurfb.2021.111768
   Liu ZQ, 2020, EUR J MED CHEM, V189, DOI 10.1016/j.ejmech.2019.112020
   Lopez Gonzalez Angel A, 2010, Front Biosci (Elite Ed), V2, P1093
   Marie PJ, 2006, BONE, V38, P10, DOI 10.1016/j.bone.2005.07.029
   Marolt G, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.582746
   Martín del Campo M, 2019, MOLECULES, V24, DOI 10.3390/molecules24091660
   Martin del Campo M, 2016, BIOMATER SCI UK, V4, P1596, DOI 10.1039/c6bm00459h
   Milkovic L, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080793
   Moore K, 1998, FREE RADICAL RES, V28, P659, DOI 10.3109/10715769809065821
   Mora Boza A, 2020, CARBOHYD POLYM, V241, DOI 10.1016/j.carbpol.2020.116269
   Mora Boza A, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 48015 5
   Park JW, 2010, ACTA BIOMATER, V6, P2843, DOI 10.1016/j.actbio.2010.01.017
   Peng SL, 2009, CELL PHYSIOL BIOCHEM, V23, P165, DOI 10.1159/000204105
   Powell SR, 2000, J NUTR, V130, p1447S, DOI 10.1093/jn/130.5.1447S
   Prasad Ananda S, 2014, Front Nutr, V1, P14, DOI 10.3389/fnut.2014.00014
   Qin J, 2022, GREEN CHEM, V24, P8113, DOI 10.1039/d2gc02638d
   Rajeshkumar S, 2018, ENZYME MICROB TECH, V117, P91, DOI 10.1016/j.enzmictec.2018.06.009
   Rojo L, 2015, J MATER CHEM B, V3, P2708, DOI 10.1039/c4tb01969e
   Sasaki J, 1983, J BURN CARE REHABIL, V4, P251
   Seo HJ, 2010, NUTR RES PRACT, V4, P356, DOI 10.4162/nrp.2010.4.5.356
   SERRAINO MR, 1984, J AGR FOOD CHEM, V32, P38, DOI 10.1021/jf00121a010
   SULLIVAN JF, 1980, AM J CLIN NUTR, V33, P51, DOI 10.1093/ajcn/33.1.51
   Tian Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102132
   Torres J, 2005, J INORG BIOCHEM, V99, P828, DOI 10.1016/j.jinorgbio.2004.12.011
   Toyokuni S, 2002, REDOX REP, V7, P189, DOI 10.1179/135100002125000596
   Tsikas D, 2017, ANAL BIOCHEM, V524, P13, DOI 10.1016/j.ab.2016.10.021
   Tunçdemir M, 2017, HUM EXP TOXICOL, V36, P813, DOI 10.1177/0960327116666619
   Wang QX, 2018, COLLOID SURFACE B, V169, P478, DOI 10.1016/j.colsurfb.2018.05.057
   Wang YP, 2017, APPL SURF SCI, V412, P29, DOI 10.1016/j.apsusc.2017.03.191
   Wu C, 2011, ADV MATER RES SWITZ, V183 185, P863, DOI 10.4028/www.scientific.net/AMR.183 185.863
   Wu SP, 2013, FOOD CHEM, V138, P1312, DOI 10.1016/j.foodchem.2012.10.118
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Yasuda H, 2021, J BONE MINER METAB, V39, P2, DOI 10.1007/s00774 020 01175 1
   Zago MP, 2000, BIOL RES, V33, P143
   Zajdel A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/147307
   Zhang H, 2021, MAT SCI ENG C MATER, V118, DOI 10.1016/j.msec.2020.111402
NR 80
TC 8
Z9 9
U1 1
U2 23
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1999 4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD FEB
PY 2023
VL 15
IS 2
AR 339
DI 10.3390/pharmaceutics15020339
PG 20
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 9L7AN
UT WOS:000941699000001
PM 36839661
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Rodríguez Ubreva, J
   Garcia Gomez, A
   Ballestar, E
AF Rodriguez Ubreva, Javier
   Garcia Gomez, Antonio
   Ballestar, Esteban
TI Epigenetic mechanisms of myeloid differentiation in the tumor
   microenvironment
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID DENDRITIC CELL DIFFERENTIATION; HEMATOPOIETIC STEM CELLS; MHC CLASS II;
   SUPPRESSOR CELLS; OSTEOCLAST DIFFERENTIATION; MULTIPLE MYELOMA; IN VIVO;
   GM CSF; INHIBITS OSTEOCLASTOGENESIS; MACROPHAGE DIFFERENTIATION
AB Myeloid cells are extremely plastic as they respond and terminally differentiate into a plethora of functional types, in the blood or tissues, in response to a variety of growth factors, cytokines and pathogenic molecules. This plasticity is also manifested by the subversion of normal differentiation into the aberrant generation of a variety of tolerogenic myeloid cells in the tumoral microenvironment, where a variety of factors are released. Epigenetic mechanisms are in great part responsible for the plasticity of myeloid cells both under physiological and tumoral conditions. The development of compounds that inhibit epigenetic enzymes provides novel therapeutic opportunities to intercept the crosstalk between cancer cells and host myeloid cells. Here, we summarize our current knowledge on the myeloid cell types generated in the cancer environment, the factors and epigenetic enzymes participating in these processes and propose a number of potential targets for future pharmacological use.
C1 [Rodriguez Ubreva, Javier; Garcia Gomez, Antonio; Ballestar, Esteban] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Programme PEBC, Chromatin & Dis Grp, Barcelona 08908, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)
RP Ballestar, E (通讯作者)，Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Programme PEBC, Chromatin & Dis Grp, Barcelona 08908, Spain.
EM eballestar@idibell.cat
RI ; Ballestar, Esteban/ABG 8561 2020; Rodriguez Ubreva,
   javier/HTP 5081 2023
OI Garcia, Antonio/0000 0003 0527 7351; RODRIGUEZ UBREVA,
   JAVIER/0000 0003 4707 4536; Ballestar, Esteban/0000 0002 1400 2440; 
FU Instituto de Salud Carlos III, an organisation of the Ministerio de
   Economia y Competitividad [SAF2014 55942 R]; FEDER funds/European
   Regional Development Fund (ERDF)  a way to build Europe; Multiple
   Myeloma Research Foundation (MMRF); Asociacion Espanola Contra el Cancer
   (AECC)
FX This work was supported by grant SAF2014 55942 R from the Instituto de
   Salud Carlos III, an organisation of the Ministerio de Economia y
   Competitividad, and was cofunded by FEDER funds/European Regional
   Development Fund (ERDF) a way to build Europe, and the Multiple Myeloma
   Research Foundation (MMRF). AGG is funded by the Asociacion Espanola
   Contra el Cancer (AECC).
CR Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Agarwal P, 2016, ONCOTARGET, V7, P6809, DOI 10.18632/oncotarget.6843
   Alvarez Errico D, 2015, NAT REV IMMUNOL, V15, P7, DOI 10.1038/nri3777
   AOE T, 1995, J EXP MED, V181, P1881, DOI 10.1084/jem.181.5.1881
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Becher B, 2016, IMMUNITY, V45, P963, DOI 10.1016/j.immuni.2016.10.026
   Beckebaum S, 2004, CLIN CANCER RES, V10, P7260, DOI 10.1158/1078 0432.CCR 04 0872
   Belkina AC, 2013, J IMMUNOL, V190, P3670, DOI 10.4049/jimmunol.1202838
   Bonavita E, 2015, CELL, V160, P700, DOI 10.1016/j.cell.2015.01.004
   Botta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00348
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown RD, 2000, BLOOD, V96, p161A
   Broz ML, 2014, CANCER CELL, V26, P638, DOI 10.1016/j.ccell.2014.09.007
   Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935
   Cekic C, 2014, CANCER RES, V74, P7250, DOI 10.1158/0008 5472.CAN 13 3583
   Chang YC, 2004, J LEUKOCYTE BIOL, V75, P486, DOI 10.1189/jlb.0903448
   Chang YC, 2008, BLOOD, V111, P5054, DOI 10.1182/blood 2007 12 130609
   Chen XF, 2012, P NATL ACAD SCI USA, V109, pE2865, DOI 10.1073/pnas.1121131109
   Cheng PY, 2008, J EXP MED, V205, P2235, DOI 10.1084/jem.20080132
   Colombo M, 2014, ONCOTARGET, V5, P10393, DOI 10.18632/oncotarget.2084
   Conejo Garcia JR, 2016, PHARMACOL THERAPEUT, V164, P97, DOI 10.1016/j.pharmthera.2016.04.003
   Dalotto Moreno T, 2013, CANCER RES, V73, P1107, DOI 10.1158/0008 5472.CAN 12 2418
   Daurkin I, 2010, CANCER IMMUNOL IMMUN, V59, P697, DOI 10.1007/s00262 009 0786 4
   de la Rica L, 2013, GENOME BIOL, V14, DOI 10.1186/gb 2013 14 9 r99
   Demoulin SA, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1008334
   Elkabets M, 2010, EUR J IMMUNOL, V40, P3347, DOI 10.1002/eji.201041037
   Fang C, 2016, J IMMUNOL, V196, P4452, DOI 10.4049/jimmunol.1501466
   Frikeche J, 2011, EXP HEMATOL, V39, P1056, DOI 10.1016/j.exphem.2011.08.004
   Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166
   Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175
   Gangenahalli GU, 2005, STEM CELLS DEV, V14, P140, DOI 10.1089/scd.2005.14.140
   Garcia Gomez Antonio, 2014, World J Stem Cells, V6, P322, DOI 10.4252/wjsc.v6.i3.322
   Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463
   Guiducci C, 2005, EUR J IMMUNOL, V35, P557, DOI 10.1002/eji.200425810
   Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712
   Hanson EM, 2009, J IMMUNOL, V183, P937, DOI 10.4049/jimmunol.0804253
   Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008 5472.CAN 05 1299
   Huang Y, 2012, GENES IMMUN, V13, P311, DOI 10.1038/gene.2011.87
   Ishii M, 2009, BLOOD, V114, P3244, DOI 10.1182/blood 2009 04 217620
   Jin ZX, 2015, MOL ENDOCRINOL, V29, P730, DOI 10.1210/me.2014 1365
   Jin ZX, 2013, MOL ENDOCRINOL, V27, P325, DOI 10.1210/me.2012 1302
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kittan NA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078045
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004
   Kumar V, 2016, IMMUNITY, V44, P303, DOI 10.1016/j.immuni.2016.01.014
   Pham L, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.216853
   Logie C, 2016, SEMIN IMMUNOL, V28, P359, DOI 10.1016/j.smim.2016.06.003
   Louis C, 2015, J IMMUNOL, V195, P134, DOI 10.4049/jimmunol.1500369
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471 4906(02)02302 5
   Mantovani A., 2017, Nature reviews Clinical oncology
   Mao YM, 2014, CLIN CANCER RES, V20, P4096, DOI 10.1158/1078 0432.CCR 14 0635
   Martino A, 2010, J IMMUNOL, V184, P2038, DOI 10.4049/jimmunol.0903348
   Mazzoni A, 2002, J IMMUNOL, V168, P689, DOI 10.4049/jimmunol.168.2.689
   Menetrier Caux C, 1998, BLOOD, V92, P4778, DOI 10.1182/blood.V92.12.4778
   Mikysková R, 2014, J LEUKOCYTE BIOL, V95, P743, DOI 10.1189/jlb.0813435
   Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166
   Mossadegh Keller N, 2013, NATURE, V497, P239, DOI 10.1038/nature12026
   Movahedi K, 2016, ANTIOXIDANTS REDOX S, P1
   Munn DH, 2016, TRENDS IMMUNOL, V37, P193, DOI 10.1016/j.it.2016.01.002
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008
   Nencioni A, 2007, CLIN CANCER RES, V13, P3933, DOI 10.1158/1078 0432.CCR 06 2903
   Nishikawa K, 2015, NAT MED, V21, P281, DOI 10.1038/nm.3774
   Norian LA, 2009, CANCER RES, V69, P3086, DOI 10.1158/0008 5472.CAN 08 2826
   Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010
   Obermajer N, 2011, BLOOD, V118, P5498, DOI 10.1182/blood 2011 07 365825
   Osawa T, 2013, CANCER RES, V73, P3019, DOI 10.1158/0008 5472.CAN 12 3231
   Pan PY, 2010, CANCER RES, V70, P99, DOI 10.1158/0008 5472.CAN 09 1882
   Pello OM, 2012, BLOOD, V119, P411, DOI 10.1182/blood 2011 02 339911
   Ragab AA, 2002, AM J PHYSIOL CELL PH, V283, pC679, DOI 10.1152/ajpcell.00421.2001
   Raimondi L, 2015, ONCOTARGET, V6, P13772, DOI 10.18632/oncotarget.3830
   Ratta M, 2002, BLOOD, V100, P230, DOI 10.1182/blood.V100.1.230
   Rosborough BR, 2012, J LEUKOCYTE BIOL, V91, P701, DOI 10.1189/jlb.0311119
   Sahakian E, 2015, MOL IMMUNOL, V63, P579, DOI 10.1016/j.molimm.2014.08.002
   Schartner JM, 2005, GLIA, V51, P279, DOI 10.1002/glia.20201
   Schübeler D, 2015, NATURE, V517, P321, DOI 10.1038/nature14192
   Segura E, 2013, IMMUNITY, V38, P336, DOI 10.1016/j.immuni.2012.10.018
   Setiadi AF, 2008, CANCER RES, V68, P9601, DOI 10.1158/0008 5472.CAN 07 5270
   Sido JM, 2015, J LEUKOCYTE BIOL, V97, P677, DOI 10.1189/jlb.1A1014 479R
   Song SS, 2014, INT IMMUNOPHARMACOL, V20, P117, DOI 10.1016/j.intimp.2014.02.027
   Standal T, 2002, BLOOD, V100, P3002, DOI 10.1182/blood 2002 04 1190
   Steinman RM, 1999, HUM IMMUNOL, V60, P562, DOI 10.1016/S0198 8859(99)00030 0
   Sun YP, 2017, J INNATE IMMUN, V9, P126, DOI 10.1159/000450681
   Terracina KP, 2016, CANCER IMMUNOL IMMUN, V65, P1061, DOI 10.1007/s00262 016 1868 8
   Tesone AJ, 2016, CELL REP, V14, P1774, DOI 10.1016/j.celrep.2016.01.056
   Torres Aguilar H, 2010, J IMMUNOL, V184, P1765, DOI 10.4049/jimmunol.0902133
   Toscano MA, 2007, NAT IMMUNOL, V8, P825, DOI 10.1038/ni1482
   Utting JC, 2010, CELL BIOCHEM FUNCT, V28, P374, DOI 10.1002/cbf.1660
   Vento Tormo R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059 015 0863 2
   Villagra A, 2009, NAT IMMUNOL, V10, P92, DOI 10.1038/ni.1673
   Walkley CR, 2007, CELL, V129, P1081, DOI 10.1016/j.cell.2007.03.055
   WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828
   Won H, 2014, BLOOD, V124, P2647, DOI 10.1182/blood 2013 10 534313
   Yasui T, 2011, J BONE MINER RES, V26, P2665, DOI 10.1002/jbmr.464
   Youn JI, 2013, NAT IMMUNOL, V14, P211, DOI 10.1038/ni.2526
   Zhang Q, 2015, NATURE, V525, P389, DOI 10.1038/nature15252
   Zhao BH, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3379
   ZHUANG J, 2012, PLOS ONE, V7
NR 101
TC 10
Z9 10
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471 4892
EI 1471 4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD AUG
PY 2017
VL 35
BP 20
EP 29
DI 10.1016/j.coph.2017.04.008
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA FS3FG
UT WOS:000419664900005
PM 28551408
DA 2025 08 17
ER

PT J
AU Chen, J
   Lu, RT
   Lai, R
   Dinh, T
   Paul, D
   Venadas, S
   Wheeler, LA
AF Chen, June
   Lu, Ryan Ta
   Lai, Ronald
   Dinh, Tim
   Paul, David
   Venadas, Steven
   Wheeler, Larry A.
TI Bimatoprost Induced Calcium Signaling in Human T Cells does not Involve
   Prostanoid FP or TP Receptors
SO CURRENT EYE RESEARCH
LA English
DT Article
DE bimatoprost; human peripheral blood T lymphoblasts; intracellular
   calcium concentration ([Ca2+]i); prostamide sensitive preparation;
   prostanoid FP receptor
ID PROSTAGLANDIN ANALOGS; DEFICIENT MICE; INTRACELLULAR CALCIUM;
   INTRAOCULAR PRESSURE; INTERNATIONAL UNION; KNOCKOUT MICE; PHARMACOLOGY;
   ETHANOLAMIDES; MECHANISM; CLASSIFICATION
AB Purpose: The prostamide bimatoprost and prostanoid FP receptor agonists are highly efficacious drugs for glaucoma treatment. The presence of both prostamide and prostanoid FP receptors in bimatoprost sensitive preparations has made prostamide receptor classification difficult. This study investigated a novel bimatoprost sensitive preparation. Methods: Human peripheral blood T lymphoblasts (Molt 3) and human osteoblasts (hFOB) were cultured for intracellular calcium signaling studies and quantitative real time PCR analysis of RNA. Results: Bimatoprost stimulated concentration related increases in [Ca2 +]i in a human T cell line that does not express human FP receptor/variants, according to PCR analysis. The calcium signal induced by bimatoprost was not antagonized by prostanoid FP receptor antagonist/partial agonist AL 8810 or selective TP receptor antagonist SQ 29548. Conversely, bimatoprost did not elevate [Ca2 +]i in human osteoblasts, which were confirmed to contain RNA of human FP receptor/variants. Conclusions: Molt 3 cells have been identified as a bimatoprost sensitive preparation in which the activity of bimatoprost is independent of prostanoid FP receptors.
C1 [Chen, June; Lu, Ryan Ta; Lai, Ronald; Dinh, Tim; Venadas, Steven; Wheeler, Larry A.] Allergan Pharmaceut Inc, Dept Biol Sci, Irvine, CA 92612 USA.
   [Paul, David] Allergan Pharmaceut Inc, Dept Biostat, Irvine, CA 92612 USA.
C3 AbbVie; Allergan; AbbVie; Allergan
RP Chen, J (通讯作者)，Allergan Pharmaceut Inc, Dept Biol Sci, 2525 Dupont Dr,RD3 2B, Irvine, CA 92612 USA.
EM chen_june@allergan.com
CR Brubaker RF, 2001, AM J OPHTHALMOL, V131, P19, DOI 10.1016/S0002 9394(00)00843 6
   Chen J, 2005, CARDIOVASC DRUG REV, V23, P231
   Chen J, 2005, BRIT J PHARMACOL, V144, P493, DOI 10.1038/sj.bjp.0706044
   Christiansen GA, 2004, OPHTHALMOLOGY, V111, P1658, DOI 10.1016/j.ophtha.2004.02.006
   COLEMAN RA, 1994, PHARMACOL REV, V46, P205
   Cooper DMF, 2003, BIOCHEM SOC T, V31, P912
   Crowston JG, 2005, INVEST OPHTH VIS SCI, V46, P4571, DOI 10.1167/iovs.05 0723
   Girard BA, 2006, J NEUROCHEM, V99, P499, DOI 10.1111/j.1471 4159.2006.04112.x
   Gomez LA, 1997, J MOL CELL CARDIOL, V29, P1255, DOI 10.1006/jmcc.1996.0363
   Griffin BW, 1999, J PHARMACOL EXP THER, V290, P1278
   Gutiérrez AA, 1999, J PHYSIOL LONDON, V517, P95, DOI 10.1111/j.1469 7793.1999.0095z.x
   Harks EGA, 2005, AM J PHYSIOL CELL PH, V289, pC130, DOI 10.1152/ajpcell.00416.2004
   Hartke J. R., 2001, Journal of Musculoskeletal & Neuronal Interactions, V2, P25
   Humphrey PPA, 1998, PHARMACOL REV, V50, P271
   Kamenetsky M, 2006, J MOL BIOL, V362, P623, DOI 10.1016/j.jmb.2006.07.045
   Kelly CR, 2003, J PHARMACOL EXP THER, V304, P238, DOI 10.1124/jpet.102.042556
   KENAKIN T, 1997, PHARM ANAL DRUG RECE, P396
   Kozak KR, 2002, J BIOL CHEM, V277, P44877, DOI 10.1074/jbc.M206788200
   Matias I, 2004, J PHARMACOL EXP THER, V309, P745, DOI 10.1124/jpet.103.061705
   Milne SA, 2003, J CLIN ENDOCR METAB, V88, P1825, DOI 10.1210/jc.2002 021368
   Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193
   Ota T, 2005, INVEST OPHTH VIS SCI, V46, P4159, DOI 10.1167/iovs.05 0494
   Ota T, 2006, INVEST OPHTH VIS SCI, V47, P3395, DOI 10.1167/iovs.06 0100
   Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901
   Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003
   Parekh AB, 2006, PFLUG ARCH EUR J PHY, V453, P303, DOI 10.1007/s00424 006 0089 y
   Rao GK, 2006, J PHARMACOL EXP THER, V317, P820, DOI 10.1124/jpet.105.100503
   Richter M, 2003, INVEST OPHTH VIS SCI, V44, P4419, DOI 10.1167/iovs.02 1281
   Samadfam R, 2006, J RHEUMATOL, V33, P1167
   Sarrazin P, 2001, PROSTAG LEUKOTR ESS, V64, P203, DOI 10.1054/plef.1999.0127
   SCHAAF TK, 1979, J MED CHEM, V22, P1340, DOI 10.1021/jm00197a012
   Spada CS, 2005, EXP EYE RES, V80, P135, DOI 10.1016/j.exer.2004.08.019
   Sugimoto Y, 2000, PROG LIPID RES, V39, P289, DOI 10.1016/S0163 7827(00)00008 4
   van der Valk R, 2005, OPHTHALMOLOGY, V112, P1177, DOI 10.1016/j.ophtha.2005.01.042
   Vysniauskiene I, 2006, INVEST OPHTH VIS SCI, V47, P295, DOI 10.1167/iovs.05 0760
   Woodward DF, 2007, BRIT J PHARMACOL, V150, P342, DOI 10.1038/sj.bjp.0706989
   Woodward DF, 2003, J PHARMACOL EXP THER, V305, P772, DOI 10.1124/jpet.102.047837
   Woodward DF, 2001, SURV OPHTHALMOL, V45, pS337, DOI 10.1016/S0039 6257(01)00224 7
   Yeh JH, 2006, BASIC CLIN PHARMACOL, V98, P416, DOI 10.1111/j.1742 7843.2006.pto_350.x
   Zhao XJ, 2003, INVEST OPHTH VIS SCI, V44, P1945, DOI 10.1167/iovs.02 0920
NR 40
TC 9
Z9 11
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271 3683
EI 1460 2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2009
VL 34
IS 3
BP 184
EP 195
AR PII 909312313
DI 10.1080/02713680802669781
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Ophthalmology
GA 416GB
UT WOS:000263992600003
PM 19274525
DA 2025 08 17
ER

PT J
AU Reginster, JY
   Wilson, KM
   Dumont, E
   Bonvoisin, B
   Barrett, J
AF Reginster, JY
   Wilson, KM
   Dumont, E
   Bonvoisin, B
   Barrett, J
TI Monthly oral ibandronate is well tolerated and efficacious in
   postmenopausal women: Results from the monthly oral pilot study
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID OSTEOPOROTIC FRACTURES; THERAPY; IMPACT; PERSISTENCE; ALENDRONATE;
   POPULATION; MORTALITY; BONE; BISPHOSPHONATES; RISEDRONATE
AB Context: Ibandronate, a potent, nitrogen containing bisphosphonate developed for intermittent administration in postmenopausal osteoporosis, aims to overcome current adherence issues with daily and weekly oral bisphosphonates through once monthly oral dosing.
   Objective: The purpose of this study was to investigate the safety, pharmacodynamics, and pharmacokinetics of once monthly oral ibandronate.
   Design: A randomized, 3 month, double blind, placebo controlled, phase I study (Monthly Oral Pilot Study) was conducted.
   Setting: The study was conducted at five clinical trial centers in the United Kingdom and Belgium.
   Patients or Other Participants: Subjects were postmenopausal women (age, 55   80 yr; >= 3 yr post menopause; n = 144).
   Intervention(s): Once monthly oral ibandronate 50, 100, or 150 mg or placebo was used. After the first cycle, the 50 mg arm was split, with participants continuing on either 50 or 100 mg.
   Main Outcome Measure(s): Primary outcome measures were safety, serum and urinary C telopeptide (CTX), and serum ibandronate AUC(0 infinity).
   Results: Once  monthly oral ibandronate was well tolerated, with a similar overall and upper gastrointestinal safety profile to placebo. Once  monthly ibandronate was also highly effective in decreasing bone turnover; substantial reductions from baseline in serum CTX ( 56.7% and  40.7% in the 150  and 100  mg arms, respectively; P < 0.001 vs. placebo) and urinary CTX ( 54.1% and  34.6%, respectively; P < 0.001 vs. placebo) were observed at d 91 (30 d after the final dose). Analysis of the area under the effect curve (d1   91) for change from baseline (percent x days) in serum CTX and urinary CTX indicated a dose  response relationship. The AUC(0 infinity) for ibandronate increased with dose but not in a dose  proportional manner.
   Conclusions: These findings indicate a potential role for once monthly oral ibandronate in the treatment of postmenopausal osteoporosis.
C1 Univ Liege, Unite Explorat Metab Os & Cartilage, B 4020 Liege, Belgium.
   F Hoffmann La Roche & Co Ltd, CH 4070 Basel, Switzerland.
   GlaxoSmithKline Inc, Collegeville, PA 19426 USA.
C3 University of Liege; Roche Holding; GlaxoSmithKline; Glaxosmithkline USA
RP Reginster, JY (通讯作者)，Ctr Hosp Univ Ctr Ville, Unite Explorat Metab Os & Cartilage, B 4020 Liege, Belgium.
EM jyreginster@ulg.ac.be
RI Reginster, Jean Yves/AGC 6097 2022
CR Barrett J, 2004, J CLIN PHARMACOL, V44, P951, DOI 10.1177/0091270004267594
   Bauss F, 2004, OSTEOPOROSIS INT, V15, P423, DOI 10.1007/s00198 004 1612 7
   Brown JP, 2002, CALCIFIED TISSUE INT, V71, P103, DOI 10.1007/s00223 002 2011 8
   Browner WS, 1996, ARCH INTERN MED, V156, P1521, DOI 10.1001/archinte.156.14.1521
   Caro JJ, 2004, OSTEOPOROSIS INT, V15, P1003, DOI 10.1007/s00198 004 1652 z
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   CHRISCHILLES EA, 1991, ARCH INTERN MED, V151, P2026, DOI 10.1001/archinte.151.10.2026
   Claxton AJ, 2001, CLIN THER, V23, P1296, DOI 10.1016/S0149 2918(01)80109 0
   Clowes JA, 2004, J CLIN ENDOCR METAB, V89, P1117, DOI 10.1210/jc.2003 030501
   COOPER C, 1993, AM J EPIDEMIOL, V137, P1001, DOI 10.1093/oxfordjournals.aje.a116756
   Cooper C, 2003, J CLIN ENDOCR METAB, V88, P4609, DOI 10.1210/jc.2003 022029
   Cramer JA, 2004, J BONE MINER RES, V19, pS448
   Delmas PD, 2004, OSTEOPOROSIS INT, V15, P792, DOI 10.1007/s00198 004 1602 9
   DIEL IJ, 2003, P ASCO, V22, P47
   Eastell R, 2002, CALCIFIED TISSUE INT, V70, P400, DOI 10.1007/s00223 001 0047 9
   Ettinger M, 2004, ARTHRITIS RHEUM, V50, pS513
   GERTZ BJ, 1995, CLIN PHARMACOL THER, V58, P288, DOI 10.1016/0009 9236(95)90245 7
   Gieschke R, 2004, OSTEOPOROSIS INT, V15, pS97
   GREENDALE GA, 1995, J AM GERIATR SOC, V43, P955, DOI 10.1111/j.1532 5415.1995.tb05557.x
   Hasserius R, 2003, OSTEOPOROSIS INT, V14, P61, DOI 10.1007/s00198 002 1316 9
   Ismail AA, 1998, OSTEOPOROSIS INT, V8, P291, DOI 10.1007/s001980050067
   Kanis JA, 1997, OSTEOPOROSIS INT, V7, P390, DOI 10.1007/BF01623782
   Kendler D, 2004, MATURITAS, V48, P243, DOI 10.1016/j.maturitas.2003.12.012
   LOMBAS C, 2000, J BONE MINER RES  S1, V15, pM406
   McClung MR, 2004, J BONE MINER RES, V19, P11, DOI 10.1359/JBMR.0301202
   McCombs JS, 2004, MATURITAS, V48, P271, DOI 10.1016/j.maturitas.2004.02.005
   Melton L., 1991, J BONE MIN RES, V6, pS136
   Melton LJ, 2003, J BONE MINER RES, V18, P1139, DOI 10.1359/jbmr.2003.18.6.1139
   Mitchell DY, 2000, J CLIN PHARMACOL, V40, P258, DOI 10.1177/00912700022008928
   Papaioannou A, 2003, OSTEOPOROSIS INT, V14, P808, DOI 10.1007/s00198 003 1431 2
   Ravn P, 1996, BONE, V19, P527, DOI 10.1016/S8756 3282(96)00229 3
   Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24
   Riis BJ, 2001, J BONE MINER RES, V16, P1871, DOI 10.1359/jbmr.2001.16.10.1871
   Schnitzer T, 2000, AGING CLIN EXP RES, V12, P1
   Segal E, 2003, ISR MED ASSOC J, V5, P859
   Simon JA, 2002, CLIN THER, V24, P1871, DOI 10.1016/S0149 2918(02)80085 6
   Tankó LB, 2003, J INTERN MED, V254, P159, DOI 10.1046/j.1365 2796.2003.01174.x
   The Final Call, 2001, Covert action in Africa: A smoking gun in Washington D.C
   Tosteson ANA, 2003, AM J MED, V115, P209, DOI 10.1016/S0002 9343(03)00362 0
   Yood RA, 2003, OSTEOPOROSIS INT, V14, P965, DOI 10.1007/s00198 003 1502 4
NR 40
TC 48
Z9 49
U1 0
U2 1
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD SEP
PY 2005
VL 90
IS 9
BP 5018
EP 5024
DI 10.1210/jc.2004 1750
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 962DM
UT WOS:000231711200003
PM 15972582
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Fraenkel, L
   Gulanski, B
   Wittink, DR
AF Fraenkel, Liana
   Gulanski, Barbara
   Wittink, Dick R.
TI Preference for hip protectors among older adults at high risk for
   osteoporotic fractures
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE osteoporosis; hip protectors; patient preferences
ID ELDERLY PEOPLE; PREVENTION; COST
AB Objective. To determine older adults' treatment preferences for osteoporosis comparing bisphosphonates and hip protectors.
   Methods. Subjects at high risk for an osteoporotic hip fracture completed a discrete choice questionnaire to determine preferences for hip protectors versus oral weekly bisphosphonates. Simulations, based on respondents' values for type of treatment and absolute reduction in risk of hip fractures over 5 years, were performed to predict treatment choices.
   Results. Seventy six patients participated in this study (92% participation rate). At the time of the study 57% of the participants were currently using bisphosphonates; none had ever heard of a hip protector. In the base case scenario, in which both options were described as being equally effective, 9% preferred hip protectors, 88% weekly oral bisphosphonates, and 3% refused all options. When hip protectors were described as being more effective than bisphosphonates, 26% preferred hip protectors, 71% weekly oral bisphosphonates, and 3% continued to refuse all options. Preference for hip protectors was stronger among participants not currently using bisphosphonates (36% vs 19%, p = 0.08), as well as among subjects preferring to avoid taking prescription drugs for most health problems (44% vs 12%, p = 0.002).
   Conclusion. When presented with tradeoffs between hip protectors and bisphosphonates, the majority of community dwelling older adults at high risk for fracture prefer the latter. Of note, however, many of the participants in this study were current bisphosphonate users. Future trials and education programs should consider targeting respondents preferring to manage health problems using nonpharmacologic treatment approaches since, based on the results of this study, adherence and proper use of hip protectors is expected to be higher among these patients.
C1 Yale Univ, Sch Med, Rheumatol Sect, New Haven, CT 06520 USA.
   Yale Univ, Sch Med, Vet Adm Connecticut Healthcare Syst, New Haven, CT 06520 USA.
C3 Yale University; Yale University
RP Fraenkel, L (通讯作者)，Yale Univ, Sch Med, Rheumatol Sect, 300 Cedar St,TAC 525,POB 208031, New Haven, CT 06520 USA.
EM liana.fraenkel@yale.edu
FU NIAMS NIH HHS [K23 AR048826, K23 AR048826 0] Funding Source: Medline
CR Black DM, 2001, OSTEOPOROSIS INT, V12, P519, DOI 10.1007/s001980170072
   BOCUZZI SJ, 2005, OSTEOPOROSIS INT S3, V16, pS24
   Braddock CH, 1999, JAMA J AM MED ASSOC, V282, P2313, DOI 10.1001/jama.282.24.2313
   Cameron ID, 2000, AGE AGEING, V29, P57, DOI 10.1093/ageing/29.1.57
   Cramer JA, 2004, ARTHRITIS RHEUM, V50, pS294
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Ganther JM, 2001, MED DECIS MAKING, V21, P133, DOI 10.1177/02729890122062389
   Heikinheimo R, 2004, AGING CLIN EXP RES, V16, P41
   Kannus P, 2000, NEW ENGL J MED, V343, P1506, DOI 10.1056/NEJM200011233432101
   Orme B, 2003, TECHNICAL PAPER SERI
   ORME B, 2001, CBC WEB ANAL MODULE
   Parker MJ, 2006, BMJ BRIT MED J, V332, P571, DOI 10.1136/bmj.38753.375324.7C
   Sawka AM, 2005, OSTEOPOROSIS INT, V16, P1461, DOI 10.1007/s00198 005 1932 2
   Segui Gomez M, 2002, INT J TECHNOL ASSESS, V18, P55
   Singh S, 2004, J RHEUMATOL, V31, P1607
   Solomon DH, 2005, ARCH INTERN MED, V165, P2414, DOI 10.1001/archinte.165.20.2414
   van Schoor NM, 2003, OSTEOPOROSIS INT, V14, P353, DOI 10.1007/s00198 003 1382 7
   Wehren Lois E, 2003, Curr Osteoporos Rep, V1, P78, DOI 10.1007/s11914 003 0013 8
   [No title captured]
NR 19
TC 13
Z9 13
U1 0
U2 0
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA
SN 0315 162X
J9 J RHEUMATOL
JI J. Rheumatol.
PD OCT
PY 2006
VL 33
IS 10
BP 2064
EP 2068
PG 5
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 094YL
UT WOS:000241275200027
PM 17014021
DA 2025 08 17
ER

PT J
AU Park, JJ
   Kang, KL
AF Park, Jung Ju
   Kang, Kyung Lhi
TI Effect of 980 nm GaAlAs diode laser irradiation on healing of extraction
   sockets in streptozotocin induced diabetic rats: a pilot study
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE LLLT; Alveolar bone healing; Osteoblast marker; Diode laser; Diabetic
   rat
ID LOW ENERGY LASER; TOOTH EXTRACTION; BONE FORMATION; IN VITRO; THERAPY;
   DIFFERENTIATION; PROLIFERATION; OSTEOBLASTS; EXPRESSION
AB Low level laser irradiation can promote the healing process in soft and hard tissue but the precise mechanisms are unclear. In this study, we examined the effect of LLLT (low level laser therapy) on the healing of extraction sockets in diabetic and healthy rats. Forty eight Sprague Dawley rats were divided into normal (n = 24) and diabetic (n = 24) rats, and streptozotocin (STZ) injection was used to induce diabetes in the latter. The left and right maxillary first molars of all the rats were extracted. In the non diabetic rats, the left extraction sockets were not irradiated (group 1) and the right ones were irradiated daily for 3, 5, 7, and 14 days after extraction with a galium aluminum arsenide (GaAlAs) diode laser (group 2), and in the diabetic rats, similarly the left ones were not irradiated (group 3) and the right ones were irradiated (group 4). Specimens acquired at these intervals were examined by hematoxylin and eosin (H&E) staining and reverse transcription polymerase chain reaction (RT PCR). Histological observations and gene expression analyses revealed that groups 2 (normal rats with LLLT) and 4 (diabetic rats with LLLT) showed faster initial healing and more new alveolar bone formation than group 1 (normal rats without LLLT) and group 3 (diabetic rats without LLLT), respectively. We conclude that 980 nm GaAlAs low intensity diode laser irradiation is beneficial for the initial stages of alveolar bone healing and for further calcification in both diabetic and normal rats when applied every day at a dose of 13.95 J/cm(2) for 60 s.
C1 [Kang, Kyung Lhi] Kyung Hee Univ, Sch Dent, Inst Oral Biol, Seoul 130701, South Korea.
   [Park, Jung Ju; Kang, Kyung Lhi] Kyung Hee Univ, Sch Dent, Dept Periodontol, Seoul 130701, South Korea.
C3 Kyung Hee University; Kyung Hee University
RP Kang, KL (通讯作者)，Kyung Hee Univ, Sch Dent, Inst Oral Biol, Seoul 130701, South Korea.
EM periokkl@khu.ac.kr
CR Bossy I, 1985, ACUPUNCTURE ELECTRO, V10, P35
   Coluzzi D J, 2000, Dent Clin North Am, V44, P753
   Conlan MJ, 1996, J CLIN PERIODONTOL, V23, P492, DOI 10.1111/j.1600 051X.1996.tb00580.x
   de Almeida JM, 2008, J PERIODONTOL, V79, P2156, DOI [10.1902/jop.2008.080103, 10.1902/jop.2008.080103 ]
   Devlin H, 1996, J ORAL MAXIL SURG, V54, P1087, DOI 10.1016/S0278 2391(96)90166 4
   Farouk AH, 2007, PHOTOMED LASER SURG, V25, P72
   Franceschi RT, 2009, CELLS TISSUES ORGANS, V189, P144, DOI 10.1159/000151747
   Götz W, 2008, CLIN ORAL IMPLAN RES, V19, P1016, DOI 10.1111/j.1600 0501.2008.01569.x
   GOODMAN WG, 1984, DIABETES, V33, P825, DOI 10.2337/diabetes.33.9.825
   Kang KL, 2009, TISSUE ENG REGEN MED, V6, P1310
   Karu TI, 2005, PHOTOMED LASER SURG, V23, P355, DOI 10.1089/pho.2005.23.355
   Kawalec Jill S, 2004, J Foot Ankle Surg, V43, P214, DOI 10.1053/j.jfas.2004.05.004
   Larmey PJ, 1982, DIABETIC MED, V9, P410
   Lee YJ, 2009, TISSUE ENG REGEN MED, V6, P568
   Lomke Mitchell A., 2009, General Dentistry, V57, P47
   MAIMAN TH, 1960, NATURE, V187, P493, DOI 10.1038/187493a0
   MESTER E, 1971, AM J SURG, V122, P532, DOI 10.1016/0002 9610(71)90482 X
   Min HJ, 2007, ORAL DIS, V13, P220, DOI 10.1111/j.1601 0825.2006.01270.x
   Nam KY, 1984, J KOR ORAL MAXILLOFA, V10, P173
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   OZAWA Y, 1995, P SOC PHOTO OPT INS, V1984, P281, DOI 10.1117/12.207040
   Ozawa Y, 1998, BONE, V22, P347, DOI 10.1016/S8756 3282(97)00294 9
   Pereira CL, 2009, INT J ORAL MAX IMPL, V24, P47
   Saito S, 1997, AM J ORTHOD DENTOFAC, V111, P525, DOI 10.1016/S0889 5406(97)70152 5
   Schindl A, 2000, J INVEST MED, V48, P312
   SCHNEIR ML, 1984, J DENT RES, V63, P23, DOI 10.1177/00220345840630010401
   SEIFTER E, 1981, ANN SURG, V194, P42, DOI 10.1097/00000658 198107000 00008
   Shin SH, 2000, J KOR MAXILLOFAC PLA, V22, P522
   Simoes A, 2009, LASER MED SCI, V24, P591, DOI 10.1007/s10103 008 0619 2
   Stein A, 2005, PHOTOMED LASER SURG, V23, P161, DOI 10.1089/pho.2005.23.161
   TAKEDA Y, 1988, INT J ORAL MAX SURG, V17, P388, DOI 10.1016/S0901 5027(88)80070 5
   Tanaka Shiho, 2007, J Oral Implantol, V33, P321, DOI 10.1563/1548 1336(2007)33[321:CONFBD]2.0.CO;2
   Tu QS, 2007, WOUND REPAIR REGEN, V15, P404, DOI 10.1111/j.1524 475X.2007.00243.x
   Yamagishi H., 1994, J JPN SOC LASER DENT, V5, P13
   Yang BK, 2000, J KOR ACAD PERIODONT, V30, P287
NR 35
TC 58
Z9 64
U1 0
U2 8
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
J9 LASER MED SCI
JI Lasers Med. Sci.
PD JAN
PY 2012
VL 27
IS 1
BP 223
EP 230
DI 10.1007/s10103 011 0944 8
PG 8
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA 876FQ
UT WOS:000299093400030
PM 21732114
DA 2025 08 17
ER

PT J
AU Deng, R
   Zhang, HL
   Huang, JH
   Cai, RZ
   Wang, Y
   Chen, YH
   Hu, BX
   Ye, ZP
   Li, ZL
   Mai, J
   Huang, Y
   Li, X
   Peng, XD
   Feng, GK
   Li, JD
   Tang, J
   Zhu, XF
AF Deng, Rong
   Zhang, Hai Liang
   Huang, Jun Hao
   Cai, Rui Zhao
   Wang, Yan
   Chen, Yu Hong
   Hu, Bing Xin
   Ye, Zhi Peng
   Li, Zhi Ling
   Mai, Jia
   Huang, Yun
   Li, Xuan
   Peng, Xiao Dan
   Feng, Gong Kan
   Li, Jun Dong
   Tang, Jun
   Zhu, Xiao Feng
TI MAPK1/3 kinase dependent ULK1 degradation attenuates mitophagy and
   promotes breast cancer bone metastasis
SO AUTOPHAGY
LA English
DT Article
DE Bone metastasis; breast cancer; MAPK1; 3 kinase; mitophagy deficiency;
   ULK1; NLRP3 inflammasome
ID PHOSPHORYLATION; AUTOPHAGY
AB The function of mitophagy in cancer is controversial. ULK1 is critical for induction of macroautophagy/autophagy and has a more specific role in mitophagy in response to hypoxia. Here, we show that ULK1 deficiency induces an invasive phenotype of breast cancer cells under hypoxia and increases osteolytic bone metastasis. Mechanistically, ULK1 depletion attenuates mitophagy ability during hypoxia. As a result, the accumulation of damaged, ROS generating mitochondria leads to activation of the NLRP3 inflammasome, which induces abnormal soluble cytokines secretion, then promotes the differentiation and maturation of osteoclasts, and ultimately results in bone metastasis. Notably, phosphorylation of ULK1 by MAPK1/ERK2 MAPK3/ERK1 kinase triggers its interaction with BTRC and subsequent K48 linked ubiquitination and proteasome degradation. Also, a clearly negative correlation between the expression levels of ULK1 and p MAPK1/3 was observed in human breast cancer tissues. The MAP2K/MEK inhibitor trametinib is sufficient to restore mitophagy function via upregulation of ULK1, leading to inhibition of NLRP3 inflammasome activation, thereby reduces bone metastasis. These results indicate that ULK1 knockout mediated mitophagy defect promotes breast cancer bone metastasis and provide evidence to explore MAP2K/MEK  MAPK1/3 pathway inhibitors for therapy, especially in cancers displaying low levels of ULK1.
C1 [Deng, Rong; Zhang, Hai Liang; Huang, Jun Hao; Cai, Rui Zhao; Wang, Yan; Chen, Yu Hong; Hu, Bing Xin; Ye, Zhi Peng; Li, Zhi Ling; Mai, Jia; Huang, Yun; Li, Xuan; Peng, Xiao Dan; Feng, Gong Kan; Li, Jun Dong; Tang, Jun; Zhu, Xiao Feng] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China.
   [Huang, Jun Hao; Cai, Rui Zhao; Wang, Yan; Tang, Jun] Sun Yat Sen Univ, Dept Breast Oncol, Canc Ctr, Guangzhou, Peoples R China.
   [Li, Jun Dong] Sun Yat Sen Univ, Dept Gynecol Oncol, Canc Ctr, Guangzhou, Peoples R China.
C3 State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen
   University; Sun Yat Sen University
RP Zhu, XF (通讯作者)，Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China.; Tang, J (通讯作者)，Sun Yat Sen Univ, Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Peoples R China.
EM tangjun@sysucc.org.cn; zhuxfeng@mail.sysu.edu.cn
RI Zi, Ye/GWM 3932 2022; Zhu, Xiaofeng/F 3601 2016
FU Natural Science Foundation of China [81630079, 81772624, 81803006,
   81972855, 81772835, 81972481, 81802789, 81972442]; Science and
   Technology Project of Guangzhou [201803010007]; Natural Science
   Foundation of Guangdong Province [2019A1515011209]; National Key R&D
   Program of China [2017YFC0908501]
FX This study was supported by the Natural Science Foundation of China
   (81630079, 81772624, 81803006, 81972855, 81772835, 81972481, 81802789,
   81972442), the Science and Technology Project of Guangzhou
   (201803010007), the Natural Science Foundation of Guangdong Province
   (2019A1515011209), the National Key R&D Program of China
   (2017YFC0908501).
CR Barnard RA, 2016, J PHARMACOL EXP THER, V358, P282, DOI 10.1124/jpet.116.233908
   Bernardini JP, 2017, ONCOGENE, V36, P1315, DOI 10.1038/onc.2016.302
   Chen Q, 2020, ADV SCI, V7, DOI 10.1002/advs.201903616
   Chiu HY, 2020, ANTIOXID REDOX SIGN, V32, P309, DOI 10.1089/ars.2019.7898
   Chourasia AH, 2015, EMBO REP, V16, P1145, DOI 10.15252/embr.201540759
   Chourasia AH, 2015, CANCER METAB, V3, DOI 10.1186/s40170 015 0130 8
   Deng R, 2020, MOL CANCER, V19, DOI 10.1186/s12943 020 01236 z
   Diot A, 2015, PHARMACOL RES, V100, P24, DOI 10.1016/j.phrs.2015.07.014
   Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008
   Elswood J, 2021, AUTOPHAGY, V17, P420, DOI 10.1080/15548627.2020.1720427
   Gargini R, 2011, AUTOPHAGY, V7, P466, DOI 10.4161/auto.7.5.14731
   Gump JM, 2014, AUTOPHAGY, V10, P1327, DOI 10.4161/auto.29394
   Han S, 2020, AUTOPHAGY, V16, P1925, DOI 10.1080/15548627.2020.1810919
   Handra Luca A, 2003, AM J PATHOL, V163, P957, DOI 10.1016/S0002 9440(10)63455 4
   Hu YM, 2012, CELL RES, V22, P399, DOI 10.1038/cr.2011.145
   Humpton TJ, 2019, CANCER DISCOV, V9, P1268, DOI 10.1158/2159 8290.CD 18 1409
   Inuzuka H, 2010, CANCER CELL, V18, P147, DOI 10.1016/j.ccr.2010.06.015
   Jiao L, 2018, AUTOPHAGY, V14, P671, DOI 10.1080/15548627.2017.1381804
   Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557
   Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662
   Kuroyanagi H, 1998, GENOMICS, V51, P76, DOI 10.1006/geno.1998.5340
   Li X, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01272 2
   Li ZL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 17395 y
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lock R, 2014, CANCER DISCOV, V4, P466, DOI 10.1158/2159 8290.CD 13 0841
   Lou GF, 2020, TRENDS MOL MED, V26, P8, DOI 10.1016/j.molmed.2019.07.002
   Lu HQ, 2013, AUTOPHAGY, V9, P1720, DOI 10.4161/auto.26550
   Lupfer C, 2013, NAT IMMUNOL, V14, P480, DOI 10.1038/ni.2563
   Macleod KF, 2020, ANNU REV CANC BIOL, V4, P41, DOI 10.1146/annurev cancerbio 030419 033405
   Mai J, 2019, THERANOSTICS, V9, P3541, DOI 10.7150/thno.32908
   Mao L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 13923 7
   Marsh T, 2020, DEV CELL, V52, P591, DOI 10.1016/j.devcel.2020.01.025
   Matrka MC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177952
   Mauro Lizcano M, 2015, AUTOPHAGY, V11, P833, DOI 10.1080/15548627.2015.1034403
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   Mourskaia AA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3361
   N'Diaye EN, 2009, EMBO REP, V10, P173, DOI 10.1038/embor.2008.238
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Shang LB, 2011, AUTOPHAGY, V7, P924, DOI 10.4161/auto.7.8.15860
   Sharifi MN, 2016, CELL REP, V15, P1660, DOI 10.1016/j.celrep.2016.04.065
   Tang J, 2012, BREAST CANCER RES TR, V134, P549, DOI 10.1007/s10549 012 2080 y
   Thangaraj A, 2020, AUTOPHAGY, V16, P289, DOI 10.1080/15548627.2019.1607686
   Towers CG, 2019, DEV CELL, V50, P690, DOI 10.1016/j.devcel.2019.07.010
   Um JH, 2018, JOVE J VIS EXP, DOI 10.3791/58099
   Vo MT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11164 2
   Wang XN, 2012, EXP THER MED, V3, P146, DOI 10.3892/etm.2011.365
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wu H., 2019, Autophagy, V15, p1882 1898
   Wu RY, 2019, CLIN CANCER RES, V25, P4530, DOI 10.1158/1078 0432.CCR 18 2840
   Wu WX, 2014, EMBO REP, V15, P566, DOI 10.1002/embr.201438501
   Xu L, 2014, J MOL MED, V92, P31, DOI 10.1007/s00109 013 1107 0
   Xu Y, 2020, AUTOPHAGY, V16, P3, DOI 10.1080/15548627.2019.1603547
   Zhang WJ, 2019, TRENDS CANCER, V5, P95, DOI 10.1016/j.trecan.2018.12.004
   Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
NR 57
TC 141
Z9 153
U1 3
U2 75
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554 8627
EI 1554 8635
J9 AUTOPHAGY
JI Autophagy
PD OCT 3
PY 2021
VL 17
IS 10
BP 3011
EP 3029
DI 10.1080/15548627.2020.1850609
EA DEC 2020
PG 19
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA WG7FR
UT WOS:000596698700001
PM 33213267
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Han, YF
   Wu, Y
   Wang, FX
   Li, GF
   Wang, J
   Wu, X
   Deng, AF
   Ren, XX
   Wang, XH
   Gao, J
   Shi, ZM
   Bai, L
   Su, JC
AF Han, Yafei
   Wu, Yan
   Wang, Fuxiao
   Li, Guangfeng
   Wang, Jian
   Wu, Xiang
   Deng, Anfu
   Ren, Xiaoxiang
   Wang, Xiuhui
   Gao, Jie
   Shi, Zhongmin
   Bai, Long
   Su, Jiacan
TI Heterogeneous DNA hydrogel loaded with Apt02 modified tetrahedral
   framework nucleic acid accelerated critical size bone defect repair
SO BIOACTIVE MATERIALS
LA English
DT Article
DE DNA hydrogel; tFNA; Aptamer02; Angiogenesis; Bone regeneration
ID OSTEOBLAST DIFFERENTIATION; PROLIFERATION; SCAFFOLDS
AB Segmental bone defects, stemming from trauma, infection, and tumors, pose formidable clinical challenges. Traditional bone repair materials, such as autologous and allogeneic bone grafts, grapple with limitations including source scarcity and immune rejection risks. The advent of nucleic acid nanotechnology, particularly the use of DNA hydrogels in tissue engineering, presents a promising solution, attributed to their biocompatibility, biodegradability, and programmability. However, these hydrogels, typically hindered by high gelation temperatures (similar to 46 degrees C) and high construction costs, limit cell encapsulation and broader application. Our research introduces a novel polymer modified DNA hydrogel, developed using nucleic acid nanotechnology, which gels at a more biocompatible temperature of 37 degrees C and is cost effective. This hydrogel then incorporates tetrahedral Framework Nucleic Acid (tFNA) to enhance osteogenic mineralization. Furthermore, considering the modifiability of tFNA, we modified its chains with Aptamer02 (Apt02), an aptamer known to foster angiogenesis. This dual approach significantly accelerates osteogenic differentiation in bone marrow stromal cells (BMSCs) and angiogenesis in human umbilical vein endothelial cells (HUVECs), with cell sequencing confirming their targeting efficacy, respectively. In vivo experiments in rats with critical size cranial bone defects demonstrate their effectiveness in enhancing new bone formation. This innovation not only offers a viable solution for repairing segmental bone defects but also opens avenues for future advancements in bone organoids construction, marking a significant advancement in tissue engineering and regenerative medicine.
C1 [Han, Yafei; Wu, Yan; Wang, Fuxiao; Li, Guangfeng; Wang, Jian; Wu, Xiang; Deng, Anfu; Ren, Xiaoxiang; Wang, Xiuhui; Bai, Long; Su, Jiacan] Shanghai Univ, Inst Translat Med, Organoid Res Ctr, Shanghai 200444, Peoples R China.
   [Su, Jiacan] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Orthoped, Shanghai 200092, Peoples R China.
   [Han, Yafei; Wu, Yan; Wang, Fuxiao; Li, Guangfeng; Wang, Jian; Wu, Xiang; Deng, Anfu; Ren, Xiaoxiang; Wang, Xiuhui; Bai, Long; Su, Jiacan] Shanghai Univ, Natl Ctr Translat Med Shanghai, SHU Branch, Shanghai 200444, Peoples R China.
   [Bai, Long] Shanghai Univ, Wenzhou Inst, Wenzhou 325000, Peoples R China.
   [Han, Yafei; Wang, Fuxiao; Li, Guangfeng; Wang, Jian; Wu, Xiang; Deng, Anfu; Gao, Jie] Shanghai Univ, Sch Med, Shanghai 200444, Peoples R China.
   [Han, Yafei; Wang, Fuxiao; Wang, Jian] Shanghai Univ, Sch Environm & Chem Engn, Shanghai 200444, Peoples R China.
   [Shi, Zhongmin] Shanghai Sixth Peoples Hosp, Natl Ctr Orthopaed, Shanghai 200233, Peoples R China.
   [Li, Guangfeng] Shanghai Zhongye Hosp, Dept Orthoped, Shanghai 200444, Peoples R China.
C3 Shanghai University; Shanghai Jiao Tong University; Shanghai University;
   Shanghai University; Shanghai University; Shanghai University; Shanghai
   Jiao Tong University
RP Bai, L; Su, JC (通讯作者)，Shanghai Univ, Inst Translat Med, Organoid Res Ctr, Shanghai 200444, Peoples R China.; Gao, J (通讯作者)，Shanghai Univ, Sch Med, Shanghai 200444, Peoples R China.; Shi, ZM (通讯作者)，Shanghai Sixth Peoples Hosp, Natl Ctr Orthopaed, Shanghai 200233, Peoples R China.
EM jmsx2021@shu.edu.cn; 18930177323@163.com; bailong@shu.edu.cn;
   drsujiacan@163.com
RI Wang, Xiuhui/O 5616 2019; Bai, Long/GZB 1842 2022; Wu,
   Yan/KFT 0036 2024; Su, Jiacan/N 7068 2019; Ren, xiaoxiang/AAQ 7900 2021;
   Wang, Jian/MSX 9437 2025
OI Su, Jiacan/0000 0001 7080 263X; Shi, Zhongmin/0000 0002 6812 2659; Ren,
   Xiaoxiang/0000 0002 1969 3148
FU National Natural Science Foundation of China [82230071, 82172098];
   Integrated Project of Major Research Plan of National Natural Science
   Foundation of China [92249303]; Shanghai Committee of Science and
   Technology [23141900600]; Shanghai Clinical Research Plan
   [SHDC2023CRT01]
FX This work was financially supported by National Natural Science
   Foundation of China (82230071, 82172098), Integrated Project of Major
   Research Plan of National Natural Science Foundation of China
   (92249303), Shanghai Committee of Science and Technology (23141900600,
   Laboratory Animal Research Project), Shanghai Clinical Research Plan of
   SHDC2023CRT01.
CR Amiryaghoubi N, 2020, MED RES REV, V40, P1833, DOI 10.1002/med.21672
   Athanasiadou D, 2023, P NATL ACAD SCI USA, V120, DOI 10.1073/pnas.2220565120
   Bai L, 2024, BIOACT MATER, V31, P525, DOI 10.1016/j.bioactmat.2023.09.005
   Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100
   Boonrungsiman S, 2012, P NATL ACAD SCI USA, V109, P14170, DOI 10.1073/pnas.1208916109
   Chim SM, 2013, CYTOKINE GROWTH F R, V24, P297, DOI 10.1016/j.cytogfr.2013.03.008
   ELIAS JA, 1992, AM J RESP CELL MOL, V7, P365, DOI 10.1165/ajrcmb/7.4.365
   Gacanin J, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201700392
   Gan SQ, 2023, ACS APPL MATER INTER, V15, P26349, DOI 10.1021/acsami.3c02528
   Gan SQ, 2023, GELS BASEL, V9, DOI 10.3390/gels9040286
   Grässel S, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926 014 0452 5
   Han YF, 2023, SMALL, V19, DOI 10.1002/smll.202301996
   Hankenson KD, 2015, ADV DRUG DELIVER REV, V94, P3, DOI 10.1016/j.addr.2015.09.008
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007
   Jin JO, 2020, BBA REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188377
   Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108
   Lex A, 2014, IEEE T VIS COMPUT GR, V20, P1983, DOI 10.1109/TVCG.2014.2346248
   Li H, 2015, CELL DEATH DIFFER, V22, P1935, DOI 10.1038/cdd.2015.99
   Li SH, 2021, SMALL, V17, DOI 10.1002/smll.202104359
   Li YL, 2023, COLLOID POLYM SCI, V301, P383, DOI 10.1007/s00396 023 05071 8
   Lin YF, 2022, INT J ORAL SCI, V14, DOI 10.1038/s41368 022 00199 9
   Liu H, 2015, BIOMATERIALS, V49, P103, DOI 10.1016/j.biomaterials.2015.01.017
   Liu HF, 2022, MATER DESIGN, V222, DOI 10.1016/j.matdes.2022.111070
   Lu Yu, 2021, Biomater Transl, V2, P214, DOI 10.12336/biomatertransl.2021.03.005
   Ma WJ, 2020, ACS APPL MATER INTER, V12, P2095, DOI 10.1021/acsami.9b19079
   Nikolova MP, 2019, BIOACT MATER, V4, P271, DOI 10.1016/j.bioactmat.2019.10.005
   Pape HC, 2010, J ORTHOP TRAUMA, V24, pS36, DOI 10.1097/BOT.0b013e3181cec4a1
   Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014
   Sadeghi A, 2022, INT J BIOL MACROMOL, V205, P341, DOI 10.1016/j.ijbiomac.2022.02.070
   Sethi S, 2022, CHEMBIOCHEM, V23, DOI 10.1002/cbic.202100446
   Shao XR, 2017, SMALL, V13, DOI 10.1002/smll.201602770
   [邵昱 Shao Yu], 2015, [高分子通报, Polymer Bulletin], P100
   Steijvers Emma, 2022, Biomater Transl, V3, P65, DOI 10.12336/biomatertransl.2022.01.007
   Sun L, 1998, CHINESE MED J PEKING, V111, P818
   Wu MH, 2024, ADV SCI, V11, DOI 10.1002/advs.202304641
   Wu MH, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202101591
   Xue X, 2022, BIOACT MATER, V12, P327, DOI 10.1016/j.bioactmat.2021.10.029
   Zhang T, 2022, ADV MATER, DOI 10.1002/adma.202107820
   Zhao D, 2021, ACS APPL MATER INTER, V13, P29439, DOI 10.1021/acsami.1c08565
   Zhou J, 2010, BIOMATERIALS, V31, P1171, DOI 10.1016/j.biomaterials.2009.10.043
NR 41
TC 36
Z9 38
U1 43
U2 171
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, Building 5, Room 411, BEIJING, DONGCHENG
   DISTRICT 100009, PEOPLES R CHINA
EI 2452 199X
J9 BIOACT MATER
JI Bioact. Mater.
PD MAY
PY 2024
VL 35
BP 1
EP 16
DI 10.1016/j.bioactmat.2024.01.009
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA PL1N2
UT WOS:001214143100001
PM 38298451
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Claramunt, D
   Gil Peña, H
   Fuente, R
   García López, E
   Frías, OH
   Ordoñez, FA
   Rodríguez Suárez, J
   Santos, F
AF Claramunt, Debora
   Gil Pena, Helena
   Fuente, Rock
   Garcia Lopez, Enrique
   Hernandez Frias, Olaya
   Ordonez, Flor A.
   Rodriguez Suarez, Julian
   Santos, Fernando
TI Effects of growth hormone treatment on growth plate, bone, and mineral
   metabolism of young rats with uremia induced by adenine
SO PEDIATRIC RESEARCH
LA English
DT Article
ID CHRONIC KIDNEY DISEASE; CHRONIC RENAL FAILURE; CHILDREN; INSUFFICIENCY;
   VOLUME
AB BACKGROUND: In a model of growth retardation secondary to chronic kidney disease (CKD) induced by adenine, this study explores the effects of growth hormone (GH) therapy on growth plate and mineral metabolism.
   METHODS: Weaning female rats receiving a 0.5% adenine diet during 21 days, untreated (AD) or treated with GH (ADGH) for 1 week, were compared with control rats receiving normal diet, either ad libitum or pair fed with AD animals. AD and ADGH rats had similarly elevated serum concentrations of urea nitrogen, parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF23).
   RESULTS: Uremia induced by adenine caused growth retardation and disturbed growth cartilage chondrocyte hypertrophy. We demonstrated marked expression of aquaporin 1 in the growth plate, but its immunohistochemical signal and the expression levels of other proteins potentially related with chondrocyte enlargement, such as Na K 2CI cotransporter, insulin like growth factor 1 (IGF 1), and IGF 1 receptor, were not different among the four groups of rats. The distribution pattern of vascular endothelial growth factor was also similar. AD rats developed femur bone structure abnormalities analyzed by micro computerized tomography.
   CONCLUSION: GH treatment accelerated longitudinal growth velocity, stimulated the proliferation and enlargement of chondrocytes, and did not modify the elevated serum PTH or FGF23 concentrations or the abnormal bone structure.
C1 [Claramunt, Debora; Fuente, Rock; Hernandez Frias, Olaya] Univ Oviedo, Dept Med, Asturias, Spain.
   [Gil Pena, Helena; Garcia Lopez, Enrique; Ordonez, Flor A.; Rodriguez Suarez, Julian; Santos, Fernando] Hosp Univ Cent Asturias, Dept Pediat, Oviedo, Spain.
C3 University of Oviedo; Central University Hospital Asturias
RP Claramunt, D (通讯作者)，Univ Oviedo, Dept Med, Asturias, Spain.
EM declata@gmail.com
RI ; Rodríguez, Julián/F 5900 2019
OI Rodriguez, Julian/0000 0003 4621 8905; FUENTE,
   ROCIO/0000 0002 2311 2836; 
FU University of Oviedo; FEDER funds; ISC III FIS [PI12 00987]; Fundacion
   Bancaria CajAstur; FundaciOn Nutricion y Crecimiento
FX This study has been partially supported by the University of Oviedo,
   FEDER funds, ISC III FIS PI12 00987, Fundacion Bancaria CajAstur, and
   FundaciOn Nutricion y Crecimiento.
CR ALLEN DB, 1992, PEDIATR RES, V31, P406, DOI 10.1203/00006450 199204000 00020
   Alvarez Garcia O, 2007, PEDIATR NEPHROL, V22, P954, DOI 10.1007/s00467 007 0456 8
   Bechtold S, 2009, HORM RES, V72, P60, DOI 10.1159/000229766
   BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   BREUR GJ, 1991, J ORTHOPAED RES, V9, P348, DOI 10.1002/jor.1100090306
   Bush PG, 2010, J BONE MINER RES, V25, P1594, DOI 10.1002/jbmr.47
   Claramunt D, 2015, AM J PHYSIOL RENAL, V309, pF57, DOI 10.1152/ajprenal.00051.2015
   Cobo A, 1996, MINER ELECTROL METAB, V22, P192
   Cooper KL, 2013, NATURE, V495, P375, DOI 10.1038/nature11940
   De Schutter TM, 2011, AM J NEPHROL, V34, P356, DOI 10.1159/000331056
   Ferrari GO, 2014, BMC NEPHROL, V15, DOI 10.1186/1471 2369 15 69
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   KNEPPER MA, 1994, P NATL ACAD SCI USA, V91, P6255, DOI 10.1073/pnas.91.14.6255
   Kovacs GT, 1996, KIDNEY INT, V49, P1413, DOI 10.1038/ki.1996.199
   Mahesh S, 2008, PEDIATR NEPHROL, V23, P41, DOI 10.1007/s00467 007 0527 x
   Mencarelli F, 2009, PEDIATR NEPHROL, V24, P1039, DOI 10.1007/s00467 008 1084 7
   Molinos I, 2006, KIDNEY INT, V70, P1955, DOI 10.1038/sj.ki.5001949
   Santos F, 2003, NEFROLOGIA, V23, P18
   Seikaly MG, 2006, PEDIATR NEPHROL, V21, P793, DOI 10.1007/s00467 006 0040 7
   Shuvy M, 2011, EXP TOXICOL PATHOL, V63, P303, DOI 10.1016/j.etp.2010.02.002
   Tönshoff B, 2005, PEDIATR NEPHROL, V20, P279, DOI 10.1007/s00467 005 1821 0
   TONSHOFF B, 1995, PEDIATR RES, V37, P86
   Troib A, 2016, NEPHROL DIAL TRANSPL, V31, P1270, DOI 10.1093/ndt/gfv373
   Troib A, 2013, KIDNEY INT, V84, P940, DOI 10.1038/ki.2013.196
NR 25
TC 3
Z9 4
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 0031 3998
EI 1530 0447
J9 PEDIATR RES
JI Pediatr. Res.
PD JUL
PY 2017
VL 82
IS 1
BP 148
EP 154
DI 10.1038/pr.2017.95
PG 7
WC Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pediatrics
GA FB6MB
UT WOS:000406256000023
PM 28376076
OA Bronze
DA 2025 08 17
ER

PT J
AU Rastegar, F
   Gao, JL
   Shenaq, D
   Luo, Q
   Shi, QO
   Kim, SH
   Jiang, W
   Wagner, ER
   Huang, EY
   Gao, YH
   Shen, JK
   Yang, K
   He, BC
   Chen, LA
   Zuo, GW
   Luo, JY
   Luo, XJ
   Bi, Y
   Liu, X
   Li, M
   Hu, N
   Wang, LY
   Luther, G
   Luu, HH
   Haydon, RC
   He, TC
AF Rastegar, Farbod
   Gao, Jian Li
   Shenaq, Deana
   Luo, Qing
   Shi, Qiong
   Kim, Stephanie H.
   Jiang, Wei
   Wagner, Eric R.
   Huang, Enyi
   Gao, Yanhong
   Shen, Jikun
   Yang, Ke
   He, Bai Cheng
   Chen, Liang
   Zuo, Guo Wei
   Luo, Jinyong
   Luo, Xiaoji
   Bi, Yang
   Liu, Xing
   Li, Mi
   Hu, Ning
   Wang, Linyuan
   Luther, Gaurav
   Luu, Hue H.
   Haydon, Rex C.
   He, Tong Chuan
TI Lysophosphatidic Acid Acyltransferase β (LPAATβ) Promotes the Tumor
   Growth of Human Osteosarcoma
SO PLOS ONE
LA English
DT Article
ID PHOSPHATIDIC ACID; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC
   DIFFERENTIATION; EXTREMITY OSTEOSARCOMA; MOLECULAR MECHANISMS; PULMONARY
   METASTASES; EXPRESSION; GENE; TARGET; INHIBITION
AB Background: Osteosarcoma is the most common primary malignancy of bone with poorly characterized molecular pathways important in its pathogenesis. Increasing evidence indicates that elevated lipid biosynthesis is a characteristic feature of cancer. We sought to investigate the role of lysophosphatidic acid acyltransferase beta (LPAAT beta, aka, AGPAT2) in regulating the proliferation and growth of human osteosarcoma cells. LPAAT beta can generate phosphatidic acid, which plays a key role in lipid biosynthesis as well as in cell proliferation and survival. Although elevated expression of LPAAT beta has been reported in several types of human tumors, the role of LPAAT beta in osteosarcoma progression has yet to be elucidated.
   Methodology/Principal Findings: Endogenous expression of LPAAT beta in osteosarcoma cell lines is analyzed by using semi quantitative PCR and immunohistochemical staining. Adenovirus mediated overexpression of LPAAT beta and silencing LPAAT beta expression is employed to determine the effect of LPAAT beta on osteosarcoma cell proliferation and migration in vitro and osteosarcoma tumor growth in vivo. We have found that expression of LPAAT beta is readily detected in 8 of the 10 analyzed human osteosarcoma lines. Exogenous expression of LPAAT beta promotes osteosarcoma cell proliferation and migration, while silencing LPAAT beta expression inhibits these cellular characteristics. We further demonstrate that exogenous expression of LPAAT beta effectively promotes tumor growth, while knockdown of LPAAT beta expression inhibits tumor growth in an orthotopic xenograft model of human osteosarcoma.
   Conclusions/Significance: Our results strongly suggest that LPAAT beta expression may be associated with the aggressive phenotypes of human osteosarcoma and that LPAAT beta may play an important role in regulating osteosarcoma cell proliferation and tumor growth. Thus, targeting LPAAT beta may be exploited as a novel therapeutic strategy for the clinical management of osteosarcoma. This is especially attractive given the availability of selective pharmacological inhibitors.
C1 [Rastegar, Farbod; Gao, Jian Li; Shenaq, Deana; Luo, Qing; Shi, Qiong; Kim, Stephanie H.; Jiang, Wei; Wagner, Eric R.; Huang, Enyi; Gao, Yanhong; Shen, Jikun; Yang, Ke; He, Bai Cheng; Chen, Liang; Zuo, Guo Wei; Luo, Jinyong; Luo, Xiaoji; Bi, Yang; Liu, Xing; Li, Mi; Hu, Ning; Wang, Linyuan; Luther, Gaurav; Luu, Hue H.; Haydon, Rex C.; He, Tong Chuan] Univ Chicago, Med Ctr, Dept Surg, Mol Oncol Lab, Chicago, IL 60637 USA.
   [Gao, Jian Li; He, Tong Chuan] Zhejiang Univ, Sch Pharm, Hangzhou 310003, Zhejiang, Peoples R China.
   [Luo, Qing; Bi, Yang; Liu, Xing; Li, Mi; He, Tong Chuan] Chongqing Med Univ, Childrens Hosp, Stem Cell Biol & Therapy Lab, Chongqing, Peoples R China.
   [Shi, Qiong; He, Bai Cheng; Chen, Liang; Zuo, Guo Wei; Luo, Jinyong; Luo, Xiaoji; Hu, Ning] Chongqing Med Univ, Diagnost Med Designated Chinese Minist Educ, Key Lab, Chongqing, Peoples R China.
   [Shi, Qiong; He, Bai Cheng; Chen, Liang; Zuo, Guo Wei; Luo, Jinyong; Luo, Xiaoji; Hu, Ning] Chongqing Med Univ, Affiliated Hosp, Chongqing, Peoples R China.
   [Huang, Enyi] Chongqing Univ, Sch Bioengn, Chongqing, Peoples R China.
   [Gao, Yanhong] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Geriatr, Shanghai 200030, Peoples R China.
   [Yang, Ke] Third Mil Med Univ, Dept Cell Biol, Chongqing, Peoples R China.
C3 University of Chicago; University of Chicago Medical Center; Zhejiang
   University; Chongqing Medical University; Chongqing Medical University;
   Chongqing Medical University; Chongqing University; Shanghai Jiao Tong
   University; Army Medical University
RP Rastegar, F (通讯作者)，Univ Chicago, Med Ctr, Dept Surg, Mol Oncol Lab, Chicago, IL 60637 USA.
EM tche@surgery.bsd.uchicago.edu
RI GAO, JianLi/J 4997 2017; GAO, Jian Li/J 4997 2017; Yang, Ya/A 7219 2016
OI GAO, JianLi/0000 0002 5977 0021; Wagner, Eric/0000 0001 9241 5702
FU Brinson Foundation; National Institutes of Health; University of Chicago
   Comprehensive Cancer Center
FX The reported work was supported in part by research grants from the
   Brinson Foundation (TCH), National Institutes of Health (TCH and HHL)
   and the Animal Imaging Pilot Grant from The University of Chicago
   Comprehensive Cancer Center (to RCH). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Andresen BT, 2002, FEBS LETT, V531, P65, DOI 10.1016/S0014 5793(02)03483 X
   Bi Y, 2009, J CELL BIOCHEM, V108, P295, DOI 10.1002/jcb.22254
   Bonham L, 2003, EXPERT OPIN THER TAR, V7, P643
   Burton A, 2006, LANCET ONCOL, V7, P893, DOI 10.1016/S1470 2045(06)70926 3
   Chen L., 2010, J Bone Miner Res
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075
   Coon M, 2003, MOL CANCER THER, V2, P1067
   Cortés VA, 2009, CELL METAB, V9, P165, DOI 10.1016/j.cmet.2009.01.002
   Diefenbach CSM, 2006, CANCER AM CANCER SOC, V107, P1511, DOI 10.1002/cncr.22184
   Douvas MG, 2006, LEUKEMIA RES, V30, P1027, DOI 10.1016/j.leukres.2005.11.018
   Eberhardt C, 1997, J BIOL CHEM, V272, P20299, DOI 10.1074/jbc.272.32.20299
   Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015
   Feugeas O, 1996, J CLIN ONCOL, V14, P467, DOI 10.1200/JCO.1996.14.2.467
   Furuta E, 2010, BBA REV CANCER, V1805, P141, DOI 10.1016/j.bbcan.2010.01.005
   Gazitt Y, 2009, INT J ONCOL, V34, P551, DOI 10.3892/ijo_00000181
   Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472
   GIENI RS, 1995, J IMMUNOL METHODS, V187, P85, DOI 10.1016/0022 1759(95)00170 F
   Gordon N, 2009, CANCER TREAT RES, V152, P497, DOI 10.1007/978 1 4419 0284 9_29
   Gorlick R, 2003, CLIN CANCER RES, V9, P5442
   Gorlick R, 2009, CANC TREAT, V152, P467, DOI 10.1007/978 1 4419 0284 9_27
   Haydon RC, 2002, INT J CANCER, V102, P338, DOI 10.1002/ijc.10719
   Haydon RC, 2002, CLIN CANCER RES, V8, P1288
   Haydon RC, 2007, CLIN ORTHOP RELAT R, P237, DOI 10.1097/BLO.0b013e31802b683c
   He BC, 2010, CLIN CANCER RES, V16, P2235, DOI 10.1158/1078 0432.CCR 09 2499
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092 8674(00)81664 5
   Hideshima T, 2003, CANCER RES, V63, P8428
   Hollenback D, 2006, J LIPID RES, V47, P593, DOI 10.1194/jlr.M500435 JLR200
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Kaste SC, 1999, CANCER AM CANCER SOC, V86, P1602, DOI 10.1002/(SICI)1097 0142(19991015)86:8<1602::AID CNCR31>3.0.CO;2 R
   La Rosée P, 2006, CLIN CANCER RES, V12, P6540, DOI 10.1158/1078 0432.CCR 06 0140
   Leung DW, 2001, FRONT BIOSCI, V6, pD944, DOI 10.2741/Leung
   LINK MP, 1986, NEW ENGL J MED, V314, P1600, DOI 10.1056/NEJM198606193142502
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luo Q, 2007, GENE, V395, P160, DOI 10.1016/j.gene.2007.02.030
   Luo XJ, 2008, CLIN ORTHOP RELAT R, V466, P2060, DOI 10.1007/s11999 008 0361 x
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Luu HH, 2005, CANCER LETT, V229, P135, DOI 10.1016/j.canlet.2005.02.015
   Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585 005 0365 9
   Magré J, 2001, NAT GENET, V28, P365, DOI 10.1038/ng585
   Mashima T, 2009, BRIT J CANCER, V100, P1369, DOI 10.1038/sj.bjc.6605007
   Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222
   Menendez JA, 2010, BBA MOL CELL BIOL L, V1801, P381, DOI 10.1016/j.bbalip.2009.09.005
   Meyers PA, 1997, PEDIATR CLIN N AM, V44, P973, DOI 10.1016/S0031 3955(05)70540 X
   Mintz MB, 2005, CANCER RES, V65, P1748, DOI 10.1158/0008 5472.CAN 04 2463
   Murphey MD, 1997, RADIOGRAPHICS, V17, P1205, DOI 10.1148/radiographics.17.5.9308111
   Niesporek S, 2005, BRIT J CANCER, V92, P1729, DOI 10.1038/sj.bjc.6602528
   Pagel JM, 2005, CLIN CANCER RES, V11, P4857, DOI 10.1158/1078 0432.CCR 04 2352
   Pakos EE, 2004, CLIN CANCER RES, V10, P6208, DOI 10.1158/1078 0432.CCR 04 0246
   Sandberg AA, 2003, CANCER GENET CYTOGEN, V145, P1, DOI 10.1016/S0165 4608(03)00105 5
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Springett GM, 2005, CANCER RES, V65, P9415, DOI 10.1158/0008 5472.CAN 05 0516
   Stamps AC, 1997, BIOCHEM J, V326, P455, DOI 10.1042/bj3260455
   Su YX, 2009, CLIN EXP METASTAS, V26, P599, DOI 10.1007/s10585 009 9259 6
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Wang XM, 2006, PROG LIPID RES, V45, P250, DOI 10.1016/j.plipres.2006.01.005
   WARD WG, 1994, J CLIN ONCOL, V12, P1849, DOI 10.1200/JCO.1994.12.9.1849
   West J, 1997, DNA CELL BIOL, V16, P691, DOI 10.1089/dna.1997.16.691
   Whelan JS, 1997, EUR J CANCER, V33, P1611, DOI 10.1016/S0959 8049(97)00251 7
   Yokoyama R, 1998, PATHOL RES PRACT, V194, P615, DOI 10.1016/S0344 0338(98)80096 4
   Yonemoto T, 1998, CLIN ORTHOP RELAT R, P194
   ZHOU Q, 2009, MED ONCOL
NR 68
TC 43
Z9 44
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD DEC 1
PY 2010
VL 5
IS 12
AR e14182
DI 10.1371/journal.pone.0014182
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 688AU
UT WOS:000284821300003
PM 21152068
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Xing, JZ
   Lu, L
   Unsworth, LD
   Major, PW
   Doschak, MR
   Kaipatur, NR
AF Xing, James Z.
   Lu, Lei
   Unsworth, Larry D.
   Major, Paul W.
   Doschak, Michael R.
   Kaipatur, Neelambar R.
TI RANKL release from self assembling nanofiber hydrogels for inducing
   osteoclastogenesis in vitro
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Nanofiber hydrogel; RANKL; Drug delivery; Controlled and sustained
   release; Osteoclastogenesis
ID KAPPA B LIGAND; DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR; ALVEOLAR
   BONE; EXPRESSION; MODEL; LOCALIZATION; MECHANISMS; MOLECULES; SCAFFOLDS
AB Purpose: To develop a nanofiber hydrogel (NF hydrogel) for sustained and controlled release of the recombinant receptor activator of NF kB ligand; (RANKL) and to characterize the release kinetics and bioactivity of the released RANKL.
   Methods: Various concentrations of fluorescently labelled RANKL protein were added to NF hydrogels, composed of Acetyl (Arg Ala Asp Ala)(4) CONH2 [(RADA)(4)] of different concentrations, to investigate the resulting in vitro release rates. The nano structures of NF hydrogel, with and without RANKL, were determined using atomic force microscopy (AFM). Released RANKL was further analyzed for changes in secondary and tertiary structure using CD spectroscopy and fluorescent emission spectroscopy, respectively. Bioactivity of released RANKL protein was determined using NFATc1 gene expression and tartrate resistant acid phosphatase (TRAP) activity of osteoclast cells as biomarkers.
   Results: NF hydrogel concentration dependent sustained release of RANKL protein was measured at concentrations between 0.5 and 2% (w/v). NF hydrogel at 2% (w/v) concentration exhibited a sustained and slow release of RANKL protein up to 48 h. Secondary and tertiary structure analyses confirmed no changes to the RANKL protein released from NF hydrogel in comparison to native RANKL. The results of NFATc1 gene mRNA expression and TRAP activities of osteoclast, showed that the release process did not affect the bioactivity of released RANKL.
   Conclusions: This novel study is the first of its kind to attempt in vitro characterization of NF hydrogel based delivery of RANKL protein to induce osteoclastogenesis. We have shown the self assembling NF hydrogel peptide system is amenable to the sustained and controlled release of RANKL locally; that could in turn increase local concentration of RANKL to induce osteoclastogenesis, for application to the controlled mobilization of tooth movement in orthodontic procedures.
   Statement of Significance
   Orthodontic tooth movement (OTM) occurs through controlled application of light forces to teeth, facilitating the required changes in the surrounding alveolar bone through the process of bone remodelling. The RANKL system regulates alveolar bone remodelling and controls root resorption during OTM. The use of exogenous RANKL to accelerate OTM has not been attempted to date because large quantities of RANKL for systemic therapy may subsequently cause serious systemic loss of skeletal bone. The controlled and sustained local release of RANKL from a carrier matrix could maximize its therapeutic benefit whilst minimizing systemic side effects. In this study a NF hydrogel was used for sustained and controlled release of RANKL and the release kinetics and biofunctionality of the released RANKL was characterized. Our results provide fundamental insight for further investigating the role of RANKL NF hydrogel release systems for inducing osteoclastogenesis in vivo. (C) 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Xing, James Z.; Major, Paul W.; Kaipatur, Neelambar R.] Univ Alberta, Sch Dent, Edmonton, AB T6G 1C9, Canada.
   [Xing, James Z.; Doschak, Michael R.] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2E1, Canada.
   [Lu, Lei; Unsworth, Larry D.] CNR, Natl Inst Nanotechnol, Edmonton, AB T6G 2M9, Canada.
   [Lu, Lei; Unsworth, Larry D.] Univ Alberta, Dept Chem & Mat Engn, Edmonton, AB T6G 2G6, Canada.
C3 University of Alberta; University of Alberta; National Research Council
   Canada; University of Alberta
RP Kaipatur, NR (通讯作者)，Univ Alberta, 5083 Edmonton Clin Hlth Acad, Edmonton, AB, Canada.
EM kaipatur@ualberta.ca
RI ; Unsworth, Larry/A 7231 2011
OI Unsworth, Larry/0000 0003 3162 3545; 
FU Canadian Institutes of Health Research (CIHR); National Science and
   Engineering Research Council (Canada); China Scholarship Council (CSC)
FX Canadian Institutes of Health Research (CIHR); National Science and
   Engineering Research Council (Canada), China Scholarship Council (CSC).
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bhandari KH, 2012, J CONTROL RELEASE, V158, P44, DOI 10.1016/j.jconrel.2011.09.096
   Bhandari KH, 2010, INT J PHARMACEUT, V394, P26, DOI 10.1016/j.ijpharm.2010.04.015
   BURSTONE MS, 1959, NATURE, V184, P476, DOI 10.1038/184476a0
   Campbell GM, 2011, OSTEOPOROSIS INT, V22, P931, DOI 10.1007/s00198 010 1283 5
   Castelli F, 2000, BIOMATERIALS, V21, P821, DOI 10.1016/S0142 9612(99)00252 5
   Davis ME, 2005, CIRCULATION, V111, P442, DOI 10.1161/01.CIR.0000153847.47301.80
   Gardern J. C., 2010, BIOMACROMOLECULES, V12, P1833
   Halleen J M, 2001, Am Clin Lab, V20, P29
   Hou QP, 2004, J MATER CHEM, V14, P1915, DOI 10.1039/b401791a
   JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0
   Kaipatur N, 2014, INT J DENT, V2014, DOI 10.1155/2014/917535
   Kaipatur N, 2015, ARCH ORAL BIOL, V60, P1681, DOI 10.1016/j.archoralbio.2015.08.008
   Kaipatur NR, 2013, AM J ORTHOD DENTOFAC, V144, P557, DOI 10.1016/j.ajodo.2013.06.015
   Kanzaki H, 2006, GENE THER, V13, P678, DOI 10.1038/sj.gt.3302707
   Kisiday J, 2002, P NATL ACAD SCI USA, V99, P9996, DOI 10.1073/pnas.142309999
   Koutsopoulos S, 2016, J BIOMED MATER RES A, V104, P1002, DOI 10.1002/jbm.a.35638
   Koutsopoulos S, 2009, P NATL ACAD SCI USA, V106, P4623, DOI 10.1073/pnas.0807506106
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Liu C., 2007, J IMMUNOL, V184, P6910
   Lloyd SAJ, 2008, CALCIFIED TISSUE INT, V82, P361, DOI 10.1007/s00223 008 9133 6
   Lu L, 2016, BIOMACROMOLECULES, V17, P1425, DOI 10.1021/acs.biomac.6b00040
   Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586
   Mostafa NZ, 2015, TISSUE ENG PT A, V21, P85, DOI [10.1089/ten.tea.2014.0075, 10.1089/ten.TEA.2014.0075]
   Nagai Y, 2006, J CONTROL RELEASE, V115, P18, DOI 10.1016/j.jconrel.2006.06.031
   Narmoneva DA, 2005, BIOMATERIALS, V26, P4837, DOI 10.1016/j.biomaterials.2005.01.005
   Newa M, 2014, MOL PHARMACEUT, V11, P81, DOI 10.1021/mp400188r
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Schneider A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001410
   Shiotani A, 2001, J ELECTRON MICROSC, V50, P365, DOI 10.1093/jmicro/50.4.365
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Sobacchi C, 2007, NAT GENET, V39, P960, DOI 10.1038/ng2076
   Soltani F, 2015, CURR PHARM DESIGN, V21, P6214, DOI 10.2174/1381612821666151027153410
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tsurukai T, 2000, J BONE MINER METAB, V18, P177, DOI 10.1007/s007740070018
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Vääräniemi J, 2004, J BONE MINER RES, V19, P1432, DOI 10.1359/JBMR.040603
   Vivian JT, 2001, BIOPHYS J, V80, P2093, DOI 10.1016/S0006 3495(01)76183 8
   Willard D, 2000, PROTEIN EXPRES PURIF, V20, P48, DOI 10.1006/prep.2000.1278
   Xu JW, 2009, J ORTHOP RES, V27, P1306, DOI 10.1002/jor.20890
   Yamaguchi M, 2009, ORTHOD CRANIOFAC RES, V12, P113, DOI 10.1111/j.1601 6343.2009.01444.x
   Yuan YY, 2008, OSTEOPOROSIS INT, V19, P625, DOI 10.1007/s00198 007 0509 7
   ZHANG SG, 1993, P NATL ACAD SCI USA, V90, P3334, DOI 10.1073/pnas.90.8.3334
NR 44
TC 20
Z9 22
U1 0
U2 35
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD FEB
PY 2017
VL 49
BP 306
EP 315
DI 10.1016/j.actbio.2016.12.006
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA EK6UU
UT WOS:000394062100024
PM 27940164
DA 2025 08 17
ER

PT J
AU Grimaldi, M
   Randino, R
   Ciaglia, E
   Scrima, M
   Buonocore, M
   Stillitano, I
   Abate, M
   Covelli, V
   Tosco, A
   Gazzerro, P
   Bifulco, M
   Rodriquez, M
   D'Ursi, AM
AF Grimaldi, Manuela
   Randino, Rosario
   Ciaglia, Elena
   Scrima, Mario
   Buonocore, Michela
   Stillitano, Ilaria
   Abate, Mario
   Covelli, Verdiana
   Tosco, Alessandra
   Gazzerro, Patrizia
   Bifulco, Maurizio
   Rodriquez, Manuela
   D'Ursi, Anna Maria
TI NMR for screening and a biochemical assay: Identification of new FPPS
   inhibitors exerting anticancer activity
SO BIOORGANIC CHEMISTRY
LA English
DT Article
DE FPPS; Isoprenoids; Adenosine derivatives; NMR enzymatic assay
ID FARNESYL PYROPHOSPHATE SYNTHASE; TRANSFER DIFFERENCE NMR; ISOPRENOID
   END PRODUCT; BIOLOGICAL EVALUATION; DIPHOSPHATE SYNTHASE; ZOLEDRONIC
   ACID; NK CELLS; T CELLS; STD NMR; N6 ISOPENTENYLADENOSINE
AB Farnesyl pyrophosphate synthase (FPPS) is a crucial enzyme for the synthesis of isoprenoids and the key target of nitrogen containing bisphosphonates (N BPs). N BPs are potent and selective FPPS inhibitors that are used in the treatment of bone related diseases, but have poor pharmacokinetic properties.
   Given the key role played by FPPS in many cancer related pathways and the pharmacokinetic limits of N BPs, hundreds of molecules have been screened to identify new FPPS inhibitors characterized by improved drug like properties that are useful for broader therapeutic applications in solid, non skeletal tumours.
   We have previously shown that N6 isopentenyladenosine (i6A) and its related compound N6 benzyladenosine (2) exert anti glioma activity by interfering with the mevalonate pathway and inhibiting FPPS. Here, we report the design and synthesis of a panel of N6 benzyladenosine derivatives (compounds 2a m) incorporating different chemical moieties on the benzyl ring. Compounds 2a m show in vitro antiproliferative activity in U87MG glioma cells and, analogous to the bisphosphonate FPPS inhibitors, exhibit immunogenic properties in ex vivo gamma delta T cells from stimulated peripheral blood mononuclear cells (PBMCs). Using saturation transfer difference (STD) and quantitative H 1 nuclear magnetic resonance (NMR) experiments, we found that 2f, the N6 benzyla denosine analogue that includes a tertbutyl moiety in the para position of the benzyl ring, is endowed with increased FPPS binding and inhibition compared to the parent compounds i6A and 2.
   N6 benzyladenosine derivatives, characterized by structural features that are significantly different from those of N BPs, have been confirmed to be promising chemical scaffolds for the development of non N BP FPPS inhibitors, exerting combined cytotoxic and immunostimulatory activities.
C1 [Grimaldi, Manuela; Randino, Rosario; Scrima, Mario; Buonocore, Michela; Stillitano, Ilaria; Covelli, Verdiana; Tosco, Alessandra; Gazzerro, Patrizia; Rodriquez, Manuela; D'Ursi, Anna Maria] Univ Salerno, Dept Pharm, Via Giovanni Paolo II 132, I 84084 Salerno, Italy.
   [Bifulco, Maurizio] Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Via Pansini, I 80131 Naples, Italy.
   [Ciaglia, Elena; Abate, Mario; Bifulco, Maurizio] Univ Salerno, Dept Med Surg & Dent, Scuola Med Salernitana, Via Salvatore Allende, I 84081 Salerno, Italy.
   [Grimaldi, Manuela] Natl Res Council Italy, Inst Polymers Composites & Biomat, Vle JF Kennedy 54,Pad 20 Mostra dOltremare, I 80125 Naples, Italy.
C3 University of Salerno; University of Naples Federico II; University of
   Salerno; Consiglio Nazionale delle Ricerche (CNR); Istituto per i
   Polimeri, Compositi e Biomateriali (IPCB CNR)
RP D'Ursi, AM (通讯作者)，Univ Salerno, Dept Pharm, Via Giovanni Paolo II 132, I 84084 Salerno, Italy.
EM dursi@unisa.it
RI D'Ursi, Anna/E 8557 2016; D'Ursi, Anna Maria/E 8557 2016; Tosco,
   Alessandra/F 6773 2011; Grimaldi, Manuela/AAQ 2981 2020; Abate,
   Mario/AAI 4684 2021; Bifulco, Maurizio/HOA 6546 2023; Buonocore,
   Michela/IAS 0408 2023; Rodriquez, Manuela/G 2459 2011; Ciaglia,
   E/AAA 7924 2019
OI D'Ursi, Anna Maria/0000 0001 6814 8472; ABATE,
   Mario/0000 0003 0578 4812; Covelli, Verdiana/0000 0001 9859 086X;
   Ciaglia, Elena/0000 0002 8035 4583; Bifulco,
   Maurizio/0000 0002 1771 4531; Buonocore, Michela/0000 0003 1189 1729;
   Randino, Rosario/0000 0002 8359 5382
FU Associazione Italiana Ricerca sul Cancro (AIRC) [IG 18999]; Fondazione
   Umberto Veronesi [1072, 2153, 2798]
FX This study was supported by the Associazione Italiana Ricerca sul Cancro
   (AIRC; IG 18999 to M. Bifulco). E.C. was also supported by a triennial
   fellowship from Fondazione Umberto Veronesi (FUV 2017, cod.1072, FUV
   2018, cod.2153 & FUV 2019 cod. 2798).
CR Abate M, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14495 6
   Ahmad F, 2019, CANCERS, V11, DOI 10.3390/cancers11020146
   Anastas PT, 2000, Green Chemistry: Theory and Practice
   Angulo J, 2011, EUR BIOPHYS J BIOPHY, V40, P1357, DOI 10.1007/s00249 011 0749 5
   [Anonymous], 2020, GraphPad Software
   Arró M, 2014, METHODS MOL BIOL, V1153, P41, DOI 10.1007/978 1 4939 0606 2_4
   Bhattarai S, 2015, J MED CHEM, V58, P6248, DOI 10.1021/acs.jmedchem.5b00802
   Bifulco M, 2008, ANTI CANCER AGENT ME, V8, P200, DOI 10.2174/187152008783497028
   Cala O, 2014, ANAL BIOANAL CHEM, V406, P943, DOI 10.1007/s00216 013 6931 0
   Castiglioni S, 2013, ANTI CANCER AGENT ME, V13, P672, DOI 10.2174/1871520611313040016
   Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028
   Charton J, 2006, BIOORGAN MED CHEM, V14, P4490, DOI 10.1016/j.bmc.2006.02.028
   Chen JB, 2011, CHEMMEDCHEM, V6, P1390, DOI 10.1002/cmdc.201100126
   Ciaglia E, 2018, INT J CANCER, V142, P176, DOI 10.1002/ijc.31036
   Ciaglia E, 2017, BRIT J PHARMACOL, V174, P2287, DOI 10.1111/bph.13824
   Ciaglia E, 2014, PHARMACOL RES, V89, P1, DOI 10.1016/j.phrs.2014.07.003
   Ciaglia E, 2013, J LEUKOCYTE BIOL, V94, P1207, DOI 10.1189/jlb.0413190
   de la Hoz A, 2005, CHEM SOC REV, V34, P164, DOI 10.1039/b411438h
   Dhar MK, 2013, NEW BIOTECHNOL, V30, P114, DOI 10.1016/j.nbt.2012.07.001
   Dolezal K, 2007, BIOORGAN MED CHEM, V15, P3737, DOI 10.1016/j.bmc.2007.03.038
   Fournier PGJ, 2008, CANCER RES, V68, P8945, DOI 10.1158/0008 5472.CAN 08 2195
   Fujii T, 1985, Nucleic Acids Symp Ser, P69
   Gao JB, 2010, CHEM COMMUN, V46, P5340, DOI 10.1039/c0cc00992j
   Gritzalis D, 2015, BIOORG MED CHEM LETT, V25, P1117, DOI 10.1016/j.bmcl.2014.12.089
   Holstein SA, 2019, EXPERT OPIN THER PAT, V29, P315, DOI 10.1080/13543776.2019.1608180
   Jahnke W, 2010, NAT CHEM BIOL, V6, P660, DOI [10.1038/NCHEMBIO.421, 10.1038/nchembio.421]
   Johnson KA, 2011, BIOCHEMISTRY US, V50, P8264, DOI 10.1021/bi201284u
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   KERSTEN H, 1984, PROG NUCLEIC ACID RE, V31, P59, DOI 10.1016/S0079 6603(08)60375 X
   Kim HY, 2018, EXP MOL MED, V50, DOI 10.1038/s12276 018 0166 2
   Kim YA, 2007, BIOCHEM PHARMACOL, V73, P1558, DOI 10.1016/j.bcp.2007.01.026
   Kondo M, 2008, CYTOTHERAPY, V10, P842, DOI 10.1080/14653240802419328
   Laezza C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.279
   Laezza C., 2014, INT J CANCER, V135, DOI [10.1038/cddis.2015.279, DOI 10.1038/CDDIS.2015.279]
   LATEN HM, 1985, P NATL ACAD SCI USA, V82, P1113, DOI 10.1073/pnas.82.4.1113
   Leung CY, 2013, J MED CHEM, V56, P7939, DOI 10.1021/jm400946f
   Lindert S, 2013, CHEM BIOL DRUG DES, V81, P742, DOI 10.1111/cbdd.12121
   Lo Presti E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01395
   Marzinzik AL, 2015, CHEMMEDCHEM, V10, P1884, DOI 10.1002/cmdc.201500338
   Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521 3773(19990614)38:12<1784::AID ANIE1784>3.0.CO;2 Q
   Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120
   Meraviglia S, 2010, CLIN EXP IMMUNOL, V161, P290, DOI 10.1111/j.1365 2249.2010.04167.x
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Nevalainen M.T., 2015, TREATMENT PROSTATE C
   Ottria R, 2010, BIOORGAN MED CHEM, V18, P8396, DOI 10.1016/j.bmc.2010.09.030
   Park J, 2017, J MED CHEM, V60, P2119, DOI 10.1021/acs.jmedchem.6b01888
   Park J, 2012, BMC STRUCT BIOL, V12, DOI 10.1186/1472 6807 12 32
   Randino R., 2014, PHOL, V3, P203
   Randino R, 2015, TETRAHEDRON LETT, V56, P5723, DOI 10.1016/j.tetlet.2015.08.082
   Ravn J, 2007, BIOORGAN MED CHEM, V15, P5440, DOI 10.1016/j.bmc.2007.05.056
   Roelofs AJ, 2009, BRIT J HAEMATOL, V144, P245, DOI 10.1111/j.1365 2141.2008.07435.x
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788
   Santoro A, 2018, INFLAMM RES, V67, P315, DOI 10.1007/s00011 017 1123 6
   Scrima M, 2014, J MED CHEM, V57, P7798, DOI 10.1021/jm500869x
   Starha P, 2013, MOLECULES, V18, P6990, DOI 10.3390/molecules18066990
   Sun ST, 2011, EXPERT OPIN THER PAT, V21, P1433, DOI 10.1517/13543776.2011.593511
   Szkopinska A, 2005, ACTA BIOCHIM POL, V52, P45
   Tan W.K., 2018, J IMMUNOL SCI, V2
   Tarkowská D, 2003, PHYSIOL PLANTARUM, V117, P579, DOI 10.1034/j.1399 3054.2003.00071.x
   Thurnher M, 2012, CLIN CANCER RES, V18, P3524, DOI 10.1158/1078 0432.CCR 12 0489
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang YS, 2004, MAGN RESON CHEM, V42, P485, DOI 10.1002/mrc.1381
   Wizard P. P., 2009, JAGUAR GLIDE
   Woo IS, 2010, NEUROSCI LETT, V474, P115, DOI 10.1016/j.neulet.2010.03.021
NR 65
TC 4
Z9 4
U1 2
U2 25
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0045 2068
EI 1090 2120
J9 BIOORG CHEM
JI Bioorganic Chem.
PD MAY
PY 2020
VL 98
AR 103449
DI 10.1016/j.bioorg.2019.103449
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Chemistry
GA LE5UC
UT WOS:000526784800036
PM 32057422
DA 2025 08 17
ER

PT J
AU Krautmann, M
   Walters, R
   Cole, P
   Tena, J
   Bergeron, LM
   Messamore, J
   Mwangi, D
   Rai, S
   Dominowski, P
   Saad, K
   Zhu, Y
   Guillot, M
   Chouinard, L
AF Krautmann, M.
   Walters, R.
   Cole, P.
   Tena, J.
   Bergeron, L. M.
   Messamore, J.
   Mwangi, D.
   Rai, S.
   Dominowski, P.
   Saad, K.
   Zhu, Y.
   Guillot, M.
   Chouinard, L.
TI Laboratory safety evaluation of bedinvetmab, a canine anti nerve growth
   factor monoclonal antibody, in dogs
SO VETERINARY JOURNAL
LA English
DT Article
DE Bedinvetmab; Canine; Nerve growth factor (NGF); Osteoarthritis pain;
   Safety
ID CLINICAL TRIALS; OSTEOARTHRITIS; PAIN; PHARMACOKINETICS; TANEZUMAB;
   NSAIDS
AB Nerve growth factor (NGF), a critical mediator of nociception, is a novel analgesic therapeutic target. Bedinvetmab, a canine monoclonal antibody (mAb), binds NGF and inhibits its interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. The objective of three integrated laboratory studies was to demonstrate the safety of bedinvetmab in adult laboratory Beagle dogs. Daily health, veterinary, clinical pathology, systemic exposure, and anti drug antibody evaluations were performed. Study 1 additionally included electrocardiography, neurologic, and ophthalmic assessments, and radiographic monitoring of joints of the appendicular skeleton. Study 2 evaluated T lymphocyte dependent immune function. Study 3 evaluated the safety of short term concurrent administration of carprofen, a nonsteroidal anti inflammatory drug (NSAID), with bedinvetmab. Studies 1 and 3 included terminal pathology and histopathology evaluations. Study designs and procedures included directed complementary morphologic and functional evaluations of a literature  and in vitro based list of potential safety issues related to the NGF signaling pathway and characteristics engineered into this mAb. Screening level general procedures evaluated effects associated with mAbs that target and inhibit soluble agonist cytokines. There were no treatment related adverse changes in clinical evaluations, clinical neurological and ophthalmic examinations, joints, immune morphology or function, and no effects of short term concurrent NSAID usage. Treatment emergent immunogenicity was not observed. Bedinvetmab (1 mg/kg SC monthly; 3x and 10x dose multiples) was well tolerated in normal laboratory Beagle dogs for 6 months and with 2 weeks' concurrent NSAID administration.
C1 [Krautmann, M.; Walters, R.; Cole, P.; Tena, J.; Bergeron, L. M.; Messamore, J.; Mwangi, D.; Rai, S.; Dominowski, P.; Saad, K.; Zhu, Y.] Zoetis Inc, 333 Portage St, Kalamazoo, MI 49007 USA.
   [Guillot, M.; Chouinard, L.] ULC, Charles River Labs Montreal, Senneville, PQ, Canada.
C3 Zoetis
RP Krautmann, M (通讯作者)，Zoetis Inc, 333 Portage St, Kalamazoo, MI 49007 USA.
EM matthew.j.krautmann@zoetis.com
OI Walters, Rodney/0000 0003 4429 439X
CR Anderson KL, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00220
   Bergeron LM, 2014, VET IMMUNOL IMMUNOP, V157, P31, DOI 10.1016/j.vetimm.2013.10.018
   Corral M.J., 2020, SO EUR VET C ONL VIR
   Dewey C.W., 2015, Practical Guide to Canine and Feline Neurology, P9
   Enomoto M, 2019, VET REC, V184, DOI 10.1136/vr.104590
   Gropp KE, 2018, TOXICOL PATHOL, V46, P408, DOI 10.1177/0192623318772501
   Hefti FF, 2006, TRENDS PHARMACOL SCI, V27, P85, DOI 10.1016/j.tips.2005.12.001
   Hochberg MC, 2021, ARTHRITIS RHEUMATOL, V73, P1167, DOI 10.1002/art.41674
   Johnston SA, 1997, VET CLIN N AM SMALL, V27, P699, DOI 10.1016/S0195 5616(97)50076 3
   Jonsson EN, 2016, BRIT J CLIN PHARMACO, V81, P688, DOI 10.1111/bcp.12850
   Lascelles BDX, 2005, VET THER, V6, P237
   Lebrec H, 2014, REGUL TOXICOL PHARM, V69, P7, DOI 10.1016/j.yrtph.2014.02.008
   LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384
   Liu LM, 2018, PROTEIN CELL, V9, P15, DOI 10.1007/s13238 017 0408 4
   Martin PL, 2012, BRIT J PHARMACOL, V166, P806, DOI 10.1111/j.1476 5381.2011.01812.x
   MCMAHON SB, 1995, NAT MED, V1, P774, DOI 10.1038/nm0895 774
   Papich MG, 2008, VET CLIN N AM SMALL, V38, P1243, DOI 10.1016/j.cvsm.2008.09.002
   Piccotti Joseph R, 2005, J Immunotoxicol, V2, P191, DOI 10.1080/15476910500362838
   Ryman JT, 2017, CPT PHARMACOMET SYST, V6, P576, DOI 10.1002/psp4.12224
   Tive L, 2019, J PAIN RES, V12, P975, DOI 10.2147/JPR.S191297
   Watson JJ, 2008, BIODRUGS, V22, P349, DOI 10.2165/0063030 200822060 00002
   Wise BL, 2021, NAT REV RHEUMATOL, V17, P34, DOI 10.1038/s41584 020 00528 4
   WOOLF CJ, 1994, NEUROSCIENCE, V62, P327, DOI 10.1016/0306 4522(94)90366 2
   Zorbas M, 2011, REGUL TOXICOL PHARM, V59, P334, DOI 10.1016/j.yrtph.2010.11.005
NR 24
TC 10
Z9 11
U1 4
U2 45
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1090 0233
EI 1532 2971
J9 VET J
JI Vet. J.
PD OCT
PY 2021
VL 276
AR 105733
DI 10.1016/j.tvjl.2021.105733
EA AUG 2021
PG 11
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA UX1EY
UT WOS:000700591500003
PM 34391918
OA hybrid
DA 2025 08 17
ER

PT J
AU Xiang, A
   Kanematsu, M
   Kumar, S
   Yamashita, D
   Kaise, T
   Kikkawa, H
   Asano, S
   Kinoshita, M
AF Xiang, Anbo
   Kanematsu, Masahiro
   Kumar, Sanjay
   Yamashita, Dennis
   Kaise, Toshihiko
   Kikkawa, Hideo
   Asano, Satoshi
   Kinoshita, Mine
TI Changes in micro CT 3D bone parameters reflect effects of a potent
   cathepsin K inhibitor (SB 553484) on bone resorption and cortical bone
   formation in ovariectomized mice
SO BONE
LA English
DT Article
DE cathepsin K; ovariectomized mice; micro CT; bone resorption; bone
   formation
ID MICROCOMPUTED TOMOGRAPHY; TRABECULAR BONE; IN VITRO; OSTEOPOROSIS;
   OSTEOPETROSIS; CONNECTIVITY; DEFICIENCY; PREVENTION; THICKNESS; VOLUME
AB Cathepsin K is a cysteine proteinase that is highly expressed by osteoclasts and is being pursued as a potential drug target for the treatment of osteoporosis. We have reported that microcomputed tomography (mu CT) analysis of bone microarchitecture may serve as a valuable tool for evaluating both antiresorptive and anabolic agents in ovariectomized (OVX) mice. The purpose of this study was to evaluate the effect of SB 553484, a novel cathepsin K inhibitor (human Ki,app=0.14 W, mouse Ki,app=26 nM), on the OVX mice by mu CT bone morphometric analysis. Seven weeks female BALB/c mice were OVX or sham operated. OVX animals were treated with SB 553484 (30 mg/kg, sc) or Rolipram (10 mg/ kg, po), a phosphodiesterase 4 inhibitor used as a positive bone anabolic agent, twice a day for 2 weeks. Both SB 553484 and Rolipram significantly prevented the decrease of trabecular bone volume as well as the deterioration of trabecular architecture in OVX mice. Interestingly, SB 553484 demonstrated a more pronounced effect in improvement of trabecular separation, number and connectivity, and a weaker effect in improvement of trabecular thickness compared to that of Rolipram. These differences indicate that SB 553484 mainly acted as an antiresorptive agent in OVX induced loss of trabecular bone. On the other hand, SB 553484 significantly increased cortical bone volume and cortical thickness as well as Rolipram in OVX mice indicating an unexpected stimulatory effect of SB 553484 on cortical bone formation. These data suggest that targeting cathepsin K may prove therapeutically beneficial in the treatment of diseases with accelerated bone loss such as postmenopausal osteoporosis not only by inhibiting bone resorption but also by potentially stimulating cortical bone formation. (c) 2007 Elsevier Inc. All rights reserved.
C1 GlaxoSmithKline KK, Dept Pharmacol, Tsukuba Res Labs, Tsukuba, Ibaraki 3004247, Japan.
   GlaxoSmithKline, Dept Musculoskeletal Dis, Collegeville, PA 19426 USA.
   GlaxoSmithKline, Dept Med Chem, Collegeville, PA 19426 USA.
C3 Eisai Co Ltd; GlaxoSmithKline; GlaxoSmithKline Japan; GlaxoSmithKline;
   Glaxosmithkline USA; GlaxoSmithKline; Glaxosmithkline USA
RP Asano, S (通讯作者)，GlaxoSmithKline KK, Dev & Med Affairs Div, Shibuya Ku, 4 6 15 Sendagaya, Tokyo 1518566, Japan.
EM satoshi.asano@gsk.com
RI kumar, Sanjay/ITT 3680 2023
CR Barou O, 2002, INVEST RADIOL, V37, P40, DOI 10.1097/00004424 200201000 00008
   Dodds RA, 2001, J BONE MINER RES, V16, P478, DOI 10.1359/jbmr.2001.16.3.478
   Eichner SF, 2003, ANN PHARMACOTHER, V37, P711, DOI 10.1345/aph.1C246
   Follin SL, 2003, AM J HEALTH SYST PH, V60, P883, DOI 10.1093/ajhp/60.9.883
   GAMERO P, 1998, J BIOL CHEM, V273, P32347
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Hildebrand T, 1997, J MICROSC OXFORD, V185, P67, DOI 10.1046/j.1365 2818.1997.1340694.x
   Hildebrand TOR, 1997, Comput Methods Biomech Biomed Engin, V1, P15, DOI 10.1080/01495739708936692
   James IE, 1999, J BONE MINER RES, V14, P1562, DOI 10.1359/jbmr.1999.14.9.1562
   Jerome C, 2005, J BONE MINER RES, V20, pS46
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Kinoshita T, 2000, BONE, V27, P811, DOI 10.1016/S8756 3282(00)00395 1
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lane NE, 1999, J BONE MINER RES, V14, P206, DOI 10.1359/jbmr.1999.14.2.206
   Lark MW, 2002, BONE, V30, P746, DOI 10.1016/S8756 3282(02)00675 0
   Lorensen W. E., 1987, COMPUT GRAPH, V21, P163, DOI DOI 10.1145/37402.37422
   Mandelin J, 2006, BONE, V38, P769, DOI 10.1016/j.bone.2005.10.017
   Nishi Y, 1999, J BONE MINER RES, V14, P1902, DOI 10.1359/jbmr.1999.14.11.1902
   ODGAARD A, 1993, BONE, V14, P173, DOI 10.1016/8756 3282(93)90245 6
   PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096
   Rosen CJ, 2005, NEW ENGL J MED, V353, P595, DOI 10.1056/NEJMcp043801
   Ruegsegger P, 1996, CALCIFIED TISSUE INT, V58, P24, DOI 10.1007/s002239900006
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Sone T, 2004, BONE, V35, P432, DOI 10.1016/j.bone.2004.05.011
   Stroup G, 2005, J BONE MINER RES, V20, pS80
   Stroup GB, 2001, J BONE MINER RES, V16, P1739, DOI 10.1359/jbmr.2001.16.10.1739
   Uchiyama T, 1997, CALCIFIED TISSUE INT, V61, P493, DOI 10.1007/s002239900373
   Votta BJ, 1997, J BONE MINER RES, V12, P1396, DOI 10.1359/jbmr.1997.12.9.1396
   Waki Y, 1999, JPN J PHARMACOL, V79, P477, DOI 10.1254/jjp.79.477
   Xiang AB, 2006, INVEST RADIOL, V41, P704, DOI 10.1097/01.rli.0000236921.77810.56
   Yang J, 2003, ACAD RADIOL, V10, P1153, DOI 10.1016/S1076 6332(03)00109 0
   Yasuma T, 1998, J MED CHEM, V41, P4301, DOI 10.1021/jm9803065
NR 32
TC 41
Z9 45
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2007
VL 40
IS 5
BP 1231
EP 1237
DI 10.1016/j.bone.2007.01.010
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 162ZS
UT WOS:000246128700007
PM 17347064
DA 2025 08 17
ER

PT J
AU McCarus, DC
AF McCarus, DC
TI Fracture prevention in postmenopausal osteoporosis: A review of
   treatment options
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Article
ID BONE MINERAL DENSITY; RANDOMIZED CONTROLLED TRIAL; HORMONE REPLACEMENT
   THERAPY; ESTROGEN PLUS PROGESTIN; GASTROINTESTINAL TRACT SAFETY;
   CLINICAL VERTEBRAL FRACTURES; ALENDRONATE 70 MG; NONVERTEBRAL FRACTURES;
   INTERVENTION TRIAL; HIP FRACTURE
AB Several treatment options are available to reduce the risk of fractures in postmenopausal women with or at risk for osteoporosis. A MEDLINE search was conducted to evaluate antifracture and adverse event data of osteoporosis therapies from trials in postmenopausal women. Among the antiresorptive therapies, the bisphosphonates alendronate and risedronate have demonstrated consistent efficacy in reducing vertebral and nonvertebral fracture risk. Once weekly alendronate and risedronate produced similar improvements in bone mineral density compared with their once daily counterparts with similar tolerability. Daily injections of teriparatide resulted in statistically significant reductions in the risk of vertebral and nonvertebral fractures, and trials of ibandronate, raloxifene, and calcitonin nasal spray showed reductions in vertebral fracture risk. Hormone therapy has demonstrated clinical fracture risk reduction; however, safety outcomes from the Women's Health Initiative study have raised concerns regarding long term use of these preparations. These data can guide clinical decision making regarding the selection of an osteoporosis therapy.
   Target Audience: Obstetricians & Gynecologists, Family Physicians. Learning Objectives: After completion of this article, the reader should be able to summarize adverse events data of osteoporosis therapies from trials in postmenopausal women, explain that only a few therapies have shown a consistent efficacy in reducing vertebral and nonvertebral fractures, and state that data from the Women's Health Initiative study have raised concerns regarding long term use of estrogenprogestin therapy.
C1 Ctr Adv Vein Treatment & Womens Hlth Care, Towson, MD USA.
RP 658 Kenilworth Dr,Suite 205, Baltimore, MD 21204 USA.
EM drmccarus@verizon.net
CR Anderson GL, 2004, JAMA J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701
   [Anonymous], 2002, Americas bone health: the state of osteoporosis and low bone mass in our nation
   Barrett Connor E, 2002, JAMA J AM MED ASSOC, V287, P847, DOI 10.1001/jama.287.7.847
   Bauer DC, 2000, ARCH INTERN MED, V160, P517, DOI 10.1001/archinte.160.4.517
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Boonen S, 2004, J AM GERIATR SOC, V52, P1832, DOI 10.1111/j.1532 5415.2004.52506.x
   Brown JP, 2002, CALCIFIED TISSUE INT, V71, P103, DOI 10.1007/s00223 002 2011 8
   Cauley JA, 2003, JAMA J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729
   CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003 4819 122 1 199501010 00002
   Cauley JA, 2001, AM J MED, V110, P442, DOI 10.1016/S0002 9343(01)00647 7
   Chesnut CH, 2005, CURR MED RES OPIN, V21, P391, DOI 10.1185/030079905X30752
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   Colina RE, 1997, AM J GASTROENTEROL, V92, P704
   COOPER C, 1993, AM J EPIDEMIOL, V137, P1001, DOI 10.1093/oxfordjournals.aje.a116756
   Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001 9002
   Cryer B, 2002, MAYO CLIN PROC, V77, P1031, DOI 10.4065/77.10.1031
   Cuddihy MT, 2002, ARCH INTERN MED, V162, P421, DOI 10.1001/archinte.162.4.421
   Cummings SR, 1998, OSTEOPOROSIS INT, V8, pS8
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403
   Delmas PD, 2003, BONE, V33, P522, DOI 10.1016/S8756 3282(03)00241 2
   Delmas PD, 2002, J CLIN ENDOCR METAB, V87, P3609, DOI 10.1210/jc.87.8.3609
   *E LILL CO, 2003, EV RAL HCI FULL PRES
   *E LILL CO, 2002, FORT TER FULL PRESCR
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   FELSENBERG D, 2005, BONE
   Gallagher TC, 2002, ARCH INTERN MED, V162, P450, DOI 10.1001/archinte.162.4.450
   Gehlbach SH, 2000, OSTEOPOROSIS INT, V11, P577, DOI 10.1007/s001980070078
   Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609
   Greenspan SL, 2002, J BONE MINER RES, V17, P1988
   Harrington JT, 2004, CALCIFIED TISSUE INT, V74, P129, DOI 10.1007/s00223 003 0042 4
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Hulley S, 2002, JAMA J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58
   Kanis JA, 2003, BONE, V33, P293, DOI 10.1016/S8756 3282(03)00200 X
   Koike Y, 1999, TOHOKU J EXP MED, V188, P139, DOI 10.1620/tjem.188.139
   Koot VCM, 2000, EUR J SURG, V166, P480
   Lanza F, 2002, AM J GASTROENTEROL, V97, P58
   Lanza FL, 2000, GASTROENTEROLOGY, V119, P631, DOI 10.1053/gast.2000.16517
   Levis S, 2002, J AM GERIATR SOC, V50, P409, DOI 10.1046/j.1532 5415.2002.50102.x
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Liberman UA, 1996, NEW ENGL J MED, V335, P1069, DOI 10.1056/NEJM199610033351416
   Lindsay R, 2001, JAMA J AM MED ASSOC, V285, P320, DOI 10.1001/jama.285.3.320
   LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003 4819 117 1 1
   Maricic M, 2002, ARCH INTERN MED, V162, P1140, DOI 10.1001/archinte.162.10.1140
   Marie PJ, 2003, OSTEOPOROSIS INT, V14, pS9, DOI 10.1007/s00198 002 1344 5
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Mellström DD, 2004, CALCIFIED TISSUE INT, V75, P462, DOI 10.1007/s00223 004 0286 7
   *MERCK CO INC, 2004, FOS AL SOD FULL PRES
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Mosca L, 2001, AM J CARDIOL, V88, P392, DOI 10.1016/S0002 9149(01)01685 X
   *NAT CANC I, DIG PAG STUD TAM RAL
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   *NOV PHARM CORP, 2003, MIC CALC SALM FULL P
   Pols HAP, 1999, OSTEOPOROSIS INT, V9, P461, DOI 10.1007/PL00004171
   *PROCT GAMBL PHARM, 2005, ACT RIS SOD FULL PRE
   QUANDT S, 2001, 1 JOINT M INT BON MI
   Quandt SA, 2005, MAYO CLIN PROC, V80, P343, DOI 10.4065/80.3.343
   Randell KM, 2002, J BONE MINER RES, V17, P528, DOI 10.1359/jbmr.2002.17.3.528
   Recker R, 2004, BONE, V34, P890, DOI 10.1016/j.bone.2004.01.008
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P5018, DOI 10.1210/jc.2004 1750
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   *ROCH, 2005, BON IB SOD FULL PRES
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Roux C, 2004, CURR MED RES OPIN, V20, P433, DOI 10.1185/030079903125003125
   Sato Y, 2005, NEUROLOGY, V64, P811, DOI 10.1212/01.WNL.0000152871.65027.76
   Schnitzer T, 2000, AGING CLIN EXP RES, V12, P1
   Shumaker SA, 2003, JAMA J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651
   Siris ES, 2001, JAMA J AM MED ASSOC, V286, P2815, DOI 10.1001/jama.286.22.2815
   Sorensen OH, 2003, BONE, V32, P120, DOI 10.1016/S8756 3282(02)00946 8
   Taggart H, 2002, MAYO CLIN PROC, V77, P262, DOI 10.4065/77.3.262
   Thomson ABR, 2002, J RHEUMATOL, V29, P1965
   Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109
   Torgerson DJ, 2001, JAMA J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891
   *US FOOD DRG ADM, FDA TALK PAP FDA UPD
   *US FOOD DRUG ADM, FDA TALK PAP FDA APP
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Walker N, 1999, NEW ZEAL MED J, V112, P269
   Watts NB, 2003, OSTEOPOROSIS INT, V14, P437, DOI 10.1007/s00198 003 1401 8
   Watts NB, 2003, J CLIN ENDOCR METAB, V88, P542, DOI 10.1210/jc.2002 020400
NR 83
TC 19
Z9 20
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029 7828
EI 1533 9866
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD JAN
PY 2006
VL 61
IS 1
BP 39
EP 50
DI 10.1097/01.ogx.0000197807.08697.06
PG 12
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Obstetrics & Gynecology
GA 999ND
UT WOS:000234395400002
PM 16359568
DA 2025 08 17
ER

PT J
AU Sui, BD
   Hu, CH
   Liao, L
   Chen, YC
   Zhang, XY
   Fu, X
   Zheng, CX
   Li, M
   Wu, L
   Zhao, XY
   Jin, Y
AF Sui, Bingdong
   Hu, Chenghu
   Liao, Li
   Chen, Yichen
   Zhang, Xinyi
   Fu, Xin
   Zheng, Chenxi
   Li, Meng
   Wu, Ling
   Zhao, Xinyi
   Jin, Yan
TI Mesenchymal progenitors in osteopenias of diverse pathologies:
   differential characteristics in the common shift from osteoblastogenesis
   to adipogenesis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MARROW STROMAL CELLS; BONE MARROW; STEM CELL; MURINE MODEL; IN VITRO;
   DEXAMETHASONE; OSTEOPOROSIS; MECHANISMS; ESTROGEN; ADIPOCYTES
AB Osteoporosis is caused by pathologic factors such as aging, hormone deficiency or excess, inflammation, and systemic diseases like diabetes. Bone marrow stromal cells (BMSCs), the mesenchymal progenitors for both osteoblasts and adipocytes, are modulated by niche signals. In differential pathologic states, the pathological characteristics of BMSCs to osteoporoses and functional differences are unknown. Here, we detected that trabecular bone loss co existed with increased marrow adiposity in 6 osteoporotic models, respectively induced by natural aging, accelerated senescence (SAMP6), ovariectomy (OVX), type 1 diabetes (T1D), excessive glucocorticoids (GIOP) and orchidectomy (ORX). Of the ex vivo characteristics of BMSCs, the colony forming efficiency and the proliferation rate in aging, SAMP6, OVX, GIOP and ORX models decreased. The apoptosis and cellular senescence increased except in T1D, with up regulation of p53 and p16 expression. The osteogenesis declined except in GIOP, with corresponding down regulation of Runt related transcription factor 2 (RUNX2) expression. The adipogenesis increased in 6 osteoporotic models, with corresponding up regulation of Peroxisome proliferator activated receptor gamma (PPAR.) expression. These findings revealed differential characteristics of BMSCs in a common shift from osteoblastogenesis to adipogenesis among different osteoporoses and between sexes, and provide theoretical basis for the functional modulation of resident BMSCs in the regenerative therapy for osteoporosis.
C1 [Sui, Bingdong; Hu, Chenghu; Liao, Li; Chen, Yichen; Zhang, Xinyi; Fu, Xin; Zheng, Chenxi; Li, Meng; Wu, Ling; Jin, Yan] Fourth Mil Med Univ, Ctr Tissue Engn, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, Peoples R China.
   [Sui, Bingdong; Hu, Chenghu; Liao, Li; Chen, Yichen; Zhang, Xinyi; Fu, Xin; Zheng, Chenxi; Wu, Ling; Jin, Yan] Xian Inst Tissue Engn & Regenerat Med, Xian 710032, Shaanxi, Peoples R China.
   [Zhao, Xinyi] Fourth Mil Med Univ, Sch Stomatol, Dept Dent Mat, Xian 710032, Shaanxi, Peoples R China.
   [Zhao, Xinyi] Fourth Mil Med Univ, Dept Dent Mat, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Air Force
   Medical University
RP Jin, Y (通讯作者)，Fourth Mil Med Univ, Ctr Tissue Engn, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, Peoples R China.; Jin, Y (通讯作者)，Xian Inst Tissue Engn & Regenerat Med, Xian 710032, Shaanxi, Peoples R China.
EM yanjin@fmmu.edu.cn
RI Sui, Bingdong/HKN 5071 2023; Liao, Li/U 6866 2017; Zhang,
   Xinyi/AAJ 4858 2021; Fu, Xin/HLH 5953 2023; Jin, Yan/I 4204 2013; Hu,
   Cheng Hu/I 4210 2013; Li, Meng/AAZ 5393 2021; Zheng,
   Chenxi/GQA 4142 2022
OI Sui, Bingdong/0000 0002 7282 0935; Liao, Li/0000 0003 0030 1009; Hu,
   Cheng Hu/0000 0003 2443 6485; 
FU National Natural Science Foundation of China [31301062, 81570937,
   81470710]; National Basic Research Program (973 Program) of China
   [2011CB964700]
FX This work was supported by grants from The National Natural Science
   Foundation of China (31301062, 81570937 and 81470710) and The National
   Basic Research Program (973 Program) of China (2011CB964700).
CR Abdalrahaman N, 2015, J BONE MINER RES, V30, P1386, DOI 10.1002/jbmr.2465
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Bonyadi M, 2003, P NATL ACAD SCI USA, V100, P5840, DOI 10.1073/pnas.1036475100
   Botolin S, 2007, ENDOCRINOLOGY, V148, P198, DOI 10.1210/en.2006 1006
   Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002
   CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277
   Clowes JA, 2005, IMMUNOL REV, V208, P207, DOI 10.1111/j.0105 2896.2005.00334.x
   De Martinis M, 2006, INFLAMM RES, V55, P399, DOI 10.1007/s00011 006 6034 x
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Devlin MJ, 2015, LANCET DIABETES ENDO, V3, P141, DOI 10.1016/S2213 8587(14)70007 5
   Erben R. G., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P225
   Ghali O, 2015, BMC CELL BIOL, V16, DOI 10.1186/s12860 015 0056 6
   Henneicke H, 2014, TRENDS ENDOCRIN MET, V25, P197, DOI 10.1016/j.tem.2013.12.006
   HERBERTSON A, 1995, J BONE MINER RES, V10, P285
   Jilka RL, 1996, J CLIN INVEST, V97, P1732, DOI 10.1172/JCI118600
   Kajkenova O, 1997, J BONE MINER RES, V12, P1772, DOI 10.1359/jbmr.1997.12.11.1772
   Ke H. Z., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P215
   Kiernan J, 2016, STEM CELL TRANSL MED, V5, P683, DOI 10.5966/sctm.2015 0231
   Kitajima Y, 2015, SCI REP UK, V5, DOI 10.1038/srep12861
   Kume S, 2005, J BONE MINER RES, V20, P1647, DOI 10.1359/JBMR.050514
   Lenzen S, 2008, DIABETOLOGIA, V51, P216, DOI 10.1007/s00125 007 0886 7
   Leskelä HV, 2006, BONE, V39, P1026, DOI 10.1016/j.bone.2006.05.003
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.348
   Liao L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.130
   Lien CY, 2009, J BONE MINER RES, V24, P837, DOI [10.1359/JBMR.081257, 10.1359/jbmr.081257]
   Lu HF, 2003, ENDOCRINOLOGY, V144, P346, DOI 10.1210/en.2002 220072
   Lukic M L, 1998, Dev Immunol, V6, P119, DOI 10.1155/1998/92198
   Mazar J, 2009, J BIOL CHEM, V284, P22022, DOI 10.1074/jbc.M109.032235
   McCabe LR, 2007, J CELL BIOCHEM, V102, P1343, DOI 10.1002/jcb.21573
   Mei SHJ, 2007, PLOS MED, V4, P1525, DOI 10.1371/journal.pmed.0040269
   Miric G, 2001, BRIT J PHARMACOL, V133, P687, DOI 10.1038/sj.bjp.0704131
   Mirsaidi A, 2012, J TISSUE ENG REGEN M, V6, P378, DOI 10.1002/term.440
   Oshina H, 2007, BONE, V41, P575, DOI 10.1016/j.bone.2007.06.022
   Patsch JM, 2013, J BONE MINER RES, V28, P1721, DOI 10.1002/jbmr.1950
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Rizzoli R, 2015, NAT REV RHEUMATOL, V11, P98, DOI 10.1038/nrrheum.2014.188
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Sadie Van Gijsen H, 2013, CELL MOL LIFE SCI, V70, P2331, DOI 10.1007/s00018 012 1211 2
   Schwartz AV, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00040
   Schwartz AV, 2013, J CLIN ENDOCR METAB, V98, P2294, DOI 10.1210/jc.2012 3949
   Selby Peter, 2004, Curr Osteoporos Rep, V2, P101, DOI 10.1007/s11914 004 0018 y
   Shen W, 2012, OSTEOPOROSIS INT, V23, P2293, DOI 10.1007/s00198 011 1873 x
   Slade JM, 2012, J DIABETES COMPLICAT, V26, P1, DOI 10.1016/j.jdiacomp.2011.11.001
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Stolzing A, 2010, CELLS TISSUES ORGANS, V191, P453, DOI 10.1159/000281826
   Sui BD, 2016, BIOGERONTOLOGY, V17, P267, DOI 10.1007/s10522 015 9609 5
   Syed FA, 2008, OSTEOPOROSIS INT, V19, P1323, DOI 10.1007/s00198 008 0574 6
   TAKEDA T, 1981, MECH AGEING DEV, V17, P183, DOI 10.1016/0047 6374(81)90084 1
   Tamura N, 2005, FERTIL STERIL, V84, P1277, DOI 10.1016/j.fertnstert.2005.06.017
   Van Belle TL, 2011, PHYSIOL REV, V91, P79, DOI 10.1152/physrev.00003.2010
   Walsh S, 2001, RHEUMATOLOGY, V40, P74, DOI 10.1093/rheumatology/40.1.74
   Wang L, 2013, STEM CELLS, V31, P1383, DOI 10.1002/stem.1388
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042
   Yang N, 2013, J BONE MINER RES, V28, P559, DOI 10.1002/jbmr.1798
   Yu W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098044
   Zhao Y, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/637415
   Zhao YF, 2013, INT J MOL MED, V31, P614, DOI 10.3892/ijmm.2013.1227
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
NR 60
TC 63
Z9 72
U1 1
U2 23
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JUL 22
PY 2016
VL 6
AR 30186
DI 10.1038/srep30186
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DR8YV
UT WOS:000380185200001
PM 27443833
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Russo, R
   Mallia, S
   Zito, F
   Lampiasi, N
AF Russo, Roberta
   Mallia, Selene
   Zito, Francesca
   Lampiasi, Nadia
TI Long Lasting Activity of ERK Kinase Depends on NFATc1 Induction and Is
   Involved in Cell Migration Fusion in Murine Macrophages RAW264.7
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE MAPKs; PD98059; FR180204; gene expression; siRNA; RANKL; osteoclast
   hallmarks
AB Macrophages are mononuclear cells that become osteoclasts (OCs) in the presence of two cytokines, macrophage colony stimulating factor (M CSF), and receptor activator of NF kappa B ligand (RANKL). RANKL binding to its specific receptor RANK leads to OCs differentiation mainly by nuclear factor of activated T cells cytoplasmic 1 (NFATc1). In our previous study, the analysis of the protein network in NFATc1 knockdown cells, using the Ingenuity Pathway Analysis (IPA), showed a link between NFATc1 and Mitogen activated protein kinase kinase (MEK) extracellular receptor kinase (ERK) signaling pathway. Therefore, this study aimed to extend our knowledge of the relationship between NFATc1 and the ERK. Here, we demonstrate that delayed ERK1/2 phosphorylation in pre OC RANKL induced depends on NFATc1. Indeed, the knockdown of NFATc1 reduced the phosphorylation of ERK1/2 (60%) and the pharmacological inhibition of the ERK1/2 kinase activity impairs the expression of NFATc1 without preventing its translocation into the nucleus. Furthermore, silencing of NFATc1 significantly reduced RANKL induced migration (p < 0.01), and most pre OCs are still mononuclear after 48 h (80 +/  5%), despite the presence of actin rings. On the other hand, the inhibitors FR180204 and PD98059 significantly reduced RANKL induced cell migration (p < 0.01), leading to a reduction in the number of multinucleated cells. Finally, we suggest that long lasting ERK activity depends on NFATc1 induction and is likely linked to cell migration, fusion, and OC differentiation.
C1 [Russo, Roberta; Mallia, Selene; Zito, Francesca; Lampiasi, Nadia] CNR, Ist Ric & Innovaz Biomed IRIB, Via Ugo La Malfa 153, I 90146 Palermo, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto Ricerca l'Innovazione
   Biomedica (IRIB CNR)
RP Lampiasi, N (通讯作者)，CNR, Ist Ric & Innovaz Biomed IRIB, Via Ugo La Malfa 153, I 90146 Palermo, Italy.
EM roberta.russo@irib.cnr.it; selenemallia93@gmail.com;
   francesca.zito@irib.cnr.it; nadia.lampiasi@irib.cnr.it
RI Lampiasi, Nadia/ADJ 5851 2022; Lampiasi, Nadia/AAR 8451 2020; Zito,
   Francesca/C 5770 2015; Zito, Francesca/AAV 4576 2020; Russo,
   Roberta/AAA 7065 2021
OI Lampiasi, Nadia/0000 0002 6831 4781; Mallia, Selene/0000 0001 9739 885X;
   Zito, Francesca/0000 0002 1278 8814; Russo, Roberta/0000 0001 8683 8872
FU Consiglio Nazionale delle Ricerche (CNR) of Italy [DSB.AD006.146.001];
   Russian Foundation for Basic Research (RFBR) [DSB.AD006.146.001]
FX This work was supported by a Joint Research Project 2015 2017
   (DSB.AD006.146.001) as part of the Bilateral Agreement of Scientific and
   Technological Cooperation between the Consiglio Nazionale delle Ricerche
   (CNR) of Italy and the Russian Foundation for Basic Research (RFBR).
CR Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347
   ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/0968 0004(96)30032 7
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bruzzaniti A, 2005, MOL BIOL CELL, V16, P3301, DOI 10.1091/mbc.E04 12 1117
   Carlson J, 2009, AM J PATHOL, V175, P1564, DOI 10.2353/ajpath.2009.090035
   Casar B, 2008, MOL CELL, V31, P708, DOI 10.1016/j.molcel.2008.07.024
   Caunt CJ, 2010, J CELL SCI, V123, P4310, DOI 10.1242/jcs.076349
   Chuderland D, 2008, MOL CELL, V31, P850, DOI 10.1016/j.molcel.2008.08.007
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226
   Horowitz MC, 2001, CYTOKINE GROWTH F R, V12, P9, DOI 10.1016/S1359 6101(00)00030 7
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481
   Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Kim BH, 2017, MOL CELLS, V40, P752, DOI 10.14348/molcells.2017.0098
   Lampiasi N, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/9089610
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097 2765(04)00161 3
   Li YY, 2019, J BONE MINER RES, V34, P1938, DOI 10.1002/jbmr.3810
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Moon SH, 2015, J PHARMACOL SCI, V129, P135, DOI 10.1016/j.jphs.2015.06.008
   Murillo A, 2010, BIOL RES, V43, P205, DOI /S0716 97602010000200009
   Oh JH, 2015, MOL CELLS, V38, P279, DOI 10.14348/molcells.2015.2340
   Ohori M, 2005, BIOCHEM BIOPH RES CO, V336, P357, DOI 10.1016/j.bbrc.2005.08.082
   Prowse CN, 2001, J BIOL CHEM, V276, P99, DOI 10.1074/jbc.M008137200
   Qiao H, 2009, FREE RADICAL BIO MED, V46, P1221, DOI 10.1016/j.freeradbiomed.2009.02.004
   Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014
   Russo R, 2019, CELLS BASEL, V8, DOI 10.3390/cells8020131
   Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978
   Segovia Silvestre T, 2009, HUM GENET, V124, P561, DOI 10.1007/s00439 008 0583 8
   Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968 0004(00)01627 3
   Sun M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.225
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tanimura S, 2017, J BIOCHEM, V162, P145, DOI 10.1093/jb/mvx048
   Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466
   Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Wolf I, 2001, J BIOL CHEM, V276, P24490, DOI 10.1074/jbc.M103352200
   Wu H, 2003, BIOESSAYS, V25, P1096, DOI 10.1002/bies.10352
   Xing LP, 2009, CURR OPIN INVEST DR, V10, P1195
   Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105 2896.2005.00336.x
   Yazicioglu MN, 2007, J BIOL CHEM, V282, P28759, DOI 10.1074/jbc.M703460200
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Zito F, 2016, EUR J CELL BIOL, V95, P552, DOI 10.1016/j.ejcb.2016.09.002
NR 55
TC 10
Z9 10
U1 0
U2 13
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2020
VL 21
IS 23
AR 8965
DI 10.3390/ijms21238965
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA PD7YO
UT WOS:000597895900001
PM 33255852
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lee, SY
   Kwon, HK
   Lee, SM
AF Lee, Sung Yeol
   Kwon, Hyoung Keun
   Lee, Sun Mee
TI 被撤回的出版物: SHINBARO, a New Herbal Medicine with Multifunctional Mechanism
   for Joint Disease: First Therapeutic Application for the Treatment of
   Osteoarthritis (Retracted Article)
SO ARCHIVES OF PHARMACAL RESEARCH
LA English
DT Article; Retracted Publication
ID CARDIOVASCULAR OUTCOMES; NAPROXEN; IBUPROFEN
AB SHINBARO is a purified extract from a mixture of 6 oriental herbs (Ledebouriellae Radix, Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, and Eucommiae Cortex) that have been used as a traditional medicine for treatment of several inflammatory diseases and bone disorders. We determined anti inflammatory and antinociceptive activities of SHINBARO in adjuvant induced (osteo) arthritis in rats. This potential anti (osteo) arthritic property of SHINBARO can be due to the downregulation of inflammatory mediators such as iNOS, COX 2, and TNF alpha, the increase of pain threshold in the peripheral system, the activation of alkaline phosphatase in osteoblasts, the suppression of proteoglycan degradation, and the inhibition of MMP 2 and MMP 9 activities as demonstrated by in vitro and in vivo experimental studies. We confirmed that SHINBARO is as effective as celecoxib, a selective COX 2 inhibitor, but it has the better safety profile in clinical trials. Finally, SHINBARO was approved as a New Herbal Medicine for treatment of osteoarthritis by Korean FDA on January 25(th), 2011.
C1 [Lee, Sung Yeol; Kwon, Hyoung Keun] Green Cross, Yongin 446770, South Korea.
   [Lee, Sun Mee] Sungkyunkwan Univ, Sch Pharm, Suwon 440746, South Korea.
C3 Sungkyunkwan University (SKKU)
RP Lee, SY (通讯作者)，Green Cross, 303 Bojeong Dong, Yongin 446770, South Korea.
EM sylee@greencross.com
CR Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   Farkouh ME, 2007, ANN RHEUM DIS, V66, P764, DOI 10.1136/ard.2006.066001
   Farkouh ME, 2004, LANCET, V364, P675, DOI 10.1016/S0140 6736(04)16894 3
   HONG ND, 1988, KOR J PHARMACOGN, V19, P102
   Ida Y, 1998, BIOORG MED CHEM LETT, V8, P2555, DOI 10.1016/S0960 894X(98)00457 0
   Kim Hyun Woo, 2002, J Vet Sci, V3, P343
   Kim SungHwa Kim SungHwa, 2005, Korean Journal of Pharmacognosy, V36, P311
   Lee ChanHo Lee ChanHo, 2005, Korean Journal of Pharmacognosy, V36, P299
   WEINBERGER M, 1989, ARTHRITIS RHEUM US, V32, P1577, DOI 10.1002/anr.1780321212
NR 9
TC 12
Z9 13
U1 1
U2 14
PU PHARMACEUTICAL SOC KOREA
PI SEOUL
PA 1489 3 SUHCHO DONG, SUHCHO KU, SEOUL 137 071, SOUTH KOREA
SN 0253 6269
EI 1976 3786
J9 ARCH PHARM RES
JI Arch. Pharm. Res.
PD NOV
PY 2011
VL 34
IS 11
SI SI
BP 1773
EP 1777
DI 10.1007/s12272 011 1121 0
PG 5
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 856NT
UT WOS:000297650300002
PM 22139679
OA Bronze
DA 2025 08 17
ER

PT J
AU Chung, CJ
   Baik, HS
   Soma, K
AF Chung, Chooryung J.
   Baik, Hyoung Seon
   Soma, Kunimichi
TI Bone formation and tooth movement are synergistically of EP4 agonist
SO AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS
LA English
DT Article
ID ENDOTHELIAL GROWTH FACTOR; PROSTAGLANDIN E 2 RECEPTOR; IN VIVO; INDUCED
   OSTEOGENESIS; PARATHYROID HORMONE; GENE TRANSFER; MICE LACKING;
   EXPRESSION; STIMULATION; OSTEOCALCIN
AB Introduction: Stimulation of the prostaglandin receptor EP4 induces bone anabolic responses to external loading. The aim of this study was to determine the possibility of synergistic enhancement of tooth movement along with bone formation in vivo through the stimulation of the prostaglandin receptor EP4. Methods: The sample consisted of 25 male rats, 6 to 7 weeks old. Experimental tooth movement was induced in the maxillary right molars with a split mouth design. During the 7 day experimental period, some rats were injected periodically with a specific EP4 agonist (ONO AE1 329), a drug that binds to the EP4 receptor to mimic the actions of ligand binding; the injection site was on the tension side in the interproximal region between the first and second molars. Other rats received vehicle injection (saline solution only). For control, EN agonist or vehicle was injected into some rats, but tooth movement was not initiated. The amounts of tooth movement and bone volume of the paradental region were evaluated by using soft x ray and micro computed tomography. Results: The injection of EP4 agonist alone did not induce notable changes in body weight, macro structures, or bone volume compared with the vehicle treated group or the untouched control side. EN agonist injection in conjunction with tooth movement significantly enhanced the amounts of tooth movement and regional bone volume in the tension side compared with the vehicle treated group (P <.05). Conclusions: Our preliminary study suggests the possibilities of synergistic enhancement of the rates of tooth movement and bone formation during tooth movement through the local injection of a specific EP4 receptor agonist. However, more study on the synergistic effect on tooth movement and bone formation in response to an EN agonist is needed to determine its mechanisms.
C1 Yonsei Univ, Coll Dent, Yongdong Severance Dent Hosp, Dept Orthodont, Seoul 120749, South Korea.
   Tokyo Med & Dent Univ, Grad Sch, Tokyo, Japan.
C3 Yonsei University; Yonsei University Health System; Institute of Science
   Tokyo; Tokyo Medical & Dental University (TMDU)
RP Chung, CJ (通讯作者)，Yonsei Univ, Coll Dent, Dent Hosp 7F, Dept Orthodont, Seoul 120749, South Korea.
EM crchung@yumc.yonsei.ac.kr
OI Chung, Chooryung/0000 0001 9399 7193
CR BILEZIKIAN JP, 2002, PRINCIPLES BONE BIOL, P979
   Chung Choo ryung J., 2004, Journal of Medical and Dental Sciences, V51, P105
   COLEMAN RA, 1994, PHARMACOL REV, V46, P205
   DEBBANE E F, 1964, Rep Congr Eur Orthod Soc, V40, P371
   Hagino H, 2005, BONE, V36, P444, DOI 10.1016/j.bone.2004.12.013
   Hagino H, 2001, J BONE MINER METAB, V19, P244, DOI 10.1007/s007740170027
   Hashimoto F, 2001, EUR J ORTHODONT, V23, P535, DOI 10.1093/ejo/23.5.535
   Hizaki H, 1999, P NATL ACAD SCI USA, V96, P10501, DOI 10.1073/pnas.96.18.10501
   Jäger A, 2005, EUR J ORTHODONT, V27, P1, DOI 10.1093/ejo/cjh089
   Kaku M, 2001, J DENT RES, V80, P1880, DOI 10.1177/00220345010800100401
   Kanzaki H, 2006, GENE THER, V13, P678, DOI 10.1038/sj.gt.3302707
   Kanzaki H, 2004, J DENT RES, V83, P920, DOI 10.1177/154405910408301206
   Kanzaki H, 2002, J BONE MINER RES, V17, P210, DOI 10.1359/jbmr.2002.17.2.210
   Kawakami M, 2004, J BONE MINER METAB, V22, P541, DOI 10.1007/s00774 004 0521 3
   Kobayashi Y, 1998, ANGLE ORTHOD, V68, P259
   Kohno S, 2005, ANGLE ORTHOD, V75, P797
   Kohno S, 2003, J DENT RES, V82, P177, DOI 10.1177/154405910308200306
   Kohno T, 2002, J Orthod, V29, P129, DOI 10.1093/ortho/29.2.129
   Krishnan V., 2006, AM J ORTHOD DENTOFAC, V129, p469., DOI [10.1016/j.ajodo.2005.10.007, DOI 10.1016/J.AJODO.2005.10.007]
   LEIKER BJ, 1995, AM J ORTHOD DENTOFAC, V108, P380, DOI 10.1016/S0889 5406(95)70035 8
   Ma YF, 1999, J BONE MINER RES, V14, P439, DOI 10.1359/jbmr.1999.14.3.439
   Machwate M, 2001, MOL PHARMACOL, V60, P36, DOI 10.1124/mol.60.1.36
   Masella RS, 2006, AM J ORTHOD DENTOFAC, V129, P458, DOI 10.1016/j.ajodo.2005.12.013
   Masuzawa M, 2005, J ORTHOP SCI, V10, P308, DOI 10.1007/s00776 005 0890 z
   Mitsui N, 2005, LIFE SCI, V77, P3168, DOI 10.1016/j.lfs.2005.03.037
   Nemoto K, 1997, PROSTAG OTH LIPID M, V54, P713, DOI 10.1016/S0090 6980(97)00145 7
   Noguchi K, 2005, ORAL DIS, V11, P157, DOI 10.1111/j.1601 0825.2005.01059.x
   Noguchi K, 2000, J DENT RES, V79, P1955, DOI 10.1177/00220345000790120601
   Ono K, 2003, BONE, V33, P798, DOI 10.1016/S8756 3282(03)00264 3
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pavlin D, 2001, CRIT REV ORAL BIOL M, V12, P414, DOI 10.1177/10454411010120050401
   Pavlin D, 2001, CONNECT TISSUE RES, V42, P135, DOI 10.3109/03008200109014255
   Ren YJ, 2002, J CLIN PERIODONTOL, V29, P757, DOI 10.1034/j.1600 051X.2002.290813.x
   Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461
   Shamir D, 2004, BONE, V34, P157, DOI 10.1016/j.bone.2003.09.008
   SMITH RK, 1980, CALCIFIED TISSUE INT, V30, P51, DOI 10.1007/BF02408606
   Soma S, 1999, J BONE MINER RES, V14, P546, DOI 10.1359/jbmr.1999.14.4.546
   Soma S, 2000, J DENT RES, V79, P1717, DOI 10.1177/00220345000790091301
   Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554
   Take I, 2005, ENDOCRINOLOGY, V146, P5204, DOI 10.1210/en.2005 0451
   Terai K, 1999, J BONE MINER RES, V14, P839, DOI 10.1359/jbmr.1999.14.6.839
   Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233
   Verna C, 2003, Orthod Craniofac Res, V6, P155
   Verna C, 1999, BONE, V24, P371, DOI 10.1016/S8756 3282(99)00009 5
   Verna C, 2000, EUR J ORTHODONT, V22, P343, DOI 10.1093/ejo/22.4.343
   Weinreb M, 2001, BONE, V28, P275, DOI 10.1016/S8756 3282(00)00447 6
   YAMASAKI K, 1980, J DENT RES, V59, P1635, DOI 10.1177/00220345800590101301
   YAMASAKI K, 1982, J DENT RES, V61, P1444, DOI 10.1177/00220345820610121401
   YAMASAKI K, 1984, AM J ORTHOD DENTOFAC, V85, P508, DOI 10.1016/0002 9416(84)90091 5
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
NR 50
TC 8
Z9 9
U1 0
U2 1
PU MOSBY ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0889 5406
EI 1097 6752
J9 AM J ORTHOD DENTOFAC
JI Am. J. Orthod. Dentofac. Orthop.
PD OCT
PY 2007
VL 132
IS 4
BP U13
EP U20
AR 427.e13
DI 10.1016/j.ajodo.2007.02.049
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 223RX
UT WOS:000250391100006
PM 17920491
DA 2025 08 17
ER

PT J
AU Funck Brentano, T
   Lin, H
   Hay, E
   Kioon, MDA
   Schiltz, C
   Hannouche, D
   Nizard, R
   Lioté, F
   Orcel, P
   de Vernejoul, MC
   Cohen Solal, ME
AF Funck Brentano, Thomas
   Lin, Hilene
   Hay, Eric
   Kioon, Marie Dominique Ah
   Schiltz, Corinne
   Hannouche, Didier
   Nizard, Remy
   Liote, Frederic
   Orcel, Philippe
   de Vernejoul, Marie Christine
   Cohen Solal, Martine Esther
TI Targeting Bone Alleviates Osteoarthritis in Osteopenic Mice and
   Modulates Cartilage Catabolism
SO PLOS ONE
LA English
DT Article
ID ESTROGEN RECEPTOR ALPHA; SUBCHONDRAL BONE; ARTICULAR CARTILAGE; KNEE
   OSTEOARTHRITIS; GENE HAPLOTYPE; MURINE MODEL; II COLLAGEN; DEGRADATION;
   OSTEOPROTEGERIN; EXPRESSION
AB Objective: Subchondral bone modifications occur early in the development of osteoarthritis (OA). The level of bone resorption might impact cartilage remodeling. We therefore assessed the in vivo and in vitro effects of targeting bone resorption in OA and cartilage metabolism.
   Methods: OA was induced by meniscectomy (MNX) in ovariectomized osteopenic mice (OP) treated with estradiol (E2), pamidronate (PAM), or phosphate buffered saline (PBS) for 6 weeks. We assessed the subchondral bone and cartilage structure and the expression of cartilage matrix proteases. To assess the involvement of bone soluble factors in cartilage metabolism, supernatant of human bone explants pre treated with E2 or PAM were transferred to cartilage explants to assess proteoglycan release and aggrecan cleavage. OPG/RANKL mRNA expression was assessed in bone explants by real time quantitative PCR. The role of osteoprotegerin (OPG) in the bone cartilage crosstalk was tested using an OPG neutralizing antibody.
   Results: Bone mineral density of OP mice and osteoclast number were restored by E2 and PAM (p<0.05). In OP mice, E2 and PAM decreased ADAMTS 4 and  5 expression, while only PAM markedly reduced OA compared to PBS (2.0+/ 0.63 vs 5.2+/ 0.95; p<0.05). OPG/RANKL mRNA was increased in human bone explants treated with both drugs (2.2 3.7 fold). Moreover, supernatants from bone explants cultured with E2 or PAM reduced aggrecan cleavage and cartilage proteoglycan release (73+/ 8.0% and 80+/ 22% of control, respectively, p<0.05). This effect was reversed with osteoprotegerin blockade.
   Conclusion: The inhibition of bone resorption by pamidronate in osteopenic mice alleviates the histological OA score with a reduction in the expression of aggrecanases. Bone soluble factors, such as osteoprotegerin, impact the cartilage response to catabolic factors. This study further highlights the importance of subchondral bone in the regulation of joint cartilage damage in OA.
C1 [Funck Brentano, Thomas; Lin, Hilene; Hay, Eric; Kioon, Marie Dominique Ah; Schiltz, Corinne; Liote, Frederic; de Vernejoul, Marie Christine; Cohen Solal, Martine Esther] Hop Lariboisiere, Ctr Viggo Petersen, INSERM, U606, F 75475 Paris, France.
   [Funck Brentano, Thomas; Lin, Hilene; Hay, Eric; Kioon, Marie Dominique Ah; Schiltz, Corinne; Hannouche, Didier; Nizard, Remy; Liote, Frederic; Orcel, Philippe; de Vernejoul, Marie Christine; Cohen Solal, Martine Esther] Univ Paris 07, Hop Lariboisiere, Paris, France.
   [Hannouche, Didier; Nizard, Remy] Hop Lariboisiere, Ctr Viggo Petersen, Dept Orthoped, F 75475 Paris, France.
   [Orcel, Philippe] Hop Lariboisiere, Ctr Viggo Petersen, Dept Rheumatol, F 75475 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Lariboisiere Fernand Widal   APHP; Assistance
   Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital
   Universitaire Lariboisiere Fernand Widal   APHP; Assistance Publique
   Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire
   Lariboisiere Fernand Widal   APHP; Universite Paris Cite; Assistance
   Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere Fernand Widal   APHP
RP Funck Brentano, T (通讯作者)，Hop Lariboisiere, Ctr Viggo Petersen, INSERM, U606, F 75475 Paris, France.
EM martine.cohen solal@inserm.fr
RI ; Funck Brentano, Thomas/AAS 7201 2020; Haÿ, Eric/HNS 9912 2023;
   Funck Brentano, Thomas/Q 5736 2016; Cohen Solal, Martine/P 7808 2017;
   Nizard, Remy/R 5845 2019; Liote, Frederic/AAD 6926 2020
OI ORCEL, Philippe/0000 0001 7028 1133; Ah Kioon, Marie
   Dominique/0000 0003 2319 0444; Liote, Frederic/0000 0003 4419 0726; Hay,
   Eric/0000 0002 0131 9983; Funck Brentano, Thomas/0000 0001 7684 2405;
   Cohen Solal, Martine/0000 0002 8582 8258; Hannouche,
   Didier/0000 0003 2060 2394
FU INSERM; Societe Francaise de Rhumatologie; Fondation pour la Recherche
   Medicale
FX TFB was supported by INSERM, "Societe Francaise de Rhumatologie" and
   "Fondation pour la Recherche Medicale". The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bellido M, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3103
   Bergink AP, 2003, ARTHRITIS RHEUM, V48, P1913, DOI 10.1002/art.11046
   Bobinac D, 2003, BONE, V32, P284, DOI 10.1016/S8756 3282(02)00982 1
   Botter SM, 2011, ARTHRITIS RHEUM US, V63, P2690, DOI 10.1002/art.30307
   Byron CR, 2010, AM J VET RES, V71, P615, DOI 10.2460/ajvr.71.6.615
   Calvo E, 2007, OSTEOARTHR CARTILAGE, V15, P69, DOI 10.1016/j.joca.2006.06.006
   Cirillo DJ, 2006, ARTHRITIS RHEUM US, V54, P3194, DOI 10.1002/art.22138
   Claassen H, 2006, BONE, V39, P310, DOI 10.1016/j.bone.2006.02.067
   Crema MD, 2010, RADIOLOGY, V256, P855, DOI 10.1148/radiol.10091467
   FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304 4165(86)90306 5
   Funck Brentano T, 2011, CYTOKINE GROWTH F R, V22, P91, DOI 10.1016/j.cytogfr.2011.04.003
   Fytili P, 2005, CLIN GENET, V68, P268, DOI 10.1111/j.1399 0004.2005.00495.x
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369
   Hayami T, 2004, ARTHRITIS RHEUM US, V50, P1193, DOI 10.1002/art.20124
   Jiao K, 2011, BONE, V48, P362, DOI 10.1016/j.bone.2010.09.010
   Jin SY, 2004, ARTHRITIS RES THER, V6, pR415, DOI 10.1186/ar1207
   Kadri A, 2008, ARTHRITIS RHEUM US, V58, P2379, DOI 10.1002/art.23638
   Kadri A, 2010, ANN RHEUM DIS, V69, P1533, DOI 10.1136/ard.2009.124586
   Lian K, 2007, OSTEOARTHR CARTILAGE, V15, P972, DOI 10.1016/j.joca.2007.02.020
   Ma HL, 2007, OSTEOARTHR CARTILAGE, V15, P695, DOI 10.1016/j.joca.2006.11.005
   Moreno Rubio J, 2010, ARTHRITIS RHEUM US, V62, P478, DOI 10.1002/art.27204
   Oestergaard S, 2006, ARTHRITIS RHEUM US, V54, P2441, DOI 10.1002/art.22009
   Pelletier JP, 2004, BONE, V34, P527, DOI 10.1016/j.bone.2003.11.021
   RADIN EL, 1986, CLIN ORTHOP RELAT R, P34
   RADIN EL, 1973, J BIOMECH, V6, P51, DOI 10.1016/0021 9290(73)90037 7
   Richette P, 2007, ANN RHEUM DIS, V66, P345, DOI 10.1136/ard.2006.059550
   Richmond RS, 2000, ARTHRITIS RHEUM, V43, P2081, DOI 10.1002/1529 0131(200009)43:9<2081::AID ANR20>3.0.CO;2 I
   Riggs BL, 2000, J CLIN INVEST, V106, P1203, DOI 10.1172/JCI11468
   Roemer FW, 2009, ANN RHEUM DIS, V68, P1461, DOI 10.1136/ard.2008.096834
   Roman Blas JA, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2791
   Shimizu S, 2007, ARTHRITIS RHEUM US, V56, P3358, DOI 10.1002/art.22941
   Sniekers YH, 2008, OSTEOARTHR CARTILAGE, V16, P533, DOI 10.1016/j.joca.2008.01.002
   Sniekers YH, 2009, OSTEOARTHR CARTILAGE, V17, P1356, DOI 10.1016/j.joca.2009.04.008
   Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417
   Tat SK, 2009, RHEUMATOLOGY, V48, P1482, DOI 10.1093/rheumatology/kep300
   Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427
   Ushiyama T, 1999, OSTEOARTHR CARTILAGE, V7, P560, DOI 10.1053/joca.1999.0260
NR 38
TC 44
Z9 51
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAR 14
PY 2012
VL 7
IS 3
AR e33543
DI 10.1371/journal.pone.0033543
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 931EO
UT WOS:000303198600076
PM 22432033
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Granados Montiel, J
   Cruz Lemini, M
   Rangel Escareño, C
   Martinez Nava, G
   Landa Solis, C
   Gomez Garcia, R
   Lopez Reyes, A
   Espinosa Gutierrez, A
   Ibarra, C
AF Granados Montiel, Julio
   Cruz Lemini, Monica
   Rangel Escareno, Claudia
   Martinez Nava, Gabriela
   Landa Solis, Carlos
   Gomez Garcia, Ricardo
   Lopez Reyes, Alberto
   Espinosa Gutierrez, Alejandro
   Ibarra, Clemente
TI SERPINA9 and SERPINB2: Novel Cartilage Lineage
   Differentiation Markers of Human Mesenchymal Stem Cells with Kartogenin
SO CARTILAGE
LA English
DT Article
DE mesenchymal stem cells; SERPINA9; SERPINB2; chondrocytes; osteoblasts
AB Objective
   Human mesenchymal stem cells (hMSCs) are a promising source for regenerative medicine, especially mesodermal lineages. Clinical applications require an understanding of the mechanisms for transcriptional control to maintain the desired cell type. The aim of this study was to identify novel markers for differentiation of hMSCs into bone or cartilage with the use of Kartogenin, by RNA analysis using microarray technology, and explore the role of RhoA Rho associated protein kinase (ROCK) inhibition in these.
   Methods
   Commercial human bone marrow derived primary mesenchymal stem cells were purchased from ATCC. Cells were differentiated in vitro in 2 dimensional cultures using Kartogenin as the main cartilage inducer and bone morphogenetic protein 2 for bone differentiation; cells were cultured with and without ROCK inhibitor Y 27632. After 21 days of culture, whole RNA was extracted and analyzed via Affimetrix microarrays. The most significant hits were validated by quantitative polymerase chain reaction.
   Results
   We found a total of 1,757 genes that were either up  or downregulated on differentiation, when compared to P1 hMSC (control) at day 0 of differentiation. Two members of the Serpin superfamily, SERPINA9 and SERPINB2, were significantly upregulated in the cartilage groups, whereas they were unchanged in the bone groups with and without ROCK inhibition.
   Conclusions
   SERPINA9 and SERPINB2 are novel differentiation markers, and molecular regulator candidates for hMSC lineage commitment toward bone and cartilage, providing a new tool for regenerative medicine. Our study highlights the roles of these 2 genes, with significant upregulation of both in cell cultures stimulated with Kartogenin.
C1 [Granados Montiel, Julio; Landa Solis, Carlos; Gomez Garcia, Ricardo; Ibarra, Clemente] Inst Nacl Rehabil Luis Guillermo Ibarra Ibarra, Tissue Engn Cell Therapy & Regenerat Med Res Unit, Calzada Mexico Xochimilco 289, Mexico City 14389, DF, Mexico.
   [Granados Montiel, Julio] Kings Coll London, Guys Hosp, Ctr Craniofacial & Regenerat Biol, London, England.
   [Cruz Lemini, Monica] Children & Womens Specialty Hosp Queretaro, Fetal Med Mexico Fdn, Queretaro, Mexico.
   [Cruz Lemini, Monica] Children & Womens Specialty Hosp Queretaro, Fetal Surg Unit, Queretaro, Mexico.
   [Rangel Escareno, Claudia] Inst Nacl Med Genom, Computat Genom Lab, Mexico City, DF, Mexico.
   [Martinez Nava, Gabriela; Lopez Reyes, Alberto] Inst Nacl Rehabil Luis Guillermo Ibarra Ibarra, Synovioanal Mol Lab, Mexico City, DF, Mexico.
   [Espinosa Gutierrez, Alejandro] Inst Nacl Rehabil Luis Guillermo Ibarra Ibarra, Hand Surg & Microsurg Dept, Mexico City, DF, Mexico.
C3 University of London; King's College London; Guy's & St Thomas' NHS
   Foundation Trust; Instituto Nacional de Medicina Genomica
RP Ibarra, C (通讯作者)，Inst Nacl Rehabil Luis Guillermo Ibarra Ibarra, Tissue Engn Cell Therapy & Regenerat Med Res Unit, Calzada Mexico Xochimilco 289, Mexico City 14389, DF, Mexico.
EM regenerative.medicine.mexico@gmail.com
RI Cruz Lemini, Monica/KCX 7092 2024; Cruz Lemini, Monica/A 4163 2015;
   Martínez Nava, Gabriela/P 3914 2014; Landa Solís, Carlos/AAY 6802 2020;
   Rangel Escareno, Claudia/F 4587 2012
OI Landa Solis, Carlos/0000 0002 0680 8516; Cruz Lemini,
   Monica/0000 0002 6807 3578; Rangel Escareno, Claudia/0000 0003 1303 0834
FU National System of Researchers (SNI), of CONACyT; Mexican National
   Council for Science and Technology (CONACyT) [PDCPN 2013 216779,
   PDCPN 2013 215138]; Coordinating Commission of National Institutes of
   Health; High Specialty Hospitals in Mexico (C.C.I.N.S.H.A.E.) [41/14]
FX The authors would like to thank our technician Xochitl Guerrero Alva,
   Juanjo Lozano, PhD, of the Bioinformatics Platform, CIBEREHD, Hospital
   Clinic Barcelona, and Dan Jerzain Gutierrez Fuentes, of the Microarray
   Facility, Instituto Nacional de Medicina Genomica, for their assistance.
   M. Cruz Lemini was supported by the National System of Researchers
   (SNI), of CONACyT. This work was funded by grants received from the
   Mexican National Council for Science and Technology (CONACyT),
   PDCPN 2013 216779 and PDCPN 2013 215138, and the Coordinating Commission
   of National Institutes of Health and High Specialty Hospitals in Mexico
   (C.C.I.N.S.H.A.E.) special grant internal number 41/14.
CR Akiyama H, 2008, MOD RHEUMATOL, V18, P213, DOI 10.1007/s10165 008 0048 x
   Berebichez Fridman R, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/2638305
   Boeuf S, 2008, OSTEOARTHR CARTILAGE, V16, P48, DOI 10.1016/j.joca.2007.05.008
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Brittberg M, 2015, CARTILAGE, V6, p4S, DOI 10.1177/1947603514536983
   Craft AM, 2015, NAT BIOTECHNOL, V33, P638, DOI [10.1038/nbt.3210, 10.10.38/nbt.3210]
   Elsafadi M, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10983 x
   Frazer JK, 2000, EUR J IMMUNOL, V30, P3039, DOI 10.1002/1521 4141(200010)30:10<3039::AID IMMU3039>3.0.CO;2 H
   Ghaneialvar H, 2018, INDIAN J CLIN BIOCHE, V33, P46, DOI 10.1007/s12291 017 0641 x
   Harmey D, 2004, J BONE MINER RES, V19, P661, DOI 10.1359/JBMR.040105
   Huang XB, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020561
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Jing Y, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10048 z
   Johnson K, 2012, SCIENCE, V336, P717, DOI 10.1126/science.1215157
   Karlsson C, 2010, OSTEOARTHR CARTILAGE, V18, P581, DOI 10.1016/j.joca.2009.12.002
   Lee JA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130136
   Li XY, 2015, BIOTECHNOL LETT, V37, P67, DOI 10.1007/s10529 014 1652 9
   Marini JC, 2012, NEW ENGL J MED, V366, P2522, DOI 10.1056/NEJMcibr1204283
   Masago Y, 2012, J CELL SCI, V125, P1118, DOI 10.1242/jcs.089748
   Mennan C., CARTILAGE
   Mithoefer K, 2009, AM J SPORT MED, V37, P2053, DOI 10.1177/0363546508328414
   Murphy MK, 2015, STEM CELLS, V33, P762, DOI 10.1002/stem.1890
   Occhetta P, 2018, P NATL ACAD SCI USA, V115, P4625, DOI 10.1073/pnas.1720658115
   Olsson M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133844
   Polacek M, 2011, CELL TRANSPLANT, V20, P1381, DOI 10.3727/096368910X550215
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Santoro A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135979
   Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200
   Smyth G. K., 2004, Statistical Applications in Genetics and Molecular Biology, V3, P1, DOI [DOI 10.2202/1544 6115.1027, 10.2202/1544 6115.1027]
   Strzelecka Kiliszek A, 2017, BBA GEN SUBJECTS, V1861, P1009, DOI 10.1016/j.bbagen.2017.02.005
   Taheem DK, 2018, STEM CELLS, V36, P1380, DOI 10.1002/stem.2844
   Wang YK, 2012, STEM CELLS DEV, V21, P1176, DOI 10.1089/scd.2011.0293
   Yu L, 2014, REGENERATION, V1, P33, DOI 10.1002/reg2.24
   Ziff JL, 2016, HUM MOL GENET, V25, P2393, DOI 10.1093/hmg/ddw106
NR 34
TC 9
Z9 9
U1 0
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1947 6035
EI 1947 6043
J9 CARTILAGE
JI Cartilage
PD JAN
PY 2021
VL 12
IS 1
BP 102
EP 111
DI 10.1177/1947603518809403
PG 10
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA PK8VO
UT WOS:000602715500010
PM 30373376
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Shakouri, SK
   Soleimanpour, J
   Salekzamani, Y
   Oskuie, MR
AF Shakouri, Seyed Kazem
   Soleimanpour, Jafar
   Salekzamani, Yagob
   Oskuie, Mohammad Reza
TI Effect of low level laser therapy on the fracture healing process
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Laser; Fracture healing; Bone
ID INTENSITY PULSED ULTRASOUND; HE NE LASER; IN VITRO; IRRADIATION; BONE;
   RATS; OSTEOBLASTS; REPAIR; DEFECTS; CELLS
AB Low level laser therapy (LLLT) is a biophysical form of intervention in the fracture repair process, which, through several mechanisms, accelerates the healing of fractures and enhances callus formation. The effect of laser on fracture healing is controversial. Some authors affirm that LLLT can accelerate bone formation by increasing osteoblastic activity. The objective of our study was to evaluate the effect of laser therapy on fracture healing. Thirty rabbits were subjected to tibial bone open osteotomies that were stabilized with external fixators. The animals were divided into two study groups: laser group and control group. Callus development and bone mineral density were quantitatively evaluated by CT; the animals were then killed and the fractures were assessed for biomechanical properties. The results demonstrated that the increasing rate of bone mineral density was higher in the laser (L) group than in the control (C) group. CT at 5 weeks revealed a mean callus density of 297 Hounsfield units (HU) for the control group and 691 HU for the L group, which was statistically significant (P = 0.001). In the L group, the mean recorded fracture tension was 190.5 N and 359.3 N for healed and intact bones, respectively, which was statistically significant (P < 0.001). The result of the study showed that the use of laser could enhance callus development in the early stage of the healing process, with doubtful improvement in biomechanical properties of the healing bone; therefore, laser therapy may be recommended as an additional treatment in non union fractures in humans.
C1 [Shakouri, Seyed Kazem; Soleimanpour, Jafar; Salekzamani, Yagob; Oskuie, Mohammad Reza] Tabriz Univ Med Sci, Tabriz, Iran.
C3 Tabriz University of Medical Science
RP Shakouri, SK (通讯作者)，Tabriz Univ Med Sci, Tabriz, Iran.
EM sk0531ir@yahoo.com
RI ; soleimanpour, jafar/M 4733 2017; soleiman pour, jafar/M 4733 2017;
   Shakouri, Seyed Amir/IAM 8913 2023
OI Shakouri, Seyed Kazem/0000 0003 3815 4091; soleiman pour,
   jafar/0000 0002 8777 9234; 
CR Buckwalter Joseph A., 1996, P261
   Claes LE, 1998, CLIN ORTHOP RELAT R, pS132
   Claes L, 2007, PROG BIOPHYS MOL BIO, V93, P384, DOI 10.1016/j.pbiomolbio.2006.07.021
   Cleary S. F., 1977, Laser applications in medicine and biology vol.3, P175
   Conlan MJ, 1996, J CLIN PERIODONTOL, V23, P492, DOI 10.1111/j.1600 051X.1996.tb00580.x
   David R, 1996, LASER SURG MED, V19, P458, DOI 10.1002/(SICI)1096 9101(1996)19:4<458::AID LSM12>3.0.CO;2 Z
   DEKEL S, 1983, CLIN SCI, V65, P429, DOI 10.1042/cs0650429
   Fukuhara E, 2006, CALCIFIED TISSUE INT, V79, P443, DOI 10.1007/s00223 006 0072 9
   Guerino MR, 2000, APPL SURF SCI, V154, P561, DOI 10.1016/S0169 4332(99)00460 2
   HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623 199401000 00004
   KARU T, 1995, J PHOTOCH PHOTOBIO B, V27, P219, DOI 10.1016/1011 1344(94)07078 3
   Lirani Galvao AP, 2006, PHOTOMED LASER SURG, V24, P735, DOI 10.1089/pho.2006.24.735
   Luger EJ, 1998, LASER SURG MED, V22, P97, DOI 10.1002/(SICI)1096 9101(1998)22:2<97::AID LSM5>3.3.CO;2 E
   McDavid VG, 2001, J PERIODONTOL, V72, P174, DOI 10.1902/jop.2001.72.2.174
   MORIMOTO Y, 1994, LASER SURG MED, V15, P191, DOI 10.1002/lsm.1900150207
   Ninomiya T, 2007, BONE, V40, P140, DOI 10.1016/j.bone.2006.07.026
   Nissan J, 2006, J ORAL REHABIL, V33, P619, DOI 10.1111/j.1365 2842.2006.01601.x
   Otremski I., 2004, Med Laser Appl, V19, P146, DOI [10.1078/1615 1615 00136, DOI 10.1078/1615 1615 00136]
   Ozawa Y, 1998, BONE, V22, P347, DOI 10.1016/S8756 3282(97)00294 9
   Pourzarandian A, 2005, J PERIODONTOL, V76, P187, DOI 10.1902/jop.2005.76.2.187
   ROCHKIND S, 1992, Neurological Research, V14, P2
   SCOTT G, 1994, J BONE JOINT SURG AM, V76A, P820, DOI 10.2106/00004623 199406000 00005
   Silva RV, 2005, INT J ORAL MAX SURG, V34, P178, DOI 10.1016/j.ijom.2004.06.005
   Stein A, 2005, PHOTOMED LASER SURG, V23, P161, DOI 10.1089/pho.2005.23.161
   Usuba M, 1998, LASER SURG MED, V22, P81, DOI 10.1002/(SICI)1096 9101(1998)22:2<81::AID LSM3>3.0.CO;2 S
   WU JJ, 1984, J BONE JOINT SURG AM, V66A, P1258, DOI 10.2106/00004623 198466080 00015
NR 26
TC 88
Z9 89
U1 0
U2 11
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD JAN
PY 2010
VL 25
IS 1
BP 73
EP 77
DI 10.1007/s10103 009 0670 7
PG 5
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA 524WL
UT WOS:000272175000010
PM 19399356
DA 2025 08 17
ER

PT J
AU Piva, R
   Ruggeri, B
   Williams, M
   Costa, G
   Tamagno, I
   Ferrero, D
   Giai, V
   Coscia, M
   Peola, S
   Massaia, M
   Pezzoni, G
   Allievi, C
   Pescalli, N
   Cassin, M
   di Giovine, S
   Nicoli, P
   de Feudis, P
   Strepponi, I
   Roato, I
   Ferracini, R
   Bussolati, B
   Camussi, G
   Jones Bolin, S
   Hunter, K
   Zhao, H
   Neri, A
   Palumbo, A
   Berkers, C
   Ovaa, H
   Bernareggi, A
   Inghirami, G
AF Piva, Roberto
   Ruggeri, Bruce
   Williams, Michael
   Costa, Giulia
   Tamagno, Ilaria
   Ferrero, Dario
   Giai, Valentina
   Coscia, Marta
   Peola, Silvia
   Massaia, Massimo
   Pezzoni, Gabriella
   Allievi, Cecilia
   Pescalli, Nicoletta
   Cassin, Mara
   di Giovine, Stefano
   Nicoli, Paola
   de Feudis, Paola
   Strepponi, Ivan
   Roato, Ilaria
   Ferracini, Riccardo
   Bussolati, Benedetta
   Camussi, Giovanni
   Jones Bolin, Susan
   Hunter, Kathryn
   Zhao, Hugh
   Neri, Antonino
   Palumbo, Antonio
   Berkers, Celia
   Ovaa, Huib
   Bernareggi, Alberto
   Inghirami, Giorgio
TI CEP 18770: A novel, orally active proteasome inhibitor with a
   tumor selective pharmacologic profile competitive with bortezomib
SO BLOOD
LA English
DT Article
ID NF KAPPA B; MULTIPLE MYELOMA; OSTEOCLAST DIFFERENTIATION;
   DOWN REGULATION; APOPTOSIS; CELLS; ACTIVATION; EXPRESSION; RESISTANCE;
   PATHWAY
AB Modulating protein ubiquitination via proteasome inhibition represents a promising target for cancer therapy, because of the higher sensitivity of cancer cells to the cytotoxic effects of proteasome inhibition. Here we show that CEP 18770 is a novel orally active inhibitor of the chymotrypsin like activity of the proteasome that down modulates the nuclear factor kappa B (NF kappa B) activity and the expression of several NF kappa B downstream effectors. CEP 18770 induces apoptotic cell death in multiple myeloma (MM) cell lines and in primary purified CD138 positive explant cultures from untreated and bortezomib treated MM patients. In vitro, CEP 18770 has a strong antiangiogenic activity and potently represses RANKL induced osteoclastogenesis. Importantly, CEP 18770 exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow progenitors, and bone marrow derived stromal cells. Intravenous and oral administration of CEP 18770 resulted in a more sustained pharmacodynamic inhibition of proteasome activity in tumors relative to normal tissues, complete tumor regression of MM xenografts and improved overall median survival in a systemic model of human MM. Collectively, these findings provide evidence for the utility of CEP 18770 as a novel orally active proteasome inhibitor with a favorable tumor selectivity profile for the treatment of MM and other malignancies responsive to proteasome inhibition.
C1 [Piva, Roberto; Costa, Giulia; Tamagno, Ilaria; Coscia, Marta; Peola, Silvia; Massaia, Massimo; Bussolati, Benedetta; Camussi, Giovanni; Inghirami, Giorgio] Univ Turin, Dept Biomed Sci & Human Oncol, CeRMS, I 10126 Turin, Italy.
   [Piva, Roberto; Inghirami, Giorgio] NYU, Sch Med, New York Univ Canc Ctr, New York, NY USA.
   [Piva, Roberto; Inghirami, Giorgio] NYU, Sch Med, Dept Pathol, New York, NY USA.
   [Ruggeri, Bruce; Williams, Michael; Jones Bolin, Susan; Hunter, Kathryn; Zhao, Hugh] Cephalon, Discovery Res, W Chester, PA USA.
   [Ferrero, Dario; Giai, Valentina; Coscia, Marta; Peola, Silvia; Massaia, Massimo; Palumbo, Antonio] Univ Turin, Div Hematol, Turin, Italy.
   [Pezzoni, Gabriella; Allievi, Cecilia; Pescalli, Nicoletta; Cassin, Mara; di Giovine, Stefano; Nicoli, Paola; de Feudis, Paola; Strepponi, Ivan] Sede Secondaria Cell Therapeut, Bresso, Italy.
   [Roato, Ilaria; Ferracini, Riccardo] San Giovanni Battista Torino, Turin, Italy.
   [Bussolati, Benedetta; Camussi, Giovanni] Univ Turin, Dept Internal Med, Turin, Italy.
   [Neri, Antonino] Osped Maggiore, IRCCS, Lab Expt Hematol & Mol Genet, Milan, Italy.
   [Berkers, Celia; Ovaa, Huib] Netherlands Canc Inst, Amsterdam, Netherlands.
   [Bernareggi, Alberto] RBM, Brescia, Italy.
C3 University of Turin; New York University; New York University; Teva
   Pharmaceutical Industries; Cephalon Inc.; University of Turin; A.O.U.
   Citta della Salute e della Scienza di Torino; AOU San Giovanni
   Battista Molinette; University of Turin; IRCCS Ca Granda Ospedale
   Maggiore Policlinico; Netherlands Cancer Institute
RP Inghirami, G (通讯作者)，Univ Turin, Dept Biomed Sci & Human Oncol, CeRMS, Via Santena 5, I 10126 Turin, Italy.
EM giorgio.inghirami@unito.it
RI Ferracini, Riccardo/AAL 4622 2020; Pezzoni, Giulia/AAC 3428 2022;
   Bussolati, Benedetta/AAA 9058 2022; Nicoli, Paola/AAR 1878 2020;
   Palumbo, Antonio/ACP 1575 2022; Piva, Roberto/H 7315 2013; ovaa,
   huib/M 2334 2016; Roato, Ilaria/ACF 6827 2022; Tamagno,
   Ilaria/AAL 4169 2021; Camussi, Giovanni/J 7624 2016; COSCIA,
   Marta/K 4832 2016; Costa, Giuliano/AAB 6137 2019; Berkers,
   Celia/I 3848 2016; Neri, Antonino/I 9690 2014; Piva,
   Roberto/B 9580 2018; coscia, marta/K 4832 2016
OI Berkers, Celia/0000 0003 0746 8565; MASSAIA,
   Massimo/0000 0002 0021 1428; ovaa, huib/0000 0002 0068 054X; Camussi,
   Giovanni/0000 0003 2795 232X; COSCIA, Marta/0000 0003 2123 7675; Roato,
   Ilaria/0000 0003 3029 4743; Tamagno, Ilaria/0000 0003 3572 8547;
   Bussolati, Benedetta/0000 0002 3663 5134; Neri,
   Antonino/0000 0001 9047 5912; Piva, Roberto/0000 0002 2273 3470; 
FU Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom
CR Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535 6108(04)00120 5
   Berenson JR, 2002, SEMIN ONCOL, V29, P11, DOI 10.1053/sonc.2002.34071
   Berkers CR, 2005, NAT METHODS, V2, P357, DOI 10.1038/nmeth759
   Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092 8674(03)00755 4
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bruno S, 2006, AM J PATHOL, V169, P2223, DOI 10.2353/ajpath.2006.060498
   Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02 0557fje
   Cavo M, 2006, LEUKEMIA, V20, P1341, DOI 10.1038/sj.leu.2404278
   Cavo M, 2006, NEW ENGL J MED, V354, P1076, DOI 10.1056/NEJMe058322
   Chauhan D, 2005, CANCER CELL, V8, P407, DOI 10.1016/j.ccr.2005.10.013
   Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104
   Conaldi PG, 1997, J INFECT DIS, V175, P693, DOI 10.1093/infdis/175.3.693
   Demo E, 2007, J HEPATOL, V46, P492, DOI 10.1016/j.jhep.2006.09.022
   Dispenzieri A, 2005, NEW ENGL J MED, V352, P2546, DOI 10.1056/NEJMe058059
   Fisher RI, 2006, J CLIN ONCOL, V24, P4867, DOI 10.1200/JCO.2006.07.9665
   Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001
   Hideshima T, 2001, CANCER RES, V61, P3071
   Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   KLEIN B, 1989, BLOOD, V73, P517
   Lombardi L, 2007, GENE CHROMOSOME CANC, V46, P226, DOI 10.1002/gcc.20404
   Ludwig H, 2005, CANCER AM CANCER SOC, V104, P1794, DOI 10.1002/cncr.21414
   Mulligan G, 2007, BLOOD, V109, P3177, DOI 10.1182/blood 2006 09 044974
   Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588
   Nalepa G, 2006, NAT REV DRUG DISCOV, V5, P596, DOI 10.1038/nrd2056
   O'Connor OA, 2005, CLIN LYMPHOMA MYELOM, V6, P191, DOI 10.3816/CLM.2005.n.046
   PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798
   Piva R, 2005, BLOOD, V105, P1750, DOI 10.1182/blood 2004 04 1360
   Piva R, 2006, BLOOD, V107, P689, DOI 10.1182/blood 2005 05 2125
   Piva R, 2006, ANTIOXID REDOX SIGN, V8, P478, DOI 10.1089/ars.2006.8.478
   Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030
   Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445
   Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288
   Roccaro AM, 2006, CANCER RES, V66, P184, DOI 10.1158/0008 5472.CAN 05 1195
   Ruiz S, 2006, MOL CANCER THER, V5, P1836, DOI 10.1158/1535 7163.MCT 06 0066
   Sezer O, 2003, BLOOD, V101, P2094, DOI 10.1182/blood 2002 09 2684
   Shishodia S, 2005, CANCER RES, V65, P9555, DOI 10.1158/0008 5472.CAN 05 1585
   Sun XJ, 2006, CANCER LETT, V232, P161, DOI 10.1016/j.canlet.2005.02.022
   Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535 6108(02)00068 5
   Terpos E, 2005, ANN ONCOL, V16, P1223, DOI 10.1093/annonc/mdi235
   Verdelli D, 2005, HAEMATOLOGICA, V90, P1541
   Williamson MJ, 2006, MOL CANCER THER, V5, P3052, DOI 10.1158/1535 7163.MCT 06 0185
   Zavrski I, 2005, BIOCHEM BIOPH RES CO, V333, P200, DOI 10.1016/j.bbrc.2005.05.098
NR 43
TC 227
Z9 248
U1 1
U2 18
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006 4971
EI 1528 0020
J9 BLOOD
JI Blood
PD MAR 1
PY 2008
VL 111
IS 5
BP 2765
EP 2775
DI 10.1182/blood 2007 07 100651
PG 11
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 269SX
UT WOS:000253671600044
PM 18057228
OA Bronze
DA 2025 08 17
ER

PT J
AU Kawamura, H
   Yamaguchi, T
   Yano, Y
   Hozumi, T
   Takaki, Y
   Matsumoto, H
   Nakano, D
   Takahashi, K
AF Kawamura, Hidetaka
   Yamaguchi, Tatsuro
   Yano, Yuuta
   Hozumi, Takahiro
   Takaki, Yasunobu
   Matsumoto, Hiroshi
   Nakano, Daisuke
   Takahashi, Keiichi
TI Characteristics and Prognostic Factors of Bone Metastasis in Patients
   With Colorectal Cancer
SO DISEASES OF THE COLON & RECTUM
LA English
DT Article
DE Bone metastasis; Colorectal carcinoma; Prognosis
ID SCORING SYSTEM; SKELETAL COMPLICATIONS; SPINAL COLUMN; SURVIVAL;
   IBANDRONATE; DISEASE; BISPHOSPHONATES; RADIOTHERAPY; MECHANISMS
AB BACKGROUND: Because bone metastasis from colorectal cancer is rare, there are little available data regarding such cases.
   OBJECTIVE: The study aim was to identify the prognostic factors and characteristics associated with survival in colorectal cancer patients with bone metastasis.
   DESIGN: This was a retrospective study from a prospectively collected database.
   SETTINGS: The study took place in a multidisciplinary, high volume tertiary cancer center in Japan.
   PATIENTS: Examined were records from 104 consecutive patients treated between 2004 and 2015 for bone metastasis from colorectal cancer.
   MAIN OUTCOME MEASURES: The primary outcome measure was overall survival.
   RESULTS: The spine was the most common site of bone metastasis from colorectal cancer. Right colon cancer correlated significantly with long bone metastasis (p = 0.046), whereas left colon cancer correlated significantly with spinal bone metastasis (p = 0.034). Liver metastasis was also significantly correlated with spinal bone metastasis (p = 0.036). The median interval between the primary therapy for colorectal cancer and the metachronous diagnosis of bone metastasis was 20.0 months (quartile 1 to quartile 3, 9.0 46.5 mo). The median survival time from diagnosis of bone metastasis from colorectal cancer was 5.0 months (95% CI, 4.0 9.0 mo), and the 1 year survival rate was 30.0% (95% CI, 21.1% 39.4%). Multivariate analysis revealed that = 2 extra bone metastatic organs, hypercalcemia, and pathologic fractures were independent poor prognostic factors (p < 0.001, 0.001, and 0.033). The number of extra bone metastatic organs correlated with prognosis.
   LIMITATIONS: This study was limited by its retrospective, nonrandomized design, as well as selection bias and performance at a single institute.
   CONCLUSIONS: The location of colorectal cancer correlates significantly with the site of bone metastasis; the prognosis of patients with bone metastasis from colorectal cancer is very poor, and the significant prognostic factors are number of extra bone metastatic organs, hypercalcemia, and pathologic fractures. See Video Abstract at http://links.lww.com/DCR/A589.
C1 [Kawamura, Hidetaka; Yamaguchi, Tatsuro; Yano, Yuuta; Matsumoto, Hiroshi; Nakano, Daisuke; Takahashi, Keiichi] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Surg, Bunkyo Ku, 3 18 22 Honkomagome, Tokyo 1138677, Japan.
   [Yamaguchi, Tatsuro] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Hereditary Tumor Res Project, Bunkyo Ku, 3 18 22 Honkomagome, Tokyo 1138677, Japan.
   [Hozumi, Takahiro] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Orthoped, Bunkyo Ku, Tokyo, Japan.
   [Takaki, Yasunobu] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Radiol, Bunkyo Ku, Tokyo, Japan.
   Saitama Med Univ, Dept Digest Tract & Gen Surg, Saitama Med Ctr, Saitama, Japan.
C3 Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome
   Hospital; Tokyo Metropolitan Cancer & Infectious Diseases Center
   Komagome Hospital; Tokyo Metropolitan Cancer & Infectious Diseases
   Center Komagome Hospital; Tokyo Metropolitan Cancer & Infectious
   Diseases Center Komagome Hospital; Saitama Medical University
RP Yamaguchi, T (通讯作者)，Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Surg, Bunkyo Ku, 3 18 22 Honkomagome, Tokyo 1138677, Japan.; Yamaguchi, T (通讯作者)，Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Hereditary Tumor Res Project, Bunkyo Ku, 3 18 22 Honkomagome, Tokyo 1138677, Japan.
EM tatsuro@yamaguchi.email.ne.jp
RI NAKANO, DAISUKE/JWP 5663 2024
FU Office of Metropolitan Hospital Management, Tokyo Metropolitan
   Government
FX This work was supported in part by the Office of Metropolitan Hospital
   Management, Tokyo Metropolitan Government.
CR Ara T, 2010, EUR J CANCER, V46, P1223, DOI 10.1016/j.ejca.2010.02.026
   Baek SJ, 2016, WORLD J SURG, V40, P982, DOI 10.1007/s00268 015 3296 x
   BAUER HCF, 1995, ACTA ORTHOP SCAND, V66, P143, DOI 10.3109/17453679508995508
   Body JJ, 2003, ANN ONCOL, V14, P1399, DOI 10.1093/annonc/mdg367
   Body JJ, 2004, PAIN, V111, P306, DOI 10.1016/j.pain.2004.07.011
   Buckwalter JA, 1997, AM FAM PHYSICIAN, V55, P1761
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Hattori Seiji, 2004, Gan To Kagaku Ryoho, V31, P271
   Heras P, 2007, EUR J CANCER CARE, V16, P539, DOI 10.1111/j.1365 2354.2007.00808.x
   Katagiri H, 2005, J BONE JOINT SURG BR, V87B, P698, DOI 10.1302/0301 620X.87B5.15185
   Khattak MA, 2012, CLIN COLORECTAL CANC, V11, P247, DOI 10.1016/j.clcc.2012.06.004
   Liu FQ, 2016, TUMOR BIOL, V37, P16127, DOI 10.1007/s13277 016 5465 4
   McDonald R, 2017, JAMA ONCOL, V3, P953, DOI 10.1001/jamaoncol.2016.6770
   Mizumoto M, 2008, CANCER AM CANCER SOC, V113, P2816, DOI 10.1002/cncr.23888
   Nozue M, 2002, ONCOL REP, V9, P109
   O'Connell JB, 2004, JNCI J NATL CANCER I, V96, P1420, DOI 10.1093/jnci/djh275
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Rades D, 2006, J CLIN ONCOL, V24, P3388, DOI 10.1200/JCO.2005.05.0542
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Roth ES, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 274
   Santini D, 2012, ANN ONCOL, V23, P2072, DOI 10.1093/annonc/mdr572
   Siegel RL, 2017, CA CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Sundermeyer Mark L, 2005, Clin Colorectal Cancer, V5, P108, DOI 10.3816/CCC.2005.n.022
   Tokuhashi Y, 2005, SPINE, V30, P2186, DOI 10.1097/01.brs.0000180401.06919.a5
   Tomita K, 2001, SPINE, V26, P298, DOI 10.1097/00007632 200102010 00016
   van der Linden YM, 2005, CANCER AM CANCER SOC, V103, P320, DOI 10.1002/cncr.20756
NR 27
TC 42
Z9 44
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0012 3706
EI 1530 0358
J9 DIS COLON RECTUM
JI Dis. Colon Rectum
PD JUN
PY 2018
VL 61
IS 6
BP 673
EP 678
DI 10.1097/DCR.0000000000001071
PG 6
WC Gastroenterology & Hepatology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Gastroenterology & Hepatology; Surgery
GA GL9RG
UT WOS:000437673500012
PM 29722726
DA 2025 08 17
ER

PT J
AU Wei, YB
   Ye, Q
   Tang, Z
   Tian, G
   Zhu, Q
   Gao, HC
   Wang, DL
   Cao, ZZ
AF Wei, Yibo
   Ye, Qing
   Tang, Zhen
   Tian, Gang
   Zhu, Qiang
   Gao, Haocheng
   Wang, Dalin
   Cao, Zhizhong
TI Calcitonin induces collagen synthesis and osteoblastic differentiation
   in human periodontal ligament fibroblasts
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE Calcitonin; Periodontitis; ECM expression; Osteoblastic differentiation
ID GENE RELATED PEPTIDE; EXTRACELLULAR MATRIX; BONE FORMATION; ALVEOLAR
   BONE; CREVICULAR FLUID; STEM CELLS; TGF BETA; TISSUE; REGENERATION;
   THERAPY
AB Background: Extracellular matrix (ECM) secretion and osteogenic differentiation in periodontal ligament fibroblasts (PDLF) facilitate the neogenesis of alveolar bone, which is the cellular basis for alveolar bone repair. Calcitonin (CT) has been reported to play an important role in promoting ECM expression and inducing osteogenic differentiation in osteoblast, but its effects on PDLys remain obscure.
   Methods: The expression of CT, transforming growth factor beta 1(TGF beta 1) and bone morphogenetic protein (BMP) in gingival crevicular fluid (GCF) was measured by ELISA. The effects of CT on collagen synthesis and osteogenic differentiation in hPDLFs were investigated by using the primarily cultured hPDLFs infected with adenovirus carrying the CT gene. Gene expression was measured by quantitative PCR and western blot.
   Results: The expression of CT in gingival crevicular fluid (GCF) of patients with periodontitis was significantly higher than that of healthy subjects. In addition, CT expression correlated with the clinical indexes including probing pocket depth (PPD), clinical attachment level (CAL), and gingival index (GI). The in vitro study demonstrated that overexpression of CT by adenovirus infection increased the expression of TGF beta 1, collagen type I and III, and osteoblastic markers including BMP 2/ 4, alkaline phosphatase and osteocalcin in human PDLFs. Moreover, CT enhanced collagen synthesis was abrogated in hPDLFs transfected with TGF beta 1 siRNA, and CT induced osteoblastic differentiation was blocked in hPDLFs by BMPs inhibitor noggin.
   Conclusions: These results suggest that CT promotes collagen synthesis and osteogenic differentiation in hPDLFs via the TGF beta 1 and BMPs signaling pathways, respectively. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Wei, Yibo; Ye, Qing; Tang, Zhen; Tian, Gang; Zhu, Qiang; Gao, Haocheng; Wang, Dalin; Cao, Zhizhong] Second Mil Med Univ, Changhai Hosp, Dept Stomatol, Shanghai 200433, Peoples R China.
C3 Naval Medical University
RP Wang, DL; Cao, ZZ (通讯作者)，Second Mil Med Univ, Changhai Hosp, Dept Stomatol, Shanghai 200433, Peoples R China.
EM wang_dento@163.com; caozhizh2014@163.com
RI YE, QING/KIG 8170 2024
FU Shanghai Municipal Natural Science Foundation [13411951202]; Science
   Foundation for Young Doctors of Changhai Hospital
FX This work was supported by the Shanghai Municipal Natural Science
   Foundation (No.13411951202) and Science Foundation for Young Doctors of
   Changhai Hospital.
CR Avila Ortiz G, 2012, CLIN ORAL IMPLAN RES, V23, P1082, DOI 10.1111/j.1600 0501.2011.02270.x
   BACCANARI D, 1975, BIOCHEMISTRY US, V14, P5267, DOI 10.1021/bi00695a006
   Barwell J, 2012, BRIT J PHARMACOL, V166, P51, DOI 10.1111/j.1476 5381.2011.01525.x
   Beertsen W, 1997, PERIODONTOL 2000, V13, P20, DOI 10.1111/j.1600 0757.1997.tb00094.x
   Chen FM, 2010, TISSUE ENG PART B RE, V16, P219, DOI [10.1089/ten.teb.2009.0562, 10.1089/ten.TEB.2009.0562]
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Cheng T, 2013, CONNECT TISSUE RES, V54, P139, DOI 10.3109/03008207.2012.760549
   Cullinan MP, 2013, PERIODONTOL 2000, V62, P271, DOI 10.1111/prd.12007
   Dangaria SJ, 2011, STEM CELLS DEV, V20, P1659, DOI 10.1089/scd.2010.0431
   Davey RA, 2013, J BONE MINER RES, V28, P973, DOI 10.1002/jbmr.1869
   El Awady AR, 2013, J CLIN PERIODONTOL, V40, P661, DOI 10.1111/jcpe.12100
   Garrett Q, 2004, INVEST OPHTH VIS SCI, V45, P1109, DOI 10.1167/iovs.03 0660
   Gay I, 2014, J PERIODONTAL RES, V49, P110, DOI 10.1111/jre.12086
   Greco KV, 2014, BIOCHEM PHARMACOL, V91, P348, DOI 10.1016/j.bcp.2014.07.034
   Jacobs C, 2013, ARCH ORAL BIOL, V58, P896, DOI 10.1016/j.archoralbio.2013.01.009
   Jin QM, 2003, J PERIODONTOL, V74, P202, DOI 10.1902/jop.2003.74.2.202
   Kao DWK, 2012, FRONT ORAL BIOL, V15, P149, DOI 10.1159/000329677
   Karachalios T, 2004, J BONE JOINT SURG BR, V86B, P350, DOI 10.1302/0301 620X.86B3.14300
   Katafuchi T, 2009, PEPTIDES, V30, P1753, DOI 10.1016/j.peptides.2009.06.012
   Keller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6215
   Konermann A, 2012, INNATE IMMUN LONDON, V18, P745, DOI 10.1177/1753425912440598
   Konstantonis D, 2013, BIOGERONTOLOGY, V14, P741, DOI 10.1007/s10522 013 9449 0
   Lallier TE, 2001, J DENT RES, V80, P1748, DOI 10.1177/00220345010800081301
   Lavery K, 2008, J BIOL CHEM, V283, P20948, DOI 10.1074/jbc.M800850200
   Lerner U. H., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P154
   Liu Y, 2008, STEM CELLS, V26, P1065, DOI 10.1634/stemcells.2007 0734
   Lv LL, 2014, J MOL HISTOL, V45, P311, DOI 10.1007/s10735 013 9551 2
   Ma WH, 2013, NEUROPEPTIDES, V47, P179, DOI 10.1016/j.npep.2012.12.002
   Mamalis A, 2011, ARCH ORAL BIOL, V56, P446, DOI 10.1016/j.archoralbio.2010.11.001
   Mi HW, 2011, GENE THER, V18, P452, DOI 10.1038/gt.2010.158
   Mitchner Natasha A, 2009, J Fam Pract, V58, pS45
   Murakami Y, 2003, J PERIODONTOL, V74, P780, DOI 10.1902/jop.2003.74.6.780
   Naot D, 2008, BONE, V43, P813, DOI 10.1016/j.bone.2008.07.003
   Naveh GRS, 2012, ARCH ORAL BIOL, V57, P1575, DOI 10.1016/j.archoralbio.2012.07.006
   Noda K, 2009, EUR J ORTHODONT, V31, P37, DOI 10.1093/ejo/cjn075
   Nokhbehsaim M, 2011, J PERIODONTAL RES, V46, P374, DOI 10.1111/j.1600 0765.2011.01357.x
   Poiate IAVP, 2009, J PERIODONTOL, V80, P1859, DOI 10.1902/jop.2009.090220
   Ramseier CA, 2012, PERIODONTOL 2000, V59, P185, DOI 10.1111/j.1600 0757.2011.00432.x
   Ripamonti U, 2009, J CRANIOFAC SURG, V20, P1544, DOI 10.1097/SCS.0b013e3181b09ca6
   Saito M, 2012, EXPERT OPIN BIOL TH, V12, P299, DOI 10.1517/14712598.2012.655267
   Shivaprasad BM, 2015, ARCH ORAL BIOL, V60, P37, DOI 10.1016/j.archoralbio.2014.08.017
   Thunell DH, 2010, J PERIODONTAL RES, V45, P148, DOI 10.1111/j.1600 0765.2009.01204.x
   Tian G, 2013, ACTA PHARMACOL SIN, V34, P1467, DOI 10.1038/aps.2013.41
   Tripuwabhrut P, 2012, EUR J ORAL SCI, V120, P311, DOI 10.1111/j.1600 0722.2012.00980.x
   Tymkiw KD, 2011, J CLIN PERIODONTOL, V38, P219, DOI 10.1111/j.1600 051X.2010.01684.x
   VANROSSEN IP, 1990, J PROSTHET DENT, V64, P198, DOI 10.1016/0022 3913(90)90179 G
   Wang L, 2011, TISSUE ENG PT A, V17, P1015, DOI 10.1089/ten.tea.2010.0140
   Xu H, 2014, AM J ORTHOD DENTOFAC, V145, P469, DOI 10.1016/j.ajodo.2013.12.019
   Yodthong N, 2013, ANGLE ORTHOD, V83, P394, DOI 10.2319/062912 534.1
   Yoshida M, 2012, INT J BIOL SCI, V8, P1062, DOI 10.7150/ijbs.4488
NR 50
TC 15
Z9 16
U1 1
U2 29
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0003 9969
EI 1879 1506
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD FEB
PY 2017
VL 74
BP 114
EP 122
DI 10.1016/j.archoralbio.2016.11.014
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA EJ2CL
UT WOS:000393017400017
PM 27930933
DA 2025 08 17
ER

PT J
AU Cao, HL
   Zhang, WJ
   Meng, FH
   Guo, JS
   Wang, DH
   Qian, S
   Jiang, XQ
   Liu, XY
   Chu, PK
AF Cao, Huiliang
   Zhang, Wenjie
   Meng, Fanhao
   Guo, Jinshu
   Wang, Donghui
   Qian, Shi
   Jiang, Xinquan
   Liu, Xuanyong
   Chu, Paul K.
TI Osteogenesis Catalyzed by Titanium Supported Silver Nanoparticles
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE silver; integrin; differentiation; osteointegration; titanium; stem
   cells
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; GALVANIC CORROSION;
   INTEGRIN; OSSEOINTEGRATION; ADHESION; BIOMATERIALS; INFECTION; IMPLANTS;
   SURFACES
AB Silver nanoparticles (Ag NPs) were widely explored for antimicrobial applications, whereas the translation into drugs and implantable antibacterial devices provoked serious concerns about their potential cytotoxicity. Herein, Ag NPs with diameters ranging from 4 to 19 nm were in situ fabricated and immobilized on titanium by using a plasma immersion ion implantation process. The particles have a population dependent capability in activating the integrin alpha 5 orchestrated MAPK/ERK signal cascade of osteoblast differentiation in rat bone marrow stem cells (BMSCs), and promoting osteointegration of titanium. It was demonstrated that the titanium supported Ag NPs played an important role in motivating integrin a5 through triggering the galvanic hydrogen evolution reactions, which was found in positive correlation with the distribution density of the immobilized Ag NPs. Since cellular uptake is a key factor determining the cytotoxic performance of Ag NPs, the extracellular effects of immobilized Ag NPs on promoting osteogenesis provided new insights into the safe application of nanomaterials, and into designing and developing renewed antibacterial devices with selective toxicity.
C1 [Cao, Huiliang; Meng, Fanhao; Guo, Jinshu; Wang, Donghui; Qian, Shi; Liu, Xuanyong] Chinese Acad Sci, State Key Lab High Performance Ceram & Superfine, Shanghai Inst Ceram, Shanghai 200050, Peoples R China.
   [Zhang, Wenjie; Jiang, Xinquan] Shanghai Jiao Tong Univ, Peoples Hosp 9, Sch Med, Dept Prosthodont, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Chu, Paul K.] City Univ Hong Kong, Dept Phys & Mat Sci, Tat Chee Ave, Kowloon, Hong Kong, Peoples R China.
C3 Chinese Academy of Sciences; Shanghai Institute of Ceramics, CAS;
   Shanghai Jiao Tong University; City University of Hong Kong
RP Cao, HL; Liu, XY (通讯作者)，Chinese Acad Sci, State Key Lab High Performance Ceram & Superfine, Shanghai Inst Ceram, Shanghai 200050, Peoples R China.; Jiang, XQ (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp 9, Sch Med, Dept Prosthodont, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM hlc@mail.sic.ac.cn; xinquanj@aliyun.com; xyliu@mail.sic.ac.cn
RI Qian, Shi/GLN 6817 2022; Chu, Paul/B 5923 2013; Wang,
   Donghui/A 8242 2019; Wang, Donghui/HMP 1218 2023; Meng,
   Fanhao/JDD 3487 2023; Liu, Xuanyong/J 2609 2018; Cao,
   Huiliang/IZE 4246 2023; Zhang, Wenjie/O 5336 2014; Cao,
   Huiliang/V 1999 2017
OI Zhang, Wenjie/0000 0002 7753 695X; Chu, Paul/0000 0002 5581 4883; Wang,
   Donghui/0000 0002 1198 0978; liu, xuan yong/0000 0001 9440 8143; Cao,
   Huiliang/0000 0002 5209 4497
FU National Science Foundation for Distinguished Young Scholars of China
   [51525207]; National Natural Science Foundation of China [31370962,
   31670980, 81225006]; Shanghai Rising Star Program [15QA1404100]; Youth
   Innovation Promotion Association CAS [2015204]; Open Research Fund of
   State Key Laboratory of Bioelectronics, Southeast University; Hong Kong
   Research Grants Council (RGC) General Research Funds (GRF) [City U
   11301215]
FX This work was jointly supported by the National Science Foundation for
   Distinguished Young Scholars of China (51525207), National Natural
   Science Foundation of China (31370962, 31670980, and 81225006), Shanghai
   Rising Star Program (15QA1404100), Youth Innovation Promotion
   Association CAS (2015204), Open Research Fund of State Key Laboratory of
   Bioelectronics, Southeast University, as well as Hong Kong Research
   Grants Council (RGC) General Research Funds (GRF) No. City U 11301215.
   XJ. would like to acknowledge the Chang Jiang Scholars Programme of the
   Ministry of Education of China.
CR Abdallah BM, 2015, BONE, V70, P28, DOI 10.1016/j.bone.2014.07.028
   Arslan H, 2008, J APPL ELECTROCHEM, V38, P853, DOI 10.1007/s10800 008 9523 5
   Busscher HJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004528
   Cao HL, 2014, J PHYS CHEM LETT, V5, P743, DOI 10.1021/jz5000269
   Cao HL, 2013, ACTA BIOMATER, V9, P5100, DOI 10.1016/j.actbio.2012.10.017
   Cao HL, 2011, BIOMATERIALS, V32, P693, DOI 10.1016/j.biomaterials.2010.09.066
   Carraro C, 2007, SURF SCI REP, V62, P499, DOI 10.1016/j.surfrep.2007.08.002
   Eble JA, 2003, BIOCHEM J, V376, P77, DOI 10.1042/BJ20030373
   Forslund M, 2013, J ELECTROCHEM SOC, V160, pC423, DOI 10.1149/2.113308jes
   Fromigué O, 2012, J CELL BIOCHEM, V113, P3029, DOI 10.1002/jcb.24181
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   Lee JS, 2013, ADV MATER, V25, P1173, DOI 10.1002/adma.201203370
   Lehenkari PP, 1999, BIOCHEM BIOPH RES CO, V259, P645, DOI 10.1006/bbrc.1999.0827
   Li M, 2016, ACS APPL MATER INTER, V8, P33972, DOI 10.1021/acsami.6b09457
   Lim YH, 2015, ACS NANO, V9, P1995, DOI 10.1021/nn507046h
   Ludwig FT, 2013, J CELL PHYSIOL, V228, P1351, DOI 10.1002/jcp.24293
   Paradise RK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015746
   Qian SY, 2006, CEMENT CONCRETE COMP, V28, P685, DOI 10.1016/j.cemconcomp.2006.05.010
   Qin H, 2015, ACS APPL MATER INTER, V7, P10785, DOI 10.1021/acsami.5b01310
   Qin H, 2014, INT J NANOMED, V9, P2469, DOI 10.2147/IJN.S59753
   Raphel J, 2016, BIOMATERIALS, V84, P301, DOI 10.1016/j.biomaterials.2016.01.016
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402 e65
   Srouji S, 2012, HUM GENE THER, V23, P167, DOI 10.1089/hum.2011.059
   Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092 8674(02)00935 2
   Vanysek P., 2000, ELECTROCHEMICAL SERI
   Verano Braga T, 2014, ACS NANO, V8, P2161, DOI 10.1021/nn4050744
   Warkus J, 2006, MATER CORROS, V57, P614, DOI 10.1002/maco.200603992
   Xie CM, 2014, ACS APPL MATER INTER, V6, P8580, DOI 10.1021/am501428e
   Xu ZQ, 2016, ACS APPL MATER INTER, V8, P16584, DOI 10.1021/acsami.6b04161
   Zhang RZ, 2015, NANOMED NANOTECHNOL, V11, P1949, DOI 10.1016/j.nano.2015.07.016
   Zhang WJ, 2014, NANOMED NANOTECHNOL, V10, P1809, DOI 10.1016/j.nano.2014.07.002
   Zhang WJ, 2013, BIOMATERIALS, V34, P3184, DOI 10.1016/j.biomaterials.2013.01.008
   Zhang WJ, 2012, INT J NANOMED, V7, P4459, DOI 10.2147/IJN.S33575
   Zhou T, 2016, PROG MATER SCI, V83, P191, DOI 10.1016/j.pmatsci.2016.04.005
NR 37
TC 62
Z9 63
U1 1
U2 168
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD FEB 15
PY 2017
VL 9
IS 6
BP 5149
EP 5157
DI 10.1021/acsami.6b15448
PG 9
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA EL2WS
UT WOS:000394481800013
PM 28111942
DA 2025 08 17
ER

PT J
AU Zhang, BP
   Yan, SF
   Zhang, Y
   Wu, YX
AF Zhang, Binpeng
   Yan, Shaofu
   Zhang, Yao
   Wu, Yunxia
TI Optimizing locally delivered periodontitis therapy: Development of
   chitosan hydroxyapatite encapsulated drug via electrospraying
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
DE artificial newral network; chitosan hydroxyapatite composites;
   controlled antibiotic delivery; electrospraying method; microparticle
   drug encapsulation; periodontitis therapy
ID ANTIMICROBIAL ACTIVITY; ELASTIC MODULUS; RELEASE; BIOMATERIALS;
   PATHOGENS; TENSILE; CHITIN; DENTIN
AB This study presents the development of an optimized drug delivery system for periodontitis treatment utilizing chitosan hydroxyapatite nanoparticles. Employing the electrospraying technique, researchers encapsulated the antibiotic amoxicillin within chitosan hydroxyapatite composite matrices while varying the concentrations of chitosan and hydroxyapatite nanoparticles. The resulting microparticles displayed sizes ranging from 276 to 386 mu m. Characterization of the produced drug encapsulations indicated that higher concentrations of chitosan and hydroxyapatite resulted in the formation of larger particles with rougher surfaces, increased mechanical strength, and enhanced thermal stability. Notably, nanoindentation analysis revealed an increase in hardness from 0.21 to 0.35 GPa, and in elastic modulus from 5.32 to 8.72 GPa with escalating chitosan and hydroxyapatite content, meeting or surpassing requirements for load bearing regenerative biomaterials. In vitro drug release assessments exhibited sustained amoxicillin release over 24 h, predominantly through diffusion and dissolution mechanisms. Formulations with lower polymer and mineral content showcased elevated release rates, with the F1 encapsulation (0.5% chitosan, 0.2% HAP) achieving a cumulative release of 78.3 +/  3.2% in contrast to 65.1 +/  2.7% for the F5 formulation (2.5% chitosan, 1% HAP). These encapsulations selectively modulated the overproduction of proinflammatory cytokines, including IL 1 beta, IL 6, and TNF alpha, in gingival fibroblasts and osteoblasts without compromising cell viability. An artificial neural network (ANN) model accurately forecasted the material properties and biological performance of the formulations based on their compositional variations, yielding correlation coefficients exceeding 0.97. This computational platform offers a virtual screening tool for refining regenerative and drug delivery therapies. The developed chitosan hydroxyapatite microparticulate system demonstrates promising potential for prolonged treatment of periodontitis through controlled antibiotic delivery, improved mechanical properties, and targeted regulation of the inflammatory response.
   Preparation, characterization, and analysis of electrosprayed chitosan HAP nanoparticle drug encapsulations. image
C1 [Zhang, Binpeng; Zhang, Yao; Wu, Yunxia] Shanxi Med Univ, Hosp 1, Dept Stomatol, Taiyuan, Peoples R China.
   [Yan, Shaofu; Wu, Yunxia] Shanxi Med Univ, Sch & Hosp Stomatol, 63 Xinjian South Rd, Taiyuan 030001, Shanxi, Peoples R China.
C3 Shanxi Medical University; Shanxi Medical University
RP Wu, YX (通讯作者)，Shanxi Med Univ, Sch & Hosp Stomatol, 63 Xinjian South Rd, Taiyuan 030001, Shanxi, Peoples R China.
EM yunxiawu02@gmail.com
CR AL Anezi MM, 2023, DENT HYPOTHESES, V14, P16, DOI 10.4103/denthyp.denthyp_147_22
   Al hamdani GM, 2023, DENT HYPOTHESES, V14, P55, DOI 10.4103/denthyp.denthyp_59_23
   Alimirzaei S, 2024, ULTRASONICS, V138, DOI 10.1016/j.ultras.2024.107249
   Andre PS, 2024, SOL ENERGY, V268, DOI 10.1016/j.solener.2023.112290
   Atila D, 2023, BIOMATER SCI UK, V11, P6711, DOI 10.1039/d3bm00719g
   Attaeyan A., 2024, IRAN J CHEM CHEM ENG, V4
   Ayatollahi MR, 2017, J COMPOS MATER, V51, P4177, DOI 10.1177/0021998317699982
   Batool F, 2021, J TISSUE ENG, V12, DOI 10.1177/20417314211041428
   Bhandare J, 2024, INT J MED SCI, V21, P253, DOI 10.7150/ijms.86720
   Bhat S, 2022, ACS BIOMATER SCI ENG, V8, P4039, DOI 10.1021/acsbiomaterials.1c00438
   Bozorgi A, 2021, BIOMATER SCI UK, V9, P4541, DOI 10.1039/d1bm00504a
   Chen S, 2024, MACROMOL MATER ENG, V309, DOI 10.1002/mame.202300361
   Chen X, 2016, CRIT REV BIOTECHNOL, V36, P760, DOI 10.3109/07388551.2015.1035693
   Chen Y, 2024, NAT COMMUN, V15, DOI 10.1038/s41467 024 48751 x
   Cirri M, 2021, INT J PHARMACEUT, V598, DOI 10.1016/j.ijpharm.2021.120375
   Darveau RP, 2010, NAT REV MICROBIOL, V8, P481, DOI 10.1038/nrmicro2337
   Dash S, 2010, ACTA POL PHARM, V67, P217
   Dinesh A., 2023, MATER TODAY PROC, DOI [10.1016/j.matpr.2023.03.652, DOI 10.1016/J.MATPR.2023.03.652]
   Dong ZX, 2021, MAT SCI ENG C MATER, V122, DOI 10.1016/j.msec.2021.111949
   Duan H, 2024, INT J PHARMACEUT, V650, DOI 10.1016/j.ijpharm.2023.123660
   Fahmy TM, 2005, BIOMATERIALS, V26, P5727, DOI 10.1016/j.biomaterials.2005.02.025
   Ferrazzano GF, 2011, MOLECULES, V16, P1486, DOI 10.3390/molecules16021486
   Ghosh R, 2022, MATER TODAY COMMUN, V31, DOI 10.1016/j.mtcomm.2022.103311
   Hajishengallis G, 2012, NAT REV MICROBIOL, V10, P717, DOI 10.1038/nrmicro2873
   Hajishengallis G, 2011, CELL HOST MICROBE, V10, P497, DOI 10.1016/j.chom.2011.10.006
   Hasanin M, 2023, STARCH STARKE, V75, DOI 10.1002/star.202200132
   Hassan DHM, 2023, DENT HYPOTHESES, V14, P52, DOI 10.4103/denthyp.denthyp_43_23
   Hu MX, 2021, J APPL POLYM SCI, V138, DOI 10.1002/app.50403
   Iranmanesh P, 2022, J ENDODONT, V48, P1301, DOI 10.1016/j.joen.2022.07.007
   Jaffar N, 2016, J BIOMED MATER RES A, V104, P2873, DOI 10.1002/jbm.a.35827
   Jahangirnezhad M, 2024, CURR STEM CELL RES T, V19, P449, DOI 10.2174/1574888X18666221227142055
   Jaworek A, 2007, J MATER SCI, V42, P266, DOI 10.1007/s10853 006 0842 9
   Jayakumar R, 2011, BIOTECHNOL ADV, V29, P322, DOI 10.1016/j.biotechadv.2011.01.005
   Ji YX, 2023, GELS BASEL, V9, DOI 10.3390/gels9090700
   Jiang ZQ, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031923
   Kalluri L, 2024, J APPL POLYM SCI, V141, DOI 10.1002/app.55224
   Kareem R.O., 2024, J. Chem. Rev, V6, p1, DOI [https://doi.org/10.48309/JCR.2024.415051.1253, 10.48309/jcr.2024.415051.1253, DOI 10.48309/JCR.2024.415051.1253]
   Kean T, 2010, ADV DRUG DELIVER REV, V62, P3, DOI 10.1016/j.addr.2009.09.004
   Khandan A, 2020, DENT HYPOTHESES, V11, P74, DOI 10.4103/denthyp.denthyp_11_20
   Khans BM, 2017, PAK J PHARM SCI, V30, P793
   Kingsley BJ, 2024, J APPL POLYM SCI, V141, DOI 10.1002/app.54826
   Kwon T, 2021, INT DENT J, V71, P462, DOI 10.1111/idj.12630
   Li TM, 2023, AIMS MATH, V8, P12373, DOI 10.3934/math.2023622
   Li XR, 2008, LANGMUIR, V24, P14145, DOI 10.1021/la802984a
   Li XY, 2024, ENDOCRINE, V83, P178, DOI 10.1007/s12020 023 03520 6
   Lipton AN, 2021, J PURE APPL MICROBIO, V15, P1455, DOI 10.22207/JPAM.15.3.39
   Luo Y, 2021, COLLOID SURFACE B, V201, DOI 10.1016/j.colsurfb.2021.111638
   Lv XL, 2024, ENG APPL ARTIF INTEL, V129, DOI 10.1016/j.engappai.2023.107572
   Merkel A, 2023, EUR CELLS MATER, V45, P14, DOI 10.22203/eCM.v045a02
   Monfared RM, 2018, THEOR APPL FRACT MEC, V96, P272, DOI 10.1016/j.tafmec.2018.05.007
   Murugeshu A., 2009, POLY D LLACTIDECOGLY
   Muthu M, 2023, J MAR SCI ENG, V11, DOI 10.3390/jmse11081480
   Naginyte M, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 41882 y
   Ngoc VTN, 2023, DENT HYPOTHESES, V14, P66, DOI 10.4103/denthyp.denthyp_18_23
   Oliver WC, 2004, J MATER RES, V19, P3, DOI 10.1557/jmr.2004.19.1.3
   Pan CH, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018 018 0930 y
   Paturi UMR, 2022, ARCH COMPUT METHOD E, V29, P3109, DOI 10.1007/s11831 021 09691 7
   Peng W, 2024, J APPL POLYM SCI, V141, DOI 10.1002/app.55433
   Predoi D, 2024, POLYMERS BASEL, V16, DOI 10.3390/polym16010125
   Raafat D, 2009, MICROB BIOTECHNOL, V2, P186, DOI 10.1111/j.1751 7915.2008.00080.x
   Rasila D., 2024, ENGINEERED BIOMATERI
   Ray RR, 2023, APPL BIOCHEM BIOTECH, V195, P17, DOI 10.1007/s12010 022 04127 9
   Rinaudo M, 2006, PROG POLYM SCI, V31, P603, DOI 10.1016/j.progpolymsci.2006.06.001
   RITGER P L, 1987, Journal of Controlled Release, V5, P37, DOI 10.1016/0168 3659(87)90035 6
   Rodríguez AN, 2024, J APPL POLYM SCI, V141, DOI 10.1002/app.54928
   Safaei MM, 2023, MATER SCI ENG B ADV, V289, DOI 10.1016/j.mseb.2022.116248
   Sajjad S, 2024, J APPL POLYM SCI, V141, DOI 10.1002/app.55200
   Shangguan WJ, 2022, MATER TODAY COMMUN, V33, DOI 10.1016/j.mtcomm.2022.104399
   Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P139, DOI 10.1016/S0169 409X(01)00112 0
   Soriente A, 2022, J BIOMED MATER RES A, V110, P266, DOI 10.1002/jbm.a.37283
   Tamilarasi GP, 2023, MINI REV MED CHEM, V23, P1653, DOI 10.2174/1389557523666230221155544
   Tang MM, 2024, J ETHNOPHARMACOL, V319, DOI 10.1016/j.jep.2023.117324
   Tawfig N., 2016, J. Dent. Probl. Solut., V3, P012, DOI DOI 10.17352/2394 8418.000026
   Tayebi M, 2022, J APPL POLYM SCI, V139, DOI 10.1002/app.51507
   Torres Giner S, 2016, POLYM ENG SCI, V56, P500, DOI 10.1002/pen.24274
   Usui M, 2021, JPN DENT SCI REV, V57, P201, DOI 10.1016/j.jdsr.2021.09.005
   Vatankhah E, 2014, ACTA BIOMATER, V10, P709, DOI 10.1016/j.actbio.2013.09.015
   Wang ZY, 2024, J ENVIRON MANAGE, V351, DOI 10.1016/j.jenvman.2023.119900
   Webster TJ, 2000, BIOMATERIALS, V21, P1803, DOI 10.1016/S0142 9612(00)00075 2
   Wei WJ, 2024, SCI CHINA CHEM, V67, P3382, DOI 10.1007/s11426 024 2097 y
   Wu TT, 2024, AGGREGATE, V5, DOI 10.1002/agt2.402
   Xu L, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15092314
   Yadav SK, 2018, ARTIF CELL NANOMED B, V46, P1180, DOI 10.1080/21691401.2017.1366331
   Yang WG, 2024, IEEE ROBOT AUTOM LET, V9, P3846, DOI 10.1109/LRA.2024.3372467
   Yildirim Y, 2023, J DRUG DELIV SCI TEC, V82, DOI 10.1016/j.jddst.2023.104322
   Yu DG, 2023, J PHARM SCI US, V112, P2719, DOI 10.1016/j.xphs.2023.08.017
   Yu DG, 2023, BIOMOLECULES, V13, DOI 10.3390/biom13071152
   Zamani M, 2013, INT J NANOMED, V8, P2997, DOI 10.2147/IJN.S43575
   Zheng JD, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.940511
NR 89
TC 0
Z9 0
U1 5
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 8995
EI 1097 4628
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD JAN 5
PY 2025
VL 142
IS 1
DI 10.1002/app.56309
EA SEP 2024
PG 27
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA N1T1O
UT WOS:001317543100001
DA 2025 08 17
ER

PT J
AU Fuggle, NR
   Curtis, B
   Clynes, M
   Zhang, J
   Ward, K
   Javaid, MK
   Harvey, NC
   Dennison, E
   Cooper, C
AF Fuggle, Nicholas R.
   Curtis, Beth
   Clynes, Michael
   Zhang, Jean
   Ward, Kate
   Javaid, Muhammad Kassim
   Harvey, Nicholas C.
   Dennison, Elaine
   Cooper, Cyrus
TI The treatment gap: The missed opportunities for osteoporosis therapy
SO BONE
LA English
DT Article
DE Osteoporosis; Bisphosphonates; Treatment gap
AB Despite substantial advances in delineation of the epidemiology, pathophysiology, risk assessment and treatment of osteoporosis over the last three decades, a substantial proportion of men and women at high risk of fracture remain untreated the so called "treatment gap". This review summarises the important patient , physicianand policyrelated causes of this treatment gap, before discussing in greater detail: (a) the evidence base for the efficacy of bisphosphonates in osteoporosis; (b) recent evidence relating to the adverse effects of this widely used therapeutic class, most notably atypical femoral fracture and osteonecrosis of the jaw; (c) available strategies to improve both secondary and primary prevention pathways for the management of this disorder.
C1 [Fuggle, Nicholas R.; Curtis, Beth; Clynes, Michael; Zhang, Jean; Ward, Kate; Javaid, Muhammad Kassim; Harvey, Nicholas C.; Dennison, Elaine; Cooper, Cyrus] Univ Southampton, Southampton Gen Hosp, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England.
   [Fuggle, Nicholas R.; Curtis, Beth; Clynes, Michael; Zhang, Jean; Harvey, Nicholas C.; Dennison, Elaine; Cooper, Cyrus] Univ Hosp Southampton NHS Fdn Trust, Dept Rheumatol, Southampton, Hants, England.
   [Ward, Kate; Harvey, Nicholas C.; Dennison, Elaine; Cooper, Cyrus] Univ Southampton, NIHR Southampton Biomed Res Ctr, Southampton, Hants, England.
   [Ward, Kate; Harvey, Nicholas C.; Dennison, Elaine; Cooper, Cyrus] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England.
   [Javaid, Muhammad Kassim; Cooper, Cyrus] Univ Oxford, NIHR Oxford Biomed Res Unit, Oxford, England.
C3 University of Southampton; University of Southampton; University
   Hospital Southampton NHS Foundation Trust; University of Southampton;
   University of Southampton; University Hospital Southampton NHS
   Foundation Trust; University of Oxford
RP Cooper, C (通讯作者)，Univ Southampton, Southampton Gen Hosp, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England.
EM cc@mrc.soton.ac.uk
RI ; Cooper, Cyrus/ADV 7232 2022; Ward, Katherine/HKV 3840 2023; Harvey,
   Nicholas/JWO 4341 2024; Fuggle, Nicholas/S 3758 2019; Curtis,
   Elizabeth/F 4587 2015
OI Harvey, Nicholas/0000 0002 8194 2512; Cooper, Cyrus/0000 0003 3510 0709;
   Clynes, Michael/0000 0001 7597 7658; Dennison,
   Elaine/0000 0002 3048 4961; Ward, Kate/0000 0001 7034 6750; Curtis,
   Elizabeth/0000 0002 5147 0550
FU UK Medical Research Council; NIHR Southampton BRC; Versus Arthritis;
   International Osteoporosis Foundation; MRC [MC_U147585827,
   MC_U147585819, G0400491, MC_UP_A620_1015, MC_UU_12011/2] Funding Source:
   UKRI; Medical Research Council [MC_UP_A620_1014, MC_U147585827,
   MC_U147585824, G0400491, MC_UU_12011/2, MC_UU_12011/1, U1475000002,
   U1475000001, MC_UP_A620_1015, MC_U147585819] Funding Source:
   researchfish; National Institute for Health Research [NF SI 0513 10085,
   ACF 2016 26 010, 10/33/04] Funding Source: researchfish; Versus
   Arthritis [19583] Funding Source: researchfish
FX This manuscript was prepared for presentation at the 50th Anniversary
   Meeting for Bisphosphonates, Sheffield, July 2019. It relies upon
   material published by the principal author in the IOF ESCEO European
   Guidelines for the Management and Treatment of Osteoporosis (1); the IOF
   Report on Closing the Osteoporosis Treatment Gap (2); the IOF Working
   Group Report on Discontinuation of Osteoporosis Therapy (3); and a
   recently published review on optimising osteoporosis therapy (4). The
   work was funded by the UK Medical Research Council, NIHR Southampton
   BRC, Versus Arthritis and International Osteoporosis Foundation.
CR Abrahamsen B, 2012, J BONE MINER RES, V27, P679, DOI 10.1002/jbmr.1481
   Adams AL, 2020, MED CARE, V58, P417, DOI 10.1097/MLR.0000000000001317
   Åkesson K, 2013, OSTEOPOROSIS INT, V24, P2135, DOI 10.1007/s00198 013 2348 z
   Axelsson KF, 2017, J INTERN MED, V282, P546, DOI 10.1111/joim.12678
   Bianchi G, 2012, OSTEOPOROSIS INT, V23, P1769, DOI 10.1007/s00198 011 1793 9
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2020, NEW ENGL J MED, V383, P743, DOI 10.1056/NEJMoa1916525
   Black DM, 2015, J BONE MINER RES, V30, P934, DOI 10.1002/jbmr.2442
   Black DM, 2012, J BONE MINER RES, V27, P243, DOI 10.1002/jbmr.1494
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Center JR, 2020, BONE, V141, DOI 10.1016/j.bone.2020.115566
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Choi WS, 2017, MAX PLAST RECONSTR S, V39, DOI 10.1186/s40902 016 0099 4
   Clark EM, 2016, OSTEOPOROSIS INT, V27, P1459, DOI 10.1007/s00198 015 3397 2
   Clark EM, 2012, J BONE MINER RES, V27, P664, DOI 10.1002/jbmr.1478
   COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cremers S, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115501
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Cummings SR, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115411
   Dell RM, 2012, J BONE MINER RES, V27, P2544, DOI 10.1002/jbmr.1719
   Delmas PD, 2004, OSTEOPOROSIS INT, V15, P792, DOI 10.1007/s00198 004 1602 9
   Delmas PD, 2006, ARTHRITIS RHEUM US, V54, P1838, DOI 10.1002/art.21918
   Dennison EM, 2019, OSTEOPOROSIS INT, V30, P1733, DOI 10.1007/s00198 019 05002 w
   Derkatch S, 2019, RADIOLOGY, V293, P405, DOI 10.1148/radiol.2019190201
   Drew S, 2016, OSTEOPOROSIS INT, V27, P1719, DOI 10.1007/s00198 015 3452 z
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Eisman JA, 2012, J BONE MINER RES, V27, P2039, DOI 10.1002/jbmr.1698
   Fuggle NR, 2020, DRUGS, V80, P1537, DOI 10.1007/s40265 020 01364 2
   Green J, 2010, BMJ BRIT MED J, V341, DOI 10.1136/bmj.c4444
   Greenspan SL, 2015, JAMA INTERN MED, V175, P913, DOI 10.1001/jamainternmed.2015.0747
   Grey A, 2016, THER ADV MUSCULOSKEL, V8, P119, DOI 10.1177/1759720X16650866
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Harris ST, 2008, CURR MED RES OPIN, V24, P237, DOI 10.1185/030079908X253717
   Harvey NCW, 2017, OSTEOPOROSIS INT, V28, P1507, DOI 10.1007/s00198 016 3894 y
   Hawley S, 2016, J BONE MINER RES, V31, P2008, DOI 10.1002/jbmr.2882
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Javaid MK, 2015, OSTEOPOROSIS INT, V26, P2573, DOI 10.1007/s00198 015 3192 0
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Khow KSF, 2017, J NUTR HEALTH AGING, V21, P83, DOI 10.1007/s12603 015 0652 3
   Lekamwasam S, 2012, Arch Osteoporos, V7, P25, DOI 10.1007/s11657 012 0070 7
   Lo JC, 2010, J ORAL MAXIL SURG, V68, P243, DOI 10.1016/j.joms.2009.03.050
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Masoodi N. A., 2009, British Journal of Medical Practitioners, V2, P11
   McCloskey E, 2018, J BONE MINER RES, V33, P1020, DOI 10.1002/jbmr.3411
   McClung MR, 2013, OSTEOPOROSIS INT, V24, P301, DOI 10.1007/s00198 012 2175 7
   Miller PD, 2014, OSTEOPOROSIS INT, V25, P349, DOI 10.1007/s00198 013 2518 z
   Miller PD, 2012, OSTEOPOROSIS INT, V23, P1747, DOI 10.1007/s00198 011 1773 0
   Mitchell PJ, 2013, CURR OSTEOPOROS REP, V11, P52, DOI 10.1007/s11914 012 0130 3
   Pazianas M, 2010, J BONE MINER RES, V25, P2, DOI 10.1359/jbmr.091201
   Reginster JY, 2006, ANN RHEUM DIS, V65, P654, DOI 10.1136/ard.2005.044958
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Reid IR, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115390
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Rizzoli R, 2011, CALCIFIED TISSUE INT, V89, P91, DOI 10.1007/s00223 011 9499 8
   Rogers MJ, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115493
   Rubin KH, 2018, OSTEOPOROSIS INT, V29, P567, DOI 10.1007/s00198 017 4326 3
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shepstone L, 2012, OSTEOPOROSIS INT, V23, P2507, DOI 10.1007/s00198 011 1876 7
   Shepstone L, 2018, LANCET, V391, P741, DOI 10.1016/S0140 6736(17)32640 5
   Stevenson M, 2005, HEALTH TECHNOL ASSES, V9, P1
   Tadrous M, 2014, OSTEOPOROSIS INT, V25, P1225, DOI 10.1007/s00198 013 2576 2
   Tomita N, 2018, COMPUT BIOL MED, V98, P8, DOI 10.1016/j.compbiomed.2018.05.011
   Turner DA, 2018, J BONE MINER RES, V33, P845, DOI 10.1002/jbmr.3381
   van der Velde RY, 2016, OSTEOPOROSIS INT, V27, P3197, DOI 10.1007/s00198 016 3650 3
NR 69
TC 42
Z9 46
U1 3
U2 36
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2021
VL 144
AR 115833
DI 10.1016/j.bone.2020.115833
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA QD8FC
UT WOS:000615747100004
PM 33359889
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Cao, ZQ
   Zhou, J
   Long, ZL
   Li, YH
   Sun, JJ
   Luo, YQ
   Wang, WC
AF Cao, Ziqin
   Zhou, Jian
   Long, Zeling
   Li, Yihan
   Sun, Jingjing
   Luo, Yingquan
   Wang, Wanchun
TI Targeting nerve growth factor, a new option for treatment of
   osteoarthritis: a network meta analysis of comparative efficacy and
   safety with traditional drugs
SO AGING US
LA English
DT Article
DE osteoarthritis; nerve growth factor; NSAIDs; opioids; pain relief
ID ACETAMINOPHEN EXTENDED RELEASE; DOUBLE BLIND; DICLOFENAC SODIUM;
   CLINICAL TRIAL; DOUBLE DUMMY; HIP PAIN; PLACEBO; KNEE; TANEZUMAB;
   ETORICOXIB
AB Objective: Osteoarthritis (OA) is the most common joint disease and leading cause of pain and disability in the elderly population. Most guidelines recommend the use of non steroidal anti inflammatory drugs (NSAIDs) and opioids for the non operative treatment of OA. Monoclonal nerve growth factor (NGF) antibodies are new drugs with the potential to provide pain relief and functional improvement in OA. We compared the efficacy (pain reduction and functional improvement), and safety of monoclonal NGF antibodies with NSAIDs and opioids in the treatment of OA with a Bayesian network meta analysis.
   Results: 38 articles, comprising 41 trials and 20489 patients with OA were included. Overall from the network meta analysis, anti NGFs were the most effective drugs for pain relief (Standardized Mean Difference or SMD compared with placebo 4.25, 95% CI 2.87 to 5.63, Surface Under the Cumulative RAnking curve or SUCRA=93.7%) and for functional improvement (SMD 4.90, 95% CI 3.46 to 6.33, SUCRA=98.3%). Although antiNGFs were associated with higher risk of peripheral sensation abnormality (paresthesia and pruritus), they were not associated with higher risk of other AEs (headaches and nausea) or with higher withdrawal rates related to AEs.
   Conclusions: Monoclonal NGF antibodies provide significantly greater pain relief and functional improvement in OA compared to NSAIDs and opioids. Monoclonal NGF antibodies are not associated with severe AEs. More studies are needed to confirm these findings.
   Methods: PubMed, CNKI, Web of Science, Scopus, Embase and Cochrane Library databases were searched for relevant studies (OA treated with anti NGFs, opioids, selective COX 2 inhibitors or NSAIDs) published between January 1999 to January 2020. Bayesian network and conventional meta analyses were conducted. Pain relief, functional improvement and AEs were assessed.
C1 [Cao, Ziqin; Zhou, Jian; Wang, Wanchun] Cent South Univ, Xiangya Hosp 2, Dept Orthoped, Changsha, Hunan, Peoples R China.
   [Long, Zeling] Mayo Clin, Dept Orthoped, Rochester, MN 55905 USA.
   [Li, Yihan] Univ Calif Davis, Dept Orthoped, Davis, CA 95817 USA.
   [Sun, Jingjing] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Anesthesiol, Hangzhou, Zhejiang, Peoples R China.
   [Luo, Yingquan] Cent South Univ, Xiangya Hosp 2, Dept Gen Med, Changsha, Hunan, Peoples R China.
C3 Central South University; Mayo Clinic; University of California System;
   University of California Davis; Zhejiang University; Central South
   University
RP Wang, WC (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Orthoped, Changsha, Hunan, Peoples R China.; Luo, YQ (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Gen Med, Changsha, Hunan, Peoples R China.
EM luoyingquan@csu.edu.cn; wanchun.wang@csu.edu.cn
RI Zhou, Jian/HKM 9766 2023
CR Ades AE, 2006, PHARMACOECONOMICS, V24, P1, DOI 10.2165/00019053 200624010 00001
   Altman RD, 2007, OSTEOARTHR CARTILAGE, V15, P454, DOI 10.1016/j.joca.2006.10.008
   Altman RD, 2009, J RHEUMATOL, V36, P1991, DOI 10.3899/jrheum.081316
   Bookman AAM, 2004, CAN MED ASSOC J, V171, P333, DOI 10.1503/cmaj.1031793
   Brooks SP, 1998, J COMPUT GRAPH STAT, V7, P434, DOI 10.2307/1390675
   Brown MT, 2013, ARTHRITIS RHEUM US, V65, P1795, DOI 10.1002/art.37950
   Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895 4356(97)00049 8
   Caldwell DM, 2010, J CLIN EPIDEMIOL, V63, P875, DOI 10.1016/j.jclinepi.2009.08.025
   Caldwell DM, 2005, BMJ BRIT MED J, V331, P897, DOI 10.1136/bmj.331.7521.897
   Cannon GW, 2000, ARTHRITIS RHEUM US, V43, P978, DOI 10.1002/1529 0131(200005)43:5<978::AID ANR4>3.0.CO;2 0
   Chen JY, 2017, PAIN MED, V18, P374, DOI 10.1093/pm/pnw262
   Dakin P, 2019, ARTHRITIS RHEUMATOL, V71, P1824, DOI 10.1002/art.41012
   Day R, 2000, ARCH INTERN MED, V160, P1781, DOI 10.1001/archinte.160.12.1781
   DeLemos BP, 2011, AM J THER, V18, P216, DOI 10.1097/MJT.0b013e3181cec307
   Ehrich EW, 1999, J RHEUMATOL, V26, P2438
   Ekman EF, 2014, J RHEUMATOL, V41, P2249, DOI 10.3899/jrheum.131294
   Emery P, 2008, CLIN THER, V30, P70, DOI 10.1016/j.clinthera.2008.01.016
   Essex MN, 2012, J INT MED RES, V40, P1357, DOI 10.1177/147323001204000414
   Essex MN, 2016, INT J RHEUM DIS, V19, P262, DOI 10.1111/1756 185X.12667
   Gana TJ, 2006, CURR MED RES OPIN, V22, P1391, DOI 10.1185/030079906X115595
   Gibofsky A, 2014, CURR MED RES OPIN, V30, P1883, DOI 10.1185/03007995.2014.946123
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   Gordo AC, 2017, J INT MED RES, V45, P59, DOI 10.1177/0300060516673707
   Higgins JP, 2011, AM J PUBLIC HEALTH, DOI DOI 10.2105/AJPH.2020.305609
   Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928
   Kivitz A, 2006, CLIN THER, V28, P352, DOI 10.1016/j.clinthera.2006.03.008
   Kolasinski SL, 2020, ARTHRIT CARE RES, V72, P149, DOI [10.1002/art.41142, 10.1002/acr.24131]
   Lane NE, 2010, NEW ENGL J MED, V363, P1521, DOI 10.1056/NEJMoa0901510
   Leung AT, 2002, CURR MED RES OPIN, V18, P49, DOI 10.1185/030079902125000282
   LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916
   LeviMontalcini R, 1996, TRENDS NEUROSCI, V19, P514, DOI 10.1016/S0166 2236(96)10058 8
   Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875
   Mayorga AJ, 2016, INT J CLIN PRACT, V70, P493, DOI 10.1111/ijcp.12807
   McKenna F, 2001, SCAND J RHEUMATOL, V30, P11
   Miceli Richard C, 2004, ANN RHEUM DIS, V63, P923, DOI 10.1136/ard.2003.017236
   Moher D, 2010, INT J SURG, V8, P336, DOI [10.1371/journal.pmed.1000097, 10.1186/2046 4053 4 1, 10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299, 10.1136/bmj.i4086]
   Nagashima H, 2011, OSTEOARTHR CARTILAGE, V19, P1405, DOI 10.1016/j.joca.2011.09.006
   National Health Research Institutes, 2010, Dental workforce 2020: education, supply and demand
   Niethard FU, 2005, J RHEUMATOL, V32, P2384
   Nüesch E, 2011, BMJ BRIT MED J, V342, DOI 10.1136/bmj.d1165
   Prior MJ, 2014, CURR MED RES OPIN, V30, P2377, DOI 10.1185/03007995.2014.949646
   Puopolo A, 2007, OSTEOARTHR CARTILAGE, V15, P1348, DOI 10.1016/j.joca.2007.05.022
   Rauck R, 2013, PAIN PRACT, V13, P18, DOI 10.1111/j.1533 2500.2012.00555.x
   Reed K, 2018, CURR MED RES OPIN, V34, P689, DOI 10.1080/03007995.2017.1417245
   Reginster Y, 2007, ANN RHEUM DIS, V66, P945, DOI 10.1136/ard.2006.059162
   Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016
   Schnitzer TJ, 2015, OSTEOARTHR CARTILAGE, V23, pS8, DOI 10.1016/j.joca.2014.10.003
   Schnitzer TJ, 2009, OSTEOARTHR CARTILAGE, V17, P1, DOI 10.1016/j.joca.2008.05.018
   Schnitzer TJ, 2019, JAMA J AM MED ASSOC, V322, P37, DOI 10.1001/jama.2019.8044
   Smith SR, 2016, OSTEOARTHR CARTILAGE, V24, P962, DOI 10.1016/j.joca.2016.01.135
   Spierings ELH, 2013, PAIN, V154, P1603, DOI 10.1016/j.pain.2013.04.035
   Sutton A, 2008, PHARMACOECONOMICS, V26, P753, DOI 10.2165/00019053 200826090 00006
   Svensson O, 2006, ANN RHEUM DIS, V65, P781, DOI 10.1136/ard.2005.040519
   Tiseo PJ, 2014, PAIN, V155, P1245, DOI 10.1016/j.pain.2014.03.018
   Varadi G, 2013, PAIN PHYSICIAN, V16, pE749
   Vojtassak J, 2011, PAIN RES TREAT, V2011, DOI 10.1155/2011/239501
   Wandel S, 2010, BMJ BRIT MED J, V341, DOI 10.1136/bmj.c4675
   Yoo MC, 2014, CURR MED RES OPIN, V30, P2399, DOI 10.1185/03007995.2014.955169
   Zacher J, 2003, CURR MED RES OPIN, V19, P725, DOI 10.1185/030079903125002469
NR 59
TC 0
Z9 0
U1 1
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945 4589
J9 AGING US
JI Aging US
PD JAN 15
PY 2021
VL 13
IS 1
BP 1051
EP 1070
PG 20
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA PX1RX
UT WOS:000611141300004
DA 2025 08 17
ER

PT J
AU Chen, YK
   Chen, YC
   Lin, WX
   Zheng, JH
   Liu, YY
   Zou, J
   Cai, JH
   Ji, ZQ
   Chen, LZ
   Li, ZY
   Chen, YX
AF Chen, Yao Kun
   Chen, Yu Chun
   Lin, Wei Xun
   Zheng, Jie Hua
   Liu, Yi Yuan
   Zou, Juan
   Cai, Jie Hui
   Ji, Ze Qi
   Chen, Ling Zhi
   Li, Zhi Yang
   Chen, Ye Xi
TI Follicular carcinoma of the thyroid with a single metastatic lesion in
   the lumbar spine: A case report
SO WORLD JOURNAL OF CLINICAL CASES
LA English
DT Article
DE Case report; Thyroid carcinoma; Lumbar spine; Metastasis; Surgery
ID CANCER; MANAGEMENT; PAPILLARY
AB BACKGROUND The bone is the second most common site of thyroid cancer metastasis, after the lung. Treatment options for bone metastasis of thyroid cancer include surgery, radioiodine therapy (RAIT), external radiation therapy, thyroid stimulating hormone (TSH) inhibition, bisphosphonates, and small molecule targeted therapies. In most cases, thyroid carcinoma is found in the thyroid tissue; reports of follicular thyroid carcinoma with a single metastasis to the lumbar spine are rare. CASE SUMMARY We report a case of bone metastasis as the only clinical manifestation of thyroid cancer. The patient was a 67 year old woman with lumbar pain for 7 years and aggravation with intermittent claudication who had previously undergone partial thyroidectomy of a benign thyroid lesion. No abnormal nodules were found in the bilateral thyroid glands. However, imaging studies were consistent with a spinal tumor, and the lesion was diagnosed as a metastatic follicular carcinoma of thyroid origin. We adopted a multidisciplinary collaboration and comprehensive treatment approach. The patient underwent lumbar spine surgery, total resection of the thyroid, postoperative TSH suppression therapy, and RAIT. There were no complications associated with the operation, and the patient had good postoperative recovery. She has experienced no recurrence. CONCLUSION Follicular thyroid carcinoma is associated with early hematogenous metastasis, and the bone is a typical site of metastasis. Single bone metastasis is not a contraindication to medical procedures, and providing the appropriate therapy can result in better outcomes and quality of life for these patients.
C1 [Chen, Yao Kun; Lin, Wei Xun; Zheng, Jie Hua; Liu, Yi Yuan; Zou, Juan; Cai, Jie Hui; Ji, Ze Qi; Chen, Ling Zhi; Li, Zhi Yang; Chen, Ye Xi] Shantou Univ, Affiliated Hosp 2, Med Coll, Dept Thyroid Breast & Hernia Surg, Shantou 515000, Guangdong Provi, Peoples R China.
   [Chen, Yu Chun] Shantou Univ, Affiliated Hosp 2, Med Coll, Dept Bone Joint & Spine Surg, Shantou 515000, Guangdong Provi, Peoples R China.
   [Chen, Ye Xi] Shantou Univ, Affiliated Hosp 2, Dept Thyroid Breast & Hernia Surg, Med Coll, 69 North Dongxia Rd, Shantou 515000, Guangdong Provi, Peoples R China.
C3 Shantou University; Shantou University; Shantou University
RP Chen, YX (通讯作者)，Shantou Univ, Affiliated Hosp 2, Dept Thyroid Breast & Hernia Surg, Med Coll, 69 North Dongxia Rd, Shantou 515000, Guangdong Provi, Peoples R China.
EM yxchen3@stu.edu.cn
RI Liu, Yiyuan/OCK 7802 2025; Zhiyang, li/ACM 8014 2022; Zheng,
   Jiehua/MEO 8999 2025; Li, Zhiyang/ACM 8014 2022
OI Li, Zhiyang/0000 0002 5481 3985
FU Medical Scientific Research Foundation of Guangdong Province, China
   [A2021432, B2021448]; Shantou Medical Science and Technology Planning
   Project [210521236491457, 210625106490696]; Undergraduate Innovation
   Training Project of Shantou University [31/38/47/54]
FX Supported by the Medical Scientific Research Foundation of Guangdong
   Province, China, No. A2021432 and B2021448; the Shantou Medical Science
   and Technology Planning Project, No. 210521236491457 and
   210625106490696; and the Undergraduate Innovation Training Project of
   Shantou University, No. 31/38/47/54.
CR Chen FK, 2018, MOL MED REP, V17, P4959, DOI 10.3892/mmr.2018.8481
   Chung SR, 2021, CANCERS, V13, DOI 10.3390/cancers13061338
   Dong P, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008215
   Durante C, 2006, J CLIN ENDOCR METAB, V91, P2892, DOI 10.1210/jc.2005 2838
   Faheem Mohd, 2011, J Med Case Rep, V5, P370, DOI 10.1186/1752 1947 5 370
   Farooki A, 2012, J CLIN ENDOCR METAB, V97, P2433, DOI 10.1210/jc.2012 1169
   Guerra G, 2014, INT J SURG, V12, pS3, DOI 10.1016/j.ijsu.2014.05.076
   Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020
   Koizumi M, 2017, CLIN NUCL MED, V42, P463, DOI 10.1097/RLU.0000000000001592
   Kushchayeva YS, 2014, THYROID, V24, P1488, DOI 10.1089/thy.2013.0633
   Kushchayeva YS, 2014, THYROID, V24, P1443, DOI 10.1089/thy.2013.0634
   Lang BHH, 2013, ANN SURG ONCOL, V20, P1329, DOI 10.1245/s10434 012 2711 x
   Li Yuan, 2014, Zhonghua Bing Li Xue Za Zhi, V43, P348
   Nervo A, 2021, J ENDOCRINOL INVEST, V44, P403, DOI 10.1007/s40618 020 01374 7
   Ramadan Sami, 2012, Head Neck Oncol, V4, P39, DOI 10.1186/1758 3284 4 39
   Schlumberger MJ, 2000, BEST PRACT RES CL EN, V14, P601, DOI 10.1053/beem.2000.0105
   Sciubba DM, 2006, SURG ONCOL, V15, P141, DOI 10.1016/j.suronc.2006.11.002
   Weber M, 2019, Q J NUCL MED MOL IM, V63, P235, DOI 10.23736/S1824 4785.19.03201 1
   Wexler JA, 2011, J CLIN ENDOCR METAB, V96, P2296, DOI 10.1210/jc.2010 1996
   Yang SP, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.721832
   Zhu XL, 2016, INT J ONCOL, V48, P2321, DOI 10.3892/ijo.2016.3485
NR 21
TC 2
Z9 2
U1 0
U2 10
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 2307 8960
J9 WORLD J CLIN CASES
JI World J. Clin. Cases
PD SEP 16
PY 2022
VL 10
IS 26
BP 9493
EP 9501
DI 10.12998/wjcc.v10.i26.9493
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 5F3KT
UT WOS:000866218600037
PM 36159419
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Steffens, JP
   Santana, LCL
   Pitombo, JCP
   Ribeiro, DO
   Albaricci, MCC
   Warnavin, SVC
   Kantarci, A
   Spolidorio, LC
AF Steffens, Joao Paulo
   Leal Santana, Luis Carlos
   Paiva Pitombo, Jonleno Coutinho
   Ribeiro, Daniel Olivio
   Costa Albaricci, Maria Carolina
   Cubas Warnavin, Stephanie von Stein
   Kantarci, Alpdogan
   Spolidorio, Luis Carlos
TI The role of androgens on periodontal repair in female rats
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article
DE androgen receptor antagonists; androgens; estrogens; inflammation;
   testosterone; wounds and injuries
ID HORMONE BINDING GLOBULIN; BONE MINERAL DENSITY; STEROID HORMONES; OLDER
   MEN; PLUS ANDROGEN; IN VIVO; TESTOSTERONE; WOMEN; RECEPTORS; ESTROGEN
AB Background: Testosterone replacement enhances cognitive function and musculoskeletal health in postmenopausal women. However, the biological role of testosterone on inflammation and bone metabolism in females is not well understood. Our objective was to measure the impact of androgens and their receptors on periodontal tissues during periodontal repair in female rats.
   Methods: Seventy female Holtzman rats were divided into seven groups (n = 10/group): negative control; repair control; androgen receptor antagonist (flutamide, 50 mg/kg, every other day); estrogen receptor antagonist (fulvestrant, 1.5 mg/kg/day); testosterone supplementation (durateston, 250 mg/kg, weekly); aromatase inhibitor (anastrozole, 0.2 mg /kg/day); testosterone plus anastrozole. Cotton ligatures were kept for 13 days, when pharmacological treatment was initiated. On day 14, the ligatures were removed. The rats were euthanized on the 17th or the 28th day (n = 5/group/period) for the evaluation of markers related to inflammation and bone. The tissue and serum samples were evaluated using a multiplexed immunoassay for the inflammatory targets. Radiographic and histologic analyses were performed to assess changes in tissues.
   Results: Blockage of androgen receptors had little effect on inflammatory cell count, although it tended to increase interleukin (IL) 4, vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF) as well as decrease IL 1, tumor necrosis factor (TNF) alpha, and IL 6. Flutamide also significantly impaired bone repair (P < 0.05) and had greater osteoclast count, although this last difference was not statistically significant. Testosterone supplementation significantly increased the inflammatory cell count, decreased the levels of IL 4, IL 10, IL 1 beta, IL 6, and TNF alpha; and increased VEGF and EGF.
   Conclusion: The blockage of androgen receptors significantly impair bone repair in females through mechanisms that are different from those related to estrogen receptors.
C1 [Steffens, Joao Paulo; Cubas Warnavin, Stephanie von Stein] Univ Fed Parana UFPR, Dept Stomatol, Curitiba, PR, Brazil.
   [Leal Santana, Luis Carlos; Paiva Pitombo, Jonleno Coutinho; Ribeiro, Daniel Olivio; Costa Albaricci, Maria Carolina; Spolidorio, Luis Carlos] Univ Estadual Paulista UNESP, Sch Dent Araraquara, Dept Physiol & Pathol, Araraquara, SP, Brazil.
   [Kantarci, Alpdogan] Forsyth Inst, Dept Appl Oral Sci, Cambridge, MA USA.
C3 Universidade Federal do Parana; Universidade Estadual Paulista; Harvard
   University; Harvard University Medical Affiliates; Forsyth Institute
RP Steffens, JP (通讯作者)，Univ Fed Parana, Dept Stomatol, 632 Pref,Lothario Meissner Ave, BR 80210170 Curitiba, PR, Brazil.
EM joao.steffens@ufpr.br
RI Santana, Luis/E 3886 2017; Steffens, Joao Paulo/B 4953 2009; Spolidorio,
   Luis Carlos/G 1857 2012; KANTARCI, Alpdogan/KLC 3979 2024; Spolidorio,
   Luís/G 1857 2012
OI Santana, Luis/0000 0001 8264 5432; Steffens, Joao
   Paulo/0000 0002 6071 553X; Spolidorio, Luis Carlos/0000 0002 0592 542X; 
FU Sao Paulo Research Foundation   FAPESP, Sao Paulo, SP, Brazil
   [2013/12014 6]; FAPESP [2013/07833 8]; MCCA [2013/23116 4]; DOR
   [2014/02280 3]; Amazon State Research Foundation   FAPEAM, Manaus, AM,
   Brazil [19894.483.36583.10102014]; Coordination for the Improvement of
   Higher Education Personnel (CAPES, Brasilia, DF, Brazil); National
   Council for Scientific and Technological Development (CNPq, Brasilia,
   DF, Brazil); Vinnova [2014 02280] Funding Source: Vinnova; Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [13/07833 8,
   13/23116 4, 14/02280 3, 13/12014 6] Funding Source: FAPESP
FX This study was supported by a grant from the Sao Paulo Research
   Foundation   FAPESP, Sao Paulo, SP, Brazil (Grant # 2013/12014 6). The
   authors also would like to thank FAPESP for the scholarship provided to
   JPS (#2013/07833 8), MCCA (#2013/23116 4) and DOR (#2014/02280 3). LCLS
   was the recipient of a scholarship from the Amazon State Research
   Foundation   FAPEAM, Manaus, AM, Brazil (#19894.483.36583.10102014).
   SVSCW is the recipient of a scholarship from the Coordination for the
   Improvement of Higher Education Personnel (CAPES, Brasilia, DF, Brazil)
   and LCS is the recipient of a fellowship from the National Council for
   Scientific and Technological Development (CNPq, Brasilia, DF, Brazil).
   The authors also thank the staff of the Life Sciences Core Facility
   (LaCTAD) from the State University of Campinas (UNICAMP, Campinas, SP,
   Brazil) for the multiplex analysis. All authors declare that they have
   no conflicts of interest related to this study.
CR Amory JK, 2004, J CLIN ENDOCR METAB, V89, P503, DOI 10.1210/jc.2003 031110
   Armitage G C, 1999, Ann Periodontol, V4, P1, DOI 10.1902/annals.1999.4.1.1
   Bain J, 2010, MATURITAS, V66, P16, DOI 10.1016/j.maturitas.2010.01.009
   Bernini GP, 1999, J CLIN ENDOCR METAB, V84, P2008, DOI 10.1210/jc.84.6.2008
   Bhasin S, 2005, J CLIN ENDOCR METAB, V90, P678, DOI 10.1210/jc.2004 1184
   Coimbra LS, 2014, J CLIN PERIODONTOL, V41, P295, DOI 10.1111/jcpe.12203
   Coimbra LS, 2011, J PERIODONTOL, V82, P767, DOI 10.1902/jop.2010.100555
   Davis S, 1999, J CLIN ENDOCR METAB, V84, P1886, DOI 10.1210/jc.84.6.1886
   Del Fabbro E, 2010, J PAIN SYMPTOM MANAG, V39, P1016, DOI 10.1016/j.jpainsymman.2009.09.021
   Gimpl G, 2002, PROG BRAIN RES, V139, P43
   Glaser R, 2015, MATURITAS, V82, P291, DOI 10.1016/j.maturitas.2015.06.002
   Glaser R, 2013, MATURITAS, V74, P230, DOI 10.1016/j.maturitas.2013.01.003
   Glaser RL, 2013, MATURITAS, V76, P342, DOI 10.1016/j.maturitas.2013.08.002
   Golden SH, 2002, AM J EPIDEMIOL, V155, P437, DOI 10.1093/aje/155.5.437
   Guay A, 2002, WORLD J UROL, V20, P106, DOI 10.1007/s00345 002 0267 2
   Haas AN, 2009, J PERIODONTOL, V80, P1380, DOI 10.1902/jop.2009.090082
   Hugoson A, 1970, J Periodontal Res Suppl, V5, P1
   Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1038/jcbfm.2010.220, 10.1111/j.1476 5381.2010.00872.x]
   Kurling Kailanto S, 2010, PHARMACOL BIOCHEM BE, V95, P422, DOI 10.1016/j.pbb.2010.02.020
   Laaksonen DE, 2004, DIABETES CARE, V27, P1036, DOI 10.2337/diacare.27.5.1036
   Laughlin GA, 2008, J CLIN ENDOCR METAB, V93, P68, DOI 10.1210/jc.2007 1792
   Laurent MR, 2016, BONE, V93, P33, DOI 10.1016/j.bone.2016.09.011
   Leblebicioglu B, 2013, PERIODONTOL 2000, V61, P54, DOI 10.1111/j.1600 0757.2011.00440.x
   LINDHE JAN, 1967, J PERIODONTAL RES, V2, P194, DOI 10.1111/j.1600 0765.1967.tb01889.x
   LOE HARALD, 1963, ACTA ODONTOL SCAND, V21, P533, DOI 10.3109/00016356309011240
   MARCONDES F. K., 2002, Braz. J. Biol., V62, P609, DOI 10.1590/S1519 69842002000400008
   Mariotti A, 2013, PERIODONTOL 2000, V61, P69, DOI 10.1111/j.1600 0757.2011.00424.x
   Mariotti A, 2013, PERIODONTOL 2000, V61, P7, DOI 10.1111/j.1600 0757.2012.00442.x
   Massafra C, 1999, J CLIN ENDOCR METAB, V84, P971, DOI 10.1210/jc.84.3.971
   Meier C, 2008, ARCH INTERN MED, V168, P47, DOI 10.1001/archinternmed.2007.2
   Mellström D, 2006, J BONE MINER RES, V21, P529, DOI 10.1359/JBMR.060110
   Moussa L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049547
   Nemere I, 2003, J CELL BIOCHEM, V88, P438, DOI 10.1002/jcb.10409
   Ohlsson C, 2009, EUR J ENDOCRINOL, V160, P883, DOI 10.1530/EJE 09 0118
   Steffens JP, 2015, BONE, V81, P683, DOI 10.1016/j.bone.2015.10.001
   Pluchino N, 2013, ARCH GYNECOL OBSTET, V288, P731, DOI 10.1007/s00404 013 2969 7
   Pöllänen E, 2011, AGING CELL, V10, P650, DOI 10.1111/j.1474 9726.2011.00701.x
   Raisz LG, 1996, J CLIN ENDOCR METAB, V81, P37, DOI 10.1210/jc.81.1.37
   Samaras N, 2014, CLIN INTERV AGING, V9, P1175, DOI 10.2147/CIA.S48918
   SAVVAS M, 1988, BMJ BRIT MED J, V297, P331, DOI 10.1136/bmj.297.6644.331
   Selvin E, 2007, DIABETES CARE, V30, P234, DOI 10.2337/dc06 1579
   Soory M, 2000, Dent Update, V27, P380
   Soory M., 2000, Current Drug Targets, V1, P309, DOI 10.2174/1389450003349119
   Steffens JP, 2014, HORM METAB RES, V46, P193, DOI 10.1055/s 0034 1367031
   Steffens JP, 2012, J PERIODONTOL, V83, P1432, DOI 10.1902/jop.2012.110658
   Steffens JP, 2015, J PERIODONTOL, V86, P1116, DOI 10.1902/jop.2015.140530
   Stellato RK, 2000, DIABETES CARE, V23, P490, DOI 10.2337/diacare.23.4.490
   Svensson J, 2010, J MOL ENDOCRINOL, V45, P45, DOI 10.1677/JME 09 0165
   WATTS NB, 1995, OBSTET GYNECOL, V85, P529, DOI 10.1016/0029 7844(94)00448 M
   Wierman ME, 2014, J CLIN ENDOCR METAB, V99, P3489, DOI 10.1210/jc.2014 2260
   Zheng ZG, 2011, P NATL ACAD SCI USA, V108, P16289, DOI 10.1073/pnas.1108312108
   ZUIDEMA J, 1994, INT J PHARM, V105, P189, DOI 10.1016/0378 5173(94)90103 1
NR 52
TC 11
Z9 12
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3492
EI 1943 3670
J9 J PERIODONTOL
JI J. Periodont.
PD APR
PY 2018
VL 89
IS 4
BP 486
EP 495
DI 10.1002/JPER.17 0435
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA GD7DQ
UT WOS:000430670400012
PM 29683499
DA 2025 08 17
ER

PT J
AU Gallagher, JC
   Jindal, PS
   Smith, LM
AF Gallagher, J. Christopher
   Jindal, Prachi S.
   Smith, Lynette M.
TI Vitamin D Supplementation in Young White and African American Women
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE PTH; CELL; TISSUE SIGNALING; ENDOCRINE PATHWAYS; CLINICAL TRIALS;
   NUTRITION; 25OHD; VITAMIN D
ID PARATHYROID HORMONE CONCENTRATIONS; 25 HYDROXYVITAMIN D CONCENTRATIONS;
   CALCIUM ABSORPTION; BLACK; RESPONSES
AB There is limited information on the effects of vitamin D on serum 25 hydroxyvitamin D (25OHD) in young people and none on African Americans. The main objective of this trial was to measure the effect of different doses of vitamin D3 on serum 25OHD and serum parathyroid hormone (PTH) in young women with vitamin D insufficiency (serum 25OHD20ng/mL (50 nmol/L). A randomized double blind placebo controlled trial of vitamin D3 was conducted in young white and African American women, age 25 to 45 years. A total of 198 healthy white (60%) and African American (40%) women were randomly assigned to placebo, or to 400, 800, 1600, or 2400 IU of vitamin D3 daily. Calcium supplements were added to maintain a total calcium intake of 1000 to 1200mg daily. The primary outcomes of the study were the final serum 25OHD and PTH levels at 12 months. The absolute increase in serum 25OHD with 400, 800, 1600, and 2400 IU of vitamin D daily was slightly greater in African American women than in white women. On the highest dose of 2400 IU/d, the mixed model predicted that mean 25OHD increased from baseline 12.4ng/mL (95% confidence interval [CI], 9.2 15.7) to 43.2ng/mL (95% CI, 38.2 48.1) in African American women and from 15.0ng/mL (95% CI, 12.3 17.6) to 39.1ng/mL (95% CI, 36.2 42.0) in white women. There was no significant effect of vitamin D dose on serum PTH in either race but there was a significant inverse relationship between final serum PTH and serum 25OHD. Serum 25OHD exceeded 20ng/mL in 97.5% of whites on the 400 IU/d dose and between 800 and 1600 IU/d for African Americans. The recommended dietary allowance (RDA) suggested by the Institute of Medicine for young people is 600 IU daily. The increase in serum 25OHD after vitamin D supplementation was similar in young and old, and in white and African American women. (c) 2014 American Society for Bone and Mineral Research.
C1 [Gallagher, J. Christopher; Jindal, Prachi S.] Creighton Univ, Med Ctr, Bone Metab Unit, Omaha, NE 68131 USA.
   [Smith, Lynette M.] Univ Nebraska Med Ctr, Coll Publ Hlth, Omaha, NE USA.
C3 Creighton University; University of Nebraska System; University of
   Nebraska Medical Center
RP Gallagher, JC (通讯作者)，Creighton Univ, Med Ctr, 601 N 30th St,Suite 6718, Omaha, NE 68131 USA.
EM jcg@creighton.edu
OI gallagher, john christopher/0000 0002 5129 9183
FU Department of Defense (DOD) [W81XWH 07 1 201]
FX This study was supported by a grant from the Department of Defense (DOD)
   (W81XWH 07 1 201). The Department of Defense was not involved in the
   study design, protocol development except for review of the safety
   aspects of the trial; it was not involved in data collection, data
   analysis, data management or interpretation, or preparation of the
   manuscript. We thank all VITADAS participants and the Bone Metabolism
   Unit Research staff for their hard work and contribution to the study
   and Corinna Suiter for performing the assays. We thank Jane Meza, PhD,
   Professor and Chair, Department of Biostatistics Director, Center for
   Collaboration on Research, Design and Analysis at College of Public
   Health University of Nebraska Medical Center for statistical advice. We
   thank members of the Data Safety and Monitoring Board (Dr Dan Bikle, Dr
   Steve Harris, and Dr John Adams) for their scientific input.
CR Absoud M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022179
   Aloia JF, 2008, AM J CLIN NUTR, V87, P1952
   BELL NH, 1985, J CLIN INVEST, V76, P470, DOI 10.1172/JCI111995
   Biancuzzo RM, 2010, AM J CLIN NUTR, V91, P1621, DOI 10.3945/ajcn.2009.27972
   Cheng SL, 2003, AM J CLIN NUTR, V78, P485, DOI 10.1093/ajcn/78.3.485
   Choi HS, 2011, J CLIN ENDOCR METAB, V96, P643, DOI 10.1210/jc.2010 2133
   Cosman F, 1997, J BONE MINER RES, V12, P958, DOI 10.1359/jbmr.1997.12.6.958
   Cosman F, 2000, OSTEOPOROSIS INT, V11, P271, DOI 10.1007/s001980050292
   DAWSONHUGHES B, 1995, J CLIN ENDOCR METAB, V80, P3068, DOI 10.1210/jc.80.10.3068
   Fitzmaurice G M, 2000, Biostatistics, V1, P141, DOI 10.1093/biostatistics/1.2.141
   Gallagher JC, 2013, J STEROID BIOCHEM, V136, P195, DOI 10.1016/j.jsbmb.2012.12.003
   Gallagher JC, 2013, J CLIN ENDOCR METAB, V98, P1137, DOI 10.1210/jc.2012 3106
   Gallagher JC, 2012, J CLIN ENDOCR METAB, V97, P3550, DOI 10.1210/jc.2012 2020
   Gallagher JC, 2012, ANN INTERN MED, V156, P425, DOI 10.7326/0003 4819 156 6 201203200 00005
   Ginde AA, 2009, ARCH INTERN MED, V169, P626, DOI 10.1001/archinternmed.2008.604
   Harris SS, 1998, AM J CLIN NUTR, V67, P1232, DOI 10.1093/ajcn/67.6.1232
   Holick MF, 2008, J CLIN ENDOCR METAB, V93, P677, DOI 10.1210/jc.2007 2308
   IOM, 2011, DIETARY REFERENCE IN
   Looker AC, 2005, J CLIN ENDOCR METAB, V90, P635, DOI 10.1210/jc.2004 1765
   Nelson ML, 2009, J NUTR, V139, P540, DOI 10.3945/jn.108.096180
   Outila TA, 2001, AM J CLIN NUTR, V74, P206
   Park T, 1997, STAT MED, V16, P1859, DOI 10.1002/(SICI)1097 0258(19970830)16:16<1859::AID SIM593>3.0.CO;2 3
   Sai AJ, 2011, J CLIN ENDOCR METAB, V96, pE436, DOI 10.1210/jc.2010 1886
   Smith SM, 2009, AM J CLIN NUTR, V89, P1092, DOI 10.3945/ajcn.2008.27189
   Sullivan SS, 2005, J AM DIET ASSOC, V105, P971, DOI 10.1016/j.jada.2005.03.002
NR 25
TC 50
Z9 50
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2014
VL 29
IS 1
BP 173
EP 181
DI 10.1002/jbmr.2010
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 274HS
UT WOS:000328598000017
PM 23761326
DA 2025 08 17
ER

PT J
AU Bi, RY
   Fan, Y
   Lauter, K
   Hu, J
   Watanabe, T
   Cradock, J
   Yuan, Q
   Gardella, T
   Mannstadt, M
AF Bi, Ruiye
   Fan, Yi
   Lauter, Kelly
   Hu, Jing
   Watanabe, Tomoyuki
   Cradock, Jim
   Yuan, Quan
   Gardella, Thomas
   Mannstadt, Michael
TI Diphtheria Toxin  and GFP Based Mouse Models of Acquired
   Hypoparathyroidism and Treatment With a Long Acting Parathyroid Hormone
   Analog
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE ANIMAL MODELS; THERAPEUTICS; DISORDERS OF CALCIUM/PHOSPHATE METABOLISM;
   CELL/TISSUE SIGNALING ENDOCRINE PATHWAYS
ID ABLATION; RECEPTOR; PTH; THERAPY; REVEALS; INTACT; BONE
AB Hypoparathyroidism (HP) arises most commonly from parathyroid (PT) gland damage associated with neck surgery, and is typically treated with oral calcium and active vitamin D. Such treatment effectively increases levels of serum calcium (sCa), but also brings risk of hypercalciuria and renal damage. There is thus considerable interest in using PTH or PTH analogs to treat HP. To facilitate study of this disease and the assessment of new treatment options, we developed two mouse models of acquired HP, and used them to assess efficacy of PTH(1 34) as well as a long acting PTH analog (LA PTH) in regulating blood calcium levels. In one model, we used PTHcre iDTR mice in which the diphtheria toxin (DT) receptor (DTR) is selectively expressed in PT glands, such that systemic DT administration selectively ablates parathyroid cells. For the second model, we generated GFP PT mice in which green fluorescent protein (GFP) is selectively expressed in PT cells, such that parathyroidectomy (PTX) is facilitated by green fluorescence of the PT glands. In the PTHcre iDTR mice, DT injection (2 x 5 mu g/kg, i.p.) resulted in moderate yet consistent reductions in serum PTH and sCa levels. The more severe hypoparathyroid phenotype was observed in GFP PT mice following GFP guided PTX surgery. In each model, a single subcutaneous injection of LA PTH increased sCa levels more effectively and for a longer duration (>24 hours) than did a 10 fold higher dose of PTH(1 34), without causing excessive urinary calcium excretion. These new mouse models thus faithfully replicate two degrees of acquired HP, moderate and severe, and may be useful for assessing potential new modes of therapy. (C) 2015 American Society for Bone and Mineral Research.
C1 [Bi, Ruiye; Lauter, Kelly; Watanabe, Tomoyuki; Gardella, Thomas; Mannstadt, Michael] Massachusetts Gen Hosp, Endocrine Unit, Thier 1123,50 Blossom St, Boston, MA 02474 USA.
   [Bi, Ruiye; Lauter, Kelly; Watanabe, Tomoyuki; Gardella, Thomas; Mannstadt, Michael] Harvard Univ, Sch Med, Boston, MA USA.
   [Bi, Ruiye; Fan, Yi] Sichuan Univ, West China Sch Stomatol, Chengdu 610064, Sichuan, Peoples R China.
   [Fan, Yi] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, 188 Longwood Ave, Boston, MA 02115 USA.
   [Hu, Jing; Yuan, Quan] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610064, Sichuan, Peoples R China.
   [Cradock, Jim] NIH, Natl Ctr Adv Translat Sci, Rockville, MD USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard University; Harvard Medical School; Sichuan
   University; Harvard University; Harvard School of Dental Medicine;
   Sichuan University; National Institutes of Health (NIH)   USA; NIH
   National Center for Advancing Translational Sciences (NCATS)
RP Mannstadt, M (通讯作者)，Massachusetts Gen Hosp, Endocrine Unit, Thier 1123,50 Blossom St, Boston, MA 02474 USA.
EM mannstadt@mgh.harvard.edu
RI yuan, quan/GZM 5597 2022; wang, meng/GWZ 9558 2022; Mannstadt,
   Michael/AAO 1124 2020
OI Yuan, Quan/0000 0002 2836 1081; Bi, Ruiye/0000 0002 8297 9691; 
FU NIH [R01 DK100584, X01 NS073537 01, P01 DK11794, T32DK007028]; China
   State Key Laboratory of Oral Diseases Open Funding [SKLOD2015OF01];
   BrIDGs Program; NIH Common Fund; National Center for Advancing
   Translational Sciences
FX This work was supported by the NIH grants R01 DK100584 and X01
   NS073537 01 (to MM), P01 DK11794, project I (to TJG), T32DK007028 (to
   KL); and China State Key Laboratory of Oral Diseases Open Funding
   SKLOD2015OF01 (to RB). This research was supported in part by the BrIDGs
   Program, the NIH Common Fund and the National Center for Advancing
   Translational Sciences. We thank Wenping Zhao for technical help; Henry
   Kronenberg, John Potts, and Deborah Mitchell for comments on this
   manuscript; and Elizabeth Monis for proofreading.
CR Berdud I, 1998, CALCIFIED TISSUE INT, V62, P457, DOI 10.1007/s002239900460
   Bilezikian JP, 2011, J BONE MINER RES, V26, P2317, DOI 10.1002/jbmr.483
   Bryant H, 2014, J BONE MINER RES S1, V29
   Buch T, 2005, NAT METHODS, V2, P419, DOI 10.1038/NMETH762
   Cusano NE, 2015, J BONE MINER RES
   Farra R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003276
   FINCO DR, 1993, CAN J VET RES, V57, P288
   FOX J, 1978, J ENDOCRINOL, V78, P379, DOI 10.1677/joe.0.0780379
   Gates FL, 1927, J EXP MED, V45, P115
   Günther T, 2000, NATURE, V406, P199, DOI 10.1038/35018111
   Hatori M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002451
   Hough TA, 2004, P NATL ACAD SCI USA, V101, P13566, DOI 10.1073/pnas.0405516101
   Leone Bay A, 2001, PHARMACEUT RES, V18, P964, DOI 10.1023/A:1010936227570
   Libutti SK, 2003, CANCER RES, V63, P8022
   Maeda A, 2013, P NATL ACAD SCI USA, V110, P5864, DOI 10.1073/pnas.1301674110
   Mannstadt M, 2013, LANCET DIABETES ENDO, V1, P275, DOI 10.1016/S2213 8587(13)70106 2
   Miao DS, 2004, ENDOCRINOLOGY, V145, P2046, DOI 10.1210/en.2003 1097
   Mitchell DM, 2012, J CLIN ENDOCR METAB, V97, P4507, DOI 10.1210/jc.2012 1808
   Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335
   Okazaki M, 2008, P NATL ACAD SCI USA, V105, P16525, DOI 10.1073/pnas.0808750105
   Rubin MR, 2010, OSTEOPOROSIS INT, V21, P1927, DOI 10.1007/s00198 009 1149 x
   Sakai A, 2005, J BONE MINER METAB, V23, P8, DOI 10.1007/s00774 004 0534 y
   Sebastian EM, 2008, BONE, V43, P1022, DOI 10.1016/j.bone.2008.07.250
   Shoback D, 2008, NEW ENGL J MED, V359, P391, DOI 10.1056/NEJMcp0803050
   Sikjaer T, 2013, J BONE MINER RES, V28, P2232, DOI 10.1002/jbmr.1964
   Tang J, 2014, J BONE MINER RES S1, V29
NR 26
TC 20
Z9 22
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2016
VL 31
IS 5
BP 975
EP 984
DI 10.1002/jbmr.2769
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DN7PX
UT WOS:000377270400007
PM 26678919
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Dimitriou, R
   Carr, IM
   West, RM
   Markham, AF
   Giannoudis, PV
AF Dimitriou, Rozalia
   Carr, Ian M.
   West, Robert M.
   Markham, Alexander F.
   Giannoudis, Peter V.
TI Genetic predisposition to fracture non union: a case control study of a
   preliminary single nucleotide polymorphisms analysis of the BMP pathway
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
ID BONE MORPHOGENETIC PROTEINS; ANTAGONIST NOGGIN; DIFFERENTIATION;
   MUTATIONS; MICE; OSTEOPOROSIS; CANCER; RISK; OVEREXPRESSION;
   SUSCEPTIBILITY
AB Background: Despite the known multi factorial nature of atrophic fracture non unions, a possible genetic predisposition for the development of this complication after long bone fractures remains unknown. This pilot study aimed to address this issue by performing a preliminary SNP analysis of specific genes known to regulate fracture healing.
   Methods: A total of fifteen SNPs within four genes of the Bone Morphogenetic Protein (BMP) pathway (BMP 2, BMP 7, NOGGIN and SMAD6) were examined, in 109 randomly selected patients with long bone fractures as a result of motor vehicle accident, fall or direct blow. There were sixty two patients with atrophic non union and forty seven patients (54 fractures) with uneventful fracture union. Overall SNPs frequencies were computed with respect to patient's age, gender, smoking habits, fracture associated parameters and the use of nonsteroidal anti inflammatory drugs (NSAIDs), and tested for their association to the impaired bone healing process, using binary logistic regression (STATA 11.1; StataCorp, Texas USA).
   Results: Statistical analysis revealed age to be an important covariate in the development of atrophic non union (p = 0.01, OR 1.05 [per year]), and two specific genotypes (G/G genotype of the rs1372857 SNP, located on NOGGIN and T/T genotype of the rs2053423 SNP, located on SMAD6) to be associated with a greater risk of fracture nonunion (p = 0.02, OR 4.56 and p = 0.04, OR 10.27, respectively, after adjustment for age).
   Conclusions: This is the first clinical study to investigate the potential existence of genetic susceptibility to fracture non union. Even though no concrete conclusions can be obtained from this pilot study, our results indicate the existence of a potential genetically predetermined impairment within the BMP signalling cascade, initiated after a fracture and when combined with other risk factors could synergistically increase the susceptibility of a patient to develop non union. Further research is desirable in order to clarify the genetic component and its role and interaction with other risk factors in the development of atrophic long bone non union, as simple genetic testing may contribute to the early identification of patients at risk in the future and the on time intervention at the biologic aspects of bone healing.
C1 [Dimitriou, Rozalia; Giannoudis, Peter V.] Leeds Teaching Hosp NHS Trust, Acad Unit Trauma & Orthopaed Surg, LIMM Sect Musculoskeletal Dis, Leeds LS1 3EX, W Yorkshire, England.
   [Carr, Ian M.; Markham, Alexander F.] Univ Leeds, Sect Translat Med, Leeds Inst Mol Med, Leeds, W Yorkshire, England.
   [West, Robert M.] Univ Leeds, Biostat Unit, Div Epidemiol & Biostat, Leeds Inst Genet, Leeds, W Yorkshire, England.
C3 University of Leeds; University of Leeds; University of Leeds
RP Giannoudis, PV (通讯作者)，Leeds Teaching Hosp NHS Trust, Acad Unit Trauma & Orthopaed Surg, LIMM Sect Musculoskeletal Dis, Great George St, Leeds LS1 3EX, W Yorkshire, England.
EM pgiannoudi@aol.com
RI Giannoudis, Peter/AAA 3617 2020; West, Robert/C 3834 2008; Carr,
   ian/KWT 6173 2024
FU AO foundation, Switzerland [03 G43]
FX This project was supported by an outside funding from the AO foundation,
   Switzerland, grant No: 03 G43, for the purchase of laboratory materials.
CR Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   Akbarian S, 2006, BRAIN RES REV, V52, P293, DOI 10.1016/j.brainresrev.2006.04.001
   Aspenberg P, 2001, J BONE MINER RES, V16, P497, DOI 10.1359/jbmr.2001.16.3.497
   Bland JM, 2000, BRIT MED J, V320, P1468, DOI 10.1136/bmj.320.7247.1468
   Brinker MR., 2003, SKELETAL TRAUMA BASI, P507
   Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455
   Cuthbert AP, 2002, GASTROENTEROLOGY, V122, P867, DOI 10.1053/gast.2002.32415
   Devlin RD, 2003, ENDOCRINOLOGY, V144, P1972, DOI 10.1210/en.2002 220918
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Dimitriou R, 2006, INJURY, V37, pS20, DOI 10.1016/j.injury.2006.02.039
   Dixon ME, 2001, GENET MED, V3, P349, DOI 10.1097/00125817 200109000 00004
   Edgar CM, 2007, BONE, V40, P1389, DOI 10.1016/j.bone.2007.01.001
   Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS151
   Garcia Closas M, 2007, CANCER EPIDEM BIOMAR, V16, P2269, DOI 10.1158/1055 9965.EPI 07 0449
   Gazzerro E, 2006, REV ENDOCR METAB DIS, V7, P51, DOI 10.1007/s11154 006 9000 6
   Giannoudis PV, 2000, J BONE JOINT SURG BR, V82B, P655, DOI 10.1302/0301 620X.82B5.9899
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Horiki M, 2004, J CELL BIOL, V165, P433, DOI 10.1083/jcb.200311015
   Hyndman ME, 2002, HYPERTENSION, V39, P919, DOI 10.1161/01.HYP.0000013703.07316.7F
   Jena N, 1997, EXP CELL RES, V230, P28, DOI 10.1006/excr.1996.3411
   Jepsen KJ, 2007, MAMM GENOME, V18, P492, DOI 10.1007/s00335 007 9017 5
   Jiang Y, 2008, J ORTHOP RES, V26, P910, DOI 10.1002/jor.20623
   Justesen J, 2002, CALCIFIED TISSUE INT, V71, P36, DOI 10.1007/s00223 001 2059 x
   Lehmann K, 2007, AM J HUM GENET, V81, P388, DOI 10.1086/519697
   LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808
   Manigrasso MB, 2008, CALCIFIED TISSUE INT, V82, P465, DOI 10.1007/s00223 008 9144 3
   Miyazono K, 1999, BONE, V25, P91, DOI 10.1016/S8756 3282(99)00113 1
   Nakamura Y, 2009, J HUM GENET, V54, P1, DOI 10.1038/jhg.2008.6
   Praemer A., 1992, Musculoskeletal conditions in the United States, P85
   Ralston SH, 2007, P NUTR SOC, V66, P158, DOI 10.1017/S002966510700540X
   RAUNIO H, 1995, GENE, V159, P113, DOI 10.1016/0378 1119(94)00448 2
   Sémonin O, 2001, AM J MED GENET, V102, P314, DOI 10.1002/ajmg.1504
   Setakis E, 2006, GENOME RES, V16, P290, DOI 10.1101/gr.4346306
   Shintani N, 2007, ARTHRITIS RHEUM, V56, P1869, DOI 10.1002/art.22701
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Urano T, 2009, J BONE MINER METAB, V27, P562, DOI 10.1007/s00774 009 0068 4
   Vonlanthen S, 2007, ANTICANCER RES, V27, P4279
   Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543
   Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756 3282(96)00259 1
   Yoshimura Y, 2001, J BONE MINER RES, V16, P876, DOI 10.1359/jbmr.2001.16.5.876
   Zhang HB, 1996, DEVELOPMENT, V122, P2977
NR 42
TC 42
Z9 46
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD FEB 10
PY 2011
VL 12
AR 44
DI 10.1186/1471 2474 12 44
PG 11
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA 730MI
UT WOS:000288037000001
PM 21310029
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Meshram, MA
   Bhise, UO
   Makhal, PN
   Kaki, VR
AF Meshram, Minakshi A.
   Bhise, Utkarsha O.
   Makhal, Priyanka N.
   Kaki, Venkata Rao
TI Synthetically tailored and nature derived dual COX 2/5 LOX inhibitors:
   Structural aspects and SAR
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE 5 Lipoxygenase; Arachidonic acid pathway; Cyclooxygenase 2; Dual
   COX 2/5 LOX inhibitors; Inflammation
ID REVERSE TRANSCRIPTASE INHIBITORS; 5 LIPOXYGENASE ENZYMES SYNTHESIS;
   BIOLOGICAL EVALUATION; IN VITRO; ANTIINFLAMMATORY AGENTS; MOLECULAR
   DOCKING; CYCLOOXYGENASE 2 COX 2; CRYSTAL STRUCTURE; BOSWELLIC ACIDS;
   CANCER CELLS
AB Inflammation is a most complex pathological process that gives birth to different diseases. Different inflammatory mediators are released during an inflammation responsible for acute pain and chronic inflammatory diseases like cancer, asthma, rheumatoid arthritis, osteoarthritis, neurodegenerative diseases, metabolic and cardiovascular disorders. The arachidonic acid pathway, which results in the production of inflammatory mediators, provides several targets for anti inflammatory intervention. The most popularly used medications for inflammation are non steroidal anti  inflammatory agents (NSAIDs) but it has some limitations, in particular traditional NSAIDs which inhibit the COX pathway nonselectively, producing gastrointestinal side effects, and other adverse effects like stroke and renal failure. On the other hand, selective COX 2 inhibitors commonly known as `coxibs' produce cardiovascular side effects. Frequent inhibition of either cyclooxygenase or lipoxygenase enzyme switches the metabolism of arachidonic acid from one to another which could lead to serious consequences. Therefore, a need to develop novel, effective and safe anti inflammatory agents which can inhibit the release of both prostaglandins and leukotrienes from the respective cyclooxygenase and lipoxygenase pathways has emerged. This resulted in the discovery of new anti inflammatory agents derived from natural and synthetic sources as dual COX 2/5 LOX inhibitors. To further contribute towards the discovery in this field, we have attempted to summarize structural features and pharmacological activities of heterocyclic scaffolds and natural products explored as dual COX 2/5 LOX inhibitors. We have emphasized the designing of the dual inhibitors inspired by the previously reported COX 2 and 5 LOX inhibitors. This outline could render us to identify the best pharmacophores catering to dual COX 2/5 LOX inhibitory activity while improving their efficiency as anti inflammatory agents. (C) 2021 Elsevier Masson SAS. All rights reserved.
C1 [Meshram, Minakshi A.; Bhise, Utkarsha O.; Makhal, Priyanka N.; Kaki, Venkata Rao] Natl Inst Pharmaceut Educ & Res, Dept Chem Sci, Hyderabad 500037, Andhra Pradesh, India.
C3 National Institute of Pharmaceutical Education & Research, Hyderabad;
   National Institute of Pharmaceutical Education & Research, S.A.S. Nagar
   (Mohali)
RP Kaki, VR (通讯作者)，Natl Inst Pharmaceut Educ & Res, Dept Chem Sci, Hyderabad 500037, Andhra Pradesh, India.
EM kvenkata.rao@niperhyd.ac.in
OI Meshram, Minakshi/0000 0002 1710 870X; Makhal,
   Priyanka/0000 0003 0833 8738; Bhise, Utkarsha/0000 0003 2255 9879; KAKI,
   VENKATA RAO/0000 0002 2840 861X
FU Department of Pharmaceuticals (DoP), Ministry of Chemicals &
   Fertilizers, Government of India; NIPER fellowship;  [NIPER H/2021/199]
FX The manuscript bears the NIPER Hyderabad communication number
   NIPER H/2021/199. All the authors are grateful to NIPERHyderabad for
   facilities and thankful to Department of Pharmaceuticals (DoP), Ministry
   of Chemicals & Fertilizers, Government of India, for the award of NIPER
   fellowship.
CR Abdelgawad MA, 2018, BIOORG CHEM, V78, P103, DOI 10.1016/j.bioorg.2018.03.011
   Abdelgawad MA, 2017, BIOORG CHEM, V74, P212, DOI 10.1016/j.bioorg.2017.08.014
   Abdu Allah H.H., 2006, Med. Chem., V6, DOI [10.4172/2161 0444.1000317, DOI 10.4172/2161 0444.1000361, 10.4172/2161 0444.1000361]
   Afsar U.AHMED, 2011, [Frontiers in Biology, 生物学前沿], V6, P274
   Ammon HPT, 2006, PLANTA MED, V72, P1100, DOI 10.1055/s 2006 947227
   Asif M., 2016, MOD CHEM APPL, V4, P1, DOI DOI 10.4172/2329 6798.1000194
   Azad R, 2018, FITOTERAPIA, V131, P189, DOI 10.1016/j.fitote.2018.10.016
   Bano S, 2011, EUR J MED CHEM, V46, P5763, DOI 10.1016/j.ejmech.2011.08.015
   Batta AK, 1998, J LIPID RES, V39, P1641
   Baytas SN, 2014, BIOORGAN MED CHEM, V22, P3096, DOI 10.1016/j.bmc.2014.04.027
   BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   Bhale PS, 2017, BIOORG MED CHEM LETT, V27, P1502, DOI 10.1016/j.bmcl.2017.02.052
   Bhavanarushi S, 2014, MED CHEM RES, V23, P158, DOI 10.1007/s00044 013 0623 3
   Blobaum AL, 2007, J MED CHEM, V50, P1425, DOI 10.1021/jm0613166
   Borne R., 2013, FOYES PRINC MED CHEM, Vseventh, P955
   Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679
   Brunton R.H.D. Laurence L, 2014, PHARM BASIS THERAPEU, Vtwelfth
   Cai H, 2016, EUR J MED CHEM, V108, P89, DOI 10.1016/j.ejmech.2015.11.013
   Caliendo G, 2001, EUR J MED CHEM, V36, P517, DOI 10.1016/S0223 5234(01)01251 X
   Charlier C, 2006, J MED CHEM, V49, P186, DOI 10.1021/jm050870x
   Charlier C, 2003, EUR J MED CHEM, V38, P645, DOI 10.1016/S0223 5234(03)00115 6
   Chhabria MT, 2016, CURR TOP MED CHEM, V16, P2841, DOI 10.2174/1568026616666160506130731
   Choppara P, 2019, ARAB J CHEM, V12, P2721, DOI 10.1016/j.arabjc.2015.05.015
   Chougala BM, 2017, EUR J MED CHEM, V125, P101, DOI 10.1016/j.ejmech.2016.09.021
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   Cihan Üstündag G, 2016, J ENZYM INHIB MED CH, V31, P369, DOI 10.3109/14756366.2015.1024673
   Collins P., 1993, NEW ENGL J MED, V31, P161, DOI [10.1515/iral.1993.31.2.161, DOI 10.1515/IRAL.1993.31.2.161]
   Corigliano DM, 2018, PEERJ, V6, DOI 10.7717/peerj.5386
   Coruzzi Gabriella, 2007, Acta Biomed, V78, P96
   de Leval X, 2002, CURR MED CHEM, V9, P941, DOI 10.2174/0929867024606713
   Efferth T., 2011, Onco Therapeutics, V2, P303
   El Nagar MKS, 2018, BIOORG CHEM, V78, P80, DOI 10.1016/j.bioorg.2018.02.023
   FORBES JA, 1982, JAMA J AM MED ASSOC, V248, P2139, DOI 10.1001/jama.248.17.2139
   Frank PV, 2007, J CHEM SCI, V119, P41, DOI 10.1007/s12039 007 0007 7
   Garrett WS, 2010, CELL, V140, P859, DOI 10.1016/j.cell.2010.01.023
   Gautam S, 2018, TOXICOL APPL PHARM, V351, P57, DOI 10.1016/j.taap.2018.04.019
   Gauthier C, 2009, BIOORGAN MED CHEM, V17, P2002, DOI 10.1016/j.bmc.2009.01.022
   Gedawy EM, 2020, EUR J MED CHEM, V189, DOI 10.1016/j.ejmech.2020.112066
   Gilbert NC, 2020, NAT CHEM BIOL, V16, P783, DOI 10.1038/s41589 020 0544 7
   GILLARD J, 1989, CAN J PHYSIOL PHARM, V67, P456, DOI 10.1139/y89 073
   Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016
   Goksen US., 2010, HACETTEPE U ECZACILI, V1, P81
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Huang YZ, 2019, EUR J MED CHEM, V180, P41, DOI 10.1016/j.ejmech.2019.07.004
   Husain Asif, 2013, J Pharm Bioallied Sci, V5, P154, DOI 10.4103/0975 7406.111822
   Iram F, 2017, ASIAN PAC J TROP BIO, V7, P513, DOI 10.1016/j.apjtb.2017.05.001
   Ispikoudi M, 2010, EUR J MED CHEM, V45, P5635, DOI 10.1016/j.ejmech.2010.09.016
   Iyer PC, 2014, BIOORG MED CHEM LETT, V24, P1702, DOI 10.1016/j.bmcl.2014.02.045
   Jacob J, 2021, MED CHEM RES, V30, P236, DOI 10.1007/s00044 020 02655 9
   Jacob PJ, 2020, BIOORG CHEM, V100, DOI 10.1016/j.bioorg.2020.103882
   Jacob PJ, 2018, EUR J PHARM SCI, V121, P356, DOI 10.1016/j.ejps.2018.06.003
   Jeong GS, 2014, MINI REV ORG CHEM, V11, P316, DOI 10.2174/1570193X1103140915111703
   Jiang T, 2006, BIOORG MED CHEM LETT, V16, P2109, DOI 10.1016/j.bmcl.2006.01.066
   Joy MJ, 2018, FOOD RES INT, V106, P164, DOI 10.1016/j.foodres.2017.12.066
   Julémont F, 2004, MINI REV MED CHEM, V4, P633, DOI 10.2174/1389557043403747
   Kam PCA, 2000, ANAESTHESIA, V55, P442, DOI 10.1046/j.1365 2044.2000.01271.x
   Ketha A, 2020, FUTUR J PHARM SCI, V6, DOI 10.1186/s43094 020 00028 y
   Kiranmai M., 2017, IOSR J PHARM BIOL SC, V12, P84, DOI [10.9790/3008 1202028493, DOI 10.9790/3008 1202028493]
   Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772
   Kumar D, 2014, BIOORG MED CHEM LETT, V24, P5170, DOI 10.1016/j.bmcl.2014.09.085
   Kumbhare RM, 2012, BIOORG MED CHEM LETT, V22, P453, DOI 10.1016/j.bmcl.2011.10.106
   Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0
   Lamie PF, 2018, ARCH PHARM, V351, DOI 10.1002/ardp.201700311
   Lamie PF, 2016, EUR J MED CHEM, V123, P803, DOI 10.1016/j.ejmech.2016.08.013
   Landa P, 2013, NAT PROD COMMUN, V8, P105
   Landa P, 2012, PLANTA MED, V78, P326, DOI 10.1055/s 0031 1280430
   Lankau HJ, 2007, EUR J MED CHEM, V42, P873, DOI 10.1016/j.ejmech.2006.12.022
   Leláková V, 2019, FOOD CHEM, V285, P431, DOI 10.1016/j.foodchem.2019.01.128
   Li Z, 2019, EUR J MED CHEM, V169, P168, DOI 10.1016/j.ejmech.2019.03.008
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   Liu JB, 2006, CANCER CHEMOTH PHARM, V58, P306, DOI 10.1007/s00280 005 0161 x
   Lucas Guillherme Nobre Cavalcanti, 2019, Braz. J. Nephrol., V41, P124, DOI [10.1590/2175 8239 JBN 2018 0107, 10.1590/2175 8239 jbn 2018 0107]
   Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196 927
   MACKENZIE MA, 1990, LANCET, V335, P1534, DOI 10.1016/0140 6736(90)93080 9
   Marnett LJ, 1999, TRENDS PHARMACOL SCI, V20, P465, DOI 10.1016/S0165 6147(99)01385 1
   Marra RKF, 2012, MOLECULES, V17, P12961, DOI 10.3390/molecules171112961
   Martel Pelletier J, 2003, ANN RHEUM DIS, V62, P501, DOI 10.1136/ard.62.6.501
   McNeil JJ, 2018, NEW ENGL J MED, V379, P1509, DOI 10.1056/NEJMoa1805819
   Mert S, 2014, EUR J MED CHEM, V78, P86, DOI 10.1016/j.ejmech.2014.03.033
   Mitra S., 2015, THESIS
   Mitra S, 2015, BIOCHEMISTRY US, V54, P6333, DOI 10.1021/acs.biochem.5b00930
   Mohammed KO, 2014, CHEM BIOL DRUG DES, V84, P473, DOI 10.1111/cbdd.12336
   Mohan H., 2010, TXB PATHOLOGY, Vsixth, DOI [10.1097/00001888 195401000 00024, DOI 10.1097/00001888 195401000 00024]
   Morphy R., 2003, BURGER MED CHEM DRUG, P249
   Moussaieff A, 2009, J PHARM PHARMACOL, V61, P1281, DOI [10.1211/jpp/61.10.0003, 10.1211/jpp.61.10.0003]
   Murata M, 2018, ENVIRON HEALTH PREV, V23, DOI 10.1186/s12199 018 0740 1
   Naaz F, 2018, BIOORG CHEM, V81, P1, DOI 10.1016/j.bioorg.2018.07.029
   Nguyen HT, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 72840 8
   Vo NNQ, 2019, J NAT PROD, V82, P3311, DOI 10.1021/acs.jnatprod.9b00538
   O'connor N, 2003, QJM INT J MED, V96, P787, DOI 10.1093/qjmed/hcg138
   Orlando BJ, 2016, ACTA CRYSTALLOGR F, V72, P772, DOI 10.1107/S2053230X16014230
   Parente L, 2003, BIOCHEM PHARMACOL, V65, P153, DOI 10.1016/S0006 2952(02)01422 3
   Park K, 2014, VASC HEALTH RISK MAN, V10, P25, DOI 10.2147/VHRM.S54159
   de Andrade FDP, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 73203 z
   Piccionello AP, 2012, EUR J MED CHEM, V50, P441, DOI 10.1016/j.ejmech.2012.02.002
   Pinto DJP, 1999, BIOORG MED CHEM LETT, V9, P919, DOI 10.1016/S0960 894X(99)00105 5
   Pirlamarla P, 2016, TRENDS CARDIOVAS MED, V26, P675, DOI 10.1016/j.tcm.2016.04.011
   Puratchikody A, 2007, BIOORGAN MED CHEM, V15, P1083, DOI 10.1016/j.bmc.2006.10.025
   Qandeel NA, 2020, BIOORG CHEM, V102, DOI 10.1016/j.bioorg.2020.103890
   Rabiu Z, 2021, ENVIRON SCI POLLUT R, V28, P40535, DOI 10.1007/s11356 020 09209 x
   Racanè L, 2003, MOLECULES, V8, P342, DOI 10.3390/80300342
   Rådmark O, 2007, TRENDS BIOCHEM SCI, V32, P332, DOI 10.1016/j.tibs.2007.06.002
   Raju G.N., 2015, INT J PHARM CHEM, V5, P104, DOI 10.7439/ijpc.v5i4.1926
   Rakesh KS., 2014, ASIAN J BIOCH PHARM, V4, P316
   Ramachandran R, 2011, EUR J MED CHEM, V46, P1926, DOI 10.1016/j.ejmech.2011.02.036
   Reddy MVR, 2008, BIOORGAN MED CHEM, V16, P3907, DOI 10.1016/j.bmc.2008.01.047
   Rouzer CA, 2011, CHEM REV, V111, P5899, DOI 10.1021/cr2002799
   Rouzer CA, 2009, J LIPID RES, V50, pS29, DOI 10.1194/jlr.R800042 JLR200
   Rowlinson SW, 2003, J BIOL CHEM, V278, P45763, DOI 10.1074/jbc.M305481200
   Sahu PK, 2012, MED CHEM RES, V21, P3826, DOI 10.1007/s00044 011 9908 6
   Salvo F, 2014, EXPERT OPIN DRUG SAF, V13, P573, DOI 10.1517/14740338.2014.907792
   Santos SA, 2015, EUR J MED CHEM, V102, P320, DOI 10.1016/j.ejmech.2015.07.047
   Schaible AM, 2013, BIOCHEM PHARMACOL, V86, P476, DOI 10.1016/j.bcp.2013.04.015
   Scrivo R, 2011, AUTOIMMUN REV, V10, P369, DOI 10.1016/j.autrev.2010.12.006
   Seth K, 2014, ACS MED CHEM LETT, V5, P512, DOI 10.1021/ml400500e
   Shaaban MA, 2020, ARCH PHARM, V353, DOI 10.1002/ardp.202000027
   Sharma RN, 2009, J ENZYM INHIB MED CH, V24, P890, DOI 10.1080/14756360802519558
   Shetty AV, 2011, INT J ONCOL, V39, P635, DOI 10.3892/ijo.2011.1061
   Sibbald B, 2004, CAN MED ASSOC J, V171, P1027, DOI 10.1503/cmaj.1041606
   Singh P, 2015, J MED CHEM, V58, P5989, DOI 10.1021/acs.jmedchem.5b00952
   Singh P, 2015, EUR J MED CHEM, V97, P104, DOI 10.1016/j.ejmech.2015.04.044
   Sinha M, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/258209
   Sisa M, 2020, EUR J MED CHEM, V204, DOI 10.1016/j.ejmech.2020.112620
   Sladojevich F, 2008, ORG BIOMOL CHEM, V6, P3328, DOI 10.1039/b808895k
   Smith W.L., 1996, BIOCH LIPIDS LIPOPRO, V31, P283, DOI DOI 10.1016/S0167 7306(02)36015 0
   Smith WL, 2011, CHEM REV, V111, P5821, DOI 10.1021/cr2002992
   Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145
   Sobeh M, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108882
   Sravanthi TV, 2016, EUR J PHARM SCI, V91, P1, DOI 10.1016/j.ejps.2016.05.025
   Sztaricskai F, 1999, ARCH PHARM, V332, P321, DOI 10.1002/(SICI)1521 4184(19999)332:9<321::AID ARDP321>3.0.CO;2 A
   Taher ES, 2019, EUR J MED CHEM, V171, P372, DOI 10.1016/j.ejmech.2019.03.042
   Tang L, 2020, J NUTR BIOCHEM, V81, DOI 10.1016/j.jnutbio.2020.108379
   Tavolari S, 2008, CARCINOGENESIS, V29, P371, DOI 10.1093/carcin/bgm265
   Telvekar VN, 2012, BIOORG MED CHEM LETT, V22, P649, DOI 10.1016/j.bmcl.2011.10.064
   Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97
   Wang GC, 2014, BIOORGAN MED CHEM, V22, P2060, DOI 10.1016/j.bmc.2014.02.028
   WHO, WHO ESS MED MOD LIST
   WISEMAN EH, 1975, J PHARM SCI, V64, P1469, DOI 10.1002/jps.2600640909
   Xing M, 2014, MED CHEM RES, V23, P3274, DOI 10.1007/s00044 014 0909 0
   Yang L, 2021, J ETHNOPHARMACOL, V267, DOI 10.1016/j.jep.2020.113631
   Yasodha A., 2009, J PHARM SCI RES, V1, P127
   Yatam S, 2018, J MOL STRUCT, V1159, P193, DOI 10.1016/j.molstruc.2018.01.060
   Yu SH, 2020, J ETHNOPHARMACOL, V260, DOI 10.1016/j.jep.2020.112985
   Zarghi A, 2011, IRAN J PHARM RES, V10, P655
   Zatelli G.A., 2016, PLANTA MEDICA LETT, V3, pe17, DOI [10.1055/s 0042 102460, DOI 10.1055/S 0042 102460]
   Zhang Z, 2018, CANCER MANAG RES, V10, P4631, DOI 10.2147/CMAR.S175212
NR 146
TC 43
Z9 48
U1 1
U2 52
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0223 5234
EI 1768 3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD DEC 5
PY 2021
VL 225
AR 113804
DI 10.1016/j.ejmech.2021.113804
EA AUG 2021
PG 27
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA WA8DV
UT WOS:000703114900054
PM 34479036
DA 2025 08 17
ER

PT J
AU Wang, QS
   Shi, QQ
   Wang, ZQ
   Lu, JW
   Hou, J
AF Wang, Qiangsheng
   Shi, Qiqin
   Wang, Zhenqian
   Lu, Jiawen
   Hou, Jian
TI Integrating plasma proteomes with genome wide association data for
   causal protein identification in multiple myeloma
SO BMC MEDICINE
LA English
DT Article
DE Plasma proteome; Multiple myeloma; Drug target; Bayesian model;
   Mendelian randomization; Enrichment pathway analysis
ID MENDELIAN RANDOMIZATION; INSTRUMENTS; ANGIOGENESIS; INHIBITION; DISEASE;
   GROWTH; CELLS; BIAS
AB Background Multiple myeloma (MM) is a severely debilitating and fatal B cell neoplastic disease. The discovery of disease associated proteins with causal genetic evidence offers a chance to uncover novel therapeutic targets. Methods First, we comprehensively investigated the causal association between 2994 proteins and MM through two sample mendelian randomization (MR) analysis using summary level data from public genome wide association studies of plasma proteome (N = 3301 healthy individuals) and MM (598 cases and 180,756 controls). Sensitivity analyses were performed for these identified causal proteins. Furthermore, we pursued the exploration of enriched biological pathways, prioritized the therapeutic proteins, and evaluated their druggability using the KEGG pathway analysis, MR Bayesian model averaging analysis, and cross reference with current databases, respectively. Results We identified 13 proteins causally associated with MM risk (false discovery rate corrected P < 0.05). Six proteins were positively associated with the risk of MM, including nicotinamide phosphoribosyl transferase (NAMPT; OR [95% CI]: 1.35 [1.18, 1.55]), tyrosine kinase with immunoglobulin like and EGF like domains 1 (TIE1; 1.14 [1.06, 1.22]), neutrophil cytosol factor 2 (NCF2; 1.27 [1.12, 1.44]), carbonyl reductase 1, cAMP specific 3',5' cyclic phosphodiesterase 4D (PDE4D), platelet activating factor acetylhydrolase IB subunit beta (PAFAH1B2). Seven proteins were inversely associated with MM, which referred to suppressor of cytokine signaling 3 (SOCS3; 0.90 [0.86, 0.94]), Fc gamma receptor III B (FCGR3B; 0.75 [0.65,0.86]), glypican 1 (GPC1; 0.69 [0.58,0.83]), follistatin related protein 1, protein tyrosine phosphatase non receptor type 4 (PTPN4), granzyme B, complement C1q subcomponent subunit C (C1QC). Three of the causal proteins, SOCS3, FCGR3B, and NCF2, were enriched in the osteoclast differentiation pathway in KEGG enrichment analyses while GPC1 (marginal inclusion probability (MIP):0.993; model averaged causal effects (MACE):   0.349), NAMPT (MIP:0.433; MACE:   0.113), and NCF2 (MIP:0.324; MACE:0.066) ranked among the top three MM associated proteins according to MR BMA analyses. Furthermore, therapeutics targeting four proteins are currently under evaluation, five are druggable and four are future breakthrough points. Conclusions Our analysis revealed a set of 13 novel proteins, including six risk and seven protective proteins, causally linked to MM risk. The discovery of these MM associated proteins opens up the possibility for identifying novel therapeutic targets, further advancing the integration of genome and proteome data for drug development.
C1 [Wang, Qiangsheng] Ningbo Hangzhou Bay Hosp, Dept Hematol, Ningbo 315000, Zhejiang, Peoples R China.
   [Shi, Qiqin] Ningbo Hangzhou Bay Hosp, Dept Ophthalmol, Ningbo 315000, Zhejiang, Peoples R China.
   [Wang, Zhenqian; Lu, Jiawen] Sun Yat Sen Univ, Sch Publ Hlth Shenzhen, Shenzhen 518107, Guangdong, Peoples R China.
   [Hou, Jian] Shanghai Jiao Tong Univ, Renji Hosp, Dept Hematol, Sch Med, Shanghai 200127, Peoples R China.
C3 Sun Yat Sen University; Shanghai Jiao Tong University
RP Hou, J (通讯作者)，Shanghai Jiao Tong Univ, Renji Hosp, Dept Hematol, Sch Med, Shanghai 200127, Peoples R China.
EM houjian@medmail.com.cn
RI Lu, Jiawen/IQT 7456 2023; Wang, Zhenqian/GRS 9626 2022
OI Wang, Zhenqian/0000 0001 8700 0836; 
FU We appreciate a lot for the funding of the Ningbo Science and Technology
   Bureau (No.2023J204 and No. 2022J053). We also appreciate all
   investigators for sharing the GWAS datasets. [2023J204, 2022J053];
   Ningbo Science and Technology Bureau
FX We appreciate a lot for the funding of the Ningbo Science and Technology
   Bureau (No.2023J204 and No. 2022J053). We also appreciate all
   investigators for sharing the GWAS datasets.
CR Bowden J, 2017, STAT MED, V36, P1783, DOI 10.1002/sim.7221
   Bowden J, 2016, INT J EPIDEMIOL, V45, P1961, DOI 10.1093/ije/dyw220
   Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965
   Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080
   Brion MJA, 2013, INT J EPIDEMIOL, V42, P1497, DOI 10.1093/ije/dyt179
   Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758
   Burgess S, 2011, INT J EPIDEMIOL, V40, P755, DOI 10.1093/ije/dyr036
   Cai XW, 2018, CANCER MED US, V7, P2504, DOI 10.1002/cam4.1463
   Cardinale A, 2018, CNS NEUROSCI THER, V24, P319, DOI 10.1111/cns.12834
   Cea M, 2012, BLOOD, V120, P3519, DOI 10.1182/blood 2012 03 416776
   Chen Y, 2021, J PROTEOME RES, V20, P2673, DOI 10.1021/acs.jproteome.1c00007
   Chiou J, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10366 2
   Considine DP, 2021, GYNECOL ONCOL, V160, P506, DOI 10.1016/j.ygyno.2020.11.016
   Cowan AJ, 2022, JAMA J AM MED ASSOC, V327, P464, DOI 10.1001/jama.2022.0003
   D'Amico G, 2014, J CLIN INVEST, V124, P824, DOI 10.1172/JCI68897
   Finan C, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag1166
   Fu J, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 39769 8
   Taliun SAG, 2020, NAT GENET, V52, P550, DOI 10.1038/s41588 020 0622 5
   Gan JQ, 2022, EXP MOL MED, V54, P1290, DOI 10.1038/s12276 022 00837 6
   Gupta DG, 2023, CANCER AM CANCER SOC, V129, P1217, DOI 10.1002/cncr.34665
   Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408
   Hemani G, 2017, PLOS GENET, V13, DOI [10.1371/journal.pgen.1007081, 10.1371/journal.pgen.1007149]
   Henry A, 2022, CIRCULATION, V145, P1205, DOI 10.1161/CIRCULATIONAHA.121.056663
   Hussain M, 2023, BLOOD REV, V57, DOI 10.1016/j.blre.2022.100999
   Joshi H, 2021, CANCER EPIDEMIOL, V73, DOI 10.1016/j.canep.2021.101974
   Julian TH, 2023, ELIFE, V12, DOI 10.7554/eLife.82546
   Kaur SP, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 88519 7
   Kim G, 2015, ONCOGENE, V34, P671, DOI 10.1038/onc.2014.4
   Klimentidis YC, 2018, INT J OBESITY, V42, P1161, DOI 10.1038/s41366 018 0120 3
   Korotchkina L, 2020, LEUKEMIA, V34, P1828, DOI 10.1038/s41375 019 0692 5
   Kumari R, 2021, BRIT J CANCER, V124, P1428, DOI 10.1038/s41416 020 01237 1
   Kurki MI, 2023, NATURE, V613, P508, DOI 10.1038/s41586 022 05473 8
   La Porta S, 2018, J CLIN INVEST, V128, P834, DOI 10.1172/JCI94674
   Lawlor DA, 2008, STAT MED, V27, P1133, DOI 10.1002/sim.3034
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Liang P, 2013, HAEMATOLOGICA, V98, P288, DOI 10.3324/haematol.2012.065607
   Liu MZ, 2019, NAT GENET, V51, P237, DOI 10.1038/s41588 018 0307 5
   Liu ZK, 2021, MOL CANCER, V20, DOI 10.1186/s12943 021 01377 9
   Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402
   Mahony R, 2016, CELL MOL LIFE SCI, V73, P3323, DOI 10.1007/s00018 016 2234 x
   Mendez D, 2019, NUCLEIC ACIDS RES, V47, pD930, DOI 10.1093/nar/gky1075
   Mishra RR, 2018, CLIN CANCER RES, V24, P1987, DOI 10.1158/1078 0432.CCR 17 2776
   Ng YLD, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 28515 1
   Palmos AB, 2022, PLOS GENET, V18, DOI 10.1371/journal.pgen.1010042
   Palumbo A, 2011, BLOOD, V118, P4519, DOI 10.1182/blood 2011 06 358812
   Paolillo R, 2022, HAEMATOLOGICA, V107, P2562, DOI 10.3324/haematol.2021.279889
   Quach ND, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 47874 2
   Rahrmann EP, 2009, CANCER RES, V69, P4388, DOI 10.1158/0008 5472.CAN 08 3901
   Raimondo S, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045 018 0689 y
   Ren HL, 2022, CANCER LETT, V541, DOI 10.1016/j.canlet.2022.215749
   Rickles RJ, 2010, BLOOD, V116, P593, DOI 10.1182/blood 2009 11 252668
   Shah N, 2020, LEUKEMIA, V34, P985, DOI 10.1038/s41375 020 0734 z
   Shanmugarajan S, 2010, ENDOCRINOLOGY, V151, P4389, DOI 10.1210/en.2010 0244
   Shao F, 2021, CURR MED CHEM, V28, P5137, DOI 10.2174/0929867328666201207202012
   Shu X, 2022, BRIT J CANCER, V127, P1507, DOI 10.1038/s41416 022 01923 2
   Smit RAJ, 2019, EPIDEMIOLOGY, V30, P813, DOI 10.1097/EDE.0000000000001072
   Sun BB, 2018, NATURE, V558, P73, DOI 10.1038/s41586 018 0175 2
   Terpos E, 2021, LANCET ONCOL, V22, pE119, DOI 10.1016/S1470 2045(20)30559 3
   Venkateshaiah SU, 2013, EXP HEMATOL, V41, P547, DOI 10.1016/j.exphem.2013.02.008
   Wang QS, 2022, INT J CANCER, V151, P1750, DOI 10.1002/ijc.34214
   Westhrin M, 2020, BLOOD, V136, P2656, DOI 10.1182/blood.2020006045
   Yang HL, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.940306
   Yang Z, 2021, J CANCER RES CLIN, V147, P3279, DOI 10.1007/s00432 021 03740 1
   Yengo L, 2018, HUM MOL GENET, V27, P3641, DOI 10.1093/hmg/ddy271
   Zhang JX, 2018, ONCOGENE, V37, P2660, DOI 10.1038/s41388 018 0162 y
   Zhong YN, 2020, J CONTROL RELEASE, V320, P421, DOI 10.1016/j.jconrel.2020.02.004
   Zhou W, 2020, NAT GENET, V52, P634, DOI 10.1038/s41588 020 0621 6
   Zhu ZH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02317 2
   Zuber V, 2021, INT J EPIDEMIOL, V50, P893, DOI 10.1093/ije/dyaa216
   Zuber V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 13870 3
NR 70
TC 19
Z9 20
U1 0
U2 26
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1741 7015
J9 BMC MED
JI BMC Med.
PD SEP 29
PY 2023
VL 21
IS 1
AR 377
DI 10.1186/s12916 023 03086 0
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA T4VY9
UT WOS:001077993700003
PM 37775746
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Haffner Luntzer, M
   Kemmler, J
   Heidler, V
   Prystaz, K
   Schinke, T
   Amling, M
   Kovtun, A
   Rapp, AE
   Ignatius, A
   Liedert, A
AF Haffner Luntzer, Melanie
   Kemmler, Julia
   Heidler, Verena
   Prystaz, Katja
   Schinke, Thorsten
   Amling, Michael
   Kovtun, Anna
   Rapp, Anna E.
   Ignatius, Anita
   Liedert, Astrid
TI Inhibition of Midkine Augments Osteoporotic Fracture Healing
SO PLOS ONE
LA English
DT Article
ID TRABECULAR BONE FORMATION; RETINOIC ACID; MICE LACKING; ESTROGEN;
   GROWTH; PROTEIN; REPAIR; PERIOD; MODEL; AGE
AB The heparin binding growth and differentiation factor midkine (Mdk) is proposed to negatively regulate osteoblast activity and bone formation in the adult skeleton. As Mdk deficient mice were protected from ovariectomy (OVX) induced bone loss, this factor may also play a role in the pathogenesis of postmenopausal osteoporosis. We have previously demonstrated that Mdk negatively influences bone regeneration during fracture healing. Here, we investigated whether the inhibition of Mdk using an Mdk antibody (Mdk Ab) improves compromised bone healing in osteoporotic OVX mice. Using a standardized femur osteotomy model, we demonstrated that Mdk serum levels were significantly enhanced after fracture in both non OVX and OVX mice, however, the increase was considerably greater in osteoporotic mice. Systemic treatment with the Mdk Ab significantly improved bone healing in osteoporotic mice by increasing bone formation in the fracture callus. On the molecular level, we demonstrated that the OVX induced reduction of the osteoanabolic beta catenin signaling in the bony callus was abolished by Mdk Ab treatment. Furthermore, the injection of the Mdk Ab increased trabecular bone mass in the skeleton of the osteoporotic mice. These results implicate that antagonizing Mdk may be useful for the therapy of osteoporosis and osteoporotic fracture healing complications.
C1 [Haffner Luntzer, Melanie; Kemmler, Julia; Heidler, Verena; Prystaz, Katja; Kovtun, Anna; Rapp, Anna E.; Ignatius, Anita; Liedert, Astrid] Univ Med Ctr Ulm, Inst Orthoped Res & Biomech, Ulm, Germany.
   [Schinke, Thorsten; Amling, Michael] Univ Med Ctr Hamburg Eppendorf, Inst Osteol & Biomech, Hamburg, Germany.
C3 Ulm University; University of Hamburg; University Medical Center
   Hamburg Eppendorf
RP Liedert, A (通讯作者)，Univ Med Ctr Ulm, Inst Orthoped Res & Biomech, Ulm, Germany.
EM astrid.liedert@uni ulm.de
RI ; Rapp, Anna Elise/L 8807 2016; Ignatius, Anita/M 6012 2013; Rapp,
   Anna/L 8807 2016; Haffner Luntzer, Melanie/L 3562 2019; Vikman,
   Anna/F 1115 2017
OI Fischer, Verena/0000 0001 7039 8008; Rapp, Anna
   Elise/0000 0001 5122 765X; Haffner Luntzer, Melanie/0000 0002 3333 2613;
   Vikman, Anna/0000 0001 8531 9712; 
FU German Research Foundation [IG 18 3/3, AM103/10 3]; Elsbeth Bonhoff
   Foundation
FX This work was supported by grants from the German Research Foundation
   (IG 18 3/3 and AM103/10 3) and from the Elsbeth Bonhoff Foundation.
   http://www.dfg.de http://www.elsbeth bonhoff stiftung.de.
CR [Anonymous], TECHNICAL REPORT
   Beil FT, 2010, J TRAUMA, V69, P1259, DOI 10.1097/TA.0b013e3181c4544d
   Bindl R, 2013, J ORTHOP RES, V31, P1851, DOI 10.1002/jor.22416
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Davey DA, 1998, S AFR MED J, V88, P1419
   Diamond Stanic MK, 2011, AM J PHYSIOL RENAL, V300, pF139, DOI 10.1152/ajprenal.00249.2010
   DIDDLE AW, 1984, SOUTH MED J, V77, P868, DOI 10.1097/00007611 198407000 00020
   Haffner Luntzer M, 2016, BRIT J PHARMACOL, V173, P2237, DOI 10.1111/bph.13503
   Haffner Luntzer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116282
   Histing T, 2013, J INVEST SURG, V26, P30, DOI 10.3109/08941939.2012.687435
   Histing T, 2012, J SURG RES, V175, P271, DOI 10.1016/j.jss.2011.03.052
   JAWORSKI ZF, 1971, ISRAEL J MED SCI, V7, P491
   Kondoh S, 2014, BONE, V60, P68, DOI 10.1016/j.bone.2013.12.005
   Kubo T, 1999, J STEROID BIOCHEM, V68, P197, DOI 10.1016/S0960 0760(99)00032 1
   Li CY, 2011, BONE, V49, P1178, DOI 10.1016/j.bone.2011.08.012
   Liedert A, 2011, BONE, V48, P945, DOI 10.1016/j.bone.2010.12.019
   Lu CY, 2008, J ORTHOP RES, V26, P1384, DOI 10.1002/jor.20667
   Lu CY, 2005, J ORTHOP RES, V23, P1300, DOI 10.1016/j.orthres.2005.04.003
   McCann RM, 2008, J ORTHOP RES, V26, P384, DOI 10.1002/jor.20505
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   MITSIADIS TA, 1995, J CELL BIOL, V129, P267, DOI 10.1083/jcb.129.1.267
   MURAMATSU T, 1993, INT J DEV BIOL, V37, P183
   Namkung Matthai H, 2001, BONE, V28, P80, DOI 10.1016/S8756 3282(00)00414 2
   Narisawa S, 2007, J BONE MINER RES, V22, P1700, DOI 10.1359/JBMR.070714
   Neunaber C, 2010, J BONE MINER RES, V25, P1724, DOI 10.1002/jbmr.75
   Nikolaou VS, 2009, INJURY, V40, P663, DOI 10.1016/j.injury.2008.10.035
   Ohta S, 1999, J BONE MINER RES, V14, P1132, DOI 10.1359/jbmr.1999.14.7.1132
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Pang J, 2014, REJUVENATION RES
   Röntgen V, 2010, J ORTHOP RES, V28, P1456, DOI 10.1002/jor.21148
   Wehrle E, 2015, DIS MODEL MECH, V8, P93, DOI 10.1242/dmm.018622
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Yukata K, 2014, BONE, V62, P79, DOI 10.1016/j.bone.2014.02.002
NR 34
TC 21
Z9 21
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUL 13
PY 2016
VL 11
IS 7
AR e0159278
DI 10.1371/journal.pone.0159278
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DQ9CP
UT WOS:000379508300077
PM 27410432
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Choi, BY
   Chang, SH
   Cho, HJ
   Kang, EH
   Shin, K
   Song, YW
   Lee, YJ
AF Choi, B. Y.
   Chang, S. H.
   Cho, H. J.
   Kang, E. H.
   Shin, K.
   Song, Y. W.
   Lee, Y. J.
TI The association of radiographic progression with serum R spondin 1
   (RSPO1) levels or Dickkopf 1 (DKK1)/RSPO1 ratios in rheumatoid arthritis
   patients: clinical evidence for reciprocal inhibition between DKK1 and
   RSPO1
SO SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
LA English
DT Article
ID WNT SIGNALING PATHWAY; OSTEOBLAST FUNCTION; JOINT DESTRUCTION;
   EXPRESSION; DIFFERENTIATION; COMPONENTS; PROTEINS; LINK
AB Objectives: To investigate the clinical implications of serum levels of R spondin 1 (RSPO1), a natural antagonist for Dickkopf 1 (DKK1), and of DKK1/RSPO1 ratios in rheumatoid arthritis (RA) patients.
   Method: Serum DKK1 and RSPO1 levels were measured in 102 RA patients and 39 age and gender matched healthy controls. In addition, DKK1 and RSPO1 levels were determined prior to and 3 months after anti tumour necrosis factor alpha (anti TNF alpha) therapy in 15 RA patients. Clinical and laboratory data and baseline radiographs of the hands and feet were obtained. Serial radiographs were evaluated in 83 RA patients. Radiographic joint damage was assessed by the modified Sharp/van der Heijde score (SHS).
   Results: Serum RSPO1 levels were significantly reduced whereas serum DKK1 levels and DKK1/RSPO1 ratios were significantly increased in RA patients compared with controls (all p < 0.0001). Anti TNF alpha treatment significantly suppressed DKK1/RSPO1 ratios (p < 0.01). In contrast to DKK1 or RSPO1 levels, the ratios were significantly associated with erosive disease, elevated acute phase reactants, Disease Activity Score in 28 joints (DAS28) > 3.2, and radiographic progression rate (all p < 0.05). Although the RA patients with radiographic progression exhibited significantly increased DKK1 and reduced RSPO1 levels (p < 0.05), only the DKK1/RSPO1 ratio (log transformed) was found to be a significant predictor of subsequent radiographic progression [odds ratio (OR) 2.07, p < 0.01].
   Conclusions: In this study, the presence of RSPO1 in the circulation was shown for the first time. Our results suggest that the serum DKK1/RSPO1 ratio represents a better predictor of structural progression than either DKK1 or RSPO1 levels alone in RA patients.
C1 [Choi, B. Y.; Chang, S. H.; Cho, H. J.; Kang, E. H.; Lee, Y. J.] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Songnam 463707, Gyeonggi Do, South Korea.
   [Choi, B. Y.; Song, Y. W.; Lee, Y. J.] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea.
   [Chang, S. H.] Seoul Natl Univ, Coll Med, WCU Dept Mol Med & Biopharmaceut Sci, Med Res Inst, Seoul, South Korea.
   [Shin, K.; Song, Y. W.] Seoul Natl Univ, Dept Internal Med, Borame Med Ctr, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University (SNU)
RP Lee, YJ (通讯作者)，Seoul Natl Univ, Bundang Hosp, Dept Internal Med, 166 Gumi Ro, Songnam 463707, Gyeonggi Do, South Korea.
EM yn35@snu.ac.kr
FU Sanofi Aventis Korea Company Ltd [800 20120446]; Korea Healthcare
   Technology RD Project; Ministry of Health and Welfare, Republic of Korea
   [A102065]; World Class University programme of the Ministry of
   Education, Science and Technology (MEST); National Research Foundation
   of Korea [R31 2008 000 10103 0]
FX This research was supported by the Sanofi Aventis Korea Company Ltd
   (Grant no. 800 20120446), a grant of the Korea Healthcare Technology R&D
   Project, the Ministry of Health and Welfare, Republic of Korea
   (A102065), and the World Class University programme of the Ministry of
   Education, Science and Technology (MEST) and the National Research
   Foundation of Korea (Grant no. R31 2008 000 10103 0).
CR Appel H, 2009, ARTHRITIS RHEUM US, V60, P3257, DOI 10.1002/art.24888
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   de Rooy DPC, 2013, ANN RHEUM DIS, V72, P769, DOI 10.1136/annrheumdis 2012 202184
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Friedman MS, 2009, J BIOL CHEM, V284, P14117, DOI 10.1074/jbc.M808337200
   Garnero P, 2008, J RHEUMATOL, V35, P2313, DOI 10.3899/jrheum.080356
   Gasparyan AY, 2011, RHEUMATOL INT, V31, P153, DOI 10.1007/s00296 010 1446 x
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Grandaunet B, 2011, ARTHRITIS RHEUM US, V63, P662, DOI 10.1002/art.30163
   Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019
   Hardy R, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4065
   Kim KA, 2006, CELL CYCLE, V5, P23, DOI 10.4161/cc.5.1.2305
   Kim KA, 2008, MOL BIOL CELL, V19, P2588, DOI 10.1091/mbc.E08 02 0187
   Knevel R, 2013, SCAND J RHEUMATOL, V42, P182, DOI 10.3109/03009742.2012.728618
   Krönke G, 2010, ARTHRITIS RHEUM US, V62, P2303, DOI 10.1002/art.27496
   Lethaby A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004525.pub2
   Lories R, 2011, NAT REV RHEUMATOL, V7, P700, DOI 10.1038/nrrheum.2011.156
   Lu WY, 2008, FEBS LETT, V582, P643, DOI 10.1016/j.febslet.2008.01.035
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Maradit Kremers H, 2005, ARTHRITIS RHEUM US, V52, P722, DOI 10.1002/art.20878
   Matzelle MM, 2012, ARTHRITIS RHEUM US, V64, P1540, DOI 10.1002/art.33504
   Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Rabelo FD, 2010, AUTOIMMUN REV, V9, P207, DOI 10.1016/j.autrev.2009.08.003
   Seror R, 2012, ARTHRITIS RHEUM US, V64, pS900
   Smolen JS, 2005, ARTHRITIS RHEUM, V52, P1020, DOI 10.1002/art.20982
   Ueland T, 2009, ARTERIOSCL THROM VAS, V29, P1228, DOI 10.1161/ATVBAHA.109.189761
   van der Heijde D, 1999, J RHEUMATOL, V26, P743
   Voorzanger Rousselot N, 2009, ANN RHEUM DIS, V68, P1513, DOI 10.1136/ard.2008.102350
   Walsh NC, 2009, J BONE MINER RES, V24, P1572, DOI [10.1359/JBMR.090320, 10.1359/jbmr.090320]
   Wang SY, 2011, J RHEUMATOL, V38, P821, DOI 10.3899/jrheum.100089
   Youssef PP, 1997, ARTHRITIS RHEUM US, V40, P1400, DOI 10.1002/art.1780400807
NR 34
TC 4
Z9 5
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300 9742
EI 1502 7732
J9 SCAND J RHEUMATOL
JI Scand. J. Rheumatol.
PY 2014
VL 43
IS 6
BP 453
EP 461
DI 10.3109/03009742.2014.905629
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA AU8OA
UT WOS:000345854600002
PM 25178409
DA 2025 08 17
ER

PT J
AU Kang, WS
   Nguyen, K
   McKenna, CE
   Sewell, WF
   McKenna, MJ
   Jung, DH
AF Kang, Woo Seok
   Nguyen, Kim
   McKenna, Charles E.
   Sewell, William F.
   McKenna, Michael J.
   Jung, David H.
TI Intracochlear Drug Delivery Through the Oval Window in Fresh Cadaveric
   Human Temporal Bones
SO OTOLOGY & NEUROTOLOGY
LA English
DT Article
DE Bisphosphonates; Fluorescence imaging; Human inner ear; Inner ear drug
   delivery; Otosclerosis
ID COCHLEAR IMPLANTATION; PERILYMPHATIC SCALAE; SPIRAL LIGAMENT;
   BISPHOSPHONATE; COMMUNICATION; EAR
AB Hypothesis:Drug delivered to the oval window can diffuse to the apex of the human cochlea.Background:We have previously demonstrated that zoledronate, a nitrogen containing bisphosphonate, can arrest the sensorineural hearing loss in cochlear otosclerosis. We have also shown that, in animals, delivery of bisphosphonate into the cochlea can dramatically increase delivery efficiency. Intracochlear drug delivery has the potential to increase local concentration of drug while decreasing the risk of systemic toxicity. In the present study, a fluorescently labeled bisphosphonate compound (6 FAM ZOL) was introduced into the human cochlea through the oval window and its distribution within the temporal bone was quantified.Methods:In three fresh human temporal bones, we introduced 6 FAM ZOL via the oval window. We compared these specimens to control specimens treated with artificial perilymph alone. Specimens were then processed, embedded into methyl methacrylate, and ground to the mid modiolar axis. We quantified the fluorescence in confocal images.Results:We found 6 FAM ZOL to be distributed up to the apical cochlear turn. In specimens treated with 6 FAM ZOL, we identified a strong baso apical gradient of fluorescent signal along the lateral cochlear wall and the modiolus both in the scala vestibuli and in the scala tympani.Conclusion:Bisphosphonate introduced via the oval window in the human cochlea can be delivered up to the apical cochlear turn. Interscalar communication is likely to play an important role in determining patterns of drug delivery in the inner ear.
C1 [Kang, Woo Seok; McKenna, Michael J.; Jung, David H.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
   [Kang, Woo Seok; Sewell, William F.; McKenna, Michael J.; Jung, David H.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
   [Kang, Woo Seok; McKenna, Michael J.; Jung, David H.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
   [Nguyen, Kim; McKenna, Charles E.] Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   Eye & Ear Infirmary; Harvard University; Harvard University Medical
   Affiliates; Massachusetts Eye & Ear Infirmary; Harvard University;
   Harvard Medical School; University of Southern California
RP Jung, DH (通讯作者)，Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
EM david_jung@meei.harvard.edu
RI Nguyen, Kim/JWP 3649 2024
FU NIDCD [R01 DC009837]
FX The authors thank Kris Kristiansen for excellent technical support. The
   authors also thank Diane Jones of the Massachusetts Eye and Ear
   Infirmary Temporal Bone Histopathology Laboratory for assistance in
   procuring the cadaveric specimens and Jeananne Phillips for assistance
   in using the Massachusetts Eye and Ear Infirmary Surgical Skills
   Laboratory. This work was primarily supported by NIDCD grant R01
   DC009837. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of Harvard University
   and its affiliated academic health care centers, or the National
   Institutes of Health.
CR Allen MR, 2011, BONE, V49, P56, DOI 10.1016/j.bone.2010.10.159
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Chole RA, 2001, OTOL NEUROTOL, V22, P249, DOI 10.1097/00129492 200103000 00023
   Doherty JK, 2004, OTOL NEUROTOL, V25, P457, DOI 10.1097/00129492 200407000 00010
   IGARASHI M, 1986, ACTA OTO LARYNGOL, V101, P161, DOI 10.3109/00016488609132823
   Kabbara B, 2015, OTOL NEUROTOL, V36, pE73, DOI 10.1097/MAO.0000000000000692
   Kang WS, 2015, OTOL NEUROTOL, V36, P953, DOI 10.1097/MAO.0000000000000786
   Kashemirov BA, 2008, BIOCONJUGATE CHEM, V19, P2308, DOI 10.1021/bc800369c
   KUCUK B, 1991, J ELECTRON MICROSC, V40, P193
   OHYAMA K, 1988, HEARING RES, V35, P119, DOI 10.1016/0378 5955(88)90111 6
   Paasche G, 2003, OTOL NEUROTOL, V24, P222, DOI 10.1097/00129492 200303000 00016
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Peters G, 2010, J LARYNGOL OTOL, V124, P1263, DOI 10.1017/S0022215110001155
   Quesnel AM, 2012, OTOL NEUROTOL, V33, P1308, DOI 10.1097/MAO.0b013e318268d1b3
   Ramsden R, 2007, ADV OTO RHINO LARYNG, V65, P328, DOI 10.1159/000098855
   Rasband, 1997, IMAGEJ
   Rask Andersen H, 2006, EAR HEARING, V27, P457, DOI 10.1097/01.aud.0000233864.32183.81
   Roy S, 2012, NANOMEDICINE UK, V7, P55, DOI [10.2217/nnm.11.84, 10.2217/NNM.11.84]
   Salt AN, 2015, JARO J ASSOC RES OTO, V16, P357, DOI 10.1007/s10162 015 0512 1
   Salt AN, 2012, HEARING RES, V283, P14, DOI 10.1016/j.heares.2011.11.012
   SALT AN, 1991, HEARING RES, V56, P37, DOI 10.1016/0378 5955(91)90151 X
   Semaan MT, 2012, AM J OTOLARYNG, V33, P608, DOI 10.1016/j.amjoto.2012.05.001
   Shinomori Y, 2001, ANN OTO RHINOL LARYN, V110, P91, DOI 10.1177/000348940111000117
   Sun ST, 2011, PHOSPHORUS SULFUR, V186, P970, DOI 10.1080/10426507.2010.526674
   U. S. National Institutes of Health, SAF TOL EFF CGF166 P
   Zou J, 2005, AUDIOL NEURO OTOL, V10, P145, DOI 10.1159/000084024
NR 26
TC 22
Z9 25
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1531 7129
EI 1537 4505
J9 OTOL NEUROTOL
JI Otol. Neurotol.
PD MAR
PY 2016
VL 37
IS 3
BP 218
EP 222
DI 10.1097/MAO.0000000000000964
PG 5
WC Clinical Neurology; Otorhinolaryngology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Otorhinolaryngology
GA DD5UK
UT WOS:000369989800002
PM 26859540
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Chmielewska, E
   Mazur, Z
   Kempinska, K
   Wietrzyk, J
   Piatek, A
   Kuryszko, JJ
   Kielbowicz, Z
   Kafarski, P
AF Chmielewska, Ewa
   Mazur, Zuzanna
   Kempinska, Katarzyna
   Wietrzyk, Joanna
   Piatek, Anita
   Kuryszko, Jan J.
   Kielbowicz, Zdzislaw
   Kafarski, Pawel
TI N ARYLAMINOMETHYLENEBISPHOSPHONATES BEARING FLUORINE ATOMS:
   SYNTHESIS AND ANTIOSTEOPOROTIC ACTIVITY
SO PHOSPHORUS SULFUR AND SILICON AND THE RELATED ELEMENTS
LA English
DT Article; Proceedings Paper
CT IRIS 14th International Symposium on Inorganic Ring Systems
CY JUL 26 31, 2015
CL Univ Regensburg, Regensburg, GERMANY
SP FCI, DFG, RSC, ChemComm, Dalton Transact, MBRAUN, Infineon, Heidolph, SIGMA, Taylor & Francis, Wiley Vch, IRIS
HO Univ Regensburg
DE Bisphosphonic acids; three component reaction; osteoporosis;
   macrophage like J774E cells
ID BISPHOSPHONATES; OSTEOPOROSIS; MECHANISMS
AB A series of N phenyl and N pyridyl aminomethylenebisphosphonates substituted in their aromatic rings with fluorine atoms or trifluoromethyl groups have been synthesized by a three component approach. They were screened for potential antiosteoporetic activity using mouse macrophage like J774E cells. Most of the compounds appeared to be moderate inhibitors of macrophage cells proliferation compared to known the antiosteoporetic drug, Incandronate. Their potency was compared with their structural analogues, hydroxymethylene bisphosphonate 2 and ethylidenebisphosphonates 3, which appeared to be equipotent. Although the aminomethylenebisphosphonates 1 show low stability in aqueous solutions, the most stable, i.e., N (3 trifluoromethylphenyl) aminomethylenebisphosphonic acid, was chosen for in vivo testing on sheep with induced osteoporosis. This compound had marginal influence on the bone structure recovery.
C1 [Chmielewska, Ewa; Mazur, Zuzanna] Wroclaw Univ Technol, Fac Chem, Dept Bioorgan Chem, PL 50370 Wroclaw, Poland.
   [Kempinska, Katarzyna; Wietrzyk, Joanna; Kafarski, Pawel] Polish Acad Sci, Inst Immunol & Expt Therapy, PL 53114 Wroclaw, Poland.
   [Piatek, Anita; Kuryszko, Jan J.; Kielbowicz, Zdzislaw] Wroclaw Univ Environm & Life Sci, Fac Vet Med, PL 50375 Wroclaw, Poland.
C3 Wroclaw University of Science & Technology; Polish Academy of Sciences;
   Hirszfeld Institute of Immunology & Experimental Therapy of the Polish
   Academy of Sciences; Wroclaw University of Environmental & Life Sciences
RP Chmielewska, E (通讯作者)，Wroclaw Univ Technol, Fac Chem, Dept Bioorgan Chem, Wybrzeze Wyspianskiego 27, PL 50370 Wroclaw, Poland.
EM ewa.chmielewska@pwr.edu.pl
RI Wietrzyk, Joanna/O 4392 2018; Kiełbowicz, Zdzisław/D 1056 2017;
   Kafarski, Paweł/AAA 9112 2019; Kempinska, Katarzyna/KRP 5597 2024
OI Wietrzyk, Joanna/0000 0003 4980 6606; 
FU Wroclaw Research Centre EIT+ under the project BioMed   European
   Regional Development Fund [POIG.01.01.02 02 003/08]
FX This work was supported in part by Wroclaw Research Centre EIT+ under
   the project BioMed (POIG.01.01.02 02 003/08) financed from the European
   Regional Development Fund (Operational Programme Innovative Economy,
   1.1.2) and by statuary activity subsidy from the Polish Ministry of
   Science and Higher Education.
CR Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387 2656(05)11004 7
   Dabrowska E, 2009, J ORGANOMET CHEM, V694, P3806, DOI 10.1016/j.jorganchem.2009.07.025
   Egermann M, 2008, LAB ANIM UK, V42, P453, DOI 10.1258/la.2007.007001
   Eriksen EF, 2014, BONE, V58, P126, DOI 10.1016/j.bone.2013.09.023
   Kantoci D, 1996, SYNTHETIC COMMUN, V26, P2037, DOI 10.1080/00397919608003560
   Kielbowicz Z, 2015, B VET I PULAWY, V59, P123, DOI 10.1515/bvip 2015 0018
   Lecouvey M, 2001, TETRAHEDRON LETT, V42, P8475, DOI 10.1016/S0040 4039(01)01844 5
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   MAIER L, 1981, PHOSPHORUS SULFUR, V11, P311, DOI 10.1080/03086648108077429
   Marcinowska Suchowierska Ewa, 2014, Reumatologia (Warsaw), V52, P238, DOI 10.5114/reum.2014.44703
   NGUYEN LM, 1987, J MED CHEM, V30, P1426, DOI 10.1021/jm00391a027
   Puljula E, 2015, ACS MED CHEM LETT, V6, P397, DOI 10.1021/ml5004603
   Rasmusson L, 2014, INT J DENT, V2014, DOI 10.1155/2014/471035
   Roelofs J. E., 2006, CANCER RES, V12, P6222
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Sharma D, 2013, VASC CELL, V5, DOI 10.1186/2045 824X 5 1
   SKEHAN P, 1990, JNCI J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Whitaker M, 2012, NEW ENGL J MED, V366, P2048, DOI 10.1056/NEJMp1202619
NR 19
TC 3
Z9 3
U1 0
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1042 6507
EI 1563 5325
J9 PHOSPHORUS SULFUR
JI Phosphorus Sulfur Silicon Relat. Elem.
PD DEC 2
PY 2015
VL 190
IS 12
SI SI
BP 2164
EP 2172
DI 10.1080/10426507.2015.1085046
PG 9
WC Chemistry, Inorganic & Nuclear; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC); Conference Proceedings Citation Index   Science (CPCI S)
SC Chemistry
GA CY3OR
UT WOS:000366319600013
DA 2025 08 17
ER

PT J
AU Batoon, L
   Millard, SM
   Raggatt, LJ
   Sandrock, C
   Pickering, E
   Williams, K
   Sun, LWH
   Wu, AC
   Irvine, KM
   Pivonka, P
   Glatt, V
   Wullschleger, ME
   Hume, DA
   Pettit, AR
AF Batoon, Lena
   Millard, Susan M.
   Raggatt, Liza J.
   Sandrock, Cheyenne
   Pickering, Edmund
   Williams, Kyle
   Sun, Lucas W. H.
   Wu, Andy C.
   Irvine, Katharine M.
   Pivonka, Peter
   Glatt, Vaida
   Wullschleger, Martin E.
   Hume, David A.
   Pettit, Allison R.
TI Treatment with a long acting chimeric CSF1 molecule enhances fracture
   healing of healthy and osteoporotic bones
SO BIOMATERIALS
LA English
DT Article
DE Osteal macrophages; Osteomacs; Bone regeneration; Fracture repair;
   Colony stimulating factor 1; Osteoporotic fracture
ID COLONY STIMULATING FACTOR; MACROPHAGE POLARIZATION; TISSUE REGENERATION;
   FACTOR I; PHASE I; REPAIR; PROLIFERATION; OSTEOGENESIS; INFLAMMATION;
   MODULATION
AB Macrophage targeted therapies, including macrophage colony stimulating factor 1 (CSF1), have been shown to have pro repair impacts post fracture. Preclinical/clinical applications of CSF1 have been expedited by development of chimeric CSF1 Fc which has extended circulating half life. Here, we used mouse models to investigate the bone regenerative potential of CSF1 Fc in healthy and osteoporotic fracture. We also explored whether combination of CSF1 Fc with interleukin (IL) 4 provided additional fracture healing benefit in osteopenic bone. Micro computed tomography, in situ histomorphometry, and bone mechanical parameters were used to assess systemic impacts of CSF1 Fc therapy in naive mice (male and female young, adult and geriatric). An intermittent CSF1 Fc regimen was optimized to mitigate undesirable impacts on bone resorption and hepatosplenomegaly, irrespective of age or gender. The intermittent CSF1 Fc regimen was tested in a mid diaphyseal femoral fracture model in healthy bones with treatment initiated 1 day post fracture. Weekly CSF1 Fc did not impact osteoclasts but increased osteal macrophages and improved fracture strength. Importantly, this treatment regimen also improved fracture union and strength in an ovariectomy model of delayed fracture repair. Combining CSF1 Fc with IL 4 initiated 1 week post fracture reduced the efficacy of CSF1 Fc. This study describes a novel strategy to specifically achieve bone regenerative actions of CSF1 Fc that has the potential to alleviate fragility fracture morbidity and mortality.
C1 [Batoon, Lena; Millard, Susan M.; Raggatt, Liza J.; Sandrock, Cheyenne; Williams, Kyle; Sun, Lucas W. H.; Wu, Andy C.; Irvine, Katharine M.; Hume, David A.; Pettit, Allison R.] Univ Queensland, Translat Res Inst, Mater Res Inst, 37 Kent St, Woolloongabba, Qld 4102, Australia.
   [Pickering, Edmund; Pivonka, Peter] Queensland Univ Technol, Sch Mech Med & Proc Engn, Brisbane, Qld 4000, Australia.
   [Pickering, Edmund; Pivonka, Peter; Glatt, Vaida] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4000, Australia.
   [Wullschleger, Martin E.] Griffith Univ, Sch Med, Southport, Qld 4215, Australia.
   [Wullschleger, Martin E.] Royal Brisbane & Womens Hosp, Herston, Qld 4029, Australia.
C3 Mater Research; University of Queensland; Queensland University of
   Technology (QUT); Queensland University of Technology (QUT); Griffith
   University; Griffith University   Gold Coast Campus; Royal Brisbane &
   Women's Hospital
RP Pettit, AR (通讯作者)，Univ Queensland, Translat Res Inst, Mater Res Inst, 37 Kent St, Woolloongabba, Qld 4102, Australia.
EM allison.pettit@mater.uq.edu.au
RI ; Millard, Susan/C 8115 2011; Pettit, Allison/O 4462 2019; Hume,
   David/N 6702 2019; Pivonka, Peter/AAL 1053 2021; Irvine,
   Katharine/A 5559 2011; Raggatt, Liza Jane/S 4530 2016; Batoon,
   Lena/ACZ 1392 2022; Pickering, Edmund/Q 7531 2017
OI Pivonka, Peter/0000 0001 9183 530X; Millard, Susan/0000 0003 1738 3362;
   Pickering, Edmund/0000 0002 9133 887X; Sandrock, Cheyenne
   Jo/0000 0002 4111 8393; Hume, David/0000 0002 2615 1478;
   /0000 0002 2499 9571; Pettit, Allison/0000 0003 4707 7892; Irvine,
   Katharine/0000 0002 6716 1605; Williams, Kyle/0000 0003 4843 7079; Wu,
   Andy C/0000 0002 0864 4447; Batoon, Lena/0000 0002 1831 4601
FU Mater Foundation; National Health and Medical Research Council
   [APP1143802]; University of Queensland Postgraduate Scholarship; Mater
   Research Frank Clair Scholarship; Australian Research Council Future
   Fellowship [FT150100335]; Australian Government
FX This work was supported by Mater Foundation and a National Health and
   Medical Research Council Project Grant [APP1143802], The University of
   Queensland Postgraduate Scholarship and Mater Research Frank Clair
   Scholarship (LB) and an Australian Research Council Future Fellowship
   [ARP, FT150100335]. This work was carried out at the Translational
   Research Institute (TRI) which is supported by a grant from the
   Australian Government. The TRI Microscopy, Histology, Preclinical
   Imaging and Flow Cytometry Core Facilities contributed technical
   expertise and the TRI Biological Research Facility contributed to animal
   husbandry and monitoring. Melissa Johnston and the laboratory technical
   services of the Science and Engineering Faculty (QUT) assisted with
   mechanical testing.
CR AHARINEJAD S, 1995, BONE, V16, P315, DOI 10.1016/8756 3282(94)00044 1
   Alexander KA, 2011, J BONE MINER RES, V26, P1517, DOI 10.1002/jbmr.354
   Alexander KA, 2017, IMMUNOL CELL BIOL, V95, P7, DOI 10.1038/icb.2016.74
   Antonova E, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 42
   Asada N, 2013, CELL STEM CELL, V12, P737, DOI 10.1016/j.stem.2013.05.001
   Au A, 2016, FRONT NEUROENDOCRIN, V40, P87, DOI 10.1016/j.yfrne.2016.01.002
   Bahney CS, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00004
   Batoon L, 2019, BIOMATERIALS, V196, P51, DOI 10.1016/j.biomaterials.2017.10.033
   Batoon L, 2017, CURR OSTEOPOROS REP, V15, P385, DOI 10.1007/s11914 017 0384 x
   Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307
   Brown BN, 2012, BIOMATERIALS, V33, P3792, DOI 10.1016/j.biomaterials.2012.02.034
   Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Cheung WH, 2016, INJURY, V47, pS21, DOI 10.1016/S0020 1383(16)47004 X
   Cho SW, 2014, P NATL ACAD SCI USA, V111, P1545, DOI 10.1073/pnas.1315153111
   Clark D, 2020, AGING CELL, V19, DOI 10.1111/acel.13112
   Cline Smith A, 2020, J BONE MINER RES, V35, P1174, DOI 10.1002/jbmr.3966
   COLE DJ, 1994, J NATL CANCER I, V86, P39, DOI 10.1093/jnci/86.1.39
   Cortet B, 2011, OSTEOPOROSIS INT, V22, P2007, DOI 10.1007/s00198 011 1612 3
   Farro G, 2017, GUT, V66, P2098, DOI 10.1136/gutjnl 2016 313144
   Forbes SJ, 2014, NAT MED, V20, P857, DOI 10.1038/nm.3653
   Garceau V, 2015, BMC BIOL, V13, DOI 10.1186/s12915 015 0121 9
   Gibon E, 2016, REGEN ENG TRANSL MED, V2, P98, DOI 10.1007/s40883 016 0016 5
   Gibon E, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0300 9
   Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507
   Gong L, 2020, ACTA BIOMATER, V117, P246, DOI 10.1016/j.actbio.2020.09.039
   Gow DJ, 2014, MOL THER, V22, P1580, DOI 10.1038/mt.2014.112
   Guihard P, 2015, AM J PATHOL, V185, P765, DOI 10.1016/j.ajpath.2014.11.008
   Hachim D, 2017, BIOMATERIALS, V112, P95, DOI 10.1016/j.biomaterials.2016.10.019
   Haffner Luntzer M, 2017, EUR J MED RES, V22, DOI 10.1186/s40001 017 0264 y
   Haffner Luntzer M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159278
   Hegde V, 2016, OSTEOPOROSIS INT, V27, P861, DOI 10.1007/s00198 015 3331 7
   Hozain S, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115479
   Hume DA, 2012, BLOOD, V119, P1810, DOI 10.1182/blood 2011 09 379214
   Irvine KM, 2020, J LEUKOCYTE BIOL, V107, P221, DOI 10.1002/JLB.MA0519 149R
   Jakubowski AA, 1996, CLIN CANCER RES, V2, P295
   Jenkins SJ, 2011, SCIENCE, V332, P1284, DOI 10.1126/science.1204351
   Julier Z, 2017, ACTA BIOMATER, V53, P13, DOI 10.1016/j.actbio.2017.01.056
   Kim SY, 2019, IMMUNOL CELL BIOL, V97, P258, DOI 10.1111/imcb.12236
   Köttstorfer J, 2013, INJURY, V44, P930, DOI 10.1016/j.injury.2013.02.028
   Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004
   Lin T, 2019, TISSUE ENG PT A, V25, P1096, DOI [10.1089/ten.tea.2018.0292, 10.1089/ten.TEA.2018.0292]
   Lloyd SA, 2011, IN VIVO, V25, P297
   Lloyd SA, 2009, J BONE MINER METAB, V27, P546, DOI 10.1007/s00774 009 0071 9
   Löffler J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02443
   Maruyama M, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00386
   Matthys R, 2009, INJURY, V40, pS103, DOI 10.1016/j.injury.2009.10.044
   McCauley J, 2020, J ORTHOP RES, V38, P1693, DOI 10.1002/jor.24603
   McDonald MM, 2008, BONE, V43, P653, DOI 10.1016/j.bone.2008.05.019
   Michalski MN, 2016, J CELL BIOCHEM, V117, P2697, DOI 10.1002/jcb.25567
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Muñoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999
   Nikolaou VS, 2009, INJURY, V40, P663, DOI 10.1016/j.injury.2008.10.035
   Odén A, 2015, OSTEOPOROSIS INT, V26, P2243, DOI 10.1007/s00198 015 3154 6
   Pang J, 2015, REJUV RES, V18, P356, DOI 10.1089/rej.2015.1682
   Raggatt LJ, 2014, AM J PATHOL, V184, P3192, DOI 10.1016/j.ajpath.2014.08.017
   Sandberg OH, 2017, BONE, V101, P129, DOI 10.1016/j.bone.2017.04.004
   Sarahrudi K, 2009, J ORTHOP RES, V27, P36, DOI 10.1002/jor.20680
   Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood 2002 02 0569
   Sauter KA, 2016, AM J PHYSIOL GASTR L, V311, pG533, DOI 10.1152/ajpgi.00116.2016
   Sauter KA, 2014, J LEUKOCYTE BIOL, V96, P265, DOI 10.1189/jlb.2A0114 006R
   Schlundt C., 2015, BONE, DOI [10.1016/j.bone.2015.10, DOI 10.1016/J.BONE.2015.10]
   Schlundt C, 2018, BONE, V106, P78, DOI 10.1016/j.bone.2015.10.019
   Shantz JAS, 2014, J ORTHOP TRAUMA, V28, pS10, DOI 10.1097/BOT.0000000000000062
   Soki FN, 2015, ONCOTARGET, V6, P35782, DOI 10.18632/oncotarget.6042
   Stutchfield BM, 2015, GASTROENTEROLOGY, V149, P1896, DOI 10.1053/j.gastro.2015.08.053
   Summers KM, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000859
   Tran T, 2018, J CLIN ENDOCR METAB, V103, P3205, DOI 10.1210/jc.2017 02656
   Ueno M, 2020, CYTOTHERAPY, V22, pS178
   Vi L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07666 0
   Vi L, 2015, J BONE MINER RES, V30, P1090, DOI 10.1002/jbmr.2422
   Wasnik S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98773
   Winkler IG, 2010, BLOOD, V116, P4815, DOI 10.1182/blood 2009 11 253534
   Wu AC, 2016, J PATHOL, V239, P218, DOI 10.1002/path.4718
   Wu Andy C, 2013, Bonekey Rep, V2, P373, DOI 10.1038/bonekey.2013.107
   Wu CKA, 2009, J BIOMED MATER RES A, V91A, P845, DOI 10.1002/jbm.a.32238
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Xing ZQ, 2010, J ORTHOP RES, V28, P1000, DOI 10.1002/jor.21087
   Xing ZQ, 2010, DIS MODEL MECH, V3, P451, DOI 10.1242/dmm.003186
   Zheng ZW, 2018, THERANOSTICS, V8, P5482, DOI 10.7150/thno.28315
NR 80
TC 11
Z9 14
U1 0
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD AUG
PY 2021
VL 275
AR 120936
DI 10.1016/j.biomaterials.2021.120936
EA JUL 2021
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA UD7TA
UT WOS:000687406200003
PM 34303178
DA 2025 08 17
ER

PT J
AU Lindberg, JS
   Culleton, B
   Wong, G
   Borah, MF
   Clark, RV
   Shapiro, WB
   Roger, SD
   Husserl, FE
   Klassen, PS
   Guo, MD
   Albizem, MB
   Coburn, JW
AF Lindberg, JS
   Culleton, B
   Wong, G
   Borah, MF
   Clark, RV
   Shapiro, WB
   Roger, SD
   Husserl, FE
   Klassen, PS
   Guo, MD
   Albizem, MB
   Coburn, JW
TI Cinacalcet HCl, an oral calcimimetic agent for the treatment of
   secondary hyperparathyroidism in Hemodialysis and peritoneal dialysis: A
   randomized, double blind, multicenter study
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID STAGE RENAL DISEASE; PARATHYROID HORMONE; MORTALITY RISK; BONE DISEASE;
   CALCIUM; CALCIFICATION; AMG 073; ASSOCIATION; PHOSPHORUS; MANAGEMENT
AB Management of secondary hyperparathyroidism is challenging with traditional therapy. The calcimimetic cinacalcet HCI acts on the calcium sensing receptor to increase its sensitivity to calcium, thereby reducing parathyroid hormone (PTH) secretion. This phase 3, multicenter, randomized, placebo controlled, double blind study evaluated the efficacy and safety of cinacalcet in hemodialysis (HD) and peritoneal dialysis (PD) patients with PTH greater than or equal to 300 pg/ml despite traditional therapy. A total of 395 patients received once daily oral cinacalcet (260 HD, 34 PD) or placebo (89 HD, 12 PD) titrated from 30 to 180 mg to achieve a target intact PTH (iPTH) level of less than or equal to 250 pg/ml. During a 10 wk efficacy assessment phase, cinacalcet was more effective than control for PTH reduction outcomes, including proportion of patients with mean iPTH levels less than or equal to 300 pg/ml (46 versus 9%), proportion of patients with greater than or equal to 30% reduction in iPTH from baseline (65 versus 13%), and proportion of patients with greater than or equal to 20, greater than or equal to 40, or greater than or equal to 50% reduction from baseline. Cinacalcet had comparable efficacy in HD and PD patients; 50% of PD patients achieved a mean iPTH less than or equal to 300 pg/ml. Cinacalcet also significantly reduced serum calcium, phosphorus, and Ca x P levels compared with control treatment. The most common side effects, nausea and vomiting, were usually mild to moderate in severity and transient. Once daily oral cinacalcet was effective in rapidly and safely reducing PTH, Ca x P, calcium, and phosphorus levels in patients who received HD or PD. Cinacalcet offers a new therapeutic option for controlling secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.
C1 New Orleans Nephrol Associates, New Orleans, LA USA.
   Alton Ochsner Med Fdn & Ochsner Clin, New Orleans, LA 70121 USA.
   Foothills Prov Gen Hosp, Calgary, AB T2N 2T9, Canada.
   Credit Valley Hosp, Mississauga, ON, Canada.
   Calif Pacific Med Ctr, San Francisco, CA 94115 USA.
   Our Lady Lourdes RMC, Lafayette, LA USA.
   Brookdale Plaza Nephrol Associates, Brooklyn, NY USA.
   Gosford Hosp, Gosford, NSW, Australia.
   Amgen Inc, Thousand Oaks, CA 91320 USA.
   Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA.
C3 Ochsner Health System; University of Calgary; University Calgary
   Hospital; University of Toronto; Trillium Health Partners; Credit Valley
   Hospital; California Pacific Medical Center; Central Coast Local Health
   District; NSW Health; Gosford Hospital; Amgen; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles
   Healthcare System; University of California System; University of
   California Los Angeles; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA
RP New Orleans Nephrol Associates, 4228 Houma Blvd, Metairie, LA 70006 USA.
EM jlindberg@bellsouth.net
CR ANDRESS DL, 1989, NEW ENGL J MED, V321, P274, DOI 10.1056/NEJM198908033210502
   Billa V, 2000, PERITON DIALYSIS INT, V20, P315
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   Goodman WG, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341017
   Goodman WG, 2001, KIDNEY INT, V59, P1187, DOI 10.1046/j.1523 1755.2001.0590031187.x
   Hammerland LG, 1998, MOL PHARMACOL, V53, P1083
   Indridason OS, 2000, KIDNEY INT, V57, P282, DOI 10.1046/j.1523 1755.2000.00819.x
   Johnson CA, 2002, AM J KIDNEY DIS, V39, P1270, DOI 10.1053/ajkd.2002.33401
   Kim J, 2003, J AM SOC NEPHROL, V14, p269A
   KURITZ SJ, 1988, ANNU REV PUBL HEALTH, V9, P123, DOI 10.1146/annurev.pu.09.050188.001011
   Lindberg JS, 2003, KIDNEY INT, V63, P248, DOI 10.1046/j.1523 1755.2003.00720.x
   Locatelli F, 2002, NEPHROL DIAL TRANSPL, V17, P723, DOI 10.1093/ndt/17.5.723
   Martin KJ, 1998, J AM SOC NEPHROL, V9, P1427
   Maung HM, 2001, AM J KIDNEY DIS, V37, P532
   Nemeth EF, 2004, J PHARMACOL EXP THER, V308, P627, DOI 10.1124/jpet.103.057273
   Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040
   NUSSBAUM SR, 1987, CLIN CHEM, V33, P1364
   Quarles LD, 2003, J AM SOC NEPHROL, V14, P575, DOI 10.1097/01.ASN.0000050224.03126.AD
   Raggi P, 2002, J AM COLL CARDIOL, V39, P695, DOI 10.1016/S0735 1097(01)01781 8
   Rayner HC, 2004, NEPHROL DIAL TRANSPL, V19, P108, DOI 10.1093/ndt/gfg483
   Ribeiro S, 1998, NEPHROL DIAL TRANSPL, V13, P2037, DOI 10.1093/ndt/13.8.2037
   Salem MM, 1997, AM J KIDNEY DIS, V29, P862, DOI 10.1016/S0272 6386(97)90459 5
   SHERRARD DJ, 1993, KIDNEY INT, V43, P436, DOI 10.1038/ki.1993.64
NR 28
TC 334
Z9 357
U1 0
U2 12
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046 6673
EI 1533 3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD MAR
PY 2005
VL 16
IS 3
BP 800
EP 807
DI 10.1681/ASN.2004060512
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 902QQ
UT WOS:000227372000029
PM 15689407
DA 2025 08 17
ER

PT J
AU Chen, CH
   Cheng, TL
   Chang, CF
   Huang, HT
   Lin, SY
   Wu, MH
   Kang, L
AF Chen, Chung Hwan
   Cheng, Tsung Lin
   Chang, Chi Fen
   Huang, Hsuan Ti
   Lin, Sung Yen
   Wu, Meng Hsing
   Kang, Lin
TI Raloxifene Ameliorates Glucosamine Induced Insulin Resistance in
   Ovariectomized Rats
SO BIOMEDICINES
LA English
DT Article
DE apoptosis; endoplasmic reticulum stress; glucosamine; pancreatic
   beta cell dysfunction; ovariectomy; raloxifene
ID PANCREATIC BETA CELLS; ENDOPLASMIC RETICULUM STRESS; PARATHYROID HORMONE
   1 34; MESENCHYMAL STEM CELLS; KNEE OSTEOARTHRITIS; POSTMENOPAUSAL WOMEN;
   DIABETES MELLITUS; ORAL GLUCOSAMINE; GENE EXPRESSION; APOPTOSIS
AB Osteoarthritis (OA) and osteoporosis (OP) are common among older women, especially postmenopausal women. Glucosamine (GlcN) is a common medication for OA, but it may induce insulin resistance and beta cell dysfunction, especially if ovarian hormones are lacking. Raloxifene (RLX) is a selective estrogen receptor modulator and also an OP drug. Previously, we found that estrogen could improve GlcN induced insulin resistance in ovariectomized (OVX) rats. Here, we further hypothesized that RLX, similarly to estrogen, can ameliorate GlcN induced insulin resistance in OVX rats. We used GlcN to induce insulin resistance in OVX rats as a model for evaluating the protective effects of RLX in vivo. We used a pancreatic beta cell line, MIN 6, to study the mechanisms underlying the effect of RLX in GlcN induced beta cell dysfunction in vitro. Increases in fasting plasma glucose, insulin, and homeostasis model assessments of insulin resistance in OVX Sprague Dawley rats treated with GlcN were reversed by RLX treatment (n = 8 in each group). Skeletal muscle GLUT 4 increased, liver PEPCK decreased, pancreatic islet hypertrophy, and beta cell apoptosis in OVX rats treated with GlcN was ameliorated by RLX. The negative effects of GlcN on insulin secretion and cell viability in MIN 6 cells were related to the upregulation of reticulum (ER) stress associated proteins (C/EBP homologous protein, phospho extracellular signal regulated kinase, phospho c JunN terminal kinase), the expression of which was reduced by RLX. Pretreatment with estrogen receptor antagonists reversed the protective effects of RLX. GlcN can induce insulin resistance, beta cell dysfunction, and apoptosis in OVX rats and increase ER stress related proteins in beta cells, whereas RLX can reverse these adverse effects. The effects of RLX act mainly through estrogen receptor alpha; therefore, RLX may be a candidate drug for postmenopausal women with OA and OP.
C1 [Chen, Chung Hwan; Cheng, Tsung Lin; Huang, Hsuan Ti; Lin, Sung Yen] Kaohsiung Med Univ, Coll Med, Orthopaed Res Ctr, Kaohsiung 80701, Taiwan.
   [Chen, Chung Hwan; Huang, Hsuan Ti; Lin, Sung Yen] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Orthoped, Kaohsiung 80701, Taiwan.
   [Chen, Chung Hwan; Cheng, Tsung Lin; Huang, Hsuan Ti; Lin, Sung Yen] Kaohsiung Med Univ, Regenerat Med & Cell Therapy Res Ctr, Kaohsiung 80701, Taiwan.
   [Chen, Chung Hwan; Huang, Hsuan Ti; Lin, Sung Yen] Kaohsiung Med Univ, Coll Med, Dept Orthoped, Kaohsiung 80701, Taiwan.
   [Chen, Chung Hwan; Huang, Hsuan Ti; Lin, Sung Yen] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Orthoped, Kaohsiung 80145, Taiwan.
   [Chen, Chung Hwan; Lin, Sung Yen] Kaohsiung Med Univ, Dept Healthcare Adm & Med Informat, Kaohsiung 80701, Taiwan.
   [Chen, Chung Hwan] Natl Sun Yat Sen Univ, Inst Med Sci & Technol, Kaohsiung 80420, Taiwan.
   [Chen, Chung Hwan] Natl Pingtung Univ Sci & Technol, Coll Vet Med, Grad Inst Anim Vaccine Technol, Pingtung 912301, Taiwan.
   [Chen, Chung Hwan] Natl Pingtung Univ Sci & Technol, Coll Engn, Grad Inst Mat Engn, Pingtung 912301, Taiwan.
   [Cheng, Tsung Lin] Kaohsiung Med Univ, Coll Med, Dept Physiol, Kaohsiung 80701, Taiwan.
   [Chang, Chi Fen] China Med Univ, Sch Med, Dept Anat, Taichung 40402, Taiwan.
   [Wu, Meng Hsing; Kang, Lin] Natl Cheng Kung Univ, Coll Med, Dept Obstet & Gynecol, Tainan 70101, Taiwan.
   [Wu, Meng Hsing; Kang, Lin] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Obstet & Gynecol, Tainan 70101, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University Hospital; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University; Kaohsiung Municipal
   Ta Tung Hospital; Kaohsiung Medical University; National Sun Yat Sen
   University; National Pingtung University Science & Technology; National
   Pingtung University Science & Technology; Kaohsiung Medical University;
   China Medical University Taiwan; National Cheng Kung University;
   National Cheng Kung University; National Cheng Kung University Hospital
RP Kang, L (通讯作者)，Natl Cheng Kung Univ, Coll Med, Dept Obstet & Gynecol, Tainan 70101, Taiwan.; Kang, L (通讯作者)，Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Obstet & Gynecol, Tainan 70101, Taiwan.
EM hwan@kmu.edu.tw; junglecc@kmu.edu.tw; cfchang@mail.cmu.edu.tw;
   hthuang@kmu.edu.tw; sungyenlin@kmu.edu.tw; mhwu68@mail.ncku.edu;
   kanglin@mail.ncku.edu.tw
RI Kang, Lin/JVD 7936 2023; Chen, Chung Hwan/D 4036 2009
OI Huang, Hsuan Ti/0000 0002 8638 1021; Chen,
   Chung Hwan/0000 0001 8941 4792; Wu, Meng Hsing/0000 0001 7542 5554;
   Kang, Lin/0000 0003 2709 5604
FU National Health Research Institute of Taiwan [NHRI EX101 9935EI];
   Kaohsiung Municipal Ta Tung Hospital [KMTTH 109 R014, KMTTH DK(B)
   110002 1]; Kaohsiung Medical University [NPUST KMU 109 P002,
   NCTUKMU108 BIO 04, KMU TC108A02 1, KMU DK(A)110003, KMU DK(B) 110002];
   National Cheng Kung University [NCKUH  10406014];  [MOST
   104 2314 B 006 071 MY2];  [108 2314 B 037 059 MY3]; 
   [110 2314 B 037 029 MY3]
FX This study was supported in part by the National Health Research
   Institute (NHRI EX101 9935EI) of Taiwan, National Cheng Kung University
   (NCKUH  10406014), Kaohsiung Municipal Ta Tung Hospital (KMTTH 109 R014
   and KMTTH DK(B) 110002 1), Kaohsiung Medical University (NPUST
   KMU 109 P002, NCTUKMU108 BIO 04, KMU TC108A02 1, KMU DK(A)110003 and
   KMU DK(B) 110002) and the Minister of Science and Technology, Taiwan
   (MOST 104 2314 B 006 071 MY2, 108 2314 B 037 059 MY3 and
   110 2314 B 037 029 MY3) of Taiwan. The funders had no role in the study
   design, data collection, and analysis; decision to publish; or
   preparation of the manuscript.
CR Anastasilakis AD, 2019, J BONE MINER RES, V34, P2220, DOI 10.1002/jbmr.3853
   Bei MJ, 2020, OSTEOARTHR CARTILAGE, V28, P344, DOI 10.1016/j.joca.2019.06.014
   Bernales S, 2006, ANNU REV CELL DEV BI, V22, P487, DOI 10.1146/annurev.cellbio.21.122303.120200
   Biggee BA, 2007, ANN RHEUM DIS, V66, P260, DOI 10.1136/ard.2006.058222
   Bliuc D, 2019, J BONE MINER RES, V34, P2001, DOI 10.1002/jbmr.3816
   Borhan S, 2019, J BONE MINER RES, V34, P838, DOI 10.1002/jbmr.3666
   Bryzgalova G, 2006, DIABETOLOGIA, V49, P588, DOI 10.1007/s00125 005 0105 3
   Centofanti F, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8030065
   Chakhtoura M, 2021, J BONE MINER RES, V36, P1942, DOI 10.1002/jbmr.4395
   Chan DC, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0463 3
   Chandra A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073553
   Chang Lo Yu, 2018, Osteoporos Sarcopenia, V4, P47, DOI 10.1016/j.afos.2018.06.001
   Chang PY, 2019, J BONE MINER RES, V34, P59, DOI 10.1002/jbmr.3576
   Chen CH, 2021, BONE JOINT RES, V10, P514, DOI 10.1302/2046 3758.108.BJR 2020 0165.R2
   Chen CL, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 55459 2
   Chen CH, 2022, CALCIFIED TISSUE INT, V110, P74, DOI 10.1007/s00223 021 00895 4
   Chen CH, 2020, CLIN INTERV AGING, V15, P111, DOI 10.2147/CIA.S228158
   Chen CH, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017912
   Chen CH, 2019, CURR MED RES OPIN, V35, P1041, DOI 10.1080/03007995.2018.1552576
   Chen CH, 2018, J APPL PHYSIOL, V124, P1177, DOI 10.1152/japplphysiol.00871.2017
   Chen CH, 2017, MENOPAUSE, V24, P617, DOI 10.1097/GME.0000000000000811
   Chen CH, 2013, MENOPAUSE, V20, P687, DOI [10.1097/gme.0b013e31828244f0, 10.1097/GME.0b013e31828244f0]
   Chen LR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092213
   Chiu CF, 2019, DRUG DES DEV THER, V13, P1609, DOI 10.2147/DDDT.S193914
   Chou HC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21196991
   Chou YS, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 70712 9
   Chu LY, 2020, J BONE MINER RES, V35, P505, DOI 10.1002/jbmr.3909
   Ciaraldi TP, 1999, ENDOCRINOLOGY, V140, P3971, DOI 10.1210/en.140.9.3971
   Conley RB, 2020, J BONE MINER RES, V35, P36, DOI 10.1002/jbmr.3877
   Crandall CJ, 2019, J BONE MINER RES, V34, P607, DOI 10.1002/jbmr.3636
   Cross M, 2014, ANN RHEUM DIS, V73, P1323, DOI 10.1136/annrheumdis 2013 204763
   D'Alessandris C, 2004, FASEB J, V18, P959, DOI 10.1096/fj.03 0725fje
   Dahl C, 2021, J BONE MINER RES, V36, P480, DOI 10.1002/jbmr.4212
   Dieli Conwright CM, 2009, ACTA PHYSIOL, V197, P187, DOI 10.1111/j.1748 1716.2009.01997.x
   Ebrahimi MN, 2020, LIFE SCI, V263, DOI 10.1016/j.lfs.2020.118573
   Galli A, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8120582
   Ghouri A, 2021, CALCIFIED TISSUE INT, V109, P339, DOI 10.1007/s00223 020 00672 9
   Grover Páez F, 2013, GYNECOL ENDOCRINOL, V29, P674, DOI 10.3109/09513590.2013.788628
   Gundamaraju R, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8100402
   Guo Q, 2019, FOOD CHEM TOXICOL, V125, P95, DOI 10.1016/j.fct.2018.12.051
   Hain BA, 2020, J BONE MINER RES, V35, P368, DOI 10.1002/jbmr.3890
   Hevener AL, 2020, ENDOCRINOLOGY, V161, DOI 10.1210/endocr/bqz017
   Ho ML, 2009, EUR J CLIN INVEST, V39, P296, DOI 10.1111/j.1365 2362.2009.02092.x
   Hozumi Y, 2000, EUR J ENDOCRINOL, V143, P427, DOI 10.1530/eje.0.1430427
   Hsu CH, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101734
   Hsu CY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186846
   Huang HT, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9111136
   Hwang MS, 2010, BIOCHEM BIOPH RES CO, V399, P111, DOI 10.1016/j.bbrc.2010.07.050
   Jiajue R, 2019, CALCIFIED TISSUE INT, V105, P466, DOI 10.1007/s00223 019 00598 x
   Juan YS, 2012, MENOPAUSE, V19, P346, DOI 10.1097/gme.0b013e31822d652d
   Kang L, 2014, MENOPAUSE, V21, P1239, DOI [10.1097/GME.0000000000000232, 10.1097/gme.0000000000000232]
   Kang L, 2012, MENOPAUSE, V19, P496, DOI 10.1097/gme.0b013e31823a40d9
   Kasher M, 2020, OSTEOPOROSIS INT, V31, P2197, DOI 10.1007/s00198 020 05504 y
   Laybutt DR, 2007, DIABETOLOGIA, V50, P752, DOI 10.1007/s00125 006 0590 z
   Le May C, 2006, P NATL ACAD SCI USA, V103, P9232, DOI 10.1073/pnas.0602956103
   Lee TC, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc 2019 000843
   Lewiecki EM, 2019, J BONE MINER RES, V34, P605, DOI 10.1002/jbmr.3671
   Li S, 2020, BONE JOINT RES, V9, P524, DOI 10.1302/2046 3758.98.BJR 2020 0089.R1
   Lin SY, 2019, ORTHOPEDICS, V42, P264, DOI 10.3928/01477447 20190723 02
   Lingard EA, 2010, AGE AGEING, V39, P234, DOI 10.1093/ageing/afp222
   Lisk R, 2020, CALCIFIED TISSUE INT, V107, P319, DOI 10.1007/s00223 020 00722 2
   Liu SH, 2009, DIABETES, V58, P2292, DOI 10.2337/db09 0257
   Luk HY, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9111050
   Macías I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051653
   Marchetti P, 2007, DIABETOLOGIA, V50, P2486, DOI 10.1007/s00125 007 0816 8
   Mauvais Jarvis F, 2013, ENDOCR REV, V34, P309, DOI 10.1210/er.2012 1055
   Monauni T, 2000, DIABETES, V49, P926, DOI 10.2337/diabetes.49.6.926
   MORIN MJ, 1983, J CELL PHYSIOL, V114, P162, DOI 10.1002/jcp.1041140204
   Mortensen SJ, 2020, CALCIFIED TISSUE INT, V107, P1, DOI 10.1007/s00223 020 00688 1
   Muniyappa R, 2006, DIABETES, V55, P3142, DOI 10.2337/db06 0714
   Nagamani M, 2008, FERTIL STERIL, V89, P614, DOI 10.1016/j.fertnstert.2007.03.083
   Osagie Clouard L, 2019, BONE JOINT RES, V8, P397, DOI 10.1302/2046 3758.88.BJR 2019 0018.R1
   Osman A, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8100409
   Pickering ME, 2020, CALCIFIED TISSUE INT, V107, P203, DOI 10.1007/s00223 020 00703 5
   Qiu SQ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 01937 4
   Riant E, 2009, ENDOCRINOLOGY, V150, P2109, DOI 10.1210/en.2008 0971
   Ribas V, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad3815
   Rodriguez C, 2001, JAMA J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460
   Saad RK, 2020, J BONE MINER RES, V35, P71, DOI 10.1002/jbmr.3870
   Scroggie DA, 2003, ARCH INTERN MED, V163, P1587, DOI 10.1001/archinte.163.13.1587
   Shao L, 2020, BONE JOINT RES, V9, P675, DOI 10.1302/2046 3758.910.BJR 2020 0018.R1
   Shieh A, 2019, J BONE MINER RES, V34, P2246, DOI 10.1002/jbmr.3856
   Silverman S, 2019, CALCIFIED TISSUE INT, V104, P193, DOI 10.1007/s00223 018 0485 2
   Tatangelo G, 2019, J BONE MINER RES, V34, P616, DOI 10.1002/jbmr.3640
   Taylor EA, 2020, CALCIFIED TISSUE INT, V106, P303, DOI 10.1007/s00223 019 00634 w
   Tei RMH, 2019, CALCIFIED TISSUE INT, V104, P102, DOI 10.1007/s00223 018 0476 3
   Tiano JP, 2012, ISLETS, V4, P173, DOI 10.4161/isl.19747
   Tiano JP, 2011, J CLIN INVEST, V121, P3331, DOI 10.1172/JCI44564
   Ukon Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102557
   Veronese N, 2019, SEMIN ARTHRITIS RHEU, V49, P9, DOI 10.1016/j.semarthrit.2019.01.005
   Wang J, 2020, BONE JOINT RES, V9, P719, DOI 10.1302/2046 3758.910.BJR 2020 0031.R3
   Wang SP, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 021 04090 2
   Wu CH, 2021, J CLIN DENSITOM, V24, P3, DOI 10.1016/j.jocd.2019.03.004
   Wu CH, 2020, BONE REP, V13, DOI 10.1016/j.bonr.2020.100729
   Wu YZ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105232
   Zhou ZQ, 2018, J BIOL CHEM, V293, P4735, DOI 10.1074/jbc.M117.805069
NR 96
TC 7
Z9 8
U1 1
U2 11
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD SEP
PY 2021
VL 9
IS 9
AR 1114
DI 10.3390/biomedicines9091114
PG 17
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA UV0XU
UT WOS:000699213700001
PM 34572301
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lau, EMC
   Chan, FWK
   Hui, DSC
   Wu, AKL
   Leung, PC
AF Lau, EMC
   Chan, FWK
   Hui, DSC
   Wu, AKL
   Leung, PC
TI Reduced bone mineral density in male Severe Acute Respiratory Syndrome
   (SARS) patients in Hong kong
SO BONE
LA English
DT Article
DE SARS; steroid; bone mineral density; Hong Kong
ID GLUCOCORTICOIDS; DIFFERENTIATION; OSTEOBLASTS; INHIBITION; MECHANISMS;
   APOPTOSIS; CORTISOL; DISEASE; LIGAND
AB During the Severe Acute Respiratory Syndrome (SARS) outbreak in Hong Kong in 2003, patients were treated with very high doses of corticosteroid and ribarivin. The detrimental effects of such treatment on the bone mineral density (BMD) of SARS patients are unknown.
   To compare the BMD of SARS patients with normal range data, a cross sectional survey was conducted. The bone mineral density of 224 patients with SARS, who were treated with an average of 2753 mg (SD = 2152 mg) prednisolone and 29,344 mg (SD = 15,849 mg) of ribarivin was compared to normal data. Six percent of men had a hip BMD Z score of <= 2 (P = 0.057 for testing the hypothesis that >2.5% of subjects should have a Z score of <= 2). Moreover, there was a negative association (r  0.25, P = 0.023) between the duration of steroid therapy and BMD in men.
   We conclude that male SARS patients had lower BMD at the hip than normal controls, and this could be attributed to prolonged steroid therapy. (c) 2005 Elsevier Inc. All rights reserved.
C1 Chinese Univ Hong Kong, Dept Med & Therapeut, Sha Tin 100083, Peoples R China.
   Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Sha Tin 100083, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong
RP Lau, EMC (通讯作者)，Hong Kong Osteoporosis Ctr Treatment & Res, Unit 1301, Hing Wai Bldg,36 Queens Rd Cent, Hong Kong, Hong Kong, Peoples R China.
EM edithmelau@netvigator.com
RI ; Hui, David/O 2754 2015
OI Hui, David/0000 0003 4382 2445; 
CR CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885
   Dubois EF, 2002, CHEST, V121, P1456, DOI 10.1378/chest.121.5.1456
   Ebeling PR, 1998, J BONE MINER RES, V13, P1283, DOI 10.1359/jbmr.1998.13.8.1283
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Iqbal F, 1999, CHEST, V116, P1616, DOI 10.1378/chest.116.6.1616
   Lau EMC, 1998, CLIN EXP ALLERGY, V28, P1066
   Lau EMC, 1998, EUR J CLIN NUTR, V52, P60, DOI 10.1038/sj.ejcn.1600516
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Pereira RC, 2002, BONE, V30, P685, DOI 10.1016/S8756 3282(02)00687 7
   Pereira RMR, 2001, BONE, V28, P484, DOI 10.1016/S8756 3282(01)00422 7
   Rubin J, 1998, ENDOCRINOLOGY, V139, P1006, DOI 10.1210/en.139.3.1006
   SAITO JK, 1995, CALCIFIED TISSUE INT, V57, P115, DOI 10.1007/BF00298431
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Tomlinson B, 2003, LANCET, V361, P1486, DOI 10.1016/S0140 6736(03)13218 7
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
NR 15
TC 25
Z9 26
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD SEP
PY 2005
VL 37
IS 3
BP 420
EP 424
DI 10.1016/j.bone.2005.04.018
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 963CD
UT WOS:000231779600015
PM 15993669
OA Green Published
DA 2025 08 17
ER

PT J
AU Liu, JL
   Zhou, ZZ
   Xia, XW
   Liu, Y
   Zhao, ZJ
   Wu, YB
   Deng, YG
   Zhang, YJ
   He, F
   Xu, Y
   Zhu, XS
AF Liu, Junlin
   Zhou, Zhangzhe
   Xia, Xiaowei
   Liu, Yang
   Zhao, Zhijian
   Wu, Yubin
   Deng, Yaoge
   Zhang, Yijian
   He, Fan
   Xu, Yong
   Zhu, Xuesong
TI Capturing cerium ions via hydrogel microspheres promotes vascularization
   for bone regeneration
SO MATERIALS TODAY BIO
LA English
DT Article
DE Cerium ions; Microfluidic; Hydrogel microspheres; Angiogenesis; Bone
   regeneration
ID SCAFFOLDS; NANOPARTICLES; THERAPY; CELLS; ENCAPSULATION; STRATEGIES
AB The rational design of multifunctional biomaterials with hierarchical porous structure and on  demand biological activity is of great consequence for bone tissue engineering (BTE) in the contemporary world. The advanced combination of trace element cerium ions (Ce3+) with bone repair materials makes the composite material capable of promoting angiogenesis and enhancing osteoblast activity. Herein, a living and phosphorylated injectable porous hydrogel microsphere (P GelMA Ce@BMSCs) is constructed by microfluidic technology and coordination reaction with metal ion ligands while loaded with exogenous BMSCs. Exogenous stem cells can adhere to and proliferate on hydrogel microspheres, thus promoting cell extracellular matrix (ECM) and cell  cell interactions. The active ingredient Ce3+ promotes the proliferation, osteogenic differentiation of rat BMSCs, and angiogenesis of endotheliocytes by promoting mineral deposition, osteogenic gene expression, and VEGF secretion. The enhancement of osteogenesis and improvement of angiogenesis of the P GelMA Ce scaffold is mainly associated with the activation of the Wnt/beta catenin pathway. This study could provide novel and meaningful insights for treating bone defects with biofunctional materials on the basis of metal ions.
C1 [Liu, Junlin; Zhou, Zhangzhe; Xia, Xiaowei; Liu, Yang; Zhao, Zhijian; Wu, Yubin; Deng, Yaoge; Zhang, Yijian; He, Fan; Xu, Yong; Zhu, Xuesong] Soochow Univ, Affiliated Hosp 1, Dept Orthopaed, Suzhou 215006, Peoples R China.
   [Liu, Junlin; Zhou, Zhangzhe; Xia, Xiaowei; Liu, Yang; Zhao, Zhijian; Wu, Yubin; Deng, Yaoge; Zhang, Yijian; He, Fan; Xu, Yong; Zhu, Xuesong] Soochow Univ, Orthopaed Inst, Med Coll, Suzhou 215007, Peoples R China.
C3 Soochow University   China; Soochow University   China
RP He, F; Xu, Y; Zhu, XS (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Orthopaed, Suzhou 215006, Peoples R China.
EM fanhe@suda.edu.cn; yxu1615@suda.edu.cn; zhuxs@suda.edu.cn
RI Zhang, Yijian/JTU 6960 2023; deng, yaoge/MZK 5928 2025; ZHU,
   XUESONG/AAI 1933 2020; LIU, YANG/HWQ 4615 2023
FU National Key R&D Program of China [2022YFC2502902]; National Natural
   Science Foundation of China [82072442, 82272494, 82302664]; Natural
   Science Foundation of Jiangsu Province [SBK2023043711, BK20230494];
   Orthopaedic Medical Innovation Center of Jiangsu [CXZX202209]; Key
   Laboratory of Orthopaedics of Suzhou [SZS2022017]; Priority Academic
   Program Development of Jiangsu Higher Education Institutions (PAPD),
   Gusu Innovation and Entrepreneur Leading Talents project [ZXL2023204]
FX This work was supported by grants from National Key R & D Program of
   China (Grant Nos: 2022YFC2502902) , National Natural Science Foundation
   of China (Grant Nos: 82072442, 82272494, 82302664) , Natural Science
   Foundation of Jiangsu Province (SBK2023043711) , the Natural Science
   Foundation of Jiangsu Province (BK20230494) , the Orthopaedic Medical
   Innovation Center of Jiangsu (CXZX202209) , Key Laboratory of
   Orthopaedics of Suzhou (SZS2022017) , the Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD), Gusu
   Innovation and Entrepreneur Leading Talents project (ZXL2023204) .
CR Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Bai Q, 2020, INT J NANOMED, V15, P9717, DOI 10.2147/IJN.S276001
   Bosch Rué E, 2023, ACTA BIOMATER, V166, P14, DOI 10.1016/j.actbio.2023.06.001
   Bosch Rué E, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.614545
   Bronckaers A, 2014, PHARMACOL THERAPEUT, V143, P181, DOI 10.1016/j.pharmthera.2014.02.013
   Brown JS, 2016, LANCET ONCOL, V17, pE23, DOI 10.1016/S1470 2045(15)00310 1
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cui JJ, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202200571
   Diomede F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093242
   Dou C, 2021, BIOACT MATER, V6, P4697, DOI 10.1016/j.bioactmat.2021.04.038
   Duncanson WJ, 2012, LAB CHIP, V12, P2135, DOI 10.1039/c2lc21164e
   Elinder F, 2003, Q REV BIOPHYS, V36, P373, DOI 10.1017/S0033583504003932
   Fang XT, 2019, J PHOTOCH PHOTOBIO B, V191, P83, DOI 10.1016/j.jphotobiol.2018.11.016
   Hached F, 2017, BEST PRACT RES CL RH, V31, P730, DOI 10.1016/j.berh.2018.05.002
   Hernández RM, 2010, ADV DRUG DELIVER REV, V62, P711, DOI 10.1016/j.addr.2010.02.004
   Holmes D, 2017, NATURE, V550, pS193, DOI 10.1038/550S193a
   Hoppe A, 2013, BIOMATER SCI UK, V1, P254, DOI 10.1039/c2bm00116k
   Huang YK, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202300748
   Huebsch N, 2015, NAT MATER, V14, P1269, DOI [10.1038/NMAT4407, 10.1038/nmat4407]
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Kuznik A, 2020, EUR J PHARMACOL, V866, DOI 10.1016/j.ejphar.2019.172773
   Lei YT, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202105084
   Alexa RL, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031841
   Li JH, 2018, ADV SCI, V5, DOI 10.1002/advs.201700678
   Li W, 2018, CHEM SOC REV, V47, P5646, DOI 10.1039/c7cs00263g
   Li XC, 2023, SMALL, V19, DOI 10.1002/smll.202207211
   Lu B, 2019, BIOFABRICATION, V11, DOI 10.1088/1758 5090/ab0676
   Lu JW, 2018, NANOMED NANOTECHNOL, V14, P811, DOI 10.1016/j.nano.2017.12.025
   Luo JC, 2023, BIOL TRACE ELEM RES, V201, P865, DOI 10.1007/s12011 022 03168 9
   Madry H, 2020, ADV MATER, V32, DOI 10.1002/adma.201906508
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Marino A, 2017, BBA GEN SUBJECTS, V1861, P386, DOI 10.1016/j.bbagen.2016.11.022
   Marrella A, 2018, MATER TODAY, V21, P362, DOI 10.1016/j.mattod.2017.10.005
   Mastrullo V, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00188
   Mouriño V, 2012, J R SOC INTERFACE, V9, P401, DOI 10.1098/rsif.2011.0611
   O'Neill E, 2018, DRUG DISCOV TODAY, V23, P879, DOI 10.1016/j.drudis.2018.01.049
   Paterson TE, 2018, APL BIOENG, V2, DOI 10.1063/1.5008556
   Piao Y., 2021, ENG REGEN, V2, P47, DOI [10.1016/J.ENGREG.2021.03.002, DOI 10.1016/J.ENGREG.2021.03.002, 10.1016/j.engreg.2021.03.002]
   Ren XC, 2020, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00469
   Shang LR, 2017, CHEM REV, V117, P7964, DOI 10.1021/acs.chemrev.6b00848
   Shim TS, 2013, PART PART SYST CHAR, V30, P9, DOI 10.1002/ppsc.201200044
   Song JL, 2023, ADV FIBER MATER, V5, P429, DOI 10.1007/s42765 022 00237 5
   Spater T, 2022, BIOACT MATER, V17, P526, DOI 10.1016/j.bioactmat.2022.03.015
   Sturgeon CM, 2014, NAT BIOTECHNOL, V32, P554, DOI 10.1038/nbt.2915
   Tang Y, 2020, THERANOSTICS, V10, P2229, DOI 10.7150/thno.40559
   Thiele J, 2017, MACROMOL CHEM PHYS, V218, DOI 10.1002/macp.201600429
   Tuckermann J, 2021, NAT REV RHEUMATOL, V17, P608, DOI 10.1038/s41584 021 00682 3
   Tran VT, 2011, INT J PHARMACEUT, V407, P1, DOI 10.1016/j.ijpharm.2011.01.027
   Vashishtha AK, 2016, J BIOL CHEM, V291, P20869, DOI 10.1074/jbc.R116.742494
   Wan QQ, 2022, ACS APPL MATER INTER, V14, P14103, DOI 10.1021/acsami.2c02079
   Wang XF, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202010068
   Wang YX, 2022, ACTA BIOMATER, V147, P342, DOI 10.1016/j.actbio.2022.05.018
   Wang ZM, 2017, NPG ASIA MATER, V9, DOI 10.1038/am.2017.171
   Wildemann B, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572 021 00289 8
   Wu L, 2020, BIOMATERIALS, V227, DOI 10.1016/j.biomaterials.2019.119555
   Xu LJ, 2020, ADV MATER, V32, DOI 10.1002/adma.201907491
   Yan J, 2016, P NATL ACAD SCI USA, V113, pE7554, DOI 10.1073/pnas.1607235113
   Yin MT, 2021, ACS NANO, V15, P17842, DOI 10.1021/acsnano.1c06036
   Zaichick S, 2011, METALLOMICS, V3, P186, DOI 10.1039/c0mt00069h
   Zambelli B, 2012, METAL IONS LIFE SCI, V10, P135, DOI 10.1007/978 94 007 2172 2_5
   Zambon A, 2021, ACS BIOMATER SCI ENG, V7, P4388, DOI 10.1021/acsbiomaterials.1c00414
   Zhang ZC, 2016, STEM CELLS, V34, P1576, DOI 10.1002/stem.2334
   Zhao FJ, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800361
   Zhao PP, 2019, CHEM ENG J, V359, P1120, DOI 10.1016/j.cej.2018.11.071
   Zhao X, 2016, ADV FUNCT MATER, V26, P2809, DOI 10.1002/adfm.201504943
   Zheng DD, 2022, CHEM ENG J, V428, DOI 10.1016/j.cej.2021.131064
NR 66
TC 20
Z9 20
U1 22
U2 81
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2590 0064
J9 MATER TODAY BIO
JI Mater. Today Bio
PD APR
PY 2024
VL 25
AR 100956
DI 10.1016/j.mtbio.2024.100956
EA JAN 2024
PG 17
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA KI4S0
UT WOS:001179323500001
PM 38322657
OA gold
DA 2025 08 17
ER

PT J
AU Song, HX
   Yu, JJ
   Yang, YJ
   Zhou, LL
   Liu, XY
   Yu, JB
   Huang, QX
   Wang, SQ
   Zhang, XY
   Liu, Y
   Zhang, DZ
   Meng, JG
   Han, TF
   Li, WF
   Niu, XF
AF Song, Huixin
   Yu, Jinjin
   Yang, Yajie
   Zhou, Lili
   Liu, Xinyao
   Yu, Jiabao
   Huang, Qiuxia
   Wang, Siqi
   Zhang, Xinya
   Liu, Yang
   Zhang, Dezhu
   Meng, Jianguo
   Han, Tengfei
   Li, Weifeng
   Niu, Xiaofeng
TI Exploring molecular mechanism of Panlongqi Tablet (PLQT) against RA:
   Integrated network pharmacology, molecular docking and experiment
   validation
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Panlongqi tablet; Rheumatoid arthritis; Network pharmacology; RAW264.7
   macrophages; T lymphocytes; Synovial angiogenesis
ID TRADITIONAL CHINESE MEDICINE; ANGIOGENESIS; TARGETS
AB Background and purpose: Panlongqi Tablet (PLQT), a proprietary Chinese medicine composed of 29 herbs, has been included in the Chinese Medical Insurance List and has shown promising therapeutic effects on patients with rheumatoid arthritis (RA) in clinical practice. However, the molecular mechanisms of PLQT against RA have not been fully elucidated. This study aimed to further decipher the active ingredients and molecular mechanism of PLQT anti RA. Methods: A Complete Freund's adjuvant (CFA) induced rat model was established to evaluate the pharmacodynamic effects of PLQT against RA, the assessment included arthritis index, paw thickness, ankle diameter, morphological and histopathological analysis. Network analysis was used to elucidate the active ingredients and underlying mechanisms of PLQT in the treatment of RA, molecular docking was conducted to assess the binding of active ingredients to key targets. In vitro and in vivo experimental verification were employed to reveal the mechanism of PLQT against RA. Results: Experimentally, PLQT improved CFA induced arthritis without evident side effects. Network analysis revealed that the active ingredients in PLQT were mainly flavonoids, biscoumarin derivatives, alklaloid and lignans. Integrated with molecular docking studies, the molecular mechanisms of PLQT against RA were enriched in inflammatory response, immune regulation, angiogenesis, osteoclast differentiation and autophagy. In vitro experiments confirmed that PLQT exerted anti inflammatory and immune regulatory effects by targeting the inflammatory response of M1 macrophages and the biological functions of T lymphocytes. In addition, In vivo experiments verified that PLQT could further inhibit synovial angiogenesis to prevent RA. Conclusion: This study integrated network pharmacology analysis, molecular docking and experimental validation to elucidate the active components of PLQT and its mechanisms in intervening the pathological progression of RA, providing a more comprehensive theoretical basis for the clinical application of PLQT in the treatment of RA.
C1 [Li, Weifeng; Niu, Xiaofeng] Xi An Jiao Tong Univ, Sch Pharm, 76 Western Yanta Rd, Xian 710061, Shaanxi, Peoples R China.
   Shaanxi Panlong Pharmaceut Grp Ltd Share LTD, Xian, Peoples R China.
C3 Xi'an Jiaotong University
RP Li, WF; Niu, XF (通讯作者)，Xi An Jiao Tong Univ, Sch Pharm, 76 Western Yanta Rd, Xian 710061, Shaanxi, Peoples R China.
EM liwf@mail.xjtu.edu.cn; niuxf@mail.xjtu.edu.cn
RI liu, xinyao/KHD 0922 2024; Yu, Jiabao/U 1179 2019; yang,
   yajie/HZK 0090 2023
FU Project of Shaanxi Traditional Chinese Medicine Administration
   [2019 13]; Special Project for Guiding Technological Innovation of
   Shaanxi Provincial Department of science and technology
   [2023QYPY2 07HZ]; Shaanxi Province, PR China
FX This study was supported by the Project of Shaanxi Traditional Chinese
   Medicine Administration (no.: 2019 13) and the Special Project for
   Guiding Technological Innovation of Shaanxi Provincial Department of
   science and technology (no.: 2023QYPY2 07HZ) (Shaanxi Province, PR
   China) .
CR Ao LM, 2022, MOL IMMUNOL, V141, P13, DOI 10.1016/j.molimm.2021.11.002
   Bao YRG, 2019, PHYTOMEDICINE, V63, DOI 10.1016/j.phymed.2019.153036
   Ben Mrid R, 2022, BIOMED PHARMACOTHER, V151, DOI 10.1016/j.biopha.2022.113126
   Black RJ, 2023, LANCET RHEUMATOL, V5, pE594, DOI 10.1016/S2665 9913(23)00211 4
   Chen H., 2023, Eval. Anal. Drug Use Hosp. China, V23, P290
   Dai WB, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.694507
   Di Matteo A, 2023, LANCET, V402, P2019, DOI 10.1016/S0140 6736(23)01525 8
   Gao C, 2024, FRONT PHARMACOL, V15, DOI 10.3389/fphar.2024.1380098
   Gao Y, 2024, MEDCOMM, V5, DOI 10.1002/mco2.509
   Guo Q, 2024, SIGNAL TRANSDUCT TAR, V9, DOI 10.1038/s41392 024 01757 9
   He YF, 2021, CHIN HERB MED, V13, P451, DOI 10.1016/j.chmed.2021.09.005
   Hu X.J., 2009, Studies on bio active constituents of four medicinal plants
   Hu Y.L., 2023, J. Med. Pharmac. Chin., V29, P21
   Hua SS, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00184
   Huang S, 2025, COMB CHEM HIGH T SCR, V28, P122, DOI 10.2174/0113862073263350231107105959
   Jia KX, 2023, CHIN HERB MED, V15, P157, DOI 10.1016/j.chmed.2022.06.014
   Jia WT, 2023, CANCER LETT, V567, DOI 10.1016/j.canlet.2023.216261
   Ju Z.X., 2020, Drugs Clinic, V33, P3011
   Karnam S, 2024, DRUG DISCOV TODAY, V29, DOI 10.1016/j.drudis.2024.104071
   Kessler J, 2021, PHARMACOL RES, V170, DOI 10.1016/j.phrs.2021.105494
   Le THV, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105387
   Li YX, 2019, INT IMMUNOPHARMACOL, V73, P362, DOI 10.1016/j.intimp.2019.05.024
   Liang HY, 2024, ANAL BIOCHEM, V684, DOI 10.1016/j.ab.2023.115360
   Lin B, 2016, PHARM BIOL, V54, P1741, DOI 10.3109/13880209.2015.1126619
   Lin P.Z., 2021, Anhui Med Pharm J., V25, P1713
   Liu S, 2021, CLIN IMMUNOL, V230, DOI 10.1016/j.clim.2021.108793
   Liu YF, 2015, CHIN HERB MED, V7, P18, DOI 10.1016/S1674 6384(15)60015 6
   Liu Z., 2023, Chin. J. Tradit. Med. Traumatol. Orthop., V31, P13
   Lu C, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906 020 2815 y
   Lü SW, 2015, J ETHNOPHARMACOL, V176, P177, DOI 10.1016/j.jep.2015.10.010
   Monu P., 2024, CYTOKINE, V179, DOI DOI 10.1016/j.cyto.2024.156616
   Mould AW, 2003, ARTHRITIS RHEUM US, V48, P2660, DOI 10.1002/art.11232
   Nasra S, 2024, ADV HEALTHC MATER, V13, DOI 10.1002/adhm.202400679
   Niu XF, 2023, J ETHNOPHARMACOL, V308, DOI 10.1016/j.jep.2023.116250
   Niu XF, 2022, IMMUNOPHARM IMMUNOT, V44, P641, DOI 10.1080/08923973.2022.2073890
   Paggi JM, 2024, ANNU REV BIOCHEM, V93, P389, DOI 10.1146/annurev biochem 030222 120000
   Ralph JA, 2008, EXPERT OPIN THER TAR, V12, P795, DOI 10.1517/14728222.12.7.795 
   Ren M, 2023, PHYTOMEDICINE, V119, DOI 10.1016/j.phymed.2023.155021
   Rufino AT, 2024, MED RES REV, V44, P497, DOI 10.1002/med.21990
   Sabi EM, 2022, INFLAMMOPHARMACOLOGY, V30, P737, DOI 10.1007/s10787 022 00974 4
   Shi SL, 2023, COMPUT BIOL MED, V157, DOI 10.1016/j.compbiomed.2023.106777
   Shin Han Byeol, 2023, Yakhak Hoeji, V67, P8, DOI 10.17480/psk.2023.67.1.8
   Standardization Project Team of Clinical Application Guidelines of the Chinese Medicines for the Treatment of Common Diseases, 2023, Chin. J. Integr. Tradit. Wes Med., V43, P261
   Wang L, 2022, PHYTOMEDICINE, V105, DOI 10.1016/j.phymed.2022.154360
   Wang Ru, 2023, Progress in Modern Biomedicine, V23, P193, DOI 10.13241/j.cnki.pmb.2023.01.038
   [卫博凯 Wei Bokai], 2024, [中草药, Chinese Traditional and Herbal Drugs], V55, P190
   Xu YY, 2023, ACTA PHARM SIN B, V13, P4417, DOI 10.1016/j.apsb.2023.05.025
   Yamaura K, 2023, AGEING RES REV, V90, DOI 10.1016/j.arr.2023.101989
   Yang M, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25052688
   Yang RY, 2023, FITOTERAPIA, V170, DOI 10.1016/j.fitote.2023.105667
   Yang XY, 2024, INT IMMUNOPHARMACOL, V142, DOI 10.1016/j.intimp.2024.113058
   Yu XM, 2024, COMPUT BIOL MED, V169, DOI 10.1016/j.compbiomed.2023.107863
   Zhang JQ, 2024, FRONT IMMUNOL, V15, DOI 10.3389/fimmu.2024.1312919
   Zhang P, 2024, BRIEF BIOINFORM, V25, DOI 10.1093/bib/bbad518
   Zhao F, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1272133
   Zhou DC, 2021, J ETHNOPHARMACOL, V268, DOI 10.1016/j.jep.2020.113683
   Zhou JB, 2022, J ORTHOP SURG RES, V17, DOI 10.1186/s13018 022 03316 w
NR 57
TC 0
Z9 0
U1 6
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JAN 10
PY 2025
VL 144
AR 113639
DI 10.1016/j.intimp.2024.113639
EA NOV 2024
PG 19
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA O4O7V
UT WOS:001370947700001
PM 39616851
DA 2025 08 17
ER

PT J
AU Palomares, I
   Ramos, R
   Martin Malo, A
   Merello, JI
   Praga, M
   Luño, J
   de Francisco, ALM
AF Palomares, I.
   Ramos, R.
   Martin Malo, A.
   Merello, J. I.
   Praga, M.
   Luno, J.
   de Francisco, A. L. M.
CA ORD Grp
TI Compliance with Mineral Metabolism Targets in Haemodialysis Patients:
   Moving Backwards?
SO BLOOD PURIFICATION
LA English
DT Article
DE Mineral metabolism; Compliance; Guidelines; Haemodialysis
ID CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE GUIDELINES; STAGE
   RENAL DISEASE; DIALYSIS OUTCOMES; BONE METABOLISM; MORTALITY;
   MANAGEMENT; RISK; PTH; HYPERPHOSPHATEMIA
AB Background: To standardize therapy and improve the clinical outcome for chronic haemodialysis (HD) patients, guidelines have been developed for mineral metabolism management. We evaluated compliance with different mineral metabolism guidelines. Methods: 2,951 chronic HD patients from 61 dialysis centres in Spain were studied. Mineral metabolism management data from a 1 year period were analysed according to KDOQI, KDIGO, and Spanish guidelines. Results: Only 1% (KDOQI), 6% (KDIGO) and 11% (Spanish guidelines) of patients continuously achieved total calcium (Ca), phosphate (P) and parathyroid hormone (PTH) target range values during the year with higher percentages if we considered the 1 year average. The yearly Ca, P and iPTH average accomplished Spanish guidelines with different percentage among centres: CA 62 100%, P 59 91%, PTH 61 89%, and 28 77% considering all three targets together. The KDIGO guidelines recommend similar percentages except for P (33 77%). No differences were found related to eKt/V, online haemodiafiltration/HD, weight, body mass index, or dialysis vintage. They were only related to age, blood flow, effective treatment time, and dialysate calcium but without relevant clinical differences. Patients outside the target ranges generated significantly higher treatment costs. Conclusions: Compliance with mineral metabolism targets in HD patients was poor and showed a wide variation between treatment centres. (C) 2013 S. Karger AG, Basel
C1 [Palomares, I.; Ramos, R.; Merello, J. I.] Fresenius Med Care, NephroCare Med Management, Madrid, Spain.
   [Praga, M.] Hosp Univ 12 Octubre, Dept Nephrol, Madrid, Spain.
   [Luno, J.] Hosp Gen Univ Gregorio Maranon, Dept Nephrol, Madrid, Spain.
   [Martin Malo, A.] Hosp Gen Univ Reina Sofia, Dept Nephrol, Cordoba, Spain.
   [de Francisco, A. L. M.] Hosp Univ Marques de Valdecilla, Dept Nephrol, Santander, Spain.
C3 Hospital Universitario 12 de Octubre; General University Gregorio
   Maranon Hospital; Hospital Universitario Marques de Valdecilla (HUMV)
RP Palomares, I (通讯作者)，Fresenius Med Care Espana, Dept Direcc Med, Ave Sur Aeropuerto Barajas 34,5A Planta, ES 28042 Madrid, Spain.
EM Ines.Palomares@fmc ag.com
RI PRAGA, MANUEL/W 4091 2017; Luno, Jose/NBY 1191 2025; RAMOS,
   Rosa/ITV 3999 2023
OI Ramos, Rosa/0000 0003 1361 5672
CR Al Aly Z, 2004, AM J NEPHROL, V24, P422, DOI 10.1159/000080087
   Arenas MD, 2006, NEPHROL DIAL TRANSPL, V21, P1663, DOI 10.1093/ndt/gfl006
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Bover J, 2008, NEFROLOGIA, V28, P637
   Danese MD, 2006, AM J KIDNEY DIS, V47, P149, DOI 10.1053/j.ajkd.2005.09.024
   Davenport A, 2010, BLOOD PURIFICAT, V30, P111, DOI 10.1159/000319954
   Davis DA, 1997, CAN MED ASSOC J, V157, P408
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Elder Grahame, 2006, Nephrology (Carlton), V11 Suppl 1, pS230, DOI 10.1111/j.1440 1797.2006.00508.x
   Fernández E, 2013, NEFROLOGIA, V33, P1, DOI 10.3265/Nefrologia.pre2012.Dec.11890
   Floege J, 2011, NEPHROL DIAL TRANSPL, V26, P1948, DOI 10.1093/ndt/gfq219
   Foley RN, 1998, J AM SOC NEPHROL, V9, P267
   Fouque D, 2013, NEPHROL DIAL TRANSPL, V28, P360, DOI 10.1093/ndt/gfs404
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   Górriz JL, 2013, NEFROLOGIA, V33, P46
   Jadoul M, 2006, KIDNEY INT, V70, P1358, DOI 10.1038/sj.ki.5001754
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kuhlmann MK, 2007, BLOOD PURIFICAT, V25, P120, DOI 10.1159/000096410
   Lorenzo V, 2006, NEPHROL DIAL TRANSPL, V21, P459, DOI 10.1093/ndt/gfi213
   Marcelli D, 2001, J NEPHROL, V14, pS94
   Marcelli D, 2002, CONTRIB NEPHROL, V137, P293
   McDonald SE, 2009, ADELAIDE AUSTR NZ DI
   Raggi P, 2002, J AM COLL CARDIOL, V39, P695, DOI 10.1016/S0735 1097(01)01781 8
   Razzaque MS, 2013, CONTRIB NEPHROL, V180, p[VIII, 154]
   Richards N, 2007, BLOOD PURIFICAT, V25, P221, DOI 10.1159/000101026
   Rodriguez Benot A, 2005, AM J KIDNEY DIS, V46, P68, DOI 10.1053/j.ajkd.2005.04.006
   Souberbielle JC, 2006, KIDNEY INT, V70, P345, DOI 10.1038/sj.ki.5001606
   Steil H, 2004, METHOD INFORM MED, V43, P83
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Torregrosa JV, 2011, NEFROLOGIA, V31, P3, DOI 10.3265/Nefrologia.pre2011.Jan.10816
   Toussaint ND, 2011, NEPHROL DIAL TRANSPL, V26, P1319, DOI 10.1093/ndt/gfq602
   Wald R, 2007, AM J KIDNEY DIS, V49, P257, DOI 10.1053/j.ajkd.2006.11.027
   Wazny LD, 2008, CANNT J, V18, P42
   Wazny LD, 2008, CANNT J, V18, P51
   Wazny LD, 2008, CANNT J, V18, P44
   Wazny Lori D, 2008, CANNT J, V18, P36
   Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523 1755.2005.00185.x
NR 38
TC 7
Z9 8
U1 0
U2 12
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 0253 5068
EI 1421 9735
J9 BLOOD PURIFICAT
JI Blood Purif.
PY 2013
VL 36
IS 2
BP 122
EP 131
DI 10.1159/000353418
PG 10
WC Hematology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Urology & Nephrology
GA 268RQ
UT WOS:000328188600010
PM 24217176
DA 2025 08 17
ER

PT J
AU Clark, JCM
   Akiyama, T
   Thomas, DM
   Labrinidis, A
   Evdokiou, A
   Galloway, SJ
   Kim, HS
   Dass, CR
   Choong, PFM
AF Clark, Jonathan C. M.
   Akiyama, Toru
   Thomas, David M.
   Labrinidis, Agatha
   Evdokiou, Andreas
   Galloway, Stuart J.
   Kim, Han Soo
   Dass, Crispin R.
   Choong, Peter F. M.
TI RECK in Osteosarcoma A Novel Role in Tumour Vasculature and Inhibition
   of Tumorigenesis in an Orthotopic Model
SO CANCER
LA English
DT Article
DE osteosarcoma; RECK; matrix metalloproteinases; VEGF; angiogenesis
ID REGULATOR RECK; CELL GROWTH; IN VIVO; METASTASIS; CANCER; EXPRESSION;
   BONE; INVASION; MATRIX METALLOPROTEINASE 9; INVASIVENESS
AB BACKGROUND: Targeted therapy in osteosarcoma (OS) is needed to improve patient outcomes. Human RECK may have a role because it inhibits cancer invasion and regulates angiogenesis. This study aimed to characterize RECK expression in human OS, to examine in vitro effects of RECK on vascular endothelium and OS cell behavior, and to analyze the effect of RECK on OS grown orthotopically in nude mice. METHODS: RECK was examined in human OS samples. Interactions between RECK and VEGF were studied in tissue and cells. RECK transfection was used to study its effects on vascular endothelial (HMEC 1) and OS (SaOS 2) cell behavior in vitro and in vivo. SaOS 2 co culture with RAW 246.7 derived osteoclasts on osteoslides was used to assess effects on osteoclast activity. RESULTS: RECK was absent from OS cells but was expressed in tumor vessel endothelium. Via microarray analysis, RECK mRNA was elevated in samples with low proliferative activity, a trend most evident in poorly differentiated samples. VEGF induced RECK expression in HMEC 1. RECK transfection inhibited HMEC 1 invasion and induced thicker, although more numerous, tube formation. RECK inhibited SaOS 2 invasion, proliferation, colony formation, and osteoclast activity but supported SaOS 2 adhesion to collagen I. In vivo, RECK inhibited SaOS 2 tumor growth, bone destruction, and consequent metastasis. CONCLUSIONS: RECK expression is downregulated in highly proliferative OS but is present in tumor vessels and upregulated in endothelium by VEGF. RECK inhibits invasion and tumorigenic properties in SaOS 2, as confirmed in vivo. Further testing of RECK delivery in OS is warranted. Cancer 2011;117:3517 28. (C) 2011 American Cancer Society.
C1 [Clark, Jonathan C. M.; Akiyama, Toru; Dass, Crispin R.; Choong, Peter F. M.] Univ Melbourne, St Vincents Hosp, Dept Orthoped, Melbourne, Vic, Australia.
   [Clark, Jonathan C. M.; Akiyama, Toru; Choong, Peter F. M.] Univ Melbourne, St Vincents Hosp, Dept Surg, Melbourne, Vic, Australia.
   [Thomas, David M.; Choong, Peter F. M.] Peter MacCallum Canc Inst, Sarcoma Serv, Melbourne, Vic 3000, Australia.
   [Labrinidis, Agatha; Evdokiou, Andreas] Univ Adelaide, Royal Adelaide Hosp, Dept Orthoped, Adelaide, SA, Australia.
   [Galloway, Stuart J.] St Vincents Hosp, Dept Anat Pathol, Melbourne, Vic, Australia.
   [Kim, Han Soo] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Orthoped Surg, Seoul, South Korea.
C3 NSW Health; St Vincents Hospital Sydney; University of Melbourne; St
   Vincent's Health; St Vincent's Hospital Melbourne; University of
   Melbourne; St Vincent's Health; St Vincent's Hospital Melbourne; NSW
   Health; St Vincents Hospital Sydney; Peter Maccallum Cancer Center;
   University of Adelaide; Royal Adelaide Hospital; NSW Health; St Vincents
   Hospital Sydney; St Vincent's Health; St Vincent's Hospital Melbourne;
   Seoul National University (SNU); Seoul National University Hospital
RP Choong, PFM (通讯作者)，St Vincents Hosp, Dept Orthopaed, 3rd Floor Daly Wing,35 Victoria Pde, Fitzroy, Vic 3065, Australia.
RI Thomas, David/AAD 2877 2019; Akiyama, Toru/AAA 5887 2020; Kim,
   Hansoo/D 5743 2012; Akiyama, Toru/F 6349 2017; Choong, Peter/F 1109 2014
OI Choong, Peter/0000 0001 7333 7665; Labrinidis,
   Agatha/0009 0000 3897 3084; Thomas, David/0000 0002 2527 5428; Akiyama,
   Toru/0000 0001 9493 4768; Dass, Crispin/0000 0001 7087 7957; Choong,
   Peter/0000 0002 3522 7374
FU Australian Orthopaedic Association; Royal Australasian College of
   Surgeons; St Vincent's Hospital; National Health and Medical Research
   Council of Australia
FX This study was supported by a grant from the Australian Orthopaedic
   Association. Jonathan C. M. Clark was supported by scholarships from the
   Royal Australasian College of Surgeons, St Vincent's Hospital, and the
   National Health and Medical Research Council of Australia.
CR Akiyama T, 2010, CLIN EXP METASTAS, V27, P207, DOI 10.1007/s10585 010 9319 y
   Ayala G, 2000, HUM PATHOL, V31, P341, DOI 10.1016/S0046 8177(00)80248 8
   BERLIN O, 1993, CANCER RES, V53, P4890
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Chang CK, 2008, J CELL MOL MED, V12, P2781, DOI 10.1111/j.1582 4934.2008.00215.x
   Chang HC, 2004, CELL SIGNAL, V16, P675, DOI 10.1016/j.cellsig.2003.11.001
   Clark JCM, 2007, CANCER METAST REV, V26, P675, DOI 10.1007/s10555 007 9093 8
   Dass CR, 2006, CLIN EXP METASTAS, V23, P367, DOI 10.1007/s10585 006 9046 6
   Dohn MR, 2009, J CELL BIOL, V184, P437, DOI 10.1083/jcb.200807096
   Dong Z, 2005, AM J PATHOL, V166, P1173, DOI 10.1016/S0002 9440(10)62337 1
   Irie K, 2001, TISSUE CELL, V33, P478
   Kang HG, 2007, J ORTHOP RES, V25, P696, DOI 10.1002/jor.20323
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104
   LODWICK GS, 1980, RADIOLOGY, V134, P577, DOI 10.1148/radiology.134.3.6928321
   Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585 005 0365 9
   Malik Faraz Arshad, 2009, Cancer Genomics & Proteomics, V6, P205
   Masui T, 2003, CLIN CANCER RES, V9, P1779
   Maupas Schwalm F, 2009, CELL SIGNAL, V21, P1925, DOI 10.1016/j.cellsig.2009.08.010
   Mintz MB, 2005, CANCER RES, V65, P1748, DOI 10.1158/0008 5472.CAN 04 2463
   Morioka Y, 2009, ONCOGENE, V28, P1454, DOI 10.1038/onc.2008.486
   Noguera Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355
   Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092 8674(01)00597 9
   ROBERTSON JH, 1976, BRIT MED J, V1, P23, DOI 10.1136/bmj.1.6000.23
   SCOTLANDI K, 1995, CANCER, V75, P806, DOI 10.1002/1097 0142(19950201)75:3<806::AID CNCR2820750310>3.0.CO;2 S
   Corrêa TCS, 2010, J CELL BIOCHEM, V110, P52, DOI 10.1002/jcb.22472
   Stoch SA, 2008, CLIN PHARMACOL THER, V83, P172, DOI 10.1038/sj.clpt.6100450
   Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445
   Takagi S, 2009, CANCER RES, V69, P1502, DOI 10.1158/0008 5472.CAN 08 2635
   Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221
   Takeuchi T, 2004, CLIN CANCER RES, V10, P5572, DOI 10.1158/1078 0432.CCR 03 0656
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
NR 32
TC 22
Z9 23
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0008 543X
EI 1097 0142
J9 CANCER AM CANCER SOC
JI Cancer
PD AUG 1
PY 2011
VL 117
IS 15
BP 3517
EP 3528
DI 10.1002/cncr.25757
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 797DD
UT WOS:000293103800026
PM 21287525
DA 2025 08 17
ER

PT J
AU Kong, WP
   Tang, YL
   Tang, KH
   Yan, ZR
   Liu, T
   Tao, QW
   Wang, JC
   Liu, J
   Yan, XP
AF Kong, Weiping
   Tang, Yulong
   Tang, Kunhai
   Yan, Zeran
   Liu, Ting
   Tao, Qingwen
   Wang, Jiucun
   Liu, Jing
   Yan, Xiaoping
TI Leukemia inhibitory factor is dysregulated in ankylosing spondylitis and
   contributes to bone formation
SO INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
LA English
DT Article
DE ankylosing spondylitis; cytokine; inflammation; leukemia inhibitory
   factor; osteogenesis
ID SPONDYLOARTHRITIS RESEARCH CONSORTIUM; RESONANCE IMAGING INDEX;
   DIAGNOSTIC CRITERIA; PATHOGENESIS; INFLAMMATION; LIF
AB Aim Ankylosing spondylitis (AS) is a chronic inflammatory disease. However, the key inflammatory cytokines disrupted in this disease are not well defined. In this study, we performed protein array and multiple protein quantification to investigate the differentially expressed cytokines in plasma between AS patients and healthy subjects. Method In the discovery cohort, 5 AS patients who never underwent biologic therapy and 5 gender  and age matched healthy subjects were enrolled in the protein array analysis. Another 40 AS patients and 20 healthy participants were recruited in the validation stage. In addition, the messenger RNA and protein levels of osteogenesis related genes were quantified in hFOB1.19 cells in an in vitro osteoblast model. Results Of the 318 cytokines found to be differentially expressed by protein array, leukemia inhibitor factor (LIF) was significantly increased in AS patients as compared to controls. The "signaling by interleukins" pathway was the most enriched pathway in AS patients, and "signaling by interleukins" related cytokines, including LIF, interleukin (IL) 6, IL 23, and IL 31, were significantly differentially expressed in the validation stage. Additionally, we correlated the expression of LIF with C reactive protein (CRP) and inflammation of magnetic resonance imaging lesions in the spine (MRI SPINE) in AS patients. We further analyzed the effects of LIF in hFOB cells and found that LIF promoted the growth factor receptor bound protein 2 / phospho extracellular signal regulated kinase / runt related transcription factor 2 / alkaline phosphatase pathway at the protein level and activated several osteogenesis related genes (RUNX2 and BGLAP). Conclusion LIF was increased in the plasma of AS patients as compared with healthy subjects and significantly correlated with inflammation indices (CRP and MRI SPINE) in AS patients. Thus, LIF may play a critical role in the pathogenesis of AS via promoting osteogenic differentiation.
C1 [Kong, Weiping; Yan, Zeran; Liu, Ting; Tao, Qingwen; Yan, Xiaoping] China Japan Friendship Hosp, Dept TCM Rheumatol, Beijing, Peoples R China.
   [Tang, Yulong; Tang, Kunhai] Fudan Univ, Sch Life Sci, Dept Anthropol & Human Genet, MOE Key Lab Contemporary Anthropol, Shanghai, Peoples R China.
   [Tang, Yulong; Wang, Jiucun; Liu, Jing] Fudan Univ, Human Phenome Inst, Shanghai, Peoples R China.
   [Tao, Qingwen] China Japan Friendship Hosp, Beijing Key Lab Immune Mediated Inflammatory Dis, Beijing, Peoples R China.
C3 China Japan Friendship Hospital; Fudan University; Fudan University;
   China Japan Friendship Hospital
RP Yan, XP (通讯作者)，China Japan Friendship Hosp, Dept TCM Rheumatol, Beijing, Peoples R China.; Liu, J (通讯作者)，Fudan Univ, Human Phenome Inst, Shanghai, Peoples R China.
EM liu_jing@fudan.edu.cn; yanxiaoping1688@126.com
RI ; Yan, ZeRan/KPA 3719 2024; Liu, Jing/NJT 2149 2025; Qingwen,
   Tao/HHC 4235 2022; TAO, ZHANG/AAY 1196 2021; Tang, Kun/GSD 3218 2022;
   Wang, Jiucun/J 8744 2012
OI Liu, Jing/0000 0003 0569 3080; Jiucun, Wang/0000 0003 2765 0620; Tang,
   Yulong/0000 0002 7794 2181; Tang, Kunhai/0000 0002 2229 6645; Liu,
   Jing/0000 0003 4346 0800; tao, qing wen/0000 0002 9163 8426; 
FU National Natural Science Foundation of China [81403378, 82001726];
   Natural Science Foundation of Beijing, China [7182148]; Beijing
   Traditional Chinese Medicine Technology Development Project
   [JJ 2020 87]; Shanghai Municipal Science and Technology Major Project
   [2017SHZDZX01]
FX Project supported by the National Natural Science Foundation of China
   (81403378), Natural Science Foundation of Beijing, China (7182148),
   Beijing Traditional Chinese Medicine Technology Development Project
   (JJ 2020 87), National Natural Science Foundation of China (82001726)
   and Shanghai Municipal Science and Technology Major Project
   (2017SHZDZX01)
CR Braun J, 2011, ANN RHEUM DIS, V70, pI97, DOI 10.1136/ard.2010.140541
   Creemers MCW, 2005, ANN RHEUM DIS, V64, P127, DOI 10.1136/ard.2004.020503
   Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407
   Jones SA, 2018, NAT REV IMMUNOL, V18, P773, DOI 10.1038/s41577 018 0066 7
   Koide M, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 70817 1
   KURZROCK R, 1991, ENDOCR REV, V12, P208, DOI 10.1210/edrv 12 3 208
   Liu CL, 2017, CYTOKINE, V91, P132, DOI 10.1016/j.cyto.2016.12.016
   Liu J, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.369
   Liu J, 2019, ANN RHEUM DIS, V78, P852, DOI 10.1136/annrheumdis 2018 214625
   Liu LF, 2021, J CELL PHYSIOL, V236, P6090, DOI 10.1002/jcp.30313
   Lu B, 2020, MOL CANCER RES, V18, P57, DOI 10.1158/1541 7786.MCR 19 0470
   Maksymowych WP, 2005, ARTHRIT RHEUM ARTHR, V53, P703, DOI 10.1002/art.21445
   Maksymowych WP, 2005, ARTHRIT RHEUM ARTHR, V53, P502, DOI 10.1002/art.21337
   METCALF D, 1991, INT J CELL CLONING, V9, P95, DOI 10.1002/stem.5530090201
   Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197
   Nicola NA, 2015, CYTOKINE GROWTH F R, V26, P533, DOI 10.1016/j.cytogfr.2015.07.001
   Raychaudhuri SP, 2014, J AUTOIMMUN, V48 49, P128, DOI 10.1016/j.jaut.2014.01.015
   Reveille JD, 2019, ANN RHEUM DIS, V78, P66, DOI 10.1136/annrheumdis 2018 213779
   Sieper J, 2017, LANCET, V390, P73, DOI 10.1016/S0140 6736(16)31591 4
   Simone D, 2018, RHEUMATOLOGY, V57, P4, DOI 10.1093/rheumatology/key001
   Sims NA, 2012, GROWTH FACTORS, V30, P76, DOI 10.3109/08977194.2012.656760
   Smith JA, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882 014 0489 6
   Sutherland L, 2018, J CELL SCI, V131, DOI 10.1242/jcs.222257
   Tam LS, 2010, NAT REV RHEUMATOL, V6, P399, DOI 10.1038/nrrheum.2010.79
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Van Vlasselaer Peter, 1992, Progress in Growth Factor Research, V4, P337, DOI 10.1016/0955 2235(92)90015 A
   VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361
   Voruganti A, 2020, IMMUNOLOGY, V161, P94, DOI 10.1111/imm.13242
   Weivoda MM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14003 6
   Wu JL, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00231
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhou XD, 2020, ANN RHEUM DIS, V79, DOI 10.1136/annrheumdis 2018 214708
NR 32
TC 8
Z9 9
U1 1
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1756 1841
EI 1756 185X
J9 INT J RHEUM DIS
JI Int. J. Rheum. Dis.
PD MAY
PY 2022
VL 25
IS 5
BP 592
EP 600
DI 10.1111/1756 185X.14312
EA MAR 2022
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 0X1FI
UT WOS:000763543400001
PM 35238474
DA 2025 08 17
ER

PT J
AU Matsumoto, MA
   Furquim, EMD
   Gonçalves, A
   Santiago, JF
   Saraiva, PP
   Cardoso, CL
   Munerato, MS
   Okamoto, R
AF Matsumoto, Mariza Akemi
   de Abreu Furquim, Elisa Mara
   Goncalves, Alade
   Santiago Junior, Joel Ferreira
   Saraiva, Patricia Pinto
   Cardoso, Camila Lopes
   Munerato, Marcelo Salles
   Okamoto, Roberta
TI Aged rats under zoledronic acid therapy and oral surgery
SO JOURNAL OF CRANIO MAXILLOFACIAL SURGERY
LA English
DT Article
DE Aging; Bisphosphonate; Oral surgery; Rats
ID BISPHOSPHONATE RELATED OSTEONECROSIS; EXPERIMENTAL MODEL; BONE;
   OSTEOPOROSIS; MECHANISMS; EXPRESSION; RESISTANCE; INFECTION; HUMANS;
   UPDATE
AB Introduction: Aging brings a number of health conditions that can compromise the healing process in elderly individuals, significantly when it comes to bone tissue. The aim of the present study was to analyze the effects of zoledronic acid (ZL) therapy on socket healing of aged male rats.
   Materials and methods: Twenty four Wistar male rats, 20 months old, underwent surgical procedures for the extraction of the upper right incisor and were divided into two groups according to the treatment: Control (C)   intravenous (IV) 0.9% saline, ZL   0.035 mg/kg of IV zoledronic acid, both every 15 days. At the fifth dose of both substances, tooth extractions were performed and the animals were euthanized after 14 and 28 days.
   Results: IV administration of ZL caused OPG RANKL system imbalance, resulting in deficient bone formation and remodeling and alteration of osteoclast morphology, as well as maintaining persistent inflammation during the healing period.
   Conclusions: IV administration of ZL delayed extracted dental socket healing of aged rats, but not enough to cause osteonecrosis, raising a question about different responses to IV BP therapy considering animal age. (C) 2017 European Association for Cranio Maxillo Facial Surgery. Published by Elsevier Ltd. All rights reserved.
C1 [Matsumoto, Mariza Akemi; de Abreu Furquim, Elisa Mara; Goncalves, Alade; Okamoto, Roberta] Sao Paulo State Univ Unesp, Sch Dent, Rua Jos Bonifacio 1193, Aracatuba, SP, Brazil.
   [Santiago Junior, Joel Ferreira; Saraiva, Patricia Pinto; Cardoso, Camila Lopes; Munerato, Marcelo Salles] Sagrado Coracao Univ USC, Sch Dent, Rua Irma Arminda 10 50, Bauru, SP, Brazil.
C3 Universidade Estadual Paulista; Universidade do Sagrado Coracao
RP Matsumoto, MA (通讯作者)，Rua Jose Bonifacio 1193, BR 16015050 Aracatuba, SP, Brazil.
EM vicmak.blv@terra.com.br
RI ; Okamoto, Roberta/C 4562 2012; Matsumoto, Mariza/AAH 2169 2019;
   Cardoso, Camila/G 4810 2012; Okamoto, Roberta/X 6438 2019; Lopes
   Cardoso, Camila/G 4810 2012; de Abreu Furquim, Elisa/AAI 2683 2020;
   Santiago Junior, Joel/E 5242 2013
OI de Abreu Furquim, Elisa Mara/0000 0002 0618 2787; Okamoto,
   Roberta/0000 0002 6773 6966; Lopes Cardoso, Camila/0000 0001 9545 6809;
   Matsumoto, Mariza Akemi/0000 0001 5389 0105; 
FU Pro Reitoria de Pesquisa (PROPe)   UNESP [671]
FX This work was supported by Pro Reitoria de Pesquisa (PROPe)   UNESP,
   grant number 671.
CR Adam E, 2003, INT J PARASITOL, V33, P1067, DOI 10.1016/S0020 7519(03)00176 0
   Allen MR, 2008, OSTEOPOROSIS INT, V19, P329, DOI 10.1007/s00198 007 0533 7
   Alleyne B, 2016, J CRANIOFAC SURG, V27, P258, DOI 10.1097/SCS.0000000000001313
   Andreollo NA, 2012, ABCD ARQ BRAS CIR DI, V25, P49, DOI 10.1590/S0102 67202012000100011
   Barba Recreo P, 2014, J CRANIO MAXILL SURG, V42, P744, DOI 10.1016/j.jcms.2013.11.005
   Chan CKY, 2016, BRIT MED BULL, V119, P129, DOI 10.1093/bmb/ldw033
   Curra C, 2016, ACTA CIR BRAS, V31, P308, DOI 10.1590/S0102 865020160050000003
   Hokugo A, 2010, J BONE MINER RES, V25, P1337, DOI 10.1002/jbmr.23
   Ishijima M, 2016, IMPLANT DENT, V25, P744, DOI 10.1097/ID.0000000000000459
   Luvizuto ER, 2010, BONE, V46, P1021, DOI 10.1016/j.bone.2009.12.016
   Manolagas SC, 2010, TRENDS ENDOCRIN MET, V21, P369, DOI 10.1016/j.tem.2010.01.010
   Marie PJ, 2014, J BONE MINER RES, V29, P1311, DOI 10.1002/jbmr.2190
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Nakagawa T, 2015, ARCH ORAL BIOL, V60, P557, DOI 10.1016/j.archoralbio.2014.09.012
   Ohe JY, 2012, CLIN ORAL INVEST, V16, P1153, DOI 10.1007/s00784 011 0614 z
   Ostan R, 2016, CLIN SCI, V130, P1711, DOI 10.1042/CS20160004
   Pascutti MF, 2003, SCAND J IMMUNOL, V58, P173, DOI 10.1046/j.1365 3083.2003.01262.x
   Pazianas M, 2016, ANN NY ACAD SCI, V1376, P5, DOI 10.1111/nyas.13166
   Pelaz A, 2015, ACTA OTORRINOLAR ESP, V66, P139, DOI 10.1016/j.otorri.2014.06.003
   Quinn R, 2005, NUTRITION, V21, P775, DOI 10.1016/j.nut.2005.04.002
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Ruggiero SL, 2009, AUST ENDOD J, V35, P119, DOI 10.1111/j.1747 4477.2009.00213.x
   Sengupta P, 2013, INT J PREVENTIVE MED, V4, P624
   Turner Bruce, 2016, Urol Nurs, V36, P111
NR 24
TC 11
Z9 11
U1 0
U2 3
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1010 5182
EI 1878 4119
J9 J CRANIO MAXILL SURG
JI J. Cranio MaxilloFac. Surg.
PD MAY
PY 2017
VL 45
IS 5
BP 781
EP 787
DI 10.1016/j.jcms.2017.02.002
PG 7
WC Dentistry, Oral Surgery & Medicine; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Surgery
GA EU5PG
UT WOS:000401084100026
PM 28318924
OA Green Published
DA 2025 08 17
ER

PT J
AU Lau, WL
   Leaf, EM
   Hu, MC
   Takeno, MM
   Kuro o, M
   Moe, OW
   Giachelli, CM
AF Lau, Wei Ling
   Leaf, Elizabeth M.
   Hu, Ming Chang
   Takeno, Marc M.
   Kuro o, Makoto
   Moe, Orson W.
   Giachelli, Cecilia M.
TI Vitamin D receptor agonists increase klotho and osteopontin while
   decreasing aortic calcification in mice with chronic kidney disease fed
   a high phosphate diet
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE chronic kidney disease; klotho; osteopontin; vascular calcification;
   vitamin D
ID ARTERIAL MEDIAL CALCIFICATION; FIBROBLAST GROWTH FACTOR 23;
   SMOOTH MUSCLE CELLS; VASCULAR CALCIFICATION; HEMODIALYSIS PATIENTS;
   MORTALITY RISK; SERUM PHOSPHORUS; D ANALOGS; 1,25 DIHYDROXYVITAMIN D 3;
   CARDIOVASCULAR DISEASE
AB Vascular calcification is common in chronic kidney disease, where cardiovascular mortality remains the leading cause of death. Patients with kidney disease are often prescribed vitamin D receptor agonists (VDRAs) that confer a survival benefit, but the underlying mechanisms remain unclear. Here we tested two VDRAs in a mouse chronic kidney disease model where dietary phosphate loading induced aortic medial calcification. Mice were given intraperitoneal calcitriol or paricalcitol three times per week for 3 weeks. These treatments were associated with half of the aortic calcification compared to no therapy, and there was no difference between the two agents. In the setting of a high phosphate diet, serum parathyroid hormone and calcium levels were not significantly altered by treatment. VDRA therapy was associated with increased serum and urine klotho levels, increased phosphaturia, correction of hyperphosphatemia, and lowering of serum fibroblast growth factor 23. There was no effect on elastin remodeling or inflammation; however, the expression of the anticalcification factor, osteopontin, in aortic medial cells was increased. Paricalcitol upregulated osteopontin secretion from mouse vascular smooth muscle cells in culture. Thus, klotho and osteopontin were upregulated by VDRA therapy in chronic kidney disease, independent of changes in serum parathyroid hormone and calcium. Kidney International (2012) 82, 1261 1270; doi:10.1038/ki.2012.322; published online 29 August 2012
C1 [Leaf, Elizabeth M.; Takeno, Marc M.; Giachelli, Cecilia M.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   [Lau, Wei Ling] Univ Washington, Dept Nephrol, Seattle, WA 98195 USA.
   [Hu, Ming Chang; Kuro o, Makoto; Moe, Orson W.] Univ Texas SW Med Ctr Dallas, Charles & Jane Pak Ctr Mineral Metab & Clin Res, Dallas, TX 75390 USA.
   [Lau, Wei Ling] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA.
   [Lau, Wei Ling] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA.
   [Kuro o, Makoto; Moe, Orson W.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.
C3 University of Washington; University of Washington Seattle; University
   of Washington; University of Washington Seattle; University of Texas
   System; University of Texas Southwestern Medical Center; University of
   Texas System; University of Texas Southwestern Medical Center;
   University of Texas System; University of Texas Southwestern Medical
   Center; University of Texas System; University of Texas Southwestern
   Medical Center
RP Giachelli, CM (通讯作者)，Univ Washington, Dept Bioengn, 3720 15th Ave NE,Foege N333C,Box 355061, Seattle, WA 98195 USA.
EM ceci@u.washington.edu
RI Lau, Wei/AAE 4397 2020; Takeno, Marc/JBS 1393 2023
OI Giachelli, Cecilia/0000 0002 6387 5993; Soberg,
   Elizabeth/0000 0002 5354 6010; Takeno, Marc/0000 0002 8384 7500
FU Abbott Laboratories; NIH [R01 HL62329, R01 HL081785, R01 DK0092461, R01
   DK091392]; American Heart Association [0865235F]; Charles and Jane Pak
   Center for Mineral Metabolism and Clinical Research, University of Texas
   Southwestern Medical Center; Simmons Family Foundation; O'Brien Kidney
   Research Center [P30 DK 079328]; National Science Foundation
   [EEC 9872882, EEC 9529161];  [T32 HL007828];  [T32 DK007467]; American
   Heart Association (AHA) [0865235F] Funding Source: American Heart
   Association (AHA)
FX This study was funded by a grant from Abbott Laboratories and NIH grants
   to CMG (R01 HL62329 and R01 HL081785). WLL received funding from T32
   HL007828 and T32 DK007467. MCH was in part supported by the American
   Heart Association (0865235F), a seed grant from the Charles and Jane Pak
   Center for Mineral Metabolism and Clinical Research, University of Texas
   Southwestern Medical Center, and NIH grant R01 DK0092461. OWM, MK, and
   MCH were in part supported by NIH grant R01 DK091392, the Simmons Family
   Foundation, and the O'Brien Kidney Research Center (P30 DK 079328). We
   gratefully acknowledge the use of the UWEB Optical Microscopy and Image
   Analysis Shared Resource, funded by the National Science Foundation
   through grants EEC 9872882 and EEC 9529161. We also thank Dr Mohga
   El Abbadi and Ms Danielle F. Peterson for assistance with data
   collection.
CR Becker LE, 2011, AM J PHYSIOL RENAL, V300, pF772, DOI 10.1152/ajprenal.00042.2010
   Bloch L, 2009, FEBS LETT, V583, P3221, DOI 10.1016/j.febslet.2009.09.009
   Block GA, 2007, KIDNEY INT, V71, P438, DOI 10.1038/sj.ki.5002059
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Brown AJ, 2002, J LAB CLIN MED, V139, P279, DOI 10.1067/mlc.2002.122819
   Cardus A, 2007, J BONE MINER RES, V22, P860, DOI 10.1359/JBMR.070305
   Chen CD, 2007, P NATL ACAD SCI USA, V104, P19796, DOI 10.1073/pnas.0709805104
   Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523 1755.2002.00434.x
   Chung AWY, 2009, CIRCULATION, V120, P792, DOI 10.1161/CIRCULATIONAHA.109.862565
   Dhingra R, 2007, ARCH INTERN MED, V167, P879, DOI 10.1001/archinte.167.9.879
   El Abbadi MM, 2009, KIDNEY INT, V75, P1297, DOI 10.1038/ki.2009.83
   Ewald AJ, 2002, DEV DYNAM, V225, P369, DOI 10.1002/dvdy.10169
   Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122
   Finch JL, 2010, AM J PHYSIOL RENAL, V298, pF1315, DOI 10.1152/ajprenal.00552.2009
   Forster RE, 2011, BIOCHEM BIOPH RES CO, V414, P557, DOI 10.1016/j.bbrc.2011.09.117
   Giachelli CM, 2009, KIDNEY INT, V75, P890, DOI 10.1038/ki.2008.644
   Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031
   Goetz R, 2010, P NATL ACAD SCI USA, V107, P407, DOI 10.1073/pnas.0902006107
   Haussler MR, 2010, J STEROID BIOCHEM, V121, P88, DOI 10.1016/j.jsbmb.2010.03.019
   Hu MC, 2011, J AM SOC NEPHROL, V22, P124, DOI 10.1681/ASN.2009121311
   Hu MC, 2010, FASEB J, V24, P3438, DOI 10.1096/fj.10 154765
   Isakova T, 2012, CLIN J AM SOC NEPHRO, V7, P820, DOI 10.2215/CJN.11721111
   Isakova T, 2011, KIDNEY INT, V79, P1370, DOI 10.1038/ki.2011.47
   Jono S, 1998, CIRCULATION, V98, P1302, DOI 10.1161/01.CIR.98.13.1302
   Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10
   Kestenbaum B, 2005, J AM SOC NEPHROL, V16, P520, DOI 10.1681/ASN.2004070602
   Koh N, 2001, BIOCHEM BIOPH RES CO, V280, P1015, DOI 10.1006/bbrc.2000.4226
   Kolek OI, 2005, AM J PHYSIOL GASTR L, V289, pG1036, DOI 10.1152/ajpgi.00243.2005
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200
   Larsson TE, 2010, NEPHROL DIAL TRANSPL, V25, P1376, DOI 10.1093/ndt/gfp784
   Lau WL, 2011, ADV CHRONIC KIDNEY D, V18, P105, DOI 10.1053/j.ackd.2010.12.002
   Li SA, 2004, CELL STRUCT FUNCT, V29, P91, DOI 10.1247/csf.29.91
   Li XW, 2010, ARTERIOSCL THROM VAS, V30, P321, DOI 10.1161/ATVBAHA.109.196576
   Lim K., 2012, Circulation
   Lopez I, 2008, KIDNEY INT, V73, P300, DOI 10.1038/sj.ki.5002675
   Mathew S, 2008, J AM SOC NEPHROL, V19, P1509, DOI 10.1681/ASN.2007080902
   Mizobuchi M, 2007, KIDNEY INT, V72, P709, DOI 10.1038/sj.ki.5002406
   Morishita K, 2001, J NUTR, V131, P3182, DOI 10.1093/jn/131.12.3182
   Naves Díaz M, 2008, KIDNEY INT, V74, P1070, DOI 10.1038/ki.2008.343
   Pai A, 2011, AM J PATHOL, V178, P764, DOI 10.1016/j.ajpath.2010.10.006
   Pilz S, 2011, AM J KIDNEY DIS, V58, P374, DOI 10.1053/j.ajkd.2011.03.020
   Price PA, 2000, ARTERIOSCL THROM VAS, V20, P317, DOI 10.1161/01.ATV.20.2.317
   Reynolds JL, 2004, J AM SOC NEPHROL, V15, P2857, DOI 10.1097/01.ASN.0000141960.01035.28
   Saito H, 2005, J BIOL CHEM, V280, P2543, DOI 10.1074/jbc.M408903200
   Schlieper G, 2010, J AM SOC NEPHROL, V21, P689, DOI 10.1681/ASN.2009080829
   Shoben AB, 2008, J AM SOC NEPHROL, V19, P1613, DOI 10.1681/ASN.2007111164
   Slatopolsky E, 2003, KIDNEY INT, V63, P2020, DOI 10.1046/j.1523 1755.2003.00029.x
   STARCHER BC, 1977, ANAL BIOCHEM, V79, P11, DOI 10.1016/0003 2697(77)90372 4
   Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070
   Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
   Tentori F, 2006, KIDNEY INT, V70, P1858, DOI 10.1038/sj.ki.5001868
   Towler DA, 2007, J AM SOC NEPHROL, V18, P369, DOI 10.1681/ASN.2006121367
   Tsujikawa H, 2003, MOL ENDOCRINOL, V17, P2393, DOI 10.1210/me.2003 0048
   Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166
   Wasse H, 2011, BMC NEPHROL, V12, DOI 10.1186/1471 2369 12 24
   Wu Wong JR, 2007, AM J PHYSIOL RENAL, V293, pF1592, DOI 10.1152/ajprenal.00492.2006
   Wu Wong JR, 2006, J PHARMACOL EXP THER, V318, P90, DOI 10.1124/jpet.106.101261
   Yu XJ, 2005, BONE, V36, P971, DOI 10.1016/j.bone.2005.03.002
   Zebger Gong H, 2011, J HYPERTENS, V29, P339, DOI 10.1097/HJH.0b013e328340aa30
NR 61
TC 209
Z9 230
U1 0
U2 46
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 0085 2538
J9 KIDNEY INT
JI Kidney Int.
PD DEC
PY 2012
VL 82
IS 12
BP 1261
EP 1270
DI 10.1038/ki.2012.322
PG 10
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 048EI
UT WOS:000311892600006
PM 22932118
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Eleftheriadis, T
   Kartsios, C
   Antoniadi, G
   Kazila, P
   Dimitriadou, M
   Sotiriadou, E
   Koltsida, M
   Golfinopoulos, S
   Liakopoulos, V
   Christopoulou Apostolaki, M
AF Eleftheriadis, Theodoros
   Kartsios, Charalambos
   Antoniadi, Georgia
   Kazila, Polizo
   Dimitriadou, Magdalini
   Sotiriadou, Eleni
   Koltsida, Maria
   Golfinopoulos, Spiridon
   Liakopoulos, Vassilios
   Christopoulou Apostolaki, Maria
TI The impact of chronic inflammation on bone turnover in hemodialysis
   patients
SO RENAL FAILURE
LA English
DT Article
DE hemodialysis; renal osteodystrophy; bone turnover; inflammation
ID NECROSIS FACTOR ALPHA; MINERAL DENSITY; RENAL OSTEODYSTROPHY;
   BIOCHEMICAL MARKERS; INTERLEUKIN 6; PREMENOPAUSAL; EXPRESSION; THERAPY;
   WOMEN; BETA
AB Background. Renal osteodystrophy is very common in hemodialysis (HD) patients. HD is a chronic inflammatory state. Studies in other pathological entities have shown an impact of chronic inflammation on bone metabolism. In the present study, the impact of chronic inflammation on bone turnover in HD patients was evaluated. Patients and methods. Thirty three anuric HD patients free of other pathological conditions or medications that affect immune system or bone metabolism and 30 healthy volunteers enrolled into the study. Intact parathyroid hormone (iPTH), the markers of inflammation IL 6 and CRP, as well as the markers of bone turnover osteocalcin (OCN) and beta isomerized C terminal cross linked peptide of collagen type I (beta CTx) were measured in the serum. Results. All evaluated factors were increased in HD patients. In the HD group, the serum marker of osteoblastic activity OCN was related inversely to patients' age (r =  0.469, p = 0.006), CRP (rho =  0.460, p = 0.007), and IL 6 (r =  0.485, p = 0.004) but positively to iPTH (r = 0.707, p < 0.001). Similarly, the serum marker of osteoclastic activity beta CTx was related inversely to patients' age (r =  0.383, p =  0.028), CRP (rho =  0.466, p = 0.006), and IL 6 (r =  0.460, p = 0.007) but positively to iPTH (r = 0.657, p < 0.001). Multiple linear regression analysis revealed that IL 6 affects bone turnover independently of PTH and to the opposite direction. Conclusion. Chronic inflammation has a negative impact on bone turnover in HD patients. Certainly, further research and large clinical trials are needed for definite conclusions and for clarifying the exact molecular mechanisms implicated in the interaction between the immune system and bone metabolism in HD patients.
C1 [Eleftheriadis, Theodoros; Antoniadi, Georgia; Golfinopoulos, Spiridon; Liakopoulos, Vassilios] Gen Hosp Serres, Dept Nephrol, Serres 62100, Greece.
   [Kartsios, Charalambos] Theagen Anticanc Hosp, Hematol Lab, Thessaloniki, Greece.
   [Kazila, Polizo] Theagen Anticanc Hosp, Microbiol Lab, Thessaloniki, Greece.
   [Dimitriadou, Magdalini; Sotiriadou, Eleni; Koltsida, Maria; Christopoulou Apostolaki, Maria] Theagen Anticanc Hosp, Biochem Lab, Thessaloniki, Greece.
RP Eleftheriadis, T (通讯作者)，Gen Hosp Serres, Dept Nephrol, 3rd Km Serres Drama, Serres 62100, Greece.
EM teleftheriadis@yahoo.com
RI ; Liakopoulos, Vassilios/AAN 1640 2020; KARTSIOS,
   CHARALAMPOS/AAD 8065 2021
OI Eleftheriadis, Theodoros/0000 0001 9302 1633; Liakopoulos,
   Vassilios/0000 0002 7564 2724; 
CR Abdallah BM, 2005, CALCIFIED TISSUE INT, V76, P90, DOI 10.1007/s00223 004 0074 4
   Abrahamsen B, 2000, J BONE MINER RES, V15, P1545, DOI 10.1359/jbmr.2000.15.8.1545
   Alexandraki K, 2006, ANN NY ACAD SCI, V1084, P89, DOI 10.1196/annals.1372.039
   Balto K, 2001, INFECT IMMUN, V69, P744, DOI 10.1128/IAI.69.2.744 750.2001
   Coen G, 1998, NEPHROL DIAL TRANSPL, V13, P2294, DOI 10.1093/ndt/13.9.2294
   Gibney EM, 2003, AM J KIDNEY DIS, V42, P1, DOI 10.1016/S0272 6386(03)00403 7
   GIRNDT M, 1995, KIDNEY INT, V47, P559, DOI 10.1038/ki.1995.70
   Grey A, 1996, J CLIN ENDOCR METAB, V81, P3450, DOI 10.1210/jc.81.10.3450
   Grimble RF, 2003, CURR OPIN CLIN NUTR, V6, P21, DOI 10.1097/00075197 200301000 00005
   Guo CY, 2000, EUR J ENDOCRINOL, V142, P451, DOI 10.1530/eje.0.1420451
   Huang W, 2003, CALCIFIED TISSUE INT, V73, P584, DOI 10.1007/s00223 003 0059 8
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   KLEIN B, 1991, BLOOD, V78, P1198
   Koh JM, 2005, OSTEOPOROSIS INT, V16, P1263, DOI 10.1007/s00198 005 1840 5
   KUSHNER I, 1993, PERSPECT BIOL MED, V36, P611
   Malluche HH, 1999, KIDNEY INT, V56, pS20, DOI 10.1046/j.1523 1755.1999.07313.x
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Montalbán C, 1999, HORM METAB RES, V31, P14, DOI 10.1055/s 2007 978689
   O'Brien CA, 2005, AM J PHYSIOL ENDOC M, V289, pE784, DOI 10.1152/ajpendo.00029.2005
   Okabe R, 2001, CLIN CHEM, V47, P1410
   Owen WF, 1998, KIDNEY INT, V54, P627, DOI 10.1046/j.1523 1755.1998.00032.x
   POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460 2075.1994.tb06368.x
   QI QL, 1995, AM J KIDNEY DIS, V26, P622, DOI 10.1016/0272 6386(95)90599 5
   Rix M, 1999, KIDNEY INT, V56, P1084, DOI 10.1046/j.1523 1755.1999.00617.x
   Saidenberg Kermanac'h N, 2004, JOINT BONE SPINE, V71, P9, DOI 10.1016/S1297 319X(03)00131 3
   Salamone LL, 1998, CALCIFIED TISSUE INT, V63, P466, DOI 10.1007/s002239900559
   Salusky IB, 2001, J AM SOC NEPHROL, V12, P1978, DOI 10.1681/ASN.V1291978
   SCHINDLER R, 1993, KIDNEY INT, V43, P712, DOI 10.1038/ki.1993.102
   STILGREN L, 2004, DAN MED B, V51, P310
   Takahashi M, 2000, CLIN CHIM ACTA, V294, P67, DOI 10.1016/S0009 8981(99)00251 X
   Walsh NC, 2005, IMMUNOL REV, V208, P228, DOI 10.1111/j.0105 2896.2005.00338.x
NR 32
TC 19
Z9 21
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0886 022X
EI 1525 6049
J9 RENAL FAILURE
JI Ren. Fail.
PY 2008
VL 30
IS 4
BP 431
EP 437
DI 10.1080/08860220801964251
PG 7
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 307XI
UT WOS:000256352500014
PM 18569918
DA 2025 08 17
ER

PT J
AU Veldhuis Vlug, AG
   Oei, L
   Souverein, PC
   Tanck, MWT
   Rivadeneira, F
   Zillikens, MC
   Kamphuisen, PW
   Maitland van der Zee, AH
   de Groot, MCH
   Hofman, A
   Uitterlinden, AG
   Fliers, E
   de Boer, A
   Bisschop, PH
AF Veldhuis Vlug, A. G.
   Oei, L.
   Souverein, P. C.
   Tanck, M. W. T.
   Rivadeneira, F.
   Zillikens, M. C.
   Kamphuisen, P. W.
   Maitland van der Zee, A. H.
   de Groot, M. C. H.
   Hofman, A.
   Uitterlinden, A. G.
   Fliers, E.
   de Boer, A.
   Bisschop, P. H.
TI Association of polymorphisms in the beta 2 adrenergic receptor gene with
   fracture risk and bone mineral density
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Beta 2 adrenergic receptor; Bone mineral density; Bone brain nervous
   system interactions; Fracture; Human association studies; Polymorphisms
ID HUMAN BETA(2) ADRENERGIC RECEPTOR; GENOME WIDE ASSOCIATION; MASS;
   METAANALYSIS; RESORPTION; CHILDREN; DESIGN; TOOL
AB Signaling through the beta 2 adrenergic receptor (B2AR) on the osteoblast influences bone remodeling in rodents. In the B2AR gene, three polymorphisms influence receptor function. We show that these polymorphisms are not associated with fracture risk or bone mineral density in the UCP, Rotterdam Study, and GEFOS cohorts.
   Introduction Signaling through the beta 2 adrenergic receptor (B2AR) on the osteoblast influences bone remodeling in rodents. In the B2AR gene, three polymorphisms are known to influence receptor function in vitro and in vivo (rs1042713, rs1042714, and rs1800888). We examined the role of these polymorphisms in the B2AR gene on human bone metabolism.
   Methods We performed nested case control studies to determine the association of these polymorphisms with fracture risk in the Utrecht Cardiovascular Pharmacogenetics (UCP) cohort and in three cohorts of the Rotterdam Study. We also determined the association of these polymorphisms with bone mineral density (BMD) in the GEFOS Consortium. UCP contains drug dispensing histories from community pharmacies linked to national registrations of hospital discharges in the Netherlands. The Rotterdam Study is a prospective cohort study investigating demographics and risk factors of chronic diseases. GEFOS is a large international collaboration studying the genetics of osteoporosis. Fractures were defined by ICD 9 codes 800 829 in the UCP cohort (158 cases and 2617 unmatched controls) and by regular X ray examinations, general practitioner, and hospital records in the Rotterdam Study (2209 cases and 8559 unmatched controls). BMD was measured at the femoral neck and lumbar spine using dual energy X ray absorptiometry in GEFOS (N = 32,961).
   Results Meta analysis of the two nested case control studies showed pooled odds ratios of 0.98 (0.91 1.05, p = 0.52), 1.04 (0.97 1.12, p = 0.28), and 1.16 (0.83 1.62, p = 0.38) for the associations between rs1042713, rs1042714, and rs1800888 per minor allele and fractures, respectively. There were no significant associations of the polymorphisms and BMD in GEFOS.
   Conclusion In conclusion, polymorphisms in the beta 2 adrenergic receptor gene are not associated with fracture risk or BMD.
C1 Univ Amsterdam, Acad Med Ctr, Dept Endocrinol & Metab, Amsterdam, Netherlands.
   [Veldhuis Vlug, A. G.; Fliers, E.; Bisschop, P. H.] Univ Amsterdam, Dept Endocrinol & Metab, Acad Med Ctr, NL 1100 DD Amsterdam, Netherlands.
   [Oei, L.; Rivadeneira, F.; Zillikens, M. C.; Uitterlinden, A. G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [Oei, L.; Rivadeneira, F.; Hofman, A.; Uitterlinden, A. G.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Oei, L.; Rivadeneira, F.; Zillikens, M. C.; Hofman, A.; Uitterlinden, A. G.] Netherlands Genom Initiat NGI Sponsored Netherlan, Consortium Hlth Aging NCHA, Leiden, Netherlands.
   [Souverein, P. C.; Maitland van der Zee, A. H.; de Groot, M. C. H.; de Boer, A.] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Dept Pharmaceut Sci, Utrecht, Netherlands.
   [Tanck, M. W. T.] Univ Amsterdam, Dept Clin Epidemiol Biostat & Bioinformat, Acad Med Ctr, NL 1100 DD Amsterdam, Netherlands.
   [Kamphuisen, P. W.] Univ Groningen, Univ Med Ctr Groningen, Dept Vasc Med, Groningen, Netherlands.
C3 University of Amsterdam; Academic Medical Center Amsterdam; University
   of Amsterdam; Academic Medical Center Amsterdam; Erasmus University
   Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Utrecht
   University; University of Amsterdam; Academic Medical Center Amsterdam;
   University of Groningen
RP Bisschop, PH (通讯作者)，Univ Amsterdam, Dept Endocrinol & Metab, Acad Med Ctr, POB 22660, NL 1100 DD Amsterdam, Netherlands.
EM p.h.bisschop@amc.uva.nl
RI Fliers, Eric/JKH 9635 2023; Rivadeneira, Fernando/O 5385 2015; Oei,
   Ling/E 8163 2013; Boer, Anthonius/B 6778 2008; de Groot,
   Mark/A 9891 2012; Tanck, Michael/AFY 1138 2022; ,
   Uitterlinden/AFV 9968 2022; Maitland van der Zee, Anke/I 9572 2016
OI Tanck, Michael/0000 0001 9828 4459; Fliers, Eric/0000 0001 8048 9050;
   Rivadeneira, Fernando/0000 0001 9435 9441; Bisschop,
   Peter/0000 0002 3583 6567; Kamphuisen, Pieter/0000 0002 6263 0177;
   Uitterlinden, Andre G/0000 0002 7276 3387; Souverein,
   Patrick/0000 0002 7452 0477; Maitland van der Zee,
   Anke/0000 0002 0414 3442
FU Netherlands Organization for Health Research and Development (ZonMw);
   Netherlands Organization for Scientific Research (NWO)
   [175.010.2005.011, 911 03 012]; Research Institute for Diseases in the
   Elderly [014 93 015]; Netherlands Genomics Initiative (NGI)/NWO
   [050 060 810]; Netherlands Forensic Institute; NGI/NWO within the
   framework of the Forensic Genomics Consortium Netherlands; Erasmus
   University Medical Center; Erasmus University Rotterdam, ZonMw; RIDE;
   Ministry of Education, Culture and Science; Ministry for Health, Welfare
   and Sports of the Netherlands; European Commission (DG XII);
   Municipality of Rotterdam; European Union
   [FP7 HEALTH F2 2008 201865 GEFOS]
FX The Netherlands Organization for Health Research and Development (ZonMw)
   provided funding for the analysis of the UCP database. The generation
   and management of GWAS genotype data for the Rotterdam Study were
   supported by a Netherlands Organization for Scientific Research (NWO)
   Investments grant (nr. 175.010.2005.011, 911 03 012). This study was
   also supported by the Research Institute for Diseases in the Elderly
   (014 93 015; RIDE2), the Netherlands Genomics Initiative (NGI)/NWO
   project no. 050 060 810, the Netherlands Forensic Institute, and by a
   grant from the NGI/NWO within the framework of the Forensic Genomics
   Consortium Netherlands. The Rotterdam Study is funded by the Erasmus
   University Medical Center, the Erasmus University Rotterdam, ZonMw, the
   RIDE, the Ministry of Education, Culture and Science, the Ministry for
   Health, Welfare and Sports of the Netherlands, the European Commission
   (DG XII), and the Municipality of Rotterdam. GEFOS is a European Union
   Seventh Framework Package funded project registered under grant
   agreement number: FP7 HEALTH F2 2008 201865 GEFOS. A list of members of
   the GEFOS consortium who participated in the creation of this dataset
   can be found online (http://www.gefos.org/?q=content/data release).
CR Adriani KS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037618
   Ahles A, 2009, TRENDS PHARMACOL SCI, V30, P188, DOI 10.1016/j.tips.2009.02.001
   [Anonymous], J HYPERTENS
   [Anonymous], OSTEOPOROS INT
   [Anonymous], PHARM WORLD SCI
   [Anonymous], J EXP MED
   [Anonymous], ANN M AM SOC HUM GEN
   [Anonymous], HAPLO STATS STAT ANA
   Arai M, 2013, EUR J PHARMACOL, V701, P7, DOI 10.1016/j.ejphar.2012.12.016
   Bonnet N, 2005, BONE, V37, P622, DOI 10.1016/j.bone.2005.07.012
   Bouxsein ML, 2009, ENDOCRINOLOGY, V150, P144, DOI 10.1210/en.2008 0843
   Brodde OE, 2008, FUND CLIN PHARMACOL, V22, P107, DOI 10.1111/j.1472 8206.2007.00557.x
   Chu X, 2009, BMC MED GENET, V10, DOI 10.1186/1471 2350 10 26
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249
   Estrada K, 2009, BIOINFORMATICS, V25, P2750, DOI 10.1093/bioinformatics/btp497
   Farr JN, 2012, J CLIN ENDOCR METAB, V97, P4219, DOI 10.1210/jc.2012 2381
   Fonseca TL, 2011, J BONE MINER RES, V26, P591, DOI 10.1002/jbmr.243
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   GREEN SA, 1994, BIOCHEMISTRY US, V33, P9414, DOI 10.1021/bi00198a006
   GREEN SA, 1993, J BIOL CHEM, V268, P23116
   Hofman A, 2013, EUR J EPIDEMIOL, V28, P889, DOI 10.1007/s10654 013 9866 z
   Johnson JA, 2011, CLIN PHARMACOL THER, V89, P366, DOI 10.1038/clpt.2010.315
   Keating BJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003583
   Kondo H, 2011, CALCIFIED TISSUE INT, V88, P23, DOI 10.1007/s00223 010 9421 9
   Kulminski AM, 2010, MECH AGEING DEV, V131, P338, DOI 10.1016/j.mad.2010.04.001
   Large V, 1997, J CLIN INVEST, V100, P3005, DOI 10.1172/JCI119854
   Leineweber K, 2009, BRIT J PHARMACOL, V158, P61, DOI 10.1111/j.1476 5381.2009.00187.x
   Liggett SB, 2000, PHARMACOLOGY, V61, P167, DOI 10.1159/000028397
   Lipworth BJ, 2013, CLIN SCI, V124, P521, DOI 10.1042/CS20120528
   Liu YJ, 2013, J CLIN ENDOCR METAB, V98, pE1278, DOI 10.1210/jc.2013 1637
   Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874
   Mitchell EJ, 2010, J ORTHOP TRAUMA, V24, P530, DOI 10.1097/BOT.0b013e3181ed147b
   Panebra A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011819
   Pierroz DD, 2012, J BONE MINER RES, V27, P1252, DOI 10.1002/jbmr.1594
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raats M. M., 1992, Food Quality and Preference, V3, P89, DOI 10.1016/0950 3293(91)90028 D
   Ralston SH, 2010, ENDOCR REV, V31, P629, DOI 10.1210/er.2009 0044
   REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334
   Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144
   Small KM, 2003, ANNU REV PHARMACOL, V43, P381, DOI 10.1146/annurev.pharmtox.43.100901.135823
   Turki J, 1996, P NATL ACAD SCI USA, V93, P10483, DOI 10.1073/pnas.93.19.10483
   Veldhuis Vlug AG, 2012, J CLIN ENDOCR METAB, V97, pE2093, DOI 10.1210/jc.2012 2823
NR 44
TC 11
Z9 13
U1 0
U2 6
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JUL
PY 2015
VL 26
IS 7
BP 2019
EP 2027
DI 10.1007/s00198 015 3087 0
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CL4VR
UT WOS:000356954500018
PM 25910744
OA hybrid, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Baddack, U
   Frahm, S
   Antolin Fontes, B
   Grobe, J
   Lipp, M
   Müller, G
   Ibañez Tallon, I
AF Baddack, Uta
   Frahm, Silke
   Antolin Fontes, Beatriz
   Grobe, Jenny
   Lipp, Martin
   Mueller, Gerd
   Ibanez Tallon, Ines
TI Suppression of Peripheral Pain by Blockade of Voltage Gated Calcium 2.2
   Channels in Nociceptors Induces RANKL and Impairs Recovery From
   Inflammatory Arthritis in a Mouse Model
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID RHEUMATOID ARTHRITIS; SUBSTANCE P; BONE LOSS; OSTEOCLAST
   DIFFERENTIATION; NEUROGENIC INFLAMMATION; OSTEOPROTEGERIN LIGAND;
   NEUROPATHIC PAIN; NERVOUS SYSTEM; KNEE JOINT; TNF ALPHA
AB Objective. A hallmark of rheumatoid arthritis (RA) is the chronic pain that accompanies inflammation and joint deformation. Patients with RA rate pain relief as the highest priority; however, few studies have addressed the efficacy and safety of therapies directed specifically toward pain pathways. The  conotoxin MVIIA (ziconotide) is used in humans to alleviate persistent pain syndromes, because it specifically blocks the voltage gated calcium 2.2 (Ca(V)2.2) channel, which mediates the release of neurotransmitters and proinflammatory mediators from peripheral nociceptor nerve terminals. The aims of this study were to investigate whether blockade of Ca(V)2.2 can suppress arthritis pain, and to examine the progression of induced arthritis during persistent Ca(V)2.2 blockade.
   Methods. Transgenic mice expressing a membrane tethered form of MVIIA under the control of a nociceptor specific gene (MVIIA transgenic mice) were used in the experiments. The mice were subjected to unilateral induction of joint inflammation using a combination of antigen and collagen.
   Results. Ca(V)2.2 blockade mediated by tethered MVIIA effectively suppressed arthritis induced pain; however, in contrast to their wild type littermates, which ultimately regained use of their injured joint as inflammation subsided, MVIIA transgenic mice showed continued inflammation, with up regulation of the osteoclast activator RANKL and concomitant joint and bone destruction.
   Conclusion. Taken together, our results indicate that alleviation of peripheral pain by blockade of Ca(V)2.2  mediated calcium influx and signaling in nociceptor sensory neurons impairs recovery from induced arthritis and point to the potentially devastating effects of using Ca(V)2.2 channel blockers as analgesics during inflammation.
C1 [Baddack, Uta; Grobe, Jenny; Lipp, Martin; Mueller, Gerd] Max Delbruck Ctr Mol Med, Berlin, Germany.
   [Baddack, Uta] CNRS, Toulouse, France.
   [Frahm, Silke] Charite, D 13353 Berlin, Germany.
   [Antolin Fontes, Beatriz; Ibanez Tallon, Ines] Rockefeller Univ, New York, NY 10065 USA.
C3 Helmholtz Association; Max Delbruck Center for Molecular Medicine;
   Centre National de la Recherche Scientifique (CNRS); Free University of
   Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin; Rockefeller University
RP Ibañez Tallon, I (通讯作者)，Rockefeller Univ, Mol Biol Lab, 1230 York Ave, New York, NY 10065 USA.
EM iibanez@rockefeller.edu
RI ; Lipp, Martin/G 2235 2010
OI Lipp, Martin/0000 0002 0087 2672; Antolin Fontes,
   Beatriz/0000 0002 5724 0932; 
FU European Union [LSHB CT 2005 518167]; German Research Foundation (DFG
   Collaborative Research Centres grant) [SFB650, SFB665]; Helmholtz
   Association [31 002]; NIH (National Institute on Drug Abuse grant)
   [1 P30 DA 035756]
FX Supported by the European Union Sixth Framework Programme (project
   INNOCHEM; grant LSHB CT 2005 518167 to Dr. Lipp), the German Research
   Foundation (DFG Collaborative Research Centres grant SFB650 to Drs. Lipp
   and Muller and grant SFB665 to Dr. Ibanez Tallon), the Helmholtz
   Association (grant 31 002 to Dr. Ibanez Tallon), and the NIH (National
   Institute on Drug Abuse grant 1 P30 DA 035756 to Dr. Ibanez Tallon).
CR Auer S, 2010, NAT METHODS, V7, P229, DOI [10.1038/NMETH.1425, 10.1038/nmeth.1425]
   Baddack U, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2625
   Brittain JM, 2011, NAT MED, V17, P822, DOI 10.1038/nm.2345
   Caceres AI, 2009, P NATL ACAD SCI USA, V106, P9099, DOI 10.1073/pnas.0900591106
   Carstens BB, 2011, CURR PHARM DESIGN, V17, P4242
   Chiu IM, 2012, NAT NEUROSCI, V15, P1063, DOI 10.1038/nn.3144
   Dray A, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2178
   Engel MA, 2011, GASTROENTEROLOGY, V141, P1346, DOI 10.1053/j.gastro.2011.07.002
   European Medicines Agency, 2005, EUR PUBL ASS REP EPA
   Feldmann M, 2002, JOINT BONE SPINE, V69, P12, DOI 10.1016/S1297 319X(01)00335 9
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   GARRETT NE, 1995, BRAIN RES, V675, P203, DOI 10.1016/0006 8993(95)00066 Y
   Harre U, 2012, J CLIN INVEST, V122, P1791, DOI 10.1172/JCI60975
   Just S, 2003, EXP BRAIN RES, V150, P379, DOI 10.1007/s00221 003 1465 x
   Just S, 2001, NEUROSCI LETT, V312, P133, DOI 10.1016/S0304 3940(01)02199 1
   Keeble JE, 2004, NEUROSCI LETT, V361, P176, DOI 10.1016/j.neulet.2003.12.020
   Kilo S, 1997, PAIN, V73, P201, DOI 10.1016/S0304 3959(97)00108 5
   Kindler LL, 2011, PAIN MANAG NURS, V12, P15, DOI 10.1016/j.pmn.2009.10.003
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   KONTTINEN YT, 1992, SCAND J RHEUMATOL, V21, P55, DOI 10.3109/03009749209095068
   Kosek E, 2000, EUR J PAIN, V4, P229, DOI 10.1053/eujp.2000.0175
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee YC, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3306
   LEVINE JD, 1984, SCIENCE, V226, P547, DOI 10.1126/science.6208609
   Lewiecki EM, 2011, NAT REV RHEUMATOL, V7, P631, DOI 10.1038/nrrheum.2011.130
   Lewin Gary R, 2014, Handb Exp Pharmacol, V220, P251, DOI 10.1007/978 3 642 45106 5_10
   Li WJ, 2006, AM J PHYSIOL CELL PH, V291, pC456, DOI 10.1152/ajpcell.00538.2005
   Lloyd S, 2010, RHEUMATOLOGY, V49, P2313, DOI 10.1093/rheumatology/keq169
   Mantyh PW, 2001, NAT MED, V7, P772, DOI 10.1038/89880
   Ostrowski SM, 2011, J INVEST DERMATOL, V131, P1530, DOI 10.1038/jid.2011.60
   Pettit AR, 2006, RHEUMATOLOGY, V45, P1068, DOI 10.1093/rheumatology/kel045
   Schaible HG, 2002, ANN NY ACAD SCI, V966, P343, DOI 10.1111/j.1749 6632.2002.tb04234.x
   Schellekens GA, 2000, ARTHRITIS RHEUM US, V43, P155, DOI 10.1002/1529 0131(200001)43:1<155::AID ANR20>3.0.CO;2 3
   Schett G, 2008, AUTOIMMUNITY, V41, P224, DOI 10.1080/08916930701694717
   Seidel MF, 2012, CURR RHEUMATOL REP, V14, P583, DOI 10.1007/s11926 012 0289 8
   Shigeyama Y, 2000, ARTHRITIS RHEUM, V43, P2523, DOI 10.1002/1529 0131(200011)43:11<2523::AID ANR20>3.0.CO;2 Z
   Sluka KA, 2013, ARTHRITIS RHEUM US, V65, P1194, DOI 10.1002/art.37862
   Snider WD, 1998, NEURON, V20, P629, DOI 10.1016/S0896 6273(00)81003 X
   Stolina M, 2005, J BONE MINER RES, V20, P1756, DOI 10.1359/JBMR.050601
   Tokuhara N, 2010, J BIOL CHEM, V285, P33294, DOI 10.1074/jbc.M109.089805
   Wang YX, 2000, PAIN, V84, P271, DOI 10.1016/S0304 3959(99)00214 6
   Wichner K, 2013, J AUTOIMMUN, V47, P58, DOI 10.1016/j.jaut.2013.08.007
   Winquist RJ, 2005, BIOCHEM PHARMACOL, V70, P489, DOI 10.1016/j.bcp.2005.04.035
NR 43
TC 11
Z9 13
U1 1
U2 12
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2326 5191
EI 2326 5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD JUN
PY 2015
VL 67
IS 6
BP 1657
EP 1667
DI 10.1002/art.39094
PG 11
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA CJ2QA
UT WOS:000355328400030
PM 25733371
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Ono, M
   Inkson, CA
   Kilts, TM
   Young, MF
AF Ono, Mitsuaki
   Inkson, Colette A.
   Kilts, Tina M.
   Young, Marian F.
TI WISP 1/CCN4 Regulates Osteogenesis by Enhancing BMP 2 Activity
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE WISP1; GROWTH FACTORS; BMP; CYTOKINES; OSTEOPROGENITORS; CCN
ID TISSUE GROWTH FACTOR; BONE MORPHOGENETIC PROTEINS; COMBINATORIAL
   GENE THERAPY; FAMILY MEMBER WISP3; CCN FAMILY; OSTEOBLAST
   DIFFERENTIATION; ALPHA V BETA 3 INTEGRIN; FACTOR CTGF/CCN2; FACTOR
   CCN2/CTGF; CELL ADHESION
AB Wnt induced secreted protein 1 (WISP 1/CCN4) is a member of the CCN family that is highly expressed in skeletal tissue and in osteoprogenitor cells induced to differentiate in vitro. To determine the function of WISP 1 during osteogeneis, osteogenic bone marrow stromal cells (BMSCs) were transduced with WISP 1 adenovirus (ad WISP 1) in the presence or absence of bone morphogenetic protein 2 (BMP 2) adenovirus (adBMP 2). WISP 1 overexpression enhanced the ability of BMP 2 to direct BMSCs toward osteogenic differentiation and appeared to work by stimulating Smad 1/5/8 phosphorylation and activation. The ability of WISP 1 to enhance BMP 2 activity also was shown in vivo using an ectopic osteogenesis assay with BMSCs transduced with WISP 1, BMP 2, or both. When BMSCs were infected with lentivirus containing human WISP1 shRNA, they formed less bone in vivo and were less responsive to BMP 2, confirming that WISP 1 and BMP 2 have a functional interaction. Immunoprecipitation (IP) and Western blot analysis showed that WISP 1 bound directly to BMP 2 and showed that WISP 1 increased BMP 2 binding to hBMSCs in a dose dependent fashion. To understand how WISP 1 enhanced BMP 2 signaling, the influence of WISP 1 on integrin expression was analyzed. WISP 1 induced the mRNA and protein levels of alpha(5) integrin and, further, was found to bind to it. Antibody blocking experiments showed that the BMP 2 binding to BMSCs that was enhanced by WISP 1 was completely neutralized by treatment with anti integrin alpha(5)beta(1) antibody. Pilot studies and the use of transgenic mice that overexpressed human WISP 1 in preosteoblasts had increased bone mineral density (BMD), trabecular thickness, and bone volume (BV/TV) over wild type controls, supporting observations using human osteoprogenitors that WISP 1 has a positive influence on osteogenesis in vivo. In conclusion, these studies show, for the first time, that WISP 1 has a. positive influence on bone cell differentiation and function and may work by enhancing the effects of BMP 2 to increase osteogenesis through a mechanism potentially involving binding to integrin alpha(5)beta(1). (C) 2011 American Society for Bone and Mineral Research.
C1 [Ono, Mitsuaki; Inkson, Colette A.; Kilts, Tina M.; Young, Marian F.] NIDCR, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH)   USA; NIH National Institute of
   Dental & Craniofacial Research (NIDCR)
RP Young, MF (通讯作者)，NIDCR, Craniofacial & Skeletal Dis Branch, NIH, Bldg 30,Room 225,9000 Rockville Pike, Bethesda, MD 20892 USA.
EM myoung@dir.nidcr.nih.gov
OI Inkson, Colette/0000 0003 1215 312X; Young, Marian F/0000 0003 0929 8854
FU Division of Intramural Research of the NIDCR, NIH
FX This work was supported by the Division of Intramural Research of the
   NIDCR of the Intramural Research Program, NIH. We are grateful to Dr S
   Kuznetsov (NIDCR) and Dr P Robey (NIDCR) for advice on the use and
   analysis of human bone marrow stromal cells, to Dr A Kulkarni (NIDCR)
   and Dr T Sreenath (NIDCR) for assistance in preparation of the WISP1 Tg
   line, and to Dr L Fisher (NIDCR) for advice on the preparation of
   anti WISP1 antisera (LF 187).
CR Abe E, 2006, ANN NY ACAD SCI, V1068, P41, DOI 10.1196/annals.1346.007
   Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826
   Arnott JA, 2008, BONE, V42, P871, DOI 10.1016/j.bone.2008.01.006
   Avsian Kretchmer O, 2004, MOL ENDOCRINOL, V18, P1, DOI 10.1210/me.2003 0227
   Balemans W, 2007, ENDOCRINOLOGY, V148, P2622, DOI 10.1210/en.2006 1352
   Benini S, 2005, ONCOGENE, V24, P4349, DOI 10.1038/sj.onc.1208620
   Bennewith KL, 2009, CANCER RES, V69, P775, DOI 10.1158/0008 5472.CAN 08 0987
   Bi YM, 2005, J BIOL CHEM, V280, P30481, DOI 10.1074/jbc.M500573200
   Bishop GB, 2007, INT ORTHOP, V31, P721, DOI 10.1007/s00264 007 0424 8
   Blom AB, 2009, ARTHRITIS RHEUM, V60, P501, DOI 10.1002/art.24247
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Colston JT, 2007, AM J PHYSIOL HEART C, V293, pH1839, DOI 10.1152/ajpheart.00428.2007
   Crockett JC, 2007, ENDOCRINOLOGY, V148, P5761, DOI 10.1210/en.2007 0473
   Dean DB, 2009, FRONT BIOSCI LANDMRK, V14, P2878, DOI 10.2741/3419
   Fontana L, 2005, FASEB J, V19, P1798, DOI 10.1096/fj.05 4134com
   French DM, 2004, AM J PATHOL, V165, P855, DOI 10.1016/S0002 9440(10)63348 2
   Gao R, 2006, GUT, V55, P856, DOI 10.1136/gut.2005.079178
   Gao RP, 2003, HEPATOL RES, V27, P214, DOI 10.1016/S1386 6346(03)00241 9
   Geyer M, 2009, OSTEOARTHR CARTILAGE, V17, P328, DOI 10.1016/j.joca.2008.07.010
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   Heath E, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471 213X 8 18
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Hoshijima M, 2006, FEBS LETT, V580, P1376, DOI 10.1016/j.febslet.2006.01.061
   Hurvitz JR, 1999, NAT GENET, V23, P94, DOI 10.1038/12699
   Inkson CA, 2008, J CELL BIOCHEM, V104, P1865, DOI 10.1002/jcb.21754
   Inkson CA, 2009, CELLS TISSUES ORGANS, V189, P153, DOI 10.1159/000151377
   Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505
   Katsube K, 2009, DEV GROWTH DIFFER, V51, P55, DOI 10.1111/j.1440 169X.2009.01077.x
   Kawaki H, 2008, BIOCHEM BIOPH RES CO, V366, P450, DOI 10.1016/j.bbrc.2007.11.155
   Kidd M, 2007, AM J PHYSIOL GASTR L, V292, pG191, DOI 10.1152/ajpgi.00131.2006
   Kleer CG, 2007, CELLS TISSUES ORGANS, V185, P95, DOI 10.1159/000101308
   Königshoff M, 2009, J CLIN INVEST, V119, P772, DOI 10.1172/JCI33950
   Koh JT, 2008, J DENT RES, V87, P845, DOI 10.1177/154405910808700906
   Kubota Satoshi, 2007, Angiogenesis, V10, P1, DOI 10.1007/s10456 006 9058 5
   Kwong FNK, 2008, J AM ACAD ORTHOP SUR, V16, P619, DOI 10.5435/00124635 200811000 00001
   Lavigne P, 2005, OSTEOARTHR CARTILAGE, V13, P310, DOI 10.1016/j.joca.2004.12.015
   Leu SJ, 2004, J BIOL CHEM, V279, P44177, DOI 10.1074/jbc.M407850200
   Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200
   Lin CG, 2005, J BIOL CHEM, V280, P8229, DOI 10.1074/jbc.M404903200
   Lin CG, 2003, J BIOL CHEM, V278, P24200, DOI 10.1074/jbc.M302028200
   Lin JM, 2005, NAT MED, V11, P387, DOI 10.1038/nm1217
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Maeda A, 2009, J BIOCHEM, V145, P207, DOI 10.1093/jb/mvn159
   Maillard M, 2001, J CLIN PATHOL MOL PA, V54, P275, DOI 10.1136/mp.54.4.275
   Minamizato T, 2007, BIOCHEM BIOPH RES CO, V354, P567, DOI 10.1016/j.bbrc.2007.01.029
   Morgan EF, 2008, BONE, V43, P1031, DOI 10.1016/j.bone.2008.07.251
   Nakamura Y, 2007, J CLIN INVEST, V117, P3075, DOI 10.1172/JCI32001
   Nishida T, 2009, BONE, V44, P24, DOI 10.1016/j.bone.2008.08.125
   Oka M, 2007, J HISTOCHEM CYTOCHEM, V55, P1245, DOI 10.1369/jhc.7A7263.2007
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Parisi MS, 2006, BONE, V38, P671, DOI 10.1016/j.bone.2005.10.005
   Patel MS, 2002, NEW ENGL J MED, V346, P1572, DOI 10.1056/NEJM200205163462011
   Pi L, 2008, HEPATOLOGY, V47, P996, DOI 10.1002/hep.22079
   Rydziel S, 2007, J BIOL CHEM, V282, P19762, DOI 10.1074/jbc.M700212200
   Segarini PR, 2001, J BIOL CHEM, V276, P40659, DOI 10.1074/jbc.M105180200
   Shimo T, 2006, J BONE MINER RES, V21, P1045, DOI 10.1359/JBMR.060416
   Smerdel Ramoya' A, 2008, ENDOCRINOLOGY, V149, P4374, DOI 10.1210/en.2008 0254
   Smerdel Ramoya A, 2008, J BIOL CHEM, V283, P22690, DOI 10.1074/jbc.M710140200
   Sommer B, 1999, CALCIFIED TISSUE INT, V64, P45, DOI 10.1007/s002239900577
   Su F, 2002, GENE DEV, V16, P46, DOI 10.1101/gad.942902
   Tan TW, 2009, J CELL BIOCHEM, V107, P345, DOI 10.1002/jcb.22132
   Tan TW, 2009, CARCINOGENESIS, V30, P258, DOI 10.1093/carcin/bgn284
   Tanaka S, 2001, ONCOGENE, V20, P5525, DOI 10.1038/sj.onc.1204723
   Urano T, 2007, J BONE MINER METAB, V25, P253, DOI 10.1007/s00774 007 0757 9
   Vallacchi V, 2008, CANCER RES, V68, P715, DOI 10.1158/0008 5472.CAN 07 2103
   van Bezooijen RL, 2007, J BONE MINER RES, V22, P19, DOI 10.1359/JBMR.061002
   Wang SX, 2007, ARTHRITIS RHEUM US, V56, P1537, DOI 10.1002/art.22574
   Williams BO, 2009, J BONE MINER RES, V24, P171, DOI [10.1359/JBMR.081235, 10.1359/jbmr.081235]
   Winkler DG, 2004, J BIOL CHEM, V279, P36293, DOI 10.1074/jbc.M400521200
   Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200
   Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008 5472.CAN 03 0666
   Xu LF, 2000, GENE DEV, V14, P585
   Yang F, 2005, CANCER RES, V65, P8887, DOI 10.1158/0008 5472.CAN 05 1702
   Yoshida Y, 2007, BIOCHEM BIOPH RES CO, V355, P611, DOI 10.1016/j.bbrc.2007.01.195
   Zhao M, 2005, J CELL BIOCHEM, V95, P1, DOI 10.1002/jcb.20411
   Zilberberg L, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471 2121 8 41
NR 79
TC 121
Z9 130
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2011
VL 26
IS 1
BP 193
EP 208
DI 10.1002/jbmr.205
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 704FD
UT WOS:000286035600021
PM 20684029
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Sterrett, JR
   Strom, J
   Stummvoll, HK
   Bahner, U
   Disney, A
   Soroka, SD
   Corpier, C
   Arruda, JA
   Schwanauer, LE
   Klassen, PS
   Olson, KA
   Block, GA
AF Sterrett, J. R.
   Strom, J.
   Stummvoll, H K
   Bahner, U.
   Disney, A.
   Soroka, S. D.
   Corpier, C.
   Arruda, J. A.
   Schwanauer, L. E.
   Klassen, P. S.
   Olson, K. A.
   Block, G. A.
TI Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for
   hemodialysis patients with secondary hyperparathyroidism
SO CLINICAL NEPHROLOGY
LA English
DT Article
DE calcimimetic; cinacalcet; hemodialysis; secondary hyperparathyroidism
ID CARDIOVASCULAR DISEASE; PARATHYROID HORMONE; MINERAL METABOLISM; BONE
   METABOLISM; MORTALITY RISK; CALCIUM; PHOSPHORUS; ASSOCIATION;
   CALCITRIOL; DIALYSIS
AB (Aims) under bar: This 1 year double blind, placebo controlled, multicenter study evaluated the long term safety and efficacy of cinacalcet for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis. (Method) under bar: Patients were randomly assigned in a 1 : 1 ratio to cinacalcet or control treatment groups. The initial dose of cinacalcet (or matching placebo) was 30 mg. Doses were titrated every 3 or 4 weeks based on the intact parathyroid hormone (iPTH) response and safety profile. Sequential doses included 30, 60, 90, 120 and 180 mg/d. Phosphate binders and vitamin D sterols were adjusted per protocol as needed to control levels of calcium and phosphorus. Efficacy and safety were compared between treatment groups among patients who completed the study (52 total weeks of treatment). Reasons for withdrawal are presented for patients who did not complete the study. (Results) under bar: A total of 210 patients completed 52 weeks of double blinded treatment with cinacalcet (n = 99) or placebo (n = 111). Over the last 6 months of the study, a greater proportion of patients in the cinacalcet group than the control group achieved an iPTH level <= 250 pg/ml (61.6 vs. 9.9 %, p < 0. 00 1) or a >= 30 % decrease in iPTH from baseline (81.8 vs. 21.6 %, p < 0.001). Mean iPTH levels decreased by  47.8% in the cinacalcet group and increased by +12.9 % in the control group. Mean percentage changes in other laboratory values in the cinacalcet and control groups included the following: serum calcium  6.5 vs. +0.9 %(p < 0.001), serum phosphorus  3.6 vs.  1.1 % (p = 0.465), and Ca x P  9.9 vs.  0.3 % (p = 0.006). The most commonly reported adverse events related to study drug by the investigators included nausea (13 % cinacalcet, 5 % control), investigator reported hypocalcemia (11 % cinacalcet, 1 % control), vomiting (9 % cinacalcet, 2 % control), dyspepsia (5 % cinacalcet, 4 % control), and diarrhea (5 % cinacalcet, 2 % control). (Conclusions) under bar: Treatment with cinacalcet is a safe and effective therapy for long term control of secondary hyperparathyroidism. 1 year therapy with cinacalcet was associated with sustained, clinically significant reductions in calcium, Ca x P and iPTH which allowed a greater percentage of patients to achieve NKF KDOQI target goals for PTH and Ca x P.
C1 St Joseph Reg Med Ctr, Paterson, NJ USA.
   Caritas St Elizabeths Med Ctr, Boston, MA USA.
   Tufts Univ, Sch Med, Boston, MA 02111 USA.
   Krankenhaus Elisabethinen Linz, Interne Abt Nephrol, Linz, Austria.
   Univ Wurzburg, KfH Kuratorium Dialyse & Nierentransplantat eV, D 97070 Wurzburg, Germany.
   Queen Elizabeth Hosp, Adelaide, SA, Australia.
   Dalhousie Univ, Clin Res Ctr, Halifax, NS, Canada.
   Dallas Nephrol Associates, Dallas, TX USA.
   Univ Illinois, Dept Med, Nephrol Sect, Chicago, IL USA.
   Amgen Inc, Thousand Oaks, CA 91320 USA.
   Denver Nephrol, Denver, CO USA.
C3 St. Elizabeth's Medical Center; Tufts University; Ordensklinikum Linz
   Elisabethinen; University of Wurzburg; Dalhousie University; Dalhousie
   University Hospital; University of Illinois System; University of
   Illinois Chicago; University of Illinois Chicago Hospital; Amgen
RP Sterrett, JR (通讯作者)，Dept Med, 6101 Pine Ridge Rd, Naples, FL 34119 USA.
EM reidsterreft@yahoo.com
RI Block, Geoffrey/AAV 8070 2021
CR Bleyer AJ, 1999, AM J KIDNEY DIS, V33, P694, DOI 10.1016/S0272 6386(99)70221 0
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Colloton M, 2005, KIDNEY INT, V67, P467, DOI 10.1111/j.1523 1755.2005.67103.x
   Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523 1755.2005.00596.x
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   GALLIENI M, 1992, KIDNEY INT, V42, P1191, DOI 10.1038/ki.1992.404
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512
   Marco MP, 2003, KIDNEY INT, V63, pS111, DOI 10.1046/j.1523 1755.63.s85.26.x
   Martinez I, 1997, AM J KIDNEY DIS, V29, P496, DOI 10.1016/S0272 6386(97)90330 9
   Mizobuchi M, 2004, J AM SOC NEPHROL, V15, P2579, DOI 10.1097/01.ASN.0000141016.20133.33
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Nemeth EF, 2004, J PHARMACOL EXP THER, V308, P627, DOI 10.1124/jpet.103.057273
   Slinin Y, 2005, J AM SOC NEPHROL, V16, P1788, DOI 10.1681/ASN.2004040275
   Sprague SM, 2003, KIDNEY INT, V63, P1483, DOI 10.1046/j.1523 1755.2003.00878.x
   Walters BAJ, 2003, J AM SOC NEPHROL, V14, p473A
   Young EW, 2004, AM J KIDNEY DIS, V44, pS34, DOI 10.1053/j.ajkd.2004.08.009
   Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523 1755.2005.00185.x
NR 21
TC 51
Z9 52
U1 0
U2 2
PU DUSTRI VERLAG DR KARL FEISTLE
PI DEISENHOFEN MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D 82032 DEISENHOFEN MUENCHEN, GERMANY
SN 0301 0430
J9 CLIN NEPHROL
JI Clin. Nephrol.
PD JUL
PY 2007
VL 68
IS 1
BP 10
EP 17
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 194IS
UT WOS:000248338700002
PM 17703830
DA 2025 08 17
ER

PT J
AU Yang, YT
   Engleberg, AI
   Yuzbasiyan Gurkan, V
AF Yang, Ya Ting
   Engleberg, Alexander I.
   Yuzbasiyan Gurkan, Vilma
TI Establishment and Characterization of Cell Lines from Canine Metastatic
   Osteosarcoma
SO CELLS
LA English
DT Article
DE osteosarcoma; metastasis; cytokines; cell lines; transcriptome; canine
   IO panel
ID PULMONARY METASTASIS; TUMOR SUPPRESSOR; BREAST CANCER; OPEN LABEL;
   EXPRESSION; PROMOTES; PATHWAY; PTEN; IMMUNOTHERAPY; EXTREMITIES
AB Despite the advancements in treatments for other cancers, the outcomes for osteosarcoma (OSA) patients have not improved in the past forty years, especially in metastatic patients. Moreover, the major cause of death in OSA patients is due to metastatic lesions. In the current study, we report on the establishment of three cell lines derived from metastatic canine OSA patients and their transcriptome as compared to normal canine osteoblasts. All the OSA cell lines displayed significant upregulation of genes in the epithelial mesenchymal transition (EMT) pathway, and upregulation of key cytokines such as CXCL8, CXCL10 and IL6. The two most upregulated genes are MX1 and ISG15. Interestingly, ISG15 has recently been identified as a potential therapeutic target for OSA. In addition, there is notable downregulation of cell cycle control genes, including CDKN2A, CDKN2B and THBS1. At the protein level, p16INK4A, coded by CDKN2A, was undetectable in all the canine OSA cell lines, while expression of the tumor suppressor PTEN was variable, with one cell line showing complete absence and others showing low levels of expression. In addition, the cells express a variety of actionable genes, including KIT, ERBB2, VEGF and immune checkpoint genes. These findings, similar to those reported in human OSA, point to some genes that can be used for prognosis, targeted therapies and novel drug development for both canine and human OSA patients.
C1 [Yang, Ya Ting; Engleberg, Alexander I.; Yuzbasiyan Gurkan, Vilma] Michigan State Univ, Coll Vet Med, Dept Small Anim Clin Sci, E Lansing, MI 48824 USA.
   [Yuzbasiyan Gurkan, Vilma] Michigan State Univ, Coll Vet Med, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.
C3 Michigan State University; Michigan State University
RP Yuzbasiyan Gurkan, V (通讯作者)，Michigan State Univ, Coll Vet Med, Dept Small Anim Clin Sci, E Lansing, MI 48824 USA.; Yuzbasiyan Gurkan, V (通讯作者)，Michigan State Univ, Coll Vet Med, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.
EM yangyat1@msu.edu; engleber@msu.edu; vygsu@msu.edu
RI ; Yang, Ya Ting/NVM 6019 2025; Yuzbasiyan Gurkan, Vilma/AAF 8459 2020
OI Engleberg, Alexander/0000 0002 2057 4306; Yang,
   Ya Ting/0000 0001 8512 5336; Yuzbasiyan Gurkan,
   Vilma/0000 0001 9720 1279; 
FU Michigan State University; Genomics Core of the Research and Technology
   Support Facility of Michigan State University
FX The authors thank the Genomics Core of the Research and Technology
   Support Facility of Michigan State University for the NanoString assay
   and Melinda Frame of the MSU Center for Advanced Microscopy for
   assistance with the confocal microscopy. Also, the authors thank Paulo
   Vilar Saavedra for helping with accrual of tissue samples from the
   Michigan State University Veterinary Teaching Hospital. Graphic abstract
   created in part by use of dog and petri dish templates from
   BioRender.Com (accessed on 16 December 2023).
CR Abarrategi A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3631764
   Alexa A, 2019, TOPGO ENRICHMENT ANA
   Aljohani AI, 2020, BREAST CANCER RES TR, V181, P541, DOI 10.1007/s10549 020 05646 x
   Ammons Dylan, 2023, Res Sq, DOI 10.21203/rs.3.rs 3232360/v1
   Anfinsen KP, 2011, CAN J VET RES, V75, P209
   Angstadt AY, 2011, GENE CHROMOSOME CANC, V50, P859, DOI 10.1002/gcc.20908
   Ansell SM, 2020, BLOOD ADV, V4, P1917, DOI 10.1182/bloodadvances.2019001079
   Barroga EF, 1999, J VET MED SCI, V61, P361
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Blattmann C, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0497 x
   Boye K, 2021, CANCER IMMUNOL IMMUN, V70, P2617, DOI 10.1007/s00262 021 02876 w
   Byrum ML, 2016, J VET INTERN MED, V30, P1187, DOI 10.1111/jvim.14257
   Cable M.G., 2017, Osteosarcoma   Biology, Behavior and Mechanisms
   Chen HY, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.756085
   Cheng ZH, 2021, ARCH MED RES, V52, P200, DOI 10.1016/j.arcmed.2020.10.018
   Christian H., Cran Package fpc
   D'Angelo SP, 2018, LANCET ONCOL, V19, P416, DOI 10.1016/S1470 2045(18)30006 8
   Danaher P, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425 017 0215 8
   Doyle HA, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2021.101205
   Ebb D, 2012, J CLIN ONCOL, V30, P2545, DOI 10.1200/JCO.2011.37.4546
   Fabregat A, 2018, NUCLEIC ACIDS RES, V46, pD649, DOI 10.1093/nar/gkx1132
   Fan TM, 2008, J VET INTERN MED, V22, P602, DOI 10.1111/j.1939 1676.2008.0089.x
   Felip E, 2022, CANCER CHEMOTH PHARM, V89, P499, DOI 10.1007/s00280 022 04414 6
   Fenger JM, 2016, BMC CANCER, V16, DOI 10.1186/s12885 016 2837 5
   Gardner HL, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003 019 0487 2
   Geer LY, 2010, NUCLEIC ACIDS RES, V38, pD492, DOI 10.1093/nar/gkp858
   Gillette JM, 2008, IN VITRO CELL DEV AN, V44, P87, DOI 10.1007/s11626 007 9075 8
   Gong T, 2017, ONCOL LETT, V14, P6744, DOI 10.3892/ol.2017.6972
   Gong W, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2021.1997385
   Gross AC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99791
   Hong SH, 1998, J VET MED SCI, V60, P757, DOI 10.1292/jvms.60.757
   Igase M, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 75533 4
   Ikeda N, 2021, J VET MED SCI, V83, P1885, DOI 10.1292/jvms.21 0217
   Judge SJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0224775
   Kahai S, 2010, FEBS LETT, V584, P233, DOI 10.1016/j.febslet.2009.11.077
   Karlsson EK, 2013, GENOME BIOL, V14, DOI 10.1186/gb 2013 14 12 r132
   Kawabata A, 2006, J VET MED SCI, V68, P1047, DOI 10.1292/jvms.68.1047
   Kim C, 2017, CAN VET J, V58, P1059
   Kito F, 2018, IN VITRO CELL DEV AN, V54, P528, DOI 10.1007/s11626 018 0274 2
   Laschi M, 2015, J CELL PHYSIOL, V230, P2718, DOI 10.1002/jcp.24996
   Letko A, 2021, GENES BASEL, V12, DOI 10.3390/genes12121964
   Levine RA, 2002, VET PATHOL, V39, P372, DOI 10.1354/vp.39 3 372
   Liao YD, 2023, AM J TRANSL RES, V15, P817
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Ligon JA, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc 2020 001772
   Lim EA, 2022, CLIN CANCER RES, V28, P4871, DOI 10.1158/1078 0432.CCR 22 0612
   Loftus JP, 2016, VET COMP ONCOL, V14, pE17, DOI 10.1111/vco.12094
   Magee K, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255798
   Malkov Vladislav A, 2009, BMC Res Notes, V2, P80, DOI 10.1186/1756 0500 2 80
   Mannheimer JD, 2023, COMMUN BIOL, V6, DOI 10.1038/s42003 023 05208 z
   Mason NJ, 2021, MABS AUSTIN, V13, DOI 10.1080/19420862.2021.2004638
   Mason NJ, 2016, CLIN CANCER RES, V22, P4380, DOI 10.1158/1078 0432.CCR 16 0088
   Meng ZJ, 2015, ONCOL REP, V34, P1388, DOI 10.3892/or.2015.4084
   Meyer Florian R L, 2016, Vet Sci, V3, DOI 10.3390/vetsci3020009
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Mitchell AL, 2019, NUCLEIC ACIDS RES, V47, pD351, DOI 10.1093/nar/gky1100
   Murphy BG, 2017, BMC VET RES, V13, DOI 10.1186/s12917 017 1113 5
   Musser ML, 2021, VET COMP ONCOL, V19, P92, DOI 10.1111/vco.12642
   NanoString, nCounter® Canine IO Panel
   Neupane M, 2008, TISSUE ENG PT A, V14, P1007, DOI [10.1089/ten.tea.2007.0207, 10.1089/tea.2007.0207]
   Patel MR, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.2624
   Peng XR, 2022, DRUG DES DEV THER, V16, P2639, DOI 10.2147/DDDT.S373780
   Pereira BP, 2009, J CELL PHYSIOL, V221, P778, DOI 10.1002/jcp.21921
   RIGGS JL, 1974, J GEN VIROL, V25, P21, DOI 10.1099/0022 1317 25 1 21
   Righi A, 2016, HUM PATHOL, V58, P15, DOI 10.1016/j.humpath.2016.07.023
   ROS, About us
   Rowell JL, 2011, TRENDS MOL MED, V17, P380, DOI 10.1016/j.molmed.2011.02.004
   Ruiz D, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2022.105158
   Russell DS, 2018, J VET DIAGN INVEST, V30, P504, DOI 10.1177/1040638718770239
   Salinas Souza C, 2013, CYTOTECHNOLOGY, V65, P347, DOI 10.1007/s10616 012 9487 5
   Samant M, 2023, J PHARMACOL EXP THER, V387, P306, DOI 10.1124/jpet.123.001771
   Sayles LC, 2019, CANCER DISCOV, V9, P46, DOI 10.1158/2159 8290.CD 17 1152
   Schilder RJ, 2022, J CLIN ONCOL, V40
   Segal NH, 2018, CLIN CANCER RES, V24, P1816, DOI 10.1158/1078 0432.CCR 17 1922
   SketchAndCalc, About us
   Slenter DN, 2018, NUCLEIC ACIDS RES, V46, pD661, DOI 10.1093/nar/gkx1064
   Steigedal TS, 2018, NEOPLASIA, V20, P387, DOI 10.1016/j.neo.2018.02.008
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sui WW, 2014, ONCOL REP, V31, P2252, DOI 10.3892/or.2014.3093
   Szewczyk M, 2015, VET RES COMMUN, V39, P61, DOI 10.1007/s11259 014 9623 0
   Tan TJ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 33834 4
   Tang XY, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen 2016 013904
   Tang Y, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006714
   Tawbi HA, 2017, LANCET ONCOL, V18, P1493, DOI 10.1016/S1470 2045(17)30624 1
   Wang DS, 2018, J BONE ONCOL, V13, P91, DOI 10.1016/j.jbo.2018.09.006
   Withrow SJ., 2001, SMALL ANIMAL CLIN ON
   Xi YM, 2017, J CELL BIOCHEM, V118, P2684, DOI 10.1002/jcb.25888
   Yang YT, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23169345
   Yang YH, 2016, ONCOTARGET, V7, P87194, DOI 10.18632/oncotarget.13554
   Zhang SH, 2022, MOL CANCER THER, V21, P999, DOI 10.1158/1535 7163.MCT 21 0726
   Zong LJ, 2022, MODERN PATHOL, V35, P266, DOI 10.1038/s41379 021 00901 y
NR 91
TC 1
Z9 1
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD JAN
PY 2024
VL 13
IS 1
AR 25
DI 10.3390/cells13010025
PG 19
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA EM0A5
UT WOS:001139213900001
PM 38201229
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Handa, K
   Kiyohara, S
   Yamakawa, T
   Ishikawa, K
   Hosonuma, M
   Sakai, N
   Karakawa, A
   Chatani, M
   Tsuji, M
   Inagaki, K
   Kiuchi, Y
   Takami, M
   Negishi Koga, T
AF Handa, Kazuaki
   Kiyohara, Shuichi
   Yamakawa, Tomoyuki
   Ishikawa, Koji
   Hosonuma, Masahiro
   Sakai, Nobuhiro
   Karakawa, Akiko
   Chatani, Masahiro
   Tsuji, Mayumi
   Inagaki, Katsunori
   Kiuchi, Yuji
   Takami, Masamichi
   Negishi Koga, Takako
TI Bone loss caused by dopaminergic degeneration and levodopa treatment in
   Parkinson's disease model mice
SO SCIENTIFIC REPORTS
LA English
DT Article
ID KAPPA B LIGAND/OSTEOPROTEGERIN; MPTP MOUSE MODEL; RECEPTOR ACTIVATOR;
   PROLACTIN; DIFFERENTIATION; HOMOCYSTEINE; OSTEOBLASTS; OSTEOPOROSIS;
   MECHANISMS; TURNOVER
AB Accumulating evidence have shown the association of Parkinson's disease (PD) with osteoporosis. Bone loss in PD patients, considered to be multifactorial and a result of motor disfunction, is a hallmark symptom that causes immobility and decreased muscle strength, as well as malnutrition and medication. However, no known experimental evidence has been presented showing deleterious effects of anti PD drugs on bone or involvement of dopaminergic degeneration in bone metabolism. Here, we show that osteoporosis associated with PD is caused by dopaminergic degeneration itself, with no deficit of motor activity, as well as treatment with levodopa, the current gold standard medication for affected patients. Our findings show that neurotoxin induced dopaminergic degeneration resulted in bone loss due to accelerated osteoclastogenesis and suppressed bone formation, which was associated with elevated prolactin. On the other hand, using an experimental model of postmenopausal osteoporosis, dopaminergic degeneration did not result in exacerbation of bone loss due to estrogen deficiency, but rather reduction of bone loss. Thus, this study provides evidence for the regulation of bone metabolism by the dopaminergic system through both gonadal steroid hormone dependent and  independent functions, leading to possible early detection of osteoporosis development in individuals with PD.
C1 [Handa, Kazuaki; Yamakawa, Tomoyuki; Ishikawa, Koji; Hosonuma, Masahiro; Inagaki, Katsunori] Showa Univ, Dept Orthopaed Surg, Sch Med, Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428555, Japan.
   [Handa, Kazuaki; Yamakawa, Tomoyuki; Hosonuma, Masahiro; Tsuji, Mayumi; Kiuchi, Yuji] Showa Univ, Sch Med, Dept Pharmacol, Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428555, Japan.
   [Handa, Kazuaki; Kiyohara, Shuichi; Yamakawa, Tomoyuki; Ishikawa, Koji; Sakai, Nobuhiro; Karakawa, Akiko; Chatani, Masahiro; Takami, Masamichi; Negishi Koga, Takako] Showa Univ, Sch Dent, Dept Pharmacol, Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428555, Japan.
   [Handa, Kazuaki; Kiyohara, Shuichi; Yamakawa, Tomoyuki; Ishikawa, Koji; Hosonuma, Masahiro; Sakai, Nobuhiro; Karakawa, Akiko; Chatani, Masahiro; Tsuji, Mayumi; Kiuchi, Yuji; Takami, Masamichi; Negishi Koga, Takako] Showa Univ, Pharmacol Res Ctr, Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428555, Japan.
   [Kiyohara, Shuichi] Showa Univ, Dept Implant Dent, Sch Dent, Ota Ku, 2 1 1 Kitasenzoku, Tokyo 1458515, Japan.
   [Hosonuma, Masahiro] Showa Univ, Dept Med, Div Rheumatol, Sch Med,Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428555, Japan.
C3 Showa University; Showa University; Showa University; Showa University;
   Showa University; Showa University
RP Negishi Koga, T (通讯作者)，Showa Univ, Sch Dent, Dept Pharmacol, Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428555, Japan.; Negishi Koga, T (通讯作者)，Showa Univ, Pharmacol Res Ctr, Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428555, Japan.
EM koga@dent.showa u.ac.jp
RI ; Ishikawa, Koji/ABC 4850 2020
OI Chatani, Masahiro/0000 0002 1002 1775; Ishikawa,
   Koji/0000 0003 3689 5662; Akiko, Karakawa/0000 0003 2099 7293; Tsuji,
   Mayumi/0000 0001 8005 9069
FU Private University Research Branding Project of the Ministry of
   Education, Culture, Sports, Science and Technology of Japan (MEXT); MEXT
   [S1411009, S1201014, S0801016]; Japan Society for the Promotion of
   Science (JSPS) [24659830, 26293398, 17H04050, 17K11993, 18K09866,
   16K20655, 17K18114, 19K18544]; Lilly Grant Office; Uehara Memorial
   Foundation; Naito Foundation; Takeda Science Foundation; Grants in Aid
   for Scientific Research [19K18544, 26293398, 17K18114, 18K09866,
   17H04050, 17K11993, 16K20655] Funding Source: KAKEN
FX We thank all members of the pharmacology laboratory for their helpful
   discussion and assistance. This work was supported in part by the
   Private University Research Branding Project of the Ministry of
   Education, Culture, Sports, Science and Technology of Japan (MEXT) to
   Showa University, and the Industry to Support Private Universities
   Building up Their Foundations of Strategic Research of MEXT (S1411009,
   S1201014, S0801016) to M.T., as well as Grant in Aids for Scientific
   Research (B) to M.T. (No. 24659830, 26293398) and T.N. K. (No.
   17H04050), and Grant in Aids for Scientific Research (C) to N.S. (No.
   17K11993) and A.K. (No. 18K09866), and Grant in Aids for Young
   Scientists (B) to A.K. (No. 16K20655) and K.I. (No. 17K18114), and a
   Grant in Aids for Young Scientists to K.I. (No. 19K18544) from the Japan
   Society for the Promotion of Science (JSPS), a grant in aid from Lilly
   Grant Office to K.H. and grant in aids from The Uehara Memorial
   Foundation, The Naito Foundation and the Takeda Science Foundation to
   T.N. K.
CR Abou Raya S, 2009, AGE AGEING, V38, P675, DOI 10.1093/ageing/afp137
   Beaulieu JM, 2015, BRIT J PHARMACOL, V172, P1, DOI 10.1111/bph.12906
   BELLOMO G, 1991, J NEUROL, V238, P19, DOI 10.1007/BF00319704
   Ben Jonathan N, 2001, ENDOCR REV, V22, P724, DOI 10.1210/er.22.6.724
   Bleickardt CJ, 2012, PARKINSONS DIS US, V2012, DOI 10.1155/2012/591094
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   C S.P., 2008, NANO, V6, P2166
   Capozzi A, 2015, GYNECOL ENDOCRINOL, V31, P506, DOI 10.3109/09513590.2015.1017810
   CILIAX BJ, 1995, J NEUROSCI, V15, P1714, DOI 10.1523/JNEUROSCI.15 03 01714.1995
   Cizza G, 2009, TRENDS ENDOCRIN MET, V20, P367, DOI 10.1016/j.tem.2009.05.003
   Clément Lacroix P, 1999, ENDOCRINOLOGY, V140, P96, DOI 10.1210/en.140.1.96
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Elefteriou F, 2008, ARCH BIOCHEM BIOPHYS, V473, P231, DOI 10.1016/j.abb.2008.03.016
   Hanami K, 2013, BONE, V56, P1, DOI 10.1016/j.bone.2013.04.019
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Hudec SMD, 2013, ENDOCR PRACT, V19, P120, DOI 10.4158/EP12059.RA
   Invernizzi M, 2009, PARKINSONISM RELAT D, V15, P339, DOI 10.1016/j.parkreldis.2009.02.009
   Itzhak Y, 1999, PHARMACOL BIOCHEM BE, V63, P101, DOI 10.1016/S0091 3057(98)00246 9
   Jackson Lewis V, 2007, NAT PROTOC, V2, P141, DOI 10.1038/nprot.2006.342
   JACKSONLEWIS V, 1995, NEURODEGENERATION, V4, P257, DOI 10.1016/1055 8330(95)90015 2
   Jacquin C, 2006, J BONE MINER RES, V21, P67, DOI 10.1359/JBMR.051007
   Kalia LV, 2015, LANCET, V386, P896, DOI 10.1016/S0140 6736(14)61393 3
   Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303
   Lotinun S, 2003, ENDOCRINE, V20, P163, DOI 10.1385/ENDO:20:1 2:163
   Majumdar Abha, 2013, J Hum Reprod Sci, V6, P168, DOI 10.4103/0974 1208.121400
   Malochet Guinamand S, 2015, JOINT BONE SPINE, V82, P406, DOI 10.1016/j.jbspin.2015.03.009
   Meredith GE, 2011, J PARKINSON DIS, V1, P19, DOI 10.3233/JPD 2011 11023
   Mhyre Timothy R, 2012, Subcell Biochem, V65, P389, DOI 10.1007/978 94 007 5416 4_16
   Minami K, 2017, SCI REP UK, V7, DOI 10.1038/srep45686
   Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046
   Nakashioya H, 2011, MOD RHEUMATOL, V21, P260, DOI 10.1007/s10165 010 0387 2
   Nash AI, 2017, J CHEM NEUROANAT, V83, P59, DOI 10.1016/j.jchemneu.2016.07.010
   Negishi Koga Takako, 2012, Bonekey Rep, V1, P183, DOI 10.1038/bonekey.2012.183
   Nicks Kristy M, 2010, Curr Osteoporos Rep, V8, P60, DOI 10.1007/s11914 010 0014 3
   Nishikawa K, 2010, J CLIN INVEST, V120, P3455, DOI 10.1172/JCI42528
   Nitkowska M, 2015, ACTA NEUROL SCAND, V131, P411, DOI 10.1111/ane.12334
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Postuma RB, 2004, NEUROLOGY, V63, P886, DOI 10.1212/01.WNL.0000137886.74175.5A
   Roos PM, 2014, J TRACE ELEM MED BIO, V28, P418, DOI 10.1016/j.jtemb.2014.08.010
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Schaefer S, 2008, J NEUROENDOCRINOL, V20, P104, DOI 10.1111/j.1365 2826.2007.01622.x
   Sedelis M, 2001, BEHAV BRAIN RES, V125, P109, DOI 10.1016/S0166 4328(01)00309 6
   Seeman E, 2008, J BONE MINER METAB, V26, P1, DOI 10.1007/s00774 007 0793 5
   Seriwatanachai D, 2008, CELL BIOL INT, V32, P1126, DOI 10.1016/j.cellbi.2008.04.026
   Seriwatanachai D, 2008, BONE, V42, P535, DOI 10.1016/j.bone.2007.11.008
   Seriwatanachai D, 2009, J CELL BIOCHEM, V107, P677, DOI 10.1002/jcb.22161
   Stocchi F, 2017, INT REV NEUROBIOL, V134, P811, DOI [10.1016/bs.irn.2017.06.003, 10.1016/bs.im.2017.06.003]
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Taniguchi R, 2013, BIOSCI BIOTECH BIOCH, V77, P266, DOI 10.1271/bbb.120671
   Vacek TP, 2013, CLIN CHEM LAB MED, V51, P579, DOI 10.1515/cclm 2012 0605
   van den Bos F, 2013, AGE AGEING, V42, P156, DOI 10.1093/ageing/afs161
   van Meurs JBJ, 2004, NEW ENGL J MED, V350, P2033, DOI 10.1056/NEJMoa032546
   Wang LP, 2015, J BONE MINER RES, V30, P1896, DOI 10.1002/jbmr.2540
   Wongdee K, 2011, MOL CELL BIOCHEM, V349, P195, DOI 10.1007/s11010 010 0674 4
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Zhang MZ, 2015, CURR OPIN NEPHROL HY, V24, P117, DOI 10.1097/MNH.0000000000000104
NR 56
TC 32
Z9 36
U1 1
U2 13
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD SEP 24
PY 2019
VL 9
AR 13768
DI 10.1038/s41598 019 50336 4
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA IZ8OP
UT WOS:000487365300043
PM 31551490
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Appel, CK
   Gallego Pedersen, S
   Andersen, L
   Kristensen, SB
   Ding, M
   Falk, S
   Sayilekshmy, M
   Gabel Jensen, C
   Heegaard, AM
AF Appel, Camilla Kristine
   Gallego Pedersen, Simone
   Andersen, Line
   Kristensen, Sophie Blancheflor
   Ding, Ming
   Falk, Sarah
   Sayilekshmy, Manasi
   Gabel Jensen, Charlotte
   Heegaard, Anne Marie
TI The Src family kinase inhibitor dasatinib delays pain related behaviour
   and conserves bone in a rat model of cancer induced bone pain
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SQUAMOUS CELL CARCINOMA; SPINAL CORD; BREAST CANCER; NMDA RECEPTOR;
   MURINE MODEL; TYROSINE PHOSPHORYLATION; PALLIATIVE RADIOTHERAPY;
   INFLAMMATORY PAIN; IN VITRO; PHASE I
AB Pain is a severe and debilitating complication of metastatic bone cancer. Current analgesics do not provide sufficient pain relief for all patients, creating a great need for new treatment options. The Src kinase, a non receptor protein tyrosine kinase, is implicated in processes involved in cancer induced bone pain, including cancer growth, osteoclastic bone degradation and nociceptive signalling. Here we investigate the role of dasatinib, an oral Src kinase family and Bcr Abl tyrosine kinase inhibitor, in an animal model of cancer induced bone pain. Daily administration of dasatinib (15 mg/kg, p.o.) from day 7 after inoculation of MRMT 1 mammary carcinoma cells significantly attenuated movement evoked and non evoked pain behaviour in cancer bearing rats. Radiographic   and microcomputed tomographic analyses showed significantly higher relative bone density and considerably preserved bone micro architecture in the dasatinib treated groups, suggesting a bone preserving effect. This was supported by a significant reduction of serum TRACP 5b levels in cancer bearing rats treated with 15 mg/kg dasatinib. Furthermore, immunoblotting of lumbar spinal segments showed an increased activation of Src but not the NMDA receptor subunit 2B. These findings support a role of dasatinib as a disease modifying drug in pain pathologies characterized by increased osteoclast activity, such as bone metastases.
C1 [Appel, Camilla Kristine; Gallego Pedersen, Simone; Andersen, Line; Kristensen, Sophie Blancheflor; Falk, Sarah; Sayilekshmy, Manasi; Heegaard, Anne Marie] Univ Copenhagen, Fac Hlth & Med Sci, Dept Drug Design & Pharmacol, DK 2100 Copenhagen, Denmark.
   [Ding, Ming] Univ Southern Denmark, Odense Univ Hosp, Inst Clin Res, Dept Orthopaed & Traumatol, DK 5320 Odense, Denmark.
   [Gabel Jensen, Charlotte] Univ Copenhagen, Fac Hlth & Med Sci, Dept Pharm, DK 2100 Copenhagen, Denmark.
C3 University of Copenhagen; University of Southern Denmark; Odense
   University Hospital; University of Copenhagen
RP Heegaard, AM (通讯作者)，Univ Copenhagen, Fac Hlth & Med Sci, Dept Drug Design & Pharmacol, DK 2100 Copenhagen, Denmark.
EM amhe@sund.ku.dk
RI Gabel Jensen, Charlotte/A 2647 2012
OI Falk, Sarah/0000 0003 3245 1845; Ding, Ming/0000 0002 6610 8079;
   Heegaard, Anne Marie/0000 0003 2754 0800
FU Advokat Bent Thorbergs Fond
FX The authors thank Camilla Skanstrom Dall and Tina Maria Estrup Axen for
   technical assistance. This project was supported by Advokat Bent
   Thorbergs Fond.
CR Araujo J, 2009, INT J CANCER, V124, P1, DOI 10.1002/ijc.23998
   Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081
   Boufker HI, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 298
   Ceko M, 2014, PAIN, V155, P1222, DOI 10.1016/j.pain.2014.03.010
   Chan CM, 2012, CLIN CANCER RES, V18, P3580, DOI 10.1158/1078 0432.CCR 11 3359
   Chang AY, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 267
   Chow E, 2012, CLIN ONCOL UK, V24, P112, DOI 10.1016/j.clon.2011.11.004
   Cleeland CS, 2013, CANCER AM CANCER SOC, V119, P832, DOI 10.1002/cncr.27789
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   De Felice M, 2016, MOL PAIN, V12, DOI 10.1177/1744806916643725
   Demetri GD, 2009, CLIN CANCER RES, V15, P6232, DOI 10.1158/1078 0432.CCR 09 0224
   Ding M, 2010, ACTA ORTHOP, V81, P5, DOI 10.3109/17453671003619037
   El Mouedden M, 2005, PHARMACOL BIOCHEM BE, V82, P109, DOI 10.1016/j.pbb.2005.07.016
   El Mouedden M, 2007, PHARMACOL BIOCHEM BE, V87, P30, DOI 10.1016/j.pbb.2007.03.017
   Falk S, 2015, EUR J PAIN, V19, P305, DOI 10.1002/ejp.547
   Falk Sarah, 2015, F1000Res, V4, P445, DOI 10.12688/f1000research.6827.3
   Falk S, 2014, J CLIN ONCOL, V32, P1647, DOI 10.1200/JCO.2013.51.7219
   Finn RS, 2007, BREAST CANCER RES TR, V105, P319, DOI 10.1007/s10549 006 9463 x
   Frost CO, 2016, CURR OPIN PHARMACOL, V28, P31, DOI 10.1016/j.coph.2016.02.007
   Furusho M, 2009, J NEUROSCI, V29, P1608, DOI 10.1523/JNEUROSCI.5615 08.2009
   Garcia Gomez A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034914
   Gingrich JR, 2004, P NATL ACAD SCI USA, V101, P6237, DOI 10.1073/pnas.0401413101
   Gnoni A, 2011, CURR DRUG TARGETS, V12, P563, DOI 10.2174/138945011794751591
   Gordon Williams Richard M, 2007, Curr Opin Support Palliat Care, V1, P6, DOI 10.1097/SPC.0b013e328133f5e9
   Gralow J, 2007, J PAIN SYMPTOM MANAG, V33, P462, DOI 10.1016/j.jpainsymman.2007.01.001
   Grond S, 1996, PAIN, V64, P107, DOI 10.1016/0304 3959(95)00076 3
   Gu XP, 2010, EUR J PAIN, V14, P496, DOI 10.1016/j.ejpain.2009.09.001
   Guo W, 2002, J NEUROSCI, V22, P6208
   Hald A, 2009, EUR J PAIN, V13, P138, DOI 10.1016/j.ejpain.2008.03.014
   Hansen RR, 2012, EUR J PHARMACOL, V688, P27, DOI 10.1016/j.ejphar.2012.05.008
   Hiasa M, 2017, CANCER RES, V77, P1283, DOI 10.1158/0008 5472.CAN 15 3545
   Hingorani P, 2009, CLIN CANCER RES, V15, P3416, DOI 10.1158/1078 0432.CCR 08 1657
   Honore P, 2000, NEUROSCIENCE, V98, P585, DOI 10.1016/S0306 4522(00)00110 X
   Jimenez Andrade JM, 2010, ANN NY ACAD SCI, V1198, P173, DOI 10.1111/j.1749 6632.2009.05429.x
   Jin SX, 2003, J NEUROSCI, V23, P4017
   Johnson FM, 2005, CLIN CANCER RES, V11, P6924, DOI 10.1158/1078 0432.CCR 05 0757
   Koreckij T, 2009, BRIT J CANCER, V101, P263, DOI 10.1038/sj.bjc.6605178
   Lee YC, 2010, ONCOGENE, V29, P3196, DOI 10.1038/onc.2010.73
   Lindauer M, 2010, RECENT RESULTS CANC, V184, P83, DOI 10.1007/978 3 642 01222 8_7
   Liu M, 2015, ONCOL REP, V33, P1365, DOI 10.3892/or.2015.3706
   Liu S, 2011, CANCER RES, V71, P4392, DOI 10.1158/0008 5472.CAN 10 3870
   Liu XJ, 2008, NAT MED, V14, P1325, DOI 10.1038/nm.1883
   Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a
   Luger NM, 2002, PAIN, V99, P397, DOI 10.1016/S0304 3959(02)00102 1
   Mantyh PW, 2002, NAT REV CANCER, V2, P201, DOI 10.1038/nrc747
   McDonald R, 2015, J BONE ONCOL, V4, P24, DOI 10.1016/j.jbo.2014.11.001
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Middlemiss T, 2011, CLIN ONCOL UK, V23, P387, DOI 10.1016/j.clon.2011.03.003
   Mitri Z, 2016, CLIN CANCER RES, V22, P5706, DOI 10.1158/1078 0432.CCR 15 2845
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160
   Rissanen JP, 2008, CALCIFIED TISSUE INT, V82, P108, DOI 10.1007/s00223 007 9091 4
   Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368
   Schott AF, 2016, BREAST CANCER RES TR, V159, P87, DOI 10.1007/s10549 016 3911 z
   Schwei MJ, 1999, J NEUROSCI, V19, P10886, DOI 10.1523/JNEUROSCI.19 24 10886.1999
   Sims JT, 2009, CANCER CHEMOTH PHARM, V64, P629, DOI 10.1007/s00280 009 1004 y
   Slack S, 2008, NEUROSCIENCE, V156, P175, DOI 10.1016/j.neuroscience.2008.07.023
   Slosky LM, 2015, CANCER GROWTH METAST, P47, DOI 10.4137/CGM.S21215
   Song Y, 2013, EUR ARCH OTO RHINO L, V270, P1397, DOI 10.1007/s00405 013 2394 3
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Stepanenko AA, 2015, GENE, V574, P193, DOI 10.1016/j.gene.2015.08.009
   Sukhtankar D, 2011, MOL PAIN, V7, DOI 10.1186/1744 8069 7 81
   Sun YG, 2009, PAIN, V144, P178, DOI 10.1016/j.pain.2009.04.011
   Sun YB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037178
   Suo ZW, 2013, NEUROPHARMACOLOGY, V70, P122, DOI 10.1016/j.neuropharm.2013.01.015
   Takahashi S, 2011, CANCER SCI, V102, P2058, DOI 10.1111/j.1349 7006.2011.02041.x
   Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513
   Tokuhisa Y, 2014, ANN SURG ONCOL, V21, P1024, DOI 10.1245/s10434 013 3387 6
   Ungard RG, 2014, PAIN, V155, P28, DOI 10.1016/j.pain.2013.08.030
   Urch CE, 2005, J PAIN, V6, P837, DOI 10.1016/j.jpain.2005.08.005
   Vandyke K, 2009, LEUKEMIA, V23, P994, DOI 10.1038/leu.2008.356
   Vandyke K, 2010, J BONE MINER RES, V25, P1759, DOI 10.1002/jbmr.85
   Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096 9896(199612)180:4<383::AID PATH686>3.0.CO;2 N
   Vermeirsch H, 2004, PHARMACOL BIOCHEM BE, V79, P243, DOI 10.1016/j.pbb.2004.07.011
   Wheeler DL, 2009, ONCOLOGIST, V14, P667, DOI 10.1634/theoncologist.2009 0009
   Xu LS, 2012, J NEUROPHYSIOL, V108, P3024, DOI 10.1152/jn.01047.2011
   Yu XM, 1999, P NATL ACAD SCI USA, V96, P7697, DOI 10.1073/pnas.96.14.7697
   Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674
   Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304 3959(83)90201 4
NR 80
TC 30
Z9 32
U1 0
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JUL 6
PY 2017
VL 7
AR 4792
DI 10.1038/s41598 017 05029 1
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EZ6PY
UT WOS:000404841100048
PM 28684771
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tomatsu, S
   Gutierrez, M
   Nishioka, T
   Yamada, M
   Yamada, M
   Tosaka, Y
   Grubb, JH
   Montaño, AM
   Vieira, MB
   Trandafirescu, GG
   Peña, OM
   Yamaguchi, S
   Orii, KO
   Orii, T
   Noguchi, A
   Laybauer, L
AF Tomatsu, S
   Gutierrez, M
   Nishioka, T
   Yamada, M
   Yamada, M
   Tosaka, Y
   Grubb, JH
   Montaño, AM
   Vieira, MB
   Trandafirescu, GG
   Peña, OM
   Yamaguchi, S
   Orii, KO
   Orii, T
   Noguchi, A
   Laybauer, L
TI Development of MPS IVA mouse (Galnstm(hc79SmC76S)slu) tolerant to human
   N acetylgalactosamine 6 sulfate sulfatase
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID MUCOPOLYSACCHARIDOSIS TYPE VII; ENZYME REPLACEMENT THERAPY; HUMAN
   BETA GLUCURONIDASE; BONE MARROW TRANSPLANTATION; CENTRAL NERVOUS SYSTEM;
   LYSOSOMAL STORAGE; CLASSICAL MORQUIO; COMMON MUTATION; GENE THERAPY;
   MURINE MODEL
AB Mucopolysaccharidosis IVA (MPS IVA) is an autosomal recessive disease caused by N acetylgalactosamine 6 sulfate sulfatase (GALNS) deficiency. In recent studies of enzyme replacement therapy for animal models with lysosomal storage diseases, cellular and humoral immune responses to the injected enzymes have been recognized as major impediments to effective treatment. To study the long term effectiveness and side effects of therapies in the absence of immune responses, we have developed an MPS IVA mouse model, which has many similarities to human MPS IVA and is tolerant to human GALNS protein. We used a construct containing both a transgene (cDNA) expressing inactive human GALNS in intron 1 and an active site mutation (C76S) in adjacent exon 2 and thereby introduced both the inactive cDNA and the C76S mutation into the murine Galns by targeted mutagenesis. Affected homozygous mice have no detectable GALNS enzyme activity and accumulate glycosaminoglycans in multiple tissues including visceral organs, brain, cornea, bone, ligament and bone marrow. At 3 months, lysosomal storage is marked within hepatocytes, reticuloendothelial Kupffer cells, and cells of the sinusoidal lining of the spleen, neurons and meningeal cells. The bone storage is also obvious, with lysosomal distention in osteoblasts and osteocytes lining the cortical bone, in chondrocytes and in the sinus lining cells in bone marrow. Ubiquitous expression of the inactive human GALNS was also confirmed by western blot using the anti GALNS monoclonal antibodies newly produced, which resulted in tolerance to immune challenge with human enzyme. The newly generated MPS IVA mouse model should provide a good model to evaluate long term administration of enzyme replacement.
C1 St Louis Univ, Pediat Res Inst, Dept Pediat, St Louis, MO 63110 USA.
   St Louis Univ, Pediat Res Inst, Dept Biochem & Mol Biol, St Louis, MO 63110 USA.
   Shimane Univ, Dept Pediat, Izumo, Shimane, Japan.
   Gifu Univ, Dept Pediat, Gifu, Japan.
   JCR Pharmaceut, Res Ctr, Asiya, Japan.
C3 Saint Louis University; Saint Louis University; Shimane University; Gifu
   University
RP Tomatsu, S (通讯作者)，St Louis Univ, Pediat Res Inst, Dept Pediat, 3662 Pk Ave, St Louis, MO 63110 USA.
EM tomatsus@slu.edu
RI Montano, Adriana/AHE 8741 2022; Tomatsu, Shunji/AAA 4360 2022
OI Montano, Adriana M./0000 0002 3971 5789; Tomatsu,
   Shunji/0000 0002 0673 2160; 
CR BASTEDO L, 1994, J CLIN INVEST, V94, P1180, DOI 10.1172/JCI117434
   BIRKENMEIER EH, 1989, J CLIN INVEST, V83, P1258, DOI 10.1172/JCI114010
   BIRKENMEIER EH, 1991, BLOOD, V78, P3081
   BOHACEK L, 1968, AM J MED TECHNOL, V34, P287
   Bunge S, 1997, HUM MUTAT, V10, P223
   Cosma MP, 2003, CELL, V113, P445, DOI 10.1016/S0092 8674(03)00348 9
   Daly TM, 2000, PEDIATR RES, V47, P757, DOI 10.1203/00006450 200006000 00012
   Daly TM, 1999, HUM GENE THER, V10, P85, DOI 10.1089/10430349950019219
   Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963
   Dierks T, 2005, CELL, V121, P541, DOI 10.1016/j.cell.2005.03.001
   Dierks T, 2003, CELL, V113, P435, DOI 10.1016/S0092 8674(03)00347 7
   Fey J, 2001, J BIOL CHEM, V276, P47021, DOI 10.1074/jbc.M108943200
   FUKUDA S, 1992, J CLIN INVEST, V90, P1049, DOI 10.1172/JCI115919
   Fukuda S, 1996, HUM MUTAT, V7, P123, DOI 10.1002/(SICI)1098 1004(1996)7:2<123::AID HUMU6>3.3.CO;2 V
   Furuta K, 2001, AM J PATHOL, V159, P449, DOI 10.1016/S0002 9440(10)61716 6
   Gao CH, 2000, MOL THER, V2, P233, DOI 10.1006/mthe.2000.0121
   HOPWOOD JJ, 2001, METABOLIC MOL BASES, V3, P3725
   HORI T, 1995, GENOMICS, V26, P535, DOI 10.1016/0888 7543(95)80172 I
   Kakkis ED, 1996, BIOCHEM MOL MED, V58, P156, DOI 10.1006/bmme.1996.0044
   Kakkis ED, 2001, MOL GENET METAB, V72, P199, DOI 10.1006/mgme.2000.3140
   Kato Z, 1997, HUM GENET, V101, P97, DOI 10.1007/s004390050594
   Kosuga M, 2000, MOL THER, V1, P406, DOI 10.1006/mthe.2000.0067
   Lewandoski M, 1997, NAT GENET, V17, P223, DOI 10.1038/ng1097 223
   LI TS, 1995, P NATL ACAD SCI USA, V92, P7700, DOI 10.1073/pnas.92.17.7700
   MARECHAL V, 1993, BLOOD, V82, P1358
   Montaño AM, 2003, HUM GENET, V113, P162, DOI 10.1007/s00439 003 0959 8
   MOULLIER P, 1993, NAT GENET, V4, P154, DOI 10.1038/ng0693 154
   NEUFELD EF, 2001, METABOLIC MOL BASES, P3421, DOI DOI 10.1036/OMMBID.165
   Nuttall JD, 1999, CALCIFIED TISSUE INT, V65, P47, DOI 10.1007/s002239900656
   OGAWA T, 1995, HUM MOL GENET, V4, P341, DOI 10.1093/hmg/4.3.341
   Ohashi T, 2000, BLOOD, V95, P3631, DOI 10.1182/blood.V95.11.3631.011k13_3631_3633
   Ohashi T, 1997, P NATL ACAD SCI USA, V94, P1287, DOI 10.1073/pnas.94.4.1287
   SANDS MS, 1993, LAB INVEST, V68, P676
   SANDS MS, 1994, J CLIN INVEST, V93, P2324, DOI 10.1172/JCI117237
   SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092 8674(95)90314 3
   Serra R, 1997, J CELL BIOL, V139, P541, DOI 10.1083/jcb.139.2.541
   Sferra TJ, 2000, HUM GENE THER, V11, P507, DOI 10.1089/10430340050015707
   Shull RM, 1996, HUM GENE THER, V7, P1595, DOI 10.1089/hum.1996.7.13 1595
   Simonaro CM, 2005, PEDIATR RES, V57, P701, DOI 10.1203/01.PDR.0000156510.96253.5A
   Sly WS, 2001, P NATL ACAD SCI USA, V98, P2205, DOI 10.1073/pnas.051623698
   STRAUCH OF, 2001, PEDIATR RES, V54, P701
   TOMATSU S, 1995, AM J HUM GENET, V57, P556
   Tomatsu S, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.018010
   Tomatsu S, 2004, J HUM GENET, V49, P490, DOI 10.1007/s10038 004 0178 8
   Tomatsu S, 2003, HUM MOL GENET, V12, P3349, DOI 10.1093/hmg/ddg366
   Tomatsu S, 2003, HUM MOL GENET, V12, P961, DOI 10.1093/hmg/ddg119
   Tomatsu S, 1996, AM J HUM GENET, V58, P950
   TOMATSU S, 1995, HUM MOL GENET, V4, P741, DOI 10.1093/hmg/4.4.741
   Tomatsu S, 1997, HUM MUTAT, V10, P368, DOI 10.1002/(SICI)1098 1004(1997)10:5<368::AID HUMU6>3.0.CO;2 B
   Tomatsu Shunji, 2004, Hum Mutat, V24, P187, DOI 10.1002/humu.9265
   Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596 545
   Vogler C, 1999, PEDIATR RES, V45, P838, DOI 10.1203/00006450 199906000 00010
   VOGLER C, 1990, AM J PATHOL, V136, P207
   VOGLER C, 1993, PEDIATR RES, V34, P837, DOI 10.1203/00006450 199312000 00028
   VONDERMARK K, 1992, ARTHRITIS RHEUM US, V35, P806, DOI 10.1002/art.1780350715
   Watson GL, 1998, GENE THER, V5, P1642, DOI 10.1038/sj.gt.3300775
   WOLFE JH, 1992, NATURE, V360, P749, DOI 10.1038/360749a0
   WOLFE JH, 1996, PROTOCOLS GENE TRANS, P2
   Yamada N, 1998, HUM MUTAT, V11, P202, DOI 10.1002/(SICI)1098 1004(1998)11:3<202::AID HUMU4>3.0.CO;2 J
   Zito E, 2005, EMBO REP, V6, P655, DOI 10.1038/sj.embor.7400454
NR 60
TC 55
Z9 59
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964 6906
EI 1460 2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD NOV 15
PY 2005
VL 14
IS 22
BP 3321
EP 3335
DI 10.1093/hmg/ddi364
PG 15
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 983FL
UT WOS:000233216600001
PM 16219627
OA Bronze
DA 2025 08 17
ER

PT J
AU Ogata, Y
   Mabuchi, Y
   Shinoda, K
   Horiike, Y
   Mizuno, M
   Otabe, K
   Suto, EG
   Suzuki, N
   Sekiya, I
   Akazawa, C
AF Ogata, Yusuke
   Mabuchi, Yo
   Shinoda, Kosuke
   Horiike, Yuta
   Mizuno, Mitsuru
   Otabe, Koji
   Suto, Eriko Grace
   Suzuki, Nobuharu
   Sekiya, Ichiro
   Akazawa, Chihiro
TI Anterior cruciate ligament derived mesenchymal stromal cells have a
   propensity to differentiate into the ligament lineage
SO REGENERATIVE THERAPY
LA English
DT Article
DE Anterior cruciate ligament; Bone marrow; Mesenchymal stem/stromal cell;
   Cell surface marker; Differentiation; Regeneration therapy
ID TRANSCRIPTION FACTOR MOHAWK; STEM CELLS; BONE MARROW; POPULATION;
   REGENERATION; SCAFFOLD
AB Introduction: The anterior cruciate ligament (ACL) consists of various components, such as collagen, elastin fibres, and fibroblasts. Because ACL has a poor regenerative ability, ACL reconstruction need require the use of autologous tendons. In recent years, tissue resident stem cells have been studied to promote ACL regeneration as an alternatively method. However, the existence of stem cells in ligaments has not been clearly defined. Here, we prospectively isolated stem cells from ACLs and characterized their properties.
   Methods: ACLs from 11 donors and bone marrows (BM) from 8 donors were obtained with total knee arthroplasty. We used flow cytometry to screen the cell surface markers on ACL cells. Frozen sections were prepared from patient ACL tissues and stained with specific antibodies. Cultured ACL derived and BM derived cells at passage 3 were differentiated into adipocytes, osteoblasts and tendon/ligament cells.
   Results: ACL derived mesenchymal stem/stromal cells (ACL MSCs) expressed high levels of CD73 and CD90. Immunohistochemical analyses revealed that ACL MSCs were located on the inner surface of ACL sinusoids. Furthermore, the expression of cell surface antigens was clearly different between ACL MSCs and bone marrow (BM) derived MSCs (BM MSCs) at the time of isolation, but the two cell populations became indistinguishable after long term culture. Interestingly, ACL MSCs are markedly different from BM MSCs in their differentiation ability and have a high propensity to differentiate into ligament committed cells.
   Conclusions: Our findings suggest that ACL MSCs express CD90 and CD73 markers, and their differentiation capacity is maintained even through culture. The cell population having tissue specific properties is an important research target for investigating the ligament therapies. (C) 2018, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.
C1 [Ogata, Yusuke; Mabuchi, Yo; Shinoda, Kosuke; Horiike, Yuta; Suto, Eriko Grace; Suzuki, Nobuharu; Akazawa, Chihiro] Tokyo Med & Dent Univ, Grad Sch Hlth Care Sci, Dept Biochem & Biophys, Tokyo, Japan.
   [Mizuno, Mitsuru; Otabe, Koji; Sekiya, Ichiro] Tokyo Med & Dent Univ, Ctr Stem Cell & Regenerat Med, Tokyo, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU)
RP Akazawa, C (通讯作者)，Tokyo Med & Dent Univ, Grad Sch Hlth Care Sci, Dept Biochem & Biophys, Tokyo, Japan.
EM c.akazawa.bb@tmd.ac.jp
RI Mabuchi, Yo/L 1535 2013; Mitsuru, Mizuno/K 3962 2017; Ogata,
   Yusuke/X 9239 2019
OI Mizuno, Mitsuru/0000 0002 4410 3621; Ogata, Yusuke/0000 0002 5993 4356
FU Japan Agency for Medical Research and Development (AMED)
   [15bk0104037h0002]; Ministry of Education, Culture, Sports, Science, and
   Technology (MEXT) in Japan [17K01753, 15K06853, 16K19191]; Grants in Aid
   for Scientific Research [17K01753, 15K06853, 16K19191] Funding Source:
   KAKEN
FX We thank Mr. Keiichiro Komori and Ms. Shizuka Fujii (Tokyo Medical and
   Dental University, Tokyo, Japan) for sample preparation and Dr. Hiroshi
   Asahara (Tokyo Medical and Dental University, Tokyo, Japan) for
   discussion on ACL histology. This work was supported by the Research
   Project for Practical Applications of Regenerative Medicine from Japan
   Agency for Medical Research and Development (AMED) (Grant no.
   15bk0104037h0002). Additional support was obtained from the Grant in Aid
   for Scientific Research (C) (C. A. (Grant no. 17K01753), Y.M. (Grant no.
   15K06853) and for young scientists (B) (E.G.S. (Grant no. 16K19191))
   from the Ministry of Education, Culture, Sports, Science, and Technology
   (MEXT) in Japan.
CR Asahara H, 2017, J BONE MINER RES, V32, P1773, DOI 10.1002/jbmr.3199
   Battula VL, 2008, DIFFERENTIATION, V76, P326, DOI 10.1111/j.1432 0436.2007.00225.x
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Figueroa D, 2014, KNEE SURG SPORT TR A, V22, P1196, DOI 10.1007/s00167 013 2471 6
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890 196803000 00009
   Fu WL, 2016, INT ORTHOP, V40, P1523, DOI 10.1007/s00264 015 2925 1
   Ghebes CA, 2017, J TISSUE ENG REGEN M, V11, P1077, DOI 10.1002/term.2009
   Grassi A, 2017, BONE JOINT J, V99B, P714, DOI [10.1302/0301 620X.99B6.BJJ 2016 0929.R2, 10.1302/0301 620X.99B6.BJJ 2016 0929]
   Gullo F, 2013, RHEUMATOLOGY, V52, P1758, DOI 10.1093/rheumatology/ket205
   Kawamoto T, 2003, ARCH HISTOL CYTOL, V66, P123, DOI 10.1679/aohc.66.123
   Kerkela E, 2016, STEM CELLS, V34, P781, DOI 10.1002/stem.2280
   Lee DH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117224
   Li HZ, 2014, STEM CELL REP, V3, P965, DOI 10.1016/j.stemcr.2014.09.018
   Liu A, 2016, SCI REP UK, V6, DOI [10.1038/srep21704, 10.1038/srep33919]
   Liu HF, 2008, BIOMATERIALS, V29, P662, DOI 10.1016/j.biomaterials.2007.10.035
   Mabuchi Y, 2016, INT J HEMATOL, V103, P138, DOI 10.1007/s12185 015 1921 y
   Mabuchi Y, 2013, STEM CELL REP, V1, P152, DOI 10.1016/j.stemcr.2013.06.001
   Mabuchi Y, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/507301
   Morikawa S, 2009, BIOCHEM BIOPH RES CO, V379, P1114, DOI 10.1016/j.bbrc.2009.01.031
   Murray MM, 2016, ORTHOP J SPORTS MED, V4, DOI 10.1177/2325967116672176
   Nagoshi N, 2008, CELL STEM CELL, V2, P392, DOI 10.1016/j.stem.2008.03.005
   Nakahara H, 2013, ARTHRITIS RHEUM US, V65, P2081, DOI 10.1002/art.38020
   Nakamichi R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12503
   Nelson F, 2006, OSTEOARTHR CARTILAGE, V14, P114, DOI 10.1016/j.joca.2005.08.005
   Ogata Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129096
   Ong WK, 2014, STEM CELL REP, V2, P171, DOI 10.1016/j.stemcr.2014.01.002
   Otabe K, 2015, J ORTHOP RES, V33, P1, DOI 10.1002/jor.22750
   Ozeki N, 2016, OSTEOARTHR CARTILAGE, V24, P1061, DOI 10.1016/j.joca.2015.12.018
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Proffen BL, 2015, AM J SPORT MED, V43, P320, DOI 10.1177/0363546514559826
   Quirici N, 2002, EXP HEMATOL, V30, P783, DOI 10.1016/S0301 472X(02)00812 3
   Rahr Wagner L, 2014, AM J SPORT MED, V42, P278, DOI 10.1177/0363546513509220
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Suto EG, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05099 1
   Swift J, 2013, SCIENCE, V341, DOI 10.1126/science.1240104
   Takashima Y, 2007, CELL, V129, P1377, DOI 10.1016/j.cell.2007.04.028
   Yasui T, 2016, J DENT RES, V95, P206, DOI 10.1177/0022034515610748
   Zaffagnini Stefano, 2015, Joints, V3, P85, DOI 10.11138/jts/2015.3.2.085
NR 38
TC 16
Z9 17
U1 3
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2352 3204
J9 REGEN THER
JI Regen. Ther.
PD JUN
PY 2018
VL 8
BP 20
EP 28
DI 10.1016/j.reth.2017.12.001
PG 9
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA GK1TG
UT WOS:000435903700004
PM 30271862
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Galaka, T
   Falcone, BN
   Li, C
   Szajnman, SH
   Moreno, SNJ
   Docampo, R
   Rodriguez, JB
AF Galaka, Tamila
   Falcone, Bruno N.
   Li, Catherine
   Szajnman, Sergio H.
   Moreno, Silvia N. J.
   Docampo, Roberto
   Rodriguez, Juan B.
TI Synthesis and biological evaluation of
   1 alkylaminomethyl 1,1 bisphosphonic acids against Trypanosoma
   cruzi and Toxoplasma gondii
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
ID FARNESYL PYROPHOSPHATE SYNTHASE; IN VITRO; DIPHOSPHATE SYNTHASE;
   FATTY ACIDS; PLASMODIUM FALCIPARUM; GROWTH INHIBITORS; POTENT
   INHIBITORS; BISPHOSPHONATES; DESIGN; BRUCEI
AB As an extension of our project aimed at the search for new chemotherapeutic agents against Chagas disease and toxoplasmosis, several 1,1 bisphosphonates were designed, synthesized and biologically evaluated against Trypanosoma cruzi and Toxoplasma gondii, the etiologic agents of these diseases, respectively. In particular, and based on the antiparasitic activity exhibited by 2 alkylaminoethyl 1,1 bisphosphonates targeting farnesyl diphosphate synthase, a series of linear 2 alkylaminomethyl  1,1 bisphosphonic acids (compounds 21 33), that is, the position of the amino group was one carbon closer to the gem phosphonate moiety, were evaluated as growth inhibitors against the clinically more relevant dividing form (amastigotes) of T. cruzi. Although all of these compounds resulted to be devoid of antiparasitic activity, these results were valuable for a rigorous SAR study. In addition, unexpectedly, the synthetic designed 2 cycloalkylaminoethyl 1,1 bisphosphonic acids 47 49 were free of antiparasitic activity. Moreover, long chain sulfur containing 1,1 bisphosphonic acids, such as compounds 54 56, 59, turned out to be nanomolar growth inhibitors of tachyzoites of T. gondii. As many bisphosphonate containing molecules are FDA approved drugs for the treatment of bone resorption disorders, their potential nontoxicity makes them good candidates to control American trypanosomiasis and toxoplasmosis.
C1 [Galaka, Tamila; Falcone, Bruno N.; Szajnman, Sergio H.; Rodriguez, Juan B.] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Organ, Pabellon 2,Ciudad Univ,C1428EHA, Buenos Aires, DF, Argentina.
   [Galaka, Tamila; Falcone, Bruno N.; Szajnman, Sergio H.; Rodriguez, Juan B.] Univ Buenos Aires, Fac Ciencias Exactas & Nat, UMYMFOR CONICET FCEyN, Pabellon 2,Ciudad Univ,C1428EHA, Buenos Aires, DF, Argentina.
   [Li, Catherine; Moreno, Silvia N. J.; Docampo, Roberto] Univ Georgia, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA.
   [Li, Catherine; Moreno, Silvia N. J.; Docampo, Roberto] Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA.
C3 University of Buenos Aires; University of Buenos Aires; Consejo Nacional
   de Investigaciones Cientificas y Tecnicas (CONICET); University System
   of Georgia; University of Georgia; University System of Georgia;
   University of Georgia
RP Rodriguez, JB (通讯作者)，Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Organ, Pabellon 2,Ciudad Univ,C1428EHA, Buenos Aires, DF, Argentina.; Rodriguez, JB (通讯作者)，Univ Buenos Aires, Fac Ciencias Exactas & Nat, UMYMFOR CONICET FCEyN, Pabellon 2,Ciudad Univ,C1428EHA, Buenos Aires, DF, Argentina.
EM jbr@qo.fcen.uba.ar
RI ; Szajnman, Sergio/AFM 1606 2022; Docampo, Roberto/X 9424 2019
OI Falcone, Bruno N./0000 0003 0114 9213; Szajnman, Sergio
   Hernan/0000 0001 6989 4768; 
FU Consejo Nacional de Investigaciones Cientificas y Tecnicas [PIP
   112 201501 00631 CO]; Agencia Nacional de Promocion Cientifica y
   Tecnologica [PICT 2015 1349]; Universidad de Buenos Aires
   [20020170100067BA]; U.S. National Institutes of Health [AI 107663,
   AI 102254]
FX We thank Melissa Storey for help with T. cruzi in vitro testing. This
   work was supported by grants from the Consejo Nacional de
   Investigaciones Cientificas y Tecnicas (PIP 112 201501 00631 CO),
   Agencia Nacional de Promocion Cientifica y Tecnologica (PICT 2015 1349),
   and the Universidad de Buenos Aires (20020170100067BA) to J.B.R., and
   the U.S. National Institutes of Health to R.D. (AI 107663) and S.N.J.M.
   (AI 102254).
CR Aripirala S, 2012, J MED CHEM, V55, P6445, DOI 10.1021/jm300425y
   Bálint E, 2016, BEILSTEIN J ORG CHEM, V12, P1493, DOI 10.3762/bjoc.12.146
   Rodriguez JB, 2012, EXPERT OPIN THER PAT, V22, P311, DOI 10.1517/13543776.2012.668886
   Bessoff K, 2013, ANTIMICROB AGENTS CH, V57, P1804, DOI 10.1128/AAC.02460 12
   Bouzahzah B, 2005, PARASITOL RES, V96, P184, DOI 10.1007/s00436 005 1331 9
   Buckner FS, 2012, INT J PARASITOL DRUG, V2, P236, DOI 10.1016/j.ijpddr.2011.12.002
   Chellan P, 2017, BIOORG MED CHEM LETT, V27, P1491, DOI 10.1016/j.bmcl.2017.01.046
   Cinque GM, 1998, J MED CHEM, V41, P1540, DOI 10.1021/jm970860z
   Coppens I, 2000, J CELL BIOL, V149, P167, DOI 10.1083/jcb.149.1.167
   Cortez E, 2009, INT J ANTIMICROB AG, V33, P185, DOI 10.1016/j.ijantimicag.2008.07.026
   Dabrowska E, 2009, J ORGANOMET CHEM, V694, P3806, DOI 10.1016/j.jorganchem.2009.07.025
   Docampo R, 2005, NAT REV MICROBIOL, V3, P251, DOI 10.1038/nrmicro1097
   Docampo R, 2008, CURR PHARM DESIGN, V14, P882, DOI 10.2174/138161208784041079
   Docampo R, 2011, CELL CALCIUM, V50, P113, DOI 10.1016/j.ceca.2011.05.012
   Docampo Roberto, 2001, Current Drug Targets   Infectious Disorders, V1, P51, DOI 10.2174/1568005013343191
   Ferella M, 2008, EXP PARASITOL, V119, P308, DOI 10.1016/j.exppara.2008.02.013
   Ferrer Casal M, 2014, BIOORGAN MED CHEM, V22, P398, DOI 10.1016/j.bmc.2013.11.010
   Gabelli SB, 2006, PROTEINS, V62, P80, DOI 10.1002/prot.20754
   Galaka T, 2017, MOLECULES, V22, DOI 10.3390/molecules22010082
   Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P286, DOI 10.1016/j.ijantimicag.2003.07.019
   Ghosh S, 2004, J MED CHEM, V47, P175, DOI 10.1021/jm030084x
   GRELLIER P, 1994, ANTIMICROB AGENTS CH, V38, P1144, DOI 10.1128/AAC.38.5.1144
   Innes EA, 2010, ZOONOSES PUBLIC HLTH, V57, P1, DOI 10.1111/j.1863 2378.2009.01276.x
   Jarstfer MB, 2002, J AM CHEM SOC, V124, P8834, DOI 10.1021/ja020410i
   Lepesheva GI, 2011, ADV PARASIT, V75, P65, DOI 10.1016/B978 0 12 385863 4.00004 6
   Li ZH, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.02628 16
   Li ZH, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003665
   Liñares GEG, 2006, CURR MED CHEM, V13, P335, DOI 10.2174/092986706775476043
   Ling Y, 2005, J MED CHEM, V48, P3130, DOI 10.1021/jm040132t
   Ling Y, 2007, J BIOL CHEM, V282, P30804, DOI 10.1074/jbc.M703178200
   Lolli ML, 2002, J ORGANOMET CHEM, V650, P77, DOI 10.1016/S0022 328X(02)01179 8
   Lüder CGK, 2001, TRENDS PARASITOL, V17, P480, DOI 10.1016/S1471 4922(01)02093 1
   Marma MS, 2007, J MED CHEM, V50, P5967, DOI 10.1021/jm0702884
   Martin MB, 2002, J MED CHEM, V45, P2904, DOI 10.1021/jm0102809
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   MCKENNA CE, 1979, J CHEM SOC CHEM COMM, P739, DOI 10.1039/c39790000739
   MCKENNA CE, 1981, J ORG CHEM, V46, P4573, DOI 10.1021/jo00335a053
   Molina I, 2014, NEW ENGL J MED, V370, P1899, DOI 10.1056/NEJMoa1313122
   Montalvetti A, 2003, J BIOL CHEM, V278, P17075, DOI 10.1074/jbc.M210467200
   Moreno SNJ, 2008, EXPERT OPIN THER TAR, V12, P253, DOI 10.1517/14728222.12.3.253
   Moreno SNJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003230
   Nair SC, 2011, J EXP MED, V208, P1547, DOI 10.1084/jem.20110039
   Ogura K, 1998, CHEM REV, V98, P1263, DOI 10.1021/cr9600464
   Pradines B, 2007, ANTIMICROB AGENTS CH, V51, P2654, DOI 10.1128/AAC.01330 06
   Recher M, 2013, EUR J MED CHEM, V60, P431, DOI 10.1016/j.ejmech.2012.12.015
   Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375
   Rodriguez JB, 2019, CHEMMEDCHEM, V14, P190, DOI 10.1002/cmdc.201800693
   Rodriguez JB, 2016, EXPERT OPIN THER PAT, V26, P993, DOI 10.1080/13543776.2016.1209487
   Rodriguez JB, 2016, EXPERT OPIN DRUG DIS, V11, P307, DOI 10.1517/17460441.2016.1143814
   Rodriguez JB, 2014, SYNTHESIS STUTTGART, V46, P1129, DOI 10.1055/s 0033 1340952
   Rosso VS, 2011, BIOORGAN MED CHEM, V19, P2211, DOI 10.1016/j.bmc.2011.02.037
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Menna Barreto RFS, 2017, CURR TOP MED CHEM, V17, P1212, DOI 10.2174/1568026616666161025161858
   Sun ST, 2011, EXPERT OPIN THER PAT, V21, P1433, DOI 10.1517/13543776.2011.593511
   Szajnman SH, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.01590 16
   Szajnman SH, 2012, ORG BIOMOL CHEM, V10, P1424, DOI 10.1039/c1ob06602a
   Szajnman SH, 2005, EUR J ORG CHEM, V2005, P3687, DOI 10.1002/ejoc.200500097
   Szajnman SH, 2003, BIOORG MED CHEM LETT, V13, P3231, DOI 10.1016/S0960 894X(03)00663 2
   Szajnman SH, 2005, BIOORG MED CHEM LETT, V15, P4685, DOI 10.1016/j.bmcl.2005.07.060
   Szajnman SH, 2001, BIOORG MED CHEM LETT, V11, P789, DOI 10.1016/S0960 894X(01)00057 9
   Szajnman SH, BIOORG MED CHEM
   TAKEUCHI M, 1993, CHEM PHARM BULL, V41, P688
   Urbina JA, 1999, J BIOL CHEM, V274, P33609, DOI 10.1074/jbc.274.47.33609
   Urbina JA, 2015, J EUKARYOT MICROBIOL, V62, P149, DOI 10.1111/jeu.12184
NR 65
TC 11
Z9 11
U1 0
U2 16
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968 0896
EI 1464 3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD AUG 15
PY 2019
VL 27
IS 16
BP 3663
EP 3673
DI 10.1016/j.bmc.2019.07.004
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA IK9AN
UT WOS:000476887000016
PM 31296439
OA Green Published, Green Accepted
DA 2025 08 17
ER

PT J
AU Dong, Z
   Ba, HX
   Zhang, W
   Coates, D
   Li, CY
AF Dong, Zhen
   Ba, Hengxing
   Zhang, Wei
   Coates, Dawn
   Li, Chunyi
TI iTRAQ Based Quantitative Proteomic Analysis of the Potentiated and
   Dormant Antler Stem Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE regeneration; antler stem cell; proteome; iTRAQ
ID ENDOTHELIAL GROWTH FACTOR; NEGATIVE REGULATOR; ENERGY METABOLISM;
   REGENERATION; PROLIFERATION; OSTEOBLAST; HYPOXIA; DIFFERENTIATION;
   QUANTIFICATION; IDENTIFICATION
AB As the only known organ that can completely regenerate in mammals, deer antler is of real significance in the field of regenerative medicine. Recent studies have shown that the regenerative capacity of the antlers comes from the pedicle periosteum and the cells resident in the periosteum possess the attributes of stem cells. Currently, the molecular mechanism of antler regeneration remains unclear. In the present study, we compared the potentiated and dormant antler stem cells using isobaric tags for the relative and absolute quantification (iTRAQ) labeling of the peptides, coupled with two dimensional liquid chromatography tandem mass spectrometry (LC MS/MS) to compare the proteome profiles. Proteins were identified by searching against the NCBI nr database and our own Cervine transcriptome database, and bioinformatics analysis was conducted to identify the differentially expressed proteins. Based on this searching strategy, we identified 169 differentially expressed proteins in total, consisting of 70 up and 99 down regulated in the potentiated vs. dormant antler stem cells. Reliability of the iTRAQ was confirmed via quantitative real time polymerase chain reaction (qRT PCR) to measure the expression of selected genes. We identified transduction pathways through the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, such as HIF 1 and PI3K AKT signaling pathways that play important roles in regulating the regeneration of antlers. In summary, the initiation stage of antler regeneration, a process from dormant to potentiated states in antler stem cells, is regulated by multiple proteins and complicated signal networks.
C1 [Dong, Zhen; Ba, Hengxing; Zhang, Wei; Li, Chunyi] Chinese Acad Agr Sci, Inst Special Wild Econ Anim & Plants, Changchun 130112, Peoples R China.
   [Dong, Zhen; Ba, Hengxing; Zhang, Wei; Li, Chunyi] State Key Lab Mol Biol Special Econ Anim, Changchun 130112, Peoples R China.
   [Coates, Dawn] Univ Otago, Sir John Walsh Res Inst, Fac Dent, POB 647, Dunedin 9054, New Zealand.
C3 Chinese Academy of Agricultural Sciences; Institute of Special Animal &
   Plant Sciences, CAAS; University of Otago
RP Li, CY (通讯作者)，Chinese Acad Agr Sci, Inst Special Wild Econ Anim & Plants, Changchun 130112, Peoples R China.; Li, CY (通讯作者)，State Key Lab Mol Biol Special Econ Anim, Changchun 130112, Peoples R China.
EM xi.andz@163.com; bahengxing@caas.cn; zw0915@163.com;
   dawn.coates@otago.ac.nz; lichunyi1959@163.com
RI ; li, chunyi/KIG 6117 2024; Coates, Dawn/B 5134 2012
OI Coates, Dawn/0000 0003 4242 6846; Dong, Zhen/0000 0002 3480 3421
FU Chinese National 863 Program [2011AA100603]; Jilin Province Science and
   Technology Development Plan item [20140204010YY]; Project of Science and
   Technology Plans of Jilin Province [20150204071NY]
FX This work was supported by the Chinese National 863 Program
   (2011AA100603), the Jilin Province Science and Technology Development
   Plan item (20140204010YY), and the Project of Science and Technology
   Plans of Jilin Province (20150204071NY). The authors would also like to
   thank Stephen Haines for kindly reading through the manuscript.
CR Battle TE, 2006, CANCER RES, V66, P3649, DOI 10.1158/0008 5472.CAN 05 3612
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Brewis IA, 2010, ADV PROTEIN CHEM STR, V80, P1, DOI [10.1016/S1876 1623(10)80001 X, 10.1016/B978 0 12 381264 3.00001 1]
   Brusselmans K, 2005, J BIOL CHEM, V280, P3493, DOI 10.1074/jbc.M406613200
   Chen J, 2011, OBES REV, V12, P1063, DOI 10.1111/j.1467 789X.2011.00917.x
   del Valle Pérez B, 2010, J BIOL CHEM, V285, P10748, DOI 10.1074/jbc.M109.062984
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Dunn LL, 2014, ANTIOXID REDOX SIGN, V20, P1723, DOI 10.1089/ars.2013.5675
   Fujie A, 2015, BIOCHEM BIOPH RES CO, V457, P451, DOI 10.1016/j.bbrc.2015.01.012
   Gao Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037656
   GNAIGER E, 1990, BIOCHIM BIOPHYS ACTA, V1016, P328, DOI 10.1016/0005 2728(90)90164 Y
   GOSS RJ, 1995, ANAT REC, V241, P291, DOI 10.1002/ar.1092410302
   GOSS RJ, 1983, DEER ANTLERS REGENER, DOI DOI 10.1038/306405C0
   Grayson WL, 2006, J CELL PHYSIOL, V207, P331, DOI 10.1002/jcp.20571
   Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb 2007 8 9 r183
   Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303
   Li C., 2003, European Journal of Morphology, V41, P23, DOI 10.1076/ejom.41.1.23.28106
   Li CY, 2007, J EXP ZOOL PART A, V307A, P95, DOI 10.1002/jez.a.352
   Li CY, 2007, CELL TISSUE RES, V328, P65, DOI 10.1007/s00441 006 0333 y
   Li CY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030026
   Li CY, 2009, CURR STEM CELL RES T, V4, P237, DOI 10.2174/157488809789057446
   Li CY, 2005, ANAT REC PART A, V282A, P163, DOI 10.1002/ar.a.20148
   Martelli AM, 2010, BBA MOL CELL RES, V1803, P991, DOI 10.1016/j.bbamcr.2010.04.005
   Müller M, 2012, MICROBIOL MOL BIOL R, V76, P444, DOI 10.1128/MMBR.05024 11
   Nakamura F, 2011, CELL ADHES MIGR, V5, P160, DOI 10.4161/cam.5.2.14401
   Okuyama H, 2006, J BIOL CHEM, V281, P15554, DOI 10.1074/jbc.M602003200
   Özcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160
   Pierce A, 2008, MOL CELL PROTEOMICS, V7, P853, DOI 10.1074/mcp.M700251 MCP200
   Robertson SP, 2005, CURR OPIN GENET DEV, V15, P301, DOI 10.1016/j.gde.2005.04.001
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Stocum DL, 2005, ADV BIOCHEM ENG BIOT, V93, P135, DOI 10.1007/b99969
   Sun HM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047367
   Sun LG, 2007, J CELL BIOL, V179, P129, DOI 10.1083/jcb.200703184
   Sun R, 2006, HEPATOLOGY, V44, P955, DOI 10.1002/hep.21344
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Teslaa T, 2015, EMBO J, V34, P138, DOI 10.15252/embj.201490446
   Treumann A, 2010, EXPERT REV PROTEOMIC, V7, P647, DOI 10.1586/EPR.10.29
   van der Flier A, 2001, BBA MOL CELL RES, V1538, P99, DOI 10.1016/S0167 4889(01)00072 6
   Wang DW, 2005, J CELL PHYSIOL, V204, P184, DOI 10.1002/jcp.20324
   Wang WS, 2013, J PROTEOMICS, V91, P453, DOI 10.1016/j.jprot.2013.06.032
   Yin Z, 2002, P NATL ACAD SCI USA, V99, P10488, DOI 10.1073/pnas.162371799
   Zhao TF, 2012, MOL BIOL REP, V39, P3541, DOI 10.1007/s11033 011 1127 1
   Zhu LL, 2005, MOL NEUROBIOL, V31, P231, DOI 10.1385/MN:31:1 3:231
NR 44
TC 24
Z9 28
U1 0
U2 15
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2016
VL 17
IS 11
AR 1778
DI 10.3390/ijms17111778
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA ED4HV
UT WOS:000388809600012
PM 27792145
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Yamashita, Y
   Sano, N
   Shimohira, D
   Danjo, A
   Goto, M
AF Yamashita, Y.
   Sano, N.
   Shimohira, D.
   Danjo, A.
   Goto, M.
TI A parallel group comparison study of celecoxib with loxoprofen sodium in
   third mandibular molar extraction patients
SO INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
DE celecoxib; loxoprofen sodium; post exodontic pain; non steroidal
   anti inflammatory drugs; analgesic effect
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RANDOMIZED CONTROLLED TRIAL;
   CYCLOOXYGENASE 2 INHIBITOR; RHEUMATOID ARTHRITIS; GASTROINTESTINAL
   TOXICITY; DOUBLE BLIND; OSTEOARTHRITIS; EFFICACY; JAPAN; ASSOCIATION
AB Non steroidal anti inflammatory drugs (NSAIDs) are used widely, but they may damage the upper gastrointestinal mucosa owing to their mechanism of action. Selective cyclooxygenase 2 (COX 2) inhibitors are known to have a reduced risk for such damage. In this comparative study, the efficacy and safety of the selective COX 2 inhibitor celecoxib for pain after third mandibular molar extraction were compared with those of loxoprofen sodium. This was a parallel group comparison study; 107 patients who had undergone third mandibular molar extraction were given celecoxib and 102 were given loxoprofen. The level of pain on a visual analogue scale (VAS) 15 min and 30 min after taking the experimental drug decreased over time, with no significant difference between the two groups. The percentage of patients taking a second dose was 64.5% for celecoxib and 80.4% for loxoprofen. The time to second dose was significantly longer for celecoxib (533.5 min) than for loxoprofen (387.4 min). There was no significant difference in the patients' impression of efficacy between the two groups, with ratings of 'excellent' and 'good' for 77.4% in the loxoprofen group and 74.5% in the celecoxib group. These results demonstrate that celecoxib is of equal clinical value to loxoprofen for acute pain after third mandibular molar extraction.
C1 [Yamashita, Y.; Sano, N.; Shimohira, D.; Danjo, A.; Goto, M.] Saga Univ, Fac Med, Dept Oral & Maxillofacial Surg, Saga 8498501, Japan.
C3 Saga University
RP Yamashita, Y (通讯作者)，Saga Univ, Fac Med, Dept Oral & Maxillofacial Surg, 5 1 1 Nabeshima, Saga 8498501, Japan.
EM yamashy2@cc.saga u.ac.jp
OI DANJO, Atsushi/0000 0002 9137 7166
CR Becker Daniel E, 2010, Anesth Prog, V57, P67, DOI 10.2344/0003 3006 57.2.67
   Bensen WG, 1999, MAYO CLIN PROC, V74, P1095, DOI 10.4065/74.11.1095
   Chan FKL, 2010, LANCET, V376, P173, DOI 10.1016/S0140 6736(10)60673 3
   Cheung R, 2007, CLIN THER, V29, P2498, DOI 10.1016/j.clinthera.2007.12.008
   GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003 4819 115 10 787
   Goldstein JL, 2000, J RHEUMATOL, V27, P25
   Jain N, 2011, J MAXILLOFAC ORAL SU, V10, P118, DOI 10.1007/s12663 011 0198 9
   Japanese Society of Gastroenterology, 2009, GUID MAN PEPT ULC
   Khan AA, 2002, CLIN PHARMACOL THER, V72, P44, DOI 10.1067/mcp.2002.125560
   Klasser Gary D, 2005, J Can Dent Assoc, V71, P575
   Leese PT, 2000, J CLIN PHARMACOL, V40, P124, DOI 10.1177/00912700022008766
   MacDonald TM, 1997, BMJ BRIT MED J, V315, P1333, DOI 10.1136/bmj.315.7119.1333
   Mizukami K, 2013, DIGEST ENDOSC, V25, P288, DOI 10.1111/j.1443 1661.2012.01379.x
   Niculescu L, 2009, CURR MED RES OPIN, V25, P729, DOI [10.1185/03007990802714382, 10.1185/03007990802714382 ]
   Saito K, 2012, CLIN THER, V34, P314, DOI 10.1016/j.clinthera.2012.01.004
   Sakamoto C, 2013, ALIMENT PHARM THER, V37, P346, DOI 10.1111/apt.12174
   Sakamoto C, 2006, EUR J CLIN PHARMACOL, V62, P765, DOI 10.1007/s00228 006 0171 6
   Sakamoto C, 2011, DIGESTION, V83, P108, DOI 10.1159/000318746
   Shirota T, 2001, Oral Therapeutics and Pharmacology, V20, P154
   Silverstein FE, 2000, JAMA J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Simon LS, 1999, JAMA J AM MED ASSOC, V282, P1921, DOI 10.1001/jama.282.20.1921
   Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407
   YAJIMA H, 2006, THER RES, V27, P1211
NR 23
TC 12
Z9 14
U1 0
U2 5
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0901 5027
EI 1399 0020
J9 INT J ORAL MAX SURG
JI Int. J. Oral Maxillofac. Surg.
PD DEC
PY 2014
VL 43
IS 12
BP 1509
EP 1513
DI 10.1016/j.ijom.2014.09.002
PG 5
WC Dentistry, Oral Surgery & Medicine; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Surgery
GA AU8BO
UT WOS:000345821900017
PM 25270186
DA 2025 08 17
ER

PT J
AU Bonzi, G
   Salmaso, S
   Scomparin, A
   Eldar Boock, A
   Satchi Fainaro, R
   Caliceti, P
AF Bonzi, Gwenaelle
   Salmaso, Stefano
   Scomparin, Anna
   Eldar Boock, Anat
   Satchi Fainaro, Ronit
   Caliceti, Paolo
TI Novel Pullulan Bioconjugate for Selective Breast Cancer Bone Metastases
   Treatment
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID POLYMER THERAPEUTICS; ANTITUMOR ACTIVITY; DRUG DELIVERY; ZOLEDRONIC
   ACID; HIGH RISK; PACLITAXEL; BISPHOSPHONATES; ALENDRONATE; CONJUGATE;
   CELLS
AB A novel polysaccharide bioconjugate was designed to selectively target breast cancer bone metastases using a bisphosphonate moiety (alendronate, ALN). Paclitaxel (PTX) was first covalently conjugated to pullulan (Pull) through a Cathepsin K sensitive tetrapeptide spacer followed by a self immolative aminobenzyl alcohol spacer to obtain Pull (GGPNle phi PTX). ALN was then conjugated to the polymeric backbone of Pull (GGPNle phi PTX) via a PEG spacer. The final bioconjugate Pull (GGPNle phi PTX) (PEG ALN) was found to assemble into colloidal spherical structures, which were physically and chemically stable under physiological conditions. In vitro studies showed that Pull (GGPNle phi PTX) (PEG ALN) had strong affinity for hydroxyapatite, which simulates the bone tissue. Paclitaxel was rapidly released from the bioconjugate by Cathepsin K cleavage under pathological conditions. All studies performed using human MDA MB 231 BM (bone metastases originated clone), murine 4T1 breast cancer cells, murine K7M2, and human SAOS 2 osteosarcoma cells showed that the bioconjugate exerted an enhanced antiproliferative activity compared to the conjugate without the ALN. Furthermore, the nanoconjugate inhibited the migration of cancer cells and further displayed potent anti angiogenic activity. In conclusion, the results showed that this conjugate has an excellent potential for selective treatment of bone neoplasms such as breast cancer bone metastases and osteosarcoma.
C1 [Bonzi, Gwenaelle; Salmaso, Stefano; Caliceti, Paolo] Univ Padua, Dept Pharmaceut & Pharmacol Sci, I 35131 Padua, Italy.
   [Scomparin, Anna; Eldar Boock, Anat; Satchi Fainaro, Ronit] Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL 69978 Tel Aviv, Israel.
C3 University of Padua; Tel Aviv University; Sackler Faculty of Medicine
RP Caliceti, P (通讯作者)，Univ Padua, Dept Pharmaceut & Pharmacol Sci, Via F Marzolo 5, I 35131 Padua, Italy.
EM paolo.caliceti@unipd.it
RI Scomparin, Anna/U 4678 2017; Scomparin, Anna/AAG 8832 2019;
   Satchi Fainaro, Ronit/F 9137 2011
OI Scomparin, Anna/0000 0003 4751 620X; Satchi Fainaro,
   Ronit/0000 0002 7360 7837
FU CARIPARO Foundation Foreign PhD Project; University of Padova
   [C98C13001480005]; Ministry of Science, Technology and Space of Israel
   (MOST); Directorate General for Political and Security Affairs of the
   Ministry of Foreign Affairs, Italy
FX We acknowledge the CARIPARO Foundation Foreign PhD Project 2010, the
   University of Padova (Ex 60%, C98C13001480005) and the Ministry of
   Science, Technology and Space of Israel (MOST) and the Directorate
   General for Political and Security Affairs of the Ministry of Foreign
   Affairs, Italy scientific cooperation for the financial support
   (GYN MIR).
CR AbdelMagid AF, 1996, J ORG CHEM, V61, P3849, DOI 10.1021/jo960057x
   Amiji M.M., 2006, Nanotechnology for Cancer Therapy, DOI [10.1201/9781420006636, DOI 10.1201/9781420006636]
   ANANTHAPADMANABHAN KP, 1985, LANGMUIR, V1, P352, DOI 10.1021/la00063a015
   Bae YH, 2011, J CONTROL RELEASE, V153, P198, DOI 10.1016/j.jconrel.2011.06.001
   BRUNEEL D, 1993, POLYMER, V34, P2628, DOI 10.1016/0032 3861(93)90600 F
   CARL PL, 1981, J MED CHEM, V24, P479, DOI 10.1021/jm00137a001
   Colleoni M, 2000, J CLIN ONCOL, V18, P3925, DOI 10.1200/JCO.2000.18.23.3925
   de Groot FMH, 2001, J ORG CHEM, V66, P8815, DOI 10.1021/jo0158884
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Eldar Boock A, 2011, BIOMATERIALS, V32, P3862, DOI 10.1016/j.biomaterials.2011.01.073
   Everts Vincent, 2005, P144
   Giménez V, 2012, J CONTROL RELEASE, V159, P290, DOI 10.1016/j.jconrel.2011.12.035
   Goldspiel BR, 1997, PHARMACOTHERAPY, V17, pS110
   Haratake M, 2008, BIOCONJUGATE CHEM, V19, P1831, DOI 10.1021/bc800086z
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Cerda Cristerna BI, 2011, J CONTROL RELEASE, V153, P269, DOI 10.1016/j.jconrel.2011.04.016
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Jasmin C, 2005, TEXTBOOK OF BONE METASTASES, pXIII
   JOHNSON MR, 1970, J ORG CHEM, V35, P1041, DOI 10.1021/jo00829a039
   Kiss L, 2013, J PHARM SCI US, V102, P1173, DOI 10.1002/jps.23458
   Kong G, 2000, CANCER RES, V60, P4440
   Kuljanin J, 2002, J PHARMACEUT BIOMED, V28, P1215, DOI 10.1016/S0731 7085(02)00021 3
   Leathers TD, 2003, APPL MICROBIOL BIOT, V62, P468, DOI 10.1007/s00253 003 1386 4
   Lee SJ, 2012, INT J PHARMACEUT, V433, P121, DOI 10.1016/j.ijpharm.2012.04.048
   Lijana R. C., 1987, AICHE, V33
   LoPachin RM, 2014, CHEM RES TOXICOL, V27, P1081, DOI 10.1021/tx5001046
   Ma P., 2013, J NANOMED NANOTECHNO, V4
   Markovsky E, 2012, J CONTROL RELEASE, V161, P446, DOI 10.1016/j.jconrel.2011.12.021
   MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025
   Miller K, 2013, BIOMATERIALS, V34, P3795, DOI 10.1016/j.biomaterials.2013.01.052
   Miller K, 2011, MOL PHARMACEUT, V8, P1052, DOI 10.1021/mp200083n
   Miller K, 2009, ANGEW CHEM INT EDIT, V48, P2949, DOI 10.1002/anie.200805133
   Morris GJ, 2007, J NATL MED ASSOC, V99, P35
   Nehate C, 2014, CURR DRUG DELIV, V11, P666, DOI 10.2174/1567201811666140609154949
   Pabst A. M., 1996, BIOL PHARM BULL, V19, P1026
   Paranjpe PV, 2004, J CONTROL RELEASE, V100, P275, DOI 10.1016/j.jconrel.2004.08.030
   Piccioli A, 2014, J ORTHOP TRAUMATOL, V15, P143, DOI 10.1007/s10195 013 0283 6
   Rose AAN, 2010, FUTURE ONCOL, V6, P55, DOI [10.2217/fon.09.138, 10.2217/FON.09.138]
   ROSE WC, 1992, ANTI CANCER DRUG, V3, P311, DOI 10.1097/00001813 199208000 00001
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Saravanakumar G, 2012, DRUG DELIVERY IN ONCOLOGY: FROM BASIC RESEARCH TO CANCER THERAPY, VOLS 1 3, P701
   Scomparin A, 2011, EUR J PHARM SCI, V42, P547, DOI 10.1016/j.ejps.2011.02.012
   Singer JW, 2005, J CONTROL RELEASE, V109, P120, DOI 10.1016/j.jconrel.2005.09.033
   SKOOG B, 1979, VOX SANG, V37, P345, DOI 10.1111/j.1423 0410.1979.tb02314.x
   SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003 2697(75)90431 5
   Uludag H, 2000, BIOTECHNOL PROGR, V16, P258, DOI 10.1021/bp990154m
   Uludag H, 2002, CURR PHARM DESIGN, V8, P1929, DOI 10.2174/1381612023393585
   Vader P, 2013, NANOMEDICINE UK, V8, P1127, DOI [10.2217/NNM.12.163, 10.2217/nnm.12.163]
   Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
NR 51
TC 40
Z9 40
U1 2
U2 43
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043 1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD MAR
PY 2015
VL 26
IS 3
BP 489
EP 501
DI 10.1021/bc500614b
PG 13
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA CD9LY
UT WOS:000351421000016
PM 25613006
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Lin, JW
   Chen, JT
   Hong, CY
   Lin, YL
   Wang, KT
   Yao, CJ
   Lai, GM
   Chen, RM
AF Lin, Jia Wei
   Chen, Juei Tai
   Hong, Chung Ye
   Lin, Yi Ling
   Wang, Kuan Ting
   Yao, Chih Jung
   Lai, Gi Ming
   Chen, Ruei Ming
TI Honokiol traverses the blood brain barrier and induces apoptosis of
   neuroblastoma cells via an intrinsic bax mitochondrion cytochrome
   c caspase protease pathway
SO NEURO ONCOLOGY
LA English
DT Article
DE apoptosis; blood brain barrier; honokiol; neuroblastoma;
   signal transducing events
ID HIGH RISK NEUROBLASTOMA; OXIDE PROTECTS OSTEOBLASTS; NITRIC OXIDE;
   ENDOTHELIAL CELLS; HUMAN CHONDROCYTES; GENE EXPRESSION; INSULTS;
   MAGNOLOL; EVENTS; DEATH
AB Neuroblastomas, an embryonic cancer of the sympathetic nervous system, often occur in young children. Honokiol, a small molecule polyphenol, has multiple therapeutic effects and pharmacological activities. This study was designed to evaluate whether honokiol could pass through the blood brain barrier (BBB) and induce death of neuroblastoma cells and its possible mechanisms. Primary cerebral endothelial cells (CECs) prepared from mouse brain capillaries were cultured at a high density for 4 days, and these cells formed compact morphologies and expressed the ZO 1 tight junction protein. A permeability assay showed that the CEC constructed barrier obstructed the passing of FITC dextran. Analyses by high performance liquid chromatography and the UV spectrum revealed that honokiol could traverse the CEC built junction barrier and the BBB of ICR mice. Exposure of neuroblastoma neuro 2a cells and NB41A3 cells to honokiol induced cell shrinkage and decreased cell viability. In parallel, honokiol selectively induced DNA fragmentation and cell apoptosis rather than cell necrosis. Sequential treatment of neuro 2a cells with honokiol increased the expression of the proapoptotic Bax protein and its translocation from the cytoplasm to mitochondria. Honokiol successively decreased the mitochondrial membrane potential but increased the release of cytochrome c from mitochondria. Consequently, honokiol induced cascade activation of caspases 9,  3, and  6. In comparison, reducing caspasc 6 activity by Z VEID FMK, an inhibitor of caspase 6, simultaneously attenuated honokiol induced DNA fragmentation and cell apoptosis. Taken together, this study showed that honokiol can pass through the BBB and induce apoptotic insults to neuroblastoma cells through a Bax mitochondrion cytochrome c caspase protease pathway. Therefore, honokiol may be a potential candidate drug for treating brain tumors.
C1 [Chen, Ruei Ming] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei 110, Taiwan.
   [Lin, Jia Wei] Taipei Med Univ, Shuang Ho Hosp, Dept Neurosurg, Taipei 110, Taiwan.
   [Chen, Juei Tai; Lin, Yi Ling; Chen, Ruei Ming] Brain Dis Res Ctr, Taipei, Taiwan.
   [Hong, Chung Ye] Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Taipei 110, Taiwan.
   [Yao, Chih Jung; Lai, Gi Ming; Chen, Ruei Ming] Taipei Med Univ, Ctr Excellence Canc Res, Taipei 110, Taiwan.
C3 Taipei Medical University; Taipei Medical University; Shuang Ho
   Hospital; Taipei Municipal WanFang Hospital; Taipei Medical University;
   Taipei Medical University
RP Chen, RM (通讯作者)，Taipei Med Univ, Coll Med, Grad Inst Med Sci, 250 Wu Hsing St, Taipei 110, Taiwan.
EM rmchen@tmu.edu.tw
RI liu, yiling/HNS 6339 2023
FU Taipei Medical Universiry Shuang Ho Hospital [98TMU SHH 09]; Wan Fang
   Hospital [100 WF EVA 002]; Department of Health [DOH97 NNB 1037,
   DOH100 TD C 111 008]; National Science Council Taipei, Taiwan
   [95 2745 B 038 001 URD]
FX This study was supported by grants from Taipei Medical Universiry Shuang
   Ho Hospital (98TMU SHH 09), Wan Fang Hospital (100 WF EVA 002), the
   Department of Health (DOH97 NNB 1037; DOH100 TD C 111 008), and the
   National Science Council (95 2745 B 038 001 URD), Taipei, Taiwan.
CR Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824
   Chang CC, 2006, J ORTHOP RES, V24, P1917, DOI 10.1002/jor.20244
   Chang HC, 2011, J CEREBR BLOOD F MET, V31, P842, DOI 10.1038/jcbfm.2010.180
   Chen LJ, 2007, J CHROMATOGR A, V1142, P115, DOI 10.1016/j.chroma.2006.09.098
   Chen RM, 2005, J ORTHOP RES, V23, P462, DOI 10.1016/j.orthres.2004.08.011
   Chen RM, 2005, CRIT CARE MED, V33, P1044, DOI 10.1097/01.CCM.0000163246.33366.51
   Chen RM, 2010, J BONE MINER RES, V25, P2193, DOI 10.1002/jbmr.121
   Chen TG, 2007, TOXICOL APPL PHARM, V219, P42, DOI 10.1016/j.taap.2006.11.031
   Cherng YG, 2008, J ORTHOP RES, V26, P1018, DOI 10.1002/jor.20578
   Doolittle N D, 2001, Neuro Oncol, V3, P46, DOI 10.1093/neuonc/3.1.46
   dos Santos LV, 2011, RECENT PAT ANTI CANC, V6, P45
   Engelhardt B, 2003, CELL TISSUE RES, V314, P119, DOI 10.1007/s00441 003 0751 z
   Esumi T, 2004, BIOORG MED CHEM LETT, V14, P2621, DOI 10.1016/j.bmcl.2004.02.067
   Fried LE, 2009, ANTIOXID REDOX SIGN, V11, P1139, DOI [10.1089/ars.2009.2440, 10.1089/ARS.2009.2440]
   Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950
   Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092 8674(01)00276 8
   Ho WP, 2009, J CELL BIOCHEM, V108, P1084, DOI 10.1002/jcb.22338
   Hoehner JC, 1996, LAB INVEST, V75, P659
   Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166 2236(00)02004 X
   Hung TY, 2010, J ETHNOPHARMACOL, V131, P70, DOI 10.1016/j.jep.2010.05.063
   Jiang QQ, 2008, BMC CANCER, V8, DOI 10.1186/1471 2407 8 242
   Kotani H, 2010, J NAT PROD, V73, P1332, DOI 10.1021/np100120c
   Laverdière C, 2005, PEDIATR BLOOD CANCER, V45, P324, DOI 10.1002/pbc.20331
   Li ZJ, 2010, JNCI J NATL CANCER I, V102, P758, DOI 10.1093/jnci/djq125
   Lin YL, 2010, J NUTR, V140, P2187, DOI 10.3945/jn.110.123505
   Lin YR, 2006, EUR J PHARMACOL, V537, P64, DOI 10.1016/j.ejphar.2006.03.035
   LO YC, 1994, BIOCHEM PHARMACOL, V47, P549, DOI 10.1016/0006 2952(94)90187 2
   Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601
   Pagliari LJ, 2005, P NATL ACAD SCI USA, V102, P17975, DOI 10.1073/pnas.0506712102
   Park JR, 2008, PEDIATR CLIN N AM, V55, P97, DOI 10.1016/j.pcl.2007.10.014
   Pearson ADJ, 2008, LANCET ONCOL, V9, P247, DOI 10.1016/S1470 2045(08)70069 X
   Raja SM, 2008, MOL CANCER THER, V7, P2212, DOI 10.1158/1535 7163.MCT 07 2409
   Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441
   Rubin Lee L., 1992, Current Opinion in Cell Biology, V4, P830, DOI 10.1016/0955 0674(92)90107 N
   Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590
   Siddharthan V, 2007, BRAIN RES, V1147, P39, DOI 10.1016/j.brainres.2007.02.029
   Tai YT, 2007, J ORTHOP RES, V25, P625, DOI 10.1002/jor.20365
   Tang Wenfu, 2008, Chin Med, V3, P5, DOI 10.1186/1749 8546 3 5
   van der Pal HJH, 2005, CANCER TREAT REV, V31, P173, DOI 10.1016/j.ctrv.2005.03.008
   Wagner LM, 2009, J CELL BIOCHEM, V107, P46, DOI 10.1002/jcb.22094
   Wang XH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018490
   Wu GJ, 2007, J CELL BIOCHEM, V101, P1520, DOI 10.1002/jcb.21268
   Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521
   Zage PE, 2008, PEDIATR BLOOD CANCER, V51, P747, DOI 10.1002/pbc.21713
   Zhai H, 2005, EUR J PHARMACOL, V516, P112, DOI 10.1016/j.ejphar.2005.04.035
NR 45
TC 114
Z9 121
U1 0
U2 32
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522 8517
EI 1523 5866
J9 NEURO ONCOLOGY
JI Neuro Oncology
PD MAR
PY 2012
VL 14
IS 3
BP 302
EP 314
DI 10.1093/neuonc/nor217
PG 13
WC Oncology; Clinical Neurology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Neurosciences & Neurology
GA 900VF
UT WOS:000300918900007
PM 22259050
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Lin, ZJ
   Song, DW
   Wei, HF
   Yang, XH
   Liu, TL
   Yan, WJ
   Xiao, JR
AF Lin, Zaijun
   Song, Dianwen
   Wei, Haifeng
   Yang, Xinghai
   Liu, Tielong
   Yan, Wangjun
   Xiao, Jianru
TI TGF β1 induced miR 202 mediates drug resistance by inhibiting apoptosis
   in human osteosarcoma
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article
DE miR 202; PDCD4; Drug resistance; Osteosarcoma
ID CELL PROLIFERATION; COLON CANCER; EXPRESSION; CHEMOTHERAPY; CARCINOMA
AB Purpose A number of studies have demonstrated that microRNAs play a critical role in osteosarcoma progression, therapy and drug resistance. MicroRNA 202 has proven to be dysregulated in many human cancer studies. This study aimed to explore miR 202 contributions to drug resistance in osteosarcoma.
   Methods miR 202 expression was measured by real time PCR in patient tissues, cell lines or cells treated with TGF beta 1, using siRNA to knock down the expression of Smad2, Smad3 and Smad4. miR 202 mimics, inhibitor and scramble siRNA were transfected into osteosarcoma cells to observe effects on cell apoptosis and drug resistance. Moreover, relationships of miR 202 level with PDCD4 were investigated by luciferase reporter assay, real time PCR and Western blotting.
   Results We found that miR 202 is overexpressed in osteosarcoma tissues when compared with normal human osteoblasts and TGF beta 1 can induce the expression of miR 202. Transfection of miR 202 mimics into osteosarcoma cell lines significantly promotes chemotherapy resistance by targeting PDCD4, a tumor suppressor which is involved in apoptosis. In contrast, transfection of miR 202 inhibitor enhances the drug sensitivity and apoptosis.
   Conclusions This study provides new insights into miRNA 202 in osteosarcoma as a potential molecular target for chemotherapy.
C1 [Lin, Zaijun; Song, Dianwen; Wei, Haifeng; Yang, Xinghai; Liu, Tielong; Yan, Wangjun; Xiao, Jianru] Second Mil Med Univ, Changzheng Hosp, Dept Bone Tumor Surg, Shanghai, Peoples R China.
C3 Naval Medical University
RP Xiao, JR (通讯作者)，Second Mil Med Univ, Changzheng Hosp, Dept Bone Tumor Surg, Shanghai, Peoples R China.
EM jianru365@163.com
RI xin, baoquan/ISB 5957 2023; Zhong, Jingqin/JRX 0740 2023
CR Cai CK, 2012, ONCOL REP, V28, P1764, DOI 10.3892/or.2012.1995
   Chan XHD, 2012, CELL REP, V2, P591, DOI 10.1016/j.celrep.2012.07.012
   Chen L, 2014, EXP THER MED, V8, P527, DOI 10.3892/etm.2014.1752
   Chen PY, 2012, CELL REP, V2, P1684, DOI 10.1016/j.celrep.2012.10.021
   Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003
   Chen Y, 2014, CELL REP, V7, P1982, DOI 10.1016/j.celrep.2014.05.007
   Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075
   Ferguson WS, 2001, CANCER INVEST, V19, P292, DOI 10.1081/CNV 100102557
   Franchi A, 1998, J PATHOL, V185, P284, DOI 10.1002/(SICI)1096 9896(199807)185:3<284::AID PATH94>3.0.CO;2 Z
   Geller David S, 2010, Clin Adv Hematol Oncol, V8, P705
   Ghosh T, 2014, CELL REP, V7, P1779, DOI 10.1016/j.celrep.2014.05.029
   Han C, 2014, CELL REP, V8, P1447, DOI 10.1016/j.celrep.2014.07.058
   Kim K, 2014, CELL REP, V7, P2066, DOI 10.1016/j.celrep.2014.05.025
   Li YG, 2014, MOL MED REP, V9, P541, DOI 10.3892/mmr.2013.1845
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Navid F, 2000, Sarcoma, V4, P93, DOI 10.1080/13577140020008057
   Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274
   Sun ZW, 2014, MOL CELL BIOCHEM, V397, P277, DOI 10.1007/s11010 014 2195 z
   Wang QF, 2014, CLIN CANCER RES, V20, P1146, DOI 10.1158/1078 0432.CCR 13 1023
   Zhang D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.240
   Zhang Y, 2014, FEBS LETT, V588, P1913, DOI 10.1016/j.febslet.2014.03.030
   Zhang YK, 2011, BIOCHEM BIOPH RES CO, V414, P233, DOI 10.1016/j.bbrc.2011.09.063
NR 22
TC 51
Z9 56
U1 1
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 5216
EI 1432 1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD JAN
PY 2016
VL 142
IS 1
BP 239
EP 246
DI 10.1007/s00432 015 2028 9
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA DD8JN
UT WOS:000370172900024
PM 26276504
DA 2025 08 17
ER

PT J
AU Liu, J
   Tan, X
   Zhao, WN
   Liu, J
   Xing, XX
   Fan, GW
   Zhang, P
   Zhang, Z
   Zhong, YX
   Kong, DX
AF Liu, Jie
   Tan, Xiao
   Zhao, Wennan
   Liu, Jing
   Xing, Xiaoxue
   Fan, Guanwei
   Zhang, Ping
   Zhang, Zhe
   Zhong, Yuxu
   Kong, Dexin
TI In Vitro and In Vivo Antimetastatic Effects of
   ZSTK474 on Prostate Cancer DU145 Cells
SO CURRENT CANCER DRUG TARGETS
LA English
DT Article
DE PI3K inhibitor; ZSTK474; antimetastasis; in vivo; DU145; prostate cancer
ID PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; GROWTH; PI3K; DISCOVERY;
   MIGRATION; BREAST; JFCR39; PANEL
AB Background: The lethality of prostate cancer is mainly due to metastasis. Inhibition of metastasis is expected to be a promising approach for prostate cancer therapy. Phosphatidylinositol 3 kinase (PI3K)/Akt pathway is reported to be closely involved in cell growth, migration, etc.
   Objective: The study investigated the antimetastatic activities of pan PI3K inhibitor ZSTK474 on DU145 cells.
   Methods: 1. The In vitro effect of ZSTK474 on the migration, invasion and adhesion of DU145 cells was determined with Transwell migration assay and wound healing assay, Tranwell invasion assay and adhesion assay. respectively. 2. In vitro effect of ZSTK474 on the signal proteins in DU145 cells was determined with Western blot analysis and ELISA. 3. Moreover, the In vivo antimetastatic effect of ZSTK474 was evaluated with MicroCT and histology analysis.
   Results: ZSTK474 potently attenuated the capability of migration, invasion and adhesion of DU145 cells, negatively regulated Girdin, Integrinf beta 1 and matrix metalloproteinases (MMPs). In addition, the expression of hypoxia inducible factor 1 alpha (HIF 1 alpha) and vascular endothelial growth factor (VEGF), which are known to be related to angiogenesis and metastasis, was also inhibited. Oral CrossMark administration of ZSTK474 (200 mg/kg) ameliorated in vivo bone metastasis of DU145 cells, with improved bone structure and bone mineral density (BMD). Tissue staining indicated a reduction in metastatic DU145 cells and osteoclasts in the bones of ZSTK474 treated mice, compared with the non treated group.
   Conclusion: Our result demonstrated the antimetastatic activity of ZSTK474 on prostate cancer DU145 cells, suggesting the potential application in prostate cancer patients.
C1 [Liu, Jie; Tan, Xiao; Zhao, Wennan; Liu, Jing; Zhang, Zhe; Kong, Dexin] Tianjin Med Univ, Sch Pharmaceut Sci, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin 300070, Peoples R China.
   [Liu, Jie; Tan, Xiao; Zhao, Wennan; Liu, Jing; Kong, Dexin] Tianjin Med Univ, Res Ctr Basic Med Sci, Tianjin 300070, Peoples R China.
   [Tan, Xiao; Liu, Jing; Zhong, Yuxu] Beijing Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, Beijing 100850, Peoples R China.
   [Xing, Xiaoxue; Fan, Guanwei] Tianjin Univ Tradit Chinese Med, State Key Lab Modern Chinese Med, Tianjin 300193, Peoples R China.
   [Zhang, Ping] Tianjin Med Univ, Sch Basic Med Sci, Dept Anat & Histol, Tianjin 300070, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; Academy of
   Military Medical Sciences   China; Tianjin University of Traditional
   Chinese Medicine; Tianjin Medical University
RP Kong, DX (通讯作者)，Tianjin Med Univ, Sch Pharmaceut Sci, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin 300070, Peoples R China.; Zhong, YX (通讯作者)，Beijing Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, Beijing 100850, Peoples R China.
EM yuxuzhong2008@aliyun.com; kongdexin@tmu.edu.cn
RI Kong, Dexin/AAL 8336 2020; guanwei, fan/M 8193 2019; zhang,
   ping/L 3901 2017
FU National Natural Science Foundation of China [81373441, 81673464]
FX We thank Miss Jie Li from the School of Basic Medical Sciences, Tianjin
   Medical University for her technical assistance in histology analysis.
   This study was supported by grants from National Natural Science
   Foundation of China (81373441, 81673464).
CR Arboleda MJ, 2003, CANCER RES, V63, P196
   Burton DW, 2005, PROSTATE, V62, P275, DOI 10.1002/pros.20146
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Corey E, 2002, PROSTATE, V52, P20, DOI 10.1002/pros.10091
   Dan S, 2010, CANCER RES, V70, P4982, DOI 10.1158/0008 5472.CAN 09 4172
   Dbouk HA, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003264
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Ferrara N, 2001, ACTA HAEMATOL BASEL, V106, P148, DOI 10.1159/000046610
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115
   Imamichi Y, 2007, CELLS TISSUES ORGANS, V185, P180, DOI 10.1159/000101319
   Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363
   Jiang P, 2008, CANCER RES, V68, P1310, DOI 10.1158/0008 5472.CAN 07 5111
   Kong DX, 2010, ACTA PHARMACOL SIN, V31, P1189, DOI 10.1038/aps.2010.150
   Kong D, 2007, CANCER SCI, V98, P1638, DOI 10.1111/j.1349 7006.2007.00580.x
   Kong DX, 2012, BIOORGAN MED CHEM, V20, P1947, DOI 10.1016/j.bmc.2012.01.017
   Kong DX, 2011, MAR DRUGS, V9, P154, DOI 10.3390/md9020154
   Kong DX, 2010, EUR J CANCER, V46, P1111, DOI 10.1016/j.ejca.2010.01.005
   Kong D, 2009, CURR MED CHEM, V16, P2839, DOI 10.2174/092986709788803222
   Kong D, 2009, EUR J CANCER, V45, P857, DOI 10.1016/j.ejca.2008.12.007
   Kong D, 2009, BIOL PHARM BULL, V32, P297, DOI 10.1248/bpb.32.297
   Liu DQ, 2015, BONE, V81, P620, DOI 10.1016/j.bone.2015.09.012
   Markham A, 2017, DRUGS, V77, P1247, DOI 10.1007/s40265 017 0771 8
   Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053
   Saudemont A, 2009, P NATL ACAD SCI USA, V106, P5795, DOI 10.1073/pnas.0808594106
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Shah A, 2015, ANN PHARMACOTHER, V49, P1162, DOI 10.1177/1060028015594813
   Torre LA, 2015, CA CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965
   Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642
   Yaguchi SI, 2006, JNCI J NATL CANCER I, V98, P545, DOI 10.1093/jnci/djj133
   Yap TA, 2015, CURR OPIN PHARMACOL, V23, P98, DOI 10.1016/j.coph.2015.05.016
   Zhao WN, 2017, ACTA PHARM SIN B, V7, P27, DOI 10.1016/j.apsb.2016.07.006
   Zhao WN, 2013, INT J MOL SCI, V14, P13577, DOI 10.3390/ijms140713577
NR 35
TC 8
Z9 9
U1 0
U2 16
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568 0096
EI 1873 5576
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PY 2019
VL 19
IS 4
BP 321
EP 329
DI 10.2174/1568009618666180911101310
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA HS4MF
UT WOS:000463836700009
PM 30205797
DA 2025 08 17
ER

PT J
AU Nogués, X
   Nolla, JM
   Casado, E
   Jódar, E
   Muñoz Torres, M
   Quesada Gómez, JM
   Canals, L
   Balcells, M
   Lizán, L
AF Nogues, X.
   Nolla, J. M.
   Casado, E.
   Jodar, E.
   Munoz Torres, M.
   Quesada Gomez, J. M.
   Canals, L.
   Balcells, M.
   Lizan, L.
TI Spanish consensus on treat to target for osteoporosis
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Management; Osteoporosis; Osteoporosis care; Treatment; Treatment
   failure; Treat to target; Treat to target strategy
ID GOAL DIRECTED TREATMENT; BONE MINERAL DENSITY; TO TARGET; DENOSUMAB;
   WOMEN; RECOMMENDATIONS; GUIDELINES; MANAGEMENT; DIAGNOSIS; UPDATE
AB To reach a Spanish expert consensus on a treat to target strategy in osteoporosis, a Delphi Consensus Study has been developed. Most of the experts (59.8%) were rheumatologist with a mean clinical experience of 21.3 years (SD 8.5). Consensus was achieved for 70% of the items. Therapeutic objectives, patient follow up scheme, treatment failure criteria, and appropriate treatment choice for use in T2T strategy in Spain have been defined.
   The paper aims to achieve a Spanish expert consensus on a treat to target (T2T) strategy in osteoporosis.
   A scientific committee led the project and was involved in expert panel identification and Delphi questionnaire development. Two Delphi rounds were completed. The first round questionnaire included 24 items and assessed, using a seven point Likert scale, the experts' wish (W) and prognosis (P) in 5 years for each topic (applicability, therapeutic objectives, patient follow up, and possible treatment to be prescribed). Items for which there was no consensus in the first round were included in the second round. Consensus was defined as >= 75% agreement (somewhat/mostly/entirely agree) or disagreement (somewhat/mostly/entirely disagree) responses.
   Of the experts, 112 and 106 completed the first and second rounds, respectively. 59.8% were rheumatologists with a mean clinical experience of 21.3 years (SD 8.5). Consensus was achieved for 70% of the items, and was established regarding the utility of a T2T strategy to define therapeutic objectives, optimal follow up, and therapeutic algorithm. Participants agreed on the utility of the bone mineral density (BMD) value (T score > 2.5 SD for spine and > 2.5/ 2.0 SD for femoral neck), lack of fractures, and fracture risk (FRAX) as therapeutic objectives. For measuring BMD changes, consensus was achieved on the suitability of hip and femoral neck locations. Experts agreed to consider treatment failure as when a significant BMD gain could not be achieved, or when a new fracture occurs within 2 3 years. There was consensus that all proposed therapies should achieve a therapeutic target through T2T strategy (treatments with the highest consensus scores were denosumab and teriparatide).
   The therapeutic objectives, patient follow up scheme, treatment failure criteria, and appropriate treatment choice for use in T2T strategy in Spain have been established by a panel of experts. Some aspects nevertheless still require further analysis.
C1 [Nogues, X.] Univ Autonoma Barcelona, Ctr Invest Biomed Red Fragilidad & Envejecimiento, Mar Inst Med Res IMIM, Barcelona, Spain.
   [Nolla, J. M.] IDIBELL Univ Hosp Bellvitge, Lhospitalet De Llobregat, Spain.
   [Casado, E.] Univ Autonoma Barcelona, Parc Tauli Univ Hosp, Inst Invest & Innovacio Parc Tauli I3PT, Sabadell, Spain.
   [Jodar, E.] Univ Europea Madrid, Univ Hosp Quiron Salud, Madrid, Spain.
   [Munoz Torres, M.] Hosp Univ Campus Salud Granada, Inst Invest Biosanitaria Ibs, Ctr Invest Biomed Red Fragilidad & Envejecimiento, Bone Metab Unit,UGC Endocrinol & Nutr, Granada, Spain.
   [Quesada Gomez, J. M.] Univ Hosp Reina Sofia, Ctr Invest Biomed Red Fragilidad & Envejecimiento, UGC Endocrinol & Nutr, Cordoba, Spain.
   [Quesada Gomez, J. M.] IMIBIC, Cordoba, Spain.
   [Canals, L.; Balcells, M.] Amgen Inc, Barcelona, Spain.
   [Lizan, L.] Univ Jaume 1, Dept Med, Outcomes 10, Castellon de La Plana, Spain.
C3 Hospital del Mar Research Institute; CIBER   Centro de Investigacion
   Biomedica en Red; CIBERFES; Autonomous University of Barcelona; Institut
   d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University
   Hospital; Autonomous University of Barcelona; Parc Tauli Hospital
   Universitari; European University of Madrid; CIBER   Centro de
   Investigacion Biomedica en Red; CIBERFES; Instituto de Investigacion
   Biosanitaria IBS Granada; CIBER   Centro de Investigacion Biomedica en
   Red; CIBERFES; Universitat Jaume I
RP Nogués, X (通讯作者)，Univ Autonoma Barcelona, Ctr Invest Biomed Red Fragilidad & Envejecimiento, Mar Inst Med Res IMIM, Barcelona, Spain.
EM XNogues@parcdesalutmar.cat
RI ; lizan, luis/AAF 1953 2020; Martínez, Jose/I 3275 2015; JODAR GIMENO,
   Esteban/JZU 0969 2024; Torres, Manuel/O 2330 2016
OI Nogues, Xavier/0000 0002 5537 1859; Nogues, Xavier/0000 0001 8201 9933;
   Casado, Enrique/0000 0001 8839 6430
CR Akins Ralitsa B, 2005, BMC Med Res Methodol, V5, P37, DOI 10.1186/1471 2288 5 37
   Anastasilakis AD, 2017, J BONE MINER RES, V32, P1291, DOI 10.1002/jbmr.3110
   [Anonymous], 1994, ANN SAUDI MED
   [Anonymous], ARTHRITIS RHEUMA S10
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Catapano AL, 2011, ATHEROSCLEROSIS, V217, P3, DOI 10.1016/j.atherosclerosis.2011.06.028
   Chapurlat R., 2016, JOINT BONE SPINE
   Cummings SR, 2017, J BONE MINER RES, V32, P3, DOI 10.1002/jbmr.3039
   Cummings SR, 2013, J BONE MINER RES, V28, P433, DOI 10.1002/jbmr.1854
   Diamond IR, 2014, J CLIN EPIDEMIOL, V67, P401, DOI 10.1016/j.jclinepi.2013.12.002
   Díez Pérez A, 2014, J BONE MINER RES, V29, P260, DOI 10.1002/jbmr.2023
   Ferrari S, 2015, OSTEOPOROSIS INT, V26, P2763, DOI 10.1007/s00198 015 3179 x
   Fischer RusselG., 1978, The Journal of Academic Librarianship, V4, P64
   Gregson CL, 2013, RHEUMATOLOGY, V52, P968, DOI 10.1093/rheumatology/ket007
   Hansen MP, 2010, SCAND J PRIM HEALTH, V28, P4, DOI 10.3109/02813431003602724
   Hawley S, 2016, J BONE MINER RES, V31, P234, DOI 10.1002/jbmr.2595
   Hsu C.C., 2007, PRACT ASSESS RES EVA, V12, P1
   Inzucchi SE, 2015, DIABETES CARE, V38, P140, DOI 10.2337/dc14 2441
   Kanis JA, 2014, OSTEOPOROSIS INT, V25, P2533, DOI 10.1007/s00198 014 2787 1
   Khan AA, 2002, CAN MED ASSOC J, V167, P1141
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lai L, 2015, COMPLEMENT THER MED, V23, P430, DOI 10.1016/j.ctim.2015.03.003
   Leder BZ, 2016, J CLIN DENSITOM, V1296
   Leslie WD, 2014, J BONE MINER RES, V29, P1074, DOI 10.1002/jbmr.2151
   Lewiecki EM, 2013, J CLIN ENDOCR METAB, V98, P946, DOI 10.1210/jc.2012 3680
   Mancia G, 2013, J HYPERTENS, V31, P1281, DOI 10.1097/01.hjh.0000431740.32696.cc
   McClung MR, 2013, OSTEOPOROSIS INT, V24, P227, DOI 10.1007/s00198 012 2052 4
   Miller PD, 2016, J CLIN ENDOCR METAB, V101, P852, DOI 10.1210/jc.2015 3156
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Papapoulos S, 2015, OSTEOPOROSIS INT, V26, P2773, DOI 10.1007/s00198 015 3234 7
   Rayens M.K., 2000, POLICY POLITICS NURS, V1, DOI DOI 10.1177/152715440000100409
   Rivadeneira F, 2007, J BONE MINER RES, V22, P1781, DOI 10.1359/JBMR.070712
   Smolen JS, 2016, ANN RHEUM DIS, V75, P3, DOI 10.1136/annrheumdis 2015 207524
   Smolen JS, 2016, CURR OPIN RHEUMATOL, V28, P297, DOI 10.1097/BOR.0000000000000284
   von der Gracht HA, 2012, TECHNOL FORECAST SOC, V79, P1525, DOI 10.1016/j.techfore.2012.04.013
   Wilhelm W., 2001, The Delta Pi Epsilon Journal, V43, P6
   WILLIAMS PL, 1994, J ADV NURS, V19, P180, DOI 10.1111/j.1365 2648.1994.tb01066.x
NR 38
TC 13
Z9 15
U1 0
U2 5
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD FEB
PY 2018
VL 29
IS 2
BP 489
EP 499
DI 10.1007/s00198 017 4310 y
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FW7TR
UT WOS:000425528400022
PM 29177559
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Petrovic, V
   Stefanovic, V
AF Petrovic, Vladimir
   Stefanovic, Vladisav
TI Dental Tissue   New Source for Stem Cells
SO THESCIENTIFICWORLDJOURNAL
LA English
DT Article
DE dental stem cells; multilineage differentiation; odontogenesis; neural
   disease; tooth tissue engineering
ID HUMAN PERIODONTAL LIGAMENT; NEURONS IN VITRO; BONE MARROW; APICAL
   PAPILLA; GROWTH FACTORS; PULP COMPLEX; TEETH; DIFFERENTIATE;
   REGENERATION; ACTIVATION
AB Stem cells have been isolated from many tissues and organs, including dental tissue. Five types of dental stem cells have been established: dental pulp stem cells, stem cells from exfoliated deciduous teeth, stem cells from apical papilla, periodontal ligament stem cells, and dental follicle progenitor cells. The main characteristics of dental stem cells are their potential for multilineage differentiation and self renewal capacity. Dental stem cells can differentiate into odontoblasts, adipocytes, neuronal like cells, glial cells, osteoblasts, chondrocytes, melanocytes, myotubes, and endothelial cells. Possible application of these cells in various fields of medicine makes them good candidates for future research as a new, powerful tool for therapy. Although the possible use of these cells in therapeutic purposes and tooth tissue engineering is still in the beginning stages, the results are promising. The efforts made in the research of dental stem cells have clarified many mechanisms underlying the biological processes in which these cells are involved. This review will focus on the new findings in the field of dental stem cell research and on their potential use in the therapy of various disorders.
C1 [Petrovic, Vladimir; Stefanovic, Vladisav] Univ Nis, Sch Med, Nish 18000, Serbia.
C3 University of Nis
RP Stefanovic, V (通讯作者)，Univ Nis, Sch Med, Nish 18000, Serbia.
EM vlada@medfak.ni.ac.rs; stefan@ni.ac.rs
OI Petrovic, Vladimir/0000 0001 8618 694X
FU Ministry of Science and Technological Development of Serbia [145004]
FX This work was supported by a grant, No 145004, from the Ministry of
   Science and Technological Development of Serbia. The authors declare no
   conflict of interests.
CR About I, 2000, AM J PATHOL, V157, P287, DOI 10.1016/S0002 9440(10)64539 7
   Arthur A, 2008, STEM CELLS, V26, P1787, DOI 10.1634/stemcells.2007 0979
   Baum BJ, 2000, J AM DENT ASSOC, V131, P309, DOI 10.14219/jada.archive.2000.0174
   Bluteau G, 2008, EUR CELLS MATER, V16, P1
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   Chang J, 2005, J DENT RES, V84, P994, DOI 10.1177/154405910508401105
   Chueh LH, 2006, J ENDODONT, V32, P1205, DOI 10.1016/j.joen.2006.07.010
   Coura GS, 2008, J PERIODONTAL RES, V43, P531, DOI 10.1111/j.1600 0765.2007.01065.x
   Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102
   d'Aquino R, 2007, CELL DEATH DIFFER, V14, P1162, DOI 10.1038/sj.cdd.4402121
   D'Souza R, 2002, SELTZER AND BENDER'S DENTAL PULP, P13
   Decup F, 2000, Clin Oral Investig, V4, P110, DOI 10.1007/s007840050126
   Duailibi MT, 2004, J DENT RES, V83, P523, DOI 10.1177/154405910408300703
   El Backly RM, 2008, AUST ENDOD J, V34, P52, DOI 10.1111/j.1747 4477.2008.00139.x
   FITZGERALD M, 1990, ARCH ORAL BIOL, V35, P707, DOI 10.1016/0003 9969(90)90093 P
   GIACOBINI MMJ, 1993, DEV BRAIN RES, V75, P65, DOI 10.1016/0165 3806(93)90066 J
   GIMBLE JM, 1995, J CELL BIOCHEM, V58, P393, DOI 10.1002/jcb.240580312
   Gronthos S, 2002, J DENT RES, V81, P531, DOI 10.1177/154405910208100806
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   He F, 2009, ARCH ORAL BIOL, V54, P216, DOI 10.1016/j.archoralbio.2008.10.003
   Honda MJ, 2007, BIOMATERIALS, V28, P680, DOI 10.1016/j.biomaterials.2006.09.039
   Honda MJ, 2008, MED MOL MORPHOL, V41, P183, DOI 10.1007/s00795 008 0416 9
   Honda MJ, 2006, J ORAL MAXIL SURG, V64, P283, DOI 10.1016/j.joms.2005.10.020
   Honda MJ, 2005, ARCH HISTOL CYTOL, V68, P89, DOI 10.1679/aohc.68.89
   Huang AHC, 2008, STEM CELLS, V26, P2654, DOI 10.1634/stemcells.2008 0285
   Huang GTJ, 2008, J ENDODONT, V34, P645, DOI 10.1016/j.joen.2008.03.001
   Iohara K, 2006, STEM CELLS, V24, P2493, DOI 10.1634/stemcells.2006 0161
   Kaigler D, 2001, J Dent Educ, V65, P456
   Kaigler D, 2003, TISSUE ENG, V9, P95, DOI 10.1089/107632703762687573
   Kémoun P, 2007, CELL TISSUE RES, V329, P283, DOI 10.1007/s00441 007 0397 3
   Király M, 2009, NEUROCHEM INT, V55, P323, DOI 10.1016/j.neuint.2009.03.017
   Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711
   Koussoulakou DS, 2009, INT J BIOL SCI, V5, P226
   Koyam N, 2009, J ORAL MAXIL SURG, V67, P501, DOI 10.1016/j.joms.2008.09.011
   Laino G, 2005, J BONE MINER RES, V20, P1394, DOI 10.1359/JBMR.050325
   Laino G, 2006, J CRANIOFAC SURG, V17, P511, DOI 10.1097/00001665 200605000 00021
   Linde Anders, 1993, Critical Reviews in Oral Biology and Medicine, V4, P679
   Liu J, 2005, IN VITRO CELL DEV AN, V41, P232
   Liu Y, 2008, STEM CELLS, V26, P1065, DOI 10.1634/stemcells.2007 0734
   Lovschall H, 2005, EUR J ORAL SCI, V113, P312, DOI 10.1111/j.1600 0722.2005.00221.x
   Mao JJ, 2006, J DENT RES, V85, P966, DOI 10.1177/154405910608501101
   Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100
   Mooney DJ, 1996, BIOTECHNOL PROGR, V12, P865, DOI 10.1021/bp960073f
   Morsczeck C, 2005, MATRIX BIOL, V24, P155, DOI 10.1016/j.matbio.2004.12.004
   MORSCZECK C, 2009, CLIN ORAL INVEST
   Morsczeck C, 2008, CLIN ORAL INVEST, V12, P113, DOI 10.1007/s00784 007 0170 8
   Mullane EM, 2008, J DENT RES, V87, P1144, DOI 10.1177/154405910808701204
   Murray PE, 2002, ORAL SURG ORAL MED O, V93, P474, DOI 10.1067/moe.2002.120974
   Murray PE, 2002, ARCH ORAL BIOL, V47, P709, DOI 10.1016/S0003 9969(02)00055 9
   Nakashima M, 2003, HUM GENE THER, V14, P591, DOI 10.1089/104303403764539369
   Nosrat IV, 2004, EUR J NEUROSCI, V19, P2388, DOI 10.1111/j.0953 816X.2004.03314.x
   Nosrat IV, 2001, DEV BIOL, V238, P120, DOI 10.1006/dbio.2001.0400
   Ohazama A, 2004, J DENT RES, V83, P518, DOI 10.1177/154405910408300702
   Papaccio G, 2006, J CELL PHYSIOL, V208, P319, DOI 10.1002/jcp.20667
   Paula Silva FWG, 2009, J DENT RES, V88, P339, DOI 10.1177/0022034509334070
   Pierdomenico L, 2005, TRANSPLANTATION, V80, P836, DOI 10.1097/01.tp.0000173794.72151.88
   Putnam AJ, 1996, NAT MED, V2, P824, DOI 10.1038/nm0796 824
   REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558
   Roberts Clark DJ, 2000, ARCH ORAL BIOL, V45, P1013, DOI 10.1016/S0003 9969(00)00075 3
   RUCH JV, 1995, INT J DEV BIOL, V39, P51
   Sasaki R, 2008, EUR J NEUROSCI, V27, P538, DOI 10.1111/j.1460 9568.2008.06026.x
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Seo BM, 2005, J DENT RES, V84, P907, DOI 10.1177/154405910508401007
   Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087
   Shi S, 2005, Orthod Craniofac Res, V8, P191, DOI 10.1111/j.1601 6343.2005.00331.x
   Shi S, 2001, BONE, V29, P532, DOI 10.1016/S8756 3282(01)00612 3
   Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696
   Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602 587
   Sloan AJ, 2007, ORAL DIS, V13, P151, DOI 10.1111/j.1601 0825.2006.01346.x
   Sloan AJ, 1999, ARCH ORAL BIOL, V44, P149, DOI 10.1016/S0003 9969(98)00106 X
   Sloan AJ, 2000, ARCH ORAL BIOL, V45, P173, DOI 10.1016/S0003 9969(99)00131 4
   Sloan AJ, 2009, INT J PAEDIATR DENT, V19, P61, DOI 10.1111/j.1365 263X.2008.00964.x
   SMITH AJ, 1995, INT J DEV BIOL, V39, P273
   Smith AJ, 2001, CRIT REV ORAL BIOL M, V12, P425, DOI 10.1177/10454411010120050501
   Sonoyama W, 2008, J ENDODONT, V34, P166, DOI 10.1016/j.joen.2007.11.021
   Sonoyama W, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000079
   Stevens A, 2008, STEM CELLS DEV, V17, P1175, DOI 10.1089/scd.2008.0012
   Techawattanawisal W, 2007, BIOCHEM BIOPH RES CO, V357, P917, DOI 10.1016/j.bbrc.2007.04.031
   Téclès O, 2005, ARCH ORAL BIOL, V50, P103, DOI 10.1016/j.archoralbio.2004.11.009
   Thompson PW, 2002, J IMMUNOL, V169, P1007, DOI 10.4049/jimmunol.169.2.1007
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   Wada N, 2009, J CELL PHYSIOL, V219, P667, DOI 10.1002/jcp.21710
   Waddington RJ, 2009, CELLS TISSUES ORGANS, V189, P268, DOI 10.1159/000151447
   Wagers AJ, 2004, CELL, V116, P639, DOI 10.1016/S0092 8674(04)00208 9
   Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092 8674(00)81692 X
   Yang KL, 2009, CYTOTHERAPY, V11, P606, DOI 10.1080/14653240902806994
   Yao S, 2008, J DENT RES, V87, P767, DOI 10.1177/154405910808700801
   Ye L, 2005, J BIOL CHEM, V280, P6197, DOI 10.1074/jbc.M412911200
   Yen AHH, 2008, CELL TISSUE RES, V331, P359, DOI 10.1007/s00441 007 0467 6
   Zhang C, 2008, J DENT RES, V87, P250, DOI 10.1177/154405910808700312
NR 91
TC 28
Z9 32
U1 0
U2 17
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1537 744X
J9 THESCIENTIFICWORLDJO
JI TheScientificWorldJOURNAL
PY 2009
VL 9
BP 1167
EP 1177
DI 10.1100/tsw.2009.125
PG 11
WC Environmental Sciences; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Science & Technology   Other Topics
GA 544SJ
UT WOS:000273679300041
PM 19838602
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Carofiglio, M
   Laurenti, M
   Genchi, GG
   Ciofani, G
   Grochowicz, M
   Cauda, V
AF Carofiglio, Marco
   Laurenti, Marco
   Genchi, Giada Graziana
   Ciofani, Gianni
   Grochowicz, Marta
   Cauda, Valentina
TI Ultrasound Triggered ZnO Based Devices for Tunable and Multifaceted
   Biomedical Applications
SO ADVANCED MATERIALS INTERFACES
LA English
DT Article
DE graphene oxide; pHEMA; reactive oxygen species (ROS); ultrasound; ZnO
ID ZINC OXIDE; NANOPARTICLES; GENERATION; THERAPY; CELLS; DYE; DEGRADATION;
   MECHANISM; TOXICITY; ADHESION
AB Smart materials able to respond to an external stimulus or an environmental condition represent milestone developments in modern medicine. Among them, zinc oxide (ZnO) is a highly intriguing inorganic material with versatile morphologies/shapes and multifunctional properties like piezoelectricity, enhanced reactive oxygen species (ROS) generation, and antimicrobial ones. Here, the fabrication of smart ZnO based films is shown that can remotely be activated by ultrasound (US). US exposure induces electrical potentials on the fabricated devices that can be exploited to stimulate electrically responsive cells or promote ROS generation for cancer treatment. ZnO microparticles with surface nanostructuring are thus synthesized and processed in the form of a paste to deposit thin films on flexible polymeric supports. ZnO paste formulation and the fabrication procedure of the final device are optimized in terms of uniformity, hydrophilicity, and purity. Graphene oxide and poly(2 hydroxyethyl methacrylate) are also layered onto the ZnO films in order to provide the devices with additional functionalities. ROS generation and electro mechanical performances upon US stimulation are evaluated for all of the developed devices. Finally, biocompatibility studies are conducted with osteoblast like cell cultures for possible applications in the contexts of bone tissue engineering/therapy.
C1 [Carofiglio, Marco; Laurenti, Marco; Cauda, Valentina] Politecn Torino, Dept Appl Sci & Technol, Corso Duca Abruzzi 24, I 10129 Turin, Italy.
   [Genchi, Giada Graziana; Ciofani, Gianni] Ist Italiano Tecnol, Smart BioInterfaces, Viale Rinaldo Piaggio 34, I 56025 Pisa, Italy.
   [Grochowicz, Marta] Marie Curie Sklodowska Univ, Dept Polymer Chem, Gliniana 33, PL 20614 Lublin, Poland.
C3 Polytechnic University of Turin; Istituto Italiano di Tecnologia   IIT;
   Maria Curie Sklodowska University
RP Cauda, V (通讯作者)，Politecn Torino, Dept Appl Sci & Technol, Corso Duca Abruzzi 24, I 10129 Turin, Italy.
EM valentina.cauda@polito.it
RI ; Genchi, Giada Graziana/AAD 9095 2022; Cauda, Valentina/W 6630 2019;
   Ciofani, Gianni/D 3761 2009
OI Genchi, Giada Graziana/0000 0002 2154 7991; Carofiglio,
   Marco/0000 0002 8798 3235; Grochowicz, Marta/0000 0002 9225 5232;
   Ciofani, Gianni/0000 0003 1192 3647
FU European Research Council (ERC) under the European Union [678151];
   Politecnico di Torino within the CRUI CARE Agreement; European Research
   Council (ERC) [678151] Funding Source: European Research Council (ERC)
FX Part of this work has received funding from the European Research
   Council (ERC) under the European Union's Horizon 2020 research and
   innovation programme (grant agreement no. 678151 Project Acronym
   "TROJANANOHORSE" ERC starting Grant).Open Access Funding provided by
   Politecnico di Torino within the CRUI CARE Agreement.
CR Akhtar MJ, 2012, INT J NANOMED, V7, P845, DOI 10.2147/IJN.S29129
   Ancona A, 2020, ULTRASON SONOCHEM, V67, DOI 10.1016/j.ultsonch.2020.105132
   Ancona A, 2018, NANOMATERIALS BASEL, V8, DOI 10.3390/nano8030143
   Arima Y, 2007, BIOMATERIALS, V28, P3074, DOI 10.1016/j.biomaterials.2007.03.013
   Azam A., INT J NANOMED, P7
   Brazzale C, 2016, NANOMEDICINE UK, V11, DOI 10.2217/nnm 2016 0293
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169 409X(02)00044 3
   BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891 5849(87)80033 3
   Canavese G, 2018, CHEM ENG J, V340, P155, DOI 10.1016/j.cej.2018.01.060
   Carofiglio M, 2020, APPL SCI BASEL, V10, DOI 10.3390/app10155194
   Cauda V, 2014, ENERGY, V65, P639, DOI 10.1016/j.energy.2013.12.025
   Chen D, 2012, CHEM REV, V112, P6027, DOI 10.1021/cr300115g
   Ciofani G, 2012, MAT SCI ENG C MATER, V32, P341, DOI 10.1016/j.msec.2011.11.001
   Ciofani G, 2010, ACS NANO, V4, P6267, DOI 10.1021/nn101985a
   Daneshvar N, 2004, J PHOTOCH PHOTOBIO A, V162, P317, DOI 10.1016/s1010 6030(03)00378 2
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   Dumontel B, 2019, NANOMEDICINE UK, V14, P2815, DOI 10.2217/nnm 2019 0231
   Friedrich J, 2009, NAT PROTOC, V4, P309, DOI 10.1038/nprot.2008.226
   Gandhi V, 2014, J PHYS CHEM C, V118, P9715, DOI 10.1021/jp411848t
   Genchi GG, 2016, ADV HEALTHC MATER, V5, P1808, DOI 10.1002/adhm.201600245
   Hasegawa T, 2001, PROG POLYM SCI, V26, P259
   Hoop M, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03992 3
   Hosono E, 2004, J SOL GEL SCI TECHN, V29, P71, DOI 10.1023/B:JSST.0000023008.14883.1e
   Ilager D, 2021, J MOL LIQ, V322, DOI 10.1016/j.molliq.2020.114552
   Katt ME, 2016, FRONT BIOENG BIOTECH, V4, DOI 10.3389/fbioe.2016.00012
   Konwar A, 2016, ACS APPL MATER INTER, V8, P20625, DOI 10.1021/acsami.6b07510
   Kulkarni DR, 2020, MATER CHEM PHYS, V246, DOI 10.1016/j.matchemphys.2020.122791
   Laurenti M, 2020, MATERIALS, V13, DOI 10.3390/ma13173821
   Laurenti M, 2019, ACS APPL MATER INTER, V11, P449, DOI 10.1021/acsami.8b20728
   Laurenti M, 2018, COATINGS, V8, DOI 10.3390/coatings8110376
   Laurenti M, 2018, MATERIALS, V11, DOI 10.3390/ma11020314
   Laurenti M, 2017, NANOMATERIALS BASEL, V7, DOI 10.3390/nano7110374
   Laurenti M, 2015, ADV MATER, V27, P4218, DOI 10.1002/adma.201501594
   Law KY, 2014, J PHYS CHEM LETT, V5, P686, DOI 10.1021/jz402762h
   Liao JF, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00139 z
   Lops C, 2019, APPL CATAL B ENVIRON, V243, P629, DOI 10.1016/j.apcatb.2018.10.078
   Ma XW, 2012, INT J NANOMED, V7, P1313, DOI 10.2147/IJN.S29371
   Marino A, 2019, J COLLOID INTERF SCI, V538, P449, DOI 10.1016/j.jcis.2018.12.014
   Marino A, 2015, ACS NANO, V9, P7678, DOI 10.1021/acsnano.5b03162
   Patterson AL, 1939, PHYS REV, V56, P978, DOI 10.1103/PhysRev.56.978
   Prideaux M, 2014, CALCIFIED TISSUE INT, V95, P183, DOI 10.1007/s00223 014 9879 y
   Racca L, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00577
   Ribeiro C, 2015, COLLOID SURFACE B, V136, P46, DOI 10.1016/j.colsurfb.2015.08.043
   Ristic M, 2005, J ALLOY COMPD, V397, pL1, DOI 10.1016/j.jallcom.2005.01.045
   Saito M, 2008, ENERG ENVIRON SCI, V1, P280, DOI 10.1039/b806096g
   Shanbhag MM, 2020, MICROCHEM J, V159, DOI 10.1016/j.microc.2020.105409
   Shetti NP, 2019, ELECTROANAL, V31, P1040, DOI 10.1002/elan.201800775
   Shetti NP, 2019, BIOSENS BIOELECTRON, V141, DOI 10.1016/j.bios.2019.111417
   Sirelkhatim A, 2015, NANO MICRO LETT, V7, P219, DOI 10.1007/s40820 015 0040 x
   Socrates, 1980, INFRARED RAMAN CHARA
   Stuart MAC, 2010, NAT MATER, V9, P101, DOI [10.1038/NMAT2614, 10.1038/nmat2614]
   Tartaj P, 2003, J PHYS D APPL PHYS, V36, pR182, DOI 10.1088/0022 3727/36/13/202
   Tenke P, 2004, INT J ANTIMICROB AG, V23, pS67, DOI 10.1016/j.ijantimicag.2003.12.007
   Tenke P, 2012, WORLD J UROL, V30, P51, DOI 10.1007/s00345 011 0689 9
   Thakur P, 2018, NANO ENERGY, V44, P456, DOI 10.1016/j.nanoen.2017.11.065
   Tugulu S, 2007, BIOMATERIALS, V28, P2536, DOI 10.1016/j.biomaterials.2007.02.006
   Vighetto V, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00374
   Wang GS, 2016, CHEM ENG J, V289, P150, DOI 10.1016/j.cej.2015.12.072
   Wang XD, 2007, NANO LETT, V7, P2475, DOI 10.1021/nl0712567
   Wang ZL, 2008, NANO RES, V1, P1, DOI 10.1007/s12274 008 8003 x
   Xia T, 2008, ACS NANO, V2, P2121, DOI 10.1021/nn800511k
   Xiong HM, 2013, ADV MATER, V25, P5329, DOI 10.1002/adma.201301732
   Xu XL, 2013, LANGMUIR, V29, P5573, DOI 10.1021/la400378t
   Yang BW, 2019, CHEM REV, V119, P4881, DOI 10.1021/acs.chemrev.8b00626
   Yoon JK, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201703853
NR 65
TC 11
Z9 11
U1 1
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2196 7350
J9 ADV MATER INTERFACES
JI Adv. Mater. Interfaces
PD NOV
PY 2021
VL 8
IS 21
AR 2101021
DI 10.1002/admi.202101021
EA OCT 2021
PG 14
WC Chemistry, Multidisciplinary; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science
GA WU5DU
UT WOS:000703739000001
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Meisenheimer, M
   Kürpig, S
   Essler, M
   Eppard, E
AF Meisenheimer, Michael
   Kuerpig, Stefan
   Essler, Markus
   Eppard, Elisabeth
TI DOTA ZOL: A Promising Tool in Diagnosis and Palliative Therapy of Bone
   Metastasis Challenges and Critical Points in Implementation into
   Clinical Routine
SO MOLECULES
LA English
DT Article
DE gallium 68; bone metastasis; radiolabelling synthesis; quality control;
   module system
ID NITROGEN CONTAINING BISPHOSPHONATES; FARNESYL PYROPHOSPHATE SYNTHASE;
   PROSTATE CANCER; MEVALONATE PATHWAY; MANAGEMENT; BINDING;
   HYDROXYAPATITE; DISSOCIATION; INHIBITION; MECHANISMS
AB The novel compound 1,4,7,10 tetraazacyclododecane 1,4,7,10 tetraacetic acid (DOTA) ZOL (DOTA conjugated zoledronic acid) is a promising candidate for the diagnosis and therapy of bone metastasis. The combination of the published methodology for this bisphosphonate with pharmaceutical and regulatory requirements turned out to be unexpectedly challenging. The scope of this work is the presentation and discussion of problems encountered during this process. Briefly, the radiolabelling process and purification, as well as the quality control published, did not meet the expectations. The constant effort setting up an automated radiolabelling procedure resulted in (a) an enhanced manual method using coated glass reactors, (b) a combination of three different reliable radio thin layer chromatography (TLC) methods instead of the published and (c) a preliminary radio high pressure liquid chromatography (HPLC) method for identification of the compound. Additionally, an automated radiolabelling process was developed, but it requires further improvement, e.g., in terms of a reactor vessel or purification of the crude product. The published purification method was found to be unsuitable for clinical routine, and an intense screening did not lead to a satisfactory result; here, more research is necessary. To sum up, implementation of DOTA ZOL was possible but revealed a lot of critical points, of which not all could be resolved completely yet.
C1 [Meisenheimer, Michael; Kuerpig, Stefan; Essler, Markus] Univ Hosp Bonn, Dept Nucl Med, D 53127 Bonn, Germany.
   [Eppard, Elisabeth] Positronpharma SA, Rancagua 878, Providencia 7500921, Chile.
C3 University of Bonn
RP Eppard, E (通讯作者)，Positronpharma SA, Rancagua 878, Providencia 7500921, Chile.
EM michael.meisenheimer@ukbonn.de; stefan.kuerpig@ukbonn.de;
   markus.essler@ukbonn.de; eeppard@positronpharma.cl
RI Eppard, Elisabeth/T 4521 2019
FU BONFOR [O 140.0008]
FX This research was funded by BONFOR, grant number O 140.0008.
CR Agarwal MG, 2015, INDIAN J ORTHOP, V49, P83, DOI 10.4103/0019 5413.143915
   [Anonymous], SUBSCR MAIN VOL S1
   Baranyai Z, 2020, EUR J INORG CHEM, V2020, P36, DOI 10.1002/ejic.201900706
   BORCHERT SJ, 1989, J PARENT SCI TECHN, V43, P67
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Coleman RE, 2010, CANCER TREAT REV, V36, P615, DOI 10.1016/j.ctrv.2010.04.003
   Damerla V, 2005, AM J CLIN ONCOL CANC, V28, P513, DOI 10.1097/01.coc.0000162425.55457.10
   Den RB, 2019, AM J CLIN ONCOL CANC, V42, P399, DOI 10.1097/COC.0000000000000528
   Dhar MK, 2013, NEW BIOTECHNOL, V30, P114, DOI 10.1016/j.nbt.2012.07.001
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Eppard E, 2014, J NUCL MED, V55, P1023, DOI 10.2967/jnumed.113.133041
   Fellner M, 2012, NUCL MED BIOL, V39, P993, DOI 10.1016/j.nucmedbio.2012.04.007
   Fellner M, 2010, EUR J NUCL MED MOL I, V37, P834, DOI 10.1007/s00259 009 1355 y
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   FLEISCH H, 1962, AM J PHYSIOL, V203, P671, DOI 10.1152/ajplegacy.1962.203.4.671
   FRIEDELL HL, 1950, AM J ROENTGENOL, V64, P559
   Gandaglia G, 2015, EUR UROL, V68, P325, DOI 10.1016/j.eururo.2014.07.020
   Gillings N, 2020, EJNMMI RADIOPHARM CH, V5, DOI 10.1186/s41181 019 0086 z
   Gonzalez Sistal A, 2011, MED IMAGING
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Hensel J, 2016, UROLOGY, V92, P6, DOI 10.1016/j.urology.2015.12.039
   Hughes EAB, 2019, J MATER CHEM B, V7, P7460, DOI 10.1039/c9tb02011j
   JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Khawar A, 2019, EJNMMI RES, V9, DOI 10.1186/s13550 019 0566 x
   Khawar A, 2019, ANN NUCL MED, V33, P404, DOI 10.1007/s12149 019 01348 7
   Kubícek V, 2005, J AM CHEM SOC, V127, P16477, DOI 10.1021/ja054905u
   KUMAR K, 1993, INORG CHEM, V32, P587, DOI 10.1021/ic00057a017
   Li Shuling, 2012, Clin Epidemiol, V4, P87, DOI 10.2147/CLEP.S28339
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Meckel M, 2016, EJNMMI RADIOPHARM CH, V1, DOI 10.1186/s41181 016 0017 1
   Meckel M, 2015, CANCER BIOTHER RADIO, V30, P94, DOI 10.1089/cbr.2014.1720
   Molavipordanjani S, 2019, DRUG DISCOV TODAY, V24, P315, DOI 10.1016/j.drudis.2018.09.018
   Neuman WilliamF., 1958, The Chemical Dynamics of Bone Mineral
   Norgaard M, 2010, J UROLOGY, V184, P162, DOI 10.1016/j.juro.2010.03.034
   Ogawa K, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/676053
   Orriss IR, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115243
   Pfannkuchen N, 2017, PHARMACEUTICALS BASE, V10, DOI 10.3390/ph10020045
   Pillai SA., 2016, J. Pharm. Sci. & Res., V8, P103
   Räikkönen J, 2011, BIOCHEM BIOPH RES CO, V407, P663, DOI 10.1016/j.bbrc.2011.03.070
   Reddy LM, 2017, ARAB J CHEM, V10, pS196, DOI 10.1016/j.arabjc.2012.07.022
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Seemann J, 2015, APPL RADIAT ISOTOPES, V98, P54, DOI 10.1016/j.apradiso.2015.01.023
   Selby PL, 2002, BONE, V31, P366, DOI 10.1016/S8756 3282(02)00817 7
   Ulmert D, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.24
   van der Toom EE, 2016, CURR OPIN BIOTECH, V40, P9, DOI 10.1016/j.copbio.2016.02.002
   vanBeek E, 1996, J BONE MINER RES, V11, P1492
   Vitha T, 2008, J MED CHEM, V51, P677, DOI 10.1021/jm7012776
   WANG XY, 1992, INORG CHEM, V31, P1095, DOI 10.1021/ic00032a034
   Ye L, 2007, INT J MOL MED, V20, P103
   Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266
NR 53
TC 11
Z9 11
U1 0
U2 7
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD JUL
PY 2020
VL 25
IS 13
AR 2988
DI 10.3390/molecules25132988
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA MM7QF
UT WOS:000550347200001
PM 32629930
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hu, J
   Zeng, XY
   Song, CC
   Zhang, L
AF Hu, Jing
   Zeng, Xianyou
   Song, Chengcheng
   Zhang, Lei
TI Lipopolysaccharide promotes the osteoclastogenesis through the
   autophagic degradation of TNF receptor associated factor 3
SO SCIENCEASIA
LA English
DT Article
DE LPS; osteoclastogenesis; autophagy; TRAF3; osteoclast precursors
ID NF KAPPA B; EXPRESSION; TRAF3; DIFFERENTIATION; ACTIVATION; APOPTOSIS;
   PATHWAY; ALPHA; CELLS
AB Lipopolysaccharide (LPS) is a pro osteoclastogenic factor and autophagic activator. TNF receptor associated factor (TRAF) 3, an anti osteoclastogenic factor, can be degraded by autophagic activation. The effect of LPS on the level of TRAF3 during the osteoclastogenesis keeps vague. In this study, we investigated the roles of LPS in the expression patterns of TRAF3 in vivo and in vitro. Combined with the application of autophagic pharmacological inhibitors, we observed the significance of LPS regulated autophagy in TRAF3 protein level. Moreover, we explored the effects of TRAF3 on LPS induced osteoclastogenesis using gain of function and loss of function assays in vitro. Our study showed that LPS could reduce the protein level of TRAF3 in osteoclast precursors (OCPs) in vitro and in vivo, while no affecting the mRNA expression of TRAF3. In addition, TRAF3 overexpression reversed LPS induced osteoclastogenesis. Importantly, LPS inhibited TRAF3 protein level was recovered by autophagic inhibition with chloroquine or bafilomycin. Furthermore, LPS induced osteoclastogenesis was suppressed by chloroquine, which was reversed by TRAF3 silencing. In conclusion, LPS can promote the autophagic degradation of TRAF3, which serves as an indispensable underlying mechanism in LPS induced osteoclastogenesis.
C1 [Hu, Jing; Zeng, Xianyou] Jinggangshan Univ, Dept Stomatol, Affiliated Hosp, Jian 343000, Jiangxi, Peoples R China.
   [Song, Chengcheng; Zhang, Lei] Dujiangyan Peoples Hosp, Dept Stomatol, Chengdu 611800, Sichuang, Peoples R China.
C3 Jinggangshan University
RP Song, CC; Zhang, L (通讯作者)，Dujiangyan Peoples Hosp, Dept Stomatol, Chengdu 611800, Sichuang, Peoples R China.
EM SCCDJY@yeah.net; 282772709@qq.com
RI Hu, Jing/GPC 4486 2022
FU Guiding Science and Technology Project of Ji'an City [2020 11 46]
FX This work was supported by Guiding Science and Technology Project of
   Ji'an City (2020 11 46).
CR Bohannon JK, 2013, SHOCK, V40, P451, DOI 10.1097/SHK.0000000000000042
   Chen LL, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.110093
   Chen M, 2017, AUTOPHAGY, V13, P1813, DOI 10.1080/15548627.2017.1356550
   Cheng L, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12789
   Devergne O, 1996, MOL CELL BIOL, V16, P7098
   Guo C, 2012, CELL PHYSIOL BIOCHEM, V30, P123, DOI 10.1159/000339052
   Häcker H, 2011, NAT REV IMMUNOL, V11, P457, DOI 10.1038/nri2998
   He LG, 2016, EUR J PHARMACOL, V779, P66, DOI 10.1016/j.ejphar.2016.03.014
   Hotokezaka H, 2007, J CELL BIOCHEM, V101, P122, DOI 10.1002/jcb.21167
   Hou GQ, 2013, INT J MOL MED, V32, P503, DOI 10.3892/ijmm.2013.1406
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Ke DS, 2020, MOL CELL ENDOCRINOL, V500, DOI 10.1016/j.mce.2019.110637
   Ke DS, 2019, BIOCHIMIE, V167, P217, DOI 10.1016/j.biochi.2019.10.008
   Ke DS, 2019, FASEB J, V33, P11082, DOI 10.1096/fj.201802597RR
   Keestra JAJ, 2015, J PERIODONTAL RES, V50, P689, DOI 10.1111/jre.12252
   Khuda IIE, 2010, IMMUNOLOGY, V131, P59, DOI 10.1111/j.1365 2567.2010.03274.x
   Laha D, 2019, AUTOPHAGY, V15, P2063, DOI 10.1080/15548627.2019.1596491
   Lee YM, 2021, SCIENCEASIA, V47, P277, DOI 10.2306/scienceasia1513 1874.2021.027
   Lei S, 2020, J ENDODONT, V46, P502, DOI 10.1016/j.joen.2020.01.009
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   Park HJ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8982147
   Park HJ, 2018, BIOCHEM PHARMACOL, V151, P9, DOI 10.1016/j.bcp.2018.02.019
   ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915
   Suda K, 2004, J IMMUNOL, V172, P2504, DOI 10.4049/jimmunol.172.4.2504
   Sul OJ, 2018, BONE, V116, P279, DOI 10.1016/j.bone.2018.08.014
   Sul OJ, 2017, MOL CELLS, V40, P880, DOI 10.14348/molcells.2017.0230
   Wang XH, 2017, BIOMED PHARMACOTHER, V96, P899, DOI 10.1016/j.biopha.2017.12.011
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Xue Y, 2019, BIOCHEM BIOPH RES CO, V508, P1088, DOI 10.1016/j.bbrc.2018.12.029
   Yao ZQ, 2009, J CLIN INVEST, V119, P3024, DOI 10.1172/JCI38716
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zheng ZY, 2021, CELL DEATH DIFFER, V28, P2001, DOI 10.1038/s41418 020 00731 6
NR 32
TC 1
Z9 1
U1 0
U2 10
PU SCIENCE SOCIETY THAILAND
PI BANGKOK
PA PUBLIC INFORMATION DEPT, 73/1 RAMA VI RD, RAJDHEVEE, BANGKOK, 00000,
   THAILAND
SN 1513 1874
J9 SCIENCEASIA
JI Scienceasia
PY 2022
VL 48
IS 6
BP 697
EP 704
DI 10.2306/scienceasia1513 1874.2022.098
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 4V8KY
UT WOS:000859722100001
OA gold
DA 2025 08 17
ER

PT J
AU Yang, HW
   Pan, H
   Yu, F
   Chen, K
   Shang, GW
   Xu, YZ
AF Yang, Huawei
   Pan, Hui
   Yu, Fang
   Chen, Kai
   Shang, Guangwei
   Xu, Yuanzhi
TI A novel model of bisphosphonate related osteonecrosis of the jaw in rats
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Bisphosphonates; BRONJ; animal model; pathogenesis; RANKL; OPG
ID NITROGEN CONTAINING BISPHOSPHONATES; SURGEONS POSITION PAPER; ZOLEDRONIC
   ACID; AMERICAN ASSOCIATION; JAWS 2009 UPDATE; ANIMAL MODEL;
   OSTEOPOROSIS; MECHANISM; THERAPY; DISEASE
AB Objective: To establish a rat model of bisphosphonate related osteonecrosis of the jaw (BRONJ) that realistically mimics major clinical manifestations of the disease. Methods: Female Sprague Dawley rats received intravenous zoledronate 80 mu g/kg once a week via the tail vein. Three weeks after intravenous injection, maxillary first molars were extracted under general anesthesia. Then 1, 4 and 12 weeks after tooth extraction, the rats were euthanized, and the intact maxillas were harvested en bloc. Macroscopic analysis, histological analysis and cytokine analysis were performed. Untreated rats with tooth extraction were used as controls. Results: 12 weeks after extraction, rats treated with zoledronate developed BRONJ like disease, including characteristic features of impaired soft tissue healing, exposed necrotic bone or sequestra, increased inflammatory infiltrates, while the controls showed normal bone healing. 4 weeks after extraction, rats treated with zoledronate exhibited the decreased receptor activator of nuclear factor kappa B ligand (RANKL) values, the increased osteoprotegerin (OPG) values and the remarkable decreased RANKL/OPG ratio when compared with the controls. Conclusion: The rats treated with zoledronate can be considered a novel, reliable and reproducible animal model to better understand the pathophysiology and pathogenesis of BRONJ and to develop a therapeutic approach.
C1 [Yang, Huawei; Yu, Fang; Chen, Kai; Shang, Guangwei; Xu, Yuanzhi] Tongji Univ, Peoples Hosp 10, Dept Stomatol, Sch Med, Shanghai 200072, Peoples R China.
   [Pan, Hui] Tongji Univ, Peoples Hosp 10, Dept Emergence, Sch Med, Shanghai 200072, Peoples R China.
C3 Tongji University; Tongji University
RP Yu, F (通讯作者)，Tongji Univ, Peoples Hosp 10, Dept Stomatol, Sch Med, Shanghai 200072, Peoples R China.
EM yufangshiyuan@163.com
RI Yang, Huawei/NSU 5250 2025; Zhang, Guangyuan/AAD 5494 2020; Yu,
   Fang/C 2933 2014
CR Abu Id MH, 2008, J CRANIO MAXILL SURG, V36, P95, DOI 10.1016/j.jcms.2007.06.008
   Allen MR, 2011, OSTEOPOROSIS INT, V22, P693, DOI 10.1007/s00198 010 1268 4
   Allen MR, 2010, J BONE MINER RES, V25, P98, DOI 10.1359/jbmr.090713
   Bi YM, 2010, AM J PATHOL, V177, P280, DOI 10.2353/ajpath.2010.090592
   Biasotto M, 2010, J ORAL PATHOL MED, V39, P390, DOI 10.1111/j.1600 0714.2009.00878.x
   Colella G, 2009, J ORAL MAXIL SURG, V67, P2698, DOI 10.1016/j.joms.2009.07.097
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Eastell R, 2011, BONE, V49, P82, DOI 10.1016/j.bone.2011.02.011
   Hasegawa T, 2013, J CRANIO MAXILL SURG, V41, P558, DOI 10.1016/j.jcms.2012.11.023
   Hokugo A, 2010, J BONE MINER RES, V25, P1337, DOI 10.1002/jbmr.23
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Lopez Jornet P, 2010, J ORAL PATHOL MED, V39, P697
   Maahs MP, 2011, HEAD NECK J SCI SPEC, V33, P199, DOI 10.1002/hed.21422
   Mehmet AE, 2011, MED ORAL PATOL ORAL, V16, pe879
   Pautke C, 2012, BONE, V51, P592, DOI 10.1016/j.bone.2012.04.020
   Reid IR, 2011, J BONE MINER RES, V26, P2261, DOI 10.1002/jbmr.438
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Sedghizadeh PP, 2008, J ORAL MAXIL SURG, V66, P767, DOI 10.1016/j.joms.2007.11.035
   Sonis ST, 2009, ORAL ONCOL, V45, P164, DOI 10.1016/j.oraloncology.2008.04.013
   Stresing V, 2011, BONE, V48, P259, DOI 10.1016/j.bone.2010.09.035
NR 21
TC 17
Z9 21
U1 0
U2 1
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936 2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 5
BP 5161
EP 5167
PG 7
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA CN4AL
UT WOS:000358370300093
PM 26191212
DA 2025 08 17
ER

PT J
AU Kemeny Suss, N
   Kasneci, A
   Rivas, D
   Afilalo, J
   Komarova, SV
   Chalifour, LE
   Duque, G
AF Kemeny Suss, Naomi
   Kasneci, Amanda
   Rivas, Daniel
   Afilalo, Jonathan
   Komarova, Svetlana V.
   Chalifour, Lorraine E.
   Duque, Gustavo
TI Alendronate affects calcium dynamics in cardiomyocytes in vitro
SO VASCULAR PHARMACOLOGY
LA English
DT Article
DE Arrhythmia; Atrial fibrillation; Bisphosphonates; Calcium;
   Cardiomyocytes
ID POLYMORPHIC VENTRICULAR TACHYCARDIA; NITROGEN CONTAINING
   BISPHOSPHONATES; FARNESYL PYROPHOSPHATE SYNTHASE; MUSCLE CELL LINE;
   ATRIAL FIBRILLATION; HL 1 CARDIOMYOCYTES; CARDIAC MYOCYTES;
   GENE EXPRESSION; SUDDEN DEATH; CA2+
AB Therapy with bisphosphonates, including alendronate (ALN), is considered a safe and effective treatment for osteoporosis. However, recent studies have reported an unexpected increase in serious atrial fibrillation (AF) in patients treated with bisphosphonates. The mechanism that explains this side effect remains unknown. Since AF is associated with an altered sarcoendoplasmic reticulum calcium load, we studied how ALN affects cardiomyocyte calcium homeostasis and protein isoprenylation in vitro. Acute and long term (48 h) treatment of atrial and ventricular cardiomyocytes with ALN (10( 8) 10( 6)M) was performed. Changes in calcium dynamics were determined by both fluorescence measurement of cytosolic free Ca2+ concentration and western blot analysis of calcium regulating proteins. Finally, effect of ALN on protein farnesylation was also identified. In both atrial and ventricular cardiomyocytes, ALN treatment delayed and diminished calcium responses to caffeine. Only in atrial cells, long term exposure to ALN induced transitory calcium oscillations and led to the development of oscillatory component in calcium responses to caffeine. Changes in calcium dynamics were accompanied by changes in expression of proteins controlling sarcoendoplasmic reticulum calcium. In contrast, ALN minimally affected protein isoprenylation in these cells. In summary, treatment of atrial cardiomyocytes with ALN induced abnormalities in calcium dynamics consistent with induction of a self stimulatory, pacemaker like behavior, which may contribute to the development of cardiac side effects associated with these drugs. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Kemeny Suss, Naomi; Komarova, Svetlana V.] McGill Univ, Fac Dent, Montreal, PQ H3A 2B2, Canada.
   [Kasneci, Amanda; Chalifour, Lorraine E.] Bank Montreal Ctr Study Heart Dis Women, Montreal, PQ H3T 1E2, Canada.
   [Kasneci, Amanda; Rivas, Daniel; Chalifour, Lorraine E.; Duque, Gustavo] McGill Univ, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.
   [Afilalo, Jonathan] McGill Univ, Jewish Gen Hosp, Div Cardiol, Montreal, PQ H3T 1E2, Canada.
   [Duque, Gustavo] Univ Sydney, Aging Bone Res Program, Nepean Clin Sch, Penrith, NSW 2750, Australia.
C3 McGill University; McGill University; Lady Davis Institute; Jewish
   General Hospital   Montreal; McGill University; University of Sydney
RP Duque, G (通讯作者)，Nepean Hosp, Nepean Clin Sch, Level 5 S Block, Penrith, NSW 2750, Australia.
EM gduque@med.usyd.edu.au
RI Komarova, Svetlana/MTR 5042 2025; Duque, Gustavo/G 6656 2015; Duque,
   Gustavo/HDO 1243 2022; Afilalo, Jonathan/AEP 0841 2022
OI Duque, Gustavo/0000 0001 8126 0637; Komarova,
   Svetlana/0000 0003 3570 3147; 
FU University of Sydney Medical Research Foundation; Nepean Medical
   Research Foundation; Canadian Institutes for Health Research; Natural
   Sciences and Engineering Research Council
FX This study was funded by grants from the University of Sydney Medical
   Research Foundation and the Nepean Medical Research Foundation (to GD),
   the Canadian Institutes for Health Research (to GD and SVK) and the
   Natural Sciences and Engineering Research Council (to LC and SVK). Dr.
   Duque holds a Fellowship from the University of Sydney Medical Research
   Foundation. Dr. Komarova holds a Canada Research Chair award. Ms.
   Kemeny Suss was supported by the CIHR Strategic Training Program in
   Skeletal Health Research.
CR Bers DM, 2008, ANNU REV PHYSIOL, V70, P23, DOI 10.1146/annurev.physiol.70.113006.100455
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Brundel BJJM, 2006, CIRC RES, V99, P1394, DOI 10.1161/01.RES.0000252323.83137.fe
   Choi BR, 2002, J PHYSIOL LONDON, V543, P615, DOI 10.1113/jphysiol.2002.024570
   Chopra N, 2007, CIRC RES, V101, P617, DOI 10.1161/CIRCRESAHA.107.157552
   Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979
   Cummings SR, 2007, NEW ENGL J MED, V356, P1895, DOI 10.1056/NEJMc076132
   De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227
   DeSantiago J, 2008, CIRC RES, V102, P1389, DOI 10.1161/CIRCRESAHA.107.169011
   di Barletta MR, 2006, CIRCULATION, V114, P1012, DOI 10.1161/CIRCULATIONAHA.106.623793
   Diel Ingo J, 2007, J Support Oncol, V5, P475
   Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960
   Duque G, 2002, BIOCHEM BIOPH RES CO, V299, P446, DOI 10.1016/S0006 291X(02)02657 8
   Fahrenbach JP, 2007, J PHYSIOL LONDON, V585, P565, DOI 10.1113/jphysiol.2007.144121
   GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0
   Heckbert SR, 2008, ARCH INTERN MED, V168, P826, DOI 10.1001/archinte.168.8.826
   HESCHELER J, 1991, CIRC RES, V69, P1476, DOI 10.1161/01.RES.69.6.1476
   Hewitt RE, 2005, CLIN EXP IMMUNOL, V139, P101, DOI 10.1111/j.1365 2249.2005.02665.x
   Keller RK, 1999, BIOCHEM BIOPH RES CO, V266, P560, DOI 10.1006/bbrc.1999.1849
   Kimmel DB, 2007, J DENT RES, V86, P1022, DOI 10.1177/154405910708601102
   Knollmann BC, 2008, NATURE, V451, P929, DOI 10.1038/nature06799
   Knollmann BC, 2006, J CLIN INVEST, V116, P2510, DOI 10.1172/JCI29128
   Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102
   Kubalova Z, 2004, J PHYSIOL LONDON, V561, P515, DOI 10.1113/jphysiol.2004.073940
   Lahat H, 2001, CIRCULATION, V103, P2822
   Lakireddy V, 2005, AM J PHYSIOL HEART C, V288, pH400, DOI 10.1152/ajpheart.00502.2004
   Lane JM, 2006, ORTHOP CLIN N AM, V37, P601, DOI 10.1016/j.ocl.2006.09.002
   Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965
   Liang PH, 2002, EUR J BIOCHEM, V269, P3339, DOI 10.1046/j.1432 1033.2002.03014.x
   Liu J, 2008, PROG BIOPHYS MOL BIO, V96, P294, DOI 10.1016/j.pbiomolbio.2007.07.009
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Ménard C, 1999, J BIOL CHEM, V274, P29063, DOI 10.1074/jbc.274.41.29063
   Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857
   Nakamura K, 2001, J CLIN INVEST, V107, P1245, DOI 10.1172/JCI12412
   Ogawa Y, 1999, ADV BIOPHYS, V36, P27, DOI 10.1016/S0065 227X(99)80004 5
   Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088 199936050 00002
   Postma AV, 2002, CIRC RES, V91, pE21, DOI 10.1161/01.RES.0000038886.18992.6B
   Priori SG, 2002, CIRCULATION, V106, P69, DOI 10.1161/01.CIR.0000020013.73106.D8
   Rauch F, 2000, EXP CELL RES, V256, P105, DOI 10.1006/excr.2000.4818
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Salama G, 2006, HEART RHYTHM, V3, P67, DOI 10.1016/j.hrthm.2005.10.025
   Sartiani L, 2002, J PHYSIOL LONDON, V545, P81, DOI 10.1113/jphysiol.2002.021535
   SIPIDO KR, 1991, CIRC RES, V69, P1487, DOI 10.1161/01.RES.69.6.1487
   Sorensen HT, 2008, BMJ BRIT MED J, V336, P813, DOI 10.1136/bmj.39507.551644.BE
   Steinberg SF, 2002, AM J PHYSIOL HEART C, V282, pH1181, DOI 10.1152/ajpheart.00871.2001
   Stepensky D, 2002, J PHARM SCI US, V91, P508, DOI 10.1002/jps.10032
   Swynghedauw B, 1997, CARDIOVASC RES, V35, P6, DOI 10.1016/S0008 6363(97)00076 X
   Tsai CT, 2007, CIRC RES, V100, P1476, DOI 10.1161/01.RES.0000268497.93085.e1
   UHLEN P, 2004, SCI STKE, P115
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   Vest JA, 2005, CIRCULATION, V111, P2025, DOI 10.1161/01.CIR.0000162461.67140.4C
   White SM, 2004, AM J PHYSIOL HEART C, V286, pH823, DOI 10.1152/ajpheart.00986.2003
   YEH YH, 2008, CIRCEP ONLINE   0430
   Yun MH, 2006, ARCH PHARM RES, V29, P328, DOI 10.1007/BF02968579
   Zizic TM, 2004, AM FAM PHYSICIAN, V70, P1293
NR 56
TC 22
Z9 23
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1537 1891
EI 1879 3649
J9 VASC PHARMACOL
JI Vasc. Pharmacol.
PD NOV DEC
PY 2009
VL 51
IS 5 6
BP 350
EP 358
DI 10.1016/j.vph.2009.09.002
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 524DP
UT WOS:000272124300007
PM 19815094
DA 2025 08 17
ER

PT J
AU Wada, K
   Yu, WL
   Elazizi, M
   Barakat, S
   Ouimet, MA
   Rosario Meléndez, R
   Fiorellini, JP
   Graves, DT
   Uhrich, KE
AF Wada, Keisuke
   Yu, Weiling
   Elazizi, Mohamad
   Barakat, Sandrine
   Ouimet, Michelle A.
   Rosario Melendez, Roselin
   Fiorellini, Joseph P.
   Graves, Dana T.
   Uhrich, Kathryn E.
TI Locally delivered salicylic acid from a poly(anhydride ester): Impact on
   diabetic bone regeneration
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Poly(anhydride ester); Salicylic acid; Diabetes; Bone regeneration
ID OSTEOCLAST LIKE CELLS; ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN E 2;
   SPINAL FUSION; IN VIVO; RESORPTION; EXPRESSION; MECHANISM;
   DIFFERENTIATION; INFLAMMATION
AB Diabetes mellitus (DM) involves metabolic changes that can impair bone repair, including a prolonged inflammatory response. A salicylic acid based poly(anhydride ester) (SA PAE) provides controlled and sustained release of salicylic acid (SA) that locally resolves inflammation. This study investigates the effect of polymer controlled SA release on bone regeneration in diabetic rats where enhanced inflammation is expected. Fifty six Sprague Dawley rats were randomly assigned to two groups: diabetic group induced by streptozotocin (STZ) injection or normoglycemic controls injected with citrate buffer alone. Three weeks after hyperglycemia development or vehicle injection, 5 mm critical sized defects were created at the rat mandibular angle and treated with SA PAE/bone graft mixture or bone graft alone. Rats were euthanized 4 and 12 weeks after surgery, then bone fill percentage in the defect region was assessed by micro computed tomography (CT) and histomorphometry. It was observed that bone fill increased significantly at 4 and 12 weeks in SA PAE/bone graft treated diabetic rats compared to diabetic rats receiving bone graft alone. Accelerated bone formation in normoglycemic rats caused by SA PAE/bone graft treatment was observed at 4 weeks but not at 12 weeks. This study shows that treatment with SA PAE enhances bone regeneration in diabetic rats and accelerates bone regeneration in normoglycemic animals. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Wada, Keisuke; Elazizi, Mohamad; Barakat, Sandrine; Fiorellini, Joseph P.; Graves, Dana T.] Univ Penn, Sch Dent Med, Dept Periodont, Philadelphia, PA 19104 USA.
   [Yu, Weiling; Uhrich, Kathryn E.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA.
   [Ouimet, Michelle A.; Rosario Melendez, Roselin; Uhrich, Kathryn E.] Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA.
C3 University of Pennsylvania; Rutgers University System; Rutgers
   University New Brunswick; Rutgers University System; Rutgers University
   New Brunswick
RP Uhrich, KE (通讯作者)，Rutgers State Univ, Dept Chem & Chem Biol, 610 Taylor Rd, Piscataway, NJ 08854 USA.
EM keuhrich@rutgers.edu
RI Uhrich, Kathryn/I 2099 2013; Wada, Keisuke/AAW 7752 2021
OI Uhrich, Kathryn/0000 0001 7273 7528; 
FU NIDCR [DE013207, AR060055]
FX This work was funded by a grant from the NIDCR DE013207 and AR060055.
   Contributions from Dr. Bryan Langowski and Mohammad Alqatani are
   gratefully acknowledged.
CR Adami S, 2009, CURR MED RES OPIN, V25, P1057, DOI [10.1185/03007990902801147, 10.1185/03007990902801147 ]
   American Diabetes Association, 2011, DIAB FACTS SHEET
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Cottrell J, 2010, PHARMACEUTICALS, V3, P1668, DOI 10.3390/ph3051668
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Dinopoulos H, 2012, SURG J R COLL SURG E, V10, P230, DOI 10.1016/j.surge.2012.04.001
   Erdmann L, 2000, BIOMATERIALS, V21, P2507, DOI 10.1016/S0142 9612(00)00118 6
   Erdmann L, 2000, BIOMATERIALS, V21, P1941, DOI 10.1016/S0142 9612(00)00073 9
   Fiorellini JP, 2005, J PERIODONTOL, V76, P605, DOI 10.1902/jop.2005.76.4.605
   Fujita D, 2003, PROSTAG LEUKOTR ESS, V68, P351, DOI 10.1016/S0952 3278(03)00027 9
   Garrison KR, 2007, HEALTH TECHNOL ASSES, V11, P1
   Göpferich A, 2002, ADV DRUG DELIVER REV, V54, P911, DOI 10.1016/S0169 409X(02)00051 0
   Govender P.V., 2002, Neurosurgical Focus, V13
   Graves DT, 2008, FRONT BIOSCI LANDMRK, V13, P1227, DOI 10.2741/2757
   Gruber R, 2002, BONE, V30, P726, DOI 10.1016/S8756 3282(02)00697 X
   Harten RD, 2005, J BIOMED MATER RES A, V72A, P354, DOI 10.1002/jbm.a.30184
   Hie M, 2010, INT J MOL MED, V26, P611, DOI 10.3892/ijmm_00000506
   Housby JN, 1999, CYTOKINE, V11, P347, DOI 10.1006/cyto.1998.0437
   Jee WSS, 1997, BONE, V21, P297, DOI 10.1016/S8756 3282(97)00147 6
   Kayal RA, 2007, J BONE MINER RES, V22, P560, DOI 10.1359/JBMR.070115
   KHAN AU, 1995, CHEM BIOL, V2, P437
   Lader CS, 1998, ENDOCRINOLOGY, V139, P3157, DOI 10.1210/en.139.7.3157
   Liu R, 2006, J DENT RES, V85, P510, DOI 10.1177/154405910608500606
   Lu HF, 2003, ENDOCRINOLOGY, V144, P346, DOI 10.1210/en.2002 220072
   Morinaga Y, 1998, J CELL PHYSIOL, V175, P247, DOI 10.1002/(SICI)1097 4652(199806)175:3<247::AID JCP2>3.3.CO;2 E
   Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195
   Pacios S, 2012, FASEB J, V26, P1423, DOI 10.1096/fj.11 196279
   Ponugoti B, 2012, EXP DIABETES RES, DOI 10.1155/2012/939751
   Ramanujam CL, 2012, CLIN PODIATR MED SUR, V29, P589, DOI 10.1016/j.cpm.2012.07.005
   Retzepi M, 2010, CLIN ORAL IMPLAN RES, V21, P71, DOI 10.1111/j.1600 0501.2009.01805.x
   Reynolds Mark A., 2007, Current Drug Delivery, V4, P233
   Sasso FC, 2005, J AM COLL CARDIOL, V46, P827, DOI 10.1016/j.jacc.2005.06.007
   Schmeltzer RC, 2005, BIOMACROMOLECULES, V6, P359, DOI 10.1021/bm049544+
   Schmeltzer RC, 2003, POLYM BULL, V49, P441, DOI 10.1007/s00289 003 0123 6
   Semb G, 2012, FRONT ORAL BIOL, V16, P124, DOI 10.1159/000337666
   SIMMONS DJ, 1985, CLIN ORTHOP RELAT R, P100
   Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554
   VANE J, 1987, FASEB J, V1, P89, DOI 10.1096/fasebj.1.2.3111928
   Whitaker Brothers K, 2006, J BIOMED MATER RES A, V76A, P470, DOI 10.1002/jbm.a.30356
   White AP, 2007, INT ORTHOP, V31, P735, DOI 10.1007/s00264 007 0422 x
NR 41
TC 37
Z9 42
U1 1
U2 39
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168 3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD OCT 10
PY 2013
VL 171
IS 1
BP 33
EP 37
DI 10.1016/j.jconrel.2013.06.024
PG 5
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 213FU
UT WOS:000324041300005
PM 23827476
OA Green Published, Green Accepted
DA 2025 08 17
ER

PT J
AU Fukagawa, M
   Komaba, H
   Onishi, Y
   Fukuhara, S
   Akizawa, T
   Kurokawa, K
AF Fukagawa, Masafumi
   Komaba, Hirotaka
   Onishi, Yoshihiro
   Fukuhara, Shunichi
   Akizawa, Tadao
   Kurokawa, Kiyoshi
CA MBD 5D Study Grp
TI Mineral Metabolism Management in Hemodialysis Patients with Secondary
   Hyperparathyroidism in Japan: Baseline Data from the MBD 5D
SO AMERICAN JOURNAL OF NEPHROLOGY
LA English
DT Article
DE Chronic kidney disease mineral and bone disorder; Hemodialysis; Japanese
   Society for Dialysis Therapy guideline; Parathyroidectomy; Secondary
   hyperparathyroidism
ID CORONARY ARTERY CALCIFICATION; SERUM ALKALINE PHOSPHATASE; STAGE
   RENAL DISEASE; PARATHYROID GLAND; CALCIUM LEVELS; VITAMIN D; DIALYSIS
   OUTCOMES; BONE TURNOVER; MORTALITY; SURVIVAL
AB Background/Aims: The Mineral and Bone Disorder Outcomes Study for Japanese CKD Stage 5D Patients (MBD 5D) is a multicenter, prospective observational study of hemodialysis patients with secondary hyperparathyroidism (SHPT) in Japan, where the national guideline recommends targets for serum calcium (8.4 10.0 mg/dl), phosphorus (3.5 6.0 mg/dl), and intact parathyroid hormone (PTH) (60 180 pg/ml). Methods: The MBD 5D involved patients who were receiving hemodialysis for more than 3 months and met at least one of the following conditions: having intact PTH levels >180 pg/ml, or receiving intravenous vitamin D receptor activators (VDRAs) or oral VDRA analog. This report describes the baseline characteristics of the study participants and examines factors associated with mineral metabolism control lability. Results: A total of 8,229 patients were registered from 86 facilities as the whole cohort, and 3,276 patients were randomly selected as the subcohort. The severity of SHPT was associated with a lower likelihood of achieving the targets for calcium and phosphorus, whereas patients with a history of parathyroidectomy were more likely to achieve these targets as compared with those who had not undergone surgery despite high PTH levels. The use of 2.5 mEq/I calcium dialysate was also associated with a higher likelihood of achieving the targets compared with the use of 3.0 mEq/I calcium dialysate. Conclusion: The severity of SHPT and the use of dialysate with higher calcium concentration are associated with practical difficulty in managing mineral metabolism in dialysis patients. Further prospective followup is needed to confirm our findings and to examine their impact on patient level outcomes. Copyright (C) 2011 S. Karger AG, Basel
C1 [Fukagawa, Masafumi; Komaba, Hirotaka] Tokai Univ, Sch Med, Div Nephrol Endocrinol & Metab, Isehara, Kanagawa 2591193, Japan.
   [Onishi, Yoshihiro] Inst Hlth Outcomes & Proc Evaluat Res, Kyoto, Japan.
   [Onishi, Yoshihiro] Inst Hlth Outcomes & Proc Evaluat Res, Tokyo, Japan.
   [Fukuhara, Shunichi] Kyoto Univ, Sch Med, Dept Epidemiol & Healthcare Res, Kyoto, Japan.
   [Akizawa, Tadao] Showa Univ, Sch Med, Div Nephrol, Tokyo 142, Japan.
   [Kurokawa, Kiyoshi] Natl Grad Inst Policy Studies, Tokyo, Japan.
C3 Tokai University; Kyoto University; Showa University; National Graduate
   Institute for Policy Studies
RP Fukagawa, M (通讯作者)，Tokai Univ, Sch Med, Div Nephrol Endocrinol & Metab, 143 Shimo Kasuya, Isehara, Kanagawa 2591193, Japan.
EM fukagawa@tokai u.jp
RI Komaba, Hirotaka/C 9199 2011
OI Komaba, Hirotaka/0000 0002 1704 4507; Fukagawa,
   Masafumi/0000 0002 7832 2339
FU Kyowa Hakko Kirin
FX The MBD 5D is supported by research grants from Kyowa Hakko Kirin,
   without restrictions on publications. M.F. has acted as a consultant for
   Kyowa Hakko Kirin, has received honoraria from Kyowa Hakko Kirin, and
   has received grants/research support from Kyowa Hakko Kirin. H.K. has
   received honoraria from Kyowa Hakko Kirin. S.F. has acted as a
   scientific advisor for Kyowa Hakko Kirin, and has received
   grants/research support from Kyowa Hakko Kirin. T.A. has acted as a
   consultant for Kyowa Hakko Kirin, has received grants/research support
   from Kyowa Hakko Kirin, and is a member of speakers' bureau of Kyowa
   Hakko Kirin. K.K. and Y.O. have nothing to declare.
CR AMANN K, 1994, J AM SOC NEPHROL, V4, P1814
   Blayney MJ, 2008, KIDNEY INT, V74, P655, DOI 10.1038/ki.2008.248
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Cannata Andia JB, 2008, J NEPHROL, V21, P290
   Danese MD, 2006, AM J KIDNEY DIS, V47, P149, DOI 10.1053/j.ajkd.2005.09.024
   Drüeke TB, 2000, J AM SOC NEPHROL, V11, P1141, DOI 10.1681/ASN.V1161141
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Floege J., NEPHROL DIA IN PRESS
   Fukagawa M, 2006, KIDNEY INT, V70, pS3, DOI 10.1038/sj.ki.5001594
   FUKAGAWA M, 1994, NEPHRON, V68, P221, DOI 10.1159/000188261
   Fukagawa M, 2008, NEPHROL DIAL TRANSPL, V23, P328, DOI 10.1093/ndt/gfm534
   Fukagawa M, 2008, THER APHER DIAL, V12, P514, DOI 10.1111/j.1744 9987.2008.00648.x
   FUKUDA N, 1993, J CLIN INVEST, V92, P1436, DOI 10.1172/JCI116720
   Fukuhara S, 2011, THER APHER DIAL, V15, P169, DOI 10.1111/j.1744 9987.2010.00906.x
   Gogusev J, 1997, KIDNEY INT, V51, P328, DOI 10.1038/ki.1997.41
   Goodkin DA, 2003, J AM SOC NEPHROL, V14, P3270, DOI 10.1097/01.ASN.0000100127.54107.57
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   GOTO S, CLIN J AM S IN PRESS
   Hamano T, 2005, BONE, V36, P909, DOI 10.1016/j.bone.2005.02.008
   Jadoul M, 2006, KIDNEY INT, V70, P1358, DOI 10.1038/sj.ki.5001754
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Kestenbaum B, 2004, KIDNEY INT, V66, P2010, DOI 10.1111/j.1523 1755.2004.00972.x
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kifor O, 1996, J CLIN ENDOCR METAB, V81, P1598, DOI 10.1210/jc.81.4.1598
   Kimata Naoki, 2007, Hemodial Int, V11, P340, DOI 10.1111/j.1542 4758.2007.00190.x
   Komaba H, 2010, CLIN J AM SOC NEPHRO, V5, P2305, DOI 10.2215/CJN.02110310
   Miller JE, 2010, AM J NEPHROL, V32, P403, DOI 10.1159/000319861
   Nakai S, 2008, THER APHER DIAL, V12, P49, DOI 10.1111/j.1744 9987.2007.00540.x
   Okuno S, 2003, NEPHROL DIAL TRANSPL, V18, P2613, DOI 10.1093/ndt/gfg451
   Palmer SC, 2007, ANN INTERN MED, V147, P840, DOI 10.7326/0003 4819 147 12 200712180 00004
   PAYNE RB, 1973, BMJ BRIT MED J, V4, P643, DOI 10.1136/bmj.4.5893.643
   Raggi P, 2002, J AM COLL CARDIOL, V39, P695, DOI 10.1016/S0735 1097(01)01781 8
   Regidor DL, 2008, J AM SOC NEPHROL, V19, P2193, DOI 10.1681/ASN.2008010014
   Shantouf R, 2009, CLIN J AM SOC NEPHRO, V4, P1106, DOI 10.2215/CJN.06091108
   Shigematsu T, 2008, THER APHER DIAL, V12, P55, DOI 10.1111/j.1744 9987.2007.00541.x
   Shoji T, 2004, NEPHROL DIAL TRANSPL, V19, P179, DOI 10.1093/ndt/gfg513
   SMOGORZEWSKI M, 1993, AM J PHYSIOL, V264, pH1998, DOI 10.1152/ajpheart.1993.264.6.H1998
   Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Tominaga Y, 1997, SEMIN SURG ONCOL, V13, P87, DOI 10.1002/(SICI)1098 2388(199703/04)13:2<87::AID SSU4>3.0.CO;2 Y
   Tominaga Y, 2006, THER APHER DIAL, V10, P198, DOI 10.1111/j.1744 9987.2006.00364.x
   Urena P, 1996, J AM SOC NEPHROL, V7, P506
   Wolf M, 2007, KIDNEY INT, V72, P1004, DOI 10.1038/sj.ki.5002451
   Yokoyama K, 2004, AM J KIDNEY DIS, V44, P383, DOI 10.1053/j.ajkd.2004.05.038
NR 44
TC 28
Z9 30
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 0250 8095
EI 1421 9670
J9 AM J NEPHROL
JI Am. J. Nephrol.
PY 2011
VL 33
IS 5
BP 427
EP 437
DI 10.1159/000327654
PG 11
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 767FQ
UT WOS:000290841100007
PM 21508631
OA hybrid
DA 2025 08 17
ER

PT J
AU Liu, BL
   Ma, YF
   Liu, H
   Wang, C
   Guo, L
   Shi, AP
   Liu, M
AF Liu, Bailong
   Ma, Yunfei
   Liu, Hui
   Wang, Chong
   Guo, Liang
   Shi, Aiping
   Liu, Min
TI Unexpected massive bleeding caused by extensive maxillary osteonecrosis
   in a breast cancer patient: a case report
SO TRANSLATIONAL CANCER RESEARCH
LA English
DT Article
DE Massive bleeding; osteonecrosis; zoledronic acid (ZA); antiangiogenesis;
   case report
ID RISK FACTORS; JAW; BISPHOSPHONATES; BONE; ANGIOGENESIS; OUTCOMES;
   THERAPY
AB Diphosphonate application is routinely recommended to treat bone metastasis (BM) in cancer patients. However, the severe side effects of diphosphonate, especially after long term use, are often overlooked by clinicians. In this article, we describe a case in which a heavily treated breast cancer patient, suffered from massive bleeding as a result of maxillary osteonecrosis by zoledronic acid (ZA) and apatinib. In October 2018, a 48 year old Chinese female with breast cancer presented at our department with brain metastases. The patient had experienced progression multiple times and had received several lines of systemic interventions. ZA was administered monthly for a rather long period of 37 months. She also took 250 mg of apatinib, a small molecular tyrosine kinase inhibitor (TKI) that targets vascular endothelial growth factor receptor 2, daily for 11 days. However, massive bleeding from the oral and nasal cavity occurred that could not be alleviated by conventional means. Computed tomography revealed severe destruction and loss of the right maxillary bone and maxillary sinus wall. A pathological examination of the exfoliated bone tissue further confirmed that the patient was suffering from necrosis rather than metastasis. An emergency interventional embolization was performed, and the bleeding was stopped. In this case, maxillary osteonecrosis developed from the antiresorptive agents. Antiangiogenesis drugs should be avoided whenever possible. In clinical practice, the high risk of osteonecrosis needs to be carefully considered. Further, care needs to be taken to ensure osteonecrosis is not misdiagnosed as BM, especially in stage IV patients. Pathology is a prerequisite for the timely and correct diagnosis and management. Life threatening toxicity such as massive bleeding, should be avoided to ensure that patients receive adequate antitumor treatments.
C1 [Liu, Bailong; Ma, Yunfei; Liu, Hui; Liu, Min] First Hosp Jilin Univ, Dept Radiat Oncol, 1 Xinmin St, Changchun 130021, Peoples R China.
   [Wang, Chong] First Hosp Jilin Univ, Dept Hepatobiliary & Pancreat Med, Changchun, Peoples R China.
   [Guo, Liang] First Hosp Jilin Univ, Dept Pathol, Changchun, Peoples R China.
   [Shi, Aiping] First Hosp Jilin Univ, Dept Breast Surg, 1 Xinmin St, Changchun 130021, Peoples R China.
C3 Jilin University; Jilin University; Jilin University; Jilin University
RP Liu, M (通讯作者)，First Hosp Jilin Univ, Dept Radiat Oncol, 1 Xinmin St, Changchun 130021, Peoples R China.; Shi, AP (通讯作者)，First Hosp Jilin Univ, Dept Breast Surg, 1 Xinmin St, Changchun 130021, Peoples R China.
EM sap@jlu.edu.cn; lmin99@jlu.edu.cn
CR Allegra A, 2007, HEMATOL ONCOL, V25, P164, DOI 10.1002/hon.819
   Allegra A, 2019, NETH J MED, V77, P67
   Allegra A, 2019, TOHOKU J EXP MED, V248, P27, DOI 10.1620/tjem.248.27
   Allegra A, 2010, ACTA HAEMATOL BASEL, V124, P79, DOI 10.1159/000313787
   Altay MA, 2020, CRANIO, V38, P333, DOI 10.1080/08869634.2018.1528711
   Body JJ, 2017, CRIT REV ONCOL HEMAT, V115, P67, DOI 10.1016/j.critrevonc.2017.04.008
   Chang J, 2018, CURR OSTEOPOROS REP, V16, P584, DOI 10.1007/s11914 018 0474 4
   Christodoulou C, 2009, ONCOLOGY BASEL, V76, P209, DOI 10.1159/000201931
   Estilo CL, 2008, J CLIN ONCOL, V26, P4037, DOI 10.1200/JCO.2007.15.5424
   Forte L, 2017, ACTA BIOMATER, V54, P419, DOI 10.1016/j.actbio.2017.02.040
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Gravis G, 2013, LANCET ONCOL, V14, P149, DOI 10.1016/S1470 2045(12)70560 0
   Hasegawa T, 2019, OSTEOPOROSIS INT, V30, P231, DOI 10.1007/s00198 018 4746 8
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   Hortobagyi GN, 2017, JAMA ONCOL, V3, P906, DOI 10.1001/jamaoncol.2016.6316
   James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140 6736(15)01037 5
   Kagami H, 2018, ORAL DIS, V24, P52, DOI 10.1111/odi.12783
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kizub DA, 2021, SUPPORT CARE CANCER, V29, P2509, DOI 10.1007/s00520 020 05748 8
   Kuchuk M, 2013, J BONE ONCOL, V2, P22, DOI 10.1016/j.jbo.2012.12.004
   Kyrgidis A, 2008, J CLIN ONCOL, V26, P4634, DOI 10.1200/JCO.2008.16.2768
   Lescaille G, 2014, BONE, V58, P103, DOI 10.1016/j.bone.2013.10.002
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Motzer RJ, 2013, NEW ENGL J MED, V369, P722, DOI 10.1056/NEJMoa1303989
   Ngamphaiboon N, 2011, CLIN BREAST CANCER, V11, P252, DOI 10.1016/j.clbc.2011.02.001
   Oteri G, 2008, CYTOKINE, V43, P103, DOI 10.1016/j.cyto.2008.05.010
   Ouyang ZX, 2018, CURR DRUG TARGETS, V19, P409, DOI 10.2174/1573399811666150615145409
   Qi WX, 2019, FUTURE ONCOL, V15, P3503, DOI 10.2217/fon 2019 0352
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Santini D, 2007, CLIN CANCER RES, V13, P4482, DOI 10.1158/1078 0432.CCR 07 0551
   Steller D, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 43798 z
   Thumbigere Math V, 2012, AM J CLIN ONCOL CANC, V35, P386, DOI 10.1097/COC.0b013e3182155fcb
   Turpin A, 2020, TRANSL ONCOL, V13, P308, DOI 10.1016/j.tranon.2019.10.012
NR 34
TC 1
Z9 1
U1 0
U2 2
PU AME PUBL CO
PI SHATIN
PA FLAT RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2218 676X
EI 2219 6803
J9 TRANSL CANCER RES
JI Transl. Cancer Res.
PD NOV
PY 2021
VL 10
IS 11
BP 5014
EP 5021
DI 10.21037/tcr 21 404
EA AUG 2021
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA XJ1ZD
UT WOS:000708895000001
PM 35116353
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Feng, X
   Zhang, XW
   Chen, YT
   Li, LY
   Sun, Q
   Zhang, LT
AF Feng, Xue
   Zhang, Xiaowei
   Chen, Yuting
   Li, Luya
   Sun, Qian
   Zhang, Lantong
TI Identification of bilobetin metabolites, in vivo and in vitro, based on
   an efficient ultra high performance liquid chromatography coupled with
   quadrupole time of flight mass spectrometry strategy
SO JOURNAL OF SEPARATION SCIENCE
LA English
DT Article
DE bilobetin; liquid chromatography; mass spectrometry; metabolites;
   traditional Chinese medicine
ID BIFLAVONOIDS; AMENTOFLAVONE
AB Bilobetin, a natural compound extracted fromGinkgo biloba, has various pharmacological activities such as antioxidation, anticancer, antibacterial, antifungal, anti inflammatory, antiviral, and promoting osteoblast differentiation. However, few studies have been conducted and there are no reports on its metabolites owing to its low content in nature. In addition, it has been reported to have potential liver and kidney toxicity. Therefore, this study aimed to identify the metabolites of bilobetin in vitro and in vivo. Bilobetin was incubated with liver microsomes to determine metabolites in vitro, and faeces and urine were collected after oral administration to rats to determine metabolites in vivo. After the samples were processed, they were measured using ultra high performance liquid chromatography coupled with quadrupole time of flight mass spectrometry. As a result, a total of 21 and 9 metabolites were detected in vivo and in vitro, respectively. Demethylation, demethylation and loss of water, demethylation and hydrogenation, demethylation and glycine conjugation, oxidation, methylation, oxidation and methylation, and hydrogenation were the main metabolic pathways. This study is the first to identify the metabolites of bilobetin and provides a theoretical foundation for the safe use of bilobetin in clinical application and the development of new drugs.
C1 [Feng, Xue; Chen, Yuting; Li, Luya; Sun, Qian; Zhang, Lantong] Hebei Med Univ, Sch Pharm, Dept Pharmaceut Anal, 361 Zhongshan Rd, Shijiazhuang 050017, Hebei, Peoples R China.
   [Zhang, Xiaowei] Hebei Med Univ, Hosp 2, Shijiazhuang 050000, Hebei, Peoples R China.
C3 Hebei Medical University; Hebei Medical University
RP Zhang, LT (通讯作者)，Hebei Med Univ, Sch Pharm, Dept Pharmaceut Anal, 361 Zhongshan Rd, Shijiazhuang 050017, Hebei, Peoples R China.
EM zhanglantong@263.net
RI Gu, Yucheng/GPX 1847 2022
FU National Natural Science Foundation of China [81473180]
FX National Natural Science Foundation of China, Grant/Award Number:
   81473180
CR 이송정, 2016, [Asian Journal of Beauty and Cosmetology, 아시안뷰티화장품학술지], V14, P66, DOI 10.20402/ajbc.2016.0027
   Chen DQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09329 0
   Chen TR, 2019, BIOORG CHEM, V92, DOI 10.1016/j.bioorg.2019.103199
   Chen YT, 2019, J PHARMACEUT BIOMED, V169, P19, DOI 10.1016/j.jpba.2019.02.034
   Chu C, 2020, J SEP SCI, V43, P2869, DOI 10.1002/jssc.201901226
   Coulerie P, 2013, PLANTA MED, V79, P1313, DOI 10.1055/s 0033 1350672
   Freitas AM, 2009, J ETHNOPHARMACOL, V126, P512, DOI 10.1016/j.jep.2009.09.005
   Guruvayoorappan C, 2008, BIOCHEMISTRY MOSCOW+, V73, P209, DOI 10.1134/S0006297908020132
   Hwang IS, 2012, MYCOPATHOLOGIA, V173, P207, DOI 10.1007/s11046 011 9503 x
   Jia MM, 2020, J SEP SCI, V43, P2539, DOI 10.1002/jssc.201900878
   Kang SS, 2005, BIOORG MED CHEM LETT, V15, P3588, DOI 10.1016/j.bmcl.2005.05.078
   Ke H, 2019, J SEP SCI, V42, P1842, DOI 10.1002/jssc.201801161
   Kim NS, 2020, J SEP SCI, V43, P2750, DOI 10.1002/jssc.201901204
   Kou XH, 2012, BRIT J PHARMACOL, V165, P2692, DOI 10.1111/j.1476 5381.2011.01727.x
   Krauze Baranowska M, 2003, Z NATURFORSCH C, V58, P65
   Lee MK, 2006, BIOORG MED CHEM LETT, V16, P2850, DOI 10.1016/j.binct.2006.03.018
   Li LY, 2019, RSC ADV, V9, P24963, DOI 10.1039/c9ra03037a
   Li LY, 2019, MOLECULES, V24, DOI 10.3390/molecules24142658
   Li M, 2019, PHYTOTHER RES, V33, P989, DOI [10.1002/ptr.6292, 10.1109/icems.2019.8922446]
   Li YY, 2019, CHIN J NAT MEDICINES, V17, P672, DOI 10.1016/S1875 5364(19)30081 0
   Liao M, 2018, RSC ADV, V8, P14925, DOI 10.1039/c8ra01221k
   Su CF, 2019, MOLECULES, V24, DOI 10.3390/molecules24112184
   van Beek TA, 2009, J CHROMATOGR A, V1216, P2002, DOI 10.1016/j.chroma.2009.01.013
   Vanzyl EJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191178
   Wang C, 2019, ANN DERMATOL, V31, P294, DOI 10.5021/ad.2019.31.3.294
   Wang G, 2015, INT J ANAL CHEM, V2015, DOI 10.1155/2015/849769
   Wang JY, 2020, J SEP SCI, V43, P378, DOI 10.1002/jssc.201900860
   Wang Q, 2019, PHYTOMEDICINE, V64, DOI 10.1016/j.phymed.2019.153073
   Wang ZH, 2018, NEUROSCI LETT, V686, P1, DOI 10.1016/j.neulet.2018.08.032
   Woldemichael GM, 2003, Z NATURFORSCH C, V58, P70
   Yoon SO, 2006, MOL CANCER THER, V5, P2666, DOI 10.1158/1535 7163.MCT 06 0321
   Zhang X, 2018, RAPID COMMUN MASS SP, V32, P1451, DOI 10.1002/rcm.8161
   Zhang X, 2017, J CHROMATOGR B, V1061, P193, DOI 10.1016/j.jchromb.2017.07.003
   Zhang Z, 2015, NEURAL REGEN RES, V10, P1125, DOI 10.4103/1673 5374.160109
   Zhao YY, 2014, CHEM BIOL INTERACT, V220, P181, DOI 10.1016/j.cbi.2014.06.029
   Zhao YY, 2014, CLIN BIOCHEM, V47, P16, DOI 10.1016/j.clinbiochem.2014.07.019
   Zhao YY, 2014, CHEM BIOL INTERACT, V215, P7, DOI 10.1016/j.cbi.2014.02.014
   Zhao YY, 2012, BIOANALYSIS, V4, P713, DOI [10.4155/BIO.12.24, 10.4155/bio.12.24]
NR 38
TC 7
Z9 8
U1 3
U2 21
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1615 9306
EI 1615 9314
J9 J SEP SCI
JI J. Sep. Sci.
PD SEP
PY 2020
VL 43
IS 17
BP 3408
EP 3420
DI 10.1002/jssc.202000313
EA JUL 2020
PG 13
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA NI8WU
UT WOS:000546103000001
PM 32573953
DA 2025 08 17
ER

PT J
AU Kim, EY
   Kim, JH
   Kim, M
   Park, JH
   Sohn, Y
   Jung, HS
AF Kim, Eun Young
   Kim, Jae Hyun
   Kim, Minsun
   Park, Jae Ho
   Sohn, Youngjoo
   Jung, Hyuk Sang
TI Abeliophyllum distichum Nakai alleviates postmenopausal
   osteoporosis in ovariectomized rats and prevents RANKL induced
   osteoclastogenesis in vitro
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Abeliophyllum distichum Nakai; RANKL; Ovariectomized rat; c fos; NFATc 1
ID NF KAPPA B; CARBONIC ANHYDRASE II; BONE RESORPTION; RECEPTOR ACTIVATOR;
   CATHEPSIN K; C FOS; ATTENUATES OSTEOCLASTOGENESIS; MINERAL DENSITY;
   DIFFERENTIATION; PATHWAYS
AB Ethnopharmacological relevance: Abeliophyllum distichum Nakai (AD), called Miseon, is one of Korea's monotypic endemic species. As a folk remedy, the AD has been used to treat inflammatory disease, stomachaches, diarrhea, and gynecologic disease in Korea. Some researchers have reported that the AD has anti cancer, anti inflammatory, and anti oxidant effects. But the protective effect of AD leaf for osteoporosis has not been reported yet.
   Aim of the study: This study aimed to analyze the effects and mechanism of AD ethyl acetate fraction (EA) extract on the osteoporosis, one of the gynecologic disease.
   Materials and methods: The RAW 264.7 cells were used as a model for RANKL induced osteoclastogenesis. We measured the TRAcP activity, expressions of NFATc1, c fos, and MAPK to investigate the effect of AD EA. OVX induced osteoporosis rat model was used as menopausal osteoporosis. After both ovaries were removed through a surgical procedure, and AD EA or 17b estradiol was orally administered for 8 weeks. BMD of femurs was measured as well as the bone morphometric parameter, such as BV/TV, trabecular thickness, number and surface using a micro CT.
   Results: AD EA significantly inhibited TRAcP activity, actin ring formation, pit formation and the expressions of osteoclast related genes in a dose dependent manner through the inhibition of the MAPK and c fos/NFATc1 pathway. In addition, low dose administration of AD EA improved the deterioration of trabecular bone microarchitecture caused by OVX through the inhibition of bone resorption by TRAcP and CTK.
   Conclusions: These results suggest that AD EA may contribute to the therapy of osteoporosis caused by menopause in women.
C1 [Kim, Eun Young; Kim, Jae Hyun; Kim, Minsun; Sohn, Youngjoo; Jung, Hyuk Sang] Kyung Hee Univ, Coll Korean Med, Dept Anat, 26 Kyunghee Dae Ro, Seoul 02447, South Korea.
   [Park, Jae Ho] Jungwon Univ, Dept Pharmaceut Sci, 85 Munmu Ro, Goesan Gun 28024, Chungbuk, South Korea.
C3 Kyung Hee University; Jungwon University
RP Jung, HS (通讯作者)，Kyung Hee Univ, Coll Korean Med, Dept Anat, 26 Kyunghee Dae Ro, Seoul 02447, South Korea.
EM turns@hanmail.net; wogusdlwl222@hanmail.net; alstjs8644@naver.com;
   parkjh@jwu.ac.kr; youngjoos@khu.ac.kr; jhs@khu.ac.kr
RI ; KIM, YOUNG JIN/E 9374 2011
OI Kim, Eun young/0000 0002 4671 8400; 
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education [2017R1D1A1B03028505]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education (2017R1D1A1B03028505).
CR Abe K, 2012, INT J MOL MED, V29, P1007, DOI 10.3892/ijmm.2012.952
   Ang E, 2011, J CELL BIOCHEM, V112, P89, DOI 10.1002/jcb.22800
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   [Anonymous], 2005, Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers Pharmacology and Toxicology Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers
   [Anonymous], [No title captured]
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bloemen V, 2010, J CELL PHYSIOL, V222, P565, DOI 10.1002/jcp.21971
   Cheng Y, 2014, NATURE, V515, P371, DOI 10.1038/nature13985
   Duong Le T, 2012, Bonekey Rep, V1, P67, DOI 10.1038/bonekey.2012.67
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Estai MA, 2011, IRAN J MED SCI, V36, P281
   Fujisaki K, 2007, LIFE SCI, V80, P1311, DOI 10.1016/j.lfs.2006.12.037
   Ginaldi Lia, 2005, Immun Ageing, V2, P14, DOI 10.1186/1742 4933 2 14
   Giro G, 2008, ORAL SURG ORAL MED O, V105, P162, DOI 10.1016/j.tripleo.2007.06.010
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Halleen JM, 1999, J BIOL CHEM, V274, P22907, DOI 10.1074/jbc.274.33.22907
   Hansen M A, 1991, Osteoporos Int, V1, P95
   Huh JE, 2014, J NAT PROD, V77, P2423, DOI 10.1021/np500417d
   Hun Park Gwang, 2014, [Korean Journal of Plant Reources., 한국자원식물학회지], V27, P209, DOI 10.7732/kjpr.2014.27.3.209
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Ishikawa T, 2001, MOL CARCINOGEN, V32, P84, DOI 10.1002/mc.1067
   Jee W. S. S., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P193
   Kajita T, 2018, J CELL BIOCHEM, V119, P6974, DOI 10.1002/jcb.26906
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Kang U, 2000, J PLANT RES, V113, P127, DOI 10.1007/PL00013923
   KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200
   Kim GS, 2005, J BONE MINER RES, V20, P1342, DOI 10.1359/JBMR.050320
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kim KA, 2013, FOOD SCI BIOTECHNOL, V22, P845, DOI 10.1007/s10068 013 0154 1
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Kum CJ, 2017, J ETHNOPHARMACOL, V205, P186, DOI 10.1016/j.jep.2017.03.017
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080873
   Lehenkari P, 1998, EXP CELL RES, V242, P128, DOI 10.1006/excr.1998.4071
   Lelovas PP, 2008, COMPARATIVE MED, V58, P424
   Li Y, 2013, J IMMUNOL, V191, P3192, DOI 10.4049/jimmunol.1300742
   Mada SB, 2017, NUTRITION, V43 44, P21, DOI 10.1016/j.nut.2017.06.010
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Nakashima D, 2019, EUR RADIOL EXP, V3, DOI 10.1186/s41747 018 0080 3
   Oh H, 2003, PHYTOTHER RES, V17, P811, DOI 10.1002/ptr.1199
   Panay Nick, 2013, Menopause Int, V19, P59, DOI 10.1177/1754045313489645
   장태원, 2018, [Korean Journal of Plant Reources., 한국자원식물학회지], V31, P228, DOI 10.7732/kjpr.2018.31.3.228
   Park Jonghoon, 2014, J Exerc Nutrition Biochem, V18, P333, DOI 10.5717/jenb.2014.18.4.333
   Park SB, 2010, J KOREAN NEUROSURG S, V48, P309, DOI 10.3340/jkns.2010.48.4.309
   Qian Y, 2010, J ORAL PATHOL MED, V39, P592, DOI 10.1111/j.1600 0714.2009.00882.x
   Seeman E, 2003, OSTEOPOROSIS INT, V14, pS2, DOI 10.1007/s00198 002 1340 9
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Yamada H, 2016, BONE, V86, P43, DOI 10.1016/j.bone.2016.02.014
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
NR 53
TC 13
Z9 13
U1 0
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUL 15
PY 2020
VL 257
AR 112828
DI 10.1016/j.jep.2020.112828
PG 13
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA LV0TI
UT WOS:000538156200008
PM 32268206
DA 2025 08 17
ER

PT J
AU Gorvin, CM
   Hannan, FM
   Cranston, T
   Valta, H
   Makitie, O
   Schalin Jantti, C
   Thakker, RV
AF Gorvin, Caroline M.
   Hannan, Fadil M.
   Cranston, Treena
   Valta, Helena
   Makitie, Outi
   Schalin Jantti, Camilla
   Thakker, Rajesh V.
TI Cinacalcet Rectifies Hypercalcemia in a Patient With Familial
   Hypocalciuric Hypercalcemia Type 2 (FHH2) Caused by a Germline
   Loss of Function G11 Mutation
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE PARATHYROID RELATED DISORDERS; DISORDERS OF CALCIUM; PHOSPHATE
   METABOLISM; THERAPEUTICS; CELL; TISSUE SIGNALING; ENDOCRINE PATHWAYS
ID CALCIUM SENSING RECEPTOR; G PROTEINS; PHOSPHOLIPASE C; ACTIVATION;
   DISORDERS; KINASE
AB G protein subunit  11 (G(11)) couples the calcium sensing receptor (CaSR) to phospholipase C (PLC) mediated intracellular calcium (Ca i(2+)) and mitogen activated protein kinase (MAPK) signaling, which in the parathyroid glands and kidneys regulates parathyroid hormone release and urinary calcium excretion, respectively. Heterozygous germline loss of function G(11) mutations cause familial hypocalciuric hypercalcemia type 2 (FHH2), for which effective therapies are currently not available. Here, we report a novel heterozygous G(11) germline mutation, Phe220Ser, which was associated with hypercalcemia in a family with FHH2. Homology modeling showed the wild type (WT) Phe220 nonpolar residue to form part of a cluster of hydrophobic residues within a highly conserved cleft region of G(11), which binds to and activates PLC; and predicted that substitution of Phe220 with the mutant Ser220 polar hydrophilic residue would disrupt PLC mediated signaling. In vitro studies involving transient transfection of WT and mutant G(11) proteins into HEK293 cells, which express the CaSR, showed the mutant Ser220 G(11) protein to impair CaSR mediated Ca i(2+) and extracellular signal regulated kinase 1/2 (ERK) MAPK signaling, consistent with diminished activation of PLC. Furthermore, engineered mutagenesis studies demonstrated that loss of hydrophobicity within the G(11) cleft region also impaired signaling by PLC. The loss of function associated with the Ser220 G(11) mutant was rectified by treatment of cells with cinacalcet, which is a CaSR positive allosteric modulator. Furthermore, in vivo administration of cinacalcet to the proband harboring the Phe220Ser G(11) mutation, normalized serum ionized calcium concentrations. Thus, our studies, which report a novel G(11) germline mutation (Phe220Ser) in a family with FHH2, reveal the importance of the G(11) hydrophobic cleft region for CaSR mediated activation of PLC, and show that allosteric CaSR modulation can rectify the loss of function Phe220Ser mutation and ameliorate the hypercalcemia associated with FHH2. (c) 2017 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
C1 [Gorvin, Caroline M.; Hannan, Fadil M.; Thakker, Rajesh V.] Univ Oxford, OCDEM, Radcliffe Dept Med, Acad Endocrine Unit, Oxford, England.
   [Hannan, Fadil M.] Univ Liverpool, Inst Ageing & Chron Dis, Dept Musculoskeletal Biol, Liverpool, Merseyside, England.
   [Cranston, Treena] Churchill Hosp, Oxford Mol Genet Lab, Oxford, England.
   [Valta, Helena; Makitie, Outi] Univ Helsinki, Childrens Hosp, Helsinki, Finland.
   [Makitie, Outi] Folkhalsan Res Ctr, Helsinki, Finland.
   [Schalin Jantti, Camilla] Univ Helsinki, Abdominal Ctr, Div Endocrinol, Helsinki, Finland.
   [Schalin Jantti, Camilla] Helsinki Univ Hosp, Helsinki, Finland.
C3 University of Oxford; University of Liverpool; University of Oxford;
   University of Helsinki; Folkhalsan Research Center; University of
   Helsinki; University of Helsinki; Helsinki University Central Hospital
RP Thakker, RV (通讯作者)，OCDEM, Acad Endocrine Unit, Oxford OX3 7LJ, England.
EM rajesh.thakker@ndm.ox.ac.uk
RI ; Pedersen, Ole/F 2476 2011; Gorvin, Caroline/T 2406 2019
OI Hannan, Fadil/0000 0002 2975 5170; Makitie, Outi/0000 0002 4547 001X;
   Gorvin, Caroline/0000 0002 1361 9174; Schalin Jantti,
   Camilla/0000 0002 2428 0161
FU Academy of Finland; Sigrid Juselius Foundation; Folkhalsan Research
   Foundation; Finska Lakaresallskapet; Helsinki University Hospital
   Research Funds; Wellcome Trust; National Institute for Health Research
   (NIHR) Oxford Biomedical Research Centre Program; NIHR Senior
   Investigator Award; MRC [G1000467, MR/P020941/1] Funding Source: UKRI;
   Medical Research Council [G1000467, MR/P020941/1] Funding Source:
   researchfish; National Institute for Health Research [NF SI 0514 10091]
   Funding Source: researchfish; Novo Nordisk Fonden [NNF16OC0021322,
   NNF17OC0027226] Funding Source: researchfish; Wellcome Trust
   [106995/Z/15/Z] Funding Source: researchfish
FX This work was supported by the Academy of Finland, Sigrid Juselius
   Foundation, and Folkhalsan Research Foundation (to OM); Finska
   Lakaresallskapet and Helsinki University Hospital Research Funds (to
   CS J); a Wellcome Trust Senior Investigator Award (to RVT); National
   Institute for Health Research (NIHR) Oxford Biomedical Research Centre
   Program (to RVT); and NIHR Senior Investigator Award (to RVT).
CR Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76
   Babinsky VN, 2016, J BIOL CHEM, V291, P10876, DOI 10.1074/jbc.M115.696401
   Bai M, 1998, J BIOL CHEM, V273, P21267, DOI 10.1074/jbc.273.33.21267
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   BROWN E, 1987, FEBS LETT, V218, P113, DOI 10.1016/0014 5793(87)81029 3
   Chakravarti B, 2012, ADV EXP MED BIOL, V740, P103, DOI 10.1007/978 94 007 2888 2_5
   Chang WH, 2000, J BIOL CHEM, V275, P19955, DOI 10.1074/jbc.M909613199
   Festen Spanjer B, 2008, CLIN ENDOCRINOL, V68, P324, DOI 10.1111/j.1365 2265.2007.03027.x
   Gorvin CM, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91103
   Gorvin CM, 2016, J BONE MINER RES, V31, P1200, DOI 10.1002/jbmr.2778
   Hannan FM, 2016, J MOL ENDOCRINOL, V57, pR127, DOI 10.1530/JME 16 0124
   Hannan FM, 2015, HUM MOL GENET, V24, P5079, DOI 10.1093/hmg/ddv226
   Hannan FM, 2013, BEST PRACT RES CL EN, V27, P359, DOI 10.1016/j.beem.2013.04.007
   Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154
   Holstein DM, 2004, J BIOL CHEM, V279, P10060, DOI 10.1074/jbc.M312039200
   Howles SA, 2016, NEW ENGL J MED, V374, P1396, DOI 10.1056/NEJMc1511646
   Johnston CA, 2007, MOL PHARMACOL, V72, P219, DOI 10.1124/mol.107.034348
   Kifor O, 1997, J BONE MINER RES, V12, P715, DOI 10.1359/jbmr.1997.12.5.715
   Kifor O, 2001, AM J PHYSIOL RENAL, V280, pF291, DOI 10.1152/ajprenal.2001.280.2.F291
   Leach K, 2014, BRIT J PHARMACOL, V171, P1142, DOI 10.1111/bph.12420
   Leach K, 2016, CELL RES, V26, P574, DOI 10.1038/cr.2016.36
   Lyon AM, 2014, STRUCTURE, V22, P1844, DOI 10.1016/j.str.2014.10.008
   Masuho I, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab4068
   Nance MR, 2013, STRUCTURE, V21, P438, DOI 10.1016/j.str.2012.12.016
   Nesbit MA, 2013, NEW ENGL J MED, V368, P2476, DOI 10.1056/NEJMoa1300253
   Nesbit MA, 2013, NAT GENET, V45, P93, DOI 10.1038/ng.2492
   Newey PJ, 2013, NEW ENGL J MED, V369, P2012, DOI 10.1056/NEJMoa1307557
   Nishimura A, 2010, P NATL ACAD SCI USA, V107, P13666, DOI 10.1073/pnas.1003553107
   Oldham WM, 2008, NAT REV MOL CELL BIO, V9, P60, DOI 10.1038/nrm2299
   Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890
   Shi GX, 2007, J EXP MED, V204, P2705, DOI 10.1084/jem.20071267
   SHOBACK DM, 1988, ENDOCRINOLOGY, V123, P382, DOI 10.1210/endo 123 1 382
   Tenhola S, 2015, J CLIN ENDOCR METAB, V100, P2515, DOI 10.1210/jc.2015 1518
   Tesmer VM, 2005, SCIENCE, V310, P1686, DOI 10.1126/science.1118890
   Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584
   Waldo GL, 2010, SCIENCE, V330, P974, DOI 10.1126/science.1193438
   WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092 8674(95)90220 1
   Wettschureck N, 2005, PHYSIOL REV, V85, P1159, DOI 10.1152/physrev.00003.2005
   WU DQ, 1992, J BIOL CHEM, V267, P1811
NR 39
TC 36
Z9 38
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2018
VL 33
IS 1
BP 32
EP 41
DI 10.1002/jbmr.3241
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FS9FX
UT WOS:000422723400007
PM 28833550
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Mao, DL
   Epple, H
   Uthgenannt, B
   Novack, DV
   Faccio, R
AF Mao, Dailing
   Epple, Holly
   Uthgenannt, Brian
   Novack, Deborah V.
   Faccio, Roberta
TI PLCγ2 regulates osteoclastogenesis via its interaction with ITAM
   proteins and GAB2
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID NF KAPPA B; NECROSIS FACTOR ALPHA; PHOSPHOLIPASE C GAMMA 2;
   RHEUMATOID ARTHRITIS; TYROSINE KINASE; NUCLEAR FACTOR; BLOCKS
   OSTEOCLASTOGENESIS; INFLAMMATORY ARTHRITIS; RECEPTOR ACTIVATOR; ADAPTER
   PROTEINS
AB Excessive bone loss in arthritic diseases is mostly due to abnormal activation of the immune system leading to stimulation of osteoclasts. While phospholipase C gamma (PLC gamma) isoforms are known modulators of T and B lymphocyte mediated immune responses, we found that blockade of PLC gamma enzymatic activity also blocks early osteoclast development and function. Importantly, targeted deletion of Plcg2 in mice led to an osteopetrotic phenotype. PLC gamma 2, independent of PLC gamma 1, was required for receptor activator of NF kappa B ligand induced (RANKL induced) osteoclastogenesis by differentially regulating nuclear factor of activated T cells cl (NFATcl), activator protein 1 (AP1), and NF kappa B. Specifically, we show that NFATcl upregulation is dependent on RANKL mediated phosphorylation of PLC gamma 2 downstream of Dap12/Fc receptor gamma (Dap12/FcR gamma) receptors and is blocked by the PLC gamma inhibitor U73122. In contrast, activation of JNK and NF kappa B was not affected by U73122 or Dap12/FcR gamma deletion. Interestingly, we found that in osteoclasts, PLC gamma 2 formed a complex with the regulatory adapter molecule GAB2, was required for GAB2 phosphorylation, and modulated GAB2 recruitment to RANK. Thus, PLC gamma 2 mediates RANKL induced osteoclastogenesis and is a potential candidate for antiresorptive therapy.
C1 Washington Univ, Sch Med, Dept Orthopaed Surg & Cell Biol, St Louis, MO 63110 USA.
   Washington Univ, Sch Med, Dept Med & Cell Biol, St Louis, MO 63110 USA.
   Washington Univ, Sch Med, Dept Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL)
RP Faccio, R (通讯作者)，Washington Univ, Sch Med, Dept Orthopaed Surg, Campus Box 8233,1 Barnes Jewish Hosp Pl,Suite 113, St Louis, MO 63110 USA.
EM faccior@wustl.edu
OI Novack, Deborah/0000 0001 7101 5582
FU NIAMS NIH HHS [AR52921, P30 AR048335, K08 AR047846, AR47846, AR48335]
   Funding Source: Medline
CR Antony P, 2004, BIOCHEM SOC T, V32, P113, DOI 10.1042/BST0320113
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   BLAKE RA, 1994, FEBS LETT, V342, P15, DOI 10.1016/0014 5793(94)80575 X
   BLEASDALE JE, 1989, ADV PROSTAG THROMB L, V19, P590
   Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200
   DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082
   Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924
   Faccio R, 2003, J CELL BIOCHEM, V90, P871, DOI 10.1002/jcb.10694
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Genovese MC, 2005, JCR J CLIN RHEUMATOL, V11, pS45, DOI 10.1097/01.rhu.0000166625.65114.5f
   Goldring SR, 2000, ARTHRITIS RES, V2, P33, DOI 10.1186/ar67
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hashimoto A, 2000, J IMMUNOL, V165, P1738, DOI 10.4049/jimmunol.165.4.1738
   Humphrey MB, 2004, J BONE MINER RES, V19, P224, DOI 10.1359/JBMR.0301234
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Kaifu T, 2003, J CLIN INVEST, V111, P323, DOI 10.1172/JCI200316923
   Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780
   Katan M, 1998, BBA MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005 2760(98)00125 8
   Katan Matilda, 2005, Biochem J, V391, pe7
   Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Mócsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101
   O'Gradaigh D, 2004, ANN RHEUM DIS, V63, P354, DOI 10.1136/ard.2003.008458
   Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Sada K, 2003, CURR MOL MED, V3, P85, DOI 10.2174/1566524033361618
   SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554
   Takasu Junichiro, 2002, BMC Blood Disord, V2, P3, DOI 10.1186/1471 2326 2 3
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Tamir I, 1998, ONCOGENE, V17, P1353, DOI 10.1038/sj.onc.1202187
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Tassi I, 2005, J IMMUNOL, V175, P749, DOI 10.4049/jimmunol.175.2.749
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Wada T, 2005, NAT MED, V11, P394, DOI 10.1038/nm1203
   Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074 7613(00)00005 4
   Wei DG, 2002, J NANOPART RES, V4, P21, DOI 10.1023/A:1020184524538
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Wiebe S H, 1996, Oral Dis, V2, P167
   Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898 6568(01)00191 7
   Xie ZH, 2002, J IMMUNOL, V168, P4682, DOI 10.4049/jimmunol.168.9.4682
   Yu P, 2005, IMMUNITY, V22, P451, DOI 10.1016/j.immuni.2005.01.018
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 49
TC 175
Z9 198
U1 0
U2 5
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD NOV
PY 2006
VL 116
IS 11
BP 2869
EP 2879
DI 10.1172/JCI28775
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 102KW
UT WOS:000241810900011
PM 17053833
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Guo, YQ
   Huang, CX
   Li, GW
   Chen, T
   Li, JX
   Huang, ZW
AF Guo, Yuanqing
   Huang, Chuangxin
   Li, Guowei
   Chen, Tao
   Li, Jinxiang
   Huang, Zongwen
TI Paxilitaxel induces apoptosis accompanied by protective autophagy in
   osteosarcoma cells through hypoxia inducible factor 1α pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE paxilitaxel; autophagy; hypoxia inducible factor 1 alpha; osteosarcoma
ID CANCER CELLS; DRUG RESISTANCE; BETA ELEMENE; INDUCTION; PACLITAXEL;
   BREAST; CHEMORESISTANCE; ACTIVATION; DEATH; MODEL
AB Paxilitaxel, a drug used in cancer chemoprevention and treatment, has shown promising anti cancer effects against a broad spectrum of tumors. However, the effect of paxilitaxel on osteoblasts has remained to be elucidated. The aim of the present study was to investigate the anti tumor effect of paxilitaxel on human osteosarcoma cancer cells, the underlying molecular mechanism as well as drug resistance involved. The results showed that paxilitaxel not only induced apoptosis via the mitochondrial pathway but also induced autophagy, which partially inhibited cell apoptosis. The present study also demonstrated that paxilitaxel induced autophagy through the hypoxia inducible factor (HIF) 1 alpha pathway. Moreover, paxilitaxel induced apoptosis decreased following incubation with with the autophagy inducer rapamycin. By contrast, co treatment with the HIF 1 alpha inhibitor YC 1 or autophagy inhibitor 3 methyladenine significantly blocked autophagy and augmented the anti tumor effects of paxilitaxel. Therefore, the results of the present study suggested that the combination of paxilitaxel with an autophagy inhibitor or a HIF 1 alpha inhibitor may be an effective and potent strategy for improved chemotherapy of osteosarcoma in the future.
C1 [Guo, Yuanqing; Huang, Chuangxin; Li, Guowei; Chen, Tao; Li, Jinxiang; Huang, Zongwen] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Orthoped, Zhuhai 519000, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Huang, ZW (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 5, Dept Orthoped, 52 Meihua East Rd, Zhuhai 519000, Guangdong, Peoples R China.
EM zongwen2014_3@163.com
RI ; Li, Guo Wei/NLO 4674 2025
OI Tao, Chen/0000 0001 9527 1142; 
CR Adesida AB, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2267
   Ait Mohamed O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024537
   Amarnath S, 2010, AUTOPHAGY, V6, P523, DOI 10.4161/auto.6.4.11811
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166 09
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood 2006 10 050260
   Dank M, 2014, ANTICANCER RES, V34, P1275
   Daw NC, 2011, CANCER AM CANCER SOC, V117, P2770, DOI 10.1002/cncr.25715
   DeRegis CJ, 2003, J VET INTERN MED, V17, P668, DOI 10.1892/0891 6640(2003)017<0668:CADTID>2.3.CO;2
   Deretic V, 2009, CURR TOP MICROBIOL, V335, P169, DOI 10.1007/978 3 642 00302 8_8
   Doublier S, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 4
   Generali D, 2009, J CLIN ONCOL, V27, P227, DOI 10.1200/JCO.2007.13.7083
   Granell S, 2008, AUTOPHAGY, V4, P375, DOI 10.4161/auto.5605
   Guo BL, 2012, MOL CELL BIOCHEM, V361, P209, DOI 10.1007/s11010 011 1105 x
   Hofius D, 2011, CELL DEATH DIFFER, V18, P1257, DOI 10.1038/cdd.2011.43
   Liu LY, 2011, AUTOPHAGY, V7, P112, DOI 10.4161/auto.7.1.14005
   Lu HH, 2010, AUTOPHAGY, V6, P725, DOI 10.4161/auto.6.6.12423
   Mani J, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1239 4
   Markiewicz Katarzyna, 2011, Med Wieku Rozwoj, V15, P25
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   Monti Elena, 2011, Curr Mol Pharmacol, V4, P62
   Moore Maxwell CA, 2004, MODERN PATHOL, V17, P241, DOI 10.1038/modpathol.3800049
   Nakamura O, 2011, INT J ONCOL, V39, P1545, DOI 10.3892/ijo.2011.1148
   Orvedahl A, 2011, NATURE, V480, P113, DOI 10.1038/nature10546
   Rasul A, 2011, ASIAN PAC J CANCER P, V12, P2499
   Von Hoff DD, 2014, NEW ENGL J MED, V370, P479, DOI 10.1056/NEJMc1314761
   Wang G, 2005, CELL MOL LIFE SCI, V62, P881, DOI 10.1007/s00018 005 5017 3
   WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003 2697(84)90782 6
   Yao YQ, 2008, CANCER LETT, V264, P127, DOI 10.1016/j.canlet.2008.01.049
   Yoneyama K, 2014, J NIPPON MED SCH, V81, P28, DOI 10.1272/jnms.81.28
   Zeng YJ, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0030312, 10.1371/journal.pone.0043478]
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zhang T, 2012, AUTOPHAGY, V8, P559, DOI 10.4161/auto.18867
   Zhao Y, 2012, J CELL PHYSIOL, V227, P639, DOI 10.1002/jcp.22768
NR 33
TC 21
Z9 23
U1 1
U2 25
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD SEP
PY 2015
VL 12
IS 3
BP 3681
EP 3687
DI 10.3892/mmr.2015.3860
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA CP5OW
UT WOS:000359933900065
PM 26017247
OA Bronze
DA 2025 08 17
ER

PT J
AU Kucherenko, YV
   Lang, F
AF Kucherenko, Yuliya V.
   Lang, Florian
TI Niflumic Acid Affects Store Operated Ca<SUP>2+</SUP> Permeable (SOC) and
   Ca<SUP>2+</SUP> Dependent K<SUP>+</SUP> and Cl<SUP> </SUP> Ion Channels
   and Induces Apoptosis in K562 Cells
SO JOURNAL OF MEMBRANE BIOLOGY
LA English
DT Article
DE K562 cells; Niflumic acid; Apoptosis; CAC; SK4; SOC channels
ID FENAMATE ANALOGS; SKELETAL MUSCLE; CA2+ RELEASE; CALCIUM; INHIBITION;
   PROLIFERATION; CYCLOOXYGENASE 2; ACTIVATION; EXPRESSION; MECHANISM
AB Non steroidal anti inflammatory drugs (NSAIDs) are known to induce apoptosis in a variety of cancer cells. However, the precise mechanisms by which NSAIDs facilitate apoptosis in tumor cells are not clear. In the present study, we show that niflumic acid (NA), a member of the fenamates group of NSAIDs and Cl  and Ca2+ activated Cl  (CAC) channels blocker, induced apoptosis (by similar to 8 %, 24 h treatment) and potentiated (by 8 10 %) apoptotic effect of endoplasmic reticulum Ca2+ mobilizer thapsigargin (Tg) in human erythroleukemic K562 cell line. The whole cell patch clamp and Fluo 3 flow cytometric experiments confirmed an inhibitory effect of NA (100 and 300 A mu M) on store operated (SOC) channels. We also found that NA blocked CAC channels were activated by acute application of Tg (2 A mu M) in K562 cells. NA blockage of CAC channels was accompanied by activation of Ca2+ activated K+ (SK4) channels. The observed effects of NA were not connected with COX 2 inhibition since 100 nM NA (IC50 for COX 2 inhibition) did not induce either apoptosis or affect the channels activity. We conclude that inhibition of SOC channels plays a major role in NA induced apoptosis. Increased apoptotic levels in Tg treated K562 cells in the presence of NA may be due to the blockage of CAC and stimulation of SK4 channels in addition to SOC channels inhibition.
C1 [Kucherenko, Yuliya V.] Inst Problems Cryobiol & Cryomed, UA 71015 Kharkov, Ukraine.
   [Lang, Florian] Univ Tubingen, Dept Physiol Inst 1, D 72076 Tubingen, Germany.
C3 National Academy of Sciences Ukraine; Institute for Problems of
   Cryobiology & Cryomedicine of NASU; Eberhard Karls University of
   Tubingen
RP Kucherenko, YV (通讯作者)，Inst Problems Cryobiol & Cryomed, UA 71015 Kharkov, Ukraine.
EM yulia_kucherenko@yahoo.com
CR Ahn SC, 2004, PFLUG ARCH EUR J PHY, V447, P426, DOI 10.1007/s00424 003 1201 1
   Astill DS, 1996, BBA BIOMEMBRANES, V1280, P178, DOI 10.1016/0005 2736(95)00281 2
   BARRY PH, 1991, J MEMBRANE BIOL, V121, P101, DOI 10.1007/BF01870526
   Becchetti A, 2011, AM J PHYSIOL CELL PH, V301, pC255, DOI 10.1152/ajpcell.00047.2011
   Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068
   Cerella C, 2011, BIOCHEM PHARMACOL, V82, P1277, DOI 10.1016/j.bcp.2011.06.028
   Chao TSO, 1997, CANCER RES, V57, P3168
   Chen GL, 2012, BRIT J PHARMACOL, V167, P1232, DOI 10.1111/j.1476 5381.2012.02058.x
   Chen YF, 2011, J MEMBRANE BIOL, V240, P121, DOI 10.1007/s00232 011 9350 1
   Dam VS, 2013, PFLUGERS AR IN PRESS
   Davis AJ, 2013, BRIT J PHARMACOL, V168, P773, DOI 10.1111/j.1476 5381.2012.02199.x
   De la Fuente R, 2008, MOL PHARMACOL, V73, P758, DOI 10.1124/mol.107.043208
   Denmeade SR, 2005, CANCER BIOL THER, V4, P14
   Feng Xian Qi, 2006, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V14, P25
   Föller M, 2006, CELL PHYSIOL BIOCHEM, V17, P201, DOI 10.1159/000094125
   Garg P, 2012, MOL PHARMACOL, V82, P795, DOI 10.1124/mol.112.079194
   Jiang HN, 2012, BIOCHEM PHARMACOL, V83, P923, DOI 10.1016/j.bcp.2012.01.014
   Kaneko H, 2006, J GEN PHYSIOL, V127, P737, DOI 10.1085/jgp.200609497
   Kim BM, 2011, CANCER LETT, V300, P134, DOI 10.1016/j.canlet.2010.09.014
   Kim JA, 2003, BIOCHEM BIOPH RES CO, V309, P291, DOI 10.1016/j.bbrc.2003.07.004
   Kovacs G, 2012, CELL CALCIUM, V52, P468, DOI 10.1016/j.ceca.2012.08.005
   Lang PA, 2003, AM J PHYSIOL CELL PH, V285, pC1553, DOI 10.1152/ajpcell.00186.2003
   Lee J, 2005, J GEN PHYSIOL, V126, P439, DOI 10.1085/jgp.200509314
   Li L, 2008, ACTA PHARMACOL SIN, V29, P789, DOI 10.1111/j.1745 7254.2008.00803.x
   Li XZ, 2013, EUR J PHARMACOL, V703, P74, DOI 10.1016/j.ejphar.2013.02.004
   Li YS, 2008, ARCH BIOCHEM BIOPHYS, V478, P110, DOI 10.1016/j.abb.2008.07.002
   Liantonio A, 2007, BRIT J PHARMACOL, V150, P235, DOI 10.1038/sj.bjp.0706954
   Liantonio A, 2006, MOL PHARMACOL, V69, P165, DOI 10.1124/mol.105.017384
   Liu HL, 2011, EXP MOL PATHOL, V91, P753, DOI 10.1016/j.yexmp.2011.09.005
   Ll Li, 2008, Shengli Xuebao, V60, P743
   Monteilh Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740
   Pifferi S, 2006, P NATL ACAD SCI USA, V103, P12929, DOI 10.1073/pnas.0604505103
   PORONNIK P, 1992, FEBS LETT, V296, P245, DOI 10.1016/0014 5793(92)80296 S
   Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105
   Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519
   Semenova SB, 2009, AM J PHYSIOL CELL PH, V296, pC1098, DOI 10.1152/ajpcell.00435.2008
   Subhashini J, 2005, CANCER LETT, V224, P31, DOI 10.1016/j.canlet.2004.11.002
   Sun YY, 2013, J BIOL CHEM, V288, P255, DOI 10.1074/jbc.M112.393918
   Tomisato W, 2004, BIOCHEM BIOPH RES CO, V323, P1032, DOI 10.1016/j.bbrc.2004.08.205
   Totzke G, 2003, ONCOGENE, V22, P8021, DOI 10.1038/sj.onc.1206837
   WANGEMANN P, 1986, PFLUG ARCH EUR J PHY, V407, pS128, DOI 10.1007/BF00584942
   Zhang GS, 2006, AM J HEMATOL, V81, P242, DOI 10.1002/ajh.20542
NR 42
TC 8
Z9 9
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0022 2631
EI 1432 1424
J9 J MEMBRANE BIOL
JI J. Membr. Biol.
PD JUL
PY 2014
VL 247
IS 7
BP 627
EP 638
DI 10.1007/s00232 014 9680 x
PG 12
WC Biochemistry & Molecular Biology; Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Physiology
GA AI9WB
UT WOS:000337292800009
PM 24858951
DA 2025 08 17
ER

PT J
AU Palumbo, FS
   Bongiovì, F
   Pavia, FC
   Vitrano, I
   La Carrubba, V
   Pitarresi, G
   Brucato, V
   Giammona, G
AF Palumbo, Fabio S.
   Bongiovi, Flavia
   Pavia, Francesco Carfi
   Vitrano, Ilenia
   La Carrubba, Vincenzo
   Pitarresi, Giovanna
   Brucato, Valerio
   Giammona, Gaetano
TI Blend scaffolds with polyaspartamide/polyester structure fabricated via
   TIPS and their RGDC functionalization to promote osteoblast adhesion and
   proliferation
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE cyclic RGDC; PHEA; PLLA; porous scaffolds; TIPS
ID INDUCED PHASE SEPARATION; COMPOSITE SCAFFOLDS; PLLA SCAFFOLDS;
   CELL ADHESION; ACID; MODEL; DRUG; MICROPARTICLES; ARCHITECTURE
AB Target of this work was to prepare a RGDC functionalized hybrid biomaterial via TIPS technique to achieve a more efficient control of osteoblast adhesion and diffusion on the three dimensional (3D) scaffolds. Starting from a crystalline poly(l lactic acid) (PLLA) and an amorphous alpha,beta poly(N 2 hydroxyethyl) (2 aminoethylcarbamate) d,l aspartamide graft polylactic acid (PHEA EDA g PLA) copolymer, blend scaffolds were characterized by an appropriate porosity and pore interconnection. The PHEA EDA PLA interpenetration with PLLA improved hydrolytic susceptibility of hybrid scaffolds. The presence of free amino groups on scaffolds allowed to tether the cyclic RGD peptide (RGDC) via Michael addition using the maleimide chemistry. Cell culture test carried out on preosteoblastic cells MC3T3 E1 incubated with scaffolds, has evidenced cell adhesion and proliferation. Furthermore, the presence of distributed bone matrix on all scaffolds was evaluated after 70 days compared to PLLA only samples.
C1 [Palumbo, Fabio S.; Bongiovi, Flavia; Pitarresi, Giovanna; Giammona, Gaetano] Univ Palermo, Dipartimento Sci & Tecnol Biol Chim & Farmaceut S, Via Archirafi 32, I 90123 Palermo, Italy.
   [Pavia, Francesco Carfi; Vitrano, Ilenia; La Carrubba, Vincenzo; Brucato, Valerio] Univ Palermo, Dipartimento Ingn, Bio & Tissue Engn Lab, Palermo, Italy.
   [Pavia, Francesco Carfi; La Carrubba, Vincenzo] Adv Technol Network ATeN Ctr, Palermo, Italy.
   [Pavia, Francesco Carfi; La Carrubba, Vincenzo; Brucato, Valerio] Interuniv Consortium Mat Sci & Technol INSTM, Palermo Res Unit, Palermo, Italy.
   [Giammona, Gaetano] Italian Natl Res Council, Inst Biophys, Palermo, Italy.
C3 University of Palermo; University of Palermo; Consiglio Nazionale delle
   Ricerche (CNR); Istituto di Biofisica (IBF CNR)
RP Pitarresi, G (通讯作者)，Univ Palermo, Dipartimento Sci & Tecnol Biol Chim & Farmaceut S, Via Archirafi 32, I 90123 Palermo, Italy.
EM giovanna.pitarresi@unipa.it
OI La Carrubba, Vincenzo/0000 0002 3185 8398; Carfi Pavia,
   Francesco/0000 0001 5107 5588
FU TMinistero dell'Istruzione, dell'Universita e della Ricerca
FX TMinistero dell'Istruzione, dell'Universita e della Ricerca
CR Berner A, 2017, J TISSUE ENG REGEN M, V11, P2081, DOI 10.1002/term.2104
   Castelli F, 1997, J CONTROL RELEASE, V45, P103, DOI 10.1016/S0168 3659(96)01552 0
   Castelli F, 2000, BIOMATERIALS, V21, P821, DOI 10.1016/S0142 9612(99)00252 5
   Cengiz Ibrahim Fatih, 2018, Biomater Res, V22, P26
   Chen LN, 2018, MATER TODAY, V21, P38, DOI 10.1016/j.mattod.2017.07.002
   Chen ZY, 2012, INT J NANOMED, V7, P3803, DOI 10.2147/IJN.S33541
   Chollet C, 2009, BIOMATERIALS, V30, P711, DOI 10.1016/j.biomaterials.2008.10.033
   Craparo EF, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957 4484/19/48/485603
   Craparo EF, 2014, INT J PHARMACEUT, V466, P172, DOI 10.1016/j.ijpharm.2014.02.047
   Craparo EF, 2013, BIOMACROMOLECULES, V14, P1838, DOI 10.1021/bm4002409
   Gao YF, 2018, MAT SCI ENG C MATER, V84, P195, DOI 10.1016/j.msec.2017.11.047
   GIAMMONA G, 1995, J CONTROL RELEASE, V33, P261, DOI 10.1016/0168 3659(94)00091 8
   Giammona G, 1997, POLYMER, V38, P3315, DOI 10.1016/S0032 3861(96)00886 5
   GIAMMONA G, 1987, J POLYM SCI POL CHEM, V25, P2813, DOI 10.1002/pola.1987.080251016
   GIAMMONA G, 1989, INT J PHARMACEUT, V57, P55, DOI 10.1016/0378 5173(89)90263 9
   Huettner N, 2018, TRENDS BIOTECHNOL, V36, P372, DOI 10.1016/j.tibtech.2018.01.008
   Karageorgiou V, 2005, BIOMATERIALS, V26, P5474, DOI 10.1016/j.biomaterials.2005.02.002
   Kuttappan S, 2016, INT J BIOL MACROMOL, V93, P1390, DOI 10.1016/j.ijbiomac.2016.06.043
   La Carrubba V, 2008, INT J MATER FORM, V1, P619, DOI 10.1007/s12289 008 0332 5
   Leng C, 2015, ACS APPL MATER INTER, V7, P16881, DOI 10.1021/acsami.5b05627
   Licciardi M, 2006, BIOMATERIALS, V27, P2066, DOI 10.1016/j.biomaterials.2005.09.027
   Lombardo ME, 2019, TISSUE CELL, V58, P33, DOI 10.1016/j.tice.2019.04.004
   Maharana T, 2009, PROG POLYM SCI, V34, P99, DOI 10.1016/j.progpolymsci.2008.10.001
   Mendichi R, 2000, POLYMER, V41, P8649, DOI 10.1016/S0032 3861(00)00185 3
   Nakagawa M, 2006, J BIOMED MATER RES A, V77A, P112, DOI 10.1002/jbm.a.30521
   Narayanan G, 2016, ADV DRUG DELIVER REV, V107, P247, DOI 10.1016/j.addr.2016.04.015
   Palumbo FS, 2019, POLYM INT, V68, P394, DOI 10.1002/pi.5722
   Palumbo FS, 2017, INT J PHARMACEUT, V519, P332, DOI 10.1016/j.ijpharm.2017.01.033
   Palumbo FS, 2016, MACROMOL BIOSCI, V16, P1485, DOI 10.1002/mabi.201600114
   Pavia FC, 2008, J BIOMED MATER RES A, V86A, P459, DOI 10.1002/jbm.a.31621
   Pavia FC, 2009, INT J MATER FORM, V2, P713, DOI 10.1007/s12289 009 0574 x
   Pavia FC, 2016, MAT SCI ENG C MATER, V67, P561, DOI 10.1016/j.msec.2016.05.040
   Pereira AD, 2016, BIOMACROMOLECULES, V17, P1179, DOI 10.1021/acs.biomac.6b00019
   Pitarresi G, 2014, J BIOMED MATER RES A, V102, P1334, DOI 10.1002/jbm.a.34818
   Pitarresi G, 2008, EUR POLYM J, V44, P3764, DOI 10.1016/j.eurpolymj.2008.08.031
   Ren J, 2008, J MATER SCI MATER M, V19, P1075, DOI 10.1007/s10856 007 3181 8
   Santoro M, 2016, ADV DRUG DELIVER REV, V107, P206, DOI 10.1016/j.addr.2016.04.019
   Triolo D, 2017, COLLOID SURFACE B, V151, P206, DOI 10.1016/j.colsurfb.2016.11.025
   Woo KM, 2007, BIOMATERIALS, V28, P2622, DOI 10.1016/j.biomaterials.2007.02.004
   Zhang PB, 2011, BIOMACROMOLECULES, V12, P2667, DOI 10.1021/bm2004725
   Zhao JH, 2012, MAT SCI ENG C MATER, V32, P1496, DOI 10.1016/j.msec.2012.04.031
NR 41
TC 2
Z9 3
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD DEC
PY 2019
VL 107
IS 12
BP 2726
EP 2735
DI 10.1002/jbm.a.36776
EA SEP 2019
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA JF1DK
UT WOS:000484902000001
PM 31404485
DA 2025 08 17
ER

PT J
AU Terukina, T
   Saito, H
   Tomita, Y
   Hattori, Y
   Otsuka, M
AF Terukina, Takayuki
   Saito, Hanae
   Tomita, Yuya
   Hattori, Yusuke
   Otsuka, Makoto
TI Development and effect of a sustainable and controllable
   simvastatin releasing device based on PLGA microspheres/carbonate
   apatite cement composite: In vitro evaluation for use as a drug
   delivery system from bone like biomaterial
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Bone regeneration; Simvastatin; Poly(lactic co glycolic acid)
   microspheres; Carbonated hydroxyapatite; Drug delivery system;
   Controlled release
ID CALCIUM PHOSPHATE CEMENT; CARBONATE APATITE; CELL CULTURES;
   HYDROXYAPATITE; MECHANISMS; MICROPARTICLES; MINERALIZATION; OSTEOBLASTS;
   PARTICLES; MATRICES
AB Carbonated apatite cement can be a potential biomaterial to be used as a drug carrier. We reported previously that sustainable release of simvastatin (SIM) from poly(lactic co glycolic acid) (PLGA) formulations could induce bone formation. The aim of this study was to develop a SIM loaded PLGA microspheres (SPLGAMs)/carbonated hydroxyapatite (CHAP) composite, and investigate the effect of SIM released from that composite in comparison with a SIM/CHAP composite used as a control. X ray diffraction analysis (XRD) and Fourier transformed infrared spectroscopy (FT IR) results showed most parts of the cement bulk powder transformed into carbonated hydroxyapatite. The SPLGAMs and SPLGAMs/CHAP composites were able to produce sustained release of SIM for 1 month, whereas the SIM/CHAP composite released SIM for 2 weeks. The mechanisms of the drug release patterns from these composites were confirmed by several mathematical models. The proliferation of MC3T3 E1 cells on the SPLGAMs/CHAP composite showed no significant difference in comparison with the SIM/CHAP composite. However, the SPLGAMs/CHAP composite significantly increased alkaline phosphate activity, a differentiation marker of MC3T3 E1 cells, compared with the SIM/CHAP composite. These results suggested that the SPLGAMs/CHAP composite could release SIM sustainably and induce proliferation and differentiation of MOT3 E1 more effectively than the SIM/CHAP composite. (C) 2016 Published by Elsevier B.V.
C1 [Terukina, Takayuki; Hattori, Yusuke; Otsuka, Makoto] Musashino Univ, Pharmaceut Sci Res Inst, 1 1 20 Shinmachi, Tokyo 2028585, Japan.
   [Saito, Hanae; Tomita, Yuya] Musashino Univ, Fac Pharm, 1 1 20 Shinmachi, Tokyo 2028585, Japan.
RP Otsuka, M (通讯作者)，Musashino Univ, Pharmaceut Sci Res Inst, 1 1 20 Shinmachi, Tokyo 2028585, Japan.
EM motsuka@mushashino u.ac.jp
RI Hattori, Yusuke/ABC 3926 2020
FU Grants in Aid for Scientific Research [15K07902] Funding Source: KAKEN
CR Boskey AL, 2007, ELEMENTS, V3, P385, DOI 10.2113/GSELEMENTS.3.6.385
   CHO SB, 1995, J AM CERAM SOC, V78, P1769, DOI 10.1111/j.1151 2916.1995.tb08887.x
   Chou J, 2013, ADV HEALTHC MATER, V2, P678, DOI 10.1002/adhm.201200342
   Della Porta G, 2016, J PHARM SCI US, V105, P2164, DOI 10.1016/j.xphs.2016.05.002
   Doi Y, 1998, J BIOMED MATER RES, V39, P603, DOI 10.1002/(SICI)1097 4636(19980315)39:4<603::AID JBM15>3.3.CO;2 8
   Doi Y, 1999, J BIOMED MATER RES, V47, P424, DOI 10.1002/(SICI)1097 4636(19991205)47:3<424::AID JBM19>3.0.CO;2 0
   DONATH K, 1987, ORAL SURG ORAL MED O, V63, P651, DOI 10.1016/0030 4220(87)90362 8
   Faisant N, 2002, EUR J PHARM SCI, V15, P355, DOI 10.1016/S0928 0987(02)00023 4
   Fredenberg S, 2011, INT J PHARMACEUT, V415, P34, DOI 10.1016/j.ijpharm.2011.05.049
   Garrett IR, 2001, CURR PHARM DESIGN, V7, P715, DOI 10.2174/1381612013397762
   Hasegawa M, 2003, J BONE JOINT SURG BR, V85B, P142, DOI 10.1302/0301 620X.85B1.13414
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   Jiang LM, 2013, J BIOMED NANOTECHNOL, V9, P1921, DOI 10.1166/jbn.2013.1692
   Kanayama K, 2011, J BIOMATER APPL, V26, P435, DOI 10.1177/0885328210374672
   Kim SS, 2006, BIOMATERIALS, V27, P1399, DOI 10.1016/j.biomaterials.2005.08.016
   KORSMEYER RW, 1983, J PHARM SCI US, V72, P1189, DOI 10.1002/jps.2600721021
   Lanao RPF, 2011, BIOMATERIALS, V32, P8839, DOI 10.1016/j.biomaterials.2011.08.005
   LeGeros RZ, 2008, CHEM REV, V108, P4742, DOI 10.1021/cr800427g
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Meng ZX, 2013, MAT SCI ENG C MATER, V33, P699, DOI 10.1016/j.msec.2012.10.021
   Meyer F, 2012, J ORTHOP RES, V30, P864, DOI 10.1002/jor.22019
   Montazerolghaem M, 2014, J BIOMED MATER RES A, V102, P340, DOI 10.1002/jbm.a.34702
   MOONGA BS, 1990, J PHYSIOL LONDON, V429, P29, DOI 10.1113/jphysiol.1990.sp018242
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Naito Y, 2014, INT J PHARMACEUT, V461, P157, DOI 10.1016/j.ijpharm.2013.11.046
   NORDSTROM EG, 1990, J MATER SCI MATER M, V1, P182, DOI 10.1007/BF00700880
   Otsuka M, 1997, PHARMACEUT RES, V14, P444, DOI 10.1023/A:1012039214184
   Qi XP, 2008, ACTA BIOMATER, V4, P1837, DOI 10.1016/j.actbio.2008.05.009
   Quinlan E, 2015, J CONTROL RELEASE, V198, P71, DOI 10.1016/j.jconrel.2014.11.021
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168 3659(87)90034 4
   Tai IC, 2013, INT J NANOMED, V8, P3895, DOI 10.2147/IJN.S48694
   Terukina T, 2016, J DRUG DELIV SCI TEC, V33, P136, DOI 10.1016/j.jddst.2016.03.005
   Versypt ANF, 2013, J CONTROL RELEASE, V165, P29, DOI 10.1016/j.jconrel.2012.10.015
   Wang JW, 2007, OSTEOPOROSIS INT, V18, P1641, DOI 10.1007/s00198 007 0412 2
   Yin H, 2012, J BIOMED MATER RES A, V100A, P2991, DOI 10.1002/jbm.a.34228
   YOHAY DA, 1994, J CELL PHYSIOL, V158, P467, DOI 10.1002/jcp.1041580311
NR 36
TC 22
Z9 23
U1 0
U2 30
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1773 2247
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PD FEB
PY 2017
VL 37
BP 74
EP 80
DI 10.1016/j.jddst.2016.10.007
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA EK0OS
UT WOS:000393626900010
DA 2025 08 17
ER

PT J
AU Zhang, JL
   Qiu, XM
   Zhang, N
   Tang, W
   Gober, HJ
   Li, DJ
   Wang, L
AF Zhang, Jia Li
   Qiu, Xue Min
   Zhang, Na
   Tang, Wei
   Gober, Hans Juergen
   Li, Da Jin
   Wang, Ling
TI Bu Shen Ning Xin decoction suppresses osteoclastogenesis by modulating
   RANKL/OPG imbalance in the CD4<SUP>+</SUP> T lymphocytes of
   ovariectomized mice
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE herbal formula; osteoimmunology; osteoclast; RANKL; postmenopausal
   osteoporosis; reproductive endocrine immune metabolic network
ID BONE LOSS; POSTMENOPAUSAL OSTEOPOROSIS; RHEUMATOID ARTHRITIS; ESTROGEN
   DEFICIENCY; RECEPTOR ACTIVATOR; IN VITRO; CELLS; LIGAND;
   OSTEOPROTEGERIN; MECHANISMS
AB Postmenopausal osteoporosis (PMO) has been recognized as an inflammatory condition. CD4(+) T cells serve a key role in the interaction between bone metabolism and the immune system. Bu Shen Ning Xin decoction (BSNXD), a traditional Chinese medicine, has been ultilized as a remedy for PMO. In the present study, the aim was to investigate the immune modulatory effects of BSNXD on CD4(+) T cells, receptor activation of nuclear factor B ligand (RANKL)/osteoprotegerin (OPG) imbalance, skeletal parameters and osteoclastogenesis. Ovariectomized (OVX) mice were treated with a series of concentrations of BSNXD and then autopsied. The bone phenotype was analyzed by micro computed tomography. CD4(+) T cells were isolated and their percentage was measured using flow cytometry (FCM). RANKL and OPG expression by the CD4(+) T cells at the transcriptional and translational levels were quantified by reverse transcription quantitative polymerase chain reaction, ELISA and FCM. CD4(+) T cells were cultured with blood serum derived from BSNXD treated OVX mice (BSNXD derived serum) and the apoptosis rate was quantified by FCM. CD4(+) T cells were co cultured with bone marrow derived macrophages and exposed to BSNXD derived serum to whether CD4(+) T cells are involved in BSNXD modulated osteoclastogenesis and the results were quantified via tartrate resistant acid phosphatase staining. The results revealed that BSNXD ameliorated OVX induced bone loss, prevented the expansion of CD4(+) T cells and restored the RANKL/OPG imbalance in the CD4(+) T cells of OVX mice. In vitro, BSNXD derived serum promoted the apoptosis of CD4(+) T cells. The co culture system demonstrated that CD4(+) T cells from OVX mice increase osteoclastogenesis, while this effect was suppressed by BSNXD administration. The findings of the study collectively suggest that BSNXD exerts an immunoprotective effect on the bone phenotype of OVX mice by ameliorating RANKL/OPG imbalance in CD4(+) T cells and attenuating osteoclastogenesis.
C1 [Zhang, Jia Li; Qiu, Xue Min; Zhang, Na; Li, Da Jin; Wang, Ling] Fudan Univ, Hosp & Inst Obstet & Gynecol, IBS, Lab Reprod Immunol, 413 Zhaozhou Rd, Shanghai 200011, Peoples R China.
   [Zhang, Jia Li; Qiu, Xue Min; Zhang, Na; Li, Da Jin; Wang, Ling] Fudan Univ, Acad Integrat Med, Shanghai 200011, Peoples R China.
   [Zhang, Jia Li; Qiu, Xue Min; Zhang, Na; Wang, Ling] Fudan Univ, Obstet & Gynecol Hosp, Shanghai Key Lab Female Reprod Endocrine Related, Shanghai 200011, Peoples R China.
   [Tang, Wei] Univ Tokyo, Grad Sch Med, Dept Surg, Hepatobiliary Pancreat Surg Div, Tokyo 1138655, Japan.
   [Gober, Hans Juergen] Johannes Kepler Univ Linz, Dept Pharm, Neuromed Campus, A 4020 Linz, Austria.
C3 Fudan University; Fudan University; Shanghai Academy of Science &
   Technology; Fudan University; University of Tokyo; Johannes Kepler
   University Linz
RP Wang, L (通讯作者)，Fudan Univ, Hosp & Inst Obstet & Gynecol, IBS, Lab Reprod Immunol, 413 Zhaozhou Rd, Shanghai 200011, Peoples R China.
EM dr.wangling@fudan.edu.cn
RI tang, wei/HZH 5205 2023; Wang, Ling/AAD 2596 2020
OI Wang, Ling/0000 0003 4905 9903
FU National Natural Science Foundation of China [31571196, 30801502,
   81401171]; Science and Technology Commission of Shanghai Municipality
   2015 YIXUEYINGDAO project [15401932200]; JSPS [P08471]; Shanghai Pujiang
   Program [11PJ1401900]; Development Project of Shanghai Peak
   Disciplines Integrated Chinese and Western Medicine [20150407]; Program
   for Outstanding Medical Academic Leader
FX The present study was supported by the National Natural Science
   Foundation of China (grant no. 31571196) to Ling Wang, the Science and
   Technology Commission of Shanghai Municipality 2015 YIXUEYINGDAO project
   (grant no. 15401932200) to Ling Wang, the FY2008 JSPS Postdoctoral
   Fellowship for Foreign Researchers P08471 to Ling Wang, the National
   Natural Science Foundation of China (grant no. 30801502) to Ling Wang,
   the Shanghai Pujiang Program (grant no. 11PJ1401900) to Ling Wang, the
   National Natural Science Foundation of China (grant no. 81401171) to
   Xue Min Qiu, Development Project of Shanghai Peak Disciplines Integrated
   Chinese and Western Medicine (grant no. 20150407) and the Program for
   Outstanding Medical Academic Leader to Da Jin Li.
CR Andreopoulou P, 2015, ANNU REV MED, V66, P329, DOI 10.1146/annurev med 070313 022841
   Bernabei R, 2014, CLIN CASES MINER BON, V11, P201, DOI 10.11138/ccmbm/2014.11.3.201
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   D'Amelio P, 2008, BONE, V43, P92, DOI 10.1016/j.bone.2008.02.017
   Danks L, 2013, J BIOCHEM, V154, P29, DOI 10.1093/jb/mvt049
   Faienza MF, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/575936
   Geusens P, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2015 000051
   Greenblatt Matthew B, 2013, Immune Netw, V13, P111, DOI 10.4110/in.2013.13.4.111
   Gui YY, 2015, BIOSCI TRENDS, V9, P169, DOI 10.5582/bst.2015.01011
   Han BH, 2017, J INTEGR MED JIM, V15, P326, DOI [10.1016/S2095 4964(17)60350 9, 10.1016/s2095 4964(17)60350 9]
   Hodis HN, 2014, J STEROID BIOCHEM, V142, P68, DOI 10.1016/j.jsbmb.2013.06.011
   Horwood NJ, 1999, BIOCHEM BIOPH RES CO, V265, P144, DOI 10.1006/bbrc.1999.1623
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   Jilka RL, 1998, J CLIN INVEST, V101, P1942, DOI 10.1172/JCI1039
   Nguyen K, 2016, J INTEGR MED JIM, V14, P465, DOI 10.1016/S2095 4964(16)60280 7
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim HR, 2014, ARTHRITIS RHEUMATOL, V66, P538, DOI 10.1002/art.38286
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529 0131(200105)44:5<1003::AID ANR179>3.3.CO;2 R
   Leibbrandt A, 2009, ADV EXP MED BIOL, V647, P130, DOI 10.1007/978 0 387 89520 8_9
   Li JY, 2011, P NATL ACAD SCI USA, V108, P768, DOI 10.1073/pnas.1013492108
   López Grueso R, 2014, ANTIOXID REDOX SIGN, V20, P236, DOI 10.1089/ars.2012.5112
   Maki PM, 2013, MENOPAUSE, V20, P695, DOI [10.1097/GME.0b013e3182960cf8, 10.1097/gme.0b013e3182960cf8]
   McCloskey EV, 2012, J BONE MINER RES, V27, P1480, DOI 10.1002/jbmr.1606
   Pacifici R, 2008, CELL IMMUNOL, V252, P68, DOI 10.1016/j.cellimm.2007.06.008
   Penno H, 2002, BIOCHEM BIOPH RES CO, V293, P451, DOI 10.1016/S0006 291X(02)00242 5
   Recker R, 2004, J BONE MINER RES, V19, P1628, DOI 10.1359/JBMR.040710
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5
   Senthilkumar R, 2009, IMMUNOBIOLOGY, V214, P153, DOI 10.1016/j.imbio.2008.05.001
   Stein NC, 2008, J BONE MINER RES, V23, P750, DOI 10.1359/JBMR.080203
   Tyagi AM, 2012, OSTEOPOROSIS INT, V23, P1151, DOI 10.1007/s00198 011 1650 x
   UTERMOHLEN O, 1994, EUR J IMMUNOL, V24, P3093, DOI 10.1002/eji.1830241227
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Walsh NC, 2013, GENES IMMUN, V14, P336, DOI 10.1038/gene.2013.29
   Wang L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.66
   Wang L, 2009, OSTEOPOROSIS INT, V20, P79, DOI 10.1007/s00198 008 0631 1
   Wang L, 2008, P NATL ACAD SCI USA, V105, P4826, DOI 10.1073/pnas.0712365105
   Wang L, 2015, DRUG DES DEV THER, V9, P5019, DOI 10.2147/DDDT.S89505
   Wang Ling, 2015, Drug Des Devel Ther, V9, P3755, DOI 10.2147/DDDT.S88512
   Wang RX, 2002, EUR J IMMUNOL, V32, P1090, DOI 10.1002/1521 4141(200204)32:4<1090::AID IMMU1090>3.3.CO;2 G
   Wang YD, 2009, J ETHNOPHARMACOL, V122, P221, DOI 10.1016/j.jep.2009.01.026
   Weitzmann MN, 2001, J BONE MINER RES, V16, P328, DOI 10.1359/jbmr.2001.16.2.328
   Zhao P, 2015, INT J CHRONIC OBSTR, V10, DOI 10.2147/COPD.S94043
   Zhao RQ, 2012, INT J MED SCI, V9, P825, DOI 10.7150/ijms.5180
NR 46
TC 13
Z9 17
U1 1
U2 23
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JUL
PY 2018
VL 42
IS 1
BP 299
EP 308
DI 10.3892/ijmm.2018.3645
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GP1MT
UT WOS:000440580900030
PM 29717766
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Qiu, WL
   Han, XX
   Yu, T
   Jiang, LJ
   Wang, XF
   Feng, RZ
   Duan, XR
   Teng, Y
   Yin, HF
   Bokarewa, M
   Deng, GM
AF Qiu, Wenlin
   Han, Xiaoxiao
   Yu, Tong
   Jiang, Lijuan
   Wang, Xuefei
   Feng, Ruizhi
   Duan, Xiaoru
   Teng, Yao
   Yin, Haifeng
   Bokarewa, Maria, I
   Deng, Guo Min
TI Inhibitory effect of hydroxychloroquine on glucocorticoid induced
   osteoporosis in lupus therapy
SO CLINICAL & TRANSLATIONAL IMMUNOLOGY
LA English
DT Article
DE glucocorticoids; hydroxychloroquine; inflammation; osteoporosis; ROS;
   systemic lupus erythematosus
ID SKIN INFLAMMATION; ERYTHEMATOSUS; MECHANISMS; SURVIVAL; DISEASE; IL 6
AB ObjectivesSystemic lupus erythematosus (SLE) is a chronic and severe autoimmune disease characterised by persistent inflammation. Hydroxychloroquine (HCQ) and glucocorticoids (GCs) are the primary agents commonly used in combination as the first line treatment for SLE. Nevertheless, the specific mechanisms responsible for the effectiveness of this combined therapy with HCQ and GCs have not been fully elucidated. This study aimed to reveal the mechanism behind combined HCQ and GC treatment in lupus.MethodsAn SLE IgG induced inflammation model was used to investigate the anti inflammatory effects of HCQ and dexamethasone (DXM). A glucocorticoid induced osteoporosis (GIOP) model was used to investigate the inhibitory effect of HCQ on osteoclastogenesis. Inflammation was assessed by haematoxylin and eosin staining. Bone metabolism was determined structurally via microcomputer tomography and in bone marrow derived osteoclast cultures.ResultsAn SLE IgG induced inflammation model demonstrated that HCQ could not ameliorate inflammation alone but could enhance the anti inflammatory effect of GCs by decreasing the expression of Fc gamma RI on macrophages. HCQ inhibited osteoclastogenesis induced by GCs and RANKL by upregulating nuclear factor erythroid 2 related factor 2 and limiting reactive oxygen species formation, which mitigated GC induced bone loss.ConclusionThe results indicate that HCQ improved the anti inflammatory effects of GCs and inhibits the osteoclastogenesis in experimental lupus. This study offers valuable insights into the mechanisms underlying the combined treatment of lupus with HCQ and GCs.
   Our results suggest that hydroxychloroquine (HCQ) cannot ameliorate the acute inflammation induced by lupus IgG but inhibits osteoclastogenesis in experimental lupus. The mechanism underlying the inhibition of dexamethasone induced osteoclastogenesis by HCQ is through the regulation of nuclear factor erythroid 2 related factor 2 expression and reactive oxygen species production. image
C1 [Qiu, Wenlin; Han, Xiaoxiao; Yu, Tong; Jiang, Lijuan; Wang, Xuefei; Feng, Ruizhi; Duan, Xiaoru; Teng, Yao; Yin, Haifeng; Deng, Guo Min] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Rheumatol & Immunol, Wuhan, Peoples R China.
   [Bokarewa, Maria, I] Gothenburg Univ, Inst Med, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden.
   [Bokarewa, Maria, I] Sahlgrens Univ Hosp, Rheumatol Clin, Gothenburg, Sweden.
C3 Huazhong University of Science & Technology; University of Gothenburg;
   Sahlgrenska University Hospital
RP Deng, GM (通讯作者)，Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Rheumatol & Immunol, Wuhan, Peoples R China.
EM gmdeng@hust.edu.cn
RI yin, haifeng/AAL 2728 2021; Yu, Tong/HGA 7225 2022
FU National Natural Science Foundation of China [82171786, 82103731];
   National Natural Science Foundation of China (NSFC)
FX This study was supported by the National Natural Science Foundation of
   China (NSFC) (GM Deng, 82171786 and Xiaoru Duan, 82103731). The funders
   provided financial support for this study, but the funders did not
   participate in the study design, experiments, data collection or
   analysis. We thank the Medical Subcenter of HUST Analytical & Testing
   Center for data acquisition for micro CT scanning and the Laboratory
   Animal Center of HUST for the animal experiments.
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Alarcón GS, 2007, ANN RHEUM DIS, V66, P1168, DOI 10.1136/ard.2006.068676
   An J, 2018, ARTHRITIS RHEUMATOL, V70, P1807, DOI 10.1002/art.40559
   Barber MRW, 2021, NAT REV RHEUMATOL, V17, P515, DOI 10.1038/s41584 021 00668 1
   Bournazos S, 2020, NAT REV IMMUNOL, V20, P633, DOI 10.1038/s41577 020 00410 0
   Bruhns P, 2015, IMMUNOL REV, V268, P25, DOI 10.1111/imr.12350
   Buckley L, 2018, NEW ENGL J MED, V379, P2547, DOI 10.1056/NEJMcp1800214
   Deng GM, 2010, ARTHRITIS RHEUM US, V62, P2424, DOI 10.1002/art.27534
   Deng GM, 2010, J IMMUNOL, V184, P7154, DOI 10.4049/jimmunol.0902514
   Dima A, 2022, THER ADV MUSCULOSKEL, V14, DOI 10.1177/1759720X211073001
   Durcan L, 2019, LANCET, V393, P2332, DOI 10.1016/S0140 6736(19)30237 5
   Fang X, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01457
   Fanouriakis A, 2019, ANN RHEUM DIS, V78, P736, DOI 10.1136/annrheumdis 2019 215089
   Franchini AM, 2013, J BIOL CHEM, V288, P25098, DOI 10.1074/jbc.M113.474106
   Garelick D, 2021, RHEUMATOLOGY, V60, P2765, DOI 10.1093/rheumatology/keaa705
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   Gilljam KM, 2020, J IMMUNOL, V204, P2133, DOI 10.4049/jimmunol.1901131
   Huscher D, 2009, ANN RHEUM DIS, V68, P1119, DOI 10.1136/ard.2008.092163
   Jiang LJ, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.824008
   Jing CZ, 2020, P NATL ACAD SCI USA, V117, P15160, DOI 10.1073/pnas.2000943117
   Kiriakidou M, 2020, ANN INTERN MED, V172, pITC81, DOI 10.7326/AITC202006020
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kuznik A, 2011, J IMMUNOL, V186, P4794, DOI 10.4049/jimmunol.1000702
   Liu LN, 2016, CLIN IMMUNOL, V165, P4, DOI 10.1016/j.clim.2016.02.007
   Lu CH, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9091127
   Manson JJ, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750 1172 1 6
   Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206
   Ohyama Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191192
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Oray M, 2016, EXPERT OPIN DRUG SAF, V15, P457, DOI 10.1517/14740338.2016.1140743
   Qiao W, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1174
   Qiu WL, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.924766
   Qu ZC, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1043975
   Rahman A, 2008, NEW ENGL J MED, V358, P929, DOI 10.1056/NEJMra071297
   Ruiz Irastorza G, 2006, LUPUS, V15, P577, DOI 10.1177/0961203306071872
   Ruiz Irastorza G, 2020, RHEUMATOLOGY, V59, P69, DOI 10.1093/rheumatology/keaa403
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584 020 0372 x
   SPERBER K, 1993, J RHEUMATOL, V20, P803
   Straub Rainer H, 2016, Rheumatology (Oxford), V55, pii6
   Sun YX, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929 015 0212 5
   Ugarte A, 2018, CURR OPIN RHEUMATOL, V30, P482, DOI 10.1097/BOR.0000000000000527
   vandenBorne BEEM, 1997, J RHEUMATOL, V24, P55
   Vera Recabarren MA, 2010, BRIT J DERMATOL, V162, P91, DOI 10.1111/j.1365 2133.2009.09472.x
   Zhang Q, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03020
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013
NR 45
TC 0
Z9 0
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2050 0068
J9 CLIN TRANSL IMMUNOL
JI Clin. Transl. Immunol.
PY 2024
VL 13
IS 10
AR e70010
DI 10.1002/cti2.70010
PG 16
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA J1C8E
UT WOS:001334526600001
PM 39416769
OA gold
DA 2025 08 17
ER

PT J
AU Olivier, S
   Fillet, M
   Malaise, M
   Piette, J
   Bours, V
   Merville, MP
   Franchimont, N
AF Olivier, S
   Fillet, M
   Malaise, M
   Piette, J
   Bours, V
   Merville, MP
   Franchimont, N
TI Sodium nitroprusside induced osteoblast apoptosis is mediated by long
   chain ceramide and is decreased by raloxifene
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE nitric oxide; ceramides; apoptosis; raloxifene; estrogen; osteoblast
ID NITRIC OXIDE SYNTHASE; ESTROGEN RECEPTOR MODULATORS; RANDOMIZED
   CLINICAL TRIAL; VERTEBRAL FRACTURE RISK; TUMOR NECROSIS FACTOR;
   POSTMENOPAUSAL WOMEN; KAPPA B; CELL CULTURES; CANCER CELLS; STRESS
AB Release of high levels of nitric oxide (NO) is associated with osteoblastic cell death. The mechanisms of NO induced cytotoxicity are not well documented and it is presently not known if estrogenic compounds prevent this effect. We studied the role of ceramides in cell death induced by the NO donor sodium nitroprusside (SNP) and we tested the possibility that 17 beta estradiol, the anti estrogen ICI 182.780 and two selective estrogen receptor modulators raloxifene and tamoxifen modify osteoblastic cell apoptosis. SNP dose dependently decreased MC3T3 E1 osteoblast viability, increased NO production in the culture media and enhanced the release of intracellular ceramides C22 and C24. Cell death induced by SNP was partially inhibited when MC3T3 E1 cells were pretreated. with raloxifene and tamoxifen but was not modified when the cells were pretreated with 17 beta estradiol or ICI 182.780. Cell death induced by SNP resulted from apoptosis as demonstrated by Annexin V and propidium iodide labeling and a reduction of SNP induced MC3T3 E1 apoptosis was confirmed in the presence of raloxifene and tamoxifen. SNP induction of C22 and C24 production was inhibited by a pretreatment with raloxifene but not with 17 beta estradiol. Moreover, the synthetic ceramide C24 (0.75 and 1 mu M) decreased MC3T3 E1 cell viability and osteoblast cell death induced by C24 was partially decreased by raloxifene and to a lesser extent by 17 beta estradiol. These data demonstrate that SNP induced cell death is mediated by the long chain ceramides C22 and C24 and that raloxifene protected osteoblast from apoptosis induced by SNP, an effect that might be relevant to its pharmacological properties on bone remodeling. (c) 2004 Elsevier Inc. All rights reserved.
C1 Univ Liege, CHU Sart Tilman, CBIG, Lab Clin Chem & Human Genet,Dept Rheumatol, B 4000 Liege, Belgium.
C3 University of Liege
RP Franchimont, N (通讯作者)，Univ Liege, CHU Sart Tilman, CBIG, Lab Clin Chem & Human Genet,Dept Rheumatol, B 4000 Liege, Belgium.
EM nfranchimont@ulg.ac.be
OI Fillet, Marianne/0000 0002 1453 6282
CR [Anonymous], N ENGL J MED
   Armour KE, 1998, ENDOCRINOLOGY, V139, P799, DOI 10.1210/en.139.2.799
   Armour KJ, 2001, ARTHRITIS RHEUM, V44, P2790, DOI 10.1002/1529 0131(200112)44:12<2790::AID ART466>3.0.CO;2 X
   BAFFET G, 1991, MOL BIOL MED, V8, P141
   Bonizzi G, 1999, BIOCHEM PHARMACOL, V57, P713, DOI 10.1016/S0006 2952(98)00353 0
   Cheung J, 2003, J ENDOCRINOL, V177, P423, DOI 10.1677/joe.0.1770423
   CLARKE R, 1990, JNCI J NATL CANCER I, V82, P1702, DOI 10.1093/jnci/82.21.1702
   Damoulis PD, 1997, J BONE MINER RES, V12, P412, DOI 10.1359/jbmr.1997.12.3.412
   Delmas PD, 2002, J CLIN ENDOCR METAB, V87, P3609, DOI 10.1210/jc.87.8.3609
   Dutertre M, 2000, J PHARMACOL EXP THER, V295, P431
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P2124
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Feger F, 2001, CANCER RES, V61, P5289
   Fillet M, 2003, BIOCHEM PHARMACOL, V65, P1633, DOI 10.1016/S0006 2952(03)00125 4
   Fillet M, 2002, J CHROMATOGR A, V949, P225, DOI 10.1016/S0021 9673(01)01422 4
   Franzen R, 2002, FEBS LETT, V532, P441, DOI 10.1016/S0014 5793(02)03727 4
   Gruber R, 1999, BONE, V24, P465, DOI 10.1016/S8756 3282(99)00017 4
   Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855
   Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190
   JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014 5793(94)01428 4
   Klein Nulend J, 1998, BIOCHEM BIOPH RES CO, V250, P108, DOI 10.1006/bbrc.1998.9270
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092 8674(94)90147 3
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kroesen BJ, 2003, J BIOL CHEM, V278, P14723, DOI 10.1074/jbc.M210756200
   Levenson AS, 1999, EUR J CANCER, V35, P1974, DOI 10.1016/S0959 8049(99)00297 X
   LOWIK CWGM, 1994, J CLIN INVEST, V93, P1465, DOI 10.1172/JCI117124
   Mancini L, 2000, BIOCHEM BIOPH RES CO, V274, P477, DOI 10.1006/bbrc.2000.3164
   Marchesini N, 2004, J BIOL CHEM, V279, P25101, DOI 10.1074/jbc.M313662200
   Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465
   Nuttall ME, 2000, AM J PHYSIOL CELL PH, V279, pC1550, DOI 10.1152/ajpcell.2000.279.5.C1550
   Powledge TM, 2004, LANCET, V363, P870, DOI 10.1016/S0140 6736(04)15776 0
   RALSTON SH, 1994, ENDOCRINOLOGY, V135, P330, DOI 10.1210/en.135.1.330
   Ralston SH, 1997, BRIT J RHEUMATOL, V36, P831
   Reiss U, 2004, J BIOL CHEM, V279, P1281, DOI 10.1074/jbc.M309646200
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092 8674(00)80091 4
   SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326
   Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537
   Simoncini T, 2003, EUR J ENDOCRINOL, V148, P281, DOI 10.1530/eje.0.1480281
   STEIN B, 1995, MOL CELL BIOL, V15, P4971
   Takeda Y, 1999, J BIOL CHEM, V274, P10654, DOI 10.1074/jbc.274.15.10654
   Taranta A, 2002, BONE, V30, P368, DOI 10.1016/S8756 3282(01)00685 8
   Tee MK, 2004, MOL BIOL CELL, V15, P1262, DOI 10.1091/mbc.E03 06 0360
   Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022 1759(95)00072 I
   Viereck V, 2003, J CLIN ENDOCR METAB, V88, P4206, DOI 10.1210/jc.2002 021877
   Yang NN, 1996, ENDOCRINOLOGY, V137, P2075, DOI 10.1210/en.137.5.2075
   Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222
NR 50
TC 29
Z9 36
U1 0
U2 3
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAR 15
PY 2005
VL 69
IS 6
BP 891
EP 901
DI 10.1016/j.bcp.2004.11.030
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 907TW
UT WOS:000227741900003
PM 15748701
OA Green Published
DA 2025 08 17
ER

PT J
AU Mehdi, SH
   Gentry, AC
   Lee, JY
   Chung, CP
   Yoon, D
AF Mehdi, Syed Hassan
   Gentry, Austin C.
   Lee, Jue Yeon
   Chung, Chong Pyoung
   Yoon, Donghoon
TI The Synthetic Collagen Binding Peptide NIPEP OSS Delays Mouse Myeloma
   Progression
SO CANCERS
LA English
DT Article
DE multiple myeloma; NIPEP OSS; bone anabolic agent; bone mineralization;
   multiple myeloma bone disease
ID MULTIPLE MYELOMA; BONE DISEASE; IN VITRO; OSTEOBLAST DIFFERENTIATION;
   WORKING GROUP; STEM CELLS; TRANSPLANTATION; OSTEOPONTIN;
   PATHOPHYSIOLOGY; RECOMMENDATIONS
AB Multiple myeloma (MM) is the second most common hematological malignancy. It is a clonal B cell disorder characterized by the proliferation of malignant plasma cells in the bone marrow, the presence of monoclonal serum immunoglobulin, and osteolytic lesions. An increasing amount of evidence shows that the interactions of MM cells and the bone microenvironment play a significant role, suggesting that these interactions may be good targets for therapy. The osteopontin derived collagen binding motif bearing peptide NIPEP OSS stimulates biomineralization and enhances bone remodeling dynamics. Due to its unique targeted osteogenic activity with a broad safety margin, we evaluated the potential of NIPEP OSS for anti myeloma activity using MM bone disease (MMBD) animal models. In a 5TGM1 engrafted NSG model, the survival rates of the control and treated groups were significantly different (p = 0.0014), with median survival times of 45 and 57 days, respectively. The bioluminescence analyses showed that myeloma slowly developed in the treated mice compared to the control mice in both models. NIPEP OSS enhanced bone formation by increasing biomineralization in the bone. We also tested NIPEP OSS in a well established 5TGM1 engrafted C57BL/KaLwRij model. Similar to the previous model, the median survival times of the control and treated groups were significantly different (p = 0.0057), with 46 and 63 days, respectively. In comparison with the control, an increase in p1NP was found in the treated mice. We concluded that NIPEP OSS delays mouse myeloma progression via bone formation in MMBD mouse models.
C1 [Mehdi, Syed Hassan; Gentry, Austin C.; Yoon, Donghoon] Univ Arkansas Med Sci, Myeloma Ctr, Little Rock, AR 72205 USA.
   [Lee, Jue Yeon; Chung, Chong Pyoung] NIBEC Co Ltd, Res Inst, 174 Yulgok Ro, Seoul 03170, South Korea.
C3 University of Arkansas System; University of Arkansas Medical Sciences
RP Yoon, D (通讯作者)，Univ Arkansas Med Sci, Myeloma Ctr, Little Rock, AR 72205 USA.
EM dyoon@uams.edu
RI ; Lee, Sang Jin/S 4056 2019
OI Mehdi, Syed/0009 0009 3333 8802; 
FU National Institute of Health [1R21 OD026618]; National Institute of
   General Medical Sciences of the National Institutes of Health
   [P20GM125503]
FX This research was funded by the National Institute of Health (1R21
   OD026618) and the National Institute of General Medical Sciences of the
   National Institutes of Health under award no. P20GM125503.
CR Andersen TL, 2009, AM J PATHOL, V174, P239, DOI 10.2353/ajpath.2009.080627
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Asosingh K, 2000, Hematol J, V1, P351, DOI 10.1038/sj.thj.6200052
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Boskey AL, 1996, CONNECT TISSUE RES, V35, P357, DOI 10.3109/03008209609029212
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   COHEN S, 1993, CLIN MATER, V13, P3, DOI 10.1016/0267 6605(93)90082 I
   Dahl T, 2003, CONNECT TISSUE RES, V44, P206, DOI 10.1080/03008200390181672
   DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365 2141.1999.01715.x
   Donzelli E, 2007, ARCH ORAL BIOL, V52, P64, DOI 10.1016/j.archoralbio.2006.07.007
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Eghbali Fatourechi GZ, 2005, NEW ENGL J MED, V352, P1959, DOI 10.1056/NEJMoa044264
   Esteve FR, 2007, BEST PRACT RES CL HA, V20, P613, DOI 10.1016/j.beha.2007.08.003
   FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365 2184.1987.tb01309.x
   FUJISAWA R, 1995, CALCIFIED TISSUE INT, V56, P140, DOI 10.1007/BF00296346
   FUJISAWA R, 1992, CALCIFIED TISSUE INT, V51, P438
   GARNERO P, 1992, J BONE MINER RES, V7, P1389
   Gnoni Antonio, 2020, Oncotarget, V11, P480, DOI 10.18632/oncotarget.27439
   He G, 2004, J BIOL CHEM, V279, P11649, DOI 10.1074/jbc.M309296200
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Ishaug Riley SL, 1998, BIOMATERIALS, V19, P1405, DOI 10.1016/S0142 9612(98)00021 0
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kumar SK, 2014, LEUKEMIA, V28, P1122, DOI 10.1038/leu.2013.313
   Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21
   Lee JY, 2007, BIOMATERIALS, V28, P4257, DOI 10.1016/j.biomaterials.2007.05.040
   Lin X, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00757
   Martin TJ, 2013, WORLD J ORTHOP, V4, P186, DOI 10.5312/wjo.v4.i4.186
   McKee MD, 1996, CONNECT TISSUE RES, V35, P197, DOI 10.3109/03008209609029192
   McKee MD, 1996, MICROSC RES TECHNIQ, V33, P141, DOI 10.1002/(SICI)1097 0029(19960201)33:2<141::AID JEMT5>3.0.CO;2 W
   McKee MD, 1996, J BONE MINER RES, V11, P873
   Mehdi SH, 2021, CANCERS, V13, DOI 10.3390/cancers13174277
   Mehdi SH, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.640954
   Mohan M, 2017, J BONE MINER RES, V32, P1261, DOI 10.1002/jbmr.3111
   Park YS, 2014, BIOMATERIALS, V35, P9747, DOI 10.1016/j.biomaterials.2014.08.007
   RADL J, 1979, J IMMUNOL, V122, P609
   RADL J, 1981, AM J PATHOL, V105, P91
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Ring ES, 2018, CALCIFIED TISSUE INT, V102, P196, DOI 10.1007/s00223 017 0351 7
   Rocha LB, 2006, J BIOMED MATER RES A, V79A, P237, DOI 10.1002/jbm.a.30782
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Saito T, 1997, BONE, V21, P305, DOI 10.1016/S8756 3282(97)00149 X
   Silbermann R, 2013, J BONE ONCOL, V2, P59, DOI 10.1016/j.jbo.2013.04.001
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Terpos E, 2010, LEUKEMIA, V24, P1700, DOI 10.1038/leu.2010.173
   Terpos E, 2021, LANCET ONCOL, V22, pE119, DOI 10.1016/S1470 2045(20)30559 3
   Terpos E, 2019, BLOOD, V133, P1534, DOI 10.1182/blood 2018 11 852459
   Terpos E, 2013, J CLIN ONCOL, V31, P2347, DOI 10.1200/JCO.2012.47.7901
   Wang YZ, 2005, BIOMATERIALS, V26, P7082, DOI 10.1016/j.biomaterials.2005.05.022
   Yaccoby S, 2010, BRIT J HAEMATOL, V149, P311, DOI 10.1111/j.1365 2141.2010.08141.x
   Zangari M, 2016, BONE, V86, P131, DOI 10.1016/j.bone.2016.02.019
NR 50
TC 0
Z9 0
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD APR 26
PY 2023
VL 15
IS 9
AR 2473
DI 10.3390/cancers15092473
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA G1YM8
UT WOS:000987197100001
PM 37173940
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lee, YC
   Lin, SC
   Yu, GY
   Zhu, M
   Song, JH
   Rivera, K
   Pappin, D
   Logothetis, CJ
   Panaretakis, T
   Wang, GC
   Yu Lee, LY
   Lin, SH
AF Lee, Yu Chen
   Lin, Song Chang
   Yu, Guoyu
   Zhu, Ming
   Song, Jian H.
   Rivera, Keith
   Pappin, Darryl
   Logothetis, Christopher J.
   Panaretakis, Theocharis
   Wang, Guocan
   Yu Lee, Li Yuan
   Lin, Sue Hwa
TI Prostate tumor induced stromal reprogramming generates Tenascin C that
   promotes prostate cancer metastasis through YAP/TAZ inhibition
SO ONCOGENE
LA English
DT Article
ID BONE; CELLS; EXPRESSION; GROWTH; PROGRESSION; RECEPTOR; INTEGRIN; LNCAP;
   PHOSPHORYLATION; ACTIVATION
AB Metastatic prostate cancer (PCa) in bone induces bone forming lesions that enhance PCa progression. How tumor induced bone formation enhances PCa progression is not known. We have previously shown that PCa induced bone originates from endothelial cells (ECs) that have undergone endothelial to osteoblast (EC to OSB) transition by tumor secreted bone morphogenetic protein 4 (BMP4). Here, we show that EC to OSB transition leads to changes in the tumor microenvironment that increases the metastatic potential of PCa cells. We found that conditioned medium (CM) from EC OSB hybrid cells increases the migration, invasion, and survival of PC3 mm2 and C4 2B4 PCa cells. Quantitative mass spectrometry (Isobaric Tags for Relative and Absolute Quantitation) identified Tenascin C (TNC) as one of the major proteins secreted from EC OSB hybrid cells. TNC expression in tumor induced OSBs was confirmed by immunohistochemistry of MDA PCa 118b xenograft and human bone metastasis specimens. Mechanistically, BMP4 increases TNC expression in EC OSB cells through the Smad1 Notch/Hey1 pathway. How TNC promotes PCa metastasis was next interrogated by in vitro and in vivo studies. In vitro studies showed that a TNC neutralizing antibody inhibits EC OSB CM mediated PCa cell migration and survival. TNC knockdown decreased, while the addition of recombinant TNC or TNC overexpression increased migration and anchorage independent growth of PC3 or C4 2b cells. When injected orthotopically, PC3 mm2 shTNC clones decreased metastasis to bone, while C4 2b TNC overexpressing cells increased metastasis to lymph nodes. TNC enhances PCa cell migration through alpha 5 beta 1 integrin mediated YAP/TAZ inhibition. These studies elucidate that tumor induced stromal reprogramming generates TNC that enhances PCa metastasis and suggest that TNC may be a target for PCa therapy.
C1 [Lee, Yu Chen; Lin, Song Chang; Yu, Guoyu; Lin, Sue Hwa] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.
   [Zhu, Ming; Song, Jian H.; Logothetis, Christopher J.; Panaretakis, Theocharis; Wang, Guocan; Lin, Sue Hwa] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
   [Rivera, Keith; Pappin, Darryl] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.
   [Yu Lee, Li Yuan] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   [Yu Lee, Li Yuan] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; Cold Spring Harbor
   Laboratory; Baylor College of Medicine; Baylor College of Medicine
RP Lin, SH (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.; Lin, SH (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
EM slin@mdanderson.org
RI Panaretakis, Theocharis/A 9354 2010; Wang, Guocan/F 1530 2011
OI Zhu, Ming/0000 0003 1916 8121
FU NIH [R01CA174798, 5P50CA140388, P30CA16672]; Cancer Prevention Research
   Institute of Texas grants [RP150179, RP190252]
FX This work was supported by grants from the NIH R01CA174798 (to S HL,
   L YY L), NIH 5P50CA140388 (to CJL, S HL), NIH P30CA16672 Core grant to
   MD Anderson Cancer Center, and Cancer Prevention Research Institute of
   Texas grants RP150179 and RP190252 (to S HL and L YY L).
CR Ben Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Carey WA, 2010, AM J PHYSIOL LUNG C, V299, pL785, DOI 10.1152/ajplung.00385.2009
   CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092 8674(86)90374 0
   Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541 7786.MCR 08 0077
   Conklin MW, 2012, CELL ADHES MIGR, V6, P249, DOI 10.4161/cam.20567
   Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008 5472.CAN 05 1891
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Fischer A, 2005, MOL CELL BIOL, V25, P8960, DOI 10.1128/MCB.25.20.8960 8970.2005
   Grahovac J, 2013, J INVEST DERMATOL, V133, P210, DOI 10.1038/jid.2012.263
   Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010
   Heindryckx F, 2015, WORLD J HEPATOL, V7, P165, DOI 10.4254/wjh.v7.i2.165
   Herold Mende C, 2002, INT J CANCER, V98, P362, DOI 10.1002/ijc.10233
   Hong CC, 2009, CYTOKINE GROWTH F R, V20, P409, DOI 10.1016/j.cytogfr.2009.10.021
   Hosein AN, 2020, NAT REV GASTRO HEPAT, V17, P487, DOI 10.1038/s41575 020 0300 1
   Huang CF, 2010, CANCER RES, V70, P4580, DOI 10.1158/0008 5472.CAN 09 3016
   Jachetti E, 2015, CANCER RES, V75, P2095, DOI 10.1158/0008 5472.CAN 14 2346
   Jiao SP, 2019, CELL, V179, P1177, DOI 10.1016/j.cell.2019.10.029
   Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279
   Katoh D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.27
   Lee YC, 2018, J PROTEOME RES, V17, P348, DOI 10.1021/acs.jproteome.7b00599
   Lee YC, 2015, CANCER RES, V75, P4949, DOI 10.1158/0008 5472.CAN 15 1215
   Lee YC, 2013, MOL CANCER RES, V11, P1401, DOI 10.1158/1541 7786.MCR 13 0108
   Lee YC, 2013, MOL CANCER RES, V11, P405, DOI 10.1158/1541 7786.MCR 12 0551
   Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008 5472.CAN 10 4374
   Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093
   Lin SC, 2017, DEV CELL, V41, P467, DOI 10.1016/j.devcel.2017.05.005
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Martin RS, 2017, CANCER RES, V77, P5977, DOI 10.1158/0008 5472.CAN 17 0064
   Midwood KS, 2016, J CELL SCI, V129, P4321, DOI 10.1242/jcs.190546
   Miroshnikova YA, 2016, NAT CELL BIOL, V18, P1336, DOI 10.1038/ncb3429
   Morrissey C, 2010, NEOPLASIA, V12, P192, DOI 10.1593/neo.91836
   Mutvei AP, 2018, ONCOGENE, V37, P6083, DOI 10.1038/s41388 018 0400 3
   Nagaharu K, 2011, AM J PATHOL, V178, P754, DOI 10.1016/j.ajpath.2010.10.015
   Ni WD, 2017, BIOCHEM BIOPH RES CO, V486, P607, DOI 10.1016/j.bbrc.2017.03.021
   Nordstrand A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041223
   Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379
   Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011
   Qiang L, 2012, CELL DEATH DIFFER, V19, P284, DOI 10.1038/cdd.2011.95
   Riedel A, 2016, NAT IMMUNOL, V17, P1118, DOI 10.1038/ni.3492
   Sarkar S, 2017, CANCER RES, V77, P3231, DOI 10.1158/0008 5472.CAN 16 2171
   SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196
   Sun Z, 2018, CANCER RES, V78, P950, DOI 10.1158/0008 5472.CAN 17 1597
   Sung SY, 2008, CANCER RES, V68, P9996, DOI 10.1158/0008 5472.CAN 08 2492
   Takada Y, 2007, GENOME BIOL, V8, DOI 10.1186/gb 2007 8 5 215
   THALMANN GN, 1994, CANCER RES, V54, P2577
   Thalmann GN, 2000, PROSTATE, V44, P91
   Totaro A, 2018, NAT CELL BIOL, V20, P888, DOI 10.1038/s41556 018 0142 z
   Tu Shi Ming, 2004, Cancer Treat Res, V118, P23
   Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912
   Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097 0215(19980911)77:6<887::AID IJC15>3.0.CO;2 Z
   Ye XC, 2012, PROSTATE, V72, P291, DOI 10.1002/pros.21431
   Yu G, 2021, ISCIENCE, V24
   Yu G, 2015, MOL CANCER RES, V13, P348, DOI 10.1158/1541 7786.MCR 14 0384 T
   Yu Lee LY, 2018, CANCER RES, V78, P2911, DOI 10.1158/0008 5472.CAN 17 1051
   Zhu M, 2021, ONCOGENE, V40, P6049, DOI 10.1038/s41388 021 02000 3
NR 55
TC 21
Z9 22
U1 0
U2 13
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950 9232
EI 1476 5594
J9 ONCOGENE
JI Oncogene
PD FEB 4
PY 2022
VL 41
IS 6
BP 757
EP 769
DI 10.1038/s41388 021 02131 7
EA NOV 2021
PG 13
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA YT5VS
UT WOS:000723571700003
PM 34845375
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Jiang, JK
   Xie, JL
   Zhou, L
   Han, W
   Ye, J
   Hu, DR
   Xie, WC
   Qiu, JB
   Chen, RF
   Wang, XL
AF Jiang, Junkai
   Xie, Jialiang
   Zhou, Liang
   Han, Wei
   Ye, Jing
   Hu, Daorun
   Xie, Weichang
   Qiu, Jianbin
   Chen, Runfu
   Wang, Xiaolei
TI Near infrared responsive nitric oxide and carbon monoxide nanoplatform
   for synergistic photodynamic therapy against periodontitis
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Periodontitis; Antibacterial; Photodynamic therapy; Nitric oxide; Carbon
   monoxide
ID RELEASE; CO; REGULATOR; PROBES
AB Periodontitis is a persistent inflammatory condition caused by plaque biofilm. To achieve successful periodontal tissue repair and halt disease progression, it is imperative to concurrently address the demands for precise antibacterial, anti inflammatory, and osteogenic interventions within the profound lesions. Herein, we synthesized an intelligent and efficient nanoplatform for the treatment of periodontitis, combining the synergistic therapeutic effects of carbon monoxide (CO) and nitric oxide (NO) gas therapy with the application of photodynamic therapy (PDT). Benefiting from the rapid adhesion to bacteria, responsive CO/NO releasing and ROS generation, the nanoplatform achieved a powerful bactericidal capacity and conspicuous biofilm elimination efficiency under 808 nm near infrared (NIR) light irradiation. In addition, the combination of CO and NO holds paramount significance, and they serve as crucial endogenous signaling molecules capable of regulating the TLR4/NF kappa B/NLRP3 pathway. This combination not only achieved critical protective effects but also fostered the promotion of osteoblast differentiation.
C1 [Xie, Jialiang; Wang, Xiaolei] Nanchang Univ, Sch Chem & Chem Engn, Nanchang 330088, Jiangxi, Peoples R China.
   [Jiang, Junkai; Hu, Daorun] Nanchang Univ, Affiliated Hosp 1, Jiangxi Med Coll, Dept Oral & Maxillofacial Surg, Nanchang 330006, Jiangxi, Peoples R China.
   [Jiang, Junkai; Xie, Jialiang; Zhou, Liang; Han, Wei; Ye, Jing; Hu, Daorun; Xie, Weichang; Qiu, Jianbin; Chen, Runfu; Wang, Xiaolei] Nanchang Univ, Inst Translat Med, Natl Engn Res Ctr Bioengn Drugs & Technol, Nanchang 330088, Jiangxi, Peoples R China.
   [Ye, Jing; Chen, Runfu] Nanchang Univ, Dept Cardiol, Affiliated Hosp 2, Nanchang, Peoples R China.
   [Zhou, Liang; Han, Wei; Qiu, Jianbin] Nanchang Univ, Affiliated Stomatol Hosp, Nanchang 330006, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University; Nanchang University; Nanchang
   University; Nanchang University
RP Wang, XL (通讯作者)，Nanchang Univ, Sch Chem & Chem Engn, Nanchang 330088, Jiangxi, Peoples R China.
EM wangxiaolei@ncu.edu.cn
FU Key Youth Project of Jiangxi Province [20202ACB216002]; Key Research and
   Development Program of Jiangxi Province [20212BBG73004]; Na tional
   Natural Science Foundation of China [82260194]
FX This work was funded by the Key Youth Project of Jiangxi Province
   (20202ACB216002 to Xiaolei Wang) , Key Research and Development Program
   of Jiangxi Province (20212BBG73004 to Xiaolei Wang) , Na tional Natural
   Science Foundation of China (No. 82260194 to Jiaxuan Qiu) .
CR Aguilar G, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.595526
   Angeluzzi NC, 2014, J MATER CHEM B, V2, P4221, DOI 10.1039/c4tb00170b
   Armitage GC, 2020, PERIODONTOL 2000, V82, P12, DOI 10.1111/prd.12303
   Castro Alférez M, 2016, SCI REP UK, V6, DOI 10.1038/srep38145
   Chen WL, 2023, J AM CHEM SOC, V145, P8130, DOI 10.1021/jacs.3c01042
   Darveau RP, 2010, NAT REV MICROBIOL, V8, P481, DOI 10.1038/nrmicro2337
   Deng QQ, 2021, ACS NANO, V15, P6604, DOI 10.1021/acsnano.0c09939
   Duan CC, 2018, J MATER CHEM B, V6, P192, DOI 10.1039/c7tb02527k
   EDWARDS AM, 1994, J PHOTOCH PHOTOBIO B, V24, P179, DOI 10.1016/1011 1344(94)07020 2
   Fan HH, 2018, CHEM COMMUN, V54, P4310, DOI [10.1039/C8CC01841C, 10.1039/c8cc01841c]
   Fan J, 2015, NANOSCALE, V7, P20055, DOI 10.1039/c5nr06630a
   Feng SM, 2017, ANAL CHEM, V89, P3754, DOI 10.1021/acs.analchem.7b00135
   Gao L, 2022, ANGEW CHEM INT EDIT, V61, DOI 10.1002/anie.202112782
   Genco RJ, 2010, NAT REV CARDIOL, V7, P479, DOI 10.1038/nrcardio.2010.120
   Greenstein G, 2006, J PERIODONTOL, V77, P565, DOI 10.1902/jop.2006.050140
   Hamblin MR, 2004, PHOTOCH PHOTOBIO SCI, V3, P436, DOI 10.1039/b311900a
   Hu HH, 2021, NAT CHEM, V13, DOI 10.1038/s41557 020 00635 5
   Huang LY, 2012, LASER SURG MED, V44, P490, DOI 10.1002/lsm.22045
   Huo MF, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202010196
   Ji HW, 2016, SMALL, V12, P6200, DOI 10.1002/smll.201601729
   Jiao Y, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0062 1
   Johnson NJJ, 2012, J AM CHEM SOC, V134, P11068, DOI 10.1021/ja302717u
   Kim HP, 2006, ANNU REV PHARMACOL, V46, P411, DOI 10.1146/annurev.pharmtox.46.120604.141053
   Kim H, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202011252
   Koo H, 2017, NAT REV MICROBIOL, V15, P740, DOI 10.1038/nrmicro.2017.99
   Kuang GZ, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202100938
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Lee JK, 2023, ADV SCI, V10, DOI 10.1002/advs.202205336
   Leea CW, 2019, MOL IMMUNOL, V112, P163, DOI 10.1016/j.molimm.2019.05.005
   Li J, 2021, J AM CHEM SOC, V143, P15427, DOI 10.1021/jacs.1c07875
   Li Y, 2016, ACS NANO, V10, P2766, DOI 10.1021/acsnano.5b07873
   Li Z, 2021, ANGEW CHEM INT EDIT, V60, P19201, DOI 10.1002/anie.202103943
   Lin YJ, 2018, ADV MATER, V30, DOI 10.1002/adma.201705605
   Ling K, 2018, J MED CHEM, V61, P2611, DOI 10.1021/acs.jmedchem.6b01153
   Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517
   Edwards AM, 2014, METHODS MOL BIOL, V1146, P3, DOI 10.1007/978 1 4939 0452 5_1
   McLean S, 2012, ANAL BIOCHEM, V427, P36, DOI 10.1016/j.ab.2012.04.026
   Mendes RT, 2018, CLIN EXP DENT RES, V4, P241, DOI 10.1002/cre2.135
   Mishra BB, 2013, NAT IMMUNOL, V14, P52, DOI 10.1038/ni.2474
   Montoya T, 2019, J AGR FOOD CHEM, V67, P5552, DOI 10.1021/acs.jafc.9b00771
   MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475
   Motterlini R, 2010, NAT REV DRUG DISCOV, V9, P728, DOI 10.1038/nrd3228
   Qi ML, 2022, NANO TODAY, V43, DOI 10.1016/j.nantod.2022.101447
   Qi ML, 2019, DENT MATER, V35, P1665, DOI 10.1016/j.dental.2019.08.115
   Schairer DO, 2012, VIRULENCE, V3, P271, DOI 10.4161/viru.20328
   Stanojevic JS, 2015, MONATSH CHEM, V146, P1787, DOI 10.1007/s00706 015 1561 1
   Sun J, 2022, J HAZARD MATER, V435, DOI 10.1016/j.jhazmat.2022.128948
   Sun XL, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202101040
   Suyver JF, 2006, J LUMIN, V117, P1, DOI 10.1016/j.jlumin.2005.03.011
   Tabe H, 2016, CHEM COMMUN, V52, P4545, DOI 10.1039/c5cc10440h
   Wang PG, 2002, CHEM REV, V102, P1091, DOI 10.1021/cr000040l
   Wang YF, 2013, ACS NANO, V7, P7200, DOI 10.1021/nn402601d
   Wimalawansa SJ, 2008, EXPERT OPIN PHARMACO, V9, P3025, DOI 10.1517/14656560802197162 
   Xue J, 2014, J CLIN INVEST, V124, P437, DOI 10.1172/JCI71362
   Yan N, 2022, NANO TODAY, V42, DOI 10.1016/j.nantod.2021.101336
   Yang BW, 2019, CHEM REV, V119, P4881, DOI 10.1021/acs.chemrev.8b00626
   Zhang WB, 2017, BASIC RES CARDIOL, V112, DOI 10.1007/s00395 017 0603 8
   Zhou BS, 2022, THERANOSTICS, V12, P2580, DOI 10.7150/thno.70277
NR 58
TC 17
Z9 18
U1 12
U2 65
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD JAN 15
PY 2024
VL 480
AR 147850
DI 10.1016/j.cej.2023.147850
EA DEC 2023
PG 18
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA ED5U7
UT WOS:001137000800001
DA 2025 08 17
ER

PT J
AU Morgan, C
   Lewis, PD
   Jones, RM
   Bertelli, G
   Thomas, GA
   Leonard, RCF
AF Morgan, Claire
   Lewis, Paul D.
   Jones, Rachel M.
   Bertelli, Gianfilippo
   Thomas, Gerry A.
   Leonard, Robert C. F.
TI The in vitro anti tumour activity of zoledronic acid and
   docetaxel at clinically achievable concentrations in prostate cancer
SO ACTA ONCOLOGICA
LA English
DT Article
ID MEMBRANE LOCALIZATION; APOPTOSIS; CELLS; BISPHOSPHONATE; BREAST;
   SURVIVAL; DOXORUBICIN; INHIBITION; BONE
AB Bisphosphonates and chemotherapy have increasingly gained favour in the treatment of metastatic hormone resistant prostate cancer. We investigated whether zoledronic acid, at a concentration found at the bone, would enhance the antitumour activity of docetaxel in the hormone resistant prostate cancer cell line PC 3. Cells were exposed to zoledronic acid (1 mM) in combination or in sequence with docetaxel (3 nM). Cell viability, apoptosis and markers for inhibition of the mevalonate pathway were analyzed 48 or 72 hours after drug treatment. Reduction in cell viability and increased apoptosis levels were most pronounced with single agent zoledronic acid. Western blot analysis showed an overall reduction in the proliferation marker Mini chromosome maintenance protein 2 (MCM2) and reduction in caspase 3 precursor for all drug treatments and a marked reduction in Rho A levels with single agent zoledronic acid and zoledronic acid docetaxel sequence. This study highlights the potency of zoledronic acid, when used at concentrations similar to those found at the bone, in reducing cell viability and causing apoptosis. Clinically, these findings suggest that in patients with bone metastases due to hormone resistance prostate cancer, who are not fit enough for systemic chemotherapy, single agent zoledronic acid may have a direct effect on viability of prostate cancer epithelial cells.
C1 Swansea Univ, Sch Med, Human Canc Studies Grp, Swansea SA2 8PP, W Glam, Wales.
   Singleton Hosp, S W Wales Canc Inst, Swansea SA2 8QA, W Glam, Wales.
C3 Swansea University; Singleton Hospital
RP Morgan, C (通讯作者)，Swansea Univ, Sch Med, Human Canc Studies Grp, Swansea SA2 8PP, W Glam, Wales.
EM Claire_Morgan70@hotmail.com
RI ; Morgan, Claire/IUQ 5577 2023; Lewis, Paul/G 9786 2012
OI Morgan, Claire/0000 0002 3969 0710; 
CR Bertelli G, 2006, CANCER CHEMOTH PHARM, V57, P46, DOI 10.1007/s00280 005 0025 4
   Coxon JP, 2004, BJU INT, V94, P164, DOI 10.1111/j.1464 4096.2004.04831.x
   Dumon JC, 2004, EUR UROL, V45, P521, DOI 10.1016/j.eururo.2003.12.012
   Gómez Lechón MJ, 2002, TOXICOL SCI, V65, P299, DOI 10.1093/toxsci/65.2.299
   Haldar S, 1997, CANCER RES, V57, P229
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   Meng MV, 2001, CLIN CANCER RES, V7, P2712
   Muenchen HJ, 2001, UROLOGY, V57, P366, DOI 10.1016/S0090 4295(00)00935 3
   Neville Webbe HL, 2005, INT J CANCER, V113, P364, DOI 10.1002/ijc.20602
   Nogawa M, 2005, ONCOL RES, V15, P1
   Oades GM, 2003, J UROLOGY, V170, P246, DOI 10.1097/01.ju.0000070685.34760.5f
   Osoba D, 1999, J CLIN ONCOL, V17, P1654, DOI 10.1200/JCO.1999.17.6.1654
   Padmanabhan V, 2004, J CLIN PATHOL, V57, P1057, DOI 10.1136/jcp.2004.016436
   Reyes Moreno C, 1998, UROLOGY, V52, P341, DOI 10.1016/S0090 4295(98)00182 4
   Riou J. F., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P385
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297
   Smaletz O, 2002, J CLIN ONCOL, V20, P3972, DOI 10.1200/JCO.2002.11.021
   Suzuki A, 1998, EUR J PHARMACOL, V343, P87, DOI 10.1016/S0014 2999(97)01520 3
   Tantivejkul K, 2005, J CELL BIOCHEM, V96, P641, DOI 10.1002/jcb.20533
   Tenta R, 2004, PROSTATE, V59, P120, DOI 10.1002/pros.10363
   Ullén A, 2005, ACTA ONCOL, V44, P644, DOI 10.1080/02841860510029617
   Wang Q, 2004, ONCOGENE, V23, P426, DOI 10.1038/sj.onc.1207040
NR 25
TC 34
Z9 35
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0284 186X
EI 1651 226X
J9 ACTA ONCOL
JI Acta Oncol.
PY 2007
VL 46
IS 5
BP 669
EP 677
DI 10.1080/02841860600996447
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 189ZK
UT WOS:000248027300011
PM 17562444
OA hybrid
DA 2025 08 17
ER

PT J
AU Oliveira, AC
   Ferraz, MP
   Monteiro, FJ
   Simoes, S
AF Oliveira, A. C.
   Ferraz, M. P.
   Monteiro, F. J.
   Simoes, S.
TI Cationic liposome DNA complexes as gene delivery vectors: Development
   and behaviour towards bone like cells
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Cationic liposomes; Gene therapy; Osteogenesis; Osteoblast
ID STEM CELLS; THERAPY; REGENERATION; LIPOPLEXES
AB Modulation of the biological pathways responsible for fracture repair and osteogenisis may accelerate regeneration. Gene therapy is an alternative method for the release of osteogenisis stimulating proteins into tissues. The development of vectors for gene release is still a problem in terms of ethics and techniques. In this work we evaluated whether cationic liposomes constitute a valuable strategy for the release of genetic material into bone tissue cells as non viral vectors. Liposomes were prepared with 1,2 dioleoyl 3 trimethylammonium propane (DOTAP) 2 dioleoyl sn glycero 3 phosphatidylethanolamine and DOTAP cholesterol, and characterized according to their size, zeta potential, DNA protection capacity and cytotoxicity. Transfection studies were also carried out using pCMV beta gal plasmid in two osteoblastic cell lines (MG63 and MC3T3 E1) and in the 294T line, varying the charge ratio and the applied DNA dose. Inclusion of transferrin to increase the expression was also tested. The results suggest that there is great dependency between the transfection activity and the lipid formulation, the charge ratios of the complexes, the applied DNA dose and the cell type. There were even some differences concerning both osteoblastic lines under study. The cells of the MC3T3 E 1 line present greater expression levels than the cells of the MG 63 line. The conjugation of the transferrin with the complexes contributes to the increase in transfection levels, possibly due to an increase in internalization of complexes. It is thus a good strategy for inducing the expression of specific genes in osteoblast like cells. (C) 2009 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Oliveira, A. C.; Ferraz, M. P.; Monteiro, F. J.] INEB, Lab Biomat, P 4150180 Oporto, Portugal.
   [Oliveira, A. C.; Monteiro, F. J.] Univ Porto, Dept Engn Met & Mat, Fac Engn, P 4100 Oporto, Portugal.
   [Ferraz, M. P.] Univ Fernando Pessoa, CEBIMED, Fac Ciencias Saude, P 4200150 Oporto, Portugal.
   [Simoes, S.] Univ Coimbra, Dept Gene Therapy, Ctr Neurosci & Cell Biol, P 3000 Coimbra, Portugal.
   [Simoes, S.] Univ Coimbra, Pharmaceut Technol Lab, Fac Pharm, P 3000 Coimbra, Portugal.
C3 Universidade do Porto; Universidade do Porto; Universidade Fernando
   Pessoa; Universidade de Coimbra; Universidade de Coimbra
RP Ferraz, MP (通讯作者)，INEB, Lab Biomat, Rua Campo Alegre 823, P 4150180 Oporto, Portugal.
EM mpferraz@ufp.pt
RI ; Ferraz, Maria Pia/M 6316 2013; Monteiro, Fernando/ABB 7538 2020;
   Simões, Susana/AAF 9496 2021; Ferraz, Maria/M 6316 2013
OI Simoes, Sergio/0000 0002 8898 7625; Ferraz, Maria
   Pia/0000 0002 0274 106X; Monteiro, Fernando/0000 0002 1361 4605; 
CR Almofti MR, 2003, ARCH BIOCHEM BIOPHYS, V410, P246, DOI 10.1016/S0003 9861(02)00725 7
   Bucholz RW, 2002, CLIN ORTHOP RELAT R, P44
   Chen Y, 2003, GENE THER, V10, P1345, DOI 10.1038/sj.gt.3301999
   Choi WJ, 2004, BIOMATERIALS, V25, P5893, DOI 10.1016/j.biomaterials.2004.01.031
   Corsi K, 2003, BIOMATERIALS, V24, P1255, DOI 10.1016/S0142 9612(02)00507 0
   da Cruz MTG, 2001, BBA BIOMEMBRANES, V1510, P136
   de Ilarduya CT, 2002, BBA BIOMEMBRANES, V1561, P209, DOI 10.1016/S0005 2736(02)00348 6
   de Lima MCP, 2001, ADV DRUG DELIVER REV, V47, P277, DOI 10.1016/S0169 409X(01)00110 7
   Dragoo JL, 2003, J ORTHOP RES, V21, P622, DOI 10.1016/S0736 0266(02)00238 3
   Düzgünes N, 1999, ADV DRUG DELIVER REV, V40, P3, DOI 10.1016/S0169 409X(99)00037 X
   Eliyahu H, 2005, MOLECULES, V10, P34, DOI 10.3390/10010034
   Hirsch Lerner D, 2005, BBA BIOMEMBRANES, V1714, P71, DOI 10.1016/j.bbamem.2005.04.008
   KATZ JL, 1996, APPL MAT MED DENTIST, P335
   Kikuchi H, 1999, J CONTROL RELEASE, V62, P269, DOI 10.1016/S0168 3659(99)00047 4
   Kirker Head CA, 2000, ADV DRUG DELIVER REV, V43, P65, DOI 10.1016/S0169 409X(00)00078 8
   KOE GS, 1997, PHARMACY, P14
   Lasic DD, 1996, ADV DRUG DELIVER REV, V20, P221, DOI 10.1016/0169 409X(96)00002 6
   Laurencin CT, 2001, BIOMATERIALS, V22, P1271, DOI 10.1016/S0142 9612(00)00279 9
   LEACH JK, 2004, EXPERT OPIN, V4
   LIMA N, 2003, BIOTECNOLOGIA FUNDAM, P368
   Liu F, 2002, J CONTROL RELEASE, V78, P259, DOI 10.1016/S0168 3659(01)00494 1
   Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889
   Luo J, 2005, CURR GENE THER, V5, P167, DOI 10.2174/1566523053544218
   Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349
   Oreffo ROC, 1999, BONE, V25, p5S, DOI 10.1016/S8756 3282(99)00124 6
   PENQUE D, 2000, B BIOTECNOL, V66, P16
   Rejman J, 2005, MOL THER, V12, P468, DOI 10.1016/j.ymthe.2005.03.038
   SIMOES S, 2005, EXPERT OPIN, V2
   Simoes S, 2003, METHOD ENZYMOL, V373, P369
   Torricelli P, 2003, BIOMED PHARMACOTHER, V57, P57, DOI 10.1016/S0753 3322(02)00329 3
   TSENG WC, 1998, RES FOCUS, V1
   Winn SR, 2000, ADV DRUG DELIVER REV, V42, P121, DOI 10.1016/S0169 409X(00)00057 0
   Zuidam NJ, 1998, BBA BIOMEMBRANES, V1368, P115, DOI 10.1016/S0005 2736(97)00187 9
NR 33
TC 49
Z9 55
U1 0
U2 18
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JUL
PY 2009
VL 5
IS 6
BP 2142
EP 2151
DI 10.1016/j.actbio.2009.02.019
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 461XS
UT WOS:000267307900032
PM 19332382
DA 2025 08 17
ER

PT J
AU Zhong, HX
   Xuan, LY
   Wang, DD
   Zhou, JH
   Li, Y
   Jiang, Q
AF Zhong, Huixiang
   Xuan, Liuyang
   Wang, Dandan
   Zhou, Jianhua
   Li, Yan
   Jiang, Qing
TI Generation of a co culture cell micropattern model to simulate lung
   cancer bone metastasis for anticancer drug evaluation
SO RSC ADVANCES
LA English
DT Article
ID MESENCHYMAL STEM CELLS; MECHANICAL PROPERTIES; TARGETED THERAPY;
   DOXORUBICIN; DIFFERENTIATION; PROLIFERATION; PLATFORM; MARKERS
AB Lung cancer bone metastases usually involve multiple interactions between cancer cells and host organs. To mimic such a structure, a cell co culture micropattern of A549 lung cancer cells and osteoblast cells (A549/OB) was developed using a m eraser strategy for anti cancer drug evaluation and also understanding cell cell communication. When applying the m eraser strategy, a PDMS stamp was pressed to induce cell lysis. Hence, the minimum pressure required to induce cell lysis was first quantified. Then the pressure and pressing time for the micropatterning process were optimized to obtain cell micropatterns of high fidelity and repeatability. For different types of cells (A549 and human mesenchymal stem cells) and different substrates (TCP and PLGA nanofiber sheets), the optimized pressure was also different (i.e., for A549 on TCP, a pressure of 24.5 kPa was pressed for 10 s). According to a live/dead assay and Alamar Blue assay, cell viability and proliferation potential were not affected by the micropatterning process. There were several advantages for the m eraser strategy: substrates were not pre treated; cell micropatterns mainly relied on the pattern of the PDMS stamp along with the micropatterning process; cells in the micropattern were not restricted in specified regions. Thus the A549/OB co culture micropattern on TCP was used to evaluate the efficacy of a therapeutic agent (doxorubicin). In the co culture micropattern, the efficacy of doxorubicin decreased when the expression of ALP in OB was elevated. The co culture micropattern model showed the potential to be used for new anti cancer drug development.
C1 [Zhong, Huixiang; Xuan, Liuyang; Wang, Dandan; Zhou, Jianhua; Li, Yan; Jiang, Qing] Sun Yat Sen Univ, Sch Engn, Dept Biomed Engn, Guangdong Prov Key Lab Sensor Technol & Biomed In, Guangzhou, Guangdong, Peoples R China.
   [Zhong, Huixiang; Xuan, Liuyang; Wang, Dandan; Zhou, Jianhua; Li, Yan; Jiang, Qing] Sun Yat Sen Univ, Guangdong Prov Engn & Technol Ctr Adv & Portable, Guangzhou, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University
RP Li, Y (通讯作者)，Sun Yat Sen Univ, Sch Engn, Dept Biomed Engn, Guangdong Prov Key Lab Sensor Technol & Biomed In, Guangzhou, Guangdong, Peoples R China.; Li, Y (通讯作者)，Sun Yat Sen Univ, Guangdong Prov Engn & Technol Ctr Adv & Portable, Guangzhou, Guangdong, Peoples R China.
EM liyan99@mail.sysu.edu.cn
RI Li, Yan/H 3298 2016
OI Li, Yan/0000 0003 3115 8380
FU National Natural Science Foundation of China [51303216]; Fundamental
   Research Funds for the Central Universities [14lgpy12, 16lgjc62];
   Guangdong Provincial Education Department [2013KJCX005]; Australia China
   Joint Institute for Health Technology and Innovation
FX This work was supported in part by National Natural Science Foundation
   of China (51303216), Fundamental Research Funds for the Central
   Universities (14lgpy12 and 16lgjc62), Guangdong Provincial Education
   Department (2013KJCX005), and the Australia China Joint Institute for
   Health Technology and Innovation.
CR AHMED SA, 1994, J IMMUNOL METHODS, V170, P211, DOI 10.1016/0022 1759(94)90396 4
   Batnyam O, 2015, RSC ADV, V5, P80357, DOI 10.1039/c5ra13332g
   Chen YL, 2016, CHINESE J PHYSIOL, V59, P331, DOI 10.4077/CJP.2016.BAF426
   Dai W, 2016, CHEMNANOMAT, V2, P447, DOI 10.1002/cnma.201500212
   Dragatogiannis DA, 2012, PLAST RUBBER COMPOS, V41, P358, DOI 10.1179/1743289811Y.0000000062
   Fujita H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164830
   Garg T, 2015, J DRUG TARGET, V23, P202, DOI 10.3109/1061186X.2014.992899
   Hochdörffer K, 2012, J MED CHEM, V55, P7502, DOI 10.1021/jm300493m
   Huh D, 2012, LAB CHIP, V12, P2156, DOI 10.1039/c2lc40089h
   In GK, 2015, TRANSL CANCER RES, V4, P340, DOI 10.3978/j.issn.2218 676X.2015.08.05
   Jian YT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149051
   Kaji H, 2011, BBA GEN SUBJECTS, V1810, P239, DOI 10.1016/j.bbagen.2010.07.002
   Lee WS, 2016, MATER DESIGN, V96, P470, DOI 10.1016/j.matdes.2016.02.049
   Lekka M, 2012, MICRON, V43, P1259, DOI 10.1016/j.micron.2012.01.019
   LeVasseur N, 2016, CANCER TREAT REV, V50, P183, DOI 10.1016/j.ctrv.2016.09.013
   Li HQ, 2012, ACTA BIOMATER, V8, P531, DOI 10.1016/j.actbio.2011.09.029
   Li Y, 2016, COLLOID SURFACE B, V141, P397, DOI 10.1016/j.colsurfb.2016.01.033
   Li Y, 2016, SMALL, V12, P1230, DOI 10.1002/smll.201501907
   Luo Q, 2016, BBA GEN SUBJECTS, V1860, P1953, DOI 10.1016/j.bbagen.2016.06.010
   Miyoshi H, 2014, TISSUE ENG PART B RE, V20, P609, DOI [10.1089/ten.teb.2013.0728, 10.1089/ten.TEB.2013.0728]
   Munshi S, 2014, J PHARMACOL TOX MET, V70, P195, DOI 10.1016/j.vascn.2014.06.005
   Nakamura K, 2004, GENE THER, V11, P1155, DOI 10.1038/sj.gt.3302276
   Navaei A, 2017, RSC ADV, V7, P3302, DOI 10.1039/c6ra26279a
   Orr F. William, 2000, Cancer, V88, P2912, DOI 10.1002/1097 0142(20000615)88:12+<2912::AID CNCR6>3.0.CO;2 8
   Popper HH, 2016, CANCER METAST REV, V35, P75, DOI 10.1007/s10555 016 9618 0
   Prabhune M, 2012, MICRON, V43, P1267, DOI 10.1016/j.micron.2012.03.023
   Pu R, 2016, ONCOL LETT, V12, P2023, DOI 10.3892/ol.2016.4879
   Song CH, 2009, J VIROL, V83, P5918, DOI 10.1128/JVI.00165 09
   Srivastava A, 2016, SCI REP UK, V6, DOI 10.1038/srep38541
   Suresh S, 2007, ACTA MATER, V55, P3989, DOI 10.1016/j.actamat.2007.04.022
   Tay CY, 2011, SMALL, V7, P1416, DOI 10.1002/smll.201002298
   Trotter TN, 2016, MATRIX BIOL, V52 54, P301, DOI 10.1016/j.matbio.2016.01.006
   Wang SH, 2016, INT J ONCOL, V48, P681, DOI 10.3892/ijo.2015.3272
   Wang Y, 2008, BRAIN RES, V1195, P104, DOI 10.1016/j.brainres.2007.11.068
   Yamazoe H, 2016, ACTA BIOMATER, V31, P231, DOI 10.1016/j.actbio.2015.12.016
   Ye WL, 2015, SCI REP UK, V5, DOI 10.1038/srep14614
   Yu T, 2013, MACROMOL BIOSCI, V13, P799, DOI 10.1002/mabi.201200481
   Zakaria N, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1086 3
   Zhang J, 2015, BIOMATERIALS, V53, P251, DOI 10.1016/j.biomaterials.2015.02.097
   Zhang LL, 2016, J COLLOID INTERF SCI, V464, P126, DOI 10.1016/j.jcis.2015.11.008
   Zukotynski KA, 2017, PET CLIN, V12, P53, DOI 10.1016/j.cpet.2016.08.008
NR 41
TC 12
Z9 13
U1 1
U2 26
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046 2069
J9 RSC ADV
JI RSC Adv.
PY 2017
VL 7
IS 35
BP 21837
EP 21847
DI 10.1039/c7ra01868a
PG 11
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA ES8MJ
UT WOS:000399810800058
OA gold
DA 2025 08 17
ER

PT S
AU Nitta, K
   Ogawa, T
   Hanafusa, N
   Tsuchiya, K
AF Nitta, Kosaku
   Ogawa, Tetsuya
   Hanafusa, Norio
   Tsuchiya, Ken
BE Nakanishi, T
   Kuragano, T
TI Recent Advances in the Management of Vascular Calcification in Patients
   with End Stage Renal Disease
SO CKD ASSOCIATED COMPLICATIONS: PROGRESS IN THE LAST HALF CENTURY
SE Contributions to Nephrology
LA English
DT Article; Proceedings Paper
CT 63rd Annual Meeting of the Japanese Society for Dialysis Therapy (JSDT)
CY JUN 29 JUL 01, 2018
CL Kobe, JAPAN
SP Japanese Soc Dialysis Therapy
ID CORONARY ARTERY CALCIFICATION; CHRONIC KIDNEY DISEASE; FIBROBLAST GROWTH
   FACTOR 23; VITAMIN K DEFICIENCY; HEMODIALYSIS PATIENTS; AORTIC
   CALCIFICATION; CARDIOVASCULAR DISEASE; EXTRACELLULAR CALCIUM; PHOSPHATE
   REGULATION; PROGRESSION
AB Background: Vascular calcification (VC) is common in patients with chronic kidney disease (CKD) including end stage renal disease (ESRD). The pathogenesis of VC is complex, resulting in increased arterial stiffening, which is associated with cardiovascular mortality. In addition to traditional cardiovascular risk factors, CKD patients also have a number of non traditional cardiovascular risk factors that may play an important role in the pathogenesis of VC. Summary: Management of CKD mineral bone disorder using conventional therapeutic approaches, which include restricting dietary phosphate, administering phosphate binders, and using active vitamin D and calcimimetics, may inhibit the progression of VC, but these approaches remain controversial because recommended biochemical targets are difficult to achieve. Current treatment strategies focus on correcting abnormal calcium, phosphate, parathyroid hormone, and vitamin D levels in ESRD patients. Novel therapies for addressing VC include magnesium and vitamin K supplementation, which are currently being investigated in randomized controlled trials. This review summarizes current treatment strategies and therapeutic targets for the management of VC in patients with ESRD. Key Messages: A better understanding of the potential therapeutic approaches to VC may lead to improved mortality rates among patients with CKD including those on dialysis. Fetuin A inhibits VC by binding to the nanoparticles of calcium and phosphate, preventing mineral accretion. These particles are known as calciprotein particles and may provide an important pathway for mineral transport and clearance. This review article summarizes the current management of VC in patients with ESRD. (C) 2019 S. Karger AG, Basel
C1 [Nitta, Kosaku] Tokyo Womens Med Univ, Dept Nephrol, Tokyo, Japan.
   [Ogawa, Tetsuya] Tokyo Womens Med Univ, Med Ctr East, Dept Med, Tokyo, Japan.
   [Hanafusa, Norio; Tsuchiya, Ken] Tokyo Womens Med Univ, Dept Blood Purificat, Tokyo, Japan.
C3 Tokyo Women's Medical University; Tokyo Women's Medical University;
   Tokyo Women's Medical University
RP Nitta, K (通讯作者)，Tokyo Womens Med Univ, Dept Nephrol, Shinjuku Ku, 8 1 Kawada Cho, Tokyo 1628666, Japan.
EM knitta@twmu.ac.jp
CR [Anonymous], KIDNEY INT
   Aoun M, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882 017 0609 3
   Asamiya Y, 2015, OSTEOPOROSIS INT, V26, P1017, DOI 10.1007/s00198 014 2934 8
   Asamiya Y., 2016, Renal Replace. Ther, V2, P8, DOI [10.1186/s41100 016 0024 4, DOI 10.1186/S41100 016 0024 4]
   Atkinson J, 2008, J APPL PHYSIOL, V105, P1643, DOI 10.1152/japplphysiol.90476.2008
   Block GA, 2005, KIDNEY INT, V68, P1815, DOI 10.1111/j.1523 1755.2005.00600.x
   Chatrou MLL, 2011, HAMOSTASEOLOGIE, V31, P251, DOI 10.5482/ha 1157
   Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624
   Chertow GM, 2004, NEPHROL DIAL TRANSPL, V19, P1489, DOI 10.1093/ndt/gfh125
   Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523 1755.2002.00434.x
   Cozzolino M, 2003, KIDNEY INT, V64, P1653, DOI 10.1046/j.1523 1755.2003.00284.x
   Del Gobbo LC, 2013, AM J CLIN NUTR, V98, P160, DOI 10.3945/ajcn.112.053132
   Drüeke TB, 2011, CLIN J AM SOC NEPHRO, V6, P700, DOI 10.2215/CJN.01370211
   ELLIOTT RJ, 1994, CALCIFIED TISSUE INT, V54, P268, DOI 10.1007/BF00295949
   Fang XX, 2016, BMC MED, V14, DOI 10.1186/s12916 016 0742 z
   Fusaro M, 2012, J BONE MINER RES, V27, P2271, DOI 10.1002/jbmr.1677
   Holden Rachel M, 2015, Can J Kidney Health Dis, V2, P17, DOI 10.1186/s40697 015 0053 x
   Ivanovski O, 2009, ATHEROSCLEROSIS, V205, P55, DOI 10.1016/j.atherosclerosis.2008.10.043
   Jahnen Dechent W, 2012, CLIN KIDNEY J, V5, P3, DOI 10.1093/ndtplus/sfr163
   Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10
   Kanbay M, 2009, BLOOD PURIFICAT, V27, P220, DOI 10.1159/000197562
   Kestenbaum B, 2005, J AM SOC NEPHROL, V16, P520, DOI 10.1681/ASN.2004070602
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kurnatowska I, 2015, POL ARCH MED WEWN, V125, P631, DOI 10.20452/pamw.3041
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200
   London GM, 2002, NEPHROL DIAL TRANSPL, V17, P1713, DOI 10.1093/ndt/17.10.1713
   Lopez I, 2006, J AM SOC NEPHROL, V17, P795, DOI 10.1681/ASN.2005040342
   Louvet L, 2013, NEPHROL DIAL TRANSPL, V28, P869, DOI 10.1093/ndt/gfs520
   Moe SM, 2008, J AM SOC NEPHROL, V19, P213, DOI 10.1681/ASN.2007080854
   Moe SM, 2007, ADV CHRONIC KIDNEY D, V14, P3, DOI 10.1053/j.ackd.2006.10.005
   Montezano AC, 2010, HYPERTENSION, V56, P453, DOI 10.1161/HYPERTENSIONAHA.110.152058
   Neradova A, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882 017 0560 3
   Nitta K, 2004, AM J KIDNEY DIS, V44, P680, DOI 10.1053/j.ajkd.2004.06.009
   Nitta K, 2011, THER APHER DIAL, V15, P513, DOI 10.1111/j.1744 9987.2011.00979.x
   Ogawa T, 2009, HEMODIAL INT, V13, P301, DOI 10.1111/j.1542 4758.2009.00366.x
   Ohtake T, 2013, J CARDIOVASC PHARM T, V18, P439, DOI 10.1177/1074248413486355
   Pasch A, 2012, J AM SOC NEPHROL, V23, P1744, DOI 10.1681/ASN.2012030240
   Pilkey RM, 2007, AM J KIDNEY DIS, V49, P432, DOI 10.1053/j.ajkd.2006.11.041
   Qu XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057720
   Raggi P, 2011, NEPHROL DIAL TRANSPL, V26, P1327, DOI 10.1093/ndt/gfq725
   Reynolds JL, 2004, J AM SOC NEPHROL, V15, P2857, DOI 10.1097/01.ASN.0000141960.01035.28
   Salazar HP, 2002, AM J CARDIOL, V89, p17B
   Schlieper G, 2011, J AM SOC NEPHROL, V22, P387, DOI 10.1681/ASN.2010040339
   Segawa H, 2003, PFLUG ARCH EUR J PHY, V446, P585, DOI 10.1007/s00424 003 1084 1
   Shanahan CM, 1999, CIRCULATION, V100, P2168, DOI 10.1161/01.CIR.100.21.2168
   Shea MK, 2009, AM J CLIN NUTR, V89, P1799, DOI 10.3945/ajcn.2008.27338
   Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081
   Shroff RC, 2007, SEMIN DIALYSIS, V20, P103, DOI 10.1111/j.1525 139X.2007.00255.x
   Tamura K, 2007, EUR J PHARMACOL, V558, P159, DOI 10.1016/j.ejphar.2006.12.006
   Taniwaki H, 2005, NEPHROL DIAL TRANSPL, V20, P2472, DOI 10.1093/ndt/gfi039
   Tzanakis IP, 2014, INT UROL NEPHROL, V46, P2199, DOI 10.1007/s11255 014 0751 9
   Westenfeld R, 2012, AM J KIDNEY DIS, V59, P186, DOI 10.1053/j.ajkd.2011.10.041
   Wyskida K, 2015, CLIN BIOCHEM, V48, P1246, DOI 10.1016/j.clinbiochem.2015.08.011
   Xu JS, 2015, EXP THER MED, V9, P1028, DOI 10.3892/etm.2015.2215
   Yang H, 2004, KIDNEY INT, V66, P2293, DOI 10.1111/j.1523 1755.2004.66015.x
   Yano S, 2004, CELL CALCIUM, V35, P257, DOI 10.1016/j.ceca.2003.10.008
NR 57
TC 12
Z9 15
U1 0
U2 5
PU KARGER
PI BASEL
PA POSTFACH, CH 4009 BASEL, SWITZERLAND
SN 0302 5144
EI 1662 2782
BN 978 3 318 06424 7
J9 CONTRIB NEPHROL
JI Contrib.Nephrol.
PY 2019
VL 198
BP 62
EP 72
DI 10.1159/000496532
PG 11
WC Urology & Nephrology
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA BO3ZP
UT WOS:000513762900008
PM 30991406
DA 2025 08 17
ER

PT J
AU Huang, JJ
   Ten, E
   Liu, G
   Finzen, M
   Yu, WL
   Lee, JS
   Saiz, E
   Tomsia, AP
AF Huang, Jijun
   Ten, Elena
   Liu, Gao
   Finzen, Matthew
   Yu, Wenli
   Lee, Janice S.
   Saiz, Eduardo
   Tomsia, Antoni P.
TI Biocomposites of pHEMA with HA/β TCP (60/40) for bone tissue
   engineering: Swelling, hydrolytic degradation, and in vitro
   behavior
SO POLYMER
LA English
DT Article
DE pHEMA; Hydrolytic degradation; N,O dimethactyloyl hydroxylamine
ID POLY(ACRYLIC ACID); HYDROGELS; COMBINATORIAL; SCAFFOLDS; COMPOSITES;
   DRUGS; BIOMATERIALS; REPLACEMENT; CHEMISTRY; NETWORKS
AB The field of bone and cartilage tissue engineering has a pressing need for novel, biocompatible, biodegradable biocomposites comprising polymers with bioceramics or bioglasses to meet numerous requirements for these applications. We created hydrolytically degradable hydrogel/bioceramic biocomposites, comprising poly(2 hydroxyethyl methacrylate) (pHEMA) hydrogels and 50 wt% biphasic hydroxyapatite/fi tricalcium phosphate (60/40) through in situ polymerization. The hydrolytic degradation starts with hydrolysis of the cross linker, N,O dimethacryloyl hydroxylamine, which was synthesized in house. Swelling and degradation were examined in details at a phosphate buffered saline solution at 37 degrees C over a 12 week period of time. To vary degradability, a co monomer, acrylic acid (AA) or 2 hydroxypropyl methacrylamide (HPMA), was introduced, coupled with altering the concentration of the cross linker and of the bioceramic. The co monomer HPMA was found to be more effective than AA in enhancing degradation, though AA led to greater swelling ratios. 33% of weight loss was achieved in some of the biocomposites containing HPMA. Porous structures were developed during swelling and degradation in biocomposites with AA but not in those containing HPMA, suggesting different degradation mechanisms: bulk erosion vs. bulk degradation. Good biocompatibility, as evidenced by attachment and proliferation of mouse derived osteoblast precursor cells from the MC3T3 E1 lineage, was observed on these biomaterials, regardless of the type of the co monomer. The rationale and approaches employed here open up new opportunities for creating novel, complex organic inorganic biomaterials in orthopedic tissue engineering. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Huang, Jijun; Ten, Elena; Tomsia, Antoni P.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Mat Sci, Berkeley, CA 94720 USA.
   [Huang, Jijun] Univ Chinese Acad Sci, Coll Mat Sci & Optoelect Technol, Beijing 100049, Peoples R China.
   [Ten, Elena] Washington State Univ, Mat Sci & Engn Program, Pullman, WA 99164 USA.
   [Liu, Gao] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Environm Energy Technol Div, Berkeley, CA 94720 USA.
   [Finzen, Matthew; Yu, Wenli; Lee, Janice S.] Univ Calif San Francisco, Dept Oral & Maxillofacial Surg, San Francisco, CA 94143 USA.
   [Saiz, Eduardo] Univ London Imperial Coll Sci Technol & Med, Ctr Adv Struct Ceram, Dept Mat, London, England.
C3 University of California System; University of California Berkeley;
   United States Department of Energy (DOE); Lawrence Berkeley National
   Laboratory; Chinese Academy of Sciences; University of Chinese Academy
   of Sciences, CAS; Washington State University; University of California
   System; University of California Berkeley; United States Department of
   Energy (DOE); Lawrence Berkeley National Laboratory; University of
   California System; University of California San Francisco; Imperial
   College London
RP Huang, JJ (通讯作者)，Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Mat Sci, Berkeley, CA 94720 USA.
EM jjho6@mit.edu
RI Liu, Gao/JCO 2803 2023; Saiz, Eduardo/F 9926 2015
OI Ten, Elena/0000 0002 5537 4646; Finzen, Matthew/0000 0003 2732 1122;
   Liu, Gao/0000 0001 6886 0507
FU National Institutes of Health/National Institute of Dental and
   Craniofacial Research (NIH/NIDCR) [1 R01 DE015633]; Engineering and
   Physical Sciences Research Council [EP/F033605/1] Funding Source:
   researchfish; EPSRC [EP/F033605/1] Funding Source: UKRI
FX This work was supported by the National Institutes of Health/National
   Institute of Dental and Craniofacial Research (NIH/NIDCR) Grant No.1 R01
   DE015633. We are indebted to Dr. Li Yang for helps with 1H NMR and Dr.
   John Kerr of Lawrence Berkeley National Laboratory for allowing us to
   use some of his experimental facilities.
CR [Anonymous], BON HLTH OST REP SUR
   Anseth KS, 2002, J CONTROL RELEASE, V78, P199, DOI 10.1016/S0168 3659(01)00500 4
   Behravesh E, 2002, BIOMACROMOLECULES, V3, P374, DOI 10.1021/bm010158r
   Bokias G, 1998, MACROMOL CHEM PHYSIC, V199, P1387, DOI 10.1002/(SICI)1521 3935(19980701)199:7<1387::AID MACP1387>3.0.CO;2 K
   Brandl F, 2007, BIOMATERIALS, V28, P134, DOI 10.1016/j.biomaterials.2006.09.017
   Brocchini S, 1998, J BIOMED MATER RES, V42, P66, DOI 10.1002/(SICI)1097 4636(199810)42:1<66::AID JBM9>3.3.CO;2 B
   Brocchini S, 1997, J AM CHEM SOC, V119, P4553, DOI 10.1021/ja970389z
   Brocchini S, 2001, ADV DRUG DELIVER REV, V53, P123, DOI 10.1016/S0169 409X(01)00224 1
   Burdick JA, 2005, BIOMATERIALS ARTIFIC, P109
   Burg KJL, 2000, BIOMATERIALS, V21, P2347, DOI 10.1016/S0142 9612(00)00102 2
   Calandrelli L, 2010, BIOMAT PROP PROD DEV, P1
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Eglin D, 2009, SOFT MATTER, V5, P938, DOI 10.1039/b803718n
   Elvira C, 1997, J MATER SCI MATER M, V8, P743, DOI 10.1023/A:1018504410878
   Ende MTA, 1996, J APPL POLYM SCI, V59, P673, DOI 10.1002/(SICI)1097 4628(19960124)59:4<673::AID APP13>3.0.CO;2 R
   Filion TM, 2011, TISSUE ENG PT A, V17, P503, DOI [10.1089/ten.tea.2010.0274, 10.1089/ten.TEA.2010.0274]
   Griffith LG, 2000, ACTA MATER, V48, P263, DOI 10.1016/S1359 6454(99)00299 2
   Hasegawa S, 2006, BIOMATERIALS, V27, P1327, DOI 10.1016/j.biomaterials.2005.09.003
   Horák D, 2004, BIOMATERIALS, V25, P5249, DOI 10.1016/j.biomaterials.2003.12.031
   Huang J. J., IN PRESS
   Huang JJ, 2012, CHEM MATER, V24, P1331, DOI 10.1021/cm203764f
   Hutmacher DW, 2007, J TISSUE ENG REGEN M, V1, P245, DOI 10.1002/term.24
   Johnson AJW, 2011, ACTA BIOMATER, V7, P16, DOI 10.1016/j.actbio.2010.07.012
   Laurencin CT, 2006, CLIN ORTHOP RELAT R, P221, DOI 10.1097/01.blo.0000194677.02506.45
   Lee J, 2008, TISSUE ENG PART B RE, V14, P61, DOI 10.1089/teb.2007.0150
   Liu XH, 2004, ANN BIOMED ENG, V32, P477, DOI 10.1023/B:ABME.0000017544.36001.8e
   Martens P, 2002, POLYMER, V43, P6093, DOI 10.1016/S0032 3861(02)00561 X
   Martens P, 2001, J PHYS CHEM B, V105, P5131, DOI 10.1021/jp004102n
   Mei Y, 2010, NAT MATER, V9, P768, DOI [10.1038/NMAT2812, 10.1038/nmat2812]
   Metters A T, 1999, Biomed Sci Instrum, V35, P33
   Metters AT, 2000, POLYMER, V41, P3993, DOI 10.1016/S0032 3861(99)00629 1
   PEPPAS NA, 1985, J BIOMED MATER RES, V19, P397, DOI 10.1002/jbm.820190405
   Ratner Buddy D., 2009, P43, DOI 10.1007/978 88 470 1104 5_5
   Rezwan K, 2006, BIOMATERIALS, V27, P3413, DOI 10.1016/j.biomaterials.2006.01.039
   Schieker M., 2006, EUROPEAN J TRAUMA, V32, P114, DOI DOI 10.1007/S00068 006 6047 8
   Shikinami Y, 2005, BIOMATERIALS, V26, P5542, DOI 10.1016/j.biomaterials.2005.02.016
   Simon CG, 2011, ADV MATER, V23, P369, DOI 10.1002/adma.201001763
   Song J, 2005, J AM CHEM SOC, V127, P3366, DOI 10.1021/ja043776z
   Song J, 2009, J BIOMED MATER RES A, V89A, P1098, DOI 10.1002/jbm.a.32110
   ULBRICH K, 1995, J CONTROL RELEASE, V34, P155, DOI 10.1016/0168 3659(95)00004 R
   ULBRICH K, 1993, J CONTROL RELEASE, V24, P181, DOI 10.1016/0168 3659(93)90177 7
   Wichterl O, 1969, J POLYM SCI POL S, P4677
   Xu JW, 2009, J ORTHOP RES, V27, P1306, DOI 10.1002/jor.20890
   Yanoso Scholl L, 2010, J BIOMED MATER RES A, V95A, P717, DOI 10.1002/jbm.a.32868
   Zainuddin, 2007, J MATER SCI MATER M, V18, P1141, DOI 10.1007/s10856 007 0135 0
NR 45
TC 26
Z9 27
U1 4
U2 100
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0032 3861
EI 1873 2291
J9 POLYMER
JI Polymer
PD FEB 5
PY 2013
VL 54
IS 3
BP 1197
EP 1207
DI 10.1016/j.polymer.2012.12.045
PG 11
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA 084SH
UT WOS:000314558900027
PM 23525522
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Brennen, WN
   Chen, SL
   Denmeade, SR
   Isaacs, JT
AF Brennen, W. Nathaniel
   Chen, Shuangling
   Denmeade, Samuel R.
   Isaacs, John T.
TI Quantification of Mesenchymal Stem Cells (MSCs) at Sites of Human
   Prostate Cancer
SO ONCOTARGET
LA English
DT Article
DE Mesenchymal Stem Cells; MSC; Inflammation; Prostate Cancer; Drug
   Delivery; CAF
ID STROMAL CELLS; BONE MARROW; INTERFERON BETA; TUMOR STROMA; GROWTH;
   FIBROBLASTS; DIFFERENTIATION; INFLAMMATION; EXPRESSION; THERAPY
AB Circulating bone marrow derived Mesenchymal Stem Cells (BM MSCs) have an innate tropism for tumor tissue in response to the inflammatory microenvironment present in malignant lesions. The prostate is bombarded by numerous infectious & inflammatory insults over a lifetime. Chronic inflammation is associated with CXCL12, CCL5, and CCL2, which are highly overexpressed in prostate cancer. Among other cell types, these chemoattractant stimuli recruit BM MSCs to the tumor. MSCs are minimally defined as plastic adhering cells characterized by the expression of CD90, CD73, and CD105 in the absence of hematopoietic markers, which can differentiate into osteoblasts, chondrocytes, and adipocytes. MSCs are immunoprivileged and have been implicated in tumorigenesis through multiple mechanisms, including promoting proliferation, angiogenesis, and metastasis, in addition to the generation of an immunosuppressive microenvironment. We have demonstrated that MSCs represent 0.01 1.1% of the total cells present in core biopsies from primary human prostatectomies. Importantly, these analyses were performed on samples prior to expansion in tissue culture. MSCs in these prostatectomy samples are FAP , CD90 , CD73 , and CD105 positive, and CD14 , CD20 , CD34 , CD45 , and HLA DR negative. Additionally, like BM MSCs, these prostate cancer derived stromal cells (PrCSCs) were shown to differentiate into osteoblasts, adipocytes, & chondrocytes. In contrast to primary prostate cancer derived epithelial cells, fluorescently labeled PrCSCs & BM MSCs were both shown to home to CWR22RH prostate cancer xenografts following IV injection. These studies demonstrate that not only are MSCs present in sites of prostate cancer where they may contribute to carcinogenesis, but these cells may also potentially be used to deliver cytotoxic or imaging agents for therapeutic and/or diagnostic purposes.
C1 [Brennen, W. Nathaniel; Chen, Shuangling; Denmeade, Samuel R.; Isaacs, John T.] Johns Hopkins, Chem Therapeut Program, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Isaacs, JT (通讯作者)，Johns Hopkins, Chem Therapeut Program, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
EM isaacjo@jhmi.edu
RI Cheng, Shiyuan/ISU 4685 2023
FU Department of Defense [W81XWH 12 1 0049]; Patrick C. Walsh Fund;
   Maryland Stem Cell Research Fund [RFA MD 07 01]; Prostate Cancer
   Foundation/Movember Challenge Award
FX The authors would like to acknowledge the Department of Defense (WNB,
   Post Doctoral Fellowship, W81XWH 12 1 0049), the Patrick C. Walsh Fund
   (JTI), the Maryland Stem Cell Research Fund (JTI, RFA MD 07 01), and the
   Prostate Cancer Foundation/Movember Challenge Award (JTI) for their
   financial support.
CR Ankrum J, 2010, TRENDS MOL MED, V16, P203, DOI 10.1016/j.molmed.2010.02.005
   Barykova YA, 2011, ONCOTARGET, V2, P289
   Bergfeld SA, 2010, CANCER METAST REV, V29, P249, DOI 10.1007/s10555 010 9222 7
   Bianchi G, 2011, HISTOL HISTOPATHOL, V26, P941, DOI 10.14670/HH 26.941
   Brennen WN, 2012, MOL CANCER THER, V11, P257, DOI 10.1158/1535 7163.MCT 11 0340
   Brohlin M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045052
   Caplan A, 2009, J PATHOL, V217, P318, DOI 10.1002/path.2469
   Chen SL, 2012, PROSTATE, V72, P1478, DOI 10.1002/pros.22503
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Dalrymple S, 2005, CANCER RES, V65, P9269, DOI 10.1158/0008 5472.CAN 04 3989
   De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   English K, 2011, J CELL BIOCHEM, V112, P1963, DOI 10.1002/jcb.23119
   Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306
   Franco OE, 2010, SEMIN CELL DEV BIOL, V21, P33, DOI 10.1016/j.semcdb.2009.10.010
   Fritz V, 2008, STEM CELLS, V26, P2981, DOI 10.1634/stemcells.2008 0139
   Fujita K, 2010, PROSTATE, V70, P473, DOI 10.1002/pros.21081
   Gao J, 2001, CANCER RES, V61, P5038
   Griend DJV, 2008, CANCER RES, V68, P9703, DOI 10.1158/0008 5472.CAN 08 3084
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hermann A, 2010, CYTOTHERAPY, V12, P17, DOI 10.3109/14653240903313941
   Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/S0008 6363(96)00063 6
   Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Khakoo AY, 2006, J EXP MED, V203, P1235, DOI 10.1084/jem.20051921
   Klopp AH, 2011, STEM CELLS, V29, P11, DOI 10.1002/stem.559
   Knoop K, 2011, MOL THER, V19, P1704, DOI 10.1038/mt.2011.93
   Krampera M, 2007, BONE, V40, P382, DOI 10.1016/j.bone.2006.09.006
   Le Blanc K, 2003, EXP HEMATOL, V31, P890, DOI 10.1016/S0301 472X(03)00110 3
   Lin GT, 2010, PROSTATE, V70, P1066, DOI 10.1002/pros.21140
   Lin VK, 2007, PROSTATE, V67, P1265, DOI 10.1002/pros.20599
   Litvinov IV, 2006, CANCER RES, V66, P8598, DOI 10.1158/0008 5472.CAN 06 1228
   Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008 5472.CAN 08 0943
   Mishra PJ, 2009, CANCER RES, V69, P1255, DOI 10.1158/0008 5472.CAN 08 3562
   Ohlsson LB, 2003, EXP MOL PATHOL, V75, P248, DOI 10.1016/j.yexmp.2003.06.001
   Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112
   Paunescu V, 2011, J CELL MOL MED, V15, P635, DOI 10.1111/j.1582 4934.2010.01044.x
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Placencio VR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012920
   Prantl L, 2010, PROSTATE, V70, P1709, DOI 10.1002/pros.21206
   Qiao L, 2008, CELL RES, V18, P500, DOI 10.1038/cr.2008.40
   Ranganath SH, 2012, CELL STEM CELL, V10, P244, DOI 10.1016/j.stem.2012.02.005
   Ren C, 2008, GENE THER, V15, P1446, DOI 10.1038/gt.2008.101
   Sarkar D, 2011, BLOOD, V118, pE184, DOI 10.1182/blood 2010 10 311464
   Sfanos KS, 2012, HISTOPATHOLOGY, V60, P199, DOI 10.1111/j.1365 2559.2011.04033.x
   Sfanos KS, 2011, ONCOTARGET, V2, P281
   Shah K, 2012, ADV DRUG DELIVER REV, V64, P739, DOI 10.1016/j.addr.2011.06.010
   Shimoda M, 2010, SEMIN CELL DEV BIOL, V21, P19, DOI 10.1016/j.semcdb.2009.10.002
   Song C, 2011, HUM GENE THER, V22, P439, DOI 10.1089/hum.2010.116
   Spaeth E, 2008, GENE THER, V15, P730, DOI 10.1038/gt.2008.39
   Studeny M, 2004, JNCI J NATL CANCER I, V96, P1593, DOI 10.1093/jnci/djh299
   Sun YX, 2003, J CELL BIOCHEM, V89, P462, DOI 10.1002/jcb.10522
   Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912
   Vaday GG, 2006, PROSTATE, V66, P124, DOI 10.1002/pros.20306
   Vindrieux D, 2009, ENDOCR RELAT CANCER, V16, P663, DOI 10.1677/ERC 09 0109
   Wagner J, 2009, CURR OPIN BIOTECH, V20, P531, DOI 10.1016/j.copbio.2009.08.009
   WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212
   Wang GX, 2012, J INT MED RES, V40, P317, DOI 10.1177/147323001204000132
   Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097 4547(20000815)61:4<364::AID JNR2>3.0.CO;2 C
   Zhao HJ, 2009, PROSTATE, V69, P991, DOI 10.1002/pros.20946
   Zhukareva V, 2010, CYTOKINE, V50, P317, DOI 10.1016/j.cyto.2010.01.004
   Zolochevska O, 2011, STEM CELLS DEV
NR 62
TC 67
Z9 74
U1 0
U2 17
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD JAN
PY 2013
VL 4
IS 1
BP 106
EP 117
DI 10.18632/oncotarget.805
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA 138IB
UT WOS:000318501100013
PM 23362217
OA hybrid, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Tao, ZS
   Zhou, WS
   Xu, HG
   Yang, M
AF Tao, Zhou Shan
   Zhou, Wan Shu
   Xu, Hong Guang
   Yang, Min
TI Simvastatin can enhance the osseointegration of titanium rods in
   ovariectomized rats maintenance treatment with valproic acid
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Osteoporosis; Osseointegration; Titanium implants; Simvastatin; Valproic
   acid
ID ANTIEPILEPTIC DRUGS; OSTEOGENIC DIFFERENTIATION; PARATHYROID HORMONE;
   BONE LOSS; OSTEOPOROSIS; STEM; CARBAMAZEPINE; LOVASTATIN; DELIVERY;
   CEMENT
AB The present work was aimed to evaluate the effect of valproic acid(VPA), simvastatin (SIM)+VPA on Ti(titanium) rods osseointegration in ovariectomized(OVX) rats and further investigation of the possible mechanism. The MC3T3 E1 cells were co cultured with VPA, SIM + VPA and induced to osteogenesis, and the cell viability, mineralization ability were observed by MTT and ALP staining, Alizarin Red staining and Western blotting. Twelve weeks after bilateral ovariectomy, all animals were randomly divided into three groups: group OVX and VPA, SIM + VPA, and all the rats received Ti implants and animals belong to group VPA, SIM + VPA received valproic acid(300 mg/kg/day), valproic acid(300 mg/kg/day) plus SIM (25 mg/kg/day), respectively, treatment until death at 12 weeks. Micro CT, histology, biomechanical testing, bone metabolism index and Reverse transcription quantitative polymerase chain reaction (RT qPCR) analysis were used to observe the therapeutic effect and explore the possible mechanism. Results shown that VPA decreased new bone formation around the surface of titanium rods and push out force other than group OVX. Histology, Micro CT and biochemical analysis results showed combined application of systemic VPA showed harmful effects than OVX group on bone formation in osteopenic rats, with the worse effects on CTX 1, P1NP and microarchitecture as well as biomechanical parameters by down regulated gene expression of Runx2, OCN, Smad1, BMP 2 and OPG, while up regulated RANKL. However, after SIM treatment, the above indicators were significantly improved. The present study suggests that systemic use of VPA may bring harm to the stability of titanium implants in osteoporosis, SIM can reverse the negative effect of VPA on the osseointegration of titanium rods in ovariectomized rats.
C1 [Tao, Zhou Shan; Yang, Min] Yijishan Hosp, Wannan Med Coll, Affiliated Hosp 1, Dept Trauma Orthoped, 2 Zhe Shan Xi Rd, Wuhu 241001, Anhui, Peoples R China.
   [Zhou, Wan Shu] Wannan Med Coll, Affiliated Hosp 2, Dept Geriatr, 123 Kangfu Rd, Wuhu 241000, Anhui, Peoples R China.
   [Xu, Hong Guang] Yijishan Hosp, Wannan Med Coll, Affiliated Hosp 1, Dept Spinal Orthoped, 2 Zhe Shan Xi Rd, Wuhu 241001, Anhui, Peoples R China.
C3 Wannan Medical College; Wannan Medical College; Wannan Medical College
RP Yang, M (通讯作者)，Yijishan Hosp, Wannan Med Coll, Affiliated Hosp 1, Dept Trauma Orthoped, 2 Zhe Shan Xi Rd, Wuhu 241001, Anhui, Peoples R China.
EM tzs19900327@yeah.net
RI Yang, Min/HPH 9264 2023; Xu, Hong Guang/F 1731 2010
FU University Natural Science Research Project of Anhui Province (CN)
   [KJ2017A266]; Funding of "Peak" Training Program and "Panfeng"
   Innovation Team Project for Scientific Research of Yijishan Hospital,
   Wannan Medical College [GF2019G04, PF2019005, GF2019T02, PF2019007];
   National Natural Science Foundation of China [82002322]; Talented
   Scholars of Wannan Medical College [YR201917]
FX This study was supported by a grant from the University Natural Science
   Research Project of Anhui Province (CN) (grant no. KJ2017A266), Funding
   of "Peak" Training Program and "Panfeng" Innovation Team Project for
   Scientific Research of Yijishan Hospital, Wannan Medical College (grant
   no. GF2019G04, PF2019005, GF2019T02 and PF2019007), National Natural
   Science Foundation of China (82002322) and Talented Scholars of Wannan
   Medical College (YR201917).
CR de Oliveira JCD, 2017, ORAL MAXILLOFAC SURG, V21, P247, DOI 10.1007/s10006 017 0624 3
   Diemar SS, 2020, PHARMACOL REP, V72, P1323, DOI 10.1007/s43440 020 00087 1
   Ecevit CG, 2004, PEDIATR NEUROL, V31, P279, DOI 10.1016/j.pediatrneurol.2004.03.021
   Fedorenko M, 2015, EPILEPSY BEHAV, V45, P217, DOI 10.1016/j.yebeh.2015.01.021
   Fu J, 2019, HORM METAB RES, V51, P511, DOI 10.1055/a 0963 0054
   Gabet Y, 2008, J BONE MINER RES, V23, P48, DOI 10.1359/JBMR.070901
   Ge YW, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1404915
   Huang D, 2020, CARBOHYD POLYM, V231, DOI 10.1016/j.carbpol.2019.115732
   Hwang D, 2007, IMPLANT DENT, V16, P13, DOI 10.1097/ID.0b013e31803276c8
   Jetté N, 2011, ARCH NEUROL CHICAGO, V68, P107, DOI 10.1001/archneurol.2010.341
   Khanna S, 2011, CNS NEUROL DISORD DR, V10, P361, DOI 10.2174/187152711794653797
   Khanna S, 2009, DRUG DISCOV TODAY, V14, P428, DOI 10.1016/j.drudis.2009.01.004
   Li H, 2018, BIOMED PHARMACOTHER, V103, P588, DOI 10.1016/j.biopha.2018.04.084
   Li YF, 2013, OSTEOPOROSIS INT, V24, P1063, DOI 10.1007/s00198 012 2258 5
   Li YF, 2010, BIOMATERIALS, V31, P9006, DOI 10.1016/j.biomaterials.2010.07.112
   Liu Y, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20193531
   López Valverde N, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072047
   Nikolaou VS, 2009, INJURY, V40, P663, DOI 10.1016/j.injury.2008.10.035
   Oki Y, 2017, J APPL ORAL SCI, V25, P498, DOI 10.1590/1678 7757 2016 0561
   Oryan A, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749 799X 9 18
   Parveen B, 2018, BONE, V113, P57, DOI 10.1016/j.bone.2018.05.011
   Patel AA, 2020, PEDIATR NEUROL, V102, P49, DOI 10.1016/j.pediatrneurol.2019.06.020
   Shahrezaee M, 2018, ENDOCRINE, V60, P138, DOI 10.1007/s12020 018 1531 6
   Siniscalchi Antonio, 2020, Psychopharmacol Bull, V50, P36
   Souverein PC, 2006, NEUROLOGY, V66, P1318, DOI 10.1212/01.wnl.0000210503.89488.88
   Takahashi E, 2017, BONE JOINT RES, V6, P351, DOI 10.1302/2046 3758.65.BJR 2017 0028.R1
   Tang CY, 2020, BIOCHEM J, V477, P2421, DOI 10.1042/BCJ20200036
   Tao ZS, 2019, J BIOMATER APPL, V34, P664, DOI 10.1177/0885328219863290
   Tao ZS, 2019, J BONE MINER METAB, V37, P1026, DOI 10.1007/s00774 019 01008 w
   Tao ZS, 2019, Z GERONTOL GERIATR, V52, P139, DOI 10.1007/s00391 018 1376 x
   Tao ZS, 2016, MED BIOL ENG COMPUT, V54, P1959, DOI 10.1007/s11517 016 1494 9
   Tao ZS, 2016, Z GERONTOL GERIATR, V49, P423, DOI 10.1007/s00391 015 0949 1
   Tao ZS, 2020, J BIOMATER APPL, V34, P1009, DOI 10.1177/0885328219889630
   Uezono M, 2013, J BIOMED MATER RES B, V101B, P1031, DOI 10.1002/jbm.b.32913
   Wang WX, 2010, J BONE MINER RES, V25, P1658, DOI 10.1002/jbmr.42
   Xu D, 2020, BIOMATER SCI UK, V8, P3286, DOI 10.1039/d0bm00443j
   Xu XC, 2014, J TRANSL MED, V12, DOI 10.1186/s12967 014 0284 0
NR 37
TC 23
Z9 23
U1 2
U2 19
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD DEC
PY 2020
VL 132
AR 110745
DI 10.1016/j.biopha.2020.110745
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OX6VM
UT WOS:000593699800006
PM 33068938
OA gold
DA 2025 08 17
ER

PT J
AU Hsieh, JY
   Fu, YS
   Chang, SJ
   Tsuang, YH
   Wang, HW
AF Hsieh, Jui Yu
   Fu, Yu Show
   Chang, Shing Jyh
   Tsuang, Yang Hwei
   Wang, Hsei Wei
TI Functional Module Analysis Reveals Differential Osteogenic and Stemness
   Potentials in Human Mesenchymal Stem Cells from Bone Marrow and
   Wharton's Jelly of Umbilical Cord
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID IN VITRO; GENE EXPRESSION; ADIPOSE TISSUE; BLOOD; TRANSCRIPTOMES;
   BIOLOGY; NEURONS; VEIN; VIVO; AGE
AB Mesenchymal stem cells (MSCs) found in bone marrow (BM) MSCs are an attractive source for the regeneration of damaged tissues. Alternative postnatal, perinatal, and fetal sources of MSCs are also under intensive investigation. MSCs from the Wharton's jelly matrix of umbilical cord (WJ) MSCs have higher pancreatic and endothelial differentiation potentials than BM MSCs, but the underlying mechanisms are poorly understood. We compared the gene expression profiles, enriched canonical pathways, and genetic networks of BM MSCs and WJ MSCs. WJ MSCs express more angiogenesis and growth related genes including epidermal growth factor and FLT1, whereas BM MSCs express more osteogenic genes such as RUNX2, DLX5, and NPR3. The gene expression pattern of BM MSCs is more similar to osteoblasts than WJ MSCs, suggesting a better osteogenic potential. In contrast, WJ MSCs are more primitive because they share more common genes with embryonic stem cells. BM MSCs are more sensitive to environmental stimulations because their molecular signatures altered more significantly in different culture conditions. WJ MSCs express genes enriched in vascular endothelial growth factor and PI3K NF kappa B canonical pathways, whereas BM MSCs express genes involved in antigen presentation and chemokine/cytokine pathways. Drylab results could be verified by wetlab experiments, in which BM MSCs were more efficient in osteogenic and adipogenic differentiation, whereas WJ MSCs proliferated better. WJ MSCs thus constitute a promising option for angiogenesis, whereas BM MSCs in bone remodeling. Our results reveal systematically the underlying genes and regulatory networks of 2 MSCs from unique ontological and anatomical origins, as well as the resulted phenotypes, thereby providing a better basis for cell based therapy and the following mechanistic studies on MSC biology.
C1 [Hsieh, Jui Yu; Wang, Hsei Wei] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan.
   [Fu, Yu Show] Natl Yang Ming Univ, Inst Anat & Cell Biol, Taipei 112, Taiwan.
   [Fu, Yu Show; Wang, Hsei Wei] Taipei City Hosp, Dept Educ & Res, Taipei, Taiwan.
   [Chang, Shing Jyh] Hsin Chu Mackay Mem Hosp, Dept Obstet & Gynecol, Hsinchu, Taiwan.
   [Tsuang, Yang Hwei] Taipei City Hosp, Dept Orthoped, Taipei, Taiwan.
   [Wang, Hsei Wei] Natl Yang Ming Univ, Yang Ming Genome Res Ctr, Vet Gen Hosp, Taipei 112, Taiwan.
C3 National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University; Taipei City Hospital; Mackay Memorial Hospital; Taipei City
   Hospital; National Yang Ming Chiao Tung University
RP Wang, HW (通讯作者)，Natl Yang Ming Univ, Inst Microbiol & Immunol, 155,Sec 2,Li Nong St, Taipei 112, Taiwan.
EM hwwang@ym.edu.tw
FU National Research Program for Genomic Medicine; National Science Council
   (NSC) [NSC97 3111 B 010 004, NSC98 2320 B 010 020 MY3]; Yen Tjing Lin
   Medical Foundation [CI 96 11]; National Health Research Institutes
   [NHRI EX97 9704BI]; Mackay Memorial Hospital [MMH HB 98 04]; Department
   of Health (Cancer Excellence Center Plan); Yang Ming University
   (Ministry of Education, Aim for the Top University Plan)
FX The authors thank Dr. Szu Ting Chen from Prof. Shie Liang Hsieh's
   laboratory for providing macrophages, and Dr. Tom K. Kuo for his
   critical reading of the manuscript. The authors acknowledge the
   technical services provided by the Microarray and Gene Expression
   Analysis Core Facility of the National Yang Ming University VGH Genome
   Research Center. The Gene Expression Analysis Core Facility was
   supported by the National Research Program for Genomic Medicine,
   National Science Council (NSC). This work was supported by the NSC
   (NSC97 3111 B 010 004 and NSC98 2320 B 010 020 MY3), the Yen Tjing Lin
   Medical Foundation (CI 96 11), the National Health Research Institutes
   (NHRI EX97 9704BI), the Mackay Memorial Hospital (MMH HB 98 04),
   Department of Health (Cancer Excellence Center Plan), and a grant from
   the Yang Ming University (Ministry of Education, Aim for the Top
   University Plan).
CR Adams JC, 2000, DEV DYNAM, V218, P280
   Agoston H, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471 213X 7 18
   Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006 0709
   Barabási AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272
   Binaschi A, 2003, REV NEUROSCIENCE, V14, P285
   Chang YC, 2004, J LEUKOCYTE BIOL, V75, P486, DOI 10.1189/jlb.0903448
   Chang YJ, 2006, STEM CELLS, V24, P679, DOI 10.1634/stemcells.2004 0308
   Chen MY, 2009, EXP HEMATOL, V37, P629, DOI 10.1016/j.exphem.2009.02.003
   Choe G, 2003, CANCER RES, V63, P2742
   Ciavarella S, 2009, STEM CELLS DEV, V18, P1211, DOI 10.1089/scd.2008.0340
   Cristofalo VJ, 1998, P NATL ACAD SCI USA, V95, P10614, DOI 10.1073/pnas.95.18.10614
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   DiCicco Bloom E, 2004, DEV BIOL, V271, P161, DOI 10.1016/j.ydbio.2004.03.028
   Fu YS, 2006, STEM CELLS, V24, P115, DOI 10.1634/stemcells.2005 0053
   Graf ER, 2004, CELL, V119, P1013, DOI 10.1016/j.cell.2004.11.035
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092 8674(00)81683 9
   Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036
   He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088
   Huang TS, 2008, STEM CELLS, V26, P1186, DOI 10.1634/stemcells.2007 0821
   Ishige I, 2009, INT J HEMATOL, V90, P261, DOI 10.1007/s12185 009 0377 3
   Janes KA, 2006, NAT REV MOL CELL BIO, V7, P820, DOI 10.1038/nrm2041
   Jaubert J, 1999, P NATL ACAD SCI USA, V96, P10278, DOI 10.1073/pnas.96.18.10278
   Kadivar M, 2006, BIOCHEM BIOPH RES CO, V340, P639, DOI 10.1016/j.bbrc.2005.12.047
   Kadner A, 2004, EUR J CARDIO THORAC, V25, P635, DOI 10.1016/j.ejcts.2003.12.038
   Kadner A, 2002, ANN THORAC SURG, V74, pS1422
   Karahuseyinoglu S, 2007, STEM CELLS, V25, P319, DOI 10.1634/stemcells.2006 0286
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood 2003 05 1670
   MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237
   Mitchell JM, 2006, J DENT RES, V85, P888, DOI 10.1177/154405910608501003
   Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21 1 50
   Mueller SM, 2001, J CELL BIOCHEM, V82, P583, DOI 10.1002/jcb.1174
   Nanaev AK, 1997, PLACENTA, V18, P53, DOI 10.1016/S0143 4004(97)90071 0
   Ozaki Y, 2007, STEM CELLS DEV, V16, P119, DOI 10.1089/scd.2006.0032
   Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029
   Panepucci RA, 2004, STEM CELLS, V22, P1263, DOI 10.1634/stemcells.2004 0024
   Romanov YA, 2003, STEM CELLS, V21, P105, DOI 10.1634/stemcells.21 1 105
   Sarugaser R, 2005, STEM CELLS, V23, P220, DOI 10.1634/stemcells.2004 0166
   Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005 0271
   Song L, 2006, STEM CELLS, V24, P1707, DOI 10.1634/stemcells.2005 0604
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   TA M, 2009, STEM CELLS DEV, V19, P117
   Troyer DL, 2008, STEM CELLS, V26, P591, DOI 10.1634/stemcells.2007 0439
   Tsai MS, 2007, STEM CELLS, V25, P2511, DOI 10.1634/stemcells.2007 0023
   Wagner W, 2006, EXP HEMATOL, V34, P536, DOI 10.1016/j.exphem.2006.01.002
   Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003
   Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004 0013
   Wang HW, 2004, NAT GENET, V36, P687, DOI 10.1038/ng1384
   Wang LM, 2009, TISSUE ENG PT A, V15, P2259, DOI 10.1089/ten.tea.2008.0393
   Weiss ML, 2006, STEM CELLS, V24, P781, DOI 10.1634/stemcells.2005 0330
   Wu LF, 2009, TISSUE ENG PT A, V15, P2865, DOI 10.1089/ten.TEA.2008.0579
   Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22
   Yang CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003336
   Yang TP, 2006, BIOINFORMATICS, V22, P2697, DOI 10.1093/bioinformatics/btl457
   Zhang ZY, 2009, STEM CELLS, V27, P126, DOI 10.1634/stemcells.2008 0456
NR 56
TC 152
Z9 174
U1 1
U2 21
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD DEC
PY 2010
VL 19
IS 12
BP 1895
EP 1910
DI 10.1089/scd.2009.0485
PG 16
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA 685KA
UT WOS:000284626400008
PM 20367285
DA 2025 08 17
ER

PT J
AU Qiu, ZC
   Zhang, FX
   Hu, XL
   Zhang, YY
   Tang, ZL
   Zhang, J
   Yang, L
   Wong, MS
   Chen, JX
   Xiao, HH
AF Qiu, Zuo Cheng
   Zhang, Feng Xiang
   Hu, Xue Ling
   Zhang, Yang Yang
   Tang, Zi Ling
   Zhang, Jie
   Yang, Li
   Wong, Man Sau
   Chen, Jia Xu
   Xiao, Hui Hui
TI Genistein Modified with 8 Prenyl Group Suppresses Osteoclast Activity
   Directly via Its Prototype but Not Metabolite by Gut Microbiota
SO MOLECULES
LA English
DT Article
DE 8 prenylgenistein; genistein; osteoclasts; gut microbiota;
   biotransformation
ID BONE LOSS; BIOAVAILABILITY; ERYTHRINA; RAT; PHARMACOKINETICS;
   DIFFERENTIATION; ISOFLAVONOIDS; MECHANISMS; FLAVONOIDS; NFATC1
AB Postmenopausal osteoporosis is a significant threat to human health globally. Genistein, a soy derived isoflavone, is regarded as a promising anti osteoporosis drug with the effects of promoting osteoblastogenesis and suppressing osteoclastogenesis. However, its oral bioavailability (6.8%) is limited by water solubility, intestinal permeability, and biotransformation. Fortunately, 8 prenelylated genistein (8PG), a derivative of genistein found in Erythrina Variegate, presented excellent predicted oral bioavailability (51.64%) with an improved osteoblastogenesis effect, although its effects on osteoclastogenesis and intestinal biotransformation were still unclear. In this study, an in vitro microbial transformation platform and UPLC QTOF/MS analysis method were developed to explore the functional metabolites of 8PG. RANKL induced RAW264.7 cells were utilized to evaluate the effects of 8PG on osteoclastogenesis. Our results showed that genistein was transformed into dihydrogenistein and 5 hydroxy equol, while 8PG metabolites were undetectable under the same conditions. The 8PG (10( 6) M) was more potent in inhibiting osteoclastogenesis than genistein (10( 5) M) and it down regulated NFATC1, cSRC, MMP 9 and Cathepsin K. It was concluded that 8 prenyl plays an important role in influencing the osteoclast activity and intestinal biotransformation of 8PG, which provides evidence supporting the further development of 8PG as a good anti osteoporosis agent.
C1 [Qiu, Zuo Cheng; Zhang, Yang Yang; Tang, Zi Ling; Zhang, Jie; Chen, Jia Xu] Jinan Univ, Sch Tradit Chinese Med, Guangzhou Key Lab Formula Pattern Tradit Chinese, Guangzhou 510632, Peoples R China.
   [Qiu, Zuo Cheng; Hu, Xue Ling; Yang, Li] Jinan Univ, Guangdong Prov Key Lab Tradit Chinese Med Informa, Guangzhou 510632, Peoples R China.
   [Zhang, Feng Xiang] Guangxi Normal Univ, Sch Chem & Pharm, State Key Lab Chem & Mol Engn Med Resources, Guilin 541004, Peoples R China.
   [Hu, Xue Ling; Yang, Li] Jinan Univ, Coll Pharm, Guangzhou 510632, Peoples R China.
   [Wong, Man Sau; Xiao, Hui Hui] Hong Kong Polytech Univ, Shenzhen Res Inst, State Key Lab Chinese Med & Mol Pharmacol Incubat, Shenzhen 518057, Peoples R China.
   [Wong, Man Sau; Xiao, Hui Hui] Hong Kong Polytech Univ, Res Ctr Chinese Med Innovat, Hong Kong 999077, Peoples R China.
C3 Jinan University; Jinan University; Guangxi Normal University; Jinan
   University; Hong Kong Polytechnic University; Hong Kong Polytechnic
   University
RP Chen, JX (通讯作者)，Jinan Univ, Sch Tradit Chinese Med, Guangzhou Key Lab Formula Pattern Tradit Chinese, Guangzhou 510632, Peoples R China.; Xiao, HH (通讯作者)，Hong Kong Polytech Univ, Shenzhen Res Inst, State Key Lab Chinese Med & Mol Pharmacol Incubat, Shenzhen 518057, Peoples R China.; Xiao, HH (通讯作者)，Hong Kong Polytech Univ, Res Ctr Chinese Med Innovat, Hong Kong 999077, Peoples R China.
EM chenjiaxu@hotmail.com; huihui.xiao@polyu.edu.hk
RI ; zhang, fengxiang/AAA 3869 2021; chen, jiaojiao/KII 6749 2024; Wong,
   Man Sau/F 2059 2015
OI Chen, Jia Xu/0000 0002 5570 6233; Tang, Ziling/0000 0002 0635 1931;
   Xiao, Hui Hui/0000 0001 7501 7112; Qiu, Zuo cheng/0000 0002 9161 5435; 
FU Huang Zhendong Research Fund for Traditional Chinese Medicine of Jinan
   University; National Natural Science Foundation of China [81903616,
   81903618]; Basic and Applied Basic Research Foundation of Guangdong
   Province [2022A1515010034]; Natural Science Foundation of Guangdong
   Province [2021A1515010648]; Administration of Traditional Chinese
   Medicine of Guangdong Province, China [20221100]; Department of
   Education of Guangdong Province "Innovative projects with
   characteristics of ordinary universities" project [2021KTSCX007];
   Guangdong Provincial Key Laboratory of Traditional Chinese Medicine
   Informatization [2021B1212040007]
FX This work was supported by Huang Zhendong Research Fund for Traditional
   Chinese Medicine of Jinan University (N/A), National Natural Science
   Foundation of China (81903616, 81903618), Basic and Applied Basic
   Research Foundation of Guangdong Province (2022A1515010034), Natural
   Science Foundation of Guangdong Province (2021A1515010648),
   Administration of Traditional Chinese Medicine of Guangdong Province,
   China (20221100), Department of Education of Guangdong Province
   "Innovative projects with characteristics of ordinary universities"
   project (2021KTSCX007), and Guangdong Provincial Key Laboratory of
   Traditional Chinese Medicine Informatization (2021B1212040007).
CR Al Maharik N, 2003, TETRAHEDRON, V59, P4177, DOI 10.1016/S0040 4020(03)00579 9
   Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Cipriani C, 2018, J ENDOCRINOL INVEST, V41, P431, DOI 10.1007/s40618 017 0761 4
   Coldham NG, 2002, EUR J DRUG METAB PH, V27, P249, DOI 10.1007/BF03192335
   Coldham NG, 2002, XENOBIOTICA, V32, P45, DOI 10.1080/00498250110085809
   Cotter A, 2003, NUTR REV, V61, P346, DOI 10.1301/nr.2003.oct.346 351
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   Fang Y, 2018, ONCOTARGET, V9, P3842, DOI [10.18632/oncotarget.23379, 10.18632/oncotarget.24823]
   Ha H, 2010, ARCH PHARM RES, V33, P625, DOI 10.1007/s12272 010 0418 8
   Kang JG, 2007, RAPID COMMUN MASS SP, V21, P857, DOI 10.1002/rcm.2897
   Kolátorová L, 2018, PHYSIOL RES, V67, pS401, DOI 10.33549/physiolres.934022
   Li XL, 2006, CHEM PHARM BULL, V54, P570, DOI 10.1248/cpb.54.570
   Lin YT, 2003, BIOL PHARM BULL, V26, P747, DOI 10.1248/bpb.26.747
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311
   Matthies A, 2012, J NUTR, V142, P40, DOI 10.3945/jn.111.148247
   Ming LG, 2013, J CELL PHYSIOL, V228, P513, DOI 10.1002/jcp.24158
   Mukai R, 2018, BIOSCI BIOTECH BIOCH, V82, P207, DOI 10.1080/09168451.2017.1415750
   Murota K, 2018, BIOSCI BIOTECH BIOCH, V82, P600, DOI 10.1080/09168451.2018.1444467
   Narod SA, 2011, NAT REV CLIN ONCOL, V8, P669, DOI 10.1038/nrclinonc.2011.110
   Nkengfack AE, 2001, PHYTOCHEMISTRY, V58, P1113, DOI 10.1016/S0031 9422(01)00368 5
   Piñero J, 2017, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943
   Savage N, 2020, NATURE, V577, pS10, DOI 10.1038/d41586 020 00196 0
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tanaka H, 2000, PLANTA MED, V66, P578, DOI 10.1055/s 2000 8602
   Terao J, 2014, ARCH BIOCHEM BIOPHYS, V559, P12, DOI 10.1016/j.abb.2014.04.002
   Trémollieres F, 2019, CLIMACTERIC, V22, P122, DOI 10.1080/13697137.2018.1555582
   Yang Z, 2012, ANTI CANCER AGENT ME, V12, P1264, DOI 10.2174/187152012803833107
   Yu F, 2019, ARCH OSTEOPOROS, V14, DOI 10.1007/s11657 018 0549 y
   Zeng XZ, 2016, ACTA PHARMACOL SIN, V37, P255, DOI 10.1038/aps.2015.85
   Zhang FX, 2022, RAPID COMMUN MASS SP, V36, DOI 10.1002/rcm.9205
   Zhang FX, 2021, FOOD FUNCT, V12, P7081, DOI [10.1039/d1fo01124c, 10.1039/D1FO01124C]
   Zhang FX, 2021, FOOD FUNCT, V12, P4325, DOI [10.1039/d1fo00104c, 10.1039/D1FO00104C]
   Zhang Y, 2008, ARCH PHARM RES, V31, P1534, DOI 10.1007/s12272 001 2147 5
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
NR 40
TC 3
Z9 3
U1 1
U2 19
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD NOV
PY 2022
VL 27
IS 22
AR 7811
DI 10.3390/molecules27227811
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 6K3DY
UT WOS:000887388500001
PM 36431913
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Oliva, R
   Torcasio, SM
   Coulembier, O
   Piperno, A
   Mazzaglia, A
   Scalese, S
   Rossi, A
   Bassi, G
   Panseri, S
   Montesi, M
   Scala, A
AF Oliva, Roberto
   Torcasio, Serena Maria
   Coulembier, Olivier
   Piperno, Anna
   Mazzaglia, Antonino
   Scalese, Silvia
   Rossi, Arianna
   Bassi, Giada
   Panseri, Silvia
   Montesi, Monica
   Scala, Angela
TI RGD tagging of star shaped PLA PEG micellar nanoassemblies enhances
   doxorubicin efficacy against osteosarcoma
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Drug delivery; Nanoparticles; Block copolymers; Dimerization; Targeting;
   Peptide
ID DRUG DELIVERY; NANOPARTICLES; DAUNORUBICIN; ADRIAMYCIN; CARRIER
AB We developed cyclic RGD tagged polymeric micellar nanoassemblies for sustained delivery of Doxorubicin (Dox) endowed with significant cytotoxic effect against MG63, SAOS 2, and U2 OS osteosarcoma cells without compromising the viability of healthy osteoblasts (hFOBs). Targeted polymeric micellar nanoassemblies (RGDNanoStar@Dox) enabled Dox to reach the nucleus of MG63, SAOS 2, and U2 OS cells causing the same cytotoxic effect as free Dox, unlike untargeted micellar nanoassemblies (NanoStar@Dox) which failed to reach the nucleus and resulted ineffective, demonstrating the crucial role of cyclic RGD peptide in driving cellular uptake and accumulation mechanisms in osteosarcoma cells. Micellar nanoassemblies were obtained by nanoformulation of three armed star PLA PEG copolymers properly synthetized with and without decoration with the cyclic RGDyK peptide (Arg Gly Asp D Tyr Lys). The optimal RGD NanoStar@Dox nanoformulation obtained by nanoprecipitation method (8 % drug loading; 35 % encapsulation efficiency) provided a prolonged and sustained drug release with a rate significantly lower than the free drug under the same experimental conditions. Moreover, the nanosystem preserved Dox from the natural degradation occurring under physiological conditions (i.e., dimerization and consequent precipitation) serving as a slow release "drug reservoir" ensuring an extended biological activity over the time.
C1 [Oliva, Roberto; Torcasio, Serena Maria; Piperno, Anna; Rossi, Arianna; Scala, Angela] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Vle F Stagno Alcontres 31, I 98166 Messina, Italy.
   [Torcasio, Serena Maria; Coulembier, Olivier] Univ Mons, Ctr Innovat & Res Mat & Polymers CIRMAP, Lab Polymer & Compos Mat, Pl Parc 23, B 7000 Mons, Belgium.
   [Mazzaglia, Antonino] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, URT Messina, CNR ISMN,Natl Council Res,Inst Study Nanostruct Ma, Vle F Stagno Alcontres 31, I 98166 Messina, Italy.
   [Scalese, Silvia] Ist Microelettron & Microsistemi, CNR IMM, Consiglio Nazl Ric, Ottava Str 5, I 95121 Catania, Italy.
   [Rossi, Arianna; Bassi, Giada; Panseri, Silvia; Montesi, Monica] Inst Sci Technol & Sustainabil Ceram, CNR ISSMC, Via Granarolo 64, I 48018 Faenza, RA, Italy.
   [Bassi, Giada] Univ Studies G DAnnunzio, Dept Neurosci Imaging & Clin Sci, I 66100 Chieti, CH, Italy.
C3 University of Messina; University of Mons; Consiglio Nazionale delle
   Ricerche (CNR); Istituto per lo Studio dei Materiali Nanostrutturati
   (ISMN CNR); University of Messina; Consiglio Nazionale delle Ricerche
   (CNR); Istituto per la Microelettronica e Microsistemi (IMM CNR)
RP Scala, A (通讯作者)，Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Vle F Stagno Alcontres 31, I 98166 Messina, Italy.
EM ascala@unime.it
RI ; Panseri, Silvia/AAW 2856 2020; Scala, Angela/JAC 5072 2023; Montesi,
   Monica/J 8861 2018; Ponce, Roberto/AAG 1061 2020; Piperno,
   Anna/K 2259 2015
OI Rossi, Arianna/0000 0001 9863 7701; Coulembier,
   Olivier/0000 0001 5753 7851; Oliva, Roberto/0000 0002 2611 2620;
   Montesi, Monica/0000 0002 9192 8554; Panseri,
   Silvia/0000 0002 8099 7132; Bassi, Giada/0000 0001 8496 5077; 
FU European Union [2022P99NY5, J53D23008760006, P202242X25,
   B53D23031930001]
FX This work was partially supported by the European Union   Next
   Generation EU Projects PRIN 2022 (2022P99NY5) "FINE" (CUP Master
   J53D23008760006) and PRIN 2022 PNRR (P202242X25) "MERCURY" (CUP Master
   B53D23031930001) . O.C. is Senior Research for F.R.S.  FNRS and an AXA
   Professor in Chemistry at UMons.
CR Agrahari V, 2018, DRUG DISCOV TODAY, V23, P1139, DOI 10.1016/j.drudis.2018.03.004
   Battistini L, 2021, EUR J ORG CHEM, V2021, P2506, DOI 10.1002/ejoc.202100240
   De La Rosa JMR, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 71396 x
   Diou O, 2014, EUR J PHARM BIOPHARM, V87, P170, DOI 10.1016/j.ejpb.2013.12.003
   Dornjak L, 2022, POLYMERS BASEL, V14, DOI 10.3390/polym14214753
   Fang ZH, 2017, BIOMED PHARMACOTHER, V85, P160, DOI 10.1016/j.biopha.2016.11.132
   Fazio E, 2015, J MATER CHEM B, V3, P9023, DOI 10.1039/c5tb01076d
   Fukushima S, 1999, COLLOID SURFACE B, V16, P227, DOI 10.1016/S0927 7765(99)00073 9
   Gianferante DM, 2017, NAT REV ENDOCRINOL, V13, P480, DOI 10.1038/nrendo.2017.16
   Govender T, 2000, INT J PHARMACEUT, V199, P95, DOI 10.1016/S0378 5173(00)00375 6
   Jin XX, 2019, BRIT J HIST SCI, V52, P117, DOI [10.1016/j.biomaterials.2018.01.051, 10.1017/S0007087418000808]
   Johnsson M, 2003, J AM CHEM SOC, V125, P757, DOI 10.1021/ja028195t
   Karmegam V, 2021, J POLYM SCI, V59, P3040, DOI 10.1002/pol.20210544
   Kovshova T, 2021, MOLECULES, V26, DOI 10.3390/molecules26040831
   Kreuzer HJ, 2003, J AM CHEM SOC, V125, P8384, DOI 10.1021/ja0350839
   Kuperkar K, 2022, POLYMERS BASEL, V14, DOI 10.3390/polym14214702
   Li CX, 2016, MAT SCI ENG C MATER, V64, P303, DOI 10.1016/j.msec.2016.03.062
   Li N, 2021, BIOLOGY BASEL, V10, DOI 10.3390/biology10070688
   Liénard R, 2020, MAT SCI ENG C MATER, V117, DOI 10.1016/j.msec.2020.111291
   Liu JM, 2023, INT J BIOL MACROMOL, V240, DOI 10.1016/j.ijbiomac.2023.124406
   Lotocki V, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12090827
   Lupusoru RV, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 63245 8
   Mineo PG, 2020, ANAL BIOANAL CHEM, V412, P4681, DOI 10.1007/s00216 020 02721 6
   Mitry MA, 2016, IJC HEART VASC, V10, P17, DOI 10.1016/j.ijcha.2015.11.004
   Nandi S, 2020, NANOSCALE ADV, V2, P5746, DOI 10.1039/d0na00575d
   Oliva R, 2023, INT J PHARMACEUT, V642, DOI 10.1016/j.ijpharm.2023.123067
   Panez Toro I, 2023, CURR OSTEOPOROS REP, V21, P330, DOI 10.1007/s11914 023 00803 9
   Parchami M, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2023.e15495
   Piorecka K, 2017, TETRAHEDRON LETT, V58, P152, DOI 10.1016/j.tetlet.2016.11.118
   Piperno A, 2021, INT J NANOMED, V16, P5981, DOI 10.2147/IJN.S321329
   Rahmani A, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 00954 8
   Ren JM, 2016, CHEM REV, V116, P6743, DOI 10.1021/acs.chemrev.6b00008
   Riley T, 2001, LANGMUIR, V17, P3168, DOI 10.1021/la001226i
   Scala A, 2018, J BIOMED MATER RES B, V106, P2778, DOI 10.1002/jbm.b.34058
   Song XY, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.639487
   Sun Y, 2017, DRUG DEVELOP RES, V78, P283, DOI 10.1002/ddr.21399
   Torcasio SM, 2022, BIOMATER ADV, V140, DOI 10.1016/j.bioadv.2022.213043
   Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781
   Wang SY, 2020, J CANCER, V11, P69, DOI 10.7150/jca.36588
   Wei HX, 2022, INT J NANOMED, V17, P3483, DOI 10.2147/IJN.S372851
   Yamada Y, 2020, ACS OMEGA, V5, P33235, DOI 10.1021/acsomega.0c04925
   Yang P, 2020, ONCOTARGETS THER, V13, P8055, DOI 10.2147/OTT.S259428
   Yokoyama M, 1998, J CONTROL RELEASE, V50, P79, DOI 10.1016/S0168 3659(97)00115 6
   Zhang CN, 2012, BIOMATERIALS, V33, P2187, DOI 10.1016/j.biomaterials.2011.11.045
   Zhang L, 2023, LANGMUIR, V39, P4766, DOI 10.1021/acs.langmuir.3c00159
   ZUNINO F, 1981, TUMORI J, V67, P399, DOI 10.1177/030089168106700502
NR 46
TC 4
Z9 4
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 5173
EI 1873 3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD MAY 25
PY 2024
VL 657
AR 124183
DI 10.1016/j.ijpharm.2024.124183
EA MAY 2024
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA TC6J0
UT WOS:001239096300001
PM 38692500
OA hybrid
DA 2025 08 17
ER

PT J
AU Gu, Q
   Mi, L
   Lai, CL
   Guan, X
   Lu, N
   Zhan, T
   Wang, GG
   Lu, C
   Xu, L
   Gao, X
   Zhang, JP
AF Gu, Qiou
   Mi, Lei
   Lai, Chuilin
   Guan, Xiao
   Lu, Na
   Zhan, Tian
   Wang, Guoguang
   Lu, Chen
   Xu, Lei
   Gao, Xiang
   Zhang, Jianping
TI CPXM1 correlates to poor prognosis and immune cell infiltration in
   gastric cancer
SO HELIYON
LA English
DT Article
DE Gastric cancer; Carboxypeptidase X (M14 family) member 1; TME; Immune
   cell infiltration; Drug sensitivity
ID CARBOXYPEPTIDASE E; EXPRESSION
AB Background: Gastric cancer (GC) is the fourth most common cause of cancer related death and the fifth most frequent malignant cancer, especially advanced GC. Carboxypeptidase X member 1 (CPXM1) is an epigenetic factor involved in many physiological processes, including osteoclast differentiation and adipogenesis. Several studies have shown the association of CPXM1 with multiple tumors; however, the mechanism of CPXM1 involvement in the progression of GC is yet to be characterized. Method: CPXM1 expression data were obtained from the Tumor Immune Estimation Resource. The Cancer Genome Atlas and the Gene Expression Omnibus databases were used to obtain patient matched clinicopathological information, and the Kaplan Meier plot database was utilized for the prognosis analysis of GC patients. The Catalog of Somatic Mutations in Cancer and cBioportal databases were adopted to study CPXM1 mutations in tumors. Next, we utilized the Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and Gene Set Enrichment Analysis for mechanism research. Furthermore, we performed tumor microenvironment and immune infiltration analysis based on CPXM1. Finally, we predicted sensitivity to several targeted drugs in GC patients based on CPXM1. CPXM1 is upregulated in GC and is correlated with poor prognosis, gender, and tumor stage in GC patients. Gene enrichment analysis suggested that CPXM1 may regulate the occurrence and progression of GC via the PI3K AKT and TGF beta pathway. Moreover, CPXM1 expression results in an increase in the proportion of immune and stromal cells. Additionally, the proportion of plasma cells was inversely related to the expression of CPXM1, whereas macrophage M2 expression was proportionate to CPXM1 expression. Finally, six small molecule drugs that showed notable variations in IC50 between two groups were screened. Conclusion: These results suggested that CPXM1 regulates the progression of GC and may represent a novel target for the detection and treatment of GC.
C1 [Gu, Qiou; Lai, Chuilin; Guan, Xiao; Lu, Na; Zhan, Tian; Wang, Guoguang; Lu, Chen; Xu, Lei; Gao, Xiang; Zhang, Jianping] Nanjing Med Univ, Affiliated Hosp 2, Dept Gen Surg, 121 Jiangjiayuan Rd, Nanjing 210009, Jiangsu, Peoples R China.
   [Mi, Lei] Nanjing Univ, Yancheng Hosp 1, Affilital Hosp, Peoples Hosp Yancheng 1,Med Sch,Dept Oncol, 66 Renmin South Rd, Yancheng 210009, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing University
RP Zhang, JP (通讯作者)，Nanjing Med Univ, Affiliated Hosp 2, Dept Gen Surg, 121 Jiangjiayuan Rd, Nanjing 210009, Jiangsu, Peoples R China.
EM gqo1993@njmu.edu.cn; 781896384@qq.com; 1477764980@qq.com;
   1477764980@qq.com; ln248457306@qq.com; 302790672@qq.com;
   ggwang@njmu.edu.cn; 294646516@qq.com; lxu_njmu_edu@163.com;
   2314005924@qq.com
RI Wang, Guoguang/AAF 6813 2019
FU National Natural Science Foundation [81874058]
FX The present study was financed by National Natural Science Foundation
   (Grant Number 81874058 to JZ) .
CR Atiakshin D., 2022, Carboxypeptidase A3   A Key Component of the Protease, P1
   Bai ZL, 2020, CANCER BIOMARK, V29, P79, DOI 10.3233/CBM 191163
   Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024
   C.B. Program, 1998, TGF  beta SIGNAL TRANSDUCTION
   Chen SS, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1037884
   Chen Y, 2021, CLIN CANCER RES, V27, P330, DOI 10.1158/1078 0432.CCR 20 2166
   Dai SL, 2015, SAUDI J GASTROENTERO, V21, P226, DOI 10.4103/1319 3767.161640
   Joshi SS, 2021, CA CANCER J CLIN, V71, P264, DOI 10.3322/caac.21657
   Kemik O, 2012, HUM EXP TOXICOL, V31, P447, DOI 10.1177/0960327111405864
   Kim YH, 2016, FASEB J, V30, P2528, DOI 10.1096/fj.201500107R
   Kim YH, 2015, BIOCHEM BIOPH RES CO, V468, P894, DOI 10.1016/j.bbrc.2015.11.053
   Kumar A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 29952 z
   Li J., 2022, Cyborg Bionic Syst, P2022, DOI DOI 10.34133/2022/9824057
   Liang C, 2022, ASN NEURO, V14, DOI 10.1177/17590914211062765
   Liu Z, 2023, GASTRIC CANCER, V26, P203, DOI 10.1007/s10120 022 01353 2
   Ma XL, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045 019 0724 7
   Mao XH, 2021, WORLD J SURG ONCOL, V19, DOI 10.1186/s12957 021 02124 6
   Pervaz S, 2023, REPROD SCI, V30, P526, DOI 10.1007/s43032 022 00987 y
   Pisano C, 2014, BIOCHEM PHARMACOL, V89, P12, DOI 10.1016/j.bcp.2014.02.010
   Sapio MR, 2014, PROTEOM CLIN APPL, V8, P327, DOI 10.1002/prca.201300090
   Sharma V.K., 2022, Cell. Mol. Life Sci, V79, P1
   Siegel RL, 2022, CA CANCER J CLIN, V72, P7, DOI 10.3322/caac.21708
   Smyth EC, 2020, LANCET, V396, P635, DOI 10.1016/S0140 6736(20)31288 5
   Stiffness H.D.A, 2022, Yes Associated Protein Targets the Transforming, P851
   Sun J, 2020, AM J CANCER RES, V10, P925
   Tewari D, 2022, SEMIN CANCER BIOL, V80, P1, DOI 10.1016/j.semcancer.2019.12.008
   Tian LY, 2022, FRONT MED LAUSANNE, V9, DOI 10.3389/fmed.2022.880326
   Vedeld HM, 2018, SEMIN CANCER BIOL, V51, P36, DOI 10.1016/j.semcancer.2017.12.004
   Wang Y, 2021, ONCOGENE, V40, P4324, DOI 10.1038/s41388 021 01844 z
   Wang YH, 2020, BLOOD ADV, V4, P644, DOI 10.1182/bloodadvances.2019001185
   Wu H, 2021, MOL CANCER, V20, DOI 10.1186/s12943 021 01365 z
   Wu M.Z., 2021, Signal Transduct. Targeted Ther, V6
   Xu XD, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03576 0
   Yuan L, 2020, MOL CANCER, V19, DOI 10.1186/s12943 020 01219 0
   Zheng MJ, 2021, CANCERS, V13, DOI 10.3390/cancers13133343
NR 35
TC 5
Z9 5
U1 0
U2 0
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2405 8440
J9 HELIYON
JI Heliyon
PD FEB 15
PY 2024
VL 10
IS 3
AR e21909
DI 10.1016/j.heliyon.2023.e21909
EA JAN 2024
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA JQ8D0
UT WOS:001174713100001
PM 38314284
OA gold
DA 2025 08 17
ER

PT J
AU Sun, J
   Zhao, JH
   Jiang, FY
   Wang, LJ
   Xiao, Q
   Han, FY
   Chen, J
   Yuan, S
   Wei, JS
   Larsson, SC
   Zhang, HH
   Dunlop, MG
   Farrington, SM
   Ding, KF
   Theodoratou, E
   Li, X
AF Sun, Jing
   Zhao, Jianhui
   Jiang, Fangyuan
   Wang, Lijuan
   Xiao, Qian
   Han, Fengyan
   Chen, Jie
   Yuan, Shuai
   Wei, Jingsun
   Larsson, Susanna C.
   Zhang, Honghe
   Dunlop, Malcolm G.
   Farrington, Susan M.
   Ding, Kefeng
   Theodoratou, Evropi
   Li, Xue
TI Identification of novel protein biomarkers and drug targets for
   colorectal cancer by integrating human plasma proteome with genome
SO GENOME MEDICINE
LA English
DT Article
DE Colorectal cancer; Protein; Proteome wide Mendelian randomization;
   Biomarker; Drug target
ID MENDELIAN RANDOMIZATION; GENETIC RISK; AFRICAN; CELLS; GREM1
AB BackgroundThe proteome is a major source of therapeutic targets. We conducted a proteome wide Mendelian randomization (MR) study to identify candidate protein markers and therapeutic targets for colorectal cancer (CRC).MethodsProtein quantitative trait loci (pQTLs) were derived from seven published genome wide association studies (GWASs) on plasma proteome, and summary level data were extracted for 4853 circulating protein markers. Genetic associations with CRC were obtained from a large scale GWAS meta analysis (16,871 cases and 26,328 controls), the FinnGen cohort (4957 cases and 304,197 controls), and the UK Biobank (9276 cases and 477,069 controls). Colocalization and summary data based MR (SMR) analyses were performed sequentially to verify the causal role of candidate proteins. Single cell type expression analysis, protein protein interaction (PPI), and druggability evaluation were further conducted to detect the specific cell type with enrichment expression and prioritize potential therapeutic targets.ResultsCollectively, genetically predicted levels of 13 proteins were associated with CRC risk. Elevated levels of two proteins (GREM1, CHRDL2) and decreased levels of 11 proteins were associated with an increased risk of CRC, among which four (GREM1, CLSTN3, CSF2RA, CD86) were prioritized with the most convincing evidence. These protein coding genes are mainly expressed in tissue stem cells, epithelial cells, and monocytes in colon tumor tissue. Two interactive pairs of proteins (GREM1 and CHRDL2; MMP2 and TIMP2) were identified to be involved in osteoclast differentiation and tumorigenesis pathways; four proteins (POLR2F, CSF2RA, CD86, MMP2) have been targeted for drug development on autoimmune diseases and other cancers, with the potentials of being repurposed as therapeutic targets for CRC.ConclusionsThis study identified several protein biomarkers to be associated with CRC risk and provided new insights into the etiology and promising targets for the development of screening biomarkers and therapeutic drugs for CRC.
C1 [Sun, Jing; Zhao, Jianhui; Jiang, Fangyuan; Chen, Jie; Li, Xue] Zhejiang Univ, Affiliated Hosp 2, Dept Big Data Hlth Sci, Sch Publ Hlth,Sch Med, Hangzhou, Zhejiang, Peoples R China.
   [Sun, Jing; Zhao, Jianhui; Jiang, Fangyuan; Chen, Jie; Li, Xue] Zhejiang Univ, Affiliated Hosp 2, Ctr Clin Big Data & Analyt, Sch Med, Hangzhou, Zhejiang, Peoples R China.
   [Wang, Lijuan; Theodoratou, Evropi; Li, Xue] Univ Edinburgh, Usher Inst, Ctr Global Hlth, Edinburgh, Midlothian, Scotland.
   [Xiao, Qian; Wei, Jingsun; Ding, Kefeng] Zhejiang Univ, Affiliated Hosp 2, Colorectal Surg & Oncol, Key Lab Canc Prevent & Intervent,Minist Educ,Sch M, Hangzhou, Peoples R China.
   [Han, Fengyan; Zhang, Honghe] Zhejiang Univ, Sch Med, Womens Hosp, Dept Pathol, Hangzhou, Zhejiang, Peoples R China.
   [Yuan, Shuai; Larsson, Susanna C.] Karolinska Inst, Inst Environm Med, Unit Cardiovasc & Nutr Epidemiol, Stockholm, Sweden.
   [Larsson, Susanna C.] Uppsala Univ, Dept Surg Sci, Unit Med Epidemiol, Uppsala, Sweden.
   [Dunlop, Malcolm G.; Farrington, Susan M.; Theodoratou, Evropi] Univ Edinburgh, Med Res Council Inst Genet & Canc, Canc Res UK Edinburgh Ctr, Edinburgh, Scotland.
   [Dunlop, Malcolm G.] Univ Edinburgh, Inst Genet & Canc, Colon Canc Genet Grp, Edinburgh, Scotland.
C3 Zhejiang University; Zhejiang University; University of Edinburgh;
   Zhejiang University; Zhejiang University; Karolinska Institutet; Uppsala
   University; University of Edinburgh; University of Edinburgh
RP Li, X (通讯作者)，Zhejiang Univ, Affiliated Hosp 2, Dept Big Data Hlth Sci, Sch Publ Hlth,Sch Med, Hangzhou, Zhejiang, Peoples R China.; Li, X (通讯作者)，Zhejiang Univ, Affiliated Hosp 2, Ctr Clin Big Data & Analyt, Sch Med, Hangzhou, Zhejiang, Peoples R China.; Li, X (通讯作者)，Univ Edinburgh, Usher Inst, Ctr Global Hlth, Edinburgh, Midlothian, Scotland.
EM xueli157@zju.edu.cn
RI Larsson, Susanna/F 6065 2015; wang, li/HMD 1420 2023; Dunlop,
   Malcolm/F 1973 2011; Theodoratou, Evropi/C 3430 2014; Yuan,
   Shuai/AAA 1161 2021; Farrington, Susan/C 7319 2013
OI Wang, Lijuan/0000 0002 9797 0753; Theodoratou,
   Evropi/0000 0001 5887 9132; Sun, Jing/0000 0003 0046 6663; 
FU The authors thank all the participants from seven proteomic studies, 11
   previous CRC GWASs, FinnGen cohort, and UK Biobank, the institutions and
   their staff for providing data.; Cancer Research UK [22804, 18927]
   Funding Source: researchfish; Medical Research Council [MC_UU_00007/1,
   MC_U127527198, MC_PC_U127527198] Funding Source: researchfish
FX The authors thank all the participants from seven proteomic studies, 11
   previous CRC GWASs, FinnGen cohort, and UK Biobank, the institutions and
   their staff for providing data.
CR Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007 MCP200
   Aran D, 2019, NAT IMMUNOL, V20, P163, DOI 10.1038/s41590 018 0276 y
   Bach DH, 2018, MOL THER ONCOLYTICS, V8, P1, DOI 10.1016/j.omto.2017.10.002
   Bai NN, 2022, MOL METAB, V63, DOI 10.1016/j.molmet.2022.101531
   Biller LH, 2021, JAMA J AM MED ASSOC, V325, P669, DOI 10.1001/jama.2021.0106
   Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586 018 0579 z
   Cheng CP, 2022, NAT CANCER, V3, P565, DOI 10.1038/s43018 022 00380 3
   Considine DP, 2021, GYNECOL ONCOL, V160, P506, DOI 10.1016/j.ygyno.2020.11.016
   Davies NM, 2018, BMJ BRIT MED J, V362, DOI 10.1136/bmj.k601
   Davis H, 2015, NAT MED, V21, P62, DOI 10.1038/nm.3750
   Ferkingstad E, 2021, NAT GENET, V53, P1712, DOI 10.1038/s41588 021 00978 w
   Folkersen L, 2020, NAT METAB, V2, P1135, DOI 10.1038/s42255 020 00287 2
   Freshour SL, 2021, NUCLEIC ACIDS RES, V49, pD1144, DOI 10.1093/nar/gkaa1084
   Giambartolomei C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004383
   Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408
   Kakourou A, 2015, CANCER CAUSE CONTROL, V26, P1449, DOI 10.1007/s10552 015 0641 1
   Kobayashi H, 2021, GASTROENTEROLOGY, V160, P1224, DOI 10.1053/j.gastro.2020.11.011
   Kou Y, 2022, SCAND J IMMUNOL, V95, DOI 10.1111/sji.13137
   Kupfer SS, 2014, CARCINOGENESIS, V35, P2025, DOI 10.1093/carcin/bgu088
   Kurki MI, 2022, medRxiv, DOI 10.1101/2022.03.03.22271360
   Landi D, 2011, MUTAT RES FUND MOL M, V717, P109, DOI 10.1016/j.mrfmmm.2010.10.002
   Li X, 2020, INT J CANCER, V147, P3431, DOI 10.1002/ijc.33191
   Liu BX, 2019, NAT GENET, V51, P768, DOI 10.1038/s41588 019 0404 0
   Mehta RS, 2014, JNCI J NATL CANCER I, V106, DOI 10.1093/jnci/dju016
   Mendez D, 2019, NUCLEIC ACIDS RES, V47, pD930, DOI 10.1093/nar/gky1075
   Mishra A, 2022, NATURE, V611, P115, DOI 10.1038/s41586 022 05165 3
   Murphy N, 2020, GASTROENTEROLOGY, V158, P1300, DOI 10.1053/j.gastro.2019.12.020
   Nebiker CA, 2014, CLIN CANCER RES, V20, P3094, DOI 10.1158/1078 0432.CCR 13 2774
   Papadimitriou N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14389 8
   Pietzner M, 2021, SCIENCE, V374, P839, DOI 10.1126/science.abj1541
   Rashkin SR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18246 6
   Suhre K, 2021, NAT REV GENET, V22, P19, DOI 10.1038/s41576 020 0268 2
   Suhre K, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14357
   Sun BB., 2022, BIORXIV, DOI DOI 10.1101/2022.06.17.496443
   Sun BB, 2018, NATURE, V558, P73, DOI 10.1038/s41586 018 0175 2
   Sun XH, 2022, CANCERS, V14, DOI 10.3390/cancers14133261
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Surapaneni A, 2022, KIDNEY INT, V102, P1167, DOI 10.1016/j.kint.2022.07.005
   Tarhini AA, 2021, IMMUNOTHERAPY UK, V13, P1011, DOI 10.2217/imt 2021 0119
   The human protein atlas, CLSTN3 PATH
   Tsilidis KK, 2008, INT J CANCER, V123, P1133, DOI 10.1002/ijc.23606
   Wang R, 2022, GENOME MED, V14, DOI 10.1186/s13073 022 01093 z
   Wingo AP, 2021, NAT GENET, V53, P143, DOI 10.1038/s41588 020 00773 z
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD608, DOI 10.1093/nar/gkx1089
   Wu Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03371 0
   Yao C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05512 x
   Yazdanpanah N, 2022, DIABETES CARE, V45, P169, DOI 10.2337/dc21 1049
   Zheng J, 2020, NAT GENET, V52, P1122, DOI 10.1038/s41588 020 0682 6
NR 50
TC 102
Z9 108
U1 17
U2 88
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756 994X
J9 GENOME MED
JI Genome Med.
PD SEP 19
PY 2023
VL 15
IS 1
AR 75
DI 10.1186/s13073 023 01229 9
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA S4FF0
UT WOS:001070734700001
PM 37726845
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chen, Y
   Guo, ZN
   He, RQ
   Huang, ZG
   Luo, JY
   Tang, W
   Huang, SN
   Chen, G
AF Chen, Yi
   Guo, Zhen Ning
   He, Rong Quan
   Huang, Zhi Guang
   Luo, Jia Yuan
   Tang, Wei
   Huang, Su Ning
   Chen, Gang
TI How has the field of metastatic breast cancer in bones evolved over the
   past 22 years?
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Breast cancer; Bone metastasis; Bibliometrics; Targeted therapy;
   Immunotherapy; Bioinformatics
ID RADIATION THERAPY; CELLS; DISEASE; BISPHOSPHONATES; RANKL/RANK/OPG;
   BIOINFORMATICS; PROSTATE; PET/CT; ACID
AB Background: Although knowledge on metastatic breast cancer in bones (MBCB) has increased rapidly over the past 22 years, a comprehensive and objective bibliometric analysis is still lacking. Materials and methods: We used R, VOSviewer, and Citespace software to conduct a bibliometric analysis of 5,497 papers on MBCB from the Web of Science Core Collection (WOSCC) using author, institution, country/region, citation, and keyword indicators. Results: A general strong sense of scholarly collaboration was noted in the MBCB field at the author, research institution, and country/region levels. We discovered some outstanding authors and highly productive in stitutions, but with less collaboration with other academic groups. Unbalanced and uncoordinated developments were observed among countries/regions in the field of MBCB research. We also found that by using various indicators and applying different analysis methods to them, we were able to broadly identify primary clinical practices, relevant clinical experiments, and directions for bioinformatics regarding MBCB, changes over the past 22 years, and current challenges in the field. The development of knowledge on MBCB is progressing greatly; however, MBCB is still incurable. Conclusion: This study is the first to use bibliometrics to provide an overall analysis of the scientific output of MBCB studies. Palliative therapies for MBCB are mostly in a mature state. However, research on the molecular mechanisms and immune response to tumors related to the development of treatments to cure MBCB remains relatively immature. Therefore, further research should be undertaken in this area.
C1 [Chen, Yi; Guo, Zhen Ning; Huang, Zhi Guang; Luo, Jia Yuan; Chen, Gang] Guangxi Med Univ, Dept Pathol, Affiliated Hosp 1, 6 Shuangyong Rd, Nanning 530021, Peoples R China.
   [He, Rong Quan] Guangxi Med Univ, Dept Med Oncol, Affiliated Hosp 1, 6 Shuangyong Rd, Nanning 530021, Peoples R China.
   [Tang, Wei] Guangxi Med Univ, Dept Breast Surg, Canc Hosp, 71 Hedi Rd, Nanning 530021, Guangxi Zhuang, Peoples R China.
   [Huang, Su Ning] Guangxi Med Univ Canc Hosp, Dept Radiotherapy, 71 Hedi Rd, Nanning 530021, Guangxi Zhuang, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University; Guangxi Medical University
RP Chen, G (通讯作者)，Guangxi Med Univ, Dept Pathol, Affiliated Hosp 1, 6 Shuangyong Rd, Nanning 530021, Peoples R China.
EM chengang@gxmu.edu.cn
RI He, Rong quan/M 8856 2019
CR Allmer J, 2021, J INTEGR BIOINFORMAT, V18, DOI 10.1515/jib 2021 0042
   Alzahrani M, 2022, SUPPORT CARE CANCER, V30, P3977, DOI 10.1007/s00520 021 06714 8
   Alzahrani M, 2021, SUPPORT CARE CANCER, V29, P6903, DOI 10.1007/s00520 021 06238 1
   Anderson EA, 2022, HISP HEALTH CARE INT, V20, P222, DOI 10.1177/15404153221116755
   Arellano DL, 2022, J BONE MINER RES, V37, P1446, DOI 10.1002/jbmr.4615
   Asano Y, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.980456
   Asano Y, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.871675
   Asgari Karchekani S, 2022, MED ONCOL, V39, DOI 10.1007/s12032 022 01817 6
   Barbanente A, 2020, J MATER CHEM B, V8, P2792, DOI 10.1039/d0tb00390e
   Baum RP, 2015, CANCER BIOTHER RADIO, V30, P152, DOI 10.1089/cbr.2014.1747
   Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593
   Boman C, 2021, CANCER TREAT REV, V99, DOI 10.1016/j.ctrv.2021.102257
   Bray F, 2022, LANCET ONCOL, V23, P719, DOI [10.1016/S1470 2045(22)00270 4, 10.1016/S1470 2045(22)00270 ]
   Breast Cancer Expert Committee of National Cancer Quality Control Center, 2022, Zhonghua Zhong Liu Za Zhi, V44, P1262, DOI 10.3760/cma.j.cn112152 20221007 00680
   Campbell DO, 2016, MOL IMAGING BIOL, V18, P768, DOI 10.1007/s11307 016 0953 x
   Candelaria Quintana D, 2012, BREAST CANCER RES TR, V132, P355, DOI 10.1007/s10549 011 1800 z
   Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585 007 9127 1
   Casimiro S, 2021, CELLS BASEL, V10, DOI 10.3390/cells10081978
   Chen MC, 2022, CANCER SCI, V113, P3751, DOI 10.1111/cas.15532
   Cheng X, 2021, DRUG DELIV, V28, P37, DOI 10.1080/10717544.2020.1856225
   Cheung E, 2020, J ONCOL PHARM PRACT, V26, P1180, DOI 10.1177/1078155220907965
   Chow E, 2000, RADIOTHER ONCOL, V56, P305, DOI 10.1016/S0167 8140(00)00238 3
   Chu ZH, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.984454
   Civelek GM, 2023, LYMPHAT RES BIOL, V21, P289, DOI 10.1089/lrb.2022.0031
   Clines GA, 2005, ENDOCR RELAT CANCER, V12, P549, DOI 10.1677/erc.1.00543
   Coleman R, 2020, ANN ONCOL, V31, P1650, DOI 10.1016/j.annonc.2020.07.019
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Coleman RE, 2013, BREAST, V22, pS50, DOI 10.1016/j.breast.2013.07.010
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   Dougall WC, 2012, CLIN CANCER RES, V18, P326, DOI 10.1158/1078 0432.CCR 10 2507
   Dwight Z., 2022, CLIN CHEM, P264
   Fang WT, 2022, CANCER MED US, V11, P764, DOI 10.1002/cam4.4469
   Feng XW, 2022, J CLIN MED, V11, DOI 10.3390/jcm11195903
   Gallivanone F, 2022, METHOD PROTOCOL, V5, DOI 10.3390/mps5050078
   Giaquinto AN, 2022, CA CANCER J CLIN, V72, P524, DOI 10.3322/caac.21754
   Gnant M, 2012, ANTI CANCER AGENT ME, V12, P114, DOI 10.2174/187152012799014931
   Gomarasca M, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.889002
   Gouveia AG, 2021, RADIOTHER ONCOL, V163, P55, DOI 10.1016/j.radonc.2021.07.022
   Groheux D, 2022, SEMIN NUCL MED, V52, P508, DOI 10.1053/j.semnuclmed.2022.05.001
   Grunbaum A, 2022, VITAM HORM, V120, P133, DOI 10.1016/bs.vh.2022.03.002
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hillner BE, 2000, J CLIN ONCOL, V18, P1378, DOI 10.1200/JCO.2000.18.6.1378
   Hsieh IS, 2013, MOL PHARMACOL, V83, P968, DOI 10.1124/mol.112.082339
   Ihle CL, 2022, PHARMACOL THERAPEUT, V239, DOI 10.1016/j.pharmthera.2022.108280
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Jiang WL, 2020, CANCER MED US, V9, P8173, DOI 10.1002/cam4.3432
   Johnson RW, 2011, CANCER RES, V71, P822, DOI 10.1158/0008 5472.CAN 10 2993
   Kang X, 2021, INT J NANOMED, V16, P6383, DOI 10.2147/IJN.S322894
   Karami Fath M., 2022, PATHOL RES PRACT, V241
   Katayama N, 2020, TRANSL CANCER RES, V9, P5096, DOI 10.21037/tcr.2020.01.35
   Koch I, 2021, BIOL CHEM, V402, P869, DOI 10.1515/hsz 2021 0298
   Korbecki J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103723
   Kumar P, 2022, CANCER METAST REV, V41, P261, DOI 10.1007/s10555 022 10029 3
   Lenga L, 2021, CANCERS, V13, DOI 10.3390/cancers13102431
   Li L, 2022, COMPUT INTEL NEUROSC, V2022, DOI 10.1155/2022/6126061
   Li XQ, 2022, CANCER RES, V82, P1560, DOI 10.1158/0008 5472.CAN 21 1331
   Li Y, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000023406
   Liu C, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/8970173
   Liu C, 2022, ACTA PHARM SIN B, V12, P364, DOI 10.1016/j.apsb.2021.06.012
   Liu HM, 2021, ANN PALLIAT MED, V10, P4435, DOI 10.21037/apm 21 438
   Lu BY, 2023, TECHNOL CANCER RES T, V22, DOI 10.1177/15330338221145246
   Magnoni F, 2022, EUR J CANCER PREV, V31, P551, DOI 10.1097/CEJ.0000000000000741
   Ming Y, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01301
   Ninkov A, 2022, PERSPECT MED EDUC, V11, P173, DOI 10.1007/s40037 021 00695 4
   Ohta M, 2001, NUCL MED COMMUN, V22, P875, DOI 10.1097/00006231 200108000 00005
   Pang LL, 2022, CANCERS, V14, DOI 10.3390/cancers14235727
   Qiao RQ, 2022, TECHNOL CANCER RES T, V21, DOI 10.1177/15330338221122642
   Ruppender NS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015451
   Sadu L, 2022, PROG BIOPHYS MOL BIO, V175, P120, DOI 10.1016/j.pbiomolbio.2022.09.008
   Sahin M, 2000, NUCL MED COMMUN, V21, P251, DOI 10.1097/00006231 200003000 00009
   Sarhangi N, 2022, MOL BIOL REP, V49, P10023, DOI 10.1007/s11033 022 07571 2
   Shang QH, 2022, EUR J NUCL MED MOL I, V49, P2096, DOI 10.1007/s00259 021 05664 x
   Shi YL, 2021, BIOENGINEERED, V12, P12246, DOI 10.1080/21655979.2021.2006552
   Simatou A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207570
   Smith SC, 2001, BEST PRACT RES CL OB, V15, P265, DOI 10.1053/beog.2001.0167
   Sogacheva V V, 2022, Stomatologiia (Mosk), V101, P85, DOI 10.17116/stomat202210106185
   Souchon R, 2010, BREAST CARE, V5, P401, DOI 10.1159/000322661
   Subramanian CR, 2021, CUREUS J MED SCIENCE, V13, DOI 10.7759/cureus.13332
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Uehara N, 2022, CANCER SCI, V113, P4219, DOI 10.1111/cas.15557
   Velev M, 2023, EUR J CANCER, V182, P66, DOI 10.1016/j.ejca.2022.12.028
   Ventura C, 2022, SEMIN ONCOL NURS, V38, DOI 10.1016/j.soncn.2022.151278
   Wang YC, 2020, INT IMMUNOPHARMACOL, V87, DOI 10.1016/j.intimp.2020.106815
   Wang Z, 2022, FRONT MED LAUSANNE, V9, DOI 10.3389/fmed.2022.840024
   Wei NM, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/fpubh.2022.1022810
   Wittrant Y, 2004, BBA REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002
   Xu WD, 2020, HUM GENE THER, V31, P863, DOI 10.1089/hum.2020.078
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Zhang L, 2023, NANOMED NANOTECHNOL, V48, DOI 10.1016/j.nano.2022.102642
   Zhao YJ, 2021, EPIGENOMICS UK, V13, P1247, DOI 10.2217/epi 2021 0210
   Zhou Y, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.669000
NR 94
TC 2
Z9 2
U1 1
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD JUN
PY 2023
VL 40
AR 100480
DI 10.1016/j.jbo.2023.100480
EA MAY 2023
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA O1SU6
UT WOS:001041696400001
PM 37251089
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, Y
   Zhu, SB
   Luo, JC
   Tong, Y
   Zheng, YX
   Ji, LC
   He, ZJ
   Jing, QA
   Huang, JQ
   Zhang, YJ
   Bi, Q
AF Li, Yong
   Zhu, Senbo
   Luo, Junchao
   Tong, Yu
   Zheng, Yixuan
   Ji, Lichen
   He, Zeju
   Jing, Qiangan
   Huang, Jiaqing
   Zhang, Yinjun
   Bi, Qing
TI The Protective Effect of Selenium Nanoparticles in Osteoarthritis: In
   vitro and in vivo Studies
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE osteoarthritis; NF kappa B p65 signaling pathway; p38/MAPK signaling
   pathway; selenium nanoparticles
ID NF KAPPA B; INFLAMMATORY MEDIATORS; MATRIX METALLOPROTEINASES; INDUCED
   EXPRESSION; OXIDATIVE STRESS; MMP EXPRESSION; CHONDROCYTES; P38;
   ACTIVATION; INHIBITION
AB Introduction: Osteoarthritis (OA) is a common chronic joint disease characterized by articular cartilage degeneration. OA usually manifests as joint pain, limited mobility, and joint effusion. Currently, the primary OA treatment is non steroidal anti inflammatory drugs (NSAIDs). Although they can alleviate the disease's clinical symptoms and signs, the drugs have some side effects. Selenium nanoparticles (SeNPs) may be an alternative to relieve OA symptoms.
   Materials and Results: We confirmed the anti inflammatory effect of selenium nanoparticles (SeNPs) in vitro and in vivo experiments for OA disease in this study. In vitro experiments, we found that SeNPs could significantly reduce the expression of nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX 2), the major inflammatory factors, and had significant anti inflammatory and anti arthritic effects. SeNPs can inhibit reactive oxygen species (ROS) production and increased glutathione peroxidase (GPx) activity in interleukin 1beta (IL 1 ss) stimulated cells. Additionally, SeNPs down regulated matrix metalloproteinase 13 (MMP 13) and thrombospondin motifs 5 (ADAMTS 5) expressions, while up regulated type II collagen (COL 2) and aggrecan (ACAN) expressions stimulated by IL 1 ss. The findings also indicated that SeNPs may exert their effects through suppressing the NF .B p65 and p38/MAPK pathways. In vivo experiments, the prevention of OA development brought on by SeNPs was demonstrated using a DMM model.
   Discussion: Our results suggest that SeNPs may be a potential anti inflammatory agent for treating OA.
C1 [Li, Yong; Zheng, Yixuan; Jing, Qiangan; Zhang, Yinjun] Zhejiang Univ Technol, Coll Biotechnol & Bioengn, Hangzhou 310014, Zhejiang, Peoples R China.
   [Li, Yong; Zhu, Senbo; Luo, Junchao; Tong, Yu; Ji, Lichen; He, Zeju; Huang, Jiaqing; Bi, Qing] Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Hangzhou Med Coll, Dept Lab Med,Lab Med Ctr, Hangzhou 310014, Zhejiang, Peoples R China.
C3 Zhejiang University of Technology; Hangzhou Medical College; Zhejiang
   Provincial People's Hospital
RP Zhang, YJ (通讯作者)，Zhejiang Univ Technol, Coll Biotechnol & Bioengn, Hangzhou 310014, Zhejiang, Peoples R China.; Bi, Q (通讯作者)，Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Hangzhou Med Coll, Dept Lab Med,Lab Med Ctr, Hangzhou 310014, Zhejiang, Peoples R China.
EM zhangyj@zjut.edu.cn; bqzjsrmyy@163.com
OI Jing, Qiangan/0009 0004 6818 0738; TONG, YU/0000 0001 9895 6948
FU National Science Foundation of China [81672769]; Health Technology
   Project of Zhejiang Province [2020KY029]; Medical Health Science and
   Technology Project of Zhejiang Provincial Health Commission [2021KY028];
   basic public welfare research plan of Zhejiang Province [LGF22H060029]
FX Acknowledgments This research was funded by grants from National Science
   Foundation of China (Grant No. 81672769) , Health Technology Project of
   Zhejiang Province (2020KY029) , Medical Health Science and Technology
   Project of Zhejiang Provincial Health Commission (2021KY028) and basic
   public welfare research plan of Zhejiang Province (LGF22H060029) .
CR Ansari MY, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110452
   Bhattacharjee S, 2019, ROS OXIDATIVE STRESS
   Bolduc JA, 2019, FREE RADICAL BIO MED, V132, P73, DOI 10.1016/j.freeradbiomed.2018.08.038
   Boostani A, 2015, ACTA SCI VET, V43
   Chen CL, 2020, EXP THER MED, V20, P3078, DOI 10.3892/etm.2020.9048
   Chen XM, 2021, BIOMED PHARMACOTHER, V137, DOI 10.1016/j.biopha.2021.111238
   Chen XX, 2019, ARTIF CELL NANOMED B, V47, P3614, DOI 10.1080/21691401.2019.1657877
   Cheng AWM, 2012, OSTEOARTHR CARTILAGE, V20, P440, DOI 10.1016/j.joca.2012.02.006
   Dabo AJ, 2020, AM J RESP CELL MOL, V62, P598, DOI 10.1165/rcmb.2019 0177OC
   Ding QH, 2018, INT IMMUNOPHARMACOL, V61, P222, DOI 10.1016/j.intimp.2018.05.026
   Dong XF, 2017, J COLLOID INTERF SCI, V504, P178, DOI 10.1016/j.jcis.2017.05.050
   Durigova M, 2008, OSTEOARTHR CARTILAGE, V16, P1245, DOI 10.1016/j.joca.2008.02.013
   Effraimidis G, 2014, EUR J ENDOCRINOL, V170, pR241, DOI 10.1530/EJE 14 0047
   El Ghazaly MA, 2017, CAN J PHYSIOL PHARM, V95, P101, DOI 10.1139/cjpp 2016 0183
   Fu YH, 2016, EXP CELL RES, V349, P184, DOI 10.1016/j.yexcr.2016.10.014
   Gao F, 2019, ARTIF CELL NANOMED B, V47, P1043, DOI 10.1080/21691401.2019.1591427
   Gundogdu G, 2020, CLIN RHEUMATOL, V39, P2399, DOI 10.1007/s10067 020 04958 z
   Han J, 2012, CARBOHYD POLYM, V90, P122, DOI 10.1016/j.carbpol.2012.04.068
   Hariharan S, 2020, INFLAMMOPHARMACOLOGY, V28, P667, DOI 10.1007/s10787 020 00690 x
   Jeong JW, 2016, INT J MOL MED, V37, P452, DOI 10.3892/ijmm.2015.2443
   Jia MM, 2019, ECOTOX ENVIRON SAFE, V170, P238, DOI 10.1016/j.ecoenv.2018.11.133
   Jiang LJ, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.703110
   Kahya MC, 2015, BRAIN INJURY, V29, P1490, DOI 10.3109/02699052.2015.1053526
   Kang DG, 2018, BIOMOL THER, V26, P560, DOI 10.4062/biomolther.2018.132
   Khan NM, 2017, FREE RADICAL BIO MED, V106, P288, DOI 10.1016/j.freeradbiomed.2017.02.041
   Landeros RV, 2017, J PHYSIOL LONDON, V595, P4663, DOI 10.1113/JP274119
   Lepetsos P, 2019, FREE RADICAL BIO MED, V132, P90, DOI 10.1016/j.freeradbiomed.2018.09.025
   Lepetsos P, 2016, BBA MOL BASIS DIS, V1862, P576, DOI 10.1016/j.bbadis.2016.01.003
   Li GY, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.771297
   Li XB, 2019, J CELL MOL MED, V23, P1940, DOI 10.1111/jcmm.14096
   Li X, 2019, DRUG DEVELOP RES, V80, P637, DOI 10.1002/ddr.21541
   Li X, 2021, NANO MICRO LETT, V13, DOI 10.1007/s40820 021 00670 y
   Lin Z, 2020, FOOD FUNCT, V11, P2654, DOI [10.1039/C9FO02552A, 10.1039/c9fo02552a]
   Lorenz J, 2014, METHODS MOL BIOL, V1194, P401, DOI 10.1007/978 1 4939 1215 5_23
   Ma ZQ, 2015, INT IMMUNOPHARMACOL, V25, P83, DOI 10.1016/j.intimp.2015.01.018
   Majeed M, 2019, PHYTOTHER RES, V33, P1457, DOI 10.1002/ptr.6338
   Malhotra S, 2016, J BIOMED MATER RES B, V104, P993, DOI 10.1002/jbm.b.33448
   Mao LW, 2021, DRUG DELIV, V28, P1861, DOI 10.1080/10717544.2021.1971798
   Medeiros DM, 2016, EXP BIOL MED, V241, P1316, DOI 10.1177/1535370216648805
   Moghimi N, 2021, INT J RHEUM DIS, V24, P694, DOI 10.1111/1756 185X.14097
   Moon SM, 2018, BIOMED PHARMACOTHER, V97, P264, DOI 10.1016/j.biopha.2017.10.130
   Ouvinha de Oliveira R., 2014, Annales Pharmaceutiques Francaises, V72, P303, DOI 10.1016/j.pharma.2014.04.006
   Ozawa M, 2015, INFLAMM RES, V64, P243, DOI 10.1007/s00011 015 0804 2
   Park DR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18208 y
   Portal Núñez S, 2016, BIOCHEM PHARMACOL, V108, P1, DOI 10.1016/j.bcp.2015.12.012
   Qiao K, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01342 8
   Qin R, 2019, AM J TRANSL RES, V11, P1460
   Qu YH, 2022, INT IMMUNOPHARMACOL, V111, DOI 10.1016/j.intimp.2022.109129
   Rocourt CRB, 2013, NUTRIENTS, V5, P1349, DOI 10.3390/nu5041349
   Schnabel R, 2008, AM HEART J, V156, P1201, DOI 10.1016/j.ahj.2008.09.004
   Scott DL, 2000, RHEUMATOLOGY, V39, P1095, DOI 10.1093/rheumatology/39.10.1095
   Shahabi R, 2021, DRUG CHEM TOXICOL, V44, P92, DOI 10.1080/01480545.2018.1560466
   Singh A, 2019, MOLECULES, V24, DOI 10.3390/molecules24081583
   Sutipornpalangkul Werasak, 2009, J Med Assoc Thai, V92 Suppl 6, pS268
   Torres Martínez M, 2016, INT J BIOCHEM CELL B, V78, P106, DOI 10.1016/j.biocel.2016.06.022
   Vieira AT, 2012, BRIT J NUTR, V108, P1829, DOI 10.1017/S0007114512000013
   Vlahos R, 2013, REDOX REP, V18, P142, DOI 10.1179/1351000213Y.0000000053
   Wang MN, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4133
   Wang Q, 2010, NATURE, V463, P339, DOI 10.1038/nature08693
   Wang YB, 2012, BIOL TRACE ELEM RES, V149, P110, DOI 10.1007/s12011 012 9395 8
   Wang ZW, 2019, WORLD J CLIN CASES, V7, P1262, DOI 10.12998/wjcc.v7.i11.1262
   Wang ZR, 2019, EUR J PHARMACOL, V844, P49, DOI 10.1016/j.ejphar.2018.11.020
   Wrobel JK, 2016, IUBMB LIFE, V68, P97, DOI 10.1002/iub.1466
   Wu YG, 2019, CURR GENE THER, V19, P255, DOI 10.2174/1566523219666190716092203
   Xi Y, 2020, EUR J PHARMACOL, V873, DOI 10.1016/j.ejphar.2020.172925
   Xiao LK, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.920824
   Yang CY, 2017, OSTEOARTHR CARTILAGE, V25, P1000, DOI 10.1016/j.joca.2017.02.791
   Yi H, 2015, PLOS ONE, V10, P25
   Zahan Oana Maria, 2020, Med Pharm Rep, V93, P12, DOI 10.15386/mpr 1422
   Zeng RM, 2018, INT IMMUNOPHARMACOL, V68, P74
   Zhang JF, 2018, BIOCHEM BIOPH RES CO, V503, P528, DOI 10.1016/j.bbrc.2018.05.066
   Zhang JS, 2008, TOXICOL SCI, V101, P22, DOI 10.1093/toxsci/kfm221
   Zheng WH, 2018, FOOD FUNCT, V9, P263, DOI [10.1039/c7fo01199g, 10.1039/C7FO01199G]
   Zheng WH, 2017, INFLAMMATION, V40, P1143, DOI 10.1007/s10753 017 0558 9
   Zhong HM, 2013, INT IMMUNOPHARMACOL, V17, P329, DOI 10.1016/j.intimp.2013.06.027
   Zhou K, 2016, INFLAMMATION, V39, P1558, DOI 10.1007/s10753 016 0391 6
   Zubair M, 2015, EFFECT SELENIUM VITA
NR 77
TC 10
Z9 13
U1 1
U2 16
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177 8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2023
VL 17
BP 1515
EP 1529
DI 10.2147/DDDT.S407122
PG 15
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA H4AR0
UT WOS:000995412800001
PM 37249927
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ostadhossein, F
   Benig, L
   Tripathi, I
   Misra, SK
   Pan, DPJ
AF Ostadhossein, Fatemeh
   Benig, Lily
   Tripathi, Indu
   Misra, Santosh K.
   Pan, Dipanjan
TI Fluorescence Detection of Bone Microcracks Using Monophosphonated Carbon
   Dots
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE bone imaging; fluorescence; carbon dot; phosphonated compounds; in vivo
ID IN VIVO; MAGNETIC RESONANCE; CONTRAST AGENT; QUANTUM DOTS;
   NANOPARTICLES; BISPHOSPHONATES; MICRODAMAGE; NANOPROBES; DIAGNOSIS;
   EMISSION
AB Phosphonated compounds, in particular, bisanalogs are widely applied in clinical settings for the treatment of severe bone turnovers and recently as imaging probes when conjugated with organic fluorophores. Herein, we introduce a bone seeking luminescent probe that shows a high binding affinity toward bone minerals based on monophosphonated carbon dots (CDs). Spheroidal CDs tethered with PEG monophosphates are synthesized in a one pot hydrothermal method and are physicochemically characterized, where the retention of phosphonates is confirmed by P 13 NMR and X ray photoelectron spectroscopy. Interestingly, the high abundance of multiple monodentate phosphonates exhibited strong binding to hydroxyapatite, the main bone mineral constituent. The remarkable optophysical properties of monophosphonated CDs were confirmed in an ex vivo model of the bovine cortical bone where the imaging feasibility of microcracks, which are calcium rich regions, was demonstrated. The in vivo studies specified the potential application of monophosphonated CDs for imaging when injected intramuscularly. The biodigestible nature and cytocompatibility of the probe presented here obviate the demand for a secondary fluorophore, while offering a nanoscale strategy for bone targeting and can eventually be employed for potential bone therapy in the future.
C1 [Ostadhossein, Fatemeh; Benig, Lily; Tripathi, Indu; Misra, Santosh K.; Pan, Dipanjan] Univ Illinois, Dept Bioengn, Urbana, IL 61801 USA.
C3 University of Illinois System; University of Illinois Urbana Champaign
RP Pan, DPJ (通讯作者)，Univ Illinois, Dept Bioengn, Urbana, IL 61801 USA.
EM dipanjan@illinois.edu
RI ; Ostadhossein, Fatemeh/AAN 5665 2020
OI Benig, Lily/0009 0005 1936 4351; Ostadhossein,
   Fatemeh/0000 0003 4213 7948; Pan, Dipanjan/0000 0003 0175 4704; Misra,
   Santosh K./0000 0002 3313 4895
FU UIUC; National Science Foundation [1660236]; Children's Discovery
   Institute; Div Of Industrial Innovation & Partnersh; Directorate For
   Engineering [1660236] Funding Source: National Science Foundation
FX Materials characterizations were done at Frederick Seitz Materials
   Research Laboratory, UIUC. Funding from UIUC, 1660236 National Science
   Foundation, and Children's Discovery Institute are acknowledged. Special
   thanks to Prof. W. Dobrucki, Dr. I. Dobrucka, Dr. R. Haasch, Dr. J.
   Soares, and C. L. Wallace for the experimental and intellectual input.
CR Alexandrino EM, 2014, J MATER CHEM B, V2, P1298, DOI 10.1039/c3tb21295e
   Baker SN, 2010, ANGEW CHEM INT EDIT, V49, P6726, DOI 10.1002/anie.200906623
   Burr DB, 1997, J BONE MINER RES, V12, P6, DOI 10.1359/jbmr.1997.12.1.6
   Cheng K, 2012, CURR MED CHEM, V19, P4767, DOI 10.2174/092986712803341458
   Cheng XY, 2014, CHEM SOC REV, V43, P2680, DOI 10.1039/c3cs60353a
   Hyun H., 2014, ANGEW CHEM, V126, P10844, DOI DOI 10.1002/ANGE.201404930
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Khan S, 2015, NANO LETT, V15, P8300, DOI 10.1021/acs.nanolett.5b03915
   Kurapati R, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201605176
   Lalatonne Y, 2008, CHEM COMMUN, P2553, DOI 10.1039/b801911h
   Landrigan MD, 2011, BONE, V48, P443, DOI 10.1016/j.bone.2010.10.160
   McMahon B, 2009, J AM CHEM SOC, V131, P17542, DOI 10.1021/ja908006r
   Nie H, 2014, CHEM MATER, V26, P3104, DOI 10.1021/cm5003669
   Ostadhossein F., 2016, WILEY INTERDISCIP RE, V9
   Ostadhossein F, 2016, SMALL, V12, P5845, DOI 10.1002/smll.201601161
   Pan D, 2013, WIRES NANOMED NANOBI, V5, P517, DOI 10.1002/wnan.1231
   Pan D, 2011, J AM CHEM SOC, V133, P9168, DOI 10.1021/ja201918u
   Pan LL, 2015, ADV MATER, V27, P7782, DOI 10.1002/adma.201503821
   Pramanik C, 2016, ACTA BIOMATER, V31, P339, DOI 10.1016/j.actbio.2015.12.008
   Roelofs AJ, 2012, J BONE MINER RES, V27, P835, DOI 10.1002/jbmr.1543
   Shen J, 2013, ADV DRUG DELIVER REV, V65, P744, DOI 10.1016/j.addr.2012.05.007
   Srivastava I, 2017, NANO RES, V10, P3269, DOI 10.1007/s12274 017 1518 2
   Taylor D, 2007, NAT MATER, V6, P263, DOI 10.1038/nmat1866
   Tower RJ, 2014, J BONE MINER RES, V29, P1993, DOI 10.1002/jbmr.2224
   Verborgt O, 2000, J BONE MINER RES, V15, P60, DOI 10.1359/jbmr.2000.15.1.60
   Wang K, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556 276X 8 122
   Wang Y, 2016, ACS NANO, V10, P4164, DOI 10.1021/acsnano.5b07401
   Wehrli FW, 2013, J MAGN RESON, V229, P35, DOI 10.1016/j.jmr.2012.12.011
   Weiner S, 1998, ANNU REV MATER SCI, V28, P271, DOI 10.1146/annurev.matsci.28.1.271
   Wilhelm S, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.14
   Wu LN, 2013, NANO RES, V6, P312, DOI 10.1007/s12274 013 0308 8
   Wyss PP, 2016, ACS OMEGA, V1, P182, DOI 10.1021/acsomega.6b00088
   Yadav V, 2013, ANGEW CHEM INT EDIT, V52, P10997, DOI 10.1002/anie.201305759
   Yang ST, 2009, J PHYS CHEM C, V113, P18110, DOI 10.1021/jp9085969
   Yin Q, 2016, P NATL ACAD SCI USA, V113, pE4601, DOI 10.1073/pnas.1603316113
   Zhang RY, 2015, THERANOSTICS, V5, P124, DOI 10.7150/thno.10014
   Zheng XT, 2015, SMALL, V11, P1620, DOI 10.1002/smll.201402648
NR 37
TC 38
Z9 40
U1 2
U2 73
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD JUN 13
PY 2018
VL 10
IS 23
BP 19408
EP 19415
DI 10.1021/acsami.8b03727
PG 8
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA GJ6WM
UT WOS:000435525100014
PM 29757601
DA 2025 08 17
ER

PT J
AU Wang, S
   Nie, X
   Siddiqui, Y
   Wang, X
   Arora, V
   Fan, X
   Thumbigere Math, V
   Chung, MK
AF Wang, S.
   Nie, X.
   Siddiqui, Y.
   Wang, X.
   Arora, V.
   Fan, X.
   Thumbigere Math, V.
   Chung, M. K.
TI Nociceptor Neurons Magnify Host Responses to Aggravate Periodontitis
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE TRPV1; nociceptors; primary afferents; bone resorption; resiniferatoxin;
   chemogenetics
ID CAPSAICIN TREATMENT; SENSORY NEURONS; PAIN; DEGENERATION; DENERVATION;
   CHANNELS; MODEL; TRPV1
AB Periodontitis is a highly prevalent chronic inflammatory disease that progressively destroys the structures supporting teeth, leading to tooth loss. Periodontal tissue is innervated by abundant pain sensing primary afferents expressing neuropeptides and transient receptor potential vanilloid 1 (TRPV1). However, the roles of nociceptive nerves in periodontitis and bone destruction are controversial. The placement of ligature around the maxillary second molar or the oral inoculation of pathogenic bacteria induced alveolar bone destruction in mice. Chemical ablation of nociceptive neurons in the trigeminal ganglia achieved by intraganglionic injection of resiniferatoxin decreased bone loss in mouse models of experimental periodontitis. Consistently, ablation of nociceptive neurons decreased the number of osteoclasts in alveolar bone under periodontitis. The roles of nociceptors were also determined by the functional inhibition of TRPV1 expressing trigeminal afferents using an inhibitory designer receptor exclusively activated by designer drugs (DREADD) receptor. Noninvasive chemogenetic functional silencing of TRPV1 expressing trigeminal afferents not only decreased induction but also reduced the progression of bone loss in periodontitis. The infiltration of leukocytes and neutrophils to the periodontium increased at the site of ligature, which was accompanied by increased amount of proinflammatory cytokines, such as receptor activator of nuclear factor kappa Beta ligand, tumor necrosis factor, and interleukin 1 beta. The extents of increase in immune cell infiltration and cytokines were significantly lower in mice with nociceptor ablation. In contrast, the ablation of nociceptors did not alter the periodontal microbiome under the conditions of control and periodontitis. Altogether, these results indicate that TRPV1 expressing afferents increase bone destruction in periodontitis by promoting hyperactive host responses in the periodontium. We suggest that specific targeting of neuroimmune and neuroskeletal regulation can offer promising therapeutic targets for periodontitis supplementing conventional treatments.
C1 [Wang, S.; Nie, X.; Siddiqui, Y.; Arora, V.; Chung, M. K.] Univ Maryland, Ctr Adv Chron Pain Res, Dept Neural & Pain Sci, Program Neurosci,Sch Dent, 650 W Baltimore St,8 South, Baltimore, MD 21201 USA.
   [Wang, X.; Thumbigere Math, V.] Univ Maryland, Sch Dent, Dept Adv Oral Sci & Therapeut, Baltimore, MD 21201 USA.
   [Fan, X.] Univ Maryland, Dept Microbiol & Immunol, Flow Cytometry Shared Serv, Sch Med, Baltimore, MD 21201 USA.
   [Chung, M. K.] Univ Maryland, Ctr Advance Chron Pain Res, Dept Neural & Pain Sci, Program Neurosci,Sch Dent, Baltimore St, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore
RP Chung, MK (通讯作者)，Univ Maryland, Ctr Adv Chron Pain Res, Dept Neural & Pain Sci, Program Neurosci,Sch Dent, 650 W Baltimore St,8 South, Baltimore, MD 21201 USA.; Chung, MK (通讯作者)，Univ Maryland, Ctr Advance Chron Pain Res, Dept Neural & Pain Sci, Program Neurosci,Sch Dent, Baltimore St, Baltimore, MD 21201 USA.
EM mchung@umaryland.edu
RI Siddiqui, Yasir Dilshad/HNR 5885 2023; Siddiqui, Yasir
   Dilshad/GMW 7146 2022; Chung, Man Kyo/S 7433 2019
OI Siddiqui, Yasir Dilshad/0000 0003 0395 0098; Chung,
   Man Kyo/0000 0001 7637 1148; Nie, Xuguang/0000 0003 3594 4020; 
FU National Institutes of Health [R01 DE027731, R35 DE030045, R00 DE028439,
   R03 DE029258]; University of Maryland School of Dentistry; Maryland
   Department of Health's Cigarette Restitution Fund Program;  [P30
   CA134274]; National Institute of Dental and Craniofacial Research
   [R01DE027731, R03DE029258] Funding Source: NIH RePORTER
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by the National Institutes of Health R01 DE027731 and R35
   DE030045 to M.K. Chung, R00 DE028439, R03 DE029258, startup funds from
   the University of Maryland School of Dentistry to V. Thumbigere Math,
   and P30 CA134274 and Maryland Department of Health's Cigarette
   Restitution Fund Program to X. Fan.
CR Abe T, 2013, J IMMUNOL METHODS, V394, P49, DOI 10.1016/j.jim.2013.05.002
   Adam C, 2000, EXP PHYSIOL, V85, P61, DOI 10.1111/j.1469 445X.2000.01930.x
   Baral P, 2019, NAT REV IMMUNOL, V19, P433, DOI 10.1038/s41577 019 0147 2
   Breivik T, 2011, OPEN DENT J, V5, P1, DOI 10.2174/1874210601105010001
   Cavanaugh DJ, 2011, J NEUROSCI, V31, P10119, DOI 10.1523/JNEUROSCI.1299 11.2011
   Chen H, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 08097 7
   Chung MK, 2012, J DENT RES, V91, P777, DOI 10.1177/0022034512450298
   Chung MK, 2011, J DENT RES, V90, P1103, DOI 10.1177/0022034511413284
   Chung MK, 2016, PHARMACEUTICALS BASE, V9, DOI 10.3390/ph9040066
   Chung MK, 2011, ADV EXP MED BIOL, V704, P615, DOI 10.1007/978 94 007 0265 3_33
   de Vries TJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01395
   Dutzan N, 2016, JOVE J VIS EXP, DOI 10.3791/53736
   Eke PI, 2012, J DENT RES, V91, P914, DOI 10.1177/0022034512457373
   Garlet GP, 2010, J DENT RES, V89, P1349, DOI 10.1177/0022034510376402
   Graves Dana T, 2011, J Oral Microbiol, V3, DOI 10.3402/jom.v3i0.5304
   Hajishengallis G, 2016, SEMIN IMMUNOL, V28, P146, DOI 10.1016/j.smim.2016.02.002
   HILL EL, 1991, NEUROSCIENCE, V44, P747, DOI 10.1016/0306 4522(91)90094 5
   Kantarci A, 2003, J PERIODONTOL, V74, P66, DOI 10.1902/jop.2003.74.1.66
   Khan J, 2019, ARCH ORAL BIOL, V102, P193, DOI 10.1016/j.archoralbio.2019.04.012
   Khosla S, 2018, J CLIN INVEST, V128, P4832, DOI 10.1172/JCI122151
   Lamont RJ, 2018, NAT REV MICROBIOL, V16, P745, DOI 10.1038/s41579 018 0089 x
   Lee CT, 2016, J IMMUNOL, V197, P2796, DOI 10.4049/jimmunol.1600859
   LEE W, 1995, J PERIODONTAL RES, V30, P23, DOI 10.1111/j.1600 0765.1995.tb01249.x
   LUTHMAN J, 1989, INT J DEV NEUROSCI, V7, P613, DOI 10.1016/0736 5748(89)90020 8
   Nagashima H, 2017, MOL PAIN, V13, DOI 10.1177/1744806916689269
   Németh J, 2003, EUR J PHARMACOL, V458, P313, DOI 10.1016/S0014 2999(02)02794 2
   Offley SC, 2005, J BONE MINER RES, V20, P257, DOI 10.1359/JBMR.041108
   Pinho Ribeiro FA, 2018, CELL, V173, P1083, DOI 10.1016/j.cell.2018.04.006
   RALEVIC V, 1995, J PHARMACOL EXP THER, V274, P64
   Razavi R, 2006, CELL, V127, P1123, DOI 10.1016/j.cell.2006.10.038
   SANN H, 1995, NEUROSCIENCE, V67, P953, DOI 10.1016/0306 4522(95)00102 O
   Takahashi N, 2016, SCI REP UK, V6, DOI 10.1038/srep29294
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Talbot S, 2015, NEURON, V87, P341, DOI 10.1016/j.neuron.2015.06.007
   Wang DH, 2001, HYPERTENSION, V37, P440, DOI 10.1161/01.HYP.37.2.440
   Wang S, 2020, MOL PAIN, V16, DOI 10.1177/1744806920973141
   Wang S, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01207
   Wang S, 2017, J PAIN, V18, P1333, DOI 10.1016/j.jpain.2017.06.005
   Xiao WM, 2015, AM J PATHOL, V185, P1085, DOI 10.1016/j.ajpath.2014.12.006
NR 39
TC 12
Z9 13
U1 3
U2 17
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD JUL
PY 2022
VL 101
IS 7
BP 812
EP 820
AR 00220345211069956
DI 10.1177/00220345211069956
EA JAN 2022
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 2G5CD
UT WOS:000751876200001
PM 35086367
OA Green Published
DA 2025 08 17
ER

PT J
AU Chen, DJ
   Xiang, ML
   Gong, YY
   Xu, L
   Zhang, TW
   He, Y
   Zhou, MJ
   Xin, LJ
   Li, J
   Song, JL
AF Chen, Duanjing
   Xiang, Mingli
   Gong, Yuanyuan
   Xu, Ling
   Zhang, Tingwei
   He, Yao
   Zhou, Mengjiao
   Xin, Liangjing
   Li, Jie
   Song, Jinlin
TI LIPUS promotes FOXO1 accumulation by downregulating miR 182 to enhance
   osteogenic differentiation in hPDLCs
SO BIOCHIMIE
LA English
DT Article
DE Low intensity pulsed ultrasound; FOXO1; miR 182; Osteogenic
   differentiation; Periodontal ligament cell
ID INTENSITY PULSED ULTRASOUND; LIGAMENTUM FLAVUM CELLS; MESENCHYMAL
   STEM CELLS; BONE FORMATION; OSTEOBLAST DIFFERENTIATION; OXIDATIVE
   STRESS; NITRIC OXIDE; SMALL RNAS; EXPRESSION; BIOGENESIS
AB Low intensity pulsed ultrasound (LIPUS) promotes bone fracture healing in clinical therapy. Transcription factor Forkhead box O1 (FOXO1) is crucial for bone differentiation. But whether FOXO1 is involved in LIPUS promoted bone differentiation is largely unknown. In the current study, treatment of human primary periodontal ligament cells (hPDLCs) with LIPUS promoted total and nucleus FOXO1 protein accumulation. LIPUS induced activation of FOXO1 further lead to higher alkaline phosphatase (ALP) and runt related transcription factor 2 (Runx2) expression and matrix mineralization. LIPUS inhibited miR 182 expression, which functioned as a repressor of FOXO1 through post transcriptional regulation. Overexpression of miR 182 reversed the LIPUS enhanced FOXO1 expression and osteogenic differentiation. Moreover, LIPUS enhanced Akt phosphorylation, which functioned in preventing active FOXO1 excessive accumulation via inducing the cytoplasm translocation of nucleus FOXO1. In conclusion, our study revealed that FOXO1, which was a target gene of miR 182, played an essential role in LIPUS promoted osteogenic differentiation. This new molecular insight throws light upon the application of LIPUS therapy on periodontal bone defect. (C) 2019 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved.
C1 [Chen, Duanjing; Xiang, Mingli; Gong, Yuanyuan; Xu, Ling; Zhang, Tingwei; He, Yao; Zhou, Mengjiao; Xin, Liangjing; Li, Jie; Song, Jinlin] Chongqing Med Univ, Coll Stomatol, 426 Songshibei Rd, Chongqing 401147, Peoples R China.
   [Chen, Duanjing; Xiang, Mingli; Gong, Yuanyuan; Xu, Ling; Zhang, Tingwei; He, Yao; Zhou, Mengjiao; Xin, Liangjing; Li, Jie; Song, Jinlin] Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing, Peoples R China.
   [Chen, Duanjing; Xiang, Mingli; Gong, Yuanyuan; Xu, Ling; Zhang, Tingwei; He, Yao; Zhou, Mengjiao; Xin, Liangjing; Li, Jie; Song, Jinlin] Chongqing Municipal Key Lab Oral Biomed Engn High, Chongqing, Peoples R China.
C3 Chongqing Medical University
RP Li, J; Song, JL (通讯作者)，Chongqing Med Univ, Coll Stomatol, 426 Songshibei Rd, Chongqing 401147, Peoples R China.
EM jieli@hospital.cqmu.edu.cn; songjinlin@hospital.cqmu.edu.cn
RI ; Li, Jie/K 3437 2018; 李, 杰/K 3437 2018
OI Song, jinlin/0000 0002 0224 6640; Li, Jie/0000 0003 2343 1658; 
FU National Natural Science Foundation of China [81771082, 81901012,
   31971282, 81700932, 81570981]; Chongqing Research Programof Basic
   Research and Frontier Technology [cstc2017jcyjBX0019]; Program for
   Innovation Team Building at Institutions of Higher Education in
   Chongqing [CXTDG201602006]
FX This work was supported by National Natural Science Foundation of China
   (Grant No. 81771082, 81901012, 31971282, 81700932 and 81570981),
   Chongqing Research Programof Basic Research and Frontier Technology
   (Grant No. cstc2017jcyjBX0019), and the Program for Innovation Team
   Building at Institutions of Higher Education in Chongqing in 2016 (Grant
   No. CXTDG201602006).
CR Ambrogini E, 2010, CELL METAB, V11, P136, DOI 10.1016/j.cmet.2009.12.009
   Bandow K, 2007, J CELL PHYSIOL, V211, P392, DOI 10.1002/jcp.20944
   Chen D., 2018, CELL PROLIFERAT
   Fox SW, 1996, AM J PHYSIOL ENDOC M, V270, pE955, DOI 10.1152/ajpendo.1996.270.6.E955
   Hantes ME, 2004, J BONE JOINT SURG AM, V86A, P2275, DOI 10.2106/00004623 200410000 00021
   Hao W, 2018, EXP BIOL MED, V243, P386, DOI 10.1177/1535370217746611
   Huang Y, 2018, J CELL PHYSIOL, V233, P6693, DOI 10.1002/jcp.26469
   Kim KM, 2012, J BONE MINER RES, V27, P1669, DOI 10.1002/jbmr.1604
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
   Kim VN, 2005, MOL CELLS, V19, P1
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Lei SF, 2011, J BONE MINER RES, V26, P72, DOI 10.1002/jbmr.186
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Liao L, 2016, STEM CELLS, V34, P1054, DOI 10.1002/stem.2274
   Lu HB, 2009, BIOCHEM BIOPH RES CO, V378, P569, DOI 10.1016/j.bbrc.2008.11.074
   Naruse K, 2000, BIOCHEM BIOPH RES CO, V268, P216, DOI 10.1006/bbrc.2000.2094
   Pitto L, 2008, CELL CYCLE, V7, P2458, DOI 10.4161/cc.7.16.6455
   Qu X, 2016, INT J MOL SCI, V17
   Rached MT, 2010, CELL METAB, V11, P147, DOI 10.1016/j.cmet.2010.01.001
   Rached MT, 2010, J CLIN INVEST, V120, P357, DOI 10.1172/JCI39901
   Reher P, 2002, BONE, V31, P236, DOI 10.1016/S8756 3282(02)00789 5
   Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703 599
   Rubin C, 2001, J BONE JOINT SURG AM, V83A, P259, DOI 10.2106/00004623 200102000 00015
   RUBIN CT, 1995, J BONE MINER RES, V10, P488
   Sena K, 2011, ULTRASONICS, V51, P639, DOI 10.1016/j.ultras.2011.01.007
   Takeuchi R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2451
   Tang L, 2017, SKELET MUSCLE, V7, DOI 10.1186/s13395 017 0145 7
   Teixeira CC, 2010, J BIOL CHEM, V285, P31055, DOI 10.1074/jbc.M109.079962
   Unsworth J, 2007, ULTRASOUND MED BIOL, V33, P1468, DOI 10.1016/j.ultrasmedbio.2006.12.003
   Walsh WR, 2007, ARTHROSCOPY, V23, P197, DOI 10.1016/j.arthro.2006.09.003
   Wang YJ, 2018, INT J MOL MED, V42, P322, DOI 10.3892/ijmm.2018.3592
   Wei FL, 2014, CELLS TISSUES ORGANS, V199, P353, DOI 10.1159/000369613
   Wu SL, 2009, PATHOBIOLOGY, V76, P99, DOI 10.1159/000209387
   Yamaguchi D, 2016, J HARD TISSUE BIOL, V25, P137, DOI 10.2485/jhtb.25.137
   Yang RS, 2005, BONE, V36, P276, DOI 10.1016/j.bone.2004.10.009
   Yang SY, 2011, J BIOL CHEM, V286, P19149, DOI 10.1074/jbc.M110.197905
   Yang XX, 2018, INT J BIOL SCI, V14, P1457, DOI 10.7150/ijbs.26686
   Yang Z, 2014, J ULTRAS MED, V33, P865, DOI 10.7863/ultra.33.5.865
   Yin JC, 2017, CELL BIOL INT, V41, P779, DOI 10.1002/cbin.10780
   Zhang X, 2017, J ULTRAS MED, V36, P2419, DOI 10.1002/jum.14239
NR 42
TC 19
Z9 20
U1 1
U2 28
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0300 9084
EI 1638 6183
J9 BIOCHIMIE
JI Biochimie
PD OCT
PY 2019
VL 165
BP 219
EP 228
DI 10.1016/j.biochi.2019.08.005
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA IX6IK
UT WOS:000485786400026
PM 31401188
DA 2025 08 17
ER

PT J
AU Gomez Brouchet, A
   Gilhodes, J
   Van Acker, N
   Brion, R
   Bouvier, C
   Assemat, P
   Gaspar, N
   Aubert, S
   Guinebretiere, JM
   Marie, B
   Larousserie, F
   Entz Werlé, N
   de Pinieux, G
   Mascard, E
   Gouin, F
   Brousset, P
   Tabone, MD
   Jimenez, M
   Le Deley, MC
   Blay, JY
   Brugieres, L
   Piperno Neumann, S
   Rédini, F
AF Gomez Brouchet, Anne
   Gilhodes, Julia
   Van Acker, Nathalie
   Brion, Regis
   Bouvier, Corinne
   Assemat, Pauline
   Gaspar, Nathalie
   Aubert, Sebastien
   Guinebretiere, Jean Marc
   Marie, Beatrice
   Larousserie, Frederique
   Entz Werle, Natacha
   de Pinieux, Gonzague
   Mascard, Eric
   Gouin, Francois
   Brousset, Pierre
   Tabone, Marie Dominique
   Jimenez, Marta
   Le Deley, Marie Cecile
   Blay, Jean Yves
   Brugieres, Laurence
   Piperno Neumann, Sophie
   Redini, Francoise
TI Characterization of Macrophages and Osteoclasts in the Osteosarcoma
   Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma
   Treatment?
SO CANCERS
LA English
DT Article
DE osteosarcoma; zoledronic acid; osteoclast; macrophage; bipotent
   macrophage; multiplex
AB Simple Summary
   Due to the great genetic instability of osteosarcoma (OS), a recurrent molecular therapeutic target has not been identified to date. Therefore, characterization of the OS tumor microenvironment (TME) might offer new therapeutic perspectives. The OS2006 trial, originally designed to evaluate the impact of zoledronic acid (ZA, osteoclast inhibitor) addition to conventional OS therapies, was ended preliminary due to a negative impact on patient survival. Through retrospective biomarker analysis of the unique biological samples collected during the trial, we demonstrate here that ZA not only acts on harmful osteoclasts but also on protective macrophages, clarifying its detrimental effect. By multiplex immunohistochemistry, applied on additional OS biopsies, an important bipotent macrophage population (CD168+/CD163+), homogenously distributed throughout OS tumor areas, was identified. These bipotent cells might play a determining role in the evolution of OS and offer a novel therapeutic approach. A clear definition of the macrophage populations present at diagnosis could re enforce therapeutic decisions.
   Biological and histopathological techniques identified osteoclasts and macrophages as targets of zoledronic acid (ZA), a therapeutic agent that was detrimental for patients in the French OS2006 trial. Conventional and multiplex immunohistochemistry of microenvironmental and OS cells were performed on biopsies of 124 OS2006 patients and 17 surgical ("OSNew") biopsies respectively. CSF 1R (common osteoclast/macrophage progenitor) and TRAP (osteoclast activity) levels in serum of 108 patients were correlated to response to chemotherapy and to prognosis. TRAP levels at surgery and at the end of the protocol were significantly lower in ZA+ than ZA  patients (p(adj) = 0.0011; 0.0132). For ZA+ patients, an increase in the CSF 1R level between diagnosis and surgery and a high TRAP level in the serum at biopsy were associated with a better response to chemotherapy (p = 0.0091; p = 0.0251). At diagnosis, high CD163+ was associated with good prognosis, while low TRAP activity was associated with better overall survival in ZA  patients only. Multiplex immunohistochemistry demonstrated remarkable bipotent CD68+/CD163+ macrophages, homogeneously distributed throughout OS regions, aside osteoclasts (CD68+/CD163 ) mostly residing in osteolytic territories and osteoid matrix associated CD68 /CD163+ macrophages. We demonstrate that ZA not only acts on harmful osteoclasts but also on protective macrophages, and hypothesize that the bipotent CD68+/CD163+ macrophages might present novel therapeutic targets.
C1 [Gomez Brouchet, Anne] Univ Toulouse, Dept Pathol, ONCOSARC CRCT,ERL CNRS 5294, CHU,IUCT Oncopole,Eq19 ONCOSARC CRCT,UMR 1037 Ins, F 31059 Toulouse, France.
   [Gilhodes, Julia] IUCT Oncopole, Biostat Unit, Inst Claudius Regaud, F 31059 Toulouse, France.
   [Van Acker, Nathalie; Brousset, Pierre] IUCT Oncopole, Dept Pathol, Imag IN Platform, CHU, F 31059 Toulouse, France.
   [Brion, Regis; Redini, Francoise] Univ Nantes, Pole Os Articulat Chirurg Plast, INSERM UMR 1238, F 44035 Nantes, France.
   [Bouvier, Corinne] CHU Timone, Dept Pathol, F 13005 Marseille, France.
   [Assemat, Pauline] Univ Toulouse, Inst Mecan Fluides Toulouse, INPT, UMR CNRS 5502, F 31400 Toulouse, France.
   [Gaspar, Nathalie] Paris Saday Univ, Gustave Roussy Canc Ctr, Dept Oncol Child & Adolescents, F 94805 Villejuif, France.
   [Aubert, Sebastien] CHRU Lille, Dept Pathol, F 59000 Lille, France.
   [Guinebretiere, Jean Marc] Curie Inst, Dept Pathol, F 75005 Paris, France.
   [Marie, Beatrice] CHRU Nancy, Dept Pathol, F 54035 Nancy, France.
   [Larousserie, Frederique] Univ Paris 05, Dept Pathol, Hop Cochin, AP HP, F 75014 Paris, France.
   [Entz Werle, Natacha] CHRU, Pediat Oncol Dept, F 67200 Strasbourg, France.
   [de Pinieux, Gonzague] CHU, Dept Pathol, F 37000 Tours, France.
   [Mascard, Eric] Hop Necker Enfants Malad, AP HP, Dept Pediat Orthoped Surg, F 75015 Paris, France.
   [Gouin, Francois] Univ Nantes, Ctr Leon Berard Lyon, CHU Nantes, INSERM UMR 1238, F 69008 Lyon, France.
   [Tabone, Marie Dominique] AP HP, Pediat Oncol Dept, F 75012 Paris, France.
   [Jimenez, Marta; Blay, Jean Yves] Unicanc, Paris, France.
   [Jimenez, Marta; Blay, Jean Yves] Claude Bernard Univ, Ctr Leon Berard, Dept Oncol, F 69008 Lyon, France.
   [Le Deley, Marie Cecile] Biostat Unit, Gustave Roussy Canc Campus, F 94805 Villejuif, France.
   [Brugieres, Laurence] Gustave Roussy, Dept Pediat Oncol, F 94805 Villejuif, France.
   [Piperno Neumann, Sophie] Inst Curie, Dept Med Oncol, F 75005 Paris, France.
C3 Universite de Toulouse; Universite Toulouse III   Paul Sabatier; CHU de
   Toulouse; UNICANCER; Institut Claudius Regaud; Universite de Toulouse;
   Universite Toulouse III   Paul Sabatier; CHU de Toulouse; Nantes
   Universite; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Aix Marseille Universite; Assistance Publique Hopitaux de
   Marseille; Universite de Toulouse; Universite Federale Toulouse
   Midi Pyrenees (ComUE); Universite Toulouse III   Paul Sabatier; Institut
   National Polytechnique de Toulouse; Centre National de la Recherche
   Scientifique (CNRS); UNICANCER; Gustave Roussy; Universite de Lille; CHU
   Lille; UNICANCER; Universite PSL; Institut Curie; CHU de Nancy;
   Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Cochin   APHP; CHU Strasbourg; CHU Tours;
   Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Necker Enfants Malades   APHP; Institut National
   de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon
   Berard; Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux
   Paris (APHP); UNICANCER; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite Claude Bernard Lyon 1;
   UNICANCER; Centre Leon Berard; UNICANCER; Gustave Roussy; UNICANCER;
   Gustave Roussy; UNICANCER; Universite PSL; Institut Curie
RP Gomez Brouchet, A (通讯作者)，Univ Toulouse, Dept Pathol, ONCOSARC CRCT,ERL CNRS 5294, CHU,IUCT Oncopole,Eq19 ONCOSARC CRCT,UMR 1037 Ins, F 31059 Toulouse, France.
EM gomez.anne@chu toulouse.fr; Githodes.Julia@iuct oncopole.fr;
   vanacker.nathalie@iuct oncopole.fr; regis.brion@univ nantes.fr;
   Corinne.BOUVIER2@ap hm.fr; pauline.assemat@imft.fr;
   Nathalie.GASPAR@gustaveroussy.fr; Sebastien.AUBERT@CHRU LILLE.FR;
   jean marc.guinebretiere@curie.net; b.marie@chru nancy.fr;
   frederique.larousserie@aphp.fr; Natacha.entz werle@chru strasbourg.fr;
   gonzague.dubouexic@univ tours.fr; Eric.mascard@wanadoo.fr;
   Francois.GOUIN@lyon.unicancer.fr; brousset.p@chu toulouse.fr;
   marie dominique.tabone@aphp.fr; m jimenez@unicancer.fr;
   m ledeley@o lambret.fr; jean yves.blay@lyon.unicancer.fr;
   Laurence.BRUGIERES@gustaveroussy.fr; sophie.piperno neumann@curie.net;
   francoise.redini@univ nantes.fr
RI ; Blay, Jean Yves/N 3966 2016; Le Deley, Marie Cécile/B 6162 2013;
   JIMENEZ, Marta/MGT 6878 2025; Gaspar, Nathalie/JRW 5505 2023; Brousset,
   Pierre/LKK 4586 2024
OI Brugieres, Laurence/0000 0002 7798 6651; Blay,
   Jean Yves/0000 0001 7190 120X; Assemat, Pauline/0000 0002 1484 6619;
   Gaspar, Nathalie/0000 0002 1827 8903; 
FU BMS foundation; Societe Francaise des Cancers et Leucemies de l'Enfant
   (SFCE); Association Etoile de Martin
FX Partial funding was obtained from the BMS foundation, the Societe
   Francaise des Cancers et Leucemies de l'Enfant (SFCE) and the
   Association Etoile de Martin.
CR Akiyama T, 2010, J PHARM PHARMACOL, V62, P470, DOI 10.1211/jpp.62.04.0009
   Alfranca A, 2015, CELL MOL LIFE SCI, V72, P3097, DOI 10.1007/s00018 015 1918 y
   Barros MHM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080908
   Battaglia S, 2011, J BONE MINER RES, V26, P2439, DOI 10.1002/jbmr.453
   Bielack SS, 2015, J CLIN ONCOL, V33, P2279, DOI 10.1200/JCO.2014.60.0734
   Biteau K, 2016, AM J CANCER RES, V6, P677
   Bousquet M, 2016, ANN ONCOL, V27, P738, DOI 10.1093/annonc/mdw009
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brard C, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen 2018 025877
   Buddingh EP, 2011, CLIN CANCER RES, V17, P2110, DOI 10.1158/1078 0432.CCR 10 2047
   Casali PG, 2014, ANN ONCOL, V25, P113, DOI 10.1093/annonc/mdu256
   Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003
   Dancsok AR, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1747340
   Deligiorgi MV, 2020, CLIN EXP METASTAS, V37, P13, DOI 10.1007/s10585 019 09997 8
   Diepenhorst NA, 2017, ANAL BIOCHEM, V519, P51, DOI 10.1016/j.ab.2016.12.010
   Dumars C, 2016, ONCOTARGET, V7, P78343, DOI 10.18632/oncotarget.13055
   Editorial Board WHO classification of tumours editorial, 2020, Soft tissue and bone tumours, V3
   Filgueira L, 2004, J HISTOCHEM CYTOCHEM, V52, P411, DOI 10.1177/002215540405200312
   Garofalo C, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00074
   Gide TN, 2018, CLIN CANCER RES, V24, P1260, DOI 10.1158/1078 0432.CCR 17 2267
   Gomez Brouchet A, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1331193
   Guerriero JL, 2018, TRENDS MOL MED, V24, P472, DOI 10.1016/j.molmed.2018.03.006
   Han Y, 2019, CANCER LETT, V440, P116, DOI 10.1016/j.canlet.2018.10.011
   HOLNESS CL, 1993, BLOOD, V81, P1607
   Ibrahim T, 2016, ONCOL LETT, V12, P2970, DOI 10.3892/ol.2016.4977
   Inagaki Y, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569 016 0053 3
   Iseulys Richert, 2020, J Bone Oncol, V20, P100271, DOI 10.1016/j.jbo.2019.100271
   Italiano A, 2020, LANCET ONCOL, V21, P446, DOI [10.1016/51470 2045(19)30825 3, 10.1016/S1470 2045(19)30825 3]
   Jayasingam SD, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01512
   Junankar S, 2015, CANCER DISCOV, V5, P35, DOI 10.1158/2159 8290.CD 14 0621
   Kelleher FC, 2017, J ADOLESC YOUNG ADUL, V6, P396, DOI 10.1089/jayao.2016.0078
   Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008 5472.CAN 06 4130
   Lamoureux F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4511
   Lampiasi N, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/9089610
   Lau SK, 2004, AM J CLIN PATHOL, V122, P794, DOI 10.1309/QHD6YFN81KQXUUH6
   Lézot F, 2014, BONE, V68, P146, DOI 10.1016/j.bone.2014.08.018
   Liverani C, 2014, BONE, V66, P214, DOI 10.1016/j.bone.2014.06.017
   Mantovani A, 2009, HUM IMMUNOL, V70, P325, DOI 10.1016/j.humimm.2009.02.008
   Marina NM, 2016, LANCET ONCOL, V17, P1396, DOI 10.1016/S1470 2045(16)30214 5
   Mercatali L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111827
   Meyers PA, 2008, J CLIN ONCOL, V26, P633, DOI 10.1200/JCO.2008.14.0095
   Nicolas Sans G.P, 2014, IMAGERIE TUMEURS OSS
   Ory B, 2005, CANCER AM CANCER SOC, V104, P2522, DOI 10.1002/cncr.21530
   Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111
   Piperno Neumann S, 2016, LANCET ONCOL, V17, P1070, DOI 10.1016/S1470 2045(16)30096 1
   Proff P, 2009, CLIN ORAL INVEST, V13, P355, DOI 10.1007/s00784 009 0268 2
   Ribatti D, 2006, CLIN EXP MED, V6, P145, DOI 10.1007/s10238 006 0117 4
   Roszer T, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/816460
   Schmieder A, 2012, SEMIN CANCER BIOL, V22, P289, DOI 10.1016/j.semcancer.2012.02.002
   Spina V, 1998, EUR J RADIOL, V27, pS98, DOI 10.1016/S0720 048X(98)00050 3
   Trama A, 2016, LANCET ONCOL, V17, P896, DOI 10.1016/S1470 2045(16)00162 5
   Xiao YL, 2017, BLOOD ADV, V1, P1993, DOI 10.1182/bloodadvances.2017008540
   Zhang C, 2020, AGING US, V12, P3486, DOI 10.18632/aging.102824
   Zhang WJ, 2017, LAB INVEST, V97, P873, DOI 10.1038/labinvest.2017.37
   Zhou Q, 2017, CANCER IMMUNOL RES, V5, P547, DOI 10.1158/2326 6066.CIR 16 0259
NR 55
TC 22
Z9 22
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD FEB
PY 2021
VL 13
IS 3
AR 423
DI 10.3390/cancers13030423
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA QC6ZM
UT WOS:000614983700001
PM 33498676
OA Green Published, Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Liu, X
   Huang, MZ
   Chen, ZY
   Zhao, XY
   Wang, CC
   Peng, W
   Yin, JL
   Li, J
   Zhu, XD
AF Liu, Xin
   Huang, Ming Zhu
   Chen, Zhi Yu
   Zhao, Xiao Yin
   Wang, Chen Chen
   Peng, Wei
   Yin, Ji Liang
   Li, Jin
   Zhu, Xiao Dong
TI LRP5 polymorphism   A potential predictor of the clinical outcome in
   advanced gastric cancer patients treated with EOF regimen
SO CHINESE JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Gastric cancer; chemotherapy; biomarker; lipoprotein related receptor 5
   (LRP5); rs3736228
ID ADVANCED ESOPHAGOGASTRIC CANCER; BONE MINERAL DENSITY; 1ST LINE THERAPY;
   PHASE III; CISPLATIN; FLUOROURACIL; CELLS; TRIAL; CAPECITABINE;
   CHEMOTHERAPY
AB Purpose: Wnt pathways control key biological processes that potentially impact on tumor progression and patient survival. The present study analyzed the polymorphism of lipoprotein related receptor 5 (LRP5) (gene with key functions in Wnt signaling) and its impact on the response to chemotherapy and survival of patients with advanced gastric cancer (AGC).
   Methods: A total of 107 consecutive patients with AGC treated with first line chemotherapy of EOF regimen were enrolled in the present retrospective study. The association between single nucleotide polymorphism (SNP) of rs3736228 in LRP5 and the clinical outcomes of the patients was studied.
   Results: The CC genotype of rs3736228 was significantly correlated with a higher disease control rate when compared to the CT and TT genotypes (89.3% and 61.8%, respectively, P<0.001). A univariate survival analysis also showed that the progression free survival (PFS) and overall survival (OS) for the patients with the TC and TT genotypes of rs3736228 were worse than for the patients with the CC genotype (PFS: 3.3 and 6.7 months, respectively, HR = 0.454, P<0.001; OS: 8.1 months and 18.8 months, respectively, HR = 3.056, P<0.001). A multivariate Cox model incorporates rs3736228 and clinical features, also identified rs3736228 was significantly associated with the PFS and OS.
   Conclusions: Our results firstly highlight the importance of LRPS gene of Wnt pathway in the treatment of AGC and identify polymorphism of rs3736228 as independent predictor of disease control rate, PFS and OS in AGC patients treated with first line chemotherapy of EOF regimen in the Chinese Han population.
C1 [Li, Jin] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.
   Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200032, Peoples R China.
C3 Fudan University; Fudan University
RP Li, J (通讯作者)，Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, 270 Dong An Rd, Shanghai 200032, Peoples R China.
EM fudanlijin@163.com; xddr@netease.com
RI Wang, Hongfeng/H 1807 2016; li, Jiaxin/GSO 0978 2022; 陈,
   文杰·/HHN 5495 2022
FU Natural Science Foundation of Shanghai [13ZR1408200]
FX We appreciate the contribution of the members participating in this
   study. This work was supported by the Natural Science Foundation of
   Shanghai (Grant No. 13ZR1408200).
CR Bashash M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059157
   Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166 4328(01)00297 2
   Cai C, 2012, MOL MED REP, V5, P1191, DOI 10.3892/mmr.2012.802
   Canto Cetina T, 2013, AM J HUM BIOL, V25, P713, DOI 10.1002/ajhb.22464
   Cebrat M, 2001, Postepy Hig Med Dosw, V55, P513
   Chou I, 2004, J CLIN ONCOL, V22, P2395, DOI 10.1200/JCO.2004.08.154
   Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149
   Gonzálex Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303
   Hansel DE, 2004, CLIN CANCER RES, V10, P6152, DOI 10.1158/1078 0432.CCR 04 0285
   Hoang BH, 2004, INT J CANCER, V109, P106, DOI 10.1002/ijc.11677
   Joiner DM, 2013, TRENDS ENDOCRIN MET, V24, P31, DOI 10.1016/j.tem.2012.10.003
   Kang YK, 2009, ANN ONCOL, V20, P666, DOI 10.1093/annonc/mdn717
   Lee SS, 2007, JPN J CLIN ONCOL, V37, P30, DOI 10.1093/jjco/hyl134
   Li H, 2013, MOL MED REP, V7, P1751, DOI 10.3892/mmr.2013.1412
   Li YY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0066567, 10.1371/journal.pone.0055108, 10.1371/journal.pone.0054369, 10.1371/journal.pone.0052093, 10.1371/journal.pone.0062036, 10.1371/journal.pone.0071994, 10.1371/journal.pone.0063648, 10.1371/journal.pone.0077685]
   Lindvall C, 2006, J BIOL CHEM, V281, P35081, DOI 10.1074/jbc.M607571200
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Mao J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.515
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427
   Parkin DM, 2005, CA CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Ross P, 2002, J CLIN ONCOL, V20, P1996, DOI 10.1200/JCO.2002.08.105
   Scholer Dahirel A, 2011, P NATL ACAD SCI USA, V108, P17135, DOI 10.1073/pnas.1104182108
   Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117
   Tran BNH, 2008, BMC MED GENET, V9, DOI 10.1186/1471 2350 9 55
   Van Cutsem E, 2006, J CLIN ONCOL, V24, P4991, DOI 10.1200/JCO.2006.06.8429
   Wang Z, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471 230X 12 137
   Webb A, 1997, J CLIN ONCOL, V15, P261, DOI 10.1200/JCO.1997.15.1.261
   Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110
NR 28
TC 4
Z9 4
U1 0
U2 3
PU CHINESE JOURNAL CANCER RESEARCH CO
PI BEIJING
PA LTD PEKING U CANCER HOSP & INST, NO 52, FUCHENG RD, HAIDIAN, BEIJING,
   100142, PEOPLES R CHINA
SN 1000 9604
EI 1993 0631
J9 CHINESE J CANCER RES
JI Chin. J. Cancer Res.
PD AUG
PY 2014
VL 26
IS 4
BP 478
EP 485
DI 10.3978/j.issn.1000 9604.2014.08.22
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AQ0ON
UT WOS:000342482700020
PM 25232223
DA 2025 08 17
ER

PT J
AU Alharthi, AA
   Kamal, NM
   Abukhatwah, MW
   Sherief, LM
AF Alharthi, Abdulla A.
   Kamal, Naglaa M.
   Abukhatwah, Mohamed W.
   Sherief, Laila M.
TI Cinacalcet in Pediatric and Adolescent Chronic Kidney Disease A
   Single Center Experience
SO MEDICINE
LA English
DT Article
ID STAGE RENAL DISEASE; SECONDARY HYPERPARATHYROIDISM; BONE DISEASE;
   VITAMIN D; DIALYSIS; RECEPTOR; HEMODIALYSIS; METABOLISM; CALCIUM; HCL
AB Cinacalcet, a calcimimetic drug, has been shown to be efficacious in adult chronic kidney disease (CKD) patients; however, it was not fully studied in pediatric CKD patients. We aimed at assessing the effect of cinacalcet on intact parathyroid hormone (iPTH) secretion in children with CKD 4/5 with iPTH consistently >= 300 pg/mL refractory to conventional treatment.
   This is a prospective cohort analysis of 28 children with uncontrolled hyper parathyroidism secondary to stage 4 and 5 CKD admitted to a tertiary center during the period from April 2012 to April 2014.
   Twenty eight patients with CKD 4/5 were assessed prospectively regarding bone biochemistry, renal ultrasonography, serum iPTH level, and medications. Patients were classified into 3 groups: group 1, 6 patients with CKD 4 on supplemental and supportive therapy; group 2, 6 patients with CKD 5 on hemodialysis and; group 3, 16 patients with CKD 5 on automated peritoneal dialysis. Patients were between the ages of 9 months and 18 years on commencing cinacalcet at doses of 0.5 to 1.5mg/kg.
   All patients showed at least a 60% reduction in iPTH (60% 97%). Highly significant reduction in iPTH and serum alkaline phosphatase levels was detected post cinacalcet. The serum calcium (Ca), phosphate (P), and Ca x P product were unaffected. Treatment was well tolerated with no hypophosphatemia, hypocalcemia, or other adverse effects almost in all patients.
   Cinacalcet use was proven safe for all pediatric and adolescent patients with CKD 4/5 during the study period, and at the same time most of the patients reached the suggested iPTH target values
C1 [Alharthi, Abdulla A.] Taif Univ, Al Hada Armed Forces Hosp, Fac Med, At Taif, Saudi Arabia.
   [Kamal, Naglaa M.] Cairo Univ, Fac Med, Cairo, Egypt.
   [Kamal, Naglaa M.; Abukhatwah, Mohamed W.] Al Hada Armed Forces Hosp, At Taif, Saudi Arabia.
   [Sherief, Laila M.] Zagazig Univ, Fac Med, Zagazig, Egypt.
C3 Taif University; Al Hada Armed Forces Hospital; Egyptian Knowledge Bank
   (EKB); Cairo University; Al Hada Armed Forces Hospital; Egyptian
   Knowledge Bank (EKB); Zagazig University
RP Kamal, NM (通讯作者)，Cairo Univ, Fac Med, Cairo, Egypt.
EM nagla.kamal@kasralainy.edu.eg
RI Sherief, Laila/AAI 8724 2020
OI Mohamed Kamal, Naglaa/0000 0002 8535 3838
CR [Anonymous], CIN TREATM SEC HYP P
   Bellasi Antonio, 2006, Hemodial Int, V10, P225, DOI 10.1111/j.1542 4758.2006.00100.x
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   BROWN EM, 1994, NEPHROL DIAL TRANSPL, V9, P1703
   Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523 1755.2005.00596.x
   Dotis J, J PEDIAT ENDOCRINOL, V26, P39
   Francisco A, 2008, EXPERT OPIN PHARMACO, V9, P795
   Gal Moscovici A, 2007, ADV CHRONIC KIDNEY D, V14, P27, DOI 10.1053/j.ackd.2006.10.010
   Goldsmith D, 2004, KIDNEY INT, V66, P1315, DOI 10.1111/j.1523 1755.2004.00895.x
   Goodman WG, 2003, PEDIATR NEPHROL, V18, P1206, DOI 10.1007/s00467 003 1290 2
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   LEFEBVRE A, 1989, KIDNEY INT, V36, P1112, DOI 10.1038/ki.1989.309
   Li YC, 1998, ENDOCRINOLOGY, V139, P4391, DOI 10.1210/en.139.10.4391
   Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512
   Mahdavi Mazdeh Mitra, 2007, Iran J Kidney Dis, V1, P25
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Muscheites J, 2008, PEDIATR NEPHROL, V23, P1823, DOI 10.1007/s00467 008 0810 5
   Nakagawa K, 2008, NEPHROL DIAL TRANSPL, V23, P2761, DOI 10.1093/ndt/gfn143
   National Kidney Foundation, 2005, AM J KIDNEY DIS S, V42, pS1
   Panda DK, 2004, J BIOL CHEM, V279, P16754, DOI 10.1074/jbc.M310271200
   Platt C, 2010, PEDIATR NEPHROL, V25, P143, DOI 10.1007/s00467 009 1294 7
   Runowski Dariusz, 2009, Pol Merkur Lekarski, V26, P343
   Sajid Crockett S, 2008, METABOLISM, V57, P517, DOI 10.1016/j.metabol.2007.11.014
   Schlieper G, 2008, PEDIATR NEPHROL, V23, P1721, DOI 10.1007/s00467 008 0900 4
   Silverstein DM, 2008, PEDIATR NEPHROL, V23, P1817, DOI 10.1007/s00467 007 0742 5
   Tasic V, 2005, TURKISH J PEDIATR, V47, P13
   Wu SF, 2004, FASEB J, V18, P143, DOI 10.1096/fj.03 0294fje
   Young EW, 2007, ADV CHRONIC KIDNEY D, V14, P13, DOI 10.1053/j.ackd.2006.10.003
   Youssef Doaa, 2012, Arab J Nephrol Transplant, V5, P51
NR 30
TC 14
Z9 15
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JAN
PY 2015
VL 94
IS 2
AR e401
DI 10.1097/MD.0000000000000401
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA AZ3QS
UT WOS:000348142400019
PM 25590845
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Gong, W
   Dou, H
   Liu, XQ
   Sun, LY
   Hou, YY
AF Gong, Wei
   Dou, Huan
   Liu, Xianqin
   Sun, Lingyun
   Hou, Yayi
TI Technetium 99 conjugated with methylene diphosphonate inhibits receptor
   activator of nuclear factor κB ligand induced osteoclastogenesis
SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
LA English
DT Article
DE osteoclastogenesis; receptor activator of nuclear factor kappa B ligand
   (RANKL); technetium 99 conjugated with methylene diphosphonate
   (99Tc MDP)
ID NECROSIS FACTOR RECEPTOR; RHEUMATOID ARTHRITIS; BONE RESORPTION; C FOS;
   DIFFERENTIATION FACTOR; IN VITRO; RAW264.7 CELLS; RANKL; KINASE; EROSION
AB In the present study, we investigated the effects of technetium 99 conjugated with methylene diphosphonate (Tc 99 MDP), an agent used in radionuclide therapy, on receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclastogenesis and explored the underlying mechanisms. The murine macrophage cell line RAW264.7 and bone marrow derived macrophages from C57BL/6 mice (BMM) were used as models for osteoclastogenesis in vitro. The expression of some key factors in RANKL (50 ng/mL) induced osteoclastogenesis in RAW264.7 cells was investigated by flow cytometry and real time reverse transcriptionpolymerase chain reaction (RT PCR). To detect multinucleated osteoclast formation, RAW264.7 cells were induced with RANKL for 4 days, whereas BMM were induced by 50 ng/mL RANKL and 20 ng/mL macrophage colony stimulating factor for 7 days, before being stained with tartrate resistant acid phosphatase. Osteoclastogenesis was evaluated using the osteoclast markers CD51, matrix metalloproteinase (MMP) 9 and cathepsin K. At 0.01 mu g/mL, Tc 99 MDP significantly inhibited RANKL induced osteoclastogenesis without any cytotoxicity. In addition, Tc 99 MDP abolished the appearance of multinucleated osteoclasts. Real time RT PCR analysis of transcription factor expression revealed that Tc 99 MDP inhibited the expression of c Fos and nuclear factor of activated T cells. In addition, Tc 99 MDP inhibited the expression of the inflammatory factors interleukin (IL) 6, tumour necrosis factor alpha and IL 1 beta. Finally, Tc 99 MDP inhibited the activation of mitogen activated protein kinases in RAW264.7 cells following RANKL stimulation. In conclusion, Tc 99 MDP possesses anti osteoclastogenic activity against RANKL induced osteoclast formation.
C1 [Gong, Wei; Dou, Huan; Hou, Yayi] Nanjing Univ, Immunol & Reprod Biol Lab, Sch Med, Nanjing 210093, Jiangsu, Peoples R China.
   [Gong, Wei; Dou, Huan; Hou, Yayi] Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Jiangsu, Peoples R China.
   [Liu, Xianqin; Sun, Lingyun] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Nanjing 210093, Jiangsu, Peoples R China.
   [Hou, Yayi] Jiangsu Key Lab Mol Med, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing University; Nanjing University; Nanjing University
RP Hou, YY (通讯作者)，Nanjing Univ, Immunol & Reprod Biol Lab, Sch Med, Nanjing 210093, Jiangsu, Peoples R China.
EM yayihou@nju.edu.cn
RI Dou, Huan/AFR 7946 2022; Sun, Lingyun/AFQ 4832 2022
FU National Natural Science Foundation of China [90813036, 81072410];
   Scientific Research Foundation of Graduate School of Jiangsu Province
   [CXZZ11 0036]; Fundamental Research Funds for the Central Universities
   [1117021406, 1118021406, 1107021460, 1094021410]; Scientific Research
   Foundation of Graduate School of Nanjing University [2010 CL04]
FX This work was supported by the National Natural Science Foundation of
   China (90813036, 81072410), the Scientific Research Foundation of
   Graduate School of Jiangsu Province (CXZZ11 0036), the Fundamental
   Research Funds for the Central Universities (1117021406, 1118021406,
   1107021460 and 1094021410) and the Scientific Research Foundation of
   Graduate School of Nanjing University (2010 CL04).
CR Ang ESM, 2012, J CELL BIOCHEM, V113, P946, DOI 10.1002/jcb.23423
   Ang ESM, 2011, FEBS LETT, V585, P2755, DOI 10.1016/j.febslet.2011.07.046
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BROMLEY M, 1984, ARTHRITIS RHEUM US, V27, P968, DOI 10.1002/art.1780270902
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   Delaissé JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hayashi H, 2008, FEBS LETT, V582, P3243, DOI 10.1016/j.febslet.2008.08.023
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Jang YJ, 2011, ARCH ORAL BIOL, V56, P1319, DOI 10.1016/j.archoralbio.2011.05.010
   Ji Ying, 2009, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V34, P684
   Karatay S, 2004, RHEUMATOLOGY, V43, P1429, DOI 10.1093/rheumatology/keh366
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lai KB, 2011, INVEST OPHTH VIS SCI, V52, P5702, DOI 10.1167/iovs.10 6370
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Li ML, 1995, Chinese patent, Patent No. [ZL94113006.1.22, 941130061]
   Liu SJ, 2010, INT J PATHOL CLIN ME, V2, P124
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Meiyanto E, 2001, BIOCHEM BIOPH RES CO, V282, P278, DOI 10.1006/bbrc.2001.4564
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200
   [穆荣 Mu Rong], 2004, [中华风湿病学杂志, Chinese Journal of Rheumatology], V8, P39
   Nakashima T, 2009, J CLIN IMMUNOL, V29, P555, DOI 10.1007/s10875 009 9316 6
   O'Gradaigh D, 2004, ANN RHEUM DIS, V63, P354, DOI 10.1136/ard.2003.008458
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Shu Xun Y, 2011, NUCL MED COMMUN, V32, P142, DOI 10.1097/MNM.0b013e32834121cb
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 1997, BIOCHEM BIOPH RES CO, V240, P279, DOI 10.1006/bbrc.1997.7404
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   TEZUKA K, 1994, J BIOL CHEM, V269, P1106
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wang CX, 2007, J TAISHAN MED COLL, V8, P640
   Wang LM, 2008, CLIN EXP PHARMACOL P, V35, P23, DOI 10.1111/j.1440 1681.2007.04738.x
   Wittrant Y, 2004, EXP CELL RES, V293, P292, DOI 10.1016/j.yexcr.2003.10.016
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang NP, 2003, CHIN J RHEUMATOL, V12, P752
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yonezawa T, 2011, EUR J PHARMACOL, V650, P511, DOI 10.1016/j.ejphar.2010.10.048
   Zhang MM, 2008, CHINA J OSTEOPOROS, V9, P569
NR 49
TC 9
Z9 10
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1440 1681
J9 CLIN EXP PHARMACOL P
JI Clin. Exp. Pharmacol. Physiol.
PD OCT
PY 2012
VL 39
IS 10
BP 886
EP 893
DI 10.1111/j.1440 1681.2012.12006.x
PG 8
WC Pharmacology & Pharmacy; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Physiology
GA 012KW
UT WOS:000309236100007
PM 23013134
DA 2025 08 17
ER

PT J
AU Roberts, BM
   Geddis, AV
   Ciuciu, A
   Reynoso, M
   Mehta, N
   Varanoske, AN
   Kelley, AM
   Walker, RJ
   Munoz, R
   Kolb, AL
   Staab, JS
   Naimo, MA
   Tomlinson, RE
AF Roberts, Brandon M.
   Geddis, Alyssa V.
   Ciuciu, Alexandra
   Reynoso, Marinaliz
   Mehta, Nikhil
   Varanoske, Alyssa N.
   Kelley, Alyssa M.
   Walker, Raymond J.
   Munoz, Rigoberto
   Kolb, Alexander L.
   Staab, Jeffery S.
   Naimo, Marshall A.
   Tomlinson, Ryan E.
TI Acetaminophen influences musculoskeletal signaling but not adaptations
   to endurance exercise training
SO FASEB JOURNAL
LA English
DT Article
DE bone; muscle; muscle protein synthesis; NSAIDs; paracetamol; Tylenol
ID HUMAN SKELETAL MUSCLE; RESISTANCE EXERCISE; BONE FORMATION; TREADMILL
   EXERCISE; CONTROLLED TRIAL; IBUPROFEN; PARACETAMOL; PERFORMANCE;
   CONSUMPTION; FRACTURE
AB Acetaminophen (ACE) is a widely used analgesic and antipyretic drug with various applications, from pain relief to fever reduction. Recent studies have reported equivocal effects of habitual ACE intake on exercise performance, muscle growth, and risks to bone health. Thus, this study aimed to assess the impact of a 6 week, low dose ACE regimen on muscle and bone adaptations in exercising and non exercising rats. Nine week old Wistar rats (n = 40) were randomized to an exercise or control (no exercise) condition with ACE or without (placebo). For the exercise condition, rats ran 5 days per week for 6 weeks at a 5% incline for 2 min at 15 cm/s, 2 min at 20 cm/s, and 26 min at 25 cm/s. A human equivalent dose of ACE was administered (379 mg/kg body weight) in drinking water and adjusted each week based on body weight. Food, water intake, and body weight were measured daily. At the beginning of week 6, animals in the exercise group completed a maximal treadmill test. At the end of week 6, rats were euthanized, and muscle cross sectional area (CSA), fiber type, and signaling pathways were measured. Additionally, three point bending and microcomputer tomography were measured in the femur. Follow up experiments in human primary muscle cells were used to explore supra physiological effects of ACE. Data were analyzed using a two way ANOVA for treatment (ACE or placebo) and condition (exercise or non exercise) for all animal outcomes. Data for cell culture experiments were analyzed via ANOVA. If omnibus significance was found in either ANOVA, a post hoc analysis was completed, and a Tukey's adjustment was used. ACE did not alter body weight, water intake, food intake, or treadmill performance (p > .05). There was a treatment by condition effect for Young's Modulus where placebo exercise was significantly lower than placebo control (p < .05). There was no treatment by condition effects for microCT measures, muscle CSA, fiber type, or mRNA expression. Phosphorylated AMPK was significantly increased with exercise (p < .05) and this was attenuated with ACE treatment. Furthermore, phospho 4EBP1 was depressed in the exercise group compared to the control (p < .05) and increased in the ACE control and ACE exercise group compared to placebo exercise (p < .05). A low dose of ACE did not influence chronic musculoskeletal adaptations in exercising rodents but acutely attenuated AMPK phosphorylation and 4EBP1 dephosphorylation post exercise.
C1 [Roberts, Brandon M.; Geddis, Alyssa V.; Reynoso, Marinaliz; Varanoske, Alyssa N.; Kelley, Alyssa M.; Walker, Raymond J.; Munoz, Rigoberto; Kolb, Alexander L.; Staab, Jeffery S.; Naimo, Marshall A.] US Army Res Inst Environm Med, Mil Performance Div, Natick, MA USA.
   [Ciuciu, Alexandra; Mehta, Nikhil; Tomlinson, Ryan E.] Thomas Jefferson Univ, Dept Orthopaed Surg, Philadelphia, PA USA.
   [Varanoske, Alyssa N.] Oak Ridge Inst Sci & Educ, Belcamp, MD USA.
   [Roberts, Brandon M.] US Army Res Inst Environm Med, Mil Performance Div, 10 Gen Greene Ave,Bldg 42, Natick, MA 01760 USA.
C3 United States Department of Defense; United States Army; Thomas
   Jefferson University; Oak Ridge Associated Universities; United States
   Department of Energy (DOE); Oak Ridge Institute for Science & Education;
   United States Department of Defense; United States Army
RP Roberts, BM (通讯作者)，US Army Res Inst Environm Med, Mil Performance Div, 10 Gen Greene Ave,Bldg 42, Natick, MA 01760 USA.
EM brandon.m.roberts38.mil@health.mil
RI Tomlinson, Ryan/AAN 7597 2021; Varanoske, Alyssa/AAS 8483 2020; Roberts,
   Brandon/H 4504 2019; Staab, Jeffery/MNP 9286 2025
OI Roberts, Brandon M./0000 0003 0395 6967; Ciuciu,
   Alexandra/0000 0001 6047 6332; Mehta, Nikhil/0009 0008 3650 8435; 
FU Military Operational Medicine Research Program (MOMRP); Military
   Operational Medicine Research Program of the U.S. Army Medical Research
   and Development Command, Fort Detrick, MD
FX This work was supported by the Military Operational Medicine Research
   Program of the U.S. Army Medical Research and Development Command, Fort
   Detrick, MD.
CR ALBERT KS, 1974, J PHARMACOKINET BIOP, V2, P381, DOI 10.1007/BF01071309
   Ali A, 2018, CUREUS J MED SCIENCE, V10, DOI 10.7759/cureus.3293
   Bergenstock M, 2005, J ORTHOP TRAUMA, V19, P717, DOI 10.1097/01.bot.0000184144.98071.5d
   Bertolini A, 2006, CNS DRUG REV, V12, P250, DOI 10.1111/j.1527 3458.2006.00250.x
   Blough ER, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00072
   Brewer CB, 2015, INFLAMMOPHARMACOLOGY, V23, P319, DOI 10.1007/s10787 015 0248 x
   Burtscher Martin, 2013, Int J Physiol Pathophysiol Pharmacol, V5, P190
   Carroll CC, 2011, J APPL PHYSIOL, V111, P508, DOI 10.1152/japplphysiol.01348.2010
   Carroll CC, 2015, AM J PHYSIOL REG I, V308, pR294, DOI 10.1152/ajpregu.00374.2014
   Carroll CC, 2012, AM J PHYSIOL REG I, V302, pR990, DOI 10.1152/ajpregu.00659.2011
   CHOW JWM, 1994, AM J PHYSIOL, V267, pE287, DOI 10.1152/ajpendo.1994.267.2.E287
   D'Lugos AC, 2018, J APPL PHYSIOL, V124, P1012, DOI 10.1152/japplphysiol.00922.2017
   Duff Whitney R D, 2016, Bone Rep, V5, P96, DOI 10.1016/j.bonr.2016.04.004
   Duff WRD, 2017, MED SCI SPORT EXER, V49, P633, DOI 10.1249/MSS.0000000000001172
   Esh CJ, 2021, PHARMACOL RES PERSPE, V9, DOI 10.1002/prp2.835
   Forwood MR, 1996, J BONE MINER RES, V11, P1688
   Gamal W, 2017, SCI REP UK, V7, DOI 10.1038/srep37541
   Garcin M, 2005, J SPORT MED PHYS FIT, V45, P604
   Gibb IA, 2008, ARCH DIS CHILD, V93, P241, DOI 10.1136/adc.2007.126896
   Graham GG, 2013, INFLAMMOPHARMACOLOGY, V21, P201, DOI 10.1007/s10787 013 0172 x
   Grgic J, 2021, SPORTS, V9, DOI 10.3390/sports9090126
   Gump BS, 2013, J APPL PHYSIOL, V115, P929, DOI 10.1152/japplphysiol.00219.2013
   Hamada T, 2006, J APPL PHYSIOL, V101, P1368, DOI 10.1152/japplphysiol.00416.2006
   Hinz B, 2008, FASEB J, V22, P383, DOI 10.1096/fj.07 8506com
   Huang TH, 2008, J BONE MINER METAB, V26, P350, DOI 10.1007/s00774 007 0831 3
   Hughes JM, 2019, J BONE MINER RES, V34, P429, DOI 10.1002/jbmr.3616
   Iwamoto J, 2004, J BONE MINER METAB, V22, P26, DOI 10.1007/s00774 003 0443 5
   Jankowski CM, 2013, EUR J APPL PHYSIOL, V113, P1127, DOI 10.1007/s00421 012 2529 z
   Jessen S, 2021, J APPL PHYSIOL, V131, P238, DOI 10.1152/japplphysiol.00108.2021
   Jetten MJA, 2012, TOXICOL APPL PHARM, V259, P320, DOI 10.1016/j.taap.2012.01.009
   Kelly JP, 2018, J AM PHARM ASSOC, V58, P492, DOI 10.1016/j.japh.2018.06.012
   Kohrt WM, 2010, J BONE MINER RES, V25, P1415, DOI 10.1002/jbmr.24
   Kumar V, 2009, J APPL PHYSIOL, V106, P2026, DOI 10.1152/japplphysiol.91481.2008
   Liu ZH, 2019, BIOMED ENG ONLINE, V18, DOI 10.1186/s12938 019 0728 0
   Lundberg TR, 2018, SCAND J MED SCI SPOR, V28, P2252, DOI 10.1111/sms.13275
   Mackey AL, 2007, J APPL PHYSIOL, V103, P425, DOI 10.1152/japplphysiol.00157.2007
   Mackey AL, 2016, FASEB J, V30, P2266, DOI 10.1096/fj.201500198R
   Markworth JF, 2014, J APPL PHYSIOL, V117, P20, DOI 10.1152/japplphysiol.01299.2013
   Matheny RW, 2022, PHYSIOL REP, V10, DOI 10.14814/phy2.15481
   Matheny RW, 2017, GROWTH HORM IGF RES, V32, P14, DOI 10.1016/j.ghir.2016.09.002
   Mauger AR, 2014, EXP PHYSIOL, V99, P164, DOI 10.1113/expphysiol.2013.075275
   Mauger AR, 2010, J APPL PHYSIOL, V108, P98, DOI 10.1152/japplphysiol.00761.2009
   Mian P, 2018, DRUG AGING, V35, P603, DOI 10.1007/s40266 018 0559 x
   Morgan PT, 2019, APPL PHYSIOL NUTR ME, V44, P434, DOI 10.1139/apnm 2018 0506
   MULLER M, 1995, CLIN PHARMACOL THER, V57, P371, DOI 10.1016/0009 9236(95)90205 8
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Notomi T, 2000, EUR J APPL PHYSIOL, V83, P469, DOI 10.1007/s004210000316
   Pagotto FD., 2018, J Exerc Physiol Online, V21, P106
   Palla AR, 2021, SCIENCE, V371, P483, DOI 10.1126/science.abc8059
   Park J, 2019, BONE, V124, P22, DOI 10.1016/j.bone.2019.04.009
   Patel SH, 2017, AM J PHYSIOL REG I, V313, pR44, DOI 10.1152/ajpregu.00019.2017
   PEAD MJ, 1989, CALCIFIED TISSUE INT, V45, P34, DOI 10.1007/BF02556658
   Portier H, 2020, LIFE BASEL, V10, DOI 10.3390/life10100217
   Prior MJ, 2012, CLIN J PAIN, V28, P204, DOI 10.1097/AJP.0b013e318227cc4f
   Rasmussen BB, 1998, J APPL PHYSIOL, V85, P1629, DOI 10.1152/jappl.1998.85.5.1629
   Reynoso M, 2023, FEBS LETT, V597, P1225, DOI 10.1002/1873 3468.14616
   Roberts BM, 2024, J SCI MED SPORT, V27, P287, DOI 10.1016/j.jsams.2024.02.002
   Roberts BM, 2024, J INT SOC SPORT NUTR, V21, DOI 10.1080/15502783.2024.2302046
   Roberts BM, 2023, PHYSIOL REP, V11, DOI 10.14814/phy2.15805
   Roberts BM, 2023, J INT SOC SPORT NUTR, V20, DOI 10.1080/15502783.2022.2164209
   Rose AJ, 2009, AM J PHYSIOL REG I, V296, pR326, DOI 10.1152/ajpregu.90806.2008
   Rosenbloom CJ, 2020, INT J PHARM PRACT, V28, P561, DOI 10.1111/ijpp.12646
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schüchen RH, 2018, J CACHEXIA SARCOPENI, V9, P1235, DOI 10.1002/jcsm.12352
   Sherk VD, 2017, MED SCI SPORT EXER, V49, P888, DOI 10.1249/MSS.0000000000001194
   Shimamura Chisato, 2002, J Orthop Sci, V7, P358, DOI 10.1007/s007760200060
   Shimodaira T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224809
   Smith IJ, 2016, AM J PHYSIOL REG I, V310, pR707, DOI 10.1152/ajpregu.00550.2015
   Smuder Ashley J, 2020, Oncotarget, V11, P3502, DOI 10.18632/oncotarget.27748
   Soltow QA, 2006, MED SCI SPORT EXER, V38, P840, DOI 10.1249/01.mss.0000218142.98704.66
   Spaulding HR, 2022, ANNU REV PHYSIOL, V84, P209, DOI 10.1146/annurev physiol 060721 095517
   Staab JS, 2021, EXP BIOL MED, V246, P1104, DOI 10.1177/1535370221993098
   Stevens CJ, 2018, SPORTS MED, V48, P525, DOI 10.1007/s40279 017 0852 6
   Trappe RA, 2002, AM J PHYSIOL ENDOC M, V282, pE551, DOI 10.1152/ajpendo.00352.2001
   Trappe TA, 2011, AM J PHYSIOL REG I, V300, pR655, DOI 10.1152/ajpregu.00611.2010
   Venkatesan PS, 2014, BIOL PHARM BULL, V37, P1184, DOI 10.1248/bpb.b14 00066
   Vestergaard P, 2012, OSTEOPOROSIS INT, V23, P1255, DOI 10.1007/s00198 011 1692 0
   Vestergaard P, 2020, HANDB EXP PHARMACOL, V262, P474, DOI 10.1007/164_2019_340
   Vicente Rodríguez G, 2006, SPORTS MED, V36, P561, DOI 10.2165/00007256 200636070 00002
   Vinel C, 2018, NAT MED, V24, P1360, DOI 10.1038/s41591 018 0131 6
   Wheatley BM, 2019, J AM ACAD ORTHOP SUR, V27, pE330, DOI 10.5435/JAAOS D 17 00727
   Williams LJ, 2011, BONE, V48, P1277, DOI 10.1016/j.bone.2011.03.435
   Williamson DL, 2006, J PHYSIOL LONDON, V573, P497, DOI 10.1113/jphysiol.2005.103481
   Wu J, 2004, J APPL PHYSIOL, V97, P806, DOI 10.1152/japplphysiol.01169.2003
   Wu MZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006430
   Zarghi A, 2011, IRAN J PHARM RES, V10, P655
NR 86
TC 3
Z9 3
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD APR 15
PY 2024
VL 38
IS 7
AR e23586
DI 10.1096/fj.202302642R
PG 17
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA MU2A2
UT WOS:001196071100001
PM 38568858
DA 2025 08 17
ER

PT J
AU Stratford, EW
   Daffinrud, J
   Munthe, E
   Castro, R
   Waaler, J
   Krauss, S
   Myklebost, O
AF Stratford, Eva Wessel
   Daffinrud, Jeanette
   Munthe, Else
   Castro, Russell
   Waaler, Jo
   Krauss, Stefan
   Myklebost, Ola
TI The tankyrase specific inhibitor JW74 affects cell cycle progression and
   induces apoptosis and differentiation in osteosarcoma cell lines
SO CANCER MEDICINE
LA English
DT Article
DE beta catenin; Differentiation; JW74; let 7; osteosarcoma; tankyrase;
   TNKS inhibitior; Wnt
ID WNT SIGNALING PATHWAY; REDUCES TUMOR GROWTH; BETA CATENIN; CANCER;
   EXPRESSION; PROTEIN; PATHOGENESIS; DISRUPTION; FACTOR 1; THERAPY
AB Wnt/beta catenin is a major regulator of stem cell self renewal and differentiation and this signaling pathway is aberrantly activated in a several cancers, including osteosarcoma (OS). Attenuation of Wnt/beta catenin activity by tankyrase inhibitors is an appealing strategy in treatment of OS. The efficacy of the tankyrase inhibitor JW74 was evaluated in three OS cell lines (KPD, U2OS, and SaOS 2) both at the molecular and functional level. At the molecular level, JW74 induces stabilization of AXIN2, a key component of the beta catenin destruction complex, resulting in reduced levels of nuclear beta catenin. At the functional level, JW74 induces reduced cell growth in all three tested cell lines, in part due to a delay in cell cycle progression and in part due to an induction of caspase 3 mediated apoptosis. Furthermore, JW74 induces differentiation in U2OS cells, which under standard conditions are resistant to osteogenic differentiation. JW74 also enhances differentiation of OS cell lines, which do not harbor a differentiation block. Interestingly, microRNAs (miRNAs) of the let 7 family, which are known tumor suppressors and inducers of differentiation, are significantly upregulated following treatment with JW74. We demonstrate for the first time that tankyrase inhibition triggers reduced cell growth and differentiation of OS cells. This may in part be due to an induction of let 7 miRNA. The presented data open for novel therapeutic strategies in the treatment of malignant OS.
C1 [Stratford, Eva Wessel; Munthe, Else; Castro, Russell; Myklebost, Ola] Oslo Univ Hosp, Canc Stem Cell Innovat Ctr, NO 0424 Oslo, Norway.
   [Stratford, Eva Wessel; Munthe, Else; Castro, Russell; Myklebost, Ola] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Tumor Biol, NO 0424 Oslo, Norway.
   [Daffinrud, Jeanette; Myklebost, Ola] Univ Oslo, Dept Mol Biosci, NO 0424 Oslo, Norway.
   [Waaler, Jo; Krauss, Stefan] Oslo Univ Hosp, SFI CAST, Biomed Innovat Ctr, Unit Cell Signaling, N 0349 Oslo, Norway.
C3 University of Oslo; University of Oslo; University of Oslo; University
   of Oslo
RP Stratford, EW (通讯作者)，Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Tumor Biol, POB 4953 Nydalen, NO 0424 Oslo, Norway.
EM evaped@rr research.no
RI ; Myklebost, Ola/GZL 6171 2022; Krauss, Sybille/L 5328 2016; Stratford,
   Eva/M 7002 2017; Stratford, Eva Wessel/M 7002 2017; Munthe,
   Else/O 3576 2017
OI Krauss, Stefan/0000 0001 6992 8091; Munthe, Else/0000 0003 3859 1582;
   Stratford, Eva Wessel/0000 0001 6312 5781; 
FU Norwegian Research Council
FX The study was supported by funding from the Norwegian Research Council.
CR Barham W, 2013, CANCER DISCOV, V3, P1286, DOI 10.1158/2159 8290.CD 13 0138
   Basu Roy U, 2012, ONCOGENE, V31, P2270, DOI 10.1038/onc.2011.405
   Blauwkamp TA, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2064
   Boyerinas B, 2010, ENDOCR RELAT CANCER, V17, pF19, DOI 10.1677/ERC 09 0184
   Brown NJM, 2009, FRONT BIOSCI LANDMRK, V14, P1684, DOI 10.2741/3333
   BRULAND OS, 1988, CANCER RES, V48, P5302
   Callow MG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022595
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Darzynkiewicz Zbigniew, 2004, Curr Protoc Immunol, VChapter 5, DOI 10.1002/0471142735.im0507s60
   Dheda K, 2004, BIOTECHNIQUES, V37, P112, DOI 10.2144/04371RR03
   Esquela Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834
   Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960 9822(99)80091 8
   Haydon RC, 2002, INT J CANCER, V102, P338, DOI 10.1002/ijc.10719
   Haydon RC, 2002, CLIN CANCER RES, V8, P1288
   He BC, 2010, CLIN CANCER RES, V16, P2235, DOI 10.1158/1078 0432.CCR 09 2499
   Hikasa H, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007955
   Hoang BH, 2004, INT J CANCER, V109, P106, DOI 10.1002/ijc.11677
   Huang K, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 252
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   James RG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050457
   Kansara M, 2007, DNA CELL BIOL, V26, P1, DOI 10.1089/dna.2006.0505
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Kresse SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048262
   Lau T, 2013, CANCER RES, V73, P3132, DOI 10.1158/0008 5472.CAN 12 4562
   Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010
   Lewis IJ, 2007, JNCI J NATL CANCER I, V99, P112, DOI 10.1093/jnci/djk015
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092 8674(02)00685 2
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   McQueen P, 2011, EXPERT REV ANTICANC, V11, P1223, DOI [10.1586/era.11.94, 10.1586/ERA.11.94]
   Mohseny AB, 2011, LAB INVEST, V91, P1195, DOI 10.1038/labinvest.2011.72
   Nair VS, 2012, JNCI J NATL CANCER I, V104, P528, DOI 10.1093/jnci/djs027
   Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717
   Polakis P, 2012, EMBO J, V31, P2737, DOI 10.1038/emboj.2012.126
   Riffell JL, 2012, NAT REV DRUG DISCOV, V11, P923, DOI 10.1038/nrd3868
   Rubin EM, 2010, MOL CANCER THER, V9, P731, DOI 10.1158/1535 7163.MCT 09 0147
   Stamos J.L., 2013, COLD SPRING HARB PER, V5, DOI DOI 10.1101/CSHPERSPECT.A007898
   Stratford Eva W., 2012, Sarcoma, V2012, P148614, DOI 10.1155/2012/148614
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445
   Trang P, 2011, MOL THER, V19, P1116, DOI 10.1038/mt.2011.48
   Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150
   van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092 8674(02)01014 0
   Verheyen EM, 2010, DEV DYNAM, V239, P34, DOI 10.1002/dvdy.22019
   Voronkov A, 2013, J MED CHEM, V56, P3012, DOI 10.1021/jm4000566
   Voronkov A, 2013, CURR PHARM DESIGN, V19, P634, DOI 10.2174/138161213804581837
   Waaler J, 2012, CANCER RES, V72, P2822, DOI 10.1158/0008 5472.CAN 11 3336
   Waaler J, 2011, CANCER RES, V71, P197, DOI 10.1158/0008 5472.CAN 10 1282
   Wagner Eric R., 2011, Sarcoma, V2011, P325238, DOI 10.1155/2011/325238
   Xing Y, 2003, GENE DEV, V17, P2753, DOI 10.1101/gad.1142603
   Yang SY, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 158
   Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443
   Zhang Y, 2011, NAT CELL BIOL, V13, P623, DOI 10.1038/ncb2222
NR 55
TC 50
Z9 61
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2045 7634
J9 CANCER MED US
JI Cancer Med.
PD FEB
PY 2014
VL 3
IS 1
BP 36
EP 46
DI 10.1002/cam4.170
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AZ4UH
UT WOS:000348218200004
PM 24403055
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Mohamed, MT
   Abuelezz, SA
   Atalla, SS
   Abd El Aziz, LF
   Gorge, SS
AF Mohamed, Maha Tarek
   Abuelezz, Sally A.
   Atalla, Suzi Sobhy
   Abd El Aziz, Lobna Fouad
   Gorge, Sonia Salib
TI The anti osteoporotic and anti atherogenic effects of alendronate and
   simvastatin in ovariectomized rats fed high fat diet: A comparative
   study of combination therapy versus monotherapy
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Ovariectomized high fat diet; Alendronate; Simvastatin; Osteoporosis;
   Athrosclerosis
ID DENSITY LIPOPROTEIN CHOLESTEROL; POSTMENOPAUSAL WOMEN; MEVALONATE
   PATHWAY; BONE LOSS; PLASMA LIPIDS; FEMALE RATS; BISPHOSPHONATES;
   CALCIFICATION; LEPTIN; ATHEROSCLEROSIS
AB Aim: Epidemiological studies suggest a possible link between osteoporosis and cardiovascular diseases. Mevalonate pathway was pointed to as a part of this link. This study was done to investigate the effects of Alendronate (Al) and Simvastatin (Sim), both act on the mevalonate pathway, on osteoporosis, dyslipidemia and atherosclerotic changes in ovariectomized (OVX) rats fed high fat diet (HFD).
   Main methods: 60 female albino rats were equally divided into 5 groups: control sham, OVX HFD untreated, OVX HFD treated with Al (3 mg/kg/d) or/and Sim (6 mg/kg/d). Treatments were taken for 4 weeks by oral gavage and were started 8 weeks after ovariectomy.
   Results: OVX HFD untreated group exhibited a significant negative alteration in lipid profile and on different bone markers e.g. alkaline phosphatase, hydroxyproline and osteocalcin. A significant increase in body weights and on serum levels of TNF alpha, iNOS and leptin were also found compared to control sham group. Vascular reactivity studies revealed a significant decrease in effective concentration 50 of phenylephrine and in acetylcholine% of relaxation and a significant increase in maximum contractile response of phenylephrine. The atherosclerotic and osteoporotic changes were further confirmed histopathologically. Treatment of OVX HFD with Al or/and Sim significantly improved these deleterious effects compared to OVX HFD untreated group. Comparing the combination therapy versus the mono therapy exhibited a significant improvement in different tested parameters which came in favor of the combination therapy.
   Conclusion: Al and Sim have anti osteoporotic, anti dyslipidemic and anti atherosclerotic beneficial effects. Their combination has more promising effects in treatment of osteoporosis, dyslipidemia and atherosclerosis. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Mohamed, Maha Tarek; Abuelezz, Sally A.; Abd El Aziz, Lobna Fouad; Gorge, Sonia Salib] Ain Shams Univ, Fac Med, Dept Pharmacol, Cairo, Egypt.
   [Atalla, Suzi Sobhy] Ain Shams Univ, Dept Histol, Fac Med, Cairo, Egypt.
C3 Egyptian Knowledge Bank (EKB); Ain Shams University; Egyptian Knowledge
   Bank (EKB); Ain Shams University
RP Abuelezz, SA (通讯作者)，Ain Shams Univ, Fac Med, Dept Pharmacol, Cairo, Egypt.
EM sallyabuelezz@yahoo.com
OI Atalla, Suzi/0000 0003 2069 8955
CR Abdel Wahab A. F., 2011, MED J CAIRO U, V79, P33
   Adami S, 2000, J BONE MINER RES, V15, P599, DOI 10.1359/jbmr.2000.15.3.599
   Ainslie DA, 2000, AM J CLIN NUTR, V71, P438
   Anagnostis P, 2009, OSTEOPOROSIS INT, V20, P197, DOI 10.1007/s00198 008 0648 5
   arhat G., 2008, CLIN CASES MINER BON, V5, P19
   Bagger YZ, 2006, J INTERN MED, V259, P598, DOI 10.1111/j.1365 2796.2006.01640.x
   Begum M, 2014, INDIAN J CLIN BIOCHE, V29, P452, DOI 10.1007/s12291 013 0393 1
   Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016
   Celiloglu M, 2009, MENOPAUSE, V16, P689, DOI 10.1097/gme.0b013e318194cafd
   Chapurlat RD, 2006, NAT CLIN PRACT ENDOC, V2, P211, DOI 10.1038/ncpendmet0121
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   Cheng S, Air supply system model with exhaust gas recirculation for improving the life of fuel cell, V2014, P1, DOI [10.1109/ITEC AP.6941250, DOI 10.1109/ITEC AP.2014.6941250]
   Danilevicius CF, 2007, BRAZ J MED BIOL RES, V40, P435, DOI 10.1590/S0100 879X2007000400001
   Deepa PR, 2005, CLIN CHIM ACTA, V355, P119, DOI 10.1016/j.cccn.2004.12.007
   Dong XL, 2016, J NUTR, V146, P1172, DOI 10.3945/jn.115.225474
   [杜志勇 DU Zhiyong], 2008, [光散射学报, Chinese Journal of Light Scattering], V20, P145
   Dubey G, 2013, J APPL PHARM SCI, V3, P52
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Guney E, 2008, NEUROENDOCRINOL LETT, V29, P252
   Hamerman D, 2005, QJM INT J MED, V98, P467, DOI 10.1093/qjmed/hci077
   Healey GD, 2016, J IMMUNOL, V196, P823, DOI 10.4049/jimmunol.1501080
   Hipmair G, 2010, NEUROENDOCRINOL LETT, V31, P155
   Hirano Keiko, 2003, Clin Calcium, V13, P128
   Hong SC, 2007, MENOPAUSE, V14, P835, DOI 10.1097/gme.0b013e31802cddca
   Ismail B, 2014, CAN J PHYSIOL PHARM, V92, P375, DOI 10.1139/cjpp 2013 0446
   Kaji H, 2005, HORM METAB RES, V37, P589, DOI 10.1055/s 2005 870538
   Li XD, 2011, ENDOCRINOLOGY, V152, P3312, DOI 10.1210/en.2011 0252
   Lin S, 2015, CALCIFIED TISSUE INT, V96, P541, DOI 10.1007/s00223 015 9975 7
   Ludgero Correia A, 2012, NUTRITION, V28, P316, DOI 10.1016/j.nut.2011.07.014
   MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195 1155
   Mansueto P, 2011, ACTA MEDICA MEDITERR, V27, P85
   Marcuzzi A, 2012, CURR PHARM DESIGN, V18, P5746, DOI 10.2174/138161212803530835
   Medei E, 2010, CAN J CARDIOL, V26, P542, DOI 10.1016/S0828 282X(10)70469 4
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Nawate S, 2005, BRIT J PHARMACOL, V144, P178, DOI 10.1038/sj.bjp.0706091
   on der Recke P., 1999, AM J MED, V106, P273
   Ono Katsuhiro, 2004, Clin Calcium, V14, P60
   Pytlik M, 2004, POL J PHARMACOL, V56, P571
   Pytlik M, 2003, POL J PHARMACOL, V55, P63
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Saeed G. N., 2014, PAK J PHYSL, V10
   Scalia R, 2001, CIRCULATION, V103, P2598
   Schulz E, 2004, J CLIN ENDOCR METAB, V89, P4246, DOI 10.1210/jc.2003 030964
   Sharma S., 2012, J EXP BIOL, V50, P28
   Shuai B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132104
   Shuto H, 2011, EUR J PHARMACOL, V651, P234, DOI 10.1016/j.ejphar.2010.10.084
   Sinnott B, 2006, CALCIFIED TISSUE INT, V78, P195, DOI 10.1007/s00223 005 0244 z
   Stojanovic OL, 2011, ARCH MED SCI, V7, P179, DOI 10.5114/aoms.2011.22066
   Tsartsalis AN, 2012, HORM INT J ENDOCRINO, V11, P126, DOI 10.14310/horm.2002.1339
   Viereck V, 2005, J CELL BIOCHEM, V96, P1244, DOI 10.1002/jcb.20598
   Vinet R, 2012, B LATINOAM CARIBE PL, V11, P35
   Wang H, 2014, CURR PHARM DESIGN, V20, P641, DOI 10.2174/13816128113199990015
   Xu XC, 2014, J TRANSL MED, V12, DOI 10.1186/s12967 014 0284 0
   Yamaguchi T, 2002, ENDOCR J, V49, P211, DOI 10.1507/endocrj.49.211
   Zhang W, 2013, VASA, V42, P421, DOI 10.1024/0301 1526/a000311
   Zhao LJ, 2008, J BONE MINER RES, V23, P17, DOI 10.1359/JBMR.070813
NR 56
TC 12
Z9 15
U1 0
U2 9
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD MAY
PY 2017
VL 89
BP 1115
EP 1124
DI 10.1016/j.biopha.2017.02.105
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA EW4JQ
UT WOS:000402468200126
PM 28298072
DA 2025 08 17
ER

PT J
AU Xiang, MX
   Xu, L
   Liu, Y
   Yan, YJ
   Hu, JY
   Su, HW
AF Xiang, Mei xian
   Xu, Li
   Liu, Yun
   Yan, Yun jun
   Hu, Jin yue
   Su, Han wen
TI In vitro evaluation of the effects of Polygonum orientale
   L. on proliferation and differentiation of osteoblastic MC3T3 E1 cell
SO JOURNAL OF MEDICINAL PLANTS RESEARCH
LA English
DT Article
DE Polygonum orientale L.; proliferation; differentiation; osteoblastic
   MC3T3 E1 cell; alkaline phosphatase
ID BONE MORPHOGENETIC PROTEIN 2; ULMUS DAVIDIANA PLANCH;
   ALKALINE PHOSPHATASE; INDUCED APOPTOSIS; MINERALIZATION; COLLAGENASE 1;
   ACTIVATION
AB In this study, the stimulative effects of ethanol extract on proliferation and differentiation of osteoblastic MC3T3 E1 cell were examined by in vitro assays, including cell proliferative CCK 8 assay, cell cycle analysis assay and alkaline phosphatase (ALP) activity assay. Cell proliferation results showed that the ethanol extract from Polygonum orientale L. stimulated cell proliferation significantly at 0.1 to 100 mu g/ml and the proportion S phase of cells increased from 20.97 to 25.05% in osteoblastic MC3T3 E1 cells. At the same time, ethanol extracts increased alkaline phosphatase (ALP) activity of MC3T3 E1 cells (significant at 1 to 100 mu g/ml). These results indicated that the herb Polygonum orientale L. could directly stimulate cell proliferation and differentiation of osteoblasts. These results preliminarily explored the pharmacological mechanism of Polygonum orientale L. to promote the curing of bone rheumatism and various fractures.
C1 [Xiang, Mei xian; Xu, Li; Liu, Yun; Yan, Yun jun] Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Wuhan 430074, Hubei Province, Peoples R China.
   [Xiang, Mei xian] S Cent Univ Nationalities, Coll Pharm, Wuhan 430074, Hubei Province, Peoples R China.
   [Hu, Jin yue; Su, Han wen] Wuhan Univ, Renmin Hosipital, Wuhan 430074, Hubei Province, Peoples R China.
C3 Huazhong University of Science & Technology; South Central Minzu
   University; Wuhan University
RP Yan, YJ (通讯作者)，Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Wuhan 430074, Hubei Province, Peoples R China.
EM yanyunjun@tom.com
RI Su, Hanwen/LGY 9195 2024
FU Natural Science Foundation of Wuhan City [SZY09005]; Ministry of
   Education, P.R. China [NCET 07 0336]; Natural Science Foundation of
   SCUEC [CZY10015]
FX This work was supported by The Natural Science Foundation of Wuhan City
   (SZY09005) and Fund for New Century Excellent Talents from Ministry of
   Education, P.R. China (NCET 07 0336) and Fund for the Natural Science
   Foundation of SCUEC (CZY10015). The authors are thankful to Professor
   Dingrong Wan in the Pharmacognosy, the College of Pharmacy, South
   Central University for Nationalities to authenticate the herb.
CR AMOS AF, 2008, EUR J PHARMACOL, V587, P35
   [Anonymous], [No title captured]
   Chae HJ, 2001, IMMUNOPHARM IMMUNOT, V23, P133, DOI 10.1081/IPH 100103855
   Chan BY, 2008, BONE, V43, P567, DOI 10.1016/j.bone.2008.04.018
   Choi EM, 2005, BIOCHEM PHARMACOL, V70, P363, DOI 10.1016/j.bcp.2005.04.019
   Han SY, 2007, J ETHNOPHARMACOL, V114, P400, DOI 10.1016/j.jep.2007.08.019
   HE J, 2010, J CELL BIOCH    0512
   Hu YM, 2008, PHYTOCHEMISTRY, V69, P2367, DOI 10.1016/j.phytochem.2008.05.023
   Isama K, 2003, BIOMATERIALS, V24, P3303, DOI 10.1016/S0142 9612(03)00216 3
   Jeong JC, 2005, J ETHNOPHARMACOL, V96, P489, DOI 10.1016/j.jep.2004.09.038
   Jeong JC, 2004, TOXICOL IN VITRO, V18, P829, DOI 10.1016/j.tiv.2004.05.002
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Kang SK, 2006, IN VITRO CELL DEV AN, V42, P225, DOI 10.1290/0510068.1
   Kim KW, 2008, J ETHNOPHARMACOL, V115, P42, DOI 10.1016/j.jep.2007.09.003
   Lee KH, 2008, EUR J PHARMACOL, V591, P1, DOI 10.1016/j.ejphar.2008.06.004
   LI YP, 1995, J BONE MINER RES, V10, P1197
   LIU JM, 2001, INDIA J CHEN B, V40, P7
   Peterson WJ, 1996, CELL PROLIFERAT, V29, P665, DOI 10.1111/j.1365 2184.1996.tb00980.x
   PHILLIPSON JD, 1989, J ETHNOPHARMACOL, V25, P61, DOI 10.1016/0378 8741(89)90045 7
   QUARLERS JD, 1999, J BONE MINER RES, V7, P683
   Shimada K, 2009, BIOCHEM BIOPH RES CO, V390, P775, DOI 10.1016/j.bbrc.2009.10.048
   Song Qin, 2009, Zhongguo Zhong Yao Za Zhi, V34, P1264
   Sreeja S, 2009, J ETHNOPHARMACOL, V126, P221, DOI 10.1016/j.jep.2009.08.041
   Suh KS, 2003, PHYTOCHEMISTRY, V63, P209, DOI 10.1016/S0031 9422(03)00101 8
   Suh SJ, 2007, J ETHNOPHARMACOL, V109, P480, DOI 10.1016/j.jep.2006.08.030
   Tulipano G, 2010, REGUL PEPTIDES, V160, P168, DOI 10.1016/j.regpep.2009.11.018
   [王开金 WANG Kaijin], 2006, [天然产物研究与开发, Natural Product R & D], V18, P151
   Xie ZT, 2005, LISHIZHEN MED MAT ME, V10, P874
   Yamaguchi M, 1998, BIOCHEM PHARMACOL, V55, P71, DOI 10.1016/S0006 2952(97)00402 4
   Zhao JY, 2010, TISSUE ENG PT A, V16, P233, DOI [10.1089/ten.tea.2009.0165, 10.1089/ten.TEA.2009.0165]
   Zheng SZ, 1998, ACTA BOT SIN, V40, P466
NR 31
TC 5
Z9 8
U1 0
U2 11
PU ACADEMIC JOURNALS
PI VICTORIA ISLAND
PA P O BOX 5170 00200 NAIROBI, VICTORIA ISLAND, LAGOS 73023, NIGERIA
SN 1996 0875
J9 J MED PLANTS RES
JI J. Med. Plants Res.
PD JAN 18
PY 2011
VL 5
IS 2
BP 231
EP 236
PG 6
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 729HI
UT WOS:000287938900013
DA 2025 08 17
ER

PT J
AU Zhao, DH
   Li, YL
   Li, Y
   Jiang, ZW
   Shen, D
   Zhao, Z
   Wang, FK
AF Zhao, Daohong
   Li, Yanlin
   Li, Yan
   Jiang, Zhaowei
   Shen, Duo
   Zhao, Zhi
   Wang, Fuke
TI MiR 181a regulates the chondrogenic differentiation in pig peripheral
   blood mesenchymal stem cells
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Chondrogenesis; miR 181a; mesenchymal stem cells
ID MARROW STROMAL CELLS; BONE MARROW; SKELETAL DEVELOPMENT; MICRORNA
   EXPRESSION; IN VITRO; TGF BETA; CARTILAGE; CHONDROCYTE; APOPTOSIS; LIMB
AB Articular cartilage injury and therapy are important clinical issues around the world. Mesenchymal stem cells (MSCs) have the ability to differentiate into chondrocytes, which makes MSCs good candidates for use in cartilage repairing. However the regulation and the mechanism of chondrogenesisin MSCs is still unclear. To clarify the factor and mechanism which contribute to the process of chondrogenic differentiation, we focus on miRNAs. Considering the role of miR 181a in chondrogenesis and osteoblast formation, we tested the expression of miR 181a in the induced chondrogenic differential pig PBMSCs by using qRT PCR. And we identified miR 181a as an up regulated miRNA in the TGF ss 3 induced pig PBMSCs chondrogenic differentiation from the early stages and maintained elevated throughout the whole process. After inhibition of the endogenesis miR 181a expression by transfecting the miR 181a inhibitor, the western blot results and immunofluorescence results indicated that the expression of differentiation related protein COL2A1, BMP2 were decreased, together with the Alcian blue assay, proving the process of differentiation was inhibited significantly. Taken together, our results demonstrated that miR 181a might be necessary in chondrogenesis of MSCs. Even so, the mechanism of miR 181a on regulating the chondrogenesis still needed to be investigated in future work. And our data would provide an experimental evidence for the research of tissue engineering.
C1 [Zhao, Daohong; Zhao, Zhi] Kunming Med Univ, Affiliated Hosp 2, Dept Orthoped, Kunming, Yunnan, Peoples R China.
   [Li, Yanlin; Wang, Fuke] Kunming Med Univ, Affiliated Hosp 1, Dept Sports Med, 295 Xichang Rd, Kunming 650032, Yunnan, Peoples R China.
   [Li, Yan; Jiang, Zhaowei] People Hosp Dehong State, Dept Orthoped, Kunming, Yunnan, Peoples R China.
   [Shen, Duo] People Hosp Longchuan Cty, Dept Orthoped, Kunming, Yunnan, Peoples R China.
C3 Kunming Medical University; Kunming Medical University
RP Li, YL (通讯作者)，Kunming Med Univ, Affiliated Hosp 1, Dept Sports Med, 295 Xichang Rd, Kunming 650032, Yunnan, Peoples R China.
EM yanlinliedu@yeah.net
RI Wang, Fuke/AGI 6319 2022; zhaowei, jiang/LOQ 9558 2024
FU National Natural Science Foundation [8140340]; Yunnan Province
   innovation team project [2014HC018]; Yunnan Province Natural Science Key
   Project [2017FE467 ( 007)]
FX We thank the center of laboratory animal science of Kunming Medical
   University for providing the peripheral blood from the small ear pigs,
   the National Natural Science Foundation (No. 8140340); Yunnan Province
   innovation team project (No. 2014HC018); the Yunnan Province Natural
   Science Key Project (No. 2017FE467 ( 007)).
CR Bakhshandeh B, 2012, MOL BIOL REP, V39, P7569, DOI 10.1007/s11033 012 1591 2
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Beyer Nardi N, 2006, HANDB EXP PHARM, V174, P249
   Bhushan R, 2013, INT J BIOCHEM CELL B, V45, P696, DOI 10.1016/j.biocel.2012.12.008
   Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903
   Chen YX, 2007, CANCER RES, V67, P976, DOI 10.1158/0008 5472.CAN 06 3667
   Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200
   Delorme Bruno, 2007, V140, P67
   Enomoto Iwamoto M, 2002, DEV BIOL, V251, P142, DOI 10.1006/dbio.2002.0802
   Fischer L, 2002, J BIOL CHEM, V277, P30870, DOI 10.1074/jbc.M109330200
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890 196803000 00009
   Fu WL, 2014, AM J SPORT MED, V42, P592, DOI 10.1177/0363546513512778
   Goldring MB, 2006, J CELL BIOCHEM, V97, P33, DOI 10.1002/jcb.20652
   Green JD, 2015, GENES DIS, V2, P307, DOI 10.1016/j.gendis.2015.09.003
   Guérit D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062582
   Handorf AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022887
   Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001
   Hartmann C, 2001, CELL, V104, P341, DOI 10.1016/S0092 8674(01)00222 7
   Hartmann C, 2000, DEVELOPMENT, V127, P3141
   Hutvágner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Javazon EH, 2004, EXP HEMATOL, V32, P414, DOI 10.1016/j.exphem.2004.02.004
   Kawakami Y, 1999, DEV GROWTH DIFFER, V41, P29
   Koay EJ, 2008, OSTEOARTHR CARTILAGE, V16, P1450, DOI 10.1016/j.joca.2008.04.007
   Kobayashi T, 2008, P NATL ACAD SCI USA, V105, P1949, DOI 10.1073/pnas.0707900105
   Laine SK, 2012, J CELL BIOCHEM, V113, P2687, DOI 10.1002/jcb.24144
   Lako M, 1998, HUM MOL GENET, V7, P813, DOI 10.1093/hmg/7.5.813
   Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372
   Lin X, 2014, J BONE MINER RES, V29, P1575, DOI 10.1002/jbmr.2163
   Liu F, 2008, CELL SIGNAL, V20, P999, DOI 10.1016/j.cellsig.2007.11.011
   Mackie EJ, 2008, INT J BIOCHEM CELL B, V40, P46, DOI 10.1016/j.biocel.2007.06.009
   Martin DR, 2002, EXP HEMATOL, V30, P879, DOI 10.1016/S0301 472X(02)00864 0
   Nilsson O, 2005, HORM RES, V64, P157, DOI 10.1159/000088791
   O'Rourke JR, 2007, DEV BIOL, V311, P359, DOI 10.1016/j.ydbio.2007.08.032
   Paik S, 2012, STEM CELLS DEV, V21, P3298, DOI 10.1089/scd.2011.0732
   Pais H, 2010, RNA, V16, P489, DOI 10.1261/rna.1701210
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Solchaga LA, 2005, J CELL PHYSIOL, V203, P398, DOI 10.1002/jcp.20238
   Sumiyoshi K, 2013, J CELL BIOCHEM, V114, P2094, DOI 10.1002/jcb.24556
   Suomi S, 2008, GENE REGUL SYST BIO, V2, P177
   Thompson BJ, 2006, CELL, V126, P767, DOI 10.1016/j.cell.2006.07.013
   Tuddenham L, 2006, FEBS LETT, V580, P4214, DOI 10.1016/j.febslet.2006.06.080
   Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519
   Wu HQ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001020
   Wu XW, 2007, ANN NY ACAD SCI, V1116, P29, DOI 10.1196/annals.1402.053
   Yang B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021679
   Zhou SH, 2004, J BONE MINER RES, V19, P463, DOI 10.1359/JBMR.0301239
NR 47
TC 4
Z9 5
U1 0
U2 2
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936 2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2018
VL 11
IS 2
BP 947
EP 955
PG 9
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA FY8EP
UT WOS:000427096500057
PM 31938188
DA 2025 08 17
ER

PT J
AU Wang, B
   Wu, W
   Xu, K
   Wu, HH
AF Wang, Bin
   Wu, Wei
   Xu, Ke
   Wu, Haihao
TI MicroRNA 223 3p is involved in fracture healing by regulating fibroblast
   growth factor receptor 2
SO BIOENGINEERED
LA English
DT Article
DE Mir 223 3p; fracture healing; fgfr2
ID OSTEOGENIC DIFFERENTIATION; GASTRIC CANCER; CELLS; EXPRESSION;
   OSTEOPOROSIS; NONUNION
AB MicroRNAs (miRNAs) are powerful modulators of fracture healing. The research explored the level of serum miR 223 3p in fracture patients and its potential mechanism in fracture healing. In the study, miR 223 3p levels in 42 patients with intra articular fracture and 40 patients with hand fracture were detected by real time fluorescence quantitative PCR reaction (qRT PCR). Subsequently, osteoblasts MC3T3 E1 was transfected with miR 223 3p mimic or inhibitor, and cell function was detected by Cell counting kit (CCK 8) assay and flow cytometry. Dual luciferase reporter assay verified the regulation mechanism of miR 223 3p and its target genes. We found that miR 223 3p was significantly elevated over time in patients with intra articular fracture and hand fracture compared with healthy individuals. Moreover, increased miR 223 3p significantly reduced cell viability and promoted cell apoptosis. The fibroblast growth factor receptor 2 (FGFR2) was the target of miR 223 3p. Serum FGFR2 was significantly decreased in patients, which was contrary to the expression of miR 223 3p. Moreover, FGFR2 levels in cells were negatively regulated by miR 223 3p. Finally, si FGFR2 significantly reversed the promotion of miR 223 3p inhibitor on cell viability and the inhibition of cell apoptosis. Our research suggested that miR 223 3p is highly expressed in fracture patients, and regulates osteoblast cell viability and apoptosis by targeting FGFR2. This may be a valuable target for fracture healing therapy and provide a new perspective for its treatment.
C1 [Wang, Bin; Wu, Wei; Xu, Ke; Wu, Haihao] Univ Chinese Acad Sci, Hwa Mei Hosp, Orthopaed Ctr, Ningbo 2 Hosp,41 North West St, Ningbo 315010, Zhejiang, Peoples R China.
C3 Chinese Academy of Sciences; University of Chinese Academy of Sciences,
   CAS
RP Xu, K (通讯作者)，Univ Chinese Acad Sci, Hwa Mei Hosp, Orthopaed Ctr, Ningbo 2 Hosp,41 North West St, Ningbo 315010, Zhejiang, Peoples R China.
EM ken589887@163.com
RI Wang, Wei/C 4364 2019; Wu, Wei/GYR 2981 2022
FU Ningbo Natural Fund [2019A610241]
FX This research is supported by "Ningbo Natural Fund" (2019A610241).
CR Cheng NX, 2020, J BIOL CHEM, V295, P10212, DOI 10.1074/jbc.RA119.012263
   Deng B, 2020, EXP THER MED, V20, P1514, DOI 10.3892/etm.2020.8864
   Dong HC, 2019, INFLAMMATION, V42, P1265, DOI 10.1007/s10753 019 00986 3
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Guan XH, 2015, STEM CELLS, V33, P1589, DOI 10.1002/stem.1947
   Guo HL, 2020, EUR REV MED PHARMACO, V24, P4652, DOI 10.26355/eurrev_202005_21151
   Hu LC, 2021, MOL THER NUCL ACIDS, V23, P1345, DOI 10.1016/j.omtn.2021.02.008
   Ji X, 2021, BIOENGINEERED, V12, P8125, DOI 10.1080/21655979.2021.1987099
   Kostenuik P, 2017, J ORTHOP RES, V35, P213, DOI 10.1002/jor.23460
   Lang Y, 2019, EUR REV MED PHARMACO, V23, P7200, DOI 10.26355/eurrev_201909_18821
   Lee JE, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 39843 6
   Li G, 2020, EXP MOL PATHOL, V117, DOI 10.1016/j.yexmp.2020.104529
   Li LJ, 2019, J CELL BIOCHEM, V120, P16867, DOI 10.1002/jcb.28944
   Li X, 2018, ONCOL LETT, V15, P8357, DOI 10.3892/ol.2018.8380
   Liu J, 2021, BIOENGINEERED, V12, P8457, DOI 10.1080/21655979.2021.1982843
   Liu S, 2020, EXP THER MED, V19, P2083, DOI 10.3892/etm.2020.8412
   Long C, 2021, HUM CELL, V34, P14, DOI 10.1007/s13577 020 00421 y
   Luo H, 2019, EFORT OPEN REV, V4, P513, DOI 10.1302/2058 5241.4.180054
   Mäkitie RE, 2018, J CLIN ENDOCR METAB, V103, P1985, DOI 10.1210/jc.2017 02585
   MalekiGorji M, 2020, J KOR ASSOC ORAL MAX, V46, P258, DOI 10.5125/jkaoms.2020.46.4.258
   Okuhara A, 2012, MOD RHEUMATOL, V22, P446, DOI 10.1007/s10165 011 0536 2
   Qu HB, 2019, MED SCI MONITOR, V25, P2289, DOI 10.12659/MSM.912392
   Ren NS, 2020, AGING US, V12, P11025, DOI 10.18632/aging.103314
   Sun J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz1410
   Sun LL, 2020, AGING US, V12, P4506, DOI 10.18632/aging.102904
   Tan JX, 2020, J BIOENERG BIOMEMBR, V52, P367, DOI 10.1007/s10863 020 09845 5
   Waki T, 2015, BONE JOINT J, V97B, P1144, DOI 10.1302/0301 620X.97B8.34966
   Xie W, 2020, EXP THER MED, V20, DOI 10.3892/etm.2020.9401
   Xu T, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951 020 00601 w
   Xu WJ, 2020, IRAN J ALLERGY ASTHM, V19, P289, DOI 10.18502/ijaai.v19i3.3456
   Yin Xia, 2011, Zhongguo Gu Shang, V24, P761
NR 31
TC 19
Z9 19
U1 1
U2 16
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2165 5979
EI 2165 5987
J9 BIOENGINEERED
JI Bioengineered
PD DEC 20
PY 2021
VL 12
IS 2
BP 12040
EP 12048
DI 10.1080/21655979.2021.2002498
PG 9
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA XL3NY
UT WOS:000728054900001
PM 34753389
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Mahoney, CM
   Morgan, MR
   Harrison, A
   Humphries, MJ
   Bass, MD
AF Mahoney, Claire M.
   Morgan, Mark R.
   Harrison, Andrew
   Humphries, Martin J.
   Bass, Mark D.
TI Therapeutic Ultrasound Bypasses Canonical Syndecan 4 Signaling to
   Activate Rac1
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID INTENSITY PULSED ULTRASOUND; CUTANEOUS WOUND REPAIR; NF KAPPA B;
   CELL ADHESION; CYCLOOXYGENASE 2 EXPRESSION; ALPHA(5)BETA(1) INTEGRIN;
   DIRECTIONAL MIGRATION; HUMAN OSTEOBLASTS; IN VITRO; FIBRONECTIN
AB The application of pulsed, low intensity ultrasound is emerging as a potent therapy for the treatment of complex bone fractures and tissue damage. Ultrasonic stimuli accelerate fracture healing by up to 40% and enhance tendon and ligament healing by promoting cell proliferation, migration, and matrix synthesis through an unresolved mechanism. Ultrasound treatment also induces closure of nonunion fractures, at a success rate (85% of cases) similar to that of surgical intervention (68 96%) while avoiding the complications associated with surgery. The regulation of cell adhesion necessary for wound healing depends on cooperative engagement of the extracellular matrix receptors, integrin and syndecan, as exemplified by the wound healing defects observed in syndecan and integrin knock out mice. This report distinguishes the influence of ultrasound on signals downstream of the prototypic fibronectin receptors, alpha(5)beta(1) integrin and syndecan 4, which cooperate to regulate Rac1 and RhoA. Ultrasonic stimulation fails to activate integrins or induce cell spreading on poor, electrostatic ligands. By contrast, ultrasound treatment overcomes the necessity of engagement or expression of syndecan 4 during the process of focal adhesion formation, which normally requires simultaneous engagement of both receptors. Ultrasound exerts an influence downstream of syndecan 4 and PKC alpha to specifically activate Rac1, itself a critical regulator of tissue repair, and to a lesser extent RhoA. The ability of ultrasound to bypass syndecan 4 signaling, which is known to facilitate efficient tissue repair, explains the reduction in healing times observed in ultrasound treated patients. By substituting for one of the key axes of adhesion dependent signaling, ultrasound therapy has considerable potential as a clinical technique.
C1 [Humphries, Martin J.] Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England.
   [Harrison, Andrew] Smith & Nephew, York YO10 5DF, N Yorkshire, England.
C3 University of Manchester; Smith & Nephew
RP Humphries, MJ (通讯作者)，Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.
EM martin.humphries@manchester.ac.uk
OI Humphries, Martin/0000 0002 4331 6967; Morgan, Mark/0000 0001 7728 9883
FU Wellcome Trust [045225, 074941]; Biotechnology and Biological Sciences
   Research Council; University of Manchester Strategic Fund
FX This work was supported by Wellcome Trust Grants 045225 and 074941 (to
   M.J.H.). The Bioimaging Facility microscopes used in this study were
   purchased with grants from the Biotechnology and Biological Sciences
   Research Council, Wellcome Trust, and the University of Manchester
   Strategic Fund. The costs of publication of this article were defrayed
   in part by the payment of page charges. This article must therefore be
   hereby marked "advertisement" in accordance with 18 U. S. C. Section
   1734 solely to indicate this fact.
CR ALKURDI D, 2008, COCHRANE DB SYST REV, V1
   Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217
   Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671
   Bass MD, 2008, J CELL BIOL, V181, P1013, DOI 10.1083/jcb.200711129
   Bass MD, 2007, J CELL BIOL, V177, P527, DOI 10.1083/jcb.200610076
   BASS MD, 2007, EUR PHYS J E, V3, P372
   Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729
   Bhadriraju K, 2007, EXP CELL RES, V313, P3616, DOI 10.1016/j.yexcr.2007.07.002
   Bloom L, 1999, MOL BIOL CELL, V10, P1521, DOI 10.1091/mbc.10.5.1521
   Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092 8674(04)00003 0
   CAVANI A, 1993, J INVEST DERMATOL, V101, P600, DOI 10.1111/1523 1747.ep12366057
   Chakravarti R, 2006, BMC GENOMICS, V7, DOI 10.1186/1471 2164 7 83
   Chen YJ, 2003, FEBS LETT, V554, P154, DOI 10.1016/S0014 5793(03)01157 8
   Coe APF, 2001, J BIOL CHEM, V276, P35854, DOI 10.1074/jbc.M103639200
   COUCHMAN JR, 1983, J CELL BIOL, V96, P177, DOI 10.1083/jcb.96.1.177
   DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612
   del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571
   Doan N, 1999, J ORAL MAXIL SURG, V57, P409, DOI 10.1016/S0278 2391(99)90281 1
   Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559
   Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523 1747.ep12365571
   Gebauer D, 2005, ULTRASOUND MED BIOL, V31, P1391, DOI 10.1016/j.ultrasmedbio.2005.06.002
   Grenache DG, 2007, J INVEST DERMATOL, V127, P455, DOI 10.1038/sj.jid.5700611
   Grose R, 2002, DEVELOPMENT, V129, P2303
   Hassanain HH, 2005, SURGERY, V137, P92, DOI 10.1016/j.surg.2004.06.012
   HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623 199401000 00004
   Hsu HC, 2007, CELL SIGNAL, V19, P2317, DOI 10.1016/j.cellsig.2007.07.006
   HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637
   Katsumi A, 2002, J CELL BIOL, V158, P153, DOI 10.1083/jcb.200201105
   Koo BK, 2006, J MOL BIOL, V355, P651, DOI 10.1016/j.jmb.2005.09.087
   Kristiansen TK, 1997, J BONE JOINT SURG AM, V79A, P961, DOI 10.2106/00004623 199707000 00002
   MAKAREM R, 1994, J BIOL CHEM, V269, P4005
   Matthews HK, 2008, DEVELOPMENT, V135, P1771, DOI 10.1242/dev.017350
   Morgan MR, 2007, NAT REV MOL CELL BIO, V8, P957, DOI 10.1038/nrm2289
   Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821
   Ng COY, 2003, ULTRASOUND MED BIOL, V29, P1501, DOI 10.1016/S0301 5629(03)01018 4
   Orr AW, 2008, CIRC RES, V103, P671, DOI 10.1161/CIRCRESAHA.108.182097
   Pankov R, 2005, J CELL BIOL, V170, P793, DOI 10.1083/jcb.200503152
   Parvizi J, 2002, J ORTHOPAED RES, V20, P51, DOI 10.1016/S0736 0266(01)00069 9
   Praemer A., 1992, Musculoskeletal conditions in the United States, P85
   Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863
   Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003
   Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578
   Saoncella S, 2004, J BIOL CHEM, V279, P47172, DOI 10.1074/jbc.C400299200
   Stepp MA, 2002, J CELL SCI, V115, P4517, DOI 10.1242/jcs.00128
   Sun D, 2006, DRUG RESIST UPDATE, V9, P274, DOI 10.1016/j.drup.2006.12.001
   Tang CH, 2007, J BIOL CHEM, V282, P25406, DOI 10.1074/jbc.M701001200
   Tang CH, 2006, MOL PHARMACOL, V69, P2047, DOI 10.1124/mol.105.022160
   Tscharntke M, 2007, J CELL SCI, V120, P1480, DOI 10.1242/jcs.03426
   Wang FS, 2004, BONE, V35, P114, DOI 10.1016/j.bone.2004.02.012
   Warden SJ, 2006, AM J SPORT MED, V34, P1094, DOI 10.1177/0363546505286139
   WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460 2075.1986.tb04265.x
   Yang KH, 1996, J ORTHOP RES, V14, P802, DOI 10.1002/jor.1100140518
   Zhou SX, 2008, CELL SIGNAL, V20, P695, DOI 10.1016/j.cellsig.2007.12.005
   Zhou SX, 2004, J BIOL CHEM, V279, P54463, DOI 10.1074/jbc.M404786200
   Zweers MC, 2007, J INVEST DERMATOL, V127, P467, DOI 10.1038/sj.jid.5700546
NR 55
TC 31
Z9 34
U1 1
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 27
PY 2009
VL 284
IS 13
BP 8889
EP 8900
DI 10.1074/jbc.M804281200
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 421ZW
UT WOS:000264397800072
PM 19147498
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Zhang, J
   Chen, F
   Yun, F
   Chen, JP
AF Zhang, Jun
   Chen, Feng
   Yun, Feng
   Chen, Jinping
TI Low level nicotine: A novel approach to reduce osteoporosis incidence
SO MEDICAL HYPOTHESES
LA English
DT Article
ID STIMULATES DNA SYNTHESIS; POST MENOPAUSAL WOMEN; OSTEOBLAST LIKE CELLS;
   BONE MINERAL DENSITY; CIGARETTE SMOKING; HIP FRACTURE; RISK FACTORS;
   EXPRESSION; THERAPY
AB Osteoporosis is a serious health problem worldwide and leads to a significant burden on society. Unfortunately, efforts to control osteoporosis are largely unsuccessful. Lowering an individual's risk for osteoporosis must focus not only on treatment but also on modification of risk factors. One of the common risk factors is smoking tobacco. Here, we review the clinical evidence on nicotine consumption and osteoporosis, and propose a possible protective mechanism. It should be note that there is no strong clinical evidence that proves nicotine is detrimental. Studies also indicated that the prime criminal for osteoporosis is smoking not nicotine. Moreover, low level nicotine has preventive efforts on osteoporosis by stimulating osteoblasts proliferation and differentiation. We present a hypothesis that low level nicotine may be a novel approach to reduce osteoporosis incidence. Crown Copyright (C) 2009 Published by Elsevier Ltd. All rights reserved.
C1 [Zhang, Jun; Chen, Jinping] Zhejiang Prov Peoples Hosp, Dept Orthopaed, Hangzhou 310014, Zhejiang, Peoples R China.
   [Zhang, Jun; Chen, Feng; Yun, Feng] Zhejiang Univ, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China.
   [Chen, Feng; Yun, Feng] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Surg Oncol, Hangzhou 310003, Zhejiang, Peoples R China.
C3 Hangzhou Medical College; Zhejiang Provincial People's Hospital;
   Zhejiang University; Zhejiang University
RP Chen, JP (通讯作者)，Zhejiang Prov Peoples Hosp, Dept Orthopaed, Hangzhou 310014, Zhejiang, Peoples R China.
EM orthopedicszj@gmail.com
CR ALOIA JF, 1985, AM J MED, V78, P95, DOI 10.1016/0002 9343(85)90468 1
   Bainbridge KE, 2004, OSTEOPOROSIS INT, V15, P439, DOI 10.1007/s00198 003 1562 5
   CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003
   DANIELL HW, 1976, ARCH INTERN MED, V136, P298, DOI 10.1001/archinte.136.3.298
   Gerdhem P, 2002, OSTEOPOROSIS INT, V13, P932, DOI 10.1007/s001980200130
   Gullihorn L, 2005, J ORTHOP TRAUMA, V19, P17, DOI 10.1097/00005131 200501000 00004
   JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602
   Johnell O, 2005, OSTEOPOROSIS INT, V16, pS3, DOI 10.1007/s00198 004 1702 6
   KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388
   Law MR, 1997, BMJ BRIT MED J, V315, P841, DOI 10.1136/bmj.315.7112.841
   MacInnis RJ, 2003, J BONE MINER RES, V18, P1650, DOI 10.1359/jbmr.2003.18.9.1650
   MORRIS BJ, 1990, MOL BRAIN RES, V7, P305, DOI 10.1016/0169 328X(90)90081 N
   PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003 4819 95 1 28
   PRYOR WA, 1983, ENVIRON HEALTH PERSP, V47, P345, DOI 10.1289/ehp.8347345
   RAMP WK, 1991, P SOC EXP BIOL MED, V197, P36
   RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605
   Rodgman A, 2000, HUM EXP TOXICOL, V19, P573, DOI 10.1191/096032700701546514
   Rothem DE, 2009, J BONE MINER METAB, V27, P555, DOI 10.1007/s00774 009 0075 5
   SCHMELTZ I, 1976, P 3 WORLD C SMOK HLT, P13
   Spangler JG, 2001, MED HYPOTHESES, V56, P553, DOI 10.1054/mehy.2000.1164
   Villablanca AC, 1998, J APPL PHYSIOL, V84, P2089, DOI 10.1152/jappl.1998.84.6.2089
   Walker LM, 2001, BONE, V28, P603, DOI 10.1016/S8756 3282(01)00427 6
   WILLIAMS AR, 1982, OBSTET GYNECOL, V60, P695
NR 23
TC 11
Z9 13
U1 0
U2 3
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306 9877
EI 1532 2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JUN
PY 2010
VL 74
IS 6
BP 1067
EP 1068
DI 10.1016/j.mehy.2009.12.024
PG 2
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 598UI
UT WOS:000277863900027
PM 20106602
DA 2025 08 17
ER

PT J
AU Prugh, AM
   Cole, SD
   Glaros, T
   Angelini, DJ
AF Prugh, Amber M.
   Cole, Stephanie D.
   Glaros, Trevor
   Angelini, Daniel J.
TI Effects of organophosphates on the regulation of mesenchymal stem cell
   proliferation and differentiation
SO CHEMICO BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Acetylcholinesterase; Differentiation; Mesenchymal stem cells;
   Organophosphates; Tissue repair
ID HUMAN BONE MARROW; ADHESIVE ROLE; ACETYLCHOLINESTERASE; PARAOXON;
   FIBROBLASTS; APOPTOSIS; TOXICITY; ROLES; AGENT; NICHE
AB Mesenchymal stem cells (MSCs) are multipotent cells located within various adult tissues. Recent literature has reported that human bone marrow derived MSCs express active acetylcholinesterase (AChE) and that disruption of AChE activity by organophosphate (OP) chemicals decreases the ability of MSCs to differentiate into osteoblasts. The potential role of AChE in regulating MSC proliferation and differentiation is currently unknown. In the present study, we demonstrate that MSCs exposed to OPs have both decreased AChE activity and abundance. In addition, exposure to these OPs induced cellular death while decreasing cellular proliferation. Exposures to these compounds also reduced the adipogenic/osteogenic differentiation potentials of the MSCs. To elucidate the possible role of AChE in MSCs signaling following OP exposure, we captured potential AChE binding partners by performing polyhistidine (His(8)) tagged AChE pulldowns, followed by protein identification using liquid chromatography mass spectrometry (LC MS). Using this method, we determined that the focal adhesion protein, vinculin, is a potential binding partner with AChE in MSCs and these initial findings were confirmed with followup co immunoprecipitation experiments. Identifying AChE binding partners helps to determine potential pathways associated with MSC proliferation and differentiation, and this understanding could lead to the development of future MSC based tissue repair therapies. Published by Elsevier Ireland Ltd.
C1 [Prugh, Amber M.; Glaros, Trevor; Angelini, Daniel J.] US Army, Edgewood Chem Biolog Ctr, Res Dev & Engn Command, Aberdeen Proving Ground, MD 21010 USA.
   [Cole, Stephanie D.] Excet Inc, Springfield, VA USA.
C3 United States Department of Defense; US Army Research, Development &
   Engineering Command (RDECOM); Edgewood Chemical Biological Center;
   Excet, Inc.
RP Angelini, DJ (通讯作者)，US Army, Edgewood Chem Biolog Ctr, 5183 Blackhawk Rd, Aberdeen Proving Ground, MD 21010 USA.
EM usarmy.apg.rdecom ecbc.mbx.biosciences@mail.mil
FU U.S. Army In House Laboratory Independent Research program at the
   Edgewood Chemical Biological Center
FX This work was funded through the U.S. Army In House Laboratory
   Independent Research program at the Edgewood Chemical Biological Center.
CR Alonso S, 2015, ONCOTARGET, V6, P14905, DOI 10.18632/oncotarget.3614
   Anderson AA, 2008, J CELL PHYSIOL, V215, P82, DOI 10.1002/jcp.21288
   Angelini DJ, 2015, INT J TOXICOL, V34, P433, DOI 10.1177/1091581815593933
   Angelini DJ, 2013, INHAL TOXICOL, V25, P37, DOI 10.3109/08958378.2012.750406
   Angelini DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011251
   Atherton P, 2016, EXP CELL RES, V343, P21, DOI 10.1016/j.yexcr.2015.11.017
   BALASUBRAMANIAN AS, 1993, FASEB J, V7, P1354, DOI 10.1096/fasebj.7.14.8224608
   Bigbee JW, 2004, NEUROCHEM RES, V29, P2043, DOI 10.1007/s11064 004 6877 x
   Carvalho FA, 2005, FEBS J, V272, P5584, DOI 10.1111/j.1742 4658.2005.04953.x
   Cheung J, 2012, J MED CHEM, V55, P10282, DOI 10.1021/jm300871x
   Colovic MB, 2013, CURR NEUROPHARMACOL, V11, P315, DOI 10.2174/1570159X11311030006
   Compston JE, 1999, LANCET, V354, P1791, DOI 10.1016/S0140 6736(99)04466 9
   Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365 2141.2000.01986.x
   Eyer Florian, 2003, Toxicological Reviews, V22, P143, DOI 10.2165/00139709 200322030 00003
   FALUGI C, 1983, BASIC APPL HISTOCHEM, V27, P205
   Fan CG, 2005, CELL TRANSPLANT, V14, P311, DOI 10.3727/000000005783983070
   Fan CG, 2005, NEUROSCI LETT, V380, P322, DOI 10.1016/j.neulet.2005.01.070
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890 196803000 00009
   Genever PG, 1999, BONE, V24, P297, DOI 10.1016/S8756 3282(98)00187 2
   Grisaru D, 1999, MOL CELL BIOL, V19, P788
   Grisaru D, 1999, EUR J BIOCHEM, V264, P672, DOI 10.1046/j.1432 1327.1999.00693.x
   Hochane M., 2016, STEM CELLS
   Holle AW, 2013, STEM CELLS, V31, P2467, DOI 10.1002/stem.1490
   Hoogduijn MJ, 2006, TOXICOL SCI, V94, P342, DOI 10.1093/toxsci/kfl101
   Hoogduijn MJ, 2009, STEM CELLS DEV, V18, P103, DOI 10.1089/scd.2008.0032
   Hulse EJ, 2014, AM J RESP CRIT CARE, V190, P1342, DOI 10.1164/rccm.201406 1150CI
   in't Anker PS, 2004, STEM CELLS, V22, P1338, DOI 10.1634/stemcells.2004 0058
   Inkson CA, 2004, BONE, V35, P819, DOI 10.1016/j.bone.2004.05.026
   Kauschke V, 2015, INT IMMUNOPHARMACOL, V29, P222, DOI 10.1016/j.intimp.2015.07.046
   Kolosova IA, 2013, STEM CELLS DEV, V22, P239, DOI 10.1089/scd.2012.0192
   Mathieu PS, 2012, TISSUE ENG PART B RE, V18, P436, DOI [10.1089/ten.teb.2012.0014, 10.1089/ten.TEB.2012.0014]
   Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100
   Paraoanu LE, 2008, FEBS J, V275, P618, DOI 10.1111/j.1742 4658.2007.06237.x
   Paraoanu LE, 2004, FEBS LETT, V576, P161, DOI 10.1016/j.febslet.2004.08.078
   Pierdomenico L, 2005, TRANSPLANTATION, V80, P836, DOI 10.1097/01.tp.0000173794.72151.88
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pohanka M, 2011, BIOMED PAP, V155, P219, DOI 10.5507/bp.2011.036
   Rastegar Farbod, 2010, World J Stem Cells, V2, P67, DOI 10.4252/wjsc.v2.i4.67
   Saleh AM, 2003, TOXICOL APPL PHARM, V190, P47, DOI 10.1016/S0041 008X(03)00126 1
   Saleh AM, 2003, J APPL TOXICOL, V23, P23, DOI 10.1002/jat.880
   Sharma KV, 1998, J NEUROSCI RES, V53, P454, DOI 10.1002/(SICI)1097 4547(19980815)53:4<454::AID JNR7>3.3.CO;2 E
   Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696
   Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589
   Steward AJ, 2015, J ANAT, V227, P717, DOI 10.1111/joa.12243
   SULTATOS LG, 1994, J TOXICOL ENV HEALTH, V43, P271, DOI 10.1080/15287399409531921
   Valtieri M, 2008, J CELL PHYSIOL, V217, P296, DOI 10.1002/jcp.21521
   Wang YK, 2013, J CELL MOL MED, V17, P823, DOI 10.1111/jcmm.12061
   Zarei MH, 2016, ENVIRON TOXICOL, V31, P1510, DOI 10.1002/tox.22155
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 49
TC 7
Z9 9
U1 1
U2 17
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009 2797
EI 1872 7786
J9 CHEM BIOL INTERACT
JI Chem. Biol. Interact.
PD MAR 25
PY 2017
VL 266
BP 38
EP 46
DI 10.1016/j.cbi.2017.01.020
PG 9
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA EO6QF
UT WOS:000396816900005
PM 28174098
DA 2025 08 17
ER

PT J
AU Yan, T
   Li, HL
   Yan, JY
   Ma, SY
   Tan, JL
AF Yan, Tong
   Li, Huilin
   Yan, Jiayin
   Ma, Siyuan
   Tan, Jiali
TI Age related mitophagy regulates orthodontic tooth movement by affecting
   PDLSCs mitochondrial function and RANKL/OPG
SO FASEB JOURNAL
LA English
DT Article
DE mechanotransduction; mitophagy; orthodontics; periodontal ligament stem
   cells; PTEN induced putative kinase 1
ID STEM CELLS; OSTEOCLASTOGENESIS
AB A thorough comprehension of age related variances in orthodontic tooth movement (OTM) and bone remodeling response to mechanical force holds significant implications for enhancing orthodontic treatment. Mitophagy plays a crucial role in bone metabolism and various age related diseases. However, the impact of mitophagy on the bone remodeling process during OTM remains elusive. Using adolescent (6 weeks old) and adult (12 months old) rats, we established OTM models and observed that orthodontic force increased the expression of the mitophagy proteins PTEN induced putative kinase 1 (PINK1) and Parkin, as well as the number of tartrate resistant acid phosphatase positive osteoclasts and osteocalcin positive osteoblasts. These biological changes were found to be age related. In vitro, compression force loading promoted PINK1/Parkin dependent mitophagy in periodontal ligament stem cells (PDLSCs) derived from adolescents (12 16 years old) and adults (25 35 years old). Furthermore, adult PDLSCs exhibited lower levels of mitophagy, impaired mitochondrial function, and a decreased ratio of RANKL/OPG compared to young PDLSCs after compression. Transfection of siRNA confirmed that inhibition of mitophagy in PDLSC resulted in decreased mitochondrial function and reduced RANKL/OPG ratio. Application of mitophagy inducer Urolithin A enhanced bone remodeling and accelerated OTM in rats, while the mitophagy inhibitor Mdivi 1 had the opposite effect. These findings indicate that force stimulated PDLSC mitophagy contributes to alveolar bone remodeling during OTM, and age related impairment of mitophagy negatively impacts the PDLSC response to mechanical stimulus. Our findings enhance the understanding of mitochondrial mechanotransduction and offer new targets to tackle current clinical challenges in orthodontic therapy.
   During tooth movement, the expression of PINK1 and Parkin as well as bone remodeling activity were lower in adult rats compared to young rats, leading to a decelerated rate of tooth movement. In vitro, mechanical compression induced PINK1/Parkin mediated mitophagy in adult PDLSCs was also lower than that observed in young PDLSCs. This age related decline in mitophagy hindered the restoration of mitochondrial dysfunction in PDLSCs under mechanical stress and down regulated the ratio of RANKL/OPG. PINK1, PTEN induced putative kinase 1; PDLSCs, periodontal ligament stem cells; ROS, reactive oxygen species; MMP, mitochondrial membrane potential; ATP, adenosine triphosphate; Ub, ubiquitin; RANKL, receptor activator for nuclear factor kappa B ligand; OPG, osteoprotegerin.image
C1 [Yan, Tong; Li, Huilin; Yan, Jiayin; Ma, Siyuan; Tan, Jiali] Sun Yat Sen Univ, Hosp Stomatol, Dept Orthodont, Guangzhou 510055, Guangdong, Peoples R China.
   [Yan, Tong; Li, Huilin; Yan, Jiayin; Ma, Siyuan; Tan, Jiali] Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, Guangzhou, Guangdong, Peoples R China.
   [Yan, Tong; Li, Huilin; Yan, Jiayin; Ma, Siyuan; Tan, Jiali] Sun Yat Sen Univ, Guanghua Sch Stomatol, Guangzhou, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University
RP Tan, JL (通讯作者)，Sun Yat Sen Univ, Hosp Stomatol, Dept Orthodont, Guangzhou 510055, Guangdong, Peoples R China.
EM tanjiali@mail.sysu.edu.cn
RI Ma, Siyuan/IVV 8174 2023
FU National Natural Science Foundation of China [82270985]; Key
   Technologies Research and Development Program of Guangzhou Municipality
   [2024B03J0497]; Basic and Applied Basic Research Foundation of Guangdong
   Province [2022A1515011094]; Guangdong Provincial Key Laboratory of
   Stomatology Open Project Fund [KF2022120102]; Characteristic Innovation
   Research Program for University Teacher [2021XCL03]
FX This study was supported by the National Natural Science Foundation of
   China (82270985), the Key Technologies Research and Development Program
   of Guangzhou Municipality (2024B03J0497), the Basic and Applied Basic
   Research Foundation of Guangdong Province (2022A1515011094), the
   Guangdong Provincial Key Laboratory of Stomatology Open Project Fund
   (KF2022120102), and the Characteristic Innovation Research Program for
   University Teacher (2021XCL03). Schematic illustrations were created
   with BioRender.com.
CR Alvarez R, 2015, INT J ORAL SCI, V7, P213, DOI 10.1038/ijos.2015.42
   Chen G, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00200
   Christensen L, 2015, BRIT DENT J, V218, P111, DOI 10.1038/sj.bdj.2015.46
   Coon BG, 2022, J CELL BIOL, V221, DOI 10.1083/jcb.202109144
   Fei DD, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.687258
   Harper JW, 2018, NAT REV MOL CELL BIO, V19, P93, DOI 10.1038/nrm.2017.129
   He YC, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.703847
   Helle SCJ, 2017, ELIFE, V6, DOI 10.7554/eLife.30292
   Huang DY, 2023, AGING DIS, V14, P1511, DOI 10.14336/AD.2023.0201
   Huang HM, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/6531216
   Jager A, 1996, J ANAT, V189, P257
   Jin SM, 2010, J CELL BIOL, V191, P933, DOI 10.1083/jcb.201008084
   Johnson SC, 2013, SCIENCE, V342, P1524, DOI 10.1126/science.1244360
   Kang L, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12779
   Kanzaki H, 2002, J BONE MINER RES, V17, P210, DOI 10.1359/jbmr.2002.17.2.210
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Krieger E, 2013, HEAD FACE MED, V9, DOI 10.1186/1746 160X 9 22
   Krishnan V, 2009, J DENT RES, V88, P597, DOI 10.1177/0022034509338914
   Li CF, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.896014
   Li X, 2016, BONE JOINT RES, V5, P492, DOI 10.1302/2046 3758.510.BJR 2016 0004.R2
   Lombardo G, 2020, EUR J PAEDIATR DENT, V21, P115, DOI 10.23804/ejpd.2020.21.02.05
   Misawa Kageyama Y, 2007, EUR J ORAL SCI, V115, P124, DOI 10.1111/j.1600 0722.2007.00428.x
   Ong MMA, 2002, AM J ORTHOD DENTOFAC, V122, P420, DOI 10.1067/mod.2002.126597
   Onishi M, 2021, EMBO J, V40, DOI 10.15252/embj.2020104705
   Palikaras K, 2017, PHARMACOL THERAPEUT, V178, P157, DOI 10.1016/j.pharmthera.2017.04.005
   Phuyal S, 2023, TRENDS CELL BIOL, V33, P1049, DOI 10.1016/j.tcb.2023.05.001
   Picca A, 2023, NAT METAB, V5, P2047, DOI 10.1038/s42255 023 00930 8
   REITAN K, 1951, Dent Rec (London), V71, P173
   Ren Y, 2003, J DENT RES, V82, P38, DOI 10.1177/154405910308200109
   Schubert A, 2020, J OROFAC ORTHOP, V81, P113, DOI 10.1007/s00056 019 00206 5
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Su EML, 2023, BIOL CELL, V115, DOI 10.1111/boc.202300010
   Titus AS, 2023, BASIC RES CARDIOL, V118, DOI 10.1007/s00395 023 01009 x
   Wang Q, 2023, ARCH ORAL BIOL, V150, DOI 10.1016/j.archoralbio.2023.105692
   Wang Q, 2023, ACS NANO, V17, P16757, DOI 10.1021/acsnano.3c03385
   Wang S, 2020, INT J BIOL SCI, V16, P2675, DOI 10.7150/ijbs.46627
   Wang YY, 2020, AGING US, V12, P16126, DOI 10.18632/aging.103587
   Wang Y, 2018, INT J ORAL SCI, V10, DOI 10.1038/s41368 018 0029 7
   Yang CY, 2018, INT J ORAL SCI, V10, DOI 10.1038/s41368 017 0004 8
   Zhai Q., 2021, Adv Sci (Weinh), V9
   Zhang JM, 2021, J CELL PHYSIOL, V236, P7504, DOI 10.1002/jcp.30386
   Zhang ZJ, 2023, CELL MOL BIOL LETT, V28, DOI 10.1186/s11658 023 00453 w
NR 42
TC 5
Z9 5
U1 4
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD AUG 15
PY 2024
VL 38
IS 15
AR e23865
DI 10.1096/fj.202401280R
PG 16
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA A5D5S
UT WOS:001282736400001
PM 39096136
DA 2025 08 17
ER

PT J
AU Li, RG
   Liang, L
   Dou, YF
   Huang, ZP
   Mo, HT
   Wang, YN
   Yu, B
AF Li, Runguang
   Liang, Liang
   Dou, Yonggang
   Huang, Zeping
   Mo, Huiting
   Wang, Yaning
   Yu, Bin
TI Mechanical Strain Regulates Osteogenic and Adipogenic Differentiation of
   Bone Marrow Mesenchymal Stem Cells
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID ADIPOCYTE DIFFERENTIATION; INHIBITS ADIPOGENESIS; TENSILE STRAIN;
   ADIPOSE TISSUE; EXPRESSION; MECHANOTRANSDUCTION; TRANSDUCTION;
   OSTEOPOROSIS; FREQUENCY; ALPHA
AB This study examined the effects of mechanical strain on osteogenic and adipogenic differentiation of cultured MSCs by stimulating MSCs cultured in general and adipogenic differentiation media using a mechanical strain device. Markers of osteogenic (Runx2, Osx, and I collagen) and adipogenic (PPAR gamma 2, C/EBP alpha, and lipid droplets) differentiation were examined using real time PCR, western blot, immunocytochemical, or histochemical stain analyses. Levels of Runx2 and Osx gradually increased in MSC groups in general medium subject to strain stimulation, as compared with in unstrained groups. After adding the stress signal, I collagen protein levels of expression were obviously promoted in cells in comparison to the controls. The levels of PPAR gamma 2 and C/EBP alpha were decreased, and the emergence of lipid droplets was delayed in MSCs groups in adipogenic differentiation medium subject to strain stimulation, as compared with in unstrained groups. Mechanical strain can promote differentiation of MSCs into osteoblasts and can impede differentiation into adipocytes. These results clarify the mechanisms underlying the effects of exercise on bone repair and reconstruction and provide a more adequate scientific basis for the use of exercise therapy in the treatment of obesity and metabolic osteoporosis.
C1 [Li, Runguang; Liang, Liang; Dou, Yonggang; Huang, Zeping; Mo, Huiting; Wang, Yaning; Yu, Bin] Southern Med Univ, Nanfang Hosp, Dept Orthoped & Traumatol, Guangzhou 510515, Guangdong, Peoples R China.
   [Li, Runguang] Southern Med Univ, Nanfang Hosp, Huiqiao Dept, Guangzhou 510515, Guangdong, Peoples R China.
   [Li, Runguang; Liang, Liang; Dou, Yonggang; Huang, Zeping; Mo, Huiting; Wang, Yaning; Yu, Bin] Southern Med Univ, Nanfang Hosp, Key Lab Bone & Cartilage Regenerat Med, Guangzhou 510515, Guangdong, Peoples R China.
C3 Southern Medical University   China; Southern Medical University  
   China; Southern Medical University   China
RP Yu, B (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Orthoped & Traumatol, Guangzhou 510515, Guangdong, Peoples R China.
EM yubincsgk@163.com
RI ; Yu, Bin/KIJ 7006 2024
OI Runguang, Li/0000 0002 4703 7180; 
FU National Natural Sciences Foundation of China [81101366, LT201212,
   81272052]; Natural Science Foundation of Guangdong Province
   [2014A030313338]; National Undergraduate Training Programs for
   Innovation and Entrepreneurship in China [201412121034]; President
   Foundation of Nanfang Hospital, Southern Medical University [2014A002]
FX This work was supported by the National Natural Sciences Foundation of
   China (Approval no. 81101366 (and its matching topics LT201212),
   81272052), Natural Science Foundation of Guangdong Province (Approval
   no. 2014A030313338), National Undergraduate Training Programs for
   Innovation and Entrepreneurship in China (Approval no. 201412121034),
   and President Foundation of Nanfang Hospital, Southern Medical
   University (Approval no. 2014A002).
CR Adams MA, 2006, BIORHEOLOGY, V43, P537
   Bei Yongshun, 2004, J Tradit Chin Med, V24, P36
   Boerckel JD, 2009, J BIOMECH ENG T ASME, V131, DOI 10.1115/1.3148472
   Case N, 2013, BONE, V52, P454, DOI 10.1016/j.bone.2012.08.122
   Charoenpanich A, 2014, TISSUE ENG PT A, V20, P67, DOI [10.1089/ten.tea.2013.0006, 10.1089/ten.TEA.2013.0006]
   Coppack SW, 2005, BIOCHEM SOC T, V33, P1049, DOI [10.1042/BST0331049, 10.1042/BST20051049]
   Cristancho AG, 2011, NAT REV MOL CELL BIO, V12, P722, DOI 10.1038/nrm3198
   Dehority W, 1999, AM J PHYSIOL ENDOC M, V276, pE62
   Frost HM, 2004, ANGLE ORTHOD, V74, P3
   Genchev GZ, 2009, CELL BIOCHEM BIOPHYS, V55, P141, DOI 10.1007/s12013 009 9064 5
   Heino TJ, 2008, CURR STEM CELL RES T, V3, P131, DOI 10.2174/157488808784223032
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Hossain MG, 2010, J BIOSCI BIOENG, V109, P297, DOI 10.1016/j.jbiosc.2009.09.003
   Jaalouk DE, 2009, NAT REV MOL CELL BIO, V10, P63, DOI 10.1038/nrm2597
   Kawai M, 2012, J INTERN MED, V272, P317, DOI 10.1111/j.1365 2796.2012.02564.x
   Kearney EM, 2010, ANN BIOMED ENG, V38, P1767, DOI 10.1007/s10439 010 9979 4
   Khayat G, 2012, DIFFERENTIATION, V83, P179, DOI 10.1016/j.diff.2011.12.004
   Klein Nulend J, 2013, BONE, V54, P182, DOI 10.1016/j.bone.2012.10.013
   Lafage Proust MH, 1998, AM J PHYSIOL REG I, V274, pR324, DOI 10.1152/ajpregu.1998.274.2.R324
   Leslie WD, 2014, CURR OPIN RHEUMATOL, V26, P440, DOI 10.1097/BOR.0000000000000064
   Li RG, 2013, MED SCI MONIT BASIC, V19, P68, DOI 10.12659/MSMBR.883790
   Li RG, 2011, INJURY, V42, P753, DOI 10.1016/j.injury.2010.11.015
   Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898
   Liu N, 2009, CELL MOL IMMUNOL, V6, P207, DOI 10.1038/cmi.2009.28
   Liu ZJ, 2009, J CELL BIOCHEM, V106, P984, DOI 10.1002/jcb.22091
   Lohberger B, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/189516
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Palomares KTS, 2009, J ORTHOP RES, V27, P1123, DOI 10.1002/jor.20863
   Park JS, 2007, FRONT BIOSCI LANDMRK, V12, P5098, DOI 10.2741/2551
   Park SR, 1999, BONE, V24, P549, DOI 10.1016/S8756 3282(99)00084 8
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Potier E, 2010, J BIOMECH, V43, P807, DOI 10.1016/j.jbiomech.2009.11.019
   Pradel W, 2008, J PHYSIOL PHARMACOL, V59, P47
   Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066
   Rubin CT, 2007, P NATL ACAD SCI USA, V104, P17879, DOI 10.1073/pnas.0708467104
   Sen B, 2008, ENDOCRINOLOGY, V149, P6065, DOI 10.1210/en.2008 0687
   Shoham N, 2012, J BIOMECH, V45, P1, DOI 10.1016/j.jbiomech.2011.10.023
   Simmons CA, 2003, J BIOMECH, V36, P1087, DOI 10.1016/S0021 9290(03)00110 6
   Stefan N, 2013, LANCET DIABETES ENDO, V1, P152, DOI 10.1016/S2213 8587(13)70062 7
   Sun YP, 2014, INT J MOL SCI, V15, P3729, DOI 10.3390/ijms15033729
   Tanabe Y, 2004, J CELL SCI, V117, P3605, DOI 10.1242/jcs.01207
   Tanabe Y, 2008, J PHARMACOL SCI, V106, P478, DOI 10.1254/jphs.FP0071886
   Tate MLK, 2008, INT J BIOCHEM CELL B, V40, P2720, DOI 10.1016/j.biocel.2008.05.011
   Turner NJ, 2008, BIOCHEM BIOPH RES CO, V377, P1147, DOI 10.1016/j.bbrc.2008.10.131
   Ward DF, 2007, STEM CELLS DEV, V16, P467, DOI 10.1089/scd.2007.0034
   Zayzafoon M, 2004, ENDOCRINOLOGY, V145, P2421, DOI 10.1210/en.2003 1156
   Zeng XJ, 2012, STEM CELL RES, V8, P357, DOI 10.1016/j.scr.2011.12.004
   Zhang JF, 2004, P NATL ACAD SCI USA, V101, P10703, DOI 10.1073/pnas.0403652101
   Zhao LM, 2011, VITAM HORM, V87, P127, DOI 10.1016/B978 0 12 386015 6.00042 1
   Zhou SH, 2004, J BONE MINER RES, V19, P463, DOI 10.1359/JBMR.0301239
NR 51
TC 57
Z9 74
U1 0
U2 18
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
VL 2015
AR 873251
DI 10.1155/2015/873251
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CF9NS
UT WOS:000352892400001
PM 25922842
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Antunes, J
   Gaspar, VM
   Ferreira, L
   Monteiro, M
   Henrique, R
   Jerónimo, C
   Mano, JF
AF Antunes, Jessica
   Gaspar, Vitor M.
   Ferreira, Luis
   Monteiro, Maria
   Henrique, Rui
   Jeronimo, Carmen
   Mano, Joao F.
TI In air production of 3D co culture tumor spheroid hydrogels for
   expedited drug screening
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Superhydrophobic surface; 3D in vitro tumor models; Spherical microgels;
   Drug screening
ID PROSTATE CANCER CELLS; HYALURONIC ACID; MICROPARTICLES; BIOMATERIAL;
   CONTACT; GROWTH; CHIP
AB Three dimensional (3D) in vitro tumor spheroids are becoming popular as pre clinical platforms for testing the performance of existing drugs or for discovery of innovative anti cancer therapeutics. This focus is correlated with in vitro 3D tumor models ability to mimic the multicellular compact structure and spatial architecture of human solid tumors. However, these microphysiological systems generally lack the preexistence of tumor ECM, a critical aspect that can affect the overall therapeutic performance and the decision of advancing candidate drugs to later stages of the pipeline. Aiming to face this drawback and mimic tumors ECM, herein we rapidly fabricated in air hyaluronan methacrylate (HA MA) and gelatin methacrylate (GeIMA) photocrosslinkable 3D spheroid microgels by using superhydrophobic surfaces. These platforms were used for establishing heterotypic 3D co culture models of prostate cancer cells (PC 3) and human osteoblasts (hOB) to mimic prostate cancer to bone metastasis cellular heterogeneity and the tumor ECM microenvironment. 3D microgel microtumors morphology, size and cell number were easily controlled via digital droplet generation on polystyrene superhydrophobic surfaces and under solvent free conditions when compared to microfluidics or electrospray. Co culture 3D micro gels formed by 2.5%HA MA 5%GeIMA and 5%HA MA 5%GeIMA ratios showed the highest calcium deposition after 14 days of culture, evidencing osteoblasts viability and the establishment of functional mineralization in the 3D hydrogel matrix. Cisplatin cytotoxicity evaluation showed that 3D microgels are more resistant to platin chemotherapeutics than single or co culture 3D multicellular spheroid counterparts. Overall, our findings indicate that solvent free, in air produced 3D microgel microenvironments are cost effective and robust tumor mimicking platforms for in vitro high throughput screening of therapeutics targeted to prostate to bone metastasis microenvironments.
   Statement of Significance The generation of robust microphysiological systems that recapitulate the complexity of the metastatic prostate to bone tumor microenvironment is crucial for pre clinical evaluation of new therapeutics that can eradicate these secondary tumors. In this study, we employed superhydrophobic (SH) surfaces to rapidly fabricate photocrosslinkable hyaluronan methacrylate/gelatin methacrylate 3D spheroid microgels for prostate cancer cells and human osteoblasts co culture models that simultaneously mimic the cellular and ECM tumor components. The use of SH platforms overcomes the issues of standard in liquid microgel production technologies by providing a robust control over 3D microgels size/morphology and cell cell co encapsulation numbers, while avoiding the use of oil based microgel droplets generation. Overall, SH surfaces allowed a solvent free, cost effective, reproducible and adaptable fabrication of heterotypic 3D spherical microgels for high throughput drug screening. (C) 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Antunes, Jessica; Gaspar, Vitor M.; Ferreira, Luis; Monteiro, Maria; Mano, Joao F.] Univ Aveiro, CICECO, Dept Chem, Campus Univ Santiago, P 3810193 Aveiro, Portugal.
   [Henrique, Rui; Jeronimo, Carmen] Univ Porto, Canc Biol & Epigenet Grp, IPO Porto Res Ctr CI IPO, Portuguese Oncol Inst Porto IPO Porto,Dept Pathol, Porto, Portugal.
   [Henrique, Rui; Jeronimo, Carmen] Univ Porto, Inst Biomed Sci Abel Salazar ICBAS, Dept Pathol & Mol Immunol, Porto, Portugal.
C3 Universidade de Aveiro; Portuguese Institute of Oncology; Universidade
   do Porto; Universidade do Porto
RP Gaspar, VM; Mano, JF (通讯作者)，Univ Aveiro, CICECO, Dept Chem, Aveiro Inst Mat, Campus Univ Santiago, P 3810193 Aveiro, Portugal.
EM vm.gaspar@ua.pt; jmano@ua.pt
RI Gaspar, Vítor/AAB 3045 2022; Jeronimo, Carmen/H 3284 2013; Jerónimo,
   Carmen/H 3284 2013; Henrique, Rui/I 2757 2013; Mano, Joao/A 4418 2009;
   Gaspar, Vitor/B 1602 2017; Mano, João/A 4418 2009
OI Monteiro, Maria/0000 0002 4963 6267; Jeronimo,
   Carmen/0000 0003 4186 5345; Ferreira, Luis/0000 0001 8395 2434;
   Henrique, Rui/0000 0003 3171 4666; Mano, Joao/0000 0002 2342 3765;
   Gaspar, Vitor/0000 0002 0372 2493; 
FU European Research Council [ERC 2014 ADG 669858, ERC 2017 PoC 789760];
   Programa Operacional Competitividade e Internacionalizacao (POCI), in
   the component FEDER; FCT/MCTES [PTDC/BTM SAL/30503/2017,
   PTDC/MEC ONC/29030/2017, UlD/CTM/50011/2019]; Portuguese Foundation for
   Science and Technology [SFRH/BD/141718/2018]; Fundação para a Ciência e
   a Tecnologia [PTDC/MEC ONC/29030/2017, SFRH/BD/141718/2018] Funding
   Source: FCT
FX The authors would like to acknowledge the support of the European
   Research Council for project ATLAS, grant agreement ERC 2014 ADG 669858,
   and for project MicroBone, grant agreement ERC 2017 PoC 789760. This
   work was also supported by the Programa Operacional Competitividade e
   Internacionalizacao (POCI), in the component FEDER, and by national
   funds (OE) through FCT/MCTES, in the scope of the project PANGEIA
   (PTDC/BTM SAL/30503/2017) and project HyTherCaP
   (PTDC/MEC ONC/29030/2017). The PANGEIA project is also acknowledged for
   the junior researcher contract of Vitor Gaspar. This work was also
   developed within the scope of the project CICECO Aveiro Institute of
   Materials, FCT Ref. UlD/CTM/50011/2019, financed by national funds
   through the FCT/MCTES. Luis Ferreira acknowledges an individual PhD
   fellowship from the Portuguese Foundation for Science and Technology
   (SFRH/BD/141718/2018).
CR Alemany Ribes M, 2014, ADV DRUG DELIVER REV, V79 80, P40, DOI 10.1016/j.addr.2014.06.004
   [Anonymous], THESIS
   [Anonymous], ACS BIOMATER SCI ENG
   [Anonymous], 2015, Anal. Chem., DOI [10.1016/j.cogdev.2010.08.003.Personal, DOI 10.1016/J.COGDEV.2010.08.003.PERSONAL]
   [Anonymous], GENES DEV
   Betsch DM, 2017, CURR ONCOL, V24, pE434, DOI 10.3747/co.24.3592
   Camci Unal G, 2013, BIOMACROMOLECULES, V14, P1085, DOI 10.1021/bm3019856
   Carvalho MR, 2015, TRENDS BIOTECHNOL, V33, P667, DOI 10.1016/j.tibtech.2015.09.009
   Chaudhuri PK, 2018, CHEM REV, V118, P6499, DOI 10.1021/acs.chemrev.8b00042
   Ciasca G, 2016, BIOINSPIR BIOMIM, V11, DOI 10.1088/1748 3190/11/1/011001
   Costa AMS, 2014, LANGMUIR, V30, P4535, DOI 10.1021/la500286v
   Cui X, 2016, COLLOID INTERFAC SCI, V14, P4, DOI 10.1016/j.colcom.2016.09.001
   Cui X, 2017, J R SOC INTERFACE, V14, DOI 10.1098/rsif.2016.0877
   Estrada Bernal A, 2011, J NEURO ONCOL, V102, P353, DOI 10.1007/s11060 010 0345 z
   Ferreira LP, 2018, BIOMATERIALS, V185, P155, DOI 10.1016/j.biomaterials.2018.09.007
   Ferreira LP, 2018, ACTA BIOMATER, V75, P11, DOI 10.1016/j.actbio.2018.05.034
   Gumulec J, 2014, INT J ONCOL, V44, P923, DOI 10.3892/ijo.2013.2223
   Gurski LA, 2009, BIOMATERIALS, V30, P6076, DOI 10.1016/j.biomaterials.2009.07.054
   Jayakumar S, 2014, BBA GEN SUBJECTS, V1840, P485, DOI 10.1016/j.bbagen.2013.10.006
   Kimura Y, 2017, SCI REP UK, V7, DOI 10.1038/srep44824
   Kwak B, 2018, J CONTROL RELEASE, V275, P201, DOI 10.1016/j.jconrel.2018.02.029
   Li XK, 2014, LAB CHIP, V14, P471, DOI 10.1039/c3lc51103k
   Lima AC, 2011, PHARM RES DORDR, V28, P1294, DOI 10.1007/s11095 011 0380 2
   Liu Z, 2016, CURR OPIN CHEM ENG, V11, P94, DOI 10.1016/j.coche.2016.01.012
   Loessner D, 2016, NAT PROTOC, V11, P727, DOI 10.1038/nprot.2016.037
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Neto AI, 2018, MATER HORIZ, V5, P379, DOI 10.1039/c7mh00877e
   Nichol JW, 2010, BIOMATERIALS, V31, P5536, DOI 10.1016/j.biomaterials.2010.03.064
   Nikitovic D, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00169
   Ojalill Marjaana, 2018, Oncotarget, V9, P32435, DOI 10.18632/oncotarget.25945
   Oliveira MB, 2013, ANAL CHEM, V85, P2391, DOI 10.1021/ac303405x
   Oliveira NM, 2018, ADV BIOSYST, V2, DOI 10.1002/adbi.201700069
   Oliveira NM, 2010, APPL PHYS EXPRESS, V3, DOI 10.1143/APEX.3.085205
   Orlandi P, 2005, J CHEMOTHERAPY, V17, P663, DOI 10.1179/joc.2005.17.6.663
   Poldervaart MT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177628
   Qu CJ, 2014, INT J BIOCHEM CELL B, V48, P45, DOI 10.1016/j.biocel.2013.12.016
   Richardson JJ, 2016, CHEM REV, V116, P14828, DOI 10.1021/acs.chemrev.6b00627
   Ruggeri BA, 2014, BIOCHEM PHARMACOL, V87, P150, DOI 10.1016/j.bcp.2013.06.020
   Sakai S, 2012, CANCER SCI, V103, P549, DOI 10.1111/j.1349 7006.2011.02187.x
   Sakai S, 2011, BIOMICROFLUIDICS, V5, DOI 10.1063/1.3516657
   Serban MA, 2019, MATRIX BIOL, V78 79, P337, DOI 10.1016/j.matbio.2018.02.010
   Shiirevnyamba A, 2011, BRIT J CANCER, V104, P505, DOI 10.1038/sj.bjc.6606070
   Shirahama H, 2016, SCI REP UK, V6, DOI 10.1038/srep31036
   Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951
   Siegel RL, 2017, CA CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Sigen A, 2018, CHEM COMMUN, V54, P1081, DOI 10.1039/c7cc08648b
   Sitarski AM, 2018, ACS BIOMATER SCI ENG, V4, P324, DOI 10.1021/acsbiomaterials.7b00097
   Sousa EJ, 2013, EPIGENETICS US, V8, P548, DOI 10.4161/epi.24519
   Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200
   Vinci M, 2015, JOVE J VIS EXP, DOI 10.3791/52686
   Weeks A, 2012, J BIOMED MATER RES A, V100A, P1972, DOI 10.1002/jbm.a.33269
   Xu X, 2012, BIOMATERIALS, V33, P9049, DOI 10.1016/j.biomaterials.2012.08.061
   Zou LJ, 2008, J ORTHOP RES, V26, P713, DOI 10.1002/jor.20539
NR 53
TC 85
Z9 98
U1 6
U2 172
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD AUG
PY 2019
VL 94
BP 392
EP 409
DI 10.1016/j.actbio.2019.06.012
PG 18
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA IN9TI
UT WOS:000479020900032
PM 31200118
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Baranowski, DC
   Buchanan, B
   Dwyer, HC
   Gabriele, JP
   Kelly, S
   Araujo, JA
AF Baranowski, David Charles
   Buchanan, Beth
   Dwyer, Heather C.
   Gabriele, Joseph P.
   Kelly, Stephanie
   Araujo, Joseph A.
TI Penetration and efficacy of transdermal NSAIDs in a model of acute joint
   inflammation
SO JOURNAL OF PAIN RESEARCH
LA English
DT Article
DE osteoarthritis; ibuprofen; celecoxib; pain; canine model
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SYNOVIAL FLUID; DOUBLE BLIND;
   RHEUMATIC CONDITIONS; CLINICAL TRIAL; ANIMAL MODELS; UNITED STATES;
   IBUPROFEN; OSTEOARTHRITIS; ARTHRITIS
AB Purpose: Prescription and OTC non steroidal anti inflammatory drugs (NSAIDs) are ubiquitous treatments for pain and inflammation; however, oral administration of these drugs may produce gastrointestinal (GI) side effects. Transdermal (TD) administration of NSAIDs circumvents these adverse events by avoiding the GI tract and, presumably, achieves regional drug levels of therapeutic effect and thereby, fewer off target complications.
   Methods: A drug quantification method was developed for ibuprofen and celecoxib in canine plasma and synovial fluid using liquid chromatography and mass spectrometry. This method was employed to evaluate the penetrance of ibuprofen and celecoxib topical formulations in dogs. Effectiveness of these topical NSAID formulations was compared to the equivalent oral drug concentration in a canine sodium urate model of acute joint inflammation. In this model, pain was quantified using a modified Canine Brief Pain Inventory questionnaire and regional inflammation using joint caliper measurements; the significance of intervention was evaluated using linear mixed models for repeated measures along with Bonferroni corrections.
   Results: After seven days of chronic topical administration, Delivra(TM) (DEL) formulations of ibuprofen and celecoxib generated serum levels of 2.9 mu g/mL and 220ng/mL and synovial fluid levels of 1.8 mu g/mL and 203 ng/mL (respectively). In the canine model of acute inflammation, the overall treatment effects as well as the treatment by time interactions were strongly significant (P<0.001) for both drugs. Oral ibuprofen proved uniquely effective at the earliest time point, while all ibuprofen formulations were effective at treating pain at 8.5 and 24.5 hours post induction. Similarly, all celecoxib formulations (oral and topical) were equally effective at 8.5 and 24.5 hours post induction.
   Conclusion: DEL formulations of ibuprofen and celecoxib successfully introduced these NSAIDs into synovial fluid at concentrations similar to those observed in circulation. Furthermore, these formulations reduced symptoms of pain associated with acute inflammation. Oral and transdermally delivered NSAIDs have similar pain relief effects; therefore, a replacement or combinatorial treatment may provide a more stable pain relief profile. In conclusion, this work supports further investigation of TD products in the treatment of regional inflammatory events.
C1 [Baranowski, David Charles; Buchanan, Beth; Dwyer, Heather C.; Gabriele, Joseph P.] Delivra Corp, Dept Res & Dev, Charlottetown, PE, Canada.
   [Kelly, Stephanie] Vivocore Inc, Toronto, ON, Canada.
   [Araujo, Joseph A.] InterVivo Solut Inc, Toronto, ON, Canada.
RP Baranowski, DC (通讯作者)，Delivra Corp, NRC PEI, Suite 407,550 Univ Ave, Charlottetown, PE C1A 4P3, Canada.
EM dbaranowski@delivrainc.com
OI Dwyer, Heather/0000 0002 9446 4003
FU Delivra Corp.
FX This project was sponsored by Delivra Corp. Formulation development of
   all test articles was performed by MNK Researchers Inc. We thank
   Professor Dr Henrik Stryhn of the Atlantic Veterinary College
   (Charlottetown, PE, Canada) in supporting the statistical analysis of
   data sets.
CR Borer LR, 2017, J VET PHARMACOL THER, V40, P148, DOI 10.1111/jvp.12348
   Cheung R, 2007, CLIN THER, V29, P2498, DOI 10.1016/j.clinthera.2007.12.008
   COX SR, 1991, J CLIN PHARMACOL, V31, P88, DOI 10.1002/j.1552 4604.1991.tb01892.x
   Dominkus M, 1996, ARZNEIMITTEL FORSCH, V46, P1138
   Dunayer E, 2004, VET MED US, V99, P580
   Efe T, 2014, KNEE SURG SPORT TR A, V22, P345, DOI 10.1007/s00167 013 2408 0
   Essex MN, 2012, J INT MED RES, V40, P1357, DOI 10.1177/147323001204000414
   GALLO JM, 1986, J CLIN PHARMACOL, V26, P65, DOI 10.1002/j.1552 4604.1986.tb02905.x
   GLASS RC, 1978, BRIT J CLIN PHARMACO, V6, pP453, DOI 10.1111/j.1365 2125.1978.tb04624.x
   Helmick CG, 2008, ARTHRITIS RHEUM US, V58, P15, DOI 10.1002/art.23177
   Hunter RR, 2005, AM J VET RES, V66, P1441, DOI 10.2460/ajvr.2005.66.1441
   Innes J, 2010, IN PRACTICE, V32, P126, DOI 10.1136/inp.c1436
   KLEINBLOESEM CH, 1995, ARZNEIMITTEL FORSCH, V45 2, P1117
   Klinge SA, 2013, PHYSICIAN SPORTSMED, V41, P64, DOI 10.3810/psm.2013.05.2016
   Kuyinu EL, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018 016 0346 5
   Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176
   MAKELA AL, 1981, SCAND J RHEUMATOL, P15
   Malfait AM, 2013, OSTEOARTHR CARTILAGE, V21, P1316, DOI 10.1016/j.joca.2013.06.003
   Martel Pelletier J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.72
   Mason L, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471 2474 5 28
   Mayo Clinic Staff, OST SYMPT CAUS DIAGN
   McDougall C, 2017, SEMIN ARTHRITIS RHEU, V46, P675, DOI 10.1016/j.semarthrit.2016.10.010
   Moore RA, 2005, ARTHRITIS RES THER, V7, pR644, DOI 10.1186/ar1704
   Mukherjee D, 2001, JAMA J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954
   Nissen SE, 2016, NEW ENGL J MED, V375, P2519, DOI 10.1056/NEJMoa1611593
   Rainsford K. D., 2009, Inflammopharmacology, V17, P275, DOI 10.1007/s10787 009 0016 x
   Rainsford K. D., 1999, American Journal of Medicine, V107, p27S
   Richardson JA, J VET EMERGENCY CRIT
   SETH PL, 1993, ARZNEIMITTELFORSCH, V43 2, P919
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   So AK, 2017, NAT REV RHEUMATOL, V13, P639, DOI 10.1038/nrrheum.2017.155
   STEELE AD, 1966, ARTHRITIS RHEUM US, V9, P430, DOI 10.1002/art.1780090308
   Tacconelli S, 2002, CURR MED RES OPIN, V18, P503, DOI 10.1185/030079902125001335
   Teeple E, 2013, AAPS J, V15, P438, DOI 10.1208/s12248 013 9454 x
   Tegeder I, 1999, CLIN PHARMACOL THER, V65, P357, DOI 10.1016/S0009 9236(99)70128 1
   VANE JR, 1971, NATURE NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   Vincent TL, 2012, RHEUMATOLOGY, V51, P1931, DOI 10.1093/rheumatology/kes035
   Wadsworth LT, 2016, CURR MED RES OPIN, V32, P241, DOI 10.1185/03007995.2015.1113400
   Whittle BJR, 2003, FUND CLIN PHARMACOL, V17, P301, DOI 10.1046/j.1472 8206.2003.00135.x
   Zhang YQ, 2010, CLIN GERIATR MED, V26, P355, DOI [10.1016/j.rdc.2012.10.004, 10.1016/j.cger.2010.03.001]
NR 40
TC 12
Z9 12
U1 0
U2 9
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 7090
J9 J PAIN RES
JI J. Pain Res.
PY 2018
VL 11
BP 2809
EP 2819
DI 10.2147/JPR.S177967
PG 11
WC Clinical Neurology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA HA5EO
UT WOS:000450291800001
PM 30519083
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chen, X
   Liu, C
   Yu, RC
   Gan, ZQ
   Zhang, Z
   Chen, ZY
   Liu, YB
   Wu, DL
   Yu, XY
   Liu, CF
   Cao, Y
AF Chen, Xin
   Liu, Chao
   Yu, Rongcheng
   Gan, Ziqi
   Zhang, Zhen
   Chen, Zhengyuan
   Liu, Yuanbo
   Wu, Dongle
   Yu, Xinyi
   Liu, Chufeng
   Cao, Yang
TI Interaction between ferroptosis and TNF α: Impact in obesity related
   osteoporosis
SO FASEB JOURNAL
LA English
DT Article
DE ferroptosis; GSH; obesity; osteoporosis; TNF alpha
ID IRON METABOLISM; ENDOTHELIAL CELLS; BODY COMPOSITION; SERUM FERRITIN;
   BONE LOSS; INFLAMMATION; MICE; ANGIOGENESIS; DEFICIENCY; OSTEOGENESIS
AB The relationship of obesity and osteoporosis has been widely studied over the past years. However, the implications of obesity for bone health remain controversial, and the underlying molecular mechanism is not yet fully understood. This study demonstrated that high fat diet induced obesity leads to significantly decreased bone volume/tissue volume (BV/TV), trabecular number (Tb.N), and cortical thickness (Ct.Th) of male rat femur after mechanical loading effects of body weight were controlled. HFD induced obese rats exhibited attenuated expression of ferroptosis inhibitory protein SLC7A11 and GPX4 in bone tissues, which was correlated with elevated serum TNF a concentration. Ferroptosis inhibitor administration could effectively rescue decreased osteogenesis associated type H vessels and osteoprogenitors, and downregulate serum levels of TNF a to ameliorate bone loss in obese rats. Since ferroptosis and TNF a both affect bone and vessel formation, we further investigated the interaction between ferroptosis and TNF a, and its impact in osteogenesis and angiogenesis in vitro. In human osteoblast like MG63 and umbilical vein endothelial cells (HUVEC), TNF a/TNFR2 signaling promoted cystine uptake and GSH biosynthesis to provide protection against low dose ferroptosis inducer erastin. While, TNF a/TNFR1 facilitated ferroptosis in the presence of high dose erastin through ROS accumulation. Moreover, TNF a regulated ferroptosis induced osteogenic and angiogenic dysfunctions based on its ferroptosis regulatory role. Meanwhile, ferroptosis inhibitors could reduce intracellular ROS overproduction and enhance osteogenesis and angiogenesis in TNF a treated MG63 and HUVECs. This study revealed the interaction between ferroptosis and TNF a and its impact in osteogenesis and angiogenesis, which provides new insights into the pathogenesis and regenerative therapy of obesity related osteoporosis.
C1 [Chen, Xin; Liu, Chao; Yu, Rongcheng; Gan, Ziqi; Zhang, Zhen; Chen, Zhengyuan; Liu, Yuanbo; Wu, Dongle; Yu, Xinyi; Cao, Yang] Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Guangzhou, Peoples R China.
   [Chen, Xin; Liu, Chao; Yu, Rongcheng; Gan, Ziqi; Zhang, Zhen; Chen, Zhengyuan; Liu, Yuanbo; Wu, Dongle; Yu, Xinyi; Cao, Yang] Guangdong Prov Key Lab Stomatol, Guangzhou, Peoples R China.
   [Liu, Chufeng] Southern Med Univ, Stomatol Hosp, Guangzhou, Peoples R China.
   [Cao, Yang] Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Guangzhou 510055, Peoples R China.
   [Liu, Chufeng] Southern Med Univ, Stomatol Hosp, Guangzhou 510260, Peoples R China.
C3 Sun Yat Sen University; Southern Medical University   China; Sun Yat Sen
   University; Southern Medical University   China
RP Cao, Y (通讯作者)，Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Guangzhou 510055, Peoples R China.; Liu, CF (通讯作者)，Southern Med Univ, Stomatol Hosp, Guangzhou 510260, Peoples R China.
EM xyzmmok@smu.edu.cn; caoyang@mail.sysu.edu.cn
RI Chen, Yanling/L 5390 2018; yu, xinyi/LPP 3094 2024; Chen,
   Zhengyuan/HRC 9719 2023; Chen, Xin/ABJ 3846 2022
FU General Scientific Research Cultivation Project of Guanghua School of
   Stomatology Sun Yat sen University [174 2018 XMZC 0001 03 0125/D 16];
   National Nature Science Foundation of China
FX the General Scientific Research Cultivation Project of Guanghua School
   of Stomatology, Sun Yat sen University, Grant/Award Number:
   174 2018 XMZC 0001 03 0125/D 16; the National Nature Science Foundation
   of China,
CR Ahmadi S, 2018, STEROIDS, V130, P31, DOI 10.1016/j.steroids.2017.12.008
   Baek K, 2014, J CELL PHYSIOL, V229, P640, DOI 10.1002/jcp.24487
   Bansal A, 2018, J CELL BIOL, V217, P2291, DOI 10.1083/jcb.201804161
   Barak MM, 2013, J STRUCT BIOL, V183, P123, DOI 10.1016/j.jsb.2013.04.009
   Behera J, 2021, THERANOSTICS, V11, P8605, DOI 10.7150/thno.63749
   BENTLEY DP, 1982, BRIT MED J, V284, P198, DOI 10.1136/bmj.284.6310.198 b
   Brenner D, 2015, NAT REV IMMUNOL, V15, P362, DOI 10.1038/nri3834
   Chang E, 2018, CURR DIABETES REP, V18, DOI 10.1007/s11892 018 1031 3
   Chi PL, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/279171
   Daru J, 2017, AM J CLIN NUTR, V106, p1634S, DOI 10.3945/ajcn.117.155960
   Deng LY, 2023, INFLAMM RES, V72, P281, DOI 10.1007/s00011 022 01672 1
   Deng X, 2012, INT IMMUNOPHARMACOL, V14, P658, DOI 10.1016/j.intimp.2012.10.001
   Dixon SJ, 2014, ELIFE, V3, DOI 10.7554/eLife.02523
   Doube M, 2011, P ROY SOC B BIOL SCI, V278, P3067, DOI 10.1098/rspb.2011.0069
   Ellulu MS, 2017, ARCH MED SCI, V13, P851, DOI 10.5114/aoms.2016.58928
   Elsayed ME, 2016, ADV CLIN CHEM, V75, P71, DOI 10.1016/bs.acc.2016.03.002
   Fujita Keiko, 2002, Okajimas Folia Anatomica Japonica, V79, P101, DOI 10.2535/ofaj.79.101
   Gandham A, 2020, J BONE MINER RES, V35, P125
   Ganz M, 2014, WORLD J GASTROENTERO, V20, P8525, DOI 10.3748/wjg.v20.i26.8525
   Gao ZH, 2022, EXP GERONTOL, V165, DOI 10.1016/j.exger.2022.111836
   Ge WW, 2022, MOL MED REP, V25, DOI 10.3892/mmr.2022.12656
   Gkastaris K, 2020, J MUSCULOSKEL NEURON, V20, P372
   Greco EA, 2015, THER ADV ENDOCRINOL, V6, P273, DOI 10.1177/2042018815611004
   Guo HH, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00146 0
   Guo Z, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.791376
   Hong J, 2009, NUTR J, V8, DOI 10.1186/1475 2891 8 11
   Horton JA, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1144163
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Jiang XJ, 2021, NAT REV MOL CELL BIO, V22, P266, DOI 10.1038/s41580 020 00324 8
   Jiang ZX, 2022, IUBMB LIFE, V74, P1052, DOI 10.1002/iub.2656
   Khanna D, 2022, CUREUS J MED SCIENCE, V14, DOI 10.7759/cureus.22711
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lewerenz J, 2013, ANTIOXID REDOX SIGN, V18, P522, DOI 10.1089/ars.2011.4391
   Li J, 2022, J MOL MED, V100, P167, DOI 10.1007/s00109 021 02164 1
   Li MY, 2006, J CELL PHYSIOL, V208, P253, DOI 10.1002/jcp.20654
   Li W, 2017, OBES RES CLIN PRACT, V11, P454, DOI 10.1016/j.orcp.2016.12.001
   Liao SC, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420 021 00698 4
   Lin YF, 2022, FASEB J, V36, DOI 10.1096/fj.202101610R
   Lingvay I, 2022, LANCET, V399, P394, DOI 10.1016/S0140 6736(21)01919 X
   Liu L, 2022, BIOCHEM BIOPH RES CO, V623, P1, DOI 10.1016/j.bbrc.2022.07.041
   Liu P, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/2634431
   Luo YL, 2020, INT J CLIN EXP PATHO, V13, P2041
   Ma HD, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9067610
   Magnani F, 2019, CURR OPIN STRUC BIOL, V59, P91, DOI 10.1016/j.sbi.2019.03.001
   MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Padwal R, 2016, ANN INTERN MED, V164, P532, DOI 10.7326/M15 1181
   Patel D, 2023, DRUG DELIV TRANSL RE, V13, P419, DOI 10.1007/s13346 022 01222 6
   Peng Y, 2020, THERANOSTICS, V10, P426, DOI 10.7150/thno.34126
   Pisoschi AM, 2021, EUR J MED CHEM, V209, DOI 10.1016/j.ejmech.2020.112891
   Polzer K, 2010, ANN RHEUM DIS, V69, P284, DOI 10.1136/ard.2008.104786
   Portal Núñez S, 2012, HISTOL HISTOPATHOL, V27, P559, DOI 10.14670/HH 27.559
   Qiu XJ., 2019, Stem Cells Int, V2019, P1
   Reid IR, 2002, BONE, V31, P547, DOI 10.1016/S8756 3282(02)00864 5
   Rolvien T, 2022, CALCIFIED TISSUE INT, V110, P592, DOI 10.1007/s00223 021 00836 1
   Sainson RCA, 2008, BLOOD, V111, P4997, DOI 10.1182/blood 2007 08 108597
   Saito T, 2014, ACTA BIOMATER, V10, P3641, DOI 10.1016/j.actbio.2014.04.021
   SATO H, 1995, BIOCHEM J, V310, P547, DOI 10.1042/bj3100547
   Sedger LM, 2014, CYTOKINE GROWTH F R, V25, P453, DOI 10.1016/j.cytogfr.2014.07.016
   Shi Q, 2022, MOL MED REP, V25, DOI 10.3892/mmr.2022.12645
   Shi R, 2021, BIOMATER SCI UK, V9, P2090, DOI 10.1039/d0bm01304h
   Singer K, 2015, J BIOL CHEM, V290, P13250, DOI 10.1074/jbc.M114.634568
   Smirnov IM, 1999, AM J PHYSIOL LUNG C, V277, pL257, DOI 10.1152/ajplung.1999.277.2.L257
   Specker BL, 2001, J BONE MINER RES, V16, P2298, DOI 10.1359/jbmr.2001.16.12.2298
   Sun YT, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110108
   Tang DL, 2021, CELL RES, V31, P107, DOI 10.1038/s41422 020 00441 1
   Tang X, 2020, J AGR FOOD CHEM, V68, P6588, DOI 10.1021/acs.jafc.0c01820
   Tomlinson DJ, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010195
   Valanezhad A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222212259
   Wang HG, 2017, KIDNEY BLOOD PRESS R, V42, P416, DOI 10.1159/000478869
   Wang L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.36
   WHO Consultation, 2000, WHO TECH REP SER, V894, P1
   Wu J, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 021 27948 4
   Xia J, 2022, BIOENGINEERED, V13, P3566, DOI 10.1080/21655979.2022.2025519
   Xu R, 2018, NAT MED, V24, P823, DOI 10.1038/s41591 018 0020 z
   Xu Z, 2017, BONE, V94, P152, DOI 10.1016/j.bone.2016.09.023
   Xue F, 2021, ELIFE, V10, DOI 10.7554/eLife.64872
   Yan CL, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/fpubh.2022.910675
   Yan HF, 2018, ENDOCR CONNECT, V7, P604, DOI 10.1530/EC 18 0054
   Yang HP, 2005, BIOCHEM J, V391, P399, DOI 10.1042/BJ20050795
   Yang YQ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00198 w
   Yang YB, 2014, OBESITY, V22, P2147, DOI 10.1002/oby.20811
   Yanoff LB, 2007, INT J OBESITY, V31, P1412, DOI 10.1038/sj.ijo.0803625
   Yao WF., 2022, Oxid Med Cell Longev, V2022, P1
   Zhang K, 2015, ENDOCRINE, V50, P239, DOI 10.1007/s12020 015 0554 5
   Zhang Z, 2022, OBES REV, V23, DOI 10.1111/obr.13493
   Zhao L, 2015, OBES REV, V16, P1081, DOI 10.1111/obr.12323
   Zhao LJ, 2007, J CLIN ENDOCR METAB, V92, P1640, DOI 10.1210/jc.2006 0572
   Zhu RJ, 2022, STEM CELLS INT, V2022, DOI 10.1155/2022/9359429
   Zhu SY, 2018, J MOL ENDOCRINOL, V60, P185, DOI 10.1530/JME 17 0218
   Zhu XL, 2014, CLIN EXP PHARMACOL P, V41, P489, DOI 10.1111/1440 1681.12240
NR 92
TC 29
Z9 34
U1 5
U2 37
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD JUN
PY 2023
VL 37
IS 6
AR e22947
DI 10.1096/fj.202201958R
PG 18
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA G8UF4
UT WOS:000991835000001
PM 37199646
OA hybrid
DA 2025 08 17
ER

PT J
AU Park, KY
   Li, WWA
   Platt, MO
AF Park, Keon Young
   Li, Weiwei A.
   Platt, Manu O.
TI Patient specific proteolytic activity of monocyte derived macrophages
   and osteoclasts predicted with temporal kinase activation states during
   differentiation
SO INTEGRATIVE BIOLOGY
LA English
DT Article
ID LEAST SQUARES REGRESSION; CATHEPSIN K LEVELS; 1,25 DIHYDROXYVITAMIN D 3;
   ENDOTHELIAL CELLS; MOLECULAR CLONING; INDUCED APOPTOSIS; SHEAR STRESS;
   CYSTATIN C; V ACTIVITY; ATHEROSCLEROSIS
AB Patient to patient variability in disease progression continues to complicate clinical decisions of treatment regimens for cardiovascular diseases, metastatic cancers and osteoporosis. Here, we investigated if monocytes, circulating white blood cells that enter tissues and contribute to disease progression by differentiating into macrophages or osteoclasts, could be useful in understanding this variability. Monocyte derived macrophages and osteoclasts produce cysteine cathepsins, powerful extracellular matrix proteases which have been mechanistically linked to accelerated atherosclerotic, osteoporotic, and tumor progression. We hypothesized that multivariate analysis of temporal kinase activation states during monocyte differentiation could predict cathepsin proteolytic responses of monocyte derived macrophages and osteoclasts in a patient specific manner. Freshly isolated primary monocytes were differentiated with M CSF or RANKL into macrophages or osteoclasts, respectively, and phosphorylation of ERK1/2, Akt, p38 MAPK, JNK, c jun, and I kappa B alpha were measured at days 1, 3, 6, and 9. In parallel, cell diameters and numbers of nuclei were measured, and multiplex cathepsin zymography was used to quantify cathepsins K, L, S, and V activity from cell extracts and conditioned media. There was extensive patient to patient variability in temporal kinase activation states, cell morphologies, and cathepsin K, L, S, and V proteolytic activity. Partial least squares regression models trained with temporal kinase activation states successfully predicted patient specific morphological characteristics (mean cell diameter and number of nuclei) and patient specific cathepsin proteolytic activity with predictability as high as 95%, even with the challenge of incorporating the complex, unknown cues from individual patients' unique genetic and biochemical backgrounds. This personalized medicine approach considers patient variability in kinase signals to predict cathepsin activity. Such analyses may provide beneficial tools for personalized kinase and protease inhibitor therapies for tissue destructive diseases.
C1 [Park, Keon Young] Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA.
   Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA.
   Emory Univ, Atlanta, GA 30332 USA.
C3 University System of Georgia; Georgia Institute of Technology;
   University System of Georgia; Georgia Institute of Technology; Emory
   University
RP Park, KY (通讯作者)，Georgia Inst Technol, Dept Biomed Engn, 315 Ferst Dr,Suite 1308, Atlanta, GA 30332 USA.
EM manu.platt@bme.gatech.edu
RI ; Platt, Manu/ABY 6057 2022
OI Li, Aileen/0000 0002 1056 5932; Platt, Manu/0000 0001 6390 4320; 
FU Georgia Cancer Coalition; Parker H. Petit Institute for Bioengineering
   and Biosciences; National Center for Advancing Translational Sciences of
   the National Institutes of Health [UL1TR000454]; NIH from the Office of
   the Director, National Institutes of Health [1DP2OD007433 01];
   Regenerative Engineering and Medicine (REM) Seed Grant
FX This work was funded in some part by the Georgia Cancer Coalition,
   Regenerative Engineering and Medicine (REM) Seed Grant, Parker H. Petit
   Institute for Bioengineering and Biosciences, the National Center for
   Advancing Translational Sciences of the National Institutes of Health
   under Award Number UL1TR000454, and NIH New Innovator grant Award Number
   1DP2OD007433 01 from the Office of the Director, National Institutes of
   Health. The content is solely the responsibility of the authors and does
   not necessarily represent the official views of the Office of the
   Director, National Institutes of Health or the National Institutes of
   Health.
CR Adolf D, 2012, MATURITAS, V71, P169, DOI 10.1016/j.maturitas.2011.11.024
   Barry ZT, 2012, J BIOL CHEM, V287, P27723, DOI 10.1074/jbc.M111.332684
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brix K, 2008, BIOCHIMIE, V90, P194, DOI 10.1016/j.biochi.2007.07.024
   BROMME D, 1995, BIOL CHEM H S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379
   Brömme D, 2009, EXPERT OPIN INV DRUG, V18, P585, DOI [10.1517/13543780902832661, 10.1517/13543780902832661 ]
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63
   Desmarais S, 2009, BIOL CHEM, V390, P941, DOI 10.1515/BC.2009.092
   Filgueira L, 2004, J HISTOCHEM CYTOCHEM, V52, P411, DOI 10.1177/002215540405200312
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   GELADI P, 1986, ANAL CHIM ACTA, V185, P1, DOI 10.1016/0003 2670(86)80028 9
   Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406
   Gocheva V, GENES DEV, V24, P241
   Inada M, 2008, BIOCHEM BIOPH RES CO, V372, P434, DOI 10.1016/j.bbrc.2008.05.041
   Janes KA, 2005, SCIENCE, V310, P1646, DOI 10.1126/science.1116598
   Janes KA, 2004, J COMPUT BIOL, V11, P544, DOI 10.1089/cmb.2004.11.544
   Jobs E, 2011, JAMA J AM MED ASSOC, V306, P1113, DOI 10.1001/jama.2011.1246
   Jordan JD, 2000, CELL, V103, P193, DOI 10.1016/S0092 8674(00)00112 4
   Keegan PM, 2012, ANEMIA, V2012, DOI 10.1155/2012/201781
   Keegan PM, 2012, MOL CELL BIOCHEM, V367, P65, DOI 10.1007/s11010 012 1320 0
   Kerschan Schindl K, 2005, EXP GERONTOL, V40, P532, DOI 10.1016/j.exger.2005.04.001
   Kitazawa R, 2002, BIOCHEM BIOPH RES CO, V290, P650, DOI 10.1006/bbrc.2001.6251
   Le Gall Celine, 2008, Curr Opin Support Palliat Care, V2, P218, DOI 10.1097/SPC.0b013e32830baea9
   Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092 8674(00)81842 5
   Li WA, 2010, ANAL BIOCHEM, V401, P91, DOI 10.1016/j.ab.2010.02.035
   Li ZQ, 2008, J MOL BIOL, V383, P78, DOI 10.1016/j.jmb.2008.07.038
   Li ZQ, 2004, J BIOL CHEM, V279, P5470, DOI 10.1074/jbc.M310349200
   Li ZQ, 2002, J BIOL CHEM, V277, P28669, DOI 10.1074/jbc.M204004200
   Liu J, 2006, ATHEROSCLEROSIS, V184, P302, DOI 10.1016/j.atherosclerosis.2005.05.012
   Liu J, 2006, ATHEROSCLEROSIS, V186, P411, DOI 10.1016/j.atherosclerosis.2005.08.001
   Liu YX, 2009, AM J CARDIOL, V103, P476, DOI 10.1016/j.amjcard.2008.10.011
   Lutgens E, 2006, CIRCULATION, V113, P98, DOI 10.1161/CIRCULATIONAHA.105.561449
   Micheletti RG, 2008, MODERN PATHOL, V21, P1019, DOI 10.1038/modpathol.2008.89
   Mikosch P, 2008, THYROID, V18, P27, DOI 10.1089/thy.2007.0186
   Miller Jensen K, 2007, NATURE, V448, P604, DOI 10.1038/nature06001
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Muñoz Torres M, 2009, MATURITAS, V64, P188, DOI 10.1016/j.maturitas.2009.09.011
   Naumnik W, 2009, FOLIA HISTOCHEM CYTO, V47, P207, DOI 10.2478/v10042 009 0024 0
   Nerenz RD, 2008, MOL ENDOCRINOL, V22, P1044, DOI 10.1210/me.2007 0380
   Novinec M, 2010, BIOCHEM J, V429, P379, DOI 10.1042/BJ20100337
   Platt MO, 2007, AM J PHYSIOL HEART C, V292, pH1479, DOI 10.1152/ajpheart.00954.2006
   Platt MO, 2006, ARTERIOSCL THROM VAS, V26, P1784, DOI 10.1161/01.ATV.0000227470.72109.2b
   Platt MO, 2009, STEM CELLS, V27, P2804, DOI 10.1002/stem.215
   Qiao JH, 1997, AM J PATHOL, V150, P1687
   Roodman GD, 2006, ANN NY ACAD SCI, V1068, P100, DOI 10.1196/annals.1346.013
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555, DOI 10.1002/jlb.59.4.555
   SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014 5793(94)01349 6
   SU B, 1994, CELL, V77, P727, DOI 10.1016/0092 8674(94)90056 6
   Sukhova GK, 1998, J CLIN INVEST, V102, P576, DOI 10.1172/JCI181
   Teitelbaum SL, 2004, J CLIN INVEST, V114, P463, DOI 10.1172/JCI200422644
   Tumminello FM, 2008, BIOMED PHARMACOTHER, V62, P130, DOI 10.1016/j.biopha.2007.07.001
   Wang D, 2002, BIOCHEMISTRY US, V41, P8849, DOI 10.1021/bi0257080
   WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106
   Wilder CL, 2011, ARCH BIOCHEM BIOPHYS, V516, P52, DOI 10.1016/j.abb.2011.09.009
   Yasuda Y, 2004, J BIOL CHEM, V279, P36761, DOI 10.1074/jbc.M403986200
NR 57
TC 23
Z9 24
U1 0
U2 7
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1757 9694
J9 INTEGR BIOL UK
JI Integr. Biol.
PY 2012
VL 4
IS 12
BP 1459
EP 1469
DI 10.1039/c2ib20197f
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 039XH
UT WOS:000311281000001
PM 23114878
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Li, M
   Fuchs, S
   Böse, T
   Schmidt, H
   Hofmann, A
   Tonak, M
   Unger, R
   Kirkpatrick, CJ
AF Li, Ming
   Fuchs, Sabine
   Boese, Thomas
   Schmidt, Harald
   Hofmann, Alexander
   Tonak, Marcus
   Unger, Ronald
   Kirkpatrick, Charles James
TI Mild Heat Stress Enhances Angiogenesis in a Co culture System Consisting
   of Primary Human Osteoblasts and Outgrowth Endothelial Cells
SO TISSUE ENGINEERING PART C METHODS
LA English
DT Article
ID HUMAN PERIPHERAL BLOOD; SHOCK PROTEIN EXPRESSION; MESENCHYMAL
   STEM CELLS; HEAT SHOCK PROTEIN 27 INDUCTION; SONIC HEDGEHOG; STROMAL
   CELLS; UP REGULATION; IN VITRO; VASCULARIZATION; OSTEOGENESIS
AB The repair and regeneration of large bone defects, including the formation of functional vasculature, represents a highly challenging task for tissue engineering and regenerative medicine. Recent studies have shown that vascularization and ossification can be stimulated by mild heat stress (MHS), which would offer the option to enhance the bone regeneration process by relatively simple means. However, the mechanisms of MHS enhanced angiogenesis and osteogenesis, as well as potential risks for the treated cells are unclear. We have investigated the direct effect of MHS on angiogenesis and osteogenesis in a co culture system of human outgrowth endothelial cells (OECs) and primary osteoblasts (pOBs), and assessed cytotoxic effects, as well as the levels of various heat shock proteins (HSPs) synthesized under these conditions. Enhanced formation of microvessel like structures was observed in co cultures exposed to MHS (41 degrees C, 1 h), twice per week, over a time period of 7 14 days. As shown by real time polymerase chain reaction (PCR), the expression of vascular endothelial growth factor (VEGF), angiopoietin 1 (Ang 1), angiopoietin 2 (Ang 2), and tumor necrosis factor alpha was up regulated in MHS treated co cultures 24 h post treatment. At the protein level, significantly elevated VEGF and Ang 1 concentrations were observed in MHS treated co cultures and pOB mono cultures compared with controls, indicating paracrine effects associated with MHS induced angiogenesis. MHS stimulated co cultures and OEC mono cultures released higher levels of Ang 2 than untreated cultures. On the other hand MHS treatment of co cultures did not result in a clear effect regarding osteogenesis. Nevertheless, real time PCR demonstrated that MHS increased the expression of mitogen activated protein kinase, interleukin 6, and bone morphogenetic protein 2, known as HSP related molecules in angiogenic and osteogenic regulation pathways. In agreement with these observations, the expression of some selected HSPs also increased at both the mRNA and protein levels in MHS treated co cultures.
C1 [Li, Ming; Fuchs, Sabine; Boese, Thomas; Unger, Ronald; Kirkpatrick, Charles James] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Pathol, REPAIR Lab, D 55101 Mainz, Germany.
   [Fuchs, Sabine] Univ Med Ctr Schleswig Holstein Kiel, Kiel, Germany.
   [Schmidt, Harald] MetaPhysiol, Essenheim, Germany.
   [Hofmann, Alexander] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Trauma Surg, D 55101 Mainz, Germany.
   [Tonak, Marcus] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Orthoped, D 55101 Mainz, Germany.
C3 Johannes Gutenberg University of Mainz; University of Kiel; Johannes
   Gutenberg University of Mainz; Johannes Gutenberg University of Mainz
RP Li, M (通讯作者)，Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Pathol, REPAIR Lab, Langenbeckstr 1, D 55101 Mainz, Germany.
EM limi@uni mainz.de; kirkpatrick@ukmainz.de
RI ; Schmidt, Harald/E 8736 2014
OI Kirkpatrick, Charles James/0000 0002 0088 418X; 
FU BMBF (German Chinese Young investigator group grant) [0315033]
FX The authors thank BMBF (German Chinese Young investigator group grant
   number 0315033) for financial support; Eva Dohle, Marlen Kolbe, Xin
   Jiang, and Bin Ma for their friendly help; and Barbara Pavic and
   Stephanie Hunerkopf for their excellent technical assistance.
CR Chung E, 2012, CELL STRESS CHAPERON, V17, P203, DOI 10.1007/s12192 011 0300 8
   COOPER LF, 1994, J BIOL CHEM, V269, P7869
   Dai J, 2007, J DENT RES, V86, P937, DOI 10.1177/154405910708601006
   Dohle E, 2010, TISSUE ENG PT A, V16, P1235, DOI [10.1089/ten.tea.2009.0493, 10.1089/ten.TEA.2009.0493]
   Dohle E, 2011, EUR CELLS MATER, V21, P144, DOI 10.22203/eCM.v021a12
   Evans IM, 2008, CELL SIGNAL, V20, P1375, DOI 10.1016/j.cellsig.2008.03.002
   Fuchs S, 2007, TISSUE ENG, V13, P2577, DOI 10.1089/ten.2007.0022
   Fuchs S, 2006, CELL TISSUE RES, V326, P79, DOI 10.1007/s00441 006 0222 4
   Fuchs S, 2009, BIOMATERIALS, V30, P1329, DOI 10.1016/j.biomaterials.2008.11.028
   Fuchs S, 2009, BIOMATERIALS, V30, P526, DOI 10.1016/j.biomaterials.2008.09.058
   Gong B, 2006, LIFE SCI, V79, P1781, DOI 10.1016/j.lfs.2006.06.025
   Harder Y, 2004, J SURG RES, V119, P100, DOI 10.1016/j.jss.2003.11.002
   Hatakeyama D, 2002, BBA MOL CELL RES, V1589, P15, DOI 10.1016/S0167 4889(01)00183 5
   Hebb MO, 2006, BRAIN RES, V1073, P146, DOI 10.1016/j.brainres.2005.12.038
   Hofmann A, 2003, J BIOMED MATER RES A, V67A, P191, DOI 10.1002/jbm.a.10594
   Jiang Aixiang, 2007, J Bioinform Comput Biol, V5, P875, DOI 10.1142/S0219720007002989
   Kato K, 2011, INT J MOL MED, V27, P423, DOI 10.3892/ijmm.2011.595
   Kolbe M, 2010, TISSUE ENG PART C ME, V16, P877, DOI [10.1089/ten.tec.2009.0492, 10.1089/ten.TEC.2009.0492]
   Kozawa O, 2001, CELL SIGNAL, V13, P535, DOI 10.1016/S0898 6568(01)00180 2
   Lanneau D, 2007, PRION, V1, P53, DOI 10.4161/pri.1.1.4059
   Laplante AF, 1998, J HISTOCHEM CYTOCHEM, V46, P1291, DOI 10.1177/002215549804601109
   Li TS, 2002, AM J PHYSIOL HEART C, V283, pH468, DOI 10.1152/ajpheart.00261.2002
   Norgaard R, 2006, ANN NY ACAD SCI, V1067, P443, DOI 10.1196/annals.1354.063
   Ogawa H, 1990, Nihon Kyosei Shika Gakkai Zasshi, V49, P485
   Park HG, 2005, CELL MOL LIFE SCI, V62, P10, DOI 10.1007/s00018 004 4208 7
   Rattan SIS, 2007, ANN NY ACAD SCI, V1100, P424, DOI 10.1196/annals.1395.047
   Riederer I, 2008, TRANSPL P, V40, P624, DOI 10.1016/j.transproceed.2008.01.026
   Rosová I, 2008, STEM CELLS, V26, P2173, DOI 10.1634/stemcells.2007 1104
   Rylander MN, 2010, INT J HYPERTHER, V26, P748, DOI 10.3109/02656736.2010.486778
   Shui CX, 2001, J BONE MINER RES, V16, P731, DOI 10.1359/jbmr.2001.16.4.731
   Song XM, 2010, BIOCHEM BIOPH RES CO, V398, P111, DOI 10.1016/j.bbrc.2010.06.046
   Sundberg C, 2002, LAB INVEST, V82, P387, DOI 10.1038/labinvest.3780433
   Tavassol F, 2011, TISSUE ENG PT A, V17, P1935, DOI [10.1089/ten.tea.2010.0603, 10.1089/ten.TEA.2010.0603]
   Tiffee JC, 2000, TISSUE CELL, V32, P141, DOI 10.1054/tice.2000.0097
   Tokuda H, 2003, EUR J ENDOCRINOL, V149, P239, DOI 10.1530/eje.0.1490239
   Ueda A, 2004, AM J PHYSIOL HEART C, V287, pH994, DOI 10.1152/ajpheart.00400.2003
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Yao YC, 2009, CIRC RES, V105, P575, DOI 10.1161/CIRCRESAHA.109.202333
   Ye CP, 2007, CELL BIOCHEM FUNCT, V25, P267, DOI 10.1002/cbf.1330
   Yoshida K, 2009, CLIN ORAL IMPLAN RES, V20, P782, DOI 10.1111/j.1600 0501.2008.01654.x
NR 41
TC 40
Z9 41
U1 2
U2 40
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3384
EI 1937 3392
J9 TISSUE ENG PART C ME
JI Tissue Eng. Part C Methods
PD APR 1
PY 2014
VL 20
IS 4
BP 328
EP 339
DI 10.1089/ten.tec.2013.0087
PG 12
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA AE0BA
UT WOS:000333627300007
PM 23998634
OA Green Published
DA 2025 08 17
ER

PT J
AU Rinella, L
   Fiorentino, G
   Compagno, M
   Grange, C
   Cedrino, M
   Marano, F
   Bosco, O
   Vissio, E
   Delsedime, L
   D'Amelio, P
   Bussolati, B
   Arvat, E
   Catalano, MG
AF Rinella, Letizia
   Fiorentino, Gloria
   Compagno, Mara
   Grange, Cristina
   Cedrino, Massimo
   Marano, Francesca
   Bosco, Ornella
   Vissio, Elena
   Delsedime, Luisa
   D'Amelio, Patrizia
   Bussolati, Benedetta
   Arvat, Emanuela
   Catalano, Maria Graziella
TI Dickkopf 1 (DKK1) drives growth and metastases in castration resistant
   prostate cancer
SO CANCER GENE THERAPY
LA English
DT Article
ID SERUM DICKKOPF 1; BONE METASTASIS; LUNG CANCER; EXPRESSION; INHIBITOR;
   PROGRESSION; CELLS; TUMOR; ADENOCARCINOMA; MECHANISMS
AB Metastatic castration resistant prostate cancer (mCRPC) is associated with a poor prognosis and remains an incurable fatal disease. Therefore, the identification of molecular markers involved in cancer progression is urgently needed to develop more effective therapies. The present study investigated the role of the Wnt signaling modulator Dickkopf 1 (DKK1) in the growth and metastatic progression of mCRPC. DKK1 silencing through siRNA and deletion via CRISPR/Cas9 editing were performed in two different metastatic castration resistant prostate cancer cell lines (PC3 and DU145). A xenograft tumor model was used to assess tumor growth and metastases. In in vitro experiments, both DKK1 silencing and deletion reduced cell growth and migration of both cell lines. DKK1 knockout clones (DKK1 KO) exhibited cell cycle arrest, tubulin reorganization, and modulation of tumor metastasis associated genes. Furthermore, in DKK1 KO cells, E cadherin re expression and its membrane co localization with beta catenin were observed, contributing to reduced migration; Cadherin 11, known to increase during epithelial mesenchymal transition, was down regulated in DKK1 KO cells. In the xenograft mouse model, DKK1 deletion not only reduced tumor growth but also inhibited the formation of lung metastases. In conclusion, our findings support the key role of DKK1 in the growth and metastatic dissemination of mCRPC, both in vitro and in vivo.
C1 [Rinella, Letizia; Fiorentino, Gloria; Grange, Cristina; Marano, Francesca; Bosco, Ornella; D'Amelio, Patrizia; Arvat, Emanuela; Catalano, Maria Graziella] Univ Turin, Dept Med Sci, Turin, Italy.
   [Compagno, Mara] Univ Turin, Molinette Hosp, Ctr Expt Res & Med Studies CeRMS, Citta Salute & Sci, Turin, Italy.
   [Cedrino, Massimo] Univ Turin, Mol Biotechnol Ctr, Turin, Italy.
   [Vissio, Elena; Delsedime, Luisa] Univ Turin, Molinette Hosp, Unit Pathol, Citta Salute & Sci, Turin, Italy.
   [Bussolati, Benedetta] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Turin, Italy.
C3 University of Turin; University of Turin; A.O.U. Citta della Salute e
   della Scienza di Torino; AOU San Giovanni Battista Molinette; University
   of Turin; University of Turin; A.O.U. Citta della Salute e della Scienza
   di Torino; AOU San Giovanni Battista Molinette; University of Turin
RP Catalano, MG (通讯作者)，Univ Turin, Dept Med Sci, Turin, Italy.
EM mariagraziella.catalano@unito.it
RI ; Catalano, Maria/J 4320 2016; D'AMELIO, PATRIZIA/K 3042 2016
OI Fiorentino, Gloria/0009 0003 1988 4678; 
FU Universit degli Studi di Torino (University of Turin); Fondazione CRT;
   Turin, Italy; University of Turin, Turin, Italy
FX The authors thank Chiara Pighi for production of Luc/GFP PC3 expressing
   cells, and Federica Antico for technical support in histology. Funding:
   This work was supported by Fondazione CRT (grant number = RF 2020.1694),
   Turin, Italy to EA; and by "Research Fund ex 60%", University of Turin,
   Turin, Italy to MGC.
CR Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439
   Bekelman JE, 2018, J CLIN ONCOL, V36, P3251, DOI 10.1200/JCO.18.00606
   Betella I, 2019, GYNECOL ONCOL, V154, P55, DOI 10.1016/j.ygyno.2019.04.132
   Betella I, 2020, GYNECOL ONCOL, V157, P765, DOI 10.1016/j.ygyno.2020.03.010
   Cho SW, 2013, MOL CELL ENDOCRINOL, V366, P90, DOI 10.1016/j.mce.2012.12.007
   Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541 7786.MCR 08 0077
   Chu TQ, 2014, BIOCHEM BIOPH RES CO, V443, P962, DOI 10.1016/j.bbrc.2013.12.076
   Cui N, 2017, PROG MOL BIOL TRANSL, V147, P1, DOI 10.1016/bs.pmbts.2017.02.005
   D'Amelio P, 2014, BMC CLIN PATHOL, V14, DOI 10.1186/1472 6890 14 11
   Doucet D, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1114822
   Fradet A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075092
   Gillette CM, 2023, CANCERS, V15, DOI 10.3390/cancers15092552
   Giralt I, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222312921
   Goldstein SD, 2016, ONCOTARGET, V7, P21114, DOI 10.18632/oncotarget.8522
   Hahn AW, 2023, ENDOCRINOLOGY, V164, DOI 10.1210/endocr/bqad078
   Hall CL, 2008, PROSTATE, V68, P1396, DOI 10.1002/pros.20805
   Hall CL, 2010, CANCER RES, V70, P9916, DOI 10.1158/0008 5472.CAN 10 0440
   Han JK, 2021, BMC NEUROL, V21, DOI 10.1186/s12883 021 02477 1
   Hayat R, 2022, CELL BIOL INT, V46, P863, DOI 10.1002/cbin.11797
   Huang CF, 2010, CANCER RES, V70, P4580, DOI 10.1158/0008 5472.CAN 09 3016
   Janiak M, 2017, APMIS, V125, P101, DOI 10.1111/apm.12638
   Jiang HW, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.847387
   Jiang T, 2013, INT J BIOL MARKER, V28, P221, DOI 10.5301/jbm.5000005
   Jiang YF, 2001, CANCER RES, V61, P2365
   Kagey MH, 2017, BRIT J PHARMACOL, V174, P4637, DOI 10.1111/bph.13894
   Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206
   Kim S, 2017, CANCER RES TREAT, V49, P643, DOI 10.4143/crt.2016.168
   Kim SU, 2015, YONSEI MED J, V56, P1296, DOI 10.3349/ymj.2015.56.5.1296
   Lee YC, 2010, J PATHOL, V221, P68, DOI 10.1002/path.2687
   Liu YQ, 2014, TUMOR BIOL, V35, P3145, DOI 10.1007/s13277 013 1411 x
   Loh CY, 2019, CELLS BASEL, V8, DOI 10.3390/cells8101118
   Longstreth JH, 2024, AM J PHYSIOL CELL PH, V326, pC1212, DOI 10.1152/ajpcell.00633.2023
   Mahmood N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094358
   Mikheev AM, 2008, BREAST CANCER RES TR, V112, P263, DOI 10.1007/s10549 007 9867 2
   Pang HL, 2018, ONCOL LETT, V15, P6739, DOI 10.3892/ol.2018.8160
   Patel R, 2020, CANCER RES, V80, P576, DOI 10.1158/0008 5472.CAN 19 1684
   Qi LS, 2012, CANCER SCI, V103, P828, DOI 10.1111/j.1349 7006.2012.02222.x
   Rachner TD, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 649
   Rinella L, 2018, CONNECT TISSUE RES, V59, P561, DOI 10.1080/03008207.2018.1424147
   Roato I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003627
   Rorive S, 2010, MODERN PATHOL, V23, P1418, DOI 10.1038/modpathol.2010.136
   Seo SH, 2021, AM J CANCER RES, V11, P4788
   Sheng SL, 2009, CLIN CHEM, V55, P1656, DOI 10.1373/clinchem.2009.125641
   Song QP, 2021, AGING US, V13, P20481, DOI 10.18632/aging.203430
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747
   Takahashi N, 2010, INT J CANCER, V126, P1611, DOI 10.1002/ijc.24865
   Thudi NK, 2011, PROSTATE, V71, P615, DOI 10.1002/pros.21277
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47
   Velho PI, 2020, EUR UROL, V77, P14, DOI 10.1016/j.eururo.2019.05.032
   Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115
   Wang L, 2018, ANN ONCOL, V29, P352, DOI 10.1093/annonc/mdx689
   Wang ZS, 2018, BIOCHEM CELL BIOL, V96, P355, DOI 10.1139/bcb 2017 0015
   Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016
   Wong SHM, 2018, CRIT REV ONCOL HEMAT, V121, P11, DOI 10.1016/j.critrevonc.2017.11.010
   Yang RH, 2023, BIOCHEM PHARMACOL, V208, DOI 10.1016/j.bcp.2022.115378
   Yao LL, 2016, J CELL MOL MED, V20, P1673, DOI 10.1111/jcmm.12862
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
   Zhang PP, 2018, THERANOSTICS, V8, P5890, DOI 10.7150/thno.27667
   Zhuang XQ, 2017, NAT CELL BIOL, V19, P1274, DOI 10.1038/ncb3613
NR 61
TC 2
Z9 3
U1 3
U2 5
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0929 1903
EI 1476 5500
J9 CANCER GENE THER
JI Cancer Gene Ther.
PD AUG
PY 2024
VL 31
IS 8
BP 1266
EP 1279
DI 10.1038/s41417 024 00783 7
EA MAY 2024
PG 14
WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Research & Experimental Medicine
GA C7T7S
UT WOS:001220911700001
PM 38740881
DA 2025 08 17
ER

PT J
AU Selvakumar, M
   Kumar, PS
   Das, B
   Dhara, S
   Chattopadhyay, S
AF Selvakumar, M.
   Kumar, P. Senthil
   Das, Bodhisatwa
   Dhara, Santanu
   Chattopadhyay, Santanu
TI Structurally Tuned Antimicrobial Mesoporous Hydroxyapatite Nanorods by
   Cyclic Oligosaccharides Regulation To Release a Drug for Osteomyelitis
SO CRYSTAL GROWTH & DESIGN
LA English
DT Article
ID GUIDED BONE REGENERATION; CALCIUM PHOSPHATE; NANOCRYSTALLINE
   HYDROXYAPATITE; HYDROTHERMAL SYNTHESIS; SONOCHEMICAL SYNTHESIS; DOPED
   HYDROXYAPATITE; NANOPARTICLES; GROWTH; NUCLEATION; FIBERS
AB This work unveils a straightforward and controlled biomimetic synthesis (combined modified coprecipitation and sonochemistry method) of rod like two dimensional (2D) hydroxyapatite (HA) nanopartides with an aspect ratio of similar to 13.2 and their mesoporous nanorods (small and large pore) by fine regulation of the morphology using a beta cyclodextrin (beta CD) oligomer. Various methodical characterization results such as from wide angle X ray diffraction, high resolution transmission electron microscopy (HRTEM), Brunauer Emmett Teller analysis, and Fourier transform infrared spectroscopy comprehensively established that beta CD acts as an effective nucleating agent by virtue of strong adsorption of alpha D glucopyranoside moieties of beta CD on the surface of calcium phosphate as well as owing to electrostatic interactions due to the toroid and cyclic structure of beta CD. Besides, improved crystallinity of HA nanorods, as well as induced crystal growth of nanorods along the [110] crystallographic direction, was observed from the HRTEM micrographs. Consequently, a plausible mechanism also is proposed for the nucleation and growth of the nanorods followed by their crystallization. Subsequently, the prepared tuned mesoporous nanorods were employed as a drug carrier and delivery system using ciprofloxacin (CFX) drug for the treatment of osteomyelitis. Eventually, CFX encapsulated beta CD wrapped mesoporous hydroxyapatite (MPHA) nanocrystals showed a greater drug loading capability (similar to 79%). They also showed sustained release characteristics (in vitro). Furthermore, antimicrobial activity showed a significant zone of inhibition of similar to 33 mm of the CFX loaded mesoporous frames, especially for the beta CD MPHA nanocrystals. A hemolysis assay with human erythrocytes displayed good blood compatibility (less than similar to 1% of hemolysis) of the prepared various HA nanorods. Besides, robust cell proliferation at day 7 as well as zero toxicity level of the prepared different HA nanocrystals was confirmed by MTT assays and monitoring of cell adhesion as well as cell morphology (cytoskeleton) by fluorescence microscopy using osteoblast cells. Thus, these structurally tuned nanocrystals along with combinatorial properties indicate a broad range of potential biomedical applications particularly as a biomaterial for osteomyelitis therapy. Likewise, they can also be used as nanofillers in fabricating a bio nanocomposite with a suitable matrix for bone tissue engineering, where infection is a major problem of osteoblast proliferation.
C1 [Selvakumar, M.; Chattopadhyay, Santanu] Indian Inst Technol, Ctr Rubber Technol, Kharagpur 721302, W Bengal, India.
   [Selvakumar, M.] Pohang Univ Sci & Technol POSTECH, Dept Mech Engn, Ctr Rapid Prototyping Based Tissue Organ Printing, 77 Cheongam Ro, Pohang 790784, Kyungbuk, South Korea.
   [Kumar, P. Senthil] VHNSN Coll, Dept Chem, Virudunagar 626001, Tamil Nadu, India.
   [Das, Bodhisatwa; Dhara, Santanu] Indian Inst Technol, Sch Med Sci & Technol, Kharagpur 721302, W Bengal, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT)   Kharagpur; Pohang University of Science & Technology
   (POSTECH); Indian Institute of Technology System (IIT System); Indian
   Institute of Technology (IIT)   Kharagpur
RP Chattopadhyay, S (通讯作者)，Indian Inst Technol, Ctr Rubber Technol, Kharagpur 721302, W Bengal, India.
EM santanuchat71@yahoo.com
RI Das, Bodhisatwa/AAA 3085 2021; Dhara, Santanu/AAS 5872 2020; Das,
   Bodhisatwa/F 7975 2018; Chattopadhyay, Prof Santanu/M 7840 2018
OI Das, Bodhisatwa/0000 0002 1447 9089; S, Dr.
   Selvakumar/0000 0001 9795 3569; Chattopadhyay,
   Santanu/0000 0002 1227 0732; Dhara, Santanu/0000 0003 4443 7610
CR Asharani PV, 2010, ADV FUNCT MATER, V20, P1233, DOI 10.1002/adfm.200901846
   Choi HW, 2006, J COLLOID INTERF SCI, V304, P277, DOI 10.1016/j.jcis.2006.05.069
   Cui WG, 2010, BIOMATERIALS, V31, P4620, DOI 10.1016/j.biomaterials.2010.02.050
   Cui WG, 2008, CRYST GROWTH DES, V8, P4576, DOI 10.1021/cg800641s
   Dalhoff A, 2015, EUR J CLIN MICROBIOL, V34, P661, DOI 10.1007/s10096 014 2296 3
   Dobrovoiskaia MA, 2008, NANO LETT, V8, P2180, DOI 10.1021/nl0805615
   He QJ, 2015, CRYST GROWTH DES, V15, P723, DOI 10.1021/cg501515c
   Hooper DC, 1999, DRUGS, V58, P6, DOI 10.2165/00003495 199958002 00002
   Hou ZY, 2009, CHEM EUR J, V15, P6973, DOI 10.1002/chem.200900269
   Huang FZ, 2007, J MATER SCI, V42, P8599, DOI 10.1007/s10853 007 1861 x
   Jamwal D, 2015, J PHYS CHEM C, V119, P5062, DOI 10.1021/jp510428z
   Jevtic M, 2008, CRYST GROWTH DES, V8, P2217, DOI 10.1021/cg7007304
   Khan AS, 2008, ACTA BIOMATER, V4, P1275, DOI 10.1016/j.actbio.2008.04.016
   Klinkamnarong J, 2009, SOLID STATE SCI, V11, P1023, DOI 10.1016/j.solidstatesciences.2009.02.003
   Kumar GS, 2014, J MATER CHEM B, V2, P5052, DOI 10.1039/c4tb00339j
   Li JH, 2012, MICROCHIM ACTA, V176, P73, DOI 10.1007/s00604 011 0693 1
   Liang T, 2013, J MATER SCI, V48, P5334, DOI 10.1007/s10853 013 7328 3
   Lin KL, 2014, ACTA BIOMATER, V10, P4071, DOI 10.1016/j.actbio.2014.06.017
   Liu J, 2009, J MATER CHEM, V19, P6073, DOI 10.1039/b900116f
   Liu YK, 2004, MATER CHEM PHYS, V86, P69, DOI 10.1016/j.matchemphys.2004.02.009
   Ma J, 2015, CRYST GROWTH DES, V15, P1273, DOI 10.1021/cg501659x
   Martins MA, 2008, J COLLOID INTERF SCI, V318, P210, DOI 10.1016/j.jcis.2007.10.008
   Matsunaga K, 2010, ACTA BIOMATER, V6, P2289, DOI 10.1016/j.actbio.2009.11.029
   Nandi SK, 2009, MAT SCI ENG C MATER, V29, P2478, DOI 10.1016/j.msec.2009.07.014
   Neira IS, 2009, CRYST GROWTH DES, V9, P466, DOI 10.1021/cg800738a
   Ostomel TA, 2006, SMALL, V2, P1261, DOI 10.1002/smll.200600177
   Ostomel TA, 2006, J AM CHEM SOC, V128, P8384, DOI 10.1021/ja061717a
   Peng Q, 2003, ANGEW CHEM INT EDIT, V42, P3027, DOI 10.1002/anie.200250695
   Pramanik N, 2012, LANGMUIR, V28, P14018, DOI 10.1021/la302066e
   Prouzet E, 2002, J MATER CHEM, V12, P1553, DOI 10.1039/b111236h
   Ramay HRR, 2004, BIOMATERIALS, V25, P5171, DOI 10.1016/j.biomaterials.2003.12.023
   Rejinold NS, 2011, J COLLOID INTERF SCI, V360, P39, DOI 10.1016/j.jcis.2011.04.006
   Roy N, 2012, J PHYS CHEM C, V116, P26551, DOI 10.1021/jp305373w
   Roy N, 2012, J PHYS CHEM C, V116, P8763, DOI 10.1021/jp210835a
   Schaechter M, 1999, MICROBIOL MOL BIOL R, V63, P265, DOI 10.1128/MMBR.63.2.265 265.1999
   Selvakumar M, 2016, ACS APPL MATER INTER, V8, P5941, DOI 10.1021/acsami.6b01014
   Selvakumar M, 2016, ACS APPL MATER INTER, V8, P4086, DOI 10.1021/acsami.5b11723
   Selvakumar M, 2015, ADV POLYM TECH, V34, DOI 10.1002/adv.21467
   Selvakumar M, 2015, J BIOMED NANOTECHNOL, V11, P291, DOI 10.1166/jbn.2015.1975
   Teng SH, 2006, J CRYST GROWTH, V290, P683, DOI 10.1016/j.jcrysgro.2006.02.014
   Toworfe GK, 2006, BIOMATERIALS, V27, P631, DOI 10.1016/j.biomaterials.2005.06.017
   Venkatasubbu GD, 2011, 3 BIOTECH, V1, P173, DOI 10.1007/s13205 011 0021 9
   Wang SF, 2006, LANGMUIR, V22, P398, DOI 10.1021/la0518647
   Wang YM, 2015, CRYST GROWTH DES, V15, P1949, DOI 10.1021/acs.cgd.5b00113
   Wu F, 2015, CRYST GROWTH DES, V15, P2452, DOI 10.1021/acs.cgd.5b00231
   Yang PP, 2008, BIOMATERIALS, V29, P4341, DOI 10.1016/j.biomaterials.2008.07.042
   Yang YS, 2014, CRYST GROWTH DES, V14, P4864, DOI 10.1021/cg501063j
   YOLLES S, 1976, ACTA PHARM SUEC, V13, P32
   Yu T, 2011, ACS NANO, V5, P5717, DOI 10.1021/nn2013904
   Zhang CM, 2009, CRYST GROWTH DES, V9, P2725, DOI 10.1021/cg801353n
   Zhou H, 2011, ACTA BIOMATER, V7, P2769, DOI 10.1016/j.actbio.2011.03.019
   Zhou YY, 2015, INT J NANOMED, V10, P3203, DOI 10.2147/IJN.S79241
   Zhu JJ, 2003, ADV MATER, V15, P156, DOI 10.1002/adma.200390033
NR 53
TC 14
Z9 14
U1 1
U2 51
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1528 7483
EI 1528 7505
J9 CRYST GROWTH DES
JI Cryst. Growth Des.
PD FEB
PY 2017
VL 17
IS 2
BP 433
EP 445
DI 10.1021/acs.cgd.6b01190
PG 13
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Crystallography; Materials Science
GA EJ6UG
UT WOS:000393354100006
DA 2025 08 17
ER

PT J
AU Takahashi, M
   Shima, K
   Tsuchiya, M
   Hagiwara, Y
   Mizoguchi, H
   Sakurada, S
   Sugawara, S
   Fujita, T
   Tadano, T
   Watanabe, M
   Fukumoto, S
   Endo, Y
AF Takahashi, Mebae
   Shima, Kazuhiro
   Tsuchiya, Masahiro
   Hagiwara, Yoshihiro
   Mizoguchi, Hirokazu
   Sakurada, Shinobu
   Sugawara, Shunji
   Fujita, Takuo
   Tadano, Takeshi
   Watanabe, Makoto
   Fukumoto, Satoshi
   Endo, Yasuo
TI Analgesic Effects of 1st Generation Anti histamines in Mice
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE anti histamine; analgesic effect; non steroidal anti inflammatory drug;
   cyproheptadine; pain; histamine H1 receptor
ID PAIN PERCEPTION; HISTAMINE; RECEPTOR; ROLES; MUSCLE; DIPHENHYDRAMINE;
   HYPERALGESIA; PHARMACOLOGY; ANTAGONISTS; MECHANISMS
AB Pain is sensed, transmitted, and modified by a variety of mediators and receptors. Histamine is a well known mediator of pain. In addition to their anti histaminic effects, the classical, or 1st generation, anti histamines (1st AHs) possess, to various degrees, anti muscarinic, anti serotonergic, anti adrenergic, and other pharmacologic effects. Although there have been attempts to use 1st Ails as analgesics and/or analgesic adjuvants, the advent of non steroidal anti inflammatory drugs (NSAIDs) discouraged such trials. We previously reported that in patients with temporomandibular disorders, osteoporosis, and/or osteoarthritis, the analgesic effects of certain 1st AHs (chlorpheniramine and diphenhydramine) are superior to those of the NSAIDs flurbiprofen and indomethacin. Here, we compared analgesic effects among 1st AHs and NSAIDs against responses shown by mice to intraperitoneally injected 0.7% acetic acid. Since 1st Ails are water soluble, we selected water soluble NSAIDs. For direct comparison, drugs were intravenously injected 30min before the above tests. Histamine H1 receptor deficient (H1R KO) mice were used for evaluating 111 receptor independent effects. The tested 1st Ails (especially cyproheptadine) displayed or tended to display analgesic effects comparable to those of NSAIDs in normal and H1R KO mice. Our data suggest that the anti serotonergic and/or anti adrenergic effects of 1st Ails make important contributions to their analgesic effects. Moreover, combination of a 1st AH with an NSAID (cyclooxygenase 1 inhibitor) produced remarkably potent analgesic effects. We propose that a 1st Ail, by itself or in combination with a cyclooxygenase 1 inhibitor, should undergo testing to evaluate its usefulness in analgesia.
C1 [Takahashi, Mebae; Shima, Kazuhiro; Sugawara, Shunji; Endo, Yasuo] Tohoku Univ, Grad Sch Dent, Div Mol Regulat, Sendai, Miyagi 9808575, Japan.
   [Takahashi, Mebae; Fukumoto, Satoshi] Tohoku Univ, Grad Sch Dent, Div Pediat Dent, Sendai, Miyagi 9808575, Japan.
   [Tsuchiya, Masahiro; Watanabe, Makoto] Tohoku Fukushi Univ, Sendai, Miyagi 9818522, Japan.
   [Hagiwara, Yoshihiro] Tohoku Univ, Grad Sch Med, Dept Orthoped Surg, Sendai, Miyagi 9808575, Japan.
   [Mizoguchi, Hirokazu; Sakurada, Shinobu] Tohoku Pharmaceut Univ, Dept Physiol & Anat, Sendai, Miyagi 9818558, Japan.
   [Fujita, Takuo] Katsuragi Hosp, Kishiwada 5960825, Japan.
   [Fujita, Takuo] Calcium Res Inst, Kishiwada 5960825, Japan.
   [Tadano, Takeshi] Kanazawa Univ, Dept Hlth Care Med Res, Venture Business Lab, Kanazawa, Ishikawa 9201192, Japan.
C3 Tohoku University; Tohoku University; Tohoku University; Tohoku Medical
   & Pharmaceutical University; Kanazawa University
RP Endo, Y (通讯作者)，Tohoku Univ, Grad Sch Dent, Div Mol Regulat, Sendai, Miyagi 9808575, Japan.
EM endo@dent.tohoku.ac.jp
RI Tsuchiya, Masahiro/C 5553 2018; TSUCHIYA, MASAHIRO/C 5553 2018
OI Tsuchiya, Masahiro/0000 0002 7000 4547; Fukumoto,
   Satoshi/0000 0002 5046 6891; 
FU Japan Society for the Promotion of Science [23390439, 24390429,
   25670813]; Grants in Aid for Scientific Research [24390429, 23390439,
   25670813, 15K08678, 16K11672] Funding Source: KAKEN
FX We are grateful to Dr. R. Timms (Birmingham, U.K) for editing the
   manuscript, and to Prof. Kazuhiko Yanai and Dr. Takeo Yoshikawa
   (Department of Pharmacology, Tohoku University Graduate School of
   Medicine, Sendai, Japan) for providing H1R KO mice. This study was
   supported by Grants from the Japan Society for the Promotion of Science
   to M. Watanabe (23390439) and M. Tsuchiya (24390429 and 25670813).
CR Apiliogullari S, 2007, EUR J ANAESTH, V24, P235, DOI 10.1017/S026502150600202X
   Bardin L, 2011, BEHAV PHARMACOL, V22, P390, DOI 10.1097/FBP.0b013e328349aae4
   Bezerra MM, 2008, PHARMACOL REP, V60, P339
   Bujalska M, 2008, PHARMACOL REP, V60, P499
   Drummond PD, 2009, EUR J PAIN, V13, P273, DOI 10.1016/j.ejpain.2008.04.008
   Endo Y, 1998, J PHYSIOL LONDON, V509, P587, DOI 10.1111/j.1469 7793.1998.587bn.x
   Farzin D, 2002, PHARMACOL BIOCHEM BE, V72, P751, DOI 10.1016/S0091 3057(02)00748 7
   Fujita T, 2013, PHARMACOLOGY, V92, P158, DOI 10.1159/000354151
   GARRISON J C, 1990, P575
   Gerdle B, 2014, J PAIN RES, V7, P313, DOI 10.2147/JPR.S59144
   Hill SJ, 1997, PHARMACOL REV, V49, P253
   Inoue I, 1996, P NATL ACAD SCI USA, V93, P13316, DOI 10.1073/pnas.93.23.13316
   Kashiba H, 1999, MOL BRAIN RES, V66, P24, DOI 10.1016/S0169 328X(98)00346 5
   Kim S, 2013, EUR J PHARMACOL, V699, P14, DOI 10.1016/j.ejphar.2012.11.031
   Meisner JG, 2007, J PAIN, V8, P556, DOI 10.1016/j.jpain.2007.02.434
   Mobarakeh JI, 2000, EUR J PHARMACOL, V391, P81, DOI 10.1016/S0014 2999(00)00060 1
   Mogil JS, 1999, P NATL ACAD SCI USA, V96, P7744, DOI 10.1073/pnas.96.14.7744
   Morimoto K, 2014, J IMMUNOL, V192, P1130, DOI 10.4049/jimmunol.1300290
   Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780
   Niijima Yaoita F, 2012, BIOL PHARM BULL, V35, P91, DOI 10.1248/bpb.35.91
   Raffa RB, 2001, J CLIN PHARM THER, V26, P81, DOI 10.1046/j.1365 2710.2001.00330.x
   Rudmann DG, 1999, TOXICOL PATHOL, V27, P111, DOI 10.1177/019262339902700121
   RUMORE MM, 1985, LIFE SCI, V36, P403, DOI 10.1016/0024 3205(85)90252 8
   RUMORE MM, 1986, PAIN, V25, P7, DOI 10.1016/0304 3959(86)90004 7
   Tiligada E, 2011, CNS NEUROSCI THER, V17, P620, DOI 10.1111/j.1755 5949.2010.00212.x
   Ueno A, 2001, BIOCHEM PHARMACOL, V62, P157, DOI 10.1016/S0006 2952(01)00654 2
   Viguier F, 2013, EUR J PHARMACOL, V716, P8, DOI 10.1016/j.ejphar.2013.01.074
   Vinegar R., 1979, Handbook of experimental pharmacology, V50, P208
   Watanabe M, 1999, J DENT RES, V78, P769, DOI 10.1177/00220345990780030901
   Yoneda H, 2013, CLIN EXP PHARMACOL P, V40, P848, DOI 10.1111/1440 1681.12167
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304 3959(83)90201 4
NR 31
TC 5
Z9 5
U1 0
U2 10
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 0918 6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD APR
PY 2016
VL 39
IS 4
BP 620
EP 624
DI 10.1248/bpb.b15 00755
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DI1HB
UT WOS:000373246100021
PM 27040636
OA gold
DA 2025 08 17
ER

PT J
AU Jin, S
   Chang, XC
   Wen, J
   Yang, J
   Ao, N
   Zhang, KY
   Suo, LN
   Du, J
AF Jin, Shi
   Chang, Xiao Cen
   Wen, Jing
   Yang, Jing
   Ao, Na
   Zhang, Ke Ying
   Suo, Lin Na
   Du, Jian
TI Decarboxylated osteocalcin, a possible drug for type 2 diabetes,
   triggers glucose uptake in MG63 cells
SO WORLD JOURNAL OF DIABETES
LA English
DT Article
DE Decarboxylated osteocalcin; Osteoblast; Glucose uptake; Glucose
   transporter 1; Type 2 diabetes
ID PROGNOSTIC FACTORS; GENE EXPRESSION; GLA PROTEIN; BETA CELL; BONE;
   OSTEOSARCOMA; TRANSPORTER; METABOLISM; GLUT1; DIFFERENTIATION
AB BACKGROUND
   Uncarboxylated osteocalcin (GluOC) has been reported to improve glucose metabolism, prevent type 2 diabetes, and decrease the severity of obesity in mice with type 2 diabetes. GluOC can increase glucose uptake in a variety of cells. Glucose metabolism is the main source of energy for osteoblast proliferation and differentiation. We hypothesized that decarboxylated osteocalcin (dcOC), a kind of GluOC, can increase glucose uptake in MG63 cells (osteoblast like osteosarcoma cells) and influence their proliferation and differentiation.
   AIM
   To investigate the effects of dcOC on glucose uptake in human osteoblast like osteosarcoma cells and the possible signaling pathways involved. METHODS MG63 cells (human osteoblast like osteosarcoma cells) were treated with dcOC (0, 0.3, 3, 10, or 30 ng/mL) for 1 and 72 h, and glucose uptake was measured by flow cytometry. The effect of dcOC on cell proliferation was measured with a CCK 8 assay, and alkaline phosphatase (ALP) enzyme activity was measured. PI3K was inhibited with LY294002, and hypoxia inducible factor 1 alpha (HIF 1 alpha) was silenced with siRNA. Then, GPRC6A (G protein coupled receptor family C group 6 subtype A), total Akt, phosphorylated Akt, HIF 1 alpha, and glucose transporter 1 (GLUT1) levels were measured by Western blot to elucidate the possible pathways by which dcOC modulates glucose uptake.
   RESULTS
   The glucose uptake of MG63 cells was significantly increased compared with that of the paired control cells after short term (1 h) treatment with dcOC at different concentrations (0.3, 3, and 10 ng/mL groups, P < 0.01; 30 ng/mL group, P < 0.05). Glucose uptake of MG63 cells was significantly increased compared with that of the paired control cells after long term (72 h) treatment with dcOC at different concentrations (0.3, 3, and 10 ng/mL groups, P < 0.01; 30 ng/mL group, P < 0.05). DcOC triggered Akt phosphorylation in a dose dependent manner, and the most effective stimulatory concentration of dcOC for short term (1 h) was 3 ng/mL (P < 0.01). LY294002 abolished the dcOC mediated (1 h) promotion of Akt phosphorylation and glucose uptake without affecting GLUT1 protein expression. Long term dcOC stimulation triggered Akt phosphorylation and increased the protein levels of HIF 1 alpha, GLUT1, and Runx2 in a dose dependent manner. Inhibition of HIF 1 alpha with siRNA abolished the dcOC mediated glucose uptake and substantially decreased GLUT1 protein expression. DcOC intervention promoted cell proliferation in a time  and dose dependent manner as determined by the CCK 8 assay. Treatment with both 3 ng/mL and 10 ng/mL dcOC affected the ALP activity in MG63 cells after 72 h (P < 0.01).
   CONCLUSION
   Short  and long term dcOC treatment can increase glucose uptake and affect proliferation and ALP activity in MG63 cells. This effect may occur through the PI3K/Akt, HIF 1 alpha, and GLUT1 signaling factors.
C1 [Jin, Shi; Chang, Xiao Cen; Wen, Jing; Yang, Jing; Ao, Na; Suo, Lin Na; Du, Jian] China Med Univ, Dept Endocrinol, Affiliated Hosp 4, 4 Chongshan Rd, Shenyang 110032, Liaoning, Peoples R China.
   [Zhang, Ke Ying] Fifth Peoples Hosp Shenyang, Dept Endocrinol, Shenyang 110023, Liaoning, Peoples R China.
C3 China Medical University
RP Du, J (通讯作者)，China Med Univ, Dept Endocrinol, Affiliated Hosp 4, 4 Chongshan Rd, Shenyang 110032, Liaoning, Peoples R China.
EM dujian_1962@163.com
RI Jin, Shi/W 6582 2019; chang, xiaocen/JAZ 0404 2023
FU Provincial Science and Technology Department Natural Fund Guidance
   Project [2019 ZD 0774]; National Natural Science Foundation of China
   [81470998]; Liaoning Ministry of Education [LQNK201715]; Liaoning
   Provincial Doctor Start up Fund [20180540008]
FX Supported by Provincial Science and Technology Department Natural Fund
   Guidance Project, No. 2019 ZD 0774; National Natural Science Foundation
   of China, No. 81470998; Liaoning Ministry of Education, No. LQNK201715;
   and Liaoning Provincial Doctor Start up Fund, No. 20180540008.
CR Askenazi DJ, 2011, PEDIATR RES, V70, P302, DOI 10.1203/PDR.0b013e3182275164
   Bacci G, 2006, CANCER AM CANCER SOC, V106, P1154, DOI 10.1002/cncr.21724
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Booth SL, 2013, NAT REV ENDOCRINOL, V9, P43, DOI 10.1038/nrendo.2012.201
   Chen R, 2019, ONCOTARGETS THER, V12, P9053, DOI 10.2147/OTT.S217324
   Divieti P, 1998, J BONE MINER RES, V13, P1835, DOI 10.1359/jbmr.1998.13.12.1835
   Endo M, 2007, JPN J CLIN ONCOL, V37, P955, DOI 10.1093/jjco/hym125
   Fan JA, 2010, CANCER BIOTHER RADIO, V25, P521, DOI 10.1089/cbr.2010.0784
   Ferrer CM, 2014, MOL CELL, V54, P820, DOI 10.1016/j.molcel.2014.04.026
   Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105
   Ferron M, 2012, BONE, V50, P568, DOI 10.1016/j.bone.2011.04.017
   Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003
   FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217
   Garzotto CK, 2000, J VET INTERN MED, V14, P587, DOI 10.1892/0891 6640(2000)014<0587:PSOSAP>2.3.CO;2
   Griffith CM, 2019, J ALZHEIMERS DIS, V68, P809, DOI 10.3233/JAD 180707
   Guedes JAC, 2018, BONE, V115, P68, DOI 10.1016/j.bone.2017.11.020
   Guo MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090518
   Guo QY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00163 2
   HATANAKA M, 1974, BIOCHIM BIOPHYS ACTA, V355, P77, DOI 10.1016/0304 419X(74)90008 0
   HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990
   Heydarzadeh S, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 020 00586 x
   Hill HS, 2014, HORM METAB RES, V46, P341, DOI 10.1055/s 0034 1368709
   Idelevich A, 2011, ARTERIOSCL THROM VAS, V31, pE55, DOI 10.1161/ATVBAHA.111.230904
   Lacombe J, 2013, MOL METAB, V2, P498, DOI 10.1016/j.molmet.2013.08.004
   Li WL, 2018, J BONE MINER RES, V33, P1183, DOI 10.1002/jbmr.3413
   Lin SS, 2019, HUM CELL, V32, P64, DOI 10.1007/s13577 018 0224 z
   Lin XZ, 2018, CALCIFIED TISSUE INT, V103, P198, DOI 10.1007/s00223 018 0400 x
   Liu JL, 2016, INT J MOL MED, V37, P173, DOI 10.3892/ijmm.2015.2412
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   Liu ZS, 2020, CELL BIOCHEM FUNCT, V38, P87, DOI 10.1002/cbf.3457
   Makinoshima H, 2015, J BIOL CHEM, V290, P17495, DOI 10.1074/jbc.M115.660498
   Molagoda IMN., 2019, BIOMOLECULES, V9
   Neve A, 2013, J CELL PHYSIOL, V228, P1149, DOI 10.1002/jcp.24278
   Pi M, 2005, J BIOL CHEM, V280, P40201, DOI 10.1074/jbc.M505186200
   Pi M, 2011, J BONE MINER RES, V26, P1680, DOI 10.1002/jbmr.390
   Pi M, 2010, J BIOL CHEM, V285, P39953, DOI 10.1074/jbc.M110.158063
   Sadikovic B, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 202
   Schwartzenberg Bar Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008 5472.CAN 03 0846
   Song K, 2014, ASIAN PAC J CANCER P, V15, P1823, DOI 10.7314/APJCP.2014.15.4.1823
   Szulc P, 1996, BONE, V19, P615, DOI 10.1016/S8756 3282(96)00265 7
   Tsuka S, 2015, BIOCHEM BIOPH RES CO, V459, P437, DOI 10.1016/j.bbrc.2015.02.123
   Wang MS, 2014, ANAL BIOANAL CHEM, V406, P4195, DOI 10.1007/s00216 014 7759 y
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Wei JW, 2014, DIABETES, V63, P1021, DOI 10.2337/db13 0887
   Wiernan HL, 2007, MOL BIOL CELL, V18, P1437, DOI 10.1091/mbc.E06 07 0593
   Xie YL, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 13353 9
   Yasutake Y, 2016, AM J PHYSIOL ENDOC M, V310, pE662, DOI 10.1152/ajpendo.00334.2015
   Zaulkffali AS, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102525
   Zhang YC, 2019, INT J CANCER, V145, P1068, DOI 10.1002/ijc.32207
   Zoidis E, 2011, MOL CELL BIOCHEM, V348, P33, DOI 10.1007/s11010 010 0634 z
NR 50
TC 6
Z9 7
U1 0
U2 4
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
EI 1948 9358
J9 WORLD J DIABETES
JI World J. Diabetes
PD JUL 15
PY 2021
VL 12
IS 7
BP 1102
EP 1115
DI 10.4239/wjd.v12.i7.1102
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA TQ9SH
UT WOS:000678615000014
PM 34326958
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Dudakovic, A
   Camilleri, E
   Riester, SM
   Lewallen, EA
   Kvasha, S
   Chen, XY
   Radel, DJ
   Anderson, JM
   Nair, AA
   Evans, JM
   Krych, AJ
   Smith, J
   Deyle, DR
   Stein, JL
   Stein, GS
   Im, HJ
   Cool, SM
   Westendorf, JJ
   Kakar, S
   Dietz, AB
   van Wijnen, AJ
AF Dudakovic, Amel
   Camilleri, Emily
   Riester, Scott M.
   Lewallen, Eric A.
   Kvasha, Sergiy
   Chen, Xiaoyue
   Radel, Darcie J.
   Anderson, Jarett M.
   Nair, Asha A.
   Evans, Jared M.
   Krych, Aaron J.
   Smith, Jay
   Deyle, David R.
   Stein, Janet L.
   Stein, Gary S.
   Im, Hee Jeong
   Cool, Simon M.
   Westendorf, Jennifer J.
   Kakar, Sanjeev
   Dietz, Allan B.
   van Wijnen, Andre J.
TI High Resolution Molecular Validation of Self Renewal and Spontaneous
   Differentiation in Clinical Grade Adipose Tissue Derived Human
   Mesenchymal Stem Cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE MESENCHYMAL STEM CELL; ADIPOSE TISSUE DERIVED STROMAL CELLS;
   PLURIPOTENT; MULTIPOTENT; CELL CYCLE; LINEAGE COMMITMENT; FIBROBLAST;
   OSTEOGENESIS; CHONDROGENESIS; ADIPOGENESIS; HISTONE; CYCLIN;
   EXTRACELLULAR MATRIX; CD44; CD73; NT5E; CD90; THY1; CD105; ENG; NES;
   ACTA2; OCT4; POU5F1; NANOG; KLF4; CCND1; CCNB2; HIST1H3H; HIST1H4A;
   HIST2H4A; HIST2H4B; E2F1; E2F7; E2F8; HINFP; NPAT; ASPN; ECM2; FMOD;
   OGN; PODN; WISP2; SFRP2; SFRP4; WNT2; WNT2A; WNT5A; WNT5B; WNT7B;
   RARRES2; TNNT3; ADH1B; H19; CHI3L1
ID HUMAN PLATELET LYSATE; FETAL BOVINE SERUM; STROMAL CELLS; CULTURE;
   EXPANSION; BONE; EXPRESSION; SCAFFOLDS; ALTERNATIVES; CARTILAGE
AB Improving the effectiveness of adipose tissue derived human mesenchymal stromal/stem cells (AMSCs) for skeletal therapies requires a detailed characterization of mechanisms supporting cell proliferation and multi potency. We investigated the molecular phenotype of AMSCs that were either actively proliferating in platelet lysate or in a basal non proliferative state. Flow cytometry combined with high throughput RNA sequencing (RNASeq) and RT qPCR analyses validate that AMSCs express classic mesenchymal cell surface markers (e.g., CD44, CD73/NT5E, CD90/THY1, and CD105/ENG). Expression of CD90 is selectively elevated at confluence. Self renewing AMSCs express a standard cell cycle program that successively mediates DNA replication, chromatin packaging, cyto architectural enlargement, and mitotic division. Confluent AMSCs preferentially express genes involved in extracellular matrix (ECM) formation and cellular communication. For example, cell cycle related biomarkers (e.g., cyclins E2 and B2, transcription factor E2F1) and histone related genes (e.g., H4, HINFP, NPAT) are elevated in proliferating AMSCs, while ECM genes are strongly upregulated (>10 fold) in quiescent AMSCs. AMSCs also express pluripotency genes (e.g., POU5F1, NANOG, KLF4) and early mesenchymal markers (e.g., NES, ACTA2) consistent with their multipotent phenotype. Strikingly, AMSCs modulate expression of WNT signaling components and switch production of WNT ligands (from WNT5A/WNT5B/WNT7B to WNT2/WNT2B), while upregulating WNT related genes (WISP2, SFRP2, and SFRP4). Furthermore, post proliferative AMSCs spontaneously express fibroblastic, osteogenic, chondrogenic, and adipogenic biomarkers when maintained in confluent cultures. Our findings validate the biological properties of self renewing and multi potent AMSCs by providing high resolution quality control data that support their clinical versatility. (C) 2014 Wiley Periodicals, Inc.
C1 [Dudakovic, Amel; Camilleri, Emily; Riester, Scott M.; Lewallen, Eric A.; Kvasha, Sergiy; Chen, Xiaoyue; Krych, Aaron J.; Westendorf, Jennifer J.; Kakar, Sanjeev; van Wijnen, Andre J.] Mayo Clin, Dept Orthoped Surg, Rochester, MN 55901 USA.
   [Radel, Darcie J.; Anderson, Jarett M.; Dietz, Allan B.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55901 USA.
   [Nair, Asha A.; Evans, Jared M.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55901 USA.
   [Nair, Asha A.; Evans, Jared M.] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN 55901 USA.
   [Smith, Jay] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN 55901 USA.
   [Deyle, David R.] Mayo Clin, Dept Med Genet, Rochester, MN 55901 USA.
   [Stein, Janet L.; Stein, Gary S.] Univ Vermont, Sch Med, Vermont Canc Ctr Basic & Translat Res, Dept Biochem, Burlington, VT 05405 USA.
   [Im, Hee Jeong] Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA.
   [Cool, Simon M.] Natl Univ Singapore, A STAR, Inst Med Biol, Singapore 117548, Singapore.
   [Westendorf, Jennifer J.; van Wijnen, Andre J.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55901 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo
   Clinic; University of Vermont; Rush University; National University of
   Singapore; Agency for Science Technology & Research (A*STAR); A*STAR  
   Institute of Medical Biology (IMB); Mayo Clinic
RP van Wijnen, AJ (通讯作者)，Mayo Clin, Dept Orthoped Surg, 200 1st St SW, Rochester, MN 55901 USA.
EM vanwijnen.andre@mayo.edu
RI ; Riester, Scott/K 7032 2015; van Wijnen, Andre/AAG 3578 2019; Cool,
   Simon/W 1257 2018; Dietz, Allan/AAI 6976 2021; Dietz, Allan/H 7414 2015
OI Cool, Simon/0000 0001 8543 3056; Dudakovic, Amel/0000 0002 8850 3977;
   Krych, Aaron/0000 0003 3248 8007; Camilleri, Emily/0000 0001 8982 6770;
   van Wijnen, Andre J./0000 0002 4458 0946; Lewallen,
   Eric/0000 0002 0777 7336; Dietz, Allan/0000 0003 3410 9621
FU Center of Regenerative Medicine at Mayo Clinic; NIH R01 [AR049069, R01
   DE020194, R01 CA139322]; Patrick J. Kelly Research Fellowship Kelly
   Fellowship award; American Hand Society; National Center for Advancing
   Translational Sciences [UL1 TR000135]
FX Grant sponsor: Center of Regenerative Medicine at Mayo Clinic and NIH
   R01; Grant numbers: AR049069, R01 DE020194, R01 CA139322; Grant sponsor:
   Patrick J. Kelly Research Fellowship Kelly Fellowship award; Grant
   sponsor: American Hand Society and the National Center for Advancing
   Translational Sciences; Grant number: UL1 TR000135.
CR Apostolou E, 2013, NATURE, V502, P462, DOI 10.1038/nature12749
   Becker KA, 2010, J CELL PHYSIOL, V222, P456, DOI 10.1002/jcp.21967
   Becker KA, 2006, J CELL PHYSIOL, V209, P883, DOI 10.1002/jcp.20776
   Becker KA, 2007, J CELL PHYSIOL, V210, P517, DOI 10.1002/jcp.20903
   Ben Azouna N, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt97
   Bieback K, 2009, STEM CELLS, V27, P2331, DOI 10.1002/stem.139
   Bourin P, 2013, CYTOTHERAPY, V15, P641, DOI 10.1016/j.jcyt.2013.02.006
   Cawston TE, 2010, CELL TISSUE RES, V339, P221, DOI 10.1007/s00441 009 0887 6
   Cholewa D, 2011, CELL TRANSPLANT, V20, P1409, DOI 10.3727/096368910X557218
   Crespo Diaz R, 2011, CELL TRANSPLANT, V20, P797, DOI 10.3727/096368910X543376
   Fekete N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043255
   Hildner F, 2015, J TISSUE ENG REGEN M, V9, P808, DOI 10.1002/term.1649
   Iudicone P, 2014, J TRANSL MED, V12, DOI 10.1186/1479 5876 12 28
   Jääger K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038833
   Jung S, 2012, BIOTECHNOL APPL BIOC, V59, P106, DOI 10.1002/bab.1006
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb 2013 14 4 r36
   Kinzebach S, 2013, ADV BIOCHEM ENG BIOT, V129, P33, DOI 10.1007/10_2012_134
   Kolle SFT, 2013, CYTOTHERAPY, V15, P1086, DOI 10.1016/j.jcyt.2013.01.217
   Lange C, 2012, EXP CELL RES, V318, P2284, DOI 10.1016/j.yexcr.2012.06.004
   Leotot J, 2013, ACTA BIOMATER, V9, P6630, DOI 10.1016/j.actbio.2013.02.003
   Lohmann M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037839
   Ma B, 2013, CALCIFIED TISSUE INT, V92, P399, DOI 10.1007/s00223 012 9675 5
   Mader EK, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 20
   Mafi P, 2012, CURR STEM CELL RES T, V7, P302, DOI 10.2174/157488812800793045
   Menard C, 2013, STEM CELLS DEV, V22, P1789, DOI 10.1089/scd.2012.0594
   Pawitan JA, 2012, CURR STEM CELL RES T, V7, P329
   Rider DA, 2008, STEM CELLS, V26, P1598, DOI 10.1634/stemcells.2007 0480
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Santo VE, 2012, J CONTROL RELEASE, V162, P19, DOI 10.1016/j.jconrel.2012.06.001
   Schallmoser Katharina, 2013, Methods Mol Biol, V946, P349, DOI 10.1007/978 1 62703 128 8_22
   Shih DTB, 2011, TRANSFUSION, V51, P770, DOI 10.1111/j.1537 2995.2010.02915.x
   Siciliano C., 2013, CYTOTECHNOLOGY
   Tokunaga M, 2014, MATRIX BIOL, V36, P28, DOI 10.1016/j.matbio.2014.03.005
   Torensma R, 2013, STEM CELLS DEV, V22, P1086, DOI 10.1089/scd.2012.0384
   Walenda G, 2012, TISSUE ENG PART C ME, V18, P924, DOI [10.1089/ten.tec.2011.0541, 10.1089/ten.TEC.2011.0541]
   Warnke PH, 2013, J CRANIO MAXILL SURG, V41, P153, DOI 10.1016/j.jcms.2012.07.003
   Witzeneder K, 2013, TRANSFUS MED HEMOTH, V40, P417, DOI 10.1159/000356236
   Wu L, 2012, TISSUE ENG PT A, V18, P1542, DOI [10.1089/ten.tea.2011.0715, 10.1089/ten.TEA.2011.0715]
   Wu L, 2013, J CELL PHYSIOL, V228, P938, DOI 10.1002/jcp.24255
   Zhang J, 2012, J BONE MINER RES, V27, P2065, DOI 10.1002/jbmr.1661
NR 40
TC 139
Z9 150
U1 0
U2 59
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD OCT
PY 2014
VL 115
IS 10
BP 1816
EP 1828
DI 10.1002/jcb.24852
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AN5XF
UT WOS:000340664800020
PM 24905804
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Gu, JF
   Liu, XL
   Cui, P
   Yi, XS
AF Gu, Jiafei
   Liu, Xiaoling
   Cui, Ping
   Yi, Xiaosu
TI Multifunctional bioactive glasses with spontaneous degradation for
   simultaneous osteosarcoma therapy and bone regeneration
SO BIOMATERIALS ADVANCES
LA English
DT Article
DE Phosphate glass; Bioactive glass; Transition metal element; Photothermal
   therapy; Degradation
ID OF THE ART; PHOTOTHERMAL ABLATION; IRON; NANOPARTICLES; NANOCRYSTALS;
   MECHANISM; AGENT; BIOCOMPATIBILITY; OSTEOBLAST; SCAFFOLDS
AB For the treatment of tumor related bone defects resulting from surgical resection, simultaneous eradication of residual tumor cells and repair of bone defects represent a challenge. To date, photothermal therapy based on photothermal materials is used to remove residual tumor cells under near infrared light. However, most of photothermal materials have no function for bone repair, and even if combined with bioactive materials to enhance osteogenesis, they still cause potential harm to the body due to inability to degrade or poor degradability. Herein, multifunctional bioactive glasses (PGFe5 1100, PGCu5 1100) based on phosphate glass doped with transition metal elements were prepared for photothermal ablation, bone regeneration, and controllable degradation. The glasses exhibited excellent photothermal effect, which was derived from the electron in band transition after light absorption due to energy level splitting of doped transition metal element and the subsequent electron nonradiative relaxation. The photothermal performance can be controlled by laser power density, element doping content and glass melting temperature. Moreover, the hyperthermia induced by the glasses can effectively kill tumor cells in vitro. In addition, the glasses degraded over time, and the released P, Ca, Na, Fe could promote bone cell proliferation and osteogenic differentiation. Therefore, these results successfully demonstrated that transition metal element doped phosphate glasses have multifunctional abilities of tumor elimination, bone regeneration, and spontaneous degradation simultaneously with better biosecurity and bioactivity, which is believed to pave the way for the design of novel biomaterials for osteosarcoma treatment.
C1 [Gu, Jiafei] Univ Nottingham Ningbo China, New Mat Inst, Ningbo 315100, Peoples R China.
   [Liu, Xiaoling; Cui, Ping; Yi, Xiaosu] Univ Nottingham Ningbo China, Fac Sci & Engn, Ningbo 315100, Peoples R China.
   [Liu, Xiaoling] Univ Nottingham Ningbo China, Dept Mech Mat & Mfg Engn, 199 Taikang Rd, Ningbo 315100, Peoples R China.
C3 University of Nottingham Ningbo China; University of Nottingham Ningbo
   China; University of Nottingham Ningbo China
RP Liu, XL (通讯作者)，Univ Nottingham Ningbo China, Dept Mech Mat & Mfg Engn, 199 Taikang Rd, Ningbo 315100, Peoples R China.
EM Xiaoling.Liu@nottingham.edu.cn
RI Liu, Xiaoling/GOP 2732 2022
FU New Materials Institute (NMI) PhD Scholarship
FX The authors would like to acknowledge New Materials Institute (NMI) PhD
   Scholarship for funding support.
CR Abbaspour N, 2014, J RES MED SCI, V19, P164
   Abou Neel EA, 2005, BIOMATERIALS, V26, P2247, DOI 10.1016/j.biomaterials.2004.07.024
   Abou Neel EA, 2009, J MATER CHEM, V19, P690, DOI 10.1039/b810675d
   Abou Neel EA, 2008, ACTA BIOMATER, V4, P523, DOI 10.1016/j.actbio.2007.11.007
   Ahmed I, 2004, BIOMATERIALS, V25, P3223, DOI 10.1016/j.biomaterials.2003.10.013
   Azevedo MM, 2010, J MATER CHEM, V20, P8854, DOI 10.1039/c0jm01111h
   Bai JC, 2021, J NON CRYST SOLIDS, V557, DOI 10.1016/j.jnoncrysol.2020.120573
   Bose S, 2013, MATER TODAY, V16, P496, DOI 10.1016/j.mattod.2013.11.017
   Chen ZG, 2013, ADV MATER, V25, P2095, DOI 10.1002/adma.201204616
   Cheng L, 2014, CHEM REV, V114, P10869, DOI 10.1021/cr400532z
   Colquhoun R, 2016, BIOMED MATER, V11, DOI 10.1088/1748 6041/11/1/014105
   Cortizo AM, 2006, INT J BIOCHEM CELL B, V38, P1171, DOI 10.1016/j.biocel.2005.12.007
   Czarnecka AM, 2020, CANCERS, V12, DOI 10.3390/cancers12082130
   Dang WT, 2018, BIOMATERIALS, V160, P92, DOI 10.1016/j.biomaterials.2017.11.020
   Dermience M, 2015, J TRACE ELEM MED BIO, V32, P86, DOI 10.1016/j.jtemb.2015.06.005
   Gao FC, 2021, MATER CHEM FRONT, V5, P5257, DOI 10.1039/d1qm00402f
   Gérard C, 2010, BIOMATERIALS, V31, P824, DOI 10.1016/j.biomaterials.2009.10.009
   Guo W, 2017, CHEM MATER, V29, P9262, DOI 10.1021/acs.chemmater.7b03241
   Gupta N, 2018, COLLOID SURFACE A, V538, P393, DOI 10.1016/j.colsurfa.2017.11.023
   Heck RK, 2006, CA CANCER J CLIN, V56, P366, DOI 10.3322/canjclin.56.6.366
   Hessel CM, 2011, NANO LETT, V11, P2560, DOI 10.1021/nl201400z
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   Hossain KMZ, 2014, Hot Topics in Biomaterials, V1st, P104, DOI [10.4155/ebo.13.352, DOI 10.4155/EBO.13.352]
   Hou YJ, 2020, INT J NANOMED, V15, P6827, DOI 10.2147/IJN.S269321
   Huang XH, 2010, METHODS MOL BIOL, V624, P343, DOI 10.1007/978 1 60761 609 2_23
   Huang XQ, 2011, NAT NANOTECHNOL, V6, P28, DOI [10.1038/nnano.2010.235, 10.1038/NNANO.2010.235]
   Ingle AP, 2014, APPL MICROBIOL BIOT, V98, P1001, DOI 10.1007/s00253 013 5422 8
   Islam MT, 2017, J TISSUE ENG, V8, DOI [10.1177/2041731417719170, 10.3329/jesnr.v8i1.24620]
   Jaque D, 2014, NANOSCALE, V6, P9494, DOI 10.1039/c4nr00708e
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Laizé V, 2009, CELL MOL LIFE SCI, V66, P3831, DOI 10.1007/s00018 009 0137 9
   Lakhkar NJ, 2012, ACTA BIOMATER, V8, P4181, DOI 10.1016/j.actbio.2012.07.023
   Lapa A, 2020, ADV APPL CERAM, V119, P1, DOI 10.1080/17436753.2018.1564413
   Le Q. H., 2019, Journal of Non Crystalline Solids: X, V4, DOI 10.1016/j.nocx.2019.100037
   Levesque JP, 2013, NAT MED, V19, P669, DOI 10.1038/nm.3231
   Lima Sousa R, 2020, MAT SCI ENG C MATER, V117, DOI 10.1016/j.msec.2020.111294
   Liu XW, 2011, BIOMATERIALS, V32, P144, DOI 10.1016/j.biomaterials.2010.08.096
   Liu YL, 2013, ADV MATER, V25, P1353, DOI 10.1002/adma.201204683
   Liu YQ, 2018, ACTA BIOMATER, V73, P531, DOI 10.1016/j.actbio.2018.04.014
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Mandal AK, 2015, MATER RES BULL, V63, P141, DOI 10.1016/j.materresbull.2014.11.052
   Mandal B, 2016, J NON CRYST SOLIDS, V450, P12, DOI 10.1016/j.jnoncrysol.2016.07.028
   Messer JG, 2009, BONE, V45, P972, DOI 10.1016/j.bone.2009.07.073
   Mulligan AM, 2003, BIOMATERIALS, V24, P1797, DOI 10.1016/S0142 9612(02)00577 X
   Pattani VP, 2012, LASER SURG MED, V44, P675, DOI 10.1002/lsm.22072
   Raina DB, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc1779
   Reichert JC, 2009, BIOMATERIALS, V30, P2149, DOI 10.1016/j.biomaterials.2008.12.050
   Robinson JT, 2010, NANO RES, V3, P779, DOI 10.1007/s12274 010 0045 1
   Roseti L, 2017, MAT SCI ENG C MATER, V78, P1246, DOI 10.1016/j.msec.2017.05.017
   Sharmin N, 2016, J MECH BEHAV BIOMED, V59, P41, DOI 10.1016/j.jmbbm.2015.12.011
   Shi HS, 2019, APPL MATER TODAY, V15, P100, DOI 10.1016/j.apmt.2019.01.002
   Tang SH, 2014, SMALL, V10, P3139, DOI 10.1002/smll.201303631
   Tian QW, 2011, ACS NANO, V5, P9761, DOI 10.1021/nn203293t
   Vitale Brovarone C, 2012, ACTA BIOMATER, V8, P1125, DOI 10.1016/j.actbio.2011.11.018
   Wang H, 2020, CHEM ENG J, V396, DOI 10.1016/j.cej.2020.125081
   Wang LT, 2022, NANO TODAY, V43, DOI 10.1016/j.nantod.2022.101401
   Wei WF, 2019, MAT SCI ENG C MATER, V104, DOI 10.1016/j.msec.2019.109891
   Westhauser F, 2021, BIOMATERIALS, V275, DOI 10.1016/j.biomaterials.2021.120977
   Wu CT, 2012, BIOMATERIALS, V33, P2076, DOI 10.1016/j.biomaterials.2011.11.042
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Wubneh A, 2018, ACTA BIOMATER, V80, P1, DOI 10.1016/j.actbio.2018.09.031
   Xia YN, 2011, ACCOUNTS CHEM RES, V44, P914, DOI 10.1021/ar200061q
   Yang J, 2011, ANGEW CHEM INT EDIT, V50, P441, DOI 10.1002/anie.201005075
   Yang Q, 2011, J BONE MINER RES, V26, P1188, DOI 10.1002/jbmr.337
   Yang T, 2017, ACS NANO, V11, P1848, DOI 10.1021/acsnano.6b07866
   Yu J, 2010, J AM CHEM SOC, V132, P1929, DOI 10.1021/ja908139y
   Zhai D, 2017, J MATER CHEM B, V5, P7297, DOI 10.1039/c7tb01931a
   Zhang EL, 2015, MAT SCI ENG C MATER, V46, P148, DOI 10.1016/j.msec.2014.10.021
   Zhao PP, 2020, CHEM ENG J, V381, DOI 10.1016/j.cej.2019.122694
   Zheng K, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00497
NR 70
TC 10
Z9 10
U1 6
U2 31
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2772 9508
J9 BIOMATER ADV
JI Biomater. Adv.
PD NOV
PY 2023
VL 154
AR 213626
DI 10.1016/j.bioadv.2023.213626
EA SEP 2023
PG 13
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA T4GI8
UT WOS:001077584600001
PM 37722164
DA 2025 08 17
ER

PT J
AU Miyabe, Y
   Miyabe, C
   Iwai, Y
   Takayasu, A
   Fukuda, S
   Yokoyama, W
   Nagai, J
   Jona, M
   Tokuhara, Y
   Ohkawa, R
   Albers, HM
   Ovaa, H
   Aoki, J
   Chun, J
   Yatomi, Y
   Ueda, H
   Miyasaka, M
   Miyasaka, N
   Nanki, T
AF Miyabe, Yoshishige
   Miyabe, Chie
   Iwai, Yoshiko
   Takayasu, Aiko
   Fukuda, Shin
   Yokoyama, Waka
   Nagai, Jun
   Jona, Masahiro
   Tokuhara, Yasunori
   Ohkawa, Ryunosuke
   Albers, Harald M.
   Ovaa, Huib
   Aoki, Junken
   Chun, Jerold
   Yatomi, Yutaka
   Ueda, Hiroshi
   Miyasaka, Masayuki
   Miyasaka, Nobuyuki
   Nanki, Toshihiro
TI Necessity of Lysophosphatidic Acid Receptor 1 for Development of
   Arthritis
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID RHEUMATOID ARTHRITIS; AUTOTAXIN; EXPRESSION; FIBROBLAST; INDUCTION;
   SYNOVIOCYTES; MARKER; GROWTH; CELLS; GENE
AB Objective. Lysophosphatidic acid (LPA) is a bioactive lipid that binds to a group of cell surface G protein coupled receptors (LPA receptors 1 6 [LPA(1 6)]) and has been implicated as an important mediator of angiogenesis, inflammation, and cancer growth. This study was undertaken to analyze the effects of LPA(1) on the development of arthritis.
   Methods. Expression of LPA receptors on synovial tissue was analyzed by immunohistochemistry and quantitative reverse transcription polymerase chain reaction. The effects of abrogation of LPA(1) on collagen induced arthritis (CIA) were evaluated using LPA(1) deficient mice or LPA(1) antagonist. Migrating fluorescence labeled CD11b+ splenocytes, which were transferred into the synovium of mice with CIA, were counted. CD4+ naive T cells were incubated under Th1 , Th2 , or Th17 polarizing conditions, and T helper cell differentiation was assessed. Osteoclast formation from bone marrow cells was examined.
   Results. LPA(1) was highly expressed in the synovium of patients with rheumatoid arthritis (RA) compared with that of patients with osteoarthritis. LPA(1) deficient mice did not develop arthritis following immunization with type II collagen (CII). LPA(1) antagonist also ameliorated murine CIA. Abrogation of LPA(1) was associated with reductions in cell infiltration, bone destruction in the joints, and interleukin 17 production from CII stimulated splenocytes. Infiltration of transferred CD11b+ macrophages from LPA(1) deficient mice into the synovium was suppressed compared with infiltration of macrophages from wild type mice. LPA(1) antagonist inhibited the infiltration of macrophages from wild type mice. Differentiation into Th17, but not Th1 or Th2, and osteoclast formation were also suppressed under conditions of LPA(1) deficiency or LPA(1) inhibition in vitro.
   Conclusion. Collectively, these results indicate that LPA/LPA(1) signaling contributes to the development of arthritis via cellular infiltration, Th17 differentiation, and osteoclastogenesis. Thus, LPA(1) may be a promising target molecule for RA therapy.
C1 [Miyabe, Yoshishige; Miyabe, Chie; Iwai, Yoshiko; Takayasu, Aiko; Fukuda, Shin; Yokoyama, Waka; Miyasaka, Nobuyuki; Nanki, Toshihiro] Tokyo Med & Dent Univ, Tokyo, Japan.
   [Miyabe, Chie] Tokyo Med Univ, Tokyo 1608402, Japan.
   [Nagai, Jun; Ueda, Hiroshi] Nagasaki Univ, Nagasaki 852, Japan.
   [Jona, Masahiro; Tokuhara, Yasunori; Ohkawa, Ryunosuke; Yatomi, Yutaka] Univ Tokyo, Tokyo, Japan.
   [Albers, Harald M.; Ovaa, Huib] Netherlands Canc Inst, Amsterdam, Netherlands.
   [Aoki, Junken] Tohoku Univ, Sendai, Miyagi 980, Japan.
   [Chun, Jerold] Scripps Res Inst, La Jolla, CA 92037 USA.
   [Miyasaka, Masayuki] Osaka Univ, Osaka, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Tokyo Medical University; Nagasaki University; University of Tokyo;
   Netherlands Cancer Institute; Tohoku University; Scripps Research
   Institute; University of Osaka
RP Nanki, T (通讯作者)，Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Med & Rheumatol, Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138519, Japan.
EM nanki.rheu@tmd.ac.jp
RI ; Ohkawa, Ryunosuke/C 5402 2017; Miyasaka, Masayuki/AAM 6343 2020; Chun,
   Jerold/Y 4670 2019; Miyabe, Yoshishige/AAR 5419 2021; ovaa,
   huib/M 2334 2016
OI Aoki, Junken/0000 0001 9435 1896; Ueda, Hiroshi/0000 0002 8002 0137;
   Ohkawa, Ryunosuke/0000 0002 8584 133X; Tokuhara,
   Yasunori/0000 0002 8322 2543; Iwai, Yoshiko/0000 0001 6103 3576; Yatomi,
   Yutaka/0000 0003 1719 4297; Nagai, Jun/0000 0003 4720 5065; ovaa,
   huib/0000 0002 0068 054X
FU Japan Society for the Promotion of Science (Global Center of
   Excellence); Takeda Science Foundation; Amira Pharmaceuticals;
   Grants in Aid for Scientific Research [24790576, 23591435, 24111001,
   24111005] Funding Source: KAKEN
FX Supported in part by the Japan Society for the Promotion of Science
   (Global Center of Excellence Program grant to the International Research
   Center for Molecular Science in Tooth and Bone Diseases at Tokyo Medical
   and Dental University), and the Takeda Science Foundation.Dr. Chun has
   received consulting fees, speaking fees, and/or honoraria from Amira
   Pharmaceuticals (less than $ 10,000) and owns stock or stock options in
   Amira Pharmaceuticals.
CR Afzali B, 2007, CLIN EXP IMMUNOL, V148, P32, DOI 10.1111/j.1365 2249.2007.03356.x
   Aletaha D, 2010, ARTHRITIS RHEUM US, V62, P2569, DOI 10.1002/art.27584
   [Anonymous], 2012, CURR OPIN RHEUMATOL, V24, P319
   Aoki J, 2004, SEMIN CELL DEV BIOL, V15, P477, DOI 10.1016/j.semcdb.2004.05.001
   Boucharaba A, 2006, P NATL ACAD SCI USA, V103, P9643, DOI 10.1073/pnas.0600979103
   Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384
   David M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009741
   Fotopoulou S, 2010, DEV BIOL, V339, P451, DOI 10.1016/j.ydbio.2010.01.007
   Furuzawa Carballeda J, 2007, AUTOIMMUN REV, V6, P169, DOI 10.1016/j.autrev.2006.10.002
   Harigai M, 2007, NEW ENGL J MED, V357, P1874, DOI 10.1056/NEJMc070728
   Hirota K, 2007, J EXP MED, V204, P41, DOI 10.1084/jem.20062259
   Hot A, 2011, ANN RHEUM DIS, V70, P341, DOI 10.1136/ard.2010.132233
   Houben AJS, 2011, CANCER METAST REV, V30, P557, DOI 10.1007/s10555 011 9319 7
   Inglis JJ, 2008, NAT PROTOC, V3, P612, DOI 10.1038/nprot.2008.19
   Ishii S, 2009, PROSTAG OTH LIPID M, V89, P57, DOI 10.1016/j.prostaglandins.2009.06.001
   Kehlen A, 2001, CLIN EXP IMMUNOL, V123, P147, DOI 10.1046/j.1365 2249.2001.01432.x
   Kinne RW, 2000, ARTHRITIS RES, V2, P189, DOI 10.1186/ar86
   Komano Y, 2011, J RHEUMATOL, V38, P1258, DOI 10.3899/jrheum.101009
   LaCamera P, 2008, NAT MED, V14, P45
   Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027
   Maeda S., 2012, International Journal of Rheumatology
   Masuda A, 2008, BRIT J HAEMATOL, V143, P60, DOI 10.1111/j.1365 2141.2008.07325.x
   Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173
   Nakamura K, 2008, CLIN CHIM ACTA, V388, P51, DOI 10.1016/j.cca.2007.10.005
   Nakamura K, 2007, ANN CLIN BIOCHEM, V44, P549, DOI 10.1258/000456307782268147
   Nanki T, 2004, J IMMUNOL, V173, P7010, DOI 10.4049/jimmunol.173.11.7010
   Nikitopoulou I, 2012, J EXP MED, V209, P923, DOI 10.1084/jem.20112012
   Nishikaw K, 2010, P NATL ACAD SCI USA, V107, P3117, DOI 10.1073/pnas.0912779107
   Nochi H, 2008, J IMMUNOL, V181, P5111, DOI 10.4049/jimmunol.181.7.5111
   Okamoto K, 2010, NATURE, V464, P1381, DOI 10.1038/nature08922
   Ritchlin C, 2000, ARTHRITIS RES, V2, P356, DOI 10.1186/ar112
   Sato A, 2010, MOD RHEUMATOL, V20, P244, DOI 10.1007/s10165 009 0265 y
   Schleicher SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022182
   Takeuchi T, 2009, MOD RHEUMATOL, V19, P478, DOI 10.1007/s10165 009 0195 8
   Tanaka M, 2006, J BIOL CHEM, V281, P25822, DOI 10.1074/jbc.M605142200
   Umezu Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026
   Watanabe K, 2010, ARTHRITIS RHEUM US, V62, P3211, DOI 10.1002/art.27650
   Xu XY, 2010, CANCER AM CANCER SOC, V116, P1739, DOI 10.1002/cncr.24907
   Yang AH, 2002, BBA MOL CELL BIOL L, V1582, P197, DOI 10.1016/S1388 1981(02)00172 5
   Zhao CQ, 2008, MOL PHARMACOL, V73, P587, DOI 10.1124/mol.107.038216
NR 40
TC 69
Z9 73
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
EI 1529 0131
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD AUG
PY 2013
VL 65
IS 8
BP 2037
EP 2047
DI 10.1002/art.37991
PG 11
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 190HD
UT WOS:000322329100013
PM 23666827
DA 2025 08 17
ER

PT J
AU Vogt, BJ
   Peters, DK
   Anseth, KS
   Aguado, BA
AF Vogt, Brandon J.
   Peters, Douglas K.
   Anseth, Kristi S.
   Aguado, Brian A.
TI Inflammatory serum factors from aortic valve stenosis patients modulate
   sex differences in valvular myofibroblast activation and osteoblast like
   differentiation
SO BIOMATERIALS SCIENCE
LA English
DT Article
ID X CHROMOSOME INACTIVATION; CYSTATIN C CONCENTRATION; ANNEXIN A2;
   REPLACEMENT; DISEASE; EXPRESSION; CALCIFICATION; METAANALYSIS;
   FIBROBLASTS; MACROPHAGES
AB Aortic valve stenosis (AVS) is a sexually dimorphic cardiovascular disease that is driven by fibrosis and calcification of the aortic valve leaflets. Circulating inflammatory factors present in serum from AVS patients contribute to sex differences in valve fibro calcification by driving the activation of valvular interstitial cells (VICs) to myofibroblasts and/or osteoblast like cells. However, the molecular mechanisms by which inflammatory factors contribute to sex specific valve fibro calcification remain largely unknown. In this study, we identified inflammatory factors present in serum samples from AVS patients that regulate sex specific myofibroblast activation and osteoblast like differentiation. After correlating serum proteomic datasets with clinical and in vitro myofibroblast datasets, we identified annexin A2 and cystatin C as candidate inflammatory factors that correlate with both AVS patient severity and myofibroblast activation measurements in vitro. Validation experiments utilizing hydrogel biomaterials as cell culture platforms that mimic the valve extracellular matrix confirmed that annexin A2 and cystatin C promote sex specific VIC activation to myofibroblasts via p38 MAPK signaling. Additionally, annexin A2 and cystatin C increase osteoblast like differentiation primarily in male VICs. Our results implicate serum inflammatory factors as potential AVS biomarkers that also contribute to sexually dimorphic AVS progression by driving VIC myofibroblast activation and/or osteoblast like differentiation. Collectively, the results herein further our overall understanding as to how biological sex may impact inflammation driven AVS and may lead to the development of sex specific drug treatment strategies.
C1 [Vogt, Brandon J.; Aguado, Brian A.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
   [Vogt, Brandon J.; Aguado, Brian A.] Sanford Consortium Regenerat Med, La Jolla, CA 92037 USA.
   [Vogt, Brandon J.; Anseth, Kristi S.] Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80303 USA.
   [Peters, Douglas K.; Anseth, Kristi S.] Univ Colorado, BioFrontiers Inst, Boulder, CO 80309 USA.
C3 University of California System; University of California San Diego;
   University of Colorado System; University of Colorado Boulder;
   University of Colorado System; University of Colorado Boulder
RP Aguado, BA (通讯作者)，Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.; Aguado, BA (通讯作者)，Sanford Consortium Regenerat Med, La Jolla, CA 92037 USA.
EM baguado@eng.ucsd.edu
RI Aguado, Brian/AAH 7044 2021
OI ANSETH, KRISTI/0000 0002 5725 5691; Vogt, Brandon/0000 0001 8025 3291
FU NIH [R00 HL148542, R25 HL145817, R01 HL132353, R01 AI151636, R01
   HL142935]; Burroughs Wellcome Fund Postdoctoral Enrichment Program;
   American Heart Association Career Development Award [942253]; American
   Heart Association (AHA) [942253] Funding Source: American Heart
   Association (AHA)
FX We acknowledge the help and resources of Dr Eric Griffis at the Nikon
   Imaging Center at the University of California San Diego and Dr Joe
   Dragavon at the BioFrontiers Advanced Light Microscopy Core located
   within the BioFrontiers Institute at the University of Colorado Boulder.
   B. J. Vogt acknowledges funding from the NIH (R00 HL148542 and R01
   HL132353). D. K. Peters acknowledges funding from the NIH (R01
   AI151636). K. S. Anseth acknowledges funding from the NIH (R01 HL142935,
   RO1 HL132353). B. A. Aguado acknowledges funding from the NIH (R00
   HL148542 and R25 HL145817), the Burroughs Wellcome Fund Postdoctoral
   Enrichment Program, and the American Heart Association Career
   Development Award (942253). Fig. 1A, 2A, 4A, and 5 were created with
   Biorender.
CR Aguado BA, 2022, CIRCULATION, V145, P513, DOI 10.1161/CIRCULATIONAHA.121.054108
   Aguado BA, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav3233
   Aguado BA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam8645
   Anila Namboodiripad P C, 2014, J Oral Biol Craniofac Res, V4, P42, DOI 10.1016/j.jobcr.2014.02.004
   Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580
   Benevolensky D, 2000, LAB INVEST, V80, P123, DOI 10.1038/labinvest.3780016
   Berletch JB, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005079
   Bernardi S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113861
   Bhatia N, 2016, J GERIATR CARDIOL, V13, P941, DOI 10.11909/j.issn.1671 5411.2016.12.004
   Chen NX, 2008, J BONE MINER RES, V23, P1798, DOI 10.1359/JBMR.080604
   Cramariuc D, 2015, HEART, V101, P209, DOI 10.1136/heartjnl 2014 306078
   de Arellano MLB, 2019, AGING US, V11, P1918, DOI 10.18632/aging.101881
   Dent THS, 2010, ATHEROSCLEROSIS, V213, P352, DOI 10.1016/j.atherosclerosis.2010.06.021
   F?lex V?lez N.E., 2022, J MATER CHEM B, V10, P7089
   Fairbanks BD, 2009, ADV MATER, V21, P5005, DOI 10.1002/adma.200901808
   Galarza S, 2020, BIOENG TRANSL MED, V5, DOI 10.1002/btm2.10148
   Gibbs LD, 2021, CANCERS, V13, DOI 10.3390/cancers13010002
   Goleski PJ, 2018, CATHETER CARDIO INTE, V91, P165, DOI 10.1002/ccd.26522
   GRAINGER DJ, 1995, NAT MED, V1, P74, DOI 10.1038/nm0195 74
   Grim JC, 2020, ARTERIOSCL THROM VAS, V40, pE296, DOI 10.1161/ATVBAHA.120.315261
   Groesbeck D, 2008, CLIN J AM SOC NEPHRO, V3, P1777, DOI 10.2215/CJN.00840208
   Gu XX, 2010, J BIOMED MATER RES A, V93A, P1620, DOI 10.1002/jbm.a.32660
   Hayes LD, 2020, EXP GERONTOL, V140, DOI 10.1016/j.exger.2020.111074
   Hulin A, 2018, FRONT CARDIOVASC MED, V5, DOI 10.3389/fcvm.2018.00021
   Humphries KH, 2012, J AM COLL CARDIOL, V60, P882, DOI 10.1016/j.jacc.2012.05.009
   Hutcheson JD, 2014, NAT REV CARDIOL, V11, P218, DOI 10.1038/nrcardio.2014.1
   Hutcheson JD, 2012, J MOL CELL CARDIOL, V53, P707, DOI 10.1016/j.yjmcc.2012.08.012
   James BD, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202100735
   Kaden JJ, 2003, ATHEROSCLEROSIS, V170, P205, DOI 10.1016/S0021 9150(03)00284 3
   Kasabova M, 2014, J BIOL CHEM, V289, P16239, DOI 10.1074/jbc.M113.542407
   Kloxin AM, 2010, BIOMATERIALS, V31, P1, DOI 10.1016/j.biomaterials.2009.09.025
   Knight K.M., 2022, J PHYS MATER
   Kodali S, 2016, ANN INTERN MED, V164, P377, DOI 10.7326/M15 0121
   Krementsov DN, 2014, ANN NEUROL, V75, P50, DOI 10.1002/ana.24020
   Kumar A, 2018, CIRC CARDIOVASC INTE, V11, DOI 10.1161/CIRCINTERVENTIONS.118.006664
   Li FH, 2005, J BONE MINER RES, V20, P1161, DOI 10.1359/JBMR.050207
   Li G, 2017, J THORAC CARDIOV SUR, V153, P1318, DOI 10.1016/j.jtcvs.2017.01.052
   Lin Zixiang, 2020, Nan Fang Yi Ke Da Xue Xue Bao, V40, P382, DOI 10.12122/j.issn.1673 4254.2020.03.16
   Liu SL, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122742
   Lokman NA, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11010069
   Masjedi S, 2017, HEART VESSELS, V32, P217, DOI 10.1007/s00380 016 0909 8
   McCoy CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039980
   Oertelt Prigione S, 2012, SEX AND GENDER ASPECTS IN CLINICAL MEDICINE, P9, DOI 10.1007/978 0 85729 832 4_3
   Osnabrugge RLJ, 2013, J AM COLL CARDIOL, V62, P1002, DOI 10.1016/j.jacc.2013.05.015
   Parra Izquierdo I, 2019, BBA MOL BASIS DIS, V1865, P2168, DOI 10.1016/j.bbadis.2019.04.014
   Peters, 2021, COLLABORATIONS ANSET
   Phimister EG, 2022, NEW ENGL J MED, V386, P1372, DOI 10.1056/NEJMcibr2200439
   Porras AM, 2017, CIRC RES, V120, P604, DOI 10.1161/CIRCRESAHA.117.310440
   Rodriguez AG, 2018, APL BIOENG, V2, DOI 10.1063/1.5042430
   Rogers JD, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2117323119
   Salgado JV, 2013, J CARDIOL, V62, P331, DOI 10.1016/j.jjcc.2013.05.015
   Sarnak MJ, 2005, ANN INTERN MED, V142, P497, DOI 10.7326/0003 4819 142 7 200504050 00008
   Schlotter F, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.015700
   Schroeder ME, 2023, BIOENG TRANSL MED, V8, DOI 10.1002/btm2.10358
   Schuliga M, 2017, AM J PHYSIOL LUNG C, V312, P1772, DOI 10.1152/ajplung.00553.2016
   Shaker MK, 2017, WORLD J HEPATOL, V9, P469, DOI 10.4254/wjh.v9.i9.469
   Shen Y, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm 20 7041
   Sritharen Y, 2017, PHYSIOLOGY, V32, P182, DOI 10.1152/physiol.00025.2016
   Steel JL, 2016, CANCER AM CANCER SOC, V122, P1270, DOI 10.1002/cncr.29906
   Sullivan S, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.010329
   Swierszcz J, 2011, J HEART VALVE DIS, V20, P639
   Swisher JFA, 2007, J LEUKOCYTE BIOL, V82, P1174, DOI 10.1189/jlb.0307154
   Swisher JFA, 2010, BLOOD, V115, P549, DOI 10.1182/blood 2009 06 226944
   Toyofuku M, 2017, CIRC J, V81, P1213, DOI 10.1253/circj.CJ 16 1244
   Tseng H, 2014, ACTA BIOMATER, V10, P173, DOI 10.1016/j.actbio.2013.09.003
   Villa P, 2005, CRIT CARE, V9, pR139, DOI 10.1186/cc3044
   Voisine M, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.015610
   Walker CJ, 2022, BIOENG TRANSL MED, V7, DOI 10.1002/btm2.10394
   Wang H, 2013, P NATL ACAD SCI USA, V110, P19336, DOI 10.1073/pnas.1306369110
   Wang HM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040996
   Wang MJ, 2005, AM J PHYSIOL ENDOC M, V288, pE321, DOI 10.1152/ajpendo.00278.2004
   Wegiel B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007953
   Xie F, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118086
   Zhang TY, 2010, ANNU REV PSYCHOL, V61, P439, DOI 10.1146/annurev.psych.60.110707.163625
   Zhang W, 2017, J ORAL MAXIL SURG, V75, P1081, DOI 10.1016/j.joms.2016.10.032
   Zhang X, 2015, ACTA BIOMATER, V14, P11, DOI 10.1016/j.actbio.2014.11.042
   Zusterzeel R, 2018, J WOMENS HEALTH, V27, P808, DOI 10.1089/jwh.2017.6760
NR 77
TC 7
Z9 7
U1 0
U2 12
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2047 4830
EI 2047 4849
J9 BIOMATER SCI UK
JI Biomater. Sci.
PD NOV 8
PY 2022
VL 10
IS 22
BP 6341
EP 6353
DI 10.1039/d2bm00844k
EA OCT 2022
PG 14
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 6C4ZM
UT WOS:000866405500001
PM 36226463
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wiontzek, M
   Matziolis, G
   Schuchmann, S
   Gaber, T
   Krocker, D
   Duda, G
   Burmester, GR
   Perka, C
   Buttgereit, F
AF Wiontzek, M.
   Matziolis, G.
   Schuchmann, S.
   Gaber, T.
   Krocker, D.
   Duda, G.
   Burmester, G.  R.
   Perka, C.
   Buttgereit, F.
TI Effects of dexamethasone and celecoxib on calcium homeostasis and
   expression of cyclooxygenase 2 mRNA in MG 63 human osteosarcoma cells
SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
LA English
DT Article
DE osteoblasts; dexamethasone; celecoxib; inflammation; intracellular Ca2+
   concentration
ID BONE MORPHOGENETIC PROTEIN 2; RHEUMATOID ARTHRITIS; IN VITRO;
   CYCLO OXYGENASE 2 INHIBITOR; INTRACELLULAR CALCIUM; OSTEOBLASTIC CELLS;
   PANCREATIC CANCER; TNF ALPHA; GLUCOCORTICOIDS; MECHANISMS
AB Objective Glucocorticoids and selective COX 2 inhibitors are potent anti inflammatory agents. They are also suggested to influence bone physiology and remodeling. Here we searched for effects of dexamethasone and celecoxib on crucial parameters of bone physiology that could be therapeutically relevant.
   Methods The human osteosarcoma cell line MG 63 was used to measure effects of these drugs on (i) intracellular calcium concentration ([Ca2+](i)) using a microfluorometric technique, (ii) alkaline phosphatase and osteocalcin levels (EIA) and (iii) the expression of cox 2 mRNA (quantitative real nine PCR). Measurements were performed in Vitamine D incubated quiescent cells and in cells stimulated with TNF alpha and IL 1 beta.
   Results We found the cytokine stimulation to increase [Ca2+](i) which was prevented by dexamethasone already after 30 min and still after 48 h. Dexamethasone was without any effect on [Ca2+](i) in quiescent cells. Celecoxib had no measurable short term or long term effects neither in quiescent nor in stimulated cells. Vitamin D stimulated the expression of cox 2 mRNA which was further enhanced by TNF alpha/IL 1 beta. Dexamethasone did not have any measurable effects on COX 2 expression after 30 min, but a pronounced inhibition was seen after 48 h. In contrast, celecoxib had no effect on COX 2 expression. Neither of the drugs had any effect on the secretion of alkaline phosphatase and osteocalcin.
   Conclusion We found dexamethasone to inhibit the [Ca2+](i) increase in MG 63 cells following stimulation and to reduce considerably COX 2 expression via the genomic pathway. In contrast, celecoxib did not show any measurable short term or long term effects on the parameters of bone physiology measured.
C1 Humboldt Univ, Dept Rheumatol & Clin Immunol, Charite Univ Hosp, D 10117 Berlin, Germany.
   Humboldt Univ, DRFZ, Charite Univ Hosp, D 10117 Berlin, Germany.
   Humboldt Univ, Ctr Musculoskeletal Surg, Charite Univ Hosp, D 10117 Berlin, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; Leibniz
   Association; Deutsches Rheuma Forschungszentrum (DRFZ); Free University
   of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin
RP Buttgereit, F (通讯作者)，Humboldt Univ, Dept Rheumatol & Clin Immunol, Charite Univ Hosp, Charitepl 1, D 10117 Berlin, Germany.
EM frank.buttgereit@charite.de
RI Duda, Georg/H 2085 2016; Burmester, Gerd/AAY 7514 2020; Perka,
   Carsten/ABG 6505 2021
OI Duda, Georg/0000 0001 7605 3908; Burmester,
   Gerd Rudiger/0000 0001 7518 1131; Perka, Carsten/0000 0002 0993 581X;
   Buttgereit, Frank/0000 0003 2534 550X
CR Brattsand R, 1996, ALIMENT PHARM THERAP, V10, P81, DOI 10.1046/j.1365 2036.1996.22164025.x
   Buttgereit F, 2004, ARTHRITIS RHEUM US, V50, P3408, DOI 10.1002/art.20583
   BUTTGEREIT F, 2000, Z RHEUMATOL S2, V59
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Cha HS, 2004, RHEUMATOL INT, V24, P207, DOI 10.1007/s00296 003 0359 3
   Cheung R, 2002, AM J PHYSIOL ENDOC M, V282, pE24, DOI 10.1152/ajpendo.2002.282.1.E24
   Chikazu D, 2002, J BONE MINER RES, V17, P1430, DOI 10.1359/jbmr.2002.17.8.1430
   Deeks JJ, 2002, BRIT MED J, V325, P619, DOI 10.1136/bmj.325.7365.619
   El Rayes BF, 2004, MOL CANCER THER, V3, P1421
   Fernandes JC, 2002, BIORHEOLOGY, V39, P237
   Gately S, 2004, SEMIN ONCOL, V31, P2, DOI 10.1053/j.seminoncol.2004.03.040
   Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736 0266(02)00079 7
   Goulding NJ, 2004, CURR OPIN PHARMACOL, V4, P629, DOI 10.1016/j.coph.2004.06.009
   Grösch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01 0299fje
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   HEREMANS H, 1978, ONCOLOGY BASEL, V35, P246, DOI 10.1159/000225298
   Hofbauer LC, 1998, BIOCHEM BIOPH RES CO, V250, P776, DOI 10.1006/bbrc.1998.9394
   Hsueh SF, 2004, MOL BRAIN RES, V125, P113, DOI 10.1016/j.molbrainres.2004.03.016
   Hughes FJ, 1999, J BIOL CHEM, V274, P1776, DOI 10.1074/jbc.274.3.1776
   Inoue H, 1999, BIOCHEM BIOPH RES CO, V254, P292, DOI 10.1006/bbrc.1998.9939
   Johnson AJ, 2002, BIOCHEM J, V366, P831, DOI 10.1042/BJ20020279
   KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36
   Kismet K, 2004, CANCER DETECT PREV, V28, P127, DOI 10.1016/j.cdp.2003.12.005
   Kusunoki N, 2002, ARTHRITIS RHEUM US, V46, P3159, DOI 10.1002/art.10692
   Langenbach R, 1999, ANN NY ACAD SCI, V889, P52, DOI 10.1111/j.1749 6632.1999.tb08723.x
   Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771 780.2001
   Levitt RJ, 2004, BIOCHEM BIOPH RES CO, V316, P421, DOI 10.1016/j.bbrc.2004.02.062
   Liang L, 2003, AM J CLIN ONCOL CANC, V26, pS114, DOI 10.1097/00000421 200308002 00015
   Lisignoli G, 1999, J RHEUMATOL, V26, P791
   Migita K, 2000, LAB INVEST, V80, P135, DOI 10.1038/labinvest.3780017
   Min YK, 1998, J BONE MINER RES, V13, P1066, DOI 10.1359/jbmr.1998.13.7.1066
   Namkung Matthäi H, 1998, EUR RESPIR J, V12, P1327, DOI 10.1183/09031936.98.12061327
   Olkku A, 2004, BONE, V34, P320, DOI 10.1016/j.bone.2003.09.010
   Park YG, 2004, INT J BIOCHEM CELL B, V36, P2270, DOI 10.1016/j.biocel.2004.04.019
   Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q
   ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006 291X(89)91819 6
   Rosenquist JB, 1996, INFLAMM RES, V45, P457, DOI 10.1007/BF02252317
   Rutz HP, 2002, LANCET, V360, P1969, DOI 10.1016/S0140 6736(02)11922 2
   Schuchmann S, 2004, CLIN EXP RHEUMATOL, V22, P184
   SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Tam VK, 1998, AM J PHYSIOL CELL PH, V274, pC1686, DOI 10.1152/ajpcell.1998.274.6.C1686
   Walsh S, 2001, RHEUMATOLOGY, V40, P74, DOI 10.1093/rheumatology/40.1.74
   Wang JL, 2004, BIOCHEM PHARMACOL, V67, P1123, DOI 10.1016/j.bcp.2003.11.004
   Wei DY, 2004, CANCER RES, V64, P2030, DOI 10.1158/0008 5472.CAN 03 1945
   WONG MM, 1990, J BONE MINER RES, V5, P803
   Yamamoto K, 2000, FEBS LETT, V465, P103, DOI 10.1016/S0014 5793(99)01727 5
   Zha S, 2004, CANCER LETT, V215, P1, DOI 10.1016/j.canlet.2004.06.014
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zhang XP, 2001, J BONE MINER RES, V16, P660, DOI 10.1359/jbmr.2001.16.4.660
   Zini N, 2003, HISTOCHEM CELL BIOL, V120, P243, DOI 10.1007/s00418 003 0563 y
NR 51
TC 9
Z9 9
U1 0
U2 2
PU CLINICAL & EXPER RHEUMATOLOGY
PI PISA
PA VIA SANTA MARIA 31, 56126 PISA, ITALY
SN 0392 856X
EI 1593 098X
J9 CLIN EXP RHEUMATOL
JI Clin. Exp. Rheumatol.
PD JUL AUG
PY 2006
VL 24
IS 4
BP 366
EP 372
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 082XF
UT WOS:000240419800005
PM 16956425
DA 2025 08 17
ER

PT J
AU Zullo, AR
   Sorial, MN
   Lee, Y
   Lary, CW
   Kiel, DP
   Berry, SD
AF Zullo, Andrew R.
   Sorial, Mark N.
   Lee, Yoojin
   Lary, Christine W.
   Kiel, Douglas P.
   Berry, Sarah D.
TI Predictors of Hip Fracture Despite Treatment with Bisphosphonates among
   Frail Older Adults
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE bisphosphonates; hip fracture; frail older adults; nursing homes;
   Medicare
ID RISK FACTORS; FALLS; OSTEOPOROSIS; WOMEN
AB OBJECTIVES Bisphosphonates are effective at preventing hip fractures among older adults, yet many patients still fracture while on treatment and may benefit from additional preventive interventions. Little data are specifically available to target such efforts among bisphosphonate users. We aimed to identify predictors of hip fracture unique to frail older adults initiating pharmacologic treatment for osteoporosis. DESIGN Retrospective cohort using 2008 2013 linked national Minimum Data Set assessments, Medicare claims, and nursing home (NH) facility data. SETTING NHs in the United States. PARTICIPANTS Long stay NH residents 65 years or older who initiated treatment with a bisphosphonate (N = 17 753). Estimates for bisphosphonate initiators were contrasted with those for calcitonin initiators (control group; N = 5348). MEASUREMENTS Hospitalized hip fracture outcomes were measured using Part A claims. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for 36 a priori selected potential predictors. RESULTS The mean (SD) age of the study population was 84 (8) years, 85% were women, and 51% had moderate to severe cognitive impairment. Predictors associated with a higher risk of hip fracture despite bisphosphonate use included age 75 years or older to 85 years (vs >= 65 to <75 y; HR = 1.25; 95% CI = 1.02 1.55), female sex (HR = 1.33; 95% CI = 1.06 1.67), white race (vs black race (HR = 1.87; 95% CI = 1.36 2.58), and body mass index = 18.5 24.9 (vs >= 30; HR = 1.93; 95% CI = 1.53 2.42). Independent ability to transfer (vs total dependence; HR = 3.11; 95% CI = 1.83 5.30) and occasional urinary incontinence (vs frequent; HR = 1.45; 95% CI = 1.18 1.78) were also important predictors. Dementia, diabetes, psychoactive drug use, and other characteristics were not associated with post prescribing hip fracture. Predictors did not differ between bisphosphonate and calcitonin users. CONCLUSION Predictors of hip fracture among frail older adults did not differ between those who were new users of bisphosphonates vs calcitonin. Given the absence of risk factors unique to bisphosphonate users, targeting of fracture prevention efforts should extend beyond pharmacologic therapy to include existing nonpharmacologic therapies, particularly fall prevention strategies.
C1 [Zullo, Andrew R.; Sorial, Mark N.] Rhode Isl Hosp, Providence, RI USA.
   [Zullo, Andrew R.; Lee, Yoojin] Brown Univ, tDept Hlth Serv Policy & Practice, Providence, RI 02912 USA.
   [Zullo, Andrew R.; Lary, Christine W.] Providence Vet Affairs Med Ctr, Ctr Innovat Long Term Serv & Supports, Providence, RI USA.
   [Kiel, Douglas P.; Berry, Sarah D.] Maine Med Ctr, Ctr Outcomes Res, Portland, ME 04102 USA.
   [Kiel, Douglas P.; Berry, Sarah D.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
   [Kiel, Douglas P.; Berry, Sarah D.] Harvard Med Sch, Hinda & Arthur Marcus Inst Aging Res, Hebrew SeniorLife, Boston, MA 02115 USA.
C3 Lifespan Health Rhode Island; Rhode Island Hospital; Brown University;
   US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Providence VA Medical Center; Maine Medical Center; Harvard University;
   Harvard University Medical Affiliates; Beth Israel Deaconess Medical
   Center; Harvard University; Harvard University Medical Affiliates;
   Hebrew SeniorLife; Harvard Medical School
RP Zullo, AR (通讯作者)，Brown Univ, 121 South Main St, Providence, RI 02912 USA.
EM andrew_zullo@brown.edu
RI Zullo, Andrew/C 6088 2017; Zullo, Andrew R/C 6088 2017
OI Sorial, Mark/0000 0002 6906 0568; Zullo, Andrew R/0000 0003 1673 4570
FU National Institutes on Aging [R01AG045441, P01AG027296, R21AG061632];
   National Institute of General Medical Sciences [U54GM115677]; Department
   of Veterans Affairs Office of Academic Affiliations Advanced Fellowship
   in Health Services Research and Development
FX This study was supported by grants R01AG045441, P01AG027296, and
   R21AG061632 from the National Institutes on Aging and by award
   U54GM115677 from the National Institute of General Medical Sciences that
   funds Andrew R. Zullo and Advance Clinical and Translational Research
   (Advance CTR). He is also supported by a Department of Veterans Affairs
   Office of Academic Affiliations Advanced Fellowship in Health Services
   Research and Development.
CR Ambrose AF, 2013, MATURITAS, V75, P51, DOI 10.1016/j.maturitas.2013.02.009
   Banerjee G, 2016, J AM MED DIR ASSOC, V17, DOI 10.1016/j.jamda.2016.06.012
   Beaupre LA, 2012, J AM GERIATR SOC, V60, P1268, DOI 10.1111/j.1532 5415.2012.04033.x
   Berry SD, 2017, OSTEOPOROSIS INT, V28, P2233, DOI 10.1007/s00198 017 4008 1
   Berry SD, 2007, ARCH INTERN MED, V167, P1971, DOI 10.1001/archinte.167.18.1971
   Berry SD, 2018, J GERONTOL A BIOL, V73, P763, DOI 10.1093/gerona/glx147
   Berry SD, 2016, J GERONTOL A BIOL, V71, P1230, DOI 10.1093/gerona/glw034
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   Colón Emeric C, 2007, OSTEOPOROSIS INT, V18, P553, DOI 10.1007/s00198 006 0260 5
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   Dore DD, 2018, J AM MED DIR ASSOC, V19, P328, DOI 10.1016/j.jamda.2017.09.015
   Friedman SM, 2010, GERIATR ORTHOP SURG, V1, P52, DOI 10.1177/2151458510389463
   Krishnaswami A, 2019, J AM COLL CARDIOL, V73, P2584, DOI 10.1016/j.jacc.2019.03.467
   Neuman MD, 2014, JAMA INTERN MED, V174, P1273, DOI 10.1001/jamainternmed.2014.2362
   Prieto Alhambra D, 2014, J BONE MINER RES, V29, P268, DOI 10.1002/jbmr.2011
   Segev Jacubovski O, 2011, EXPERT REV NEUROTHER, V11, P1057, DOI [10.1586/ern.11.69, 10.1586/ERN.11.69]
   Shen J, 2016, J CLIN ENDOCR METAB, V101, P476, DOI 10.1210/jc.2015 3123
   Szabo SM, 2018, ADV THER, V35, P1831, DOI 10.1007/s12325 018 0796 8
   Tricco AC, 2017, JAMA J AM MED ASSOC, V318, P1687, DOI 10.1001/jama.2017.15006
   Tromp AM, 1998, J BONE MINER RES, V13, P1932, DOI 10.1359/jbmr.1998.13.12.1932
   Xing D, 2014, OSTEOPOROSIS INT, V25, P105, DOI 10.1007/s00198 013 2446 y
   Zullo AR, 2019, J AM GERIATR SOC, V67, P768, DOI 10.1111/jgs.15725
   Zullo AR, 2018, J AM GERIATR SOC, V66, P539, DOI 10.1111/jgs.15264
   Zullo AR, 2018, CLIN GERIATR MED, V34, P39, DOI 10.1016/j.cger.2017.09.003
NR 25
TC 5
Z9 6
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0002 8614
EI 1532 5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD FEB
PY 2020
VL 68
IS 2
BP 256
EP 260
DI 10.1111/jgs.16176
EA OCT 2019
PG 5
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA KH7AC
UT WOS:000488670800001
PM 31580488
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Reikvam, H
   Hatfield, KJ
   Lassalle, P
   Kittang, AO
   Ersvær, E
   Bruserud, O
AF Reikvam, Hakon
   Hatfield, Kimberley Joanne
   Lassalle, Philippe
   Kittang, Astrid Olsnes
   Ersvaer, Elisabeth
   Bruserud, Oystein
TI Targeting the angiopoietin (Ang)/Tie 2 pathway in the crosstalk between
   acute myeloid leukaemia and endothelial cells: studies of Tie 2 blocking
   antibodies, exogenous Ang 2 and inhibition of constitutive agonistic
   Ang 1 release
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Article
DE acute myelogenous leukaemia; angiopoietin; CXCL8; Tie 2
ID ACUTE MYELOGENOUS LEUKEMIA; PROTEIN KINASE C; IN VITRO CULTURE;
   GROWTH FACTOR; TUMOR GROWTH; INCREASE PROLIFERATION; AML CELLS; KAPPA B;
   ANGIOGENESIS; EXPRESSION
AB Background. The Tie 2 receptor can bind its agonistic ligand Angiopoietin 1 (Ang 1) and the potential antagonist Ang 2. Tie 2 can be expressed both by primary human acute myeloid leukaemia (AML) cells and endothelial cells, and Tie 2 blocking antibodies are now being evaluated in clinical trials for cancer treatment. Design and methods: We investigated the effects of Tie 2 blocking antibodies, exogenous Ang 2 and pharmacological agents on AML cell proliferation and the release of angioregulatory mediators. Results: Tie 2 blocking antibodies had a growth inhibitory effect on human AML cells co cultured with microvascular endothelial cells, but this inhibition was not observed when leukaemic cells were co cultured with fibroblasts or osteoblasts. AML cell viability in co cultures was not altered by anti Tie 2. Furthermore, anti Tie 2 decreased hepatocyte growth factor (HGF) levels and increased CXCL8 levels in co cultures, whereas the levels of endocan (a proteoglycan released by endothelial cells) were not altered. The only significant effects of exogenous Ang 2 were decreased levels of HGF and endocan. Constitutive AML cell release of agonistic Ang 1 was decreased by the proteasomal inhibitor bortezomib and the specific I kappa B kinase/NF kappa B inhibitor BMS 345541. Conclusion: We conclude that various strategies for inhibition of Tie 2 mediated signalling should be considered in AML therapy, possibly in combination with other antiangiogenic strategies.
C1 [Reikvam, Hakon; Hatfield, Kimberley Joanne; Kittang, Astrid Olsnes; Ersvaer, Elisabeth; Bruserud, Oystein] Univ Bergen, Inst Internal Med, Div Haematol, Bergen, Norway.
   [Kittang, Astrid Olsnes; Bruserud, Oystein] Haukeland Hosp, Div Haematol, Dept Med, N 5021 Bergen, Norway.
   [Lassalle, Philippe] Inst Pasteur, INSERM, U416, F 59019 Lille, France.
C3 University of Bergen; University of Bergen; Haukeland University
   Hospital; Pasteur Network; Universite de Lille; Institut Pasteur Lille;
   Institut National de la Sante et de la Recherche Medicale (Inserm)
RP Bruserud, O (通讯作者)，Univ Bergen, Inst Internal Med, Div Haematol, Bergen, Norway.
EM oystein.bruserud@helse bergen.no
RI Lassalle, Philippe/L 6705 2018; Reikvam, Håkon/AAX 4238 2020; Ersvaer,
   Elisabeth/F 8646 2010; Kittang, Astrid/C 9899 2017; Ersvaer,
   Elisabeth/GWR 3762 2022
OI lassalle, philippe/0000 0001 6434 0344; Ersvaer,
   Elisabeth/0000 0002 9617 9329
FU Norwegian Cancer Society
FX The study received financial support from the Norwegian Cancer Society.
CR Aguayo A, 1999, BLOOD, V94, P3717, DOI 10.1182/blood.V94.11.3717.423k09_3717_3721
   ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489
   Bechard D, 2000, J VASC RES, V37, P417, DOI 10.1159/000025758
   Bruserud O, 2005, J CANCER RES CLIN, V131, P377, DOI 10.1007/s00432 004 0650 z
   Bruserud O, 2004, HAEMATOLOGICA, V89, P391
   Bruserud O, 2003, HAEMATOLOGICA, V88, P416
   Bruserud O, 2001, STEM CELLS, V19, P1, DOI 10.1634/stemcells.19 1 1
   BRUSERUD O, 1995, LEUKEMIA, V9, P1910
   Bruserud O, 1996, LEUKEMIA RES, V20, P65, DOI 10.1016/0145 2126(95)00112 3
   Bruserud O, 2007, HAEMATOLOGICA, V92, P332, DOI 10.3324/haematol.10148
   Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092 8674(00)81812 7
   Eklund L, 2006, EXP CELL RES, V312, P630, DOI 10.1016/j.yexcr.2005.09.002
   Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140 6736(06)69780 8
   Ferrara F, 2008, CRIT REV ONCOL HEMAT, V66, P181, DOI 10.1016/j.critrevonc.2007.09.008
   Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534 5807(02)00217 4
   Glenjen N, 2003, EUR J HAEMATOL, V71, P163, DOI 10.1034/j.1600 0609.2003.00130.x
   Hampson P, 2005, BLOOD, V106, P1362, DOI 10.1182/blood 2004 10 4117
   Hatfield KJ, 2008, LEUKEMIA, V22, P287, DOI 10.1038/sj.leu.2404985
   Hatfield K, 2006, INT J CANCER, V119, P2313, DOI 10.1002/ijc.22180
   Hatfield K, 2009, BRIT J HAEMATOL, V144, P53, DOI 10.1111/j.1365 2141.2008.07411.x
   Hatfield KJ, 2005, CURR CANCER DRUG TAR, V5, P229, DOI 10.2174/1568009054064651
   Herbst RS, 2009, J CLIN ONCOL, V27, P3557, DOI 10.1200/JCO.2008.19.6683
   Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994
   Irish JM, 2007, BLOOD, V109, P2589, DOI 10.1182/blood 2006 02 004234
   Jendreyko N, 2005, P NATL ACAD SCI USA, V102, P8293, DOI 10.1073/pnas.0503168102
   Joiakim A, 2003, DRUG METAB DISPOS, V31, P1279, DOI 10.1124/dmd.31.11.1279
   Latagliata R, 2006, ANN ONCOL, V17, P281, DOI 10.1093/annonc/mdj112
   Le Quément C, 2008, AM J PHYSIOL LUNG C, V294, pL1076, DOI 10.1152/ajplung.00489.2007
   Loges S, 2005, J CLIN ONCOL, V23, P1109, DOI 10.1200/JCO.2005.05.058
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Martin V, 2008, HISTOL HISTOPATHOL, V23, P773, DOI 10.14670/HH 23.773
   Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415
   Niu Q, 2004, CANCER BIOL THER, V3, P402, DOI 10.4161/cbt.3.4.735
   Oliner J, 2004, CANCER CELL, V6, P507, DOI 10.1016/j.ccr.2004.09.030
   Olsnes AM, 2009, BRIT J HAEMATOL, V145, P761, DOI 10.1111/j.1365 2141.2009.07691.x
   Pitera JE, 2004, AM J PATHOL, V165, P1895, DOI 10.1016/S0002 9440(10)63242 7
   Popkov M, 2005, CANCER RES, V65, P972
   Rhee J, 2005, EXPERT OPIN PHARMACO, V6, P1701, DOI 10.1517/14656566.6.10.1701
   Riccioni R, 2007, STEM CELLS, V25, P1862, DOI 10.1634/stemcells.2006 0700
   Ryningen A, 2007, CURR PHARM BIOTECHNO, V8, P401, DOI 10.2174/138920107783018462
   Ryningen A, 2006, LEUKEMIA RES, V30, P1531, DOI 10.1016/j.leukres.2006.02.014
   Saharinen P, 2005, J CELL BIOL, V169, P239, DOI 10.1083/jcb.200411105
   Shim WSN, 2007, MOL CANCER RES, V5, P655, DOI 10.1158/1541 7786.MCR 07 0072
   Stapnes C, 2007, BRIT J HAEMATOL, V136, P814, DOI 10.1111/j.1365 2141.2007.06504.x
   Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002 9440(10)65733 1
   Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419
   Teichert Kuliszewska K, 2001, CARDIOVASC RES, V49, P659, DOI 10.1016/S0008 6363(00)00231 5
   Tomida M, 2004, ONCOGENE, V23, P679, DOI 10.1038/sj.onc.1207190
   Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904
   Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465
   Zagzag D, 1999, EXP NEUROL, V159, P391, DOI 10.1006/exnr.1999.7162
NR 51
TC 35
Z9 39
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354 3784
EI 1744 7658
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PD FEB
PY 2010
VL 19
IS 2
BP 169
EP 183
DI 10.1517/13543780903485659
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 550NN
UT WOS:000274134800001
PM 20050812
DA 2025 08 17
ER

PT J
AU Chen, YC
   Lin, YH
   Wang, SH
   Lin, SP
   Shung, KK
   Wu, CC
AF Chen, Yen Chu
   Lin, Yi Hsun
   Wang, Shyh Hau
   Lin, Shih Ping
   Shung, K. Kirk
   Wu, Chia Ching
TI Monitoring tissue inflammation and responses to drug treatments in early
   stages of mice bone fracture using 50 MHz ultrasound
SO ULTRASONICS
LA English
DT Article
DE 50 MHz ultrasound; Echogenicity; Inflammation; Fracture; NSAIDs
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; K DISTRIBUTION; STATISTICAL MODEL;
   INHIBITION; TRANSDUCERS; APOPTOSIS; SPECKLE; INJURY; COX 2; CELL
AB Bone fracture induces moderate inflammatory responses that are regulated by cyclooxygenase 2 (COX 2) or 5 lipoxygenase (5 LO) for initiating tissue repair and bone formation. Only a handful of non invasive techniques focus on monitoring acute inflammation of injured bone currently exists. In the current study, we monitored in vivo inflammation levels during the initial 2 weeks of the inflammatory stage after mouse bone fracture utilizing 50 MHz ultrasound. The acquired ultrasonic images were correlated well with histological examinations. After the bone fracture in the tibia, dynamic changes in the soft tissue at the medial posterior compartment near the fracture site were monitored by ultrasound on the days of 0, 2, 4, 7, and 14. The corresponding echogenicity increased on the 2nd, 4th, and 7th day, and subsequently declined to basal levels after the 14th day. An increase of cell death was identified by the positive staining of deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay and was consistent with ultrasound measurements. The increases of both COX 2 and Leukotriene B4 receptor 1 (BLT1, 5 LO relative receptor), which are regulators for tissue inflammation, in the immunohistochemistry staining revealed their involvement in bone fracture injury. Monitoring the inflammatory response to various non steroidal anti inflammatory drugs (NSAIDs) treatments was investigated by treating injured mice with a daily oral intake of aspirin (Asp), indomethacin (IND), and a selective COX 2 inhibitor (SC 236). The Asp treatment significantly reduced fracture increased echogenicity (hyperechogenicity, p < 0.05) in ultrasound images as well as inhibited cell death, and expression of COX 2 and BLT1. In contrast, treatment with IND or SC 236 did not reduce the hyperechogenicity, as confirmed by cell death (TUNEL) and expression levels of COX 2 or BLT1. Taken together, the current study reports the feasibility of a non invasive ultrasound method capable of monitoring post fracture tissue inflammation that positively correlates with histological findings. Results of this study also suggest that this approach may be further applied to elucidate the underlying mechanisms of inflammatory processes and to develop therapeutic strategies for facilitating fracture healing. (C) 2013 Elsevier B. V. All rights reserved.
C1 [Chen, Yen Chu; Wu, Chia Ching] Natl Cheng Kung Univ, Dept Cell Biol & Anat, Tainan 701, Taiwan.
   [Lin, Yi Hsun; Wang, Shyh Hau] Natl Cheng Kung Univ, Dept Comp Sci & Informat Engn, Tainan 701, Taiwan.
   [Wang, Shyh Hau; Wu, Chia Ching] Natl Cheng Kung Univ, Med Device & Innovat Ctr, Tainan 701, Taiwan.
   [Lin, Shih Ping; Wu, Chia Ching] Natl Cheng Kung Univ, Dept Biomed Engn, Tainan 701, Taiwan.
   [Shung, K. Kirk] Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA.
C3 National Cheng Kung University; National Cheng Kung University; National
   Cheng Kung University; National Cheng Kung University; University of
   Southern California
RP Wu, CC (通讯作者)，1 Univ Rd, Tainan, Taiwan.
EM joshccwu@mail.ncku.edu.tw
FU National Health Research Institute (Taiwan) [NHRI EX101 10115EC];
   National Science Council (Taiwan) [NSC 99 2320 B 006 002 MY3, NSC
   98 2627 B 006 010 MY3]
FX The authors thank for the funding supports from National Health Research
   Institute (Taiwan) by Grant NHRI EX101 10115EC and in part by National
   Science Council (Taiwan) Grants NSC 99 2320 B 006 002 MY3 and NSC
   98 2627 B 006 010 MY3. The authors are very grateful to Dr. Michael W.
   Hughes for valuable suggestions.
CR Abdul Hadi O, 2009, J BONE JOINT SURG AM, V91A, P2020
   Brown KM, 2004, J BONE JOINT SURG AM, V86A, P116, DOI 10.2106/00004623 200401000 00017
   BURCKHARDT CB, 1978, IEEE T SON ULTRASON, V25, P1, DOI 10.1109/T SU.1978.30978
   Cannata JM, 2003, IEEE T ULTRASON FERR, V50, P1548, DOI 10.1109/TUFFC.2003.1251138
   Chan AT, 2006, CIRCULATION, V113, P1578, DOI 10.1161/CIRCULATIONAHA.105.595793
   Cottrell JA, 2009, J BONE JOINT SURG AM, V91A, P2653, DOI 10.2106/JBJS.H.01844
   Dimmen S, 2008, ACTA ORTHOP, V79, P438, DOI 10.1080/17453670710015373
   Dimmen S, 2009, CLIN ORTHOP RELAT R, V467, P1992, DOI 10.1007/s11999 009 0783 0
   Duckett AS, 2004, ULTRASOUND MED BIOL, V30, P665, DOI 10.1016/j.ultrasmedbio.2004.02.012
   DUTT V, 1994, ULTRASONIC IMAGING, V16, P265, DOI 10.1006/uimg.1994.1016
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   Harder AT, 2003, J CLIN PHARMACOL, V43, P807, DOI 10.1177/0091270003256061
   HILTUNEN A, 1993, J ORTHOP RES, V11, P305, DOI 10.1002/jor.1100110219
   Kawabata A, 2011, BIOL PHARM BULL, V34, P1170, DOI 10.1248/bpb.34.1170
   Keating JF, 2000, J BONE JOINT SURG BR, V82B, P1113, DOI 10.1302/0301 620X.82B8.10566
   Kim HH, 2008, IEEE T ULTRASON FERR, V55, P2683, DOI 10.1109/TUFFC.2008.983
   Knapik DA, 2000, IEEE T ULTRASON FERR, V47, P1540, DOI 10.1109/58.883543
   Kolar P, 2010, TISSUE ENG PART B RE, V16, P427, DOI [10.1089/ten.teb.2009.0687, 10.1089/ten.TEB.2009.0687]
   Lin YH, 2011, PHYS MED BIOL, V56, P757, DOI 10.1088/0031 9155/56/3/014
   Liou JY, 2008, MOL PHARMACOL, V74, P1399, DOI 10.1124/mol.108.049569
   Liu C, 2012, J CELL BIOCHEM, V113, P148, DOI 10.1002/jcb.23338
   MAFFULLI N, 1995, INJURY, V26, P5, DOI 10.1016/0020 1383(95)90544 8
   Manigrasso MB, 2010, ACTA ORTHOP, V81, P748, DOI 10.3109/17453674.2010.533931
   Marcouiller P, 2005, J RHEUMATOL, V32, P704
   Marsell R, 2011, INJURY, V42, P551, DOI 10.1016/j.injury.2011.03.031
   Murphy RC, 2007, BIOCHEM J, V405, P379, DOI 10.1042/BJ20070289
   Naik AA, 2009, J BONE MINER RES, V24, P251, DOI [10.1359/jbmr.081002, 10.1359/JBMR.081002]
   Protopappas VC, 2005, IEEE T BIO MED ENG, V52, P1597, DOI 10.1109/TBME.2005.851507
   Remedios A, 1999, VET CLIN N AM SMALL, V29, P1029, DOI 10.1016/S0195 5616(99)50101 0
   RICCIARDI L, 1993, CLIN ORTHOP RELAT R, P71
   Ring EFJ, 2012, PHYSIOL MEAS, V33, pR33, DOI 10.1088/0967 3334/33/3/R33
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   Schulze M, 2009, AM J ROENTGENOL, V192, P1708, DOI 10.2214/AJR.08.1764
   Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276
   SHANKAR PM, 1995, PHYS MED BIOL, V40, P1633, DOI 10.1088/0031 9155/40/10/006
   Shankar PM, 2001, IEEE T ULTRASON FERR, V48, P1716, DOI 10.1109/58.971725
   Shung K.K., 2006, Diagnostic Ultrasound, imaging and Blood flow measurement
   SIMON LS, 1980, NEW ENGL J MED, V302, P1179
   Soleymaninejadian E, 2012, AM J REPROD IMMUNOL, V67, P1, DOI 10.1111/j.1600 0897.2011.01069.x
   Su FC, 2011, J MED BIOL ENG, V31, P233, DOI 10.5405/jmbe.944
   Tsui PH, 2007, ULTRASOUND MED BIOL, V33, P608, DOI 10.1016/j.ultrasmedbio.2006.10.005
   WAGNER RF, 1987, J OPT SOC AM A, V4, P910, DOI 10.1364/JOSAA.4.000910
   WENG L, 1991, J ACOUST SOC AM, V89, P2992, DOI 10.1121/1.400818
   Xie C, 2008, BONE, V43, P1075, DOI 10.1016/j.bone.2008.08.109
NR 44
TC 16
Z9 18
U1 0
U2 90
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0041 624X
EI 1874 9968
J9 ULTRASONICS
JI Ultrasonics
PD JAN
PY 2014
VL 54
IS 1
BP 177
EP 186
DI 10.1016/j.ultras.2013.06.008
PG 10
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA 215XJ
UT WOS:000324244100021
PM 23871514
OA Green Accepted
DA 2025 08 17
ER

PT J
AU von Scheven, E
   Corbin, KJ
   Stefano, S
   Cimaz, R
AF von Scheven, Emily
   Corbin, Kathleen Jo
   Stefano, Stagi
   Cimaz, Rolando
TI Glucocorticoid Associated Osteoporosis in Chronic Inflammatory Diseases:
   Epidemiology, Mechanisms, Diagnosis, and Treatment
SO CURRENT OSTEOPOROSIS REPORTS
LA English
DT Article
DE Children; Pediatric; Rheumatic disease; Juvenile idiopathic arthritis;
   Systemic lupus erythematosus; Juvenile dermatomyositis; Crohn's disease;
   Osteoporosis; Bone density; Glucocorticoids; Corticosteroids
ID BONE MINERAL DENSITY; JUVENILE IDIOPATHIC ARTHRITIS;
   SYSTEMIC LUPUS ERYTHEMATOSUS; X RAY ABSORPTIOMETRY;
   CORTICOSTEROID INDUCED OSTEOPOROSIS; EXCLUSIVE ENTERAL NUTRITION;
   CROHNS DISEASE; YOUNG ADULTS; VITAMIN D; MUSCULOSKELETAL ABNORMALITIES
AB Children with chronic illnesses such as Juvenile Idiopathic Arthritis and Crohn's disease, particularly when taking glucocorticoids, are at significant risk for bone fragility. Furthermore, when childhood illness interferes with achieving normal peak bone mass, life long fracture risk is increased. Osteopenia and osteoporosis, which is increasingly recognized in pediatric chronic disease, likely results from numerous disease  and treatment related factors, including glucocorticoid exposure. Diagnosing osteoporosis in childhood is complicated by the limitations of current noninvasive techniques such as DXA, which despite its limitations remains the gold standard. The risk: benefit ratio of treatment is confounded by the potential for spontaneous restitution of bone mass deficits and reshaping of previously fractured vertebral bodies. Bisphosphonates have been used to treat secondary osteoporosis in children, but limited experience and potential long term toxicity warrant caution in routine use. This article reviews the factors that influence loss of normal bone strength and evidence for effective treatments, in particular in patients with gastrointestinal and rheumatologic disorders who are receiving chronic glucocorticoid therapy.
C1 [von Scheven, Emily; Corbin, Kathleen Jo] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Stefano, Stagi; Cimaz, Rolando] Univ Florence Italy, Florence, Italy.
C3 University of California System; University of California San Francisco
RP von Scheven, E (通讯作者)，Univ Calif San Francisco, 505 Parnassus Ave,Box 0105, San Francisco, CA 94143 USA.
EM evonsche@peds.ucsf.edu
RI Stagi, Stefano/R 1453 2016; CIMAZ, Rolando/AAA 9058 2019
OI Stagi, Stefano/0000 0002 2259 4685; CIMAZ, Rolando/0000 0002 3260 4226
CR Adams JE, 2014, J CLIN DENSITOM, V17, P258, DOI 10.1016/j.jocd.2014.01.006
   Akki A, 2014, AGE, V36, P21, DOI 10.1007/s11357 013 9540 0
   Alsufyani KA, 2005, J RHEUMATOL, V32, P729
   Bachrach LK, 2009, J CLIN ENDOCR METAB, V94, P400, DOI 10.1210/jc.2008 1531
   Barbehenn EK, 2001, TRENDS ENDOCRIN MET, V12, P383, DOI 10.1016/S1043 2760(01)00489 1
   Bechtold S, 2012, GROWTH HORM IGF RES, V22, P180, DOI 10.1016/j.ghir.2012.07.002
   Bernstein CN, 2000, ANN INTERN MED, V133, P795, DOI 10.7326/0003 4819 133 10 200011210 00012
   Bianchi ML, 2000, ARTHRITIS RHEUM US, V43, P1960, DOI 10.1002/1529 0131(200009)43:9<1960::AID ANR6>3.0.CO;2 J
   Bishop N, 2014, J CLIN DENSITOM, V17, P275, DOI 10.1016/j.jocd.2014.01.004
   Bonjour JP, 2009, SALUD PUBLICA MEXICO, V51, pS5
   Boot AM, 1998, GUT, V42, P188, DOI 10.1136/gut.42.2.188
   Brabnikova Maresova K., 2011, J OSTEOPOROS, V2011
   Burnham JM, 2006, ANN RHEUM DIS, V65, P1074, DOI 10.1136/ard.2005.048835
   Burnham JM, 2004, J BONE MINER RES, V19, P1961, DOI 10.1359/JBMR.040908
   Burnham JM, 2008, ARTHRITIS RHEUM US, V58, P2518, DOI 10.1002/art.23683
   Burnham JM, 2012, CURR OPIN RHEUMATOL, V24, P548, DOI 10.1097/BOR.0b013e328356b0c2
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Casella CB, 2012, LUPUS, V21, P1335, DOI 10.1177/0961203312454929
   Cassidy JT, 1997, RHEUM DIS CLIN N AM, V23, P499, DOI 10.1016/S0889 857X(05)70345 8
   Cimaz R, 2002, BEST PRACT RES CL RH, V16, P397, DOI 10.1053/berh.2002.0236
   Compeyrot Lacassagne S, 2007, ARTHRITIS RHEUM US, V56, P1966, DOI 10.1002/art.22691
   Compston J, 2010, NAT REV RHEUMATOL, V6, P82, DOI 10.1038/nrrheum.2009.259
   Cowan FJ, 1997, ARCH DIS CHILD, V76, P325, DOI 10.1136/adc.76.4.325
   Crabtree NJ, 2014, J CLIN DENSITOM, V17, P225, DOI 10.1016/j.jocd.2014.01.003
   Cundy T, 2012, CALCIFIED TISSUE INT, V90, P439, DOI 10.1007/s00223 012 9588 3
   de Jong DJ, 2002, AM J GASTROENTEROL, V97, P2011, DOI 10.1016/S0002 9270(02)04273 9
   de Vries F, 2007, ARTHRITIS RHEUM US, V56, P208, DOI 10.1002/art.22294
   Dempster DW, 1997, J ENDOCRINOL, V154, P397, DOI 10.1677/joe.0.1540397
   Dubner SE, 2009, GASTROENTEROLOGY, V136, P123, DOI 10.1053/j.gastro.2008.09.072
   Epstein S, 2003, J BONE MINER RES, V18, P2083, DOI 10.1359/jbmr.2003.18.12.2083
   Falcini F, 1996, J ENDOCRINOL INVEST, V19, P165, DOI 10.1007/BF03349860
   Felin EMO, 2007, ARTHRITIS RHEUM, V56, P984, DOI 10.1002/art.22420
   Fewtrell MS, 2003, ARCH DIS CHILD, V88, P795, DOI 10.1136/adc.88.9.795
   Fredlani B, 2004, CLIN EXP RHEUMATOL, V22, P313
   Gokhale R, 1998, GASTROENTEROLOGY, V114, P902, DOI 10.1016/S0016 5085(98)70309 9
   Gunter KB, 2012, EXERC SPORT SCI REV, V40, P13, DOI 10.1097/JES.0b013e318236e5ee
   Guo Z, 2013, DIGEST DIS SCI, V58, P915, DOI 10.1007/s10620 012 2465 0
   Hanaoka BY, 2012, NAT REV RHEUMATOL, V8, P448, DOI 10.1038/nrrheum.2012.85
   Henderson CJ, 2000, ARTHRITIS RHEUM US, V43, P531, DOI 10.1002/1529 0131(200003)43:3<531::AID ANR8>3.0.CO;2 X
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Huber AM, 2010, ARTHRIT CARE RES, V62, P516, DOI 10.1002/acr.20171
   Hyams JS, 1997, J PEDIATR GASTR NUTR, V24, P289, DOI 10.1097/00005176 199703000 00011
   Jahnsen J, 1997, GUT, V40, P313, DOI 10.1136/gut.40.3.313
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204
   Karalus Jolanta, 2011, Pediatr Endocrinol Diabetes Metab, V17, P35
   La Torre F, 2012, ARTHRITIS RHEUM US, V64, P4143, DOI 10.1002/art.34652
   Lamb EJ, 2002, ALIMENT PHARM THER, V16, P1895, DOI 10.1046/j.1365 2036.2002.01363.x
   Leonard MB, 2007, PEDIATRICS, V119, pS166, DOI 10.1542/peds.2006 2023J
   Lien G, 2003, ARTHRITIS RHEUM US, V48, P2214, DOI 10.1002/art.11097
   Lin YT, 2011, AUTOIMMUN REV, V10, P482, DOI 10.1016/j.autrev.2011.02.001
   Linglart A, 2011, J CLIN ENDOCR METAB, V96, P3308, DOI 10.1210/jc.2011 1359
   Long AR, 2010, CURR OPIN RHEUMATOL, V22, P213, DOI 10.1097/BOR.0b013e328335d1a2
   Lurati A, 2008, REUMATISMO, V60, P224, DOI 10.4081/reumatismo.2008.224
   Malleson PN, 1996, J RHEUMATOL, V23, P1059
   Maresova KB, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 51
   Maresova KB, 2013, RHEUMATOL INT, V33, P2001, DOI 10.1007/s00296 013 2678 3
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Nakhla M, 2009, J PEDIATR US, V154, P438, DOI 10.1016/j.jpeds.2008.09.023
   Nisar MK, 2013, CLIN RHEUMATOL, V32, P729, DOI 10.1007/s10067 012 2159 1
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Omori CH, 2012, ARTHRIT CARE RES, V64, P1186, DOI 10.1002/acr.21684
   Pappa H, 2011, J PEDIATR GASTR NUTR, V53, P11, DOI 10.1097/MPG.0b013e31821988a3
   Peitz J FO, 2012, RHEUMATOL CURR RES S, VS2, DOI [10.4172/2161 1149.S2 006, DOI 10.4172/2161 1149.S2 006]
   Pepmueller PH, 1996, ARTHRITIS RHEUM, V39, P746, DOI 10.1002/art.1780390506
   PIGOT F, 1992, DIGEST DIS SCI, V37, P1396, DOI 10.1007/BF01296010
   Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647
   Rabinovich CE, 2000, J RHEUMATOL, V27, P34
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   REED AM, 1993, J PEDIATR US, V122, P693, DOI 10.1016/S0022 3476(06)80006 5
   Regio PL, 2008, LUPUS, V17, P787, DOI 10.1177/0961203308089446
   Ringold S, 2009, J RHEUMATOL, V36, P1330, DOI 10.3899/jrheum.081028
   Rodd C, 2012, ARTHRIT CARE RES, V64, P122, DOI 10.1002/acr.20589
   Roth J, 2004, ARTHRITIS RHEUM US, V50, P1277, DOI 10.1002/art.20128
   Rouster Stevens KA, 2007, ARTHRITIS RHEUM, V56, P977, DOI 10.1002/art.22433
   Rubin J, 1998, ENDOCRINOLOGY, V139, P1006, DOI 10.1210/en.139.3.1006
   Sampaio Barros PD, 2005, CLIN EXP RHEUMATOL, V23, P180
   Santiago RA, 2008, SCAND J RHEUMATOL, V37, P40, DOI 10.1080/03009740701687226
   Schoenau E., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P232
   Semeao EJ, 1997, GASTROENTEROLOGY, V112, P1710, DOI 10.1016/S0016 5085(97)70055 6
   Semeao EJ, 1999, J PEDIATR US, V135, P593, DOI 10.1016/S0022 3476(99)70058 2
   Shinjo SK, 2011, RHEUMATOL INT, V31, P1075, DOI 10.1007/s00296 010 1421 6
   Simonini G, 2005, RHEUMATOLOGY, V44, P777, DOI 10.1093/rheumatology/keh592
   Soo J, 2013, DIGEST DIS SCI, V58, P3584, DOI 10.1007/s10620 013 2855 y
   Souza RBC, 2006, SCAND J RHEUMATOL, V35, P384, DOI 10.1080/03009740600704296
   Stagi S, 2005, RHEUMATOLOGY, V44, P517, DOI 10.1093/rheumatology/keh531
   Stagi S, 2014, LUPUS, V23, P57, DOI 10.1177/0961203313511679
   Stagi S, 2010, J RHEUMATOL, V37, P1935, DOI 10.3899/jrheum.091241
   Stewart WA, 2003, ARTHRITIS RHEUM, V48, P2294, DOI 10.1002/art.11211
   Sylvester FA, 2002, J BONE MINER RES, V17, P695, DOI 10.1359/jbmr.2002.17.4.695
   Sylvester FA, 2007, INFLAMM BOWEL DIS, V13, P42, DOI 10.1002/ibd.20006
   Takayanagi H, 2012, NAT REV RHEUMATOL, V8, P684, DOI 10.1038/nrrheum.2012.167
   Thayu M, 2010, GASTROENTEROLOGY, V139, P430, DOI 10.1053/j.gastro.2010.04.044
   Thayu M, 2008, CLIN GASTROENTEROL H, V6, P1378, DOI 10.1016/j.cgh.2008.07.010
   Thornton J, 2006, ARCH DIS CHILD, V91, P753, DOI 10.1136/adc.2006.093997
   Trapani S, 1998, RHEUMATOL INT, V18, P45, DOI 10.1007/s002960050056
   Tsampalieros A, 2013, KIDNEY INT, V83, P495, DOI 10.1038/ki.2012.347
   Tsampalieros A, 2013, J BONE MINER RES, V28, P480, DOI 10.1002/jbmr.1785
   Tuchman S, 2008, J PEDIATR US, V153, P484, DOI 10.1016/j.jpeds.2008.04.028
   Ubesie AC, 2013, J PEDIATR GASTR NUTR, V57, P372, DOI 10.1097/MPG.0b013e31829c10eb
   Uziel Y, 2009, PEDIATR RHEUMATOL, V7, DOI 10.1186/1546 0096 7 16
   Valta H, 2007, J RHEUMATOL, V34, P831
   van Bodegraven AA, 2014, GUT, V63, P1424, DOI 10.1136/gutjnl 2013 305523
   van Staa TP, 2000, RHEUMATOLOGY, V39, P1383, DOI 10.1093/rheumatology/39.12.1383
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Van Staa TP, 2003, J BONE MINER RES, V18, P913, DOI 10.1359/jbmr.2003.18.5.913
   Varghese S, 2002, J PEDIATR GASTR NUTR, V35, P641, DOI 10.1097/00005176 200211000 00010
   VARONOS S, 1987, CALCIFIED TISSUE INT, V41, P75, DOI 10.1007/BF02555248
   Vortia E, 2011, CURR OPIN PEDIATR, V23, P545, DOI 10.1097/MOP.0b013e32834a7810
   Ward L, 2007, COCHRANE DB SYST REV, V4
   Ward LM, 2010, OSTEOPOROSIS INT, V21, P331, DOI 10.1007/s00198 009 0969 z
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Werkstetter KJ, 2013, ANN NUTR METAB, V63, P10, DOI 10.1159/000350369
   Zemel Babette S, 2011, Curr Osteoporos Rep, V9, P284, DOI 10.1007/s11914 011 0076 x
   Zemel BS, 2011, J CLIN ENDOCR METAB, V96, P3160, DOI 10.1210/jc.2011 1111
   Zemel BS, 2010, J CLIN ENDOCR METAB, V95, P1265, DOI 10.1210/jc.2009 2057
NR 117
TC 44
Z9 48
U1 1
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1544 1873
EI 1544 2241
J9 CURR OSTEOPOROS REP
JI Curr. Osteoporos. Rep.
PD SEP
PY 2014
VL 12
IS 3
BP 289
EP 299
DI 10.1007/s11914 014 0228 x
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AY0JZ
UT WOS:000347284200006
PM 25001898
DA 2025 08 17
ER

PT J
AU Tuure, L
   Hämäläinen, M
   Nummenmaa, E
   Moilanen, T
   Moilanen, E
AF Tuure, Lauri
   Hamalainen, Mari
   Nummenmaa, Elina
   Moilanen, Teemu
   Moilanen, Eeva
TI Downregulation of microsomal prostaglandin E synthase 1 (mPGES 1)
   expression in chondrocytes is regulated by MAP kinase phosphatase 1
   (MKP 1)
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Pharmacology; mPGES 1; MAP kinases; MKP 1; Arthritis
ID ACTIVATED PROTEIN KINASE; CARTILAGE; OSTEOARTHRITIS; DEGRADATION;
   ARTHRITIS; ROLES; E 2
AB Objectives: Microsomal prostaglandin E synthase 1 (mPGES 1) catalyses the formation of PGE(2) in inflammatory tissues. It is considered a potential drug target in inflammatory conditions to achieve clinical benefits comparable to NSAIDs with a better tolerability. Inhibitors of mPGES 1 are under development but the pharmacological regulation of mPGES 1 expression remains poorly known. MAP kinase phosphatase 1 (MKP 1) is an enzyme that limits the activity of pro inflammatory MAP kinases p38 and JNK. In the present study, we discovered that dexamethasone down regulates mPGES 1 expression in articular chondrocytes in an MKP 1 and p38 kinase dependent manner.
   Methods: Primary human chondrocytes were isolated from cartilage samples obtained from osteoarthritis (OA) patients undergoing knee replacement surgery. Primary mouse chondrocytes were isolated from cartilage samples of MKP 1 deficient (knock out, KO) and corresponding wild type (WT) mice. Expression of mPGES 1 and MKP 1 were measured by quantitative reverse transcription polymerase chain reaction (qRT PCR) and Western blot, and MAP kinase phosphorylation by Western blot.
   Results: Dexamethasone inhibited the expression of mPGES 1 in primary human chondrocytes and in chondrocytes from wild type but not from MKP 1 deficient mice. Dexamethasone enhanced MKP 1 expression in chondrocytes from wild type mice as well as in primary human OA chondrocytes. Dexamethasone induced the dephosphorylation of both p38 and JNK, whereas mPGES 1 expression was downregulated by selective inhibitors of p38 only.
   Conclusions: The results show that MICP 1 is a crucial mediator of pharmacological control of inflammatory mPGES 1 expression by glucocorticoids, and underline MKP 1 as a potential anti inflammatory drug target.
C1 [Tuure, Lauri; Hamalainen, Mari; Nummenmaa, Elina; Moilanen, Teemu; Moilanen, Eeva] Tampere Univ, Fac Med & Hlth Technol, Immunopharmacol Res Grp, Arvo Bldg,Arvo Ylpon Katu 34, Tampere 33014, Finland.
   [Tuure, Lauri; Hamalainen, Mari; Nummenmaa, Elina; Moilanen, Teemu; Moilanen, Eeva] Tampere Univ Hosp, Tampere, Finland.
   [Moilanen, Teemu] Coxa Hosp Joint Replacement, Tampere, Finland.
C3 Tampere University; Tampere University; Tampere University Hospital;
   Coxa Hospital for Joint Replacement
RP Moilanen, E (通讯作者)，Tampere Univ, Fac Med & Hlth Technol, Immunopharmacol Res Grp, Arvo Bldg,Arvo Ylpon Katu 34, Tampere 33014, Finland.
EM eeva.moilanen@tuni.fi
OI Nummenmaa, Elina/0000 0001 7041 2375; Hamalainen,
   Mari/0000 0002 6409 3758
FU Pirkanmaa Hospital District, Finland; Paulo Foundation, Finland;
   Research Foundation of Rheumatic Diseases, Finland
FX This study was supported by grants from the competitive research funding
   of the Pirkanmaa Hospital District, Finland; The Paulo Foundation,
   Finland and Research Foundation of Rheumatic Diseases, Finland.
CR Guerrero MD, 2009, EUR J PHARMACOL, V620, P112, DOI 10.1016/j.ejphar.2009.08.007
   Dorfman K, 1996, ONCOGENE, V13, P925
   Gupta J, 2015, FEBS J, V282, P1841, DOI 10.1111/febs.13250
   Harirforoosh S, 2013, J PHARM PHARM SCI, V16, P821, DOI 10.18433/J3VW2F
   Idborg H, 2013, PROSTAG OTH LIPID M, V107, P18, DOI 10.1016/j.prostaglandins.2013.07.004
   Jonason JH, 2015, METHODS MOL BIOL, V1226, P11, DOI 10.1007/978 1 4939 1619 1_2
   Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108
   Koeberle A, 2015, BIOCHEM PHARMACOL, V98, P1, DOI 10.1016/j.bcp.2015.06.022
   Kojima F, 2008, J IMMUNOL, V180, P8361, DOI 10.4049/jimmunol.180.12.8361
   Korhonen R, 2014, BASIC CLIN PHARMACOL, V114, P24, DOI 10.1111/bcpt.12141
   Korotkova M, 2014, BASIC CLIN PHARMACOL, V114, P64, DOI 10.1111/bcpt.12162
   Koskinen A, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3512
   Lee AS, 2013, GENE, V527, P440, DOI 10.1016/j.gene.2013.05.069
   Li X, 2009, ARTHRITIS RHEUM US, V60, P513, DOI 10.1002/art.24258
   Li YQ, 2018, EXP THER MED, V16, P3211, DOI 10.3892/etm.2018.6538
   Masuko Hongo K, 2004, ARTHRITIS RHEUM US, V50, P2829, DOI 10.1002/art.20437
   Sun HY, 2017, CYTOKINE, V90, P135, DOI 10.1016/j.cyto.2016.11.002
   Tas SW, 2016, METHODS MOL BIOL, V1371, P143, DOI 10.1007/978 1 4939 3139 2_9
   Tuure L, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00646
   Westman M, 2004, ARTHRITIS RHEUM US, V50, P1774, DOI 10.1002/art.20286
   Zhang Y, 2014, CELL TISSUE RES, V358, P633, DOI 10.1007/s00441 014 2010 x
NR 21
TC 8
Z9 11
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JUN
PY 2019
VL 71
BP 139
EP 143
DI 10.1016/j.intimp.2019.03.014
PG 5
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA IC4NE
UT WOS:000470941800018
PM 30897501
DA 2025 08 17
ER

PT J
AU Catrina, AI
   af Klint, E
   Ernestam, S
   Catrina, SB
   Makrygiannakis, D
   Botusan, IR
   Klareskog, L
   Ulfgren, AK
AF Catrina, AI
   af Klint, E
   Ernestam, S
   Catrina, SB
   Makrygiannakis, D
   Botusan, IR
   Klareskog, L
   Ulfgren, AK
TI Anti tumor necrosis factor therapy increases synovial osteoprotegerin
   expression in rheumatoid arthritis
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID COLLEGE OF RHEUMATOLOGY; KAPPA B LIGAND; FACTOR ALPHA; RECEPTOR
   ACTIVATOR; BONE RESORPTION; METHOTREXATE; ETANERCEPT; VALIDATION;
   TISSUE; CELLS
AB Objective. Treatment of rheumatoid arthritis (RA) with tumor necrosis factor (TNF) blocking agents, including etanercept and infliximab, has resulted in reductions in the radiographic progression of RA. However, the exact mechanism by which this protection occurs has not been determined. In order to add to such knowledge, we investigated the effect of anti TNF therapy on the expression of osteoprotegerin (OPG) and receptor activator of NF kappa B ligand (RANKL) in synovial tissue.
   Methods. The expression of OPG and RANKL in synovial biopsy specimens was evaluated by immunohistochemistry. Serial synovial biopsy specimens were obtained from 18 patients with RA, before and after treatment with etanercept (9 patients) or infliximab (9 patients). Biopsy specimens were evaluated by double blind semiquantitative analysis and image analysis. The in vitro effect of TNF antagonists on the RANKL/OPG expression in osteoblasts and endothelial cells was evaluated by Western blotting. Statistical analysis was performed using Wilcoxon's signed rank test, followed by the Bonferroni correction for multiple comparisons of paired samples. The results of in vitro experiments were evaluated by one way analysis of variance, with Tukey's post hoe test.
   Results. Treatment with both infliximab and etanercept increased the expression of OPG in synovial tissue. After 8 weeks of treatment, neither infliximab nor etanercept influenced RANKL expression. In both groups of patients, the RANKL:OPG ratio decreased following therapy. In vitro, both of the TNF antagonists mimicked the in vivo effect, inducing a decrease in the RANKL:OPG ratio in TNF primed osteoblasts and endothelial cells.
   Conclusion. Therapy with TNF antagonists in RA modulates the OPG/RANKL system, a potential mechanism that could explain the retardation of radiographic damage observed following anti TNF therapy.
C1 Karolinska Univ Hosp, Karolinska Inst, Solna, Sweden.
   Carol Davila Univ Med, Bucharest, Romania.
   Karolinska Univ Hosp, Karolinska Inst, Huddinge, Sweden.
C3 Karolinska Institutet; Karolinska University Hospital; Carol Davila
   University of Medicine & Pharmacy; Karolinska Institutet; Karolinska
   University Hospital
RP Karolinska Univ Hosp, Rheumatol Res Lab, CMM L8 04, S 17176 Stockholm, Sweden.
EM Anca.Catrina@ki.se
OI Catrina, Sergiu/0000 0002 6914 3902; Klareskog,
   Lars/0000 0001 9601 6186; Botusan, Ileana/0000 0002 9803 0325
CR ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Brennan FM, 1997, BRIT J RHEUMATOL, V36, P643
   Catrina AI, 2002, RHEUMATOLOGY, V41, P484, DOI 10.1093/rheumatology/41.5.484
   Catrina AI, 2002, ANN RHEUM DIS, V61, P934, DOI 10.1136/ard.61.10.934
   Catrina SB, 2004, DIABETES, V53, P3226, DOI 10.2337/diabetes.53.12.3226
   Crotti TN, 2002, ANN RHEUM DIS, V61, P1047, DOI 10.1136/ard.61.12.1047
   FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602
   Goldring Steven R, 2002, Curr Rheumatol Rep, V4, P226, DOI 10.1007/s11926 002 0069 y
   Haynes DR, 2003, RHEUMATOLOGY, V42, P123, DOI 10.1093/rheumatology/keg047
   Horwood NJ, 1999, BIOCHEM BIOPH RES CO, V265, P144, DOI 10.1006/bbrc.1999.1623
   Klareskog L, 2004, LANCET, V363, P675, DOI 10.1016/S0140 6736(04)15640 7
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202
   PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756 3282(01)00682 2
   THOMSON BM, 1987, J IMMUNOL, V138, P775
   vanGestel AM, 1996, ARTHRITIS RHEUM, V39, P34, DOI 10.1002/art.1780390105
   Zannettino ACW, 2005, J CELL PHYSIOL, V204, P714, DOI 10.1002/jcp.20354
NR 19
TC 88
Z9 104
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
EI 1529 0131
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD JAN
PY 2006
VL 54
IS 1
BP 76
EP 81
DI 10.1002/art.21528
PG 6
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 002IO
UT WOS:000234605200011
PM 16385498
DA 2025 08 17
ER

PT J
AU Ziegler, AL
   Blikslager, AT
AF Ziegler, A. L.
   Blikslager, A. T.
TI Sparing the gut: COX 2 inhibitors herald a new era for treatment of
   horses with surgical colic
SO EQUINE VETERINARY EDUCATION
LA English
DT Article
DE horse; NSAIDs; COX selective; colic; endotoxaemia; gut barrier
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; THROMBOXANE SYNTHETASE INHIBITOR;
   LONG TERM SURVIVAL; FLUNIXIN MEGLUMINE; SOMATIC NOCICEPTION; EQUINE
   JEJUNUM; RECOVERY; OSTEOARTHRITIS; ENDOTOXEMIA; CIMICOXIB
AB Nonsteroidal anti inflammatory drugs (NSAIDs) are commonly used to manage a wide variety of conditions in horses, including management of colic. Flunixin meglumine is by far the most commonly used drug in the control of colic pain and inflammation and has become a go to for not only veterinarians but also horse owners and nonmedical equine professionals. NSAID use, however, has always been controversial in critical cases due to a high risk of adverse effects associated with their potent cyclo oxygenase (COX) inhibition. There are two important COX isoenzymes: COX 1 is generally beneficial for normal renal and gastrointestinal functions and COX 2 is associated with the pain and inflammation of disease. Newer selective NSAIDs can target COX 2 driven pathology while sparing important COX 1 driven physiology, which is of critical importance in horses with severe gastrointestinal disease. Emerging research suggests that firocoxib, a COX 2 selective NSAID labelled for use in horses, may be preferable for use in colic cases in spite of the decades long dogma that flunixin saves lives.
C1 [Ziegler, A. L.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27515 USA.
   [Ziegler, A. L.; Blikslager, A. T.] North Carolina State Univ, Coll Vet Med, Dept Clin Sci, Raleigh, NC 27695 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; North Carolina State
   University
RP Blikslager, AT (通讯作者)，North Carolina State Univ, Coll Vet Med, Dept Clin Sci, Raleigh, NC 27695 USA.
EM Anthony_blikslager@ncsu.edu
RI Ziegler, Amanda/AAA 3189 2020
OI Ziegler, Amanda/0000 0003 4450 0536
FU UNC CGIBD Basic Science Research Training Fellowship [NIH T32
   5T32DK007737]
FX A.L. Ziegler's salary was funded by the UNC CGIBD Basic Science Research
   Training Fellowship (NIH T32 5T32DK007737) at the time of the manuscript
   preparation.
CR Atukorala I, 2013, EXPERT OPIN PHARMACO, V14, P1077, DOI 10.1517/14656566.2013.783568
   Bienhoff SE, 2012, VET SURG, V41, P336, DOI 10.1111/j.1532 950X.2011.00942.x
   Blikslager AT, 1999, COMP CONT EDUC PRACT, V21, P548
   Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   Clark JO, 1999, VET CLIN N AM EQUINE, V15, P705, DOI 10.1016/S0749 0739(17)30140 2
   Cook VL, 2008, EQUINE VET J, V40, P353, DOI 10.2746/042516408X293574
   Cook VL, 2015, J VET EMERG CRIT CAR, V25, P76, DOI 10.1111/vec.12271
   Cook VL, 2009, AM J VET RES, V70, P992, DOI 10.2460/ajvr.70.8.992
   Cox S, 2013, VET J, V198, P382, DOI 10.1016/j.tvjl.2013.07.035
   Duz M., 2019, UK Vet Equine, V3, P6, DOI 10.12968/ukve.2019.3.1.6
   Duz M, 2019, EQUINE VET J, V51, P147, DOI 10.1111/evj.12997
   Elfenbein JR, 2009, VET ANAESTH ANALG, V36, P162, DOI 10.1111/j.1467 2995.2008.00441.x
   EWERT KM, 1985, AM J VET RES, V46, P24
   Fessler J F, 1989, Equine Vet J Suppl, P24, DOI 10.1111/j.2042 3306.1989.tb05650.x
   Fogle J, 2017, EQUINE VET J, V49, P155, DOI 10.1111/evj.12582
   Freeman DE, 2019, EQUINE VET J, V51, P422, DOI 10.1111/evj.13078
   Goodrich LR, 2006, VET J, V171, P51, DOI 10.1016/j.tvjl.2004.07.008
   HARDEE MM, 1986, RES VET SCI, V40, P152, DOI 10.1016/S0034 5288(18)30505 8
   Kim TW, 2015, NEW ZEAL VET J, V63, P92, DOI 10.1080/00480169.2014.950355
   Kim TW, 2014, VET J, V200, P77, DOI 10.1016/j.tvjl.2013.12.020
   Knych HK, 2017, VET CLIN N AM EQUINE, V33, P1, DOI 10.1016/j.cveq.2016.11.001
   Little D, 2007, AM J VET RES, V68, P614, DOI 10.2460/ajvr.68.6.614
   Marshall JF, 2011, EQUINE VET J, V43, P140, DOI 10.1111/j.2042 3306.2011.00398.x
   Mathews KA, 2000, VET CLIN N AM SMALL, V30, P783, DOI 10.1016/S0195 5616(08)70007 X
   MOORE JN, 1981, EQUINE VET J, V13, P95, DOI 10.1111/j.2042 3306.1981.tb04122.x
   MOORE JN, 1981, J AM VET MED ASSOC, V179, P473
   MOORE JN, 1988, VET CLIN N AM EQUINE, V4, P105, DOI 10.1016/S0749 0739(17)30653 3
   Naylor RJ, 2014, EQUINE VET J, V46, P427, DOI 10.1111/evj.12224
   Payne Johnson M, 2015, VET REC, V176, P284, DOI 10.1136/vr.102397
   Proudman CJ, 2002, EQUINE VET J, V34, P438, DOI 10.2746/042516402776117881
   Proudman CJ, 2002, EQUINE VET J, V34, P432, DOI 10.2746/042516402776117845
   Reymond N, 2012, J VET PHARMACOL THER, V35, P175, DOI 10.1111/j.1365 2885.2011.01297.x
   Robertson SA, 2005, EQUINE VET J, V37, P122, DOI 10.2746/0425164054223723
   SEMRAD SD, 1985, AM J VET RES, V46, P2474
   SEMRAD SD, 1987, PROSTA LEUKOTR MED, V27, P169, DOI 10.1016/0262 1746(87)90069 2
   SEMRAD SD, 1987, RES VET SCI, V43, P137, DOI 10.1016/S0034 5288(18)30762 8
   SEMRAD SD, 1987, EQUINE VET J, V19, P201, DOI 10.1111/j.2042 3306.1987.tb01380.x
   Sibbald B, 2004, CAN MED ASSOC J, V171, P1027, DOI 10.1503/cmaj.1041606
   Simon LS, 1999, JAMA J AM MED ASSOC, V282, P1921, DOI 10.1001/jama.282.20.1921
   Thomas Lewis, 1974, The Lives of a Cell: Notes of a Biology Watcher
   Tinker MK, 1997, EQUINE VET J, V29, P448, DOI 10.1111/j.2042 3306.1997.tb03157.x
   Tinker MK, 1997, EQUINE VET J, V29, P454, DOI 10.1111/j.2042 3306.1997.tb03158.x
   Tomlinson JE, 2005, EQUINE VET J, V37, P75, DOI 10.2746/0425164054406865
   Tomlinson JE, 2004, AM J VET RES, V65, P761, DOI 10.2460/ajvr.2004.65.761
   USDA, 2016, BAS REF EQ HLTH MAN
   VANE JR, 1971, NATURE NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   VANE JR, 1995, ADV PROSTAG THROMB L, V23, P41
   Ziegler AL, 2019, EQUINE VET J, V51, P329, DOI 10.1111/evj.13013
   Ziegler A, 2017, JAVMA J AM VET MED A, V250, P1271, DOI 10.2460/javma.250.11.1271
NR 49
TC 7
Z9 7
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0957 7734
EI 2042 3292
J9 EQUINE VET EDUC
JI Equine Vet. Educ.
PD NOV
PY 2020
VL 32
IS 11
BP 611
EP 616
DI 10.1111/eve.13189
EA OCT 2019
PG 6
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA NW9CP
UT WOS:000491590800001
PM 34305336
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Barragan Adjemian, C
   Lausten, L
   Ang, DB
   Johnson, M
   Katz, J
   Bonewald, LF
AF Barragan Adjemian, C.
   Lausten, L.
   Ang, D. B.
   Johnson, M.
   Katz, J.
   Bonewald, L. F.
TI Bisphosphonate Related Osteonecrosis of the Jaw: Model and Diagnosis
   with Cone Beam Computerized Tomography
SO CELLS TISSUES ORGANS
LA English
DT Article; Proceedings Paper
CT 9th International Conference on the Chemistry and Biology of Mineralized
   Tissues
CY NOV 04 08, 2007
CL Lakeland, TX
DE Osteonecrosis of the jaw; Bisphosphonates; Cone beam computerized
   tomography; Involucrums; Sequestrums
ID AVASCULAR NECROSIS; ASSOCIATION
AB Intravenous bisphosphonate (BP) therapy has become the standard of care for the treatment of cancers that metastasize to bone. BPs are associated with osteonecrosis of alveolar bones, a condition known as osteonecrosis of the jaw (ONJ). The incidence or pathogenesis of ONJ is largely unknown. The lesions are characterized by areas of exposed necrotic bone that do not heal after 8 weeks in the absence of radiation to the head and neck. ONJ lesions have been recalcitrant to conventional therapies. Lesions in cancer patients treated with BPs develop in association with periodontal disease, tooth extraction and/or in association with increased mechanical force due to partial/complete dentures. We hypothesized that intravenous BPs in cancer patients impair normal bone remodeling, thereby increasing the incidence of osteonecrotic lesions and that these lesions can be detected using cone beam computerized tomography (CBCT). From CBCTs taken at the University of Missouri at Kansas City School of Dentistry, 26 subjects had a cancer diagnosis and were on BP therapy. From these 26 subjects, 18 presented visible, exposed necrotic bone. We observed both sclerotic and radiolucent lesions. Lesions could be detected and measured in reconstructed images where most were found to expand to large areas of the bone. We were able to identify necrotic bodies or 'involucrums' within the ONJ lesions, suggesting that this could be the mechanism for the formation of a clinically visible sequestrum. We propose that CBCT can potentially identify and follow the progression of both pre  and postclinical lesions in ONJ patients, allowing better diagnosis and assessment of disease status. Copyright (C) 2008 S. Karger AG, Basel
C1 [Barragan Adjemian, C.] Univ Missouri, Sch Dent, Special Patient Care Clin, Kansas City, MO 64108 USA.
   [Barragan Adjemian, C.; Johnson, M.; Bonewald, L. F.] Univ Missouri, Dept Oral Biol Biol Sci, Kansas City, MO 64108 USA.
   [Ang, D. B.] Univ Missouri, Periodont Grad Program, Kansas City, MO 64108 USA.
   [Katz, J.] Univ Missouri, Dept Radiol, Kansas City, MO 64108 USA.
C3 University of Missouri System; University of Missouri Kansas City;
   University of Missouri System; University of Missouri Kansas City;
   University of Missouri System; University of Missouri Kansas City;
   University of Missouri System; University of Missouri Kansas City
RP Barragan Adjemian, C (通讯作者)，Univ Missouri, Sch Dent, Special Patient Care Clin, 650 E 25th St, Kansas City, MO 64108 USA.
EM barraganc@umkc.edu
RI Bonewald, Lynda/Q 3638 2019
CR Abu Id MH, 2006, ORAL MAXILLOFAC SURG, V10, P73, DOI 10.1007/s10006 005 0670 0
   [Anonymous], N ENGL J MED
   Bagan JV, 2006, ORAL ONCOL, V42, P327, DOI 10.1016/j.oraloncology.2005.08.001
   Bagan JV, 2005, J ORAL PATHOL MED, V34, P120, DOI 10.1111/j.1600 0714.2004.00269.x
   Carter G, 2005, MED J AUSTRALIA, V182, P413, DOI 10.5694/j.1326 5377.2005.tb06761.x
   Carter GD, 2003, AUST DENT J, V48, P268
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Ficarra G, 2005, J CLIN PERIODONTOL, V32, P1123, DOI 10.1111/j.1600 051X.2005.00842.x
   Jimenez Soriano Yolanda, 2005, Med Oral Patol Oral Cir Bucal, V10 Suppl 2, pE88
   Ludlow JB, 2003, DENTOMAXILLOFAC RAD, V32, P229, DOI 10.1259/dmfr/26310390
   Magremanne M, 2006, Rev Stomatol Chir Maxillofac, V107, P423, DOI 10.1016/S0035 1768(06)77081 4
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Migliorati CA, 2005, ORAL SURG ORAL MED O, V99, P135, DOI 10.1016/j.tripleo.2004.10.001
   Nelson MVB, 2005, BRIT DENT J, V198, P628, DOI 10.1038/sj.bdj.4812376
   Robinson NA, 2004, ANN ACAD MED SINGAP, V33, P48
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Shane E, 2006, J BONE MINER RES, V21, P1503, DOI 10.1359/JBMR.060712
   Shlomi Binyamin, 2005, Harefuah, V144, P536
   Statz TA, 2007, J PERIODONTOL, V78, P2203, DOI 10.1902/jop.2007.070104
   Vannucchi Alessandro M, 2005, Br J Haematol, V128, P738, DOI 10.1111/j.1365 2141.2005.05382.x
   Woeller A, 2006, Rev Stomatol Chir Maxillofac, V107, P417, DOI 10.1016/S0035 1768(06)77080 2
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Wooltorton E, 2005, CAN MED ASSOC J, V172, P1684, DOI 10.1503/cmaj.050640
NR 24
TC 26
Z9 27
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1422 6405
EI 1422 6421
J9 CELLS TISSUES ORGANS
JI Cells Tissues Organs
PY 2009
VL 189
IS 1 4
BP 284
EP 288
DI 10.1159/000151451
PG 5
WC Anatomy & Morphology; Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Anatomy & Morphology; Cell Biology; Developmental Biology
GA 384VJ
UT WOS:000261772000049
PM 18703870
DA 2025 08 17
ER

PT J
AU Rittler, D
   Baranyi, M
   Molnár, E
   Garay, T
   Jalsovszky, I
   Varga, IK
   Hegedus, L
   Aigner, C
   Tóvári, J
   Tímár, J
   Hegedus, B
AF Rittler, Dominika
   Baranyi, Marcell
   Molnar, Eszter
   Garay, Tamas
   Jalsovszky, Istvan
   Varga, Imre Karoly
   Hegedus, Luca
   Aigner, Clemens
   Tovari, Jozsef
   Timar, Jozsef
   Hegedus, Balazs
TI The Antitumor Effect of Lipophilic Bisphosphonate BPH1222 in Melanoma
   Models: The Role of the PI3K/Akt Pathway and the Small G Protein Rheb
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE melanoma; lipophilic bisphosphonate; prenylation inhibition; Rheb
ID ZOLEDRONIC ACID; CELL LINES; IN VITRO; SIGNALING PATHWAYS; GROWTH PHASE;
   CANCER CELLS; BREAST; BONE; INHIBITION; INSIGHTS
AB Malignant melanoma is one of the most metastatic cancer types, and despite recent success with novel treatment strategies, there is still a group of patients who do not respond to any therapies. Earlier, the prenylation inhibitor hydrophilic bisphosphonate zoledronic acid (ZA) was found to inhibit melanoma growth in vitro, but only a weaker effect was observed in vivo due to its hydrophilic properties. Recently, lipophilic bisphosphonates (such as BPH1222) were developed. Accordingly, for the first time, we compared the effect of BPH1222 to ZA in eight melanoma lines using viability, cell cycle, clonogenic and spheroid assays, videomicroscopy, immunoblot, and xenograft experiments. Based on 2D and spheroid assays, the majority of cell lines were more sensitive to BPH. The activation of Akt and S6 proteins, but not Erk, was inhibited by BPH. Additionally, BPH had a stronger apoptotic effect than ZA, and the changes of Rheb showed a correlation with apoptosis. In vitro, only M24met cells were more sensitive to ZA than to BPH; however, in vivo growth of M24met was inhibited more strongly by BPH. Here, we present that lipophilic BPH is more effective on melanoma cells than ZA and identify the PI3K pathway, particularly Rheb as an important mediator of growth inhibition.
C1 [Rittler, Dominika; Baranyi, Marcell; Molnar, Eszter; Garay, Tamas; Timar, Jozsef; Hegedus, Balazs] Semmelweis Univ, Dept Pathol, H 1091 Budapest, Hungary.
   [Garay, Tamas] Pazmany Peter Catholic Univ, Fac Informat Technol & Bion, H 1083 Budapest, Hungary.
   [Garay, Tamas] Semmelweis Univ, Oncol Ctr, H 1091 Budapest, Hungary.
   [Jalsovszky, Istvan; Varga, Imre Karoly] Eotvos Lorand Univ, Fac Sci, Inst Chem, Dept Organ Chem, H 1117 Budapest, Hungary.
   [Hegedus, Luca; Aigner, Clemens; Hegedus, Balazs] Univ Duisburg Essen, Ruhrlandklin, Dept Thorac Surg, D 45239 Essen, Germany.
   [Tovari, Jozsef] Natl Inst Oncol, Dept Expt Pharmacol, H 1122 Budapest, Hungary.
C3 Semmelweis University; Pazmany Peter Catholic University; Semmelweis
   University; Eotvos Lorand University; Hungarian Academy of Sciences;
   Chemical Research Center   HAS; University of Duisburg Essen; National
   Institute of Oncology Hungary
RP Hegedus, B (通讯作者)，Semmelweis Univ, Dept Pathol, H 1091 Budapest, Hungary.; Hegedus, B (通讯作者)，Univ Duisburg Essen, Ruhrlandklin, Dept Thorac Surg, D 45239 Essen, Germany.
EM rittlerdomi@gmail.com; baranyi2marci@gmail.com;
   m.molnareszter@gmail.com; garayt@gmail.com; jalso@caesar.elte.hu;
   vukracs@caesar.elte.hu; luca.hegedues@rlk.uk essen.de;
   clemens.aigner@ruhrlandklinik.uk essen.de; jtimar@gmail.com;
   jtovari@yahoo.com; balazs.hegedues@rlk.uk essen.de
RI Hegedus, Balazs/B 6076 2008; Aigner, Clemens/A 7284 2019; Eszter,
   Molnar/F 1894 2014; Hegedűs, Luca/AFL 9911 2022; Hegedus,
   Balazs/HKE 7559 2023
OI Hegedus, Balazs/0000 0002 4341 4153; Aigner,
   Clemens/0000 0002 7787 991X; 
FU [NKFIH K112371];  [KTIA NAPB 13 2 2014 0021];  [NVKP_16 1 2016 0020]; 
   [NVKP 16 1 2016 0004]
FX This work was supported by the grants NKFIH K112371,
   KTIA NAPB 13 2 2014 0021, NVKP_16 1 2016 0020, and NVKP 16 1 2016 0004
   (Jozsef Timar). The funding agencies had no role in the design of the
   study, in collection, analysis, and interpretation of data, nor in
   writing of the manuscript.
CR AMIN D, 1992, J LIPID RES, V33, P1657
   Bani MR, 1996, CANCER RES, V56, P3075
   Beaumont KA, 2014, HEALTHCARE BASEL, V2, P27, DOI 10.3390/healthcare2010027
   Birner P, 2014, ARCH DERMATOL RES, V306, P873, DOI 10.1007/s00403 014 1490 6
   Boissier S, 2000, CANCER RES, V60, P2949
   Boulmier A, 2017, INORG CHEM, V56, P7558, DOI 10.1021/acs.inorgchem.7b01114
   Chen L, 2013, INT J NANOMED, V8, P137, DOI 10.2147/IJN.S38928
   Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389
   Denoyelle C, 2003, BRIT J CANCER, V88, P1631, DOI 10.1038/sj.bjc.6600925
   Ding HS, 2014, HAEMATOLOGICA, V99, P60, DOI 10.3324/haematol.2013.087734
   Domingues B, 2018, IMMUNOTARGETS THER, V7, P35, DOI 10.2147/ITT.S134842
   Dzhambazov B, 2001, CARYOLOGIA, V54, P313, DOI 10.1080/00087114.2001.10589242
   Eriksson J, 2016, ONCOTARGET, V7, P15065, DOI 10.18632/oncotarget.7604
   Finlay GA, 2007, CANCER RES, V67, P9878, DOI 10.1158/0008 5472.CAN 07 1394
   Forsea AM, 2004, BRIT J CANCER, V91, P803, DOI 10.1038/sj.bjc.6602052
   Fragni M, 2016, N S ARCH PHARMACOL, V389, P529, DOI 10.1007/s00210 016 1224 8
   Garay T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117021
   Garay T, 2013, EXP CELL RES, V319, P3094, DOI 10.1016/j.yexcr.2013.08.018
   GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417
   Goldvaser H, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864 019 0623 8
   Green JR, 2002, AM J CLIN ONCOL CANC, V25, pS3, DOI 10.1097/00000421 200212001 00002
   Hanker AB, 2010, ONCOGENE, V29, P380, DOI 10.1038/onc.2009.336
   Hegemann M, 2019, ASIAN J ANDROL, V21, P12, DOI 10.4103/aja.aja_59_17
   HERLYN M, 1985, JNCI J NATL CANCER I, V74, P283
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Hirbe AC, 2009, BONE, V44, P908, DOI 10.1016/j.bone.2009.01.010
   Johnpulle RAN, 2016, CURR ONCOL REP, V18, DOI 10.1007/s11912 015 0485 6
   Kim EH, 2016, ONCOTARGET, V7, P70869, DOI 10.18632/oncotarget.12281
   Kozyrakis D, 2018, ADV UROL, V2018, DOI 10.1155/2018/1525832
   Kunz M, 2019, CANCERS, V11, DOI 10.3390/cancers11040465
   Lee JT, 2010, PIGM CELL MELANOMA R, V23, P820, DOI 10.1111/j.1755 148X.2010.00763.x
   Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43
   Malwal SR, 2018, J AM CHEM SOC, V140, P7568, DOI 10.1021/jacs.8b02363
   Mandalá M, 2014, CRIT REV ONCOL HEMAT, V92, P107, DOI 10.1016/j.critrevonc.2014.05.005
   Meier F, 2005, FRONT BIOSCI LANDMRK, V10, P2986, DOI 10.2741/1755
   Miyakoshi J, 1997, INT J RADIAT BIOL, V71, P75, DOI 10.1080/095530097144445
   MUELLER BM, 1991, CANCER RES, V51, P2193
   Muñoz Couselo E, 2017, ONCOTARGETS THER, V10, P3941, DOI 10.2147/OTT.S117121
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Nikolaou VA, 2012, J INVEST DERMATOL, V132, P854, DOI 10.1038/jid.2011.421
   Perera E, 2014, HEALTHCARE BASEL, V2, P1, DOI 10.3390/healthcare2010001
   Pirker C, 2003, MELANOMA RES, V13, P483, DOI 10.1097/00008390 200310000 00007
   Posch C, 2013, P NATL ACAD SCI USA, V110, P4015, DOI 10.1073/pnas.1216013110
   Roux C, 1999, DRUGS, V58, P823, DOI 10.2165/00003495 199958050 00005
   Sambrook PN, 2002, CURR PHARM DESIGN, V8, P1877, DOI 10.2174/1381612023393648
   Santini D, 2006, RECENT PAT ANTI CANC, V1, P383, DOI 10.2174/157489206778776989
   Tsubaki M, 2013, BIOCHEM PHARMACOL, V85, P163, DOI 10.1016/j.bcp.2012.10.009
   Vincent KM, 2017, ONCOTARGET, V8, P10498, DOI 10.18632/oncotarget.14443
   Watson IR, 2014, CANCER RES, V74, P4845, DOI 10.1158/0008 5472.CAN 14 1232 T
   Weiss HM, 2008, DRUG METAB DISPOS, V36, P2043, DOI 10.1124/dmd.108.021071
   Xia YF, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010382
   Yamagishi S, 2004, AM J PATHOL, V165, P1865, DOI 10.1016/S0002 9440(10)63239 7
   Yuen T, 2014, P NATL ACAD SCI USA, V111, P17989, DOI 10.1073/pnas.1421410111
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
   Zuo Q, 2018, ONCOGENE, V37, P3275, DOI 10.1038/s41388 018 0205 4
NR 55
TC 11
Z9 11
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2019
VL 20
IS 19
AR 4917
DI 10.3390/ijms20194917
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JK4FF
UT WOS:000494798300258
PM 31623406
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Xie, XT
   Wei, JM
   Zhang, B
   Xiong, W
   He, ZY
   Zhang, YY
   Gao, CH
   Zhao, YD
   Liu, B
AF Xie, Xiaoting
   Wei, Jiemao
   Zhang, Bin
   Xiong, Wei
   He, Zhiyi
   Zhang, Yayun
   Gao, Chenghao
   Zhao, Yuandi
   Liu, Bo
TI A self assembled bilayer polypeptide engineered hydrogel for
   spatiotemporal modulation of bactericidal and anti inflammation process
   in osteomyelitis treatment
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE Engineered polypeptide hydrogel; Antibacterial; Spatiotemporal
   regulation; Bone repairing; Osteomyelitis
ID ARTIFICIAL PROTEIN HYDROGELS
AB Background: Drug resistance of pathogens and immunosuppression are the main causes of clinical stagnation of osteomyelitis. The ideal treatment strategy for osteomyelitis is to achieve both efficient antibacterial and bone healing through spatiotemporal modulation of immune microenvironment.
   Methods: In this study, a bilayer hydrogel based on genetically engineered polypeptide AC(10)A and AC(10)A RGD was prepared by self assembly. Ag2S QDs@DSPE mPEG(2000) Ce6/Aptamer (AD Ce6/Apt) was loaded in the top layer AC(10)A hydrogel (AA) for antibacterial, and bone marrow derived mesenchymal stem cells (BMSCs) were loaded in the lower layer AC(10)ARGD hydrogel (MAR) for bone healing. The AD Ce6/Apt can be released from the AA hydrogel to target S. aureus before bacterial biofilm formation and achieved significant bactericidal effect under irradiation with a 660 nm laser. Moreover, AD Ce6/Apt can induce M1 type polarization of macrophages to activate the immune system and eliminate residual bacteria. Subsequently, BMSCs released from the MAR hydrogel can differentiate into osteoblasts and promote the formation of an anti inflammatory microenvironment by regulating the M2 type polarization of macrophages. The bilayer AA MAR hydrogel possessed good biocompatibility.
   Results: The in vitro and in vivo results showed that the AA MAR hydrogel not only realized efficient photodynamic therapy of S. aureus infection, but also promoted the transformation of immune microenvironment to fulfill the different needs of each stage, which ultimately improved bone regeneration and mechanical properties post surgery.
   Conclusion: This work presents an approach for spatiotemporal modulation of immune microenvironment in the treatment of osteomyelitis.
   [GRAPHICS]
   .
C1 [Xie, Xiaoting; Zhang, Bin; Zhao, Yuandi; Liu, Bo] Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Britton Chance Ctr Biomed Photon, Wuhan Natl Lab Optoelect Hubei Bioinformat, Wuhan 430074, Hubei, Peoples R China.
   [Xie, Xiaoting; Zhang, Bin; Zhao, Yuandi; Liu, Bo] Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Dept Biomed Engn, Mol Imaging Key Lab, Wuhan 430074, Hubei, Peoples R China.
   [Wei, Jiemao; Xiong, Wei; He, Zhiyi; Zhang, Yayun; Gao, Chenghao] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Orthoped Surg, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
   [Zhao, Yuandi] Huazhong Univ Sci & Technol, Key Lab Biomed Photon HUST, Minist Educ, Wuhan 430074, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology; Huazhong University of Science & Technology;
   Huazhong University of Science & Technology
RP Zhao, YD; Liu, B (通讯作者)，Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Britton Chance Ctr Biomed Photon, Wuhan Natl Lab Optoelect Hubei Bioinformat, Wuhan 430074, Hubei, Peoples R China.; Zhao, YD; Liu, B (通讯作者)，Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Dept Biomed Engn, Mol Imaging Key Lab, Wuhan 430074, Hubei, Peoples R China.; Xiong, W (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Orthoped Surg, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.; Zhao, YD (通讯作者)，Huazhong Univ Sci & Technol, Key Lab Biomed Photon HUST, Minist Educ, Wuhan 430074, Hubei, Peoples R China.
EM xcxgreatwellus@hotmail.com; zydi@mail.hust.edu.cn;
   lbyang@mail.hust.edu.cn
RI He, Zhiyi/AAQ 5150 2020; Zhang, Bin/C 9887 2013; Xie,
   XiaoTing/NPI 9699 2025; Xiong, Wei/HKV 1747 2023; gao,
   chenghao/ABH 4408 2020; Liu, Bo/L 2761 2017
FU National Key Research and Development Program of China [2018YFE0113400];
   National Natural Science Foundation of China [81871414, 82072405,
   81971658, 91959109]
FX This work was supported by the National Key Research and Development
   Program of China (2018YFE0113400), the National Natural Science
   Foundation of China (Grant No. 81871414, 82072405, 81971658, 91959109).
CR Anas A, 2021, J PHOTOCH PHOTOBIO C, V49, DOI 10.1016/j.jphotochemrev.2021.100452
   Beck Broichsitter BE, 2015, CURR OPIN INFECT DIS, V28, P240, DOI 10.1097/QCO.0000000000000155
   Cao HY, 2019, ANGEW CHEM INT EDIT, V58, P1626, DOI 10.1002/anie.201809716
   Chang YC, 2013, SCI REP UK, V3, DOI 10.1038/srep01863
   Chen H, 2019, NPG ASIA MATER, V11, DOI 10.1038/s41427 018 0103 9
   Chen ZT, 2017, NANOSCALE, V9, P18129, DOI 10.1039/c7nr05913b
   Cheng K, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201803118
   Cho DI, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2013.135
   Cortés Penfield NW, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz181
   Fukushima N, 2005, ARCH ORTHOP TRAUM SU, V125, P169, DOI 10.1007/s00402 004 0785 z
   Gimza BD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.638085
   Jia BQ, 2022, ADV SCI, V9, DOI 10.1002/advs.202105252
   Jiang YX, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd0492
   Johnson CT, 2018, P NATL ACAD SCI USA, V115, pE4960, DOI 10.1073/pnas.1801013115
   Kavanagh N, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00084 17
   Li CQ, 2022, ACTA BIOMATER, V140, P547, DOI 10.1016/j.actbio.2021.12.013
   Liu B, 2010, J AM CHEM SOC, V132, P13630, DOI 10.1021/ja1054669
   Liu XY, 2020, MATER TODAY, V36, P102, DOI 10.1016/j.mattod.2019.12.026
   Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806
   Min JH, 2016, ACS NANO, V10, P4441, DOI 10.1021/acsnano.6b00087
   Nandi SK, 2016, BIOTECHNOL ADV, V34, P1305, DOI 10.1016/j.biotechadv.2016.09.005
   Olson ME, 2013, CELL HOST MICROBE, V13, P629, DOI 10.1016/j.chom.2013.05.015
   Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697
   Sadtler K, 2016, SCIENCE, V352, P366, DOI 10.1126/science.aad9272
   Scherr TD, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00037
   Shao MY, 2021, NANO TODAY, V39, DOI 10.1016/j.nantod.2021.101224
   Shen W, 2006, NAT MATER, V5, P153, DOI 10.1038/nmat1573
   Shen W, 2007, MACROMOLECULES, V40, P689, DOI 10.1021/ma0615194
   Wang JH, 2019, ACS NANO, V13, P11686, DOI 10.1021/acsnano.9b05608
   Wang JH, 2018, NANOSCALE, V10, P132, DOI 10.1039/c7nr06373c
   Wang JX, 2021, ADV SCI, V8, DOI 10.1002/advs.202004010
   Wang P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 08680 6
   Xiao H, 2020, ACS CENTRAL SCI, V6, P1208, DOI 10.1021/acscentsci.9b01235
   Xu DD, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201807727
   Yang G, 2021, ANGEW CHEM INT EDIT, V60, P5386, DOI 10.1002/anie.202013228
   Yang ZF, 2021, ADV SCI, V8, DOI 10.1002/advs.202003627
   Yao MH, 2014, CHEM COMMUN, V50, P9405, DOI 10.1039/c4cc04018j
   Zhang J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21964 0
   Zhang K, 2020, ACS NANO, V14, P7170, DOI 10.1021/acsnano.0c02110
   Zhang XS, 2022, CHEM ENG J, V433, DOI 10.1016/j.cej.2021.133196
   Zhao L, 2020, TISSUE ENG REGEN MED, V17, P717, DOI 10.1007/s13770 020 00282 4
   Zhao ZW, 2017, ACS NANO, V11, P4428, DOI 10.1021/acsnano.7b00041
   Zhu JW, 2021, SMALL, V17, DOI 10.1002/smll.202101495
NR 43
TC 18
Z9 18
U1 18
U2 132
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477 3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD SEP 15
PY 2022
VL 20
IS 1
AR 416
DI 10.1186/s12951 022 01614 3
PG 19
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA 4O6FC
UT WOS:000854790300003
PM 36109760
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sun, LJ
   Zhang, JB
   Fang, K
   Ding, Y
   Zhang, LY
   Zhang, YL
AF Sun, Lijun
   Zhang, Jianbao
   Fang, Kun
   Ding, Yan
   Zhang, Liyu
   Zhang, Yali
TI Flavonoids from persimmon (Diospyros kaki) leaves (FPL) attenuate
   H2O2 induced apoptosis in MC3T3 E1 cells
   via the NF κB pathway
SO FOOD & FUNCTION
LA English
DT Article
ID OXIDATIVE STRESS; OSTEOGENIC DIFFERENTIATION; HYDROGEN PEROXIDE; HERBAL
   MEDICINE; ACTIVATION; QUERCETIN; DAMAGE; OSTEOPOROSIS; EXPRESSION;
   SYSTEM
AB The leaves of persimmon (Diospyros kaki L.) have long been used in Chinese medicine for the treatment of paralysis, frostbite, burns, and to stop bleeding. Flavonoids of persimmon leaves (FPL) are known for their antioxidant activity in murine osteoblast MC3T3 E1 cells, but their mechanisms in osteoblast cells injured by oxidative stress are unknown. In this study, the effects of FPL on oxidative damage were investigated by addressing their potential therapeutic or toxic effects on H2O2 stimulated MC3T3 E1 cells. MC3T3 E1 cells were pretreated with FPL (1.25, 2.5 and 5 mu g mL( 1)) for 24 h and were then exposed to 250 mu M H2O2 for an additional 6 h. FPL pre incubated with MC3T3 E1 cells did not present any cytotoxicity, instead they increased cell viability and Delta Psi(m) in a dose dependent manner when challenged with H2O2. Treatment with this pro incubated FPL also significantly suppressed the production of MDA and NO and the activity of iNOS. The mRNA expression of iNOS, COX 2, Bax, Bcl 2, and caspase 3 and the protein expression of NF kappa B/p65 showed that FPL significantly inhibited apoptosis in H2O2 stimulated MC3T3 E1 cells. These results suggest that the molecular mechanism of FPL in anti apoptosis was associated with the suppression of the translocation of NF kappa B/p65 into the nucleus. The protective effect of FPL could provide a promising approach for the treatment of osteoporosis.
C1 [Sun, Lijun; Zhang, Jianbao; Ding, Yan; Zhang, Liyu; Zhang, Yali] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ, Key Lab Biomed Informat Engn, Xian 710049, Peoples R China.
   [Fang, Kun] Xi An Jiao Tong Univ, Xian Jiaotong Univ Hosp, Xian 710049, Peoples R China.
   [Sun, Lijun] Shaanxi Normal Univ, Inst Sports Biol, Xian 710100, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Shaanxi Normal
   University
RP Sun, LJ (通讯作者)，Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ, Key Lab Biomed Informat Engn, Xian 710049, Peoples R China.
EM yar.lee@mail.xjtu.edu.cn
RI Sun, Lijun/E 8170 2015; Fang, Kun/GSD 6040 2022; Zhang,
   Yali/HNR 3900 2023
FU National Natural Science Foundation of China [31101266, 10972177];
   Scientific and Technical Foundation of Shaanxi Province [JM4025];
   Scientific and Technical Foundation of Xi'an City [SF09031(3)]; Project
   of Basic Research of Xi'an Jiaotong University [08143011]; Institute of
   Mitochondrial Biology and Medical, Xi'an Jiaotong University, Xi'an
   China
FX This work was financed by the National Natural Science Foundation of
   China (31101266, 10972177), the Scientific and Technical Foundation of
   Shaanxi Province (2011, JM4025), the Scientific and Technical Foundation
   of Xi'an City (2009, SF09031(3)), and by a Project of Basic Research of
   Xi'an Jiaotong University (08143011). This work was partly supported by
   the Institute of Mitochondrial Biology and Medical, Xi'an Jiaotong
   University, Xi'an China.
CR Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891 5849(99)00242 7
   Arnoult D, 2002, CELL DEATH DIFFER, V9, P65, DOI 10.1038/sj.cdd.4400951
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Bei WJ, 2004, NEUROSCI LETT, V363, P262, DOI 10.1016/j.neulet.2004.04.031
   Chang CC, 2006, J ORTHOP RES, V24, P1917, DOI 10.1002/jor.20244
   Chen G, 2002, CLIN CHIM ACTA, V326, P169, DOI 10.1016/S0009 8981(02)00298 X
   Farombi EO, 2006, HUM EXP TOXICOL, V25, P251, DOI 10.1191/0960327106ht621oa
   FUNAYAMA S, 1979, CHEM PHARM BULL, V27, P2865
   Ghibelli L, 2010, MITOCHONDRION, V10, P604, DOI 10.1016/j.mito.2010.08.003
   Gius D, 1999, TOXICOL LETT, V106, P93, DOI 10.1016/S0378 4274(99)00024 7
   Hamada Y, 2009, BONE, V45, pS35, DOI 10.1016/j.bone.2009.02.004
   Han M, 2004, LIFE SCI, V75, P675, DOI 10.1016/j.lfs.2003.12.022
   KAMEDA K, 1987, J NAT PROD, V50, P680, DOI 10.1021/np50052a017
   Kawakami K, 2011, PHYTOCHEM ANALYSIS, V22, P403, DOI 10.1002/pca.1295
   Kawakami K, 2010, BIOSCI BIOTECH BIOCH, V74, P1380, DOI 10.1271/bbb.100056
   Kleinert H, 2004, EUR J PHARMACOL, V500, P255, DOI 10.1016/j.ejphar.2004.07.030
   Lago J, 2005, TOXICON, V46, P579, DOI 10.1016/j.toxicon.2005.07.007
   Lee KH, 2008, EUR J PHARMACOL, V591, P1, DOI 10.1016/j.ejphar.2008.06.004
   Lee YH, 2013, J ENDODONT, V39, P236, DOI 10.1016/j.joen.2012.11.006
   Liu HJ, 2012, J ORTHOP RES, V30, P1051, DOI 10.1002/jor.22054
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Oh KW, 2005, CLIN ENDOCRINOL, V62, P92, DOI 10.1111/j.1365 2265.2004.02179.x
   Papiez MA, 2008, FOOD CHEM TOXICOL, V46, P3053, DOI 10.1016/j.fct.2008.06.006
   Sánchez Rodríguez MA, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 124
   Shouhed D, 2005, J CELL BIOCHEM, V95, P1276, DOI 10.1002/jcb.20497
   Suk K, 2005, NEUROSIGNALS, V14, P23, DOI 10.1159/000085383
   Sun LJ, 2011, FOOD CHEM TOXICOL, V49, P2689, DOI 10.1016/j.fct.2011.07.042
   Tang Y, 2013, STEM CELLS DEV, V22, P668, DOI 10.1089/scd.2012.0226
   Tilstra JS, 2011, AGING DIS, V2, P449
   Wattel A, 2003, BIOCHEM PHARMACOL, V65, P35, DOI 10.1016/S0006 2952(02)01445 4
   Xu ZS, 2011, FREE RADICAL BIO MED, V50, P1314, DOI 10.1016/j.freeradbiomed.2011.02.016
   Yin L, 2005, J CELL BIOCHEM, V94, P433, DOI 10.1002/jcb.20277
   Zhang JF, 2010, MOL CELL ENDOCRINOL, V314, P70, DOI 10.1016/j.mce.2009.08.012
NR 33
TC 19
Z9 24
U1 1
U2 40
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2042 6496
EI 2042 650X
J9 FOOD FUNCT
JI Food Funct.
PD MAR
PY 2014
VL 5
IS 3
BP 471
EP 479
DI 10.1039/c3fo60522a
PG 9
WC Biochemistry & Molecular Biology; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Food Science & Technology
GA AD4MU
UT WOS:000333226000007
PM 24488014
DA 2025 08 17
ER

PT J
AU Krishnan, AG
   Jayaram, L
   Biswas, R
   Nair, M
AF Krishnan, Amit G.
   Jayaram, Lakshmi
   Biswas, Raja
   Nair, Manitha
TI Evaluation of Antibacterial Activity and Cytocompatibility of
   Ciprofloxacin Loaded Gelatin Hydroxyapatite Scaffolds as a Local Drug
   Delivery System for Osteomyelitis Treatment
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID STAPHYLOCOCCUS AUREUS; POROUS HYDROXYAPATITE; CELLS; DIFFERENTIATION;
   INTERNALIZATION; POROSITY; RELEASE; DEVICES
AB Surgical debridement of the dead bone and subsequent systemic antibiotic therapy is often ineffective in eliminating Staphylococcus aureus infections in osteomyelitic patients. The recurrence of S. aureus infection is mainly due to the intracellular growth of bacterial colonies within osteoblast cells that protect the organism from extracellular host defences and/or antibiotic therapy. In this study, porous gelatin hydroxyapatite (HAP) scaffolds with various amounts of ciprofloxacin (1, 2, 5, and 10 wt%) were fabricated by freeze drying technique and the release of the antibiotic was characterized, as was the efficacy of the released antibiotic against methicillin sensitive and methicillin resistant S. aureus. Furthermore, the impact of the released antibiotic on the viability and osteogenic differentiation of human adipose derived mesenchymal stem cells (ADMSCs) cultured on the scaffolds were assessed. Finally, the efficacy of the released ciprofloxacin to enter the cells and abate intracellularly located S. aureus was evaluated. All the groups of CGHA scaffolds displayed sustained release of ciprofloxacin against S. aureus for 60 days above the minimum inhibitory concentration for the target species with zero order kinetics and Korsmeyer Peppas models. While comparing, the released antibiotic from CGHA5 scaffolds was found to be effective at reducing S. aureus through the study period, without detrimental effects on human ADMSC viability or osteogenic potential. When stem cells internalized with S. aureus were cultured onto the drug loaded scaffolds, a significant reduction in the colony count of internalized bacteria was observed, resulting in the osteogenic differentiation capability of those cells. Our results clearly demonstrate that the ciprofloxacin incorporated gelatin HAP scaffolds, which were cytocompatible and could target both intracellular and extracellular S. aureus, defining its potential to be used as local drug delivery system.
C1 [Nair, Manitha] Amrita Vishwa Vidyapeetham Univ, Amrita Inst Med Sci, Amrita Ctr Nanosci & Mol Med, Cochin 682041, Kerala, India.
   Amrita Vishwa Vidyapeetham Univ, Cochin 682041, Kerala, India.
C3 Amrita Vishwa Vidyapeetham; Amrita Vishwa Vidyapeetham Kochi; Amrita
   Vishwa Vidyapeetham; Amrita Vishwa Vidyapeetham Kochi
RP Nair, M (通讯作者)，Amrita Vishwa Vidyapeetham Univ, Amrita Inst Med Sci, Amrita Ctr Nanosci & Mol Med, Cochin 682041, Kerala, India.
EM manithanair@aims.amrita.edu
RI Nair, Manitha/B 6725 2013
FU Science and Engineering Research Board, Department of Science and
   Technology, Government of India (DST fast track project)
   [SR/FT/LS 65/2012]; DST, India
FX The research was funded by the Science and Engineering Research Board,
   Department of Science and Technology, Government of India (DST fast
   track project) (Project No. SR/FT/LS 65/2012). Lakshmi got her M. Tech.
   fellowship from DST, India. The authors acknowledge Mr. Sajin P. Ravi,
   Mr. Sarath, and Dr. Sreerekha for technical help and Dr. R. Jayakumar
   for providing the ciprofloxacin drug.
CR Anagnostakos K, 2006, ACTA ORTHOP, V77, P628, DOI 10.1080/17453670610012719
   Andrades JA, 2013, REGENERATIVE MEDICINE AND TISSUE ENGINEERING, P615, DOI 10.5772/56389
   [Anonymous], ASIAN J PHARM CLIN R
   Azami M, 2010, INT J ARTIF ORGANS, V33, P86
   Balcerzak J, 2010, PROG CHEM APPL CHITI, V15, P117
   Biswas R, 2006, FEMS MICROBIOL LETT, V259, P260, DOI 10.1111/j.1574 6968.2006.00281.x
   Cazedey E. C. L., 2013, J PHARM ANAL, V3, P282
   Dash S, 2010, ACTA POL PHARM, V67, P217
   El Ghannam A, 2005, EXPERT REV MED DEVIC, V2, P87, DOI 10.1586/17434440.2.1.87
   Ferraz M P, 2004, J Appl Biomater Biomech, V2, P74
   Garzoni C, 2009, TRENDS MICROBIOL, V17, P59, DOI 10.1016/j.tim.2008.11.005
   Gomes D, 2013, BRAZ J PHARM SCI, V49, P13, DOI 10.1590/S1984 82502013000100003
   Gordon JAR, 2007, BONE, V41, P462, DOI 10.1016/j.bone.2007.04.191
   Haas DW, 1996, AM J MED, V101, P550, DOI 10.1016/S0002 9343(96)00260 4
   HENRY SL, 1995, CLIN PHARMACOKINET, V29, P36, DOI 10.2165/00003088 199529010 00005
   Holtom PD, 2000, J ORTHOP RES, V18, P721, DOI 10.1002/jor.1100180507
   Hudson MC, 1995, MICROB PATHOGENESIS, V19, P409, DOI 10.1006/mpat.1995.0075
   Jevon M, 1999, INFECT IMMUN, V67, P2677, DOI 10.1128/IAI.67.5.2677 2681.1999
   Jiang JL, 2012, INFLAMM RES, V61, P207, DOI 10.1007/s00011 011 0402 x
   Karageorgiou V, 2005, BIOMATERIALS, V26, P5474, DOI 10.1016/j.biomaterials.2005.02.002
   Kluin OS, 2013, EXPERT OPIN DRUG DEL, V10, P341, DOI 10.1517/17425247.2013.751371
   Landi E, 2008, ACTA BIOMATER, V4, P1620, DOI 10.1016/j.actbio.2008.05.023
   Lazzarini L, 2004, J BONE JOINT SURG AM, V86A, P2305, DOI 10.2106/00004623 200410000 00028
   Levison ME, 2004, INFECT DIS CLIN N AM, V18, P451, DOI 10.1016/j.idc.2004.04.012
   Lew DP, 2004, LANCET, V364, P369, DOI 10.1016/S0140 6736(04)16727 5
   MAYBERRYCARSON KJ, 1984, INFECT IMMUN, V43, P825, DOI 10.1128/IAI.43.3.825 833.1984
   Miclau T, 1998, J ORTHOPAED RES, V16, P509, DOI 10.1002/jor.1100160417
   Mobini S, 2008, ADV APPL CERAM, V107, P4, DOI 10.1179/174367608X246817
   Murphy CM, 2010, BIOMATERIALS, V31, P461, DOI 10.1016/j.biomaterials.2009.09.063
   Nair M, 2014, CURR DRUG DELIV, V11, P687, DOI 10.2174/1567201811666140414120002
   Nair MB, 2011, CURR OPIN BIOTECH, V22, P721, DOI 10.1016/j.copbio.2011.02.005
   Nair MB, 2009, TISSUE ENG PT A, V15, P1619, DOI 10.1089/ten.tea.2008.0229
   Saito T, 2002, J BIOMED MATER RES, V63, P245, DOI 10.1002/jbm.10179
   Shi SF, 2013, EXP THER MED, V5, P257, DOI 10.3892/etm.2012.758
   Shi SF, 2012, EXP THER MED, V3, P367, DOI 10.3892/etm.2011.423
   Simpson AHRW, 2001, J BONE JOINT SURG BR, V83B, P403, DOI 10.1302/0301 620X.83B3.10727
   Sisto F, 2014, CYTOTHERAPY, V16, P181, DOI 10.1016/j.jcyt.2013.11.009
   Tsuruga E, 1997, J BIOCHEM TOKYO, V121, P317
   Varma P, 2010, J FOOD SCI, V75, pM546, DOI 10.1111/j.1750 3841.2010.01818.x
   Wong BS, 2012, DRUG DELIV TRANSL RE, V2, P272, DOI 10.1007/s13346 012 0096 9
   Zilberman M, 2008, J CONTROL RELEASE, V130, P202, DOI 10.1016/j.jconrel.2008.05.020
NR 41
TC 23
Z9 25
U1 1
U2 40
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD APR 1
PY 2015
VL 21
IS 7 8
BP 1422
EP 1431
DI 10.1089/ten.tea.2014.0605
PG 10
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA CF5RC
UT WOS:000352613600022
PM 25567452
DA 2025 08 17
ER

PT J
AU Yang, MJ
   Tang, ZY
   Li, XY
   Yu, YZ
   He, LZ
   Chen, TF
AF Yang, Meijin
   Tang, Zhiying
   Li, Xiaoying
   Yu, Yanzi
   He, Lizhen
   Chen, Tianfeng
TI Designing macrophage membrane engineered ruthenium/selenium
   nanoparticles to block bone metastasis of breast cancer
SO NANO RESEARCH
LA English
DT Article
DE cell membrane nanoparticles; biomimetic modification; ruthenium
   complexes; selenium nanoparticles; tumor bone metastasis
ID COMPLEXES
AB Bone metastasis along with osteolysis is a common complication of advanced breast cancer, which directly destroys bone function and becomes one of the major causes of cancer related mortality. It is crucial to develop a new strategy to achieve effective cancer therapy and inhibition of osteolytic bone metastasis. Metal ruthenium (Ru) complexes exhibit therapeutic potential in cancer chemotherapy. However, the clinical applications of Ru complexes were limited by poor bioavailability, lacking targeting, nonspecific distribution. Therefore, in this study, engineering of cell membrane biomimetic modification was used to construct a highly biocompatible nanoplatform with carrying Ru metal complex of RuPOP and Se nanoparticles (SeNPs). Strikingly, the obtained RPSR nanoparticles can efficiently inhibit the proliferation, invasion and migration of breast cancer cells (MDA MB 231 cells) in vitro. More importantly, RPSR nanoparticles can induce cycle arrest, apoptosis by generating excessive intracellular (reactive oxygen species, ROS) to disrupt the normal redox balance and induce DNA damage in tumor cells. Furthermore, RPSR nanoparticles can also reshape bone microenvironment by regulating selenoproteins to inhibit osteoclasts and avoid osteolytic bone metastasis induced by tumor development. Taken together, this study not only provides an effective cell membrane biomimetic strategy to enhance the shortcomings of metal complexes, but also demonstrates potential clinical significance for the combined treatment of anti cancer and bone metastasis inhibition.
C1 [Yang, Meijin; Tang, Zhiying; Li, Xiaoying; Yu, Yanzi; He, Lizhen; Chen, Tianfeng] Jinan Univ, Affiliated Hosp 1, Coll Chem & Mat Sci, Dept Oncol, Guangzhou 510632, Peoples R China.
C3 Jinan University
RP He, LZ; Chen, TF (通讯作者)，Jinan Univ, Affiliated Hosp 1, Coll Chem & Mat Sci, Dept Oncol, Guangzhou 510632, Peoples R China.
EM hlz6371@jnu.edu.cn; tchentf@jnu.edu.cn
FU National Science Fund for Distinguished Young Scholars [82225025];
   National Key R&D Program of China [2023YFC3402800]; National Natural
   Science Foundation of China [32171296, 32271351]; Science and Technology
   Projects in Guangzhou [202201011044]
FX This work has been supported by the National Science Fund for
   Distinguished Young Scholars (No. 82225025), the National Key R&D
   Program of China (No. 2023YFC3402800), the National Natural Science
   Foundation of China (Nos. 32171296 and 32271351), and the Science and
   Technology Projects in Guangzhou (No. 202201011044).
CR Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Calandria JM, 2023, CELL DEATH DIS, V14, DOI 10.1038/s41419 023 06334 6
   Chen YL, 2020, NANO RES, V13, P2617, DOI 10.1007/s12274 020 2931 5
   Clézardin P, 2021, PHYSIOL REV, V101, P797, DOI 10.1152/physrev.00012.2019
   Fang RH, 2023, NAT REV CLIN ONCOL, V20, P33, DOI 10.1038/s41571 022 00699 x
   Fang RH, 2018, ADV MATER, V30, DOI 10.1002/adma.201706759
   Gao X, 2023, NANO RES, V16, P5322, DOI 10.1007/s12274 022 5223 4
   Gilbert Annie K, 2022, Free Radic Biol Med, V190, P148, DOI 10.1016/j.freeradbiomed.2022.08.002
   Goldman JW, 2021, LANCET ONCOL, V22, P51, DOI 10.1016/S1470 2045(20)30539 8
   Gu TX, 2020, NANO RES, V13, P2209, DOI 10.1007/s12274 020 2838 1
   Guimaraes D, 2021, INT J PHARMACEUT, V601, DOI 10.1016/j.ijpharm.2021.120571
   Hao HS, 2021, NANO RES, V14, P2491, DOI 10.1007/s12274 020 3265 z
   He GL, 2023, ANGEW CHEM INT EDIT, V62, DOI 10.1002/anie.202218768
   He ZH, 2020, MAT SCI ENG C MATER, V106, DOI 10.1016/j.msec.2019.110298
   Hou YH, 2021, BONE, V149, DOI 10.1016/j.bone.2021.115974
   Huang C., 2021, ANGEW CHEM, V133, P9560, DOI DOI 10.1002/ANGE.202015671
   Huang H, 2020, NANO RES, V13, P3105, DOI 10.1007/s12274 020 2980 9
   Huang HJ, 2024, NANO RES, V17, P4350, DOI 10.1007/s12274 023 6342 2
   Khosravi N, 2022, J CONTROL RELEASE, V348, P706, DOI 10.1016/j.jconrel.2022.06.026
   Kim H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22565 7
   Lee SY, 2020, DRUG DES DEV THER, V14, P5375, DOI 10.2147/DDDT.S275007
   Li FF, 2015, CHEM SOC REV, V44, P2529, DOI 10.1039/c4cs00343h
   Li HL, 2021, NEOPLASMA, V68, P10, DOI 10.4149/neo_2020_200905N951
   Li JM, 2021, BIOACT MATER, V6, P3839, DOI 10.1016/j.bioactmat.2021.03.039
   Li ZM, 2023, BIOACT MATER, V19, P550, DOI 10.1016/j.bioactmat.2022.04.029
   Liu C, 2024, NANO RES, V17, P4844, DOI 10.1007/s12274 024 6454 3
   Liu XB, 2024, NEUROSCIENCE, V545, P158, DOI 10.1016/j.neuroscience.2024.03.019
   Liu Y, 2019, NANO MICRO LETT, V11, DOI 10.1007/s40820 019 0330 9
   Mani A, 2023, ANGEW CHEM INT EDIT, V62, DOI 10.1002/anie.202218347
   Oroojalian F, 2021, SMALL, V17, DOI 10.1002/smll.202006484
   Qi CX, 2022, NANO RES, V15, P1680, DOI 10.1007/s12274 021 3868 z
   Ren XX, 2022, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.820468
   Song ZB, 2023, NANO RES, V16, P11164, DOI 10.1007/s12274 023 5807 7
   Su SH, 2022, EUR J MED CHEM, V243, DOI 10.1016/j.ejmech.2022.114680
   Sun H, 2023, BIOACT MATER, V24, P477, DOI 10.1016/j.bioactmat.2022.12.021
   Tao HQ, 2020, ACTA BIOCH BIOPH SIN, V52, P1055, DOI 10.1093/abbs/gmaa098
   Venkataraman S, 2011, ADV DRUG DELIVER REV, V63, P1228, DOI 10.1016/j.addr.2011.06.016
   Wang HJ, 2020, BIOMATER SCI UK, V8, P552, DOI 10.1039/c9bm01392j
   Wang J, 2020, J AM CHEM SOC, V142, P2709, DOI 10.1021/jacs.9b11013
   Wang TR, 2021, NANO RES, V14, P4487, DOI 10.1007/s12274 021 3450 8
   Wang YL, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202001014
   Wu YS, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01746 6
   Xiong ZS, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202212970
   Xu RH, 2024, ADV FUNCT MATER, V34, DOI 10.1002/adfm.202313122
   Yang T, 2022, MOLECULES, V27, DOI 10.3390/molecules27020392
   Yang YX, 2021, ADV SCI, V8, DOI 10.1002/advs.202102330
   Yuan XX, 2021, THERANOSTICS, V11, P1429, DOI 10.7150/thno.45351
   Zeng HW, 2013, NUTRIENTS, V5, P97, DOI 10.3390/nu5010097
   Zhang F, 2023, BIOMOLECULES, V13, DOI 10.3390/biom13050799
   Zhang J, 2023, J AGR FOOD CHEM, DOI 10.1021/acs.jafc.2c08275
   Zhao ZN, 2022, ANGEW CHEM INT EDIT, V61, DOI 10.1002/anie.202202855
   Zhu LW, 2023, NANO RES, V16, P5169, DOI 10.1007/s12274 022 5065 0
   ZOU BH, IN PRESS, DOI DOI 10.1002/ADMA.202401620
   Zou BH, 2022, BIOMATERIALS, V285, DOI 10.1016/j.biomaterials.2022.121549
NR 54
TC 8
Z9 8
U1 10
U2 19
PU TSINGHUA UNIV PRESS
PI BEIJING
PA B605D, XUE YAN BUILDING, BEIJING, 100084, PEOPLES R CHINA
SN 1998 0124
EI 1998 0000
J9 NANO RES
JI Nano Res.
PD AUG
PY 2024
VL 17
IS 8
BP 7504
EP 7512
DI 10.1007/s12274 024 6760 9
EA JUN 2024
PG 9
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA A5P8K
UT WOS:001246521800002
DA 2025 08 17
ER

PT J
AU Kim, KA
   Kook, SH
   Song, JH
   Lee, JC
AF Kim, Kyoung A.
   Kook, Sung Ho
   Song, Ji Hye
   Lee, Jeong Chae
TI A Phenolic Acid Phenethyl Urea Derivative Protects Against
   Irradiation Induced Osteoblast Damage by Modulating Intracellular Redox
   State
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE IRRADIATION; OXIDATIVE STRESS; ANTIOXIDANT; HEME OXYGENASE 1; NUCLEAR
   FACTOR E2 P45 RELATED FACTOR 2
ID NF KAPPA B; OXIDATIVE STRESS; MC3T3 E1 CELLS; SIGNALING PATHWAYS;
   IN VITRO; RADIATION; ANTIOXIDANT; DIFFERENTIATION; PROLIFERATION;
   APOPTOSIS
AB Because irradiation may cause osteoradionecrosis, antioxidant supplementation is often used to suppress irradiation mediated injury. This study examined whether a synthetic phenethyl urea compound, (E) 1 (3,4 rea (DPDS U), prevents irradiation mediated cellular damage in MC3T3 E1 osteoblastic cells. A relatively high dose of irradiation (>4Gy) decreased cell viability and proliferation and induced DNA damage and cell cycle arrest at the G(2)/M phase with the attendant increase of cyclin B1. Irradiation with 8Gy induced intracellular reactive oxygen species (ROS) production and lipid peroxidation, and reduced glutathione content and superoxide dismutase activity in the cells. These events were significantly suppressed by treatment with 200 mu M DPDS U or 5mM N acetyl cysteine (NAC). DPDS U or irradiation alone significantly increased heme oxygenase 1 (HO 1) expression and nuclear factor E2 p45 related factor 2 (Nrf2) nuclear translocation. Interestingly, pretreatment with DPDS U facilitated irradiation induced activation of the Nrf2/HO 1 pathway. The potential of DPDS U to mediate HO 1 induction and protect against irradiation mediated cellular damage was almost completely attenuated by transient transfection with Nrf2 specific siRNA or treatment with a pharmacological HO 1 inhibitor, zinc protoporphyrin IX. Additional experiments revealed that DPDS U induced a radioprotective mechanism that differs from that induced by NAC through activation of Nrf2/HO 1 signaling. Collectively, our data suggest that DPDS U induced radioprotection is due to its dual function as an antioxidant to remove directly excessive intracellular ROS and as a prooxidant to stimulate intracellular redox sensitive survival signal. J. Cell. Biochem. 115: 1877 1887, 2014. (c) 2014 Wiley Periodicals, Inc.
C1 [Kim, Kyoung A.] Chonbuk Natl Univ, Dept Oral & Maxillofacial Radiol, Jeonju 561756, South Korea.
   [Kim, Kyoung A.] Chonbuk Natl Univ, Res Inst Clin Med, Jeonju 561756, South Korea.
   [Kook, Sung Ho; Song, Ji Hye; Lee, Jeong Chae] Chonbuk Natl Univ, Dept Orthodont, Jeonju 561756, South Korea.
   [Kook, Sung Ho; Song, Ji Hye; Lee, Jeong Chae] Chonbuk Natl Univ, Inst Oral Biosci, Jeonju 561756, South Korea.
   [Lee, Jeong Chae] Chonbuk Natl Univ, Res Ctr Bioact Mat, Jeonju 561756, South Korea.
C3 Jeonbuk National University; Jeonbuk National University; Jeonbuk
   National University; Jeonbuk National University; Jeonbuk National
   University
RP Lee, JC (通讯作者)，Chonbuk Natl Univ, Res Ctr Bioact Mat, Dept Orthodont, Jeonju 561756, South Korea.
EM leejc88@jbnu.ac.kr
FU Ministry of Education, Science and Technology [2011 0010073,
   NRF 2012R1A1B6001778]
FX Grant sponsor: Ministry of Education, Science and Technology; Grant
   numbers: 2011 0010073, NRF 2012R1A1B6001778.
CR Arai M, 2007, IUBMB LIFE, V59, P27, DOI 10.1080/15216540601156188
   Granado Serrano AB, 2010, BRIT J NUTR, V103, P168, DOI 10.1017/S0007114509991747
   Chen JS, 2011, ATHEROSCLEROSIS, V214, P301, DOI 10.1016/j.atherosclerosis.2010.11.010
   Choi KC, 2010, FOOD CHEM TOXICOL, V48, P2747, DOI 10.1016/j.fct.2010.07.001
   Dare A, 1997, J DENT RES, V76, P658, DOI 10.1177/00220345970760020601
   Gal TJ, 2000, ARCH OTOLARYNGOL, V126, P1124, DOI 10.1001/archotol.126.9.1124
   He J, 2011, J CRANIOFAC SURG, V22, P1635, DOI 10.1097/SCS.0b013e31822e5f66
   Ho SY, 2011, CHEM BIOL INTERACT, V193, P162, DOI 10.1016/j.cbi.2011.06.007
   Hwang JM, 2010, INT IMMUNOPHARMACOL, V10, P526, DOI 10.1016/j.intimp.2010.01.016
   Iborra M, 2011, BIOCHEM SOC T, V39, P1102, DOI 10.1042/BST0391102
   Kim JH, 2009, BMB REP, V42, P806, DOI 10.5483/BMBRep.2009.42.12.806
   Kim KA, 2013, FOOD SCI BIOTECHNOL, V22, P845, DOI 10.1007/s10068 013 0154 1
   Kim SS, 2005, REDOX REP, V10, P311, DOI 10.1179/135100005X83734
   King AD, 2010, EUR J RADIOL, V73, P629, DOI 10.1016/j.ejrad.2008.12.016
   Kostyuk SV, 2012, MUTAT RES FUND MOL M, V729, P52, DOI [10.1016/j.mrfmmm.2011.09.005, 10.16/j.mrfmmm.2011.09.005]
   Lau P, 2010, RADIAT ENVIRON BIOPH, V49, P271, DOI 10.1007/s00411 010 0272 6
   Lee JC, 2010, RADIAT RES, V173, P590, DOI 10.1667/RR1522.1
   Lin TH, 2010, J CELL PHYSIOL, V222, P757, DOI 10.1002/jcp.22008
   Maines MD, 2001, ADV EXP MED BIOL, V502, P249
   Matsumura S, 1996, CALCIFIED TISSUE INT, V59, P307, DOI 10.1007/s002239900129
   Monga J, 2011, PHARM BIOL, V49, P428, DOI 10.3109/13880209.2010.521513
   Pramojanee SN, 2012, ARCH ORAL BIOL, V57, P252, DOI 10.1016/j.archoralbio.2011.09.004
   Prasad NR, 2009, J PHOTOCH PHOTOBIO B, V95, P196, DOI 10.1016/j.jphotobiol.2009.03.007
   Schultze Mosgau S, 2005, INT J RADIAT ONCOL, V61, P1189, DOI 10.1016/j.ijrobp.2004.12.008
   Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688
   Shi Y, 2013, ACTA PHARMACOL SIN, V34, P1140, DOI 10.1038/aps.2013.59
   Shin SM, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/763257
   Shinozaki K, 2011, J RADIAT RES, V52, P229, DOI 10.1269/jrr.10089
   Singh PK, 2012, RADIAT RES, V177, P133, DOI 10.1667/RR2627.1
   Son YO, 2006, EUR J PHARMACOL, V529, P24, DOI 10.1016/j.ejphar.2005.10.041
   Son YO, 2009, J CELL BIOCHEM, V108, P989, DOI 10.1002/jcb.22332
   Ueno T, 2011, J BIOMED MATER RES A, V99A, P523, DOI 10.1002/jbm.a.33211
   Wagner AE, 2010, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472 6882 11 1
   Wambi C, 2008, RADIAT RES, V169, P384, DOI 10.1667/RR1204.1
   Yu JY, 2011, TOXICOL IN VITRO, V25, P1654, DOI 10.1016/j.tiv.2011.07.002
   Yu JY, 2010, MOL CELLS, V30, P303, DOI 10.1007/s10059 010 0119 7
   Yu J, 2013, TOXICOL LETT, V218, P224, DOI 10.1016/j.toxlet.2013.01.028
NR 37
TC 14
Z9 16
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD NOV
PY 2014
VL 115
IS 11
BP 1877
EP 1887
DI 10.1002/jcb.24857
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AP4TC
UT WOS:000342070700004
PM 24905050
OA Bronze
DA 2025 08 17
ER

PT J
AU Weinreich, J
   Schott, TC
   Königsrainer, I
   Küper, M
   Königsrainer, A
   Schott, H
AF Weinreich, Juergen
   Schott, Timm C.
   Koenigsrainer, Ingmar
   Kueper, Markus
   Koenigsrainer, Alfred
   Schott, Herbert
TI Cytostatic Activity of a 5 Fluoro 2′ deoxyuridine Alendronate Conjugate
   against Gastric Adenocarcinoma and Non malignant Intestinal and
   Fibroblast Cell Lines
SO ANTICANCER RESEARCH
LA English
DT Article
DE Bisphosphonates; 5 fluoro 2 ' deoxyuridine alendronate; gastric cancer
   cell lines; intestinal cell lines; fibroblast cell lines
ID PHASE III TRIAL; DELIVERY SYSTEMS; CANCER; CISPLATIN; BISPHOSPHONATES;
   OSTEOSARCOMA; FLUOROURACIL; CHEMOTHERAPY; METHOTREXATE; DOXORUBICIN
AB Background: 5 Fluoro 2' deoxyuridine (5 FdU), a drug against gastric cancer, was covalently linked via its nucleobase with the amino bisphosphonate alendronate (Ale), resulting in a new antimetabolite bisphosphonate conjugate (5 FdU Ale), designed for bone targeting. Materials and Methods: The cytostatic effect of 5 FdU Ale was evaluated in vitro compared to monomers and mixtures using CASY Technologies and the human gastric adenocarcinoma cell lines 23132/87 and MKN 45, in comparison to the intestinal CCL 241 and dermal fibroblast NHDF neonatal cell lines. Results: The adenocarcinoma cell lines demonstrated a slightly higher sensitivity, with respect to the cell lines CCL 241 and NHDF, to incubation with 5 FdU Ale. In comparison to 5 FdU, 5 FU and an equimolar mixture of Ale+5 FdU and Ale+5 FU, the cytostatic activity of the 5 FdU Ale was markedly reduced. Conclusion: 5 FdU Ale was only partially or not at all metabolized to a mixture of cytostatic metabolites in vitro. Therefore an in vivo evaluation of the conjugates is indicated.
C1 [Weinreich, Juergen; Koenigsrainer, Ingmar; Kueper, Markus; Koenigsrainer, Alfred] Univ Tubingen, Dept Gen Visceral & Transplant Surg, D 72072 Tubingen, Germany.
   [Schott, Timm C.] Univ Tubingen, Dept Orthodont, Ctr Dent Oral Med & Maxillofacial Surg, D 72072 Tubingen, Germany.
   [Schott, Herbert] Univ Tubingen, Inst Organ Chem, D 72072 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital; Eberhard Karls University
   of Tubingen
RP Weinreich, J (通讯作者)，Univ Tubingen, Dept Gen Visceral & Transplant Surg, Waldhornlestr 22, D 72072 Tubingen, Germany.
EM juergen.weinreich@med.uni tuebingen.de
RI Schott, Timm/K 7339 2017
CR Alberts SR, 2003, ANN ONCOL, V14, P31, DOI 10.1093/annonc/mdg726
   Chou I, 2004, J CLIN ONCOL, V22, P2395, DOI 10.1200/JCO.2004.08.154
   Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Fabulet O, 1995, PHOSPHORUS SULFUR, V101, P225, DOI 10.1080/10426509508042521
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Hohenberger P, 2003, LANCET, V362, P305, DOI 10.1016/S0140 6736(03)13975 X
   Kang BW, 2009, MED ONCOL, V26, P32, DOI 10.1007/s12032 008 9077 8
   Kim HS, 2007, ONCOLOGY BASEL, V73, P192, DOI [10.1159/000127386, 10.4143/crt.2011.43.4.244]
   KLENNER T, 1990, CANCER TREAT REV, V17, P253, DOI 10.1016/0305 7372(90)90056 L
   Knight LA, 2005, ANTI CANCER DRUG, V16, P969, DOI 10.1097/01.cad.0000176500.56057.66
   Lee J, 2007, ANN ONCOL, V18, P886, DOI 10.1093/annonc/mdl501
   Ohtsu A, 2003, J CLIN ONCOL, V21, P54, DOI 10.1200/JCO.2003.04.130
   Ora M, 2008, J ORG CHEM, V73, P4123, DOI 10.1021/jo800317e
   Reinholz MM, 2010, BONE, V47, P12, DOI 10.1016/j.bone.2010.03.006
   Schott H, 2011, BIOORGAN MED CHEM, V19, P3520, DOI 10.1016/j.bmc.2011.04.015
   Schott S, 2012, INVEST NEW DRUG, V30, P1750, DOI 10.1007/s10637 011 9688 3
   STURTZ G, 1993, EUR J MED CHEM, V28, P899, DOI 10.1016/0223 5234(93)90043 E
   Vanhoefer U, 2000, J CLIN ONCOL, V18, P2648, DOI 10.1200/JCO.2000.18.14.2648
   Weinreich J, 2011, INVEST NEW DRUG, V29, P1294, DOI 10.1007/s10637 010 9483 6
NR 20
TC 7
Z9 8
U1 0
U2 11
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250 7005
EI 1791 7530
J9 ANTICANCER RES
JI Anticancer Res.
PD OCT
PY 2012
VL 32
IS 10
BP 4299
EP 4305
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 024LX
UT WOS:000310111800013
PM 23060550
DA 2025 08 17
ER

PT J
AU Liu, M
   Goss, PE
   Ingle, JN
   Kubo, M
   Furukawa, Y
   Batzler, A
   Jenkins, GD
   Carlson, EE
   Nakamura, Y
   Schaid, DJ
   Chapman, JAW
   Shepherd, LE
   Ellis, MJ
   Khosla, S
   Wang, L
   Weinshilboum, RM
AF Liu, Mohan
   Goss, Paul E.
   Ingle, James N.
   Kubo, Michiaki
   Furukawa, Yoichi
   Batzler, Anthony
   Jenkins, Gregory D.
   Carlson, Erin E.
   Nakamura, Yusuke
   Schaid, Daniel J.
   Chapman, Judy Anne W.
   Shepherd, Lois E.
   Ellis, Matthew J.
   Khosla, Sundeep
   Wang, Liewei
   Weinshilboum, Richard M.
TI Aromatase Inhibitor Associated Bone Fractures: A Case Cohort GWAS and
   Functional Genomics
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID EARLY BREAST CANCER; POSTMENOPAUSAL WOMEN; WIDE ASSOCIATION; MINERAL
   DENSITY; CATHEPSIN K; PHASE III; OSTEOPOROSIS; ANASTROZOLE; EXPRESSION;
   TRIAL
AB Bone fractures are a major consequence of osteoporosis. There is a direct relationship between serum estrogen concentrations and osteoporosis risk. Aromatase inhibitors (AIs) greatly decrease serum estrogen levels in postmenopausal women, and increased incidence of fractures is a side effect of AI therapy. We performed a discovery case cohort genome wide association study (GWAS) using samples from 1071 patients, 231 cases and 840 controls, enrolled in the MA. 27 breast cancer AI trial to identify genetic factors involved in AI related fractures, followed by functional genomic validation. Association analyses identified 20 GWAS single nucleotide polymorphism (SNP) signals with P < 5E 06. After removal of signals in gene deserts and those composed entirely of imputed SNPs, we applied a functional validation "decision cascade" that resulted in validation of the CTSZ SLMO2 ATP5E, TRAM2 TMEM14A, and MAP4K4 genes. These genes all displayed estradiol (E2) dependent induction in human fetal osteoblasts transfected with estrogen receptor alpha, and their knockdown altered the expression of known osteoporosis related genes. These same genes also displayed SNP dependent variation in E2 induction that paralleled the SNP dependent induction of known osteoporosis genes, such as osteoprotegerin. In summary, our case cohort GWAS identified SNPs in or near CTSZ SLMO2 ATP5E, TRAM2 TMEM14A, and MAP4K4 that were associated with risk for bone fracture in estrogen receptor positive breast cancer patients treated with AIs. These genes displayed E2 dependent induction, their knockdown altered the expression of genes related to osteoporosis, and they displayed SNP genotype dependent variation in E2 induction. These observations may lead to the identification of novel mechanisms associated with fracture risk in postmenopausal women treated with AIs.
C1 [Liu, Mohan; Wang, Liewei; Weinshilboum, Richard M.] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Div Clin Pharmacol, Rochester, MN 55905 USA.
   [Ingle, James N.] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA.
   [Batzler, Anthony; Jenkins, Gregory D.; Carlson, Erin E.; Schaid, Daniel J.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA.
   [Khosla, Sundeep] Mayo Clin, Div Endocrinol, Rochester, MN 55905 USA.
   [Goss, Paul E.] Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Kubo, Michiaki; Furukawa, Yoichi] Rikagaku Kenkyusho Ctr Integrat Med Sci, Yokohama, Kanagawa 2300045, Japan.
   [Nakamura, Yusuke] Univ Chicago, Sch Med, Chicago, IL 60637 USA.
   [Chapman, Judy Anne W.; Shepherd, Lois E.] Natl Canc Inst Canada Clin Trials Grp, Kingston, ON K7L 3N6, Canada.
   [Ellis, Matthew J.] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Harvard University;
   Harvard University Medical Affiliates; Massachusetts General Hospital;
   RIKEN; University of Chicago; Queens University   Canada; Canadian
   Cancer Trials Group; Washington University (WUSTL)
RP Weinshilboum, RM (通讯作者)，Mayo Clin, 200 First St SW, Rochester, MN 55905 USA.
EM weinshilboum.richard@mayo.edu
RI Kubo, Michiaki/N 7947 2015; Khosla, Sundeep/AAE 6170 2020
OI Khosla, Sundeep/0000 0002 2936 4372
FU National Institutes of Health (Pharmacogenomics Research Network) [U19
   GM61388, U01 HG005137, R01 CA138461, R01 CA133049, P50 CA166201];
   Pharmaceutical Research and Manufacturers of America Foundation Center
   of Excellence in Clinical Pharmacology award; Mayo Center for
   Individualized Medicine; Rikagaku Kenkyusho Center for Integrative
   Medical Science; Biobank Japan Project   Ministry of Education, Culture,
   Sports, and Technology, Japan; Avon Foundation, New York; Grants in Aid
   for Scientific Research [221S0001] Funding Source: KAKEN
FX This work was supported in part by National Institutes of Health Grants
   U19 GM61388 (The Pharmacogenomics Research Network), U01 HG005137, R01
   CA138461, R01 CA133049, and P50 CA166201 (Mayo Clinic Breast Cancer
   Specialized Program of Research Excellence); a Pharmaceutical Research
   and Manufacturers of America Foundation Center of Excellence in Clinical
   Pharmacology award; the Mayo Center for Individualized Medicine; and the
   Rikagaku Kenkyusho Center for Integrative Medical Science and the
   Biobank Japan Project funded by the Ministry of Education, Culture,
   Sports, and Technology, Japan. P. E. G. is supported in part by the Avon
   Foundation, New York; ClinicalTrials.gov study NCT00283608.
CR Amir E, 2011, JNCI J NATL CANCER I, V103, P1299, DOI 10.1093/jnci/djr242
   Bouzakri K, 2007, J BIOL CHEM, V282, P7783, DOI 10.1074/jbc.M608602200
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Brueggemeier R W, 2001, Am J Ther, V8, P333, DOI 10.1097/00045391 200109000 00007
   Coleman RE, 2007, LANCET ONCOL, V8, P119, DOI 10.1016/S1470 2045(07)70003 7
   Confavreux CB, 2007, BONE, V41, P346, DOI 10.1016/j.bone.2007.06.004
   Cree MW, 2003, OSTEOPOROSIS INT, V14, P722, DOI 10.1007/s00198 003 1430 3
   Cuzick J, 2010, LANCET ONCOL, V11, P1135, DOI 10.1016/S1470 2045(10)70257 6
   Deng FY, 2010, OSTEOPOROSIS INT, V21, P579, DOI 10.1007/s00198 009 0998 7
   Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249
   Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222 6233.2002
   Goss P, 2007, J CLIN ONCOL, V25, P4961, DOI 10.1200/JCO.2006.09.5455
   Goss PE, 2013, J CLIN ONCOL, V31, P1398, DOI 10.1200/JCO.2012.44.7805
   Grimm SW, 1997, DRUG METAB DISPOS, V25, P598
   Han SH, 2009, IMMUNOPHARM IMMUNOT, V31, P428, DOI 10.1080/08923970902751651
   HARRIS SA, 1995, J CELL BIOCHEM, V59, P193, DOI 10.1002/jcb.240590209
   Ho MF, 2014, ANN RHEUM DIS, V73, P349, DOI 10.1136/annrheumdis 2014 eular.5382
   Holzer G, 2005, J LAB CLIN MED, V146, P13, DOI 10.1016/j.lab.2005.03.016
   Ingle JN, 2013, CANCER DISCOV, V3, P812, DOI 10.1158/2159 8290.CD 13 0038
   Ingle JN, 2011, STEROIDS, V76, P765, DOI 10.1016/j.steroids.2011.02.021
   Ingle JN, 2010, J CLIN ONCOL, V28, P4674, DOI 10.1200/JCO.2010.28.5064
   Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013
   Lang T, 2004, J LAB CLIN MED, V144, P163, DOI 10.1016/j.lab.2004.06.001
   Lewiecki EM, 2009, ENDOCR PRACT, V15, P573, DOI 10.4158/EP09107.RA
   Li LP, 2008, CANCER RES, V68, P9141, DOI 10.1158/0008 5472.CAN 08 1127
   Liu M, 2013, MOL ENDOCRINOL, V27, P657, DOI 10.1210/me.2012 1397
   Liu MH, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3137
   Marie P, 2008, M S MED SCI, V24, P105, DOI 10.1051/medsci/2008241105
   Mendoza N, 2012, CLIMACTERIC, V15, P587, DOI 10.3109/13697137.2012.656160
   Niu NF, 2010, GENOME RES, V20, P1482, DOI 10.1101/gr.107672.110
   Patterson N, 2006, PLOS GENET, V2, P2074, DOI 10.1371/journal.pgen.0020190
   Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Rabaglio M, 2009, ANN ONCOL, V20, P1489, DOI 10.1093/annonc/mdp033
   Richards JB, 2012, NAT REV GENET, V13, P576, DOI 10.1038/nrg3228
   Therneau TM, 1999, LIFETIME DATA ANAL, V5, P99, DOI 10.1023/A:1009691327335
   Vakulenko V I, 1990, Stomatologiia (Mosk), V69, P9
   Wang LW, 2011, NEW ENGL J MED, V364, P1144, DOI 10.1056/NEJMra1010600
   Wang MX, 2013, MOL CELL BIOL, V33, P678, DOI 10.1128/MCB.00618 12
   Wilson TJ, 2009, MOL CANCER RES, V7, P1224, DOI 10.1158/1541 7786.MCR 09 0028
NR 40
TC 38
Z9 44
U1 1
U2 4
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0888 8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD OCT
PY 2014
VL 28
IS 10
BP 1740
EP 1751
DI 10.1210/me.2014 1147
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AX3KA
UT WOS:000346837000015
PM 25148458
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Chan, K
   Leung, HCM
   Tsoi, JKH
AF Chan, Ki
   Leung, Henry Chi Ming
   Tsoi, James Kit Hon
TI Predictive QSAR model confirms flavonoids in Chinese medicine can
   activate voltage gated calcium (CaV) channel in osteogenesis
SO CHINESE MEDICINE
LA English
DT Article
DE QSAR; Flavonoids; Voltage gated calcium channels; Computer modelling
ID QSPR MODELS; INHIBITION; PHARMACOPHORE; PARAMETERS; DAIDZEIN; DESIGN
AB Background Flavonoids in Chinese Medicine have been proven in animal studies that could aid in osteogenesis and bone formation. However, there is no consented mechanism for how these phytochemicals action on the bone forming osteoblasts, and henceforth the prediction model of chemical screening for this specific biochemical function has not been established. The purpose of this study was to develop a novel selection and effective approach of flavonoids on the prediction of bone forming ability via osteoblastic voltage gated calcium (CaV) activation and inhibition using molecular modelling technique. Method Quantitative structure activity relationship (QSAR) in supervised maching learning approach is applied in this study to predict the behavioral manifestations of flavonoids in the CaV channels, and developing statistical correlation between the biochemical features and the behavioral manifestations of 24 compounds (Training set: Kaempferol, Taxifolin, Daidzein, Morin, Scutellarein, Quercetin, Apigenin, Myricetin, Tamarixetin, Rutin, Genistein, 5,7,2 ' Trihydroxyflavone, Baicalein, Luteolin, Galangin, Chrysin, Isorhamnetin, Naringin, 3 Methyl galangin, Resokaempferol; test set: 5 Hydroxyflavone, 3,6,4 ' Trihydroxyflavone, 3,4 ' Dihydroxyflavone and Naringenin). Based on statistical algorithm, QSAR provides a reasonable basis for establishing a predictive correlation model by a variety of molecular descriptors that are able to identify as well as analyse the biochemical features of flavonoids that engaged in activating or inhibiting the CaV channels for osteoblasts. Results The model has shown these flavonoids have high activating effects on CaV channel for osteogenesis. In addition, scutellarein was ranked the highest among the screened flavonoids, and other lower ranked compounds, such as daidzein, quercetin, genistein and naringin, have shown the same descending order as previous animal studies. Conclusion This predictive modelling study has confirmed and validated the biochemical activity of the flavonoids in the osteoblastic CaV activation.
C1 [Chan, Ki; Tsoi, James Kit Hon] Univ Hong Kong, Fac Dent, Div Appl Oral Sci & Community Dent Care, Dent Mat Sci,Pokfulam, Hong Kong, Peoples R China.
   [Leung, Henry Chi Ming] Univ Hong Kong, Fac Engn, Dept Comp Sci, Pokfulam, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong
RP Tsoi, JKH (通讯作者)，Univ Hong Kong, Fac Dent, Div Appl Oral Sci & Community Dent Care, Dent Mat Sci,Pokfulam, Hong Kong, Peoples R China.
EM jkhtsoi@hku.hk
RI ; Chan, Ki/AAO 5469 2020; Tsoi, James/F 6203 2012
OI Chan, Ki/0000 0002 7207 3511; Tsoi, James Kit Hon/0000 0002 0698 7155
CR Ali F, 2017, INT J FOOD PROP, V20, P1197, DOI 10.1080/10942912.2016.1207188
   Bergh JJ, 2006, AM J PHYSIOL CELL PH, V290, pC822, DOI 10.1152/ajpcell.00403.2005
   Bhadoriya KS, 2016, J SAUDI CHEM SOC, V20, pS256, DOI 10.1016/j.jscs.2012.11.001
   Blair H. C., 2007, V45, P539
   Cao XC, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1341 4
   Chakravarti SK, 2019, FRONT ARTIF INTELL, V2, DOI 10.3389/frai.2019.00017
   de Molfetta FA, 2008, J MOL MODEL, V14, P975, DOI 10.1007/s00894 008 0332 x
   Fernandez M, 2008, QSAR COMB SCI, V27, P866, DOI 10.1002/qsar.200760157
   Gao HW, 2018, PHYTOMEDICINE, V38, P145, DOI 10.1016/j.phymed.2017.11.012
   Goyal M, 2014, MED CHEM RES, V23, P2122, DOI 10.1007/s00044 013 0810 2
   Gramatica P, 2016, J CHEM INF MODEL, V56, P1127, DOI 10.1021/acs.jcim.6b00088
   Jain Shailesh V, 2012, Org Med Chem Lett, V2, P22, DOI 10.1186/2191 2858 2 22
   Jorgensen NR, 2003, J BIOL CHEM, V278, P4082, DOI 10.1074/jbc.M205880200
   Kawaguchi K, 2004, BIOL PHARM BULL, V27, P679, DOI 10.1248/bpb.27.679
   Khalatbary AR, 2010, BRAIN RES, V1306, P168, DOI 10.1016/j.brainres.2009.09.109
   Kholodovych V, 2004, POLYMER, V45, P7367, DOI 10.1016/j.polymer.2004.09.002
   Kim KH, 2006, FOOD CHEM, V95, P466, DOI 10.1016/j.foodchem.2005.01.032
   Laurenz R, 2017, J SCI FOOD AGR, V97, P3342, DOI 10.1002/jsfa.8184
   Lee SH, 1999, ANN NUTR METAB, V43, P173, DOI 10.1159/000012783
   Li W, 1997, AM J PHYSIOL ENDOC M, V273, pE599, DOI 10.1152/ajpendo.1997.273.3.E599
   Liu WQ, 2006, QSAR COMB SCI, V25, P936, DOI 10.1002/qsar.200510177
   Lo YC, 2018, DRUG DISCOV TODAY, V23, P1538, DOI 10.1016/j.drudis.2018.05.010
   Nishiya Y, 2002, CALCIFIED TISSUE INT, V70, P30, DOI 10.1007/s00223 001 1010 5
   Popova M, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aap7885
   Riddle RC, 2006, AM J PHYSIOL CELL PH, V290, pC776, DOI 10.1152/ajpcell.00082.2005
   RITCHIE CK, 1994, ENDOCRINOLOGY, V135, P996, DOI 10.1210/en.135.3.996
   Saponara S, 2011, BRIT J PHARMACOL, V164, P1684, DOI 10.1111/j.1476 5381.2011.01476.x
   TODESCHINI R, 2000, HDB MOL DESCRIPTORS, DOI DOI 10.1002/9783527613106
   Wang W, 2016, J SEP SCI, V39, P1357, DOI 10.1002/jssc.201501287
   Wong RWK, 2008, J ORTHOP RES, V26, P1061, DOI 10.1002/jor.20638
   Wong Ricky W K, 2010, Front Biosci (Elite Ed), V2, P764, DOI 10.2741/e136
   Wong RWK, 2009, FRONT BIOSCI LANDMRK, V14, P3673, DOI 10.2741/3479
   Wong RWK, 2006, BIOMATERIALS, V27, P1824, DOI 10.1016/j.biomaterials.2005.11.009
   Yu XL, 2008, J MOL MODEL, V14, P1065, DOI 10.1007/s00894 008 0339 3
NR 34
TC 8
Z9 8
U1 0
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 8546
J9 CHIN MED UK
JI Chin. Med.
PD MAR 31
PY 2020
VL 15
IS 1
AR 31
DI 10.1186/s13020 020 00313 1
PG 16
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA KZ0NI
UT WOS:000522968500001
PM 32256687
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chou, KN
   Park, DJ
   Hori, YS
   Persad, AR
   Chuang, CF
   Emrich, SC
   Ustrzynski, L
   Tayag, A
   Kumar, KA
   Usoz, M
   Mendoza, M
   Rahimy, E
   Pollom, E
   Soltys, SG
   Lo, CH
   Chang, SD
AF Chou, Kuan Nien
   Park, David J.
   Hori, Yusuke S.
   Persad, Amit R.
   Chuang, Cynthia F.
   Emrich, Sara C.
   Ustrzynski, Louisa
   Tayag, Armine
   Kumar, Kiran A.
   Usoz, Melissa
   Mendoza, Maria
   Rahimy, Elham
   Pollom, Erqi
   Soltys, Scott G.
   Lo, Cheng Hsiang
   Chang, Steven D.
TI Stereotactic body radiotherapy for painful spinal metastases: a decade
   of experience at a single institution
SO JOURNAL OF NEUROSURGERY SPINE
LA English
DT Article
DE antiresorptive agents; pain relief; spinal bone metastases; stereotactic
   body radiotherapy; oncology
ID RADIATION THERAPY; BONE METASTASES; PREOPERATIVE EVALUATION; SCORING
   SYSTEM; CANCER PAIN; CONSENSUS; FRACTIONATION; GUIDELINES; MANAGEMENT;
   DISEASE
AB OBJECTIVE This study aimed to retrospectively evaluate the efficacy of stereotactic body radiotherapy (SBRT) for pain relief in patients with painful spinal bone metastases (SBMs) and to identify key factors contributing to treatment outcomes. METHODS The authors conducted a retrospective analysis of adult patients who underwent SBRT for painful solid tumor SBMs between March 2012 and January 2023. During this period, SBRT was performed adhering to the International Spine Radiosurgery Consortium guidelines and international consensus recommendations for target volume delineation. To be included, patients needed to experience persistent pain directly associated with SBMs, warranting regular opioid treatment. Positive pain relief post SBRT was defined by three criteria: 1) a decrease in the severity of pain; 2) reduction in opioid dosage; and 3) concurrent improvement in daily activities. The revised Tokuhashi score and Spine Instability Neoplastic Score were used to identify crucial factors influencing treatment outcomes. RESULTS This study included 377 patients, covering 576 lesions across 759 vertebrae. Of these, 332 lesions showed significant pain relief within 3 months following SBRT. Lower pain relief rates were observed in patients with a revised Tokuhashi score of 0 8 or in patients with diabetes mellitus. In contrast, higher relief rates were linked to treating a single painful SBM in 1 SBRT course, and greater contouring of the involved sectors according to International Spine Radiosurgery Consortium guidelines and international consensus recommendations. The highest pain relief rate was observed in patients with prostate cancer (73.8%), whereas the lowest rate was observed in patients with hepatocellular carcinoma (36.4%). The presence of pre SBRT vertebral fractures, the dosage and fraction of SBRT, and the use of concurrent systemic cancer therapies or antiresorptive agents, including bisphosphonates and denosumab, did not notably influence the pain relief efficacy of SBRT. Comprehensive medical records 6 months after SBRT treatment were available for only 362 lesions. The overall rate of pain relief observed was 32.6%. CONCLUSIONS SBRT is an effective treatment approach for managing painful SBMs, achieving a pain relief rate of 57.6% within 3 months and maintaining a rate of 32.6% at 6 months after treatment. The transition to osteoblastic lesions may potentially improve the stability of SBMs, indicated by lower Spine Instability Neoplastic Score, which in turn could extend pain relief management.
C1 [Chou, Kuan Nien; Park, David J.; Hori, Yusuke S.; Persad, Amit R.; Emrich, Sara C.; Ustrzynski, Louisa; Tayag, Armine; Chang, Steven D.] Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA USA.
   [Chuang, Cynthia F.; Kumar, Kiran A.; Usoz, Melissa; Mendoza, Maria; Rahimy, Elham; Pollom, Erqi; Soltys, Scott G.] Stanford Univ, Dept Radiat Oncol, Sch Med, Stanford, CA USA.
   [Chou, Kuan Nien] Univ Paris, Dept Neurol Surg, Erlangen, Germany.
   [Lo, Cheng Hsiang] Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Radiat Oncol, Taipei, Taiwan.
C3 Stanford University; Stanford University; Tri Service General Hospital;
   National Defense Medical University
RP Chang, SD (通讯作者)，Stanford Univ, Sch Med, Stanford, CA 94305 USA.
EM sdchang@stanford.edu
RI ; Chang, Yu Chan/W 3582 2019
OI Rahimy, Elham/0000 0001 7356 3996; Hori, Yusuke S./0000 0001 9921 6810;
   Park, David Jaehyun/0000 0002 9858 2592
CR Aielli F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020280
   Aman MM, 2021, J PAIN RES, V14, P2139, DOI 10.2147/JPR.S315585
   Burton Allen W, 2012, J Support Oncol, V10, P89, DOI 10.1016/j.suponc.2011.08.004
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Cox BW, 2012, INT J RADIAT ONCOL, V83, pE597, DOI 10.1016/j.ijrobp.2012.03.009
   Davila D, 2015, SEMIN NUCL MED, V45, P3, DOI 10.1053/j.semnuclmed.2014.07.004
   Dennis K, 2013, RADIOTHER ONCOL, V106, P5, DOI 10.1016/j.radonc.2012.12.009
   Dunne EM, 2020, RADIOTHER ONCOL, V145, P21, DOI 10.1016/j.radonc.2019.11.026
   Fairchild A, 2009, INT J RADIAT ONCOL, V75, P1501, DOI 10.1016/j.ijrobp.2008.12.084
   Falkmer U, 2003, ACTA ONCOL, V42, P620, DOI 10.1080/02841860310014895
   Fisher CG, 2010, SPINE, V35, pE1221, DOI 10.1097/BRS.0b013e3181e16ae2
   Habberstad R, 2022, J PAIN SYMPTOM MANAG, V64, P330, DOI 10.1016/j.jpainsymman.2022.06.018
   Hagedorn JM, 2020, J PAIN RES, V13, P3295, DOI 10.2147/JPR.S263857
   Hochberg U, 2020, PAIN PHYSICIAN, V23, pE451
   Jensen GL, 2021, CUREUS J MED SCIENCE, V13, DOI 10.7759/cureus.15417
   Jimenez Andrade JM, 2010, ANN NY ACAD SCI, V1198, P173, DOI 10.1111/j.1749 6632.2009.05429.x
   Khan Majid, 2019, Top Magn Reson Imaging, V28, P85, DOI 10.1097/RMR.0000000000000199
   Li Gordon, 2007, Neurosurg Focus, V23, pE2
   Li KK, 2008, CLIN ONCOL UK, V20, P83, DOI 10.1016/j.clon.2007.09.009
   Lozano Ondoua AN, 2013, NEUROSCI LETT, V557, P52, DOI 10.1016/j.neulet.2013.08.003
   Mantyh PW, 2014, CURR OPIN SUPPORT PA, V8, P83, DOI 10.1097/SPC.0000000000000048
   Mureb M, 2021, J NEUROSURG, V135, P237, DOI 10.3171/2020.4.JNS192780
   Paice JA, 2023, J CLIN ONCOL, V41, P914, DOI 10.1200/JCO.22.02198
   Palma DA, 2019, LANCET, V393, P2051, DOI 10.1016/S0140 6736(18)32487 5
   Park C, 2008, INT J RADIAT ONCOL, V70, P847, DOI 10.1016/j.ijrobp.2007.10.059
   Pielkenrood BJ, 2021, INT J RADIAT ONCOL, V110, P358, DOI 10.1016/j.ijrobp.2020.11.060
   Pinho Ribeiro FA, 2017, TRENDS IMMUNOL, V38, P5, DOI 10.1016/j.it.2016.10.001
   Rich SE, 2018, RADIOTHER ONCOL, V126, P547, DOI 10.1016/j.radonc.2018.01.003
   Rief H, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748 717X 8 200
   Roos DE, 2015, ANN PALLIAT MED, V4, P220, DOI 10.3978/j.issn.2224 5820.2015.08.03
   Schlampp I, 2014, STRAHLENTHER ONKOL, V190, P792, DOI 10.1007/s00066 014 0651 z
   Stearns LJ, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.1549
   Stearns LM, 2020, ANESTH ANALG, V130, P289, DOI 10.1213/ANE.0000000000004425
   Steinberger JM, 2020, NEURO ONCOL PRACT, V7, P33, DOI 10.1093/nop/npaa048
   Takei D, 2023, J BONE MINER METAB, V41, P327, DOI 10.1007/s00774 022 01382 y
   Tokuhashi Y, 2005, SPINE, V30, P2186, DOI 10.1097/01.brs.0000180401.06919.a5
   Tokuhashi Y, 2009, SPINE, V34, P69, DOI 10.1097/BRS.0b013e3181913f19
   Vakaet LAML, 2004, INT J DEV BIOL, V48, P599, DOI 10.1387/ijdb.041817lv
   Wang Q, 2019, J RADIAT RES, V60, P394, DOI 10.1093/jrr/rry098
   Wu JSY, 2003, INT J RADIAT ONCOL, V55, P594, DOI 10.1016/S0360 3016(02)04147 0
   Yang YL, 2023, BMC NURS, V22, DOI 10.1186/s12912 023 01259 z
   Zajaczkowska R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236047
   Zaveri GR, 2021, INDIAN J ORTHOP, V55, P799, DOI 10.1007/s43465 021 00368 8
   Zeng KL, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00337
   Zhang HR, 2020, TECHNOL CANCER RES T, V19, DOI 10.1177/1533033820945798
   Zhu XC, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S87568
NR 46
TC 2
Z9 2
U1 0
U2 0
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 1547 5654
EI 1547 5646
J9 J NEUROSURG SPINE
JI J. Neurosurg. Spine
PD OCT
PY 2024
VL 41
IS 4
BP 532
EP 540
DI 10.3171/2024.5.SPINE231326
PG 9
WC Clinical Neurology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Surgery
GA K4B9B
UT WOS:001343353800007
PM 39126716
OA hybrid
DA 2025 08 17
ER

PT J
AU Curylofo Zotti, FA
   Elburki, MS
   Oliveira, PA
   Cerri, PS
   Santos, LA
   Lee, HM
   Johnson, F
   Golub, LM
   Rossa, C
   Guimaraes Stabili, MR
AF Curylofo Zotti, Fabiana Almeida
   Elburki, Muna S.
   Oliveira, Priscilla Aparecida
   Cerri, Paulo Sergio
   Santos, Leandro Alves
   Lee, Hsi Ming
   Johnson, Francis
   Golub, Lorne M.
   Rossa Junior, Carlos
   Guimaraes Stabili, Morgana Rodrigues
TI Differential effects of natural Curcumin and chemically modified
   curcumin on inflammation and bone resorption in model of experimental
   periodontitis
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE Bone resorption; Chemically modified curcumin (CMC2.24); Periodontal
   disease; Lipopolysaccharide; Inflammation
ID NF KAPPA B; ANIMAL MODELS; APOPTOSIS; INHIBITION; EXPRESSION; THERAPY;
   EXTRACT; DISEASE; TISSUE; GENES
AB Objective: The purpose of this study was to compare the effects of the oral administration of natural curcumin and a chemically modified curcumin (CMC2.24) on osteoclast mediated bone resorption, apoptosis, and inflammation in a murine model of experimental periodontal disease.
   Design: Fifty male rats were distributed among the following treatment groups: (i) 2% carboxymethylcellulose, (ii) CMC2.24 30 mg/kg body weight, (iii) Curcumin 100 mg/kg body weight and (iv) no treatment. Compounds were administered daily by oral intubation over a 15 day period of time. Periodontal disease was induced by injections of LPS (lipopolysaccharide) into the gingival tissues three times per week. Contralateral sides were injected with the same volume of PBS (phosphate buffered saline) vehicle. After 15 days, hemimaxillae and gingival tissues were harvested. Bone resorption was assessed by mu CT (microcomputer tomography). Formalinfixed, paraffin embedded histological sections were stained with haematoxylin/eosin (H/E) for the assessment of cellular infiltrate or subjected to immunohistochemistry for detecting TRAP (tartrate resistant acid phosphatase) positive cells and caspase 3. Apoptosis was assessed in the gingival tissues by DNA fragmentation.
   Results: CMC2.24 and curcumin caused a significant reduction of the inflammatory cell infiltrate, however mu CT analysis showed that only CMC2.24 reduced bone resorption and the number of TRAP positive multinucleated cells (osteoclasts). Curcumin, but not CMC2.24, significantly reduced the number of apoptotic cells in the gingival tissues and of osteocytes in the alveolar bone crest.
   Conclusions: The results suggest that CMC2.24 and curcumin inhibit inflammation by different mechanisms, but only CMC2.24 was capable of reducing alveolar bone resorption in the LPS induced model of periodontitis.
C1 [Curylofo Zotti, Fabiana Almeida; Santos, Leandro Alves; Rossa Junior, Carlos; Guimaraes Stabili, Morgana Rodrigues] Univ Sao Paulo, Dept Restorat Dent, Sch Dent Riberao Preto, Ribeirao Preto, SP, Brazil.
   [Elburki, Muna S.; Lee, Hsi Ming; Golub, Lorne M.] SUNY Stony Brook, Sch Dent Med, Dept Oral Biol & Pathol, Stony Brook, NY 11794 USA.
   [Oliveira, Priscilla Aparecida; Cerri, Paulo Sergio] UNESP, Sch Dent Araraquara, Lab Histol & Embryol, Araraquara, SP, Brazil.
   [Johnson, Francis] SUNY Stony Brook, Dept Chem & Pharmacol Sci, Stony Brook, NY 11794 USA.
   [Curylofo Zotti, Fabiana Almeida] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Restorat Dent, Ribeirao Preto, SP, Brazil.
C3 Universidade de Sao Paulo; State University of New York (SUNY) System;
   Stony Brook University; Universidade Estadual Paulista; State University
   of New York (SUNY) System; Stony Brook University; Universidade de Sao
   Paulo
RP Guimaraes Stabili, MR (通讯作者)，Univ Sao Paulo, Dept Restorat Dent, Sch Dent Riberao Preto, Ribeirao Preto, SP, Brazil.
EM morganaguimaraes@foar.unesp.br
RI Almeida Curylofo Zotti, Fabiana/C 8954 2014; Rossa Jr,
   Carlos/D 8328 2012; Curylofo Zotti, Fabiana/C 8954 2014; Elburki,
   Muna/H 3405 2019; Cerri, Paulo/F 5338 2012; guimaraes,
   morgana/C 8966 2014; STABILI, MORGANA/ABC 9852 2021; Cerri,
   Paulo/AAC 5797 2019
OI Almeida Curylofo Zotti, Fabiana/0000 0002 0482 6956; Elburki,
   Muna/0000 0003 2657 6078; Rossa Jr, Carlos/0000 0003 1705 5481; Cerri,
   Paulo/0000 0001 5756 5828; Alves dos Santos,
   Leandro/0000 0001 8088 5790; guimaraes, morgana/0000 0002 1297 9717; 
FU FAPESP [2010/19660 2]; Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [10/19660 2] Funding Source: FAPESP
FX Financial support provided by FAPESP < gn1 > 2010/19660 2 < /gn1 >.
CR Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Bundy R, 2004, J ALTERN COMPLEM MED, V10, P1015, DOI 10.1089/acm.2004.10.1015
   Cabahug Zuckerman P, 2016, J BONE MINER RES, V31, P1356, DOI 10.1002/jbmr.2807
   Corrêa MG, 2017, J PERIODONTAL RES, V52, P201, DOI 10.1111/jre.12382
   Dentino A, 2013, PERIODONTOL 2000, V61, P16, DOI 10.1111/j.1600 0757.2011.00397.x
   DEODHAR SD, 1980, INDIAN J MED RES, V71, P632
   Di Martino RMC, 2017, EXPERT OPIN THER PAT, V27, P579, DOI 10.1080/13543776.2017.1276566
   Elburki MS, 2017, J PERIODONTAL RES, V52, P186, DOI 10.1111/jre.12381
   Elburki MS, 2017, INFLAMMATION, V40, P1436, DOI 10.1007/s10753 017 0587 4
   Elburki MS, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/959471
   Emoto Y, 2013, IN VIVO, V27, P583
   Garcea G, 2004, BRIT J CANCER, V90, P1011, DOI 10.1038/sj.bjc.6601623
   Golub L M, 1992, Curr Opin Dent, V2, P80
   Graves DT, 2012, FRONT ORAL BIOL, V15, P117, DOI 10.1159/000329675
   Guimaraes MR, 2011, J PERIODONTAL RES, V46, P269, DOI 10.1111/j.1600 0765.2010.01342.x
   Guimaraes MR, 2012, INNATE IMMUN LONDON, V18, P155, DOI 10.1177/1753425910392935
   Hajishengallis G, 2015, VIRULENCE, V6, P229, DOI 10.4161/21505594.2014.990806
   Hanai H, 2006, CLIN GASTROENTEROL H, V4, P1502, DOI 10.1016/j.cgh.2006.08.008
   Heng MCY, 2000, BRIT J DERMATOL, V143, P937, DOI 10.1046/j.1365 2133.2000.03767.x
   Holt PR, 2005, DIGEST DIS SCI, V50, P2191, DOI 10.1007/s10620 005 3032 8
   Jain A, 2018, MOL CELL BIOCHEM, V442, P81, DOI 10.1007/s11010 017 3195 6
   Jancinova Viera, 2011, Interdiscip Toxicol, V4, P11, DOI 10.2478/v10102 011 0003 0
   Jancinová V, 2009, EUR J PHARMACOL, V612, P161, DOI 10.1016/j.ejphar.2009.03.080
   Jilka RL, 2016, CURR OSTEOPOROS REP, V14, P16, DOI 10.1007/s11914 016 0297 0
   Komori T, 2016, HORM METAB RES, V48, P755, DOI 10.1055/s 0042 110571
   Kumar A, 2010, CRIT REV THER DRUG, V27, P279, DOI 10.1615/CritRevTherDrugCarrierSyst.v27.i4.10
   Lao Christopher D, 2006, BMC Complement Altern Med, V6, P10, DOI 10.1186/1472 6882 6 10
   Li W, 2017, MOL MED REP, V16, P4710, DOI 10.3892/mmr.2017.7205
   Liou AT, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/4063865
   Lu YM, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317698353
   Montazeri M, 2016, INT J PHARMACEUT, V509, P244, DOI 10.1016/j.ijpharm.2016.05.039
   Pfeffer CM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020448
   Prasad NS, 2004, PROSTAG LEUKOTR ESS, V70, P521, DOI 10.1016/j.plefa.2003.11.006
   Rashi K, 2017, BIOCHEM PHARMACOL, V143, P140, DOI 10.1016/j.bcp.2017.07.009
   Saha L, 2016, INDIAN J EXP BIOL, V54, P133
   Schwertheim S, 2017, J CANCER RES CLIN, V143, P1143, DOI 10.1007/s00432 017 2380 z
   Seo JA, 2016, CANCER LETT, V371, P30, DOI 10.1016/j.canlet.2015.11.021
   Sharma RA, 2001, CLIN CANCER RES, V7, P1894
   Sharma RA, 2004, CLIN CANCER RES, V10, P6847, DOI 10.1158/1078 0432.CCR 04 0744
   Sharma RA, 2005, EUR J CANCER, V41, P1955, DOI 10.1016/j.ejca.2005.05.009
   Shehzad A, 2013, CHEM BIOL INTERACT, V206, P394, DOI 10.1016/j.cbi.2013.10.007
   Shi J, 2017, MOL MED REP, V16, P2588, DOI 10.3892/mmr.2017.6935
   Shoba G, 1998, PLANTA MED, V64, P353, DOI 10.1055/s 2006 957450
   Vernillo A T, 1994, Curr Opin Periodontol, P111
   Zhang Y, 2012, CURR MED CHEM, V19, P4367, DOI 10.2174/092986712802884240
   Zhou QM, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935 017 0453 3
   Zhou T, 2013, ACTA ODONTOL SCAND, V71, P349, DOI 10.3109/00016357.2012.682092
NR 47
TC 43
Z9 49
U1 0
U2 34
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0003 9969
EI 1879 1506
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD JUL
PY 2018
VL 91
BP 42
EP 50
DI 10.1016/j.archoralbio.2018.04.007
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA GG5XF
UT WOS:000432768400006
PM 29669267
OA Green Published
DA 2025 08 17
ER

PT J
AU Milanez, FM
   Saad, CGS
   Viana, VT
   Moraes, JCB
   Périco, GV
   Sampaio Barros, PD
   Goncalves, CR
   Bonfá, E
AF Milanez, Fernanda Manente
   Saad, Carla G. S.
   Viana, Vilma T.
   Moraes, Julio C. B.
   Perico, Gregory Vinicius
   Sampaio Barros, Percival Degrava
   Goncalves, Celio R.
   Bonfa, Eloisa
TI IL 23/Th17 axis is not influenced by TNF blocking agents in ankylosing
   spondylitis patients
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE Ankylosing spondylitis; Anti TNF drugs; Inflammation; Interleukin 23;
   Interleukin 17; Prostaglandin E2
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RADIOGRAPHIC PROGRESSION;
   DISEASE ACTIVITY; BONE FORMATION; INTERLEUKIN 23; SPONDYLOARTHRITIS;
   ANTIBODY; TARGET; CELLS; RECOMMENDATIONS
AB Background: Advances in pathophysiology and treatment of ankylosing spondylitis (AS) was recently demonstrated. However, the effect of anti TNF in the newly described inflammatory pathways involved pathogenesis of this disease remains to be determined. The aim of our study was, therefore, to investigate long term influence of anti TNF drugs in IL 23/IL 17 axis of AS patients and their possible correlation with treatment, clinical, laboratory and radiographic parameters.
   Methods: Eighty six AS anti TNF naive patients, 47 referred for anti TNF therapy (active AS; BASDAI >= 4) and 39 with BASDAI < 4 (control AS) were included. The active group was evaluated at baseline, 12 months and 24 months after TNF blockade and compared at baseline to control AS group and to 47 healthy age and gender matched controls. Plasma levels of IL 17A, IL 22, IL 23 and PGE2 were measured. Non steroidal anti inflammatory drugs (NSAIDs) intake were recorded every 6 months. Radiographic severity and progression was assessed by mSASSS at baseline and 24 months after therapy.
   Results: At baseline, active AS group presented higher IL 23 and PGE2 levels compared to control AS group (p < 0.001 and p = 0.008) and to healthy controls (p < 0.001 and p = 0.02). After 24 months of TNF blockade, IL 23 and PGE2 remained elevated with higher levels compared with the healthy group (p < 0.001 and p = 0.03) in spite of significant improvements in all clinical/inflammatory parameters (p < 0.001). Further analysis of 27 anti TNF treated patients who achieved a good response (ASDAS CRP < 2.1, with a drop >= 1.1) at 24 months revealed that IL 23 plasma levels remained higher than healthy controls (p < 0.001) and higher than control AS group with similar disease activity (ASDAS CRP < 2.1, p = 0.01). In active AS group (n = 47), there was a strong correlation between IL 23 and IL 17A at baseline, 12 months and 24 months after anti TNF therapy (p <= 0.001).
   Conclusion: This study provides novel data demonstrating that the IL 23/IL 17 axis is not influenced by TNF blockade in AS patients despite clinical and inflammation improvements and NSAID intake.
C1 [Milanez, Fernanda Manente; Saad, Carla G. S.; Viana, Vilma T.; Moraes, Julio C. B.; Sampaio Barros, Percival Degrava; Goncalves, Celio R.; Bonfa, Eloisa] Univ Sao Paulo Reumatol, Fac Med, Div Rheumatol, Ave Dr Arnaldo 455,3 Andar,Sala 3192, BR 05403010 Sao Paulo, SP, Brazil.
   [Perico, Gregory Vinicius] URC, Rua Antonio de Lucca 139, BR 88811503 Criciuma, SC, Brazil.
RP Saad, CGS (通讯作者)，Univ Sao Paulo Reumatol, Fac Med, Div Rheumatol, Ave Dr Arnaldo 455,3 Andar,Sala 3192, BR 05403010 Sao Paulo, SP, Brazil.
EM goncalves carla@uol.com.br
RI Bonfa, Eloisa/B 8438 2012; Saad, Carla/P 5230 2014; Moraes,
   Julio/J 8538 2014; BARROS, PERCIVAL/B 3298 2014
OI Bonfa, Eloisa/0000 0002 0520 4681; SAMPAIO BARROS,
   PERCIVAL/0000 0001 9843 6686; 
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2009/51897 5]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico [301411/2009 3]; Frederico Foundation
FX Acknowledgements This study was supported by grants from Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP #2009/51897 5 to EB),
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (#301411/2009 3 to EB), and the Frederico Foundation (to CGSS, PDS B,
   and EB).
CR Appel H, 2013, ARTHRITIS RHEUM US, V65, P1522, DOI 10.1002/art.37937
   Baeten D, 2013, LANCET, V382, P1705, DOI 10.1016/S0140 6736(13)61134 4
   Baraliakos X, 2009, J RHEUMATOL, V36, P997, DOI 10.3899/jrheum.080871
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Bowness P, 2011, J IMMUNOL, V186, P2672, DOI 10.4049/jimmunol.1002653
   Chai W, 2013, PLOS ONE, V19
   Chen WS, 2012, J CHIN MED ASSOC, V75, P303, DOI 10.1016/j.jcma.2012.05.006
   Ciccia F, 2014, ANN RHEUM DIS, V73, P1566, DOI 10.1136/annrheumdis 2012 202925
   Ciccia F, 2009, ARTHRITIS RHEUM US, V60, P955, DOI 10.1002/art.24389
   Colbert RA, 2014, MOL IMMUNOL, V57, P44, DOI 10.1016/j.molimm.2013.07.013
   Cortes A, 2015, ANN RHEUM DIS, V74, P1387, DOI 10.1136/annrheumdis 2013 204835
   Creemers MCW, 2005, ANN RHEUM DIS, V64, P127, DOI 10.1136/ard.2004.020503
   Dougados M, 2011, ANN RHEUM DIS, V70, P249, DOI 10.1136/ard.2010.133488
   Gagliardi MC, 2010, J LEUKOCYTE BIOL, V88, P947, DOI 10.1189/jlb.0310139
   Gaston JSH, 2011, ARTHRITIS RHEUM US, V63, P3668, DOI 10.1002/art.30600
   Haroon N, 2013, ARTHRITIS RHEUM US, V65, P2645, DOI 10.1002/art.38070
   Hreggvidsdottir HS, 2014, MOL IMMUNOL, V57, P28, DOI 10.1016/j.molimm.2013.07.016
   Kenna TJ, 2012, ARTHRITIS RHEUM US, V64, P1420, DOI 10.1002/art.33507
   Leonardi C, 2012, NEW ENGL J MED, V366, P1190, DOI 10.1056/NEJMoa1109997
   Li M, 2007, INT ORTHOP, V31, P767, DOI 10.1007/s00264 007 0406 x
   Machado P, 2011, ANN RHEUM DIS, V70, P47, DOI 10.1136/ard.2010.138594
   Maksymowych WP, 2013, NAT REV RHEUMATOL, V9, P507, DOI 10.1038/nrrheum.2013.123
   McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698
   Mei Y, 2011, CLIN RHEUMATOL, V30, P269, DOI 10.1007/s10067 010 1647 4
   Melis L, 2010, ANN RHEUM DIS, V69, P618, DOI 10.1136/ard.2009.107649
   Miossec P, 2012, NAT REV DRUG DISCOV, V11, P763, DOI 10.1038/nrd3794
   Newport M, 2007, NAT GENET, V39, P1329, DOI 10.1038/ng.2007.17
   Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017
   Poddubnyy D, 2014, ANN RHEUM DIS, V73, P817, DOI 10.1136/annrheumdis 2013 204248
   Poddubnyy D, 2012, ANN RHEUM DIS, V71, P1616, DOI 10.1136/annrheumdis 2011 201252
   Poddubnyy D, 2012, ARTHRITIS RHEUM US, V64, P1388, DOI 10.1002/art.33465
   Ramiro S, 2015, ANN RHEUM DIS, V74, P52, DOI 10.1136/annrheumdis 2013 204055
   Sherlock JP, 2014, MOL IMMUNOL, V57, P38, DOI 10.1016/j.molimm.2013.06.010
   Sherlock JP, 2012, NAT MED, V18, P1069, DOI 10.1038/nm.2817
   Sieper J, 2009, ANN RHEUM DIS, V68, P1, DOI 10.1136/ard.2008.104018
   Smith JA, 2014, ARTHRITIS RHEUMATOL, V66, P231, DOI 10.1002/art.38291
   Smolen JS, 2014, ANN RHEUM DIS, V73, P6, DOI 10.1136/annrheumdis 2013 203419
   Sveaas SH, 2015, SCAND J RHEUMATOL, V44, P118, DOI 10.3109/03009742.2014.956142
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P1324, DOI 10.1002/art.23471
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P3063, DOI 10.1002/art.23901
   van der Heijde D, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2794
   van der Heijde SJ, 2010, ANN RHEUM DIS, V2011, P905, DOI DOI 10.1136/ARD.2011.151563
   VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361
   Wanders A, 2005, ARTHRITIS RHEUM US, V52, P1756, DOI 10.1002/art.21054
   Wang XW, 2009, RHEUMATOL INT, V29, P1343, DOI 10.1007/s00296 009 0883 x
   Yeremenko N, 2014, CURR OPIN RHEUMATOL, V26, P361, DOI 10.1097/BOR.0000000000000069
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
   Zeng L, 2011, ARTHRITIS RHEUM US, V63, P3807, DOI 10.1002/art.30593
   Zhang JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087706
   Zúñiga LA, 2013, IMMUNOL REV, V252, P78, DOI 10.1111/imr.12036
NR 50
TC 35
Z9 37
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD FEB 24
PY 2016
VL 18
AR 52
DI 10.1186/s13075 016 0949 6
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA DE7SN
UT WOS:000370837100001
PM 26912133
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ghidini, G
   Mori, D
   Pulcini, S
   Vescovi, P
   Sala, R
AF Ghidini, Giulia
   Mori, Daniele
   Pulcini, Stefano
   Vescovi, Paolo
   Sala, Roberto
TI Photobiomodulation with a 645 nm Diode Laser of Saos 2 Cells and
   Platelet Rich Plasma: The Potential for a New Mechanism of Action
SO PHOTOBIOMODULATION PHOTOMEDICINE AND LASER SURGERY
LA English
DT Article
DE low level laser; cell differentiation; osteoblast; cell proliferation
ID LIGHT THERAPY
AB Objective: The main focus of this in vitro study was to highlight possible differences between outcomes of photobiomodulation performed in the presence or absence of growth factors derived from platelet rich plasma.
   Background: Photobiomodulation has garnered increasing attention, thanks to a large number of controlled clinical trials that have proven its efficacy in various oral pathologies. Nevertheless, the mechanism of action is still a matter of debate.
   Materials and methods: The cell model used was Saos 2ATTC HTB 85, a human osteosarcoma cell line that retains an osteogenic potential matching that of osteoblastic cells. Photobiomodulation was performed with a 645 nm diode laser; we investigated three different fluence values (2, 5, and 10 J/cm(2)) delivered with 3 different irradiation times (1, 2, and 4 min). The design of the study included a case control structure. Cell viability was assessed by resazurin reduction assay before laser irradiation. We assessed cell differentiation by Alizarin red Sigma Aldrich assay 48 h after the last laser irradiation.
   Results: Results show that the combination of photobiomodulation and platelet rich plasma can lead to a statistically significant increase in both proliferation and differentiation rates.
   Conclusions: Only a defined amount of energy, that is, a fluence of 5 J/cm(2) delivered in 2 min and of 10 J/cm(2) in 4 min, was proven to be the most effective in the presence of platelet rich plasma to induce cell proliferation and calcium deposition.
C1 [Ghidini, Giulia] Univ Parma, Mol Med, Parma, Italy.
   [Ghidini, Giulia; Vescovi, Paolo] Univ Parma, Univ Ctr Dent, Dept Med & Surg, Oral Med & Oral Surg Laser Unit, I 43100 Parma, Italy.
   [Mori, Daniele; Pulcini, Stefano; Sala, Roberto] Univ Parma, Dept Med & Surg, Gen Pathol Unit, Parma, Italy.
C3 University of Parma; University of Parma; University of Parma
RP Vescovi, P (通讯作者)，Univ Parma, Univ Ctr Dent, Dept Med & Surg, Oral Med & Oral Surg Laser Unit, I 43100 Parma, Italy.
EM paolo.vescovi@unipr.it
RI Sala, Roberto/B 9736 2013; Ghidini, Giulia/LIC 2880 2024
OI Sala, Roberto/0000 0002 9167 0020; Ghidini, Giulia/0000 0002 5211 2595; 
FU Universita degli Studi di Parma [FIL2019]
FX This work was supported by the Universita degli Studi di Parma (grant
   FIL2019 to RS).
CR Aleksic V, 2010, LASER MED SCI, V25, P559, DOI 10.1007/s10103 010 0761 5
   Alves R, 2018, SKIN APPENDAGE DISOR, V4, P18, DOI 10.1159/000477353
   Amable PR, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt218
   Budi EH, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa9432
   Chang B, 2019, MED SCI MONITOR, V25, P8744, DOI 10.12659/MSM.920396
   de Freitas LF, 2016, IEEE J SEL TOP QUANT, V22, DOI 10.1109/JSTQE.2016.2561201
   Deana AM, 2018, LASER MED SCI, V33, P1147, DOI 10.1007/s10103 018 2486 9
   Ferraresi C, 2015, PHOTOCHEM PHOTOBIOL, V91, P411, DOI 10.1111/php.12397
   Ghiacci G, 2019, J APPL ORAL SCI, V27, DOI 10.1590/1678 7757 2018 0014
   Ghidini G, 2019, J DENT INDONES, V26, P75, DOI 10.14693/jdi.v26i2.1321
   Huang YY, 2011, DOSE RESPONSE, V9, P602, DOI 10.2203/dose response.11 009.Hamblin
   Jacques SL, 2013, PHYS MED BIOL, V58, pR37, DOI 10.1088/0031 9155/58/11/R37
   Karu TI, 2008, PHOTOCHEM PHOTOBIOL, V84, P1091, DOI 10.1111/j.1751 1097.2008.00394.x
   Kobayashi E, 2016, CLIN ORAL INVEST, V20, P2353, DOI 10.1007/s00784 016 1719 1
   Martinotti S, 2014, CURR PHARM BIOTECHNO, V15, P120, DOI 10.2174/1389201015666140604121407
   O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432 1327.2000.01606.x
   Ogino Y, 2006, ORAL SURG ORAL MED O, V101, P724, DOI 10.1016/j.tripleo.2005.08.016
   Pandeshwar P, 2016, J INVESTIG CLIN DENT, V7, P114, DOI 10.1111/jicd.12148
   Pastore D, 2000, INT J RADIAT BIOL, V76, P863, DOI 10.1080/09553000050029020
   Prideaux M, 2014, CALCIFIED TISSUE INT, V95, P183, DOI 10.1007/s00223 014 9879 y
   Salehpour F, 2019, PHOTOBIOMOD PHOTOMED, V37, P581, DOI 10.1089/photob.2019.4676
   Tani A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071946
   Zhang F, 2016, CELL MOL LIFE SCI, V73, P4577, DOI 10.1007/s00018 016 2282 2
   Zhang Z, 2020, AGING CELL, V19, DOI 10.1111/acel.13054
NR 24
TC 3
Z9 3
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
EI 2578 5478
J9 PHOTOBIOMOD PHOTOMED
JI Photobiomodulation Photomed. Laser Surg.
PD FEB 1
PY 2021
VL 39
IS 2
BP 86
EP 93
DI 10.1089/photob.2020.4839
EA JAN 2021
PG 8
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA QJ2AR
UT WOS:000610545600001
PM 33471588
DA 2025 08 17
ER

PT J
AU Torres, PU
AF Torres, Pablo Urena
TI Cinacalcet HCl: A novel treatment for secondary hyperparathyroidism
   caused by chronic kidney disease
SO JOURNAL OF RENAL NUTRITION
LA English
DT Article; Proceedings Paper
CT 4th International Congress on Uremia Research and Toxicity
CY SEP 14 17, 2006
CL Izmir, TURKEY
SP Int Soc Uremic Toxic
ID PARATHYROID HORMONE LEVELS; CHRONIC RENAL FAILURE;
   CARDIOVASCULAR DISEASE; CA2+ SENSING RECEPTOR; CALCIMIMETIC AMG 073;
   SENSING RECEPTOR; SHORT TERM; CALCIUM; METABOLISM; PATHOPHYSIOLOGY
AB Secondary hyperparathyroidism (SHPT) develops as a result of impaired calcium homeostasis when the failing kidneys disturb the complicated interactions between parathyroid hormone (PTH), calcium, phosphorus, and vitamin D. Twelve years ago, the calcium sensing receptor (CaR) of the parathyroid gland was first cloned and identified as the principal regulator of PTH secretion. The activation of the CaR by small changes in extracellular calcium ((ec)(Ca2+)) regulates PTH, calcitonin secretion, urinary calcium excretion, and ultimately, bone turnover. The CaR became an ideal target for the development of calcimimetics, which are able to amplify its sensitivity to (ec)(Ca2+) suppressing PTH secretion. Cinacalcet HCl, a first in class calcimimetic, approved in both the United States and the European Union, offers a new therapeutic approach to the treatment of SHPT. The efficacy of cinacalcet HCl in treating SHPT in dialysis patients (n = 1,136) was studied in three similarly designed phase III clinical trials comparing patients receiving standard SHPT therapy plus cinacalcet HCl or plus placebo. Cinacalcet HCl, dosed from 30 to 180 mg/day, significantly reduced PTH while simultaneously lowering calcium, phosphorus, and calcium phosphorus product in each of the three studies. Respective to the National Kidney Foundation Kidney Disease Outcomes and Quality Initiative (NKF K/DOQI) recommended targets for bone and mineral metabolism, 41% of cinacalcet HCl treated patients achieved both PTH and calcium phosphorus product targets, compared with only 6% in the placebo group. Results from 2 recent phase IIIb studies (TARGET and CONTROL) conducted in the United States also showed that cinacalcet HCl can significantly reduce or maintain reduction in PTH while simultaneously lowering calcium, phosphorus, and calcium phosphorus product. In addition, patients taking vitamin D at baseline of these 2 trials were able to see significant mean reductions in vitamin D dose. Further assessment of cinacalcet HCl trial data has shown some important effects in SHPT patient clinical outcomes. A combined post hoc analysis of clinical events using data from 4 (n = 1,184) cinacalcet HCl phase II and III studies suggests that treatment with cinacalcet HCl has a beneficial effect on relative risks of parathyroidectomy, fracture, and hospitalization for cardiovascular complications. Nausea and vomiting occurred more often in patients taking cinacalcet HCl than in those taking a placebo. There were also transient episodes of hypocalcemia in 5% of cinacalcet HCl patients versus 1% of placebo patients. However, these episodes were rarely associated with symptoms. The development of calcimimetics has already changed the treatment of SHPT in renal patients. Its effectiveness on the control of PTH secretion, along with simultaneous reductions in calcium, phosphorus, and calcium phosphorus product, give this agent an advantage over traditional therapies in all levels of severity of SHPT. (C) 2006 by the National Kidney Foundation, Inc.
C1 Serv Nephrol & Dialyse, Clin Orangerie, F 93300 Aubervilliers, France.
   Hop Necker Enfants Malad, Serv Physiol Explorat Fonct, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Necker Enfants Malades   APHP
RP Torres, PU (通讯作者)，Serv Nephrol & Dialyse, Clin Orangerie, 11 Blvd Anatole France, F 93300 Aubervilliers, France.
EM urena.pablo@wanadoo.fr
RI Torres, Pablo/LBH 6671 2024
CR AMANN K, 1995, NEPHROL DIAL TRANSPL, V10, P2043
   Amann K, 1997, Adv Ren Replace Ther, V4, P212
   [Anonymous], J AM SOC NEPHROLOGY
   Antonsen JE, 1998, KIDNEY INT, V53, P223, DOI 10.1046/j.1523 1755.1998.00735.x
   ARNOLD A, 1995, J CLIN INVEST, V95, P2047, DOI 10.1172/JCI117890
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0
   BUSHINSKY DA, 2004, OFF EV S ASN 2004 AM
   Coburn J. W., 2000, Journal of the American Society of Nephrology, V11, p573A
   Collins MT, 1998, J CLIN ENDOCR METAB, V83, P1083, DOI 10.1210/jc.83.4.1083
   Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523 1755.2005.00596.x
   Drueke T., 2001, Journal of the American Society of Nephrology, V12, p764A
   Evenepoel P, 2004, NEPHROL DIAL TRANSPL, V19, P1281, DOI 10.1093/ndt/gfh128
   FUKUDA N, 1993, J CLIN INVEST, V92, P1436, DOI 10.1172/JCI116720
   GAGNE ER, 1992, J AM SOC NEPHROL, V3, P1008
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Gogusev J, 1997, KIDNEY INT, V51, P328, DOI 10.1038/ki.1997.41
   Goodman WG, 2000, KIDNEY INT, V58, P436, DOI 10.1046/j.1523 1755.2000.00183.x
   Kessler A, 2004, BIOORG MED CHEM LETT, V14, P3345, DOI 10.1016/j.bmcl.2004.03.056
   Kifor O, 1996, J CLIN ENDOCR METAB, V81, P1598, DOI 10.1210/jc.81.4.1598
   Kosch M, 2000, CARDIOVASC RES, V47, P813, DOI 10.1016/S0008 6363(00)00130 9
   Kruse AE, 2005, NEPHROL DIAL TRANSPL, V20, P1311, DOI 10.1093/ndt/gfh924
   Lindberg JS, 2003, KIDNEY INT, V63, P248, DOI 10.1046/j.1523 1755.2003.00720.x
   London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414
   MASSRY SG, 1994, SEMIN NEPHROL, V14, P219
   Moe SM, 2005, NEPHROL DIAL TRANSPL, V20, P2186, DOI 10.1093/ndt/gfh966
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040
   Petrel C, 2004, J BIOL CHEM, V279, P18990, DOI 10.1074/jbc.M400724200
   Quarles LD, 2003, J AM SOC NEPHROL, V14, P575, DOI 10.1097/01.ASN.0000050224.03126.AD
   RAMIREZ JA, 1993, J CLIN ENDOCR METAB, V76, P1489, DOI 10.1210/jc.76.6.1489
   Rodriguez M, 2005, AM J PHYSIOL RENAL, V288, pF253, DOI 10.1152/ajprenal.00302.2004
   Rostand SG, 1999, KIDNEY INT, V56, P383, DOI 10.1046/j.1523 1755.1999.00575.x
   Rubin MR, 2004, J BONE MINER RES, V19, pS103
   Serra AL, 2005, NEPHROL DIAL TRANSPL, V20, P1315, DOI 10.1093/ndt/gfh925
   Shigematsu T, 2004, AM J KIDNEY DIS, V44, P250, DOI 10.1053/j.ajkd.2004.04.029
   Silver J, 2002, AM J PHYSIOL RENAL, V283, pF367, DOI 10.1152/ajprenal.00061.2002
   SLATOPOL.E, 1966, J CLIN INVEST, V45, P672, DOI 10.1172/JCI105382
   Tominaga Y, 1997, SEMIN SURG ONCOL, V13, P78, DOI 10.1002/(SICI)1098 2388(199703/04)13:2<78::AID SSU3>3.0.CO;2 Z
   TOMINAGA Y, 1995, CLIN NEPHROL, V44, pS42
   Tominaga Y, 1996, WORLD J SURG, V20, P744, DOI 10.1007/s002689900113
   URENA P, 1994, KIDNEY INT, V45, P605, DOI 10.1038/ki.1994.79
   URENA P, 1989, KIDNEY INT, V36, P120, DOI 10.1038/ki.1989.170
   URENA P, 2003, 40 ERA EDTA WORLD C
   VANABEL M, 2003, J AM SOC NEPHROL, V15
   Young EW, 2004, AM J KIDNEY DIS, V44, pS34, DOI 10.1053/j.ajkd.2004.08.009
NR 46
TC 62
Z9 73
U1 0
U2 11
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 1051 2276
EI 1532 8503
J9 J RENAL NUTR
JI J. Renal Nutr.
PD JUL
PY 2006
VL 16
IS 3
BP 253
EP 258
DI 10.1053/j.jrn.2006.04.010
PG 6
WC Nutrition & Dietetics; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Nutrition & Dietetics; Urology & Nephrology
GA 067CN
UT WOS:000239279400018
PM 16825031
DA 2025 08 17
ER

PT J
AU Myo, AC
   Kobayashi, Y
   Niki, Y
   Kamimoto, H
   Moriyama, K
AF Myo, Aye Chan
   Kobayashi, Yukiho
   Niki, Yuki
   Kamimoto, Hiroyuki
   Moriyama, Keiji
TI Exosome mediated small interfering RNA delivery inhibits aberrant
   osteoblast differentiation in Apert syndrome model mice
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE Apert syndrome; Craniosynostosis; Osteogenic differentiation; Exosomes;
   SiRNA
ID FACTOR RECEPTOR 2 FGFR2; DRUG CARRIERS; SOLUBLE FORM; ACTIVATION; CELLS;
   CRANIOSYNOSTOSIS; MECHANISMS; MUTATIONS; SECRETION; VEHICLES
AB Objective: Apert syndrome, an autosomal dominant congenital disorder characterized by craniosynostosis, is caused by a missense mutation (S252W or P253R) in fibroblast growth factor receptor 2 (FGFR2). Exosomes are naturally occurring carriers that deliver nucleic acids, including small interfering RNA (siRNA), to induce gene silencing. This study aimed to develop siRNA loaded exosomes (Ex siRNAFgfr2S252W) to silence the Fgfr2S252W gain of function mutation, thereby inhibiting the increased osteoblastic differentiation caused by the constitutive activation of FGFR2 signaling in calvarial osteoblastic cells isolated from Apert syndrome model mice.Design: Primary calvarial osteoblast like cells were isolated from the embryonic calvarial sutures of the Apert syndrome model (Fgfr2S252W/+) and littermate wild type mice (Ap Ob and Wt Ob, respectively). Exosomes were extracted from the serum of wild type mice, validated using biomarkers, and used to encapsulate siRNAs. After exosome mediated siRNA transfection, cells were analyzed under a fluorescence microscope to validate the delivery of Ex siRNAFgfr2S252W, followed by western blot and real time reverse transcription polymerase chain reaction analyses.Results: After 24 h of Ex siRNAFgfr2S252W delivery in both Ap Ob and Wt Ob, siRNA loaded exosome delivery was validated. Moreover, p44/42 mitogen activated protein kinase (MAPK) phosphorylation, runt related transcription factor 2 (Runx2), and collagen type 1 alpha 1 (Col1a1) mRNA expression, and alkaline phosphatase (ALP) activity were significantly increased in Ap Ob. The levels of phospho p44/42 protein, Runx2, Col1a1, and ALP were significantly decreased after Ex siRNAFgfr2S252W transfection but did not affect Wt Ob. Conclusions: These results indicate that exosome mediated delivery of siRNA targeting Fgfr2S252W is a potential non invasive treatment for aberrant FGF/FGFR signaling.
C1 [Myo, Aye Chan; Kobayashi, Yukiho; Niki, Yuki; Kamimoto, Hiroyuki; Moriyama, Keiji] Tokyo Med & Dent Univ TMDU, Grad Sch Med & Dent Sci, Dept Maxillofacial Orthognath, Div Maxillofacial & Neck Reconstruct, 1 5 45 Bunkyo Ku, Tokyo 1138549, Japan.
   [Kobayashi, Yukiho] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Maxillofacial Orthognath, Div Maxillofacial & Neck Reconstruct, 1 5 45 Yushima,Bunkyo Ku, Tokyo 1138549, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU)
RP Kobayashi, Y (通讯作者)，Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Maxillofacial Orthognath, Div Maxillofacial & Neck Reconstruct, 1 5 45 Yushima,Bunkyo Ku, Tokyo 1138549, Japan.
EM yukimort@tmd.ac.jp
RI Moriyama, Keiji/AAC 3193 2019
FU Japan Society for the Promotion of Science (JSPS) KAKENHI [JP19H03857,
   JP19K10400]
FX Funding This work was supported by the Japan Society for the Promotion
   of Science (JSPS) KAKENHI Grant in Aid for Scientific Research KAKENHI
   (JP19H03857 and JP19K10400) .
CR Batrakova EV, 2015, J CONTROL RELEASE, V219, P396, DOI 10.1016/j.jconrel.2015.07.030
   Chaudhary LR, 1997, BIOCHEM BIOPH RES CO, V238, P134, DOI 10.1006/bbrc.1997.7256
   Chen L, 2003, BONE, V33, P169, DOI 10.1016/S8756 3282(03)00222 9
   David S, 2010, PHARMACOL RES, V62, P100, DOI 10.1016/j.phrs.2009.11.013
   Deng Y, 2014, GENE, V538, P217, DOI 10.1016/j.gene.2013.12.019
   Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1074>3.0.CO;2 C
   Gandhi NS, 2014, J CONTROL RELEASE, V194, P238, DOI 10.1016/j.jconrel.2014.09.001
   Ha D, 2016, ACTA PHARM SIN B, V6, P287, DOI 10.1016/j.apsb.2016.02.001
   Ibrahimi OA, 2001, P NATL ACAD SCI USA, V98, P7182, DOI 10.1073/pnas.121183798
   Johnson D, 2011, EUR J HUM GENET, V19, P369, DOI 10.1038/ejhg.2010.235
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Kim HJ, 2003, DEV DYNAM, V227, P335, DOI 10.1002/dvdy.10319
   Kim HJ, 2016, ADV DRUG DELIVER REV, V104, P61, DOI 10.1016/j.addr.2016.06.011
   Kim YJ, 2017, BIOCHEM BIOPH RES CO, V493, P1102, DOI 10.1016/j.bbrc.2017.09.056
   Kobayashi H, 2000, BIOCHEM BIOPH RES CO, V273, P630, DOI 10.1006/bbrc.2000.2981
   Kojima R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03733 8
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821
   Kowal J, 2014, CURR OPIN CELL BIOL, V29, P116, DOI 10.1016/j.ceb.2014.05.004
   Lemonnier J, 2000, EXP CELL RES, V256, P158, DOI 10.1006/excr.2000.4820
   Liao W, 2019, ACTA BIOMATER, V86, P1, DOI 10.1016/j.actbio.2018.12.045
   Lomri A, 1998, J CLIN INVEST, V101, P1310
   Martínez Abadías N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026425
   Mathieu M, 2019, NAT CELL BIOL, V21, P9, DOI 10.1038/s41556 018 0250 9
   Morita J, 2014, DEV DYNAM, V243, P560, DOI 10.1002/dvdy.24099
   Shukla V, 2007, NAT GENET, V39, P1145, DOI 10.1038/ng2096
   Spector JA, 2005, PLAST RECONSTR SURG, V115, P838, DOI 10.1097/01.PRS.0000153035.73507.7B
   Suzuki H, 2012, J CELL PHYSIOL, V227, P3267, DOI 10.1002/jcp.24021
   Swe NMM, 2021, DEV DYNAM, V250, P465, DOI 10.1002/dvdy.239
   Tan A, 2013, ADV DRUG DELIVER REV, V65, P357, DOI 10.1016/j.addr.2012.06.014
   Tanimoto Y, 2004, J BIOL CHEM, V279, P45926, DOI 10.1074/jbc.M404824200
   Teven CM, 2014, GENES DIS, V1, P199, DOI 10.1016/j.gendis.2014.09.005
   Wilkie AOM, 1997, HUM MOL GENET, V6, P1647, DOI 10.1093/hmg/6.10.1647
   WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295 165
   Wu XW, 2019, INT J BIOL SCI, V15, P298, DOI 10.7150/ijbs.29183
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Yokota M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101693
   Yong TY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11718 4
NR 38
TC 5
Z9 5
U1 2
U2 6
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0003 9969
EI 1879 1506
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD SEP
PY 2023
VL 153
AR 105753
DI 10.1016/j.archoralbio.2023.105753
EA JUN 2023
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA N0NN3
UT WOS:001034087800001
PM 37348363
DA 2025 08 17
ER

PT J
AU Fujio, M
   Xing, Z
   Sharabi, N
   Xue, Y
   Yamamoto, A
   Hibi, H
   Ueda, M
   Fristad, I
   Mustafa, K
AF Fujio, Masahito
   Xing, Zhe
   Sharabi, Niyaz
   Xue, Ying
   Yamamoto, Akihito
   Hibi, Hideharu
   Ueda, Minoru
   Fristad, Inge
   Mustafa, Kamal
TI Conditioned media from hypoxic cultured human dental pulp cells promotes
   bone healing during distraction osteogenesis
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE distraction osteogenesis; conditioned media; regeneration; bone;
   angiogenesis
ID MESENCHYMAL STEM CELLS; GROWTH FACTOR; IN VIVO; REGENERATIVE MECHANISMS;
   ENDOTHELIAL CELLS; MESSENGER RNA; TIE2 RECEPTOR; ANGIOGENESIS;
   ANGIOPOIETIN 2; MODEL
AB Distraction osteogenesis (DO) is a surgical procedure used to correct various skeletal disorders. Improving the technique by reducing the healing time would be of clinical relevance. The aim of this study was to determine the angiogenic and regenerative potential of conditioned media (CMs) collected from human dental pulp cells (hDPCs) grown under different culture conditions. CM collected from cells under hypoxia was used to improve bone healing and the DO procedure in vivo. The angiogenic potentials of CMs collected from hDPCs grown under normoxic ( Nor) and hypoxic ( Hyp) conditions were evaluated by quantitative PCR (VEGF A, angiopoietin 1, angiopoietin 2, interleukin 6 (IL 6) and CXCL12), ELISA assays (VEGF A, Ang 2), tube formation and wound healing assays, using human umbilical vein endothelial cells. The results demonstrated that hypoxic CM had significantly higher angiogenic potential than normoxic CM. Human fetal osteoblasts (hFOBs) were exposed to CM, followed by alizarin red staining, to assess the osteogenic potential. It was found that CM did not enhance the mineralization capacity of hFOBs. DO was performed in the tibiae of 30 mice, followed by a local injection of 20 mu l CM (CM Nor and CM Hyp groups) or serum free DMEM (control group) into the distraction zone every second day. The mice were sacrificed at days 13 and 27. The CM Hyp treatment revealed a higher X ray density than the control group (p<0.05). Our study suggests that the angiogenic effect promoted by hypoxic culture conditions is dependent on VEGF A and Ang 2 released from hDPCs. Furthermore, CM Hyp treatment may thus improve the DO procedure, accelerating bone healing. (c) 2015 The Authors. Journal of Tissue Engineering and Regenerative Medicine published by John Wiley & Sons, Ltd.
C1 [Fujio, Masahito; Xing, Zhe; Sharabi, Niyaz; Xue, Ying; Fristad, Inge; Mustafa, Kamal] Univ Bergen, Dept Clin Dent, Ctr Clin Dent Res, Arstadsv 19, N 5009 Bergen, Norway.
   [Fujio, Masahito; Yamamoto, Akihito; Hibi, Hideharu; Ueda, Minoru] Nagoya Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Nagoya, Aichi, Japan.
C3 University of Bergen; Nagoya University
RP Fujio, M; Mustafa, K (通讯作者)，Univ Bergen, Dept Clin Dent, Ctr Clin Dent Res, Arstadsv 19, N 5009 Bergen, Norway.
EM m fujio@med.nagoya u.ac.jp; kamal.mustafa@iko.uib.no
RI Hibi, Hideharu/E 4443 2015; Mustafa, Kamal/ABD 4458 2020; Xing,
   Zhe/D 9743 2014; Fristad, Inge/LDS 0405 2024; Fristad,
   Inge/KUC 5425 2024
OI Hibi, Hideharu/0000 0003 0248 7476; Xing, Zhe/0000 0002 7419 2012;
   Fristad, Inge/0000 0002 3054 6501
FU University of Bergen; Meltzer Foundation; Grants in Aid for Scientific
   Research [26293427, 25293408, 26670863] Funding Source: KAKEN
FX The authors thank Dr Yuji Ando and Ms Siren Ostvold for their
   encouragement to complete this study, which was supported by the
   University of Bergen and the Meltzer Foundation.
CR Abbaspour A, 2009, BONE, V44, P917, DOI 10.1016/j.bone.2009.01.007
   Al Sharabi N, 2014, TISSUE ENG PT A, V20, P3063, DOI [10.1089/ten.tea.2013.0718, 10.1089/ten.TEA.2013.0718]
   Alge DL, 2010, J TISSUE ENG REGEN M, V4, P73, DOI 10.1002/term.220
   Alkaisi A, 2013, J ORAL MAXILLOFAC SU, V71, pe1, DOI DOI 10.1016/J.J0MS.2013.05.016
   Ando Y, 2014, BONE, V61, P82, DOI 10.1016/j.bone.2013.12.029
   Aranha AMF, 2010, J ENDODONT, V36, P1633, DOI 10.1016/j.joen.2010.05.013
   Ashton AW, 1999, J BIOL CHEM, V274, P35562, DOI 10.1074/jbc.274.50.35562
   Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603 653
   Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075
   Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886
   Egusa H, 2012, J PROSTHODONT RES, V56, P151, DOI 10.1016/j.jpor.2012.06.001
   Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090
   Fujio M, 2011, BONE, V49, P693, DOI 10.1016/j.bone.2011.06.024
   Gong QM, 2010, J ENDODONT, V36, P1499, DOI 10.1016/j.joen.2010.05.011
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Halin C, 2008, AM J PATHOL, V173, P265, DOI 10.2353/ajpath.2008.071074
   Hung SC, 2007, STEM CELLS, V25, P2363, DOI 10.1634/stemcells.2006 0686
   Ide C, 2010, BRAIN RES, V1332, P32, DOI 10.1016/j.brainres.2010.03.043
   ILIZAROV GA, 1989, CLIN ORTHOP RELAT R, P263
   Inukai T, 2013, BIOCHEM BIOPH RES CO, V430, P763, DOI 10.1016/j.bbrc.2012.11.074
   Isefuku S, 2000, BONE, V27, P661, DOI 10.1016/S8756 3282(00)00385 9
   Kanczler JM, 2008, EUR CELLS MATER, V15, P100, DOI 10.22203/eCM.v015a08
   Kim HZ, 2009, BBA MOL CELL RES, V1793, P772, DOI 10.1016/j.bbamcr.2009.01.018
   Li G, 1999, J ORTHOP RES, V17, P362, DOI 10.1002/jor.1100170310
   Lobov IB, 2002, P NATL ACAD SCI USA, V99, P11205, DOI 10.1073/pnas.172161899
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Morishita R, 1999, HYPERTENSION, V33, P1379, DOI 10.1161/01.HYP.33.6.1379
   Osugi M, 2012, TISSUE ENG PT A, V18, P1479, DOI [10.1089/ten.tea.2011.0325, 10.1089/ten.TEA.2011.0325]
   Park YS, 2003, MICROVASC RES, V65, P125, DOI 10.1016/S0026 2862(02)00035 3
   Pichiule P, 2004, J BIOL CHEM, V279, P12171, DOI 10.1074/jbc.M305146200
   Rubin J, 2006, GENE, V367, P1, DOI 10.1016/j.gene.2005.10.028
   Sakai K, 2012, J CLIN INVEST, V122, P80, DOI 10.1172/JCI59251
   Shen KK, 2010, CELL BIOL INT, V34, P1213, DOI 10.1042/CBI20100185
   Shi S, 2001, BONE, V29, P532, DOI 10.1016/S8756 3282(01)00612 3
   Stamatovic SM, 2006, J IMMUNOL, V177, P2651, DOI 10.4049/jimmunol.177.4.2651
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092 8674(00)81813 9
   Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442
   Wang JHC, 2006, BIOMECH MODEL MECHAN, V5, P1, DOI 10.1007/s10237 005 0012 z
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Watson J Tracy, 2006, J Am Acad Orthop Surg, V14, pS168
   Yamada Y, 2004, TISSUE ENG, V10, P955, DOI 10.1089/1076327041348284
NR 43
TC 43
Z9 45
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD JUL
PY 2017
VL 11
IS 7
BP 2116
EP 2126
DI 10.1002/term.2109
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA EZ6DO
UT WOS:000404808800017
PM 26612624
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ibrahim, NI
   Mohamed, N
   Shuid, AN
AF Ibrahim, Nurul 'Izzah
   Mohamed, Norazlina
   Shuid, Ahmad Nazrun
TI Update on Statins: Hope for Osteoporotic Fracture Healing Treatment
SO CURRENT DRUG TARGETS
LA English
DT Article
DE Fracture healing; osteoporosis; HMG CoA reductase inhibitor; BMP 2; VEGF
ID BONE MINERAL DENSITY; ENDOTHELIAL GROWTH FACTOR; ESTROGEN PLUS
   PROGESTIN; HEALTHY POSTMENOPAUSAL WOMEN; RANDOMIZED CONTROLLED TRIAL;
   OVARIECTOMIZED RAT MODEL; COA REDUCTASE INHIBITORS; OSTEOBLAST
   DIFFERENTIATION; MORPHOGENETIC PROTEIN 2; MECHANICAL PROPERTIES
AB Fracture healing is a process of recovering injured bone tissue forms and functions. Osteoporosis can delay the healing process, which contributes to personal suffering and loss of activities. Osteoporosis patients tend to lose bone mass at the metaphyseal region which require treatment to increase bone mass. Postmenopausal osteoporosis is the most common osteoporosis that occurs in women which subsequently resulted in fractures even under slight trauma. Estrogen Replacement Therapy (ERT), the recommended therapy for postmenopausal osteoporosis, is associated with higher risk of breast cancer, ovarian cancer and cardiovascular diseases. As osteoporotic fractures are becoming a public health issue, alternative treatment is now being thoroughly explored. The potential agent is statins, the HMG CoA reductase inhibitor which is widely used for hypercholesterolemia treatment. Statins have been found to increase bone mass by stimulation of Bone morphogenetic protein 2 (BMP 2) expression and Vascular Endothelial Growth Factor (VEGF) production. However, these bone forming effects were achieved at very high systemic doses. Therefore, studies on locally applied statins are required to further explore the ability of statins to stimulate bone formation at acceptable doses for better fracture healing. This review highlights the animal and clinical studies on fracture healing promotions by statins and the mechanisms involved.
C1 [Ibrahim, Nurul 'Izzah; Mohamed, Norazlina; Shuid, Ahmad Nazrun] Univ Kebangsaan Malaysia, Dept Pharmacol, Fac Med, Kuala Lumpur 50300, Malaysia.
C3 Universiti Kebangsaan Malaysia
RP Shuid, AN (通讯作者)，Univ Kebangsaan Malaysia, Dept Pharmacol, Fac Med, Kuala Lumpur Campus, Kuala Lumpur 50300, Malaysia.
EM anazrun@yahoo.com
RI SHUID, AHMAD/AAS 7556 2020; Ibrahim, Nurul/X 7167 2019; Mohamed,
   Norazlina/M 7306 2017
OI shuid, ahmad nazrun/0000 0003 3526 990X; 
FU University Kebangsaan Malaysia (UKM); Ministry of Higher Education
   [ERGS/1/2012/SKK03/UKM/02/1]
FX The author would like to thank the University Kebangsaan Malaysia (UKM)
   and the Ministry of Higher Education for the grant
   (ERGS/1/2012/SKK03/UKM/02/1) and the Pharmacology Department staff for
   their technical support.
CR Abdul Majeed S, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/960742
   Aerssens J, 1996, ENDOCRINOLOGY, V137, P1358, DOI 10.1210/en.137.4.1358
   AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871
   Ali H, 2010, INT J PHARMACEUT, V389, P223, DOI 10.1016/j.ijpharm.2010.01.018
   [Anonymous], 1994, World Health Organ Tech Rep Ser, V843, P1
   [Anonymous], FUNDAMENTALS PHYSL H
   Arjmandi BH, 1996, J NUTR, V126, P161, DOI 10.1093/jn/126.1.161
   Bauer DC, 2004, ARCH INTERN MED, V164, P146, DOI 10.1001/archinte.164.2.146
   Bauer DC, 1999, J BONE MINER RES, V14, pS179
   Bostrom MPG, 1998, CLIN ORTHOP RELAT R, pS116, DOI 10.1097/00003086 199810001 00013
   Bottroff M, 2000, ARCH INTERN MED, V279, P2273
   Buehler J, 2001, BONE, V29, P176, DOI 10.1016/S8756 3282(01)00484 7
   Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Cao YP, 2002, J BONE MINER RES, V17, P2237, DOI 10.1359/jbmr.2002.17.12.2237
   Chan KA, 2000, LANCET, V355, P2185, DOI 10.1016/S0140 6736(00)02400 4
   Chlebowski RT, 2003, JAMA J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243
   Christiansen C, 1990, Osteoporos Int, V1, P7
   Chung YS, 2000, J CLIN ENDOCR METAB, V85, P1137, DOI 10.1210/jc.85.3.1137
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Cruess RL, 1975, TXB SMALL ANIMAL ORT, P1
   Dai KR, 2007, ADVANCED BIOIMAGING TECHNOLOGIES IN ASSESSMENT OF THE QUALITY OF BONE AND SCAFFOLD MATERIALS: TECHNIQUES AND APPLICATIONS, P531, DOI 10.1007/978 3 540 45456 4_33
   DANIELSEN CC, 1993, CALCIFIED TISSUE INT, V52, P26, DOI 10.1007/BF00675623
   Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667
   EINHORN TA, 1995, J BONE JOINT SURG AM, V77A, P940, DOI 10.2106/00004623 199506000 00016
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   Ferguson C, 1999, MECH DEVELOP, V87, P57, DOI 10.1016/S0925 4773(99)00142 2
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603 669
   Fujino H, 1999, DRUG METABOLISM PHAR, V14, P415
   Gambacciani M, 2000, CURR OPIN OBSTET GYN, V12, P189, DOI 10.1097/00001703 200006000 00005
   Garrett IR, 2007, J ORTHOP RES, V25, P1351, DOI 10.1002/jor.20391
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   GRUNDNES O, 1993, ACTA ORTHOP SCAND, V64, P340, DOI 10.3109/17453679308993640
   Gutierrez GE, 2008, J BONE MINER RES, V23, P1722, DOI 10.1359/JBMR.080603
   Guyton JR, 2006, AM J CARDIOL, V97, p95C, DOI 10.1016/j.amjcard.2005.12.016
   Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200
   Hagihara M, 2011, J BIOL CHEM, V286, P5157, DOI 10.1074/jbc.M110.180919
   Hatanaka T, 2000, CLIN PHARMACOKINET, V39, P397, DOI 10.2165/00003088 200039060 00002
   Hauser CJ, 1997, J TRAUMA, V42, P895, DOI 10.1097/00005373 199705000 00021
   Hausman MR, 2001, BONE, V29, P560, DOI 10.1016/S8756 3282(01)00608 1
   Hiltunen MO, 2003, FASEB J, V17, P1147, DOI 10.1096/fj.02 0514fje
   Horiuchi N, 2006, ORAL DIS, V12, P85, DOI 10.1111/j.1601 0825.2005.01172.x
   Hwang R, 2004, J BIOL CHEM, V279, P21239, DOI 10.1074/jbc.M312771200
   International Osteoporosis Foundation (IOF), 2010, HIGH DEATH DIS RAT D
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959 437X(98)80069 5
   Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510
   LaCroix AZ, 2003, ANN INTERN MED, V139, P97, DOI 10.7326/0003 4819 139 2 200307150 00009
   Lindsay R, 1997, OSTEOPOROSIS INT, V7, P1
   LIPS P, 1997, AM J MED, V103, pS8
   Loh K Y, 2007, Med J Malaysia, V62, P355
   Maeda T, 2003, ENDOCRINOLOGY, V144, P681, DOI 10.1210/en.2002 220682
   Margolis RN, 1996, J CLIN ENDOCR METAB, V81, P872, DOI 10.1210/jc.81.3.872
   Maritz FJ, 2001, ARTERIOSCL THROM VAS, V21, P1636, DOI 10.1161/hq1001.097781
   MCADAMMARX C, 2007, P & T, V32, P392
   Meier CR, 2000, JAMA J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205
   Meunier PJ, 2002, J CLIN ENDOCR METAB, V87, P2060, DOI 10.1210/jc.87.5.2060
   Mostaza JM, 2001, CLIN CHIM ACTA, V308, P133, DOI 10.1016/S0009 8981(01)00476 4
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Mundy GR, 1996, BRIT J OBSTET GYNAEC, V103, P32
   Murphy Frederick T, 2003, J Am Osteopath Assoc, V103, pS6
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293
   Nochowitz B, 2009, AM J THER, V16, P437, DOI 10.1097/MJT.0b013e31818637de
   Noma K, 2006, AM J PHYSIOL CELL PH, V290, pC661, DOI 10.1152/ajpcell.00459.2005
   Nyman JS, 2009, J BIOMECH, V42, P891, DOI 10.1016/j.jbiomech.2009.01.016
   Ogasawara T, 2004, MOL CELL BIOL, V24, P6560, DOI 10.1128/mcb.24.15.6560 6568.2004
   Ohnaka K, 2001, BIOCHEM BIOPH RES CO, V287, P337, DOI 10.1006/bbrc.2001.5597
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Papapoulos S, 2012, END ABSTR, V29
   Pasco JA, 2002, ARCH INTERN MED, V162, P537, DOI 10.1001/archinte.162.5.537
   Patil S, 2009, J ORTHOP RES, V27, P281, DOI 10.1002/jor.20572
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   PENG Z, 1994, BONE, V15, P523, DOI 10.1016/8756 3282(94)90276 3
   Ray WA, 2002, INJ PREV, V8, P276, DOI 10.1136/ip.8.4.276
   Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398 247
   Reinoso RF, 2002, METHOD FIND EXP CLIN, V24, P593
   RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Schachter M, 2005, FUND CLIN PHARMACOL, V19, P117, DOI 10.1111/j.1472 8206.2004.00299.x
   Schachter M., 2001, BR J CARDIOL, V8, P311
   Shokri N, 2011, DARU, V19, P12
   Shumaker SA, 2003, JAMA J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651
   Siris ES, 2001, JAMA J AM MED ASSOC, V286, P2815, DOI 10.1001/jama.286.22.2815
   Skoglund B, 2002, J BONE MINER RES, V17, P2004, DOI 10.1359/jbmr.2002.17.11.2004
   Street J, 2000, CLIN ORTHOP RELAT R, P224, DOI 10.1097/00003086 200009000 00033
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   Tatsuyama K, 2000, EUR J HISTOCHEM, V44, P269
   Uzzan B, 2007, BONE, V40, P1581, DOI 10.1016/j.bone.2007.02.019
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   van Staa TP, 2001, JAMA J AM MED ASSOC, V285, P1850, DOI 10.1001/jama.285.14.1850
   Vico L, 2007, EUR CELL MAT  S1, V14, P32
   Wang DS, 1997, ENDOCRINOLOGY, V138, P2953, DOI 10.1210/en.138.7.2953
   WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582
   Wang JW, 2007, OSTEOPOROSIS INT, V18, P1641, DOI 10.1007/s00198 007 0412 2
   Wasnich Richard D., 1996, P249
   Whitfield James F, 2003, Curr Rheumatol Rep, V5, P45, DOI 10.1007/s11926 003 0083 8
   Yue JR, 2010, MENOPAUSE, V17, P1071, DOI 10.1097/gme.0b013e3181d3e036
   Zelzer E, 2002, DEVELOPMENT, V129, P1893
   Zhou SQ, 2013, MOL MED REP, V8, P89, DOI 10.3892/mmr.2013.1489
   Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955 0674(96)80050 0
NR 106
TC 20
Z9 24
U1 0
U2 13
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389 4501
EI 1873 5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD DEC
PY 2013
VL 14
IS 13
SI SI
BP 1524
EP 1532
DI 10.2174/13894501113149990195
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 258VA
UT WOS:000327485600002
PM 23876090
DA 2025 08 17
ER

PT J
AU Wan, L
   Song, HY
   Chen, X
   Zhang, Y
   Yue, Q
   Pan, PP
   Su, JC
   Elzatahry, AA
   Deng, YH
AF Wan, Li
   Song, Hongyuan
   Chen, Xiao
   Zhang, Yu
   Yue, Qin
   Pan, Panpan
   Su, Jiacan
   Elzatahry, Ahmed A.
   Deng, Yonghui
TI A Magnetic Field Guided Interface Coassembly Approach to Magnetic
   Mesoporous Silica Nanochains for Osteoclast Targeted Inhibition and
   Heterogeneous Nanocatalysis
SO ADVANCED MATERIALS
LA English
DT Article
DE catalysis; core shell; magnetic mesoporous materials; nanochain;
   osteoclasts differentiation
ID IRON OXIDE NANOPARTICLES; DRUG DELIVERY; SHELL; CORE; MICROSPHERES;
   NANOMATERIALS; DIFFERENTIATION; NANOSTRUCTURES; OSTEOPOROSIS; EFFICIENT
AB 1D core shell magnetic materials with mesopores in shell are highly desired for biocatalysis, magnetic bioseparation, and bioenrichment and biosensing because of their unique microstructure and morphology. In this study, 1D magnetic mesoporous silica nanochains (Fe3O4@nSiO(2)@mSiO(2) nanochain, Magn MSNCs named as FDUcs 17C) are facilely synthesized via a novel magnetic field guided interface coassembly approach in two steps. Fe3O4 particles are coated with nonporous silica in a magnetic field to form 1D Fe3O4@nSiO(2) nanochains. A further interface coassembly of cetyltrimethylammonium bromide and silica source in water/n hexane biliquid system leads to 1D Magn MSNCs with core shell shell structure, uniform diameter (approximate to 310 nm), large and perpendicular mesopores (7.3 nm), high surface area (317 m(2) g( 1)), and high magnetization (34.9 emu g( 1)). Under a rotating magnetic field, the nanochains with loaded zoledronate (a medication for treating bone diseases) in the mesopores, show an interesting suppression effect of osteoclasts differentiation, due to their 1D nanostructure that provides a shearing force in dynamic magnetic field to induce sufficient and effective reactions in cells. Moreover, by loading Au nanoparticles in the mesopores, the 1D Fe3O4@nSiO(2)@mSiO(2) Au nanochains can service as a catalytically active magnetic nanostirrer for hydrogenation of 4 nitrophenol with high catalytic performance and good magnetic recyclability.
C1 [Wan, Li; Zhang, Yu; Yue, Qin; Deng, Yonghui] Fudan Univ, Shanghai Key Lab Mol Catalysis & Innovat Mat iChE, State Key Lab Mol Engn Polymers, Dept Chem, Shanghai 200433, Peoples R China.
   [Song, Hongyuan; Chen, Xiao; Pan, Panpan; Su, Jiacan] Second Mil Med Univ, Changhai Hosp, Dept Ophthalmol, Dept Orthopaed Trauma, Shanghai 200433, Peoples R China.
   [Elzatahry, Ahmed A.] Qatar Univ, Coll Arts & Sci, Mat Sci & Technol Program, Doha 2713, Qatar.
   [Deng, Yonghui] Chinese Acad Sci, Shanghai Inst Microsyst & Informat Technol, State Key Lab Transducer Technol, Shanghai 200050, Peoples R China.
C3 Fudan University; Naval Medical University; Qatar University; Chinese
   Academy of Sciences; Shanghai Institute of Microsystem & Information
   Technology, CAS
RP Deng, YH (通讯作者)，Fudan Univ, Shanghai Key Lab Mol Catalysis & Innovat Mat iChE, State Key Lab Mol Engn Polymers, Dept Chem, Shanghai 200433, Peoples R China.; Su, JC (通讯作者)，Second Mil Med Univ, Changhai Hosp, Dept Ophthalmol, Dept Orthopaed Trauma, Shanghai 200433, Peoples R China.; Deng, YH (通讯作者)，Chinese Acad Sci, Shanghai Inst Microsyst & Informat Technol, State Key Lab Transducer Technol, Shanghai 200050, Peoples R China.
EM Jiacansu@smmu.edu.cn; yhdeng@fudan.edu.cn
RI Elzatahry, Ahmed/A 2548 2012; Chen, Xiao/N 1298 2017; Deng,
   Yonghui/E 7107 2011; Salah, Ahmed/AAH 3158 2020; Pan,
   Panpan/GRJ 2514 2022; Su, Jiacan/N 7068 2019; Song,
   Hongyuan/AAD 2521 2020
OI Elzatahry, Ahmed/0000 0002 7291 5723; Su, Jiacan/0000 0001 7080 263X;
   Deng, Yonghui/0000 0002 0657 9397; Song, Hongyuan/0000 0001 8187 2799; 
FU NSF of China [51372041, 51422202, 91749204, 21271047, 21673048]; Key
   Basic Research Program of Science and Technology Commission of Shanghai
   Municipality [17JC1400100]; Youth Top notch Talent Support Program of
   China; state key laboratory of Transducer Technology of China [SKT1503];
   Outstanding Talents Cultivation Program of Shanghai Health System; Qatar
   University [GCC 2017 001]
FX This work was supported by the NSF of China (51372041, 51422202,
   91749204, 21271047 and 21673048), Key Basic Research Program of Science
   and Technology Commission of Shanghai Municipality (17JC1400100), Youth
   Top notch Talent Support Program of China, the state key laboratory of
   Transducer Technology of China (Grant No. SKT1503), the Outstanding
   Talents Cultivation Program of Shanghai Health System, and Qatar
   University Grant GCC 2017 001. The authors thank Prof. Guangrong Zhou
   for assistance in TEM characterization.
CR Argyo C, 2014, CHEM MATER, V26, P435, DOI 10.1021/cm402592t
   Baig RBN, 2013, CHEM COMMUN, V49, P752, DOI 10.1039/c2cc35663e
   Chen JS, 2011, CHEM COMMUN, V47, P2631, DOI 10.1039/c0cc04471g
   Chen Y, 2014, ACCOUNTS CHEM RES, V47, P125, DOI 10.1021/ar400091e
   Chen Y, 2010, ACS NANO, V4, P529, DOI 10.1021/nn901398j
   Chong WH, 2013, ANGEW CHEM INT EDIT, V52, P8570, DOI 10.1002/anie.201303249
   Conners CM, 2017, J BIOMED MATER RES B, V105, P21, DOI 10.1002/jbm.b.33527
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   D'Mello SR, 2017, NAT NANOTECHNOL, V12, P523, DOI [10.1038/nnano.2017.67, 10.1038/NNANO.2017.67]
   Deng Y, 2008, J AM CHEM SOC, V130, P28, DOI 10.1021/ja0777584
   Deng YH, 2011, CHEM PHYS LETT, V510, P1, DOI 10.1016/j.cplett.2011.04.093
   Deng YH, 2010, J AM CHEM SOC, V132, P8466, DOI 10.1021/ja1025744
   Fang JS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01742 7
   Fanord F, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/3/035102
   Frey NA, 2009, CHEM SOC REV, V38, P2532, DOI 10.1039/b815548h
   Gao MR, 2011, J MATER CHEM, V21, P16888, DOI 10.1039/c1jm13517a
   Gautier J, 2013, J CONTROL RELEASE, V169, P48, DOI 10.1016/j.jconrel.2013.03.018
   Ge JP, 2007, ANGEW CHEM INT EDIT, V46, P4342, DOI 10.1002/anie.200700197
   Geng H, 2017, NANOSCALE, V9, P12516, DOI 10.1039/c7nr04365a
   Gera S, 2017, CURR DRUG DELIV, V14, P904, DOI 10.2174/1567201813666161230142123
   Graeser M, 2007, ADV MATER, V19, P4244, DOI 10.1002/adma.200700849
   He L, 2012, ACCOUNTS CHEM RES, V45, P1431, DOI 10.1021/ar200276t
   He M. M., 2010, J MATER CHEM, V20, P7965
   Heo DN, 2014, ACS NANO, V8, P12049, DOI 10.1021/nn504329u
   Hiligsmann M, 2015, CURR RHEUMATOL REP, V17, DOI 10.1007/s11926 015 0533 0
   Hill LJ, 2014, ACS APPL MATER INTER, V6, P6022, DOI 10.1021/am405786u
   Hu L, 2014, NANOSCALE, V6, P14064, DOI 10.1039/c4nr05108d
   Jiang YJ, 2017, BIOMATERIALS, V115, P9, DOI 10.1016/j.biomaterials.2016.11.006
   Juárez J, 2011, CHEM EUR J, V17, P7366, DOI 10.1002/chem.201003679
   Khosla S, 2017, J BONE MINER RES, V32, P424, DOI 10.1002/jbmr.3074
   Kumar CSSR, 2011, ADV DRUG DELIVER REV, V63, P789, DOI 10.1016/j.addr.2011.03.008
   Lee D, 2016, SCI REP UK, V6, DOI 10.1038/srep27336
   Lee MS, 2016, INT J NANOMED, V11, P4583, DOI 10.2147/IJN.S112415
   Lee N, 2012, CHEM SOC REV, V41, P2575, DOI 10.1039/c1cs15248c
   Liao CS, 2017, BONE, V101, P10, DOI 10.1016/j.bone.2017.04.003
   Liu J, 2009, ANGEW CHEM INT EDIT, V48, P5875, DOI 10.1002/anie.200901566
   Liu J, 2011, SMALL, V7, P425, DOI 10.1002/smll.201001402
   Liu Y, 2011, J MATER CHEM, V21, P18359, DOI 10.1039/c1jm13789a
   Lu AH, 2007, ANGEW CHEM INT EDIT, V46, P1222, DOI 10.1002/anie.200602866
   Niu DC, 2010, J AM CHEM SOC, V132, P15144, DOI 10.1021/ja1070653
   Pan LM, 2012, J AM CHEM SOC, V134, P5722, DOI 10.1021/ja211035w
   Reddy LH, 2012, CHEM REV, V112, P5818, DOI 10.1021/cr300068p
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Rossi LM, 2014, GREEN CHEM, V16, P2906, DOI 10.1039/c4gc00164h
   Rouquerol F., 2012, ADSORPTION POWDERS P, V2nd, DOI [10.1016/C2010 0 66232 8, DOI 10.1016/C2010 0 66232 8]
   Sheparovych R, 2006, CHEM MATER, V18, P591, DOI 10.1021/cm051274u
   Sun JF, 2007, ANGEW CHEM INT EDIT, V46, P4767, DOI 10.1002/anie.200604474
   Sun ZK, 2016, NANO TODAY, V11, P464, DOI 10.1016/j.nantod.2016.07.003
   Sun ZK, 2014, J MATER CHEM A, V2, P18322, DOI 10.1039/c4ta04414b
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Wang D, 2014, CHEM REV, V114, P6949, DOI 10.1021/cr500134h
   Wang H, 2009, LANGMUIR, V25, P7135, DOI 10.1021/la900234n
   Wang YR, 2014, SMALL, V10, P2815, DOI 10.1002/smll.201400239
   Wang Y, 2015, ADV MATER, V27, P576, DOI 10.1002/adma.201401124
   Wei J, 2012, ANGEW CHEM INT EDIT, V51, P6149, DOI 10.1002/anie.201202232
   Weitzmann MN, 2016, NAT REV ENDOCRINOL, V12, P518, DOI 10.1038/nrendo.2016.91
   Xiong L, 2016, SMALL, V12, P4735, DOI 10.1002/smll.201600531
   Yang SL, 2015, ANGEW CHEM INT EDIT, V54, P2661, DOI 10.1002/anie.201410360
   Yuan JY, 2011, CHEM SOC REV, V40, P640, DOI 10.1039/c0cs00087f
   Yue Q, 2017, J AM CHEM SOC, V139, P15486, DOI 10.1021/jacs.7b09055
   Yue Q, 2017, J AM CHEM SOC, V139, P4954, DOI 10.1021/jacs.7b01464
   Yue Q, 2015, J AM CHEM SOC, V137, P13282, DOI 10.1021/jacs.5b05619
   Zanganeh S, 2016, NAT NANOTECHNOL, V11, P986, DOI [10.1038/nnano.2016.168, 10.1038/NNANO.2016.168]
   Zhang F, 2008, J PHYS CHEM C, V112, P15151, DOI 10.1021/jp804452r
   Zhang L, 2008, ADV MATER, V20, P805, DOI 10.1002/adma.200700900
   Zhang Q, 2010, ADV FUNCT MATER, V20, P2201, DOI 10.1002/adfm.201000428
   Zhang ZB, 2010, LANGMUIR, V26, P6676, DOI 10.1021/la904010y
   Zhou JJ, 2015, CHEM MATER, V27, P3071, DOI 10.1021/acs.chemmater.5b00524
   Zhu M, 2014, ACS APPL MATER INTER, V6, P5456, DOI 10.1021/am405013t
   Zhu Y., 2005, ANGEW CHEM, V117, P5213, DOI DOI 10.1002/ANGE.200501500
NR 70
TC 120
Z9 126
U1 10
U2 392
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0935 9648
EI 1521 4095
J9 ADV MATER
JI Adv. Mater.
PD JUN 20
PY 2018
VL 30
IS 25
AR 1707515
DI 10.1002/adma.201707515
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA GJ3XA
UT WOS:000435258600014
PM 29733478
DA 2025 08 17
ER

PT J
AU Rambhia, KJ
   Sun, HL
   Feng, K
   Kannan, R
   Doleyres, Y
   Holzwarth, JM
   Doepker, M
   Franceschi, R
   Ma, PX
AF Rambhia, Kunal J.
   Sun, Hongli
   Feng, Kai
   Kannan, Rahasudha
   Doleyres, Yasmine
   Holzwarth, Jeremy M.
   Doepker, Mikayla
   Franceschi, Renny
   Ma, Peter X.
TI Nanofibrous 3D scaffolds capable of individually controlled BMP and FGF
   release for the regulation of bone regeneration
SO ACTA BIOMATERIALIA
LA English
DT Article
DE BMP 7; FGF 2; Controlled release; Bone regeneration; Nanofibrous
   scaffold
ID FIBROBLAST GROWTH FACTOR 2; MESENCHYMAL STEM CELLS; MORPHOGENETIC
   PROTEIN 2; IN VITRO; OSTEOGENIC DIFFERENTIATION; OSTEOBLAST
   DIFFERENTIATION; SIGNALING PATHWAYS; POLYMER SCAFFOLDS; STROMAL CELLS;
   DRUG RELEASE
AB The current clinical applications of bone morphogenetic proteins (BMPs) are limited to only a few specific indications. Locally controlled delivery of combinations of growth factors can be a promising strategy to improve BMP based bone repair. However, the success of this approach requires the development of an effective release system and the correct choice of growth factors capable of enhancing BMP activity. Basic fibroblast growth factor (bFGF, also known as FGF 2) has shown promise in promoting bone repair, although conflicting results have been reported. Considering the complex biological activities of FGF 2, we hypothesized that FGF 2 can promote BMP induced bone regeneration only if the dosage and kinetic parameters of the two factors are individually tailored. In this study, we conducted systematic in vitro studies on cell proliferation, differentiation, and mineralization in response to factor dose, delivery mode (sequential or simultaneous), and release rate. Subsequently, we designed individually controlled BMP 7 and FGF 2 release poly(lactide co glycolide) (PLGA) nanospheres attached to the poly(L lactic acid) (PLLA) nanofibrous scaffolds. The data showed that BMP 7induced bone formation was accelerated by a relatively higher FGF 2 dose (100 ng/scaffold) delivered at a faster release rate, or by a relatively lower FGF 2 dose (10 ng/scaffold) at a slower release rate in an in vivo bone regeneration model. In contrast, a very high dose of FGF 2 (1000 ng/scaffold) inhibited bone regeneration under all conditions. In vitro and in vivo data suggest that FGF 2 improved BMP 7 induced bone regeneration by coordinating FGF 2 dosage and release kinetics to enhance stem cell migration, proliferation, and angiogenesis. Statement of significance: Bone morphogenetic proteins (BMPs) are the most potent growth/differentiation factors in bone development and regeneration. However, the clinical applications of BMPs have been limited to only a few specific indications due to the required supraphysiological dosages with the current BMP products and their side effects. Locally controlled delivery of BMPs and additional growth factors that can enhance their osteogenic potency are highly desired. However, different growth factors act with different mechanisms. Here we report a nanofibrous scaffold that mimics collagen in size and geometry and is immobilized with biodegradable nano  spheres to achieve local and distinct release profiles of BMP7 and FGF2. Systematic studies demonstrated low dose BMP7 and FGF2 with different temporal release profiles can optimally enhance bone regeneration.
C1 [Rambhia, Kunal J.; Kannan, Rahasudha; Holzwarth, Jeremy M.; Ma, Peter X.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Sun, Hongli; Ma, Peter X.] Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.
   [Feng, Kai; Doleyres, Yasmine; Ma, Peter X.] Univ Michigan, Macromol Sci & Engn Ctr, Ann Arbor, MI 48109 USA.
   [Doepker, Mikayla] Kalamazoo Coll, Dept Biol, Kalamazoo, MI 49006 USA.
   [Franceschi, Renny] Univ Michigan, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   [Ma, Peter X.] Univ Michigan, Dept Mat Sci & Engn, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; Kalamazoo College; University of Michigan
   System; University of Michigan; University of Michigan System;
   University of Michigan
RP Ma, PX (通讯作者)，1011 N Univ Ave,Room 2211, Ann Arbor, MI 48109 USA.
EM mapx@umich.edu
RI ; FRANCESCHI, RENNY/K 3533 2019; FENG, KAI/D 8756 2015; X,
   Peter/E 4895 2011; Sun, Hongli/F 9057 2011
OI Franceschi, Renny/0000 0003 1405 2541; Holzwarth,
   Jeremy/0000 0002 0583 7307; 
FU NIH [R01 DE022327, R01 DE027662, R01 DE017689, R01 DE11723, T32
   HD007505]; DOD [W81XWH 1220008, W81XWH 2010572]; NSF [DMR 1206575]
FX This work was supported by NIH R01 DE022327 (PXM), R01 DE027662 (PXM),
   R01 DE017689 (PXM), and R01 DE11723 (RTF), DOD W81XWH 1220008 and
   W81XWH 2010572 (PXM), NSF DMR 1206575 (PXM), as well as a training grant
   fellowship from NIH T32 HD007505 (KJR). KJR, HS, and PXM designed these
   studies. KJR, HS, KF, JMH, RK, and MD carried out the experiments. Data
   collection was done by KJR, HS, RK, YRD and MD. Data analysis was done
   by KJR and HS. The manuscript was drafted and revised by HS, KJR, RTF
   and PXM.
CR Ang CY, 2014, SINGAP MED J, V55, P526, DOI 10.11622/smedj.2014135
   Bouyer M, 2016, BIOMATERIALS, V104, P168, DOI 10.1016/j.biomaterials.2016.06.001
   Cahill KS, 2009, JAMA J AM MED ASSOC, V302, P58, DOI 10.1001/jama.2009.956
   Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165 6147(00)01676 X
   Dang M, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0025 8
   Dang M, 2017, BIOMATERIALS, V114, P1, DOI 10.1016/j.biomaterials.2016.10.049
   Dupree MA, 2006, BIOPHYS J, V91, P3097, DOI 10.1529/biophysj.106.087098
   EDELMAN ER, 1993, P NATL ACAD SCI USA, V90, P1513, DOI 10.1073/pnas.90.4.1513
   Einhorn TA, 2003, J BONE JOINT SURG AM, V85A, P82, DOI 10.2106/00004623 200300003 00014
   EPPLEY BL, 1988, J ORAL MAXIL SURG, V46, P391, DOI 10.1016/0278 2391(88)90223 6
   Fujimura K, 2002, ARCH ORAL BIOL, V47, P577, DOI 10.1016/S0003 9969(02)00046 8
   Gao YG, 2023, BIOMOLECULES, V13, DOI 10.3390/biom13030483
   Gautschi OP, 2007, ANZ J SURG, V77, P626, DOI 10.1111/j.1445 2197.2007.04175.x
   Graham SM, 2010, EXPERT OPIN BIOL TH, V10, P885, DOI 10.1517/14712598.2010.481669
   Grayson ACR, 2004, J BIOMAT SCI POLYM E, V15, P1281, DOI 10.1163/1568562041959991
   Guldberg RE, 2009, J BONE MINER RES, V24, P1507, DOI [10.1359/JBMR.090801, 10.1359/jbmr.090801]
   Gupte MJ, 2012, J DENT RES, V91, P227, DOI 10.1177/0022034511417441
   Hanada K, 1997, J BONE MINER RES, V12, P1606, DOI 10.1359/jbmr.1997.12.10.1606
   Hankenson KD, 2015, ADV DRUG DELIVER REV, V94, P3, DOI 10.1016/j.addr.2015.09.008
   HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665
   Holzwarth JM, 2011, BIOMATERIALS, V32, P9622, DOI 10.1016/j.biomaterials.2011.09.009
   Hu J, 2009, BIOMATERIALS, V30, P5061, DOI 10.1016/j.biomaterials.2009.06.013
   Hughes Fulford M, 2011, J ORTHOP SURG RES, V6, DOI 10.1186/1749 799X 6 8
   James AW, 2016, TISSUE ENG PART B RE, V22, P284, DOI [10.1089/ten.TEB.2015.0357, 10.1089/ten.teb.2015.0357]
   Jin QM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001729
   Kakudo N, 2006, WOUND REPAIR REGEN, V14, P336, DOI 10.1111/j.1743 6109.2006.00129.x
   Kempen DHR, 2009, BIOMATERIALS, V30, P2816, DOI 10.1016/j.biomaterials.2009.01.031
   Kim TH, 1997, TISSUE ENG, V3, P303, DOI 10.1089/ten.1997.3.303
   Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955 2235(89)90012 4
   Kuhn LT, 2013, J GERONTOL A BIOL, V68, P1170, DOI 10.1093/gerona/glt018
   Laurencin C, 2006, EXPERT REV MED DEVIC, V3, P49, DOI 10.1586/17434440.3.1.49
   Li GH, 2009, TISSUE ENG PT A, V15, P2123, DOI 10.1089/ten.tea.2008.0214
   Lienemann PS, 2020, ADV SCI, V7, DOI 10.1002/advs.201903395
   Liu XH, 2004, ANN BIOMED ENG, V32, P477, DOI 10.1023/B:ABME.0000017544.36001.8e
   Liu YC, 2015, J TISSUE ENG REGEN M, V9, P85, DOI 10.1002/term.1617
   Ponte AL, 2007, STEM CELLS, V25, P1737, DOI 10.1634/stemcells.2007 0054
   Ma PX, 2008, ADV DRUG DELIVER REV, V60, P184, DOI 10.1016/j.addr.2007.08.041
   Ma PX., 2005, ENCYCL POLYM SCI, V12, P261
   Mackie EJ, 2008, INT J BIOCHEM CELL B, V40, P46, DOI 10.1016/j.biocel.2007.06.009
   Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378 1119(03)00748 0
   Martino MM, 2015, ADV DRUG DELIVER REV, V94, P41, DOI 10.1016/j.addr.2015.04.007
   Nakamura Y, 2005, BONE, V36, P399, DOI 10.1016/j.bone.2004.11.010
   Novais A, 2021, CELLS BASEL, V10, DOI 10.3390/cells10040932
   Orellana BR, 2014, MAT SCI ENG C MATER, V43, P243, DOI 10.1016/j.msec.2014.06.044
   Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702
   Parsegian K, 2023, CONNECT TISSUE RES, V64, P53, DOI 10.1080/03008207.2022.2094789
   Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708
   Rambhia KJ, 2015, J CONTROL RELEASE, V219, P119, DOI 10.1016/j.jconrel.2015.08.049
   Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101 1029
   Saito N, 2005, ADV DRUG DELIVER REV, V57, P1037, DOI 10.1016/j.addr.2004.12.016
   Samee M, 2008, J PHARMACOL SCI, V108, P18, DOI 10.1254/jphs.08036FP
   Schwarting T, 2015, INT ORTHOP, V39, P799, DOI 10.1007/s00264 015 2688 8
   Shen BJ, 2010, J CELL BIOCHEM, V109, P406, DOI 10.1002/jcb.22412
   Shen XF, 2016, BIOMATERIALS, V106, P205, DOI 10.1016/j.biomaterials.2016.08.023
   Smith LA, 2010, BIOMATERIALS, V31, P5526, DOI 10.1016/j.biomaterials.2010.03.065
   Sohier J, 2003, J CONTROL RELEASE, V87, P57, DOI 10.1016/S0168 3659(02)00350 4
   Stegen S, 2015, BONE, V70, P19, DOI 10.1016/j.bone.2014.09.017
   Su N, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.3
   Sun HL, 2010, BIOMATERIALS, V31, P1133, DOI 10.1016/j.biomaterials.2009.10.030
   Takayama K, 2009, J BONE MINER METAB, V27, P402, DOI 10.1007/s00774 009 0054 x
   Tamura S, 2001, BONE, V29, P169, DOI 10.1016/S8756 3282(01)00498 7
   Tanaka E, 2006, ANN BIOMED ENG, V34, P717, DOI 10.1007/s10439 006 9092 x
   Vieira WA, 2019, DEV BIOL, V451, P146, DOI 10.1016/j.ydbio.2019.04.008
   Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105
   Wan DC, 2007, J BIOL CHEM, V282, P26450, DOI 10.1074/jbc.M703282200
   Wei GB, 2006, J CONTROL RELEASE, V112, P103, DOI 10.1016/j.jconrel.2006.01.011
   Wei GB, 2007, BIOMATERIALS, V28, P2087, DOI 10.1016/j.biomaterials.2006.12.028
   Wei GB, 2006, J BIOMED MATER RES A, V78A, P306, DOI 10.1002/jbm.a.30704
   Whang K, 2000, BIOMATERIALS, V21, P2545, DOI 10.1016/S0142 9612(00)00122 8
   Woo KM, 2007, BIOMATERIALS, V28, P335, DOI 10.1016/j.biomaterials.2006.06.013
   Woo KM, 2009, TISSUE ENG PT A, V15, P2155, DOI 10.1089/ten.tea.2008.0433
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Yamamoto M, 2000, J CONTROL RELEASE, V64, P133, DOI 10.1016/S0168 3659(99)00129 7
   Zhang ZP, 2015, ADV FUNCT MATER, V25, P350, DOI 10.1002/adfm.201402618
   Zhou XZ, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 01173 z
NR 75
TC 4
Z9 4
U1 10
U2 22
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD DEC
PY 2024
VL 190
BP 50
EP 63
DI 10.1016/j.actbio.2024.10.044
EA DEC 2024
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA O6N8N
UT WOS:001372279100001
PM 39486780
DA 2025 08 17
ER

PT J
AU El Kady, AM
   Kamel, NA
   Elnashar, MM
   Farag, MM
AF El Kady, Abeer M.
   Kamel, Nagwa A.
   Elnashar, Magdy M.
   Farag, Mohammad M.
TI Production of bioactive glass/chitosan scaffolds by freeze gelation for
   optimized vancomycin delivery: Effectiveness of glass presence on
   controlling the drug release kinetics
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Scaffolds; Freeze gelation; Drug release; Bioactive glass; Composites;
   Vancomycin; Higuchi model
ID IN VITRO; MECHANICAL PROPERTIES; HUMAN OSTEOBLASTS; POROUS SCAFFOLDS;
   PARTICLE SIZE; CHITOSAN; NANOPARTICLES; VIVO; ACETYLATION; DEGRADATION
AB The major objective of this work was the creation of vancomycin loaded composite scaffolds designed for bone treatment from inexpensive and biocompatible materials such as chitosan. Bioactive glass was chosen as filler due to its outstanding bioactivity and ability for bone regeneration. The scaffolds were prepared using the freezegelation method, which was efficient and cost effective. They included different glass contents (0, 25, and 50 wt %) and symbolized as C, C25, and C50, respectively. The SEM/EDXA, TGA and the FTIR were used to characterize the scaffolds. The degradation properties of the scaffolds were controlled through modifying their glass contents. Furthermore, the kinetics of the released drug was improved as the glass content increased. The final cumulative percentages of released drug from scaffolds C, C25, and C50 reached 52.49, 70.82 and 98.22%, respectively. The Higuchi model proved that the drug was released through a diffusion controlled mechanism. For neat polymer scaffold, the drug was released in two following stages. In contrast, for composite scaffolds, the release pattern was modulated and differentiated into four stages. That modulation was attributed to glass presence and deposition of apatite layer on their surfaces. Additionally, cell viability was enhanced by the presence of glass. In brief, glass presence was highly effective in controlling degradation properties and improving the drug release kinetics of the scaffolds. Therefore, the scaffolds made of chitosan and bioactive glass could be a good candidate for localized bone treatment.
C1 [El Kady, Abeer M.; Farag, Mohammad M.] Natl Res Ctr, Glass Res Dept, 33 El Bohooth St, Cairo 12622, Egypt.
   [Kamel, Nagwa A.] Natl Res Ctr, Microwave Phys & Dielect Dept, Phys Div, Cairo, Egypt.
   [Elnashar, Magdy M.] Natl Res Ctr, Polymers Dept, 33 El Bohooth St, Cairo 12622, Egypt.
C3 Egyptian Knowledge Bank (EKB); National Research Centre (NRC); Egyptian
   Knowledge Bank (EKB); National Research Centre (NRC); Egyptian Knowledge
   Bank (EKB); National Research Centre (NRC)
RP El Kady, AM; Farag, MM (通讯作者)，Natl Res Ctr, Glass Res Dept, 33 El Bohooth St, Cairo 12622, Egypt.
EM abeerelkady_2000@yahoo.co.uk; mmfaragnrc@gmail.com
RI Farag, Mohammad/Y 4052 2018; kamel, nagwa/N 8276 2019; Elnashar,
   Magdy/K 3036 2012
OI Farag, Mohammad/0000 0001 5069 9030; Elnashar,
   Magdy/0000 0001 9936 3271; Kamel, Nagwa/0000 0003 3462 3911
CR Aranaz I., 2009, CURRENT CHEM BIOL, V3, P203, DOI DOI 10.2174/187231309788166415
   Aulton M.E., 1988, SCI DOSAGE FORM DESI, P289
   Berger J, 2004, EUR J PHARM BIOPHARM, V57, P19, DOI 10.1016/s0939 6411(03)00161 9
   Cerruti MG, 2005, BIOMATERIALS, V26, P4903, DOI 10.1016/j.biomaterials.2005.01.013
   Chatelet C, 2001, BIOMATERIALS, V22, P261, DOI 10.1016/S0142 9612(00)00183 6
   El Kady A.M., 2012, J. Genet. Eng. Biotechnol, V10, P229, DOI [10.1016/j.jgeb.2012.07.002, DOI 10.1016/J.JGEB.2012.07.002]
   El Kady AM, 2020, J NON CRYST SOLIDS, V534, DOI 10.1016/j.jnoncrysol.2020.119889
   El Kady AM, 2019, J NON CRYST SOLIDS, V521, DOI 10.1016/j.jnoncrysol.2019.119471
   El Kady AM, 2016, EUR J PHARM SCI, V91, P243, DOI 10.1016/j.ejps.2016.05.004
   El Kady AM, 2015, J NANOMATER, V2015, DOI 10.1155/2015/839207
   El Kady AM, 2010, CERAM INT, V36, P995, DOI 10.1016/j.ceramint.2009.11.012
   El Kady AM, 2010, MAT SCI ENG C MATER, V30, P120, DOI 10.1016/j.msec.2009.09.008
   El Meliegy E, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 30720 2
   El Meliegy E, 2018, CERAM INT, V44, P9140, DOI 10.1016/j.ceramint.2018.02.122
   El Meliegy E, 2017, J NON CRYST SOLIDS, V475, P59, DOI 10.1016/j.jnoncrysol.2017.08.034
   El Sayed SAM, 2020, J DRUG DELIV SCI TEC, V57, DOI 10.1016/j.jddst.2020.101757
   Elnashar MMM, 2009, J APPL POLYM SCI, V114, P17, DOI 10.1002/app.30535
   FOWLER BO, 1974, INORG CHEM, V13, P194, DOI 10.1021/ic50131a039
   Granja PL, 2004, KEY ENG MAT, V254 2, P573, DOI 10.4028/www.scientific.net/KEM.254 256.573
   Greenspan DC, 2016, INT J APPL GLASS SCI, V7, P134, DOI 10.1111/ijag.12204
   HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022 1759(89)90397 9
   Hench LL, 2006, J MATER SCI MATER M, V17, P967, DOI 10.1007/s10856 006 0432 z
   Hench LL, 2016, J NON CRYST SOLIDS, V432, P2, DOI 10.1016/j.jnoncrysol.2014.12.038
   Hench LL, 1998, J AM CERAM SOC, V81, P1705
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   Ho MH, 2004, BIOMATERIALS, V25, P129, DOI 10.1016/S0142 9612(03)00483 6
   Hsieh CY, 2007, CARBOHYD POLYM, V67, P124, DOI 10.1016/j.carbpol.2006.05.002
   Illum L, 1998, PHARM RES DORDR, V15, P1326
   Jodati H, 2020, CERAM INT, V46, P15725, DOI 10.1016/j.ceramint.2020.03.192
   Kargozar S, 2018, TRENDS BIOTECHNOL, V36, P430, DOI 10.1016/j.tibtech.2017.12.003
   Koide SS, 1998, NUTR RES, V18, P1091, DOI 10.1016/S0271 5317(98)00091 8
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   KOKUBO T, 1990, J BIOMED MATER RES, V24, P331, DOI 10.1002/jbm.820240306
   Kumar P, 2020, INT J BIOL MACROMOL, V149, P1, DOI 10.1016/j.ijbiomac.2020.01.035
   Lahiji A, 2000, J BIOMED MATER RES, V51, P586
   Lee D.W., 2009, Open Biomater. J, V1
   Liverani L, 2018, BIOACT MATER, V3, P55, DOI 10.1016/j.bioactmat.2017.05.003
   Mahmoud EM, 2020, INT J BIOL MACROMOL, V165, P1346, DOI 10.1016/j.ijbiomac.2020.10.014
   Mourino V, 2019, CURR OPIN BIOMED ENG, V10, P23, DOI 10.1016/j.cobme.2019.02.002
   Naga S. M., 2018, Advances in Natural Sciences: Nanoscience and Nanotechnology, V9, DOI 10.1088/2043 6254/aae9f7
   Peter M, 2010, CARBOHYD POLYM, V80, P687, DOI 10.1016/j.carbpol.2009.11.050
   Radin S, 2009, BIOMATERIALS, V30, P850, DOI 10.1016/j.biomaterials.2008.09.066
   Rashki S, 2021, CARBOHYD POLYM, V251, DOI 10.1016/j.carbpol.2020.117108
   Ren DW, 2005, CARBOHYD RES, V340, P2403, DOI 10.1016/j.carres.2005.07.022
   REY C, 1989, CALCIFIED TISSUE INT, V45, P157, DOI 10.1007/BF02556059
   Rinaudo M, 2006, PROG POLYM SCI, V31, P603, DOI 10.1016/j.progpolymsci.2006.06.001
   Roberts G. A. F., 1992, Chitin Chemistry, P1
   Sarkar N, 2017, EUR J PHARM SCI, V109, P359, DOI 10.1016/j.ejps.2017.08.015
   Shah SR, 2014, PHARM RES DORDR, V31, P3379, DOI 10.1007/s11095 014 1427 y
   Shaltooki M, 2019, MAT SCI ENG C MATER, V105, DOI 10.1016/j.msec.2019.110138
   Soni R, 2019, MATER TODAY PROC, V15, P294, DOI 10.1016/j.matpr.2019.05.008
   Tamjid E, 2011, MAT SCI ENG C MATER, V31, P1526, DOI 10.1016/j.msec.2011.06.013
   Tao FH, 2021, CARBOHYD POLYM, V251, DOI 10.1016/j.carbpol.2020.117063
   Wang YH, 2021, MAT SCI ENG C MATER, V119, DOI 10.1016/j.msec.2020.111442
   Wong J., GLASS STRUCTURE SPEC
   Xynos ID, 2000, BIOCHEM BIOPH RES CO, V276, P461, DOI 10.1006/bbrc.2000.3503
   Yang YM, 2007, J MATER SCI MATER M, V18, P2117, DOI 10.1007/s10856 007 3013 x
   Zadpoor AA, 2014, MAT SCI ENG C MATER, V35, P134, DOI 10.1016/j.msec.2013.10.026
   Zamani D, 2019, INT J BIOL MACROMOL, V137, P1256, DOI 10.1016/j.ijbiomac.2019.06.182
   Zhang H, 2001, BIOMATERIALS, V22, P1653, DOI 10.1016/S0142 9612(00)00326 4
   Zhou L, 2021, BIOACT MATER, V6, P890, DOI 10.1016/j.bioactmat.2020.09.012
NR 61
TC 22
Z9 23
U1 0
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1773 2247
EI 2588 8943
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PD DEC
PY 2021
VL 66
AR 102779
DI 10.1016/j.jddst.2021.102779
EA AUG 2021
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA WD5MN
UT WOS:000704984600003
DA 2025 08 17
ER

PT J
AU Liu, C
   Sun, J
AF Liu, Chao
   Sun, Jiao
TI Potential Application of Hydrolyzed Fish Collagen for Inducing the
   Multidirectional Differentiation of Rat Bone Marrow Mesenchymal Stem
   Cells
SO BIOMACROMOLECULES
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; AMINO ACID; GENE; HYDROXYAPATITE;
   PROLIFERATION; OSTEOGENESIS; STIMULATION; ACTIVATION; EXPRESSION;
   PEPTIDES
AB Hydrolyzed fish collagen (HFC) has recently attracted considerable attention because of its outstanding bioactivity. However, few studies have been performed to determine the biological effects of HFC on bone marrow mesenchymal stem cells (BMSCs), which are often used in regenerative medicine. In this study, the molecular weight, amino acid composition, and contact angle of HFC were measured. The influence of HFC on cell viability and the multidirectional differentiation of BMSCs into osteogenic, endothelial, adipogenic, chondrogenic, and neural lineages were also assessed. Furthermore, the mechanism by which HFC promotes osteogenesis was investigated at the protein level. The molecular weight of HFC ranged from 700 to 1300 Da, the contact angle of HFC was approximately 26 degrees, and HFC was found to be composed of various amino acids, including glycine, proline, and hydroxyproline. At a concentration of 0.2 mg/mL, HFC promoted cell viability, and significantly up regulated the expression of osteogenic markers (RUNX2, ALP, OPN, and OCN), as well as endothelial markers (CD31, VE cadherin, and VEGFR2). Western blot results indicated that treatment of BMSCs with 0.2 mg/mL HFC could activate the MAPK/ERK signaling pathway and then increase the protein level of RUNX2, while treatment with PD98059, a specific inhibitor of ERK1/2, could significantly inhibit the expression of P ERK and RUNX2. Interestingly, real time PCR demonstrated that HFC inhibited the expression of adipogenic markers (LPL and ADFP) and chondrogenic markers (aggrecan and COLII), whereas it had no effect on neural differentiation markers (MAP2 and beta 3 tubulin). In summary, this study suggests that without the use of any additional inducing reagent, HFC has the potential to actively promote osteogenic and endothelial differentiation because of its high hydrophilicity and the optimal extracellular microenvironment supplied by its amino acids. This research also revealed that HFC inhibited adipogenic and chondrogenic differentiation, but it had no influence on the neural differentiation of rat bone marrow mesenchymal stem cells (rBMSCs).
C1 [Liu, Chao; Sun, Jiao] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Biomat Res & Testing Ctr, Sch Med, Shanghai 200023, Peoples R China.
C3 Shanghai Jiao Tong University
RP Sun, J (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Biomat Res & Testing Ctr, Sch Med, Shanghai 200023, Peoples R China.
EM jiaosun59@yahoo.com
OI Liu, Chao/0000 0001 8683 3473
FU Shanghai Sci Tech Committee Foundation [13DZ2291100]
FX The authors are grateful to Qisheng Gu, Institute of Shanghai Qisheng
   Biomaterial Technology, for technical advice and to Nanping Wang at
   Shanghai Fisheries Research Institute for providing the hydrolyzed fish
   collagen. This work was supported by grants from Shanghai Sci Tech
   Committee Foundation (13DZ2291100).
CR Boanini E, 2006, BIOMATERIALS, V27, P4428, DOI 10.1016/j.biomaterials.2006.04.019
   Dimitrievska S, 2011, J BIOMED MATER RES A, V98A, P576, DOI 10.1002/jbm.a.32964
   Eames BF, 2004, DEV BIOL, V274, P188, DOI 10.1016/j.ydbio.2004.07.006
   Fuentes P, 2010, J ENDOCRINOL, V206, P75, DOI 10.1677/JOE 10 0049
   Giuliani N, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/312501
   Gu QL, 2012, PHARMACOGN MAG, V8, P202, DOI 10.4103/0973 1296.99285
   Kang YQ, 2012, BIOMATERIALS, V33, P6998, DOI 10.1016/j.biomaterials.2012.06.061
   Leem KH, 2013, J MED FOOD, V16, P447, DOI 10.1089/jmf.2012.2461
   Lin L, 2010, APMIS, V118, P595, DOI 10.1111/j.1600 0463.2010.02634.x
   Liu X, 2010, BIOMATERIALS, V31, P8198, DOI 10.1016/j.biomaterials.2010.07.069
   Mizuno M, 2001, J BIOCHEM TOKYO, V129, P133, DOI 10.1093/oxfordjournals.jbchem.a002824
   Moll R, 2009, CELL TISSUE RES, V335, P109, DOI 10.1007/s00441 008 0700 y
   Nakamura Y, 2009, CELL TISSUE RES, V336, P203, DOI 10.1007/s00441 009 0767 0
   Oesser S, 2003, CELL TISSUE RES, V311, P393, DOI 10.1007/s00441 003 0702 8
   Ohara H, 2010, J DERMATOL, V37, P330, DOI 10.1111/j.1346 8138.2010.00827.x
   Raabe O, 2010, HISTOCHEM CELL BIOL, V134, P545, DOI 10.1007/s00418 010 0760 4
   Sauer H, 2013, STEM CELLS DEV, V22, P1443, DOI 10.1089/scd.2012.0640
   Schadow S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053955
   Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738
   Sengupta S, 2010, TISSUE ENG PT A, V16, P3623, DOI [10.1089/ten.tea.2010.0302, 10.1089/ten.TEA.2010.0302]
   Siebert HC, 2010, PROTEIN CELL, V1, P393, DOI 10.1007/s13238 010 0038 6
   Stötzel S, 2012, CHEMPHYSCHEM, V13, P3117, DOI 10.1002/cphc.201200284
   Tang QQ, 2005, P NATL ACAD SCI USA, V102, P9766, DOI 10.1073/pnas.0503891102
   Vieira JM, 2010, ORGANOGENESIS, V6, P97, DOI 10.4161/org.6.2.11686
   Wang C, 2013, BIOMATERIALS, V34, P64, DOI 10.1016/j.biomaterials.2012.09.021
   Wang Y, 2011, INT J NANOMED, V6, P667, DOI 10.2147/IJN.S17547
   Washington JM, 2010, AM J PHYSIOL CELL PH, V298, pC982, DOI 10.1152/ajpcell.00498.2009
   Yamada S, 2013, DENT MATER J, V32, P233, DOI 10.4012/dmj.2012 188
   Yamada S, 2013, DENT MATER J, V32, P88, DOI 10.4012/dmj.2012 220
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Zhang F, 2012, ARCH ORAL BIOL, V57, P460, DOI 10.1016/j.archoralbio.2011.10.008
   Zhou Y, 2013, BIOTECHNOL BIOENG, V110, P1794, DOI 10.1002/bit.24827
NR 32
TC 52
Z9 54
U1 0
U2 41
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525 7797
EI 1526 4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD JAN
PY 2014
VL 15
IS 1
BP 436
EP 443
DI 10.1021/bm401780v
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 292CO
UT WOS:000329879800046
PM 24359018
DA 2025 08 17
ER

PT J
AU Qing, FZ
   Xie, PF
   Liem, YS
   Chen, Y
   Chen, XN
   Zhu, XD
   Fan, YJ
   Yang, X
   Zhang, XD
AF Qing, Fangzhu
   Xie, Pengfei
   Liem, Yacincha Selushia
   Chen, Ying
   Chen, Xuening
   Zhu, Xiangdong
   Fan, Yujiang
   Yang, Xiao
   Zhang, Xingdong
TI Administration duration influences the effects of low magnitude,
   high frequency vibration on ovariectomized rat bone
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
ID WHOLE BODY VIBRATION; MESENCHYMAL STEM CELLS; RANDOMIZED
   CONTROLLED TRIAL; LOW BACK PAIN; POSTMENOPAUSAL WOMEN; OSTEOPOROTIC
   FRACTURES; MECHANICAL SIGNALS; MINERAL DENSITY; LOW AMPLITUDE; STRENGTH
AB Low magnitude, high frequency vibration (LMHFV) has been proposed as a non drug anti osteoporosis treatment. However, the influence of administration duration on its effect is seldom investigated. In this study, the effect of 16 week LMHFV (0.3g, 30Hz, 20min/day) on the bone mineral densities (BMDs), bone mechanical properties, and cellular responses of osteoporotic and healthy rats was examined by in vivo peripheral quantitative computed tomography (pQCT), fracture tests, cell assays, and mRNA quantification. Forty eight adult rats were equally assigned to sham surgery (SHM), sham surgery with LMHFV (SHM+V), ovariectomy (OVX), and ovariectomy with LMHFV (OVX+V) groups. At week 8, LMHFV ameliorated ovariectomy induced deterioration of trabecular bone, with a significantly higher tibia trabecular BMD (+11.2%) being noted in OVX+V rats (vs. OVX). However, this positive effect was not observed at later time points. Furthermore, 16 weeks of LMHFV caused significant reductions in the vertebral mean BMD ( 13.0%), trabecular BMD ( 15.7%), and maximum load ( 21.5%) in OVX+V rats (vs. OVX). Osteoblasts derived from osteoporotic rat bone explants showed elevated BSP and OSX mRNA expression induced by LMHFV on day 1. However, no further positive effect on osteoblastic mRNA expression, alkaline phosphatase activity, or calcium deposition was observed with prolonged culture time. A higher ratio of RANKL/OPG induced by LMHFV suggests that osteoclastogenesis may be activated. Together, these results demonstrate that administration duration played an important role in the effect of LMHFV. Early exposure to LMHFV can positively modulate osteoporotic bone and osteoblasts; however, the beneficial effect seems not to persist over time. (c) 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:1147 1157, 2016.
C1 [Qing, Fangzhu; Xie, Pengfei; Chen, Ying; Chen, Xuening; Zhu, Xiangdong; Fan, Yujiang; Yang, Xiao; Zhang, Xingdong] Sichuan Univ, Natl Engn Res Ctr Biomat, Chengdu 610064, Peoples R China.
   [Qing, Fangzhu] Univ Elect Sci & Technol China, Chengdu 610054, Peoples R China.
   [Liem, Yacincha Selushia; Yang, Xiao] Natl Univ Singapore, Fac Biomed Engn, Singapore 117576, Singapore.
C3 Sichuan University; University of Electronic Science & Technology of
   China; National University of Singapore
RP Fan, YJ; Yang, X (通讯作者)，Sichuan Univ, Natl Engn Res Ctr Biomat, Chengdu 610064, Peoples R China.; Yang, X (通讯作者)，Natl Univ Singapore, Fac Biomed Engn, Singapore 117576, Singapore.
EM fan_yujiang@scu.edu.cn; xiaoyang114@scu.edu.cn
RI Xie, Pengfei/Q 6424 2016
FU National Science and Technology Supporting Project [2012BAI17B01];
   National Basic Research Program of China (973 project) [2011CB606201]
FX Grant sponsor: National Science and Technology Supporting Project; Grant
   number: 2012BAI17B01; Grant sponsor: National Basic Research Program of
   China (973 project); Grant number: 2011CB606201
CR Andarawis Puri N, 2012, J ORTHOP RES, V30, P1327, DOI 10.1002/jor.22059
   Bemben DA, 2010, BONE, V47, P650, DOI 10.1016/j.bone.2010.06.019
   Brouwers JEM, 2010, J ORTHOP RES, V28, P62, DOI 10.1002/jor.20951
   Declercq H, 2004, BIOMATERIALS, V25, P757, DOI 10.1016/S0142 9612(03)00580 5
   Declerq HA, 2005, BIOMATERIALS, V26, P4964, DOI 10.1016/j.biomaterials.2005.01.025
   Giner M, 2011, EUR J PHARMACOL, V650, P682, DOI 10.1016/j.ejphar.2010.10.058
   Jiang JMY, 2008, J NUTR, V138, P2106, DOI 10.3945/jn.108.093781
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Judex S, 2007, J BIOMECH, V40, P1333, DOI 10.1016/j.jbiomech.2006.05.014
   Lai CL, 2013, CLIN INTERV AGING, V8, P1603, DOI 10.2147/CIA.S53591
   Lau E, 2011, J ORTHOP RES, V29, P1075, DOI 10.1002/jor.21334
   Lau E, 2010, BONE, V46, P1508, DOI 10.1016/j.bone.2010.02.031
   Lings S, 2000, INT ARCH OCC ENV HEA, V73, P290, DOI 10.1007/s004200000118
   Lynch MA, 2011, J ORTHOP RES, V29, P465, DOI 10.1002/jor.21280
   Maddalozzo GF, 2008, INT J OBESITY, V32, P1348, DOI 10.1038/ijo.2008.111
   Mosig RA, 2007, HUM MOL GENET, V16, P1113, DOI 10.1093/hmg/ddm060
   NELSON ME, 1994, JAMA J AM MED ASSOC, V272, P1909, DOI 10.1001/jama.272.24.1909
   Nyman JS, 2011, J BONE MINER RES, V26, P1252, DOI 10.1002/jbmr.326
   Pasqualini M, 2013, BONE, V55, P69, DOI 10.1016/j.bone.2013.03.013
   Perrini S, 2008, ENDOCRINOLOGY, V149, P1302, DOI 10.1210/en.2007 1349
   Prè D, 2009, TISSUE ENG PART C ME, V15, P669, DOI [10.1089/ten.tec.2008.0599, 10.1089/ten.TEC.2008.0599]
   Prisby RD, 2008, AGEING RES REV, V7, P319, DOI 10.1016/j.arr.2008.07.004
   Roelofsen J, 1995, J BIOMECH, V28, P1493, DOI 10.1016/0021 9290(95)00097 6
   Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122
   Saxon LK, 2005, BONE, V36, P454, DOI 10.1016/j.bone.2004.12.001
   Sehmisch S, 2009, OSTEOPOROSIS INT, V20, P1999, DOI 10.1007/s00198 009 0892 3
   Sen B, 2008, ENDOCRINOLOGY, V149, P6065, DOI 10.1210/en.2008 0687
   Sen B, 2011, J BIOMECH, V44, P593, DOI 10.1016/j.jbiomech.2010.11.022
   Shi Y, 2011, J CELL PHYSIOL, V226, P2159, DOI 10.1002/jcp.22551
   Simmons CA, 2003, J BIOMECH, V36, P1087, DOI 10.1016/S0021 9290(03)00110 6
   Slatkovska L, 2011, ANN INTERN MED, V155, P668, DOI 10.7326/0003 4819 155 10 201111150 00005
   Stolzenberg N, 2013, J MUSCULOSKEL NEURON, V13, P66
   Stuermer EK, 2014, BONE, V64, P187, DOI 10.1016/j.bone.2014.04.008
   Tanaka SM, 2003, J BIOMECH, V36, P73, DOI 10.1016/S0021 9290(02)00245 2
   Tezval M, 2011, CALCIFIED TISSUE INT, V88, P33, DOI 10.1007/s00223 010 9423 7
   Thompson WR, 2015, SCI REP UK, V5, DOI 10.1038/srep11049
   Tiemessen IJH, 2008, OCCUP ENVIRON MED, V65, P667, DOI 10.1136/oem.2007.035147
   Tjandrawinata RR, 1997, FASEB J, V11, P493, DOI 10.1096/fasebj.11.6.9194530
   TURNER CH, 1995, J BONE MINER RES, V10, P1544
   Uusi Rasi K, 1998, J BONE MINER RES, V13, P133, DOI 10.1359/jbmr.1998.13.1.133
   Uzer G, 2015, STEM CELLS, V33, P2063, DOI 10.1002/stem.2004
   Uzer G, 2013, J BIOMECH, V46, P2296, DOI 10.1016/j.jbiomech.2013.06.008
   van der Jagt OP, 2012, J BONE MINER METAB, V30, P40, DOI 10.1007/s00774 011 0293 5
   Vanleene M, 2013, BONE, V53, P507, DOI 10.1016/j.bone.2013.01.023
   Verschueren SMP, 2011, J BONE MINER RES, V26, P42, DOI 10.1002/jbmr.181
   von Stengel S, 2011, OSTEOPOROSIS INT, V22, P317, DOI 10.1007/s00198 010 1215 4
   Wang XF, 2013, MOL MED REP, V7, P1169, DOI 10.3892/mmr.2013.1335
   Wehrle E, 2014, J ORTHOP RES, V32, P1006, DOI 10.1002/jor.22629
   Wysocki A, 2011, ANN INTERN MED, V155, P680, DOI 10.7326/0003 4819 155 10 201111150 00006
   Yamazaki Satoru, 2002, Spine J, V2, P415, DOI 10.1016/S1529 9430(02)00427 8
   Yang X, 2013, BONE, V52, P308, DOI 10.1016/j.bone.2012.09.039
   Yang X, 2011, BONE, V48, P1154, DOI 10.1016/j.bone.2011.02.007
   Zaki ME, 2014, J OSTEOPOROS, V2014, P1
   Zhang R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092312
   Zhou Y, 2011, EUR CELLS MATER, V22, P12, DOI 10.22203/eCM.v022a02
NR 55
TC 14
Z9 16
U1 0
U2 29
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD JUL
PY 2016
VL 34
IS 7
BP 1147
EP 1157
DI 10.1002/jor.23128
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA DR6OT
UT WOS:000380021900006
PM 26662723
OA Bronze
DA 2025 08 17
ER

PT J
AU Lo, KWH
   Kan, HM
   Laurencin, CT
AF Lo, Kevin W.  H.
   Kan, Ho Man
   Laurencin, Cato T.
TI Short term administration of small molecule phenamil induced a
   protracted osteogenic effect on osteoblast like MC3T3 E1 cells
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE small molecules; cell adhesion; biomaterials; regenerative engineering;
   osteogenesis; growth factors
ID BONE MORPHOGENETIC PROTEINS; FOCAL ADHESION KINASE; SIGNALING PATHWAY;
   CYCLIC AMP; DIFFERENTIATION; BIOMATERIALS; ROAD
AB Sustained administration (21 day treatment) of the small molecule phenamil has been proposed as an alternative osteogenic factor when used in conjunction with a biodegradable scaffold for in vitro osteogenesis. While promising, the major issue associated with small molecules is non specific cytotoxicity. The aim of this study was to minimize the side effects from small molecule drugs by reducing the frequency of administration. Toward this goal, we investigated whether a shorter phenamil treatment is sufficient to induce in vitro osteogenesis. We compared the effects of short term (12 h) and continuous treatments of phenamil on osteoblastic differentiation and mineralization. Alkaline phosphatase (ALP) and osteopontin (OPN) activity were used as markers for osteoblastic differentiation. Measurement of the calcium content of the extracellular matrix was used as the hallmark for in vitro bone formation after 21 days of culture. Our findings revealed that both short and continuous phenamil treatment triggers osteoblastic differentiation and mineralization of MC3T3 E1 cells on a biodegradable polymeric scaffold composed of polylactic co glycolic acid (PLAGA) at the same time points. In addition, in order to fabricate a phenamil loaded PLAGA scaffold, the small molecule phenamil was physically absorbed onto the surface of scaffolds and the bioactivity of the loaded scaffolds was evaluated. Furthermore, biochemical analysis indicated that short phenamil treatment of cells was accompanied by upregulation in protein expression of integrin alpha 5, p125(FAK) and phosphorylation of CREB. These effects may contribute to the downstream signalling cascade necessary for osteogenesis, and such responses may account for our observed protracted osteogenic differentiation in vitro. Copyright (C) 2013 John Wiley & Sons, Ltd.
C1 [Kan, Ho Man; Laurencin, Cato T.] Univ Connecticut, Sch Med, Ctr Hlth, Dept Orthoped Surg, Farmington, CT USA.
   [Lo, Kevin W.  H.; Kan, Ho Man; Laurencin, Cato T.] Univ Connecticut, Sch Med, Ctr Hlth, Inst Regenerat Engn, Farmington, CT 06030 USA.
   [Lo, Kevin W.  H.; Kan, Ho Man; Laurencin, Cato T.] Univ Connecticut, Sch Med, Ctr Hlth, Raymond & Beverly Sackler Ctr Biomed Biol Phys &, Farmington, CT USA.
   [Laurencin, Cato T.] Univ Connecticut, Sch Engn, Dept Chem Mat & Biomol Engn, Storrs, CT USA.
   [Lo, Kevin W.  H.] Univ Connecticut, Ctr Hlth, Sch Med, Dept Med,Div Endocrinol, Farmington, CT USA.
   [Lo, Kevin W.  H.; Laurencin, Cato T.] Univ Connecticut, Sch Engn, Dept Biomed Engn, Storrs, CT USA.
C3 University of Connecticut; University of Connecticut; University of
   Connecticut; University of Connecticut; University of Connecticut;
   University of Connecticut
RP Lo, KWH; Laurencin, CT (通讯作者)，Univ Connecticut, Sch Med, Ctr Hlth, Inst Regenerat Engn, Farmington, CT 06030 USA.
EM wlo@uchc.edu; laurencin@uchc.edu
FU National Institutes of Health (NIH) [R21AR060480]; Presidential Faculty
   Fellowship Award; Presidential Award for Excellence in Science,
   Mathematics, and Engineering Mentorship
FX We would like to thank Mr Clarke Nelson for his comments. The authors
   gratefully acknowledge funding from the National Institutes of Health
   (NIH; Grant No. R21AR060480). Professor Cato Laurencin was the recipient
   of the Presidential Faculty Fellowship Award from President William
   Clinton and the Presidential Award for Excellence in Science,
   Mathematics, and Engineering Mentorship from President Barack Obama.
CR Alves H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026678
   Bessa PC, 2008, J TISSUE ENG REGEN M, V2, P1, DOI 10.1002/term.63
   Bessa PC, 2008, J TISSUE ENG REGEN M, V2, P81, DOI 10.1002/term.74
   Brey DM, 2011, BIOTECHNOL BIOENG, V108, P163, DOI 10.1002/bit.22925
   Cary Leslie A., 1999, Frontiers in Bioscience, V4, pD102, DOI 10.2741/Cary
   Cho MJ, 1996, TRENDS BIOTECHNOL, V14, P153, DOI 10.1016/0167 7799(96)10024 X
   Doorn J, 2012, TISSUE ENG PT A, V18, P1431, DOI [10.1089/ten.tea.2011.0484, 10.1089/ten.TEA.2011.0484]
   Egusa H, 2010, J ORAL BIOSCI, V52, P107, DOI 10.2330/joralbiosci.52.107
   El Amin SF, 2004, CLIN ORTHOP RELAT R, P220, DOI 10.1097/01.blo.0000137556.51604.0c
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357 2725(97)00051 4
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   Han CYE, 2009, BIOORG MED CHEM LETT, V19, P1442, DOI 10.1016/j.bmcl.2009.01.025
   Johansson Staffan, 1997, Frontiers in Bioscience (online), V2, pD126
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kumari A, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041488, 10.1371/journal.pone.0041230]
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Lo Kevin W. H., 2011, Recent Patents on Biomedical Engineering, V4, P153, DOI 10.2174/1874764711104030153
   Lo KWH, 2012, ADV DRUG DELIVER REV, V64, P1277, DOI 10.1016/j.addr.2012.03.014
   Lo KWH, 2012, J TISSUE ENG REGEN M, V6, P40, DOI 10.1002/term.395
   Lo KWH, 2011, J ORTHOP RES, V29, P602, DOI 10.1002/jor.21276
   Lo KWH, 2012, REGEN MED, V7, P535, DOI [10.2217/rme.12.33, 10.2217/RME.12.33]
   Lo KW H, 2012, J TISSUE ENG REGEN M, DOI 10.1002/term.1573
   Lo KWH, 2006, J BIOL CHEM, V281, P9552, DOI 10.1074/jbc.M511721200
   Malich G, 1997, TOXICOLOGY, V124, P179, DOI 10.1016/S0300 483X(97)00151 0
   Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539
   Marquis ME, 2009, FRONT BIOSCI LANDMRK, V14, P1023, DOI 10.2741/3293
   Overman JR, 2013, TISSUE ENG PT A, V19, P571, DOI [10.1089/ten.tea.2012.0133, 10.1089/ten.TEA.2012.0133]
   Park KW, 2009, MOL CELL BIOL, V29, P3905, DOI 10.1128/MCB.00002 09
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092 8674(85)90322 8
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Sefcik Lauren S, 2008, Organogenesis, V4, P215
   Shah AK, 1999, BIOL CELL, V91, P131, DOI 10.1016/S0248 4900(99)80037 9
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   Siddappa R, 2010, J TISSUE ENG REGEN M, V4, P356, DOI 10.1002/term.246
   Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517
   Tintut Y, 1998, J BIOL CHEM, V273, P7547, DOI 10.1074/jbc.273.13.7547
   Weiss WA, 2007, NAT CHEM BIOL, V3, P739, DOI 10.1038/nchembio1207 739
   Widaa A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040586
   YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681
   YOUNG MF, 1992, CLIN ORTHOP RELAT R, P275
NR 43
TC 16
Z9 22
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD JUN
PY 2016
VL 10
IS 6
BP 518
EP 526
DI 10.1002/term.1786
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA DR6QA
UT WOS:000380025200007
PM 23913855
DA 2025 08 17
ER

PT J
AU Ito, H
   Koefoed, M
   Tiyapatanaputi, P
   Gromov, K
   Goater, JJ
   Carmouche, J
   Zhang, XP
   Rubery, PT
   Rabinowitz, J
   Samulski, RJ
   Nakamura, T
   Soballe, K
   O'Keefe, RJ
   Boyce, BF
   Schwarz, EM
AF Ito, H
   Koefoed, M
   Tiyapatanaputi, P
   Gromov, K
   Goater, JJ
   Carmouche, J
   Zhang, XP
   Rubery, PT
   Rabinowitz, J
   Samulski, RJ
   Nakamura, T
   Soballe, K
   O'Keefe, RJ
   Boyce, BF
   Schwarz, EM
TI Remodeling of cortical bone allografts mediated by adherent rAAV RANKL
   and VEGF gene therapy
SO NATURE MEDICINE
LA English
DT Article
ID DEBRIS INDUCED OSTEOLYSIS; IN VIVO; OSTEOCLAST DIFFERENTIATION;
   OSTEOPROTEGERIN LIGAND; RECEPTOR ACTIVATOR; REPAIR; BIOLOGY; CELL;
   REGENERATION; CARTILAGE
AB Structural allograft healing is limited because of a lack of vascularization and remodeling. To study this we developed a mouse model that recapitulates the clinical aspects of live autograft and processed allograft healing. Gene expression analyses showed that there is a substantial decrease in the genes encoding RANKL and VEGF during allograft healing. Loss of function studies showed that both factors are required for autograft healing. To determine whether addition of these signals could stimulate allograft vascularization and remodeling, we developed a new approach in which rAAV can be freeze dried onto the cortical surface without losing infectivity. We show that combination rAAV RANKL  and rAAV VEGF coated allografts show marked remodeling and vascularization, which leads to a new bone collar around the graft. In conclusion, we find that RANKL and VEGF are necessary and sufficient for efficient autograft remodeling and can be transferred using rAAV to revitalize structural allografts.
C1 Univ Rochester, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
   Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Kyoto 6068507, Japan.
   Aarhus Univ Hosp, Dept Orthoped, DK 8000 Aarhus, Denmark.
   Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.
C3 University of Rochester; Kyoto University; Aarhus University; University
   of North Carolina; University of North Carolina Chapel Hill; University
   of North Carolina; University of North Carolina Chapel Hill
RP Univ Rochester, Ctr Musculoskeletal Res, 601 Elmwood Ave,Box 665, Rochester, NY 14642 USA.
EM edward_schwarz@urmc.rochester.edu
RI Gromov, Kirill/AAM 2270 2020
OI Gromov, Kirill/0000 0002 8114 5193; Soballe, Kjeld/0000 0001 8872 9856
FU NHLBI NIH HHS [P01 HL066973, P01 HL051818, HL066973] Funding Source:
   Medline; NIAMS NIH HHS [AR48149, AR43510, R01 AR051469, R01 AR043510,
   AR51469, R01 AR048149, AR48681, R01 AR048681] Funding Source: Medline;
   NIEHS NIH HHS [ES011854, P01 ES011854] Funding Source: Medline; NIGMS
   NIH HHS [P01 GM059299] Funding Source: Medline
CR Baltzer AWA, 2004, GENE THER, V11, P344, DOI 10.1038/sj.gt.3302195
   BERREY BH, 1990, J BONE JOINT SURG AM, V72A, P825, DOI 10.2106/00004623 199072060 00005
   Boden SD, 2002, SPINE, V27, P2662, DOI 10.1097/00007632 200212010 00005
   Bonadio J, 1999, NAT MED, V5, P753, DOI 10.1038/10473
   BOS GD, 1983, J BONE JOINT SURG AM, V65, P89, DOI 10.2106/00004623 198365010 00012
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BURCHARDT H, 1987, ORTHOP CLIN N AM, V18, P187
   Childs LM, 2002, J BONE MINER RES, V17, P192, DOI 10.1359/jbmr.2002.17.2.192
   Childs LM, 2001, J BONE JOINT SURG AM, V83A, P1789, DOI 10.2106/00004623 200112000 00004
   Colnot C, 2003, DEVELOPMENT, V130, P4123, DOI 10.1242/dev.00559
   Deckers M, 2001, LAB INVEST, V81, P5, DOI 10.1038/labinvest.3780207
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   Enneking WE, 2001, J BONE JOINT SURG AM, V83A, P971, DOI 10.2106/00004623 200107000 00001
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603 669
   Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS160
   Gamradt SC, 2004, ANN BIOMED ENG, V32, P136, DOI 10.1023/B:ABME.0000007798.78548.b8
   Garbuz DS, 1998, ORTHOP CLIN N AM, V29, P199, DOI 10.1016/S0030 5898(05)70318 7
   Goater J, 2000, J RHEUMATOL, V27, P983
   Goldberg V M, 1993, Semin Arthroplasty, V4, P58
   Gould SE, 2000, J ORTHOP RES, V18, P920, DOI 10.1002/jor.1100180611
   Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200
   Hidaka C, 2003, J ORTHOPAED RES, V21, P573, DOI 10.1016/S0736 0266(02)00264 4
   Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lieberman JR, 2002, MOL THER, V6, P141, DOI 10.1006/mthe.2000.0663
   LORD CF, 1988, J BONE JOINT SURG AM, V70A, P369, DOI 10.2106/00004623 198870030 00008
   Musatov S, 2004, P NATL ACAD SCI USA, V101, P3627, DOI 10.1073/pnas.0308289101
   Musgrave DS, 2000, CLIN ORTHOP RELAT R, P290
   Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153
   Rabinowitz JE, 2000, VIROLOGY, V278, P301, DOI 10.1006/viro.2000.0707
   Sandhu HS, 2003, SPINE, V28, pS85, DOI 10.1097/00007632 200308011 00014
   Schwarz EM, 2000, CLIN ORTHOP RELAT R, pS31, DOI 10.1097/00003086 200010001 00005
   Stevenson S, 1997, J BONE JOINT SURG AM, V79A, P1
   Tiyapatanaputi P, 2004, J ORTHOP RES, V22, P1254, DOI 10.1016/j.orthres.2004.03.017
   Ulrich Vinther M, 2002, J BONE JOINT SURG AM, V84A, P1405, DOI 10.2106/00004623 200208000 00017
   Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410
   Wu D, 2003, J CELL BIOCHEM, V88, P467, DOI 10.1002/jcb.10332
   Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224 2232.1998
   Zhang R, 2003, J BIOL CHEM, V278, P51267, DOI 10.1074/jbc.M310678200
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 40
TC 227
Z9 271
U1 3
U2 29
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1078 8956
EI 1546 170X
J9 NAT MED
JI Nat. Med.
PD MAR
PY 2005
VL 11
IS 3
BP 291
EP 297
DI 10.1038/nm1190
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 905BA
UT WOS:000227541300024
PM 15711561
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Ren, ZY
   Tang, LG
   Ding, ZH
   Song, J
   Zheng, HL
   Li, DZ
AF Ren, Zhiyong
   Tang, Liguo
   Ding, Zhonghua
   Song, Jun
   Zheng, Hailiang
   Li, Dongzhu
TI Dried root of Rehmannia glutinosa extracts prevents
   steroid induced avascular necrosis of femoral head by activating the
   wingless type (Wnt)/β catenin signal pathway
SO TOXICON
LA English
DT Article
DE Dried root of Rehmannia glutinosa; Steroid induced avascular necrosis of
   femoral head; Wnt/beta catenin signaling pathway; Apoptosis
ID APOPTOSIS; CATENIN; EXPRESSION; FORMULA; CELLS
AB Steroid induced avascular necrosis of femoral head (SANFH) is one of the most common complications caused by long term or excessive clinical use of glucocorticoids. This study aimed to investigate the effects of dried root of Rehmannia glutinosa extracts (DRGE) in SANFH. First, SANFH rat model was established by dexamethasone (Dex). Tissue change and proportion of empty lacunae were detected by hematoxylin and eosin staining. Protein levels were detected by western bloting analysis. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was performed to assess apoptosis of femoral head tissue. Cell viability and apoptosis of MC3T3 E1 cells were assessed by Cell Counting Kit 8 assay and flow cytometry. ALP activity and cell mineralization were detected by ALP staining assay and Alizarin red staining. The findings showed that DRGE improved tissue damage, inhibited apoptosis, and promoted osteogenesis in SANFH rats. In vitro, DRGE increased cell viability, inhibited cell apoptosis, promoted osteoblast differentiation, reduced the levels of p GSK 3 beta/GSK 3 beta, but increased the levels of beta catenin in cells treated with Dex. Furthermore, DKK 1, an inhibitor of the wingless type (Wnt)/beta catenin signaling pathway, reversed the effect of DRGE on cell apoptosis and ALP activity in cells treated with Dex. In conclusion, DRGE prevents SANFH by activating the Wnt/beta catenin signaling pathway, indicating that DRGE may be a hopeful choice drug to prevent and treat patients with SANFH.
C1 [Ren, Zhiyong; Tang, Liguo; Ding, Zhonghua; Song, Jun; Zheng, Hailiang; Li, Dongzhu] Sunshine Union Hosp, Dept Orthoped Ctr, Weifang 261000, Shandong, Peoples R China.
   [Ren, Zhiyong] Sunshine Union Hosp, Dept Orthoped Ctr, 9000 Yingqian St, Weifang 261000, Shandong, Peoples R China.
RP Ren, ZY (通讯作者)，Sunshine Union Hosp, Dept Orthoped Ctr, 9000 Yingqian St, Weifang 261000, Shandong, Peoples R China.
EM doctor89898@163.com
RI Tang, LG/G 3360 2010
CR Berlier JL, 2019, BIOCHEM BIOPH RES CO, V508, P1175, DOI 10.1016/j.bbrc.2018.11.178
   Colaianni G, 2015, J Biol Regul Homeost Agents, V29, P39
   Cui DP, 2018, INT J BIOL MACROMOL, V116, P106, DOI 10.1016/j.ijbiomac.2018.04.181
   Danieau G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153751
   Deng P, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/5692735
   Goel S, 2012, J BIOL CHEM, V287, P16454, DOI 10.1074/jbc.M112.362137
   Gong W, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163964
   Gu J, 2021, BIOENGINEERED, V12, P6855, DOI 10.1080/21655979.2021.1972079
   Hou WX, 2021, DRUG DES DEV THER, V15, P3845, DOI 10.2147/DDDT.S308713
   Huang P, 2019, PHARMACOL THERAPEUT, V196, P79, DOI 10.1016/j.pharmthera.2018.11.008
   Huang W., 2020, J CELL MOL MED, V24
   Huang W., INT J BIOL MACROMOL, V157
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Li HY, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 018 1054 0
   Li WW, 2019, MOL MED REP, V19, P3676, DOI 10.3892/mmr.2019.10040
   Lim DW, 2013, MOLECULES, V18, P5804, DOI 10.3390/molecules18055804
   Lin J, 2019, J BIOCHEM MOL TOXIC, V33, DOI 10.1002/jbt.22265
   Liu CY, 2017, J ETHNOPHARMACOL, V198, P351, DOI 10.1016/j.jep.2017.01.021
   Liu HX, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9050754
   Liu S, 2018, EXP THER MED, V16, P5047, DOI 10.3892/etm.2018.6827
   Morris SAL, 2016, GENES DIS, V3, P41, DOI 10.1016/j.gendis.2015.12.003
   Nowak DA, 2015, J CUTAN MED SURG, V19, P358, DOI 10.1177/1203475415579759
   Oh KO, 2003, CLIN CHIM ACTA, V334, P185, DOI 10.1016/S0009 8981(03)00238 9
   Pang QR, 2019, CANCER BIOTHER RADIO, V34, P436, DOI 10.1089/cbr.2019.2771
   Shin SW, 2008, AM J CHINESE MED, V36, P1159, DOI 10.1142/S0192415X08006491
   Song HM, 2015, MOL MED REP, V12, P8155, DOI 10.3892/mmr.2015.4478
   Wang YG, 2018, REPROD SCI, V25, P1161, DOI 10.1177/1933719118759440
   Xia BJ, 2014, J ETHNOPHARMACOL, V153, P133, DOI 10.1016/j.jep.2014.01.040
   Xia TS, 2019, MOLECULES, V24, DOI 10.3390/molecules24020253
   Yu Y, 2021, BIOENGINEERED, V12, P12544, DOI 10.1080/21655979.2021.2010315
   Zhan J., 2020, FOOD FUNCT, V11
   Zhi JY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123751
NR 32
TC 2
Z9 3
U1 0
U2 4
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041 0101
EI 1879 3150
J9 TOXICON
JI Toxicon
PD JUL
PY 2023
VL 230
AR 107174
DI 10.1016/j.toxicon.2023.107174
EA MAY 2023
PG 8
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA K7QP1
UT WOS:001018351600001
PM 37236550
DA 2025 08 17
ER

PT J
AU Sukanya, VS
   Mohanan, PV
AF Sukanya, V. S.
   Mohanan, P. V.
TI Degradation of Poly(ε caprolactone) and bio interactions with mouse bone
   marrow mesenchymal stem cells
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Mesenchymal stem cells; Poly(epsilon caprolactone); Degradation;
   Cytotoxicity; ROS; Hemocompatibility
ID ZINC OXIDE NANOPARTICLES; IN VITRO; OSTEOGENIC DIFFERENTIATION;
   POLYCAPROLACTONE; ASSAY; VIVO; BIOCOMPATIBILITY; MECHANISMS; NANOFIBERS;
   SCAFFOLDS
AB Bio inspired scaffolds in bone tissue engineering using multipotential mesenchymal stem cells grow at a rapid rate found its successful use in orthopedic injury treatment. Poly(epsilon caprolactone)/PCL is widely used in medical devices, tissue engineering, and drug delivery systems. Most desirable property of biodegradable polymer to be employed in medical application is synchronization of degradation with functional tissue regeneration. Limited studies have incorporated the degradation kinetics and implication of degradation products of pure unmodified PCL. The present study analyzes short term in vitro degradation profile of PCL films in physiological condition. The study reports weight loss, changes in molecular weight distribution and morphological variation in PCL thin film over a period of 90 day degradation. When the degradable material is in contact with host tissue, there exists robust and dynamic microenvironment controlling the cell functionality. To comprehend the biocompatibility aspects of polymer material, the study considered mouse bone marrow mesenchymal stem cells (BMSCs) as model system mimicking in vivo. There was no indication of toxicity revealed with MTT, LDH leakage, direct contact assay and clonogenic assay. Absence of oxidative stress and apoptosis denotes BMSCs functional integrity sustained upon exposure to PCL degradation products. Cell cycle analysis and DNA ladder assay confirmed cell survival and genomic stability. The study revealed that the topography of pure unmodified PCL surface is suitable for cell adhesion. It was also observed that the viability of differentiated cells (osteoblasts) was maintained in presence of PCL extract. Furthermore, polymer and its degradation products were proved to be hemocompatible. These results synergistically suggest that pure unmodified PCL and its degradation products are non toxic at molecular level. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Sukanya, V. S.; Mohanan, P. V.] Sree Chitra Tirunal Inst Med Sci & Technol, Biomed Technol Wing, Thiruvananthapuram 695012, Kerala, India.
C3 Department of Science & Technology (India); Sree Chitra Tirunal
   Institute for Medical Sciences Technology (SCTIMST)
RP Mohanan, PV (通讯作者)，Sree Chitra Tirunal Inst Med Sci & Technol, Biomed Technol Wing, Thiruvananthapuram 695012, Kerala, India.
EM mohanpv@sctimst.ac.in
CR Anderson J.M., 2008, SEMINARS IMMUNOLOGY
   Augustine R, 2016, INT J POLYM MATER PO, V65, P28, DOI 10.1080/00914037.2015.1055628
   Bielby R, 2007, INJURY, V38, pS26, DOI 10.1016/j.injury.2007.02.007
   Bölgen N, 2005, J BIOMAT SCI POLYM E, V16, P1537, DOI 10.1163/156856205774576655
   Bosworth LA, 2010, POLYM DEGRAD STABIL, V95, P2269, DOI 10.1016/j.polymdegradstab.2010.09.007
   Chairuangkitti P, 2013, TOXICOL IN VITRO, V27, P330, DOI 10.1016/j.tiv.2012.08.021
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Chen JP, 2011, COLLOID SURFACE B, V86, P169, DOI 10.1016/j.colsurfb.2011.03.038
   Czekanska EM, 2014, J BIOMED MATER RES A, V102, P2636, DOI 10.1002/jbm.a.34937
   de Campos A, 2005, BRAZ ARCH BIOL TECHN, V48, P235, DOI 10.1590/S1516 89132005000200010
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Gopferich A, 1996, BIOMATERIALS, V17, P103, DOI 10.1016/0142 9612(96)85755 3
   Henkel J, 2013, BONE RES, V1, P216, DOI 10.4248/BR201303002
   Joshi P, 2008, POLYM DEGRAD STABIL, V93, P1901, DOI 10.1016/j.polymdegradstab.2008.07.002
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188
   Leijten J, 2016, CELL STEM CELL, V18, P20, DOI 10.1016/j.stem.2015.12.013
   Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762
   Lyublinskaya OG, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/502105
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Mygind T, 2007, BIOMATERIALS, V28, P1036, DOI 10.1016/j.biomaterials.2006.10.003
   Perry SW, 2011, BIOTECHNIQUES, V50, P98, DOI 10.2144/000113610
   Persenaire O, 2001, BIOMACROMOLECULES, V2, P288, DOI 10.1021/bm0056310
   Reith G, 2015, BMC SURG, V15, DOI 10.1186/s12893 015 0081 6
   Remya NS, 2014, COLLOID SURFACE B, V117, P389, DOI 10.1016/j.colsurfb.2014.02.004
   SAOTOME K, 1989, TOXICOL IN VITRO, V3, P317, DOI 10.1016/0887 2333(89)90039 8
   Serrano MC, 2004, BIOMATERIALS, V25, P5603, DOI 10.1016/j.biomaterials.2004.01.037
   Singh S, 2011, TISSUE ENG PT A, V17, P1819, DOI [10.1089/ten.tea.2010.0708, 10.1089/ten.TEA.2010.0708]
   SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Sruthi S, 2015, COLLOID SURFACE B, V133, P1, DOI 10.1016/j.colsurfb.2015.05.041
   Suma RN, 2015, CURR DRUG METAB, V16, P932, DOI 10.2174/1389200216666151015113720
   Syama S, 2017, 2D MATER, V4, DOI 10.1088/2053 1583/aa65c2
   Tang ZG, 2004, BIOMATERIALS, V25, P4741, DOI 10.1016/j.biomaterials.2003.12.003
   Nguyen TH, 2013, J BIOMED MATER RES A, V101, P797, DOI 10.1002/jbm.a.34382
   Van Natta FJ, 1934, J AM CHEM SOC, V56, P455, DOI 10.1021/ja01317a053
   WAN CP, 1993, J IMMUNOL METHODS, V159, P131, DOI 10.1016/0022 1759(93)90150 6
   Woodruff MA, 2010, PROG POLYM SCI, V35, P1217, DOI 10.1016/j.progpolymsci.2010.04.002
   World Health Organization, 2015, GLOB STAT REP ROAD 2
   Yang SR, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/486263
NR 41
TC 39
Z9 39
U1 1
U2 44
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD MAR 1
PY 2018
VL 163
BP 107
EP 118
DI 10.1016/j.colsurfb.2017.12.039
PG 12
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA FY9WJ
UT WOS:000427217300013
PM 29287231
DA 2025 08 17
ER

PT J
AU Ding, Y
   Wang, YX
   Li, JX
   Tang, MM
   Chen, HR
   Wang, GC
   Guo, J
   Gui, SY
AF Ding, Yang
   Wang, Yuxiao
   Li, Jiaxin
   Tang, Maomao
   Chen, Hairong
   Wang, Guichun
   Guo, Jian
   Gui, Shuangying
TI Microemulsion thermosensitive gel composites as in situ forming
   drug reservoir for periodontitis tissue repair through alveolar bone and
   collagen regeneration strategy
SO PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
LA English
DT Article
DE Periodontitis; baicalin; microemulsion; thermosensitive gel;
   osteogenesis
ID ESSENTIAL OIL; CLOVE OIL; BAICALIN; EUGENOL; MUCOADHESIVE; MECHANISMS;
   EXPRESSION; HYDROGEL; DELIVERY; SAFETY
AB A satisfactory clinical effect in treating periodontitis is often difficult to achieve by conventional non surgical systemic drug delivery due to the narrow anatomical structure of the periodontal pocket and insufficient drug concentration at lesion sites. In addition, the feasibility of combating periodontal tissue lesions by restoring the alveolar bone and allowing collagen regeneration has not been fully explored. The objective of this study was to prepare a microemulsion integrating the anti inflammatory and osteogenic active ingredients of baicalin and clove oil (BC MEs). Then, the composite hydrogel obtained by mixing poloxamer 407 and 188 was used as the thermosensitive gel matrix to load BC MEs and form a drug reservoir (Gel BC MEs) injectable in situ. Gel BC MEs exhibited a significant, sustained release of baicalin for 12 h, gelation temperature was 33.4 +/  0.36 degrees C, and pH was 5.45 +/  0.12. The experiment on a rat periodontitis model demonstrated that Gel BC MEs significantly improved periodontal tissue repair by collagen regeneration and osteogenesis by inhibiting osteoclast infiltration. This study proposes a novel strategy for periodontal tissue repair by enhancing the therapeutic potential of a microemulsion using an in situ nano gel delivery system.
C1 [Ding, Yang; Wang, Yuxiao; Li, Jiaxin; Tang, Maomao; Chen, Hairong; Wang, Guichun; Guo, Jian; Gui, Shuangying] Anhui Univ Chinese Med, Dept Pharm, Hefei 230012, Anhui, Peoples R China.
   [Ding, Yang; Guo, Jian; Gui, Shuangying] Anhui Acad Chinese Med, Inst Pharmaceut, Hefei, Anhui, Peoples R China.
   [Ding, Yang; Guo, Jian; Gui, Shuangying] Anhui Prov Key Lab Pharmaceut Technol & Applicat, Hefei, Anhui, Peoples R China.
   [Ding, Yang; Guo, Jian; Gui, Shuangying] Anhui Educ Dept AUCM, Engn Technol Res Ctr Modernized Pharmaceut, Hefei, Anhui, Peoples R China.
C3 Anhui University of Chinese Medicine; Anhui University of Chinese
   Medicine
RP Guo, J; Gui, SY (通讯作者)，Anhui Univ Chinese Med, Dept Pharm, Hefei 230012, Anhui, Peoples R China.
EM guojian@ahtcm.edu.cn; guishy0520@ahtcm.edu.cn
RI ; Guo, Jian/LXB 0445 2024; Li, Jiaxin/ABA 8425 2021; Wang,
   Jianming/HGA 5239 2022
OI Ding, Yang/0000 0001 9377 4360; 
FU National Natural Science Foundation of China; University Natural Science
   Research Project of Anhui Province; Postgraduate Education Foundation of
   College of Pharmacy of Anhui University of Chinese Medicine; 
   [81873019];  [KJ2021A0541];  [KJ2021A0538];  [21pyjj05]
FX This research was funded by the National Natural Science Foundation of
   China (Nos. 81873019), the University Natural Science Research Project
   of Anhui Province (KJ2021A0541, KJ2021A0538) and the Postgraduate
   Education Foundation of College of Pharmacy of Anhui University of
   Chinese Medicine (21pyjj05).
CR Al Musawi S, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11010032
   Almoshari Y, 2020, BIOMATERIALS, V261, DOI 10.1016/j.biomaterials.2020.120293
   Blaszyk M, 1998, INT J FOOD MICROBIOL, V39, P175, DOI 10.1016/S0168 1605(97)00134 7
   Boonlai W, 2018, AAPS PHARMSCITECH, V19, P2103, DOI 10.1208/s12249 018 1010 7
   Cai Xia, 2008, Zhonghua Kou Qiang Yi Xue Za Zhi, V43, P281
   Callender SP, 2017, INT J PHARMACEUT, V526, P425, DOI 10.1016/j.ijpharm.2017.05.005
   Cirri M, 2012, EUR J PHARM BIOPHARM, V80, P46, DOI 10.1016/j.ejpb.2011.07.015
   Darveau RP, 2010, NAT REV MICROBIOL, V8, P481, DOI 10.1038/nrmicro2337
   Deves C, 2013, BONE, V52, P167, DOI 10.1016/j.bone.2012.09.026
   Dumortier G, 2006, PHARM RES DORDR, V23, P2709, DOI 10.1007/s11095 006 9104 4
   Elburki MS, 2017, J PERIODONTAL RES, V52, P186, DOI 10.1111/jre.12381
   Elburki MS, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/959471
   Fu SL, 2016, VET RES, V47, DOI 10.1186/s13567 016 0359 4
   Giuliano E, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030159
   Guo J, 2018, DRUG DELIV, V25, P1802, DOI 10.1080/10717544.2018.1516006
   Hamed R, 2019, INT J PHARMACEUT, V570, DOI 10.1016/j.ijpharm.2019.118684
   Jung YS, 2017, CARBOHYD POLYM, V156, P403, DOI 10.1016/j.carbpol.2016.08.068
   Kassebaum NJ, 2014, J DENT RES, V93, P1045, DOI 10.1177/0022034514552491
   Lamont RJ, 2018, NAT REV MICROBIOL, V16, P745, DOI 10.1038/s41579 018 0089 x
   Li AQ, 2021, DRUG DES DEV THER, V15, P3937, DOI 10.2147/DDDT.S328722
   Liu ZN, 2018, ACS NANO, V12, P9785, DOI 10.1021/acsnano.7b08976
   Lu L, 2017, J CELL MOL MED, V21, P1361, DOI 10.1111/jcmm.13066
   Luo W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051008
   Mayo L, 2008, EUR J PHARM BIOPHARM, V70, P199, DOI 10.1016/j.ejpb.2008.04.025
   Moghimi SM, 2000, TRENDS BIOTECHNOL, V18, P412, DOI 10.1016/S0167 7799(00)01485 2
   Moon SE, 2011, ARCH ORAL BIOL, V56, P907, DOI 10.1016/j.archoralbio.2011.02.005
   Moore J, 2020, AM J DENT, V33, P161
   Nuñez L, 2012, BRAZ J MICROBIOL, V43, P1255, DOI 10.1590/S1517 83822012000400003
   Pagano C, 2020, EUR J PHARM SCI, V142, DOI 10.1016/j.ejps.2019.105125
   Pramod K, 2010, NAT PROD COMMUN, V5, P1999
   Read E, 2021, NAT REV GASTRO HEPAT, V18, P731, DOI 10.1038/s41575 021 00488 4
   Ruel Gariépy E, 2004, EUR J PHARM BIOPHARM, V58, P409, DOI 10.1016/j.ejpb.2004.03.019
   Russo E, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11120671
   Sadrameli M, 2020, CURR OPIN NEUROL, V33, P230, DOI 10.1097/WCO.0000000000000797
   Sanz M, 2020, J CLIN PERIODONTOL, V47, P268, DOI [10.5334/gh.400, 10.1111/jcpe.13189]
   Schenkein HA, 2020, PERIODONTOL 2000, V83, P90, DOI 10.1111/prd.12304
   Sheshala R, 2019, DRUG DELIV TRANSL RE, V9, P434, DOI 10.1007/s13346 018 0488 6
   Sun JY, 2016, INT IMMUNOPHARMACOL, V36, P86, DOI 10.1016/j.intimp.2016.04.012
   Swain Ganesh P, 2019, J Oral Biol Craniofac Res, V9, P190, DOI 10.1016/j.jobcr.2019.04.001
   Tenjarla S, 1999, CRIT REV THER DRUG, V16, P461, DOI 10.1615/CritRevTherDrugCarrierSyst.v16.i5.20
   Tian YJ, 2022, BIOACT MATER, V9, P428, DOI 10.1016/j.bioactmat.2021.07.033
   Timmerman MF, 1996, J CLIN PERIODONTOL, V23, P707, DOI 10.1111/j.1600 051X.1996.tb00599.x
   Wang GF, 2006, PHARMACOLOGY, V77, P71, DOI 10.1159/000092853
   Zhang Y, 2017, MICROB PATHOGENESIS, V113, P396, DOI 10.1016/j.micpath.2017.10.054
NR 44
TC 15
Z9 15
U1 8
U2 16
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1083 7450
EI 1097 9867
J9 PHARM DEV TECHNOL
JI Pharm. Dev. Technol.
PD JAN 2
PY 2023
VL 28
IS 1
BP 30
EP 39
DI 10.1080/10837450.2022.2161574
EA DEC 2022
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 8V2EY
UT WOS:000904697600001
PM 36541732
DA 2025 08 17
ER

PT J
AU Maekawa, T
   Briones, RA
   Resuello, RRG
   Tuplano, JV
   Hajishengallis, E
   Kajikawa, T
   Koutsogiannaki, S
   Garcia, CAG
   Ricklin, D
   Lambris, JD
   Hajishengallis, G
AF Maekawa, Tomoki
   Briones, Ruel A.
   Resuello, R. R. G.
   Tuplano, Joel V.
   Hajishengallis, Evlambia
   Kajikawa, Tetsuhiro
   Koutsogiannaki, Sophia
   Garcia, Cristina A. G.
   Ricklin, Daniel
   Lambris, John D.
   Hajishengallis, George
TI Inhibition of pre existing natural periodontitis in non human primates
   by a locally administered peptide inhibitor of complement C3
SO JOURNAL OF CLINICAL PERIODONTOLOGY
LA English
DT Article
DE complement; compstatin; cytokines; inflammation; non human primates;
   periodontitis
ID LIGATURE INDUCED PERIODONTITIS; GINGIVAL CREVICULAR FLUID;
   PORPHYROMONAS GINGIVALIS; INFLAMMATORY RESPONSE; BONE LOSS; FACTOR B;
   DISEASES; EXPRESSION; CLEAVAGE; IMMUNE
AB AimHuman periodontitis is associated with overactivation of complement, which is triggered by different mechanisms converging on C3, the central hub of the system. We assessed whether the C3 inhibitor Cp40 inhibits naturally occurring periodontitis in non human primates (NHPs).
   Materials and MethodsNon human primates with chronic periodontitis were intra gingivally injected with Cp40 either once (5 animals) or three times (10 animals) weekly for 6weeks followed by a 6 week follow up period. Clinical periodontal examinations and collection of gingival crevicular fluid and biopsies of gingiva and bone were performed at baseline and during the study. A one way repeated measures anova was used for data analysis.
   ResultsWhether administered once or three times weekly, Cp40 caused a significant reduction in clinical indices that measure periodontal inflammation (gingival index and bleeding on probing), tissue destruction (probing pocket depth and clinical attachment level) or tooth mobility. These clinical changes were associated with significantly reduced levels of pro inflammatory mediators and decreased numbers of osteoclasts in bone biopsies. The protective effects of Cp40 persisted, albeit at reduced efficacy, for at least 6weeks following drug discontinuation.
   ConclusionCp40 inhibits pre existing chronic periodontal inflammation and osteoclastogenesis in NHPs, suggesting a novel adjunctive anti inflammatory therapy for treating human periodontitis.
C1 [Maekawa, Tomoki; Kajikawa, Tetsuhiro; Hajishengallis, George] Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA.
   [Maekawa, Tomoki] Niigata Univ, Grad Sch Med & Dent Sci, Res Ctr Adv Oral Sci, Niigata, Japan.
   [Briones, Ruel A.; Garcia, Cristina A. G.] Manila Cent Univ, Coll Dent, Caloocan City, Philippines.
   [Resuello, R. R. G.; Tuplano, Joel V.] Simian Conservat Breeding & Res Ctr SICONBREC, Makati, Philippines.
   [Hajishengallis, Evlambia] Univ Penn, Sch Dent Med, Div Pediat Dent, Dept Prevent & Restorat Sci, Philadelphia, PA 19104 USA.
   [Koutsogiannaki, Sophia; Ricklin, Daniel; Lambris, John D.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Niigata University; Manila Central
   University; University of Pennsylvania; University of Pennsylvania
RP Lambris, JD (通讯作者)，Univ Penn, Perelman Sch Med, 422 Curie Blvd, Philadelphia, PA 19104 USA.; Hajishengallis, G (通讯作者)，Univ Penn, Sch Dent Med, 240 South 40th St, Philadelphia, PA 19104 USA.
EM lambris@upenn.edu; geoh@upenn.edu
RI Lambris, John/O 8507 2019; Lambris, John/Q 5633 2018; Maekawa,
   Tomoki/AAA 4673 2020; Ricklin, Daniel/F 5104 2011; Hajishengallis,
   George/K 1117 2019
OI Hajishengallis, George/0000 0001 7392 8852; Lambris,
   John/0000 0002 9370 5776; Koutsogiannaki, Sophia/0000 0003 3555 1681;
   Ricklin, Daniel/0000 0001 6140 0233; Maekawa,
   Tomoki/0000 0002 4597 1316; Kajikawa, Tetsuhiro/0000 0001 8416 9126; 
FU National Institutes of Health [AI068730, AI030040, DE015254, DE017138,
   DE021685, DE024716]; European Commission [FP7 DIREKT 602699]
FX G.H. and J.D.L. have a joint patent application that describes the use
   of complement inhibitors for therapeutic purposes in periodontitis.
   J.D.L. is the founder of Amyndas Pharmaceuticals, which is developing
   complement inhibitors for clinical applications. This work was supported
   by grants from the National Institutes of Health (AI068730 and AI030040
   to J.D.L.; DE015254, DE017138, DE021685 and DE024716 to G.H.) and the
   European Commission (FP7 DIREKT 602699 to J.D.L.).
CR Abe T, 2014, J IMMUNOL, V193, P1383, DOI 10.4049/jimmunol.1400970
   Abe T, 2012, J IMMUNOL, V189, P5442, DOI 10.4049/jimmunol.1202339
   Abusleme L, 2013, ISME J, V7, P1016, DOI 10.1038/ismej.2012.174
   Armitage GC, 2002, PERIODONTOL 2000, V30, P9, DOI 10.1034/j.1600 0757.2002.03002.x
   Asgari E, 2013, BLOOD, V122, P3473, DOI 10.1182/blood 2013 05 502229
   Assuma R, 1998, J IMMUNOL, V160, P403
   ATTSTROM R, 1975, J PERIODONTAL RES, V10, P19, DOI 10.1111/j.1600 0765.1975.tb00003.x
   Beikler T, 2011, PERIODONTOL 2000, V55, P87, DOI 10.1111/j.1600 0757.2010.00360.x
   Belibasakis GN, 2012, J CLIN PERIODONTOL, V39, P239, DOI 10.1111/j.1600 051X.2011.01810.x
   Boespflug ND, 2014, BLOOD, V123, P2084, DOI 10.1182/blood 2013 06 510909
   Bostanci N, 2009, CLIN EXP IMMUNOL, V157, P415, DOI 10.1111/j.1365 2249.2009.03972.x
   Bostanci N, 2007, J CLIN PERIODONTOL, V34, P370, DOI 10.1111/j.1600 051X.2007.01061.x
   BRECX MC, 1985, J PERIODONTAL RES, V20, P165, DOI 10.1111/j.1600 0765.1985.tb00423.x
   Breivik T, 2011, J PERIODONTAL RES, V46, P643, DOI 10.1111/j.1600 0765.2011.01383.x
   Cappelli D, 2000, ORAL DIS, V6, P124
   Chapple ILC, 2014, BMJ BRIT MED J, V348, DOI 10.1136/bmj.g2645
   Colombo APV, 2012, J PERIODONTOL, V83, P1279, DOI 10.1902/jop.2012.110566
   COURTS FJ, 1977, J DENT RES, V56, P327, DOI 10.1177/00220345770560032001
   Demmer RT, 2010, PERIODONTOL 2000, V53, P28, DOI 10.1111/j.1600 0757.2009.00326.x
   Devi S, 2013, NAT MED, V19, P107, DOI 10.1038/nm.3024
   Ebersole JL, 2016, MOL ORAL MICROBIOL, V31, P18, DOI 10.1111/omi.12121
   Ebersole Jeffrey L, 2002, Ann Periodontol, V7, P102, DOI 10.1902/annals.2002.7.1.102
   Ebersole JL, 2014, J CLIN PERIODONTOL, V41, P853, DOI 10.1111/jcpe.12286
   Eke PI, 2012, J DENT RES, V91, P914, DOI 10.1177/0022034512457373
   Eke PI, 2015, J PERIODONTOL, V86, P611, DOI 10.1902/jop.2015.140520
   Eskan MA, 2012, NAT IMMUNOL, V13, P465, DOI 10.1038/ni.2260
   Genco RJ, 2014, J EVID BASED DENT PR, V14, P4, DOI 10.1016/j.jebdp.2014.03.003
   Gonzalez O. A., 2015, J PERIODONTAL RES, V41, P952
   Graves D, 2008, J PERIODONTOL, V79, P1585, DOI 10.1902/jop.2008.080183
   Hajishengallis G, 2014, MOL ORAL MICROBIOL, V29, P248, DOI 10.1111/omi.12065
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Hajishengallis G, 2014, J ORAL BIOSCI, V56, P30, DOI 10.1016/j.job.2013.09.001
   Hajishengallis G, 2011, CELL HOST MICROBE, V10, P497, DOI 10.1016/j.chom.2011.10.006
   Hajishengallis G, 2010, BIOCHEM PHARMACOL, V80, P1992, DOI 10.1016/j.bcp.2010.06.017
   Hajishengallis G, 2010, TRENDS IMMUNOL, V31, P154, DOI 10.1016/j.it.2010.01.002
   Han Y W, 2014, Adv Dent Res, V26, P47, DOI 10.1177/0022034514528334
   Hasturk H, 2007, J IMMUNOL, V179, P7021, DOI 10.4049/jimmunol.179.10.7021
   Heitz Mayfield LJA, 2005, J CLIN PERIODONTOL, V32, P196, DOI 10.1111/j.1600 051X.2005.00803.x
   Kebschull M, 2010, J DENT RES, V89, P879, DOI 10.1177/0022034510375281
   Kirjavainen V, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000140
   KORNMAN KS, 1981, J PERIODONTAL RES, V16, P363, DOI 10.1111/j.1600 0765.1981.tb00987.x
   Koziel J, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926 014 0408 9
   Lalla E, 2011, NAT REV ENDOCRINOL, V7, P738, DOI 10.1038/nrendo.2011.106
   LALLY ET, 1982, J PERIODONTAL RES, V17, P257, DOI 10.1111/j.1600 0765.1982.tb01152.x
   Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007
   Lamont RJ, 2015, TRENDS MOL MED, V21, P172, DOI 10.1016/j.molmed.2014.11.004
   Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552
   Li KL, 1996, J PERIODONTAL RES, V31, P525, DOI 10.1111/j.1600 0765.1996.tb00516.x
   Liang S, 2011, J IMMUNOL, V186, P869, DOI 10.4049/jimmunol.1003252
   Maekawa T, 2014, CELL HOST MICROBE, V15, P768, DOI 10.1016/j.chom.2014.05.012
   Maekawa T, 2014, J IMMUNOL, V192, P6020, DOI 10.4049/jimmunol.1400569
   Marsh PD, 2003, MICROBIOL SGM, V149, P279, DOI 10.1099/mic.0.26082 0
   Mastellos DC, 2016, MOL ORAL MICROBIOL, V31, P3, DOI 10.1111/omi.12129
   Mastellos DC, 2015, EUR J CLIN INVEST, V45, P423, DOI 10.1111/eci.12419
   Miossec P, 2012, NAT REV DRUG DISCOV, V11, P763, DOI 10.1038/nrd3794
   Miyake K, 2007, SEMIN IMMUNOL, V19, P3, DOI 10.1016/j.smim.2006.12.002
   Moritz AJ, 1998, J PERIODONTOL, V69, P686, DOI 10.1902/jop.1998.69.6.686
   Moutsopoulos NM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007696
   Moutsopoulos NM, 2012, J AUTOIMMUN, V39, P294, DOI 10.1016/j.jaut.2012.03.003
   NIEKRASH CE, 1986, J PERIODONTAL RES, V21, P233
   NIEKRASH CE, 1985, J PERIODONTAL RES, V20, P268, DOI 10.1111/j.1600 0765.1985.tb00434.x
   NIKOLOPOULOUPAPACONSTANTINOU AA, 1987, ACTA ODONTOL SCAND, V45, P187
   NISENGARD R, 1989, IMMUNOL INVEST, V18, P225, DOI 10.3109/08820138909112239
   OFFENBACHER S, 1987, J PERIODONTAL RES, V22, P473, DOI 10.1111/j.1600 0765.1987.tb02058.x
   Page RC, 2007, ORAL MICROBIOL IMMUN, V22, P162, DOI 10.1111/j.1399 302X.2007.00337.x
   Page R.C., 1982, PERIODONTITIS MAN OT
   PATTERS MR, 1989, J CLIN PERIODONTOL, V16, P33, DOI 10.1111/j.1600 051X.1989.tb01609.x
   PERSSON CR, 1994, INFECT IMMUN, V62, P1026, DOI 10.1128/IAI.62.3.1026 1031.1994
   PIERCE A, 1987, ORAL SURG ORAL MED O, V64, P216, DOI 10.1016/0030 4220(87)90094 6
   Qu HC, 2013, IMMUNOBIOLOGY, V218, P496, DOI 10.1016/j.imbio.2012.06.003
   Rams TE, 2014, J PERIODONTOL, V85, P160, DOI 10.1902/jop.2013.130142
   Rautemaa R, 1996, J DENT RES, V75, P568, DOI 10.1177/00220345960750010901
   Ricklin D, 2013, J IMMUNOL, V190, P3839, DOI 10.4049/jimmunol.1203200
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Risitano AM, 2014, BLOOD, V123, P2094, DOI 10.1182/blood 2013 11 536573
   Roberts FA, 2004, INFECT IMMUN, V72, P1166, DOI 10.1128/IAI.72.2.1166 1168.2004
   Schaefer L, 2010, CURR OPIN PHARMACOL, V10, P185, DOI 10.1016/j.coph.2009.11.007
   SCHENKEIN HA, 1977, J PERIODONTOL, V48, P778, DOI 10.1902/jop.1977.48.12.778
   Shin J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5380
   Tonetti MS, 2007, NEW ENGL J MED, V356, P911, DOI 10.1056/NEJMoa063186
   TOTO PD, 1978, J DENT RES, V57, P696, DOI 10.1177/00220345780570050501
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   White DA, 2012, BRIT DENT J, V213, P567, DOI 10.1038/sj.bdj.2012.1088
   Zenobia C, 2015, PERIODONTOL 2000, V69, P142, DOI 10.1111/prd.12083
   Zhan YB, 2014, J PERIODONTOL, V85, P1059, DOI 10.1902/jop.2014.130523
   Zhang XH, 2007, BLOOD, V110, P228, DOI 10.1182/blood 2006 12 063636
   Zou L, 2013, J IMMUNOL, V191, P5625, DOI 10.4049/jimmunol.1301903
NR 87
TC 53
Z9 54
U1 1
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0303 6979
EI 1600 051X
J9 J CLIN PERIODONTOL
JI J. Clin. Periodontol.
PD MAR
PY 2016
VL 43
IS 3
BP 238
EP 249
DI 10.1111/jcpe.12507
PG 12
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA DH8FU
UT WOS:000373029700004
PM 26728318
OA Green Accepted
DA 2025 08 17
ER

PT J
AU van Lierop, AHJM
   Hamdy, NAT
   Papapoulos, SE
AF van Lierop, Antoon H. J. M.
   Hamdy, Neveen A. T.
   Papapoulos, Socrates E.
TI Glucocorticoids Are Not Always Deleterious for Bone
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BONE RESORPTION; BONE FORMATION; VAN BUCHEM DISEASE; PREDNISONE
   SCLEROSTIN
ID VAN BUCHEM DISEASE; HYPEROSTOSIS CORTICALIS GENERALISATA; BIOCHEMICAL
   MARKERS; ENGELMANNS DISEASE; SOST GENE; OSTEOBLASTS; THERAPY;
   SCLEROSTEOSIS; METABOLISM; TURNOVER
AB A 23 year old man with the rare sclerosing bone disorder van Buchem disease presented with progressively worsening headaches that eventually became persistent and associated with papilledema Increased intracranial pressure was diagnosed, and the patient had a ventriculoperitoneal drain inserted as well as simultaneously receiving treatment with prednisone Before starting treatment, there was biochemical evidence for increased bone turnover and for steady increases in bone mineral density (BMD) at the spine and total hip despite the patient having reached his peak height of 197 cm at the age of 19 years Treatment with prednisone for 2 years resulted in biochemical and histologic suppression of bone formation as well as of bone resorption and arrest of further bone accumulation Our data suggest that glucocorticoids (GCs) may represent an attractive alternative to the high risk surgical approaches used in the management of patients with progressive sclerosing bone disorders Our findings also suggest that whereas sclerostin may not be required for the action of GCs on bone formation, it may well be important for the action of GCs on bone resorption The exact mechanism by which sclerostin may be involved in the regulation of bone resorption is as yet to be explored (C) 2010 American Society for Bone and Mineral Research
C1 [van Lierop, Antoon H. J. M.; Hamdy, Neveen A. T.; Papapoulos, Socrates E.] Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, NL 2333 ZA Leiden, Netherlands.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden
   University   Excl LUMC
RP Papapoulos, SE (通讯作者)，Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, Albinusdreef 2, NL 2333 ZA Leiden, Netherlands.
RI Hamdy, Neveen/AAL 9841 2021
FU EU [Health F2 2008 201099]
FX Special thanks to Dr Pascale Chavassieux for performing the
   histomorphometric analysis of the bone biopsy This work was funded by EU
   FP7 (TALOS Health F2 2008 201099)
CR ALLEN DT, 1970, PEDIATRICS, V46, P523
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bornefalk E, 1998, CALCIFIED TISSUE INT, V63, P9, DOI 10.1007/s002239900482
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Dovio A, 2004, J CLIN ENDOCR METAB, V89, P4923, DOI 10.1210/jc.2004 0164
   DUPLESSIS JJ, 1993, J NEUROSURG, V78, P388, DOI 10.3171/jns.1993.78.3.0388
   Frediani B, 2004, J RHEUMATOL, V31, P1083
   Fujita K, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 71
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gram J, 1998, BONE, V23, P297, DOI 10.1016/S8756 3282(98)00097 0
   Hamersma H, 2003, CLIN GENET, V63, P192, DOI 10.1034/j.1399 0004.2003.00036.x
   Hayashi K, 2009, BIOCHEM BIOPH RES CO, V379, P261, DOI 10.1016/j.bbrc.2008.12.035
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Humphrey EL, 2006, BONE, V38, P652, DOI 10.1016/j.bone.2005.10.004
   Janssens K, 2006, J MED GENET, V43, P1, DOI 10.1136/jmg.2005.033522
   Kuroki Y, 2008, J BONE MINER METAB, V26, P271, DOI 10.1007/s00774 007 0821 5
   López JM, 2008, BONE, V43, P405, DOI 10.1016/j.bone.2008.04.011
   MARMARY Y, 1989, INT J ORAL MAX SURG, V18, P155, DOI 10.1016/S0901 5027(89)80115 8
   MINFORD AMB, 1981, J BONE JOINT SURG BR, V63, P597, DOI 10.1302/0301 620X.63B4.7298693
   Ogoshi T, 2008, MOD RHEUMATOL, V18, P552, DOI 10.1007/s10165 008 0096 2
   Paglia F, 2001, CLIN CHEM, V47, P1314
   Pearce G, 1998, J CLIN ENDOCR METAB, V83, P801, DOI 10.1210/jc.83.3.801
   PRUMMEL MF, 1991, J CLIN ENDOCR METAB, V72, P382, DOI 10.1210/jcem 72 2 382
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Staehling Hampton K, 2002, AM J MED GENET, V110, P144, DOI 10.1002/ajmg.10401
   Ton FN, 2005, J BONE MINER RES, V20, P464, DOI 10.1359/JBMR.041125
   van Bezooijen RL, 2009, J DENT RES, V88, P569, DOI 10.1177/0022034509338340
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   van Bezooijen RL, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 1, 3RD EDITION, P139, DOI 10.1016/B978 0 12 373884 4.00014 8
   VANBUCHEM FSP, 1955, ACTA RADIOL, V44, P109, DOI 10.3109/00016925509170789
   Vanhoenacker FM, 2003, SKELETAL RADIOL, V32, P708, DOI 10.1007/s00256 003 0675 4
   Vidal NOA, 1998, J ENDOCRINOL, V159, P191, DOI 10.1677/joe.0.1590191
   Weinstein R S, 2001, Rev Endocr Metab Disord, V2, P65, DOI 10.1023/A:1010007108155
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wergedal JE, 2003, J CLIN ENDOCR METAB, V88, P5778, DOI 10.1210/jc.2003 030201
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
   Yun SI, 2009, J BONE MINER METAB, V27, P140, DOI 10.1007/s00774 008 0019 5
NR 41
TC 23
Z9 24
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD DEC
PY 2010
VL 25
IS 12
BP 2520
EP 2524
DI 10.1002/jbmr.151
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 691LB
UT WOS:000285080200026
PM 20549703
DA 2025 08 17
ER

PT J
AU Liu, NN
   Tu, SC
   Zhang, S
   Chen, DD
   Xiao, XF
   Zhang, T
   Zheng, H
AF Liu, Nannan
   Tu, Shaochen
   Zhang, Sen
   Chen, Dongdong
   Xiao, Xiufeng
   Zhang, Tao
   Zheng, Hong
TI A pH and near infrared light dual responsive drug delivery system based
   on TiO2 nanotube arrays modified with polydopamine and Fe<SUP>3+</SUP>
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Article
DE TiO 2 nanotube arrays; Polydopamine; Alendronate; Drug delivery;
   pH responsive; Near infrared light triggered
ID TITANIA NANOTUBES; RELEASE; IMPLANTS; BONE
AB This paper reports a novel drug delivery system based on TiO2 nanotube arrays (TNTs) modified with polydopamine (PDA) and Fe3+, which can load and release alendronate (NaAL), a drug for osteoporosis treatment, in a pH responsive and near infrared light triggered manner. The samples were characterized by electron scanning microscopy(SEM/EDS), Fourier Transform infrared spectroscopy(FTIR), X ray diffraction(XRD), X ray Photoelectron Spectroscopy(XPS) and Thermogravimetry(TG). The drug release behavior of the samples was investigated under different pH and light conditions. The results showed that the TNTs PDA Fe3+ had improved drug loading capacity compared with the TNTs and TNTs PDA. The drug release was pH responsive and near infrared light triggered, the drug release from the sample with a pH of 4.6 was much greater than the pH of 11 and 7.4, and the photothermal conversion effificiency of TNTs PDA Fe3+ NaAL was 32.9%. The drug release mechanism was attributed to the coordination bond between Fe3+ and NaAL, and the photothermal effect of the PDA. The cytotoxicity and biocompatibility of the samples were evaluated by MTT assay using mouse embryonic osteoblasts cells. The results indicated that the samples had no obvious cytotoxicity and could promote the cell proliferation and differentiation. The paper concludes that the TNTs PDA Fe3+ NaAL system is a potential implantable drug delivery platform for bone related diseases.
C1 [Liu, Nannan; Tu, Shaochen; Zhang, Sen; Chen, Dongdong; Zhang, Tao; Zheng, Hong] Fuzhou Second Hosp, Dept Orthoped, Fuzhou 350007, Fujian, Peoples R China.
   [Xiao, Xiufeng] Fujian Normal Univ, Coll Chem & Mat Sci, Fujian Prov Key Lab Adv Mat Oriented Chem Engn, Fuzhou 350007, Fujian, Peoples R China.
C3 Fujian Normal University
RP Zhang, T; Zheng, H (通讯作者)，Fuzhou Second Hosp, Dept Orthoped, Fuzhou 350007, Fujian, Peoples R China.; Xiao, XF (通讯作者)，Fujian Normal Univ, Coll Chem & Mat Sci, Fujian Prov Key Lab Adv Mat Oriented Chem Engn, Fuzhou 350007, Fujian, Peoples R China.
EM xfxiao@fjnu.edu.cn; tzhang78@126.com; hongfsh@163.com
FU Fujian Provincial Clinical Medical Research Center for First Aid and
   Rehabilitation in Orthopaedic Trauma [2020Y2014]; Fujian Natural Science
   Foundation Project [2021J011321, 2023J011538]; Guiding project of Fujian
   Provincial Science and Technology Department [2023D013]; Medical
   innovation project of Fujian Provincial Health Commission [2020CXB037];
   Fuzhou health innovation platform construction project [2021 S wp2,
   2020 S wp2]; Fujian Provincial Department of Science and Technology
   Central Leading Local Science and Technology Development Project
   [2022L3031]; Fuzhou Science and Technology Plan technology innovation
   platform project [2022 P 018, 2021 S 159]; Fuzhou health innovation
   platform construction project [2020 S wp3]
FX This work was financially supported by Fujian Provincial Clinical
   Medical Research Center for First Aid and Rehabilitation in Orthopaedic
   Trauma (2020Y2014) ,Fujian Natural Science Foundation Project
   (2021J011321,2023J011538) , Guiding project of Fujian Provincial Science
   and Technology Department (2023D013) ,Medical innovation project of
   Fujian Provincial Health Commission (2020CXB037) , Fuzhou health
   innovation platform construction project (2021 S wp2, 2020 S wp2)
   ,Fujian Provincial Department of Science and Technology Central Leading
   Local Science and Technology Development Project (2022L3031) ,Fuzhou
   Science and Technology Plan technology innovation platform project
   (2022 P 018, 2021 S 159) , Fuzhou health innovation platform
   construction project (2020 S wp3) .
CR Abniki M, 2021, IET NANOBIOTECHNOL, V15, P664, DOI 10.1049/nbt2.12063
   Amugongo SK, 2014, OSTEOPOROSIS INT, V25, P1735, DOI 10.1007/s00198 014 2678 5
   Aw MS, 2013, INT J PHARMACEUT, V443, P154, DOI 10.1016/j.ijpharm.2013.01.004
   Camarada MB, 2017, J PHYS CHEM A, V121, P8124, DOI 10.1021/acs.jpca.7b08272
   Chen JJ, 2020, THERANOSTICS, V10, P109, DOI 10.7150/thno.38388
   Chennell P, 2013, INT J PHARMACEUT, V455, P298, DOI 10.1016/j.ijpharm.2013.07.014
   Effendy WNFWE, 2023, J MATER RES, V38, P4068, DOI 10.1557/s43578 023 01126 2
   Fard NT, 2022, J MOL LIQ, V349, DOI 10.1016/j.molliq.2021.118149
   Feng SP, 2022, CHEM ENG J, V435, DOI 10.1016/j.cej.2022.134886
   Feng S, 2020, J COLLOID INTERF SCI, V559, P51, DOI 10.1016/j.jcis.2019.09.120
   Gonzaga EV, 2016, CRYST GROWTH DES, V16, P6891, DOI 10.1021/acs.cgd.6b01064
   Grosvenor AP, 2004, SURF INTERFACE ANAL, V36, P1564, DOI 10.1002/sia.1984
   Gulati K, 2013, PROC SPIE, V8812, DOI 10.1117/12.2027151
   Gulati K, 2012, THER DELIV, V3, P857, DOI 10.4155/TDE.12.66
   Khoshnood N, 2017, MAT SCI ENG C MATER, V77, P748, DOI 10.1016/j.msec.2017.03.293
   Li LF, 2020, J DRUG DELIV SCI TEC, V56, DOI 10.1016/j.jddst.2020.101537
   Li Y., 2020, Nanoscale Horizons, V5, P1310
   Liu J, 2015, J MATER CHEM B, V3, P6117, DOI 10.1039/c5tb00664c
   Liu Y, 2019, J NANOMATER, V2019, DOI 10.1155/2019/6395760
   Lu JY, 2022, ACTA BIOMATER, V148, P310, DOI 10.1016/j.actbio.2022.06.001
   Mahdavijalal M, 2023, J DRUG DELIV SCI TEC, V79, DOI 10.1016/j.jddst.2022.104066
   Paarakh M. P., 2018, International Journal of Pharmacy Research & Technology (IJPRT), V8, P12, DOI 10.31838/ijprt/08.01.02
   Padmaja S., 2002, Int. J. Pharm., V26, P789
   Shrestha NK, 2009, ANGEW CHEM INT EDIT, V48, P969, DOI 10.1002/anie.200804429
   Singhvi G., 2011, Int. J Pharm. Stu. Res, V2, P77
   Sirivisoot S, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/8/085101
   Sobhani M, 2021, INT J PHARMACEUT, V607, DOI 10.1016/j.ijpharm.2021.120985
   Soltani ER, 2023, MATER CHEM PHYS, V295, DOI 10.1016/j.matchemphys.2022.127159
   Wang KL, 2021, J CONTROL RELEASE, V339, P445, DOI 10.1016/j.jconrel.2021.10.005
   Wang Q, 2017, INT J NANOMED, V12, DOI 10.2147/IJN.S117498
   Wójcik Pastuszka D, 2019, MATERIALS, V12, DOI 10.3390/ma12081202
   Wu C, 2020, J ALLOY COMPD, V845, DOI 10.1016/j.jallcom.2020.156301
   Wu Q, 2012, J HAZARD MATER, V199, P410, DOI 10.1016/j.jhazmat.2011.11.031
   Wu S, 2019, ACS APPL MATER INTER, V11, P1254, DOI 10.1021/acsami.8b17530
   Xu JW, 2016, ANGEW CHEM INT EDIT, V55, P593, DOI 10.1002/anie.201508710
   Xu QQ, 2022, COORDIN CHEM REV, V469, DOI 10.1016/j.ccr.2022.214687
   Xu Y, 2021, NANO RES, V14, P4046, DOI 10.1007/s12274 021 3338 7
   Yang Y, 2018, ACS APPL MATER INTER, V10, P7649, DOI 10.1021/acsami.7b06108
NR 38
TC 1
Z9 1
U1 9
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1773 2247
EI 2588 8943
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PD SEP
PY 2024
VL 99
AR 106003
DI 10.1016/j.jddst.2024.106003
EA JUL 2024
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA A8G9J
UT WOS:001284878700001
DA 2025 08 17
ER

PT J
AU Anderson, KE
   Polsky, D
   Dy, S
   Sen, AP
AF Anderson, Kelly E.
   Polsky, Daniel
   Dy, Sydney
   Sen, Aditi P.
TI Prescribing of low  versus high cost Part B drugs in Medicare Advantage
   and traditional Medicare
SO HEALTH SERVICES RESEARCH
LA English
DT Article
DE drug costs; Medicare; Medicare Part B; economics; Medicare Part C;
   prescription drugs; reimbursement mechanisms
ID ZOLEDRONIC ACID; BONE METASTASES; DENOSUMAB; CANCER; CARE; ENROLLEES;
   PATTERNS; OUTCOMES; QUALITY; PAYMENT
AB Objective Examine whether Medicare Advantage (MA) coverage is associated with more efficient prescribing of Part B drugs than traditional Medicare (TM) coverage. Data Sources Twenty percent sample of 2016 outpatient and carrier TM claims and MA encounter records and Master Beneficiary Summary File data. Study Design We analyzed whether MA enrollees compared to TM enrollees more often received the low cost Part B drug in four clinical scenarios where multiple similarly effective drugs exist: (1) anti VEGF agents to treat macular degeneration, (2) bone resorption inhibitors for osteoporosis, (3) bone resorption inhibitors for malignant neoplasms, and (4) intravenous iron for iron deficiency anemia. We then estimated differences in spending if TM prescribing aligned with MA prescribing. Finally, using linear probability models, we examined whether differences in MA and TM prescribing patterns were attributable to differences in the hospitals and clinician practices who treat MA and TM enrollees or differences in how these hospitals and clinician practices treat their MA versus TM patients. Data Collection/Extraction Methods Not applicable. Principal Findings In all cases, a larger share of MA enrollees received the low cost drug compared to TM enrollees, ranging from 8 percentage points higher for anemia to 16 percentage points higher for macular degeneration in the unadjusted analysis. Results were similar in regression analyses controlling for enrollee characteristics and market factors (5 13 percentage points). If TM prescribing matched MA prescribing, we estimated savings ranging from 6% to 20% of TM spending for each scenario. Differences in prescribing patterns were driven both by MA enrollees receiving treatment at more efficient hospitals and clinician practices and hospitals and clinician practices more often prescribing low cost drugs to their MA patients. Conclusions Our findings show MA enrollees were more likely than TM enrollees to receive low cost Part B drugs in four clinical scenarios where multiple similarly or equally effective treatment options exist.
C1 [Anderson, Kelly E.; Sen, Aditi P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA.
   [Polsky, Daniel] Hopkins Business Hlth Initiat, Johns Hopkins Carey Business Sch, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA.
   [Dy, Sydney] Johns Hopkins Sch Med, Dept Hlth Policy & Management, Div Gen Internal Med, Baltimore, MD USA.
   [Sen, Aditi P.] Res & Policy Hlth Care Cost Inst, 1100 G St NW, Washington, DC 20005 USA.
C3 Johns Hopkins University; Johns Hopkins Bloomberg School of Public
   Health; Johns Hopkins University; Johns Hopkins Bloomberg School of
   Public Health; Johns Hopkins University; Johns Hopkins Medicine
RP Anderson, KE (通讯作者)，Univ Colorado, Dept Clin Pharm, Skaggs Sch Pharm & Pharmaceut Sci, 12850 E Montview Blvd,Room V20 1203,Mail Stop C23, Aurora, CO 80045 USA.
EM kelly.e.anderson@cuanschutz.edu
OI Anderson, Kelly/0000 0002 1471 6283
FU Agency for Healthcare Research and Quality [T32HS000029]; Arnold
   Ventures
FX Agency for Healthcare Research and Quality, Grant/Award Number:
   T32HS000029; Arnold Ventures
CR Adkinson NF, 2018, AM J HEMATOL, V93, P683, DOI 10.1002/ajh.25060
   *AETN, 2020, EV COV AETN MED SEL
   Afendulis CC, 2017, AM J HEALTH ECON, V3, P254, DOI 10.1162/ajhe_a_00074
   ANDERSON KE, AM J MANAG CARE
   *ASPE, 2020, MED B
   Auerbach M, 2008, KIDNEY INT, V73, P528, DOI 10.1038/sj.ki.5002779
   Ayanian JZ, 2013, HEALTH AFFAIR, V32, P1228, DOI 10.1377/hlthaff.2012.0773
   Bach PB, 2011, HEALTH AFFAIR, V30, P500, DOI 10.1377/hlthaff.2010.0752
   Baisiwala S, 2016, OSLI RETINA, V47, P555, DOI 10.3928/23258160 20160601 07
   Baker LC, 2020, J HEALTH ECON, V70, DOI 10.1016/j.jhealeco.2019.102278
   Bundorf MK, 2004, HEALTH SERV RES, V39, P131
   Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL 2020 0524SUPPL
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140 6736(13)61501 9
   *CMS, FR
   CMS, 2021, ONC CAR MOD OV
   CREIGHTON S, 2019, HLTH AFFAIRS BL 0225, DOI DOI 10.1377/HBLOG20190221.696651/FULL/.ACCESSED
   Cubanski J., 2018, Sources of Supplemental Coverage Among Medicare Beneficiaries in 2016
   Dean EB, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.34776
   Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650 199801000 00004
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   *GAO, 2017, MED ADV LTD PROGR MA
   Geruso M, 2020, J POLIT ECON, V128, P984, DOI 10.1086/704756
   GINSBURG PB, 2017, HLTH AFFAIRS BL 1127, DOI DOI 10.1377/HBLOG20171117.667415/FULL/.ACCESSED
   Gupta A, 2020, JAMA ONCOL, V6, P296, DOI 10.1001/jamaoncol.2019.5426
   Hambley BC, 2020, AM J MANAG CARE, V26, P516, DOI 10.37765/ajmc.2020.88539
   Huckfeldt P. J., 2017, Health Affairs, V36, P91, DOI 10.1377/hlthaff.2016.1027
   *HUM, YOUR 2020 EV COV
   Hutton D, 2014, HEALTH AFFAIR, V33, P931, DOI 10.1377/hlthaff.2013.0832
   JOHNSON A, 2018, MED ADVANTAGE MA ENC
   Kim D, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3555
   Landon BE, 2015, AM J MANAG CARE, V21, P559
   Lyu HC, 2019, J CLIN ENDOCR METAB, V104, P1753, DOI 10.1210/jc.2018 02236
   Martin DF, 2020, OPHTHALMOLOGY, V127, pS135, DOI 10.1016/j.ophtha.2020.01.029
   *MEDPAC, 2016, MED ADV PROGR PAYM S
   MEDPAC, 2016, OUTP DIAL SERV PAYM
   *MEDPAC, 2019, MED HLTH CAR DEL S B, pCH3
   Mehmood T, 2014, BLOOD, V124
   Meyers DJ, 2021, HEALTH AFFAIR, V40, P945, DOI 10.1377/hlthaff.2021.00118
   Meyers DJ, 2018, HEALTH AFFAIR, V37, P78, DOI 10.1377/hlthaff.2017.0714
   *NAT AC SCI, 2021, MED SINGL DOS VIALS
   *OIG, 2018, MED ADV ENC DAT SHOW
   Park S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.1809
   PERMANENTE K, 2020, EVIDENCE COVERAGE YO
   Roberts ET, 2021, HEALTH AFFAIR, V40, P552, DOI 10.1377/hlthaff.2020.02272
   Schwartz AL, 2021, JAMA HEALTH FORUM, V2, DOI 10.1001/jamahealthforum.2021.0859
   SCHWARTZ AY, 2021, HLTH AFFAIRS BL 0607
   Schwartz ML, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.10622
   Snedecor Sonya J, 2013, J Med Econ, V16, P19, DOI 10.3111/13696998.2012.719054
   Socal MP, 2020, VALUE HEALTH, V23, P481, DOI 10.1016/j.jval.2019.12.007
   Stagg V., 2015, ELIXHAUSER: Stata module to calculate Elixhauser index of comorbidity
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   *U HEALTHC, 2021, EV COV 2021 AARP MED
   Virgili G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub3
   Welch WP, 2019, MED CARE, V57, P795, DOI 10.1097/MLR.0000000000001193
   WERBLE C, 2017, MED B, DOI DOI 10.1377/HPB20171008.000171/FULL/.ACCESSED
   Yasaitis L, 2019, HEALTH AFFAIR, V38, P812, DOI 10.1377/hlthaff.2018.05083
NR 56
TC 17
Z9 17
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0017 9124
EI 1475 6773
J9 HEALTH SERV RES
JI Health Serv. Res.
PD JUN
PY 2022
VL 57
IS 3
BP 537
EP 547
DI 10.1111/1475 6773.13912
EA DEC 2021
PG 11
WC Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services
GA 1G4MT
UT WOS:000729795100001
PM 34806171
OA Green Published
DA 2025 08 17
ER

PT J
AU Kafali, M
   Sahinoglu, OB
   Tufan, Y
   Orsel, ZC
   Aygun, E
   Alyuz, B
   Saritas, EU
   Erdem, EY
   Ercan, B
AF Kafali, Melisa
   Sahinoglu, O. Berkay
   Tufan, Yigithan
   Orsel, Z. Cemre
   Aygun, Elif
   Alyuz, Beril
   Saritas, Emine Ulku
   Erdem, E. Yegan
   Ercan, Batur
TI Antibacterial properties and osteoblast interactions of microfluidically
   synthesized chitosan   SPION composite nanoparticles
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE antibacterial; magnetic field; microfluidics; osteoblast; SPION
ID IRON OXIDE NANOPARTICLES; FE3O4 NANOPARTICLES; MAGNETIC NANOPARTICLES;
   THERMAL STABILITY; DELIVERY; DRUG; TOXICITY
AB In this research, a multi step microfluidic reactor was used to fabricate chitosan   superparamagnetic iron oxide composite nanoparticles (Ch   SPIONs), where composite formation using chitosan was aimed to provide antibacterial property and nanoparticle stability for magnetic resonance imaging (MRI). Monodispersed Ch   SPIONs had an average particle size of 8.8 +/  1.2 nm with a magnetization value of 32.0 emu/g. Ch   SPIONs could be used as an MRI contrast agent by shortening T 2 relaxation parameter of the surrounding environment, as measured on a 3 T MRI scanner. In addition, Ch   SPIONs with concentrations less than 1 g/L promoted bone cell (osteoblast) viability up to 7 days of culture in vitro in the presence of 0.4 T external static magnetic field. These nanoparticles were also tested against Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa), which are dangerous pathogens that cause infection in tissues and biomedical devices. Upon interaction of Ch   SPIONs with S. aureus and P. aeruginosa at 0.01 g/L concentration, nearly a 2 fold reduction in the number of colonies was observed for both bacteria strains at 48 h of culture. Results cumulatively showed that Ch   SPIONs were potential candidates as a cytocompatible and antibacterial agent that can be targeted to biofilm and imaged using an MRI.
C1 [Kafali, Melisa; Tufan, Yigithan; Orsel, Z. Cemre; Ercan, Batur] Middle East Tech Univ, Dept Met & Mat Engn, Ankara, Turkiye.
   [Sahinoglu, O. Berkay; Erdem, E. Yegan] Bilkent Univ, Dept Mech Engn, Ankara, Turkiye.
   [Aygun, Elif; Alyuz, Beril; Saritas, Emine Ulku] Bilkent Univ, Dept Elect & Elect Engn, Ankara, Turkiye.
   [Aygun, Elif; Alyuz, Beril; Saritas, Emine Ulku] Bilkent Univ, Natl Magnet Resonance Res Ctr UMRAM, Ankara, Turkiye.
   [Saritas, Emine Ulku] Bilkent Univ, Neurosci Grad Program, Ankara, Turkiye.
   [Erdem, E. Yegan] Bilkent Univ, Natl Nanotechnol Res Ctr UNAM, Ankara, Turkiye.
   [Ercan, Batur] Middle East Tech Univ, Ctr Excellence Biomat & Tissue Engn, BIOMATEN, Ankara, Turkiye.
   [Ercan, Batur] Middle East Tech Univ, Biomed Engn Program, Ankara, Turkiye.
   [Ercan, Batur] Middle East Tech Univ, Dept Met & Mat Engn, TR 06800 Ankara, Turkiye.
C3 Middle East Technical University; Ihsan Dogramaci Bilkent University;
   Ihsan Dogramaci Bilkent University; Ihsan Dogramaci Bilkent University;
   Ihsan Dogramaci Bilkent University; Ihsan Dogramaci Bilkent University;
   Middle East Technical University; Middle East Technical University;
   Middle East Technical University
RP Ercan, B (通讯作者)，Middle East Tech Univ, Dept Met & Mat Engn, TR 06800 Ankara, Turkiye.
EM baercan@metu.edu.tr
RI Erdem, Emine Yegan/J 3880 2014; Tufan, Yiğithan/LLN 1161 2024; Saritas,
   Emine/A 3730 2013; ERCAN, BATUR/A 1232 2016; KAFALI,
   Melisa/JAX 7413 2023; ERCAN, BATUR/AAY 8833 2021
OI Erdem, Emine Yegan/0000 0001 9852 2293; Tufan,
   Yigithan/0000 0001 7549 8040; Aygun, Elif/0000 0003 2934 6948; ERCAN,
   BATUR/0000 0003 1657 1142; Orsel, Z. Cemre/0000 0001 5207 4325
FU Scientific Research Council of Turkey [219M480, 118M652, 117M187]; TUEBA
   (Outstanding Young Scientists Award, GEB_IP); Bilim Akademisi (Science
   Academy's Young Scientist Awards Program)
FX The Scientific Research Council of Turkey, Grant/Award Numbers: 219M480,
   118M652, 117M187; TUEBA (Outstanding Young Scientists Award, GEB_IP) and
   Bilim Akademisi (Science Academy's Young Scientist Awards Program)
CR Wahab MA, 2020, J MICROMECH MICROENG, V30, DOI 10.1088/1361 6439/ab8dd2
   Abou hassan A., 2019, MICROFLUIDICS SYNTHE
   Ahrberg CD, 2018, BEILSTEIN J NANOTECH, V9, P2413, DOI 10.3762/bjnano.9.226
   Alipour A, 2018, MAGN RESON IMAGING, V49, P16, DOI 10.1016/j.mri.2017.09.013
   [Anonymous], S INFORM MAT SCI
   Arakha M, 2015, SCI REP UK, V5, DOI 10.1038/srep14813
   Arsalani S, 2019, J MAGN MAGN MATER, V475, P458, DOI 10.1016/j.jmmm.2018.11.132
   Balk M., 2021, NANOMATERIALS BASEL, V11, P1
   Baptista PV, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01441
   Braim FS, 2022, ULTRASON SONOCHEM, V88, DOI 10.1016/j.ultsonch.2022.106072
   Chevalier S, 2017, FEMS MICROBIOL REV, V41, P698, DOI 10.1093/femsre/fux020
   Christopher GF, 2007, J PHYS D APPL PHYS, V40, pR319, DOI 10.1088/0022 3727/40/19/R01
   Dulinska Litewka J, 2019, MATERIALS, V12, DOI 10.3390/ma12040617
   Erdem EY, 2014, SMALL, V10, P1076, DOI 10.1002/smll.201302379
   Freire TM, 2016, CARBOHYD POLYM, V151, P760, DOI 10.1016/j.carbpol.2016.05.095
   Frenz L, 2008, ANGEW CHEM INT EDIT, V47, P6817, DOI 10.1002/anie.200801360
   Gadkari RR, 2019, CARBOHYD POLYM, V226, DOI 10.1016/j.carbpol.2019.115298
   Ghosh S, 2020, FOOD CHEM TOXICOL, V136, DOI 10.1016/j.fct.2019.110989
   Gokduman K, 2018, NANOMEDICINE UK, V13, P1267, DOI 10.2217/nnm 2017 0387
   Jabali MK, 2022, COLLOID SURFACE A, V632, DOI 10.1016/j.colsurfa.2021.127743
   James M., 2020, NANOMATERIALS BASEL, V10, P1, DOI DOI 10.3390/NANO10112113
   Li JH, 2020, EUR POLYM J, V138, DOI 10.1016/j.eurpolymj.2020.109984
   Li XB, 2019, ADV SCI, V6, DOI 10.1002/advs.201900972
   Mahmoudi M, 2011, ADV DRUG DELIVER REV, V63, P24, DOI 10.1016/j.addr.2010.05.006
   Marroquin JB, 2013, CARBOHYD POLYM, V92, P1783, DOI 10.1016/j.carbpol.2012.11.042
   Miyakoshi J, 2005, PROG BIOPHYS MOL BIO, V87, P213, DOI 10.1016/j.pbiomolbio.2004.08.008
   Mohammadi Samani S, 2013, RES PHARM SCI, V8, P25
   Mulani MS, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00539
   Nehra P, 2018, BRIT J BIOMED SCI, V75, P13, DOI 10.1080/09674845.2017.1347362
   Niculescu AG, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11040864
   Park W, 2014, BIOMATERIALS, V35, P7239, DOI 10.1016/j.biomaterials.2014.05.010
   Quan KC, 2020, ACS BIOMATER SCI ENG, V6, P205, DOI 10.1021/acsbiomaterials.9b01425
   Queiroz MF, 2015, MAR DRUGS, V13, P141, DOI 10.3390/md13010141
   Sahariah P, 2014, MAR DRUGS, V12, P4635, DOI 10.3390/md12084635
   Samrot AV., 2021, CURR RES GREEN SUSTA, V4, DOI [DOI 10.1016/J.CRGSC.2020.100042, 10 . 1016 /j.crgsc.2020.100042]
   Seabra AB., 2017, ANTIMICROBIAL APPL S
   Sibov TT, 2014, INT J NANOMED, V9, P337, DOI 10.2147/IJN.S53299
   Stephen ZR., 2011, MAT TODAY KIDLINGTON, V23, P1
   Suciu M, 2020, BEILSTEIN J NANOTECH, V11, P1092, DOI 10.3762/bjnano.11.94
   Sun C, 2008, ADV DRUG DELIVER REV, V60, P1252, DOI 10.1016/j.addr.2008.03.018
   Tasar C, 2023, CERAM INT, V49, P12925, DOI 10.1016/j.ceramint.2022.12.164
   Thakor AS, 2016, J NUCL MED, V57, P1833, DOI 10.2967/jnumed.116.181362
   Thangudu S, 2022, BIOMATER SCI UK, V10, P5032, DOI 10.1039/d2bm00692h
   Vakili Ghartavol R, 2020, ARTIF CELL NANOMED B, V48, P443, DOI 10.1080/21691401.2019.1709855
   Wahajuddin, 2012, INT J NANOMED, V7, P3445, DOI 10.2147/IJN.S30320
   Wang CZ, 2017, SMALL, V13, DOI 10.1002/smll.201604255
   Wiegand I, 2008, NAT PROTOC, V3, P163, DOI 10.1038/nprot.2007.521
   Wiskirchen J, 1999, MAGNET RESON MED, V41, P464, DOI 10.1002/(SICI)1522 2594(199903)41:3<464::AID MRM6>3.0.CO;2 R
   Yang JC, 2018, BIOL TRACE ELEM RES, V184, P214, DOI 10.1007/s12011 017 1161 5
   Yasmeen S., 2016, International Research Journal of Pure and Applied Chemistry, V10, P1
   Zhang L, 2020, ACS APPL BIO MATER, V3, P107, DOI 10.1021/acsabm.9b00853
   Zhao GH, 2014, CHEM ASIAN J, V9, P546, DOI 10.1002/asia.201301072
   Zhu AP, 2008, INT J PHARMACEUT, V350, P361, DOI 10.1016/j.ijpharm.2007.09.004
   Ziegler Borowska M, 2015, J THERM ANAL CALORIM, V119, P499, DOI 10.1007/s10973 014 4122 7
NR 54
TC 13
Z9 13
U1 1
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD NOV
PY 2023
VL 111
IS 11
BP 1662
EP 1677
DI 10.1002/jbm.a.37575
EA MAY 2023
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA R7AI2
UT WOS:000995337500001
PM 37232403
OA hybrid
DA 2025 08 17
ER

PT J
AU Campos, RMS
   de Mello, MT
   Tock, L
   da Silva, PL
   Corgosinho, FC
   Carnier, J
   de Piano, A
   Sanches, PL
   Masquio, DCL
   Tufik, S
   Dâmaso, AR
AF Campos, Raquel M. S.
   de Mello, Marco Tulio
   Tock, Lian
   da Silva, Patricia Leao
   Corgosinho, Flavia C.
   Carnier, June
   de Piano, Aline
   Sanches, Priscila L.
   Masquio, Deborah C. L.
   Tufik, Sergio
   Damaso, Ana R.
TI Interaction of bone mineral density, adipokines and hormones in obese
   adolescents girls submitted in an interdisciplinary therapy
SO JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE adipokines; adolescents; bone mineral density; hormone; obesity
ID ADIPOSE TISSUE; ADIPONECTIN; GHRELIN; BODY; MASS; FAT; OSTEOBLAST;
   PREDICTOR; PROTEIN; LEPTIN
AB Obesity is a chronic inflammatory condition with numerous metabolic consequences to the organism, highlighting its influence on bone mass. Therefore, the aim of this study was to verify the role of visceral fat, leptin, adiponectin and ghrelin on bone mineral density in obese post puberty adolescents girls, submitted to an interdisciplinary therapy. The study involved 20 post puberty obese adolescent girls: 16 +/  1.5 years of age, 98.9 +/  15.8 kg (weight), 1.60 +/  0.72 m (height) and 37.2 +/  4.8 kg/m(2) [body mass index (BMI)]. Anthropometric measurements, body composition, visceral fat, subcutaneous fat, bone mineral density and content were determined. Ghrelin, leptin and adiponectin were analyzed and the leptin/adiponectin ratio was calculated. Our findings showed a significant increase in adiponectin concentration and a reduction in body weight, BMI, total fat mass, visceral and subcutaneous fat. In addition, ghrelin (r(2)= 0.53; p=0.02)visceral fat (r(2)= 0.46, p=0.04) (r(2)  0.66, p=0.001) and leptin/adiponectin ratio (r(2)  0.56, p=0.01) were negative predictors for bone mineral density and content in obese adolescent girls, respectively. It provides a novel physiologically concept that may shed light on the etiology of osteoporosis and help to identify new therapeutic targets. However this should be confirmed in a large cohort study.
C1 [Campos, Raquel M. S.] Univ Fed Sao Paulo, Postgrad Program Nutr, BR 04020050 Sao Paulo, SP, Brazil.
   [Damaso, Ana R.] Univ Fed Sao Paulo, Dept Biosci, BR 11060001 Santos, SP, Brazil.
   [de Mello, Marco Tulio; Tufik, Sergio] Univ Fed Sao Paulo, Dept Psychobiol, Sao Paulo, Brazil.
   [Tock, Lian; da Silva, Patricia Leao; Corgosinho, Flavia C.; Carnier, June; de Piano, Aline; Sanches, Priscila L.; Masquio, Deborah C. L.; Damaso, Ana R.] Univ Fed Sao Paulo, Post Grad Program Nutr, Sao Paulo, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao
   Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP);
   Universidade Federal de Sao Paulo (UNIFESP)
RP Campos, RMS (通讯作者)，Univ Fed Sao Paulo, Postgrad Program Nutr, Rua Francisco de Castro 93, BR 04020050 Sao Paulo, SP, Brazil.
EM raquel@cepebr.org; ana.damaso@unifesp.br
RI Campos, Raquel/D 1994 2013; Masquio, Deborah/GLQ 5953 2022; da Silva
   Agostinho, Patrícia/AAJ 2815 2021; de Piano, Aline/J 8334 2016;
   Corgosinho, Flavia/G 4045 2015; de Mello, Marco Tulio/G 3237 2010; de
   Mello, Marco/G 3237 2010; Dâmaso, Ana/AAT 6058 2021; Tufik,
   Sergio/D 7606 2012
OI Campos, Raquel/0000 0001 6132 4349; de Piano, Aline/0000 0001 6433 0816;
   de Mello, Marco Tulio/0000 0003 3896 2208; 
CR Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI200214588
   Bandeira F, 2010, ARQ BRAS ENDOCRINOL, V54, P85, DOI 10.1590/S0004 27302010000200001
   [Branca F. World Health Organisation World Health Organisation], 2007, CHALLENGE OBESITY WH
   Brandao PP, 2010, NEUROENDOCRINOL LETT, V31, P353
   Campos RMS, 2012, ENDOCRINE, V42, P146, DOI 10.1007/s12020 012 9613 3
   Campos RMS, 2012, ARQ BRAS ENDOCRINOL, V56, P12, DOI 10.1590/S0004 27302012000100003
   Cao YL, 2008, INT J CARDIOL, V128, P399, DOI 10.1016/j.ijcard.2007.05.033
   Cao YL, 2008, DIABETES RES CLIN PR, V79, P214, DOI 10.1016/j.diabres.2007.08.030
   Corgosinho FC, 2012, INFLAMMATION, V35, P944, DOI 10.1007/s10753 011 9397 2
   Delhanty PJD, 2006, J ENDOCRINOL, V188, P37, DOI 10.1677/joe.1.06404
   do Prado WL, 2009, J BONE MINER METAB, V27, P613, DOI 10.1007/s00774 009 0082 6
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   FELSON DT, 1993, J BONE MINER RES, V8, P567, DOI 10.1002/jbmr.5650080507
   Hardy R, 2009, J ENDOCRINOL, V201, P309, DOI 10.1677/JOE 08 0568
   Instituto Brasileiro de Geografia e Estatistica, 2010, POF 2008 2009 ANTR E
   Klöting N, 2010, AM J PHYSIOL ENDOC M, V299, pE506, DOI 10.1152/ajpendo.00586.2009
   Kos K, 2009, CLIN ENDOCRINOL, V70, P383, DOI 10.1111/j.1365 2265.2008.03321.x
   Li S., 2008, JAMA J AM MED ASSOC, V302, P179
   Lindsay RS, 2002, LANCET, V360, P57, DOI 10.1016/S0140 6736(02)09335 2
   Makovey J, 2007, CLIN ENDOCRINOL, V66, P530, DOI 10.1111/j.1365 2265.2007.02768.x
   Morberg CM, 2003, J CLIN ENDOCR METAB, V88, P5795, DOI 10.1210/jc.2003 030496
   Oshima K, 2005, BIOCHEM BIOPH RES CO, V331, P520, DOI 10.1016/j.bbrc.2005.03.210
   Pacifico L, 2009, BONE, V45, P274, DOI 10.1016/j.bone.2009.04.204
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Rocha VZ, 2011, INT J INFLAMM, V2011, DOI 10.4061/2011/529061
   Russell M, 2010, J CLIN ENDOCR METAB, V95, P1247, DOI 10.1210/jc.2009 1475
   Silva DAS, 2011, EUR J PEDIATR, V170, P1541, DOI 10.1007/s00431 011 1460 3
   Silva Carla C, 2004, J Pediatr (Rio J), V80, P461, DOI 10.1590/S0021 75572004000800007
   Snehalatha C, 2003, DIABETES CARE, V26, P3226, DOI 10.2337/diacare.26.12.3226
   Trayhurn P, 2005, BIOCHEM SOC T, V33, P1078, DOI 10.1042/BST20051078
   Wang MC, 2005, BONE, V37, P474, DOI 10.1016/j.bone.2005.04.038
   Wang YF, 2008, OBESITY, V16, P2323, DOI 10.1038/oby.2008.351
NR 32
TC 15
Z9 17
U1 0
U2 13
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D 10785 BERLIN, GERMANY
SN 0334 018X
EI 2191 0251
J9 J PEDIATR ENDOCR MET
JI J. Pediatr. Endocrinol. Metab.
PD AUG
PY 2013
VL 26
IS 7 8
BP 663
EP 668
DI 10.1515/jpem 2012 0336
PG 6
WC Endocrinology & Metabolism; Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Pediatrics
GA 200FA
UT WOS:000323052000010
PM 23612645
DA 2025 08 17
ER

PT J
AU Mebarki, M
   Coquelin, L
   Layrolle, P
   Battaglia, S
   Tossou, M
   Hernigou, P
   Rouard, H
   Chevallier, N
AF Mebarki, Miryam
   Coquelin, Laura
   Layrolle, Pierre
   Battaglia, Severine
   Tossou, Marine
   Hernigou, Philippe
   Rouard, Helene
   Chevallier, Nathalie
TI Enhanced human bone marrow mesenchymal stromal cell adhesion on
   scaffolds promotes cell survival and bone formation
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Mesenchymal stem cells; Biomaterial; Cell therapy; Bone tissue
   engineering; HA/beta TCP; Tutoplast
ID MESSENGER RNA EXPRESSION; TISSUE ENGINEERED BONE; STEM CELLS; IN VIVO;
   ALLOGRAFTS; REPAIR; RECRUITMENT; OSTEOCLAST; MIGRATION; DEFECTS
AB In order to induce an efficient bone formation with human bone marrow mesenchymal stromal cells (hBMSC) associated to a scaffold, it is crucial to determine the key points of the hBMSC action after in vivo transplantation as well as the appropriate features of a scaffold. To this aim we compared the hBMSC behavior when grafted onto two biomaterials allowing different bone potential in vivo. The cancellous devitalized Tutoplast (R) processed bone (TPB) and the synthetic hydroxyapatite/beta tricalcium phos phate (HA/beta TCP) which give at 6 weeks 100% and 50% of bone formation respectively. We first showed that hBMSC adhesion is two times favored on TPB in vitro and in vivo compared to HA/beta TCP. Biomaterial structure analysis indicated that the better cell adhesion on TPB is associated to its higher and smooth open pore architecture as well as its content in collagen. Our 6 week time course analysis, showed using qPCR that only adherent cells are able to survive in vivo giving thus an advantage in term of cell number on TPB during the first 4 weeks after graft. We then showed that grafted hBMSC survival is crucial as cells participate directly to bone formation and play a paracrine action via the secretion of hIGF1 and hRANKL which are known to regulate the bone formation and resorption pathways respectively. Altogether our results point out the importance of developing a smooth and open pore scaffold to optimize hBMSC adhesion and ensure cell survival in vivo as it is a prerequisite to potentiate their direct and paracrine functions.
   Statement of Significance
   Around 10% of skeletal fractures do not heal correctly causing nonunion. An approach involving mesenchymal stromal cells (MSC) associated with biomaterials emerges as an innovative strategy for bone repair. The diversity of scaffolds is a source of heterogeneity for bone formation efficiency. In order to better determine the characteristics of a powerful scaffold it is crucial to understand their relationship with cells after graft. Our results highlight that a biomaterial architecture similar to cancellous bone is important to promote MSC adhesion and ensure cell survival in vivo. Additionally, we demonstrated that the grafted MSC play a direct role coupled to a paracrine effect to enhance bone formation and that both of those roles are governed by the used scaffold. (C) 2017 Acta Materialia Inc. Published by Elsevier Ltd.
C1 [Mebarki, Miryam; Coquelin, Laura; Tossou, Marine; Hernigou, Philippe; Rouard, Helene; Chevallier, Nathalie] INSERM, IMRB U955 E10, Creteil, France.
   [Mebarki, Miryam; Coquelin, Laura; Tossou, Marine; Hernigou, Philippe; Rouard, Helene; Chevallier, Nathalie] Paris Est Univ, Fac Med, Creteil, France.
   [Mebarki, Miryam; Coquelin, Laura; Tossou, Marine; Rouard, Helene; Chevallier, Nathalie] Etab Francais Sang, Engn & Cellular Therapy Unit, Creteil, France.
   [Hernigou, Philippe] Henri Mondor AP HP Hosp, Orthopaed Surg Dept, Creteil, France.
   [Layrolle, Pierre; Battaglia, Severine] Univ Nantes, Lab Pathophysiol Bone Resorpt, INSERM U957, Fac Med, Nantes, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Paris Est Creteil Val de Marne (UPEC); Universite
   Paris Est Creteil Val de Marne (UPEC); Assistance Publique Hopitaux
   Paris (APHP); Assistance Publique Hopitaux Paris (APHP); Universite
   Paris Est Creteil Val de Marne (UPEC); Hopital Universitaire
   Henri Mondor   APHP; Nantes Universite; Institut National de la Sante et
   de la Recherche Medicale (Inserm)
RP Chevallier, N (通讯作者)，Etab Francais Sang Ile de France, Unite Ingn & Therapie Cellulaire, 5 Rue Gustave Eiffel, F 94017 Creteil, France.
EM nathalie.chevallier@efs.sante.fr
RI BATTAGLIA, Severine/K 8715 2015; Layrolle, Pierre/K 9257 2015
OI ROUARD, Helene/0000 0003 0711 2999; Mebarki, Miryam/0000 0003 3413 0463;
   COQUELIN, laura/0000 0003 4591 6939; Chevallier,
   Nathalie/0000 0002 1800 2579; Layrolle, Pierre/0000 0001 9800 5210
FU EFS Ile de France (APR); European Commission [241879]; Assistance
   Publique   Hopitaux de Paris
FX This work was supported by EFS Ile de France (APR   2014) and by the 7th
   Framework Program of the European Commission through the project REBORNE
   no. 241879. M. Mebarki was supported by Assistance Publique   Hopitaux
   de Paris. The authors are grateful to Franck Chiappini for helpful
   statistical analysis, Guy Louarn from the Institut des Materiaux de
   Nantes, Beatrice Laurent and Sabine Louis for technical help, Najat
   Raddi for her critical review of the manuscript, Michael Marden for the
   rereading of the manuscript, SEM platform of University Paris Est, with
   special thanks to Dr Patrick Ausset for his precious help and the Centre
   de Recherches Chirurgicales Dominique Chopin for animal platform
   facilities. The authors are grateful to the company Ceraver, which
   kindly provided the HA/beta TCP ceramics.
CR Bi L, 2012, XENOTRANSPLANTATION, V19, P122, DOI 10.1111/j.1399 3089.2012.00694.x
   Bianco P, 2001, NATURE, V414, P118, DOI 10.1038/35102181
   Brennan MA, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt504
   Campana V, 2014, J MATER SCI MATER M, V25, P2445, DOI 10.1007/s10856 014 5240 2
   Cancedda R, 2003, MATRIX BIOL, V22, P81, DOI 10.1016/S0945 053X(03)00012 X
   Centeno CJ, 2010, CURR STEM CELL RES T, V5, P81, DOI 10.2174/157488810790442796
   Chakar C, 2014, INT J BIOMATER, V2014, DOI 10.1155/2014/367265
   CHEN J, 1994, HISTOCHEM J, V26, P67
   Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886
   Chevallier N, 2010, BIOMATERIALS, V31, P270, DOI 10.1016/j.biomaterials.2009.09.043
   Coquelin L, 2012, TISSUE ENG PT A, V18, P1921, DOI [10.1089/ten.tea.2011.0645, 10.1089/ten.TEA.2011.0645]
   Cristofalo VJ, 1998, P NATL ACAD SCI USA, V95, P10614, DOI 10.1073/pnas.95.18.10614
   Cypher T J, 1996, J Foot Ankle Surg, V35, P413
   Davison NL, 2014, BIOMATERIALS, V35, P7441, DOI 10.1016/j.biomaterials.2014.05.048
   de Bruyn JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056764
   Deijkers RLM, 1999, J BONE JOINT SURG BR, V81B, P538, DOI 10.1302/0301 620X.81B3.9265
   Delloye C, 2007, J BONE JOINT SURG BR, V89B, P574, DOI 10.1302/0301 620X.89B5.19039
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Gamblin AL, 2014, BIOMATERIALS, V35, P9660, DOI 10.1016/j.biomaterials.2014.08.018
   Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856
   Garrison KR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006950.pub2
   Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723
   Granero Moltó F, 2011, STEM CELLS, V29, P1537, DOI 10.1002/stem.697
   Holm E, 2015, BONE, V71, P145, DOI 10.1016/j.bone.2014.10.007
   Homma Y, 2013, INJURY, V44, pS46, DOI 10.1016/S0020 1383(13)70011 1
   Kawaguchi H, 2010, J BONE MINER RES, V25, P2459, DOI 10.1002/jbmr.146
   Kitaori T, 2009, ARTHRITIS RHEUM US, V60, P813, DOI 10.1002/art.24330
   Kuznetsov SA, 2013, J TISSUE ENG REGEN M, V7, P226, DOI 10.1002/term.515
   Lebouvier A, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0036 y
   Léotot J, 2015, CELL TRANSPLANT, V24, P1945, DOI 10.3727/096368914X685276
   Leotot J, 2013, ACTA BIOMATER, V9, P6630, DOI 10.1016/j.actbio.2013.02.003
   Lienemann PS, 2012, ADV DRUG DELIVER REV, V64, P1078, DOI 10.1016/j.addr.2012.03.010
   Lin CY, 2010, BIOMATERIALS, V31, P3222, DOI 10.1016/j.biomaterials.2010.01.030
   Ponte AL, 2007, STEM CELLS, V25, P1737, DOI 10.1634/stemcells.2007 0054
   Mankani MH, 2007, EXP HEMATOL, V35, P995, DOI 10.1016/j.exphem.2007.01.051
   Mankani MH, 2001, BIOTECHNOL BIOENG, V72, P96, DOI 10.1002/1097 0290(20010105)72:1<96::AID BIT13>3.0.CO;2 A
   Marcacci M, 2007, TISSUE ENG, V13, P947, DOI 10.1089/ten.2006.0271
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Murphy MB, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.94
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   O'Brien FJ, 2005, BIOMATERIALS, V26, P433, DOI 10.1016/j.biomaterials.2004.02.052
   Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Quarto R, 2001, NEW ENGL J MED, V344, P385, DOI 10.1056/NEJM200102013440516
   Seebach C, 2010, INJURY, V41, P731, DOI 10.1016/j.injury.2010.02.017
   Shinohara K, 2011, J ORTHOP RES, V29, P1064, DOI 10.1002/jor.21374
   Shiwaku Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132903
   Tasso R, 2013, STEM CELLS DEV, V22, P3178, DOI 10.1089/scd.2013.0313
   Tasso R, 2010, BIOMATERIALS, V31, P2121, DOI 10.1016/j.biomaterials.2009.11.064
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Viateau V, 2016, J TISSUE ENG REGEN M, V10, pE177, DOI 10.1002/term.1782
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   YAO KL, 1994, J BONE MINER RES, V9, P231
NR 53
TC 69
Z9 69
U1 1
U2 34
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD SEP 1
PY 2017
VL 59
BP 94
EP 107
DI 10.1016/j.actbio.2017.06.018
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA FE4JD
UT WOS:000408179300009
PM 28636926
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Kim, DS
   Lee, SY
   Lee, JH
   Bae, YC
   Jung, JS
AF Kim, Da Sol
   Lee, Sun Young
   Lee, Jung Hee
   Bae, Yong Chan
   Jung, Jin Sup
TI MicroRNA 103a 3p controls proliferation and osteogenic differentiation
   of human adipose tissue derived stromal cells
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID LUNG CANCER CELLS; STEM CELLS; OSTEOBLAST DIFFERENTIATION;
   COLORECTAL CANCER; BONE FORMATION; IN VITRO; EXPRESSION; MICRORNAS;
   CDK6; CARCINOMA
AB The elucidation of the molecular mechanisms underlying the differentiation and proliferation of human adipose tissue derived stromal cells (hADSCs) represents a critical step in the development of hADSCs based cellular therapies. To examine the role of the microRNA 103a 3p (miR 103a 3p) in hADSCs functions, miR 103a 3p mimics were transfected into hADSCs in order to overexpress miR 103a 3p. Osteogenic differentiation was induced for 14 days in an osetogenic differentiation medium and assessed by using an Alizarin Red S stain. The regulation of the expression of CDK6 (cyclin dependent kinase 6), a predicted target of miR 103a 3p, was determined by western blot, real time PCR and luciferase reporter assays. Overexpression of miR 103a 3p inhibited the proliferation and osteogenic differentiation of hADSCs. In addition, it downregulated protein and mRNA levels of predicted target of miR 103a 3p (CDK6 and DICER1). In contrast, inhibition of miR 103a 3p with 2' O methyl antisense RNA increased the proliferation and osteogenic differentiation of hADSCs. The luciferase reporter activity of the construct containing the miR 103a 3p target site within the CDK6 and DICER1 3' untranslated regions was lower in miR 103a 3p transfected hADSCs than in control miRNA transfected hADSCs. RNA interference mediated downregulation of CDK6 and DICER1 in hADSCs inhibited their proliferation and osteogenic differentiation. The results of the current study indicate that miR 103a 3p regulates the osteogenic differentiation of hADSCs and proliferation of hADSCs by direct targeting of CDK6 and DICER1 partly. These findings further elucidate the molecular mechanisms governing the differentiation and proliferation of hADSCs.
C1 [Kim, Da Sol; Lee, Sun Young; Lee, Jung Hee; Jung, Jin Sup] Pusan Natl Univ, Sch Med, Dept Physiol, Yangsan, South Korea.
   [Bae, Yong Chan] Pusan Natl Univ, Sch Med, Dept Plast Surg, Pusan 609735, South Korea.
C3 Pusan National University; Pusan National University Hospital; Pusan
   National University; Pusan National University Hospital
RP Jung, JS (通讯作者)，Pusan Natl Univ, Sch Med, Dept Physiol, Yangsan Si 626870, Gyeongsangnam D, South Korea.
EM jsjung@pusan.ac.kr
FU National Research Foundation of Korea (NRF)   Ministry of Science, ICT
   and Future Planning [NRF 2012M3A9B4028558]
FX This research was supported by the National Research Foundation of Korea
   (NRF) funded by the Ministry of Science, ICT and Future Planning
   (NRF 2012M3A9B4028558).
CR Ahmed FE, 2013, CANCER GENOM PROTEOM, V10, P93
   Annibali D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040269
   Bai Y, 2013, INT J ONCOL, V42, P1317, DOI 10.3892/ijo.2013.1831
   Boren T, 2008, GYNECOL ONCOL, V110, P206, DOI 10.1016/j.ygyno.2008.03.023
   Cairo S, 2010, P NATL ACAD SCI USA, V107, P20471, DOI 10.1073/pnas.1009009107
   Chakraborty C, 2013, CURR DRUG TARGETS, V14, P1110, DOI 10.2174/13894501113149990182
   Chen L, 2014, STEM CELLS, V32, P902, DOI 10.1002/stem.1615
   Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002
   Feinberg Gorenshtein G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078713
   Gaur T, 2010, DEV BIOL, V340, P10, DOI 10.1016/j.ydbio.2010.01.008
   Geng L, 2014, INT J MOL SCI, V15, P8458, DOI 10.3390/ijms15058458
   Grossel MJ, 2006, CELL CYCLE, V5, P266, DOI 10.4161/cc.5.3.2385
   Hong Z, 2014, BMB REP, V47, P500, DOI 10.5483/BMBRep.2014.47.9.212
   Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kaneshiro S, 2014, J BONE MINER METAB, V32, P378, DOI 10.1007/s00774 013 0514 1
   Kanji MS, 2013, DIABETES, V62, P1602, DOI 10.2337/db12 0841
   Kikkawa N, 2014, INT J ONCOL, V44, P2085, DOI 10.3892/ijo.2014.2349
   Kim JH, 2013, STEM CELLS, V31, P2848, DOI 10.1002/stem.1591
   Kim YJ, 2007, CELL PHYSIOL BIOCHEM, V20, P867, DOI 10.1159/000110447
   Kim YJ, 2009, STEM CELLS, V27, P3093, DOI 10.1002/stem.235
   Kim YJ, 2009, J BONE MINER RES, V24, P816, DOI 10.1359/JBMR.081230
   Liao YL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012976
   Liu T, 2012, ACTA BIOCH BIOPH SIN, V44, P197, DOI 10.1093/abbs/gmr127
   Liu X, 2013, ONCOL REP, V29, P1415, DOI 10.3892/or.2013.2263
   Luense LJ, 2009, TRENDS ENDOCRIN MET, V20, P265, DOI 10.1016/j.tem.2009.05.001
   MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460 2075.1992.tb05360.x
   Moro T, 2005, J CELL PHYSIOL, V204, P927, DOI 10.1002/jcp.20350
   Oskowitz AZ, 2011, INT J BIOCHEM CELL B, V43, P1563, DOI 10.1016/j.biocel.2011.07.005
   Scheffer AR, 2014, WORLD J UROL, V32, P353, DOI 10.1007/s00345 012 1010 2
   Schober A, 2014, NAT MED, V20, P368, DOI 10.1038/nm.3487
   Shi XE, 2014, INT J MOL SCI, V15, P8526, DOI 10.3390/ijms15058526
   Shin KK, 2014, CELL PHYSIOL BIOCHEM, V33, P758, DOI 10.1159/000358650
   Suzuki D, 2012, CALCIFIED TISSUE INT, V91, P88, DOI 10.1007/s00223 012 9614 5
   Trajkovski M, 2011, NATURE, V474, P649, DOI 10.1038/nature10112
   Ukai T, 2012, J ORTHOP RES, V30, P1915, DOI 10.1002/jor.22157
   Wang HY, 2014, CLIN CHEM, V60, P773, DOI 10.1373/clinchem.2013.214213
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wilfred BR, 2007, MOL GENET METAB, V91, P209, DOI 10.1016/j.ymgme.2007.03.011
   Zhang YH, 2013, GENET TEST MOL BIOMA, V17, P625, DOI 10.1089/gtmb.2013.0055
   Zhu XL, 2013, FEBS LETT, V587, P73, DOI 10.1016/j.febslet.2012.11.004
   Zhu XX, 2012, ONCOL REP, V28, P218, DOI 10.3892/or.2012.1770
   Zuk P., 2013, ISRN STEM CELLS, V2013, P1, DOI DOI 10.1155/2013/713959
NR 43
TC 23
Z9 26
U1 0
U2 17
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1226 3613
EI 2092 6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD JUL
PY 2015
VL 47
AR e172
DI 10.1038/emm.2015.39
PG 10
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA CN7DV
UT WOS:000358595100002
PM 26160438
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Diao, TY
   Wang, L
   Che, CT
   Wong, MS
AF Zhang, Yan
   Diao, Teng Yue
   Wang, Liang
   Che, Chun Tao
   Wong, Man Sau
TI Protective effects of water fraction of Fructus Ligustri Lucidi extract
   against hypercalciuria and trabecular bone deterioration in
   experimentally type 1 diabetic mice
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Fructus Ligustri Lucidi; Calcium; Diabetes; Trabecular bone;
   Calcium sensing receptor; Kidney
ID CALCIUM SENSING RECEPTOR; ETHANOL EXTRACT; OVARIECTOMIZED RATS;
   GENE EXPRESSION; FEMALE RATS; BALANCE; IMPROVEMENT; STREPTOZOTOCIN;
   METABOLISM; ABSORPTION
AB Ethnopharmacological relevance: Fructus Ligustri Lucidi (FLL), the fruit of Ligustrum lucidum Ait, is a commonly prescribed herb to nourish the endocrine and renal systems and to strengthen the bones in Traditional Chinese Medicine. This study was aimed to determine the effects of water fraction of FLL ethanol extract (WF EE) on urinary calcium excretion and trabecular bone properties in type 1 diabetic mice.
   Materials and methods: The DBA/2J mice with type 1 diabetes induced by streptozotocin injection were orally administered with WF EE. After 6 weeks of treatment, the level of biomarkers, including serum calcium, parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF 23) and urine calcium, was measured. Micro CT was performed to detect trabecular bone properties of the proximal tibial metaphysis. The expression of active calcium transporting proteins in kidney and duodenum was determined by RT PCR, immunoblotting and immunostaining.
   Results: Type 1 diabetes induced hypercalciuria and trabecular bone deterioration. The WF EE could significantly inhibit hypercalciuria and ameliorate the micro structure of trabecular bone as well as increase serum PTH and FGF 23 levels in type 1 diabetic mice. The gene expressions of active calcium transporting proteins in duodenum were up regulated, and the gene and protein expressions of calcium sensing receptor (CaSR) in kidney were dramatically down regulated in diabetic mice in response to the treatment with WF EE.
   Conclusions: The present study demonstrated the protective effects of the water fraction of Fructus Ligustri Lucidi ethanol extract against hypercalciuria and trabecular bone deterioration in experimentally type 1 diabetic mice, and the underlying mechanism may be attributed to its regulations on duodenal calcium transporting proteins and renal CaSR. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Zhang, Yan] Bright Dairy Res Inst, State Key Lab Dairy Biotechnol, Shanghai 200436, Peoples R China.
   [Zhang, Yan; Diao, Teng Yue] Univ Shanghai Sci & Technol, Ctr Syst Biomed Sci, Shanghai 200093, Peoples R China.
   [Wang, Liang] Chinese Peoples Liberat Army, Hosp 309, Dept Orthopaed, Beijing 100091, Peoples R China.
   [Che, Chun Tao] Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA.
   [Wong, Man Sau] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China.
C3 University of Shanghai for Science & Technology; University of Illinois
   System; University of Illinois Chicago; University of Illinois Chicago
   Hospital; Hong Kong Polytechnic University
RP Zhang, Y (通讯作者)，Univ Shanghai Sci & Technol, Ctr Syst Biomed Sci, 445 Mail Box,Jungong Rd 516, Shanghai 200093, Peoples R China.
EM medicineyan@aliyun.com
RI Che, Chun Tao/AAV 2795 2020; Wong, Man Sau/F 2059 2015
OI Wong, Man Sau/0000 0002 0729 8618
FU Open Project Program of State Key Laboratory of Dairy Biotechnology;
   Bright Dairy Food Co. Ltd. [SKLDB2012 008]; National Natural Science
   Foundation of China [81202894]; China Postdoctoral Science Foundation
   [2012M511115]
FX This work was sponsored by the Open Project Program of State Key
   Laboratory of Dairy Biotechnology, Bright Dairy & Food Co. Ltd., (No.
   SKLDB2012 008), National Natural Science Foundation of China (No.
   81202894) and China Postdoctoral Science Foundation funded project
   (2012M511115).
CR Ba JM, 2004, CELL CALCIUM, V35, P229, DOI 10.1016/j.ceca.2003.10.016
   Carnevale V, 2004, DIABETES METAB RES, V20, P196, DOI 10.1002/dmrr.449
   Cheng SX, 2012, AM J PHYSIOL GASTR L, V303, pG60, DOI 10.1152/ajpgi.00425.2011
   David V, 2013, ENDOCRINOLOGY, V154, P4469, DOI 10.1210/en.2013 1627
   Diao TY, 2014, J BONE MINER METAB, V32, P261, DOI 10.1007/s00774 013 0500 7
   Dong XL, 2014, MENOPAUSE, V21, P286, DOI 10.1097/GME.0b013e3182966fd3
   Dong XL, 2012, BRIT J NUTR, V108, P92, DOI 10.1017/S0007114511005186
   Dong XL, 2010, MENOPAUSE, V17, P1174, DOI 10.1097/gme.0b013e3181e39a2b
   Drake MT, 2012, J CLIN ENDOCR METAB, V97, P1861, DOI 10.1210/jc.2011 3058
   Feng X, 2014, CALCIFIED TISSUE INT, V94, P433, DOI 10.1007/s00223 013 9825 4
   Hoenderop JGJ, 2005, PHYSIOL REV, V85, P373, DOI 10.1152/physrev.00003.2004
   Li G, 2010, PHYTOTHER RES, V24, P571, DOI 10.1002/ptr.2987
   Isidro ML, 2010, CURR DIABETES REV, V6, P144, DOI 10.2174/157339910791162970
   Lyu Y., 2013, J BONE MINERAL METAB
   Montagnani A, 2011, AGING CLIN EXP RES, V23, P84, DOI 10.1007/BF03351073
   Nijenhuis T, 2005, PFLUG ARCH EUR J PHY, V451, P181, DOI 10.1007/s00424 005 1430 6
   RASKIN P, 1978, CLIN ENDOCRINOL, V9, P329, DOI 10.1111/j.1365 2265.1978.tb02218.x
   Reyes Garcia R, 2014, DIABETES CARE, V37, pE89, DOI 10.2337/dc13 2235
   Riccardi D, 2012, J AM SOC NEPHROL, V23, P1766, DOI 10.1681/ASN.2012090955
   Riccardi D, 2010, AM J PHYSIOL RENAL, V298, pF485, DOI 10.1152/ajprenal.00608.2009
   Siu WS, 2013, PHYTOTHER RES, V27, P484, DOI 10.1002/ptr.4743
   Sun Y, 2008, PHYTOTHER RES, V22, P267, DOI 10.1002/ptr.2291
   Zanchi C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070775
   Zhang H, 2008, MATURITAS, V61, P334, DOI 10.1016/j.maturitas.2008.09.023
   Zhang Y, 2008, OSTEOPOROSIS INT, V19, P235, DOI 10.1007/s00198 007 0442 9
   Zhang Y, 2006, BIOL PHARM BULL, V29, P291, DOI 10.1248/bpb.29.291
   Zhang Y, 2011, OSTEOPOROSIS INT, V22, P1781, DOI 10.1007/s00198 010 1404 1
   Zhang Y, 2008, BRIT J NUTR, V99, P494, DOI 10.1017/S0007114507801589
   Zhang Y, 2008, MENOPAUSE, V15, P558, DOI 10.1097/gme.0b013e31814fad27
   Zhang Y, 2014, J RENIN ANGIO ALDO S, V15, P218, DOI 10.1177/1470320312471229
NR 30
TC 23
Z9 30
U1 1
U2 23
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD DEC 2
PY 2014
VL 158
BP 239
EP 245
DI 10.1016/j.jep.2014.10.025
PN A
PG 7
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA AZ2TG
UT WOS:000348084600022
PM 25456432
DA 2025 08 17
ER

PT J
AU Ota, Y
   Niiro, H
   Ota, S
   Ueki, N
   Tsuzuki, H
   Nakayama, T
   Mishima, K
   Higashioka, K
   Jabbarzadeh Tabrizi, S
   Mitoma, H
   Akahoshi, M
   Arinobu, Y
   Kukita, A
   Yamada, H
   Tsukamoto, H
   Akashi, K
AF Ota, Yuri
   Niiro, Hiroaki
   Ota, Shun ichiro
   Ueki, Naoko
   Tsuzuki, Hirofumi
   Nakayama, Tsuyoshi
   Mishima, Koji
   Higashioka, Kazuhiko
   Jabbarzadeh Tabrizi, Siamak
   Mitoma, Hiroki
   Akahoshi, Mitsuteru
   Arinobu, Yojiro
   Kukita, Akiko
   Yamada, Hisakata
   Tsukamoto, Hiroshi
   Akashi, Koichi
TI Generation mechanism of RANKL<SUP>+</SUP> effector memory B cells:
   relevance to the pathogenesis of rheumatoid arthritis
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE B cells; RANKL; Rheumatoid arthritis
ID GAMMA INDUCIBLE PROTEIN 10; JOINT DAMAGE; RECEPTOR ACTIVATOR; T CELLS;
   OSTEOCLASTOGENESIS; EXPRESSION; DIFFERENTIATION; LYMPHOCYTE; CYTOKINES;
   TH1
AB Background: The efficacy of B cell depleting therapies for rheumatoid arthritis underscores antibody independent functions of effector B cells such as cognate T B interactions and production of pro inflammatory cytokines. Receptor activator of nuclear factor kappa B ligand (RANKL) is a key cytokine involved in bone destruction and is highly expressed in synovial fluid B cells in patients with rheumatoid arthritis. In this study we sought to clarify the generation mechanism of RANKL(+) effector B cells and their impacts on osteoclast differentiation.
   Methods: Peripheral blood and synovial fluid B cells from healthy controls and patients with rheumatoid arthritis were isolated using cell sorter. mRNA expression of RANKL, osteoprotegerin, tumor necrosis factor (TNF) alpha, and Blimp 1 was analyzed by quantitative real time polymerase chain reaction. Levels of RANKL, CD80, CD86, and CXCR3 were analyzed using flow cytometry. Functional analysis of osteoclastogenesis was carried out in the co culture system using macrophage RAW264 reporter cells.
   Results: RANKL expression was accentuated in CD80(+)CD86(+) B cells, a highly activated B cell subset more abundantly observed in patients with rheumatoid arthritis. Upon activation via B cell receptor and CD40, switched memory B cells predominantly expressed RANKL, which was further augmented by interferon gamma (IFN gamma) but suppressed by interleukin 21. Strikingly, IFN gamma also enhanced TNF alpha expression, while it strongly suppressed osteoprotegerin expression in B cells. IFN gamma increased the generation of CXCR3(+)RANKL(+) effector B cells, mimicking the synovial B cell phenotype in patients with rheumatoid arthritis. Finally, RANKL(+) effector B cells in concert with TNF alpha facilitated osteoclast differentiation in vitro.
   Conclusions: Our current findings have shed light on the generation mechanism of pathogenic RANKL(+) effector B cells that would be an ideal therapeutic target for rheumatoid arthritis in the future.
C1 [Niiro, Hiroaki] Kyushu Univ Hosp, Clin Educ Ctr, Higashi Ku, 3 1 1 Maidashi, Fukuoka 8128582, Japan.
   [Ota, Yuri; Ota, Shun ichiro; Ueki, Naoko; Tsuzuki, Hirofumi; Nakayama, Tsuyoshi; Mishima, Koji; Higashioka, Kazuhiko; Jabbarzadeh Tabrizi, Siamak; Mitoma, Hiroki; Akahoshi, Mitsuteru; Arinobu, Yojiro; Tsukamoto, Hiroshi; Akashi, Koichi] Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Higashi Ku, 3 1 1 Maidashi, Fukuoka 8128582, Japan.
   [Kukita, Akiko] Saga Univ, Fac Med, Dept Microbiol, 5 1 1 Nabeshima, Saga 8498501, Japan.
   [Yamada, Hisakata] Kyushu Univ, Med Inst Bioregulat, Div Host Def, Higashi Ku, 3 1 1 Maidashi, Fukuoka 8128582, Japan.
C3 Kyushu University; Kyushu University; Saga University; Kyushu University
RP Niiro, H (通讯作者)，Kyushu Univ Hosp, Clin Educ Ctr, Higashi Ku, 3 1 1 Maidashi, Fukuoka 8128582, Japan.
EM hniiro@med.kyushu u.ac.jp
RI NIIRO, HIROAKI/KMX 5542 2024
FU Ministry of Education, Culture, Sports, Science, and Technology in
   Japan; Grants in Aid for Scientific Research [15K09528] Funding Source:
   KAKEN
FX The plasmid p CS2 Venus was kindly provided by Dr. A. Miyawaki (Brain
   Science Institute, RIKEN, Japan). This work was supported in part by a
   Grant in Aid from the Ministry of Education, Culture, Sports, Science,
   and Technology in Japan (HN and KA).
CR Aletaha D, 2013, ANN RHEUM DIS, V72, P7, DOI 10.1136/annrheumdis 2012 201970
   Berglund LJ, 2013, BLOOD, V122, P3940, DOI 10.1182/blood 2013 06 506865
   Braun T, 2012, CURR OSTEOPOROS REP, V10, P101, DOI 10.1007/s11914 012 0104 5
   Braun T, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3380
   Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389
   Catrina AI, 2014, NAT REV RHEUMATOL, V10, P645, DOI 10.1038/nrrheum.2014.115
   Danks L, 2016, ANN RHEUM DIS, V75, P1187, DOI 10.1136/annrheumdis 2014 207137
   Fillatreau S, 2002, NAT IMMUNOL, V3, P944, DOI 10.1038/ni833
   Finnegan A, 2012, AUTOIMMUNITY, V45, P353, DOI 10.3109/08916934.2012.665526
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Han XZ, 2006, J IMMUNOL, V176, P625, DOI 10.4049/jimmunol.176.1.625
   Hanaoka R, 2003, ARTHRITIS RES THER, V5, pR74, DOI 10.1186/ar616
   James EA, 2014, ARTHRITIS RHEUMATOL, V66, P1712, DOI 10.1002/art.38637
   Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180
   Keystone E, 2009, ANN RHEUM DIS, V68, P216, DOI 10.1136/ard.2007.085787
   Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529 0131(200105)44:5<1003::AID ANR179>3.3.CO;2 R
   Kukita A, 2011, ARTHRITIS RHEUM US, V63, P2744, DOI 10.1002/art.30455
   Kwak HB, 2008, ARTHRITIS RHEUM US, V58, P1332, DOI 10.1002/art.23372
   Lee EY, 2013, AUTOIMMUN REV, V12, P554, DOI 10.1016/j.autrev.2012.10.001
   Lee EY, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3385
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Meednu N, 2016, ARTHRITIS RHEUMATOL, V68, P805, DOI 10.1002/art.39489
   Nanki T, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2823
   Niiro H, 2012, BLOOD, V119, P2263, DOI 10.1182/blood 2011 04 351965
   Oliver Bell J, 2015, MOL ORAL MICROBIOL, V30, P160, DOI 10.1111/omi.12082
   Tabrizi SJ, 2009, J IMMUNOL, V182, P1490, DOI 10.4049/jimmunol.182.3.1490
   Tak PP, 2011, ANN RHEUM DIS, V70, P39, DOI 10.1136/ard.2010.137703
   Tak PP, 2000, ARTHRITIS RHEUM US, V43, P2619, DOI 10.1002/1529 0131(200012)43:12<2619::AID ANR1>3.0.CO;2 V
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Watanabe T, 2004, J ENDOCRINOL, V180, P193, DOI 10.1677/joe.0.1800193
   Yamada H, 2008, ANN RHEUM DIS, V67, P1299, DOI 10.1136/ard.2007.080341
   Yellin M, 2012, ARTHRITIS RHEUM US, V64, P1730, DOI 10.1002/art.34330
   Yeo L, 2015, ANN RHEUM DIS, V74, P928, DOI 10.1136/annrheumdis 2013 204116
   Yeo L, 2011, ANN RHEUM DIS, V70, P2022, DOI 10.1136/ard.2011.153312
   Yun TJ, 1998, J IMMUNOL, V161, P6113
NR 37
TC 50
Z9 54
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD MAR 16
PY 2016
VL 18
AR 67
DI 10.1186/s13075 016 0957 6
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA DG5KA
UT WOS:000372115600001
PM 26980135
OA Green Published, Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Stuermer, EK
   Komrakova, M
   Sehmisch, S
   Tezval, M
   Dullin, C
   Schaefer, N
   Hallecker, J
   Stuermer, KM
AF Stuermer, Ewa K.
   Komrakova, Marina
   Sehmisch, Stephan
   Tezval, Mohammad
   Dullin, Christian
   Schaefer, Nadine
   Hallecker, Jan
   Stuermer, Klaus M.
TI Whole body vibration during fracture healing intensifies the effects of
   estradiol and raloxifene in estrogen deficient rats
SO BONE
LA English
DT Article
DE Whole body vibration; Osteoporosis; Fracture healing; Estrogens;
   Raloxifene
ID RECEPTOR ALPHA; MECHANICAL STRAIN; OVARIECTOMIZED RAT; CANCELLOUS BONE;
   FREQUENCY; OSTEOPOROSIS; STRENGTH; SIGNALS; WEIGHT; MUSCLE
AB Current osteoporosis therapies aim to delay bone destruction and have additional anabolic effects. While they have demonstrated some positive effects on bone healing, more progress is needed in this area. This study used the well known osteoporotic agents estrogen (E) and raloxifene (R) in conjunction with biomechanical whole body vibration (WBV) at a frequency of 70 Hz twice daily for six weeks to stimulate bone healing. Eighty four 3 month old female Sprague Dawley rats (12 per group) were bilaterally ovariectomized to develop osteopenia within eight weeks. Osteotomy of the metaphyseal tibiae was performed and fracture healing was then studied using mechanical tests, histomorphometry, computed tomography (mu CT), and gene analysis. We found that E and R improved the structure of osteopenic bones as did WBV alone, although significant levels for WBV were seldom reached. Combination treatments significantly enhanced stiffness (R + WBV; p < 0.05), endosteal bone (R + WBV; p < 0.01), and trabecular density (E + WBV; p < 0.05, R + WBV; p < 0.05). In addition, the expression of osteoclast specific Trap was significantly reduced after treatment with E, R, or their combination with WBV (p < 0.01). The effects were additive and not inhibitory, leading us to conclude that the combined applications of WBV with E or R may improve the healing of osteopenic bones. The therapies studied are all currently approved for human use, suggesting ready applicability to clinical practice. To better understand the effects of WBV on osteopenic bones, the ideal vibration regime will require further study. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Stuermer, Ewa K.; Schaefer, Nadine] Univ Witten Herdecke, Sch Med, Fac Hlth, Inst Res Operat Med, Cologne, Germany.
   [Stuermer, Ewa K.; Komrakova, Marina; Sehmisch, Stephan; Tezval, Mohammad; Hallecker, Jan; Stuermer, Klaus M.] Univ Gottingen, Dept Trauma Surg & Reconstruct Surg, D 37075 Gottingen, Germany.
   [Dullin, Christian] Univ Gottingen, Dept Radiol, D 37075 Gottingen, Germany.
C3 Witten Herdecke University; University of Gottingen; University of
   Gottingen
RP Stuermer, EK (通讯作者)，Univ Witten Herdecke, Sch Med, Fac Hlth, Inst Res Operat Med, Cologne, Germany.
EM ewa.stuermer@uni.wh.de
OI Dullin, Christian/0000 0003 4297 8077; Komrakova,
   Marina/0000 0002 6225 4378
FU German Research Foundation (DFG) [STU 478/3 1]
FX The present study was supported by the German Research Foundation (DFG,
   STU 478/3 1). The authors are grateful to their colleagues R.
   Castro Machguth and A. Witt for their assistance.
CR Abercromby AFJ, 2007, MED SCI SPORT EXER, V39, P1794, DOI 10.1249/mss.0b013e3181238a0f
   Bashir A, 2005, STEROIDS, V70, P847, DOI 10.1016/j.steroids.2005.04.011
   Beil FT, 2010, J TRAUMA, V69, P1259, DOI 10.1097/TA.0b013e3181c4544d
   Bogaerts A, 2007, J GERONTOL A BIOL, V62, P630, DOI 10.1093/gerona/62.6.630
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brouwers JEM, 2010, J ORTHOP RES, V28, P62, DOI 10.1002/jor.20951
   Cao YP, 2002, J BONE MINER RES, V17, P2237, DOI 10.1359/jbmr.2002.17.12.2237
   Damien E, 1998, J BONE MINER RES, V13, P1275, DOI 10.1359/jbmr.1998.13.8.1275
   Damien E, 2000, J BONE MINER RES, V15, P2169, DOI 10.1359/jbmr.2000.15.11.2169
   Florencio Silva R, 2013, CLIMACTERIC, V16, P709, DOI 10.3109/13697137.2013.769096
   GALLAGHER A, 1993, ENDOCRINOLOGY, V133, P2787, DOI 10.1210/en.133.6.2787
   GOODSHIP AE, 1985, J BONE JOINT SURG BR, V67, P650, DOI 10.1302/0301 620X.67B4.4030869
   Jessop HL, 2001, J BONE MINER RES, V16, P1045, DOI 10.1359/jbmr.2001.16.6.1045
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Judex S, 2007, J BIOMECH, V40, P1333, DOI 10.1016/j.jbiomech.2006.05.014
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Kolios L, 2010, CALCIFIED TISSUE INT, V86, P23, DOI 10.1007/s00223 009 9318 7
   Komrakova M, 2013, CALCIFIED TISSUE INT, V92, P509, DOI 10.1007/s00223 013 9706 x
   Lanyon L, 2004, J ENDOCRINOL, V182, P183, DOI 10.1677/joe.0.1820183
   LEE TC, 1994, CVGIP GRAPH MODEL IM, V56, P462, DOI 10.1006/cgip.1994.1042
   Leung KS, 2009, J ORTHOP RES, V27, P458, DOI 10.1002/jor.20753
   Merriman H, 2009, J GERIATR PHYS THER, V32, P134, DOI 10.1519/00139143 200932030 00009
   Nordlund MM, 2007, SCAND J MED SCI SPOR, V17, P12, DOI 10.1111/j.1600 0838.2006.00586.x
   O'Donnell S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005326.pub2
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pietrogrande L, 2011, AGING CLIN EXP RES, V23, P65
   Remedios A, 1999, VET CLIN N AM SMALL, V29, P1029, DOI 10.1016/S0195 5616(99)50101 0
   Roush K, 2011, AM J NURS, V111, P26, DOI 10.1097/01.NAJ.0000403358.44058.f7
   Roush K, 2011, AM J NURS, V111, P38, DOI 10.1097/01.NAJ.0000398539.52283.55
   Rubin C, 2002, BONE, V30, P445, DOI 10.1016/S8756 3282(01)00689 5
   Rubin C, 2006, AGE AGEING, V35, P32, DOI 10.1093/ageing/afl082
   SARMIENTO A, 1977, J BONE JOINT SURG AM, V59, P369, DOI 10.2106/00004623 197759030 00014
   Sehmisch S, 2009, OSTEOPOROSIS INT, V20, P1999, DOI 10.1007/s00198 009 0892 3
   Seidel EJ, 2012, PHYS MED REHAB KUROR, V22, pA63
   Slatkovska L, 2010, OSTEOPOROSIS INT, V21, P1969, DOI 10.1007/s00198 010 1228 z
   Spiro AS, 2013, J BONE MINER METAB, V31, P629, DOI 10.1007/s00774 013 0461 x
   Stuermer EK, 2013, OSTEOLOGIE, V22, P290
   Stuermer EK, 2010, LANGENBECK ARCH SURG, V395, P163, DOI 10.1007/s00423 008 0436 x
   Stuermer EK, 2010, CALCIFIED TISSUE INT, V87, P168, DOI 10.1007/s00223 010 9381 0
   Stürmer EK, 2006, J BONE MINER RES, V21, P89, DOI 10.1359/JBMR.050913
   Sunters A, 2010, J BIOL CHEM, V285, P8743, DOI 10.1074/jbc.M109.027086
   Surazynski A, 2003, INT J MOL MED, V12, P803
   Tezval M, 2011, CALCIFIED TISSUE INT, V88, P33, DOI 10.1007/s00223 010 9423 7
   van den Berg F., 1999, ANGEWANDTE PHYSL BIN
   van der Jagt OP, 2012, J BONE MINER METAB, V30, P40, DOI 10.1007/s00774 011 0293 5
   Webb JCJ, 2000, CURR ORTHOPAED, V14, P457, DOI 10.1054/cuor.2000.0145
   Wu SH, 2012, INT J MED SCI, V9, P801, DOI 10.7150/ijms.4838
   Wysocki A, 2011, ANN INTERN MED, V155, P680, DOI 10.7326/0003 4819 155 10 201111150 00006
   YAMAGISHI M, 1955, J BONE JOINT SURG AM, V37, P1035, DOI 10.2106/00004623 195537050 00013
   Yamaji T, 2001, J Orthop Sci, V6, P571, DOI 10.1007/s007760100014
   Zaman G, 2006, J BONE MINER RES, V21, P1297, DOI 10.1359/JBMR.060504
NR 51
TC 28
Z9 34
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2014
VL 64
BP 187
EP 194
DI 10.1016/j.bone.2014.04.008
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AI6UC
UT WOS:000337011500026
PM 24735975
DA 2025 08 17
ER

PT J
AU Mohamedbhai, H
   Mamdani, S
   Compeyrot Lacassagne, S
   Saeed, N
AF Mohamedbhai, Hussein
   Mamdani, Sajida
   Compeyrot Lacassagne, Sandrine
   Saeed, Nadeem
TI Collaborative approach to paediatric chronic non bacterial osteomyelitis
   of the mandible: Great Ormond Street Hospital case series
SO BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY
LA English
DT Article
DE Chronic non bacterial osteomyelitis (CNO); Chronic recurrent multifocal
   osteomyelitis (CRMO); Sclerosing osteomyelitis
ID DIFFUSE SCLEROSING OSTEOMYELITIS; PATHOGENESIS
AB This paper outlines a 10  patient case series of chronic non bacterial osteomyelitis (CNO) of the mandible at a tertiary paediatric hospital in the UK. Our fi ndings highlight the homogeneous presenting signs and symptoms of an intermittently painful, swollen angle and ramus of the mandible. We present the typical laboratory investigative fi ndings (normal in fl ammatory markers) and imaging appearances (sclerosis and periosteal oedema). Our paper outlines an investigation protocol, including recommendations for extraoral bone biopsies and systemic magnetic resonance imaging (MRI). We explain the importance of multidisciplinary care, with combined care by rheumatologists and infectious disease specialists. Finally we demonstrate the ef fi cacy of our treatment algorithm for oral non steroidal anti in fl ammatory drugs (NSAIDs), and in those cases refractory to NSAIDS, intravenous pamidronate. This paper provides a useful addition to the literature by informing OMF surgeons of this rare condition and given the clinical equipoise in treatments, it can hopefully guide clinicians in an investigation pathway and management protocol. (c) 2024 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
C1 [Mohamedbhai, Hussein; Mamdani, Sajida; Compeyrot Lacassagne, Sandrine; Saeed, Nadeem] Great Ormond St Hosp Sick Children, Great Ormond St, London WC1N 3JH, England.
C3 University of London; University College London; Great Ormond Street
   Hospital for Children NHS Foundation Trust
RP Mohamedbhai, H (通讯作者)，Great Ormond St Hosp Sick Children, Great Ormond St, London WC1N 3JH, England.
EM hussein.mohamedbhai@nhs.net
CR Baltensperger M, 2004, J CRANIO MAXILL SURG, V32, P43, DOI 10.1016/j.jcms.2003.07.008
   Ferguson PJ, 2012, CURR RHEUMATOL REP, V14, DOI 10.1007/s11926 012 0239 5
   Gaal A, 2020, PEDIATR RHEUMATOL, V18, DOI 10.1186/s12969 019 0384 8
   Heggie AA, 2003, INT J ORAL MAX SURG, V32, P459, DOI 10.1054/ijom.2003.0417
   Hofmann SR, 2017, CURR OSTEOPOROS REP, V15, P542, DOI 10.1007/s11914 017 0405 9
   KAHN MF, 1994, ORAL SURG ORAL MED O, V78, P594, DOI 10.1016/0030 4220(94)90170 8
   Lentrodt S, 2007, J ORAL MAXIL SURG, V65, P186, DOI 10.1016/j.joms.2005.11.106
   Murray GM, 2021, LANCET RHEUMATOL, V3, pE90, DOI 10.1016/S2665 9913(20)30414 8
   Otsuka K, 1999, J ORAL MAXIL SURG, V57, P1013, DOI 10.1016/S0278 2391(99)90028 9
   Padwa BL, 2016, J ORAL MAXIL SURG, V74, P2393, DOI 10.1016/j.joms.2016.05.021
   Renapurkar S, 2016, J ORAL MAXIL SURG, V74, P1368, DOI 10.1016/j.joms.2016.01.027
   Schnabel A, 2022, CLIN IMMUNOL, V238, DOI 10.1016/j.clim.2022.109018
   van de Meent MM, 2020, BRIT J ORAL MAX SURG, V58, P385, DOI 10.1016/j.bjoms.2020.01.012
   Zeus M, 2019, ANN RHEUM DIS, V78, P546, DOI 10.1136/annrheumdis 2019 eular.7875
   Zhao DYD, 2021, J TRANSL AUTOIMMUN, V4, DOI 10.1016/j.jtauto.2021.100095
   Zhao Y, 2018, ARTHRIT CARE RES, V70, P1228, DOI 10.1002/acr.23462
NR 16
TC 1
Z9 1
U1 1
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0266 4356
EI 1532 1940
J9 BRIT J ORAL MAX SURG
JI Br. J. Oral Maxillofac. Surg.
PD MAY
PY 2024
VL 62
IS 4
BP 373
EP 377
DI 10.1016/j.bjoms.2023.12.022
EA MAY 2024
PG 5
WC Dentistry, Oral Surgery & Medicine; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Surgery
GA TN2C6
UT WOS:001241867500001
PM 38599930
DA 2025 08 17
ER

PT J
AU Wang, KY
   Gu, Y
   Liao, YH
   Bang, SS
   Donnelly, CR
   Chen, O
   Tao, XS
   Mirando, AJ
   Hilton, MJ
   Ji, RR
AF Wang, Kaiyuan
   Gu, Yun
   Liao, Yihan
   Bang, Sangsu
   Donnelly, Christopher R.
   Chen, Ouyang
   Tao, Xueshu
   Mirando, Anthony J.
   Hilton, Matthew J.
   Ji, Ru Rong
TI PD 1 blockade inhibits osteoclast formation and murine bone cancer pain
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID QUALITY OF LIFE; SQUAMOUS CELL CARCINOMA; RECEPTOR; ANTIBODY; SAFETY;
   CONTRIBUTES; MECHANISMS; EXPRESSION; MANAGEMENT; NIVOLUMAB
AB Emerging immune therapy, such as with the anti programmed cell death 1 (anti PD 1) monoclonal antibody nivolumab, has shown efficacy in tumor suppression. Patients with terminal cancer suffer from cancer pain as a result of bone metastasis and bone destruction, but how PD 1 blockade affects bone cancer pain remains unknown. Here, we report that mice lacking Pdcd1 (Pd1( / )) demonstrated remarkable protection against bone destruction induced by femoral inoculation of Lewis lung cancer cells. Compared with WT mice, Pd1( / ) mice exhibited increased baseline pain sensitivity, but the development of bone cancer pain was compromised in Pd1( / ) mice. Consistently, these beneficial effects in Pd1( / ) mice were recapitulated by repeated i.v. applications of nivolumab in WT mice, even though nivolumab initially increased mechanical and thermal pain. Notably, PD 1 deficiency or nivolumab treatment inhibited osteoclastogenesis without altering tumor burden. PD L1 and CCL2 are upregulated within the local tumor microenvironment, and PD L1 promoted RANKL induced osteoclastogenesis through JNK activation and CCL2 secretion. Bone cancer upregulated CCR2 in primary sensory neurons, and CCR2 antagonism effectively reduced bone cancer pain. Our findings suggest that, despite a transient increase in pain sensitivity following each treatment, anti PD 1 immunotherapy could produce long term benefits in preventing bone destruction and alleviating bone cancer pain by suppressing osteoclastogenesis.
C1 [Wang, Kaiyuan; Gu, Yun; Bang, Sangsu; Donnelly, Christopher R.; Chen, Ouyang; Tao, Xueshu; Ji, Ru Rong] Duke Univ, Med Ctr, Dept Anesthesiol, Ctr Translat Pain Med, Durham, NC 27710 USA.
   [Liao, Yihan] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA.
   [Liao, Yihan; Mirando, Anthony J.; Hilton, Matthew J.] Duke Univ, Med Ctr, Dept Orthoped Surg, Durham, NC USA.
   [Hilton, Matthew J.; Ji, Ru Rong] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.
   [Ji, Ru Rong] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA.
C3 Duke University; Duke University; Duke University; Duke University; Duke
   University
RP Wang, KY; Ji, RR (通讯作者)，MSRB 3,3 Genome Court, Durham, NC 27710 USA.
EM kaiyuan.wang@duke.edu; ru rong.ji@duke.edu
RI ; Chen, Ouyang/ABD 4017 2020; Ji, Ru Rong/L 7070 2017; bang,
   sangsu/U 4313 2017; Bang, Sangsu/AAN 7238 2020
OI Liao, Yihan/0000 0002 2622 9036; Ji, Ru Rong/0000 0002 9355 3688;
   Donnelly, Christopher/0000 0003 2487 8881; Chen,
   Ouyang/0000 0003 1387 9408; Hilton, Matthew/0000 0003 3165 267X; Wang,
   Kaiyuan/0000 0002 8374 6427; bang, sangsu/0000 0002 9092 0075; 
FU Duke University funds; NIH [R01 DE17794 13, R01AR063071]
FX This study was supported by Duke University funds and NIH grants R01
   DE17794 13 (to RRJ) and R01AR063071 (to MJH).
CR Abbadie C, 2009, BRAIN RES REV, V60, P125, DOI 10.1016/j.brainresrev.2008.12.002
   Ansari J, 2018, CASE REP IMMUNOL, V2018, DOI 10.1155/2018/1623957
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Brahmer JR, 2017, LANCET ONCOL, V18, P1600, DOI 10.1016/S1470 2045(17)30690 3
   Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694
   Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609
   Chen G, 2018, NATURE, V560, P382, DOI 10.1038/s41586 018 0392 8
   Chen G, 2017, NAT NEUROSCI, V20, P917, DOI 10.1038/nn.4571
   Chen G, 2015, J CLIN INVEST, V125, P3226, DOI 10.1172/JCI80883
   Cleeland CS, 2005, ANN ONCOL, V16, P972, DOI 10.1093/annonc/mdi191
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Costa L, 2008, SUPPORT CARE CANCER, V16, P879, DOI 10.1007/s00520 008 0418 0
   Costantini M, 2009, ANN ONCOL, V20, P729, DOI 10.1093/annonc/mdn700
   Cui WG, 2007, P NATL ACAD SCI USA, V104, P14436, DOI 10.1073/pnas.0702811104
   Falk S, 2014, J CLIN ONCOL, V32, P1647, DOI 10.1200/JCO.2013.51.7219
   Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252
   Fornetti J, 2018, J BONE MINER RES, V33, P2099, DOI 10.1002/jbmr.3618
   Gao YJ, 2009, EXP NEUROL, V219, P146, DOI 10.1016/j.expneurol.2009.05.006
   Gao YJ, 2009, J NEUROSCI, V29, P4096, DOI 10.1523/JNEUROSCI.3623 08.2009
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Harrington KJ, 2017, LANCET ONCOL, V18, P1104, DOI 10.1016/S1470 2045(17)30421 7
   Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999
   Ji RR, 2013, PAIN, V154, pS10, DOI 10.1016/j.pain.2013.06.022
   Ji RR, 2009, BRAIN RES REV, V60, P135, DOI 10.1016/j.brainresrev.2008.12.011
   Jin HT, 2011, CURR TOP MICROBIOL, V350, P17, DOI 10.1007/82_2010_116
   Khan UA, 2016, J CELL BIOCHEM, V117, P382, DOI 10.1002/jcb.25282
   Kim MS, 2005, J BIOL CHEM, V280, P16163, DOI 10.1074/jbc.M412713200
   Li HY, 2017, CANCER IMMUNOL RES, V5, P767, DOI 10.1158/2326 6066.CIR 16 0365
   Lin H, 2018, J CLIN INVEST, V128, P805, DOI 10.1172/JCI96113
   Mantyh P, 2013, PAIN, V154, pS54, DOI 10.1016/j.pain.2013.07.044
   Mantyh PW, 2002, NAT REV CANCER, V2, P201, DOI 10.1038/nrc747
   Martín Fernández M, 2017, TRANSL ONCOL, V10, P255, DOI 10.1016/j.tranon.2016.12.001
   Minas K, 2006, CRIT REV IMMUNOL, V26, P213, DOI 10.1615/CritRevImmunol.v26.i3.20
   Nagahama K, 2004, BONE, V35, P1059, DOI 10.1016/j.bone.2004.06.018
   Napolitano M, 2019, CASE REP ONCOL, V12, P709, DOI 10.1159/000502858
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Schmidt BL, 2014, NEUROSCIENTIST, V20, P546, DOI 10.1177/1073858414525828
   Schug SA, 2015, EXPERT OPIN PHARMACO, V16, P5, DOI 10.1517/14656566.2015.980723
   Siva A, 2008, CANCER IMMUNOL IMMUN, V57, P987, DOI 10.1007/s00262 007 0429 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   van den Beuken van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   von Moos R, 2017, EUR J CANCER, V71, P80, DOI 10.1016/j.ejca.2016.10.021
   Wang CC, 2016, J CLIN INVEST, V126, P1471, DOI 10.1172/JCI80672
   Wang ZL, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw6471
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Xie RG, 2018, NEUROSCI BULL, V34, P13, DOI 10.1007/s12264 017 0106 5
   Yang Y, 2015, J NEUROSCI, V35, P7950, DOI 10.1523/JNEUROSCI.5250 14.2015
   Zhao CZ, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad9055
NR 49
TC 136
Z9 152
U1 3
U2 26
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUL 1
PY 2020
VL 130
IS 7
BP 3603
EP 3620
DI 10.1172/JCI133334
PG 18
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA OC8QV
UT WOS:000579422200001
PM 32484460
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Tseng, PJ
   Yan, MT
AF Tseng, Po Jung
   Yan, Ming Tso
TI Acute Diffuse Renal Tubulopathy in a Patient With Lung Cancer: A Case
   Report
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE drug therapy; acute kidney injury; comorbidity; creatinine;
   electrolytes; pembrolizumab; immune checkpoint inhibitors; case report
ID IMMUNE CHECKPOINT INHIBITORS; ACUTE INTERSTITIAL NEPHRITIS; ADVERSE
   EVENTS; THERAPY
AB Immune checkpoints inhibitors (ICPIs), as either a frontline or adjuvant therapy, showed favorable outcomes among diverse malignancies. Immune related adverse events (IRAEs) are increasingly encountered, but the kidneys are rarely affected. A 67 year old man with stage IV squamous cell carcinoma of the lung presented with acute kidney injury and hypercalcemia secondary to bone metastasis. After an aggressive saline infusion and subcutaneous denosumab 60mg administration, his renal function and serum calcium level were recovered on day 4. Due to his intolerance to chemotherapy, immunotherapy with a monoclonal antibody targeting programmed cell death protein 1 (PD 1), pembrolizumab 2mg/kg, was used on day 4. On day 11, polyuria, non albumin dominant proteinuria, and severe deficiencies of electrolytes (potassium 2.5 mmol/L, calcium 5.5 mg/dL, magnesium 1.3 mg/dL, and phosphate 1.5 mg/dL) along with concomitant renal wasting were developed acutely. Except for postponing the next pembrolizumab, prednisolone at 1 mg/kg/day was given on day 13. On day 27, his polyuria subsided and urine protein loss resolved. Serum levels of potassium, phosphate, calcium, and magnesium all returned within the reference range. This case highlighted that renal IRAEs, even though uncommon, could be severe and potentially life threatening if left unrecognized and untreated. Early recognition of renal IRAEs and prompt withdrawal of ICPIs may result in lower renal morbidity.
C1 [Tseng, Po Jung; Yan, Ming Tso] Fu Jen Catholic Univ, Cathay Gen Hosp, Sch Med, Dept Med,Div Nephrol, Taipei, Taiwan.
   [Yan, Ming Tso] Natl Def Med Ctr, Grad Inst Med Sci, Taipei, Taiwan.
C3 Cathay General Hospital; Fu Jen Catholic University; National Defense
   Medical University
RP Yan, MT (通讯作者)，Fu Jen Catholic Univ, Cathay Gen Hosp, Sch Med, Dept Med,Div Nephrol, Taipei, Taiwan.; Yan, MT (通讯作者)，Natl Def Med Ctr, Grad Inst Med Sci, Taipei, Taiwan.
EM qqhaibear@gmail.com
CR Baxi S, 2018, BMJ BRIT MED J, V360, DOI 10.1136/bmj.k793
   Cortazar FB, 2020, J AM SOC NEPHROL, V31, P435, DOI 10.1681/ASN.2019070676
   Cortazar FB, 2016, KIDNEY INT, V90, P638, DOI 10.1016/j.kint.2016.04.008
   Darvin P, 2018, EXP MOL MED, V50, DOI 10.1038/s12276 018 0191 1
   Dave V, 2015, AM J NEPHROL, V41, P129, DOI 10.1159/000380960
   Dyck L, 2017, EUR J IMMUNOL, V47, P765, DOI 10.1002/eji.201646875
   El Bitar S, 2018, CASE REP ONCOL MED, V2018, DOI 10.1155/2018/8408015
   Herrmann SM, 2020, KIDNEY INT REP, V5, P1139, DOI 10.1016/j.ekir.2020.04.018
   Izzedine H, 2019, CLIN KIDNEY J, V12, P81, DOI 10.1093/ckj/sfy100
   Li B, 2019, CURR MED CHEM, V26, P3009, DOI 10.2174/0929867324666170804143706
   Liede A, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1480301
   Megapanou E, 2020, DRUG SAFETY, V43, P197, DOI 10.1007/s40264 019 00888 1
   Michot JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/j.ejca.2015.11.016
   Murakami N, 2016, CLIN KIDNEY J, V9, P411, DOI 10.1093/ckj/sfw024
   Perazella MA, 2018, J AM SOC NEPHROL, V29, P2039, DOI 10.1681/ASN.2018050488
   Perazella MA, 2016, KIDNEY INT, V90, P474, DOI 10.1016/j.kint.2016.05.024
   Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMra1703481, 10.1056/NEJMc1801663]
   Ramos Casals M, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 0160 6
   Shirali AC, 2016, AM J KIDNEY DIS, V68, P287, DOI 10.1053/j.ajkd.2016.02.057
   Suzuki T, 2017, NUTRIENTS, V9, DOI 10.3390/nu9080871
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Wanchoo R, 2017, AM J NEPHROL, V45, P160, DOI 10.1159/000455014
NR 22
TC 2
Z9 2
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 2296 858X
J9 FRONT MED LAUSANNE
JI Front. Med.
PD OCT 4
PY 2021
VL 8
AR 742489
DI 10.3389/fmed.2021.742489
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA WV3RU
UT WOS:000717158000001
PM 34671624
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, XP
   Xie, C
   Lin, LJ
AF Wang, Xiaoping
   Xie, Chao
   Lin, Lijun
TI Development and validation of a cuproptosis related lncRNA model
   correlated to the cancer associated fibroblasts enable the prediction
   prognosis of patients with osteosarcoma
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Osteosarcoma; lncRNA; Cancer associated fibroblasts; Cuproptosis;
   Prognoses
ID CELL DEATH
AB Background: Osteosarcoma is the most common primary pediatric and adolescent bone malignancy. An imbal ance in copper homeostasis caused by copper ion accumulation could increase intracellular toxicity and regulate cancer cell growth. This study aimed to identify long non coding RNAs (lncRNAs) associated with cuproptosis to predict prognosis and target drug use to improve patient survival.Methods: RNA sequencing and relevant clinical information of ninety three osteosarcoma patients were obtained from the TARGET database. We then identified thirteen prognostic cuproptosis related lncRNAs(CRLncs) using coexpression and univariate Cox analyses. The prognostic risk model with three CRLncs was constructed using the least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analysis. Patients were divided into low risk and high risk subgroups using the median risk score. The tumor microenvironment (TME) and immune status of identified subgroups were analyzed using ESTIMATE, CIBERSORT, MCP counter, xCELL, EPIC, and ssGSEA analyses. Functional analyses were conducted to elucidate the underlying mecha nisms, including GO, KEGG, GSVA, and GSEA analyses. Also, the relationships between the model, tumor im munity, and drug sensitivity were explored. Lastly, the expression level of ZNF37BP, AL353759.1, and AC005034.5 was validated in vitro.Results: We constructed a model containing three CRLncs (ZNF37BP, AL353759.1, and AC005034.5) and vali dated its excellent prognostic and predictive power. The AUC curves for 1 year, 3 year, and 5 year survival probabilities were 0.76, 0.84, and 0.89, respectively. Patients in the high risk group had a shorter overall survival (OS) time than those in the low risk. The stroma score and cancer associated fibroblasts (CAFs) were significantly higher in the low risk group. Immune cells such as T cells CD4 naive, T cells gamma delta, NK cells resting, dendritic cells resting, and mast cells activated were significantly upregulated in the high risk group. Based on functional analyses, the PI3K Akt pathway was identified as a critical metabolic pathway in osteosarcoma. Additionally, we obtained three potentially effective drugs for OS: erlotinib, MP470, and WH 4 023 targeting the PI3K Akt pathway. The expression level of ZNF37BP was significantly elevated in OS cell lines than in normal osteoblast hFOB1.19 cells, and that of ATP7A, LIPT1, AL353759.1, and AC005034.5 were decreased consider ably in OS cell lines.Conclusion: Cuproptosis related lncRNAs are correlated with the CAFs of osteosarcoma, and this could serve as a foundation for OS survival prediction and treatment.
C1 [Wang, Xiaoping; Xie, Chao; Lin, Lijun] Southern Med Univ, Dept Joint & Orthoped, Zhujiang Hosp, 253 GongYeDaDao Rd, Guangzhou 510282, Peoples R China.
   [Wang, Xiaoping] Southern Med Univ, Affiliated Xiaolan Hosp, Xiaolan Peoples Hosp, Dept Orthoped, Guangzhou, Peoples R China.
C3 Southern Medical University   China; Southern Medical University   China
RP Lin, LJ (通讯作者)，Southern Med Univ, Dept Joint & Orthoped, Zhujiang Hosp, 253 GongYeDaDao Rd, Guangzhou 510282, Peoples R China.
EM gost1@smu.edu.cn
RI WANG, Xiaoping/AAG 7348 2019; Xie, Chao/JWA 0080 2024
FU Natural Science Founda tion of Guangdong Guangdong Province; 
   [2022A1515010293]
FX Acknowledgement This study is financially supported by the Natural
   Science Founda tion of Guangdong Guangdong Province (Grant no.
   2022A1515010293) .
CR Akiyama T, 2008, MOL CANCER THER, V7, P3461, DOI 10.1158/1535 7163.MCT 08 0530
   Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591 018 0014 x
   Blockhuys S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040871
   Brunson Jason Cory, 2020, Journal of open source software, V5, DOI 10.21105/joss.02017
   Cangkrama M, 2022, CANCER RES, V82, P3701, DOI 10.1158/0008 5472.CAN 22 0162
   Chen CL, 2021, CANCER LETT, V500, P1, DOI 10.1016/j.canlet.2020.12.024
   Chen X, 2017, EUR J PHARMACOL, V815, P147, DOI 10.1016/j.ejphar.2017.09.003
   Chen XM, 2019, NAT REV DRUG DISCOV, V18, P99, DOI 10.1038/s41573 018 0004 1
   Corre I, 2020, CELLS BASEL, V9, DOI 10.3390/cells9040976
   Fernandes I, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020813
   Geeleher P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107468
   Ghafouri Fard S, 2021, BIOMED PHARMACOTHER, V135, DOI 10.1016/j.biopha.2021.111217
   Gill J, 2021, NAT REV CLIN ONCOL, V18, P609, DOI 10.1038/s41571 021 00519 8
   Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591 018 0136 1
   Li SR, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 01014 x
   Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004
   Liu H, 2022, TRANSL PEDIATR, V11, P1182, DOI 10.21037/tp 22 253
   Mao XQ, 2021, MOL CANCER, V20, DOI 10.1186/s12943 021 01428 1
   Park D, 2020, CELL, V181, P486, DOI 10.1016/j.cell.2020.03.013
   Park EG, 2022, BRIEF BIOINFORM, V23, DOI 10.1093/bib/bbab504
   Qian H, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.673827
   Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568 019 0238 1
   Tsvetkov P, 2022, SCIENCE, V375, P1254, DOI 10.1126/science.abf0529
   Ugel S, 2021, ANNU REV PATHOL MECH, V16, P93, DOI 10.1146/annurev pathmechdis 012418 013058
   Veiga N, 2021, MOLECULES, V26, DOI 10.3390/molecules26216520
   Wang GW, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.917935
   Yang CF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21196985
   Zhang YM, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.880459
   Zhang YM, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.780780
   Zhao X, 2021, BIOMED ENG ONLINE, V20, DOI 10.1186/s12938 021 00860 0
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
NR 31
TC 17
Z9 17
U1 1
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD FEB
PY 2023
VL 38
AR 100463
DI 10.1016/j.jbo.2022.100463
EA DEC 2022
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 7A4VI
UT WOS:000898455400001
PM 36569351
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liu, YL
   Nie, X
   Wu, YH
   Lin, LF
   Liao, Q
   Li, JJ
   Lee, SMY
   Li, H
   Zhang, JM
AF Liu, Yuling
   Nie, Xin
   Wu, Yihan
   Lin, Longfei
   Liao, Qian
   Li, Jingjing
   Lee, Simon Ming Yuen
   Li, Hui
   Zhang, Jinming
TI Carrier Free Gambogic Acid Dimer Self Assembly Nanomedicines for
   Rheumatoid Arthritis Treatment
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE gambogic acid dimers; carrier  free nanoparticles; self  assembly;
   rheumatoid arthritis; macrophage; osteoclast
ID MICELLES; SAFE
AB Introduction: The insufficient targeting delivery of therapeutic agents greatly impeded the treatment outcomes of rheumatoid arthritis (RA). Despite the recognized therapeutic advantages of gambogic acid (GBA) in inflammatory diseases, its high delivery efficiency to inflammatory site still limits its clinical application. Self assembly of drug dimers into carrier free nanoparticles (NPs) has become a straightforward and attractive approach to develop nanomedicines for RA treatment. Herein, homodimers of GBA were designed to form the carrier free NPs by self assembly for RA treatment. Methods: The synthetic gambogic acid dimers (GBA2) were self assembled into NPs using a one step solvent evaporation method. The size distribution, morphology, drug loading efficiency (DLE) and storage stability were evaluated. A molecular dynamic simulation was conducted to gain further insight into the self assembly mechanisms of GBA2/NPs. Besides, we investigated the cytotoxicity, apoptosis and cellular uptake profiles of GBA2/NPs in macrophages and osteoclasts. Finally, the specific biodistribution on the ankles of adjuvant induced arthritis (AIA) mice, and the anti RA efficacy of the AIA rat model were assessed. Results: GBA2/NPs exhibited the uniform spherical structure, possessing excellent colloidal stability, high self assembly stability, high drug loading and low hemolytic activity. Comparing with GBA, GBA2/NPs showed higher cytotoxicity, cellular uptake and apoptosis rate against osteoclasts. In addition, GBA2/NPs exhibited much higher accumulation in ankle joints in vivo. As expected, the systematic administration of GBA2/NPs resulted in the greater alleviation of arthritic symptoms, cartilage protection, and inflammation, notably the reduced systemic toxicity compared to free GBA. Conclusion: GBA2/NPs formed GBA dimers exhibited the superior accumulation in the inflamed joint and anti RA activity, potentially attributing to the similar extravasation through leaky vasculature and subsequent inflammatory cell mediated sequestration ("ELVIS") effects in inflamed joint and the enhanced cellular uptake in macrophages and osteoclasts. Our findings provide substantial evidence that self assembly of GBA2/NPs would be a promising therapeutic alternative for RA treatment.
C1 [Liu, Yuling; Lin, Longfei; Li, Hui] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China.
   [Nie, Xin; Wu, Yihan; Zhang, Jinming] Chengdu Univ Tradit Chinese Med, Pharm Sch, State Key Lab Southwestern Chinese Med Resources, Chengdu, Peoples R China.
   [Nie, Xin; Lee, Simon Ming Yuen] Univ Macau, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.
   [Nie, Xin; Lee, Simon Ming Yuen] Univ Macau, Inst Chinese Med Sci, Macau, Peoples R China.
   [Li, Jingjing] Hong Kong Polytech Univ, Fac Hlth & Social Sci, Dept Rehabil Sci, Hong Kong, Peoples R China.
   [Li, Hui] China Acad Chinese Med Sci, Inst Tradit Chinese Med Hlth Ind, Nanchang, Peoples R China.
   [Zhang, Jinming] Chengdu Univ Tradit Chinese Med, State Key Lab Southwestern Chinese Med Resource, Chengdu, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Institute of Chinese Materia
   Medica, CACMS; Chengdu University of Traditional Chinese Medicine;
   University of Macau; University of Macau; Hong Kong Polytechnic
   University; China Academy of Chinese Medical Sciences; Chengdu
   University of Traditional Chinese Medicine
RP Li, H (通讯作者)，China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China.; Zhang, JM (通讯作者)，Chengdu Univ Tradit Chinese Med, State Key Lab Southwestern Chinese Med Resource, Chengdu, Peoples R China.
EM lihuiyiren@163.com; cdutcmzjm@126.com
RI Liu, Yuling/HGV 1868 2022; lee, Simon Ming Yuen/NOE 8462 2025; Lee,
   Simon/NOE 8462 2025
OI lee, Simon Ming Yuen/0000 0002 3966 6569; Li,
   Jingjing/0000 0003 3636 0537; 
FU Scientific and Technological Innovation Project of the China Academy of
   Chinese Medical Sciences [CI2021A04305, CI2021B014]; Innovation Team and
   Talents Cultivation Program of the National Administration of
   Traditional Chinese Medicine [ZYYCXTD D 202209]; National Natural
   Science Foundation of China [81803743]; Fundamental Research Funds for
   the Central Public Welfare Research Institutes [ZZ13 YQ  041, ZXKT21013]
FX Acknowledgments This study was supported by the Scientific and
   Technological Innovation Project of the China Academy of Chinese Medical
   Sciences (CI2021A04305, CI2021B014) , Innovation Team and Talents
   Cultivation Program of the National Administration of Traditional
   Chinese Medicine (No: ZYYCXTD D 202209) , the National Natural Science
   Foundation of China (81803743) , and Fundamental Research Funds for the
   Central Public Welfare Research Institutes (ZZ13 YQ  041, ZXKT21013) .
CR Cascao R, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/195327
   Deng CF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22454 z
   Dickerson TJ, 2012, J AUTOIMMUN, V39, P369, DOI 10.1016/j.jaut.2012.06.001
   Fu SW, 2022, ACTA PHARM SIN B, V12, P92, DOI 10.1016/j.apsb.2021.08.012
   Hatami E, 2020, BBA REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188381
   Karaosmanoglu S, 2021, J CONTROL RELEASE, V329, P805, DOI 10.1016/j.jconrel.2020.10.014
   Li CH, 2017, J CONTROL RELEASE, V246, P133, DOI 10.1016/j.jconrel.2016.12.027
   Li JX, 2023, INT J PHARMACEUT, V632, DOI 10.1016/j.ijpharm.2022.122572
   Li SM, 2020, J CONTROL RELEASE, V326, P510, DOI 10.1016/j.jconrel.2020.07.036
   Liu R, 2023, CHINESE CHEM LETT, V34, DOI 10.1016/j.cclet.2022.05.032
   Liu Y, 2021, ACTA BIOMATER, V121, P541, DOI 10.1016/j.actbio.2020.11.027
   Liu YL, 2020, INT J NANOMED, V15, P10385, DOI 10.2147/IJN.S277645
   Nguyen A, 2022, BIOMATER SCI UK, V10, P3122, DOI 10.1039/d1bm01947c
   Nguyen A, 2020, BIOMATER SCI UK, V8, P4626, DOI 10.1039/d0bm00711k
   Rahman M, 2017, J PHARM PHARMACOL, V69, P1, DOI 10.1111/jphp.12661
   Shi JF, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00934 0
   Siouti E, 2019, BIOCHEM PHARMACOL, V165, P152, DOI 10.1016/j.bcp.2019.03.029
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140 6736(16)30173 8
   Szentpétery A, 2017, AUTOIMMUN REV, V16, P313, DOI 10.1016/j.autrev.2017.01.014
   Wang L, 2021, J ETHNOPHARMACOL, V273, DOI 10.1016/j.jep.2021.113988
   Wang Q, 2021, ACTA PHARM SIN B, V11, P1158, DOI 10.1016/j.apsb.2021.03.013
   Wang Q, 2017, BIOMATERIALS, V122, P10, DOI 10.1016/j.biomaterials.2017.01.008
   Wang X, 2021, THERANOSTICS, V11, P7896, DOI 10.7150/thno.61337
   Wu XD, 2017, MOL MED REP, V16, P7112, DOI 10.3892/mmr.2017.7459
   Xu Y, 2020, NANO LETT, V20, P2558, DOI 10.1021/acs.nanolett.9b05340
   Zhang XB, 2020, MED RES REV, V40, P1754, DOI 10.1002/med.21669
   Zhang YJ, 2021, MATER ADV, V2, P4733, DOI 10.1039/d1ma00285f
   Zhao JK, 2021, CHINESE CHEM LETT, V32, P66, DOI 10.1016/j.cclet.2020.11.048
NR 28
TC 6
Z9 6
U1 6
U2 32
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2023
VL 18
BP 5457
EP 5472
DI 10.2147/IJN.S422096
PG 16
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA T0WT1
UT WOS:001075285300001
PM 37771407
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Dahiya, A
   Chaudhari, VS
   Kushram, P
   Bose, S
AF Dahiya, Aditi
   Chaudhari, Vishal Sharad
   Kushram, Priya
   Bose, Susmita
TI 3D Printed SiO2 Tricalcium Phosphate Scaffolds Loaded with
   Carvacrol Nanoparticles for Bone Tissue Engineering Application
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IN VITRO; CONTROLLED RELEASE; ESCHERICHIA COLI; OXIDATIVE STRESS;
   DRUG RELEASE; THYMOL; DIFFERENTIATION; MECHANISMS; POLYMERS; CELLS
AB Bone damage resulting from trauma or aging poses challenges in clinical settings that need to be addressed using bone tissue engineering (BTE). Carvacrol (CA) possesses anti inflammatory, anticancer, and antibacterial properties. Limited solubility and physicochemical stability restrict its biological activity, requiring a stable carrier system for delivery. Here, we investigate the utilization of a three dimensional printed (3DP) SiO2 doped tricalcium phosphate (TCP) scaffold functionalized with carvacrol loaded lipid nanoparticles (CA LNPs) to improve bone health. It exhibits a negative surface charge with an entrapment efficiency of similar to 97% and size similar to 129 nm with polydispersity index (PDI) and zeta potential values of 0.18 and  16 mV, respectively. CA LNPs exhibit higher and long term release over 35 days. The CA LNP loaded SiO2 doped TCP scaffold demonstrates improved antibacterial properties against Staphylococcus aureus and Pseudomonas aeruginosa by >90% reduction in bacterial growth. Functionalized scaffolds result in 3 fold decrease and 2 fold increase in osteosarcoma and osteoblast cell viability, respectively. These findings highlight the therapeutic potential of the CA LNP loaded SiO2 doped TCP scaffold for bone defect treatment.
C1 [Dahiya, Aditi; Bose, Susmita] Washington State Univ, Dept Chem, Pullman, WA 99164 USA.
   [Dahiya, Aditi; Chaudhari, Vishal Sharad; Kushram, Priya; Bose, Susmita] Washington State Univ, Sch Mech & Mat Engn, WM Keck Biomed Mat Res Lab, Pullman, WA 99164 USA.
C3 Washington State University; Washington State University
RP Bose, S (通讯作者)，Washington State Univ, Dept Chem, Pullman, WA 99164 USA.; Bose, S (通讯作者)，Washington State Univ, Sch Mech & Mat Engn, WM Keck Biomed Mat Res Lab, Pullman, WA 99164 USA.
EM sbose@wsu.edu
RI Chaudhari, Vishal/JBS 7647 2023
OI Dahiya, Aditi/0000 0001 5009 3952
FU , National Institute of Arthritis and Musculoskeletal and Skin Diseases
   [R01 DE029204 01]; National Institute of Dental and Craniofacial
   Research (NIDCR) of the NIH [R56 AR066361 06]; National Institute of
   Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National
   Institutes of Health, USA; National Institutes of Health
FX The authors wish to express their gratitude for the funding received
   from The National Institute of Dental and Craniofacial Research (NIDCR)
   of the NIH, Grant Number R01 DE029204 01 (PI: Bose) and the National
   Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of
   the National Institutes of Health, USA, under Award Number R56
   AR066361 06 (PI: Bose). The views expressed in this content are those of
   the authors alone and may not reflect the official stance of the
   National Institutes of Health. We acknowledge the Franceschi Microscopy
   & Imaging Center at Washington State University for their assistance.
CR Adepu S, 2021, MOLECULES, V26, DOI 10.3390/molecules26195905
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Bergmann C, 2010, J EUR CERAM SOC, V30, P2563, DOI 10.1016/j.jeurceramsoc.2010.04.037
   Bhattacharjee A, 2022, MATER DESIGN, V221, DOI 10.1016/j.matdes.2022.110903
   Bidyarani N, 2020, J NANOPART RES, V22, DOI 10.1007/s11051 020 05037 9
   Bilgili E, 2016, PHARM DEV TECHNOL, V21, P499, DOI 10.3109/10837450.2015.1022788
   Bose S, 2020, TRENDS BIOTECHNOL, V38, P404, DOI 10.1016/j.tibtech.2019.11.005
   Bose S, 2019, MAT SCI ENG C MATER, V105, DOI 10.1016/j.msec.2019.110096
   Bose S, 2018, MATER TODAY CHEM, V8, P110, DOI 10.1016/j.mtchem.2018.03.005
   Bose S, 2018, ANN BIOMED ENG, V46, P1241, DOI 10.1007/s10439 018 2040 8
   Bose S, 2013, MATER TODAY, V16, P496, DOI 10.1016/j.mattod.2013.11.017
   Bose S, 2012, TRENDS BIOTECHNOL, V30, P546, DOI 10.1016/j.tibtech.2012.07.005
   Bose S, 2011, BONE, V48, P1282, DOI 10.1016/j.bone.2011.03.685
   Burt SA, 2005, J FOOD PROTECT, V68, P919, DOI 10.4315/0362 028X 68.5.919
   Cacciatore FA, 2022, FOOD MICROBIOL, V108, DOI 10.1016/j.fm.2022.104116
   Carvalho FO, 2020, N S ARCH PHARMACOL, V393, P445, DOI 10.1007/s00210 019 01731 1
   Chauhan AK, 2014, RES MICROBIOL, V165, P559, DOI 10.1016/j.resmic.2014.07.001
   Cicalau GIP, 2021, MOLECULES, V26, DOI 10.3390/molecules26226899
   Cieza A, 2020, LANCET, V396, P2006, DOI 10.1016/S0140 6736(20)32340 0
   Dang M, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0025 8
   Davies JE, 2007, BIOMATERIALS, V28, P5058, DOI 10.1016/j.biomaterials.2007.07.049
   Do AV, 2015, ADV HEALTHC MATER, V4, P1742, DOI 10.1002/adhm.201500168
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Eliaz N, 2017, MATERIALS, V10, DOI 10.3390/ma10040334
   Fielding G, 2013, ACTA BIOMATER, V9, P9137, DOI 10.1016/j.actbio.2013.07.009
   Fielding GA, 2012, DENT MATER, V28, P113, DOI 10.1016/j.dental.2011.09.010
   Fu Y, 2010, EXPERT OPIN DRUG DEL, V7, P429, DOI 10.1517/17425241003602259
   Garvey MI, 2011, INT J ANTIMICROB AG, V37, P145, DOI 10.1016/j.ijantimicag.2010.10.027
   Gavanji S, 2023, CHEM BIODIVERS, V20, DOI 10.1002/cbdv.202201098
   Gellatly SL, 2013, PATHOG DIS, V67, P159, DOI 10.1111/2049 632X.12033
   Götz W, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11030117
   Griffin SG, 1999, FLAVOUR FRAG J, V14, P322, DOI [10.1002/(SICI)1099 1026(199909/10)14:5<322::AID FFJ837>3.0.CO;2 4, 10.1002/(SICI)1099 1026(199909/10)14:5<322::AID FFJ837>3.3.CO;2 W]
   Heimann R. B., 2015, BIOCERAMIC COATINGS
   Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004
   Hollister SJ, 2005, NAT MATER, V4, P518, DOI 10.1038/nmat1421
   Ikada Y, 2006, J R SOC INTERFACE, V3, P589, DOI 10.1098/rsif.2006.0124
   Kachur K, 2020, CRIT REV FOOD SCI, V60, P3042, DOI 10.1080/10408398.2019.1675585
   Keawchaoon L, 2011, COLLOID SURFACE B, V84, P163, DOI 10.1016/j.colsurfb.2010.12.031
   Knowles JR, 2005, APPL ENVIRON MICROB, V71, P797, DOI 10.1128/AEM.71.2.797 803.2005
   Koski C, 2020, J MATER CHEM B, V8, P2048, DOI 10.1039/c9tb01462d
   Krause U, 2011, METHODS MOL BIOL, V698, P215, DOI 10.1007/978 1 60761 999 4_17
   Laird NZ, 2021, ADV DRUG DELIVER REV, V174, P613, DOI 10.1016/j.addr.2021.05.009
   Landa P, 2009, ARCH PHARM RES, V32, P75, DOI 10.1007/s12272 009 1120 6
   Lee JH, 2015, CHEM ENG SCI, V125, P75, DOI 10.1016/j.ces.2014.08.046
   LeGeros RZ, 2008, CHEM REV, V108, P4742, DOI 10.1021/cr800427g
   Loh QL, 2013, TISSUE ENG PART B RE, V19, P485, DOI [10.1089/ten.teb.2012.0437, 10.1089/ten.TEB.2012.0437]
   Lv YT, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.641130
   Ma PX, 2008, ADV DRUG DELIVER REV, V60, P184, DOI 10.1016/j.addr.2007.08.041
   Matluobi D, 2018, MICROVASC RES, V115, P20, DOI 10.1016/j.mvr.2017.08.003
   Mitchell MJ, 2021, NAT REV DRUG DISCOV, V20, P101, DOI 10.1038/s41573 020 0090 8
   Nazzaro F, 2013, PHARMACEUTICALS, V6, P1451, DOI 10.3390/ph6121451
   Ngo TD, 2018, COMPOS PART B ENG, V143, P172, DOI 10.1016/j.compositesb.2018.02.012
   Niaza KV, 2016, J PHYS CONF SER, V741, DOI 10.1088/1742 6596/741/1/012068
   Patra JK, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951 018 0392 8
   Pei RS, 2009, J FOOD SCI, V74, pM379, DOI 10.1111/j.1750 3841.2009.01287.x
   Pietak AM, 2007, BIOMATERIALS, V28, P4023, DOI 10.1016/j.biomaterials.2007.05.003
   Sahoo S, 2021, ADV MATER SCI ENG, V2021, DOI 10.1155/2021/1539230
   Sarkar N, 2020, ACTA BIOMATER, V114, P407, DOI 10.1016/j.actbio.2020.07.006
   Sarkar N, 2019, ACS APPL MATER INTER, V11, P17184, DOI 10.1021/acsami.9b01218
   Schröter L, 2020, ACTA BIOMATER, V117, P1, DOI 10.1016/j.actbio.2020.09.031
   Sivandzade F, 2019, BIO PROTOCOL, V9, DOI 10.21769/BioProtoc.3128
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Suntres ZE, 2015, CRIT REV FOOD SCI, V55, P304, DOI 10.1080/10408398.2011.653458
   van Alphen LB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045343
   Vu AA, 2022, ACS APPL BIO MATER, V5, P1120, DOI 10.1021/acsabm.1c01181
   Vu AA, 2021, ADDIT MANUF, V39, DOI 10.1016/j.addma.2021.101870
   Vu AA, 2020, ACS APPL MATER INTER, V12, P52383, DOI 10.1021/acsami.0c14993
   Wang WH, 2017, BIOACT MATER, V2, P224, DOI 10.1016/j.bioactmat.2017.05.007
   Xue WC, 2009, ACTA BIOMATER, V5, P1686, DOI 10.1016/j.actbio.2009.01.012
   Yang D, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.692474
   Zafar MJ, 2019, MATERIALS, V12, DOI 10.3390/ma12203361
   Zhang SO, 2022, ANTI CANCER AGENT ME, V22, P1714, DOI 10.2174/1871520621666210901111932
   Zhang XZ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 32868 y
   Zhou SD, 2011, BIOTECHNOL J, V6, P513, DOI 10.1002/biot.201000254
NR 74
TC 13
Z9 13
U1 5
U2 17
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD DEC 26
PY 2023
VL 67
IS 4
BP 2745
EP 2757
DI 10.1021/acs.jmedchem.3c01884
EA DEC 2023
PG 13
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA IO1Z1
UT WOS:001158869700001
PM 38146876
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Yao, N
   Chen, GC
   Lu, YY
   Xu, XM
   Zhao, CAX
   Huang, XJ
   Liu, WG
   Peng, S
   Wu, H
AF Yao Nan
   Chen Guocai
   Lu Yanyan
   Xu Xuemeng
   Zhao Chuanxi
   Huang Xuejun
   Liu Wengang
   Peng Sha
   Wu Huai
TI Bushen Qiangjin capsule (sic) inhibits the Wnt/β catenin pathway to
   ameliorate papain induced knee osteoarthritis in rats
SO JOURNAL OF TRADITIONAL CHINESE MEDICINE
LA English
DT Article
DE papain; osteoarthritis; knee; Wnt signaling pathway; cartilage; Bushen
   Qiangjin capsule
ID NF KAPPA B; CARTILAGE DEGRADATION; CHONDROCYTE APOPTOSIS; PROLIFERATION
AB OBJECTIVE: To evaluate the molecular mechanism underlying the beneficial effect of Bushen Qiangjin capsule ((sic), BSQJ), a Traditional Chinese Medicine, on knee osteoarthritis (KOA).
   METHODS: In the present study, 32 female Sprague Dawley rats were randomly divided into four groups: control, KOA, high dose BSQJ (H BSQJ), and low dose BSQJ (L BSQJ). After successfully establishing the KOA model by intra articular injection of papain, H BS QJ and L BSQJ groups were intragastrically administered 0.243 and 0.122 g/kg BSQJ, respectively, daily for 6 weeks. At the end of the experiment, knee articular cartilage tissues of rats were collected for evaluation by hematoxylin and eosin staining, Safranin O Fast Green staining, and terminal deoxynucleotidyl transferase mediated dUTP nick  end labeling assay. Serum interleukin 1 beta and tumor necrosis factor alpha levels of rats were detected with an enzyme linked immunosorbent assay method. Gene expression of Wnt 4, beta catenin, Frizzled 2, glycogen synthase kinase 3 beta (GSK 3 beta), cysteinyl aspartate specific proteinases 3 and 9 (caspases 3 and 9), collagen type. alpha 1 (Col2a1), and matrix metalloproteinases 1 and 13 (MMP 1 and MMP 3) of rat knee articular cartilage was quantified by reverse transcription quantitative polymerase chain reaction analysis. Wnt 4, beta catenin, Frizzled 2, GSK 3 beta, cleaved caspase 3, and cleaved caspase 9 protein expression in rat knee articular cartilage was determined by western blot analysis.
   RESULTS: BSQJ obviously reduced pathological damage and matrix degradation of articular cartilage in KOA rats. Compared with the KOA group, H BSQJ rats exhibited downregulated mRNA and protein expression of Wnt 4, beta catenin, Frizzled 2, and caspase 3, as well as upregulated mRNA and protein expression of GSK 3 beta. In addition, H BSQJ significantly increased mRNA expression of Col2a1 and decreased mRNA expression of MMP  1 and MMP 13.
   CONCLUSION: BSQJ exerted a beneficial effect on KOA by a mechanism involving downregulation of the Wnt/beta catenin pathway, which inhibited both cartilage extracellular matrix degradation and chondrocyte apoptosis to ameliorate KOA in rats. (C) 2021 JTCM. All rights reserved.
C1 [Yao Nan; Xu Xuemeng; Zhao Chuanxi; Huang Xuejun; Liu Wengang; Peng Sha; Wu Huai] Guangdong Second Tradit Chinese Med Hosp, Guangdong Prov Engn Technol Res Inst Tradit Chine, Guangzhou 510095, Peoples R China.
   [Yao Nan; Chen Guocai; Lu Yanyan; Xu Xuemeng; Zhao Chuanxi; Huang Xuejun; Liu Wengang; Peng Sha; Wu Huai] Guangzhou Univ Chinese Med, Clin Coll 5, Guangzhou 510095, Guangdong, Peoples R China.
   [Yao Nan; Huang Xuejun; Peng Sha] Guangdong Prov Key Lab Res & Dev Tradit Chinese M, Guangzhou 510095, Peoples R China.
   [Chen Guocai] Guangzhou Univ Chinese Med, Foshan Hosp Tradit Chinese Med, Foshan 528000, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine
RP Xu, XM (通讯作者)，Guangdong Second Tradit Chinese Med Hosp, Guangdong Prov Engn Technol Res Inst Tradit Chine, Guangzhou 510095, Peoples R China.
EM xuxuemeng@163.com
FU Guangdong Basic and Applied Basic Re search Foundation, China
   [2018A030313584]; Science and Technology Planning Project of Guangzhou,
   China [201804010217]; Project of Administration of Traditional Chinese
   Medicine of Guangdong Province, China [20194002, 20183001, 20164002]
FX Supported by Guangdong Basic and Applied Basic Re search Foundation,
   China (No. 2018A030313584) ; Science and Technology Planning Project of
   Guangzhou, China (No. 201804010217) ; and Project of Administration of
   Traditional Chinese Medicine of Guangdong Province, China (No. 20194002,
   20183001, and 20164002)
CR Ahmed S, 2005, EVID BASED COMPL ALT, V2, P301, DOI 10.1093/ecam/neh117
   Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140 6736(11)60243 2
   Chen D, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.44
   Cheng F, 2019, PHARM BIOL, V57, P649, DOI 10.1080/13880209.2019.1651874
   De Santis M, 2018, BIOMED RES INT UK, V2018, DOI 10.1155/2018/7402947
   Ding QH, 2018, INT IMMUNOPHARMACOL, V61, P222, DOI 10.1016/j.intimp.2018.05.026
   Egloff C, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13583
   Hashimoto S, 1998, ARTHRITIS RHEUM US, V41, P1632, DOI 10.1002/1529 0131(199809)41:9<1632::AID ART14>3.0.CO;2 A
   He YZ, 2019, MOL MED REP, V20, P312, DOI 10.3892/mmr.2019.10239
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Hunter DJ, 2005, J RHEUMATOL, V32, P2192
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Kim HT, 2002, OSTEOARTHR CARTILAGE, V10, P747, DOI 10.1053/joca.2002.0828
   Liao CR, 2019, REDOX BIOL, V28
   Lin MN, 2017, EXP THER MED, V14, P3674, DOI 10.3892/etm.2017.4984
   Liu W.G., 2017, HENAN TRADIT CHIN ME, V37, P911
   Ma YH, 2018, INT J MOL MED, V42, P61, DOI 10.3892/ijmm.2018.3587
   Miao ZL., 2018, World J Integr Trad West Med, V13, P710
   Musumeci G, 2011, KNEE SURG SPORT TR A, V19, P307, DOI 10.1007/s00167 010 1215 0
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Rao TP, 2010, CIRC RES, V106, P1798, DOI 10.1161/CIRCRESAHA.110.219840
   Sassi N, 2014, J RECEPT SIG TRANSD, V34, P73, DOI 10.3109/10799893.2013.863919
   Tang X, 2016, ARTHRITIS RHEUMATOL, V68, P648, DOI 10.1002/art.39465
   Tetlow LC, 2001, ARTHRITIS RHEUM US, V44, P585, DOI 10.1002/1529 0131(200103)44:3<585::AID ANR107>3.3.CO;2 3
   Usami Y, 2016, LAB INVEST, V96, P186, DOI 10.1038/labinvest.2015.142
   van den Bosch MH, 2016, RHEUMATOLOGY, V55, P1536, DOI 10.1093/rheumatology/kev402
   Wang J, 2016, FREE RADICAL RES, V50, P767, DOI 10.1080/10715762.2016.1174775
   Wang YD, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 019 0411 x
   Weng XP, 2014, INT J MOL MED, V34, P1045, DOI 10.3892/ijmm.2014.1869
   Woo SH, 2002, INT J ONCOL, V21, P57
   Wu GW, 2014, MOL MED REP, V10, P2525, DOI 10.3892/mmr.2014.2527
   Yao N, 2017, EXP THER MED, V13, P3013, DOI 10.3892/etm.2017.4349
   Yu J, 2014, BIOSCIENCE REP, V34, P593, DOI 10.1042/BSR20140119
   Zhao Z, 2012, ARCH ORTHOP TRAUM SU, V132, P1547, DOI 10.1007/s00402 012 1586 4
   Zhong Gang, 2018, Cell Physiol Biochem, V51, P2575, DOI 10.1159/000495926
   Zhu M, 2008, ARTHRITIS RHEUM US, V58, P2053, DOI 10.1002/art.23614
   Zhu M, 2009, J BONE MINER RES, V24, P12, DOI [10.1359/jbmr.080901, 10.1359/JBMR.080901]
NR 37
TC 10
Z9 13
U1 2
U2 15
PU JOURNAL TRADITIONAL CHINESE MED
PI BEIJING
PA 16 NANXIAOJIE, DONGZHIMEN NEI, BEIJING, 100700, PEOPLES R CHINA
SN 0255 2922
EI 1577 7014
J9 J TRADIT CHIN MED
JI J. Tradit. Chin. Med.
PD DEC
PY 2021
VL 41
IS 6
BP 935
EP 942
DI 10.19852/j.cnki.jtcm.2021.06.010
PG 8
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA XN0CX
UT WOS:000729184200001
PM 34939390
DA 2025 08 17
ER

PT J
AU Amer, H
   Griffin, MD
   Stegall, MD
   Cosio, FG
   Park, WD
   Kremers, WK
   Heilman, RL
   Mazur, MJ
   Hamawi, K
   Larson, TS
   Kumar, R
AF Amer, H.
   Griffin, M. D.
   Stegall, M. D.
   Cosio, F. G.
   Park, W. D.
   Kremers, W. K.
   Heilman, R. L.
   Mazur, M. J.
   Hamawi, K.
   Larson, T. S.
   Kumar, R.
TI Oral Paricalcitol Reduces the Prevalence of Posttransplant
   Hyperparathyroidism: Results of an Open Label Randomized Trial
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Bone disease; hyperparathyroidism; kidney transplant; paricalcitol;
   vitamin D receptor agonist
ID KIDNEY TRANSPLANT RECIPIENTS; RENAL TRANSPLANTATION; SECONDARY
   HYPERPARATHYROIDISM; VITAMIN D; BONE LOSS; DISEASE; PARATHYROIDECTOMY;
   HEMODIALYSIS; MECHANISMS; CALCITRIOL
AB Postkidney transplant hyperparathyroidism is a significant problem. Vitamin D receptor agonists are known to suppress parathyroid hormone (PTH) secretion. We examined the effect of oral paricalcitol on posttransplant secondary hyperparathyroidism by conducting an open label randomized trial in which 100 incident kidney transplant recipients were randomized 1:1 to receive oral paricalcitol, 2g per day, for the first year posttransplant or no additional therapy. Serial measurements of serum PTH, calcium and bone alkaline phosphatase, 24 h urine calcium and bone density were performed. The primary endpoint was the frequency of hyperparathyroidism 1 year posttransplant. Eighty seven patients completed the trial. One year posttransplant, 29% of paricalcitol treated subjects had hyperparathyroidism compared with 63% of untreated patients (p=0.0005). Calcium supplementation was discontinued in two control and 15 treatment patients due to mild hypercalcemia or hypercalcuria. Paricalcitol was discontinued in four patients due to hypercalcuria/hypercalcemia and in one for preference. Two subjects required decreasing the dose of paricalcitol to 1g daily. Hypercalcemia was asymptomatic and reversible. Incidence of acute rejection, BK nephropathy and renal function at 1 year were similar between groups. Moderate renal allograft fibrosis was reduced in treated patients. Oral paricalcitol is effective in decreasing posttransplant hyperparathyroidism and may have beneficial effects on renal allograft histology.
C1 [Amer, H.; Cosio, F. G.; Larson, T. S.; Kumar, R.] Mayo Clin, Dept Med, Div Nephrol & Hypertens, Rochester, MN 55905 USA.
   [Griffin, M. D.] Natl Univ Ireland, Regenerat Med Inst, Galway, Ireland.
   [Stegall, M. D.] Mayo Clin, Dept Surg, Div Transplant Surg, Rochester, MN USA.
   [Park, W. D.; Kremers, W. K.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
   [Heilman, R. L.; Mazur, M. J.; Hamawi, K.] Mayo Clin, Dept Transplantat, Scottsdale, AZ USA.
C3 Mayo Clinic; Ollscoil na Gaillimhe University of Galway; Mayo Clinic;
   Mayo Clinic; Mayo Clinic; Mayo Clinic Phoenix
RP Amer, H (通讯作者)，Mayo Clin, Dept Med, Div Nephrol & Hypertens, Rochester, MN 55905 USA.
EM amer.hatem@mayo.edu
RI Stegall, Mark/AAX 6496 2020; Heilman, Raymond/AAW 5138 2020; Amer,
   Hatem/AAN 2676 2020; Griffin, Matthew/A 1688 2009
OI Kumar, Rajiv/0000 0003 3497 3057; Park, Walter/0000 0002 0536 9515;
   Griffin, Matthew/0000 0002 8701 8056; Stegall, Mark/0000 0002 1392 0792;
   Amer, Hatem/0000 0002 9570 0506; 
FU Abbott Laboratories (Abbot Park, IL); Mayo Clinic
FX This trial was funded by Abbott Laboratories (Abbot Park, IL) through an
   investigator initiated research grant. The sponsor had access to the
   data but did not influence the conduct of the study. Mayo Clinic and not
   the industry sponsor supported the study's consultant statistician.
CR Cosio FG, 2005, AM J TRANSPLANT, V5, P2464, DOI 10.1111/j.1600 6143.2005.01050.x
   Coyne D, 2006, AM J KIDNEY DIS, V47, P263, DOI 10.1053/j.ajkd.2005.10.007
   de Zeeuw D, 2010, LANCET, V376, P1543, DOI 10.1016/S0140 6736(10)61032 X
   El Agroudy AE, 2003, J AM SOC NEPHROL, V14, P2975, DOI 10.1097/01.ASN.0000093255.56474.B4
   Evenepoel P, 2005, NEPHROL DIAL TRANSPL, V20, P1714, DOI 10.1093/ndt/gfh892
   Heaf J, 2003, CLIN TRANSPLANT, V17, P268, DOI 10.1034/j.1399 0012.2003.00047.x
   Jeffery JR, 2003, TRANSPLANTATION, V76, P1498, DOI 10.1097/01.TP.0000092523.30277.13
   Kasiske BL, 2000, CLIN TRANSPL, P135
   Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003 4819 145 4 200608150 00004
   Lieben L, 2012, J STEROID BIOCH MOL
   Meier Kriesche HU, 2004, AM J TRANSPLANT, V4, P1289, DOI 10.1111/j.1600 6143.2004.00515.x
   Nogueira PCK, 2000, PEDIATR NEPHROL, V14, P342
   Ojo AO, 2006, TRANSPLANTATION, V82, P603, DOI 10.1097/01.tp.0000235527.81917.fe
   Park JW, 2012, EUR J PHARMACOL, V683, P301, DOI 10.1016/j.ejphar.2012.03.019
   Park JW, 2010, KIDNEY INT, V77, P1076, DOI 10.1038/ki.2010.69
   Park WD, 2010, J AM SOC NEPHROL, V21, P1987, DOI 10.1681/ASN.2010010049
   Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523 1755.1999.00299.x
   Saini RK, 2013, CALCIFIED TISSUE INT, V92, P339, DOI 10.1007/s00223 012 9683 5
   Saini RK, 2012, CALCIF TISSUE INT
   Schmid T, 1997, NEPHROL DIAL TRANSPL, V12, P2393, DOI 10.1093/ndt/12.11.2393
   Shoji T, 2004, NEPHROL DIAL TRANSPL, V19, P179, DOI 10.1093/ndt/gfg513
   Snyder JJ, 2009, KIDNEY INT, V75, P317, DOI 10.1038/ki.2008.580
   Stubbs JR, 2011, SEMIN DIALYSIS, V24, P298, DOI 10.1111/j.1525 139X.2011.00935.x
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
   Thadhani R, 2012, JAMA J AM MED ASSOC, V307, P674, DOI 10.1001/jama.2012.120
   Vervaet BA, 2009, NEPHROL DIAL TRANSPL, V24, P2030, DOI 10.1093/ndt/gfp115
   Webster AC, 2007, AM J TRANSPLANT, V7, P2140, DOI 10.1111/j.1600 6143.2007.01908.x
   Wilson DM, 1997, AM J KIDNEY DIS, V30, P646, DOI 10.1016/S0272 6386(97)90488 1
   Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303
   Zhang RB, 2008, AM J MED SCI, V335, P120, DOI 10.1097/MAJ.0b013e3180a5e947
NR 30
TC 39
Z9 40
U1 0
U2 1
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1600 6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2013
VL 13
IS 6
BP 1576
EP 1585
DI 10.1111/ajt.12227
PG 10
WC Surgery; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery; Transplantation
GA 154WM
UT WOS:000319706900025
PM 23601186
OA hybrid
DA 2025 08 17
ER

PT J
AU Lim, KT
   Jin, H
   Seonwoo, H
   Kim, HB
   Kim, J
   Kim, JW
   Renji, C
   Choung, PH
   Chung, JH
AF Lim, Ki Taek
   Jin, Hexiu
   Seonwoo, Hoon
   Kim, Hye Been
   Kim, Jangho
   Kim, Jin Woo
   Renji, Chen
   Choung, Pill Hoon
   Chung, Jong Hoon
TI Physical Stimulation Based Osteogenesis: Effect of Secretion In
   Vitro on Fluid Dynamic Shear Stress of Human Alveolar Bone Derived
   Mesenchymal Stem Cells
SO IEEE TRANSACTIONS ON NANOBIOSCIENCE
LA English
DT Article
DE Fluid shear stress; hABMSCs conditioned secretion media; human alveolar
   bone derived mesenchymal stem cells; osteogenic differentiation;
   physical stimulation
ID MARROW STROMAL CELLS; OSTEOBLAST DIFFERENTIATION; MATRIX
   METALLOPROTEINASES; TRANSCRIPTION FACTORS; TGF BETA; EXPRESSION;
   COLLAGENASE; ACTIVATION; PATHWAYS; PROFILE
AB Human alveolar bone derived mesenchymal stem cells (hABMSCs) are promising candidates for bone therapies, which have the capacity to differentiate into osteoblasts. Recently, secretion of inducible cytokines and growth factors from mesenchymal stem cells (MSCs) has been discovered, and we also have reported the osteogenic effects of cell physical stimulation. In this study, we investigated the effects of hABMSCs conditioned secretion media (B CSM) on osteogenic differentiation of hABMSCs in vitro. Furthermore, we analyzed the B CSM by proteomics array to identify inducible factors which facilitate osteogenic differentiation. To determine optimal concentration, B CSM was firstly added at varying amounts (5, 10, 20, 40, and 60%) relative to culture medium. The viability and proliferation of hABMSCs were higher after treating with 5 20% B CSM to the cells, compared to 40 60%. In addition, the expression of stem cells markers CD146 and STRO 1 was increased in the cells treated with 5 20% B CSM, but decreased with 40 60%. We also found that B CSM promoted osteogenic differentiation of hABMSCs such as mineralized nodules were strongly generated by 5 20%. B CSM was most effective in increasing the expression of Vinculin and osteocalcin (OCN) in osteogenic differentiation of hABMSCs. Taken together, the results of our study ultimately indicate that B CSM from hABMSCs induced by physical stimulation induce the proliferation and osteogenic differentiation of hABMSCs.
C1 [Lim, Ki Taek; Kim, Hye Been] Kangwon Natl Univ, Dept Biosyst Engn, Chunchon 24341, South Korea.
   [Jin, Hexiu; Renji, Chen] Capital Med Univ, Sch Stomatol, Beijing 10050, Peoples R China.
   [Seonwoo, Hoon; Chung, Jong Hoon] Seoul Natl Univ, Dept Biosyst & Biomat Sci & Engn, Seoul 151921, South Korea.
   [Kim, Jangho] Chonnam Natl Univ, Dept Rural & Biosyst Engn, Kwangju 500757, South Korea.
   [Kim, Jin Woo] Univ Arkansas, Dept Biol & Agr Engn, Inst Nanosci & Engn, Fayetteville, AR 72701 USA.
   [Choung, Pill Hoon] Seoul Natl Univ, Dept Oral & Maxillofacial Surg, Sch Dent, Seoul 03080, South Korea.
   [Choung, Pill Hoon] Seoul Natl Univ, Dent Res Inst, Sch Dent, Seoul 03080, South Korea.
C3 Kangwon National University; Capital Medical University; Seoul National
   University (SNU); Chonnam National University; University of Arkansas
   System; University of Arkansas Fayetteville; Seoul National University
   (SNU); Seoul National University (SNU)
RP Chung, JH (通讯作者)，Seoul Natl Univ, Dept Biosyst & Biomat Sci & Engn, Seoul 151921, South Korea.
EM jchung@snu.ac.kr
RI ; Kim, Jin Woo/H 5148 2011; Chung, Jong/AAR 8179 2021; Lim,
   Ki Taek/AAI 9518 2021
OI Chung, Jong Hoon/0000 0003 0711 5655; Lim, Ki Taek/0000 0003 2091 788X
FU Kangwon National University, South Korea; National Research Foundation
   of Korea (NRF)   Korea government [NRF 2016M3A9B4919374]; Korea Health
   Technology R&D Project through the Korea Health Industry Development
   Institute (KHIDI); Ministry of Health & Welfare, South Korea [HI15C0968]
FX This work was supported by the 2015 Research Grant from Kangwon National
   University, South Korea. This work was also carried out with the support
   of the National Research Foundation of Korea (NRF) grant funded by the
   Korea government (NRF 2016M3A9B4919374) and a grant of the Korea Health
   Technology R&D Project through the Korea Health Industry Development
   Institute (KHIDI), funded by the Ministry of Health & Welfare, South
   Korea (HI15C0968).
CR Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886
   DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455
   Davidson ENB, 2007, OSTEOARTHR CARTILAGE, V15, P597, DOI 10.1016/j.joca.2007.02.005
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Dowling P, 2011, PROTEOMICS, V11, P794, DOI 10.1002/pmic.201000530
   Franchimont N, 1997, J BIOL CHEM, V272, P12144, DOI 10.1074/jbc.272.18.12144
   Grellier M, 2009, J TISSUE ENG REGEN M, V3, P302, DOI 10.1002/term.166
   Hu JB, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477 7819 12 68
   Huang YC, 2005, J BONE MINER RES, V20, P848, DOI 10.1359/JBMR.041226
   Kanczler JM, 2008, EUR CELLS MATER, V15, P100, DOI 10.22203/eCM.v015a08
   Kang YH, 2011, TISSUE ENG PT A, V17, P349, DOI 10.1089/ten.TEA.2010.0327
   Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756 3282(02)00979 1
   Kilroy GE, 2007, J CELL PHYSIOL, V212, P702, DOI 10.1002/jcp.21068
   Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57
   Kitoh H, 2004, BONE, V35, P892, DOI 10.1016/j.bone.2004.06.013
   Kobayashi T, 2005, ENDOCRINOLOGY, V146, P1012, DOI 10.1210/en.2004 1343
   Kreke MR, 2005, BONE, V36, P1047, DOI 10.1016/j.bone.2005.03.008
   Lim KT, 2013, TISSUE ENG PART C ME, V19, P128, DOI 10.1089/ten.tec.2012.0017
   Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756 3282(96)00138 X
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   McClelland P, 1998, J CELL BIOCHEM, V70, P391
   Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067
   MEIKLE MC, 1992, J CELL SCI, V103, P1093
   Nishimura R, 2012, J BIOCHEM, V151, P247, DOI 10.1093/jb/mvs004
   Prockop DJ, 2012, MOL THER, V20, P14, DOI 10.1038/mt.2011.211
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Sahni A, 1998, J BIOL CHEM, V273, P7554, DOI 10.1074/jbc.273.13.7554
   Samanna V, 2007, J CELL PHYSIOL, V213, P710, DOI 10.1002/jcp.21137
   Schinköthe T, 2008, STEM CELLS DEV, V17, P199, DOI 10.1089/scd.2007.0175
   Schmitz Spanke S, 2011, PROTEOMICS, V11, P644, DOI 10.1002/pmic.201000403
   Sykaras Nikitas, 2003, J Oral Sci, V45, P57
   Takiguchi T, 1998, J PERIODONTAL RES, V33, P476
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
NR 34
TC 7
Z9 9
U1 1
U2 10
PU IEEE INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855 4141 USA
SN 1536 1241
EI 1558 2639
J9 IEEE T NANOBIOSCI
JI IEEE Trans. Nanobiosci.
PD DEC
PY 2016
VL 15
IS 8
BP 881
EP 890
DI 10.1109/TNB.2016.2627053
PG 10
WC Biochemical Research Methods; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Science & Technology   Other Topics
GA EK7NB
UT WOS:000394111400012
PM 27849546
DA 2025 08 17
ER

PT J
AU Bergmann, F
   Moldenhauer, G
   Herpel, E
   Gaida, MM
   Strobel, O
   Werner, J
   Esposito, I
   Müerköster, SS
   Schirmacher, P
   Kern, MA
AF Bergmann, Frank
   Moldenhauer, Gerhard
   Herpel, Esther
   Gaida, Matthias M.
   Strobel, Oliver
   Werner, Jens
   Esposito, Irene
   Mueerkoester, Susanne Sebens
   Schirmacher, Peter
   Kern, Michael A.
TI Expression of L1CAM, COX 2, EGFR, c KIT and Her2/neu in anaplastic
   pancreatic cancer: putative therapeutic targets?
SO HISTOPATHOLOGY
LA English
DT Article
DE anaplastic carcinoma; chemotherapy; pancreatic cancer; targeted therapy
ID EPIDERMAL GROWTH FACTOR; CELL LUNG CANCER; FACTOR RECEPTOR;
   CYCLOOXYGENASE 2 EXPRESSION; PHASE II; UNDIFFERENTIATED CARCINOMA;
   HEPATOCELLULAR CARCINOMA; GENE EXPRESSION; TUMOR GROWTH; FACTOR ALPHA
AB Aims:
   Undifferentiated (anaplastic) pancreatic cancer and undifferentiated pancreatic carcinoma with osteoclast like giant cells (giant cell tumour) are rare variants of pancreatic ductal adenocarcinoma. Representing biologically highly aggressive neoplasms, they are frequently diagnosed at an advanced stage. The response to established chemo  or radiochemotherapeutic treatment regimens is poor, and undifferentiated pancreatic cancer generally has a dismal prognosis. As additional therapeutic options have not yet been investigated in undifferentiated pancreatic cancer, the aim was to analyse the expression of putative therapeutic targets that have shown promising results in various other neoplasms.
   Methods and results:
   Fifteen cases of undifferentiated pancreatic cancer (seven containing osteoclast like giant cells) were investigated clinicopathologically and immunohistochemically for putative therapeutic targets. Whereas L1CAM, cyclooxygenase (COX) 2 and epidermal growth factor receptor (EGFR) were found to be significantly expressed in 80%, 93% and 87% of the investigated tumours, respectively, there was no substantial expression of c kit (CD117) and there was no detectable expression of Her2/neu.
   Conclusions:
   The expression of L1CAM, COX 2 and EGFR in the majority of undifferentiated pancreatic carcinomas suggests that they might represent targets for adjuvant therapy in anaplastic pancreatic cancer. On the other hand, c kit and Her2/neu seem to have no relevance for the therapy of these tumours.
C1 [Bergmann, Frank; Herpel, Esther; Gaida, Matthias M.; Esposito, Irene; Schirmacher, Peter; Kern, Michael A.] Heidelberg Univ, Inst Pathol, D 69120 Heidelberg, Germany.
   [Strobel, Oliver; Werner, Jens] Heidelberg Univ, Dept Gen Surg, D 69120 Heidelberg, Germany.
   [Moldenhauer, Gerhard] German Canc Res Ctr, Translat Immunol Unit D015, D 6900 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)
RP Bergmann, F (通讯作者)，Heidelberg Univ, Inst Pathol, Neuenheimer Feld 220, D 69120 Heidelberg, Germany.
EM frank.bergmann@med.uni heidelberg.de
RI ; Arribas, Francisco/H 5275 2015; Sebens, Susanne/C 1222 2010; Esposito,
   Irene/AAQ 2891 2021
OI Esposito, Irene/0000 0002 0554 2402; Strobel, Oliver/0000 0001 5100 8449
FU Tumorzentrum Heidelberg/Mannheim; Deutsche Krebshilfe [Ke10 7685]
FX The authors thank Mrs Vesna Vukovic and Mrs Eva Eiteneuer for their
   excellent technical assistance. This study was supported by a grant from
   the Tumorzentrum Heidelberg/Mannheim (F.B.) and the Deutsche Krebshilfe
   (Ke10 7685).
CR Albazaz R, 2005, PANCREATOLOGY, V5, P361, DOI 10.1159/000086536
   Ali S, 2005, MOL CANCER THER, V4, P1943, DOI 10.1158/1535 7163.MCT 05 0065
   Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652
   Arlt MJE, 2006, CANCER RES, V66, P936, DOI 10.1158/0008 5472.CAN 05 1818
   Bae SH, 2001, CLIN CANCER RES, V7, P1410
   BARTON CM, 1991, J PATHOL, V163, P111, DOI 10.1002/path.1711630206
   Bateman AC, 2008, PANCREAS, V36, P76, DOI 10.1097/mpa.0b013e3181469881
   Benedix F, 2008, INT J COLORECTAL DIS, V23, P729, DOI 10.1007/s00384 008 0441 0
   Bergmann F, 2007, AM J SURG PATHOL, V31, P1919, DOI 10.1097/PAS.0b013e318067bca8
   Bergmann F, 2009, AM J GASTROENTEROL, V104, P171, DOI 10.1038/ajg.2008.33
   Bergmann F, 2009, HUM PATHOL, V40, P50, DOI 10.1016/j.humpath.2008.06.021
   Bertagnolli MM, 2006, NEW ENGL J MED, V355, P873, DOI 10.1056/NEJMoa061355
   Boo YJ, 2007, ANN SURG ONCOL, V14, P1703, DOI 10.1245/s10434 006 9281 8
   Büchler P, 2005, INT J ONCOL, V27, P1125
   Cao DF, 2006, MODERN PATHOL, V19, P1157, DOI 10.1038/modpathol.3800647
   Cho BC, 2007, J CLIN ONCOL, V25, P2528, DOI 10.1200/JCO.2006.10.4166
   DERYNCK R, 1987, CANCER RES, V47, P707
   Dong M, 1998, ANTICANCER RES, V18, P4613
   EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016 5085(94)90246 1
   Esposito I, 2002, LAB INVEST, V82, P1481, DOI 10.1097/01.LAB.0000036875.21209.F9
   Feld R, 2006, J THORAC ONCOL, V1, P367, DOI 10.1097/01243894 200605000 00018
   Fogel M, 2003, CANCER LETT, V189, P237, DOI 10.1016/S0304 3835(02)00513 X
   Gast D, 2008, ONCOGENE, V27, P1281, DOI 10.1038/sj.onc.1210747
   Gast D, 2005, INT J CANCER, V115, P658, DOI 10.1002/ijc.20869
   Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051
   Half E, 2007, CANCER LETT, V251, P237, DOI 10.1016/j.canlet.2006.11.020
   Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190
   Hida T, 1998, CANCER RES, V58, P3761
   Hoorens A, 1998, J PATHOL, V185, P53
   Hruban RH, 2007, AFIP ATLAS TUMOR PAT, P177
   Huszar M, 2006, HUM PATHOL, V37, P1000, DOI 10.1016/j.humpath.2006.03.014
   Issa Y, 2009, J MOL MED, V87, P99, DOI 10.1007/s00109 008 0410 7
   JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805
   Kaifi JT, 2006, MODERN PATHOL, V19, P399, DOI 10.1038/modpathol.3800547
   Kaifi JT, 2006, WORLD J GASTROENTERO, V12, P94, DOI 10.3748/wjg.v12.i1.94
   Kern MA, 2004, CARCINOGENESIS, V25, P1193, DOI 10.1093/carcin/bgh110
   Kern MA, 2002, HEPATOLOGY, V36, P885, DOI 10.1053/jhep.2002.36125
   Kern MA, 2006, CANCER RES, V66, P7059, DOI 10.1158/0008 5472.CAN 06 0325
   Kloppel G, 2000, World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System, P221
   Kokawa A, 2001, CANCER, V91, P333, DOI 10.1002/1097 0142(20010115)91:2<333::AID CNCR1006>3.0.CO;2 N
   Lanza Jacoby S, 2006, CLIN CANCER RES, V12, P6161, DOI 10.1158/1078 0432.CCR 06 0042
   Larbouret C, 2007, CLIN CANCER RES, V13, P3356, DOI 10.1158/1078 0432.CCR 06 2302
   LEMOINE NR, 1992, J PATHOL, V166, P7, DOI 10.1002/path.1711660103
   Molberg KH, 1998, CANCER AM CANCER SOC, V82, P1279, DOI 10.1002/(SICI)1097 0142(19980401)82:7<1279::AID CNCR10>3.0.CO;2 3
   Molina MA, 1999, CANCER RES, V59, P4356
   Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525
   Mürköster SS, 2007, ONCOGENE, V26, P2759, DOI 10.1038/sj.onc.1210076
   Nio Y, 2003, ANTI CANCER DRUG, V14, P313, DOI 10.1097/00001813 200304000 00009
   Novak Hofer I, 2008, CANCER LETT, V261, P193, DOI 10.1016/j.canlet.2007.11.012
   Paal E, 2001, Ann Diagn Pathol, V5, P129, DOI 10.1053/adpa.2001.25404
   Papouchado B, 2005, MODERN PATHOL, V18, P1329, DOI 10.1038/modpathol.3800427
   Philip P. A., 2008, CANCER RES, V2, pS16
   Potti A, 2003, ANTICANCER RES, V23, P2671
   Pryczynicz A, 2008, ANTICANCER RES, V28, P1399
   Reckamp KL, 2006, CLIN CANCER RES, V12, P3381, DOI 10.1158/1078 0432.CCR 06 0112
   Rich TA, 2003, AM J CLIN ONCOL CANC, V26, pS110, DOI 10.1097/01.COC.0000074148.37768.3E
   Saeki H, 2007, ONCOL REP, V18, P433
   Safran H, 2001, AM J CLIN ONCOL CANC, V24, P496, DOI 10.1097/00000421 200110000 00016
   Saxby AJ, 2005, AM J SURG PATHOL, V29, P1125, DOI 10.1097/01.pas.0000160979.85457.73
   Siu LL, 2007, J CLIN ONCOL, V25, P2178, DOI 10.1200/JCO.2006.07.6547
   Sorli CH, 1998, P NATL ACAD SCI USA, V95, P1788, DOI 10.1073/pnas.95.4.1788
   Souglakos J, 2007, ANN ONCOL, V18, P305, DOI 10.1093/annonc/mdl392
   Ueda S, 2006, MODERN PATHOL, V19, P788, DOI 10.1038/modpathol.3800582
   Uegaki K, 1997, ANTICANCER RES, V17, P3841
   Went PT, 2004, J CLIN ONCOL, V22, P4514, DOI 10.1200/JCO.2004.10.125
   Woodburn JR, 1999, PHARMACOL THERAPEUT, V82, P241, DOI 10.1016/S0163 7258(98)00045 X
   Wülfing P, 2003, J CANCER RES CLIN, V129, P375, DOI 10.1007/s00432 003 0459 1
   YAMANAKA Y, 1993, HUM PATHOL, V24, P1127, DOI 10.1016/0046 8177(93)90194 L
   Yang F, 2004, J BIOL CHEM, V279, P35403, DOI 10.1074/jbc.M404055200
   Zampino MG, 2007, CANCER, V110, P752, DOI 10.1002/cncr.22851
NR 70
TC 26
Z9 30
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0309 0167
EI 1365 2559
J9 HISTOPATHOLOGY
JI Histopathology
PD MAR
PY 2010
VL 56
IS 4
BP 440
EP 448
DI 10.1111/j.1365 2559.2010.03499.x
PG 9
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Pathology
GA 570KR
UT WOS:000275676000004
PM 20459551
DA 2025 08 17
ER

PT J
AU Chin, CJ
   Li, SW
   Corselli, M
   Casero, D
   Zhu, YH
   Bin He, C
   Hardy, R
   Péault, B
   Crooks, GM
AF Chin, Chee Jia
   Li, Suwen
   Corselli, Mirko
   Casero, David
   Zhu, Yuhua
   Bin He, Chong
   Hardy, Reef
   Peault, Bruno
   Crooks, Gay M.
TI Transcriptionally and Functionally Distinct Mesenchymal Subpopulations
   Are Generated from Human Pluripotent Stem Cells
SO STEM CELL REPORTS
LA English
DT Article
ID EX VIVO EXPANSION; BONE MARROW MICROENVIRONMENT; ENDOTHELIAL CELLS;
   HEMATOPOIETIC NICHE; STROMAL CELLS; HUMAN ORGANS; PDGFR ALPHA;
   DIFFERENTIATION; VESSELS; TRANSPLANTATION
AB Various mesenchymal cell types have been identified as critical components of the hematopoietic stem/progenitor cell (HSPC) niche. Although several groups have described the generation of mesenchyme from human pluripotent stem cells (hPSCs), the capacity of such cells to support hematopoiesis has not been reported. Here, we demonstrate that distinct mesenchymal subpopulations co emerge from mesoderm during hPSC differentiation. Despite co expression of common mesenchymal markers (CD73, CD105, CD90, and PDGFR beta), a subset of cells defined as CD146(hi)CD73(hi) expressed genes associated with the HSPC niche and supported the maintenance of functional HSPCs ex vivo, while CD146(lo)CD73(lo) cells supported differentiation. Stromal support of HSPCs was contact dependent and mediated in part through high JAG1 expression and low WNT signaling. Molecular profiling revealed significant transcriptional similarity between hPSC derived CD146(++) and primary human CD146(++) perivascular cells. The derivation of functionally diverse types of mesenchyme from hPSCs opens potential avenues to model the HSPC niche and develop PSC based therapies.
C1 [Chin, Chee Jia; Li, Suwen; Casero, David; Zhu, Yuhua; Bin He, Chong; Peault, Bruno; Crooks, Gay M.] UCLA, DGSOM, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
   [Corselli, Mirko] Becton Dickinson, San Diego, CA 92121 USA.
   [Hardy, Reef; Peault, Bruno] UCLA, DGSOM, Dept Orthoped, Los Angeles, CA 90095 USA.
   [Hardy, Reef; Peault, Bruno] UCLA, Orthoped Hosp Res Ctr, Los Angeles, CA 90095 USA.
   [Hardy, Reef; Peault, Bruno; Crooks, Gay M.] UCLA, BSCRC, Los Angeles, CA 90095 USA.
   [Hardy, Reef] Univ Indiana, Dept Med, Indianapolis, IN 46202 USA.
   [Peault, Bruno] Univ Edinburgh, Ctr Regenerat Med, Edinburgh EH16 4UU, Midlothian, Scotland.
   [Crooks, Gay M.] UCLA, DGSOM, Dept Pediat, Los Angeles, CA 90095 USA.
   [Crooks, Gay M.] UCLA, JCCC, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Becton Dickinson; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; David Geffen School of Medicine at UCLA;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   Indiana University System; Indiana University Indianapolis; University
   of Edinburgh; University of California System; University of California
   Los Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer
   Center; University of California System; University of California Los
   Angeles
RP Crooks, GM (通讯作者)，UCLA, DGSOM, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.; Crooks, GM (通讯作者)，UCLA, BSCRC, Los Angeles, CA 90095 USA.; Crooks, GM (通讯作者)，UCLA, DGSOM, Dept Pediat, Los Angeles, CA 90095 USA.; Crooks, GM (通讯作者)，UCLA, JCCC, Los Angeles, CA 90095 USA.
EM gcrooks@mednet.ucla.edu
RI ; Casero, David/E 7365 2010
OI He, Chong Bin/0009 0006 3044 4122; Li, Suwen/0000 0002 2296 6389;
   Casero, David/0000 0002 7347 3330
FU California Institute of Regenerative Medicine (CIRM) [RB3 05217,
   TR2 01821]; California Institute for Regenerative Medicine [TG2 01169];
   UCLA BSCRC Training Program; Genomics Shared Resource (GSR) in the UCLA
   Jonsson Comprehensive Cancer Center [NIH/NCI 5P30CA016042]; UCLA Center
   for AIDS Research (CFAR) Virology Core Lab [NIH/NIAID AI028697]; MRC
   [G1000816, MR/K017047/1] Funding Source: UKRI; National Cancer Institute
   [P30CA016042] Funding Source: NIH RePORTER; Medical Research Council
   [G1000816, MR/K017047/1] Funding Source: researchfish
FX We thank J. Scholes and F. Codrea at the UCLA Broad Stem Cell Research
   Center (BSCRC) Flow Cytometry Core for assistance with cell sorting and
   R. Chan for assistance with specimen processing. The research was made
   possible by grants from the California Institute of Regenerative
   Medicine (CIRM), grant numbers RB3 05217 (to G.M.C.) and TR2 01821 (to
   B.P.). C.J.C. and M.C. acknowledge the support of the California
   Institute for Regenerative Medicine Training Grant (TG2 01169), and S.L.
   acknowledges the support of a fellowship grant from the UCLA BSCRC
   Training Program. Core services were supported by the Genomics Shared
   Resource (GSR) in the UCLA Jonsson Comprehensive Cancer Center (NIH/NCI
   5P30CA016042), the BSCRC Flow Cytometry Core, and the UCLA Center for
   AIDS Research (CFAR) Virology Core Lab (NIH/NIAID AI028697).
CR Charbord P, 2014, CELL STEM CELL, V15, P376, DOI 10.1016/j.stem.2014.06.005
   Chin CJ, 2016, STEM CELLS, V34, P1239, DOI 10.1002/stem.2351
   Corselli M, 2013, BLOOD, V121, P2891, DOI 10.1182/blood 2012 08 451864
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Crisan M, 2009, ANN NY ACAD SCI, V1176, P118, DOI 10.1111/j.1749 6632.2009.04967.x
   Dar A, 2012, CIRCULATION, V125, P87, DOI 10.1161/CIRCULATIONAHA.111.048264
   Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783
   Evseenko D, 2010, P NATL ACAD SCI USA, V107, P13742, DOI 10.1073/pnas.1002077107
   Famili F, 2016, STEM CELL REP, V6, P652, DOI 10.1016/j.stemcr.2016.04.009
   Ferrell PI, 2014, STEM CELLS DEV, V23, P1355, DOI 10.1089/scd.2013.0497
   Greenbaum A, 2013, NATURE, V495, P227, DOI 10.1038/nature11926
   Hoffman CM, 2014, MOL ENDOCRINOL, V28, P1592, DOI 10.1210/me.2014 1079
   Hofmeister CC, 2007, BONE MARROW TRANSPL, V39, P11, DOI 10.1038/sj.bmt.1705538
   Huynh HD, 2008, STEM CELLS, V26, P1628, DOI 10.1634/stemcells.2008 0064
   Itkin T, 2016, NATURE, V532, P323, DOI 10.1038/nature17624
   Khan JA, 2016, SCIENCE, V351, P176, DOI 10.1126/science.aad0084
   Kobayashi H, 2010, NAT CELL BIOL, V12, P1046, DOI 10.1038/ncb2108
   Kunisaki Y, 2013, NATURE, V502, P637, DOI 10.1038/nature12612
   Kusuma S, 2013, P NATL ACAD SCI USA, V110, P12601, DOI 10.1073/pnas.1306562110
   Li HZ, 2014, STEM CELL REP, V3, P965, DOI 10.1016/j.stemcr.2014.09.018
   Luis TC, 2011, CELL STEM CELL, V9, P345, DOI 10.1016/j.stem.2011.07.017
   Méndez Ferrer S, 2008, NATURE, V452, P442, DOI 10.1038/nature06685
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Murray IR, 2014, CELL MOL LIFE SCI, V71, P1353, DOI 10.1007/s00018 013 1462 6
   Nakamura Ishizu A, 2012, BLOOD, V119, P5429, DOI 10.1182/blood 2011 11 393645
   Orlova VV, 2014, ARTERIOSCL THROM VAS, V34, P177, DOI 10.1161/ATVBAHA.113.302598
   Pinho S, 2013, J EXP MED, V210, P1351, DOI 10.1084/jem.20122252
   Poulos MG, 2013, CELL REP, V4, P1022, DOI 10.1016/j.celrep.2013.07.048
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Vodyanik MA, 2010, CELL STEM CELL, V7, P718, DOI 10.1016/j.stem.2010.11.011
   Zhang CC, 2008, BLOOD, V111, P3415, DOI 10.1182/blood 2007 11 122119
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
NR 33
TC 17
Z9 19
U1 0
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213 6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD FEB 13
PY 2018
VL 10
IS 2
BP 436
EP 446
DI 10.1016/j.stemcr.2017.12.005
PG 11
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA FV9KW
UT WOS:000424907600011
PM 29307583
OA Green Published
DA 2025 08 17
ER

PT S
AU Takeda, E
   Yamamoto, H
   Nishida, Y
   Sato, T
   Sawada, N
   Taketani, Y
AF Takeda, Eiji
   Yamamoto, Hironori
   Nishida, Yuka
   Sato, Tadatoshi
   Sawada, Naoki
   Taketani, Yutaka
BE Suzuki, H
   Kimmel, PL
TI Phosphate restriction in diet therapy
SO NUTRITION AND KIDNEY DISEASE: A NEW ERA
SE Contributions to Nephrology
LA English
DT Article
ID PARATHYROID HORMONE; MORTALITY RISK; LOW PHOSPHORUS;
   HEMODIALYSIS PATIENTS; CALCIUM; CALCIFICATION; FGF 23; PRODUCT; PROTEIN;
   HYPERPARATHYROIDISM
AB Hyperphosphatemia and hyperparathyroidism, frequently observed in patients with end stage renal disease, are associated with renal osteodystrophy, organ calcification, cardiovascular disease and sudden death. Restriction of dietary protein and phosphorus is beneficial in slowing the progression of renal failure. Dietary phosphorus restriction must be prescribed at all stages of renal failure in adults. It may be achieved by decreasing protein intake and avoiding foods rich in phosphorus. An average of 60 80% of the phosphorus intake is absorbed in the gut in dialysis patients. If phosphate binders are employed, the phosphorus absorbed from the diet may be reduced to 40%. Conventional hemodialysis with a high flux, high efficiency dialyzer removes approximately 30 mmol (900 mg) phosphorus during each dialysis performed three times weekly. Therefore, 750 mg of phosphorus intake should be the critical value above which a positive balance of phosphor us may occur. This value corresponds to a protein diet of 45 50 g/day or 0.8 g/kg body weight/day for a 60 kg patient. Target levels should become 9.2 9.6 mg/dl for calcium, 2.5 5.5 mg/dl for phosphorus, < 55 mg(2)/dl(2) for the calcium phosphorus product, and 100 200 pg/ml for intact parathyroid hormone. Copyright (c) 2007 S. Karger AG, Basel.
C1 Univ Tokushima, Grad Sch, Dept Clin Nutr, Inst Hlth Biosci, Tokushima 7708503, Japan.
C3 Tokushima University
RP Takeda, E (通讯作者)，Univ Tokushima, Grad Sch, Dept Clin Nutr, Inst Hlth Biosci, 3 18 15 Kuramoto Cho, Tokushima 7708503, Japan.
EM takeda@nutr.med.tokushima u.ac.jp
RI Yamamoto, Hironori/E 3902 2015
CR APARICIO M, 1993, NEPHRON, V63, P122, DOI 10.1159/000187162
   BARSOTTI G, 1983, KIDNEY INT, V24, P824
   BARSOTTI G, 1984, CLIN NEPHROL, V21, P54
   Blacher J, 2001, HYPERTENSION, V38, P938, DOI 10.1161/hy1001.096358
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   BLUMENKRANTZ MJ, 1982, KIDNEY INT, V21, P849, DOI 10.1038/ki.1982.109
   BORLE AB, 1978, ENDOCRINOLOGY, V102, P1725, DOI 10.1210/endo 102 6 1725
   Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523 1755.2002.00434.x
   CIARDELLA F, 1986, NEPHRON, V42, P196, DOI 10.1159/000183666
   Cozzolino M, 2001, J AM SOC NEPHROL, V12, P2511, DOI 10.1681/ASN.V12112511
   DELMEZ JA, 1992, AM J KIDNEY DIS, V19, P303, DOI 10.1016/S0272 6386(12)80446 X
   Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   GIN H, 1987, METABOLISM, V36, P1080, DOI 10.1016/0026 0495(87)90029 1
   HULTING J, 1994, CHEST, V105, P383
   Imanishi Y, 2004, KIDNEY INT, V65, P1943, DOI 10.1111/j.1523 1755.2004.00604.x
   Kestenbaum B, 2005, J AM SOC NEPHROL, V16, P520, DOI 10.1681/ASN.2004070602
   Koiwa F, 2005, THER APHER DIAL, V9, P336, DOI 10.1111/j.1744 9987.2005.00293.x
   LAFAGE MH, 1992, KIDNEY INT, V42, P1217, DOI 10.1038/ki.1992.407
   LAFLAMME GH, 1972, J CLIN INVEST, V51, P2834, DOI 10.1172/JCI107106
   Larsson T, 2003, KIDNEY INT, V64, P2272, DOI 10.1046/j.1523 1755.2003.00328.x
   LIM VS, 1990, KIDNEY INT, V37, P1557, DOI 10.1038/ki.1990.149
   London GM, 2000, J AM SOC NEPHROL, V11, P778, DOI 10.1681/ASN.V114778
   LORENZO V, 1995, NEPHROL DIAL TRANSPL, V10, P1885
   Martinez I, 1997, AM J KIDNEY DIS, V29, P496, DOI 10.1016/S0272 6386(97)90330 9
   Maschio G, 1983, Kidney Int Suppl, V16, pS273
   MCCRORY WW, 1987, J PEDIATR US, V111, P410, DOI 10.1016/S0022 3476(87)80467 5
   MOTOCK GT, 1991, J AM SOC NEPHROL, V2, pA627
   Nakanishi S, 2005, KIDNEY INT, V67, P1171, DOI 10.1111/j.1523 1755.2005.00184.x
   Narang R, 1997, INT J CARDIOL, V60, P73, DOI 10.1016/S0167 5273(97)02971 9
   PORTALE AA, 1984, J CLIN INVEST, V73, P1580, DOI 10.1172/JCI111365
   RAMIREZ JA, 1986, KIDNEY INT, V30, P753, DOI 10.1038/ki.1986.252
   Ribeiro S, 1998, NEPHROL DIAL TRANSPL, V13, P2037, DOI 10.1093/ndt/13.8.2037
   Rocco MV, 1999, SEMIN DIALYSIS, V12, P195, DOI 10.1046/j.1525 139X.1999.99012.x
   SCHOENFELD PY, 1983, KIDNEY INT S13, V23, P80
   SHEIKH MS, 1989, J CLIN INVEST, V83, P66, DOI 10.1172/JCI113886
   Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264
   SLATOPOLSKY E, 1992, KIDNEY INT, V42, pS43
   SLATOPOLSKY E, 1994, AM J KIDNEY DIS, V23, P229, DOI 10.1016/S0272 6386(12)80977 2
   Takeda E, 2000, ADV ENZYME REGUL, V40, P285, DOI 10.1016/S0065 2571(99)00036 9
   Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696
NR 42
TC 12
Z9 15
U1 0
U2 0
PU KARGER
PI BASEL
PA POSTFACH, CH 4009 BASEL, SWITZERLAND
SN 0302 5144
EI 1662 2782
BN 978 3 8055 8302 2
J9 CONTRIB NEPHROL
JI Contrib.Nephrol.
PY 2007
VL 155
BP 113
EP 124
PG 12
WC Nutrition & Dietetics; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics; Urology & Nephrology
GA BGC29
UT WOS:000245982900011
PM 17369719
DA 2025 08 17
ER

PT J
AU Zhang, X
   Feng, CG
   Yuan, T
   Wang, Y
   Wang, HJ
   Lu, QZ
   Lv, YS
   Li, ZQ
   Fu, CY
   Sun, S
AF Zhang, Xin
   Feng, Changgong
   Yuan, Tao
   Wang, Yi
   Wang, Haojue
   Lu, Qizhen
   Lv, YongShuang
   Li, Ziqing
   Fu, Chuanyun
   Sun, Shui
TI Inhibition of protein disulfide isomerase mitigates steroid induced
   osteonecrosis of the femoral head by suppressing osteoclast activity
   through the reduction of cellular oxidative stress
SO CHEMICO BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Steroid induced osteonecrosis of the femoral; head (SIONFH); Protein
   disulfide isomerase (PDI); Bioinformatics; Osteoclast; Reactive oxygen
   species (ROS)
ID NF KAPPA B; DRUG DISCOVERY; RIBOSTAMYCIN; PHARMACOKINETICS
AB Osteonecrosis of the femoral head (ONFH) is a devastating and irreversible hip disease usually associated with increased oxidative stress due to the clinical application of high dose or long term glucocorticoids (GCs). Previous publications have demonstrated protein disulfide isomerase (PDI) plays a critical role in regulating cellular production of reactive oxygen species (ROS). We therefore ask whether interfering PDI could affect GCsstimulated osteoclastogenesis. To test the hypothesis, we conducted bioinformatics and network analysis based on potential gene targets of steroid induced osteonecrosis of the femoral head (SIONFH) in light of multiple databases and concomitantly verified the associated biological effect via the in vitro model of dexamethasone (DEX) stimulated osteoclastogenesis. The results revealed 70 potential gene targets for SIONFH intervention, including the P4HB gene that encodes PDI. Further analysis based on network topology based analysis techniques (NTA), protein protein interaction (PPI) networks, and mouse cell atlas database identified the importance of PDI in regulating the cellular redox state of osteoclast during ONFH. Western blotting (WB) validations also indicated that PDI may be a positive regulator in the process of DEX stimulated osteoclastogenesis. Hence, various PDI inhibitors were subjected to molecular docking with PDI and their performances were analyzed, including 3 Methyltoxoflavin (3 M) which inhibits PDI expression, and ribostamycin sulfate (RS) which represses PDI chaperone activity. The binding energies of DEX, 3 M, and RS to PDI were  5.3547,  4.2324, and  5.9917 kcal/mol, respectively. The Protein Ligand Interaction Profiler (PLIP) analysis demonstrated that both hydrogen bonds and hydrophobic interactions were the key contributions to the DEX PDI and 3M PDI complexes, while only hydrogen bonds were identified as the predominant driving forces in the RSPDI complex. Subsequent experiments showed that both 3 M and RS reduced osteoclast differentiation and bone resorption activity by stifling the expression of osteoclastic markers. This reduction was primarily due to the PDI inhibitors boosting the antioxidant system, thereby reducing the production of intracellular ROS. In conclusion, our results supported PDI's involvement in SIONFH progression by regulating ROS in osteoclasts and highlighted PDI inhibitors may serve as potential options for SIONFH treatment.
C1 [Zhang, Xin; Feng, Changgong; Wang, Yi; Lu, Qizhen; Lv, YongShuang; Li, Ziqing; Sun, Shui] Shandong First Med Univ, Shandong Prov Hosp, Dept Joint Surg, Jinan 250021, Shandong, Peoples R China.
   [Zhang, Xin; Feng, Changgong; Wang, Yi; Lu, Qizhen; Lv, YongShuang; Li, Ziqing; Sun, Shui] Shandong First Med Univ & Shandong Acad Med Sci, Med Sci & Technol Innovat Ctr, Orthopaed Res Lab, Jinan 250117, Shandong, Peoples R China.
   [Yuan, Tao; Wang, Haojue; Sun, Shui] Shandong Univ, Shandong Prov Hosp, Cheeloo Coll Med, Dept Joint Surg, Jinan 250012, Shandong, Peoples R China.
   [Fu, Chuanyun] Shandong First Med Univ, Shandong Prov Hosp, Dept Stomatol, Jinan 250021, Shandong, Peoples R China.
   [Fu, Chuanyun] Shandong First Med Univ & Shandong Acad Med Sci, Sch Stomatol, Jinan 250117, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong First Medical University & Shandong Academy of
   Medical Sciences; Shandong First Medical University & Shandong Academy
   of Medical Sciences; Shandong University; Shandong First Medical
   University & Shandong Academy of Medical Sciences; Shandong First
   Medical University & Shandong Academy of Medical Sciences
RP Sun, S (通讯作者)，Shandong First Med Univ, Shandong Prov Hosp, Dept Joint Surg, Jinan 250021, Shandong, Peoples R China.; Fu, CY (通讯作者)，Shandong First Med Univ, Shandong Prov Hosp, Dept Stomatol, Jinan 250021, Shandong, Peoples R China.
EM fuchuanyun@sdfmu.edu.cn; sunshui@sdfmu.edu.cn
RI Li, Ziqing/GST 4574 2022; Lu, qizhen/LJK 7788 2024
FU National Natural Science Foundation of China [82272485]; Shandong
   Provincial Natural Science Foun dation [ZR2021MH352]; Medical and Health
   Science and Technology Development Project of Shandong Province
   [202308030310]
FX This work was supported by the National Natural Science Foundation of
   China (no.82272485) , Shandong Provincial Natural Science Foun dation
   (no. ZR2021MH352) and Medical and Health Science and Technology
   Development Project of Shandong Province (no. 202308030310) . Draft of
   Fig. 9 was created with the BioRender (https:// www.biorender.com /) .
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Anselmino N, 2020, ANTIOXID REDOX SIGN, V32, P1243, DOI 10.1089/ars.2019.7879
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Blangy A, 2020, J CELL SCI, V133, DOI 10.1242/jcs.244798
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cao HL, 2010, J CLIN INVEST, V120, P2755, DOI 10.1172/JCI42106
   Chen K, 2020, INT J BIOL SCI, V16, P1888, DOI 10.7150/ijbs.40917
   Chen YW, 2022, J ORTHOP TRANSL, V32, P28, DOI 10.1016/j.jot.2021.07.004
   Daina A, 2017, SCI REP UK, V7, DOI 10.1038/srep42717
   Fathallah N, 2023, METABOLITES, V13, DOI 10.3390/metabo13101044
   Fei LJ, 2022, NAT GENET, V54, P1051, DOI 10.1038/s41588 022 01118 8
   Ghose AK, 1999, J COMB CHEM, V1, P55, DOI 10.1021/cc9800071
   Hachemi Y, 2018, J MOL ENDOCRINOL, V61, pR75, DOI 10.1530/JME 18 0024
   Horibe T, 2001, BIOCHEM BIOPH RES CO, V289, P967, DOI 10.1006/bbrc.2001.6105
   Jha V, 2021, ANTIOXID REDOX SIGN, V35, P1093, DOI 10.1089/ars.2021.0018
   Jiang HY, 2024, PHYTOTHER RES, V38, P156, DOI 10.1002/ptr.8031
   Kalhori F, 2022, LUMINESCENCE, V37, P1836, DOI 10.1002/bio.4360
   Khan MMG, 2011, ONCOL RES, V19, P445, DOI 10.3727/096504011X13123323849717
   Kim HJ, 2022, J BONE MINER RES, V37, P505, DOI 10.1002/jbmr.4478
   Kim JM, 2018, BMB REP, V51, P230, DOI 10.5483/BMBRep.2018.51.5.198
   Ko MHK, 2004, EXP CELL RES, V295, P25, DOI 10.1016/j.yexcr.2003.12.013
   Kubo Y, 2021, ANTIOXID REDOX SIGN, V35, P357, DOI 10.1089/ars.2020.8163
   Kyani A, 2018, CHEMMEDCHEM, V13, P164, DOI 10.1002/cmdc.201700629
   Li XD, 2019, APPL ENVIRON MICROB, V85, DOI 10.1128/AEM.00106 19
   Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401
   Lin TY, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02464 9
   Linz A, 2015, J BONE MINER RES, V30, P1481, DOI 10.1002/jbmr.2484
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169 409X(96)00423 1
   McKerrow JH, 2017, INT J PARASITOL DRUG, V7, P248, DOI 10.1016/j.ijpddr.2017.05.003
   Mei J, 2022, PHYSICIAN SPORTSMED, V50, P280, DOI 10.1080/00913847.2021.1936685
   Park Byung Lae, 2003, Hum Mutat, V22, P257, DOI 10.1002/humu.9170
   Ping SN, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.213
   Powell LE, 2021, CANCER MED US, V10, P2812, DOI 10.1002/cam4.3836
   Puhl AC, 2023, BIOORGAN MED CHEM, V83, DOI 10.1016/j.bmc.2023.117239
   Quan HY, 2023, ACTA BIOMATER, V164, P15, DOI 10.1016/j.actbio.2023.04.005
   Sadoghi P, 2013, J ARTHROPLASTY, V28, P1329, DOI 10.1016/j.arth.2013.01.012
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Sattar Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084045
   Sharifi Rad A, 2021, J BIOMOL STRUCT DYN, V39, P1029, DOI 10.1080/07391102.2020.1724568
   Shergalis AG, 2020, PHARMACOL THERAPEUT, V210, DOI 10.1016/j.pharmthera.2020.107525
   Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580 020 0230 3
   Stevenson JR, 2023, PSYCHONEUROENDOCRINO, V153, DOI 10.1016/j.psyneuen.2023.106121
   Sun XX, 2000, BBA PROTEIN STRUCT M, V1481, P45, DOI 10.1016/S0167 4838(00)00122 9
   Veis DJ, 2023, ANNU REV PATHOL MECH, V18, P257, DOI 10.1146/annurev pathmechdis 031521 040919
   Wang A, 2018, GENE, V671, P103, DOI 10.1016/j.gene.2018.05.091
   Wang L, 2023, TRENDS BIOCHEM SCI, V48, P40, DOI 10.1016/j.tibs.2022.06.011
   Wang RY, 2023, NUCLEIC ACIDS RES, V51, P501, DOI 10.1093/nar/gkac633
   Wang Y, 2024, INFLAMMATION, V47, P626, DOI 10.1007/s10753 023 01933 z
   Wang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112708
   Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761
   Xiao Y, 2018, INFLAMMATION, V41, P614, DOI 10.1007/s10753 017 0717 z
   Xiong B, 2020, EXP MOL MED, V52, P390, DOI 10.1038/s12276 020 0401 5
   Xu XL, 2021, BRIT J PHARMACOL, V178, P2911, DOI 10.1111/bph.15493
   YAMASAKU F, 1980, JPN J ANTIBIOT, V33, P1318
   Zeeshan HMA, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030327
   Zhang F, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 04226 1
   Zhang Z, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.11.005
   Zhao B, 2023, CELL PROLIFERAT, V56, DOI 10.1111/cpr.13341
   Zhi X, 2020, J CELL MOL MED, V24, P5122, DOI 10.1111/jcmm.15153
   ZHOU SL, 1992, CLIN PHARMACOKINET, V22, P144
   Zhu J, 2007, J BIOL CHEM, V282, P26656, DOI 10.1074/jbc.M705064200
NR 61
TC 0
Z9 0
U1 2
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009 2797
EI 1872 7786
J9 CHEM BIOL INTERACT
JI Chem. Biol. Interact.
PD DEC 1
PY 2024
VL 404
AR 111263
DI 10.1016/j.cbi.2024.111263
EA OCT 2024
PG 16
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA J4Z0Z
UT WOS:001337151800001
PM 39393751
DA 2025 08 17
ER

PT J
AU Reginster, JY
   Hattersley, G
   Williams, GC
   Hu, MY
   Fitzpatrick, LA
   Lewiecki, EM
AF Reginster, Jean Yves
   Hattersley, Gary
   Williams, Gregory C.
   Hu, Ming yi
   Fitzpatrick, Lorraine A.
   Lewiecki, E. Michael
TI Abaloparatide is an Effective Treatment Option for Postmenopausal
   Osteoporosis: Review of the Number Needed to Treat Compared with
   Teriparatide
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Postmenopausal osteoporosis; Abaloparatide; Number needed to treat;
   ACTIVE trial; Fracture risk reduction
ID BONE MINERAL DENSITY; VERTEBRAL FRACTURES; OVARIECTOMIZED RATS; PTH1
   RECEPTOR; WOMEN; TRIAL; RISK; ALENDRONATE; THERAPIES; ACTIVATOR
AB Abaloparatide (ABL) is a 34 amino acid peptide designed to be a selective activator of the parathyroid hormone receptor type 1 signaling pathway. In the Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE), subcutaneous ABL reduced the risk of new vertebral, nonvertebral, clinical, and major osteoporotic fracture compared with placebo and of major osteoporotic fracture compared with teriparatide. To further evaluate the effectiveness of ABL, we calculated the number needed to treat (NNT) to prevent one fracture using ACTIVE data. To estimate the potential effectiveness of ABL in populations at higher fracture risk than in ACTIVE, we calculated NNT for vertebral fracture using reference populations from historical placebo controlled trials, assuming an 86% relative risk reduction in vertebral fracture with ABL treatment as observed in ACTIVE. NNT was calculated as the reciprocal of the absolute risk reduction in ACTIVE. The projected NNT for ABL in other populations was calculated based on incidence rate (IR) for vertebral fractures in the placebo arms of the FREEDOM (placebo IR 7.2%), FIT 1 (placebo IR 15.0%), and FIT 2 (placebo IR 3.8%) trials. NNT for ABL in ACTIVE was 28 for vertebral, 55 for nonvertebral, 37 for clinical, and 34 for major osteoporotic fracture. NNT for these fracture types for teriparatide in ACTIVE were 30, 92, 59, and 75, respectively. Using placebo IRs from FREEDOM, FIT 1, and FIT 2, projected NNTs for vertebral fracture with ABL were 17, 8, and 31. These data are useful for further evaluating ABL for the treatment of osteoporosis in postmenopausal women.
C1 [Reginster, Jean Yves] Univ Liege, Pl 20 Aout 7, B 4000 Liege, Belgium.
   [Hattersley, Gary; Williams, Gregory C.; Hu, Ming yi; Fitzpatrick, Lorraine A.] Radius Hlth Inc, 950 Winter St, Waltham, MA 02451 USA.
   [Lewiecki, E. Michael] New Mexico Clin Res & Osteoporosis Ctr Inc, 300 Oak St SE, Albuquerque, NM 87106 USA.
C3 University of Liege; Radius Health, Inc.; New Mexico Clinical Research &
   Osteoporosis Center
RP Hattersley, G (通讯作者)，Radius Hlth Inc, 950 Winter St, Waltham, MA 02451 USA.
EM ghattersley@radiuspharm.com
RI Reginster, Jean Yves/AGC 6097 2022; Lewiecki, E./B 3706 2018
OI Lewiecki, E. Michael/0000 0003 2026 9587; 
FU Radius Health, Inc., Waltham, MA; Radius Health, Inc.
FX ACTIVE and this analysis were funded by Radius Health, Inc., Waltham,
   MA. Data in this paper were presented as a poster at the Annual Meeting
   of the American Society for Bone and Mineral Research, September 19,
   2016; poster ID #MO0280 and at the World Congress on Osteoporosis, March
   25, 2017; oral presentation #OC18. Medical writing support was provided
   by Gregory Bezkorovainy, MA, Adelphi Communications, New York and was
   funded by Radius Health, Inc.
CR Bahar H, 2016, CALCIFIED TISSUE INT, V99, P489, DOI 10.1007/s00223 016 0171 1
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bone HG, 2018, J CLIN ENDOCR METAB, V103, P2949, DOI 10.1210/jc.2018 00163
   Cosman F, 2017, MAYO CLIN PROC, V92, P200, DOI 10.1016/j.mayocp.2016.10.009
   Cosman F, 2017, J BONE MINER RES, V32, P17, DOI 10.1002/jbmr.2991
   Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001 9002
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Esbrit P, 2016, CALCIFIED TISSUE INT, V98, P359, DOI 10.1007/s00223 015 0050 1
   Gielen E, 2017, CALCIFIED TISSUE INT, V101, P111, DOI 10.1007/s00223 017 0266 3
   Hattersley G, 2016, ENDOCRINOLOGY, V157, P141, DOI 10.1210/en.2015 1726
   Kanis JA, 2014, CALCIFIED TISSUE INT, V94, P469, DOI 10.1007/s00223 014 9844 9
   LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605
   Leder BZ, 2015, J CLIN ENDOCR METAB, V100, P697, DOI 10.1210/jc.2014 3718
   Lewiecki EM, 2014, J CLIN DENSITOM, V17, P490, DOI 10.1016/j.jocd.2013.09.018
   McCloskey EV, 2017, J BONE MINER RES, V32, P1625, DOI 10.1002/jbmr.3163
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Moreira CA, 2017, BONE, V97, P314, DOI 10.1016/j.bone.2016.11.004
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ralston SH, 2016, CALCIFIED TISSUE INT, V98, P317, DOI 10.1007/s00223 016 0127 5
   Varela A, 2017, BONE, V95, P143, DOI 10.1016/j.bone.2016.11.027
   Varela A, 2017, J BONE MINER RES, V32, P24, DOI 10.1002/jbmr.3003
NR 22
TC 23
Z9 25
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD NOV
PY 2018
VL 103
IS 5
BP 540
EP 545
DI 10.1007/s00223 018 0450 0
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GX7PH
UT WOS:000447965400009
PM 29951742
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Diaz Rodriguez, P
   Erndt Marino, JD
   Gharat, T
   Pinto, DJM
   Samavedi, S
   Bearden, R
   Grunlan, MA
   Saunders, WB
   Hahn, MS
AF Diaz Rodriguez, Patricia
   Erndt Marino, Josh D.
   Gharat, Tanmay
   Pinto, Dany J. Munoz
   Samavedi, Satyavrata
   Bearden, Robert
   Grunlan, Melissa A.
   Saunders, W. Brian
   Hahn, Mariah S.
TI Toward zonally tailored scaffolds for osteochondral differentiation of
   synovial mesenchymal stem cells
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B APPLIED BIOMATERIALS
LA English
DT Article
DE chondrogenesis; osteochondral tissue; osteogenesis; PEG scaffolds;
   synovium derived mesenchymal stem cells
ID CHONDROITIN SULFATE; PEG HYDROGELS; CHONDROGENIC DIFFERENTIATION;
   IN VITRO; ARTICULAR CARTILAGE; BONE MARROW; SEMIINTERPENETRATING
   NETWORKS; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION;
   EXTRACELLULAR MATRIX
AB Synovium derived mesenchymal stem cells (SMSCs) are an emerging cell source for regenerative medicine applications, including osteochondral defect (OCD) repair. However, in contrast to bone marrow MSCs, scaffold compositions which promote SMSC chondrogenesis/osteogenesis are still being identified. In the present manuscript, we examine poly(ethylene) glycol (PEG) based scaffolds containing zonally specific biochemical cues to guide SMSC osteochondral differentiation. Specifically, SMSCs were encapsulated in PEG based scaffolds incorporating glycosaminoglycans (hyaluronan or chondroitin 6 sulfate [CSC]), low dose of chondrogenic and osteogenic growth factors (TGF beta 1 and BMP2, respectively), or osteoinductive poly(dimethylsiloxane) (PDMS). Initial studies suggested that PEG CSC TGF beta 1 scaffolds promoted enhanced SMSC chondrogenic differentiation, as assessed by significant increases in Sox9 and aggrecan. Conversely, PEG PDMS BMP2 scaffolds stimulated increased levels of osteoblastic markers with significant mineral deposition. A "Transition" zone formulation was then developed containing a graded mixture of the chondrogenic and osteogenic signals present in the PEG CSC TGF beta 1 and PEG PDMS BMP2 constructs. SMSCs within the "Transition" formulation displayed a phenotypic profile similar to hypertrophic chondrocytes, with the highest expression of collagen X, intermediate levels of osteopontin, and mineralization levels equivalent to "bone" formulations. Overall, these results suggest that a graded transition from PEG CSC TGF beta 1 to PEG PDMS BMP2 scaffolds elicits a gradual SMSC phenotypic shift from chondrocyte to hypertrophic chondrocyte to osteoblast like. As such, further development of these scaffold formulations for use in SMSC based OCD repair is warranted. (c) 2018 Wiley Periodicals, Inc.
C1 [Diaz Rodriguez, Patricia; Erndt Marino, Josh D.; Pinto, Dany J. Munoz; Samavedi, Satyavrata] Rensselaer Polytech Inst, Dept Biomed Engn, Troy, NY 12180 USA.
   [Gharat, Tanmay; Hahn, Mariah S.] Rensselaer Polytech Inst, Dept Chem & Biol Engn, Troy, NY 12180 USA.
   [Bearden, Robert; Saunders, W. Brian] Texas A&M Univ, Vet Med & Biomed Sci, College Stn, TX USA.
   [Grunlan, Melissa A.] Texas A&M Univ, Dept Biomed Engn, College Stn, TX USA.
C3 Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute;
   Texas A&M University System; Texas A&M University College Station; Texas
   A&M University System; Texas A&M University College Station
RP Hahn, MS (通讯作者)，Rensselaer Polytech Inst, Dept Chem & Biol Engn, Troy, NY 12180 USA.
EM hahnm@rpi.edu
RI ; Diaz Rodriguez, Patricia/AAA 8425 2019
OI Grunlan, Melissa/0000 0002 5428 0461; Diaz Rodriguez,
   Patricia/0000 0002 7576 2013
FU American Kennel Club Canine Health Foundation [02078]; National
   Institutes of Health [R01 DE025886R03 EB015202 01]
FX Contract grant sponsor: American Kennel Club Canine Health Foundation;
   contract grant number: 02078 Contract grant sponsor: National Institutes
   of Health; contract grant number: R01 DE025886R03 EB015202 01
CR Aerssens J, 1998, ENDOCRINOLOGY, V139, P663, DOI 10.1210/en.139.2.663
   Amann E, 2017, ACTA BIOMATER, V52, P130, DOI 10.1016/j.actbio.2017.01.064
   Angel MJ, 2003, SPORTS MED ARTHROSC, V11, P168, DOI 10.1097/00132585 200311030 00002
   [Anonymous], CARTILAGE
   [Anonymous], CARTILAGE OSTEOARTHR
   Au AY, 2010, J BIOMED MATER RES A, V94A, P380, DOI 10.1002/jbm.a.32668
   Bahney CS, 2011, FASEB J, V25, P1486, DOI 10.1096/fj.10 165514
   Bailey BM, 2013, ACTA BIOMATER, V9, P8254, DOI 10.1016/j.actbio.2013.05.012
   Bailey BM, 2012, ACTA BIOMATER, V8, P4324, DOI 10.1016/j.actbio.2012.07.034
   Bauer C, 2016, J INFLAMM LOND, V13, DOI 10.1186/s12950 016 0139 y
   Bearden RN, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0639 6
   Benoit DSW, 2008, NAT MATER, V7, P816, DOI 10.1038/nmat2269
   Bhosale AM, 2008, BRIT MED BULL, V87, P77, DOI 10.1093/bmb/ldn025
   Bryant SJ, 2002, J BIOMED MATER RES, V59, P63, DOI 10.1002/jbm.1217
   Burdick JA, 2004, LANGMUIR, V20, P5153, DOI 10.1021/la049298n
   Burdick JA, 2002, J CONTROL RELEASE, V83, P53, DOI 10.1016/S0168 3659(02)00181 5
   Burdick JA, 2002, BIOMATERIALS, V23, P4315, DOI 10.1016/S0142 9612(02)00176 X
   Buxton AN, 2007, TISSUE ENG, V13, P2549, DOI 10.1089/ten.2007.0075
   Chatterjee K, 2010, BIOMATERIALS, V31, P5051, DOI 10.1016/j.biomaterials.2010.03.024
   Cheng SH, 2013, PHYSIOL GENOMICS, V45, P917, DOI 10.1152/physiolgenomics.00111.2013
   Chung C, 2009, TISSUE ENG PT A, V15, P243, DOI 10.1089/ten.tea.2008.0067
   Corradetti B, 2016, STEM CELL TRANSL MED, V5, P670, DOI 10.5966/sctm.2015 0233
   Costantini M, 2016, BIOFABRICATION, V8, DOI 10.1088/1758 5090/8/3/035002
   De Bari C, 2001, ARTHRITIS RHEUM US, V44, P1928, DOI 10.1002/1529 0131(200108)44:8<1928::AID ART331>3.0.CO;2 P
   DeLong SA, 2005, BIOMATERIALS, V26, P3227, DOI 10.1016/j.biomaterials.2004.09.021
   Ding XL, 2015, INT J NANOMED, V10, P6955, DOI 10.2147/IJN.S87347
   Discher DE, 2007, BIOPHYS J, p32A
   Dy P, 2012, DEV CELL, V22, P597, DOI 10.1016/j.devcel.2011.12.024
   Erndt Marino JD, 2017, J BIOMED MATER RES A, V105, P984, DOI 10.1002/jbm.a.35964
   Erndt Marino JD, 2015, ACS BIOMATER SCI ENG, V1, P1220, DOI 10.1021/acsbiomaterials.5b00445
   Fan JB, 2009, TISSUE ENG PART B RE, V15, P75, DOI 10.1089/ten.teb.2008.0586
   Findlay DM, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.28
   Fossey SL, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 81
   Fragiadaki M, 2011, MOL BIOL CELL, V22, P1836, DOI 10.1091/mbc.E10 08 0669
   Gama CI, 2006, NAT CHEM BIOL, V2, P467, DOI 10.1038/nchembio810
   Gao Y., 2014, Biomed Res. Int., V2014, P1, DOI [DOI 10.1155/2014/648459, 10.1155/2014/648459]
   Garetto L P, 1995, Implant Dent, V4, P235, DOI 10.1097/00008505 199500440 00002
   Gharat TP, 2018, J BIOMED MATER RES A, V106, P2382, DOI 10.1002/jbm.a.36430
   GOMBOTZ WR, 1991, J BIOMED MATER RES, V25, P1547, DOI 10.1002/jbm.820251211
   Hahn MS, 2006, ADV MATER, V18, P2679, DOI 10.1002/adma.200600647
   Hahn MS, 2006, BIOMATERIALS, V27, P2519, DOI 10.1016/j.biomaterials.2005.11.045
   Hahn MS, 2005, ADV MATER, V17, P2939, DOI 10.1002/adma.200500184
   He XN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104061
   Hjelle K, 2002, ARTHROSCOPY, V18, P730, DOI 10.1053/jars.2002.32839
   Hou YP, 2010, BIOMACROMOLECULES, V11, P648, DOI 10.1021/bm9012293
   Huebsch N, 2010, NAT MATER, V9, P518, DOI [10.1038/nmat2732, 10.1038/NMAT2732]
   Huey DJ, 2012, SCIENCE, V338, P917, DOI 10.1126/science.1222454
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Ingavle GC, 2012, J MATER SCI MATER M, V23, P157, DOI 10.1007/s10856 011 4499 9
   Jimenez Vergara AC, 2011, ACTA BIOMATER, V7, P3964, DOI 10.1016/j.actbio.2011.06.034
   Jones BA, 2012, TISSUE ENG PART B RE, V18, P301, DOI [10.1089/ten.teb.2012.0002, 10.1089/ten.TEB.2012.0002]
   Kang BJ, 2012, J VET SCI, V13, P299, DOI 10.4142/jvs.2012.13.3.299
   Kim MH, 2015, INT J MOL SCI, V16, P10324, DOI 10.3390/ijms160510324
   Kim SE, 2014, CARBOHYD POLYM, V114, P123, DOI 10.1016/j.carbpol.2014.08.005
   Kim YI, 2014, BIOCHEM BIOPH RES CO, V450, P1593, DOI 10.1016/j.bbrc.2014.07.045
   Koga H, 2008, CELL TISSUE RES, V333, P207, DOI 10.1007/s00441 008 0633 5
   Koizumi K, 2016, OSTEOARTHR CARTILAGE, V24, P1413, DOI 10.1016/j.joca.2016.03.006
   Kudo T, 2017, BIOL PHARM BULL, V40, P2075, DOI 10.1248/bpb.b17 00059
   Kurth T, 2007, OSTEOARTHR CARTILAGE, V15, P1178, DOI 10.1016/j.joca.2007.03.015
   Lee J, 2014, J MECH BEHAV BIOMED, V38, P209, DOI 10.1016/j.jmbbm.2014.01.009
   Lee S, 2009, TISSUE ENG PT A, V15, P3401, DOI [10.1089/ten.tea.2008.0466, 10.1089/ten.TEA.2008.0466]
   Lin S, 2011, PHARM RES DORDR, V28, P1422, DOI 10.1007/s11095 011 0378 9
   Liu HW, 2007, TISSUE ENG, V13, P1113, DOI 10.1089/ten.2006.0209
   Liu HW, 2006, BONE, V39, P825, DOI 10.1016/j.bone.2006.04.027
   Lopa S, 2014, TISSUE ENG PT A, V20, P2052, DOI 10.1089/ten.tea.2013.0356
   Mann BK, 2001, BIOMATERIALS, V22, P439, DOI 10.1016/S0142 9612(00)00196 4
   Masters KS, 2005, BIOMATERIALS, V26, P2517, DOI 10.1016/j.biomaterials.2004.07.018
   Matsiko A, 2012, J MECH BEHAV BIOMED, V11, P41, DOI 10.1016/j.jmbbm.2011.11.012
   McCall JD, 2012, DRUG DELIV TRANSL RE, V2, P305, DOI 10.1007/s13346 012 0090 2
   McMahon LA, 2008, REGEN MED, V3, P743, DOI 10.2217/17460751.3.5.743
   Moeinzadeh S, 2012, BIOMACROMOLECULES, V13, P2073, DOI 10.1021/bm300453k
   Morello E, 2011, VET J, V189, P268, DOI 10.1016/j.tvjl.2010.08.014
   Munoz Pinto DJ, 2012, TISSUE ENG PT A, V18, P1710, DOI [10.1089/ten.tea.2011.0348, 10.1089/ten.TEA.2011.0348]
   Munoz Pinto DJ, 2010, J BIOMED MATER RES A, V94A, P112, DOI 10.1002/jbm.a.32695
   Munoz Pinto DJ, 2009, BIOTECHNOL BIOENG, V104, P821, DOI 10.1002/bit.22436
   Ng J, 2016, METHODS MOL BIOL, V1416, P35, DOI 10.1007/978 1 4939 3584 0_3
   Nguyen QT, 2012, BIOMATERIALS, V33, P6682, DOI 10.1016/j.biomaterials.2012.06.005
   Nicodemus GD, 2008, J BIOMECH, V41, P1528, DOI 10.1016/j.jbiomech.2008.02.034
   Nicodemus GD, 2011, ACTA BIOMATER, V7, P492, DOI 10.1016/j.actbio.2010.08.021
   Nie FL, 2013, J BIOMED MATER RES A, V101, P1694, DOI 10.1002/jbm.a.34472
   Nukavarapu SP, 2013, BIOTECHNOL ADV, V31, P706, DOI 10.1016/j.biotechadv.2012.11.004
   Nuttelman CR, 2006, BIOMATERIALS, V27, P1377, DOI 10.1016/j.biomaterials.2005.08.014
   O'Driscoll SW, 1998, J BONE JOINT SURG AM, V80A, P1795, DOI 10.2106/00004623 199812000 00011
   Olivotto E, 2007, J CELL PHYSIOL, V210, P417, DOI 10.1002/jcp.20864
   Pan JF, 2015, SCI TECHNOL ADV MAT, V16, DOI 10.1088/1468 6996/16/4/045001
   Pan JF, 2014, J MATER CHEM B, V2, P8346, DOI 10.1039/c4tb01221f
   Panseri S, 2012, KNEE SURG SPORT TR A, V20, P1182, DOI 10.1007/s00167 011 1655 1
   Paoloni M, 2009, BMC GENOMICS, V10, DOI 10.1186/1471 2164 10 625
   Parekh SH, 2011, BIOMATERIALS, V32, P2256, DOI 10.1016/j.biomaterials.2010.11.065
   Park JS, 2011, BIOMATERIALS, V32, P3921, DOI 10.1016/j.biomaterials.2011.02.019
   Pei M, 2008, DIFFERENTIATION, V76, P1044, DOI 10.1111/j.1432 0436.2008.00299.x
   Pfeifer CG, 2016, MATERIALS, V9, DOI 10.3390/ma9050381
   Qu X, 2011, ACTA BIOMATER, V7, P1031, DOI 10.1016/j.actbio.2010.11.020
   Radhakrishnan J, 2017, CARBOHYD POLYM, V175, P63, DOI 10.1016/j.carbpol.2017.07.063
   Re'em T, 2012, BIOMATERIALS, V33, P751, DOI 10.1016/j.biomaterials.2011.10.007
   Requicha JF, 2012, STEM CELL REV REP, V8, P1211, DOI 10.1007/s12015 012 9397 0
   Rodrigues MT, 2011, CURR OPIN BIOTECH, V22, P726, DOI 10.1016/j.copbio.2011.04.006
   Saik JE, 2011, ACTA BIOMATER, V7, P133, DOI 10.1016/j.actbio.2010.08.018
   Sakaguchi Y, 2005, ARTHRITIS RHEUM US, V52, P2521, DOI 10.1002/art.21212
   Salinas CN, 2008, J TISSUE ENG REGEN M, V2, P296, DOI 10.1002/term.95
   Salinas CN, 2008, BIOMATERIALS, V29, P2370, DOI 10.1016/j.biomaterials.2008.01.035
   Samavedi S, 2017, TISSUE ENG PT A, V23, P101, DOI [10.1089/ten.tea.2016.0007, 10.1089/ten.TEA.2016.0007]
   Seo H, 2017, RSC ADV, V7, P28684, DOI 10.1039/c7ra04492e
   Shibata S, 2006, J ANAT, V208, P169, DOI 10.1111/j.1469 7580.2006.00525.x
   Shields LBE, 2006, SPINE, V31, P542, DOI 10.1097/01.brs.0000201424.27509.72
   Shimomura K, 2015, CARTILAGE, V6, p13S, DOI 10.1177/1947603515571002
   Shimomura K, 2014, TISSUE ENG PT A, V20, P2291, DOI 10.1089/ten.tea.2013.0414
   Smucker JD, 2006, SPINE, V31, P2813, DOI 10.1097/01.brs.0000245863.52371.c2
   Sottnik JL, 2014, J CELL BIOCHEM, V115, P1420, DOI 10.1002/jcb.24793
   Steinmetz NJ, 2012, BIOTECHNOL BIOENG, V109, P2671, DOI 10.1002/bit.24519
   Tu XL, 2016, MICROELECTRON ENG, V158, P30, DOI 10.1016/j.mee.2016.03.007
   Varghese S, 2008, MATRIX BIOL, V27, P12, DOI 10.1016/j.matbio.2007.07.002
   Villanueva I, 2010, MATRIX BIOL, V29, P51, DOI 10.1016/j.matbio.2009.08.004
   Wang DA, 2007, NAT MATER, V6, P385, DOI 10.1038/nmat1890
   Wang YJ, 2010, J BIOMAT SCI POLYM E, V21, P1227, DOI 10.1163/092050609X12481751806259
   Williams CG, 2003, TISSUE ENG, V9, P679, DOI 10.1089/107632703768247377
   Wu XM, 2012, INT J NANOMED, V7, P1215, DOI 10.2147/IJN.S28101
   Yang PJ, 2009, TISSUE ENG PART B RE, V15, P127, DOI 10.1089/ten.teb.2008.0371
NR 118
TC 10
Z9 11
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1552 4973
EI 1552 4981
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD AUG
PY 2019
VL 107
IS 6
BP 2019
EP 2029
DI 10.1002/jbm.b.34293
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA JD4VY
UT WOS:000489979100026
PM 30549205
OA Green Accepted
DA 2025 08 17
ER

PT S
AU Baile, CA
   Yang, JY
   Rayalam, S
   Hartzell, DL
   Lai, CY
   Andersen, C
   Della Fera, MA
AF Baile, Clifton A.
   Yang, Jeong Yeh
   Rayalam, Srujana
   Hartzell, Diane L.
   Lai, Ching Yi
   Andersen, Charlotte
   Della Fera, Mary Anne
BE Vang, O
   Das, DK
TI Effect of resveratrol on fat mobilization
SO RESVERATROL AND HEALTH
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT 1st International Conference of Resveratrol and Health
CY SEP 13 16, 2010
CL Copenhagen, DENMARK
DE adipocytes; natural products; rodents; phytochemicals; obesity;
   osteoporosis
ID MESENCHYMAL STEM CELLS; DECREASES ADIPOCYTE FORMATION; 3T3 L1
   ADIPOCYTES; MITOCHONDRIAL FUNCTION; OSTEOBLAST DIFFERENTIATION; INHIBITS
   ADIPOGENESIS; POLYGONUM CUSPIDATUM; PPAR GAMMA; BONE LOSS; APOPTOSIS
AB Higher levels of body fat are associated with increased risk for development of numerous adverse health conditions. Phytochemicals are potential agents to inhibit differentiation of preadipocytes, stimulate lipolysis, and induce apoptosis of existing adipocytes, thereby reducing adipose tissue mass. Resveratrol decreased adipogenesis and viability in maturing preadipocytes; these effects were mediated not only through down regulating adipocyte specific transcription factors and enzymes but also by genes that modulate mitochondrial function. Additionally, resveratrol increased lipolysis and reduced lipogenesis in mature adipocytes. In addition, combining resveratrol with other natural products produced synergistic activities from actions on multiple molecular targets in the adipocyte life cycle. Treatment of mice with resveratrol alone was shown to improve resistance to weight gain caused by a high fat diet. Moreover, dietary supplementation of aged ovariectomized rats with a combination of resveratrol and vitamin D, quercetin, and genistein not only decreased weight gain but also inhibited bone loss. Combining several phytochemicals, including resveratrol, or using them as templates for synthesizing new drugs, provides a large potential for using phytochemicals to target adipocyte adipogenesis, apoptosis, and lipolysis.
C1 [Baile, Clifton A.; Yang, Jeong Yeh; Rayalam, Srujana; Hartzell, Diane L.; Lai, Ching Yi; Della Fera, Mary Anne] Univ Georgia, Athens, GA 30602 USA.
   [Andersen, Charlotte] Univ Copenhagen, Fac Life Sci, Dept Vet Dis Biol, Frederiksberg C, Denmark.
C3 University System of Georgia; University of Georgia; University of
   Copenhagen
RP Baile, CA (通讯作者)，Univ Georgia, 425 River Rd, Athens, GA 30602 USA.
EM cbaile@uga.edu
OI Rayalam, Srujana/0000 0003 3550 6741; Della Fera, Mary
   Anne/0000 0002 6660 8727
CR Ahn J, 2007, BIOCHEM BIOPH RES CO, V364, P972, DOI 10.1016/j.bbrc.2007.10.109
   Ambati S, 2009, PHYTOTHER RES, V23, P513, DOI 10.1002/ptr.2663
   ARICHI H, 1982, CHEM PHARM BULL, V30, P1766
   AUWERX J, 1992, CRIT REV CL LAB SCI, V29, P243, DOI 10.3109/10408369209114602
   Aziz MH, 2006, MOL CANCER THER, V5, P1335, DOI 10.1158/1535 7163.MCT 05 0526
   Bäckesjö CM, 2009, CELLS TISSUES ORGANS, V189, P93, DOI 10.1159/000151744
   Bäckesjö CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415
   Calixto Joao B., 2004, Planta Medica, V70, P93
   Cantó C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4
   Cooper C, 1999, OSTEOPOROSIS INT, V9, P2
   Dai Z, 2007, PHYTOMEDICINE, V14, P806, DOI 10.1016/j.phymed.2007.04.003
   de Simone G, 2008, NUTR METAB CARDIOVAS, V18, P337, DOI 10.1016/j.numecd.2008.03.008
   Ferry Dumazet H, 2002, CARCINOGENESIS, V23, P1327, DOI 10.1093/carcin/23.8.1327
   Fischer Posovszky P, 2010, AM J CLIN NUTR, V92, P5, DOI 10.3945/ajcn.2009.28435
   FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092 8674(95)90445 X
   Fullerton MD, 2010, DIABETES, V59, P551, DOI 10.2337/db09 1732
   Gennari L, 2009, EXPERT OPIN INV DRUG, V18, P839, DOI 10.1517/13543780902953715
   Gerhart Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633
   Gonzales AM, 2008, NUTR METAB, V5, DOI 10.1186/1743 7075 5 17
   Gregoire FM, 2001, EXP BIOL MED, V226, P997, DOI 10.1177/153537020122601106
   HABOLD C, 2010, J BONE MINE IN PRESS
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200
   Kao CL, 2010, STEM CELLS DEV, V19, P247, DOI 10.1089/scd.2009.0186
   Kessler RC, 2001, ANN INTERN MED, V135, P262, DOI 10.7326/0003 4819 135 4 200108210 00011
   Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   LAI CY, 2010, J MED FOOD IN PRESS
   Lazar MA, 2002, GENE DEV, V16, P1, DOI 10.1101/gad.964002
   Liang YC, 2003, BIOCHEM PHARMACOL, V65, P1053, DOI 10.1016/S0006 2952(03)00011 X
   Liu K, 2010, BIOCHIMIE, V92, P789, DOI 10.1016/j.biochi.2010.02.024
   Liu ZP, 2005, J MED FOOD, V8, P14, DOI 10.1089/jmf.2005.8.14
   Mader I, 2010, FASEB J, V24, P1997, DOI 10.1096/fj.09 142943
   Mayer MA, 2009, CURR CLIN PHARMACOL, V4, P53, DOI 10.2174/157488409787236128
   Mingrone G, 2005, DIABETOLOGIA, V48, P2108, DOI 10.1007/s00125 005 1918 9
   Mizutani K, 2000, J NUTR SCI VITAMINOL, V46, P78, DOI 10.3177/jnsv.46.78
   Mizutani K, 1998, BIOCHEM BIOPH RES CO, V253, P859, DOI 10.1006/bbrc.1998.9870
   Olholm J, 2010, INT J OBESITY, V34, P1546, DOI 10.1038/ijo.2010.98
   PAIRAULT J, 1979, P NATL ACAD SCI USA, V76, P5138, DOI 10.1073/pnas.76.10.5138
   Park HJ, 2008, J MED FOOD, V11, P773, DOI 10.1089/jmf.2008.0077
   Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583
   Post TM, 2010, CLIN PHARMACOKINET, V49, P89, DOI 10.2165/11318150 000000000 00000
   Rayalam S, 2008, PHYTOTHER RES, V22, P1367, DOI 10.1002/ptr.2503
   Rayalam S, 2007, J NUTR, V137, P2668, DOI 10.1093/jn/137.12.2668
   Rayalam S, 2009, J MED FOOD, V12, P846, DOI 10.1089/jmf.2008.0158
   Rayalarn S, 2007, BIOCHEM BIOPH RES CO, V364, P450, DOI 10.1016/j.bbrc.2007.10.051
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Sakaguchi K, 2000, PROSTAG LEUKOTR ESS, V62, P319, DOI 10.1054/plef.2000.0161
   Shi T, 2005, J BIOL CHEM, V280, P13560, DOI 10.1074/jbc.M414670200
   Szkudelska K, 2010, EUR J PHARMACOL, V635, P1, DOI 10.1016/j.ejphar.2010.02.054
   Szkudelska K, 2009, J STEROID BIOCHEM, V113, P17, DOI 10.1016/j.jsbmb.2008.11.001
   SZTALRYD C, 1995, J CLIN INVEST, V95, P2652, DOI 10.1172/JCI117967
   Um JH, 2010, DIABETES, V59, P554, DOI 10.2337/db09 0482
   UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644
   Visscher TLS, 2001, ANNU REV PUBL HEALTH, V22, P355, DOI 10.1146/annurev.publhealth.22.1.355
   Wang YH, 2006, J NUTR, V136, P2953, DOI 10.1093/jn/136.12.2953
   World Health Organization, 2009, WORLD HLTH STAT
   Yang JY, 2007, BIOFACTORS, V30, P159, DOI 10.1002/biof.5520300303
   Yang JY, 2008, LIFE SCI, V82, P1032, DOI 10.1016/j.lfs.2008.03.003
   Yang JY, 2008, OBESITY, V16, P16, DOI 10.1038/oby.2007.24
   Zhang JD, 2006, BIOCHEM J, V397, P519, DOI 10.1042/BJ20050977
   Zorzano A, 2004, Rev Med Univ Navarra, V48, P30
NR 62
TC 113
Z9 122
U1 2
U2 37
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA
SN 0077 8923
BN 978 1 57331 814 3
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2011
VL 1215
BP 40
EP 47
DI 10.1111/j.1749 6632.2010.05845.x
PG 8
WC Multidisciplinary Sciences
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA BTX00
UT WOS:000288345400006
PM 21261640
OA Bronze
DA 2025 08 17
ER

PT J
AU Han, GS
   Jing, YY
   Zhang, YH
   Yue, ZJ
   Hu, XW
   Wang, LX
   Liang, JC
   Liu, JM
AF Han, Guosheng
   Jing, Yingying
   Zhang, Yuhui
   Yue, Zhijian
   Hu, Xiaowu
   Wang, Laixing
   Liang, Jinchuan
   Liu, Jianmin
TI Osteogenic differentiation of bone marrow mesenchymal stem cells by
   adenovirus mediated expression of leptin
SO REGULATORY PEPTIDES
LA English
DT Article
DE Leptin; Adenovirus; Mesenchymal stem cells; Osteogenic differentiation
ID STROMAL CELLS; GENE THERAPY; BODY WEIGHT; PROGENITOR CELLS; LONG TERM;
   MINERALIZATION; PROLIFERATION; OSTEOBLASTS; PHENOTYPE; APOPTOSIS
AB Previous studies demonstrate that leptin has an osteogenic differentiation effect on bone marrow mesenchymal stem cells (MSCs) However, the effect of adenovirus mediated leptin on MSCs differentiation has not been reported. To explore the mechanism, we constructed a recombinant adenoviral vector Ad leptin and transfected propagated MSCs in vitro. The effects of Ad leptin on MSCs growth and osteogenic differentiation were examined The results showed that Ad leptin inhibited the transfected MSCs growth significantly, and up regulated osteocalcin expression and alkaline phosphatase activity The expression of Cbf alpha 1 and Cbf beta which were the key factors in osteogenic differentiation was also up regulated All the findings suggest that genetic engineering of MSCs to express leptin gene may have potential application in the treatment of several genetic diseases and bone reconstruction. (C) 2010 Elsevier B V All rights reserved
C1 [Han, Guosheng; Zhang, Yuhui; Yue, Zhijian; Hu, Xiaowu; Wang, Laixing; Liang, Jinchuan; Liu, Jianmin] Second Mil Med Univ, Changhai Hosp, Dept Neurosurg, Shanghai 200433, Peoples R China.
   [Jing, Yingying] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Tumor Immunol & Gene Therapy Ctr, Shanghai 200438, Peoples R China.
C3 Naval Medical University; Naval Medical University
RP Liu, JM (通讯作者)，Second Mil Med Univ, Changhai Hosp, Dept Neurosurg, Shanghai 200433, Peoples R China.
RI ; Liu, Jianmin/KEI 9744 2024
OI wang, laixing/0000 0001 6474 1754; 
CR Aleffi S, 2005, HEPATOLOGY, V42, P1339, DOI 10.1002/hep.20965
   Ben Hamouda K, 2003, J NEUROSURG, V99, P157, DOI 10.3171/spi.2003.99.2.0157
   Conget PA, 2000, EXP HEMATOL, V28, P382, DOI 10.1016/S0301 472X(00)00134 X
   Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301 472X(00)00482 3
   Dhillon H, 2001, MOL THER, V4, P139, DOI 10.1006/mthe.2001.0427
   Dhillon H, 2001, REGUL PEPTIDES, V99, P69, DOI 10.1016/S0167 0115(01)00237 3
   Dhillon H, 2000, REGUL PEPTIDES, V92, P97, DOI 10.1016/S0167 0115(00)00155 5
   Dube MG, 2002, DIABETES, V51, P1729, DOI 10.2337/diabetes.51.6.1729
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Gordeladze JO, 2002, J CELL BIOCHEM, V85, P825, DOI 10.1002/jcb.10156
   Hess R, 2005, J CELL BIOCHEM, V94, P50, DOI 10.1002/jcb.20330
   Jäger M, 2005, ANN BIOMED ENG, V33, P1319, DOI 10.1007/s10439 005 5889 2
   Majumdar MK, 1998, J CELL PHYSIOL, V176, P57, DOI 10.1002/(SICI)1097 4652(199807)176:1<57::AID JCP7>3.0.CO;2 7
   Marion NW, 2006, METHOD ENZYMOL, V420, P339, DOI 10.1016/S0079 6879(06)20016 8
   Mehlhorn AT, 2006, TISSUE ENG, V12, P1393, DOI 10.1089/ten.2006.12.1393
   Phinney DG, 2002, J CELL BIOCHEM, P7, DOI 10.1002/jcb.10084
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Qu Petersen ZQ, 2002, J CELL BIOL, V157, P851, DOI 10.1083/jcb.200108150
   Reseland JE, 2001, J BONE MINER RES, V16, P1426, DOI 10.1359/jbmr.2001.16.8.1426
   Rodríguez JP, 2004, J CELL BIOCHEM, V93, P721, DOI 10.1002/jcb.20234
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630
   Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442
   Xie YF, 2008, CANCER BIOTHER RADIO, V23, P310, DOI 10.1089/cbr.2007.0453
   Yoo JU, 1998, CLIN ORTHOP RELAT R, pS73
   Zhang FM, 2005, VITAM HORM, V71, P345, DOI 10.1016/S0083 6729(05)71012 8
   ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 29
TC 18
Z9 19
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167 0115
EI 1873 1686
J9 REGUL PEPTIDES
JI Regul. Pept.
PD AUG 9
PY 2010
VL 163
IS 1 3
BP 107
EP 112
DI 10.1016/j.regpep.2010.04.006
PG 6
WC Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Physiology
GA 627OS
UT WOS:000280050000016
PM 20433876
DA 2025 08 17
ER

PT J
AU Linderbäck, P
   Areva, S
   Aspenberg, P
   Tengvall, P
AF Linderback, Paula
   Areva, Sami
   Aspenberg, Per
   Tengvall, Pentti
TI Sol gel derived titania coating with immobilized bisphosphonate enhances
   screw fixation in rat tibia
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE screw; bone; bisphosphonates; sol gel; rat
ID CALCIUM PHOSPHATE FORMATION; STAINLESS STEEL; SURFACE STRUCTURE;
   IN VITRO; BONE; IMPLANTS; TIO2; MECHANISMS; DELIVERY; INSIGHTS
AB A variety of surface modifications have been tested for the enhancement of screw fixation in bone, and locally delivered anti osteoporosis drugs such as bisphosphonates (BP) are then of interest. In this in vivo study, the impact of surface immobilized BP was compared with systemic BP delivery and screws with no BP. After due in vitro characterization, differently treated stainless steel (SS) screws were divided into four groups with 10 rats each. Three of the groups received screws coated with sol gel derived TiO2 and calcium phosphate (SS+TiO2+CaP). One of these had no further treatment, one had alendronate (BP) adsorbed to calcium phosphate mineral, and one received systemic BP treatment. The fourth group received uncoated SS screws and no BP (control). The screw pullout force was measured after 4 weeks of implantation in rat tibiae. The immobilized amount and release rate of alendronate could be controlled by different immersion times. The SS+TiO2+CaP coating did not increase the pullout force compared to SS alone. Surface delivered alendronate enhanced the pullout force by 93% [p = 0.000; 95% Confidence Interval (CI): 67 118%] compared to SS, and by 39% (p = 0.044; 95% CI: 7 71%) compared to systemic alendronate delivery. Both surface immobilized and systemically delivered alendronate improved implant fixation. Also, locally delivered, that is, surface immobilized alendronate showed a better fixation than systemically delivered. Using sot gel derived TiO2 as a platform, it is possible to administer controllable amounts of a variety of BPs. (C) 2010 Wiley Periodicals, Inc. J Biomed Mater Res 94A: 389 395, 2010
C1 [Linderback, Paula; Tengvall, Pentti] Linkoping Univ, Appl Phys Lab, Dept Phys Chem & Biol, SE 58183 Linkoping, Sweden.
   [Areva, Sami] Univ Turku, Turku Biomat Ctr, FIN 20520 Turku, Finland.
   [Aspenberg, Per] Linkoping Univ, Sect Orthoped, Fac Hlth Sci, Inst Clin & Expt Med, SE 58185 Linkoping, Sweden.
   [Tengvall, Pentti] Univ Gothenburg, Sahlgrenska Acad, Dept Biomat Sci, SE 40530 Gothenburg, Sweden.
C3 Linkoping University; University of Turku; Linkoping University;
   University of Gothenburg
RP Linderbäck, P (通讯作者)，Linkoping Univ, Appl Phys Lab, Dept Phys Chem & Biol, SE 58183 Linkoping, Sweden.
EM palin@ifm.liu.se
FU Ostra Gotalands Landsting; Linkoping University
FX Contract grant sponsors: Ostra Gotalands Landsting; Linkoping University
   via the strategic research programme "Materials in Medicine"
CR Areva S, 2004, J BIOMED MATER RES A, V70A, P169, DOI 10.1002/jbm.a.20120
   Gao Y, 2009, BIOMATERIALS, V30, P1790, DOI 10.1016/j.biomaterials.2008.12.025
   Jokinen M, 1998, J BIOMED MATER RES, V42, P295, DOI 10.1002/(SICI)1097 4636(199811)42:2<295::AID JBM15>3.0.CO;2 I
   Kajiwara H, 2005, BIOMATERIALS, V26, P581, DOI 10.1016/j.biomaterials.2004.02.072
   Kim HM, 1999, J BIOMED MATER RES, V45, P100, DOI 10.1002/(SICI)1097 4636(199905)45:2<100::AID JBM4>3.0.CO;2 0
   KOKUBO T, 1991, BIOMATERIALS, V12, P155, DOI 10.1016/0142 9612(91)90194 F
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   KOKUBO T, 1990, J BIOMED MATER RES, V24, P721, DOI 10.1002/jbm.820240607
   LI PJ, 1993, J BIOMED MATER RES, V27, P1495, DOI 10.1002/jbm.820271205
   Mjoberg B, 1997, ORTHOPEDICS, V20, P1169
   Nagano M, 1996, BIOMATERIALS, V17, P1771, DOI 10.1016/0142 9612(95)00357 6
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Paldan H, 2008, J MATER SCI MATER M, V19, P1283, DOI 10.1007/s10856 007 3234 z
   Peltola T, 1999, J BIOMED MATER RES, V44, P12, DOI 10.1002/(SICI)1097 4636(199901)44:1<12::AID JBM2>3.0.CO;2 E
   Peter B, 2005, BONE, V36, P52, DOI 10.1016/j.bone.2004.10.004
   Peter B, 2006, J BIOMED MATER RES A, V76A, P133, DOI 10.1002/jbm.a.30456
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756 3282(99)00070 8
   Rossi S, 2007, J BIOMED MATER RES A, V82A, P965, DOI 10.1002/jbm.a.31245
   Rossi S, 2008, CLIN ORAL IMPLAN RES, V19, P348, DOI 10.1111/j.1600 0501.2007.01478.x
   Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Tengvall P, 2004, BIOMATERIALS, V25, P2133, DOI 10.1016/j.biomaterials.2003.08.049
   Voggenreiter G, 2003, BIOMATERIALS, V24, P247, DOI 10.1016/S0142 9612(02)00312 5
   Wermelin K, 2008, BONE, V42, P365, DOI 10.1016/j.bone.2007.10.013
   Wermelin K, 2008, J BIOMED MATER RES A, V86A, P220, DOI 10.1002/jbm.a.31583
   Wermelin K, 2007, ACTA ORTHOP, V78, P385, DOI 10.1080/17453670710013979
   Yoshinari M, 2002, BIOMATERIALS, V23, P2879, DOI 10.1016/S0142 9612(01)00415 X
   Yoshinari M, 2001, BIOMATERIALS, V22, P709, DOI 10.1016/S0142 9612(00)00234 9
NR 30
TC 16
Z9 16
U1 0
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD AUG
PY 2010
VL 94A
IS 2
BP 389
EP 395
DI 10.1002/jbm.a.32708
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 620EU
UT WOS:000279482600006
PM 20186735
DA 2025 08 17
ER

PT J
AU Benova, A
   Ferencakova, M
   Bardova, K
   Funda, J
   Prochazka, J
   Spoutil, F
   Cajka, T
   Dzubanova, M
   Balcaen, T
   Kerckhofs, G
   Willekens, W
   van Lenthe, GH
   Alquicer, G
   Pecinova, A
   Mracek, T
   Horakova, O
   Rossmeisl, M
   Kopecky, J
   Tencerova, M
AF Benova, Andrea
   Ferencakova, Michaela
   Bardova, Kristina
   Funda, Jiri
   Prochazka, Jan
   Spoutil, Frantisek
   Cajka, Tomas
   Dzubanova, Martina
   Balcaen, Tim
   Kerckhofs, Greet
   Willekens, Wouter
   van Lenthe, G. Harry
   Alquicer, Glenda
   Pecinova, Alena
   Mracek, Tomas
   Horakova, Olga
   Rossmeisl, Martin
   Kopecky, Jan
   Tencerova, Michaela
TI Novel thiazolidinedione analog reduces a negative impact on bone and
   mesenchymal stem cell properties in obese mice compared to classical
   thiazolidinediones
SO MOLECULAR METABOLISM
LA English
DT Article
DE Obesity induced bone fragility; Bone microstructure; Bone marrow
   mesenchymal stem cells; Bone marrow adiposity; Thiazoli dinedione analog
   MSDC 0602K; Pioglitazone
ID MARROW ADIPOSE TISSUE; ACTIVATED RECEPTOR GAMMA; DIET INDUCED OBESITY;
   PPAR GAMMA; INSULIN SENSITIVITY; ROSIGLITAZONE; MASS; DIFFERENTIATION;
   PIOGLITAZONE; IDENTIFICATION
AB Objective: The use of thiazolidinediones (TZDs) as insulin sensitizers has been shown to have side effects including increased accumulation of bone marrow adipocytes (BMAds) associated with a higher fracture risk and bone loss. A novel TZD analog MSDC 0602K with low affinity to PPARg has been developed to reduce adverse effects of TZD therapy. However, the effect of MSDC 0602K on bone phenotype and bone marrow mesenchymal stem cells (BM MSCs) in relation to obesity has not been intensively studied yet.Methods: Here, we investigated whether 8 week treatment with MSDC 0602K has a less detrimental effect on bone loss and BM MSC properties in obese mice in comparison to first generation of TZDs, pioglitazone. Bone parameters (bone microstructure, bone marrow adiposity, bone strength) were examined by mCT and 3 point bending test. Primary BM MSCs were isolated and measured for osteoblast and adipocyte differentiation. Cellular senescence, bioenergetic profiling, nutrient consumption and insulin signaling were also determined.Results: The findings demonstrate that MSDC 0602K improved bone parameters along with increased proportion of smaller BMAds in tibia of obese mice when compared to pioglitazone. Further, primary BM MSCs isolated from treated mice and human BM MSCs revealed decreased adipocyte and higher osteoblast differentiation accompanied with less inflammatory and senescent phenotype induced by MSDC 0602K vs. pioglitazone. These changes were further reflected by increased glycolytic activity differently affecting glutamine and glucose cellular metabolism in MSDC 0602K treated cells compared to pioglitazone, associated with higher osteogenesis.Conclusion: Our study provides novel insights into the action of MSDC 0602K in obese mice, characterized by the absence of detrimental effects on bone quality and BM MSC metabolism when compared to classical TZDs and thus suggesting a potential therapeutical use of MSDC 0602K in both metabolic and bone diseases.(c) 2022 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Benova, Andrea; Ferencakova, Michaela; Dzubanova, Martina; Alquicer, Glenda; Tencerova, Michaela] Czech Acad Sci, Inst Physiol, Lab Mol Physiol Bone, Prague 14220, Czech Republic.
   [Benova, Andrea; Dzubanova, Martina] Charles Univ Prague, Fac Sci, Prague, Czech Republic.
   [Bardova, Kristina; Funda, Jiri; Horakova, Olga; Rossmeisl, Martin; Kopecky, Jan] Czech Acad Sci, Inst Physiol, Lab Adipose Tissue Biol, Prague 14220, Czech Republic.
   [Prochazka, Jan; Spoutil, Frantisek] Czech Acad Sci, Inst Mol Genet, Czech Ctr Phenogen, Prague, Czech Republic.
   [Prochazka, Jan; Spoutil, Frantisek] Czech Acad Sci, Inst Mol Genet, Lab Transgen Models Dis, Prague, Czech Republic.
   [Cajka, Tomas] Czech Acad Sci, Inst Physiol, Lab Translat Metab, Prague 14220, Czech Republic.
   [Balcaen, Tim; Kerckhofs, Greet] UCLouvain, Inst Mech Mat & Civil Engn, Biomech Lab, Louvain La Neuve, Belgium.
   [Kerckhofs, Greet] Katholieke Univ Leuven, Dept Mat Engn, Leuven, Belgium.
   [Kerckhofs, Greet] Katholieke Univ Leuven, Div Skeletal Tissue Engn, Prometheus, B 3000 Leuven, Belgium.
   [Kerckhofs, Greet] UCLouvain, Inst Expt & Clin Res, Pole Morphol, Brussels, Belgium.
   [Balcaen, Tim] Katholieke Univ Leuven, Dept Chem Mol Design & Synth, Leuven, Belgium.
   [Willekens, Wouter] Katholieke Univ Leuven, FIBEr, Leuven, Belgium.
   [van Lenthe, G. Harry] Katholieke Univ Leuven, Dept Mech Engn, Leuven, Belgium.
   [Pecinova, Alena; Mracek, Tomas] Czech Acad Sci, Inst Physiol, Lab Bioenerget, Prague, Czech Republic.
C3 Czech Academy of Sciences; Institute of Physiology of the Czech Academy
   of Sciences; Charles University Prague; Czech Academy of Sciences;
   Institute of Physiology of the Czech Academy of Sciences; Czech Academy
   of Sciences; Institute of Molecular Genetics of the Czech Academy of
   Sciences; Czech Academy of Sciences; Institute of Molecular Genetics of
   the Czech Academy of Sciences; Czech Academy of Sciences; Institute of
   Physiology of the Czech Academy of Sciences; Universite Catholique
   Louvain; KU Leuven; KU Leuven; Universite Catholique Louvain; KU Leuven;
   KU Leuven; KU Leuven; Czech Academy of Sciences; Institute of Physiology
   of the Czech Academy of Sciences
RP Tencerova, M (通讯作者)，Czech Acad Sci, Inst Physiol, Mol Physiol Bone, Videnska 1083, Prague 14220 4, Czech Republic.
EM michaela.tencerova@fgu.cas.cz
RI Mracek, Tomas/C 5003 2012; Funda, Jiri/V 3799 2017; Bardova,
   Kristina/C 3493 2015; Kopecky, Jan/B 8244 2012; Pecinova,
   Alena/A 8695 2010; Ferenčáková, Michaela/AIC 6235 2022; Alquicer
   Barrera, Glenda/AAQ 4383 2021; Ferencakova, Michaela/AIC 6235 2022;
   Pecinová, Alena/A 8695 2010; Cajka, Tomas/A 8914 2008; Spoutil,
   Frantisek/I 6725 2019; Rossmeisl, Martin/C 1892 2012; Alquicer,
   Glenda/AAQ 4383 2021; Balcaen, Tim/NRZ 0120 2025; van Lenthe, Harry
   (GH)/C 1030 2008; Tencerova, Michaela/G 8089 2017; Benova,
   Andrea/AGZ 8886 2022; Prochazka, Jan/HQZ 4419 2023; Kerckhofs,
   Greet/J 5006 2016; Horakova, Olga/C 8001 2012; Beňová,
   Andrea/AGZ 8886 2022
OI Funda, Jiri/0000 0002 4228 0325; Pecinova, Alena/0000 0002 0204 7502;
   Ferencakova, Michaela/0000 0002 9999 0854; Cajka,
   Tomas/0000 0002 9728 3355; Alquicer, Glenda/0000 0003 1773 5540; van
   Lenthe, Harry (GH)/0000 0001 8303 4959; Balcaen,
   Tim/0000 0001 5108 525X; Bardova, Kristina/0000 0002 2297 5066; Benova,
   Andrea/0000 0001 6839 5289; Dzubanova, Martina/0000 0002 4889 5822;
   Kopecky, Jan/0000 0001 8072 2035; Kerckhofs, Greet/0000 0002 1750 8324;
   Horakova, Olga/0000 0003 0933 4616; 
FU START UP Research programme by Institute of Physiology; Czech Science
   Foundation [GACR 20 03586S, GACR 19 02411S]; EFSD/NovoNordisk foundation
   Future leaders award [NNF20SA0066174]; National Institute for Research
   of Metabolic and Cardiovascular Diseases (Programme EXCELES)
   [LX22NPO5104]; European Union Next Generation EU; Grant Agency of
   Charles University [GAUK 339821]; FRIA [40004158]
FX We would like to thank Histology Core facility at CCP Biocev for their
   excellent work in preparation of bone samples. We thank Kimberly Crevits
   at FIBEr, KU Leuven, for performing the three point bending tests. We
   are grateful for help with writing of MATLAB script used for automatic
   histogram windowing and relative gray value normalization of CECT images
   to Arne Maes from KU Leuven. Further. We are grateful to Prof. Moustapha
   Kassem, KMEB SDU Odense for his generous gift of immortalized human cell
   line hBM MSC TERT. We thank dr. Jerry Colca from Cirius Therapeutics
   (Kalamazoo, USA) for providing us MSDC 0602K. We thank Dr. Siobhan
   Craige for the critical reading of the manuscript and discussion. The
   authors would like to acknowledge the Metabolomics Core Facility at the
   Institute of Physiology of the Czech Academy of Sciences for global
   metabolomic and lipidomic pro filing. This work was supported by START
   UP Research programme by Institute of Physiology and the Czech Science
   Foundation GACR 20 03586S (MT) , GACR 19 02411S (JK) , EFSD/NovoNordisk
   foundation Future leaders award (NNF20SA0066174) , National Institute
   for Research of Metabolic and Cardiovascular Diseases (Programme
   EXCELES, ID Project No. LX22NPO5104)  Funded by the European Union Next
   Generation EU, Grant Agency of Charles University GAUK 339821 (AB) and
   FRIA grant 40004158 (TB) .
CR Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059
   Ackert Bicknell CL, 2009, ENDOCRINOLOGY, V150, P1330, DOI 10.1210/en.2008 0936
   Alam F, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 41854 2
   Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Bäckdahl J, 2021, CELL METAB, V33, P1869, DOI 10.1016/j.cmet.2021.07.018
   Bardova K, 2020, NUTRIENTS, V12, DOI 10.3390/nu12123737
   Benova A, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00294
   Bowden JA, 2017, J LIPID RES, V58, P2275, DOI 10.1194/jlr.M079012
   Callewaert F, 2010, J BONE MINER RES, V25, P617, DOI 10.1359/jbmr.090828
   Chen ZJ, 2012, J BIOL CHEM, V287, P23537, DOI 10.1074/jbc.M112.363960
   Choi JH, 2011, NATURE, V477, P477, DOI 10.1038/nature10383
   Colca JR, 2022, MOL METAB, V55, DOI 10.1016/j.molmet.2021.101409
   Colca JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061551
   Colca JR, 2004, AM J PHYSIOL ENDOC M, V286, pE252, DOI 10.1152/ajpendo.00424.2003
   Ding M, 2006, CALCIFIED TISSUE INT, V78, P113, DOI 10.1007/s00223 005 0028 5
   Divakaruni AS, 2013, P NATL ACAD SCI USA, V110, P5422, DOI 10.1073/pnas.1303360110
   Doucette CR, 2015, J CELL PHYSIOL, V230, P2032, DOI 10.1002/jcp.24954
   Farr JN, 2016, J BONE MINER RES, V31, P1920, DOI 10.1002/jbmr.2892
   Fukunaga T, 2015, J BONE MINER RES, V30, P508, DOI 10.1002/jbmr.2364
   Hamam D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.462
   Harrison SA, 2020, J HEPATOL, V72, P613, DOI 10.1016/j.jhep.2019.10.023
   Jafari A, 2015, STEM CELLS, V33, P2219, DOI 10.1002/stem.2013
   Jardí F, 2019, J BONE MINER RES, V34, P508, DOI 10.1002/jbmr.3625
   Jin LH, 2018, TISSUE ENG REGEN MED, V15, P311, DOI 10.1007/s13770 018 0117 y
   Kanda J, 2017, J PHARMACOL SCI, V135, P22, DOI 10.1016/j.jphs.2017.08.004
   Kerckhofs G, 2018, BIOMATERIALS, V159, P1, DOI 10.1016/j.biomaterials.2017.12.016
   Kerckhofs G, 2014, CARTILAGE, V5, P55, DOI 10.1177/1947603513501175
   Kuda O, 2009, DIABETOLOGIA, V52, P941, DOI 10.1007/s00125 009 1305 z
   Kus V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027126
   Kyle KA, 2011, ENDOCRINOLOGY, V152, P457, DOI 10.1210/en.2010 1098
   Lazarenko OP, 2007, ENDOCRINOLOGY, V148, P2669, DOI 10.1210/en.2006 1587
   Lecka Czernik B, 2015, MOL CELL ENDOCRINOL, V410, P35, DOI 10.1016/j.mce.2015.01.001
   Lecka Czernik Beata, 2010, Curr Osteoporos Rep, V8, P178, DOI 10.1007/s11914 010 0027 y
   Lee KY, 2019, EMBO J, V38, DOI 10.15252/embj.201899291
   Liu LC, 2013, BONE, V52, P247, DOI 10.1016/j.bone.2012.09.038
   McCommis KS, 2017, HEPATOLOGY, V65, P1543, DOI 10.1002/hep.29025
   McCommis KS, 2015, BIOCHEM J, V466, P443, DOI 10.1042/BJ20141171
   Mittelstaedt D, 2015, CARTILAGE, V6, P216, DOI 10.1177/1947603515596418
   Naka K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9039
   Reguera DP, 2020, CELLS BASEL, V9, DOI 10.3390/cells9020443
   Panic V, 2020, ELIFE, V9, DOI 10.7554/eLife.52558
   Pavo I, 2003, J CLIN ENDOCR METAB, V88, P1637, DOI 10.1210/jc.2002 021786
   Pop LM, 2017, OSTEOPOROSIS INT, V28, P3261, DOI 10.1007/s00198 017 4164 3
   Quansah E, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024 018 0260 x
   Ramstead AG, 2020, CELL REP, V30, P2889, DOI 10.1016/j.celrep.2020.02.042
   Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178
   Scheller EL, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00102
   Scheller EL, 2014, METHOD ENZYMOL, V537, P123, DOI 10.1016/B978 0 12 411619 1.00007 0
   Sharma D, 2021, ELIFE, V10, DOI [10.7554/eLife.71595, 10.7554/eLife.71595.sa1, 10.7554/eLife.71595.sa2]
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   Stechschulte LA, 2016, EBIOMEDICINE, V10, P174, DOI 10.1016/j.ebiom.2016.06.040
   Tan YJ, 2012, MOL PHARMACOL, V82, P68, DOI 10.1124/mol.111.076679
   Tanis SP, 2018, BIOORGAN MED CHEM, V26, P5870, DOI 10.1016/j.bmc.2018.10.033
   Tedesco S, 2020, DIABETES, V69, P1562, DOI 10.2337/db19 0640
   Tencerova M, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0076 5
   Tencerova M, 2019, CELL REP, V27, P2050, DOI 10.1016/j.celrep.2019.04.066
   Tencerova M, 2018, J BONE MINER RES, V33, P1154, DOI 10.1002/jbmr.3408
   Tornvig L, 2001, CALCIFIED TISSUE INT, V69, P46, DOI 10.1007/s002230020018
   Twine NA, 2018, JBMR PLUS, V2, P257, DOI 10.1002/jbm4.10050
   Vacanti NM, 2014, MOL CELL, V56, P425, DOI 10.1016/j.molcel.2014.09.024
   Veliova M, 2020, EMBO REP, V21, DOI 10.15252/embr.201949634
   Wang SB, 2016, PHARMACOL RES, V111, P76, DOI 10.1016/j.phrs.2016.02.028
   Wu HC, 2013, J CELL BIOCHEM, V114, P1969, DOI 10.1002/jcb.24534
   Wu SF, 2011, ENDOCRINOLOGY, V152, P468, DOI 10.1210/en.2010 0803
   Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451
   Yang CD, 2014, MOL CELL, V56, P414, DOI 10.1016/j.molcel.2014.09.025
   Yang H, 2018, BRIT J PHARMACOL, V175, P3610, DOI 10.1111/bph.14434
   Yea K, 2009, J BIOL CHEM, V284, P33833, DOI 10.1074/jbc.M109.024869
   Yu YL, 2019, CELL METAB, V29, P966, DOI 10.1016/j.cmet.2019.01.016
NR 69
TC 23
Z9 23
U1 0
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2212 8778
J9 MOL METAB
JI Mol. Metab.
PD NOV
PY 2022
VL 65
AR 101598
DI 10.1016/j.molmet.2022.101598
EA SEP 2022
PG 20
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 5O6UA
UT WOS:000872604500004
PM 36103974
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Little, GH
   Baniwal, SK
   Adisetiyo, H
   Groshen, S
   Chimge, NO
   Kim, SY
   Khalid, O
   Hawes, D
   Jones, JO
   Pinski, J
   Schones, DE
   Frenkel, B
AF Little, Gillian H.
   Baniwal, Sanjeev K.
   Adisetiyo, Helty
   Groshen, Susan
   Chimge, Nyam Osor
   Kim, Sun Young
   Khalid, Omar
   Hawes, Debra
   Jones, Jeremy O.
   Pinski, Jacek
   Schones, Dustin E.
   Frenkel, Baruch
TI Differential Effects of RUNX2 on the Androgen Receptor in Prostate
   Cancer: Synergistic Stimulation of a Gene Set Exemplified by SNAI2 and
   Subsequent Invasiveness
SO CANCER RESEARCH
LA English
DT Article
ID TRANSCRIPTION FACTOR RUNX2; BREAST CANCER; CELL PROLIFERATION;
   OSTEOBLAST DIFFERENTIATION; TUMOR PROGRESSION; EXPRESSION; METASTASIS;
   GROWTH; REPRESSION; PROTEIN
AB Changes to androgen signaling during prostate carcinogenesis are associated with both inhibition of cellular differentiation and promotion of malignant phenotypes. The androgen receptor (AR) binding transcription factor RUNX2 has been linked to prostate cancer progression but the underlying mechanisms have not been fully defined. In this study, we investigated the genome wide influence of RUNX2 on androgen induced gene expression and AR DNA binding in prostate cancer cells. RUNX2 inhibited the androgen response partly by promoting the dissociation of AR from its target genes such as the tumor suppressor NKX3 1. However, AR activity persists in the presence of RUNX2 at other AR target genes, some of which are cooperatively stimulated by androgen and RUNX2 signaling. These genes are associated with putative enhancers co occupied by AR and RUNX2. One such gene, the invasion promoting Snail family transcription factor SNAI2, was co activated by AR and RUNX2. Indeed, these two transcription factors together, but neither alone stimulated prostate cancer cell invasiveness, which could be abolished by SNAI2 silencing. Furthermore, an immunohistochemical analysis of SNAI2 in archived primary prostate cancer specimens revealed a correlation with the RUNX2 histoscore, and simultaneous strong staining for SNAI2, RUNX2, and AR (but not any pair alone) was associated with disease recurrence. Overall, our findings suggest cooperation between AR and RUNX in the stimulation of oncogenes such as SNAI2, which might be targeted for individualized prostate cancer therapy. (C) 2014 AACR.
C1 [Little, Gillian H.; Adisetiyo, Helty; Chimge, Nyam Osor; Frenkel, Baruch] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA.
   [Baniwal, Sanjeev K.; Frenkel, Baruch] Univ So Calif, Keck Sch Med, Dept Orthoped Surg, Los Angeles, CA 90033 USA.
   [Groshen, Susan] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
   [Chimge, Nyam Osor; Pinski, Jacek] Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA.
   [Little, Gillian H.; Baniwal, Sanjeev K.; Adisetiyo, Helty; Kim, Sun Young; Khalid, Omar; Frenkel, Baruch] Univ So Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA.
   [Groshen, Susan; Hawes, Debra; Pinski, Jacek] Univ So Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
   [Jones, Jeremy O.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Pharmacol, Duarte, CA 91010 USA.
   [Schones, Dustin E.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA.
C3 University of Southern California; University of Southern California;
   University of Southern California; University of Southern California;
   University of Southern California; University of Southern California;
   University Southern California Hospital; City of Hope; Beckman Research
   Institute of City of Hope; City of Hope; Beckman Research Institute of
   City of Hope
RP Little, GH (通讯作者)，Univ So Calif, Inst Med Genet, 2250 Alcazar St,CSC 240, Los Angeles, CA 90033 USA.
EM glittle@usc.edu; frenkel@usc.edu
OI Schones, Dustin/0000 0001 7692 8583; Kim, Sunyoung/0000 0001 7974 2418
FU NIH from National Institute of Diabetes and Digestive and Kidney
   Diseases [R01 DK07112, R01 DK07112S]; NIH from the National Cancer
   Institute [P30 CA014089]; Wright Foundation; Zumberge Foundation
FX This work was supported by NIH grants R01 DK07112 and R01 DK07112S from
   the National Institute of Diabetes and Digestive and Kidney Diseases to
   B. Frenkel, NIH grant P30 CA014089 from the National Cancer Institute to
   S. Groshen (Biostatistics Core), as well as grants from the Wright
   Foundation to G.H. Little and from the Zumberge Foundation to S.K.
   Baniwal. B. Frenkel holds the J. Harold and Edna L. LaBriola Chair in
   Genetic Orthopedic Research at USC.
CR Akech J, 2010, ONCOGENE, V29, P811, DOI 10.1038/onc.2009.389
   Balbin M, 1996, J BIOL CHEM, V271, P15175, DOI 10.1074/jbc.271.25.15175
   Baniwal SK, 2012, J CELL PHYSIOL, V227, P2276, DOI 10.1002/jcp.22966
   Baniwal SK, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 258
   Baniwal SK, 2009, MOL ENDOCRINOL, V23, P1203, DOI 10.1210/me.2008 0470
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Baygi ME, 2010, TUMOR BIOL, V31, P297, DOI 10.1007/s13277 010 0037 5
   Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607
   Blyth K, 2010, BLOOD CELL MOL DIS, V45, P117, DOI 10.1016/j.bcmd.2010.05.007
   Bowen C, 2000, CANCER RES, V60, P6111
   Brubaker KD, 2003, PROSTATE, V56, P13, DOI 10.1002/pros.10233
   Chimge NO, 2013, ONCOGENE, V32, P2121, DOI 10.1038/onc.2012.328
   Chimge NO, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3073
   Chimge NO, 2012, CLIN CANCER RES, V18, P901, DOI 10.1158/1078 0432.CCR 11 1530
   Chua CW, 2009, CLIN CANCER RES, V15, P4322, DOI 10.1158/1078 0432.CCR 08 3157
   Frenkel B, 2010, J CELL PHYSIOL, V224, P305, DOI 10.1002/jcp.22159
   Ito Y, 2008, ADV CANCER RES, V99, P33, DOI 10.1016/S0065 230X(07)99002 8
   Jia L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003645
   Kawate H, 2007, J STEROID BIOCHEM, V105, P46, DOI 10.1016/j.jsbmb.2006.11.020
   Khalid O, 2008, ENDOCRINOLOGY, V149, P5984, DOI 10.1210/en.2008 0680
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lim M, 2010, LAB INVEST, V90, P222, DOI 10.1038/labinvest.2009.128
   Lin BY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006589
   Little GH, 2012, NUCLEIC ACIDS RES, V40, P3538, DOI 10.1093/nar/gkr1219
   Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58
   Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306 11
   Massie CE, 2007, EMBO REP, V8, P871, DOI 10.1038/sj.embor.7401046
   Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158
   McCarthy TL, 2003, J BIOL CHEM, V278, P43121, DOI 10.1074/jbc.M306531200
   Onodera Y, 2010, CANCER SCI, V101, P2670, DOI 10.1111/j.1349 7006.2010.01742.x
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Paredes R, 2004, MOL CELL BIOL, V24, P8847, DOI 10.1128/MCB.24.20.8847 8861.2004
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Pratap J, 2008, CANCER RES, V68, P7795, DOI 10.1158/0008 5472.CAN 08 1078
   Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328
   Steffan JJ, 2011, CANCER LETT, V310, P109, DOI 10.1016/j.canlet.2011.06.011
   Tan PY, 2012, MOL CELL BIOL, V32, P399, DOI 10.1128/MCB.05958 11
   Tepper CG, 2002, CANCER RES, V62, P6606
   Thomas MA, 2010, BIOCHEM J, V425, P575, DOI 10.1042/BJ20091109
   Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935
   van der Deen M, 2010, J CELL BIOCHEM, V109, P828, DOI 10.1002/jcb.22463
   Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041
   Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056
   Wu KJ, 2012, MOL ENDOCRINOL, V26, P1496, DOI 10.1210/me.2011 1360
   Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555 008 9169 0
   Yun SJ, 2012, PROSTATE CANCER P D, V15, P369, DOI 10.1038/pcan.2012.31
   Zhang HJ, 2011, CANCER RES, V71, P3257, DOI 10.1158/0008 5472.CAN 10 2603
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb 2008 9 9 r137
NR 48
TC 28
Z9 30
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD MAY 15
PY 2014
VL 74
IS 10
BP 2857
EP 2868
DI 10.1158/0008 5472.CAN 13 2003
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AI2WW
UT WOS:000336720700021
PM 24648349
OA Green Submitted, Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU van Zoelen, EJ
   Duarte, I
   Hendriks, JM
   van der Woning, SP
AF van Zoelen, Everardus J.
   Duarte, Isabel
   Hendriks, Jose M.
   van der Woning, Sebastian P.
TI TGFβ induced switch from adipogenic to osteogenic differentiation of
   human mesenchymal stem cells: identification of drug targets for
   prevention of fat cell differentiation
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Mesenchymal stem cell; Adipogenesis; Osteogenesis; Osteoporosis; Bone
   marrow; Histone deacetylase; Metalloproteinase; Aldo keto reductase
ID TUMOR MARKER AKR1B10; GROWTH FACTOR BETA; MATRIX METALLOPROTEINASE
   INHIBITORS; ADIPOCYTE DIFFERENTIATION; BONE MARROW;
   SELECTIVE INHIBITION; HISTONE DEACETYLASES; BREAST CANCER; OSTEOPOROSIS;
   FAMILY
AB Background: Patients suffering from osteoporosis show an increased number of adipocytes in their bone marrow, concomitant with a reduction in the pool of human mesenchymal stem cells (hMSCs) that are able to differentiate into osteoblasts, thus leading to suppressed osteogenesis.
   Methods: In order to be able to interfere with this process, we have investigated in vitro culture conditions whereby adipogenic differentiation of hMSCs is impaired and osteogenic differentiation is promoted. By means of gene expression microarray analysis, we have investigated genes which are potential targets for prevention of fat cell differentiation.
   Results: Our data show that BMP2 promotes both adipogenic and osteogenic differentiation of hMSCs, while transforming growth factor beta (TGF beta) inhibits differentiation into both lineages. However, when cells are cultured under adipogenic differentiation conditions, which contain cAMP enhancing agents such as IBMX of PGE2, TGF beta promotes osteogenic differentiation, while at the same time inhibiting adipogenic differentiation. Gene expression and immunoblot analysis indicated that IBMX induced suppression of HDAC5 levels plays an important role in the inhibitory effect of TGF beta on osteogenic differentiation. By means of gene expression microarray analysis, we have investigated genes which are downregulated by TGF beta under adipogenic differentiation conditions and may therefore be potential targets for prevention of fat cell differentiation. We thus identified nine genes for which FDA approved drugs are available. Our results show that drugs directed against the nuclear hormone receptor PPARG, the metalloproteinase ADAMTS5, and the aldo keto reductase AKR1B10 inhibit adipogenic differentiation in a dose dependent manner, although in contrast to TGF beta they do not appear to promote osteogenic differentiation.
   Conclusions: The approach chosen in this study has resulted in the identification of new targets for inhibition of fat cell differentiation, which may not only be relevant for prevention of osteoporosis, but also of obesity.
C1 [van Zoelen, Everardus J.; Duarte, Isabel; Hendriks, Jose M.; van der Woning, Sebastian P.] Radboud Univ Nijmegen, Fac Sci, Dept Cell & Appl Biol, POB 9010, NL 6500 GL Nijmegen, Netherlands.
   [van Zoelen, Everardus J.; Duarte, Isabel; Hendriks, Jose M.; van der Woning, Sebastian P.] Radboud Univ Nijmegen, Dept Cell & Appl Biol, Heyendaalseweg 135, NL 6525 AJ Nijmegen, Netherlands.
   [Duarte, Isabel] Univ Algarve, Syst Biol & Bioinformat Lab SysBioLab, Faro, Portugal.
   [Hendriks, Jose M.] Radboud Univ Nijmegen, Dept Phys Organ Chem, Nijmegen, Netherlands.
   [van der Woning, Sebastian P.] ARGENX BVBA, Technol Pk 30, B 9052 Zwijnaarde, Belgium.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Universidade
   do Algarve; Radboud University Nijmegen
RP van Zoelen, EJ (通讯作者)，Radboud Univ Nijmegen, Fac Sci, Dept Cell & Appl Biol, POB 9010, NL 6500 GL Nijmegen, Netherlands.; van Zoelen, EJ (通讯作者)，Radboud Univ Nijmegen, Dept Cell & Appl Biol, Heyendaalseweg 135, NL 6525 AJ Nijmegen, Netherlands.
EM jovazo@wxs.nl
RI ; Duarte, Isabel/NWV 8667 2025; van Zoelen, Everardus/D 9192 2012
OI dos Santos Duarte, Guilhermina Isabel/0000 0003 0060 2936; 
FU ERASysBio + [90201174]; Merck Sharpe & Dohme (Oss, the Netherlands)
FX The authors would like to thank Dr Ester Piek and Ingrid de Grijs for
   their contributions in the initial phase of the project and Dr W. Olijve
   for fruitful discussions. The present studies were made possible by a
   grant from ERASysBio + to the LINCONET consortium (Dutch contribution
   obtained from ZonMw, grant 90201174). Merck Sharpe & Dohme (Oss, the
   Netherlands) is acknowledged for financial support in the initial phase
   of this project. Microarray hybridizations were carried out by the
   MicroArray Department at the University of Amsterdam.
CR Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bermeo S, 2014, CURR OSTEOPOROS REP, V12, P235, DOI 10.1007/s11914 014 0199 y
   Bouloumié A, 2001, DIABETES, V50, P2080, DOI 10.2337/diabetes.50.9.2080
   Bourlier V, 2005, J PHARMACOL EXP THER, V312, P1272, DOI 10.1124/jpet.104.077263
   Chalk C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004572.pub2
   Davidson ENB, 2007, OSTEOARTHR CARTILAGE, V15, P597, DOI 10.1016/j.joca.2007.02.005
   Devlin MJ, 2015, LANCET DIABETES ENDO, V3, P141, DOI 10.1016/S2213 8587(14)70007 5
   Durigova M, 2011, MATRIX BIOL, V30, P145, DOI 10.1016/j.matbio.2010.10.007
   Eijssen LMT, 2013, NUCLEIC ACIDS RES, V41, pW71, DOI 10.1093/nar/gkt293
   Endo S, 2010, BIOL PHARM BULL, V33, P886, DOI 10.1248/bpb.33.886
   Fukumoto S, 2005, CLIN CANCER RES, V11, P1776, DOI 10.1158/1078 0432.CCR 04 1238
   Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369
   Gorski DJ, 2015, MATRIX BIOL, V47, P66, DOI 10.1016/j.matbio.2015.03.008
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Ito H, 2014, CURR OSTEOPOROS REP, V12, P230, DOI 10.1007/s11914 014 0201 8
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729
   Khokha R, 2013, NAT REV IMMUNOL, V13, P649, DOI 10.1038/nri3499
   Kim EK, 2012, J CELL PHYSIOL, V227, P1680, DOI 10.1002/jcp.22892
   Kleiveland CR, 2008, EXP CELL RES, V314, P1831, DOI 10.1016/j.yexcr.2008.02.004
   Komm BS, 2015, EXPERT REV CLIN PHAR, V8, P769, DOI 10.1586/17512433.2015.1099432
   Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026
   Liu JH, 2009, RECENT PAT ANTI CANC, V4, P246, DOI 10.2174/157489209789206931
   Liu ZW, 2012, BIOCHEM J, V442, P273, DOI 10.1042/BJ20111322
   Ma J, 2008, J BIOL CHEM, V283, P3418, DOI 10.1074/jbc.M707650200
   Mannello F, 2006, RECENT PAT ANTI CANC, V1, P91, DOI 10.2174/157489206775246421
   Pino AM, 2012, BIOL RES, V45, P279, DOI 10.4067/S0716 97602012000300009
   Maroni P, 2012, BIOCHEM BIOPH RES CO, V428, P271, DOI 10.1016/j.bbrc.2012.10.044
   Matsunaga T, 2009, BIOCHEM BIOPH RES CO, V389, P128, DOI 10.1016/j.bbrc.2009.08.107
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097 4652(199910)181:1<153::AID JCP16>3.0.CO;2 K
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Neuzillet C, 2015, PHARMACOL THERAPEUT, V147, P22, DOI 10.1016/j.pharmthera.2014.11.001
   Penning TM, 2015, CHEM BIOL INTERACT, V234, P236, DOI 10.1016/j.cbi.2014.09.024
   Piek E, 2010, BONE, V46, P613, DOI 10.1016/j.bone.2009.10.024
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   ROBINSON SP, 1992, ANTICANCER RES, V12, P73
   Roelen Bernard A J, 2003, J Orthop Sci, V8, P740, DOI 10.1007/s00776 003 0702 2
   Rosen CJ, 2009, CRIT REV EUKAR GENE, V19, P109, DOI 10.1615/CritRevEukarGeneExpr.v19.i2.20
   Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066
   Rothenberg ML, 1999, STEM CELLS, V17, P237, DOI 10.1002/stem.170237
   SANTAMBROGIO L, 1993, J IMMUNOL, V151, P1116
   Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703
   Smyth G. K., 2004, Statistical Applications in Genetics and Molecular Biology, V3, P1, DOI [DOI 10.2202/1544 6115.1027, 10.2202/1544 6115.1027]
   Sotoca AM, 2013, MED ADV AGING REGENE, P76
   Sparano JA, 2004, J CLIN ONCOL, V22, P4683, DOI 10.1200/JCO.2004.08.054
   Tian XY, 2008, BONE, V42, P914, DOI 10.1016/j.bone.2007.12.228
   Tuljapurkar SR, 2011, J ANAT, V219, P574, DOI 10.1111/j.1469 7580.2011.01423.x
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   Wrzesinski SH, 2007, CLIN CANCER RES, V13, P5262, DOI 10.1158/1078 0432.CCR 07 1157
   Zhang WY, 2014, CANCER LETT, V355, P273, DOI 10.1016/j.canlet.2014.09.031
   Zhou YF, 2014, EUR J CELL BIOL, V93, P170, DOI 10.1016/j.ejcb.2014.03.001
NR 54
TC 61
Z9 61
U1 1
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD AUG 26
PY 2016
VL 7
AR 123
DI 10.1186/s13287 016 0375 3
PG 13
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA DX7UJ
UT WOS:000384594600001
PM 27562730
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Bai, CY
   Chen, SM
   Gao, YH
   Shan, ZQ
   Guan, WJ
   Ma, YH
AF Bai, Chunyu
   Chen, Shuming
   Gao, Yuhua
   Shan, Zhiqiang
   Guan, Weijun
   Ma, Yuehui
TI Multi Lineage Potential Research of Bone Marrow Mesenchymal Stem Cells
   From Bama Miniature Pig
SO JOURNAL OF EXPERIMENTAL ZOOLOGY PART B MOLECULAR AND DEVELOPMENTAL
   EVOLUTION
LA English
DT Article
ID STROMAL CELLS; IN VITRO; OSTEOBLAST DIFFERENTIATION; PROGENITOR CELLS;
   DEFECTS; EXPRESS; PATHWAY; INSULIN
AB Bone marrow mesenchymal stem cells (BMSCs) are easy to obtain and thought to be ideal candidate cells for reconstruction of tissues and organs. Pigs are an appropriate animal model because their physiological structure, organ size, nutritional metabolism, and pathological reactions are similar to those of humans. In this study, bone marrow was collection from Bama miniature pigs to isolate BMSCs (B BMSCs) by whole bone marrow culture method. We then examined their biological characteristics such as growth kinetics, surface antigen, and multilineage potential. B BMSCs could be cultured for 36 passages in vitro. Growth kinetics and colony forming assay analyses indicated that B BMSCs had a strong capacity for self renewal in vitro and their proliferation rate appeared to decrease with passaging. These findings were supported by the animal cytophysiology in vitro. Surface antigen detection showed that B BMSCs expressed CD29, CD44, CD71, CD73, and CD90, but not the endothelial cell marker CD31 or hematopoietic cell specific marker CD34. This result was consistent with the characteristics of B BMSCs. Furthermore, under appropriate conditions for multidirectional differentiation, B BMSCs were induced to differentiate into adipocytes, osteoblasts, neuron like cells, islet cells, liver like cells, and endothelial cells as indicated by reverse transcription polymerase chain reaction (RT PCR) and immunofluorescence. These results verified the differentiation potential of B BMSCs. In this study, B BMSCs were isolated from Bama miniature pigs, and the self renewal ability and differential potential was evaluated in vitro. The present study has important bearing on the potential application of B BMSCs as a stem cell source for regenerative therapies. (C) 2015 Wiley Periodicals, Inc.
C1 [Bai, Chunyu; Gao, Yuhua; Shan, Zhiqiang; Guan, Weijun; Ma, Yuehui] Chinese Acad Agr Sci, Inst Anim Sci, Beijing 100193, Peoples R China.
   [Chen, Shuming; Shan, Zhiqiang] Shanxi Agr Univ, Coll Anim Sci & Technol, Taigu, Peoples R China.
C3 Chinese Academy of Agricultural Sciences; Institute of Animal Science,
   CAAS; Shanxi Agricultural University
RP Guan, WJ (通讯作者)，Chinese Acad Agr Sci, Inst Anim Sci, Beijing 100193, Peoples R China.
EM weijunguan301@gmail.com; yuehui_ma@hotmail.com
FU Agricultural Science and Technology Innovation Program [ASTIP  IAS01];
   National Infrastructure of Animal Germplasm Resources; Ministry of
   Agriculture of China for Transgenic Research Program
   [2014ZX08009 003 006, 2014ZX08012 002 06]
FX Grant sponsor: Agricultural Science and Technology Innovation Program;
   grant number: ASTIP  IAS01; grant sponsor: National Infrastructure of
   Animal Germplasm Resources (2015 year); grant sponsor: Ministry of
   Agriculture of China for Transgenic Research Program; grant numbers:
   2014ZX08009 003 006, 2014ZX08012 002 06.
CR Anjos Afonso Fernando, 2008, Curr Protoc Stem Cell Biol, VChapter 2, DOI 10.1002/9780470151808.sc02b03s7
   Bosnakovski D, 2004, EXP HEMATOL, V32, P502, DOI 10.1016/j.exphem.2004.02.009
   Hou Ling Ling, 2003, Shengli Xuebao, V55, P153
   Huang Y, 2009, J BIOMED SCI, V16, DOI 10.1186/1423 0127 16 87
   Inoue H, 2008, J BIOMED OPT, V13, DOI 10.1117/1.3042266
   Kawarai S, 2006, VET IMMUNOL IMMUNOP, V113, P30, DOI 10.1016/j.vetimm.2006.03.006
   Kon E, 2000, J BIOMED MATER RES, V49, P328
   Kume N, 2010, CIRC J, V74, P1399, DOI 10.1253/circj.CJ 09 0924
   LAVANIA UC, 1981, BIOSYSTEMS, V14, P171, DOI 10.1016/0303 2647(81)90066 6
   Lee KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469
   Li LF, 2009, J GENET GENOMICS, V36, P133, DOI 10.1016/S1673 8527(08)60100 9
   Liu YC, 2002, TISSUE ENG, V8, P709, DOI 10.1089/107632702760240616
   Majumdar MK, 2000, J CELL PHYSIOL, V185, P98
   Moriscot C, 2005, STEM CELLS, V23, P594, DOI 10.1634/stemcells.2004 0123
   Muller S, 1997, HUM GENET, V101, P149, DOI 10.1007/s004390050604
   Oh SH, 2004, LAB INVEST, V84, P607, DOI 10.1038/labinvest.3700074
   Oh SH, 2000, BIOCHEM BIOPH RES CO, V279, P500, DOI 10.1006/bbrc.2000.3985
   Reyes M, 2001, BLOOD, V98, P2615, DOI 10.1182/blood.V98.9.2615
   Sahara H, 2010, TRANSPLANTATION, V90, P1336, DOI 10.1097/TP.0b013e3181ff8730
   Schwartz RE, 2002, J CLIN INVEST, V109, P1291, DOI 10.1172/JCI200215182
   Sordi V, 2005, BLOOD, V106, P419, DOI 10.1182/blood 2004 09 3507
   Tamama K, 2008, STEM CELLS DEV, V17, P897, DOI 10.1089/scd.2007.0155
   Tashiro K, 2009, STEM CELLS, V27, P1802, DOI 10.1002/stem.108
   Tashiro K, 2009, BIOCHEM BIOPH RES CO, V379, P127, DOI 10.1016/j.bbrc.2008.12.055
   Uzan Georges, 2004, Rev Prat, V54, P1515
   Wu F.C., 2001, ACTA BIOL EXP SINICA, V34, P115
NR 26
TC 11
Z9 12
U1 1
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1552 5007
EI 1552 5015
J9 J EXP ZOOL PART B
JI J. Exp. Zool. Part B
PD DEC 15
PY 2015
VL 324
IS 8
BP 671
EP 685
DI 10.1002/jez.b.22646
PG 15
WC Evolutionary Biology; Developmental Biology; Zoology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Evolutionary Biology; Developmental Biology; Zoology
GA CZ4SB
UT WOS:000367091900004
PM 26352790
DA 2025 08 17
ER

PT J
AU Gonzaga, EV
   Viana, ALM
   Viana, OMMS
   Doriguetto, AC
AF Gonzaga, Edeilson V.
   Viana, Andre L. M.
   Viana, Olimpia M. M. S.
   Doriguetto, Antonio C.
TI Solid State Phase Transition Mechanism and Physical Chemical Study of
   the Crystal Forms of Monosodium Alendronate: Trihydrate versus Anhydrate
SO CRYSTAL GROWTH & DESIGN
LA English
DT Article
ID X RAY DIFFRACTION; PHARMACEUTICAL DOSAGE FORMULATIONS;
   DISSOCIATION CONSTANTS; ION CHROMATOGRAPHY; BINDING PROPERTIES; DRUG
   CRYSTALS; IN VITRO; BISPHOSPHONATES; BONE; ACID
AB Alendronic acid is one of the most effective diphosphonate compounds used for clinical treatment of bone disorders. It is administered orally as its monosodium salt, for which hydrate and anhydrous crystal forms are known. The monosodium alendronate trihydrate form (NaH(4)A center dot 3H(2)O) is incorporated into medicines as the Active Pharmaceutical Ingredient (API). The NaH(4)A center dot 3H(2)O form can be dehydrated at temperatures above 115 degrees C, resulting in the anhydrous form (NaH(4)A). Although the crystal structures of both forms have already been reported, an investigation of the reversible dehydration/hydration solid phase transition is presented here for the first time. A solid state mechanism for the phase transition, which involves the reversible dehydration hydration of the NaH(4)A center dot 3H(2)O and NaH(4)A forms, is also proposed. A systematic study comparing the equilibrium solubility and discriminatory intrinsic dissolution of the NaH(4)A center dot 3H(2)O and NaH(4)A forms is included. To achieve this goal, an alternative method of quantifying alendronate anions released from the crystal forms into solution, flame photometry, is proposed and validated. The stability and interconversion of the NaH(4)A center dot 3H(2)O and NaH(4)A forms are probed by differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy attenuated total reflectance (FTIR ATR), and powder X ray diffraction (PXRD).
C1 [Gonzaga, Edeilson V.; Viana, Olimpia M. M. S.] Univ Fed Alfenas, Fac Ciencias Farmaceut, Nucleo Controle Qualidade, BR 37130000 Alfenas, MG, Brazil.
   [Viana, Andre L. M.] Univ Fed Alfenas, Fac Ciencias Farmaceut, Lab Cent Anal Clin, BR 37130000 Alfenas, MG, Brazil.
   [Gonzaga, Edeilson V.; Viana, Olimpia M. M. S.; Doriguetto, Antonio C.] Univ Fed Alfenas, Inst Quim, Lab Cristallog, BR 37130000 Alfenas, MG, Brazil.
C3 Universidade Federal de Alfenas; Universidade Federal de Alfenas;
   Universidade Federal de Alfenas
RP Doriguetto, AC (通讯作者)，Univ Fed Alfenas, Inst Quim, Lab Cristallog, BR 37130000 Alfenas, MG, Brazil.
EM doriguetto@unifal mg.edu.br
RI ; Doriguetto, Antonio/B 6531 2008; Viana, Olimpia/V 3925 2019
OI Doriguetto, Antonio Carlos/0000 0002 2726 1265; 
FU FINEP [134/08]; CNPq [552387/2011 8, 308354/2012 5, 448723/2014 0,
   308162/2015 3]; CAPES [AUX PE PNPD 2347/2011]; FAPEMIG [APQ 00273 14,
   APQ 02486 14, CEX RED 00010 14]
FX The authors thank FINEP (ref 134/08), CNPq (552387/2011 8;
   308354/2012 5; 448723/2014 0; 308162/2015 3), CAPES (AUX
   PE PNPD 2347/2011), and FAPEMIG (APQ 00273 14 and APQ 02486 14) for
   financial support. We also thank CNPq, FAPEMIG, and CAPES for research
   fellowships (E.V.G.; A.C.D.). This work is a collaborative research
   project by members of the Rede Mineira de Quimica (RQ MG), supported by
   FAPEMIG (Project: CEX RED 00010 14).
CR Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890
   Alvarez E, 2013, CRYSTENGCOMM, V15, P9899, DOI 10.1039/c3ce41346b
   [Anonymous], 1996, INT C HARM GUID IND
   [Anonymous], 2013, MERCK INDEX ENCY CHE
   [Anonymous], 2015, UNITED STATES PHARMA
   Asnani M, 2009, J PHARM SCI US, V98, P2113, DOI 10.1002/jps.21561
   BOGARDUS JB, 1979, J PHARM SCI, V68, P188, DOI 10.1002/jps.2600680218
   Boichenko A. P., 2010, KHARKOV U B, V895, P56
   Boichenko AP, 2009, CENT EUR J CHEM, V7, P8, DOI [10.2478/s11532 008 0099 z, 10.1109/PTC.2009.5282263]
   Bonfilio R, 2014, J PHARMACEUT BIOMED, V88, P562, DOI 10.1016/j.jpba.2013.10.020
   Bonfilio R, 2012, J PHARM SCI US, V101, P794, DOI 10.1002/jps.22799
   CIPLA, 2023, CIPLA
   COIRO VM, 1989, ACTA CRYSTALLOGR C, V45, P446, DOI 10.1107/S0108270188011576
   Compain JD, 2010, CHEM EUR J, V16, P13741, DOI 10.1002/chem.201001626
   Cong H. L., 2010, J MOL LIQ, V154, P76
   Cremers S, 2011, BONE, V49, P42, DOI 10.1016/j.bone.2011.01.014
   Deacon GB, 2015, CRYST GROWTH DES, V15, P4646, DOI 10.1021/acs.cgd.5b00917
   Deacon GB, 2011, J COORD CHEM, V64, P179, DOI 10.1080/00958972.2010.538389
   deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403
   Demadis KD, 2013, CRYST GROWTH DES, V13, P4480, DOI 10.1021/cg4009625
   Demoro B, 2012, DALTON T, V41, P6468, DOI 10.1039/c2dt12179d
   Dyba M, 1996, J CHEM SOC DALTON, P1119, DOI 10.1039/dt9960001119
   El Moll H, 2012, DALTON T, V41, P9955, DOI 10.1039/c2dt30534h
   El Moll H, 2012, INORG CHEM, V51, P7921, DOI 10.1021/ic3010079
   Ellena J, 2012, CRYST GROWTH DES, V12, P5138, DOI 10.1021/cg3011794
   Epstein S, 2006, DRUG AGING, V23, P617, DOI 10.2165/00002512 200623080 00001
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Fernández D, 2003, ACTA CRYSTALLOGR C, V59, pM543, DOI 10.1107/S0108270103025599
   Fernández D, 2004, ACTA CRYSTALLOGR C, V60, pM73, DOI 10.1107/S0108270104000216
   Fernández D, 2002, ACTA CRYSTALLOGR C, V58, pM494, DOI 10.1107/S010827010201497X
   Fernandez D., 2003, ACTA CRYSTALLOGR C, V59
   Finkelstein N., 2004, U.S. Patent No, Patent No. [6696601, 6,696,601]
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Fleisch H., 1995, BISPHOSPHONATES BONE
   Fleisch H., 2000, BISPHOSPHONATES BONE
   Gossman WL, 2003, ACTA CRYSTALLOGR C, V59, pM33, DOI 10.1107/S0108270102021996
   Gossman WL, 2002, ACTA CRYSTALLOGR C, V58, pM599, DOI 10.1107/S0108270102019522
   Guénin E, 2007, EUR J ORG CHEM, V2007, P3380, DOI 10.1002/ejoc.200601067
   Hage D. S., 2012, QUIMICA ANALITICA AN, P460
   Hägele G, 2000, HETEROATOM CHEM, V11, P562
   Hounslow AM, 2008, J MED CHEM, V51, P4170, DOI 10.1021/jm7015792
   Kabachnik M. N., 1978, CHEM INFORMATIONSDIE, V9, P433
   Kieczykowski G. R., 1990, U.S. Patent No, Patent No. [4,922,007, 49220097]
   Kuljanin J, 2002, J PHARMACEUT BIOMED, V28, P1215, DOI 10.1016/S0731 7085(02)00021 3
   Lamprecht G, 2009, J PHARM SCI US, V98, P3575, DOI 10.1002/jps.21639
   Legendre AO, 2012, CRYSTENGCOMM, V14, P2532, DOI 10.1039/c1ce06181j
   LEROUX Y, 1991, PHOSPHORUS SULFUR, V63, P181, DOI 10.1080/10426509108029442
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Llinás A, 2008, DRUG DISCOV TODAY, V13, P198, DOI 10.1016/j.drudis.2007.11.006
   Lovdahl MJ, 1999, J CHROMATOGR A, V850, P143, DOI 10.1016/S0021 9673(99)00622 6
   Macrae CF, 2008, J APPL CRYSTALLOGR, V41, P466, DOI 10.1107/S0021889807067908
   Mahmood A, 2015, CR CHIM, V18, P422, DOI 10.1016/j.crci.2014.07.009
   Malpezzi L, 2012, J THERM ANAL CALORIM, V109, P373, DOI 10.1007/s10973 011 1698 z
   Man SP, 2006, POLYHEDRON, V25, P1017, DOI 10.1016/j.poly.2005.12.009
   Marcus R, 1996, EM AS BASES FARMACOL, P61
   Martins FT, 2013, CRYSTENGCOMM, V15, P3767, DOI 10.1039/c3ce40303c
   Martins FT, 2012, CRYSTENGCOMM, V14, P6173, DOI 10.1039/c2ce25766a
   Martins FT, 2011, CRYSTENGCOMM, V13, P5737, DOI 10.1039/c1ce05453h
   Martins FT, 2010, CRYST GROWTH DES, V10, P1885, DOI 10.1021/cg9015959
   Martins FT, 2010, CRYST GROWTH DES, V10, P676, DOI 10.1021/cg901103r
   Martins FT, 2009, CRYST GROWTH DES, V9, P5283, DOI 10.1021/cg900790f
   Martins FT, 2009, CRYST GROWTH DES, V9, P3235, DOI 10.1021/cg801322x
   Santos OMM, 2016, MOLECULES, V21, DOI 10.3390/molecules21030328
   Santos OMM, 2014, BRAZ J PHARM SCI, V50, P1, DOI 10.1590/S1984 82502011000100002
   Meloun M, 2011, J CHEM ENG DATA, V56, P3848, DOI 10.1021/je200512e
   Merck & Co, 1995, AL PRESCR INF
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Nesterenko V. F., 1994, C P COLORADO SPRINGS, P1173
   Ohanessian J, 1997, PHOSPHORUS SULFUR, V129, P99, DOI 10.1080/10426509708031585
   OlexSys Ltd, 2016, OLEX2
   Papapoulos SE, 2008, BEST PRACT RES CL EN, V22, P831, DOI 10.1016/j.beem.2008.07.001
   QIN XZ, 1994, J CHROMATOGR A, V686, P205, DOI 10.1016/0021 9673(94)00798 5
   Roldán EJA, 2005, ARZNEIMITTELFORSCH, V55, P93
   Ruscica R, 2010, J PHARM SCI US, V99, P4962, DOI 10.1002/jps.22223
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Ryan JM, 1998, RADIOLOGY, V206, P389, DOI 10.1148/radiology.206.2.9457190
   Saad A, 2015, CHEM EUR J, V21, P10537, DOI 10.1002/chem.201406565
   Saad A, 2014, J CLUST SCI, V25, P795, DOI 10.1007/s10876 013 0655 3
   Santos LM, 2016, J PHARMACEUT BIOMED, V118, P101, DOI 10.1016/j.jpba.2015.10.015
   Santos OMM, 2014, CRYST GROWTH DES, V14, P3711, DOI 10.1021/cg500877z
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Shinkai I, 1996, BIOORGAN MED CHEM, V4, P3, DOI 10.1016/0968 0896(96)00042 9
   Sienkiewicz B., 2005, U.S. Patent Application, Patent No. [20050113343, US 2005/0113343A1]
   Sikorska M, 2012, ACTA CRYSTALLOGR E, V68, pM820, DOI 10.1107/S1600536812022532
   Su YH, 2010, J SOLID STATE CHEM, V183, P1588, DOI 10.1016/j.jssc.2010.05.008
   Tan HQ, 2011, DALTON T, V40, P8414, DOI 10.1039/c0dt01729a
   Tan HQ, 2010, DALTON T, V39, P1245, DOI 10.1039/b912321k
   TSAI EW, 1992, J CHROMATOGR, V626, P245, DOI 10.1016/0021 9673(92)85416 Q
   TSAI EW, 1992, J CHROMATOGR, V596, P217, DOI 10.1016/0021 9673(92)85010 Q
   TSAI EW, 1994, J PHARMACEUT BIOMED, V12, P983, DOI 10.1016/0731 7085(94)00047 6
   Vachal P, 2006, J MED CHEM, V49, P3060, DOI 10.1021/jm060398v
   Van Brussel EM, 2003, ACTA CRYSTALLOGR C, V59, pO93, DOI 10.1107/S0108270102020450
   Vega D, 2002, ACTA CRYSTALLOGR C, V58, pM77, DOI 10.1107/S0108270101019655
   Vega D, 1998, ACTA CRYSTALLOGR C, V54, P324, DOI 10.1107/S0108270197013553
   Vega D, 1996, ACTA CRYSTALLOGR C, V52, P2198, DOI 10.1107/S0108270196006105
   Zacharis CK, 2008, J PHARMACEUT BIOMED, V48, P483, DOI 10.1016/j.jpba.2008.05.028
   Zhang YH, 2007, J MED CHEM, V50, P6067, DOI 10.1021/jm700991k
NR 97
TC 21
Z9 21
U1 1
U2 43
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1528 7483
EI 1528 7505
J9 CRYST GROWTH DES
JI Cryst. Growth Des.
PD DEC
PY 2016
VL 16
IS 12
BP 6891
EP 6902
DI 10.1021/acs.cgd.6b01064
PG 12
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Crystallography; Materials Science
GA EE5DD
UT WOS:000389624200028
DA 2025 08 17
ER

PT J
AU Zhang, L
   Xie, HQ
   Li, SL
AF Zhang, Ling
   Xie, Haiqin
   Li, Shiliang
TI LncRNA LOXL1 AS1 controls osteogenic and adipocytic differentiation of
   bone marrow mesenchymal stem cells in postmenopausal osteoporosis
   through regulating the miR 196a 5p/Hmga2 axis
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE LOXL1 AS1; miR 196a 5p; Hmga2; Bone marrow mesenchymal stem cells;
   Postmenopausal osteoporosis
ID METASTASIS; PPAR; PROMOTES; CANCER; HMGA2; ADIPOGENESIS; EXPRESSION;
   OSTEOBLAST; FATE
AB Introduction Exploring molecular mechanisms of human bone marrow mesenchymal stem cells (hBMMSCs) differentiation, a crucial step for bone formation, is a new direction for treating postmenopausal osteoporosis. LncRNAs are involved in lots of biological processes including hBMMSCs differentiation. The present study aimed to explore the effect of LOXL1 AS1 on hBMMSCs differentiation. Materials and methods We examined the expression levels of LOXL1 AS1, miR 196a 5p and Hmga2 in peripheral blood from postmenopausal osteoporosis patients by RT qPCR, and detected their changes during the osteogenic differentiation of hBMMSCs by RT qPCR. RT qPCR and western blot measured the level of biomarkers of bone formation and osteogenic differentiation (osteopontin, OPN; Alkaline phosphatase, ALP; Runt related transcription factor 2, Runx 2). The effects of LOXL1 AS1 on the osteogenic and adipocytic differentiation of hBMMSCs were, respectively, determined by ALP, ARS staining assays and oil red O staining assay. Results The abnormal high expression of LOXL1 AS1 was found in patients. LOXL1 AS1 expression showed a gradual decrease during the osteogenic differentiation of hBMMSCs. However, LOXL1 AS1 overexpression inhibited the hBMMSCs osteogenic differentiation but promoted adipocytic differentiation. Furthermore, LOXL1 AS1 was identified to be a sponge of miR 196a 5p and Hmga2 as a target gene of miR 196a 5p. Besides, LOXL1 AS1 sponged miR 196a 5p to mediate Hmga2 expression, which played contrary effects on regulating osteogenic and adipocytic differentiation of hBMMSCs. Moreover, LOXL1 AS1/miR 196a 5p/Hmga2 axis regulated hBMMSCs differentiation through controlling C/EBP beta mediated PPAR gamma expression. Conclusion These findings facilitate understanding the molecular mechanism of hBMMSCs differentiation and bring up a novel sight for postmenopausal osteoporosis therapy.
C1 [Zhang, Ling] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Geriatr, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.
   [Xie, Haiqin] Peking Univ, Dept Ultrasound, Shenzhen Hosp, Shenzhen 518036, Guangdong, Peoples R China.
   [Li, Shiliang] Sun Yat Sen Univ, Affiliated Hosp 1, Healthcare Off, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Peking University; Sun Yat Sen University
RP Zhang, L (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 1, Dept Geriatr, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.
EM zlwwx214@126.com
RI li, shiliang/K 9864 2018
CR Aghebati Maleki L, 2019, J CELL PHYSIOL, V234, P8570, DOI 10.1002/jcp.27833
   Bai TL, 2019, IUBMB LIFE, V71, P1537, DOI 10.1002/iub.2075
   Chen S, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190447
   Dong HT, 2020, MOL THER NUCL ACIDS, V19, P696, DOI 10.1016/j.omtn.2019.12.016
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Farmer SR, 2005, INT J OBESITY, V29, pS13, DOI 10.1038/sj.ijo.0802907
   Gao GC, 2020, EUR REV MED PHARMACO, V24, P526, DOI 10.26355/eurrev_202001_20029
   Hammond SM, 2008, CELL, V135, P1013, DOI 10.1016/j.cell.2008.11.026
   Hauser MA, 2015, HUM MOL GENET, V24, P6552, DOI 10.1093/hmg/ddv347
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kumar MM, 2017, CURR TOP MED CHEM, V17, P1750, DOI 10.2174/1568026617666161116144744
   Long B, 2018, BIOCHEM BIOPH RES CO, V505, P561, DOI 10.1016/j.bbrc.2018.09.160
   Maruyama T, 2018, ONCOL LETT, V15, P2349, DOI 10.3892/ol.2017.7562
   Morishita A, 2013, CANCER RES, V73, P4289, DOI 10.1158/0008 5472.CAN 12 3848
   Pan JC, 2020, MOL CANCER, V19, DOI 10.1186/s12943 020 1133 9
   Peng WX, 2017, ONCOGENE, V36, P5661, DOI 10.1038/onc.2017.184
   Qi M, 2017, THERANOSTICS, V7, P4498, DOI 10.7150/thno.17949
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Styrkarsdottir U, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09860 0
   Sun HL, 2013, STEM CELLS, V31, P2183, DOI 10.1002/stem.1455
   Thu HE, 2018, J AYURVEDA INTEGR ME, V9, P272, DOI 10.1016/j.jaim.2017.04.005
   Wang C, 2016, MED SCI MONITOR, V22, P226, DOI 10.12659/MSM.897044
   Wang HJ, 2018, BIOCHEM BIOPH RES CO, V500, P518, DOI 10.1016/j.bbrc.2018.04.133
   Wei JF, 2014, STEM CELLS DEV, V23, P1452, DOI 10.1089/scd.2013.0600
   Wrobel E, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658 016 0027 8
   Wu YS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06898 4
   Xi Y, 2016, BIOCHEM BIOPH RES CO, V472, P617, DOI 10.1016/j.bbrc.2016.03.015
   Xiao X, 2018, BIOCHEM BIOPH RES CO, V495, P821, DOI 10.1016/j.bbrc.2017.11.082
   Xin H, 2019, BMC CANCER, V19, DOI 10.1186/s12885 018 5245 1
   Xu CY, 2016, CURR STEM CELL RES T, V11, P247, DOI 10.2174/1574888X10666150723145707
   Xu JC, 2016, SPORTS MED, V46, P1165, DOI 10.1007/s40279 016 0494 0
   Zhang SZ, 2019, INT J ONCOL, V55, P775, DOI 10.3892/ijo.2019.4856
   Zhang Y, 2020, BIOCHEM BIOPH RES CO, V521, P9, DOI 10.1016/j.bbrc.2019.09.122
   Zhong F, 2018, ACTA BIOCH BIOPH SIN, V50, P1190, DOI 10.1093/abbs/gmy130
   Zhou QZ, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/7067984
   Zhou Q, 2019, J INTEGR NEUROSCI, V18, P431, DOI 10.31083/j.jin.2019.04.1194
   Zhu Y, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1143 y
NR 39
TC 32
Z9 36
U1 1
U2 16
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD NOV
PY 2020
VL 38
IS 6
BP 794
EP 805
DI 10.1007/s00774 020 01123 z
EA JUL 2020
PG 12
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA OO1EO
UT WOS:000547222200001
PM 32651705
DA 2025 08 17
ER

PT J
AU Angelucci, A
   Garofalo, S
   Speca, S
   Bovadilla, A
   Gravina, GL
   Muzi, P
   Vicentini, C
   Bologna, M
AF Angelucci, Adriano
   Garofalo, Stefania
   Speca, Silvia
   Bovadilla, Antonella
   Gravina, Giovanni Luca
   Muzi, Paola
   Vicentini, Carlo
   Bologna, Mauro
TI Arachidonic acid modulates the crosstalk between prostate carcinoma and
   bone stromal cells
SO ENDOCRINE RELATED CANCER
LA English
DT Article
ID CANCER CELLS; TRABECULAR BONE; FATTY ACIDS; NUDE MICE; CYCLOOXYGENASE 2;
   METASTASIS; INHIBITION; GROWTH; 5 LIPOXYGENASE; METABOLISM
AB Diets high in n 6 fatty acids are associated with an increased risk of bone metastasis from prostate carces (PCa). The molecular mechanism underlying this phenomenon is largely unknown. Arachidonic acid (AA) and its precursor linoleic acid can be metabolized to produce pro inflammatory cytokines that act as autocrine and paracrine regulators of cancer behavior. We and other authors have previously reported that factors released by PCa cells excite an aberrant response in bone marrow stromal cells (BMSCs). We planned to study how AA may modulate in vitro the interaction between PCa cells and human BMSCs. First, we observed that AA is a potent mitogenic factor for PCa cells through the production of both 5 lipoxygenase (5 LOX) and cyclooxygenase 2 (COX 2) metabolites. While 5 LOX controls cell survival through the regulation of the Bcl 2/Bax ratio, COX 2 activity stimulates the release of transforming growth factor alpha (TGF alpha) and pro inflammatory cytokines. The blockade of COX 2 activity through a specific inhibitor is sufficient to repress AA induced gene transcription. The over expression of transforming growth factor  alpha (TGF alpha), tumour necrosis factor alpha (TNF alpha) and interleukin 1 beta (IL 1 beta) by AA primed PCa cells resulted particularly effective in modifying cell behavior of cultured human BMSCs. In fact, we observed an increment in the cell number of BMSCs, due prevalently to the action of TGF alpha, the number of osteoblasts, and the production of receptor activator for nuclear factor kappa B ligand (RANKL), events mainly controlled by inflammatory cytokines. These findings provide a possible molecular mechanism by which dietary n 6 fatty acids accumulating in bone marrow may influence the formation of PCa derived metastatic lesions and indicate new molecular targets for the therapy of metastatic PCa.
C1 [Angelucci, Adriano; Garofalo, Stefania; Speca, Silvia; Bovadilla, Antonella; Bologna, Mauro] Univ Aquila, Dept Basic & Appl Biol, I 67100 Laquila, Italy.
   [Gravina, Giovanni Luca; Muzi, Paola; Bologna, Mauro] Univ Aquila, Dept Expt Med, I 67100 Laquila, Italy.
   [Vicentini, Carlo] Univ Aquila, Dept Surg, I 67100 Laquila, Italy.
C3 University of L'Aquila; University of L'Aquila; University of L'Aquila
RP Angelucci, A (通讯作者)，Univ Aquila, Dept Basic & Appl Biol, I 67100 Laquila, Italy.
EM adriano.angelucci@gmail.com
RI ; Angelucci, Adriano/B 7134 2013; Speca, Silvia/S 8547 2016
OI PARADISO GALATIOTO, Giuseppe/0000 0002 9453 7858; Angelucci,
   Adriano/0000 0002 8755 1889; BOLOGNA, Mauro/0000 0002 6306 6897; Speca,
   Silvia/0000 0001 8494 3329; Gravina, Giovanni Luca/0000 0002 6797 8324;
   VICENTINI, Carlo/0000 0003 0776 0312
CR Angelucci A, 2006, ENDOCR RELAT CANCER, V13, P197, DOI 10.1677/erc.1.01100
   Brown MD, 2006, BRIT J CANCER, V94, P842, DOI 10.1038/sj.bjc.6603030
   BURKHARDT R, 1987, BONE, V8, P157, DOI 10.1016/8756 3282(87)90015 9
   Ciapetti G, 2006, BIOMATERIALS, V27, P6150, DOI 10.1016/j.biomaterials.2006.08.025
   Cuendet M, 2000, Drug Metabol Drug Interact, V17, P109
   Fürstenberger G, 2006, INT J CANCER, V119, P2247, DOI 10.1002/ijc.22153
   Gamradt SC, 2005, ANTICANCER RES, V25, P107
   Ghosh J, 1998, P NATL ACAD SCI USA, V95, P13182, DOI 10.1073/pnas.95.22.13182
   Ghosh J, 1998, NUTRITION, V14, P48
   Gugliucci A, 2002, J BIOL CHEM, V277, P31789, DOI 10.1074/jbc.M204450200
   Hassan S, 2006, REGUL PEPTIDES, V133, P105, DOI 10.1016/j.regpep.2005.09.031
   Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132
   Kitaura H, 2004, J IMMUNOL, V173, P4838, DOI 10.4049/jimmunol.173.8.4838
   Kobayashi N, 2006, CLIN CANCER RES, V12, P4662, DOI 10.1158/1078 0432.CCR 06 0459
   Madaan S, 2000, BJU INT, V86, P736, DOI 10.1046/j.1464 410x.2000.00867.x
   Moretti RM, 2004, INT J CANCER, V112, P87, DOI 10.1002/ijc.20387
   Nuttall ME, 1998, J BONE MINER RES, V13, P371, DOI 10.1359/jbmr.1998.13.3.371
   PARKAR BA, 1990, BIOCHEM BIOPH RES CO, V169, P422, DOI 10.1016/0006 291X(90)90348 Q
   Riendeau D, 2001, J PHARMACOL EXP THER, V296, P558
   Rose DP, 1997, AM J CLIN NUTR, V66, P1513
   Terry PD, 2003, AM J CLIN NUTR, V77, P532, DOI 10.1093/ajcn/77.3.532
   Tokuda Y, 2003, BJU INT, V91, P716, DOI 10.1046/j.1464 410X.2003.04218.x
   Vessella RL, 2006, CLIN CANCER RES, V12, p6285S, DOI 10.1158/1078 0432.CCR 06 0813
   WANG Y, 1995, J NATL CANCER I, V87, P1456, DOI 10.1093/jnci/87.19.1456
   WYNDER EL, 1994, NUTR CANCER, V22, P1, DOI 10.1080/01635589409514327
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
NR 26
TC 21
Z9 28
U1 0
U2 3
PU SOC ENDOCRINOLOGY
PI BRISTOL
PA 22 APEX COURT, WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND
SN 1351 0088
J9 ENDOCR RELAT CANCER
JI Endocr. Relat. Cancer
PD MAR
PY 2008
VL 15
IS 1
BP 91
EP 100
DI 10.1677/ERC 07 0100
PG 10
WC Oncology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Endocrinology & Metabolism
GA 276EB
UT WOS:000254123000008
PM 18310278
OA hybrid
DA 2025 08 17
ER

PT J
AU Chen, YZ
   Zhang, QZ
   Yang, SY
   Li, GY
   Shi, CC
   Hu, XW
   Asahina, S
   Asano, N
   Zhang, Y
AF Chen, Yazhou
   Zhang, Qizheng
   Yang, Shenyu
   Li, Guanying
   Shi, Chaochen
   Hu, Xunwu
   Asahina, Shunsuke
   Asano, Natsuko
   Zhang, Ye
TI Formulate Adaptive Biphasic Scaffold via Sequential Protein Instructed
   Peptide Co Assembly
SO ADVANCED SCIENCE
LA English
DT Article
DE adaptive scaffold; biphasic scaffold; dual targeting peptide;
   peptide co assembly; protein instructed peptide assembly
ID EXTRACELLULAR MATRIX; CELL; DIFFERENTIATION; OSTEOGENESIS; FIBRONECTIN;
   ECM
AB To ensure compositional consistency while mitigating potential immunogenicity for stem cell therapy, synthetic scaffolds have emerged as compelling alternatives to native extracellular matrix (ECM). Substantial progress has been made in emulating specific natural traits featuring consistent chemical compositions and physical structures. However, recapitulating the dynamic responsiveness of the native ECM involving chemical transitions and physical remodeling during differentiation, remains a challenging endeavor. Here, the creation of adaptive scaffolds is demonstrated through sequential protein instructed molecular assembly, utilizing stage specific proteins, and incorporating in situ assembly technique. The procedure is commenced by introducing a dual targeting peptide at the onset of stem cell differentiation. In response to highly expressed integrins and heparan sulfate proteoglycans (HSPGs) on human mesenchymal stem cell (hMSC), the peptides assembled in situ, creating customized extracellular scaffolds that adhered to hMSCs promoting osteoblast differentiation. As the expression of alkaline phosphatase (ALP) and collagen (COL 1) increased in osteoblasts, an additional peptide is introduced that interacts with ALP, initiating peptide assembly and facilitating calcium phosphate (CaP) deposition. The growth and entanglement of peptide assemblies with collagen fibers efficiently incorporated CaP into the network resulting in an adaptive biphasic scaffold that enhanced healing of bone injuries.
   Utilizing a sequential protein instructed molecular assembly approach, adaptive scaffolds are developed that emulate the dynamic responsiveness of the native extracellular matrix (ECM). By incorporating peptides interacting with stage specific proteins during osteogenesis, the scaffolds demonstrate remarkable adaptability to the everchanging cellular microenvironment enhancing bone injury healing. image
C1 [Chen, Yazhou; Shi, Chaochen] Zhengzhou Univ, Henan Inst Adv Technol, Zhengzhou 450003, Henan, Peoples R China.
   [Zhang, Qizheng; Hu, Xunwu; Zhang, Ye] Songshan Lake Mat Lab, Act Soft Matter Grp, Dongguan 523808, Guangdong, Peoples R China.
   [Yang, Shenyu] Zhengzhou Univ, Affiliated Hosp 1, Med Printing Ctr 3D, Zhengzhou 450052, Henan, Peoples R China.
   [Li, Guanying] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Biophys, Xian 71006, Shaanxi, Peoples R China.
   [Asahina, Shunsuke; Asano, Natsuko] JEOL Ltd, SM Applicat Planning Grp, Akishima, Tokyo 1968588, Japan.
   [Asahina, Shunsuke] Tohoku Univ, Inst Multidisciplinary Res Adv Mat IMRAM, Sendai 9808577, Japan.
C3 Zhengzhou University; Songshan Lake Materials Laboratory; Zhengzhou
   University; Xi'an Jiaotong University; Jeol Ltd; Tohoku University
RP Zhang, Y (通讯作者)，Songshan Lake Mat Lab, Act Soft Matter Grp, Dongguan 523808, Guangdong, Peoples R China.
EM zhangye@sslab.org.cn
RI Zhang, Ye/G 2208 2015; Li, Guanying/E 1477 2016; Li, GY/GZM 4918 2022
OI Zhang, Ye/0000 0001 7433 1820; Li, Guanying/0000 0003 4048 2887; 
FU Songshan Lake Materials Laboratory [82102219]; Songshan Lake Materials
   Laboratory, National Natural Science Foundation of China [2022SLABFK05];
   Open research fund of Songshan Lake Materials Laboratory
FX This work was supported by Songshan Lake Materials Laboratory, National
   Natural Science Foundation of China (Grant No. 82102219), and the open
   research fund of Songshan Lake Materials Laboratory (Grant No.
   2022SLABFK05).
CR Aisenbrey EA, 2020, NAT REV MATER, V5, P539, DOI 10.1038/s41578 020 0199 8
   Asenath Smith E, 2012, ADV FUNCT MATER, V22, P2891, DOI 10.1002/adfm.201200300
   Baker BM, 2015, NAT MATER, V14, P1262, DOI [10.1038/nmat4444, 10.1038/NMAT4444]
   Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904
   Carrow JK, 2018, P NATL ACAD SCI USA, V115, pE3905, DOI 10.1073/pnas.1716164115
   Chrisnandy A, 2022, NAT MATER, V21, P479, DOI 10.1038/s41563 021 01136 7
   Clark AY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14000 9
   Dalby MJ, 2014, NAT MATER, V13, P558, DOI [10.1038/NMAT3980, 10.1038/nmat3980]
   DALTON BA, 1995, J CELL SCI, V108, P2083
   Dhavalikar P, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.202000795
   Du J, 2011, P NATL ACAD SCI USA, V108, P9466, DOI 10.1073/pnas.1106467108
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Faia Torres AB, 2015, ACS APPL MATER INTER, V7, P2367, DOI 10.1021/am506951c
   Frith JE, 2012, STEM CELLS DEV, V21, P2442, DOI 10.1089/scd.2011.0615
   Hu XW, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 32686 2
   Hull SM, 2023, SCI ADV, V9, DOI 10.1126/sciadv.ade7880
   Hussey GS, 2018, NAT REV MATER, V3, P159, DOI 10.1038/s41578 018 0023 x
   Jasuja R, 2004, J BIOL CHEM, V279, P51289, DOI 10.1074/jbc.M408129200
   Jia XF, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 30622 y
   Jia XF, 2020, ADV MATER, V32, DOI 10.1002/adma.201905942
   Jia XF, 2019, SMALL, V15, DOI 10.1002/smll.201804640
   Klein RM, 2008, MOL BIOL CELL, V19, P498, DOI 10.1091/mbc.E07 09 0895
   Kuang Y, 2014, ANGEW CHEM INT EDIT, V53, P8104, DOI 10.1002/anie.201402216
   Li GY, 2021, NANO LETT, V21, P747, DOI 10.1021/acs.nanolett.0c04435
   Li GY, 2017, CHEM US, V2, P283, DOI 10.1016/j.chempr.2017.01.002
   Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962 8924(98)01362 2
   Mang DZ, 2021, ACS APPL MATER INTER, V13, P17236, DOI 10.1021/acsami.1c00934
   Mang DZ, 2020, LANGMUIR, V36, P3750, DOI 10.1021/acs.langmuir.0c00291
   Minami K, 2017, ACS APPL MATER INTER, V9, P30553, DOI 10.1021/acsami.7b11445
   Nardone G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15321
   Nguyen EH, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551 017 0096
   Özkale B, 2021, BIOMATERIALS, V267, DOI 10.1016/j.biomaterials.2020.120497
   Pan JX, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0018 7
   Pittenger MF, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536 019 0083 6
   Roy SR, 2020, ACS APPL MATER INTER, V12, P19277, DOI 10.1021/acsami.0c02235
   Shao L, 2022, CHEMNANOMAT, V8, DOI 10.1002/cnma.202100542
   Shekaranab A., 2014, BIOMATERIALS, V35, P9
   Streuli C, 1999, CURR OPIN CELL BIOL, V11, P634, DOI 10.1016/S0955 0674(99)00026 5
   Wei Y, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202000015
   Yang CL, 2020, LAB INVEST, V100, P1494, DOI 10.1038/s41374 020 0451 2
   Zhao D., 2023, ADV HEALTHC MATER, V13
NR 41
TC 5
Z9 5
U1 8
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD AUG
PY 2024
VL 11
IS 29
DI 10.1002/advs.202401478
EA MAY 2024
PG 13
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA C3F8G
UT WOS:001230217100001
PM 38785178
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ohta, H
   Uemura, Y
   Sone, T
   Tanaka, S
   Soen, S
   Mori, S
   Hagino, H
   Fukunaga, M
   Nakamura, T
   Orimo, H
   Shiraki, M
AF Ohta, Hiroaki
   Uemura, Yukari
   Sone, Teruki
   Tanaka, Shiro
   Soen, Satoshi
   Mori, Satoshi
   Hagino, Hiroshi
   Fukunaga, Masao
   Nakamura, Toshitaka
   Orimo, Hajime
   Shiraki, Masataka
CA Adequate Treatment Osteoporosis
TI Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and
   Fracture Risk in Osteoporosis: Randomized Comparative Study Between
   Minodronic Acid and Raloxifene
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Cholesterol; Nitrogen containing bisphosphonates; Selective estrogen
   receptor modulators; Fractures; Osteoporosis
ID POSTMENOPAUSAL WOMEN; MINERAL DENSITY; BISPHOSPHONATES; ASSOCIATION;
   MECHANISM
AB The positive link between osteoporosis and hypercholesterolemia has been documented, and bone resorption inhibitors, such as nitrogen containing bisphosphonates (N BP) and selective estrogen receptor modulators (SERMs), are known to reduce serum cholesterol levels. However, the relationship between the baseline cholesterol level and incident fracture rate under the treatment using the bone resorption inhibitors has not been documented. We investigated the relation between vertebral fracture incident and the baseline cholesterol levels and cholesterol lowering effect of N BP and SERM in osteoporosis through a prospective randomized open label study design. Patients with osteoporosis (n = 3986) were allocated into two groups based on the drug used for treatment: minodronic acid (MIN) (n = 1624) as an N BP and raloxifene (RLX) as an SERM (n = 1623). Serum levels of cholesterol and incidence of vertebral fracture were monitored for 2 years. The vertebral fracture rates between the two groups were compared using the pre specified stratification factors. The patients receiving MIN with baseline low density lipoprotein (LDL) cholesterol level of >= 140 mg/dL, high density lipoprotein cholesterol level < 40 mg/dL, age group of >= 75 years, and T score of BMD >=  3 SD had significantly lower vertebral fracture rates than those receiving RLX (incidence rate ratios (IRR) 0.45 [95% confidence interval (CI) 0.30 0.75, p = 0.001], 0.25 [95% CI 0.09 0.65, p = 0.005], 0.71 [95% CI 0.56 0.91, p = 0.006], 0.47 [95% CI 0.30 0.75, p = 0.0012], respectively). The cholesterol lowering effect was stronger in the RLX group than in the MIN group, regardless of prior statin use. These results indicated that MIN treatment was more effective in reducing fracture risk in patients with higher LDL cholesterol levels, although its cholesterol lowering ability was lesser than the RLX treatment.Trial registration University Hospital Medical Information Network Clinical Trials Registry (UMIN CTR), No. UMIN000005433; date: April 13, 2011.
C1 [Ohta, Hiroaki] Kawasaki Med Sch, Dept Obstet & Gynecol 2, Okayama, Japan.
   [Uemura, Yukari] Natl Ctr Global Hlth & Med, Ctr Clin Sci, Dept Data Sci, Biostat Sect, 1 21 1 Toyama,Shinjyuku Ku, Tokyo 1628655, Japan.
   [Sone, Teruki] Kawasaki Med Sch, Dept Nucl Med, Okayama, Japan.
   [Tanaka, Shiro] Kyoto Univ, Grad Sch Med, Dept Clin Biostat, Kyoto, Japan.
   [Soen, Satoshi] Osteoporosis & Rheumatol Clin, Soen Orthopaed, Hyogo, Japan.
   [Mori, Satoshi] Seirei Hamamatu Gen Hosp, Bone & Joint Surg, Shizuoka, Japan.
   [Hagino, Hiroshi] Tottori Univ, Sch Hlth Sci, Fac Med, Tottori, Japan.
   [Fukunaga, Masao] Kawasaki Med Sch, Okayama, Japan.
   [Nakamura, Toshitaka] Touto Sangenjaya Rehabil Hosp, Tokyo, Japan.
   [Orimo, Hajime] Japan Osteoporosis Fdn, Tokyo, Japan.
   [Shiraki, Masataka] Res Inst & Practice Involut Dis, Dept Internal Med, Nagano, Japan.
C3 Kawasaki Medical School; Japan Institute for Health Security (JIHS);
   National Center for Global Health & Medicine   Japan; Kawasaki Medical
   School; Kyoto University; Tottori University; Kawasaki Medical School
RP Uemura, Y (通讯作者)，Natl Ctr Global Hlth & Med, Ctr Clin Sci, Dept Data Sci, Biostat Sect, 1 21 1 Toyama,Shinjyuku Ku, Tokyo 1628655, Japan.
EM yuemura@hosp.ncgm.go.jp
RI 田中, 司朗/GON 6916 2022
OI Mori, Satoshi/0000 0002 7660 5562; Ohta, Hiroaki/0000 0003 2490 3442;
   Uemura, Yukari/0000 0002 3013 7775
CR Adami S, 2000, J BONE MINER RES, V15, P599, DOI 10.1359/jbmr.2000.15.3.599
   Baldini V, 2005, J Endocrinol Invest, V28, P69
   Barrett Connor E, 2006, NEW ENGL J MED, V355, P125, DOI 10.1056/NEJMoa062462
   Cummings SR, 2010, NEW ENGL J MED, V362, P686, DOI 10.1056/NEJMoa0808692
   Dominic E, 2020, BONE REP, V12, DOI 10.1016/j.bonr.2020.100244
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Edwards CJ, 2000, LANCET, V355, P2218, DOI 10.1016/S0140 6736(00)02408 9
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Ghorabi S, 2019, ENDOCR RES, V44, P168, DOI 10.1080/07435800.2019.1625057
   Grese TA, 1997, P NATL ACAD SCI USA, V94, P14105, DOI 10.1073/pnas.94.25.14105
   Guney E, 2008, NEUROENDOCRINOL LETT, V29, P252
   Insull W Jr, 2005, METABOLISM, V54, P939, DOI 10.1016/j.metabol.2005.02.010
   Jeong IK, 2010, CALCIFIED TISSUE INT, V87, P507, DOI 10.1007/s00223 010 9427 3
   Johnston CC, 2000, ARCH INTERN MED, V160, P3444, DOI 10.1001/archinte.160.22.3444
   Kinoshita M, 2018, J ATHEROSCLER THROMB, V25, P846, DOI 10.5551/jat.GL2017
   Makovey J, 2009, BONE, V44, P208, DOI 10.1016/j.bone.2008.09.020
   Mandal CC, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00165
   Meier CR, 2000, JAMA J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205
   Orimo, 2007, OSTEOPOROS JPN, V15, P351
   Parhami F, 1999, J BONE MINER RES, V14, P2067, DOI 10.1359/jbmr.1999.14.12.2067
   Tankó LB, 2005, J BONE MINER RES, V20, P1912, DOI 10.1359/JBMR.050711
   Uemura Y, 2020, CURR MED RES OPIN, V36, P1847, DOI 10.1080/03007995.2020.1816537
   Uemura Y, 2019, J BONE MINER METAB, V37, P491, DOI 10.1007/s00774 018 0942 z
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   von der Recke P, 1999, AM J MED, V106, P273, DOI 10.1016/S0002 9343(99)00028 5
   Wang YM, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00030
NR 27
TC 7
Z9 7
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD APR
PY 2023
VL 112
IS 4
BP 430
EP 439
DI 10.1007/s00223 023 01060 9
EA JAN 2023
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 9Y1SR
UT WOS:000918555400001
PM 36707436
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Taya, M
   Hammes, SR
AF Taya, Manisha
   Hammes, Stephen R.
TI Glycoprotein Non Metastatic Melanoma Protein B (GPNMB) and Cancer: A
   Novel Potential Therapeutic Target
SO STEROIDS
LA English
DT Article; Proceedings Paper
CT FASEB Science Research Conference on Rapid Signaling and Genomic Steroid
   Hormone Actions in Health and Disease
CY JUN 11 16, 2017
CL Snowmass, CO
SP FASEB
DE GPNMB; Melanoma; Breast cancer; Invasion; Matrix metalloproteinase;
   Antibody drug conjugate
ID CONJUGATE GLEMBATUMUMAB VEDOTIN; DC HIL; OSTEOBLAST DIFFERENTIATION;
   PROGNOSTIC INDICATOR; PROMOTES GROWTH; CELL LINES; PHASE I/II;
   OSTEOACTIVIN; EXPRESSION; ADHESION
AB Glycoprotein non metastatic melanoma protein B (GPNMB) is a transmembrane protein enriched on the cell surface of cancer cells, including melanoma, glioblastoma, and triple negative breast cancer. There is growing evidence identifying GPNMB as a tumor promoter; however, despite its biological and clinical significance, the molecular mechanisms engaged by GPNMB to promote tumorigenesis are not well understood. GPNMB promotes aggressive behaviors such as tumor cell proliferation, migration, and invasion. The extracellular domain of GPNMB shed from the cell surface interacts with integrins to facilitate in the recruitment of immune suppressive and pro angiogenic cells to the tumor microenvironment, thereby enhancing tumor migration and invasion. GPNMB also modulates receptor tyrosine kinases and integrin signaling in a cell autonomous fashion, leading to downstream kinase signaling that in turn triggers the expression and secretion of tumorigenic factors such as matrix metalloproteinases (MMPs) and cytokines. Therefore, GPNMB exerts its pro tumorigenic role both intracellularly and in a paracrine fashion through shedding its extracellular domain. This review highlights the importance of GPNMB in cancer progression and discusses molecular mediators of GPNMB induced tumor growth and invasion.
C1 Univ Rochester, Med Ctr, Dept Med, Div Endocrinol & Metab, Rochester, NY 14642 USA.
   Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA.
C3 University of Rochester; University of Rochester
RP Taya, M (通讯作者)，Univ Rochester, Sch Med & Dent, Div Endocrinol & Metab, 601 Elmwood Ave, Rochester, NY 14642 USA.
EM Manisha_Taya@urmc.rochester.edu; Stephen_Hammes@urmc.rochester.edu
FU National Institutes of Health [R01CA193583]
FX This work was supported by the National Institutes of Health
   (R01CA193583).
CR Abdelmagid SM, 2008, EXP CELL RES, V314, P2334, DOI 10.1016/j.yexcr.2008.02.006
   Abdelmagid SM, 2007, J CELL PHYSIOL, V210, P26, DOI 10.1002/jcp.20841
   Ahn JH, 2002, BLOOD, V100, P1742, DOI 10.1182/blood.V100.5.1742.h81702001742_1742_1754
   Bendell J, 2014, J CLIN ONCOL, V32, P3619, DOI 10.1200/JCO.2013.52.5683
   Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800
   Bradshaw JM, 2010, CELL SIGNAL, V22, P1175, DOI 10.1016/j.cellsig.2010.03.001
   Carter PJ, 2008, CANCER J, V14, P154, DOI 10.1097/PPO.0b013e318172d704
   Chung JS, 2007, J IMMUNOL, V179, P5778, DOI 10.4049/jimmunol.179.9.5778
   Chung JS, 2007, BLOOD, V109, P4320, DOI 10.1182/blood 2006 11 053769
   Chung JS, 2009, J IMMUNOL, V183, P5190, DOI 10.4049/jimmunol.0901319
   Fiorentini C, 2014, EXP CELL RES, V323, P100, DOI 10.1016/j.yexcr.2014.02.025
   Hoashi T, 2010, FASEB J, V24, P1616, DOI 10.1096/fj.09 151019
   Ibraghimov Beskrovnaya O, 2000, HUM MOL GENET, V9, P1641, DOI 10.1093/hmg/9.11.1641
   Kolb B. A., 2014, PEDIAT BLOOD CANC, V61
   Kuan CT, 2006, CLIN CANCER RES, V12, P1970, DOI 10.1158/1078 0432.CCR 05 2797
   Li B, 2010, FASEB J, V24, P4767, DOI 10.1096/fj.10 154757
   Li YN, 2014, APMIS, V122, P140, DOI 10.1111/apm.12107
   Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295
   Maric G, 2015, ONCOGENE, V34, P5494, DOI 10.1038/onc.2015.8
   Maric G, 2013, ONCOTARGETS THER, V6, P839, DOI 10.2147/OTT.S44906
   Moussa FM, 2014, J CELL BIOCHEM, V115, P1243, DOI 10.1002/jcb.24760
   Okita Y, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aak9397
   Onaga M, 2003, J HEPATOL, V39, P779, DOI 10.1016/S0168 8278(03)00361 1
   Ott PA, 2014, J CLIN ONCOL, V32, P3659, DOI 10.1200/JCO.2013.54.8115
   Oyewumi MO, 2016, ONCOTARGET, V7, P13932, DOI 10.18632/oncotarget.7323
   Pollack VA, 2007, CANCER CHEMOTH PHARM, V60, P423, DOI 10.1007/s00280 007 0490 z
   Prizant H, 2016, ENDOCR RELAT CANCER, V23, P265, DOI 10.1530/ERC 15 0505
   Qian XZ, 2008, MOL ONCOL, V2, P81, DOI 10.1016/j.molonc.2008.02.002
   Rich JN, 2003, J BIOL CHEM, V278, P15951, DOI 10.1074/jbc.M211498200
   Ripoll VM, 2008, GENE, V413, P32, DOI 10.1016/j.gene.2008.01.014
   Ripoll VM, 2007, J IMMUNOL, V178, P6557, DOI 10.4049/jimmunol.178.10.6557
   Rose A.A.N., 2017, PHARM THER
   Rose AAN, 2007, MOL CANCER RES, V5, P1001, DOI 10.1158/1541 7786.MCR 07 0119
   Rose AAN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012093
   Rose AAN, 2010, CLIN CANCER RES, V16, P2147, DOI 10.1158/1078 0432.CCR 09 1611
   Rose AAN, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1791
   Selim AA, 2003, CRIT REV EUKAR GENE, V13, P265, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.180
   Selim AA, 2009, MED SCI MONITOR, V15, pMT19
   Sheng MHC, 2008, FEBS LETT, V582, P1451, DOI 10.1016/j.febslet.2008.03.030
   Shi FY, 2014, J MOL NEUROSCI, V54, P234, DOI 10.1007/s12031 014 0280 0
   Shikano S, 2001, J BIOL CHEM, V276, P8125, DOI 10.1074/jbc.M008539200
   Singh M, 2010, CRIT REV EUKAR GENE, V20, P341, DOI 10.1615/CritRevEukarGeneExpr.v20.i4.50
   Tomihari M, 2010, CANCER RES, V70, P5778, DOI 10.1158/0008 5472.CAN 09 2538
   Tomihari M, 2009, EXP DERMATOL, V18, P586, DOI 10.1111/j.1600 0625.2008.00830.x
   Trail PA, 2017, PHARM THER
   Tse KF, 2006, CLIN CANCER RES, V12, P1373, DOI 10.1158/1078 0432.CCR 05 2018
   WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111
   Wu AM, 2005, NAT BIOTECHNOL, V23, P1137, DOI 10.1038/nbt1141
   Yardley DA, 2015, J CLIN ONCOL, V33, P1609, DOI 10.1200/JCO.2014.56.2959
   Zhang YX, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317699119
   Zhou LT, 2012, NEOPLASMA, V59, P1, DOI 10.4149/neo_2012_001
NR 51
TC 78
Z9 87
U1 1
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039 128X
EI 1878 5867
J9 STEROIDS
JI Steroids
PD MAY
PY 2018
VL 133
SI SI
BP 102
EP 107
DI 10.1016/j.steroids.2017.10.013
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA GC4OD
UT WOS:000429763400018
PM 29097143
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Kretschmer, A
   Zhang, F
   Somasekharan, SP
   Tse, C
   Leachman, L
   Gleaye, A
   Li, B
   Asmaro, I
   Huang, T
   Kotula, L
   Sorensen, PH
   Gleave, ME
AF Kretschmer, Alexander
   Zhang, Fan
   Somasekharan, Syam Prakash
   Tse, Charan
   Leachman, Lauren
   Gleaye, Anna
   Li, Brian
   Asmaro, Ivan
   Huang, Teresa
   Kotula, Leszek
   Sorensen, Poul H.
   Gleave, Martin E.
TI Stress induced tunneling nanotubes support treatment adaptation in
   prostate cancer
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CELL CELL COMMUNICATION; ANDROGEN RECEPTOR; PROGRESSION; CASTRATION;
   THERAPY; ACTIN; EPS8; DEPRIVATION; METABOLISM; AUTOPHAGY
AB Tunneling nanotubes (TNTs) are actin based membranous structures bridging distant cells for intercellular communication. We define roles for TNTs in stress adaptation and treatment resistance in prostate cancer (PCa). Androgen receptor (AR) blockade and metabolic stress induce TNTs, but not in normal prostatic epithelial or osteoblast cells. Co culture assays reveal enhanced TNT formation between stressed and unstressed PCa cells as well as from stressed PCa to osteoblasts. Stress induced chaperones clusterin and YB 1 localize within TNTs, are transported bi directionally via TNTs and facilitate TNT formation in PI3K/AKT and Eps8 dependent manner. AR variants, induced by AR antagonism to mediate resistance to AR pathway inhibition, also enhance TNT production and rescue loss of clusterin  orYB 1 repressed TNT formation. TNT disruption sensitizes PCa to treatment induced cell death. These data define a mechanistic network involving stress induction of chaperone and AR variants, PI3K/AKT signaling, actin remodeling and TNT mediated intercellular communication that confer stress adaptative cell survival.
C1 [Kretschmer, Alexander; Zhang, Fan; Somasekharan, Syam Prakash; Tse, Charan; Leachman, Lauren; Gleaye, Anna; Li, Brian; Asmaro, Ivan; Huang, Teresa; Gleave, Martin E.] Univ British Columbia, Dept Urol Sci, Vancouver Prostate Ctr, 2775 Laurel St, Vancouver, BC V6H 3Z6, Canada.
   [Kotula, Leszek] SUNY Upstate Med Univ, Dept Urol Biochem & Mol Biol, Med, Syracuse, NY 13210 USA.
   [Sorensen, Poul H.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6H 3Z6, Canada.
C3 University of British Columbia; State University of New York (SUNY)
   System; SUNY Upstate Medical University; University of British Columbia
RP Gleave, ME (通讯作者)，Univ British Columbia, Dept Urol Sci, Vancouver Prostate Ctr, 2775 Laurel St, Vancouver, BC V6H 3Z6, Canada.
EM m.gleave@ubc.ca
RI ; Zhang, Fan/AAB 1175 2020; Kretschmer, Alexander/AAU 5922 2021
OI Somasekharan, Syam/0000 0002 9006 8206; Gleave,
   Martin/0000 0003 4235 0167; Kotula, Leszek/0000 0002 7977 7124
FU Terry Fox New Frontiers Program; Prostate Cancer Canada Movember Team
   Grant; German Research Foundation [KR 4676/1 1]
FX This study was supported by grants from the Terry Fox New Frontiers
   Program and Prostate Cancer Canada Movember Team Grant. A.K. was
   supported by a grant from the German Research Foundation (KR 4676/1 1).
CR Abounit Saida, 2015, Curr Protoc Cell Biol, V67, DOI 10.1002/0471143030.cb1210s67
   Abounit S, 2012, J CELL SCI, V125, P1089, DOI 10.1242/jcs.083279
   Ady JW, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00400
   Akamatsu S, 2015, CELL REP, V12, P922, DOI 10.1016/j.celrep.2015.07.012
   Ammar H, 2008, J BIOL CHEM, V283, P12851, DOI 10.1074/jbc.M800403200
   Austefjord Magnus Wiger, 2014, Commun Integr Biol, V7, pe27934, DOI 10.4161/cib.27934
   Bénard M, 2015, BIOL CELL, V107, P419, DOI 10.1111/boc.201500004
   Bracq L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00260
   Brücher BLDM, 2014, CELL PHYSIOL BIOCHEM, V34, P213, DOI 10.1159/000362978
   Carruba G, 1999, ANAL QUANT CYTOL, V21, P54
   Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008
   Cato L, 2019, CANCER CELL, V35, P401, DOI 10.1016/j.ccell.2019.01.008
   Chi KN, 2010, J CLIN ONCOL, V28, P4247, DOI 10.1200/JCO.2009.26.8771
   Delage E, 2016, SCI REP UK, V6, DOI 10.1038/srep39632
   Desir S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 27649 x
   Desir S, 2016, ONCOTARGET, V7, P43150, DOI 10.18632/oncotarget.9504
   Doshi BM, 2009, CELL STRESS CHAPERON, V14, P445, DOI 10.1007/s12192 008 0098 1
   Dupont M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00043
   Gerdes HH, 2007, FEBS LETT, V581, P2194, DOI 10.1016/j.febslet.2007.03.071
   Gleave M, 1999, CLIN CANCER RES, V5, P2891
   Gousset K, 2009, NAT CELL BIOL, V11, P328, DOI 10.1038/ncb1841
   Hanna SJ, 2019, J CELL SCI, V132, DOI 10.1242/jcs.223321
   Hekmatshoar Y, 2018, BIOCHEM J, V475, P2305, DOI 10.1042/BCJ20170712
   Hensel J, 2016, UROLOGY, V92, P6, DOI 10.1016/j.urology.2015.12.039
   Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079
   Kadiu I, 2011, J PROTEOME RES, V10, P3225, DOI 10.1021/pr200262q
   Knudsen KE, 2009, CLIN CANCER RES, V15, P4792, DOI 10.1158/1078 0432.CCR 08 2660
   Lamoureux F, 2013, CLIN CANCER RES, V19, P833, DOI 10.1158/1078 0432.CCR 12 3114
   Law JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012661
   Lee SH, 2015, J BIOL CHEM, V290, P2759, DOI 10.1074/jbc.M114.607846
   Leprivier G, 2013, CELL, V153, P1064, DOI 10.1016/j.cell.2013.04.055
   Li YA, 2017, EUR UROL, V71, P68, DOI 10.1016/j.eururo.2016.04.028
   Liu LL, 2014, ONCOGENE, V33, P3140, DOI 10.1038/onc.2013.284
   Lou E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033093
   Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024
   Maeda S, 2011, CELL MOL LIFE SCI, V68, P1115, DOI 10.1007/s00018 010 0551 z
   Marzo L, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00072
   Matsumoto H, 2013, CANCER RES, V73, P5206, DOI 10.1158/0008 5472.CAN 13 0359
   Miyake H, 2000, CANCER RES, V60, P2547
   Morel E, 2017, ANNU REV PHARMACOL, V57, P375, DOI 10.1146/annurev pharmtox 010716 104936
   Offenhäuser N, 2004, MOL BIOL CELL, V15, P91, DOI 10.1091/mbc.E03 06 0427
   Önfelt B, 2004, J IMMUNOL, V173, P1511, DOI 10.4049/jimmunol.173.3.1511
   Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579
   Pasquier J, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 94
   Polak R, 2015, BLOOD, V126, P2404, DOI 10.1182/blood 2015 03 634238
   Rocchi P, 2004, CANCER RES, V64, P6595, DOI 10.1158/0008 5472.CAN 03 3998
   Roffers Agarwal J, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471 2121 6 36
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133
   Sáenz de Santa María I, 2017, ONCOTARGET, V8, P20939, DOI 10.18632/oncotarget.15467
   Sartori Rupp A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 08178 7
   Shiota M, 2016, JNCI J NATL CANCER I, V108, DOI 10.1093/jnci/djw005
   Shiota M, 2012, J UROLOGY, V187, P707, DOI 10.1016/j.juro.2011.09.147
   Somasekharan SP, 2015, J CELL BIOL, V208, P913, DOI 10.1083/jcb.201411047
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Veranic P, 2008, BIOPHYS J, V95, P4416, DOI 10.1529/biophysj.108.131375
   Vidulescu C, 2004, J CELL MOL MED, V8, P388, DOI 10.1111/j.1582 4934.2004.tb00328.x
   Wang Y, 2011, CELL DEATH DIFFER, V18, P732, DOI 10.1038/cdd.2010.147
   Wek RC, 2010, EMBO J, V29, P1946, DOI 10.1038/emboj.2010.110
   Wyatt AW, 2015, EMBO MOL MED, V7, P878, DOI 10.15252/emmm.201303701
   Yamamoto Y, 2015, CLIN CANCER RES, V21, P1675, DOI 10.1158/1078 0432.CCR 14 1108
   Zhang F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6775
   Zhang HL, 2005, NAT CELL BIOL, V7, P909, DOI 10.1038/ncb1291
   Zoubeidi A, 2012, INT J BIOCHEM CELL B, V44, P1646, DOI 10.1016/j.biocel.2012.04.010
   Zoubeidi A, 2010, MOL CANCER RES, V8, P119, DOI 10.1158/1541 7786.MCR 09 0277
NR 64
TC 55
Z9 58
U1 0
U2 8
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAY 24
PY 2019
VL 9
AR 7826
DI 10.1038/s41598 019 44346 5
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA HZ4ZC
UT WOS:000468859400041
PM 31127190
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Fan, SY
   Zhang, CL
   Sun, X
   Su, CC
   Xue, YW
   Song, X
   Deng, RZ
AF Fan, Siyu
   Zhang, Cunliang
   Sun, Xin
   Su, Chuanchao
   Xue, Yiwen
   Song, Xiao
   Deng, Runzhi
TI Metformin enhances osteogenic differentiation of BMSC by modulating
   macrophage M2 polarization
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; REGENERATION
AB Bone marrow derived mesenchymal stem cells (BMSCs) are capable of developing into osteoblastic cell lines in vitro and regenerating bone tissue in vivo, and they are considered to be a reliable source for bone regenerative medicine. In recent years, studies have shown that the immune microenvironment is important for osteogenesis, in which macrophages are an important component of innate immunity and coordinate with stem cells. Metformin (Met), a hypoglycemic drug that exerts a powerful effect on metabolic signaling, has been shown to modulate inflammatory responses and osteogenic activity. However, whether metformin modulates macrophage polarization and subsequently affects osteogenesis remains to be elucidated. In the present study, we investigated the potential immunomodulatory capacity of metformin on macrophage inflammatory responses and phenotypic switching, and the subsequent effects on osteogenic differentiation of BMSCs. Flow cytometry and qPCR were used to study the effects of metformin on macrophage phenotypic regulation. qPCR, ALP, ARS and calcium content measurement and ALP activity assay were used to determine the effects of macrophage secreted activators on the osteogenic differentiation of BMSCs. Our study demonstrates that metformin can improve the immune microenvironment by modulating macrophage polarization towards an anti inflammatory phenotype, promoting an increase in a range of anti inflammatory factors and inhibiting pro inflammatory factors. This was characterized by increased expression of IL 10 and CD206, Arg 1 and decreased expression of IL 1 beta, TNF alpha, IL 6 and iNOS. In addition, metformin modulated macrophage conditioned medium promoted osteogenic differentiation of BMSCs, increased the expression levels of genes (ALP, Runx 2, OCN, and Col 1), enhanced ALP activity, and significantly formed mineralized nodules. In conclusion, our new study elucidates that metformin can promote osteogenic differentiation of BMSCs by modulating macrophage phenotype and thereby.
C1 [Fan, Siyu; Zhang, Cunliang; Sun, Xin; Su, Chuanchao; Xue, Yiwen; Song, Xiao; Deng, Runzhi] Nanjing Univ, Nanjing Stomatol Hosp, Affiliated Hosp Med Sch, Res Inst Stomatol,Dept Oral & Maxillofacial Surg, Nanjing, Jiangsu, Peoples R China.
   [Fan, Siyu; Zhang, Cunliang; Sun, Xin; Su, Chuanchao; Xue, Yiwen] Nanjing Univ, Nanjing Stomatol Hosp, Med Sch, Cent Lab Stomatol,Affiliated Hosp, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing University; Nanjing University
RP Deng, RZ (通讯作者)，Nanjing Univ, Nanjing Stomatol Hosp, Affiliated Hosp Med Sch, Res Inst Stomatol,Dept Oral & Maxillofacial Surg, Nanjing, Jiangsu, Peoples R China.
EM doctord@163.com
FU Nanjing Medical Science and Technique Development Foundation
FX No Statement Available
CR Arthur A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249759
   Chen SF, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.634650
   Dong K, 2023, J PERIODONTAL IMPLAN, V53, P54, DOI 10.5051/jpis.2106240312
   Eshghjoo S, 2022, GENES BASEL, V13, DOI 10.3390/genes13050756
   Gong L, 2016, ANN CLIN LAB SCI, V46, P65
   Goodman SB, 2022, CURR OSTEOPOROS REP, V20, P43, DOI 10.1007/s11914 022 00720 3
   Jing YY, 2018, MOL CELL ENDOCRINOL, V461, P256, DOI 10.1016/j.mce.2017.09.025
   Lei T, 2021, INT J BIOCHEM CELL B, V141, DOI 10.1016/j.biocel.2021.106086
   Li DL, 2023, RHEUMATOLOGY, V62, P1652, DOI 10.1093/rheumatology/keac467
   Lin T, 2019, TISSUE ENG PT A, V25, P1096, DOI [10.1089/ten.tea.2018.0292, 10.1089/ten.TEA.2018.0292]
   Liu YC, 2014, INT J BIOL SCI, V10, P520, DOI 10.7150/ijbs.8879
   Mills LA, 2017, ACTA ORTHOP, V88, P434, DOI 10.1080/17453674.2017.1321351
   Nicolini AC, 2019, CLIN ORAL INVEST, V23, P2659, DOI 10.1007/s00784 018 2666 9
   Pajarinen J, 2019, BIOMATERIALS, V196, P80, DOI 10.1016/j.biomaterials.2017.12.025
   Qiao D, 2023, ACTA BIOMATER, V162, P135, DOI 10.1016/j.actbio.2023.03.027
   Qing LM, 2019, AM J TRANSL RES, V11, P655
   Schlundt C, 2021, ACTA BIOMATER, V133, P46, DOI 10.1016/j.actbio.2021.04.052
   Schuiveling M, 2018, CURR DRUG TARGETS, V19, P945, DOI 10.2174/1389450118666170613081730
   Shen M, 2022, STEM CELLS INT, V2022, DOI 10.1155/2022/9498876
   Shi MS, 2018, J BIOMED MATER RES A, V106, P1236, DOI 10.1002/jbm.a.36321
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Tu B, 2015, EXP CELL RES, V339, P81, DOI 10.1016/j.yexcr.2015.10.015
   Vallés G, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 1578 1
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wang MJ, 2020, BIOL PHARM BULL, V43, P129, DOI 10.1248/bpb.b19 00689
   Wang YH, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 03199 y
   Wu AM, 2021, LANCET HEALTH LONGEV, V2, pE580, DOI 10.1016/S2666 7568(21)00172 0
   Yan Z, 2018, MOL MED, V24, DOI 10.1186/s10020 018 0013 x
   Yuan D, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.811372
   Zhang J, 2017, CURR STEM CELL RES T, V12, P357, DOI 10.2174/1574888X11666160921121555
   Zhang YL, 2022, EXP CELL RES, V418, DOI 10.1016/j.yexcr.2022.113269
   Zura R, 2016, JAMA SURG, V151, DOI 10.1001/jamasurg.2016.2775
NR 32
TC 8
Z9 8
U1 1
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD AUG 31
PY 2024
VL 14
IS 1
AR 20267
DI 10.1038/s41598 024 71318 1
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA E6H9X
UT WOS:001304007200009
PM 39217251
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Peng, SP
   He, TT
   Liu, Y
   Zheng, LL
   Zhong, YC
   Niu, ZY
   Zhang, MJ
   Yang, S
AF Peng, Shuping
   He, Tiantian
   Liu, Ying
   Zheng, Leliang
   Zhong, Yancheng
   Niu, Zhiyuan
   Zhang, Mojian
   Yang, Sheng
TI Lnc PPP2R1B Mediates the Alternative Splicing of PPP2R1B by Interacting
   and Stabilizing HNRNPLL and Promotes Osteogenesis of MSCs
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article
DE Lnc PPP2R1B; MSCs, osteogenesis; HNRNPLL; PPP2R1B; Alternative splicing
ID PROTEIN PHOSPHATASE 2A; BONE; DIFFERENTIATION; DEGRADATION; DEFICIENCY;
   EXPRESSION; OSTERIX
AB Osteogeinc differentiation from mesenchymal stem cells (MSCs) into osteoblasts is a key step for bone tissue engineering in regenerative medicine. The insight into regulatory mechanism of osteogenesis of MSCs facilitates achieving better recovery effect. Long non coding RNAs are regarded as a family of important moderators in osteogenesis. In this study, we found a novel lncRNA, lnc PPP2R1B was up regulated during osteogenesis of MSCs by Illumina HiSeq transcritome sequencing. We demonstrated lnc PPP2R1B overexpression promoted osteogenesis and knockdown of lnc PPP2R1B inhibited osteogenesis of MSCs. Mechanically, it physically interacted with and up regulated heterogeneous nuclear ribonucleoprotein L Like (HNRNPLL), which is a master regulator of activation induced alternative splicing in T cells. We found lnc PPP2R1B knockdown or HNRNPLL knockdown decreased transcript 201 of Protein Phosphatase 2A, Regulatory Subunit A, Beta Isoform (PPP2R1B) while increased transcript 203 of PPP2R1B, and did not affect transcript 202/204/206. PPP2R1B is a constant regulatory subunit of protein phosphatase 2 (PP2A), which activates Wnt/beta catenin pathway by removing phosphorylation and stabilization of beta catenin and translocation into nucleus. The transcript 201 retained exon 2 and 3, compared to transcript 203. And it was reported the exon 2 and 3 of PPP2R1B were one part of B subunit binding domain on A subunit in PP2A trimer, and therefore retaining exon 2 and 3 promised formation and enzyme function of PP2A. Finally, lnc PPP2R1B promoted ectopic osteogenesis in vivo. Conclusively, lnc PPP2R1B mediated alternative splicing of PPP2R1B through retaining exon 2 and 3 by interacting with HNRNPLL and then promoted osteogenesis, which may facilitate an in depth understanding of function and mechanism of lncRNAs in osteogenesis.
C1 [Peng, Shuping; He, Tiantian; Liu, Ying; Zheng, Leliang; Zhong, Yancheng; Niu, Zhiyuan; Zhang, Mojian] Cent South Univ, NHC Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China.
   [Peng, Shuping; He, Tiantian; Liu, Ying; Zheng, Leliang; Zhong, Yancheng; Niu, Zhiyuan; Zhang, Mojian] Cent South Univ, Hunan Canc Hosp, Hunan Key Lab Canc Metab, Changsha, Hunan, Peoples R China.
   [Peng, Shuping; He, Tiantian; Liu, Ying; Zheng, Leliang; Zhong, Yancheng; Niu, Zhiyuan; Zhang, Mojian] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Hunan, Peoples R China.
   [Peng, Shuping; He, Tiantian; Liu, Ying; Zheng, Leliang; Zhong, Yancheng; Niu, Zhiyuan; Zhang, Mojian] Cent South Univ, Chinese Minist Educ, Canc Res Inst, Key Lab Carcinogenesis & Canc Invas,Xiangya Hosp, Changsha, Hunan, Peoples R China.
   [Peng, Shuping; He, Tiantian; Liu, Ying; Zheng, Leliang; Zhong, Yancheng; Niu, Zhiyuan; Zhang, Mojian] Cent South Univ, Xiangya Hosp 3, Dis Genome Res Ctr, Hunan Key Lab Non Resolving Inflammat & Canc, Changsha, Peoples R China.
   [Yang, Sheng] Shenzhen Univ, Reprod Med Ctr, Affiliated Hosp 3, Shenzhen, Peoples R China.
C3 Central South University; Central South University; Central South
   University; Central South University; Central South University; Shenzhen
   University
RP Peng, SP (通讯作者)，Cent South Univ, NHC Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China.; Peng, SP (通讯作者)，Cent South Univ, Hunan Canc Hosp, Hunan Key Lab Canc Metab, Changsha, Hunan, Peoples R China.; Peng, SP (通讯作者)，Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Hunan, Peoples R China.; Peng, SP (通讯作者)，Cent South Univ, Chinese Minist Educ, Canc Res Inst, Key Lab Carcinogenesis & Canc Invas,Xiangya Hosp, Changsha, Hunan, Peoples R China.; Peng, SP (通讯作者)，Cent South Univ, Xiangya Hosp 3, Dis Genome Res Ctr, Hunan Key Lab Non Resolving Inflammat & Canc, Changsha, Peoples R China.; Yang, S (通讯作者)，Shenzhen Univ, Reprod Med Ctr, Affiliated Hosp 3, Shenzhen, Peoples R China.
EM shuping@csu.edu.cn; shengyang@szu.edu.cn
RI ; Niu, Zhiyuan/KJM 5383 2024
OI Peng, shuping/0000 0001 9567 9295; Yang, Sheng/0000 0002 0649 0077; 
FU Natural Science Foundation of China [82072084, 81871498]; Natural
   Science Foundation of Guangdong Province [2021A030413428]; Shenzhen
   Fundamental Research Program [JCYJ20190808122003692]; Shenzhen Peacock
   Plan [RC00339]; Hunan Provincial Innovation Foundation for Postgraduate
   [CX20200263, 2020zzts223]
FX This study was supported by the Natural Science Foundation of China
   (82072084, 81871498), Natural Science Foundation of Guangdong Province
   (2021A030413428), Shenzhen Fundamental Research Program
   (JCYJ20190808122003692), Shenzhen Peacock Plan (RC00339), Hunan
   Provincial Innovation Foundation for Postgraduate (CX20200263) and
   Innovation for graduate students of Central South University 2020
   (2020zzts223).
CR Cao LH, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12814
   Du MF, 2021, FASEB J, V35, DOI 10.1096/fj.202002810R
   Feng P, 2018, ADV SCI, V5, DOI 10.1002/advs.201700817
   He SW, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2148 2
   HEMMINGS BA, 1990, BIOCHEMISTRY US, V29, P3166, DOI 10.1021/bi00465a002
   Kalla C, 2007, EUR J CANCER, V43, P1328, DOI 10.1016/j.ejca.2007.02.005
   KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139
   Mathot F, 2021, NEURAL REGEN RES, V16, P1613, DOI 10.4103/1673 5374.303031
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nishimura R, 2012, J BIOL CHEM, V287, P33179, DOI 10.1074/jbc.M111.337063
   Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022
   Oberdoerffer S, 2008, SCIENCE, V321, P686, DOI 10.1126/science.1157610
   Qi FW, 2022, ADDIT MANUF, V52, DOI 10.1016/j.addma.2022.102694
   Qiao YY, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm 20 5583
   Shuai CJ, 2021, BIOACT MATER, V6, P490, DOI 10.1016/j.bioactmat.2020.09.001
   Shur I, 2004, GENE, V334, P113, DOI 10.1016/j.gene.2004.03.012
   Wang X, 2021, EMBO J, V40, DOI 10.15252/embj.2020104729
   Xiao ZS, 2005, DEV BIOL, V283, P345, DOI 10.1016/j.ydbio.2005.04.028
   Xiao ZS, 2004, J BIOL CHEM, V279, P20307, DOI 10.1074/jbc.M401109200
   Xie QX, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02011 z
   Yabas M, 2021, IMMUNOL CELL BIOL, V99, P532, DOI 10.1111/imcb.12433
   Yabas M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026440
   Yang QL, 2018, STEM CELL REV REP, V14, P297, DOI 10.1007/s12015 018 9801 5
   Yang YW, 2021, BIOACT MATER, V6, P1230, DOI 10.1016/j.bioactmat.2020.10.017
   Yang YW, 2020, VIRTUAL PHYS PROTOTY, V15, P278, DOI 10.1080/17452759.2020.1748381
   Yin HJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 24315 1
NR 26
TC 5
Z9 5
U1 1
U2 18
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629 3269
EI 2629 3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
PD AUG
PY 2023
VL 19
IS 6
BP 1981
EP 1993
DI 10.1007/s12015 023 10559 5
EA MAY 2023
PG 13
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA N4FI6
UT WOS:000995789600002
PM 37243830
DA 2025 08 17
ER

PT J
AU Savaridas, T
   Wallace, RJ
   Salter, DM
   Simpson, AHRW
AF Savaridas, T.
   Wallace, R. J.
   Salter, D. M.
   Simpson, A. H. R. W.
TI Do bisphosphonates inhibit direct fracture healing? A LABORATORY
   INVESTIGATION USING AN ANIMAL MODEL
SO BONE & JOINT JOURNAL
LA English
DT Article
ID SUPPRESSED BONE TURNOVER; ZOLEDRONIC ACID; ALENDRONATE; REPAIR;
   OSTEOPOROSIS; MICRODAMAGE; INCREASES; STRENGTH; THERAPY; WOMEN
AB Fracture repair occurs by two broad mechanisms: direct healing, and indirect healing with callus formation. The effects of bisphosphonates on fracture repair have been assessed only in models of indirect fracture healing.
   A rodent model of rigid compression plate fixation of a standardised tibial osteotomy was used. Ten skeletally mature Sprague Dawley rats received daily subcutaneous injections of 1 mu g/kg ibandronate (IBAN) and ten control rats received saline (control). Three weeks later a tibial osteotomy was rigidly fixed with compression plating. Six weeks later the animals were killed. Fracture repair was assessed with mechanical testing, radiographs and histology.
   The mean stress at failure in a four point bending test was significantly lower in the IBAN group compared with controls (8.69 Nmm( 2) (SD 7.63) vs 24.65 Nmm( 2) (SD 6.15); p = 0.017). On contact radiographs of the extricated tibiae the mean bone density assessment at the osteotomy site was lower in the IBAN group than in controls (3.7 mmAl (SD 0.75) vs 4.6 mmAl (SD 0.57); p = 0.01). In addition, histological analysis revealed progression to fracture union in the controls but impaired fracture healing in the IBAN group, with predominantly cartilage like and undifferentiated mesenchymal tissue (p = 0.007).
   Bisphosphonate treatment in a therapeutic dose, as used for risk reduction in fragility fractures, had an inhibitory effect on direct fracture healing. We propose that bisphosphonate therapy not be commenced until after the fracture has united if the fracture has been rigidly fixed and is undergoing direct osteonal healing.
C1 [Savaridas, T.] Univ Edinburgh, Edinburgh EH16 4SU, Midlothian, Scotland.
   [Wallace, R. J.; Simpson, A. H. R. W.] Univ Edinburgh, Royal Infirm Edinburgh, Dept Orthopaed, Edinburgh EH16 4SU, Midlothian, Scotland.
   [Salter, D. M.] Univ Edinburgh, Osteoarticular Res Grp, Ctr Mol Med MRC IGMM, Edinburgh EH8 9AG, Midlothian, Scotland.
C3 University of Edinburgh; University of Edinburgh; Royal Infirmary of
   Edinburgh; University of Edinburgh
RP Savaridas, T (通讯作者)，Northern Deanery Orthopaed Training Programme, Waterfront 4,Goldcrest Way, Newcastle Upon Tyne NE15 8NY, Tyne & Wear, England.
EM tsavaridas@doctors.net.uk
RI Simpson, Alasdair/F 1887 2013; Simpson, Hamish/F 1887 2013; Wallace,
   Robert/B 3918 2016
OI Simpson, Hamish/0000 0001 7793 642X; 
FU Osteosynthesis and Trauma Care (OTC); Association Internationale Pour
   L'Osteosynthese Dynamique (AIOD); Royal College of Surgeons of Edinburgh
   (RCSEd)
FX Aided by grants from Osteosynthesis and Trauma Care (OTC) in
   collaboration with Association Internationale Pour L'Osteosynthese
   Dynamique (AIOD) and The Royal College of Surgeons of Edinburgh (RCSEd).
   The authors would like to thank Mr M. S. Gaston for his contributions
   towards the study design, Dr S. P. Whiley for measuring the Al.Eq
   density of the osteotomy site on radiographs, and Mr R. Tyagi for
   scoring the visibility of the osteotomy line.
CR Allen MR, 2007, J BONE MINER RES, V22, P1759, DOI 10.1359/JBMR.070720
   Amanat N, 2005, J ORTHOP RES, V23, P1029, DOI 10.1016/j.orthres.2005.03.004
   Amanat N, 2007, J BONE MINER RES, V22, P867, DOI 10.1359/JBMR.070318
   Bauer DC, 2004, J BONE MINER RES, V19, P1250, DOI 10.1359/JBMR.040512
   Bauss F, 2002, J RHEUMATOL, V29, P990
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Blokhuis TJ, 2001, SKELETAL RADIOL, V30, P151, DOI 10.1007/s002560000317
   Cao Y, 2003, NIHON SEIKEIGEKA GAK, V77, pS1094
   Cao YP, 2002, J BONE MINER RES, V17, P2237, DOI 10.1359/jbmr.2002.17.12.2237
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Goh SK, 2007, J BONE JOINT SURG BR, V89B, P349, DOI 10.1302/0301 620X.89B3.18146
   Goldhahn J, 2010, BONE, V46, P267, DOI 10.1016/j.bone.2009.10.004
   Goodship A E, 1994, Ann Oncol, V5 Suppl 7, pS53
   HYVONEN PM, 1994, PHARMACOL TOXICOL, V75, P384, DOI 10.1111/j.1600 0773.1994.tb00379.x
   Ito M, 1999, BONE, V25, P447, DOI 10.1016/S8756 3282(99)00197 0
   Khan SA, 1997, J BONE MINER RES, V12, P1700, DOI 10.1359/jbmr.1997.12.10.1700
   Koivukangas A, 2003, CLIN ORTHOP RELAT R, P268, DOI 10.1097/01.blo.0000053054.62337.e1
   LENEHAN TM, 1985, J ORTHOP RES, V3, P499, DOI 10.1002/jor.1100030413
   Li J, 2001, CALCIFIED TISSUE INT, V69, P281, DOI 10.1007/s002230010036
   Li JL, 1999, J BONE MINER RES, V14, P969, DOI 10.1359/jbmr.1999.14.6.969
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   McDonald MM, 2008, BONE, V43, P653, DOI 10.1016/j.bone.2008.05.019
   MCKIBBIN B, 1978, J BONE JOINT SURG BR, V60, P150, DOI 10.1302/0301 620X.60B2.350882
   National Institute for Health and Clinical Excellence, 2010, TA161 ALENDRONATE ET
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Perren SM, 2002, J BONE JOINT SURG BR, V84B, P1093, DOI 10.1302/0301 620X.84B8.13752
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Savaridas T, 2012, BONE JOINT RES, V1, P289, DOI 10.1302/2046 3758.111.2000087
   Schell H, 2006, BONE, V38, P547, DOI 10.1016/j.bone.2005.09.018
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   SEDLIN ED, 1966, ACTA ORTHOP SCAND, V37, P29, DOI 10.3109/17453676608989401
   SIGN, 2003, GUID 71 MAN OST
   Young W.C., 1989, Roark's formulas for stress and strain, VSeventh
NR 34
TC 38
Z9 43
U1 0
U2 11
PU BRITISH EDITORIAL SOC BONE JOINT SURGERY
PI LONDON
PA 22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND
SN 2049 4394
J9 BONE JOINT J
JI Bone Joint J.
PD SEP
PY 2013
VL 95B
IS 9
BP 1263
EP 1268
DI 10.1302/0301 620X.95B9.31562
PG 6
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA 221QT
UT WOS:000324674200021
PM 23997143
DA 2025 08 17
ER

PT J
AU Jiao, DL
   Cao, LY
   Liu, Y
   Wu, JN
   Zheng, A
   Jiang, XQ
AF Jiao, Delong
   Cao, Lingyan
   Liu, Yang
   Wu, Jiannan
   Zheng, Ao
   Jiang, Xinquan
TI Synergistic Osteogenesis of Biocompatible Reduced Graphene Oxide with
   Methyl Vanillate in BMSCs
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE methyl vanillate; graphene oxide; Wnt/beta catenin; endocytosis
ID CARBON NANOTUBES; RAMAN SPECTROSCOPY; TARGETED DELIVERY; GRAPHITE OXIDE;
   DIFFERENTIATION; NANOSHEETS; CANCER; GROWTH; NANOPARTICLES;
   OSTEOSARCOMAS
AB Methyl vanillate (MV), a recently characterized small molecule, can promote the Wnt/beta catenin signaling pathway and induce osteoblast differentiation both in vitro and in vivo. On the other hand, graphene based materials have been introduced into the field of biomedical sciences in the past decade, and graphene oxide (GO), which serves as an efficient nanocarrier for drug delivery, has attracted great attention for its biomedical applications in tissue engineering. This study aimed to develop a biocompatible gelatin reduced graphene oxide (GOG) for MV delivery so as to realize the effective osteogenesis for bone repair. First, GOG was prepared, and its morphology as well as properties were then characterized using scanning electron microscope (SEM), transmission electron microscopy (TEM), atomic force microscope (AFM), Raman spectroscopy, X ray photoelectron spectroscopy (XPS), X ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), and thermal gravimetric analysis (TGA), respectively. In addition, the endocytosis of GOG in bone marrow stromal cells (BMSCs) was also investigated with the treatment of Rhodamine 6G (R6G) labeled GOG. Our results found that GOG could be easily absorbed by cells and was distributed in both nucleus and cytoplasm, thus suggesting the favorable biocompatibility of GOG. Moreover, the effect of MV on osteogenesis was also tested, the results of which indicated that MV could promote BMSC osteogenesis in a concentration dependent manner, and significant enhancement could be achieved at the concentration of 1 mu g/mL. In addition, the complex containing different concentrations of GOG and an optimal concentration of MV was used to investigate the synergistic effect between GOG and MV on pro osteogenesis. The results revealed that the weight ratio of MV/GOG of 1:1000 could attain remarkably enhanced osteoinduction in BMSCs, as evaluated by alkaline phosphatase (ALP) assay, alizarin red S (ARS) staining, immunofluorescence staining, and gene expression of related osteogenic markers. Taken together, these data had provided strong evidence that the complex of MV and GOG could induce osteogenesis, which was promising for bone tissue engineering.
C1 [Jiao, Delong; Cao, Lingyan; Wu, Jiannan; Zheng, Ao; Jiang, Xinquan] Shanghai Jiao Tong Univ, Sch Med, Dept Prosthodont, Coll Stomatol,Shanghai Peoples Hosp 9, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Jiao, Delong; Cao, Lingyan; Wu, Jiannan; Zheng, Ao; Jiang, Xinquan] Natl Clin Res Ctr Oral Dis, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Jiao, Delong; Cao, Lingyan; Wu, Jiannan; Zheng, Ao; Jiang, Xinquan] Shanghai Key Lab Stomatol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Jiao, Delong; Cao, Lingyan; Wu, Jiannan; Zheng, Ao; Jiang, Xinquan] Shanghai Res Inst Stomatol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Liu, Yang] East China Univ Sci & Technol, State Key Lab Bioreactor Engn, 130 Meilong Rd, Shanghai 200237, Peoples R China.
   [Jiao, Delong; Cao, Lingyan; Wu, Jiannan; Zheng, Ao; Jiang, Xinquan] Shanghai Engn Res Ctr Adv Dent Technol & Mat, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University; East China University of Science &
   Technology
RP Jiang, XQ (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Dept Prosthodont, Coll Stomatol,Shanghai Peoples Hosp 9, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.; Jiang, XQ (通讯作者)，Natl Clin Res Ctr Oral Dis, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.; Jiang, XQ (通讯作者)，Shanghai Key Lab Stomatol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.; Jiang, XQ (通讯作者)，Shanghai Res Inst Stomatol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.; Jiang, XQ (通讯作者)，Shanghai Engn Res Ctr Adv Dent Technol & Mat, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM xinquanj@aliyun.com
RI ; jiao, delong/AAC 7618 2020; cao, lingyan/GXH 7921 2022; Zheng,
   Ao/ABG 6623 2020
OI jiao, delong/0000 0001 5911 3841; 
FU National Natural Science Foundation of China [81620108006, 31500787,
   81430012, 51703127, 81801006, 31600777]; National Key Research and
   Development Program of China [2016YFC1102900]; Young Elite Scientist
   Sponsorship Program, CAST [2017QNRC001]; Shanghai Sailing Program
   [16YF1406600]; Interdisciplinary Program of Shanghai Jiao Tong
   University [YG2015ZD06]
FX This study was supported by the National Natural Science Foundation of
   China (81620108006, 31500787, 81430012, 51703127, 81801006, 31600777),
   the National Key Research and Development Program of China
   (2016YFC1102900), the Young Elite Scientist Sponsorship Program by CAST
   (2017QNRC001), the Shanghai Sailing Program (16YF1406600), and the
   Interdisciplinary Program of Shanghai Jiao Tong University (YG2015ZD06).
CR Akbulut M, 2008, LANGMUIR, V24, P9636, DOI 10.1021/la800487b
   Alzhavan O, 2013, CARBON, V59, P200, DOI 10.1016/j.carbon.2013.03.010
   Bandmann V, 2012, FEBS LETT, V586, P3626, DOI 10.1016/j.febslet.2012.08.008
   Barati D, 2016, J CONTROL RELEASE, V223, P126, DOI 10.1016/j.jconrel.2015.12.031
   Basko DM, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.165413
   Bhowmick T, 2012, J CONTROL RELEASE, V157, P485, DOI 10.1016/j.jconrel.2011.09.067
   Bianco A, 2005, CURR OPIN CHEM BIOL, V9, P674, DOI 10.1016/j.cbpa.2005.10.005
   Boruah PK, 2017, CHEMOSPHERE, V168, P1058, DOI 10.1016/j.chemosphere.2016.10.103
   Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628
   Cha PH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085546
   Chen GY, 2015, BIOMATERIALS, V40, P12, DOI 10.1016/j.biomaterials.2014.11.034
   Crowder SW, 2013, NANOSCALE, V5, P4171, DOI 10.1039/c3nr00803g
   Dai CL, 2011, BIOMATERIALS, V32, P8506, DOI 10.1016/j.biomaterials.2011.07.090
   Ding ZH, 2014, CHEM ENG J, V257, P248, DOI 10.1016/j.cej.2014.07.034
   El Say KM, 2017, INT J PHARMACEUT, V528, P675, DOI 10.1016/j.ijpharm.2017.06.052
   Fang YP, 2003, ADV FUNCT MATER, V13, P955, DOI 10.1002/adfm.200304470
   Ferrari AC, 2000, PHYS REV B, V61, P14095, DOI 10.1103/PhysRevB.61.14095
   Ferrari AC, 2007, SOLID STATE COMMUN, V143, P47, DOI 10.1016/j.ssc.2007.03.052
   Ferrari AC, 2013, NAT NANOTECHNOL, V8, P235, DOI 10.1038/nnano.2013.46
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Hilder TA, 2009, SMALL, V5, P300, DOI 10.1002/smll.200800321
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Igarashi M, 2004, J MOL HISTOL, V35, P3, DOI 10.1023/B:HIJO.0000020883.33256.fe
   Jauris IM, 2016, PHYS CHEM CHEM PHYS, V18, P1526, DOI 10.1039/c5cp05940b
   Jiang XQ, 2009, BIOMATERIALS, V30, P4522, DOI 10.1016/j.biomaterials.2009.05.021
   Johnson ML, 2007, CURR OPIN RHEUMATOL, V19, P376, DOI 10.1097/BOR.0b013e32816e06f9
   Karousis N, 2016, CHEM REV, V116, P4850, DOI 10.1021/acs.chemrev.5b00611
   Kim MG, 2015, BIOMATERIALS, V48, P129, DOI 10.1016/j.biomaterials.2015.01.009
   King AAK, 2016, SCI REP UK, V6, DOI 10.1038/srep19491
   Kloen P, 1997, CANCER, V80, P2230
   Kudin KN, 2008, NANO LETT, V8, P36, DOI 10.1021/nl071822y
   Lamichhane N, 2018, MOLECULES, V23, DOI 10.3390/molecules23020288
   Latil S, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.201402
   Li N, 2006, J PHYS CHEM B, V110, P11561, DOI 10.1021/jp060653n
   Linares J, 2014, ACS APPL MATER INTER, V6, P13697, DOI 10.1021/am5031598
   Liu HY, 2016, NANOSCALE RES LETT, V11, DOI 10.1186/s11671 016 1423 8
   Liu KP, 2011, J MATER CHEM, V21, P12034, DOI 10.1039/c1jm10749f
   Liu Z, 2007, ACS NANO, V1, P50, DOI 10.1021/nn700040t
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Lv Y, 2016, MAT SCI ENG C MATER, V59, P652, DOI 10.1016/j.msec.2015.10.065
   Ma JY, 2015, SCI REP UK, V5, DOI 10.1038/srep10820
   Makharza S, 2013, J NANOPART RES, V15, DOI 10.1007/s11051 013 2099 y
   Massagué J, 2000, CELL, V103, P295, DOI 10.1016/S0092 8674(00)00121 5
   Mu QX, 2012, ACS APPL MATER INTER, V4, P2259, DOI 10.1021/am300253c
   Nayak TR, 2011, ACS NANO, V5, P4670, DOI 10.1021/nn200500h
   Norimatsu W, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.161410
   Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896
   Pei SJ, 2001, PHARM BIOL, V39, P74, DOI [10.1076/phbi.39.s1.74.0005, 10.1076/phbi.39.7.74.5869]
   Rahman MA, 2010, J APPL POLYM SCI, V117, P2075, DOI 10.1002/app.32034
   Reina A, 2009, NANO LETT, V9, P30, DOI 10.1021/nl801827v
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Sawadogo WR, 2012, BIOCHEM PHARMACOL, V84, P1225, DOI 10.1016/j.bcp.2012.07.021
   Schulz WL, 2012, J VIROL, V86, P12665, DOI 10.1128/JVI.01861 12
   Selvakumar D, 2016, J MATER SCI MATER EL, V27, P6232, DOI 10.1007/s10854 016 4554 x
   Shan CS, 2009, LANGMUIR, V25, P12030, DOI 10.1021/la903265p
   Shareena TPD, 2018, NANO MICRO LETT, V10, DOI 10.1007/s40820 018 0206 4
   Stankovich S, 2006, J MATER CHEM, V16, P155, DOI 10.1039/b512799h
   Stankovich S, 2007, CARBON, V45, P1558, DOI 10.1016/j.carbon.2007.02.034
   Sun XM, 2008, NANO RES, V1, P203, DOI 10.1007/s12274 008 8021 8
   Takahashi T, 2004, JPN J APPL PHYS 1, V43, P3636, DOI 10.1143/JJAP.43.3636
   Urbonaite S, 2008, CARBON, V46, P1942, DOI 10.1016/j.carbon.2008.08.004
   Vasudeva N, 2012, CHIN J INTEGR MED, V18, P473, DOI 10.1007/s11655 012 1120 0
   Wang YM, 2015, INT J NANOMED, V10, P4605, DOI 10.2147/IJN.S82354
   Wu YQ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05392 z
   Yasuda H, 2012, J ORTHOP SCI, V17, P299, DOI 10.1007/s00776 012 0196 x
   Zhang JJ, 2009, ANAL CHEM, V81, P6641, DOI 10.1021/ac900628y
   Zhang JH, 2012, COMPLEMENT THER MED, V20, P100, DOI 10.1016/j.ctim.2011.09.004
   Zhang LM, 2010, SMALL, V6, P537, DOI 10.1002/smll.200901680
   Zheng W, 2007, ELECTROCHEM COMMUN, V9, P1619, DOI 10.1016/j.elecom.2007.03.007
NR 69
TC 12
Z9 12
U1 3
U2 67
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD APR
PY 2019
VL 5
IS 4
BP 1920
EP 1936
DI 10.1021/acsbiomaterials.8b01264
PG 33
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA HT0FQ
UT WOS:000464241400025
PM 33405565
DA 2025 08 17
ER

PT J
AU Jang, WG
   Kim, EJ
   Bae, IH
   Lee, KN
   Kim, YD
   Kim, DK
   Kim, SH
   Lee, CH
   Franceschi, RT
   Choi, HS
   Koh, JT
AF Jang, Won Gu
   Kim, Eun Jung
   Bae, In Ho
   Lee, Kkot Nim
   Kim, Yong Deuk
   Kim, Don Kyu
   Kim, Sun Hun
   Lee, Chul Ho
   Franceschi, Renny T.
   Choi, Hueng Sik
   Koh, Jeong Tae
TI Metformin induces osteoblast differentiation via orphan nuclear receptor
   SHP mediated transactivation of Runx2
SO BONE
LA English
DT Article
DE Metformin; AMPK; Compound C; SHP; Osteoblast differentiation
ID ACTIVATED PROTEIN KINASE; SMALL HETERODIMER PARTNER; BONE MORPHOGENETIC
   PROTEIN 2; TRANSCRIPTION FACTORS; GENE EXPRESSION; ENDOCRINE REGULATION;
   OSTEOCALCIN GENE; DNA BINDING; CELLS; UPSTREAM
AB Metformin is an oral anti diabetic drug of the biguanide class that is commonly used to treat type 2 diabetes mellitus. This study examined the molecular mechanism for the action of metformin on osteoblast differentiation. Metformin induced mRNA expression of the osteogenic genes and small heterodimer partner (SHP) in MC3T3E1 cells were determined by RT PCR and real time PCR. Metformin increased significantly the expression of the key osteogenic genes, such as alkaline phosphatase (ALP), osteocalcin (OC) and bone sialoprotein (BSP) as well as SHP. Transient transfection assays were performed in MC3T3E1 cells to confirm the effects of metformin on SHP, OC and Runx2 promoter activities. Metformin increased the transcription of the SHP and OC genes, and the metformin effect was inhibited by dominant negative form of AMPK (DN AMPK) or compound C (an inhibitor of AMPK). The adenoviral overexpression of SHP increased significantly the level of ALP staining and OC production. However, metformin did not have any significant effect on osteogenic gene expression, ALP staining and activity, and OC production in SHP null (SHP / ) primary calvarial cells. Moreover, upstream stimulatory factor 1 (USF 1) specifically mediated metformin induced SHP gene expression. In addition, metformin induced AMPK activation increased the level of Runx2 mRNA and protein. However, USF 1 and SHP were not involved in metformin induced Runx2 expression. Transient transfection and chromatin immunoprecipitation assays confirmed that metformin induced SHP interacts physically and forms a complex with Runx2 on the osteocalcin gene promoter in MC3T3E1 cells. These results suggest that metformin may stimulate osteoblast differentiation through the transactivation of Runx2 via AMPK/USF 1/SHP regulatory cascade in mouse calvaria derived cells. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Koh, Jeong Tae] Chonnam Natl Univ, Sch Dent, Dept Pharmacol & Dent Therapeut, Dent Sci Res Inst, Kwangju 500757, South Korea.
   [Jang, Won Gu; Kim, Eun Jung; Bae, In Ho; Lee, Kkot Nim; Kim, Sun Hun; Koh, Jeong Tae] Chonnam Natl Univ, Sch Dent, BK21, Kwangju 500757, South Korea.
   [Kim, Yong Deuk; Kim, Don Kyu; Choi, Hueng Sik] Chonnam Natl Univ, Sch Biol Sci & Technol, Hormone Res Ctr, Kwangju 500757, South Korea.
   [Lee, Chul Ho] Korea Res Inst Biosci & Biotechnol, Taejon 305806, South Korea.
   [Franceschi, Renny T.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   [Choi, Hueng Sik] Chonnam Natl Univ, Sch Med, Dept Biomed Sci, Res Inst Med Sci, Kwangju 501746, South Korea.
C3 Chonnam National University; Chonnam National University; Chonnam
   National University; Korea Research Institute of Bioscience &
   Biotechnology (KRIBB); University of Michigan System; University of
   Michigan; Chonnam National University
RP Koh, JT (通讯作者)，Chonnam Natl Univ, Sch Dent, Dept Pharmacol & Dent Therapeut, Dent Sci Res Inst, Kwangju 500757, South Korea.
EM jangwg@chonnam.ac.kr; eunjungk@paran.com; inovation15@hotmail.com;
   diqndiqn@naver.com; ydkim94@cchonnam.ac.kr; signal323@yahoo.co.kr;
   ksh@chonnam.ac.kr; chullee@kribb.re.kr; rennyf@umich.edu;
   hsc@chonnam.ac.kr; jtkoh@chonnam.ac.kr
RI Lee, Chul Ho/MBV 8603 2025
FU Korean Government (MOEHRD) [KRF 2007 313 E00469]; Ministry for Health,
   Welfare & Family Affairs, Republic of Korea [A100588]
FX This study was supported by a Korea Research Foundation Grant funded by
   the Korean Government (MOEHRD) to J.T.K. (KRF 2007 313 E00469), and
   H.S.C. was supported by grant from the Korea Healthcare technology R&D
   Project, Ministry for Health, Welfare & Family Affairs, Republic of
   Korea (A100588).
CR Bailey CJ, 1996, NEW ENGL J MED, V334, P574, DOI 10.1056/NEJM199602293340906
   Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097 4644(19970701)66:1<1::AID JCB1>3.0.CO;2 V
   BOUILLON R, 1991, CALCIFIED TISSUE INT, V49, P155, DOI 10.1007/BF02556109
   Bright NJ, 2009, ACTA PHYSIOL, V196, P15, DOI 10.1111/j.1748 1716.2009.01971.x
   Chanda D, 2008, AM J PHYSIOL ENDOC M, V295, pE368, DOI 10.1152/ajpendo.00800.2007
   Chanda D, 2008, ENDOCR J, V55, P253, DOI 10.1507/endocrj.K07E 103
   Chanda D, 2009, J BIOL CHEM, V284, P28510, DOI 10.1074/jbc.M109.022244
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   D'Souza DR, 2009, J BIOL CHEM, V284, P17947, DOI 10.1074/jbc.M109.002378
   Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005
   DUCY P, 1995, MOL CELL BIOL, V15, P1858
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fowlkes JL, 2008, ENDOCRINOLOGY, V149, P1697, DOI 10.1210/en.2007 1408
   Franceschi RT, 2007, ANN NY ACAD SCI, V1116, P196, DOI 10.1196/annals.1402.081
   Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972
   Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540
   Ichida F, 2004, J BIOL CHEM, V279, P34015, DOI 10.1074/jbc.M403621200
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   JEONG BC, 2009, J BONE MINER RES
   Jüttner KV, 2007, BONE, V41, P25, DOI 10.1016/j.bone.2007.03.012
   Kanazawa I, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471 2121 8 51
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Kasai T, 2009, J CELL PHYSIOL, V221, P740, DOI 10.1002/jcp.21917
   Kim BG, 2006, PROTEOMICS, V6, P1166, DOI 10.1002/pmic.200500289
   Kim JH, 2008, J MOL BIOL, V383, P502, DOI 10.1016/j.jmb.2008.08.036
   Kim JY, 2004, MOL ENDOCRINOL, V18, P2880, DOI 10.1210/me.2004 0211
   Kim YD, 2008, DIABETES, V57, P306, DOI 10.2337/db07 0381
   Kirpichnikov D, 2002, ANN INTERN MED, V137, P25, DOI 10.7326/0003 4819 137 1 200207020 00009
   Komori T, 2005, J CELL BIOCHEM, V95, P445, DOI 10.1002/jcb.20420
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lee M, 2003, J BIOL CHEM, V278, P39653, DOI 10.1074/jbc.M306104200
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Lee YS, 2008, BIOCHEM J, V413, P559, DOI 10.1042/BJ20071637
   Lee YS, 2007, INT REV CYTOL, V261, P117, DOI 10.1016/S0074 7696(07)61003 1
   Lu HF, 2003, ENDOCRINOLOGY, V144, P346, DOI 10.1210/en.2002 220072
   MANOLAGAS SC, 1981, J BIOL CHEM, V256, P7115
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530
   Molinuevo M.S., 2009, J Bone Miner Res
   Mundlos S, 1999, J MED GENET, V36, P177
   Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074
   Oakhill JS, 2009, ACTA PHYSIOL, V196, P3, DOI 10.1111/j.1748 1716.2009.01977.x
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Park YJ, 2008, HEPATOLOGY, V47, P1578, DOI 10.1002/hep.22196
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336
   Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781
   Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339 3351.2003
   Strotmeyer Elsa S, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P429, DOI 10.1097/MED.0b013e3282f1cba3
   Tsuji K, 2004, J BONE MINER RES, V19, P1481, DOI 10.1359/JBMR.040601
   van Deursen D, 2008, DIABETOLOGIA, V51, P2078, DOI 10.1007/s00125 008 1125 6
   Westendorf JJ, 2006, J CELL BIOCHEM, V98, P54, DOI 10.1002/jcb.20805
   Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Yanai K, 1997, J BIOL CHEM, V272, P30558, DOI 10.1074/jbc.272.48.30558
   Zang MW, 2004, J BIOL CHEM, V279, P47898, DOI 10.1074/jbc.M408149200
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
NR 58
TC 161
Z9 181
U1 0
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD APR 1
PY 2011
VL 48
IS 4
BP 885
EP 893
DI 10.1016/j.bone.2010.12.003
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 742DQ
UT WOS:000288920900026
PM 21147283
DA 2025 08 17
ER

PT J
AU Turro, E
   Greene, D
   Wijgaerts, A
   Thys, C
   Lentaigne, C
   Bariana, TK
   Westbury, SK
   Kelly, AM
   Selleslag, D
   Stephens, JC
   Papadia, S
   Simeoni, I
   Penkett, CJ
   Ashford, S
   Attwood, A
   Austin, S
   Bakchoul, T
   Collins, P
   Deevi, SVV
   Favier, R
   Kostadima, M
   Lambert, MP
   Mathias, M
   Millar, CM
   Peerlinck, K
   Perry, DJ
   Schulman, S
   Whitehorn, D
   Wittevrongel, C
   De Maeyer, M
   Rendon, A
   Gomez, K
   Erber, WN
   Mumford, AD
   Nurden, P
   Stirrups, K
   Bradley, JR
   Raymond, FL
   Laffan, MA
   Van Geet, C
   Richardson, S
   Freson, K
   Ouwehand, WH
AF Turro, Ernest
   Greene, Daniel
   Wijgaerts, Anouck
   Thys, Chantal
   Lentaigne, Claire
   Bariana, Tadbir K.
   Westbury, Sarah K.
   Kelly, Anne M.
   Selleslag, Dominik
   Stephens, Jonathan C.
   Papadia, Sofia
   Simeoni, Ilenia
   Penkett, Christopher J.
   Ashford, Sofie
   Attwood, Antony
   Austin, Steve
   Bakchoul, Tamam
   Collins, Peter
   Deevi, Sri V. V.
   Favier, RMi
   Kostadima, Myrto
   Lambert, Michele P.
   Mathias, Mary
   Millar, Carolyn M.
   Peerlinck, Kathelijne
   Perry, David J.
   Schulman, Sol
   Whitehorn, Deborah
   Wittevrongel, Christine
   De Maeyer, Marc
   Rendon, Augusto
   Gomez, Keith
   Erber, Wendy N.
   Mumford, Andrew D.
   Nurden, Paquita
   Stirrups, Kathleen
   Bradley, John R.
   Raymond, F. Lucy
   Laffan, Michael A.
   Van Geet, Chris
   Richardson, Sylvia
   Freson, Kathleen
   Ouwehand, Willem H.
CA BRIDGE BPD Consortium
TI A dominant gain of function mutation in universal tyrosine kinase
   SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone
   pathologies
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID HUMAN PHENOTYPE ONTOLOGY; PLATELET; PODOSOMES; MATRIX; MEGAKARYOCYTES;
   CONFORMATION; OSTEOCLASTS; IMATINIB; UNRAVEL; COMPLEX
AB The Src family kinase (SFK) member SRC is a major target in drug development because it is activated in many human cancers, yet deleterious SRC germline mutations have not been reported. We used genome sequencing and Human Phenotype Ontology patient coding to identify a gain of function mutation in SRC causing thrombocytopenia, myelofibrosis, bleeding, and bone pathologies in nine cases. Modeling of the E527K substitution predicts loss of SRC's self inhibitory capacity, which we confirmed with in vitro studies showing increased SRC kinase activity and enhanced Tyr(419) phosphorylation in COS 7 cells overexpressing E527K SRC. The active form of SRC predominates in patients' platelets, resulting in enhanced overall tyrosine phosphorylation. Patients with myelofibrosis have hypercellular bone marrow with trilineage dysplasia, and their stem cells grown in vitro form more myeloid and megakaryocyte (MK) colonies than control cells. These MKs generate platelets that are dysmorphic, low in number, highly variable in size, and have a paucity of alpha granules. Overactive SRC in patient derived MKs causes a reduction in proplatelet formation, which can be rescued by SRC kinase inhibition. Stem cells transduced with lentiviral E527K SRC form MKs with a similar defect and enhanced tyrosine phosphorylation levels. Patient derived and E527K transduced MKs show Y419 SRC positive stained podosomes that induce altered actin organization. Expression of mutated src in zebrafish recapitulates patients' blood and bone phenotypes. Similar studies of platelets and MKs may reveal the mechanism underlying the severe bleeding frequently observed in cancer patients treated with next generation SFK inhibitors.
C1 [Turro, Ernest; Greene, Daniel; Kelly, Anne M.; Stephens, Jonathan C.; Papadia, Sofia; Simeoni, Ilenia; Penkett, Christopher J.; Ashford, Sofie; Attwood, Antony; Deevi, Sri V. V.; Kostadima, Myrto; Whitehorn, Deborah; Rendon, Augusto; Stirrups, Kathleen; Ouwehand, Willem H.] Univ Cambridge, Dept Haematol, Cambridge Biomed Campus, Cambridge CB2 0PT, England.
   [Turro, Ernest; Kelly, Anne M.; Stephens, Jonathan C.; Attwood, Antony; Kostadima, Myrto; Whitehorn, Deborah; Ouwehand, Willem H.] Natl Hlth Serv NHS Blood & Transplant, Cambridge Biomed Campus, Cambridge CB2 0PT, England.
   [Turro, Ernest; Greene, Daniel; Richardson, Sylvia] Cambridge Inst Publ Hlth, MRC, Biostat Unit, Cambridge Biomed Campus, Cambridge CB2 0SR, England.
   [Turro, Ernest; Greene, Daniel; Stephens, Jonathan C.; Papadia, Sofia; Simeoni, Ilenia; Penkett, Christopher J.; Ashford, Sofie; Attwood, Antony; Deevi, Sri V. V.; Stirrups, Kathleen; Bradley, John R.; Raymond, F. Lucy; Ouwehand, Willem H.] Cambridge Univ Hosp, Natl Inst Hlth Res NIHR BioResource Rare Dis, Cambridge Biomed Campus, Cambridge CB2 0PT, England.
   [Wijgaerts, Anouck; Thys, Chantal; Peerlinck, Kathelijne; Wittevrongel, Christine; Van Geet, Chris; Freson, Kathleen] Univ Leuven, Ctr Mol & Vasc Biol, Dept Cardiovasc Sci, B 3000 Leuven, Belgium.
   [Lentaigne, Claire; Millar, Carolyn M.; Laffan, Michael A.] Univ London Imperial Coll Sci Technol & Med, Imperial Coll Acad Hlth Sci Ctr, Ctr Haematol, Hammersmith Campus, London W12 0HS, England.
   [Lentaigne, Claire; Millar, Carolyn M.; Laffan, Michael A.] Imperial Coll Healthcare NHS Trust, Du Cane Rd, London W12 0HS, England.
   [Bariana, Tadbir K.; Gomez, Keith] UCL, Inst Canc, Dept Haematol, London WC1E 6BT, England.
   [Bariana, Tadbir K.; Gomez, Keith] Royal Free London NHS Fdn Trust, Katharine Dormandy Haemophilia Ctr, London NW3 2QG, England.
   [Bariana, Tadbir K.; Gomez, Keith] Royal Free London NHS Fdn Trust, Thrombosis Unit, London NW3 2QG, England.
   [Westbury, Sarah K.; Mumford, Andrew D.] Univ Bristol, Sch Clin Sci, Bristol BS2 8DZ, Avon, England.
   [Selleslag, Dominik] Acad Ziekenhuis Sint Jan Brugge Oostende, B 8000 Brugge, Belgium.
   [Austin, Steve] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London SE1 7EH, England.
   [Bakchoul, Tamam] Univ Med Greifswald, Inst Immunol & Transfus Med, D 17475 Greifswald, Germany.
   [Collins, Peter] Cardiff Univ, Sch Med, Inst Infect & Immun, Arthur Bloom Haemophilia Ctr, Cardiff CF14 4XN, Wales.
   [Favier, RMi] Armand Trousseau Children Hosp, AP HP, F 75012 Paris, France.
   [Favier, RMi] INSERM, U1170, F 94805 Villejuif, France.
   [Lambert, Michele P.] Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA.
   [Lambert, Michele P.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
   [Mathias, Mary] Great Ormond St Hosp Children NHS Fdn Trust, Dept Haematol, London WC1N 3JH, England.
   [Perry, David J.] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Dept Haematol, Cambridge Biomed Campus, Cambridge CB2 0QQ, England.
   [Schulman, Sol] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
   [De Maeyer, Marc] Univ Leuven, Biochem Mol & Struct Biol Sect, B 3001 Leuven, Belgium.
   [Rendon, Augusto] Genom England Ltd, London EC1M 6BQ, England.
   [Erber, Wendy N.] Univ Western Australia, Pathol & Lab Med, Crawley, WA 6009, Australia.
   [Mumford, Andrew D.] Univ Bristol, Sch Cellular & Mol Med, Bristol BS8 1TD, Avon, England.
   [Nurden, Paquita] Hop Xavier Arnozan, Inst Hosp Univ LIRYC, PTIB, F 33600 Pessac, France.
   [Bradley, John R.] Cambridge Univ Hosp NHS Fdn Trust, Res & Dev, Cambridge CB2 0QQ, England.
   [Raymond, F. Lucy] Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Cambridge CB2 0XY, England.
   [Ouwehand, Willem H.] Wellcome Trust Sanger Inst, Human Genet, Wellcome Trust Genome Campus, Cambridge CB10 15A, England.
C3 University of Cambridge; University of Cambridge; MRC Biostatistics
   Unit; University of Cambridge; KU Leuven; Imperial College London;
   Imperial College London; University of London; University College
   London; University of London; University College London; Royal Free
   London NHS Foundation Trust; University of London; University College
   London; Royal Free London NHS Foundation Trust; University of Bristol;
   Guy's & St Thomas' NHS Foundation Trust; Universitat Greifswald;
   Greifswald Medical School; Cardiff University; Assistance Publique
   Hopitaux Paris (APHP); Sorbonne Universite; Hopital Universitaire
   Armand Trousseau   APHP; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite Paris Saclay; University of
   Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia;
   University of Pennsylvania; University of London; University College
   London; Great Ormond Street Hospital for Children NHS Foundation Trust;
   Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's
   Hospital; University of Cambridge; Harvard University; Harvard
   University Medical Affiliates; Beth Israel Deaconess Medical Center;
   Harvard Medical School; KU Leuven; University of Western Australia;
   University of Bristol; Universite de Bordeaux; CHU Bordeaux; University
   of Cambridge; University of Cambridge; Wellcome Trust Sanger Institute
RP Freson, K (通讯作者)，Univ Leuven, Ctr Mol & Vasc Biol, Dept Cardiovasc Sci, B 3000 Leuven, Belgium.
EM kathleen.freson@med.kuleuven.be
RI ; Richardson, Sylvia/G 4691 2015; Erber, Wendy/A 1955 2012; Raymond,
   F/F 4018 2010; Lambert, Michele/AAB 9225 2021; Mathias,
   Mary/JXW 6315 2024
OI Westbury, Sarah/0000 0002 0950 8148; Ouwehand,
   Willem/0000 0002 7744 1790; Heemskerk, Johan/0000 0002 2848 5121;
   mumford, andrew/0000 0002 5523 511X; Gomez, Keith/0000 0002 8934 0700;
   freson, kathleen/0000 0002 4381 2442; Van Geet,
   Chris/0000 0003 1342 6265; Rendon, Augusto/0000 0001 8994 0039;
   schulman, sol/0000 0002 5229 3592; Richardson,
   Sylvia/0000 0003 1998 492X; Laffan, Michael/0000 0002 8268 3268; Turro,
   Ernest/0000 0002 1820 6563; Stephens, Jonathan/0000 0003 2020 9330;
   Deevi, Sri Vishnu Vardhan/0000 0002 0405 4335; Erber,
   Wendy/0000 0002 1028 9376; Bradley, John/0000 0002 7774 8805; Kostadima,
   Myrto Areti/0000 0002 1818 4050
FU Fund for Scientific Research Flanders (FWO Vlaanderen, Belgium)
   [G.0B17.13N]; Research Council of the University of Leuven (BOF KU
   Leuven, Belgium) [OT/14/098]; National Institute for Health Research of
   England (NIHR) [RG65966]; NIHR; British Heart Foundation; NHS Blood and
   Transplant; Medical Research Council (MRC) Clinical Training Fellowships
   [MR/K023489/1]; British Society for Haematology/NHS Blood and Transplant
   grant; Imperial College London Biomedical Research Centre; NIHR Bristol
   Cardiovascular Biomedical Research Unit; NIHR Cambridge Biomedical
   Research Centre; MRC; Cambridge Biomedical Research Centre; NIHR
   BioResource Rare Diseases;  [RG59534];  [RG/09/12/28096]; MRC
   [MR/J011711/1, MC_UP_0801/1, MR/K023489/1, MC_UU_00002/10] Funding
   Source: UKRI; British Heart Foundation [RG/09/012/28096] Funding Source:
   researchfish; Medical Research Council [MC_UU_00002/10, MC_UP_0801/1,
   MR/J011711/1, MR/K023489/1] Funding Source: researchfish; National
   Institute for Health Research [NF SI 0510 10214, NF SI 0512 10014,
   NF SI 0513 10151, RP PG 0310 1002] Funding Source: researchfish
FX K.F., C.T., K.P., A.W., C.W., and C.V.G. are supported by the Fund for
   Scientific Research Flanders (FWO Vlaanderen, Belgium; G.0B17.13N) and
   by the Research Council of the University of Leuven (BOF KU Leuven,
   Belgium; OT/14/098). E.T., D.G., J.C.S., S.P., I.S., C.J.P., S.A., A.A.,
   and K.S. are supported by the NIHR BioResource Rare Diseases, which is
   funded by the National Institute for Health Research of England (NIHR,
   www.nihr.ac.uk; award number RG65966). Research in the Ouwehand
   laboratory is supported by program grants from the NIHR and the British
   Heart Foundation to J.C.S. and W.H.O., under grants RG59534 and
   RG/09/12/28096; the laboratory also received funding from NHS Blood and
   Transplant for A.M.K.; C.L. and S.K.W. are supported by the Medical
   Research Council (MRC) Clinical Training Fellowships (grant
   MR/K023489/1) and T.K.B. by a British Society for Haematology/NHS Blood
   and Transplant grant. M.A.L. and C.L. are supported by the Imperial
   College London Biomedical Research Centre; A.D.M. is supported by the
   NIHR Bristol Cardiovascular Biomedical Research Unit; J.R.B.
   acknowledges support by the NIHR Cambridge Biomedical Research Centre;
   and S.R. is supported by the MRC and Cambridge Biomedical Research
   Centre. C.V.G. is holder of the Bayer and Norbert Heimburger (CSL
   Behring) Chairs.
CR Albers CA, 2011, NAT GENET, V43, P735, DOI 10.1038/ng.885
   Ayrapetov MK, 2006, J BIOL CHEM, V281, P23776, DOI 10.1074/jbc.M604219200
   Ballmaier M, 2001, BLOOD, V97, P139, DOI 10.1182/blood.V97.1.139
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Blake JA, 2014, NUCLEIC ACIDS RES, V42, pD810, DOI 10.1093/nar/gkt1225
   Boerner RJ, 1996, BIOCHEMISTRY US, V35, P9519, DOI 10.1021/bi960248u
   Bonnefoy A, 2006, BLOOD, V107, P955, DOI 10.1182/blood 2004 12 4856
   Breccia M, 2014, MEDITERR J HEMATOL I, V6, DOI 10.4084/MJHID.2014.003
   Chen L, 2014, SCIENCE, V345, P1580, DOI 10.1126/science.1251033
   CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206
   Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695
   Cooper GM, 2005, GENOME RES, V15, P901, DOI 10.1101/gr.3577405
   Cowan Jacob SW, 2005, STRUCTURE, V13, P861, DOI 10.1016/j.str.2005.03.012
   Davidson AJ, 2004, ONCOGENE, V23, P7233, DOI 10.1038/sj.onc.1207943
   Di Michele M, 2011, J PROTEOMICS, V74, P902, DOI 10.1016/j.jprot.2011.03.007
   Dovas Athanassios, 2010, Commun Integr Biol, V3, P101
   Durek P, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471 2105 10 117
   Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779
   Freson K, 2014, INT J LAB HEMATOL, V36, P313, DOI 10.1111/ijlh.12213
   Freson K, 2008, BLOOD, V111, P1885, DOI 10.1182/blood 2007 06 098558
   GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852
   Guerrero JA, 2014, BLOOD, V124, P3624, DOI 10.1182/blood 2014 04 566760
   Hermans C, 2009, J THROMB HAEMOST, V7, P1356, DOI 10.1111/j.1538 7836.2009.03520.x
   Hunter T, 2015, P NATL ACAD SCI USA, V112, P7877, DOI 10.1073/pnas.1508223112
   Ibrahimi A, 2009, HUM GENE THER, V20, P845, DOI 10.1089/hum.2008.188
   Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971
   Kantarjian HM, 2012, BLOOD, V119, P1123, DOI 10.1182/blood 2011 08 376087
   Kelley Laura C, 2011, Commun Integr Biol, V4, P205, DOI 10.4161/cib.4.2.14420
   Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892
   Köhler S, 2009, AM J HUM GENET, V85, P457, DOI 10.1016/j.ajhg.2009.09.003
   Kohler Sebastian, 2013, F1000Res, V2, P30, DOI 10.12688/f1000research.2 30.v1
   Lazner F, 1999, HUM MOL GENET, V8, P1839, DOI 10.1093/hmg/8.10.1839
   LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142
   Lin HF, 2005, BLOOD, V106, P3803, DOI 10.1182/blood 2005 01 0179
   Linder S, 2000, J IMMUNOL, V165, P221, DOI 10.4049/jimmunol.165.1.221
   Louwette S, 2012, J THROMB HAEMOST, V10, P2215, DOI 10.1111/j.1538 7836.2012.04903.x
   Louwette S, 2013, HUM MOL GENET, V22, P61, DOI 10.1093/hmg/dds401
   Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094
   Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141
   Olivier A, 2006, MOL THER, V13, P729, DOI 10.1016/j.ymthe.2005.11.003
   Patwardhan P, 2010, MOL CELL BIOL, V30, P4094, DOI 10.1128/MCB.00246 10
   Robinson PN, 2008, AM J HUM GENET, V83, P610, DOI 10.1016/j.ajhg.2008.09.017
   Robinson PN, 2014, GENOME RES, V24, P340, DOI 10.1101/gr.160325.113
   Rooryck C, 2011, NAT GENET, V43, P197, DOI 10.1038/ng.757
   Rous P, 1911, J EXP MED, V13, P397, DOI 10.1084/jem.13.4.397
   Rous P, 1910, J EXP MED, V12, P696, DOI 10.1084/jem.12.5.696
   Sabri S, 2006, BLOOD, V108, P134, DOI 10.1182/blood 2005 03 1219
   Saltel F, 2008, EUR J CELL BIOL, V87, P459, DOI 10.1016/j.ejcb.2008.01.001
   Schachtner H, 2013, CYTOSKELETON, V70, P572, DOI 10.1002/cm.21119
   Schachtner H, 2013, BLOOD, V121, P2542, DOI 10.1182/blood 2012 07 443457
   Seeliger MA, 2007, STRUCTURE, V15, P299, DOI 10.1016/j.str.2007.01.015
   Senis YA, 2014, BLOOD, V124, P2013, DOI 10.1182/blood 2014 01 453134
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Turro E, 2014, BIOINFORMATICS, V30, P180, DOI 10.1093/bioinformatics/btt624
   Turro E, 2011, GENOME BIOL, V12, DOI 10.1186/gb 2011 12 2 r13
   WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0
   Westbury SK, 2015, GENOME MED, V7, DOI 10.1186/s13073 015 0151 5
   Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366
   ZAMBONINZALLONE A, 1988, J BONE MINER RES, V3, P517
NR 59
TC 85
Z9 88
U1 0
U2 22
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAR 2
PY 2016
VL 8
IS 328
AR 328ra30
DI 10.1126/scitranslmed.aad7666
PG 15
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA DG4YL
UT WOS:000372079000004
PM 26936507
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Ishizawa, M
   Takano, M
   Kittaka, A
   Matsumoto, T
   Makishima, M
AF Ishizawa, Michiyasu
   Takano, Masashi
   Kittaka, Atsushi
   Matsumoto, Taro
   Makishima, Makoto
TI 2α Substituted Vitamin D Derivatives Effectively Enhance the Osteoblast
   Differentiation of Dedifferentiated Fat Cells
SO BIOMOLECULES
LA English
DT Article
DE vitamin D derivatives; vitamin D receptor; osteoblast differentiation;
   dedifferentiated fat cells
ID 1,25 DIHYDROXYVITAMIN D 3; BIOLOGICAL ACTIVITIES; STROMAL CELLS;
   ANALOGS; MOUSE; 1 ALPHA,25 DIHYDROXYVITAMIN D 3; PROLIFERATION;
   EXPRESSION; EFFICIENT; 1 ALPHA
AB The active form of vitamin D3, 1 alpha,25 dihydroxyvitamin D3 [1,25(OH)2D3], is a principal regulator of calcium homeostasis through activation of the vitamin D receptor (VDR). Previous studies have shown that 2 alpha (3 hydroxypropyl) 1,25D3 (O1C3) and 2 alpha (3 hydroxypropoxy) 1,25D3 (O2C3), vitamin D derivatives resistant to inactivation enzymes, can activate VDR, induce leukemic cell differentiation, and increase blood calcium levels in rats more effectively than 1,25(OH)2D3. In this study, to further investigate the usefulness of 2 alpha substituted vitamin D derivatives, we examined the effects of O2C3, O1C3, and their derivatives on VDR activity in cells and mouse tissues and on osteoblast differentiation of dedifferentiated fat (DFAT) cells, a cell type with potential therapeutic application in regenerative medicine. In cell culture experiments using kidney derived HEK293 cells, intestinal mucosa derived CaCO2 cells, and osteoblast derived MG63 cells, and in mouse experiments, O2C2, O2C3, O1C3, and O1C4 had a weaker effect than or equivalent effect to 1,25(OH)2D3 in VDR transactivation and induction of the VDR target gene CYP24A1, but they enhanced osteoblast differentiation in DFAT cells equally to or more effectively than 1,25(OH)2D3. In long term treatment with the compound without the medium change (7 days), the derivatives enhanced osteoblast differentiation more effectively than 1,25(OH)2D3. O2C3 and O1C3 were more stable than 1,25(OH)2D3 in DFAT cell culture. These results indicate that 2 alpha substituted vitamin D derivatives, such as inactivation resistant O2C3 and O1C3, are more effective than 1,25(OH)2D3 in osteoblast differentiation of DFAT cells, suggesting potential roles in regenerative medicine with DFAT cells and other multipotent cells.
C1 [Ishizawa, Michiyasu; Makishima, Makoto] Nihon Univ, Sch Med, Div Biochem, Dept Biomed Sci, Itabashi Ku, Tokyo 1738610, Japan.
   [Takano, Masashi; Kittaka, Atsushi] Teikyo Univ, Fac Pharmaceut Sci, 2 11 1 Kaga,Itabashi Ku, Tokyo 1738605, Japan.
   [Matsumoto, Taro] Nihon Univ, Sch Med, Dept Funct Morphol, Div Cell Regenerat & Transplantat, Tokyo 1738610, Japan.
C3 Nihon University; Teikyo University; Nihon University
RP Ishizawa, M; Makishima, M (通讯作者)，Nihon Univ, Sch Med, Div Biochem, Dept Biomed Sci, Itabashi Ku, Tokyo 1738610, Japan.
EM ishizawa.michiyasu@nihon u.ac.jp; mtakano@pharm.teikyo u.ac.jp;
   akittaka@pharm.teikyo u.ac.jp; matsumoto.taro@nihon u.ac.jp;
   makishima.makoto@nihon u.ac.jp
FU Research Committee on Fat Soluble Vitamins (2013); Nihon University
   School of Medicine Alumni Association 60th Anniversary Fund Research
   Grant (2015); MEXT [S1411018]; Nihon University
FX This research was partly supported by the Project Research Grant from
   the Research Committee on Fat Soluble Vitamins (2013), by the Nihon
   University School of Medicine Alumni Association 60th Anniversary Fund
   Research Grant (2015), by the MEXT supported Program for the Strategic
   Research Foundation at Private Universities (S1411018), by the Nihon
   University President Grant Initiative (2018 2020) and by the Research
   Grant from the Chairperson and the President of Nihon University
   (2021 2022).
CR Chen JX, 2020, EUR J MED CHEM, V207, DOI 10.1016/j.ejmech.2020.112738
   De Kok I J, 2006, J Oral Implantol, V32, P103, DOI 10.1563/760.1
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Egbuna O, 2009, AM J PHYSIOL RENAL, V297, pF720, DOI 10.1152/ajprenal.00164.2009
   Fuggle NR, 2020, AGING CLIN EXP RES, V32, P547, DOI 10.1007/s40520 020 01515 1
   Ha NNY, 2024, REGEN THER, V25, P147, DOI 10.1016/j.reth.2023.12.003
   Haussler MR, 2013, CALCIFIED TISSUE INT, V92, P77, DOI 10.1007/s00223 012 9619 0
   Hourai S, 2006, J MED CHEM, V49, P5199, DOI 10.1021/jm0604070
   Inaba Y, 2007, MOL PHARMACOL, V71, P1298, DOI 10.1124/mol.106.032318
   Ishizawa M, 2008, J LIPID RES, V49, P763, DOI 10.1194/jlr.M700293 JLR200
   Jing W, 2010, BIOCHEM BIOPH RES CO, V392, P442, DOI 10.1016/j.bbrc.2010.01.043
   Jumabay M, 2012, J MOL CELL CARDIOL, V53, P790, DOI 10.1016/j.yjmcc.2012.09.005
   Jumabay M, 2010, CARDIOVASC RES, V85, P17, DOI 10.1093/cvr/cvp267
   Kazama T, 2008, BIOCHEM BIOPH RES CO, V377, P780, DOI 10.1016/j.bbrc.2008.10.046
   Kishimoto N, 2018, ORAL DIS, V24, P1161, DOI 10.1111/odi.12832
   Kishimoto N, 2014, CLIN ORAL INVEST, V18, P1893, DOI 10.1007/s00784 013 1166 1
   Kittaka A, 2018, CHIMIA, V72, P859, DOI 10.2533/chimia.2018.859
   Maekawa K, 2023, BIOMOLECULES, V13, DOI 10.3390/biom13071082
   Maestro MA, 2019, J MED CHEM, V62, P6854, DOI 10.1021/acs.jmedchem.9b00208
   Matsumoto T, 2008, J CELL PHYSIOL, V215, P210, DOI 10.1002/jcp.21304
   Matsumoto T, 2020, J BONE MINER METAB, V38, P522, DOI 10.1007/s00774 020 01091 4
   Meyer MB, 2007, J BIOL CHEM, V282, P22344, DOI 10.1074/jbc.M703475200
   Nakahashi O, 2014, J CLIN BIOCHEM NUTR, V54, P102, DOI 10.3164/jcbn.13 109
   Nguyen Yamamoto L, 2010, J AM SOC NEPHROL, V21, P1713, DOI 10.1681/ASN.2009050531
   Okita N, 2015, TISSUE ENG PT A, V21, P1695, DOI [10.1089/ten.tea.2014.0282, 10.1089/ten.TEA.2014.0282]
   ORIMO H, 1994, CALCIFIED TISSUE INT, V54, P370, DOI 10.1007/BF00305521
   Pike JW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222212352
   Rosen CJ, 2012, ENDOCR REV, V33, P456, DOI 10.1210/er.2012 1000
   Saito N, 2004, J ORG CHEM, V69, P7463, DOI 10.1021/jo0491051
   Sakuma T, 2009, J UROLOGY, V182, P355, DOI 10.1016/j.juro.2009.02.103
   Suhara Y, 2001, J ORG CHEM, V66, P8760, DOI 10.1021/jo010375i
   Suhara Y, 2000, BIOORG MED CHEM LETT, V10, P1129, DOI 10.1016/S0960 894X(00)00189 X
   Takahashi E, 2006, BIOL PHARM BULL, V29, P2246, DOI 10.1248/bpb.29.2246
   Tanimoto K, 2022, REGEN THER, V19, P35, DOI 10.1016/j.reth.2021.12.006
   Watarai Y, 2015, J MED CHEM, V58, P9510, DOI 10.1021/acs.jmedchem.5b00792
   Xu Y, 2006, MOL PHARMACOL, V69, P56, DOI 10.1124/mol.105.017392
   Yagi K, 2004, BIOCHEM BIOPH RES CO, V321, P967, DOI 10.1016/j.bbrc.2004.07.055
   Yang DQ, 2018, J STEROID BIOCHEM, V177, P83, DOI 10.1016/j.jsbmb.2017.09.005
   Yasuda K, 2013, J STEROID BIOCHEM, V133, P84, DOI 10.1016/j.jsbmb.2012.09.006
   Zhou YS, 2006, CHINESE MED J PEKING, V119, P1278, DOI 10.1097/00029330 200608010 00008
NR 40
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2218 273X
J9 BIOMOLECULES
JI Biomolecules
PD JUN
PY 2024
VL 14
IS 6
AR 706
DI 10.3390/biom14060706
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA WK2W0
UT WOS:001254707800001
PM 38927109
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Nam, HY
   Raghavendran, HRB
   Pingguan Murphy, B
   Abbas, AA
   Merican, AM
   Kamarul, T
AF Nam, Hui Yin
   Raghavendran, Hanumantha Rao Balaji
   Pingguan Murphy, Belinda
   Abbas, Azlina A.
   Merican, Azhar M.
   Kamarul, Tunku
TI Fate of tenogenic differentiation potential of human bone marrow stromal
   cells by uniaxial stretching affected by stretch activated calcium
   channel agonist gadolinium
SO PLOS ONE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; ION CHANNELS; SIGNALING PATHWAYS;
   MECHANICAL STRESS; TENDON REPAIR; STRAIN; CHONDROCYTES; OSTEOBLASTS;
   APOPTOSIS; DEATH
AB The role for mechanical stimulation in the control of cell fate has been previously proposed, suggesting that there may be a role of mechanical conditioning in directing mesenchymal stromal cells (MSCs) towards specific lineage for tissue engineering applications. Although previous studies have reported that calcium signalling is involved in regulating many cellular processes in many cell types, its role in managing cellular responses to tensile loading (mechanotransduction) of MSCs has not been fully elucidated. In order to establish this, we disrupted calcium signalling by blocking stretch activated calcium channel (SACC) in human MSCs (hMSCs) in vitro. Passaged 2 hMSCs were exposed to cyclic tensile loading (1 Hz + 8% for 6, 24, 48, and 72 hours) in the presence of the SACC blocker, gadolinium. Analyses include image observations of immunochemistry and immunofluorescence staining from extracellular matrix (ECM) production, and measuring related tenogenic and apoptosis gene marker expression. Uniaxial tensile loading increased the expression of tenogenic markers and ECM production. However, exposure to strain in the presence of 20 mu M gadolinium reduced the induction of almost all tenogenic markers and ECM staining, suggesting that SACC acts as a mechanosensor in strain induced hMSC tenogenic differentiation process. Although cell death was observed in prolonged stretching, it did not appear to be apoptosis mediated. In conclusion, the knowledge gained in this study by elucidating the role of calcium in MSC mechanotransduction processes, and that in prolonged stretching results in non apoptosis mediated cell death may be potential useful for regenerative medicine applications.
C1 [Nam, Hui Yin; Raghavendran, Hanumantha Rao Balaji; Abbas, Azlina A.; Merican, Azhar M.; Kamarul, Tunku] Univ Malaya, Fac Med, Dept Orthopaed Surg NOCERAL, Tissue Engn Grp, Kuala Lumpur, Malaysia.
   [Pingguan Murphy, Belinda] Univ Malaya, Fac Engn, Dept Biomed Engn, Kuala Lumpur, Malaysia.
C3 Universiti Malaya; Universiti Malaya
RP Nam, HY; Kamarul, T (通讯作者)，Univ Malaya, Fac Med, Dept Orthopaed Surg NOCERAL, Tissue Engn Grp, Kuala Lumpur, Malaysia.
EM huiyin26@yahoo.com; tkzrea@um.edu.my
RI ABBAS, AZLINA/B 5405 2010; raghavendran, hanumantha/B 8507 2012;
   Kamarul, Tunku/B 9633 2011; Nam, Hui Yin/F 5013 2013; Merican,
   Azhar/S 2982 2019; Abbas, Azlina Amir/B 5405 2010; Pingguan Murphy,
   Belinda/B 8332 2010; Tunku Zainol Abidin, Tunku Kamarul
   Zaman/B 9633 2011
OI Kamarul, Tunku/0000 0002 6028 1313; Abbas, Azlina
   Amir/0000 0003 4423 4653; 
FU High Impact Research Ministry of Education, HIR MoE
   [UM.C/625/1/HIR/MOHE/CHAN/03, A000003 50001]; University of Malaya
FX This work was supported by High Impact Research Ministry of Education,
   HIR MoE Grant (Reference number   UM.C/625/1/HIR/MOHE/CHAN/03, account
   number   A000003 50001). We also thank the University of Malaya for a
   PhD thesis scholarship for the first author. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.This work was supported by High Impact
   Research Ministry of Education, HIR MoE Grant (Reference number
   UM.C/625/1/HIR/MOHE/CHAN/03, account number   A000003 50001). We also
   thank the University of Malaya for a PhD thesis scholarship for the
   first author.
CR [Anonymous], 2015, J REGEN MED TISSUE E
   Banes AJ, 1999, CLIN ORTHOP RELAT R, pS356
   Banes AJ., 2001, CURRENT OPINION ORTH, V12, P389
   Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035
   Blatt NB, 2001, BIOORGAN MED CHEM, V9, P1371, DOI 10.1016/S0968 0896(01)00041 4
   Bootman MD, 2001, SEMIN CELL DEV BIOL, V12, P3, DOI 10.1006/scdb.2000.0211
   Boudreault F, 2002, AM J PHYSIOL CELL PH, V282, pC219, DOI 10.1152/ajpcell.00317.2001
   Bullough R, 2008, DISABIL REHABIL, V30, P1746, DOI 10.1080/09638280701788258
   Cain K, 2003, DRUG METAB REV, V35, P337, DOI 10.1081/DMR 120026497
   Caldwell RA, 1998, AM J PHYSIOL CELL PH, V275, pC619, DOI 10.1152/ajpcell.1998.275.2.C619
   Chuen FS, 2004, J HISTOCHEM CYTOCHEM, V52, P1151, DOI 10.1369/jhc.3A6232.2004
   Cigognini D, 2013, DRUG DISCOV TODAY, V18, P1099, DOI 10.1016/j.drudis.2013.06.007
   Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028
   Coirault C, 1999, EUR RESPIR J, V14, P1297, DOI 10.1183/09031936.99.14612979
   Costa P, 2012, INT J BIOCHEM CELL B, V44, P2233, DOI 10.1016/j.biocel.2012.09.003
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092 8674(04)00046 7
   Docheva D, 2015, ADV DRUG DELIVER REV, V84, P222, DOI 10.1016/j.addr.2014.11.015
   Dook JE, 1997, MED SCI SPORT EXER, V29, P291, DOI 10.1097/00005768 199703000 00002
   Ge DX, 2009, BIOCHEM BIOPH RES CO, V381, P317, DOI 10.1016/j.bbrc.2009.01.173
   Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685
   Hamill OP, 1996, PHARMACOL REV, V48, P231
   Hung CT, 1996, J BIOMECH, V29, P1411, DOI 10.1016/0021 9290(96)84536 2
   Huo B, 2010, PHILOS T R SOC A, V368, P617, DOI 10.1098/rsta.2009.0221
   Jang JY, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/860652
   Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540
   Kawano S, 2002, CELL CALCIUM, V32, P165, DOI 10.1016/S0143416002001240
   Kearney EM, 2010, ANN BIOMED ENG, V38, P1767, DOI 10.1007/s10439 010 9979 4
   Kearney EM, 2008, J BIOMECH ENG T ASME, V130, DOI 10.1115/1.2979870
   Khatib L, 2004, FASEB J, V18, P1903, DOI 10.1096/fj.04 1814fje
   Killian ML, 2012, J SHOULDER ELB SURG, V21, P228, DOI 10.1016/j.jse.2011.11.002
   Kim TJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109378
   Lebart MC, 2006, FEBS J, V273, P3415, DOI 10.1111/j.1742 4658.2006.05350.x
   Liu YK, 2009, BIOMED MATER, V4, DOI 10.1088/1748 6041/4/2/025004
   Maeda T, 2011, CURR BIOL, V21, P933, DOI 10.1016/j.cub.2011.04.007
   Massoud EIE, 2013, WORLD J ORTHOP, V4, P229, DOI 10.5312/wjo.v4.i4.229
   Matthews BD, 2006, J CELL SCI, V119, P508, DOI 10.1242/jcs.02760
   Mayr M, 2002, FASEB J, V16, P1423, DOI 10.1096/fj.02 0042fje
   McKayed K.K., 2012, Stem Cells and Cancer Stem Cells, V3, P199
   McMahon LA, 2008, ANN BIOMED ENG, V36, P185, DOI 10.1007/s10439 007 9416 5
   Miyauchi A, 2000, J BIOL CHEM, V275, P3335, DOI 10.1074/jbc.275.5.3335
   Mobasheri A, 2002, CELL BIOL INT, V26, P1, DOI 10.1006/cbir.2001.0826
   Nam HY, 2015, BIOMECH MODEL MECHAN, V14, P649, DOI 10.1007/s10237 014 0628 y
   Nam HY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4309
   Nowycky MC, 2002, J CELL SCI, V115, P3715, DOI 10.1242/jcs.00078
   Park JS, 2004, BIOTECHNOL BIOENG, V88, P359, DOI 10.1002/bit.20250
   Park JY, 2002, BIOCHEM BIOPH RES CO, V290, P1176, DOI 10.1006/bbrc.2001.6323
   Pingguan Murphy B, 2005, ARCH BIOCHEM BIOPHYS, V444, P45, DOI 10.1016/j.abb.2005.09.015
   Riddle RC, 2006, AM J PHYSIOL CELL PH, V290, pC776, DOI 10.1152/ajpcell.00082.2005
   ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0
   RUKNUDIN A, 1993, AM J PHYSIOL, V264, pH960, DOI 10.1152/ajpheart.1993.264.3.H960
   Salameh A, 2013, BBA BIOMEMBRANES, V1828, P147, DOI 10.1016/j.bbamem.2011.12.030
   Scott A, 2007, ARTHRITIS RHEUM US, V56, P871, DOI 10.1002/art.22426
   SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337
   Sun XH, 2012, BONE, V51, P860, DOI 10.1016/j.bone.2012.08.116
   Sun XH, 2012, BONE, V50, P581, DOI 10.1016/j.bone.2011.12.015
   Tan JL, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.3
   Thompson WR, 2012, GENE, V503, P179, DOI 10.1016/j.gene.2012.04.076
   Tonelli FMP, 2012, ADV EXP MED BIOL, V740, P891, DOI 10.1007/978 94 007 2888 2_40
   Wall M. E., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P70
   Wang ECY, 2003, AM J PHYSIOL RENAL, V285, pF651, DOI 10.1152/ajprenal.00403.2002
   Wang JHC, 2006, J BIOMECH, V39, P1563, DOI 10.1016/j.jbiomech.2005.05.011
   Wang JHC, 2000, CONNECT TISSUE RES, V41, P29, DOI 10.3109/03008200009005639
   Wedhas N, 2005, FASEB J, V19, P1986, DOI 10.1096/fj.05 4198com
   Wright MO, 1997, J ORTHOPAED RES, V15, P742, DOI 10.1002/jor.1100150517
   YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333
   Yano S, 2004, J INVEST DERMATOL, V122, P783, DOI 10.1111/j.0022 202X.2004.22328.x
   Yao L, 2006, TISSUE ENG, V12, P1843, DOI 10.1089/ten.2006.12.1843
NR 67
TC 9
Z9 12
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUN 27
PY 2017
VL 12
IS 6
AR e0178117
DI 10.1371/journal.pone.0178117
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EZ2LT
UT WOS:000404541500012
PM 28654695
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Teo, HK
   Wong, J
AF Teo, Hooi Khee
   Wong, Jiunn
TI Unusual cause of hypercalcaemia in end stage renal failure patients
SO HEMODIALYSIS INTERNATIONAL
LA English
DT Article
DE Immobility induced hypercalcaemia; dialysis
ID IMMOBILIZATION HYPERCALCEMIA; BONE; INHIBITOR; DENOSUMAB; MECHANISM
AB Immobility induced hypercalcaemia is rarely considered in patients on dialysis and is a challenging diagnosis to make. This is especially so due to the lack of biomarkers as well as the notion that calcium metabolism is mostly related to chronic kidney disease metabolic bone disorder due to the role of iPTH. We present two cases of our dialysis patients, who were clinically unwell from hypercalcemia. We were initially uncertain of the cause of hypercalcemia as despite our attempts to adjust treatment based on their biochemical findings, we were unable to correct the hypercalcemia. We did not have appropriate bone turnover markers to guide us and out of desperation, anti resorptives calcitonin and bisphosphonate were given with good clinical response. We concluded that the hypercalcemia was related to immobility induced hypercalcemia and the inappropriately low iPTH was a red herring. Immobility induced hypercalcaemia should be considered in patients with end stage renal failure on renal replacement therapy, especially in those with recent and significant immobility. In these patients, pamidronate can be considered should the hypercalcaemia persist.
C1 [Teo, Hooi Khee; Wong, Jiunn] Singapore Gen Hosp, Dept Renal Med, Outram Rd, Singapore 169608, Singapore.
C3 Singapore General Hospital
RP Wong, J (通讯作者)，Singapore Gen Hosp, Outram Rd, Singapore 169608, Singapore.
EM wong.jiunn@singhealth.com.sg
CR Albright F, 1941, J CLIN ENDOCRINOL, V1, P711, DOI 10.1210/jcem 1 9 711
   Cano Torres EA, 2016, CLIN CASES MINER BON, V13, P46, DOI 10.11138/ccmbm/2016.13.1.046
   Barreto FC, 2008, KIDNEY INT, V73, P771, DOI 10.1038/sj.ki.5002769
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Chen CL, 2014, J CLIN ENDOCR METAB, V99, P2426, DOI 10.1210/jc.2014 1154
   Cheng CJ, 2006, SOUTH MED J, V99, P371, DOI 10.1097/01.smj.0000210142.76331.b4
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   de Beus E, 2012, CLIN KIDNEY J, V5, P566, DOI 10.1093/ckj/sfs116
   DRIVAS G, 1975, BRIT MED J, V3, P468, DOI 10.1136/bmj.3.5981.468
   GALLACHER SJ, 1990, POSTGRAD MED J, V66, P918, DOI 10.1136/pgmj.66.781.918
   Gopal H, 2000, AM J KIDNEY DIS, V35, P969, DOI 10.1016/S0272 6386(00)70272 1
   KDIGO, 2009, KIDNEY INT S113, V76, pS3
   Maeno Y, 2005, CLIN CHEM, V51, P2312, DOI 10.1373/clinchem.2005.051524
   Mazzaferro S, 2014, SEMIN NEPHROL, V34, P598, DOI 10.1016/j.semnephrol.2014.09.006
   MCINTYRE HD, 1989, POSTGRAD MED J, V65, P244, DOI 10.1136/pgmj.65.762.244
   Sánchez MC, 2000, AM J KIDNEY DIS, V36, P953, DOI 10.1053/ajkd.2000.19093
   Sharma O P, 2000, Curr Opin Pulm Med, V6, P442, DOI 10.1097/00063198 200009000 00010
   Spatz JM, 2015, J BIOL CHEM, V290, P16744, DOI 10.1074/jbc.M114.628313
   Yajima A, 2001, INT J UROL, V8, pS76, DOI 10.1046/j.1442 2042.2001.00340.x
NR 20
TC 1
Z9 1
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1492 7535
EI 1542 4758
J9 HEMODIAL INT
JI Hemodial. Int.
PD APR
PY 2017
VL 21
IS 2
BP E40
EP E44
DI 10.1111/hdi.12512
PG 5
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA ER1SU
UT WOS:000398574500004
PM 27866377
DA 2025 08 17
ER

PT J
AU Ottewell, PD
   Lefley, DV
   Cross, SS
   Evans, CA
   Coleman, RE
   Holen, I
AF Ottewell, Penelope D.
   Lefley, Diane V.
   Cross, Simon S.
   Evans, C. Alyson
   Coleman, Robert E.
   Holen, Ingunn
TI Sustained inhibition of tumor growth and prolonged survival following
   sequential administration of doxorubicin and zoledronic acid in a breast
   cancer model
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE doxorubicin; zoledronic acid; breast cancer; apoptosis; cell cycle
ID NITROGEN CONTAINING BISPHOSPHONATES; CELL CYCLE ARREST; INDUCED
   APOPTOSIS; PROSTATE CANCER; IMATINIB MESYLATE; BONE METASTASIS; MOUSE
   MODEL; IN VITRO; OSTEOSARCOMA; ADRIAMYCIN
AB Combination therapy, using agents that target the microenvironment as well as the cancer cells, is common in the treatment of advanced breast cancer. Here, we show that a 6 week course of weekly sequential administration of the cytotoxic drug doxorubicin (2 mg/kg followed 24 hr later by the antiresorptive agent zoledronic acid (100 mu g/kg), causes substantial inhibition of subcutaneous MDA MB 436 breast tumor growth in immunocompromised mice, leading to significantly increased survival. Tumor growth did not resume following withdrawal of treatment after 6 weeks, with 60% of the animals in this group surviving for more than 160 days. In comparison, animals receiving single agent therapy all died within 50 days. Molecular analysis of the tumors showed no effect on cell cycle or apoptosis following administration of 100 mu g/kg zoledronic acid or 2 mg/kg doxorubicin alone. When doxorubicin was administered 24 hr before zoledronic acid, tumors displayed decreased expression of CYCLINS E1, B, D1 and D3 as well as CDK2, CDC2, CDK4 and CDK7, indicative of cell cycle inhibition. Tumors from animals receiving sequential treatment also showed induction of both intrinsic  and extrinsic apoptotic pathways, with increased expression of BAX, decreased expression of BCL 2 and activation of CASPASE 3, 8 and 9. Accumulation of the unprenylated form of RAP1a, a surrogate marker for uptake of zoledronic acid, was only detected in tumors from animals treated with doxorubicin 24 hr before zoledronic acid. Our data are the first to show a sustained antitumor effect in vivo following a limited course of sequential administration of doxorubicin followed by zoledronic acid.
C1 [Ottewell, Penelope D.; Lefley, Diane V.; Cross, Simon S.; Evans, C. Alyson; Coleman, Robert E.; Holen, Ingunn] Univ Sheffield, Sch Med & Biomed Sci, Acad Unit Clin Oncol, Sheffield S10 2RX, S Yorkshire, England.
C3 University of Sheffield
RP Holen, I (通讯作者)，Univ Sheffield, Sch Med & Biomed Sci, Acad Unit Clin Oncol, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM I.Holen@sheffield.ac.uk
OI Holen, Ingunn/0000 0002 8759 6913; Cross, Simon/0000 0003 2044 1754;
   Ottewell, Penelope/0000 0002 4826 0771
FU Breast Cancer Campaign, United Kingdom
FX Grant sponsor: Breast Cancer Campaign, United Kingdom
CR Bar On O, 2007, ANTI CANCER DRUG, V18, P1113, DOI 10.1097/CAD.0b013e3282ef4571
   BERLIN V, 1981, J BIOL CHEM, V256, P4747
   Caraglia M, 2007, J CELL PHYSIOL, V211, P533, DOI 10.1002/jcp.20960
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Clézardin P, 2005, CANCER TREAT REV, V31, pS1, DOI 10.1016/j.ctrv.2005.09.002
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   ELSTNER E, 1995, CANCER RES, V55, P2822
   FORNARI FA, 1994, MOL PHARMACOL, V45, P649
   Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141
   Gao M, 2008, TRANSL RES, V151, P79, DOI [10.1016/j.trs1.2007.11.005, 10.1016/j.trsl.2007.11.005]
   Giono LE, 2007, MOL CELL BIOL, V27, P4166, DOI 10.1128/MCB.01967 06
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Gnant M, 2008, LANCET ONCOL, V9, P840, DOI 10.1016/S1470 2045(08)70204 3
   Heymann D, 2005, BONE, V37, P74, DOI 10.1016/j.bone.2005.02.020
   Hiraga T, 2003, INT J CANCER, V106, P973, DOI 10.1002/ijc.11330
   Jackson JG, 2006, MOL CELL BIOL, V26, P2501, DOI 10.1128/MCB.26.7.2501 2510.2006
   Kim SJ, 2005, CANCER RES, V65, P3707, DOI 10.1158/0008 5472.CAN 04 3601
   Kubista B, 2006, J ORTHOP RES, V24, P1145, DOI 10.1002/jor.20129
   Kuroda J, 2004, CANCER SCI, V95, P186, DOI 10.1111/j.1349 7006.2004.tb03202.x
   Kuroda J, 2003, BLOOD, V102, P2229, DOI 10.1182/blood 2003 01 0305
   Le Gac G, 2006, J BIOL CHEM, V281, P24161, DOI 10.1074/jbc.M603724200
   Li X, 2007, J BIOL CHEM, V282, P36177, DOI 10.1074/jbc.M706912200
   Li YY, 2008, LUNG CANCER, V59, P180, DOI 10.1016/j.lungcan.2007.08.026
   Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008 5472.CAN 06 1278
   Lopes MA, 2008, NEUROTOXICOLOGY, V29, P286, DOI 10.1016/j.neuro.2007.12.003
   Ma SL, 2008, BBA MOL CELL RES, V1783, P935, DOI 10.1016/j.bbamcr.2008.01.008
   Melisi D, 2005, ENDOCR RELAT CANCER, V12, P1051, DOI 10.1677/erc.1.01061
   Neville Webbe HL, 2005, INT J CANCER, V113, P364, DOI 10.1002/ijc.20602
   Ory B, 2007, MOL PHARMACOL, V71, P333, DOI 10.1124/mol.106.028837
   Ottewell PD, 2008, JNCI J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240
   Ottewell PD, 2008, CLIN CANCER RES, V14, P4658, DOI 10.1158/1078 0432.CCR 07 1545
   Park SS, 2005, BIOCHEM BIOPH RES CO, V334, P1014, DOI 10.1016/j.bbrc.2005.06.192
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Sang MX, 2006, BIOCHEM BIOPH RES CO, V347, P327, DOI 10.1016/j.bbrc.2006.06.079
   Sankala HM, 2007, CANCER RES, V67, P10466, DOI 10.1158/0008 5472.CAN 07 2090
   Santini D, 2006, NAT CLIN PRACT ONCOL, V3, P325, DOI 10.1038/ncponc0520
   Segawa H, 2005, BRIT J HAEMATOL, V130, P558, DOI 10.1111/j.1365 2141.2005.05648.x
   Sewing L, 2008, APOPTOSIS, V13, P782, DOI 10.1007/s10495 008 0211 z
   SILBER R, 1987, NATL CANCER I MONOGR, V4, P111
   SLIWINSKA MA, 2008, MECH AGEING DEV
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003 2697(85)90442 7
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Vayssade M, 2005, INT J CANCER, V116, P860, DOI 10.1002/ijc.21033
   Welsh CF, 2004, BREAST CANCER RES TR, V84, P33, DOI 10.1023/B:BREA.0000018425.31633.07
   Yuasa T, 2007, CURR MED CHEM, V14, P2126
   Zhou ZC, 2005, CANCER AM CANCER SOC, V104, P1713, DOI 10.1002/cncr.21383
NR 48
TC 69
Z9 71
U1 1
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0020 7136
EI 1097 0215
J9 INT J CANCER
JI Int. J. Cancer
PD JAN 15
PY 2010
VL 126
IS 2
BP 522
EP 532
DI 10.1002/ijc.24756
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 538NC
UT WOS:000273190200024
PM 19621384
OA Bronze
DA 2025 08 17
ER

PT J
AU Foster, BL
   Ao, M
   Salmon, CR
   Chavez, MB
   Kolli, TN
   Tran, AB
   Chu, EY
   Kantovitz, KR
   Yadav, M
   Narisawa, S
   Milián, JL
   Nociti, FH
   Somerman, M
AF Foster, B. L.
   Ao, M.
   Salmon, C. R.
   Chavez, M. B.
   Kolli, T. N.
   Tran, A. B.
   Chu, E. Y.
   Kantovitz, K. R.
   Yadav, M.
   Narisawa, S.
   Milian, J. L.
   Nociti, F. H., Jr.
   Somerman, Mj.
TI Osteopontin regulates dentin and alveolar bone development and
   mineralization
SO BONE
LA English
DT Article
DE Extracellular matrix; Mineralization; Periodontal tissues; Tooth
   development; Dental cementum; Bone biology
ID ALKALINE PHOSPHATASE ACTIVITY; MICE LACKING OSTEOPONTIN;
   PERIODONTAL LIGAMENT; HYDROXYAPATITE FORMATION; ROOT FORMATION; MOUSE
   MODEL; POSTTRANSLATIONAL MODIFICATION; SKELETAL MINERALIZATION;
   EXTRACELLULAR MATRIX; CRYSTAL FORMATION
AB The periodontal complex is essential for tooth attachment and function and includes the mineralized tissues, cementum and alveolar bone, separated by the unmineralized periodontal ligament (PDL). To gain insights into factors regulating cementum PDL and bone PDL borders and protecting against ectopic calcification within the PDI, we employed a proteomic approach to analyze PDL tissue from progressive ankylosis knock  out (Ank( / )) mice, featuring reduced PP,, rapid cementogenesis, and excessive acellular cementum. Using this approach, we identified the matrix protein osteopontin (Sppl/OPN) as an elevated factor of interest in Ank( / ) mouse molar PDL We studied the role of OPN in dental and periodontal development and function. During tooth development in wild type (WT) mice, Spp1 mRNA was transiently expressed by cementoblasts and strongly by alveolar bone osteoblasts. Developmental analysis from 14 to 240 days postnatal (dpn) indicated normal histological structures in Spp1( / ) comparable to WT control mice. Microcomputed tomography (micro CT) analysis at 30 and 90 dpn revealed significantly increased volumes and tissue mineral densities of Sppl( / ) mouse dentin and alveolar bone, while pulp and PDL volumes were decreased and tissue densities were increased. However, acellular cementum growth was unaltered in Sppl( / ) mice. Quantitative PCR of periodontal derived mRNA failed to identify potential local compensators influencing cementum in Spp1( / ) vs. WT mice at 26 dpn. We genetically deleted Spp1 on the Ank( / ) mouse background to determine whether increased Sppl/OPN was regulating periodontal tissues when the PDL space is challenged by hypercementosis in Ank( / ) mice. AnICh Sppl( / ) double deficient mice did not exhibit greater hypercementosis than that in Anic( / ) mice. Based on these data, we conclude that OPN has a non redundant role regulating formation and mineralization of dentin and bone, influences tissue properties of PDL and pulp, but does not control acellular cementum apposition. These findings may inform therapies targeted at controlling soft tissue calcification. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Foster, B. L.; Chavez, M. B.; Kolli, T. N.] Ohio State Univ, Coll Dent, Div Biosci, 4163 Postle Hall,305 W 12th Ave, Columbus, OH 43210 USA.
   [Ao, M.; Tran, A. B.; Chu, E. Y.; Somerman, Mj.] Natl Inst Arthrit & Musculoskeletal & Skin Dis NI, NIH, Bethesda, MD USA.
   [Salmon, C. R.; Nociti, F. H., Jr.] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Prosthodont & Periodont, Div Periodont, Sao Paulo, Brazil.
   [Kantovitz, K. R.] Soo Leopoldo Mand Res Ctr, Dept Dent Mat, Campinas, SP, Brazil.
   [Yadav, M.; Narisawa, S.; Milian, J. L.] Sanford Burnham Prebys Med Res Inst, Sanford Childrens Hlth Res Ctr, La Jolla, CA USA.
C3 University System of Ohio; Ohio State University; National Institutes of
   Health (NIH)   USA; NIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS); Universidade Estadual de
   Campinas; Sanford Burnham Prebys Medical Discovery Institute
RP Foster, BL (通讯作者)，Ohio State Univ, Coll Dent, Div Biosci, 4163 Postle Hall,305 W 12th Ave, Columbus, OH 43210 USA.
EM foster.1004@osu.edu
RI Kantovitz, Kamila/J 4567 2013; SALMON, CRISTIANE/A 9772 2015; Kolli,
   Tamara/LQJ 9986 2024; Nociti, Francisco/G 4907 2015; Chavez,
   Michael/AAF 9453 2019; Foster, Brian/H 8375 2015
OI Kantovitz, Kamila/0000 0003 2045 7924; Kolli,
   Tamara/0009 0007 8652 7717; Chavez, Michael/0000 0003 0893 2139; Foster,
   Brian/0000 0003 3444 0576
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   (NIAMS) of the National Institutes of Health (NIH, Bethesda, MD) [AR
   066110]; National Institute of Dental and Craniofacial Research (NIDCR)
   /NIH [DE 12889]; Intramural Research Program of NIAMS
FX The authors declare that they have no conflicts of interest with the
   contents of this article. This research was supported by grant AR 066110
   to BLF from the National Institute of Arthritis and Musculoskeletal and
   Skin Diseases (NIAMS) of the National Institutes of Health (NIH,
   Bethesda, MD), grant DE 12889 to JLM from the National Institute of
   Dental and Craniofacial Research (NIDCR) /NIH, and the Intramural
   Research Program of NIAMS (MJS). We thank Dr. Susan Rittling (Forsyth
   Institute, Boston, MA, USA) for allowing access to and study of Spp1
   mice. We thank Dr. Kristina Zaal (Light Imaging Section, NIAMS/NIH) for
   assistance in slide scanning and Nasrin Kalantaripour and Kathryn
   Hemstreet (NIAMS/NIH) for additional histological sectioning. We thank
   the editor and anonymouse reviewers for their suggested revisions that
   improved this manucript.
CR Addison WN, 2007, J BIOL CHEM, V282, P15872, DOI 10.1074/jbc.M701116200
   Addison WN, 2010, J BONE MINER RES, V25, P695, DOI 10.1359/jbmr.090832
   ALATLIKUT I, 1994, SCAND J DENT RES, V102, P260
   Barros NMT, 2013, J BONE MINER RES, V28, P688, DOI 10.1002/jbmr.1766
   Beertsen W, 1997, PERIODONTOL 2000, V13, P20, DOI 10.1111/j.1600 0757.1997.tb00094.x
   Bonyadi M, 1997, NAT GENET, V15, P207, DOI 10.1038/ng0297 207
   Boskey AL, 2012, BIOCHEM BIOPH RES CO, V419, P333, DOI 10.1016/j.bbrc.2012.02.024
   BOSKEY AL, 1993, BONE MINER, V22, P147, DOI 10.1016/S0169 6009(08)80225 5
   Boskey AL, 2002, CALCIFIED TISSUE INT, V71, P145, DOI 10.1007/s00223 001 1121 z
   Bosshardt DD, 1998, ANAT REC, V250, P13, DOI 10.1002/(SICI)1097 0185(199801)250:1<13::AID AR3>3.0.CO;2 F
   Boukpessi T, 2017, BONE, V95, P151, DOI 10.1016/j.bone.2016.11.019
   Bronckers ALJJ, 1998, EUR J ORAL SCI, V106, P795, DOI 10.1046/j.0909 8836.1998.eos106306.x
   BRONCKERS ALJJ, 1994, J BONE MINER RES, V9, P833
   Carleton SM, 2008, BONE, V42, P681, DOI 10.1016/j.bone.2007.12.215
   Chellaiah MA, 2003, MOL BIOL CELL, V14, P173, DOI 10.1091/mbc.E02 06 0354
   Chellaiah MA, 2003, CALCIFIED TISSUE INT, V72, P197, DOI 10.1007/s00223 002 1025 6
   Chien YC, 2009, CELLS TISSUES ORGANS, V189, P38, DOI 10.1159/000151374
   Christensen B, 2012, J BIOL CHEM, V287, P3788, DOI 10.1074/jbc.M111.277996
   Chu EY, 2010, ANAT REC, V293, P1214, DOI 10.1002/ar.21152
   Chung CJ, 2008, J CELL PHYSIOL, V214, P614, DOI 10.1002/jcp.21250
   Coley WD, 2016, HUM MOL GENET, V25, P130, DOI 10.1093/hmg/ddv460
   DErrico JA, 1997, BONE, V20, P117, DOI 10.1016/S8756 3282(96)00348 1
   Doetschman Thomas, 2009, V530, P423, DOI 10.1007/978 1 59745 471 1_23
   Eshraghi M, 2016, HUM MOL GENET, V25, P4494, DOI 10.1093/hmg/ddw278
   Fisher LW, 2003, CONNECT TISSUE RES, V44, P33, DOI 10.1080/03008200390152061
   Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146
   Flores IL, 2016, CLIN SCI, V130, P785, DOI 10.1042/CS20150646
   Fong H, 2009, ARCH ORAL BIOL, V54, P570, DOI 10.1016/j.archoralbio.2009.02.011
   Fong H, 2009, J PERIODONTOL, V80, P1348, DOI 10.1902/jop.2009.090129
   Fong RKM, 2016, J MORPHOL, V277, P916, DOI 10.1002/jmor.20545
   Foster BL, 2015, BONE, V78, P150, DOI 10.1016/j.bone.2015.05.007
   Foster BL, 2013, J DENT RES, V92, P166, DOI 10.1177/0022034512469026
   Foster BL, 2013, J BONE MINER RES, V28, P271, DOI 10.1002/jbmr.1767
   Foster BL, 2011, CELLS TISSUES ORGANS, V194, P382, DOI 10.1159/000323457
   Foster B. L., 2012, Mineralized tissues in Oral and craniofacial science: Biological principles and clinical correlates, P169
   Foster BL, 2014, ENDOCR REV, V35, P1, DOI 10.1210/er.2013 1009
   Foster BL, 2013, STEM CELLS IN CRANIOFACIAL DEVELOPMENT AND REGENERATION, P153
   Foster BL, 2012, INT J ORAL SCI, V4, P119, DOI 10.1038/ijos.2012.57
   Foster BL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038393
   Fujihara S, 2006, J BONE MINER RES, V21, P956, DOI 10.1359/JBMR.060315
   Ge CX, 2016, J BONE MINER RES, V31, P2193, DOI 10.1002/jbmr.2893
   Gericke A, 2005, CALCIFIED TISSUE INT, V77, P45, DOI 10.1007/s00223 004 1288 1
   GOLDBERG HA, 1995, ANN NY ACAD SCI, V760, P305, DOI 10.1111/j.1749 6632.1995.tb44642.x
   Goldberg HA, 2001, CONNECT TISSUE RES, V42, P25, DOI 10.3109/03008200109014246
   GROENEVELD MC, 1995, J DENT RES, V74, P1374, DOI 10.1177/00220345950740070901
   GROENEVELD MC, 1993, J DENT RES, V72, P1344, DOI 10.1177/00220345930720091501
   Gurley KA, 2006, J BONE MINER RES, V21, P1238, DOI 10.1359/JBMR.060515
   Harmey D, 2004, AM J PATHOL, V164, P1199, DOI 10.1016/S0002 9440(10)63208 7
   Harmey D, 2006, J BONE MINER RES, V21, P1377, DOI 10.1359/JBMR.060619
   Holm E, 2014, BIOCHEM J, V464, P355, DOI 10.1042/BJ20140702
   Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239
   Hunter GK, 1996, BIOCHEM J, V317, P59, DOI 10.1042/bj3170059
   HUNTER GK, 1994, BIOCHEM J, V300, P723, DOI 10.1042/bj3000723
   Hunter GK, 2013, CALCIFIED TISSUE INT, V93, P348, DOI 10.1007/s00223 013 9698 6
   Ishii T, 2004, BIOCHEM BIOPH RES CO, V316, P809, DOI 10.1016/j.bbrc.2004.02.124
   Ishijima M, 2002, J BONE MINER RES, V17, P661, DOI 10.1359/jbmr.2002.17.4.661
   Ishijima M, 2001, J EXP MED, V193, P399, DOI 10.1084/jem.193.3.399
   Johnson K, 2003, J BONE MINER RES, V18, P994, DOI 10.1359/jbmr.2003.18.6.994
   Jono S, 2000, J BIOL CHEM, V275, P20197, DOI 10.1074/jbc.M909174199
   Kagayama M, 1997, J PERIODONTAL RES, V32, P273, DOI 10.1111/j.1600 0765.1997.tb00534.x
   Kaipatur NR, 2008, J DENT RES, V87, P839, DOI 10.1177/154405910808700907
   Kawasaki K, 2006, J EXP ZOOL PART B, V306B, P295, DOI 10.1002/jez.b.21088
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   LeBlanc ARH, 2016, J CLIN PERIODONTOL, V43, P323, DOI 10.1111/jcpe.12508
   LeBlanc AG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065351
   Leong NL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035980
   Li Y, 2013, CELLS TISSUES ORGANS, V198, P448, DOI 10.1159/000360157
   Liaw L, 1998, J CLIN INVEST, V101, P1468
   Luan XH, 2009, EVOL DEV, V11, P247, DOI 10.1111/j.1525 142X.2009.00327.x
   MacNeil R L, 1995, Connect Tissue Res, V33, P1, DOI 10.3109/03008209509016974
   MacNeil RL, 1998, ARCH ORAL BIOL, V43, P779, DOI 10.1016/S0003 9969(98)00054 5
   Matias MA, 2003, J PERIODONTAL RES, V38, P502, DOI 10.1034/j.1600 0765.2003.00682.x
   McIntosh JE, 2002, MICROSC RES TECHNIQ, V59, P449, DOI 10.1002/jemt.10222
   McKee MD, 2013, J DENT RES, V92, P721, DOI 10.1177/0022034513490958
   MCKEE MD, 1995, MICROSC RES TECHNIQ, V31, P44, DOI 10.1002/jemt.1070310105
   McKee MD, 1996, ANAT RECORD, V245, P293, DOI 10.1002/(SICI)1097 0185(199606)245:2<293::AID AR13>3.0.CO;2 K
   Millan J.L., 2006, MAMMALIAN ALKALINE P, P337, DOI [10.1002/3527608060, DOI 10.1002/3527608060]
   Millán JL, 2016, CALCIFIED TISSUE INT, V98, P398, DOI 10.1007/s00223 015 0079 1
   Mo L, 2007, AM J PHYSIOL RENAL, V293, pF1935, DOI 10.1152/ajprenal.00383.2007
   Narisawa S, 1997, DEV DYNAM, V208, P432, DOI 10.1002/(SICI)1097 0177(199703)208:3<432::AID AJA13>3.0.CO;2 1
   Narisawa S, 2013, J BONE MINER RES, V28, P1587, DOI 10.1002/jbmr.1901
   Neame PJ, 1996, CONNECT TISSUE RES, V35, P145, DOI 10.3109/03008209609029185
   Nociti FH, 2002, J DENT RES, V81, P817, DOI 10.1177/154405910208101204
   Ohma N, 2000, EUR J ORAL SCI, V108, P222, DOI 10.1034/j.1600 0722.2000.108003222.x
   Piróg KA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085145
   PRINCE CW, 1987, J BIOL CHEM, V262, P2900
   Qin C, 2004, CRIT REV ORAL BIOL M, V15, P126, DOI 10.1177/154411130401500302
   Rajachar RM, 2008, J MATER SCI MATER M, V19, P3279, DOI 10.1007/s10856 008 3455 9
   Rios HF, 2008, J PERIODONTOL, V79, P1480, DOI [10.1902/jop.2008.070624, 10.1902/jop.2008.070624 ]
   Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101
   Saito K, 2016, J DENT RES, V95, P1034, DOI 10.1177/0022034516645333
   Salih E, 1996, J BIOL CHEM, V271, P16897, DOI 10.1074/jbc.271.28.16897
   Salmon B, 2014, CONNECT TISSUE RES, V55, P79, DOI 10.3109/03008207.2014.923864
   Salmon CR, 2017, BONE, V101, P219, DOI 10.1016/j.bone.2017.05.014
   Salmon CR, 2016, J PROTEOMICS, V141, P12, DOI 10.1016/j.jprot.2016.03.036
   Sanford LP, 1997, DEVELOPMENT, V124, P2659
   Sanford LP, 2000, METH MOL B, V158, P217
   Schiviz A, 2014, J THROMB HAEMOST, V12, P1940, DOI 10.1111/jth.12700
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Sodek J, 2000, CRIT REV ORAL BIOL M, V11, P279, DOI 10.1177/10454411000110030101
   Soenjaya Y, 2015, J DENT RES, V94, P1276, DOI 10.1177/0022034515592581
   SOMERMAN MJ, 1990, J BIOL BUCCALE, V18, P207
   Speer MY, 2005, CARDIOVASC RES, V66, P324, DOI 10.1016/j.cardiores.2005.01.023
   Speer MY, 2002, J EXP MED, V196, P1047, DOI 10.1084/jem.20020911
   Staines KA, 2012, J ENDOCRINOL, V214, P241, DOI 10.1530/JOE 12 0143
   STEINFORT J, 1990, J DENT RES, V69, P1287, DOI 10.1177/00220345900690061301
   STEINFORT J, 1989, J BIOL CHEM, V264, P2840
   Steitz SA, 2002, AM J PATHOL, V161, P2035, DOI 10.1016/S0002 9440(10)64482 3
   Takano Y, 2003, J ELECTRON MICROSC, V52, P573, DOI 10.1093/jmicro/52.6.573
   van den Bos T, 1999, J PERIODONTAL RES, V34, P1
   VandenBos T, 1999, J DENT RES, V78, P1688, DOI 10.1177/00220345990780110501
   Walker CG, 2010, BONE, V47, P1020, DOI 10.1016/j.bone.2010.08.025
   Wang L, 2014, J DENT RES, V93, P780, DOI 10.1177/0022034514541126
   Wesson JA, 2003, J AM SOC NEPHROL, V14, P139, DOI 10.1097/01.ASN.0000040593.93815.9D
   Xu H, 2016, MATRIX BIOL, V52 54, P266, DOI 10.1016/j.matbio.2016.01.002
   Yadav MC, 2014, J BONE MINER RES, V29, P2369, DOI 10.1002/jbmr.2281
   Ye L, 2008, J DENT RES, V87, P624, DOI 10.1177/154405910808700708
   Yuan Q, 2014, J BONE MINER RES, V29, P693, DOI 10.1002/jbmr.2079
   Zweifler LE, 2016, J DENT RES, V95, P742, DOI 10.1177/0022034516640246
   Zweifler LE, 2015, INT J ORAL SCI, V7, P27, DOI 10.1038/ijos.2014.62
NR 120
TC 106
Z9 113
U1 2
U2 36
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2018
VL 107
BP 196
EP 207
DI 10.1016/j.bone.2017.12.004
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FT2XS
UT WOS:000423009900023
PM 29313816
OA Green Accepted
DA 2025 08 17
ER

PT J
AU He, P
   Liu, FY
   Li, MZ
   Ren, MX
   Wang, X
   Deng, YJ
   Wu, XH
   Li, YZ
   Yang, S
   Song, JL
AF He, Ping
   Liu, Fengyi
   Li, Mingzheng
   Ren, Mingxing
   Wang, Xu
   Deng, Yangjia
   Wu, Xianghao
   Li, Yuzhou
   Yang, Sheng
   Song, Jinlin
TI Mitochondrial Calcium Ion Nanogluttons Alleviate Periodontitis via
   Controlling mPTPs
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE macrophages; mitochondrial calcium ions; mitochondrial permeability
   transition; nanoparticles; periodontitis
ID PERMEABILITY TRANSITION; PAMAM DENDRIMERS; INNATE; DELIVERY; CELLS; ROS;
   AM
AB The mitochondrial permeability transition (mPT) directly affects mitochondrial function in macrophages. Under inflammatory conditions, mitochondrial calcium ion (mitoCa(2+)) overload triggers the persistent opening of mPT pores (mPTPs), further aggravating Ca2+ overload and increasing reactive oxygen species (ROS) to form an adverse cycle. However, there are currently no effective drugs targeting mPTPs to confine or unload excess Ca2+. It is novelly demonstrated that the initiation of periodontitis and the activation of proinflammatory macrophages depend on the persistent overopening of mPTPs, which is mainly triggered by mitoCa(2+) overload and facilitates further mitochondrial ROS leakage into the cytoplasm. To solve the above problems, mitochondrial targeted "nanogluttons" with PEG TPP conjugated to the surface of PAMAM and BAPTA AM encapsulated in the core are designed. These nanogluttons can efficiently "glut" Ca2+ around and inside mitochondria to effectively control the sustained opening of mPTPs. As a result, the nanogluttons significantly inhibit the inflammatory activation of macrophages. Further studies also unexpectedly reveal that the alleviation of local periodontal inflammation in mice is accompanied by diminished osteoclast activity and reduced bone loss. This provides a promising strategy for mitochondria targeted intervention in inflammatory bone loss in periodontitis and can be extended to treat other chronic inflammatory diseases associated with mitoCa(2+) overload.
C1 [He, Ping; Ren, Mingxing; Wang, Xu; Deng, Yangjia; Wu, Xianghao] Chongqing Med Univ, Coll Stomatol, Chongqing 401147, Peoples R China.
   [Liu, Fengyi; Li, Mingzheng; Li, Yuzhou; Yang, Sheng; Song, Jinlin] Chongqing Med Univ, Stomatol Hosp, Chongqing 401147, Peoples R China.
   [Liu, Fengyi; Li, Mingzheng; Li, Yuzhou; Yang, Sheng; Song, Jinlin] Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing 401147, Peoples R China.
   [Liu, Fengyi; Li, Mingzheng; Li, Yuzhou; Yang, Sheng; Song, Jinlin] Chongqing Municipal Key Lab Oral Biomed Engn Highe, Chongqing 401147, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University
RP Yang, S; Song, JL (通讯作者)，Chongqing Med Univ, Stomatol Hosp, Chongqing 401147, Peoples R China.; Yang, S; Song, JL (通讯作者)，Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing 401147, Peoples R China.; Yang, S; Song, JL (通讯作者)，Chongqing Municipal Key Lab Oral Biomed Engn Highe, Chongqing 401147, Peoples R China.
EM 500283@cqmu.edu.cn; songjinlin@hospital.cqmu.edu.cn
RI ; He, Ping/NYS 5771 2025; Wu, Xianghao/AAB 8394 2020
OI He, Ping/0000 0002 8047 1157; Song, jinlin/0000 0002 0224 6640; 
FU National Natural Science Foundation of China [U22A20314, 82171010];
   Natural Science Foundation of Chongqing [cstc2021jcyj jqX0028]; Program
   for Youth Innovation in Future Medicine, Chongqing Medical University
   [W0079]; National Key R&D of Program of China [2022YFC2504200]; Project
   of Chongqing Graduate Tutor Team [dstd201903]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 82171010), the Natural Science Foundation of Chongqing
   (Grant No. cstc2021jcyj jqX0028), Program for Youth Innovation in Future
   Medicine, Chongqing Medical University (W0079), National Key R&D of
   Program of China (Grant NO. 2022YFC2504200), National Natural Science
   Foundation of China (Grant No. U22A20314), and Project of Chongqing
   Graduate Tutor Team (dstd201903).
CR Abedi Gaballu F, 2018, APPL MATER TODAY, V12, P177, DOI 10.1016/j.apmt.2018.05.002
   Aguirre S, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.37
   Behnen M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00184
   Bolisetty S, 2013, INT J MOL SCI, V14, P6306, DOI 10.3390/ijms14036306
   Bonora M, 2022, NAT REV MOL CELL BIO, V23, P266, DOI 10.1038/s41580 021 00433 y
   Boyenle ID, 2022, MITOCHONDRION, V63, P57, DOI 10.1016/j.mito.2022.01.006
   Ellis Davies GCR, 2006, CELL CALCIUM, V39, P471, DOI 10.1016/j.ceca.2006.02.002
   Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131
   Fu ZL, 2019, ACS APPL MATER INTER, V11, P39574, DOI 10.1021/acsami.9b13690
   Giorgi C, 2018, NAT REV MOL CELL BIO, V19, P713, DOI 10.1038/s41580 018 0052 8
   Gogvadze V, 2009, SEMIN CANCER BIOL, V19, P57, DOI 10.1016/j.semcancer.2008.11.007
   Grayson WL, 2015, NAT REV ENDOCRINOL, V11, P140, DOI 10.1038/nrendo.2014.234
   Gu LL, 2019, REDOX BIOL, V26, DOI 10.1016/j.redox.2019.101307
   Hajishengallis G, 2021, NAT REV IMMUNOL, V21, P426, DOI 10.1038/s41577 020 00488 6
   Halestrap AP, 2015, J MOL CELL CARDIOL, V78, P129, DOI 10.1016/j.yjmcc.2014.08.018
   Hausenloy DJ, 2020, J CELL MOL MED, V24, P7102, DOI 10.1111/jcmm.15341
   HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003 9861(79)90371 0
   Pérez MJ, 2018, REDOX BIOL, V19, P290, DOI 10.1016/j.redox.2018.09.001
   Karki R, 2021, TRENDS IMMUNOL, V42, P681, DOI 10.1016/j.it.2021.06.001
   Kesharwani P, 2015, MATER TODAY, V18, P565, DOI 10.1016/j.mattod.2015.06.003
   Kuroda Y, 2019, INFLAMM REGEN, V39, DOI 10.1186/s41232 019 0109 x
   Li F, 2022, J AM CHEM SOC, V144, P4667, DOI 10.1021/jacs.2c00823
   Li XF, 2022, CELL, V185, P1709, DOI 10.1016/j.cell.2022.03.043
   Liew SS, 2021, ANGEW CHEM INT EDIT, V60, P2232, DOI 10.1002/anie.201915826
   Lin X, 2021, ADV SCI, V8, DOI 10.1002/advs.202002834
   Lisa P. B. F. D., 2016, NEW ENGL J MED, V374, P88
   Liu PS, 2018, MITOCHONDRION, V41, P45, DOI 10.1016/j.mito.2017.11.002
   Love DT, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101602
   Marchi S, 2023, NAT REV IMMUNOL, V23, P159, DOI 10.1038/s41577 022 00760 x
   Meirow Y, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00206 z
   Meyer A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00536
   Mills EL, 2017, NAT IMMUNOL, V18, P488, DOI 10.1038/ni.3704
   Murphy MP, 2018, NAT REV DRUG DISCOV, V17, P865, DOI 10.1038/nrd.2018.174
   Naik S, 2022, NATURE, V607, P249, DOI 10.1038/s41586 022 04919 3
   Namgaladze D, 2019, CELLS BASEL, V8, DOI 10.3390/cells8091088
   Nesci S, 2020, MED RES REV, V40, P811, DOI 10.1002/med.21635
   NORDSTROM T, 1994, FEBS LETT, V350, P82, DOI 10.1016/0014 5793(94)00738 1
   Oliveira ER, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020903
   Qi H, 2021, CHAOS, V31, DOI 10.1063/5.0065400
   Qin JB, 2021, NANOSCALE, V13, P7108, DOI 10.1039/d1nr01068a
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Regmi S, 2019, EUR J CELL BIOL, V98, DOI 10.1016/j.ejcb.2019.04.002
   Ren MX, 2021, J MATER CHEM B, V9, P2831, DOI 10.1039/d0tb02926b
   Rizzuto R, 2012, NAT REV MOL CELL BIO, V13, P566, DOI 10.1038/nrm3412
   Robinson N, 2019, REDOX BIOL, V26, DOI 10.1016/j.redox.2019.101239
   Roca FJ, 2019, CELL, V178, P1344, DOI 10.1016/j.cell.2019.08.004
   Rottenberg H, 2017, AGING CELL, V16, P943, DOI 10.1111/acel.12650
   Shi YF, 2018, NAT REV NEPHROL, V14, P493, DOI 10.1038/s41581 018 0023 5
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Sima C, 2019, J LEUKOCYTE BIOL, V105, P473, DOI 10.1002/JLB.1RU0818 310R
   Szabo I, 2021, REDOX BIOL, V42, DOI 10.1016/j.redox.2020.101846
   Tang Q, 2007, BIOCHEM PHARMACOL, V74, P1596, DOI 10.1016/j.bcp.2007.07.042
   Tschopp J, 2011, EUR J IMMUNOL, V41, P1196, DOI 10.1002/eji.201141436
   Viniegra A, 2018, J DENT RES, V97, P1160, DOI 10.1177/0022034518777973
   Visca H, 2022, MOL IMAGING BIOL, V24, P874, DOI 10.1007/s11307 022 01737 x
   Waldmeier PC, 2003, CURR MED CHEM, V10, P1485, DOI 10.2174/0929867033457160
   Wang L, 2022, BIOACT MATER, V18, P254, DOI 10.1016/j.bioactmat.2022.02.008
   Wang P, 2005, GENOME BIOL, V6, DOI 10.1186/gb 2005 6 7 226
   Weinberg SE, 2015, IMMUNITY, V42, P406, DOI 10.1016/j.immuni.2015.02.002
   West AP, 2011, NAT REV IMMUNOL, V11, P389, DOI 10.1038/nri2975
   Zhai QM, 2022, ADV SCI, V9, DOI 10.1002/advs.202103839
   Zhao QY, 2020, CELL, V183, P76, DOI 10.1016/j.cell.2020.08.009
   Zheng X. W. S., 2022, TRENDS CELL BIOL, V33, P312
   Zhou Y, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01392 y
NR 64
TC 21
Z9 22
U1 8
U2 70
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2192 2640
EI 2192 2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD JUN
PY 2023
VL 12
IS 15
DI 10.1002/adhm.202203106
EA MAR 2023
PG 12
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics; Materials Science
GA J4FH9
UT WOS:000954960800001
PM 36906927
DA 2025 08 17
ER

PT J
AU Zheng, DK
   Wang, BC
   Zhu, XL
   Hu, JL
   Sun, JJ
   Xuan, JZ
   Ge, ZW
AF Zheng, Daokuo
   Wang, Baocai
   Zhu, Xiliang
   Hu, Junlong
   Sun, Junjie
   Xuan, Jizhong
   Ge, Zhenwei
TI LncRNA OIP5 AS1 inhibits osteoblast differentiation of valve
   interstitial cells via miR 137/TWIST11 axis
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Long non coding RNA; miR 137; OIP5 AS1; Osteoblast differentiation;
   Valve interstitial cells
ID H19; PROLIFERATION; METASTASIS; SPONGES; DISEASE
AB OIP5 AS1, a highly abundant imprinted long non coding RNA (IncRNA), has been implicated in calcific aortic valve disease (CAVD). However, the function and underlying mechanism of OIP5 AS1 in CAVD progression remains unknown. In this study, osteoblastic differentiation of valve interstitial cells (VICs) isolated from human calcific aortic valves was induced by osteogenic medium. The protein levels of osteogenic markers were determined by immunofluorescence and western blotting.OIP5 AS1, miR 137 and TWIST related protein 1 (TWIST1) expressions were detected by quantitative real time PCR (qRTPCR). ALP activity was evaluated by spectrophotometry. Mineralized bone matrix formation was assessed by Alizarin Red S staining. The interaction between OIP5 AS1 and miR 137 was studied using luciferase reporter assay, RNA pull down assay and RNA binding protein immunoprecipitation (RIP) assay. Luciferase reporter assay was also used to identify the possible interaction between miR 137 and TWIST11. The results showed that downregulated expression of OIP5 AS1 was observed in human aortic VICs after osteogenic induction. In vitro experiments revealed that OIP5 AS1 acted as a negative regulator of osteogenic differentiation. Mechanistically, we further showed that OIP5 AS1 could relieve osteogenic differentiation of VICs via upregulating miR 137 target gene TWIST1. Our study provides novel mechanistic insights into the cross talk between OIP5 AS1, miR 137, and TWIST11, shedding light on the therapy for CAVD. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Zheng, Daokuo; Wang, Baocai; Zhu, Xiliang; Hu, Junlong; Sun, Junjie; Xuan, Jizhong; Ge, Zhenwei] Henan Univ, Dept Cardiovasc Surg, Henan Prov Peoples Hosp, Zhengzhou 461464, Henan, Peoples R China.
   [Wang, Baocai; Zhu, Xiliang; Hu, Junlong; Sun, Junjie; Xuan, Jizhong; Ge, Zhenwei] Fuwai Cent China Cardiovasc Hosp, Dept Cardiovasc Surg, Zhengzhou 461464, Henan, Peoples R China.
C3 Henan University; Zhengzhou University
RP Ge, ZW (通讯作者)，1 Fuwai Rd, Zhengzhou 461464, Henan, Peoples R China.
EM ge_zhw@sohu.com
FU Key Science and Technology Research Projects in Henan Province
   [15210230149]
FX This work was supported by The Key Science and Technology Research
   Projects in Henan Province (grant no. 15210230149).
CR Arunkumar G, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 25451 3
   Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534 5807(04)00058 9
   Chen LL, 2014, ADV EXP MED BIOL, V825, P129, DOI 10.1007/978 1 4939 1221 6_4
   Cirka Heather A, 2015, J Long Term Eff Med Implants, V25, P3
   Deng X, 2017, BIOMED PHARMACOTHER, V90, P100, DOI 10.1016/j.biopha.2017.03.031
   Hadji F, 2016, CIRCULATION, V134, P1848, DOI 10.1161/CIRCULATIONAHA.116.023116
   Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027
   Katrina C., 2014, PLOS ONE, V9
   Liang WC, 2015, ONCOTARGET, V6, P22513, DOI 10.18632/oncotarget.4154
   Liang Z., 2018, J CELL PHYSL, P233
   Liu S, 2014, TUMOR BIOL, V35, P9131, DOI 10.1007/s13277 014 2177 5
   Poggio P, 2013, CARDIOVASC RES, V98, P402, DOI 10.1093/cvr/cvt055
   Shang MH, 2018, ONCOTARGETS THER, V11, P639, DOI 10.2147/OTT.S157638
   Towler DA, 2013, CIRC RES, V113, P198, DOI 10.1161/CIRCRESAHA.113.300155
   Wang YJ, 2015, J CARDIOVASC PHARM, V66, P63, DOI 10.1097/FJC.0000000000000244
   Wei W, 2017, J CELL BIOCHEM, V118, P3349, DOI 10.1002/jcb.25988
   Xiao XX, 2017, INT J CARDIOL, V243, P404, DOI 10.1016/j.ijcard.2017.05.037
   Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027
   Yu C, 2018, CARDIOVASC RES, V114, P168, DOI 10.1093/cvr/cvx180
   Yutzey KE, 2014, ARTERIOSCL THROM VAS, V34, P2387, DOI 10.1161/ATVBAHA.114.302523
   Zhang XW, 2014, J THORAC CARDIOV SUR, V148, P1700, DOI 10.1016/j.jtcvs.2014.02.084
   Zhang Z, 2018, BIOMED PHARMACOTHER, V101, P14, DOI 10.1016/j.biopha.2018.02.026
   Zou YM, 2018, EUR J CELL BIOL, V97, P369, DOI 10.1016/j.ejcb.2018.04.005
NR 23
TC 29
Z9 29
U1 0
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 16
PY 2019
VL 511
IS 4
BP 826
EP 832
DI 10.1016/j.bbrc.2019.02.109
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA HT5TK
UT WOS:000464626000017
PM 30846207
DA 2025 08 17
ER

PT J
AU Rodrigues, M
   Turner, O
   Stolz, D
   Griffith, LG
   Wells, A
AF Rodrigues, Melanie
   Turner, Omari
   Stolz, Donna
   Griffith, Linda G.
   Wells, Alan
TI Production of Reactive Oxygen Species by Multipotent Stromal
   Cells/Mesenchymal Stem Cells Upon Exposure to Fas Ligand
SO CELL TRANSPLANTATION
LA English
DT Article
DE Reactive oxygen species (ROS); Multipotent stromal cells; Marrow stromal
   cells; Multipotent stem cells; Mesenchymal stem cells
ID EPIDERMAL GROWTH FACTOR; NADPH OXIDASE ACTIVATION; INDUCED APOPTOSIS;
   UNCOUPLING PROTEIN 2; OXIDATIVE STRESS; EPITHELIAL CELLS; NK CELLS;
   IN VITRO; MARROW; BONE
AB Multipotent stromal cells (MSCs) can be differentiated into osteoblasts and chondrocytes, making these cells candidates to regenerate cranio facial injuries and lesions in long bones. A major problem with cell replacement therapy, however, is the loss of transplanted MSCs at the site of graft. Reactive oxygen species (ROS) and nonspecific inflammation generated at the ischemic site have been hypothesized to lead to MSCs loss; studies in vitro show MSCs dying both in the presence of ROS or cytokines like FasL. We questioned whether MSCs themselves may be the source of these death inducers, specifically whether MSCs produce ROS under cytokine challenge. On treating MSCs with FasL, we observed increased ROS production within 2 h, leading to apoptotic death after 6 h of exposure to the cytokine. N acetyl cysteine, an antioxidant, is able to protect MSCs from FasL induced ROS production and subsequent ROS dependent apoptosis, though the MSCs eventually succumb to ROS independent death signaling. Epidermal growth factor (EGF), a cell survival factor, is able to protect cells from FasL induced ROS production initially; however, the protective effect wanes with continued FasL exposure. In parallel, FasL induces upregulation of the uncoupling protein UCP2, the main uncoupling protein in MSCs, which is not abrogated by EGF; however, the production of ROS is followed by a delayed apoptotic cell death despite moderation by UCP2. FasL induced ROS activates the stress induced MAPK pathways JNK and p38MAPK as well as ERK, along with the activation of Bad, a proapoptotic protein, and suppression of survivin, an antiapoptotic protein; the latter two key modulators of the mitochondrial death pathway. FasL by itself also activates its canonical extrinsic death pathway noted by a time dependent degradation of c FLIP and activation of caspase 8. These data suggest that MSCs participate in their own demise due to nonspecific inflammation, holding implications for replacement therapies.
C1 [Rodrigues, Melanie; Wells, Alan] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA.
   [Turner, Omari] Meharry Med Coll, Nashville, TN 37208 USA.
   [Stolz, Donna] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA USA.
   [Griffith, Linda G.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Meharry Medical College; Pennsylvania Commonwealth System
   of Higher Education (PCSHE); University of Pittsburgh; Massachusetts
   Institute of Technology (MIT)
RP Wells, A (通讯作者)，S 713 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.
EM wellsa@upmc.edu
RI ; griffith, linda/GWC 8754 2022
OI Griffith, Linda/0000 0002 1801 5548; Wells, Alan/0000 0002 1637 8150;
   Rodrigues, Melanie/0000 0003 3708 9398; 
FU National Institute of General Medical Sciences; National Institute of
   Dental and Craniofacial Research [GM069668, DE019523]
FX We thank the members of the Wells and Griffith labs for comments and
   suggestions. We also thank Bennett van Houten for suggestions, Donald
   Taylor for statistical help, Kenichi Tamama for the NAC reagent, and
   Moore lab for survivin antibody Contract Grant Sponsor: National
   Institute of General Medical Sciences and National Institute of Dental
   and Craniofacial Research (GM069668, DE019523). The authors declare no
   conflicts of interest.
CR Affourtit C, 2011, FREE RADICAL BIO MED, V50, P609, DOI 10.1016/j.freeradbiomed.2010.12.020
   Aguirre A, 2010, BIOCHEM BIOPH RES CO, V400, P284, DOI 10.1016/j.bbrc.2010.08.073
   Altieri DC, 2010, BIOCHEM J, V430, P199, DOI 10.1042/BJ20100814
   Angoulvant D, 2011, J HEART LUNG TRANSPL, V30, P95, DOI 10.1016/j.healun.2010.08.023
   Ball WB, 2011, J IMMUNOL, V187, P1322, DOI 10.4049/jimmunol.1004237
   Banki K, 1999, J IMMUNOL, V162, P1466
   Beltrán B, 2002, P NATL ACAD SCI USA, V99, P8892, DOI 10.1073/pnas.092259799
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034
   Bugger H, 2011, CANCER CHEMOTH PHARM, V67, P1381, DOI 10.1007/s00280 010 1441 7
   Carmona Cuenca I, 2006, J CELL PHYSIOL, V207, P322, DOI 10.1002/jcp.20568
   Chen YL, 2003, J IMMUNOL, V171, P1183, DOI 10.4049/jimmunol.171.3.1183
   Chess PR, 2005, J APPL PHYSIOL, V99, P1226, DOI 10.1152/japplphysiol.01105.2004
   Cheung Eric C C, 2004, Sci STKE, V2004, pPE45
   Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022
   Cotgreave I A, 1997, Adv Pharmacol, V38, P205
   Crop MJ, 2011, CELL TRANSPLANT, V20, P1547, DOI 10.3727/096368910X564076
   Drowley L, 2010, MOL THER, V18, P1865, DOI 10.1038/mt.2010.160
   Echtay KS, 2007, REDOX REP, V12, P26, DOI 10.1179/135100007X162158
   Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a
   Fan VH, 2007, STEM CELLS, V25, P1241, DOI 10.1634/stemcells.2006 0320
   FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504
   Ghannam S, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt2
   Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612
   Götherström C, 2011, CYTOTHERAPY, V13, P269, DOI 10.3109/14653249.2010.523077
   Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092 8674(03)00314 3
   Gulbins E, 1996, IMMUNOLOGY, V89, P205, DOI 10.1046/j.1365 2567.1996.d01 743.x
   Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388
   Iyer AKV, 2008, J CELL PHYSIOL, V214, P504, DOI 10.1002/jcp.21232
   Iyer AKV, 2007, J CELL PHYSIOL, V211, P748, DOI 10.1002/jcp.20986
   Jin S, 2008, AM J PHYSIOL GASTR L, V294, pG928, DOI 10.1152/ajpgi.00219.2007
   Jung SN, 2009, EXP CELL RES, V315, P2433, DOI 10.1016/j.yexcr.2009.05.018
   Kefaloyianni E, 2006, CELL SIGNAL, V18, P2238, DOI 10.1016/j.cellsig.2006.05.004
   Minh KL, 2011, J SURG RES, V171, P742, DOI 10.1016/j.jss.2010.04.028
   Kim WK, 2010, J CELL BIOCHEM, V111, P1199, DOI 10.1002/jcb.22846
   Kolf CM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2116
   La Manna G, 2011, CELL TRANSPLANT, V20, P1193, DOI 10.3727/096368910X543394
   Lee YS, 2004, FREE RADICAL RES, V38, P405, DOI 10.1080/10715760410001665262
   Liu SP, 2010, CELL TRANSPLANT, V19, P1261, DOI 10.3727/096368910X507204
   Mantel C, 2010, CELL CYCLE, V9, P2008, DOI 10.4161/cc.9.10.11733
   Mazar J, 2009, J BIOL CHEM, V284, P22022, DOI 10.1074/jbc.M109.032235
   McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775
   Mias C, 2008, STEM CELLS, V26, P1749, DOI 10.1634/stemcells.2007 1000
   Monks TJ, 2006, DRUG METAB REV, V38, P755, DOI 10.1080/03602530600959649
   Mookerjee SA, 2010, MECH AGEING DEV, V131, P463, DOI 10.1016/j.mad.2010.03.010
   NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366
   Okamoto T, 2002, BIOCHEM BIOPH RES CO, V295, P354, DOI 10.1016/S0006 291X(02)00661 7
   Oshima H, 2005, MOL THER, V12, P1130, DOI 10.1016/j.ymthe.2005.07.686
   PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857
   Peterson KM, 2011, LIFE SCI, V88, P65, DOI 10.1016/j.lfs.2010.10.023
   Pi J, 2010, DIABETES OBES METAB, V12, P141, DOI 10.1111/j.1463 1326.2010.01269.x
   Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Poggi A, 2005, J IMMUNOL, V175, P6352, DOI 10.4049/jimmunol.175.10.6352
   Ponnusamy M, 2011, AM J PHYSIOL RENAL, V301, pF650, DOI 10.1152/ajprenal.00215.2011
   Rasmusson I, 2003, TRANSPLANTATION, V76, P1208, DOI 10.1097/01.TP.0000082540.43730.80
   Rodrigues M, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt32
   Sato T, 2004, J IMMUNOL, V173, P285, DOI 10.4049/jimmunol.173.1.285
   Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20 6 530
   Sémont A, 2010, CELL DEATH DIFFER, V17, P952, DOI 10.1038/cdd.2009.187
   Song H, 2010, STEM CELLS, V28, P555, DOI 10.1002/stem.302
   Spaggiari GM, 2006, BLOOD, V107, P1484, DOI 10.1182/blood 2005 07 2775
   Strasser A, 2009, IMMUNITY, V30, P180, DOI 10.1016/j.immuni.2009.01.001
   Suzuki Y, 1998, FEBS LETT, V425, P209, DOI 10.1016/S0014 5793(98)00228 2
   Tamama K, 2006, STEM CELLS, V24, P686, DOI 10.1634/stemcells.2005 0176
   Tamama K, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/795385
   Tate CC, 2010, CELL TRANSPLANT, V19, P973, DOI 10.3727/096368910X494885
   Toime LJ, 2010, FREE RADICAL BIO MED, V49, P606, DOI 10.1016/j.freeradbiomed.2010.05.010
   Urish KL, 2009, MOL BIOL CELL, V20, P509, DOI 10.1091/mbc.E08 03 0274
   Wei H, 2010, J CELL BIOCHEM, V111, P967, DOI 10.1002/jcb.22785
   Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001
   Yagi H, 2010, CELL TRANSPLANT, V19, P823, DOI 10.3727/096368910X508942
   Yang K, 2010, CARDIOVASC DIABETOL, V9, DOI 10.1186/1475 2840 9 66
   Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092 8674(00)81382 3
   Zhang AY, 2007, ANTIOXID REDOX SIGN, V9, P817, DOI 10.1089/ars.2007.1509
   Zhang AY, 2006, HYPERTENSION, V47, P74, DOI 10.1161/01.HYP.0000196727.53300.62
   Zhu WQ, 2006, STEM CELLS, V24, P416, DOI 10.1634/stemcells.2005 0121
NR 77
TC 44
Z9 53
U1 1
U2 16
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0963 6897
EI 1555 3892
J9 CELL TRANSPLANT
JI Cell Transplant.
PY 2012
VL 21
IS 10
BP 2171
EP 2187
DI 10.3727/096368912X639035
PG 17
WC Cell & Tissue Engineering; Medicine, Research & Experimental;
   Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine; Transplantation
GA 066NK
UT WOS:000313227300007
PM 22526333
OA Green Published, Green Accepted
DA 2025 08 17
ER

PT J
AU Mahl, C
   Egea, V
   Megens, RTA
   Pitsch, T
   Santovito, D
   Weber, C
   Ries, C
AF Mahl, Christian
   Egea, Virginia
   Megens, Remco T. A.
   Pitsch, Thomas
   Santovito, Donato
   Weber, Christian
   Ries, Christian
TI RECK (reversion inducing cysteine rich protein with Kazal motifs)
   regulates migration, differentiation and Wnt/β catenin signaling in
   human mesenchymal stem cells
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE RECK; hMSC; Chemotactic migration; Osteogenic differentiation; Canonical
   Wnt/beta catenin signaling
ID TISSUE INHIBITOR; STROMAL CELLS; BETA CATENIN; OSTEOBLAST
   DIFFERENTIATION; FUNCTIONAL INTERACTION; NEGATIVE REGULATOR; EXPRESSION;
   METALLOPROTEINASE; MATRIX METALLOPROTEINASE 9; TRANSCRIPTION
AB The membrane anchored glycoprotein RECK (reversion inducing cysteine rich protein with Kazal motifs) inhibits expression and activity of certain matrix metalloproteinases (MMPs), thereby suppressing tumor cell metastasis. However, RECK's role in physiological cell function is largely unknown. Human mesenchymal stem cells (hMSCs) are able to differentiate into various cell types and represent promising tools in multiple clinical applications including the regeneration of injured tissues by endogenous or transplanted hMSCs. RNA interference of RECK in hMSCs revealed that endogenous RECK suppresses the transcription and biosynthesis of tissue inhibitor of metalloproteinases (TIMP) 2 but does not influence the expression of MMP 2, MMP 9, membrane type (MT)1 MMP and TIMP 1 in these cells. Knockdown of RECK in hMSCs promoted monolayer regeneration and chemotactic migration of hMSCs, as demonstrated by scratch wound and chemotaxis assay analyses. Moreover, expression of endogenous RECK was upregulated upon osteogenic differentiation and diminished after adipogenic differentiation of hMSCs. RECK depletion in hMSCs reduced their capacity to differentiate into the osteogenic lineage whereas adipogenesis was increased, demonstrating that RECK functions as a master switch between both pathways. Furthermore, knockdown of RECK in hMSCs attenuated the Wnt/beta catenin signaling pathway as indicated by reduced stability and impaired transcriptional activity of beta catenin. The latter was determined by analysis of the beta catenin target genes Dickkopf1 (DKK1), axis inhibition protein 2 (AXIN2), runt related transcription factor 2 (RUNX2) and a luciferase based beta catenin activated reporter (BAR) assay. Our findings demonstrate that RECK is a regulator of hMSC functions suggesting that modulation of RECK may improve the development of hMSC based therapeutical approaches in regenerative medicine.
C1 [Mahl, Christian; Egea, Virginia; Megens, Remco T. A.; Pitsch, Thomas; Santovito, Donato; Weber, Christian; Ries, Christian] Univ Munich, Inst Cardiovasc Prevent, Pettenkoferstr 9b, D 80336 Munich, Germany.
   [Megens, Remco T. A.; Weber, Christian] Maastricht Univ, Cardiovasc Res Inst Maastricht, NL 6200 MD Maastricht, Netherlands.
   [Weber, Christian] German Ctr Cardiovasc Res, Partner Site Munich Heart Alliance, Munich, Germany.
C3 University of Munich; Maastricht University; Munich Heart Alliance;
   German Centre for Cardiovascular Research
RP Ries, C (通讯作者)，Univ Munich, Inst Cardiovasc Prevent, Pettenkoferstr 9b, D 80336 Munich, Germany.
EM christian.ries@med.uni muenchen.de
RI megens, remco/B 2615 2012; Weber, Christian/AAW 2153 2020; Santovito,
   Donato/I 2170 2019; Ries, Christian/A 9687 2012
OI Weber, Christian/0000 0003 4610 8714; Santovito,
   Donato/0000 0003 1811 4746; megens, remco/0000 0001 9871 6696; 
FU Institute of Cardiovascular Prevention, Ludwig Maximilians University of
   Munich; Deutsche Forschungsgemeinschaft [SFB 1123 A1, SFB 1123 Z1]
FX Microscopic analysis and data evaluation of the scratch assay were
   performed with kind help from Maximilian Saller. The BAR was established
   and kindly provided by Randall T. Moon (University of Washington, USA).
   This work was funded by grants from the Institute of Cardiovascular
   Prevention, Ludwig Maximilians University of Munich and was supported by
   Deutsche Forschungsgemeinschaft (SFB 1123 A1 and Z1).
CR Accorsi Mendonca T, 2008, J MOL HISTOL, V39, P201, DOI 10.1007/s10735 007 9152 z
   Alexander D, 2011, CELL BIOL INT, V35, P973, DOI 10.1042/CBI20100836
   Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596
   Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374
   Biechele TL, 2009, COLD SPRING HARB PRO, V2009
   Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871
   Chen YH, 2011, J BIOL CHEM, V286, P10671, DOI 10.1074/jbc.M110.199612
   Clark JCM, 2011, CANCER AM CANCER SOC, V117, P3517, DOI 10.1002/cncr.25757
   D'Alimonte I, 2013, STEM CELL REV REP, V9, P642, DOI 10.1007/s12015 013 9436 5
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Egea V, 2011, CELL DEATH DIFFER, V18, P853, DOI 10.1038/cdd.2010.154
   Egea V, 2012, P NATL ACAD SCI USA, V109, pE309, DOI 10.1073/pnas.1115083109
   Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465
   Fiorina P, 2009, J IMMUNOL, V183, P993, DOI 10.4049/jimmunol.0900803
   Gattu AK, 2013, FASEB J, V27, P4384, DOI 10.1096/fj.13 232900
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Guo HZ, 2014, MOL CELL BIOCHEM, V390, P155, DOI 10.1007/s11010 014 1966 x
   Heggebö J, 2014, ORTHOP REV, V6, P65, DOI 10.4081/or.2014.5242
   Ho IAW, 2014, FASEB J, V28, P4359, DOI 10.1096/fj.14 252551
   Hoelters J, 2005, J GENE MED, V7, P718, DOI 10.1002/jgm.731
   Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234
   Jacomasso T, 2014, MELANOMA RES, V24, P32, DOI 10.1097/CMR.0000000000000039
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kimura T, 2010, AM J PATHOL, V176, P2858, DOI 10.2353/ajpath.2010.091003
   Lee YM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084520
   LIPTON A, 1971, P NATL ACAD SCI USA, V68, P2799, DOI 10.1073/pnas.68.11.2799
   Mackenzie TC, 2001, BLOOD CELL MOL DIS, V27, P601, DOI 10.1006/bcmd.2001.0424
   Malinowski M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050709
   Mankani MH, 2006, STEM CELLS, V24, P2140, DOI 10.1634/stemcells.2005 0567
   Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097 2765(01)00224 6
   Martens TP, 2009, CELL TRANSPLANT, V18, P297, DOI 10.3727/096368909788534915
   Miki T, 2007, J BIOL CHEM, V282, P12341, DOI 10.1074/jbc.M610948200
   Miki T, 2010, MOL CANCER RES, V8, P665, DOI 10.1158/1541 7786.MCR 09 0351
   Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092 8674(00)80112 9
   Namwat N, 2011, J GASTROENTEROL, V46, P664, DOI 10.1007/s00535 010 0345 y
   Naumann K, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/283649
   Neth P, 2006, STEM CELLS, V24, P1892, DOI 10.1634/stemcells.2005 0503
   Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892
   Nolte A, 2013, NEW BIOTECHNOL, V30, P159, DOI 10.1016/j.nbt.2012.10.001
   Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092 8674(01)00597 9
   Oh J, 2006, ONCOGENE, V25, P4230, DOI 10.1038/sj.onc.1209444
   Oh J, 2004, CANCER RES, V64, P9062, DOI 10.1158/0008 5472.CAN 04 1981
   Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ponte AL, 2012, STEM CELLS DEV, V21, P3162, DOI 10.1089/scd.2012.0048
   Qiu WM, 2007, J BONE MINER RES, V22, P1720, DOI 10.1359/JBMR.070721
   Rayleigh, 1919, PHILOS MAG, V37, P321, DOI 10.1080/14786440408635894
   Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936
   Ries C, 2007, BIOCHEM J, V405, P547, DOI 10.1042/BJ20070191
   Ries C, 2007, BLOOD, V109, P4055, DOI 10.1182/blood 2006 10 051060
   Ringdén O, 2006, TRANSPLANTATION, V81, P1390, DOI 10.1097/01.tp.0000214462.63943.14
   Ryan JM, 2007, CLIN EXP IMMUNOL, V149, P353, DOI 10.1111/j.1365 2249.2007.03422.x
   Salazar KD, 2009, AM J PHYSIOL LUNG C, V297, pL1002, DOI 10.1152/ajplung.90347.2008
   Corrêa TCS, 2010, J CELL BIOCHEM, V110, P52, DOI 10.1002/jcb.22472
   Takagi S, 2009, CANCER RES, V69, P1502, DOI 10.1158/0008 5472.CAN 08 2635
   Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221
   Tanaka F, 2008, LIFE SCI, V83, P771, DOI 10.1016/j.lfs.2008.09.016
   Visigalli D, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 147
   Walsh LA, 2015, ONCOGENE, V34, P2189, DOI 10.1038/onc.2014.175
   Wu GD, 2003, TRANSPLANTATION, V75, P679, DOI 10.1097/01.TP.0000048488.35010.95
   Yoshida D, 2008, J NEURO ONCOL, V89, P141, DOI 10.1007/s11060 008 9606 5
   Yoshida Y, 2012, ONCOGENE, V31, P4128, DOI 10.1038/onc.2011.570
   Zambuzzi WF, 2009, MOL CELL BIOCHEM, V322, P143, DOI 10.1007/s11010 008 9951 x
   Zhao CP, 2007, CYTOTHERAPY, V9, P414, DOI 10.1080/14653240701376413
NR 66
TC 21
Z9 23
U1 0
U2 16
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420 682X
EI 1420 9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD APR
PY 2016
VL 73
IS 7
BP 1489
EP 1501
DI 10.1007/s00018 015 2054 4
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DH2GQ
UT WOS:000372602900013
PM 26459448
OA Green Published
DA 2025 08 17
ER

PT J
AU Zhang, X
   Yuan, Z
   Cui, S
AF Zhang, X.
   Yuan, Z.
   Cui, S.
TI Identifying candidate genes involved in osteoarthritis through
   bioinformatics analysis
SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
LA English
DT Article
DE osteoarthritis; differentially expressed genes; protein protein
   interaction; perturbation analysis; pathway cross talk
ID KNEE OSTEOARTHRITIS; EXPRESSION; CARTILAGE; ASSOCIATION; PROTEIN;
   IDENTIFICATION
AB Objective
   This study aims to identify candidate genes and critical pathways involved in osteoarthritis (OA).
   Methods
   Gene expression data of synovial membrane from OA patients and normal controls (NCs) were downloaded from database. Totally, 15 OA and 14 NC chips were available. Differentially expressed genes (DEGs) were identified through limma package (log, fold change >0.585, false discovery rate (FDR) < 0.05), and protein protein interaction (PPI) network was constructed using STRING. Moreover, perturbation and pathway enrichment analyses were performed through PerturbationAnalyzer in Cytoscape (iterative criteria <1xe( 10)) and clusterProfiler package (FDR <0.05), respectively.
   Results
   Totally, 236 up regulated and 290 down regulated DEGs were identified. In PPI network, 10 hub genes were found, including VEGFA, IL6, JUN, IL1B, ICAM1, ATF3, IL8, EGR1, CDKN1A, and JUNB. After perturbation analysis, 32 DEGs were passively and significantly changed, like PISD, RARRES3, EIF4G1, and EPHA3. Furthermore, 526 DEGs were enriched in 176 pathways, and pathway cross talk network was constructed, involving 12 pathways and 66 cross talks.
   Conclusion
   Pathways like rheumatoid arthritis, osteoclast differentiation, and cytokine cytokine receptor interaction might play critical roles in OA, and previously unreported genes VEGFA, JUN, JUNB, PISD, RARRES3, EIF4G1, and EPHA3 might participate in OA, providing novel directions for drug targeting.
C1 [Zhang, X.; Yuan, Z.; Cui, S.] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Microsurg, Luoyang 471000, Henan Province, Peoples R China.
C3 Henan University of Science & Technology
RP Zhang, X (通讯作者)，Henan Univ Sci & Technol, Affiliated Hosp 1, Microsurg Ward Sect, 24 Jinghua Rd, Luoyang 471000, Henan Province, Peoples R China.
EM zhangxinying01@163.com
RI Yuan, Zheng/ITT 0806 2023
CR Abramson SB, 2004, J RHEUMATOL, V31, P70, DOI 10.1097/BOR.0b013e328349c2b1
   [Anonymous], PREPROCESS CORE COLL
   [Anonymous], BIOSTATISTICS
   [Anonymous], 2009, ENCY DISTANCES, DOI DOI 10.1007/978 3 642 30958 8
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Cuadra VMB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097690
   Coggon D, 2001, INT J OBESITY, V25, P622, DOI 10.1038/sj.ijo.0801585
   Cooper C., 2013, Medicographia, V35, P145, DOI DOI 10.1007/978 1 910315 16 3_
   Enomoto H, 2003, AM J PATHOL, V162, P171, DOI 10.1016/S0002 9440(10)63808 4
   Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094
   Geurts J, 2014, OSTEOARTHR CARTILAGE, V22, pS127, DOI 10.1016/j.joca.2014.02.233
   Harden JJ, 2011, STATE POLIT POLICY Q, V11, P223, DOI 10.1177/1532440011406233
   Huber R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2485
   Iagnocco A, 2014, CLIN EXP RHEUMATOL, V32, pS48
   Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480
   Ivanavicius SP, 2007, PAIN, V128, P272, DOI 10.1016/j.pain.2006.12.022
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Kerkhof HJM, 2010, ARTHRITIS RHEUM US, V62, P499, DOI 10.1002/art.27184
   Lavigne P, 2004, BONE, V35, P463, DOI 10.1016/j.bone.2003.12.030
   Li F, 2010, BIOINFORMATICS, V26, P275, DOI 10.1093/bioinformatics/btp634
   Ma HL, 2007, OSTEOARTHR CARTILAGE, V15, P695, DOI 10.1016/j.joca.2006.11.005
   Martel Pelletier J., 2005, Arthritis and Allied Conditioned:A textbook of Rheumatology, P2199
   Pham L, 2011, P NATL ACAD SCI USA, V108, P13347, DOI 10.1073/pnas.1100891108
   Polur I, 2010, HISTOL HISTOPATHOL, V25, P599, DOI 10.14670/HH 25.599
   Sellam J, 2010, NAT REV RHEUMATOL, V6, P625, DOI 10.1038/nrrheum.2010.159
   Shabalin AA, 2008, BIOINFORMATICS, V24, P1154, DOI 10.1093/bioinformatics/btn083
   Smith AJP, 2004, GENES IMMUN, V5, P451, DOI 10.1038/sj.gene.6364107
   Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0 387 29362 0_23
   Snelling S, 2014, OSTEOARTHR CARTILAGE, V22, P334, DOI 10.1016/j.joca.2013.12.009
   Spector T. D., 2004, Osteoarthritis and Cartilage, V12, P39, DOI 10.1016/j.joca.2003.09.005
   Székely GJ, 2005, J CLASSIF, V22, P151, DOI 10.1007/s00357 005 0012 9
   Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520
   Tsai FM, 2007, CELL SIGNAL, V19, P989, DOI 10.1016/j.cellsig.2006.11.005
   Ungethuem U, 2010, PHYSIOL GENOMICS, V42A, P267, DOI 10.1152/physiolgenomics.00004.2010
   Valcamonica E, 2014, CLIN EXP RHEUMATOL, V32, P243
   Valverde Franco G, 2012, ARTHRITIS RHEUM US, V64, P3614, DOI 10.1002/art.34638
   Van Manen MD, 2012, J AM OSTEOPATH ASSOC, V112, P709
   Wang FL, 2000, OSTEOARTHR CARTILAGE, V8, P161, DOI 10.1053/joca.1999.0295
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang B, 2013, EUR REV MED PHARMACO, V17, P2097
NR 41
TC 12
Z9 12
U1 0
U2 11
PU CLINICAL & EXPER RHEUMATOLOGY
PI PISA
PA VIA SANTA MARIA 31, 56126 PISA, ITALY
SN 0392 856X
EI 1593 098X
J9 CLIN EXP RHEUMATOL
JI Clin. Exp. Rheumatol.
PD MAR APR
PY 2016
VL 34
IS 2
BP 282
EP 290
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA DL0ZB
UT WOS:000375360000017
PM 26968041
DA 2025 08 17
ER

PT J
AU Castano, D
   Comeau Gauthier, M
   Luna, JLRG
   Drager, J
   Harvey, E
   Merle, G
AF Castano, Daniel
   Comeau Gauthier, Marianne
   Luna, Jose Luis Ramirez Garcia
   Drager, Justin
   Harvey, Edward
   Merle, Geraldine
TI Noninvasive Localized Cold Therapy: A New Mode of Bone Repair
   Enhancement
SO TISSUE ENGINEERING PART A
LA English
DT Article
DE cold; bone regeneration; mouse model; angiogenesis; osteoclasts; hypoxia
ID ENDOTHELIAL GROWTH FACTOR; AUDITORY CANAL EXOSTOSES; PARANASAL SINUS
   EXOSTOSES; BLOOD FLOW; CRYOTHERAPY; VEGF; INJURY; WATER; ANGIOGENESIS;
   HYPOTHERMIA
AB A new bone healing strategy that is based on localized cold is reported. A murine bone healing model was used, in which a unicortical defect was surgically created bilaterally within the femurs. After daily immersion in an ice bath for 28 days, a large increase in bone regeneration within a femoral cortical defect compared with the nontreated limb was observed. Bone regeneration mechanism within the defect upon cold was studied at 1 and 4 weeks using micro computed tomography and immunohistochemical analysis and compared with the contralateral limb controls. The more advanced healing stage of the bone structure combined with the increased vascular channel density for the cold treated group matched with an increased expression of vascular endothelial growth factor (VEGF), and a greater number of CD34+ stained cells in the early phase of repair in the cold group. This indicates an elevation in tissue angiogenesis secondary to VEGF expression in the cold group potentially through a temporary vasoconstriction of the local vasculature leading to a temporary state of relative hypoxia. Local cold therapy may be an unrecognized tool with which to accelerate bone regeneration. The absence of observed systemic or local side effects and enhanced bone healing indicates further study is warranted to develop potential clinical protocols.
   Impact Statement A variety of biological, mechanical, and physical therapeutic modalities of varying complexity, efficacy, cost, and safety profile have been developed to enhance bone healing. There have been sporadic reports of spontaneous bone formation after repeated cold exposure. In this study we report for the first time, the anabolic effect of cold exposure on bone healing in vivo resulting in a doubling of bone volume. Although the precise mechanism is not fully understood, cold is well known to stimulate osteoclastogenesis and modulate inflammation. The impact of this finding is considerable for tissue regeneration because cold application is noninvasive, safe, and easily implemented.
C1 [Castano, Daniel; Drager, Justin; Harvey, Edward; Merle, Geraldine] McGill Univ, Montreal Gen Hosp, Div Orthoped Surg, Dept Surg, 1650 Cedar Ave,Room A7 118, Montreal, PQ H3G 1A4, Canada.
   [Comeau Gauthier, Marianne; Luna, Jose Luis Ramirez Garcia] McGill Univ, Expt Surg, Fac Med, Montreal, PQ, Canada.
   [Luna, Jose Luis Ramirez Garcia] McGill Univ, Montreal Gen Hosp, Bone Engn Labs, Res Inst,Hlth Ctr, Montreal, PQ, Canada.
C3 McGill University; McGill University; McGill University
RP Merle, G (通讯作者)，McGill Univ, Montreal Gen Hosp, Div Orthoped Surg, Dept Surg, 1650 Cedar Ave,Room A7 118, Montreal, PQ H3G 1A4, Canada.
EM geraldine.merle@mcgill.ca
RI Ramirez GarciaLuna, Jose/I 6798 2019
OI Ramirez GarciaLuna, Jose Luis/0000 0002 3953 9762
FU Orthopedic Trauma Association
FX The research was supported by the Orthopedic Trauma Association resident
   grant as co first authors. D.C. and M.C. G. contributed equally to this
   work as co first authors. E. Harvey and G. Merle contributed equally to
   this work.
CR ABRAMSON DI, 1966, J AMER MED ASSOC, V198, P1082
   Adelson RT, 2013, LARYNGOSCOPE, V123, P24, DOI 10.1002/lary.23616
   Adie S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007911.pub2
   Adie S, 2010, J ARTHROPLASTY, V25, P709, DOI 10.1016/j.arth.2009.07.010
   Aisha MD, 2014, EXP CELL RES, V326, P46, DOI 10.1016/j.yexcr.2014.06.003
   Aisha M.D., 2013, Bone (Abstracts), V1, P192
   Aisha M.D., 2013, Bone (Abstracts), V1, P193
   Aisha M.D., 2012, Regenerative Research, V1, P62
   Alexander V, 2015, EUR ARCH OTO RHINO L, V272, P1643, DOI 10.1007/s00405 014 2950 5
   Algafly AA, 2007, BRIT J SPORT MED, V41, P365, DOI 10.1136/bjsm.2006.031237
   [Anonymous], COCHRANE DATABASE SY
   Attlmayr B, 2015, J LARYNGOL OTOL, V129, P440, DOI 10.1017/S0022215115000316
   Azizi MH, 2011, INT J OCCUP ENV MED, V2, P20
   Behrends DA, 2017, CLIN ORTHOP RELAT R, V475, P906, DOI 10.1007/s11999 016 5159 7
   Behrends DA, 2014, EUR CELLS MATER, V28, P209, DOI 10.22203/eCM.v028a14
   Bleakley CM, 2006, BRIT J SPORT MED, V40, P700, DOI 10.1136/bjsm.2006.025932
   Bleakley CM, 2012, BRIT J SPORT MED, V46, P296, DOI 10.1136/bjsm.2011.086116
   Bleakley C, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008262.pub2
   Martimbianco ALC, 2014, PHYS THER SPORT, V15, P261, DOI 10.1016/j.ptsp.2014.02.008
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   Chiba S, 2001, J VET MED SCI, V63, P603, DOI 10.1292/jvms.63.603
   Dolan MG, 1997, J ATHL TRAINING, V32, P233
   Drager J, 2017, TISSUE ENG PT A, V23, P1372, DOI [10.1089/ten.tea.2016.0526, 10.1089/ten.TEA.2016.0526]
   Drager J, 2016, ACTA BIOMATER, V42, P411, DOI 10.1016/j.actbio.2016.07.037
   Drager J, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.4
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   Fenton JE, 1996, LARYNGOSCOPE, V106, P624, DOI 10.1097/00005537 199605000 00020
   Fowler EP, 1942, ARCHIV OTOLARYNGOL, V36, P455
   Froemming GRA, 2012, BONE, V50, pS73, DOI 10.1016/j.bone.2012.02.209
   Gao C, 2013, EUR CELLS MATER, V26, P195, DOI 10.22203/eCM.v026a14
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gibbons CER, 2001, INT ORTHOP, V25, P250, DOI 10.1007/s002640100227
   Guillot X, 2014, EXPERT REV CLIN IMMU, V10, P281, DOI 10.1586/1744666X.2014.870036
   Haffey T, 2012, LARYNGOSCOPE, V122, P1893, DOI 10.1002/lary.23384
   Haines J, 1967, Physiotherapy, V53, P222
   HARRISON D F, 1962, Ann R Coll Surg Engl, V31, P187
   Hasuike A, 2011, J HARD TISSUE BIOL, V20, P217, DOI 10.2485/jhtb.20.217
   HO SSW, 1994, AM J SPORT MED, V22, P537, DOI 10.1177/036354659402200417
   Hurst W, 2004, J LARYNGOL OTOL, V118, P348, DOI 10.1258/002221504323086525
   KENNEDY GE, 1986, AM J PHYS ANTHROPOL, V71, P401, DOI 10.1002/ajpa.1330710403
   Khoshnevis S, 2016, J BIOMECH ENG T ASME, V138, DOI 10.1115/1.4032126
   KIAER T, 1992, J ORTHOPAED RES, V10, P807, DOI 10.1002/jor.1100100609
   Kroon DF, 2002, OTOLARYNG HEAD NECK, V126, P499, DOI 10.1067/mhn.2002.124474
   Lee H, 2005, MED SCI SPORT EXER, V37, P1093, DOI 10.1249/01.mss.0000169611.21671.2e
   Lennon P, 2016, IRISH J MED SCI, V185, P183, DOI 10.1007/s11845 015 1265 x
   Linthicum FH, 2005, OTOL NEUROTOL, V26, P1243, DOI 10.1097/01.mao.0000194895.18474.6e
   Mac Auley DC, 2001, INT J SPORTS MED, V22, P379
   Merrick MA, 1999, MED SCI SPORT EXER, V31, P1516, DOI 10.1097/00005768 199911000 00004
   Nakagawa M, 2000, FEBS LETT, V473, P161, DOI 10.1016/S0014 5793(00)01520 9
   Nakanishi H, 2011, OTOLARYNG HEAD NECK, V145, P80, DOI 10.1177/0194599811402041
   Ni SH, 2015, KNEE SURG SPORT TR A, V23, P3354, DOI 10.1007/s00167 014 3135 x
   Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293
   OSTERMAN AL, 1984, J TRAUMA, V24, P811, DOI 10.1097/00005373 198409000 00006
   Patel JJ, 2012, EXP CELL RES, V318, P2237, DOI 10.1016/j.yexcr.2012.06.021
   Rabie ABM, 2002, AM J ORTHOD DENTOFAC, V122, P202, DOI 10.1067/mod.2002.125991
   Radkowski Christopher A, 2007, J Surg Orthop Adv, V16, P67
   Ramakrishnan JB, 2010, LARYNGOSCOPE, V120, P2532, DOI 10.1002/lary.21101
   Ramirez GarciaLuna JL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174396
   Raynor Mathew C, 2005, J Knee Surg, V18, P123
   SAPEGA AA, 1988, J BONE JOINT SURG AM, V70A, P1500, DOI 10.2106/00004623 198870100 00010
   Schaser KD, 2006, J TRAUMA, V61, P642, DOI 10.1097/01.ta.0000174922.08781.2f
   Schaser KD, 2007, AM J SPORT MED, V35, P93, DOI 10.1177/0363546506294569
   Schwartz K M, 2012, Open Neuroimag J, V6, P90, DOI 10.2174/1874440001206010090
   Serrat MA, 2008, P NATL ACAD SCI USA, V105, P19348, DOI 10.1073/pnas.0803319105
   Speer K P, 1996, J Shoulder Elbow Surg, V5, P62, DOI 10.1016/S1058 2746(96)80032 2
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Swenson C, 1996, SCAND J MED SCI SPOR, V6, P193, DOI 10.1111/j.1600 0838.1996.tb00090.x
   Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434
   Westermann S, 1999, SURGERY, V126, P881, DOI 10.1067/msy.2099.100474
   Wong BJF, 1999, ARCH OTOLARYNGOL, V125, P969, DOI 10.1001/archotol.125.9.969
   Wong RWK, 2005, BRIT J ORAL MAX SURG, V43, P46, DOI 10.1016/j.bjoms.2004.08.014
   Yang QL, 2008, MATRIX BIOL, V27, P589, DOI 10.1016/j.matbio.2008.06.005
   Zhang Q, 2008, J BIOL CHEM, V283, P13491, DOI 10.1074/jbc.M708055200
NR 73
TC 7
Z9 8
U1 0
U2 18
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD APR 1
PY 2019
VL 25
IS 7 8
BP 554
EP 562
DI 10.1089/ten.tea.2018.0191
EA OCT 2018
PG 9
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA HU3BE
UT WOS:000448936900001
PM 30187830
DA 2025 08 17
ER

PT J
AU Nakai, K
   Tobinai, M
   Hashimoto, J
   Iida, S
   Kawanishi, T
AF Nakai, Kiyohiko
   Tobinai, Masato
   Hashimoto, Junko
   Iida, Satofumi
   Kawanishi, Takehiko
TI The optimal oral dose selection of ibandronate in Japanese patients with
   osteoporosis based on pharmacokinetic and pharmacodynamic properties
SO EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
LA English
DT Article
DE Ibandronate; Japanese; Pharmacokinetics; Pharmacodynamics
ID BISPHOSPHONATES; RISEDRONATE; MODEL; BONE
AB Ibandronate is a drug widely used outside Japan for the treatment of osteoporosis. It is available in formulations for intermittent intravenous (i.v.) administration and for intermittent (once monthly) oral administration. Ibandronate was recently approved in Japan as an i.v. injection with a dosing regimen of 1.0 mg once a month. To establish the optimal dose for oral administration of ibandronate in Japanese osteoporotic patients, we investigated the pharmacokinetics of and pharmacodynamic response to ibandronate following oral and intravenous administrations to Japanese subjects. Ibandronate (20, 50, 100, or 150 mg) was given orally to healthy postmenopausal Japanese women and to Japanese patients with primary osteoporosis. Serial measurements were obtained for the concentrations of serum ibandronate and urinary cross linked C telopeptide of Type I collagen (uCTX). Pharmacokinetic parameters and the time profiles of creatinine corrected uCTX were compared with those obtained from postmenopausal Japanese women with osteopenia after administration of 1.0 mg i.v. ibandronate. Following oral administration of ibandronate, the area under the serum ibandronate concentration time curve (AUC(inf)) increased dose proportionally for doses up to 100 mg; at 150 mg, AUC(inf) increased beyond the dose proportionality seen with doses up to 100 mg. The AUC(inf) within the linear range following administration of 100 mg oral ibandronate was similar to that following 1.0 mg i.v. ibandronate. Additionally, corrected uCTX decreased after administration of 100 mg oral ibandronate and remained decreased for 1 month; the magnitude of the decrease was similar to or greater than that obtained after 1.0 mg i.v. ibandronate. From a clinical pharmacological perspective, administration of 100 mg/month oral ibandronate was equivalent to that of 1.0 mg/month i.v. ibandronate.
C1 [Nakai, Kiyohiko; Tobinai, Masato; Iida, Satofumi; Kawanishi, Takehiko] Chugai Pharmaceut Co Ltd, Clin Res Planning Dept, Chuo Ku, 2 1 1 Nihonbashi Muromachi, Tokyo 1038324, Japan.
   [Hashimoto, Junko] Chugai Pharmaceut Co Ltd, Primary Life Cycle Management Dept, Tokyo 1038324, Japan.
C3 Chugai Pharmaceutical Co., Ltd.; Roche Holding; Roche Holding Japan;
   Roche Holding; Roche Holding Japan; Chugai Pharmaceutical Co., Ltd.
RP Nakai, K (通讯作者)，Chugai Pharmaceut Co Ltd, Clin Res Planning Dept, Chuo Ku, 2 1 1 Nihonbashi Muromachi, Tokyo 1038324, Japan.
EM nakaikyh@chugai pharm.co.jp
RI Hashimoto, Jun/M 5480 2018
CR Barrett J, 2004, J CLIN PHARMACOL, V44, P951, DOI 10.1177/0091270004267594
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Endele R, 2005, J PHARMACEUT BIOMED, V39, P246, DOI 10.1016/j.jpba.2005.03.020
   Gieschke R, 2003, 30 EUR S CALC TISS E
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Nakamura T, 2007, J BONE MINER RES, V22, pS333
   Nakamura T, 2013, CALCIFIED TISSUE INT, V93, P137, DOI 10.1007/s00223 013 9734 6
   Ogura Y, 2004, J BONE MINER METAB, V22, P111, DOI 10.1007/s00774 003 0458 y
   Pillai G, 2006, INT J CLIN PHARM TH, V44, P655
   Pillai G, 2004, BRIT J CLIN PHARMACO, V58, P618, DOI 10.1111/j.1365 2125.2004.02224.x
   Reginster JY, 2006, CURR DRUG METAB, V7, P827, DOI 10.2174/138920006778520624
NR 11
TC 7
Z9 8
U1 0
U2 3
PU SPRINGER FRANCE
PI PARIS
PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE
SN 0378 7966
EI 2107 0180
J9 EUR J DRUG METAB PH
JI Eur. J. Drug Metabol. Pharmacokinet.
PD APR
PY 2016
VL 41
IS 2
BP 139
EP 147
DI 10.1007/s13318 014 0242 5
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DM3MU
UT WOS:000376251300005
PM 25476995
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Mikkelsen, UR
   Langberg, H
   Helmark, IC
   Skovgaard, D
   Andersen, LL
   Kjær, M
   Mackey, AL
AF Mikkelsen, U. R.
   Langberg, H.
   Helmark, I. C.
   Skovgaard, D.
   Andersen, L. L.
   Kjaer, M.
   Mackey, A. L.
TI Local NSAID infusion inhibits satellite cell proliferation in human
   skeletal muscle after eccentric exercise
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE muscle damage; myogenic precursor cells; Pax7; neural cell adhesion
   molecule; cyclooxygenase inhibitor; indomethacin
ID COX 2 PATHWAY; CONTRACTIONS; HYPERTROPHY; ACTIVATION; GROWTH;
   REGENERATION; DAMAGE; GENE; SORENESS; BIOPSIES
AB Mikkelsen UR, Langberg H, Helmark IC, Skovgaard D, Andersen LL, Kjaer M, Mackey AL. Local NSAID infusion inhibits satellite cell proliferation in human skeletal muscle after eccentric exercise. J Appl Physiol 107: 1600 1611, 2009. First published August 27, 2009; doi:10.1152/japplphysiol.00707.2009. Despite the widespread consumption of nonsteroidal anti inflammatory drugs (NSAIDs), the influence of these drugs on muscle satellite cells is not fully understood. The aim of the present study was to investigate the effect of a local NSAID infusion on satellite cells after unaccustomed eccentric exercise in vivo in human skeletal muscle. Eight young healthy males performed 200 maximal eccentric contractions with each leg. An NSAID was infused via a microdialysis catheter into the vastus lateralis muscle of one leg (NSAID leg) before, during, and for 4.5 h after exercise, with the other leg working as a control (unblocked leg). Muscle biopsies were collected before and 8 days after exercise. Changes in satellite cells and inflammatory cell numbers were investigated by immunohistochemistry. Satellite cells were identified using antibodies against neural cell adhesion molecule and Pax7. The number of Pax7(+) cells per myofiber was increased by 96% on day 8 after exercise in the unblocked leg (0.14 +/  0.04, mean +/  SE) compared with the prevalue (0.07 +/  0.02, P < 0.05), whereas the number of Pax7(+) cells was unchanged in the leg muscles exposed to the NSAID (0.07 +/  0.01). The number of inflammatory cells (CD68(+) or CD16(+) cells) was not significantly increased in either of the legs 8 days after exercise and was unaffected by the NSAID. The main finding in the present study was that the NSAID infusion for 7.5 h during the exercise day suppressed the exercise induced increase in the number of satellite cells 8 days after exercise. These results suggest that NSAIDs negatively affect satellite cell activity after unaccustomed eccentric exercise.
C1 [Mikkelsen, U. R.; Langberg, H.; Helmark, I. C.; Skovgaard, D.; Kjaer, M.; Mackey, A. L.] Bispebjerg Hosp, Inst Sports Med, DK 2400 Copenhagen, Denmark.
   [Mikkelsen, U. R.; Langberg, H.; Helmark, I. C.; Skovgaard, D.; Kjaer, M.; Mackey, A. L.] Univ Copenhagen, Fac Hlth Sci, Ctr Healthy Ageing, Copenhagen, Denmark.
   [Andersen, L. L.] Natl Res Ctr Working Environm, Copenhagen, Denmark.
C3 University of Copenhagen; Bispebjerg Hospital; Copenhagen University
   Hospital; University of Copenhagen; National Research Centre for the
   Working Environment
RP Mikkelsen, UR (通讯作者)，Bispebjerg Hosp, Inst Sports Med, Bispebjerg Bakke 23, DK 2400 Copenhagen, Denmark.
EM ullaramer@hotmail.com
RI Andersen, Lars/C 1198 2012; Kjaer, Michael/W 6842 2019; Mackey,
   Abigail/D 1060 2009
OI Langberg, Henning/0000 0001 8454 6534; Andersen, Lars
   L./0000 0003 2777 8085; Kjaer, Michael/0000 0002 4582 8755; Mackey,
   Abigail/0000 0002 2017 4580
FU H:S Research Foundation (Copenhagen University Hospitals); The Danish
   Rheumatism Association; Lundbeck Foundation
FX This work was supported by grants from the H:S Research Foundation
   (Copenhagen University Hospitals), The Danish Rheumatism Association,
   and the Lundbeck Foundation. The embryonic myosin antibody (F1.652)
   developed by H. M. Blau was obtained from the Developmental Studies
   Hybridoma Bank developed under the auspices of the National Institute of
   Child Health and Human Development and maintained by the Department of
   Biology of The University of Iowa (Iowa City, IA).
CR Alaranta A, 2008, SPORTS MED, V38, P449, DOI 10.2165/00007256 200838060 00002
   Andersen LL, 2005, J APPL PHYSIOL, V99, P87, DOI 10.1152/japplphysiol.00091.2005
   Anderson J, 2002, NITRIC OXIDE BIOL CH, V7, P36, DOI 10.1016/S1089 8603(02)00011 3
   Beaton LJ, 2002, J PHYSIOL LONDON, V544, P849, DOI 10.1113/jphysiol.2002.022350
   BERGSTROM J, 1975, SCAND J CLIN LAB INV, V35, P606
   Bondesen BA, 2006, AM J PHYSIOL CELL PH, V290, pC1651, DOI 10.1152/ajpcell.00518.2005
   Bondesen BA, 2004, AM J PHYSIOL CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004
   Boushel R, 2002, J PHYSIOL LONDON, V543, P691, DOI 10.1113/jphysiol.2002.021477
   CARLSON BM, 1983, MED SCI SPORT EXER, V15, P187
   Child R, 1999, CLIN SCI, V96, P105, DOI 10.1042/CS19980146
   Crameri RM, 2007, J PHYSIOL LONDON, V583, P365, DOI 10.1113/jphysiol.2007.128827
   Crameri RM, 2004, J PHYSIOL LONDON, V558, P333, DOI 10.1113/jphysiol.2004.061846
   *DAN RHEUM ASS, GIGTF
   Dreyer HC, 2006, MUSCLE NERVE, V33, P242, DOI 10.1002/mus.20461
   Hill M, 2003, J PHYSIOL LONDON, V549, P409, DOI 10.1113/jphysiol.2002.035832
   Hill M, 2003, J ANAT, V203, P89, DOI 10.1046/j.1469 7580.2003.00195.x
   Horsley V, 2003, J CELL BIOL, V161, P111, DOI 10.1083/jcb.200208085
   Hubal MJ, 2008, AM J PHYSIOL REG I, V294, pR1628, DOI 10.1152/ajpregu.00853.2007
   Krentz JR, 2008, APPL PHYSIOL NUTR ME, V33, P470, DOI 10.1139/H08 019
   Lanier AB, 2003, SPORTS MED, V33, P177
   Li YP, 2003, AM J PHYSIOL CELL PH, V285, pC370, DOI 10.1152/ajpcell.00453.2002
   Lindström M, 2009, HISTOCHEM CELL BIOL, V132, P141, DOI 10.1007/s00418 009 0606 0
   Mackey AL, 2007, J APPL PHYSIOL, V103, P425, DOI 10.1152/japplphysiol.00157.2007
   Mackey AL, 2009, MUSCLE NERVE, V40, P455, DOI 10.1002/mus.21369
   Mackey AL, 2004, J APPL PHYSIOL, V97, P197, DOI 10.1152/japplphysiol.01174.2003
   Mendias CL, 2004, MUSCLE NERVE, V30, P497, DOI 10.1002/mus.20102
   Mikkelsen UR, 2008, J APPL PHYSIOL, V104, P534, DOI 10.1152/japplphysiol.01016.2007
   Novak ML, 2009, AM J PHYSIOL REG I, V296, pR1132, DOI 10.1152/ajpregu.90874.2008
   O'Reilly C, 2008, MUSCLE NERVE, V38, P1434, DOI 10.1002/mus.21146
   Otis JS, 2005, EXP CELL RES, V310, P417, DOI 10.1016/j.yexcr.2005.08.009
   PAULSEN G, SCAND J MED IN PRESS
   PAULSEN G, MED SCI SPO IN PRESS
   Przybyla B, 2006, EXP GERONTOL, V41, P320, DOI 10.1016/j.exger.2005.12.007
   Reimann J, 2004, CELL TISSUE RES, V315, P233, DOI 10.1007/s00441 003 0833 y
   Serrano AL, 2008, CELL METAB, V7, P33, DOI 10.1016/j.cmet.2007.11.011
   Shen W, 2005, AM J PATHOL, V167, P1105, DOI 10.1016/S0002 9440(10)61199 6
   Shen W, 2006, J APPL PHYSIOL, V101, P1215, DOI 10.1152/japplphysiol.01331.2005
   Soltow QA, 2006, MED SCI SPORT EXER, V38, P840, DOI 10.1249/01.mss.0000218142.98704.66
   Trappe RA, 2002, AM J PHYSIOL ENDOC M, V282, pE551, DOI 10.1152/ajpendo.00352.2001
   Tscholl P, 2009, AM J SPORT MED, V37, P260, DOI 10.1177/0363546508324307
   Warner DC, 2002, J ADOLESCENT HEALTH, V30, P150, DOI 10.1016/S1054 139X(01)00325 1
   Wozniak AC, 2005, MUSCLE NERVE, V31, P283, DOI 10.1002/mus.20263
   Yu JG, 2002, HISTOCHEM CELL BIOL, V118, P29, DOI 10.1007/s00418 002 0423 1
   Yu JG, 2003, HISTOCHEM CELL BIOL, V119, P383, DOI 10.1007/s00418 003 0522 7
   Yu JG, 2002, HISTOCHEM CELL BIOL, V118, P171, DOI 10.1007/s00418 002 0427 x
NR 45
TC 145
Z9 164
U1 2
U2 33
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750 7587
EI 1522 1601
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD NOV
PY 2009
VL 107
IS 5
BP 1600
EP 1611
DI 10.1152/japplphysiol.00707.2009
PG 12
WC Physiology; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology; Sport Sciences
GA 515KO
UT WOS:000271468900030
PM 19713429
OA Green Published
DA 2025 08 17
ER

PT J
AU He, BC
   Gao, JL
   Zhang, BQ
   Luo, Q
   Shi, QO
   Kim, SH
   Huang, EY
   Gao, YH
   Yang, K
   Wagner, ER
   Wang, LY
   Tang, N
   Luo, JY
   Liu, X
   Li, M
   Bi, Y
   Shen, JK
   Luther, G
   Hu, N
   Zhou, QX
   Luu, HH
   Haydon, RC
   Zhao, YM
   He, TC
AF He, Bai Cheng
   Gao, Jian Li
   Zhang, Bing Qiang
   Luo, Qing
   Shi, Qiong
   Kim, Stephanie H.
   Huang, Enyi
   Gao, Yanhong
   Yang, Ke
   Wagner, Eric R.
   Wang, Linyuan
   Tang, Ni
   Luo, Jinyong
   Liu, Xing
   Li, Mi
   Bi, Yang
   Shen, Jikun
   Luther, Gaurav
   Hu, Ning
   Zhou, Qixin
   Luu, Hue H.
   Haydon, Rex C.
   Zhao, Yingming
   He, Tong Chuan
TI Tetrandrine Inhibits Wnt/β Catenin Signaling and Suppresses Tumor Growth
   of Human Colorectal Cancer
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID MESENCHYMAL STEM CELLS; LUNG CARCINOMA CELLS; HUMAN OSTEOSARCOMA;
   NATURAL PRODUCTS; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC
   DIFFERENTIATION; G(1) ARREST; APOPTOSIS; WNT; CYTOTOXICITY
AB As one of the most common malignancies, colon cancer is initiated by abnormal activation of the Wnt/beta catenin pathway. Although the treatment options have increased for some patients, overall progress has been modest. Thus, there is a great need to develop new treatments. We have found that bisbenzylisoquinoline alkaloid tetrandrine (TET) exhibits anticancer activity. TET is used as a calcium channel blocker to treat hypertensive and arrhythmic conditions in Chinese medicine. Here, we investigate the molecular basis underlying TET's anticancer activity. We compare TET with six chemotherapy drugs in eight cancer lines and find that TET exhibits comparable anticancer activities with camptothecin, vincristine, paclitaxel, and doxorubicin, and better than that of 5 fluorouracil (5 FU) and carboplatin. TET IC50 is <5 mu M in most of the tested cancer lines. TET exhibits synergistic anticancer activity with 5 FU and reduces migration and invasion capabilities of HCT116 cells. Furthermore, TET induces apoptosis and inhibits xenograft tumor growth of colon cancer. TET treatment leads to a decrease in beta catenin protein level in xenograft tumors, which is confirmed by T cell factor/lymphocyte enhancer factor and c Myc reporter assays. It is noteworthy that HCT116 cells with allelic oncogenic beta catenin deleted are less sensitive to TET mediated inhibition of proliferation, viability, and xenograft tumor growth. Thus, our findings strongly suggest that the anticancer effect of TET in colon cancer may be at least in part mediated by targeting beta catenin activity. Therefore, TET may be used alone or in combination as an effective anticancer agent.
C1 [He, Bai Cheng; Gao, Jian Li; Zhang, Bing Qiang; Shi, Qiong; Kim, Stephanie H.; Huang, Enyi; Yang, Ke; Wagner, Eric R.; Wang, Linyuan; Tang, Ni; Luo, Jinyong; Liu, Xing; Li, Mi; Bi, Yang; Shen, Jikun; Luther, Gaurav; Hu, Ning; Luu, Hue H.; Haydon, Rex C.; He, Tong Chuan] Univ Chicago, Med Ctr, Mol Oncol Lab, Dept Surg, Chicago, IL 60637 USA.
   [He, Bai Cheng; Gao, Jian Li; Zhang, Bing Qiang; Shi, Qiong; Tang, Ni; Luo, Jinyong; Liu, Xing; Li, Mi; Bi, Yang; Hu, Ning; Zhou, Qixin; He, Tong Chuan] Chongqing Med Univ, Dept Pharmacol, Chongqing, Peoples R China.
   [He, Bai Cheng; Gao, Jian Li; Zhang, Bing Qiang; Shi, Qiong; Tang, Ni; Luo, Jinyong; Liu, Xing; Li, Mi; Bi, Yang; Hu, Ning; Zhou, Qixin; He, Tong Chuan] Chongqing Med Univ, Key Lab Diagnost Med Chinese Minist Educ, Chongqing, Peoples R China.
   [Luo, Qing; Liu, Xing; Li, Mi; Bi, Yang; He, Tong Chuan] Med Univ, Childrens Hosp Chongqing, Stem Cell Biol & Therapy Lab, Chongqing, Peoples R China.
   [Huang, Enyi] Chongqing Univ, Sch Bioengn, Chongqing 630044, Peoples R China.
   [Gao, Yanhong] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Geriatr, Shanghai 200030, Peoples R China.
   [Yang, Ke] Third Mil Med Univ, Dept Cell Biol, Chongqing, Peoples R China.
   [Zhao, Yingming] Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA.
C3 University of Chicago; University of Chicago Medical Center; Chongqing
   Medical University; Chongqing Medical University; Chongqing University;
   Shanghai Jiao Tong University; Army Medical University; University of
   Chicago
RP He, TC (通讯作者)，Univ Chicago, Med Ctr, Mol Oncol Lab, Dept Surg, 5841 S Maryland Ave,MC3079, Chicago, IL 60637 USA.
EM tche@surgery.bsd.uchicago.edu
RI ; GAO, JianLi/J 4997 2017; Tang, Ni/Z 5133 2019; Yang, Ya/A 7219 2016;
   GAO, Jian Li/J 4997 2017
OI Wagner, Eric/0000 0001 9241 5702; GAO, JianLi/0000 0002 5977 0021; 
FU National Cancer Institute [CA106569]; National Institute of Arthritis
   and Musculoskeletal and Skin Diseases [AR50142, AR054381]; National
   Institutes of Health National Center for Complementary and Alternative
   Medicine [AT004418]; National Basic Research Program of China
   [2011CB70790]
FX This work was supported in part by the National Cancer Institute [Grant
   CA106569]; the f National Institute of Arthritis and Musculoskeletal and
   Skin Diseases [Grants AR50142, AR054381]; the National Institutes of
   Health National Center for Complementary and Alternative Medicine [Grant
   AT004418]; and the National Basic Research Program of China [Grant
   2011CB70790].
CR Aggarwal S, 2005, ONCOLOGY NY, V19, P589
   Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999
   Chen XL, 2008, CANCER BIOL THER, V7, P1073
   Chen Y, 2009, INT J CANCER, V124, P2260, DOI 10.1002/ijc.24208
   Cho HS, 2009, J VET SCI, V10, P23, DOI 10.4142/jvs.2009.10.1.23
   Cragg GM, 2009, CHEM REV, V109, P3012, DOI 10.1021/cr900019j
   Haydon RC, 2002, INT J CANCER, V102, P338, DOI 10.1002/ijc.10719
   Haydon RC, 2002, CLIN CANCER RES, V8, P1288
   He BC, 2010, CLIN CANCER RES, V16, P2235, DOI 10.1158/1078 0432.CCR 09 2499
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518
   KING VF, 1988, J BIOL CHEM, V263, P2238
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092 8674(00)81333 1
   Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038/nrd1657
   Lee JH, 2002, INT J ONCOL, V21, P1239
   Li XL, 2010, EUR J PHARM BIOPHARM, V75, P334, DOI 10.1016/j.ejpb.2010.04.016
   Liu BR, 2008, CANCER LETT, V268, P166, DOI 10.1016/j.canlet.2008.03.059
   Luo JY, 2007, LAB INVEST, V87, P97, DOI 10.1038/labinvest.3700509
   Luo JY, 2010, J BIOL CHEM, V285, P29588, DOI 10.1074/jbc.M110.130518
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luo XJ, 2008, CLIN ORTHOP RELAT R, V466, P2060, DOI 10.1007/s11999 008 0361 x
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Luu HH, 2005, CANCER LETT, V229, P135, DOI 10.1016/j.canlet.2005.02.015
   Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585 005 0365 9
   Mann J, 2002, NAT REV CANCER, V2, P143, DOI 10.1038/nrc723
   Meng LH, 2004, CANCER RES, V64, P9086, DOI 10.1158/0008 5472.CAN 04 0313
   Ng LT, 2006, AM J CHINESE MED, V34, P125, DOI 10.1142/S0192415X06003692
   Nomura M, 2007, ANTICANCER RES, V27, P3187
   Oh SH, 2003, BIOCHEM PHARMACOL, V66, P725, DOI 10.1016/S0006 2952(03)00397 6
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Su YX, 2009, CLIN EXP METASTAS, V26, P599, DOI 10.1007/s10585 009 9259 6
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Wang G, 2004, TRENDS PHARMACOL SCI, V25, P120, DOI 10.1016/j.tips.2004.01.009
   Wu JM, 2010, CANCER LETT, V287, P187, DOI 10.1016/j.canlet.2009.06.009
   Xu WL, 2006, LEUKEMIA RES, V30, P407, DOI 10.1016/j.leukres.2005.08.005
   Zhou L, 2003, CANCER LETT, V193, P161, DOI 10.1016/S0304 3835(03)00013 2
   Zhou L, 2002, BIOTECHNIQUES, V33, P1126, DOI 10.2144/02335dd07
NR 38
TC 141
Z9 155
U1 1
U2 32
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3995 USA
SN 0026 895X
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD FEB
PY 2011
VL 79
IS 2
BP 211
EP 219
DI 10.1124/mol.110.068668
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 707TT
UT WOS:000286311800001
PM 20978119
OA Green Published
DA 2025 08 17
ER

PT J
AU Qi, L
   Pan, CC
   Yan, JG
   Ge, WW
   Wang, J
   Liu, L
   Zhang, L
   Lin, D
   Shen, SGF
AF Qi, Lei
   Pan, Cancan
   Yan, Jinge
   Ge, Weiwen
   Wang, Jing
   Liu, Lu
   Zhang, Lei
   Lin, Dan
   Shen, Steve G. F.
TI Mesoporous bioactive glass scaffolds for the delivery of bone marrow
   stem cell derived osteoinductive extracellular vesicles lncRNA promote
   senescent bone defect repair by targeting the miR 1843a 5p/Mob3a/YAP
   axis
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Senescent bone regeneration; Mesoporous bioactive glass (MBG);
   Extracellular vesicles (EVs); Long non  coding RNA (lncRNA); Competing
   endogenous RNA (ceRNA)
ID OSTEOGENIC DIFFERENTIATION; EXOSOMES; CATENIN; YAP; REGENERATION;
   OSTEOCLASTS; HOMEOSTASIS; MODULATION; MICRORNAS; INCREASES
AB Bone repair in elderly patients poses a huge challenge due to the age  related progressive decline in regenerative abilities attributed to the senescence of bone marrow stem cells (BMSCs). Bioactive scaffolds have been applied in bone regeneration due to their various biological functions. In this study, we aimed to fabricate functionalized bioactive scaffolds through loading osteoinductive extracellular vesicles (OIEVs) based on mesoporous bioactive glass (MBG) scaffolds (10 10 particles/scaffold) and to investigate its effects on osteogenesis and senescence of BMSCs . The results suggested that OI EVs upregulate the proliferative and osteogenic capacities of senescent BMSCs. More importantly, The results showed that loading OI EVs into MBG scaffolds achieved better bone regeneration. Furthermore, OI EVs and BMSCs RNAs bioinformatics analysis indicated that OI EVs play roles through transporting pivotal lncRNA acting as a "sponge" to compete with Mob3a for miR 1843a 5p to promote YAP dephosphorylation and nuclear translocation, ultimately resulting in elevated proliferation and osteogenic differentiation and reduced senescence  related phenotypes. Collectively, these results suggested that the OI EVs lncRNA ceRNA regulatory networks might be the key point for senescent osteogenesis. More importantly, the study indicated the feasibility of loading OI EVs into scaffolds and provided novel insights into biomaterial design for facilitating bone regeneration in the treatment of senescent bone defects. Statement of significance Constructing OI EVs/MBG delivering system and verification of its bone regeneration enhancement in senescent defect repair. Aging bone repair poses a huge challenge due to the age  related progressive degenerative decline in regenerative abilities attributed to the senescence of BMSCs. OI EVs/MBG delivering system were expected as promising treatment for senescent bone repair, which could provide an effective strategy for bone regeneration in elderly patients. Clarification of potential OI EVs lncRNA ceRNA regulatory mechanism in senescent bone regeneration OI EVs play important roles through transferring lncRNA ENSRNOG0 0 0 0 0 056625 sponging miR1843a 5p that targeted Mob3a to activate YAP translocation into nucleus, ultimately alleviate senescence, promote proliferation and osteogenic differentiation in O BMSCs, which provides theoretical basis for EVsmediated therapy in future clinical works. (c) 2024 Published by Elsevier Ltd on behalf of Acta Materialia Inc.
C1 [Qi, Lei; Pan, Cancan; Yan, Jinge; Ge, Weiwen; Wang, Jing; Liu, Lu; Zhang, Lei; Shen, Steve G. F.] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Oral & Craniomaxillofacial Surg, Sch Med,Shanghai Key Lab Stomatol,Coll Stomatol,Sc, Shanghai 200011, Peoples R China.
   [Qi, Lei; Pan, Cancan; Yan, Jinge; Ge, Weiwen; Wang, Jing; Liu, Lu; Zhang, Lei; Shen, Steve G. F.] Shanghai Res Inst Stomatol, Shanghai 200011, Peoples R China.
   [Lin, Dan] Shanghai Univ Med & Hlth Sci, Shanghai 201318, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai University of Medicine & Health
   Sciences
RP Zhang, L; Shen, SGF (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Oral & Craniomaxillofacial Surg, Sch Med,Shanghai Key Lab Stomatol,Coll Stomatol,Sc, Shanghai 200011, Peoples R China.; Zhang, L; Shen, SGF (通讯作者)，Shanghai Res Inst Stomatol, Shanghai 200011, Peoples R China.; Lin, D (通讯作者)，Shanghai Univ Med & Hlth Sci, Shanghai 201318, Peoples R China.
EM ZHANGL1156@sh9hospital.org.cn; lind@sumhs.edu.cn; shengf1428@sjtu.edu.cn
RI Lin, Dan/GQY 4693 2022
FU National Natural Science Foundation of China [81970973, 32201104];
   Science and Technology Commission of Shanghai Municipality
   [22010502600]; Shanghai Science and Technology Commission Experimental
   Animal Research [21140900102]; Natural Science Foundation of Shanghai
   [20ZR1432200]; Disciplinary Characteristic Biobank Project of Ninth
   People's Hospital affiliated to Shanghai Jiao Tong University School of
   Medicine [YBKB202110]; Young Talents Program of the Orthodontics
   Committee of Chinese Stomatological Association;  [COS B2021 04]
FX The authors gratefully acknowledge the support of the National Natural
   Science Foundation of China (No. 81970973 , No. 32201104) , and the
   Science and Technology Commission of Shanghai Municipality (No.
   22010502600) , Shanghai Science and Technology Commission Experimental
   Animal Research (No. 21140900102) , Natural Science Foundation of
   Shanghai (No. 20ZR1432200) , Disciplinary Characteristic Biobank Project
   of Ninth People's Hospital affiliated to Shanghai Jiao Tong University
   School of Medicine (No. YBKB202110) , Young Talents Program of the
   Orthodontics Committee of Chinese Stomatological Association
   (COS B2021 04) .
CR Abdelmagid SM, 2015, LIFE SCI, V123, P25, DOI 10.1016/j.lfs.2014.11.011
   Ambrosi TH, 2021, NATURE, V597, P256, DOI 10.1038/s41586 021 03795 7
   Arnett TR, 1996, BONE, V18, P277, DOI 10.1016/8756 3282(95)00486 6
   Avnet S, 2019, CANCER METAST REV, V38, P133, DOI 10.1007/s10555 019 09790 9
   Baino F, 2016, ACTA BIOMATER, V42, P18, DOI 10.1016/j.actbio.2016.06.033
   Baker N, 2015, BONE, V70, P37, DOI 10.1016/j.bone.2014.10.014
   Beck J, 2020, VET PATHOL, V57, P747, DOI 10.1177/0300985820943841
   Behera J, 2021, THERANOSTICS, V11, P7715, DOI 10.7150/thno.58410
   Biskobing DM, 2000, CALCIFIED TISSUE INT, V67, P178, DOI 10.1007/s00223001107
   Dey A, 2020, NAT REV DRUG DISCOV, V19, P480, DOI 10.1038/s41573 020 0070 z
   dos Santos JAC, 2022, LIFE SCI, V304, DOI 10.1016/j.lfs.2022.120723
   Dutchak K, 2022, MOL CANCER RES, V20, P770, DOI 10.1158/1541 7786.MCR 21 0767
   El Kebir D, 2017, J LEUKOCYTE BIOL, V102, P1388, DOI 10.1189/jlb.3A0117 041R
   El Fiqi A, 2021, COLLOID SURFACE B, V206, DOI 10.1016/j.colsurfb.2021.111932
   Farr JN, 2019, BONE, V121, P121, DOI 10.1016/j.bone.2019.01.015
   Fu DP, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 020 02075 x
   Galipeau J, 2018, CELL STEM CELL, V22, P824, DOI 10.1016/j.stem.2018.05.004
   Ganguly P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222212225
   Ghafouri Fard S, 2021, BIOMED PHARMACOTHER, V143, DOI 10.1016/j.biopha.2021.112132
   Hartl FU, 2016, ANNU REV BIOCHEM, V85, P1, DOI 10.1146/annurev biochem 011116 110806
   Henriksen K, 2007, OSTEOPOROSIS INT, V18, P751, DOI 10.1007/s00198 006 0298 4
   Hensley AP, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115760
   Herman AB, 2022, MOL CELL, V82, P2252, DOI 10.1016/j.molcel.2022.05.027
   Isaac R, 2021, CELL METAB, V33, P1744, DOI 10.1016/j.cmet.2021.08.006
   Jia YC, 2020, CALCIFIED TISSUE INT, V106, P509, DOI 10.1007/s00223 019 00656 4
   Jin SS, 2023, ADV MATER, V35, DOI 10.1002/adma.202211602
   Jurk D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5172
   Kang Y, 2022, BIOACT MATER, V18, P26, DOI 10.1016/j.bioactmat.2022.02.012
   Khazaei F, 2023, TISSUE CELL, V80, DOI 10.1016/j.tice.2022.102007
   Kulkarni R, 2018, STEM CELLS, V36, P420, DOI 10.1002/stem.2756
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   Li B, 2017, ORTHOP SURG, V9, P319, DOI 10.1111/os.12321
   Li GC, 2021, ADV SCI, V8, DOI 10.1002/advs.202100964
   Li JF, 2022, BIOACT MATER, V15, P53, DOI 10.1016/j.bioactmat.2021.11.034
   Li L, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 020 02160 0
   Li XX, 2022, J TISSUE ENG REGEN M, V16, P311, DOI 10.1002/term.3279
   Liang WC, 2016, SCI REP UK, V6, DOI 10.1038/srep20121
   Limyati Y, 2022, CURR CARDIOL REV, V18, P24, DOI 10.2174/1573403X18666220404152924
   Lin H, 2019, BIOMATERIALS, V203, P96, DOI 10.1016/j.biomaterials.2018.06.026
   Liu AQ, 2021, BIOMATERIALS, V272, DOI 10.1016/j.biomaterials.2021.120718
   Liu WL, 2019, ACS APPL MATER INTER, V11, P9557, DOI 10.1021/acsami.8b20580
   Mori MA, 2019, CELL METAB, V30, P656, DOI 10.1016/j.cmet.2019.07.011
   Moses JC, 2022, ACS APPL MATER INTER, V14, P14961, DOI 10.1021/acsami.2c00093
   Moya IM, 2019, NAT REV MOL CELL BIO, V20, P211, DOI 10.1038/s41580 018 0086 y
   Ouyang ZX, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2689 4
   Pan JX, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0018 7
   Patel DB, 2017, BIOENG TRANSL MED, V2, P170, DOI 10.1002/btm2.10065
   Prattichizzo F, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1656044
   Qi L, 2020, ARTIF CELL NANOMED B, V48, P920, DOI 10.1080/21691401.2020.1773482
   Qi XL, 2015, J MED GENET, V52, P710, DOI 10.1136/jmedgenet 2015 103334
   Rayess H, 2012, INT J CANCER, V130, P1715, DOI 10.1002/ijc.27316
   Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640
   Saeed H, 2014, PAK J PHARM SCI, V27, P321
   Sakata T, 2018, ANAL CHEM, V90, P12731, DOI 10.1021/acs.analchem.8b03070
   Salètes M, 2021, BIOMIMETICS BASEL, V6, DOI 10.3390/biomimetics6010009
   Saul D, 2022, ENDOCR REV, V43, P984, DOI 10.1210/endrev/bnac008
   Schumacher M, 2021, BIOACT MATER, V6, P1921, DOI 10.1016/j.bioactmat.2020.12.007
   Si YJ, 2017, INT J CLIN EXP PATHO, V10, P7767
   Sladitschek Martens HL, 2022, NATURE, V607, P790, DOI 10.1038/s41586 022 04924 6
   Statello L, 2021, NAT REV MOL CELL BIO, V22, P96, DOI 10.1038/s41580 020 00315 9
   Su T, 2019, ACS NANO, V13, P2450, DOI 10.1021/acsnano.8b09375
   Tang SA, 2019, STEM CELLS, V37, P270, DOI 10.1002/stem.2937
   Théry C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855
   Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043
   Torres IM, 2017, AM J PHYSIOL LUNG C, V313, pL126, DOI 10.1152/ajplung.00524.2016
   Tull Frank, 2003, J Am Acad Orthop Surg, V11, P431
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Vita F, 2022, MEDICINA LITHUANIA, V58, DOI 10.3390/medicina58060767
   Wang J, 2018, NAT REV CARDIOL, V15, P672, DOI 10.1038/s41569 018 0063 3
   Wang W, 2019, INT J BIOL SCI, V15, P2156, DOI 10.7150/ijbs.35670
   Wang XB, 2018, J CELL BIOCHEM, V119, P4990, DOI 10.1002/jcb.26738
   Wei F, 2019, ACTA BIOMATER, V86, P480, DOI 10.1016/j.actbio.2019.01.006
   Wei Y, 2018, ADV EXP MED BIOL, V1086, P189, DOI 10.1007/978 981 13 1117 8_12
   Widjaja G, 2022, INT IMMUNOPHARMACOL, V105, DOI 10.1016/j.intimp.2022.108537
   Workie AB, 2022, RSC ADV, V12, P1592, DOI 10.1039/d1ra06113e
   Wu M, 2020, BIOMACROMOLECULES, V21, P2409, DOI 10.1021/acs.biomac.0c00347
   Wu QJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00224 x
   Xu D, 2013, ADV DRUG DELIVER REV, V65, P368, DOI 10.1016/j.addr.2012.07.010
   Xu RY, 2018, AGING CELL, V17, DOI 10.1111/acel.12794
   Xu RY, 2016, EXP GERONTOL, V84, P71, DOI 10.1016/j.exger.2016.09.001
   Xun JQ, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02449 9
   Yan XX, 2004, ANGEW CHEM INT EDIT, V43, P5980, DOI 10.1002/anie.200460598
   Yang BC, 2020, BIOCHEM BIOPH RES CO, V524, P883, DOI 10.1016/j.bbrc.2020.02.001
   Yang XC, 2019, AGING US, V11, P8777, DOI 10.18632/aging.102264
   Yao RW, 2019, NAT CELL BIOL, V21, P542, DOI 10.1038/s41556 019 0311 8
   Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044
   Zhai MM, 2020, ADV SCI, V7, DOI 10.1002/advs.202001334
   Zhang J, 2015, GENOM PROTEOM BIOINF, V13, P17, DOI 10.1016/j.gpb.2015.02.001
   Zhang JL, 2018, INT J MOL MED, V41, P213, DOI 10.3892/ijmm.2017.3215
   Zhang N, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01782 9
   Zhang YT, 2021, ACS APPL MATER INTER, V13, P18472, DOI 10.1021/acsami.0c22671
   Zhao HJ, 2022, BIOACT MATER, V18, P507, DOI 10.1016/j.bioactmat.2022.03.001
   Zhao HX, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.1011371
   Zhu JJ, 2013, SCI CHINA LIFE SCI, V56, P876, DOI 10.1007/s11427 013 4553 6
   Zou WC, 2023, ADV SCI, V10, DOI 10.1002/advs.202204826
NR 96
TC 9
Z9 9
U1 9
U2 34
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD MAR 15
PY 2024
VL 177
BP 486
EP 505
DI 10.1016/j.actbio.2024.01.044
EA MAR 2024
PG 20
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA PL6O8
UT WOS:001214275600001
PM 38311197
DA 2025 08 17
ER

PT J
AU Swarnkar, G
   Naaz, M
   Mims, D
   Gupta, P
   Peterson, T
   Christopher, MJ
   Singamaneni, S
   Mbalaviele, G
   Abu Amer, Y
AF Swarnkar, Gaurav
   Naaz, Musarrat
   Mims, Dorothy
   Gupta, Prashant
   Peterson, Timothy
   Christopher, Matthew J.
   Singamaneni, Srikanth
   Mbalaviele, Gabriel
   Abu Amer, Yousef
TI IĸBζ as a Central Modulator of Inflammatory Arthritis Pathogenesis
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID NF KAPPA B; RHEUMATOID ARTHRITIS; EPIDEMIOLOGY; OSTEOCLASTS; ITACONATE
AB ObjectiveCurrent therapies targeting individual factors in inflammatory arthritis show variable efficacy, often requiring treatment with combinations of drugs, and are associated with undesirable side effects. NF & kgreen;B is critical for the production and function of most inflammatory cytokines. However, given its essential role in physiologic processes, targeting NF & kgreen;B is precarious. Hence, identifying pathways downstream of NF & kgreen;B that selectively govern the expression of inflammatory cytokines in inflammatory arthritis would be advantageous. We have previously identified I & kgreen;B zeta as a unique inflammatory signature of NF & kgreen;B that controls the transcription of inflammatory cytokines only under pathologic conditions while sparing physiologic NF & kgreen;B signals.MethodsWe generated mice harboring myeloid, lymphoid, and global deletion of Nfkbiz (the gene encoding I & kgreen;B zeta). These models were subjected to serum transfer induced arthritis. Additionally, pharmacologic inhibitors of I & kgreen;B zeta were injected intraperitonially. Joint swelling, microcomputed tomography, immunohistochemistry, flow cytometry, and cytokine measurements were conducted using synovial tissue samples.ResultsGlobal deletion of Nfkbiz or depletion of neutrophils (vastly I & kgreen;B zeta+ cells) reduced inflammatory synovial cells and increased anti inflammatory and regenerative synovial cells, plummeted expression of inflammatory factors and ameliorated experimental mouse inflammatory arthritis. Further, expression of immune responsive gene 1, the enzyme responsible for itaconate production, was increased in synovial cells. Accordingly, the itaconate derivative dimethyl itaconate (DI) inhibited I & kgreen;B zeta mediated inflammatory factors. Further, in silico screen identified 8 hydroxyquinoline (HQ) as a putative inhibitor of I & kgreen;B zeta not affecting physiologic NF & kgreen;B activity. Congruently, systemic administration of either DI or HQ inhibited joint swelling and damage.ConclusionOur study positions I & kgreen;B zeta as an inflammation specific target for therapeutic consideration in rheumatoid arthritis because its inhibition spares the beneficial functions of NF & kgreen;B. imageConclusionOur study positions I & kgreen;B zeta as an inflammation specific target for therapeutic consideration in rheumatoid arthritis because its inhibition spares the beneficial functions of NF & kgreen;B. image
C1 [Swarnkar, Gaurav; Naaz, Musarrat; Mims, Dorothy; Christopher, Matthew J.; Mbalaviele, Gabriel] Washington Univ, Sch Med, St Louis, MO USA.
   [Gupta, Prashant; Singamaneni, Srikanth] Washington Univ St Louis, St Louis, MO USA.
   [Peterson, Timothy] Washington Univ, HealthSpan Technol Inc, Sch Med, St Louis, MO USA.
   [Peterson, Timothy] Bioio Inc, St. Louis, MO USA.
   [Abu Amer, Yousef] Washington Univ, Sch Med, St Louis, MO 63131 USA.
   [Abu Amer, Yousef] Shriners Hosp Children, St. Louis, MO 63131 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL); Washington University (WUSTL)
RP Abu Amer, Y (通讯作者)，Washington Univ, Sch Med, St Louis, MO 63131 USA.; Abu Amer, Y (通讯作者)，Shriners Hosp Children, St. Louis, MO 63131 USA.
EM abuamery@wustl.edu
RI SWARNKAR, GAURAV/AAE 3223 2021; Singamaneni, Srikanth/A 8010 2008
FU NIH Core Center for Musculoskeletal Biology and Medicine
FX Supported by the NIH and National Institute of Arthritis and
   Musculoskeletal and Skin Diseases (grants R01 AR072623, R01 AR082192,
   and R01 AR081270 to Dr Abu Amer, grants R01 AR076758, R01 AG077732, and
   R01 AI161022 to Dr Mbalaviele), the Shriners Hospital for Children
   (grant 85109 to Dr Abu Amer), and the NIH Core Center for
   Musculoskeletal Biology and Medicine (grant P30 AR074992 to Dr
   Abu Amer).r No Statement Availabler No Statement Available
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Abu Amer Y, 2008, AUTOIMMUNITY, V41, P204, DOI 10.1080/08916930701694543
   Aletaha D, 2018, JAMA J AM MED ASSOC, V320, P1360, DOI 10.1001/jama.2018.13103
   Aletaha D, 2011, ANN RHEUM DIS, V70, P733, DOI 10.1136/ard.2010.138693
   Alivernini S, 2020, NAT MED, V26, P1295, DOI 10.1038/s41591 020 0939 8
   Arra M, 2022, BONE RES, V10, DOI 10.1038/s41413 021 00183 9
   Arra M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 17242 0
   Bakker AD, 2012, METHODS MOL BIOL, V816, P19, DOI 10.1007/978 1 61779 415 5_2
   Bambouskova M, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108756
   Bambouskova M, 2018, NATURE, V556, P501, DOI 10.1038/s41586 018 0052 z
   Chen C, 2019, EUR J MED CHEM, V181, DOI 10.1016/j.ejmech.2019.111563
   Cherdtrakulkiat R, 2020, DRUG DEVELOP RES, V81, P127, DOI 10.1002/ddr.21611
   Choi MC, 2018, ARTHRITIS RHEUMATOL, V70, P1440, DOI 10.1002/art.40514
   Chopra A, 2008, BEST PRACT RES CL RH, V22, P583, DOI 10.1016/j.berh.2008.07.001
   Clohisy JC, 2003, J IMMUNOL, V171, P5547, DOI 10.4049/jimmunol.171.10.5547
   Corsello SM, 2020, NAT CANCER, V1, P235, DOI 10.1038/s43018 019 0018 6
   Croft AP, 2019, NATURE, V570, P246, DOI 10.1038/s41586 019 1263 7
   Cross M, 2014, ANN RHEUM DIS, V73, P1316, DOI 10.1136/annrheumdis 2013 204627
   Culemann S, 2019, NATURE, V572, P670, DOI 10.1038/s41586 019 1471 1
   Gasparini C, 2012, CURR PHARM DESIGN, V18, P5735, DOI 10.2174/138161212803530763
   Gautam P, 2022, CLIN TRANSL MED, V12, DOI 10.1002/ctm2.1032
   Guo QY, 2018, BAMBOO SILK, V1, P1, DOI [10.1163/24689246 00101001, 10.1038/s41413 018 0016 9]
   HASTINGS DE, 1975, J BONE JOINT SURG AM, V57, P930, DOI 10.2106/00004623 197557070 00009
   Helmick CG, 2008, ARTHRITIS RHEUM US, V58, P15, DOI 10.1002/art.23177
   Hooftman A, 2020, CELL METAB, V32, P468, DOI 10.1016/j.cmet.2020.07.016
   Huang J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.686155
   Jacobs NC., 2023, BIORXIV, DOI [10.1101/487157, DOI 10.1101/487157]
   Ke K, 2019, J BONE MINER RES, V34, P1880, DOI 10.1002/jbmr.3759
   Li WZ, 2023, CELL REP, V42, DOI 10.1016/j.celrep.2023.112145
   Li ZY, 2023, INFLAMMATION, V46, P1177, DOI 10.1007/s10753 023 01819 0
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Mandal A, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb6049
   Marrelli K, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01395
   McInnes IB, 2005, NAT CLIN PRACT RHEUM, V1, P31, DOI 10.1038/ncprheum0020
   Mohammed R. H., 2024, StatPearls
   Murphy MP, 2018, CELL, V174, P780, DOI 10.1016/j.cell.2018.07.030
   Okamoto K, 2010, NATURE, V464, P1381, DOI 10.1038/nature08922
   Oliveri V, 2014, CHEM EUR J, V20, P8954, DOI 10.1002/chem.201402690
   Otero JE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038694
   Palominos PE, 2021, EXPERT OPIN EMERG DR, V26, P303, DOI 10.1080/14728214.2021.1964472
   Pasparakis M, 2009, NAT REV IMMUNOL, V9, P778, DOI 10.1038/nri2655
   Peace CG, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI148548
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Shams S, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.680043
   Shiratori T, 2018, J IMMUNOL, V200, P218, DOI 10.4049/jimmunol.1602035
   Silman AJ, 2002, ARTHRITIS RES THER, V4, pS265, DOI 10.1186/ar578
   Slowikowski K, 2020, P NATL ACAD SCI USA, V117, P5532, DOI 10.1073/pnas.1912702117
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Swarnkar G, 2016, SCI REP UK, V6, DOI 10.1038/srep29896
   Swarnkar G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091421
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Tak PP, 2001, BEST PRACT RES CL RH, V15, P17, DOI 10.1053/berh.2000.0123
   Tak PP, 2001, ARTHRITIS RHEUM, V44, P1897, DOI 10.1002/1529 0131(200108)44:8<1897::AID ART328>3.0.CO;2 4
   Waterborg CEJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00742
   Yan ML, 2022, NAT IMMUNOL, V23, P1330, DOI 10.1038/s41590 022 01285 0
   Yap HY, 2018, CELLS BASEL, V7, DOI 10.3390/cells7100161
   Yu XH, 2019, IMMUNOL CELL BIOL, V97, P134, DOI 10.1111/imcb.12218
NR 58
TC 1
Z9 1
U1 2
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2326 5191
EI 2326 5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD FEB
PY 2025
VL 77
IS 2
BP 124
EP 139
DI 10.1002/art.42990
EA OCT 2024
PG 16
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 0WC5R
UT WOS:001342156100001
PM 39279148
DA 2025 08 17
ER

PT J
AU Tsukioka, T
   Hiratsuka, T
   Nakamura, M
   Watanabe, T
   Kitamura, Y
   Isobe, K
   Okudera, T
   Okudera, H
   Azuma, A
   Uematsu, K
   Nakata, K
   Kawase, T
AF Tsukioka, Tsuneyuki
   Hiratsuka, Takahiro
   Nakamura, Masayuki
   Watanabe, Taisuke
   Kitamura, Yutaka
   Isobe, Kazushige
   Okudera, Toshimitsu
   Okudera, Hajime
   Azuma, Akihiko
   Uematsu, Kohya
   Nakata, Koh
   Kawase, Tomoyuki
TI An on site preparable, novel bone grafting complex consisting of human
   platelet rich fibrin and porous particles made of a recombinant
   collagen like protein
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B APPLIED BIOMATERIALS
LA English
DT Article
DE bone grafting material; platelet rich fibrin; collagen like protein; RDG
   motif; calvarial bone defect; coagulation
ID MESENCHYMAL STEM CELLS; GROWTH FACTOR; PLASMA PRP; LEUKOCYTE; PEPTIDE;
   INFLAMMATION; COAGULATION; ACTIVATION; ADHESION; RECEPTOR
AB Platelet rich fibrin (PRF) is widely used in regenerative medicine. Nonetheless, major issues include its controversial effects on bone regeneration and a lack of quality assured glass tubes required for coagulation. We used porous particles (FBG) comprising a recombinant RGD motif enriched collagen I like protein to activate the coagulation pathway and examined the effects of the resulting PRF FBG complex on bone regeneration. Human whole blood samples were mixed with FBG in plastic tubes and centrifuged to prepare a PRF FBG complex. Platelet derived growth factor BB (PDGF BB) levels and cell growth activity were determined by ELISA and a bioassay using osteoblasts. Bone regenerative activity was assessed using a mouse model of calvarial bone defect. FBG facilitated PRF like matrix formation during centrifugation. In this PRF FBG complex, the microstructure of fibrin fibers was similar to that of PRF prepared conventionally in glass tubes. PDGF BB levels and mitogenic action were not significantly influenced by FBG. In the bone defect model, although PRF did not exert any significant positive effects on its own, in combination with FBG, it synergistically stimulated new bone formation. This study demonstrated that incorporation of FBG into whole blood samples induces PRF formation without the aid of glass tubes. The resulting PRF FBG complex could be a promising bone grafting material in clinical settings. (c) 2018 The Authors. Journal of Biomedical Materials Research Part B: Applied Biomaterials published by Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 107B: 1420 1430, 2019.
C1 [Tsukioka, Tsuneyuki; Nakamura, Masayuki; Watanabe, Taisuke; Kitamura, Yutaka; Isobe, Kazushige; Okudera, Toshimitsu; Okudera, Hajime] Tokyo Plast Dent Soc, Tokyo, Japan.
   [Hiratsuka, Takahiro; Azuma, Akihiko] FIJIFILM Corp, Biosci & Technol Dev Ctr, Yokohama, Kanagawa, Japan.
   [Uematsu, Kohya] Niigata Univ, Med & Dent Hosp, Div Implantol, Niigata, Japan.
   [Nakata, Koh] Niigata Univ, Med & Dent Hosp, Biosci Med Res Ctr, Niigata, Japan.
   [Kawase, Tomoyuki] Niigata Univ, Inst Med & Dent, Div Oral Bioengn, Niigata, Japan.
C3 Niigata University; Niigata University; Niigata University
RP Kawase, T (通讯作者)，Niigata Univ, Inst Med & Dent, Div Oral Bioengn, Niigata, Japan.
EM kawase@dent.niigata u.ac.jp
RI ; Kawase, Tomoyuki/AFT 1502 2022
OI Watanabe, Taisuke/0000 0003 1281 7117; Azuma, Arata/0000 0003 0506 9966;
   Kitamura, Yutaka/0000 0002 3270 7831
CR Al Hamed FS, 2017, J ORAL MAXIL SURG, V75, P1124, DOI 10.1016/j.joms.2017.01.022
   Anitua E, 2015, J BIOMED MATER RES A, V103, P1011, DOI 10.1002/jbm.a.35244
   [Anonymous], GAKKAIKAISHI, DOI [10.2329/perio.59.68, DOI 10.2329/PERIO.59.68]
   Castro AB, 2017, J CLIN PERIODONTOL, V44, P225, DOI 10.1111/jcpe.12658
   Chen WC, 2013, TISSUE ENG PT A, V19, P915, DOI [10.1089/ten.tea.2012.0172, 10.1089/ten.TEA.2012.0172]
   Davis VL, 2014, J ORAL IMPLANTOL, V40, P511, DOI 10.1563/AAID JOI D 12 00106
   Garg P, 2017, ORTHOP SURG, V9, P13, DOI 10.1111/os.12304
   Hartshorne J., 2016, Int Dent, V6, P34
   Heller M, 2018, J BIOMED MATER RES A, V106, P419, DOI 10.1002/jbm.a.36255
   Horimizu M, 2013, CRYOBIOLOGY, V66, P223, DOI 10.1016/j.cryobiol.2013.01.006
   Isobe K, 2017, INT J IMPLANT DENT, V3, DOI 10.1186/s40729 017 0081 7
   Isobe K, 2017, INT J IMPLANT DENT, V3, DOI 10.1186/s40729 017 0068 4
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Javed F, 2011, ARCH ORAL BIOL, V56, P1476, DOI 10.1016/j.archoralbio.2011.06.020
   Kawase T, 2005, AM J PHYSIOL CELL PH, V289, pC811, DOI 10.1152/ajpcell.00504.2004
   Kawase T, 2003, EUR J PHARMACOL, V470, P125, DOI 10.1016/S0014 2999(03)01763 1
   Kawase T, 2017, REGEN THER, V7, P80, DOI 10.1016/j.reth.2017.10.002
   Kawase T, 2016, INT J RADIAT BIOL, V92, P796, DOI 10.1080/09553002.2016.1230242
   Kawase T, 2015, ODONTOLOGY, V103, P126, DOI 10.1007/s10266 015 0209 2
   Kawase T, 2015, J BIOMED MATER RES B, V103, P825, DOI 10.1002/jbm.b.33262
   Kawase T, 2014, CYTOTHERAPY, V16, P653, DOI 10.1016/j.jcyt.2013.11.003
   Kiliç SC, 2017, CLIN IMPLANT DENT R, V19, P959, DOI 10.1111/cid.12522
   Kitamura Y, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00004
   Kizil C, 2015, EMBO REP, V16, P416, DOI 10.15252/embr.201439702
   Kobayashi M, 2015, INT J IMPLANT DENT, V1, DOI 10.1186/s40729 015 0032 0
   Kobayashi M, 2012, BIOLOGICALS, V40, P323, DOI 10.1016/j.biologicals.2012.07.004
   Kobayashi Y, 2016, J ORTHOP SCI, V21, P683, DOI 10.1016/j.jos.2016.07.009
   Kratz A, 2006, ARCH PATHOL LAB MED, V130, P39
   Marcazzan S, 2018, PLATELETS, V29, P326, DOI 10.1080/09537104.2017.1327652
   MARGOLIS J, 1956, NATURE, V178, P805, DOI 10.1038/178805b0
   Masuki H, 2016, INT J IMPLANT DENT, V2, DOI 10.1186/s40729 016 0052 4
   Matsui R., 2008, J Jpn Assoc Regener Dent, V6, P9, DOI 10.11223/jard.6.9
   Miron RJ, 2017, CLIN ORAL INVEST, V21, P1913, DOI 10.1007/s00784 017 2133 z
   Nakamura K, 2016, TRANSPL INT, V29, P1039, DOI 10.1111/tri.12810
   Nakamura K, 2010, J CONTROL RELEASE, V148, P351, DOI 10.1016/j.jconrel.2010.09.005
   RAPAPORT SI, 1954, SCAND J CLIN LAB INV, V6, P82
   Ryu JJ, 2013, INT J ORAL MAX IMPL, V28, P963, DOI 10.11607/jomi.2421
   Toyoda T, 2018, INT J IMPLANT DENT, V4, DOI 10.1186/s40729 018 0134 6
   Watanabe Taisuke, 2017, Dent J (Basel), V5, DOI 10.3390/dj5010007
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xu ZL, 2017, SCI REP UK, V7, DOI 10.1038/srep43301
   Yoshioka Y, 2016, BIOCH CLIN, V31, P61
NR 42
TC 14
Z9 16
U1 4
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1552 4973
EI 1552 4981
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD JUL
PY 2019
VL 107
IS 5
BP 1420
EP 1430
DI 10.1002/jbm.b.34234
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA IB1MJ
UT WOS:000470029000010
PM 30270545
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU El Kady, AM
   Ahmed, MM
   Abd El Hady, BM
   Ali, AF
   Ibrahim, AM
AF El Kady, Abeer M.
   Ahmed, Manar M.
   Abd El Hady, Bothaina M.
   Ali, Ashraf F.
   Ibrahim, Alaa M.
TI Optimization of ciprofloxacin release kinetics of novel Nano bioactive
   glasses: Effect of glass modifier content on drug loading and release
   mechanism
SO JOURNAL OF NON CRYSTALLINE SOLIDS
LA English
DT Article
DE Bioactive glass; Drug delivery; Ciprofloxacin; Osteomyelitis treatment;
   Glass modifier
ID RANDOM NETWORK MODEL; GEL DERIVED GLASSES; DELIVERY; BONE;
   NANOPARTICLES; NANOSPHERES; PARTICLES; OSTEOBLASTS; FABRICATION;
   SCAFFOLDS
AB This work aimed to prepare novel nano bioactive glass compositions, belonging to the SiO2 CaO system, for local ciprofloxacin administration. As a new approach, drug loading and its release kinetics of glass nanoparticles were optimized by increasing the modifier content at the expense of glass former. Four different Glass samples, of 3.2, 13.8, 24.2, and 34.5 mol% CaO content, were prepared (coded as CS1, CS2, CS3 and CS4, respectively). They were characterized by TEM, DSC, TGA and FTIR. The glass samples exhibited specific surface areas of 299.3, 140.5, 81.59, and 17.58 (m(2).g( 1)), respectively. A strong correlation was established between the modifier contents of the glass samples and drug loading or release doses. Modeling the drug release profiles of all glass samples confirmed that drug was released via a controlled diffusion mean. All glass samples induced hydroxyapatite layer onto their surfaces after immersion in simulated body fluid.
C1 [El Kady, Abeer M.; Ahmed, Manar M.] Natl Res Ctr, Glass Res Dept, 33 El Bohooth St, Cairo 12622, Egypt.
   [Abd El Hady, Bothaina M.] Natl Res Ctr, Polymers & Pigments Dept, 33 El Bohooth St, Cairo 12622, Egypt.
   [Ali, Ashraf F.] Jouf Univ, Fac Sci, Sakakah, Saudi Arabia.
   [Ibrahim, Alaa M.] Ain Shams Univ, Phys Dept, Univ Collage Women Arts Sci & Educ, Cairo, Egypt.
C3 Egyptian Knowledge Bank (EKB); National Research Centre (NRC); Egyptian
   Knowledge Bank (EKB); National Research Centre (NRC); Al Jouf
   University; Egyptian Knowledge Bank (EKB); Ain Shams University
RP El Kady, AM (通讯作者)，Natl Res Ctr, Glass Res Dept, 33 El Bohooth St, Cairo 12622, Egypt.
EM abeerelkady_2000@yahoo.co.uk
RI ; Ali, Ashraf/H 9630 2012
OI Ali, Ashraf/0000 0001 6441 1288; Ali, Ashraf/0000 0002 5820 2700; 
CR Aguiar H, 2009, J NON CRYST SOLIDS, V355, P475, DOI 10.1016/j.jnoncrysol.2009.01.010
   Arcos D, 2014, ACTA BIOMATER, V10, P1793, DOI 10.1016/j.actbio.2014.01.004
   Beck Broichsitter BE, 2015, CURR OPIN INFECT DIS, V28, P240, DOI 10.1097/QCO.0000000000000155
   Birt MC, 2017, J ORTHOP, V14, P45, DOI 10.1016/j.jor.2016.10.004
   BOGUSH GH, 1988, J NON CRYST SOLIDS, V104, P95, DOI 10.1016/0022 3093(88)90187 1
   BOGUSH GH, 1991, J COLLOID INTERF SCI, V142, P19, DOI 10.1016/0021 9797(91)90030 C
   Brinker C.J., 1990, PHYS CHEM SOL GEL PR
   Catauro M, 2016, THERMOCHIM ACTA, V625, P20, DOI 10.1016/j.tca.2015.12.004
   Chen SY, 2017, CERAM INT, V43, P2239, DOI 10.1016/j.ceramint.2016.11.007
   Chen XF, 2009, J NON CRYST SOLIDS, V355, P791, DOI 10.1016/j.jnoncrysol.2009.02.005
   Coleman NJ, 2000, CERAM INT, V26, P171, DOI 10.1016/S0272 8842(99)00037 1
   Dziadek M, 2018, MATER LETT, V215, P87, DOI 10.1016/j.matlet.2017.12.075
   El Kady AM, 2016, EUR J PHARM SCI, V91, P243, DOI 10.1016/j.ejps.2016.05.004
   El Kady AM, 2012, CERAM INT, V38, P1195, DOI 10.1016/j.ceramint.2011.07.069
   El Meliegy E, 2017, J NON CRYST SOLIDS, V475, P59, DOI 10.1016/j.jnoncrysol.2017.08.034
   El Rashidy AA, 2017, ACTA BIOMATER, V62, P1, DOI 10.1016/j.actbio.2017.08.030
   ElBatal FH, 2008, MATER CHEM PHYS, V110, P352, DOI 10.1016/j.matchemphys.2008.02.011
   Fan Y, 2009, J PHYS CHEM C, V113, P7826, DOI 10.1021/jp900515x
   Goudouri OM, 2014, ACTA BIOMATER, V10, P3795, DOI 10.1016/j.actbio.2014.03.028
   Gupta N, 2018, WOODH PUBL SER BIOM, P63, DOI 10.1016/B978 0 08 100936 9.00003 4
   Gupta N, 2016, J MATER CHEM B, V4, P7605, DOI 10.1039/c6tb01528j
   Hench LL, 2016, J NON CRYST SOLIDS, V432, P2, DOI 10.1016/j.jnoncrysol.2014.12.038
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   Hogan A, 2013, ARCH ORTHOP TRAUM SU, V133, P1183, DOI 10.1007/s00402 013 1785 7
   Hoppe A, 2015, FRONT ORAL BIOL, V17, P22, DOI 10.1159/000381690
   Hum J, 2016, INORGANIC CONTROLLED, P139
   Kaya S, 2018, MAT SCI ENG C MATER, V83, P99, DOI 10.1016/j.msec.2017.11.003
   Labbaf S, 2011, BIOMATERIALS, V32, P1010, DOI 10.1016/j.biomaterials.2010.08.082
   Lee JH, 2017, BIOMATERIALS, V142, P62, DOI 10.1016/j.biomaterials.2017.07.014
   Li B, 2016, J NON CRYST SOLIDS, V447, P98, DOI 10.1016/j.jnoncrysol.2016.05.041
   Li DD, 2017, J BIONIC ENG, V14, P672, DOI 10.1016/S1672 6529(16)60433 X
   Li N, 2014, J NON CRYST SOLIDS, V383, P28, DOI 10.1016/j.jnoncrysol.2013.04.049
   Li N, 2014, PHYS CHEM CHEM PHYS, V16, P1500, DOI 10.1039/c3cp53192a
   Li Y, 2013, J MATER SCI MATER M, V24, P1951, DOI 10.1007/s10856 013 4960 z
   Liu X, 2011, ACTA BIOMATER, V7, P406, DOI 10.1016/j.actbio.2010.08.025
   MacKenzie KJD., 2002, MULTINUCLEAR SOLID S
   Midha S, 2013, ACTA BIOMATER, V9, P9169, DOI 10.1016/j.actbio.2013.07.014
   Naruphontjirakul P., 2016, BIOMEDICAL GLASSES, P72, DOI DOI 10.1515/BGLASS 2016 0009
   Naruphontjiralcul P, 2018, ACTA BIOMATER, V66, P67, DOI 10.1016/j.actbio.2017.11.008
   Radin S, 2009, BIOMATERIALS, V30, P850, DOI 10.1016/j.biomaterials.2008.09.066
   Salinas AJ, 2018, WOODH PUBL SER BIOM, P337, DOI 10.1016/B978 0 08 100936 9.00014 9
   Saravanapavan P, 2004, BIO MED MATER ENG, V14, P467
   Saravanapavan P, 2001, J BIOMED MATER RES, V54, P608, DOI 10.1002/1097 4636(20010315)54:4<608::AID JBM180>3.3.CO;2 L
   Shah AT, 2015, J MATER SCI, V50, P1794, DOI 10.1007/s10853 014 8742 x
   Shahrabi S, 2011, CERAM INT, V37, P2737, DOI 10.1016/j.ceramint.2011.04.025
   Tang JY, 2017, MATER LETT, V209, P626, DOI 10.1016/j.matlet.2017.08.033
   Taygun ME, 2018, WOODH PUBL SER BIOM, P235, DOI 10.1016/B978 0 08 100936 9.00012 5
   Tsigkou O, 2009, BIOMATERIALS, V30, P3542, DOI 10.1016/j.biomaterials.2009.03.019
   Vallet Regí M, 2017, RSC SMART MATER, V23, P393
   Wang X, 2017, COLLOID SURFACE B, V160, P406, DOI 10.1016/j.colsurfb.2017.09.051
   Wang X, 2016, CERAM INT, V42, P3609, DOI 10.1016/j.ceramint.2015.11.024
   Wong J., 1977, Glass: Structure by Spectroscopy
   Wu CT, 2013, J MATER CHEM B, V1, P2710, DOI 10.1039/c3tb20275e
   Xia W, 2007, MATER LETT, V61, P3251, DOI 10.1016/j.matlet.2006.11.048
   Xue YM, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201700630
   Xue YM, 2015, J MATER CHEM B, V3, P3831, DOI 10.1039/c5tb00204d
   Xynos ID, 2000, BIOCHEM BIOPH RES CO, V276, P461, DOI 10.1006/bbrc.2000.3503
   Yan XX, 2010, MICROPOR MESOPOR MAT, V132, P282, DOI 10.1016/j.micromeso.2010.03.009
   Yu M, 2017, ACS APPL MATER INTER, V9, P8460, DOI 10.1021/acsami.6b13874
   Yun HS, 2011, ACTA BIOMATER, V7, P2651, DOI 10.1016/j.actbio.2011.02.014
   Zhang Y, 2016, MAT SCI ENG C MATER, V67, P205, DOI 10.1016/j.msec.2016.05.019
   Zhou Y, 2018, IEEE T INTELL TRANSP, V19, P1973, DOI 10.1109/TITS.2017.2740303
   Zhu M, 2012, J MATER SCI, V47, P2256, DOI 10.1007/s10853 011 6037 z
NR 63
TC 15
Z9 15
U1 3
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022 3093
EI 1873 4812
J9 J NON CRYST SOLIDS
JI J. Non Cryst. Solids
PD OCT 1
PY 2019
VL 521
AR 119471
DI 10.1016/j.jnoncrysol.2019.119471
PG 12
WC Materials Science, Ceramics; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA IW0ID
UT WOS:000484644700003
DA 2025 08 17
ER

PT J
AU Charoensuk, T
   Sirisathitkul, C
   Boonyang, U
   Macha, IJ
   Santos, J
   Grossin, D
   Ben Nissan, B
AF Charoensuk, Thanida
   Sirisathitkul, Chitnarong
   Boonyang, Upsorn
   Macha, Innocent J.
   Santos, Jerran
   Grossin, David
   Ben Nissan, Besim
TI In vitro bioactivity and stem cells attachment of
   three dimensionally ordered macroporous bioactive glass incorporating
   iron oxides
SO JOURNAL OF NON CRYSTALLINE SOLIDS
LA English
DT Article
DE Magnetic bioactive glass; Mesopore; Macropore; In vitro bioactivity;
   Stem cells attachment
ID CERAMIC SCAFFOLDS; SBF
AB Three dimensionally ordered macroporous bioactive SiO2 CaO Na2O P2O5 glass (3DOM BG) is synthesized by using the sol gel method. After an in vitro test in simulated body fluid (SBF), the hydroxyapatite (HAp) crystalline phase is clearly formed on its surface as confirmed by X ray diffractometry (XRD) and Raman spectroscopy. Magnetic 3DOM BG/Fe samples are synthesized by partial substitution of SiO2 with iron oxide. Whilst the HAp layer is not confirmed, energy dispersive spectroscopy (EDS), Fourier transform infrared spectroscopy (FTIR) and XRD analysis reveal calcium phosphate layer on the surface of 3DOM BG/Fe samples after the SBF soaking. The growth of HAp like layer is slower with increasing iron oxides. The initial mechanism that thought to induce bone formation is reduced due to the replacement of Ca2+ with Fe ions in the glass network. The formation of HAp like layer is modified by the sedimentation of Ca and P while the nonmagnetic 3DOM BG forms the calcium phosphate by the ionic exchange following the Hench mechanism. The adult human adipose tissue derived stem cells (hADSCs) can be closely attached and well spread on the flat plate of all 3DOM BG/Fe and 3DOM BG. Without detectable cytotoxicity possibly induced by iron oxides, the osteoblast can be grown and proliferated. In addition to these bioactivity and biocompatibility, porous structures can allow their possible use in targeted drug delivery and magnetic properties of 3DOM BG/Fe can essentially be implemented in hyperthermia therapy. (C) 2016 Elsevier B.V. Affrights reserved.
C1 [Charoensuk, Thanida; Sirisathitkul, Chitnarong; Boonyang, Upsorn] Walailak Univ, Sch Sci, Mol Technol Res Unit, Nakhon Si Thammarat, Thailand.
   [Macha, Innocent J.; Santos, Jerran; Ben Nissan, Besim] Univ Technol Sydney, Sch Life Sci, Adv Tissue Regenerat & Drug Delivery Grp, Sydney, NSW 2007, Australia.
   [Grossin, David] Univ Toulouse, CIRIMAT Carrot Inst, UMR, Toulouse, France.
   [Macha, Innocent J.] Univ Dar Es Salaam, Dar Es Salaam, Tanzania.
C3 Walailak University; University of Technology Sydney; Universite de
   Toulouse; Universite Toulouse III   Paul Sabatier; University of Dar es
   Salaam
RP Sirisathitkul, C (通讯作者)，Walailak Univ, Sch Sci, Mol Technol Res Unit, Nakhon Si Thammarat, Thailand.
EM chitnarong.siri@gmail.com
RI Macha, Innocent/R 4793 2019; GROSSIN, David/C 3217 2009; Ben Nissan,
   Besim/AAR 4445 2020; Santos, Jerran/P 7868 2016
OI Macha, Innocent/0000 0002 7517 4537; GROSSIN, David/0000 0002 4320 2919;
   Boonyang, Upsorn/0000 0001 8371 7098; Sirisathitkul,
   Chitnarong/0000 0002 7837 3515; Ben Nissan, Besim/0009 0006 5422 4693;
   Santos, Jerran/0000 0003 4067 220X
FU Walailak University (Molecular Technology Research Unit); Shell
   Centennial Education Fund; Shell Companies in Thailand; Australian
   Academy of Science; European Union's Horizon 2020 research and
   innovation programme under Marie Sklodowska Curie grant [645749]; Marie
   Curie Actions (MSCA) [645749] Funding Source: Marie Curie Actions (MSCA)
FX This work is financially supported by Walailak University (Molecular
   Technology Research Unit grant) and Shell Centennial Education Fund
   (2013), Shell Companies in Thailand. Dr. D. Grossin, Dr. I. Macha and
   Prof B. Ben Nissan were supported by the Australian Academy of Science
   and the European Union's Horizon 2020 research and innovation programme
   under the Marie Sklodowska Curie grant agreement No 645749.
CR Adams L.A., 2013, New J. Glas. Ceram, V3, P11, DOI DOI 10.4236/NJGC.2013.31003
   Baino F, 2016, J NON CRYST SOLIDS, V432, P15, DOI 10.1016/j.jnoncrysol.2015.02.015
   Charoensuk T, 2016, J CERAM SCI TECHNOL, V7, P139, DOI 10.4416/JCST2015 00065
   Choi SW, 2010, LANGMUIR, V26, P19001, DOI 10.1021/la104206h
   Ciobanu CS, 2011, NANOSCALE RES LETT, V6, P1, DOI 10.1186/1556 276X 6 613
   De Vasconcellos L.M.R., 2012, BIOMEDICAL ENG TECHN, P47, DOI 10.5772/47816
   ElMeliegy E, 2012, GLASSES AND GLASS CERAMICS FOR MEDICAL APPLICATIONS, P1, DOI 10.1007/978 1 4614 1228 1
   Gao CD, 2014, INT J MOL SCI, V15, P4714, DOI 10.3390/ijms15034714
   Gerhardt LC, 2010, MATERIALS, V3, P3867, DOI 10.3390/ma3073867
   Gunawidjaja PN, 2012, PHILOS T R SOC A, V370, P1376, DOI 10.1098/rsta.2011.0257
   Hanesch M, 2009, GEOPHYS J INT, V177, P941, DOI 10.1111/j.1365 246X.2009.04122.x
   Hench L.L., 2013, New Journal of Glass and Ceramics, V03, P67
   Hench LL, 2016, J NON CRYST SOLIDS, V432, P2, DOI 10.1016/j.jnoncrysol.2014.12.038
   Hench LL, 2002, SCIENCE, V295, P1014, DOI 10.1126/science.1067404
   Kaur G, 2014, J BIOMED MATER RES A, V102, P254, DOI 10.1002/jbm.a.34690
   Kiani A, 2012, ACTA BIOMATER, V8, P333, DOI 10.1016/j.actbio.2011.08.025
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Li GD, 2011, J MATER SCI MATER M, V22, P2197, DOI 10.1007/s10856 011 4417 1
   Liu J, 2010, MICROPOR MESOPOR MAT, V130, P26, DOI 10.1016/j.micromeso.2009.10.008
   Lucas Girot A, 2011, J NON CRYST SOLIDS, V357, P3322, DOI 10.1016/j.jnoncrysol.2011.06.002
   Lutisanová G, 2011, CERAM SILIKATY, V55, P199
   Luz GM, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/49/494014
   Oh SJ, 1998, HYPERFINE INTERACT, V112, P59, DOI 10.1023/A:1011076308501
   Paiva A.O., 2006, COMPOS MAT RES, V9, P417, DOI DOI 10.1590/S1516 14392006000400013
   Peter M, 2010, CHEM ENG J, V158, P353, DOI 10.1016/j.cej.2010.02.003
   Radev L., 2010, Process. Appl. Ceram, V4, P15
   Santocildes Romero ME, 2015, J TISSUE ENG REGEN M, V9, P619, DOI 10.1002/term.2003
   Silver IA, 2001, BIOMATERIALS, V22, P175, DOI 10.1016/S0142 9612(00)00173 3
   Soler M.A., 2012, RAMAN SPECTROSCOPY N, P379, DOI [10.1007/978 3 642 20620 7_14, DOI 10.1007/978 3 642 20620 7_14, 10.1007/978 3 642  ]
   Tartaj P, 2003, J PHYS D APPL PHYS, V36, pR182, DOI 10.1088/0022 3727/36/13/202
   Wang D, 2013, SCI TECHNOL ADV MAT, V14, DOI 10.1088/1468 6996/14/2/025004
   Wu CT, 2012, INTERFACE FOCUS, V2, P292, DOI 10.1098/rsfs.2011.0121
   Wu CT, 2011, ACTA BIOMATER, V7, P3563, DOI 10.1016/j.actbio.2011.06.028
   Zhang K, 2005, BIOMATERIALS, V26, P4532, DOI 10.1016/j.biomaterials.2004.11.030
NR 34
TC 23
Z9 23
U1 0
U2 23
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022 3093
EI 1873 4812
J9 J NON CRYST SOLIDS
JI J. Non Cryst. Solids
PD NOV 15
PY 2016
VL 452
BP 62
EP 73
DI 10.1016/j.jnoncrysol.2016.08.019
PG 12
WC Materials Science, Ceramics; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA EC3TY
UT WOS:000388050800011
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Dettin, M
   Bagno, A
   Morpurgo, M
   Cacchioli, A
   Conconi, MT
   Di Bello, C
   Gabbi, C
   Gambaretto, R
   Parnigotto, PP
   Pizzinato, S
   Ravanetti, F
   Guglielmi, M
AF Dettin, Monica
   Bagno, Andrea
   Morpurgo, Margherita
   Cacchioli, Antonio
   Conconi, Maria Teresa
   Di Bello, Carlo
   Gabbi, Carlo
   Gambaretto, Roberta
   Parnigotto, Pier Paolo
   Pizzinato, Sara
   Ravanetti, Francesca
   Guglielmi, Massimo
TI Evaluation of silicon dioxide based coating enriched with bioactive
   peptides mapped on human vitronectin and fibronectin:: in vitro
   and in vivo assays
SO TISSUE ENGINEERING
LA English
DT Article; Proceedings Paper
CT Workshop on Tissue Engineering   The Next Generation
CY MAY 02 04, 2005
CL Boston, MA
ID PHOTOLITHOGRAPHIC TECHNIQUES; SURFACE ROUGHNESS; CELL INTERACTIONS;
   DRUG DELIVERY; TITANIUM; BONE; IMPLANTS; ADHESION; ORGANIZATION;
   BEHAVIOR
AB A wide range of biochemical signals promoting cell functions ( adhesion, migration, proliferation, and differentiation) and thereby improving the osseointegration process are currently investigated. Unfortunately, their application for the production of bioactive implantable devices is often hampered by their insolubility; instability; and limited availability of a large amount of inexpensive, high purity samples.
   An attractive alternative is the use of short peptides carrying the minimum active sequence of the natural factors. Synthetic peptides mapped on fibronectin and vitronectin have been demonstrated to enhance cell adhesion both to polystyrene and acellular bone matrix; in particular, a nonapeptide sequence from human vitronectin works via an osteoblast specific adhesion mechanism.
   In this study, we incorporated these peptides into a sol gel silica dressing applied to coat sand blasted and acid attacked titanium samples; measured the kinetic of peptide release; and used titanium disks, coated with a peptide enriched film, as substrates to determine the peptide concentration that maximizes cell adhesion in vitro. We also evaluated in vivo the capacity of the vitronectin derived peptide to improve osteogenic activity: histologic analysis revealed markedly improved osteogenic activity around peptide enriched samples.
   This article also discusses the role of surface characteristics and the importance of bioactive peptides.
C1 Univ Padua, Dept Chem Proc Engn, Padua, Italy.
   Univ Padua, Dept Pharmaceut Sci, Padua, Italy.
   Univ Padua, Dept Mech Engn, Padua, Italy.
   Univ Parma, Dept Anim Hlth, I 43100 Parma, Italy.
C3 University of Padua; University of Padua; University of Padua;
   University of Parma
RP Bagno, A (通讯作者)，Univ Padua, Dept Chem Proc Engn, Padua, Italy.
EM andrea.bagno@unipd.it
RI ; morpurgo, margherita/I 7911 2012; Bagno, Andrea/K 5002 2016
OI Ravanetti, Francesca/0000 0001 8729 3237; Guglielmi,
   Massimo/0000 0002 8032 2653; morpurgo, margherita/0000 0002 8767 1995;
   Bagno, Andrea/0000 0002 4296 3601
CR Anderson SI, 1998, J MATER SCI MATER M, V9, P731, DOI 10.1023/A:1008955002955
   Bagno A, 2004, BIOMATERIALS, V25, P2437, DOI 10.1016/j.biomaterials.2003.09.018
   Bagno A, 2004, J MATER SCI MATER M, V15, P935, DOI 10.1023/B:JMSM.0000042679.28493.7f
   BAGNO A, 2003, BIOCERAMIC SURFACES, P113
   Bessho K, 1999, CLIN ORAL IMPLAN RES, V10, P212, DOI 10.1034/j.1600 0501.1999.100304.x
   Bigerelle M, 2002, BIOMATERIALS, V23, P1563, DOI 10.1016/S0142 9612(01)00271 X
   Böttcher H, 1998, J SOL GEL SCI TECHN, V13, P277, DOI 10.1023/A:1008603622543
   Boyan BD, 1996, BIOMATERIALS, V17, P137, DOI 10.1016/0142 9612(96)85758 9
   Brinker C.J., 1989, Sol Gel Science: The Physics and Chemistry of Sol Gel Processing
   CLARK P, 1990, DEVELOPMENT, V108, P635
   Cochran DL, 1996, CLIN ORAL IMPLAN RES, V7, P240, DOI 10.1034/j.1600 0501.1996.070306.x
   Dee KC, 1998, J BIOMED MATER RES, V40, P371, DOI 10.1002/(SICI)1097 4636(19980605)40:3<371::AID JBM5>3.0.CO;2 C
   Deligianni DD, 2001, BIOMATERIALS, V22, P1241, DOI 10.1016/S0142 9612(00)00274 X
   Dettin M, 2002, J BIOMED MATER RES, V60, P466, DOI 10.1002/jbm.10066
   DETTIN M, 2004, Patent No. 000065
   Elmengaard B, 2005, BIOMATERIALS, V26, P3521, DOI 10.1016/j.biomaterials.2004.09.039
   Falaize S, 1999, J AM CERAM SOC, V82, P969, DOI 10.1111/j.1151 2916.1999.tb01861.x
   Ferris DM, 1999, BIOMATERIALS, V20, P2323, DOI 10.1016/S0142 9612(99)00161 1
   GABBI C, 2003, ANN FM VET PARMA 23, V87
   Grzesiak JJ, 1997, BIOMATERIALS, V18, P1625, DOI 10.1016/S0142 9612(97)00103 8
   Healy KE, 1996, BIOMATERIALS, V17, P195, DOI 10.1016/0142 9612(96)85764 4
   KASEMO B, 1986, CRIT REV BIOCOMPAT, V2, P335
   Kasemo B, 1999, Adv Dent Res, V13, P8
   Koroleff F., 1983, Methods of Seawater Analysis, P174
   Kortesuo P, 2000, BIOMATERIALS, V21, P193, DOI 10.1016/S0142 9612(99)00148 9
   Kortesuo P, 1999, J BIOMED MATER RES, V44, P162, DOI 10.1002/(SICI)1097 4636(199902)44:2<162::AID JBM6>3.3.CO;2 G
   Lai W, 2002, BIOMATERIALS, V23, P213, DOI 10.1016/S0142 9612(01)00097 7
   Lee MH, 2006, BIOMATERIALS, V27, P1907, DOI 10.1016/j.biomaterials.2005.11.003
   Lee SJ, 2000, YONSEI MED J, V41, P704, DOI 10.3349/ymj.2000.41.6.704
   Li DH, 2002, J BIOMED MATER RES, V60, P325, DOI 10.1002/jbm.10063
   Lüthen F, 2005, BIOMATERIALS, V26, P2423, DOI 10.1016/j.biomaterials.2004.07.054
   Palumbo G, 1997, J MATER SCI MATER M, V8, P417, DOI 10.1023/A:1018553505001
   Puleo DA, 1999, BIOMATERIALS, V20, P2311, DOI 10.1016/S0142 9612(99)00160 X
   Radin S, 2002, BIOMATERIALS, V23, P3113, DOI 10.1016/S0142 9612(02)00051 0
   RAHN BA, 1971, STAIN TECHNOL, V46, P125, DOI 10.3109/10520297109067836
   Ratner BD, 1996, J MOL RECOGNIT, V9, P617, DOI 10.1002/(SICI)1099 1352(199634/12)9:5/6<617::AID JMR310>3.0.CO;2 D
   Rezania A, 1999, BIOTECHNOL PROGR, V15, P19, DOI 10.1021/bp980083b
   RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022
   Roccuzzo M, 2001, CLIN ORAL IMPLAN RES, V12, P572, DOI 10.1034/j.1600 0501.2001.120604.x
   Schmidmaier G, 2001, BONE, V28, P341, DOI 10.1016/S8756 3282(00)00456 7
   Schottner G, 2001, CHEM MATER, V13, P3422, DOI 10.1021/cm011060m
   Scotchford CA, 2003, BIOMATERIALS, V24, P1147, DOI 10.1016/S0142 9612(02)00488 X
   STUART AJ, 1992, AVIAN DIS, V36, P447, DOI 10.2307/1591527
   Suzuki Y, 2000, J BIOMED MATER RES, V50, P405, DOI 10.1002/(SICI)1097 4636(20000605)50:3<405::AID JBM15>3.0.CO;2 Z
   Tweden K S, 1995, J Heart Valve Dis, V4 Suppl 1, pS90
   UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871
   UNGER K, 1983, DRUG DEV IND PHARM, V9, P69, DOI 10.3109/03639048309048546
   Winkelmann M, 2003, BIOMATERIALS, V24, P1133, DOI 10.1016/S0142 9612(02)00449 0
   Yokose S, 1996, ENDOCRINOLOGY, V137, P469, DOI 10.1210/en.137.2.469
   Zinger O, 2004, BIOMATERIALS, V25, P2695, DOI 10.1016/j.biomaterials.2003.09.111
NR 50
TC 16
Z9 17
U1 0
U2 13
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1076 3279
J9 TISSUE ENG
JI Tissue Eng.
PD DEC
PY 2006
VL 12
IS 12
BP 3509
EP 3523
DI 10.1089/ten.2006.12.3509
PG 15
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Cell Biology
GA 122CB
UT WOS:000243202200021
PM 17518687
DA 2025 08 17
ER

PT J
AU Whelton, A
   Gibofsky, A
AF Whelton, Andrew
   Gibofsky, Allan
TI Minimizing Cardiovascular Complications During the Treatment of
   Osteoarthritis
SO AMERICAN JOURNAL OF THERAPEUTICS
LA English
DT Article
DE cardiovascular disease; osteoarthritis; risk factors; NSAIDs; blood
   pressure
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CONGESTIVE HEART FAILURE; OXIDE
   DONATOR NAPROXCINOD; BLOOD PRESSURE; RHEUMATOID ARTHRITIS;
   CYCLO OXYGENASE 2 INHIBITORS; CYCLOOXYGENASE 2 INHIBITORS;
   GASTROINTESTINAL TOXICITY; SECONDARY PREVENTION; CARBONIC ANHYDRASE
AB Individuals with osteoarthritis face an increased risk of cardiovascular (CV) disease compared with age matched control subjects. Both conditions share some common risk factors (eg, age, obesity, and hypertension) and the consequences or treatment of osteoarthritis may increase CV risk by impairing physical activity and exacerbating CV risk factors. Nonsteroidal anti inflammatory drugs may have prothrombotic and/or hypertensive effects and a negative impact on renal function, all of which contribute to the increased risk of CV disease associated with these agents. The magnitude of these effects differs between agents and is, in part, determined by the relative balance of cyclo oxygenase 1 or cyclo oxygenase 2 inhibition. To minimize risk of CV disease in patients with osteoarthritis taking nonsteroidal anti inflammatory drugs, physicians need to 1) monitor blood pressure and the new appearance or exacerbation of edema; 2) encourage lifestyle changes/nonpharmacologic treatments for pain/risk factor management; 3) choose the lowest effective dose of appropriate drug therapy to achieve adequate pain relief while minimizing CV risk; 4) change nonsteroidal anti inflammatory drugs as needed to one with lower propensity to aggravate CV risk; and 5) modulate antihypertensive therapy and diuretic management as needed to maintain target blood pressure and weight.
C1 [Whelton, Andrew] Universal Clin Res Ctr Inc, Baltimore, MD USA.
   [Whelton, Andrew] Johns Hopkins Univ, Baltimore, MD USA.
   [Gibofsky, Allan] Cornell Univ, Hosp Special Surg, Weill Med Coll, New York, NY 10021 USA.
C3 Johns Hopkins University; Cornell University; Weill Cornell Medicine
RP Whelton, A (通讯作者)，1737 Beaver Brook Lane, Hunt Valley, MD 21030 USA.
EM huntvalley@aol.com
FU NicOx, Inc.
FX Editorial support was provided by Catherine Rees on behalf of the
   Lippincott CME Institute, Inc through an educational grant provided by
   NicOx, Inc.
CR Abraham NS, 2007, ALIMENT PHARM THER, V25, P913, DOI 10.1111/j.1365 2036.2007.03292.x
   Aldington Sarah, 2005, N Z Med J, V118, pU1755
   Aldington Sarah, 2005, N Z Med J, V118, pU1684
   ALTMAN R, 1994, BMJ BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Anning PB, 2006, BLOOD, V108, P4059, DOI 10.1182/blood 2006 02 005330
   [Anonymous], 2000, Arthritis Rheumatism, V43, P1905
   [Anonymous], HYPERTENSION AWARENE
   Aw TJ, 2005, ARCH INTERN MED, V165, P490, DOI 10.1001/archinte.165.5.IOI50013
   BLACKSHEAR JL, 1983, ARCH INTERN MED, V143, P1130, DOI 10.1001/archinte.143.6.1130
   Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   Bruehl S, 2004, NEUROSCI BIOBEHAV R, V28, P395, DOI 10.1016/j.neubiorev.2004.06.004
   Chen YF, 2008, HEALTH TECHNOL ASSES, V12, P1, DOI 10.3310/hta12110
   CHOBANIAN AV, 2003, JAMA J AM MED ASSOC, V289, P2560, DOI DOI 10.1161/01.HYP.0000107251.49515.C2
   COOK NR, 1995, ARCH INTERN MED, V155, P701, DOI 10.1001/archinte.155.7.701
   Curtis SP, 2006, CURR MED RES OPIN, V22, P2365, DOI 10.1185/030079906X148238
   Farkouh ME, 2009, AM J CARDIOL, V103, P1227, DOI 10.1016/j.amjcard.2009.01.014
   FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607
   FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288
   Franklin SS, 1997, CIRCULATION, V96, P308
   Funk CD, 2007, J CARDIOVASC PHARM, V50, P470, DOI 10.1097/FJC.0b013e318157f72d
   GERBER JG, 1983, ANN INTERN MED, V99, P555, DOI 10.7326/0003 4819 99 4 555
   Goodson N, 2005, ANN RHEUM DIS, V64, P1595, DOI 10.1136/ard.2004.034777
   Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291
   Gu QP, 2010, AM J HYPERTENS, V23, P38, DOI 10.1038/ajh.2009.191
   Hochber MC, 2008, CLIN EXP RHEUMATOL, V26, pS120
   Johnson AG, 1998, DRUG AGING, V12, P17, DOI 10.2165/00002512 199812010 00003
   JOHNSON AG, 1994, ANN INTERN MED, V121, P289, DOI 10.7326/0003 4819 121 4 199408150 00011
   Juni P, 2004, LANCET, V364, P2021, DOI 10.1016/S0140 6736(04)17514 4
   Karlsson J, 2009, J RHEUMATOL, V36, P1290, DOI 10.3899/jrheum.081011
   Kearney PM, 2006, BMJ BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302
   Knights KM, 2006, BRIT J CLIN PHARMACO, V61, P738, DOI 10.1111/j.1365 2125.2006.02678.x
   Knudsen JF, 2004, INFLAMMATION, V28, P285, DOI 10.1007/s10753 004 6052 1
   Lawes CMM, 2008, LANCET, V371, P1513, DOI 10.1016/S0140 6736(08)60655 8
   Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176
   Lee C, 2004, ARTHRIT RHEUM ARTHR, V51, P746, DOI 10.1002/art.20698
   Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140 6736(02)11911 8
   Mamdani M, 2004, LANCET, V363, P1751, DOI 10.1016/S0140 6736(04)16299 5
   McGettigan P, 2006, JAMA J AM MED ASSOC, V296, P1633, DOI 10.1001/jama.296.13.jrv60011
   Nussmeier NA, 2005, NEW ENGL J MED, V352, P1081, DOI 10.1056/NEJMoa050330
   Okonofua EC, 2006, HYPERTENSION, V47, P345, DOI 10.1161/01.HYP.0000200702.76436.4b
   Page J, 2000, ARCH INTERN MED, V160, P777, DOI 10.1001/archinte.160.6.777
   Patrono C, 1998, CHEST, V114, p470S, DOI 10.1378/chest.114.5_Supplement.470S
   POPE JE, 1993, ARCH INTERN MED, V153, P477, DOI 10.1001/archinte.153.4.477
   Rashid P, 2003, STROKE, V34, P2741, DOI 10.1161/01.STR.0000092488.40085.15
   Rosendorff C, 2007, CIRCULATION, V115, P2761, DOI 10.1161/CIRCULATIONAHA.107.183885
   Scheiman James M, 2005, Rev Cardiovasc Med, V6 Suppl 4, pS23
   Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140 6736(04)16893 1
   Scott PA, 2008, EUR J HEART FAIL, V10, P1102, DOI 10.1016/j.ejheart.2008.07.013
   Silverstein FE, 2000, JAMA J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Singh G, 2002, AM J MANAG CARE, V8, pS383
   Smith SC, 2006, CIRCULATION, V113, P2363, DOI 10.1161/CIRCULATIONAHA.106.174516
   Sowers JR, 2005, ARCH INTERN MED, V165, P161, DOI 10.1001/archinte.165.2.161
   Towheed TE, 1997, J RHEUMATOL, V24, P349
   Turesson C, 2004, ANN RHEUM DIS, V63, P952, DOI 10.1136/ard.2003.018101
   Turnbull F, 2003, LANCET, V362, P1527
   VANDENOUWELAND FA, 1988, AGE AGEING, V17, P8, DOI 10.1093/ageing/17.1.8
   VANE JR, 1971, NATURE NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   Weber A, 2004, J MED CHEM, V47, P550, DOI 10.1021/jm030912m
   Whelton A, 2002, AM J CARDIOL, V90, P959, DOI 10.1016/S0002 9149(02)02661 9
   Whelton A, 2000, Am J Ther, V7, P159, DOI 10.1097/00045391 200007030 00004
   Whelton A., 1999, Am J Med, V106, p13S, DOI [10.1016/S0002 9343(99)00113 8, DOI 10.1016/S0002 9343(99)00113 8]
   White WB, 2007, AM J CARDIOL, V99, P91, DOI 10.1016/j.amjcard.2006.07.069
   White WB, 2009, AM J CARDIOL, V104, P840, DOI 10.1016/j.amjcard.2009.05.014
   Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646
NR 64
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1075 2765
EI 1536 3686
J9 AM J THER
JI Am. J. Ther.
PD NOV
PY 2011
VL 18
IS 6
BP 466
EP 476
DI 10.1097/MJT.0b013e3181e1e218
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 845WO
UT WOS:000296857600022
PM 21048434
DA 2025 08 17
ER

PT J
AU Tsai, CL
   Chen, WC
   Hsieh, HL
   Chi, PL
   Hsiao, LD
   Yang, CM
AF Tsai, Chia Lan
   Chen, Wei Chung
   Hsieh, Hsi Lung
   Chi, Pei Ling
   Hsiao, Li Der
   Yang, Chuen Mao
TI TNF α induces matrix metalloproteinase 9 dependent soluble intercellular
   adhesion molecule 1 release via TRAF2 mediated MAPKs and NF κB
   activation in osteoblast like MC3T3 E1 cells
SO JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Article
DE TNF alpha; MMP 9; Soluble ICAM 1; MAPKs; Osteoblast like MC3T3 E1 cells
ID NECROSIS FACTOR ALPHA; INDUCED MATRIX METALLOPROTEINASE 9 EXPRESSION;
   FUNCTION ASSOCIATED ANTIGEN 1; TRANSCRIPTION FACTOR; MESANGIAL CELLS;
   C SRC; INVOLVEMENT; ICAM 1; JOINT; DIFFERENTIATION
AB Background: Matrix metalloproteinase 9 (MMP 9) has been shown to be induced by cytokines including TNF alpha and may contribute to bone inflammatory diseases. However, the mechanisms underlying MMP 9 expression induced by TNF alpha in MC3T3 E1 cells remain unclear.
   Results: We applied gelatin zymography, Western blot, RT PCR, real time PCR, selective pharmacological inhibitors of transcription (actinomycin D, Act. D), translation (cycloheximide, CHI), c Src (PP1), MEK1/2 (U0126), p38 MAPK (SB202190), JNK1/2 (SP600125), and NF kappa B (Bay11 7082), respective siRNAs transfection, promoter assay, immunofluorescence staining, and ELISA to investigate the MMP 9 expression and soluble ICAM 1 (sICAM 1) release induced by TNF alpha in MC3T3 E1 cells. Here we demonstrated that TNF alpha induced MMP 9 expression was attenuated by Act. D, CHI, PP1, U0126, SB202190, SP600125, and Bay11 7082, and by the transfection with siRNAs for ERK2, p38 MAPK, and JNK2. TNF alpha stimulated TNFR1, TRAF2, and c Src complex formation was revealed by immunoprecipitation and Western blot. Furthermore, TNF alpha stimulated NF kappa B phosphorylation and translocation were blocked by Bay11 7082, but not by PP1, U0126, SB202190, or SP600125. TNF alpha time dependently induced MMP 9 promoter activity which was also inhibited by PP1, U0126, SB202190, SP600125, or Bay11 7082. Up regulation of MMP 9 was associated with the release of sICAM 1 into the cultured medium, which was attenuated by the pretreatment with MMP 2/9i, an MMP 9 inhibitor.
   Conclusions: In this study, we demonstrated that TNF alpha up regulates MMP 9 expression via c Src, MAPKs, and NF kappa B pathways. In addition, TNF alpha induced MMP 9 expression may contribute to the production of sICAM 1 by MC3T3 E1 cells. The interplay between MMP 9 expression and sICAM 1 release may exert an important role in the regulation of bone inflammatory diseases.
C1 [Tsai, Chia Lan; Chen, Wei Chung; Chi, Pei Ling; Hsiao, Li Der; Yang, Chuen Mao] Chang Gung Univ, Dept Physiol & Pharmacol, Tao Yuan, Taiwan.
   [Tsai, Chia Lan; Chen, Wei Chung; Chi, Pei Ling; Hsiao, Li Der; Yang, Chuen Mao] Chang Gung Univ, Coll Med, Hlth Ageing Res Ctr, Tao Yuan, Taiwan.
   [Hsieh, Hsi Lung] Chang Gung Univ Sci & Technol, Dept Nursing, Div Basic Med Sci, Tao Yuan, Taiwan.
C3 Chang Gung University; Chang Gung University; Chang Gung University of
   Science & Technology
RP Yang, CM (通讯作者)，Chang Gung Univ, Dept Physiol & Pharmacol, Tao Yuan, Taiwan.
EM chuenmao@mail.cgu.edu.tw
RI ; Chen, Mei/I 2763 2016
OI Yang, Chuen Mao/0000 0002 3208 5438; Chi, Pei Ling/0000 0003 0332 6682;
   Hsieh, Hsi Lung/0000 0001 8302 2472; 
FU Ministry of Education, Taiwan [EMRPD1D0231, EMRPD1D0241]; National
   Science Council, Taiwan [NSC102 2321 B 182 011,
   NSC101 2320 B 182 039 MY3, NSC99 2321 B182 003,
   NSC102 2320 B 255 005 MY3]; Chang Gung Medical Research Foundation
   [CMRPD180373, CMRPD1B0381, CMRPD1C0101, CMRPF1A0063]
FX This work was supported by the Ministry of Education, Taiwan, Grant
   number: EMRPD1D0231 and EMRPD1D0241; National Science Council, Taiwan,
   Grant number: NSC102 2321 B 182 011, NSC101 2320 B 182 039 MY3,
   NSC99 2321 B182 003, and NSC102 2320 B 255 005 MY3; Chang Gung Medical
   Research Foundation, Grant number: CMRPD180373, CMRPD1B0381,
   CMRPD1C0101, and CMRPF1A0063.
CR Abbas S, 2003, CYTOKINE, V22, P33, DOI 10.1016/S1043 4666(03)00106 6
   Ahrens D, 1996, ARTHRITIS RHEUM, V39, P1576, DOI 10.1002/art.1780390919
   Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506
   Ben David D, 2008, HISTOCHEM CELL BIOL, V129, P589, DOI 10.1007/s00418 008 0391 1
   Catrina AI, 2006, ARTHRITIS RHEUM US, V54, P76, DOI 10.1002/art.21528
   Chandrasekar B, 2006, J BIOL CHEM, V281, P15099, DOI 10.1074/jbc.M600200200
   Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788
   Eda H, 2011, RHEUMATOL INT, V31, P1525, DOI 10.1007/s00296 010 1688 7
   Fernandes JC, 2008, J BONE MINER METAB, V26, P543, DOI 10.1007/s00774 008 0866 0
   HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033
   Harada H, 1998, ENDOCRINOLOGY, V139, P3967, DOI 10.1210/en.139.9.3967
   Hisanaga T, 2011, CELL TISSUE RES, V346, P79, DOI 10.1007/s00441 011 1236 0
   Hsieh HL, 2004, CELL SIGNAL, V16, P1163, DOI 10.1016/j.cellsig.2004.03.021
   Hsieh HL, 2008, GLIA, V56, P619, DOI 10.1002/glia.20637
   Kaneko M, 2001, RHEUMATOLOGY, V40, P247, DOI 10.1093/rheumatology/40.3.247
   Krane SM, 2008, BONE, V43, P7, DOI 10.1016/j.bone.2008.03.020
   KURACHI T, 1993, BIOCHIM BIOPHYS ACTA, V1178, P259, DOI 10.1016/0167 4889(93)90202 Z
   KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0
   Lavigne P, 2005, EXPERT OPIN BIOL TH, V5, P313, DOI 10.1517/14712598.5.3.313
   Lee IT, 2010, J CELL PHYSIOL, V224, P454, DOI 10.1002/jcp.22142
   Lee MH, 2003, J BIOL CHEM
   Lee WJ, 2003, GLIA, V41, P15, DOI 10.1002/glia.10131
   Li W, 2010, BIOL REPROD, V83, P481, DOI 10.1095/biolreprod.109.082578
   Lin CC, 2008, TOXICOL APPL PHARM, V229, P386, DOI 10.1016/j.taap.2008.01.032
   Lynch CC, 2011, BONE, V48, P44, DOI 10.1016/j.bone.2010.06.007
   Moon SK, 2004, J CELL PHYSIOL, V198, P417, DOI 10.1002/jcp.10435
   Mousa SA, 2008, MOL BIOTECHNOL, V38, P33, DOI 10.1007/s12033 007 0072 7
   Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378 1119(03)00841 2
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Ohno N, 1997, INFLAMMATION, V21, P313, DOI 10.1023/A:1027349900279
   Okada Y, 2002, ENDOCR J, V49, P483, DOI 10.1507/endocrj.49.483
   Page McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   Pincheira R, 2008, J IMMUNOL, V181, P1288, DOI 10.4049/jimmunol.181.2.1288
   Powers JLT, 2010, BIOCHEMISTRY US, V49, P7821, DOI 10.1021/bi100726n
   Prasadam I, 2010, ARTHRITIS RHEUM US, V62, P1349, DOI 10.1002/art.27397
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Rengel Y, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2304
   Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756 3282(01)00682 2
   Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108
   Lacativa PGS, 2010, ARQ BRAS ENDOCRINOL, V54, P123, DOI 10.1590/S0004 27302010000200007
   Scian R, 2011, INFECT IMMUN, V79, P192, DOI 10.1128/IAI.00934 10
   Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955 0674(02)00363 0
   Shi Q, 2007, OSTEOARTHR CARTILAGE, V15, P300, DOI 10.1016/j.joca.2006.08.010
   Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   van Vliet C, 2005, NAT IMMUNOL, V6, P253, DOI 10.1038/ni1169
   Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400
   Witkowska AM, 2004, EUR CYTOKINE NETW, V15, P91
   Yang CM, 2013, BIOCHEM PHARMACOL, V85, P1115, DOI 10.1016/j.bcp.2013.01.013
   Yokoo T, 1996, AM J PHYSIOL RENAL, V270, pF123, DOI 10.1152/ajprenal.1996.270.1.F123
NR 50
TC 59
Z9 62
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1021 7770
EI 1423 0127
J9 J BIOMED SCI
JI J. Biomed. Sci.
PD FEB 5
PY 2014
VL 21
AR 12
DI 10.1186/1423 0127 21 12
PG 19
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA AF3WE
UT WOS:000334642300001
PM 24502696
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Suhana, MRE
   Farihah, HS
   Faizah, O
   Nazrun, SA
   Norazlina, M
   Norliza, M
   Nirwana, SI
AF Suhana, M. R. Elvy
   Farihah, H. S.
   Faizah, O.
   Nazrun, S. Ahmad
   Norazlina, M.
   Norliza, M.
   Nirwana, S. Ima
TI Piper sarmentosum Prevents Glucocorticoid Induced osteoporotic
   Bone Resorption by Increasing 11β Hydroxysteroid Dehydrogenase Type 1
   Activity
SO CLINICA TERAPEUTICA
LA English
DT Article
DE dexamethasone; glucocorticoids; osteoporosis; piper sarmentosum; 11
   beta hydroxysteroid dehydrogenase type 1
ID WATER EXTRACT; EXPRESSION; MINERALIZATION; OSTEOBLASTS; INHIBITION;
   MECHANISMS; APOPTOSIS; TURNOVER; CELLS
AB Aims. Osteoporosis is a proven complication of long tem glucocorticoid therapy. Concern on glucocorticoid induced osteoporosis has increased dramatically in recent years with the widespread use of synthetic glucocorticoids. Glucocorticoid action in bone depends upon the activity of 11 beta hydroxysteroid dehydrogenase type 1 enzyme (11 beta HSD1). This enzyme plays an important role in regulating corticosteroids by locally interconverting cortisone into active cortisol. This has been demonstrated in primary cultures of human, mouse or rat osteoblasts. Therefore, inhibition of this enzyme may reduce bone resorption markers. Piper sarmentosum (Ps) is a potent inhibitor of 11 beta HSD1 in liver and adipose tissue. In this study we determined the effect of Ps on 11 beta HSD1 activity in bones of glucocorticoid induced osteoporotic rats.
   Materials and Methods. Three month old male Sprague Dawley rats were adrenalectomised to remove the main source of circulating glucocorticoids. The animals were administered with dexamethasone 120 mu g/kg body weight/day. Treatment with Ps 125 mg/kg body weight and glycirrhizic acid (GCA) 120 mg/kg body weight were given simultaneously.
   Results. The results showed that Ps extract reduced plasma corticosterone concentration (1.05 +/  0.02 mu g/ml) and induced 11 beta HSD1 dehydrogenase activity in bone (87.69 +/  1.41%). Consequently, it also reduced the bone resorption marker, pyridinoline, in dexamethasone treated adrenalectomised rats (2.07 +/  0.62/L). Despite that, our data showed an inverse relationship between the plasma corticosterone level and the dehydrogenase activity of 11 beta HSD1 in the bone.
   Conclusions. This suggests that 11 beta HSD1 acts as the local regulator of glucocorticoid and its activity in bone was not correlated to systemic corticosterone level. Clin Ter 2011; 162(4):313 318
C1 [Nirwana, S. Ima] Univ Kebangsaan Malaysia, UKM Med Ctr, Dept Pharmacol, Kuala Lumpur 50300, Malaysia.
   [Suhana, M. R. Elvy; Farihah, H. S.; Faizah, O.] Univ Kebangsaan Malaysia, Dept Anat, Kuala Lumpur 50300, Malaysia.
C3 Universiti Kebangsaan Malaysia; Universiti Kebangsaan Malaysia
RP Nirwana, SI (通讯作者)，Univ Kebangsaan Malaysia, UKM Med Ctr, Dept Pharmacol, Kuala Lumpur 50300, Malaysia.
EM imasoel@medic.ukm.my
RI Soelaiman, Ima/C 4289 2017; SHUID, AHMAD/AAS 7556 2020
CR ALWAHAIBI A, 2007, TROP MED PLANTS, V8, P21
   Azlina AA, 2009, INT J PHARMACOL, V5, P362
   Canalis E, 1996, J CLIN ENDOCR METAB, V81, P3441, DOI 10.1210/jc.81.10.3441
   Cheng SL, 1996, J CELL BIOCHEM, V61, P182, DOI 10.1002/(SICI)1097 4644(19960501)61:2<182::AID JCB3>3.0.CO;2 Q
   Chiodini I, 1998, J CLIN ENDOCR METAB, V83, P1863, DOI 10.1210/jc.83.6.1863
   Cooper MS, 2001, J BONE MINER RES, V16, P1037, DOI 10.1359/jbmr.2001.16.6.1037
   Cooper MS, 2002, J BONE MINER RES, V17, P979, DOI 10.1359/jbmr.2002.17.6.979
   Cooper MS, 2000, BONE, V27, P375, DOI 10.1016/S8756 3282(00)00344 6
   Cushing H, 1932, B JOHNS HOPKINS HOSP, V50, P137
   DEFRANCO DJ, 1992, ENDOCRINOLOGY, V131, P114, DOI 10.1210/en.131.1.114
   HERBERTSON A, 1995, J BONE MINER RES, V10, P285
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Huizenga NA, 1998, J CLIN ENDOCR METAB, V83, P44
   IBA K, 1995, CELL STRUCT FUNCT, V20, P319, DOI 10.1247/csf.20.319
   Ima Nirwana S, 2002, Med J Malaysia, V57, P136
   Ima Nirwana S, 2004, J MED FOOD, V7, P45, DOI 10.1089/109662004322984699
   Lems WF, 1998, BRIT J RHEUMATOL, V37, P27
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Pereira RMR, 2001, BONE, V28, P484, DOI 10.1016/S8756 3282(01)00422 7
   Peungvicha P, 1998, J ETHNOPHARMACOL, V60, P27, DOI 10.1016/S0378 8741(97)00127 X
   Pierotti S, 2008, J STEROID BIOCHEM, V108, P292, DOI 10.1016/j.jsbmb.2007.09.018
   PRUMMEL MF, 1991, J CLIN ENDOCR METAB, V72, P382, DOI 10.1210/jcem 72 2 382
   Rubin J, 1998, ENDOCRINOLOGY, V139, P1006, DOI 10.1210/en.139.3.1006
   Seckl JR, 2001, ENDOCRINOLOGY, V142, P1371, DOI 10.1210/en.142.4.1371
   TANNIN GM, 1991, J BIOL CHEM, V266, P16653
   Weinstein R S, 2001, Rev Endocr Metab Disord, V2, P65, DOI 10.1023/A:1010007108155
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
NR 27
TC 8
Z9 8
U1 0
U2 5
PU SOC EDITRICE UNIV
PI ROME
PA VIA G B MORGAGNI 1, ROME, 10061, ITALY
SN 0009 9074
EI 1972 6007
J9 CLIN TER
JI Clin. Ter.
PD JUL AUG
PY 2011
VL 162
IS 4
BP 313
EP 318
PG 6
WC Medicine, General & Internal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Pharmacology & Pharmacy
GA 825CV
UT WOS:000295249400004
PM 21912818
DA 2025 08 17
ER

PT J
AU Jeon, E
   Yun, YR
   Kang, W
   Lee, S
   Koh, YH
   Kim, HW
   Suh, CK
   Jang, JH
AF Jeon, Eunyi
   Yun, Ye Rang
   Kang, Wonmo
   Lee, Sujin
   Koh, Young Hyag
   Kim, Hae Won
   Suh, Chang Kook
   Jang, Jun Hyeog
TI Investigating the Role of FGF18 in the Cultivation and Osteogenic
   Differentiation of Mesenchymal Stem Cells
SO PLOS ONE
LA English
DT Article
ID FIBROBLAST GROWTH FACTOR; FACTOR (FGF) 18; PROLIFERATION; OSTEOBLAST;
   FACTOR 18; FGF 18; EXPRESSION; THERAPY; SIGNALS; PROTEIN
AB Fibroblast growth factor18 (FGF18) belongs to the FGF family and is a pleiotropic protein that stimulates proliferation in several tissues. Bone marrow mesenchymal stem cells (BMSCs) participate in the normal replacement of damaged cells and in disease healing processes within bone and the haematopoietic system. In this study, we constructed FGF18 and investigated its effects on rat BMSCs (rBMSCs). The proliferative effects of FGF18 on rBMSCs were examined using an MTS assay. To validate the osteogenic differentiation effects of FGF18, ALP and mineralization activity were examined as well as osteogenic differentiation related gene levels. FGF18 significantly enhanced rBMSCs proliferation (p < 0.001) and induced the osteogenic differentiation by elevating ALP and mineralization activity of rBMSCs (p < 0.001). Furthermore, these osteogenic differentiation effects of FGF18 were confirmed via increasing the mRNA levels of collagen type I (Col I), bone morphogenetic protein 4 (BMP4), and Runt related transcription factor 2 (Runx2) at 3 and 7 days. These results suggest that FGF18 could be used to improve bone repair and regeneration.
C1 [Jeon, Eunyi; Kang, Wonmo; Lee, Sujin; Jang, Jun Hyeog] Inha Univ, Sch Med, Dept Biochem, Inchon, South Korea.
   [Yun, Ye Rang; Kim, Hae Won] Dankook Univ, Inst Tissue Regenerat Engn, Cheonan 330714, South Korea.
   [Koh, Young Hyag] Korea Univ, Dept Denatal Lab Sci & Engn, Seoul, South Korea.
   [Kim, Hae Won] Dankook Univ, Grad Sch, Dept Nanobiomed Sci, Cheonan, South Korea.
   [Kim, Hae Won] Dankook Univ, Grad Sch, WCU Res Ctr, Cheonan, South Korea.
   [Kim, Hae Won] Dankook Univ, Sch Dent, Dept Biomat Sci, Cheonan, South Korea.
   [Suh, Chang Kook] Inha Univ, Sch Med, Dept Physiol & Biophys, Inchon, South Korea.
C3 Inha University; Dankook University; Korea University; Dankook
   University; Dankook University; Dankook University; Inha University
RP Jeon, E (通讯作者)，Inha Univ, Sch Med, Dept Biochem, Inchon, South Korea.
EM kimhw@dku.edu; juhjang@inha.ac.kr
RI Jang, Jun Hyeog/P 6957 2014
FU Priority Research Centers Program through the National Research
   Foundation (NRF) [2009 0093829]; WCU (World Class University) through
   the National Research Foundation (NRF) [R31 10069]; Basic Science
   Research program through the National Research Foundation (NRF);
   Ministry of Education, Science and Technology through the National
   Research Foundation (NRF) [2010 0022628]; Ministry of Education, Science
   and Technology; Korea Healthcare technology R&D Project, Ministry of
   Health & Welfare, Republic of Korea [A110416]; Inha University
FX This work was supported by Priority Research Centers Program (grant#:
   2009 0093829) and WCU (World Class University) program (grant#:
   R31 10069) and Basic Science Research program through the National
   Research Foundation (NRF) funded by the Ministry of Education, Science
   and Technology (grant#: 2010 0022628) through the National Research
   Foundation (NRF) funded by the Ministry of Education, Science and
   Technology and a grant of the Korea Healthcare technology R&D Project,
   Ministry of Health & Welfare, Republic of Korea (A110416) and Inha
   University Grant. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR [Anonymous], CELL BIOL I IN PRESS
   Behr B, 2011, TISSUE ENG PT A, V17, P2061, DOI [10.1089/ten.TEA.2010.0719, 10.1089/ten.tea.2010.0719]
   Beyer Nardi N, 2006, HANDB EXP PHARM, V174, P249
   Bond SR, 2011, J BONE MINER RES, V26, P2911, DOI 10.1002/jbmr.509
   Davidson D, 2005, J BIOL CHEM, V280, P20509, DOI 10.1074/jbc.M410148200
   Ellsworth JL, 2002, OSTEOARTHR CARTILAGE, V10, P308, DOI 10.1053/joca.2002.0514
   Grayson WL, 2004, BIOTECHNOL PROGR, V20, P905, DOI 10.1021/bp034296z
   Hamidouche Z, 2010, J CELL PHYSIOL, V224, P509, DOI 10.1002/jcp.22152
   Hu MCT, 1999, ONCOGENE, V18, P2635, DOI 10.1038/sj.onc.1202616
   Hu MCT, 1998, MOL CELL BIOL, V18, P6063, DOI 10.1128/MCB.18.10.6063
   Kassem M, 2006, ANN NY ACAD SCI, V1067, P436, DOI 10.1196/annals.1354.062
   Kimelman N, 2006, REGEN MED, V1, P549, DOI 10.2217/17460751.1.4.549
   Li YG, 2011, KNEE SURG SPORT TR A, V19, P2153, DOI 10.1007/s00167 011 1506 0
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092 8674(95)90276 7
   Liu ZH, 2002, GENE DEV, V16, P859, DOI 10.1101/gad.965602
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539
   Martin I, 1997, ENDOCRINOLOGY, V138, P4456, DOI 10.1210/en.138.10.4456
   Moore EE, 2005, OSTEOARTHR CARTILAGE, V13, P623, DOI 10.1016/j.joca.2005.03.003
   Oh SA, 2010, J TISSUE ENG, V1, DOI 10.4061/2010/475260
   Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161
   Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pri Chen S, 1998, BONE, V23, P111, DOI 10.1016/S8756 3282(98)00087 8
   Shimoaka T, 2002, J BIOL CHEM, V277, P7493, DOI 10.1074/jbc.M108653200
   Smith SML, 2007, ARCH BIOCHEM BIOPHYS, V468, P244, DOI 10.1016/j.abb.2007.10.006
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Teplyuk NM, 2008, J BIOL CHEM, V283, P27585, DOI 10.1074/jbc.M802453200
   Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411
   Yun YR, 2010, J TISSUE ENG, V1, DOI 10.4061/2010/218142
NR 31
TC 35
Z9 37
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
EI 1932 6203
J9 PLOS ONE
JI PLoS One
PD AUG 24
PY 2012
VL 7
IS 8
AR e43982
DI 10.1371/journal.pone.0043982
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 998GM
UT WOS:000308225500132
PM 22937141
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Ates, GB
   Ak, A
   Garipcan, B
   Gülsoy, M
AF Ates, Gamze Bolukbasi
   Ak, Ayse
   Garipcan, Bora
   Gulsoy, Murat
TI Methylene blue mediated photobiomodulation on human osteoblast cells
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Photobiomodulation (PBM); Photodynamic therapy (PDT); Osteoblast;
   Methylene blue; Low level laser therapy (LLLT); 635 nm
ID LEVEL LASER THERAPY; PHOTODYNAMIC THERAPY; IN VITRO; STEM CELLS;
   PROMOTES PROLIFERATION; IRRADIATION; DIFFERENTIATION; LIGHT; GROWTH;
   PHOTOCHEMOTHERAPY
AB Photobiomodulation (PBM) and photodynamic therapy (PDT) are two major methods, which use light in medicine and dentistry. PBM uses low level laser light to induce cell proliferation and activity. In contrast, PDT use laser light combined with a photosensitizer (PS) to cause cell death. Due to similar, not fully understood mechanisms and biphasic response of light, unexpected and complex outcomes may be observed. In the present study, the effect of 635 nm laser light, with power density 50 mW/cm(2), at three different energy densities (0.5, 1, and 2 J/cm(2) which last 10, 20, and 40 s, respectively) mediated by methylene blue (MB) on the human osteoblast cell line (ATCC CRL 11372, Rockville, MD, USA) was investigated. Cell viability (MTT assay and acridine orange/propidium iodide staining) and proliferation (Alamar Blue assay) were assessed at 24, 48, and 72 h post irradiation. Alkaline phosphatase (ALP) activity, mineralization (Alizarin Red staining) and gene expressions (RT PCR analysis) were analyzed at 7th and 14th days after treatment. Five groups were formed as the control group (no MB, no irradiation), MB (only 0.05 mu M MB), MB + 0.5 J/cm(2), MB + 1 J/cm(2), and MB + 2 J/cm(2). Cell viability was decreased at 72 h (ANOVA; p < 0.05) for MB + 0.5 J/cm(2), MB + 1 J/cm(2), and MB + 2 J/cm(2) groups. Although proliferation does not seem to be effected by MB mediated laser application, osteo anabolic activity is altered. ALP activity was significantly increased at day 7 (ANOVA; p < 0.05) for MB combined laser groups; on the other hand, mineralization was significantly decreased (ANOVA; p < 0.05) in all treatment groups. Alkaline phosphatase and collagen I expressions were upregulated in MB + 2 J/cm(2) group at 7th and 14th days, respectively. These results may contribute to the low dose PDT researches and understanding PBM effects on osteoblast behavior but further studies are needed since inappropriate conditions may lead to undesirable results for both therapies.
C1 [Ates, Gamze Bolukbasi; Garipcan, Bora; Gulsoy, Murat] Bogazici Univ, Inst Biomed Engn, TR 34684 Istanbul, Turkey.
   [Ak, Ayse] Erzincan Univ, Engn Fac, Biomed Engn, TR 24100 Erzincan, Turkey.
C3 Bogazici University; Erzincan Binali Yildirim University
RP Ates, GB (通讯作者)，Bogazici Univ, Inst Biomed Engn, TR 34684 Istanbul, Turkey.
EM gbolukbasi@boun.edu.tr
RI AK, Ayşe/AAR 1485 2020; Gülsoy, Murat/L 1345 2018; Garipcan,
   Bora/AAM 1061 2020
OI Ak, Ayse/0000 0002 1385 5847; Gulsoy, Murat/0000 0002 0773 9567; 
FU Scientific and Research Council of Turkey (TUBITAK) [113Z059]
FX This study was supported by grant (113Z059) of the Scientific and
   Research Council of Turkey (TUBITAK).
CR Almeida Lopes L, 2001, LASER SURG MED, V29, P179, DOI 10.1002/lsm.1107
   Ates GB, 2017, LASER MED SCI, V32, P591, DOI 10.1007/s10103 017 2153 6
   BARUSHKA O, 1995, BONE, V16, P47, DOI 10.1016/S8756 3282(94)00006 9
   Blázquez Castro A, 2014, PHOTOCH PHOTOBIO SCI, V13, P1235, DOI 10.1039/c4pp00113c
   Blázquez Castro A, 2012, EUR J CELL BIOL, V91, P216, DOI 10.1016/j.ejcb.2011.12.001
   Borzabadi Farahani A, 2016, J PHOTOCH PHOTOBIO B, V162, P577, DOI 10.1016/j.jphotobiol.2016.07.022
   Bezerra SJC, 2015, CASE REP DENT, V2015, DOI 10.1155/2015/132656
   Crous A, 2016, PHOTOMED LASER SURG, V34, P525, DOI 10.1089/pho.2015.3979
   de Almeida JM, 2007, J PERIODONTOL, V78, P566, DOI 10.1902/jop.2007.060214
   de Villiers JA, 2011, STEM CELL REV REP, V7, P869, DOI 10.1007/s12015 011 9244 8
   Ebrahimi T, 2012, J Dent (Tehran), V9, P238
   Fekrazad R, 2016, PHOTOMED LASER SURG, V34, P533, DOI 10.1089/pho.2015.4029
   Fekrazad R, 2016, PHOTOMED LASER SURG, V34, P543, DOI 10.1089/pho.2015.4028
   Barboza CAG, 2014, EINSTEIN SAO PAULO, V12, P75, DOI 10.1590/S1679 45082014AO2824
   Ginani F, 2015, LASER MED SCI, V30, P2189, DOI 10.1007/s10103 015 1730 9
   Hawkins D, 2006, PHOTOMED LASER SURG, V24, P705, DOI 10.1089/pho.2006.24.705
   Huang YY, 2011, DOSE RESPONSE, V9, P602, DOI 10.2203/dose response.11 009.Hamblin
   Huang ZY, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0882 0
   Juarranz A, 2008, CLIN TRANSL ONCOL, V10, P148, DOI 10.1007/s12094 008 0172 2
   Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011 1344(98)00219 X
   Kim HK, 2009, LASER MED SCI, V24, P214, DOI 10.1007/s10103 008 0550 6
   KONIG K, 1987, J CANCER RES CLIN, V113, P301, DOI 10.1007/BF00396390
   Kreisler M, 2003, LASER MED SCI, V18, P100, DOI 10.1007/s10103 003 0265 7
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   Kushibiki T, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/974864
   LEE YS, 1995, CANCER LETT, V88, P141, DOI 10.1016/0304 3835(94)03629 W
   Lim HJ, 2014, LASER MED SCI, V29, P659, DOI 10.1007/s10103 013 1363 9
   Luger EJ, 1998, LASER SURG MED, V22, P97, DOI 10.1002/(SICI)1096 9101(1998)22:2<97::AID LSM5>3.3.CO;2 E
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Mellish KJ, 2002, PHOTOCHEM PHOTOBIOL, V75, P392, DOI 10.1562/0031 8655(2002)075<0392:IVPAOA>2.0.CO;2
   Min KH, 2015, AESTHET PLAST SURG, V39, P778, DOI 10.1007/s00266 015 0524 6
   Moore P, 2005, LASER SURG MED, V36, P8, DOI 10.1002/lsm.20117
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Murayama H, 2012, LASER MED SCI, V27, P87, DOI 10.1007/s10103 011 0924 z
   Mvula B, 2008, LASER MED SCI, V23, P277, DOI 10.1007/s10103 007 0479 1
   Oliveira CF, 2010, LASER PHYS, V20, P1659, DOI 10.1134/S1054660X10130153
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Orth K, 1998, LANGENBECK ARCH SURG, V383, P276, DOI 10.1007/s004230050132
   Peng F, 2010, 2010 S PHOT OPT, P1, DOI [10.1109/SOPO.2010.5504091, DOI 10.1109/SOPO.2010.5504091]
   Peng F, 2012, LASER MED SCI, V27, P645, DOI 10.1007/s10103 011 1005 z
   Peplow PV, 2010, PHOTOMED LASER SURG, V28, pS3, DOI 10.1089/pho.2010.2771
   Pogrel MA, 1997, LASER SURG MED, V20, P426, DOI 10.1002/(SICI)1096 9101(1997)20:4<426::AID LSM8>3.0.CO;2 S
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Saito S, 1997, AM J ORTHOD DENTOFAC, V111, P525, DOI 10.1016/S0889 5406(97)70152 5
   Saygun I, 2008, LASER MED SCI, V23, P211, DOI 10.1007/s10103 007 0477 3
   Schindl A, 2003, BRIT J DERMATOL, V148, P334, DOI 10.1046/j.1365 2133.2003.05070.x
   Schwartz HO, 2011, LASER MED SCI, V26, P539, DOI 10.1007/s10103 011 0902 5
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Stein A, 2005, PHOTOMED LASER SURG, V23, P161, DOI 10.1089/pho.2005.23.161
   Tabatabaei FS, 2015, LASER PHYS, V25, DOI 10.1088/1054 660X/25/9/095602
   Tardivo JP, 2005, PHOTODIAGN PHOTODYN, V2, P175, DOI 10.1016/S1572 1000(05)00097 9
   Theocharidou A, 2017, LASER MED SCI, V32, P201, DOI 10.1007/s10103 016 2102 9
   TRAGANOS F, 1977, J HISTOCHEM CYTOCHEM, V25, P46, DOI 10.1177/25.1.64567
   Tuby H, 2007, LASER SURG MED, V39, P373, DOI 10.1002/lsm.20492
   TUITE EM, 1993, J PHOTOCH PHOTOBIO B, V21, P103, DOI 10.1016/1011 1344(93)80173 7
   Wan J, 2015, INT IMMUNOPHARMACOL, V28, P44, DOI 10.1016/j.intimp.2015.05.025
   Woodruff LD, 2004, PHOTOMED LASER SURG, V22, P241, DOI 10.1089/1549541041438623
   Cavalcanti MFXB, 2015, PHOTOMED LASER SURG, V33, P610, DOI 10.1089/pho.2014.3864
   Xu M, 2009, PHOTOMED LASER SURG, V27, P309, DOI 10.1089/pho.2008.2283
   Yu Hyeong Gon, 2003, Korean J Ophthalmol, V17, P29
   Zancanela DC, 2011, PHOTOMED LASER SURG, V29, P699, DOI 10.1089/pho.2010.2929
NR 61
TC 34
Z9 36
U1 0
U2 46
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD NOV
PY 2017
VL 32
IS 8
BP 1847
EP 1855
DI 10.1007/s10103 017 2286 7
PG 9
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA FK6NK
UT WOS:000413620900016
PM 28776111
DA 2025 08 17
ER

PT J
AU Tohidnezhad, M
   Wruck, CJ
   Slowik, A
   Kweider, N
   Beckmann, R
   Bayer, A
   Houben, A
   Brandenburg, LO
   Varoga, D
   Sönmez, TT
   Stoffel, M
   Jahr, H
   Lippross, S
   Pufe, T
AF Tohidnezhad, Mersedeh
   Wruck, Christoph Jan
   Slowik, Alexander
   Kweider, Nisreen
   Beckmann, Rainer
   Bayer, Andreas
   Houben, Astrid
   Brandenburg, Lars Ove
   Varoga, Deike
   Soenmez, Tolga Taha
   Stoffel, Marcus
   Jahr, Holger
   Lippross, Sebastian
   Pufe, Thomas
TI Role of platelet released growth factors in detoxification of reactive
   oxygen species in osteoblasts
SO BONE
LA English
DT Article
DE Nrf2; PRP; VEGF; Fracture healing
ID RICH PLASMA; OXIDATIVE STRESS; INTRAARTICULAR INJECTION; PROTEIN KINASE;
   CELLS; NRF2; EXPRESSION; PROLIFERATION; BETA; VEGF
AB Introduction: Oxidative stress can impair fracture healing. To protect againstoxidative damage, a system of detoxifying and antioxidative enzymes works to reduce the cellular stress. The transcription of these enzymes is regulated by antioxidant response element (ARE). The nuclear factor (erythroid derived 2) like2 (Nrf2) plays a major role in transcriptional activation of ARE driven genes. Recently it has been shown that vascular endothelial growth factor (VEGF) prevents oxidative damage via activation of the Nrf2 pathway in vitro. Platelet released growth factor (PRGF) is a mixture of autologous proteins and growth factors, prepared from a determined volume of platelet rich plasma (PRP). It has already used to enhance fracture healing in vitro. The aim of the present study was to elucidate if platelets can lead to upregulation of VEGF and if platelets can regulate the activity of Nrf2 ARE system in primary human osteoblast (hOB) and in osteoblast like cell line (SAOS 2),
   Methods: Platelets and PRGF were obtained from healthy human donors.
   HOB and SAOS 2 osteosarcoma cell line were used. The ARE activity was analysed using a dual luciferase reporter assay system. We used Western blot to detect the nuclear accumulation of Nrf2 and the amount of cytosolic antioxidant Thioredoxin Reductase 1 (TXNRD 1), Heme Oxygenase 1 (HO 1) and NAD(P)H quinine oxidoreductase 1 (NQO1). Gene expression analysis was performed by real time RT PCR. ELISA was used for the quantification of growth factors.
   Results: The activity of ARE was increased in the presence of PRGF up to 50%. Western blotting demonstrated enhanced nuclear accumulation of Nrf2. This was followed by an increase in the protein expression of the aforementioned downstream targets of Nrf2; Real time RTPCR data showed an upregulation in the gene expression of the VEGF after PRGF treatment This was confirmed by ELISA, where the treatment with PRGF induced the protein level of VEGF in both cells.
   Conclusions: These results provide a new insight into PRGF's mode of action in osteoblasts. PRGF not only leads to increase the endogenous VEGF, but also it may be involved in preventing oxidative damage through the Nrf2 ARE signalling. Nrf2 activation via PRGF may have great potential as an effective therapeutic drug target in fracture healing. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Tohidnezhad, Mersedeh; Wruck, Christoph Jan; Slowik, Alexander; Kweider, Nisreen; Beckmann, Rainer; Houben, Astrid; Brandenburg, Lars Ove; Pufe, Thomas] Rhein Westfal TH Aachen, Dept Anat & Cell Biol, D 52074 Aachen, Germany.
   [Bayer, Andreas; Varoga, Deike; Lippross, Sebastian] Univ Hosp Schleswig Holstein, Dept Trauma Surg, D 24105 Kiel, Germany.
   [Soenmez, Tolga Taha] Rhein Westfal TH Aachen, Dept Oral & Maxillofacial Surg, D 52074 Aachen, Germany.
   [Stoffel, Marcus] Rhein Westfal TH Aachen, Inst Gen Mech, D 52062 Aachen, Germany.
   [Jahr, Holger] Rhein Westfal TH Aachen, Dept Orthopaed Surg, D 52074 Aachen, Germany.
C3 RWTH Aachen University; University of Kiel; Schleswig Holstein
   University Hospital; RWTH Aachen University; RWTH Aachen University;
   RWTH Aachen University
RP Tohidnezhad, M (通讯作者)，Rhein Westfal TH Aachen, Dept Anat & Cell Biol, Wendlingweg 2, D 52074 Aachen, Germany.
EM mtohidnezhad@ukaachen.de; cwruck@ukaachen.de; aslowik@ukaachen.de;
   nkweider@ukaachen.de; rbeckmann@ukaachen.de; andreasbayer kiel@web.de;
   astrid.houben@ukmuenster.de; lbrandenburg@ukaachen.de;
   deike.varoga@uksh kiel.de; tsoenmez@ukaachen.de;
   Stoffel@iam.rwth aachen.de; hjahr@ukaachen.de;
   sebastian.lippross@uksh kiel.de; tpufe@ukaachen.de
RI ; Sönmez, Tolga/D 6863 2013; Jahr, Holger/M 3099 2015
OI Pufe, Thomas/0000 0002 7886 9211; Dr. Slowik,
   Alexander/0000 0001 9907 2263; Jahr, Holger/0000 0001 7308 5584;
   Stoffel, Marcus/0000 0001 8756 2310
FU German Research Foundation (Deutsche Forschungsgemeinschaft) [DR449/2 1,
   PU214/5 2, VA 220/2 1, PU214/4 2, PU214/3 2]; Medical Faculty Kiel
   (FoFo); Forschungsschwerpunkt Muskel  und Skelettsystem
   (Musculo Skeletal Science Kiel, MSS Kiel) of the University Hospital of
   Schleswig Holstein, Kiel; German society for orthopaedics and
   orthopaedics surgery (DGOOC); Interdisciplinary Centre for Clinical
   Research (IZKF) within the faculty of Medicine at the RWTH Aachen
   University [T9 5]
FX The study was supported by German Research Foundation (Deutsche
   Forschungsgemeinschaft) grants DR449/2 1, PU214/5 2, VA 220/2 1,
   PU214/4 2, and PU214/3 2; by a grant from the Medical Faculty Kiel
   (FoFo); by the Forschungsschwerpunkt Muskel  und Skelettsystem
   (Musculo Skeletal Science Kiel, MSS Kiel) of the University Hospital of
   Schleswig Holstein, Kiel; by German society for orthopaedics and
   orthopaedics surgery (DGOOC); and by a grant from the Interdisciplinary
   Centre for Clinical Research (IZKF) within the faculty of Medicine at
   the RWTH Aachen University (T9 5).
CR Akeda K, 2006, OSTEOARTHR CARTILAGE, V14, P1272, DOI 10.1016/j.joca.2006.05.008
   Anitua E, 2005, J ORTHOP RES, V23, P281, DOI 10.1016/j.orthres.2004.08.015
   Arpornmaeklong P, 2004, INT J ORAL MAX SURG, V33, P60, DOI 10.1054/ijom.2003.0492
   Bielecki T, 2008, EUR SURG RES, V40, P289, DOI 10.1159/000114967
   Brandenburg LO, 2010, INFLAMM RES, V59, P443, DOI 10.1007/s00011 009 0116 5
   Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731
   Chang IC, 2010, J BIOMED MATER RES A, V95A, P327, DOI 10.1002/jbm.a.32839
   Foster TE, 2009, AM J SPORT MED, V37, P2259, DOI 10.1177/0363546509349921
   Fuerst G, 2004, CLIN ORAL IMPLAN RES, V15, P301, DOI 10.1046/j.1600 0501.2003.01007.x
   Graziani F, 2006, CLIN ORAL IMPLAN RES, V17, P212, DOI 10.1111/j.1600 0501.2005.01203.x
   Graziani F, 2005, Minerva Stomatol, V54, P15
   HARADA S, 1995, CLIN ORTHOP RELAT R, P76
   HARRISON P, 1993, BLOOD REV, V7, P52, DOI 10.1016/0268 960X(93)90024 X
   Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997
   Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023
   Ji LL, 2014, INT J CLIN EXP PATHO, V7, P1124
   Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005
   JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195
   Kensler TW, 2013, TOP CURR CHEM, V329, P163, DOI 10.1007/128_2012_339
   Kweider N, 2011, J BIOL CHEM, V286, P42863, DOI 10.1074/jbc.M111.286880
   Lee JM, 2005, FASEB J, V19, P1061, DOI 10.1096/fj.04 2591hyp
   Lippross S, 2011, ARTHRITIS RHEUM US, V63, P3344, DOI 10.1002/art.30547
   Margolis DJ, 2001, DIABETES CARE, V24, P483, DOI 10.2337/diacare.24.3.483
   Mehrotra M, 2004, J CELL BIOCHEM, V93, P741, DOI 10.1002/jcb.20138
   NASH TJ, 1994, BONE, V15, P203, DOI 10.1016/8756 3282(94)90709 9
   Nishimoto S, 2007, WOUND REPAIR REGEN, V15, P156, DOI 10.1111/j.1524 475X.2006.00196.x
   Ray PS, 2009, NATURE, V457, P915, DOI 10.1038/nature07598
   Sanchez M, 2008, CLIN EXP RHEUMATOL, V26, P910
   Shibuya A, 2010, BIOCHEM BIOPH RES CO, V398, P581, DOI 10.1016/j.bbrc.2010.06.124
   Sönmez TT, 2013, BIOMATERIALS, V34, P2674, DOI 10.1016/j.biomaterials.2013.01.016
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Takahata Y, 2009, J CELL PHYSIOL, V218, P268, DOI 10.1002/jcp.21594
   Tohidnezhad M, 2011, HISTOCHEM CELL BIOL, V135, P453, DOI 10.1007/s00418 011 0808 0
   Tohidnezhad M, 2012, PLATELETS, V23, P217, DOI 10.3109/09537104.2011.610908
   Tohidnezhad M, 2011, INJURY, V42, P682, DOI 10.1016/j.injury.2010.12.010
   Trebec Reynolds DP, 2010, J CELL BIOCHEM, V110, P343, DOI 10.1002/jcb.22542
   Turgut A, 1999, ACTA ORTHOP SCAND, V70, P487, DOI 10.3109/17453679909000986
   Varoga D, 2008, J ANAT, V213, P749, DOI 10.1111/j.1469 7580.2008.00992.x
   Virchenko O, 2006, ACTA ORTHOP, V77, P806, DOI 10.1080/17453670610013033
   Weibrich G, 2002, J CRANIO MAXILL SURG, V30, P97, DOI 10.1054/jcms.2002.0285
   Wruck CJ, 2007, J NEURAL TRANSM SUPP, P57
   Wruck CJ, 2008, MOL PHARMACOL, V73, P1785, DOI 10.1124/mol.107.042499
   Yeager RL, 2009, TOXICOL SCI, V111, P238, DOI 10.1093/toxsci/kfp115
   Yeler H, 2005, CELL BIOCHEM FUNCT, V23, P137, DOI 10.1002/cbf.1199
   Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683 07.2007
NR 45
TC 63
Z9 66
U1 0
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD AUG
PY 2014
VL 65
BP 9
EP 17
DI 10.1016/j.bone.2014.04.029
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AJ8YV
UT WOS:000337994900002
PM 24798492
DA 2025 08 17
ER

PT J
AU Drescher, W
   Alarifi, M
AF Drescher, W.
   Alarifi, M.
TI An update on femoral head necrosis
SO MINERVA ORTOPEDICA E TRAUMATOLOGICA
LA English
DT Article
DE Femur head necrosis; Hip; Arthroplasty, replacement, hip
ID TOTAL HIP ARTHROPLASTY; BONE MARROW EDEMA; STEROID RELATED
   COMPLICATIONS; HIGH DOSE METHYLPREDNISOLONE; EXTRACORPOREAL SHOCK WAVES;
   AVASCULAR NECROSIS; ATRAUMATIC OSTEONECROSIS; CORE DECOMPRESSION;
   FLEXION OSTEOTOMY; SURVIVAL ANALYSIS
AB Femoral head necrosis is an ischemic bone necrosis of traumatic or nontraumatic pathogenesis which can lead to hip joint destruction in young age. It is today the indication for 10% of all the total hip joint replacements. Known etiologies of nontraumatic femoral head necrosis are alcoholism, steroids, sickle cell anemia, caisson, and Gaucher's disease. Further risk factors are chemotherapy, chronic inflammatory bowel disease, systemic lupus erythematosus, and multiple sclerosis, in which also steroids are involved. Gravidity is another risk factor, but still idiopathic pathogenesis is found. In diagnosis, the ARCO classification of the Association for the Research of Osseous Circulation is essential. While stage 0 can only be found histologically, the reversible early stage 1 shows MR signal changes. In the irreversible early stage 2, first native X ray changes are seen as lower radiolucency reflects new bone apposition on dead trabeculae. In stage. 3, subchondral fracture follows, and in stage 4 secondary arthritis of the hip. Established therapy in stage 1 is core decompression, physiotherapy, and also bisphosphonates. Sufficient data to support extracorporeal shock wave therapy are still lacking. Stem cell therapy seems to be a promising new therapy method in stage 2. In stage 2 and 3 mainly proximal femoral osteotomies and (non) vascularized bone transplantation are performed. In stage 4, depending on size and location of the necrotic zone and pathology of the adjacent bone, resurfacing or short stem hip arthroplasty can be performed. However, conventional THA still is golden standard. The problem and challenge, however, is the often young patient age in femoral head necrosis. Especially chemotherapy associated osteonecrosis in leukemia is found in patients in their second decade of life. Therefore, the hip should be preserved as long as possible.
C1 [Drescher, W.] RWTH Aachen Univ Hosp, Aachen, Germany.
   [Alarifi, M.] King Saud bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia.
C3 RWTH Aachen University; RWTH Aachen University Hospital; King Saud Bin
   Abdulaziz University for Health Sciences
RP Drescher, W (通讯作者)，RWTH Aachen Univ Hosp, Aachen, Germany.
EM wdrescher@ukaachen.de
CR Abu Shakra M, 2003, CLIN REV ALLERG IMMU, V25, P13, DOI 10.1385/CRIAI:25:1:13
   Agarwala S, 2009, J BONE JOINT SURG BR, V91B, P1013, DOI 10.1302/0301 620X.91B8.21518
   Aigner N, 2009, ORTHOP CLIN N AM, V40, P241, DOI 10.1016/j.ocl.2008.10.007
   Akbar M, 2008, ORTHOPADE, V37, P672, DOI 10.1007/s00132 008 1277 6
   Aldridge JM, 2004, J BONE JOINT SURG AM, V86A, P1955, DOI 10.2106/00004623 200409000 00014
   Alves EM, 2009, CLIN RHEUMATOL, V28, P1247, DOI 10.1007/s10067 009 1231 y
   Aricò M, 2003, HAEMATOLOGICA, V88, P747
   Atsumi T, 2000, J BONE JOINT SURG BR, V82B, P392, DOI 10.1302/0301 620X.82B3.10193
   Baumgarten KM, 2001, CLIN ORTHOP RELAT R, P191
   Berend KR, 2003, J BONE JOINT SURG AM, V85A, P987, DOI 10.2106/00004623 200306000 00001
   Castro FP, 1999, J ARTHROPLASTY, V14, P672, DOI 10.1016/S0883 5403(99)90221 8
   Ce P, 2006, EUR J NEUROL, V13, P857, DOI 10.1111/j.1468 1331.2006.01375.x
   Chang JD, 2008, CLIN ORTHOP RELAT R, V466, P1041, DOI 10.1007/s11999 008 0147 1
   Chiu KH, 1997, J ARTHROPLASTY, V12, P683, DOI 10.1016/S0883 5403(97)90142 X
   Cui Q, 1997, J BONE JOINT SURG AM, V79A, P1054, DOI 10.2106/00004623 199707000 00012
   Dean GS, 2001, CLIN ORTHOP RELAT R, P106
   Delling G, 2007, ORTHOPADE, V36, P404, DOI 10.1007/s00132 007 1080 9
   Disch AC, 2005, J BONE JOINT SURG BR, V87B, P560, DOI 10.1302/0301 620X.87B4.15658
   Draenert FG, 2011, CLIN IMPLANT DENT R, V13, P238, DOI 10.1111/j.1708 8208.2009.00199.x
   Drescher W, 2004, J ORTHOPAED RES, V22, P501, DOI 10.1016/j.orthres.2003.10.002
   Drescher W, 2003, J BONE JOINT SURG BR, V85B, P969, DOI 10.1302/0301 620X.85B7.14155
   Drescher W, 2001, J BONE JOINT SURG BR, V83B, P274, DOI 10.1302/0301 620X.83B2.10323
   Drescher W, 2006, J BONE JOINT SURG AM, V88A, P173, DOI 10.2106/JBJS.F.00773
   FICAT RP, 1985, J BONE JOINT SURG BR, V67, P3, DOI 10.1302/0301 620X.67B1.3155745
   Fink B, 2000, ORTHOPADE, V29, P449
   Floerkemeier T, 2011, INT ORTHOP, V35, P489, DOI 10.1007/s00264 009 0940 9
   FRYER JP, 1994, CLIN TRANSPLANT, V8, P224
   FRYER JP, 1994, TRANSPL P, V26, P91
   Fung Daniel A, 2008, Orthopedics, V31, P614
   Gangji V, 2004, J BONE JOINT SURG AM, V86A, P1153, DOI 10.2106/00004623 200406000 00006
   Glueck CJ, 1997, CLIN ORTHOP RELAT R, P43
   Gulow J, 2007, ORTHOPADE, V36, P353, DOI 10.1007/s00132 007 1071 x
   Hauzeur JP, 2009, ACTA GASTRO ENT BELG, V72, P327
   Heller KD, 1998, Z ORTHOP GRENZGEB, V136, P390, DOI 10.1055/s 2008 1053674
   Hernigou P, 2002, CLIN ORTHOP RELAT R, P14, DOI 10.1097/01.blo.0000038472.05771.79
   Hernigou P, 2005, J BONE JOINT SURG BR, V87B, P896, DOI 10.1302/0301 620X.87B7.16289
   HOFMANN S, 1993, J BONE JOINT SURG BR, V75, P210, DOI 10.1302/0301 620X.75B2.8444939
   Hungerford MW, 2009, ORTHOP CLIN N AM, V40, P283, DOI 10.1016/j.ocl.2008.10.006
   Jäger M, 2010, ORTHOPADE, V39, P449, DOI [10.1007/s00132 009 1583 7, 10.4081/or.2010.e20]
   JONES JP, 1993, CLIN ORTHOP RELAT R, P294
   JONES JP, 1992, CLIN ORTHOP RELAT R, V277, P41
   Katz K, 1996, J BONE JOINT SURG AM, V78A, P14, DOI 10.2106/00004623 199601000 00003
   Keizer SB, 2006, J BONE JOINT SURG BR, V88B, P460, DOI 10.1302/0301 620x.88b4.16950
   Kim SY, 2005, J BONE JOINT SURG AM, V87A, P2012, DOI 10.2106/JBJS.D.02593
   Kim YH, 2003, J BONE JOINT SURG AM, V85A, P675, DOI 10.2106/00004623 200304000 00014
   Klingenstein G, 2005, ALIMENT PHARM THER, V21, P243, DOI 10.1111/j.1365 2036.2005.02231.x
   Kramer J, 2009, RADIOLOGE, V49, P410, DOI 10.1007/s00117 009 1831 1
   Le TB, 2000, CLIN ORTHOP RELAT R, P141
   MANKIN HJ, 1992, NEW ENGL J MED, V326, P1473
   Marston SB, 2002, J BONE JOINT SURG AM, V84A, P2145, DOI 10.2106/00004623 200212000 00004
   MITCHELL DG, 1987, RADIOLOGY, V162, P709, DOI 10.1148/radiology.162.3.3809484
   Mont MA, 2003, CLIN ORTHOP RELAT R, P84, DOI 10.1097/01.blo.0000096826.67494.38
   MONT MA, 1995, J BONE JOINT SURG AM, V77A, P459, DOI 10.2106/00004623 199503000 00018
   Mont MA, 2000, J BONE JOINT SURG AM, V82A, P1279, DOI 10.2106/00004623 200009000 00008
   Mont MA, 2000, J RHEUMATOL, V27, P1766
   Mont MA, 2006, J BONE JOINT SURG AM, V88A, P90, DOI 10.2106/JBJS.F.00543
   Mukisi Mukaza M, 2000, ORTHOPEDICS, V23, P357
   Neumayr LD, 2006, J BONE JOINT SURG AM, V88A, P2573, DOI 10.2106/JBJS.E.01454
   Nöth U, 2007, ORTHOPADE, V36, P466, DOI 10.1007/s00132 007 1087 2
   OHZONO K, 1992, CLIN ORTHOP RELAT R, P79
   Öner AF, 1999, LEUKEMIA LYMPHOMA, V33, P361
   Plakseychuk AY, 2003, J BONE JOINT SURG AM, V85A, P589, DOI 10.2106/00004623 200304000 00001
   Reck F, 2007, Z ORTHOP UNFALLCHIR, V145, P448, DOI 10.1055/s 2007 965268
   Revell MP, 2006, J BONE JOINT SURG AM, V88A, P98, DOI 10.2106/JBJS.F.01070
   Rijnen WHC, 2003, CLIN ORTHOP RELAT R, P74, DOI 10.1097/01.blo.0000096823.67494.64
   Saini A, 2004, CLIN RADIOL, V59, P1079, DOI 10.1016/j.crad.2004.04.014
   Saisu T, 1996, TRANSPLANT P, V28, P1559
   Sakagoshi D, 2010, J ARTHROPLASTY, V25, P1282, DOI 10.1016/j.arth.2009.09.002
   SCHNEIDER E, 1989, FORTSCHR RONTG NEUEN, V150, P402
   Schneider W, 2002, J BONE JOINT SURG BR, V84B, P817, DOI 10.1302/0301 620X.84B6.12837
   Schneider W, 2000, ORTHOPADE, V29, P420
   Scully SP, 1998, J BONE JOINT SURG AM, V80A, P1270, DOI 10.2106/00004623 199809000 00004
   Seyler TM, 2008, CLIN ORTHOP RELAT R, V466, P1125, DOI 10.1007/s11999 008 0211 x
   Stronach Ben M, 2010, J ARTHROPLASTY, V25, P1168
   Stulberg BN, 1997, CLIN ORTHOP RELAT R, P116
   Tingart M, 2008, CALCIFIED TISSUE INT, V82, P300, DOI 10.1007/s00223 008 9111 z
   Tingart M, 2009, J ORTHOP RES, V27, P1175, DOI 10.1002/jor.20873
   Ugwonali Obinwanne F, 2008, Orthopedics, V31, P183, DOI 10.3928/01477447 20080201 36
   Varitimidis SE, 2009, ACTA ORTHOP, V80, P20, DOI 10.1080/17453670902804877
   Wang CJ, 2005, J BONE JOINT SURG AM, V87A, P2380, DOI 10.2106/JBJS.E.00174
   Wirth SM, 2009, ORTHOPEDICS, V32, P900, DOI 10.3928/01477447 20091020 16
   Wirtz DC, 1998, Z ORTHOP GRENZGEB, V136, P138, DOI 10.1055/s 2008 1051296
   Yoo MC, 2008, CLIN ORTHOP RELAT R, V466, P1133, DOI 10.1007/s11999 008 0204 9
NR 83
TC 1
Z9 1
U1 0
U2 22
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83 85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0026 4911
EI 1827 1707
J9 MINERVA ORTOP TRAUMA
JI Minerva Ortop. Traumatol.
PD FEB
PY 2013
VL 64
IS 1
BP 15
EP 24
PG 10
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 127NS
UT WOS:000317706300002
DA 2025 08 17
ER

PT J
AU Zhang, XL
   Guan, TG
   Zhu, RJ
   Qi, SC
   Wu, ZG
AF Zhang, Xueliang
   Guan, Tonggeng
   Zhu, Rujian
   Qi, Shuchao
   Wu, Zigang
TI Enhancement of Bone Properties by Alendronate Nanoparticle Formulation
   in Rat Model of Osteoporosis
SO JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING
LA English
DT Article
DE Alendronate Nanoparticles; Bone; Rat; Osteoporosis
AB Recent studies have shown that Bisphosphonates like Alendronate are highly effective in reducing fractures as well as improving bone density. To evaluate its effectiveness the present investigations formulates Alendronate chitosan nanoparticles to target drug at bone site in order to enhance bone properties. Ionotropic gelation method was found to be successful in preparing Alendronate chitosan nanoparticles. Thus prepared nanoparticles were found to be smooth surfaced with excellent flow properties and showing in vitro release of 94.32% with initial burst release of 20.23%. Both male and female wistar rats of 3 month old with average weight 78 gms were selected for study and made osteoporotic (Glucocorticoid induced osteoporosis) via intramuscular injection of methyl prednisolone as 3 mg/kg/day for up to 9 weeks and these osteoporotic animals were divided into 3 groups; first with no treatment of Alendronate Nanoparticles received second and third group with administration of nanoparticles as 1 mg/kg and 2 mg/kg respectively, fourth being control group with no disease induction. After period of treatment the experimental animals were evaluated for various aspects. The results obtained showed that Animals receiving treatment shows optimum growth. Histological evaluation showed that Alendronate nanoparticles were found to be useful in maintaining thick and continuous bone structure as thick, continuous trabecullae was observed in case of group II, III when compared to group I. Biomechanical study has also revealed the excellent bone strength for group II and III. The Aforementioned results confirmed Fact of alendronate having good bone resorption properties.
C1 [Zhang, Xueliang] Lanzhou Univ, Dept Orthoped, Hosp 1, Lanzhou 730000, Gansu, Peoples R China.
   [Guan, Tonggeng; Wu, Zigang] Second People Hosp Dezhou, Dept Orthoped, Dezhou 253000, Shandong, Peoples R China.
   [Zhu, Rujian] Wucheng Cty Peoples Hosp, Dept Orthoped, Wucheng 253300, Shandong, Peoples R China.
   [Qi, Shuchao] West Hosp Dezhou, Dept Orthoped, Dezhou 253000, Shandong, Peoples R China.
C3 Lanzhou University
RP Wu, ZG (通讯作者)，Second People Hosp Dezhou, Dept Orthoped, Dezhou 253000, Shandong, Peoples R China.
CR ALLEMANN E, 1993, EUR J PHARM BIOPHARM, V39, P173
   Dolatabadi JEN, 2014, COLLOID SURFACE B, V117, P21, DOI 10.1016/j.colsurfb.2014.01.055
   Golob AL, 2015, MED CLIN N AM, V99, P587, DOI 10.1016/j.mcna.2015.01.010
   Haddad Patricia Tanios, 2015, Rev. bras. ortop., V50, P100, DOI 10.1016/j.rboe.2014.12.007
   Handa R, 2008, BEST PRACT RES CL RH, V22, P693, DOI 10.1016/j.berh.2008.04.002
   Kaveh K., 2010, American Journal of Animal and Veterinary Sciences, V5, P139
   Kim David H, 2006, Spine J, V6, P479, DOI 10.1016/j.spinee.2006.04.013
   Li Y, 2018, J BIOMATER TISS ENG, V8, P792, DOI 10.1166/jbt.2018.1808
   McCarthy EA, 2002, PEDIATR RES, V52, P660, DOI 10.1203/01.PDR.0000032068.76811.0D
   Nelson HD, 2010, ANN INTERN MED, V153, P99, DOI 10.7326/0003 4819 153 2 201007200 00262
   Reid IR, 1997, EUR J ENDOCRINOL, V137, P209, DOI 10.1530/eje.0.1370209
   Wade SW, 2014, ARCH OSTEOPOROS, V9, DOI 10.1007/s11657 014 0182 3
   Waugh EJ, 2009, OSTEOPOROSIS INT, V20, P1, DOI 10.1007/s00198 008 0643 x
   Wells G, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004523.pub3
   Wen L.D., 2009, POLYMER, V75, P385, DOI DOI 10.1016/j.carbpol.2008.07.039
   Willson T, 2015, CLIN EPIDEMIOL, V7, P65, DOI 10.2147/CLEP.S40966
   World Health Organization (WHO), CHRON RHEUM COND
   Zhu HG, 2018, J BIOMATER TISS ENG, V8, P632, DOI 10.1166/jbt.2018.1791
NR 18
TC 1
Z9 1
U1 0
U2 38
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 2157 9083
EI 2157 9091
J9 J BIOMATER TISS ENG
JI J. Biomater. Tissue Eng.
PD OCT
PY 2018
VL 8
IS 10
BP 1458
EP 1463
DI 10.1166/jbt.2018.1889
PG 6
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA HD5GE
UT WOS:000452555700009
DA 2025 08 17
ER

PT J
AU Kim, JG
   Son, KM
   Park, HC
   Zhu, T
   Kwon, JH
   Yang, HC
AF Kim, Jong Gil
   Son, Kyung M.
   Park, Hee C.
   Zhu, Tingting
   Kwon, Ji H.
   Yang, Hyeong Cheol
TI Stimulating effects of quercetin and phenamil on differentiation of
   human dental pulp cells
SO EUROPEAN JOURNAL OF ORAL SCIENCES
LA English
DT Article
DE dental pulp cells; differentiation; odontogenicity; phenamil; quercetin
ID ALKALINE PHOSPHATASE ACTIVITY; BONE MORPHOGENETIC PROTEINS;
   ODONTOBLASTIC DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC
   DIFFERENTIATION; N ACETYLCYSTEINE; RETINOIC ACID; ESTROGEN;
   TRANSCRIPTION; EXPRESSION
AB Dentin formation is preferred in the healing response of the pulp to pulp capping agents during vital pulp therapy. Enhancement of the dentinogenic differentiation of dental pulp cells is thought to accelerate pulp repair. The aim of this study was to evaluate the dentinogenic activity of small molecules (three flavonoids and phenamil) that have been shown previously to induce osteoblast differentiation. Among the flavonoids (quercetin, genistein and baicalin), quercetin induced the highest alkaline phosphatase (ALP) activity of human dental pulp (HDP) cells. Phenamil, an amiloride derivative, elicited higher ALP activity than quercetin. However, increased expression of dentin sialophosphoprotein (DSPP) mRNA and mineral deposition were seen in cultures treated with quercetin compared with phenamil. This would seem to suggest that quercetin is the most dentinogenic agent among the tested chemicals. The increase in ALP activity in the quercetin treated cells was not affected by ICI 182,780, an estrogen receptor inhibitor, and was partially blocked by PD98059, an extracellular signal regulated kinase 1/2 (ERK1/2) inhibitor. This suggests that ERK1/2 is activated in the quercetin induced differentiation of HDP cells without the mediation of estrogen receptors, which are known to be involved in osteoblast differentiation induced by quercetin.
C1 [Yang, Hyeong Cheol] Seoul Natl Univ, Sch Dent, Dept Dent Biomat Sci, Seoul 110749, South Korea.
   Seoul Natl Univ, Sch Dent, Dent Res Inst, Seoul 110749, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU)
RP Yang, HC (通讯作者)，Seoul Natl Univ, Sch Dent, Dept Dent Biomat Sci, 28 Yongon Dong, Seoul 110749, South Korea.
EM yanghc@snu.ac.kr
FU Korea Health Technology R&D Project, Ministry of Health & Welfare,
   Republic of Korea [A120822]
FX This study was supported by a grant of the Korea Health Technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea (A120822).
CR Guo AJY, 2012, J BIOL CHEM, V287, P6958, DOI 10.1074/jbc.A111.236281
   Heim M, 2004, ENDOCRINOLOGY, V145, P848, DOI 10.1210/en.2003 1014
   Huang XF, 2012, MOL MED REP, V6, P547, DOI 10.3892/mmr.2012.974
   Jukic Krmek S, 2003, ORAL SURG ORAL MED O, V95, P340, DOI 10.1067/moe.2003.9
   Karanxha L, 2013, J ENDODONT, V39, P76, DOI 10.1016/j.joen.2012.10.013
   Kim JM, 2008, J CELL BIOCHEM, V104, P1906, DOI 10.1002/jcb.21760
   Kim NR, 2011, J BIOMED MATER RES B, V98B, P300, DOI 10.1002/jbm.b.31852
   Kim NR, 2010, J ENDODONT, V36, P1844, DOI 10.1016/j.joen.2010.08.005
   Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Lee DH, 2006, CELL BIOL TOXICOL, V22, P39, DOI 10.1007/s10565 006 0018 z
   Lee SY, 2012, J DENT RES, V91, P407, DOI 10.1177/0022034511436113
   Li YC, 2011, ARCH ORAL BIOL, V56, P1221, DOI 10.1016/j.archoralbio.2011.05.002
   Lo KW, J TISSUE ENG REGEN M, DOI [10.1002/term.1573., DOI 10.1002/TERM.1573.[]
   Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008
   NAKASHIMA M, 1994, J DENT RES, V73, P1515, DOI 10.1177/00220345940730090601
   NAKAYAMA Y, 1990, FEBS LETT, V261, P93, DOI 10.1016/0014 5793(90)80644 X
   Ohishi M, 1999, J ENDODONT, V25, P683, DOI 10.1016/S0099 2399(99)80355 0
   Park KW, 2009, MOL CELL BIOL, V29, P3905, DOI 10.1128/MCB.00002 09
   Prouillet C, 2004, BIOCHEM PHARMACOL, V67, P1307, DOI 10.1016/j.bcp.2003.11.009
   Qin W, 2012, J ENDODONT, V38, P66, DOI 10.1016/j.joen.2011.09.025
   Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756 3282(97)00276 7
   Qu Q, 1999, J CELL BIOCHEM, V73, P500, DOI 10.1002/(SICI)1097 4644(19990615)73:4<500::AID JCB8>3.3.CO;2 5
   Sloan AJ, 2000, ARCH ORAL BIOL, V45, P173, DOI 10.1016/S0003 9969(99)00131 4
   Washio A, 2012, INT J DENT, V2012, DOI 10.1155/2012/258469
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   Yang L, 2010, J CELL BIOCHEM, V110, P1342, DOI 10.1002/jcb.22649
NR 27
TC 21
Z9 22
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0909 8836
EI 1600 0722
J9 EUR J ORAL SCI
JI Eur. J. Oral Sci.
PD DEC
PY 2013
VL 121
IS 6
BP 559
EP 565
DI 10.1111/eos.12086
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA AA3DO
UT WOS:000330973300008
PM 24102669
DA 2025 08 17
ER

PT J
AU Ma, PC
   He, MX
   Lian, HS
   Li, JM
   Gao, Y
   Wu, JP
   Men, K
   Men, Y
   Li, CJ
AF Ma, Pingchuan
   He, Mingxia
   Lian, Haosen
   Li, Jingmei
   Gao, Yan
   Wu, Jieping
   Men, Ke
   Men, Yi
   Li, Chunjie
TI Systemic and Local Administration of a Dual siRNA Complex Efficiently
   Inhibits Tumor Growth and Bone Invasion in Oral Squamous Cell Carcinoma
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE gene therapy; siRNA delivery; oral squamouscell carcinoma; bone invasion
ID COLON CANCER; FACTOR BETA; DELIVERY; GENE; HEAD; NANOPARTICLES; THERAPY;
   POLYMER; RANKL; VEGF
AB Oral squamous cell carcinoma (OSCC) accounts for nearly 90% of oral and oropharyngeal cancer cases and is characterized by high mortality and poor prognosis. RNA based gene therapies have been developed as an emerging option for cancer treatment, but it has not been widely explored in OSCC. In this work, we developed an efficient siRNA cationic micelle DOTAP mPEG PCL (DMP) by self assembling the cationic lipid DOTAP and monomethoxy poly(ethylene glycol) poly(epsilon caprolactone) (mPEG PCL) polymer. We tested the characteristics and transformation efficiency of this micelle and combined DMP with siRNA targeting STAT3 and TGF beta to evaluate the antitumor effect and bone invasion interfering in vitro and in vivo. The average size of the DMP was 28.27 +/  1.62 nm with an average zeta potential of 54.60 +/  0.29 mV. The DMP/siRNA complex showed high delivery efficiency, with rates of 97.47 +/  0.42% for HSC 3. In vitro, the DMP/siSTAT3 complex exhibited an obvious cell growth inhibition effect detected by MTT assay (an average cell viability of 25.1%) and clonogenic assay (an average inhibition rate of 51.9%). Besides, the supernatant from HSC 3 transfected by DMP/siTGF beta complexes was found to interfere with osteoclast differentiation in vitro. Irrespective of local or systemic administration, DMP/siSTAT3+siTGF beta showed antitumor effects and bone invasion inhibition in the OSCC mice mandibular invasion model according to tumor volume assays and Micro CT scanning. The complex constructed by DMP cationic micelles and siSTAT3+siTGF beta represents a potential RNA based gene therapy delivery system for OSCC.
C1 [Ma, Pingchuan; Lian, Haosen; Men, Yi; Li, Chunjie] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis & Natl Ctr Stomatol, Chengdu 610041, Sichuan, Peoples R China.
   [Ma, Pingchuan; Lian, Haosen; Men, Yi; Li, Chunjie] Sichuan Univ, West China Hosp Stomatol, Natl Ctr Stomatol, Chengdu 610041, Sichuan, Peoples R China.
   [Ma, Pingchuan; Lian, Haosen; Men, Yi; Li, Chunjie] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu 610041, Sichuan, Peoples R China.
   [Ma, Pingchuan; Lian, Haosen; Men, Yi; Li, Chunjie] Sichuan Univ, West China Hosp Stomatol, Dept Head & Neck Oncol, Chengdu 610041, Sichuan, Peoples R China.
   [He, Mingxia] Henan Univ, Sch Basic Med, Joint Natl Lab Antibody Drug Engn, Kaifeng 475004, Peoples R China.
   [Li, Jingmei; Gao, Yan; Wu, Jieping; Men, Ke] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
   [Li, Jingmei; Gao, Yan; Wu, Jieping; Men, Ke] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University; Sichuan
   University; Henan University; Sichuan University; Sichuan University
RP Men, Y; Li, CJ (通讯作者)，Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis & Natl Ctr Stomatol, Chengdu 610041, Sichuan, Peoples R China.; Men, Y; Li, CJ (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Ctr Stomatol, Chengdu 610041, Sichuan, Peoples R China.; Men, Y; Li, CJ (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu 610041, Sichuan, Peoples R China.; Men, Y; Li, CJ (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dept Head & Neck Oncol, Chengdu 610041, Sichuan, Peoples R China.
EM yurimen@163.com; lichunjie07@qq.com
RI ; Wu, Jieping/LRC 5157 2024; Li, Chunjie/AAG 6790 2020
OI Ma, Pingchuan/0000 0003 2298 7224; gao, yan/0000 0002 1933 724X; 
FU National Natural Science Foundation of China [82270994]; National
   Natural Science Foundation [2021YFS0217]; Research Program of Science
   and Technology Department of Sichuan Province
FX This work was supported by the National Natural Science Foundation
   (82270994) and Research Program of Science and Technology Department of
   Sichuan Province (2021YFS0217).
CR Chen HY, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 01088 9
   Chen J, 2012, MOL CANCER THER, V11, P277, DOI 10.1158/1535 7163.MCT 11 0648
   Chen WH, 2015, CANCER LETT, V359, P65, DOI 10.1016/j.canlet.2014.12.052
   Duan XM, 2012, NANOSCALE, V4, P2400, DOI 10.1039/c2nr30079f
   Elmusrati AA, 2017, BRIT J CANCER, V117, P867, DOI 10.1038/bjc.2017.239
   Esposito M, 2021, NAT CELL BIOL, V23, P257, DOI 10.1038/s41556 021 00641 w
   Gingery A, 2008, EXP CELL RES, V314, P2725, DOI 10.1016/j.yexcr.2008.06.006
   Guo YB, 2008, BONE, V43, P386, DOI 10.1016/j.bone.2008.03.026
   Hacker UT, 2020, CANCERS, V12, DOI 10.3390/cancers12071889
   Haga K, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2021.101236
   Hattori Y, 2019, J DRUG TARGET, V27, P217, DOI 10.1080/1061186X.2018.1502775
   Hattori Y, 2016, J DRUG TARGET, V24, P309, DOI 10.3109/1061186X.2015.1070856
   Hu B, 2019, J GENE MED, V21, DOI 10.1002/jgm.3097
   Huang CY, 2017, J IMMUNOTHER, V40, P175, DOI 10.1097/CJI.0000000000000166
   Huang SH, 2013, MED ORAL PATOL ORAL, V18, pE233, DOI 10.4317/medoral.18772
   Jimi E, 2011, ORAL DIS, V17, P462, DOI 10.1111/j.1601 0825.2010.01781.x
   Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8
   Lei SB, 2020, J BIOMED NANOTECHNOL, V16, P1018, DOI 10.1166/jbn.2020.2961
   Li JM, 2021, MOL PHARMACEUT, V18, P4029, DOI 10.1021/acs.molpharmaceut.1c00461
   Li ZH, 2017, MOL MED REP, V16, P8380, DOI 10.3892/mmr.2017.7625
   Lo YL, 2020, THERANOSTICS, V10, P6695, DOI 10.7150/thno.45164
   Ma PC, 2022, INT J NANOMED, V17, P2925, DOI 10.2147/IJN.S357702
   Men K, 2018, J BIOMED NANOTECHNOL, V14, P1719, DOI 10.1166/jbn.2018.2593
   Men K, 2018, RSC ADV, V8, P12104, DOI 10.1039/c7ra13656k
   Nakamura R, 2015, BIOCHEM BIOPH RES CO, V458, P777, DOI 10.1016/j.bbrc.2015.02.013
   Nakatani K, 2022, J ORAL PATHOL MED, V51, P126, DOI 10.1111/jop.13268
   Omori H, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay3324
   Park J, 2021, BIOCHEM BIOPH RES CO, V534, P381, DOI 10.1016/j.bbrc.2020.11.073
   Park J, 2019, J CLIN INVEST, V129, P5381, DOI 10.1172/JCI125336
   Pittella F, 2012, J CONTROL RELEASE, V161, P868, DOI 10.1016/j.jconrel.2012.05.005
   Quan JJ, 2012, CANCER METAST REV, V31, P209, DOI 10.1007/s10555 011 9335 7
   Rafiei S, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 605
   Rahman MA, 2012, J CONTROL RELEASE, V159, P384, DOI 10.1016/j.jconrel.2012.01.045
   Scherman D, 2017, GENE THER, V24, P151, DOI 10.1038/gt.2017.6
   Selvam C, 2017, CHEM BIOL DRUG DES, V90, P665, DOI 10.1111/cbdd.12993
   Shaikh MH, 2017, ORAL ONCOL, V68, P9, DOI 10.1016/j.oraloncology.2017.02.016
   Shao F, 2021, CURR MED CHEM, V28, P5137, DOI 10.2174/0929867328666201207202012
   Solomon B, 2018, SEMIN CANCER BIOL, V52, P228, DOI 10.1016/j.semcancer.2018.01.008
   Song YD, 2018, BIOMATERIALS, V185, P117, DOI 10.1016/j.biomaterials.2018.09.017
   Tang QM, 2019, ADV SCI, V6, DOI 10.1002/advs.201900667
   Taniguchi H, 2021, INT J CANCER, V149, P646, DOI 10.1002/ijc.33579
   Torre LA, 2015, CA CANCER J CLIN, V65, P108, DOI [DOI 10.3322/caac.20115, 10.3322/caac.21262]
   Wang J, 2021, PHOTODIAGN PHOTODYN, V36, DOI 10.1016/j.pdpdt.2021.102581
   Xia YH, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 31475 1
   Xu XD, 2018, SMALL, V14, DOI 10.1002/smll.201802565
   Xu XD, 2017, NANO LETT, V17, P4427, DOI 10.1021/acs.nanolett.7b01571
   Xue VW, 2020, EXPERT OPIN BIOL TH, V20, P767, DOI 10.1080/14712598.2020.1738377
   Yang ZC, 2019, EBIOMEDICINE, V47, P44, DOI 10.1016/j.ebiom.2019.08.013
   Zhang HJ, 2020, INT J NANOMED, V15, P9875, DOI 10.2147/IJN.S277845
   Zhang PF, 2013, COPD, V10, P650, DOI 10.3109/15412555.2013.813928
   Zhang XY, 2013, ORAL ONCOL, V49, P119, DOI 10.1016/j.oraloncology.2012.08.004
NR 51
TC 4
Z9 4
U1 3
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543 8384
EI 1543 8392
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JAN 4
PY 2024
VL 21
IS 2
BP 661
EP 676
DI 10.1021/acs.molpharmaceut.3c00802
PG 16
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA HF9H6
UT WOS:001158190300001
PM 38175819
DA 2025 08 17
ER

PT J
AU Qiu, L
   Lv, GC
   Cao, Y
   Chen, LP
   Yang, H
   Luo, SN
   Zou, MF
   Lin, JG
AF Qiu, Ling
   Lv, Gaochao
   Cao, Yang
   Chen, Liping
   Yang, Hui
   Luo, Shineng
   Zou, Meifen
   Lin, Jianguo
TI Synthesis and biological evaluation of novel platinum complexes of
   imidazolyl containing bisphosphonates as potential anticancer agents
SO JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
LA English
DT Article
DE Platinum complex; Imidazolyl containing bisphosphonate; Hydroxyapatite
   (HA) affinity; Cytotoxicity; DNA binding
ID BONE; DELIVERY; DNA; MECHANISMS; RESISTANCE; BINDING; DRUGS; ACID
AB Four novel platinum complexes, [Pt(en)](2)ZL (1), [Pt(en)](2)IPrBP (2), [Pt(en)](2)MIBP (3) and [Pt(en)](2)EIBP (4) [en = ethylenediamine; ZL = 1 hydroxy 3 (1H imidazol 1 yl)ethane 1,1 diylbisphosphonic acid, commonly known as zoledronic acid; IPrBP = 1 hydroxy 3 (1H imidazol 1 yl)propane 1,1 diylbisphosphonic acid; MIBP = 1 hydroxy 2 (2 methyl 1H imidazol 1 yl)ethane 1,1 diylbisphosphonic acid; EIBP = 1 hydroxy 2 (2 ethyl 1H imidazol 1 yl)ethane 1,1 diylbisphosphonic acid], were prepared and evaluated against five human cancer cell lines, including U2OS, A549, HCT116, MDA MB 231 and HepG2. While exhibiting lower efficacy on the inhibition of cancer cell lines than cisplatin (CDDP), four complexes showed higher cytotoxicity than the corresponding ligands and relatively stronger cytotoxic effect on the hepatoma cell lines HepG2, and the complex 1 showed higher cytotoxicity than others on the whole. These complexes have better selectivity than the corresponding ligands in inhibiting hepatocarcinoma cells rather than normal liver cells, and the selective inhibitory effect of the complex 1 at the high concentration (100 mu M) is better than that at the low concentration. Morphology studies exhibited typical characteristics of cell apoptosis and the cell cycle distribution analysis indicated that the complexes can inhibit cancer cells by inducing the cell cycle arrest at the G2/M phase, exhibiting a similar mechanism of action to CDDP. The binding interaction of complex with DNA has been explored by circular dichroism (CD) and UV Vis absorption spectra, demonstrating these new complexes have moderate binding affinity for DNA.
C1 [Qiu, Ling; Lv, Gaochao; Cao, Yang; Chen, Liping; Yang, Hui; Luo, Shineng; Zou, Meifen; Lin, Jianguo] Minist Hlth, Key Lab Nucl Med, Jiangsu Key Lab Mol Nucl Med, Jiangsu Inst Nucl Med, Wuxi 214063, Peoples R China.
RP Luo, SN (通讯作者)，Minist Hlth, Key Lab Nucl Med, Jiangsu Key Lab Mol Nucl Med, Jiangsu Inst Nucl Med, Wuxi 214063, Peoples R China.
EM luoshineng@jsinm.org; linjianguo@jsinm.org
FU National Natural Science Foundation of China [21371082, 21001055];
   Natural Science Foundation of Jiangsu Province [BK20141102, BK20151118];
   Key Medical Talent Project of Jiangsu Province [RC2011097]; Science
   Foundation of Health Department of Jiangsu Province [Q201204]; Public
   Service Platform for Science and Technology Infrastructure Construction
   Project of Jiangsu Province [BM2012066]
FX The authors are grateful to the financial support from National Natural
   Science Foundation of China (21371082 and 21001055), Natural Science
   Foundation of Jiangsu Province (BK20141102 and BK20151118), Key Medical
   Talent Project of Jiangsu Province (RC2011097), Science Foundation of
   Health Department of Jiangsu Province (Q201204) and Public Service
   Platform for Science and Technology Infrastructure Construction Project
   of Jiangsu Province (BM2012066).
CR BARTON JK, 1984, J AM CHEM SOC, V106, P2172, DOI 10.1021/ja00319a043
   Chen AC, 2010, CHEM REV, V110, P3767, DOI 10.1021/cr9003902
   Dancey JE, 2006, NAT REV DRUG DISCOV, V5, P649, DOI 10.1038/nrd2089
   de Rosales RTM, 2009, CHEM COMMUN, P4847, DOI 10.1039/b908652h
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Ferri N, 2015, BIOORGAN MED CHEM, V23, P2538, DOI 10.1016/j.bmc.2015.03.044
   Heffeter P, 2008, DRUG RESIST UPDATE, V11, P1, DOI 10.1016/j.drup.2008.02.002
   Iafisco M, 2009, J MATER CHEM, V19, P8385, DOI 10.1039/b914379c
   IVANOV VI, 1973, BIOPOLYMERS, V12, P89, DOI 10.1002/bip.1973.360120109
   Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n
   Langer R, 2001, SCIENCE, V293, P58, DOI 10.1126/science.1063273
   Leu CT, 2006, BONE, V38, P628, DOI 10.1016/j.bone.2005.07.023
   Lin JG, 2011, NUCL MED BIOL, V38, P619, DOI 10.1016/j.nucmedbio.2010.12.005
   Lipton A, 2011, EXPERT OPIN PHARMACO, V12, P749, DOI 10.1517/14656566.2011.538384
   LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003 4819 100 5 704
   MACQUET JP, 1978, EUR J BIOCHEM, V83, P375, DOI 10.1111/j.1432 1033.1978.tb12103.x
   Margiotta N, 2007, DALTON T, P3131, DOI 10.1039/b705239a
   Margiotta N, 2009, DALTON T, P10904, DOI 10.1039/b919721d
   Margiotta N, 2008, J INORG BIOCHEM, V102, P2078, DOI 10.1016/j.jinorgbio.2008.07.008
   Muhammad N, 2014, CURR OPIN CHEM BIOL, V19, P144, DOI 10.1016/j.cbpa.2014.02.003
   PASINI A, 1993, SYN REACT INORG MET, V23, P1021, DOI 10.1080/15533179308016879
   Piccinonna S, 2012, DALTON T, V41, P9689, DOI 10.1039/c2dt30712j
   Qiu L, 2014, AUST J CHEM, V67, P192, DOI 10.1071/CH13194
   Qiu L, 2013, MED CHEM RES, V22, P6154, DOI 10.1007/s00044 013 0613 5
   Rabik CA, 2007, CANCER TREAT REV, V33, P9, DOI 10.1016/j.ctrv.2006.09.006
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sanchez Cano C, 2009, DALTON T, P10702, DOI 10.1039/b912708a
   Strebhardt K, 2008, NAT REV CANCER, V8, P473, DOI 10.1038/nrc2394
   TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0
   van Zutphen S, 2005, COORDIN CHEM REV, V249, P2845, DOI 10.1016/j.ccr.2005.03.005
   Wang XY, 2013, CHEM SOC REV, V42, P202, DOI 10.1039/c2cs35259a
   Wheate NJ, 2010, DALTON T, V39, P8113, DOI 10.1039/c0dt00292e
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Wong E, 1999, CHEM REV, V99, P2451, DOI 10.1021/cr980420v
   Xue ZQ, 2010, CHEM COMMUN, V46, P1212, DOI 10.1039/b922222g
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
   Zhao J, 2013, INORG CHEM, V52, P8163, DOI 10.1021/ic400907t
NR 39
TC 15
Z9 15
U1 1
U2 43
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0949 8257
EI 1432 1327
J9 J BIOL INORG CHEM
JI J. Biol. Inorg. Chem.
PD DEC
PY 2015
VL 20
IS 8
BP 1263
EP 1275
DI 10.1007/s00775 015 1305 z
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA CX4ZQ
UT WOS:000365710000005
PM 26531104
DA 2025 08 17
ER

PT J
AU Ma, CX
   Guan, X
   Wei, R
   Wang, S
   Quan, JC
   Zhao, ZX
   Chen, HP
   Liu, Z
   Jiang, Z
   Wang, XS
AF Ma, Chen xi
   Guan, Xu
   Wei, Ran
   Wang, Song
   Quan, Ji chuan
   Zhao, Zhi xun
   Chen, Hai peng
   Liu, Zheng
   Jiang, Zheng
   Wang, Xi shan
TI The Distinction of Clinicopathological Characteristics, Treatment
   Strategy and Outcome in Colorectal Cancer Patients With Synchronous vs.
   Metachronous Bone Metastasis
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE colorectal cancer; bone metastasis; synchronous; metachronous; cancer
   specific survival; prognostic factor
ID PRIMARY TUMOR RESECTION; QUALITY OF LIFE; COLON CANCER; SPINAL
   METASTASES; SURVIVAL; LUNG; BISPHOSPHONATES; PREDICT; BREAST; TRIALS
AB Background:The impact of the timing of bone metastasis (BM) diagnosis on colorectal cancer (CRC) patients is unclear. Our study aimed to explore the differences in clinicopathological characteristics, treatments and prognosis between synchronous BM (SBM) and metachronous BM (MBM) from CRC. Methods:We retrospectively investigated clinical data of CRC patients with SBM or MBM from 2008 to 2017 at Chinese National Cancer Center. Cancer specific survival (CSS) after BM diagnosis was estimated using the Kaplan Meier method. The multivariable COX regression model identified the prognostic factors of CSS. Results:Finally, 63 CRC patients with SBM and 138 CRC patients with MBM were identified. Compared to SBM from CRC, MBM significantly was more involving multiple bone lesions (63.0 vs. 7.9%;p< 0.001), and more frequently originated from rectal cancer (60.9 vs. 41.3%;p= 0.033). The therapeutic strategies in SBM and MBM group were contrasted including systemic treatment, bisphosphonates, radiotherapy and metastasectomy for BM. 85.5% of patients in MBM group and 25.4% of patients in SBM group underwent primary tumor resection at initial diagnosis (p< 0.001). The median CSS was 11 months in both SBM and MBM group (p= 0.556), yet MBM patients developed from CRC in early AJCC stage presented obviously longer survival than those from advanced stage. Furthermore, patients could have improved CSS from primary tumor resection while there might be no survival benefit from targeted therapy in both SBM and MBM groups. Bisphosphonates was associated with a better CSS for patients with SBM, while radiotherapy for BM was related to a better CSS for patients with MBM. Conclusion:The CRC patients in SBM and MBM group represented different clinicopathological characteristics and treatment modalities, which affected the prognosis in different ways. Distinct consideration for CRC patients with SBM and MBM in clinical decision making is required.
C1 [Ma, Chen xi; Guan, Xu; Wei, Ran; Quan, Ji chuan; Zhao, Zhi xun; Chen, Hai peng; Liu, Zheng; Jiang, Zheng; Wang, Xi shan] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Colorectal Surg, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China.
   [Wang, Song] Harbin Med Univ, Dept Colorectal Surg, Affiliated Hosp 2, Harbin, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College; Cancer Institute & Hospital   CAMS; Harbin
   Medical University
RP Guan, X; Jiang, Z; Wang, XS (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Colorectal Surg, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China.
EM drguanxu@163.com; 812818858@qq.com; wxshan_1208@126.com
FU CAMS Innovation Fund for Medical Sciences (CIFMS) [2016 I2M 1 001];
   Beijing Science and Technology Program [D17110002617004]
FX This work was supported by CAMS Innovation Fund for Medical Sciences
   (CIFMS) (2016 I2M 1 001) and Beijing Science and Technology Program
   (D17110002617004).
CR Alawadi Z, 2016, CANCER, V123, P1124, DOI DOI 10.1002/cncr.30230
   Benson AB III, 2017, J NATL COMPR CANC NE, V15, P370, DOI 10.6004/jnccn.2017.0036
   Bockhorn M, 2008, J GASTROINTEST SURG, V12, P1399, DOI 10.1007/s11605 008 0508 9
   Choi D, 2015, NEUROSURGERY, V77, P698, DOI 10.1227/NEU.0000000000000907
   Chow E, 2007, J CLIN ONCOL, V25, P1423, DOI 10.1200/JCO.2006.09.5281
   Christensen TD, 2018, J BONE ONCOL, V13, P97, DOI 10.1016/j.jbo.2018.09.009
   Colloca GA, 2020, CLIN TRANSL ONCOL, V22, P1399, DOI 10.1007/s12094 019 02277 7
   Donskov F, 2020, EUR UROL ONCOL, V3, P530, DOI 10.1016/j.euo.2020.01.001
   Flannery TW, 2003, LUNG CANCER, V42, P327, DOI 10.1016/S0169 5002(03)00357 X
   Ghiringhelli F, 2014, DIGEST LIVER DIS, V46, P854, DOI 10.1016/j.dld.2014.05.011
   KATOH M, 1995, J GASTROENTEROL, V30, P615, DOI 10.1007/BF02367787
   Khattak MA, 2012, CLIN COLORECTAL CANC, V11, P247, DOI 10.1016/j.clcc.2012.06.004
   Liu J, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002014
   Malvezzi M, 2017, ANN ONCOL, V28, P1117, DOI 10.1093/annonc/mdx033
   McDonald R, 2017, JAMA ONCOL, V3, P953, DOI 10.1001/jamaoncol.2016.6770
   Mekenkamp LJM, 2010, BRIT J CANCER, V103, P159, DOI 10.1038/sj.bjc.6605737
   O'Connell JB, 2004, JNCI J NATL CANCER I, V96, P1420, DOI 10.1093/jnci/djh275
   Park HS, 2011, ONCOLOGY BASEL, V80, P142, DOI 10.1159/000328507
   Roemer Becuwe C, 2003, B CANCER, V90, P1097
   Santini D, 2012, ANN ONCOL, V23, P2072, DOI 10.1093/annonc/mdr572
   Shahjehan F, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.e15063
   Stillwell AP, 2010, WORLD J SURG, V34, P797, DOI 10.1007/s00268 009 0366 y
   Sundermeyer Mark L, 2005, Clin Colorectal Cancer, V5, P108, DOI 10.3816/CCC.2005.n.022
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Turner N, 2015, CLIN COLORECTAL CANC, V14, P185, DOI 10.1016/j.clcc.2015.02.004
   van der Geest LGM, 2015, CLIN EXP METASTAS, V32, P457, DOI 10.1007/s10585 015 9719 0
   van Rooijen KL, 2018, EUR J CANCER, V91, P99, DOI 10.1016/j.ejca.2017.12.014
   Wang XS, 2012, LANCET ONCOL, V13, P395, DOI 10.1016/S1470 2045(11)70384 9
   Wibmer C, 2011, SPINE, V36, P1977, DOI 10.1097/BRS.0b013e3182011f84
   Wong SF, 2016, CLIN COLORECTAL CANC, V15, pE125, DOI 10.1016/j.clcc.2015.12.010
NR 30
TC 6
Z9 7
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2234 943X
J9 FRONT ONCOL
JI Front. Oncol.
PD JUN 19
PY 2020
VL 10
AR 974
DI 10.3389/fonc.2020.00974
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA MJ9IG
UT WOS:000548398900001
PM 32637357
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Keller, KK
   Lindgaard, LM
   Wogensen, L
   Dagnæs Hansen, F
   Thomsen, JS
   Sakaguchi, S
   Stengaard Pedersen, K
   Hauge, EM
AF Keller, Kresten Krarup
   Lindgaard, Lisa Mejlvang
   Wogensen, Lise
   Dagnaes Hansen, Frederik
   Thomsen, Jesper Skovhus
   Sakaguchi, Shimon
   Stengaard Pedersen, Kristian
   Hauge, Ellen Margrethe
TI SKG arthritis as a model for evaluating therapies in rheumatoid
   arthritis with special focus on bone changes
SO RHEUMATOLOGY INTERNATIONAL
LA English
DT Article
DE Rheumatoid arthritis; Bone; Animal models; Experimental arthritis;
   Osteoclast; SKG mouse
ID AUTOIMMUNE ARTHRITIS; MICE; DIFFERENTIATION; OSTEOPROTEGERIN;
   DISTURBANCES; METHOTREXATE; CYTOKINE
AB The aim was to further characterize the SKG model of rheumatoid arthritis (RA) and its potential for studying intervention treatments, with special focus on bone targeting therapies. Three individual studies were conducted, using a total of 71 SKG mice, comparing arthritis induction with mannan versus zymosan A, female versus male mice, and the effect of dexamethasone intervention treatment initiated at different time points after arthritis induction. Hind paws were embedded undecalcified in methyl methacrylate, and sections were stained with Masson Goldner trichrome. Areal Bone Mineral Density (aBMD) of the femora was determined with pDXA. RNA was extracted from the hind paws followed by the quantification by reverse transcriptase PCR. SKG mice stimulated with mannan presented a higher arthritis score than mice stimulated with zymosan A. Female SKG mice developed a more severe arthritis than male SKG mice. Dexamethasone inhibited arthritis clinically as well as histologically when the treatment was initiated prophylactically or within the first week of arthritis. Femoral aBMD was lower in animals with arthritis than in control animals. The RANKL RNA expression was elevated in arthritic mice, whereas OPG RNA expression was unchanged. The results suggest mannan as arthritis inductor and female instead of male mice in experiments as well as an optimal time window for the initiation of treatment. Systemic bone loss as well as local up regulation of RANKL was present early in SKG arthritis. These results demonstrate that SKG arthritis is a suitable new model for evaluating therapies in RA.
C1 [Keller, Kresten Krarup] Aarhus Univ Hosp, Dept Rheumatol, DK 8000 Aarhus C, Denmark.
   [Lindgaard, Lisa Mejlvang; Wogensen, Lise] Aarhus Univ Hosp, Res Lab Biochem Pathol, DK 8000 Aarhus C, Denmark.
   [Dagnaes Hansen, Frederik] Aarhus Univ, Inst Med Microbiol & Immunol, DK 8000 Aarhus C, Denmark.
   [Thomsen, Jesper Skovhus] Aarhus Univ, Inst Anat, DK 8000 Aarhus C, Denmark.
   [Sakaguchi, Shimon] Kyoto Univ, Dept Expt Pathol, Inst Frontier Med Sci, Kyoto 6068507, Japan.
   [Stengaard Pedersen, Kristian; Hauge, Ellen Margrethe] Aarhus Univ Hosp, Dept Rheumatol, DK 8000 Aarhus C, Denmark.
C3 Aarhus University; Aarhus University; Aarhus University; Aarhus
   University; Kyoto University; Aarhus University
RP Keller, KK (通讯作者)，Aarhus Univ Hosp, Dept Rheumatol, Norrebrogade 44, DK 8000 Aarhus C, Denmark.
EM kresten@ana.au.dk
RI ; Sakaguchi, Shimon/C 9535 2009; Thomsen, Jesper/HKN 2794 2023; Keller,
   Kresten/S 2067 2019
OI Stengaard Pedersen, Kristian/0000 0001 7991 2456; Keller, Kresten
   Krarup/0000 0003 2474 3389; Thomsen, Jesper Skovhus/0000 0001 9386 6679;
   Dagnaes Hansen, Frederik/0000 0002 6622 0853; 
FU Danish Rheumatism Association; Horslev Foundation; Clinical Institute
   Aarhus University; Peter Ryholts Grant; Hede Nielsens Family Foundation;
   A.P. Moller Foundation for the Advancement of Medical Science; Aase and
   Ejnar Danielsens Foundation
FX The authors are grateful for the technical assistance of Dorthe Clausen,
   Jette Barlach, and Lotte Arentoft. This work was supported by the Danish
   Rheumatism Association, the Horslev Foundation, Clinical Institute
   Aarhus University, Peter Ryholts Grant, the Hede Nielsens Family
   Foundation, The A.P. Moller Foundation for the Advancement of Medical
   Science and Aase and Ejnar Danielsens Foundation.
CR Asquith DL, 2009, EUR J IMMUNOL, V39, P2040, DOI 10.1002/eji.200939578
   Caetano Lopes J, 2009, CLIN EXP RHEUMATOL, V27, P475
   Caetano Lopes J, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2908
   Das Roy L, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2345
   Erben RG, 1996, ANAT REC, V246, P39, DOI 10.1002/(SICI)1097 0185(199609)246:1<39::AID AR5>3.0.CO;2 A
   Gerosa M, 2008, WOMENS HEALTH, V4, P195, DOI 10.2217/17455057.4.2.195
   Graudal N, 2010, ARTHRITIS RHEUM US, V62, P2852, DOI 10.1002/art.27592
   Hashimoto M, 2010, J EXP MED, V207, P1135, DOI 10.1084/jem.20092301
   Hata H, 2004, J CLIN INVEST, V114, P582, DOI 10.1172/JCI200421795
   Hetland ML, 2006, ARTHRITIS RHEUM US, V54, P1401, DOI 10.1002/art.21796
   HOLMDAHL R, 1986, ARTHRITIS RHEUM US, V29, P1501, DOI 10.1002/art.1780291212
   HOLMDAHL R, 1986, ARTHRITIS RHEUM, V29, P106, DOI 10.1002/art.1780290114
   Keller KK, 2011, CLIN EXP RHEUMATOL, V29, P536
   Keystone EC, 2004, ARTHRITIS RHEUM, V50, P1400, DOI 10.1002/art.20217
   Kobayashi K, 2006, INFLAMM RES, V55, P335, DOI 10.1007/s00011 006 5208 x
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Roux C, 2011, OSTEOPOROSIS INT, V22, P421, DOI 10.1007/s00198 010 1319 x
   Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119
   Sakaguchi S, 2006, SEMIN IMMUNOL, V18, P199, DOI 10.1016/j.smim.2006.03.007
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Yoshitomi H, 2005, J EXP MED, V201, P949, DOI 10.1084/jem.20041758
NR 23
TC 21
Z9 23
U1 1
U2 6
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0172 8172
J9 RHEUMATOL INT
JI Rheumatol. Int.
PD MAY
PY 2013
VL 33
IS 5
BP 1127
EP 1133
DI 10.1007/s00296 012 2500 7
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 133WU
UT WOS:000318172400003
PM 22948540
DA 2025 08 17
ER

PT J
AU Vlase, G
   Albu, P
   Doca, SC
   Mateescu, M
   Vlase, T
AF Vlase, Gabriela
   Albu, Paul
   Doca, Sorin Cristian
   Mateescu, Madalina
   Vlase, Titus
TI The kinetic study of the thermally induced degradation and an evaluation
   of the drug excipient interactions performed for a new generation
   bisphosphonate risedronate
SO JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY
LA English
DT Article
DE Risedronate excipients mixture; Thermally induced interactions;
   Non isothermal kinetics
ID NONPARAMETRIC KINETICS; THERMOGRAVIMETRIC DATA; THERMOANALYTICAL DATA;
   SODIUM ALENDRONATE; BONE; OSTEOPOROSIS; HYDROXYAPATITE; NANOPARTICLES;
   MECHANISMS; BEHAVIOR
AB Sodium risedronate (Rise) is a third generation of bisphosphonates, compounds active in suppressing the bone resorption and therefore used in orthopedy, dentistry and bone cancer treatment. The stability of Rise as bioactive compound was studied by thermoanalysis (TA) and kinetic analysis under non isothermal conditions, as well as by FTIR spectroscopy of samples treated at different temperatures. The data were compared with these obtained for similar compounds (sodium alendronate and zoledronic acid) and reveal a low stability: The decomposition begins under 100 degrees C, and the activation energy is relatively small. The possibilities of increasing the thermal stability were studied using binary mixture (1:1) in mass parts of Rise with talc, silica, mannitol, starch, microcrystalline cellulose and magnesium stearate. By both methods, TA and FTIR interaction between Rise and mannitol was detected. Regarding the kinetic analysis, the nonparametric kinetic methods reveal its advantages by an objective and complete kinetic description of Rise thermal decomposition.
C1 [Vlase, Gabriela; Albu, Paul; Mateescu, Madalina; Vlase, Titus] West Univ Timisoara, Res Ctr Thermal Anal Environm Problems, 16 Pestalozzi St, Timisoara 300115, Romania.
   [Doca, Sorin Cristian] Univ Med & Farm Timisoara, Fac Med, Eftimie Murgu Sq 2, Timisoara 300041, Romania.
C3 West University of Timisoara; Victor Babes University of Medicine &
   Pharmacy, Timisoara
RP Vlase, T (通讯作者)，West Univ Timisoara, Res Ctr Thermal Anal Environm Problems, 16 Pestalozzi St, Timisoara 300115, Romania.
EM titus.vlase@e uvt.ro
RI ; Vlase, Titus/C 4852 2011; Grădinaru, Madalina/AAS 2844 2021; Vlase,
   Gabriela/GQQ 0809 2022; Vlase, Gabriela/S 3781 2019; Albu,
   Paul/AAS 7190 2021
OI Gradinaru, Madalina/0000 0001 8313 5055; Vlase,
   Titus/0000 0002 7480 7486; Vlase, Gabriela/0000 0002 1307 7010; 
CR Albu P, 2017, J THERM ANAL CALORIM, V130, P403, DOI 10.1007/s10973 017 6537 4
   Albu P, 2017, J THERM ANAL CALORIM, V127, P571, DOI 10.1007/s10973 016 5745 7
   [Anonymous], 2004, INFRARED SPECTROSCOP, DOI DOI 10.1002/0470011149.CH7
   [Anonymous], 2003, PRACTICAL APPROACH M, DOI [DOI 10.1007/0 306 47815 3_5, 10.1007/0 306 47815 3_5]
   Bedoya DA, 2017, APPL CLAY SCI, V141, P257, DOI 10.1016/j.clay.2017.03.001
   Brown ME, 2000, THERMOCHIM ACTA, V355, P125, DOI 10.1016/S0040 6031(00)00443 3
   Ceban I, 2016, J THERM ANAL CALORIM, V126, P195, DOI 10.1007/s10973 016 5729 7
   Doca SC, 2016, J THERM ANAL CALORIM, V126, P189, DOI 10.1007/s10973 016 5619 z
   estk J., 1971, THERMOCHIM ACTA, V3, P1, DOI [10.1016/0040 6031(71)85051 7, DOI 10.1016/0040 6031(71)85051 7]
   FLYNN JH, 1966, J POLYM SCI POL LETT, V4, P323, DOI 10.1002/pol.1966.110040504
   Friedman H.L., 1964, Journal of Polymer Science Part C: Polymer Symposia, V6, P183, DOI DOI 10.1002/POLC.5070060121
   Fulias A, 2016, J THERM ANAL CALORIM, V125, P759, DOI 10.1007/s10973 015 5052 8
   Gupta MS, 2014, CELL TISSUE RES, V358, P527, DOI 10.1007/s00441 014 1962 1
   Hongo M, 2015, J BONE MINER METAB, V33, P432, DOI 10.1007/s00774 014 0603 9
   Khajuria DK, 2016, MAT SCI ENG C MATER, V63, P78, DOI 10.1016/j.msec.2016.02.062
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Malavasi M, 2016, ARCH ORAL BIOL, V68, P43, DOI 10.1016/j.archoralbio.2016.03.021
   Mathoo Julian M R, 2004, Curr Osteoporos Rep, V2, P17, DOI 10.1007/s11914 004 0010 6
   Mendonca LT, 2017, J CLIN DENSITOM, V20, P44, DOI 10.1016/j.jocd.2016.08.004
   Molvik H, 2015, OSTEOPOROSIS INT, V26, P1251, DOI 10.1007/s00198 014 3007 8
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   OZAWA T, 1965, B CHEM SOC JPN, V38, P1881, DOI 10.1246/bcsj.38.1881
   Pasqualone M, 2017, MAT SCI ENG C MATER, V76, P652, DOI 10.1016/j.msec.2017.03.147
   Patrutescu C, 2015, J THERM ANAL CALORIM, V121, P983, DOI 10.1007/s10973 015 4620 2
   Rawat P, 2016, INT J PHARMACEUT, V506, P253, DOI 10.1016/j.ijpharm.2016.04.049
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Serra R, 1998, J THERM ANAL CALORIM, V52, P933, DOI 10.1023/A:1010120203389
   Serra R, 1998, THERMOCHIM ACTA, V316, P37, DOI 10.1016/S0040 6031(98)00295 0
   Torstrick FB, 2014, CURR OSTEOPOROS REP, V12, P33, DOI 10.1007/s11914 014 0191 6
   Vlase G, 2016, J THERM ANAL CALORIM, V126, P287, DOI 10.1007/s10973 016 5509 4
   Vlase T, 2005, J THERM ANAL CALORIM, V80, P59, DOI 10.1007/s10973 005 0613 x
   Vlase T, 2009, J THERM ANAL CALORIM, V97, P467, DOI 10.1007/s10973 009 0219 9
NR 33
TC 7
Z9 7
U1 0
U2 23
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388 6150
EI 1588 2926
J9 J THERM ANAL CALORIM
JI J. Therm. Anal. Calorim.
PD OCT
PY 2018
VL 134
IS 1
BP 721
EP 730
DI 10.1007/s10973 018 7216 9
PG 10
WC Thermodynamics; Chemistry, Analytical; Chemistry, Physical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Thermodynamics; Chemistry
GA GT7UX
UT WOS:000444736600071
DA 2025 08 17
ER

PT J
AU Yang, F
   Yan, GG
   Li, Y
   Han, ZB
   Zhang, L
   Chen, S
   Feng, C
   Huang, Q
   Ding, FZ
   Yu, Y
   Bi, CW
   Cai, BZ
   Yang, L
AF Yang, Fan
   Yan, Gege
   Li, Yuan
   Han, Zhenbo
   Zhang, Lai
   Chen, Simon
   Feng, Chao
   Huang, Qi
   Ding, Fengzhi
   Yu, Ying
   Bi, Chongwei
   Cai, Benzhi
   Yang, Lei
TI Astragalus Polysaccharide Attenuated Iron Overload Induced Dysfunction
   of Mesenchymal Stem Cells via Suppressing Mitochondrial ROS
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Astragalus polysaccharide; Iron overload; Senescence; ROS; Proliferation
ID MARROW STROMAL CELLS; BONE MARROW; OXIDATIVE STRESS; OSTEOGENIC
   DIFFERENTIATION; CHELATION THERAPY; KAPPA B; RATS; CHANNELS; FAILURE;
   PATHWAY
AB Background/Aims: Bone marrow derived mesenchymal stem cells (BMSCs) have the ability to differentiate into multilineage cells such as osteoblasts, chondrocytes, and cardiomyocytes. Dysfunction of BMSCs in response to pathological stimuli participates in the development of diseases such as osteoporosis. Astragalus polysaccharide (APS) is a major active ingredient of Astragalus membranaceus, a commonly used anti aging herb in traditional Chinese medicine. The aim of this study was to investigate whether APS protects against iron overload induced dysfunction of BMSCs and its underlying mechanisms. Methods: BMSCs were exposed to ferric ammonium citrate (FAC) with or without different concentrations of APS. The viability and proliferation of BMSCs were assessed by CCK 8 assay and EdU staining. Cell apoptosis, senescence and pluripotency were examined utilizing TUNEL staining, beta galactosidase staining and qRT PCR respectively. The reactive oxygen species (ROS) level was assessed in BMSCs with a DCFH DA probe and MitoSOX Red staining. Results: Firstly, we found that iron overload induced by FAC markedly reduced the viability and proliferation of BMSCs, but treatment with APS at 10, 30 and 100 mu g/mL was able to counter the reduction of cell proliferation. Furthermore, exposure to FAC led to apoptosis and senescence in BMSCs, which were partially attenuated by APS. The pluripotent genes Nanog, Sox2 and Oct4 were shown to be downregulated in BMSCs after FAC treatment, however APS inhibited the reduction of Nanog, Sox2 and Oct4 expression. Further study uncovered that APS treatment abrogated the increase of intracellular and mitochondrial ROS level in FAC treated BMSCs. Conclusion: Treatment of BMSCs with APS to impede mitochondrial ROS accumulation can remarkably inhibit apoptosis, senescence, and the reduction of proliferation and pluripotency of BMSCs caused by FAC induced iron overload. (C) 2016 The Author(s) Published by S. Karger AG, Basel
C1 [Yang, Lei] Harbin Med Univ, Affiliated Hosp 1, Dept Orthoped, Harbin, Peoples R China.
   [Yang, Fan; Yan, Gege; Li, Yuan; Han, Zhenbo; Zhang, Lai; Feng, Chao; Huang, Qi; Ding, Fengzhi; Yu, Ying; Bi, Chongwei; Cai, Benzhi] Harbin Med Univ, Coll Pharm, State Prov Key Labs Biomed Pharmaceut China, Dept Pharmacol, Harbin, Peoples R China.
   [Chen, Simon] Univ Calgary, Cumming Sch Med, Calgary, AB, Canada.
C3 Harbin Medical University; Harbin Medical University; University of
   Calgary
RP Yang, L (通讯作者)，Harbin Med Univ, Affiliated Hosp 1, Dept Orthoped, Harbin, Peoples R China.; Cai, BZ (通讯作者)，Harbin Med Univ, Dept Pharmacol, Coll Pharm, Harbin 150081, Peoples R China.
EM caibenzhi@163.com; yangray83@vip.qq.com
RI Han, Zhenbo/AAE 2017 2021; Li, Yuan/AGZ 7685 2022; zhang,
   lai/GVS 4725 2022
OI Ding, Fengzhi/0000 0002 1327 601X; Li, Yuan/0000 0002 4552 5180; 
FU Natural Science Foundation of China [81501920/81573434]; Natural Science
   Foundation of Heilongjiang Province [LC2015027/ H2015056]
FX This study was supported by the Natural Science Foundation of China
   (81501920/81573434), and the Natural Science Foundation of Heilongjiang
   Province (LC2015027/ H2015056).
CR Altamura S, 2014, CELL METAB, V20, P359, DOI 10.1016/j.cmet.2014.07.007
   Bird RJ, 2012, INTERN MED J, V42, P450, DOI 10.1111/j.1445 5994.2012.02734.x
   Cai BZ, 2015, STEM CELL TRANSL MED, V4, P1425, DOI 10.5966/sctm.2015 0032
   Cai BZ, 2014, J CELL MOL MED, V18, P1407, DOI 10.1111/jcmm.12287
   Chen W, 2010, J DIABETES COMPLICAT, V24, P199, DOI 10.1016/j.jdiacomp.2008.12.003
   De Buck E, 2012, J HEPATOL, V57, P1126, DOI 10.1016/j.jhep.2012.04.040
   DIXON RM, 1994, HEPATOLOGY, V19, P904, DOI 10.1002/hep.1840190416
   Doyard M, 2012, OSTEOPOROSIS INT, V23, P2435, DOI 10.1007/s00198 011 1871 z
   Ghodsizad A, 2013, CARDIOVASC THER, V31, P323, DOI 10.1111/1755 5922.12032
   Han DO, 2009, METHOD FIND EXP CLIN, V31, P95, DOI 10.1358/mf.2009.31.2.1353846
   He YF, 2013, BIOL TRACE ELEM RES, V152, P292, DOI 10.1007/s12011 013 9605 z
   Jia P, 2012, J ORTHOP RES, V30, P1843, DOI 10.1002/jor.22133
   Kleven MD, 2016, GASTROENTEROLOGY, V150, P556, DOI 10.1053/j.gastro.2016.01.016
   Li SG, 2007, INT IMMUNOPHARMACOL, V7, P23, DOI 10.1016/j.intimp.2006.08.016
   Liu Y, 2014, CELL STEM CELL, V15, P66, DOI 10.1016/j.stem.2014.03.005
   Lu JZ, 2013, INT J MOL MED, V31, P1463, DOI 10.3892/ijmm.2013.1335
   Luo T, 2015, INFLAMM RES, V64, P205, DOI 10.1007/s00011 015 0798 9
   Messer JG, 2009, BONE, V45, P972, DOI 10.1016/j.bone.2009.07.073
   Patková J, 2014, CELL PHYSIOL BIOCHEM, V33, P1439, DOI 10.1159/000358709
   Rathore Ajit Singh, 2016, Int J Appl Basic Med Res, V6, P28, DOI 10.4103/2229 516X.174005
   Rossi F, 2014, HAEMATOLOGICA, V99, P1876, DOI 10.3324/haematol.2014.104463
   Satija NK, 2009, J CELL MOL MED, V13, P4385, DOI 10.1111/j.1582 4934.2009.00857.x
   Shen Bin, 2011, Zhongguo Gu Shang, V24, P652
   Sun L, 2014, CELL PHYSIOL BIOCHEM, V34, P1614, DOI 10.1159/000366364
   Temraz S, 2014, CRIT REV ONCOL HEMAT, V91, P64, DOI 10.1016/j.critrevonc.2014.01.006
   Tsay J, 2010, BLOOD, V116, P2582, DOI 10.1182/blood 2009 12 260083
   Wang N, 2015, J CELL BIOCHEM, V116, P242, DOI 10.1002/jcb.24961
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Xu MF, 2004, CIRCULATION, V110, P2658, DOI 10.1161/01.CIR.0000145609.20435.36
   Yang F, 2013, CELL PHYSIOL BIOCHEM, V32, P1072, DOI 10.1159/000354507
   Yao Chang, 2011, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V25, P1481
   Yue R, 2016, CELL STEM CELL, V18, P782, DOI 10.1016/j.stem.2016.02.015
   Zhang Q, 2015, J NANOSCI NANOTECHNO, V15, P6444, DOI 10.1166/jnn.2015.10709
   Zhang YW, 2007, J ETHNOPHARMACOL, V114, P387, DOI 10.1016/j.jep.2007.08.024
   Zhang YC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120219
   Zhao GY, 2012, BIOL TRACE ELEM RES, V150, P487, DOI 10.1007/s12011 012 9511 9
   Zhou Y, 2010, BRIT J PHARMACOL, V161, P1542, DOI 10.1111/j.1476 5381.2010.00998.x
NR 37
TC 69
Z9 81
U1 4
U2 41
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2016
VL 39
IS 4
BP 1369
EP 1379
DI 10.1159/000447841
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA DX5IQ
UT WOS:000384415000012
PM 27607448
OA gold
DA 2025 08 17
ER

PT J
AU Diederichs, S
   Dreher, SI
   Nueesch, SA
   Schmidt, S
   Merle, C
   Richter, W
AF Diederichs, Solvig
   Dreher, Simon I.
   Nueesch, Sarah Anna
   Schmidt, Sven
   Merle, Christian
   Richter, Wiltrud
TI Mesenchymal stromal cell chondrogenesis under ALK1/2/3 specific BMP
   inhibition: a revision of the prohypertrophic signalling network concept
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Chondrogenesis; Cartilage; Hypertrophy; TGF beta; ALK2; ALK3; ALK4;
   ALK5; In vivo; BMP; PTHrP; Bone
ID GROWTH FACTOR BETA; HYPERTROPHY; EXPRESSION; PROTEIN; PHOSPHORYLATION;
   DIFFERENTIATION
AB Background In vitro chondrogenesis of mesenchymal stromal cells (MSCs) driven by the essential chondro inducer transforming growth factor (TGF) beta is instable and yields undesired hypertrophic cartilage predisposed to bone formation in vivo. TGF beta can non canonically activate bone morphogenetic protein associated ALK1/2/3 receptors. These have been accused of driving hypertrophic MSC misdifferentiation, but data remained conflicting. We here tested the antihypertrophic capacity of two highly specific ALK1/2/3 inhibitors   compound A (CompA) and LDN 212854 (LDN21)   in order to reveal potential prohypertrophic contributions of these BMP/non canonical TGF beta receptors during MSC in vitro chondrogenesis. Methods Standard chondrogenic pellet cultures of human bone marrow derived MSCs were treated with TGF beta and CompA (500 nM) or LDN21 (500 nM). Daily 6 hour pulses of parathyroid hormone related peptide (PTHrP[1 34], 2.5 nM, from day 7) served as potent antihypertrophic control treatment. Day 28 samples were subcutaneously implanted into immunodeficient mice. Results All groups underwent strong chondrogenesis, but GAG/DNA deposition and ACAN expression were slightly but significantly reduced by ALK inhibition compared to solvent controls along with a mild decrease of the hypertrophy markers IHH , SPP1 mRNA, and Alkaline phosphatase (ALP) activity. When corrected for the degree of chondrogenesis (COL2A1 expression), only pulsed PTHrP but not ALK1/2/3 inhibition qualified as antihypertrophic treatment. In vivo, all subcutaneous cartilaginous implants mineralized within 8 weeks, but PTHrP pretreated samples formed less bone and attracted significantly less haematopoietic marrow than ALK1/2/3 inhibitor groups. Conclusions Overall, our data show that BMP ALK1/2/3 inhibition cannot program mesenchymal stromal cells toward stable chondrogenesis. BMP ALK1/2/3 signalling is no driver of hypertrophic MSC misdifferentiation and BMP receptor induction is not an adverse prohypertrophic side effect of TGF beta that leads to endochondral MSC misdifferentiation. Instead, the prohypertrophic network comprises misregulated PTHrP/hedgehog signalling and WNT activity, and a potential contribution of TGF beta ALK4/5 mediated SMAD1/5/9 signalling should be further investigated to decide about its postulated prohypertrophic activity. This will help to successfully engineer cartilage replacement tissues from MSCs in vitro and translate these into clinical cartilage regenerative therapies.
C1 [Diederichs, Solvig; Dreher, Simon I.; Nueesch, Sarah Anna; Schmidt, Sven; Richter, Wiltrud] Heidelberg Univ Hosp, Orthopaed Univ Hosp, Res Ctr Expt Orthopaed, Schlierbacher Landstr 200a, D 69118 Heidelberg, Germany.
   [Merle, Christian] Heidelberg Univ Hosp, Orthopaed Univ Hosp, Heidelberg, Germany.
   [Merle, Christian] Diakonieklinikum Stuttgart, Orthopad Klin Paulinenhilfe, Stuttgart, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg
RP Diederichs, S (通讯作者)，Heidelberg Univ Hosp, Orthopaed Univ Hosp, Res Ctr Expt Orthopaed, Schlierbacher Landstr 200a, D 69118 Heidelberg, Germany.
EM solvig.diederichs@med.uni heidelberg.de
RI Dreher, Simon/AAH 3138 2021
FU Universittsklinikum Heidelberg (8914)
FX The authors thank Nina Hofmann, Birgit Frey, and Felina Zahnow for their
   excellent technical help.
CR Chasan S, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202109176
   Chawla S, 2020, J Cell Sci, P133
   Daly AC, 2008, MOL CELL BIOL, V28, P6889, DOI 10.1128/MCB.01192 08
   Dexheimer V, 2016, SCI REP UK, V6, DOI 10.1038/srep36655
   Diederichs S, 2019, CELL MOL LIFE SCI, V76, P3875, DOI 10.1007/s00018 019 03099 0
   Fischer J, 2016, J CELL PHYSIOL, V231, P2673, DOI 10.1002/jcp.25369
   Fischer J, 2014, STEM CELLS DEV, V23, P2513, DOI 10.1089/scd.2014.0101
   Franco RAG, 2022, STEM CELL REP, V17, P616, DOI 10.1016/j.stemcr.2022.01.016
   Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743
   Grönroos E, 2012, MOL CELL BIOL, V32, P2904, DOI 10.1128/MCB.00231 12
   Hellingman CA, 2011, TISSUE ENG PT A, V17, P1157, DOI [10.1089/ten.tea.2010.0043, 10.1089/ten.TEA.2010.0043]
   Horbelt D, 2015, J BIOL CHEM, V290, P3390, DOI 10.1074/jbc.M114.604397
   Kleinschmidt K, 2013, BIOMATERIALS, V34, P5926, DOI 10.1016/j.biomaterials.2013.04.029
   Luckgen J, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02843 x
   Mohedas AH, 2013, ACS CHEM BIOL, V8, P1291, DOI 10.1021/cb300655w
   Mueller MB, 2013, INT ORTHOP, V37, P945, DOI 10.1007/s00264 013 1800 1
   Murakami M, 2009, GENES CELLS, V14, P469, DOI 10.1111/j.1365 2443.2009.01283.x
   Narcisi R, 2015, STEM CELL REP, V4, P459, DOI 10.1016/j.stemcr.2015.01.017
   Occhetta P, 2018, P NATL ACAD SCI USA, V115, P4625, DOI 10.1073/pnas.1720658115
   Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626
   Pelttari K, 2006, ARTHRITIS RHEUM US, V54, P3254, DOI 10.1002/art.22136
   Santibañez JF, 2011, CLIN SCI, V121, P233, DOI 10.1042/CS20110086
   Thielen NGM., 2019, TGFbeta/BMP Signal Pathw Cartil Homeost Cells, V8, P969
   van den Bosch MH, 2014, CELL SIGNAL, V26, P951, DOI 10.1016/j.cellsig.2014.01.021
   Wang WG, 2014, BIRTH DEFECTS RES C, V102, P37, DOI 10.1002/bdrc.21058
   Weiss S, 2010, J CELL PHYSIOL, V223, P84, DOI 10.1002/jcp.22013
   Winter A, 2003, ARTHRITIS RHEUM US, V48, P418, DOI 10.1002/art.10767
   Wrighton KH, 2009, J BIOL CHEM, V284, P9755, DOI 10.1074/jbc.M809223200
   Yoo JU, 1998, J BONE JOINT SURG AM, V80A, P1745, DOI 10.2106/00004623 199812000 00004
NR 29
TC 2
Z9 2
U1 1
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD APR 5
PY 2024
VL 15
IS 1
AR 98
DI 10.1186/s13287 024 03710 7
PG 15
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA NA8O1
UT WOS:001197810600001
PM 38581019
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Sun, J
   Dong, ZW
   Zhang, Y
   He, XN
   Fei, DD
   Jin, F
   Yuan, L
   Li, B
   Jin, Y
AF Sun, Jin
   Dong, Zhiwei
   Zhang, Yang
   He, Xiaoning
   Fei, Dongdong
   Jin, Fang
   Yuan, Lin
   Li, Bei
   Jin, Yan
TI Osthole improves function of periodontitis periodontal ligament stem
   cells via epigenetic modification in cell sheets engineering
SO SCIENTIFIC REPORTS
LA English
DT Article
ID STIMULATES OSTEOBLAST DIFFERENTIATION; MODULATES OSTEOGENIC
   DIFFERENTIATION; BONE FORMATION; INHIBITION; TISSUE; DELIVERY; MOZ
AB Inflammatory microenvironment causes the change of epigenetic modification in periodontal ligament stem cells derived from periodontitis tissues (P PDLSCs), which results in defective osteogenic differentiation compared to cells from healthy tissues. It's urgent to explore therapeutic strategies aimed at epigenetic targets associated with the regenerative ability of PDLSCs. Osthole, a small molecule compound extracted from Chinese herbs, has been documented to promote osteogenesis and cell sheets formation of healthy PDLSCs. However, whether osthole shows same effect on P PDLSCs and the mechanism of promotive effect is still unknown. The purpose of this study was to determine whether Osthole could restore defective osteogenic differentiation of P PDLSCs via epigenetic modification. We demonstrated that 10( 7) Mol/L of Osthole was the best concentration for osteogenic differentiation and proliferation of P PDLSCs. Mechanistically, we also found that Osthole upregulated MOZ and MORF, histone acetylases that specifically catalyze acetylation of Histone3 lisine9 ( H3K9) and Histone3 lisine14 ( H3K14), which are key regulators in osteogenic differentiation of P PDLSCs. Furthermore, Osthole treatment improved cell sheet formation and enhanced the bone formation of PDLSC sheets in animal models of periodontitis. Our study suggests that Osthole is a promising drug to cure periodontitis via regulating epigenetic modification in cell sheets engineering.
C1 [Sun, Jin; He, Xiaoning; Fei, Dongdong; Li, Bei; Jin, Yan] Fourth Mil Med Univ, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, Peoples R China.
   [Sun, Jin; He, Xiaoning; Fei, Dongdong; Li, Bei; Jin, Yan] Fourth Mil Med Univ, Natl Clin Res Ctr Oral Dis, Xian 710032, Shaanxi, Peoples R China.
   [Sun, Jin; He, Xiaoning; Fei, Dongdong; Li, Bei; Jin, Yan] Fourth Mil Med Univ, Shaanxi Key Lab Oral Dis, Ctr Tissue Engn, Xian 710032, Shaanxi, Peoples R China.
   [He, Xiaoning; Fei, Dongdong; Li, Bei; Jin, Yan] Xian Inst Tissue Engn & Regenerat Med, Xian 710032, Shaanxi, Peoples R China.
   [Sun, Jin] South Med Univ, Affiliated Shenzhen Matern & Child Healthcare Hos, Dept Stomatol, Shenzhen 518048, Guangdong, Peoples R China.
   [Dong, Zhiwei] Gen Hosp Shenyang Mil Area Command, Dept Oral & Maxillofacial Surg, Shenyang 110840, Liaoning, Peoples R China.
   [Zhang, Yang] Fourth Mil Med Univ, Xijing Hosp, Dept Orthopaed, Xian 710032, Shaanxi, Peoples R China.
   [Jin, Fang] Fourth Mil Med Univ, Sch Stomatol, Dept Orthodont, Xian 710032, Shaanxi, Peoples R China.
   [Yuan, Lin] Guangzhou Med Univ, Affiliated Hosp 1, Dept Stomatol, Guangzhou 510140, Guangdong, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Air Force
   Medical University; Southern Medical University   China; Air Force
   Medical University; Air Force Medical University; Guangzhou Medical
   University
RP Li, B; Jin, Y (通讯作者)，Fourth Mil Med Univ, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, Peoples R China.; Li, B; Jin, Y (通讯作者)，Fourth Mil Med Univ, Natl Clin Res Ctr Oral Dis, Xian 710032, Shaanxi, Peoples R China.; Li, B; Jin, Y (通讯作者)，Fourth Mil Med Univ, Shaanxi Key Lab Oral Dis, Ctr Tissue Engn, Xian 710032, Shaanxi, Peoples R China.; Li, B; Jin, Y (通讯作者)，Xian Inst Tissue Engn & Regenerat Med, Xian 710032, Shaanxi, Peoples R China.
EM lbfmmu@163.com; yanjin@fmmu.edu.cn
RI JIN, YAN/HPC 7389 2023; lin, yuan/JXL 9592 2024
FU National Key Research and Development Program of China [2016YFC1101400];
   National Natural Science Foundation of China [81570976, 81501885,
   31501121, 31401255]; Natural Science Foundation research project of
   Shaanxi Province [2016JQ8019]
FX This work was supported by the National Key Research and Development
   Program of China (No. 2016YFC1101400), and the grants from the National
   Natural Science Foundation of China (No. 81570976, 81501885, 31501121,
   and 31401255) and Natural Science Foundation research project of Shaanxi
   Province (2016JQ8019).
CR Addison WN, 2014, MOL CELL BIOL, V34, P3076, DOI 10.1128/MCB.00185 14
   Ali M, 2012, J MOL BIOL, V424, P328, DOI 10.1016/j.jmb.2012.10.004
   Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913
   Cai B, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/792161
   Campeau PM, 2012, HUM MUTAT, V33, P1520, DOI 10.1002/humu.22141
   Chen FM, 2012, BIOMATERIALS, V33, P6320, DOI 10.1016/j.biomaterials.2012.05.048
   Chen FM, 2011, J CONTROL RELEASE, V149, P92, DOI 10.1016/j.jconrel.2010.10.021
   Chen FM, 2009, MED RES REV, V29, P472, DOI 10.1002/med.20144
   Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888
   Gao LN, 2013, BIOMATERIALS, V34, P9937, DOI 10.1016/j.biomaterials.2013.09.017
   Gupta GK, 2013, NANOMEDICINE UK, V8, P757, DOI [10.2217/NNM.12.171, 10.2217/nnm.12.171]
   Harrison C, 2013, NAT REV DRUG DISCOV, V12, P188, DOI 10.1038/nrd3961
   Hu N, 2013, CELL PHYSIOL BIOCHEM, V32, P486, DOI 10.1159/000354453
   Huang WJ, 2010, CHEMMEDCHEM, V5, P598, DOI 10.1002/cmdc.200900494
   Imamura T, 2003, GENE CHROMOSOME CANC, V36, P413, DOI 10.1002/gcc.10172
   Irwandi RA, 2016, ARCH ORAL BIOL, V72, P66, DOI 10.1016/j.archoralbio.2016.08.014
   Jeong HM, 2011, BIOCHEM BIOPH RES CO, V409, P82, DOI 10.1016/j.bbrc.2011.04.113
   Jiang Y. H., 2014, ANNU REV GENOM HUM G, V5, P479
   Kaiser J., 2010, SCIENCE, V330
   Kim K., 2015, J TISSUE ENG REGEN M
   Kushwaha P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.350
   Li B, 2016, SCI REP UK, V6, DOI 10.1038/srep26542
   Li QZ, 2016, J MICROBIOL BIOTECHN, V26, P1, DOI 10.4014/jmb.1505.05049
   Liu N, 2011, J BONE MINER RES, V26, P2082, DOI 10.1002/jbmr.440
   Liu YL, 2011, STEM CELLS, V29, P1804, DOI 10.1002/stem.728
   Martins MD, 2016, J DENT RES, V95, P215, DOI 10.1177/0022034515611876
   Pai JT, 2015, MOLECULES, V20, P8000, DOI 10.3390/molecules20058000
   Pelletier N, 2002, ONCOGENE, V21, P2729, DOI 10.1038/sj.onc.1205367
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Sen P, 2016, CELL, V166, P822, DOI 10.1016/j.cell.2016.07.050
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   You L, 2009, NAT PROD COMMUN, V4, P297
   Zimecki M, 2009, Z NATURFORSCH C, V64, P361
NR 33
TC 42
Z9 48
U1 1
U2 37
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JUL 12
PY 2017
VL 7
AR 5254
DI 10.1038/s41598 017 05762 7
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FA4PJ
UT WOS:000405425000058
PM 28701802
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Abbasi, H
   Sharif, M
   John, P
   Bhatti, A
   Hayat, MQ
   Mansoor, Q
AF Abbasi, Huda
   Sharif, Maria
   John, Peter
   Bhatti, Attya
   Hayat, Muhammad Qasim
   Mansoor, Qaisar
TI Phytochemical, Cytoprotective Profiling, and Anti Inflammatory Potential
   of Colchicum luteum in Rheumatoid Arthritis: An Experimental and
   Simulation Study
SO NUTRIENTS
LA English
DT Article
DE plant extract; anti inflammatory; NSAIDs; acute toxicity;
   phytochemicals; bioactive compound compounds; simulations
ID PSORIATIC ARTHRITIS; COX 2; DERIVATIVES; THERAPY; BAKER
AB Background: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by severe pain, inflammation, and joint deformity. Currently, it affects 1% of the population, with a projection to exceed 23 million cases by 2030. Despite significant advancements, non steroidal anti inflammatory drugs (NSAIDs), the first line of treatment, are associated with a range of adverse effects. Consequently, plant based derivatives are being utilized as an effective alternative. This study evaluates the anti inflammatory and safety profile of Colchicum luteum hydroethanolic extract (CLHE) in comparison to NSAIDs, with a focus on COX 2 and TNF alpha inhibition. Methods: CLHE potential was evaluated by phytochemical screening and in vitro bioactivity assays. Toxicity profile was conducted in Human Colon Epithelial Cells (HCEC) and Balb/c mice. Anti inflammatory potential was explored in a collagen induced arthritic (CIA) mice model. Bioactive compounds were identified computationally from GCMS data and subjected to docking and simulation studies against COX2 and TNF alpha. Results: CLHE demonstrated significant antioxidant (IC 50 = 6.78 mu g/mL) and anti inflammatory (IC 50 = 97.39 mu g/mL) activity. It maintained 50% cell viability at 78.5 mu g/mu L in HCEC cells and exhibited no toxicity at a dose of 5000 mg/kg in mice. In the CIA model, CLHE significantly reduced paw swelling, arthritic scoring, C reactive protein levels, and spleen indices, outperforming ibuprofen. Expression analysis confirmed the downregulation of COX 2, TNF alpha, and MMP 9. Histopathological analysis indicated the superior efficacy of CLHE compared to ibuprofen in reducing inflammation, synovial hyperplasia, and bone erosion. Computational studies identified compound 15 (CL15), (4 (4,7 dimethoxy 1,3 benzodioxol 5 yl) 2 oxo pyrrolidine 3 carboxylic acid), a non toxic compound with strong binding affinities to COX 2 ( 12.9 KJ/mol), and TNF alpha ( 5.8 KJ/mol). Conclusions: The findings suggest the potential of Colchicum luteum as a safer, anti inflammatory, and multi targeted alternative to NSAIDs for RA treatment.
C1 [Abbasi, Huda; Sharif, Maria; John, Peter; Bhatti, Attya; Hayat, Muhammad Qasim] Natl Univ Sci & Technol, Atta Ur Rahman Sch Appl Biosci, Sect H 12, Islamabad 44000, Pakistan.
   [Mansoor, Qaisar] Inst Biomed & Genet Engn IBGE, Sect G 9 4, Islamabad 44000, Pakistan.
C3 National University of Sciences & Technology   Pakistan
RP John, P (通讯作者)，Natl Univ Sci & Technol, Atta Ur Rahman Sch Appl Biosci, Sect H 12, Islamabad 44000, Pakistan.
EM habbasi.phdabs14asab@asab.nust.edu.pk;
   msharif.phdabs22asab@student.nust.edu.pk; pjohn@asab.nust.edu.pk;
   attyabhatti@asab.nust.edu.pk; m.qasim@asab.nust.edu.pk; qmibge@gmail.com
RI Hayat, Muhammad/E 8340 2011; Hayat, Muhammad Qasim/E 8340 2011; Sharif,
   Maria/MDT 3667 2025
OI Hayat, Muhammad Qasim/0000 0003 1053 5327; Abbasi,
   Huda/0000 0001 5767 1137
CR Abraham Mark James, 2015, SoftwareX, V1 2, P19, DOI 10.1016/j.softx.2015.06.001
   Abramson SB, 1999, OSTEOARTHR CARTILAGE, V7, P380, DOI 10.1053/joca.1998.0217
   Ahmad W., 2020, Am. J. PharmTech Res, V10, P268, DOI [10.46624/ajptr.2020.v10.i4.022, DOI 10.46624/AJPTR.2020.V10.I4.022]
   Ahmed EA, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/6665601
   Ahmed S, 2022, LIFE BASEL, V12, DOI 10.3390/life12081148
   Akbar S., 2020, Handbook of 200 Medicinal Plants, P691
   Aryal S, 2019, PLANTS BASEL, V8, DOI 10.3390/plants8040096
   Banerjee P, 2024, NUCLEIC ACIDS RES, V52, pW513, DOI 10.1093/nar/gkae303
   Berry JM, 2005, J MED CHEM, V48, P639, DOI 10.1021/jm040859h
   Bosque I, 2014, J ORG CHEM, V79, P3982, DOI 10.1021/jo500446f
   Creton S, 2010, CRIT REV TOXICOL, V40, P50, DOI 10.3109/10408440903401511
   Dong J, 2018, J CHEMINFORMATICS, V10, DOI 10.1186/s13321 018 0283 x
   Enechi Osmund C., 2020, Tropical Journal of Natural Product Research, V4, P812, DOI 10.26538/tjnpr/v4i10.25
   Erhirhie Earnest Oghenesuvwe, 2018, Interdiscip Toxicol, V11, P5, DOI 10.2478/intox 2018 0001
   Frolov NA, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24032937
   Fürst R, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/146832
   Gulcin I, 2023, PROCESSES, V11, DOI 10.3390/pr11082248
   Hor SY, 2012, REGUL TOXICOL PHARM, V63, P106, DOI 10.1016/j.yrtph.2012.03.006
   Hosseinzadeh L, 2017, RES PHARM SCI, V12, P290, DOI 10.4103/1735 5362.212046
   Jannat A, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420 019 0222 2
   Jimenez RV, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.619564
   Joshi VR., 1973, PROBE, V13, P22
   Ju ZR, 2022, ACTA PHARM SIN B, V12, P2790, DOI 10.1016/j.apsb.2022.01.002
   Kapri A, 2022, PHARM CHEM J+, V56, P461, DOI 10.1007/s11094 022 02661 8
   Katiyar Chandrakant, 2012, Ayu, V33, P10, DOI 10.4103/0974 8520.100295
   Khan MN, 2022, PAK HEART J, V55, P231, DOI 10.47144/phj.v55i3.2304
   Konturek PC, 2004, INFLAMM RES, V53, pS27, DOI 10.1007/s00011 003 0312 7
   Kotecha M., 2015, Sci. Res. J, V2
   Kwon TH, 2003, J NEUROTRAUM, V20, P337, DOI 10.1089/089771503765172291
   Lewgowd W, 2007, ARCH PHARM, V340, P65, DOI 10.1002/ardp.200500194
   Lianxu C, 2006, OSTEOARTHR CARTILAGE, V14, P367, DOI 10.1016/j.joca.2005.10.009
   Luan J, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10371
   Lubrano E, 2012, REUMATISMO, V64, P107, DOI 10.4081/reumatismo.2012.107
   Mease P, 2004, ANN RHEUM DIS, V63, P755, DOI 10.1136/ard.2004.020719
   Nair V, 2012, INFLAMMATION, V35, P881, DOI 10.1007/s10753 011 9389 2
   Nair V, 2011, J ETHNOPHARMACOL, V133, P303, DOI 10.1016/j.jep.2010.09.027
   Nakao S, 2002, MOL CELL BIOCHEM, V238, P11, DOI 10.1023/A:1019927616000
   Nash P, 2005, ANN RHEUM DIS, V64, P74, DOI 10.1136/ard.2004.030783
   Njinga NS, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04853
   Ongtanasup T, 2022, PLANTS BASEL, V11, DOI 10.3390/plants11141835
   Oniga SD, 2017, MOLECULES, V22, DOI 10.3390/molecules22091507
   Orozco MN, 2010, J NUTR, V140, P1105, DOI 10.3945/jn.109.111104
   Radu AF, 2021, CELLS BASEL, V10, DOI 10.3390/cells10112857
   Rajkumar P., 2022, J. Sci. Res, V14, P671, DOI [10.3329/jsr.v14i2.56648, DOI 10.3329/JSR.V14I2.56648]
   Sahoo CR, 2021, DRUG DEVELOP RES, V82, P1079, DOI 10.1002/ddr.21848
   Sapra S, 2013, MED CHEM RES, V22, P531, DOI 10.1007/s00044 012 0077 z
   Sarkar S, 2024, BMC COMPLEMENT MED, V24, DOI 10.1186/s12906 024 04606 y
   Shibata H, 2007, BBA PROTEINS PROTEOM, V1774, P1029, DOI 10.1016/j.bbapap.2007.05.003
   Siddiqui MZ, 2019, Int J Res Anal Rev, V6, P328
   Spassov DS, 2023, FRONT MOL BIOSCI, V9, DOI 10.3389/fmolb.2022.1066029
   Sriuttha P, 2018, INT J HEPATOL, V2018, DOI 10.1155/2018/5253623
   Steensma A, 2004, ENVIRON TOXICOL PHAR, V16, P131, DOI 10.1016/j.etap.2003.11.008
   Teixeira JH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215436
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   van Loo G, 2023, NAT REV IMMUNOL, V23, P289, DOI 10.1038/s41577 022 00792 3
   Volobueva AS, 2021, MOLECULES, V26, DOI 10.3390/molecules26226794
   Zhang L, 2011, J AGR FOOD CHEM, V59, P12361, DOI 10.1021/jf203146e
NR 57
TC 1
Z9 1
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD DEC
PY 2024
VL 16
IS 23
AR 4020
DI 10.3390/nu16234020
PG 22
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA P2T7S
UT WOS:001376505300001
PM 39683414
OA gold
DA 2025 08 17
ER

PT J
AU Guo, RK
   Wu, CH
   Liu, F
   Dong, TH
   Zhang, T
AF Guo, Rongkang
   Wu, Chaohan
   Liu, Fan
   Dong, Tianhua
   Zhang, Tao
TI Biomimetic composite hydrogel promotes new bone formation in rat bone
   defects through regulation of miR 19b 3p/WWP1 axis by loaded
   extracellular vesicles
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE Biomimetic composite hydrogel; Extracellular vesicles; miR 19b 3p; WWP1;
   Bone defect repair; BMSCs; Osteogenic differentiation; Rat model
ID CELL; SYSTEM
AB ObjectiveThis study aims to investigate the mechanism by which biomimetic composite hydrogels loaded with bone marrow mesenchymal stem cells (BMSCs) derived microRNA 19b 3p/WWP1 axis through extracellular vesicles (EVs) affect the new bone formation in rat bone defects.MethodsFirst, synthesize the bionic composite hydrogel Gel OCS/MBGN. Characterize it through field emission scanning electron microscopy (FE SEM), X ray diffraction (XRD), and FTIR. Then, conduct performance tests such as rheology, dynamic mechanical analysis, in vitro mineralization, and degradation. Rat BMSCs were selected for in vitro cell experiments, and EVs derived from BMSCs were obtained by differential centrifugation. The EVs were loaded onto Gel OCS/MBGN to obtain Gel OCS/MBGN@EVs hydrogel. Cell viability and proliferation were detected by live/dead cell staining and CCK 8 assay, respectively. ALP and ARS staining was used to evaluate the osteogenic differentiation of BMSCs. Differential gene expression analysis of osteogenic differentiation was performed using high throughput sequencing. TargetScan database predicted the binding site between miR 19b 3p and WWP1, and a dual luciferase reporter assay was performed to confirm the targeting binding site. A rat bone defect model was established, and new bone formation was evaluated by Micro CT, H&E staining, and Masson's trichrome staining. Immunofluorescence staining and immunohistochemistry were used to detect the expression levels of osteogenic related factors in rat BMSCs. RT qPCR and Western blot were used to detect the expression levels of genes and proteins in tissues and cells.ResultGel OCS/MBGN was successfully constructed and loaded with EVs, resulting in Gel OCS/MBGN@EVs. The in vitro drug release experiment results show that Gel OCS/MBGN could sustainably release EVs. Further experiments have shown that Gel OCS/MBGN@EVs could significantly promote the differentiation of BMSCs into osteoblasts. Experiments have shown that WWP1 is a key factor in osteogenic differentiation and is regulated by miR 19b 3p. EVs promote osteogenic differentiation by suppressing WWP1 expression through the transmission of miR 19b 3p. In vivo animal experiments have demonstrated that Gel OCS/MBGN@EVs significantly promote bone repair in rats with bone defects by regulating the miR 19b 3p/WWP1 signaling axis.ConclusionFunctional Gel OCS/MBGN@EVs were obtained by constructing Gel OCS/MBGN and loading EVs onto it. EVs could deliver miR 19b 3p to BMSCs, inhibit the expression of WWP1, and promote the osteogenic differentiation of BMSCs, ultimately promoting bone regeneration in rats with bone defects.
C1 [Guo, Rongkang; Wu, Chaohan; Liu, Fan; Dong, Tianhua; Zhang, Tao] Hebei Med Univ, Hosp 3, Dept Emergency Trauma Ctr, 139 Ziqiang Rd, Shijiazhuang 050051, Hebei, Peoples R China.
C3 Hebei Medical University
RP Zhang, T (通讯作者)，Hebei Med Univ, Hosp 3, Dept Emergency Trauma Ctr, 139 Ziqiang Rd, Shijiazhuang 050051, Hebei, Peoples R China.
EM zt50500@hebmu.edu.cn
RI Zhang, Tao/F 8301 2011
FU Key Science and Technology Research Program of Hebei Provincial Health
   Commission
FX Not applicable.
CR Borzi C, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2003 5
   Chen HW, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 2033 5
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Dalhat MH, 2022, CLIN TRANSL MED, V12, DOI 10.1002/ctm2.1045
   Ferner F, 2021, UNFALLCHIRURG, V124, P412, DOI 10.1007/s00113 020 00916 1
   Xiaoling GL, 2020, BMC MED GENET, V21, DOI 10.1186/s12881 020 0948 y
   Ghandforoushan P, 2022, DRUG DELIV TRANSL RE, V12, P2960, DOI 10.1007/s13346 022 01161 2
   Hertel FC, 2022, BIOLOGY BASEL, V11, DOI 10.3390/biology11050733
   Hu HX, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1778883
   Hu JX, 2020, J CELL MOL MED, V24, P1893, DOI 10.1111/jcmm.14885
   Hu XY, 2020, CARBOHYD POLYM, V234, DOI 10.1016/j.carbpol.2020.115920
   Huang CC, 2021, ACTA BIOMATER, V126, P199, DOI 10.1016/j.actbio.2021.03.030
   Huang W, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/5358923
   Huang Y, 2021, EXP MOL MED, V53, P973, DOI 10.1038/s12276 021 00631 w
   Huang Y, 2020, J BONE ONCOL, V21, DOI 10.1016/j.jbo.2020.100280
   Irrera N, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00506
   Jin JH, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02400 y
   Jin Z, 2020, CELL TISSUE RES, V381, P99, DOI 10.1007/s00441 020 03193 x
   Jing H, 2018, TRANSL RES, V196, P1, DOI 10.1016/j.trsl.2018.01.005
   Lange T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183435
   Li J, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.01119
   Li LM, 2020, NANO LETT, V20, P4298, DOI 10.1021/acs.nanolett.0c00929
   Li RZ, 2022, BIOACT MATER, V18, P267, DOI 10.1016/j.bioactmat.2022.02.011
   Li TG, 2022, AGING US, V14, P1508, DOI 10.18632/aging.203894
   Li XQ, 2022, BIOMED PHARMACOTHER, V146, DOI 10.1016/j.biopha.2021.112499
   Liang WS, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.833840
   Liu D, 2021, J CELL MOL MED, V25, P990, DOI 10.1111/jcmm.16159
   Lou ZK, 2019, J BONE MINER METAB, V37, P815, DOI 10.1007/s00774 019 00997 y
   Meng WR, 2020, DRUG DELIV, V27, P585, DOI 10.1080/10717544.2020.1748758
   Ou QM, 2019, BIOMATER SCI UK, V7, P1973, DOI 10.1039/c8bm01653d
   Peculis R, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0265306
   Qamar SA, 2022, J BASIC MICROB, V62, P1319, DOI 10.1002/jobm.202100596
   Wan JB, 2021, BIOENGINEERED, V12, P2592, DOI 10.1080/21655979.2021.1936892
   Wang DX, 2022, MEMBRANES BASEL, V12, DOI 10.3390/membranes12070716
   Wang L, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.564731
   Wang XQ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193059
   Wei JQ, 2022, J SHOULDER ELB SURG, V31, pE190, DOI 10.1016/j.jse.2021.10.023
   Wu D, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00958 6
   Wu Q, 2018, J MOL NEUROSCI, V65, P234, DOI 10.1007/s12031 018 1093 3
   Xie P, 2019, J BIOL CHEM, V294, P10379, DOI 10.1074/jbc.W119.009585
   Xiong A, 2020, BIOMATER SCI UK, V8, P6069, DOI 10.1039/d0bm01251c
   Xu GH, 2019, J CELL PHYSIOL, V234, P10205, DOI 10.1002/jcp.27690
   Xu YW, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120596
   Yang JY, 2020, INT J NANOMED, V15, P5911, DOI 10.2147/IJN.S249129
   Yi GZ, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02721 6
   Zhang ST, 2016, J ORTHOP SCI, V21, P493, DOI 10.1016/j.jos.2016.04.010
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
   Zhao L, 2011, STEM CELLS, V29, P1601, DOI 10.1002/stem.703
   Zhao Y, 2020, BIOENGINEERED, V11, P1189, DOI 10.1080/21655979.2020.1831349
   Zhou L, 2021, BIOACT MATER, V6, P890, DOI 10.1016/j.bioactmat.2020.09.012
   Zhou XC, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14051012
   Zhu Y, 2019, CELL BIOL INT, V43, P565, DOI 10.1002/cbin.11133
NR 52
TC 8
Z9 8
U1 2
U2 18
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477 3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD NOV 30
PY 2023
VL 21
IS 1
AR 459
DI 10.1186/s12951 023 02201 w
PG 23
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA Z4HF4
UT WOS:001111695100002
PM 38037135
OA gold
DA 2025 08 17
ER

PT J
AU Chiu, CY
   Quirante, LPN
   Hsu, YT
   Thien, DV
   Li, CH
   Ho, MH
AF Chiu, Chun Yuan
   Quirante, Lumapat Paul Noel
   Hsu, Yu Tung
   Thien, Doan Van Hong
   Li, Chung Hsing
   Ho, Ming Hua
TI Preparation of NO Releasing electrospun chitosan nanofibrous scaffolds
   for osteoconduction
SO MATERIALS TECHNOLOGY
LA English
DT Article
DE Bone tissue engineering; chitosan; drug delivery; nanofibers;
   osteoconduction; sodium nitroprusside (SNP)
ID NITRIC OXIDE; OSTEOBLAST DIFFERENTIATION; MUCOADHESIVE PROPERTIES;
   SODIUM NITROPRUSSIDE; BONE REGENERATION; IN VITRO; DELIVERY; CELLS;
   FABRICATION; DENDRIMERS
AB This study focuses on fabricating sodium nitroprusside releasing chitosan based (CS/SNP) nanofibers through electrospinning. Based on SEM images and FTIR spectroscopy, the application of one step photocrosslinking significantly improved the stability of the nanofibers in aqueous environments. SEM images showed that the porous nanofibrous structure was maintained for up to 24 h. Incorporating SNP into the nanofibrous scaffolds demonstrated an enhanced biocompatibility with osteogenic cells. The cell viability increased with rising SNP content. Enhanced cell attachment, spreading, and proliferation were also observed through fluorescence microscope images of CS/SNP nanofibers, followed by the positive regulation of Smad and Runx2 pathway. The crosstalk between CS and NO reduced the possible toxicity and enhanced the osteoinductivity of NO. Furthermore, the nanofibers contributed to escalated osteogenic differentiation and mineralization, as evidenced by heightened expression of osteogenic markers such as alkaline phosphatase (ALP) expression and calcium deposition. Overall, the photo crosslinked electrospun CS/SNP nanofibers demonstrate substantial potential as scaffolds in the field of bone tissue engineering.
C1 [Chiu, Chun Yuan; Li, Chung Hsing] Triserv Gen Hosp, Dept Orthodont & Pediat Dent, Taipei, Taiwan.
   [Chiu, Chun Yuan; Li, Chung Hsing] Natl Def Med Ctr, Sch Dent, Taipei, Taiwan.
   [Quirante, Lumapat Paul Noel] Univ Liege, Dept Bioengn & Biomed Engn, Liege, Belgium.
   [Hsu, Yu Tung] Natl Taiwan Univ, Dept Pharm, Taipei, Taiwan.
   [Thien, Doan Van Hong] Can Tho Univ, Dept Chem Engn, Can Tho, Vietnam.
   [Ho, Ming Hua] Natl Taiwan Univ Sci & Technol, Dept Chem Engn, Taipei, Taiwan.
   [Ho, Ming Hua] Natl Taiwan Univ Sci & Technol, R&D Ctr Membrane Technol, Taipei, Taiwan.
C3 Tri Service General Hospital; National Defense Medical University;
   University of Liege; National Taiwan University; Can Tho University;
   National Taiwan University of Science & Technology; National Taiwan
   University of Science & Technology
RP Li, CH (通讯作者)，Triserv Gen Hosp, Dept Orthodont & Pediat Dent, Taipei, Taiwan.; Ho, MH (通讯作者)，Natl Taiwan Univ Sci & Technol, Dept Chem Engn, Taipei, Taiwan.
EM pedoortholi@gmail.com; mhho@mail.ntust.edu.tw
RI Doan, Van Hong Thien/AAW 8166 2020
OI Thien, Doan Van Hong/0000 0003 3023 6148
CR Aadil KR, 2018, MATER TECHNOL, V33, P507, DOI 10.1080/10667857.2018.1473234
   AITKEN D, 1977, CAN ANAESTH SOC J, V24, P651, DOI 10.1007/BF03006709
   Akins R., 2013, Biomaterials Science, VThird, P332
   Bakolitsa C, 2004, NATURE, V430, P583, DOI 10.1038/nature02610
   Baldik Y, 2005, BONE, V37, P32, DOI 10.1016/j.bone.2004.10.002
   Cho JY, 2006, J FOOD ENG, V74, P500, DOI 10.1016/j.jfoodeng.2005.01.047
   Chung TW, 2003, ARTIF ORGANS, V27, P155, DOI 10.1046/j.1525 1594.2003.07045.x
   Civitelli R, 2008, ARCH BIOCHEM BIOPHYS, V473, P188, DOI 10.1016/j.abb.2008.04.005
   Deitzel JM, 2001, POLYMER, V42, P261, DOI 10.1016/S0032 3861(01)00336 6
   Demir MM, 2002, POLYMER, V43, P3303, DOI 10.1016/S0032 3861(02)00136 2
   Diwan AD, 2000, J BONE MINER RES, V15, P342, DOI 10.1359/jbmr.2000.15.2.342
   Evans DM, 1996, J BONE MINER RES, V11, P300
   Fan JB, 2014, TISSUE ENG PT A, V20, P2169, DOI [10.1089/ten.TEA.2013.0523, 10.1089/ten.tea.2013.0523]
   Felka T., 2014, J Stem Cell Res Ther, V4, pe1187, DOI [10.4172/2157 7633.1000195, DOI 10.4172/2157 7633.1000195]
   Hay E, 2000, J CELL PHYSIOL, V183, P117, DOI 10.1002/(SICI)1097 4652(200004)183:1<117::AID JCP14>3.0.CO;2 #
   He P, 1998, INT J PHARMACEUT, V166, P75, DOI 10.1016/S0378 5173(98)00027 1
   Ho MH, 2014, INT J NANOMED, V9, P4293, DOI 10.2147/IJN.S68012
   HOLZBECHER M, 1971, CAN J CHEMISTRY, V49, P1413, DOI 10.1139/v71 233
   Huang RL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.101
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kang J, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/265980
   Keselowsky BG, 2005, P NATL ACAD SCI USA, V102, P5953, DOI 10.1073/pnas.0407356102
   Kim SM, 2021, ANN NY ACAD SCI, V1487, P21, DOI 10.1111/nyas.14486
   Koh A, 2013, ANAL CHEM, V85, P10488, DOI 10.1021/ac402312b
   Koh A, 2013, ACS APPL MATER INTER, V5, P7956, DOI 10.1021/am402044s
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   LEEUWENKAMP OR, 1984, PHARM WEEKBLAD, V6, P129, DOI 10.1007/BF01954040
   LEHR CM, 1992, INT J PHARM, V78, P43, DOI 10.1016/0378 5173(92)90353 4
   Li CH, 2014, COLLOID SURFACE B, V115, P1, DOI 10.1016/j.colsurfb.2013.11.006
   Li L, 2015, BIOMATERIALS, V37, P218, DOI 10.1016/j.biomaterials.2014.10.015
   Lienemann PS, 2012, ADV DRUG DELIVER REV, V64, P1078, DOI 10.1016/j.addr.2012.03.010
   Liu D, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb7422
   Liu HA, 2009, CHEM MATER, V21, P5032, DOI 10.1021/cm901358z
   Lowe A, 2014, MATER LETT, V125, P221, DOI 10.1016/j.matlet.2014.03.174
   Lu Y, 2014, BIOMATERIALS, V35, P1716, DOI 10.1016/j.biomaterials.2013.11.015
   Lu Y, 2013, BIOMACROMOLECULES, V14, P3589, DOI 10.1021/bm400961r
   Mit uppatham C, 2004, MACROMOL CHEM PHYS, V205, P2327, DOI 10.1002/macp.200400225
   Sadati SMM, 2022, MATER TECHNOL, V37, P1276, DOI 10.1080/10667857.2021.1934367
   Nablo BJ, 2005, BIOMATERIALS, V26, P6984, DOI 10.1016/j.biomaterials.2005.05.017
   Park ES, 2010, MOL ENDOCRINOL, V24, P846, DOI 10.1210/me.2009 0392
   Park J W., 1991, Arch Pharm Res, V14, P118, DOI [10.1007/BF02892015, DOI 10.1007/BF02892015]
   Porter JR, 2009, BIOTECHNOL PROGR, V25, P1539, DOI 10.1002/btpr.246
   Rangaswami H, 2009, J BIOL CHEM, V284, P14796, DOI 10.1074/jbc.M806486200
   Roszer T., 2014, Systems biology of free radicals and antioxidants, P2895
   Salehi F, 2017, RSC ADV, V7, P43141, DOI 10.1039/c7ra06793c
   Sangsanoh P, 2006, BIOMACROMOLECULES, V7, P2710, DOI 10.1021/bm060286l
   Saura M, 2010, THESCIENTIFICWORLDJO, V10, P624, DOI 10.1100/tsw.2010.58
   Shaw CK, 2001, J FORMOS MED ASSOC, V100, P805
   Son WK, 2004, J POLYM SCI POL PHYS, V42, P5, DOI 10.1002/polb.10668
   Srouji S, 2011, TISSUE ENG PT A, V17, P269, DOI [10.1089/ten.tea.2010.0250, 10.1089/ten.TEA.2010.0250]
   Stains JP, 2005, BIOCHEM BIOPH RES CO, V328, P721, DOI 10.1016/j.bbrc.2004.11.078
   Tang S, 2011, ELECTROCHIM ACTA, V56, P10473, DOI 10.1016/j.electacta.2011.01.073
   TAYLOR TH, 1970, BRIT J ANAESTH, V42, P859, DOI 10.1093/bja/42.10.859
   Tejeda Montes E, 2014, ACTA BIOMATER, V10, P134, DOI 10.1016/j.actbio.2013.09.001
   Thierry B, 2005, J BIOMED MATER RES A, V75A, P556, DOI 10.1002/jbm.a.30450
   Vesey C.J., 1977, J Clin Pharm Therapeutics, V2, P105, DOI [DOI 10.1111/J.1365 2710.1977.TB00080.X, 10.1111/j.1365 2710.1977.tb00080.x]
   Wang K, 2015, MATER TECHNOL, V30, pB198, DOI 10.1179/17535557B15Y.000000008
   Wimalawansa SJ, 2008, EXPERT OPIN PHARMACO, V9, P3025, DOI 10.1517/14656560802197162 
   Wold KA, 2012, ACS APPL MATER INTER, V4, P3022, DOI 10.1021/am300383w
   Worley BV, 2016, ACS BIOMATER SCI ENG, V2, P426, DOI 10.1021/acsbiomaterials.6b00032
   Worley BV, 2014, BIOCONJUGATE CHEM, V25, P918, DOI 10.1021/bc5000719
   Yeom YE, 2019, MATER TECHNOL, V34, P851, DOI 10.1080/10667857.2019.1638671
   Yilgor P, 2009, BIOMATERIALS, V30, P3551, DOI 10.1016/j.biomaterials.2009.03.024
   Yun YP, 2013, TISSUE ENG REGEN MED, V10, P122, DOI 10.1007/s13770 013 0386 4
NR 64
TC 2
Z9 2
U1 4
U2 73
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1066 7857
EI 1753 5557
J9 MATER TECHNOL
JI Mater. Technol.
PD DEC 31
PY 2024
VL 39
IS 1
AR 2286834
DI 10.1080/10667857.2023.2286834
PG 15
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA Z6VL4
UT WOS:001113431600001
OA hybrid
DA 2025 08 17
ER

PT J
AU Onoda, N
   Kashiwagi, T
   Nakamura, T
   Niitsu, Y
   Omata, M
   Kurihara, S
AF Onoda, N
   Kashiwagi, T
   Nakamura, T
   Niitsu, Y
   Omata, M
   Kurihara, S
TI Parathyroid interventions for secondary hyperparathyroidism in
   hemodialyzed patients
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Article; Proceedings Paper
CT 16th Meeting of the
   Japanese Society for Kidney Disease and Vitamin D Therapy
CY FEB 26, 2005
CL Tokyo, JAPAN
SP Japanese Soc Kidney Dis & Vitamin D Therapy
DE parathyroid interventions; percutaneous ethanol injection therapy;
   secondary hyperparathyroidism
AB Although parathyroidectomy (PTX) is the ultimate treatment for secondary hyperparathyroidism (SHPT) that is resistant to medical treatment, recent advances in ultrasonographic techniques have increased the treatment options in Japan. Percutaneous ethanol injection therapy (PEIT) of the parathyroid was approved under the national health insurance system in 2004, and there have been trials of direct injection of vitamin D (VD) preparations. We followed 30 patients for at least 1 year who had undergone PEIT at the same institution. The overall mean concentration of intact parathyroid hormone (PTH) fell from 865.3 +/  388.4 pg/mL to 291.9 +/  277.8 pg/ mL, or 34% of the pretreatment value. The effect was even more pronounced for one or two glands, with 68.4% reaching the target of intact PTH <= 300 pg/mL recommended in the K/DOQI guidelines, in comparison with 36.4% of cases of hypertrophy of three or four glands. The average time taken to achieve the target PTH concentration was 4 months. No correlation was found between the response to PEIT and the total parathyroid volume, or the volume of glands with suspected nodular hyperplasia. Cases in which PTH does not fall sufficiently after five or more injections should be considered refractory to PEIT and evaluated for PTX. Following PEIT, PTH falls relatively slowly, whereas after total PTX with forearm autograft the PTH concentration falls immediately and may still be less than 60 pg/mL 4 or 5 years later. Bone biopsies performed 1 year after total PTX with autograft showed a change from an osteitis fibrosa pattern to an adynamic bone disease pattern. In some cases of hypertrophy of three to four glands, markers of bone metabolism kept decreasing more than did PTH, corresponding to marked improvement in the patients' quality of life. Important considerations for treatment selection include: (i) ultrasonography of the cervical region as screening; (ii) earlier recognition of the limits of medical therapy; and (iii) the number of affected glands, the age of the patient, and the likely course postintervention.
C1 Sekishinkai Sayama Hosp, Div Endocrinol & Metab, Sayama, Saitama 3501323, Japan.
   Sekishinkai Sayama Hosp, Div Renal Dis, Sayama, Saitama 3501323, Japan.
   Sekishinkai Sayama Hosp, Sayama Gen Clin Hemodialysis Ctr, Sayama, Saitama 3501323, Japan.
RP Onoda, N (通讯作者)，Sekishinkai Sayama Hosp, Div Endocrinol & Metab, 1 33 Unoki, Sayama, Saitama 3501323, Japan.
EM noritaka onoda@sayamahp.org
CR Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   FUKAGAWA M, 1994, NEPHRON, V68, P221, DOI 10.1159/000188261
   Onoda N, 2004, CLIN NEPHROL, V61, P68
   Onoda N, 2003, NEPHROL DIAL TRANSPL, V18, P34, DOI 10.1093/ndt/gfg1009
NR 4
TC 7
Z9 9
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1744 9979
EI 1744 9987
J9 THER APHER DIAL
JI Ther. Apher. Dial.
PD AUG
PY 2005
VL 9
SU 1
BP S11
EP S15
DI 10.1111/j.1744 9987.2005.00301.x
PG 5
WC Hematology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Hematology; Urology & Nephrology
GA 984RG
UT WOS:000233321400004
PM 16109135
DA 2025 08 17
ER

PT J
AU Fuhrman Luck, RA
   Stansfield, SH
   Stephens, CR
   Loessner, D
   Clements, JA
AF Fuhrman Luck, Ruth A.
   Stansfield, Scott H.
   Stephens, Carson R.
   Loessner, Daniela
   Clements, Judith A.
TI Prostate Cancer Associated Kallikrein Related Peptidase 4 Activates
   Matrix Metalloproteinase 1 and Thrombospondin 1
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE prostate cancer; kallikrein related peptidase; proteomics; substrate;
   bone metastases
ID MUSCLE CELL MIGRATION; DEPENDENT ACTIVATION; PROTEOLYTIC EVENTS;
   SERINE PROTEASE; SAPOSIN C; EXPRESSION; METASTASIS; PROLIFERATION;
   ANTIGEN; KLK4
AB Prostate cancer metastasis to bone is terminal; thus, novel therapies are required to prevent end stage disease. Kallikrein related peptidase 4 (KLK4) is a serine protease that is overproduced in localized prostate cancer and is abundant in prostate cancer bone metastases. In vitro, KLK4 induces tumor promoting phenotypes; however, the underlying proteolytic mechanism is undefined. The protein topography and migration analysis platform (PROTOMAP) was used for high depth identification of KLK4 substrates secreted by prostate cancer bone metastasis derived PC 3 cells to delineate the mechanism of KLK4 action in advanced prostate cancer. Thirty six putative novel substrates were determined from the PROTOMAP analysis. In addition, KLK4 cleaved the established substrate, urokinase type plasminogen activator, thus validating the approach. KLK4 activated matrix metalloproteinase 1 (MMP1), a protease that promotes prostate tumor growth and metastasis. MMP1 was produced in the tumor compartment of prostate cancer bone metastases, highlighting its accessibility to KLK4 at this site. KLK4 further liberated an N terminal product, with purported angiogenic activity, from thrombospondin 1 (TSP1) and cleaved TSP1 in an osteoblast derived matrix. This is the most comprehensive analysis of the proteolytic action of KLK4 in an advanced prostate cancer model to date, highlighting KLK4 as a potential multifunctional regulator of prostate cancer progression.
C1 [Fuhrman Luck, Ruth A.; Stephens, Carson R.; Clements, Judith A.] Queensland Univ Technol, Translat Res Inst, Inst Hlth & Biomed Innovat, Australian Prostate Canc Res Ctr Queensland, 37 Kent St, Woolloongabba, Qld 4102, Australia.
   [Fuhrman Luck, Ruth A.; Stansfield, Scott H.; Stephens, Carson R.; Loessner, Daniela; Clements, Judith A.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, 60 Musk Ave, Kelvin Grove, Qld 4059, Australia.
C3 University of Queensland; Queensland University of Technology (QUT);
   Queensland University of Technology (QUT)
RP Clements, JA (通讯作者)，Queensland Univ Technol, Translat Res Inst, Inst Hlth & Biomed Innovat, Australian Prostate Canc Res Ctr Queensland, 37 Kent St, Woolloongabba, Qld 4102, Australia.; Clements, JA (通讯作者)，Queensland Univ Technol, Inst Hlth & Biomed Innovat, 60 Musk Ave, Kelvin Grove, Qld 4059, Australia.
EM j.dements@qut.edu.au
RI Loessner, Daniela/L 2265 2017; Fuhrman Luck, Ruth/F 1807 2014
OI Loessner, Daniela/0000 0001 5891 3441; Clements,
   Judith/0000 0001 6026 1964
FU National Health and Medical Research Council of Australia [1010144];
   Cancer Council Queensland [614273, 1064484]; Queensland Government Smart
   Futures Ph.D. scholarship; Australian Postgraduate Award; Queensland
   University of Technology (QUT); Institute of Health and Biomedical
   Innovation (QUT)
FX Funding was provided by the National Health and Medical Research Council
   of Australia (#1010144) and the Cancer Council Queensland (#614273,
   #1064484 Morris Ronald Huggett Research Project). J.C. is a National
   Health and Medical Research Council Principal Research Fellow
   (#1005717). R.F. L. was a recipient of a Queensland Government Smart
   Futures Ph.D. scholarship, Australian Postgraduate Award, and
   scholarships from Queensland University of Technology (QUT) and the
   Institute of Health and Biomedical Innovation (QUT). LC MS/MS analysis
   was performed by Alun Jones and staff at the Institute for Molecular
   Bioscience, University of Queensland. We acknowledge Boris M. Holzapfel
   for providing paraffin embedded tissue sections, Johannes C. Reichert
   and Dietmar W. Hutmacher for providing human osteoblast derived matrix,
   and Lez J. Burke for digesting osteoblast derived matrix with KLK4. We
   thank Ali Shokoohmand for his helpful review of the manuscript.
CR Amend SR, 2015, J BONE MINER RES, V30, P106, DOI 10.1002/jbmr.2308
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Avgeris M, 2011, PROSTATE, V71, P1780, DOI 10.1002/pros.21395
   Bateman A, 2015, NUCLEIC ACIDS RES, V43, pD204, DOI 10.1093/nar/gku989
   Bonnefoy A, 2000, THROMB RES, V98, P323, DOI 10.1016/S0049 3848(99)00242 X
   Catena R, 2013, CANCER DISCOV, V3, P578, DOI 10.1158/2159 8290.CD 12 0476
   Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885
   COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037
   Craig R, 2004, BIOINFORMATICS, V20, P1466, DOI 10.1093/bioinformatics/bth092
   Deutsch EW, 2010, PROTEOMICS, V10, P1150, DOI 10.1002/pmic.200900375
   Ding Y, 2011, J CELL BIOCHEM, V112, P818, DOI 10.1002/jcb.22977
   Dix MM, 2008, CELL, V134, P679, DOI 10.1016/j.cell.2008.06.038
   do Outeiro Bernstein MAF, 2002, MATRIX BIOL, V21, P311, DOI 10.1016/S0945 053X(02)00010 0
   Dong Y, 2005, ENDOCR RELAT CANCER, V12, P875, DOI 10.1677/erc.1.01062
   Du P, 2006, BIOINFORMATICS, V22, P2059, DOI 10.1093/bioinformatics/btl355
   DuBose KB, 2012, BIOCHEM BIOPH RES CO, V422, P488, DOI 10.1016/j.bbrc.2012.05.020
   Escaff S, 2010, BRIT J CANCER, V102, P922, DOI 10.1038/sj.bjc.6605569
   Ferlay J, 2013, GLOBOCAN 2012 V1 0 C
   Firlej V, 2011, CANCER RES, V71, P7649, DOI 10.1158/0008 5472.CAN 11 0833
   Gao J, 2007, PROSTATE, V67, P348, DOI 10.1002/pros.20465
   Geer LY, 2004, J PROTEOME RES, V3, P958, DOI 10.1021/pr0499491
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hart CA, 2002, BRIT J CANCER, V86, P1136, DOI 10.1038/sj/bjc/6600207
   Hart PS, 2004, J MED GENET, V41, P545, DOI 10.1136/jmg.2003.017657
   Harvey Tracey J, 2003, Methods Mol Med, V81, P241
   Herrera I, 2013, J BIOL CHEM, V288, P25964, DOI 10.1074/jbc.M113.459784
   Holzapfel BM, 2014, BIOMATERIALS, V35, P4108, DOI 10.1016/j.biomaterials.2014.01.062
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Husmann K, 2013, BBA MOL BASIS DIS, V1832, P347, DOI 10.1016/j.bbadis.2012.11.006
   Imai K, 2006, NAT REV CANCER, V6, P714, DOI 10.1038/nrc1913
   KAIGHN ME, 1979, INVEST UROL, V17, P16
   Kersey PJ, 2004, PROTEOMICS, V4, P1985, DOI 10.1002/pmic.200300721
   Kleifeld O, 2011, NAT PROTOC, V6, P1578, DOI 10.1038/nprot.2011.382
   Kleifeld O, 2010, NAT BIOTECHNOL, V28, P281, DOI 10.1038/nbt.1611
   Klokk TI, 2007, CANCER RES, V67, P5221, DOI 10.1158/0008 5472.CAN 06 4728
   Lam H, 2007, PROTEOMICS, V7, P655, DOI 10.1002/pmic.200600625
   Lawrence MG, 2010, ENDOCR REV, V31, P407, DOI 10.1210/er.2009 0034
   Lee TJ, 2004, MOL CANCER, V3, DOI 10.1186/1476 4598 3 31
   Matsumura M, 2005, PROSTATE, V62, P1, DOI 10.1002/pros.20101
   Miyata Y, 2013, INT J MOL SCI, V14, P12249, DOI 10.3390/ijms140612249
   Mize GJ, 2008, MOL CANCER RES, V6, P1043, DOI 10.1158/1541 7786.MCR 08 0096
   Mu XD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059105
   Nunes SS, 2008, J CELL PHYSIOL, V214, P828, DOI 10.1002/jcp.21281
   Overall CM, 2006, BRIT J CANCER, V94, P941, DOI 10.1038/sj.bjc.6603043
   Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522 2683(19991201)20:18<3551::AID ELPS3551>3.0.CO;2 2
   Pulukuri SMK, 2008, INT J ONCOL, V32, P757
   R Core Team, 2022, R: A language and environment for statistical computing
   Ramsay AJ, 2008, J BIOL CHEM, V283, P12293, DOI 10.1074/jbc.M709493200
   Reichert JC, 2010, BIOMATERIALS, V31, P7928, DOI 10.1016/j.biomaterials.2010.06.055
   Schlage P, 2015, MATRIX BIOL, V44 46, P232, DOI 10.1016/j.matbio.2015.01.003
   Schröder FH, 2012, EUR UROL, V62, P745, DOI 10.1016/j.eururo.2012.05.068
   Seiz L, 2010, BIOL CHEM, V391, P391, DOI 10.1515/BC.2010.033
   Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468
   Staes A, 2008, PROTEOMICS, V8, P1362, DOI 10.1002/pmic.200700950
   Stein JJ, 2014, SURGERY, V155, P228, DOI 10.1016/j.surg.2013.08.003
   Takayama TK, 2001, BIOCHEMISTRY US, V40, P15341, DOI 10.1021/bi015775e
   Taraboletti G, 2000, FASEB J, V14, P1674
   The Global Proteome Machine Organization, COMM REP ADV PROT
   Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092
   Vallon R, 1997, EUR J BIOCHEM, V244, P81, DOI 10.1111/j.1432 1033.1997.00081.x
   Venkatraman L, 2012, BIOPHYS J, V103, P1060, DOI 10.1016/j.bpj.2012.06.050
   Venne AS, 2013, J PROTEOME RES, V12, P3823, DOI 10.1021/pr400435d
   Veveris Lowe TL, 2005, ENDOCR RELAT CANCER, V12, P631, DOI 10.1677/erc.1.00958
   von Au A, 2013, NEOPLASIA, V15, P925, DOI 10.1593/neo.13762
   Wang W, 2009, AM J PATHOL, V174, P541, DOI 10.2353/ajpath.2009.080509
   Wright JT, 2006, EUR J ORAL SCI, V114, P13, DOI 10.1111/j.1600 0722.2006.00291.x
   Zhong WD, 2008, ONCOLOGY BASEL, V75, P230, DOI 10.1159/000163852
NR 68
TC 22
Z9 24
U1 2
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535 3893
EI 1535 3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD AUG
PY 2016
VL 15
IS 8
BP 2466
EP 2478
DI 10.1021/acs.jproteome.5b01148
PG 13
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA DT1IW
UT WOS:000381235900011
PM 27378148
DA 2025 08 17
ER

PT J
AU Roemer, FW
   Hayes, CW
   Miller, CG
   Hoover, K
   Guermazi, A
AF Roemer, F. W.
   Hayes, C. W.
   Miller, C. G.
   Hoover, K.
   Guermazi, A.
TI Imaging atlas for eligibility and on study safety of potential shoulder
   adverse events in anti NGF studies (Part 3)
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Imaging; Safety; Shoulder; a NGF; Osteoarthritis
ID HUMERAL HEAD; MILWAUKEE SHOULDER; OSTEOARTHRITIS; OSTEONECROSIS;
   TANEZUMAB; KNEE; PAIN
AB Despite promising results, the U.S. Food and Drug Administration (FDA) put on hold trials assessing anti nerve growth factor (a NGF) compounds due to concerns over accelerated rates of OA progression. The mechanism of these events is unclear but joint adverse events were observed particularly in patients using a NGFs in combination with non steroidal anti inflammatory drugs (NSAIDs), suggesting that the significantly greater analgesic effect of these separate classes of drugs prompted patients to permit increased joint load without experiencing the usual pain that would limit joint stress. Development of a NGF drugs is continuing with stringent safety criteria included in future trials as a NGF therapies offer potential as the first new class of analgesics in many years. Potential imaging joint safety findings and exclusionary criteria for eligibility for the large weight bearing joints were presented in parts I and II of this atlas.
   The shoulder as a non weight bearing joint is likely to be less affected by increased loading due to efficacious pain reduction. However, it remains prone to degeneration especially due to concomitant rotator cuff pathology and previous trauma and inflammatory disorders. This third part of the atlas illustrates imaging findings relevant for eligibility and potential joint safety findings such as osteonecrosis, incidental findings such as large cystic lesions, inflammatory disorders, bone marrow disorders and metastases. (C) 2014 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
C1 [Roemer, F. W.; Guermazi, A.] Boston Univ, Sch Med, Dept Radiol, Quantitat Imaging Ctr, Boston, MA 02118 USA.
   [Roemer, F. W.] Univ Erlangen Nurnberg, Dept Radiol, D 91054 Erlangen, Germany.
   [Hayes, C. W.; Hoover, K.] Virginia Commonwealth Univ, Sch Med, Dept Radiol, Richmond, VA USA.
   [Miller, C. G.] BioClinica, Med Affairs, Newtown, PA USA.
C3 Boston University; University of Erlangen Nuremberg; Virginia
   Commonwealth University; Synarc
RP Roemer, FW (通讯作者)，Boston Univ, Sch Med, Dept Radiol, FGH Bldg,3rd Floor,820 Harrison Ave, Boston, MA 02118 USA.
EM frank.roemer@klinikum augsburg.de
RI Guermazi, Ali/F 6014 2013; Roemer, Frank/AAS 6317 2020
OI Roemer, Frank/0000 0001 9238 7350; 
FU BioClinica, Inc.; Boston Imaging Core Lab, LLC.
FX BioClinica, Inc. and Boston Imaging Core Lab, LLC. funded this
   supplement. Pfizer or other pharmaceutical companies involved in a NGF
   programs did not financially support development of this manuscript.
CR Brown MT, 2012, J PAIN, V13, P790, DOI 10.1016/j.jpain.2012.05.006
   Chevalier X, 2013, NAT REV RHEUMATOL, V9, P400, DOI 10.1038/nrrheum.2013.44
   Chillemi C, 2005, KNEE SURG SPORT TR A, V13, P483, DOI 10.1007/s00167 004 0608 3
   Genta MS, 2006, NEW ENGL J MED, V354, pE2, DOI 10.1056/NEJMicm050094
   Harreld KL, 2009, J AM ACAD ORTHOP SUR, V17, P345, DOI 10.5435/00124635 200906000 00003
   Hochberg MC, 2012, ARTHRITIS RHEUM US, V64, pS113
   Kobayashi T, 2014, J SHOULDER ELB SURG, V23, P613, DOI 10.1016/j.jse.2013.11.031
   Lane NE, 2010, NEW ENGL J MED, V363, P1521, DOI 10.1056/NEJMoa0901510
   MCCARTY DJ, 1981, ARTHRITIS RHEUM, V24, P464, DOI 10.1002/art.1780240303
   Mont MA, 2000, J RHEUMATOL, V27, P1766
   Poignard A, 2012, J BONE JOINT SURG AM, V94A, P156, DOI [10.2106/JBJS.J.00919, 10.2106/JBJSJ.00919]
   Seidel MF, 2013, OSTEOARTHR CARTILAGE, V21, P1223, DOI 10.1016/j.joca.2013.06.004
NR 12
TC 7
Z9 7
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063 4584
EI 1522 9653
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD JAN
PY 2015
VL 23
SU 1
SI SI
BP S59
EP S68
DI 10.1016/j.joca.2014.09.018
PG 10
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA AW7DB
UT WOS:000346423700007
PM 25527220
OA Bronze
DA 2025 08 17
ER

PT J
AU Mann, V
   Huber, C
   Kogianni, G
   Collins, F
   Noble, B
AF Mann, Val
   Huber, Christene
   Kogianni, Giolanta
   Collins, Frances
   Noble, Brendon
TI The antioxidant effect of estrogen and Selective Estrogen Receptor
   Modulators in the inhibition of osteocyte apoptosis in vitro
SO BONE
LA English
DT Article
DE osteocyte; apoptosis; estrogen; SERMs; antioxidant
ID OXIDATIVE STRESS; HYDROGEN PEROXIDE; BONE; ESTRADIOL; DEATH;
   ASSOCIATION; OSTEOCLASTS; MORPHOLOGY; HYPOXIA; DENSITY
AB Withdrawal of estrogen represents the primary factor determining post menopausal bone loss and has been associated with negative indicators of bone quality including the apoptotic, death of osteocytes in vivo. While hormone replacement therapy in the form of Estrogen or Selective Estrogen Receptor Modulators (SERMs) demonstrates clear estrogen receptor (ER) mediated benefits to bone mass, less is known regarding the mechanism of action of these compounds in the maintenance of bone cell populations. We have investigated the potential antioxidant effects of estrogen, estrogen derivatives and the SERMs Raloxifene and LY 117018 in the prevention of oxidative stress induced apoptosis in the osteocyte like cell line MLO Y4.
   Treatment of MLO Y4 with 0.3 mM H2O2 induced apoptosis that was significantly inhibited (p <= 0.002) when the cells were pre treated for I h with either 17 beta estradiol, Raloxifene or LY 117018 (10 nM). The stereoisomer 17 alpha estradiol also prevented H2O2 induced apoptosis in MLO Y4. Importantly, pre treatment of ER negative HEK293 cells with either 1 mu M, 100 nM or 10 nM 17 beta estradiol, Raloxifene or LY117018 significantly inhibited H2O2 induced apoptosis in these cells (p <= 54.2x 10( 5)) indicating an estrogen receptor independent effect of these compounds. Comparisons of 17 beta estradiol and similar molecules containing the putative free radical scavenger C3 OH moiety on the steroid A ring (17 alpha estradiol, 17 alpha ethinytestradiol; 10 nM) with structurally related molecules lacking the C3 OH grouping (Mestranol and Quinestrol; 10 nM) demonstrated that only compounds containing the C3 OH moiety showed anti apoptotic behavior in these studies (p <= 0.0033). Similarly the identification of the presence of reactive oxygen species (ROS) in cells as evidenced by the free radical indicator 2'7' dichlorodihydrofluorescein diacetate demonstrated that 17 beta estradiol, SERMs and related molecules with C3 OH moiety were capable of blocking ROS generated in cells by H2O2 (p <= 0.002) while Mestranol and Quinestrol showed no such blockade. It is possible that the loss of osteocytes during estrogen insufficiency may occur through a failure to suppress the activity of naturally occurring or disease associated oxidant molecules. These data suggest that the osteocyte protective effects of estrogen and SERMs may operate through a common receptor independent mechanism which may be related to the antioxidant activity of these molecules. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Edinburgh, Sch Med, Musculoskeletal Tissue Engn Collaborat, Edinburgh EH16 4SB, Midlothian, Scotland.
   Univ Edinburgh, Sch Med, Ctr Reprod Biol, MRC Human Reprod Sci Unit, Edinburgh EH16 4SB, Midlothian, Scotland.
C3 University of Edinburgh; University of Edinburgh
RP Noble, B (通讯作者)，Univ Edinburgh, Sch Med, Musculoskeletal Tissue Engn Collaborat, Level 1,Chancellors Bldg,49 Little France Crescen, Edinburgh EH16 4SB, Midlothian, Scotland.
EM Brendon.Noble@ed.ac.uk
OI Noble, Brendon/0009 0004 9788 3475
FU Medical Research Council [MC_U127685844] Funding Source: Medline;
   Medical Research Council [MC_U127685844] Funding Source: researchfish;
   MRC [MC_U127685844] Funding Source: UKRI
CR AARDEN EM, 1994, J CELL BIOCHEM, V55, P287, DOI 10.1002/jcb.240550304
   Ammann P, 2003, OSTEOPOROSIS INT, V14, pS13, DOI 10.1007/s00198 002 1345 4
   Basu S, 2001, BIOCHEM BIOPH RES CO, V288, P275, DOI 10.1006/bbrc.2001.5747
   Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846
   Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535
   BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647
   BURR DB, 1993, CALCIFIED TISSUE INT, V53, pS75, DOI 10.1007/BF01673407
   Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500
   Collins AJ, 2003, NEPHROL DIAL TRANSPL, V18, P2, DOI 10.1093/ndt/gfg1058
   DAUVOIS S, 1993, J CELL SCI, V106, P1377
   Dodd JS, 1999, AM J PHYSIOL CELL PH, V277, pC598, DOI 10.1152/ajpcell.1999.277.3.C598
   DUNSTAN CR, 1993, CALCIFIED TISSUE INT, V53, pS113, DOI 10.1007/BF01673417
   Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619
   Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623
   Ferretti JL, 2003, MECH AGEING DEV, V124, P269, DOI 10.1016/S0047 6374(02)00194 X
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525 1373.1999.d01 140.x
   Frost H M, 1998, J Orthop Sci, V3, P272, DOI 10.1007/s007760050053
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   Green PS, 1997, J NEUROSCI, V17, P511
   Gu G, 2005, APOPTOSIS, V10, P583, DOI 10.1007/s10495 005 1893 0
   Hernandez CJ, 2004, BONE, V35, P1095, DOI 10.1016/j.bone.2004.07.002
   Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kikuyama A, 2002, CALCIFIED TISSUE INT, V71, P243, DOI 10.1007/s00223 001 1110 2
   Kogianni G, 2004, LIFE SCI, V75, P2879, DOI 10.1016/j.lfs.2004.04.048
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Lean JM, 2005, ENDOCRINOLOGY, V146, P728, DOI 10.1210/en.2004 1021
   Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859
   Lee D, 2001, J MED CHEM, V44, P2015, DOI 10.1021/jm0100537
   Marotti G, 1998, ANN ANAT, V180, P449, DOI 10.1016/S0940 9602(98)80106 4
   Noble BS, 2003, AM J PHYSIOL CELL PH, V284, pC934, DOI 10.1152/ajpcell.00234.2002
   Pedram A, 2002, J BIOL CHEM, V277, P50768, DOI 10.1074/jbc.M210106200
   PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0
   Power J, 2001, CALCIFIED TISSUE INT, V69, P13, DOI 10.1007/s00223 001 0013 6
   Qiu S, 2002, BONE, V31, P709, DOI 10.1016/S8756 3282(02)00907 9
   Reilly GC, 2001, ANN BIOMED ENG, V29, P1074, DOI 10.1114/1.1424910
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   STEINBECK MJ, 1994, J CELL BIOL, V126, P765, DOI 10.1083/jcb.126.3.765
   Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004 1064
   Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128
   Tomkinson A, 1998, J BONE MINER RES, V13, P1243, DOI 10.1359/jbmr.1998.13.8.1243
   van Lenthe GH, 2002, J BIOMECH, V35, P1191, DOI 10.1016/S0021 9290(02)00081 7
   Zaman G, 1999, J BONE MINER RES, V14, P1123, DOI 10.1359/jbmr.1999.14.7.1123
NR 44
TC 84
Z9 97
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2007
VL 40
IS 3
BP 674
EP 684
DI 10.1016/j.bone.2006.10.014
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 141CA
UT WOS:000244552800014
PM 17174166
DA 2025 08 17
ER

PT J
AU Ishii, M
   Koike, C
   Igarashi, A
   Yamanaka, K
   Pan, H
   Higashi, Y
   Kawaguchi, H
   Sugiyama, M
   Kamata, N
   Iwata, T
   Matsubara, T
   Nakamura, K
   Kurihara, H
   Tsuji, K
   Kato, Y
AF Ishii, M
   Koike, C
   Igarashi, A
   Yamanaka, K
   Pan, H
   Higashi, Y
   Kawaguchi, H
   Sugiyama, M
   Kamata, N
   Iwata, T
   Matsubara, T
   Nakamura, K
   Kurihara, H
   Tsuji, K
   Kato, Y
TI Molecular markers distinguish bone marrow mesenchymal stem cells from
   fibroblasts
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE bone marrow; marker genes; mesenchymal stem cell; regenerative medicine
ID STROMAL CELLS; IN VITRO; RECEPTORS; TISSUE; EXPRESSION; DEFECTS;
   BIOLOGY; MATRIX; MOUSE; VIVO
AB To characterize mesenchymal stem cells (MSC), we compared gene expression profiles in human bone marrow MSC (11 lines) and human fibroblasts (4 lines) by RT PCR and real time PCR. Messenger RNA levels of MHC DR alpha, MHC DR beta, MHC DR associated protein CD74. tissue factor pathway inhibitor 2, and neuroserpin were much higher in MSC than in fibroblasts, even in the presence of large interindividual variations. Those of adrenomedullin, apolipoprotein D, C type lectin superfamily member 2, collagen type XV alpha 1, CUG triplet repeat RNA binding protein, matrix metalloproteinase 1, protein tyrosine kinase 7, and Sam68 like phosphotyrosine protein/T STAR were lower in MSC than in fibroblasts. FACS analysis showed that cell surface expression of MHC DR was also higher in MSC than in fibroblasts. MHC DR expression decreased after osteogenic differentiation, whereas the expression of adrenomedullin a potent stimulator of osteoblast activity along with collagen XV alpha 1 and apolipoprotein D increased after osteogenic differentiation. The marker genes identified in this Study should be useful for characterization of MSC both in basic and clinical studies. (c) 2005 Elsevier Inc. All rights reserved.
C1 Hiroshima Univ, Grad Sch Biomed Sci, Dept Dent & Med Biochem, Hiroshima 730, Japan.
   Two Cells Co Ltd, Hiroshima, Japan.
   Hiroshima Univ, Grad Sch Biomed Sci, Dept Cardiovasc Physiol & Med, Hiroshima 730, Japan.
   Hiroshima Univ, Grad Sch Biomed Sci, Dept Periodontal Med, Hiroshima 730, Japan.
   Hiroshima Univ, Grad Sch Biomed Sci, Dept Oral & Maxillofacial Surg, Hiroshima 730, Japan.
   Univ Tokyo, Grad Sch Med, Dept Orthoped Surg, Tokyo, Japan.
C3 Hiroshima University; Hiroshima University; Hiroshima University;
   Hiroshima University; University of Tokyo
RP Hiroshima Univ, Grad Sch Biomed Sci, Dept Dent & Med Biochem, Hiroshima 730, Japan.
EM ykato@hiroshima u.ac.jp
RI ; Kurihara, Hidemi/G 5730 2019; Higashi, Yukihito/G 5343 2019
OI Iwata, Tomoyuki/0000 0001 7345 7480; 
CR Arai F, 2002, J EXP MED, V195, P1549, DOI 10.1084/jem.20011700
   Bensidhoum M, 2004, BLOOD, V103, P3313, DOI 10.1182/blood 2003 04 1121
   Bianchi G, 2003, EXP CELL RES, V287, P98, DOI 10.1016/S0014 4827(03)00138 1
   Cherry RJ, 2003, BIOCHEM SOC T, V31, P1028
   Cornish J, 1997, AM J PHYSIOL ENDOC M, V273, pE1113, DOI 10.1152/ajpendo.1997.273.6.E1113
   Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301 472X(00)00482 3
   Di Fruscio M, 1999, P NATL ACAD SCI USA, V96, P2710, DOI 10.1073/pnas.96.6.2710
   Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097 0215(19970611)71:6<1061::AID IJC24>3.0.CO;2 F
   Eklund L, 2001, P NATL ACAD SCI USA, V98, P1194, DOI 10.1073/pnas.031444798
   GRONTHOS S, 1994, BLOOD, V84, P4164, DOI 10.1182/blood.V84.12.4164.bloodjournal84124164
   HAYNESWORTH SE, 1992, BONE, V13, P69, DOI 10.1016/8756 3282(92)90363 2
   Herman MP, 2001, J CLIN INVEST, V107, P1117, DOI 10.1172/JCI10403
   Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529
   Kawahara K, 2003, J PERIODONTAL RES, V38, P242, DOI 10.1034/j.1600 0765.2003.00654.x
   Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711
   Kuznetsov SA, 2001, J CELL BIOL, V153, P1133, DOI 10.1083/jcb.153.5.1133
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   Leung WCY, 2004, CIRC RES, V95, P179, DOI 10.1161/01.RES.0000135482.74178.14
   Lu XW, 2004, NATURE, V430, P93, DOI 10.1038/nature02677
   Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298
   Matsubara T, 2004, BIOCHEM BIOPH RES CO, V313, P503, DOI 10.1016/j.bbrc.2003.11.143
   Matsubara T, 2005, J BONE MINER RES, V20, P399, DOI 10.1359/JBMR.041117
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Quarto R, 2001, NEW ENGL J MED, V344, P385, DOI 10.1056/NEJM200102013440516
   Ramchandran R, 1999, BIOCHEM BIOPH RES CO, V255, P735, DOI 10.1006/bbrc.1999.0248
   Rombouts WJC, 2003, LEUKEMIA, V17, P160, DOI 10.1038/sj.leu.2402763
   SANT AJ, 1994, CURR OPIN IMMUNOL, V6, P57, DOI 10.1016/0952 7915(94)90034 5
   Tsutsumi S, 2001, BIOCHEM BIOPH RES CO, V288, P413, DOI 10.1006/bbrc.2001.5777
   Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959
   Wimalawansa SJ, 1996, ENDOCR REV, V17, P533, DOI 10.1210/er.17.5.533
   Yepes M, 2004, TRENDS CARDIOVAS MED, V14, P173, DOI 10.1016/j.tcm.2004.03.004
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 32
TC 134
Z9 191
U1 1
U2 22
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUN 24
PY 2005
VL 332
IS 1
BP 297
EP 303
DI 10.1016/j.bbrc.2005.04.118
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 929OK
UT WOS:000229355200041
PM 15896330
DA 2025 08 17
ER

PT J
AU Li, G
   Hu, J
   Chen, H
   Chen, L
   Zhang, N
   Zhao, LS
   Wen, N
   Yang, YJ
AF Li, Guang
   Hu, Jing
   Chen, Hui
   Chen, Liang
   Zhang, Na
   Zhao, Lisheng
   Wen, Ning
   Yang, Yongjin
TI Enamel matrix derivative enhances the proliferation and osteogenic
   differentiation of human periodontal ligament stem cells on the titanium
   implant surface
SO ORGANOGENESIS
LA English
DT Article
DE Akt; Enamel matrix derivative; mTOR; osteogenic differentiation;
   osteoblasts; periodontal ligament stem cells
ID OSTEOBLAST LIKE CELLS; IN VITRO; BONE MARROW; GENE EXPRESSION;
   REGENERATION; PROMOTES; PATHWAY; RAPAMYCIN; CAPACITY; BEHAVIOR
AB Periodontal ligament stem cells (PDLSCs) have mesenchymal stem cells like qualities, and are considered as one of the candidates of future clinical application in periodontal regeneration therapy. Enamel matrix derivative (EMD) is widely used in promoting periodontal regeneration. However, the effects of EMD on the proliferation and osteogenic differentiation of human PDLSCs grown on the Ti implant surface are still no clear. Therefore, this study examined the effects of EMD on human PDLSCs in vitro. Human PDLSCs were isolated from healthy participants, and seeded on the surface of Ti implant disks and stimulated with various concentrations of EMD. Cell proliferation was determined with Cell Counting Kit 8 (CCK 8). The osteogenic differentiation of PDLSCs was evaluated by the measurement of alkaline phosphatase (ALP) activity, Alizarin red staining, and real time polymerase chain reaction (qRT PCR) and Western blotting, respectively. The results indicated that EMD at concentrations (5 60 mu g/ml) increased the viability and proliferation of PDLSCs. The treatment with 30 and 60 mu g/ml of EMD significantly elevated ALP activity, augmented mineralized nodule formation and calcium deposition, and upregulated the mRNA and protein levels of Runx 2 and osteocalcin (OCN) in the PDLSCs grown on the Ti surface. Further investigation found that EMD treatment did not change the protein levels of phosphatidylinositol 3 kinase (PI3K), p PI3K, Akt and mTOR, but significantly upregulated the phosphorylated levels of Akt and mTOR. Collectively, these results suggest that EMD stimulation can promote the proliferation and osteogenic differentiation of PDLSCs grown on Ti surface, which is possibly associated with the activation of Akt/mTOR signaling pathway.
C1 [Li, Guang; Zhao, Lisheng; Wen, Ning] Chinese Peoples Liberat Army Gen Hosp, Dept Stomatol, Beijing 100853, Peoples R China.
   [Li, Guang; Zhang, Na; Yang, Yongjin] PLA, Dept Stomatol, Rocket Force Gen Hosp, Beijing 100088, Peoples R China.
   [Hu, Jing] Beijing PLA, Dept Stomatol, Mil Gen Hosp, Beijing, Peoples R China.
   [Chen, Hui; Chen, Liang] Jinan Stomatol Hosp, Dept Endodont, Jinan, Shandong, Peoples R China.
C3 Chinese People's Liberation Army General Hospital
RP Wen, N (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Stomatol, Beijing 100853, Peoples R China.; Yang, YJ (通讯作者)，PLA, Dept Stomatol, Rocket Force Gen Hosp, Beijing 100088, Peoples R China.
EM wenningpla@126.com; yyongj@yeah.net
FU National Natural Science Foundation of China [51472270]; Military
   Logistics Research Programs [BWS11C009]
FX This study was granted from National Natural Science Foundation of China
   (No.51472270) and Military Logistics Research Programs (No. BWS11C009).
CR Abusleme L, 2013, ISME J, V7, P1016, DOI 10.1038/ismej.2012.174
   Aimetti M, 2017, CLIN ORAL INVEST, V21, P327, DOI 10.1007/s00784 016 1795 2
   An N, 2010, J BIOMED MATER RES A, V93A, P364, DOI 10.1002/jbm.a.32539
   Birang Reza, 2012, Dent Res J (Isfahan), V9, P790
   Cao FY, 2016, NANOMED NANOTECHNOL, V12, P1313, DOI 10.1016/j.nano.2016.01.010
   Casati MZ, 2002, J PERIODONTOL, V73, P789, DOI 10.1902/jop.2002.73.7.789
   Freitas GP, 2016, J ORAL IMPLANTOL, V42, P240, DOI 10.1563/aaid joi D 14 00254
   Grandin HM, 2012, TISSUE ENG PART B RE, V18, P181, DOI [10.1089/ten.TEB.2011.0365, 10.1089/ten.teb.2011.0365]
   Hama H, 2008, J PERIODONTAL RES, V43, P179, DOI 10.1111/j.1600 0765.2007.01010.x
   Houshmand B, 2013, INT J ORAL MAX IMPL, V28, pE440, DOI 10.11607/jomi.te24
   Isomoto S, 2007, J ORTHOP SCI, V12, P83, DOI 10.1007/s00776 006 1079 9
   Jue SS, 2010, CLIN ORAL IMPLAN RES, V21, P741, DOI 10.1111/j.1600 0501.2009.01901.x
   Kadonishi Y, 2012, J BONE JOINT SURG BR, V94B, P205, DOI 10.1302/0301 620X.94B2.26904
   Kato H, 2013, J PERIODONTOL, V84, P1476, DOI 10.1902/jop.2012.120469
   Kondo R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090681
   Kwun IS, 2010, BONE, V46, P732, DOI 10.1016/j.bone.2009.11.003
   Lee JE, 2016, MOL NEUROBIOL, V53, P3771, DOI 10.1007/s12035 015 9325 9
   Lee KW, 2010, STEM CELLS DEV, V19, P557, DOI 10.1089/scd.2009.0147
   Lindroos B, 2008, BIOCHEM BIOPH RES CO, V368, P329, DOI 10.1016/j.bbrc.2008.01.081
   Lossdörfer S, 2007, J DENT RES, V86, P980, DOI 10.1177/154405910708601012
   Manescu A, 2016, J PERIODONTAL RES, V51, P112, DOI 10.1111/jre.12289
   Matarasso M, 2015, CLIN ORAL INVEST, V19, P1581, DOI 10.1007/s00784 015 1491 7
   Menicanin D, 2014, STEM CELLS DEV, V23, P1001, DOI 10.1089/scd.2013.0490
   Moshaverinia A, 2014, TISSUE ENG PT A, V20, P611, DOI 10.1089/ten.TEA.2013.0229
   Nii T, 2015, EXP HEMATOL, V43, P901, DOI 10.1016/j.exphem.2015.06.001
   Osathanon T, 2015, ARCH ORAL BIOL, V60, P29, DOI 10.1016/j.archoralbio.2014.08.018
   Qu Z, 2011, ORAL SURG ORAL MED O, V111, P517, DOI 10.1016/j.tripleo.2010.10.011
   Rathe F, 2009, TISSUE ENG PART B RE, V15, P215, DOI 10.1089/ten.teb.2008.0065
   Rausch fan XH, 2008, DENT MATER, V24, P102, DOI 10.1016/j.dental.2007.03.001
   Sakka S, 2011, MED ORAL PATOL ORAL, V16, pE42, DOI 10.4317/medoral.16.e42
   Schroeder Tania M., 2005, Birth Defects Research, V75, P213, DOI 10.1002/bdrc.20043
   Schwartz Arad D, 2008, IMPLANT DENT, V17, P200, DOI 10.1097/ID.0b013e3181777906
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shen T, 2014, INT J CLIN EXP PATHO, V7, P7872
   Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411
   Stenport VF, 2003, J CLIN PERIODONTOL, V30, P359, DOI 10.1034/j.1600 051X.2003.00326.x
   Tong YX, 2015, BMC BIOCHEM, V16, DOI 10.1186/s12858 015 0031 z
   Wada Y, 2008, J PERIODONTOL, V79, P341, DOI [10.1902/jop.2008.070197, 10.1902/jop.2008.070197 ]
   Wen Y, 2012, ARCH ORAL BIOL, V57, P1241, DOI 10.1016/j.archoralbio.2012.02.017
   Xu JP, 2009, STEM CELLS DEV, V18, P487, DOI 10.1089/scd.2008.0113
   Yang HJ, 2015, J MOL NEUROSCI, V55, P977, DOI 10.1007/s12031 014 0454 9
   Zhang LQ, 2016, BBA GEN SUBJECTS, V1860, P2211, DOI 10.1016/j.bbagen.2016.05.003
   Zhang WJ, 2016, NANOSCALE, V8, P5291, DOI 10.1039/c5nr08580b
   Ziros PG, 2008, INT J BIOCHEM CELL B, V40, P1659, DOI 10.1016/j.biocel.2007.05.024
   zur Nieden NI, 2003, DIFFERENTIATION, V71, P18, DOI 10.1046/j.1432 0436.2003.700602.x
NR 45
TC 21
Z9 25
U1 0
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1547 6278
EI 1555 8592
J9 ORGANOGENESIS
JI Organogenesis
PY 2017
VL 13
IS 3
BP 103
EP 113
DI 10.1080/15476278.2017.1331196
PG 11
WC Biochemistry & Molecular Biology; Developmental Biology; Engineering,
   Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Developmental Biology; Engineering
GA FN2UQ
UT WOS:000415850600005
PM 28598248
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Othman, A
   Winogradzki, M
   Patel, S
   Holmes, W
   Blank, A
   Pratap, J
AF Othman, Ahmad
   Winogradzki, Marcus
   Patel, Shreya
   Holmes, Waddell
   Blank, Alan
   Pratap, Jitesh
TI The Role of Runx2 in Microtubule Acetylation in Bone Metastatic Breast
   Cancer Cells
SO CANCERS
LA English
DT Article
DE bone metastasis; breast cancer; microtubules; Runx2; tubulin
   acetylation; HDAC6
ID KINASE; CYTOSKELETON; ACTIVATION; AUTOPHAGY; RECEPTOR; HDAC6; GENE
AB Simple Summary Breast cancer is the most commonly diagnosed cancer type, making up a quarter of all cases among women. While modern day research has shown tremendous progress in the development of treatment options, complications related to bone metastasis remain an obstacle that demands further attention. Cancer cells that migrate into the bone microenvironment show significant alterations in their metabolism and gene expression profiles. In this study, we set out to better understand the changes induced by Runx2 in bone derived breast cancer cells. We identified key changes in the stability of the microtubule cytoskeleton of bone derived cells expressing Runx2. These changes have implications on a variety of processes related to metabolism, cellular stress response, and response to common chemotherapies. These studies help to shed light on the changes that take place as a tumor begins to metastasize and to better predict which therapies will benefit patients with bone metastasis. Bone metastasis of breast cancer results in severe bone loss, fractures, and death. Crosstalk between breast cancer cells and bone resident cells promotes osteoclast activity and the release of growth factors from the bone matrix resulting in aggressive tumor growth and bone loss. We and others have shown that Runt related transcription factor 2 (Runx2) promotes metastatic tumor growth associated bone loss. Breast cancer cells also induce autophagy to survive metabolic stress at the metastatic site. Recently, we reported a Runx2 dependent increase in autophagy. In this study, to examine the underlying mechanisms of metastasis and tumor resistance to stress, we used a bone metastatic isogenic variant of breast cancer MDA MB 231 cells isolated from a xenograft tumor mouse model of metastasis. Our results with immunofluorescence and biochemical approaches revealed that Runx2 promotes microtubule (MT) stability to facilitate autophagy. Stable MTs are critical for autophagosome trafficking and display increased acetylation at Lysine 40 of alpha tubulin. Runx2 silencing decreases acetylated alpha tubulin levels. The expression levels of HDAC6 and alpha TAT1, which serve to regulate the acetylation of alpha tubulin, were not altered with Runx2 silencing. We found that HDAC6 interaction with alpha tubulin is inhibited by Runt related factor 2 (Runx2). We show that the expression of wild type Runx2 can restore the acetylated polymer of MTs in Runx2 knockdown cells, while the C terminal deletion mutant fails to rescue the polymer of MTs. Importantly, cellular stress, such as glucose starvation also increases the acetylation of alpha tubulin. We found that the loss of Runx2 increases the sensitivity of breast cancer cells to MT targeting agents. Overall, our results indicate a novel regulatory mechanism of microtubule acetylation and suggest that Runx2 and acetylated microtubules may serve as therapeutic targets for bone metastatic tumors.
C1 [Othman, Ahmad; Winogradzki, Marcus; Patel, Shreya; Holmes, Waddell; Blank, Alan; Pratap, Jitesh] Rush Univ, Dept Anat & Cell Biol, Med Ctr, Suite 507,Armour Acad Bldg, Chicago, IL 60612 USA.
   [Othman, Ahmad] Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA.
C3 Rush University; Northwestern University; Feinberg School of Medicine
RP Pratap, J (通讯作者)，Rush Univ, Dept Anat & Cell Biol, Med Ctr, Suite 507,Armour Acad Bldg, Chicago, IL 60612 USA.
EM ahmad.othman@northwestern.edu; marcus_c_winogradzki@rush.edu;
   shreya_patel@rush.edu; b_holmes@rush.edu; alan_blank@rush.edu;
   jitesh_pratap@rush.edu
RI ; Blank, Alan/AAG 2137 2019
OI Othman, Ahmad/0000 0001 9995 1233; Patel, Shreya/0000 0002 1266 8599;
   Blank, Alan/0000 0003 2531 5976
FU Swim Across America Foundation; NIH/NCI [R21CA245609]; National Cancer
   Institute [R21CA245609] Funding Source: NIH RePORTER
FX This research was funded by Swim Across America Foundation (AB and JP)
   and NIH/NCI R21CA245609 (JP).
CR Akech J, 2010, ONCOGENE, V29, P811, DOI 10.1038/onc.2009.389
   Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008 5472.CAN 03 3851
   Boggs AE, 2015, CANCER RES, V75, P203, DOI 10.1158/0008 5472.CAN 13 3563
   Chimge NO, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3073
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046 2023(03)00032 X
   Eshun Wilson L, 2019, P NATL ACAD SCI USA, V116, P10366, DOI 10.1073/pnas.1900441116
   Even A, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax2705
   Geiger RC, 2006, GENE THER, V13, P725, DOI 10.1038/sj.gt.3302693
   Harrison RE, 2001, NEOPLASIA, V3, P385, DOI 10.1038/sj.neo.7900180
   Janke C, 2014, J CELL BIOL, V206, P461, DOI 10.1083/jcb.201406055
   Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102
   Li L, 2015, CELL MOL LIFE SCI, V72, P4237, DOI 10.1007/s00018 015 2000 5
   Lock R, 2014, CANCER DISCOV, V4, P466, DOI 10.1158/2159 8290.CD 13 0841
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10 06 0500
   Mackeh R, 2014, J BIOL CHEM, V289, P11816, DOI 10.1074/jbc.M113.507400
   Mahboubi H, 2016, MOL PHARMACOL, V90, P460, DOI 10.1124/mol.116.105494
   Mercado Matos J, 2017, J BIOL CHEM, V292, P7806, DOI 10.1074/jbc.M117.785832
   Onishi K, 2007, GENES CELLS, V12, P535, DOI 10.1111/j.1365 2443.2007.01071.x
   Pockwinse SM, 2006, J CELL PHYSIOL, V206, P354, DOI 10.1002/jcp.20469
   Pratap J, 2009, CANCER RES, V69, P6807, DOI 10.1158/0008 5472.CAN 09 1471
   Roodman GD, 2001, J CLIN ONCOL, V19, P3562, DOI 10.1200/JCO.2001.19.15.3562
   Shah N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04121 y
   Siegel RL, 2021, CA CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654
   Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339 3351.2003
   Tandon M, 2016, ONCOGENE, V35, P4730, DOI 10.1038/onc.2015.518
   Tandon M, 2018, J CELL PHYSIOL, V233, P559, DOI 10.1002/jcp.25916
   Tandon M, 2014, J CELL BIOCHEM, V115, P2208, DOI 10.1002/jcb.24939
   Tandon M, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3611
   Vaughan EE, 2008, MOL THER, V16, P1841, DOI 10.1038/mt.2008.190
   WEBSTER DR, 1989, J CELL SCI, V92, P57
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982 7992.2002
   Williams KA, 2013, J BIOL CHEM, V288, P33156, DOI 10.1074/jbc.M113.472506
   Xie R, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 89
   Young DW, 2007, NATURE, V445, P442, DOI 10.1038/nature05473
NR 35
TC 6
Z9 7
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD JUL
PY 2022
VL 14
IS 14
AR 3436
DI 10.3390/cancers14143436
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 3H6CH
UT WOS:000832121600001
PM 35884497
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Shang, Q
   Zhao, WH
   Shen, GY
   Yu, X
   Zhang, ZD
   Huang, X
   Qin, WC
   Chen, GF
   Yu, FY
   Tang, K
   Chen, HL
   Li, JM
   Liang, D
   Tang, JJ
   Jiang, XB
   Ren, H
AF Shang, Qi
   Zhao, Wenhua
   Shen, Gengyang
   Yu, Xiang
   Zhang, Zhida
   Huang, Xuan
   Qin, Weicheng
   Chen, Guifeng
   Yu, Fuyong
   Tang, Kai
   Chen, Honglin
   Li, Juanmin
   Liang, De
   Tang, Jingjing
   Jiang, Xiaobing
   Ren, Hui
TI Jingui Shenqi Pills Regulate Bone Fat Balance in Murine
   Ovariectomy Induced Osteoporosis with Kidney Yang Deficiency
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID CELL FATE; METABOLOMICS; APOPTOSIS; MASS
AB Jingui Shenqi Pills (JGSQP) have been a staple of traditional Chinese medicine for thousands of years, used primarily as a treatment for kidney yang deficiency (KYD). In vitro analyses of JGSQP revealed strong induction of osteogenic differentiation and inhibition of adipogenic differentiation in bone marrow derived mesenchymal stem/stromal cells. However, the mechanisms by which JGSQP regulate the bone fat balance in murine ovariectomy induced osteoporosis with KYD have not been reported. Materials and Methods. Two month old female C57BL/6 mice were divided randomly into three groups: those receiving a sham operation (Sham); those undergoing bilateral ovariectomy and selection of KYD syndrome (Model); and those subjected to both bilateral ovariectomy and KYD syndrome selection for 8 weeks, followed by JGSQP treatment for 4 weeks (JGSQP). In the Sham and Model groups, mice were given the same dose of distilled water orally for 4 weeks. Animals from all three groups were euthanised at the 12th week. Vertebral microarchitecture and histomorphology were examined by micro CT and H&E staining, respectively. In addition, we examined the mRNA expression of Akt, Wnt10b, Osterix (Osx), Fndc5, PPAR gamma, and Fabp4, as well as the protein of AKT, phosphorylation AKT (p AKT), BMP2, COL1A1, and FNDC5. Results. JGSQP treatment improved bone microarchitecture and mitigated histomorphological damage relative to the Model group. The osteoblast number (Ob.N/BS) and area (Ob.S/BS) were increased, whereas adipocyte number (adipocyte/tissue area) and area (adipocyte area/tissue area) were decreased in the JGSQP group. JGSQP treatment reduced the mRNA expression of Akt and adipogenesis related genes (Fndc5, PPAR gamma, and Fabp4) while promoting osteogenesis related genes (Wnt10b and Osx) mRNA expression. Additionally, the expression of p AKT, BMP2, and COL1A1 proteins was increased and FNDC5 protein expression was decreased after JGSQP treatment. Conclusions. JGSQP treatment reversed murine ovariectomy induced osteoporosis with KYD by controlling bone fat balance via AKT pathway.
C1 [Shang, Qi; Zhao, Wenhua; Zhang, Zhida; Huang, Xuan; Qin, Weicheng; Chen, Guifeng; Yu, Fuyong; Tang, Kai] Guangzhou Univ Chinese Med, Guangzhou 510405, Peoples R China.
   [Shang, Qi; Zhao, Wenhua; Shen, Gengyang; Yu, Xiang; Zhang, Zhida; Huang, Xuan; Qin, Weicheng; Chen, Guifeng; Yu, Fuyong; Tang, Kai; Chen, Honglin; Li, Juanmin; Liang, De; Tang, Jingjing; Jiang, Xiaobing; Ren, Hui] Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Guangzhou 510405, Peoples R China.
   [Shen, Gengyang; Yu, Xiang; Chen, Honglin; Li, Juanmin; Liang, De; Tang, Jingjing; Jiang, Xiaobing; Ren, Hui] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Spinal Surg, Guangzhou 510405, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine
RP Jiang, XB; Ren, H (通讯作者)，Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Guangzhou 510405, Peoples R China.; Jiang, XB; Ren, H (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Spinal Surg, Guangzhou 510405, Peoples R China.
EM 2509758975@qq.com; 13539961409@163.com; 15920198161@163.com;
   20172101019@stu.gzucm.edu.cn; 20182101017@stu.gzucm.edu.cn;
   484358305@qq.com; 2461808460@qq.com; 1144299492@qq.com;
   804149771@qq.com; 20191109205@stu.gzucm.edu.cn; 1158977935@qq.com;
   1347085982@qq.com; 513469239@qq.com; 249943192@qq.com;
   spinedrjxb@sina.com; renhuispine@163.com
RI Zhida, Zhang/HME 3183 2023; Li, Juanmin/HCI 2575 2022
OI Shang, Qi/0000 0001 9135 2666; Shen, Gengyang/0000 0001 8940 7912
FU National Natural Science Foundation of China [81904225, 81674000,
   81774338, 81503591]; Guangdong Province Universities and Colleges Pearl
   River Scholar Funded Scheme (2018); Science and Technology Program of
   Guangzhou [201707010298]; Youth Scientific Research Training Project of
   GZUCM [2019QNPY04]; Key Project of Basic Research and Applied Basic
   Research of the Department of Education of Guangdong Province
   [2018KZDXM021]; Guangdong Natural Science Foundation [2018A030310615]
FX This work was generously supported by National Natural Science
   Foundation of China (81904225, 81674000, 81774338, and 81503591),
   Guangdong Province Universities and Colleges Pearl River Scholar Funded
   Scheme (2018), Science and Technology Program of Guangzhou
   (201707010298), the Youth Scientific Research Training Project of GZUCM
   (2019QNPY04), Key Project of Basic Research and Applied Basic Research
   of the Department of Education of Guangdong Province (2018KZDXM021), and
   Guangdong Natural Science Foundation (2018A030310615).
CR Ambrogini E, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04047 5
   An S, 2000, Zhongguo Zhong Xi Yi Jie He Za Zhi, V20, P907
   Boroumand P, 2020, J CELL SCI, V133, DOI 10.1242/jcs.238394
   Briot A, 2018, ARTERIOSCL THROM VAS, V38, P1134, DOI 10.1161/ATVBAHA.118.310797
   Che Wen jun, 2005, Chin J Integr Med, V11, P300
   Chen J Y, 1993, Zhongguo Zhong Yao Za Zhi, V18, P619
   Cheng Z. A., 2018, ZHONGGUO ZHONG XI YI, V33, P261
   Crujeiras AB, 2015, CLIN ENDOCRINOL, V82, P467, DOI 10.1111/cen.12627
   Ding LZ, 2018, INT J MOL MED, V41, P2517, DOI 10.3892/ijmm.2018.3506
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Fu Y, 2014, CELL PROLIFERAT, V47, P604, DOI 10.1111/cpr.12131
   Garin Shkolnik T, 2014, DIABETES, V63, P900, DOI 10.2337/db13 0436
   Hayashi M, 2019, CELL METAB, V29, P627, DOI 10.1016/j.cmet.2018.12.021
   Huang L, 2018, BIOMATERIALS, V182, P58, DOI 10.1016/j.biomaterials.2018.07.046
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Ji B, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/7253240
   Kao ST, 2018, J ETHNOPHARMACOL, V227, P181, DOI 10.1016/j.jep.2018.08.028
   Kim HN, 2017, EXP THER MED, V13, P2134, DOI 10.3892/etm.2017.4286
   Kim H, 2018, CELL, V175, P1756, DOI 10.1016/j.cell.2018.10.025
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Li J, 2020, CYTOKINE GROWTH F R, V52, P88, DOI 10.1016/j.cytogfr.2020.02.003
   Li JB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10677 0
   Li YC, 2015, EXP THER MED, V10, P1089, DOI 10.3892/etm.2015.2616
   Lin Bing hui, 2002, Zhongguo Zhong Xi Yi Jie He Za Zhi, V22, P33
   Liu Xu dong, 2015, Zhongguo Zhong Yao Za Zhi, V40, P4908
   Long Y. L., 2015, ZHONGGUO ZHONG XI YI, V33, P967
   Mallon PWG, 2014, CURR OPIN HIV AIDS, V9, P428, DOI 10.1097/COH.0000000000000080
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001
   Pang Bing, 2019, Zhongguo Zhong Yao Za Zhi, V44, P3895, DOI 10.19540/j.cnki.cjcmm.20190416.504
   Sale JEM, 2014, CLIN GERIATR MED, V30, P317, DOI 10.1016/j.cger.2014.01.009
   Schäcke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163 7258(02)00297 8
   Schreiber C, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008216
   Schwartz AV, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00040
   Shen GY, 2020, THERANOSTICS, V10, P4334, DOI 10.7150/thno.42982
   Shen GY, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102626
   Shin HT, 2003, AM J CHINESE MED, V31, P675, DOI 10.1142/S0192415X03001454
   Si L, 2015, OSTEOPOROSIS INT, V26, P1929, DOI 10.1007/s00198 015 3093 2
   Song LG, 2012, J BONE MINER RES, V27, P2344, DOI 10.1002/jbmr.1694
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Tang Xiao Ran, 2018, Zhongguo Zhong Yao Za Zhi, V43, P2365, DOI 10.19540/j.cnki.cjcmm.20180408.002
   Thulkar Jyoti, 2016, J Midlife Health, V7, P108
   Tikhonova AN, 2019, NATURE, V569, P222, DOI 10.1038/s41586 019 1104 8
   Tyagi AM, 2018, IMMUNITY, V49, P1116, DOI 10.1016/j.immuni.2018.10.013
   Wang Jing, 2010, Zhong Xi Yi Jie He Xue Bao, V8, P781, DOI 10.3736/jcim20100809
   Wang LY, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/510146
   Wang XF, 2015, J TRADIT CHIN MED, V35, P238, DOI 10.1016/S0254 6272(15)30035 2
   Xie Y M, 1997, Zhongguo Zhong Xi Yi Jie He Za Zhi, V17, P526
   Xiong Xing Jiang, 2019, Zhongguo Zhong Yao Za Zhi, V44, P3903, DOI 10.19540/j.cnki.cjcmm.20190403.503
   Xiong XJ, 2015, COMPLEMENT THER MED, V23, P484, DOI 10.1016/j.ctim.2015.04.008
   Xu B., 2018, ZHONGGUO GU SHANG, V25, P766
   Xu Cui Ping, 2013, Zhongguo Zhong Xi Yi Jie He Za Zhi, V33, P252
   Yang JX, 2008, J ETHNOPHARMACOL, V119, P166, DOI 10.1016/j.jep.2008.06.027
   Yin N, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658 019 0177 6
   Yu B, 2018, CELL STEM CELL, V23, P193, DOI 10.1016/j.stem.2018.06.009
   Zhang AH, 2017, MOL BIOSYST, V13, P320, DOI 10.1039/c6mb00677a
   Zhang FL, 2018, CELL PHYSIOL BIOCHEM, V51, P154, DOI 10.1159/000495171
   Zhang Y, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/2049497
   Zhao LJ, 2016, J PROTEOME RES, V15, P2327, DOI 10.1021/acs.jproteome.6b00409
NR 58
TC 9
Z9 14
U1 1
U2 17
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD SEP 7
PY 2020
VL 2020
AR 1517596
DI 10.1155/2020/1517596
PG 9
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA NV6DN
UT WOS:000574409800003
PM 32963560
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Kanwal, R
   Shukla, S
   Walker, E
   Gupta, S
AF Kanwal, Rajnee
   Shukla, Sanjeev
   Walker, Ethan
   Gupta, Sanjay
TI Acquisition of tumorigenic potential and therapeutic resistance in
   CD133+subpopulation of prostate cancer cells exhibiting stem cell like
   characteristics
SO CANCER LETTERS
LA English
DT Article
DE Cancer stem cells; Biomarkers; Therapeutic target; Prostate cancer; Gene
   expression
ID HEMATOPOIETIC STEM; PROSPECTIVE IDENTIFICATION; RADICAL PROSTATECTOMY;
   CD133; EXPRESSION; MARKERS; GROWTH; SUBPOPULATION; ENRICHMENT;
   OSTEOBLAST
AB The role of CD133 (Prominin 1) as a cancer stem cell marker may be useful for therapeutic approaches and prognostication in prostate cancer patients. We investigated the stem cell related function and biological features of a subpopulation of CD133+ cells isolated from established primary human prostate cancer cell lines. The CD133+ cells sorted from human prostate cancer 22Rv1 exhibited high clonogenic and tumorigenic capabilities, sphere forming capacity and serially reinitiated transplantable tumors in NOD SCID mice. Gene profiling analysis of CD133 + cells showed upregulation of markers of stem cell differentiation (CD44, Oct4, SOX9 and Nanog), epithelial to mesenchymal transition (c myc and BMW, osteoblastic differentiation (Runx2), and skeletal morphogenesis (BMP2), compared to side population of CD133 cells. These cells are highly malignant and resistant to gamma radiation and chemotherapeutic drug, docetaxel. Importantly, a docetaxel resistant subclone was more enriched in CD133 + cells with significant increase in Runx2 expression, compared to CD133 cells. Furthermore, knockdown of Runx2 in these cells resulted in differential response to chemotherapy, sensitizing them to increased cell death. These results demonstrate therapy resistant population with stem like features are distinct subpopulation of malignant cells that resides within parental cell lines. The molecular signature of CD133 + cells may lead to identification of novel therapeutic targets and prognostic markers in the treatment of prostate cancer.
C1 [Kanwal, Rajnee; Shukla, Sanjeev; Gupta, Sanjay] Case Western Reserve Univ, Sch Med, Dept Urol, Cleveland, OH 44106 USA.
   [Kanwal, Rajnee; Shukla, Sanjeev; Gupta, Sanjay] Univ Hosp Cleveland, Med Ctr, Inst Urol, Cleveland, OH 44106 USA.
   [Kanwal, Rajnee; Gupta, Sanjay] Louis Stokes Cleveland Vet Affairs Med Ctr, Dept Urol, Cleveland, OH 44106 USA.
   [Walker, Ethan] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA.
   [Gupta, Sanjay] Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA.
   [Gupta, Sanjay] Case Comprehens Canc Ctr, Div Gen Med Sci, Cleveland, OH 44106 USA.
C3 University System of Ohio; Case Western Reserve University; University
   Hospitals of Cleveland; University System of Ohio; Case Western Reserve
   University; Case Western Reserve University Hospital; University System
   of Ohio; Case Western Reserve University; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Louis Stokes Cleveland
   Veterans Affairs Medical Center; University System of Ohio; Case Western
   Reserve University; University System of Ohio; Case Western Reserve
   University; University System of Ohio; Case Western Reserve University
RP Gupta, S (通讯作者)，Case Western Reserve Univ, Dept Urol, James & Eilleen Dicke Res Lab, 10900 Euclid Ave, Cleveland, OH 44106 USA.
EM sanjay.gupta@case.edu
OI Gupta, Sanjay/0000 0002 9492 3249
FU United States Public Health Service Grant [R01CA108512, R21CA193080,
   R03CA186179]; VA Merit Award [1I01BX002494]; Department of Defense grant
   [W81XWH 15 1 0558]; Case Comprehensive Cancer Center [P30 CA43703]
FX The research work is supported by United States Public Health Service
   Grant R01CA108512, R21CA193080, R03CA186179, VA Merit Award 1I01BX002494
   and Department of Defense grant W81XWH 15 1 0558 (SG).We are grateful to
   the Case Comprehensive Cancer Center (P30 CA43703) for providing the
   following core facilities used in this research: Radiation Resources,
   Athymic Animal and Xenograft, Flow Cytometry and Translational Research.
   We also thank Michael Sramkoski (Flow Cytometry Core Facility) for
   assistance with the flow cytometry data analysis, and Dr. Nancy Oleinick
   (Department of Radiation Oncology, Case Western Reserve University) for
   assistance with radiation resources.
CR Abdollah F, 2013, EUR UROL, V64, P557, DOI 10.1016/j.eururo.2013.03.006
   Al Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Ayob AZ, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929 018 0426 4
   Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008 5472.CAN 04 3931
   Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106
   Boesch M, 2016, BBA REV CANCER, V1866, P276, DOI 10.1016/j.bbcan.2016.10.003
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797 730
   Boorjian SA, 2011, EUR UROL, V59, P893, DOI 10.1016/j.eururo.2011.02.026
   Calcagno AM, 2010, JNCI J NATL CANCER I, V102, P1637, DOI 10.1093/jnci/djq361
   Ceder JA, 2008, EUR UROL, V53, P524, DOI 10.1016/j.eururo.2007.11.028
   Cheng SL, 1998, J BONE MINER RES, V13, P633, DOI 10.1359/jbmr.1998.13.4.633
   Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008 5472.CAN 05 2018
   Corbeil D, 2013, ADV EXP MED BIOL, V777, P3, DOI 10.1007/978 1 4614 5894 4_1
   Deichmann M, 1997, BLOOD, V89, P3522, DOI 10.1182/blood.V89.10.3522.3522_3522_3528
   Eaton CL, 2010, PROSTATE, V70, P875, DOI 10.1002/pros.21121
   Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283
   Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008 5472.CAN 05 1343
   Fossati N, 2017, EUR UROL, V71, P886, DOI 10.1016/j.eururo.2016.07.028
   Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008 5472.CAN 04 1364
   GOWDA SD, 1986, J CLIN INVEST, V77, P271, DOI 10.1172/JCI112287
   Griend DJV, 2008, CANCER RES, V68, P9703, DOI 10.1158/0008 5472.CAN 08 3084
   Grosse Gehling P, 2013, J PATHOL, V229, P355, DOI 10.1002/path.4086
   Gupta A, 2012, MOL CANCER, V11, DOI 10.1186/1476 4598 11 66
   Hurt EM, 2008, BRIT J CANCER, V98, P756, DOI 10.1038/sj.bjc.6604242
   Kalantari E, 2017, PATHOL ONCOL RES, V23, P793, DOI 10.1007/s12253 016 0169 z
   Le Magnen C, 2013, CLIN CANCER RES, V19, P5361, DOI 10.1158/1078 0432.CCR 12 2857
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   LEWINSOHN DM, 1990, BLOOD, V75, P589
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008 5472.CAN 06 2030
   Miki J, 2007, CANCER RES, V67, P3153, DOI 10.1158/0008 5472.CAN 06 4429
   Miraglia S, 1997, BLOOD, V90, P5013, DOI 10.1182/blood.V90.12.5013.5013_5013_5021
   Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587
   Piscitelli E, 2015, METHODS MOL BIOL, V1235, P243, DOI 10.1007/978 1 4939 1785 3_18
   Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0600 4
   Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104
   Reyes E.E., 2015, J TRANSLAT SCI, V1, DOI [10.15761/JTS.1000104pli, DOI 10.15761/JTS.1000104PLI]
   Ricci Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Richardson GD, 2004, J CELL SCI, V117, P3539, DOI 10.1242/jcs.01222
   Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489
   Shankar E, 2017, MOLECULES, V22, DOI 10.3390/molecules22020264
   Shepherd CJ, 2008, PROSTATE, V68, P1007, DOI 10.1002/pros.20765
   Shukla S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053527
   Singh SK, 2003, CANCER RES, V63, P5821
   Soner BC, 2014, INT J MOL MED, V34, P1249, DOI 10.3892/ijmm.2014.1930
   Sramkoski RM, 1999, IN VITRO CELL DEV AN, V35, P403
   Tondreau T, 2005, STEM CELLS, V23, P1105, DOI 10.1634/stemcells.2004 0330
   Trerotola M, 2010, AM J TRANSL RES, V2, P135
   Valenti MT, 2016, ONCOL LETT, V12, P4167, DOI 10.3892/ol.2016.5182
   Wang L, 2013, INT J BIOL SCI, V9, P472, DOI 10.7150/ijbs.5855
   WILSON MJ, 1993, CELL MOL BIOL RES, V39, P751
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012
   Yu CY, 2011, IN VIVO, V25, P69
   Zhang XH, 2015, INT J CANCER, V136, P1321, DOI 10.1002/ijc.29094
NR 54
TC 48
Z9 55
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3835
EI 1872 7980
J9 CANCER LETT
JI Cancer Lett.
PY 2018
VL 430
BP 25
EP 33
DI 10.1016/j.canlet.2018.05.014
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA GL1ZG
UT WOS:000436912200003
PM 29775627
DA 2025 08 17
ER

PT J
AU Barrera Lopez, JF
   Cumplido Laso, G
   Olivera Gomez, M
   Garrido Jimenez, S
   Diaz Chamorro, S
   Mateos Quiros, CM
   Benitez, DA
   Centeno, F
   Mulero Navarro, S
   Roman, AC
   Carvajal Gonzalez, JM
AF Barrera Lopez, Juan F.
   Cumplido Laso, Guadalupe
   Olivera Gomez, Marcos
   Garrido Jimenez, Sergio
   Diaz Chamorro, Selene
   Mateos Quiros, Clara M.
   Benitez, Dixan A.
   Centeno, Francisco
   Mulero Navarro, Sonia
   Roman, Angel C.
   Carvajal Gonzalez, Jose M.
TI Early Atf4 activity drives airway club and goblet cell differentiation
SO LIFE SCIENCE ALLIANCE
LA English
DT Article
ID STEM CELLS; TRANSCRIPTION FACTORS; GENE EXPRESSION; DIOXIN RECEPTOR;
   LUNG; FOXJ1; DEDIFFERENTIATION; CILIOGENESIS; INHIBITION; FACTOR 4
AB Activating transcription factor 4 (Atf4), which is modulated by the protein kinase RNA like ER kinase (PERK), is a stress induced transcription factor responsible for controlling the expression of a wide range of adaptive genes, enabling cells to withstand stressful conditions. However, the impact of the Atf4 signaling pathway on airway regeneration remains poorly understood. In this study, we used mouse airway epithelial cell culture models to investigate the role of PERK/Atf4 in respiratory tract differentiation. Through pharmacological inhibition and silencing of ATF4, we uncovered the crucial involvement of PERK/Atf4 in the differentiation of basal stem cells, leading to a reduction in the number of secretory cells. ChIP seq analysis revealed direct binding of ATF4 to regulatory elements of genes associated with osteoblast differentiation and secretory cell function. Our findings provide valuable insights into the role of ATF4 in airway epithelial differentiation and its potential involvement in innate immune responses and cellular adaptation to stress.
C1 [Barrera Lopez, Juan F.; Cumplido Laso, Guadalupe; Olivera Gomez, Marcos; Garrido Jimenez, Sergio; Diaz Chamorro, Selene; Mateos Quiros, Clara M.; Benitez, Dixan A.; Centeno, Francisco; Mulero Navarro, Sonia; Roman, Angel C.; Carvajal Gonzalez, Jose M.] Univ Extremadura, Fac Formac Profesorade, Dept Bioquim Biol Mol & Genet, Badajoz, Spain.
C3 Universidad de Extremadura
RP Barrera Lopez, JF (通讯作者)，Univ Extremadura, Fac Formac Profesorade, Dept Bioquim Biol Mol & Genet, Badajoz, Spain.
EM jmcarvaj@unex.es
RI ; Centeno, Francisco/F 7287 2016; Carvajal Gonzalez, Jose/ABC 6780 2020;
   Benitez López, Dixan Agustín/ISV 0405 2023
OI Benitez Lopez, Dixan Agustin/0009 0005 7398 042X; Centeno,
   Francisco/0000 0001 6154 5424; Mulero Navarro,
   Sonia/0000 0001 5739 8062; Olivera Gomez, Marcos/0009 0001 3211 0090
FU Ministry of Economy [PID2021 126905NB I00, BFU2017 85547 P, IB18014];
   Junta de Extremadura [GR21140]; Universidad de Extremadura; European
   Union FEDER program;  [TED2021 130560B I00]
FX Confocal microscopy and scanning electron microscopy were performed at
   the UEX microscopy core facilities. This work was supported by
   BFU2017 85547 P, TED2021 130560B I00, and PID2021 126905NB I00 grants
   from the Ministry of Economy, IB18014 from Junta de Extremadura to JM
   Carvajal Gonzalez, and GR21140 from Junta de Extremadura to S
   Mulero Navarro. S Garrido  Jimenez was a recipient of a Fellowship from
   the Universidad de Extremadura. S Diaz Chamorro and CM Mateos Quiros
   were recipients of a Fellowship from Junta de Extremadura. All Spanish
   funding is co sponsored by the European Union FEDER program.
CR Aggarwal S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120694
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Bray NL, 2016, NAT BIOTECHNOL, V34, P525, DOI 10.1038/nbt.3519
   Bustamante Marin XM, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a028241
   Cardoso WV, 2001, ANNU REV PHYSIOL, V63, P471, DOI 10.1146/annurev.physiol.63.1.471
   Choksi SP, 2014, DEVELOPMENT, V141, P3410, DOI 10.1242/dev.108209
   Davis JD, 2021, MUCOSAL IMMUNOL, V14, P978, DOI 10.1038/s41385 020 00370 7
   De Angelis R, 2003, FEBS LETT, V547, P15, DOI 10.1016/S0014 5793(03)00659 8
   Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012
   Drost J, 2018, NAT REV CANCER, V18, P407, DOI 10.1038/s41568 018 0007 6
   Feng JX, 2012, NAT PROTOC, V7, P1728, DOI 10.1038/nprot.2012.101
   García SR, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.177428
   Garrido Jimenez S, 2021, FASEB J, V35, DOI 10.1096/fj.202100638R
   Grünig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hewitt RJ, 2021, NAT REV IMMUNOL, V21, P347, DOI 10.1038/s41577 020 00477 9
   Jopling C, 2011, NAT REV MOL CELL BIO, V12, P79, DOI 10.1038/nrm3043
   Kim S, 2002, AM J PHYSIOL LUNG C, V283, pL67, DOI 10.1152/ajplung.00404.2001
   Look DC, 2001, AM J PATHOL, V159, P2055, DOI 10.1016/S0002 9440(10)63057 X
   Mateos Quiros CM, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.622515
   Merrell AJ, 2016, NAT REV MOL CELL BIO, V17, P413, DOI 10.1038/nrm.2016.24
   Montoro DT, 2018, NATURE, V560, P319, DOI 10.1038/s41586 018 0393 7
   Mulero Navarro S, 2006, CARCINOGENESIS, V27, P1099, DOI 10.1093/carcin/bgi344
   Pakos Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195
   Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236
   Park KS, 2007, J CLIN INVEST, V117, P978, DOI 10.1172/JCI29176
   Plasschaert LW, 2018, NATURE, V560, P377, DOI 10.1038/s41586 018 0394 6
   Rabouw HH, 2019, P NATL ACAD SCI USA, V116, P2097, DOI 10.1073/pnas.1815767116
   Rawlins EL, 2006, DEVELOPMENT, V133, P2455, DOI 10.1242/dev.02407
   Rawlins EL, 2009, CELL STEM CELL, V4, P525, DOI 10.1016/j.stem.2009.04.002
   Revinski DR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06768 z
   Rock JR, 2010, DIS MODEL MECH, V3, P545, DOI 10.1242/dmm.006031
   Rock JR, 2009, P NATL ACAD SCI USA, V106, P12771, DOI 10.1073/pnas.0906850106
   Roman AC, 2008, P NATL ACAD SCI USA, V105, P1632, DOI 10.1073/pnas.0708366105
   Sherman BT, 2022, NUCLEIC ACIDS RES, V50, pW216, DOI 10.1093/nar/gkac194
   Steiling K, 2013, AM J RESP CRIT CARE, V187, P933, DOI 10.1164/rccm.201208 1449OC
   Stubbs JL, 2012, NAT CELL BIOL, V14, P140, DOI 10.1038/ncb2406
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sudhakar A, 2000, BIOCHEMISTRY US, V39, P12929, DOI 10.1021/bi0008682
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Tadokoro T, 2014, P NATL ACAD SCI USA, V111, pE3641, DOI 10.1073/pnas.1409781111
   Tata PR, 2013, NATURE, V503, P218, DOI 10.1038/nature12777
   Tsao PN, 2009, DEVELOPMENT, V136, P2297, DOI 10.1242/dev.034884
   Vanderheiden A, 2020, J VIROL, V94, DOI 10.1128/JVI.00985 20
   Vladar EK, 2007, J CELL BIOL, V178, P31, DOI 10.1083/jcb.200703064
   Wang QW, 2022, CURR PROTOC, V2, DOI 10.1002/cpz1.585
   Whitsett JA, 2015, NAT IMMUNOL, V16, P27, DOI 10.1038/ni.3045
   Wills Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258
   Woo AJ, 2019, BLOOD ADV, V3, P2499, DOI 10.1182/bloodadvances.2018030551
   Wu MR, 2022, RESP RES, V23, DOI 10.1186/s12931 022 02042 5
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xiao GZ, 2005, J BIOL CHEM, V280, P30689, DOI 10.1074/jbc.M500750200
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yang XL, 2004, J BIOL CHEM, V279, P47109, DOI 10.1074/jbc.M410010200
   Yang Y, 2018, DEV CELL, V44, P752, DOI 10.1016/j.devcel.2018.03.001
   You YJ, 2002, AM J PHYSIOL LUNG C, V283, pL1315, DOI 10.1152/ajplung.00169.2002
   You YJ, 2004, AM J PHYSIOL LUNG C, V286, pL650, DOI 10.1152/ajplung.00170.2003
   Yu XW, 2008, NAT GENET, V40, P1445, DOI 10.1038/ng.263
   Zyryanova AF, 2018, SCIENCE, V359, P1533, DOI 10.1126/science.aar5129
NR 59
TC 3
Z9 3
U1 0
U2 2
PU LIFE SCIENCE ALLIANCE LLC
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
EI 2575 1077
J9 LIFE SCI ALLIANCE
JI Life Sci. Alliance
PD MAR
PY 2024
VL 7
IS 3
AR e202302284
DI 10.26508/lsa.202302284
PG 14
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA FB2Q9
UT WOS:001143227800002
PM 38176727
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Pourhabib, Z
   Ranjbar, H
AF Pourhabib, Zahra
   Ranjbar, Hassan
TI Prediction of radiation dose to adult human from radiopharmaceutical
   manufactured by third generation bisphosphonate labeled with Rhenium
SO NUCLEAR ENGINEERING AND TECHNOLOGY
LA English
DT Article
DE Dosimetry; Third generation bisphosphonate; 188 Re ZNA; OLINDA software
ID BIODISTRIBUTION DATA
AB Introduction: The crucial step in preclinical process of radiopharmaceutical production is internal dosimetry evaluation by different ways to realize radiobiological dose response relationships and to extract the results for clinical use. Till now several bone seeking radiopharmaceuticals have been developed for bone metastasis. Interesting features of bisphosphonates attracted attentions to them in the field of radiopharmaceutical therapy and studies on new generation of them have been doing too. Materials and methods: In this study, we used ZNA as representative of the third generation. The radiopharmaceutical 188Re ZNA was produced and its radiochemical purity was investigated. Then, the biological distribution of the produced radiopharmaceutical at 1, 2, 4 and 24 h after injection on different organs of mice were investigated. Finally, the absorbed dose of organs in the human body was assessed using the RADAR method. Results: The results show 96% radiochemical purity of the 188Re ZNA radiopharmaceutical. The amount of %ID/g in bone is 1.131% after 1 h and in 24 hit has a significant amount compared to other organs, that is 0.516%. Also dosimetric results show that the highest absorption dose is related to bone and the amount of this dose is 0.050 mGy/MBq. Conclusion: Considering the possibility of producing the 188Re ZNA radiopharmaceutical, as well as the proper distribution of this radiopharmaceutical in target and non target organs and increasing the absorbed dose in bone, it can be concluded that this radiopharmaceutical can be useful in the "radiopharmaceutical therapy" in metastases. (c) 2023 Korean Nuclear Society, Published by Elsevier Korea LLC. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/4.0/).
C1 [Pourhabib, Zahra] Payame Noor Univ, Dept Phys, POB 193953697, Tehran, Iran.
   [Ranjbar, Hassan] Nucl Sci & Technol Res Inst, Nucl Fuel Cycle Res Sch, Tehran, Iran.
C3 Payame Noor University
RP Ranjbar, H (通讯作者)，Nucl Sci & Technol Res Inst, Nucl Fuel Cycle Res Sch, Tehran, Iran.
EM hranjbar@aeoi.org.ir
RI Ranjbar, Hassan/ADN 7020 2022
CR Kesner A.L., 2018, SOC NUCL MED
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Lahooti A, 2013, RADIAT PROT DOSIM, V154, P1, DOI 10.1093/rpd/ncs137
   McParland BJ, 2010, NUCLEAR MEDICINE RADIATION DOSIMETRY: ADVANCED THEORETICAL PRINCIPLES, P1, DOI 10.1007/978 1 84882 126 2
   Pourhabib Z, 2020, RADIAT PROT DOSIM, V190, P158, DOI 10.1093/rpd/ncaa087
   pubchem.ncbi, US
   Ranjbar H, 2016, J RADIOANAL NUCL CH, V307, P1439, DOI 10.1007/s10967 015 4324 x
   Saha G.B., 2004, Fundamentals of Nuclear Pharmacy
   Siegel JA, 1999, J NUCL MED, V40, p37S
   Smith MR, 2008, UROL ONCOL SEMIN ORI, V26, P420, DOI 10.1016/j.urolonc.2007.11.004
   Stabin MG, 2005, J NUCL MED, V46, P1023
   Stabin MG, 2003, HEALTH PHYS, V85, P294, DOI 10.1097/00004032 200309000 00006
   Thierens H.M., 2006, ENCY MED DEVICES INS
NR 13
TC 1
Z9 1
U1 0
U2 4
PU KOREAN NUCLEAR SOC
PI DAEJEON
PA NUTOPIA BLDG, 342 1 JANGDAE DONG, DAEJEON, 305 308, SOUTH KOREA
SN 1738 5733
J9 NUCL ENG TECHNOL
JI Nucl. Eng. Technol.
PD FEB
PY 2023
VL 55
IS 2
BP 669
EP 673
DI 10.1016/j.net.2022.10.022
EA FEB 2023
PG 5
WC Nuclear Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nuclear Science & Technology
GA G8WD0
UT WOS:000991884800001
OA gold
DA 2025 08 17
ER

PT J
AU Wang, J
   Wei, WH
   Zhang, XF
   Cao, SQ
   Hu, BT
   Ye, Y
   Jiang, M
   Wang, TQ
   Zuo, JP
   He, SJ
   Yang, CH
AF Wang, Jie
   Wei, Wenhui
   Zhang, Xiaofei
   Cao, Shiqi
   Hu, Bintao
   Ye, Yang
   Jiang, Min
   Wang, Tianqi
   Zuo, Jianping
   He, Shijun
   Yang, Chunhao
TI Synthesis and Biological Evaluation of C 17 Amino Substituted
   Pyrazole Fused Betulinic Acid Derivatives as Novel Agents for
   Osteoarthritis Treatment
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION; CARTILAGE HISTOPATHOLOGY; DRUG DISCOVERY;
   ANIMAL MODELS; IN VITRO; PAIN; INFLAMMATION; PRINCIPLES; SOLUBILITY;
   MECHANISM
AB A series of pyrazole fused betulinic acid (BA) derivatives were designed and synthesized by replacing the carboxyl group at C 17 with aliphatic amine, amide, and urea groups. The suppressive effects of the compounds on osteoclast (OC) formation and inflammatory cytokine production were evaluated on murine macrophages, RAW264.7 cells, conditioned with receptor activator for nuclear factor kappa B ligand (RANKL)/macrophage colony stimulating factor (M CSF) or lipopolysaccharide (LPS), respectively. Results showed that, compared with betulinic acid, most of these compounds exhibited significant improvements in inhibitory potency. Compound 25 exhibited distinguished activities on inhibiting OC differentiation with an IC50 value of 1.86 mu M. Meanwhile, compound 25, displaying the most promising suppression on IL 1 beta secretion from RAW264.7 cells, was further found to possess therapeutic effects in the sodium monoiodoacetate (MIA) induced osteoarthritis rat model. Dose dependent benefits were observed in MIA elicited rats with ameliorated joint pain as well as decreased cartilage damage and bone changes after compound 25 treatment.
C1 [Wang, Jie; Zhang, Xiaofei; Yang, Chunhao] Chinese Acad Sci, Shanghai Inst Mat Med, Dept Med Chem, State Key Lab Drug Res, Shanghai 201203, Peoples R China.
   [Wang, Jie; Wei, Wenhui; Cao, Shiqi; Hu, Bintao; Ye, Yang; Zuo, Jianping; He, Shijun; Yang, Chunhao] Univ Chinese Acad Sci, Sch Pharm, Beijing 100049, Peoples R China.
   [Wei, Wenhui; Cao, Shiqi; Zuo, Jianping; He, Shijun] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Lab Immunopharmacol, Shanghai 201203, Peoples R China.
   [Hu, Bintao; Ye, Yang] Chinese Acad Sci, Shanghai Inst Mat Med, Nat Prod Chem Dept, State Key Lab Drug Res, Shanghai 201203, Peoples R China.
   [Jiang, Min; Wang, Tianqi] Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Shanghai Inst Traumatol & Orthopaed, Shanghai Key Lab Bone & Joint Dis,Sch Med, Shanghai 200025, Peoples R China.
C3 Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS;
   Chinese Academy of Sciences; University of Chinese Academy of Sciences,
   CAS; Chinese Academy of Sciences; Shanghai Institute of Materia Medica,
   CAS; Chinese Academy of Sciences; Shanghai Institute of Materia Medica,
   CAS; Shanghai Jiao Tong University
RP Yang, CH (通讯作者)，Chinese Acad Sci, Shanghai Inst Mat Med, Dept Med Chem, State Key Lab Drug Res, Shanghai 201203, Peoples R China.; Zuo, JP; He, SJ; Yang, CH (通讯作者)，Univ Chinese Acad Sci, Sch Pharm, Beijing 100049, Peoples R China.; Zuo, JP; He, SJ (通讯作者)，Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Lab Immunopharmacol, Shanghai 201203, Peoples R China.
EM jpzuo@simm.ac.cn; heshijun@simm.ac.cn; chyang@simm.ac.cn
RI Wang, Tianqi/KIC 1831 2024; Zhang, Xiafoei/C 8471 2014
FU Science and Technology Commission of Shanghai Municipality
   [18431907100]; State Key Laboratory of Drug Research Program
   [SIMM1903ZZ 03]
FX This work was supported by grants from the Science and Technology
   Commission of Shanghai Municipality (18431907100) and by the State Key
   Laboratory of Drug Research Program (SIMM1903ZZ 03).
CR Alves CH, 2016, CLIN REV ALLERG IMMU, V51, P27, DOI 10.1007/s12016 015 8522 7
   Aly Maha Nasr Sayed, 2008, Recent Pat Drug Deliv Formul, V2, P231
   Ashraf S, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 41140 1
   Ashraf S, 2014, ANN RHEUM DIS, V73, P1710, DOI 10.1136/annrheumdis 2013 203416
   Atobe M, 2019, J MED CHEM, V62, P1468, DOI 10.1021/acs.jmedchem.8b01615
   Chen QX, 2017, EUR J MED CHEM, V139, P926, DOI 10.1016/j.ejmech.2017.08.048
   Cross M, 2014, ANN RHEUM DIS, V73, P1323, DOI 10.1136/annrheumdis 2013 204763
   Di L, 2012, DRUG DISCOV TODAY, V17, P486, DOI 10.1016/j.drudis.2011.11.007
   DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301
   Enwerem NM, 2001, PHYTOMEDICINE, V8, P112, DOI 10.1078/0944 7113 00023
   Eriksen EF, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115352
   Fontanay S, 2008, J ETHNOPHARMACOL, V120, P272, DOI 10.1016/j.jep.2008.09.001
   FUJIOKA T, 1994, J NAT PROD, V57, P243, DOI 10.1021/np50104a008
   Fusco R, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9060511
   Gautam R, 2009, MED RES REV, V29, P767, DOI 10.1002/med.20156
   Ghosh P, 2002, SEMIN ARTHRITIS RHEU, V32, P10, DOI 10.1053/sarh.2002.33720
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   Harvey AL, 2015, NAT REV DRUG DISCOV, V14, P111, DOI 10.1038/nrd4510
   Hong EH, 2015, BIOMOL THER, V23, P345, DOI 10.4062/biomolther.2015.019
   Isah MB, 2016, PARASITOLOGY, V143, P1219, DOI 10.1017/S0031182016000718
   Ivanavicius SP, 2007, PAIN, V128, P272, DOI 10.1016/j.pain.2006.12.022
   Jagtap AD, 2017, CURR MED CHEM, V24, P622, DOI 10.2174/0929867323666161129124915
   Jung YK, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e2
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Laavola M, 2016, J NAT PROD, V79, P274, DOI 10.1021/acs.jnatprod.5b00709
   Larsen C, 2008, J PHARM SCI US, V97, P4622, DOI 10.1002/jps.21346
   Li G, 2018, MED RES REV, V38, P1255, DOI 10.1002/med.21474
   Lingaraju MC, 2015, EUR J PHARM SCI, V70, P12, DOI 10.1016/j.ejps.2015.01.001
   Liu YT, 2021, AUTOPHAGY, V17, P3753, DOI 10.1080/15548627.2021.1896924
   Liu Z., U. S. Pat e n t, Patent No. [US20,130,296,554A12013, 20130296554120]
   Ma T, 2004, CYTOKINE, V26, P138, DOI 10.1016/j.cyto.2004.02.001
   Marker CL, 2012, METHODS MOL BIOL, V851, P239, DOI 10.1007/978 1 61779 561 9_18
   Moghaddam M. G., 2012, Pharmacology and Pharmacy, V3, P119, DOI 10.4236/pp.2012.32018
   Moilanen LJ, 2015, OSTEOARTHR CARTILAGE, V23, P2017, DOI 10.1016/j.joca.2015.09.008
   Mugnaini C, 2020, J MED CHEM, V63, P7369, DOI 10.1021/acs.jmedchem.0c00595
   Newman DJ, 2020, J NAT PROD, V83, P770, DOI 10.1021/acs.jnatprod.9b01285
   Okun A, 2012, PAIN, V153, P924, DOI 10.1016/j.pain.2012.01.022
   Park DR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18208 y
   Park JH, 2017, MOL CELLS, V40, P706
   Pauli C, 2012, OSTEOARTHR CARTILAGE, V20, P476, DOI 10.1016/j.joca.2011.12.018
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Richette P, 2015, EXPERT OPIN DRUG SAF, V14, P1259, DOI 10.1517/14740338.2015.1056776
   Roth SH, 2011, PHYSICIAN SPORTSMED, V39, P62, DOI 10.3810/psm.2011.09.1922
   Sagar DR, 2010, ARTHRITIS RHEUM US, V62, P3666, DOI 10.1002/art.27698
   Steele JCP, 1999, PHYTOTHER RES, V13, P115, DOI 10.1002/(SICI)1099 1573(199903)13:2<115::AID PTR404>3.0.CO;2 1
   Williams HD, 2013, PHARMACOL REV, V65, P315, DOI 10.1124/pr.112.005660
   Xu J, 2012, J MED CHEM, V55, P3122, DOI 10.1021/jm201540h
   Zhang DM, 2015, MED RES REV, V35, P1127, DOI 10.1002/med.21353
NR 48
TC 25
Z9 26
U1 3
U2 66
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD SEP 23
PY 2021
VL 64
IS 18
BP 13676
EP 13692
DI 10.1021/acs.jmedchem.1c01019
EA SEP 2021
PG 17
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA UY4RS
UT WOS:000701513400032
PM 34491054
DA 2025 08 17
ER

PT J
AU Zhou, TY
   Zhou, ZY
   Wang, YB
AF Zhou, Tianyou
   Zhou, Zeyan
   Wang, Yingbo
TI Photothermal Antibacterial and Osteoinductive Polypyrrole@Cu Implants
   for Biological Tissue Replacement
SO MATERIALS
LA English
DT Article
DE multiple antibacterial mechanisms; potent durable antibacterial;
   osteoinductive properties; photothermal; biomaterial coating
ID TITANIUM; SURFACE; NANOPARTICLES; PAMIDRONATE; HYDROGEL; COATINGS
AB The treatment of bone defects caused by disease or accidents through the use of implants presents significant clinical challenges. After clinical implantation, these materials attract and accumulate bacteria and hinder the integration of the implant with bone tissue due to the lack of osteoinductive properties, both of which can cause postoperative infection and even lead to the eventual failure of the operation. This work successfully prepared a novel biomaterial coating with multiple antibacterial mechanisms for potent and durable and osteoinductive biological tissue replacement by pulsed PED (electrochemical deposition). By effectively regulating PPy (polypyrrole), the uniform composite coating achieved sound physiological stability. Furthermore, the photothermal analysis showcased exceptional potent photothermal antibacterial activity. The antibacterial assessments revealed a bacterial eradication rate of 100% for the PPy@Cu/PD composite coating following a 24 h incubation. Upon the introduction of NIR (near infrared) irradiation, the combined effects of multiple antibacterial mechanisms led to bacterial reduction rates of 99% for E. coli and 98% for S. aureus after a 6 h incubation. Additionally, the successful promotion of osteoblast proliferation was confirmed through the application of the osteoinductive drug PD (pamidronate disodium) on the composite coating's surface. Therefore, the antimicrobial Ti based coatings with osteoinductive properties and potent and durable antibacterial properties could serve as ideal bone implants.
C1 [Zhou, Tianyou] Xinjiang Inst Engn, Coll Control Engn, 1350 Aidinghu Rd, Urumqi 830023, Peoples R China.
   [Zhou, Zeyan] Hunan Univ, Coll Mat Sci & Engn, 2 South Lushan Rd, Changsha 410082, Peoples R China.
   [Wang, Yingbo] Xinjiang Normal Univ, Coll Chem Engn, 102 Xinyi Rd, Urumqi 830054, Peoples R China.
C3 Xinjiang Institute of Engineering; Hunan University; Xinjiang Normal
   University
RP Wang, YB (通讯作者)，Xinjiang Normal Univ, Coll Chem Engn, 102 Xinyi Rd, Urumqi 830054, Peoples R China.
EM tyzhou_power@163.com; zhouzeyan@hnu.edu.cn; ybwang20002575@163.com
RI ; Zhou, Zeyan/HZM 3236 2023
OI Zhou, Zeyan/0000 0002 4306 1677; Wang, Yingbo/0000 0002 5602 5616
FU National Natural Science Foundation of China [52063027]; Outstanding
   Youth Natural Science Foundation Project of Xinjiang [2021D01E16]
FX This work was supported by the National Natural Science Foundation of
   China (52063027) and the Outstanding Youth Natural Science Foundation
   Project of Xinjiang (2021D01E16)
CR Abbasizadeh N, 2020, INT J POLYM MATER PO, V69, P629, DOI 10.1080/00914037.2019.1596913
   Ahmed AI, 2022, AM J PHYSIOL CELL PH, V322, pC977, DOI 10.1152/ajpcell.00413.2021
   Chen HJ, 2017, MAT SCI ENG C MATER, V70, P1047, DOI 10.1016/j.msec.2016.04.013
   Chen S, 2017, ACS APPL MATER INTER, V9, P20895, DOI 10.1021/acsami.7b04956
   De Giglio E, 2001, BIOMATERIALS, V22, P2609, DOI 10.1016/S0142 9612(00)00449 X
   Ding ZL, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10010068
   Geetha M, 2009, PROG MATER SCI, V54, P397, DOI 10.1016/j.pmatsci.2008.06.004
   Gérard C, 2010, BIOMATERIALS, V31, P824, DOI 10.1016/j.biomaterials.2009.10.009
   Guo CC, 2020, ACS OMEGA, V5, P10562, DOI 10.1021/acsomega.0c00986
   Harmankaya N, 2013, ACTA BIOMATER, V9, P7064, DOI 10.1016/j.actbio.2013.02.040
   He Y, 2018, ACTA BIOMATER, V80, P412, DOI 10.1016/j.actbio.2018.09.036
   Hu DF, 2017, ACS NANO, V11, P9330, DOI 10.1021/acsnano.7b04731
   Huang L, 2016, J BIOMED MATER RES A, V104, P1437, DOI 10.1002/jbm.a.35667
   Jiang K, 2023, DEVICE, V1, DOI 10.1016/j.device.2023.100117
   Jin C, 2019, MATER DESIGN, V177, DOI 10.1016/j.matdes.2019.107845
   Kajiwara H, 2005, BIOMATERIALS, V26, P581, DOI 10.1016/j.biomaterials.2004.02.072
   Kim S, 2018, ACS APPL MATER INTER, V10, P33032, DOI 10.1021/acsami.8b11546
   Liu FF, 2021, INT J BIOL MACROMOL, V167, P1338, DOI 10.1016/j.ijbiomac.2020.11.088
   Liu XY, 2004, MAT SCI ENG R, V47, P49, DOI 10.1016/j.mser.2004.11.001
   Lu SX, 2022, COLLOID SURFACE B, V217, DOI 10.1016/j.colsurfb.2022.112695
   Luo JH, 2021, COLLOID INTERFAC SCI, V43, DOI 10.1016/j.colcom.2021.100435
   Ma SH, 2022, J CLEAN PROD, V336, DOI 10.1016/j.jclepro.2022.130431
   Ma YX, 2022, J BIOMED MATER RES A, V110, P954, DOI 10.1002/jbm.a.37344
   Maimaiti B, 2020, COLLOID SURFACE B, V186, DOI 10.1016/j.colsurfb.2019.110731
   Mitra D, 2019, ACS APPL MATER INTER, V11, P73, DOI 10.1021/acsami.8b09640
   Mitra I, 2021, MATER TODAY, V45, P20, DOI 10.1016/j.mattod.2020.11.021
   Mukherjee D, 2019, J DRUG DELIV SCI TEC, V52, P915, DOI 10.1016/j.jddst.2019.06.001
   Panek PT, 2016, J PHYS CHEM LETT, V7, P3084, DOI 10.1021/acs.jpclett.6b01451
   Ren WZ, 2015, ADV HEALTHC MATER, V4, P1526, DOI 10.1002/adhm.201500273
   Rivera LR, 2021, BIOACT MATER, V6, P1479, DOI 10.1016/j.bioactmat.2020.11.001
   Seo JJ, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120593
   Tabesh E, 2019, SURF COAT TECH, V364, P239, DOI 10.1016/j.surfcoat.2019.02.040
   Tan L, 2018, ADV MATER, V30, DOI 10.1002/adma.201801808
   Tao BL, 2021, J IND ENG CHEM, V104, P345, DOI 10.1016/j.jiec.2021.08.035
   Tao BL, 2019, J MATER CHEM B, V7, P2534, DOI 10.1039/c8tb03272f
   Wang CH, 2016, SMALL, V12, P4070, DOI 10.1002/smll.201601905
   Wang YB, 2018, BIOMATER SCI UK, V6, P575, DOI 10.1039/c7bm01104k
   Xu N, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.202000681
   Yang Y., 2017, Angew. Chem., V129, P16457, DOI [10.1002/ange.201708971, DOI 10.1002/ANGE.201708971]
   Yang Y, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201705708
   Yoshinari M, 2001, BIOMATERIALS, V22, P709, DOI 10.1016/S0142 9612(00)00234 9
   Yuan Z, 2021, J MATER SCI TECHNOL, V78, P51, DOI 10.1016/j.jmst.2020.10.066
   Zhang PY, 2017, APPL CATAL B ENVIRON, V206, P328, DOI 10.1016/j.apcatb.2017.01.051
   Zhang YF, 2021, MACROMOL BIOSCI, V21, DOI 10.1002/mabi.202000194
   Zhao YH, 2020, BIOMATERIALS, V255, DOI 10.1016/j.biomaterials.2020.120164
   Zhou ML, 2021, CHEM ENG J, V422, DOI 10.1016/j.cej.2021.130147
   Zhou T, 2019, SMALL, V15, DOI 10.1002/smll.201805440
NR 47
TC 1
Z9 1
U1 5
U2 15
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1996 1944
J9 MATERIALS
JI Materials
PD AUG
PY 2024
VL 17
IS 15
AR 3882
DI 10.3390/ma17153882
PG 15
WC Chemistry, Physical; Materials Science, Multidisciplinary; Metallurgy &
   Metallurgical Engineering; Physics, Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science; Metallurgy & Metallurgical Engineering;
   Physics
GA C1P7U
UT WOS:001287157200001
PM 39124546
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wu, YB
   Fang, M
   Luo, J
   Jin, C
   Hao, SW
   Tian, B
   Fang, C
   Li, XM
   Ning, ZP
AF Wu, Yingbiao
   Fang, Ming
   Luo, Jun
   Jin, Can
   Hao, Shuwen
   Tian, Bei
   Fang, Chao
   Li, Xinming
   Ning, Zhongping
TI Exploration of potential biomarkers involved in acute myocardial
   infarction
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Acute myocardial infarction; differentially expressed genes; miRNAs;
   functional analysis
ID PROSPECTIVE NATURAL HISTORY; EARLY DIAGNOSIS; TNF ALPHA; PROTEIN;
   EXPRESSION; SERUM; INTERLEUKIN 6; CYTOSCAPE; PLAQUES; PLASMA
AB Objective: The aim of the current study was to screen potential novel biomarkers involved in AMI. Methods: Microarray data of AMI (GSE66360) was obtained from the Gene Expression Omnibus (GEO) database. Usingthe limma package, differentially expressed genes (DEGs) between samples from AMI and healthy controls were screened. Based on the DAVID tool, functional analysis was carried out Protein protein interaction (PPI) and transcription factor (TF) miRNA target gene regulatory networks were visualized using Cytoscape software. Finally, drug gene interactions were predicted using the DGIdb database. Results: A total of 339 DEGs between samples from AMI and healthy controls were identified. Upregulated DEGs were mainly enriched in 32 pathways, including osteoclast differentiation, TNF signaling pathways, and transcriptional mis regulation in cancer. Cytokine cytokine receptor interaction was the main functional enrichment for downregulated DEGs. IL8, JUN, IL1B, TNF, and FOS were key nodes in the PPI network. In addition, three miRNAs, including has miR 191, has miR 101, and has miR 20, nine TFs, including NFKAPPAB, SRF, IK3, and NFKAPPAB65, and 34 regulatory relationship pairs were integrated. Prediction results revealed that TNF, IL1B, and TLR4 might be potential druggable genes for AMI patients. Conclusion: IL8, JUN, IL1B might be novel markers for atherosclerotic plaque instability. MicroRNAs, including miR 191, miR 101, and miR 20, might provide a window for exploration of potential biomarkers for diagnosis and prognosis for AMI patients.
C1 [Wu, Yingbiao; Fang, Ming; Luo, Jun; Jin, Can; Hao, Shuwen; Tian, Bei; Fang, Chao; Li, Xinming; Ning, Zhongping] Shanghai Pudong New Dist Zhoupu Hosp, Dept Cardiol, 1500 Zhouyuan Rd, Shanghai 201318, Peoples R China.
RP Li, XM; Ning, ZP (通讯作者)，Shanghai Pudong New Dist Zhoupu Hosp, Dept Cardiol, 1500 Zhouyuan Rd, Shanghai 201318, Peoples R China.
EM 964951345@qq.com; jingzhong86puzh@163.com
FU Outstanding Young's Training in the Health System of Shanghai Pudong New
   Area [PWRq2015 25]; Cardiovascular Disease Subject Construction Project
   of Clinical Plateau Subject of Health System in Pudong New Area
   [PWYgy2018 03]
FX This work was supported by the Outstanding Young's Training in the
   Health System of Shanghai Pudong New Area (grant number PWRq2015 25) and
   the Cardiovascular Disease Subject Construction Project of Clinical
   Plateau Subject of Health System in Pudong New Area (grant number
   PWYgy2018 03).
CR Asaria P, 2017, LANCET PUBLIC HEALTH, V2, pE191, DOI 10.1016/S2468 2667(17)30032 4
   Bandettini WP, 2012, J CARDIOVASC MAGN R, V14, DOI 10.1186/1532 429X 14 83
   Barbato E, 2016, J AM COLL CARDIOL, V68, P2247, DOI 10.1016/j.jacc.2016.08.055
   Barrett T, 2005, NUCLEIC ACIDS RES, V33, pD562
   Bochaton Piallat ML, 2018, CARDIOVASC RES, V114, P477, DOI 10.1093/cvr/cvy031
   Dabek Jozefa, 2009, Pol Merkur Lekarski, V27, P265
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Ghaderian SMH, 2011, MOL BIOL REP, V38, P4971, DOI 10.1007/s11033 010 0641 x
   Grootaert MOJ, 2018, CARDIOVASC RES, V114, P622, DOI 10.1093/cvr/cvy007
   Guo ML, 2017, EUR REV MED PHARMACO, V21, P1054
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jha HC, 2011, IMMUNOL INVEST, V40, P206, DOI 10.3109/08820139.2010.534217
   Keller T, 2009, NEW ENGL J MED, V361, P868, DOI 10.1056/NEJMoa0903515
   Li CC, 2015, EUR J MED RES, V20, DOI 10.1186/s40001 015 0148 y
   Lund J, 2006, ANN MED, V38, P221, DOI 10.1080/07853890500525883
   Muse ED, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12166 0
   Nie Y, 2011, INT J BIOL SCI, V7, P762, DOI 10.7150/ijbs.7.762
   Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29
   Prondzinsky R, 2012, MED KLIN INTENSIVMED, V107, P476, DOI 10.1007/s00063 012 0117 y
   Puz P, 2017, ATHEROSCLEROSIS, V263, P97, DOI 10.1016/j.atherosclerosis.2017.06.008
   Reichlin T, 2015, AM J MED, V128, P369, DOI 10.1016/j.amjmed.2014.10.032
   Reynolds K, 2017, AM J MED, V130, P317, DOI 10.1016/j.amjmed.2016.09.014
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0 387 29362 0_23
   Stone GW, 2011, NEW ENGL J MED, V364, P226, DOI 10.1056/NEJMoa1002358
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Tang Y, 2015, BIOSYSTEMS, V127, P67, DOI 10.1016/j.biosystems.2014.11.005
   Wagner AH, 2016, NUCLEIC ACIDS RES, V44, pD1036, DOI 10.1093/nar/gkv1165
   Wang GK, 2010, EUR HEART J, V31, P659, DOI 10.1093/eurheartj/ehq013
   Wang Y, 2018, BIOMED PHARMACOTHER, V103, P1287, DOI 10.1016/j.biopha.2018.04.161
   Wang ZH, 2017, MED SCI MONITOR, V23, P5728, DOI 10.12659/MSM.904933
   Yan YY, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8079372
   Yi J, 2018, EUR REV MED PHARMACO, V22, P540, DOI 10.26355/eurrev_201801_14207
   Zhang K, 2012, ARCH BIOCHEM BIOPHYS, V528, P127, DOI 10.1016/j.abb.2012.09.007
NR 34
TC 0
Z9 0
U1 0
U2 5
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940 5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2019
VL 12
IS 8
BP 9793
EP 9803
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA IV2PI
UT WOS:000484118700028
DA 2025 08 17
ER

PT J
AU Tsao, YT
   Huang, YJ
   Wu, HH
   Liu, YA
   Liu, YS
   Lee, OK
AF Tsao, Yu Tzu
   Huang, Yi Jeng
   Wu, Hao Hsiang
   Liu, Yu An
   Liu, Yi Shiuan
   Lee, Oscar K.
TI Osteocalcin Mediates Biomineralization during Osteogenic Maturation in
   Human Mesenchymal Stromal Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE mesenchymal stromal cells (MSCs); osteocalcin; osteogenic
   differentiation; non collagenous protein; mineralization;
   hydroxyapatite; Raman spectroscopy
ID EMBRYONIC STEM CELLS; RAMAN SPECTROSCOPY; LIVING CELLS; BONE;
   MINERALIZATION; PHOSPHATE; THERAPY; CULTURE; TOOL
AB There is a growing interest in cell therapies using mesenchymal stromal cells (MSCs) for repairing bone defects. MSCs have the ability to differentiate into osteoprogenitors and osteoblasts as well as to form calcified bone matrix. However, the molecular mechanisms governing mineralization during osteogenic differentiation remain unclear. Non collagenous proteins in the extracellular matrix are believed to control different aspects of the mineralization. Since osteocalcin is the most abundant non collagenous bone matrix protein, the purpose of this study is to investigate the roles of osteocalcin in mineral species production during osteogenesis of MSCs. Using Raman spectroscopy, we found that the maturation of mineral species was affected by osteocalcin expression level. After osteocalcin was knocked down, the mineral species maturation was delayed and total hydroxyapatite was lower than the control group. In addition, the expression of osteogenic marker genes, including RUNX2, alkaline phosphatase, type I collagen, and osteonectin, was downregulated during osteogenic differentiation compared to the control group; whereas gene expression of osterix was upregulated after the knockdown. Together, osteocalcin plays an essential role for the maturation of mineral species and modulates osteogenic differentiation of MSCs. The results offer new insights into the enhancement of new bone formation, such as for the treatments of osteoporosis and fracture healing.
C1 [Tsao, Yu Tzu; Lee, Oscar K.] Natl Yang Ming Univ, Inst Clin Med, Taipei 11221, Taiwan.
   [Tsao, Yu Tzu] Taoyuan Gen Hosp, Div Nephrol, Dept Med, Minist Hlth & Welf, Taoyuan 33004, Taiwan.
   [Huang, Yi Jeng; Wu, Hao Hsiang] Natl Yang Ming Univ, Inst Biophoton, Taipei 11221, Taiwan.
   [Liu, Yu An; Liu, Yi Shiuan; Lee, Oscar K.] Natl Yang Ming Univ, Stem Cell Res Ctr, Taipei 11221, Taiwan.
   [Lee, Oscar K.] Taipei City Hosp, Taipei 10341, Taiwan.
   [Lee, Oscar K.] Taipei Vet Gen Hosp, Dept Med Res, Taipei 11217, Taiwan.
   [Lee, Oscar K.] Taipei Vet Gen Hosp, Dept Orthopaed & Traumatol, Taipei 11217, Taiwan.
C3 National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University; National Yang Ming Chiao Tung University; Taipei City
   Hospital; Taipei Veterans General Hospital; Taipei Veterans General
   Hospital
RP Lee, OK (通讯作者)，Natl Yang Ming Univ, Inst Clin Med, Taipei 11221, Taiwan.; Liu, YS; Lee, OK (通讯作者)，Natl Yang Ming Univ, Stem Cell Res Ctr, Taipei 11221, Taiwan.; Lee, OK (通讯作者)，Taipei City Hosp, Taipei 10341, Taiwan.; Lee, OK (通讯作者)，Taipei Vet Gen Hosp, Dept Med Res, Taipei 11217, Taiwan.; Lee, OK (通讯作者)，Taipei Vet Gen Hosp, Dept Orthopaed & Traumatol, Taipei 11217, Taiwan.
EM tsaoyutzu@gmail.com; hieiinuyasha@gmail.com; haohsiang.wu@gmail.com;
   yuan_01@hotmail.com; lyspub1@gmail.com; DAV47@tpech.gov.tw
RI Liu, Yi Shiuan/AAI 3803 2020; Lee, Oscar/MEK 9750 2025
OI Tsao, Yu Tzu/0000 0002 2413 1684; Liu, Yi Shiuan/0000 0003 3205 8963
FU Novel Bioengineering and Technological Approaches to Solve Two Major
   Health Problems in Taiwan   Taiwan Ministry of Science and Technology
   Academic Excellence Program [MOST 105 2633 B 009 003]; Ministry of
   Science and Technology, Taiwan [MOST 103 2314 B 010 053 MY3, MOST
   104 2321 B 010 008, MOST 106 2911 I 010 502]; Ministry of Education
FX This work was supported in part by the Novel Bioengineering and
   Technological Approaches to Solve Two Major Health Problems in Taiwan
   sponsored by the Taiwan Ministry of Science and Technology Academic
   Excellence Program under Grant Number: MOST 105 2633 B 009 003. The
   authors acknowledge financial support from the Ministry of Science and
   Technology, Taiwan (MOST 103 2314 B 010 053 MY3, MOST
   104 2321 B 010 008, and MOST 106 2911 I 010 502). This study was also
   supported by Aiming for the Top University Plan, a grant from Ministry
   of Education.
CR [Anonymous], STEM CELLS INT
   Boonrungsiman S, 2012, P NATL ACAD SCI USA, V109, P14170, DOI 10.1073/pnas.1208916109
   BOSKEY AL, 1985, CALCIFIED TISSUE INT, V37, P57, DOI 10.1007/BF02557680
   BOSKEY AL, 1992, CLIN ORTHOP RELAT R, P244
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267
   Ghasroldasht MM, 2014, CELL BIOL INT, V38, P1081, DOI 10.1002/cbin.10293
   Hung PS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065438
   JOHNSSON MSA, 1992, CRIT REV ORAL BIOL M, V3, P61, DOI 10.1177/10454411920030010601
   Kanazawa I, 2015, WORLD J DIABETES, V6, P1345, DOI 10.4239/wjd.v6.i18.1345
   Kendall C, 2003, J PATHOL, V200, P602, DOI 10.1002/path.1376
   Knepper Nicolai B, 2002, BIOMOL ENG, V19, P227, DOI 10.1016/S1389 0344(02)00036 9
   Kuo TK, 2009, CELL TRANSPLANT, V18, P1013, DOI 10.3727/096368909X471206
   Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood 2003 05 1670
   McManus LL, 2011, ANALYST, V136, P2471, DOI 10.1039/c1an15167c
   Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007 1122
   Mitchell A, 2015, CYTOM PART A, V87A, P1012, DOI 10.1002/cyto.a.22777
   Mitchell A, 2015, ANALYST, V140, P7347, DOI 10.1039/c5an01595b
   Mouras R, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.11.116011
   Neve A, 2013, J CELL PHYSIOL, V228, P1149, DOI 10.1002/jcp.24278
   Notingher I, 2004, ANAL CHEM, V76, P3185, DOI 10.1021/ac0498720
   Notingher I, 2003, BIOPOLYMERS, V72, P230, DOI 10.1002/bip.10378
   Petry R, 2003, CHEMPHYSCHEM, V4, P14, DOI 10.1002/cphc.200390004
   PUPPELS GJ, 1990, NATURE, V347, P301, DOI 10.1038/347301a0
   Rammelt S, 2005, J BIOMED MATER RES A, V73A, P284, DOI 10.1002/jbm.a.30263
   ROACH HI, 1994, CELL BIOL INT, V18, P617, DOI 10.1006/cbir.1994.1088
   SAUER GR, 1994, CALCIFIED TISSUE INT, V54, P414, DOI 10.1007/BF00305529
   Schulze HG, 2010, ANAL CHEM, V82, P5020, DOI 10.1021/ac902697q
   Stewart S, 2002, J RAMAN SPECTROSC, V33, P536, DOI 10.1002/jrs.892
   Tarnowski CP, 2002, J BONE MINER RES, V17, P1118, DOI 10.1359/jbmr.2002.17.6.1118
   Wolf G, 1996, NUTR REV, V54, P332, DOI 10.1111/j.1753 4887.1996.tb03798.x
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 33
TC 192
Z9 216
U1 4
U2 28
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2017
VL 18
IS 1
AR 159
DI 10.3390/ijms18010159
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA EJ2HL
UT WOS:000393030600157
PM 28106724
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Vijayakumar, SC
   Venkatakrishnan, K
   Tan, B
AF Vijayakumar, Sivaprasad Chinnakkannu
   Venkatakrishnan, Krishnan
   Tan, Bo
TI Bio functionalizing heterogeneous phase activated titanium by
   multiphoton ionization energy mechanism to harmonize cell proliferative
   behavior
SO MATERIALS SCIENCE AND ENGINEERING C MATERIALS FOR BIOLOGICAL
   APPLICATIONS
LA English
DT Article
DE Titanium; NIH3T3 and MC3T3 cell; Phase activation; Hongquiite;
   Multi photon ionization
ID HYDROGEN PHOSPHATE/GELATIN COMPOSITES; ADHESION; ABLATION; SURFACES;
   SYMMETRY; SOLIDS; GROWTH
AB Cellular interactions are regulated by various mechanical, physical and chemical factors that are either introduced to or are pre existing in their local microenvironments. These factors include geometric confinement, cell substrate interactions and cell cell contacts. The systematic elucidation of these dictating mechanisms is crucial for fundamental understanding of regenerative medicine and for designing biomedical devices. Here, we have developed an elegant multi photon ionization based mechanism, which accomplishes selective surface bio functionalization of native titanium substrates, to achieve stable cellular confinements. In particular, we applied selective titanium phase activation for cellular confinement of mouse fibroblasts and osteoblast cells in an effort to examine their directionality and proliferative behavior under confinement. The experimental results suggest, both mouse fibroblasts and osteoblasts can be manipulated, guided and aligned along an induced orientation by selective hongquiite phase activation. The cell viability of both fibroblast and osteoblast cells were observed through fluorescent assays and SEM techniques. The phase activated surface fabricated influenced both nuclei and actin cytoskeletal re arrangement of cell structures. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Vijayakumar, Sivaprasad Chinnakkannu; Venkatakrishnan, Krishnan] Ryerson Univ, Micro Nanofabricat Facil, Dept Mech & Ind Engn, 350 Victoria St, Toronto, ON M5B 2K3, Canada.
   [Vijayakumar, Sivaprasad Chinnakkannu] Ryerson Univ & St Michaels Hosp, Inst Biomed Engn Sci & Technol iBEST, Toronto, ON M5B 1W8, Canada.
   [Venkatakrishnan, Krishnan] St Michaels Hosp, Keenan Res Ctr Biomed Sci, 209 Victoria St, Toronto, ON M5B 1TB, Canada.
   [Tan, Bo] Ryerson Univ, Dept Aerosp Engn, Nanocharacterizat Lab, 350 Victoria St, Toronto, ON M5B 2K3, Canada.
C3 Toronto Metropolitan University; University of Toronto; Saint Michaels
   Hospital Toronto; University of Toronto; Saint Michaels Hospital
   Toronto; Toronto Metropolitan University
RP Venkatakrishnan, K (通讯作者)，St Michaels Hosp, Keenan Res Ctr Biomed Sci, 209 Victoria St, Toronto, ON M5B 1TB, Canada.
EM venkat@ryerson.ca
RI Tan, Bo/NXX 9807 2025; Chinnakkannu Vijayakumar, Sivaprasad/A 7558 2013
OI Tan, Bo/0000 0001 8141 4819; Chinnakkannu Vijayakumar,
   Sivaprasad/0000 0002 7363 8588; Venkatakrishnan,
   Krishnan/0000 0002 6491 3971
FU Natural Science and Engineering Research Council of Canada (NSERC)
   [126042, 119087]
FX The authors would like to thank Mr. Advait Pai for his assistance with
   illustrations. This research is funded by Natural Science and
   Engineering Research Council of Canada (NSERC Discovery Grant 126042,
   119087).
CR Anselme K, 2000, BIOMATERIALS, V21, P1567, DOI 10.1016/S0142 9612(00)00042 9
   Bass JD, 2010, J BIOMED MATER RES A, V93A, P96, DOI 10.1002/jbm.a.32477
   Bhatia SN, 1999, FASEB J, V13, P1883, DOI 10.1096/fasebj.13.14.1883
   Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955 0674(98)80040 9
   Curtis ASG, 2004, IEEE T NANOBIOSCI, V3, P61, DOI 10.1109/TNB.2004.824276
   Curtis ASG, 2001, BIOPHYS CHEM, V94, P275, DOI 10.1016/S0301 4622(01)00247 2
   Dalby MJ, 2004, BIOMATERIALS, V25, P5415, DOI 10.1016/j.biomaterials.2003.12.049
   Fan JD, 2013, ACS APPL MATER INTER, V5, P9872, DOI 10.1021/am402344d
   Flaim CJ, 2005, NAT METHODS, V2, P119, DOI 10.1038/NMETH736
   Fouchard J, 2011, CELL ADHES MIGR, V5, P16, DOI 10.4161/cam.5.1.13281
   Gamaly EG, 2011, PHYS REP, V508, P91, DOI 10.1016/j.physrep.2011.07.002
   Gamaly EG, 2002, PHYS PLASMAS, V9, P949, DOI 10.1063/1.1447555
   Garg S, 2013, NAT REV CARDIOL, V10, P248, DOI 10.1038/nrcardio.2013.13
   Gashti MP, 2016, INT J APPL CERAM TEC, V13, P1069, DOI 10.1111/ijac.12578
   Gashti MP, 2016, NEW J CHEM, V40, P5495, DOI 10.1039/c5nj03575a
   Gashti MP, 2015, CURR APPL PHYS, V15, P1075, DOI 10.1016/j.cap.2015.06.009
   Gashti MP, 2014, J COLLOID INTERF SCI, V431, P149, DOI 10.1016/j.jcis.2014.06.010
   Gashti MP, 2014, PLASMA PROCESS POLYM, V11, P37, DOI 10.1002/ppap.201300100
   Gashti MP, 2013, COLLOID SURFACE B, V110, P426, DOI 10.1016/j.colsurfb.2013.04.051
   Gashti MP, 2013, CRYST GROWTH DES, V13, P2166, DOI 10.1021/cg4002434
   Gashti MP, 2013, J MATER CHEM B, V1, P1501, DOI 10.1039/c3tb00088e
   HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955 0674(95)80112 X
   Karagkiozaki V, 2012, INT J NANOMED, V7, P6063, DOI 10.2147/IJN.S34320
   Kloxin AM, 2012, INTEGR BIOL UK, V4, P1540, DOI 10.1039/c2ib20212c
   Kolind K, 2010, BIOMATERIALS, V31, P9182, DOI 10.1016/j.biomaterials.2010.08.048
   Leitz KH, 2011, PHYSCS PROC, V12, P230, DOI 10.1016/j.phpro.2011.03.128
   Lim JY, 2007, TISSUE ENG, V13, P1879, DOI 10.1089/ten.2006.0154
   Mani G, 2007, BIOMATERIALS, V28, P1689, DOI 10.1016/j.biomaterials.2006.11.042
   Maznichenko D, 2013, J PHYS CHEM C, V117, P578, DOI 10.1021/jp310193a
   Nikkhah M, 2012, BIOMATERIALS, V33, P5230, DOI 10.1016/j.biomaterials.2012.03.079
   Price RL, 2003, BIOMATERIALS, V24, P1877, DOI 10.1016/S0142 9612(02)00609 9
   Qin D, 2010, NAT PROTOC, V5, P491, DOI 10.1038/nprot.2009.234
   Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962 8924(98)80005 6
   Shirk MD, 1998, J LASER APPL, V10, P18, DOI 10.2351/1.521827
   Sudani N, 2011, MATER MANUF PROCESS, V26, P661, DOI 10.1080/10426910903180029
   Szot K, 1996, APPL PHYS A MATER, V62, P335
   Takemoto S, 2004, BIOMATERIALS, V25, P3485, DOI 10.1016/j.biomaterials.2003.10.070
   Vaquila I., 1999, J PHYS CONDENS MATT, V5, pA157
   Veljkovic I, 2008, MATER LETT, V62, P2769, DOI 10.1016/j.matlet.2008.01.039
   Vijayakumar SC, 2016, EXP CELL RES, V340, P274, DOI 10.1016/j.yexcr.2015.11.001
   Webb K, 1998, J BIOMED MATER RES, V41, P422, DOI 10.1002/(SICI)1097 4636(19980905)41:3<422::AID JBM12>3.0.CO;2 K
   Wei HY, 2012, J APPL PHYS, V111, DOI 10.1063/1.3698318
   Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835
   Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607
NR 44
TC 0
Z9 0
U1 1
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD JUL 1
PY 2017
VL 76
BP 448
EP 456
DI 10.1016/j.msec.2017.03.111
PG 9
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA FA6GP
UT WOS:000405541600053
PM 28482549
DA 2025 08 17
ER

PT J
AU Kindler, V
   Paccaud, J
   Hannouche, D
   Laumonier, T
AF Kindler, Vincent
   Paccaud, Joris
   Hannouche, Didier
   Laumonier, Thomas
TI Human myoblasts differentiate in various mesenchymal lineages and
   inhibit allogeneic T cell proliferation through an indolamine 2,3
   dioxygenase dependent pathway
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Human myoblast; Human mesenchymal stromal cell; Multipotency;
   Immunomodulation; Indolamine 2,3 dioxygenase (IDO)
ID HUMAN SKELETAL MUSCLE; STEM CELLS; STROMAL CELLS; SATELLITE CELLS;
   LYMPHOCYTE PROLIFERATION; IN VITRO; BONE; THERAPY; MESOANGIOBLASTS;
   TRANSPLANTATION
AB Muscle stem cells (MuSC) are considered as a reliable source of therapeutic cells to restore diseased muscles. However in most cases, injected MuSC derived myoblasts are rapidly destroyed by the host immune response, which impairs the beneficial effect. By contrast, human mesenchymal stromal cells (MSC), have been reported to exhibit potent immune regulatory functions. Thus, we investigated, in vitro, the multipotent differentiation  and immunosuppressive capacities of human myoblasts and compared these features with those of human MSC. Myoblasts shared numerous cell surface markers with MSC, including CD73, CD90, CD105 and CD146. Both cell type were negative for HLA DR and CD45, CD34 and CD31. CD56, a myogenic marker, was expressed by myoblasts exclusively. Myoblasts displayed multipotent potential capabilities with differentiation in chondrocytes, adipocytes and osteoblasts in vitro. Myoblasts also inhibited allogenic T cell proliferation in vitro in a dose dependent manner, very similarly to MSC. This effect was partly mediated via the activation of indolamine 2,3 dioxygenase enzyme (IDO) after IFN gamma exposure. Altogether, these data demonstrate that human myoblasts can differentiate in various mesenchymal linages and exhibit powerful immunosuppressive properties in vitro. Such features may open new therapeutic strategies for MuSC derived myoblasts.
C1 [Kindler, Vincent; Paccaud, Joris; Hannouche, Didier; Laumonier, Thomas] Geneva Univ Hosp, Dept Orthoped Surg, Geneva, Switzerland.
   [Kindler, Vincent; Paccaud, Joris; Hannouche, Didier; Laumonier, Thomas] Fac Med, Rue Gabrielle Perret Gentil 4, CH 1211 Geneva 14, Switzerland.
   [Hannouche, Didier; Laumonier, Thomas] Fac Med, Dept Cell Physiol & Metab, Geneva, Switzerland.
C3 University of Geneva; University of Geneva; University of Geneva
RP Laumonier, T (通讯作者)，Fac Med, Rue Gabrielle Perret Gentil 4, CH 1211 Geneva 14, Switzerland.; Laumonier, T (通讯作者)，Geneva Univ Hosp, Dept Orthoped Surg, Cell Therapy & Musculoskeletal Disorders Lab, Rue Gabrielle Perret Gentil 4, CH 1211 Geneva 14, Switzerland.
EM thomas.laumonier@unige.ch
RI ; Laumonier, Thomas/AAA 4656 2019
OI Laumonier, Thomas/0000 0002 8662 2972; Kindler,
   Vincent/0000 0002 5349 1857; 
FU Fondation Pour la Recherche Osteo Articulaire; Fondation Suisse de
   Recherche sur les Maladies Musculaires
FX This work was supported by the Fondation Pour la Recherche
   Osteo Articulaire (D.H) and by the Fondation Suisse de Recherche sur les
   Maladies Musculaires (T.L).
CR Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301 472X(01)00769 X
   Bouché M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/821950
   Chakkalakal JV, 2014, DEVELOPMENT, V141, P1649, DOI 10.1242/dev.100842
   Chen CW, 2009, CYTOKINE GROWTH F R, V20, P429, DOI 10.1016/j.cytogfr.2009.10.014
   Choi S, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012357
   Cossu G, 2015, EMBO MOL MED, V7, P1513, DOI 10.15252/emmm.201505636
   Covas DT, 2008, EXP HEMATOL, V36, P642, DOI 10.1016/j.exphem.2007.12.015
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   DelaRosa O, 2009, TISSUE ENG PT A, V15, P2795, DOI [10.1089/ten.tea.2008.0630, 10.1089/ten.TEA.2008.0630]
   Dellavalle A, 2007, NAT CELL BIOL, V9, P255, DOI 10.1038/ncb1542
   DENCKLA WD, 1967, J LAB CLIN MED, V69, P160
   Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364
   Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   El Fahime E, 2000, EXP CELL RES, V258, P279, DOI 10.1006/excr.2000.4962
   English K, 2013, STEM CELLS DEV, V22, P512, DOI 10.1089/scd.2012.0386
   Fan Y, 1996, MUSCLE NERVE, V19, P853, DOI 10.1002/(SICI)1097 4598(199607)19:7<853::AID MUS7>3.0.CO;2 8
   Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528
   Galvez BG, 2006, J CELL BIOL, V174, P231, DOI 10.1083/jcb.200512085
   Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43922
   Guttinger M, 2006, EXP CELL RES, V312, P3872, DOI 10.1016/j.yexcr.2006.08.012
   Haniffa MA, 2009, HAEMATOL HEMATOL J, V94, P258, DOI 10.3324/haematol.13699
   Judson RN, 2020, NPJ REGEN MED, V5, DOI 10.1038/s41536 020 0094 3
   Kim J, 2017, STEM CELL RES, V23, P87, DOI 10.1016/j.scr.2017.07.013
   Krampera M, 2003, BLOOD, V101, P3722, DOI 10.1182/blood 2002 07 2104
   Krampera M, 2006, STEM CELLS, V24, P386, DOI 10.1634/stemcells.2005 0008
   Laumonier T, 2020, J ORTHOP RES, V38, P1398, DOI 10.1002/jor.24579
   Laumonier T, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03703 y
   Laumonier T, 2013, CELL TRANSPLANT, V22, P1213, DOI 10.3727/096368912X657224
   LAW PK, 1990, LANCET, V336, P114, DOI 10.1016/0140 6736(90)91628 N
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   Le Blanc K., LANCET LOND
   LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140 6736(08)60690 X
   Lecourt S, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/412610
   Lecourt S, 2010, EXP CELL RES, V316, P2513, DOI 10.1016/j.yexcr.2010.04.020
   Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415
   Mastrogiacomo M, 2005, J CELL PHYSIOL, V204, P594, DOI 10.1002/jcp.20325
   Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007 1122
   Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood 2003 11 3909
   MENDELL JR, 1995, NEW ENGL J MED, V333, P832, DOI 10.1056/NEJM199509283331303
   Meng JH, 2018, STEM CELL RES, V30, P43, DOI 10.1016/j.scr.2018.05.004
   Meng JH, 2014, MOL THER, V22, P1008, DOI 10.1038/mt.2014.26
   Montarras D, 2005, SCIENCE, V309, P2064, DOI 10.1126/science.1114758
   Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood 2007 02 069716
   Negroni E, 2006, PATHOL BIOL, V54, P100, DOI 10.1016/j.patbio.2005.09.001
   PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pradier A, 2011, CELL TRANSPLANT, V20, P681, DOI 10.3727/096368910X536545
   Quattrocelli M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.401
   Relaix F, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20760 6
   Relaix F, 2012, DEVELOPMENT, V139, P2845, DOI 10.1242/dev.069088
   Sambasivan R, 2011, DEVELOPMENT, V138, P3647, DOI 10.1242/dev.067587
   Sampaolesi M, 2006, NATURE, V444, P574, DOI 10.1038/nature05282
   Skuk D, 2015, EXPERT OPIN BIOL TH, V15, P1307, DOI 10.1517/14712598.2015.1057564
   Squillaro T, 2016, CELL TRANSPLANT, V25, P829, DOI 10.3727/096368915X689622
   Stellavato A, 2016, J CELL BIOCHEM, V117, P2158, DOI 10.1002/jcb.25556
   Suva D, 2004, J CELL PHYSIOL, V198, P110, DOI 10.1002/jcp.10396
   Suva D, 2008, J CELL PHYSIOL, V214, P588, DOI 10.1002/jcp.21244
   Tedesco FS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003541
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb 2002 3 7 research0034
   WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212
   WALSH FS, 1981, NATURE, V289, P60, DOI 10.1038/289060a0
   WEBSTER C, 1988, EXP CELL RES, V174, P252, DOI 10.1016/0014 4827(88)90159 0
NR 63
TC 5
Z9 5
U1 2
U2 5
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD JUN 1
PY 2021
VL 403
IS 1
AR 112586
DI 10.1016/j.yexcr.2021.112586
EA APR 2021
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA RU4DD
UT WOS:000645097800008
PM 33839146
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Garg, G
   Pradeep, AR
   Thorat, MK
AF Garg, Garima
   Pradeep, A. R.
   Thorat, Manoj Kumar
TI Effect of nonsurgical periodontal therapy on crevicular fluid levels of
   Cathepsin K in periodontitis
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE Gingival crevicular fluid; Cathepsin K; Periodontal health; Gingivitis;
   Chronic periodontitis; Scaling and root planing
ID RHEUMATOID ARTHRITIS; MESSENGER RNA; EXPRESSION; BONE; ATHEROSCLEROSIS;
   OSTEOPOROSIS; COLLAGEN; RAT
AB Objectives: Cathepsin K (CTSK), predominantly expressed in osteoclasts, is a potent extracellular matrix degrading enzyme that plays a critical role in osteoclast mediated bone resorption. Its increased gingival crevicular fluid (GCF) levels in periodontal disease have been reported in a previous study. The present study has been carried out to assess the role of CTSK in periodontal disease and to determine the effect of periodontal treatment on CTSK concentration in GCF.
   Design: 60 subjects were divided into three groups (n = 20) based on gingival index (GI), probing pocket depth (PPD) and clinical attachment loss (CAL): healthy (group I), gingivitis (group II) and chronic periodontitis (group III). A fourth group (group M consisted of 20 subjects from group III, 6 8 weeks after nonsurgical periodontal therapy (scaling and root planing). GCF samples collected from each patient were quantified for CTSK using ELISA.
   Results: The mean CTSK concentration in GCF was found to be the highest in group III, i.e. 55.55 pmol/l. The mean CTSK concentration in GCF in group I and group II was 5.95 pmol/l and 6.90 pmol/l respectively. The mean CTSK concentration in GCF in group IV decreased to 11.15 pmol/l, slightly more than that in groups I and II.
   Conclusions: GCF CTSK levels increased in periodontitis and correlated negatively with clinical parameters like GI, PPD and CAL. CTSK levels decreased after nonsurgical treatment of periodontitis. Thus, CTSK can be considered as a 'marker of osteoclastic activity' in periodontal disease and also deserves further consideration as a therapeutic target. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Garg, Garima] Govt Dent Coll & Res Inst, Dept Periodont, Bangalore 560002, Karnataka, India.
RP Garg, G (通讯作者)，Govt Dent Coll & Res Inst, Dept Periodont, Bangalore 560002, Karnataka, India.
EM garg_gg@yahoo.co.in
OI KARVEKAR, DR SHRUTI/0000 0003 3670 9540
FU Colgate Palmolive India Ltd., Mumbai, India
FX The authors acknowledge Colgate Palmolive India Ltd., Mumbai, India, for
   partly funding the project.
CR AHLBERG J, 1985, J BIOL CHEM, V260, P5847
   Dickinson DP, 2002, CRIT REV ORAL BIOL M, V13, P238, DOI 10.1177/154411130201300304
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Everts V, 2003, CALCIFIED TISSUE INT, V73, P380, DOI 10.1007/s00223 002 2092 4
   Giannobile WV, 2008, J PERIODONTOL, V79, P1592, DOI 10.1902/jop.2008.080174
   Goto T, 2003, J ELECTRON MICROSC, V52, P551, DOI 10.1093/jmicro/52.6.551
   Griffiths GS, 2003, PERIODONTOL 2000, V31, P32, DOI 10.1034/j.1600 0757.2003.03103.x
   Hie M, 2007, BONE, V41, P1045, DOI 10.1016/j.bone.2007.08.030
   Hummel KM, 1998, J RHEUMATOL, V25, P1887
   Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535 6108(04)00111 4
   Kafienah W, 1998, BIOCHEM J, V331, P727, DOI 10.1042/bj3310727
   LOE HARALD, 1963, ACTA ODONTOL SCAND, V21, P533, DOI 10.3109/00016356309011240
   Lutgens E, 2006, CIRCULATION, V113, P98, DOI 10.1161/CIRCULATIONAHA.105.561449
   Meier C, 2006, CLIN LAB, V52, P1
   Mogi M, 2007, ARCH ORAL BIOL, V52, P894, DOI 10.1016/j.archoralbio.2007.01.006
   Montonen M, 2006, J ORAL PATHOL MED, V35, P620, DOI 10.1111/j.1600 0714.2006.00454.x
   Ohba Y, 2000, ARCH ORAL BIOL, V45, P63, DOI 10.1016/S0003 9969(99)00104 1
   Pentikäinen MO, 2000, J INTERN MED, V247, P359, DOI 10.1046/j.1365 2796.2000.00655.x
   Röcken C, 2006, J PATHOL, V210, P478, DOI 10.1002/path.2076
   Rünger TM, 2007, J INVEST DERMATOL, V127, P293, DOI 10.1038/sj.jid.5700535
   Sassi ML, 2000, BONE, V26, P367, DOI 10.1016/S8756 3282(00)00235 0
   Skoumal M, 2005, ARTHRITIS RES THER, V7, pR65, DOI 10.1186/ar1461
   Strbac GD, 2006, J CLIN PERIODONTOL, V33, P302, DOI 10.1111/j.1600 051X.2006.00904.x
   Stroup GB, 2001, J BONE MINER RES, V16, P1739, DOI 10.1359/jbmr.2001.16.10.1739
   Wendling D, 2008, JOINT BONE SPINE, V75, P559, DOI 10.1016/j.jbspin.2008.01.026
   Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013
   Xiao Y, 2006, J CLIN ENDOCR METAB, V91, P4520, DOI 10.1210/jc.2005 2486
   Zavasnik Bergant T, 2006, TISSUE ANTIGENS, V67, P349, DOI 10.1111/j.1399 0039.2006.00585.x
NR 28
TC 22
Z9 26
U1 0
U2 1
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0003 9969
EI 1879 1506
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD NOV
PY 2009
VL 54
IS 11
BP 1046
EP 1051
DI 10.1016/j.archoralbio.2009.08.007
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 515AV
UT WOS:000271439500010
PM 19782963
DA 2025 08 17
ER

PT J
AU Shen, ZH
   Yu, T
   Ye, JD
AF Shen, Zhonghua
   Yu, Tao
   Ye, Jiandong
TI Microstructure and properties of alendronate loaded calcium phosphate
   cement
SO MATERIALS SCIENCE & ENGINEERING C MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Calcium phosphate cement; Alendronate; Rheological property;
   Injectability
ID BONE CEMENTS; IN VITRO; DRUG; BISPHOSPHONATES; DELIVERY; RELEASE;
   HYDROXYAPATITE; MECHANISM; SYSTEM; ZOLEDRONATE
AB Calcium phosphate cement (CPC), as an injectable bone substitute material is significant in bone defect treatment. Drugs and biological molecules are often incorporated into CPC to promote the healing of bone defects and treat some bone diseases. In this work, alendronate (ALN) loaded CPC was prepared and the influences of the content of ALN on the setting time, microstructure of hydrate porosity, mechanical strength, in vitro drug release, rheological properties and injectability of CPC were systematically investigated. The results showed that the addition of ALN had no effect on the final hydration product of CPC. The setting time of CPC was prolonged, while the prolonging effect became weak when the larger amount of ALN was added. With the increment of ALN content, the hydroxyapatite crystals of cured CPC became smaller, and the hydrated CPC became more compact with lower porosity, which resulted in the improvement of compressive strength of CPC with a drug loaded amount less than 1 wt%. The injectability was dramatically improved due to the addition of ALN, which was corresponding to the decrease of viscosity. The thixotropy of the CPC slurry was promoted with increasing the ALN content, which could enhance the stability of the slurry. However, it was worth noting that an inverted thixotropic loop appeared when the drug content was higher than 3.0 wt%. During the in vitro drug release, the initial burst release turned up for all formulations and the degree of burst release was different from each other. This work would allow advances in understanding the effect of ALN on the setting process and physical and chemical properties of CPC, and we should think over the appropriate content when adding ALN into CPC. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Shen, Zhonghua; Yu, Tao; Ye, Jiandong] S China Univ Technol, Sch Mat Sci & Engn, Guangzhou 510641, Peoples R China.
   [Yu, Tao] Univ Hong Kong, Dept Orthopaed & Traumatol, Pokfulam, Hong Kong, Peoples R China.
C3 South China University of Technology; University of Hong Kong
RP Yu, T (通讯作者)，S China Univ Technol, Sch Mat Sci & Engn, Guangzhou 510641, Peoples R China.
EM ytbio@hotmail.com; jdye@scut.edu.cn
RI YE, Jiandong/C 3444 2011
FU National Natural Science Foundation of China [51172074, 51302089];
   National Basic Research Program of China [2012CB619100]; Fundamental
   Research Funds for the Central Universities [2013ZZ0010]
FX This research was supported by the National Natural Science Foundation
   of China (grant nos. 51172074 and 51302089), the National Basic Research
   Program of China (grant no. 2012CB619100) and the Fundamental Research
   Funds for the Central Universities (grant no. 2013ZZ0010).
CR [Anonymous], ORTHOPEDICS
   Boanini E, 2007, ADV MATER, V19, P2499, DOI 10.1002/adma.200602497
   BROWN WE, 1983, J DENT RES, V62, P672
   Chen FP, 2011, MATER CHEM PHYS, V125, P818, DOI 10.1016/j.matchemphys.2010.09.050
   Chen WC, 2003, J BIOMED MATER RES A, V64A, P664, DOI 10.1002/jbm.a.10250
   Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
   Fatimi A, 2012, J MATER SCI MATER M, V23, P1593, DOI 10.1007/s10856 012 4640 4
   Faucheux C, 2009, J BIOMED MATER RES A, V89A, P46, DOI 10.1002/jbm.a.31989
   Gbureck U, 2004, BIOMATERIALS, V25, P2187, DOI 10.1016/j.biomaterials.2003.08.066
   Giger EV, 2013, J CONTROL RELEASE, V167, P175, DOI 10.1016/j.jconrel.2013.01.032
   Ginebra MP, 2012, ADV DRUG DELIVER REV, V64, P1090, DOI 10.1016/j.addr.2012.01.008
   Ginebra MP, 2006, BIOMATERIALS, V27, P2171, DOI 10.1016/j.biomaterials.2005.11.023
   Ginebra MP, 2001, J BIOMED MATER RES, V57, P113, DOI 10.1002/1097 4636(200110)57:1<113::AID JBM1149>3.0.CO;2 5
   Guo H, 2006, BIOMED MATER, V1, P193, DOI 10.1088/1748 6041/1/4/003
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   Josse S, 2005, BIOMATERIALS, V26, P2073, DOI 10.1016/j.biomaterials.2004.05.019
   Kuljanin J, 2002, J PHARMACEUT BIOMED, V28, P1215, DOI 10.1016/S0731 7085(02)00021 3
   Lewis G, 2011, J BIOMED MATER RES B, V98B, P171, DOI 10.1002/jbm.b.31835
   Li M, 2010, CLIN ORTHOP RELAT R, V468, P1978, DOI 10.1007/s11999 010 1321 9
   Liu CS, 2006, BIOMATERIALS, V27, P5003, DOI 10.1016/j.biomaterials.2006.05.043
   Lopez Heredia MA, 2011, BIOMATERIALS, V32, P5411, DOI 10.1016/j.biomaterials.2011.04.010
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Panzavolta S, 2010, J INORG BIOCHEM, V104, P1099, DOI 10.1016/j.jinorgbio.2010.06.008
   Panzavolta S, 2009, J INORG BIOCHEM, V103, P101, DOI 10.1016/j.jinorgbio.2008.09.012
   Pazianas M, 2011, BONE, V49, P103, DOI 10.1016/j.bone.2011.01.003
   Peter B, 2005, BONE, V36, P52, DOI 10.1016/j.bone.2004.10.004
   Pina S, 2010, J MATER SCI MATER M, V21, P431, DOI 10.1007/s10856 009 3890 2
   Reed J.S., 1995, Principles of Ceramics Processing
   Reinstorf A, 2004, J MATER SCI MATER M, V15, P451, DOI 10.1023/B:JMSM.0000021119.14870.3d
   Roussière H, 2005, J MATER CHEM, V15, P3869, DOI 10.1039/b503680a
   Roussiere H, 2008, CHEM MATER, V20, P182, DOI 10.1021/cm702584d
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Schnitzler V, 2011, ACTA BIOMATER, V7, P759, DOI 10.1016/j.actbio.2010.09.017
   Tanvetyanon T, 2006, ANN ONCOL, V17, P897, DOI 10.1093/annonc/mdj105
   TUNG IC, 1995, ARTIF CELL BLOOD SUB, V23, P81, DOI 10.3109/10731199509117669
   Verron E, 2012, ACTA BIOMATER, V8, P3541, DOI 10.1016/j.actbio.2012.06.022
   Wang XP, 2007, J BIOMED MATER RES A, V81A, P781, DOI 10.1002/jbm.a.31059
   Wang XP, 2008, J MATER SCI MATER M, V19, P813, DOI 10.1007/s10856 006 0029 6
   Wu CC, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/3/035009
NR 39
TC 31
Z9 31
U1 0
U2 57
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD SEP 1
PY 2014
VL 42
BP 303
EP 311
DI 10.1016/j.msec.2014.05.043
PG 9
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA AN6EJ
UT WOS:000340687400040
PM 25063123
DA 2025 08 17
ER

PT J
AU Tähtelä, R
   Seppänen, J
   Laitinen, K
   Katajamäki, A
   Risteli, J
   Välimäki, MJ
AF Tähtelä, R
   Seppänen, J
   Laitinen, K
   Katajamäki, A
   Risteli, J
   Välimäki, MJ
TI Serum tartrate resistant acid phosphatase 5b in monitoring
   bisphosphonate treatment with clodronate: a comparison with urinary
   N terminal telopeptide of type I collagen and serum type I procollagen
   amino terminal propeptide
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE clodronate; NTX; osteoporosis; PINP; TRACP 5b; treatment
ID HORMONE REPLACEMENT THERAPY; EARLY POSTMENOPAUSAL WOMEN; LIVER
   ENDOTHELIAL CELLS; VERTEBRAL FRACTURE RISK; BONE MINERAL DENSITY;
   BIOCHEMICAL MARKERS; CALCIUM SUPPLEMENTATION; BIOLOGICAL VARIABILITY;
   ALENDRONATE TREATMENT; ELDERLY WOMEN
AB Osteoclastic tartrate resistant acid phosphatase activity in serum (S TRACP 5b) was measured in postmenopausal women (n = 59, mean age 56.1 years) with vertebral osteopenia before and during 2 year treatment with an 800 mg daily dose of clodronate, with a non amino bisphosphonate. Changes in TRACP 5b were compared with those in urinary excretion of type I collagen amino terminal telopeptide (U NTX), corrected for creatinine excretion, a well established marker of bone resorption, and to serum type I procollagen amino terminal propeptide (S PINP), a marker of bone formation. Marker changes 1 year after start of treatment were correlated with changes in bone mineral density (BMD). The least significant change (LSC) for each marker and BMD was calculated from values for subjects receiving placebo. Responders to treatment were those exhibiting a change larger than LSC. In response to clodronate treatment S TRACP 5b ( mean change up to) 18%) decreased less than did U NTX ( up to) 51%) or S PINP ( up to) 46%). Marker changes correlated with changes in lumbar spine and trochanter BMD. The most efficient marker for finding responders to treatment was S PINP, which changed more than the LSC (32%) in 72% of the subjects at the 1 year time point and in 79% at the 2 year time point. S TRACP 5b change exceeded the LSC (27%) in 40% and 34% of the subjects at each time point, while U NTX change exceeded the LSC (55%) in 55% and 40%, respectively. We conclude that, in terms of the proportion of subjects exhibiting any change exceeding the LSC, S TRACP 5b did not appear to be superior to U NTX and S PINP in the follow up of clodronate treatment. The reason may lie in the mechanism of action of clodronate, which rather than reducing the number of TRACP 5b secreting osteoclasts, reduces the activity of bone proteolytic enzymes and thus the rate of bone organic matrix degradation. This is seen in decreased amounts of type I collagen breakdown products (U NTX), and through coupling of bone resorption with bone formation, in a decrease in circulating levels of the marker that reflects new collagen formation (S PINP).
C1 Mehilainen Oy Lab Palvelut, Helsinki 00330, Finland.
   Finnish Canc Registry, FIN 00170 Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Med, Div Endocrinol, Helsinki, Finland.
   United Labs Ltd, Helsinki, Finland.
   Oulu Univ Hosp, Dept Clin Chem, Oulu, Finland.
C3 Finnish Cancer Registry; University of Helsinki; Helsinki University
   Central Hospital; University of Oulu
RP Mehilainen Oy Lab Palvelut, Runeberginkatu 47, Helsinki 00330, Finland.
EM riitta.tahtela@mehilainen.fi
RI Valimaki, Matti/NJS 8843 2025
CR Andersson G, 1995, ACTA ORTHOP SCAND, V66, P189, DOI 10.3109/17453679509157689
   Bauer DC, 2004, J BONE MINER RES, V19, P1250, DOI 10.1359/JBMR.040512
   Bauer DC, 1999, J BONE MINER RES, V14, P1404, DOI 10.1359/jbmr.1999.14.8.1404
   Bjarnason NH, 2001, OSTEOPOROSIS INT, V12, P922, DOI 10.1007/s001980170020
   Blom E, 1998, CLIN CHIM ACTA, V270, P125, DOI 10.1016/S0009 8981(97)00217 9
   Blumsohn A, 1997, ANN CLIN BIOCHEM, V34, P449, DOI 10.1177/000456329703400501
   BLUMSOHN A, 1994, J CLIN ENDOCR METAB, V79, P730, DOI 10.1210/jc.79.3.730
   Cabrera CD, 1998, OSTEOPOROSIS INT, V8, P147, DOI 10.1007/BF02672511
   Christgau S, 2000, BONE, V26, P505, DOI 10.1016/S8756 3282(00)00248 9
   CLARK SA, 1989, J BONE MINER RES, V4, P399
   Clowes JA, 2002, BONE, V30, P886, DOI 10.1016/S8756 3282(02)00728 7
   Eastell R, 2003, J BONE MINER RES, V18, P1051, DOI 10.1359/jbmr.2003.18.6.1051
   Garnero P, 1998, OSTEOPOROSIS INT, V8, P563, DOI 10.1007/s001980050100
   GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P1693, DOI 10.1210/jc.79.6.1693
   GARNERO P, 1995, J BONE MINER RES, V10, P641
   Greenspan SL, 1998, J BONE MINER RES, V13, P1431, DOI 10.1359/jbmr.1998.13.9.1431
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   Halleen JM, 1998, ARCH BIOCHEM BIOPHYS, V352, P97, DOI 10.1006/abbi.1998.0600
   Halleen JM, 1999, J BIOL CHEM, V274, P22907, DOI 10.1074/jbc.274.33.22907
   Halleen JM, 2001, CLIN CHEM, V47, P597
   Halleen JM, 2000, J BONE MINER RES, V15, P1337, DOI 10.1359/jbmr.2000.15.7.1337
   Hannon R, 1998, J BONE MINER RES, V13, P1124, DOI 10.1359/jbmr.1998.13.7.1124
   Hannon RA, 2004, BONE, V34, P187, DOI 10.1016/j.bone.2003.04.002
   HASSAGER C, 1992, J BONE MINER RES, V7, P1307
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   LAM WKW, 1978, CLIN CHEM, V24, P1105
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Li ZQ, 2001, STAT MED, V20, P3175, DOI 10.1002/sim.984
   Marcus R, 1999, J BONE MINER RES, V14, P1583, DOI 10.1359/jbmr.1999.14.9.1583
   McCloskey E, 2004, J BONE MINER RES, V19, P728, DOI 10.1359/JBMR.040116
   MELKKO J, 1994, J EXP MED, V179, P405, DOI 10.1084/jem.179.2.405
   Melton LJ, 1997, J BONE MINER RES, V12, P1083, DOI 10.1359/jbmr.1997.12.7.1083
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Panteghini M, 1996, ANN CLIN BIOCHEM, V33, P36, DOI 10.1177/000456329603300105
   Peris P, 1999, BONE, V25, P349, DOI 10.1016/S8756 3282(99)00175 1
   PROCKOP DJ, 1979, NEW ENGL J MED, V301, P77, DOI 10.1056/NEJM197907123010204
   PROCKOP DJ, 1979, NEW ENGL J MED, V301, P13, DOI 10.1056/NEJM197907053010104
   Ravn P, 1999, J CLIN ENDOCR METAB, V84, P2363, DOI 10.1210/jc.84.7.2363
   RISTELI L, 1993, ANN MED, V25, P385, DOI 10.3109/07853899309147301
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rosen CJ, 1997, J CLIN ENDOCR METAB, V82, P1904, DOI 10.1210/jc.82.6.1904
   Rosen HN, 2000, CALCIFIED TISSUE INT, V66, P100, DOI 10.1007/PL00005830
   SEIBEL MJ, 2000, OSTEOPOROS INT S6, V10, pS18
   Selander KS, 1996, MOL PHARMACOL, V50, P1127
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
   SMEDSROD B, 1990, BIOCHEM J, V271, P345, DOI 10.1042/bj2710345
   Stepan J. J., 2002, Calcified Tissue International, V70, P279
   Stepán JJ, 1999, CLIN CHIM ACTA, V288, P121, DOI 10.1016/S0009 8981(99)00151 5
   Teronen O, 1999, ANN NY ACAD SCI, V878, P453, DOI 10.1111/j.1749 6632.1999.tb07702.x
   Välimäki MJ, 2002, OSTEOPOROSIS INT, V13, P937, DOI 10.1007/s001980200131
   Woitge HW, 1999, J BONE MINER RES, V14, P792, DOI 10.1359/jbmr.1999.14.5.792
NR 51
TC 20
Z9 29
U1 0
U2 4
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD SEP
PY 2005
VL 16
IS 9
BP 1109
EP 1116
DI 10.1007/s00198 004 1819 7
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 960PB
UT WOS:000231604500013
PM 15605190
DA 2025 08 17
ER

PT J
AU Barkin, RL
AF Barkin, Robert L.
TI Topical Nonsteroidal Anti Inflammatory Drugs: The Importance of Drug,
   Delivery, and Therapeutic Outcome
SO AMERICAN JOURNAL OF THERAPEUTICS
LA English
DT Article
ID RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE INJURIES; DICLOFENAC SODIUM
   GEL; CONTROLLED CLINICAL TRIAL; CHRONIC KNEE PAIN; DOUBLE BLIND;
   DIMETHYL SULFOXIDE; HEALTHY VOLUNTEERS; ORAL IBUPROFEN; DHEP PLASTERS
AB Nonsteroidal anti inflammatory drugs (NSAIDs) are widely used in the treatment of pain associated with a variety of indications, including arthritic conditions, but their usefulness is often limited by dose dependent adverse events (AEs), such as gastrointestinal disturbances, cardiovascular events, and renal toxicity. The risk of such effects could be reduced by the use of topical formulations, which offer the potential to deliver analgesic concentrations locally, at the site of inflammation, while minimizing systemic concentrations. The topical preparations currently approved in the United States are diclofenac sodium 1.5% topical solution (containing dimethyl sulfoxide as a penetration enhancer), diclofenac sodium gel 1%, and a diclofenac hydroxyethylpyrrolidine 1.3% patch. Each of these topical NSAIDs provide drug delivery to subcutaneous tissues for the management of pain associated with osteoarthritis or soft tissue injuries. Furthermore, these formulations are not significantly associated with the systemic AEs associated with oral NSAIDs; the most common AEs associated with topical formulations are local skin reactions, which are usually mild and self limiting. Other topical NSAID preparations approved in the European Union include ibuprofen creams and gels, ketoprofen gel, felbinac gel and cutaneous foam, and piroxicam gel. Meta analyses have confirmed the efficacy and safety of these preparations. However, it is important to recognize that pharmacokinetic absorption from topical formulations can vary markedly, even between different formulations of the same drug, depending on the agent, the underlying disorder, and the site of application. It is therefore essential to consider the patient, the drug, and the drug delivery mechanism when selecting a topical NSAID preparation.
C1 [Barkin, Robert L.] Rush Univ, Dept Anesthesiol, Med Ctr, Chicago, IL 60612 USA.
   [Barkin, Robert L.] Rush Univ, Dept Family Med, Med Ctr, Chicago, IL 60612 USA.
   [Barkin, Robert L.] Rush Univ, Dept Pharmacol, Med Ctr, Chicago, IL 60612 USA.
   [Barkin, Robert L.] Pain Ctr Skokie & Evanston Hosp, Dept Anesthesiol, North Shore Univ Hlth Syst, Skokie, IL USA.
C3 Rush University; Rush University; Rush University
RP Barkin, RL (通讯作者)，1211 Blackthorn Lane, Deerfield, IL 60015 USA.
EM rbarkin@rush.edu
FU Mallinckrodt Inc., a Covidien company, Hazelwood, MO
FX Technical editorial and writing support for the preparation of this
   manuscript was provided by Michael Shaw, PhD, and Synchrony Medical,
   LLC, West Chester, PA. Funding for technical editorial and writing
   support of this manuscript was provided by Mallinckrodt Inc., a Covidien
   company, Hazelwood, MO.
CR Altman RD, 2000, ARTHRITIS RHEUM US, V43, P1905
   Altman R, 2009, POSTGRAD MED, V121, P139, DOI 10.3810/pgm.2009.03.1986
   Altman RD, 2009, J RHEUMATOL, V36, P1991, DOI 10.3899/jrheum.081316
   *AM PAIN SOC, 2003, PRINC AN US TREATM A
   American Academy of Orthopaedic Surgery, 2008, TREATM OST KNEE NON
   [Anonymous], 2010, PENNSAID PRESCR INF
   [Anonymous], 2011, KET 2 5 W W GEL SUMM
   [Anonymous], 1998, PIR GEL SUMM PROD CH
   Antman EM, 2007, CIRCULATION, V115, P1634, DOI 10.1161/CIRCULATIONAHA.106.181424
   Baer PA, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471 2474 6 44
   BAIXAULI F, 1990, J INT MED RES, V18, P372, DOI 10.1177/030006059001800505
   Barkin RL, 2010, DRUG AGING, V27, P775, DOI 10.2165/11539430 000000000 00000
   Barkin Robert L, 2010, J Pain Palliat Care Pharmacother, V24, P180, DOI 10.3109/15360281003727875
   Barkin RL, 2009, AM J CARDIOL, V104, P1315, DOI 10.1016/j.amjcard.2009.08.002
   Barthel HR, 2010, POSTGRAD MED, V122, P98, DOI 10.3810/pgm.2010.11.2227
   Barthel HR, 2009, SEMIN ARTHRITIS RHEU, V39, P203, DOI 10.1016/j.semarthrit.2009.09.002
   BELLAMY N, 1993, J RHEUMATOL, V20, P999
   BERNER B, 1989, J PHARM SCI US, V78, P402, DOI 10.1002/jps.2600780512
   BERNER G, 1987, ARZNEIMITTELFORSCH, V37 2, P814
   BOLTEN W, 1989, Z RHEUMATOL, V48, P317
   Bookman AAM, 2004, CAN MED ASSOC J, V171, P333, DOI 10.1503/cmaj.1031793
   BOUCHIERHAYES TA, 1990, BRIT J CLIN PRACT, V44, P319
   Brewer AR, 2010, PHYSICIAN SPORTSMED, V38, P62, DOI 10.3810/psm.2010.06.1784
   BROBYN RD, 1975, ANN NY ACAD SCI, V243, P497, DOI 10.1111/j.1749 6632.1975.tb25394.x
   Brühlmann P, 2003, CLIN EXP RHEUMATOL, V21, P193
   Brühlmann P, 2006, CURR MED RES OPIN, V22, P2429, DOI 10.1185/030079906X154123
   Brunner M, 2005, BRIT J CLIN PHARMACO, V60, P573, DOI 10.1111/j.1365 2125.2005.02484.x
   CAMPBELL J, 1994, J ACCID EMERG MED, V11, P178
   Cevc G, 2002, BBA BIOMEMBRANES, V1564, P21, DOI 10.1016/S0005 2736(02)00401 7
   DALTON PA, 1981, SOUTHERN MED J, V74, P1035, DOI 10.1097/00007611 198108000 00053
   DAVID NA, 1972, ANNU REV PHARMACOLOG, V12, P353, DOI 10.1146/annurev.pa.12.040172.002033
   DAWSON M, 1988, EUR J CLIN PHARMACOL, V33, P639, DOI 10.1007/BF00542502
   Diaz RL, 2006, CONTACT DERMATITIS, V54, P239, DOI 10.1111/j.0105 1873.2006.00797.x
   DREISER RL, 1993, DRUG EXP CLIN RES, V19, P117
   Egorin MJ, 1998, J CLIN ONCOL, V16, P610, DOI 10.1200/JCO.1998.16.2.610
   Esparza F, 2007, BRIT J SPORT MED, V41, P134, DOI 10.1136/bjsm.2006.030239
   EVANS JMM, 1995, BMJ BRIT MED J, V311, P22, DOI 10.1136/bmj.311.6996.22
   EVANS JMM, 1995, QJM MON J ASSOC PHYS, V88, P551
   GALEAZZI M, 1993, DRUG EXP CLIN RES, V19, P107
   GALLACCHI G, 1993, DRUG EXP CLIN RES, V19, P95
   Gan TJ, 2010, CURR MED RES OPIN, V26, P1715, DOI 10.1185/03007995.2010.486301
   GIESE U, 1990, ARZNEIMITTELFORSCH, V40 1, P84
   Gniazdowska B, 1999, CONTACT DERMATITIS, V40, P63, DOI 10.1111/j.1600 0536.1999.tb05992.x
   Gschwend MH, 2005, ARZNEIMITTEL FORSCH, V55, P403
   Hadgraft J, 2003, SKIN PHARMACOL APPL, V16, P137, DOI 10.1159/000069759
   Haroutiunian S, 2010, PAIN MED, V11, P535, DOI 10.1111/j.1526 4637.2010.00809.x
   Hewitt PG, 1998, PHARMACEUT RES, V15, P988, DOI 10.1023/A:1011961607089
   Heyneman CA, 2000, DRUGS, V60, P555, DOI 10.2165/00003495 200060030 00004
   HUCKER HB, 1967, J PHARMACOL EXP THER, V155, P309
   Hui XY, 1998, PHARM RES DORDR, V15, P1589, DOI 10.1023/A:1011911302005
   HUSKISSON EC, 1982, J RHEUMATOL, V9, P768
   Jacob SW, 1983, ANN NY ACAD SCI, V411, pxiii
   JENOURE P, 1993, DRUG EXP CLIN RES, V19, P125
   Kienzler JL, 2010, J CLIN PHARMACOL, V50, P50, DOI 10.1177/0091270009336234
   Kilminster SG, 1999, CLIN DRUG INVEST, V18, P345, DOI 10.2165/00044011 199918050 00002
   KLEINBLOESEM CH, 1995, ARZNEIMITTEL FORSCH, V45 2, P1117
   KLIGMAN AM, 1965, J AMER MED ASSOC, V193, P796, DOI 10.1001/jama.1965.03090100042010
   KROLL MP, 1989, CLIN THER, V11, P382
   Laine L, 2009, AM J GASTROENTEROL, V104, P356, DOI 10.1038/ajg.2008.149
   LEE E H, 1991, SMJ Singapore Medical Journal, V32, P238
   LEQUESNE MG, 1987, SCAND J RHEUMATOL, P85
   Lin FY, 2004, BMJ BRIT MED J, V329, P324, DOI 10.1136/bmj.38159.639028.7C
   LUERY NM, 1984, DRUG INTEL CLIN PHAR, V18, P591
   Machen J, 2002, INT J CLIN PRACT, V56, P102
   Madway G, 2007, WALL STREET J
   Mahler P, 2003, DRUG EXP CLIN RES, V29, P45
   MARKS R, 1994, SKIN PHARMACOL, V7, P340
   Mason L, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471 2474 5 28
   Mason Lorna, 2004, BMC Fam Pract, V5, P10, DOI 10.1186/1471 2296 5 10
   Mazières B, 2005, J RHEUMATOL, V32, P1563
   Mazières B, 2005, AM J SPORT MED, V33, P515, DOI 10.1177/0363546504268135
   Mazieres Bernard, 2005, Drugs R D, V6, P337, DOI 10.2165/00126839 200506060 00003
   MCLATCHIE GR, 1989, BRIT J CLIN PRACT, V43, P277
   Moore RA, 1998, BRIT MED J, V316, P333, DOI 10.1136/bmj.316.7128.333
   OLSON RJ, 1982, J TOXICOL CUTAN OCUL, V1, P147
   Patel RK, 1996, CLIN THER, V18, P497, DOI 10.1016/S0149 2918(96)80031 2
   Petersen B, 2009, CLIN DRUG INVEST, V29, P1, DOI 10.2165/0044011 200929010 00001
   Predel HG, 2004, BRIT J SPORT MED, V38, P318, DOI 10.1136/bjsm.2003.005017
   RADERMACHER J, 1991, BRIT J CLIN PHARMACO, V31, P537, DOI 10.1111/j.1365 2125.1991.tb05576.x
   Rosenstein ED, 1999, RHEUM DIS CLIN N AM, V25, P899, DOI 10.1016/S0889 857X(05)70109 5
   ROSENTHAL M, 1993, DRUG EXP CLIN RES, V19, P99
   Roth SH, 2004, ARCH INTERN MED, V164, P2017, DOI 10.1001/archinte.164.18.2017
   Rother M, 2007, ANN RHEUM DIS, V66, P1178, DOI 10.1136/ard.2006.065128
   RUSSELL AL, 1991, CLIN INVEST MED, V14, P35
   Schnitzer TJ, 2002, J PAIN SYMPTOM MANAG, V23, pS24, DOI 10.1016/S0885 3924(02)00372 X
   Scott D, 2007, CLIN EVID
   Sekiya I, 2010, AAPS PHARMSCITECH, V11, P154, DOI 10.1208/s12249 009 9367 2
   SETH PL, 1993, ARZNEIMITTELFORSCH, V43 2, P919
   Shainhouse JZ, 2010, AM J THER, V17, P566, DOI 10.1097/MJT.0b013e3181d169b5
   Simon LS, 2009, PAIN, V143, P238, DOI 10.1016/j.pain.2009.03.008
   SINGH P, 1994, J PHARMACOL EXP THER, V268, P144
   SIOUFI A, 1994, BIOPHARM DRUG DISPOS, V15, P441, DOI 10.1002/bdd.2510150602
   SWANSON BN, 1983, ARTHRITIS RHEUM, V26, P791, DOI 10.1002/art.1780260614
   Takahashi K, 2002, DRUG DEV IND PHARM, V28, P1285, DOI 10.1081/DDC 120015362
   Taylor RS, 2011, CURR MED RES OPIN, V27, P605, DOI 10.1185/03007995.2010.550606
   Trnavsky K, 2004, J RHEUMATOL, V31, P565
   Tugwell PS, 2004, J RHEUMATOL, V31, P2002
   Underwood M, 2008, HEALTH TECHNOL ASSES, V12, pIII
   Underwood M, 2008, BMJ BRIT MED J, V336, P138, DOI 10.1136/bmj.39399.656331.25
   Whitefield M, 2002, J CLIN PHARM THER, V27, P409, DOI 10.1046/j.1365 2710.2002.00439.x
   Zacher J, 2008, CURR MED RES OPIN, V24, P925, DOI 10.1185/030079908X273066 
   Zhang W, 2007, OSTEOARTHR CARTILAGE, V15, P981, DOI 10.1016/j.joca.2007.06.014
   Zhang W, 2010, OSTEOARTHR CARTILAGE, V18, P476, DOI 10.1016/j.joca.2010.01.013
   Zhang W, 2009, ANN RHEUM DIS, V68, P8, DOI 10.1136/ard.2007.084772
NR 104
TC 69
Z9 74
U1 2
U2 35
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1075 2765
EI 1536 3686
J9 AM J THER
JI Am. J. Ther.
PD SEP OCT
PY 2015
VL 22
IS 5
BP 388
EP 407
DI 10.1097/MJT.0b013e3182459abd
PG 20
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CR6KC
UT WOS:000361454500010
PM 22367354
DA 2025 08 17
ER

PT J
AU Li, LH
   Chen, X
   Lv, S
   Dong, MM
   Zhang, L
   Tu, JH
   Yang, J
   Zhang, LL
   Song, YA
   Xu, LT
   Zou, J
AF Li, Lihui
   Chen, Xi
   Lv, Shuang
   Dong, Miaomiao
   Zhang, Li
   Tu, Jiaheng
   Yang, Jie
   Zhang, Lingli
   Song, Yinan
   Xu, Leiting
   Zou, Jun
TI Influence of Exercise on Bone Remodeling Related Hormones and Cytokines
   in Ovariectomized Rats: A Model of Postmenopausal Osteoporosis
SO PLOS ONE
LA English
DT Article
ID MINERAL DENSITY; MECHANICAL PROPERTIES; REPLACEMENT THERAPY; ENDURANCE
   EXERCISE; OLDER WOMEN; ESTROGEN; MASS; METABOLISM; RESORPTION; RECEPTOR
AB This study aims to explore the effects of exercise on postmenopausal osteoporosis and the mechanisms by which exercise affects bone remodeling. Sixty three Wistar female rats were randomly divided into five groups: (1) control group, (2) shamoperated group, (3) OVX (Ovariectomy) group, (4) DES OVX (Diethylstilbestrol OVX) group, and (5) Ex OVX (Exercise OVX) group. The rat osteoporosis model was established through ovariectomy. The Ex OVX rats were made to run 251.2 meters every day, 6 d/wk for 3 months in a running wheel. Trabecular bone volume (TBV%), total resorption surface (TRS%), trabecular formation surface (TFS%), mineralization rate (MAR), bone cortex mineralization rate (mAR), and osteoid seam width (OSW) were determined by bone histomorphometry. The mRNA and protein levels of interleukin 1 beta (IL 1 beta(2)), interleukin 6 (IL 6), and cyclooxygenase 2 (Cox 2) were determined by in situ hybridization and immunohistochemistry, respectively. Serum levels of estrogen estradiol (E 2), calcitonin (CT), osteocalcin (BGP), and parathyroid hormone (PTH) were determined by ELISA assays. The investigation revealed that compared to the control and the sham operated groups, the OVX group showed significantly lower levels of TBV%, E 2, and CT, but much higher levels of TRS%, TFS%, MAR, OSW, BGP, and PTH. The Ex OVX group showed increased TBV% and serum levels of E 2 and CT compared to the OVX group. Ovariectomy also led to a significant increase in IL 1 beta mRNA and protein levels in the bone marrow and IL 6 and Cox 2 protein levels in tibias. In addition, the Ex OVX group showed lower levels of IL beta mRNA and protein, IL 6 mRNA, and Cox 2 mRNA and protein than those in the OVX group. The upshot of the study suggests that exercise can significantly increase bone mass in postmenopausal osteoporosis rat models by inhibiting bone resorption and increasing bone formation, especially in trabecular bones.
C1 [Li, Lihui; Chen, Xi; Lv, Shuang; Dong, Miaomiao; Zhang, Li; Tu, Jiaheng; Yang, Jie; Zhang, Lingli; Song, Yinan; Xu, Leiting] Shanghai Univ Sport, Sch Kinesiol, Shanghai, Peoples R China.
   [Zou, Jun] Shanghai Univ Sport, Sci Res Dept, Shanghai, Peoples R China.
   [Xu, Leiting] Ningbo Univ, Sch Med, Ningbo 315211, Zhejiang, Peoples R China.
   [Chen, Xi] Wenzhou Med Univ, Sch Sports Sci, Wenzhou, Peoples R China.
C3 Shanghai University of Sport; Shanghai University of Sport; Ningbo
   University; Wenzhou Medical University
RP Xu, LT (通讯作者)，Shanghai Univ Sport, Sch Kinesiol, Shanghai, Peoples R China.
EM xuleiting@nbu.edu.cn; zoujun777@126.com
RI Li, Lihui/KYO 9431 2024; Dong, Miaomiao/MSX 3314 2025; Chen,
   Xi/AGS 6702 2022; Zou, Jun/KYQ 8156 2024
FU Shanghai Key Lab of Human Sport Competence Development and Maintenance
   (Shanghai University of sport) [11DZ2261100]; National Natural Science
   Foundation of China [81170323]
FX This work was supported by Shanghai Key Lab of Human Sport Competence
   Development and Maintenance (Shanghai University of sport) (NO.
   11DZ2261100), The National Natural Science Foundation of China (Grant
   No. 81170323). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR BARENGOLTS EI, 1994, BONE MINER, V26, P133, DOI 10.1016/S0169 6009(08)80058 X
   BARENGOLTS EI, 1993, J BONE MINER RES, V8, P937
   Campbell KL, 2007, CANCER EPIDEM BIOMAR, V16, P731, DOI 10.1158/1055 9965.EPI 06 0784
   Carrillo López N, 2009, J AM SOC NEPHROL, V20, P2009, DOI 10.1681/ASN.2008121258
   Chachra D, 2000, BIOMED SCI INSTRUM, V395, P123
   Charatcharoenwitthaya N, 2007, J BONE MINER RES, V22, P724, DOI 10.1359/JBMR.070207
   Chen YJ, 2011, EUR J APPL PHYSIOL, V111, P1759, DOI 10.1007/s00421 010 1820 0
   Cummings SR, 2010, NEW ENGL J MED, V362, P686, DOI 10.1056/NEJMoa0808692
   de Araújo RF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066391
   Denkert C, 2004, CLIN CANCER RES, V10, P5580, DOI 10.1158/1078 0432.CCR 04 0070
   Doggrell SA, 2004, EXPERT OPIN PHARMACO, V5, P1635, DOI 10.1517/14656566.5.7.1635
   Edwards CJ, 2010, OSTEOPOROSIS INT, V21, P1287, DOI 10.1007/s00198 010 1192 7
   Evans EM, 2007, MENOPAUSE, V14, P481, DOI 10.1097/01.gme.0000243570.78570.f7
   Gesty Palmer D, 2011, BRIT J PHARMACOL, V164, P59, DOI 10.1111/j.1476 5381.2011.01450.x
   Going S, 2003, OSTEOPOROSIS INT, V14, P637, DOI 10.1007/s00198 003 1436 x
   Gong YS, 2006, J ASIAN NAT PROD RES, V8, P649, DOI 10.1080/10286020500246063
   Inada Masaki, 2011, Clin Calcium, V21, P164, DOI CliCa1102164170
   Iwamoto Jun, 1998, Keio Journal of Medicine, V47, P162
   Joo YI, 2003, BONE, V33, P485, DOI 10.1016/S8756 3282(03)00212 6
   Karsdal MA, 2008, BIODRUGS, V22, P137, DOI 10.2165/00063030 200822030 00001
   Kemmler W, 2010, ARCH INTERN MED, V170, P179, DOI 10.1001/archinternmed.2009.499
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lacey JV, 2002, JAMA J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334
   LeBlanc A, 2013, OSTEOPOROSIS INT, V24, P2105, DOI 10.1007/s00198 012 2243 z
   Liu M, 2012, CHINESE MED J PEKING, V125, P1784, DOI 10.3760/cma.j.issn.0366 6999.2012.10.018
   Liu SQ, 1996, CHINESE J PATHOL, V25, P49
   Nakamura M, 2003, ENDOCRINOLOGY, V144, P5441, DOI 10.1210/en.2003 0717
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872
   Prestwood KM, 2003, JAMA J AM MED ASSOC, V290, P1042, DOI 10.1001/jama.290.8.1042
   PRICE PA, 1980, J CLIN INVEST, V66, P878, DOI 10.1172/JCI109954
   Sakakura Y, 2001, J BONE MINER METAB, V19, P159, DOI 10.1007/s007740170036
   SAVILLE PD, 1969, J AM GERIATR SOC, V17, P155, DOI 10.1111/j.1532 5415.1969.tb03169.x
   Scott JPR, 2014, J CLIN ENDOCR METAB, V99, P1774, DOI 10.1210/jc.2013 3027
   Steeve KT, 2004, CYTOKINE GROWTH F R, V15, P49, DOI 10.1016/j.cytogfr.2003.10.005
   Subbaramaiah K, 2003, J BIOL CHEM, V278, P37637, DOI 10.1074/jbc.M301481200
   Tromp AM, 2006, CALCIFIED TISSUE INT, V79, P404, DOI 10.1007/s00223 006 0045 z
   Wallace BA, 2000, CALCIFIED TISSUE INT, V67, P10, DOI 10.1007/s00223001089
   Winters Stone KM, 2013, OSTEOPOROSIS INT, V24, P1637, DOI 10.1007/s00198 012 2143 2
   Wood CE, 2012, TOXICOL PATHOL, V40, P55, DOI 10.1177/0192623311425509
   Yuk TH, 2002, AM J CHINESE MED, V30, P95, DOI 10.1142/S0192415X02000119
   Zhao X, 2011, J ETHNOPHARMACOL, V137, P1083, DOI 10.1016/j.jep.2011.07.017
NR 42
TC 54
Z9 60
U1 0
U2 38
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD NOV 13
PY 2014
VL 9
IS 11
AR e112845
DI 10.1371/journal.pone.0112845
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AY6YT
UT WOS:000347709300112
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Pollari, S
   Käkönen, RS
   Mohammad, KS
   Rissanen, JP
   Halleen, JM
   Wärri, A
   Nissinen, L
   Pihlavisto, M
   Marjamäki, A
   Perälä, M
   Guise, TA
   Kallioniemi, O
   Käkönen, SM
AF Pollari, Sirkku
   Kakonen, Rami S.
   Mohammad, Khalid S.
   Rissanen, Jukka P.
   Halleen, Jussi M.
   Warri, Anni
   Nissinen, Liisa
   Pihlavisto, Marjo
   Marjamaki, Anne
   Perala, Merja
   Guise, Theresa A.
   Kallioniemi, Olli
   Kakonen, Sanna Maria
TI Heparin like Polysaccharides Reduce Osteolytic Bone Destruction and
   Tumor Growth in a Mouse Model of Breast Cancer Bone Metastasis
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID LOW MOLECULAR WEIGHT; ESCHERICHIA COLI K5; IN VITRO; UNFRACTIONATED
   HEPARIN; ADVANCED MALIGNANCY; INHIBITION; SULFATE; DALTEPARIN; THERAPY;
   RESORPTION
AB TGF beta regulates several steps in cancer metastasis, including the establishment of bone metastatic lesions. TGF beta is released from bone during osteoclastic bone resorption and it stimulates breast cancer cells to produce osteolytic factors such as interleukin 11 (IL 11). We conducted a cell based siRNA screen and identified heparan sulfate 6 O sulfotransferase 2 (HS6ST2) as a critical gene for TGF beta induced IL 11 production in highly bone metastatic MDA MB 231(SA) breast cancer cells. HS6ST2 attaches sulfate groups to glucosamine residues in heparan sulfate glycosaminoglycans. We subsequently showed how heparin and a high molecular weight Escherichia coli K5 derived heparin like polysaccharide (K5 NSOS) inhibited TGF beta induced IL 11 production in MDA MB 231 (SA) cells. In addition, K5 NSOS inhibited bone resorption activity of human osteoclasts in vitro. We evaluated the therapeutic potential of K5 NSOS and fragmin in a mouse model of breast cancer bone metastasis. MDA MB 231 (SA) cells were inoculated into the left cardiac ventricle of athymic nude mice which were treated with fragmin, K5 NSOS, or vehicle once a day for four weeks. Both heparin like glycosaminoglycans inhibited weight reduction, decreased osteolytic lesion area, and reduced tumor burden in bone. In conclusion, our data imply novel mechanisms involved in TGF beta induction and support the critical role of heparan sulfate glycosaminoglycans in cancer metastasis as well as indicate that K5 NSOS is a potential antimetastatic and antiresorptive agent for cancer therapy. This study illustrates the potential to translate in vitro siRNA screening results toward in vivo therapeutic concepts. Mol Cancer Res; 10(5); 597 604. (C) 2012 AACR.
C1 [Pollari, Sirkku; Perala, Merja; Kallioniemi, Olli] Univ Turku, VTT Tech Res Ctr Finland, FIN 20520 Turku, Finland.
   [Pollari, Sirkku; Perala, Merja; Kallioniemi, Olli] Univ Turku, Turku Ctr Biotechnol, FIN 20520 Turku, Finland.
   [Warri, Anni; Kakonen, Sanna Maria] Univ Turku, Inst Biomed, FIN 20520 Turku, Finland.
   [Kakonen, Rami S.; Rissanen, Jukka P.; Halleen, Jussi M.] Pharmatest Serv Ltd, Turku, Finland.
   [Nissinen, Liisa; Pihlavisto, Marjo; Marjamaki, Anne] Biotie Therapies Corp, Turku, Finland.
   [Mohammad, Khalid S.; Guise, Theresa A.] Indiana Univ, Indianapolis, IN 46204 USA.
   [Kallioniemi, Olli] Univ Helsinki, FIMM, Helsinki, Finland.
C3 University of Turku; VTT Technical Research Center Finland; University
   of Turku; University of Turku; Pharmatest Services; Indiana University
   System; Indiana University Indianapolis; University of Helsinki
RP Pollari, S (通讯作者)，Univ Turku, VTT Tech Res Ctr Finland, POB 106, FIN 20520 Turku, Finland.
EM sielpo@utu.fi
RI ; Kallioniemi, Olli/H 5111 2011; Mohammad, Khalid/AFE 4205 2022;
   Kallioniemi, Olli/H 4738 2012
OI Nissinen, Liisa/0000 0002 6743 6736; Kakonen,
   Sanna Maria/0000 0001 9393 6235; Warri, Anni/0000 0002 0535 847X;
   Kallioniemi, Olli/0000 0002 3231 0332; Perala, Merja/0000 0002 5035 1699
FU Academy of Finland; Verein zur Forderung der Krebsforschung (TIME
   project); Finnish Cancer Organisations; Sigrid Juselius Foundation; Drug
   Discovery Graduate School; Finnish Cultural Foundation; Cancer Society
   of Southwestern Finland; NIH [R01CA69158, R01DK067333, R01DK065837,
   U01CA143057]; Mary Kay Ash Foundation; V Foundation; Jerry W. and Peggy
   S. Throgmartin Endowment of Indiana University; Indiana Economic
   Development Fund; Susan Komen Foundation
FX This work was supported by Academy of Finland, Verein zur Forderung der
   Krebsforschung (TIME project), Finnish Cancer Organisations, and Sigrid
   Juselius Foundation (to O. Kallioniemi); Drug Discovery Graduate School,
   Finnish Cultural Foundation, and Cancer Society of Southwestern Finland
   (to S. Pollari); NIH grants R01CA69158, R01DK067333, R01DK065837, and
   U01CA143057, the Mary Kay Ash Foundation, the V Foundation, the Jerry W.
   and Peggy S. Throgmartin Endowment of Indiana University, the Indiana
   Economic Development Fund, and Susan Komen Foundation (to T.A. Guise).
CR ARGUELLO F, 1988, CANCER RES, V48, P6876
   Bhandari M, 1998, THROMB HAEMOSTASIS, V80, P413, DOI 10.1055/s 0037 1615222
   Borgenström M, 2007, SEMIN THROMB HEMOST, V33, P547, DOI 10.1055/s 2007 982087
   Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598
   CASU B, 1994, CARBOHYD RES, V263, P271, DOI 10.1016/0008 6215(94)00172 3
   DELAISSE JM, 1980, BIOCHEM J, V192, P365, DOI 10.1042/bj1920365
   Douketis JD, 1996, THROMB HAEMOSTASIS, V75, P254
   Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955 2235(94)00007 8
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Gupta J, 2011, CANCER BIOL THER, V11, P311, DOI 10.4161/cbt.11.3.14096
   Handschin AE, 2005, BRIT J SURG, V92, P177, DOI 10.1002/bjs.4809
   Hawkins David, 2005, Expert Opin Drug Saf, V4, P583, DOI 10.1517/14740338.4.3.583
   Hettiarachchi RJK, 1999, THROMB HAEMOSTASIS, V82, P947, DOI 10.1055/s 0037 1615937
   Kakkar AK, 2004, J CLIN ONCOL, V22, P1944, DOI 10.1200/JCO.2004.10.002
   Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102
   Klerk CPW, 2005, J CLIN ONCOL, V23, P2130, DOI 10.1200/JCO.2005.03.134
   Kock HJ, 2002, CLIN APPL THROMB HEM, V8, P251, DOI 10.1177/107602960200800309
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Kragh M, 2005, ONCOL REP, V14, P99
   Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000
   LYON M, 1994, BIOCHEM SOC T, V22, P365, DOI 10.1042/bst0220365
   MCCAFFREY TA, 1994, J CELL PHYSIOL, V159, P51, DOI 10.1002/jcp.1041590108
   MCCAFFREY TA, 1989, J CELL BIOL, V109, P441, DOI 10.1083/jcb.109.1.441
   Mohammad KS, 2011, CANCER RES, V71, P175, DOI 10.1158/0008 5472.CAN 10 2651
   Muir JM, 1996, BLOOD, V88, P1314, DOI 10.1182/blood.V88.4.1314.bloodjournal8841314
   Nakato H, 2002, BBA GEN SUBJECTS, V1573, P312, DOI 10.1016/S0304 4165(02)00398 7
   Nelson Piercy C, 1998, SCAND J RHEUMATOL, P68
   Nishiyama M, 1997, JPN J PHARMACOL, V74, P59, DOI 10.1254/jjp.74.59
   Poggi A, 2002, SEMIN THROMB HEMOST, V28, P383, DOI 10.1055/s 2002 34308
   Pollari S, 2011, BREAST CANCER RES TR, V125, P421, DOI 10.1007/s10549 010 0848 5
   Rajgopal R, 2008, THROMB RES, V122, P293, DOI 10.1016/j.thromres.2006.10.025
   Rissanen JP, 2009, J BONE MINER METAB, V27, P105, DOI 10.1007/s00774 008 0002 1
   Rusnati M, 2005, CURR PHARM DESIGN, V11, P2489, DOI 10.2174/1381612054367553
   SELANDER K, 1994, CALCIFIED TISSUE INT, V55, P368, DOI 10.1007/BF00299317
   SHAUGHNESSY SG, 1995, BLOOD, V86, P1368, DOI 10.1182/blood.V86.4.1368.bloodjournal8641368
   Szende B, 2005, ANTICANCER RES, V25, P2869
   Yee CK, 2008, CLIN EXP METASTAS, V25, P903, DOI 10.1007/s10585 008 9212 0
NR 37
TC 38
Z9 42
U1 2
U2 18
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1541 7786
EI 1557 3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD MAY
PY 2012
VL 10
IS 5
BP 597
EP 604
DI 10.1158/1541 7786.MCR 11 0482
PG 8
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA 956EZ
UT WOS:000305074200003
PM 22522458
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Zhang, X
   Chen, J
   Meng, Q
   Li, D
   Hu, FZ
   Zhu, YQ
   Huang, YY
   Liu, YN
   Sun, L
   Liang, QH
AF Zhang, Xue
   Chen, Jing
   Meng, Qiang
   Li, Dong
   Hu, Fang Zhi
   Zhu, Yu Qing
   Huang, Yuan Yuan
   Liu, Ya Nan
   Sun, Lin
   Liang, Qiu Hua
TI The protective effects of long non coding RNA ANCR on arterial
   calcification
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Arterial calcification; Vascular smooth muscle cells; Osteoblastic
   differentiation; ANCR; Autophagy
ID SMOOTH MUSCLE CELLS; VASCULAR CALCIFICATION; AUTOPHAGY; DIFFERENTIATION;
   SUPPRESSION; EXPRESSION; APOPTOSIS; DISEASE
AB Introduction Arterial calcification is a major factor for cardiovascular events and is characterized by vascular smooth muscle cells (VSMCs) transformed into osteoblast like cells. Long non coding RNAs (lncRNA) were recognized as important regulators of diverse biological processes. Previous studies have demonstrated that lncRNAs could regulate the proliferation and apoptosis of VSMCs. LncRNA ANCR (Anti differentiation ncRNA) is an essential mediator governing the differentiation of human osteoblast. However, it is unclear whether ANCR could regulate the osteoblastic differentiation of VSMCs. In this study, we determined the effect of ANCR on VSMCs differentiation and arterial calcification. Materials and Methods Both cellular and mouse model of arterial calcification were, respectively, established to investigate the role of ANCR in the mechanism of arterial calcification. ANCR overexpressing lentivirus were used to investigate the effects of ANCR on the expression of bone proteins and autophagy related molecules. Results ANCR could inhibit beta glycerophosphate (beta GP) induced VSMCs osteoblastic differentiation and mineralization due to decreased expressions of Runt related transcription factor 2, bone morphogenetic protein 2, and formation of mineralized nodule, and attenuate high calcitriol induced mice model of arterial calcification. Furthermore, ANCR could significantly increase LC3 and autophagy protein 5 expression in beta GP stimulated VSMCs, and the effect could be inhibited by 3 methyladenine, a pharmacological inhibitor of autophagy. Conclusion ANCR may inhibit the osteoblastic differentiation of VSMCs and attenuate mice arterial calcification through activating autophagy.
C1 [Zhang, Xue; Chen, Jing; Meng, Qiang; Li, Dong; Hu, Fang Zhi; Zhu, Yu Qing; Huang, Yuan Yuan; Liu, Ya Nan; Sun, Lin; Liang, Qiu Hua] Jining Med Univ, Affiliated Hosp, Dept Endocrinol, Jining, Shandong, Peoples R China.
C3 Jining Medical University
RP Sun, L; Liang, QH (通讯作者)，Jining Med Univ, Affiliated Hosp, Dept Endocrinol, Jining, Shandong, Peoples R China.
EM sunlinsddx@sina.com; liangqiuhua_meta@163.com
RI Han, Xiaoping/A 4132 2019; Zhu, Yuqing/KLZ 7450 2024
FU National Natural Science Foundation of China [81400860] Funding Source:
   Medline; Natural Science Foundation of Shandong Province [ZR2017LH024]
   Funding Source: Medline; Medical and Health Technology Development
   Program in Shandong Province [2016WS0168] Funding Source: Medline
CR Byon CH, 2011, ARTERIOSCL THROM VAS, V31, P1387, DOI 10.1161/ATVBAHA.110.222547
   Chen J, 2019, NEPHRON, V141, P287, DOI 10.1159/000495885
   Congrains A, 2012, BIOCHEM BIOPH RES CO, V419, P612, DOI 10.1016/j.bbrc.2012.02.050
   CONNERTY HV, 1966, AM J CLIN PATHOL, V45, P290
   Dai XY, 2013, KIDNEY INT, V83, P1042, DOI 10.1038/ki.2012.482
   Du YY, 2011, CIRC RES, V108, P917, DOI 10.1161/CIRCRESAHA.110.234328
   Füllgrabe J, 2013, NATURE, V500, P468, DOI 10.1038/nature12313
   Goettsch C, 2016, J CLIN INVEST, V126, P1323, DOI 10.1172/JCI80851
   Heath JM, 2014, CIRC RES, V114, P1094, DOI 10.1161/CIRCRESAHA.114.302968
   Jia Q, 2015, ARCH ORAL BIOL, V60, P234, DOI 10.1016/j.archoralbio.2014.10.007
   Kim JH, 2015, ARTERIOSCL THROM VAS, V35, P2384, DOI 10.1161/ATVBAHA.115.306102
   Kretz M, 2012, GENE DEV, V26, P338, DOI 10.1101/gad.182121.111
   Liang QH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033126
   Liu DM, 2014, CELL PHYSIOL BIOCHEM, V33, P129, DOI 10.1159/000356656
   Mathew S, 2008, J AM SOC NEPHROL, V19, P1092, DOI 10.1681/ASN.2007070760
   Motterle A, 2012, HUM MOL GENET, V21, P4021, DOI 10.1093/hmg/dds224
   Ng SY, 2012, EMBO J, V31, P522, DOI 10.1038/emboj.2011.459
   Panizo S, 2016, J AM SOC NEPHROL, V27, P824, DOI 10.1681/ASN.2014050520
   Peng YQ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03801 x
   Petrova NL, 2014, OSTEOPOROSIS INT, V25, P1197, DOI 10.1007/s00198 013 2511 6
   Shi L, 2018, BIOCHEM BIOPH RES CO, V501, P688, DOI 10.1016/j.bbrc.2018.05.049
   Torremadé N, 2016, J BONE MINER RES, V31, P1865, DOI 10.1002/jbmr.2852
   Wang LM, 2019, ECOTOX ENVIRON SAFE, V167, P169, DOI 10.1016/j.ecoenv.2018.10.008
   Wang YNZ, 2016, HYPERTENSION, V68, P736, DOI 10.1161/HYPERTENSIONAHA.116.07259
   Wang YZ, 2013, INFLAMMATION, V36, P121, DOI 10.1007/s10753 012 9526 6
   Wu GZ, 2014, CIRCULATION, V130, P1452, DOI 10.1161/CIRCULATIONAHA.114.011675
   Xu MM, 2017, LIFE SCI, V179, P23, DOI 10.1016/j.lfs.2016.11.025
   Xu TH, 2019, J CELL PHYSIOL, V234, P14306, DOI 10.1002/jcp.28130
   Zhu L, 2013, BIOCHEM BIOPH RES CO, V432, P612, DOI 10.1016/j.bbrc.2013.02.036
NR 29
TC 20
Z9 24
U1 0
U2 10
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD JUL
PY 2020
VL 38
IS 4
BP 421
EP 431
DI 10.1007/s00774 019 01076 y
PG 11
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA MD1EN
UT WOS:000543718300001
PM 31974677
DA 2025 08 17
ER

PT J
AU Farkouh, ME
   Verheugt, FWA
   Ruland, S
   Kirshner, H
   Jeger, R
   Gitton, X
   Krammer, G
   Stricker, K
   Sallstig, P
   Mellein, B
   Matchaba, P
   Chesebro, JH
AF Farkouh, Michael E.
   Verheugt, Freek W. A.
   Ruland, Sean
   Kirshner, Howard
   Jeger, Raban
   Gitton, Xavier
   Krammer, Gerhard
   Stricker, Kirstin
   Sallstig, Peter
   Mellein, Bernhard
   Matchaba, Patrice
   Chesebro, James H.
TI A Comparison of the Blood Pressure Changes of Lumiracoxib With Those of
   Ibuprofen and Naproxen
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Article
ID THERAPEUTIC ARTHRITIS RESEARCH; GASTROINTESTINAL EVENT TRIAL;
   NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYCLOOXYGENASE 2 INHIBITORS;
   OSTEOARTHRITIS; HYPERTENSION; CELECOXIB; TOLERABILITY; METAANALYSIS;
   PREVALENCE
AB The 52 week Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) investigated the gastrointestinal and cardiovascular safety profile of lumiracoxib 400 mg once daily compared with, 2 traditional nonsteroidal anti inflammatory drugs (NSAIDs): ibuprofen 800 mg 3 times daily and naproxen 500 mg twice daily. Data from TARGET were analyzed to examine the effect of lumiracoxib compared with ibuprofen and naproxen on blood pressure (BP), incidence of de novo and aggravated hypertension, prespecified edema events, and congestive heart failure. Lumiracoxib resulted in smaller changes in BP as early as week 4. Least squares mean change from baseline at week 4 for systolic BP was +0.57 mm Hg with lumiracoxib compared with +3.14 mm Hg with ibuprofen (P<.0001) and +0.43 with lumiracoxib compared with +1.80 mm Hg with naproxen (P<.0001). In conclusion, the use of lumiracoxib and traditional NSAIDs results in differing BP cbanges; these might be of clinical relevance. J Clin Hypertens (Greenwich). 2 008; 10:592 602. (c) 2008 Le Jacq
C1 [Farkouh, Michael E.] Mt Sinai Sch Med, Mt Sinai Cardiovasc Inst, Clin Trials Unit, New York, NY 10029 USA.
   [Verheugt, Freek W. A.] Univ Med Ctr, Dept Cardiol, Nijmegen, Netherlands.
   [Ruland, Sean] Univ Illinois, Dept Neurol & Rehabil, Chicago, IL USA.
   [Kirshner, Howard] Vanderbilt Univ, Sch Med, Dept Neurol, Nashville, TN 37212 USA.
   [Jeger, Raban] Univ Basel Hosp, Dept Cardiol, CH 4031 Basel, Switzerland.
   [Gitton, Xavier; Krammer, Gerhard; Stricker, Kirstin; Sallstig, Peter; Mellein, Bernhard] Novartis Pharma AG, Basel, Switzerland.
   [Matchaba, Patrice] Novartis Pharmaceut, E Hanover, NJ USA.
   [Chesebro, James H.] Univ Massachusetts, Mem Med Ctr, Worcester, MA 01605 USA.
C3 Icahn School of Medicine at Mount Sinai; Radboud University Nijmegen;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Vanderbilt University;
   University of Basel; Novartis; Novartis; Novartis USA; University of
   Massachusetts System; University of Massachusetts Worcester
RP Farkouh, ME (通讯作者)，Mt Sinai Sch Med, Mt Sinai Cardiovasc Inst, Clin Trials Unit, 1 Gustave L Levy Pl,Box 1074, New York, NY 10029 USA.
EM michael.farkouh@mssm.edu
RI Jeger, Raban/ABG 1678 2021; Kirshner, Howard/HZM 5507 2023; Verheugt,
   F.W.A./H 8105 2014
OI Jeger, Raban/0000 0003 1290 5491; Kirshner, Howard/0000 0002 0188 3306; 
FU Novartis Pharma AG; Glaxo Smith Kline, Merck, Roche; VIA
   Pharmaceuticals; Northstar Neuroscience Inc.; National Institutes of
   Health; Boehringer Ingelheim PRoFESS; Bristol Myers Squibb/ Sanofi
   MATCH; Bristol Myers Squibb/Sanofi
FX The authors would like to thank the investigators and patients who
   participated in the original trial. The authors would also like to thank
   Rebecca Douglas from ACUMED for bell) with preparing this manuscript.
   The study, statistical analyses, and manuscript preparation were funded
   by the sponsor, Novartis Pharma AG. Michael Farkouh has received
   research grants from Glaxo Smith Kline, Merck, Roche and VIA
   Pharmaceuticals. He has two consultancy/advisory, board relationships
   with Novartis, and has served as an advisor to CV Therapeutics and
   AstraZeneca. Freek Verheugt has a consultancy/advisory board
   relationship with Novartis (TARGET study and Cardiovascular Advisor),
   Board). Sean Ruland has received research grants from Northstar
   Neuroscience Inc.; payment for speakers' bureau appointments from
   Genentech, Boehringer Ingelheim, and Vissol Inc.; and honoraria from
   various review courses and has a consultancy/advisory board relationship
   with Novartis. Howard Kirshner has received research grants for National
   Institutes of Health funded trials (SPS3, ALIAS, and MR Rescue) and
   industry funded trials (Boehringer Ingelheim PRoFESS and Bristol Myers
   Squibb/ Sanofi MATCH) and payment for speakers' bureau appointments from
   Bristol Myers Squibb/Sanofi, Boehringer Ingelheim, Pfizer, Janssen, and
   Novartis and has consultancy/advisory board relationships with
   AstraZeneca, Pfizer, and Bristol Myers Squibb/Sanofi. Xavier Gitton,
   Gerhard Krammer, Kirstin Stricker, Peter Sallstig, and Bernd Mellein are
   employees of, and own stock options in, Novartis Pharma AG, Basel,
   Switzerland. Patrice Matchaba is an employee of, and owns stock options
   in, Novartis Pharmaceuticals Corporation, East Hanover, NJ. James
   Chesebro has received payment for STRIVE (an independent speakers'
   bureau funded by educational grants front Sanofi Aventis and
   Bristol Myers Squibb), and honoraria from multiple medical centers and
   has a consultancy/advisory board relationship with Novartis (TARGET
   study and Cardiovascular Advisory Board). Raban Jeger has nothing to
   disclose.
CR Aw TJ, 2005, ARCH INTERN MED, V165, P490, DOI 10.1001/archinte.165.5.IOI50013
   Brater DC, 2001, AM J NEPHROL, V21, P1, DOI 10.1159/000046212
   Bruehl S, 2005, CLIN J PAIN, V21, P147, DOI 10.1097/00002508 200503000 00006
   Brune K, 2004, SCAND J RHEUMATOL, V33, P1, DOI 10.1080/03009740310004766
   Farkouh ME, 2004, LANCET, V364, P675, DOI 10.1016/S0140 6736(04)16894 3
   Harris RC, 2002, J HYPERTENS, V20, pS3
   Hartmann S., 2003, P124
   Hawkey CJ, 2004, ALIMENT PHARM THER, V20, P51, DOI 10.1111/j.1365 2036.2004.02026.x
   Jeger Raban V, 2005, Expert Rev Clin Immunol, V1, P37, DOI 10.1586/1744666X.1.1.37
   JOHNSON AG, 1994, ANN INTERN MED, V121, P289, DOI 10.7326/0003 4819 121 4 199408150 00011
   *JOINT NAT COMM PR, 2004, PUBL NIH
   Lehmann R, 2005, CURR MED RES OPIN, V21, P517, DOI 10.1185/030079905X38196
   MACDONALD TM, 2007, OSTEOARTHRITIS CA S3, V15, pC149
   Maillard M, 2006, EXPERT OPIN DRUG SAF, V5, P83, DOI 10.1517/14740338.5.1.83
   Mancia G, 2007, EUR HEART J, V28, P1462, DOI 10.1093/eurheartj/ehm236
   Morgan TO, 2000, AM J HYPERTENS, V13, P1161, DOI 10.1016/S0895 7061(00)01204 8
   POPE JE, 1993, ARCH INTERN MED, V153, P477, DOI 10.1001/archinte.153.4.477
   Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140 6736(04)16893 1
   Schwartz JI, 2002, CLIN PHARMACOL THER, V72, P50, DOI 10.1067/mcp.2002.126182
   Scott G, 2004, CLIN PHARMACOKINET, V43, P467, DOI 10.2165/00003088 200443070 00003
   Sheldon E, 2005, CLIN THER, V27, P64, DOI 10.1016/j.clinthera.2005.01.002
   Singh G, 2003, J RHEUMATOL, V30, P714
   Singh G, 2002, AM J MANAG CARE, V8, pS383
   Weaver ML, 2003, ANN RHEUM DIS, V62, P378
   Whelton A, 2002, AM J CARDIOL, V90, P959, DOI 10.1016/S0002 9149(02)02661 9
   Whelton A, 2001, Am J Ther, V8, P85, DOI 10.1097/00045391 200103000 00003
   WHITEHEAD A, 2006, OSTEOARTHR CARTILAGE, V14, pS168
   Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646
NR 28
TC 6
Z9 6
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1524 6175
EI 1751 7176
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD AUG
PY 2008
VL 10
IS 8
BP 592
EP 602
DI 10.1111/j.1751 7176.2008.07802.x
PG 11
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology
GA 375FR
UT WOS:000261100000002
PM 18772641
OA Green Published
DA 2025 08 17
ER

PT J
AU Rouach, V
   Goldshtein, I
   Buch, A
   Catane, R
   Chodick, G
   Stern, N
   Shalev, V
   Cohen, D
AF Rouach, Vanessa
   Goldshtein, Inbal
   Buch, Assaf
   Catane, Raphael
   Chodick, Gabriel
   Stern, Naftali
   Shalev, Varda
   Cohen, Daniel
TI The association between adherence with oral bisphosphonates and the risk
   of breast cancer in post menopausal women
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Bisphosphonates; Breast cancer; Osteoporosis
ID NITROGEN CONTAINING BISPHOSPHONATES; BONE DENSITY; ALENDRONATE;
   MECHANISMS
AB Background: Several observational studies have suggested a protective effect of oral bisphosphonates (BP) on the risk of breast cancer, but no such association has been seen in randomized control trials. The role of oral BP in breast cancer prevention remains unclear.
   Aim: To investigate the association between different levels of BP exposure and breast cancer incidence in a cohort of osteoporotic post menopausal women.
   Subjects and methods: This historical prospective study was conducted using the computerized databases of Maccabi Healthcare Services (MHS) in Israel. Included in the study were osteopenic and osteoporotic women aged 55 75 years who started BP therapy between 1998 and 2012. The subjects were enrolled in MHS for at least 3 years before therapy initiation, and had a minimum follow up of 5 years in MHS. Women with a previous cancer, and women treated with selective estrogen receptor modulators (SERMs) were excluded. BP exposure was expressed in quintiles of proportion of days covered (PDC) with BP during follow up period and cancer incidence was ascertained by the Israel National Tumor Registry. Person years of follow up began on January 1st, 1998 and ended at the date of cancer diagnosis, death, or December 31st, 2012, whichever occurred first.
   Results: A total of 11,717 patients (mean age = 66.87 +/  4.38) were eligible for the analysis. During a total of 130,252 person years of follow up, (mean 7.2 years) 173 incident cases of breast cancer were diagnosed. Compared to women with a PDC with BP of 20% or lower, the adjusted hazard ratio for breast cancer were HR = 0.81 (95%CI: 0.48 1.39), HR = 0.82 (95%CI: 0.50 1.33), HR = 0.72 (95%CI:0.45 1.15) and HR = 1.14 (95%CI:0.76 1.70) among women with 20 40%, 40 60%, 60% 80%, and 80% or higher, PDC, respectively.
   Conclusion: In this study, we did not find a significant association between oral BP therapy for osteoporosis and the risk of breast cancer in postmenopausal women. The discrepancy between our results and the reports of such an association in observational studies might originate from an indication bias.
C1 [Rouach, Vanessa; Buch, Assaf; Stern, Naftali] Tel Aviv Sourasky Med Ctr, Inst Endocrinol Metab & Hypertens, 6 Weizmann St, IL 64239 Tel Aviv, Israel.
   [Goldshtein, Inbal; Chodick, Gabriel; Shalev, Varda] Maccabi Healthcare Serv, Epidemiol & Database Res, Tel Aviv, Israel.
   [Catane, Raphael] Sheba Med Ctr, Oncol Div, Ramat Gan, Israel.
   [Chodick, Gabriel; Cohen, Daniel] Tel Aviv Univ, Sch Publ Hlth, Tel Aviv, Israel.
   [Chodick, Gabriel; Cohen, Daniel] Tel Aviv Univ, Stanley Steyer Inst Canc Epidemiol & Res, Tel Aviv, Israel.
   [Rouach, Vanessa; Buch, Assaf] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky
   Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Tel
   Aviv University; Tel Aviv University; Tel Aviv University; Sackler
   Faculty of Medicine
RP Rouach, V (通讯作者)，Tel Aviv Sourasky Med Ctr, Inst Endocrinol Metab & Hypertens, 6 Weizmann St, IL 64239 Tel Aviv, Israel.
EM vanessar@tlvmc.gov.il
RI ; chodick, gabby/AFP 0827 2022; Buch, Assaf/R 5993 2019; Goldshtein,
   Inbal/D 2113 2011
OI /0000 0002 5189 8995; Goldshtein, Inbal/0000 0002 5317 2848; Cohen,
   Daniel/0000 0003 2664 2303
CR [Anonymous], 2006, BMI classification. Global Database on Body Mass Index
   [Anonymous], BONE
   [Anonymous], 2003, WHO TECHN REP SER, V921
   Black D.M, 2007, NEW ENGL J MED, V18, P1809
   Caraglia M, 2006, ENDOCR RELAT CANCER, V13, P7, DOI 10.1677/erc.1.01094
   Cardwell CR, 2012, INT J CANCER, V131, pE717, DOI 10.1002/ijc.27389
   Cauley JA, 1996, JAMA J AM MED ASSOC, V276, P1404, DOI 10.1001/jama.276.17.1404
   Chen Z, 2008, CANCER AM CANCER SOC, V113, P907, DOI 10.1002/cncr.23674
   Chlebowski R. T., 2010, J CLIN ONCOL, V28
   Chodick G, 2003, EUR J EPIDEMIOL, V18, P1143, DOI 10.1023/B:EJEP.0000006635.36802.c8
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Fishler Y., 2003, Estimation of completeness of The Cancer Registry in Israel
   Heymann Anthony D, 2007, Harefuah, V146, P15
   Hue TF, 2014, JAMA INTERN MED, V174, P1550, DOI 10.1001/jamainternmed.2014.3634
   Israel Central Bureau of Statistics, 2008, CHARA GEOGR UN SOC L
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Karve S, 2009, VALUE HEALTH, V12, P989, DOI 10.1111/j.1524 4733.2009.00543.x
   Kaufmann SHE, 1996, P NATL ACAD SCI USA, V93, P2272, DOI 10.1073/pnas.93.6.2272
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Liu J, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002014
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Newcomb PA, 2010, BRIT J CANCER, V102, P799, DOI 10.1038/sj.bjc.6605555
   Papapoulos SE, 2008, BEST PRACT RES CL EN, V22, P831, DOI 10.1016/j.beem.2008.07.001
   Peterson AM, 2007, VALUE HEALTH, V10, P3, DOI 10.1111/j.1524 4733.2006.00139.x
   Rennert G, 2010, J CLIN ONCOL, V28, P3577, DOI 10.1200/JCO.2010.28.1113
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212
   Shalev V, 2011, INT J CARDIOL, V152, P345, DOI 10.1016/j.ijcard.2010.08.002
   Thompson K, 2010, ADV EXP MED BIOL, V658, P11, DOI 10.1007/978 1 4419 1050 9_2
   Vestergaard P, 2011, CALCIFIED TISSUE INT, V88, P255, DOI 10.1007/s00223 011 9463 7
NR 32
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD JUN
PY 2019
VL 16
AR 100202
DI 10.1016/j.jbo.2018.10.001
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA IM0TA
UT WOS:000477701100001
PM 31334001
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ahn, JH
   Hwang, SH
   Cho, HS
   Lee, M
AF Ahn, Jun Ho
   Hwang, Sung Hee
   Cho, Hyun Soo
   Lee, Michael
TI Differential Gene Expression Common to Acquired and Intrinsic Resistance
   to BRAF Inhibitor Revealed by RNA Seq Analysis
SO BIOMOLECULES & THERAPEUTICS
LA English
DT Article
DE BRAF inhibitor; Drug resistance; Melanoma; RNA Seq analysis
ID MAPK PATHWAY; KINASE INHIBITOR; MELANOMA CELLS; RAF INHIBITORS; B RAF;
   CANCER; SENSITIVITY; ONTOLOGY; ERK
AB Melanoma cells have been shown to respond to BRAF inhibitors; however, intrinsic and acquired resistance limits their clinical application. In this study, we performed RNA Seq analysis with BRAF inhibitor sensitive (A375P) and  resistant (A375P/Mdr with acquired resistance and SK MEL 2 with intrinsic resistance) melanoma cell lines, to reveal the genes and pathways potentially involved in intrinsic and acquired resistance to BRAF inhibitors. A total of 546 differentially expressed genes (DEGs), including 239 up regulated and 307 down regulated genes, were identified in both intrinsic and acquired resistant cells. Gene ontology (GO) analysis revealed that the top 10 biological processes associated with these genes included angiogenesis, immune response, cell adhesion, antigen processing and presentation, extracellular matrix organization, osteoblast differentiation, collagen catabolic process, viral entry into host cell, cell migration, and positive regulation of protein kinase B signaling. In addition, using the PANTHER GO classification system, we showed that the highest enriched GOs targeted by the 546 DEGs were responses to cellular processes (ontology: biological process), binding (ontology: molecular function), and cell subcellular localization (ontology: cellular component). Ingenuity pathway analysis (IPA) network analysis showed a network that was common to two BRAF inhibitor resistant cells. Taken together, the present study may provide a useful platform to further reveal biological processes associated with BRAF inhibitor resistance, and present areas for therapeutic tool development to overcome BRAF inhibitor resistance.
C1 [Ahn, Jun Ho] Korea Inst Toxicol, Syst Toxicol Res Ctr, Daejeon 34114, South Korea.
   [Hwang, Sung Hee; Lee, Michael] Incheon Natl Univ, Coll Life Sci & Bioengn, Div Life Sci, Incheon 22012, South Korea.
   [Cho, Hyun Soo] Korea Res Inst Biosci & Biotechnol, Stem Cell Res Ctr, Daejeon 34141, South Korea.
   [Cho, Hyun Soo] Korea Univ Sci & Technol, Dept Funct Genom, Daejeon 34113, South Korea.
C3 Korea Institute of Toxicology; Incheon National University; Korea
   Research Institute of Bioscience & Biotechnology (KRIBB); University of
   Science & Technology (UST)
RP Lee, M (通讯作者)，Incheon Natl Univ, Coll Life Sci & Bioengn, Div Life Sci, Incheon 22012, South Korea.
EM mikelee@inu.ac.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education, Science and Technology
   [2016R1D1A1B03930193]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science and Technology (2016R1D1A1B03930193).
CR Agianian B, 2018, J MED CHEM, V61, P5775, DOI 10.1021/acs.jmedchem.7b01306
   Ahn JH, 2015, BIOMOL THER, V23, P320, DOI 10.4062/biomolther.2015.007
   Ahn JH, 2013, BIOMOL THER, V21, P114, DOI 10.4062/biomolther.2013.012
   Ahn JH, 2009, MOL CELL BIOCHEM, V332, P189, DOI 10.1007/s11010 009 0191 5
   Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044
   Arozarena I, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.06.09
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Dobbelstein M, 2014, NAT REV DRUG DISCOV, V13, P179, DOI 10.1038/nrd4201
   Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011
   Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092 8674(00)80919 8
   Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755 148X.2010.00685.x
   Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833
   Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040
   Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Ji ZY, 2015, J INVEST DERMATOL, V135, P1863, DOI 10.1038/jid.2015.105
   Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627
   Kim JH, 2017, CANCER RES TREAT, V49, P947, DOI 10.4143/crt.2016.280
   Kim YK, 2012, CANCER LETT, V320, P215, DOI 10.1016/j.canlet.2012.03.006
   Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159 8290.CD 13 0424
   Lu HQ, 2018, CANCER RES, V78, P4191, DOI 10.1158/0008 5472.CAN 18 0270
   Martin JA, 2011, NAT REV GENET, V12, P671, DOI 10.1038/nrg3068
   Pattani KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045534
   Rapino F, 2018, NATURE, V558, P605, DOI 10.1038/s41586 018 0243 7
   Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078 0432.CCR 13 3122
   Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159 8290.CD 13 0642
   Tripathi SC, 2017, CANCER RES, V77, P4414, DOI 10.1158/0008 5472.CAN 16 2874
   van Duin M, 2011, HAEMATOL HEMATOL J, V96, P1662, DOI 10.3324/haematol.2010.037978
   Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683
   Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023
   Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982
NR 35
TC 18
Z9 21
U1 0
U2 6
PU KOREAN SOC APPLIED PHARMACOLOGY
PI SEOUL
PA RM 805, KOREAN FEDERATION SCIENCE & TECHNOLOGY B/D, 635 4 YEOKSAM DONG,
   KANGNAM GU, SEOUL, 135 703, SOUTH KOREA
SN 1976 9148
EI 2005 4483
J9 BIOMOL THER
JI Biomol. Ther.
PD MAY
PY 2019
VL 27
IS 3
BP 302
EP +
DI 10.4062/biomolther.2018.133
PG 296
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA HY6GH
UT WOS:000468227600010
PM 30293252
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Kim, GM
   Park, DR
   Nguyen, TTH
   Kim, J
   Kim, J
   Sohn, MH
   Lee, WK
   Lee, SY
   Shim, H
AF Kim, Gyeong Min
   Park, Doo Ri
   Nguyen, Thi Thu Ha
   Kim, Jiseon
   Kim, Jihee
   Sohn, Myung Ho
   Lee, Won Kyu
   Lee, Soo Young
   Shim, Hyunbo
TI Development of Anti OSCAR Antibodies for the Treatment of Osteoarthritis
SO BIOMEDICINES
LA English
DT Article
DE OSCAR; osteoarthritis; human antibody; chondrocyte; disease modifying
   osteoarthritis drugs; DMOAD
ID OSTEOCLAST ASSOCIATED RECEPTOR; COLLAGEN RECOGNITION; STRUCTURAL BASIS;
   MODEL; DESTABILIZATION; ACTIVATION; CELLS
AB Osteoarthritis (OA) is the most common joint disease that causes local inflammation and pain, significantly reducing the quality of life and normal social activities of patients. Currently, there are no disease modifying OA drugs (DMOADs) available, and treatment relies on pain relief agents or arthroplasty. To address this significant unmet medical need, we aimed to develop monoclonal antibodies that can block the osteoclast associated receptor (OSCAR). Our recent study has revealed the importance of OSCAR in OA pathogenesis as a novel catabolic regulator that induces chondrocyte apoptosis and accelerates articular cartilage destruction. It was also shown that blocking OSCAR with a soluble OSCAR decoy receptor ameliorated OA in animal models. In this study, OSCAR neutralizing monoclonal antibodies were isolated and optimized by phage display. These antibodies bind to and directly neutralize OSCAR, unlike the decoy receptor, which binds to the ubiquitously expressed collagen and may result in reduced efficacy or deleterious off target effects. The DMOAD potential of the anti OSCAR antibodies was assessed with in vitro cell based assays and an in vivo OA model. The results demonstrated that the anti OSCAR antibodies significantly reduced cartilage destruction and other OA signs, such as subchondral bone plate sclerosis and loss of hyaline cartilage. Hence, blocking OSCAR with a monoclonal antibody could be a promising treatment strategy for OA.
C1 [Kim, Gyeong Min; Park, Doo Ri; Nguyen, Thi Thu Ha; Kim, Jiseon; Kim, Jihee; Lee, Soo Young; Shim, Hyunbo] Ewha Womans Univ, Dept Life Sci, Seoul 03760, South Korea.
   [Kim, Gyeong Min; Park, Doo Ri; Kim, Jihee; Lee, Soo Young] Ewha Womans Univ, Res Ctr Cellular Homeostasis, Seoul 03760, South Korea.
   [Sohn, Myung Ho; Lee, Won Kyu] Osong Med Innovat Fdn, New Drug Dev Ctr, Cheongju 28160, South Korea.
C3 Ewha Womans University; Ewha Womans University; Osong Medical Innovation
   Foundation
RP Lee, SY; Shim, H (通讯作者)，Ewha Womans Univ, Dept Life Sci, Seoul 03760, South Korea.; Lee, SY (通讯作者)，Ewha Womans Univ, Res Ctr Cellular Homeostasis, Seoul 03760, South Korea.
EM wwwwvvv@nate.com; pdr315@naver.com; hanguyen15490@gmail.com;
   abcdefg108@naver.com; maydate@naver.com; sohnho2@kbiohealth.kr;
   gre7@kbiohealth.kr; leesy@ewha.ac.kr; hshim@ewha.ac.kr
RI ; Kim, Hyung Kwan/ITU 6159 2023; Lee, Won Kyu/A 6591 2011; KIM,
   JEONGSEON/AAA 4643 2022; Lee, Won Kyu/GSO 2749 2022; Kim,
   Gyeong Min/AAJ 1669 2020
OI Shim, Hyunbo/0000 0001 8415 3976; Lee, Won Kyu/0000 0003 4040 1100; Kim,
   Jiseon/0009 0003 2648 4103; Kim, Jihee/0000 0002 4755 3169; LEE, SOO
   YOUNG/0000 0002 2590 3084; 
FU Korea Drug Development Fund   Ministry of Science and ICT; Ministry of
   Trade, Industry, and Energy; Ministry of Health and Welfare [HN21C0317];
   Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education [2021R1A6A1A10039823]; National
   Research Foundation of Korea [RS 2023 00217798, 2021R1A2C3003675]; Korea
   Basic Science Institute National Research Facilities & Equipment Center
   grant [2019R1A6C1010020]; National Research Foundation of Korea (NRF)  
   Ministry of Science, ICT & Future Planning [2017M3A9C8030537]
FX This research was supported by grants from the Korea Drug Development
   Fund, which was funded by the Ministry of Science and ICT, the Ministry
   of Trade, Industry, and Energy, and the Ministry of Health and Welfare
   (HN21C0317 to H.S.); the Basic Science Research Program through the
   National Research Foundation of Korea (NRF), which is funded by the
   Ministry of Education (2021R1A6A1A10039823 to H.S.); the National
   Research Foundation of Korea (RS 2023 00217798 and 2021R1A2C3003675 to
   S.Y.L.); a Korea Basic Science Institute National Research Facilities &
   Equipment Center grant (2019R1A6C1010020); and the National Research
   Foundation of Korea (NRF),which is funded by the Ministry of Science,
   ICT & Future Planning (2017M3A9C8030537 to S.Y.L.).
CR Akkiraju H, 2015, J DEV BIOL, V3, P177, DOI 10.3390/jdb3040177
   Bai XL, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23116255
   Bai X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141045
   Barrow AD, 2011, J CLIN INVEST, V121, P3505, DOI 10.1172/JCI45913
   Belluzzi E, 2023, PROCESSES, V11, DOI 10.3390/pr11041014
   Cho Y, 2021, EXP MOL MED, V53, P1689, DOI 10.1038/s12276 021 00710 y
   Choi HK, 2011, CELL SIGNAL, V23, P1633, DOI 10.1016/j.cellsig.2011.05.017
   Crotti TN, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4088
   Culley KL, 2015, METHODS MOL BIOL, V1226, P143, DOI 10.1007/978 1 4939 1619 1_12
   Fang H, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21184 5
   Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Gosset M, 2008, NAT PROTOC, V3, P1253, DOI 10.1038/nprot.2008.95
   GRAM H, 1992, P NATL ACAD SCI USA, V89, P3576, DOI 10.1073/pnas.89.8.3576
   Haywood J, 2016, P NATL ACAD SCI USA, V113, P1038, DOI 10.1073/pnas.1522572113
   Hu Y, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00147 z
   Hwang HS, 2015, INT J MOL SCI, V16, P26035, DOI 10.3390/ijms161125943
   Itzstein C, 2012, METHODS MOL BIOL, V816, P177, DOI 10.1007/978 1 61779 415 5_12
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Karsdal MA, 2016, OSTEOARTHR CARTILAGE, V24, P2013, DOI 10.1016/j.joca.2016.07.017
   Kim GM, 2022, JOINT BONE SPINE, V89, DOI 10.1016/j.jbspin.2022.105400
   Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681
   Ko BK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134600
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Loeser RF, 2012, ARTHRITIS RHEUM US, V64, P1697, DOI 10.1002/art.34453
   Lories RJ, 2011, NAT REV RHEUMATOL, V7, P43, DOI 10.1038/nrrheum.2010.197
   Merck E, 2004, BLOOD, V104, P1386, DOI 10.1182/blood 2004 03 0850
   Nedeva IR, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.641162
   Nemeth K, 2011, J IMMUNOL, V186, P13, DOI 10.4049/jimmunol.1002483
   Newton PT, 2012, INT J MOL MED, V30, P1187, DOI 10.3892/ijmm.2012.1114
   Park DR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18208 y
   Pettenuzzo S, 2023, BIOMEDICINES, V11, DOI 10.3390/biomedicines11071942
   Temu TM, 2010, AM J PHYSIOL ENDOC M, V299, pE325, DOI 10.1152/ajpendo.00145.2010
   Troeberg L, 2012, BBA PROTEINS PROTEOM, V1824, P133, DOI 10.1016/j.bbapap.2011.06.020
   Weitzner BD, 2015, STRUCTURE, V23, P302, DOI 10.1016/j.str.2014.11.010
   Yang HY, 2009, MOL CELLS, V27, P225, DOI 10.1007/s10059 009 0028 9
   Yang S, 2010, NAT MED, V16, P687, DOI 10.1038/nm.2153
   Zhou L, 2016, BLOOD, V127, P529, DOI 10.1182/blood 2015 08 667055
   Zhu XB, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.607764
NR 39
TC 3
Z9 3
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD OCT
PY 2023
VL 11
IS 10
AR 2844
DI 10.3390/biomedicines11102844
PG 16
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA W8NL2
UT WOS:001094139200001
PM 37893216
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Requicha, JF
   Moura, T
   Leonor, IB
   Martins, T
   Muñoz, F
   Reis, RL
   Gomes, ME
   Viegas, CA
AF Requicha, Joao F.
   Moura, Tiago
   Leonor, Isabel B.
   Martins, Teresa
   Munoz, Fernando
   Reis, Rui L.
   Gomes, Manuela E.
   Viegas, Carlos A.
TI Evaluation of a Starch Based Double Layer Scaffold for Bone Regeneration
   in a Rat Model
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE bone regeneration; scaffold; silanol groups; rat; mandibular model
ID TISSUE ENGINEERING APPLICATIONS; OSTEOBLAST LIKE CELLS; MANDIBULAR
   DEFECTS; STEM CELLS; MECHANICAL PROPERTIES; DRUG DELIVERY; FIBER MESHES;
   IN VITRO; MEMBRANES; DEGRADATION
AB Damages in the maxillofacial bones are frequent in humans following trauma, metabolic diseases, neoplasia, or inflammatory processes. Many of the available treatments to regenerate bone are often ineffective. The goal of this work was to assess the in vivo behavior of an innovative double layered scaffold based on a blend of starch and polycaprolactone (SPCL) that comprises a membrane obtained by solvent casting, which aims to act as a guided tissue regeneration membrane, and a wet spun fiber mesh (in some cases functionalized with osteoconductive silanol groups) targeting bone regeneration. The behavior of the double layer scaffold, functionalized with silanol groups (SPCL Si) or without (SPCL), was assessed in a mandibular rodent model and compared to a commercial collagen membrane (positive control) and to empty defects (negative control). After 8 weeks of implantation, the micro computed tomography and the histomorphometric analysis revealed that the SPCL Si scaffolds induced significantly higher new bone formation compared to the collagen membrane and to the empty defects, although they had a similar performance when compared to the SPCL scaffolds. (c) 2014 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 32:904 909, 2014.
C1 [Requicha, Joao F.; Moura, Tiago; Martins, Teresa; Viegas, Carlos A.] Univ Tras os Montes & Alto Douro, Dept Vet Sci, Vila Real, Portugal.
   [Requicha, Joao F.; Leonor, Isabel B.; Martins, Teresa; Reis, Rui L.; Gomes, Manuela E.; Viegas, Carlos A.] Univ Minho, Res Grp Biomat Biodegradables & Biomimet 3Bs, Headquarters European Inst Excellence Tissue Engn, Caldas Das Taipas, Guimaraes, Portugal.
   [Requicha, Joao F.; Leonor, Isabel B.; Martins, Teresa; Reis, Rui L.; Gomes, Manuela E.; Viegas, Carlos A.] ICVS 3Bs PT Govt Associated Lab, Braga, Portugal.
   [Munoz, Fernando] Univ Santiago de Compostela, Dept Vet Clin Sci, Fac Vet, Lugo 27001, Spain.
C3 University of Tras os Montes & Alto Douro; Universidade do Minho;
   Laboratorio Associado ICVS 3B's; Universidade de Santiago de Compostela
RP Viegas, CA (通讯作者)，Univ Tras os Montes & Alto Douro, Dept Vet Sci, POB 1013 5001 801, Vila Real, Portugal.
EM cviegas09@gmail.com
RI Reis, Rui/A 8938 2008; Requicha, Joao/E 6506 2012; Requicha,
   João/E 6506 2012; Muñoz, Fernando/I 1858 2015; Leonor,
   Isabel/P 6723 2019; Viegas, Carlos/D 2207 2014; Reis, Rui
   L./A 8938 2008; Leonor, Isabel/B 5260 2011; Gomes, Manuela/B 6282 2009;
   Munoz, Fernando/I 1858 2015
OI Requicha, Joao/0000 0002 9463 1625; UMinho, 3B's Research
   Group/0000 0002 5195 3456; Viegas, Carlos/0000 0002 8796 5037; Reis, Rui
   L./0000 0002 4295 6129; Leonor, Isabel/0000 0002 4319 4883; Gomes,
   Manuela/0000 0002 2036 6291; Munoz, Fernando/0000 0002 4130 1526
FU Portuguese Foundation for Science and Technology (FCT)
   [SFRH/BD/44143/2008]; national funds through FCT under the scope of the
   project [MIT/ECE/0047/2009]; Fundação para a Ciência e a Tecnologia
   [SFRH/BD/44143/2008] Funding Source: FCT
FX J.F. Requicha thanks the Portuguese Foundation for Science and
   Technology (FCT) for providing a PhD scholarship (Grant No.
   SFRH/BD/44143/2008). This work was supported by national funds through
   FCT under the scope of the project MIT/ECE/0047/2009. The authors thank
   Professor Monica Pena of the Veterinary Faculty of the University of
   Santiago the Compostela (Spain) for her assistance analyzing the data
   from histology.
CR Azevedo HS, 2003, BIOMACROMOLECULES, V4, P1703, DOI 10.1021/bm0300397
   Balmayor ER, 2009, ACTA BIOMATER, V5, P1035, DOI 10.1016/j.actbio.2008.11.006
   Carvalho PP, 2014, J BIOMED MATER RES A, V102, P3102, DOI 10.1002/jbm.a.34983
   Chen FM, 2011, J CONTROL RELEASE, V149, P92, DOI 10.1016/j.jconrel.2010.10.021
   DAHLIN C, 1988, PLAST RECONSTR SURG, V81, P672, DOI 10.1097/00006534 198805000 00004
   Deppe H, 2004, LASER MED SCI, V18, P190, DOI 10.1007/s10103 003 0279 1
   DONATH K, 1982, J ORAL PATHOL MED, V11, P318, DOI 10.1111/j.1600 0714.1982.tb00172.x
   Gomes ME, 2008, J TISSUE ENG REGEN M, V2, P243, DOI 10.1002/term.89
   Gomes ME, 2002, MAT SCI ENG C BIO S, V20, P19, DOI 10.1016/S0928 4931(02)00008 5
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Hoogeveen EJ, 2009, INT J ORAL MAX SURG, V38, P870, DOI 10.1016/j.ijom.2009.04.002
   Jiang XQ, 2009, BIOMATERIALS, V30, P4522, DOI 10.1016/j.biomaterials.2009.05.021
   Kikuchi M, 2004, BIOMATERIALS, V25, P5979, DOI 10.1016/j.biomaterials.2004.02.001
   LACZKO J, 1975, MIKROSKOPIE, V31, P1
   Leonor IB, 2011, J TISSUE ENG REGEN M, V5, P104, DOI 10.1002/term.294
   Liao S, 2005, BIOMATERIALS, V26, P7564, DOI 10.1016/j.biomaterials.2005.05.050
   Lin NH, 2008, AUST DENT J, V53, P108, DOI 10.1111/j.1834 7819.2008.00019.x
   Link DP, 2013, J BIOMED MATER RES A, V101, P3059, DOI 10.1002/jbm.a.34614
   Mrozik KM, 2012, CLIN ORAL INVEST, V16, P867, DOI 10.1007/s00784 011 0558 3
   Nevins M, 2005, J PERIODONTOL, V76, P2205, DOI 10.1902/jop.2005.76.12.2205
   Parrilla C, 2010, HEAD NECK J SCI SPEC, V32, P310, DOI 10.1002/hed.21185
   Petrovic V, 2012, OR SURG OR MED OR PA, V114, pE1, DOI 10.1016/j.oooo.2012.02.030
   Reffitt DM, 2003, BONE, V32, P127, DOI 10.1016/S8756 3282(02)00950 X
   Requicha JF, 2016, J TISSUE ENG REGEN M, V10, P392, DOI 10.1002/term.1816
   Rodrigues AI, 2012, ACTA BIOMATER, V8, P3765, DOI 10.1016/j.actbio.2012.05.025
   Rodrigues MT, 2011, J TISSUE ENG REGEN M, V5, P41, DOI 10.1002/term.287
   SANDBERG E, 1993, J ORAL MAXIL SURG, V51, P1106, DOI 10.1016/S0278 2391(10)80450 1
   Santos TC, 2010, ACTA BIOMATER, V6, P4314, DOI 10.1016/j.actbio.2010.06.020
   Schliephake H, 2009, INT J ORAL MAX SURG, V38, P166, DOI 10.1016/j.ijom.2008.11.018
   Stamatialis DF, 2008, J MEMBRANE SCI, V308, P1, DOI 10.1016/j.memsci.2007.09.059
   Tobita M, 2008, TISSUE ENG PT A, V14, P945, DOI 10.1089/ten.tea.2007.0048
   van Leeuwen AC, 2012, ACTA BIOMATER, V8, P1422, DOI 10.1016/j.actbio.2011.12.004
   Xynos ID, 2001, J BIOMED MATER RES, V55, P151, DOI 10.1002/1097 4636(200105)55:2<151::AID JBM1001>3.0.CO;2 D
   ZELLIN G, 1995, BIOMATERIALS, V16, P601, DOI 10.1016/0142 9612(95)93857 A
NR 34
TC 25
Z9 26
U1 0
U2 34
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD JUL
PY 2014
VL 32
IS 7
BP 904
EP 909
DI 10.1002/jor.22609
PG 6
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA AG5ST
UT WOS:000335479700007
PM 24604772
OA Bronze
DA 2025 08 17
ER

PT J
AU Xin, W
   Wang, XX
   Zhang, WJ
   Zhu, HY
   Dong, R
   Zhang, J
AF Xin, Wei
   Wang, Xuxia
   Zhang, Wenjuan
   Zhu, Haiyan
   Dong, Rui
   Zhang, Jun
TI Tumor Necrosis Factor α Inhibits Bone Marrow Stem Cell Differentiation
   into Osteoblasts by Downregulating microRNA 34a Expression
SO ANNALS OF CLINICAL AND LABORATORY SCIENCE
LA English
DT Article
DE Tumor Necrosis Factor alpha; Osteogenesis; MicroRNAs; miR 34a; Bone
   Marrow Stem Cell
ID TNF ALPHA; CYTOKINE; BMSCS
AB Objective. In this study, we aimed to investigate the role of microRNAs in modulating osteogenesis in the inflammatory milieu. Methods. Bone marrow stem cells were isolated from C57/BL mice. Tumor necrosis factor alpha (TNF alpha) (0 10 ng/ml) was added to the cell medium to mimic an inflammatory reaction. Cell apoptosis and proliferation were evaluated by flow cytometry and CyQUANT direct cell proliferation assay respectively. MicroRNA expression was measured by real time PCR. Then miR 34a precursors were transfected into BMSCs to evaluate the influence of miR 34a on TNF alpha induced suppression. Results. Our results indicated that TNF alpha significantly inhibited BMSC proliferation and differentiation in a dose dependent manner. In addition, TNF alpha significantly decreased mRNA expression level of osteocalcin (OC) and alkaline phosphatase (ALP). TNF alpha treatment decreased miR 34a levels, and miR 34a precursors reversed the impact of TNF alpha on BMSC proliferation and differentiation. Conclusions. Importantly, miR 34a promotes osteogenic differentiation and reverses proinflammatory cytokine influence, indicating that a miR 34a targeted therapy could be a promising approach to promote bone regeneration.
C1 [Xin, Wei; Wang, Xuxia; Dong, Rui; Zhang, Jun] Shandong Univ, Sch Stomatol, Shandong Prov Key Lab Oral Tissue Regenerat, Jinan, Shandong, Peoples R China.
   [Xin, Wei; Wang, Xuxia; Dong, Rui; Zhang, Jun] Shandong Univ, Fac Stomatol, Dept Orthodont, Jinan, Shandong, Peoples R China.
   [Zhang, Wenjuan] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Stomatol, Jinan, Shandong, Peoples R China.
   [Xin, Wei; Zhu, Haiyan] Weihai Municipal Hosp, Dept Stomatol, Weihai, Peoples R China.
C3 Shandong University; Shandong University; Shandong University of
   Traditional Chinese Medicine
RP Zhang, J (通讯作者)，Shandong Univ, Sch Stomatol, 44 1 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.
EM zhangj@protonmail.com
RI zhu, xueqiong/U 1320 2019
FU National Natural Science Foundation of China [81371180]
FX This study was supported by the National Natural Science Foundation of
   China (grant no. 81371180).
CR Abbas S, 2003, CYTOKINE, V22, P33, DOI 10.1016/S1043 4666(03)00106 6
   Al Aly Z, 2007, ARTERIOSCL THROM VAS, V27, P2589, DOI 10.1161/ATVBAHA.107.153668
   Chen C, 2016, MOL MED REP, V13, P2492, DOI 10.3892/mmr.2016.4814
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Hamshere S, 2015, EUR HEART J, V36, P3061, DOI 10.1093/eurheartj/ehv390
   Haroon NN, 2014, SEMIN ARTHRITIS RHEU, V44, P155, DOI 10.1016/j.semarthrit.2014.05.008
   Hu N, 2015, INT J MOL SCI, V16, P10491, DOI 10.3390/ijms160510491
   Huang J, 2016, SCI REP UK, V6, DOI 10.1038/srep29938
   Jia D., 2017, Oncology research
   Kaka GR, 2017, J NEUROSURG SCI, V61, P486, DOI 10.23736/S0390 5616.16.03061 7
   Kim N, 2013, KOREAN J INTERN MED, V28, P387, DOI 10.3904/kjim.2013.28.4.387
   Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375
   Li QC, 2018, CANCER BIOMARK, V21, P135, DOI 10.3233/CBM 170452
   Ma YF, 2013, BIOCHEM BIOPH RES CO, V441, P958, DOI 10.1016/j.bbrc.2013.11.010
   McCoy CE, 2011, FRONT BIOSCI LANDMRK, V16, P2161, DOI 10.2741/3845
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Polymeri A, 2016, HORM METAB RES, V48, P700, DOI 10.1055/s 0042 118458
   Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531
   Su X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.221
   Taipaleenmäki H, 2018, CURR OSTEOPOROS REP, V16, P1, DOI 10.1007/s11914 018 0417 0
   Wang LX, 2016, BOUND VALUE PROBL, DOI 10.1186/s13661 016 0584 9
   Wang N, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.150258
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Wu XH, 2015, INT J IMMUNOPATH PH, V28, P351, DOI 10.1177/0394632015593228
   Xu L, 2018, MOL CELLS
   Zeng HC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15000
NR 26
TC 9
Z9 12
U1 0
U2 4
PU ASSOC CLINICAL SCIENTISTS
PI MIDDLEBURY
PA PO BOX 1287, MIDDLEBURY, VT 05753 USA
SN 0091 7370
EI 1550 8080
J9 ANN CLIN LAB SCI
JI Ann. Clin. Lab. Sci.
PD MAY JUN
PY 2019
VL 49
IS 3
BP 324
EP 329
PG 6
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Medical Laboratory Technology
GA JW6KL
UT WOS:000503158400007
PM 31308031
DA 2025 08 17
ER

PT J
AU Modukuri, RK
   Choudhary, D
   Gupta, S
   Rao, KB
   Adhikary, S
   Sharma, T
   Siddiqi, MI
   Trivedi, R
   Sashidhara, KV
AF Modukuri, Ram K.
   Choudhary, Dharmendra
   Gupta, Sampa
   Rao, K. Bhaskara
   Adhikary, Sulekha
   Sharma, Tanuj
   Siddiqi, Mohammad Imran
   Trivedi, Ritu
   Sashidhara, Koneni V.
TI Benzofuran dihydropyridine hybrids: A new class of potential bone
   anabolic agents
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Benzofuran dihydropyridine hybrids; Alkaline phosphatase; Bone
   morphogenic protein 2; Molecular hybridization
ID IN VITRO; MINERAL DENSITY; SUBSTITUTED BENZOTHIOPHENE; ANTIHYPERTENSIVE
   DRUGS; CHALCONE HYBRIDS; UP REGULATORS; OSTEOPOROSIS; DERIVATIVES;
   PROTEIN; MICE
AB A series of novel benzofuran dihydropyridine hybrids were designed by molecular hybridization approach and evaluated for bone anabolic activities. Among the screened library, ethyl 4 (7 (sec butyl) 2 (4 methylbenzoyl)benzofuran 5 yl) 2 methyl 5 oxo 1,4,5,6,7,8 hexahydroquinoline 3 carboxylate (compound 21) significantly enhanced the ALP production and mineralized nodule formation, which are primary requisites in the process of in vitro osteogenesis. Oral administration of compound 21 at 10 mg. kg( 1) day( 1) for two weeks led to restoration of trabecular bone microarchitecture in drill hole fracture model by significantly increasing BV/TV and Tb.N. Furthermore, histological and molecular studies showed compound 21 triggering the new bone regeneration in a drill hole defect site by increasing BMP expression. Furthermore, molecular modeling studies were performed to gain insight into the binding approach, which revealed that both benzofuran and dihydropyridine moieties are essential to show similar binding interactions to fit into the active site of BMP2 receptor, an important target of the osteogenic agents. Our results suggest that compound 21 stimulates BMP2 synthesis in osteoblast cells that promotes new bone formation (similar to 40%) at the fracture site which helps in shorten the healing period. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Modukuri, Ram K.; Gupta, Sampa; Rao, K. Bhaskara; Sashidhara, Koneni V.] CSIR, Cent Drug Res Inst, Med & Proc Chem Div, BS 10 1,Sect 10,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
   [Choudhary, Dharmendra; Adhikary, Sulekha; Trivedi, Ritu] CSIR, Cent Drug Res Inst, Endocrinol Div, BS 10 1,Sect 10,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
   [Sharma, Tanuj; Siddiqi, Mohammad Imran] CSIR, Cent Drug Res Inst, Mol & Struct Biol Div, BS 10 1,Sect 10,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI); Council of Scientific & Industrial Research (CSIR)  
   India; CSIR   Central Drug Research Institute (CDRI)
RP Sashidhara, KV (通讯作者)，CSIR, Cent Drug Res Inst, Med & Proc Chem Div, BS 10 1,Sect 10,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.; Trivedi, R (通讯作者)，CSIR, Cent Drug Res Inst, Endocrinol Div, BS 10 1,Sect 10,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
EM ritu_trivedi@cdri.res.in; kv_sashidhara@cdri.res.in
RI ; Gupta, Sampa/V 7503 2019; modukuri, ram/M 5547 2013; Choudhary,
   Dharmendra/ACH 7934 2022; Koneni, Sashidhara/B 7845 2009; Karri,
   Bhaskara Rao/IZE 7373 2023
OI SHARMA, TANUJ/0000 0003 0054 6153; Choudhary,
   Dharmendra/0000 0002 8657 6005; Karri, Bhaskara Rao/0009 0001 1008 9606
FU CSIR, New Delhi;  [BSC0201]
FX Instrumentation facilities from SAIF, CDRI are gratefully acknowledged.
   R.K.M., D.C., B.R.K, and S.G. are thankful to CSIR, New Delhi for
   financial support. Financial support from "BSC0201 (Anabolic Skeletal
   Targets in Health & Illness)" is acknowledged. We thank Dr.Kavita Singh
   of EM unit, CSIR central drug research institute for collecting confocal
   microscopy data reported in this paper and Dr. KalyanMitra for
   facilitating confocal imaging. We also acknowledge Mr. G.K. Nagar, for
   his support in histology. The authors are grateful to the Director,
   CDRI, Lucknow, India for constant encouragement in drug development
   program. This is CSIR CDRI Communication No 9577.
CR Adler RA, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.1
   Åkesson K, 2003, B WORLD HEALTH ORGAN, V81, P657
   [Anonymous], 2011, LANCET, V377, P2152, DOI 10.1016/S0140 6736(11)60943 4
   Bansal Y, 2014, EUR J MED CHEM, V76, P31, DOI 10.1016/j.ejmech.2014.01.060
   Barrett Connor E, 2005, J BONE MINER RES, V20, P185, DOI 10.1359/JBMR.041007
   Berg C, 2003, NAT REV DRUG DISCOV, V2, P257, DOI 10.1038/nrd1068
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Dawood KM, 2013, EXPERT OPIN THER PAT, V23, P1133, DOI 10.1517/13543776.2013.801455
   Egermann M, 2006, HUM GENE THER, V17, P507, DOI 10.1089/hum.2006.17.507
   Ertl P, 2010, J CHEMINFORMATICS, V2, DOI 10.1186/1758 2946 2 1
   Fontana S. A., 1996, US, Patent No. [5489587 A 19960206, 5489587]
   Ghosh M, 2014, ENDOCRINE, V46, P397, DOI 10.1007/s12020 014 0167 4
   GUGGINO SE, 1989, P NATL ACAD SCI USA, V86, P2957, DOI 10.1073/pnas.86.8.2957
   Guo HF, 2010, J MED CHEM, V53, P1819, DOI 10.1021/jm901685n
   Kamal M., 2011, International Journal of Medical and Pharmaceutical Sciences, V1, P1, DOI DOI 10.4103/1735 1995.172835
   Kang KY, 2013, J KOREAN MED SCI, V28, P1139, DOI 10.3346/jkms.2013.28.8.1139
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   Kumar P, 2014, BIOORG MED CHEM LETT, V24, P2664, DOI 10.1016/j.bmcl.2014.04.056
   Kumar S, 2007, BONE, V40, P122, DOI 10.1016/j.bone.2006.07.015
   Kushwaha P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.350
   Kushwaha P, 2016, EUR J PHARMACOL, V788, P65, DOI 10.1016/j.ejphar.2016.06.003
   Marco Contelles J, 2011, CURR TOP MED CHEM, V11, P2714, DOI 10.2174/156802611798184382
   Mckay WF, 2007, INT ORTHOP, V31, P729, DOI 10.1007/s00264 007 0418 6
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Mulder JE, 2006, NAT CLIN PRACT ENDOC, V2, P670, DOI 10.1038/ncpendmet0325
   Nishiya Y, 2001, BIOL PHARM BULL, V24, P628, DOI 10.1248/bpb.24.628
   Oishi Y, 2006, Jpn. Kokai Tokkyo Koho, Patent No. [JP 2006225303 A 20060831, 2006225303]
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Riley EH, 1996, CLIN ORTHOP RELAT R, P39, DOI 10.1097/00003086 199603000 00006
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   SAMPATH TK, 1990, J BIOL CHEM, V265, P13198
   Sashidhara KV, 2016, MEDCHEMCOMM, V7, P2349, DOI 10.1039/c6md00447d
   Sashidhara KV, 2015, EUR J MED CHEM, V103, P418, DOI 10.1016/j.ejmech.2015.09.004
   Sashidhara KV, 2015, EUR J MED CHEM, V89, P638, DOI 10.1016/j.ejmech.2014.10.068
   Sashidhara KV, 2013, EUR J MED CHEM, V70, P802, DOI 10.1016/j.ejmech.2013.10.060
   Sashidhara KV, 2013, EUR J MED CHEM, V68, P38, DOI 10.1016/j.ejmech.2013.07.009
   Sashidhara KV, 2013, J MED CHEM, V56, P109, DOI 10.1021/jm301281e
   Sashidhara KV, 2012, BIOORGAN MED CHEM, V20, P2971, DOI 10.1016/j.bmc.2012.03.011
   Sashidhara KV, 2012, J MED CHEM, V55, P2769, DOI 10.1021/jm201697v
   Sashidhara KV, 2011, BIOORG MED CHEM LETT, V21, P4480, DOI 10.1016/j.bmcl.2011.06.002
   Sebald W, 2004, BIOL CHEM, V385, P697, DOI 10.1515/BC.2004.086
   Sekhar B, 2007, PCT Int. Appl, Patent No. [WO 2007139887 A2 20071206, 2007139887]
   Sharan K, 2011, J BONE MINER RES, V26, P2096, DOI 10.1002/jbmr.434
   Siris ES, 2001, JAMA J AM MED ASSOC, V286, P2815, DOI 10.1001/jama.286.22.2815
   Stille JR, 1996, TETRAHEDRON LETT, V37, P9267, DOI 10.1016/S0040 4039(97)82938 3
   Subbiah V, 2010, OSTEOPOROSIS INT, V21, P1041, DOI 10.1007/s00198 009 1004 0
   Sugerman Deborah Tolmach, 2014, JAMA, V311, P104, DOI 10.1001/jama.2013.283009
   Trivedi R, 2008, MOL CELL ENDOCRINOL, V289, P85, DOI 10.1016/j.mce.2008.02.027
   Trivedi R, 2010, EXPERT OPIN INV DRUG, V19, P995, DOI 10.1517/13543784.2010.501077
   Ushijima K, 2010, EUR J PHARMACOL, V635, P227, DOI 10.1016/j.ejphar.2010.02.039
   van den Bergh JP, 2012, NAT REV RHEUMATOL, V8, P163, DOI 10.1038/nrrheum.2011.217
   Viegas Junior C, 2007, CURR MED CHEM, V14, P1829
   Wang BX, 2014, EXP THER MED, V7, P649, DOI 10.3892/etm.2014.1475
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Weber D, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472 6807 7 6
   Wu CJ, 2008, J DENT SCI, V3, P13
   Xue ST, 2015, EUR J MED CHEM, V96, P151, DOI 10.1016/j.ejmech.2015.04.016
   Yasothan U, 2008, NAT REV DRUG DISCOV, V7, P725, DOI 10.1038/nrd2620
   Zhang ZM, 2011, BIOINFORMATICS, V27, P2083, DOI 10.1093/bioinformatics/btr331
NR 60
TC 16
Z9 16
U1 0
U2 25
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968 0896
EI 1464 3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD DEC 15
PY 2017
VL 25
IS 24
BP 6450
EP 6466
DI 10.1016/j.bmc.2017.10.018
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA FN4NV
UT WOS:000415984900020
PM 29097030
DA 2025 08 17
ER

PT J
AU Roddy, E
   Muller, S
   Paskins, Z
   Hider, SL
   Blagojevic Bucknall, M
   Mallen, CD
AF Roddy, Edward
   Muller, Sara
   Paskins, Zoe
   Hider, Samantha L.
   Blagojevic Bucknall, Milisa
   Mallen, Christian D.
TI Incident acute pseudogout and prior bisphosphonate use: Matched
   case control study in the UK Clinical Practice Research Datalink
SO MEDICINE
LA English
DT Article
DE acute pseudogout; bisphosphonates; calcium pyrophosphate crystal
   deposition; case control study; primary care
ID PRACTICE RESEARCH DATABASE; AMERICAN SOCIETY; VASCULAR EVENTS;
   TASK FORCE; BONE; CHONDROCALCINOSIS; RISK; GOUT; OSTEOARTHRITIS;
   EPIDEMIOLOGY
AB Oral bisphosphonates are the most commonly used drugs to treat postmenopausal osteoporosis. Acute pseudogout is anecdotally reported to occur following bisphosphonate initiation but empirical data are lacking. We investigated whether treatment with oral bisphosphonates is a risk factor for incident acute pseudogout.
   A matched case control study was undertaken using data from the UK Clinical Practice Research Datalink. Adults who consulted for incident acute pseudogout between 1987 and 2012 were each matched for gender, age at pseudogout diagnosis, and general practice to up to 4 control subjects without pseudogout. The exposure of interest was a prescription for an oral bisphosphonate issued within the 60 day period prior to the date of incident acute pseudogout. Associations between incident acute pseudogout and prior bisphosphonate prescription were examined using conditional logistic regression, adjusting for hyperparathyroidism, osteoarthritis, rheumatoid arthritis, hemochromatosis, hypophosphatasia, and prescriptions for diuretics and oral corticosteroids.
   Two thousand eleven acute pseudogout cases were compared with 8013 matched controls without acute pseudogout (mean age [standard deviation] 72 years [14]; 52% male). One hundred twenty three cases (6.1%) had received an oral bisphosphonate prescription in the 60 day exposure period compared with 305 controls (3.8%) (adjusted incidence rate ratio [IRR] 1.33; 95% confidence interval [CI] 1.05 1.69). This association was stronger in females (adjusted IRR 1.49; 95% CI 1.15 1.94) and was nonsignificant in males (0.83; 0.48 1.44).
   Incident acute pseudogout was associated with prescription of an oral bisphosphonate in the preceding 60 days. Prescribers should be aware of acute pseudogout as a possible side effect of bisphosphonate treatment. Further research is needed to explore the risks conferred by different bisphosphonates and the mechanism underlying this association.
C1 [Roddy, Edward; Muller, Sara; Paskins, Zoe; Hider, Samantha L.; Blagojevic Bucknall, Milisa; Mallen, Christian D.] Keele Univ, Res Inst Primary Care & Hlth Sci, Keele ST5 5BG, Staffs, England.
C3 Keele University
RP Roddy, E (通讯作者)，Keele Univ, Res Inst Primary Care & Hlth Sci, Keele ST5 5BG, Staffs, England.
EM e.roddy@keele.ac.uk
RI ; Muller, Sara/AAA 7017 2019
OI Roddy, Edward/0000 0002 8954 7082; paskins, zoe/0000 0002 7783 2986;
   Blagojevic Bucknall, Milica/0000 0001 7230 7771; Mallen,
   Christian/0000 0002 2677 1028; Hider, Samantha Lara/0000 0002 9958 3909;
   Muller, Sara/0000 0001 6645 5751
FU National Institute for Health Research (NIHR) Collaborations for
   Leadership in Applied Health Research and Care West Midlands; NIHR
   School for Primary Care Research; NIHR Research Professorship; NIHR;
   National Institute for Health Research [SPCR 023, RP_2014 04 026,
   SPCR 004] Funding Source: researchfish
FX CDM is funded by the National Institute for Health Research (NIHR)
   Collaborations for Leadership in Applied Health Research and Care West
   Midlands, NIHR School for Primary Care Research, and an NIHR Research
   Professorship. SM and MB B are funded by the NIHR School for Primary
   Care Research. This article presents independent research funded by the
   NIHR. The views expressed are those of the author(s) and not necessarily
   those of the NHS, the NIHR or the Department of Health.
CR Abhishek A, 2014, ANN RHEUM DIS, V73, P1997, DOI 10.1136/annrheumdis 2013 203400
   Abhishek A, 2011, NAT REV RHEUMATOL, V7, P96, DOI 10.1038/nrrheum.2010.182
   [Anonymous], 2015, STATACORPSTATA STAT
   [Anonymous], [No title captured]
   [Anonymous], 2014, PRESCR COST AN ENGL
   Bjerre LM, 2000, BRIT MED J, V320, P503, DOI 10.1136/bmj.320.7233.503
   Carda S, 2010, J RHEUMATOL, V37, P1076, DOI 10.3899/jrheum.091016
   Clarson LE, 2015, ANN RHEUM DIS, V74, P642, DOI 10.1136/annrheumdis 2014 205252
   DOHERTY M, 1993, BRIT J RHEUMATOL, V32, P189
   GALLACHER SJ, 1991, SCOT MED J, V36, P49, DOI 10.1177/003693309103600207
   GEELHOED GW, 1989, SURGERY, V106, P1036
   Gold DT, 2006, CURR MED RES OPIN, V22, P2383, DOI 10.1185/030079906X154042
   Hancock AT, 2014, CAN MED ASSOC J, V186, pE495, DOI 10.1503/cmaj.140266
   Herrett E, 2010, BRIT J CLIN PHARMACO, V69, P4, DOI 10.1111/j.1365 2125.2009.03537.x
   JONES AC, 1992, SEMIN ARTHRITIS RHEU, V22, P188, DOI 10.1016/0049 0172(92)90019 A
   Khan NF, 2010, BRIT J GEN PRACT, V60, DOI 10.3399/bjgp10X483562
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kothawala P, 2007, MAYO CLIN PROC, V82, P1493, DOI 10.4065/82.12.1493
   Kuo CF, 2015, ANN RHEUM DIS, V74, P661, DOI 10.1136/annrheumdis 2013 204463
   Malnick SDH, 1997, ANN PHARMACOTHER, V31, P499, DOI 10.1177/106002809703100422
   McAvoy B., 2008, ALENDRONATE PREVENTS
   Mikuls TR, 2005, ANN RHEUM DIS, V64, P267, DOI 10.1136/ard.2004.024091
   Muller S, 2014, ANN RHEUM DIS, V73, P1769, DOI 10.1136/annrheumdis 2013 203465
   Neame RL, 2003, ANN RHEUM DIS, V62, P513, DOI 10.1136/ard.62.6.513
   Orcel P, 2002, JOINT BONE SPINE, V69, P19, DOI 10.1016/S1297 319X(01)00336 0
   Reid IR, 2003, CURR OPIN RHEUMATOL, V15, P458, DOI 10.1097/00002281 200307000 00014
   Rho YH, 2012, RHEUMATOLOGY, V51, P2070, DOI 10.1093/rheumatology/kes204
   Richette P, 2009, RHEUMATOLOGY, V48, P711, DOI 10.1093/rheumatology/kep081
   RODRIGUEZVALVERDE V, 1980, ARTHRITIS RHEUM US, V23, P471, DOI 10.1002/art.1780230410
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Shinozaki T, 1996, J RHEUMATOL, V23, P677
   WALTON RJ, 1975, CLIN SCI MOL MED, V49, P45, DOI 10.1042/cs0490045
   Watanabe Hiroshi, 2006, Mod Rheumatol, V16, P117, DOI 10.1007/s10165 006 0468 4
   Watson DJ, 2003, J RHEUMATOL, V30, P1196
   Wendling D, 2008, CLIN RHEUMATOL, V27, P1205, DOI 10.1007/s10067 008 0923 z
   Young Min SA, 2005, RHEUMATOLOGY, V44, P131, DOI 10.1093/rheumatology/keh428
   Zhang W, 2011, ANN RHEUM DIS, V70, P563, DOI 10.1136/ard.2010.139105
NR 37
TC 15
Z9 16
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD MAR
PY 2017
VL 96
IS 12
AR e6177
DI 10.1097/MD.0000000000006177
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA EP8IT
UT WOS:000397619800006
PM 28328803
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Dziadek, M
   Dziadek, K
   Checinska, K
   Zagrajczuk, B
   Cholewa Kowalska, K
AF Dziadek, Michal
   Dziadek, Kinga
   Checinska, Kamila
   Zagrajczuk, Barbara
   Cholewa Kowalska, Katarzyna
TI Bioactive Glasses Modulate Anticancer Activity and Other
   Polyphenol Related Properties of Polyphenol Loaded PCL/Bioactive Glass
   Composites
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE composite; bone substitute; bioactive glass; polyphenols; plant extract;
   drug delivery; anticancer activity
ID GALLIC ACID; SURFACE FUNCTIONALIZATION; BIOLOGICAL SIGNIFICANCE;
   SALVIA OFFICINALIS; NATURAL MOLECULES; ROSMARINIC ACID; APOPTOSIS;
   HEALTHY; OSTEOSARCOMA; ANTIOXIDANT
AB In this work, bioactive glass (BG) particles obtained by three different methods (melt quenching, sol gel, and sol gel EISA) were used as modifiers of polyphenol loaded PCL based composites. The composites were loaded with polyphenolic compounds (PPh) extracted from sage (Salvia officinalis L.). It was hypothesized that BG particles, due to their different textural properties (porosity, surface area) and surface chemistry (content of silanol groups), would act as an agent to control the release of polyphenols from PCL/BG composite films and other significant properties associated with and affected by the presence of PPh. The polyphenols improved the hydrophilicity, apatite forming ability, and mechanical properties of the composites and provided antioxidant and anticancer activity. As the BG particles had different polyphenol binding capacities, they modulated the kinetics of polyphenol release from the composites and the aforementioned properties to a great extent. Importantly, the PPh loaded materials exhibited multifaceted and selective anticancer activity, including ROS mediated cell cycle arrest and apoptosis of osteosarcoma (OS) cells (Saos 2) via Cdk2 , GADD45G , and caspase 3/7 dependent pathways. The materials showed a cytotoxic and antiproliferative effect on cancerous osteoblasts but not on normal human osteoblasts. These results suggest that the composites have great potential as biomaterials for treating bone defects, particularly following surgical removal of OS tumors.
C1 [Dziadek, Michal; Checinska, Kamila; Zagrajczuk, Barbara; Cholewa Kowalska, Katarzyna] AGH Univ Sci & Technol, Fac Mat Sci & Ceram, Dept Glass Technol & Amorphous Coatings, PL 30059 Krakow, Poland.
   [Dziadek, Kinga] Agr Univ Krakow, Fac Food Technol, Dept Human Nutr & Dietet, PL 30149 Krakow, Poland.
C3 AGH University of Krakow; University of Agriculture in Krakow
RP Dziadek, M; Cholewa Kowalska, K (通讯作者)，AGH Univ Sci & Technol, Fac Mat Sci & Ceram, Dept Glass Technol & Amorphous Coatings, PL 30059 Krakow, Poland.
EM dziadek@agh.edu.pl; cholewa@agh.edu.pl
RI Dziadek, Michał/T 1939 2017; Checinska, Kamila/LVA 0927 2024;
   Cholewa Kowalska, Katarzyna/P 1607 2019; Dziadek, Michal/T 1939 2017
OI Checinska, Kamila/0000 0002 5113 9817; Dziadek,
   Michal/0000 0001 5661 5467; Cholewa Kowalska,
   Katarzyna/0000 0002 5669 465X
FU National Science Centre, Poland [2017/27/B/ST8/00195,
   2019/32/C/ST5/00386]; AGH University of Krakow [1449]
FX This work was supported by the National Science Centre, Poland Grant
   nos. 2017/27/B/ST8/00195 (KCK) and 2019/32/C/ST5/00386 (MD). The SEM
   investigation was performed at the Faculty of Materials Science and
   Ceramics in the Laboratory of Scanning Electron Microscopy and
   Microanalysis. The purchase of the SEM equipment was supported by the
   project "Excellence Initiative   Research University" for the AGH
   University of Krakow, Grant ID 1449.
CR Abdelgeliel AS, 2019, COATINGS, V9, DOI 10.3390/coatings9060394
   Alaswad HA, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22063085
   Bodhak S, 2009, ACTA BIOMATER, V5, P2178, DOI 10.1016/j.actbio.2009.02.023
   Bossard C, 2019, ACS BIOMATER SCI ENG, V5, P5906, DOI 10.1021/acsbiomaterials.9b01245
   Carpi S, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.574317
   Cazzola M, 2017, J MATER SCI, V52, P9211, DOI 10.1007/s10853 017 0872 5
   Cazzola M, 2016, APPL SURF SCI, V367, P237, DOI 10.1016/j.apsusc.2016.01.138
   Chang R, 2014, INT J NANOMED, V9, P461, DOI 10.2147/IJN.S55505
   Chimento A, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24021680
   Corazzari I, 2016, COLLOID SURFACE B, V148, P592, DOI 10.1016/j.colsurfb.2016.09.034
   Curti V, 2017, SEMIN CANCER BIOL, V46, P119, DOI 10.1016/j.semcancer.2017.08.005
   Dana PM, 2022, CELL MOL BIOL LETT, V27, DOI 10.1186/s11658 021 00301 9
   Dziadek M, 2023, SUSTAIN MATER TECHNO, V35, DOI 10.1016/j.susmat.2023.e00568
   Dziadek M, 2021, BIOACT MATER, V6, P1811, DOI 10.1016/j.bioactmat.2020.11.025
   Dziadek M, 2018, J MATER SCI, V53, P3939, DOI 10.1007/s10853 017 1839 2
   Dziadek M, 2017, J MATER SCI, V52, P12960, DOI 10.1007/s10853 017 1424 8
   Dziadek M, 2016, COMPOS PART A APPL S, V90, P90, DOI 10.1016/j.compositesa.2016.07.001
   Dziadek M, 2016, CERAM INT, V42, P14700, DOI 10.1016/j.ceramint.2016.06.095
   Dziadek M, 2015, J BIOMED MATER RES B, V103, P1580, DOI 10.1002/jbm.b.33350
   Dziadek M, 2015, MAT SCI ENG C MATER, V56, P9, DOI 10.1016/j.msec.2015.06.020
   Fabbri P, 2010, COMPOS SCI TECHNOL, V70, P1869, DOI 10.1016/j.compscitech.2010.05.029
   Ferlenda G, 2021, ACS BIOMATER SCI ENG, V7, P96, DOI 10.1021/acsbiomaterials.0c01170
   Ferraris S, 2016, J NON CRYST SOLIDS, V432, P167, DOI 10.1016/j.jnoncrysol.2015.05.023
   Gill J, 2021, NAT REV CLIN ONCOL, V18, P609, DOI 10.1038/s41571 021 00519 8
   Hench LL, 2009, J EUR CERAM SOC, V29, P1257, DOI 10.1016/j.jeurceramsoc.2008.08.002
   Hoppe A, 2013, BIOMATER SCI UK, V1, P254, DOI 10.1039/c2bm00116k
   Jafari F, 2020, ANN DIAGN PATHOL, V49, DOI 10.1016/j.anndiagpath.2020.151654
   Jang HJ, 2021, INTEGR CANCER THER, V20, DOI 10.1177/15347354211006191
   Jell G, 2006, J MATER SCI MATER M, V17, P997, DOI 10.1007/s10856 006 0435 9
   Jiang Yuanyuan., 2016, Botanics: Targets and Therapy, V6, P25, DOI DOI 10.2147/BTAT.S98610
   Jiménez N, 2019, MACROMOLECULES, V52, P9724, DOI 10.1021/acs.macromol.9b01694
   Jones JR, 2013, ACTA BIOMATER, V9, P4457, DOI 10.1016/j.actbio.2012.08.023
   Karadas O, 2019, APPL BIOCHEM BIOTECH, V188, P514, DOI 10.1007/s12010 018 02934 7
   Kim M, 2012, CARBOHYD POLYM, V90, P592, DOI 10.1016/j.carbpol.2012.05.082
   KOKUBO T, 1990, J BIOMED MATER RES, V24, P331, DOI 10.1002/jbm.820240306
   Kontogianni VG, 2013, FOOD CHEM, V136, P120, DOI 10.1016/j.foodchem.2012.07.091
   Kuo SW, 2001, J POLYM SCI POL PHYS, V39, P1348, DOI 10.1002/polb.1107
   Lei B, 2013, MAT SCI ENG C MATER, V33, P1102, DOI 10.1016/j.msec.2012.11.039
   Lo YC, 2017, AM J CHINESE MED, V45, P1761, DOI [10.1142/S0192415X17500951, 10.1142/s0192415x17500951]
   Maciag F, 2023, J ELECTROCHEM SOC, V170, DOI 10.1149/1945 7111/ace9ff
   Maciag F, 2023, METALL MATER TRANS A, V54, P241, DOI 10.1007/s11661 022 06864 2
   Migneco C, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10122571
   Monavari M, 2021, MAT SCI ENG C MATER, V131, DOI 10.1016/j.msec.2021.112470
   Mukundan LM, 2023, J MATER SCI, V58, P3094, DOI 10.1007/s10853 023 08206 y
   Mukundan LM, 2021, MATER LETT, V293, DOI 10.1016/j.matlet.2021.129677
   Mukundan Lakshmi M, 2013, Biomatter, V3, DOI 10.4161/biom.24288
   Mukundan LM, 2022, J MATER CHEM B, V10, P10112, DOI 10.1039/d2tb01692c
   Rabelo ACS, 2022, J FOOD BIOCHEM, V46, DOI 10.1111/jfbc.14026
   Sarkar N, 2020, ACS APPL MATER INTER, V12, P13644, DOI 10.1021/acsami.9b22474
   Sarkar N, 2019, ACS APPL MATER INTER, V11, P17184, DOI 10.1021/acsami.9b01218
   Shao SJ, 2011, INT J PHARMACEUT, V421, P310, DOI 10.1016/j.ijpharm.2011.09.033
   Sirajudeen F, 2024, BIOMOL THER, V32, P38, DOI 10.4062/biomolther.2023.054
   Slika H, 2022, BIOMED PHARMACOTHER, V146, DOI 10.1016/j.biopha.2021.112442
   Smith JM, 2013, J MATER CHEM B, V1, P1296, DOI 10.1039/c3tb00408b
   Tamjid E, 2011, MAT SCI ENG C MATER, V31, P1526, DOI 10.1016/j.msec.2011.06.013
   Tamura RE, 2012, CURR MOL MED, V12, P634
   Tang B, 2015, ARCH ORAL BIOL, V60, P167, DOI 10.1016/j.archoralbio.2014.09.011
   Varshney Jyotika, 2016, Vet Sci, V3, DOI 10.3390/vetsci3010003
   Xavier CPR, 2009, NUTR CANCER, V61, P564, DOI 10.1080/01635580802710733
   Xynos ID, 2001, J BIOMED MATER RES, V55, P151, DOI 10.1002/1097 4636(200105)55:2<151::AID JBM1001>3.0.CO;2 D
   Yesil Celiktas O, 2010, PLANT FOOD HUM NUTR, V65, P158, DOI 10.1007/s11130 010 0166 4
   Zagrajczuk B, 2017, CERAM INT, V43, P12742, DOI 10.1016/j.ceramint.2017.06.160
   Zhang X, 2013, APPL SURF SCI, V287, P329, DOI 10.1016/j.apsusc.2013.09.151
   Zhang X, 2013, APPL SURF SCI, V287, P341, DOI 10.1016/j.apsusc.2013.09.152
   Zhou RC, 2012, APPL SURF SCI, V258, P3578, DOI 10.1016/j.apsusc.2011.11.119
NR 65
TC 1
Z9 1
U1 6
U2 20
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD MAY 6
PY 2024
VL 16
IS 19
BP 24261
EP 24273
DI 10.1021/acsami.4c02418
EA MAY 2024
PG 13
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA RL3A4
UT WOS:001225070200001
PM 38709741
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Jiang, H
   Wang, YC
   Deng, ZT
   Jin, JW
   Meng, J
   Chen, S
   Wang, J
   Qiu, Y
   Guo, T
   Zhao, JN
AF Jiang, Hui
   Wang, Yicun
   Deng, Zhantao
   Jin, Jiewen
   Meng, Jia
   Chen, Shuo
   Wang, Jun
   Qiu, Yang
   Guo, Ting
   Zhao, Jianning
TI Construction and Evaluation of a Murine Calvarial Osteolysis Model by
   Exposure to CoCrMo Particles in Aseptic Loosening
SO JOVE JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Medicine; Issue 132; osteolysis; aseptic loosening; murine model; CoCrMo
   particle; total hip arthroplasty; total knee arthroplasty
ID PERI IMPLANT OSTEOLYSIS; TNF ALPHA; EXPRESSION; APOPTOSIS; PROTECTS;
   STRESS; RANKL
AB Wear particle induced osteolysis is a major cause of aseptic loosening in arthroplasty failure, but the underlying mechanism remains unclear. Due to long follow ups necessary for detection and sporadic occurrence, it is challenging to assess the pathogenesis ofparticle induced osteolysis in clinical cases. Hence, optimal animal models are required for further studies. The murine model of calvarial osteolysis established by exposure to CoCrMo particles is an effective and valid tool for assessing the interactions between particles and various cells in aseptic loosening. In this model, CoCrMo particles were first obtained by high vacuum three electrode direct current and resuspended in phosphate buffered saline at a concentration of 50 mg/mL. Then, 50 mu L of the resulting suspension was applied to the middle of the murine calvaria after separation of the cranial periosteum by sharp dissection. After two weeks, the mice were sacrificed, and calvaria specimens were harvested; qualitative and quantitative evaluations were performed by hematoxylin and eosin staining and micro computed tomography. The strengths of this model include procedure simplicity, quantitative evaluation of bone loss, rapidity of osteolysis development, potential use transgenic or knockout models, and a relatively low cost. However, this model cannot to be used to assess the mechanical force and chronic effects of particles in aseptic loosening. Murine calvarial osteolysis model generated by exposure to CoCrMo particles is an ideal tool for assessing the interactions between wear particles and various cells, e.g., macrophages, fibroblasts, osteoblasts and osteoclasts, in aseptic loosening.
C1 [Jiang, Hui; Wang, Yicun; Deng, Zhantao; Meng, Jia; Chen, Shuo; Wang, Jun; Qiu, Yang; Guo, Ting; Zhao, Jianning] Nanjing Univ, Jinling Hosp, Sch Med, Dept Orthoped, Nanjing, Jiangsu, Peoples R China.
   [Deng, Zhantao; Jin, Jiewen] Nanjing Univ, Sch Med, Ctr Translat Med, Nanjing, Jiangsu, Peoples R China.
   [Deng, Zhantao; Jin, Jiewen] Nanjing Univ, Sch Med, Jiangsu Key Lab Mol Med, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing University; Nanjing University; Nanjing University
RP Deng, ZT (通讯作者)，Nanjing Univ, Jinling Hosp, Sch Med, Dept Orthoped, Nanjing, Jiangsu, Peoples R China.; Deng, ZT (通讯作者)，Nanjing Univ, Sch Med, Ctr Translat Med, Nanjing, Jiangsu, Peoples R China.; Deng, ZT (通讯作者)，Nanjing Univ, Sch Med, Jiangsu Key Lab Mol Med, Nanjing, Jiangsu, Peoples R China.
EM dengzhantao_med@163.com
FU National Natural Science Foundation of China [81572111]; Clinical
   Science and Technology Project Foundation of Jiangsu Province
   [BL2012002]; Scientific Research Project of Nanjing [201402007]; Natural
   Science Foundation of Jiangsu Province [BK20161385]; Special Foundation
   of Chinese Medical Doctor Association [2015COS0810]
FX This study was supported by the National Natural Science Foundation of
   China (81572111), the Clinical Science and Technology Project Foundation
   of Jiangsu Province (BL2012002), the Scientific Research Project of
   Nanjing (201402007), the Natural Science Foundation of Jiangsu Province
   (BK20161385), and the Special Foundation of Chinese Medical Doctor
   Association (2015COS0810).
CR Catelas Isabelle, 2010, Instr Course Lect, V59, P3
   Chen S, 2015, SCI REP UK, V5, DOI 10.1038/srep12853
   Deng ZT, 2017, ACTA BIOMATER, V49, P541, DOI 10.1016/j.actbio.2016.11.051
   Dong L, 2008, J ORTHOP RES, V26, P1114, DOI 10.1002/jor.20607
   Langlois J, 2011, INT ORTHOP, V35, P245, DOI 10.1007/s00264 010 1143 0
   Liu AQ, 2015, ACTA BIOMATER, V23, P38, DOI 10.1016/j.actbio.2015.05.016
   Liu NC, 2016, BIOCHEM BIOPH RES CO, V473, P133, DOI 10.1016/j.bbrc.2016.03.065
   Neuerburg C, 2015, ACTA BIOMATER, V14, P125, DOI 10.1016/j.actbio.2014.11.051
   Wang Peng, 2011, Chinese Journal of Nonferrous Metals, V21, P2236
   Wang R, 2013, BIOMATERIALS, V34, P2611, DOI 10.1016/j.biomaterials.2013.01.025
   Wang ZH, 2017, ACTA BIOMATER, V48, P489, DOI 10.1016/j.actbio.2016.11.020
   Wang ZH, 2015, AUTOPHAGY, V11, P2358, DOI 10.1080/15548627.2015.1106779
   Wang ZH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137774
   Wang ZH, 2015, ACTA BIOMATER, V24, P352, DOI 10.1016/j.actbio.2015.06.024
   Yang SY, 2002, ARTHRITIS RHEUM, V46, P2514, DOI 10.1002/art.10527
NR 15
TC 9
Z9 9
U1 0
U2 11
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940 087X
J9 JOVE J VIS EXP
JI J. Vis. Exp.
PD FEB
PY 2018
IS 132
AR e56276
DI 10.3791/56276
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FX9UK
UT WOS:000426453400014
PM 29553545
OA Green Published
DA 2025 08 17
ER

PT J
AU Bruce, A
   Evans, R
   Mezan, R
   Shi, L
   Moses, BS
   Martin, KH
   Gibson, LF
   Yang, Y
AF Bruce, Allison
   Evans, Rebecca
   Mezan, Ryan
   Shi, Lin
   Moses, Blake S.
   Martin, Karen H.
   Gibson, Laura F.
   Yang, Yong
TI Three Dimensional Microfluidic Tri Culture Model of the Bone Marrow
   Microenvironment for Study of Acute Lymphoblastic Leukemia
SO PLOS ONE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; DRUG RESISTANCE; CANCER CELLS; HEMATOPOIETIC
   MICROENVIRONMENT; EXTRACELLULAR MATRIX; INTERSTITIAL FLOW;
   PROSTATE CANCER; TUMOR CELLS; 3D; COLLAGEN
AB Acute lymphoblastic leukemia (ALL) initiates and progresses in the bone marrow, and as such, the marrow microenvironment is a critical regulatory component in development of this cancer. However, ALL studies were conducted mainly on flat plastic substrates, which do not recapitulate the characteristics of marrow microenvironments. To study ALL in a model of in vivo relevance, we have engineered a 3 D microfluidic cell culture platform. Biologically relevant populations of primary human bone marrow stromal cells, osteoblasts and human leukemic cells representative of an aggressive phenotype were encapsulated in 3 D collagen matrix as the minimal constituents and cultured in a microfluidic platform. The matrix stiffness and fluidic shear stress were controlled in a physiological range. The 3 D microfluidic as well as 3 D static models demonstrated coordinated cell cell interactions between these cell types compared to the compaction of the 2 D static model. Tumor cell viability in response to an antimetabolite chemotherapeutic agent, cytarabine in tumor cells alone and tri culture models for 2 D static, 3 D static and 3 D microfluidic models were compared. The present study showed decreased chemotherapeutic drug sensitivity of leukemic cells in 3 D tri culture models from the 2 D models. The results indicate that the bone marrow microenvironment plays a protective role in tumor cell survival during drug treatment. The engineered 3 D microfluidic tri culture model enables systematic investigation of effects of cell cell and cell matrix interactions on cancer progression and therapeutic intervention in a controllable manner, thus improving our limited comprehension of the role of microenvironmental signals in cancer biology.
C1 [Bruce, Allison; Mezan, Ryan; Shi, Lin; Yang, Yong] W Virginia Univ, Dept Chem Engn, Morgantown, WV 26506 USA.
   [Evans, Rebecca; Moses, Blake S.; Gibson, Laura F.] W Virginia Univ, Mary Babb Randolph Canc Ctr, Alexander B Osborn Hematopoiet Malignancy & Trans, Morgantown, WV 26506 USA.
   [Martin, Karen H.] W Virginia Univ, Dept Neurobiol & Anat, Morgantown, WV 26506 USA.
   [Gibson, Laura F.] W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA.
C3 West Virginia University; West Virginia University; West Virginia
   University; West Virginia University
RP Gibson, LF (通讯作者)，W Virginia Univ, Mary Babb Randolph Canc Ctr, Alexander B Osborn Hematopoiet Malignancy & Trans, Morgantown, WV 26506 USA.
EM lgibson@hsc.wvu.edu; yong.yang@mail.wvu.edu
RI Yang, Yong/N 3049 2016
OI Yang, Yong/0000 0003 4305 8029; Martin, Karen/0000 0001 8916 4092;
   Moses, Blake/0000 0001 8045 3066; Gibson, Laura/0000 0002 7291 9046
FU Directorate For Engineering [1227766] Funding Source: National Science
   Foundation; Div Of Chem, Bioeng, Env, & Transp Sys [1227766] Funding
   Source: National Science Foundation; NIGMS NIH HHS [P30 GM103488, U54
   GM104942] Funding Source: Medline
CR Abhyankar VV, 2008, LAB CHIP, V8, P1507, DOI 10.1039/b803533d
   Aljitawi OS, 2014, LEUKEMIA LYMPHOMA, V55, P378, DOI 10.3109/10428194.2013.793323
   Ayala F, 2009, LEUKEMIA, V23, P2233, DOI 10.1038/leu.2009.175
   Bergfeld SA, 2014, MOL CANCER THER, V13, P962, DOI 10.1158/1535 7163.MCT 13 0400
   Bersini S, 2014, BIOMATERIALS, V35, P2454, DOI 10.1016/j.biomaterials.2013.11.050
   Brown E, 2003, NAT MED, V9, P796, DOI 10.1038/nm879
   Buchanan CF, 2014, TISSUE ENG PART C ME, V20, P64, DOI [10.1089/ten.tec.2012.0731, 10.1089/ten.TEC.2012.0731]
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chang SF, 2008, P NATL ACAD SCI USA, V105, P3927, DOI 10.1073/pnas.0712353105
   Cheng SY, 2007, LAB CHIP, V7, P763, DOI 10.1039/b618463d
   CLAVEL C, 1989, INT J CANCER, V44, P548, DOI 10.1002/ijc.2910440329
   Dafni H, 2002, CANCER RES, V62, P6731
   Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695
   Ding L, 2013, NATURE, V495, P231, DOI 10.1038/nature11885
   Ellis WJ, 2003, UROLOGY, V61, P277, DOI 10.1016/S0090 4295(02)02291 4
   Fischbach C, 2007, NAT METHODS, V4, P855, DOI 10.1038/NMETH1085
   Gao BT, 2014, BIOMATERIALS, V35, P2181, DOI 10.1016/j.biomaterials.2013.11.060
   Haessler U, 2012, INTEGR BIOL UK, V4, P401, DOI 10.1039/c1ib00128k
   HAMILTON R, 1991, ANAT REC, V231, P218, DOI 10.1002/ar.1092310210
   Herrmann D, 2014, CARCINOGENESIS, V35, P1671, DOI 10.1093/carcin/bgu108
   HILLSLEY MV, 1994, BIOTECHNOL BIOENG, V43, P573, DOI 10.1002/bit.260430706
   Howe GA, 2012, CELL ADHES MIGR, V6, P71, DOI 10.4161/cam.20077
   Hsieh YT, 2013, BLOOD, V121, P1814, DOI 10.1182/blood 2012 01 406272
   Huang CP, 2009, LAB CHIP, V9, P1740, DOI 10.1039/b818401a
   Huebsch N, 2010, NAT MATER, V9, P518, DOI [10.1038/nmat2732, 10.1038/NMAT2732]
   Ibbetson SJ, 2013, AM J PATHOL, V183, P930, DOI 10.1016/j.ajpath.2013.05.014
   IMAMURA T, 1995, PANCREAS, V11, P357, DOI 10.1097/00006676 199511000 00007
   Inaba H, 2013, LANCET, V381, P1943, DOI 10.1016/S0140 6736(12)62187 4
   Janouskova H, 2012, CANCER RES, V72, P3463, DOI 10.1158/0008 5472.CAN 11 4199
   Jiglaire CJ, 2014, EXP CELL RES, V321, P99, DOI 10.1016/j.yexcr.2013.12.010
   Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004
   Kihara T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082382
   Klein CA, 2002, LANCET, V360, P683, DOI 10.1016/S0140 6736(02)09838 0
   KLEIN G, 1995, EXPERIENTIA, V51, P914, DOI 10.1007/BF01921741
   Lam CRI, 2014, MOL PHARMACEUT, V11, P2016, DOI 10.1021/mp500059q
   Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027
   Ling Y, 2007, LAB CHIP, V7, P756, DOI 10.1039/b615486g
   Liu J, 2012, NAT MATER, V11, P734, DOI [10.1038/NMAT3361, 10.1038/nmat3361]
   Loessner D, 2010, BIOMATERIALS, V31, P8494, DOI 10.1016/j.biomaterials.2010.07.064
   MAYANI H, 1992, EUR J HAEMATOL, V49, P225
   Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078 0432.CCR 07 2223
   Nair RR, 2010, BIOCHEM PHARMACOL, V80, P602, DOI 10.1016/j.bcp.2010.04.003
   Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010
   Pickl M, 2009, ONCOGENE, V28, P461, DOI 10.1038/onc.2008.394
   Polacheck WJ, 2011, P NATL ACAD SCI USA, V108, P11115, DOI 10.1073/pnas.1103581108
   Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741 7015 6 11
   Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007
   Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001
   Ramanujan S, 2002, BIOPHYS J, V83, P1650, DOI 10.1016/S0006 3495(02)73933 7
   Rhodes NP, 2004, J MATER SCI MATER M, V15, P391, DOI 10.1023/B:JMSM.0000021108.74004.7e
   Rutkowski JM, 2007, TRENDS CELL BIOL, V17, P44, DOI 10.1016/j.tcb.2006.11.007
   Santini MT, 2000, CRIT REV ONCOL HEMAT, V36, P75, DOI 10.1016/S1040 8428(00)00078 0
   Schmidt Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100
   Shieh AC, 2011, CANCER RES, V71, P790, DOI 10.1158/0008 5472.CAN 10 1513
   Siegel R, 2012, CA CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Song JW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005756
   Steimberg N, 2014, J. Pediatr. Oncol., V2, P40, DOI 10.14205/2309 3021.2014.02.01.5
   Szot CS, 2011, BIOMATERIALS, V32, P7905, DOI 10.1016/j.biomaterials.2011.07.001
   Talukdar S, 2012, ADV FUNCT MATER, V22, P4778, DOI 10.1002/adfm.201200375
   Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821
   Windus LCE, 2012, EXP CELL RES, V318, P2507, DOI 10.1016/j.yexcr.2012.07.013
   Winer JP, 2009, TISSUE ENG PT A, V15, P147, DOI 10.1089/ten.tea.2007.0388
   Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006
   Yang Y, 2004, POLYMER, V45, P1959, DOI 10.1016/j.polymer.2004.01.015
   Yang Y, 2012, ACS NANO, V6, P8591, DOI 10.1021/nn301713d
   Yang Y, 2011, LAB CHIP, V11, P1638, DOI 10.1039/c0lc00736f
   Zervantonakis IK, 2012, P NATL ACAD SCI USA, V109, P13515, DOI 10.1073/pnas.1210182109
   Zustiak S, 2014, BIOTECHNOL BIOENG, V111, P396, DOI 10.1002/bit.25097
NR 68
TC 81
Z9 85
U1 3
U2 31
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD OCT 21
PY 2015
VL 10
IS 10
AR e0140506
DI 10.1371/journal.pone.0140506
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CU0ZM
UT WOS:000363248400056
PM 26488876
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Zhao, Q
   Liu, XD
   Zhang, LF
   Shen, X
   Qi, J
   Wang, JS
   Qian, ND
   Deng, LF
AF Zhao, Qiang
   Liu, Xiaodong
   Zhang, Lianfang
   Shen, Xing
   Qi, Jin
   Wang, Jinshen
   Qian, Niandong
   Deng, Lianfu
TI Bone Selective Protective Effect of a Novel Bone seeking Estrogen on
   Trabecular Bone in Ovariectomized Rats
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Bone seeking estrogen; Estrogen; Postmenopausal osteoporosis; Side
   effects; Trabecular architecture
ID HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL OSTEOPOROSIS; MICRONIZED
   PROGESTERONE; TRANSDERMAL ESTRADIOL; MINERAL DENSITY; BREAST CANCER;
   17 BETA ESTRADIOL; PATHOGENESIS; MECHANISMS; CYTOKINES
AB The drawbacks of estrogen restrict the clinical use of hormone replacement therapy, and it would be most helpful to explore new estrogenic substances that could prevent bone loss and be free from any adverse effects. We synthesized a new compound named bone seeking estrogen (SE2) by combining 17 beta estradiol (E 2) with iminodiacetic acid through the Mannich reaction. E 2 and SE2 were labeled with isotope H 3, and the tissue distribution tests of E 2 H 3 and SE2 H 3 were analyzed by the radioactivity. The specific nuclear binding of E 2 and SE2 in osteoblasts was measured. SE2 exhibited significantly greater affinity for bone but lower affinity for ovary and uterus than did E 2, and SE2 maintained a high affinity for the estrogen receptor alpha similar to that of E 2. SE2 administration did not induce uterine hypertrophy. Body weight increase was significantly suppressed by treatment with E 2 but not by SE2 after ovariectomy (OVX). SE2 decreased bone turnover as E 2 after OVX detected by serum biochemical markers. Bone histology and micro CT analysis revealed that SE2 administration, similar to E 2, could improve bone mass and trabecular architecture after OVX. Biomechanical analyses showed that SE2 treatment effectively increased mechanical properties after OVX. The results suggested that SE2 was effective in preventing OVX induced bone loss and exhibited few side effects on body weight and uterine hypertrophy, which was beneficial in reducing the adverse effects caused by E 2. SE2 may be a better choice than E 2 for the prevention of postmenopausal osteoporosis.
C1 [Zhao, Qiang; Zhang, Lianfang; Shen, Xing; Qi, Jin; Wang, Jinshen; Qian, Niandong; Deng, Lianfu] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai Inst Traumatol & Orthopaed,Shanghai Key, Shanghai 200025, Peoples R China.
   [Liu, Xiaodong] Cent Hosp YangPu Dist, Dept Orthopaed, Shanghai 200090, Peoples R China.
C3 Shanghai Jiao Tong University
RP Deng, LF (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai Inst Traumatol & Orthopaed,Shanghai Key, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China.
EM lfdeng@msn.com
FU National Natural Science Foundation of China [30872641]; Shanghai
   Natural Science Foundation [11ZR1434100]; Shanghai Municipal Health
   Bureau project [2010117]
FX This work was supported by the National Natural Science Foundation of
   China (Grant 30872641), Shanghai Natural Science Foundation (Grant
   11ZR1434100) and Shanghai Municipal Health Bureau project (Grant
   2010117).
CR Barrett Connor E, 2006, NEW ENGL J MED, V355, P125, DOI 10.1056/NEJMoa062462
   Bauss F, 1996, CALCIFIED TISSUE INT, V59, P168, DOI 10.1007/s002239900104
   Beral V, 1999, J Epidemiol Biostat, V4, P191
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140 6736(96)07113 9
   Duvall CL, 2004, AM J PHYSIOL HEART C, V287, pH302, DOI 10.1152/ajpheart.00928.2003
   Fox J, 2006, CALCIFIED TISSUE INT, V79, P262, DOI 10.1007/s00223 006 0108 1
   Gallo D, 2005, MENOPAUSE, V12, P589, DOI 10.1097/01.GME.0000156348.61767.D5
   Güerri Fernandez RC, 2012, THER ADV MUSCULOSKEL, V4, P55, DOI 10.1177/1759720X11435677
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Inada Masaki, 2010, Clin Calcium, V20, P1467, DOI CliCa101014671472
   Iwaniec UT, 2001, BONE, V29, P352, DOI 10.1016/S8756 3282(01)00582 8
   Karsdal MA, 2007, J BONE MINER RES, V22, P487, DOI 10.1359/JBMR.070109
   Kim TH, 2011, J NUTR BIOCHEM, V22, P8, DOI 10.1016/j.jnutbio.2009.11.002
   Lacey JV, 2002, JAMA J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334
   LaCroix AZ, 1997, LANCET, V350, P1042, DOI 10.1016/S0140 6736(97)22041 6
   Lidegaard O, 2012, NEW ENGL J MED, V366, P2257, DOI 10.1056/NEJMoa1111840
   Lin JC, 1999, OSTEOPOROSIS INT, V9, P516
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   McCann RM, 2008, J ORTHOP RES, V26, P384, DOI 10.1002/jor.20505
   Miller SC, 2008, PHARM RES DORDR, V25, P2889, DOI 10.1007/s11095 008 9706 0
   Mo Zhengji, 1998, Yaoxue Xuebao, V33, P645
   Mueck AO, 2012, CLIMACTERIC, V15, P11, DOI 10.3109/13697137.2012.669624
   Mukherjee M, 2006, PHYTOTHER RES, V20, P21, DOI 10.1002/ptr.1795
   Neale JR, 2009, BIOORG MED CHEM LETT, V19, P680, DOI 10.1016/j.bmcl.2008.12.051
   Novack DV, 2007, CELL METAB, V6, P254, DOI 10.1016/j.cmet.2007.09.007
   Pacifici R, 1998, ENDOCRINOLOGY, V139, P2659, DOI 10.1210/en.139.6.2659
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   RAISZ LG, 1993, J BONE MINER RES, V8, pS457
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Simon JA, 2012, CLIMACTERIC, V15, P3, DOI 10.3109/13697137.2012.669332
   Takeyama M, 2008, BRIT J HAEMATOL, V142, P962, DOI 10.1111/j.1365 2141.2008.07289.x
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Yoon KH, 2012, J KOREAN NEUROSURG S, V51, P323, DOI 10.3340/jkns.2012.51.6.323
   Zhao Q, 2012, BONE, V50, P763, DOI 10.1016/j.bone.2011.12.003
NR 35
TC 24
Z9 27
U1 0
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD AUG
PY 2013
VL 93
IS 2
BP 172
EP 183
DI 10.1007/s00223 013 9739 1
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 186GM
UT WOS:000322030100008
PM 23780350
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Yang, D
   Okamura, H
   Morimoto, H
   Teramachi, J
   Haneji, T
AF Yang, Di
   Okamura, Hirohiko
   Morimoto, Hiroyuki
   Teramachi, Jumpei
   Haneji, Tatsuji
TI Protein phosphatase 2A Cα regulates proliferation, migration, and
   metastasis of osteosarcoma cells
SO LABORATORY INVESTIGATION
LA English
DT Article
ID OKADAIC ACID; MURINE OSTEOSARCOMA; PANCREATIC CANCER; KAPPA B;
   OSTEOBLAST DIFFERENTIATION; MITOCHONDRIAL METABOLISM; CHEMOTHERAPEUTIC
   DRUGS; PULMONARY METASTASIS; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR
AB Osteosarcoma is the most frequent primary bone tumor. Serine/threonine protein phosphatase 2A (PP2A) participates in regulating many important physiological processes, such as cell cycle, growth, apoptosis, and signal transduction. In this study, we examined the expression and function of PP2A C alpha in osteosarcoma cells. PP2A C alpha expression was expected to be higher in malignant osteosarcoma tissues. PP2A C alpha expression level and PP2A activity was higher in malignant osteosarcoma LM8 cells compared with that in primary osteoblasts and in the osteoblast like cell line MC3T3 E1. Okadaic acid, an inhibitor of PP2A, reduced cell viability and induced apoptosis in LM8 cells. PP2A C alpha knockdown LM8 cells (shPP2A) exhibited less striking filopodial and lamellipodial structures than that in original LM8 cells. Focal adhesion kinase phosphorylation and NF kappa B activity decreased in shPP2A treated cells. Sensitivity to serum deprivation induced apoptosis increased in shPP2A treated cells, accompanied by a lower expression level of anti apoptotic BCL 2 in these cells. Reduction of PP2A C alpha resulted in a decrease in the migration ability of LM8 cells in vitro. Reduction in PP2A C alpha levels in vivo suppressed proliferation and metastasis in LM8 cells. PP2A C alpha expression was also higher in human osteosarcoma MG63 and SaOS 2 cells than that in primary osteoblasts and MC3T3 E1 cells, and reduction in PP2A C alpha levels suppressed the cell proliferation rate and migration ability of MG63 cells. These results indicate that PP2A C alpha has a critical role in the proliferation and metastasis of osteosarcoma cells; therefore, its inhibition could potentially suppress the malignancy of osteosarcoma cells.
C1 [Yang, Di] China Med Univ, Sch Stomatol, Dept Endodont, Shenyang, Peoples R China.
   [Okamura, Hirohiko; Teramachi, Jumpei; Haneji, Tatsuji] Univ Tokushima, Grad Sch, Inst Biomed Sci, Dept Histol & Oral Histol, Tokushima, Japan.
   [Morimoto, Hiroyuki] Univ Occupat & Environm Hlth, Sch Med, Dept Anat, Kitakyushu, Fukuoka, Japan.
C3 China Medical University; Tokushima University; University of
   Occupational & Environmental Health   Japan
RP Yang, D (通讯作者)，China Med Univ, Sch Stomatol, Dept Endodont, Shenyang, Peoples R China.; Okamura, H (通讯作者)，Inst Biomed Sci, Dept Histol & Oral Histol, Tokushima 7708504, Japan.
EM missyangdi@hotmail.com; okamura@tokushima u.ac.jp
RI Okamura, Hirohiko/I 5917 2019
OI Okamura, Hirohiko/0000 0002 3254 5238
FU Ministry of Education, Science, Sports, and Culture of Japan [23592703];
   Ichiro Kanehara Foundation for the Promotion of Medical Sciences and
   Medical Care; Takeda Science Foundation; Nakatomi Foundation;
   Grants in Aid for Scientific Research [16K11504, 26462786, 23592703]
   Funding Source: KAKEN
FX We would like to thank Dr Omar MM Rodis for help in the preparation of
   this manuscript. We also thank Drs Hideaki Horikawa and Shigeo Misawa in
   the Support Center for Advanced Medical Sciences, Institute of Health
   Biosciences, Tokushima University Graduate School, for technical
   support. This study was supported by grants from the Grant in Aid for
   Scientific Research from the Ministry of Education, Science, Sports, and
   Culture of Japan (23592703, HO), the Ichiro Kanehara Foundation for the
   Promotion of Medical Sciences and Medical Care, Takeda Science
   Foundation, and the Nakatomi Foundation.
CR [Anonymous], 2009, FRONT BIOSCI ELITE E
   Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038
   Asai T, 1998, INT J CANCER, V76, P418, DOI 10.1002/(SICI)1097 0215(19980504)76:3<418::AID IJC21>3.3.CO;2 E
   Bacci G, 2006, CANCER AM CANCER SOC, V106, P1154, DOI 10.1002/cncr.21724
   Bai XL, 2014, MOL CANCER THER, V13, P2062, DOI 10.1158/1535 7163.MCT 13 0800
   Bai XL, 2014, CANCER LETT, V355, P281, DOI 10.1016/j.canlet.2014.09.048
   Botter SM, 2014, CURR OPIN PHARMACOL, V16, P15, DOI 10.1016/j.coph.2014.02.002
   Dedinszki D, 2015, CELL SIGNAL, V27, P363, DOI 10.1016/j.cellsig.2014.11.021
   Dome J S, 1997, Cancer Treat Res, V92, P215
   Eichhorn PJA, 2009, BBA REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005
   Ferguson WS, 2001, CANCER INVEST, V19, P292, DOI 10.1081/CNV 100102557
   Götz J, 2000, MECH DEVELOP, V93, P83, DOI 10.1016/S0925 4773(00)00267 7
   Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370
   Haneji T, 2013, INT J ONCOL, V42, P1904, DOI 10.3892/ijo.2013.1911
   Hotchkiss RS, 1999, J IMMUNOL, V162, P4148
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264 6021:3530417
   Janssens V, 2008, TRENDS BIOCHEM SCI, V33, P113, DOI 10.1016/j.tibs.2007.12.004
   Jose C, 2011, BBA BIOENERGETICS, V1807, P552, DOI 10.1016/j.bbabio.2010.10.012
   Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008 5472.CAN 06 1501
   Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897 358
   Krishna S, 2011, BIOCHEM J, V435, P545, DOI 10.1042/BJ20101996
   Kvansakul M, 2015, APOPTOSIS, V20, P136, DOI 10.1007/s10495 014 1051 7
   Li W, 2011, EUR J CANCER, V47, P2654, DOI 10.1016/j.ejca.2011.08.014
   MORI S, 1995, INT J CANCER, V61, P148, DOI 10.1002/ijc.2910610125
   Morimoto H, 2005, MOL CELL BIOCHEM, V276, P211, DOI 10.1007/s11010 005 4440 y
   Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034
   Nakamura A, 2012, BMC CELL BIOL, V13, DOI 10.1186/1471 2121 13 24
   Nishimura A, 2011, CANCER GENE THER, V18, P250, DOI 10.1038/cgt.2010.75
   Okamura H, 2013, J CELL PHYSIOL, V228, P1031, DOI 10.1002/jcp.24250
   Okamura H, 2013, FEBS LETT, V587, P48, DOI 10.1016/j.febslet.2012.10.041
   Okamura H, 2011, BONE, V49, P368, DOI 10.1016/j.bone.2011.06.004
   Ozaki A, 2006, J CELL BIOCHEM, V99, P1275, DOI 10.1002/jcb.20873
   Raimundo N, 2011, TRENDS MOL MED, V17, P641, DOI 10.1016/j.molmed.2011.06.001
   Ren L, 2012, CANCER RES, V72, P1001, DOI 10.1158/0008 5472.CAN 11 0210
   Sablina AA, 2008, CANCER METAST REV, V27, P137, DOI 10.1007/s10555 008 9116 0
   Schapira AHV, 2012, LANCET, V379, P1825, DOI 10.1016/S0140 6736(11)61305 6
   Schoenthal Axel H., 1998, Frontiers in Bioscience, V3, pD1262
   Seshacharyulu P, 2013, CANCER LETT, V335, P9, DOI 10.1016/j.canlet.2013.02.036
   Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006
   Shi YG, 2009, SCI CHINA SER C, V52, P135, DOI 10.1007/s11427 009 0018 3
   Shou LM, 2013, ONCOL REP, V30, P1059, DOI 10.3892/or.2013.2601
   Sæter G, 1999, ACTA ORTHOP SCAND, V70, P74, DOI 10.1080/17453674.1999.11744828
   SUGANUMA M, 1990, CANCER RES, V50, P3521
   SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768
   Tomonaga M, 2012, INT J ONCOL, V40, P409, DOI 10.3892/ijo.2011.1209
   Wen X, 2012, CELL PROLIFERAT, V45, P217, DOI 10.1111/j.1365 2184.2012.00814.x
   Westermarck J, 2008, TRENDS MOL MED, V14, P152, DOI 10.1016/j.molmed.2008.02.001
   Wiren KM, 2006, OSTEOBLAST OSTEOCYTE, P637
   Wu MY, 2014, ONCOL REP, V32, P513, DOI 10.3892/or.2014.3266
   Xiong SB, 2014, PROTEIN CELL, V5, P737, DOI 10.1007/s13238 014 0089 1
   Yui Y, 2010, CLIN EXP METASTAS, V27, P619, DOI 10.1007/s10585 010 9352 x
   Zeren T, 2014, ACTA HISTOCHEM, V116, P1251, DOI 10.1016/j.acthis.2014.07.007
   Zheng H, 2013, J BIOL CHEM, V288, P25727, DOI 10.1074/jbc.M113.462291
NR 54
TC 21
Z9 25
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 0023 6837
EI 1530 0307
J9 LAB INVEST
JI Lab. Invest.
PD OCT
PY 2016
VL 96
IS 10
BP 1050
EP 1062
DI 10.1038/labinvest.2016.82
PG 13
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pathology
GA DX0EV
UT WOS:000384035500002
PM 27617401
OA Bronze
DA 2025 08 17
ER

PT J
AU Kim, YM
   Lim, HM
   Lee, EC
   Ki, GE
   Seo, YK
AF Kim, Yu Mi
   Lim, Han Moi
   Lee, Eun Chul
   Ki, Ga Eun
   Seo, Young Kwon
TI Synergistic effect of electromagnetic fields and nanomagnetic particles
   on osteogenesis through calcium channels and p ERK signaling
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE calcium channel; calvarial defect model; electromagnetic fields;
   nanomagnetic particle; osteogenesis
ID MESENCHYMAL STEM CELLS; IRON OXIDE NANOPARTICLES; BONE FORMATION;
   MAGNETITE NANOPARTICLES; GOLD NANOPARTICLES; GENE EXPRESSION;
   DIFFERENTIATION; PROLIFERATION; PROTEIN; STIMULATION
AB Electromagnetic fields (EMFs) are widely used in a number of cell therapies and bone disorder treatments, and nanomagnetic particles (NMPs) also promote cell activity. In this study, we investigated the synergistic effects of EMFs and NMPs on the osteogenesis of the human Saos 2 osteoblast cell line and in a rat calvarial defect model. The Saos 2 cells and critical size calvarial defects of the rats were exposed to EMF (1 mT, 45 Hz, 8 h/day) with or without Fe3O4 NMPs. Biocompatibility was evaluated with MTT (3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyltetrazolium bromide) and LDH (lactate dehydrogenase) assays. This analysis showed that NMP and EMF did not induce cell toxicity. Quantitative reverse transcription polymerase chain reaction indicated that the osteogenesis related markers were highly expressed in the NMP incorporated Saos 2 cells after exposure to EMF. Also, the expression of gene encoding proteins involved in calcium channels was activated and the calcium concentration of the NMP incorporated + EMF exposed group was increased compared with the control group. In particular, in the NMP incorporated + EMF exposed group, all osteogenic proteins were more abundantly expressed than in the control group. This indicated that the NMP incorporation + EMF exposure induced a signaling pathway through activation of p ERK and calcium channels. Also, in vivo evaluation revealed that rat calvarial defects treated with EMFs and NMPs had good regeneration results with new bone formation and increased mineral density after 6 weeks. Altogether, these results suggest that NMP treatment or EMF exposure of Saos 2 cells can increase osteogenic activity and NMP incorporation following EMF exposure which is synergistically efficient for osteogenesis.
C1 [Kim, Yu Mi; Lim, Han Moi; Lee, Eun Chul; Ki, Ga Eun; Seo, Young Kwon] Dongguk Univ, Dept Med Biotechnol, BK21 Plus Team, Goyang Si 10326, South Korea.
C3 Dongguk University
RP Seo, YK (通讯作者)，Dongguk Univ, Dept Med Biotechnol, BK21 Plus Team, Goyang Si 10326, South Korea.
EM bioseo@dongguk.edu
OI Ki, Ga Eun/0000 0003 1441 3845; , Eun Cheol Lee/0000 0002 3552 0132
FU National Research Foundation of Korea [NRF 2019R1I1A2A01063305]
FX National Research Foundation of Korea, Grant/Award Number:
   NRF 2019R1I1A2A01063305
CR Azuma N, 2000, J VASC SURG, V32, P789, DOI 10.1067/mva.2000.107989
   BASSETT CA, 1964, NATURE, V204, P652, DOI 10.1038/204652a0
   BASSETT CAL, 1974, SCIENCE, V184, P575
   BASSETT CAL, 1962, SCIENCE, V137, P1063, DOI 10.1126/science.137.3535.1063
   BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0
   BILLS CE, 1971, JOHNS HOPKINS MED J, V128, P194
   Cartmell Sarah H, 2002, IEEE Trans Nanobioscience, V1, P92, DOI 10.1109/TNB.2002.806945
   Chang WHS, 2004, BIOELECTROMAGNETICS, V25, P457, DOI 10.1002/bem.20016
   CHEN JK, 1991, MATRIX, V11, P133, DOI 10.1016/S0934 8832(11)80217 9
   Cho H, 2013, BIOTECHNOL APPL BIOC, V60, P596, DOI 10.1002/bab.1109
   Dayem AA, 2018, NANOMATERIALS BASEL, V8, DOI 10.3390/nano8100761
   De Mattei M, 1999, BIOELECTROMAGNETICS, V20, P177, DOI 10.1002/(SICI)1521 186X(1999)20:3<177::AID BEM4>3.0.CO;2 #
   Diniz P, 2002, BIOELECTROMAGNETICS, V23, P398, DOI 10.1002/bem.10032
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Duncan RL, 1998, SEMIN NEPHROL, V18, P178
   FARLEY JR, 1993, METABOLISM, V42, P97, DOI 10.1016/0026 0495(93)90179 R
   FUKADA E, 1957, J PHYS SOC JPN, V12, P1158, DOI 10.1143/JPSJ.12.1158
   Goodarzi H, 2019, TISSUE ENG REGEN MED, V16, P237, DOI 10.1007/s13770 019 00184 0
   Grace KLR, 1998, ORTHOPEDICS, V21, P297
   Grassi C, 2004, CELL CALCIUM, V35, P307, DOI 10.1016/j.ceca.2003.09.001
   Greenwald RB, 2003, ADV DRUG DELIVER REV, V55, P217, DOI 10.1016/S0169 409X(02)00180 1
   Hou YH, 2013, INT J NANOMED, V8, P3619, DOI 10.2147/IJN.S38992
   Huang J, 2017, SAUDI PHARM J, V25, P575, DOI 10.1016/j.jsps.2017.04.026
   HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562
   Jazayeri M, 2017, CELL J YAKHTEH, V1, P3
   Jeong HM, 2014, ARCH PHARM RES, V37, P276, DOI 10.1007/s12272 013 0178 3
   Jiráková K, 2016, INT J NANOMED, V11, P6267, DOI 10.2147/IJN.S116171
   Kang KS, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.11
   Kim IS, 2011, TISSUE ENG PT A, V17, P337, DOI [10.1089/ten.tea.2010.0408, 10.1089/ten.TEA.2010.0408]
   Kim JA, 2011, BIOMATERIALS, V32, P2871, DOI 10.1016/j.biomaterials.2011.01.019
   Kim SE, 2013, TISSUE ENG REGEN MED, V10, P353, DOI 10.1007/s13770 013 1098 5
   Klees RF, 2005, MOL BIOL CELL, V16, P881, DOI 10.1091/mbc.e04 08 0695
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Lee DH, 2015, J NANOSCI NANOTECHNO, V15, P5512, DOI 10.1166/jnn.2015.10193
   LUBEN RA, 1991, HEALTH PHYS, V61, P15, DOI 10.1097/00004032 199107000 00002
   Martino CF, 2008, BIOELECTROMAGNETICS, V29, P125, DOI 10.1002/bem.20372
   Mitchell D.B., 1980, Journal of tissue culture methods, V6, P113, DOI DOI 10.1007/BF02082861
   Oldenhof AD, 2002, AM J PHYSIOL CELL PH, V283, pC1530, DOI 10.1152/ajpcell.00607.2001
   Pall ML, 2014, ELECTROMAGN BIOL MED, V33, P251, DOI 10.3109/15368378.2014.906447
   Pankhurst QA, 2003, J PHYS D APPL PHYS, V36, pR167, DOI 10.1088/0022 3727/36/13/201
   Paun IA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020495
   Pilla Arthur A, 2002, J Orthop Sci, V7, P420, DOI 10.1007/s007760200073
   Pillarisetti S, 2019, TISSUE ENG REGEN MED, V16, P451, DOI 10.1007/s13770 019 00218 7
   RAIF EM, 1993, BIOMATERIALS, V14, P978, DOI 10.1016/0142 9612(93)90189 9
   Raouf A, 2002, BONE, V30, P463, DOI 10.1016/S8756 3282(01)00699 8
   Russo T, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10030577
   Salasznyk RM, 2004, CELL COMMUN ADHES, V11, P137, DOI 10.1080/15419060500242836
   Santini SJ, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/5076271
   Seeherman H, 2005, CYTOKINE GROWTH F R, V16, P329, DOI 10.1016/j.cytogfr.2005.05.001
   Spadaro JA, 1997, BIOELECTROMAGNETICS, V18, P193, DOI 10.1002/(SICI)1521 186X(1997)18:3<193::AID BEM1>3.0.CO;2 Y
   Sun LY, 2010, BIOELECTROMAGNETICS, V31, P209, DOI 10.1002/bem.20550
   TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092 8674(81)90037 4
   Tsai MT, 2009, J ORTHOP RES, V27, P1169, DOI 10.1002/jor.20862
   von Kóssa J, 1901, BEITR PATHOL ANAT AL, V29, P163
   Wang QW, 2016, BIOMATERIALS, V86, P11, DOI 10.1016/j.biomaterials.2016.02.004
   Wei M, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951 017 0310 5
   Wozney JM, 1998, CLIN ORTHOP RELAT R, P26
   YAMAGUCHI DT, 1987, J BIOL CHEM, V262, P7711
   Yi CQ, 2010, ACS NANO, V4, P6439, DOI 10.1021/nn101373r
   Yong Y, 2016, J TISSUE ENG REGEN M, V10, pE537, DOI 10.1002/term.1864
   Yoon MY, 2014, TISSUE ENG REGEN MED, V11, P230, DOI 10.1007/s13770 014 0017 8
   Zhang X, 2015, MOL CELL BIOCHEM, V407, P41, DOI 10.1007/s11010 015 2452 9
   Zhang Y, 2002, BIOMATERIALS, V23, P1553, DOI 10.1016/S0142 9612(01)00267 8
   Zhang YH, 2017, THERANOSTICS, V7, P1214, DOI 10.7150/thno.17252
NR 65
TC 7
Z9 7
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD AUG
PY 2021
VL 39
IS 8
BP 1633
EP 1646
DI 10.1002/jor.24905
EA JAN 2021
PG 14
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA TY3JW
UT WOS:000607315400001
PM 33150984
OA Green Published
DA 2025 08 17
ER

PT J
AU Zhou, LS
   Quan, RF
   Yang, J
   Xu, H
AF Zhou, Lishen
   Quan, Renfu
   Yang, Jun
   Xu, Hong
TI Healing of bone defects by induced pluripotent stem cell derived bone
   marrow mesenchymal stem cells seeded on hydroxyapatite zirconia
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Induced pluripotent stem cell (iPSC); bone marrow mesenchymal stem cells
   (BMSCs); bone regeneration; hydroxyapatite zirconia (HA; ZrO2)
ID SURFACE; REPAIR; MSCS; DERIVATION; COMPOSITE; PATHWAY
AB Background: Induced pluripotent stem cells (iPSCs) can generate bone marrow mesenchymal stem cells (BMSCs) as seed cells for tissue engineered bone to repair bone defects. In this study, we investigated the effects of hydroxyapatite zirconia (HA/ZrO2) composites combined with iPSC derived BMSCs as a bone substitute on repairing skull defects in rats. Methods: Human urinary cells isolated from a healthy donor were reprogramed into iPSCs and then induced into BMSCs. Immunocytochemistry (IHC) and reverse transcription polymerase chain reaction (RT PCR) were used to examine the characteristics of the induced MSCs. The iPSC derived BMSCs were cultured on HA/ZrO2 composites, and cytocompatibility of the composite was analyzed by cell counting kit 8 (CCK 8) assays, RT PCR, and scanning electron microscopy. Then, HA/ZrO2 combined with iPSCderived expanded potential stem cells (EpSCs) were transplanted onto skull defects of rats. The effects of this composite on bone repair were evaluated by IHC. Results: The results showed that MSCs induced from iPSCs displayed the phenotypes and property of normal BMSCs. After seeding on the HA/ZrO2, iPSC derived BMSCs had the ability to proliferate and differentiate into osteoblasts. After transplantation, iPSC derived BMSCs on HA/ZrO2 promoted construction of bone on rat skulls. Conclusions: These results indicated that transplantation of a HA/ZrO2 combined with iPS derived BMSCs is feasible to reconstruct bones and may be a substantial reference for iPSC based therapy for bone defects.
C1 [Zhou, Lishen; Quan, Renfu; Yang, Jun; Xu, Hong] Xiaoshan Hosp Tradit Chinese Med, Dept Orthoped Surg, Hangzhou 311201, Peoples R China.
RP Zhou, LS (通讯作者)，Xiaoshan Hosp Tradit Chinese Med, Dept Orthoped Surg, Hangzhou 311201, Peoples R China.
EM zhoulishen1992@163.com
FU Zhejiang Medical and Health Science and Technology Project [2014KYA191];
   Major Science and Technology Projects in Zhejiang Province [2014C03031]
FX Funding: This study was supported by Zhejiang Medical and Health Science
   and Technology Project (2014KYA191) and Major Science and Technology
   Projects in Zhejiang Province (2014C03031) .
CR Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Arvidson K, 2011, J CELL MOL MED, V15, P718, DOI 10.1111/j.1582 4934.2010.01224.x
   Atluri S, 2020, PAIN PHYSICIAN, V23, pE71
   Chen BL, 2016, INT J MOL MED, V38, P1531, DOI 10.3892/ijmm.2016.2757
   Cheng MQ, 2015, ACS APPL MATER INTER, V7, P13053, DOI 10.1021/acsami.5b03209
   D'Elía NL, 2015, NANOSCALE, V7, P18751, DOI 10.1039/c5nr04850h
   Ducheyne P, 2012, NAT MATER, V11, P652, DOI 10.1038/nmat3392
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   Ferreira E, 2013, J BIOL CHEM, V288, P29494, DOI 10.1074/jbc.M113.471268
   Gao CD, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.59
   Gao F, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.327
   Gratama JW, 2006, CYTOTHERAPY, V8, P528, DOI 10.1080/14653240601056354
   Hannan NRF, 2009, CLONING STEM CELLS, V11, P427, DOI 10.1089/clo.2009.0024
   Hasan A, 2018, J TISSUE ENG REGEN M, V12, P1448, DOI 10.1002/term.2677
   Illich DJ, 2011, STEM CELLS, V29, P555, DOI 10.1002/stem.611
   Jeong KJ, 2017, J BIOMED MATER RES A, V105, P1637, DOI 10.1002/jbm.a.35993
   Johnson PC, 2007, TISSUE ENG, V13, P2827, DOI 10.1089/ten.2007.0335
   Kagami H, 2011, INT J BIOCHEM CELL B, V43, P286, DOI 10.1016/j.biocel.2010.12.006
   Kashirina A, 2019, BIOMATER SCI UK, V7, P3961, DOI 10.1039/c9bm00664h
   Khan SA, 2014, INT J APPL CERAM TEC, V11, P590, DOI 10.1111/ijac.12191
   Lian QZ, 2007, STEM CELLS, V25, P425, DOI 10.1634/stemcells.2006 0420
   Lian QZ, 2010, CIRCULATION, V121, P1113, DOI 10.1161/CIRCULATIONAHA.109.898312
   Liang YH, 2012, ACS APPL MATER INTER, V4, P6719, DOI 10.1021/am301895u
   Lim JM, 2013, ORGANOGENESIS, V9, P245, DOI 10.4161/org.26202
   Lou An Ni, 2015, Nan Fang Yi Ke Da Xue Xue Bao, V35, P1457
   Calvo Guirado JL, 2015, CLIN IMPLANT DENT R, V17, P525, DOI 10.1111/cid.12162
   Moghadasi S, 2021, J TRANSL MED, V19, DOI 10.1186/s12967 021 02980 6
   Moroi A, 2018, J BIOMED MATER RES B, V106, P191, DOI 10.1002/jbm.b.33833
   O'Keefe RJ, 2011, TISSUE ENG PART B RE, V17, P389, DOI [10.1089/ten.teb.2011.0475, 10.1089/ten.TEB.2011.0475]
   Orosa B, 2015, J BONE MINER METAB, V33, P383, DOI 10.1007/s00774 014 0607 5
   Ozeki K, 2014, BIO MED MATER ENG, V24, P1793, DOI 10.3233/BME 140990
   Qi J, 2014, COMPOS INTERFACE, V9, P151
   Raggi Chiara, 2012, Muscles Ligaments Tendons J, V2, P239
   Shanti RM, 2007, J ORAL MAXIL SURG, V65, P1640, DOI 10.1016/j.joms.2007.04.008
   Sheyn D, 2016, STEM CELL TRANSL MED, V5, P1447, DOI 10.5966/sctm.2015 0311
   Shie MY, 2013, BIOMATERIALS, V34, P6589, DOI 10.1016/j.biomaterials.2013.05.075
   Shu P, 2020, HUM GENE THER, V31, P286, DOI 10.1089/hum.2019.306
   Stosich MS, 2007, TISSUE ENG, V13, P2881, DOI 10.1089/ten.2007.0078
   Tanaka K, 2014, CALCIFIED TISSUE INT, V94, P454, DOI 10.1007/s00223 013 9828 1
   Touboul T, 2010, HEPATOLOGY, V51, P1754, DOI 10.1002/hep.23506
   Turnbull G, 2018, BIOACT MATER, V3, P278, DOI 10.1016/j.bioactmat.2017.10.001
   Vallier L, 2005, STEM CELL REV, V1, P119, DOI 10.1385/SCR:1:2:119
   Vieira AE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128021
   Villa Diaz LG, 2012, STEM CELLS, V30, P1174, DOI 10.1002/stem.1084
   Xiao Y, 2020, THERANOSTICS, V10, P1500, DOI 10.7150/thno.39471
   Yang JZ, 2014, INT J APPL CERAM TEC, V11, P22, DOI 10.1111/ijac.12024
   Zhang JQ, 2011, CELL STEM CELL, V8, P31, DOI 10.1016/j.stem.2010.12.002
   Zhang X, 2003, CURR OPIN RHEUMATOL, V15, P387, DOI 10.1097/00002281 200307000 00004
   Zhou ML, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02249 1
NR 49
TC 5
Z9 5
U1 1
U2 26
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305 5839
EI 2305 5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD DEC
PY 2021
VL 9
IS 23
DI 10.21037/atm 21 5402
EA NOV 2021
PG 17
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA YI9ZY
UT WOS:000731542200001
PM 35071417
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Finnerty, F
   Walker Bone, K
   Tariq, S
AF Finnerty, Fionnuala
   Walker Bone, Karen
   Tariq, Shema
TI Osteoporosis in postmenopausal women living with HIV
SO MATURITAS
LA English
DT Article
DE HIV; Women; Osteoporosis; Menopause
ID BONE LOSS; VITAMIN D; DENSITY; TRIAL
AB The widespread availability of effective antiretroviral therapy (ART) has transformed HIV from a life limiting condition to one with near normal life expectancy. HIV is associated with an increased risk of osteopenia and osteoporosis, with people living with HIV (PLHIV) potentially experiencing these conditions at a younger age than their HIV negative counterparts. The mechanisms driving bone disease in HIV are complex and include: an increased prevalence of traditional risk factors; other comorbid conditions; and HIV associated factors such as viral effects, systemic inflammation, and ART related factors.
   One third of PLHIV in the United Kingdom are female, and increasing numbers of women living with HIV (WLHIV) are reaching menopausal age. Oestrogen decline in the context of an elevated background risk of poor bone health results in WLHIV being at greater risk of osteoporosis than women without HIV. European HIV guidelines therefore recommend routine screening of postmenopausal WLHIV using FRAX (c) for clinical risk factors, with or without bone mineral density scanning.
   Data support the use of calcium and vitamin D supplementation, and bisphosphonates in the treatment of osteoporosis in PLHIV. Additionally, some patients with confirmed osteoporosis may benefit from a switch to an ART agent with a better bone safety profile. However, there remains a notable paucity of data on HIV and menopause, including the impact of hormone replacement therapy on the bone health of WLHIV.
   In conclusion, it is important that clinicians are aware that postmenopausal WLHIV are a group at particular risk of bone disease, who require proactive screening and advice about preventative measures. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Finnerty, Fionnuala] Brighton Univ Hosp, Lawson Unit, Eastern Rd, Brighton BN2 5BE, E Sussex, England.
   [Finnerty, Fionnuala] Sussex Univ Hosp, Lawson Unit, Eastern Rd, Brighton BN2 5BE, E Sussex, England.
   [Walker Bone, Karen] Southampton Gen Hosp, Arthrit Res UK MRC Ctr Musculoskeletal Hlth & Wor, MRC Lifecourse Epidemiol Unit, Tremona Rd, Southampton SO16 6YD, Hants, England.
   [Tariq, Shema] UCL, Mortimer Market Ctr, Res Dept Infect & Populat Hlth, Capper St, London WC1E 6JB, England.
C3 University of Brighton; University of Sussex; University of Southampton;
   University of London; University College London
RP Tariq, S (通讯作者)，UCL, Mortimer Market Ctr, Res Dept Infect & Populat Hlth, Capper St, London WC1E 6JB, England.
EM fionnuala.finnerty@bsuh.nhs.uk; kwb@mrc.soton.ac.uk; s.tariq@ucl.ac.uk
RI ; Walker Bone, Karen/AAE 5255 2019
OI Tariq, Shema/0000 0001 9802 7727; Walker Bone,
   Karen/0000 0002 5992 1459; 
FU National Institute of Health Research (NIHR) [PDF 2014 07 071]; MRC
   [MC_UU_12011/5] Funding Source: UKRI; Medical Research Council
   [MC_UU_12011/5] Funding Source: researchfish; National Institute for
   Health Research [PDF 2014 07 071] Funding Source: researchfish; National
   Institutes of Health Research (NIHR) [PDF 2014 07 071] Funding Source:
   National Institutes of Health Research (NIHR)
FX ST is funded by the National Institute of Health Research (NIHR) in the
   form of a postdoctoral fellowship (grant number: PDF 2014 07 071). Any
   views expressed in this paper are those of the authors, and not
   necessarily those of the funders.
CR Compston J, 2016, J INTERN MED, V280, P350, DOI 10.1111/joim.12520
   Cortés YI, 2015, J ASSOC NURSE AIDS C, V26, P387, DOI 10.1016/j.jana.2015.03.005
   Cotter EJ, 2007, AIDS RES HUM RETROV, V23, P1521, DOI 10.1089/aid.2007.0112
   de Menezes E. G., 2016, J BONE MINER METAB
   Liu AY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023688
   May MT, 2014, AIDS, V28, P1193, DOI 10.1097/QAD.0000000000000243
   McComsey GA, 2010, CLIN INFECT DIS, V51, P937, DOI 10.1086/656412
   Mills A, 2016, LANCET INFECT DIS, V16, P43, DOI 10.1016/S1473 3099(15)00348 5
   National Institute for Health and Care Excellence (NICE), 2015, MEN DIAGN MAN
   Negredo E, 2016, CURR OPIN HIV AIDS, V11, P351, DOI 10.1097/COH.0000000000000271
   Ofotokun I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9282
   Overton ET, 2015, ANN INTERN MED, V162, P815, DOI 10.7326/M14 1409
   Public Health England, 2015, HIV UK SIT REP 2015
   Shiau S, 2013, AIDS, V27, P1949, DOI 10.1097/QAD.0b013e328361d241
   Tariq S, 2016, MATURITAS, V88, P76, DOI 10.1016/j.maturitas.2016.03.015
   Wohl DA, 2014, ANTIVIR THER, V19, P191, DOI 10.3851/IMP2721
   Yin MT, 2016, JAIDS J ACQ IMM DEF, V72, P513, DOI 10.1097/QAI.0000000000000998
NR 17
TC 21
Z9 22
U1 0
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 5122
EI 1873 4111
J9 MATURITAS
JI Maturitas
PD JAN
PY 2017
VL 95
BP 50
EP 54
DI 10.1016/j.maturitas.2016.10.015
PG 5
WC Geriatrics & Gerontology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology; Obstetrics & Gynecology
GA EF7ME
UT WOS:000390512900008
PM 27889053
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Liao, HT
   Lin, YF
   Tsai, CY
   Chou, TC
AF Liao, H T
   Lin, Y F
   Tsai, C Y
   Chou, T C
TI Bone morphogenetic proteins and Dickkopf 1 in ankylosing spondylitis
SO SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RADIOGRAPHIC PROGRESSION;
   DISEASE ACTIVITY; SPONDYLOARTHRITIS; INDEX; CYCLOOXYGENASE 2; ARTHRITIS;
   TURNOVER; PATHWAY; FUSION
AB Objectives: To determine bone morphogenetic proteins (BMPs) and Dickkopf homologue 1 (Dkk 1) levels in ankylosing spondylitis (AS).
   Method: Serum BMPs and Dkk 1 were measured in 72 AS patients and 30 healthy controls. For AS patients, we recorded the demographic data, disease activity, functional index, and global assessment with questionnaires, and image changes with roentgenography. We also measured human leucocyte antigen B27 and systemic inflammatory reactants.
   Results: BMPs were higher but Dkk 1 was significantly lower in AS patients than in controls. Dkk 1 was higher in AS patients who received non steroidal anti inflammatory drugs (NSAIDs) regularly in the past year (p = 0.001). Serum BMP 7 level and the BMP 7/Dkk 1 ratio correlated significantly with sacroiliitis severity, Bath Ankylosing Spondylitis Radiology Index (BASRI) total, modified Stoke Ankylosing Spondylitis Spinal Score, and disease duration. There were also significant positive correlations among serum levels of BMP 2,  4, and  6, BASRI total, and disease duration (p <0.05). However, BMP 2/Dkk 1 was only significantly correlated with disease duration. The calculated area under the standard receiver operating characteristics curve suggested that BMP 2/Dkk 1 and serum BMP 2 are good indicators to predict disease activity, functional index, and patient global assessment in AS patients.
   Conclusion: BMPs and BMPs/Dkk 1 were significantly correlated with disease activity, and radiological and functional indices in AS patients. Dkk 1 was lower in AS patients than in controls. Among AS patients, Dkk 1 was higher in those taking NSAIDs regularly. BMP or Dkk 1 may be taken as a biomarker for disease severity or a treatment outcome predictor in AS, but this needs further study.
C1 [Liao, H T; Lin, Y F] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan.
   [Liao, H T; Tsai, C Y; Chou, T C] Taipei Vet Gen Hosp, Dept Internal Med, Div Allergy Immunol & Rheumatol, Taipei, Taiwan.
   [Liao, H T] Taipei Med Univ, Dept Internal Med, Coll Med, Div Allergy Immunol & Rheumatol,Sch Med, Taipei, Taiwan.
   [Liao, H T; Tsai, C Y; Chou, T C] Natl Yang Ming Univ, Sch Med, Coll Med, Taipei, Taiwan.
   [Lin, Y F] Taipei Med Univ, Shuang Ho Hosp, Div Nephrol, Dept Internal Med, New Taipei, Taiwan.
C3 Taipei Medical University; Taipei Veterans General Hospital; Taipei
   Medical University; National Yang Ming Chiao Tung University; Taipei
   Medical University; Shuang Ho Hospital
RP Chou, TC (通讯作者)，Taipei Vet Gen Hosp, Dept Med, Div Allergy Immunol & Rheumatol, 201,Sect 2,Shipai Rd, Taipei 112, Taiwan.
EM b8201098@tmu.edu.tw
RI Tsai, Chang Youh/G 1747 2013
CR Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Braun J, 2003, ANN RHEUM DIS, V62, P817, DOI 10.1136/ard.62.9.817
   Braun J, 2011, ANN RHEUM DIS, V70, pI97, DOI 10.1136/ard.2010.140541
   CALIN A, 1994, J RHEUMATOL, V21, P2281
   Calin A, 1999, J RHEUMATOL, V26, P988
   Carter S, 2012, THER ADV MUSCULOSKEL, V4, P293, DOI 10.1177/1759720X12444175
   Chang JK, 2005, CONNECT TISSUE RES, V46, P200, DOI 10.1080/03008200500344025
   Chen HA, 2010, J RHEUMATOL, V37, P2126, DOI 10.3899/jrheum.100200
   Corr M, 2014, CLIN RHEUMATOL, V33, P759, DOI 10.1007/s10067 014 2663 6
   Creemers MCW, 2005, ANN RHEUM DIS, V64, P127, DOI 10.1136/ard.2004.020503
   Daoussis D, 2010, ARTHRITIS RHEUM US, V62, P150, DOI 10.1002/art.27231
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   GARRETT S, 1994, J RHEUMATOL, V21, P2286
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736 0266(02)00079 7
   Haroon N, 2015, CLIN RHEUMATOL, V34, P1003, DOI 10.1007/s10067 015 2956 4
   Haroon N, 2012, ANN RHEUM DIS, V71, P1593, DOI 10.1136/annrheumdis 2012 201844
   Hsu WK, 2008, SPINE J, V8, P419, DOI 10.1016/j.spinee.2008.01.008
   Jones SD, 1996, BRIT J RHEUMATOL, V35, P66
   Joo YB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104966
   KHAN MA, 1990, RHEUM DIS CLIN N AM, V16, P551
   Konstantinidis I, 2013, REV RECENT CLIN TRIA, V8, P48, DOI 10.2174/1574887111308010008
   Kroon F, 2012, ANN RHEUM DIS, V71, P1623, DOI 10.1136/annrheumdis 2012 201370
   Kwon SR, 2012, RHEUMATOL INT, V32, P2523, DOI 10.1007/s00296 011 1981 0
   Lories R, 2011, NAT REV RHEUMATOL, V7, P700, DOI 10.1038/nrrheum.2011.156
   Lories RJU, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2135
   Lories RJU, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2642
   Lories RJU, 2005, CYTOKINE GROWTH F R, V16, P287, DOI 10.1016/j.cytogfr.2005.02.009
   Lories RJU, 2005, J CLIN INVEST, V115, P1571, DOI 10.1172/JCI23738
   Marzo Ortega H, 2002, J RHEUMATOL, V29, P1583
   Park MC, 2008, SCAND J RHEUMATOL, V37, P200, DOI 10.1080/03009740701774941
   Poddubnyy D, 2012, ANN RHEUM DIS, V71, P1616, DOI 10.1136/annrheumdis 2011 201252
   Polzer K, 2008, JOINT BONE SPINE, V75, P105, DOI 10.1016/j.jbspin.2007.10.005
   Rossini M, 2016, CALCIFIED TISSUE INT, V98, P438, DOI 10.1007/s00223 015 0093 3
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Uderhardt S, 2010, ANN RHEUM DIS, V69, P592, DOI 10.1136/ard.2008.102046
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   van Esch RW, 2013, MED HYPOTHESES, V81, P343, DOI 10.1016/j.mehy.2013.03.042
   VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361
   Vuolteenaho K, 2008, BASIC CLIN PHARMACOL, V102, P10, DOI 10.1111/j.1742 7843.2007.00149.x
   Wanders A, 2005, ARTHRITIS RHEUM US, V52, P1756, DOI 10.1002/art.21054
   Wendling D, 2007, JOINT BONE SPINE, V74, P304, DOI 10.1016/j.jbspin.2006.11.005
   Zochling J, 2005, RHEUMATOLOGY, V44, P1483, DOI 10.1093/rheumatology/kei047
NR 43
TC 32
Z9 34
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300 9742
EI 1502 7732
J9 SCAND J RHEUMATOL
JI Scand. J. Rheumatol.
PY 2018
VL 47
IS 1
BP 56
EP 61
DI 10.1080/03009742.2017.1287305
PG 6
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA FU1PO
UT WOS:000423622100007
PM 28303752
DA 2025 08 17
ER

PT J
AU Havelin, J
   Imbert, I
   Cormier, J
   Allen, J
   Porreca, F
   King, T
AF Havelin, Joshua
   Imbert, Ian
   Cormier, Jennifer
   Allen, Joshua
   Porreca, Frank
   King, Tamara
TI Central Sensitization and Neuropathic Features of Ongoing Pain in a Rat
   Model of Advanced Osteoarthritis
SO JOURNAL OF PAIN
LA English
DT Article
DE Advanced osteoarthritis; neuropathic pain; duloxetine; central
   sensitization; descending facilitation
ID KNEE OSTEOARTHRITIS; DESCENDING PAIN; OLDER ADULTS; CANCER PAIN;
   SPINAL CORD; NERVE; HYPERSENSITIVITY; ANTIDEPRESSANTS; FACILITATION;
   MODULATION
AB Osteoarthritis. (OA) pain is most commonly characterized by movement triggered joint pain. However, in advanced disease, OA pain becomes persistent, ongoing and resistant to treatment with nonsteroidal anti inflammatory drugs (NSAIDs). The mechanisms underlying ongoing pain in advanced OA are poorly understood. We recently showed that intra articular (i.a.) injection of monosodium iodoacetate (MIA) into the rat knee joint produces concentration dependent outcomes. Thus, a low dose of i.a.. MIA produces NSAID sensitive weight asymmetry without evidence of ongoing pain and a high i.a. MIA dose produces weight asymmetry and NSAID resistant ongoing pain. In the present study, palpation of the ipsilateral hind limb of rats treated 14 days previously with high, but not low, doses of i.a. MIA produced expression of the early oncogene, FOS, in the spinal dorsal horn. Inactivation of descending pain facilitatory pathways using a microinjection of lidocaine within the rostra! ventromedial medulla induced conditioned place preference selectively in rats treated with the high dose of MIA. Conditioned place preference to intra articular lidocaine was blocked by pretreatment with duloxetine (30 mg/kg, intraperitoneally at 30 minutes). These observations are consistent with the likelihood of a neuropathic component of OA that elicits ongoing, NSAID resistant pain and central sensitization that is mediated, in part, by descending modulatory mechanisms. This model provides a basis for exploration of underlying mechanisms promoting neuropathic components of OA pain and for the identification of mechanisms that might guide drug discovery for treatment of advanced OA pain without the need for joint replacement.
   Perspective: Difficulty in managing advanced OA pain often results in joint replacement therapy in these patients. Improved understanding of mechanisms driving NSAID resistant ongoing OA pain might facilitate development of alternatives to joint replacement therapy. Our findings suggest that central sensitization and neuropathic features contribute to NSAID resistant ongoing OA joint pain. (C) 2016 by the American Pain Society
C1 [Havelin, Joshua; Imbert, Ian; Cormier, Jennifer; Allen, Joshua; King, Tamara] Univ New England, Ctr Excellence Neurosci, Coll Osteopath Med, Dept Biomed Sci, Biddeford, ME USA.
   [Porreca, Frank] Univ Arizona, Arizona Hlth Sci Ctr, Dept Pharmacol, Tucson, AZ USA.
C3 University of New England   Maine; University of Arizona; University of
   Arizona Health Sciences
RP King, T (通讯作者)，Ctr Excellence Neurosci, Coll Osteopath Med, Dept Biomed Sci, 11 Hills Beach Rd, Biddeford, ME 04005 USA.
EM tking6@une.edu
FU Center of Biomedical Research Excellence [P20GM103643]
FX This work supported in part by a Center of Biomedical Research
   Excellence grant (P20GM103643: PI: I. Meng).
CR Ansari A, 2000, HARVARD REV PSYCHIAT, V7, P257
   Arendt Nielsen L, 2010, PAIN, V149, P573, DOI 10.1016/j.pain.2010.04.003
   Bee L.A., 2009, F1000 medicine reports, V1, P83, DOI [10.3410/M1 83, DOI 10.3410/M1 83]
   Brenchat A, 2009, PAIN, V141, P239, DOI 10.1016/j.pain.2008.11.009
   Burnham LJ, 2013, J PHARMACOL EXP THER, V344, P696, DOI 10.1124/jpet.112.199489
   Devor M, 2009, EXP BRAIN RES, V196, P115, DOI 10.1007/s00221 009 1724 6
   Dogrul A, 2009, BRAIN RES, V1280, P52, DOI 10.1016/j.brainres.2009.05.001
   Esin E, 2014, ONCOTARGETS THER, V7, P599, DOI 10.2147/OTT.S60995
   Fishbain DA, 2000, PAIN MED, V1, P310, DOI 10.1046/j.1526 4637.2000.00042.x
   Gwilym SE, 2009, ARTHRIT RHEUM ARTHR, V61, P1226, DOI 10.1002/art.24837
   Haanpaa ML, 2010, MAYO CLIN PROC, V85, pS15, DOI 10.4065/mcp.2009.0645
   Hawker GA, 2008, OSTEOARTHR CARTILAGE, V16, P415, DOI 10.1016/j.joca.2007.12.017
   Hawker GA, 2006, CURR OPIN RHEUMATOL, V18, P526
   Hochman JR, 2011, OSTEOARTHR CARTILAGE, V19, P647, DOI 10.1016/j.joca.2011.03.007
   Hochman JR, 2010, ARTHRIT CARE RES, V62, P1019, DOI 10.1002/acr.20142
   Honore P, 2000, NEUROSCIENCE, V98, P585, DOI 10.1016/S0306 4522(00)00110 X
   Ivanavicius SP, 2007, PAIN, V128, P272, DOI 10.1016/j.pain.2006.12.022
   King T, 2009, NAT NEUROSCI, V12, P1364, DOI 10.1038/nn.2407
   Kosek E, 2000, EUR J PAIN, V4, P229, DOI 10.1053/eujp.2000.0175
   Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012
   Liu P, 2011, NEUROSCI LETT, V493, P72, DOI 10.1016/j.neulet.2011.01.027
   Lluch E, 2014, EUR J PAIN, V18, P1367, DOI 10.1002/j.1532 2149.2014.499.x
   Lunn MPT, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007115.pub3
   Ma QP, 1996, PAIN, V67, P307, DOI 10.1016/0304 3959(96)03132 6
   Murphy SL, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3449
   Okun A, 2012, PAIN, V153, P924, DOI 10.1016/j.pain.2012.01.022
   Ossipov MH, 2000, ANN NY ACAD SCI, V909, P12
   Ossipov MH, 2014, CURR OPIN SUPPORT PA, V8, P143, DOI 10.1097/SPC.0000000000000055
   Ossipov MH, 2010, J CLIN INVEST, V120, P3779, DOI 10.1172/JCI43766
   Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix
   Pomonis JD, 2005, PAIN, V114, P339, DOI 10.1016/j.pain.2004.11.008
   Qu CL, 2011, PAIN, V152, P1641, DOI 10.1016/j.pain.2011.03.002
   Schaible HG, 2012, CURR RHEUMATOL REP, V14, P549, DOI 10.1007/s11926 012 0279 x
   Schwei MJ, 1999, J NEUROSCI, V19, P10886, DOI 10.1523/JNEUROSCI.19 24 10886.1999
   Suzuki R, 2004, TRENDS PHARMACOL SCI, V25, P613, DOI 10.1016/j.tips.2004.10.002
   Suzuki R, 2004, BRAIN RES, V1019, P68, DOI 10.1016/j.brainres.2004.05.108
   Thakur M, 2014, NAT REV RHEUMATOL, V10, P374, DOI 10.1038/nrrheum.2014.47
   Thakur M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033730
   Trivedi JR, 2013, NEUROL CLIN, V31, P377, DOI 10.1016/j.ncl.2013.01.003
   Wang RZ, 2013, J PAIN, V14, P845, DOI 10.1016/j.jpain.2013.02.011
   Wood LRJ, 2007, OSTEOARTHR CARTILAGE, V15, P615, DOI 10.1016/j.joca.2006.12.001
   Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030
   YAKSH TL, 1985, PHARMACOL BIOCHEM BE, V22, P845, DOI 10.1016/0091 3057(85)90537 4
   Zhang ET, 2007, PAIN, V129, P143, DOI 10.1016/j.pain.2006.10.009
NR 44
TC 74
Z9 84
U1 0
U2 13
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526 5900
J9 J PAIN
JI J. Pain
PD MAR
PY 2016
VL 17
IS 3
BP 374
EP 382
DI 10.1016/j.jpain.2015.12.001
PG 9
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA DH3FH
UT WOS:000372672400010
PM 26694132
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Hoeres, T
   Wilhelm, M
   Smetak, M
   Holzmann, E
   Schulze Tanzil, G
   Birkmann, J
AF Hoeres, T.
   Wilhelm, M.
   Smetak, M.
   Holzmann, E.
   Schulze Tanzil, G.
   Birkmann, J.
TI Immune cells regulate VEGF signalling via release of VEGF and
   antagonistic soluble VEGF receptor 1
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE gamma delta; interleukin 2; monocyte; soluble VEGF receptor; VEGF
ID ENDOTHELIAL GROWTH FACTOR; DELTA T CELLS; TUMOR ASSOCIATED MACROPHAGES;
   ZOLEDRONIC ACID; INHIBITS ANGIOGENESIS; HUMAN MONOCYTES; POTENTIAL ROLE;
   IN VITRO; CANCER; EXPRESSION
AB Vascular endothelial growth factor (VEGF) is an important regulator of physiological and pathological angiogenesis. Besides malignant and stromal cells, local immune cells shape VEGF signalling in the tumour microenvironment. Aminobisphosphonates such as zoledronic acid (Zol) are drugs known to inhibit osteoclast activity and bone resorption, but also have immunomodulatory and anti tumour effects. These properties have been linked previously to the down regulation of VEGF and interference with tumour neo angiogenesis. It was therefore surprising to find that treatment with Zol in combination with low dose interleukin (IL) 2 increased serum VEGF levels in cancer patients. In this study we aimed to characterize the effect of Zol and IL 2 on VEGF signalling of blood derived immune cells in vitro. Upon stimulation with IL 2, T cells and natural killer (NK) cells increase production of VEGF consecutively to the release of proinflammatory interferon (IFN) gamma, and Zol accelerates this response specifically in gamma delta T cells. VEGF can, in turn, be antagonized by soluble VEGF receptor (sVEGFR) 1, which is released depending on stimulatory conditions and the presence of monocytes. Additionally, malignant cells represented by leukaemia and lymphoma cell lines produce VEGF and some release sVEGFR 1 simultaneously. Our findings indicate a mechanism by which the VEGF and the sVEGFR 1 production by immune cells regulates local VEGF signalling. Therefore, immunotherapeutic interventions may enable both pro as well as anti tumour effects via immune cell mediated alterations of VEGF homeostasis.
C1 [Hoeres, T.; Wilhelm, M.; Smetak, M.; Holzmann, E.; Birkmann, J.] Paracelsus Med Univ, Dept Hematol & Med Oncol, Nurnberg, Germany.
   [Schulze Tanzil, G.] Paracelsus Med Univ, Inst Anat, Nurnberg, Germany.
RP Hoeres, T (通讯作者)，Klinikum Nurnberg, Med Klin 5, Prof Ernst Nathan Str 1, D 90419 Nurnberg, Germany.
EM Timm.Hoeres@klinikum nuernberg.de
RI Höres, Timm/GSE 0296 2022
FU Verein Hilfe fur Krebskranke e.V.; W. Lutz Stiftung
FX This study was supported by Verein Hilfe fur Krebskranke e.V. and a
   scholarship for Timm Hoeres from W. Lutz Stiftung.
CR Atkins MB, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4505
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Barleon Bernhard, 2001, Angiogenesis, V4, P143, DOI 10.1023/A:1012245307884
   Basu A, 2010, J IMMUNOL, V184, P545, DOI 10.4049/jimmunol.0900397
   Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027
   Bottomley MJ, 1999, CLIN EXP IMMUNOL, V117, P171
   BURDACH S, 1991, J CLIN INVEST, V87, P2114, DOI 10.1172/JCI115242
   Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629
   Edelbauer M, 2010, BLOOD, V116, P1980, DOI 10.1182/blood 2009 11 252460
   Eubank TD, 2004, IMMUNITY, V21, P831, DOI 10.1016/j.immuni.2004.10.011
   Eubank TD, 2003, J IMMUNOL, V171, P2637, DOI 10.4049/jimmunol.171.5.2637
   FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Finley SD, 2015, DRUG DISCOV TODAY, V20, P187, DOI 10.1016/j.drudis.2014.09.026
   Fisher JPH, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27572
   FREEMAN MR, 1995, CANCER RES, V55, P4140
   Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096 1096
   Gavalas NG, 2012, BRIT J CANCER, V107, P1869, DOI 10.1038/bjc.2012.468
   Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909
   Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Gunsilius E, 2000, ONCOLOGY BASEL, V58, P169, DOI 10.1159/000012095
   Insalaco L, 2012, J CELL MOL MED, V16, P2186, DOI 10.1111/j.1582 4934.2012.01527.x
   Justiniano SE, 2013, J BIOL CHEM, V288, P26800, DOI 10.1074/jbc.M113.485185
   Kabelitz D, 2004, J IMMUNOL, V173, P6767, DOI 10.4049/jimmunol.173.11.6767
   Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   Kishuku M, 2009, J IMMUNOL, V183, P8176, DOI 10.4049/jimmunol.0803849
   Kridel R, 2015, HAEMATOLOGICA, V100, P143, DOI 10.3324/haematol.2015.124008
   Kunzmann V, 2000, BLOOD, V96, P384
   Kunzmann V, 2012, J IMMUNOTHER, V35, P205, DOI 10.1097/CJI.0b013e318245bb1e
   Laggner U, 2011, J IMMUNOL, V187, P2783, DOI 10.4049/jimmunol.1100804
   Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054
   LEVITT LJ, 1991, J CLIN INVEST, V88, P67, DOI 10.1172/JCI115306
   Li YL, 2016, CANCER BIOL MED, V13, P206, DOI 10.20892/j.issn.2095 3941.2015.0070
   Matsuyama W, 2002, IMMUNOLOGY, V106, P96, DOI 10.1046/j.1365 2567.2002.01395.x
   Melton DW, 2015, AUTOIMMUNITY, V48, P161, DOI 10.3109/08916934.2015.1027816
   Mor F, 2004, J IMMUNOL, V172, P4618, DOI 10.4049/jimmunol.172.7.4618
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Panelli MC, 2002, GENOME BIOL, V3
   Pavlakovic H, 2010, ANN NY ACAD SCI, V1207, pE7, DOI 10.1111/j.1749 6632.2010.05714.x
   R&D Systems Inc, 2015, QUANTIKINE ELISA HUM
   Rei M, 2015, CANCER RES, V75, P798, DOI 10.1158/0008 5472.CAN 14 3228
   Reinders MEJ, 2003, J CLIN INVEST, V112, P1655, DOI 10.1172/JCI200317712
   Roeckl W, 1998, EXP CELL RES, V241, P161, DOI 10.1006/excr.1998.4039
   Sabatino M, 2009, J CLIN ONCOL, V27, P2645, DOI 10.1200/JCO.2008.19.1106
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   Santini D, 2007, CLIN CANCER RES, V13, P4482, DOI 10.1158/1078 0432.CCR 07 0551
   Santos SCR, 2004, BLOOD, V103, P3883, DOI 10.1182/BLOOD 2003 05 1634
   Schilbach K, 2008, J IMMUNOTHER, V31, P896, DOI 10.1097/CJI.0b013e31818955ad
   Shin JY, 2009, CELL IMMUNOL, V256, P72, DOI 10.1016/j.cellimm.2009.01.006
   Stefanini MO, 2008, BMC SYST BIOL, V2, DOI 10.1186/1752 0509 2 77
   Steidl C, 2010, NEW ENGL J MED, V362, P875, DOI 10.1056/NEJMoa0905680
   Terme M, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25156
   Van Acker HH, 2016, PHARMACOL THERAPEUT, V158, P24, DOI 10.1016/j.pharmthera.2015.11.008
   Viey E, 2005, J IMMUNOL, V174, P1338, DOI 10.4049/jimmunol.174.3.1338
   Voron T, 2015, J EXP MED, V212, P139, DOI 10.1084/jem.20140559
   Wakita D, 2010, EUR J IMMUNOL, V40, P1927, DOI 10.1002/eji.200940157
   Wilhelm M, 2003, BLOOD, V102, P200, DOI 10.1182/blood 2002 12 3665
   Wu FTH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005108
   Wu WK, 2015, AM J PATHOL, V185, P2324, DOI 10.1016/j.ajpath.2015.04.013
   Wu WK, 2010, IMMUNOBIOLOGY, V215, P796, DOI 10.1016/j.imbio.2010.05.025
   Zhang JS, 2010, CIRC RES, V107, P408, DOI 10.1161/CIRCRESAHA.109.210963
   Zloza A, 2017, CANCER IMMUNOL IMMUN, V66, P9, DOI 10.1007/s00262 016 1916 4
NR 67
TC 20
Z9 22
U1 1
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0009 9104
EI 1365 2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD APR
PY 2018
VL 192
IS 1
BP 54
EP 67
DI 10.1111/cei.13090
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA FY5EC
UT WOS:000426848200006
PM 29235095
OA Green Published
DA 2025 08 17
ER

PT J
AU Paull, DR
   Lee, C
   Atkinson, SJ
   Fisher, AD
AF Paull, D. R.
   Lee, C.
   Atkinson, S. J.
   Fisher, A. D.
TI Effects of meloxicam or tolfenamic acid administration on the pain and
   stress responses of Merino lambs to mulesing
SO AUSTRALIAN VETERINARY JOURNAL
LA English
DT Article
DE analgesia; lambs; meloxicam; mulesing; tolenamic acid
ID INTERFERON GAMMA PRODUCTION; SUBSTANCE P RECEPTOR; ACUTE PHASE PROTEINS;
   BEHAVIORAL RESPONSES; FEED INTAKE; POSTOPERATIVE PAIN;
   ORTHOPEDIC SURGERY; BULL CALVES; PHARMACODYNAMICS; CORTISOL
AB Objective To determine the effectiveness of two long acting non steroidal anti inflammatory drugs (NSAIDs) at reducing the pain and stress responses to mulesing in lambs.
   Procedures Merino lambs (n = 60) were allocated at 5 weeks of age to six treatment groups: (1) sham mules; (2) mules; (3) tolfenamic acid sham mules; (4) tolfenamic acid administered 45 min before mulesing; (5) tolfenamic acid at the time of mulesing; (6) meloxicam at the time of mulesing. Plasma cortisol was measured at  0.75,  0.25, 0, 0.5, 1, 3, 6, 12, 24, 48 and 72 h relative to mulesing. Beta endorphin concentrations in plasma were determined at 0, 0.5, 1, 6, 12, 24, and 48 h. Haematology was performed on blood samples taken at 0.75, 0, 24, 48 and 72 h. Plasma haptoglobin was measured at 0, 12, 24, 48 and 72 h. Rate of wound healing was determined 72 h post mulesing, and animal behaviour, including posture, was measured for 6 h after mulesing.
   Results The mulesed lambs exhibited large increases in plasma concentrations of cortisol, beta endorphin and haptoglobin. All mulesed animals lost weight significantly in the week after mulesing, regardless of analgesic administration, but the difference in weight between mulesed and unmulesed lambs was less at the final measurement, 2 weeks after mulesing. Mulesed lambs spent significantly less time lying ventrally than control lambs. All lambs that were mulesed, including those administered NSAIDs, spent more time standing with a hunched posture and less time walking normally than control lambs.
   Conclusions The NSAID treatments applied 45 min before or at the time of mulesing at the dose levels used in this study were not effective in reducing the acute response of lambs to mulesing.
C1 [Paull, D. R.; Lee, C.; Atkinson, S. J.; Fisher, A. D.] CSIRO Livestock Ind, FD McMaster Lab, Armidale, NSW 2350, Australia.
C3 Commonwealth Scientific & Industrial Research Organisation (CSIRO)
RP Paull, DR (通讯作者)，CSIRO Livestock Ind, FD McMaster Lab, Locked Bag 1, Armidale, NSW 2350, Australia.
EM Andrew.Fisher@csiro.au
RI Lee, Caroline/B 9427 2008
OI Fisher, Andrew/0000 0002 2505 2160
CR Arifah AK, 2001, AM J VET RES, V62, P77, DOI 10.2460/ajvr.2001.62.77
   CHAPMAN RE, 1994, AUST VET J, V71, P243, DOI 10.1111/j.1751 0813.1994.tb03420.x
   DRAY A, 1995, BRIT J ANAESTH, V75, P125, DOI 10.1093/bja/75.2.125
   FELL LR, 1989, APPL ANIM BEHAV SCI, V22, P283, DOI 10.1016/0168 1591(89)90023 3
   Fisher AD, 1997, J ANIM SCI, V75, P1899
   Fisher AD, 1996, J ANIM SCI, V74, P2336
   Fisher AD, 1997, J ANIM SCI, V75, P1041
   GILMOUR AR, 2002, ASREML USER GUIDE RE
   GRANDEMANGE E, 2004, P 23 WORLD BUIATR C, P313
   Grant C, 1996, AUST VET J, V73, P129, DOI 10.1111/j.1751 0813.1996.tb10004.x
   Grant C, 2004, APPL ANIM BEHAV SCI, V87, P255, DOI 10.1016/j.applanim.2004.01.011
   Grisneaux E, 1999, J AM VET MED ASSOC, V215, P1105
   Johnson RW, 1997, J ANIM SCI, V75, P1244
   JONES GE, 1984, RES VET SCI, V37, P87, DOI 10.1016/S0034 5288(18)31933 7
   Landoni MF, 1996, RES VET SCI, V61, P26, DOI 10.1016/S0034 5288(96)90106 X
   Landoni MF, 1999, J VET PHARMACOL THER, V22, P349, DOI 10.1046/j.1365 2885.1999.00209.x
   Laredo FG, 2004, VET REC, V155, P667, DOI 10.1136/vr.155.21.667
   Lascelles BDX, 1998, VET SURG, V27, P568, DOI 10.1111/j.1532 950X.1998.tb00533.x
   Lees P, 1998, VET J, V155, P275, DOI 10.1016/S1090 0233(05)80024 3
   Lester SJ, 1996, NEW ZEAL VET J, V44, P45, DOI 10.1080/00480169.1996.35933
   MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521
   Mamet J, 2002, J NEUROSCI, V22, P10662
   Mantyh PW, 1997, SCIENCE, V278, P275, DOI 10.1126/science.278.5336.275
   Mather LE, 2000, REGION ANESTH PAIN M, V25, P174, DOI 10.1053/rapm.2000.0250174
   Mathews KA, 2002, J VET EMERG CRIT CAR, V12, P89, DOI 10.1046/j.1435 6935.2002.00007.x
   Mathews KA, 2001, AM J VET RES, V62, P882, DOI 10.2460/ajvr.2001.62.882
   MCCORMACK K, 1991, DRUGS, V41, P533, DOI 10.2165/00003495 199141040 00003
   MCKELLAR QA, 1994, EUR J PHARMACOL, V253, P191, DOI 10.1016/0014 2999(94)90191 0
   Mehlisch Donald R, 1999, Cancer Control, V6, P5
   Moiniche S, 2002, ANESTHESIOLOGY, V96, P725, DOI 10.1097/00000542 200203000 00032
   MOLONY V, 1993, RES VET SCI, V55, P236, DOI 10.1016/0034 5288(93)90087 V
   Paull DR, 2007, AUST VET J, V85, P98, DOI 10.1111/j.1751 0813.2007.00115.x
   *R DEV COR TEAM, 2004, R LANG ENV STAT COMP
   SHUTT DA, 1987, AUST J BIOL SCI, V40, P97, DOI 10.1071/BI9870097
   Sidhu PK, 2006, RES VET SCI, V80, P79, DOI 10.1016/j.rvsc.2005.04.008
   Sidhu PK, 2005, J VET PHARMACOL THER, V28, P109, DOI 10.1111/j.1365 2885.2004.00633.x
   STEEN KH, 1995, PAIN, V62, P339, DOI 10.1016/0304 3959(95)00011 G
   Voilley Nicolas, 2004, Current Drug Targets   Inflammation and Allergy, V3, P71, DOI 10.2174/1568010043483980
NR 38
TC 44
Z9 47
U1 0
U2 35
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0005 0423
J9 AUST VET J
JI Aust. Vet. J.
PD AUG
PY 2008
VL 86
IS 8
BP 303
EP 311
DI 10.1111/j.1751 0813.2008.00325.x
PG 9
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA 335IR
UT WOS:000258284800026
PM 18673471
DA 2025 08 17
ER

PT J
AU Mitsimponas, KT
   Moest, T
   Iliopoulos, C
   Rueger, T
   Mueller, C
   Lutz, R
   Shakib, K
   Neukam, FW
   Schlegel, KA
AF Mitsimponas, K. T.
   Moest, T.
   Iliopoulos, C.
   Rueger, T.
   Mueller, C.
   Lutz, R.
   Shakib, K.
   Neukam, F. W.
   Schlegel, K. A.
TI Search for a reliable model for bisphosphonate related osteonecrosis of
   the jaw: establishment of a model in pigs and description of its
   histomorphometric characteristics
SO BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY
LA English
DT Article
DE Bisphosphonates; Bisphosphonate Related Osteonecrosis of the Jaws;
   Experimental model
ID ANIMAL MODEL; BONE; MECHANISMS; NECROSIS; FEATURES; DISEASE; RATS; MICE
AB The pathogenesis of bisphosphonate related osteonecrosis of the jaw (BRONJ) remains unknown, and the development of a reliable experimental model would help to improve our understanding of it. We used 12 domestic pigs of which 6 made up the experimental group and were treated with zoledronate 4 mg intravenously weekly for 5 weeks, while the control group (n = 6) were given no drugs. On day 60 the right second maxillary and mandibular third molars were extracted. Thirty days later 3 animals in each group were killed; the rest were killed 90 days later. Histopathological specimens from the extraction sites were analysed for bone density, collagen architecture, density of osteons, and the amount of non mineralised bone. Bone density, amount of non mineralised bone, and density of osteons differed significantly between the 2 groups (p < 0.001 in each case), but the chromatic pattern dictated by the collagen architecture did not. Our results correspond to the observations that have been made in patients with BRONJ, which means that the histomorphometric conditions seen in patients can be reproduced in this experimental setting. (C) 2016 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
C1 [Mitsimponas, K. T.; Moest, T.; Iliopoulos, C.; Rueger, T.; Mueller, C.; Lutz, R.; Neukam, F. W.; Schlegel, K. A.] Univ Hosp Erlangen, Dept Oral & Maxillofacial Surg, Glueckstr 11, D 91054 Erlangen, Germany.
   [Mitsimponas, K. T.; Shakib, K.] Chase Farm Hosp, Royal Free NHS Trust, Dept Oral & Maxillofacial Surg, 127 Ridgeway, Enfield EN2 8JL, Middx, England.
C3 University of Erlangen Nuremberg; University of London; University
   College London; Royal Free London NHS Foundation Trust
RP Mitsimponas, KT (通讯作者)，Chase Farm Hosp, Royal Free NHS Trust, Dept Oral & Maxillofacial Surg, 127 Ridgeway, Enfield EN2 8JL, Middx, England.
EM konstantinos.mitsimponas@nhs.net
RI Lutz, Rainer/JEO 6102 2023; Rueger, Theresa/AAC 9492 2019; Mitsimponas,
   Konstantinos/MZQ 7589 2025; Schlegel, Karl/D 1015 2010
OI Lutz, Rainer/0000 0003 0199 9437; Mitsimponas,
   Konstantinos/0000 0002 2177 2195; 
FU International Team for Implantology (ITI) Foundation Research Grant [AZ
   841 2012]
FX This study was financed by the International Team for Implantology (ITI)
   Foundation Research Grant AZ 841 2012.
CR Aguirre JI, 2010, ORAL DIS, V16, P674, DOI 10.1111/j.1601 0825.2010.01677.x
   Bedogni A, 2008, ORAL SURG ORAL MED O, V105, P358, DOI 10.1016/j.tripleo.2007.08.040
   Bi YM, 2010, AM J PATHOL, V177, P280, DOI 10.2353/ajpath.2010.090592
   Biasotto M, 2010, J ORAL PATHOL MED, V39, P390, DOI 10.1111/j.1600 0714.2009.00878.x
   Burr DB, 2009, ORTHOD CRANIOFAC RES, V12, P221, DOI 10.1111/j.1601 6343.2009.01456.x
   DONATH K, 1982, J ORAL PATHOL MED, V11, P318, DOI 10.1111/j.1600 0714.1982.tb00172.x
   Favia G, 2009, BONE, V45, P406, DOI 10.1016/j.bone.2009.05.008
   Fliefel R, 2015, INT J ORAL MAX SURG, V44, P568, DOI 10.1016/j.ijom.2015.01.026
   Gorski JP, 1998, CRIT REV ORAL BIOL M, V9, P201, DOI 10.1177/10454411980090020401
   Hansen T, 2006, J ORAL PATHOL MED, V35, P155, DOI 10.1111/j.1600 0714.2006.00391.x
   Hikita H, 2009, J BONE MINER METAB, V27, P663, DOI 10.1007/s00774 009 0090 6
   Huja SS, 2011, J ORAL MAXIL SURG, V69, P418, DOI 10.1016/j.joms.2010.05.062
   Ikebe T, 2013, ORAL SCI INT, V10, P1, DOI 10.1016/S1348 8643(12)00045 6
   Kikuiri T, 2010, J BONE MINER RES, V25, P1668, DOI 10.1002/jbmr.37
   Kobayashi Y, 2010, J BONE MINER METAB, V28, P165, DOI 10.1007/s00774 009 0128 9
   Kühl S, 2012, ORAL ONCOL, V48, P938, DOI 10.1016/j.oraloncology.2012.03.028
   Landesberg R, 2011, ANN NY ACAD SCI, V1218, P62, DOI 10.1111/j.1749 6632.2010.05835.x
   Paparella ML, 2012, HISTOPATHOLOGY, V60, P514, DOI 10.1111/j.1365 2559.2011.04061.x
   Mitsimponas KT, 2014, INT J CLIN EXP PATHO, V7, P496
   Pautke C, 2012, BONE, V51, P592, DOI 10.1016/j.bone.2012.04.020
   Rauner M, 2007, INT ARCH ALLERGY IMM, V143, P31, DOI 10.1159/000098223
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Schlegel KA, 2003, INT J ORAL MAX IMPL, V18, P505
   Sipos W, 2007, J VET MED A, V54, P504, DOI 10.1111/j.1439 0442.2007.00968.x
   Sonis ST, 2009, ORAL ONCOL, V45, P164, DOI 10.1016/j.oraloncology.2008.04.013
NR 25
TC 9
Z9 11
U1 0
U2 4
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0266 4356
EI 1532 1940
J9 BRIT J ORAL MAX SURG
JI Br. J. Oral Maxillofac. Surg.
PD OCT
PY 2016
VL 54
IS 8
BP 883
EP 888
DI 10.1016/j.bjoms.2016.05.025
PG 6
WC Dentistry, Oral Surgery & Medicine; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Surgery
GA ED7EG
UT WOS:000389024300008
PM 27282083
DA 2025 08 17
ER

PT J
AU Kline, GA
   Holmes, DT
AF Kline, Gregory A.
   Holmes, Daniel T.
TI Bone turnover markers for assessment of anti resorptive effect in
   clinical practice: A good idea meets the problem of measurement
   uncertainty
SO CLINICAL BIOCHEMISTRY
LA English
DT Article
DE Osteoporosis; Bone turnover markers; Bisphosphonate; Clinical chemistry
ID POSTMENOPAUSAL WOMEN; BIOLOGICAL VARIABILITY; BIOCHEMICAL MARKERS;
   FRACTURE RISK; OSTEOPOROSIS; RISEDRONATE; REDUCTION; THERAPY; DENSITY;
   PINP
AB Objectives: Bone turnover markers (BTM) are measures for understanding the effect of anti resorptives upon osteoclast activity. Post hoc trial data suggests reduction in BTM of 40% may represent a target for defining appropriate response to therapy. We modeled clinical application of this target threshold in an individual patient setting where assay measurement uncertainty and biological variation are included.Design: Using serum C telo peptide (B CTX), we constructed hypothetical scenarios of B CTX measurement pre and post bisphosphonate therapy. Using typical B CTX assay characteristics (analytical coefficient of variation, CV 5.0%) and published intra individual B CTX data for post menopausal women (CV 18.0%), we calculated the post therapy B CTX that must be seen on single repeat measure for 95% confidence that the observed result was >= 40% below baseline. Sensitivity analyses considered greater and lesser variations in the combined sources of variation.Results: The one tailed 95% reference change value for any detectable therapeutic decrease in B CTX was 22%. However, to have 95% confidence of having achieved a reduction >= 40%, an observed B CTX decrease of >= 56% is required. Larger decreases are needed for scenarios of greater analytical or intra individual variation.Conclusions: Although population data suggest a B CTX decrease of 40% is commensurate with adequate ther apeutic response to anti resorptives, application to an individual patient where measurement and natural vari ation are present is problematic. B CTX decreases much >40% are required to be confident of having achieved the optimal treatment response. It is uncertain whether this is a legitimate change to be expected in all individual patients and therefore clinical application of this threshold is uncertain.
C1 [Kline, Gregory A.] Univ Calgary, Fac Med, Cumming Sch Med, Div Endocrinol, Calgary, AB, Canada.
   [Holmes, Daniel T.] St Pauls Hosp, Dept Pathol & Lab Med, Vancouver, BC, Canada.
   [Holmes, Daniel T.] Univ British Columbia, Dept Pathol & Lab, Vancouver, BC, Canada.
   [Kline, Gregory A.] Univ Calgary, Med Endocrinol, 1820 Richmond Rd SW, Calgary, AB T2T 5C7, Canada.
C3 University of Calgary; St. Paul's Hospital; University of British
   Columbia; University of Calgary
RP Kline, GA (通讯作者)，Univ Calgary, Med Endocrinol, 1820 Richmond Rd SW, Calgary, AB T2T 5C7, Canada.
EM Gregory.kline@ahs.ca
OI Kline, Gregory/0000 0002 8129 9360; Holmes, Daniel/0000 0003 2189 9214
CR Bauer DC, 2004, J BONE MINER RES, V19, P1250, DOI 10.1359/JBMR.040512
   Bonlokke SE, 2022, OSTEOPOROSIS INT, V33, P2155, DOI 10.1007/s00198 022 06457 0
   Borgen TT, 2022, JBMR PLUS, V6, DOI 10.1002/jbm4.10633
   Burch J, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18110
   Camacho PM, 2016, ENDOCR PRACT, V22, P1, DOI 10.4158/EP161435.GL
   Cavalier E, 2020, OSTEOPOROSIS INT, V31, P1461, DOI 10.1007/s00198 020 05362 8
   Clowes JA, 2002, BONE, V30, P886, DOI 10.1016/S8756 3282(02)00728 7
   Delmas PD, 2009, J BONE MINER RES, V24, P1544, DOI [10.1359/JBMR.090310, 10.1359/jbmr.090310]
   Eastell R, 2007, J BONE MINER RES, V22, P1656, DOI 10.1359/JBMR.07090B
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Eastell R, 2018, EUR J ENDOCRINOL, V178, pR19, DOI 10.1530/EJE 17 0585
   Eastell R, 2017, LANCET DIABETES ENDO, V5, P908, DOI 10.1016/S2213 8587(17)30184 5
   Eastell R, 2011, J BONE MINER RES, V26, P1662, DOI 10.1002/jbmr.342
   Eastell R, 2011, J BONE MINER RES, V26, P530, DOI 10.1002/jbmr.251
   Fraser CG, 2012, CLIN CHEM LAB MED, V50, P807, DOI 10.1515/CCLM.2011.733
   Garnero P, 2003, J BONE MINER RES, V18, P1789, DOI 10.1359/jbmr.2003.18.10.1789
   Gonnelli S, 1999, CALCIFIED TISSUE INT, V65, P359, DOI 10.1007/s002239900713
   Greenspan SL, 1998, J BONE MINER RES, V13, P1431, DOI 10.1359/jbmr.1998.13.9.1431
   Ivaska KK, 2022, CALCIFIED TISSUE INT, V111, P288, DOI 10.1007/s00223 022 00996 8
   Kline GA, 2022, J CLIN ENDOCR METAB, V107, P1662, DOI 10.1210/clinem/dgac051
   Kline GA, 2021, J CLIN ENDOCR METAB, V106, P2718, DOI 10.1210/clinem/dgab211
   LeBoff MS, 2022, OSTEOPOROSIS INT, V33, P2049, DOI 10.1007/s00198 021 05900 y
   Morin SN, 2020, OSTEOPOROSIS INT, V31, P867, DOI 10.1007/s00198 019 05248 4
   Naylor KE, 2016, OSTEOPOROSIS INT, V27, P21, DOI 10.1007/s00198 015 3145 7
   Qaseem A, 2008, ANN INTERN MED, V149, P404, DOI 10.7326/0003 4819 149 6 200809160 00007
   Takahashi M, 2002, ENDOCR RES, V28, P257, DOI 10.1081/ERC 120015063
   Watts NB, 2005, J BONE MINER RES, V20, P2097, DOI 10.1359/JBMR.050814
   Widjaja A, 1999, CLIN CHEM, V45, P561
NR 28
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009 9120
EI 1873 2933
J9 CLIN BIOCHEM
JI Clin. Biochem.
PD JUN
PY 2023
VL 116
BP 100
EP 104
DI 10.1016/j.clinbiochem.2023.04.007
EA APR 2023
PG 5
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Medical Laboratory Technology
GA J3SN0
UT WOS:001008845300001
PM 37084998
DA 2025 08 17
ER

PT J
AU Grassi, F
   Fan, X
   Rahnert, J
   Weitzmann, MN
   Pacifici, R
   Nanes, MS
   Rubin, J
AF Grassi, F.
   Fan, X.
   Rahnert, J.
   Weitzmann, M. N.
   Pacifici, R.
   Nanes, M. S.
   Rubin, J.
TI Bone re/modeling is more dynamic in the endothelial nitric oxide
   synthase<SUP>( / )</SUP> mouse
SO ENDOCRINOLOGY
LA English
DT Article
ID OSTEOBLAST LIKE CELLS; MORPHOMETRIC ANALYSIS; REPLACEMENT THERAPY; DONOR
   NITROGLYCERIN; MINERAL DENSITY; FUNCTIONAL ROLE; STROMAL CELLS; MICE
   LACKING; ESTROGEN; EXPRESSION
AB Nitric oxide is a ubiquitous estrogen  regulated signaling molecule that has been implicated in the regulation of bone maturation and remodeling. To better understand the role that bone cell secreted nitric oxide plays in ovariectomy induced modifications of bone turnover, we examined the expression of endothelial NO synthase (eNOS) in bone cells and bone progenitor cells at regular intervals up to 10 wk after acute estrogen deprivation. Ovariectomy led to an anticipated initial decline in bone cell eNOS production, but surprisingly, 17 d after ovariectomy, eNOS expression by bone and marrow stromal cells dramatically rebounded and was maintained at high levels for at least 10 wk after surgery. We examined the long term consequences of eNOS in the process of ovariectomy induced bone loss by prospectively analyzing bone mineral density in wild type and eNOS(( / )) mice for 10 wk after ovariectomy. Ovariectomized eNOS(( / )) mice were observed to undergo an exaggerated state of estrogen deficiency induced bone remodeling compared with wild type controls, suggesting that eNOS may act to mitigate this process. Furthermore, we found that whereas bone formation in estrogen replete wild type mice slowed between 14 and 20 wk of age, eNOS knockout mice continued to accrue basal bone mass at a high rate and showed no sign of entering a remodeling stage. Our data suggest that eNOS may play an important role in limiting ovariectomy induced bone remodeling as well as regulating the transition from basal modeling to remodeling.
C1 Univ N Carolina, Div Endocrinol & Metab, Dept Med, CH Sch Med, Chapel Hill, NC 27599 USA.
   Emory Univ, Div Endocrinol Metab & Lipids, Atlanta, GA 30332 USA.
   Ist Ortoped Rizzoli, Lab Immunol & Genet, I 40136 Bologna, Italy.
   Vet Affairs Med Ctr, Atlanta, GA 30033 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   Emory University; IRCCS Istituto Ortopedico Rizzoli; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA
   Health Care System
RP Rubin, J (通讯作者)，Univ N Carolina, Div Endocrinol & Metab, Dept Med, CH Sch Med, CB 7170, Chapel Hill, NC 27599 USA.
EM jrubin@med.unc.edu
RI Grassi, Francesco/AAE 2443 2021
OI Grassi, Francesco/0000 0002 5127 9561
FU NIAMS NIH HHS [AR42360, AR52014] Funding Source: Medline; NIDDK NIH HHS
   [DK067389] Funding Source: Medline
CR Afzal F, 2004, J PATHOL, V202, P503, DOI 10.1002/path.1536
   Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   Armour KE, 1998, ENDOCRINOLOGY, V139, P799, DOI 10.1210/en.139.2.799
   Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   Beamer WG, 1996, BONE, V18, P397, DOI 10.1016/8756 3282(96)00047 6
   Brodt MD, 1999, J BONE MINER RES, V14, P2159, DOI 10.1359/jbmr.1999.14.12.2159
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100
   Chambliss KL, 2002, ENDOCR REV, V23, P665, DOI 10.1210/er.2001 0045
   Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347
   Collin Osdoby P, 2000, J BONE MINER RES, V15, P474, DOI 10.1359/jbmr.2000.15.3.474
   Fan M, 2006, J CELL PHYSIOL, V207, P454, DOI 10.1002/jcp.20581
   Fan X, 2004, ENDOCRINOLOGY, V145, P751, DOI 10.1210/en.2003 0726
   Fox SW, 1996, AM J PHYSIOL ENDOC M, V270, pE955, DOI 10.1152/ajpendo.1996.270.6.E955
   Gödecke A, 1998, CIRC RES, V82, P186
   HAYASHI T, 1995, BIOCHEM BIOPH RES CO, V214, P847, DOI 10.1006/bbrc.1995.2364
   Helfrich, 1997, J BONE MINER RES, V12, P1538
   Helfrich MH, 1997, J BONE MINER RES, V12, P1108, DOI 10.1359/jbmr.1997.12.7.1108
   Hildebrand T, 1999, J BONE MINER RES, V14, P1167, DOI 10.1359/jbmr.1999.14.7.1167
   HORSMAN A, 1977, BRIT J RADIOL, V50, P504, DOI 10.1259/0007 1285 50 595 504
   HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0
   Hukkanen M, 2003, BONE, V32, P142, DOI 10.1016/S8756 3282(02)00955 9
   Hukkanen MVJ, 1999, J BONE MINER RES, V14, P868, DOI 10.1359/jbmr.1999.14.6.868
   Jamal SA, 1998, J BONE MINER RES, V13, P1755, DOI 10.1359/jbmr.1998.13.11.1755
   Koyama A, 2000, EUR J PHARMACOL, V391, P225, DOI 10.1016/S0014 2999(00)00100 X
   MacPherson H, 1999, BONE, V24, P179, DOI 10.1016/S8756 3282(98)00173 2
   MacRitchie AN, 1997, CIRC RES, V81, P355, DOI 10.1161/01.RES.81.3.355
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Muller R, 1997, ST HEAL T, V40, P61
   Müller R, 1998, BONE, V23, P59, DOI 10.1016/S8756 3282(98)00068 4
   Nenonen A, 2005, J BONE MINER RES, V20, P1804, DOI 10.1359/JBMR.050403
   Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841
   RIANCHO JA, 1995, J BONE MINER RES, V10, P439
   Rubin J, 2002, J BONE MINER RES, V17, P1452, DOI 10.1359/jbmr.2002.17.8.1452
   Rubin J, 2000, AM J PHYSIOL CELL PH, V278, pC1126, DOI 10.1152/ajpcell.2000.278.6.C1126
   Rubin J, 2003, J BIOL CHEM, V278, P34018, DOI 10.1074/jbc.M302822200
   Samuels A, 2001, BONE, V29, P24, DOI 10.1016/S8756 3282(01)00471 9
   Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176
   van't Hof RJ, 2004, ENDOCRINOLOGY, V145, P5068, DOI 10.1210/en.2004 0205
   Wimalawansa S, 2000, J BONE MINER RES, V15, P1119, DOI 10.1359/jbmr.2000.15.6.1119
   Wimalawansa SJ, 2000, J BONE MINER RES, V15, P2240, DOI 10.1359/jbmr.2000.15.11.2240
   Wimalawansa SJ, 2000, J CLIN DENSITOM, V3, P187, DOI 10.1385/JCD:3:2:187
   WRONSKI TJ, 1989, CALCIFIED TISSUE INT, V45, P360, DOI 10.1007/BF02556007
   Zaman G, 1999, J BONE MINER RES, V14, P1123, DOI 10.1359/jbmr.1999.14.7.1123
   Zhu W, 2001, J BONE MINER RES, V16, P535, DOI 10.1359/jbmr.2001.16.3.535
NR 45
TC 35
Z9 37
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD SEP
PY 2006
VL 147
IS 9
BP 4392
EP 4399
DI 10.1210/en.2006 0334
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 074CM
UT WOS:000239790100043
PM 16763060
OA Bronze
DA 2025 08 17
ER

PT J
AU Takeno, A
   Yamamoto, M
   Notsu, M
   Sugimoto, T
AF Takeno, Ayumu
   Yamamoto, Masahiro
   Notsu, Masakazu
   Sugimoto, Toshitsugu
TI Administration of anti receptor activator of nuclear factor kappa B
   ligand (RANKL) antibody for the treatment of osteoporosis was associated
   with amelioration of hepatitis in a female patient with growth hormone
   deficiency: a case report
SO BMC ENDOCRINE DISORDERS
LA English
DT Article
DE Growth hormone deficiency (GHD); Non alcoholic fatty liver disease
   (NAFLD); Non alcoholic steatohepatitis (NASH); Receptor activator of
   nuclear factor kappa B ligand (RANKL); Denosumab
ID FATTY LIVER DISEASE; NONALCOHOLIC STEATOHEPATITIS; POSTMENOPAUSAL WOMEN;
   REPLACEMENT THERAPY; FRACTURES; DENOSUMAB
AB Background: Growth hormone deficiency (GHD) is associated with non alcoholic fatty liver disease (NAFLD). A recent animal study showed that hepatocyte specific receptor activator of nuclear factor kappa B (RANK) knockout mice had significantly lower liver fat content compared with control mice concomitant with a decrease in production of inflammatory cytokines such as tumor necrosis factor alpha (TNF alpha) from hepatocytes and kupffer cells. The role of anti RANK ligand (RANKL) antibody for osteoporosis on hepatitis in patients with aGHD is still unknown.
   Case presentation: A forty seven year old female patient was referred to our hospital to investigate chronic hepatitis caused by unknown etiology. She had past history of craniopharyngioma treated with craniotomy and post surgical radiotherapy. She was for the first time diagnosed as panhypopituitarism including growth hormone deficiency and osteoporosis by endocrine examinations and bone mineral densitometry, respectively. In addition, non alcoholic steatohepatitis (NASH) was histologically confirmed by liver biopsy in this time. Sixty mg anti RANKL antibody, which was subcutaneously injected to treat the osteoporosis every six months after replacement of 5 mg hydrocortisone and 30 mu g oral desmopressin, rapidly decreased the levels of her liver enzymes (ALT and gamma GTP were 133 to 72 U/L and 284 to 99 U/L at 16 months after the beginning of the treatment, respectively). Additional amelioration of liver dysfunction was not observed after growth hormone replacement.
   Conclusions: The clinical course of the present case suggested that RANKL RANK signaling may be a key pathological mechanism in establishment or development of NAFLD or NASH in patients with panhypopituitarism including GHD.
C1 [Takeno, Ayumu; Yamamoto, Masahiro; Notsu, Masakazu; Sugimoto, Toshitsugu] Shimane Univ, Fac Med, Internal Med 1, 89 1 Enya Cho, Izumo, Shimane 6938501, Japan.
C3 Shimane University
RP Takeno, A (通讯作者)，Shimane Univ, Fac Med, Internal Med 1, 89 1 Enya Cho, Izumo, Shimane 6938501, Japan.
EM atakeno@med.shimane u.ac.jp
CR Boonen S, 2011, J CLIN ENDOCR METAB, V96, P1727, DOI 10.1210/jc.2010 2784
   Buzzetti E, 2016, METABOLISM, V65, P1038, DOI 10.1016/j.metabol.2015.12.012
   Copaci Ionel, 2006, J Gastrointestin Liver Dis, V15, P363
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   El Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683
   Ichikawa T, 2003, GUT, V52, P914, DOI 10.1136/gut.52.6.914
   Kiechl S, 2013, NAT MED, V19, P358, DOI 10.1038/nm.3084
   Koteish A, 2002, BEST PRACT RES CL GA, V16, P679, DOI 10.1053/bega.2002.0332
   Matsumoto R, 2014, GROWTH HORM IGF RES, V24, P174, DOI 10.1016/j.ghir.2014.07.002
   Nishizawa H, 2012, EUR J ENDOCRINOL, V167, P67, DOI 10.1530/EJE 12 0252
   Takahashi Y, 2007, GASTROENTEROLOGY, V132, P938, DOI 10.1053/j.gastro.2006.12.024
   Takano S, 1997, ARCH DIS CHILD, V76, P537, DOI 10.1136/adc.76.6.537
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 13
TC 14
Z9 15
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472 6823
J9 BMC ENDOCR DISORD
JI BMC Endocr. Disord.
PD NOV 24
PY 2016
VL 16
AR 66
DI 10.1186/s12902 016 0148 0
PG 4
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA ED6YN
UT WOS:000389003000001
PM 27881164
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU El Ghannam, A
   Ricci, K
   Malkawi, A
   Jahed, K
   Vedantham, K
   Wyan, H
   Allen, LD
   Dréau, D
AF El Ghannam, Ahmed
   Ricci, Krista
   Malkawi, Ahmed
   Jahed, Kiarash
   Vedantham, Kumar
   Wyan, Heather
   Allen, Lauren D.
   Dreau, Didier
TI A ceramic based anticancer drug delivery system to treat breast cancer
SO JOURNAL OF MATERIALS SCIENCE MATERIALS IN MEDICINE
LA English
DT Article
ID OSTEOBLAST GENE EXPRESSION; SI RICH NANOCOMPOSITE; SOLID TUMORS;
   IN VITRO; ANTITUMOR ACTIVITY; CONTROLLED RELEASE; BONE; PACLITAXEL;
   5 FLUOROURACIL; PENETRATION
AB Drug delivery systems offer the advantage of sustained targeted release with minimal side effect. In the present study, the therapeutic efficacy of a porous silica calcium phosphate nanocomposite (SCPC) as a new delivery system for 5 Fluorouracil (5 FU) was evaluated in vitro and in vivo. In vitro studies showed that two formulations; SCPC50/5 FU and SCPC75/5 FU hybrids were very cytotoxic for 4T1 mammary tumor cells. In contrast, control SCPCs without drug did not show any measurable toxic effect. Release kinetics studies showed that SCPC75/5 FU hybrid provided a burst release of 5 FU in the first 24 h followed by a sustained release of a therapeutic dose (30.7 mu g/day) of the drug for up to 32 days. Moreover, subcutaneous implantation of SCPC75/5 FU hybrid disk in an immunocompetent murine model of breast cancer stopped 4T1 tumor growth. Blood analyses showed comparable concentrations of Ca, P and Si in animals implanted with or without SCPC75 disks. These results strongly suggest that SCPC/5 FU hybrids can provide an effective treatment for solid tumors with minimal side effects.
C1 [El Ghannam, Ahmed; Vedantham, Kumar] Univ N Carolina, Dept Mech Engn & Engn Sci, Charlotte, NC 28223 USA.
   [Ricci, Krista; Wyan, Heather; Allen, Lauren D.; Dreau, Didier] Univ N Carolina, Cellular & Mol Biol Div, Dept Biol, Charlotte, NC 28223 USA.
   [Malkawi, Ahmed] Univ Kentucky, Dept Pharmacol, Sch Pharm, Lexington, KY 40536 USA.
   [Jahed, Kiarash] Univ Louisville, Sch Med, Dept Med, Louisville, KY 40292 USA.
C3 University of North Carolina; University of North Carolina Charlotte;
   University of North Carolina; University of North Carolina Charlotte;
   University of Kentucky; University of Louisville
RP El Ghannam, A (通讯作者)，Univ N Carolina, Dept Mech Engn & Engn Sci, DCH 177,9201 Univ City Blvd, Charlotte, NC 28223 USA.
EM arelgha@uncc.edu
OI Dreau, Didier/0000 0002 7094 650X
FU UNC Charlotte
FX The authors would like to acknowledge the support of UNC Charlotte
   through a research grant (AE and DD) and of the vivarium personnel for
   animal care.
CR Akbuga J, 1996, J MICROENCAPSUL, V13, P161, DOI 10.3109/02652049609052904
   Al Ghananeem AM, 2009, AAPS PHARMSCITECH, V10, P410, DOI 10.1208/s12249 009 9222 5
   Au JLS, 2001, J CONTROL RELEASE, V74, P31, DOI 10.1016/S0168 3659(01)00308 X
   Benghuzzi H, 2001, Biomed Sci Instrum, V37, P275
   Ciftci K, 1997, Pharm Dev Technol, V2, P151, DOI 10.3109/10837459709022620
   Curnis F, 2002, J CLIN INVEST, V110, P475, DOI 10.1172/JCI200215223
   Dhanikula AB, 1999, INT J PHARMACEUT, V183, P85, DOI 10.1016/S0378 5173(99)00087 3
   Dréau D, 2006, CLIN EXP METASTAS, V23, P41, DOI 10.1007/s10585 006 9016 z
   Dreher MR, 2006, JNCI J NATL CANCER I, V98, P335, DOI 10.1093/jnci/djj070
   Durand RE, 2001, CANCER METAST REV, V20, P57, DOI 10.1023/A:1013181107707
   El Ghannam A, 2005, EXPERT REV MED DEVIC, V2, P87, DOI 10.1586/17434440.2.1.87
   El Ghannam A, 2006, J BIOMED MATER RES A, V76A, P386, DOI 10.1002/jbm.a.30517
   El Ghannam A, 2005, J BIOMED MATER RES B, V73B, P277, DOI 10.1002/jbm.b.30209
   El Ghannam A, 2004, J BIOMED MATER RES A, V71A, P377, DOI 10.1002/jbm.a.30128
   El Ghannam A, 2007, J ORAL MAXIL SURG, V65, P1495, DOI 10.1016/j.joms.2006.10.031
   El Ghannam AR, 2004, J BIOMED MATER RES A, V69A, P490, DOI 10.1002/jbm.a.30022
   El Kareh AW, 1997, CRIT REV BIOMED ENG, V25, P503, DOI 10.1615/CritRevBiomedEng.v25.i6.20
   ELGHANNAM A, 2009, J BIOMED A IN PRESS
   ELGHANNAM A, 2008, 8 WORLD BIOM C AMSTR
   Fontana G, 2005, DRUG DELIV, V12, P385, DOI 10.1080/10717540590968855
   Goldberg EP, 2002, J PHARM PHARMACOL, V54, P159, DOI 10.1211/0022357021778268
   Gupta G, 2007, J BIOMED MATER RES B, V81B, P387, DOI 10.1002/jbm.b.30675
   Gupta G, 2007, J BIOMED MATER RES A, V80A, P486, DOI 10.1002/jbm.a.31005
   Hampel S, 2008, NANOMEDICINE UK, V3, P175, DOI 10.2217/17435889.3.2.175
   He M, 2009, INT J PHARMACEUT, V373, P165, DOI 10.1016/j.ijpharm.2009.02.012
   He YC, 2003, WORLD J GASTROENTERO, V9, P1795, DOI 10.3748/wjg.v9.i8.1795
   Hiraga T, 2005, ONCOL REP, V14, P695
   Huwyler J, 2008, INT J NANOMED, V3, P21
   Itokazu M, 1998, J BIOMED MATER RES, V39, P536, DOI 10.1002/(SICI)1097 4636(19980315)39:4<536::AID JBM5>3.0.CO;2 K
   Jang SH, 2003, PHARM RES DORDR, V20, P1337, DOI 10.1023/A:1025785505977
   JENSEN MM, 2008, BMC MED IMAGING, V18, P8
   Kim JH, 2006, J CONTROL RELEASE, V111, P228, DOI 10.1016/j.jconrel.2005.12.013
   Lee H, 2008, BIOCONJUGATE CHEM, V19, P1319, DOI 10.1021/bc8000485
   Liang YY, 2002, INT J ONCOL, V21, P1259
   Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893
   Netz DJA, 2001, INT J PHARMACEUT, V213, P117, DOI 10.1016/S0378 5173(00)00659 1
   Ning CQ, 2005, J MATER SCI MATER M, V16, P355, DOI 10.1007/s10856 005 0635 8
   Nishiyama N, 2003, CANCER RES, V63, P8977
   Owen MR, 2004, J THEOR BIOL, V226, P377, DOI 10.1016/j.jtbi.2003.09.004
   Phan PV, 2003, J BIOMED MATER RES A, V67A, P1001, DOI 10.1002/jbm.a.10162
   Ragupathi G, 2000, INT J CANCER, V85, P659, DOI 10.1002/(SICI)1097 0215(20000301)85:5<659::AID IJC11>3.0.CO;2 5
   Raymond E, 1997, ANTI CANCER DRUG, V8, P876, DOI 10.1097/00001813 199710000 00009
   Renoir JM, 2006, J STEROID BIOCHEM, V102, P114, DOI 10.1016/j.jsbmb.2006.09.001
   Schlemmer HP, 1999, CANCER RES, V59, P2363
   Shenoy B. Dinesh, 1999, Indian Journal of Physiology and Pharmacology, V43, P259
   Soo PL, 2008, EUR J PHARM BIOPHARM, V69, P149, DOI 10.1016/j.ejpb.2007.11.003
   Tzafriri AR, 2005, CLIN CANCER RES, V11, P826
   Wu P, 2006, BIOMATERIALS, V27, P2450, DOI 10.1016/j.biomaterials.2005.11.031
   Yang Y, 2009, J MATER SCI MATER M, V20, P301, DOI 10.1007/s10856 008 3577 0
   Yapp DTT, 1997, INT J RADIAT ONCOL, V39, P497, DOI 10.1016/S0360 3016(97)00331 3
   Zafirau W, 1996, Biomed Sci Instrum, V32, P63
   Zhang C, 2008, BIOMATERIALS, V29, P1233, DOI 10.1016/j.biomaterials.2007.11.029
NR 52
TC 28
Z9 31
U1 0
U2 19
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957 4530
J9 J MATER SCI MATER M
JI J. Mater. Sci. Mater. Med.
PD SEP
PY 2010
VL 21
IS 9
BP 2701
EP 2710
DI 10.1007/s10856 010 4121 6
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 648EO
UT WOS:000281673400020
PM 20644983
DA 2025 08 17
ER

PT J
AU Makita, K
   Hamamoto, Y
   Kanzaki, H
   Nagasaki, K
   Kozuki, T
AF Makita, Kenji
   Hamamoto, Yasushi
   Kanzaki, Hiromitsu
   Nagasaki, Kei
   Kozuki, Toshiyuki
TI Local control of bone metastasis treated with palliative radiotherapy in
   patients with lung cancer: An observational retrospective cohort study
SO ONCOLOGY LETTERS
LA English
DT Article
DE bone metastasis; lung cancer; palliative; radiotherapy; local control
ID TO LYMPHOCYTE RATIO; RADIATION THERAPY; SKELETAL METASTASES; ZOLEDRONIC
   ACID; CHEMOTHERAPY; INFLAMMATION; DENOSUMAB; SURVIVAL
AB Bone metastasis is common in advanced lung cancer, with the incidence reported to be 30%, and radiotherapy (RT) is used for pain relief from bone metastasis. The present study aimed to identify factors affecting local control (LC) of bone metastasis from lung cancer and to assess the significance of moderate RT dose escalation. This was a retrospective cohort study, where LC of bone metastasis from lung cancer that had received palliative RT was reviewed. LC at RT sites was evaluated with follow up computed tomography (CT). The influence of treatment , cancer  and patient related risk factors for LC was assessed. A total of 317 metastatic lesions in 210 patients with lung cancer were evaluated. The median RT dose (biologically effective dose calculated using an alpha/beta of 10 Gy; BED10) was 39.0 Gy (range, 14.4 50.7 Gy). The median follow up time for survival and median radiographic follow up time were 8 (range, 1 127) and 4 (range, 1 124) months, respectively. The 0.5 year overall survival and LC rates were 58.9 and 87.7%, respectively. The local recurrence rate in RT sites was 11.0%, and bone metastatic progression, except in RT sites, was observed in 46.1% at the time of local recurrence or the last follow up CT of the RT sites. According to multivariate analysis, RT sites, pre RT neutrophil to lymphocyte ratio (NLR), post RT non administration of molecular targeting agents (MTs), and non administration of bone modifying agents (BMAs) were significant unfavorable factors for LC of bone metastasis. Moderate RT dose escalation (BED10 >39 Gy) tended to improve the LC of RT sites. In cases without MTs, moderate dose escalation of RT dose improved the LC of RT sites. In conclusion, treatment (post RT MTs and BMAs), cancer (RT sites) and patient (pre RT NLR) related risk factors had a large impact on improving the LC of RT sites. Moderate RT dose escalation seemed to have a small impact on improving the LC of RT sites.
C1 [Makita, Kenji; Hamamoto, Yasushi; Kanzaki, Hiromitsu; Nagasaki, Kei] Natl Hosp Org, Dept Radiat Oncol, Shikoku Canc Ctr, Matsuyama, Ehime 7910280, Japan.
   [Makita, Kenji] Ehime Univ, Grad Sch Med, Dept Radiol, Toon, Ehime 7910295, Japan.
   [Makita, Kenji] Ehime Prefectural Cent Hosp, Dept Radiol, Matsuyama, Ehime 7900024, Japan.
   [Kozuki, Toshiyuki] Natl Hosp Org, Dept Thorac Oncol & Med, Shikoku Canc Ctr, Matsuyama, Ehime 7910280, Japan.
   [Makita, Kenji] Natl Hosp Org, Shikoku Canc Ctr, Dept Radiat Oncol, Kou 160 Minami Umenomoto Machi, Matsuyama, Ehime 7910280, Japan.
C3 Ehime University
RP Makita, K (通讯作者)，Natl Hosp Org, Shikoku Canc Ctr, Dept Radiat Oncol, Kou 160 Minami Umenomoto Machi, Matsuyama, Ehime 7910280, Japan.
EM makita.kenji.wy@mail.hosp.go.jp
RI KOZUKI, TOSHIYUKI/AGB 0305 2022
CR Aggarwal BB, 2009, CLIN CANCER RES, V15, P425, DOI 10.1158/1078 0432.CCR 08 0149
   Antonia SJ, 2018, NEW ENGL J MED, V379, P2342, DOI 10.1056/NEJMoa1809697
   Cannon NA, 2015, J THORAC ONCOL, V10, P280, DOI 10.1097/JTO.0000000000000399
   Chen JJ, 2021, ADV RADIAT ONCOL, V6, DOI 10.1016/j.adro.2021.100665
   Coleman R, 2020, ANN ONCOL, V31, P1650, DOI 10.1016/j.annonc.2020.07.019
   Detterbeck FC, 2017, CHEST, V151, P193, DOI 10.1016/j.chest.2016.10.010
   Diem S, 2017, LUNG CANCER, V111, P176, DOI 10.1016/j.lungcan.2017.07.024
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Grossman SA, 2015, J NATL COMPR CANC NE, V13, P1225, DOI 10.6004/jnccn.2015.0151
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Horn L, 2018, NEW ENGL J MED, V379, P2220, DOI 10.1056/NEJMoa1809064
   Lutz S, 2017, PRACT RADIAT ONCOL, V7, P4, DOI 10.1016/j.prro.2016.08.001
   Makita K, 2022, MOL CLIN ONCOL, V17, DOI 10.3892/mco.2022.2585
   Makita K, 2021, RADIAT ONCOL, V16, DOI 10.1186/s13014 021 01940 0
   O'Callaghan DS, 2010, J THORAC ONCOL, V5, P2024, DOI 10.1097/JTO.0b013e3181f387e4
   Rades D, 2012, STRAHLENTHER ONKOL, V188, P910, DOI 10.1007/s00066 012 0158 4
   Rades D, 2016, J CLIN ONCOL, V34, P597, DOI 10.1200/JCO.2015.64.0862
   Rades D, 2011, INT J RADIAT ONCOL, V79, P524, DOI 10.1016/j.ijrobp.2009.10.073
   Ramalingam SS, 2020, NEW ENGL J MED, V382, P41, DOI 10.1056/NEJMoa1913662
   Sande TA, 2009, RADIOTHER ONCOL, V91, P261, DOI 10.1016/j.radonc.2009.02.014
   Scagliotti GV, 2012, J THORAC ONCOL, V7, P1823, DOI 10.1097/JTO.0b013e31826aec2b
   Singh R, 2020, RADIOTHER ONCOL, V146, P76, DOI 10.1016/j.radonc.2020.01.030
   Smit EF, 1998, BRIT J CANCER, V77, P347, DOI 10.1038/bjc.1998.54
   Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948
   Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]
   Suzuki R, 2018, RADIOTHER ONCOL, V126, P499, DOI 10.1016/j.radonc.2017.12.030
   Tanaka H, 2020, J RADIAT RES, V61, P494, DOI 10.1093/jrr/rraa020
   Templeton AJ, 2014, JNCI J NATL CANCER I, V106, DOI 10.1093/jnci/dju124
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   TOFE AJ, 1975, J NUCL MED, V16, P986
   Tokito T, 2013, CANCER CHEMOTH PHARM, V71, P1493, DOI 10.1007/s00280 013 2148 3
   Tsuya A, 2007, LUNG CANCER, V57, P229, DOI 10.1016/j.lungcan.2007.03.013
   Vadhan Raj S, 2012, ANN ONCOL, V23, P3045, DOI 10.1093/annonc/mds175
   Vassiliou V, 2007, INT J RADIAT ONCOL, V67, P264, DOI 10.1016/j.ijrobp.2006.08.022
   YAES RJ, 1991, INT J RADIAT ONCOL, V20, P1353, DOI 10.1016/0360 3016(91)90249 4
   Zeng KL, 2022, INT J RADIAT ONCOL, V114, P293, DOI 10.1016/j.ijrobp.2022.05.043
NR 36
TC 2
Z9 2
U1 0
U2 0
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD JUL
PY 2023
VL 26
IS 1
AR 303
DI 10.3892/ol.2023.13889
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA J2LR9
UT WOS:001007982400001
PM 37323814
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ilangovan, R
   Sittadjody, S
   Balaganesh, M
   Sivakumar, R
   Sankar, BR
   Balasubramanian, K
   Srinivasan, S
   Subramanian, C
   Thompson, DM
   Queimado, L
   Srinivasan, N
AF Ilangovan, Ramachandran
   Sittadjody, Sivanandane
   Balaganesh, Muthusamy
   Sivakumar, Ramadoss
   Sankar, Bhaskaran Ravi
   Balasubramanian, Karundevi
   Srinivasan, Subramanian
   Subramanian, Chinappa
   Thompson, David M.
   Queimado, Lurdes
   Srinivasan, Narasimhan
TI Dihydrotestosterone is a determinant of calcaneal bone mineral density
   in men
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article
DE Androgens; DHT; IGFs; IGFBPs; Cytokines; BMD
ID GROWTH FACTOR I; ELDERLY MEN; SEX STEROIDS; OLDER MEN; BIOCHEMICAL
   PARAMETERS; TESTOSTERONE THERAPY; PARATHYROID HORMONE; HYPOGONADAL MEN;
   IGF I; OSTEOPOROSIS
AB Male osteoporosis is an increasingly important health problem worldwide. Though androgen deficiency leads to bone loss in men, information on the relative contribution of aromatizable and non aromatizable androgens in maintaining bone mineral density (BMD) and the mechanisms involved are unclear. This cross sectional study was designed to explore the same. Hundred osteoporotic men with age matched normal were studied for serum levels of sex steroids, PTH, IGF system components, cytokines and bone turnover markers. Our findings show that serum DHT, IGF I, IGF II and IGFBP 3 levels were significantly decreased while IL 1 beta and bone turnover markers were significantly increased in osteoporotic men compared to normal. Pearson correlation analysis revealed that serum DHT, IGF I, IGF II and IGFBP 3 levels were positively and strongly correlated with BMD, while serum IL 1 beta levels were negatively correlated with BMD. Serum PTH, testosterone, estradiol, IGFBP 4. TNF alpha, IL 4 and IFN gamma levels were similar between the two groups. We observed that DHT levels significantly declined with age. However, the significant difference in DHT between the osteoporotic and normal groups is the same regardless of age. A multiple regression model adjusted for age demonstrated that DHT/BMD association is fairly stronger among those with osteoporosis than the normal. Our findings for the first time point out that DHT is an important determinant of BMD in men. Most importantly, the strong positive correlation of serum DHT with BMD offers new perspectives in understanding the role of non aromatizable androgen in regulating bone metabolism in men, and might serve as a potential clinical marker in the diagnosis of male osteoporosis. (D 2009 Elsevier Ltd. All rights reserved.
C1 [Ilangovan, Ramachandran; Sittadjody, Sivanandane; Balaganesh, Muthusamy; Sivakumar, Ramadoss; Sankar, Bhaskaran Ravi; Balasubramanian, Karundevi; Srinivasan, Narasimhan] Univ Madras, Dept Endocrinol, Dr ALM Post Grad Inst Basic Med Sci, Madras 600113, Tamil Nadu, India.
   [Ilangovan, Ramachandran; Queimado, Lurdes] Univ Oklahoma, Hlth Sci Ctr, Dept Otorhinolaryngol, Oklahoma City, OK 73104 USA.
   [Srinivasan, Subramanian] Sai Orthocare Clin, Madras 600017, Tamil Nadu, India.
   [Subramanian, Chinappa] Sri Ramachandra Med Coll & Res Inst, Dept Orthoped, Madras 600116, Tamil Nadu, India.
   [Thompson, David M.] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK 73104 USA.
C3 University of Madras; University of Oklahoma System; University of
   Oklahoma Health Sciences Center; Sri Ramachandra Institute of Higher
   Education & Research; University of Oklahoma System; University of
   Oklahoma Health Sciences Center
RP Srinivasan, N (通讯作者)，Univ Madras, Dept Endocrinol, Dr ALM Post Grad Inst Basic Med Sci, Taramani Campus, Madras 600113, Tamil Nadu, India.
EM n_srini2000@yahoo.com
RI Bhaskaran, Ravi Sankar/Q 2823 2016; Queimado, Lurdes/L 7465 2013;
   Narayanasamy, Srinivasan/I 3898 2018; Bhaskaran, Ravi/Q 2823 2016
OI Bhaskaran, Ravi Sankar/0000 0002 2003 6276; Queimado,
   Lurdes/0000 0002 1106 4873; Karundevi,
   Balasubramanian/0009 0002 6355 2454; Narayanasamy,
   Srinivasan/0000 0002 5658 4530; 
FU Department of Science and Technology Government of India
   [SP/SO/1306/98]; Council for Scientific and Industrial Research (CSIR),
   Government of India; Elder Pharmaceuticals (India)
FX This work was supported by grant from the Department of Science and
   Technology (Grant no. SP/SO/1306/98), Government of India. The financial
   assistance provided by Council for Scientific and Industrial Research
   (CSIR), Government of India, as Senior Research Fellowship to Dr. R.
   Ilangovan is acknowledged. We thank Dr. M. Michael Aruldhas and Dr. J.
   Arunakaran for their suggestions during the preparation of the
   manuscript. We also thank Mr. Sridhar Muthusami and Mr. R.C. Vignesh for
   their help during bone density screening camps, and Dr. P. Supriya
   during cytokine assays. The kind gift of testosterone antiserum by Dr.
   E. Nieschlag for radioimmunoassay of testosterone is gratefully
   acknowledged. The help rendered by Elder Pharmaceuticals (India) in
   determining BMD is gratefully appreciated.
CR Amin S, 2006, AM J MED, V119, P426, DOI 10.1016/j.amjmed.2005.10.048
   Amory JK, 2004, J CLIN ENDOCR METAB, V89, P503, DOI 10.1210/jc.2003 031110
   ANDERSCH MA, 1947, AM J CLIN PATHOL, V17, P571, DOI 10.1093/ajcp/17.7_ts.571
   Anderson RA, 2003, J CLIN ENDOCR METAB, V88, P2784, DOI 10.1210/jc.2002 021960
   Basurto L, 2008, AGING MALE, V11, P140, DOI 10.1080/13685530802273715
   Behre HM, 1997, J CLIN ENDOCR METAB, V82, P2386, DOI 10.1210/jc.82.8.2386
   Boonen S, 1999, J BONE MINER RES, V14, P2150, DOI 10.1359/jbmr.1999.14.12.2150
   CANALIS E, 1986, ENDOCRINOLOGY, V118, P74, DOI 10.1210/endo 118 1 74
   Center JR, 1999, J CLIN ENDOCR METAB, V84, P3626, DOI 10.1210/jc.84.10.3626
   Center JR, 2000, J BONE MINER RES, V15, P1405, DOI 10.1359/jbmr.2000.15.7.1405
   Compston JE, 2001, PHYSIOL REV, V81, P419, DOI 10.1152/physrev.2001.81.1.419
   Compston JE, 2002, J ENDOCRINOL, V173, DOI 10.1677/joe.0.1730387
   Daniell HW, 2000, J UROLOGY, V163, P181, DOI 10.1016/S0022 5347(05)68000 7
   DEQUEKER J, 1985, ACTA ENDOCRINOL COP, V110, P45
   Fink HA, 2006, J CLIN ENDOCR METAB, V91, P3908, DOI 10.1210/jc.2006 0173
   Gennari L, 2003, J CLIN ENDOCR METAB, V88, P5327, DOI 10.1210/jc.2003 030736
   GHIRON LJ, 1995, J BONE MINER RES, V10, P1844
   Goltzman D, 2008, ARCH BIOCHEM BIOPHYS, V473, P218, DOI 10.1016/j.abb.2008.03.003
   Gori F, 1999, ENDOCRINOLOGY, V140, P5579, DOI 10.1210/en.140.12.5579
   GULER HP, 1988, P NATL ACAD SCI USA, V85, P4889, DOI 10.1073/pnas.85.13.4889
   Hanada K, 2003, BIOL PHARM BULL, V26, P1563, DOI 10.1248/bpb.26.1563
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hofbauer LC, 1999, EUR J ENDOCRINOL, V140, P271, DOI 10.1530/eje.0.1400271
   Issa S, 2002, J CLIN ENDOCR METAB, V87, P5401, DOI 10.1210/jc.2001 011902
   Janssen JAMJL, 1998, GROWTH HORM IGF RES, V8, P47, DOI 10.1016/S1096 6374(98)80321 3
   Jehle Peter M., 2003, Eur J Intern Med, V14, P32, DOI 10.1016/S0953 6205(02)00183 8
   KASPERK C, 1990, J CLIN ENDOCR METAB, V71, P1322, DOI 10.1210/jcem 71 5 1322
   Khalkhali Ellis Z, 2002, J RHEUMATOL, V29, P1843
   Kurland ES, 1998, J CLIN ENDOCR METAB, V83, P2576, DOI 10.1210/jc.83.7.2576
   LACEY DL, 1995, ENDOCRINOLOGY, V136, P2367, DOI 10.1210/en.136.6.2367
   LAMORTE A, 1994, J STEROID BIOCHEM, V48, P297, DOI 10.1016/0960 0760(94)90160 0
   Legrand E, 2001, BONE, V29, P90, DOI 10.1016/S8756 3282(01)00478 1
   Leslie WD, 2006, J CLIN DENSITOM, V9, P22, DOI 10.1016/j.jocd.2006.05.004
   Li J, 2009, CANCER PREV RES, V2, P518, DOI 10.1158/1940 6207.CAPR 08 0241
   McPhaul MJ, 2001, J AM ACAD DERMATOL, V45, pS87, DOI 10.1067/mjd.2001.117429
   Mellström D, 2006, J BONE MINER RES, V21, P529, DOI 10.1359/JBMR.060110
   Miller PD, 2002, J BONE MINER RES, V17, P2222, DOI 10.1359/jbmr.2002.17.12.2222
   Mohan S., 1995, Progress in Growth Factor Research, V6, P465, DOI 10.1016/0955 2235(95)00027 5
   PILBEAM CC, 1990, J BONE MINER RES, V5, P1183
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   ROODMAN GD, 1993, CALCIFIED TISSUE INT, V53, pS94, DOI 10.1007/BF01673412
   Saad F, 2009, J STEROID BIOCHEM, V114, P40, DOI 10.1016/j.jsbmb.2008.12.022
   Slemenda CW, 1997, J CLIN INVEST, V100, P1755, DOI 10.1172/JCI119701
   SUFI SB, 1986, TESTOSTERONE ESTRADI, P57
   Syed F, 2005, BIOCHEM BIOPH RES CO, V328, P688, DOI 10.1016/j.bbrc.2004.11.097
   Szulc P, 2001, J CLIN ENDOCR METAB, V86, P192, DOI 10.1210/jc.86.1.192
   Takei S, 2000, LIFE SCI, V66, pPL277, DOI 10.1016/S0024 3205(00)00526 9
   TASHJIAN AH, 1987, ENDOCRINOLOGY, V120, P2029, DOI 10.1210/endo 120 5 2029
   TENNISWOOD M, 1976, CAN J BIOCHEM CELL B, V54, P350, DOI 10.1139/o76 051
   Thompson PW, 1998, J CLIN DENSITOM, V1, P219, DOI 10.1385/JCD:1:3:219
   TURNER RT, 1990, J ORTHOP RES, V8, P612, DOI 10.1002/jor.1100080418
   Vandenput L, 2001, BIOCHEM BIOPH RES CO, V285, P70, DOI 10.1006/bbrc.2001.5101
   VANDERSCHUEREN D, 1993, J BONE MINER RES, V8, P801
   Vanderschueren D, 2000, ENDOCRINOLOGY, V141, P1642, DOI 10.1210/en.141.5.1642
NR 54
TC 11
Z9 11
U1 0
U2 1
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD NOV
PY 2009
VL 117
IS 4 5
BP 132
EP 138
DI 10.1016/j.jsbmb.2009.08.004
PG 7
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 528AQ
UT WOS:000272412900007
PM 19732831
DA 2025 08 17
ER

PT J
AU Zhu, WB
   Xu, DD
   Mei, JW
   Lu, BL
   Wang, QJ
   Zhu, C
   Zhang, XZ
   Zhang, XL
AF Zhu, Wanbo
   Xu, Dongdong
   Mei, Jiawei
   Lu, Baoliang
   Wang, Qiaojie
   Zhu, Chen
   Zhang, Xianzuo
   Zhang, Xianlong
TI Metformin reverses impaired osteogenesis due to hyperglycemia induced
   neutrophil extracellular traps formation
SO BONE
LA English
DT Article
DE Neutrophil extracellular traps; Metformin; Osteogenesis; Diabetes
ID BONE; METABOLISM
AB Diabetic patients suffer from delayed fracture healing and impaired osteogenic function, but the underlying pathophysiological mechanisms are not fully understood. Neutrophil extracellular traps (NETs) formed by neutrophils in high glucose microenvironments affect the healing of wounds and other tissues. Some evidence supports that NETs may inhibit osteogenic processes in the microenvironment through sustained inflammatory activation. In this study, we observed that high glucose induced NETs led to sustained inflammatory activation of macrophages. Pro inflammatory NETs inhibited the osteogenic function of osteoblasts in vitro. A bone defect healing model based on diabetic rat animal models confirmed that bone healing was impaired in a high glucose environment, but this process could be reversed by DNase I, a NETs clearance agent. More importantly, the classic hypoglycemic drug metformin had a similar antagonistic effect as DNase I and could reverse the inhibitory effect of NETs on osteogenesis in a high glucose environment. In summary, we found that NETs formation induced by high glucose microenvironment is a potential cause of osteogenic dysfunction in diabetic patients, and metformin can reverse this osteogenic disadvantage.
C1 [Zhu, Wanbo; Xu, Dongdong; Wang, Qiaojie; Zhang, Xianlong] Shanghai Jiao Tong Univ, Sch Med, Dept Orthoped, Shanghai Peoples Hosp Affiliated 6, Shanghai 200233, Peoples R China.
   [Mei, Jiawei; Zhu, Chen; Zhang, Xianzuo] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Orthoped, Hefei 230001, Anhui, Peoples R China.
   [Lu, Baoliang] Bengbu Med Coll, Bengbu 233000, Anhui, Peoples R China.
C3 Shanghai Jiao Tong University; Chinese Academy of Sciences; University
   of Science & Technology of China, CAS; Bengbu Medical University
RP Zhang, XL (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Dept Orthoped, Shanghai Peoples Hosp Affiliated 6, Shanghai 200233, Peoples R China.; Zhang, XZ (通讯作者)，Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Orthoped, Hefei 230001, Anhui, Peoples R China.
EM zhangxianzuo@ustc.edu.cn; dr_zhangxianlong@sjtu.edu.cn
RI Xu, Dongdong/D 9673 2015; Zhu, Wanbo/HNJ 6651 2023; Zhang,
   Xianzuo/ACI 0276 2022
FU National Natural Science Foundation of China [82202672]; Key Research
   and Development Program of Anhui Province [202004j07020013,
   2022e07020017]; Natural Science Foundation of Anhui Province
   [2108085QH319]
FX This work was supported by the National Natural Science Foundation of
   China (Grant Nos. 82202672), the Key Research and Development Program of
   Anhui Province (No. 202004j07020013 and 2022e07020017) and the Natural
   Science Foundation of Anhui Province (Grant No. 2108085QH319). All
   authors have approved the final version of this manuscript. All animal
   experiments were approved by the Animal Ethical and Welfare Committee of
   the First Affiliated Hospital of the University of Science and
   Technology of China (2022 N 087). All surgical procedures followed the
   standard guidelines
CR Angeletti A, 2021, CELLS BASEL, V10, DOI 10.3390/cells10102667
   Armstrong DG, 2011, DIABETES TECHNOL THE, V13, P951, DOI 10.1089/dia.2011.0007
   Berezin A, 2019, DIABETES METAB SYND, V13, P3017, DOI 10.1016/j.dsx.2018.07.010
   Bloomgarden Z, 2021, J DIABETES, V13, P530, DOI 10.1111/1753 0407.13186
   Chatzigeorgiou A, 2020, THROMB HAEMOSTASIS, V120, P1587, DOI 10.1055/s 0040 1714371
   Chen M, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.753194
   Dalan R, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108230
   Donath MY, 2019, NAT REV IMMUNOL, V19, P734, DOI 10.1038/s41577 019 0213 9
   Eller Vainicher C, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/7608964
   Epstein S, 2016, OSTEOPOROSIS INT, V27, P1931, DOI 10.1007/s00198 015 3454 x
   Fu HY, 2019, MOL METAB, V30, P250, DOI 10.1016/j.molmet.2019.10.005
   Garishah FM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.629167
   Hirota T, 2020, MICROCIRCULATION, V27, DOI 10.1111/micc.12617
   Hofbauer LC, 2022, LANCET DIABETES ENDO, V10, P207, DOI 10.1016/S2213 8587(21)00347 8
   Josefs T, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.134796
   Keenan HA, 2016, CURR OSTEOPOROS REP, V14, P351, DOI 10.1007/s11914 016 0338 8
   Kurra S, 2011, DIABETES METAB RES, V27, P430, DOI 10.1002/dmrr.1197
   Lai SW, 2022, OSTEOPOROSIS INT, V33, P953, DOI 10.1007/s00198 022 06309 x
   Li GW, 2019, DIABETES CARE, V42, P507, DOI 10.2337/dc18 1965
   Liu C, 2021, DIABETES CARE, V44, P2503, DOI 10.2337/dc21 0342
   Liu D, 2019, CLIN SCI, V133, P565, DOI 10.1042/CS20180600
   Lv ZQ, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00191
   Menegazzo L, 2018, ACTA DIABETOL, V55, P593, DOI 10.1007/s00592 018 1129 8
   Mu W, 2022, PHARMACEUTICALS BASE, V15, DOI 10.3390/ph15101274
   Mulay SR, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092130
   Pernicova I, 2014, NAT REV ENDOCRINOL, V10, P143, DOI 10.1038/nrendo.2013.256
   Rathinavelu S, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/6354787
   Shafqat A, 2022, FRONT MED LAUSANNE, V9, DOI 10.3389/fmed.2022.995993
   Thålin C, 2019, ARTERIOSCL THROM VAS, V39, P1724, DOI 10.1161/ATVBAHA.119.312463
   Thierry AR, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092942
   Ursini F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01236
   Wada J, 2016, NAT REV NEPHROL, V12, P13, DOI 10.1038/nrneph.2015.175
   Wang HT, 2015, ARTHRITIS RHEUMATOL, V67, P3190, DOI 10.1002/art.39296
   Wong SL, 2015, NAT MED, V21, P815, DOI 10.1038/nm.3887
   Yeram PB, 2022, CHEM BIODIVERS, V19, DOI 10.1002/cbdv.202200067
   Zhang B, 2021, J PERIODONTAL RES, V56, P991, DOI 10.1111/jre.12912
   Zheng FF, 2022, DIABETES, V71, P2739, DOI 10.2337/db22 0153
   Zhou QY, 2022, AGING US, V14, P272, DOI 10.18632/aging.203729
   Zhu WB, 2022, ADV MATER, V34, DOI 10.1002/adma.202207961
NR 39
TC 5
Z9 5
U1 2
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD NOV
PY 2023
VL 176
AR 116889
DI 10.1016/j.bone.2023.116889
EA SEP 2023
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA T8OG5
UT WOS:001080516700001
PM 37660937
DA 2025 08 17
ER

PT J
AU Yeremenko, N
   Zwerina, K
   Rigter, G
   Pots, D
   Fonseca, JE
   Zwerina, J
   Schett, G
   Baeten, D
AF Yeremenko, Nataliya
   Zwerina, Karin
   Rigter, Gemma
   Pots, Desiree
   Fonseca, Joao E.
   Zwerina, Jochen
   Schett, Georg
   Baeten, Dominique
TI Tumor Necrosis Factor and Interleukin 6 Differentially Regulate Dkk 1 in
   the Inflamed Arthritic Joint
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; DICKKOPF 1;
   SPONDYLARTHRITIS; CLASSIFICATION; TOCILIZUMAB; CRITERIA; THERAPY
AB Objective. Tumor necrosis factor (TNF) drives bone destruction, but it also inhibits new bone formation by inducing Dkk 1, an inhibitor of the Wnt pathway. Accordingly, blocking of Dkk 1 reverses the phenotype in experimental arthritis from a pattern of bone destruction to a pattern of bone formation. To delineate the potential role of Dkk 1 in the structural phenotype of human arthritis, we analyzed the expression of Dkk 1 and its regulation by proinflammatory cytokines in the inflamed peripheral joints of patients with spondyloarthritis (SpA) and rheumatoid arthritis (RA).
   Methods. Expression of Dkk 1 and proinflammatory cytokines was determined by enzyme linked immunosorbent assay and microarray analysis in synovial fluid (SF) and synovial tissue, respectively. Regulation of Dkk 1 production by proinflammatory cytokines was assessed in fibroblast like synoviocyte (FLS) cultures.
   Results. TNF and interleukin 1 beta (IL 1 beta) levels, were higher in RA SF than in SpA SF (P < 0.001 for both), whereas levels of IL 6 were not. Levels of Dkk 1 were similar in SpA SF and RA SF and were not correlated with TNF and IL 1 beta levels. However, Dkk 1 levels showed an inverse correlation with IL 6 levels in both SpA SF (r= 0.31, P=0.04) and RA SF (r= 0.39, P=0.01); this result was reproduced at the messenger RNA level in synovial tissue. In vitro experiments with FLS confirmed that Dkk 1 production was strongly induced by TNF but clearly suppressed by IL 6. Moreover, IL 6 was able to suppress the TNF induced up regulation of Dkk 1 production by FLS.
   Conclusion. The inverse correlation of Dkk 1 levels with IL 6 levels observed in vivo in the inflamed joints was mirrored by the differential regulation of Dkk 1 production by TNF and IL 6 in vitro. The relative balance between these and other factors in the arthritic joints may determine functional Wnt signaling and tissue remodeling.
C1 [Yeremenko, Nataliya; Rigter, Gemma; Pots, Desiree; Baeten, Dominique] Univ Amsterdam, Acad Med Ctr, NL 1105 AZ Amsterdam, Netherlands.
   [Zwerina, Karin; Zwerina, Jochen; Schett, Georg] Univ Erlangen Nurnberg, D 91054 Erlangen, Germany.
   [Fonseca, Joao E.] Hosp Santa Maria, Lisbon Acad Med Ctr, Lisbon, Portugal.
   [Fonseca, Joao E.] Inst Med Mol, Lisbon, Portugal.
C3 University of Amsterdam; Academic Medical Center Amsterdam; University
   of Erlangen Nuremberg; Universidade de Lisboa; Hospital Santa Maria;
   Universidade de Lisboa
RP Baeten, D (通讯作者)，Univ Amsterdam, Acad Med Ctr, Dept Clin Immunol & Rheumatol, F4 105,Meibergdreef 9, NL 1105 AZ Amsterdam, Netherlands.
EM d.l.baeten@amc.uva.nl
RI Yeremenko, Nataliya/AAR 2962 2020; Fonseca, Joao/KHW 7048 2024
OI Fonseca, Joao/0000 0003 1432 3671; 
FU Dutch Arthritis Foundation (Reumafonds); Deutsche Forschungsgemeinschaft
   [SPP 1468 ImmunoBone]; Netherlands Organization for Scientific Research
   (NWO); Pfizer; Merck Sharp Dohme; UCB; Celgene; Janssen; AbbVie; Roche;
   Astro Pharma; Bristol Myers Squibb
FX Supported by grants from the Dutch Arthritis Foundation (Reumafonds) (to
   Drs. Yeremenko and Baeten) and the Deutsche Forschungsgemeinschaft
   (grant SPP 1468 ImmunoBone) (to Drs. J. Zwerina and Schett). Dr.
   Baeten's work was also supported by a Vici grant from the Netherlands
   Organization for Scientific Research (NWO).Dr. Fonseca has received
   consulting fees, speaking fees, and/or honoraria from Pfizer, Merck
   Sharp & Dohme, UCB, Celgene, Janssen, and AbbVie. Dr. J. Zwerina has
   received consulting fees, speaking fees, and/or honoraria from Roche,
   Astro Pharma, Merck Sharp & Dohme, UCB, Pfizer, AbbVie, and
   Bristol Myers Squibb.
CR Aletaha D, 2010, ARTHRITIS RHEUM US, V62, P2569, DOI 10.1002/art.27584
   Appel H, 2009, ARTHRITIS RHEUM US, V60, P3257, DOI 10.1002/art.24888
   Baron Roland, 2007, Curr Osteoporos Rep, V5, P73
   Brandt J, 2000, ARTHRITIS RHEUM US, V43, P1346, DOI 10.1002/1529 0131(200006)43:6<1346::AID ANR18>3.0.CO;2 E
   Briot K, 2015, JOINT BONE SPINE, V82, P109, DOI 10.1016/j.jbspin.2014.10.015
   Charles P, 1999, J IMMUNOL, V163, P1521
   Daoussis D, 2010, ARTHRITIS RHEUM US, V62, P150, DOI 10.1002/art.27231
   DesRooy DP, 2013, ANN RHEUM DIS, V72, P769
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   DOUGADOS M, 1991, ARTHRITIS RHEUM, V34, P1218, DOI 10.1002/art.1780341003
   Heiland GR, 2012, ANN RHEUM DIS, V71, P572, DOI 10.1136/annrheumdis 2011 200216
   Honsawek S, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 257
   Shimamoto K, 2013, J RHEUMATOL, V40, P1074, DOI 10.3899/jrheum.121389
   Terpos E, 2011, CLIN EXP RHEUMATOL, V29, P921
   Uderhardt S, 2010, ANN RHEUM DIS, V69, P592, DOI 10.1136/ard.2008.102046
   Vandooren B, 2009, ARTHRITIS RHEUM US, V60, P966, DOI 10.1002/art.24406
   Yeremenko N, 2013, ARTHRITIS RHEUM US, V65, P174, DOI 10.1002/art.37704
NR 17
TC 58
Z9 62
U1 1
U2 10
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2326 5191
EI 2326 5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD AUG
PY 2015
VL 67
IS 8
BP 2071
EP 2075
DI 10.1002/art.39183
PG 5
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA CN7JA
UT WOS:000358609300012
PM 25941031
DA 2025 08 17
ER

PT J
AU Mendelsohn, DH
   Niedermair, T
   Walter, N
   Alt, V
   Rupp, M
   Brochhausen, C
AF Mendelsohn, Daniel H.
   Niedermair, Tanja
   Walter, Nike
   Alt, Volker
   Rupp, Markus
   Brochhausen, Christoph
TI Ultrastructural Evidence of Mitochondrial Dysfunction in Osteomyelitis
   Patients
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteomyelitis; mitochondria; mitochondrial ultrastructure; mitochondrial
   dysfunction; mitochondrial dynamics
ID ISCHEMIA REPERFUSION INJURY; ROS; OXYGEN; TRANSPLANTATION; HYPOXIA
AB Osteomyelitis is a difficult to treat disease with high chronification rates. First studies suggest increases in mitochondrial fission and mitochondrial dysfunction as possible contributors to the accumulation of intracellular reactive oxygen species and thereby to the cell death of infected bone cells. The aim of the present study is to analyze the ultrastructural impact of bacterial infection on osteocytic and osteoblastic mitochondria. Human infected bone tissue samples were visualized via light microscopy and transmission electron microscopy. Osteoblasts, osteocytes and their mitochondria were analyzed histomorphometrically and compared with the control group of noninfectious human bone tissue samples. The results depicted swollen hydropic mitochondria including depleted cristae and a decrease in matrix density in the infected samples. Furthermore, perinuclear clustering of mitochondria could also be observed regularly. Additionally, increases in relative mitochondrial area and number were found as a correlate for increased mitochondrial fission. In conclusion, mitochondrial morphology is altered during osteomyelitis in a comparable way to mitochondria from hypoxic tissues. This gives new perspectives on the treatment strategies since the manipulation of mitochondrial dynamics may improve bone cell survival as a potential new target for the therapy of osteomyelitis.
C1 [Mendelsohn, Daniel H.; Niedermair, Tanja; Brochhausen, Christoph] Univ Regensburg, Inst Pathol, D 93053 Regensburg, Germany.
   [Mendelsohn, Daniel H.; Niedermair, Tanja; Brochhausen, Christoph] Univ Regensburg, Univ Hosp Regensburg, Cent Biobank Regensburg, D 93053 Regensburg, Germany.
   [Mendelsohn, Daniel H.; Walter, Nike; Alt, Volker; Rupp, Markus] Univ Med Ctr Regensburg, Dept Trauma Surg, D 93053 Regensburg, Germany.
   [Brochhausen, Christoph] Univ Med Ctr Mannheim, Inst Pathol, D 68167 Mannheim, Germany.
C3 University of Regensburg; University of Regensburg; University of
   Regensburg; Ruprecht Karls University Heidelberg
RP Brochhausen, C (通讯作者)，Univ Regensburg, Inst Pathol, D 93053 Regensburg, Germany.; Brochhausen, C (通讯作者)，Univ Regensburg, Univ Hosp Regensburg, Cent Biobank Regensburg, D 93053 Regensburg, Germany.; Brochhausen, C (通讯作者)，Univ Med Ctr Mannheim, Inst Pathol, D 68167 Mannheim, Germany.
EM christoph.brochhausen delius@umm.de
RI ; Rupp, Markus/ABH 5784 2022
OI Alt, Volker/0000 0003 0208 4650; Mendelsohn, Daniel
   H./0000 0001 9172 6031; Walter, Nike/0000 0002 0654 2076; Rupp,
   Markus/0000 0001 7221 3783; 
FU University of Regensburg
FX This research received no external funding. This paper includes parts of
   the medical dissertation of D.H.M. He received a scholarship from the
   University of Regensburg for his medical dissertation.
CR Al Mehdi AB, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002712
   Almeida M, 2010, MOL ENDOCRINOL, V24, P2030, DOI 10.1210/me.2010 0189
   Andrieux P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111338
   Annesley SJ, 2019, CELLS BASEL, V8, DOI 10.3390/cells8070680
   Bonucci E., 1990, ULTRASTRUCTURE SKELE, P223
   Bordt EA, 2017, DEV CELL, V40, P583, DOI 10.1016/j.devcel.2017.02.020
   Borsche M, 2021, J PARKINSON DIS, V11, P45, DOI 10.3233/JPD 201981
   Bosse MJ, 2005, J BONE JOINT SURG AM, V87A, P1343, DOI 10.2106/JBJS.D.02649
   Cadenas S, 2018, FREE RADICAL BIO MED, V117, P76, DOI 10.1016/j.freeradbiomed.2018.01.024
   Chang X, 2023, INT J BIOL SCI, V19, P426, DOI 10.7150/ijbs.76223
   Charlson M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112479
   Chen YK, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.928651
   Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318
   Cowan DB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160889
   Devraj G, 2017, MICROBES INFECT, V19, P144, DOI 10.1016/j.micinf.2016.11.003
   Ding MG, 2017, CARDIOVASC DIABETOL, V16, DOI 10.1186/s12933 017 0501 2
   Disatnik MH, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000461
   Eckl EM, 2021, CELL MOL LIFE SCI, V78, P5925, DOI 10.1007/s00018 021 03887 7
   Ennker Ina Carolin, 2014, GMS Interdiscip Plast Reconstr Surg DGPW, V3, pDoc07, DOI 10.3205/iprs000048
   Evans A, 2016, MOL CELL, V61, P641, DOI 10.1016/j.molcel.2016.02.002
   Ferver A, 2021, FRONT VET SCI, V8, DOI 10.3389/fvets.2021.640901
   Fujioka H, 2012, ANAT REC, V295, P1455, DOI 10.1002/ar.22523
   Genestier AL, 2005, J CLIN INVEST, V115, P3117, DOI 10.1172/JCI22684
   Gimza BD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.638085
   Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011
   Govaert GAM, 2020, J ORTHOP TRAUMA, V34, P8, DOI 10.1097/BOT.0000000000001614
   Granata V, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1048505
   Grazioli S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00832
   Ham PB, 2017, PROG NEUROBIOL, V157, P92, DOI 10.1016/j.pneurobio.2016.06.006
   Hart BB, 2021, UNDERSEA HYPERBAR M, V48, P297
   Huang C, 2023, INT J BIOL MACROMOL, V235, DOI 10.1016/j.ijbiomac.2023.123755
   Jang S, 2020, MITOCHONDRION, V51, P30, DOI 10.1016/j.mito.2019.11.006
   Jang S, 2017, ARCH BIOCHEM BIOPHYS, V630, P1, DOI 10.1016/j.abb.2017.07.009
   Jezek J, 2021, BIOLOGY BASEL, V10, DOI 10.3390/biology10010033
   Jezek J, 2018, ANTIOXIDANTS BASEL, V7, DOI 10.3390/antiox7010013
   Liò P, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471 2105 13 S14 S12
   Lyamzaev KG, 2020, BIOCHEMISTRY MOSCOW+, V85, P1484, DOI 10.1134/S0006297920120020
   Ma KL, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00467
   Maassen JA, 2004, DIABETES, V53, pS103, DOI 10.2337/diabetes.53.2007.S103
   McCully JD, 2017, MITOCHONDRION, V34, P127, DOI 10.1016/j.mito.2017.03.004
   McCully JD, 2016, CLIN TRANSL MED, V5, DOI 10.1186/s40169 016 0095 4
   McCully JD, 2009, AM J PHYSIOL HEART C, V296, pH94, DOI 10.1152/ajpheart.00567.2008
   McNally M, 2021, BONE JOINT J, V103B, P18, DOI 10.1302/0301 620X.103B1.BJJ 2020 1381.R1
   Mendelsohn DH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23094571
   Meng Y, 2023, CURR GENET, V69, P1, DOI 10.1007/s00294 023 01261 7
   Nesson ET, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232113006
   Nunnari J, 2012, CELL, V148, P1145, DOI 10.1016/j.cell.2012.02.035
   Park A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094793
   Ren ZH, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01992
   Rupp M, 2021, BONE JOINT RES, V10, P742, DOI [10.1302/2046 3758.1011.BJR 2021 0371, 10.1302/2046 3758.1011]
   Rupp M., 2022, ORTHOPAEDIC KNOWLEDG, V6, P149
   Sasaki H, 2019, J ENDODONT, V45, P181, DOI 10.1016/j.joen.2018.10.007
   Schaffer K, 2015, FEBS J, V282, P2260, DOI 10.1111/febs.13270
   Scherft J.P., 1990, ULTRASTRUCTURE SKELE, P209, DOI DOI 10.1007/978 1 4613 1487 5_11
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   Sun C, 2019, THERANOSTICS, V9, P3595, DOI 10.7150/thno.33100
   Swerdlow RH, 2018, J ALZHEIMERS DIS, V62, P1403, DOI 10.3233/JAD 170585
   Sybenga AB, 2020, J FOOT ANKLE SURG, V59, P75, DOI 10.1053/j.jfas.2019.06.007
   Tiemann A, 2014, GMS Interdiscip Plast Reconstr Surg DGPW, V3, pDoc08, DOI 10.3205/iprs000049
   Tilokani L, 2018, ESSAYS BIOCHEM, V62, P341, DOI 10.1042/EBC20170104
   Twig G, 2011, ANTIOXID REDOX SIGN, V14, P1939, DOI 10.1089/ars.2010.3779
   Urish KL, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00932 19
   Walter N, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10081064
   Watkins KE, 2020, ADV APPL MICROBIOL, V112, P105, DOI 10.1016/bs.aambs.2020.05.001
   Yamada Y, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10010083
   Yoo SM, 2018, MOL CELLS, V41, P18, DOI 10.14348/molcells.2018.2277
   Zelmer AR, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00227 8
   Zhang L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175262
   Zhang W, 2022, MSYSTEMS, V7, DOI 10.1128/msystems.00380 22
   Zhou ML, 2021, CARDIOLOGY, V146, P781, DOI 10.1159/000518879
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013
NR 71
TC 8
Z9 8
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2023
VL 24
IS 6
AR 5709
DI 10.3390/ijms24065709
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA C0HR4
UT WOS:000958839200001
PM 36982790
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Nikukar, H
   Reid, S
   Tsimbouri, PM
   Riehle, MO
   Curtis, ASG
   Dalby, MJ
AF Nikukar, Habib
   Reid, Stuart
   Tsimbouri, P. Monica
   Riehle, Mathis O.
   Curtis, Adam S. G.
   Dalby, Matthew J.
TI Osteogenesis of Mesenchymal Stem Cells by Nanoscale Mechanotransduction
SO ACS NANO
LA English
DT Article
DE nanoscale; mechanotransduction; osteogenesis; mesenchymal stem cells
ID IN VITRO; OSTEOBLASTIC DIFFERENTIATION; TRANSCRIPTION FACTOR;
   SIGNAL TRANSDUCTION; ADHESION FORMATION; STROMAL CELLS; BONE; FORCE;
   TOPOGRAPHY; FIELD
AB It Is likely that mesenchymal stem cells will find use in many autologous regenerative therapies. However, our ability to control cell stem growth and differentiation is presently limited, and this is a major hurdle to the clinical use of these multlpotent cells especially when considering the desire not to use soluble factors or complex media formulations in culture. Also, the large number of cells required to be clinically useful is currently a hurdle to using materials based (stiffness, chemistry, nanotopography, etc.) culture substrates. Here we give a first demonstration of using nanoscale sinusoidal mechanotransductive protocols (10 14 nm displacements at 1 kHz frequency), "nanokIcking", to promote osteoblastogenesis In human mesenchymal stem cell cultures. On the basis of application of the reverse piezo effect, we use interferometry to develop the optimal stem cell stimulation conditions, allowing delivery of nanoscale cues across the entire surface of the Petri dishes used. A combination of immundluorescence, PCR, and microarray has then been used to demonstrate osteoblastogenesis, and the arrays implicate RhoA as central to osteoblastic differentiation in agreement with materials based strategies. We validate this with pharmacological inhibition of RhoA klnase. It Is easy to envisage such stimulation protocols being up scaled to form largescale osteoblast bloreactors as standard cell culture plates and incubators are used In the
C1 [Nikukar, Habib; Tsimbouri, P. Monica; Riehle, Mathis O.; Curtis, Adam S. G.; Dalby, Matthew J.] Univ Glasgow, Coll Med Vet & Life Sci, Inst Mol Cell & Syst Biol, Ctr Cell Engn, Glasgow G12 8QQ, Lanark, Scotland.
   [Reid, Stuart] Univ West Scotland, Thin Film Ctr, SUPA, Paisley PA1 2BE, Renfrew, Scotland.
   [Nikukar, Habib] Shahid Sadoughi Univ Med Sci, Yazd, Iran.
C3 University of Glasgow; University of West Scotland; Shahid Sadoughi
   University of Medical Sciences
RP Reid, S (通讯作者)，Univ West Scotland, Thin Film Ctr, SUPA, Paisley PA1 2BE, Renfrew, Scotland.
EM stuart.reid@uws.ac.uk; matthew.dalby@glasgow.ac.uk
RI Nikukar, Habib/AAJ 3000 2020; Dalby, Matthew/G 2426 2012; Riehle,
   Mathis/A 3427 2011; Nikukar, Habib/Q 1492 2016; Tsimbouri,
   Penelope/F 4373 2010
OI Reid, Stuart/0000 0002 9728 3507; Riehle, Mathis/0000 0001 7988 1514;
   Nikukar, Habib/0000 0001 9225 6019; Tsimbouri,
   Penelope/0000 0001 5124 7458; Dalby, Matthew/0000 0002 0528 3359
FU Ministry of Health and Medical Education of I.R. Iran; BBSRC; STFC;
   University of Glasgow; University of the West of Scotland; Royal Society
   of Edinburgh; Scottish Government; Biotechnology and Biological Sciences
   Research Council [JF20604, BB/G008868/1] Funding Source: researchfish;
   Science and Technology Facilities Council [ST/L502509/1, ST/L000938/1,
   ST/L000938/1 Gravitational Waves, Gravitational Waves] Funding Source:
   researchfish; BBSRC [BB/G008868/1] Funding Source: UKRI; STFC
   [ST/L000938/1, ST/L502509/1, Gravitational Waves] Funding Source: UKRI
FX We would like to thank the Ministry of Health and Medical Education of
   I.R. Iran for funding this project. We would like to thank Linn Products
   Ltd, Prof. Rein Ulijn, Prof. James Hough, Prof. James Faller, and Dr.
   Fiona Henriquez for useful discussions and their interest in this work.
   We are grateful for the additional financial support provided by BBSRC,
   STFC, the University of Glasgow, and the University of the West of
   Scotland. We also thank the Royal Society of Edinburgh and the Scottish
   Government for providing a research fellowship for S.R. We also thank
   Carol Anne Smith, Peter Chung, and Margaret Mullin for laboratory
   assistance.
CR Alizadeh Meghrazi M, 2012, PM&R, V4, P963, DOI 10.1016/j.pmrj.2012.08.012
   Andersson AS, 2003, BIOMATERIALS, V24, P3427, DOI 10.1016/S0142 9612(03)00208 4
   Biggs MJP, 2008, J R SOC INTERFACE, V5, P1231, DOI 10.1098/rsif.2008.0035
   Biggs MJP, 2009, J BIOMED MATER RES A, V91A, P195, DOI 10.1002/jbm.a.32196
   Biggs MJP, 2009, BIOMATERIALS, V30, P5094, DOI 10.1016/j.biomaterials.2009.05.049
   Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055
   Cheema U, 2007, ADV FUNCT MATER, V17, P2426, DOI 10.1002/adfm.200700116
   CHEN IIH, 1988, BIOMATER ARTIF CELL, V15, P737
   Child HW, 2011, ACS NANO, V5, P7910, DOI 10.1021/nn202163v
   Conde J, 2012, ACS NANO, V6, P8316, DOI 10.1021/nn3030223
   Dai Z, 2007, PHYTOMEDICINE, V14, P806, DOI 10.1016/j.phymed.2007.04.003
   Dalby MJ, 2007, NAT MATER, V6, P997, DOI 10.1038/nmat2013
   Dalby MJ, 2002, EXP CELL RES, V276, P1, DOI 10.1006/EXCR.2002.5498
   Dalby MJ, 2002, BIOMATERIALS, V23, P2945, DOI 10.1016/S0142 9612(01)00424 0
   Day TF, 2008, J BONE JOINT SURG AM, V90A, P19, DOI 10.2106/JBJS.G.01174
   del Rio A, 2009, SCIENCE, V323, P638, DOI 10.1126/science.1162912
   Eastwood M, 1998, P I MECH ENG H, V212, P85, DOI 10.1243/0954411981533854
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   EVANS E, 1989, CELL MOTIL CYTOSKEL, V14, P544, DOI 10.1002/cm.970140411
   Evans J, 2008, BIOPHYS J, V94, P4134, DOI 10.1529/biophysj.107.117952
   Fernández JR, 2012, J THEOR BIOL, V292, P86, DOI 10.1016/j.jtbi.2011.09.032
   Finkelstein EI, 2007, CELL MOTIL CYTOSKEL, V64, P833, DOI 10.1002/cm.20227
   Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153
   Gao L, 2010, STEM CELLS, V28, P564, DOI 10.1002/stem.308
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Goldstein C, 2010, J ORTHOP TRAUMA, V24, pS62, DOI 10.1097/BOT.0b013e3181cdde1b
   Guilak F, 2009, CELL STEM CELL, V5, P17, DOI 10.1016/j.stem.2009.06.016
   Hamilton DW, 2007, BIOMATERIALS, V28, P1806, DOI 10.1016/j.biomaterials.2006.11.041
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   Huang YF, 2012, J BONE MINER RES, V27, P1093, DOI 10.1002/jbmr.1548
   Ingber DE, 2008, J BODYW MOV THER, V12, P198, DOI 10.1016/j.jbmt.2008.04.038
   James AW, 2010, TISSUE ENG PT A, V16, P2605, DOI [10.1089/ten.tea.2010.0048, 10.1089/ten.TEA.2010.0048]
   Jang WG, 2012, J BIOL CHEM, V287, P905, DOI 10.1074/jbc.M111.253187
   KANAKA TS, 1990, PARAPLEGIA, V28, P399, DOI 10.1038/sc.1990.53
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Kim WK, 2010, J CELL BIOCHEM, V111, P1199, DOI 10.1002/jcb.22846
   Knight MM, 2002, BBA GEN SUBJECTS, V1570, P1, DOI 10.1016/S0304 4165(02)00144 7
   KROL AY, 1990, EUR BIOPHYS J, V19, P93, DOI 10.1007/BF00185092
   Liu J, 2012, INT J ARTIF ORGANS, V35, P323, DOI 10.5301/ijao.5000085
   Longo UG, 2012, CURR STEM CELL RES T, V7, P272
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   McMurray RJ, 2011, NAT MATER, V10, P637, DOI [10.1038/NMAT3058, 10.1038/nmat3058]
   Mycielska ME, 2004, J CELL SCI, V117, P1631, DOI 10.1242/jcs.01125
   Noris Suárez K, 2007, BIOMACROMOLECULES, V8, P941, DOI 10.1021/bm060828z
   Oh S, 2009, P NATL ACAD SCI USA, V106, P2130, DOI 10.1073/pnas.0813200106
   Park SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046689
   Pelling AE, 2007, J MOL RECOGNIT, V20, P467, DOI 10.1002/jmr.832
   Pierres A, 2008, BIOPHYS J, V94, P4114, DOI 10.1529/biophysj.107.125278
   Pierres A, 2009, TRENDS CELL BIOL, V19, P428, DOI 10.1016/j.tcb.2009.05.009
   Pingguan Murphy B, 2005, ARCH BIOCHEM BIOPHYS, V444, P45, DOI 10.1016/j.abb.2005.09.015
   POMPEIANO O, 1975, ARCH ITAL BIOL, V113, P280
   Rappaz B, 2009, BLOOD CELL MOL DIS, V42, P228, DOI 10.1016/j.bcmd.2009.01.018
   REINISH GB, 1975, NATURE, V253, P626, DOI 10.1038/253626a0
   Sawada Y, 2002, J CELL BIOL, V156, P609, DOI 10.1083/jcb.200110068
   Sawada Y, 2006, CELL, V127, P1015, DOI 10.1016/j.cell.2006.09.044
   Schäffler A, 2007, STEM CELLS, V25, P818, DOI 10.1634/stemcells.2006 0589
   Shamri R, 2005, NAT IMMUNOL, V6, P497, DOI 10.1038/ni1194
   Shi Y, 2012, J CELL BIOCHEM, V113, P3133, DOI 10.1002/jcb.24190
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Szabó B, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.041910
   Tamma R, 2009, ULTRASOUND MED BIOL, V35, P2093, DOI 10.1016/j.ultrasmedbio.2009.05.022
   Tare RS, 2008, MOL CELL ENDOCRINOL, V288, P11, DOI 10.1016/j.mce.2008.02.017
   Tsimbouri PM, 2012, ACS NANO, V6, P10239, DOI 10.1021/nn304046m
   Vater C, 2011, ACTA BIOMATER, V7, P463, DOI 10.1016/j.actbio.2010.07.037
   Vogel V, 2006, NAT REV MOL CELL BIO, V7, P265, DOI 10.1038/nrm1890
   Ward DF, 2007, STEM CELLS DEV, V16, P467, DOI 10.1089/scd.2007.0034
   Willis DM, 2002, J BIOL CHEM, V277, P37280, DOI 10.1074/jbc.M206482200
   Wysocki A, 2011, ANN INTERN MED, V155, P680, DOI 10.7326/0003 4819 155 10 201111150 00006
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Yim EKF, 2005, BIOMATERIALS, V26, P5405, DOI 10.1016/j.biomaterials.2005.01.058
   Yim EKF, 2007, EXP CELL RES, V313, P1820, DOI 10.1016/j.yexcr.2007.02.031
   Yim EKF, 2010, BIOMATERIALS, V31, P1299, DOI 10.1016/j.biomaterials.2009.10.037
NR 72
TC 114
Z9 122
U1 2
U2 155
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936 0851
EI 1936 086X
J9 ACS NANO
JI ACS Nano
PD MAR
PY 2013
VL 7
IS 3
BP 2758
EP 2767
DI 10.1021/nn400202j
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA 115YB
UT WOS:000316846700097
PM 23442213
DA 2025 08 17
ER

PT J
AU Simonen, M
   Ibig Rehm, Y
   Hofmann, G
   Zimmermann, J
   Albrecht, G
   Magnier, M
   Heidinger, V
   Gabriel, D
AF Simonen, Marjo
   Ibig Rehm, Yvonne
   Hofmann, Gabriele
   Zimmermann, Johann
   Albrecht, Genevieve
   Magnier, Maxime
   Heidinger, Valerie
   Gabriel, Daniela
TI High content assay to study protein prenylation
SO JOURNAL OF BIOMOLECULAR SCREENING
LA English
DT Article
DE mevalonate pathway; protein prenylation; high content analysis; green
   fluorescent protein (GFP); plasma membrane localization
ID NITROGEN CONTAINING BISPHOSPHONATES; FARNESYL PYROPHOSPHATE SYNTHASE;
   IN VIVO; GERANYLGERANYLTRANSFERASE I; TRANSFERASE INHIBITORS;
   DIPHOSPHATE SYNTHASE; MAMMALIAN CELLS; PLASMA MEMBRANE; TUMOR CELLS;
   H RAS
AB The mevalonate pathway leads to synthesis of cholesterol and isoprenoid lipids. Prenyltransferases attach the isoprenoid lipids to the C terminus of several small guanosine triphosphate binding proteins. The prenyl groups are essential for the biological activity of these proteins. The prenyltransferases and other components of the mevalonate pathway are either present or potential drug targets for cancer, osteoporosis, restenosis, or high serum cholesterol level. Until recently, cellular assays to study protein prenylation have been tedious, low throughput assays. The authors have developed a high content imaging based assay to study protein prenylation. The assay is based on a green fluorescent protein (GFP) reporter, which is tagged with the prenylation motif of human H Ras. The C terminus of H Ras targets GFP to the plasma membrane. When protein prenylation is inhibited, the tagged GFP cannot be localized to plasma membrane but is soluble in the cells. The localization of the GFP reporter can be analyzed in the 96  or 384 well format using automated microscopy and automated image analysis. Information about cell number and nuclear intensity can be obtained from the same images. In compound screening, these readouts provide valuable information about the toxicity of the compounds. The authors have validated their assay using several inhibitors of the mevalonate pathway as well as siRNA against farnesyl pyrophosphate synthase, a critical enzyme in the synthesis of the isoprenoid lipids.
C1 [Simonen, Marjo; Ibig Rehm, Yvonne; Hofmann, Gabriele; Zimmermann, Johann; Albrecht, Genevieve; Magnier, Maxime; Heidinger, Valerie; Gabriel, Daniela] Novartis Inst BioMed Res, CH 4002 Basel, Switzerland.
C3 Novartis
RP Simonen, M (通讯作者)，WEJ 350 3 12 Postfach, CH 4002 Basel, Switzerland.
EM marjo.simonen@novartis.com
CR Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Bivona TG, 2006, METHOD ENZYMOL, V407, P128, DOI 10.1016/S0076 6879(05)07012 6
   Boijoux O, 2005, MOL PHARMACOL, V67, P1829, DOI 10.1124/mol.105.011163
   Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092 8674(00)80607 8
   Cohen LH, 2000, BIOCHEM PHARMACOL, V60, P1061, DOI 10.1016/S0006 2952(00)00386 5
   Conte P, 2004, ONCOLOGIST, V9, P28, DOI 10.1634/theoncologist.9 90004 28
   Corish P, 1999, PROTEIN ENG, V12, P1035, DOI 10.1093/protein/12.12.1035
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   DER CJ, 1982, P NATL ACAD SCI BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   El Oualid F, 2006, CURR MED CHEM, V13, P2385, DOI 10.2174/092986706777935078
   Fleisch H, 2001, EXPERT OPIN THER PAT, V11, P1371, DOI 10.1517/13543776.11.9.1371
   Gelb MH, 2006, NAT CHEM BIOL, V2, P518, DOI 10.1038/nchembio818
   Glickman JF, 2007, ASSAY DRUG DEV TECHN, V5, P205, DOI 10.1089/adt.2007.057
   Green JR, 1997, INT J PHARM, V153, P59, DOI 10.1016/S0378 5173(97)00094 X
   HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092 8674(89)90054 8
   Keller RK, 1999, BIOCHEM BIOPH RES CO, V266, P560, DOI 10.1006/bbrc.1999.1849
   Knight LA, 2005, ANTI CANCER DRUG, V16, P969, DOI 10.1097/01.cad.0000176500.56057.66
   Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221
   Lommerse PHM, 2005, J CELL SCI, V118, P1799, DOI 10.1242/jcs.02300
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Mikic I, 2006, METHOD ENZYMOL, V414, P150, DOI 10.1016/S0076 6879(06)14010 0
   Park EJ, 2001, J CHROMATOGR B, V754, P327, DOI 10.1016/S0378 4347(00)00620 4
   Perrin D, 2000, EXS, V89, P153
   Qian YM, 1999, BIOORGAN MED CHEM, V7, P3011, DOI 10.1016/S0968 0896(99)00252 7
   Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654
   Roskoski R, 2003, BIOCHEM BIOPH RES CO, V303, P1, DOI 10.1016/S0006 291X(03)00323 1
   Scharovsky OG, 2000, J BIOMED SCI, V7, P292, DOI 10.1007/BF02253247
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Shi YJ, 2003, MOL CANCER THER, V2, P563
   Swanson KM, 2006, CURR CANCER DRUG TAR, V6, P15, DOI 10.2174/156800906775471743
   Tamanoi F, 2001, CELL MOL LIFE SCI, V58, P1636, DOI 10.1007/PL00000802
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   van Beek ER, 1998, BONE, V23, P437, DOI 10.1016/S8756 3282(98)00120 3
   Vasudevan A, 1999, J MED CHEM, V42, P1333, DOI 10.1021/jm9900873
   Vita F, 1996, EXP CELL RES, V227, P367, DOI 10.1006/excr.1996.0286
   Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224
   Ward SM, 2002, J MOL CELL CARDIOL, V34, P1217, DOI 10.1006/jmcc.2002.7023
   Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459
   Willumsen BM, 1996, ONCOGENE, V13, P1901
NR 41
TC 17
Z9 17
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1087 0571
EI 1552 454X
J9 J BIOMOL SCREEN
JI J. Biomol. Screen
PD JUL
PY 2008
VL 13
IS 6
BP 456
EP 467
DI 10.1177/1087057108318757
PG 12
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry
GA 324UW
UT WOS:000257545900003
PM 18509097
OA hybrid
DA 2025 08 17
ER

PT J
AU Beltran Bless, AA
   Clemons, MJ
   Fesl, C
   Greil, R
   Pond, GR
   Balic, M
   Vandermeer, L
   Bjelic Radisic, V
   Singer, CF
   Steger, GG
   Helfgott, R
   Egle, D
   Sölkner, L
   Gampenrieder, SP
   Kacerovsky Strobl, S
   Suppan, C
   Ritter, M
   Rinnerthaler, G
   Pfeiler, G
   Fohler, H
   Hlauschek, D
   Hilton, J
   Gnant, M
AF Beltran Bless, Ana Alicia
   Clemons, Mark J.
   Fesl, Christian
   Greil, Richard
   Pond, Gregory R.
   Balic, Marija
   Vandermeer, Lisa
   Bjelic Radisic, Vesna
   Singer, Christian F.
   Steger, Guenther G.
   Helfgott, Ruth
   Egle, Daniel
   Soelkner, Lidija
   Gampenrieder, Simon P.
   Kacerovsky Strobl, Stephanie
   Suppan, Christoph
   Ritter, Magdalena
   Rinnerthaler, Gabriel
   Pfeiler, Georg
   Fohler, Hannes
   Hlauschek, Dominik
   Hilton, John
   Gnant, Michael
TI Does the number of 6 monthly adjuvant zoledronate infusions received
   affect treatment efficacy for early breast cancer? A sub study of
   ABCSG 12
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Breast cancer; Adjuvant bisphosphonate; Duration; Zoledronate
ID ENDOCRINE THERAPY; BONE METASTASES; POSTMENOPAUSAL WOMEN;
   CLINICAL PRACTICE; ACID; BISPHOSPHONATES; PHASE 3; SAFETY; TRIAL; CARE
AB Background: The widespread adoption of adjuvant bisphosphonate therapy for postmenopausal early breast cancer (EBC) patients was based on results of the Early Breast Cancer Trialist Group (EBCTCG) meta analysis. Despite multiple regimens evaluated, there was no signal of varying efficacy with type, dose/dose intensity of bisphosphonate administra tion. We evaluated the effect of early treatment cessation using long term outcome data from the ABCSG 12 trial.Patients and methods: ABCSG 12 randomized 1803 hormone receptor positive EBC patients on ovarian suppression between 1999 and 2006 to receive 4 mg zoledronic acid 6 monthly or not (and tamoxifen or anastrozole, 2:2 factorial design). In the current study, we evaluated whether the number of zoledronate infusions had an impact on breast cancer specific out comes. We hypothesized that amongst patients who received at least one zoledronate infusion, the number of infusions had no effect on outcomes. Time to event endpoints were analysed with Cox models and Kaplan Meier curves starting from a 3 year landmark. BMD analysis was restricted to patients who participated in the BMD sub study.Results: 725 patients who received at least one zoledronate infusion were included in the time  to event analysis. There was no statistically significant difference in disease free or overall sur vival in the patients who received <6 zoledronate infusions (n = 170) compared to those who received >7 zoledronate infusions (n = 555). Conclusions: Comparable to efforts to de escalate treatment duration in metastatic bone dis ease, there was no evidence to indicate that a reduced number of zoledronate infusions is asso ciated with reduced adjuvant efficacy. Further studies to define optimal regimens of adjuvant bone targeted therapies are required. Crown Copyright 2022 Published by Elsevier Ltd. All rights reserved.
C1 [Beltran Bless, Ana Alicia; Clemons, Mark J.; Hilton, John] Ottawa Hosp, Canc Ctr, Div Med Oncol, Ottawa, ON, Canada.
   [Beltran Bless, Ana Alicia; Clemons, Mark J.; Hilton, John] Univ Ottawa, Ottawa, ON, Canada.
   [Clemons, Mark J.; Vandermeer, Lisa; Hilton, John] Ottawa Hosp Res Inst, Canc Therapeut Program, Ottawa, ON, Canada.
   [Fesl, Christian; Soelkner, Lidija; Fohler, Hannes; Hlauschek, Dominik; Gnant, Michael] Austrian Breast & Colorectal Canc Study Grp, Vienna, Austria.
   [Greil, Richard; Gampenrieder, Simon P.] Salzburg Canc Res Inst, Salzburg, Austria.
   [Greil, Richard; Gampenrieder, Simon P.] Paracelsus Med Univ Salzburg, 3D Med Dept, Salzburg, Austria.
   [Greil, Richard; Gampenrieder, Simon P.] Canc Cluster Salzburg, Salzburg, Austria.
   [Pond, Gregory R.; Rinnerthaler, Gabriel] McMaster Univ, Dept Oncol, Ontario Clin Oncol Grp, Hamilton, ON, Canada.
   [Balic, Marija; Suppan, Christoph] Med Univ Graz, Dept Internal Med, Div Oncol, Graz, Austria.
   [Balic, Marija; Suppan, Christoph] Med Univ Graz, Comprehens Canc Ctr, Graz, Austria.
   [Bjelic Radisic, Vesna] Helios Univ Hosp Wuppertal, Breast Unit, Wuppertal, Germany.
   [Bjelic Radisic, Vesna] Univ Witten Herdecke, Witten, Germany.
   [Bjelic Radisic, Vesna] Med Univ Graz, Dept Gynecol & Obstet, Graz, Austria.
   [Singer, Christian F.; Pfeiler, Georg] Med Univ Vienna, Comprehens Canc Ctr, Dept Gynecol & Gynecol Oncol, Vienna, Austria.
   [Steger, Guenther G.] Med Univ Vienna, Dept Internal Med 1, Vienna, Austria.
   [Helfgott, Ruth] Ordensklinikum Linz, Dept Surg, Linz, Austria.
   [Helfgott, Ruth] Ordensklinikum Linz, Breast Hlth Ctr, Linz, Austria.
   [Egle, Daniel; Ritter, Magdalena] Med Univ Innsbruck, Dept Obstet & Gynecol, Innsbruck, Austria.
   [Kacerovsky Strobl, Stephanie] St Francis Hosp Vienna, Breast Hlth Ctr, Vienna, Austria.
   [Gnant, Michael] Med Univ Vienna, Comprehens Canc Ctr, Waehringer Guertel 18 20, A 1090 Vienna, Austria.
C3 University of Ottawa; Ottawa Hospital Research Institute; University of
   Ottawa; University of Ottawa; Ottawa Hospital Research Institute;
   Paracelsus Private Medical University; McMaster University; Medical
   University of Graz; Medical University of Graz; Witten Herdecke
   University; Medical University of Graz; Medical University of Vienna;
   Medical University of Vienna; Medical University of Innsbruck; Medical
   University of Vienna
RP Gnant, M (通讯作者)，Med Univ Vienna, Comprehens Canc Ctr, Waehringer Guertel 18 20, A 1090 Vienna, Austria.
EM michael.gnant@meduniwien.ac.at
RI ; Greil, Richard/C 7673 2017; Gnant, Michael/AAN 7054 2020;
   Gampenrieder, Simon/AFM 7798 2022; Pond, Gregory/JOZ 2926 2023;
   Rinnerthaler, Gabriel/AGD 9598 2022; Balic, Marija/LPQ 3522 2024
OI Hlauschek, Dominik/0009 0009 1009 3777; Rinnerthaler,
   Gabriel/0000 0001 7438 1465; Pond, Gregory/0000 0003 1033 0882; 
CR Amadori D, 2013, LANCET ONCOL, V14, P663, DOI 10.1016/S1470 2045(13)70174 8
   Awan A, 2021, J BONE ONCOL, V26, DOI 10.1016/j.jbo.2020.100343
   Awan AA, 2019, BREAST CANCER RES TR, V176, P507, DOI 10.1007/s10549 019 05265 1
   Balic M, 2019, BREAST CARE, V14, P103, DOI 10.1159/000499931
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Brown JE, 2007, CLIN CANCER RES, V13, P5406, DOI 10.1158/1078 0432.CCR 07 0247
   Brufsky A., 2020, BISPHOSPHONATE CHOIC
   Clemons M, 2012, BREAST CANCER RES TR, V134, P453, DOI 10.1007/s10549 012 2077 6
   Clemons MJ., 2019, AM SOC CLIN ONCOL
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Coleman R, 2013, ANN ONCOL, V24, P398, DOI 10.1093/annonc/mds277
   Coleman R, 2020, LANCET ONCOL, V21, P60, DOI 10.1016/S1470 2045(19)30687 4
   Dhesy Thind S, 2017, J CLIN ONCOL, V35, P2062, DOI 10.1200/JCO.2016.70.7257
   Eisen A, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.21.02647
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Gnant M, 2015, ANN ONCOL, V26, P313, DOI 10.1093/annonc/mdu544
   Gnant M, 2019, LANCET ONCOL, V20, P339, DOI 10.1016/S1470 2045(18)30862 3
   Gnant M, 2012, CANCER TREAT REV, V38, P407, DOI 10.1016/j.ctrv.2011.09.003
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Gnant MPG, 2022, ASCO ANN M
   Gralow JR, 2020, JNCI J NATL CANCER I, V112, P698, DOI 10.1093/jnci/djz215
   Greenspan SL, 2015, JAMA INTERN MED, V175, P913, DOI 10.1001/jamainternmed.2015.0747
   Grey A, 2017, CAN MED ASSOC J, V189, pE1130, DOI 10.1503/cmaj.161207
   Hadji P, 2016, ANN ONCOL, V27, P379, DOI 10.1093/annonc/mdv617
   Haider MT, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00335
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Hortobagyi GN, 2017, JAMA ONCOL, V3, P906, DOI 10.1001/jamaoncol.2016.6316
   Jacobs C, 2014, EXPERT OPIN PHARMACO, V15, P1109, DOI 10.1517/14656566.2014.903925
   Janni W., 2018, AACR
   Korde LA, 2018, CANCER EPIDEM BIOMAR, V27, P165, DOI 10.1158/1055 9965.EPI 17 0556
   Kremer R, 2014, JNCI J NATL CANCER I, V106, DOI 10.1093/jnci/dju264
   McGee S, 2021, BREAST CANCER RES TR, V187, P477, DOI 10.1007/s10549 021 06147 1
   McGee S, 2021, J BONE ONCOL, V27, DOI 10.1016/j.jbo.2021.100351
   Ofotokun I, 2016, CLIN INFECT DIS, V63, P663, DOI 10.1093/cid/ciw331
   Omokehinde T, 2021, ADV EXP MED BIOL, V1329, P35, DOI 10.1007/978 3 030 73119 9_2
   Porter I, 2021, J BONE ONCOL, V31, DOI 10.1016/j.jbo.2021.100402
   Risson E, 2020, NAT CANCER, V1, P672, DOI 10.1038/s43018 020 0088 5
   Suarez Almazor ME, 2020, CANCER AM CANCER SOC, V126, P3929, DOI 10.1002/cncr.33035
NR 39
TC 5
Z9 5
U1 0
U2 4
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0959 8049
EI 1879 0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD FEB
PY 2023
VL 180
BP 108
EP 116
DI 10.1016/j.ejca.2022.12.003
EA DEC 2022
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 8P6CL
UT WOS:000926609500001
PM 36592505
DA 2025 08 17
ER

PT J
AU Tantikanlayaporn, D
   Wichit, P
   Weerachayaphorn, J
   Chairoungdua, A
   Chuncharunee, A
   Suksamrarn, A
   Piyachaturawat, P
AF Tantikanlayaporn, Duangrat
   Wichit, Patsorn
   Weerachayaphorn, Jittima
   Chairoungdua, Arthit
   Chuncharunee, Aporn
   Suksamrarn, Apichart
   Piyachaturawat, Pawinee
TI Bone Sparing Effect of a Novel Phytoestrogen Diarylheptanoid from
   Curcuma comosa Roxb. in Ovariectomized Rats
SO PLOS ONE
LA English
DT Article
ID POSTMENOPAUSAL OSTEOPOROSIS; ESTROGEN THERAPY; TRABECULAR BONE;
   FRACTURES; PATHOGENESIS; ACTIVATION; TURNOVER; MECHANISMS; DAIDZEIN;
   DENSITY
AB Phytoestrogens have been implicated in the prevention of bone loss in postmenopausal osteoporosis. Recently, an active phytoestrogen from Curcuma comosa Roxb, diarylheptanoid (DPHD), (3R) 1,7 diphenyl (4E,6E) 4,6 heptadien 3 ol, was found to strongly promote human osteoblast function in vitro. In the present study, we demonstrated the protective effect of DPHD on ovariectomy induced bone loss (OVX) in adult female Sprague Dawley rats with 17 beta estradiol (E 2, 10 mu g/kg Bw) as a positive control. Treatment of OVX animals with DPHD at 25, 50, and 100 mg/kg Bw for 12 weeks markedly increased bone mineral density (BMD) of tibial metaphysis as measured by peripheral Quantitative Computed Tomography (pQCT). Histomorphometric analysis of bone structure indicated that DPHD treatment retarded the ovariectomy induced deterioration of bone microstructure. Ovariectomy resulted in a marked decrease in trabecular bone volume, number and thickness and these changes were inhibited by DPHD treatment, similar to that seen with E 2. Moreover, DPHD decreased markers of bone turnover, including osteocalcin and tartrate resistant acid phosphatase (TRAP) activity. These results suggest that DPHD has a bone sparing effect in ovariectomy induced trabecular bone loss and prevents deterioration of bone microarchitecture by suppressing the rate of bone turnover. Therefore, DPHD appears to be a promising candidate for preserving bone mass and structure in the estrogen deficient women with a potential role in reducing postmenopausal osteoporosis.
C1 [Tantikanlayaporn, Duangrat; Wichit, Patsorn; Weerachayaphorn, Jittima; Chairoungdua, Arthit; Piyachaturawat, Pawinee] Mahidol Univ, Fac Sci, Dept Physiol, Bangkok 10400, Thailand.
   [Chuncharunee, Aporn] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Anat, Bangkok 10700, Thailand.
   [Suksamrarn, Apichart] Ramkhamhang Univ, Fac Sci, Dept Chem, Bangkok, Thailand.
C3 Mahidol University; Mahidol University; Ramkhamhaeng University
RP Piyachaturawat, P (通讯作者)，Mahidol Univ, Fac Sci, Dept Physiol, Bangkok 10400, Thailand.
EM pawinee.pia@mahidol.ac.th
RI ; Piyachaturawat, Pawinee/R 5817 2019; Suksamrarn, Apichart/R 8782 2019;
   Tantikanlayaporn, Duangrat/AAB 3358 2021
OI Tantikanlayaporn, Duangrat/0000 0002 1197 4957; 
FU Thailand Research Fund (TRF) [PHD/0103/2549]; TRF; Office of the Higher
   Education Commission; Mahidol University under the National Research and
   Universities Initiative; National Research Council of Thailand
FX This study was supported by the Thailand Research Fund (TRF) through the
   Royal Golden Jubilee Ph.D. Program (grant PHD/0103/2549 to DT and PP),
   the Strategic Basic Research Grant of TRF (to PP and to AS), the Office
   of the Higher Education Commission and Mahidol University under the
   National Research and Universities Initiative, and The National Research
   Council of Thailand. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bhukhai K, 2012, J BIOL CHEM, V287, P36168, DOI 10.1074/jbc.M112.344747
   Blair HC, 1996, J CELL BIOCHEM, V61, P629, DOI 10.1002/(SICI)1097 4644(19960616)61:4<629::AID JCB17>3.0.CO;2 A
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Breen SA, 1996, CALCIFIED TISSUE INT, V58, P449, DOI 10.1007/BF02509446
   Cauley JA, 2000, OSTEOPOROSIS INT, V11, P556, DOI 10.1007/s001980070075
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Dang ZC, 2005, TRENDS ENDOCRIN MET, V16, P207, DOI 10.1016/j.tem.2005.05.001
   Downey PA, 2006, PHYS THER, V86, P77, DOI 10.1093/ptj/86.1.77
   FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601
   GASSER JA, 1995, BONE, V17, pS145, DOI 10.1016/8756 3282(95)00287 N
   Habermann B, 2007, ACTA ORTHOP, V78, P221, DOI 10.1080/17453670710013717
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   LAU KHW, 1987, CLIN CHEM, V33, P458
   Lelovas PP, 2008, COMPARATIVE MED, V58, P424
   Lerner UH, 2006, J DENT RES, V85, P584, DOI 10.1177/154405910608500703
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Messina MJ, 2008, NUTR J, V7, DOI 10.1186/1475 2891 7 17
   Ott SM, 2008, CLIN J AM SOC NEPHRO, V3, pS151, DOI 10.2215/CJN.04301206
   PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096
   Peng XB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058361
   Piyachaturawat P, 1995, INT J PHARMACOGN, V33, P334, DOI 10.3109/13880209509065388
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Ren P, 2007, PHARMACOLOGY, V79, P129, DOI 10.1159/000098115
   Sample SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043215
   Stevenson M, 2005, HEALTH TECHNOL ASSES, V9, P1
   Sugimoto E, 2000, BIOCHEM PHARMACOL, V59, P471, DOI 10.1016/S0006 2952(99)00351 2
   Suksamrarn A, 2008, BIOORGAN MED CHEM, V16, P6891, DOI 10.1016/j.bmc.2008.05.051
   Suntornsaratoon P, 2010, AM J PHYSIOL ENDOC M, V299, pE426, DOI 10.1152/ajpendo.00134.2010
   Tantikanlayaporn D, 2013, PHYTOMEDICINE, V20, P676, DOI 10.1016/j.phymed.2013.02.008
   Tham DM, 1998, J CLIN ENDOCR METAB, V83, P2223, DOI 10.1210/jc.83.7.2223
   Thampithak A, 2009, NEUROSCI LETT, V462, P171, DOI 10.1016/j.neulet.2009.06.094
   Urasopon N, 2007, MATURITAS, V56, P322, DOI 10.1016/j.maturitas.2006.09.007
   Vanderschueren D, 2004, ENDOCR REV, V25, P389, DOI 10.1210/er.2003 0003
   Weerachayaphorn J, 2011, J ETHNOPHARMACOL, V137, P956, DOI 10.1016/j.jep.2011.06.040
   WEINSTEIN RS, 1994, J BONE MINER RES, V9, P1797
   Winuthayanon W, 2009, ENVIRON HEALTH PERSP, V117, P1155, DOI 10.1289/ehp.0900613
   Winuthayanon W, 2009, J AGR FOOD CHEM, V57, P840, DOI 10.1021/jf802702c
   WRONSKI TJ, 1988, ENDOCRINOLOGY, V123, P681, DOI 10.1210/endo 123 2 681
   WRONSKI TJ, 1988, CALCIFIED TISSUE INT, V43, P179, DOI 10.1007/BF02571317
NR 40
TC 38
Z9 40
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD NOV 11
PY 2013
VL 8
IS 11
AR e78739
DI 10.1371/journal.pone.0078739
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 255EG
UT WOS:000327221600057
PM 24244350
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Kawashiri, SY
   Endo, Y
   Nishino, A
   Okamoto, M
   Tsuji, S
   Takatani, A
   Shimizu, T
   Sumiyoshi, R
   Koga, T
   Iwamoto, N
   Ichinose, K
   Tamai, M
   Nakamura, H
   Origuchi, T
   Aramaki, T
   Ueki, Y
   Yoshitama, T
   Eiraku, N
   Matsuoka, N
   Okada, A
   Fujikawa, K
   Hamada, H
   Nagano, S
   Tada, Y
   Kawakami, A
AF Kawashiri, Shin Ya
   Endo, Yushiro
   Nishino, Ayako
   Okamoto, Momoko
   Tsuji, Sosuke
   Takatani, Ayuko
   Shimizu, Toshimasa
   Sumiyoshi, Remi
   Koga, Tomohiro
   Iwamoto, Naoki
   Ichinose, Kunihiro
   Tamai, Mami
   Nakamura, Hideki
   Origuchi, Tomoki
   Aramaki, Toshiyuki
   Ueki, Yukitaka
   Yoshitama, Tamami
   Eiraku, Nobutaka
   Matsuoka, Naoki
   Okada, Akitomo
   Fujikawa, Keita
   Hamada, Hiroaki
   Nagano, Shuji
   Tada, Yoshifumi
   Kawakami, Atsushi
TI Effect of abatacept treatment on serum osteoclast related biomarkers in
   patients with rheumatoid arthritis (RA) A multicenter RA ultrasound
   prospective cohort in Japan
SO MEDICINE
LA English
DT Article
DE abatacept; musculoskeletal ultrasound; rheumatoid arthritis; sRANKL;
   TRACP 5b
ID BONE MINERAL DENSITY; RADIOGRAPHIC PROGRESSION; DOUBLE BLIND; SAFETY;
   EFFICACY; DISEASE; RECOMMENDATIONS; CLASSIFICATION; INHIBITION;
   METABOLISM
AB We evaluated the effect of abatacept treatment on osteoclast related biomarkers and explored whether the biomarkers are associated with the therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept. We enrolled 44 RA patients treated with abatacept from a multicenter prospective ultrasound cohort study of patients who received biologic or targeted synthetic disease modifying antirheumatic drug therapy. We evaluated the disease activity score (DAS) 28 CRP (C reactive protein), musculoskeletal ultrasound scores including the total grayscale score (GS)/power Doppler (PD) score and the serum concentrations of isoform 5b of tartrate resistant acid phosphate (TRACP 5b) and soluble receptor activator of nuclear factor kappa B ligand (sRANKL) at baseline and at 3 and 6 months of treatment. "PD responder" was defined as a patient whose Delta total PD score over 6 months was greater than the median change of that. Abatacept significantly improved DAS28 CRP as well as the total GS/PD score over 6 months. Serum TRACP 5b was significantly elevated and serum sRANKL was significantly decreased at 6 months (P P < .01, respectively). At 6 months, serum sRANKL was significantly decreased in the patients who achieved DAS28 CRP remission and the PD responders but not in those who did not. However, serum TRACP 5b rose regardless of the therapeutic response. Among RA patients treated with abatacept, serum sRANKL decreased in the patients with a good therapeutic response, but serum TRACP 5b elevated paradoxically regardless of the therapeutic response.
C1 [Kawashiri, Shin Ya] Nagasaki Univ, Dept Community Med, Grad Sch Biomed Sci, 1 12 4 Sakamoto, Nagasaki 8528523, Japan.
   [Kawashiri, Shin Ya; Endo, Yushiro; Nishino, Ayako; Okamoto, Momoko; Tsuji, Sosuke; Takatani, Ayuko; Shimizu, Toshimasa; Sumiyoshi, Remi; Koga, Tomohiro; Iwamoto, Naoki; Ichinose, Kunihiro; Tamai, Mami; Nakamura, Hideki; Origuchi, Tomoki; Aramaki, Toshiyuki; Kawakami, Atsushi] Nagasaki Univ, Div Adv Prevent Med Sci, Immunol & Rheumatol, Grad Sch Biomed Sci, Nagasaki, Japan.
   [Ueki, Yukitaka; Yoshitama, Tamami; Eiraku, Nobutaka; Matsuoka, Naoki; Okada, Akitomo; Fujikawa, Keita; Hamada, Hiroaki; Nagano, Shuji; Tada, Yoshifumi] Kyushu Multictr Rheumatoid Arthrit Ultrasound Pro, Kyushu, Japan.
C3 Nagasaki University; Nagasaki University
RP Kawashiri, SY (通讯作者)，Nagasaki Univ, Dept Community Med, Grad Sch Biomed Sci, 1 12 4 Sakamoto, Nagasaki 8528523, Japan.
EM shin ya@nagasaki u.ac.jp
RI ; Iwamoto, Naoki/AAP 2533 2020; Nagano, Shuji/GQH 8492 2022; Ichinose,
   Kunihiro/I 2126 2019; Kawakami, Atsushi/D 3785 2019; Koga,
   Tomohiro/V 9397 2019
OI Koga, Tomohiro/0000 0003 2077 4428; 
FU Bristol Myers Squibb; Ono Pharmaceutical Co.; Grants in Aid for
   Scientific Research [21K08439] Funding Source: KAKEN
FX This work was supported by Bristol Myers Squibb and Ono Pharmaceutical
   Co.
CR Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Axmann R, 2008, ANN RHEUM DIS, V67, P1603, DOI 10.1136/ard.2007.080713
   Bathon J, 2011, ANN RHEUM DIS, V70, P1949, DOI 10.1136/ard.2010.145268
   Bozec A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007764
   Cagnotto G, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 2100 y
   Colebatch AN, 2013, ANN RHEUM DIS, V72, P804, DOI 10.1136/annrheumdis 2012 203158
   D'Agostino MA, 2016, ANN RHEUM DIS, V75, P1902, DOI 10.1136/annrheumdis 2016 209646
   D'Agostino MA, 2016, RMD OPEN, V2, DOI 10.1136/rmdopen 2015 000237
   Emery P, 2015, ANN RHEUM DIS, V74, P19, DOI 10.1136/annrheumdis 2014 206106
   Endo Y, 2020, SCAND J RHEUMATOL, V49, P13, DOI 10.1080/03009742.2019.1627411
   Endo Y, 2020, IMMUNOL MED, V43, P115, DOI 10.1080/25785826.2020.1757920
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Harigai M, 2019, MOD RHEUMATOL, V29, P747, DOI 10.1080/14397595.2018.1524998
   Harigai M, 2016, MOD RHEUMATOL, V26, P491, DOI 10.3109/14397595.2015.1123211
   Janckila AJ, 2008, J BONE MINER RES, V23, P1287, DOI 10.1359/JBMR.080329
   Jansen DTSL, 2018, RMD OPEN, V4, DOI 10.1136/rmdopen 2017 000564
   Kremer JM, 2011, ANN RHEUM DIS, V70, P1826, DOI 10.1136/ard.2010.139345
   Matsubara T, 2018, RMD OPEN, V4, DOI 10.1136/rmdopen 2018 000813
   Moreland LW, 2002, ARTHRITIS RHEUM, V46, P1470, DOI 10.1002/art.10294
   Nenonen A, 2005, J BONE MINER RES, V20, P1804, DOI 10.1359/JBMR.050403
   Nishino A, 2018, ARTHRIT CARE RES, V70, P1719, DOI 10.1002/acr.23551
   Nishizawa Y, 2008, J BONE MINER METAB, V26, P265, DOI 10.1007/s00774 007 0826 0
   Oi K, 2019, CLIN EXP IMMUNOL, V196, P392, DOI 10.1111/cei.13271
   Okada H, 2019, J BONE MINER RES, V34, P1744, DOI 10.1002/jbmr.3754
   Picerno V, 2015, CLIN EXP RHEUMATOL, V33, P551
   Roser Page S, 2014, ARTHRITIS RHEUMATOL, V66, P990, DOI 10.1002/art.38319
   Schett G, 2017, MOD RHEUMATOL, V27, P193, DOI 10.1080/14397595.2016.1265907
   Schiff M, 2014, ANN RHEUM DIS, V73, P86, DOI 10.1136/annrheumdis 2013 203843
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Smolen JS, 2020, ANN RHEUM DIS, V79, P685, DOI 10.1136/annrheumdis 2019 216655
   Smolen JS, 2016, ANN RHEUM DIS, V75, P3, DOI 10.1136/annrheumdis 2015 207524
   Steffen U, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01483
   Suzuki T, 2018, THER CLIN RISK MANAG, V14, P453, DOI 10.2147/TCRM.S156350
   Szentpétery A, 2017, AUTOIMMUN REV, V16, P313, DOI 10.1016/j.autrev.2017.01.014
   Tada M, 2018, RHEUMATOL INT, V38, P777, DOI 10.1007/s00296 017 3922 z
   Toussirot E, 2017, EUR J RHEUMATOL, V4, P189, DOI 10.5152/eurjrheum.2017.17006
   Zerbini CAF, 2017, OSTEOPOROSIS INT, V28, P429, DOI 10.1007/s00198 016 3769 2
NR 38
TC 3
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUL 16
PY 2021
VL 100
IS 28
DI 10.1097/MD.0000000000026592
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA TJ5ET
UT WOS:000673505300022
PM 34260539
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, X
   Liu, YC
   Zheng, PM
   Xie, X
   Li, ZZ
   Yang, R
   Jin, L
   Mei, ZW
   Chen, PP
   Zhou, LM
AF Liu, Xing
   Liu, Yichen
   Zheng, Peimin
   Xie, Xun
   Li, Zhouzhou
   Yang, Rui
   Jin, Lie
   Mei, Ziwei
   Chen, Peipei
   Zhou, Limei
TI Effects of active vitamin D analogs and calcimimetic agents on PTH and
   bone mineral biomarkers in hemodialysis patients with SHPT: a network
   meta analysis
SO EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE Hemodialysis; Secondary hyperparathyroidism; Active vitamin D analogs;
   Calcimimetic agents
ID CHRONIC KIDNEY DISEASE; HIGH DOSE CHOLECALCIFEROL; PATIENTS RECEIVING
   HEMODIALYSIS; QUALITY OF LIFE; SECONDARY HYPERPARATHYROIDISM;
   DOUBLE BLIND; PARATHYROID HORMONE; CINACALCET HYDROCHLORIDE; DIALYSIS
   PATIENTS; D DEFICIENCY
AB ObjectiveActive vitamin D analogs and calcimimetic agents are primary drugs for patients with secondary hyperparathyroidism. Due to the different pharmacological mechanisms, they have different effects on the level of parathyroid hormone, serum calcium, phosphorus, and bone turnover biomarkers. This study aimed to evaluate the active vitamin D analogs and calcimimetic agents in hemodialysis patients with secondary hyperparathyroidism.MethodsWe included randomized clinical trials of hemodialysis patients with secondary hyperparathyroidism, comparing active vitamin D analogs to calcimimetic agents or placebo/control. The primary outcome was the change of PTH level from baseline to end up. The secondary outcome was the change in serum calcium, phosphorus, calcium phosphorus product, and bone turnover biomarkers. A network meta analysis method was applied to complete this study. The forest plots reflected statistical differences in the outcomes between active vitamin D analogs and calcimimetic agents. The SUCRA result presented the ranking of impact on the outcomes.ResultsTwenty one randomized clinical trials with 4653 patients were included in this network meta analysis. Global and splitting node inconsistencies provided no evidence of inconsistency in this study. There was no statistical difference between two active vitamin D analogs and three calcimimetic agents in the PTH, and phosphorus levels changed. Considering serum calcium level, compared with placebo, calcitriol (9.73, 3.09 to 16.38) and paricalcitol (9.74, 3.87 to 15.60) increase serum calcium. However, cinacalcet (  1.94,   3.72 to   0.15) and etelcalcetide (  7.80,   11.80 to   3.80) reduced the serum calcium, even a joint use of cinacalcet with active vitamin D analogs (  5.83,   9.73 to   1.93). Three calcimimetic agents decreased calcium levels much more than calcitriol and paricalcitol. The same type of drugs was not distinct, with each one affecting the change in calcium level. Cinacalcet reduced calcium phosphorus product much more than paricalcitol (  3.66,   6.72 to   0.60). Evocalcet decreased calcium phosphorus product more than cinacalcet (  5.64,   8.91 to   2.37), calcitriol (  9.36,   14.81 to   3.92), and paricalcitol (  9.30,   13.78 to   4.82). Compared with paricalcitol, cinacalcet significantly increases the level of ALP (24.50, 23.05 to 25.95) and bALP (0.67, 0.03 to 1.31). The incidence of gastrointestinal disorders in cinacacet (29.35, 1.71 to 504.98) and etelcalcetide (20.92, 1.20 to 365.68) was notably higher than in paricalcitol. Etelcalcetide (0.71, 0.53 to 0.96) and evocalcet (0.46, 0.33 to 0.64) presented a lower rate of gastrointestinal disorders than cinacalcet. Cinacalcet ranked first in adverse gastrointestinal, nervous, and respiratory reactions.ConclusionThe same kinds of agents perform similar efficacy on the level of PTH, serum calcium, phosphorus, and calcium phosphorus product. Paricalcitol did not lead to more hypercalcemia than calcitriol. The calcium decrease induced by cinacalcet was not settled even by associating it with active vitamin D analogs. Cinacalcet and evocalcet were superior to calcitriol and paricacitol in reducing calcium phosphorus product. Calcimimetics induced more gastrointestinal disorders than active vitamin D analogs, especially cinacalcet.
C1 [Liu, Xing; Liu, Yichen; Zheng, Peimin; Xie, Xun; Li, Zhouzhou; Yang, Rui] Nanchang Univ, Jiangxi Med Coll, Nanchang 330006, Jiangxi, Peoples R China.
   [Jin, Lie; Mei, Ziwei; Chen, Peipei; Zhou, Limei] Wenzhou Med Univ, Affiliated Hosp 5, Lishui Cent Hosp, Lishui 323000, Zhejiang, Peoples R China.
C3 Nanchang University; Wenzhou Medical University
RP Zhou, LM (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 5, Lishui Cent Hosp, Lishui 323000, Zhejiang, Peoples R China.
EM zlm_870603@163.com
FU The Research and Development Project of Zhejiang "top soldiers" and
   "leading geese"
FX No Statement Available
CR Akiba T, 2008, THER APHER DIAL, V12, P117, DOI 10.1111/j.1744 9987.2008.00556.x
   Alexander ST, 2015, MOL PHARMACOL, V88, P853, DOI 10.1124/mol.115.098392
   Alvarez JA, 2013, EUR J CLIN NUTR, V67, P264, DOI 10.1038/ejcn.2012.217
   Alvarez JA, 2012, AM J CLIN NUTR, V96, P672, DOI 10.3945/ajcn.112.040642
   Andress D, 2007, DRUGS, V67, P1999, DOI 10.2165/00003495 200767140 00003
   Armas LAG, 2012, CLIN J AM SOC NEPHRO, V7, P1428, DOI 10.2215/CJN.12761211
   Bacchetta J, 2020, PEDIATR NEPHROL, V35, P493, DOI 10.1007/s00467 019 04400 w
   Bell G, 2015, CURR MED RES OPIN, V31, P943, DOI 10.1185/03007995.2015.1031731
   Bhan I, 2015, CLIN J AM SOC NEPHRO, V10, P611, DOI 10.2215/CJN.06910714
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Block GA, 2017, JAMA J AM MED ASSOC, V317, P156, DOI 10.1001/jama.2016.19468
   Cai PP, 2016, INT UROL NEPHROL, V48, P571, DOI 10.1007/s11255 015 1195 6
   Chandra Prakash, 2008, Endocr Pract, V14, P10
   Cozzolino M, 2014, NEPHROL DIAL TRANSPL, V29, P1815, DOI 10.1093/ndt/gft514
   Cozzolino M, 2014, NEPHROL DIAL TRANSPL, V29, P899, DOI 10.1093/ndt/gfu011
   Delanaye P, 2013, NEPHROL DIAL TRANSPL, V28, P1779, DOI 10.1093/ndt/gft001
   Drüeke TB, 2004, NEPHROL DIAL TRANSPL, V19, P20, DOI 10.1093/ndt/gfh1052
   Dusilová Sulková S, 2009, J RENAL CARE, V35, P39, DOI 10.1111/j.1755 6686.2009.00066.x
   Eddington H, 2021, BMC NEPHROL, V22, DOI 10.1186/s12882 021 02312 2
   El Shafey EM, 2011, THER APHER DIAL, V15, P547, DOI 10.1111/j.1744 9987.2011.00994.x
   Evenepoel P, 2021, NEPHROL DIAL TRANSPL, V36, P42, DOI 10.1093/ndt/gfaa192
   Fukagawa M, 2008, NEPHROL DIAL TRANSPL, V23, P328, DOI 10.1093/ndt/gfm534
   Fukagawa M, 2018, KIDNEY INT, V94, P818, DOI 10.1016/j.kint.2018.05.013
   Fukagawa M, 2017, NEPHROL DIAL TRANSPL, V32, P1723, DOI 10.1093/ndt/gfw408
   Gafor AHA, 2009, NEPHROLOGY, V14, P488, DOI 10.1111/j.1440 1797.2008.01058.x
   Haffner D, 2020, PEDIATR NEPHROL, V35, P485, DOI 10.1007/s00467 019 04399 0
   Hannan FM, 2018, NAT REV ENDOCRINOL, V15, P33, DOI 10.1038/s41574 018 0115 0
   Hewitt NA, 2013, CLIN J AM SOC NEPHRO, V8, P1143, DOI 10.2215/CJN.02840312
   Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154
   Ikizler TA, 2020, AM J KIDNEY DIS, V76, pS11
   Iorga C, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1191914
   Ketteler M, 2012, NEPHROL DIAL TRANSPL, V27, P3270, DOI 10.1093/ndt/gfs018
   Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001
   Kumar R, 2011, J AM SOC NEPHROL, V22, P216, DOI 10.1681/ASN.2010020186
   Lavi Moshayoff V, 2010, AM J PHYSIOL RENAL, V299, pF882, DOI 10.1152/ajprenal.00360.2010
   Li D, 2013, ENDOCRINE, V43, P68, DOI 10.1007/s12020 012 9711 2
   Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512
   Liu YP, 2022, CURR PHARM DESIGN, V28, P3289, DOI 10.2174/1381612829666221027110656
   Lozano Ortega G, 2018, J COMP EFFECT RES, V7, P693, DOI 10.2217/cer 2018 0015
   Mager DR, 2017, CLIN NUTR, V36, P686, DOI 10.1016/j.clnu.2016.05.012
   Marckmann P, 2012, NEPHROL DIAL TRANSPL, V27, P3523, DOI 10.1093/ndt/gfs138
   Massart A, 2014, AM J KIDNEY DIS, V64, P696, DOI 10.1053/j.ajkd.2014.04.020
   Mei CL, 2016, HEMODIAL INT, V20, P589, DOI 10.1111/hdi.12410
   Meireles MS, 2016, CLIN NUTR, V35, P1251, DOI 10.1016/j.clnu.2016.04.014
   Messa P, 2008, CLIN J AM SOC NEPHRO, V3, P36, DOI 10.2215/CJN.03591006
   Miskulin DC, 2016, J AM SOC NEPHROL, V27, P1801, DOI 10.1681/ASN.2015040468
   Nitta K, 2017, INTERNAL MED, V56, P3271, DOI 10.2169/internalmedicine.8618 16
   Ortiz A, 2023, KIDNEY DIS BASEL, V9, P187, DOI 10.1159/000528784
   Quarles LD, 2003, J AM SOC NEPHROL, V14, P575, DOI 10.1097/01.ASN.0000050224.03126.AD
   Raggi P, 2011, NEPHROL DIAL TRANSPL, V26, P1327, DOI 10.1093/ndt/gfq725
   Riccio E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118174
   Rodzon Norwicz M, 2023, ENDOKRYNOL POL, V74, P490, DOI 10.5603/ep.95820
   Rottembourg J, 2019, CLIN KIDNEY J, V12, P871, DOI 10.1093/ckj/sfz021
   Sato T, 2004, AM J KIDNEY DIS, V44, P481, DOI 10.1053/j.ajkd.2004.05.026
   Seibert E, 2017, EUR J NUTR, V56, P621, DOI 10.1007/s00394 015 1106 8
   Silver J, 2005, KIDNEY INT, V67, pS8, DOI 10.1111/j.1523 1755.2005.09501.x
   Sprague SM, 2001, AM J KIDNEY DIS, V38, pS51, DOI 10.1053/ajkd.2001.28110
   Sun YT, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882 019 1639 9
   Susantitaphong P, 2019, RENAL FAILURE, V41, P326, DOI 10.1080/0886022X.2018.1562356
   Tokmak F, 2008, NEPHROL DIAL TRANSPL, V23, P4016, DOI 10.1093/ndt/gfn367
   Ureña Torres P, 2013, NEPHROL DIAL TRANSPL, V28, P1241, DOI 10.1093/ndt/gfs568
   Veceric Haler Z, 2016, THER APHER DIAL, V20, P261, DOI 10.1111/1744 9987.12434
   Wang GQ, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21397 8
   Wu CH, 2021, J CLIN DENSITOM, V24, P3, DOI 10.1016/j.jocd.2019.03.004
   Xu J, 2019, INT UROL NEPHROL, V51, P2027, DOI 10.1007/s11255 019 02271 6
   Xu W, 2020, EXP THER MED, V20, P3237, DOI 10.3892/etm.2020.9044
   Zhang Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048070
   Zhang T, 2019, THER APHER DIAL, V23, P73, DOI 10.1111/1744 9987.12760
   Zheng FY, 2024, CLIN PHARM DRUG DEV, V13, P96, DOI 10.1002/cpdd.1328
NR 70
TC 2
Z9 2
U1 3
U2 12
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0031 6970
EI 1432 1041
J9 EUR J CLIN PHARMACOL
JI Eur. J. Clin. Pharmacol.
PD OCT
PY 2024
VL 80
IS 10
BP 1555
EP 1569
DI 10.1007/s00228 024 03730 5
EA JUL 2024
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA F6J5P
UT WOS:001270800300001
PM 39002024
DA 2025 08 17
ER

PT J
AU Forte, L
   Sarda, S
   Combes, C
   Brouillet, F
   Gazzano, M
   Marsan, O
   Boanini, E
   Bigi, A
AF Forte, Lucia
   Sarda, Stephanie
   Combes, Christele
   Brouillet, Fabien
   Gazzano, Massimo
   Marsan, Olivier
   Boanini, Elisa
   Bigi, Adriana
TI Hydroxyapatite functionalization to trigger adsorption and release of
   risedronate
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Bisphosphonate; Risedronate; Hydroxyapatite; Poly ethylenimine; Zinc;
   Adsorption; Release
ID BETA TRICALCIUM PHOSPHATE; DRUG DELIVERY; NANOCRYSTALLINE APATITES;
   IN VITRO; BISPHOSPHONATE; BONE; ZINC; POLYETHYLENIMINE; MINERALIZATION;
   BIOMATERIALS
AB Bisphosphonates are widely employed drugs for the treatment of pathologies characterized by excessive bone resorption, and display a great affinity for apatitic supports. In this work we investigate how hydroxyapatite functionalization can influence the processes of adsorption and release of a bisphosphonate, namely risedronate. To this aim, pure hydroxyapatite (HA), hydroxyapatite with a partial substitution of Zn to Ca (ZnHA) and poly ethylenimine functionalized hydroxyapatite (HAPEI) were submitted to interaction with risedronate solution. The results indicate that the mechanisms of adsorption and release are greatly influenced by the type of the apatitic support. All the apatitic supports display Langmuir isotherms for risedronate adsorption. However in the case of HAPEI the plateau is not reached even at high equilibrium concentrations in solution. The data suggest that risedronate adsorption on HAPEI mineral organic support occurs not only through chemisorption on apatitic phase, as on HA and ZnHA, but also through physisorption involved by PEI coating, which modulates also bisphosphonate release. These properties of tailor made hydroxyapatite supports could be exploited to develop delivery systems for antiresorptive agents directly on osteoporotic sites. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Forte, Lucia; Boanini, Elisa; Bigi, Adriana] Univ Bologna, Dept Chem G Ciamician, Via Selmi 2, I 40126 Bologna, Italy.
   [Sarda, Stephanie] Univ Paul Sabatier, Univ Toulouse, CIRIMAT, INPT CNRS UPS, 4 Allee Emile Monso, F 31030 Toulouse 4, France.
   [Combes, Christele; Marsan, Olivier] Univ Toulouse, ENSIACET, CIRIMAT, INPT CNRS UPS, 4 Allee Emile Monso, F 31030 Toulouse 4, France.
   [Brouillet, Fabien] Univ Toulouse, Fac Sci Pharmaceut, CIRIMAT, INPT CNRS UPS, 35 Chemin Maraichers, F 31062 Toulouse 9, France.
   [Gazzano, Massimo] ISOF CNR, Via Gobetti 101, I 40129 Bologna, Italy.
C3 University of Bologna; Universite de Toulouse; Universite Federale
   Toulouse Midi Pyrenees (ComUE); Universite Toulouse III   Paul Sabatier;
   Institut National Polytechnique de Toulouse; Centre National de la
   Recherche Scientifique (CNRS); Universite de Toulouse; Universite
   Federale Toulouse Midi Pyrenees (ComUE); Universite Toulouse III   Paul
   Sabatier; Institut National Polytechnique de Toulouse; Centre National
   de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite
   Federale Toulouse Midi Pyrenees (ComUE); Universite Toulouse III   Paul
   Sabatier; Institut National Polytechnique de Toulouse; Centre National
   de la Recherche Scientifique (CNRS); Consiglio Nazionale delle Ricerche
   (CNR); Istituto per la Sintesi Organica e la Fotoreattivita (ISOF CNR)
RP Boanini, E (通讯作者)，Univ Bologna, Dept Chem G Ciamician, Via Selmi 2, I 40126 Bologna, Italy.
EM elisa.boanini@unibo.it
RI Boanini, Elisa/AAT 9957 2021; MARSAN, Olivier/HMW 0895 2023; Gazzano,
   Massimo/D 9880 2012; BROUILLET, fabien/HKO 3785 2023; Bigi,
   Adriana/R 6341 2016
OI Gazzano, Massimo/0000 0003 1352 9547; BROUILLET,
   Fabien/0000 0002 8860 9069; Boanini, Elisa/0000 0003 3754 0273; Bigi,
   Adriana/0000 0003 2668 8627; Sarda, Stephanie/0000 0002 9525 4403;
   COMBES, Christele/0000 0001 5009 1973
FU European COST action (New Generation Biomimetic and Customized Implants
   for Bone Engineering (NEWGEN) [MP 1301]; University of Bologna
FX The authors thank the European MP 1301 COST action (New Generation
   Biomimetic and Customized Implants for Bone Engineering (NEWGEN);
   2013 2017) and the University of Bologna (Marco Polo program 2016) for
   supporting this bilateral research work.
CR Al Kattan A, 2010, ADV ENG MATER, V12, pB224, DOI 10.1002/adem.200980084
   Bigi A, 2004, J MATER CHEM, V14, P274, DOI 10.1039/b308687a
   BIGI A, 1995, J INORG BIOCHEM, V58, P49, DOI 10.1016/0162 0134(94)00036 A
   Bigi A., 2016, Biominer. Biomater, P235, DOI DOI 10.1016/B978 1 78242 338 6.00008 9
   Boanini E, 2015, COLLOID SURFACE B, V136, P449, DOI 10.1016/j.colsurfb.2015.09.044
   Boanini E, 2012, BIOMATERIALS, V33, P722, DOI 10.1016/j.biomaterials.2011.09.092
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928 0987(01)00095 1
   Eichert D., 2008, Nanocrystalline Apatite Based Biomaterials, P93
   Errassifi F, 2014, J COLLOID INTERF SCI, V420, P101, DOI 10.1016/j.jcis.2014.01.017
   Fatnassi M, 2014, POWDER TECHNOL, V255, P44, DOI 10.1016/j.powtec.2013.08.027
   Favia G, 2009, BONE, V45, P406, DOI 10.1016/j.bone.2009.05.008
   Fazil M, 2015, DRUG DELIV, V22, P1, DOI 10.3109/10717544.2013.870259
   FERRARI M, 1994, J APPL PHYS, V76, P7246, DOI 10.1063/1.358006
   FUIERER TA, 1994, LANGMUIR, V10, P4721, DOI 10.1021/la00024a054
   Gomes S, 2012, ACTA BIOMATER, V8, P1180, DOI 10.1016/j.actbio.2011.12.003
   Hayakawa S., 2015, HYDROXYAPATITE HAP B, P85, DOI DOI 10.1016/B978 1 78242 033 0.00004 3
   Josse S, 2005, BIOMATERIALS, V26, P2073, DOI 10.1016/j.biomaterials.2004.05.019
   Lakard S, 2004, J MOL STRUC THEOCHEM, V685, P83, DOI 10.1016/j.theochem.2004.06.042
   Murakami Y, 2011, TALANTA, V85, P1298, DOI 10.1016/j.talanta.2011.06.004
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Panzavolta S, 2010, J INORG BIOCHEM, V104, P1099, DOI 10.1016/j.jinorgbio.2010.06.008
   Pascaud P, 2014, J MATER SCI MATER M, V25, P2373, DOI 10.1007/s10856 014 5218 0
   Pascaud P, 2013, LANGMUIR, V29, P2224, DOI 10.1021/la3046548
   Penel G, 1998, CALCIFIED TISSUE INT, V63, P475, DOI 10.1007/s002239900561
   Popa NC, 1998, J APPL CRYSTALLOGR, V31, P176, DOI 10.1107/S0021889897009795
   Ren FZ, 2009, ACTA BIOMATER, V5, P3141, DOI 10.1016/j.actbio.2009.04.014
   Rizzoli R, 2011, OSTEOPOROSIS INT, V22, P373, DOI 10.1007/s00198 010 1453 5
   Roussiere H, 2008, CHEM MATER, V20, P182, DOI 10.1021/cm702584d
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Shepherd DV, 2014, J BIOMED MATER RES A, V102, P4136, DOI 10.1002/jbm.a.35089
   Shkilnyy A, 2008, LANGMUIR, V24, P2102, DOI 10.1021/la702523p
   Sokolova V, 2010, J MATER SCI, V45, P4952, DOI 10.1007/s10853 009 4159 3
   Song RQ, 2010, ADV MATER, V22, P1301, DOI 10.1002/adma.200901365
   Tang RK, 2001, LANGMUIR, V17, P3480, DOI 10.1021/la001730n
   Verron E, 2010, BIOMATERIALS, V31, P7776, DOI 10.1016/j.biomaterials.2010.06.047
   Verron E, 2010, DRUG DISCOV TODAY, V15, P547, DOI 10.1016/j.drudis.2010.05.003
NR 37
TC 25
Z9 26
U1 0
U2 46
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD DEC 1
PY 2017
VL 160
BP 493
EP 499
DI 10.1016/j.colsurfb.2017.09.055
PG 7
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA FR3PL
UT WOS:000418978500059
PM 28992488
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Liu, YF
   Liu, R
   Li, XY
   Song, Z
   Zhao, XH
AF Liu, Ya Feng
   Liu, Rui
   Li, Xue Yang
   Song, Zhen
   Zhao, Xue Hang
TI Development of docetaxel and alendronate loaded chitosan conjugated
   polylactide co glycolide nanoparticles: In vitro characterization
   in osteosarcoma cells
SO TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH
LA English
DT Article
DE Chitosan; Docetaxel; Alendronate; Nanocarriers; Sustained release
   kinetics; Polylactide co glycolide; Osteosarcoma; Cellular uptake
ID ANTITUMOR EFFICACY; DELIVERY; BONE; DRUG; BISPHOSPHONATES
AB Purpose: To develop docetaxel (DTX) and alendronate (ALN) loaded, chitosan (CS) conjugated polylactide co glycolide (PLGA) nanoparticles (NPs) to increase therapeutic efficacy in osteosarcoma cells.
   Methods: Drug loaded PLGA NPs were prepared by nanoprecipitation and chemically conjugated by the carboxylic group of PLGA to the amine bearing CS polymer. The nanocarrier was characterized by dynamic light scattering, transmission electron microscopy, scanning electron microscopy, and differential scanning calorimetry as well as by in vitro drug release and cell culture studies.
   Results: NP size was within the tumour targeting range (similar to 200 nm) with an effective positive charge (20 mV), thus increasing cellular uptake efficiency. Morphological analysis revealed clear spherical particles with uniform dispersion. The NPs exhibited identical sustained release kinetics for both DTX and ALN. CS conjugated PLGA with dual drug loaded (DTX and AL) NPs showed typical time dependent cellular uptake and also displayed superior cytotoxicity in MG 63 cells compared with blank NPs, which were safe and biocompatible.
   Conclusion: Combined loading of DTX and ALN in NPs increased the therapeutic efficacy of the formulation for osteosarcoma treatment, thus indicating the potential benefit of a combinatorial drug regimen using nanocarriers for effective treatment of osteosarcoma.
C1 [Liu, Ya Feng; Liu, Rui; Li, Xue Yang; Song, Zhen; Zhao, Xue Hang] KaiFeng Cent Hosp, Dept Orthoped, Henan 475000, Peoples R China.
RP Liu, YF (通讯作者)，KaiFeng Cent Hosp, Dept Orthoped, Henan 475000, Peoples R China.
EM liuyafeng68@hotmail.com
FU Technical Grant of KaiFeng Central Hospital, China
FX The study was funded by Technical Grant of KaiFeng Central Hospital,
   China.
CR Berenson JR, 1999, ANNU REV MED, V50, P237
   Broadhead Matthew L., 2011, Sarcoma, V2011, P959248, DOI 10.1155/2011/959248
   Cotterill SJ, 2004, PEDIATR BLOOD CANCER, V42, P59, DOI 10.1002/pbc.10437
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   Ernsting MJ, 2012, J CONTROL RELEASE, V162, P575, DOI 10.1016/j.jconrel.2012.07.043
   He JP, 2014, ASIAN PAC J CANCER P, V15, P5967, DOI 10.7314/APJCP.2014.15.15.5967
   Jia J, 2009, NAT REV DRUG DISCOV, V8, P111, DOI 10.1038/nrd2683
   Karl S, 2009, J CELL MOL MED, V13, P4239, DOI 10.1111/j.1582 4934.2009.00888.x
   Lipton A, 2008, CANCER TREAT REV, V34, pS25, DOI 10.1016/j.ctrv.2008.03.008
   Pradhan R, 2013, J NANOSCI NANOTECHNO, V13, P5948, DOI 10.1166/jnn.2013.7735
   Ramasamy T, 2014, J BIOMED NANOTECHNOL, V10, P1304, DOI 10.1166/jbn.2014.1821
   Ruttala HB, 2015, COLLOID SURFACE B, V128, P419, DOI 10.1016/j.colsurfb.2015.02.040
   Saad M, 2008, NANOMEDICINE UK, V3, P761, DOI 10.2217/17435889.3.6.761
   Wang H, 2011, BIOMATERIALS, V32, P8281, DOI 10.1016/j.biomaterials.2011.07.032
NR 14
TC 11
Z9 11
U1 0
U2 27
PU PHARMACOTHERAPY GROUP
PI BENIN CITY
PA UNIV BENIN, FACULTY PHARMACY, BENIN CITY, 00000, NIGERIA
SN 1596 5996
J9 TROP J PHARM RES
JI Trop. J. Pharm. Res.
PD JUL
PY 2016
VL 15
IS 7
BP 1353
EP 1360
DI 10.4314/tjpr.v15i7.1
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DU0YT
UT WOS:000381931800001
OA gold
DA 2025 08 17
ER

PT J
AU Li, ZK
   Zhu, XD
   Xu, RJ
   Wang, Y
   Hu, RX
   Xu, W
AF Li, Zhikun
   Zhu, Xiaodong
   Xu, Ruijun
   Wang, Yi
   Hu, Ruixi
   Xu, Wei
TI Deacylcynaropicrin Inhibits RANKL Induced Osteoclastogenesis by
   Inhibiting NF κB and MAPK and Promoting M2 Polarization of Macrophages
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE deacylcynaropicrin; osteoclastogenesis; MAPK; NF kappa B; macrophages
ID PARTICLE INDUCED OSTEOLYSIS; BONE RESORPTION; ECONOMIC BURDEN; ANTI TNF;
   OSTEOPOROSIS; OSTEOIMMUNOLOGY; ACTIVATION; PROTECTS; THERAPY; ALPHA
AB Inflammation can promote the maturity of osteoclasts and bone resorption in many bone disease such as osteoporosis and arthritis. Here, we aimed to investigate the inhibitory effects of deacylcynaropicrin (DAC) on osteoclastogenesis and bone resorption induced by RANKL. Bone marrow derived macrophages were used for assessing the influence of DAC on polarization of macrophages and osteoclastogenesis in vitro. Inducible nitric oxide synthase (iNOS) and CD206, as well as osteoclastogenesis markers, nuclear factor of activated T cells 1 (NFATc1), and c Fos, were qualitatively analyzed by immunofluorescence, flow cytometry, reverse transcription polymerase chain reaction, and Western blotting. The results showed that DAC significantly inhibited osteoclastogenesis by suppressing the expression levels of c Fos and NFATc1 through nuclear factor kappa B, c Jun N terminal kinase (JNK), and Akt pathway. Moreover, immunohistochemistry and enzyme linked immunosorbent assays showed that DAC reduced the release of tumor necrosis factor alpha, interleukin (IL) 1 beta, and IL 6 in vivo. Finally, DAC also promoted macrophage polarization from M1 to M2 types. In conclusion, these results demonstrated that DAC suppressed RANKL induced inflammation and osteoclastogenesis and therefore it can be used as a potential treatment for osteoporosis, arthritis, osteolysis, and aseptic loosening of artificial prostheses.
C1 [Li, Zhikun; Zhu, Xiaodong; Xu, Ruijun; Wang, Yi; Hu, Ruixi; Xu, Wei] Shanghai Jiao Tong Univ, Sch Med, TongRen Hosp, Dept Orthopaed, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Xu, W (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, TongRen Hosp, Dept Orthopaed, Shanghai, Peoples R China.
EM XW2107@shtrhospital.com
RI ; XU, WEI/AAA 4666 2019; Xu, Ruijun/JOZ 1031 2023
OI Li, zhikun/0000 0002 1732 5931; 
FU Excellent young medical talents training plan of the Shanghai Health
   Planning Commission [2018YQ46]; K.C. Wong Education Foundation, Hong
   Kong
FX The study was supported by the Excellent young medical talents training
   plan of the Shanghai Health Planning Commission (2018YQ46) and K.C. Wong
   Education Foundation, Hong Kong.
CR Dou C, 2018, J BONE MINER RES, V33, P899, DOI 10.1002/jbmr.3364
   Gruber R, 2019, J CLIN PERIODONTOL, V46, P52, DOI 10.1111/jcpe.13056
   Guan HF, 2015, FASEB J, V29, P1092, DOI 10.1096/fj.14 262055
   Ha TJ, 2003, ARCH PHARM RES, V26, P925, DOI 10.1007/BF02980201
   Ha YC, 2017, CALCIFIED TISSUE INT, V101, P623, DOI 10.1007/s00223 017 0320 1
   Hopkins RB, 2016, OSTEOPOROSIS INT, V27, P3023, DOI 10.1007/s00198 016 3631 6
   Kimura K, 2012, FEMS IMMUNOL MED MIC, V64, P219, DOI 10.1111/j.1574 695X.2011.00888.x
   Lechner J, 2018, CLIN COSMET INVESTIG, V10, P251, DOI 10.2147/CCIDE.S184498
   Lin TH, 2014, ACTA BIOMATER, V10, P3747, DOI 10.1016/j.actbio.2014.04.034
   Liu X, 2014, ACTA BIOMATER, V10, P4912, DOI 10.1016/j.actbio.2014.07.025
   Liu Y, 2019, J CELL PHYSIOL, V234, P13832, DOI 10.1002/jcp.28063
   Looney RJ, 2006, CURR OPIN RHEUMATOL, V18, P80, DOI 10.1097/01.bor.0000198004.88568.96
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Nich Christophe, 2011, Arthritis Res Ther, V13, pR100, DOI 10.1186/ar3381
   Oh E, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2015.83
   Ouyang ZX, 2014, BIOCHEM PHARMACOL, V90, P276, DOI 10.1016/j.bcp.2014.06.009
   Perdiguero EG, 2015, NATURE, V518, P547, DOI 10.1038/nature13989
   Qu SX, 2013, J BIOMED MATER RES A, V101, P394, DOI 10.1002/jbm.a.34327
   Ren WP, 2009, BONE, V44, P671, DOI 10.1016/j.bone.2008.12.015
   Saeed J, 2016, IMMUNOL LETT, V175, P8, DOI 10.1016/j.imlet.2016.04.004
   Santo AIE, 2015, BIOCHEM BIOPH RES CO, V464, P1145, DOI 10.1016/j.bbrc.2015.07.094
   Saqib Uzma, 2018, Oncotarget, V9, P17937, DOI 10.18632/oncotarget.24788
   Schwarz EM, 2008, J AM ACAD ORTHOP SUR, V16, pS72, DOI 10.5435/00124635 200800001 00015
   Schwarz EM, 2000, ARTHRITIS RES, V2, P165, DOI 10.1186/ar81
   Shakeri A, 2019, NAT PROD RES, V33, P2016, DOI 10.1080/14786419.2018.1483926
   Shao HG, 2015, BIOMATERIALS, V60, P92, DOI 10.1016/j.biomaterials.2015.04.048
   Sosa A, 2011, PHARM BIOL, V49, P675, DOI 10.3109/13880200903431467
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Trial JA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00287
   Vasconcelos DP, 2013, BIOMATERIALS, V34, P9952, DOI 10.1016/j.biomaterials.2013.09.012
   Walsh MC, 2018, NAT REV RHEUMATOL, V14, P146, DOI 10.1038/nrrheum.2017.213
   Wang CD, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00407
   Wedemeyer C, 2007, CALCIFIED TISSUE INT, V81, P394, DOI 10.1007/s00223 007 9077 2
   Wu X, 2012, J BONE MINER RES, V27, P1298, DOI 10.1002/jbmr.1576
   Xu Q, 2019, BIOCHEM BIOPH RES CO, V508, P902, DOI 10.1016/j.bbrc.2018.11.201
   Zhai ZJ, 2014, BIOMATERIALS, V35, P6299, DOI 10.1016/j.biomaterials.2014.04.044
   Zhang GN, 2016, NITRIC OXIDE BIOL CH, V61, P20, DOI 10.1016/j.niox.2016.09.006
   Zhu X, 2016, J BONE MINER RES, V31, P560, DOI 10.1002/jbmr.2710
NR 38
TC 17
Z9 18
U1 0
U2 19
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 7
PY 2019
VL 10
AR 599
DI 10.3389/fphar.2019.00599
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA IC7OG
UT WOS:000471163900001
PM 31231214
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lee, HP
   Lin, CY
   Shih, JS
   Fong, YC
   Wang, SW
   Li, TM
   Tang, CH
AF Lee, Hsiang Ping
   Lin, Chih Yang
   Shih, Jhao Sheng
   Fong, Yi Chin
   Wang, Shih Wei
   Li, Te Mao
   Tang, Chih Hsin
TI Adiponectin promotes VEGF A dependent angiogenesis in human
   chondrosarcoma through PI3K, Akt, mTOR, and HIF α pathway
SO ONCOTARGET
LA English
DT Article
DE adiponectin; chondrosarcoma; angiogenesis; VEGF A; HIF
ID ENDOTHELIAL GROWTH FACTOR; PROSTATE CANCER CELLS; FACTOR EXPRESSION;
   BREAST CANCER; HYPOXIA; OSTEOBLASTS; GENE; INCREASES; RECEPTOR;
   TRANSCRIPTION
AB Chondrosarcoma is a type of highly malignant tumor with a potent capacity to invade locally and cause distant metastasis. Adiponectin is a protein hormone secreted predominantly by differentiated adipocytes. On the other hand, angiogenesis is a critical step in tumor growth and metastasis. However, the relationship of adiponectin with vascular endothelial growth factor A (VEGF A) expression and angiogenesis in human chondrosarcoma is mostly unknown. In this study we first demonstrated that the expression of adiponectin was correlated with tumor stage of human chondrosarcoma tissues. In addition, we also found that adiponectin increased VEGF A expression in human chondrosarcoma cells and subsequently induced migration and tube formation in human endothelial progenitor cells (EPCs). Adiponectin promoted VEGF A expression through adiponectin receptor (AdipoR), phosphoinositide 3 kinase (PI3K), Akt, mammalian target of rapamycin (mTOR), and hypoxia inducible factor 1 alpha (HIF) 1 alpha signaling cascades. Knockdown of adiponectin decreased VEGF A expression and also abolished chondrosarcoma conditional medium mediated tube formation in EPCs in vitro as well as angiogenesis effects in the chick chorioallantoic membrane and Matrigel plug nude mice model in vivo. Therefore, adiponectin is crucial for tumor angiogenesis and growth, which may represent a novel target for anti angiogenic therapy in human chondrosarcoma.
C1 [Lee, Hsiang Ping] China Med Univ, Grad Inst Chinese Med, Taichung, Taiwan.
   [Lee, Hsiang Ping] China Med Univ Hosp, Dept Chinese Med, Taichung, Taiwan.
   [Lin, Chih Yang; Shih, Jhao Sheng; Tang, Chih Hsin] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan.
   [Fong, Yi Chin] China Med Univ, Dept Sports Med, Taichung, Taiwan.
   [Fong, Yi Chin] China Med Univ Hosp, Dept Orthoped Surg, Taichung, Taiwan.
   [Wang, Shih Wei] Mackay Med Coll, Dept Med, New Taipei, Taiwan.
   [Li, Te Mao] China Med Univ, Sch Chinese Med, Taichung, Taiwan.
   [Tang, Chih Hsin] China Med Univ, Sch Med, Dept Pharmacol, Taichung, Taiwan.
   [Tang, Chih Hsin] Asia Univ, Coll Hlth Sci, Dept Biotechnol, Taichung, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Hospital   Taiwan; China Medical University Taiwan;
   China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Hospital   Taiwan; Mackay Medical University; China
   Medical University Taiwan; China Medical University Taiwan; Asia
   University Taiwan
RP Tang, CH (通讯作者)，China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan.
EM leedemaw@mail.cmu.edu.tw; chtang@mail.cmu.edu.tw
RI Yen, Ching/A 2771 2013; Tang, Chih/O 5212 2015; Wang,
   Shih Wei/AAH 1967 2020
FU Ministry of Science and Technology of Taiwan [MOST103 2628 B 039 002,
   NSC 101 2314 B 039 002 MY3]; China Medical University [CMU102 S 07]
FX We thank Dr. W.M. Fu for providing HIF 1 alpha mutant and HRE promoter
   construct. This work was supported by grants from the Ministry of
   Science and Technology of Taiwan (MOST103 2628 B 039 002;
   NSC 101 2314 B 039 002 MY3). China Medical University (CMU102 S 07).
CR Ahluwalia A, 2012, CURR MED CHEM, V19, P90, DOI 10.2174/092986712803413944
   Bhat TA, 2013, CANC PREV RES PHILA
   BLOCK JA, 1991, J BONE JOINT SURG AM, V73A, P647, DOI 10.2106/00004623 199173050 00002
   Bovée JVMG, 2010, NAT REV CANCER, V10, P481, DOI 10.1038/nrc2869
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chen JC, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/396839
   Chen PC, 2014, ONCOTARGET, V5, P1595, DOI 10.18632/oncotarget.1570
   Chiu YC, 2009, CARCINOGENESIS, V30, P1651, DOI 10.1093/carcin/bgp156
   Choi Y.K., 2013, EVID BASED COMPL ALT, V2013, P1
   De Francesco EM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3458
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Gao QR, 2015, TUMOR BIOL, V36, P4287, DOI 10.1007/s13277 015 3067 1
   Goktas S, 2005, UROLOGY, V65, P1168, DOI 10.1016/j.urology.2004.12.053
   Hong M., 2013, MED CLIN BARCELONA, P1
   Hsieh JY, 2013, NUCL ACIDS RES
   Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697
   Huang CY, 2012, ARTHRITIS RHEUM US, V64, P3344, DOI 10.1002/art.34557
   Jia ZM, 2014, CELL BIOCHEM BIOPHYS, V70, P1239, DOI 10.1007/s12013 014 0047 9
   Kadowaki T, 2006, J CLIN INVEST, V116, P1784, DOI 10.1172/JCI29126
   Keating AM, 2011, OCUL SURF, V9, P227, DOI 10.1016/S1542 0124(11)70035 0
   Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995 4004.2001
   Lee YA, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2013.141
   Lin CY, 2014, BIOCHEM PHARMACOL, V91, P522, DOI 10.1016/j.bcp.2014.08.008
   Ling N, 2013, ONCOLOGY REPORTS
   Liu LP, 2012, CLIN CANCER RES, V18, P5662, DOI 10.1158/1078 0432.CCR 12 0552
   Ma JX, 2012, ONCOL RES, V20, P359, DOI 10.3727/096504013X13657689382932
   Miyoshi Y, 2003, CLIN CANCER RES, V9, P5699
   Nickols NG, 2007, ACS CHEM BIOL, V2, P561, DOI 10.1021/cb700110z
   PASSANITI A, 1992, LAB INVEST, V67, P519
   Pescador D, 2012, INT J SURG CASE REP, V3, P134, DOI 10.1016/j.ijscr.2011.11.009
   SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746
   Schneiderbauer MM, 2004, CLIN ORTHOP RELAT R, P232, DOI 10.1097/01.blo.0000136905.44818.65
   Schwartzberg LS, 2013, CLIN CANCER RES, V19, P2745, DOI 10.1158/1078 0432.CCR 12 3177
   Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471 4914(02)02317 1
   Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877
   Shin J, 2013, CANC LETT, V1, P1
   Su CM., 2014, EXP OPIN ORPH DRUGS, V2, P1
   Tang CH, 2007, J BIOL CHEM, V282, P25406, DOI 10.1074/jbc.M701001200
   Tang CH, 2012, BIOMEDICINE TAIWAN, V2, P92, DOI 10.1016/j.biomed.2012.01.001
   Tang CH, 2010, ARTHRITIS RHEUM US, V62, P3615, DOI 10.1002/art.27755
   Tang CH, 2009, PROSTATE, V69, P1781, DOI 10.1002/pros.21029
   Tseng WP, 2010, J CELL PHYSIOL, V223, P810, DOI 10.1002/jcp.22104
   Tzeng HE, 2015, CLIN SCI, V129, P147, DOI 10.1042/CS20140390
   Tzeng HE, 2013, BIOCHEM PHARMACOL, V85, P531, DOI 10.1016/j.bcp.2012.11.021
   Wu MH, 2014, ONCOGENE, V33, P1725, DOI 10.1038/onc.2013.109
   Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705
   Yamauchi T, 2013, CELL METAB, V17, P185, DOI 10.1016/j.cmet.2013.01.001
   Yin MC, 2012, BIOMEDICINE TAIWAN, V2, P83, DOI 10.1016/j.biomed.2012.08.001
   Yu HS, 2014, BIOCHEM PHARMACOL, V87, P243, DOI 10.1016/j.bcp.2013.10.016
NR 49
TC 74
Z9 76
U1 0
U2 18
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 3
PY 2015
VL 6
IS 34
BP 36746
EP 36761
DI 10.18632/oncotarget.5479
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA CY0QZ
UT WOS:000366111900127
PM 26468982
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lee, SM
   Jeong, Y
   Simms, J
   Warner, ML
   Poyner, DR
   Chung, KY
   Pioszak, AA
AF Lee, Sang Min
   Jeong, Yejin
   Simms, John
   Warner, Margaret L.
   Poyner, David R.
   Chung, Ka Young
   Pioszak, Augen A.
TI Calcitonin Receptor N Glycosylation Enhances Peptide Hormone Affinity by
   Controlling Receptor Dynamics
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE G protein coupled receptor (GPCR); N linked glycosylation; peptide
   hormone; ligand binding kinetics; dynamic allostery
ID LINKED GLYCOSYLATION; AMYLIN RECEPTOR; PARATHYROID HORMONE; PROTEIN
   STRUCTURES; SALMON CALCITONIN; LIGAND BINDING; EXPRESSION; MECHANISMS;
   GLYCAN; BIOSYNTHESIS
AB The class B G protein coupled receptor (GPCR) calcitonin receptor (CTR) is a drug target for osteoporosis and diabetes. N glycosylation of asparagine 130 in its extracellular domain (ECD) enhances calcitonin hormone affinity with the proximal GlcNAc residue mediating this effect through an unknown mechanism. Here, we present two crystal structures of salmon calcitonin bound, GlcNAc bearing CTR ECD at 1.78 and 2.85 angstrom resolutions and analyze the mechanism of the glycan effect. The N130 GlcNAc does not contact the hormone. Surprisingly, the structures are nearly identical to a structure of hormone bound, N glycan free ECD, which suggested that the GlcNAc might affect CTR dynamics not observed in the static crystallographic snapshots. Hydrogen deuterium exchange mass spectrometry and molecular dynamics simulations revealed that glycosylation stabilized a beta sheet adjacent to the N130 GlcNAc and the N terminal alpha helix near the peptide binding site while increasing flexibility of the peptide binding site turret loop. These changes due to N glycosylation increased the ligand on rate and decreased its off rate. The glycan effect extended to RAMP CTR amylin receptor complexes and was also conserved in the related CGRP receptor. These results reveal that N glycosylation can modulate GPCR function by altering receptor dynamics. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Lee, Sang Min; Warner, Margaret L.; Pioszak, Augen A.] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA.
   [Jeong, Yejin; Chung, Ka Young] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea.
   [Simms, John; Poyner, David R.] Aston Univ, Sch Life & Hlth Sci, Birmingham, W Midlands, England.
   [Lee, Sang Min] High Point Univ, Fred Wilson Sch Pharm, Dept Basic Pharmaceut Sci, High Point, NC 27268 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; Sungkyunkwan University (SKKU); Aston University
RP Pioszak, AA (通讯作者)，975 NE 10th St BRC 462B, Oklahoma City, OK 73126 USA.
EM augen pioszak@ouhsc.edu
RI ; Chung, Ka/AAO 7984 2020
OI Lee, Sangmin/0000 0002 7262 159X; Poyner, David R/0000 0003 1590 112X;
   Jeong, Yejin/0000 0002 2083 581X
FU DOE Office of Science [DE AC0206CH11357]; Michigan Economic Development
   Corporation; Michigan Technology TriCorridor [085P1000817]; NIH
   [R01GM104251]; National Research Foundation of Korea
   [NRF2018R1A2B6001554]; NIH COBRE award [P20GM103640]; BBSRC
   [BB/M007529/1]; Biotechnology and Biological Sciences Research Council
   [BB/M007529/1] Funding Source: researchfish; National Institute of
   General Medical Sciences [P20GM103640] Funding Source: NIH RePORTER;
   BBSRC [BB/M007529/1] Funding Source: UKRI
FX We thank Elena Kondrashkina for assistance with remote data collection
   at LS CAT beamline 21 ID F/G of the Advanced Photon Source, Argonne
   National Laboratory. This research used resources of the Advanced Photon
   Source, a U.S. Department of Energy (DOE) Office of Science User
   Facility operated for the DOE Office of Science by Argonne National
   Laboratory under Contract No. DE AC0206CH11357. Use of the LS CAT Sector
   21 was supported by the Michigan Economic Development Corporation and
   the Michigan Technology TriCorridor (Grant 085P1000817). We thank Dr.
   Ann West and Skyler Hebdon for helping us use their biolayer
   interferometry instrument. This work was supported by NIH grant
   R01GM104251 to AAP, the National Research Foundation of Korea grant
   NRF2018R1A2B6001554 to KYC, and use of the crystal imaging microscope
   was supported by NIH COBRE award P20GM103640. DRP and JS were supported
   by the BBSRC grant BB/M007529/1; research data relating to this is
   accessible via https://researchdata.aston.ac.uk/cgi/users/home?
   screen=EPrint::View&eprintid=433.
CR Agirre J, 2016, ACTA CRYSTALLOGR D, V72, P254, DOI 10.1107/S2059798315024237
   Agirre J, 2015, NAT STRUCT MOL BIOL, V22, P833, DOI 10.1038/nsmb.3115
   ALBRANDT K, 1995, ENDOCRINOLOGY, V136, P5377, DOI 10.1210/en.136.12.5377
   Aricescu AR, 2006, ACTA CRYSTALLOGR D, V62, P1243, DOI 10.1107/S0907444906029799
   Armour SL, 1999, J PHARMACOL TOXICOL, V42, P217, DOI 10.1016/S1056 8719(00)00074 5
   Assil IQ, 2001, AM J PHYSIOL ENDOC M, V281, pE1015, DOI 10.1152/ajpendo.2001.281.5.E1015
   Bisello A, 1996, BIOCHEMISTRY US, V35, P15890, DOI 10.1021/bi962111+
   Booe JM, 2018, MOL PHARMACOL, V93, P355, DOI 10.1124/mol.117.110916
   Booe JM, 2015, MOL CELL, V58, P1040, DOI 10.1016/j.molcel.2015.04.018
   Bower RL, 2016, AM J PHYSIOL REG I, V310, pR788, DOI 10.1152/ajpregu.00539.2015
   Cao YJ, 2001, BBA PROTEIN STRUCT M, V1548, P139, DOI 10.1016/S0167 4838(01)00227 8
   Chen QA, 2010, AM J PHYSIOL ENDOC M, V299, pE62, DOI 10.1152/ajpendo.00067.2010
   Chesnut CH, 2008, OSTEOPOROSIS INT, V19, P479, DOI 10.1007/s00198 007 0490 1
   Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235
   Couvineau A, 1996, BIOCHEMISTRY US, V35, P1745, DOI 10.1021/bi952022h
   dal Maso E, 2019, ACS PHARMACOL TRANSL, V2, P31, DOI 10.1021/acsptsci.8b00056
   Devaurs D, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00013
   Dong MQ, 2004, J BIOL CHEM, V279, P1167, DOI 10.1074/jbc.M305719200
   Ehrenmann J, 2018, NAT STRUCT MOL BIOL, V25, P1086, DOI 10.1038/s41594 018 0151 4
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Gingell JJ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.12
   Gujer R, 2001, BIOCHEMISTRY US, V40, P5392, DOI 10.1021/bi002497v
   Haliloglu T, 2015, CURR OPIN STRUC BIOL, V35, P17, DOI 10.1016/j.sbi.2015.07.007
   Hay DL, 2015, PHARMACOL REV, V67, P564, DOI 10.1124/pr.115.010629
   Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364
   Ho HH, 1999, BIOCHEMISTRY US, V38, P1866, DOI 10.1021/bi981195e
   Hoare SRJ, 2005, DRUG DISCOV TODAY, V10, P417, DOI 10.1016/S1359 6446(05)03370 2
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263 7855(96)00018 5
   IMPERIALI B, 1995, P NATL ACAD SCI USA, V92, P97, DOI 10.1073/pnas.92.1.97
   Johansson E, 2016, J BIOL CHEM, V291, P13689, DOI 10.1074/jbc.M116.726034
   Johswich A, 2014, J BIOL CHEM, V289, P15927, DOI 10.1074/jbc.M114.563734
   Kamitani S, 2001, BBA MOL CELL RES, V1539, P131, DOI 10.1016/S0167 4889(01)00100 8
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lebedev AA, 2012, ACTA CRYSTALLOGR D, V68, P431, DOI 10.1107/S090744491200251X
   Lee HS, 2015, SCI REP UK, V5, DOI 10.1038/srep08926
   Lee SM, 2017, BIOCHEMISTRY US, V56, P3380, DOI 10.1021/acs.biochem.7b00256
   Lee SM, 2016, J BIOL CHEM, V291, P8686, DOI 10.1074/jbc.M115.713628
   Liang YL, 2018, NATURE, V561, P492, DOI 10.1038/s41586 018 0535 y
   Liang YL, 2017, NATURE, V546, P118, DOI 10.1038/nature22327
   Liberini CG, 2016, EUR J NEUROSCI, V43, P653, DOI 10.1111/ejn.13163
   Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045
   Live DH, 1996, P NATL ACAD SCI USA, V93, P12759, DOI 10.1073/pnas.93.23.12759
   Long F, 2017, ACTA CRYSTALLOGR D, V73, P112, DOI 10.1107/S2059798317000067
   Masi L, 2007, CLIN CASES MINER BON, V4, P117
   McElroy CA, 2009, STRUCTURE, V17, P54, DOI 10.1016/j.str.2008.10.019
   McQueen J, 2005, AM J HEALTH SYST PH, V62, P2363, DOI 10.2146/ajhp050341
   MOSELEY JM, 1983, BIOCHEM J, V212, P609, DOI 10.1042/bj2120609
   Motlagh HN, 2014, NATURE, V508, P331, DOI 10.1038/nature13001
   Muff R, 1999, ENDOCRINOLOGY, V140, P2924, DOI 10.1210/en.140.6.2924
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255
   Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076 6879(97)76066 X
   Pang RTK, 1999, ENDOCRINOLOGY, V140, P5102, DOI 10.1210/en.140.11.5102
   Pioszak AA, 2008, P NATL ACAD SCI USA, V105, P5034, DOI 10.1073/pnas.0801027105
   Purdue BW, 2002, RECEPTOR CHANNEL, V8, P243, DOI 10.1080/10606820213681
   Quiza M, 1997, ENDOCRINOLOGY, V138, P530, DOI 10.1210/en.138.2.530
   Ramya L, 2020, J BIOMOL STRUCT DYN, V38, P1649, DOI 10.1080/07391102.2019.1614999
   Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13419, DOI 10.1073/pnas.212519299
   Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316
   Roehrkasse AM, 2018, J BIOL CHEM, V293, P15840, DOI 10.1074/jbc.RA118.005062
   Soto AG, 2015, P NATL ACAD SCI USA, V112, pE3600, DOI 10.1073/pnas.1508838112
   Whitaker GM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032675
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Wormald MR, 1999, STRUCTURE, V7, pR155, DOI 10.1016/S0969 2126(99)80095 1
   Xin FX, 2012, BIOINFORMATICS, V28, P2905, DOI 10.1093/bioinformatics/bts541
NR 65
TC 35
Z9 38
U1 0
U2 19
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022 2836
EI 1089 8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD MAR 27
PY 2020
VL 432
IS 7
BP 1996
EP 2014
DI 10.1016/j.jmb.2020.01.028
PG 19
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA LN1IG
UT WOS:000532698400010
PM 32035902
OA Green Submitted, Green Accepted, hybrid
DA 2025 08 17
ER

PT J
AU Yang, YP
   Shuai, B
   Shen, L
   Xu, XJ
   Ma, C
   Lv, L
AF Yang, Yan ping
   Shuai, Bo
   Shen, Lin
   Xu, Xiao juan
   Ma, Chen
   Lv, Lin
TI Effect of Qing'e formula on circulating sclerostin levels in patients
   with postmenopausal osteoporosis
SO JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY MEDICAL
   SCIENCES
LA English
DT Article
DE serum sclerostin; Qing'e formula; 25 hydroxyvitamin D; bone mineral
   density
ID BONE MINERAL DENSITY; VAN BUCHEM DISEASE; SERUM SCLEROSTIN;
   PARATHYROID HORMONE; SOST GENE; VITAMIN D; WOMEN; TURNOVER; STRENGTH;
   DELETION
AB Serum sclerostin is positively associated with serum 25 hydroxyvitamin D concentration. Our preliminary studies confirmed that Qing'e formula (QEF) could effectively increase serum 25 hydroxyvitamin D concentration in patients with postmenopausal osteoporosis (PMOP), but the effect of supplementation with QEF on serum sclerostin is unknown. This study investigated the effects of supplementation of QEF on serum sclerostin levels in patients with PMOP. Totally 120 outpatients and inpatients with PMOP treated in our hospital between January and October 2012 were randomly divided into QEF+calcium group, alfacalcidol+calcium group, and placebo+calcium group (n=40 each), with a follow up period of 2 years. The serum levels of sclerostin, 25 hydroxyvitamin D, and bone turnover markers (beta CTX, N MID and T PINP) at baseline and at the 6th month, 1st year, 1.5th year, and 2nd year after treatment were measured. The results showed that the levels of circulating sclerostin were increased significantly at the 6th month after treatment in QEF+calcium group and alfacalcidol+calcium group as compared with placebo+calcium group (P < 0.05), but there was no significant difference between the former two groups (P > 0.05). The levels of beta CTX, N MID and T PINP in serum were decreased in both QEF+calcium group and alfacalcidol+calcium group at the 6th month after treatment, without significant difference between the two groups (P > 0.05). But the levels were significantly lower than that in placebo+calcium group (P < 0.05). These results suggest that the mechanism by which QEF modulates bone metabolism in patients with PMOP might be related with the effect of QEF in increasing sclerostin expression. Our findings provide a scientific rationale for using QEF as an effective drug to prevent bone loss in PMOP.
C1 [Yang, Yan ping; Shuai, Bo; Shen, Lin; Xu, Xiao juan; Ma, Chen; Lv, Lin] Huazhong Univ Sci & Technol, Dept Integrated Tradit Chinese & Western Med, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China.
C3 Huazhong University of Science & Technology
RP Shen, L (通讯作者)，Huazhong Univ Sci & Technol, Dept Integrated Tradit Chinese & Western Med, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China.
EM yanpingy11@163.com; bobo3137@126.com; shenlinhb@sina.cn
RI Yang, Yanping/I 1614 2018
OI Shuai, Bo/0000 0002 9298 8129
FU Huazhong University of Science and Technology [2013QN235]; National
   Natural Science Foundation of China [81403257, 81473492, 81102692,
   81072943]
FX This project was supported by grants from Innovation Fund of Huazhong
   University of Science and Technology (No. 2013QN235), and National
   Natural Science Foundation of China (Nos. 81403257, 81473492, 81102692
   and 81072943).
CR Ardawi MSM, 2011, J BONE MINER RES, V26, P2812, DOI 10.1002/jbmr.479
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Dawson Hughes B, 2014, EUR J ENDOCRINOL, V170, P645, DOI 10.1530/EJE 13 0862
   Dawson Hughes B, 2014, J CLIN ENDOCR METAB, V99, pE149, DOI 10.1210/jc.2013 3148
   DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003
   Drake MT, 2010, J CLIN ENDOCR METAB, V95, P5056, DOI 10.1210/jc.2010 0720
   Durosier C, 2013, J CLIN ENDOCR METAB, V98, P3873, DOI 10.1210/jc.2013 2113
   Fazeli PK, 2013, OSTEOPOROSIS INT, V24, P2433, DOI 10.1007/s00198 013 2353 2
   Garnero P, 2013, OSTEOPOROSIS INT, V24, P489, DOI 10.1007/s00198 012 1978 x
   Gennari L, 2012, J CLIN ENDOCR METAB, V97, P1737, DOI 10.1210/jc.2011 2958
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Mirza FS, 2010, J CLIN ENDOCR METAB, V95, P1991, DOI 10.1210/jc.2009 2283
   Mödder UI, 2011, J BONE MINER RES, V26, P373, DOI 10.1002/jbmr.217
   Sheng ZF, 2012, CLIN ENDOCRINOL, V76, P797, DOI 10.1111/j.1365 2265.2011.04315.x
   Shuai B, 2014, CHIN MED UK, V5, P113
   Shuai Bo, 2008, Zhongguo Gu Shang, V21, P850
   Shuai Bo Shuai Bo, 2014, Chinese Medicine, V5, P145
   Staehling Hampton K, 2002, AM J MED GENET, V110, P144, DOI 10.1002/ajmg.10401
   Szulc P, 2013, J BONE MINER RES, V28, P855, DOI 10.1002/jbmr.1823
   Xu XJ, 2013, CHINESE MED J PEKING, V126, P2480, DOI 10.3760/cma.j.issn.0366 6999.20130104
NR 24
TC 7
Z9 13
U1 0
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1672 0733
EI 1993 1352
J9 J HUAZHONG U SCI MED
JI J. Huazhong Univ. Sci. Tech. Med.
PD AUG
PY 2015
VL 35
IS 4
BP 525
EP 530
DI 10.1007/s11596 015 1464 8
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA CN9JC
UT WOS:000358762100010
PM 26223921
DA 2025 08 17
ER

PT J
AU Gao, Y
   Feng, Y
   Shen, JK
   Lin, M
   Choy, E
   Cote, GM
   Harmon, DC
   Mankin, HJ
   Hornicek, FJ
   Duan, ZF
AF Gao, Yan
   Feng, Yong
   Shen, Jacson K.
   Lin, Min
   Choy, Edwin
   Cote, Gregory M.
   Harmon, David C.
   Mankin, Henry J.
   Hornicek, Francis J.
   Duan, Zhenfeng
TI CD44 is a direct target of miR 199a 3p and contributes to aggressive
   progression in osteosarcoma
SO SCIENTIFIC REPORTS
LA English
DT Article
ID EPITHELIAL OVARIAN CANCER; DRUG RESISTANCE; LUNG METASTASIS;
   UP REGULATION; EXPRESSION; CELLS; CHEMORESISTANCE; PROLIFERATION;
   EPIDEMIOLOGY; HYALURONAN
AB Osteosarcoma is the most common primary bone malignancy in children and adolescents. Herein, we investigated the role of cluster of differentiation 44 (CD44), a cell surface glycoprotein involved in cell cell interactions, cell adhesion, and migration in osteosarcoma. We constructed a human osteosarcoma tissue microarray with 114 patient tumor specimens, including tumor tissues from primary, metastatic, and recurrent stages, and determined the expression of CD44 by immunohistochemistry. Results showed that CD44 was overexpressed in metastatic and recurrent osteosarcoma as compared with primary tumors. Higher expression of CD44 was found in both patients with shorter survival and patients who exhibited unfavorable response to chemotherapy before surgical resection. Additionally, the 3' untranslated region of CD44 mRNA was the direct target of microRNA 199a 3p (miR 199a 3p). Overexpression of miR 199a 3p significantly inhibited CD44 expression in osteosarcoma cells. miR 199a 3p is one of the most dramatically decreased miRs in osteosarcoma cells and tumor tissues as compared with normal osteoblast cells. Transfection of miR 199a 3p significantly increased the drug sensitivity through down regulation of CD44 in osteosarcoma cells. Taken together, these results suggest that the CD44 miR 199a 3p axis plays an important role in the development of metastasis, recurrence, and drug resistance of osteosarcoma. Developing strategies to target CD44 may improve the clinical outcome of osteosarcoma.
C1 [Gao, Yan; Feng, Yong; Shen, Jacson K.; Lin, Min; Choy, Edwin; Cote, Gregory M.; Harmon, David C.; Mankin, Henry J.; Hornicek, Francis J.; Duan, Zhenfeng] Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Biol Lab, Boston, MA 02114 USA.
   [Gao, Yan; Feng, Yong; Shen, Jacson K.; Lin, Min; Choy, Edwin; Cote, Gregory M.; Harmon, David C.; Mankin, Henry J.; Hornicek, Francis J.; Duan, Zhenfeng] Harvard Univ, Sch Med, Boston, MA 02114 USA.
   [Gao, Yan] Zhengzhou Univ, Affiliated Hosp 3, Dept Clin Lab, Zhengzhou 450052, Henan Province, Peoples R China.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard University; Harvard Medical School; Zhengzhou
   University
RP Duan, ZF (通讯作者)，Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Biol Lab, Boston, MA 02114 USA.
EM zduan@mgh.harvard.edu
RI ; Duan, Zhenfeng/AAK 5587 2020; Lin, Min/F 1348 2018
OI Hornicek, Francis/0000 0002 6916 8042; Cote,
   Gregory/0000 0003 0181 886X; Lin, Min/0000 0002 3259 1955; 
FU Gattegno and Wechsler funds; Kenneth Stanton Fund; Sarcoma Foundation of
   America (SFA); National Cancer Institute (NCI)/National Institutes of
   Health (NIH) [UO1, CA 151452 01]; Sarcoma SPORE/NIH; Academic Enrichment
   Fund of MGH Orthopaedics; China Scholarship Council; Excellent Doctorial
   Dissertations Grant of Zhengzhou University
FX This work was supported, in part, by the Gattegno and Wechsler funds,
   the Kenneth Stanton Fund. Dr. Duan is supported, in part, through a
   grant from Sarcoma Foundation of America (SFA), a grant from National
   Cancer Institute (NCI)/National Institutes of Health (NIH), UO1, CA
   151452 01, a pilot grant from Sarcoma SPORE/NIH, and a grant from an
   Academic Enrichment Fund of MGH Orthopaedics. Dr. Gao is supported by
   scholarship from the China Scholarship Council and Excellent Doctorial
   Dissertations Grant of Zhengzhou University. The authors also want thank
   Chungdak Namgyal in the Tissue Microarray and Imaging Core at the
   Dana Farber/Harvard Cancer Center for help with the construction of
   osteosarcoma TMA.
CR Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540
   Cain JW, 2011, MOL CANCER RES, V9, P637, DOI 10.1158/1541 7786.MCR 09 0237
   Chen H, 2009, BRIT J CANCER, V101, P432, DOI 10.1038/sj.bjc.6605185
   Cheng WW, 2012, FEBS J, V279, P2047, DOI 10.1111/j.1742 4658.2012.08589.x
   Dieudonné FX, 2010, CANCER RES, V70, P5399, DOI 10.1158/0008 5472.CAN 10 0090
   Duan ZF, 2011, MOL CANCER THER, V10, P1337, DOI 10.1158/1535 7163.MCT 11 0096
   Esquela Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fletcher C.D.M., 2013, World Health Organization Classification of Tumours of Soft Tissue and Bone: Pathology and Genetics of Tumours of Soft Tissue and Bone
   Fornari F, 2010, CANCER RES, V70, P5184, DOI 10.1158/0008 5472.CAN 10 0145
   Gao Y, 2015, ONCOTARGET, V6, P9313, DOI 10.18632/oncotarget.3220
   Gorlick R, 2010, J BONE MINER RES, V25, P683, DOI 10.1002/jbmr.77
   Gvozdenovic A, 2013, J BONE MINER RES, V28, P838, DOI 10.1002/jbmr.1817
   Hattinger CM, 2010, EXPERT OPIN EMERG DR, V15, P615, DOI 10.1517/14728214.2010.505603
   Henry JC, 2010, BIOCHEM BIOPH RES CO, V403, P120, DOI 10.1016/j.bbrc.2010.10.130
   Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681
   Ishimoto T, 2014, CARCINOGENESIS, V35, P1003, DOI 10.1093/carcin/bgt402
   Kayastha S, 1999, CLIN CANCER RES, V5, P1073
   Kim S, 2008, J BIOL CHEM, V283, P18158, DOI 10.1074/jbc.M800186200
   Kuryu M, 1999, J CANCER RES CLIN, V125, P646, DOI 10.1007/s004320050329
   Lakshman M, 2004, EXP MOL PATHOL, V77, P18, DOI 10.1016/j.yexmp.2004.03.002
   Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284
   Meyers PA, 1997, PEDIATR CLIN N AM, V44, P973, DOI 10.1016/S0031 3955(05)70540 X
   Meyers PA, 2009, EXPERT REV ANTICANC, V9, P1035, DOI 10.1586/ERA.09.69
   Miletti González KE, 2005, CANCER RES, V65, P6660, DOI 10.1158/0008 5472.CAN 04 3478
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Miwa S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071362
   Naor D, 2002, CRIT REV CL LAB SCI, V39, P527, DOI 10.1080/10408360290795574
   Osborne TS, 2012, J COMP PATHOL, V146, P132, DOI 10.1016/j.jcpa.2011.12.007
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Ouyang L, 2013, MED ONCOL, V30, DOI 10.1007/s12032 012 0340 7
   Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004
   Ryan BM, 2010, NAT REV CANCER, V10, P389, DOI 10.1038/nrc2867
   Shiratori H, 2001, CANCER LETT, V170, P177, DOI 10.1016/S0304 3835(01)00587 0
   Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274
   Song B, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 96
   Su YJ, 2011, EMBO J, V30, P3186, DOI 10.1038/emboj.2011.211
   Tian R, 2014, AM J CANCER RES, V4, P738
   Weber GF, 2002, CANCER RES, V62, P2281
   Ween MP, 2011, INT J MOL SCI, V12, P1009, DOI 10.3390/ijms12021009
NR 39
TC 76
Z9 80
U1 0
U2 15
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JUN 16
PY 2015
VL 5
AR 11365
DI 10.1038/srep11365
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CK8SY
UT WOS:000356509800001
PM 26079799
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yang, Y
   Tian, YP
   Zhang, QH
   Li, XQ
   Fu, Y
   Pei, HT
   Lui, D
AF Yang, Yong
   Tian, Yaping
   Zhang, Qinghe
   Li, Xiaoqing
   Fu, Yun
   Pei, Haotian
   Lui, Dan
TI Comparative Effects of Flavonoids from Fructus Sophorae on
   Rat Osteoblasts in vitro
SO RECORDS OF NATURAL PRODUCTS
LA English
DT Article
DE Fructus Sophorae; flavonoid; phytoestrogens; estrogen receptor;
   osteoporosis
ID ER BETA; OSTEOPOROSIS; PHYTOESTROGENS; OSTEOGENESIS; LEGUMINOSAE;
   GENISTEIN
AB Fructus Sophorae (FS), the dry mature fruit of Sophora japonica Leguminosae, is a valuable traditional Chinese medicine resource with flavonoids as the major active ingredients. To identify the plant derived estrogenlike flavonoids serving as potential osteoporosis chemopreventive agents, we isolated and identified 27 flavonoids compounds, including 17 compounds obtained for the first time from FS. To screen out the flavonoids with estrogen like biological behavior from the 11 high yield compounds, we set up an in vitro screening system in rat osteoblast MC3T3 E1 cells including MTT assay, alkaline phosphatase staining and Alizarin red S staining assay to examine the effects on cell proliferation, differentiation and mineralization of osteoblast cells respectively. Six flavonoids, including genistein, sophoricoside, sophorabioside, sophoraflavonoloside, nicotiflorin and rutin, significantly increased the cellular activity of MC3T3 E1 cells. Furthermore, blocking the estrogen receptor signaling by tamoxifen compromised the effects above significantly, suggesting the 6 compounds behave as estrogen like reagents. Moreover, the interaction between the six flavonoids from FS and estrogen receptor was clarified by molecular docking method from Glide XP. Collectively, being used as food and medicine in China, FS is rich in flavonoids with estrogen like effects, may be used as healthy supplementary in treating postmenopausal women osteoporosis.
C1 [Yang, Yong; Li, Xiaoqing; Fu, Yun; Pei, Haotian; Lui, Dan] Jilin Univ, Sch Pharmaceut Sci, Fujin Rd 1266, Changchun 130021, Jilin, Peoples R China.
   [Tian, Yaping] Jilin Univ, Hosp 1, Dept Dermatol & Venerol, Changchun 130021, Jilin, Peoples R China.
   [Zhang, Qinghe] Changchun Univ Chinese Med, Coll Pharm, Boshuo Rd 1035, Changchun 130000, Jilin, Peoples R China.
C3 Jilin University; Jilin University; Changchun University of Chinese
   Medicine
RP Lui, D (通讯作者)，Jilin Univ, Sch Pharmaceut Sci, Fujin Rd 1266, Changchun 130021, Jilin, Peoples R China.
EM ludan@jlu.edu.cn
RI Yang, Yong/LBZ 9282 2024
OI Yang, Yong/0000 0003 4115 0008
FU Jilin University [419080600013]
FX This research was supported by Jilin University (Grant number
   419080600013). Thank Cuizhu Wang, Zhenzhou Wang and Linxin Xiong for the
   method of molecular docking. Thank Yang Chen for helping in the in vitro
   activity experiments. Thank Professor Hui Xu for language editing and
   discussion for MTT and ALP staining assay.
CR Abdallah HM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098559
   Al Anazi Abdullah Foraih, 2011, J Nat Sci Biol Med, V2, P154, DOI 10.4103/0976 9668.92322
   Antonelli ML, 2005, TALANTA, V66, P1025, DOI 10.1016/j.talanta.2005.01.004
   Bilezikian JP, 2002, J BONE MINER RES, V17, P563, DOI 10.1359/jbmr.2002.17.4.563
   Cao LH, 2003, J CELL BIOCHEM, V89, P152, DOI 10.1002/jcb.10486
   Cosman F, 2018, CURR OPIN RHEUMATOL, V30, P420, DOI 10.1097/BOR.0000000000000509
   Eastell R, 2013, LANCET, V382, P5, DOI 10.1016/S0140 6736(13)60984 8
   Fu SW, 2014, NUTR RES, V34, P467, DOI 10.1016/j.nutres.2014.05.003
   Guo DY, 2011, J ETHNOPHARMACOL, V138, P451, DOI 10.1016/j.jep.2011.09.034
   Kerlikowske K, 2010, J CLIN ONCOL, V28, P3830, DOI 10.1200/JCO.2009.26.4770
   Kim YS, 2015, PHYTOMEDICINE, V22, P993, DOI 10.1016/j.phymed.2015.08.003
   Li XY, 2017, BIOCHEM BIOPH RES CO, V493, P100, DOI 10.1016/j.bbrc.2017.09.068
   Lin X, 2015, CLIN INTERV AGING, V10, P1017, DOI 10.2147/CIA.S54613
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Santen RJ, 2010, J CLIN ENDOCR METAB, V95, pS7, DOI 10.1210/jc.2009 2509
   Shim JG, 2005, ARCH PHARM RES, V28, P106, DOI 10.1007/BF02975144
   Smolinski D, 2005, J ALTERN COMPLEM MED, V11, P483, DOI 10.1089/acm.2005.11.483
   Sterner RM, 2018, J IMMUNOL, V201, P1086, DOI 10.4049/jimmunol.1800174
   Tei RMH, 2019, CALCIFIED TISSUE INT, V104, P102, DOI 10.1007/s00223 018 0476 3
   Wang J., 2002, BOT J OVERSEAS MED, V17, P58
   Wang YX, 2016, ARCH MED RES, V47, P255, DOI 10.1016/j.arcmed.2016.07.002
   Wang ZL, 2006, PHYTOMEDICINE, V13, P718, DOI 10.1016/j.phymed.2005.09.005
   Wei H. M., 2010, ASIA PACIFIC TRADITI, V6, P115
   Wei H. M., 2011, SHANNXI J TRADIT CHI, V32, P1231
   Yang C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170674
   Yang C, 2015, BIOL TRACE ELEM RES, V168, P453, DOI 10.1007/s12011 015 0374 8
   Yang JC, 2018, BIOL TRACE ELEM RES, V184, P214, DOI 10.1007/s12011 017 1161 5
   Zhi XR, 2015, PHARMACOGN MAG, V11, P196, DOI 10.4103/0973 1296.149739
NR 28
TC 8
Z9 9
U1 7
U2 62
PU ACG PUBLICATIONS
PI GEBZE KOCAELI
PA YENIKENT MAHALLESI, FIRAT CADDESI, 1 3, GEBZE KOCAELI, 41400, TURKEY
SN 1307 6167
J9 REC NAT PROD
JI Rec. Nat. Prod.
PD JAN FEB
PY 2020
VL 14
IS 1
BP 65
EP 76
DI 10.25135/rnp.138.19.04.1262
PG 12
WC Plant Sciences; Chemistry, Applied; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Chemistry; Pharmacology & Pharmacy
GA IX8UQ
UT WOS:000485964000008
OA gold
DA 2025 08 17
ER

PT J
AU King, AJ
   Siegel, M
   He, Y
   Nie, BM
   Wang, J
   Koo McCoy, S
   Minassian, NA
   Jafri, Q
   Pan, D
   Kohler, J
   Kumaraswamy, P
   Kozuka, K
   Lewis, JG
   Dragoli, D
   Rosenbaum, DP
   O'Neill, D
   Plain, A
   Greasley, PJ
   Jönsson Rylander, AC
   Karlsson, D
   Behrendt, M
   Strömstedt, M
   Ryden Bergsten, T
   Knöpfel, T
   Arroyo, EMP
   Hernando, N
   Marks, J
   Donowitz, M
   Wagner, CA
   Alexander, RT
   Caldwell, JS
AF King, Andrew J.
   Siegel, Matthew
   He, Ying
   Nie, Baoming
   Wang, Ji
   Koo McCoy, Samantha
   Minassian, Natali A.
   Jafri, Qumber
   Pan, Deng
   Kohler, Jill
   Kumaraswamy, Padmapriya
   Kozuka, Kenji
   Lewis, Jason G.
   Dragoli, Dean
   Rosenbaum, David P.
   O'Neill, Debbie
   Plain, Allein
   Greasley, Peter J.
   Jonsson Rylander, Ann Cathrine
   Karlsson, Daniel
   Behrendt, Margareta
   Stromstedt, Maria
   Ryden Bergsten, Tina
   Knopfel, Thomas
   Arroyo, Eva M. Pastor
   Hernando, Nati
   Marks, Joanne
   Donowitz, Mark
   Wagner, Carsten A.
   Alexander, R. Todd
   Caldwell, Jeremy S.
TI Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract
   by tenapanor reduces paracellular phosphate permeability
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID CHRONIC KIDNEY DISEASE; STAGE RENAL DISEASE; GROWTH FACTOR 23; SERUM
   PHOSPHATE; TIGHT JUNCTION; PARATHYROID HORMONE; BONE DISORDER; PILL
   BURDEN; VITAMIN D; ABSORPTION
AB Hyperphosphatemia is common in patients with chronic kidney disease and is increasingly associated with poor clinical outcomes. Current management of hyperphosphatemia with dietary restriction and oral phosphate binders often proves inadequate. Tenapanor, a minimally absorbed, small molecule inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3), acts locally in the gastrointestinal tract to inhibit sodium absorption. Because tenapanor also reduces intestinal phosphate absorption, it may have potential as a therapy for hyperphosphatemia. We investigated the mechanism by which tenapanor reduces gastrointestinal phosphate uptake, using in vivo studies in rodents and translational experiments on human small intestinal stem cell derived enteroid monolayers to model ion transport physiology. We found that tenapanor produces its effect by modulating tight junctions, which increases transepithelial electrical resistance (TEER) and reduces permeability to phosphate, reducing paracellular phosphate absorption. NHE3 deficient monolayers mimicked the phosphate phenotype of tenapanor treatment, and tenapanor did not affect TEER or phosphate flux in the absence of NHE3. Tenapanor also prevents active transcellular phosphate absorption compensation by decreasing the expression of NaPi2b, the major active intestinal phosphate transporter. In healthy human volunteers, tenapanor (15 mg, given twice daily for 4 days) increased stool phosphorus and decreased urinary phosphorus excretion. We determined that tenapanor reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux, an effect mediated exclusively via on target NHE3 inhibition.
C1 [King, Andrew J.; Siegel, Matthew; He, Ying; Nie, Baoming; Wang, Ji; Koo McCoy, Samantha; Minassian, Natali A.; Jafri, Qumber; Pan, Deng; Kohler, Jill; Kumaraswamy, Padmapriya; Kozuka, Kenji; Lewis, Jason G.; Dragoli, Dean; Rosenbaum, David P.; Caldwell, Jeremy S.] Ardelyx Inc, Fremont, CA 94555 USA.
   [O'Neill, Debbie; Plain, Allein; Alexander, R. Todd] Univ Alberta, Edmonton, AB T6G 1C9, Canada.
   [Greasley, Peter J.] AstraZeneca Gothenburg, Early Clin Dev Innovat Med & Early Dev IMED Biote, Cardiovasc & Metab Dis CVMD Translat Med Unit, S 43150 Molndal, Sweden.
   [Jonsson Rylander, Ann Cathrine; Karlsson, Daniel; Behrendt, Margareta; Stromstedt, Maria] AstraZeneca Gothenburg, IMED Biotech Unit, Biosci CVMD, S 43150 Molndal, Sweden.
   [Ryden Bergsten, Tina] AstraZeneca Gothenburg, IMED Biotech Unit, CVMD, S 43150 Molndal, Sweden.
   [Knopfel, Thomas; Arroyo, Eva M. Pastor; Hernando, Nati; Wagner, Carsten A.] Univ Zurich, Inst Physiol, CH 8057 Zurich, Switzerland.
   [Knopfel, Thomas; Arroyo, Eva M. Pastor; Hernando, Nati; Wagner, Carsten A.] Natl Ctr Competence Res Kidney Control Homeostasi, CH 8057 Zurich, Switzerland.
   [Marks, Joanne] UCL, Dept Neurosci Physiol & Pharmacol, Royal Free Campus, London NW3 2PF, England.
   [Donowitz, Mark] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.
C3 University of Alberta; AstraZeneca; AstraZeneca; AstraZeneca; University
   of Zurich; University of London; University College London; Johns
   Hopkins University
RP King, AJ (通讯作者)，Ardelyx Inc, Fremont, CA 94555 USA.
EM aking@ardelyx.com
RI ; Marks, Joanne/H 9086 2019; King, Andrew/LFR 6912 2024; HE,
   YING/B 3952 2010; Alexander, R./G 1373 2012; Nie, Baoming/H 4316 2012;
   He, Ying/B 3952 2010; Wagner, Carsten/KYQ 2484 2024
OI He, Ying/0000 0002 7527 5565; Kohler, Jill/0000 0003 0594 7239; Wagner,
   Carsten/0000 0002 9874 8898; Jafri, Qumber/0000 0001 5179 5489; HE,
   YING/0000 0002 2052 8350; Knopfel, Thomas/0000 0002 8274 0736; Nie,
   Baoming/0000 0002 8343 0262; Plain, Allein/0000 0001 9841 9499;
   Alexander, R Todd/0000 0001 7396 7894; 
FU Ardelyx; Kidney Foundation of Canada [KFOC170002]; National Centre for
   Competence in Research (NCCR) Kidney; Swiss National Science Foundation;
   Emulate Inc.; NIH/National Institute of Diabetes and Digestive and
   Kidney Diseases [RO1DK02653, R24DK99803, UO1DK10316, P30DK089501];
   NIH/National Institute of Allergy and Infectious Diseases [PO1AI25181]
FX This work was funded by Ardelyx, The Kidney Foundation of Canada
   (KFOC170002 to R.T.A.), and the National Centre for Competence in
   Research (NCCR) Kidney (to C.A.W.). C.A.W. is supported by the Swiss
   National Science Foundation. M.D. received funds from Emulate Inc.,
   NIH/National Institute of Diabetes and Digestive and Kidney Diseases
   (RO1DK02653, R24DK99803, UO1DK10316, and P30DK089501), and NIH/National
   Institute of Allergy and Infectious Diseases (PO1AI25181).
CR AGARWAL R, 1994, GASTROENTEROLOGY, V107, P548, DOI 10.1016/0016 5085(94)90184 8
   ALOIA JF, 1985, BONE, V6, P73, DOI 10.1016/8756 3282(85)90310 2
   Amanzadeh J, 2006, NAT CLIN PRACT NEPHR, V2, P136, DOI 10.1038/ncpneph0124
   Benner D, 2012, J RENAL CARE, V38, P2, DOI 10.1111/j.1755 6686.2012.00233.x
   Block G. A., 2018, NEPHROL DIAL TRANSPL
   Block GA, 2017, J AM SOC NEPHROL, V28, P1933, DOI 10.1681/ASN.2016080855
   Borovac J, 2012, AM J PHYSIOL CELL PH, V303, pC1278, DOI 10.1152/ajpcell.00434.2011
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Cannata Andía B, 2013, KIDNEY INT, V84, P998, DOI 10.1038/ki.2013.185
   Careras C., 2014, Patent No. 2014169094
   Charmot D., 2010, Compounds and methods for inhibiting NHE mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders, Patent No. [2010078449 A2, 2010078449, WO2010078449 A2]
   Chiu YW, 2009, CLIN J AM SOC NEPHRO, V4, P1089, DOI 10.2215/CJN.00290109
   Collins AJ, 2009, CLIN J AM SOC NEPHRO, V4, pS5, DOI 10.2215/CJN.05980809
   DAVIS GR, 1983, GASTROENTEROLOGY, V85, P908
   Eddington H, 2010, CLIN J AM SOC NEPHRO, V5, P2251, DOI 10.2215/CJN.00810110
   Farrand KF, 2014, INT J NEPHROL RENOV, V7, P261, DOI 10.2147/IJNRD.S58037
   Fissell RB, 2016, HEMODIAL INT, V20, P38, DOI 10.1111/hdi.12315
   Forster IC, 2006, J MEMBRANE BIOL, V212, P177, DOI 10.1007/s00232 006 0016 3
   Gawenis LR, 2002, AM J PHYSIOL GASTR L, V282, pG776, DOI 10.1152/ajpgi.00297.2001
   Günzel D, 2013, PHYSIOL REV, V93, P525, DOI 10.1152/physrev.00019.2012
   Günzel D, 2012, COMPR PHYSIOL, V2, P1819, DOI 10.1002/cphy.c110045
   Günzel D, 2009, J CELL SCI, V122, P1507, DOI 10.1242/jcs.040113
   Hachiya S., 2014, Tetrahydrobenzothiophene compound, Patent No. [US8729068 B2, 8729068]
   Hernando N, 2015, J BONE MINER RES, V30, P1925, DOI 10.1002/jbmr.2523
   HILDMANN B, 1982, AM J PHYSIOL, V242, pG533, DOI 10.1152/ajpgi.1982.242.5.G533
   Hruska KA, 2008, KIDNEY INT, V74, P148, DOI 10.1038/ki.2008.130
   Isakova T, 2011, JAMA J AM MED ASSOC, V305, P2432, DOI 10.1001/jama.2011.826
   Isakova T, 2011, KIDNEY INT, V79, P1370, DOI 10.1038/ki.2011.47
   Joson CG, 2016, J RENAL NUTR, V26, P141, DOI 10.1053/j.jrn.2015.09.004
   Karamanidou C, 2008, BMC NEPHROL, V9, DOI 10.1186/1471 2369 9 2
   Kato A, 2011, ANNU REV PHYSIOL, V73, P261, DOI 10.1146/annurev physiol 012110 142244
   Kestenbaum B, 2005, J AM SOC NEPHROL, V16, P520, DOI 10.1681/ASN.2004070602
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   KIMIZUKA H, 1964, J THEOR BIOL, V6, P290, DOI 10.1016/0022 5193(64)90035 9
   KINSELLA JL, 1980, AM J PHYSIOL, V238, pF461, DOI 10.1152/ajprenal.1980.238.6.F461
   Komaba H, 2016, KIDNEY INT, V90, P753, DOI 10.1016/j.kint.2016.03.039
   Kovesdy CP, 2008, KIDNEY INT, V73, P1296, DOI 10.1038/ki.2008.64
   Kozuka K, 2017, STEM CELL REP, V9, P1976, DOI 10.1016/j.stemcr.2017.10.013
   Krug SM, 2014, SEMIN CELL DEV BIOL, V36, P166, DOI 10.1016/j.semcdb.2014.09.002
   Labonté ED, 2015, J AM SOC NEPHROL, V26, P1138, DOI 10.1681/ASN.2014030317
   LEE DBN, 1986, AM J PHYSIOL, V251, pG90, DOI 10.1152/ajpgi.1986.251.1.G90
   Lee GJ, 2015, PEDIATR NEPHROL, V30, P363, DOI 10.1007/s00467 014 2759 x
   Marks J, 2006, EXP PHYSIOL, V91, P531, DOI 10.1113/expphysiol.2005.032516
   Marks J, 2013, CURR OPIN NEPHROL HY, V22, P481, DOI 10.1097/MNH.0b013e3283621310
   Marks J, 2010, AM J PHYSIOL RENAL, V299, pF285, DOI 10.1152/ajprenal.00508.2009
   McGovern AP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074996
   ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331
   Palmer SC, 2011, JAMA J AM MED ASSOC, V305, P1119, DOI 10.1001/jama.2011.308
   Pan WL, 2012, AM J PHYSIOL RENAL, V302, pF943, DOI 10.1152/ajprenal.00504.2010
   Plain A, 2016, PFLUG ARCH EUR J PHY, V468, P293, DOI 10.1007/s00424 015 1748 7
   Port FK, 2006, CLIN J AM SOC NEPHRO, V1, P246, DOI 10.2215/CJN.01050905
   Rievaj J, 2013, AM J PHYSIOL GASTR L, V305, pG303, DOI 10.1152/ajpgi.00490.2012
   Sabbagh Y, 2011, ADV CHRONIC KIDNEY D, V18, P85, DOI 10.1053/j.ackd.2010.11.004
   Sabbagh Y, 2009, J AM SOC NEPHROL, V20, P2348, DOI 10.1681/ASN.2009050559
   Schiavi SC, 2012, J AM SOC NEPHROL, V23, P1691, DOI 10.1681/ASN.2011121213
   Schwarz S, 2006, CLIN J AM SOC NEPHRO, V1, P825, DOI 10.2215/CJN.02101205
   Spencer AG, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007790
   STIEGER B, 1983, EUR J BIOCHEM, V135, P95
   Sullivan C, 2009, JAMA J AM MED ASSOC, V301, P629, DOI 10.1001/jama.2009.96
   Toussaint ND, 2012, NEPHROLOGY, V17, P433, DOI 10.1111/j.1440 1797.2012.01618.x
   Turner JR, 2000, AM J PHYSIOL CELL PH, V279, pC1918, DOI 10.1152/ajpcell.2000.279.6.C1918
   Vastag M, 2005, PFLUG ARCH EUR J PHY, V449, P384, DOI 10.1007/s00424 004 1341 y
   Wagner CA, 2014, PFLUG ARCH EUR J PHY, V466, P139, DOI 10.1007/s00424 013 1418 6
   WALTON J, 1979, CLIN SCI, V56, P407, DOI 10.1042/cs0560407
   Wang S, 2014, NEPHROL DIAL TRANSPL, V29, P2092, DOI 10.1093/ndt/gft280
   Weber CR, 2015, ELIFE, V4, DOI 10.7554/eLife.09906
   Williams KB, 2007, AM J PHYSIOL ENDOC M, V292, pE1917, DOI 10.1152/ajpendo.00654.2006
   Zhou C, 2016, CHINESE MED J PEKING, V129, P2275, DOI 10.4103/0366 6999.190678
NR 68
TC 123
Z9 130
U1 1
U2 7
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD AUG 29
PY 2018
VL 10
IS 456
AR eaam6474
DI 10.1126/scitranslmed.aam6474
PG 17
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA GR8ZA
UT WOS:000443027100001
PM 30158152
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Mas Moruno, C
   Fraioli, R
   Abericio, F
   Manero, JM
   Gil, FJ
AF Mas Moruno, Carlos
   Fraioli, Roberta
   Abericio, Fernando
   Maria Manero, Jose
   Javier Gil, F.
TI Novel Peptide Based Platform for the Dual Presentation of Biologically
   Active Peptide Motifs on Biomaterials
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE biofunctionalization; cell adhesive peptide; cell adhesion; peptide
   platform; titanium; RGD peptide; PHSRN peptide
ID CYCLIC RGD PEPTIDES; BIOCOMPATIBLE IMPLANT SURFACES; OSTEOBLAST ADHESIVE
   PEPTIDES; ROUGH TITANIUM SURFACES; MEDIATED CELL ADHESION; SER ARG ASN;
   HUMAN FIBRONECTIN; IN VIVO; REGENERATIVE MEDICINE; INTEGRIN SPECIFICITY
AB Biofunctionalization of metallic materials with cell adhesive molecules derived from the extracellular matrix is a feasible approach to improve cell material interactions and enhance the biointegration of implant materials (e.g., osseointegration of bone implants). However, classical biomimetic strategies may prove insufficient to elicit complex and multiple biological signals required in the processes of tissue regeneration. Thus, newer strategies are focusing on installing multifunctionality on biomaterials. In this work, we introduce a novel peptide based divalent platform with the capacity to simultaneously present distinct bioactive peptide motifs in a chemically controlled fashion. As a proof of concept, the integrin binding sequences RGD and PHSRN were selected and introduced in the platform. The biofunctionalization of titanium with this platform showed a positive trend towards increased numbers of cell attachment, and statistically higher values of spreading and proliferation of osteoblast like cells compared to control noncoated samples. Moreover, it displayed statistically comparable or improved cell responses compared to samples coated with the single peptides or with an equimolar mixture of the two motifs. Osteoblast like cells produced higher levels of alkaline phosphatase on surfaces functionalized with the platform than on control titanium; however, these values were not statistically significant. This study demonstrates that these peptidic structures are versatile tools to convey multiple biofunctionality to biomaterials in a chemically defined manner.
C1 [Mas Moruno, Carlos; Fraioli, Roberta; Maria Manero, Jose; Javier Gil, F.] Tech Univ Catalonia UPC, Biomat Biomech & Tissue Engn Grp, Dept Mat Sci & Met Engn, Barcelona 08028, Spain.
   [Mas Moruno, Carlos; Fraioli, Roberta; Abericio, Fernando; Maria Manero, Jose; Javier Gil, F.] Biomed Res Networking Ctr Bioengn Biomat & Nanome, Zaragoza 50018, Spain.
   [Mas Moruno, Carlos; Fraioli, Roberta] Univ Politecn Cataluna, Ctr Res NanoEngn CRNE, E 08028 Barcelona, Spain.
   [Abericio, Fernando] Inst Res Biomed IRB Barcelona, Barcelona 08028, Spain.
   [Abericio, Fernando] Univ Barcelona, Dept Organ Chem, E 08028 Barcelona, Spain.
   [Abericio, Fernando] Univ KwaZulu Natal, Sch Chem & Phys, ZA 4001 Durban, South Africa.
C3 Universitat Politecnica de Catalunya; CIBER   Centro de Investigacion
   Biomedica en Red; CIBERBBN; Universitat Politecnica de Catalunya;
   Barcelona Institute of Science & Technology; Institute for Research in
   Biomedicine   IRB Barcelona; University of Barcelona; University of
   Kwazulu Natal
RP Mas Moruno, C (通讯作者)，Tech Univ Catalonia UPC, Biomat Biomech & Tissue Engn Grp, Dept Mat Sci & Met Engn, Ave Diagonal 647, Barcelona 08028, Spain.
EM carles.mas.moruno@upc.edu
RI Fraioli, Roberta/E 3644 2015; Albericio, Fernando/B 4383 2013;
   Mas Moruno, Carlos/H 7511 2015; Albericio, Fernando/AFP 2699 2022;
   Manero, Jose Maria/B 4169 2015; Manero, José/B 4169 2015
OI Fraioli, Roberta/0000 0003 2554 0807; Albericio,
   Fernando/0000 0002 8946 0462; Mas Moruno, Carlos/0000 0001 8337 0872;
   Manero, Jose Maria/0000 0002 1673 4389; 
FU Ministry of Economy and Competitiveness (MINECO) of the Spanish
   Government [MAT2012 30706]; Agency for Administration of University and
   Research Grants of the Government of Catalonia [SGR2009 1039]; Secretary
   for Universities and Research of the Ministry of Economy and Knowledge
   of the Government of Catalonia [2011 BP B 00042]; People Programme
   (Marie Curie Actions) of the European Union's Seventh Framework
   Programme (FP7 PEOPLE CIG, REA) [321985]; Government of Catalonia
FX This study was supported by the Ministry of Economy and Competitiveness
   (MINECO) of the Spanish Government (Project: MAT2012 30706) and the
   Agency for Administration of University and Research Grants of the
   Government of Catalonia (SGR2009 1039). C.M. M. thanks the support of
   the Secretary for Universities and Research of the Ministry of Economy
   and Knowledge of the Government of Catalonia (2011 BP B 00042) and the
   People Programme (Marie Curie Actions) of the European Union's Seventh
   Framework Programme (FP7 PEOPLE 2012 CIG, REA grant agreement 321985).
   R.F. thanks the Government of Catalonia for a predoctoral fellowship.
   The authors also express their gratitude to Mrs. Montse Dominguez for
   her useful technical assistance regarding the XPS analysis.
CR Ahmed S, 2011, BIOMACROMOLECULES, V12, P1265, DOI 10.1021/bm101549y
   AOTA S, 1994, J BIOL CHEM, V269, P24756
   Auernheimer J, 2005, CHEMBIOCHEM, V6, P2034, DOI 10.1002/cbic.200500031
   Barker TH, 2011, BIOMATERIALS, V32, P4211, DOI 10.1016/j.biomaterials.2011.02.027
   Bauer S, 2013, PROG MATER SCI, V58, P261, DOI 10.1016/j.pmatsci.2012.09.001
   Bell BF, 2011, CLIN ORAL IMPLAN RES, V22, P865, DOI 10.1111/j.1600 0501.2010.02074.x
   Bellis SL, 2011, BIOMATERIALS, V32, P4205, DOI 10.1016/j.biomaterials.2011.02.029
   Benoit DSW, 2005, BIOMATERIALS, V26, P5209, DOI 10.1016/j.biomaterials.2005.01.045
   Broggini N, 2012, J BIOMED MATER RES A, V100A, P703, DOI 10.1002/jbm.a.34004
   CARPINO LA, 1993, J AM CHEM SOC, V115, P4397, DOI 10.1021/ja00063a082
   Chen X, 2013, COLLOID SURFACE B, V107, P189, DOI 10.1016/j.colsurfb.2013.02.005
   Collier JH, 2011, BIOMATERIALS, V32, P4198, DOI 10.1016/j.biomaterials.2011.02.030
   Dahmen C, 2004, ANGEW CHEM INT EDIT, V43, P6649, DOI 10.1002/anie.200460770
   Dee KC, 1998, J BIOMED MATER RES, V40, P371, DOI 10.1002/(SICI)1097 4636(19980605)40:3<371::AID JBM5>3.0.CO;2 C
   Dettin M, 2002, J BIOMED MATER RES, V60, P466, DOI 10.1002/jbm.10066
   Dillow AK, 2001, BIOMATERIALS, V22, P1493, DOI 10.1016/S0142 9612(00)00304 5
   Elmengaard B, 2005, BIOMATERIALS, V26, P3521, DOI 10.1016/j.biomaterials.2004.09.039
   Elmengaard B, 2005, J BIOMED MATER RES A, V75A, P249, DOI 10.1002/jbm.a.30301
   Farrera Sinfreu J, 2002, TETRAHEDRON LETT, V43, P7813, DOI 10.1016/S0040 4039(02)01605 2
   Geissler U, 2000, J BIOMED MATER RES, V51, P752, DOI 10.1002/1097 4636(20000915)51:4<752::AID JBM25>3.0.CO;2 7
   Grant RP, 1997, J BIOL CHEM, V272, P6159, DOI 10.1074/jbc.272.10.6159
   Guillem Marti J, 2013, CLIN ORAL IMPLAN RES, V24, P770, DOI 10.1111/j.1600 0501.2012.02451.x
   Hasenbein ME, 2002, BIOMATERIALS, V23, P3937, DOI 10.1016/S0142 9612(02)00129 1
   HEALY KE, 1992, J COLLOID INTERF SCI, V150, P404, DOI 10.1016/0021 9797(92)90210 D
   Heckmann D, 2007, METHOD ENZYMOL, V426, P463, DOI 10.1016/S0076 6879(07)26020 3
   Hersel U, 2003, BIOMATERIALS, V24, P4385, DOI 10.1016/S0142 9612(03)00343 0
   Jeschke B, 2002, BIOMATERIALS, V23, P3455, DOI 10.1016/S0142 9612(02)00052 2
   Johansson Staffan, 1997, Frontiers in Bioscience (online), V2, pD126
   Kantlehner M, 2000, CHEMBIOCHEM, V1, P107, DOI 10.1002/1439 7633(20000818)1:2<107::AID CBIC107>3.0.CO;2 4
   Kao WJ, 2001, J BIOMED MATER RES, V55, P79, DOI 10.1002/1097 4636(200104)55:1<79::AID JBM110>3.0.CO;2 Z
   Kao WYJ, 2001, BIOMATERIALS, V22, P2901, DOI 10.1016/S0142 9612(01)00037 0
   Kennedy SB, 2006, BIOMATERIALS, V27, P3817, DOI 10.1016/j.biomaterials.2006.02.044
   Kim TI, 2002, BIOTECHNOL LETT, V24, P2029, DOI 10.1023/A:1021368519336
   Langel W, 2003, SURF SCI, V538, P1, DOI 10.1016/S0039 6028(03)00723 4
   Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092 8674(00)81002 8
   Lee MH, 2006, BIOMATERIALS, V27, P1907, DOI 10.1016/j.biomaterials.2005.11.003
   Lopez Garcia M., 2007, HDB BIOMINERALIZATIO, P109
   Love JC, 2005, CHEM REV, V105, P1103, DOI 10.1021/cr0300789
   Mardilovich A, 2006, LANGMUIR, V22, P3259, DOI 10.1021/la052756n
   Martino MM, 2009, BIOMATERIALS, V30, P1089, DOI 10.1016/j.biomaterials.2008.10.047
   Mas Moruno C, 2013, BIOMATERIALS SURFACE SCIENCE, P337
   Mas Moruno C, 2013, J BIOMED MATER RES A, V101, P87, DOI 10.1002/jbm.a.34303
   Mas Moruno C, 2009, BIOPOLYMERS, V92, P508, DOI 10.1002/bip.21285
   MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089
   Mora P, 2006, J PEPT SCI, V12, P491, DOI 10.1002/psc.755
   Moursi AM, 1997, J CELL SCI, V110, P2187
   Ochsenhirt SE, 2006, BIOMATERIALS, V27, P3863, DOI 10.1016/j.biomaterials.2005.12.012
   Pallarola D, 2014, ADV FUNCT MATER, V24, P943, DOI 10.1002/adfm.201302411
   Pegueroles M, 2010, ACTA BIOMATER, V6, P291, DOI 10.1016/j.actbio.2009.07.030
   Pegueroles M, 2012, BIOINTERPHASES, V7, DOI 10.1007/s13758 012 0048 4
   Petrie TA, 2008, BIOMATERIALS, V29, P2849, DOI 10.1016/j.biomaterials.2008.03.036
   Petrie TA, 2006, BIOMATERIALS, V27, P5459, DOI 10.1016/j.biomaterials.2006.06.027
   Petrie TA, 2009, J CELL MOL MED, V13, P2602, DOI 10.1111/j.1582 4934.2008.00476.x
   PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0
   Rahmouni S, 2013, ADV MATER, V25, P5869, DOI 10.1002/adma.201301338
   Rammelt S, 2004, J ORTHOPAED RES, V22, P1025, DOI 10.1016/j.orthres.2004.02.011
   Rechenmacher F, 2013, CHEM EUR J, V19, P9218, DOI 10.1002/chem.201301478
   Rechenmacher F, 2013, ANGEW CHEM INT EDIT, V52, P1572, DOI 10.1002/anie.201206370
   Rezania A, 1999, BIOTECHNOL PROGR, V15, P19, DOI 10.1021/bp980083b
   Rezania A, 1999, LANGMUIR, V15, P6931, DOI 10.1021/la990024n
   Rico P, 2010, COLLOID SURFACE B, V78, P310, DOI 10.1016/j.colsurfb.2010.03.019
   Schmidt DR, 2007, J BIOMED MATER RES A, V83A, P617, DOI 10.1002/jbm.a.31270
   Schuler M, 2009, J BIOMED MATER RES B, V91B, P517, DOI 10.1002/jbm.b.31425
   Shapira L, 2009, CLIN ORAL IMPLAN RES, V20, P50, DOI 10.1111/j.1600 0501.2008.01594.x
   Shekaran A, 2011, J BIOMED MATER RES A, V96A, P261, DOI 10.1002/jbm.a.32979
   Siebers MC, 2005, BIOMATERIALS, V26, P137, DOI 10.1016/j.biomaterials.2004.02.021
   Song DP, 2010, ACTA BIOMATER, V6, P684, DOI 10.1016/j.actbio.2009.07.032
   Subirós Funosas R, 2009, CHEM EUR J, V15, P9394, DOI 10.1002/chem.200900614
   Susuki Y, 2002, CHEM PHARM BULL, V50, P1229, DOI 10.1248/cpb.50.1229
   Tosatti S, 2004, J BIOMED MATER RES A, V68A, P458, DOI 10.1002/jbm.a.20082
   von der Mark K, 2013, PROG MATER SCI, V58, P327, DOI 10.1016/j.pmatsci.2012.09.002
   Welander M, 2007, J CLIN PERIODONTOL, V34, P452, DOI 10.1111/j.1600 051X.2007.01073.x
   Williams DF, 2011, BIOMATERIALS, V32, P4195, DOI 10.1016/j.biomaterials.2011.02.025
   Xiao SJ, 1998, LANGMUIR, V14, P5507, DOI 10.1021/la980257z
   Xiao SJ, 1997, J MATER SCI MATER M, V8, P867, DOI 10.1023/A:1018501804943
NR 75
TC 71
Z9 73
U1 2
U2 75
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD MAY 14
PY 2014
VL 6
IS 9
BP 6525
EP 6536
DI 10.1021/am5001213
PG 12
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA AH4CV
UT WOS:000336075300064
PM 24673628
DA 2025 08 17
ER

PT J
AU Ghosh, YA
   Pullara, J
   Rattan, R
   Melville, JC
AF Ghosh, Yohaann A.
   Pullara, Jonathon
   Rattan, Rishabh
   Melville, James C.
TI Case report: golimumab related osteonecrosis of the jaw
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
LA English
DT Article
ID TNF ALPHA
AB Medication related osteonecrosis of the jaw is an uncommon but highly morbid adverse event of certain medical therapies. Although classically induced by bisphosphonates, the recent advent of monoclonal antibodies is contributing to a rise in cases. In this case report, we present a rare case of golimumab associated medication related osteonecrosis of the jaw and discuss the possible mechanisms of pathogenesis.
C1 [Ghosh, Yohaann A.] Griffith Univ, Sch Med & Dent, Gold Coast, Australia.
   [Ghosh, Yohaann A.] Dept Head & Neck Surg, Integrated Prosthet & Reconstruct, Sydney, NSW, Australia.
   [Pullara, Jonathon; Rattan, Rishabh; Melville, James C.] Univ Texas Hlth Sci Ctr Houston, Bernard & Gloria Pepper Katz Dept Oral & Maxillof, Houston, TX 77030 USA.
C3 Griffith University; Griffith University   Gold Coast Campus; University
   of Texas System; University of Texas Health Science Center Houston
RP Melville, JC (通讯作者)，Univ Texas Hlth Sci Ctr Houston, Bernard & Gloria Pepper Katz Dept Oral & Maxillof, Houston, TX 77030 USA.
EM James.c.melville@uth.tmc.edu
RI ; Melville, James/AFG 4580 2022
OI Ghosh, Yohaann Ali/0000 0003 0289 731X; Melville,
   James/0000 0002 6527 4585; 
CR Al Sadi R, 2013, AM J PATHOL, V183, P1871, DOI 10.1016/j.ajpath.2013.09.001
   Brijs K, 2020, INT J ORAL MAX SURG, V49, P317, DOI 10.1016/j.ijom.2019.08.007
   Cook AD, 2018, TRENDS IMMUNOL, V39, P240, DOI 10.1016/j.it.2017.12.003
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Gkouveris I, 2022, CANCERS, V14, DOI 10.3390/cancers14020330
   Gupta L, 2021, OR SURG OR MED OR PA, V131, pE157, DOI 10.1016/j.oooo.2020.10.005
   Idriss HT, 2000, MICROSC RES TECHNIQ, V50, P184, DOI 10.1002/1097 0029(20000801)50:3<184::AID JEMT2>3.0.CO;2 H
   Lu RM, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929 019 0592 z
   Luiz ALSDF, Oral Surg Oral Med Oval Parkol Oral Radiol, V130, pe227
   Manzie T, 2020, AUST DENT J, V65, P305, DOI 10.1111/adj.12723
   Mazumdar S, 2009, MABS AUSTIN, V1, P422, DOI 10.4161/mabs.1.5.9286
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Parameswaran N, 2010, CRIT REV EUKAR GENE, V20, P87, DOI 10.1615/CritRevEukarGeneExpr.v20.i2.10
   Lima MSR, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017285
   Ruggiero SL, 2022, J ORAL MAXIL SURG, V80, P920, DOI 10.1016/j.joms.2022.02.008
   Sacco R, 2020, BRIT J ORAL MAX SURG, V58, P25, DOI 10.1016/j.bjoms.2019.09.023
   Wat Winnie Zee Man, 2016, Dent J (Basel), V4, DOI 10.3390/dj4040038
   Yamairi F, 2020, RHEUMATOL THER, V7, P811, DOI 10.1007/s40744 020 00228 1
   Zhang J, 2020, CELL DEATH DIFFER, V27, P1569, DOI 10.1038/s41418 019 0441 3
NR 19
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2212 4403
EI 2212 4411
J9 OR SURG OR MED OR PA
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol.
PD NOV
PY 2023
VL 136
IS 5
BP E149
EP E152
DI 10.1016/j.oooo.2023.05.017
EA NOV 2023
PG 4
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA Y0AA9
UT WOS:001101971600001
PM 37661466
DA 2025 08 17
ER

PT J
AU Yu, T
   Tang, J
AF Yu, Tammy
   Tang, Jie
TI Hypercalcemia during initiation of antiretroviral therapy in human
   immunodeficiency virus and Leishmania coinfection: A case report
SO MEDICINE
LA English
DT Article
DE human immunodeficiency virus; hypercalcemia; immune reconstitution
   inflammatory syndrome; leishmaniasis
ID GRANULOMATOUS INFLAMMATION; MACROPHAGES
AB Rationale:Hypercalcemia is a common complication of many granulomatous diseases but is not typically associated with leishmaniasis. Here we report an unusual case of hypercalcemia during the initiation of antiviral therapy in a patient with acquired immunodeficiency syndrome coinfected with visceral leishmaniasis. Patient Concerns:Our patient presented with malaise and altered mental status following antiretroviral therapy initiation. He was found to have de novo hypercalcemia complicated by acute kidney injury. Diagnosis, interventions, and outcomes:An extensive workup for other etiologies of hypercalcemia was negative. The patient was ultimately thought to have hypercalcemia secondary to visceral leishmaniasis in the setting of immune reconstitution inflammatory syndrome. He was treated with intravenous volume expansion, bisphosphonates, and oral corticosteroid therapy with complete resolution. Lessons:This case highlights an unusual presentation of immune reconstitution inflammatory syndrome, in which proinflammatory cytokine signaling during the restoration of cellular immunity may have led to increased ectopic calcitriol production by granuloma macrophages, thereby altering bone mineral metabolism and driving hypercalcemia.
C1 [Yu, Tammy; Tang, Jie] Brown Univ, Providence, RI 02912 USA.
C3 Brown University
RP Yu, T (通讯作者)，Brown Univ, Providence, RI 02912 USA.
EM tammy_yu@brown.edu; jie.tang@brownphysicians.org
OI Yu, Tammy/0000 0001 9614 804X; tang, jie/0000 0002 8054 7019
CR ADAMS JS, 1983, J CLIN INVEST, V72, P1856, DOI 10.1172/JCI111147
   Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Boulware DR, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000384
   Burza S, 2018, LANCET, V392, P951, DOI 10.1016/S0140 6736(18)31204 2
   Carrick AI, 2018, EMERG MED CLIN N AM, V36, P549, DOI 10.1016/j.emc.2018.04.008
   Flynn JL, 2011, MUCOSAL IMMUNOL, V4, P271, DOI 10.1038/mi.2011.14
   Gopal R, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0042 2016
   Kaye PM, 2016, SEMIN IMMUNOPATHOL, V38, P249, DOI 10.1007/s00281 015 0548 7
   Lopez DV, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.722806
   Meintjes G, 2012, CURR HIV AIDS REP, V9, P238, DOI 10.1007/s11904 012 0129 5
   Meintjes G, 2008, AM J RESP CRIT CARE, V178, P1083, DOI 10.1164/rccm.200806 858OC
   Pisarski K, 2019, TROP MED INFECT DIS, V4, DOI 10.3390/tropicalmed4010044
   Moreira PRR, 2016, VET PARASITOL, V226, P69, DOI 10.1016/j.vetpar.2016.06.032
   Rolot M, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/2790627
   Sharma O P, 2000, Curr Opin Pulm Med, V6, P442, DOI 10.1097/00063198 200009000 00010
   van Griensven J, 2012, INFECT DIS CLIN N AM, V26, P309, DOI 10.1016/j.idc.2012.03.005
   Vinnard C, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.TNMI7 0035 2016
NR 17
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUN 16
PY 2023
VL 102
IS 24
DI 10.1097/MD.0000000000033848
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA J8PY9
UT WOS:001012201900055
PM 37327295
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Okamoto, H
   Iwamoto, T
   Kotake, S
   Momohara, S
   Yamanaka, H
   Kamatani, N
AF Okamoto, H
   Iwamoto, T
   Kotake, S
   Momohara, S
   Yamanaka, H
   Kamatani, N
TI Inhibition of NF κB signaling by fenofibrate, a peroxisome
   proliferator activated receptor α ligand, presents a therapeutic
   strategy for rheumatoid arthritis
SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
LA English
DT Article
DE peroxisome proliferator activated receptor alpha; rheumatoid arthritis;
   NF kappa B
ID TUMOR NECROSIS FACTOR; PPAR GAMMA; SYNOVIAL FIBROBLASTS; TNF ALPHA;
   INDUCTION; OSTEOCLAST; EXPRESSION; APOPTOSIS; AGONIST; ADIPOGENESIS
AB Objectives Inflammatory mediators such as interleukin 6 and tumor necosis factor alpha play an important role in the pathogenesis of rheumatoid arthritis (RA) by promoting chronic inflammation and joint damage. NF kappa B is a transcriptional activator of genes for these cytokines. It also plays an important role in the regulation of osteoclast differentiation which plays a key role in joint destruction in RA. Ligands for peroxisome proliferator activated receptor (PPAR)  gamma have recently been reported to inhibit the development of RA. In this study, we investigated the role of PPAR alpha in RA.
   Methods We analyzed the protein expression of PPAR alpha and  gamma in rheumatoid synovial fibroblasts (RSF) from RA patients and analyzed the effects of ligands for PPAR alpha and  gamma on cytokine production from RSF, NF kappa B activations in RSF and osteoclast differentiation from osteocalst progenitor in the peripheral blood. Moreover we analyzed the effects of oral administration of PPAR alpha and  gamma ligands on the development of adjuvant induced arthritis (AIA) in female Lewis rats.
   Results We confirmed the expression of PPAR alpha in RSF and also demonstrated that fenofibrate, a ligand for PPAR a, inhibited cytokine production from RSF NF kappa B activation in RSF and osteoclast differentiation from osteoclast progenitor cells. Furthermore, we demonstrated that fenofibrate inhibits the development of arthritis in a rat model of human RA.
   Conclusions These results indicate that fenofibrate suppresses the development of arthritis by inhibition of NF kappa B signaling; therefore, this compound offers possible anti rheumatic drug.
C1 Tokyo Womens Med Univ, Inst Rheumatol, Shinjuku Ku, Tokyo 1620054, Japan.
C3 Tokyo Women's Medical University
RP Tokyo Womens Med Univ, Inst Rheumatol, Shinjuku Ku, 10 22 Kawada Cho, Tokyo 1620054, Japan.
RI ; Iwamoto, Takuji/L 3075 2013
OI Yamanaka, Hisashi/0000 0001 8453 6731; 
CR ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286
   Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782
   Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354
   Brown PJ, 1999, J MED CHEM, V42, P3785, DOI 10.1021/jm9903601
   Campion GV, 1996, ARTHRITIS RHEUM, V39, P1092, DOI 10.1002/art.1780390704
   Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364
   Delerive P, 2000, J BIOL CHEM, V275, P36703, DOI 10.1074/jbc.M004045200
   Diab A, 2002, J IMMUNOL, V168, P2508, DOI 10.4049/jimmunol.168.5.2508
   Eguchi I, 2002, CLIN EXP RHEUMATOL, V20, P647
   ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140 6736(94)90628 9
   Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092 8674(00)81109 5
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Greene M. E., 1995, Gene Expression, V4, P281
   HOPKINS SJ, 1988, CLIN EXP IMMUNOL, V73, P88
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184
   Kalajdzic T, 2002, ARTHRITIS RHEUM, V46, P494, DOI 10.1002/art.10055
   Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652
   KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854
   Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529 0131(200105)44:5<1003::AID ANR179>3.3.CO;2 R
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092 8674(95)90199 X
   Mbalaviele G, 2000, J BIOL CHEM, V275, P14388, DOI 10.1074/jbc.275.19.14388
   Meyer Bahlburg A, 2004, CLIN EXP RHEUMATOL, V22, P278
   Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301
   Okamoto H, 2000, VIROLOGY, V272, P402, DOI 10.1006/viro.2000.0396
   Reddy SV, 1998, CRIT REV EUKAR GENE, V8, P1, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.10
   Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178
   Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520
   Sakurada S, 1996, INT IMMUNOL, V8, P1483, DOI 10.1093/intimm/8.10.1483
   SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283
   Serhan CN, 1996, NATURE, V384, P23, DOI 10.1038/384023a0
   Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092 8674(00)81359 8
   Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701
   Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844
   Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092 8674(94)90006 X
   TSURUMI K, 1986, ARZNEIMITTELFORSCH, V36 2, P1810
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057 3070.2001
   Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784
   Wayman NS, 2002, FASEB J, V16, P1027, DOI 10.1096/fj.01 0793com
   Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460 2075.1996.tb00845.x
   Yoshida S, 1999, INT IMMUNOL, V11, P151, DOI 10.1093/intimm/11.2.151
   Yue TL, 2001, CIRCULATION, V104, P2588, DOI 10.1161/hc4601.099403
NR 46
TC 107
Z9 116
U1 0
U2 4
PU CLINICAL & EXPER RHEUMATOLOGY
PI PISA
PA VIA SANTA MARIA 31, 56126 PISA, ITALY
SN 0392 856X
EI 1593 098X
J9 CLIN EXP RHEUMATOL
JI Clin. Exp. Rheumatol.
PD MAY JUN
PY 2005
VL 23
IS 3
BP 323
EP 330
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 935GJ
UT WOS:000229767400009
PM 15971419
DA 2025 08 17
ER

PT J
AU Corrigan, MA
   Coyle, S
   Eichholz, KF
   Riffault, M
   Lenehan, B
   Hoey, DA
AF Corrigan, Michele A.
   Coyle, Siobhan
   Eichholz, Kian F.
   Riffault, Mathieu
   Lenehan, Brian
   Hoey, David A.
TI Aged Osteoporotic Bone Marrow Stromal Cells Demonstrate Defective
   Recruitment, Mechanosensitivity, and Matrix Deposition
SO CELLS TISSUES ORGANS
LA English
DT Article
DE Bone; Mesenchymal stem; stromal cells; Osteoporosis; Mineralisation;
   Oscillatory fluid shear
ID MESENCHYMAL STEM CELLS; OSTEOGENIC LINEAGE COMMITMENT; DIFFERENTIATION;
   BMP 2; OSTEOINDUCTION; MIGRATION; THERAPY; DENSITY; GROWTH; MSCS
AB Bone formation requires the replenishment of the osteoblast from a progenitor or stem cell population, which must be recruited, expanded, and differentiated to ensure continued anabolism. How this occurs and whether it is altered in the osteoporotic environment is poorly understood. Furthermore, given that emerging treatments for osteoporosis are targeting this progenitor population, it is critical to determine the regenerative capacity of this cell type in the setting of osteoporosis. Human bone marrow stromal cells (hMSCs) from a cohort of aged osteoporotic patients were compared to MSCs isolated from healthy donors in terms of the ability to undergo recruitment and proliferation, and also respond to both the biophysical and biochemical cues that drive osteogenic matrix deposition. hMSCs isolated from healthy donors demonstrate good recruitment, mechanosensitivity, proliferation, and differentiation capacity. Contrastingly, hMSCs isolated from aged osteoporotic patients had significantly diminished regenerative potential. Interestingly, we demonstrated that osteoporotic hMSCs no longer responded to chemokine directing recruitment and became desensitised to mechanical stimulation. The osteoporotic MSCs had a reduced proliferative potential and, importantly, they demonstrated an attenuated differentiation capability with reduced mineral and lipid formation. Moreover, during osteogenesis, despite minimal differences in the quantity of deposited collagen, the distribution of collagen was dramatically altered in osteoporosis, suggesting a potential defect in matrix quality. Taken together, this study has demonstrated that hMSCs isolated from aged osteoporotic patients demonstrate defective cell behaviour on multiple fronts, resulting in a significantly reduced regenerative potential, which must be considered during the development of new anabolic therapies that target this cell population.
C1 [Corrigan, Michele A.; Eichholz, Kian F.; Riffault, Mathieu; Hoey, David A.] Trinity Coll Dublin, Trinity Ctr Biomed Engn, Trinity Biomed Sci Inst, Dublin, Ireland.
   [Corrigan, Michele A.; Eichholz, Kian F.; Riffault, Mathieu; Hoey, David A.] Trinity Coll Dublin, Sch Engn, Dept Mech & Mfg Engn, Dublin, Ireland.
   [Coyle, Siobhan; Lenehan, Brian] Univ Hosp Limerick, Dept Trauma & Orthopaed, Limerick, Ireland.
   [Coyle, Siobhan; Lenehan, Brian] Univ Limerick, Grad Entry Med Sch, Limerick, Ireland.
   [Hoey, David A.] Trinity Coll Dublin, Adv Mat & Bioengn Res Ctr, Dublin, Ireland.
   [Hoey, David A.] RCSI, Dublin, Ireland.
C3 Trinity College Dublin; Trinity College Dublin; University of Limerick;
   University of Limerick; Trinity College Dublin; Royal College of
   Surgeons   Ireland
RP Hoey, DA (通讯作者)，Trinity Coll Dublin, Trinity Ctr Biomed Engn, Dept Mech & Mfg Engn, Dublin D02 R590, Ireland.
EM dahoey@tcd.ie
RI Hoey, David/X 9231 2019; Eichholz, Kian/HTM 1495 2023; Hoey,
   David/G 3301 2013
OI Riffault, Mathieu/0000 0002 1689 8199; Hoey, David/0000 0001 5898 0409
FU European Research Council (ERC) [336882, 825905]; Science Foundation
   Ireland (SFI) [SFI 13/ERC/L2864]; Irish Research Council
   [GOIPG/2014/493]; Irish Research Council (IRC) [GOIPG/2014/493] Funding
   Source: Irish Research Council (IRC); European Research Council (ERC)
   [825905] Funding Source: European Research Council (ERC)
FX The authors would like to acknowledge funding: a European Research
   Council (ERC) starting and proof of concept grant (336882 & 825905), a
   Science Foundation Ireland (SFI) support grant SFI 13/ERC/L2864, and an
   Irish Research Council postgraduate scholarship (GOIPG/2014/493).
CR Ahmed Abu Shufian Ishtiaq, 2017, World J Exp Med, V7, P1, DOI 10.5493/wjem.v7.i1.1
   Antebi B, 2014, CURR OSTEOPOROS REP, V12, P41, DOI 10.1007/s11914 013 0184 x
   Astudillo P, 2008, J CELL BIOCHEM, V103, P1054, DOI 10.1002/jcb.21516
   Bianco P, 2015, DEVELOPMENT, V142, P1023, DOI 10.1242/dev.102210
   Bitar M, 2008, BIOMACROMOLECULES, V9, P129, DOI 10.1021/bm701112w
   Bodenner D, 2007, CLIN INTERV AGING, V2, P499
   Brady RT, 2015, BIOCHEM BIOPH RES CO, V459, P118, DOI 10.1016/j.bbrc.2015.02.080
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Chan CKF, 2018, CELL, V175, P43, DOI 10.1016/j.cell.2018.07.029
   Chen JC, 2016, FASEB J, V30, P1504, DOI 10.1096/fj.15 276402
   Corrigan MA, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 22174 3
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   D'Ippolito G, 1999, J BONE MINER RES, V14, P1115, DOI 10.1359/jbmr.1999.14.7.1115
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Donoso O, 2015, J CELL BIOCHEM, V116, P1267, DOI 10.1002/jcb.25082
   Haasters F, 2014, BIOCHEM BIOPH RES CO, V452, P118, DOI 10.1016/j.bbrc.2014.08.055
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Janderová L, 2003, OBES RES, V11, P65, DOI 10.1038/oby.2003.11
   Katsimbri P, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12740
   KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kristensen HB, 2014, AM J PATHOL, V184, P778, DOI 10.1016/j.ajpath.2013.11.022
   Levi B, 2011, J BIOL CHEM, V286, P39497, DOI 10.1074/jbc.M111.256529
   Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   McClung MR, 2017, THER ADV MUSCULOSKEL, V9, P263, DOI 10.1177/1759720X17726744
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Melton LJ, 1998, J BONE MINER RES, V13, P1915, DOI 10.1359/jbmr.1998.13.12.1915
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Muschler GF, 2001, J ORTHOP RES, V19, P117, DOI 10.1016/S0736 0266(00)00010 3
   Nahhas RW, 2013, AM J PHYS ANTHROPOL, V150, P68, DOI 10.1002/ajpa.22142
   Oryan A, 2017, CELLS TISSUES ORGANS, V204, P59, DOI 10.1159/000469704
   Phillips JE, 2010, ACTA BIOMATER, V6, P12, DOI 10.1016/j.actbio.2009.07.023
   Prall WC, 2013, BIOCHEM BIOPH RES CO, V440, P617, DOI 10.1016/j.bbrc.2013.09.114
   Robey Pamela, 2017, F1000Res, V6, DOI 10.12688/f1000research.10955.1
   Rodríguez JP, 2000, J CELL BIOCHEM, V79, P557, DOI 10.1002/1097 4644(20001215)79:4<557::AID JCB40>3.0.CO;2 H
   Rodríguez JP, 1999, J CELL BIOCHEM, V75, P414, DOI 10.1002/(SICI)1097 4644(19991201)75:3<414::AID JCB7>3.3.CO;2 3
   Sanghani Kerai A, 2017, BONE JOINT RES, V6, P358, DOI 10.1302/2046 3758.66.BJR 2016 0259.R1
   Shima WN, 2015, EXP THER MED, V9, P2202, DOI 10.3892/etm.2015.2381
   Stavenschi E, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1025 8
   Stavenschi E, 2017, J BIOMECH, V55, P99, DOI 10.1016/j.jbiomech.2017.02.002
   Stenderup K, 2001, J BONE MINER RES, V16, P1120, DOI 10.1359/jbmr.2001.16.6.1120
   Tewari D, 2015, STEM CELL REV REP, V11, P309, DOI 10.1007/s12015 014 9573 5
   Turner CH, 1998, BONE, V22, P463, DOI 10.1016/S8756 3282(98)00041 6
   Valenti MT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020363
   Veronesi F, 2011, CRIT REV EUKAR GENE, V21, P363, DOI 10.1615/CritRevEukarGeneExpr.v21.i4.60
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 47
TC 7
Z9 8
U1 1
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1422 6405
EI 1422 6421
J9 CELLS TISSUES ORGANS
JI Cells Tissues Organs
PD NOV
PY 2019
VL 207
IS 2
BP 83
EP 96
DI 10.1159/000503444
PG 14
WC Anatomy & Morphology; Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology; Cell Biology; Developmental Biology
GA KC6LM
UT WOS:000507286700002
PM 31655814
DA 2025 08 17
ER

PT J
AU Liu, W
   Wang, DW
   Liu, LD
   Wang, L
   Yan, M
AF Liu, Wei
   Wang, Dunwei
   Liu, Lidi
   Wang, Lin
   Yan, Ming
TI miR 140 inhibits osteosarcoma progression by impairing USP22 mediated
   LSD1 stabilization and promoting p21 expression
SO MOLECULAR THERAPY NUCLEIC ACIDS
LA English
DT Article
ID SUPPRESSES PROLIFERATION; INVASION; CELLS; MICRORNA 140 5P; CANCER;
   TUMORIGENESIS; APOPTOSIS; MIGRATION; GROWTH
AB Osteosarcoma is a bone tumor frequently diagnosed in children and young adults. Despite advances in chemotherapy and surgical resection, tumors metastasize in 30% of osteosarcoma patients. In addition, side effects caused by chemotherapeutic drugs, as well as the development of chemoresistance, highlight the need to identify the molecular mechanisms involved in the pathogenesis of osteosarcoma. We compared 65 osteosarcoma samples to their adjacent normal tissues, as well as commercially obtained osteosarcoma cell lines with normal osteoblast cell lines, and identified a role for the microRNA (miR) 140/ubiquitin specific protease 22 (USP22)/lysine specific demethylase 1 (LSD1)/p21 axis in the development of osteosarcoma. Osteosarcoma tissues and cells exhibited poor miR 140 and p21 expression, whereas the expression of USP22 and LSD1 was increased. Overexpression of miR 140 inhibited cell proliferation, migration, and invasion and promoted cell apoptosis by directly targeting USP22, resulting in its decreased expression. Overexpression of USP22 reversed the effects of miR 140 overexpression in osteosarcoma cells. Overexpression of miR 140 or USP22 knockdown led to the ubiquitination and degradation of LSD1. miR 140 overexpression also suppressed tumorigenesis in vivo. This study revealed a role for miR 140 in the restriction of osteosarcoma development and identified miR 140 as a potential target for therapeutic intervention.
C1 [Liu, Wei; Liu, Lidi; Yan, Ming] First Hosp Jilin Univ, Dept Spine Surg, 1 Xinmin Rd, Changchun 130021, Jilin, Peoples R China.
   [Wang, Dunwei] First Hosp Jilin Univ, Dept Anesthesiol, Changchun 130021, Peoples R China.
   [Wang, Lin] First Hosp Jilin Univ, Cardiovasc Ctr, 1 Xinmin Rd, Changchun 130021, Jilin, Peoples R China.
C3 Jilin University; Jilin University; Jilin University
RP Yan, M (通讯作者)，First Hosp Jilin Univ, Dept Spine Surg, 1 Xinmin Rd, Changchun 130021, Jilin, Peoples R China.; Wang, L (通讯作者)，First Hosp Jilin Univ, Cardiovasc Ctr, 1 Xinmin Rd, Changchun 130021, Jilin, Peoples R China.
EM wanglinjdyy@jlu.edu.cn; yanmingdr@163.com
CR Bennani Baiti IM, 2012, HUM PATHOL, V43, P1300, DOI 10.1016/j.humpath.2011.10.010
   Chang JL, 2016, ONCOTARGET, V7, P85650, DOI 10.18632/oncotarget.13333
   Duan JY, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.110031
   Fujii R, 2019, CANCER GENOM PROTEOM, V16, P71, DOI 10.21873/cgp.20113
   Geller David S, 2010, Clin Adv Hematol Oncol, V8, P705
   Gu FY, 2020, CELL MOL LIFE SCI, V77, P3341, DOI 10.1007/s00018 020 03489 9
   He Y, 2017, EXP THER MED, V13, P2003, DOI 10.3892/etm.2017.4204
   Ji XG, 2018, BIOCHEM BIOPH RES CO, V495, P1342, DOI 10.1016/j.bbrc.2017.11.120
   Jiang W, 2019, ONCOTARGETS THER, V12, P10275, DOI 10.2147/OTT.S226465
   Liang WJ, 2020, ONCOL LETT, V19, P2272, DOI 10.3892/ol.2020.11313
   Liu YW, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0588 9
   Lulla Rishi R., 2011, Sarcoma, V2011, P732690, DOI 10.1155/2011/732690
   Ma GF, 2019, J CELL PHYSIOL, V234, P14145, DOI 10.1002/jcp.28107
   Meng YC, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00405 3
   Miwa S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010170
   Morrow James J., 2015, Critical Reviews in Oncogenesis, V20, P173, DOI 10.1615/CritRevOncog.2015013713
   Moukengue B, 2020, EBIOMEDICINE, V53, DOI 10.1016/j.ebiom.2020.102704
   Niwa H, 2020, CHEMMEDCHEM, V15, P787, DOI 10.1002/cmdc.202000014
   Poos K, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003210
   Qu ZB, 2020, ADV CLIN EXP MED, V29, P295, DOI 10.17219/acem/115089
   Su LR, 2020, MOL CARCINOGEN, V59, P520, DOI 10.1002/mc.23176
   Won YS, 2020, FOOD CHEM TOXICOL, V138, DOI 10.1016/j.fct.2020.111221
   Wu LY, 2020, EXP NEUROL, V326, DOI 10.1016/j.expneurol.2020.113179
   Xiao QR, 2017, ONCOL RES, V25, P267, DOI 10.3727/096504016X14732510786564
   Yang L, 2018, BIOCHEM BIOPH RES CO, V502, P493, DOI 10.1016/j.bbrc.2018.05.198
   Yi X, 2020, EXP CELL RES, V387, DOI 10.1016/j.yexcr.2019.111804
   Yin RF, 2020, ONCOTARGETS THER, V13, P2261, DOI 10.2147/OTT.S240022
   Zhang DF, 2017, ONCOL RES, V25, P743, DOI 10.3727/096504016X14772395226335
   Zhang N, 2019, EUR REV MED PHARMACO, V23, P8971, DOI 10.26355/eurrev_201910_19296
   Zhang R, 2020, NEOPLASMA, V67, P371, DOI 10.4149/neo_2020_190514N432
   Zhao X, 2018, ONCOL REP, V39, P289, DOI 10.3892/or.2017.6065
   Zhao ZY, 2019, EUR REV MED PHARMACO, V23, P9781, DOI 10.26355/eurrev_201911_19541
   Zhou AD, 2016, NAT CELL BIOL, V18, P954, DOI 10.1038/ncb3396
   Zhu FB, 2019, ONCOTARGETS THER, V12, P10129, DOI 10.2147/OTT.S225360
NR 34
TC 21
Z9 22
U1 0
U2 29
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162 2531
J9 MOL THER NUCL ACIDS
JI Mol. Ther. Nucl. Acids
PD JUN 4
PY 2021
VL 24
BP 436
EP 448
DI 10.1016/j.omtn.2021.01.029
EA MAR 2021
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA SN7ZR
UT WOS:000658506500006
PM 33868787
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sun, XH
   Xu, XN
   Xue, RH
   Zhang, LG
   Liu, LB
AF Sun, Xiaohui
   Xu, Xiaoning
   Xue, Renhao
   Zhang, Ligang
   Liu, Libin
TI Surface modification of zirconium alloy implants by collagen
   encapsulated strontium ranelate@PCN 224 coating to improve
   biocompatibility and promote osseointegration
SO MATERIALS CHEMISTRY AND PHYSICS
LA English
DT Article
DE Bioactive coatings; Strontium ranelate; Osteogenesis; Metal organic
   Frameworks(MOFs); MOFs drug  loading
ID OSTEOGENIC DIFFERENTIATION; IN VITRO; OXIDE; DELIVERY; FLUORIDE
AB Implant materials were extensively used in bone fracture and replacement therapies. However, implants gradually loosen and eventually fail over time. Therefore, the bone integration ability of bone implant materials needs further study. There are many methods and materials for enhancing osseointegration properties of Zr alloy by surface loading of osteogenic drugs. Compared with the traditional porous drug loading materials (such as zeolite and molecular sieve), the metal organic framework (MOFs) materials have the advantages of large specific surface area, easy adjustment of pore structure, more active adsorption sites and large adsorption capacity, so they had a wide range of applications in adsorption separation and controlled drug release. In this paper, the metal organic skeleton PCN 224 with large porosity and specific surface area was synthesized by hydrothermal reaction with H2TCPP and zirconium salt as raw materials. In order to understand the microstructure and physical and chemical properties of the materials and explore their adsorption mechanism, the prepared materials were characterized by XRD, SEM, TEM, FTIR, TG RSC, surface area analyzer and BET. The particle size of the synthesized PCN 224 was 209.67 +/  25.24 nm. The surface area analyzer (BET) showed that the specific surface area of PCN 224 was 735.96 cm(3) g( 1), the pore size was 2.18 +/  0.12 nm, and the maximum pore volume was 1.47 cm(3) g( 1) nm( 1). By comparing the changes of SEM, EDS and XRD before and after PCN 224 was immersed in strontium ranelate solution, the results show that strontium ranelate has been successfully loaded into the pore structure of PCN 224 without destroying the original crystal structure of PCN 224, and its adsorption process conforms to pseudo second order kinetics. The maximum adsorption capacity of SR was up to 112.67 +/  2.14 mg g( 1). The SR@PCN 224 was mixed with type I collagen and adhered to the anodized Zr alloy surface with a crosslinking agent. The sustained release performance of coated strontium ranelate showed that the complete release time was 13 days. In vitro biological experiments confirmed that Zr Col SR@PCN 224 coating could promote osteoblast proliferation and osteogenic differentiation. Metal organic frame materials loaded with osteogenic drugs can improve the osseointegration performance of bone implant materials, providing a novel idea and strategy for improving the osseointegration performance of bone implant materials.
C1 [Sun, Xiaohui; Xu, Xiaoning; Xue, Renhao; Zhang, Ligang; Liu, Libin] Cent South Univ, Sch Mat Sci & Engn, Changsha, Peoples R China.
   [Liu, Libin] Cent South Univ, State Key Lab Powder Met, Changsha, Peoples R China.
C3 Central South University; Central South University
RP Zhang, LG; Liu, LB (通讯作者)，Cent South Univ, Sch Mat Sci & Engn, Changsha, Peoples R China.; Liu, LB (通讯作者)，Cent South Univ, State Key Lab Powder Met, Changsha, Peoples R China.
EM ligangzhang@csu.edu.cn; pdc@csu.edu.cn
OI sun, xiao hui/0000 0002 0183 9575
FU National Natural Science Foundation of China; Natural Science Foundation
   of Hunan Province China [52071339, 51671218];  [2020JJ4739]
FX This work was supported by National Natural Science Foundation of China
   (Grant No. 52071339, 51671218) and Natural Science Foundation of Hunan
   Province China (Grant No. 2020JJ4739).
CR Almeida MM, 2016, TISSUE CELL, V48, P183, DOI 10.1016/j.tice.2016.03.009
   Altuna P, 2016, INT J ORAL MAX SURG, V45, P842, DOI 10.1016/j.ijom.2016.01.004
   Andersen OZ, 2013, BIOMATERIALS, V34, P5883, DOI 10.1016/j.biomaterials.2013.04.031
   Annamalai J, 2022, CHEMOSPHERE, V298, DOI 10.1016/j.chemosphere.2022.134184
   Bashirom N, 2016, PROCEDIA CHEM, V19, P611, DOI 10.1016/j.proche.2016.03.060
   Bieniek A, 2021, PROG MATER SCI, V117, DOI 10.1016/j.pmatsci.2020.100743
   Cai W, 2015, SMALL, V11, P4806, DOI 10.1002/smll.201500802
   Chang J, 2020, BIOACTIVE MATERIALS FOR BONE REGENERATION, P105, DOI 10.1016/B978 0 12 813503 7.00002 9
   Chen XY, 2019, MAT SCI ENG C MATER, V99, P710, DOI 10.1016/j.msec.2019.02.013
   Cheng JY, 2020, ENVIRON SCI ECOTECH, V3, DOI 10.1016/j.ese.2020.100035
   Choi S.J., 2020, T AM NUCL SOC, V122, P85
   Denry I, 2018, ACTA BIOMATER, V75, P463, DOI 10.1016/j.actbio.2018.05.047
   Frandsen CJ, 2011, MAT SCI ENG C MATER, V31, P1716, DOI 10.1016/j.msec.2011.07.016
   Gao MK, 2021, TRAC TREND ANAL CHEM, V137, DOI 10.1016/j.trac.2021.116226
   Gilarska A, 2020, INT J BIOL MACROMOL, V155, P938, DOI 10.1016/j.ijbiomac.2019.11.052
   Goel H, 2021, INT J BIOL MACROMOL, V174, P240, DOI 10.1016/j.ijbiomac.2021.01.166
   Han KM, 2021, J NON CRYST SOLIDS, V564, DOI 10.1016/j.jnoncrysol.2021.120827
   Hosseini S, 2019, COLLOID SURFACE B, V173, P662, DOI 10.1016/j.colsurfb.2018.10.035
   Hou Y, 2020, INORG CHEM COMMUN, V114, DOI 10.1016/j.inoche.2020.107825
   Hu SW, 2022, INTERMETALLICS, V140, DOI 10.1016/j.intermet.2021.107401
   Huang YB, 2017, CHEM SOC REV, V46, P126, DOI 10.1039/c6cs00250a
   Jabed A, 2019, SURF COAT TECH, V372, P278, DOI 10.1016/j.surfcoat.2019.05.036
   Jiang X, 2022, APPL SURF SCI, V575, DOI 10.1016/j.apsusc.2021.151769
   Karakeçili A, 2022, BIOMATER ADV, V136, DOI 10.1016/j.bioadv.2022.212757
   Katunar MR, 2017, MAT SCI ENG C MATER, V75, P957, DOI 10.1016/j.msec.2017.02.139
   Kravanja KA, 2022, MATER DESIGN, V217, DOI 10.1016/j.matdes.2022.110653
   Kumar S, 2020, CERAM INT, V46, P16235, DOI 10.1016/j.ceramint.2020.03.180
   Lázaro IA, 2019, COORDIN CHEM REV, V380, P230, DOI 10.1016/j.ccr.2018.09.009
   Lee NH, 2021, BIOMATERIALS, V276, DOI 10.1016/j.biomaterials.2021.121025
   Li L, 2021, MAT SCI ENG C MATER, V127, DOI 10.1016/j.msec.2021.112191
   Li N, 2019, CHEM ENG J, V371, P618, DOI 10.1016/j.cej.2019.04.017
   Li T, 2019, COLLOID SURFACE A, V577, P456, DOI 10.1016/j.colsurfa.2019.06.012
   Li XP, 2021, TOXICOL IN VITRO, V70, DOI 10.1016/j.tiv.2020.105019
   Li YQ, 2021, ACTA BIOMATER, V119, P432, DOI 10.1016/j.actbio.2020.10.030
   Liu C., 2021, Eng. Regen, V2, P105, DOI DOI 10.1016/J.ENGREG.2021.09.001
   Liu L, 2022, CERAM INT, V48, P4401, DOI 10.1016/j.ceramint.2021.11.028
   Lu ZH, 2019, BIOMATERIALS, V218, DOI 10.1016/j.biomaterials.2019.05.001
   Marx D, 2020, BONE REP, V12, DOI 10.1016/j.bonr.2020.100273
   Matlinska MA, 2019, ACS APPL MATER INTER, V11, P32739, DOI 10.1021/acsami.9b11004
   Moghanian A, 2021, CERAM INT, V47, P23762, DOI 10.1016/j.ceramint.2020.11.139
   Mredha MTI, 2017, BIOMATERIALS, V132, P85, DOI 10.1016/j.biomaterials.2017.04.005
   Nair M, 2020, BIOMATERIALS, V254, DOI 10.1016/j.biomaterials.2020.120109
   Narayanan A, 2019, LIFE SCI, V232, DOI 10.1016/j.lfs.2019.116676
   Nezhad EZ, 2022, SURF INTERFACES, V28, DOI 10.1016/j.surfin.2021.101623
   Ni YL, 2022, CERAM INT, V48, P495, DOI 10.1016/j.ceramint.2021.09.125
   Ou D, 2019, SENSOR ACTUAT B CHEM, V285, P398, DOI 10.1016/j.snb.2019.01.079
   Pantazi A, 2020, J MECH BEHAV BIOMED, V112, DOI 10.1016/j.jmbbm.2020.104084
   Patil NA, 2020, CERAM INT, V46, P4041, DOI 10.1016/j.ceramint.2019.10.220
   Pilmane M, 2017, MAT SCI ENG C MATER, V78, P1222, DOI 10.1016/j.msec.2017.05.042
   Rabiee N, 2022, MICROPOR MESOPOR MAT, V335, DOI 10.1016/j.micromeso.2021.111670
   Safari B, 2022, EUR POLYM J, V171, DOI 10.1016/j.eurpolymj.2022.111220
   Santos Coquillat A, 2021, SURF COAT TECH, V422, DOI 10.1016/j.surfcoat.2021.127508
   Shen XK, 2022, CHEM ENG J, V430, DOI 10.1016/j.cej.2021.133094
   Tapia Lopez LV, 2020, SURF COAT TECH, V402, DOI 10.1016/j.surfcoat.2020.126307
   Tousi NS, 2013, MAT SCI ENG C MATER, V33, P2757, DOI 10.1016/j.msec.2013.02.044
   Usman M, 2021, ACTA CRYSTALLOGR E, V77, P1243, DOI 10.1107/S2056989021011361
   Velzenberger E, 2009, COLLOID SURFACE B, V68, P238, DOI 10.1016/j.colsurfb.2008.10.022
   Wan MC, 2021, ACTA BIOMATER, V136, P137, DOI 10.1016/j.actbio.2021.09.039
   Wang QZ, 2021, CHEM ENG J, V420, DOI 10.1016/j.cej.2021.129955
   Wang ZW, 2022, CHEM ENG J, V440, DOI 10.1016/j.cej.2022.135883
   Xie BX, 2022, J SOLID STATE CHEM, V306, DOI 10.1016/j.jssc.2021.122803
   Xue RH, 2020, MATERIALS, V13, DOI 10.3390/ma13225130
   Yan BC, 2022, BIOMATER ADV, V134, DOI 10.1016/j.msec.2022.112699
   Zhang L, 2012, SURF COAT TECH, V212, P192, DOI 10.1016/j.surfcoat.2012.09.049
   Zhang L, 2021, INT J MECH SCI, V197, DOI 10.1016/j.ijmecsci.2021.106331
   Zheng ZW, 2020, CHEM ENG J, V396, DOI 10.1016/j.cej.2020.125241
NR 66
TC 6
Z9 6
U1 8
U2 60
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0254 0584
EI 1879 3312
J9 MATER CHEM PHYS
JI Mater. Chem. Phys.
PD JAN 1
PY 2023
VL 293
AR 126910
DI 10.1016/j.matchemphys.2022.126910
EA NOV 2022
PG 14
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 6C9NK
UT WOS:000882331000001
DA 2025 08 17
ER

PT J
AU Parker, CC
   Pascoe, S
   Chodacki, A
   O'Sullivan, JM
   Germá, JR
   O'Bryan Tear, CG
   Haider, T
   Hoskin, P
AF Parker, Christopher C.
   Pascoe, Sarah
   Chodacki, Ales
   O'Sullivan, Joe M.
   Germa, Josep R.
   O'Bryan Tear, Charles Gillies
   Haider, Trond
   Hoskin, Peter
TI A Randomized, Double Blind, Dose Finding, Multicenter, Phase 2 Study of
   Radium Chloride (Ra 223) in Patients with Bone Metastases and
   Castration Resistant Prostate Cancer
SO EUROPEAN UROLOGY
LA English
DT Article
DE alpha Pharmaceutical; Bone alkaline phosphatase; Bone metastases;
   Castration resistant prostate cancer; Prostate specific antigen; Radium
   chloride Ra 223; Targeted alpha emitter
ID SKELETAL METASTASES; EMITTING RA 223; BISPHOSPHONATES; THERAPY; SEEKING
AB Background: Patients with castration resistant prostate cancer (CRPC) and bone metastases have an unmet clinical need for effective treatments that improve quality of life and survival with a favorable safety profile.
   Objective: To prospectively evaluate the efficacy and safety of three different doses of radium chloride (Ra 223) in patients with CRPC and bone metastases.
   Design, setting, and participants: In this phase 2 double blind multicenter study, 122 patients were randomized to receive three injections of Ra 223 at 6 wk intervals, at doses of 25 kBq/kg (n = 41), 50 kBq/kg (n = 39), or 80 kBq/kg (n = 42). The study compared the proportion of patients in each dose group who had a confirmed decrease of >= 50% in baseline prostate specific antigen (PSA) levels.
   Outcome measurements and statistical analysis: Efficacy was evaluated using blood samples to measure PSA and other tumor markers, recorded skeletal related events, and pain assessments. Safety was evaluated using adverse events (AEs), physical examination, and clinical laboratory tests. The Jonckheere Terpstra test assessed trends between groups.
   Results and limitations: The study met its primary end point with a statistically significant dose response relationship in confirmed >= 50% PSA declines for no patients (0%) in the 25 kBq/kg dose group, two patients (6%) in the 50 kBq/kg dose group, and five patients (13%) in the 80 kBq/kg dose group (p = 0.0297). A >= 50% decrease in bone alkaline phosphatase levels was identified in six patients (16%), 24 patients (67%), and 25 patients (66%) in the 25 , 50 , and 80 kBq/kg dose groups, respectively (p < 0.0001). The most common treatment related AEs (>= 10%) occurring up to week 24 across all dose groups were diarrhea (21%), nausea (16%), and anemia (14%). No difference in incidence of hematologic events was seen among dose groups. Potential limitations include small patient numbers and differences among dose groups at baseline.
   Conclusions: Ra 223 had a dose dependent effect on serum markers of CRPC activity, suggesting that control of bone disease with Ra 223 may affect cancer related outcomes. Ra 223 was well tolerated at all doses.
   Trial registration: ClinicalTrials.gov: NCT00337155. (C) 2012 European Association of Urology. Published by Elsevier B. V. All rights reserved.
C1 [Parker, Christopher C.] Royal Marsden Hosp, Acad Urol Unit, Sutton SM2 5PT, Surrey, England.
   [Pascoe, Sarah] Derriford Hosp, Plymouth PL6 8DH, Devon, England.
   [Chodacki, Ales] Hosp Chomutov, Chomutov, Czech Republic.
   [O'Sullivan, Joe M.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland.
   [Germa, Josep R.] IDIBELL Inst Catala Oncol, Barcelona, Spain.
   [O'Bryan Tear, Charles Gillies] Algeta ASA, Oslo, Norway.
   [Haider, Trond] LINK Med Res AS, Oslo, Norway.
   [Hoskin, Peter] Mt Vernon Hosp, Middlesex, England.
C3 Royal Marsden NHS Foundation Trust; Derriford Hospital; Queens
   University Belfast; Institut d'Investigacio Biomedica de Bellvitge
   (IDIBELL); Institut Catala d'Oncologia
RP Parker, CC (通讯作者)，Royal Marsden Hosp, Acad Urol Unit, Downs Rd, Sutton SM2 5PT, Surrey, England.
EM chris.parker@rmh.nhs.uk
OI O'Sullivan, Joe/0000 0001 6999 2739; Hoskin, Peter/0000 0001 8323 9567
FU Algeta; Bayer HealthCare Pharmaceuticals; Algeta ASA, Oslo, Norway
FX Christopher C. Parker certifies that all conflicts of interest,
   including specific financial interests and relationships and
   affiliations relevant to the subject matter or materials discussed in
   the manuscript (eg, employment/affiliation, grants or funding,
   consultancies, honoraria, stock ownership or options, expert testimony,
   royalties, or patents filed, received, or pending), are the following:
   Christopher C. Parker has served as a consultant or advisor to Bayer
   (compensated) and Algeta (uncompensated). Ales Chodacki has received
   research funding from Algeta. Charles Gillies O'Bryan Tear is employed
   by, and has an ownership interest in, Algeta. Trond Haider has served as
   a consultant or advisor for Algeta. Research support in the design and
   conduct of the study, collection and management of the data, analysis,
   and interpretation of the data was provided by Algeta ASA, Oslo, Norway.
   Medical writing assistance was provided by Heather Nyce, PhD, of
   SciStrategy Communications, funded by Bayer HealthCare Pharmaceuticals.
CR Adami S, 1997, CANCER, V80, P1674, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1674::AID CNCR18>3.0.CO;2 X
   [Anonymous], EUR MULT CANC C SEPT
   [Anonymous], PALL CAR SYMPT MAN E
   Armstrong AJ, 2007, J CLIN ONCOL, V25, P3965, DOI 10.1200/JCO.2007.11.4769
   Armstrong AJ, 2009, ONCOLOGIST, V14, P816, DOI 10.1634/theoncologist.2009 0043
   Bruland OS, 2006, CLIN CANCER RES, V12, p6250S, DOI 10.1158/1078 0432.CCR 06 0841
   Cook RJ, 2006, CLIN CANCER RES, V12, P3361, DOI 10.1158/1078 0432.CCR 06 0269
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Henriksen G, 2003, J NUCL MED, V44, P252
   Henriksen G, 2002, CANCER RES, V62, P3120
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Kerr C, 2002, LANCET ONCOL, V3, P453, DOI 10.1016/S1470 2045(02)00835 5
   Lange PH, 1998, CANCER METAST REV, V17, P331, DOI 10.1023/A:1006106209527
   Lewington VJ, 2005, J NUCL MED, V46, p38S
   Li Yong, 2004, Expert Rev Anticancer Ther, V4, P459, DOI 10.1586/14737140.4.3.459
   Liepe K, 2009, CURR OPIN INVEST DR, V10, P1346
   McDevitt MR, 1998, EUR J NUCL MED, V25, P1341, DOI 10.1007/s002590050306
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nilsson S, 2005, CLIN CANCER RES, V11, P4451, DOI 10.1158/1078 0432.CCR 04 2244
   Nilsson S, 2012, EUR J CANCER, V48, P678, DOI 10.1016/j.ejca.2011.12.023
   Nilsson S, 2009, EJC SUPPL, P411
   Nilsson S, 2007, LANCET ONCOL, V8, P587, DOI 10.1016/S1470 2045(07)70147 X
   Pirie W., 1983, ENCY STAT SCI, V4, P315
   Saylor PJ, 2010, PROSTATE CANCER P D, V13, P20, DOI 10.1038/pcan.2009.50
   Silberstein EB, 2000, SEMIN RADIAT ONCOL, V10, P240, DOI 10.1053/srao.2000.6592
   Sonpavde G, 2012, UROL ONCOL SEMIN ORI, V30, P607, DOI 10.1016/j.urolonc.2010.07.002
   US Food and Drug Administration, 2004, FDA PUBL WORKSH CLIN
NR 27
TC 140
Z9 146
U1 1
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302 2838
EI 1873 7560
J9 EUR UROL
JI Eur. Urol.
PD FEB
PY 2013
VL 63
IS 2
BP 189
EP 197
DI 10.1016/j.eururo.2012.09.008
PG 9
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 071FE
UT WOS:000313572100007
PM 23000088
DA 2025 08 17
ER

PT J
AU Ma, ZY
   Wei, YB
   Zhang, L
   Shi, XQ
   Xing, RL
   Liao, TY
   Yang, N
   Li, XC
   Jie, LS
   Wang, PM
AF Ma, Zhenyuan
   Wei, Yibao
   Zhang, Li
   Shi, Xiaoqing
   Xing, Runlin
   Liao, Taiyang
   Yang, Nan
   Li, Xiaochen
   Jie, Lishi
   Wang, Peimin
TI GCTOF MS Combined LC QTRAP MS/MS Reveals Metabolic Difference Between
   Osteoarthritis and Osteoporotic Osteoarthritis and the Intervention
   Effect of Erxian Decoction
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE knee osteoarthritis; osteoporosis; metabolomics; erxian decoction;
   osteoporotic osteoarthritis
ID CHINESE HERBAL FORMULA; ER XIAN DECOCTION; CARTILAGE; DIFFERENTIATION;
   OSTEOBLAST
AB PurposeOP and OA are chronic bone diseases with high incidence in the middle aged and elderly populations. The latest research shows that the pathological environment of OP may be involved in the aggravation of the pathological process of OA, and the pathological state of OP plays an important role in the aggravation of OA pathology. EXD is a traditional Chinese medicine decoction that has been used to treat osteoporosis. Therefore, we further study whether OA will be aggravated in the OP environment and whether EXD can alleviate OA by intervening in the OP environment. The purpose of this study was to analyze the effect of OP on OA metabolites by using metabolomic methods and to explore the intervention mechanism of EXD on osteoporotic OA. MethodThirty two SD rats were randomly divided into normal group, OA group, OP OA group, and EXD group. EXD was administered by gavage. Histopathological evaluation of cartilage tissue was performed using Saffron fast green and HE staining. Western blot and qRT PCR were used to detect the expression levels of chondrogenesis genes SOX9, COL2A1, and COMP in cartilage tissue. GC TOFMS and LC QTRAP MS/MS metabolomics methods were used to analyze the changes of metabolites in serum samples of rats in each group. ResultThe slice results showed that the cartilage damage in the OP OA group was more serious than that in the OA group, which was significantly relieved after EXD intervention, indicating that the cartilage damage in the OP OA group was more severe than that in the OA group and further reduced the protein and gene expressions of cartilage markers SOX9, COL2A1, and COMP. Thirty seven substances were identified, and gentiopicroside, emodin, quercetin, and diosmetin were analyzed as possible active components of EXD. EXD treatment significantly reduced cartilage damage and reversed the expression of these markers. Metabolomics showed that EXD attenuated cartilage destruction by modulating the expression of cystine, chenodeoxycholate, and D Turanose, involving glycolysis/gluconeogenesis, pantothenate, and CoA biosynthesis metabolic pathways. ConclusionThe OP environment may promote the progression of OA through metabolic factors. The benign intervention of EXD in osteoporotic OA involves cystine, chenodeoxycholate, and D Turanose, and their associated glycolysis/gluconeogenesis, pantothenate, and CoA biosynthesis metabolic pathways. Therefore, we have a deep understanding of the metabolic related intervention of EXD in osteoporotic OA and are eager to better understand the mechanism of multi targeted intervention of EXD in bone metabolic lesions.
C1 [Ma, Zhenyuan; Wei, Yibao; Zhang, Li; Shi, Xiaoqing; Xing, Runlin; Liao, Taiyang; Yang, Nan; Li, Xiaochen; Jie, Lishi; Wang, Peimin] Nanjing Univ Chinese Med, Dept Orthoped, Affiliated Hosp, Nanjing, Peoples R China.
   [Ma, Zhenyuan; Wei, Yibao; Zhang, Li; Shi, Xiaoqing; Liao, Taiyang; Yang, Nan; Jie, Lishi; Wang, Peimin] Nanjing Univ Chinese Med, Coll Clin Med 1, Key Lab Metab Dis Chinese Med, Nanjing, Peoples R China.
   [Xing, Runlin; Li, Xiaochen; Wang, Peimin] Jiangsu Prov Hosp Chinese Med, Dept Tradit Chinese Med Orthoped, Nanjing, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing University of Chinese Medicine
RP Wang, PM (通讯作者)，Nanjing Univ Chinese Med, Dept Orthoped, Affiliated Hosp, Nanjing, Peoples R China.; Wang, PM (通讯作者)，Nanjing Univ Chinese Med, Coll Clin Med 1, Key Lab Metab Dis Chinese Med, Nanjing, Peoples R China.; Wang, PM (通讯作者)，Jiangsu Prov Hosp Chinese Med, Dept Tradit Chinese Med Orthoped, Nanjing, Peoples R China.
EM drwpm@163.com
RI ; Liao, Taiyang/KLD 0868 2024
OI Liao, Taiyang/0000 0003 2290 7634; 
FU Peak Academic Talent Project of Jiangsu Province Hospital of Chinese
   Medicine [y2021rc02, y2021rc20]; General Project of Natural Fund of
   Nanjing University of Traditional Chinese Medicine [k2021x05]
FX This work was supported by the Peak Academic Talent Project of Jiangsu
   Province Hospital of Chinese Medicine(y2021rc02, y2021rc20) and the
   General Project of Natural Fund of Nanjing University of Traditional
   Chinese Medicine (k2021x05).
CR Abdallah HM, 2020, NUTRIENTS, V12, DOI 10.3390/nu12072075
   Aleidi SM, 2021, METABOLITES, V11, DOI 10.3390/metabo11090628
   Batushansky A, 2019, OSTEOARTHR CARTILAGE, V27, P1361, DOI 10.1016/j.joca.2019.05.010
   Chen P, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889 016 3712 7
   Chen Y, 2020, PHYTOTHER RES, V34, P1310, DOI 10.1002/ptr.6596
   Cui YC, 2021, EXP BIOL MED, V246, P1177, DOI 10.1177/1535370220985468
   Deveza LA, 2017, OSTEOARTHR CARTILAGE, V25, P1926, DOI 10.1016/j.joca.2017.08.009
   Dragojevic J, 2013, J BONE MINER METAB, V31, P512, DOI 10.1007/s00774 013 0445 x
   Geng XL, 2015, EXP THER MED, V10, P1066, DOI 10.3892/etm.2015.2615
   Guo DY, 2011, J ETHNOPHARMACOL, V138, P451, DOI 10.1016/j.jep.2011.09.034
   Herrero Beaumont G, 2020, OSTEOARTHR CARTILAGE, V28, P239, DOI 10.1016/j.joca.2019.10.015
   Hsu YL, 2008, J BONE MINER RES, V23, P949, DOI 10.1359/JBMR.080219
   Hu HL, 2021, LIFE SCI, V269, DOI 10.1016/j.lfs.2020.119001
   Hu Y, 2019, FREE RADICAL BIO MED, V145, P146, DOI 10.1016/j.freeradbiomed.2019.09.024
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Jiang HJ, 2021, J CELL MOL MED, V25, P10825, DOI 10.1111/jcmm.16410
   Khan NM, 2017, FREE RADICAL BIO MED, V106, P288, DOI 10.1016/j.freeradbiomed.2017.02.041
   Lane JM, 2000, CLIN ORTHOP RELAT R, P139
   Li DH, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.00304
   Li JY, 2017, CLIN INTERV AGING, V12, P45, DOI 10.2147/CIA.S117597
   Li NH, 2013, J ORTHOP SCI, V18, P478, DOI 10.1007/s00776 013 0362 9
   Liu MM, 2017, J TISSUE ENG REGEN M, V11, P276, DOI 10.1002/term.1911
   Liu SF, 2017, JOVE J VIS EXP, DOI 10.3791/55654
   Liu YJ, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.831894
   Luo YY, 2017, AM J TRANSL RES, V9, P3517
   Maly K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052242
   MANKIN HJ, 1981, J BONE JOINT SURG AM, V63, P131, DOI 10.2106/00004623 198163010 00017
   Nian H, 2006, J ETHNOPHARMACOL, V108, P96, DOI 10.1016/j.jep.2006.04.020
   Palermo A, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13060544
   Roomi Ali B, 2021, J Obes, V2021, P5325813, DOI 10.1155/2021/5325813
   Song H, 2020, SEMIN CANCER BIOL, V67, P12, DOI 10.1016/j.semcancer.2020.04.008
   Tsai WY, 2016, J ORTHOP RES, V34, P650, DOI 10.1002/jor.23069
   Tsiklauri L, 2018, OSTEOARTHR CARTILAGE, V26, P1225, DOI 10.1016/j.joca.2018.06.001
   Wehland M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249596
   Xing RL, 2017, ARCH RHEUMATOL, V32, P96, DOI 10.5606/ArchRheumatol.2017.6061
   Xue LM, 2011, INT J MOL SCI, V12, P7635, DOI 10.3390/ijms12117635
   Yan ZW, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/780149
   Yang L, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6641838
   Zhang FZ, 2018, J CELL PHYSIOL, V233, P4626, DOI 10.1002/jcp.26187
   Zhao L, 2015, J ETHNOPHARMACOL, V172, P100, DOI 10.1016/j.jep.2015.06.031
   Zheng HQ, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen 2014 007568
NR 41
TC 12
Z9 15
U1 2
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD JUL 28
PY 2022
VL 13
AR 905507
DI 10.3389/fendo.2022.905507
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 3R6FT
UT WOS:000839006800001
PM 35966099
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wiesli, MG
   Huber, MW
   Weisse, B
   Zboray, R
   Kiderlen, S
   González Vázquez, A
   Maniura Weber, K
   Rottmar, M
   Lackington, WA
AF Wiesli, Matthias Guido
   Huber, Matthias Werner
   Weisse, Bernhard
   Zboray, Robert
   Kiderlen, Stefanie
   Gonzalez Vazquez, Arlyng
   Maniura Weber, Katharina
   Rottmar, Markus
   Lackington, William Arthur
TI Immunomodulation Using BMP 7 and IL 10 to Enhance the Mineralization
   Capacity of Bone Progenitor Cells in a Fracture Hematoma Like
   Environment
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE BMP 7; fracture hematoma; IL 10; immunomodulation; mineralization
ID IN VITRO; HYDROXYAPATITE SCAFFOLDS; COLLAGEN SCAFFOLD; DELIVERY; MODEL;
   REGENERATION; OSTEOBLASTS; ACTIVATION; EXPRESSION; STIFFNESS
AB Following biomaterial implantation, a failure to resolve inflammation during the formation of a fracture hematoma can significantly limit the biomaterial's ability to facilitate bone regeneration. This study aims to combine the immunomodulatory and osteogenic effects of BMP 7 and IL 10 with the regenerative capacity of collagen hydroxyapatite (CHA) scaffolds to enhance in vitro mineralization in a hematoma like environment. Incubation of CHA scaffolds with human whole blood leads to rapid adsorption of fibrinogen, significant stiffening of the scaffold, and the formation of a hematoma like environment characterized by a limited capacity to support the infiltration of human bone progenitor cells, a significant upregulation of inflammatory cytokines and acute phase proteins, and significantly reduced osteoconductivity. CHA scaffolds functionalized with BMP 7 and IL 10 significantly downregulate the production of key inflammatory cytokines, including IL 6, IL 8, and leptin, creating a more permissive environment for mineralization, ultimately enhancing the biomaterial's osteoconductivity. In conclusion, targeting the onset of inflammation in the early phase of bone healing using BMP 7 and IL 10 functionalized CHA scaffolds is a promising approach to effectively downregulate inflammatory processes, while fostering a more permissive environment for bone regeneration.
   This study presents BMP 7 and IL 10 functionalized collagen hydroxyapatite scaffolds as an immunomodulatory therapy for bone repair. The impact of a hematoma like environment on cell material interactions, inflammatory cytokine production, and osteogenesis is presented. BMP 7 and IL 10 target inflammation, downregulating key inflammatory cytokines to create a more environment for mineralization and effective bone healing. image
C1 [Wiesli, Matthias Guido; Huber, Matthias Werner; Maniura Weber, Katharina; Rottmar, Markus; Lackington, William Arthur] Empa Swiss Fed Labs Mat Sci & Technol, Lab Biointerfaces, CH 9014 St Gallen, Switzerland.
   [Weisse, Bernhard] Empa, Lab Mech Syst Engn, CH 8600 Dubendorf, Switzerland.
   [Zboray, Robert] Empa, Ctr Xray Analyt, CH 8600 Dubendorf, Switzerland.
   [Kiderlen, Stefanie] Prospect Instruments, A 6850 Dornbirn, Austria.
   [Gonzalez Vazquez, Arlyng] Univ Med & Hlth Sci, Royal Coll Surg Ireland, Tissue Engn Res Grp, Dublin, Ireland.
C3 Swiss Federal Institutes of Technology Domain; Swiss Federal
   Laboratories for Materials Science & Technology (EMPA); Swiss Federal
   Institutes of Technology Domain; Swiss Federal Laboratories for
   Materials Science & Technology (EMPA); Swiss Federal Institutes of
   Technology Domain; Swiss Federal Laboratories for Materials Science &
   Technology (EMPA); Royal College of Surgeons   Ireland
RP Rottmar, M; Lackington, WA (通讯作者)，Empa Swiss Fed Labs Mat Sci & Technol, Lab Biointerfaces, CH 9014 St Gallen, Switzerland.
EM markus.rottmar@empa.ch; william.lackington@empa.ch
RI Maniura, Katharina/N 2955 2016; Rottmar, Markus/K 1235 2017; Zboray,
   Robert/GWC 5612 2022; Vazquez, Arlyng/G 9653 2012; Lackington,
   William/ITU 7718 2023
OI Maniura, Katharina/0000 0001 7895 3563; Wiesli,
   Matthias/0000 0002 7422 5777; Weisse, Bernhard/0000 0002 5267 5777;
   Zboray, Robert/0000 0003 0811 7396
FU ON/ORS Kick Starter Grant [21 351]
FX The authors would like to thank ON/ORS Kick Starter Grant (#21 351) and
   Empa   Swiss Federal Laboratories for Materials Science and Technology,
   for funding. Stefanie Guimond and Yvonne Elbs Glatz are particularly
   thanked for supporting the lab work. The authors would also like to
   thank Lukas Krainer for providing resources to facilitate the
   multiphoton microscopy analysis.
CR Abbasi N, 2020, J SCI ADV MATER DEV, V5, P1, DOI 10.1016/j.jsamd.2020.01.007
   Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   Arthur A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249759
   Berner A, 2015, STEM CELL TRANSL MED, V4, P503, DOI 10.5966/sctm.2014 0244
   Bhan I, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/561214
   Bian Q, 2023, J MATER CHEM B, V11, P3713, DOI 10.1039/d3tb00332a
   BIRCH MA, 1993, J BONE MINER RES, V8, P1155
   Blair HC, 2016, LAB INVEST, V96, P763, DOI 10.1038/labinvest.2016.51
   Boda R, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24087562
   Cabezas MD, 2019, ACS NANO, V13, P11144, DOI 10.1021/acsnano.9b03937
   Caliari SR, 2014, ADV HEALTHC MATER, V3, P1086, DOI 10.1002/adhm.201300646
   Camarero Espinosa S, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202101415
   Capulli M, 2018, J BONE MINER RES, V33, P1141, DOI 10.1002/jbmr.3406
   Castaño IM, 2016, SCI REP UK, V6, DOI 10.1038/srep27941
   Chen X, 2022, BIOSURF BIOTRIBOL, V8, P1, DOI 10.1049/bsb2.12029
   Cheng A, 2019, J ORTHOP RES, V37, P299, DOI 10.1002/jor.24186
   Cheng M, 2018, INT J CLIN EXP PATHO, V11, P1610
   Chimutengwende Gordon M, 2017, INJURY, V48, P206, DOI 10.1016/j.injury.2013.11.022
   Clayton SW, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 78206 4
   Cunniffe GM, 2010, J MATER SCI MATER M, V21, P2293, DOI 10.1007/s10856 009 3964 1
   Currie HN, 2014, CYTOKINE, V66, P112, DOI 10.1016/j.cyto.2014.01.001
   Curtin C, 2018, ACTA BIOMATER, V70, P84, DOI 10.1016/j.actbio.2018.02.004
   Curtin CM, 2015, ADV HEALTHC MATER, V4, P223, DOI 10.1002/adhm.201400397
   Curtin CM, 2012, ADV MATER, V24, P749, DOI 10.1002/adma.201103828
   de Wildt BWM, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202206992
   Dewey MJ, 2020, RSC ADV, V10, P15629, DOI [10.1039/D0RA01336F, 10.1039/d0ra01336f]
   Dresner Pollak R, 2004, GASTROENTEROLOGY, V127, P792, DOI 10.1053/j.gastro.2004.06.013
   Ehnert S, 2021, WORLD J STEM CELLS, V13, P1667, DOI 10.4252/wjsc.v13.i11.1667
   Ehrbar M, 2011, BIOPHYS J, V100, P284, DOI 10.1016/j.bpj.2010.11.082
   Evans JC, 2017, MOL PHARMACEUT, V14, P42, DOI 10.1021/acs.molpharmaceut.6b00646
   Gillman CE, 2021, MAT SCI ENG C MATER, V130, DOI 10.1016/j.msec.2021.112466
   Gleeson JP, 2010, EUR CELLS MATER, V20, P218
   Gong TJ, 2023, INT ORTHOP, V47, P631, DOI 10.1007/s00264 022 05684 8
   Guo HL, 2020, SOFT MATTER, V16, P1897, DOI 10.1039/c9sm01999e
   Haugh MG, 2010, TISSUE ENG PART C ME, V16, P887, DOI 10.1089/ten.TEC.2009.0422
   Horst K, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/126060
   Isenberg JS, 2008, BLOOD, V111, P613, DOI 10.1182/blood 2007 06 098392
   Kaneider NC, 2010, THROMB J, V8, DOI 10.1186/1477 9560 8 2
   Kitaura H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145169
   Kolar P, 2010, TISSUE ENG PART B RE, V16, P427, DOI [10.1089/ten.teb.2009.0687, 10.1089/ten.TEB.2009.0687]
   Kolar P, 2011, CLIN ORTHOP RELAT R, V469, P3118, DOI 10.1007/s11999 011 1865 3
   Kopf BS, 2015, ACTA BIOMATER, V19, P180, DOI 10.1016/j.actbio.2015.03.022
   Kostov K, 2022, BIOENGINEERING BASEL, V9, DOI 10.3390/bioengineering9030119
   Kowalska MA, 2010, THROMB RES, V125, P292, DOI 10.1016/j.thromres.2009.11.023
   Lackington WA, 2022, ACTA BIOMATER, V149, P189, DOI 10.1016/j.actbio.2022.07.012
   Lackington WA, 2022, MATER TODAY BIO, V15, DOI 10.1016/j.mtbio.2022.100303
   Lackington WA, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.582012
   Lackington WA, 2019, J CONTROL RELEASE, V304, P51, DOI 10.1016/j.jconrel.2019.05.001
   Laronha H, 2020, CELLS BASEL, V9, DOI 10.3390/cells9051076
   Lee K. B., 1985, J ORTHOP RES, V30, P2012
   Li W, 2023, ANIM MODEL EXP MED, V6, P573, DOI 10.1002/ame2.12342
   Ligorio C, 2023, NAT REV BIOENG, V1, P518, DOI 10.1038/s44222 023 00055 3
   Lishko VK, 2004, J BIOL CHEM, V279, P44897, DOI 10.1074/jbc.M408012200
   Litvinov R. I., 2017, MATRIX BIOL, V110, P60
   Liu Y, 2023, ACTA BIOMATER, V162, P164, DOI 10.1016/j.actbio.2023.03.028
   Lund SA, 2009, J CELL COMMUN SIGNAL, V3, P311, DOI 10.1007/s12079 009 0068 0
   Lyons FG, 2014, CLIN ORTHOP RELAT R, V472, P1318, DOI 10.1007/s11999 013 3438 0
   Maitz MF, 2019, ACTA BIOMATER, V94, P33, DOI 10.1016/j.actbio.2019.06.019
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Mericli AF, 2023, PLAST RECONSTR SURG, V151, P885, DOI 10.1097/PRS.0000000000010014
   Mondino A, 2004, TRENDS IMMUNOL, V25, P450, DOI 10.1016/j.it.2004.06.004
   Noori A, 2017, INT J NANOMED, V12, P4937, DOI 10.2147/IJN.S124671
   O'Brien Fergal J., 2011, Materials Today, V14, P88, DOI 10.1016/S1369 7021(11)70058 X
   O'Brien FJ, 2005, BIOMATERIALS, V26, P433, DOI 10.1016/j.biomaterials.2004.02.052
   O'Brien FJ, 2004, BIOMATERIALS, V25, P1077, DOI 10.1016/S0142 9612(03)00630 6
   O'Leary C, 2016, BIOMATERIALS, V85, P111, DOI 10.1016/j.biomaterials.2016.01.065
   Park SH, 2002, J ORTHOP RES, V20, P1197, DOI 10.1016/S0736 0266(02)00072 4
   Patel T, 2023, CHEMISTRYSELECT, V8, DOI 10.1002/slct.202302206
   Pfeiffenberger M, 2020, ALTEX ALTERN ANIM EX, V37, P561, DOI 10.14573/altex.1910211
   Procaccini C, 2012, MOL ASPECTS MED, V33, P35, DOI 10.1016/j.mam.2011.10.012
   Quinlan E, 2017, J TISSUE ENG REGEN M, V11, P1097, DOI 10.1002/term.2013
   Quinlan E, 2015, J CONTROL RELEASE, V207, P112, DOI 10.1016/j.jconrel.2015.03.028
   Reinke S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004754
   Rocher C, 2012, CAN J PHYSIOL PHARM, V90, P947, DOI [10.1139/Y2012 102, 10.1139/y2012 102]
   Rogers GF, 2012, J CRANIOFAC SURG, V23, P323, DOI 10.1097/SCS.0b013e318241dcba
   Roth A, 2014, ADV DRUG DELIVER REV, V69, P179, DOI 10.1016/j.addr.2013.12.005
   Sadowska JM, 2024, ADV MATER, V36, DOI 10.1002/adma.202307639
   Sapudom J, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536 021 00193 5
   Schell H, 2017, J Exp Orthop, V4, P5, DOI 10.1186/s40634 017 0079 3
   Schmidt Bleek K, 2016, J AM ACAD ORTHOP SUR, V24, pE134, DOI 10.5435/JAAOS D 16 00513
   Shanley LC, 2023, ACTA BIOMATER, V160, P311, DOI 10.1016/j.actbio.2023.01.058
   Sheen JR, 2023, Fracture healing overview
   Shimoide T, 2018, ENDOCRINOLOGY, V159, P1875, DOI 10.1210/en.2018 00085
   Shouval DS, 2014, ADV IMMUNOL, V122, P177, DOI 10.1016/B978 0 12 800267 4.00005 5
   Sin MC, 2015, INT J POLYM MATER PO, V64, P865, DOI 10.1080/00914037.2015.1030657
   Singla DK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147897
   Sun YY, 2021, BIOMATERIALS, V274, DOI 10.1016/j.biomaterials.2021.120828
   TAICHMAN RS, 1992, INFLAMMATION, V16, P587, DOI 10.1007/BF00919342
   Takahashi T, 2011, CELL TISSUE RES, V344, P321, DOI 10.1007/s00441 011 1154 1
   Territo M., 1976, IMMUNOBIOLOGY MACROP, P593, DOI DOI 10.1016/B978 0 12 514550 3.50029 3
   Tripathi S, 2021, 3 BIOTECH, V11, DOI 10.1007/s13205 020 02567 w
   van de Wouw J, 2022, CLIN KIDNEY J, V15, P624, DOI 10.1093/ckj/sfab194
   Vellekamp G., 1998, G VELLEKAMP
   Wang X, 2016, SCI REP UK, V6, DOI 10.1038/srep35645
   Wang Y, 2023, INT J BIOL MACROMOL, V232, DOI 10.1016/j.ijbiomac.2023.123330
   Wang ZH, 2014, BIOMATERIALS, V35, P5700, DOI 10.1016/j.biomaterials.2014.03.078
   Wolberg AS, 2007, BLOOD REV, V21, P131, DOI 10.1016/j.blre.2006.11.001
   Woloszyk A, 2023, BIOMATER ADV, V148, DOI 10.1016/j.bioadv.2023.213366
   Woloszyk A, 2022, BIOMATER ADV, V139, DOI 10.1016/j.bioadv.2022.213027
   Xiong Y, 2020, J CELL MOL MED, V24, P1076, DOI 10.1111/jcmm.14832
   Yi HX, 2022, CELL TRANSPLANT, V31, DOI 10.1177/09636897211051743
NR 101
TC 3
Z9 3
U1 6
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2192 2640
EI 2192 2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD FEB
PY 2025
VL 14
IS 5
SI SI
DI 10.1002/adhm.202400077
EA APR 2024
PG 16
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics; Materials Science
GA Y8T0F
UT WOS:001202777800001
PM 38599586
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Peng, MZ
   Qiang, L
   Xu, Y
   Li, CD
   Li, T
   Wang, JW
AF Peng, Mingzheng
   Qiang, Lei
   Xu, Yan
   Li, Cuidi
   Li, Tao
   Wang, Jinwu
TI Inhibition of JNK and activation of the AMPK Nrf2 axis by corosolic acid
   suppress osteolysis and oxidative stress
SO NITRIC OXIDE BIOLOGY AND CHEMISTRY
LA English
DT Article
DE Corosolic acid; AMPK; Osteoclastogenesis; Nrf2; Reactive oxygen species
ID NF KAPPA B; ESTROGEN RECEPTOR MODULATORS; OSTEOCLAST DIFFERENTIATION;
   INSULIN RESISTANCE; DRUG TARGETS; IN VIVO; EXPRESSION; OSTEOPOROSIS;
   APOPTOSIS; CELL
AB The intracellular reactive oxygen species contribute to RANKL induced osteoclastogenesis and osteolysis. Nuclear factor erythroid 2 related factor 2 (Nrf2), a redox sensitive transcription factor, is critical in the cellular defense against oxidative stress by induction of antioxidants and cytoprotective enzymes. In the current study, it was first demonstrated that RANKL induced osteoclastogenesis and hydroxylapatite resorption were suppressed by Corosolic acid (CA) via inhibiting p JNK and activating p AMPK. Meanwhile, p 65, p 38, Akt, and GSK 3 beta were partly inhibited during the treatment of CA. Osteoclastogenesis related genes, including NFATc1, c fos, cathepsin K, and CTR were down regulated by CA as well. Furthermore, the intracellular oxidative stress of CA treated osteoclasts was dramatically decreased and Nrf2 was translocated into the nucleus to activate antioxidants including HO 1, NQO 1, and GCLC by CA. The LPS induced mice calvarial osteolysis model was established for the in vivo investigation. Micro CT morphometric analysis revealed that the treatment of CA restored LPS induced bone loss and formation of osteoclasts. Besides, p p65 and p JNK were activated in the LPS group but inhibited by CA in vivo. The treatment of CA also activated p AMPK during its attenuating LPS induced osteolysis. Conclusively, CA effectively protects against LPS induced osteolysis by suppressing osteoclastogenesis and oxidative stress through the inhibition of the JNK and activation of the AMPK Nrf2 axis.
C1 [Peng, Mingzheng; Li, Tao; Wang, Jinwu] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Orthopaed Surg,Shanghai Key Lab Orthopaed Im, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Qiang, Lei; Xu, Yan] Southwest Jiaotong Univ, Coll Med, 111 North Sect,2nd Ring Rd, Chengdu 610031, Sichuan, Peoples R China.
   [Li, Cuidi] Shanghai Jiao Tong Univ, Sch Biomed Engn, Med X Res Inst, 1804 Huashan Rd, Shanghai 200030, Peoples R China.
C3 Shanghai Jiao Tong University; Southwest Jiaotong University; Shanghai
   Jiao Tong University
RP Wang, JW (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Orthopaed Surg,Shanghai Key Lab Orthopaed Im, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM Jinwu_wang@163.com
RI ; Wang, Jinwu/AAG 4431 2021
OI Li, Cuidi/0000 0002 8201 1322; Wang, Jinwu/0000 0003 1411 057X
FU National Natural Science Foundation of China [81772326]; National Key
   R&D Program of China [2018YFB1105600]
FX The study was supported by National Natural Science Foundation of China
   (Grant No. 81772326) and National Key R&D Program of China
   (2018YFB1105600). We appreciate the kind support and help from the whole
   staff of Shanghai Key Laboratory of Orthopaedic Implants.
CR Ahn KS, 1998, PLANTA MED, V64, P468, DOI 10.1055/s 2006 957487
   Bagheri M, 2017, BBA MOL CELL RES, V1864, P177, DOI 10.1016/j.bbamcr.2016.11.008
   Balakrishnan A, 2016, PAK J PHARM SCI, V29, P1133
   Brunetti G, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00354
   Chakraborty C, 2013, CURR DRUG TARGETS, V14, P1707, DOI 10.2174/13894501113146660233
   Chen X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00647
   Dallas SL, 2012, METHODS MOL BIOL, V816, P425, DOI 10.1007/978 1 61779 415 5_26
   Deal C, 2009, NAT CLIN PRACT RHEUM, V5, P20, DOI 10.1038/ncprheum0977
   Dharmapatni A., 2017, INFLAMMATION
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891 5849(91)90192 6
   Guo XL, 2016, EUR J PHARMACOL, V791, P578, DOI 10.1016/j.ejphar.2016.09.031
   Hasan MK, 2018, ENDOCRINOLOGY, V159, P1416, DOI 10.1210/en.2018 00126
   Hong SE, 2017, FREE RADICAL BIO MED, V112, P191, DOI 10.1016/j.freeradbiomed.2017.07.030
   Hsiao FY, 2017, JPN J CLIN ONCOL, V47, P935, DOI 10.1093/jjco/hyx111
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Ito K, 2001, J BIOL CHEM, V276, P30208, DOI 10.1074/jbc.M103604200
   Jin J, 2014, FOOD CHEM TOXICOL, V73, P95, DOI 10.1016/j.fct.2014.08.009
   Kanzaki H, 2016, REDOX BIOL, V8, P186, DOI 10.1016/j.redox.2016.01.006
   Kanzaki H, 2014, FREE RADICAL BIO MED, V77, P239, DOI 10.1016/j.freeradbiomed.2014.09.006
   Kanzaki H, 2013, J BIOL CHEM, V288, P23009, DOI 10.1074/jbc.M113.478545
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Kim H, 2017, J BONE MINER RES, V32, P397, DOI 10.1002/jbmr.2974
   Kim SJ, 2016, BMB REP, V49, P276, DOI 10.5483/BMBRep.2016.49.5.241
   Kumar A, 2018, REDOX BIOL, V15, P192, DOI 10.1016/j.redox.2017.12.005
   Kumar R, 2018, MOL CARCINOGEN, V57, P57, DOI 10.1002/mc.22731
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Leung AD, 2018, CURR DRUG TARGETS, V19, P1233, DOI 10.2174/1389450118666170925155044
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li XQ, 2016, SCI REP UK, V6, DOI 10.1038/srep26854
   Li Y, 2016, ANTIOXID REDOX SIGN, V24, P893, DOI 10.1089/ars.2015.6479
   Matthews BG, 2017, BONE, V103, P1, DOI 10.1016/j.bone.2017.06.004
   Nishimura K, 2016, FREE RADICAL BIO MED, V97, P330, DOI 10.1016/j.freeradbiomed.2016.06.021
   Oloyede HOB, 2017, MICROB PATHOGENESIS, V111, P338, DOI 10.1016/j.micpath.2017.08.012
   Pellegrini GG, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070423
   Stadler K, 2008, AM J PHYSIOL ENDOC M, V295, pE456, DOI 10.1152/ajpendo.00015.2008
   Thummuri D, 2017, J MOL MED, V95, P1065, DOI 10.1007/s00109 017 1553 1
   Wakabayashi N, 2010, ANTIOXID REDOX SIGN, V13, P1649, DOI 10.1089/ars.2010.3216
   Wang CD, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00407
   Wells PG, 2009, TOXICOL SCI, V108, P4, DOI 10.1093/toxsci/kfn263
   Wu HB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0540 y
   Xu BB, 2017, J DIABETES COMPLICAT, V31, P773, DOI 10.1016/j.jdiacomp.2016.12.010
   Xu YF, 2009, CANCER LETT, V284, P229, DOI 10.1016/j.canlet.2009.04.028
   Yang J, 2016, PHYTOMEDICINE, V23, P181, DOI 10.1016/j.phymed.2015.12.018
   Zeng XZ, 2016, ACTA PHARMACOL SIN, V37, P255, DOI 10.1038/aps.2015.85
   Zhao WJ, 2016, CELL SIGNAL, V28, P1401, DOI 10.1016/j.cellsig.2016.06.018
   Zhou W, 2017, CELL PHYSIOL BIOCHEM, V43, P331, DOI 10.1159/000480413
   Zhou XH, 2018, BBA MOL BASIS DIS, V1864, P488, DOI 10.1016/j.bbadis.2017.11.009
NR 47
TC 27
Z9 29
U1 0
U2 29
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 1089 8603
EI 1089 8611
J9 NITRIC OXIDE BIOL CH
JI Nitric Oxide Biol. Chem.
PD JAN 1
PY 2019
VL 82
BP 12
EP 24
DI 10.1016/j.niox.2018.11.002
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA HI1SN
UT WOS:000456225400002
PM 30453049
DA 2025 08 17
ER

PT J
AU Attar, BM
   Razavi, SM
   Daneshmand, M
   Davoudi, A
AF Attar, B. Movahedian
   Razavi, S. M.
   Daneshmand, M.
   Davoudi, A.
TI Protective effects of resveratrol against osteonecrosis at the
   extraction site in bisphosphonate treated rats
SO INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
DE antioxidant; bisphosphonate; BRONJ; resveratrol
ID ZOLEDRONIC ACID; DNA DAMAGE; BONE; MECHANISMS; PREVENTION; ANGIOGENESIS;
   ALENDRONATE; GROWTH; JAWS
AB Resveratrol (RSV) is a phytoestrogen with a wide range of therapeutic effects, including antioxidant and anti inflammatory effects. This study was performed to evaluate the protective role of RSV against osteonecrosis after tooth extraction in rats treated with bisphosphonates. Thirty nine male Wistar rats, weighing 300 350 g, were divided into three groups (n = 13) according to the planned drug regimen: alendronate + dexamethasone (AL/DEX), alendronate + dexamethasone + RSV (AL/DEX/RSV), and no drugs (control group). The first and second molars of each rat were extracted and the extraction sites were analysed histologically 14 days later. The data collected were subjected to statistical analysis by means of Kruskal Wallis, Mann Whitney, chi(2), and Fisher's exact tests using IBM SPSS software at a significance level of 0.05. The incidence of osteonecrosis was significantly lower in the AL/DEX/RSV group (P = 0.001) and control group (P = 0.041) than in the AL/DEX group, while the amount of new bone formation did not differ significantly between the AL/DEX/RSV and AL/DEX groups (P > 0.05). RSV showed a protective effect by significantly reducing osteonecrosis, which could be due to its antioxidant effects.
C1 [Attar, B. Movahedian] Isfahan Univ Med Sci, Dent Res Ctr, Dent Res Inst, Dept Oral & Maxillofacial Surg, Esfahan, Iran.
   [Razavi, S. M.] Isfahan Univ Med Sci, Dent Res Ctr, Dent Res Inst, Dept Oral & Maxillofacial Pathol, Esfahan, Iran.
   [Daneshmand, M.] Shahrekord Univ Med Sci, Dent Sch, Dept Oral & Maxillofacial Surg, Shahrekord, Iran.
   [Davoudi, A.] Isfahan Univ Med Sci, Dent Sch, Dept Prosthodont, Esfahan, Iran.
C3 Isfahan University of Medical Sciences; Isfahan University of Medical
   Sciences; Shahrekord University Medical Sciences; Isfahan University of
   Medical Sciences
RP Daneshmand, M (通讯作者)，Isfahan Univ Med Sci, Sch Dent, Hezarjarib St, Esfahan, Iran.
EM b_movahedian@dnt.mui.ac.ir; razavi@dnt.mui.ac.ir;
   mehrandaneshmand66@gmail.com; Amindvi@yahoo.com
RI Davoudi, Amin/AAH 9848 2021; Daneshmand, Mehran/AAK 3689 2020
CR Abtahi J, 2012, J ORAL PATHOL MED, V41, P494, DOI 10.1111/j.1600 0714.2011.01125.x
   Aeinehchi M, 2003, INT ENDOD J, V36, P225, DOI 10.1046/j.1365 2591.2003.00652.x
   Aguirre JI, 2010, ORAL DIS, V16, P674, DOI 10.1111/j.1601 0825.2010.01677.x
   Ahmed T, 2017, MOL NEUROBIOL, V54, P2622, DOI 10.1007/s12035 016 9839 9
   de la Lastral CA, 2007, BIOCHEM SOC T, V35, P1156, DOI 10.1042/BST0351156
   Altundal H, 2004, INT J ORAL MAX SURG, V33, P286, DOI 10.1006/ijom.2002.0472
   Bhattarai G, 2016, ACTA BIOMATER, V29, P398, DOI 10.1016/j.actbio.2015.10.031
   Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008 5472.CAN 05 0651
   Brasnyó P, 2011, BRIT J NUTR, V106, P383, DOI 10.1017/S0007114511000316
   Chen Y, 2007, IN VIVO, V21, P365
   Chiang SS, 2013, APPL MICROBIOL BIOT, V97, P1489, DOI 10.1007/s00253 012 4675 y
   Cozin M, 2011, J ORAL MAXIL SURG, V69, P2564, DOI 10.1016/j.joms.2011.03.005
   Csiszar A, 2011, ANN NY ACAD SCI, V1215, P117, DOI 10.1111/j.1749 6632.2010.05848.x
   Fenner M, 2010, J CRANIO MAXILL SURG, V38, P47, DOI 10.1016/j.jcms.2009.07.011
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   FLEISCH H, 1987, BONE, V8, pS23
   Hikita H, 2009, J BONE MINER METAB, V27, P663, DOI 10.1007/s00774 009 0090 6
   Kim CW, 2016, PHYTOMEDICINE, V23, P1787, DOI 10.1016/j.phymed.2016.10.016
   Landesberg R, 2011, ANN NY ACAD SCI, V1218, P62, DOI 10.1111/j.1749 6632.2010.05835.x
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Migliorati CA, 2005, CANCER, V104, P83, DOI 10.1002/cncr.21130
   Mobasheri A, 2013, ANN NY ACAD SCI, V1290, P59, DOI 10.1111/nyas.12145
   Ohnuki H, 2012, ARCH ORAL BIOL, V57, P906, DOI 10.1016/j.archoralbio.2011.11.015
   Pabst AM, 2012, CLIN ORAL INVEST, V16, P87, DOI 10.1007/s00784 010 0507 6
   Sener G, 2005, PROSTAG LEUKOTR ESS, V72, P1, DOI 10.1016/j.plefa.2004.04.005
   Shahi S, 2010, J ENDODONT, V36, P899, DOI 10.1016/j.joen.2010.01.001
   Sonis ST, 2009, ORAL ONCOL, V45, P164, DOI 10.1016/j.oraloncology.2008.04.013
   Tseng PC, 2011, J BONE MINER RES, V26, P2552, DOI 10.1002/jbmr.460
   Tseng SH, 2004, CLIN CANCER RES, V10, P2190, DOI 10.1158/1078 0432.CCR 03 0105
   Uysal T, 2011, ORTHOD CRANIOFAC RES, V14, P80, DOI 10.1111/j.1601 6343.2011.01511.x
   Varoni EM, 2016, FRONT NUTR, V3, DOI 10.3389/fnut.2016.00008
   Yen GC, 2003, FREE RADICAL RES, V37, P509, DOI 10.1080/1071576031000083099
NR 32
TC 7
Z9 7
U1 4
U2 7
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0901 5027
EI 1399 0020
J9 INT J ORAL MAX SURG
JI Int. J. Oral Maxillofac. Surg.
PD NOV
PY 2020
VL 49
IS 11
BP 1518
EP 1522
DI 10.1016/j.ijom.2020.02.019
PG 5
WC Dentistry, Oral Surgery & Medicine; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Surgery
GA OF9QI
UT WOS:000581532000020
PM 32241581
DA 2025 08 17
ER

PT J
AU de Almeida, AS
   Rigo, FK
   De Prá, SDT
   Milioli, AM
   Dalenogare, DP
   Pereira, GC
   Ritter, CD
   Peres, DS
   Antoniazzi, CTD
   Stein, C
   Moresco, RN
   Oliveira, SM
   Trevisan, G
AF de Almeida, Amanda Spring
   Rigo, Flavia Karine
   De Pra, Samira Dal Toe
   Milioli, Alessandra Marcone
   Dalenogare, Diessica Padilha
   Pereira, Gabriele Cheiran
   Ritter, Camila dos Santos
   Peres, Diulle Spat
   de David Antoniazzi, Caren Tatiane
   Stein, Carolina
   Moresco, Rafael Noal
   Oliveira, Sara Marchesan
   Trevisan, Gabriela
TI Characterization of Cancer Induced Nociception in a Murine Model of
   Breast Carcinoma
SO CELLULAR AND MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Allodynia; Opioids; NSAIDs; Cannabinoid; Bone metastasis; WIN 55; 212 2
ID BONE METASTASIS; PAIN; OSTEOLYSIS
AB Severe and poorly treated pain often accompanies breast cancer. Thus, novel mechanisms involved in breast cancer induced pain should be investigated. Then, it is necessary to characterize animal models that are reliable with the symptoms and progression of the disease as observed in humans. Explaining cancer induced nociception in a murine model of breast carcinoma was the aim of this study. 4T1 (10(4)) lineage cells were inoculated in the right fourth mammary fat pad of female BALB/c mice; after this, mechanical and cold allodynia, or mouse grimace scale (MGS) were observed for 30 days. To determine the presence of bone metastasis, we performed the metastatic clonogenic test and measure calcium serum levels. At 20 days after tumor induction, the antinociceptive effect of analgesics used to relieve pain in cancer patients (acetaminophen, naproxen, codeine or morphine) or a cannabinoid agonist (WIN 55,212 2) was tested. Mice inoculated with 4T1 cells developed mechanical and cold allodynia and increased MGS. Bone metastasis was confirmed using the clonogenic assay, and hypercalcemia was observed 20 days after cells inoculation. All analgesic drugs reduced the mechanical and cold allodynia, while the MGS was decreased only by the administration of naproxen, codeine, or morphine. Also, WIN 55,212 2 improved all nociceptive measures. This pain model could be a reliable form to observe the mechanisms of breast cancer induced pain or to observe the efficacy of novel analgesic compounds.
C1 [de Almeida, Amanda Spring; Dalenogare, Diessica Padilha; Pereira, Gabriele Cheiran; Ritter, Camila dos Santos; Peres, Diulle Spat; de David Antoniazzi, Caren Tatiane; Trevisan, Gabriela] Univ Fed Santa Maria UFSM, Programa Posgrad Farmacol, Ave Roraima 1000,Bldg 21,Room 5207, BR 97105900 Santa Maria, RS, Brazil.
   [Rigo, Flavia Karine; De Pra, Samira Dal Toe; Milioli, Alessandra Marcone; Trevisan, Gabriela] Univ Extremo Sul Catarinense Unesc, Programa Posgrad Ciencias Saude, BR 88006000 Criciuma, SC, Brazil.
   [Stein, Carolina; Moresco, Rafael Noal] Univ Fed Santa Maria UFSM, Programa Posgrad Ciencias Farmaceut, BR 97105900 Santa Maria, RS, Brazil.
   [Oliveira, Sara Marchesan] Univ Fed Santa Maria UFSM, Programa Posgrad Ciencias Biol Bioquim Toxicol, BR 97105900 Santa Maria, RS, Brazil.
C3 Universidade Federal de Santa Maria (UFSM); Universidade do Extremo Sul
   Catarinense; Universidade Federal de Santa Maria (UFSM); Universidade
   Federal de Santa Maria (UFSM)
RP Trevisan, G (通讯作者)，Univ Fed Santa Maria UFSM, Programa Posgrad Farmacol, Ave Roraima 1000,Bldg 21,Room 5207, BR 97105900 Santa Maria, RS, Brazil.; Trevisan, G (通讯作者)，Univ Extremo Sul Catarinense Unesc, Programa Posgrad Ciencias Saude, BR 88006000 Criciuma, SC, Brazil.
EM gabriela.trevisan santos@ufsm.br
RI Trevisan dos Santos, Gabriela/K 8120 2014; Antoniazzi,
   Caren/LFS 6919 2024; Padilha Dalenogare, Diéssica/IUM 5367 2023;
   Trevisan, Gabriela/K 8120 2014; De Prá, Samira/AAW 3183 2021; Moresco,
   Rafael/K 6118 2017
OI Trevisan dos Santos, Gabriela/0000 0003 0137 5034; oliveira,
   sara/0000 0003 2960 5284; Antoniazzi, Caren/0000 0003 4285 8956;
   Moresco, Rafael/0000 0003 3072 5080
FU National Research Council of Brazil (CNPq) [422376/20167]
FX National Research Council of Brazil (CNPq; #422376/20167) supported this
   work.
CR Abdelaziz DM, 2015, BREAST CANCER RES TR, V153, P9, DOI 10.1007/s10549 015 3517 x
   Abdelaziz DM, 2014, BREAST CANCER RES TR, V143, P227, DOI 10.1007/s10549 013 2799 0
   Adler D, 2018, ORTHOPADE, V47, P594, DOI 10.1007/s00132 018 3540 9
   Akintola Titilola, 2017, Neurobiol Pain, V2, P13, DOI 10.1016/j.ynpai.2017.10.001
   [Anonymous], 2015, MEDIATORS INFLAMM
   [Anonymous], BR J ANAESTH
   [Anonymous], BMJ
   [Anonymous], NEUROSCIENCE
   [Anonymous], BR J PHARM
   [Anonymous], CANC IMMUNOL IMMUNOT
   [Anonymous], LIFE SCI
   [Anonymous], DRUG DES DEV THER
   [Anonymous], PLOS ONE
   [Anonymous], PHARM BIOCH BEHAV
   [Anonymous], INFLAMMATION
   [Anonymous], PHARM BIOCH BEHAV
   [Anonymous], 2016, SCI REP
   [Anonymous], BREAST CANC RES TREA
   [Anonymous], PAIN
   [Anonymous], 1986, Cancer Pain Relief
   [Anonymous], HEALTHCARE
   [Anonymous], CANC SCI
   [Anonymous], NAT MED
   [Anonymous], CLIN EXP METASTASIS
   [Anonymous], PHARM BIOCH BEHAV
   [Anonymous], SPINE J
   [Anonymous], BREAST CANC RES TREA
   [Anonymous], NEUROSCIENCE
   [Anonymous], PAIN
   [Anonymous], CANC GROWTH METASTAS
   [Anonymous], INT J EXP PATHOL
   [Anonymous], PAIN THER
   Bednarz Knoll N, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2940
   Bokhari F, 2009, PAIN MANAG NURS, V10, P197, DOI 10.1016/j.pmn.2008.04.002
   Bottos A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12258
   Bouchlaka MN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048049
   Carlesimo B, 2009, G CHIR, V30, P487
   Cintolo Gonzalez JA, 2017, BREAST CANCER RES TR, V164, P263, DOI 10.1007/s10549 017 4247 z
   Cox TR, 2015, NATURE, V522, P106, DOI 10.1038/nature14492
   Currie GL, 2014, CURR PAIN HEADACHE R, V18, DOI 10.1007/s11916 014 0423 6
   Derry S, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012332.pub2
   DeSantis C, 2014, CA CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203
   Doré Savard L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013774
   Falk S, 2013, ANTICANCER RES, V33, P1963
   Goblirsch MJ, 2005, J CELL BIOCHEM, V96, P682, DOI 10.1002/jcb.20589
   Goddard ET, 2016, JOVE J VIS EXP, DOI 10.3791/54903
   Herzberg U, 1997, NEUROSCI LETT, V221, P157, DOI 10.1016/S0304 3940(96)13308 5
   Hiasa M, 2017, CANCER RES, V77, P1283, DOI 10.1158/0008 5472.CAN 15 3545
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Langford DJ, 2010, NAT METHODS, V7, P447, DOI [10.1038/NMETH.1455, 10.1038/nmeth.1455]
   Leach MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035656
   Lipton A, 2011, BONE, V48, P96, DOI 10.1016/j.bone.2010.10.161
   Lozano Ondoua AN, 2013, J BONE MINER RES, V28, P92, DOI 10.1002/jbmr.1732
   Lozano Ondoua AN, 2010, LIFE SCI, V86, P646, DOI 10.1016/j.lfs.2010.02.014
   Luo KW, 2015, ONCOL REP, V34, P477, DOI 10.3892/or.2015.4001
   Mall C, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1075114
   Mantyh P, 2013, PAIN, V154, pS54, DOI 10.1016/j.pain.2013.07.044
   Mantyh PW, 2002, NAT REV CANCER, V2, P201, DOI 10.1038/nrc747
   Matsumiya LC, 2012, J AM ASSOC LAB ANIM, V51, P42
   Millner AJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141606
   Monty A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055627
   Pereira JX, 2016, BMC CANCER, V16, DOI 10.1186/s12885 016 2679 1
   Peuckmann V, 2009, EUR J PAIN, V13, P478, DOI 10.1016/j.ejpain.2008.05.015
   Plante GE, 2010, METABOLISM, V59, pS47, DOI 10.1016/j.metabol.2010.07.010
   Pulaski B.A., 2001, CURR PROTOC IMMUNOL
   Raskovic A, 2015, EUR REV MED PHARMACO, V19, P165
   Satija A, 2014, INDIAN J MED RES, V139, P216
   Schwei MJ, 1999, J NEUROSCI, V19, P10886, DOI 10.1523/JNEUROSCI.19 24 10886.1999
   Shenoy PA, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00286
   Slosky LM, 2016, PAIN, V157, P2605, DOI 10.1097/j.pain.0000000000000681
   Swarm Robert, 2007, J Natl Compr Canc Netw, V5, P726
   Trevisan G, 2013, CANCER RES, V73, P3120, DOI 10.1158/0008 5472.CAN 12 4370
   Trevisan G, 2012, J PHARMACOL EXP THER, V343, P258, DOI 10.1124/jpet.112.195909
   Uhelski ML, 2013, NEUROSCIENCE, V247, P84, DOI 10.1016/j.neuroscience.2013.05.003
   Vanderah TW, 2000, J NEUROSCI, V20, P7074, DOI 10.1523/JNEUROSCI.20 18 07074.2000
   Withana NP, 2012, CANCER RES, V72, P1199, DOI 10.1158/0008 5472.CAN 11 2759
   Wright LE, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.31
   Yue GGL, 2018, CHIN MED UK, V13, DOI 10.1186/s13020 018 0222 9
   Zhu XC, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S87568
NR 79
TC 14
Z9 14
U1 0
U2 11
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0272 4340
EI 1573 6830
J9 CELL MOL NEUROBIOL
JI Cell. Mol. Neurobiol.
PD JUL
PY 2019
VL 39
IS 5
BP 605
EP 617
DI 10.1007/s10571 019 00666 8
PG 13
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA HZ7KQ
UT WOS:000469033100004
PM 30850915
OA Bronze
DA 2025 08 17
ER

PT J
AU Steckling, FM
   Lima, FD
   Farinha, JB
   Rosa, PC
   Royes, LFF
   Cuevas, MJ
   Bresciani, G
   Soares, FA
   González Gallego, J
   Barcelos, RP
AF Steckling, Flavia M.
   Lima, Frederico D.
   Farinha, Juliano B.
   Rosa, Pamela Carvalho
   Royes, Luiz Fernando Freire
   Cuevas, Maria J.
   Bresciani, Guilherme
   Soares, Felix Alexandre
   Gonzalez Gallego, Javier
   Barcelos, Romulo P.
TI Diclofenac attenuates inflammation through TLR4 pathway and improves
   exercise performance after exhaustive swimming
SO SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS
LA English
DT Article
DE exhaustive swimming; inflammation; nonsteroidal anti inflammatory drugs;
   TLR4 pathway
ID HUMAN SKELETAL MUSCLE; KAPPA B; RESISTANCE EXERCISE; ENDURANCE EXERCISE;
   OXIDATIVE STRESS; LIVER INJURY; REDOX STATUS; TIME; ADAPTATIONS;
   IBUPROFEN
AB Background The use of NSAIDs has become a common practice to counteract the pro inflammatory acute effects of exercise, in order to improve sports performance. The liver, due to its central role in energy metabolism, may be involved primarily in the process of ROS generation and consequently inflammation after exhaustive exercise. Objective To analyze the influence of diclofenac on the liver TLR4 pathway and time to exhaustion in rats submitted to repeated exhaustive swimming. Methods An exhaustive test was performed in order to mimic athletes' routine, and inflammatory status and oxidative stress markers were evaluated in the liver. Animals were divided into sedentary and exhaustion groups, with this last performing three exhaustive swimming bouts. At the same time, diclofenac or saline was pre administered once a day for nine days. Results Data showed significantly increased COX 2, TLR4, and MyD88 protein content in the liver after exhaustive swimming bouts. The levels of pro inflammatory cytokines also increased after exhaustive exercise, while these effects were attenuated in the group treated with diclofenac plus exhaustive swimming bouts. The anti inflammatory modulation provoked by diclofenac treatment was associated with an increased time to exhaustion in the exercise bouts. The exhaustive exercise increased TBARS formation, but diclofenac treatment blunted this elevation, while GSH/GSSG ratios in both exhaustion saline and exhaustion diclofenac treated groups were lower than in the sedentary saline group. Conclusions Our findings suggest that diclofenac may improve exercise performance and represent an effective tool to ameliorate the pro inflammatory status in liver when associated with exhaustive exercise, and the liver may be a possible therapeutic target.
C1 [Steckling, Flavia M.; Rosa, Pamela Carvalho; Soares, Felix Alexandre; Barcelos, Romulo P.] Univ Fed Santa Maria, CCNE, Programa Posgrad Bioquim Toxicol, Santa Maria, RS, Brazil.
   [Lima, Frederico D.; Royes, Luiz Fernando Freire] Univ Fed Santa Maria, Dept Metodos & Tecn Desport, Ctr Educ Fis & Desportos, Santa Maria, RS, Brazil.
   [Farinha, Juliano B.] Univ Fed Rio Grande do Sul, Escola Educ Fis Fisioterapia & Danca, Programa Posgrad Ciencias Movimento Humano, Santa Maria, RS, Brazil.
   [Cuevas, Maria J.; Gonzalez Gallego, Javier] Univ Leon, Inst Biomed IBIOMED, Leon, Spain.
   [Cuevas, Maria J.; Gonzalez Gallego, Javier] Univ Leon, Ctr Invest Biomed Red CIBERehd, Leon, Spain.
   [Bresciani, Guilherme] Pontificia Univ Catolica Valparaiso, Escuela Educ Fis, Grp Invest Rendimiento Fis & Salud IRyS, Valparaiso, Chile.
   [Barcelos, Romulo P.] Univ Passo Fundo, Programa Posgrad Bioexpt, Passo Fundo, RS, Brazil.
C3 Universidade Federal de Santa Maria (UFSM); Universidade Federal de
   Santa Maria (UFSM); Universidade Federal do Rio Grande do Sul;
   Universidad de Leon; CIBER   Centro de Investigacion Biomedica en Red;
   CIBEREHD; Universidad de Leon; Pontificia Universidad Catolica de
   Valparaiso; Universidade de Passo Fundo
RP Barcelos, RP (通讯作者)，Univ Passo Fundo, Programa Posgrad Med Vet, Inst Ciencias Biol, 285 Sao Jose, BR 99052900 Passo Fundo, RS, Brazil.
EM romulo1604@hotmail.com
RI ; Barcelos, Rômulo/J 8231 2015; Soares, Félix/AAE 6251 2020; Soares,
   Felix/K 7611 2012; Bresciani, Guilherme/M 6805 2014; Barcelos,
   Romulo/J 8231 2015; Farinha, Juliano/HDN 8796 2022; GONZÁLEZ,
   MARÍA/M 4927 2015; Gonzalez Gallego, Javier/D 8219 2012; Lima,
   Frederico/P 8479 2015; royes, luiz/T 3581 2019
OI da Rosa, Pamela Carvalho/0000 0002 4827 7063; Soares,
   Felix/0000 0002 6453 7902; Barcelos, Romulo/0000 0002 6366 6366;
   Gonzalez Gallego, Javier/0000 0002 4386 9342; Bresciani,
   Guilherme/0000 0003 1526 5573; Boufleur Farinha,
   Juliano/0000 0003 4589 256X; Steckling, Flavia/0000 0002 6527 9837; 
FU CAPES/PROEX [23038.005848/2018 31] Funding Source: Medline;
   PRONEM/CNPq/FAPERGS [16/25510000248 7] Funding Source: Medline
CR Ascensao A, 2013, MITOCHONDRION, V13, P862, DOI 10.1016/j.mito.2013.07.002
   Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438
   Barcelos RP, 2017, APPL PHYSIOL NUTR ME, V42, P757, DOI 10.1139/apnm 2016 0593
   Barcelos RP, 2017, FREE RADICAL RES, V51, P222, DOI 10.1080/10715762.2017.1291942
   Bondesen BA, 2006, AM J PHYSIOL CELL PH, V290, pC1651, DOI 10.1152/ajpcell.00518.2005
   Brown WMC, 2015, SPORTS MED OPEN, V1, DOI 10.1186/s40798 015 0032 x
   de Araujo GG, 2007, COMP BIOCHEM PHYS A, V148, P888, DOI 10.1016/j.cbpa.2007.09.002
   Georgakouli K, 2015, EXP THER MED, V10, P2015, DOI 10.3892/etm.2015.2792
   Gleeson M, 2006, EXERC IMMUNOL REV, V12, P34
   Gorski T, 2011, BRIT J SPORT MED, V45, P85, DOI 10.1136/bjsm.2009.062166
   Hörl WH, 2010, PHARMACEUTICALS, V3, P2291, DOI 10.3390/ph3072291
   Huang CC, 2013, MOLECULES, V18, P1741, DOI 10.3390/molecules18021741
   Huang GJ, 2012, EUR J MED CHEM, V48, P371, DOI 10.1016/j.ejmech.2011.12.008
   Ivy JL, 1999, CLIN SPORT MED, V18, P469, DOI 10.1016/S0278 5919(05)70162 9
   Jones TW, 2017, EUR J SPORT SCI, V17, P326, DOI 10.1080/17461391.2016.1236148
   Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002
   Kwon OS, 2015, AM J PHYSIOL ENDOC M, V309, pE11, DOI 10.1152/ajpendo.00124.2015
   LEEUWENBURGH C, 1995, ARCH BIOCHEM BIOPHYS, V316, P941, DOI 10.1006/abbi.1995.1125
   Lima FD, 2016, SCAND J MED SCI SPOR, V26, P1160, DOI 10.1111/sms.12549
   Liu HY, 2018, ONCOTARGET, V9, P2887, DOI [10.18632/oncotarget.20812, 10.18632/oncotarget.23208]
   Lundberg TR, 2018, SCAND J MED SCI SPOR, V28, P2252, DOI 10.1111/sms.13275
   Mazur Bialy AI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040701
   Mikkelsen UR, 2009, J APPL PHYSIOL, V107, P1600, DOI 10.1152/japplphysiol.00707.2009
   Morelli KM, 2018, AM J SPORT MED, V46, P224, DOI 10.1177/0363546517697957
   Nikolaidis MG, 2008, SPORTS MED, V38, P579, DOI 10.2165/00007256 200838070 00005
   Pedersen BK, 2015, SCAND J MED SCI SPOR, V25, P1, DOI 10.1111/sms.12581
   Phillips K, 2013, ARTHRITIS RHEUM US, V65, P291, DOI 10.1002/art.37739
   Barcelos RP, 2016, LIFE SCI, V148, P247, DOI 10.1016/j.lfs.2016.02.006
   Ramm S, 2013, TOXICOLOGY, V312, P83, DOI 10.1016/j.tox.2013.08.002
   Reid N, 2018, OSTEOPOROSIS INT, V29, P1341, DOI 10.1007/s00198 018 4428 6
   Rodriguez Miguelez P, 2014, AGE, V36, DOI 10.1007/s11357 014 9734 0
   Santos Alves E, 2014, EUR J CLIN INVEST, V44, P668, DOI 10.1111/eci.12285
   Schreijenberg M, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1432 5
   Shi FD, 2011, NAT REV IMMUNOL, V11, P658, DOI 10.1038/nri3065
   Sunami Y, 2012, HEPATOLOGY, V56, P1117, DOI 10.1002/hep.25711
   Trappe TA, 2011, AM J PHYSIOL REG I, V300, pR655, DOI 10.1152/ajpregu.00611.2010
   Trefts E, 2015, PROG MOL BIOL TRANSL, V135, P203, DOI 10.1016/bs.pmbts.2015.07.010
   Weinheimer EM, 2007, AM J PHYSIOL REG I, V292, pR2241, DOI 10.1152/ajpregu.00718.2006
   Zbinden Foncea H, 2012, MED SCI SPORT EXER, V44, P1463, DOI 10.1249/MSS.0b013e31824e0d5d
   Ziltener J.  L., 2010, Annals of Physical and Rehabilitation Medicine, V53, P278, DOI 10.1016/j.rehab.2010.03.001
NR 40
TC 14
Z9 16
U1 1
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0905 7188
EI 1600 0838
J9 SCAND J MED SCI SPOR
JI Scand. J. Med. Sci. Sports
PD FEB
PY 2020
VL 30
IS 2
BP 264
EP 271
DI 10.1111/sms.13579
PG 8
WC Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Sport Sciences
GA KE5QG
UT WOS:000508609600006
PM 31618484
DA 2025 08 17
ER

PT J
AU Borden, CP
   Shapiro, CL
   Ramirez, MT
   Kotur, L
   Farrar, W
AF Borden, Charles P.
   Shapiro, Charles L.
   Ramirez, Maria Teresa
   Kotur, Linda
   Farrar, William
TI Quality Improvement in Breast Cancer Project: Compliance With
   Antiresorptive Agents and Changing Patterns of Drug Use
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
AB The Ohio State University Comprehensive Cancer Center James Cancer Hospital and So love Research Institute participated in NCCN's Quality Improvement in Breast Cancer initiative. The Opportunities for Improvement (OH) team elected to improve concordance with the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer recommendation that all patients diagnosed with skeletal metastases receive bisphosphonates. Assembling a multidisciplinary team of clinicians, researchers, and administrative stakeholders, the OH team followed Six Sigma's approach to problem solving known as DMAIC (define, measure, analyze, improve, and control). Baseline concordance was 79%, which was below the recommended target range. Initial analysis quickly revealed that 5 cases were concordant, resulting in a new baseline of 89%. The key root cause identified for the remaining gap was lack of documentation. The solution included education regarding documentation for existing staff, in addition to hard wiring the material into new physician orientation, discussion of all patients with bone disease at tumor board meetings, and improved consistency with use of the new electronic medical record system. After implementation, the reported concordance was 92%, and the lack of documentation problem decreased from 11% in the baseline study to 6%. The team concluded that use of the NCCN Oncology Outcomes Database as an opportunity for clinical quality improvement initiatives not only is possible but also should be an essential element of any clinical program looking to continuously improve.
C1 [Shapiro, Charles L.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
   [Shapiro, Charles L.] Solove Res Inst, Columbus, OH 43210 USA.
C3 James Cancer Hospital & Solove Research Institute; University System of
   Ohio; Ohio State University; James Cancer Hospital & Solove Research
   Institute
RP Shapiro, CL (通讯作者)，Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, 320 West 10th St, Columbus, OH 43210 USA.
EM Charles.shapiro@osumc.edu
NR 0
TC 2
Z9 2
U1 0
U2 5
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540 1405
EI 1540 1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD FEB
PY 2014
VL 12
SU 1
BP S33
EP S35
PG 3
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AC4MI
UT WOS:000332495000010
PM 24614050
DA 2025 08 17
ER

PT J
AU Wei, CB
   Liu, ZF
   Jiang, FF
   Zeng, BH
   Huang, MD
   Yu, DS
AF Wei, Changbo
   Liu, Zifeng
   Jiang, Fangfang
   Zeng, Binghui
   Huang, Mingdi
   Yu, Dongsheng
TI Cellular behaviours of bone marrow derived mesenchymal stem cells
   towards pristine graphene oxide nanosheets
SO CELL PROLIFERATION
LA English
DT Article
ID OSTEOGENIC DIFFERENTIATION; IN VIVO; OSTEOBLAST DIFFERENTIATION;
   GENE EXPRESSION; REGENERATION; CYTOCOMPATIBILITY; CYTOTOXICITY; THERAPY;
   PROTEIN; SURFACE
AB ObjectivesGraphene oxide (GO), the derivative of graphene with unique properties, has attracted much attention for applications in dental implants. The aim of this study was, by two biomimetic cell culture methods, to investigate the quantitative relationship between the concentration of pristine GO nanosheets and their cellular behaviours towards bone marrow derived mesenchymal stem cells (BMSCs).
   Materials and methodsThe cells were firstly characterized according to their morphology, self renewal capabilities and multipotency. Subsequently, adhesion density, proliferation, alkaline phosphatase activity and mineralization of BMSCs treated with various concentrations of GO were analysed. In addition, osteogenic related proteins were measured for further verification of the GO induced osteogenic differentiation.
   ResultsPristine GO nanosheets inhibited the proliferation of BMSCs at a high concentration of 10g/mL during the first 3days with two seeding methods and facilitated proliferation of BMSCs at a low concentration of 0.1g/mL after 5days with a sequential seeding method compared to a co seeding method. Analogously, osteogenic differentiation was promoted when BMSCs were treated with 0.1g/mL of GO. Both the proliferation and differentiation showed concentration dependent behaviour. Interestingly, Wnt/ catenin signalling pathway appeared to be involved in osteogenic differentiation induced by pristine GO nanosheets.
   ConclusionsPristine GO nanosheets at a concentration of 0.1g/mL provide benefits to promote BMSCs proliferation and osteogenesis under a sequential seeding method, contributing to the use of GO for dental implantation.
C1 [Wei, Changbo; Liu, Zifeng; Jiang, Fangfang; Zeng, Binghui; Huang, Mingdi; Yu, Dongsheng] Sun Yat Sen Univ, Hosp Stomatol, Guangdong Prov Key Lab Stomatol, Guanghua Sch Stomatol, Guangzhou 510055, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Yu, DS (通讯作者)，Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Guangzhou 510055, Guangdong, Peoples R China.
EM yudsh@mail.sysu.edu.cn
FU National Natural Science Foundation of China [81472526]; Guangdong
   Science and Technology Project [2016A020216007]; Natural Science
   Foundation of Guangdong Province [2014A030313126]
FX National Natural Science Foundation of China, Grant/Award Number:
   81472526; Guangdong Science and Technology Project, Grant/Award Number:
   2016A020216007; Natural Science Foundation of Guangdong Province,
   Grant/Award Number: 2014A030313126
CR Akhavan O, 2012, J MATER CHEM, V22, P20626, DOI 10.1039/c2jm34330d
   Arioka M, 2013, BIOCHEM BIOPH RES CO, V440, P677, DOI 10.1016/j.bbrc.2013.09.126
   Bortz DR, 2012, MACROMOLECULES, V45, P238, DOI 10.1021/ma201563k
   Chen JQ, 2016, NANOSCALE RES LETT, V11, DOI 10.1186/s11671 016 1288 x
   Dinescu S, 2014, BIO MED MATER ENG, V24, P2249, DOI 10.3233/BME 141037
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   García AJ, 2005, J DENT RES, V84, P407, DOI 10.1177/154405910508400502
   Goiato MC, 2014, J CLIN DIAGN RES, V8, P300, DOI 10.7860/JCDR/2014/8074.4158
   Guo N, 2016, NANOSCALE, V8, P16065, DOI 10.1039/c6nr04607j
   Honda MJ, 2007, BIOMATERIALS, V28, P680, DOI 10.1016/j.biomaterials.2006.09.039
   Hu WB, 2010, ACS NANO, V4, P4317, DOI 10.1021/nn101097v
   Hu Y, 2013, GENET MOL RES, V12, P6527, DOI 10.4238/2013.December.11.4
   La WG, 2014, INT J NANOMED, V9, P107, DOI 10.2147/IJN.S50742
   La WG, 2013, SMALL, V9, DOI 10.1002/smll.201300571
   Lee JY, 2009, INTEGR BIOL, V1, P460, DOI 10.1039/b905757a
   Lee WC, 2011, ACS NANO, V5, P7334, DOI 10.1021/nn202190c
   Li N, 2011, BIOMATERIALS, V32, P9374, DOI 10.1016/j.biomaterials.2011.08.065
   Liu F, 2010, ADV FUNCT MATER, V20, P1930, DOI 10.1002/adfm.201000287
   Liu SB, 2011, ACS NANO, V5, P6971, DOI 10.1021/nn202451x
   Long MW, 2001, BLOOD CELL MOL DIS, V27, P677, DOI 10.1006/bcmd.2001.0431
   Lu JY, 2013, ADV FUNCT MATER, V23, P3494, DOI 10.1002/adfm.201203637
   Luo Y, 2015, ACS APPL MATER INTER, V7, P6331, DOI 10.1021/acsami.5b00862
   Makharza S, 2013, J MATER CHEM B, V1, P6107, DOI 10.1039/c3tb21090a
   Nair M, 2015, NANOTECHNOLOGY, V26, DOI 10.1088/0957 4484/26/16/161001
   Nayak TR, 2011, ACS NANO, V5, P4670, DOI 10.1021/nn200500h
   Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896
   Pan K, 2010, CELL PROLIFERAT, V43, P219, DOI 10.1111/j.1365 2184.2010.00670.x
   Park J, 2015, ACS NANO, V9, P4987, DOI 10.1021/nn507149w
   Park KO, 2016, APPL SPECTROSC REV, V51, P540, DOI 10.1080/05704928.2016.1165687
   Park KH, 2011, J ADV PROSTHODONT, V3, P63
   Park S, 2010, ADV MATER, V22, P1736, DOI 10.1002/adma.200903611
   Park S, 2009, NAT NANOTECHNOL, V4, P217, DOI [10.1038/nnano.2009.58, 10.1038/NNANO.2009.58]
   Peng JM, 2017, MAT SCI ENG C MATER, V71, P10, DOI 10.1016/j.msec.2016.09.070
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rosa V, 2016, DENT MATER, V32, P1019, DOI 10.1016/j.dental.2016.05.008
   Sales VL, 2007, TISSUE ENG, V13, P525, DOI 10.1089/ten.2006.0128
   Sasidharan A, 2011, NANOSCALE, V3, P2461, DOI 10.1039/c1nr10172b
   Sawai J, 2000, WORLD J MICROB BIOT, V16, P187, DOI 10.1023/A:1008916209784
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Talukdar Y, 2014, BIOMATERIALS, V35, P4863, DOI 10.1016/j.biomaterials.2014.02.054
   Treiser MD, 2010, P NATL ACAD SCI USA, V107, P610, DOI 10.1073/pnas.0909597107
   Wetteland CL, 2016, ACTA BIOMATER, V35, P341, DOI 10.1016/j.actbio.2016.02.032
   Wu YQ, 2015, CELL PROLIFERAT, V48, P375, DOI 10.1111/cpr.12185
   Yang D, 2013, J BIOL CHEM, V288, P33530, DOI 10.1074/jbc.M113.497040
   Yang K, 2010, NANO LETT, V10, P3318, DOI 10.1021/nl100996u
   Zhang WD, 2015, TOXICOL LETT, V237, P61, DOI 10.1016/j.toxlet.2015.05.021
   Zhao L, 2016, J NANOMATER, V2016, DOI 10.1155/2016/6709764
NR 47
TC 71
Z9 73
U1 0
U2 49
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0960 7722
EI 1365 2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD OCT
PY 2017
VL 50
IS 5
AR e12367
DI 10.1111/cpr.12367
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA FF7LQ
UT WOS:000409197900005
PM 28771866
OA Green Published
DA 2025 08 17
ER

PT J
AU Schreiber, C
   Saraswati, S
   Harkins, S
   Gruber, A
   Cremers, N
   Thiele, W
   Rothley, M
   Plaumann, D
   Korn, C
   Armant, O
   Augustin, HG
   Sleeman, JP
AF Schreiber, Caroline
   Saraswati, Supriya
   Harkins, Shannon
   Gruber, Annette
   Cremers, Natascha
   Thiele, Wilko
   Rothley, Melanie
   Plaumann, Diana
   Korn, Claudia
   Armant, Olivier
   Augustin, Hellmut G.
   Sleeman, Jonathan P.
TI Loss of ASAP1 in mice impairs adipogenic and osteogenic differentiation
   of mesenchymal progenitor cells through dysregulation of FAK/Src and AKT
   signaling
SO PLOS GENETICS
LA English
DT Article
ID GTPASE ACTIVATING PROTEIN; FOCAL ADHESION KINASE; OSTEOBLAST
   DIFFERENTIATION; PROMOTES ADIPOGENESIS; STEM CELLS; EXPRESSION;
   MOTILITY; CYTOSKELETAL; ORGANIZATION; FIBROBLASTS
AB ASAP1 is a multi domain adaptor protein that regulates cytoskeletal dynamics, receptor recycling and intracellular vesicle trafficking. Its expression is associated with poor prognosis for a variety of cancers, and promotes cell migration, invasion and metastasis. Little is known about its physiological role. In this study, we used mice with a gene trap inactivated ASAP1 locus to study the functional role of ASAP1 in vivo, and found defects in tissues derived from mesenchymal progenitor cells. Loss of ASAP1 led to growth retardation and delayed ossification typified by enlarged hypertrophic zones in growth plates and disorganized chondro osseous junctions. Furthermore, loss of ASAP1 led to delayed adipocyte development and reduced fat depot formation. Consistently, deletion of ASAP1 resulted in accelerated chondrogenic differentiation of mesenchymal cells in vitro, but suppressed osteo  and adipogenic differentiation. Mechanistically, we found that FAK/Src and PI3K/AKT signaling is compromised in Asap1(GT/GT) MEFs, leading to impaired adipogenic differentiation. Dysregulated FAK/Src and PI3K/AKT signaling is also associated with attenuated osteogenic differentiation. Together these observations suggest that ASAP1 plays a decisive role during the differentiation of mesenchymal progenitor cells.
   Author summary Mesenchymal progenitor cells are capable of differentiating into a number of lineages including osteoblasts, chondrocytes and adipocytes, and have therefore attracted interest for their potential application in regenerative medicine. Furthermore, defects in mesenchymal progenitor cell differentiation are considered to contribute to various diseases including metabolic syndrome, obesity and osteoporosis. In this study, we analyzed mice deficient in the multi adaptor protein ASAP1, which has been implicated in tumor progression and metastasis. These mice display growth retardation, and a delayed development of bone and fat tissue. Consistently, mesenchymal progenitor cells deficient in ASAP1 exhibited enhanced differentiation into chondrocytes, but impaired differentiation into adipocytes and osteoblasts. Together these observations suggest that ASAP1 plays a decisive role during the differentiation of mesenchymal stem cells, which may be relevant for a number of diseases such as cancer.
C1 [Schreiber, Caroline; Saraswati, Supriya; Harkins, Shannon; Gruber, Annette; Cremers, Natascha; Thiele, Wilko; Rothley, Melanie; Plaumann, Diana; Augustin, Hellmut G.; Sleeman, Jonathan P.] Heidelberg Univ, Med Fac Mannheim, European Ctr Angiosci ECAS, Mannheim, Germany.
   [Cremers, Natascha; Thiele, Wilko; Rothley, Melanie; Plaumann, Diana; Armant, Olivier; Sleeman, Jonathan P.] Inst Toxicol & Genet, KIT Campus Nord, Karlsruhe, Germany.
   [Korn, Claudia; Augustin, Hellmut G.] German Canc Res Ctr DKFZ ZMBH Alliance, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Helmholtz Association; Karlsruhe
   Institute of Technology; Helmholtz Association; German Cancer Research
   Center (DKFZ)
RP Schreiber, C (通讯作者)，Heidelberg Univ, Med Fac Mannheim, European Ctr Angiosci ECAS, Mannheim, Germany.
EM caroline.schreiber@medma.uni heidelberg.de
RI Sleeman, Jonathan/H 2515 2013; Augustin, Hellmut/AAA 5246 2020; Thiele,
   Wilko/AAF 7856 2020
OI Sleeman, Jonathan/0000 0003 1718 7687; armant,
   olivier/0000 0001 7101 9209
FU Worldwide Cancer Research [08 0015]; Deutsche Forschungsgemeinschaft
   [CRC1366, 39404578]; Deutsche Akademische Austausch Dienst (DAAD)
FX SS gratefully acknowledges receipt of a scholarship from the Deutsche
   Akademische Austausch Dienst (DAAD). Part of this work was funded by a
   grant from the Association for International Cancer Research (now
   Worldwide Cancer Research), grant number 08 0015 (to J.P. S.) and the
   Deutsche Forschungsgemeinschaft (project C5 within CRC1366 "Vascular
   control of organ function" [project number 39404578 to H.G. A.]. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802
   Bharti S, 2007, MOL CELL BIOL, V27, P8271, DOI 10.1128/MCB.01781 06
   Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792
   Boulay PL, 2008, J BIOL CHEM, V283, P36425, DOI 10.1074/jbc.M803603200
   Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038
   Campa F, 2008, CELL ADHES MIGR, V2, P258, DOI 10.4161/cam.2.4.6959
   CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148
   Tien DN, 2014, SCI REP UK, V4, DOI 10.1038/srep05094
   Ehlers JP, 2005, CLIN CANCER RES, V11, P3609, DOI 10.1158/1078 0432.CCR 04 1941
   Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001
   Furman C, 2002, J BIOL CHEM, V277, P7962, DOI 10.1074/jbc.M109149200
   Ghaben AL, 2019, NAT REV MOL CELL BIO, V20, P242, DOI 10.1038/s41580 018 0093 z
   GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519
   Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521 1878(200002)22:2<138::AID BIES5>3.0.CO;2 4
   Hammarstedt A, 2018, PHYSIOL REV, V98, P1911, DOI 10.1152/physrev.00034.2017
   Hashimoto A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023359
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   King FJ, 1999, MOL CELL BIOL, V19, P2330
   Kita K, 2008, GENES CELLS, V13, P839, DOI 10.1111/j.1365 2443.2008.01209.x
   Lee JS, 2013, BIOCHEM BIOPH RES CO, V435, P696, DOI 10.1016/j.bbrc.2013.05.045
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI [10.1093/bioinformatics/btp324, 10.1093/bioinformatics/btp698, 10.1093/bioinformatics/btp352]
   Lin D, 2008, CANCER RES, V68, P4352, DOI 10.1158/0008 5472.CAN 07 5237
   Liu YH, 2005, J BIOL CHEM, V280, P8884, DOI 10.1074/jbc.M412200200
   Liu YH, 2002, MOL BIOL CELL, V13, P2147, DOI 10.1091/mbc.E02 01 0018
   Long FX, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008334
   Maes C, 2017, SEMIN CELL DEV BIOL, V62, P16, DOI 10.1016/j.semcdb.2016.05.007
   Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311
   Mathieu PS, 2012, TISSUE ENG PART B RE, V18, P436, DOI [10.1089/ten.teb.2012.0014, 10.1089/ten.TEB.2012.0014]
   Mauvais Jarvis F, 2017, CELL METAB, V25, P1216, DOI 10.1016/j.cmet.2017.04.033
   Müller T, 2010, ONCOGENE, V29, P2393, DOI 10.1038/onc.2010.6
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Onodera Y, 2005, EMBO J, V24, P963, DOI 10.1038/sj.emboj.7600588
   Onodera Y, 2012, J CELL BIOL, V197, P983, DOI 10.1083/jcb.201201065
   Pala D, 2008, J BIOL CHEM, V283, P9239, DOI 10.1074/jbc.M705175200
   Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Peruzzi B, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1651
   Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200
   Rajshankar D, 2017, FASEB J, V31, P937, DOI 10.1096/fj.201600645R
   Randazzo PA, 2000, P NATL ACAD SCI USA, V97, P4011, DOI 10.1073/pnas.070552297
   Rodríguez JP, 2004, J CELL BIOCHEM, V93, P721, DOI 10.1002/jcb.20234
   Rosen ED, 2014, CELL, V156, P20, DOI 10.1016/j.cell.2013.12.012
   SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680
   Schatz O, 2005, BIOTECHNIQUES, V39, P650, DOI 10.2144/000112034
   Shin H, 2016, J CELL PHYSIOL, V231, P1822, DOI 10.1002/jcp.25290
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Song MQ, 2019, CANCER RES, V79, P1019, DOI 10.1158/0008 5472.CAN 18 2738
   Stryke D, 2003, NUCLEIC ACIDS RES, V31, P278, DOI 10.1093/nar/gkg064
   Stubbins RE, 2012, EUR J NUTR, V51, P861, DOI 10.1007/s00394 011 0266 4
   Sun YT, 2005, BIOCHEMISTRY US, V44, P14455, DOI 10.1021/bi0509090
   Thorvaldsdóttir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017
   TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092 8674(94)90006 X
   Treiser MD, 2010, P NATL ACAD SCI USA, V107, P610, DOI 10.1073/pnas.0909597107
   Wang FF, 2013, P NATL ACAD SCI USA, V110, P18656, DOI 10.1073/pnas.1314863110
   Xu JF, 2004, J BIOL CHEM, V279, P35914, DOI 10.1074/jbc.M402297200
NR 56
TC 35
Z9 38
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553 7404
J9 PLOS GENET
JI PLoS Genet.
PD JUN
PY 2019
VL 15
IS 6
AR e1008216
DI 10.1371/journal.pgen.1008216
PG 25
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA II8TK
UT WOS:000475464900034
PM 31246957
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Ye, ML
   An, CJ
   Liu, H
   Zheng, LJ
AF Ye, Mengliang
   An, Chuanjing
   Liu, Hong
   Zheng, Lijing
TI Synergistic Effects and Mechanisms of Ultrasound Assisted Pretreatments
   on the Release of Yak (Bos grunniens) Bone Collagen Derived
   Osteogenic Peptides in Enzymatic Hydrolysis
SO FOOD AND BIOPROCESS TECHNOLOGY
LA English
DT Article
DE Yak bone collagen; Ultrasonic and formic acid; Osteogenic activity
   peptides; Response surface methodology; Mechanisms
ID RESPONSE SURFACE METHODOLOGY; ACE INHIBITORY PEPTIDES; OSTEOBLAST
   PROLIFERATION; BY PRODUCTS; PROTEIN; IDENTIFICATION; STABILITY;
   OPTIMIZATION; PURIFICATION; ENZYMOLYSIS
AB Yak bone is one of the major components of Tibetan medicine (traditional Chinese medicine) and its function is mainly related to an improvement of bone health. Yak bone collagens were considered one promising substrate to prepare osteogenic activity peptides. However, due to the complexed triple helical structures, yak bone collagen is not easy and accessible for enzymatic cleavage of most proteases. Herein, the purpose of this study was to investigate the effects of five different pretreatment approaches (ultrasonic, formic acid, alkali, ultrasonic and formic acid, and ultrasonic and alkali) on the release of osteogenic activity peptides during the subsequent enzymatic hydrolysis. On the basis of our results, combined ultrasonic (ultrasonic power of 339 w, ultrasonic frequencies of 23.8 kHz, ultrasonic pulsed model of 6 s/5 s, and ultrasonic processing time of 36 min) and formic acid pretreatment of yak bone collagen was considered the optimum operating condition, which could significantly expedite the release of osteogenic activity peptides from the complex triple helix of yak bone collagen during the subsequent enzymatic hydrolysis, in terms of secondary structure, microstructures, the content of free sulfhydryl (SH) and/or disulfide bond (SS), degree of hydrolysis (DH), the content of soluble peptides (CSP), in vitro digestibility, and osteogenic bioactivity of yak bone collagen hydrolysates (P < 0.05). Based on the experimental data, yak bone collagen hydrolysates after ultrasonic combined acid pretreatment displayed the highest SH content of 43.4 Rmol/g, DH value of 24.6%, highest digestibility of 61.4%, osteoblastic proliferation rate of 147.7%, and maximum soluble peptide content of 79.8 mg/100 mg, respectively. During these procedure, formic acid could assist the hydrolysis of highly and complexed cross linked yak bone collagen and the ultrasonic could simultaneously break the covalent bonds between different yak bone collagen fibers. The combined effect could undoubtedly damage the complexed triple helical structures in yak bone collagens and ultimately expose more inner enzymatic cutting sites for the subsequent hydrolysis. Collectively, these findings of this work highlighted that ultrasound assisted formic acid pretreatment method exhibited highest efficiency for pretreating yak bone collagen, and maybe one promising strategy to prepare osteogenic activity peptides from collagen rich raw materials.
C1 [Ye, Mengliang; An, Chuanjing] Peking Univ, Sch Pharmaceut Sci, Dept Chem Biol, State Key Lab Nat & Biomimet Drugs, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
   [Liu, Hong] Chinese Acad Agr Sci, Inst Food Sci & Technol, Key Lab Agroprod Proc, Minist Agr, Beijing 100193, Peoples R China.
   [Zheng, Lijing] Beijing Agr Technol Extens Stn, Beijing 100029, Peoples R China.
C3 Peking University; Chinese Academy of Agricultural Sciences; Institute
   of Food Science & Technology, CAAS
RP Ye, ML (通讯作者)，Peking Univ, Sch Pharmaceut Sci, Dept Chem Biol, State Key Lab Nat & Biomimet Drugs, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM yemengliang413@163.com
RI zheng, lijing/C 6723 2012; Ye, Mengliang/AAB 4643 2020
OI Ye, Mengliang/0000 0001 9511 9757
FU National Natural Science Foundation of China [82103977]; China
   Postdoctoral Science Foundation [2020M670072]; Science and Technology
   Special Project of Tibet Autonomous Region (Characteristic Agro products
   Processing Technologies and Product Development Program); National
   Agricultural Science and Technology Innovation Program
FX The present work was financially supported by the National Natural
   Science Foundation of China (Grant No: 82103977), China Postdoctoral
   Science Foundation (Grant No: 2020M670072), Science and Technology
   Special Project of Tibet Autonomous Region (Characteristic Agro products
   Processing Technologies and Product Development Program), and the
   National Agricultural Science and Technology Innovation Program.
CR Agyei D, 2016, FOOD BIOPROD PROCESS, V98, P244, DOI 10.1016/j.fbp.2016.02.003
   Ahn CB, 2012, PROCESS BIOCHEM, V47, P2240, DOI 10.1016/j.procbio.2012.08.019
   Ao J, 2013, FOOD RES INT, V52, P334, DOI 10.1016/j.foodres.2013.03.036
   Ashraf J, 2020, ULTRASON SONOCHEM, V66, DOI 10.1016/j.ultsonch.2020.105121
   Chang HJ, 2012, FOOD BIOPROCESS TECH, V5, P285, DOI 10.1007/s11947 009 0269 9
   Cui PF, 2020, ULTRASON SONOCHEM, V62, DOI 10.1016/j.ultsonch.2019.104859
   Dou ZM, 2019, FOOD HYDROCOLLOID, V96, P568, DOI 10.1016/j.foodhyd.2019.06.002
   Fadimu GJ, 2021, FOOD BIOPROCESS TECH, V14, P2004, DOI 10.1007/s11947 021 02700 4
   Fan FJ, 2017, J AGR FOOD CHEM, V65, P7179, DOI 10.1021/acs.jafc.7b02067
   Hernández Ledesma B, 2011, ADV COLLOID INTERFAC, V165, P23, DOI 10.1016/j.cis.2010.11.001
   Hong H, 2018, FOOD CHEM, V258, P174, DOI 10.1016/j.foodchem.2018.03.036
   Huang GP, 2019, ULTRASON SONOCHEM, V51, P315, DOI 10.1016/j.ultsonch.2018.09.033
   Hyung JH, 2018, FOOD CHEM, V242, P156, DOI 10.1016/j.foodchem.2017.09.043
   Jin J, 2016, ULTRASON SONOCHEM, V30, P44, DOI 10.1016/j.ultsonch.2015.11.021
   Li F, 2009, LWT FOOD SCI TECHNOL, V42, P945, DOI 10.1016/j.lwt.2008.12.005
   Ma S, 2018, ULTRASON SONOCHEM, V43, P227, DOI 10.1016/j.ultsonch.2018.01.017
   Ma XB, 2016, FOOD BIOPROCESS TECH, V9, P1249, DOI 10.1007/s11947 016 1689 y
   Mohammadi R, 2016, FOOD CHEM, V190, P186, DOI 10.1016/j.foodchem.2015.05.073
   Munir M, 2020, ULTRASON SONOCHEM, V67, DOI 10.1016/j.ultsonch.2020.105140
   Ochoa Rivas A, 2017, FOOD BIOPROCESS TECH, V10, P543, DOI 10.1007/s11947 016 1838 3
   Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092 8674(02)00963 7
   Quirós A, 2008, INT DAIRY J, V18, P279, DOI 10.1016/j.idairyj.2007.09.006
   Resendiz Vazquez JA, 2017, ULTRASON SONOCHEM, V37, P436, DOI 10.1016/j.ultsonch.2017.01.042
   Shi PJ, 2018, FOOD BIOSCI, V22, P19, DOI 10.1016/j.fbio.2017.12.011
   Siewe FB, 2020, ULTRASON SONOCHEM, V65, DOI 10.1016/j.ultsonch.2020.105055
   Sila A, 2016, J FUNCT FOODS, V21, P10, DOI 10.1016/j.jff.2015.11.007
   Singh P, 2022, FOOD BIOPROCESS TECH, V15, P833, DOI 10.1007/s11947 021 02726 8
   Stefanovic AB, 2017, FOOD BIOPROCESS TECH, V10, P1224, DOI 10.1007/s11947 017 1884 5
   Tagliazucchi D, 2017, INT DAIRY J, V71, P6, DOI 10.1016/j.idairyj.2017.03.001
   Timón ML, 2014, LWT FOOD SCI TECHNOL, V57, P359, DOI 10.1016/j.lwt.2014.01.020
   Wang B, 2016, ULTRASON SONOCHEM, V32, P307, DOI 10.1016/j.ultsonch.2016.03.023
   Wang J, 2021, ULTRASON SONOCHEM, V71, DOI 10.1016/j.ultsonch.2020.105409
   Wen CT, 2018, ULTRASON SONOCHEM, V49, P294, DOI 10.1016/j.ultsonch.2018.08.018
   Wu WF, 2021, ULTRASON SONOCHEM, V77, DOI 10.1016/j.ultsonch.2021.105670
   Wu WM, 2019, FOOD CHEM, V284, P80, DOI 10.1016/j.foodchem.2019.01.103
   Xie NN, 2014, EUR FOOD RES TECHNOL, V239, P577, DOI 10.1007/s00217 014 2253 5
   Xu Z, 2019, J AGR FOOD CHEM, V67, P1572, DOI 10.1021/acs.jafc.8b06530
   Yang X, 2020, ULTRASON SONOCHEM, V64, DOI 10.1016/j.ultsonch.2020.104964
   Ye ML, 2021, WASTE BIOMASS VALORI, V12, P1553, DOI 10.1007/s12649 020 01078 2
   Ye ML, 2020, FOOD FUNCT, V11, P1498, DOI [10.1039/c9fo01944h, 10.1039/C9FO01944H]
   Ye ML, 2020, J SCI FOOD AGR, V100, P2600, DOI 10.1002/jsfa.10286
   Ye ML, 2020, CURR TOP NUTRACEUT R, V18
   Ye ML, 2019, RSC ADV, V9, P14627, DOI 10.1039/c9ra00945k
   Yu WL, 2018, FOOD CHEM, V253, P101, DOI 10.1016/j.foodchem.2018.01.093
   Zarena AS, 2012, FOOD BIOPROCESS TECH, V5, P1181, DOI 10.1007/s11947 010 0404 7
   Zhang YH, 2017, ULTRASON SONOCHEM, V36, P88, DOI 10.1016/j.ultsonch.2016.11.008
   Zhou CS, 2013, ULTRASON SONOCHEM, V20, P1390, DOI 10.1016/j.ultsonch.2013.04.005
   Zhu LY, 2020, J FUNCT FOODS, V64, DOI 10.1016/j.jff.2019.103697
   Zou Y, 2016, ULTRASON SONOCHEM, V28, P294, DOI 10.1016/j.ultsonch.2015.08.006
NR 49
TC 8
Z9 8
U1 5
U2 89
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1935 5130
EI 1935 5149
J9 FOOD BIOPROCESS TECH
JI Food Bioprocess Technol.
PD JUL
PY 2022
VL 15
IS 7
BP 1658
EP 1675
DI 10.1007/s11947 022 02841 0
EA JUN 2022
PG 18
WC Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology
GA 2G7ZN
UT WOS:000809288900002
DA 2025 08 17
ER

PT J
AU Dapunt, U
   Prior, B
   Oelkrug, C
   Kretzer, JP
AF Dapunt, Ulrike
   Prior, Birgit
   Oelkrug, Christopher
   Kretzer, Jan Philippe
TI IgY Targeting Bacterial Quorum Sensing Molecules in Implant Associated
   Infections
SO MOLECULES
LA English
DT Article
DE implant associated infections; biofilms; quorum sensing molecules;
   GroEL; AtlE; PIA; IgY
ID EGG YOLK ANTIBODIES; STAPHYLOCOCCUS EPIDERMIDIS; BIOFILM FORMATION;
   ESCHERICHIA COLI; MECHANISMS; PREVENTION; RESISTANCE; DIAGNOSIS
AB Background: Implant associated infections are still a major complication in the field of orthopedics. Bacteria can form biofilms on implant surfaces, making them more difficult to detect and treat. Since standard antibiotic therapy is often impaired in biofilm infections, particular interest is directed towards finding treatment alternatives. Biofilm formation is a well organized process during which bacteria communicate via quorum sensing molecules (QSM). The aim of this study was to inhibit bacterial communication by directing avian IgY against specific QSM.Methods: Chicken were immunized against the following QSM: (1) AtlE, a member of the autolysin family which mediates attachment to a surface inStaphylococcus epidermidis; (2) GroEL, the bacterial heat shock protein; (3) PIA (polysaccharide intercellular adhesion), which is essential for cell cell adhesion in biofilms.Staphylococcus epidermidisbiofilms were grown and inhibition of biofilm formation by IgYs was evaluated. Additionally, human osteoblasts were cultivated and biocompatibility of IgYs was tested.Results: We were able to demonstrate that all IgYs reduced biofilm formation, also without prior immunization. Therefore, the response was probably not specific with regard to the QSM. Osteoblasts were activated by all IgYs which was demonstrated by microscopy and an increased release of IL 8.Conclusions: In conclusion, avian IgY inhibits biofilm formation, though the underlying mechanism is not yet clear. However, adverse effects on local tissue cells (osteoblasts) were also observed.
C1 [Dapunt, Ulrike] Heidelberg Univ Hosp, Ctr Orthoped Trauma Surg & Spinal Cord Injury, Schlierbacher Landstr 200a, D 69118 Heidelberg, Germany.
   [Prior, Birgit] Heidelberg Univ Hosp, Dept Anesthesiol, Neuenheimer Feld 672, D 69120 Heidelberg, Germany.
   [Oelkrug, Christopher] Oelkrug Enterprises UG Haftungsbeschraenkt, Gerhart Hauptmann Str 10, D 59387 Ascheberg, Germany.
   [Kretzer, Jan Philippe] Heidelberg Univ Hosp, Ctr Orthoped Trauma Surg & Spinal Cord Injury, Lab Biomech & Implant Res, Schlierbacher Landstr 200a, D 69118 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg; Ruprecht Karls University Heidelberg
RP Dapunt, U (通讯作者)，Heidelberg Univ Hosp, Ctr Orthoped Trauma Surg & Spinal Cord Injury, Schlierbacher Landstr 200a, D 69118 Heidelberg, Germany.
EM Ulrike.Dapunt@med.uni heidelberg.de;
   Birgit.Prior@immu.uni heidelberg.de;
   christopher.oelkrug@oelkrug enterprises.com;
   Philippe.Kretzer@med.uni heidelberg.de
OI Dapunt, Ulrike/0000 0001 7396 6074
FU Stiftung Endoprothetik
FX This study was funded by "Stiftung Endoprothetik".
CR Baranova IN, 2012, J IMMUNOL, V188, P1371, DOI 10.4049/jimmunol.1100350
   Bassler BL, 2002, CELL, V109, P421, DOI 10.1016/S0092 8674(02)00749 3
   Biswas R, 2006, FEMS MICROBIOL LETT, V259, P260, DOI 10.1111/j.1574 6968.2006.00281.x
   Cai YC, 2012, PARASITOL INT, V61, P385, DOI 10.1016/j.parint.2012.01.008
   Carlander D, 2000, IMMUNOL RES, V21, P1, DOI 10.1385/IR:21:1:1
   Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318
   Costerton JW, 2005, INT J ARTIF ORGANS, V28, P1062, DOI 10.1177/039139880502801103
   D'Angelo F, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.01296 18
   Dapunt U, 2016, MATERIALS, V9, DOI 10.3390/ma9110871
   Dapunt U, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftw035
   Dimopoulos G, 2020, INTENS CARE MED, V46, P350, DOI 10.1007/s00134 019 05905 6
   Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167 193.2002
   Dunne WM, 2002, CLIN MICROBIOL REV, V15, P155, DOI 10.1128/CMR.15.2.155 166.2002
   Flemming HC, 2002, APPL MICROBIOL BIOT, V59, P629, DOI 10.1007/s00253 002 1066 9
   Fuqua C, 2002, NAT REV MOL CELL BIO, V3, P685, DOI 10.1038/nrm907
   Fux CA, 2005, TRENDS MICROBIOL, V13, P34, DOI 10.1016/j.tim.2004.11.010
   Gaida MM, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftw004
   Galdbart JO, 2000, J INFECT DIS, V182, P351, DOI 10.1086/315660
   GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792
   Haenle M, 2012, ORTHOPADE, V41, P467, DOI 10.1007/s00132 012 1939 2
   Hall Stoodley L, 2004, NAT REV MICROBIOL, V2, P95, DOI 10.1038/nrmicro821
   Hall Stoodley L, 2009, CELL MICROBIOL, V11, P1034, DOI 10.1111/j.1462 5822.2009.01323.x
   Henke JM, 2004, TRENDS CELL BIOL, V14, P648, DOI 10.1016/j.tcb.2004.09.012
   Hoiby N, 2010, INT J ANTIMICROB AG, V35, P322, DOI 10.1016/j.ijantimicag.2009.12.011
   Jefferson KK, 2004, FEMS MICROBIOL LETT, V236, P163, DOI 10.1016/j.femsle.2004.06.005
   Johnson LR, 2008, J THEOR BIOL, V251, P24, DOI 10.1016/j.jtbi.2007.10.039
   Kalia VC, 2013, BIOTECHNOL ADV, V31, P224, DOI 10.1016/j.biotechadv.2012.10.004
   Karatan E, 2009, MICROBIOL MOL BIOL R, V73, P310, DOI 10.1128/MMBR.00041 08
   Kong KF, 2006, INT J MED MICROBIOL, V296, P133, DOI 10.1016/j.ijmm.2006.01.042
   LeClaire RD, 2002, INFECT IMMUN, V70, P2278, DOI 10.1128/IAI.70.5.2278 2281.2002
   Lee EN, 2002, POULTRY SCI, V81, P632, DOI 10.1093/ps/81.5.632
   Marquardt RR, 1999, FEMS IMMUNOL MED MIC, V23, P283, DOI 10.1016/S0928 8244(98)00147 3
   Maurer S, 2015, J BIOTECHNOL BIOMATE, V5, P176, DOI [10.4172/2155 952x.1000176, DOI 10.4172/2155 952X.1000176]
   O'Gara JP, 2007, FEMS MICROBIOL LETT, V270, P179, DOI 10.1111/j.1574 6968.2007.00688.x
   Otto M, 2004, FEMS MICROBIOL LETT, V241, P135, DOI 10.1016/j.femsle.2004.11.016
   Rahman S, 2013, HUM VACC IMMUNOTHER, V9, P1039, DOI 10.4161/hv.23383
   Rampioni G, 2014, BIOORG CHEM, V55, P60, DOI 10.1016/j.bioorg.2014.04.005
   Rupp ME, 1999, INFECT IMMUN, V67, P2627, DOI 10.1128/IAI.67.5.2627 2632.1999
   Sambri A, 2019, J MICROBIOL METH, V156, P81, DOI 10.1016/j.mimet.2018.12.006
   Sambri A, 2019, ORTHOPEDICS, V42, P28, DOI 10.3928/01477447 20181010 06
   Sambri A, 2018, CLIN ORTHOP RELAT R, V476, P137, DOI 10.1007/s11999.0000000000000060
   Sarker SA, 2001, J PEDIATR GASTR NUTR, V32, P19, DOI 10.1097/00005176 200101000 00009
   Speziale P, 2009, FUTURE MICROBIOL, V4, P1337, DOI 10.2217/FMB.09.102
   Stewart PS, 2001, LANCET, V358, P135, DOI 10.1016/S0140 6736(01)05321 1
   Stoodley P, 2011, CURR ORTHOP PRACT, V22, P558, DOI 10.1097/BCO.0b013e318230efcf
   Tini M, 2002, COMP BIOCHEM PHYS A, V131, P569, DOI 10.1016/S1095 6433(01)00508 6
   Tsubokura K, 1997, CLIN EXP IMMUNOL, V108, P451, DOI 10.1046/j.1365 2249.1997.3901288.x
   WARR GW, 1995, IMMUNOL TODAY, V16, P392, DOI 10.1016/0167 5699(95)80008 5
   YOUNG DB, 1987, IMMUNOL TODAY, V8, P215, DOI 10.1016/0167 5699(87)90168 X
   Zimmerli W, 2004, NEW ENGL J MED, V351, P1645, DOI 10.1056/NEJMra040181
   Zimmerli W, 2011, SEMIN IMMUNOPATHOL, V33, P295, DOI 10.1007/s00281 011 0275 7
NR 51
TC 7
Z9 7
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD SEP
PY 2020
VL 25
IS 17
AR 4027
DI 10.3390/molecules25174027
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA NQ7TP
UT WOS:000571072500001
PM 32899313
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sedghizadeh, PP
   Kumar, SKS
   Gorur, A
   Schaudinn, C
   Shuler, CF
   Costerton, JW
AF Sedghizadeh, Parish P.
   Kumar, Satish K. S.
   Gorur, Amita
   Schaudinn, Christoph
   Shuler, Charles F.
   Costerton, J. William
TI Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the
   jaw secondary to bisphosphonate therapy
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Article
DE Osteomyelitis; osteonecrosis; jawbones; bisphosphonates; biofilms
ID INFECTIONS; MICROORGANISMS; EXPERIENCE; RESISTANCE; BACTERIA
AB Background. The authors report their observations with respect to microbial biofilms in osteomyelitis of the jaw (OMJ), compare these findings with those for osteonecrosis of the jaw (ONJ) secondary to bisphosphonate therapy and discuss recent findings that the pathogenesis of ONJ may represent a biofilm mediated infectious disease in the context of bisphosphonate therapy.
   Methods. In 2004, a program was established at the University of Southern California, Los Angeles, to evaluate, treat and monitor patients who have OMJ and ONJ. Twenty people from this cohort of study patients who were scheduled to undergo surgical debridement or sequestrectomy and who met the authors' inclusion criteria gave informed consent for the study. The authors examined bone samples histopathologically and via scanning electron microscopy, a technique applicable to biofilm characterization.
   Results. Specimens from all patients with OMJ and ONJ exhibited large surface areas of bone occluded with well developed biofilms comprising microbial organisms embedded in an extracellular polymeric substance. Actinomyces predominated in OMJ cases, whereas ONJ cases represented more diverse bacterial organisms in addition to fungal organisms not seen in OMJ. The authors observed resorption pits, septic clots, putative nanowires and host inflammatory cells in all specimens.
   Conclusions. The findings of this study support a role for microbial biofilms in both disease processes.
   Clinical Implications. Microbial biofilms are a potential target for therapy that includes antibiofilm. modalities in the treatment and prevention of OMJ and ONJ.
C1 [Sedghizadeh, Parish P.; Gorur, Amita; Schaudinn, Christoph; Costerton, J. William] Univ So Calif, Sch Dent, USC Ctr Biofilms, Los Angeles, CA 90089 USA.
   [Kumar, Satish K. S.] Univ So Calif, Div Diagnost Sci, Orofacial Pain & Oral Med Ctr, Los Angeles, CA 90089 USA.
   [Shuler, Charles F.] Univ British Columbia, Fac Dent, Vancouver, BC V5Z 1M9, Canada.
C3 University of Southern California; University of Southern California;
   University of British Columbia
RP Sedghizadeh, PP (通讯作者)，Univ So Calif, Sch Dent, USC Ctr Biofilms, 925 W 34th St,DEN 411OA, Los Angeles, CA 90089 USA.
EM sedghiza@usc.edu
RI ; Sedghizadeh, Parish/AAI 8453 2020
OI Sedghizadeh, Parish/0000 0003 4190 0497; Kumar,
   Satish/0000 0001 7655 2766; 
CR Assouline Dayan Y, 2002, SEMIN ARTHRITIS RHEU, V32, P94, DOI 10.1053/sarh.2002.33724
   Badros A, 2006, J CLIN ONCOL, V24, P945, DOI 10.1200/JCO.2005.04.2465
   Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318
   Costerton JW, 2005, CLIN ORTHOP RELAT R, P7, DOI 10.1097/01.blo.0000175128.44966.d9
   Dannemann C, 2006, SWISS MED WKLY, V136, P504
   Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167 193.2002
   DUGUID IG, 1992, J ANTIMICROB CHEMOTH, V30, P803, DOI 10.1093/jac/30.6.803
   Ehrlich GD, 2005, CLIN ORTHOP RELAT R, P59, DOI 10.1097/01.blo.0000175125.60214.a4
   Gorby YA, 2006, P NATL ACAD SCI USA, V103, P11358, DOI 10.1073/pnas.0604517103
   Hansen T, 2007, VIRCHOWS ARCH, V451, P1009, DOI 10.1007/s00428 007 0516 2
   Harrington DJ, 1996, INFECT IMMUN, V64, P1885, DOI 10.1128/IAI.64.6.1885 1891.1996
   Henderson B, 2003, TRENDS MICROBIOL, V11, P570, DOI 10.1016/j.tim.2003.10.005
   Jauregui, 1995, DIAGNOSIS MANAGEMENT, P37
   Lazzarini L, 2004, J BONE JOINT SURG AM, V86A, P2305, DOI 10.2106/00004623 200410000 00028
   Lew DP, 2004, LANCET, V364, P369, DOI 10.1016/S0140 6736(04)16727 5
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   MAY JW, 1991, ANN SURG, V214, P241, DOI 10.1097/00000658 199109000 00007
   MAY JW, 1991, ANN SURG, V214, P250
   McDowell A, 2005, CLIN ORTHOP RELAT R, P74, DOI 10.1097/01.blo.0000175123.58428.93
   Migliorati CA, 2006, LANCET ONCOL, V7, P508, DOI 10.1016/S1470 2045(06)70726 4
   Nelson CL, 2005, CLIN ORTHOP RELAT R, P25, DOI 10.1097/01.blo.0000175715.68624.3d
   Patel R, 2005, CLIN ORTHOP RELAT R, P41, DOI 10.1097/01.blo.0000175714.68624.74
   PRICE JD, 1982, BRIT DENT J, V153, P331, DOI 10.1038/sj.bdj.4804936
   Reid IR, 2009, BONE, V44, P4, DOI 10.1016/j.bone.2008.09.012
   Ripamonti CI, 2009, ANN ONCOL, V20, P137, DOI 10.1093/annonc/mdn526
   Ruggiero SL, 2006, ORAL SURG ORAL MED O, V102, P433, DOI 10.1016/j.tripleo.2006.06.004
   Sedghizadeh PP, 2008, J ORAL MAXIL SURG, V66, P767, DOI 10.1016/j.joms.2007.11.035
   Stewart PS, 2001, LANCET, V358, P135, DOI 10.1016/S0140 6736(01)05321 1
   Veeh RH, 2003, J INFECT DIS, V188, P519, DOI 10.1086/377001
   Wade W, 2002, J ROY SOC MED, V95, P81, DOI 10.1258/jrsm.95.2.81
   WALKER S, 1981, ORAL SURG ORAL MED O, V51, P243, DOI 10.1016/0030 4220(81)90052 9
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
NR 32
TC 137
Z9 149
U1 0
U2 11
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002 8177
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD OCT
PY 2009
VL 140
IS 10
BP 1259
EP 1265
DI 10.14219/jada.archive.2009.0049
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 502ZI
UT WOS:000270499300017
PM 19797556
DA 2025 08 17
ER

PT J
AU Kim, MH
   Lee, GS
   Jung, EM
   Choi, YC
   Jeung, EB
AF Kim, Man Hee
   Lee, Geun Shik
   Jung, Eui Man
   Choi, Yung Chul
   Jeung, Eui Bae
TI The negative effect of dexamethasone on calcium processing gene
   expressions is associated with a glucocorticoid induced
   calcium absorbing disorder
SO LIFE SCIENCES
LA English
DT Article
DE Glucocorticoids; Calcium processing genes; CaBP 9k; TRPV6; TRVP5;
   PMCA1b; NCX1
ID VITAMIN D RECEPTOR; INDUCED OSTEOPOROSIS; PARATHYROID HORMONE;
   CALBINDIN D9K GENE; MESSENGER RNA; MOUSE MODEL; SECONDARY
   HYPERPARATHYROIDISM; BINDING PROTEIN; ABSORPTION; KIDNEY
AB Aims: Although dexamethasone (Dex) is used widely as an anti inflammatory and immunosuppressive drug, Dex appears to have severe side effects, including osteoporosis. This study determined the effects of Dex on duodenal and renal expressions of the calcium processing genes transient receptor potential cation channel, subfamily V, member 5/6 (TRPV5/6), calbindin D9k/ D28k (CaBP 9k/28k), Na+/Ca2+ exchanger 1 (NCX1), and plasma membrane Ca2+ ATPase (PMCA) 1b.
   Main methods: Mice were injected subcutaneously with Dex for 1 or 5 days. The mRNA and protein expression levels of these calcium processing genes were measured by real time PCR and immunohistochemistry/immunoblot analysis, respectively. In addition, serum parathyroid hormone (PTH) levels were measured following Dex treatments.
   Key findings: Treatment with Dex for 24 h resulted in the inductions of duodenal TRPV6, CaBP 9k and PMCA1b transcripts and renal TRPV5, CaBP 9k, and NCX1 transcripts, while it reduced the transcription of renal TRPV6. Although the expressional changes were weak, duodenal expressions of glucocorticoid receptor (GR), the vitamin D receptor (VDR), and renal expressions of the parathyroid hormone receptor (PTHR) and VDR were increased following 24 h treatment with Dex. A five day treatment with Dex reduced the transcriptional levels of duodenal TRPV6 and CaBP 9k by 60%. Transcripts for VDR and GR in the duodenum increased marginally.
   Significance: These results suggest that the expressions of TRPV6 and CaBP 9k in the duodenum appear to be a major regulatory target for glucocorticoids (GCs), and may be involved in the negative regulation of calcium absorption in GC induced osteoporosis (GIO). The transcriptional regulation of TRPV6 and CaBP 9k in the duodenum seems complex given that there is an increase at 1 day treatment followed by a decrease at 5 day treatment. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Kim, Man Hee; Lee, Geun Shik; Jung, Eui Man; Choi, Yung Chul; Jeung, Eui Bae] Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem & Mol Biol, Cheongju 361763, Chungbuk, South Korea.
C3 Chungbuk National University
RP Jeung, EB (通讯作者)，Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem & Mol Biol, Cheongju 361763, Chungbuk, South Korea.
EM ebjeung@chungbuk.ac.kr
RI ; Jung, Eui Man/ABF 2510 2021
OI Jung, Eui Man/0000 0002 1145 402X; 
FU BioGreen 21 program [20070401034011]; Rural Development Administration,
   Republic of Korea
FX This work was supported by a grant (20070401034011) from BioGreen 21
   program, Rural Development Administration, Republic of Korea.
CR Abel M, 2005, N S ARCH PHARMACOL, V371, P295, DOI 10.1007/s00210 005 1021 2
   ADLER RA, 1994, ENDOCRIN METAB CLIN, V23, P641, DOI 10.1016/S0889 8529(18)30090 2
   Akeno N, 2000, J ENDOCRINOL, V164, P339, DOI 10.1677/joe.0.1640339
   BACSKAI BJ, 1990, NATURE, V347, P388, DOI 10.1038/347388a0
   Barley NF, 1999, BIOCHEM J, V341, P491, DOI 10.1042/0264 6021:3410491
   BASTL CP, 1989, AM J PHYSIOL, V257, pF1027, DOI 10.1152/ajprenal.1989.257.6.F1027
   BEAULIEU JF, 1985, COMP BIOCHEM PHYS A, V82, P91, DOI 10.1016/0300 9629(85)90709 1
   BESNARD P, 1989, FEBS LETT, V258, P293, DOI 10.1016/0014 5793(89)81677 1
   Carling T, 2000, J CLIN ENDOCR METAB, V85, P2000, DOI 10.1210/jc.85.5.2000
   Choi KC, 2008, J CELL MOL MED, V12, P409, DOI 10.1111/j.1582 4934.2007.00209.x
   CHRISTAKOS S, 1992, J NUTR, V122, P678, DOI 10.1093/jn/122.suppl_3.678
   Dang VH, 2007, TOXICOL SCI, V98, P408, DOI 10.1093/toxsci/kfm120
   DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097
   FARMAN N, 1991, AM J PHYSIOL, V260, pC226, DOI 10.1152/ajpcell.1991.260.2.C226
   FARMAN N, 1988, PATHOL BIOL, V36, P839
   FEHER JJ, 1992, AM J PHYSIOL, V262, pC517, DOI 10.1152/ajpcell.1992.262.2.C517
   HIRST M, 1982, ENDOCRINOLOGY, V111, P1400, DOI 10.1210/endo 111 4 1400
   Hong EJ, 2007, MOL REPROD DEV, V74, P1188, DOI 10.1002/mrd.20627
   HUANG YC, 1989, J BIOL CHEM, V264, P17454
   Hurson CJ, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 12
   Huybers S, 2007, AM J PHYSIOL GASTR L, V292, pG92, DOI 10.1152/ajpgi.00317.2006
   IACOPINO AM, 1990, J BIOL CHEM, V265, P10177
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   KIMBERG DV, 1971, J CLIN INVEST, V50, P1309, DOI 10.1172/JCI106610
   Lafage Proust MH, 2003, JOINT BONE SPINE, V70, P109, DOI 10.1016/S1297 319X(03)00016 2
   Lee GS, 2007, J BONE MINER RES, V22, P1968, DOI 10.1359/JBMR.070801
   Lee GS, 2007, MOL CELL ENDOCRINOL, V277, P42, DOI 10.1016/j.mce.2007.07.009
   Lee GS, 2007, AM J PHYSIOL ENDOC M, V293, pE132, DOI 10.1152/ajpendo.00666.2006
   Lee GS, 2006, AM J PHYSIOL ENDOC M, V290, pE299, DOI 10.1152/ajpendo.00232.2005
   Li YC, 2001, AM J PHYSIOL ENDOC M, V281, pE558, DOI 10.1152/ajpendo.2001.281.3.E558
   Liu Y, 2004, J BONE MINER RES, V19, P479, DOI 10.1359/JBMR.0301242
   LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003 4819 112 5 352
   Manolagas SC, 1999, J BONE MINER RES, V14, P1061, DOI 10.1359/jbmr.1999.14.7.1061
   McLaughlin F, 2002, BONE, V30, P924, DOI 10.1016/S8756 3282(02)00737 8
   MORRIS HA, 1990, CALCIFIED TISSUE INT, V46, P305, DOI 10.1007/BF02563820
   Nagpal S, 2005, ENDOCR REV, V26, P662, DOI 10.1210/er.2004 0002
   Nijenhuis T, 2004, J AM SOC NEPHROL, V15, P549, DOI 10.1097/01.ASN.0000113318.56023.B6
   Orcel P, 2000, ANN MED INTERNE, V151, P497
   Panda DK, 2004, J BIOL CHEM, V279, P16754, DOI 10.1074/jbc.M310271200
   Patschan D, 2001, BONE, V29, P498, DOI 10.1016/S8756 3282(01)00610 X
   Popp AW, 2006, EUR SPINE J, V15, P1035, DOI 10.1007/s00586 005 0056 x
   PRUMMEL MF, 1991, J CLIN ENDOCR METAB, V72, P382, DOI 10.1210/jcem 72 2 382
   Rabadan Diehl C, 1998, ENDOCRINOLOGY, V139, P3220, DOI 10.1210/en.139.7.3220
   Sheppard KE, 1999, AM J PHYSIOL GASTR L, V277, pG541, DOI 10.1152/ajpgi.1999.277.3.G541
   SHULTZ TD, 1982, P NATL ACAD SCI BIOL, V79, P3542, DOI 10.1073/pnas.79.11.3542
   Song YR, 2003, J NUTR, V133, P374, DOI 10.1093/jn/133.2.374
   SUZUKI Y, 1983, METABOLISM, V32, P151, DOI 10.1016/0026 0495(83)90221 4
   Tinnanooru P, 2008, MOL CELL ENDOCRINOL, V285, P26, DOI 10.1016/j.mce.2008.01.011
   Valín A, 2001, ENDOCRINOLOGY, V142, P2752, DOI 10.1210/en.142.7.2752
   Wang TT, 2005, MOL ENDOCRINOL, V19, P2685, DOI 10.1210/me.2005 0106
   Zheng W, 2004, J BIOL CHEM, V279, P52406, DOI 10.1074/jbc.M405562200
NR 51
TC 31
Z9 37
U1 0
U2 5
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD JUL 15
PY 2009
VL 85
IS 3 4
BP 146
EP 152
DI 10.1016/j.lfs.2009.05.013
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 464RQ
UT WOS:000267524100008
PM 19490920
DA 2025 08 17
ER

PT J
AU Kunimatsu, R
   Gunji, H
   Tsuka, Y
   Yoshimi, Y
   Awada, T
   Sumi, K
   Nakajima, K
   Kimura, A
   Hiraki, T
   Abe, T
   Naoto, H
   Yanoshita, M
   Tanimoto, K
AF Kunimatsu, Ryo
   Gunji, Hidemi
   Tsuka, Yuji
   Yoshimi, Yuki
   Awada, Tetsuya
   Sumi, Keisuke
   Nakajima, Kengo
   Kimura, Aya
   Hiraki, Tomoka
   Abe, Takaharu
   Naoto, Hirose
   Yanoshita, Makoto
   Tanimoto, Kotaro
TI Effects of high frequency near infrared diode laser irradiation on the
   proliferation and migration of mouse calvarial osteoblasts
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Lasers; Cell proliferation; LLLT; MAPK/ERK signaling
ID BONE REPAIR; CELL PROLIFERATION; PERIODONTAL TISSUE; STEM CELLS;
   THERAPY; LIGHT; PHOTOBIOMODULATION; ACTIVATION; DIFFERENTIATION;
   EXPRESSION
AB Laser irradiation activates a range of cellular processes and can promote tissue repair. Here, we examined the effects of high frequency near infrared (NIR) diode laser irradiation on the proliferation and migration of mouse calvarial osteoblastic cells (MC3T3 E1). MC3T3 E1 cells were cultured and exposed to high frequency (30 kHz) 910 nm diode laser irradiation at a dose of 0, 1.42, 2.85, 5.7, or 17.1 J/cm(2). Cell proliferation was evaluated with BrdU and ATP concentration assays. Cell migration was analyzed by quantitative assessment of wound healing using the Incucyt(A (R)) ZOOM system. In addition, phosphorylation of mitogen activated protein kinase (MAPK) family members including p38 mitogen activated protein kinase (p38), stress activated protein kinase/Jun amino terminal kinase (SAPK/JNK), and extracellular signal regulated protein kinase (ERK)1/2) after laser irradiation was examined with western blotting. Compared to the control, cell proliferation was significantly increased by laser irradiation at a dose of 2.85, 5.7, or 17.1 J/cm(2). Laser irradiation at a dose of 2.85 J/cm(2) induced MC3T3 E1 cells to migrate more rapidly than non irradiated control cells. Irradiation with the high frequency 910 nm diode laser at a dose of 2.85 J/cm(2) induced phosphorylation of MAPK/ERK1/2 15 and 30 min later. However, phosphorylation of p38 MAPK and SAPK/JNK was not changed by NIR diode laser irradiation at a dose of 2.85 J/cm(2). Irradiation with a high frequency NIR diode laser increased cell division and migration of MT3T3 E1 cells, possibly via MAPK/ERK signaling. These observations may be important for enhancing proliferation and migration of osteoblasts to improve regeneration of bone tissues.
C1 [Kunimatsu, Ryo; Gunji, Hidemi; Tsuka, Yuji; Yoshimi, Yuki; Awada, Tetsuya; Sumi, Keisuke; Nakajima, Kengo; Kimura, Aya; Hiraki, Tomoka; Abe, Takaharu; Naoto, Hirose; Yanoshita, Makoto; Tanimoto, Kotaro] Hiroshima Univ, Grad Sch Biomed Sci, Dept Orthodont & Craniofacial Dev Biol, Minami Ku, 1 2 3 Kasumi, Hiroshima 7348553, Japan.
C3 Hiroshima University
RP Kunimatsu, R (通讯作者)，Hiroshima Univ, Grad Sch Biomed Sci, Dept Orthodont & Craniofacial Dev Biol, Minami Ku, 1 2 3 Kasumi, Hiroshima 7348553, Japan.
EM ryoukunimatu@hiroshima u.ac.jp
FU JSPS KAKENHI [16K11790, 16K20644, 25862016, 17K17327, 15K20595];
   Grants in Aid for Scientific Research [16K11790, 25862016, 17K17330,
   15K20595, 16K20644, 17K17327] Funding Source: KAKEN
FX This work was supported by grants from the JSPS KAKENHI (numbers
   16K11790, 16K20644, 25862016, 17K17327, and 15K20595).
CR Al Watban FAH, 2004, J CLIN LASER MED SUR, V22, P15, DOI 10.1089/104454704773660921
   AlGhamdi KM, 2012, LASER MED SCI, V27, P237, DOI 10.1007/s10103 011 0885 2
   Aoki A, 2004, PERIODONTOL 2000, V36, P59, DOI 10.1111/j.1600 0757.2004.03679.x
   Ates GB, 2017, LASER MED SCI, V32, P591, DOI 10.1007/s10103 017 2153 6
   Ball KA, 2011, J PHOTOCH PHOTOBIO B, V102, P182, DOI 10.1016/j.jphotobiol.2010.12.002
   Ballini A, 2015, J BIOL REG HOMEOS AG, V29, P813
   Barolet D, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3477186
   Baroni BM, 2010, EUR J APPL PHYSIOL, V110, P789, DOI 10.1007/s00421 010 1562 z
   Bloise N, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.12.128006
   Capon A, 2003, AM J CLIN DERMATOL, V4, P1, DOI 10.2165/00128071 200304010 00001
   Crisan Liana, 2015, Clujul Med, V88, P224, DOI 10.15386/cjmed 433
   Ejiri K, 2014, LASER MED SCI, V29, P1339, DOI 10.1007/s10103 013 1292 7
   Fabre HSC, 2015, J PHYS THER SCI, V27, P1645, DOI 10.1589/jpts.27.1645
   Fekrazad R, 2012, J LASERS MED SCI, V3, P135
   Giannunzio GA, 2008, IMPLANT DENT, V17, P118, DOI 10.1097/ID.0b013e318166d800
   Ginani F, 2015, LASER MED SCI, V30, P2189, DOI 10.1007/s10103 015 1730 9
   Sella VRG, 2015, LASER MED SCI, V30, P1061, DOI 10.1007/s10103 015 1710 0
   Gupta A, 2015, J BIOPHOTONICS, V8, P489, DOI 10.1002/jbio.201400058
   Gupta A, 2014, LASER MED SCI, V29, P257, DOI 10.1007/s10103 013 1319 0
   Gupta A, 2013, BIOTECHNOL ADV, V31, P607, DOI 10.1016/j.biotechadv.2012.08.003
   Hashmi JT, 2010, LASER SURG MED, V42, P450, DOI 10.1002/lsm.20950
   Izumi Y, 2011, PERIODONTOL 2000, V56, P166, DOI 10.1111/j.1600 0757.2010.00366.x
   Jafarabadi MR, 2016, LASER MED SCI, V31, P1827, DOI 10.1007/s10103 016 2058 9
   Joensen J, 2012, PHOTOMED LASER SURG, V30, P688, DOI 10.1089/pho.2012.3306
   Karu TI, 2005, PHOTOMED LASER SURG, V23, P355, DOI 10.1089/pho.2005.23.355
   Karu TI, 2010, IUBMB LIFE, V62, P607, DOI 10.1002/iub.359
   Keshri GK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166705
   Kim EK, 2010, BBA MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009
   Kymplová J, 2003, J CLIN LASER MED SUR, V21, P35, DOI 10.1089/10445470360516725
   Lane N, 2006, NATURE, V443, P901, DOI 10.1038/443901a
   Lirani Galvao AP, 2006, PHOTOMED LASER SURG, V24, P735, DOI 10.1089/pho.2006.24.735
   Mester E., 1969, Z. Exper. Surgery, V2, P94
   Miyata H, 2006, INT ENDOD J, V39, P238, DOI 10.1111/j.1365 2591.2006.01080.x
   Noda M, 2016, LASER SURG MED, V48, P955, DOI 10.1002/lsm.22560
   Ohshiro T, 1991, J Clin Laser Med Surg, V9, P267
   Ozawa Y, 1998, BONE, V22, P347, DOI 10.1016/S8756 3282(97)00294 9
   Pretel H, 2007, LASER SURG MED, V39, P788, DOI 10.1002/lsm.20585
   Pyo SJ, 2013, LASER MED SCI, V28, P543, DOI 10.1007/s10103 012 1109 0
   Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392
   Ren C, 2016, LASER MED SCI, V31, P1493, DOI 10.1007/s10103 016 2026 4
   Reynolds Mark A, 2012, J Evid Based Dent Pract, V12, P118, DOI 10.1016/S1532 3382(12)70023 4
   Roelandts R, 2005, PHOTODERMATOL PHOTO, V21, P115, DOI 10.1111/j.1600 0781.2005.00160.x
   Saracino S, 2009, LASER SURG MED, V41, P298, DOI 10.1002/lsm.20762
   SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337
   Shakouri SK, 2010, LASER MED SCI, V25, P73, DOI 10.1007/s10103 009 0670 7
   Shefer G, 2001, J CELL PHYSIOL, V187, P73, DOI 10.1002/1097 4652(2001)9999:9999<::AID JCP1053>3.0.CO;2 9
   Soares DM, 2015, LASER MED SCI, V30, P1171, DOI 10.1007/s10103 013 1436 9
   Soleimani M, 2012, LASER MED SCI, V27, P423, DOI 10.1007/s10103 011 0930 1
   Suzuki R, 2016, LASER MED SCI, V31, P1683, DOI 10.1007/s10103 016 2038 0
   Takahashi H, 2004, ARCH DERMATOL RES, V296, P74, DOI 10.1007/s00403 004 0478 z
   Tschon M, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.7.078002
   Wagner VP, 2016, LASER MED SCI, V31, P665, DOI 10.1007/s10103 016 1904 0
   Walsh LJ, 1997, AUST DENT J, V42, P302, DOI 10.1111/j.1834 7819.1997.tb00134.x
   Wu JY, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0044027, 10.1371/journal.pone.0046393]
   Yadav A, 2016, J PHOTOCH PHOTOBIO B, V162, P77, DOI 10.1016/j.jphotobiol.2016.06.031
   Yang JJ, 2009, NEUROCHEM RES, V34, P1685, DOI 10.1007/s11064 009 9963 2
NR 56
TC 25
Z9 25
U1 0
U2 21
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD JUL
PY 2018
VL 33
IS 5
BP 959
EP 966
DI 10.1007/s10103 017 2426 0
PG 8
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA GJ7SJ
UT WOS:000435589100003
PM 29302842
DA 2025 08 17
ER

PT J
AU Huang, YJ
   Zhao, SC
   Zhang, CQ
   Li, XL
AF Huang, Yinjun
   Zhao, Shichang
   Zhang, Changqing
   Li, Xiaolin
TI Downregulation of connective tissue growth factor reduces migration and
   invasiveness of osteosarcoma cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE connective tissue growth factor; statin; invasion; migration;
   chemotherapy resistance
ID GERANYLGERANYLTRANSFERASE I INHIBITORS; IMMEDIATE EARLY GENE;
   BREAST CANCER; OSTEOBLAST DIFFERENTIATION; EXTRACELLULAR MATRIX;
   TRANSCRIPTION FACTOR; ZOLEDRONIC ACID; CCN PROTEINS; STATINS; CYR61
AB As one of the most serious types of primary bone tumor, osteosarcoma (OSA) features metastatic lesions, and resistance to chemotherapy is common. The underlying mechanisms of these characteristics may account for the failure of treatments and the poor prognosis of patients with OSA. It has been reported that inhibition of Cyr61 suppresses OSA cell proliferation as it represents a target of statins. In addition to cystein rich protein 61 (Cyr61) and nephroblastoma overexpression, connective tissue growth factor (CTGF) is a member of the CCN family and may therefore exhibit effects on human OSA cells similar to those of Cyr61. In the current study, acridine orange/ethidium bromide staining were used to determine the rate of apoptosis. The present study demonstrated that small interfering RNA mediated silencing of CTGF promoted cell death and suppressed OSA cell migration and invasion, as indicated by wound healing and Transwell assays, while lentivirus mediated overexpression of CTGF reversed these effects. Furthermore, a colorimetric caspase assay demonstrated that CTGF knockdown enhanced the efficacy of chemotherapeutic drugs. The results of the present study provided a novel molecular target which may be utilized for the treatment of metastatic OSA.
C1 [Huang, Yinjun; Zhao, Shichang; Zhang, Changqing; Li, Xiaolin] Shanghai Jiao Tong Univ, Dept Orthoped Surg, Shanghai Peoples Hosp 6, 600 Yishan Rd, Shanghai 200233, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Li, XL (通讯作者)，Shanghai Jiao Tong Univ, Dept Orthoped Surg, Shanghai Peoples Hosp 6, 600 Yishan Rd, Shanghai 200233, Shanghai, Peoples R China.
EM lixiaolin@sjtu.edu.cn
RI changqing, zhang/JJE 9538 2023
OI zhang, changqing/0000 0002 7408 4126
CR Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355
   Beri A, 2009, AM J CARDIOVASC DRUG, V9, P361, DOI 10.2165/11315710 000000000 00000
   Bleau AM, 2005, FRONT BIOSCI LANDMRK, V10, P998, DOI 10.2741/1594
   Cao Y, 2005, CANCER RES, V65, P1124, DOI 10.1158/0008 5472.CAN 04 2128
   Cao Y, 2008, MOL CANCER RES, V6, P119, DOI 10.1158/1541 7786.MCR 07 0090
   Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289
   Chen CC, 2009, INT J BIOCHEM CELL B, V41, P771, DOI 10.1016/j.biocel.2008.07.025
   Delarue FL, 2007, ONCOGENE, V26, P633, DOI 10.1038/sj.onc.1209819
   Entz Werlé N, 2005, INT J CANCER, V117, P349, DOI 10.1002/ijc.21068
   Farwell WR, 2008, JNCI J NATL CANCER I, V100, P134, DOI 10.1093/jnci/djm286
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Fromigué O, 2006, CELL DEATH DIFFER, V13, P1845, DOI 10.1038/sj.cdd.4401873
   Fromigué O, 2008, J BIOL CHEM, V283, P30549, DOI 10.1074/jbc.M801436200
   Fromigué O, 2008, J PHARMACOL EXP THER, V325, P595, DOI 10.1124/jpet.108.136127
   Fromigue O, 2011, J BONE MINER RES, V26, P1533, DOI 10.1002/jbmr.343
   Gonyeau MJ, 2010, PHARMACOTHERAPY, V30, P177, DOI 10.1592/phco.30.2.177
   Hall Glenn F, 2011, CELL MOL LIFE SCI, V68, P3209, DOI 10.1007/s00018 011 0782 7
   Hiraga T, 2001, CANCER RES, V61, P4418
   Holbourn KP, 2008, TRENDS BIOCHEM SCI, V33, P461, DOI 10.1016/j.tibs.2008.07.006
   Istvan E, 2003, ATHEROSCLEROSIS SUPP, V4, P3, DOI 10.1016/S1567 5688(03)00003 5
   Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599
   Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982
   Kubota S, 2011, J CELL COMMUN SIGNAL, V5, P209, DOI 10.1007/s12079 011 0123 5
   LADANYI M, 1993, CANCER RES, V53, P16
   Leask A, 2006, J CELL SCI, V119, P4803, DOI 10.1242/jcs.03270
   Lee MV, 2001, CANCER RES, V61, P2602
   Manara MC, 2002, AM J PATHOL, V160, P849, DOI 10.1016/S0002 9440(10)64908 5
   Marra M, 2009, INT J CANCER, V125, P2004, DOI 10.1002/ijc.24648
   Martirosyan A, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 103
   McTaggart SJ, 2006, CELL MOL LIFE SCI, V63, P255, DOI 10.1007/s00018 005 5298 6
   Menéndez JA, 2003, ENDOCR RELAT CANCER, V10, P141, DOI 10.1677/erc.0.0100141
   Nguyen N, 2006, CANCER RES, V66, P2658, DOI 10.1158/0008 5472.CAN 05 2082
   O'Farrill JS, 2014, ADV EXP MED BIOL, V804, P147, DOI 10.1007/978 3 319 04843 7_8
   Ory B, 2005, CANCER AM CANCER SOC, V104, P2522, DOI 10.1002/cncr.21530
   Perbal B, 2008, CLIN CANCER RES, V14, P701, DOI 10.1158/1078 0432.CCR 07 0806
   Pompetti F, 1996, J CELL BIOCHEM, V63, P37
   Schmidmaier R, 2007, EUR J HAEMATOL, V79, P240, DOI 10.1111/j.1600 0609.2007.00902.x
   Sebti SM, 2000, ONCOGENE, V19, P6584, DOI 10.1038/sj.onc.1204146
   Sonnemann J, 2001, ANTI CANCER DRUG, V12, P459, DOI 10.1097/00001813 200106000 00007
   Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187
   van der Spek E, 2007, HAEMATOLOGICA, V92, pE130, DOI 10.3324/haematol.12071
   van der Spek E, 2006, HAEMATOLOGICA, V91, P542
   WANG ZQ, 1995, CANCER RES, V55, P6244
   YANG GP, 1991, CELL GROWTH DIFFER, V2, P351
   Zhang PY, 2008, CLIN CANCER RES, V14, P2962, DOI 10.1158/1078 0432.CCR 07 1992
   Zhang YJ, 2014, TUMOR BIOL, V35, P5055, DOI 10.1007/s13277 014 1799 y
NR 46
TC 4
Z9 4
U1 0
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD FEB
PY 2016
VL 13
IS 2
BP 1888
EP 1894
DI 10.3892/mmr.2015.4701
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA DC9PO
UT WOS:000369553700110
PM 26707502
OA Bronze
DA 2025 08 17
ER

PT J
AU Salesi, M
   Mottaghi, P
   Karimifar, M
   Farajzadegan, Z
AF Salesi, Mansour
   Mottaghi, Peyman
   Karimifar, Mansour
   Farajzadegan, Ziba
TI Intravenous pamidronate for refractory rheumatoid arthritis
SO JOURNAL OF RESEARCH IN MEDICAL SCIENCES
LA English
DT Article
DE Rheumatoid Arthritis; Refractory; Pamidronate
ID ANKYLOSING SPONDYLITIS; BONE TURNOVER; BISPHOSPHONATES; AMELIORATION;
   MACROPHAGES; ALENDRONATE; MECHANISMS; MIGRATION; INFUSION; EFFICACY
AB Background: Patients with rheumatoid arthritis may be resistant to conventional treatment with disease modifying antirheumatic drugs (DMARDs). On the other hand, biologic therapy is costly and may be inconvenient for many patients. Pamidronate is a potent bisphosphonate with the capacity of modifying the biological activity of the immune system cells. It may thus be used as an anti inflammatory agent in patients with inflammatory joint diseases. Materials and Methods: To assess the effectiveness of pamidronate in the management of rheumatoid arthritis, we selected 38 patients with rheumatoid arthritis to enroll in a pilot study to receive pamidronate and conventional treatment with prednisolone and DMARDs in combination. These patients received 60 mg of pamidronate for 3 consecutive months and were followed for 6 months since the first infusion. Results: The mean visual analogue score (VAS) and disease activity score (DAS28) fell steadily until one month after the third infusion. However, no improvements were observed during the 3 months after the last infusion of the drug. All patients, except one, reported decreased pain in response to 3 consecutive pulses of pamidronate and most had improvements in the assessed laboratory and clinical indices. The drug was tolerated well in our patients. Conclusion: Pamidronate infusions had beneficial effects on various clinical and laboratory parameters of patients, but alleviation of symptoms were temporary and did not last for more than 6 months. This treatment option can be a choice for difficult cases of rheumatoid arthritis with severe pain and osteoporosis.
C1 [Salesi, Mansour; Mottaghi, Peyman; Karimifar, Mansour] Isfahan Univ Med Sci, Sch Med, Dept Rheumatol, Esfahan, Iran.
   [Farajzadegan, Ziba] Isfahan Univ Med Sci, Sch Med, Dept Community Med, Esfahan, Iran.
C3 Isfahan University of Medical Sciences; Isfahan University of Medical
   Sciences
RP Mottaghi, P (通讯作者)，Isfahan Univ Med Sci, Sch Med, Dept Rheumatol, Esfahan, Iran.
EM motaghi@med.mui.ac.ir
RI Mottaghi, Peyman/W 4782 2019; salesi, mansour/AAA 4561 2020;
   farajzadegan, ziba/AAA 1362 2020; Karimifar, Mansoor/D 2074 2018
OI Mottaghi, Peyman/0000 0002 9810 4136; salesi,
   mansour/0000 0001 7108 6188; farajzadegan, ziba/0000 0001 8548 2843;
   Karimifar, Mansoor/0000 0003 4688 991X
FU Isfahan University of Medical Sciences, Isfahan, Iran [187074]
FX The authors would like to thank nurses at the rheumatology wards of Al
   Zahra Hospital for their technical assistance. This work was supported
   in part by grants from Isfahan University of Medical Sciences, Isfahan,
   Iran (No. 187074).
CR Anderson John J, 2004, J Foot Ankle Surg, V43, P285, DOI 10.1053/j.jfas.2004.07.005
   Beigi AA, 2011, IRAN RED CRESCENT ME, V13, P263
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Cairns AP, 2005, ANN RHEUM DIS, V64, P338, DOI 10.1136/ard.2004.022871
   Cantatore FP, 1999, J RHEUMATOL, V26, P2318
   de VE, 1982, IMMUNOLOGY, V47, P157
   EGGELMEIJER F, 1994, J RHEUMATOL, V21, P2016
   GALLACHER SJ, 1991, ANN RHEUM DIS, V50, P930, DOI 10.1136/ard.50.12.930
   Gnant M., 2011, Clinical Investigation, V1, P97, DOI 10.4155/cli.10.15
   Goldring SR, 2000, ARTHRITIS RES, V2, P33, DOI 10.1186/ar67
   Goldring SR, 2002, CURR OPIN RHEUMATOL, V14, P406, DOI 10.1097/00002281 200207000 00013
   Goronzy J.J., 1997, Primer on Rheumatic Diseases, V11, P155
   Grover R, 2006, ANN RHEUM DIS, V65, P688, DOI 10.1136/ard.2005.041392
   Haibel H., 2003, Rheumatology (Oxford), V42, P1018, DOI 10.1093/rheumatology/keg256
   Haugeberg G, 2003, CURR OPIN RHEUMATOL, V15, P469, DOI 10.1097/00002281 200307000 00016
   Kinne RW, 1995, ARTHRITIS RHEUM US, V38, P1777, DOI 10.1002/art.1780381211
   Maksymowych WP, 2001, J RHEUMATOL, V28, P144
   McGonagle D, 1999, ARTHRITIS RHEUM, V42, P1706, DOI 10.1002/1529 0131(199908)42:8<1706::AID ANR20>3.0.CO;2 Z
   Naqvi A, 2008, AM J MED SCI, V335, P145, DOI 10.1097/MAJ.0b013e3180a5e957
   O'Dell JR, 2004, NEW ENGL J MED, V350, P2591, DOI 10.1056/NEJMra040226
   Pappagallo M, 2003, J PAIN SYMPTOM MANAG, V26, P678, DOI 10.1016/S0885 3924(03)00201 X
   PENNANEN N, 1995, PHARMACEUT RES, V12, P916, DOI 10.1023/A:1016281608773
   Pietschmann P, 1998, CALCIFIED TISSUE INT, V63, P325, DOI 10.1007/s002239900535
   RALSTON SH, 1989, ANN RHEUM DIS, V48, P396, DOI 10.1136/ard.48.5.396
   Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212
   Salesi M, 2011, J RES MED SCI, V16, P703
   STEVENSON PH, 1986, CALCIFIED TISSUE INT, V38, P227, DOI 10.1007/BF02556715
   Toussirot E, 2006, CLIN EXP RHEUMATOL, V24, P348
   Valleala H, 2003, J RHEUMATOL, V30, P468
   Van Offel JF, 2001, CLIN EXP RHEUMATOL, V19, P13
NR 30
TC 4
Z9 4
U1 0
U2 1
PU ISFAHAN UNIV MED SCIENCES
PI ISFAHAN
PA HEZARJERIB AVE, PO BOX 81745 319, ISFAHAN, 00000, IRAN
SN 1735 1995
J9 J RES MED SCI
JI J. Res. Med. Sci.
PD MAY
PY 2012
VL 17
IS 5
BP 422
EP 427
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 997QB
UT WOS:000308179800002
PM 23626604
DA 2025 08 17
ER

PT J
AU Romeo, C
   Li, Q
   Copeland, L
AF Romeo, Cristina
   Li, Quan
   Copeland, Larry
TI Severe pegfilgrastim induced bone pain completely alleviated with
   loratadine: A case report
SO JOURNAL OF ONCOLOGY PHARMACY PRACTICE
LA English
DT Article
ID COLONY STIMULATING FACTOR; CLINICAL PRACTICE GUIDELINE; GROWTH FACTORS;
   CANCER; RELEASE; UPDATE; CELLS
AB Febrile neutropenia is an oncologic emergency that can result in serious consequences. Granulocyte colony stimulating factors (G CSFs) are often used as prophylaxis for febrile neutropenia. Bone pain is the most notorious adverse effect caused by G CSFs. Specifically, with pegfilgrastim (Neulasta (R)), the incidence of bone pain is higher in practice than was observed during clinical trials. Traditional analgesics, such as non steroidal anti inflammatory drugs (NSAIDs) and opioids, can be ineffective in severe pegfilgrastim induced bone pain. With the high frequency of this adverse effect, it is clear that health practitioners need additional treatment options for patients who experience severe pegfilgrastim induced bone pain. The mechanisms of bone pain secondary to G CSFs are not fully known, but research has shown that histamine release is involved in the inflammatory process. There is scant previous clinical data on antihistamine use in the management of G CSF induced pain. We present the first case report in which loratadine prophylaxis completely alleviated NSAID resistant severe pain secondary to pegfilgrastim. The result showed that loratadine may be a promising option for severe, resistant pegfilgrastim induced bone pain. Further clinical studies are warranted and ongoing.
C1 [Romeo, Cristina] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA.
   [Li, Quan] Ohio State Univ, James Canc Hosp, Columbus, OH 43210 USA.
   [Copeland, Larry] Ohio State Univ, Coll Med, Columbus, OH 43210 USA.
C3 University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute; University System of Ohio; Ohio State
   University; University System of Ohio; Ohio State University
RP Li, Q (通讯作者)，Ohio State Univ, James Canc Hosp, 410 W 10th Ave,Doan Rm 110, Columbus, OH 43210 USA.
EM Quan.Li@osumc.edu
CR BENNETT A, 1988, CANCER SURV, V7, P55
   Cheng Kuo Chu, 2006, Journal of Microbiology Immunology and Infection, V39, P206
   CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305
   Freifeld AG, 2011, CLIN INFECT DIS, V52, P427, DOI 10.1093/cid/ciq147
   Gregory SA., 2010, COMM ONCOL, V7, P297, DOI [10.1016/S1548 5315(11)70402 8, DOI 10.1016/S1548 5315(11)70402 8]
   GUDI R, 1995, ANN INTERN MED, V123, P236, DOI 10.7326/0003 4819 123 3 199508010 00019
   Kirshner JJ, 2012, J CLIN ONCOL, V30, P1974, DOI 10.1200/JCO.2011.37.8364
   Kirshner JJ., 2007, COMMUN ONCOL, V4, P455, DOI [10.1016/S1548 5315(11)70107 3, DOI 10.1016/S1548 5315(11)70107 3]
   KONIG B, 1994, INFECT IMMUN, V62, P2085
   Lambertini M, 2014, CRIT REV ONCOL HEMAT, V89, P112, DOI 10.1016/j.critrevonc.2013.08.006
   Ogata SI, 2005, J CLIN ONCOL S, V16
   Philpot EE, 2000, ALLERGY ASTHMA PROC, V21, P15, DOI 10.2500/108854100778249033
   Smith TJ, 2006, J CLIN ONCOL, V24, P3187, DOI 10.1200/JCO.2006.06.4451
NR 13
TC 18
Z9 19
U1 0
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1078 1552
EI 1477 092X
J9 J ONCOL PHARM PRACT
JI J. Oncol. Pharm. Pract.
PD AUG
PY 2015
VL 21
IS 4
BP 301
EP 304
DI 10.1177/1078155214527858
PG 4
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA CL9KR
UT WOS:000357297600010
PM 24664474
DA 2025 08 17
ER

PT J
AU Tuure, L
   Hämäläinen, M
   Moilanen, T
   Moilanen, E
AF Tuure, L.
   Hamalainen, M.
   Moilanen, T.
   Moilanen, E.
TI Aurothiomalate inhibits the expression of mPGES 1 in primary human
   chondrocytes
SO SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
LA English
DT Article
ID PROSTAGLANDIN E SYNTHASE 1; OSTEOARTHRITIC CARTILAGE;
   RHEUMATOID ARTHRITIS; GOLD; IDENTIFICATION; DELETION; ENZYMES; TARGET;
   DRUGS; COX 2
AB Objectives: Microsomal prostaglandin E synthase 1 (mPGES 1) is a terminal enzyme in the production of prostaglandin E 2 (PGE(2)) and its expression is upregulated during inflammation. mPGES 1 is considered as a potential drug target for the treatment of arthritis to reduce adverse effects related to the current non steroidal anti inflammatory drugs (NSAIDs). Our aim was to study the expression of mPGES 1 in primary human chondrocytes and whether the expression is affected by clinically used antirheumatic drugs.
   Method: Primary human chondrocytes were isolated from cartilage samples obtained from patients undergoing total knee replacement surgery. Expression of mPGES 1 was studied by quantitative real time polymerase chain reaction (PCR) and Western blot analysis. PGE(2) levels were measured by enzyme linked immunosorbent assay (ELISA).
   Results: mPGES 1 expression in primary human chondrocytes was enhanced when the cells were exposed to interleukin 1 beta (IL 1 beta) and mPGES 1 protein levels continued to increase up to the 96 h follow up. Aurothiomalate inhibited mPGES 1 expression and PGE(2) production in a dose dependent manner, as did the anti inflammatory steroid dexamethasone. Other disease modifying antirheumatic drugs (DMARDs) studied (sulfasalazine, methotrexate, and hydroxychloroquine) did not alter mPGES 1 expression.
   Conclusions: The results introduce aurothiomalate as the first, and so far the only, DMARD found to be able to inhibit mPGES 1 expression. The effect is likely involved in the mechanisms of action of this gold containing DMARD in rheumatic diseases. The results are implicated in the regulatory mechanisms of mPGES 1 expression, which are under intensive research.
C1 [Tuure, L.; Hamalainen, M.; Moilanen, T.; Moilanen, E.] Univ Tampere, Sch Med, Immunopharmacol Res Grp, FIN 33014 Tampere, Finland.
   [Tuure, L.; Hamalainen, M.; Moilanen, T.; Moilanen, E.] Tampere Univ Hosp, Tampere, Finland.
   [Moilanen, T.] Coxa Hosp Joint Replacement, Tampere, Finland.
C3 Tampere University; Tampere University; Tampere University Hospital;
   Coxa Hospital for Joint Replacement
RP Moilanen, E (通讯作者)，Univ Tampere, Sch Med, Immunopharmacol Res Grp, FIN 33014 Tampere, Finland.
EM eeva.moilanen@uta.fi
OI Tuure, Lauri/0000 0003 1284 3008; Hamalainen, Mari/0000 0002 6409 3758
FU Medical Research Fund of Tampere University Hospital, Finland; Academy
   of Finland
FX We thank Ms Meiju Kukkonen for excellent technical assistance and Mrs
   Heli Maatta for skillful secretarial help. This study was supported by
   grants from the Medical Research Fund of Tampere University Hospital,
   Finland, and the Academy of Finland.
CR Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140 6736(13)60900 9
   Chang HH, 2011, FUTURE MED CHEM, V3, P1909, DOI [10.4155/FMC.11.136, 10.4155/fmc.11.136]
   Cheng Y, 2006, J CLIN INVEST, V116, P1391, DOI 10.1172/JCI27540
   Freyberg RH, 1941, J CLIN INVEST, V20, P401, DOI 10.1172/JCI101235
   GERBER RC, 1972, ANN RHEUM DIS, V31, P308, DOI 10.1136/ard.31.4.308
   Hämäläinen M, 2011, PLANTA MED, V77, P1504, DOI 10.1055/s 0030 1270762
   Idborg H, 2013, PROSTAG OTH LIPID M, V107, P18, DOI 10.1016/j.prostaglandins.2013.07.004
   Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220
   Kawabata A, 2011, BIOL PHARM BULL, V34, P1170, DOI 10.1248/bpb.34.1170
   Kean W. F., 2008, Inflammopharmacology, V16, P112, DOI 10.1007/s10787 007 0021 x
   Korotkova M, 2005, ARTHRITIS RHEUM US, V52, P3439, DOI 10.1002/art.21390
   Korotkova M, 2014, BASIC CLIN PHARMACOL, V114, P64, DOI 10.1111/bcpt.12162
   Koskinen A, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3512
   Leclerc P, 2013, PROSTAG OTH LIPID M, V107, P26, DOI 10.1016/j.prostaglandins.2013.09.001
   Leistad L, 2011, SCAND J RHEUMATOL, V40, P308, DOI 10.3109/03009742.2010.547872
   Li XF, 2005, J RHEUMATOL, V32, P887
   Nieminen R, 2008, EUR J PHARMACOL, V587, P309, DOI 10.1016/j.ejphar.2008.03.016
   Nieminen R, 2010, ARTHRITIS RHEUM US, V62, P1650, DOI 10.1002/art.27409
   Norberg JK, 2013, PHARM PAT ANAL, V2, P265, DOI [10.4155/PPA.12.90, 10.4155/ppa.12.90]
   Park SJ, 2012, BIOORG MED CHEM LETT, V22, P7335, DOI 10.1016/j.bmcl.2012.10.085
   PENNEYS NS, 1974, J INVEST DERMATOL, V63, P356, DOI 10.1111/1523 1747.ep12680840
   Rantalaiho V, 2012, CLIN EXP RHEUMATOL, V30, pS27
   Samuelsson B, 2007, PHARMACOL REV, V59, P207, DOI 10.1124/pr.59.3.1
   Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469
   Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100
   Westman M, 2004, ARTHRITIS RHEUM US, V50, P1774, DOI 10.1002/art.20286
NR 26
TC 6
Z9 6
U1 0
U2 5
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69 77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0300 9742
EI 1502 7732
J9 SCAND J RHEUMATOL
JI Scand. J. Rheumatol.
PY 2015
VL 44
IS 1
BP 74
EP 79
DI 10.3109/03009742.2014.927917
PG 6
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA AY2GY
UT WOS:000347408000012
PM 25314295
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Movérare Skrtic, S
   Wu, JY
   Henning, P
   Gustafsson, KL
   Sjögren, K
   Windahl, SH
   Koskela, A
   Tuukkanen, J
   Börjesson, AE
   Lagerquist, MK
   Lerner, UH
   Zhang, FP
   Gustafsson, JÅ
   Poutanen, M
   Ohlsson, C
AF Moverare Skrtic, Sofia
   Wu, Jianyao
   Henning, Petra
   Gustafsson, Karin L.
   Sjogren, Klara
   Windahl, Sara H.
   Koskela, Antti
   Tuukkanen, Juha
   Borjesson, Anna E.
   Lagerquist, Marie K.
   Lerner, Ulf H.
   Zhang, Fu Ping
   Gustafsson, Jan Ake
   Poutanen, Matti
   Ohlsson, Claes
TI The bone sparing effects of estrogen and WNT16 are independent of each
   other
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE WNT16; estrogen; cortical bone; trabecular bone; transgenic mice
ID WNT/BETA CATENIN; MINERAL DENSITY; GENOME WIDE; SOST GENE; MASS;
   OSTEOPOROSIS; SCLEROSTIN; METAANALYSIS; DICKKOPF 1; MUTATION
AB Wingless type MMTV integration site family (WNT)16 is a key regulator of bone mass with high expression in cortical bone, and Wnt16( / ) mice have reduced cortical bone mass. As Wnt16 expression is enhanced by estradiol treatment, we hypothesized that the bone sparing effect of estrogen in females is WNT16 dependent. This hypothesis was tested in mechanistic studies using two genetically modified mouse models with either constantly high osteoblastic Wnt16 expression or no Wnt16 expression. We developed a mouse model with osteoblast specific Wnt16 overexpression (Obl Wnt16). These mice had several fold elevated Wnt16 expression in both trabecular and cortical bone compared with wild type (WT) mice. Obl Wnt16 mice displayed increased total body bone mineral density (BMD), surprisingly caused mainly by a substantial increase in trabecular bone mass, resulting in improved bone strength of vertebrae L 3. Ovariectomy (ovx) reduced the total body BMD and the trabecular bone mass to the same degree in Obl Wnt16 mice and WT mice, suggesting that the bone sparing effect of estrogen is WNT16 independent. However, these bone parameters were similar in ovx Obl Wnt16 mice and sham operated WT mice. The role of WNT16 for the bone sparing effect of estrogen was also evaluated in Wnt16( / ) mice. Treatment with estradiol increased the trabecular and cortical bone mass to a similar extent in both Wnt16 /  and WT mice. In conclusion, the bone sparing effects of estrogen and WNT16 are independent of each other. Furthermore, loss of endogenous WNT16 results specifically in cortical bone loss, whereas overexpression of WNT16 surprisingly increases mainly trabecular bone mass. WNT16 targeted therapies might be useful for treatment of postmenopausal trabecular bone loss.
C1 [Moverare Skrtic, Sofia; Wu, Jianyao; Henning, Petra; Gustafsson, Karin L.; Sjogren, Klara; Windahl, Sara H.; Borjesson, Anna E.; Lagerquist, Marie K.; Lerner, Ulf H.; Poutanen, Matti; Ohlsson, Claes] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Ctr Bone & Arthrit Res, SE 41345 Gothenburg, Sweden.
   [Koskela, Antti; Tuukkanen, Juha] Univ Oulu, MRC Oulu, Unit Canc Res & Translat Med, FI 90014 Oulu, Finland.
   [Koskela, Antti; Tuukkanen, Juha] Univ Oulu, Dept Anat & Cell Biol, FI 90014 Oulu, Finland.
   [Borjesson, Anna E.] Univ Edinburgh, Western Gen Hosp, MRC,Inst Genet & Mol Med, Rheumatol & Bone Dis Unit,Ctr Genom & Expt Med, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Zhang, Fu Ping; Poutanen, Matti] Univ Turku, Dept Physiol, Turku Ctr Dis modeling, Inst Biomed, FI 20520 Turku, Finland.
   [Gustafsson, Jan Ake] Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, Houston, TX 77204 USA.
C3 University of Gothenburg; University of Oulu; University of Oulu;
   University of Edinburgh; University of Turku; University of Houston
   System; University of Houston
RP Gustafsson, JÅ (通讯作者)，Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, Houston, TX 77204 USA.
EM jgustafsson@uh.edu; Claes.Ohlsson@medic.gu.se
RI Windahl, Sara/HJI 2465 2023; Ohlsson, Claes/HIR 6959 2022; Poutanen,
   Matti/I 1700 2018; Tuukkanen, Juha/R 3728 2018; Skrtic,
   Sofia/AAQ 1585 2020; Henning, Petra/KIL 4650 2024; Horkeby,
   Karin/IUN 8177 2023; Lagerquist, Marie/A 9531 2010; Ohlsson,
   Claes/AGP 3544 2022
OI Henning, Petra/0000 0002 9330 6265; Tornqvist, Anna/0000 0003 2621 9038;
   Lagerquist, Marie/0000 0002 9089 8605; Ohlsson,
   Claes/0000 0002 9633 2805; Windahl, Sara/0000 0002 6611 6001; Tuukkanen,
   Juha/0000 0002 1723 6461; Sjogren, Klara/0000 0001 5776 7278; Koskela,
   Antti/0000 0001 7371 2488; Poutanen, Matti/0000 0002 8953 1734; Lerner,
   Ulf/0000 0002 3579 1960
FU Swedish Research Council; Swedish Foundation for Strategic Research;
   ALF/LUA research grant from Sahlgrenska University Hospital; Lundberg
   Foundation; Torsten and Ragnar Soderberg's Foundation; Novo Nordisk
   Foundation; Swedish Cancer Society; Cancer Prevention and Research
   Institute of Texas [RP110444 P1]; Texas Emerging Technology Fund
   [300 9 1958]; Robert A. Welch Foundation [E 0004]; Novo Nordisk Fonden
   [NNF15OC0015080, NNF14OC0010513, NNF13OC0005785] Funding Source:
   researchfish
FX We are grateful to A. Hansevi, B. Aleksic, and C. Uggla for technical
   assistance. This study was supported by the Swedish Research Council,
   the Swedish Foundation for Strategic Research, the ALF/LUA research
   grant from the Sahlgrenska University Hospital, the Lundberg Foundation,
   the Torsten and Ragnar Soderberg's Foundation, the Novo Nordisk
   Foundation, the Swedish Cancer Society, the Cancer Prevention and
   Research Institute of Texas (Grant RP110444 P1), the Texas Emerging
   Technology Fund under Agreement 18 No. 300 9 1958, and the Robert A.
   Welch Foundation (E 0004).
CR Armstrong VJ, 2007, J BIOL CHEM, V282, P20715, DOI 10.1074/jbc.M703224200
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140 6736(97)08233 0
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012
   Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140 6736(96)07113 9
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249
   Gao YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082436
   García Ibarbia C, 2013, OSTEOPOROSIS INT, V24, P2449, DOI 10.1007/s00198 013 2302 0
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hendrickx G, 2014, BONE, V59, P57, DOI 10.1016/j.bone.2013.10.022
   Hou XN, 2004, MOL ENDOCRINOL, V18, P3035, DOI 10.1210/me.2004 0259
   Khosla S, 2011, J BONE MINER RES, V26, P441, DOI 10.1002/jbmr.262
   Koller DL, 2013, J BONE MINER RES, V28, P547, DOI 10.1002/jbmr.1796
   Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Li XD, 2011, J BONE MINER RES, V26, P2610, DOI 10.1002/jbmr.472
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lim SK, 2011, FASEB J, V25, P3004, DOI 10.1096/fj.10 169136
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Medina Gomez C, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002718
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Turner RT, 1999, J BONE MINER RES, V14, P187, DOI 10.1359/jbmr.1999.14.2.187
   Vandenput L, 2009, NAT REV ENDOCRINOL, V5, P437, DOI 10.1038/nrendo.2009.112
   Vanderschueren D, 2014, ENDOCR REV, V35, P906, DOI 10.1210/er.2014 1024
   Wergedal JE, 2015, ENDOCRINOLOGY, V156, P1023, DOI 10.1210/en.2014 1702
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Windahl SH, 1999, J CLIN INVEST, V104, P895, DOI 10.1172/JCI6730
   Zhang QG, 2008, J NEUROSCI, V28, P8430, DOI 10.1523/JNEUROSCI.2752 08.2008
   Zheng HF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002745
NR 38
TC 55
Z9 60
U1 0
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 1
PY 2015
VL 112
IS 48
BP 14972
EP 14977
DI 10.1073/pnas.1520408112
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CX8XR
UT WOS:000365988900065
PM 26627248
OA Green Published
DA 2025 08 17
ER

PT J
AU Mavrokokki, T
   Cheng, A
   Stein, B
   Goss, A
AF Mavrokokki, Tony
   Cheng, Andrew
   Stein, Brien
   Goss, Alastair
TI Nature and frequency of bisphosphonate associated osteonecrosis of the
   jaws in Australia
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
ID AVASCULAR NECROSIS; SKELETAL COMPLICATIONS; RISK FACTORS; CANCER;
   PREVENTION; MECHANISMS
AB Purpose: The purpose of this study is to estimate the frequency and describe the clinical characteristics of patients diagnosed with bisphosphonate associated osteonecrosis of the jaws (ONJ) in Australia.
   Materials and Methods: Cases of ONJ were identified in 2004 and 2005 primarily by a postal survey of Australian Oral and Maxillofacial Surgeons (OMS) with additional cases from other dental specialists and the Commonwealth of Australia Adverse Drug Reaction Committee (ADRAC). The clinical characteristics were recorded. The frequency of ONJ cases was estimated from prescription and dental extraction data. Univariate and bivariate statistics were calculated.
   Results: One hundred fifty eight cases of ONJ were identified. These were primarily in patients with bone malignancy (72%) and the main trigger was dental extraction (73%). The reported number of cases varied between different Australian States with the highest frequency being reported in the States with the best integrated health systems. The frequency of ONJ in osteoporotic patients, mainly on weekly oral alendronate was 1 in 2,260 to 8,470 (0.01% to 0.04%) patients. If extractions were carried out, the calculated frequency was 1 in 296 to 1,130 cases (0.09% to 0.34%). The total close of oral alendronate at the onset of ONJ was 9,060 (+/ 7,269) mg. The frequency of ONJ for Paget's disease cases was 1 in 56 to 380 (0.26% to 1.8%). If extractions were carried out, the calculated frequency of ONJ was 1 in 7.4 to 48 (2.1% to 13.5%). The frequency of ONJ in bone malignancy cases, treated with mainly intravenous zoledronate or pamidronate was 1 in 87 to 114 (0.88% to 1.15%). If extractions were carried out, the calculated frequency of ONJ was 1 in 11 to 15 (6.67% to 9.1%) The total close of pamidronate was 3,285 (+/  2,530) mg and zoledronate 62 (+/  54.28) mg at the onset of ONJ. The median time to onset of ONJ was 12 months for zoledronate, 24 months for pamidronate, and 24 months alendronate.
   Conclusions: Before the prescription of bisphosphonates for bone disease the patient should be made dentally fit so that the need for subsequent dental extractions is minimized. Appropriate informed consent for the risk of ONJ for different bisphosphonates, for osteoporosis, and malignancy both in general and in particular for dental extractions can be provided using this data. (C) 2007 American Association of Oral and Maxillofacial Surgeons.
C1 Univ Adelaide, Oral & Maxillofacial Surg Unit, Sch Dent, Adelaide, SA 5005, Australia.
   Adelaide Dent Hosp, Oral & Maxillofacial Surg Unit, Adelaide, SA, Australia.
   Royal Adelaide Hosp, Oral & Maxillofacial Surg Unit, Adelaide, SA 5000, Australia.
   Ashford Canc Ctr, Ashford, Kent, England.
C3 University of Adelaide; Royal Adelaide Hospital
RP Goss, A (通讯作者)，Univ Adelaide, Oral & Maxillofacial Surg Unit, Sch Dent, Adelaide, SA 5005, Australia.
EM oral.surgery@adelaide.edu.au
OI Stein, Brian/0000 0002 9562 6326
CR [Anonymous], NATL DENT TELEPHONE
   Badros A, 2006, J CLIN ONCOL, V24, P945, DOI 10.1200/JCO.2005.04.2465
   Bagan JV, 2005, J ORAL PATHOL MED, V34, P120, DOI 10.1111/j.1600 0714.2004.00269.x
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Brennan DS, 2004, INT J ORAL MAX SURG, V33, P598, DOI 10.1016/j.ijom.2004.02.004
   Carter G, 2005, MED J AUSTRALIA, V182, P413, DOI 10.5694/j.1326 5377.2005.tb06761.x
   Carter GD, 2003, AUST DENT J, V48, P268
   Cheng A, 2005, AUST DENT J, V50, pS4, DOI 10.1111/j.1834 7819.2005.tb00384.x
   DAMATO K, EXPERT PANEL RECOMME
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Fleisch H, 2003, EUR SPINE J, V12, pS142, DOI 10.1007/s00586 003 0622 z
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Hellstein JW, 2005, J ORAL MAXIL SURG, V63, P682, DOI 10.1016/j.joms.2005.01.010
   Hortobagyi GN, 1998, J CLIN ONCOL, V16, P2038, DOI 10.1200/JCO.1998.16.6.2038
   Lugassy G, 2004, AM J MED, V117, P440, DOI 10.1016/j.amjmed.2004.04.015
   Maerevoet M, 2005, NEW ENGL J MED, V353, P100
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Migliorati CA, 2005, J AM DENT ASSOC, V136, P1658, DOI 10.14219/jada.archive.2005.0108
   Migliorati CA, 2003, J CLIN ONCOL, V21, P4253, DOI 10.1200/JCO.2003.99.132
   Pogrel MA, 2004, J ORAL MAXIL SURG, V62, P391, DOI 10.1016/j.joms.2003.11.003
   Purcell PM, 2005, MED J AUSTRALIA, V182, P417, DOI 10.5694/j.1326 5377.2005.tb06762.x
   Ruggiero S, 2006, J ONCOL PRACT, V2, P7, DOI 10.1200/JOP.2.1.7
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Sambrook Philip, 2006, Aust Fam Physician, V35, P801
   Schirmer I, 2005, ORAL MAXILLOFAC SURG, V9, P239, DOI 10.1007/s10006 005 0616 6
   Sparidans RW, 1998, PHARM WORLD SCI, V20, P206, DOI 10.1023/A:1008626026484
   SWAN N, 2006, ABC RADIO NATL  0327
   Tarassoff P, 2003, J ORAL MAXIL SURG, V61, P1238, DOI 10.1016/j.joms.2003.09.001
   Vudiniabola S, 2000, INT J ORAL MAX SURG, V29, P435, DOI 10.1034/j.1399 0020.2000.290608.x
   Wang J, 2003, J ORAL MAXIL SURG, V61, P1104, DOI 10.1016/S0278 2391(03)00328 8
   Wong R, 2002, Cochrane Database Syst Rev, pCD002068
NR 35
TC 467
Z9 514
U1 0
U2 33
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0278 2391
EI 1531 5053
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD MAR
PY 2007
VL 65
IS 3
BP 415
EP 423
DI 10.1016/j.joms.2006.10.061
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 144XU
UT WOS:000244830600008
PM 17307586
DA 2025 08 17
ER

PT J
AU Liu, Y
   Fang, JR
   Zhang, Q
   Zhang, XG
   Cao, YL
   Chen, W
   Shao, ZW
   Yang, SH
   Wu, DC
   Hung, M
   Zhang, YZ
   Tong, W
   Tian, HT
AF Liu, Yong
   Fang, Jiarui
   Zhang, Quan
   Zhang, Xiaoguang
   Cao, Yulin
   Chen, Wei
   Shao, Zengwu
   Yang, Shuhua
   Wu, Dongcheng
   Hung, Man
   Zhang, Yingze
   Tong, Wei
   Tian, Hongtao
TI Wnt10b overexpressing umbilical cord mesenchymal stem cells promote
   critical size rat calvarial defect healing by enhanced osteogenesis and
   VEGF mediated angiogenesis
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE Angiogenesis; Bone regeneration; Umbilical cord MSCs; Wnt signalling
   pathway
ID BONE REGENERATION; GENE THERAPY; DIFFERENTIATION; OSTEOBLAST;
   PROLIFERATION; HYPOXIA
AB Background/objectives: Accelerating the process of bone regeneration is of great interest for surgeons and basic scientists alike. Recently, umbilical cord mesenchymal stem cells (UCMSCs) are considered clinically applicable for tissue regeneration due to their noninvasive harvesting and better viability. Nonetheless, the bone regenerative ability of human UCMSCs (HUCMSCs) is largely unknown. This study aimed to investigate whether Wnt10b overexpressing HUCMSCs have enhanced bone regeneration ability in a rat model.
   Method: A rat calvarial defect was performed on 8 week old male Sprague Dawley rats. Commercially purchased HUCMSCsEmp in hydrogel, HUCMSCsWnt10b in hydrogel and HUCMSCsWnt10b with IWR 1 were placed in the calvarial bone defect right after surgery on rats (N = 8 rats for each group). Calvaria were harvested for micro CT analysis and histology four weeks after surgery. CFU F and multi differentiation assay by oil red staining, alizarin red staining and RT PCR (real time polymerase chain reaction) were performed on HUCMSCsEmp and HUCMSCsWnt10b in vitro. Conditioned media from HUCMSCsEmp and HUCMSCsWnt10b were collected and used to treat human umbilical cord vein endothelial cells in Matrigel to access vessel formation capacity by tube formation assay.
   Results: Alizarin red staining, oil red staining and RT PCR results showed robust osteogenic differentiation but poor adipogenic differentiation ability of HUCMSCsWnt10b. Furthermore, HUCMSCsWnt10b could accelerate bone defect healing, which was likely due to enhanced angiogenesis after the HUCMSCsWnt10b treatment, because more CD31thorn vessels and increased vascular endothelial growth factor A (VEGF A) expression were observed, compared with the HUCMSCsEmp treatment. Conditioned media from HUCMSCsWnt10b also induced endothelial cells to form vessel tubes in a tube formation assay, which could be abolished by SU5416, an angiogenesis inhibitor.
   Conclusion: To our knowledge, this is the first study providing empirical evidence that HUCMSCsWnt10b can enhance their ability to heal calvarial bone defects via VEGF mediated angiogenesis.
   The translational potential of this article: HUCMSCsWnt10b can accelerate critical size calvaria and are a new promising therapeutic cell source for fracture nonunion healing.
C1 [Liu, Yong; Fang, Jiarui; Zhang, Xiaoguang; Cao, Yulin; Shao, Zengwu; Yang, Shuhua; Tong, Wei; Tian, Hongtao] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Orthopaed, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.
   [Zhang, Quan; Wu, Dongcheng] Wuhan Hamilton Biotechnol Co Ltd, Wuhan 430075, Hubei, Peoples R China.
   [Wu, Dongcheng] Wuhan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Wuhan, Peoples R China.
   [Chen, Wei; Zhang, Yingze] Hebei Med Univ, Hosp 3, 139 Ziqiang Rd, Shijiazhuang 050051, Hebei, Peoples R China.
   [Hung, Man] Roseman Univ Hlth Sci, Coll Dent Med, 10984 S River Front Pkwy, South Jordan, UT 84095 USA.
C3 Huazhong University of Science & Technology; Wuhan University; Hebei
   Medical University
RP Tong, W; Tian, HT (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Orthopaed, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.
EM 961836059@qq.com; fangjiarui1992@163.com; 470558642@qq.com;
   zhangxiaoguang0095@163.com; caoyulin1220@126.com; 754958715@qq.com;
   381712554@qq.com; 1010948762@qq.com; bcdcwu@hotmail.com;
   mhung@roseman.edu; 258974810@qq.com; tongwei312@126.com;
   tianhongtao@vip.163.com
RI Shao, Z W/AGN 6158 2022; tong, wei/AAJ 1093 2021; Fang,
   Jiarui/HCH 9554 2022; Tong, Wei/AAJ 1093 2021; Zhang,
   Xiaoguang/LOS 4256 2024; Chen, Wei/GRX 2231 2022
OI tong, wei/0000 0001 8031 0380; Zhang, Xiaoguang/0000 0002 0000 5245;
   cao, yu lin/0000 0002 6612 6218; Chen, Wei/0000 0001 5451 6430
FU Roseman University College of Dental Medicine Clinical Outcomes Research
   and Education in Utah, United States; NSFC [81672235, 81702157]
FX The authors are grateful to Xianrong Zhang from the Department of
   Orthopaedic Surgery, Nanfang Hospital, Guangzhou, China, for her
   technical expertise in IHC staining. The authors also thank Roseman
   University College of Dental Medicine Clinical Outcomes Research and
   Education in Utah, United States for supporting this study. This study
   was supported by NSFC grant 81672235 (to Hongtao Tian) and NSFC grant
   81702157 (to Wei Tong).
CR [Anonymous], 2019, J CLIN MED, DOI DOI 10.3390/JCM8060847
   Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006 0709
   Balasubramanian S, 2012, CYTOTHERAPY, V14, P26, DOI 10.3109/14653249.2011.605119
   Bartolucci J, 2017, CIRC RES, V121, P1192, DOI 10.1161/CIRCRESAHA.117.310712
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Blau HM, 2019, NEW ENGL J MED, V380, P1748, DOI 10.1056/NEJMra1716145
   Bougioukli S, 2019, HUM GENE THER, V30, P906, DOI 10.1089/hum.2018.054
   Chen WQ, 2015, P NATL ACAD SCI USA, V112, pE3893, DOI 10.1073/pnas.1501759112
   Chen WC, 2018, J TISSUE ENG REGEN M, V12, P191, DOI 10.1002/term.2395
   Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dilogo IH, 2017, INT J SURG CASE REP, V34, P11, DOI 10.1016/j.ijscr.2017.03.002
   Ding DC, 2015, CELL TRANSPLANT, V24, P339, DOI 10.3727/096368915X686841
   Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478 811X 9 12
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Ishikawa T, 2001, DEVELOPMENT, V128, P25
   Jong WC, 2013, ALZHEIMERS DEMENTI S, V9, pP291
   Lee HJ, 2015, STEM CELLS, V33, P2182, DOI 10.1002/stem.2020
   Li B, 2016, CELL PROLIFERAT, V49, P36, DOI 10.1111/cpr.12236
   Liu F, 2008, CELL SIGNAL, V20, P999, DOI 10.1016/j.cellsig.2007.11.011
   Liu YQ, 2012, J CLIN INVEST, V122, P3101, DOI 10.1172/JCI61209
   Longo KA, 2004, J BIOL CHEM, V279, P35503, DOI 10.1074/jbc.M402937200
   Matas J, 2019, STEM CELL TRANSL MED, V8, P215, DOI 10.1002/sctm.18 0053
   Paik DT, 2015, CIRC RES, V117, P804, DOI 10.1161/CIRCRESAHA.115.306886
   Patel ZS, 2008, BONE, V43, P931, DOI 10.1016/j.bone.2008.06.019
   Peng LY, 2016, CYTOTECHNOLOGY, V68, P1615, DOI 10.1007/s10616 014 9818 9
   Spicer PP, 2012, NAT PROTOC, V7, P1918, DOI 10.1038/nprot.2012.113
   Todeschi MR, 2015, STEM CELLS DEV, V24, P1570, DOI 10.1089/scd.2014.0490
   Tzioupis C, 2007, INJURY, V38, pS3, DOI 10.1016/S0020 1383(07)80003 9
   Wang LQ, 2019, J BONE MINER RES, V34, P520, DOI 10.1002/jbmr.3626
   Wilk K, 2017, STEM CELL REP, V8, P933, DOI 10.1016/j.stemcr.2017.03.002
   Zhang XS, 2004, J GENE MED, V6, P4, DOI 10.1002/jgm.477
   Zhang YT, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12570
   Zhou D, 2017, INT J NANOMED, V12, P2673, DOI 10.2147/IJN.S131251
NR 34
TC 35
Z9 38
U1 1
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD JUL
PY 2020
VL 23
BP 29
EP 37
DI 10.1016/j.jot.2020.02.009
PG 9
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA NA7CZ
UT WOS:000559976200007
PM 32477867
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Mayer, H
   Bertram, H
   Lindenmaier, W
   Korff, T
   Weber, H
   Weich, H
AF Mayer, H
   Bertram, H
   Lindenmaier, W
   Korff, T
   Weber, H
   Weich, H
TI Vascular endothelial growth factor (VEGF A) expression in human
   mesenchymal stem cells: Autocrine and paracrine role on osteoblastic and
   endothelial differentiation
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE stem cells; human; VEGF A; VEGF R; hypoxia; osteogenesis;
   neoangiogenesis; adenovirus
ID BONE FORMATION; ANGIOGENESIS; QUANTIFICATION; ISOFORMS; DEFECTS; REPAIR;
   TISSUE
AB Angiogenesis is essential in bone fracture healing for restoring blood flow to the fracture site. Vascular endothelial growth factor NEGF) and its receptor have been implicated in this process. Despite the importance of angiogenesis for the healing processes of damaged bones, the role of VEGF signaling in modulation of osteogenic differentiation in human mesenchymal stem cells has not been investigated in great detail. We examined the expression of VEGF A and VEGFR 1 inhuman adult mesenchymal stem cells derived from trabecular bone (hTBCs). VEGF A was found to be secreted in a differentiation dependent manner during osteogenesis. Transcripts for VEGF A were also seen to be elevated during osteogenesis. in addition, transcripts for VEGF A and the corresponding receptor VEGFR 1 were upregulated under hypoxic conditions in undifferentiated hTBCs. To investigate the signaling of VEGF A on osteogenesis recombinant hTBCs were generated. High expression of VEGF A stimulated mineralization, whereas high expression of sFLT 1, an antagonist to VEGF A, reduced mineralization suggesting that VEGF A acts as autocrine factor for osteoblast differentiation. In addition, VEGF A secreted by hTBCs promotes sprouting of endothelial cells (HUVE) demonstrating a paracrine role in blood vessel formation. In summary, an in vitro analysis of transgene effects on cellular behavior can be used to predict an effective ex vivo gene therapy. (c) 2005 Wiley Liss, Inc.
C1 German Res Ctr Biotechnol, Dept Gene Regulat & Differentiat, D 38124 Braunschweig, Germany.
   Heidelberg Univ, Dept Orthopaed Surg, D 69118 Heidelberg, Germany.
   Univ Gottingen, Sch Med, Dept Gynecol & Obstet, Cell Biol Lab, D 37075 Gottingen, Germany.
   Tumor Biol Ctr, Res Inst Mol Oncol, Dept Vasc Biol & Angiogenesis, D 79106 Freiburg, Germany.
C3 Helmholtz Association; Helmholtz Center for Infection Research; Ruprecht
   Karls University Heidelberg; University of Gottingen
RP German Res Ctr Biotechnol, Dept Gene Regulat & Differentiat, Mascheroderweg 1, D 38124 Braunschweig, Germany.
EM hma@gbf.de
CR Akeno N, 2001, ENDOCRINOLOGY, V142, P959, DOI 10.1210/en.142.2.959
   Bando H, 2004, INT J CANCER, V111, P184, DOI 10.1002/ijc.20211
   Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097 4644(199702)64:2<278::AID JCB11>3.0.CO;2 F
   BRUDRE SP, 1998, CLIN ORTHOP RELAT R, V247, P256
   Carlevaro MF, 2000, J CELL SCI, V113, P59
   COLLINOSDOBY P, 1994, J CELL BIOCHEM, V55, P304, DOI 10.1002/jcb.240550306
   Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   Ferguson C, 1999, MECH DEVELOP, V87, P57, DOI 10.1016/S0925 4773(99)00142 2
   Furumatsu T, 2003, J BIOCHEM, V133, P633, DOI 10.1093/jb/mvg081
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Glowacki J, 1998, CLIN ORTHOP RELAT R, pS82, DOI 10.1097/00003086 199810001 00010
   GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331
   Harper J, 2001, J CELL BIOCHEM, V81, P82, DOI 10.1002/1097 4644(20010401)81:1<82::AID JCB1025>3.0.CO;2 P
   Hornig C, 1999, Angiogenesis, V3, P33, DOI 10.1023/A:1009033017809
   Hornig C, 1999, J IMMUNOL METHODS, V226, P169, DOI 10.1016/S0022 1759(99)00065 4
   Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341
   Korff T, 2001, FASEB J, V15, P447, DOI 10.1096/fj.00 0139com
   Kraus KH, 1999, J INVEST SURG, V12, P115
   Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925 4773(01)00601 3
   Maes C, 2004, J CLIN INVEST, V113, P188, DOI 10.1172/JCI200419383
   Mayer H, 2004, CELLS TISSUES ORGANS, V177, P57, DOI 10.1159/000079181
   Nakagawa M, 2000, FEBS LETT, V473, P161, DOI 10.1016/S0014 5793(00)01520 9
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Saadeh PB, 2000, ENDOCRINOLOGY, V141, P2075, DOI 10.1210/en.141.6.2075
   Sensebe L, 1997, BRIT J HAEMATOL, V98, P274, DOI 10.1046/j.1365 2141.1997.1953012.x
   Sottile V, 2002, BONE, V30, P699, DOI 10.1016/S8756 3282(02)00674 9
   Steinbrech DS, 2000, AM J PHYSIOL CELL PH, V278, pC853, DOI 10.1152/ajpcell.2000.278.4.C853
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   STREETEN EA, 1990, BONE MINER, V10, P85, DOI 10.1016/0169 6009(90)90084 S
   Tuli R, 2003, STEM CELLS, V21, P681, DOI 10.1634/stemcells.21 6 681
   Turgeman G, 2001, J GENE MED, V3, P240
   Zelzer E, 2002, DEVELOPMENT, V129, P1893
   Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925 4773(01)00428 2
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 38
TC 273
Z9 327
U1 2
U2 45
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JUL 1
PY 2005
VL 95
IS 4
BP 827
EP 839
DI 10.1002/jcb.20462
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 936EZ
UT WOS:000229839600017
PM 15838884
DA 2025 08 17
ER

PT J
AU Tripathi, R
   Singh, P
   Singh, A
   Chagtoo, M
   Khan, S
   Tiwari, S
   Agarwal, G
   Meeran, SM
   Godbole, MM
AF Tripathi, Ranu
   Singh, Preeti
   Singh, Aru
   Chagtoo, Megha
   Khan, Sajid
   Tiwari, Swasti
   Agarwal, Gaurav
   Meeran, Syed Musthapa
   Godbole, Madan M.
TI Zoledronate and Molecular Iodine Cause Synergistic Cell Death in Triple
   Negative Breast Cancer through Endoplasmic Reticulum Stress
SO NUTRITION AND CANCER AN INTERNATIONAL JOURNAL
LA English
DT Article
ID INDUCED APOPTOSIS; CARCINOMA CELLS; MAMMARY GLAND; BISPHOSPHONATES;
   INHIBITION; PATHWAY; TUMORS; RAT; PROLIFERATION; ACTIVATION
AB Women consuming molecular iodine (I 2) through seaweeds suffer the least from breast cancers. Zoledronate (Zol) is in clinical use for alleviation of bone pain in cancer patients. Triple negative breast cancers exhibit high mortality due to lack of neoadjuvant chemotherapy. vivovivoand Zol independently cause weak antiproliferative and apoptotic effect. So far, their combined effects have not been tested. We analyzed the effect of combination of I 2 with Zol as a potent adjuvant therapeutic agent for triple negative breast cancer cells (MDA MBA 231) and in the mice model of breast cancer. Cell viability, terminal deoxynucleotidyl transferase dUTP nick end labeling staining, Western blotting, real time PCR, flow cytometry, and other assays were performed for assessing cell death, calcium levels, and migration potential, respectively, in treated cells. The increased caspase 8, increased [Ca2+] c levels, and endoplasmic reticulum (ER) stress resulted in apoptosis. Real time and fluorescence based analysis demonstrated that the combination treatment targets ER Ca2+ homeostasis chaperons leading to apoptosis. Combination therapy reduces metalloproteinases 2 and 9, inhibits invasion/migration of cells, and prevents growth of tumor in mice. I 2 + Zol combination treatment induces synergistic increase in ER mediated apoptosis, reduces invasion/migration potential of MDA MB 231 cells, and exhibits antiproliferative property in vivo demonstrating its potential as combination therapy.
C1 [Tripathi, Ranu; Singh, Preeti; Godbole, Madan M.] Sanjay Gandhi Postgrad Inst Med Sci, Dept Endocrinol, Raebareli Rd, Lucknow 226014, Uttar Pradesh, India.
   [Singh, Aru; Chagtoo, Megha; Tiwari, Swasti; Godbole, Madan M.] Sanjay Gandhi Postgrad Inst Med Sci, Dept Mol Med & Biotechnol, Raebareli Rd, Lucknow 226014, Uttar Pradesh, India.
   [Khan, Sajid; Meeran, Syed Musthapa] Sanjay Gandhi Postgrad Inst Med Sci, Dept Endocrine Surg, Raebareli Rd, Lucknow 226014, Uttar Pradesh, India.
   [Agarwal, Gaurav] Cent Drug Res Inst, Dept Endocrinol, Lucknow 226001, Uttar Pradesh, India.
C3 Sanjay Gandhi Postgraduate Institute of Medical Sciences; Sanjay Gandhi
   Postgraduate Institute of Medical Sciences; Sanjay Gandhi Postgraduate
   Institute of Medical Sciences; Council of Scientific & Industrial
   Research (CSIR)   India; CSIR   Central Drug Research Institute (CDRI)
RP Godbole, MM (通讯作者)，Sanjay Gandhi Postgrad Inst Med Sci, Dept Endocrinol & Mol Med & Biotechnol, Raebareli Rd, Lucknow 226014, Uttar Pradesh, India.
EM madangodbole@yahoo.co.in
RI Khan, Sajid/AAR 8954 2020; Agarwal, Gaurav/K 2998 2013; Singh,
   Prabhat/AEW 7188 2022; Meeran, Syed/AAG 2157 2020
OI Sajid, Khan/0000 0003 1331 8846; CHAGTOO, MEGHA/0000 0003 2168 7860;
   Agarwal, Gaurav/0000 0003 4194 2670; 
FU Department of Biotechnology, New Delhi [BT/PR 9822/MED/30/42/2007];
   Indian Council of Medical Research, New Delhi [3/2/152/2008/NCD III]
FX This work was supported by the Department of Biotechnology, New Delhi
   (Grant BT/PR 9822/MED/30/42/2007 to Godbole M M) and research fellowship
   from the Indian Council of Medical Research, New Delhi
   (3/2/152/2008/NCD III to Ranu Tripathi).
CR Aceves C, 2005, J MAMMARY GLAND BIOL, V10, P189, DOI 10.1007/s10911 005 5401 5
   Aceves C, 2013, THYROID, V23, P938, DOI 10.1089/thy.2012.0579
   Alfaro Y, 2013, MOL CANCER, V12, DOI 10.1186/1476 4598 12 45
   [Anonymous], SCIENTIFICA
   [Anonymous], INT J CELL BIOL
   Arroyo Helguera O, 2006, ENDOCR RELAT CANCER, V13, P1147, DOI 10.1677/erc.1.01250
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   ESKIN BA, 1995, BIOL TRACE ELEM RES, V49, P9, DOI 10.1007/BF02788999
   ESKIN BA, 1975, CANCER RES, V35, P2332
   Funahashi H, 1999, JPN J CANCER RES, V90, P922, DOI 10.1111/j.1349 7006.1999.tb00836.x
   Funahashi H, 1996, J SURG ONCOL, V61, P209, DOI 10.1002/(SICI)1096 9098(199603)61:3<209::AID JSO9>3.0.CO;2 F
   Gärtner R, 2010, HORM INT J ENDOCRINO, V9, P60
   García Solís P, 2005, MOL CELL ENDOCRINOL, V236, P49, DOI 10.1016/j.mce.2005.03.001
   GHENT WR, 1993, CAN J SURG, V36, P453
   Lacerna L, 2003, SEMIN ONCOL, V30, P150, DOI 10.1053/j.seminoncol.2003.08.017
   Lan YC, 2013, ANTICANCER RES, V33, P3807
   Liang X, 2014, CELL BIOSCI, V4, DOI 10.1186/2045 3701 4 10
   Ma YG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037451
   OKADA CY, 1982, CELL, V29, P33, DOI 10.1016/0092 8674(82)90087 3
   Rösner H, 2010, EXP CLIN ENDOCR DIAB, V118, P410, DOI 10.1055/s 0029 1225615
   Roger S, 2004, BBA BIOMEMBRANES, V1667, P190, DOI 10.1016/j.bbamem.2004.10.002
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Shiraishi H, 2006, J CELL SCI, V119, P3958, DOI 10.1242/jcs.03160
   Shrivastava A, 2006, J BIOL CHEM, V281, P19762, DOI 10.1074/jbc.M600746200
   Shuda M, 2003, J HEPATOL, V38, P605, DOI 10.1016/S0168 8278(03)00029 1
   Singh P, 2011, BIOCHEM BIOPH RES CO, V415, P181, DOI 10.1016/j.bbrc.2011.10.054
   Song SD, 2013, ONCOL LETT, V6, P953, DOI 10.3892/ol.2013.1510
   Stoddard Frederick R 2nd, 2008, Int J Med Sci, V5, P189
   Venturi S, 2001, BREAST, V10, P379, DOI 10.1054/brst.2000.0267
   Verdijk R, 2007, CANCER LETT, V246, P308, DOI 10.1016/j.canlet.2006.03.011
   Zhu YJ, 2014, LIFE SCI, V94, P37, DOI 10.1016/j.lfs.2013.10.030
NR 31
TC 8
Z9 8
U1 1
U2 12
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0163 5581
EI 1532 7914
J9 NUTR CANCER
JI Nutr. Cancer
PY 2016
VL 68
IS 4
BP 679
EP 688
DI 10.1080/01635581.2016.1158293
PG 10
WC Oncology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Nutrition & Dietetics
GA DP0HX
UT WOS:000378171700015
PM 27116040
DA 2025 08 17
ER

PT J
AU Huang, W
   Liu, WQ
   She, ZD
   Wu, HK
   Shi, XT
AF Huang, Wei
   Liu, Weiqiang
   She, Zhending
   Wu, Hongkai
   Shi, Xuetao
TI Alendronate decorated nano hydroxyapatite in mesoporous silica:
   Cytotoxicity and osteogenic properties
SO APPLIED SURFACE SCIENCE
LA English
DT Article
DE Mesoporous silica; Hydroxyapatite; Cytotoxicity; Alendronate;
   Osteogenesis
ID DRUG DELIVERY; IN VITRO; BISPHOSPHONATES; DIFFERENTIATION;
   PROLIFERATION; MECHANISMS; RELEASE; SYSTEM; CELLS
AB Mesoporous silica is a promising drug delivery vehicle due to its large surface area and order porous structure. Hydroxyapatite modified mesoporous silica materials (MSH) have been developed, and the cytotoxicity of MSH and unmodified mesoporous silica (HMS) has also been studied in this work. The results indicated that MSH exhibited lower cytotoxicity than HMS. The drug release property of MSH was also investigated in this paper. Alendronate (AL) was laden into MSH and HMS, respectively. MSH exhibited long release period lasting over 30 days with a weak burst release in the first 5 days; however, the AL release period of HMS was just 5 days with a remarkable burst release. In addition, the osteogenic commitment induced in human marrow mesenchymal stem cells (MSCs) by MSH alendronate (MSH AL) was also investigated, and the osteogenesis of MSCs was evaluated by alkaline phosphatase (ALP) assay. The osteogenesis of MSCs induced by MSH AL is comparable to that induced by the osteogenic medium. Taken together, MSH can be severed as potential bone repair materials with lower cytotoxicity. (C) 2011 Elsevier B. V. All rights reserved.
C1 [Huang, Wei; Liu, Weiqiang; She, Zhending] Ctr Adv Mat & Biotechnol, Key Lab Biomed Mat & Implant Shenzhen, Shenzhen 518057, Peoples R China.
   [Wu, Hongkai; Shi, Xuetao] Tohoku Univ, WPI AIMR, Aoba Ku, Sendai, Miyagi 9808577, Japan.
C3 Tohoku University
RP She, ZD (通讯作者)，Ctr Adv Mat & Biotechnol, Key Lab Biomed Mat & Implant Shenzhen, Shenzhen 518057, Peoples R China.
EM shezhending@gmail.com; mrshixuetao@gmail.com
RI ; Wu, Houkai/AGY 9480 2022; Shi, Xuetao/D 5180 2012
OI Shi, Xuetao/0000 0001 9919 8931; 
FU Promotion of key labs in Shenzhen program [ZD200904300071A,
   CXB200903090054A]; WPI AIMR, Japan
FX This research was supported by Promotion of key labs in Shenzhen program
   (Grant ZD200904300071A and CXB200903090054A), and WPI AIMR, Japan.
CR CARLISLE EM, 1982, NUTR REV, V40, P210
   Di Pasqua AJ, 2008, J INORG BIOCHEM, V102, P1416, DOI 10.1016/j.jinorgbio.2007.12.028
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Gomez Vega JM, 2001, J MATER SCI MATER M, V12, P923, DOI 10.1023/A:1012888410936
   Gu J, 2007, SMALL, V3, P1740, DOI 10.1002/smll.200700311
   Handa P, 2007, MICROPOR MESOPOR MAT, V100, P146, DOI 10.1016/j.micromeso.2006.10.024
   Hazar ABY, 2007, CERAM INT, V33, P687, DOI 10.1016/j.ceramint.2006.12.013
   Hudson SP, 2008, BIOMATERIALS, V29, P4045, DOI 10.1016/j.biomaterials.2008.07.007
   Kim HJ, 2006, ADV MATER, V18, P3083, DOI 10.1002/adma.200600387
   Kuljanin J, 2002, J PHARMACEUT BIOMED, V28, P1215, DOI 10.1016/S0731 7085(02)00021 3
   Li X, 2007, MICROPOR MESOPOR MAT, V102, P151, DOI 10.1016/j.micromeso.2006.12.048
   Lin YS, 2005, CHEM MATER, V17, P4570, DOI 10.1021/cm051014c
   Nielsen FH, 2004, J TRACE ELEM EXP MED, V17, P137, DOI 10.1002/jtra.20004
   Pietak AM, 2005, BIOMATERIALS, V26, P3819, DOI 10.1016/j.biomaterials.2004.10.013
   Radu DR, 2004, J AM CHEM SOC, V126, P13216, DOI 10.1021/ja046275m
   Reffitt DM, 2003, BONE, V32, P127, DOI 10.1016/S8756 3282(02)00950 X
   REGINA M, 1993, J BIOMED MATER RES, V27, P445
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   SCHWARZ K, 1973, P NATL ACAD SCI USA, V70, P1608, DOI 10.1073/pnas.70.5.1608
   Shi XT, 2008, J MATER SCI MATER M, V19, P2933, DOI 10.1007/s10856 008 3424 3
   Shi XT, 2009, BIOMATERIALS, V30, P3996, DOI 10.1016/j.biomaterials.2009.04.021
   Shi XT, 2009, ACTA BIOMATER, V5, P1697, DOI 10.1016/j.actbio.2009.01.010
   Shi XT, 2009, PHARM RES DORDR, V26, P422, DOI 10.1007/s11095 008 9759 0
   Tang QL, 2006, J CONTROL RELEASE, V114, P41, DOI 10.1016/j.jconrel.2006.05.006
   Vallet Regi M, 2001, CHEM MATER, V13, P308, DOI 10.1021/cm0011559
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Xynos ID, 2000, BIOCHEM BIOPH RES CO, V276, P461, DOI 10.1006/bbrc.2000.3503
NR 28
TC 17
Z9 17
U1 0
U2 57
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169 4332
J9 APPL SURF SCI
JI Appl. Surf. Sci.
PD SEP 15
PY 2011
VL 257
IS 23
BP 9757
EP 9761
DI 10.1016/j.apsusc.2011.06.002
PG 5
WC Chemistry, Physical; Materials Science, Coatings & Films; Physics,
   Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science; Physics
GA 807GD
UT WOS:000293883400011
DA 2025 08 17
ER

PT J
AU Orosco, A
   Fromigué, O
   Bazille, C
   Entz Werle, N
   Levillain, P
   Marie, PJ
   Modrowski, D
AF Orosco, Armelle
   Fromigue, Olivia
   Bazille, Celine
   Entz Werle, Natacha
   Levillain, Pierre
   Marie, Pierre J.
   Modrowski, Dominique
TI Syndecan 2 affects the basal and chemotherapy induced apoptosis in
   osteosarcoma
SO CANCER RESEARCH
LA English
DT Article
ID HEPARAN SULFATE PROTEOGLYCANS; BONE MORPHOGENETIC PROTEIN 2;
   COLON CARCINOMA CELLS; OSTEOBLAST DIFFERENTIATION; TUMORIGENIC ACTIVITY;
   EXPRESSION; TUMOR; OVEREXPRESSION; PROLIFERATION; RESISTANCE
AB Syndecans are transmembrane heparan sulfate proteoglycans controlling cell adhesion, migration, and proliferation. We previously showed that syndecan 2 is involved in the control of apoptosis in cultured osteosarcoma cells. These data led us to the hypothesis that syndecan 2 may play a role in the apoptotic signaling in bone tumors. We immunohistochemically analyzed tissue sections from biopsies from 21 patients with well characterized osteosarcoma. These tissues expressed low levels of syndecan 2 compared with osteoblasts and osteocytes in normal bone. Cultured human osteosarcoma cells also produced lower mRNA levels of syndecan 2 than normal osteoblastic cells. Moreover, the presence of syndecan 2 correlated with spontaneous apoptosis in osteosarcoma tissues as assessed by detection of DNA fragmentation in situ. Overexpression of syndecan 2 resulted in decreased number of migrating and invading U2OS osteosarcoma cells in Matrigel. In addition, overexpression of syridecan 2 sensitized human osteosarcoma cells to chemotherapy induced apoptosis, increasing the response to methotrexate, doxorubicin, and cisplatin. Consistently, knockdown of the proteoglycan using stable transfection with a plasmid coding small interfering RNA resulted in inhibition of chemotherapy induced apoptosis. Analysis of syndecan 2 expression both in biopsies and in corresponding postchemotherapy resected tumors, as well as in cells treated with methotrexate or doxorubicin, showed that the cytotoxic action of chemotherapy can be associated with an increase in syndecan 2. These results provide support for a tumor suppressor function for syndecan 2 and suggest that dysregulation of apoptosis may be related to abnormal syndecan 2 expression or induction in osteosarcoma. Moreover, our data identify syndecan 2, as a new factor mediating the antioncogenic effect of chemotherapeutic drugs.
C1 INSERM, U606, Paris, France.
   Univ Paris 07, Paris, France.
   CHRU Hautepierre, Dept Biochem & Mol Biol, Strasbourg, France.
   Med Univ Poitiers, Dept Anat & Pathol Cytol, Poitiers, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Paris Cite; CHU Strasbourg; Universite de Poitiers; CHU
   Poitiers
RP Modrowski, D (通讯作者)，Hop Lariboisiere, INSERM, Unit 606, 2 rue Ambroise Pare, F 75475 Paris 10, France.
EM dominique.modrowskj@larib.inserm.fr
RI Modrowski, Dominique/N 6578 2018; Fromigue, Olivia/B 8225 2013
OI Modrowski, Dominique/0000 0003 1103 7127; Fromigue,
   Olivia/0000 0002 3050 6155
CR Ahdjoudj S, 2001, J CELL BIOCHEM, V81, P23, DOI 10.1002/1097 4644(20010401)81:1<23::AID JCB1021>3.0.CO;2 H
   Aref Salah, 2003, Hematology, V8, P221, DOI 10.1080/1024533031000153630
   Bacci G, 2003, J PEDIAT HEMATOL ONC, V25, P845, DOI 10.1097/00043426 200311000 00006
   Barbareschi M, 2003, CANCER AM CANCER SOC, V98, P474, DOI 10.1002/cncr.11515
   Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137
   Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729
   Birch MA, 1999, BONE, V24, P571, DOI 10.1016/S8756 3282(99)00088 5
   Cao Y, 2005, CANCER RES, V65, P1124, DOI 10.1158/0008 5472.CAN 04 2128
   Dardalhon V, 2001, GENE THER, V8, P190, DOI 10.1038/sj.gt.3301378
   DAVID G, 1993, DEVELOPMENT, V119, P841
   dePollak C, 1997, J CELL BIOCHEM, V64, P128, DOI 10.1002/(SICI)1097 4644(199701)64:1<128::AID JCB15>3.3.CO;2 K
   Duan Z, 2002, CYTOKINE, V17, P234, DOI 10.1006/cyto.2001.1008
   Gibbs C Parker Jr, 2002, Instr Course Lect, V51, P413
   Gutierrez J, 2006, J CELL PHYSIOL, V206, P58, DOI 10.1002/jcp.20428
   Hay E, 1999, J CELL BIOCHEM, V72, P81, DOI 10.1002/(SICI)1097 4644(19990101)72:1<81::AID JCB9>3.0.CO;2 N
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   INKI P, 1994, BRIT J CANCER, V70, P319, DOI 10.1038/bjc.1994.300
   Kim Y, 2003, ONCOGENE, V22, P826, DOI 10.1038/sj.onc.1206068
   Kusano Y, 2000, EXP CELL RES, V256, P434, DOI 10.1006/excr.2000.4802
   Lafleur EA, 2004, CLIN CANCER RES, V10, P8114, DOI 10.1158/1078 0432.CCR 04 0353
   Leppa S, 1996, J CELL SCI, V109, P1393
   LINK MP, 1986, NEW ENGL J MED, V314, P1600, DOI 10.1056/NEJM198606193142502
   Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825
   Meyers PA, 1997, PEDIATR CLIN N AM, V44, P973, DOI 10.1016/S0031 3955(05)70540 X
   Modrowski D, 2005, BONE, V37, P180, DOI 10.1016/j.bone.2005.04.010
   Modrowski D, 2000, J BIOL CHEM, V275, P9178, DOI 10.1074/jbc.275.13.9178
   Munesue S, 2002, BIOCHEM J, V363, P201, DOI 10.1042/0264 6021:3630201
   Németh Z, 2005, J CRANIOFAC SURG, V16, P205
   Orosco A, 2006, J CELL BIOCHEM, V98, P838, DOI 10.1002/jcb.20826
   Park H, 2005, CANCER RES, V65, P9899, DOI 10.1158/0008 5472.CAN 05 1386
   Park H, 2002, J BIOL CHEM, V277, P29730, DOI 10.1074/jbc.M202435200
   Soukka T, 2000, J ORAL PATHOL MED, V29, P308, DOI 10.1034/j.1600 0714.2000.290704.x
   Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187
NR 33
TC 43
Z9 46
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2007
VL 67
IS 8
BP 3708
EP 3715
DI 10.1158/0008 5472.CAN 06 4164
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 158GL
UT WOS:000245779600032
PM 17440083
OA Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Fernández Villa, D
   Aguilar, MR
   Rojo, L
AF Fernandez Villa, Daniel
   Aguilar, Maria Rosa
   Rojo, Luis
TI Europium tannic acid nanocomplexes devised for bone regeneration under
   oxidative or inflammatory environments
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID FREE RADICALS; SCAFFOLDS; NANOPARTICLES; COMPLEXATION; IONS
AB Europium ions (Eu3+) are gaining attention in the field of regenerative medicine due to increasing evidence of their osteogenic properties. However, inflammatory and oxidative environments present in many bone diseases, such as osteoporosis or rheumatoid arthritis, are known to hinder this regenerative process. Herein, we describe a straightforward synthetic procedure to prepare Eu3+ tannic acid nanocomplexes (EuTA NCs) with modulable physicochemical characteristics, as well as antioxidant, anti inflammatory, and osteogenic properties. EuTA NCs were rationally synthesized to present different contents of Eu3+ on their structure to evaluate the effect of the cation on the biological properties of the formulations. In all the cases, EuTA NCs were stable in distilled water at physiological pH, had a highly negative surface charge (zeta approximate to  25.4 mV), and controllable size (80 < D h < 160 nm). In vitro antioxidant tests revealed that Eu3+ complexation did not significantly alter the total radical scavenging activity (RSA) of TA but enhanced its ability to scavenge H2O2 and ferrous ions, thus improving its overall antioxidant potential. At the cellular level, EuTA NCs reduced the instantaneous toxicity of high concentrations of free TA, resulting in better antioxidant (13.3% increase of RSA vs. TA) and anti inflammatory responses (17.6% reduction of nitric oxide production vs. TA) on cultures of H2O2  and LPS stimulated macrophages, respectively. Furthermore, the short term treatment of osteoblasts with EuTA NCs was found to increase their alkaline phosphatase activity and their matrix mineralization capacity. Overall, this simple and tunable platform is a potential candidate to promote bone growth in complex environments by simultaneously targeting multiple pathophysiological mechanisms of disease.
C1 [Fernandez Villa, Daniel; Aguilar, Maria Rosa; Rojo, Luis] CSIC, Inst Ciencia & Tecnol Polimeros ICTP, Madrid 28006, Spain.
   [Fernandez Villa, Daniel; Aguilar, Maria Rosa; Rojo, Luis] Ctr Invest Biomed Red Bioingn Biomat & Nanomed CIB, Madrid 28029, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC   Instituto
   de Ciencia & Tecnologia de Polimeros (ICTP)
RP Rojo, L (通讯作者)，CSIC, Inst Ciencia & Tecnol Polimeros ICTP, Madrid 28006, Spain.; Rojo, L (通讯作者)，Ctr Invest Biomed Red Bioingn Biomat & Nanomed CIB, Madrid 28029, Spain.
EM rojodelolmo@ictp.csic.es
RI Fernández Villa, Daniel/ABD 7475 2021; Rojo, Luis/B 3073 2009; Rojo del
   Olmo, Luis/B 3073 2009; Aguilar, Maria Rosa/C 2593 2014
OI Fernandez Villa, Daniel/0000 0001 7420 9104; Rojo del Olmo,
   Luis/0000 0001 6334 6736; Aguilar, Maria Rosa/0000 0001 7395 5754
FU Spanish MICINN [PID2020 114086RB I00]; Comunidad Autonoma de Madrid
   [S2022/BMD 7406]; Predoctoral program MICINN [FPU18/04683]
FX This paper is dedicated to the memory of Blanca Vazquez Lasa, who
   participated in the conceptualization and preliminary studies of this
   work, but lamentably passed away on 31st January 2023. This research has
   been funded by the Spanish MICINN (PID2020 114086RB I00) and Comunidad
   Autonoma de Madrid (S2022/BMD 7406). D. F. V. is financially supported
   by a predoctoral program MICINN FPU18/04683. M. R. A. and L. R. are
   members of PTI SusPlast+ and Nanomedicine CSIC. The authors would like
   to acknowledge David Gomez, Pedro Gonzalez Esperanza Benito and Pilar
   Posadas of the Characterization Service at the Instituto de Ciencia y
   Tecnologia de Polimeros (CSIC) for the technical support and EM
   facilities of the CIB Margarita Salas (CSIC) for support in grid
   screening and preparation.
CR Abdollahi M., 2005, Therapy, V2, P787, DOI [10.1586/14750708.2.5.787, DOI 10.2217/14750708.2.5.787]
   akar S., 2019, J PHOTOCH PHOTOBIO A, V371, P282
   Alicka M, 2019, MAT SCI ENG C MATER, V99, P1257, DOI 10.1016/j.msec.2019.02.073
   Arciszewska Z, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23020888
   Augustine R, 2017, J MATER CHEM B, V5, P4660, DOI 10.1039/c7tb00518k
   Bigham A, 2022, CHEM ENG J, V432, DOI 10.1016/j.cej.2021.134146
   CERVELLATI C, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/569563
   Chariyarangsitham W, 2021, ARAB J CHEM, V14, DOI 10.1016/j.arabjc.2021.103312
   Chatterjee S, 2016, OXIDATIVE STRESS AND BIOMATERIALS, P35, DOI 10.1016/B978 0 12 803269 5.00002 4
   Chen MM, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.964130
   Choi S, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11071812
   Costa G.G., 2018, Open Chem. J., V5, DOI [10.2174/1874842201805010158, DOI 10.2174/1874842201805010158]
   Di Pompo G., 2021, CANCERS, V13, P1
   DINIS TCP, 1994, ARCH BIOCHEM BIOPHYS, V315, P161, DOI 10.1006/abbi.1994.1485
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Fan G, 2022, ACS APPL BIO MATER, V5, P4687, DOI 10.1021/acsabm.2c00136
   Fan HL, 2017, MACROMOLECULES, V50, P666, DOI 10.1021/acs.macromol.6b02106
   Fernández Villa D, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms231710054
   Fernndez Villa D., 2021, EUR J MED CHEM, V212
   Gambini J, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10040753
   Guo JL, 2014, ANGEW CHEM INT EDIT, V53, P5546, DOI 10.1002/anie.201311136
   Guo ZH, 2021, J MATER CHEM B, V9, P4098, DOI 10.1039/d1tb00383f
   Hapidin H, 2022, MOLECULES, V27, DOI 10.3390/molecules27020451
   Hapidin H, 2019, MICROSC RES TECHNIQ, V82, P1928, DOI 10.1002/jemt.23361
   Hem J.D., 1960, U.S. Geological Survey Water Supply Paper, P75, DOI DOI 10.3133/WSP1459D
   Huang YQ, 2020, CHEM ENG J, V397, DOI 10.1016/j.cej.2020.125352
   Huerta Madroñal M, 2021, CARBOHYD POLYM, V273, DOI 10.1016/j.carbpol.2021.118619
   Iantomasi T, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24043772
   Iglesias J, 2001, HYPERFINE INTERACT, V134, P109, DOI 10.1023/A:1013838600599
   Jiménez M, 2019, J MATER CHEM B, V7, P1974, DOI 10.1039/c8tb02738b
   Jing W, 2022, BIOMED PHARMACOTHER, V154, DOI 10.1016/j.biopha.2022.113561
   Kang L, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.956355
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   Kim HY, 2018, J FOOD BIOCHEM, V42, DOI 10.1111/jfbc.12664
   Kim H, 2020, JOVE J VIS EXP, DOI 10.3791/60682
   KLEINVELD HA, 1989, SCAND J RHEUMATOL, V18, P341, DOI 10.3109/03009748909102095
   Li F, 2018, J BIOMED NANOTECHNOL, V14, P756, DOI 10.1166/jbn.2018.2504
   Liu M, 2021, NANOSCALE, V13, P1181, DOI 10.1039/d0nr05608a
   Liu W, 2016, OSTEOPOROSIS INT, V27, P93, DOI 10.1007/s00198 015 3217 8
   Lopes GKB, 1999, BBA GEN SUBJECTS, V1472, P142, DOI 10.1016/S0304 4165(99)00117 8
   Pontes Quero GM, 2021, MAT SCI ENG C MATER, V121, DOI 10.1016/j.msec.2020.111793
   Martin del Campo M, 2016, BIOMATER SCI UK, V4, P1596, DOI 10.1039/c6bm00459h
   Marycz K, 2020, MAT SCI ENG C MATER, V110, DOI 10.1016/j.msec.2020.110634
   Mathew S, 2015, J FOOD SCI TECH MYS, V52, P5790, DOI 10.1007/s13197 014 1704 0
   Miao GH, 2014, J SOL GEL SCI TECHN, V69, P250, DOI 10.1007/s10971 013 3209 0
   Moreau P, 2015, INORG CHIM ACTA, V432, P81, DOI 10.1016/j.ica.2015.03.036
   Mouriño V, 2012, J R SOC INTERFACE, V9, P401, DOI 10.1098/rsif.2011.0611
   Newman H, 2021, BIOMATERIALS, V277, DOI 10.1016/j.biomaterials.2021.121114
   Onat B, 2018, EUR POLYM J, V103, P101, DOI 10.1016/j.eurpolymj.2018.03.034
   Pham TH, 2024, J PERIODONTAL RES, V59, P204, DOI 10.1111/jre.13208
   Pucci C, 2022, ACS APPL MATER INTER, V14, P15927, DOI 10.1021/acsami.1c24576
   Qiao W, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 30195 w
   Ru Q, 2023, BONE RES, V11, DOI 10.1038/s41413 023 00247 y
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Sánchez Moreno C, 1998, J SCI FOOD AGR, V76, P270, DOI 10.1002/(SICI)1097 0010(199802)76:2<270::AID JSFA945>3.3.CO;2 0
   Sharma J. N., 2007, Inflammopharmacology, V15, P252, DOI 10.1007/s10787 007 0013 x
   Shenoy N, 2017, LAB INVEST, V97, P494, DOI 10.1038/labinvest.2017.18
   Shi MC, 2017, BIOMATERIALS, V144, P176, DOI 10.1016/j.biomaterials.2017.08.027
   Sikora M, 2019, MATERIALS, V12, DOI 10.3390/ma12223779
   Song D, 2018, BIOCHEM BIOPH RES CO, V503, P3078, DOI 10.1016/j.bbrc.2018.08.096
   Steffi C, 2019, POLYMERS BASEL, V11, DOI 10.3390/polym11081256
   Sun YC, 2022, FRONT MATER, V8, DOI 10.3389/fmats.2021.801369
   Szwed Georgiou A, 2023, ACS BIOMATER SCI ENG, V9, P5222, DOI 10.1021/acsbiomaterials.3c00609
   Taciak B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198943
   Taha M, 2016, J INORG BIOCHEM, V157, P25, DOI 10.1016/j.jinorgbio.2016.01.017
   TAN WM, 1993, BIOMATERIALS, V14, P1003, DOI 10.1016/0142 9612(93)90193 6
   Terkawi MA, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031786
   Tondi G, 2015, IND CROP PROD, V65, P422, DOI 10.1016/j.indcrop.2014.11.005
   Torre E, 2017, PHYTOCHEM REV, V16, P1183, DOI 10.1007/s11101 017 9529 x
   Wang HC, 2022, BIOMATER SCI UK, V10, P5786, DOI 10.1039/d2bm00969b
   Wu CT, 2016, ACS APPL MATER INTER, V8, P11342, DOI 10.1021/acsami.6b03100
   Wu K., 2021, ADV HEALTHC MATER, V10, P1
   Wu KK, 2022, CHEM ENG J, V446, DOI 10.1016/j.cej.2022.136835
   Wu YL, 2023, BIOACT MATER, V20, P111, DOI 10.1016/j.bioactmat.2022.05.021
   Xie WS, 2021, THERANOSTICS, V11, P6407, DOI 10.7150/thno.58711
   Xiong F, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951 020 00694 3
   Yang Q, 2017, PHARM BIOL, V55, P428, DOI 10.1080/13880209.2016.1245346
   Zhang Y, 2018, NANOMATERIALS BASEL, V8, DOI 10.3390/nano8110961
   Zhu W., 2017, J MATER SCI MATER M, V28, P1
NR 79
TC 5
Z9 5
U1 4
U2 11
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PD JUL 24
PY 2024
VL 12
IS 29
BP 7153
EP 7170
DI 10.1039/d4tb00697f
EA JUL 2024
PG 18
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA ZJ7L5
UT WOS:001260701500001
PM 38952270
OA hybrid
DA 2025 08 17
ER

PT J
AU Sorrentino, A
   Ferracin, M
   Castelli, G
   Biffoni, M
   Tomaselli, G
   Baiocchi, M
   Fatica, A
   Negrini, M
   Peschle, C
   Valtieri, M
AF Sorrentino, Antonio
   Ferracin, Manuela
   Castelli, Germana
   Biffoni, Mauro
   Tomaselli, Giada
   Baiocchi, Marta
   Fatica, Alessandro
   Negrini, Massimo
   Peschle, Cesare
   Valtieri, Mauro
TI Isolation and characterization of CD146<SUP>+</SUP> multipotent
   mesenchymal stromal cells
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Article
ID HUMAN BONE MARROW; COLONY STIMULATING FACTOR; STEM CELLS; HEMATOPOIETIC
   STEM; PROGENITOR CELLS; UMBILICAL CORD; GROWTH FACTOR; IN VITRO;
   RECEPTOR; MICRORNAS
AB Mesenchymal stromal cells (MSCs) represent a bone marrow (BM) population, classically defined by five functional properties: extensive proliferation, ability to differentiate into osteoblasts, chondrocytes, adipocytes, and stromal cells  supporting hematopoiesis. However, research progress in this area has been hampered by lack of suitable markers and standardized procedures for MSC isolation. We have isolated a CD146(+) multipotent MSC population from 20 human BM donors displaying the phenotype of self renewing osteoprogenitors; an extensive 12 week proliferation; and the ability to differentiate in osteoblasts, chondrocytes, adipocytes, and stromal cells supporting hematopoiesis. Furthermore, the CD146+ MSCs secrete a complex combination of growth factors (GFs) controlling hematopoietic stem cells (HSCs) function, while providing a > 2 log increase in the long term culture (LTC) colony output in 8 week LTC over conventional assays. The hematopoietic stromal function exhibited by the MSCs was further characterized by manipulating LTCs with the chemical inhibitors Imatinib or SU 5416, targeting two GF receptors (GFRs), KIT or VEGFR2/1, respectively. Both treatments similarly impaired LTC colony output, indicating key roles for these two GF/GFR interactions to support LTC initiating cell activity. CD146+ MSCs may thus represent a tool to explore the NISC HSC cross talk in an in vitro surrogate model for HSC "niches," and for regenerative therapy studies. In addition, the MSC microRNA (miRNA) expression profile was analyzed by microarrays in both basic conditions and chondrogenic differentiation. Our analysis revealed that several miRNAs are modulated during chondrogenesis, and many of their putative targets are genes involved in chondrogenic differentiation. (c) 2008 ISEH   Society for Hematology and Stem Cells. Published by Elsevier Inc.
C1 [Sorrentino, Antonio; Castelli, Germana; Biffoni, Mauro; Tomaselli, Giada; Baiocchi, Marta; Peschle, Cesare; Valtieri, Mauro] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I 00161 Rome, Italy.
   [Ferracin, Manuela; Negrini, Massimo] Univ Ferrara, Dept Expt & Diagnost Med, I 44100 Ferrara, Italy.
   [Ferracin, Manuela; Negrini, Massimo] Univ Ferrara, Interdept Ctr Canc Res, I 44100 Ferrara, Italy.
   [Fatica, Alessandro] Univ Roma La Sapienza, Dept Genet & Mol Biol, Inst Pasteur Cenci Bolognetti, Rome, Italy.
C3 Istituto Superiore di Sanita (ISS); University of Ferrara; University of
   Ferrara; Fondazione Cenci Bolognetti; Sapienza University Rome
RP Valtieri, M (通讯作者)，Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I 00161 Rome, Italy.
EM valtieri@iss.it
RI Biffoni, Mauro/J 8318 2016; Fatica, Alessandro/L 2866 2019; castelli,
   germana/J 7244 2016; Ferracin, Manuela/K 2097 2016; valtieri,
   mauro/H 1044 2016; Negrini, Massimo/J 2377 2016; NEGRINI,
   Massimo/J 2377 2016
OI Biffoni, Mauro/0000 0002 1304 9060; Baiocchi, Marta/0000 0003 0976 0690;
   castelli, germana/0000 0002 3593 1230; Fatica,
   Alessandro/0000 0002 0743 7905; Ferracin, Manuela/0000 0002 1595 6887;
   valtieri, mauro/0000 0002 9139 6754; NEGRINI,
   Massimo/0000 0002 0007 1920
CR Anjos Afonso F, 2007, BLOOD, V109, P1298, DOI 10.1182/blood 2006 06 030551
   Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006 0709
   Ball SG, 2007, J CELL BIOL, V177, P489, DOI 10.1083/jcb.200608093
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139
   Bianco P, 2001, NATURE, V414, P118, DOI 10.1038/35102181
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chitu V, 2006, CURR OPIN IMMUNOL, V18, P39, DOI 10.1016/j.coi.2005.11.006
   Cristofalo VJ, 1998, CRIT REV EUKAR GENE, V8, P43, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.30
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Delorme B, 2008, BLOOD, V111, P2631, DOI 10.1182/blood 2007 07 099622
   Detmer K, 2002, CYTOKINE, V17, P36, DOI 10.1006/cyto.2001.0984
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Eklund L, 2006, EXP CELL RES, V312, P630, DOI 10.1016/j.yexcr.2005.09.002
   Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023
   Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102
   Fleetwood AJ, 2005, CRIT REV IMMUNOL, V25, P405, DOI 10.1615/CritRevImmunol.v25.i5.50
   Fontana L, 2007, NAT CELL BIOL, V9, P775, DOI 10.1038/ncb1613
   GABBIANELLI M, 1995, BLOOD, V86, P1661, DOI 10.1182/blood.V86.5.1661.bloodjournal8651661
   Gang EJ, 2007, BLOOD, V109, P1743, DOI 10.1182/blood 2005 11 010504
   Greco SJ, 2007, P NATL ACAD SCI USA, V104, P15484, DOI 10.1073/pnas.0703037104
   Han W, 2006, CELL RES, V16, P189, DOI 10.1038/sj.cr.7310026
   Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363
   Kassis I, 2006, BONE MARROW TRANSPL, V37, P967, DOI 10.1038/sj.bmt.1705358
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Kuznetsov SA, 2004, J CELL BIOL, V167, P1113, DOI 10.1083/jcb.200408079
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092 8674(03)01018 3
   Li Q, 2003, J PATHOL, V201, P296, DOI 10.1002/path.1443
   Li WM, 2004, EXP HEMATOL, V32, P1226, DOI 10.1016/j.exphem.2004.09.001
   Liles WC, 2003, BLOOD, V102, P2728, DOI 10.1182/blood 2003 02 0663
   LINENBERGER ML, 1995, EXP HEMATOL, V23, P1104
   Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101
   Mansilla E, 2006, TRANSPL P, V38, P967, DOI 10.1016/j.transproceed.2006.02.053
   Martinez C, 2007, BLOOD, V109, P4245, DOI 10.1182/blood 2006 08 039347
   Metcalf D, 2007, STEM CELLS, V25, P2390, DOI 10.1634/stemcells.2007 0544
   Miller FD, 2007, CELL STEM CELL, V1, P129, DOI 10.1016/j.stem.2007.07.007
   Nakano T, 1996, INT J HEMATOL, V65, P1
   Ong SY, 2006, BIOMATERIALS, V27, P4087, DOI 10.1016/j.biomaterials.2006.03.022
   Pelosi E, 2002, BLOOD, V100, P3203, DOI 10.1182/blood 2002 05 1511
   Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Roy H, 2006, FEBS LETT, V580, P2879, DOI 10.1016/j.febslet.2006.03.087
   Rubin BP, 2007, LANCET, V369, P1731, DOI 10.1016/S0140 6736(07)60780 6
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Schwab KE, 2007, HUM REPROD, V22, P2903, DOI 10.1093/humrep/dem265
   Scott CL, 2000, BLOOD, V96, P1588, DOI 10.1182/blood.V96.4.1588.h8001588_1588_1590
   Seruya M, 2004, CELL TRANSPLANT, V13, P93, DOI 10.3727/000000004773301762
   Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696
   SLANICKA KM, 1998, EXP HEMATOL, V26, P365
   Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016
   Takakura N, 1996, J EXP MED, V184, P2301, DOI 10.1084/jem.184.6.2301
   VALTIERI M, 1994, CANCER RES, V54, P4398
   Verfaillie CM, 1998, BLOOD, V92, P2609, DOI 10.1182/blood.V92.8.2609
   Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003
   Wang DJ, 2004, J BIOL CHEM, V279, P43725, DOI 10.1074/jbc.M407368200
   Wenisch S, 2006, BONE, V38, P911, DOI 10.1016/j.bone.2005.10.021
   Ye C, 2006, TOXICOL IN VITRO, V20, P154, DOI 10.1016/j.tiv.2005.06.047
   Yin T, 2006, J CLIN INVEST, V116, P1195, DOI 10.1172/JCI28568
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553
NR 66
TC 208
Z9 238
U1 0
U2 28
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0301 472X
EI 1873 2399
J9 EXP HEMATOL
JI Exp. Hematol.
PD AUG
PY 2008
VL 36
IS 8
BP 1035
EP 1046
DI 10.1016/j.exphem.2008.03.004
PG 12
WC Hematology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Research & Experimental Medicine
GA 334FH
UT WOS:000258207200014
PM 18504067
OA Bronze
DA 2025 08 17
ER

PT J
AU Yan, CY
   Huang, D
   Shen, X
   Qin, NB
   Jiang, KM
   Zhang, DW
   Zhang, Q
AF Yan, Chunyan
   Huang, Dong
   Shen, Xia
   Qin, Ningbo
   Jiang, Keming
   Zhang, Dawei
   Zhang, Qian
TI Identification and characterization of a polysaccharide from the roots
   of Morinda officinalis, as an inducer of bone formation by
   up regulation of target gene expression
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Morinda officinalis; Polysaccharides; Anti osteoporosis
ID ANTI OSTEOPOROSIS ACTIVITY; STRUCTURAL CHARACTERIZATION; OSTEOBLAST
   DIFFERENTIATION; ANTIOXIDANT ACTIVITY; DEVELOPMENTAL EXPRESSION;
   ACHYRANTHES BIDENTATA; ALKALINE PHOSPHATASE; MESSENGER RNA; IN VITRO;
   FRUCTAN
AB Morinda officinalis is an important traditional tonic herbal medicine. In the present study, we found that crude polysaccharides extracted from M. officinalis, named MO90, could significantly increase the bone mineral density (BMD) of the whole femur, distal femur, and proximal femur in ovariectomized (OVX) rats. In addition, MO90 decreased the level of bone turnover markers and prevented the deterioration of trabecular microarchitecture. To investigate the fractions responsible for anti osteoporosis activity, one novel inulin type fructan, MOW90 1, was isolated from MOP90. Structural analysis indicated that MOW90 1 consists of a backbone of (2  > 1) linked beta D Fruf, and is terminated with (1  >) linked alpha D Glcp and (2  >) linked beta D Fruf. Furthermore, an in vitro anti osteoporosis assay indicated that MOW90 1 promoted proliferation, differentiation, and mineralization of MOT3 E1 cells by up regulating the expression of runt related transcription factor 2, osterix, osteopontin, and osteocalcin. In conclusion, our studies provide supporting evidence for future use of this novel M. officinalis fructan as a key nutrient of health products. (C) 2019 Elsevier B.V. All rights reserved.
C1 [Yan, Chunyan; Huang, Dong; Qin, Ningbo; Jiang, Keming; Zhang, Qian] Guangdong Pharmaceut Univ, Sch Pharm, Guangzhou 510006, Guangdong, Peoples R China.
   [Shen, Xia] Guangdong Med Univ, Dept Pharmacol, Dongguan 523808, Guangdong, Peoples R China.
   [Zhang, Dawei] Shaanxi Univ Chinese Med, Xian 712046, Shaanxi, Peoples R China.
C3 Guangdong Pharmaceutical University; Guangdong Medical University;
   Shaanxi University of Chinese Medicine
RP Yan, CY; Zhang, Q (通讯作者)，Guangdong Pharmaceut Univ, Sch Pharm, Guangzhou 510006, Guangdong, Peoples R China.
EM ycybridge@gdpu.edu.cn; zqdrug@gdpu.edu.cn
RI 秦, 宁波/AAA 5900 2021; Zhang, Dawei/IAN 9726 2023; Zhang,
   Qian/AAO 9963 2020
FU National Natural Science Foundation of China [81673557, U1703110];
   Education Program of Guangdong Province [2017KZDXM048]
FX The study was financially supported by the National Natural Science
   Foundation of China (Nos. 81673557 and U1703110) and the Education
   Program of Guangdong Province (No. 2017KZDXM048).
CR BRADBURY JH, 1984, CARBOHYD RES, V126, P125, DOI 10.1016/0008 6215(84)85131 9
   Canderelli R, 2007, J AM ACAD NURSE PRAC, V19, P635, DOI 10.1111/j.1745 7599.2007.00269.x
   CARPITA NC, 1991, CARBOHYD RES, V217, P127, DOI 10.1016/0008 6215(91)84123 V
   Cérantola S, 2004, CARBOHYD RES, V339, P2445, DOI 10.1016/j.carres.2004.07.020
   CHEN JK, 1992, J BONE MINER RES, V7, P987
   Choi J, 2005, BIOL PHARM BULL, V28, P1915, DOI 10.1248/bpb.28.1915
   Clemens TL, 2011, J BONE MINER RES, V26, P677, DOI 10.1002/jbmr.321
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Foresta C, 2010, J CLIN ENDOCR METAB, V95, P3502, DOI 10.1210/jc.2009 2557
   Fu SW, 2014, NUTR RES, V34, P467, DOI 10.1016/j.nutres.2014.05.003
   He CB, 2009, CHEM J CHINESE U, V30, P2391
   Huang J.H., 2004, Chin. J. Clin. Pharmacol. Ther, V9, P1069
   Huang YT, 2015, CARBOHYD POLYM, V134, P752, DOI 10.1016/j.carbpol.2015.08.067
   KASUGAI S, 1992, J CELL PHYSIOL, V152, P467, DOI 10.1002/jcp.1041520305
   Khosla S, 2005, ENDOCRIN METAB CLIN, V34, P1015, DOI 10.1016/j.ecl.2005.07.009
   Kirmani S, 2011, J BONE MINER RES, V26, P2212, DOI 10.1002/jbmr.421
   Klinck RJ, 2008, MED ENG PHYS, V30, P888, DOI 10.1016/j.medengphy.2007.11.004
   Kulminskaya AA, 2003, BBA PROTEINS PROTEOM, V1650, P22, DOI 10.1016/S1570 9639(03)00187 0
   Kwun IS, 2010, BONE, V46, P732, DOI 10.1016/j.bone.2009.11.003
   Laib A, 2001, OSTEOPOROSIS INT, V12, P936, DOI 10.1007/s001980170022
   Lane NE, 2002, OSTEOPOROSIS INT, V13, P816, DOI 10.1007/s001980200113
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Li NS, 2013, INT J BIOL MACROMOL, V57, P285, DOI 10.1016/j.ijbiomac.2013.03.030
   Li N, 2017, J FUNCT FOODS, V29, P29, DOI 10.1016/j.jff.2016.11.033
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Martineau C, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12117
   MERRY K, 1993, J CELL SCI, V104, P1013
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Park BR, 2024, OBSTET GYNECOL SCI, V67, P430, DOI 10.5468/ogs.2017.60.2.213
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Seo HJ, 2010, NUTR RES PRACT, V4, P356, DOI 10.4162/nrp.2010.4.5.356
   Shih CC, 2001, J ETHNOPHARMACOL, V77, P233, DOI 10.1016/S0378 8741(01)00302 6
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Stevenson JC, 2005, MATURITAS, V51, P113, DOI 10.1016/j.maturitas.2005.01.012
   Sun LW, 2010, CARBOHYD POLYM, V79, P180, DOI 10.1016/j.carbpol.2009.07.044
   Tsukune N, 2017, BIOCHEM BIOPH RES CO, V488, P664, DOI 10.1016/j.bbrc.2017.02.110
   Wang CS, 2017, IND CROP PROD, V108, P458, DOI 10.1016/j.indcrop.2017.07.018
   Wang CS, 2015, IND CROP PROD, V70, P427, DOI 10.1016/j.indcrop.2015.03.051
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Wang XQ, 2017, CARBOHYD POLYM, V174, P48, DOI 10.1016/j.carbpol.2017.06.051
   Wheeler JC, 2000, SEMIN CELL DEV BIOL, V11, P369, DOI 10.1006/scdb.2000.0184
   Wu YB, 2009, MOLECULES, V14, P573, DOI 10.3390/molecules14010573
   Yang D, 2013, J BIOL CHEM, V288, P33530, DOI 10.1074/jbc.M113.497040
   Yang ZM, 2011, CARBOHYD POLYM, V83, P1997, DOI 10.1016/j.carbpol.2010.11.006
   Yi P., 2015, CARBOHYD POLYM, V134, P752
   Yi P, 2015, CARBOHYD POLYM, V121, P183, DOI 10.1016/j.carbpol.2014.11.034
   Yin Y., 2005, NOR HORTICUL, V12, P124
   YOHAY DA, 1994, J CELL PHYSIOL, V158, P467, DOI 10.1002/jcp.1041580311
   Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704
   Zhang, 2016, Mod. Chin. Med, V18, P482, DOI DOI 10.13313/J.ISSN.1673 4890.2016.4.020
   Zhang DW, 2008, PHYTOMEDICINE, V15, P55, DOI 10.1016/j.phymed.2007.04.002
   Zhang HL, 2009, INT J BIOL MACROMOL, V44, P257, DOI 10.1016/j.ijbiomac.2008.12.010
   Zhang HL, 2013, INT J BIOL MACROMOL, V58, P7, DOI 10.1016/j.ijbiomac.2013.03.031
   Zhang R, 2009, BONE, V45, P553, DOI 10.1016/j.bone.2008.08.127
   Zhao X, 2011, J ETHNOPHARMACOL, V137, P1083, DOI 10.1016/j.jep.2011.07.017
   Zhu MY, 2008, INT J BIOL MACROMOL, V43, P276, DOI 10.1016/j.ijbiomac.2008.06.008
   Zhu XH, 2008, TRANSL RES, V152, P18, DOI 10.1016/j.trsl.2008.05.003
NR 57
TC 42
Z9 49
U1 3
U2 75
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD JUL 15
PY 2019
VL 133
BP 446
EP 456
DI 10.1016/j.ijbiomac.2019.04.084
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA IE9HO
UT WOS:000472685700049
PM 30991070
DA 2025 08 17
ER

PT J
AU Zhou, Y
   Zou, PJ
   Chen, XM
   Chen, P
   Shi, M
   Lang, JY
   Chen, MH
AF Zhou, Yi
   Zou, Pingjin
   Chen, Xingmin
   Chen, Ping
   Shi, Min
   Lang, Jinyi
   Chen, Meihua
TI Overcoming Barriers in Photodynamic Therapy Harnessing Nanogenerators
   Strategies
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE photodynamic therapy; nanogenerators; treatment resistance; cancer
   treatment; reactive oxygen species
ID NEAR INFRARED LIGHT; UP CONVERSION NANOPARTICLES; IN VIVO; TRIBOELECTRIC
   NANOGENERATOR; OSTEOBLASTS PROLIFERATION; OPTICAL PROPERTIES;
   CELLULAR UPTAKE; HUMAN SKIN; CANCER; PHOTOSENSITIZERS
AB Photodynamic therapy (PDT) represents a targeted approach for cancer treatment that employs light and photosensitizers (PSs) to induce the generation of reactive oxygen species (ROS). However, PDT faces obstacles including insufficient PS localization, limited light penetration, and treatment resistance. A potential solution lies in nanogenerators (NGs), which function as self powered systems capable of generating electrical energy. Recent progress in piezoelectric and triboelectric NGs showcases promising applications in cancer research and drug delivery. Integration of NGs with PDT holds the promise of enhancing treatment efficacy by ensuring sustained PS illumination, enabling direct electrical control of cancer cells, and facilitating improved drug administration. This comprehensive review aims to augment our comprehension of PDT principles, explore associated challenges, and underscore the transformative capacity of NGs in conjunction with PDT. By harnessing NG technology alongside PDT, significant advancement in cancer treatment can be realized. Herein, we present the principal findings and conclusions of this study, offering valuable insights into the integration of NGs to overcome barriers in PDT.
C1 [Zhou, Yi; Chen, Ping] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Affiliated Canc Hosp, Sichuan Canc Ctr,Sichuan Clin Res Ctr Canc,Dept Ab, Chengdu, Peoples R China.
   [Zou, Pingjin; Chen, Xingmin; Lang, Jinyi; Chen, Meihua] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Affiliated Canc Hosp, Sichuan Canc Ctr,Sichuan Clin Res Ctr Canc,Dept Ra, Chengdu 610041, Peoples R China.
   [Shi, Min] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Affiliated Canc Hosp, Sichuan Canc Ctr,Sichuan Clin Res Ctr Canc,Dept Pa, Chengdu 610041, Peoples R China.
C3 University of Electronic Science & Technology of China; University of
   Electronic Science & Technology of China; University of Electronic
   Science & Technology of China
RP Chen, MH (通讯作者)，Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Affiliated Canc Hosp, Sichuan Canc Ctr,Sichuan Clin Res Ctr Canc,Radiat, Chengdu 610041, Peoples R China.
EM chenmeihua@scszlyy.org.cn
RI Zou, Pingjin/KHV 2360 2024; Chen, Ping/MCX 8558 2025; Chen,
   Meihua/AAY 9585 2020
FU Health Commission of Sichuan Province [2024 803]; Chengdu Technology
   Bureau [2024 YF05 02230 SN]; Youth Innovation Project of Sichuan Medical
   Association [Q19010]
FX Acknowledgements This work was supported by Health Commission of Sichuan
   Province (2024 803) ; Chengdu Technology Bureau (2024 YF05 02230 SN) ;
   Youth Innovation Project of Sichuan Medical Association (Q19010) .
CR Ackroyd R, 2001, PHOTOCHEM PHOTOBIOL, V74, P656, DOI 10.1562/0031 8655(2001)074<0656:THOPAP>2.0.CO;2
   Adadi N, 2020, ADV MATER TECHNOL US, V5, DOI 10.1002/admt.201900820
   Agostinis P, 2004, PHOTOCH PHOTOBIO SCI, V3, P721, DOI 10.1039/b315237e
   Agwa MM, 2023, INT J BIOL MACROMOL, V239, DOI 10.1016/j.ijbiomac.2023.124294
   Al Mutairi DA, 2007, FREE RADICAL RES, V41, P89, DOI 10.1080/10715760600952869
   Alagumalai A, 2021, NANO ENERGY, V83, DOI 10.1016/j.nanoen.2021.105844
   Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264 6021:3570593
   Alluri NR, 2016, SENSOR ACTUAT B CHEM, V237, P534, DOI 10.1016/j.snb.2016.06.134
   Aniogo EC, 2020, MOLECULES, V25, DOI 10.3390/molecules25225308
   Barolet D, 2008, SEMIN CUTAN MED SURG, V27, P227, DOI 10.1016/j.sder.2008.08.003
   Bashkatov AN, 2005, J PHYS D APPL PHYS, V38, P2543, DOI 10.1088/0022 3727/38/15/004
   Benov L, 2015, MED PRIN PRACT, V24, P14, DOI 10.1159/000362416
   Bok M, 2018, NANOSCALE, V10, P13502, DOI 10.1039/c8nr02192a
   Brancaleon L, 2002, LASER MED SCI, V17, P173, DOI 10.1007/s101030200027
   Broekgaarden M, 2015, CANCER METAST REV, V34, P643, DOI 10.1007/s10555 015 9588 7
   Cai Y, 2020, ANGEW CHEM INT EDIT, V59, P14014, DOI 10.1002/anie.202001107
   Casas A, 2011, CURR MED CHEM, V18, P2486, DOI 10.2174/092986711795843272
   Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894
   Castano AP, 2004, PHOTODIAGN PHOTODYN, V1, P279, DOI 10.1016/S1572 1000(05)00007 4
   Chen CH, 2017, NANO ENERGY, V42, P241, DOI 10.1016/j.nanoen.2017.10.064
   Chen DP, 2020, SMALL, V16, DOI 10.1002/smll.202001059
   Chen GY, 2014, CHEM REV, V114, P5161, DOI 10.1021/cr400425h
   Chen Q, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.950146
   Chen Y, 2021, ACS NANO, V15, P11514, DOI 10.1021/acsnano.1c01312
   Chen ZK, 2018, ACS NANO, V12, P8633, DOI 10.1021/acsnano.8b04371
   Chilakamarthi U, 2017, CHEM REC, V17, P775, DOI 10.1002/tcr.201600121
   Chu ESM, 2008, TOXICOL LETT, V181, P7, DOI 10.1016/j.toxlet.2008.06.860
   Coupienne I, 2011, BIOCHEM PHARMACOL, V81, P606, DOI 10.1016/j.bcp.2010.12.015
   Cui SS, 2013, ACS NANO, V7, P676, DOI 10.1021/nn304872n
   Damaraju SM, 2017, BIOMATERIALS, V149, P51, DOI 10.1016/j.biomaterials.2017.09.024
   Dang JJ, 2017, BIOMATER SCI UK, V5, P1500, DOI 10.1039/c7bm00392g
   Deng KR, 2017, SMALL, V13, DOI 10.1002/smll.201702299
   Deng WL, 2022, CHEM SOC REV, V51, P3380, DOI 10.1039/d1cs00858g
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468
   Derycke ASL, 2004, ADV DRUG DELIVER REV, V56, P17, DOI 10.1016/j.addr.2003.07.014
   Dewaele M, 2011, J CELL MOL MED, V15, P1402, DOI 10.1111/j.1582 4934.2010.01118.x
   Di Venosa G, 2015, PHOTOCH PHOTOBIO SCI, V14, P1451, DOI 10.1039/c4pp00445k
   Domagala A, 2018, BMC CANCER, V18, DOI 10.1186/s12885 018 4126 y
   Dong K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 16642 6
   Epe B, 2012, PHOTOCH PHOTOBIO SCI, V11, P98, DOI 10.1039/c1pp05190c
   Estrella V, 2013, CANCER RES, V73, P1524, DOI 10.1158/0008 5472.CAN 12 2796
   Fan FR, 2012, NANO ENERGY, V1, P328, DOI 10.1016/j.nanoen.2012.01.004
   Fan WP, 2016, CHEM SOC REV, V45, P6488, DOI 10.1039/c6cs00616g
   Fan YJ, 2020, NANO ENERGY, V69, DOI 10.1016/j.nanoen.2019.104407
   Fathallah Shaykh HM, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002810
   Feng LZ, 2017, BIOMATERIALS, V127, P13, DOI 10.1016/j.biomaterials.2016.11.027
   Friberg EG, 2003, CANCER LETT, V195, P73, DOI 10.1016/S0304 3835(03)00150 2
   Ghosh K, 2023, ADV ENERGY MATER, V13, DOI 10.1002/aenm.202203476
   Gilaberte Y, 2014, J INVEST DERMATOL, V134, P2428, DOI 10.1038/jid.2014.178
   Girotti AW, 2001, J PHOTOCH PHOTOBIO B, V63, P103, DOI 10.1016/S1011 1344(01)00207 X
   Girotti AW, 2004, ANTIOXID REDOX SIGN, V6, P301, DOI 10.1089/152308604322899369
   Goldberg RM, 2002, J CLIN ONCOL, V20, P4591, DOI 10.1200/JCO.2002.03.039
   Golstein P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI 10.1016/j.tibs.2006.11.001
   Gu L, 2013, NANO LETT, V13, P91, DOI 10.1021/nl303539c
   Guan HY, 2023, NANO ENERGY, V105, DOI 10.1016/j.nanoen.2022.108002
   Guéraud F, 2010, FREE RADICAL RES, V44, P1098, DOI 10.3109/10715762.2010.498477
   Guo WZ, 2018, NANOSCALE, V10, P17751, DOI 10.1039/c8nr05292a
   Han Q, 2024, NANO ENERGY, V125, DOI [10.1016/j.nanoen.2024.109374, 10.1016/j.nanoen.2024.109530]
   Hao ZN, 2024, SMALL, V20, DOI 10.1002/smll.202309487
   He LC, 2020, J AM CHEM SOC, V142, P6822, DOI 10.1021/jacs.0c02497
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Helbig D, 2011, INT J HYPERTHER, V27, P802, DOI 10.3109/02656736.2011.569966
   Hemmer E, 2017, J MATER CHEM B, V5, P4365, DOI 10.1039/c7tb00403f
   Hensley CT, 2016, CELL, V164, P681, DOI 10.1016/j.cell.2015.12.034
   Hoang QT, 2023, ADV MATER, V35, DOI 10.1002/adma.202300437
   Hoop M, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03992 3
   Hsieh YJ, 2003, J CELL PHYSIOL, V194, P363, DOI 10.1002/jcp.10273
   Hu YF, 2012, ADV MATER, V24, P110, DOI 10.1002/adma.201103727
   Huang Z, 2015, J INNOV OPT HEAL SCI, V8, DOI 10.1142/S1793545815300025
   Indira SS, 2019, NANOMATERIALS BASEL, V9, DOI 10.3390/nano9050773
   Iskratsch T, 2014, NAT REV MOL CELL BIO, V15, P825, DOI 10.1038/nrm3903
   Jalili A, 2004, CLIN CANCER RES, V10, P4498, DOI 10.1158/1078 0432.CCR 04 0367
   Ji HT, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 91
   Jiang W, 2018, ADV MATER, V30, DOI 10.1002/adma.201801895
   Jiang XY, 2019, NAT NANOTECHNOL, V14, P874, DOI 10.1038/s41565 019 0499 6
   Jie Y, 2015, ACS NANO, V9, P8376, DOI 10.1021/acsnano.5b03052
   Jin L, 2018, NANO ENERGY, V50, P632, DOI 10.1016/j.nanoen.2018.05.068
   Johar MA, 2018, ACTA MATER, V161, P237, DOI 10.1016/j.actamat.2018.09.030
   Johar MA, 2017, J ALLOY COMPD, V726, P765, DOI 10.1016/j.jallcom.2017.08.006
   Justus CR, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00354
   Kao FC, 2022, SCI TECHNOL ADV MAT, V23, P1, DOI 10.1080/14686996.2021.2015249
   Kessel D, 2018, PHOTOCHEM PHOTOBIOL, V94, P213, DOI 10.1111/php.12857
   Khandelwal G, 2022, ACS OMEGA, DOI 10.1021/acsomega.2c06335
   Kim J, 2019, NAT BIOTECHNOL, V37, P389, DOI 10.1038/s41587 019 0045 y
   Kim JI, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201907330
   Kim S, 2007, J AM CHEM SOC, V129, P2669, DOI 10.1021/ja0680257
   Kim TH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09439 9
   Kimáková P, 2017, BIOMED PHARMACOTHER, V85, P749, DOI 10.1016/j.biopha.2016.11.093
   Kong Y, 2021, ADV SCI, V8, DOI 10.1002/advs.202100962
   Korbelik M, 2011, PHOTOCH PHOTOBIO SCI, V10, P664, DOI 10.1039/c0pp00343c
   Kotagiri N, 2015, NAT NANOTECHNOL, V10, P370, DOI [10.1038/nnano.2015.17, 10.1038/NNAN0.2015.17]
   Kumari R, 2020, J CONTROL RELEASE, V319, P135, DOI 10.1016/j.jconrel.2019.12.041
   Kwiatkowski S, 2018, BIOMED PHARMACOTHER, V106, P1098, DOI 10.1016/j.biopha.2018.07.049
   Lan GX, 2019, J AM CHEM SOC, V141, P4204, DOI 10.1021/jacs.8b13804
   Lee DC, 2015, CELL, V161, P595, DOI 10.1016/j.cell.2015.03.011
   Li BH, 2007, PHOTOCHEM PHOTOBIOL, V83, P1505, DOI 10.1111/j.1751 1097.2007.00194.x
   Li ML, 2019, J AM CHEM SOC, V141, P2695, DOI 10.1021/jacs.8b13141
   Li Q, 2018, CYTOM PART A, V93A, P997, DOI 10.1002/cyto.a.23596
   Li SS, 2020, J AM CHEM SOC, V142, P5649, DOI 10.1021/jacs.9b12929
   Li WZ, 2024, J MECH BEHAV BIOMED, V150, DOI 10.1016/j.jmbbm.2023.106306
   Li W, 2017, J CONTROL RELEASE, V258, P171, DOI 10.1016/j.jconrel.2017.05.015
   Li XS, 2018, ANGEW CHEM INT EDIT, V57, P11522, DOI 10.1002/anie.201805138
   Li XS, 2018, ANGEW CHEM INT EDIT, V57, P9885, DOI 10.1002/anie.201806551
   Li X, 2018, CHEM SOC REV, V47, P1174, DOI 10.1039/c7cs00594f
   Li ZL, 2016, NANO ENERGY, V22, P548, DOI 10.1016/j.nanoen.2016.03.002
   Lim CM, 2019, AUSTRALAS J DERMATOL, V60, P339, DOI 10.1111/ajd.13043
   Lin T, 2023, NANO ENERGY, V116, DOI 10.1016/j.nanoen.2023.108826
   Liu HJ, 2019, ACS NANO, V13, P12638, DOI 10.1021/acsnano.9b04181
   Liu X., 2021, Smart Mater. Med., V2, P150, DOI [10.1016/j.smaim.2021.05.002, DOI 10.1016/J.SMAIM.2021.05.002]
   Liu ZY, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00903 7
   Liu ZR, 2020, ACS NANO, V14, P15458, DOI 10.1021/acsnano.0c06100
   Liu ZR, 2019, ADV MATER, V31, DOI 10.1002/adma.201807795
   Liu Z, 2020, ACS NANO, V14, P8074, DOI 10.1021/acsnano.0c00675
   Luo TK, 2020, J AM CHEM SOC, V142, P7334, DOI 10.1021/jacs.0c02129
   Maher EA, 2012, NMR BIOMED, V25, P1234, DOI 10.1002/nbm.2794
   Maiuri MC, 2010, EMBO J, V29, P515, DOI 10.1038/emboj.2009.377
   Mang TS, 2004, PHOTODIAGN PHOTODYN, V1, P43, DOI 10.1016/S1572 1000(04)00012 2
   Manzoor AA, 2008, J CLIN INVEST, V118, P1616, DOI 10.1172/JCI35543
   Sanabria LM, 2013, BBA REV CANCER, V1835, P36, DOI 10.1016/j.bbcan.2012.10.001
   Mishchenko T, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04851 4
   MOAN J, 1987, PHOTOCHEM PHOTOBIOL, V46, P713, DOI 10.1111/j.1751 1097.1987.tb04837.x
   Moghassemi S, 2021, J CONTROL RELEASE, V339, P75, DOI 10.1016/j.jconrel.2021.09.024
   Mohammad Hadi L, 2018, NANOSCALE, V10, P1570, DOI 10.1039/c7nr07739d
   Mohile SG, 2021, LANCET, V398, P1894, DOI 10.1016/S0140 6736(21)01789 X
   Molina JR, 2018, NAT MED, V24, P1036, DOI 10.1038/s41591 018 0052 4
   Mroz Pawel, 2011, Cancers (Basel), V3, P2516, DOI 10.3390/cancers3022516
   Murillo G, 2017, ADV MATER, V29, DOI 10.1002/adma.201605048
   Ni YH, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.637675
   Nie JH, 2018, ACS NANO, V12, P1491, DOI 10.1021/acsnano.7b08014
   Novohradsky V, 2019, ANGEW CHEM INT EDIT, V58, P6311, DOI 10.1002/anie.201901268
   Pawlicki M, 2009, ANGEW CHEM INT EDIT, V48, P3244, DOI 10.1002/anie.200805257
   Peng MZ, 2016, ACS NANO, V10, P1572, DOI 10.1021/acsnano.5b07217
   Petruk G, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10111572
   Preise D, 2009, CANCER IMMUNOL IMMUN, V58, P71, DOI 10.1007/s00262 008 0527 0
   Pu X, 2023, NATL SCI REV, V10, DOI 10.1093/nsr/nwac170
   Qian J, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3083427
   Qin Y, 2008, NATURE, V451, P809, DOI [10.1038/nature06601, 10.1038/nature066O1]
   Rangasamy S, 2015, J MED CHEM, V58, P6864, DOI 10.1021/acs.jmedchem.5b01095
   Robey RW, 2005, CANCER BIOL THER, V4, P187
   ROCHA L.G. B., 2016, Development of a novel photosensitizer for photodynamic therapy of cancer
   Rodrigues JA, 2019, IEEE J SEL TOP QUANT, V25, DOI 10.1109/JSTQE.2018.2889426
   Rodrigues JA, 2022, CELLS BASEL, V11, DOI 10.3390/cells11243995
   Rodríguez ME, 2016, PHOTOCH PHOTOBIO SCI, V15, P1090, DOI 10.1039/c6pp00097e
   Samuel ELG, 2015, P NATL ACAD SCI USA, V112, P2343, DOI 10.1073/pnas.1417047112
   Sando Y, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 74174 x
   Sarkar C, 2008, CLIN CANCER RES, V14, P2502, DOI 10.1158/1078 0432.CCR 07 1778
   Scaffidi JP, 2011, ACS NANO, V5, P4679, DOI 10.1021/nn200511m
   Sen O, 2022, MATER TODAY BIO, V13, DOI 10.1016/j.mtbio.2021.100196
   Shadel GS, 2015, CELL, V163, P560, DOI 10.1016/j.cell.2015.10.001
   Shan L., 2004, Molecular Imaging and Contrast Agent Database (MICAD)
   Sharma A, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.849040
   Shen ZJ, 2021, NPG ASIA MATER, V13, DOI 10.1038/s41427 021 00303 1
   Sheng C, 2004, PHOTOCHEM PHOTOBIOL, V79, P520, DOI 10.1562/MU 03 33.1
   Shi LL, 2020, ACS NANO, V14, P2183, DOI 10.1021/acsnano.9b09032
   Shin SH, 2016, NANOSCALE, V8, P1314, DOI 10.1039/c5nr07185b
   Shin SH, 2014, ACS NANO, V8, P2766, DOI 10.1021/nn406481k
   Simpson CR, 1998, PHYS MED BIOL, V43, P2465, DOI 10.1088/0031 9155/43/9/003
   Smith AM, 2009, NAT NANOTECHNOL, V4, P710, DOI 10.1038/nnano.2009.326
   Soares HT, 2016, CHEMBIOCHEM, V17, P836, DOI 10.1002/cbic.201500573
   Song W, 2018, ACS NANO, V12, P1978, DOI 10.1021/acsnano.7b09112
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02 0746
   Sun BB, 2020, ANGEW CHEM INT EDIT, V59, P20582, DOI 10.1002/anie.202008708
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tang DL, 2019, CELL RES, V29, P347, DOI 10.1038/s41422 019 0164 5
   Tang W, 2015, ACS NANO, V9, P7867, DOI 10.1021/acsnano.5b03567
   TANNOCK IF, 1989, CANCER RES, V49, P4373
   Teh DBL, 2020, ADV MATER, V32, DOI 10.1002/adma.202001459
   Theodoraki MN, 2017, PHOTODIAGN PHOTODYN, V19, P194, DOI 10.1016/j.pdpdt.2017.05.015
   Tian G, 2012, ADV MATER, V24, P1226, DOI 10.1002/adma.201104741
   Tian JJ, 2019, NANO ENERGY, V59, P705, DOI 10.1016/j.nanoen.2019.02.073
   Timin AS, 2018, ACS APPL MATER INTER, V10, P34849, DOI 10.1021/acsami.8b09810
   van Hell AJ, 2010, J CONTROL RELEASE, V141, P347, DOI 10.1016/j.jconrel.2009.09.012
   van Nostrum CF, 2004, ADV DRUG DELIVER REV, V56, P9, DOI 10.1016/j.addr.2003.07.013
   Vankayala R, 2018, ADV MATER, V30, DOI 10.1002/adma.201706320
   Viale A, 2015, CANCER RES, V75, P3687, DOI 10.1158/0008 5472.CAN 15 0491
   Viswanath D, 2022, ACS BIOMATER SCI ENG, V8, P3644, DOI 10.1021/acsbiomaterials.2c00287
   Wan YL, 2021, ADV MATER, V33, DOI 10.1002/adma.202103978
   Wang AC, 2019, NANOMATERIALS BASEL, V9, DOI 10.3390/nano9030349
   Wang C, 2011, BIOMATERIALS, V32, P6145, DOI 10.1016/j.biomaterials.2011.05.007
   Wang HR, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201902440
   Wang H, 2021, SCI BULL, V66, P490, DOI 10.1016/j.scib.2020.10.002
   Wang HR, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120621
   Wang H, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120609
   Wang K, 2019, CHEM MATER, V31, P3313, DOI 10.1021/acs.chemmater.9b00265
   Wang LY, 2013, NANOSCALE, V5, P416, DOI 10.1039/c2nr32506c
   Wang XQ, 2021, BIOMATERIALS, V266, DOI 10.1016/j.biomaterials.2020.120474
   Wang XX, 2018, ACS NANO, V12, P8588, DOI 10.1021/acsnano.8b04244
   Wang XC, 2021, J PHOTOCH PHOTOBIO B, V222, DOI 10.1016/j.jphotobiol.2021.112274
   Wang YL, 2019, ACCOUNTS CHEM RES, V52, P1507, DOI 10.1021/acs.accounts.9b00126
   Wang Y, 2023, ACS NANO, V17, P3557, DOI 10.1021/acsnano.2c09948
   Wang ZZ, 2021, J PHYS CHEM C, V125, P23098, DOI 10.1021/acs.jpcc.1c04878
   Wang ZL, 2017, MATER TODAY, V20, P74, DOI 10.1016/j.mattod.2016.12.001
   Wang ZL, 2015, ENERG ENVIRON SCI, V8, P2250, DOI 10.1039/c5ee01532d
   Wang ZJ, 1999, PHOTOCHEM PHOTOBIOL, V70, P773, DOI 10.1562/0031 8655(1999)070<0773:PTDAPT>2.3.CO;2
   Wang ZL, 2006, SCIENCE, V312, P242, DOI 10.1126/science.1124005
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Wen JX, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 01196 6
   Wigfield SM, 2008, BRIT J CANCER, V98, P1975, DOI 10.1038/sj.bjc.6604356
   WILSON BC, 1985, PHOTOCHEM PHOTOBIOL, V42, P153, DOI 10.1111/j.1751 1097.1985.tb01554.x
   Wu YH, 2021, CARBOHYD POLYM, V255, DOI 10.1016/j.carbpol.2020.117490
   Xia YQ, 2022, ACS BIOMATER SCI ENG, V8, P1892, DOI 10.1021/acsbiomaterials.1c01311
   Xiang QQ, 2022, SMALL, V18, DOI 10.1002/smll.202107809
   Xie JL, 2021, CHEM SOC REV, V50, P9152, DOI 10.1039/d0cs01370f
   Xu S, 2010, NAT NANOTECHNOL, V5, P366, DOI [10.1038/NNANO.2010.46, 10.1038/nnano.2010.46]
   Xue XY, 2016, NANO ENERGY, V26, P148, DOI 10.1016/j.nanoen.2016.05.021
   Yang BW, 2019, CHEM REV, V119, P4881, DOI 10.1021/acs.chemrev.8b00626
   Yang DH, 2023, NANOSCALE, V15, P6709, DOI 10.1039/d3nr00507k
   Yao SC, 2022, ADV MATER, V34, DOI 10.1002/adma.202205881
   Yao SC, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202209142
   Yao SC, 2022, ADV MATER, V34, DOI 10.1002/adma.202109568
   Yin Z, 2010, BIOMATERIALS, V31, P2163, DOI 10.1016/j.biomaterials.2009.11.083
   Yoon JK, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201703853
   Yoshida T, 2008, AURIS NASUS LARYNX, V35, P545, DOI 10.1016/j.anl.2007.10.008
   Yu AF, 2016, ACS NANO, V10, P3944, DOI 10.1021/acsnano.5b07407
   Yu JT, 2023, ACTA BIOMATER, V170, P330, DOI 10.1016/j.actbio.2023.08.025
   Yu XT, 2022, BIOMATER ADV, V135, DOI 10.1016/j.bioadv.2022.212725
   Yu X, 2018, NANO ENERGY, V46, P29, DOI 10.1016/j.nanoen.2018.01.033
   Yuan H, 2021, ANGEW CHEM INT EDIT, V60, P8174, DOI 10.1002/anie.202014959
   Yuan MM, 2021, ACS APPL MATER INTER, V13, P54762, DOI 10.1021/acsami.1c16748
   Yuneva MO, 2012, CELL METAB, V15, P157, DOI 10.1016/j.cmet.2011.12.015
   Zamarrón A, 2015, PHOTOCH PHOTOBIO SCI, V14, P1378, DOI 10.1039/c4pp00448e
   Zhang HL, 2013, NANO ENERGY, V2, P1019, DOI 10.1016/j.nanoen.2013.03.024
   Zhang JN, 2022, ACS BIOMATER SCI ENG, V8, P1956, DOI 10.1021/acsbiomaterials.2c00138
   Zhang XD, 2020, NANOSCALE HORIZ, V5, P481, DOI 10.1039/c9nh00643e
   Zhang ZX, 2017, SMALL, V13, DOI 10.1002/smll.201602962
   Zhao CC, 2022, ACS NANO, V16, P8493, DOI 10.1021/acsnano.2c03768
   Zhao CC, 2022, MATERIALS, V15, DOI 10.3390/ma15062060
   Zhao CC, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201808640
   Zhao XZ, 2021, CHEM SOC REV, V50, P4185, DOI 10.1039/d0cs00173b
   Zhao Y, 2024, Small Methods, V8
   Zheng MJ, 2023, ACS APPL MATER INTER, V15, P7855, DOI 10.1021/acsami.2c21878
   Zheng XH, 2021, BIOACT MATER, V6, P4301, DOI 10.1016/j.bioactmat.2021.04.030
   Zhong SJ, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202305625
   Zhou JH, 2022, ACS BIOMATER SCI ENG, DOI 10.1021/acsbiomaterials.2c00992
   Zhou ZJ, 2016, CHEM SOC REV, V45, P6597, DOI 10.1039/c6cs00271d
   Zhu GA, 2010, NANO LETT, V10, P3151, DOI 10.1021/nl101973h
   Zou PJ, 2023, ADV SCI, V10, DOI 10.1002/advs.202302731
NR 237
TC 1
Z9 1
U1 9
U2 12
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2024
VL 20
IS 14
BP 5673
EP 5694
DI 10.7150/ijbs.100317
PG 22
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA J4A4E
UT WOS:001336503000007
PM 39494340
OA gold
DA 2025 08 17
ER

PT J
AU Nikishina, IP
   Arsenyeva, SV
   Matkava, VG
   Arefieva, AN
   Kaleda, MI
   Smirnov, AV
   Blank, LM
   Kostik, MM
AF Nikishina, Irina P.
   Arsenyeva, Svetlana V.
   Matkava, Valeria G.
   Arefieva, Alia N.
   Kaleda, Mariya I.
   Smirnov, Alexandr V.
   Blank, Leonid M.
   Kostik, Mikhail M.
TI Successful experience of tofacitinib treatment in patients with
   Fibrodysplasia Ossificans Progressiva
SO PEDIATRIC RHEUMATOLOGY
LA English
DT Article
DE Fibrodysplasia ossificans progressiva; FOP; Heterotopic ossification;
   Tofacitinib; Autoinflammation; Spondyloarthritis like disease; ACVR1
   gene; Bone morphogenetic protein; BMP
AB Fibrodysplasia ossificans progressive (FOP) is an ultra rare genetic disorder that is caused by a mutation in the ACVR1 gene and provokes severe heterotopic ossification. Since flares of the disease are associated with inflammation, it is assumed that JAK inhibitors can control active FOP due to blocking multiple signaling pathways.Aim of Study To assess the safety and efficacy of tofacitinib in patients with FOP refractory to standard of care treatment.Material and Methods In the retrospective observation study we included information about 13 genetically confirmed FOP patients who were treated with tofacitinib 5 mg twice a day. All patients initially failed treatment with NSAIDs, corticosteroids, and bisphosphonates. We evaluated the patients 12 months before the beginning of their treatment with tofacitinib and continued evaluating to at least 12 months of their tofacitinib treatment period.Results In 7 boys (54%) and six girls (46%) tofacitinib was prescribed at the age of 10.2 (ranged 2.2 19.6) years. Onset age was 1.5 (ranged 0.1 6.0) years. Main clinical features were malformed great toes (n = 13; 100%), short malformed thumbs (n = 9; 69%), peripheral osteochondromas (n = 9; 69%), abnormalities of the cervical spine (n = 13; 100%), multiple heterotopic ossifications (n = 13; 100%). The mean diagnostics delay was 44 (range: 1; 165) months. During the trial, the median (25%; 75%) frequency of flares decreased from 10 (6; 12) during 12 months before the baseline to 0 (0; 2) in the following 12 months and 0 (0; 0) in 24 months of treatment. There were no deteriorations of the CAJIS index during the study, except for only one patient whose CAJIS index deteriorated by 1 point. Improvement in the range of motion in the large joints was noted in 31% of patients. NSAID, oral and intravenous corticosteroids were successfully decreased from 100%; 61.5%, and 15.4% (baseline) to 46.2%, 7.7%, and 0% (12 months) and 22.2%, 0%, and 0% (24 months), consequently. The drug tolerance was good. No severe adverse events were registered.Conclusion Tofacitinib is a highly efficient, well tolerated option that may prevent FOP flares. Further studies of the therapeutic potential of JAK kinase inhibitors in FOP patients are needed.
C1 [Nikishina, Irina P.; Arsenyeva, Svetlana V.; Matkava, Valeria G.; Arefieva, Alia N.; Kaleda, Mariya I.; Smirnov, Alexandr V.; Blank, Leonid M.] VA Nasonova Res Inst Rheumatol, Kashirskoe Shosse 34A, Moscow 115522, Russia.
   [Kostik, Mikhail M.] St Petersburg State Pediat Med Univ, Hosp Pediatry Dept, St Petersburg, Russia.
C3 Saint Petersburg State Pediatric Medical University
RP Nikishina, IP (通讯作者)，VA Nasonova Res Inst Rheumatol, Kashirskoe Shosse 34A, Moscow 115522, Russia.
EM irpetnik_vip@mail.ru
RI Kostik, Mikhail/E 3572 2014; Nikishina, Irina/V 7749 2019; Arsenyeva,
   Svetlana/AAF 2883 2021
OI Kaleda, Maria/0000 0002 0513 6826; Arefeva, Alia/0000 0002 4156 5062;
   Smirnov, Alexander/0000 0001 7418 9369; Arsen'eva,
   Svetlana/0000 0001 9803 0221; Matkava, Valeriia/0000 0002 3815 0608
FU Not applicable.
FX Not applicable.
CR Barruet E, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122958
   Barruet E, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0372 6
   Haviv R, 2019, PEDIATR RHEUMATOL, V17, DOI 10.1186/s12969 019 0386 6
   Kaplan FS, 2008, BEST PRACT RES CL RH, V22, P191, DOI 10.1016/j.berh.2007.11.007
   Kaplan FS, 2021, BONE, V150, DOI 10.1016/j.bone.2021.116016
   Kaplan FS, 2018, BONE, V109, P276, DOI 10.1016/j.bone.2017.07.019
   Kaplan FS, 2017, BONE, V101, P123, DOI 10.1016/j.bone.2017.04.015
   Kaplan FS., 2022, Proc Intl Clin Council FOP, V2, P1
   Kostik MM, 2022, FRONT PEDIATR, V10, DOI 10.3389/fped.2022.820586
   Matkava V, PEDIATR RHEUMATOL, V20
   Nikishina I, 2021, CLIN EXP RHEUMATOL, V39, P1256
   Nikishina I, 2022, PEDIATR RHEUMATOL, VP048, P45, DOI [10.1186/s12969 022 00729 z, DOI 10.1186/S12969 022 00729 Z]
   Pignolo RJ, 2022, J BONE MINER RES, V37, P1891, DOI 10.1002/jbmr.4655
   Pignolo RJ, 2022, J BONE MINER RES, V37, P475, DOI 10.1002/jbmr.4492
   Ruperto N, 2021, LANCET, V398, P1984, DOI 10.1016/S0140 6736(21)01255 1
   Smilde BJ, 2022, BMC MUSCULOSKEL DIS, V23, DOI 10.1186/s12891 022 05471 x
   Smolen JS, 2020, ANN RHEUM DIS, V79, P685, DOI 10.1136/annrheumdis 2019 216655
   Sulko J, 2019, JOINT BONE SPINE, V86, P783, DOI 10.1016/j.jbspin.2019.06.005
   Vanhoutte F, 2020, J CLIN PHARMACOL, V60, P1424, DOI 10.1002/jcph.1638
   Williams E, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.95042
NR 20
TC 14
Z9 14
U1 1
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1546 0096
J9 PEDIATR RHEUMATOL
JI Pediatr. Rheumatol.
PD AUG 29
PY 2023
VL 21
IS 1
AR 92
DI 10.1186/s12969 023 00856 1
PG 9
WC Pediatrics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pediatrics; Rheumatology
GA Q5AZ2
UT WOS:001057657900001
PM 37644581
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ding, ZH
   Chen, WJ
   Wu, H
   Li, WJ
   Mao, X
   Su, WW
   Zhang, YQ
   Lin, N
AF Ding, Zihe
   Chen, Wenjia
   Wu, Hao
   Li, Weijie
   Mao, Xia
   Su, Weiwei
   Zhang, Yanqiong
   Lin, Na
TI Integrative network fusion based multi omics study for biomarker
   identification and patient classification of rheumatoid arthritis
SO CHINESE MEDICINE
LA English
DT Article
DE Rheumatoid arthritis; Patient classification; Biomarker identification;
   Precision medicine; Integration of the multi omics data
ID INFLAMMATORY RESPONSES; NALP3 INFLAMMASOME; IL4I1; ACTIVATION;
   EXPRESSION; IMMUNITY; GROWTH; CELLS
AB BackgroundCold dampness Syndrome (RA Cold) and Hot dampness Syndrome (RA Hot) are two distinct groups of rheumatoid arthritis (RA) patients with different clinical symptoms based on traditional Chinese medicine (TCM) theories and clinical empirical knowledge. However, the biological basis of the two syndromes has not been fully elucidated, which may restrict the development of personalized medicine and drug discovery for RA diagnosis and therapy.MethodsAn integrative strategy combining clinical transcriptomics, phenomics, and metabolomics data based on clinical cohorts and adjuvant induced arthritis rat models was performed to identify novel candidate biomarkers and to investigate the biological basis of RA Cold and RA Hot.ResultsThe main clinical symptoms of RA Cold patients are joint swelling, pain, and contracture, which may be associated with the dysregulation of T cell mediated immunity, osteoblast differentiation, and subsequent disorders of steroid biosynthesis and phenylalanine metabolism. In contrast, the main clinical symptoms of RA Hot patients are fever, irritability, and vertigo, which may be associated with various signals regulating angiogenesis, adrenocorticotropic hormone release, and NLRP3 inflammasome activation, leading to disorders of steroid biosynthesis, nicotinamide, and sphingolipid metabolism. IL17F, 5 HT, and IL4I1 were identified as candidate biomarkers of RA Cold, while S1P and GLNS were identified as candidate biomarkers of RA Hot.ConclusionsThe current study presents the most comprehensive metabonomic and transcriptomic profiling of serum, urine, synovial fluid, and synovial tissue samples obtained from RA Cold and RA Hot patients and experimental animal models to date. Through the integration of multi omics data and clinical independent validation, a list of novel candidate biomarkers of RA Cold and RA Hot syndromes were identified, that may be useful in improving RA diagnosis and therapy.
C1 [Ding, Zihe; Chen, Wenjia; Li, Weijie; Mao, Xia; Zhang, Yanqiong; Lin, Na] China Acad Chinese Med Sci, Inst Chinese Mat Med, Res Ctr Tradit Chinese Med Theory & Literatures, 16 Nanxiaojie, Beijing 100700, Peoples R China.
   [Wu, Hao; Su, Weiwei] Sun Yat Sen Univ, Sch Life Sci, Guangzhou 510275, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Institute of Chinese Materia
   Medica, CACMS; Sun Yat Sen University
RP Zhang, YQ; Lin, N (通讯作者)，China Acad Chinese Med Sci, Inst Chinese Mat Med, Res Ctr Tradit Chinese Med Theory & Literatures, 16 Nanxiaojie, Beijing 100700, Peoples R China.
EM yqzhang@icmm.ac.cn; nlin@icmm.ac.cn
FU National Key Research and Development Program of China [2018YFC1705201];
   CACMS Innovation Fund [CI2021A03808]; National Natural Science
   Foundation of China [81630107]
FX This study is funded by National Key Research and Development Program of
   China (2018YFC1705201), CACMS Innovation Fund (CI2021A03808) and
   National Natural Science Foundation of China (81630107). No study
   sponsors are involved in the research process of this project.
CR Ahern GP, 2011, CURR OPIN PHARMACOL, V11, P29, DOI 10.1016/j.coph.2011.02.004
   Archer KJ, 2014, CANCER INFORM, V13, P187, DOI 10.4137/CIN.S20806
   Boulland ML, 2007, BLOOD, V110, P220, DOI 10.1182/blood 2006 07 036210
   Buch MH, 2021, NAT REV RHEUMATOL, V17, P17, DOI 10.1038/s41584 020 00541 7
   Buck MD, 2017, CELL, V169, P570, DOI 10.1016/j.cell.2017.04.004
   Burmester GR, 2017, LANCET, V389, P2338, DOI 10.1016/S0140 6736(17)31491 5
   Chabbi Achengli Y, 2016, AM J PATHOL, V186, P927, DOI 10.1016/j.ajpath.2015.11.018
   Chen GY., 2019, J CHINA JAPAN FRIEND, V33, P212
   Chen Z, 2019, NAT REV RHEUMATOL, V15, P9, DOI 10.1038/s41584 018 0109 2
   Chi W, 2014, P NATL ACAD SCI USA, V111, P11181, DOI 10.1073/pnas.1402819111
   Choulaki C, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0775 2
   FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341
   Guo C, 2018, CLIN EXP IMMUNOL, V194, P231, DOI 10.1111/cei.13167
   Guo QY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 0160 8
   Hendriks M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.602278
   Hot A, 2011, ANN RHEUM DIS, V70, P727, DOI 10.1136/ard.2010.143768
   Hughes MM, 2018, IMMUNOL REV, V281, P88, DOI 10.1111/imr.12608
   Jiang Q., 2018, J Trad Chinese Med., V59, P1794, DOI DOI 10.13288/J.11 2166/R.2018.20.018
   Joo SY, 2016, INT J BIOMETEOROL, V60, P1217, DOI 10.1007/s00484 015 1116 5
   Kaul NC, 2020, RHEUMATOLOGY, V59, P1148, DOI 10.1093/rheumatology/kez587
   Kim EK, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.490
   Kim HW, 2017, CLIN EXP RHEUMATOL, V35, P630
   Kolly L, 2010, IMMUNOLOGY, V129, P178, DOI 10.1111/j.1365 2567.2009.03174.x
   Kovanicová Z, 2021, METABOLITES, V11, DOI 10.3390/metabo11090619
   Lam WC, 2019, PHARM MED, V33, P373, DOI 10.1007/s40290 019 00295 y
   Langan D, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042017
   Lasoudris F, 2011, EUR J IMMUNOL, V41, P1629, DOI 10.1002/eji.201041119
   Lauterbach MA, 2021, AUTOPHAGY, V17, P1947, DOI 10.1080/15548627.2020.1804677
   Lee CH, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10111706
   Li Cong chong, 2022, Yaoxue Xuebao, V57, P1044, DOI 10.16438/j.0513 4870.2021 1585
   Li WJ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.743086
   Li WJ, 2020, PHYTOMEDICINE, V67, DOI 10.1016/j.phymed.2019.153156
   Linghu KG, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.547913
   Liu CF, 2020, J ETHNOPHARMACOL, V260, DOI 10.1016/j.jep.2020.113039
   Liu Wenqian, 2021, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V37, P79
   Luan HM, 2021, J TRANSL MED, V19, DOI 10.1186/s12967 021 03169 7
   Mangan MSJ, 2018, NAT REV DRUG DISCOV, V17, P588, DOI [10.1038/nrd.2018.97, 10.1038/nrd.2018.149]
   Mao X, 2020, PHARMACOL RES, V153, DOI 10.1016/j.phrs.2020.104658
   Marques C, 2013, WORLD J GASTROENTERO, V19, P4464, DOI 10.3748/wjg.v19.i28.4464
   Martin Rodriguez S, 2015, EUR J CLIN INVEST, V45, P160, DOI 10.1111/eci.12392
   Neumann E, 2018, ANN RHEUM DIS, V77, P1619, DOI 10.1136/annrheumdis 2018 212954
   Nevius E, 2016, CLIN REV ALLERG IMMU, V51, P59, DOI 10.1007/s12016 015 8520 9
   Psachoulia K, 2016, BRAIN, V139, P3121, DOI 10.1093/brain/aww254
   Rao DA, 2017, NATURE, V542, P110, DOI 10.1038/nature20810
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 77
   Ruscitti P, 2015, CLIN EXP IMMUNOL, V182, P35, DOI 10.1111/cei.12667
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140 6736(16)30173 8
   Solos I., 2021, Chinese Medicine and Culture, V4, P86
   Song WX, 2020, ACTA PHARMACOL SIN B, V10, P61, DOI 10.1016/j.apsb.2019.12.006
   Souto Carneiro M, 2020, ANN RHEUM DIS, V79, P499, DOI 10.1136/annrheumdis 2019 216374
   Spiljar M, 2021, CELL METAB, V33, P2231, DOI 10.1016/j.cmet.2021.10.002
   Takahashi S, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1283 3
   Vialard F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.588387
   [王建 Wang Jian], 2018, [中医杂志, Journal of Traditional Chinese Medicine], V59, P963
   Wang WM, 2020, MOL CELL, V80, P384, DOI 10.1016/j.molcel.2020.09.006
   Weyand CM, 2021, NAT IMMUNOL, V22, P10, DOI 10.1038/s41590 020 00816 x
   Wierzbicki AS, 2020, CIRCULATION, V142, P821, DOI 10.1161/CIRCULATIONAHA.119.045407
   Wörheide MA, 2021, ANAL CHIM ACTA, V1141, P144, DOI 10.1016/j.aca.2020.10.038
   Wu GS, 2021, CHIN MED UK, V16, DOI 10.1186/s13020 021 00521 3
   Wu H, 2019, PHARMACOL RES, V140, P100, DOI 10.1016/j.phrs.2018.06.015
   Xie Y, 2021, PHYTOMEDICINE, V85, DOI 10.1016/j.phymed.2021.153522
   Xu HY, 2021, ACTA PHARM SIN B, V11, P1379, DOI 10.1016/j.apsb.2021.03.024
   Yang ZW, 2016, JOINT BONE SPINE, V83, P282, DOI 10.1016/j.jbspin.2015.07.006
NR 63
TC 7
Z9 8
U1 3
U2 23
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 8546
J9 CHIN MED UK
JI Chin. Med.
PD MAY 4
PY 2023
VL 18
IS 1
AR 48
DI 10.1186/s13020 023 00750 8
PG 16
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA F3SV4
UT WOS:000981585600001
PM 37143094
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Peltonen, T
   Näpänkangas, J
   Vuolteenaho, O
   Ohtonen, P
   Soini, Y
   Juvonen, T
   Satta, J
   Ruskoaho, H
   Taskinen, P
AF Peltonen, Tuomas
   Napankangas, Julia
   Vuolteenaho, Olli
   Ohtonen, Pasi
   Soini, Ylermi
   Juvonen, Tatu
   Satta, Jari
   Ruskoaho, Heikki
   Taskinen, Panu
TI Apelin and its Receptor APJ in Human Aortic Valve Stenosis
SO JOURNAL OF HEART VALVE DISEASE
LA English
DT Article
ID PROTEIN COUPLED RECEPTOR; SUPPRESSES APOPTOSIS; CELL PROLIFERATION;
   ENDOTHELIAL CELLS; ANGIOGENIC FACTOR; HEART FAILURE; EXPRESSION; SYSTEM;
   LIGAND; ASSOCIATION
AB Background and aim of the study: Aortic valve stenosis (AS) is an actively regulated pathobiological process that shows some hallmarks of atherosclerosis. Apelin and its receptor, APJ, are highly expressed in the heart, and the proposed effects of the apelin APJ system are opposite to those of the angiotensin II AT(1) receptor pathway. The role of the apelin APJ signaling pathway in calcified aortic valve disease is unknown.
   Methods: The study involved the characterization and comparison of expression of apelin and APJ as well as angiotensin II receptors (AT(1) and AT(2)) in the aortic valves of patients with normal valves (n = 6), aortic regurgitation (n = 9 AR), regurgitation and fibrosis/mild sclerosis (n = 14), and AS (n = 25).
   Results: By employing the reverse transcriptase polymerase chain reaction (RT PCR), the gene expression of apelin (3.63 fold, p = 0.001) and the APJ receptor (2.70 fold, P = 0.01) were shown to be significantly up regulated in stenotic valves when compared to controls. In addition, APJ receptor mRNA levels were higher (2.9 fold, p = 0.010) in the AR + sclerosis group when compared to controls. Using immunohistochemistry, apelin was shown to be localized in stenotic aortic valves to the valvular endothelial layer of the aortic valve, to vascular endothelial cells in neovessels, and to fibroblasts and macrophages adjacent to vessels in the stromal area. AT(2) receptor mRNA levels were 90% (p <0.001) lower in stenotic valves. In contrast, the gene expression of AT(1) receptors did not differ significantly among the groups.
   Conclusion: Aortic valve stenosis is characterized by an up regulation of the apelin APJ signaling pathway, revealing a possible novel target for drug discovery in calcified aortic valve disease by suppressing chemotaxis, angiogenesis and osteoblast activity, all of which are well documented phenomena in the disease process.
C1 [Ruskoaho, Heikki] Univ Oulu, Dept Pharmacol & Toxicol, Inst Biomed, Bioctr Oulu, Oulu 90014, Finland.
   [Napankangas, Julia; Soini, Ylermi] Univ Oulu, Dept Pathol, Bioctr Oulu, Oulu 90014, Finland.
   [Vuolteenaho, Olli] Univ Oulu, Dept Physiol, Bioctr Oulu, Oulu 90014, Finland.
   [Ohtonen, Pasi] Oulu Univ Hosp, Dept Anaesthesiol, Oulu, Finland.
   [Juvonen, Tatu; Satta, Jari; Taskinen, Panu] Oulu Univ Hosp, Dept Cardiovasc Surg, Oulu, Finland.
C3 University of Oulu; University of Oulu; University of Oulu; University
   of Oulu; University of Oulu
RP Ruskoaho, H (通讯作者)，Univ Oulu, Dept Pharmacol & Toxicol, Inst Biomed, Bioctr Oulu, POB 5000, Oulu 90014, Finland.
EM heikki.ruskoaho@oulu.fi
OI Peltonen, Tuomas/0000 0001 7704 5643; Napankangas,
   Juha/0000 0003 3088 5180
FU Academy of Finland; Finnish Medical Foundation; Finnish Foundation for
   Cardiovascular Research; Sigrid Juselius Foundation; Finnish Society of
   Angiology; Emil Aaltonen Foundation; Einar and Karin Stroems Foundation;
   Maud Kuistila's Memory Foundation; Research and Science Foundation of
   Farmos; Aarne Koskelo Foundation; Ida Montin Foundation; Paavo
   Ahvenainen Foundation
FX The authors thank Marja Arbelius, Kaisa Penttila and Manu Tuovinen for
   their expert technical assistance. These studies were supported by
   grants from the Academy of Finland, the Finnish Medical Foundation,
   Finnish Foundation for Cardiovascular Research, Sigrid Juselius
   Foundation, Finnish Society of Angiology, Emil Aaltonen Foundation,
   Einar and Karin Stroems Foundation, Maud Kuistila's Memory Foundation,
   Research and Science Foundation of Farmos, Aarne Koskelo Foundation, Ida
   Montin Foundation, and the Paavo Ahvenainen Foundation.
CR Chandrasekaran B, 2008, EUR J HEART FAIL, V10, P725, DOI 10.1016/j.ejheart.2008.06.002
   Chun HJ, 2008, J CLIN INVEST, V118, P3343, DOI 10.1172/JCI34871
   Cox CM, 2006, DEV BIOL, V296, P177, DOI 10.1016/j.ydbio.2006.04.452
   de Gasparo M, 2000, PHARMACOL REV, V52, P415
   Eyries M, 2008, CIRC RES, V103, P432, DOI 10.1161/CIRCRESAHA.108.179333
   Freeman RV, 2005, CIRCULATION, V111, P3316, DOI 10.1161/CIRCULATIONAHA.104.486738
   Hakuno D, 2009, J MOL MED, V87, P17, DOI 10.1007/s00109 008 0400 9
   Harada K, 1999, CIRCULATION, V100, P2093, DOI 10.1161/01.CIR.100.20.2093
   Helske S, 2004, J AM COLL CARDIOL, V44, P1859, DOI 10.1016/j.jacc.2004.07.054
   Helske S, 2008, ATHEROSCLEROSIS, V196, P190, DOI 10.1016/j.atherosclerosis.2007.03.040
   Kälin RE, 2007, DEV BIOL, V305, P599, DOI 10.1016/j.ydbio.2007.03.004
   Kasai A, 2004, BIOCHEM BIOPH RES CO, V325, P395, DOI 10.1016/j.bbrc.2004.10.042
   Katugampola SD, 2001, BRIT J PHARMACOL, V132, P1255, DOI 10.1038/sj.bjp.0703939
   Kim S, 2000, PHARMACOL REV, V52, P11
   Lee DK, 2006, TRENDS PHARMACOL SCI, V27, P190, DOI 10.1016/j.tips.2006.02.006
   Lee DK, 2000, J NEUROCHEM, V74, P34, DOI 10.1046/j.1471 4159.2000.0740034.x
   LINDROOS M, 1993, J AM COLL CARDIOL, V21, P1220, DOI 10.1016/0735 1097(93)90249 Z
   O'Brien KD, 2002, CIRCULATION, V106, P2224, DOI 10.1161/01.CIR.0000035655.45453.D2
   ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378 1119(93)90495 O
   Otto CM, 1999, NEW ENGL J MED, V341, P142, DOI 10.1056/NEJM199907153410302
   Otto CM, 1997, CIRCULATION, V95, P2262, DOI 10.1161/01.CIR.95.9.2262
   Peltonen TO, 2007, CIRCULATION, V116, P1283, DOI 10.1161/CIRCULATIONAHA.106.685743
   Quertermous T, 2007, DEV CELL, V12, P319, DOI 10.1016/j.devcel.2007.02.005
   Roberts WC, 2005, CIRCULATION, V111, P920, DOI 10.1161/01.CIR.0000155623.48408.C5
   Saint Geniez M, 2002, MECH DEVELOP, V110, P183, DOI 10.1016/S0925 4773(01)00558 5
   Sorli SC, 2007, ONCOGENE, V26, P7692, DOI 10.1038/sj.onc.1210573
   Stewart BF, 1997, J AM COLL CARDIOL, V29, P630, DOI 10.1016/S0735 1097(96)00563 3
   STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710
   Tang SY, 2007, PEPTIDES, V28, P708, DOI 10.1016/j.peptides.2006.10.005
   Tsutsumi Y, 1998, CIRC RES, V83, P1035, DOI 10.1161/01.RES.83.10.1035
   Xie H, 2007, APOPTOSIS, V12, P247, DOI 10.1007/s10495 006 0489 7
NR 31
TC 29
Z9 30
U1 0
U2 1
PU I C R PUBLISHERS
PI NORTHWOOD
PA CRISPIN HOUSE, 12/A SOUTH APPROACH, MOOR PARK, NORTHWOOD HA6 2ET,
   ENGLAND
SN 0966 8519
J9 J HEART VALVE DIS
JI J. Heart Valve Dis.
PD NOV
PY 2009
VL 18
IS 6
BP 644
EP 652
PG 9
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology
GA 537SP
UT WOS:000273134600009
PM 20099713
DA 2025 08 17
ER

PT J
AU Wu, JH
   Zeng, ZW
   Li, YY
   Qin, HY
   Zuo, CQ
   Zhou, CH
   Xu, DH
AF Wu, Jiahuan
   Zeng, Zhanwei
   Li, Yuyun
   Qin, Huiyi
   Zuo, Changqing
   Zhou, Chenhui
   Xu, Daohua
TI Cycloastragenol protects against glucocorticoid induced osteogenic
   differentiation inhibition by activating telomerase
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE cycloastragenol; glucocorticoid; E1 cell; osteogenic differentiation;
   telomerase
ID OSTEOBLAST DIFFERENTIATION; ASTRAGALOSIDE IV; MINERALIZATION; ZEBRAFISH;
   PHOSPHORYLATION; PLAYS; CELLS
AB Glucocorticoid induced osteoporosis (GIOP) that is mainly featured as low bone density and increased risk of fracture is prone to occur with the administration of excessive glucocorticoids. Cycloastragenol (CAG) has been verified to be a small molecule that activates telomerase. Studied showed that up regulated telomerase was associated with promoting osteogeneic differentiation, so we explored whether CAG could promote osteogenic differentiation to protect against GIOP and telomerase would be the target that CAG exerted its function. Our results demonstrated that CAG prominently increased the ALP activity, mineralization, mRNA of runt related transcription factor 2, osteocalcin, osteopontin, collagen type I in both MC3T3 E1 cells and dexamethasone (DEX) treated MC3T3 E1 cells. CAG up regulated telomerase reverse transcriptase and the protective effect of CAG was blocked by telomerase inhibitor TMPyP4. Moreover, CAG improved bone mineralization in DEX induced bone damage in a zebrafish larvea model. Therefore, the study showed that CAG could alleviate the osteogenic differentiation inhibition induced by DEX in vitro and in vivo, and CAG might be considered as a candidate drug for the treatment of GIOP.
C1 [Wu, Jiahuan; Zeng, Zhanwei; Li, Yuyun; Zuo, Changqing; Xu, Daohua] Guangdong Med Univ, Marine Biomed Res Inst, Publ Serv Platform South China Sea R&D Marine Bio, Guangdong Key Lab Res & Dev Nat Drugs, Zhanjiang, Peoples R China.
   [Wu, Jiahuan; Zeng, Zhanwei; Li, Yuyun; Qin, Huiyi; Zuo, Changqing; Xu, Daohua] Guangdong Med Univ, Inst Tradit Chinese Med & New Pharm Dev, Dept Pharmacol, Dongguan, Peoples R China.
   [Zhou, Chenhui] Guangdong Med Univ, Sch Nursing, Dongguan, Peoples R China.
C3 Guangdong Medical University; Guangdong Medical University; Guangdong
   Medical University
RP Xu, DH (通讯作者)，Guangdong Med Univ, Dept Pharmacol, Dongguan 523808, Peoples R China.
EM daohuax108@163.com
OI Zuo, Changqing/0000 0002 0536 5733
FU "Group type" Special Supporting Project for Educational Talents in
   Universities [4SG19057G 4SG19045G]; Guangdong Provincial Natural Science
   Foundation [2017A030313641]; Scientific Research Fund of The Public
   Service Platform of South China Sea for R&D Marine Biomedicine Resources
   [GDMUK201818]
FX "Group type" Special Supporting Project for Educational Talents in
   Universities, Grant/Award Number: 4SG19057G 4SG19045G; Guangdong
   Provincial Natural Science Foundation, Grant/Award Number:
   2017A030313641; Scientific Research Fund of The Public Service Platform
   of South China Sea for R&D Marine Biomedicine Resources, Grant/Award
   Number: GDMUK201818
CR Barbazuk WB, 2000, GENOME RES, V10, P1351, DOI 10.1101/gr.144700
   Barros TP, 2008, BRIT J PHARMACOL, V154, P1400, DOI 10.1038/bjp.2008.249
   de Jesus BB, 2013, TRENDS GENET, V29, P513, DOI 10.1016/j.tig.2013.06.007
   de Jesus BB, 2011, AGING CELL, V10, P604, DOI 10.1111/j.1474 9726.2011.00700.x
   Buckley L, 2018, NEW ENGL J MED, V379, P2547, DOI 10.1056/NEJMcp1800214
   Carnovali M, 2016, PHARMACOL RES, V104, P1, DOI 10.1016/j.phrs.2015.12.009
   Chen Q, 2014, STEM CELLS, V32, P327, DOI 10.1002/stem.1567
   Compston J, 2010, NAT REV RHEUMATOL, V6, P82, DOI 10.1038/nrrheum.2009.259
   Ding LZ, 2018, INT J MOL MED, V41, P2517, DOI 10.3892/ijmm.2018.3506
   Geurtzen K, 2017, J BONE MINER RES, V32, P2476, DOI 10.1002/jbmr.3231
   Gu CB, 2017, MOLECULES, V22, DOI 10.3390/molecules22101735
   Gu M, 2017, PHARMACOL RES, V121, P22, DOI 10.1016/j.phrs.2017.04.021
   Hardy RS, 2018, ENDOCR REV, V39, P519, DOI 10.1210/er.2018 00097
   Henneicke H, 2014, TRENDS ENDOCRIN MET, V25, P197, DOI 10.1016/j.tem.2013.12.006
   Hwang ST, 2019, PHYTOMEDICINE, V59, DOI 10.1016/j.phymed.2019.152907
   Ip FCF, 2014, NEUROSIGNALS, V22, P52, DOI 10.1159/000365290
   Jie YL, 2018, INT J BIOL MACROMOL, V118, P1848, DOI 10.1016/j.ijbiomac.2018.07.029
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Kim H., 2016, IEEE Transactions on Mobile Computing, DOI DOI 10.1063/1.4961692
   Konieczna N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112670
   Li L, 2017, FUND CLIN PHARMACOL, V31, P17, DOI 10.1111/fcp.12232
   Liu L, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00228
   Liu QC, 2020, CURR MOL MED, V20, P79, DOI 10.2174/1566524019666191007104816
   LUO Q, 2019, FRONT PHARMACOL, V10
   Luo SY, 2016, ACTA PHARMACOL SIN, V37, P1370, DOI 10.1038/aps.2016.62
   MacRae CA, 2015, NAT REV DRUG DISCOV, V14, P721, DOI 10.1038/nrd4627
   Murshed M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031229
   Neve A, 2013, J CELL PHYSIOL, V228, P1149, DOI 10.1002/jcp.24278
   Ozeki K, 2008, J MATER SCI MATER M, V19, P1753, DOI 10.1007/s10856 007 3288 y
   Park KD, 2011, STEM CELLS DEV, V20, P149, DOI 10.1089/scd.2009.0523
   Qiu YY, 2014, PHARMACOLOGY, V94, P51, DOI 10.1159/000362843
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Ran RX, 2016, MOLECULES, V21, DOI 10.3390/molecules21121616
   Ricard Blum S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004978
   Saeed H, 2015, BIOGERONTOLOGY, V16, P733, DOI 10.1007/s10522 015 9596 6
   Saito A, 2016, BIOCHEM BIOPH RES CO, V473, P537, DOI 10.1016/j.bbrc.2016.03.109
   Schmidt JC, 2015, GENE DEV, V29, P1095, DOI 10.1101/gad.263863.115
   Sevimli Gür C, 2011, J ETHNOPHARMACOL, V134, P844, DOI 10.1016/j.jep.2011.01.030
   Tasadduq R, 2017, J CELL PHYSIOL, V232, P540, DOI 10.1002/jcp.25449
   Turner KJ, 2019, CELLS BASEL, V8, DOI 10.3390/cells8010073
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Wan Y, 2018, EUR J PHARMACOL, V833, P545, DOI 10.1016/j.ejphar.2018.06.016
   Wang WZ, 2012, J ETHNOPHARMACOL, V142, P168, DOI 10.1016/j.jep.2012.04.033
   Wang YX, 2019, BRIT J PHARMACOL, V176, P282, DOI 10.1111/bph.14515
   Whittier X, 2016, RHEUM DIS CLIN N AM, V42, P177, DOI 10.1016/j.rdc.2015.08.005
   Xie BC, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00411
   Yu YJ, 2018, EXP THER MED, V16, P2175, DOI 10.3892/etm.2018.6501
   Zhang SQ, 2018, TISSUE ENG REGEN MED, V15, P751, DOI 10.1007/s13770 018 0138 6
NR 48
TC 18
Z9 21
U1 7
U2 38
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 418X
EI 1099 1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD APR
PY 2021
VL 35
IS 4
BP 2034
EP 2044
DI 10.1002/ptr.6946
EA NOV 2020
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA RK9JM
UT WOS:000587515100001
PM 33165990
DA 2025 08 17
ER

PT J
AU Doumouchtsis, KK
   Kostakis, AI
   Doumouchtsis, SK
   Tziamalis, MP
   Tsigris, C
   Kostaki, MA
   Perrea, DN
AF Doumouchtsis, K. K.
   Kostakis, A. I.
   Doumouchtsis, S. K.
   Tziamalis, M. P.
   Tsigris, C.
   Kostaki, M. A.
   Perrea, D. N.
TI SRANKL/osteoprotegerin complex and biochemical markers in a cohort of
   male and female hemodialysis patients
SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
LA English
DT Article
DE sRANKL; osteoprotegerin; hemodialysis; biochemical markers; male female
   patients
ID OSTEOCLASTOGENESIS INHIBITORY FACTOR; OSTEOPROTEGERIN SERUM LEVELS;
   DIFFERENTIATION FACTOR; RENAL OSTEODYSTROPHY; MATURE OSTEOCLASTS;
   LIGAND; WOMEN; OSTEOBLASTS; ACTIVATION; ESTROGEN
AB Objective: The processes involved in bone remodeling are under the control of a multitude of systemic and local factors. Receptor activator of nuclear factor kappa B ligand (RANKL)/osteoprotegerin (OPG) complex seems to be one of the major modulators of bone remodeling. In chronic renal failure, the cytokine systems involved in the regulation of bone turnover may be influenced, and are therefore likely to contribute to the pathogenesis of renal bone disease. The aim of the present study was the evaluation of RANKL/OPG complex in concert with other biochemical parameters in hemodialysis (HD) patients and the investigation of possible correlations between the serum levels of its components and several clinical parameters of these patients. Methods: We measured serum levels of intact PTH (iPTH), total serum RANKL (sRANKL), osteoprotegerin (OPG), alkaline phosphatase, osteocalcin (OC), and tartrate resistant acid phosphatase (TRAP) in 104 HD patients and in 40 healthy controls. Results: The average serum OPG level was significantly higher, whereas the average serum concentration of RANKL was nonsignificantly lower in patients on HD therapy than in age matched healthy controls. Consequently, the mean sRANKL/OPG ratio was significantly lower in patients. Among HD patients, serum level of OPG increased significantly with aging and with a longer duration of hemodialysis. RANKL levels were inversely correlated with age nonsignificantly in the whole group of patients and significantly in the female subgroup (r= 0.322, p=0.035), whereas RANKL/OPG ratio declined significantly with age in the entire cohort of patients (r= 0.259, p=0.008). In addition, iPTH, OC, TRAP were significantly higher in female, whereas RANKL/OPG ratio was significantly higher in male than female patients. Conclusions: Lower values of sRANKL/OPG ratio in HD patients, as well as the age and duration of HD dependent increase of serum OPG and the age dependent decrease of sRANKL concentration especially in women cannot be explained by the elimination of renal clearance only. Alterations in sRANKL/OPG ratio might reflect a compensatory mechanism to modulate bone remodeling in these patients.
C1 Univ Athens, Lab Expt Surg & Surg Res, Athens, Greece.
   Univ Athens, Dept Propedeut Surg, Athens, Greece.
   Kastoria Gen Hosp, Dept Nephrol & Dialysis, Kastoria, Greece.
   Univ Athens, Dept Surg 1, Athens, Greece.
C3 National & Kapodistrian University of Athens; National & Kapodistrian
   University of Athens; National & Kapodistrian University of Athens
RP Doumouchtsis, KK (通讯作者)，13 Fthiotidos St, GR 11523 Athens, Greece.
EM konsdoum@yahoo.gr
RI ; Doumouchtsis, Stergios/I 5984 2014
OI Kostaki, Maria/0000 0002 6353 8399; Doumouchtsis,
   Stergios/0000 0002 0404 6335
CR Akatsu T, 1998, BIOCHEM BIOPH RES CO, V250, P229, DOI 10.1006/bbrc.1998.9294
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Coen G, 2002, NEPHROL DIAL TRANSPL, V17, P233, DOI 10.1093/ndt/17.2.233
   Doi S, 2004, THER APHER DIAL, V8, P335, DOI 10.1111/j.1526 0968.2004.00159.x
   Fahrleitner Pammer A, 2003, WIEN KLIN WOCHENSCHR, V115, P291, DOI 10.1007/BF03040334
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   González EA, 2000, NEPHROL DIAL TRANSPL, V15, P945, DOI 10.1093/ndt/15.7.945
   Hakeda Y, 1998, BIOCHEM BIOPH RES CO, V251, P796, DOI 10.1006/bbrc.1998.9523
   Kazama JJ, 2002, AM J KIDNEY DIS, V39, P525, DOI 10.1053/ajkd.2002.31402
   Kazama JJ, 2002, NEPHROL DIAL TRANSPL, V17, P1860, DOI 10.1093/ndt/17.10.1860
   Khosla S, 2002, OSTEOPOROSIS INT, V13, P394, DOI 10.1007/s001980200045
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Liu Jian min, 2004, Zhonghua Nei Ke Za Zhi, V43, P447
   Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586
   Nakamichi Y, 2007, J IMMUNOL, V178, P192, DOI 10.4049/jimmunol.178.1.192
   Quinn JMW, 2005, BIOCHEM BIOPH RES CO, V328, P739, DOI 10.1016/j.bbrc.2004.11.076
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Szulc P, 2001, J CLIN ENDOCR METAB, V86, P3162, DOI 10.1210/jc.86.7.3162
   Yano K, 1999, J BONE MINER RES, V14, P518, DOI 10.1359/jbmr.1999.14.4.518
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zallone A, 2006, ANN NY ACAD SCI, V1068, P173, DOI 10.1196/annals.1346.019
NR 22
TC 20
Z9 21
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1720 8386
J9 J ENDOCRINOL INVEST
JI J. Endocrinol. Invest.
PD OCT
PY 2007
VL 30
IS 9
BP 762
EP 766
DI 10.1007/BF03350814
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 235TD
UT WOS:000251256300009
PM 17993768
DA 2025 08 17
ER

PT J
AU Marra, M
   Salzano, G
   Leonetti, C
   Tassone, P
   Scarsella, M
   Zappavigna, S
   Calimeri, T
   Franco, R
   Liguori, G
   Cigliana, G
   Ascani, R
   La Rotonda, MI
   Abbruzzese, A
   Tagliaferri, P
   Caraglia, M
   De Rosa, G
AF Marra, Monica
   Salzano, Giuseppina
   Leonetti, Carlo
   Tassone, Pierfrancesco
   Scarsella, Marco
   Zappavigna, Silvia
   Calimeri, Teresa
   Franco, Renato
   Liguori, Giuseppina
   Cigliana, Giovanni
   Ascani, Roberta
   La Rotonda, Maria Immacolata
   Abbruzzese, Alberto
   Tagliaferri, Pierosandro
   Caraglia, Michele
   De Rosa, Giuseppe
TI Nanotechnologies to use bisphosphonates as potent anticancer agents: the
   effects of zoledronic acid encapsulated into liposomes
SO NANOMEDICINE NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Stealth liposomes; Zoledronic acid; Prostate cancer; Multiple myeloma;
   Aminobisphosphonates; Tumor targeting
ID IN VITRO; GROWTH INHIBITION; INDUCE APOPTOSIS; CANCER PATIENTS;
   BONE DISEASE; PROSTATE; ANGIOGENESIS; BREAST; CELLS; CARCINOMA
AB Zoledronic acid (ZOL) is a potent amino bisphosphonate used for the treatment of bone metastases with recently reported antitumor activity. However, the short plasma half life and rapid accumulation in bone limits the use of ZOL as an antitumor agent in extraskeletal tissues. Therefore, we developed stealth liposomes encapsulating ZOL (LipoZOL) to increase extraskeletal drug availability. Compared to free ZOL, LipoZOL induced a stronger inhibition of growth of a range of different cancer cell lines in vitro. LipoZOL also caused significantly larger inhibition of tumor growth and increased the overall survival in murine models of human prostate cancer and multiple myeloma, in comparison with ZOL. Moreover, a strong inhibition of vasculogenetic events without evidence of necrosis in the tumor xenografts from prostate cancer was recorded after treatment with LipoZOL. We demonstrated both antitumor activity and tolerability of LipoZOL in preclinical animal models of both solid and hematopoietic malignancies, providing a rationale for early exploration of use of LipoZOL as a potential anticancer agent in cancer patients.
   From the Clinical Editor: The short plasma half life and rapid accumulation in bone limits the use of zoledronic acid as an antitumor agent in extraskeletal tissues. Therefore, stealth liposomes encapsulating ZOL (LipoZOL) have been developed to increase extraskeletal drug availability. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Marra, Monica; Zappavigna, Silvia; Abbruzzese, Alberto; Caraglia, Michele] Univ Naples 2, Dept Biochem & Biophys, I 80131 Naples, Italy.
   [Salzano, Giuseppina; La Rotonda, Maria Immacolata; De Rosa, Giuseppe] Univ Naples Federico II, Dept Pharmaceut & Toxicol Chem, I 80131 Naples, Italy.
   [Leonetti, Carlo; Scarsella, Marco] Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Rome, Italy.
   [Tassone, Pierfrancesco; Calimeri, Teresa; Tagliaferri, Pierosandro] Magna Graecia Univ Catanzaro, Med Oncol Unit, Catanzaro, Italy.
   [Franco, Renato; Liguori, Giuseppina] INT Pascale, Pathol Unit, Naples, Italy.
   [Cigliana, Giovanni; Ascani, Roberta] Regina Elena Inst Canc Res, UOSD Patol Clin, Rome, Italy.
C3 Universita della Campania Vanvitelli; University of Naples Federico II;
   IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena;
   Magna Graecia University of Catanzaro; IRCCS Fondazione Pascale; IRCCS
   Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena
RP Caraglia, M (通讯作者)，Univ Naples 2, Dept Biochem & Biophys, Via Costantinopoli 16, I 80131 Naples, Italy.
EM michele.caraglia@unina2.it
RI Salzano, Giuseppina/IQV 5941 2023; LIGUORI, GIUSEPPINA/AAA 1679 2020;
   Caraglia, Michele/AFY 9729 2022; De Rosa, Giuseppe/G 6343 2012;
   Leonetti, Carlo/B 2860 2018; Cigliana, Giovanni/AAA 6570 2019;
   Scarsella, Marco/AAA 1486 2020; Tassone, Pierfrancesco/AIA 5373 2022;
   Tagliaferri, Pierosandro/K 9546 2016; Caraglia, Michele/N 5670 2015
OI liguori, giuseppina/0000 0002 0726 7889; Tassone,
   Pierfrancesco/0000 0002 8298 6787; Calimeri, Teresa/0000 0003 0833 4761;
   Franco, Renato/0000 0002 8340 3184; Leonetti, Carlo/0000 0002 3526 7827;
   Scarsella, Marco/0000 0002 3386 9664; , Silvia
   Zappavigna/0000 0003 4787 3776; Caraglia, Michele/0000 0003 2408 6091
FU "Regione Campania" Laboratori Pubblici "Hauteville"; MIUR; Italian
   Association for Cancer Research (AIRC); Ministero della Salute; Italian
   Foundation for Cancer Research (FIRC)
FX M.C., G.D. and A.A. received a grant from "Regione Campania" Laboratori
   Pubblici "Hauteville". A.A. received a grant from MIUR PRIN 2008. C.L.
   received grants from the Italian Association for Cancer Research (AIRC)
   and Ministero della Salute. M.P. is recipient of a fellowship from the
   Italian Foundation for Cancer Research (FIRC). The authors thank Dr.
   Ingunn Holen (University of Sheffield, United Kingdom) for her critical
   reading of the manuscript and for her valuable suggestions.
CR [Anonymous], CANCER
   Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892
   Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304 3835(01)00412 8
   Boissier S, 2000, CANCER RES, V60, P2949
   Caraglia M, 2004, ONCOGENE, V23, P6900, DOI 10.1038/sj.onc.1207814
   Caraglia M, 2005, CURR DRUG TARGETS, V6, P301, DOI 10.2174/1389450053765833
   Caraglia M, 2007, J CELL PHYSIOL, V211, P533, DOI 10.1002/jcp.20960
   Caraglia M, 2010, EXPERT OPIN PHARMACO, V11, P141, DOI 10.1517/14656560903485664
   Cattel L, 2004, J CHEMOTHERAPY, V16, P94, DOI 10.1179/joc.2004.16.Supplement 1.94
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Danenberg HD, 2003, CIRCULATION, V108, P2798, DOI 10.1161/01.CIR.0000097002.69209.CD
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Fenske DB, 2008, EXPERT OPIN DRUG DEL, V5, P25, DOI 10.1517/17425247.5.1.25
   Fournier P, 2002, CANCER RES, V62, P6538
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Gnant M, 2009, CURR CANCER DRUG TAR, V9, P824, DOI 10.2174/156800909789760267
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Haluska P, 2002, EUR J CANCER, V38, P1685, DOI 10.1016/S0959 8049(02)00166 1
   HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092 8674(89)90054 8
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Hwang C, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756 8722 3 26
   Lee MV, 2001, CANCER RES, V61, P2602
   LITZINGER DC, 1994, BBA BIOMEMBRANES, V1190, P99, DOI 10.1016/0005 2736(94)90038 8
   Marra M, 2009, CURR CANCER DRUG TAR, V9, P791, DOI 10.2174/156800909789760285
   Miwa S, 2009, JPN J CLIN ONCOL, V39, P745, DOI 10.1093/jjco/hyp122
   Neri P, 2007, CLIN CANCER RES, V13, P5903, DOI 10.1158/1078 0432.CCR 07 0753
   Northfelt DW, 1998, J CLIN ONCOL, V16, P2445, DOI 10.1200/JCO.1998.16.7.2445
   Räikkönen J, 2009, BRIT J PHARMACOL, V157, P427, DOI 10.1111/j.1476 5381.2009.00160.x
   Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Sewing L, 2008, APOPTOSIS, V13, P782, DOI 10.1007/s10495 008 0211 z
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Skerjanec A, 2003, J CLIN PHARMACOL, V43, P154, DOI 10.1177/0091270002239824
   Sommer K, 2001, INT J ONCOL, V18, P1145
   STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003 2697(80)90269 9
   SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194
   Tassone P, 2000, LEUKEMIA, V14, P841, DOI 10.1038/sj.leu.2401770
   Tassone P, 2004, BLOOD, V104, P3688, DOI 10.1182/blood 2004 03 0963
   Tassone P, 2009, CURR CANCER DRUG TAR, V9, P854, DOI 10.2174/156800909789760393
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135
   van Rooijen N, 2002, J LIPOSOME RES, V12, P81, DOI 10.1081/LPR 120004780
   van Rooijen N, 2010, METHODS MOL BIOL, V605, P189, DOI 10.1007/978 1 60327 360 2_13
   WEIDNER N, 1993, AM J PATHOL, V143, P401
   Weiss HM, 2008, DRUG METAB DISPOS, V36, P2043, DOI 10.1124/dmd.108.021071
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Zhang JAA, 2000, EUR J PHARM BIOPHARM, V50, P357
NR 48
TC 93
Z9 99
U1 1
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1549 9634
EI 1549 9642
J9 NANOMED NANOTECHNOL
JI Nanomed. Nanotechnol. Biol. Med.
PD DEC
PY 2011
VL 7
IS 6
BP 955
EP 964
DI 10.1016/j.nano.2011.03.004
PG 10
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Research & Experimental Medicine
GA 857EV
UT WOS:000297699900032
PM 21453789
DA 2025 08 17
ER

PT J
AU Hosseini, S
   Parsaei, H
   Moosavifar, M
   Tavakoli, N
   Ahadi, R
   Roshanbinfar, K
AF Hosseini, SeyedJamal
   Parsaei, Houman
   Moosavifar, MirJavad
   Tavakoli, Narjes
   Ahadi, Reza
   Roshanbinfar, Kaveh
TI Static magnetic field enhances the bone remodelling capacity of human
   demineralized bone matrix in a rat animal model of cranial bone defects
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID PULSED ELECTROMAGNETIC FIELDS; POROUS HYDROXYAPATITE SCAFFOLDS;
   OSTEOBLAST PROLIFERATION; IN VITRO; TISSUE; CHITOSAN; CELLS;
   DIFFERENTIATION; STIMULATION; FABRICATION
AB The regeneration of bone defects that exceed 2 cm is a challenge for the human body, necessitating interventional therapies. Demineralized bone matrices (DBM) derived from biological tissues have been employed for bone regeneration and possess notable osteoinductive and osteoconductive characteristics. Nevertheless, their efficiency in regenerating critically sized injuries is limited, and therefore additional signaling cues are required. Thanks to the piezoelectric properties of the bone, external physical stimulation is shown to accelerate tissue healing. We have implanted human DBM in critically sized cranial bone defects in rat animal models and exposed them to an external magnetic field (1 T) to enhance endogenous bone formation. Our in vitro experiments showed the superior cytocompatibility of DBM compared to cell culture plates. Furthermore, alkaline phosphatase activity after 14 days and Alizarin red staining at 28 days demonstrated differentiation of rat bone marrow mesenchymal stem cells into bone lineage on DBM. Computer tomography images together with histological analyses showed that implanting DBM in the injured rats significantly enhanced bone regeneration. Notably, combining DBM transplantation with a 2 h daily exposure to a 1 T magnetic field for 2 weeks (day 7 to 21 post surgery) significantly improved bone regeneration compared to DBM transplantation alone. This research indicates that utilizing external magnetic stimulation significantly enhances the potential of bone allografts to regenerate critically sized bone defects.
   Transplantation of demineralized bone matrix and simultaneous periodic magnetic field stimulation enhances bone regeneration in critically sized injury in rat animal models.
C1 [Hosseini, SeyedJamal; Moosavifar, MirJavad] Amirkabir Univ Technol, Biomed Engn Dept, Tehran 1591634311, Iran.
   [Hosseini, SeyedJamal; Moosavifar, MirJavad] Iran Univ Med Sci, Fac Med, Cellular & Mol Res Ctr, Tehran 1449614535, Iran.
   [Parsaei, Houman] Semnan Univ Med Sci, Nervous Syst Stem Cells Res Ctr, Semnan 3513138111, Iran.
   [Moosavifar, MirJavad] Rhein Westfal TH Aachen, Inst Experimentelle Molekulare Bildgebung, D 52074 Aachen, Germany.
   [Tavakoli, Narjes] Univ Tehran, Coll Fine Arts, Sch Ind Design, Tehran 1415564583, Iran.
   [Ahadi, Reza] Iran Univ Med Sci, Fac Med, Dept Anat, Tehran 1449614535, Iran.
   [Roshanbinfar, Kaveh] Friedrich Alexander Univ Erlangen Nurnberg FAU, Inst Pathol, Dept Nephropathol, Expt Renal & Cardiovasc Res, D 91058 Erlangen, Germany.
C3 Amirkabir University of Technology; Iran University of Medical Sciences;
   Semnan University of Medical Sciences; RWTH Aachen University;
   University of Tehran; Iran University of Medical Sciences; University of
   Erlangen Nuremberg
RP Roshanbinfar, K (通讯作者)，Friedrich Alexander Univ Erlangen Nurnberg FAU, Inst Pathol, Dept Nephropathol, Expt Renal & Cardiovasc Res, D 91058 Erlangen, Germany.
EM Kaveh.Roshanbinfar@uk erlangen.de
RI ahadi, reza/AAN 1578 2021; Roshanbinfar, Kaveh/O 1811 2017; Parsaie,
   Houman/JMP 8009 2023; Hosseini, SeyedJamal/GQQ 5590 2022
OI Roshanbinfar, Kaveh/0000 0001 6067 5585; 
FU Universitatsklinikum Erlangen ELAN IZKF [P093/Aktenzeichen:
   21 05 20 1 Roshanbinfar]
FX Authors would like to acknowledge Preclinical Lab, Core Facility, Tehran
   University of Medical Sciences, Tehran, Iran for providing the image
   processing service as well as Mrs Bita Kohnavard from Cellular and
   Molecular Research Center in Iran University of Medical Sciences,
   Tehran, Iran for her assistance with cell culture. This research was
   funded by Universitatsklinikum Erlangen ELAN IZKF, grant number
   P093/Aktenzeichen: 21 05 20 1 Roshanbinfar.
CR AARON RK, 1989, J BONE MINER RES, V4, P227, DOI 10.1002/jbmr.5650040215
   Bloise N, 2020, MATERIALS, V13, DOI 10.3390/ma13143052
   Borciani G, 2022, METHOD PROTOCOL, V5, DOI 10.3390/mps5010008
   Bouyer M, 2016, BIOMATERIALS, V104, P168, DOI 10.1016/j.biomaterials.2016.06.001
   Chang CY, 2020, INT J RADIAT BIOL, V96, P1207, DOI 10.1080/09553002.2020.1787545
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen G., 2020, Stem Cell Res. Ther, V11, P1
   Chen JY, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1464 x
   Daish C, 2018, ANN BIOMED ENG, V46, P525, DOI 10.1007/s10439 018 1982 1
   de Abreu MC, 2016, J APPL ORAL SCI, V24, P162, DOI 10.1590/1678 775720150336
   Diaz Rodriguez P, 2019, MAR DRUGS, V17, DOI 10.3390/md17080471
   Eagle MJ, 2015, J BIOMED MATER RES B, V103, P1023, DOI 10.1002/jbm.b.33280
   Ghasemi Mobarakeh L, 2011, J TISSUE ENG REGEN M, V5, pE17, DOI 10.1002/term.383
   Ghodbane S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/602987
   Gruskin E, 2012, ADV DRUG DELIVER REV, V64, P1063, DOI 10.1016/j.addr.2012.06.008
   Hoseini J, 2014, J BIOMATER TISS ENG, V4, P138, DOI 10.1166/jbt.2014.1150
   Huang JH, 2010, J BIOMED MATER RES A, V93A, P164, DOI 10.1002/jbm.a.32511
   Khan Y, 2008, J BONE JOINT SURG AM, V90A, P36, DOI 10.2106/JBJS.G.01260
   Kotani H, 2002, J BONE MINER RES, V17, P1814, DOI 10.1359/jbmr.2002.17.10.1814
   Li L, 2019, MAT SCI ENG C MATER, V98, P1241, DOI 10.1016/j.msec.2019.01.075
   Lin HY, 2011, BIOELECTROMAGNETICS, V32, P552, DOI 10.1002/bem.20668
   Liu MY, 2018, NANOMATERIALS BASEL, V8, DOI 10.3390/nano8120999
   Liu SN, 2020, TECHNOL HEALTH CARE, V28, pS47, DOI 10.3233/THC 209006
   LogithKumar R, 2016, CARBOHYD POLYM, V151, P172, DOI 10.1016/j.carbpol.2016.05.049
   Lv HH, 2023, FASEB J, V37, DOI 10.1096/fj.202202131RR
   Ma CY, 2021, APPL MATER TODAY, V22, DOI 10.1016/j.apmt.2020.100902
   Marino A, 2015, ACS APPL MATER INTER, V7, P25574, DOI 10.1021/acsami.5b08764
   Marino A, 2014, ACTA BIOMATER, V10, P4304, DOI 10.1016/j.actbio.2014.05.032
   Marycz K, 2018, STEM CELL REV REP, V14, P785, DOI 10.1007/s12015 018 9847 4
   Miyamoto H, 2019, BIOELECTROMAGNETICS, V40, P412, DOI 10.1002/bem.22207
   Mohajerani H, 2019, J STOMATOL ORAL MAXI, V120, P390, DOI 10.1016/j.jormas.2019.02.022
   Moosavifar M, 2022, ACS BIOMATER SCI ENG, V8, P1258, DOI 10.1021/acsbiomaterials.1c01331
   NORTON LA, 1988, J ORTHOP RES, V6, P559, DOI 10.1002/jor.1100060413
   Pollock R, 2008, EUR SPINE J, V17, P845, DOI 10.1007/s00586 008 0648 3
   Polo Corrales L, 2014, J NANOSCI NANOTECHNO, V14, P15, DOI 10.1166/jnn.2014.9127
   Rasch A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218404
   Roddy Erika, 2018, Eur J Orthop Surg Traumatol, V28, P351, DOI 10.1007/s00590 017 2063 0
   Rohde M, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00422
   Rosen AD, 2003, CELL BIOCHEM BIOPHYS, V39, P163, DOI 10.1385/CBB:39:2:163
   Roshanbinfar K, 2013, J BIOMATER TISS ENG, V3, P284, DOI 10.1166/jbt.2013.1093
   Roshanbinfar K, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201803951
   Roshanbinfar K, 2017, RSC ADV, V7, P31980, DOI 10.1039/c7ra03780e
   Ross CL, 2017, ELECTROMAGN BIOL MED, V36, P74, DOI 10.3109/15368378.2016.1160408
   Sadraie SH, 2014, J BIOMATER TISS ENG, V4, P562, DOI 10.1166/jbt.2014.1203
   Salgado AJ, 2004, MACROMOL BIOSCI, V4, P743, DOI 10.1002/mabi.200400026
   Saravanan S, 2016, INT J BIOL MACROMOL, V93, P1354, DOI 10.1016/j.ijbiomac.2016.01.112
   Shahriarpanah S, 2016, INT J BIOL MACROMOL, V93, P1069, DOI 10.1016/j.ijbiomac.2016.09.045
   Sharifi E, 2016, MAT SCI ENG C MATER, V59, P533, DOI 10.1016/j.msec.2015.09.037
   Sheen JR, 2024, Fracture healing overview. statpearls. treasure island (FL) ineligible companies
   Shibuya N, 2015, CLIN PODIATR MED SUR, V32, P21, DOI 10.1016/j.cpm.2014.09.011
   Smrke D, 2013, REGENERATIVE MEDICINE AND TISSUE ENGINEERING, P325, DOI 10.5772/55987
   Soundarya SP, 2018, INT J BIOL MACROMOL, V119, P1228, DOI 10.1016/j.ijbiomac.2018.08.056
   Stoppel WL, 2016, ADV DRUG DELIVER REV, V96, P135, DOI 10.1016/j.addr.2015.07.009
   Suryani L, 2019, TISSUE ENG PART C ME, V25, P114, DOI [10.1089/ten.tec.2018.0364, 10.1089/ten.TEC.2018.0364]
   Tai GP, 2018, BURNS TRAUMA, V6, DOI 10.1186/s41038 018 0123 2
   Tang D, 2016, BIOMATERIALS, V83, P363, DOI 10.1016/j.biomaterials.2016.01.024
   Tang XJ, 2016, INT J NANOMED, V11, P4991, DOI 10.2147/IJN.S114302
   Topal O, 2020, ELECTROMAGN BIOL MED, V39, P206, DOI 10.1080/15368378.2020.1762636
   Tsai MT, 2007, BIOELECTROMAGNETICS, V28, P519, DOI 10.1002/bem.20336
   Voigt J, 2011, INT J LOW EXTR WOUND, V10, P190, DOI 10.1177/1534734611424648
   Wang JP, 2023, PROG BIOPHYS MOL BIO, V178, P91, DOI 10.1016/j.pbiomolbio.2022.12.007
   Wang SH, 2023, BIOMED ENG ONLINE, V22, DOI 10.1186/s12938 023 01170 3
   Wang Y., 2022, J. Nanomater
   Xie F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152262
   Xu S., 2010, J. Evidence Based Complementary Altern. Med
   Yang JC, 2021, INT J RADIAT BIOL, V97, P746, DOI 10.1080/09553002.2021.1900944
   Yang W, 2008, ELECTROMAGN BIOL MED, V27, P298, DOI 10.1080/15368370802289604
   Yu W, 2017, BIOMATER SCI UK, V5, P1690, DOI 10.1039/c7bm00315c
   Yuan J, 2018, CELL PHYSIOL BIOCHEM, V46, P1581, DOI 10.1159/000489206
   Zhang B, 2020, BIOELECTROMAGNETICS, V41, P263, DOI 10.1002/bem.22258
   Zhang J, 2014, PROG BIOPHYS MOL BIO, V114, P146, DOI 10.1016/j.pbiomolbio.2014.02.001
   Zhang Y, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1275 0
   Zhao YZ, 2021, MAT SCI ENG C MATER, V122, DOI 10.1016/j.msec.2021.111877
   Zhu YX, 2023, MICROBIOL SPECTR, V11, DOI 10.1128/spectrum.03659 22
NR 74
TC 6
Z9 6
U1 10
U2 21
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PD APR 17
PY 2024
VL 12
IS 15
BP 3774
EP 3785
DI 10.1039/d3tb02299d
EA MAR 2024
PG 12
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA NW5N0
UT WOS:001191333900001
PM 38535706
OA hybrid
DA 2025 08 17
ER

PT J
AU Rodríguez Lozano, FJ
   Insausti, CL
   Iniesta, F
   Blanquer, M
   Ramírez, MD
   Meseguer, L
   Meseguer Henarejos, AB
   Marín, N
   Martínez, S
   Moraleda, JM
AF Rodriguez Lozano, Francisco Javier
   Insausti, Carmen Luisa
   Iniesta, Francisca
   Blanquer, Miguel
   Ramirez, Maria del Carmen
   Meseguer, Luis
   Meseguer Henarejos, Ana Belen
   Marin, Noemi
   Martinez, Salvador
   Moraleda, Jose Maria
TI Mesenchymal dental stem cells in regenerative dentistry
SO MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL
LA English
DT Article
DE Dental stem cells; regenerative dentistry; mesenchymal stem cells;
   tissue engineering; stem cells
ID STROMAL CELLS; BONE MARROW; THERAPY; BIOLOGY; PULP
AB In the last decade, tissue engineering is a field that has been suffering an enormous expansion in the regenerative medicine and dentistry. The use of cells as mesenchymal dental stem cells of easy access for dentist and oral surgeon, immunosuppressive properties, high proliferation and capacity to differentiate into odontoblasts, cementoblasts, osteoblasts and other cells implicated in the teeth, suppose a good perspective of future in the clinical dentistry. However, is necessary advance in the known of growth factors and signalling molecules implicated in tooth development and regeneration of different structures of teeth. Furthermore, these cells need a fabulous scaffold that facility their integration, differentiation, matrix synthesis and promote multiple specific interactions between cells.
   In this review, we give a brief description of tooth development and anatomy, definition and classification of stem cells, with special attention of mesenchymal stem cells, commonly used in the cellular therapy for their trasdifferentiation ability, non ethical problems and acceptable results in preliminary clinical trials.
   In terms of tissue engineering, we provide an overview of different types of mesenchymal stem cells that have been isolated from teeth, including dental pulp stem cells (DPSCs), stem cells from human exfoliated deciduous teeth (SHEDs), periodontal ligament stem cells (PDLSCs), dental follicle progenitor stem cells (DFPCs), and stem cells from apical papilla (SCAPs), growth factors implicated in regeneration teeth and types of scaffolds for dental tissue regeneration.
C1 [Rodriguez Lozano, Francisco Javier; Insausti, Carmen Luisa; Iniesta, Francisca; Blanquer, Miguel; Meseguer, Luis; Meseguer Henarejos, Ana Belen; Marin, Noemi; Moraleda, Jose Maria] Univ Murcia, Cell Therapy Unit, Hosp Univ Virgen de la Arrixaca, Fac Med & Odontol, E 30001 Murcia, Spain.
   [Ramirez, Maria del Carmen; Martinez, Salvador] Univ Miguel Hernandez, Inst Neurosci, Alicante, Spain.
C3 University of Murcia; Hospital Clinico Universitario Virgen de la
   Arrixaca; Universidad Miguel Hernandez de Elche
RP Rodríguez Lozano, FJ (通讯作者)，Hosp Univ Virgen de la Arrixaca, Serv Hematol & Hemoterapia, Unidad Trasplante Hematopoyet & Terapia Celular, Ctra Madrid Cartagena, Murcia 30120, Spain.
EM fcojavier@um.es
RI Meseguer Olmo, Luis/A 3141 2011; Marin Atucha, Noemi/F 6002 2014;
   Mratinez, Salvador/L 4896 2014; Atucha, Noemi/F 6002 2014; Iniesta,
   Francisca/G 2049 2016; Moraleda, José/AAB 4119 2020; Blanquer,
   Miguel/B 8732 2008; Martinez, Salvador/L 4896 2014; Rodríguez Lozano,
   Francisco Javier/J 1743 2017; Blanquer Blanquer, Miguel/B 8732 2008
OI Meseguer Olmo, Luis/0000 0003 3858 8148; Marin Atucha,
   Noemi/0000 0003 4667 3270; Martinez, Salvador/0000 0002 2910 8926;
   Martinez, Salvador/0000 0002 9320 4103; Blanquer Blanquer,
   Miguel/0000 0002 1471 8828
FU ISCIII [FIS EC07/90762, RETICS RD/0010/2012]; Junction Program of
   Biomedical Research in Advanced Therapies and Regenerative Medicine;
   Fundacion Seneca [08859/PI/08]
FX This work was supported by FIS EC07/90762, RETICS RD/0010/2012 grants
   from the ISCIII, the Junction Program of Biomedical Research in Advanced
   Therapies and Regenerative Medicine among the ISCIII and FFIS 2007, and
   by the Fundacion Seneca (grant 08859/PI/08).
CR Amabile G, 2009, TRENDS MOL MED, V15, P59, DOI 10.1016/j.molmed.2008.12.003
   Bakopoulou A, 2011, ARCH ORAL BIOL, V56, P709, DOI 10.1016/j.archoralbio.2010.12.008
   BERGENHOLTZ G, 1985, J DENT RES, V64, P631, DOI 10.1177/002203458506400422
   Bluteau G, 2008, EUR CELLS MATER, V16, P1
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Chung IH, 2009, STEM CELLS, V27, P866, DOI 10.1002/stem.2
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   Fortier LA, 2005, VET SURG, V34, P415, DOI 10.1111/j.1532 950X.2005.00063.x
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365 2184.1970.tb00347.x
   Galler KM, 2011, REGEN MED, V6, P111, DOI [10.2217/rme.10.86, 10.2217/RME.10.86]
   GORSKI JP, 1992, CRIT REV ORAL BIOL M, V3, P185, DOI 10.1177/10454411920030030201
   Griffin CJ, 1972, CELL STEM CELL, V17, P913
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood 2003 05 1664
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Hughes FJ, 2010, P I MECH ENG H, V224, P1345, DOI 10.1243/09544119JEIM820
   Insausti CL, 2010, WOUND REPAIR REGEN, V18, P368, DOI 10.1111/j.1524 475X.2010.00604.x
   Laino G, 2006, J CELL PHYSIOL, V206, P693, DOI 10.1002/jcp.20526
   Leeb C, 2010, STEM CELL REV REP, V6, P15, DOI 10.1007/s12015 009 9102 0
   McKay R, 2000, NATURE, V406, P361, DOI 10.1038/35019186
   Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100
   Mjör IA, 2001, QUINTESSENCE INT, V32, P537
   Moraleda JM, 2006, TRANSPL IMMUNOL, V17, P74, DOI 10.1016/j.trim.2006.09.030
   Morsczeck C, 2005, MATRIX BIOL, V24, P155, DOI 10.1016/j.matbio.2004.12.004
   Murray PE, 2007, J ENDODONT, V33, P377, DOI 10.1016/j.joen.2006.09.013
   Nadig Roopa R, 2009, J Conserv Dent, V12, P131, DOI 10.4103/0972 0707.58329
   Nuñez J, 2010, J PERIODONTOL, V81, P1064, DOI 10.1902/jop.2010.090678
   OWEN M, 1988, J CELL SCI, P63
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Ripamonti U, 2007, TISSUE ENG, V13, P51, DOI 10.1089/ten.2006.0167
   Rodríguez Lozano FJ, 2011, INT ENDOD J, V44, P800, DOI 10.1111/j.1365 2591.2011.01877.x
   Rothová M, 2011, INT J DEV BIOL, V55, P59, DOI 10.1387/ijdb.103083mr
   Scheller EL, 2009, J ORAL REHABIL, V36, P368, DOI 10.1111/j.1365 2842.2009.01939.x
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Sonoyama W, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000079
   Taba M Jr, 2005, Orthod Craniofac Res, V8, P292
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
NR 39
TC 65
Z9 75
U1 0
U2 36
PU MEDICINA ORAL S L
PI VALENCIA
PA CALLE DANIEL BALACIART N 4 PTA 17, VALENCIA, 46020, SPAIN
SN 1698 6946
J9 MED ORAL PATOL ORAL
JI Med. Oral Patol. Oral Cir. Bucal
PD NOV
PY 2012
VL 17
IS 6
BP E1062
EP E1067
AR 17925
DI 10.4317/medoral.17925
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 082OP
UT WOS:000314401800024
PM 22926467
OA Green Published, Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Pan, Y
   Liu, T
   Li, LF
   He, L
   Pan, S
   Liu, YW
AF Pan, Yu
   Liu, Tao
   Li, Linfeng
   He, Liang
   Pan, Shu
   Liu, Yuwei
TI Exploration of Key Regulatory Factors in Mesenchymal Stem Cell
   Continuous Osteogenic Differentiation via Transcriptomic Analysis
SO GENES
LA English
DT Article
DE MSCs; lineage change; transcriptomic sequencing; dynamic regulation;
   osteogenesis
AB Background/Objectives: Mesenchymal stem cells (MSCs) possess the remarkable ability to differentiate into various cell types, including osteoblasts. Understanding the molecular mechanisms governing MSC osteogenic differentiation is crucial for advancing clinical applications and our comprehension of complex disease processes. However, the key biological molecules regulating this process remain incompletely understood. Methods: In this study, we conducted systematic re analyses of published high throughput transcriptomic datasets to identify and validate key biological molecules that dynamically regulate MSC osteogenic differentiation. Our approach involved a comprehensive analysis of gene expression patterns across human tissues, followed by the rigorous experimental validation of the identified candidates. Results: Through integrated analytical and experimental approaches, we utilized high throughput transcriptomics to identify four critical regulators of MSC osteogenic differentiation: PTBP1, H2AFZ, BCL6, and TTPAL (C20ORF121). Among these, PTBP1 and H2AFZ functioned as positive regulators, while BCL6 and TTPAL acted as negative regulators in osteogenesis. The regulatory roles of these genes in osteogenesis were further validated via overexpression experiments. Conclusions: Our findings advance our understanding of MSC differentiation fate determination and open new therapeutic possibilities for bone related disorders. The identification of these regulators provides a foundation for developing targeted interventions in regenerative medicine.
C1 [Pan, Yu; Liu, Tao] Jiangsu Univ, Affiliated Peoples Hosp, Dept Cardiothorac Surg, Zhenjiang 212002, Peoples R China.
   [Pan, Yu; Liu, Yuwei] Jiangsu Univ, Sch Med, Zhenjiang 2012013, Peoples R China.
   [Li, Linfeng] 958th Hosp Chinese Peoples Liberat Army, Southwest Hosp Jiangbei Area, Dept Orthoped Surg, Chongqing 400020, Peoples R China.
   [He, Liang] Tongji Univ, Sch Med, Shanghai 201619, Peoples R China.
   [Pan, Shu] Jiangsu Univ Sci & Technol, Comp Sci Sch, Zhenjiang 212003, Peoples R China.
C3 Jiangsu University; Jiangsu University; Tongji University; Jiangsu
   University of Science & Technology
RP Liu, YW (通讯作者)，Jiangsu Univ, Sch Med, Zhenjiang 2012013, Peoples R China.; Pan, S (通讯作者)，Jiangsu Univ Sci & Technol, Comp Sci Sch, Zhenjiang 212003, Peoples R China.
EM panyu@stmail.ujs.edu.cn; taotao4426@aliyun.com; lilinfeng0809@163.com;
   heliangasd123@163.com; jsjxy_ps@just.edu.cn; liuyuwei@ujs.edu.cn
RI Pan, Yu/LWI 6216 2024; Liu, Yuwei/GSI 7363 2022
OI Liu, Yuwei/0000 0002 5495 2926
FU Natural Science Foundation of Jiangsu Province; China Postdoctoral
   Science Foundation [2020M681232]; National Natural Science Foundation of
   China [82101630];  [BK20221288]
FX This research was funded by the Natural Science Foundation of Jiangsu
   Province, grant number BK20221288 to Tao Liu, China Postdoctoral Science
   Foundation, grant number 2020M681232 to Yuwei Liu, and National Natural
   Science Foundation of China, grant number 82101630 to Yuwei Liu.
CR Alves LNR, 2023, GENES BASEL, V14, DOI 10.3390/genes14071364
   Alves RDAM, 2014, BMC GENOMICS, V15, DOI 10.1186/1471 2164 15 965
   Ben Dror J, 2022, GENES BASEL, V13, DOI 10.3390/genes13060960
   Bozoky B, 2022, BMC BIOINFORMATICS, V23, DOI 10.1186/s12859 022 05097 9
   Bruedigam C, 2023, CELLS BASEL, V12, DOI 10.3390/cells12202462
   Cai WJ, 2023, ADV SCI, V10, DOI 10.1002/advs.202204871
   Castiglioni S, 2022, GENES BASEL, V13, DOI 10.3390/genes13030514
   Cherubini A, 2019, NUCLEIC ACIDS RES, V47, P5325, DOI 10.1093/nar/gkz199
   Cui JR, 2022, AGEING RES REV, V77, DOI 10.1016/j.arr.2022.101608
   Delgado Calle J, 2022, PHYSIOL REV, V102, DOI 10.1152/physrev.00043.2020
   Deng C, 2023, J NANOBIOTECHNOL, V21, DOI 10.1186/s12951 023 02098 5
   Deng P, 2021, CELL STEM CELL, V28, P1057, DOI 10.1016/j.stem.2021.01.010
   Diesel Luciana Fraga da Costa, 2015, J Stem Cells, V10, P225, DOI jsc.2015.10.4.225
   Fujie A, 2015, BIOCHEM BIOPH RES CO, V457, P451, DOI 10.1016/j.bbrc.2015.01.012
   Gao YC, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 39958 5
   Gong Y, 2021, DEV CELL, V56, P2103, DOI 10.1016/j.devcel.2021.06.011
   Guan GZ, 2023, GENES BASEL, V14, DOI 10.3390/genes14020272
   Guo YY, 2021, REDOX BIOL, V41, DOI 10.1016/j.redox.2021.101915
   Han YY, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 00932 0
   Hoang DM, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 01134 4
   Hochmann S, 2023, SCI TRANSL MED, V15, DOI 10.1126/scitranslmed.abm7477
   Iacomino G, 2023, GENES BASEL, V14, DOI 10.3390/genes14020314
   Jia FZ, 2022, GENES BASEL, V13, DOI 10.3390/genes13030471
   Jiang ZW, 2023, BIOENG TRANSL MED, V8, DOI 10.1002/btm2.10334
   Jiao DL, 2021, BIOACT MATER, V6, P2011, DOI 10.1016/j.bioactmat.2020.12.003
   Kim P, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 31697 3
   Lee KS, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12152
   Li CJ, 2018, J CLIN INVEST, V128, P5251, DOI 10.1172/JCI99044
   Li PS, 2019, PHARMACOL THERAPEUT, V200, P42, DOI 10.1016/j.pharmthera.2019.04.005
   Li WX, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI150051
   Lim J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba1334
   Liu F, 2021, REDOX BIOL, V43, DOI 10.1016/j.redox.2021.101963
   Liu ZZ, 2021, AUTOPHAGY, V17, P2766, DOI 10.1080/15548627.2020.1839286
   Ma Q, 2022, NAT REV MOL CELL BIO, V23, P303, DOI 10.1038/s41580 022 00466 x
   Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539
   Mo CY, 2022, EMBO J, V41, DOI 10.15252/embj.2021108415
   Mollentze Jamie, 2021, Stem Cells Int, V2021, P9919361, DOI 10.1155/2021/9919361
   Nantavisai S, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 77656 0
   Nguyen M, 2022, GENES BASEL, V13, DOI 10.3390/genes13010142
   Pfeffer G, 2022, GENES BASEL, V13, DOI 10.3390/genes13060963
   Qiu JF, 2022, GENES BASEL, V13, DOI 10.3390/genes13040604
   Sjöstedt E, 2020, SCIENCE, V367, P1090, DOI 10.1126/science.aay5947
   Soliman H, 2021, CELL STEM CELL, V28, P1690, DOI 10.1016/j.stem.2021.09.001
   Song N, 2020, TRENDS PHARMACOL SCI, V41, P653, DOI 10.1016/j.tips.2020.06.009
   Tsai JN, 2019, LANCET DIABETES ENDO, V7, P767, DOI 10.1016/S2213 8587(19)30255 4
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Tu W, 2024, CHEM BIOL DRUG DES, V103, DOI 10.1111/cbdd.14380
   Wang Y, 2022, CELL STEM CELL, V29, P1515, DOI 10.1016/j.stem.2022.10.001
   Wang Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 19360 1
   Wu JY, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1185587
   Xing WR, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0064 9
   Yang M, 2022, CANCER IMMUNOL RES, V10, P1398, DOI 10.1158/2326 6066.CIR 22 0249
   Yoshida G, 2022, AUTOPHAGY, V18, P2323, DOI 10.1080/15548627.2021.2017587
   Yu HX, 2022, AGEING RES REV, V80, DOI 10.1016/j.arr.2022.101684
   Zavala EI, 2022, GENES BASEL, V13, DOI 10.3390/genes13010129
   Zha KK, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.824812
   Zhang HG, 2022, CELL DEATH DIFFER, V29, P351, DOI 10.1038/s41418 021 00858 0
   Zhang L, 2022, PHARMACOL THERAPEUT, V232, DOI 10.1016/j.pharmthera.2021.108004
   Zhang P, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01338 2
   Zhang YG, 2023, LEUKEMIA, V37, P2261, DOI 10.1038/s41375 023 02014 8
   Zhao LX, 2024, SCI REP UK, V14, DOI 10.1038/s41598 024 69629 4
   Zhao PF, 2023, J TRANSL MED, V21, DOI 10.1186/s12967 023 04029 2
   Zhong HG, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1058627
   Zong C, 2023, HEPATOLOGY, V78, P434, DOI 10.1002/hep.32738
NR 64
TC 1
Z9 1
U1 4
U2 7
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4425
J9 GENES BASEL
JI Genes
PD DEC
PY 2024
VL 15
IS 12
AR 1568
DI 10.3390/genes15121568
PG 16
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA Q3X8B
UT WOS:001384060300001
PM 39766835
OA gold
DA 2025 08 17
ER

PT J
AU Galler, KM
   Grätz, EM
   Widbiller, M
   Buchalla, W
   Knüttel, H
AF Galler, Kerstin M.
   Gratz, Eva Maria
   Widbiller, Matthias
   Buchalla, Wolfgang
   Knuttel, Helge
TI Pathophysiological mechanisms of root resorption after dental trauma: a
   systematic scoping review
SO BMC ORAL HEALTH
LA English
DT Article
DE Root resorption; Tooth resorption; Osteoclast; Receptor activator of
   nuclear factor kappa B; RANK ligand; Osteoprotegerin
ID PERIODONTAL LIGAMENT CELLS; KAPPA B LIGAND; EXTERNAL CERVICAL
   RESORPTION; COLONY STIMULATING FACTOR; OSTEOCLAST DIFFERENTIATION
   FACTOR; AVULSED PERMANENT INCISORS; NECROSIS FACTOR RECEPTOR;
   HORMONE RELATED PROTEIN; HUMAN DECIDUOUS TEETH; BONE RESORPTION
AB Background The objective of this scoping review was to systematically explore the current knowledge of cellular and molecular processes that drive and control trauma associated root resorption, to identify research gaps and to provide a basis for improved prevention and therapy. Methods Four major bibliographic databases were searched according to the research question up to February 2021 and supplemented manually. Reports on physiologic, histologic, anatomic and clinical aspects of root resorption following dental trauma were included. Duplicates were removed, the collected material was screened by title/abstract and assessed for eligibility based on the full text. Relevant aspects were extracted, organized and summarized. Results 846 papers were identified as relevant for a qualitative summary. Consideration of pathophysiological mechanisms concerning trauma related root resorption in the literature is sparse. Whereas some forms of resorption have been explored thoroughly, the etiology of others, particularly invasive cervical resorption, is still under debate, resulting in inadequate diagnostics and heterogeneous clinical recommendations. Effective therapies for progressive replacement resorptions have not been established. Whereas the discovery of the RANKL/RANK/OPG system is essential to our understanding of resorptive processes, many questions regarding the functional regulation of osteo /odontoclasts remain unanswered. Conclusions This scoping review provides an overview of existing evidence, but also identifies knowledge gaps that need to be addressed by continued laboratory and clinical research.
C1 [Galler, Kerstin M.; Gratz, Eva Maria; Widbiller, Matthias; Buchalla, Wolfgang] Univ Hosp Regensburg, Dept Conservat Dent & Periodontol, Franz Josef Str Allee 11, D 93053 Regensburg, Germany.
   [Knuttel, Helge] Univ Regensburg, Univ Lib, Regensburg, Germany.
C3 University of Regensburg; University of Regensburg
RP Galler, KM (通讯作者)，Univ Hosp Regensburg, Dept Conservat Dent & Periodontol, Franz Josef Str Allee 11, D 93053 Regensburg, Germany.
EM kerstin.galler@klinik.uni regensburg.de
RI Widbiller, Matthias/M 9031 2015; Galler, Kerstin/F 5355 2019
OI Widbiller, Matthias/0000 0002 7917 9466; 
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL.
CR AAE, 2019, GLOSS END TERMS
   AKAMINE A, 1994, ENDOD DENT TRAUMATOL, V10, P121
   Albrektsson T, 1985, Swed Dent J Suppl, V28, P193
   ANDERSEN M, 1992, ENDOD DENT TRAUMATOL, V8, P104
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   ANDERSSON L, 1989, ENDOD DENT TRAUMATOL, V5, P38
   ANDREASEN F M, 1985, Endodontics and Dental Traumatology, V1, P207
   ANDREASEN J. O., 1966, ACTA ODONTOL SCAND, V24, P287, DOI 10.3109/00016356609028223
   Andreasen J O, 1981, J Endod, V7, P294, DOI 10.1016/S0099 2399(81)80095 7
   Andreasen J O, 1992, Proc Finn Dent Soc, V88 Suppl 1, P95
   ANDREASEN JO, 1981, ACTA ODONTOL SCAND, V39, P1
   ANDREASEN JO, 1981, INT J ORAL MAXILLOF, V10, P54, DOI 10.1016/S0300 9785(81)80008 7
   ANDREASEN JO, 1995, ENDOD DENT TRAUMATOL, V11, P76
   ANDREASEN JO, 1975, ACTA ODONTOL SCAND, V33, P325, DOI 10.3109/00016357509004637
   ANDREASEN JO, 1985, INT ENDOD J, V18, P109, DOI 10.1111/j.1365 2591.1985.tb00427.x
   ANDREASEN JO, 1995, ENDOD DENT TRAUMATOL, V11, P59
   Andreasen JO., 1993, Textbook and Color Atlas of Traumatic Injuries to the Teeth, V3rd
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Arksey H, 2005, Int J Soc Res Methodol, V8, P19, DOI [10.1080/1364557032000119616, DOI 10.1080/1364557032000119616]
   Armstrong R, 2011, J PUBLIC HEALTH UK, V33, P147, DOI 10.1093/pubmed/fdr015
   ASH P, 1980, NATURE, V283, P669, DOI 10.1038/283669a0
   BAB IA, 1979, INFLAMMATION, V3, P345, DOI 10.1007/BF00913493
   Babaji P, 2017, ANN AFR MED, V16, P39, DOI 10.4103/aam.aam_97_16
   BAKLAND L K, 1992, Dental Clinics of North America, V36, P491
   Bansal Parul, 2015, J Conserv Dent, V18, P70, DOI 10.4103/0972 0707.148900
   Bar Shavit Z, 2007, J CELL BIOCHEM, V102, P1130, DOI 10.1002/jcb.21553
   BARON R, 1986, AM J PATHOL, V122, P363
   BIRKEDAL.H, 1974, CALC TISS RES, V15, P77, DOI 10.1007/BF02059045
   BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   BLOMLOF L, 1983, J DENT RES, V62, P912, DOI 10.1177/00220345830620081301
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   BOYDE A, 1984, BRIT DENT J, V156, P216, DOI 10.1038/sj.bdj.4805313
   Bratteberg M, 2021, DENT TRAUMATOL, V37, P294, DOI 10.1111/edt.12635
   BRUDVIK P, 1994, EUR J ORTHODONT, V16, P249, DOI 10.1093/ejo/16.4.249
   Caliskan MK, 1997, ENDOD DENT TRAUMATOL, V13, P75
   Casa MA, 2006, ANGLE ORTHOD, V76, P1015, DOI 10.2319/071505 233
   Cavalleri G, 1995, ENDOD DENT TRAUMATOL, V11, P294
   CHAMBERS TJ, 1984, J CELL SCI, V66, P383
   Chellaiah M, 1996, MOL BIOL CELL, V7, P743, DOI 10.1091/mbc.7.5.743
   Chikazu D, 2001, J BONE MINER RES, V16, P2074, DOI 10.1359/jbmr.2001.16.11.2074
   Choi BK, 2005, J PERIODONTOL, V76, P813, DOI 10.1902/jop.2005.76.5.813
   Cochran DL, 2008, J PERIODONTOL, V79, P1569, DOI 10.1902/jop.2008.080233
   Cohen MM, 2006, AM J MED GENET A, V140A, P2646, DOI 10.1002/ajmg.a.31368
   Cohen S, 2006, ARTHRIT RHEUM ARTHR, V55, P15, DOI 10.1002/art.21706
   da Silva LAB, 2021, CLIN ORAL INVEST, V25, P1255, DOI 10.1007/s00784 020 03430 1
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   DATTA HK, 1995, EXP PHYSIOL, V80, P713, DOI 10.1113/expphysiol.1995.sp003880
   DAVIDOVITCH Z, 1972, AMER J ORTHODONTICS, V62, P95, DOI 10.1016/0002 9416(72)90133 9
   Davies S, 2012, SYST REV, V1, DOI 10.1186/2046 4053 1 5
   Domon T, 1997, ANAT REC, V249, P449, DOI 10.1002/(SICI)1097 0185(199712)249:4<449::AID AR4>3.0.CO;2 M
   Dunsche A, 2009, ORAL AND IMPLANT SURGERY: PRINCIPLES AND PROCEDURES
   EGERTON M, 1995, J MOL ENDOCRINOL, V14, P179, DOI 10.1677/jme.0.0140179
   Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146
   FRIEDMAN S, 1988, ENDOD DENT TRAUMATOL, V4, P23
   Fukushima H, 2003, EUR J ORAL SCI, V111, P346, DOI 10.1034/j.1600 0722.2003.00051.x
   FULLER K, 1993, J EXP MED, V178, P1733, DOI 10.1084/jem.178.5.1733
   FURSETH R, 1968, ARCH ORAL BIOL, V13, P417, DOI 10.1016/0003 9969(68)90168 4
   Fuss Z, 2003, DENT TRAUMATOL, V19, P175, DOI 10.1034/j.1600 9657.2003.00192.x
   Garlet TP, 2008, CYTOKINE, V42, P330, DOI 10.1016/j.cyto.2008.03.003
   Geblinger D, 2010, J CELL SCI, V123, P1503, DOI 10.1242/jcs.060954
   Götz W, 2000, CONNECT TISSUE RES, V41, P185, DOI 10.3109/03008200009005289
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Gregorczyk Maga I, 2019, ARCH ORAL BIOL, V99, P82, DOI 10.1016/j.archoralbio.2019.01.003
   Haapasalo M., 2008, Endodontic Topics, V14, P60, DOI [DOI 10.1111/J.1601 1546.2008.00226.X, 10.1111/j.1601 1546.2008.00226.x]
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   HAMMARSTROM L, 1985, INT ENDOD J, V18, P93, DOI 10.1111/j.1365 2591.1985.tb00426.x
   Harokopakis Hajishengallis Evlambia, 2007, J Oral Sci, V49, P1, DOI 10.2334/josnusd.49.1
   Hatakeyama J, 2003, J BIOL CHEM, V278, P35743, DOI 10.1074/jbc.M306284200
   Heinrich J, 2005, ARCH ORAL BIOL, V50, P897, DOI 10.1016/j.archoralbio.2005.02.007
   Heithersay G S, 1999, Aust Endod J, V25, P79
   Heithersay G S, 1994, Ann R Australas Coll Dent Surg, V12, P46
   Heithersay GS, 1999, QUINTESSENCE INT, V30, P83
   HOROWITZ M, 1984, P NATL ACAD SCI BIOL, V81, P2181, DOI 10.1073/pnas.81.7.2181
   Iglesias Linares A, 2017, J DENT RES, V96, P145, DOI 10.1177/0022034516677539
   Irinakis E, 2020, J ENDODONT, V46, P1420, DOI 10.1016/j.joen.2020.05.021
   JONES SJ, 1984, ANAT EMBRYOL, V170, P247, DOI 10.1007/BF00318728
   Kamat Mamata, 2013, J Oral Maxillofac Pathol, V17, P228, DOI 10.4103/0973 029X.119736
   Kandalgaonkar Shilpa D, 2013, J Int Oral Health, V5, P124
   Kanzaki H, 2002, J BONE MINER RES, V17, P210, DOI 10.1359/jbmr.2002.17.2.210
   Karsdal MA, 2008, BIOCHEM BIOPH RES CO, V366, P483, DOI 10.1016/j.bbrc.2007.11.168
   KEMBER NF, 1960, J BONE JOINT SURG BR, V42, P824, DOI 10.1302/0301 620X.42B4.824
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Koehne T, 2020, IN VIVO, V34, P1875, DOI 10.21873/invivo.11983
   Kohli Sarvraj Singh, 2011, Indian J Endocrinol Metab, V15, P175, DOI 10.4103/2230 8210.83401
   Komine M, 2001, BONE, V28, P474, DOI 10.1016/S8756 3282(01)00420 3
   KURIHARA N, 1989, BLOOD, V74, P1295
   LASFARGUES JJ, 1993, ANAT REC, V237, P458, DOI 10.1002/ar.1092370404
   Lerner UH, 2004, CRIT REV ORAL BIOL M, V15, P64, DOI 10.1177/154411130401500202
   Levac D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748 5908 5 69
   LEVANDER E, 1988, EUR J ORTHODONT, V10, P30, DOI 10.1093/ejo/10.1.30
   LINDSKOG S, 1980, SCAND J DENT RES, V88, P161
   LINDSKOG S, 1987, J CLIN PERIODONTOL, V14, P390, DOI 10.1111/j.1600 051X.1987.tb01542.x
   Lossdörfer S, 2002, CALCIFIED TISSUE INT, V71, P45, DOI 10.1007/s00223 001 2086 7
   Low E, 2005, AM J ORTHOD DENTOFAC, V128, P497, DOI 10.1016/j.ajodo.2004.03.038
   Mavridou AM, 2016, INT ENDOD J, V49, P287, DOI 10.1111/iej.12450
   Mavridou AM, 2017, J ENDODONT, V43, P1602, DOI 10.1016/j.joen.2017.05.026
   Mavridou AM, 2016, J ENDODONT, V42, P1737, DOI 10.1016/j.joen.2016.06.007
   Mavridou AM, 2019, J ENDODONT, V45, P459, DOI 10.1016/j.joen.2018.12.013
   McGowan J, 2016, J CLIN EPIDEMIOL, V75, P40, DOI 10.1016/j.jclinepi.2016.01.021
   Mediero A, 2018, FASEB J, V32, P3487, DOI 10.1096/fj.201700217R
   MELCHER AH, 1972, J PERIODONTAL RES, P16
   MELCHER AH, 1976, J PERIODONTOL, V47, P256, DOI 10.1902/jop.1976.47.5.256
   Souza BDM, 2018, J ENDODONT, V44, P1216, DOI 10.1016/j.joen.2018.03.002
   Miyamoto T, 2000, BLOOD, V96, P4335, DOI 10.1182/blood.V96.13.4335.h8004335_4335_4343
   Mizuno A, 2002, J BONE MINER METAB, V20, P337, DOI 10.1007/s007740200049
   Moher D, 2010, INT J SURG, V8, P336, DOI [10.1371/journal.pmed.1000097, 10.1186/2046 4053 4 1, 10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299, 10.1136/bmj.i4086]
   Müller DD, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 59843 1
   MUNDY GR, 1977, SCIENCE, V196, P1109, DOI 10.1126/science.16343
   Nakamura I, 1996, J BONE MINER RES, V11, P1873
   Nakchbandi IA, 2000, P NATL ACAD SCI USA, V97, P7296, DOI 10.1073/pnas.110553397
   Ne RF, 1999, QUINTESSENCE INT, V30, P9
   NILSEN R, 1979, ARCH ORAL BIOL, V24, P833, DOI 10.1016/0003 9969(79)90047 5
   Nishimi M, 2020, PEDIATR DENT J, V30, P72, DOI 10.1016/j.pdj.2020.05.002
   OIKARINEN K, 1987, ENDOD DENT TRAUMATOL, V3, P296
   Oka H, 2007, J DENT RES, V86, P974, DOI 10.1177/154405910708601011
   Oliveira deaguiar santos B., 2011, RSBO, V8, P439
   Oshiro T, 2001, ANAT REC, V264, P305, DOI 10.1002/ar.1127
   Patel S, 2018, INT ENDOD J, V51, P1205, DOI 10.1111/iej.12942
   Patel S, 2010, J ENDODONT, V36, P1107, DOI 10.1016/j.joen.2010.03.014
   Patel S, 2009, J ENDODONT, V35, P616, DOI 10.1016/j.joen.2009.01.015
   Patel Shanon, 2007, Dent Update, V34, P218
   Peterson J, 2017, J AM ASSOC NURSE PRA, V29, P12, DOI 10.1002/2327 6924.12380
   Philbrick WM, 1998, P NATL ACAD SCI USA, V95, P11846, DOI 10.1073/pnas.95.20.11846
   PIERCE AM, 1989, ENDOD DENT TRAUMATOL, V5, P255
   PIERCE AM, 1989, J SUBMICR CYTOL PATH, V21, P501
   Qian HY, 2018, J CRANIO MAXILL SURG, V46, P808, DOI 10.1016/j.jcms.2018.02.009
   Rani C. S. Sheela, 2000, Molecular Cell Biology Research Communications, V3, P145, DOI 10.1006/mcbr.2000.0205
   Rathe Florian, 2006, Schweiz Monatsschr Zahnmed, V116, P245
   RIFKIN BR, 1980, CELL TISSUE RES, V210, P493
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Rucci N, 2008, CLIN CASES MINER BON, V5, P49
   Rumpler M, 2013, CALCIFIED TISSUE INT, V93, P526, DOI 10.1007/s00223 013 9786 7
   Sae Lim V, 1998, ENDOD DENT TRAUMATOL, V14, P127
   Sahara N, 1998, ANAT RECORD, V252, P215, DOI 10.1002/(SICI)1097 0185(199810)252:2<215::AID AR7>3.0.CO;2 1
   Sahara N, 1996, ANAT REC, V244, P33
   SASAKI T, 1988, AM J ANAT, V183, P303, DOI 10.1002/aja.1001830404
   Sasaki T, 2003, MICROSC RES TECHNIQ, V61, P483, DOI 10.1002/jemt.10370
   Schaffner P, 2003, CELL MOL LIFE SCI, V60, P119, DOI 10.1007/s000180300008
   Schmucker C, 2013, BUNDESGESUNDHEITSBLA, V56, P1390, DOI 10.1007/s00103 013 1818 y
   Schoppet M, 2002, ARTERIOSCL THROM VAS, V22, P549, DOI 10.1161/01.ATV.0000012303.37971.DA
   SHAW DR, 1981, NATURE, V289, P409, DOI 10.1038/289409a0
   Silva I, 2011, ACTA REUMATOL PORT, V36, P209
   Sojod B, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00338
   Speziani C, 2007, EUR J IMMUNOL, V37, P747, DOI 10.1002/eji.200636534
   Sringkarnboriboon S, 2003, J DENT RES, V82, P486, DOI 10.1177/154405910308200616
   STASHENKO P, 1992, J ENDODONT, V18, P422, DOI 10.1016/S0099 2399(06)80841 1
   STASHENKO P, 1991, J PERIODONTOL, V62, P504, DOI 10.1902/jop.1991.62.8.504
   Stenbeck G, 2000, J CELL SCI, V113, P1577
   Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sutton A, 2019, HEALTH INFO LIBR J, V36, P202, DOI 10.1111/hir.12276
   Takeda S, 2008, J NEUROENDOCRINOL, V20, P802, DOI 10.1111/j.1365 2826.2008.01732.x
   TATAKIS DN, 1993, J PERIODONTOL, V64, P416
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   TEITELBAUM SL, 1979, CALCIFIED TISSUE INT, V27, P255, DOI 10.1007/BF02441194
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18 0850
   TRONSTAD L, 1988, ENDOD DENT TRAUMATOL, V4, P241
   Trope M, 1998, Pract Periodontics Aesthet Dent, V10, P515
   Trope M., 2002, Endod. Topics, V1, P79, DOI [DOI 10.1034/J.1601 1546.2002.10106.X, 10.1034/j.1601 1546.2002.10106.x]
   Tsilingaridis G, 2015, DENT TRAUMATOL, V31, P171, DOI 10.1111/edt.12161
   Tyrovola Joanna B, 2008, J Oral Sci, V50, P367
   Väänänen HK, 2000, J CELL SCI, V113, P377
   VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305
   von Arx T., 1998, ACTA MED DENT HELV, V3, P196
   Walsh NC, 2005, IMMUNOL REV, V208, P228, DOI 10.1111/j.0105 2896.2005.00338.x
   WANNFORS K, 1985, INT J ORAL MAXILLOF, V14, P493, DOI 10.1016/S0300 9785(85)80055 7
   WEDENBERG C, 1987, SCAND J DENT RES, V95, P205
   WEDENBERG C, 1990, ENDOD DENT TRAUMATOL, V6, P255
   WEDENBERG C, 1985, Endodontics and Dental Traumatology, V1, P221
   WESSELINK PR, 1986, CALCIFIED TISSUE INT, V39, P11, DOI 10.1007/BF02555735
   Wise GE, 2002, ARCH ORAL BIOL, V47, P247, DOI 10.1016/S0003 9969(01)00109 1
   Yamaguchi M, 2006, J DENT RES, V85, P751, DOI 10.1177/154405910608500812
   Yamamoto T, 2006, J PERIODONTAL RES, V41, P554, DOI 10.1111/j.1600 0765.2006.00905.x
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhang D, 2004, ARCH ORAL BIOL, V49, P71, DOI 10.1016/S0003 9969(03)00201 2
NR 179
TC 48
Z9 50
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472 6831
J9 BMC ORAL HEALTH
JI BMC Oral Health
PD MAR 26
PY 2021
VL 21
IS 1
AR 163
DI 10.1186/s12903 021 01510 6
PG 14
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA RG0SG
UT WOS:000635245600002
PM 33771147
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, XM
   Wei, YQ
   Xuan, CK
   Liu, L
   Lai, C
   Chai, MY
   Zhang, ZG
   Wang, L
   Shi, XT
AF Liu, Xuemin
   Wei, Yingqi
   Xuan, Chengkai
   Liu, Lei
   Lai, Chen
   Chai, Muyuan
   Zhang, Zhaoguo
   Wang, Lin
   Shi, Xuetao
TI A Biomimetic Biphasic Osteochondral Scaffold with Layer Specific Release
   of Stem Cell Differentiation Inducers for the Reconstruction of
   Osteochondral Defects
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE bilayer scaffolds; osteochondral repair; simultaneous reconstruction;
   stem cell differentiation; tissue engineering
ID ENGINEERED CARTILAGE; ALENDRONATE; FABRICATION; INHIBITION;
   NANOPARTICLES; HYDROGELS; REPAIR
AB There is a great challenge in regenerating osteochondral defects because they involve lesions of both cartilage and subchondral bone, which have remarkable differences in their chemical compositions and biological lineages. Thus, considering the complicated requirements in osteochondral reconstruction, a biomimetic biphasic osteochondral scaffold (BBOS) with the layer specific release of stem cell differentiation inducers are developed. The cartilage regeneration layer (cartilage scaffold, CS) in the BBOS contains a hyaluronic acid hydrogel to mimic the composition of cartilage, which is mechanically enhanced by host guest supramolecular units to control the release of kartogenin (KGN). Additionally, a 3D printed hydroxyapatite (HAp) scaffold releasing alendronate (ALN) is employed as the bone regeneration layer (bone scaffold, BS). The two layers are bound by semi immersion and could regulate the hierarchical targeted differentiation behavior of the stem cells. Compared to the drug free scaffold, the MSCs in the BBOS could be promoted to differentiate into both chondrocytes and osteoblasts. The in vivo results demonstrate the strong promotion of cartilage or bone regeneration in their respective layers. It is expected that this BBOS with layer specific inducer release can become a new strategy for osteochondral regeneration.
C1 [Liu, Xuemin; Xuan, Chengkai; Chai, Muyuan; Zhang, Zhaoguo; Wang, Lin; Shi, Xuetao] South China Univ Technol, Natl Engn Res Ctr Tissue Restorat & Reconstruct, Guangzhou 510006, Peoples R China.
   [Wei, Yingqi] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal Pelv Floor Dis, Guangdong Inst Gastroenterol, Guangzhou 510655, Peoples R China.
   [Liu, Lei; Shi, Xuetao] South China Univ Technol, Key Lab Biomed Engn Guangdong Prov, Guangzhou 510006, Peoples R China.
   [Lai, Chen; Shi, Xuetao] Peking Univ, Shenzhen Inst, Shenzhen 518055, Peoples R China.
   [Shi, Xuetao] China Guangzhou Regenerat Med & Hlth Guangdong La, Guangzhou 510005, Peoples R China.
C3 South China University of Technology; Sun Yat Sen University; South
   China University of Technology; Peking University
RP Wang, L; Shi, XT (通讯作者)，South China Univ Technol, Natl Engn Res Ctr Tissue Restorat & Reconstruct, Guangzhou 510006, Peoples R China.; Shi, XT (通讯作者)，South China Univ Technol, Key Lab Biomed Engn Guangdong Prov, Guangzhou 510006, Peoples R China.; Shi, XT (通讯作者)，Peking Univ, Shenzhen Inst, Shenzhen 518055, Peoples R China.; Shi, XT (通讯作者)，China Guangzhou Regenerat Med & Hlth Guangdong La, Guangzhou 510005, Peoples R China.
EM wanglin3@scut.edu.cn; shxt@scut.edu.cn
RI Shi, Xuetao/D 5180 2012; Chen, Yunhua/C 9978 2010; Chai,
   Muyuan/JQJ 0462 2023
OI Chai, Muyuan/0000 0002 7955 2363; Wei, Yingqi/0000 0002 7406 1231; Liu,
   Lei/0000 0002 0500 6239; Liu, Xuemin/0000 0002 5853 8116; 
FU Shenzhen Science and Technology Program [JCYJ20170815153105076,
   GJHZ20180411143347603]; National Natural Science Foundation of China
   [31771027]; Science and Technology Program of Guangdong Province
   [2017B090911008]; Guangdong Natural Science Funds for Distinguished
   Young Scholars [2016A030306018, 2019B151502029]; Pearl River Nova
   Program of Guangzhou [201806010156]
FX This work was funded by the Shenzhen Science and Technology Program
   (JCYJ20170815153105076, GJHZ20180411143347603), National Natural Science
   Foundation of China (31771027), the Science and Technology Program of
   Guangdong Province (2017B090911008), the Guangdong Natural Science Funds
   for Distinguished Young Scholars (2016A030306018, 2019B151502029), Pearl
   River Nova Program of Guangzhou (201806010156). L.W. thanks the Funds
   for Young Pearl River Scholars. X.L. and Y.W. contributed equally to
   this work.
CR Alsalameh S, 2004, ARTHRITIS RHEUM US, V50, P1522, DOI 10.1002/art.20269
   Armiento AR, 2018, ACTA BIOMATER, V65, P1, DOI 10.1016/j.actbio.2017.11.021
   Bardsley K, 2017, BIOMATERIALS, V112, P313, DOI 10.1016/j.biomaterials.2016.10.014
   Beck GR, 1998, J CELL BIOCHEM, V68, P269, DOI 10.1002/(SICI)1097 4644(19980201)68:2<269::AID JCB13>3.0.CO;2 A
   Bian LM, 2013, P NATL ACAD SCI USA, V110, P10117, DOI 10.1073/pnas.1214100110
   Chen F, 2017, CARBOHYD POLYM, V166, P31, DOI 10.1016/j.carbpol.2017.02.059
   Ding CM, 2013, BIOMATERIALS, V34, P6706, DOI 10.1016/j.biomaterials.2013.05.038
   Dua R, 2014, J BIOMED MATER RES B, V102, P922, DOI 10.1002/jbm.b.33073
   Findlay DM, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.28
   Fu LJ, 2008, BONE, V43, P40, DOI 10.1016/j.bone.2008.03.008
   Harley BA, 2010, J BIOMED MATER RES A, V92A, P1078, DOI 10.1002/jbm.a.32387
   Henneman ZJ, 2008, J BIOMED MATER RES A, V85A, P993, DOI 10.1002/jbm.a.31599
   Johnson K, 2012, SCIENCE, V336, P717, DOI 10.1126/science.1215157
   Keller L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10165 5
   Kim CW, 2010, J CONTROL RELEASE, V147, P45, DOI 10.1016/j.jconrel.2010.06.016
   Li XZ, 2016, ACS APPL MATER INTER, V8, P5148, DOI 10.1021/acsami.5b12212
   Li XZ, 2015, REGEN BIOMATER, V2, P221, DOI 10.1093/rb/rbv015
   Liao JF, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.18
   Liu XM, 2020, BIOMATERIALS, V232, DOI 10.1016/j.biomaterials.2019.119644
   Makris EA, 2015, NAT REV RHEUMATOL, V11, P21, DOI 10.1038/nrrheum.2014.157
   Miot S, 2012, EUR CELLS MATER, V23, P222, DOI 10.22203/eCM.v023a17
   Moon HJ, 2011, BIOCHEM BIOPH RES CO, V413, P194, DOI 10.1016/j.bbrc.2011.08.057
   Na JH, 2011, BIOMATERIALS, V32, P5252, DOI 10.1016/j.biomaterials.2011.03.076
   Namgung S, 2011, ACS NANO, V5, P7383, DOI 10.1021/nn2023057
   Neve A, 2013, J CELL PHYSIOL, V228, P1149, DOI 10.1002/jcp.24278
   Nukavarapu SP, 2013, BIOTECHNOL ADV, V31, P706, DOI 10.1016/j.biotechadv.2012.11.004
   Ohtsuki C, 2009, J R SOC INTERFACE, V6, pS349, DOI 10.1098/rsif.2008.0419.focus
   Owan I, 1997, AM J PHYSIOL CELL PH, V273, pC810, DOI 10.1152/ajpcell.1997.273.3.C810
   Palazzo B, 2007, ADV FUNCT MATER, V17, P2180, DOI 10.1002/adfm.200600361
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Ren KX, 2015, BIOMATERIALS, V51, P238, DOI 10.1016/j.biomaterials.2015.02.026
   Shi DQ, 2016, ACS NANO, V10, P1292, DOI 10.1021/acsnano.5b06663
   Stuckensen K, 2018, ADV MATER, V30, DOI 10.1002/adma.201706754
   Swetha M, 2010, INT J BIOL MACROMOL, V47, P1, DOI 10.1016/j.ijbiomac.2010.03.015
   Thambyah A, 2009, OSTEOARTHR CARTILAGE, V17, P456, DOI 10.1016/j.joca.2008.09.005
   Wang ZF, 2019, MATER HORIZONS, V6, P733, DOI [10.1039/C8MH01208C, 10.1039/c8mh01208c]
   Wang ZF, 2018, ANGEW CHEM INT EDIT, V57, P9008, DOI 10.1002/anie.201804400
   Will J, 2008, J MATER SCI MATER M, V19, P2781, DOI 10.1007/s10856 007 3346 5
   Wu Y, 2014, ADV FUNCT MATER, V24, P4473, DOI 10.1002/adfm.201304304
   Zengerink M, 2010, KNEE SURG SPORT TR A, V18, P238, DOI 10.1007/s00167 009 0942 6
   Zhao CY, 2013, BIOMATER SCI UK, V1, P703, DOI 10.1039/c3bm00199g
   Zhou H, 2011, ACTA BIOMATER, V7, P2769, DOI 10.1016/j.actbio.2011.03.019
   Zhu DQ, 2017, BIOMATERIALS, V127, P132, DOI 10.1016/j.biomaterials.2017.02.010
   Zhu Y, 2013, BIOMACROMOLECULES, V14, P342, DOI 10.1021/bm301523p
NR 44
TC 56
Z9 60
U1 5
U2 305
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2192 2640
EI 2192 2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD DEC
PY 2020
VL 9
IS 23
SI SI
AR 2000076
DI 10.1002/adhm.202000076
EA APR 2020
PG 11
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics; Materials Science
GA PB3JM
UT WOS:000528610000001
PM 32338462
DA 2025 08 17
ER

PT J
AU Pacheco Pantoja, EL
   Fraser, WD
   Wilson, PJM
   Gallagher, JA
AF Pacheco Pantoja, Elda L.
   Fraser, William D.
   Wilson, Peter J. M.
   Gallagher, James A.
TI Differential effects of adiponectin in osteoblast like cells
SO JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION
LA English
DT Article
DE AdipoR1; AdipoR2; adiponectin; alkaline phosphatase; GPI PLD
ID BODY MASS INDEX; ALKALINE PHOSPHATASE; PHOSPHOLIPASE D; BONE TURNOVER;
   POSTMENOPAUSAL WOMEN; INSULIN RESISTANCE; STATIN THERAPY; EXPRESSION;
   OBESE; PROLIFERATION
AB The skeleton should maintain an adequate volume, vigour and strength to carry out the role for which it is designed: to hold the whole soft tissue mass that shapes the body and to protect the vital organs. To fulfil this task a satisfactory food intake is required and regulators that are released in the feeding and fasting states, among other signals indicate how much soft mass needs to be built up. Those signals include the secretion of adipocytokines which could represent a relevant link between soft mass (adipose tissue) and skeleton. We studied the presence of adiponectin receptors (AdipoR1, AdipoR2) and its direct effects in osteosarcoma cell line Saos 2. The results indicated that adiponectin receptors were present in the osteoblastic cells with a higher expression of AdipoR1. Human recombinant globular adiponectin was able to increase viability levels and decrease cytotoxicity rates in cell cultures. Also, adiponectin significantly inhibited alkaline phosphatase activity in supernatants. Osteoprotegerin mRNA expression was significantly reduced after 72 h treatment. The FOS induction was studied and the results exhibited a significant increase caused by adiponectin. In conclusion, all these observations suggest that adiponectin influences bone metabolism decreasing the levels of bone formation. Regulators of adiponectin or its receptors could be circulating to modulate the activities of this peptide.
C1 [Pacheco Pantoja, Elda L.] Univ Anahuac Mayab, Escuela Med, Merida 97310, Yucatan, Mexico.
   [Fraser, William D.] Univ E Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England.
   [Wilson, Peter J. M.; Gallagher, James A.] Univ Liverpool, Musculoskeletal Biol Dept, Liverpool L69 3BX, Merseyside, England.
C3 University of East Anglia; University of Liverpool
RP Pacheco Pantoja, EL (通讯作者)，Univ Anahuac Mayab, Escuela Med, Km 15 5 Carr Merida Progreso, Merida 97310, Yucatan, Mexico.
EM elda.pacheco@anahuac.mx
RI ; Hunt, John/G 6366 2012
OI PACHECO PANTOJA, ELDA LEONOR/0000 0003 4327 2826; 
FU Mexican Council for Science and Technology (CONACyT)
FX This work was partly supported by the Mexican Council for Science and
   Technology (CONACyT). The authors declare no conflict of interest.
CR Avbersek Luznik I, 2007, CLIN CHEM LAB MED, V45, P1014, DOI 10.1515/CCLM.2007.186
   Berner HS, 2004, BONE, V35, P842, DOI 10.1016/j.bone.2004.06.008
   Bowler WB, 1999, J BIOL CHEM, V274, P14315, DOI 10.1074/jbc.274.20.14315
   Burshell AL, 2010, BONE, V46, P935, DOI 10.1016/j.bone.2009.12.032
   Chen TH, 2006, BBA MOL BASIS DIS, V1762, P711, DOI 10.1016/j.bbadis.2006.06.008
   De Laet C, 2005, OSTEOPOROSIS INT, V16, P1330, DOI 10.1007/s00198 005 1863 y
   Deeg MA, 2001, AM J PHYSIOL ENDOC M, V281, pE147, DOI 10.1152/ajpendo.2001.281.1.E147
   Deeg MA, 2007, TRANSL RES, V150, P153, DOI 10.1016/j.trsl.2007.03.008
   Díez JJ, 2010, MINI REV MED CHEM, V10, P856
   Ding PYA, 2009, ACTA CARDIOL SIN, V25, P183
   Doran AC, 2008, CIRC RES, V103, P624, DOI 10.1161/CIRCRESAHA.108.175893
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   English PJ, 2003, OBES RES, V11, P839, DOI 10.1038/oby.2003.115
   Gallagher J. A., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P125
   Gartland A, 2012, FRONT BIOSCI LANDMRK, V17, P16, DOI 10.2741/3912
   Gregory P, 2005, BONE, V37, P139, DOI 10.1016/j.bone.2005.04.015
   Henriksen DB, 2003, J BONE MINER RES, V18, P2180, DOI 10.1359/jbmr.2003.18.12.2180
   Kobayashi H, 2004, CIRC RES, V94, pE27, DOI 10.1161/01.RES.0000119921.86460.37
   Konukoglu D, 2000, MATURITAS, V36, P203, DOI 10.1016/S0378 5122(00)00153 5
   Körner A, 2005, BIOCHEM BIOPH RES CO, V337, P540, DOI 10.1016/j.bbrc.2005.09.064
   Kress BC, 1999, CLIN CHEM, V45, P1009
   Lewinson D, 2003, J HISTOCHEM CYTOCHEM, V51, P1161, DOI 10.1177/002215540305100906
   Luo XH, 2005, EXP CELL RES, V309, P99, DOI 10.1016/j.yexcr.2005.05.021
   Luo XH, 2006, J BONE MINER RES, V21, P1648, DOI 10.1359/JBMR.060707
   Luo XH, 2009, J BONE MINER RES, V24, P1461, DOI [10.1359/JBMR.090227, 10.1359/jbmr.090227]
   Maahs DM, 2005, CIRCULATION, V111, P747, DOI 10.1161/01.CIR.0000155251.03724.A5
   Miller M, 2009, J IMMUNOL, V182, P684, DOI 10.4049/jimmunol.182.1.684
   Moss DW, 1997, CLIN CHIM ACTA, V257, P133, DOI 10.1016/S0009 8981(96)06438 8
   Napoli N, 2007, CALCIFIED TISSUE INT, V80, P227, DOI 10.1007/s00223 007 9014 4
   Ohashi K, 2009, MOL CELL BIOL, V29, P3487, DOI 10.1128/MCB.00126 09
   Oshima K, 2005, BIOCHEM BIOPH RES CO, V331, P520, DOI 10.1016/j.bbrc.2005.03.210
   Pacheco Pantoja Elda L., 2011, BMC Physiology, V11, P12, DOI 10.1186/1472 6793 11 12
   Peirson SN, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng073
   Raikwar NS, 2010, METABOLISM, V59, P1413, DOI 10.1016/j.metabol.2008.11.021
   Revilla M, 1997, CALCIFIED TISSUE INT, V61, P134, DOI 10.1007/s002239900310
   Ricci TA, 2001, AM J CLIN NUTR, V73, P347
   Ross PD, 1998, J BONE MINER RES, V13, P297, DOI 10.1359/jbmr.1998.13.2.297
   Sadie Van Gijsen H, 2013, CELL MOL LIFE SCI, V70, P2331, DOI 10.1007/s00018 012 1211 2
   Schofield JN, 2002, MOL GENET METAB, V75, P154, DOI 10.1006/mgme.2001.3287
   Seibel MJ, 2007, WIEN MED WOCHENSCHR, V157, P582, DOI 10.1007/s10354 007 0487 6
   Shinoda Y, 2006, J CELL BIOCHEM, V99, P196, DOI 10.1002/jcb.20890
   Sodi R, 2009, CLIN BIOCHEM, V42, P1375, DOI 10.1016/j.clinbiochem.2009.06.003
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Swarbrick Michael M., 2008, Metabolic Syndrome and Related Disorders, V6, P87, DOI 10.1089/met.2007.0029
   Talbott SM, 1998, J NUTR, V128, P640, DOI 10.1093/jn/128.3.640
   TIETZ NW, 1983, CLIN CHEM, V29, P751
   Tu QS, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.152405
   Wang Y, 2006, CANCER RES, V66, P11462, DOI 10.1158/0008 5472.CAN 06 1969
   Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930
   Xing YH, 2011, J CELL PHYSIOL, V226, P2350, DOI 10.1002/jcp.22579
   Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705
   Zeni SN, 2003, BONE, V33, P606, DOI 10.1016/S8756 3282(03)00203 5
   Zhang Y., 2014, Pharmacol Res
NR 53
TC 11
Z9 12
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1079 9893
EI 1532 4281
J9 J RECEPT SIG TRANSD
JI J. Recept. Signal Transduct.
PD OCT
PY 2014
VL 34
IS 5
BP 351
EP 360
DI 10.3109/10799893.2014.898658
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AP8WM
UT WOS:000342360100007
PM 24673523
DA 2025 08 17
ER

PT J
AU Almuqrin, AH
   Wjihi, S
   Aouaini, F
   Ben Lamine, A
AF Almuqrin, Aljawhara H.
   Wjihi, Sarra
   Aouaini, Fatma
   Ben Lamine, Abdelmottaleb
TI New insights on physico chemical investigation of bisphosphonate
   adsorption isotherm into apatite substrate using statistical physics
   treatment
SO JOURNAL OF MOLECULAR LIQUIDS
LA English
DT Article
DE Adsorption isotherm; Statistical physics model; Osteoporosis disease;
   Thermodynamics function
ID BONE; TILUDRONATE; MECHANISMS; RAMAN; NMR
AB In this paper, a well crystallized hydroxyapatite (HA) and nanocrystalline apatites (NCA) were used to interpret the adsorption process of two bisphosphonates (BPs), namely Tiludronate (Tilu) and Risedronate (Rise). These BPs are among the most prescribed classes of drugs for the treatment of bone disorders disease, particularly Osteoporosis. The equilibrium data used to express the variation of uptake capacity as a function of concentration were determined by varying some experimental physicochemical conditions (e.g. temperature and pH). A preliminary analysis of all the adsorption isotherms obviously indicates that the adsorption quantity tends towards a saturation level. This suggests a finite number of adsorbed layers involved in the adsorption mechanisms. To give a reasonable analysis of the drug adsorption process, three advanced models are proposed and developed in the light of a statistical physics treatment which is tested and discussed. The modeling analysis reveals that the adsorption of the two drugs occurs by the formation of two different adsorbed layers on the apatite surface. Based on the analysis of the selected model parameters, it was deduced that both drugs molecules were anchored alternately with parallel and non parallel positions on the apatite substrate. The study of the uptake capacities at saturation showed that these parameters followed the sequence: Q(asat) (Rise NCA) (>) Q(asat) (Rise HA) (>) Qasat (Tilu HA), indicating that the NCA adsorbent was more effective for the Rise drug adsorption than the HA adsorbent. The estimated adsorption energies globally varied from 9.20 to 19.52 kJ/mol, confirming the physical nature of the adsorption process for the investigated systems. Conventionally, to characterize the adsorption process, the entropy (S a), the enthalpy of Gibbs (G) and the internal energy (E int) were treated and interpreted. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Almuqrin, Aljawhara H.; Aouaini, Fatma] Princess Nourah Bint Abdulrahman Univ, Fac Sci, Phys Dept, Riyadh, Saudi Arabia.
   [Wjihi, Sarra; Aouaini, Fatma; Ben Lamine, Abdelmottaleb] Fac Sci Monastir, Lab Quantum & Stat Phys, LR18ES18, Monastir, Tunisia.
C3 Princess Nourah bint Abdulrahman University; Universite de Monastir
RP Wjihi, S (通讯作者)，Fac Sci Monastir, Dept Phys, Blvd Environm, Monastir 5019, Tunisia.
EM sarawjihi@yahoo.fr
RI ; Aouaini, Fatma/CAG 7577 2022
OI Almuqren, Aljawhara/0000 0002 4731 9081; Ben Lamine,
   Abdelmottaleb/0000 0002 8225 8464; 
FU Center for Promising Research in Social Research andWomen's
   StudiesDeanship of Scientific Research, at Princess Nourah Bint
   Abdulrahman University
FX The authorswould like to thank the Center for Promising Research in
   Social Research andWomen's StudiesDeanship of Scientific Research, at
   Princess Nourah Bint Abdulrahman University for funding this Project in
   2020.
CR Baral SS, 2006, BIOCHEM ENG J, V31, P216, DOI 10.1016/j.bej.2006.08.003
   Browning FH, 1996, LANGMUIR, V12, P5231, DOI 10.1021/la9603277
   Couture L, 1992, J ELLIPSES, V375
   Cukrowski I, 2007, BONE, V41, P668, DOI 10.1016/j.bone.2007.05.008
   Demerjian N, 1999, CLIN RHEUMATOL, V18, P349, DOI 10.1007/s100670050116
   Eichert D., 2008, BIOMATER RES ADV, V93
   Elliott SN, 1997, LIFE SCI, V62, P77, DOI 10.1016/S0024 3205(97)01040 0
   Errassifi F., 2010, 8 PAC RIM C CER GLAS, P159
   Josse S, 2005, BIOMATERIALS, V26, P2073, DOI 10.1016/j.biomaterials.2004.05.019
   Juillard A, 2010, BONE, V47, P895, DOI 10.1016/j.bone.2010.07.018
   KAN AT, 1994, LANGMUIR, V10, P1450, DOI 10.1021/la00017a022
   Khalfaoui M, 2002, ADSORPT SCI TECHNOL, V20, P17, DOI 10.1260/026361702760120908
   Khalfaoui M, 2003, J COLLOID INTERF SCI, V263, P350, DOI 10.1016/S0021 9797(03)00139 5
   KINNIBURGH DG, 1983, J COLLOID INTERF SCI, V95, P370, DOI 10.1016/0021 9797(83)90197 2
   Kos M., 2009, Biosci. Hypotheses, V2, P34, DOI [DOI 10.1016/J.BIHY.2008.08.004, 10.1016/j.bihy.2008.08.004]
   MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030
   Mönkkönen J, 1998, LIFE SCI, V62, pPL95, DOI 10.1016/S0024 3205(97)01178 8
   Mukherjee S, 2008, J AM CHEM SOC, V130, P1264, DOI 10.1021/ja0759949
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Palazzo B, 2007, ADV FUNCT MATER, V17, P2180, DOI 10.1002/adfm.200600361
   Pascaud P, 2014, J MATER SCI MATER M, V25, P2373, DOI 10.1007/s10856 014 5218 0
   Pascaud P, 2013, LANGMUIR, V29, P2224, DOI 10.1021/la3046548
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   VONOEPEN B, 1991, CHEMOSPHERE, V22, P285, DOI 10.1016/0045 6535(91)90318 8
   WARD TM, 1965, J AGR FOOD CHEM, V13, P334, DOI 10.1021/jf60140a013
   Wjihi S, 2017, J MOL LIQ, V238, P402, DOI 10.1016/j.molliq.2017.04.021
NR 27
TC 9
Z9 9
U1 0
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167 7322
EI 1873 3166
J9 J MOL LIQ
JI J. Mol. Liq.
PD JUL 15
PY 2020
VL 310
AR 113230
DI 10.1016/j.molliq.2020.113230
PG 9
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Physics
GA LV7SA
UT WOS:000538635300066
DA 2025 08 17
ER

EF